{"columns":["tier","record_id","save_as","fulltext_status","design_class","first_author","year","title","journal","publisher","doi","doi_url","pmid","pubmed_url","unpaywall_url","registry_ids"],"rows":[["1","R0001853","R0001853.pdf","paywalled","randomized_trial","Stefanakis K","2026","Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156493","https://doi.org/10.1016/j.metabol.2026.156493","41513169","https://pubmed.ncbi.nlm.nih.gov/41513169/",null,"ClinicalTrials.gov:NCT02944500"],["1","R0002218","R0002218.pdf","paywalled","randomized_trial","Liu M","2026","Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-04623","https://doi.org/10.7326/annals-25-04623","42372276","https://pubmed.ncbi.nlm.nih.gov/42372276/",null,"ClinicalTrials.gov:NCT06256549"],["1","R0002627","R0002627.pdf","paywalled","randomized_trial","Yeung EK","2026","A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001158","https://doi.org/10.2215/cjn.0000001158","42335037","https://pubmed.ncbi.nlm.nih.gov/42335037/",null,"ClinicalTrials.gov:NCT06058585; ClinicalTrials.gov:NCT06268873; ClinicalTrials.gov:NCT06742723"],["1","R0002665","R0002665.pdf","paywalled","randomized_trial","Del Prato S","2026","Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-05602","https://doi.org/10.7326/annals-25-05602","42184419","https://pubmed.ncbi.nlm.nih.gov/42184419/",null,"ClinicalTrials.gov:NCT05433584"],["1","R0002960","R0002960.pdf","paywalled","randomized_trial","Wexler DJ","2026","Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2025.107332","https://doi.org/10.1016/j.ahj.2025.107332","41456635","https://pubmed.ncbi.nlm.nih.gov/41456635/",null,"ClinicalTrials.gov:NCT05390892"],["1","R0003091","R0003091.pdf","paywalled","randomized_trial","Badulescu S","2026","Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100916","https://doi.org/10.1016/j.medj.2025.100916","41218611","https://pubmed.ncbi.nlm.nih.gov/41218611/",null,"ClinicalTrials.gov:NCT04466345"],["1","R0003186","R0003186.pdf","paywalled","randomized_trial","Goldberger JJ","2026","The Liraglutide Effects in Atrial Fibrillation (LEAF) Study.","JACC. Clinical electrophysiology","Elsevier BV","10.1016/j.jacep.2026.03.026","https://doi.org/10.1016/j.jacep.2026.03.026","42159524","https://pubmed.ncbi.nlm.nih.gov/42159524/",null,"ClinicalTrials.gov:NCT03856632"],["1","R0003407","R0003407.pdf","paywalled","randomized_trial","Ji L","2026","Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101063","https://doi.org/10.1016/j.medj.2026.101063","41875890","https://pubmed.ncbi.nlm.nih.gov/41875890/",null,"ClinicalTrials.gov:NCT01904913; ClinicalTrials.gov:NCT04904913"],["1","R0003866","R0003866.pdf","paywalled","randomized_trial","Chang LS","2026","Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.","American heart journal","Elsevier BV","10.1016/j.ahj.2026.107359","https://doi.org/10.1016/j.ahj.2026.107359","41610902","https://pubmed.ncbi.nlm.nih.gov/41610902/",null,"ClinicalTrials.gov:NCT06046560"],["1","R0004235","R0004235.pdf","paywalled","randomized_trial","Aroda VR","2026","Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00126-9","https://doi.org/10.1016/s2213-8587(26)00126-9","42251860","https://pubmed.ncbi.nlm.nih.gov/42251860/",null,"ClinicalTrials.gov:NCT06323174"],["1","R0004267","R0004267.pdf","paywalled","randomized_trial","Buse JB","2026","Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00125-7","https://doi.org/10.1016/s2213-8587(26)00125-7","42251859","https://pubmed.ncbi.nlm.nih.gov/42251859/",null,"ClinicalTrials.gov:NCT06065540"],["1","R0004786","R0004786.pdf","paywalled","randomized_trial","Rosenstock J","2026","Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)01022-6","https://doi.org/10.1016/s0140-6736(26)01022-6","42251856","https://pubmed.ncbi.nlm.nih.gov/42251856/",null,"ClinicalTrials.gov:NCT06323161"],["1","R0004982","R0004982.pdf","paywalled","randomized_trial","Zhu D","2026","Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-025-06593-2","https://doi.org/10.1007/s00125-025-06593-2","41272211","https://pubmed.ncbi.nlm.nih.gov/41272211/",null,"ClinicalTrials.gov:NCT04994288"],["1","R0005491","R0005491.pdf","paywalled","randomized_trial","Klein KR","2026","Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)01865-9","https://doi.org/10.1016/s0140-6736(26)01865-9","42815506","https://pubmed.ncbi.nlm.nih.gov/42815506/",null,"ClinicalTrials.gov:NCT05803421"],["1","R0005768","R0005768.pdf","paywalled","randomized_trial","Ji L","2026","Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00136-1","https://doi.org/10.1016/s2213-8587(26)00136-1","42594928","https://pubmed.ncbi.nlm.nih.gov/42594928/",null,"ClinicalTrials.gov:NCT06269107"],["1","R0005832","R0005832.pdf","paywalled","randomized_trial","Rosenstock J","2026","Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00202-3","https://doi.org/10.1016/s0140-6736(26)00202-3","41765029","https://pubmed.ncbi.nlm.nih.gov/41765029/",null,"ClinicalTrials.gov:NCT06045221"],["1","R0005838","R0005838.pdf","paywalled","randomized_trial","Zhu D","2026","Mazdutide versus placebo in Chinese adults with type 2 diabetes.","Nature","Springer Science and Business Media LLC","10.1038/s41586-025-10026-w","https://doi.org/10.1038/s41586-025-10026-w","41407859","https://pubmed.ncbi.nlm.nih.gov/41407859/",null,null],["1","R0007237","R0007237.pdf","paywalled","randomized_trial","Wharton S","2026","Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2607219","https://doi.org/10.1056/nejmoa2607219","42820639","https://pubmed.ncbi.nlm.nih.gov/42820639/",null,"ClinicalTrials.gov:NCT06066528"],["1","R0007335","R0007335.pdf","paywalled","randomized_trial","Guo L","2026","Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.","Nature","Springer Science and Business Media LLC","10.1038/s41586-025-10031-z","https://doi.org/10.1038/s41586-025-10031-z","41407860","https://pubmed.ncbi.nlm.nih.gov/41407860/",null,"ClinicalTrials.gov:NCT05606913"],["1","R0007530","R0007530.pdf","paywalled","randomized_trial","Yamauchi T","2026","Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00402-4","https://doi.org/10.1016/s2213-8587(25)00402-4","42009015","https://pubmed.ncbi.nlm.nih.gov/42009015/",null,"ClinicalTrials.gov:NCT05813925"],["1","R0007652","R0007652.pdf","paywalled","randomized_trial","Horn DB","2026","Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)02165-8","https://doi.org/10.1016/s0140-6736(25)02165-8","41275875","https://pubmed.ncbi.nlm.nih.gov/41275875/",null,"ClinicalTrials.gov:NCT05872620"],["1","R0007653","R0007653.pdf","paywalled","randomized_trial","Welch M","2026","Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00800-7","https://doi.org/10.1016/s0140-6736(26)00800-7","42259339","https://pubmed.ncbi.nlm.nih.gov/42259339/",null,"ClinicalTrials.gov:NCT06192108"],["1","R0008183","R0008183.pdf","paywalled","randomized_trial","le Roux CW","2026","Survodutide Once Weekly for the Treatment of Adults with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2600751","https://doi.org/10.1056/nejmoa2600751","42253238","https://pubmed.ncbi.nlm.nih.gov/42253238/",null,"ClinicalTrials.gov:NCT06066515"],["1","R0008978","R0008978.pdf","paywalled","randomized_trial","Yabe D","2026","Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00138-5","https://doi.org/10.1016/s2213-8587(26)00138-5","42607698","https://pubmed.ncbi.nlm.nih.gov/42607698/",null,"ClinicalTrials.gov:NCT06010004"],["1","R0009259","R0009259.pdf","paywalled","randomized_trial","Bajaj HS","2026","Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00967-0","https://doi.org/10.1016/s0140-6736(26)00967-0","42250575","https://pubmed.ncbi.nlm.nih.gov/42250575/",null,"ClinicalTrials.gov:NCT06354660"],["1","R0009652","R0009652.pdf","paywalled","randomized_trial","Guo L","2026","Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00133-6","https://doi.org/10.1016/s2213-8587(26)00133-6","42575111","https://pubmed.ncbi.nlm.nih.gov/42575111/",null,"ClinicalTrials.gov:NCT06041217"],["1","R0010184","R0010184.pdf","paywalled","randomized_trial","Bellido V","2026","Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)01861-1","https://doi.org/10.1016/s0140-6736(26)01861-1","42810372","https://pubmed.ncbi.nlm.nih.gov/42810372/",null,"ClinicalTrials.gov:NCT05929079"],["1","R0010399","R0010399.pdf","paywalled","randomized_trial","Hsia SH","2026","Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00160-9","https://doi.org/10.1016/s2213-8587(26)00160-9","42628555","https://pubmed.ncbi.nlm.nih.gov/42628555/",null,"ClinicalTrials.gov:NCT06124807"],["1","R0010544","R0010544.pdf","paywalled","randomized_trial","Jastreboff AM","2026","Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2604169","https://doi.org/10.1056/nejmoa2604169","42814954","https://pubmed.ncbi.nlm.nih.gov/42814954/",null,"ClinicalTrials.gov:NCT05929066"],["1","R0010858","R0010858.pdf","paywalled","randomized_trial","Helsted MM","2026","Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00075-6","https://doi.org/10.1016/s2213-8587(26)00075-6","42173109","https://pubmed.ncbi.nlm.nih.gov/42173109/",null,"ClinicalTrials.gov:NCT05078255"],["1","R0010921","R0010921.pdf","paywalled","randomized_trial","Aroda VR","2026","Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00802-0","https://doi.org/10.1016/s0140-6736(26)00802-0","42259343","https://pubmed.ncbi.nlm.nih.gov/42259343/",null,"ClinicalTrials.gov:NCT06579105; CTIS:2024-512562-34-00"],["1","R0012174","R0012174.pdf","paywalled","randomized_trial","Ji L","2026","Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71193","https://doi.org/10.1111/dom.71193","42755112","https://pubmed.ncbi.nlm.nih.gov/42755112/",null,"ClinicalTrials.gov:NCT06973681"],["1","R0012964","R0012964.pdf","paywalled","randomized_trial","Yin Y","2026","Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101183","https://doi.org/10.1016/j.medj.2026.101183","42296968","https://pubmed.ncbi.nlm.nih.gov/42296968/",null,"ClinicalTrials.gov:NCT05963022"],["1","R0013285","R0013285.pdf","paywalled","randomized_trial","Horn DB","2026","Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00656-2","https://doi.org/10.1016/s0140-6736(26)00656-2","42119587","https://pubmed.ncbi.nlm.nih.gov/42119587/",null,"ClinicalTrials.gov:NCT06047548"],["1","R0016221","R0016221.pdf","paywalled","randomized_trial","Katrevula A","2026","Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","Springer Science and Business Media LLC","10.1007/s12664-025-01856-7","https://doi.org/10.1007/s12664-025-01856-7","41066034","https://pubmed.ncbi.nlm.nih.gov/41066034/",null,"ClinicalTrials.gov:NCT05442450"],["1","R0020979","R0020979.pdf","paywalled","randomized_trial","Mora P","2026","Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)01248-1","https://doi.org/10.1016/s0140-6736(26)01248-1","42532080","https://pubmed.ncbi.nlm.nih.gov/42532080/",null,"ClinicalTrials.gov:NCT06542874"],["1","R0021369","R0021369.pdf","paywalled","randomized_trial","Mora P","2026","Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)01247-x","https://doi.org/10.1016/s0140-6736(26)01247-x","42532079","https://pubmed.ncbi.nlm.nih.gov/42532079/",null,"ClinicalTrials.gov:NCT06542874"],["1","R0029422","R0029422.pdf","paywalled","randomized_trial","Noureddin M","2026","The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(26)00130-5","https://doi.org/10.1016/s2468-1253(26)00130-5","42480572","https://pubmed.ncbi.nlm.nih.gov/42480572/",null,"ClinicalTrials.gov:NCT06410924"],["1","R0033124","R0033124.pdf","paywalled","randomized_trial","XIAOYING LI","2026","2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db26-2609-p","https://doi.org/10.2337/db26-2609-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06500299"],["1","R0034356","R0034356.pdf","paywalled","randomized_trial","Mihirkumar Patel","2026","Perspectives and Insights on Glucagon-Like Peptide-1 Receptor Agonists: From Development to Submission of a Clinical Trial Application in Canada","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21339162","https://doi.org/10.5281/zenodo.21339162",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05132088"],["1","R0035390","R0035390.pdf","paywalled","randomized_trial","Sky Qiu","2026","Improving the Efficiency of Subgroup Analysis in Randomized Controlled Trials with TMLE","arXiv (Cornell University)",null,"10.48550/arxiv.2605.15483","https://doi.org/10.48550/arxiv.2605.15483",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0036730","R0036730.pdf","paywalled","randomized_trial","Georgios Ponirakis","2026","Central and peripheral neurodegeneration in diabetes and dementia","e-space (Manchester Metropolitan University)",null,"10.83056/mmu.32479965","https://doi.org/10.83056/mmu.32479965",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02887625"],["1","R0037205","R0037205.pdf","paywalled","randomized_trial","LINONG JI","2026","1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial","Diabetes","American Diabetes Association","10.2337/db26-1225-or","https://doi.org/10.2337/db26-1225-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06164873"],["1","R0037289","R0037289.pdf","paywalled","randomized_trial","Michelle Dalton","2026","1695-P: Effect of CagriSema on Eating Control and Behavior: REDEFINE 1","Diabetes","American Diabetes Association","10.2337/db26-1695-p","https://doi.org/10.2337/db26-1695-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05567796"],["1","R0037391","R0037391.pdf","paywalled","randomized_trial","YUQIAN BAO","2026","2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study","Diabetes","American Diabetes Association","10.2337/db26-2636-p","https://doi.org/10.2337/db26-2636-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06921486"],["1","R0039612","R0039612.pdf","paywalled","randomized_trial","Ildiko Lingvay","2026","2813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study","Diabetes","American Diabetes Association","10.2337/db26-2813-lb","https://doi.org/10.2337/db26-2813-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06525935"],["1","R0039726","R0039726.pdf","paywalled","randomized_trial","FRANCESCO GIORGINO","2026","1253-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5","Diabetes","American Diabetes Association","10.2337/db26-1253-or","https://doi.org/10.2337/db26-1253-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06109311"],["1","R0039926","R0039926.pdf","paywalled","randomized_trial","XIAOYING LI","2026","1034-OR: Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db26-1034-or","https://doi.org/10.2337/db26-1034-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06886126"],["1","R0045097","R0045097.pdf","paywalled","randomized_trial","STANLEY HSIA","2026","1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight","Diabetes","American Diabetes Association","10.2337/db26-1733-p","https://doi.org/10.2337/db26-1733-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06124807"],["1","R0045424","R0045424.pdf","paywalled","randomized_trial","LIN XIE","2026","2836-LB: HbA1c and Weight Outcomes among Adults with Type 2 Diabetes on 25 mg Oral Semaglutide Previously Treated with Metformin Only: A Post hoc Analysis from PIONEER PLUS","Diabetes","American Diabetes Association","10.2337/db26-2836-lb","https://doi.org/10.2337/db26-2836-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04707469"],["1","R0045628","R0045628.pdf","paywalled","randomized_trial","Mary Rinella","2026","1701-P: Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1","Diabetes","American Diabetes Association","10.2337/db26-1701-p","https://doi.org/10.2337/db26-1701-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04822181"],["1","R0045743","R0045743.pdf","paywalled","randomized_trial","YINGYING LUO","2026","1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial","Diabetes","American Diabetes Association","10.2337/db26-1226-or","https://doi.org/10.2337/db26-1226-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06184568"],["1","R0045777","R0045777.pdf","paywalled","randomized_trial","Dayu Lv","2026","2866-LB: Semaglutide Use Along with Neural Network Fully Closed-Loop Systems Improves Time in Range (TIR) to 87% in Adults with Type 1 diabetes: In Silico Study","Diabetes","American Diabetes Association","10.2337/db26-2866-lb","https://doi.org/10.2337/db26-2866-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05537233"],["1","R0046222","R0046222.pdf","paywalled","randomized_trial","Hui Liu (33624)","2026","2624-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities","Diabetes","American Diabetes Association","10.2337/db26-2624-p","https://doi.org/10.2337/db26-2624-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06023095"],["1","R0046578","R0046578.pdf","paywalled","randomized_trial","ZHIGUANG ZHOU","2026","3090-LB: UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db26-3090-lb","https://doi.org/10.2337/db26-3090-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07177469"],["1","R0053457","R0053457.pdf","paywalled","randomized_trial","LINONG JI","2026","2849-LB: Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study","Diabetes","American Diabetes Association","10.2337/db26-2849-lb","https://doi.org/10.2337/db26-2849-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07073417"],["1","R0053498","R0053498.pdf","paywalled","randomized_trial","RYAN HUSS","2026","2869-LB: Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study","Diabetes","American Diabetes Association","10.2337/db26-2869-lb","https://doi.org/10.2337/db26-2869-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05822544"],["1","R0054588","R0054588.pdf","paywalled","randomized_trial","MICHELLE D. WELCH","2026","1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin","Diabetes","American Diabetes Association","10.2337/db26-1254-or","https://doi.org/10.2337/db26-1254-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06192108"],["1","R0054780","R0054780.pdf","paywalled","randomized_trial","CHUNXIU GONG","2026","1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial","Diabetes","American Diabetes Association","10.2337/db26-1133-or","https://doi.org/10.2337/db26-1133-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06536023"],["1","R0005129","R0005129.pdf","paywalled","randomized_trial","Billings LK","2025","Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-03849","https://doi.org/10.7326/annals-24-03849","40183678","https://pubmed.ncbi.nlm.nih.gov/40183678/",null,"ClinicalTrials.gov:NCT05564039"],["1","R0006211","R0006211.pdf","paywalled","randomized_trial","He Y","2025","Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00196-2","https://doi.org/10.1016/s2213-8587(25)00196-2","40854315","https://pubmed.ncbi.nlm.nih.gov/40854315/",null,"ClinicalTrials.gov:NCT05680129"],["1","R0006537","R0006537.pdf","paywalled","randomized_trial","Wharton S","2025","Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2511774","https://doi.org/10.1056/nejmoa2511774","40960239","https://pubmed.ncbi.nlm.nih.gov/40960239/",null,"ClinicalTrials.gov:NCT05869903"],["1","R0007826","R0007826.pdf","paywalled","randomized_trial","Garvey WT","2025","Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2502081","https://doi.org/10.1056/nejmoa2502081","40544433","https://pubmed.ncbi.nlm.nih.gov/40544433/",null,"ClinicalTrials.gov:NCT05567796"],["1","R0007868","R0007868.pdf","paywalled","randomized_trial","Davies MJ","2025","Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2502082","https://doi.org/10.1056/nejmoa2502082","40544432","https://pubmed.ncbi.nlm.nih.gov/40544432/",null,"ClinicalTrials.gov:NCT05394519"],["1","R0009287","R0009287.pdf","paywalled","randomized_trial","Ji L","2025","Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00141-x","https://doi.org/10.1016/s2213-8587(25)00141-x","40555243","https://pubmed.ncbi.nlm.nih.gov/40555243/",null,"ClinicalTrials.gov:NCT05813795"],["1","R0009296","R0009296.pdf","paywalled","randomized_trial","Wang Q","2025","Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-025-01569-2","https://doi.org/10.1007/s40262-025-01569-2","40991141","https://pubmed.ncbi.nlm.nih.gov/40991141/",null,"ClinicalTrials.gov:NCT04998032"],["1","R0009645","R0009645.pdf","paywalled","randomized_trial","Rosenstock J","2025","Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2505669","https://doi.org/10.1056/nejmoa2505669","40544435","https://pubmed.ncbi.nlm.nih.gov/40544435/",null,"ClinicalTrials.gov:NCT05971940"],["1","R0010009","R0010009.pdf","paywalled","randomized_trial","Coskun T","2025","Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00092-0","https://doi.org/10.1016/s2213-8587(25)00092-0","40609566","https://pubmed.ncbi.nlm.nih.gov/40609566/",null,"ClinicalTrials.gov:NCT04867785"],["1","R0010555","R0010555.pdf","paywalled","randomized_trial","Mathieu C","2025","Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00096-8","https://doi.org/10.1016/s2213-8587(25)00096-8","40482671","https://pubmed.ncbi.nlm.nih.gov/40482671/",null,"ClinicalTrials.gov:NCT05352815"],["1","R0010656","R0010656.pdf","paywalled","randomized_trial","Jastreboff AM","2025","Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2504214","https://doi.org/10.1056/nejmoa2504214","40549887","https://pubmed.ncbi.nlm.nih.gov/40549887/",null,"ClinicalTrials.gov:NCT05669599"],["1","R0010915","R0010915.pdf","paywalled","randomized_trial","Billings LK","2025","Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00052-x","https://doi.org/10.1016/s2213-8587(25)00052-x","40482670","https://pubmed.ncbi.nlm.nih.gov/40482670/",null,"ClinicalTrials.gov:NCT05013229"],["1","R0011082","R0011082.pdf","paywalled","randomized_trial","Gasiorek A","2025","Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)01176-6","https://doi.org/10.1016/s0140-6736(25)01176-6","40550229","https://pubmed.ncbi.nlm.nih.gov/40550229/",null,"ClinicalTrials.gov:NCT05369390"],["1","R0011234","R0011234.pdf","paywalled","randomized_trial","Beetz N","2025","A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15984","https://doi.org/10.1111/dom.15984","39373311","https://pubmed.ncbi.nlm.nih.gov/39373311/",null,"ClinicalTrials.gov:NCT04903509"],["1","R0011391","R0011391.pdf","paywalled","randomized_trial","Noureddin M","2025","Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)02114-2","https://doi.org/10.1016/s0140-6736(25)02114-2","41237796","https://pubmed.ncbi.nlm.nih.gov/41237796/",null,"ClinicalTrials.gov:NCT05989711"],["1","R0011665","R0011665.pdf","paywalled","randomized_trial","Hannon TS","2025","Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)01774-x","https://doi.org/10.1016/s0140-6736(25)01774-x","40975112","https://pubmed.ncbi.nlm.nih.gov/40975112/",null,"ClinicalTrials.gov:NCT05260021"],["1","R0013019","R0013019.pdf","paywalled","randomized_trial","Dahl K","2025","Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)01185-7","https://doi.org/10.1016/s0140-6736(25)01185-7","40550231","https://pubmed.ncbi.nlm.nih.gov/40550231/",null,"ClinicalTrials.gov:NCT06064006"],["1","R0013080","R0013080.pdf","paywalled","randomized_trial","Ji L","2025","Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2411528","https://doi.org/10.1056/nejmoa2411528","40421736","https://pubmed.ncbi.nlm.nih.gov/40421736/",null,"ClinicalTrials.gov:NCT05607680"],["1","R0013532","R0013532.pdf","paywalled","randomized_trial","Kjaergaard J","2025","Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.","Circulation. Cardiovascular interventions","Ovid Technologies (Wolters Kluwer Health)","10.1161/circinterventions.124.014961","https://doi.org/10.1161/circinterventions.124.014961","40265262","https://pubmed.ncbi.nlm.nih.gov/40265262/",null,"ClinicalTrials.gov:NCT02673931"],["1","R0015125","R0015125.pdf","paywalled","randomized_trial","Guo L","2025","Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00248-7","https://doi.org/10.1016/s2213-8587(25)00248-7","41167231","https://pubmed.ncbi.nlm.nih.gov/41167231/",null,"ClinicalTrials.gov:NCT05691712"],["1","R0016015","R0016015.pdf","paywalled","randomized_trial","Wharton S","2025","Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2500969","https://doi.org/10.1056/nejmoa2500969","40934115","https://pubmed.ncbi.nlm.nih.gov/40934115/",null,"ClinicalTrials.gov:NCT05564117"],["1","R0016174","R0016174.pdf","paywalled","randomized_trial","Patino LR","2025","A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2025.04.046","https://doi.org/10.1016/j.jad.2025.04.046","40203970","https://pubmed.ncbi.nlm.nih.gov/40203970/",null,"ClinicalTrials.gov:NCT00845507"],["1","R0016237","R0016237.pdf","paywalled","randomized_trial","Lingvay I","2025","Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00225-6","https://doi.org/10.1016/s2213-8587(25)00225-6","40961953","https://pubmed.ncbi.nlm.nih.gov/40961953/",null,"ClinicalTrials.gov:NCT05649137"],["1","R0016489","R0016489.pdf","paywalled","randomized_trial","Wharton S","2025","Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00226-8","https://doi.org/10.1016/s2213-8587(25)00226-8","40961952","https://pubmed.ncbi.nlm.nih.gov/40961952/",null,"ClinicalTrials.gov:NCT05646706"],["1","R0016602","R0016602.pdf","paywalled","randomized_trial","Lim S","2025","Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00164-0","https://doi.org/10.1016/s2213-8587(25)00164-0","40825340","https://pubmed.ncbi.nlm.nih.gov/40825340/",null,"ClinicalTrials.gov:NCT04998136"],["1","R0016732","R0016732.pdf","paywalled","randomized_trial","Kadowaki T","2025","Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(24)00377-2","https://doi.org/10.1016/s2213-8587(24)00377-2","40031941","https://pubmed.ncbi.nlm.nih.gov/40031941/",null,"ClinicalTrials.gov:NCT04844918"],["1","R0017153","R0017153.pdf","paywalled","randomized_trial","Shah VN","2025","Semaglutide in Adults with Type 1 Diabetes and Obesity.","NEJM evidence","Massachusetts Medical Society","10.1056/evidoa2500173","https://doi.org/10.1056/evidoa2500173","40550013","https://pubmed.ncbi.nlm.nih.gov/40550013/",null,"ClinicalTrials.gov:NCT05537233"],["1","R0017565","R0017565.pdf","paywalled","randomized_trial","Linetzky B","2025","Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-02623","https://doi.org/10.7326/annals-24-02623","40550133","https://pubmed.ncbi.nlm.nih.gov/40550133/",null,"ClinicalTrials.gov:NCT04184622"],["1","R0017665","R0017665.pdf","paywalled","randomized_trial","Jastreboff AM","2025","Tirzepatide for Obesity Treatment and Diabetes Prevention.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2410819","https://doi.org/10.1056/nejmoa2410819","39536238","https://pubmed.ncbi.nlm.nih.gov/39536238/",null,"ClinicalTrials.gov:NCT04184622"],["1","R0017742","R0017742.pdf","paywalled","randomized_trial","Packer M","2025","Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2410027","https://doi.org/10.1056/nejmoa2410027","39555826","https://pubmed.ncbi.nlm.nih.gov/39555826/",null,"ClinicalTrials.gov:NCT04847557"],["1","R0018169","R0018169.pdf","paywalled","randomized_trial","Bonaca MP","2025","Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)00509-4","https://doi.org/10.1016/s0140-6736(25)00509-4","40169145","https://pubmed.ncbi.nlm.nih.gov/40169145/",null,"ClinicalTrials.gov:NCT04560998"],["1","R0018425","R0018425.pdf","paywalled","randomized_trial","Fox CK","2025","Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2407379","https://doi.org/10.1056/nejmoa2407379","39258838","https://pubmed.ncbi.nlm.nih.gov/39258838/",null,"ClinicalTrials.gov:NCT04775082"],["1","R0021091","R0021091.pdf","paywalled","randomized_trial","Liu Y","2025","The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16285","https://doi.org/10.1111/dom.16285","40028667","https://pubmed.ncbi.nlm.nih.gov/40028667/",null,null],["1","R0029705","R0029705.pdf","paywalled","randomized_trial","Xiang L","2025","Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2024.12.006","https://doi.org/10.1016/j.jhep.2024.12.006","39709140","https://pubmed.ncbi.nlm.nih.gov/39709140/",null,"ClinicalTrials.gov:NCT05943886"],["1","R0032683","R0032683.pdf","paywalled","randomized_trial","Jamy D. Ard","2025","144-OR: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)","Diabetes","American Diabetes Association","10.2337/db25-144-or","https://doi.org/10.2337/db25-144-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05556512"],["1","R0037996","R0037996.pdf","paywalled","randomized_trial","Laurent Castera","2025","S2805 The Use of Non-Invasive Tests to Characterise the Total Baseline Population in the Phase 3 Essence Trial","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138680.36161.70","https://doi.org/10.14309/01.ajg.0001138680.36161.70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04822181"],["1","R0038036","R0038036.pdf","paywalled","randomized_trial","Sean Wharton","2025","1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial","Diabetes","American Diabetes Association","10.2337/db25-1966-lb","https://doi.org/10.2337/db25-1966-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05646706"],["1","R0038263","R0038263.pdf","paywalled","randomized_trial","Ali Azarbarzin","2025","Tirzepatide-related improvement in sleep disordered breathing and hypoxic burden and its association with sleep apnoea cardiometabolic outcomes",null,"European Respiratory Society","10.1183/23120541.sleepandbreathing-2025.73","https://doi.org/10.1183/23120541.sleepandbreathing-2025.73",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05412004"],["1","R0038416","R0038416.pdf","paywalled","randomized_trial","Kirsten Dahl","2025","2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial","Diabetes","American Diabetes Association","10.2337/db25-2002-lb","https://doi.org/10.2337/db25-2002-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06064006"],["1","R0038882","R0038882.pdf","paywalled","randomized_trial",null,"2025","2025 Late Breaking Abstracts","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001589","https://doi.org/10.1097/hep.0000000000001589","41201154","https://pubmed.ncbi.nlm.nih.gov/41201154/",null,"ClinicalTrials.gov:NCT05989711"],["1","R0045020","R0045020.pdf","paywalled","randomized_trial","Matthias Blüher","2025","S746 Pharmacogenomic Analysis of the GLP-1 Receptor in a Phase 2 Trial of Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, in Adults With Obesity","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130444.00553.d1","https://doi.org/10.14309/01.ajg.0001130444.00553.d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04667377"],["1","R0045356","R0045356.pdf","paywalled","randomized_trial","Xiaoying Du","2025","Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20254m6bwa9n","https://doi.org/10.1681/asn.20254m6bwa9n",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06415214"],["1","R0045884","R0045884.pdf","paywalled","randomized_trial","Massimo Nardone","2025","Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025m7ss8e68","https://doi.org/10.1681/asn.2025m7ss8e68",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05205928"],["1","R0045923","R0045923.pdf","paywalled","randomized_trial","Atul Malhotra","2025","Tirzepatide Improved Sleep Disordered Breathing in Adults with Obstructive Sleep Apnea with Obesity: Results from SURMOUNT-OSA Trials.","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807558","https://doi.org/10.1055/s-0045-1807558",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05412004"],["1","R0046280","R0046280.pdf","paywalled","randomized_trial","Melissa‐Rosina Pasqua","2025","798-P: Semaglutide Effect during Mixed-Meal Tolerance Test (MMTT) with Fully Closed-Loop Therapy in Type 1 Diabetes (T1D)","Diabetes","American Diabetes Association","10.2337/db25-798-p","https://doi.org/10.2337/db25-798-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05205928"],["1","R0047281","R0047281.pdf","paywalled","randomized_trial","Michael B. Paladino","2025","Once-Weekly Semaglutide in Adults With Alcohol Use Disorder","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ybv8-qp05","https://doi.org/10.17615/ybv8-qp05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05520775"],["1","R0047758","R0047758.pdf","paywalled","randomized_trial","Yuqian Bao","2025","738-P: Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study","Diabetes","American Diabetes Association","10.2337/db25-738-p","https://doi.org/10.2337/db25-738-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06732960"],["1","R0048629","R0048629.pdf","paywalled","randomized_trial","Allon N. Friedman","2025","Effect of Semaglutide on Hemoglobin A1c and Body Weight Change by CKD Stage: Post Hoc Analysis from the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025fr6fq33q","https://doi.org/10.1681/asn.2025fr6fq33q",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["1","R0048963","R0048963.pdf","paywalled","randomized_trial","ALEXANDRA STEINBERG","2025","125-OR: Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity","Diabetes","American Diabetes Association","10.2337/db25-125-or","https://doi.org/10.2337/db25-125-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04838405"],["1","R0049519","R0049519.pdf","paywalled","randomized_trial","Neda Rasouli","2025","291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial","Diabetes","American Diabetes Association","10.2337/db25-291-or","https://doi.org/10.2337/db25-291-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04560998"],["1","R0049575","R0049575.pdf","paywalled","randomized_trial","Dennis Kannenkeril","2025","EFFECTS OF THE GLP-1 RA SEMAGLUTIDE ON VASCULAR STRUCTURE AND FUNCTION IN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF A PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001115440.99912.21","https://doi.org/10.1097/01.hjh.0001115440.99912.21",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05303857"],["1","R0049852","R0049852.pdf","paywalled","randomized_trial","Lixin Guo","2025","1729-P: Achieving BMI <25 kg/m2 Was Associated with Reduced Predicted Risk of Atherosclerotic Cardiovascular Disease in People with Obesity or Overweight—A Post Hoc Analysis of SURMOUNT-1, -3, and -CN","Diabetes","American Diabetes Association","10.2337/db25-1729-p","https://doi.org/10.2337/db25-1729-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT05024032"],["1","R0050051","R0050051.pdf","paywalled","randomized_trial","YIJUN DU","2025","142-OR: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study","Diabetes","American Diabetes Association","10.2337/db25-142-or","https://doi.org/10.2337/db25-142-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06640647; ClinicalTrials.gov:NCT06637020"],["1","R0050399","R0050399.pdf","paywalled","randomized_trial","Lixin Guo","2025","839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial","Diabetes","American Diabetes Association","10.2337/db25-839-p","https://doi.org/10.2337/db25-839-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06739044"],["1","R0050905","R0050905.pdf","paywalled","randomized_trial","Christopher Bull Granger","2025","Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/fxhs-bj80","https://doi.org/10.17615/fxhs-bj80",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03936660"],["1","R0050967","R0050967.pdf","paywalled","randomized_trial","Rohit S. Loomba","2025","Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807443","https://doi.org/10.1055/s-0045-1807443",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04166773"],["1","R0051328","R0051328.pdf","paywalled","randomized_trial","Nikolaj Klausholt Bak","2025","1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity","Diabetes","American Diabetes Association","10.2337/db25-1969-lb","https://doi.org/10.2337/db25-1969-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06207877"],["1","R0051654","R0051654.pdf","paywalled","randomized_trial","ILDIKO LINGVAY","2025","1978-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity and Type 2 Diabetes—STEP UP T2D Trial","Diabetes","American Diabetes Association","10.2337/db25-1978-lb","https://doi.org/10.2337/db25-1978-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05649137"],["1","R0052201","R0052201.pdf","paywalled","randomized_trial","ALEXANDRA STEINBERG","2025","763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-763-p","https://doi.org/10.2337/db25-763-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04838405; ClinicalTrials.gov:NCT06628362"],["1","R0052501","R0052501.pdf","paywalled","randomized_trial","SILVIO E. INZUCCHI","2025","292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial","Diabetes","American Diabetes Association","10.2337/db25-292-or","https://doi.org/10.2337/db25-292-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03914326"],["1","R0055235","R0055235.pdf","paywalled","randomized_trial","Philip Noel Newsome","2025","P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-basl.19","https://doi.org/10.1136/gutjnl-2025-basl.19",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04822181"],["1","R0007372","R0007372.pdf","paywalled","randomized_trial","Bliddal H","2024","Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2403664","https://doi.org/10.1056/nejmoa2403664","39476339","https://pubmed.ncbi.nlm.nih.gov/39476339/",null,"ClinicalTrials.gov:NCT05064735"],["1","R0007740","R0007740.pdf","paywalled","randomized_trial","Meissner WG","2024","Trial of Lixisenatide in Early Parkinson's Disease.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2312323","https://doi.org/10.1056/nejmoa2312323","38598572","https://pubmed.ncbi.nlm.nih.gov/38598572/",null,"ClinicalTrials.gov:NCT03439943"],["1","R0010709","R0010709.pdf","paywalled","randomized_trial","Blood AJ","2024","Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.124.069494","https://doi.org/10.1161/circulationaha.124.069494","38583146","https://pubmed.ncbi.nlm.nih.gov/38583146/",null,"ClinicalTrials.gov:NCT06046560"],["1","R0011719","R0011719.pdf","paywalled","randomized_trial","McGarry A","2024","Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.","The Lancet. Neurology","Elsevier BV","10.1016/s1474-4422(23)00378-2","https://doi.org/10.1016/s1474-4422(23)00378-2","38101901","https://pubmed.ncbi.nlm.nih.gov/38101901/",null,"ClinicalTrials.gov:NCT04154072"],["1","R0013333","R0013333.pdf","paywalled","randomized_trial","Patel SA","2024","Letter: GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003205","https://doi.org/10.1227/neu.0000000000003205","39360816","https://pubmed.ncbi.nlm.nih.gov/39360816/",null,"ClinicalTrials.gov:NCT05347147"],["1","R0013517","R0013517.pdf","paywalled","randomized_trial","le Roux CW","2024","Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(23)00356-x","https://doi.org/10.1016/s2213-8587(23)00356-x","38330987","https://pubmed.ncbi.nlm.nih.gov/38330987/",null,"ClinicalTrials.gov:NCT04667377; EudraCT:2020-002479-37"],["1","R0015914","R0015914.pdf","paywalled","randomized_trial","Mu Y","2024","Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(23)00388-1","https://doi.org/10.1016/s2213-8587(23)00388-1","38330988","https://pubmed.ncbi.nlm.nih.gov/38330988/",null,"ClinicalTrials.gov:NCT04251156"],["1","R0017651","R0017651.pdf","paywalled","randomized_trial","Wysham C","2024","Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2403953","https://doi.org/10.1056/nejmoa2403953","39254740","https://pubmed.ncbi.nlm.nih.gov/39254740/",null,"ClinicalTrials.gov:NCT05362058"],["1","R0018381","R0018381.pdf","paywalled","randomized_trial","Loomba R","2024","Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2401943","https://doi.org/10.1056/nejmoa2401943","38856224","https://pubmed.ncbi.nlm.nih.gov/38856224/",null,"ClinicalTrials.gov:NCT04166773"],["1","R0019192","R0019192.pdf","paywalled","randomized_trial","Kosiborod MN","2024","Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)01643-x","https://doi.org/10.1016/s0140-6736(24)01643-x","39222642","https://pubmed.ncbi.nlm.nih.gov/39222642/",null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0019647","R0019647.pdf","paywalled","randomized_trial","Perkovic V","2024","Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2403347","https://doi.org/10.1056/nejmoa2403347","38785209","https://pubmed.ncbi.nlm.nih.gov/38785209/",null,"ClinicalTrials.gov:NCT03819153"],["1","R0019781","R0019781.pdf","paywalled","randomized_trial","McElroy SL","2024","Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.","Journal of clinical psychopharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcp.0000000000001803","https://doi.org/10.1097/jcp.0000000000001803","38227621","https://pubmed.ncbi.nlm.nih.gov/38227621/",null,"ClinicalTrials.gov:NCT03158805"],["1","R0026367","R0026367.pdf","paywalled","randomized_trial","O'Donnell C","2024","Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1513/annalsats.202309-821oc","https://doi.org/10.1513/annalsats.202309-821oc","38096106","https://pubmed.ncbi.nlm.nih.gov/38096106/",null,"ClinicalTrials.gov:NCT04186494"],["1","R0037038","R0037038.pdf","paywalled","randomized_trial","Linong Ji","2024","1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1","Diabetes","American Diabetes Association","10.2337/db24-1857-lb","https://doi.org/10.2337/db24-1857-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05607680"],["1","R0037287","R0037287.pdf","paywalled","randomized_trial","John B. Buse","2024","230-OR: Comparative Effectiveness of Semaglutide in Type 2 Diabetes—Year 2 Results of a Randomized Pragmatic Clinical Trial","Diabetes","American Diabetes Association","10.2337/db24-230-or","https://doi.org/10.2337/db24-230-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03596450"],["1","R0038344","R0038344.pdf","paywalled","randomized_trial","Gianluca Iacobellis","2024","449-P: Liraglutide Rapid Effects on Glucose and Adipose Tissue during and after CABG","Diabetes","American Diabetes Association","10.2337/db24-449-p","https://doi.org/10.2337/db24-449-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03260881"],["1","R0038802","R0038802.pdf","paywalled","randomized_trial","Irene Caballero Mateos","2024","Efficacy of a Digital Educational Intervention for Patients With Type 2 Diabetes Mellitus: Multicenter, Randomized, Prospective, 6-Month Follow-Up Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.60758","https://doi.org/10.2196/preprints.60758",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06850129"],["1","R0039045","R0039045.pdf","paywalled","randomized_trial","Linong Ji","2024","1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)","Diabetes","American Diabetes Association","10.2337/db24-1856-lb","https://doi.org/10.2337/db24-1856-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05607680"],["1","R0039583","R0039583.pdf","paywalled","randomized_trial","HONGWEI JIANG","2024","1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more","Diabetes","American Diabetes Association","10.2337/db24-1866-lb","https://doi.org/10.2337/db24-1866-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04904913"],["1","R0039683","R0039683.pdf","paywalled","randomized_trial","MING LIU","2024","1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db24-1869-lb","https://doi.org/10.2337/db24-1869-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05413369"],["1","R0045727","R0045727.pdf","paywalled","randomized_trial","Lin Liu","2024","733-P: Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db24-733-p","https://doi.org/10.2337/db24-733-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06118008"],["1","R0045830","R0045830.pdf","paywalled","randomized_trial","Yi Wen","2024","Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2862","https://doi.org/10.1093/eurheartj/ehae666.2862",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04867785"],["1","R0048817","R0048817.pdf","paywalled","randomized_trial","Wretlind, Asger","2024","Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","Figshare",null,"10.6084/m9.figshare.c.6853731.v1","https://doi.org/10.6084/m9.figshare.c.6853731.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02545738; ClinicalTrials.gov:NCT03449654"],["1","R0048823","R0048823.pdf","paywalled","randomized_trial","Philip Scheltens","2024","Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000205079","https://doi.org/10.1212/wnl.0000000000205079","39977949","https://pubmed.ncbi.nlm.nih.gov/39977949/",null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0050171","R0050171.pdf","paywalled","randomized_trial","Theresa M. Hunter","2024","1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial","Diabetes","American Diabetes Association","10.2337/db24-1700-p","https://doi.org/10.2337/db24-1700-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04657003"],["1","R0050541","R0050541.pdf","paywalled","randomized_trial","Slobodan I Macura","2024","Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/n0b9-k834","https://doi.org/10.17615/n0b9-k834",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03989232; EudraCT:2018-004529-96"],["1","R0051793","R0051793.pdf","paywalled","randomized_trial","Theresa M. Hunter","2024","1676-P: Tirzepatide Improved Mental and Psychosocial Function in Adults with Obesity or Overweight in the SURMOUNT-3 Trial","Diabetes","American Diabetes Association","10.2337/db24-1676-p","https://doi.org/10.2337/db24-1676-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04657016"],["1","R0008612","R0008612.pdf","paywalled","randomized_trial","Gerstein HC","2023","Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.","Diabetes care","American Diabetes Association","10.2337/dc22-2397","https://doi.org/10.2337/dc22-2397","36897834","https://pubmed.ncbi.nlm.nih.gov/36897834/",null,"ClinicalTrials.gov:NCT01394952"],["1","R0008897","R0008897.pdf","paywalled","randomized_trial","Frias JP","2023","Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(23)01302-8","https://doi.org/10.1016/s0140-6736(23)01302-8","37369232","https://pubmed.ncbi.nlm.nih.gov/37369232/",null,"ClinicalTrials.gov:NCT05048719"],["1","R0009553","R0009553.pdf","paywalled","randomized_trial","Wharton S","2023","Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2302392","https://doi.org/10.1056/nejmoa2302392","37351564","https://pubmed.ncbi.nlm.nih.gov/37351564/",null,"ClinicalTrials.gov:NCT05051579"],["1","R0012625","R0012625.pdf","paywalled","randomized_trial","Rosenstock J","2023","Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(23)01053-x","https://doi.org/10.1016/s0140-6736(23)01053-x","37385280","https://pubmed.ncbi.nlm.nih.gov/37385280/",null,"ClinicalTrials.gov:NCT04867785"],["1","R0015688","R0015688.pdf","paywalled","randomized_trial","Jastreboff AM","2023","Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2301972","https://doi.org/10.1056/nejmoa2301972","37366315","https://pubmed.ncbi.nlm.nih.gov/37366315/",null,"ClinicalTrials.gov:NCT04881760"],["1","R0016435","R0016435.pdf","paywalled","randomized_trial","Knop FK","2023","Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(23)01185-6","https://doi.org/10.1016/s0140-6736(23)01185-6","37385278","https://pubmed.ncbi.nlm.nih.gov/37385278/",null,"ClinicalTrials.gov:NCT05035095"],["1","R0017436","R0017436.pdf","paywalled","randomized_trial","Xu Z","2023","Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2023.2188192","https://doi.org/10.1080/17512433.2023.2188192","36883362","https://pubmed.ncbi.nlm.nih.gov/36883362/",null,"ClinicalTrials.gov:NCT05029076"],["1","R0037265","R0037265.pdf","paywalled","randomized_trial","Juan P. Frías","2023","53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-53-or","https://doi.org/10.2337/db23-53-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04982575"],["1","R0037302","R0037302.pdf","paywalled","randomized_trial","PEGBIO STUDY GROUP","2023","770-P: Efficacy and Safety of Once-Weekly PB-119 Monotherapy vs. Placebo in Chinese Patients with Type 2 Diabetes in a Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db23-770-p","https://doi.org/10.2337/db23-770-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04504370"],["1","R0038398","R0038398.pdf","paywalled","randomized_trial","John B. Buse","2023","776-P: Comparative Effectiveness of SC Semaglutide in Adults with T2D in U.S. Routine Clinical Practice—Year 1 Results of SEPRA, a Randomized Pragmatic Clinical Trial","Diabetes","American Diabetes Association","10.2337/db23-776-p","https://doi.org/10.2337/db23-776-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03596450"],["1","R0038889","R0038889.pdf","paywalled","randomized_trial","Althagafi, Loai K.","2023","MRI Assessment of Subclinical Cardiac Dysfunction and its Association With Ectopic Fat in Adults With Type 2 Diabetes","University of Leicester",null,"10.25392/leicester.data.24441001","https://doi.org/10.25392/leicester.data.24441001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02043054; ClinicalTrials.gov:NCT02590822"],["1","R0046643","R0046643.pdf","paywalled","randomized_trial","QINGHUA WANG","2023","757-P: Efficacy and Safety of Supaglutide Monotherapy in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-757-p","https://doi.org/10.2337/db23-757-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04994288"],["1","R0047550","R0047550.pdf","paywalled","randomized_trial","Carel Wynand le Roux","2023","51-OR: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db23-51-or","https://doi.org/10.2337/db23-51-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04667377"],["1","R0047721","R0047721.pdf","paywalled","randomized_trial","J WU","2023","95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db23-95-lb","https://doi.org/10.2337/db23-95-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05347758"],["1","R0047935","R0047935.pdf","paywalled","randomized_trial","Kun He","2023","763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study","Diabetes","American Diabetes Association","10.2337/db23-763-p","https://doi.org/10.2337/db23-763-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05152277"],["1","R0050781","R0050781.pdf","paywalled","randomized_trial","Cliona O’Donnell","2023","Liraglutide-Based Weight Loss versus CPAP Therapy in improving Sleep Quality and Quality of Life of Patients with Obstructive Sleep Apnoea - an Explorative, Proof of Concept Study",null,"European Respiratory Society","10.1183/23120541.sleepandbreathing-2023.110","https://doi.org/10.1183/23120541.sleepandbreathing-2023.110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04186494"],["1","R0051200","R0051200.pdf","paywalled","randomized_trial","DILBAR ANWAR","2023","778-P: Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-778-p","https://doi.org/10.2337/db23-778-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04998032"],["1","R0051791","R0051791.pdf","paywalled","randomized_trial","N Dyrby Johansen","2023","801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-801-p","https://doi.org/10.2337/db23-801-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03017352"],["1","R0051922","R0051922.pdf","paywalled","randomized_trial","Chantal Mathieu","2023","54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM","Diabetes","American Diabetes Association","10.2337/db23-54-or","https://doi.org/10.2337/db23-54-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04982575"],["1","R0053367","R0053367.pdf","paywalled","randomized_trial","Cliona O’Donnell","2023","The effect of CPAP therapy on coronary artery plaque volume in obstructive sleep apnoea: data from a proof-of-concept study",null,"European Respiratory Society","10.1183/13993003.congress-2023.oa3287","https://doi.org/10.1183/13993003.congress-2023.oa3287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04186494"],["1","R0006153","R0006153.pdf","paywalled","randomized_trial","Ruff CT","2022","Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-021-01584-3","https://doi.org/10.1038/s41591-021-01584-3","34873344","https://pubmed.ncbi.nlm.nih.gov/34873344/",null,"ClinicalTrials.gov:NCT01455896"],["1","R0006810","R0006810.pdf","paywalled","randomized_trial","Kobayati A","2022","Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14637","https://doi.org/10.1111/dom.14637","34989070","https://pubmed.ncbi.nlm.nih.gov/34989070/",null,null],["1","R0010502","R0010502.pdf","paywalled","randomized_trial","Kårhus ML","2022","Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(22)00198-4","https://doi.org/10.1016/s2468-1253(22)00198-4","35868334","https://pubmed.ncbi.nlm.nih.gov/35868334/",null,"EudraCT:2018-003575-34"],["1","R0011324","R0011324.pdf","paywalled","randomized_trial","Gastaldelli A","2022","Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00070-5","https://doi.org/10.1016/s2213-8587(22)00070-5","35468325","https://pubmed.ncbi.nlm.nih.gov/35468325/",null,"ClinicalTrials.gov:NCT03882970"],["1","R0011434","R0011434.pdf","paywalled","randomized_trial","Heise T","2022","Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00085-7","https://doi.org/10.1016/s2213-8587(22)00085-7","35468322","https://pubmed.ncbi.nlm.nih.gov/35468322/",null,"ClinicalTrials.gov:NCT03951753"],["1","R0014993","R0014993.pdf","paywalled","randomized_trial","Urva S","2022","LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(22)02033-5","https://doi.org/10.1016/s0140-6736(22)02033-5","36354040","https://pubmed.ncbi.nlm.nih.gov/36354040/",null,"ClinicalTrials.gov:NCT04143802"],["1","R0018032","R0018032.pdf","paywalled","randomized_trial","Bajaj HS","2022","Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2022.02.003","https://doi.org/10.1016/j.jcjd.2022.02.003","35752566","https://pubmed.ncbi.nlm.nih.gov/35752566/",null,"ClinicalTrials.gov:NCT03819790"],["1","R0018763","R0018763.pdf","paywalled","randomized_trial","Battelino T","2022","Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00077-8","https://doi.org/10.1016/s2213-8587(22)00077-8","35468321","https://pubmed.ncbi.nlm.nih.gov/35468321/",null,"ClinicalTrials.gov:NCT03882970"],["1","R0021744","R0021744.pdf","paywalled","randomized_trial","Xu J","2022","Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-021-01921-5","https://doi.org/10.1007/s12325-021-01921-5","34787823","https://pubmed.ncbi.nlm.nih.gov/34787823/",null,"ClinicalTrials.gov:NCT01667900"],["1","R0022033","R0022033.pdf","paywalled","randomized_trial","Li R","2022","Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.","Archives of gynecology and obstetrics","Springer Science and Business Media LLC","10.1007/s00404-022-06700-3","https://doi.org/10.1007/s00404-022-06700-3","35829765","https://pubmed.ncbi.nlm.nih.gov/35829765/",null,"ChiCTR:ChiCTR-IIR-16008084"],["1","R0022193","R0022193.pdf","paywalled","randomized_trial","Kadowaki T","2022","Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00008-0","https://doi.org/10.1016/s2213-8587(22)00008-0","35131037","https://pubmed.ncbi.nlm.nih.gov/35131037/",null,"ClinicalTrials.gov:NCT03811574"],["1","R0022257","R0022257.pdf","paywalled","randomized_trial","Cohen S","2022","Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-022-01461-4","https://doi.org/10.1007/s11892-022-01461-4","35441935","https://pubmed.ncbi.nlm.nih.gov/35441935/",null,"ClinicalTrials.gov:NCT03819153"],["1","R0022655","R0022655.pdf","paywalled","randomized_trial","Westman K","2022","Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2021.108110","https://doi.org/10.1016/j.jdiacomp.2021.108110","35101325","https://pubmed.ncbi.nlm.nih.gov/35101325/",null,"EudraCT:2012-001941-42"],["1","R0022903","R0022903.pdf","paywalled","randomized_trial","Arendt Nielsen T","2022","Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.","Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","SAGE Publications","10.1089/jop.2021.0055","https://doi.org/10.1089/jop.2021.0055","34918951","https://pubmed.ncbi.nlm.nih.gov/34918951/",null,"ClinicalTrials.gov:NCT02138045"],["1","R0028961","R0028961.pdf","paywalled","randomized_trial","Cheng A","2022","Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m2: A 5-year randomized controlled trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.109900","https://doi.org/10.1016/j.diabres.2022.109900","35513159","https://pubmed.ncbi.nlm.nih.gov/35513159/",null,"ClinicalTrials.gov:NCT02041234"],["1","R0033796","R0033796.pdf","paywalled","randomized_trial","Endocrine Society 2020","2022","Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial","Underline Science Inc.",null,"10.48448/h3pm-va31","https://doi.org/10.48448/h3pm-va31",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02918279"],["1","R0046344","R0046344.pdf","paywalled","randomized_trial","Charles Benson","2022","333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db22-333-or","https://doi.org/10.2337/db22-333-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03325387; ClinicalTrials.gov:NCT03928379"],["1","R0046797","R0046797.pdf","paywalled","randomized_trial","YIFAN HE","2022","850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial","Diabetes","American Diabetes Association","10.2337/db22-850-p","https://doi.org/10.2337/db22-850-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03798054"],["1","R0046954","R0046954.pdf","paywalled","randomized_trial","Thomas Fremming Dejgaard","2022","734-P: The Effect of Adjunctive Therapy with Liraglutide on Insulin Sensitivity in Overweight Persons with Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-734-p","https://doi.org/10.2337/db22-734-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01612468"],["1","R0048082","R0048082.pdf","paywalled","randomized_trial","Colm P. O’Donnell","2022","The effect of CPAP therapy on aortic inflammation in obstructive sleep apnoea: data from a proof-of-concept PET-CT study","04.02 - Clinical and epidemiological respiratory sleep medicine","European Respiratory Society","10.1183/13993003.congress-2022.2126","https://doi.org/10.1183/13993003.congress-2022.2126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04186494"],["1","R0048974","R0048974.pdf","paywalled","randomized_trial","Jeffrey L. Cummings","2022","Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo","Alzheimer s & Dementia","Wiley","10.1002/alz.062382","https://doi.org/10.1002/alz.062382",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0049133","R0049133.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2022","The Effect of Semaglutide on Kidney Function: Post Hoc Analysis of Three Randomized Controlled Trials in Non-Alcoholic Fatty Liver Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1850a","https://doi.org/10.1681/asn.20223311s1850a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03357380; ClinicalTrials.gov:NCT02970942; ClinicalTrials.gov:NCT03987451"],["1","R0052456","R0052456.pdf","paywalled","randomized_trial","Vlado Perkovic","2022","FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac126.002","https://doi.org/10.1093/ndt/gfac126.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["1","R0053166","R0053166.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2022","MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A Post Hoc Analysis of the Sustain 6 Trial","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac070.076","https://doi.org/10.1093/ndt/gfac070.076",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446"],["1","R0053199","R0053199.pdf","paywalled","randomized_trial","N Dyrby Johansen","2022","745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-745-p","https://doi.org/10.2337/db22-745-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03017352"],["1","R0053617","R0053617.pdf","paywalled","randomized_trial","Alireza Atri","2022","evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease","Alzheimer s & Dementia","Wiley","10.1002/alz.062415","https://doi.org/10.1002/alz.062415",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0054682","R0054682.pdf","paywalled","randomized_trial","Richard E. Pratley","2022","747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial","Diabetes","American Diabetes Association","10.2337/db22-747-p","https://doi.org/10.2337/db22-747-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["1","R0055527","R0055527.pdf","paywalled","randomized_trial","EDWARD J. PRATT","2022","336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db22-336-or","https://doi.org/10.2337/db22-336-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03929744"],["1","R0009376","R0009376.pdf","paywalled","randomized_trial","Saxena AR","2021","Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-021-01391-w","https://doi.org/10.1038/s41591-021-01391-w","34127852","https://pubmed.ncbi.nlm.nih.gov/34127852/",null,"ClinicalTrials.gov:NCT03538743"],["1","R0014308","R0014308.pdf","paywalled","randomized_trial","Paneni F","2021","Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab636","https://doi.org/10.1093/eurheartj/ehab636","34724707","https://pubmed.ncbi.nlm.nih.gov/34724707/",null,"ClinicalTrials.gov:NCT04255433"],["1","R0014843","R0014843.pdf","paywalled","randomized_trial","Enebo LB","2021","Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)00845-x","https://doi.org/10.1016/s0140-6736(21)00845-x","33894838","https://pubmed.ncbi.nlm.nih.gov/33894838/",null,"ClinicalTrials.gov:NCT03600480"],["1","R0016044","R0016044.pdf","paywalled","randomized_trial","Rosenstock J","2021","Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)01324-6","https://doi.org/10.1016/s0140-6736(21)01324-6","34186022","https://pubmed.ncbi.nlm.nih.gov/34186022/",null,"ClinicalTrials.gov:NCT03954834"],["1","R0017801","R0017801.pdf","paywalled","randomized_trial","Ludvik B","2021","Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)01443-4","https://doi.org/10.1016/s0140-6736(21)01443-4","34370970","https://pubmed.ncbi.nlm.nih.gov/34370970/",null,"ClinicalTrials.gov:NCT03882970"],["1","R0019366","R0019366.pdf","paywalled","randomized_trial","Del Prato S","2021","Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)02188-7","https://doi.org/10.1016/s0140-6736(21)02188-7","34672967","https://pubmed.ncbi.nlm.nih.gov/34672967/",null,"ClinicalTrials.gov:NCT03730662"],["1","R0022738","R0022738.pdf","paywalled","randomized_trial","Frías JP","2021","Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(21)00174-1","https://doi.org/10.1016/s2213-8587(21)00174-1","34293304","https://pubmed.ncbi.nlm.nih.gov/34293304/",null,"ClinicalTrials.gov:NCT03989232; EudraCT:2018-004529-96"],["1","R0023248","R0023248.pdf","paywalled","randomized_trial","Neeland IJ","2021","Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(21)00179-0","https://doi.org/10.1016/s2213-8587(21)00179-0","34358471","https://pubmed.ncbi.nlm.nih.gov/34358471/",null,"ClinicalTrials.gov:NCT03038620"],["1","R0024162","R0024162.pdf","paywalled","randomized_trial","Thakur U","2021","Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-020-04850-4","https://doi.org/10.1007/s11695-020-04850-4","32656729","https://pubmed.ncbi.nlm.nih.gov/32656729/",null,null],["1","R0031571","R0031571.pdf","paywalled","randomized_trial","Domenica Rubino","2021","84-OR: Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Diabetes","American Diabetes Association","10.2337/db21-84-or","https://doi.org/10.2337/db21-84-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03552757"],["1","R0032050","R0032050.pdf","paywalled","randomized_trial","Sean Wharton","2021","85-OR: Semaglutide 2.4 mg Improves Patient Reported Outcome Measures of Physical Functioning in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Diabetes","American Diabetes Association","10.2337/db21-85-or","https://doi.org/10.2337/db21-85-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03552757"],["1","R0033659","R0033659.pdf","paywalled","randomized_trial","Endocrine Society 2021","2021","Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)","Underline Science Inc.",null,"10.48448/egbg-am77","https://doi.org/10.48448/egbg-am77",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03548987"],["1","R0042347","R0042347.pdf","paywalled","randomized_trial","GR Dagenais","2021","Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","Figshare",null,"10.26181/5ffbea8a7ffa7","https://doi.org/10.26181/5ffbea8a7ffa7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01394952"],["1","R0046904","R0046904.pdf","paywalled","randomized_trial","Thomas Fremming Dejgaard","2021","675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two","Diabetes","American Diabetes Association","10.2337/db21-675-p","https://doi.org/10.2337/db21-675-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01836523; ClinicalTrials.gov:NCT02098395"],["1","R0050257","R0050257.pdf","paywalled","randomized_trial","Julio Rosenstock","2021","670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial","Diabetes","American Diabetes Association","10.2337/db21-670-p","https://doi.org/10.2337/db21-670-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02863328"],["1","R0050369","R0050369.pdf","paywalled","randomized_trial","Victoria Parker","2021","674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD","Diabetes","American Diabetes Association","10.2337/db21-674-p","https://doi.org/10.2337/db21-674-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03550378"],["1","R0050403","R0050403.pdf","paywalled","randomized_trial","Juan P. Frías","2021","101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db21-101-or","https://doi.org/10.2337/db21-101-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03989232"],["1","R0050908","R0050908.pdf","paywalled","randomized_trial","IRENE M. HRAMIAK","2021","95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada","Diabetes","American Diabetes Association","10.2337/db21-95-lb","https://doi.org/10.2337/db21-95-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03767543"],["1","R0052083","R0052083.pdf","paywalled","randomized_trial","Paul Edison","2021","Evaluation of liraglutide in the treatment of Alzheimer's disease","Alzheimer s & Dementia","Wiley","10.1002/alz.057848","https://doi.org/10.1002/alz.057848",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01843075"],["1","R0053391","R0053391.pdf","paywalled","randomized_trial","Ildiko Lingvay","2021","83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)","Diabetes","American Diabetes Association","10.2337/db21-83-or","https://doi.org/10.2337/db21-83-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03552757"],["1","R0007630","R0007630.pdf","paywalled","randomized_trial","Terauchi Y","2020","Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14036","https://doi.org/10.1111/dom.14036","32291880","https://pubmed.ncbi.nlm.nih.gov/32291880/",null,"ClinicalTrials.gov:NCT02752828"],["1","R0010730","R0010730.pdf","paywalled","randomized_trial","Bergmann NC","2020","No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc19-0578","https://doi.org/10.2337/dc19-0578","31949084","https://pubmed.ncbi.nlm.nih.gov/31949084/",null,"ClinicalTrials.gov:NCT03526289"],["1","R0012616","R0012616.pdf","paywalled","randomized_trial","Dejgaard TF","2020","Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13911","https://doi.org/10.1111/dom.13911","31696598","https://pubmed.ncbi.nlm.nih.gov/31696598/",null,null],["1","R0012880","R0012880.pdf","paywalled","randomized_trial","Kaneto H","2020","Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14005","https://doi.org/10.1111/dom.14005","32072742","https://pubmed.ncbi.nlm.nih.gov/32072742/",null,"ClinicalTrials.gov:NCT02752412"],["1","R0015226","R0015226.pdf","paywalled","randomized_trial","Johansen NJ","2020","Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(20)30030-9","https://doi.org/10.1016/s2213-8587(20)30030-9","32135138","https://pubmed.ncbi.nlm.nih.gov/32135138/",null,"ClinicalTrials.gov:NCT03017352"],["1","R0018421","R0018421.pdf","paywalled","randomized_trial","Yabe D","2020","Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(20)30074-7","https://doi.org/10.1016/s2213-8587(20)30074-7","32333876","https://pubmed.ncbi.nlm.nih.gov/32333876/",null,"ClinicalTrials.gov:NCT03015220"],["1","R0019465","R0019465.pdf","paywalled","randomized_trial","Capehorn MS","2020","Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2019.101117","https://doi.org/10.1016/j.diabet.2019.101117","31539622","https://pubmed.ncbi.nlm.nih.gov/31539622/",null,null],["1","R0019611","R0019611.pdf","paywalled","randomized_trial","Da Porto A","2020","Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2020.03.009","https://doi.org/10.1016/j.dsx.2020.03.009","32289741","https://pubmed.ncbi.nlm.nih.gov/32289741/",null,null],["1","R0020707","R0020707.pdf","paywalled","randomized_trial","van Eyk HJ","2020","Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2019.12.005","https://doi.org/10.1016/j.numecd.2019.12.005","32127340","https://pubmed.ncbi.nlm.nih.gov/32127340/",null,"ClinicalTrials.gov:NCT01761318"],["1","R0020854","R0020854.pdf","paywalled","randomized_trial","Elkind-Hirsch KE","2020","Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107548","https://doi.org/10.1016/j.jdiacomp.2020.107548","32046931","https://pubmed.ncbi.nlm.nih.gov/32046931/",null,"ClinicalTrials.gov:NCT01234649"],["1","R0029871","R0029871.pdf","paywalled","randomized_trial","Visentin R","2020","Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13939","https://doi.org/10.1111/dom.13939","31808298","https://pubmed.ncbi.nlm.nih.gov/31808298/",null,"ClinicalTrials.gov:NCT02411825"],["1","R0037754","R0037754.pdf","paywalled","randomized_trial","Ofri Mosenzon","2020","956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin","Diabetes","American Diabetes Association","10.2337/db20-956-p","https://doi.org/10.2337/db20-956-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03021187"],["1","R0038091","R0038091.pdf","paywalled","randomized_trial","Seino, Yutaka","2020","A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus","Figshare",null,"10.6084/m9.figshare.11830233","https://doi.org/10.6084/m9.figshare.11830233",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01098461"],["1","R0039753","R0039753.pdf","paywalled","randomized_trial","Min Xu","2020","945-P: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of 12 Once-Weekly Subcutaneous Doses of PB-119 to Patients with Type 2 Diabetes Mellitus as Monotherapy","Diabetes","American Diabetes Association","10.2337/db20-945-p","https://doi.org/10.2337/db20-945-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03520972"],["1","R0043256","R0043256.pdf","paywalled","randomized_trial","R.A. Patel","2020","Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/mtwd-4906","https://doi.org/10.17615/mtwd-4906",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01144338"],["1","R0043331","R0043331.pdf","paywalled","randomized_trial","N. Iqbal","2020","Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/wt81-5t92","https://doi.org/10.17615/wt81-5t92",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01144338"],["1","R0043360","R0043360.pdf","paywalled","randomized_trial","M.A. Nauck","2020","Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: Results from the LEADER randomized trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/t29z-8831","https://doi.org/10.17615/t29z-8831",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0043973","R0043973.pdf","paywalled","randomized_trial","B. Zinman","2020","Hypoglycemia, cardiovascular outcomes, and death: The LEADER experience","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/k65w-3s34","https://doi.org/10.17615/k65w-3s34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0044861","R0044861.pdf","paywalled","randomized_trial","R. Simpson","2020","The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/64ky-dq52","https://doi.org/10.17615/64ky-dq52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0045841","R0045841.pdf","paywalled","randomized_trial","Aixin Shi","2020","941-P: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects","Diabetes","American Diabetes Association","10.2337/db20-941-p","https://doi.org/10.2337/db20-941-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03288740"],["1","R0046810","R0046810.pdf","paywalled","randomized_trial","J.C. LaRocque","2020","Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/sf7g-9004","https://doi.org/10.17615/sf7g-9004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02849080; EudraCT:2015-005593-38"],["1","R0047322","R0047322.pdf","paywalled","randomized_trial","Maria Sejersten Ripa","2020","Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ae5y-tp29","https://doi.org/10.17615/ae5y-tp29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446"],["1","R0048083","R0048083.pdf","paywalled","randomized_trial","Jan Westerink","2020","Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3069","https://doi.org/10.1093/ehjci/ehaa946.3069",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["1","R0048295","R0048295.pdf","paywalled","randomized_trial","Julie Rehné Lundgren","2020","2028-P: Adding Exercise to Liraglutide Treatment in Weight Loss Maintenance Abolishes the Increase in Heart Rate Seen with Liraglutide Alone: The S-LITE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db20-2028-p","https://doi.org/10.2337/db20-2028-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04122716"],["1","R0049018","R0049018.pdf","paywalled","randomized_trial","Subodh Verma","2020","Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.13814","https://doi.org/10.1161/circ.142.suppl_3.13814",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["1","R0049463","R0049463.pdf","paywalled","randomized_trial","Jeff Unger","2020","922-P: LIRA-PRIME: A Randomized Trial in Primary Care Settings of Liraglutide vs. OAD for Glycemic Control in Patients with Type 2 Diabetes Not in Control on Metformin","Diabetes","American Diabetes Association","10.2337/db20-922-p","https://doi.org/10.2337/db20-922-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02730377"],["1","R0049649","R0049649.pdf","paywalled","randomized_trial","Emilie H. Zobel","2020","The Importance of Addressing Multiple Risk Markers in Type 2 Diabetes: Results from the LEADER Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1337c","https://doi.org/10.1681/asn.20203110s1337c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0049975","R0049975.pdf","paywalled","randomized_trial","Julio Rosenstock","2020","88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting","Diabetes","American Diabetes Association","10.2337/db20-88-lb","https://doi.org/10.2337/db20-88-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02787551"],["1","R0050069","R0050069.pdf","paywalled","randomized_trial","Jonathan Matthew Wilson","2020","Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.13426","https://doi.org/10.1161/circ.142.suppl_3.13426",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04255433"],["1","R0050083","R0050083.pdf","paywalled","randomized_trial","Matthias G. von Herrath","2020","278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-278-or","https://doi.org/10.2337/db20-278-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02443155"],["1","R0050170","R0050170.pdf","paywalled","randomized_trial","Charlotte Janus","2020","1974-P: Diet-Induced Weight Loss Improves Sleep Quality and These Improvements Are Sustained with One Year of Weight Maintenance with Exercise: The S-LITE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db20-1974-p","https://doi.org/10.2337/db20-1974-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04122716"],["1","R0050381","R0050381.pdf","paywalled","randomized_trial","John B. Buse","2020","Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ap66-xf68","https://doi.org/10.17615/ap66-xf68",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01952145"],["1","R0050869","R0050869.pdf","paywalled","randomized_trial","Richard E. Pratley","2020","927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4","Diabetes","American Diabetes Association","10.2337/db20-927-p","https://doi.org/10.2337/db20-927-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02863419"],["1","R0052101","R0052101.pdf","paywalled","randomized_trial","Aiden R. Liu","2020","1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada","Diabetes","American Diabetes Association","10.2337/db20-1163-p","https://doi.org/10.2337/db20-1163-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02863328"],["1","R0007263","R0007263.pdf","paywalled","randomized_trial","Blonde L","2019","Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc19-1357","https://doi.org/10.2337/dc19-1357","31530665","https://pubmed.ncbi.nlm.nih.gov/31530665/",null,"ClinicalTrials.gov:NCT02787551"],["1","R0007277","R0007277.pdf","paywalled","randomized_trial","Mora PF","2019","EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0615","https://doi.org/10.4158/ep-2018-0615","31241362","https://pubmed.ncbi.nlm.nih.gov/31241362/",null,"ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147"],["1","R0007584","R0007584.pdf","paywalled","randomized_trial","Lingvay I","2019","EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0284","https://doi.org/10.4158/ep-2018-0284","30383495","https://pubmed.ncbi.nlm.nih.gov/30383495/",null,null],["1","R0009458","R0009458.pdf","paywalled","randomized_trial","Rosenstock J","2019","Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.","Diabetes care","American Diabetes Association","10.2337/dc18-2648","https://doi.org/10.2337/dc18-2648","31320446","https://pubmed.ncbi.nlm.nih.gov/31320446/",null,"ClinicalTrials.gov:NCT02057172"],["1","R0015836","R0015836.pdf","paywalled","randomized_trial","Pratley R","2019","Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(19)31271-1","https://doi.org/10.1016/s0140-6736(19)31271-1","31186120","https://pubmed.ncbi.nlm.nih.gov/31186120/",null,"ClinicalTrials.gov:NCT02863419; EudraCT:2015-005210-30"],["1","R0020457","R0020457.pdf","paywalled","randomized_trial","Zinman B","2019","Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30066-x","https://doi.org/10.1016/s2213-8587(19)30066-x","30833170","https://pubmed.ncbi.nlm.nih.gov/30833170/",null,"ClinicalTrials.gov:NCT03086330"],["1","R0020820","R0020820.pdf","paywalled","randomized_trial","Aroda VR","2019","Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30184-6","https://doi.org/10.1016/s2213-8587(19)30184-6","31189519","https://pubmed.ncbi.nlm.nih.gov/31189519/",null,"ClinicalTrials.gov:NCT02501161"],["1","R0021443","R0021443.pdf","paywalled","randomized_trial","Nielsen R","2019","Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","Elsevier BV","10.1007/s12350-017-1000-2","https://doi.org/10.1007/s12350-017-1000-2","28770459","https://pubmed.ncbi.nlm.nih.gov/28770459/",null,"ClinicalTrials.gov:NCT01472640"],["1","R0022858","R0022858.pdf","paywalled","randomized_trial","Shaddinger BC","2019","Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.04.018","https://doi.org/10.1016/j.diabres.2019.04.018","31004676","https://pubmed.ncbi.nlm.nih.gov/31004676/",null,null],["1","R0023629","R0023629.pdf","paywalled","randomized_trial","Shaddinger BC","2019","A Randomized, Double-Blind, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.606","https://doi.org/10.1002/cpdd.606","30063297","https://pubmed.ncbi.nlm.nih.gov/30063297/",null,"ClinicalTrials.gov:NCT02660736"],["1","R0025321","R0025321.pdf","paywalled","randomized_trial","Tillner J","2019","A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13494","https://doi.org/10.1111/dom.13494","30091218","https://pubmed.ncbi.nlm.nih.gov/30091218/",null,"ClinicalTrials.gov:NCT02411825"],["1","R0025415","R0025415.pdf","paywalled","randomized_trial","Gilbert MP","2019","Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.","Annals of internal medicine","American College of Physicians","10.7326/m18-1569","https://doi.org/10.7326/m18-1569","30508430","https://pubmed.ncbi.nlm.nih.gov/30508430/",null,null],["1","R0038364","R0038364.pdf","paywalled","randomized_trial","Martin Haluzı́k","2019","146-OR: Differences in HbA1c-Lowering Effect and Hypoglycemia Risk between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial","Diabetes","American Diabetes Association","10.2337/db19-146-or","https://doi.org/10.2337/db19-146-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02738151"],["1","R0039599","R0039599.pdf","paywalled","randomized_trial","Yongquan Shi","2019","2313-PUB: Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients","Diabetes","American Diabetes Association","10.2337/db19-2313-pub","https://doi.org/10.2337/db19-2313-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01644500; ClinicalTrials.gov:NCT01648582"],["1","R0045427","R0045427.pdf","paywalled","randomized_trial","Julio Rosenstock","2019","1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial","Diabetes","American Diabetes Association","10.2337/db19-1146-p","https://doi.org/10.2337/db19-1146-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02787551"],["1","R0045794","R0045794.pdf","paywalled","randomized_trial","Stefano Del Prato","2019","1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)","Diabetes","American Diabetes Association","10.2337/db19-1139-p","https://doi.org/10.2337/db19-1139-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02787551"],["1","R0046862","R0046862.pdf","paywalled","randomized_trial","Lawrence Blonde","2019","149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)","Diabetes","American Diabetes Association","10.2337/db19-149-or","https://doi.org/10.2337/db19-149-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02787551"],["1","R0048616","R0048616.pdf","paywalled","randomized_trial","Bernard Zinman","2019","985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8","Diabetes","American Diabetes Association","10.2337/db19-985-p","https://doi.org/10.2337/db19-985-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03021187"],["1","R0048676","R0048676.pdf","paywalled","randomized_trial","Richard E. Pratley","2019","55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4","Diabetes","American Diabetes Association","10.2337/db19-55-or","https://doi.org/10.2337/db19-55-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02863419"],["1","R0050695","R0050695.pdf","paywalled","randomized_trial","John B. Buse","2019","983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7","Diabetes","American Diabetes Association","10.2337/db19-983-p","https://doi.org/10.2337/db19-983-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02849080"],["1","R0050846","R0050846.pdf","paywalled","randomized_trial","Eduard Montanya","2019","54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2","Diabetes","American Diabetes Association","10.2337/db19-54-or","https://doi.org/10.2337/db19-54-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02863328"],["1","R0051874","R0051874.pdf","paywalled","randomized_trial","Hirotaka Watada","2019","148-OR: IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy","Diabetes","American Diabetes Association","10.2337/db19-148-or","https://doi.org/10.2337/db19-148-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02911948"],["1","R0052839","R0052839.pdf","paywalled","randomized_trial","Olga Lavrynenko","2019","1047 Changes in Liver Fibrosis Scores in Patients With New Onset Type 2 Diabetes on Triple Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Year Two Results","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000593724.46248.7e","https://doi.org/10.14309/01.ajg.0000593724.46248.7e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01107717"],["1","R0054288","R0054288.pdf","paywalled","randomized_trial","Ofri Mosenzon","2019","1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5","Diabetes","American Diabetes Association","10.2337/db19-1004-p","https://doi.org/10.2337/db19-1004-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02827708"],["1","R0011685","R0011685.pdf","paywalled","randomized_trial","McElroy SL","2018","Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature.","Medical hypotheses","Elsevier BV","10.1016/j.mehy.2017.12.029","https://doi.org/10.1016/j.mehy.2017.12.029","29407005","https://pubmed.ncbi.nlm.nih.gov/29407005/",null,null],["1","R0014565","R0014565.pdf","paywalled","randomized_trial","Pratley RE","2018","Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(18)30024-x","https://doi.org/10.1016/s2213-8587(18)30024-x","29397376","https://pubmed.ncbi.nlm.nih.gov/29397376/",null,"ClinicalTrials.gov:NCT02648204"],["1","R0014618","R0014618.pdf","paywalled","randomized_trial","Hvistendahl M","2018","Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study.","JPEN. Journal of parenteral and enteral nutrition","Wiley","10.1177/0148607116672265","https://doi.org/10.1177/0148607116672265","27875281","https://pubmed.ncbi.nlm.nih.gov/27875281/",null,"EudraCT:2013-005499-16"],["1","R0016210","R0016210.pdf","paywalled","randomized_trial","Muskiet MHA","2018","Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(18)30268-7","https://doi.org/10.1016/s2213-8587(18)30268-7","30292589","https://pubmed.ncbi.nlm.nih.gov/30292589/",null,"ClinicalTrials.gov:NCT01147250"],["1","R0016215","R0016215.pdf","paywalled","randomized_trial","Frias JP","2018","Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(18)32260-8","https://doi.org/10.1016/s0140-6736(18)32260-8","30293770","https://pubmed.ncbi.nlm.nih.gov/30293770/",null,"ClinicalTrials.gov:NCT03131687"],["1","R0016247","R0016247.pdf","paywalled","randomized_trial","Wiberg S","2018","The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest.","Critical care medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/ccm.0000000000002814","https://doi.org/10.1097/ccm.0000000000002814","29189347","https://pubmed.ncbi.nlm.nih.gov/29189347/",null,"ClinicalTrials.gov:NCT02442791"],["1","R0017387","R0017387.pdf","paywalled","randomized_trial","Tuttle KR","2018","Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(18)30104-9","https://doi.org/10.1016/s2213-8587(18)30104-9","29910024","https://pubmed.ncbi.nlm.nih.gov/29910024/",null,"ClinicalTrials.gov:NCT01621178"],["1","R0018235","R0018235.pdf","paywalled","randomized_trial","O'Neil PM","2018","Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(18)31773-2","https://doi.org/10.1016/s0140-6736(18)31773-2","30122305","https://pubmed.ncbi.nlm.nih.gov/30122305/",null,"ClinicalTrials.gov:NCT02453711; ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987"],["1","R0020627","R0020627.pdf","paywalled","randomized_trial","Lingvay I","2018","A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.","Diabetes care","American Diabetes Association","10.2337/dc17-2381","https://doi.org/10.2337/dc17-2381","30026333","https://pubmed.ncbi.nlm.nih.gov/30026333/",null,"ClinicalTrials.gov:NCT02461589"],["1","R0020680","R0020680.pdf","paywalled","randomized_trial","Ahmann AJ","2018","Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc17-0417","https://doi.org/10.2337/dc17-0417","29246950","https://pubmed.ncbi.nlm.nih.gov/29246950/",null,"ClinicalTrials.gov:NCT01885208"],["1","R0021336","R0021336.pdf","paywalled","randomized_trial","Verma S","2018","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.034516","https://doi.org/10.1161/circulationaha.118.034516","30566004","https://pubmed.ncbi.nlm.nih.gov/30566004/",null,"ClinicalTrials.gov:NCT01179048"],["1","R0021441","R0021441.pdf","paywalled","randomized_trial","Frøssing S","2018","Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13053","https://doi.org/10.1111/dom.13053","28681988","https://pubmed.ncbi.nlm.nih.gov/28681988/",null,"ClinicalTrials.gov:NCT02073929"],["1","R0022760","R0022760.pdf","paywalled","randomized_trial","Ambery P","2018","MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(18)30726-8","https://doi.org/10.1016/s0140-6736(18)30726-8","29945727","https://pubmed.ncbi.nlm.nih.gov/29945727/",null,"ClinicalTrials.gov:NCT02548585"],["1","R0025252","R0025252.pdf","paywalled","randomized_trial","Jendle J","2018","Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.","Journal of the American Society of Hypertension : JASH","Elsevier BV","10.1016/j.jash.2018.02.003","https://doi.org/10.1016/j.jash.2018.02.003","29548934","https://pubmed.ncbi.nlm.nih.gov/29548934/",null,"ClinicalTrials.gov:NCT01425580"],["1","R0025536","R0025536.pdf","paywalled","randomized_trial","Dubé MC","2018","Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13063","https://doi.org/10.1111/dom.13063","28722271","https://pubmed.ncbi.nlm.nih.gov/28722271/",null,"ClinicalTrials.gov:NCT01787916"],["1","R0025861","R0025861.pdf","paywalled","randomized_trial","Salamun V","2018","Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-18-0175","https://doi.org/10.1530/eje-18-0175","29703793","https://pubmed.ncbi.nlm.nih.gov/29703793/",null,null],["1","R0038087","R0038087.pdf","paywalled","randomized_trial","Piya Sen Gupta","2018","Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1250-p","https://doi.org/10.2337/db18-1250-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ISRCTN:ISRCTN00151053"],["1","R0048008","R0048008.pdf","paywalled","randomized_trial","Britta Goebel","2018","Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-72-or","https://doi.org/10.2337/db18-72-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02411825"],["1","R0048720","R0048720.pdf","paywalled","randomized_trial","Ronan Roussel","2018","Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study","Diabetes","American Diabetes Association","10.2337/db18-1029-p","https://doi.org/10.2337/db18-1029-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02738151"],["1","R0048994","R0048994.pdf","paywalled","randomized_trial","Phil Ambery","2018","Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1067-p","https://doi.org/10.2337/db18-1067-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02548585"],["1","R0049483","R0049483.pdf","paywalled","randomized_trial","Mansoor Husain","2018","P2518Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p2518","https://doi.org/10.1093/eurheartj/ehy565.p2518",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0049824","R0049824.pdf","paywalled","randomized_trial","CORNELIS TACK","2018","Liraglutide Effects in Insulin-Treated Patients in LEADER","Diabetes","American Diabetes Association","10.2337/db18-438-p","https://doi.org/10.2337/db18-438-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["1","R0051324","R0051324.pdf","paywalled","randomized_trial","ALICE Y.Y. CHENG","2018","Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study","Diabetes","American Diabetes Association","10.2337/db18-301-or","https://doi.org/10.2337/db18-301-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02738151"],["1","R0052642","R0052642.pdf","paywalled","randomized_trial","Geremia B. Bolli","2018","Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study","Diabetes","American Diabetes Association","10.2337/db18-1032-p","https://doi.org/10.2337/db18-1032-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02738151"],["1","R0052736","R0052736.pdf","paywalled","randomized_trial","Jeff Unger","2018","LIRA-PRIME Trial Design and Baseline Data—Efficacy in Controlling Glycemia with Liraglutide in a Primary Care Setting","Diabetes","American Diabetes Association","10.2337/db18-1082-p","https://doi.org/10.2337/db18-1082-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02730377"],["1","R0053009","R0053009.pdf","paywalled","randomized_trial","Darren C. Robertson","2018","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study","Diabetes","American Diabetes Association","10.2337/db18-1070-p","https://doi.org/10.2337/db18-1070-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02548585"],["1","R0053354","R0053354.pdf","paywalled","randomized_trial","Meena Jain","2018","MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db18-78-or","https://doi.org/10.2337/db18-78-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02548585"],["1","R0054967","R0054967.pdf","paywalled","randomized_trial","Serge A Jabbour","2018","DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone","Diabetes","American Diabetes Association","10.2337/db18-104-lb","https://doi.org/10.2337/db18-104-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02229396"],["1","R0055149","R0055149.pdf","paywalled","randomized_trial","Vanita R. Aroda","2018","Effect and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes—PIONEER 1 Trial","Diabetes","American Diabetes Association","10.2337/db18-2-lb","https://doi.org/10.2337/db18-2-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02906930"],["1","R0010620","R0010620.pdf","paywalled","randomized_trial","Ishøy PL","2017","No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.","Acta psychiatrica Scandinavica","Wiley","10.1111/acps.12711","https://doi.org/10.1111/acps.12711","28260235","https://pubmed.ncbi.nlm.nih.gov/28260235/",null,"ClinicalTrials.gov:NCT01794429"],["1","R0011151","R0011151.pdf","paywalled","randomized_trial","Wang Y","2017","Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-017-0569-1","https://doi.org/10.1007/s40261-017-0569-1","28932995","https://pubmed.ncbi.nlm.nih.gov/28932995/",null,"ClinicalTrials.gov:NCT01342042"],["1","R0011803","R0011803.pdf","paywalled","randomized_trial","Kumarathurai P","2017","Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000001275","https://doi.org/10.1097/hjh.0000000000001275","28129251","https://pubmed.ncbi.nlm.nih.gov/28129251/",null,"ClinicalTrials.gov:NCT01595789"],["1","R0013296","R0013296.pdf","paywalled","randomized_trial","Shaddinger BC","2017","Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.","Journal of clinical pharmacology","Wiley","10.1002/jcph.940","https://doi.org/10.1002/jcph.940","28543352","https://pubmed.ncbi.nlm.nih.gov/28543352/",null,"ClinicalTrials.gov:NCT02496221"],["1","R0014141","R0014141.pdf","paywalled","randomized_trial","Home PD","2017","Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.06.013","https://doi.org/10.1016/j.diabres.2017.06.013","28683300","https://pubmed.ncbi.nlm.nih.gov/28683300/",null,"ClinicalTrials.gov:NCT00849056; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838903; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527"],["1","R0020247","R0020247.pdf","paywalled","randomized_trial","Pastel E","2017","GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.","Clinical science (London, England : 1979)","Portland Press Ltd.","10.1042/cs20160803","https://doi.org/10.1042/cs20160803","28049736","https://pubmed.ncbi.nlm.nih.gov/28049736/",null,null],["1","R0021319","R0021319.pdf","paywalled","randomized_trial","Okuda I","2017","Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2016.1261817","https://doi.org/10.1080/03007995.2016.1261817","27852119","https://pubmed.ncbi.nlm.nih.gov/27852119/",null,"ClinicalTrials.gov:NCT01777282"],["1","R0021907","R0021907.pdf","paywalled","randomized_trial","Ahrén B","2017","Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(17)30092-x","https://doi.org/10.1016/s2213-8587(17)30092-x","28385659","https://pubmed.ncbi.nlm.nih.gov/28385659/",null,"ClinicalTrials.gov:NCT01930188"],["1","R0022992","R0022992.pdf","paywalled","randomized_trial","Halawi H","2017","Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(17)30285-6","https://doi.org/10.1016/s2468-1253(17)30285-6","28958851","https://pubmed.ncbi.nlm.nih.gov/28958851/",null,"ClinicalTrials.gov:NCT02647944"],["1","R0023234","R0023234.pdf","paywalled","randomized_trial","von Scholten BJ","2017","The effect of liraglutide on renal function: A randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12808","https://doi.org/10.1111/dom.12808","27753201","https://pubmed.ncbi.nlm.nih.gov/27753201/",null,"ClinicalTrials.gov:NCT02545738"],["1","R0024316","R0024316.pdf","paywalled","randomized_trial","Macut D","2017","Insulin and the polycystic ovary syndrome.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.06.011","https://doi.org/10.1016/j.diabres.2017.06.011","28646699","https://pubmed.ncbi.nlm.nih.gov/28646699/",null,null],["1","R0024428","R0024428.pdf","paywalled","randomized_trial","Meneilly GS","2017","Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-2143","https://doi.org/10.2337/dc16-2143","28188240","https://pubmed.ncbi.nlm.nih.gov/28188240/",null,"ClinicalTrials.gov:NCT01798706"],["1","R0024710","R0024710.pdf","paywalled","randomized_trial","Yu M","2017","Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2017.10.002","https://doi.org/10.1016/j.clinthera.2017.10.002","29110972","https://pubmed.ncbi.nlm.nih.gov/29110972/",null,"ClinicalTrials.gov:NCT02152371"],["1","R0025781","R0025781.pdf","paywalled","randomized_trial","le Roux CW","2017","3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(17)30069-7","https://doi.org/10.1016/s0140-6736(17)30069-7","28237263","https://pubmed.ncbi.nlm.nih.gov/28237263/",null,"ClinicalTrials.gov:NCT01272219"],["1","R0025797","R0025797.pdf","paywalled","randomized_trial","von Scholten BJ","2017","Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2017.04.003","https://doi.org/10.1016/j.jdiacomp.2017.04.003","28462892","https://pubmed.ncbi.nlm.nih.gov/28462892/",null,"ClinicalTrials.gov:NCT01272219; ClinicalTrials.gov:NCT01272232"],["1","R0025976","R0025976.pdf","paywalled","randomized_trial","Bays H","2017","Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2016.1251892","https://doi.org/10.1080/03007995.2016.1251892","27817208","https://pubmed.ncbi.nlm.nih.gov/27817208/",null,"ClinicalTrials.gov:NCT01272219; ClinicalTrials.gov:NCT01272232; ClinicalTrials.gov:NCT01557166"],["1","R0027033","R0027033.pdf","paywalled","randomized_trial","Liu X","2017","Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.","Clinical endocrinology","Wiley","10.1111/cen.13454","https://doi.org/10.1111/cen.13454","28834553","https://pubmed.ncbi.nlm.nih.gov/28834553/",null,null],["1","R0044409","R0044409.pdf","paywalled","randomized_trial","Chu, Lisa","2017","Randomized Comparison of initiating insulin Glargine or Iglarlixi in South Asian Subjects With T2D : Variation 2 Sa Trial","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5d9b6229ea541d6ca84938ab","https://doi.org/10.26226/morressier.5d9b6229ea541d6ca84938ab",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819790"],["1","R0048567","R0048567.pdf","paywalled","randomized_trial","Marina Anderson","2017","OC-001 Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk’s first nhs endobarrier service for diabesity","Oral Presentations","BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2017-314472.1","https://doi.org/10.1136/gutjnl-2017-314472.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ISRCTN:ISRCTN00151053"],["1","R0051397","R0051397.pdf","paywalled","randomized_trial","Matthias Blüher","2017","3-year efficacy and safety for liraglutide 3.0 mg in adults with obesity/overweight, prediabetes and baseline BMI < 35 vs. ≥35 kg/m2 in the SCALE Obesity and Prediabetes, double-blind, placebo-controlled trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0037-1601675","https://doi.org/10.1055/s-0037-1601675",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272219"],["1","R0018472","R0018472.pdf","paywalled","randomized_trial","Aroda VR","2016","Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-1495","https://doi.org/10.2337/dc16-1495","27650977","https://pubmed.ncbi.nlm.nih.gov/27650977/",null,"ClinicalTrials.gov:NCT02058160"],["1","R0021096","R0021096.pdf","paywalled","randomized_trial","Lingvay I","2016","Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2016.1252","https://doi.org/10.1001/jama.2016.1252","26934259","https://pubmed.ncbi.nlm.nih.gov/26934259/",null,"ClinicalTrials.gov:NCT01952145"],["1","R0021793","R0021793.pdf","paywalled","randomized_trial","Frías JP","2016","Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(16)30267-4","https://doi.org/10.1016/s2213-8587(16)30267-4","27651331","https://pubmed.ncbi.nlm.nih.gov/27651331/",null,"ClinicalTrials.gov:NCT02229396; ClinicalTrials.gov:NCT02597049"],["1","R0021851","R0021851.pdf","paywalled","randomized_trial","Chen WR","2016","Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.","Circulation. Cardiovascular imaging","Ovid Technologies (Wolters Kluwer Health)","10.1161/circimaging.116.005146","https://doi.org/10.1161/circimaging.116.005146","27940956","https://pubmed.ncbi.nlm.nih.gov/27940956/",null,"ClinicalTrials.gov:NCT02001363"],["1","R0023150","R0023150.pdf","paywalled","randomized_trial","Vanderheiden A","2016","Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-3906","https://doi.org/10.1210/jc.2015-3906","26909799","https://pubmed.ncbi.nlm.nih.gov/26909799/",null,"ClinicalTrials.gov:NCT01505673"],["1","R0023437","R0023437.pdf","paywalled","randomized_trial","Dejgaard TF","2016","Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(15)00436-2","https://doi.org/10.1016/s2213-8587(15)00436-2","26656289","https://pubmed.ncbi.nlm.nih.gov/26656289/",null,"ClinicalTrials.gov:NCT01612468"],["1","R0025363","R0025363.pdf","paywalled","randomized_trial","Mathieu C","2016","Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0691","https://doi.org/10.2337/dc16-0691","27506222","https://pubmed.ncbi.nlm.nih.gov/27506222/",null,"ClinicalTrials.gov:NCT01836523"],["1","R0025982","R0025982.pdf","paywalled","randomized_trial","Chen WR","2016","Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-015-0798-0","https://doi.org/10.1007/s12020-015-0798-0","26573925","https://pubmed.ncbi.nlm.nih.gov/26573925/",null,null],["1","R0026048","R0026048.pdf","paywalled","randomized_trial","Chen WR","2016","Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2015.12.009","https://doi.org/10.1016/j.ijcard.2015.12.009","26849684","https://pubmed.ncbi.nlm.nih.gov/26849684/",null,null],["1","R0026243","R0026243.pdf","paywalled","randomized_trial","O'Neil PM","2016","EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep151181.or","https://doi.org/10.4158/ep151181.or","27482610","https://pubmed.ncbi.nlm.nih.gov/27482610/",null,null],["1","R0026257","R0026257.pdf","paywalled","randomized_trial","Gilbert MP","2016","COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep15758.or","https://doi.org/10.4158/ep15758.or","26574791","https://pubmed.ncbi.nlm.nih.gov/26574791/",null,"ClinicalTrials.gov:NCT00294723"],["1","R0013159","R0013159.pdf","paywalled","randomized_trial","Jensterle M","2015","A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.","Hormones (Athens, Greece)","Springer Science and Business Media LLC","10.1007/bf03401383","https://doi.org/10.1007/bf03401383","25885106","https://pubmed.ncbi.nlm.nih.gov/25885106/",null,null],["1","R0015848","R0015848.pdf","paywalled","randomized_trial","Giorgino F","2015","Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).","Diabetes care","American Diabetes Association","10.2337/dc14-1625","https://doi.org/10.2337/dc14-1625","26089386","https://pubmed.ncbi.nlm.nih.gov/26089386/",null,"ClinicalTrials.gov:NCT01075282"],["1","R0016408","R0016408.pdf","paywalled","randomized_trial","Pieber TR","2015","Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12473","https://doi.org/10.1111/dom.12473","25855340","https://pubmed.ncbi.nlm.nih.gov/25855340/",null,"ClinicalTrials.gov:NCT01536665"],["1","R0018020","R0018020.pdf","paywalled","randomized_trial","Blonde L","2015","Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(15)60936-9","https://doi.org/10.1016/s0140-6736(15)60936-9","26009229","https://pubmed.ncbi.nlm.nih.gov/26009229/",null,"ClinicalTrials.gov:NCT01191268"],["1","R0020721","R0020721.pdf","paywalled","randomized_trial","Chen WR","2015","Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","American heart journal","Elsevier BV","10.1016/j.ahj.2015.07.014","https://doi.org/10.1016/j.ahj.2015.07.014","26542491","https://pubmed.ncbi.nlm.nih.gov/26542491/",null,null],["1","R0021434","R0021434.pdf","paywalled","randomized_trial","Robert SA","2015","Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2015.03.005","https://doi.org/10.1016/j.orcp.2015.03.005","25870084","https://pubmed.ncbi.nlm.nih.gov/25870084/",null,"ClinicalTrials.gov:NCT01739049"],["1","R0022092","R0022092.pdf","paywalled","randomized_trial","Meier JJ","2015","Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.","Diabetes care","American Diabetes Association","10.2337/dc14-1984","https://doi.org/10.2337/dc14-1984","25887358","https://pubmed.ncbi.nlm.nih.gov/25887358/",null,"ClinicalTrials.gov:NCT01596504"],["1","R0022640","R0022640.pdf","paywalled","randomized_trial","Hompesch M","2015","Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12398","https://doi.org/10.1111/dom.12398","25263215","https://pubmed.ncbi.nlm.nih.gov/25263215/",null,"ClinicalTrials.gov:NCT01475734"],["1","R0022910","R0022910.pdf","paywalled","randomized_trial","Lovshin JA","2015","Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/dc14-1958","https://doi.org/10.2337/dc14-1958","25414155","https://pubmed.ncbi.nlm.nih.gov/25414155/",null,"ClinicalTrials.gov:NCT01755572"],["1","R0023744","R0023744.pdf","paywalled","randomized_trial","Lind M","2015","Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2014.07.010","https://doi.org/10.1016/j.pcd.2014.07.010","25175385","https://pubmed.ncbi.nlm.nih.gov/25175385/",null,"ClinicalTrials.gov:NCT02113332"],["1","R0025966","R0025966.pdf","paywalled","randomized_trial","Schernthaner G","2015","Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12471","https://doi.org/10.1111/dom.12471","25846577","https://pubmed.ncbi.nlm.nih.gov/25846577/",null,"ClinicalTrials.gov:NCT00359762"],["1","R0026018","R0026018.pdf","paywalled","randomized_trial","Wysham CH","2015","Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2015.01.008","https://doi.org/10.1016/j.mayocp.2015.01.008","25744115","https://pubmed.ncbi.nlm.nih.gov/25744115/",null,"ClinicalTrials.gov:NCT00308139"],["1","R0026754","R0026754.pdf","paywalled","randomized_trial","Tang A","2015","Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc14-2548","https://doi.org/10.2337/dc14-2548","25813773","https://pubmed.ncbi.nlm.nih.gov/25813773/",null,"ClinicalTrials.gov:NCT01399645"],["1","R0048271","R0048271.pdf","paywalled","randomized_trial","MJ Armstrong","2015","OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2015-309861.16","https://doi.org/10.1136/gutjnl-2015-309861.16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01237119"],["1","R0048658","R0048658.pdf","paywalled","randomized_trial","Matthias Blüher","2015","Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE™ Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial","Experimental and Clinical Endocrinology & Diabetes","Georg Thieme Verlag KG","10.1055/s-0035-1549086","https://doi.org/10.1055/s-0035-1549086",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272219"],["1","R0051008","R0051008.pdf","paywalled","randomized_trial","Michael J. Davies","2015","Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1556576","https://doi.org/10.1055/s-0035-1556576",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272232"],["1","R0052673","R0052673.pdf","paywalled","randomized_trial","Patrick J. O’Neil","2015","Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56-week SCALE Obesity and Prediabetes trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1556574","https://doi.org/10.1055/s-0035-1556574",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272219"],["1","R0016819","R0016819.pdf","paywalled","randomized_trial","Gough SC","2014","Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(14)70174-3","https://doi.org/10.1016/s2213-8587(14)70174-3","25190523","https://pubmed.ncbi.nlm.nih.gov/25190523/",null,"ClinicalTrials.gov:NCT01336023"],["1","R0018403","R0018403.pdf","paywalled","randomized_trial","Buse JB","2014","Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).","Diabetes care","American Diabetes Association","10.2337/dc14-0785","https://doi.org/10.2337/dc14-0785","25114296","https://pubmed.ncbi.nlm.nih.gov/25114296/",null,null],["1","R0020061","R0020061.pdf","paywalled","randomized_trial","van Bloemendaal L","2014","GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.","Diabetes","American Diabetes Association","10.2337/db14-0849","https://doi.org/10.2337/db14-0849","25071023","https://pubmed.ncbi.nlm.nih.gov/25071023/",null,"ClinicalTrials.gov:NCT01281228"],["1","R0020558","R0020558.pdf","paywalled","randomized_trial","Rosenstock J","2014","Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.","Diabetes care","American Diabetes Association","10.2337/dc14-0001","https://doi.org/10.2337/dc14-0001","24898300","https://pubmed.ncbi.nlm.nih.gov/24898300/",null,"ClinicalTrials.gov:NCT00976391"],["1","R0020934","R0020934.pdf","paywalled","randomized_trial","Dungan KM","2014","Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(14)60976-4","https://doi.org/10.1016/s0140-6736(14)60976-4","25018121","https://pubmed.ncbi.nlm.nih.gov/25018121/",null,"ClinicalTrials.gov:NCT01624259"],["1","R0021859","R0021859.pdf","paywalled","randomized_trial","Nandy D","2014","The effect of liraglutide on endothelial function in patients with type 2 diabetes.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164114547358","https://doi.org/10.1177/1479164114547358","25212693","https://pubmed.ncbi.nlm.nih.gov/25212693/",null,"ClinicalTrials.gov:NCT00620282"],["1","R0022390","R0022390.pdf","paywalled","randomized_trial","Diamant M","2014","Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(14)70029-4","https://doi.org/10.1016/s2213-8587(14)70029-4","24731672","https://pubmed.ncbi.nlm.nih.gov/24731672/",null,"ClinicalTrials.gov:NCT00641056"],["1","R0022865","R0022865.pdf","paywalled","randomized_trial","Umpierrez G","2014","Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).","Diabetes care","American Diabetes Association","10.2337/dc13-2759","https://doi.org/10.2337/dc13-2759","24842985","https://pubmed.ncbi.nlm.nih.gov/24842985/",null,"ClinicalTrials.gov:NCT01126580"],["1","R0025635","R0025635.pdf","paywalled","randomized_trial","Young MA","2014","Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2014.05.2754","https://doi.org/10.3810/pgm.2014.05.2754","24918790","https://pubmed.ncbi.nlm.nih.gov/24918790/",null,"ClinicalTrials.gov:NCT00938158; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527"],["1","R0026284","R0026284.pdf","paywalled","randomized_trial","Shao N","2014","Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2561","https://doi.org/10.1002/dmrr.2561","24823873","https://pubmed.ncbi.nlm.nih.gov/24823873/",null,null],["1","R0026389","R0026389.pdf","paywalled","randomized_trial","Buse JB","2014","Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2014.896329","https://doi.org/10.1185/03007995.2014.896329","24621255","https://pubmed.ncbi.nlm.nih.gov/24621255/",null,"ClinicalTrials.gov:NCT00765817"],["1","R0026414","R0026414.pdf","paywalled","randomized_trial","Retnakaran R","2014","Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.","Diabetes care","American Diabetes Association","10.2337/dc14-0893","https://doi.org/10.2337/dc14-0893","25249651","https://pubmed.ncbi.nlm.nih.gov/25249651/",null,"ClinicalTrials.gov:NCT01270789"],["1","R0051239","R0051239.pdf","paywalled","randomized_trial","Brian D. Hoyle","2014","Liraglutide Helps Achieve Significant Weight Loss in Overweight or Obese Patients","MD Conference Express","CLOCKSS Archive","10.1177/155989771447008","https://doi.org/10.1177/155989771447008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272219"],["1","R0016299","R0016299.pdf","paywalled","randomized_trial","Buse JB","2013","Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(12)61267-7","https://doi.org/10.1016/s0140-6736(12)61267-7","23141817","https://pubmed.ncbi.nlm.nih.gov/23141817/",null,"ClinicalTrials.gov:NCT01029886"],["1","R0016483","R0016483.pdf","paywalled","randomized_trial","Niswender K","2013","Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01673.x","https://doi.org/10.1111/j.1463-1326.2012.01673.x","22862847","https://pubmed.ncbi.nlm.nih.gov/22862847/",null,null],["1","R0019490","R0019490.pdf","paywalled","randomized_trial","Grimm M","2013","Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2013.05.2660","https://doi.org/10.3810/pgm.2013.05.2660","23748506","https://pubmed.ncbi.nlm.nih.gov/23748506/",null,"ClinicalTrials.gov:NCT00308139; ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT00676338; ClinicalTrials.gov:NCT00877890; ClinicalTrials.gov:NCT01029886"],["1","R0019662","R0019662.pdf","paywalled","randomized_trial","Hari Kumar KV","2013","Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2013.01.020","https://doi.org/10.1016/j.diabres.2013.01.020","23490599","https://pubmed.ncbi.nlm.nih.gov/23490599/",null,"ClinicalTrials.gov:NCT01235819"],["1","R0021623","R0021623.pdf","paywalled","randomized_trial","Nauck M","2013","Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12003","https://doi.org/10.1111/dme.12003","22937895","https://pubmed.ncbi.nlm.nih.gov/22937895/",null,"ClinicalTrials.gov:NCT00755287"],["1","R0023762","R0023762.pdf","paywalled","randomized_trial","Wadden TA","2013","Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/ijo.2013.120","https://doi.org/10.1038/ijo.2013.120","23812094","https://pubmed.ncbi.nlm.nih.gov/23812094/",null,"ClinicalTrials.gov:NCT00781937"],["1","R0023875","R0023875.pdf","paywalled","randomized_trial","Flint A","2013","The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12108","https://doi.org/10.1111/dom.12108","23551925","https://pubmed.ncbi.nlm.nih.gov/23551925/",null,null],["1","R0025751","R0025751.pdf","paywalled","randomized_trial","Pinget M","2013","Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12121","https://doi.org/10.1111/dom.12121","23627775","https://pubmed.ncbi.nlm.nih.gov/23627775/",null,"ClinicalTrials.gov:NCT00763815"],["1","R0025752","R0025752.pdf","paywalled","randomized_trial","Malloy J","2013","Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2013.05.2661","https://doi.org/10.3810/pgm.2013.05.2661","23748507","https://pubmed.ncbi.nlm.nih.gov/23748507/",null,"ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00676338"],["1","R0026731","R0026731.pdf","paywalled","randomized_trial","Nauck M","2013","Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12012","https://doi.org/10.1111/dom.12012","22985213","https://pubmed.ncbi.nlm.nih.gov/22985213/",null,null],["1","R0047508","R0047508.pdf","paywalled","randomized_trial","Brian D. Hoyle","2013","Improved Treatment of Type 2 Diabetes: Results from the 4B Trial","MD Conference Express","CLOCKSS Archive","10.1177/155989771317003","https://doi.org/10.1177/155989771317003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00960661"],["1","R0048002","R0048002.pdf","paywalled","randomized_trial","Mabel Korsah Cunningham","2013","Metformin/Pioglitazone/Exenatide Triple Therapy Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed Type 2 Diabetes","MD Conference Express","CLOCKSS Archive","10.1177/155989771311007","https://doi.org/10.1177/155989771311007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01107717"],["1","R0049258","R0049258.pdf","paywalled","randomized_trial","Brian D. Hoyle","2013","Once-Weekly Exenatide Allows Sustained HbA1C Control","MD Conference Express","CLOCKSS Archive","10.1177/155989771317004","https://doi.org/10.1177/155989771317004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00641056"],["1","R0049328","R0049328.pdf","paywalled","randomized_trial","Brian D. Hoyle","2013","Liraglutide is a Safe and Beneficial Adjunct to Insulin in Glycemic Control in Type 1 Diabetes","MD Conference Express","CLOCKSS Archive","10.1177/155989771317005","https://doi.org/10.1177/155989771317005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01536665"],["1","R0052449","R0052449.pdf","paywalled","randomized_trial","Brian D. Hoyle","2013","Once-Weekly Dulaglutide Produces Superior Glycemic Control Compared with Metformin","MD Conference Express","CLOCKSS Archive","10.1177/155989771317007","https://doi.org/10.1177/155989771317007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01126580"],["1","R0012548","R0012548.pdf","paywalled","randomized_trial","Xiao C","2012","Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.","Arteriosclerosis, thrombosis, and vascular biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvbaha.112.246207","https://doi.org/10.1161/atvbaha.112.246207","22492091","https://pubmed.ncbi.nlm.nih.gov/22492091/",null,"ClinicalTrials.gov:NCT01056549"],["1","R0018919","R0018919.pdf","paywalled","randomized_trial","Pencek R","2012","Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2012.07.2567","https://doi.org/10.3810/pgm.2012.07.2567","22913891","https://pubmed.ncbi.nlm.nih.gov/22913891/",null,"ClinicalTrials.gov:NCT00039026; ClinicalTrials.gov:NCT00039013; ClinicalTrials.gov:NCT00082381; ClinicalTrials.gov:NCT00035984; ClinicalTrials.gov:NCT00082407; ClinicalTrials.gov:NCT00381342; ClinicalTrials.gov:NCT00360334; ClinicalTrials.gov:NCT00375492; ClinicalTrials.gov:NCT00603239; ClinicalTrials.gov:NCT00765817; ClinicalTrials.gov:NCT00577824; ClinicalTrials.gov:NCT00434954"],["1","R0019328","R0019328.pdf","paywalled","randomized_trial","Inagaki N","2012","Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.07.007","https://doi.org/10.1016/j.clinthera.2012.07.007","22884767","https://pubmed.ncbi.nlm.nih.gov/22884767/",null,"ClinicalTrials.gov:NCT00935532"],["1","R0021567","R0021567.pdf","paywalled","randomized_trial","Grunberger G","2012","Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03745.x","https://doi.org/10.1111/j.1464-5491.2012.03745.x","22804250","https://pubmed.ncbi.nlm.nih.gov/22804250/",null,null],["1","R0024303","R0024303.pdf","paywalled","randomized_trial","Horowitz M","2012","Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2012.02.016","https://doi.org/10.1016/j.diabres.2012.02.016","22446097","https://pubmed.ncbi.nlm.nih.gov/22446097/",null,null],["1","R0025149","R0025149.pdf","paywalled","randomized_trial","Camilleri M","2012","Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.","American journal of physiology. Gastrointestinal and liver physiology","American Physiological Society","10.1152/ajpgi.00076.2012","https://doi.org/10.1152/ajpgi.00076.2012","22517769","https://pubmed.ncbi.nlm.nih.gov/22517769/",null,null],["1","R0026680","R0026680.pdf","paywalled","randomized_trial","Violante R","2012","A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03624.x","https://doi.org/10.1111/j.1464-5491.2012.03624.x","22375612","https://pubmed.ncbi.nlm.nih.gov/22375612/",null,"ClinicalTrials.gov:NCT00870194"],["1","R0026887","R0026887.pdf","paywalled","randomized_trial","Gallwitz B","2012","Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(12)60479-6","https://doi.org/10.1016/s0140-6736(12)60479-6","22683137","https://pubmed.ncbi.nlm.nih.gov/22683137/",null,"ClinicalTrials.gov:NCT00359762; EudraCT:2005-005448-21"],["1","R0027064","R0027064.pdf","paywalled","randomized_trial","Zhang H","2012","Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.","Kidney & blood pressure research","S. Karger AG","10.1159/000337929","https://doi.org/10.1159/000337929","22687869","https://pubmed.ncbi.nlm.nih.gov/22687869/",null,null],["1","R0027141","R0027141.pdf","paywalled","randomized_trial","Forst T","2012","Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03589.x","https://doi.org/10.1111/j.1464-5491.2012.03589.x","22288732","https://pubmed.ncbi.nlm.nih.gov/22288732/",null,"ClinicalTrials.gov:NCT01208012"],["1","R0021934","R0021934.pdf","paywalled","randomized_trial","Barrington P","2011","LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01365.x","https://doi.org/10.1111/j.1463-1326.2011.01365.x","21251179","https://pubmed.ncbi.nlm.nih.gov/21251179/",null,null],["1","R0024125","R0024125.pdf","paywalled","randomized_trial","Bode BW","2011","Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.","The American journal of geriatric pharmacotherapy","Elsevier BV","10.1016/j.amjopharm.2011.09.007","https://doi.org/10.1016/j.amjopharm.2011.09.007","22055210","https://pubmed.ncbi.nlm.nih.gov/22055210/",null,null],["1","R0024203","R0024203.pdf","paywalled","randomized_trial","Kapitza C","2011","The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-011-0044-y","https://doi.org/10.1007/s12325-011-0044-y","21792552","https://pubmed.ncbi.nlm.nih.gov/21792552/",null,null],["1","R0024392","R0024392.pdf","paywalled","randomized_trial","Barrington P","2011","A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01364.x","https://doi.org/10.1111/j.1463-1326.2011.01364.x","21251178","https://pubmed.ncbi.nlm.nih.gov/21251178/",null,null],["1","R0024686","R0024686.pdf","paywalled","randomized_trial","Jiang J","2011","The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.","Journal of clinical pharmacology","Wiley","10.1177/0091270010389468","https://doi.org/10.1177/0091270010389468","21273395","https://pubmed.ncbi.nlm.nih.gov/21273395/",null,null],["1","R0025273","R0025273.pdf","paywalled","randomized_trial","Davies M","2011","Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2010.03074.x","https://doi.org/10.1111/j.1464-5491.2010.03074.x","21309842","https://pubmed.ncbi.nlm.nih.gov/21309842/",null,null],["1","R0027084","R0027084.pdf","paywalled","randomized_trial","Yang W","2011","Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01323.x","https://doi.org/10.1111/j.1463-1326.2010.01323.x","21114607","https://pubmed.ncbi.nlm.nih.gov/21114607/",null,null],["1","R0027649","R0027649.pdf","paywalled","randomized_trial","Blevins T","2011","DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2010-2081","https://doi.org/10.1210/jc.2010-2081","21307137","https://pubmed.ncbi.nlm.nih.gov/21307137/",null,null],["1","R0035661","R0035661.pdf","paywalled","randomized_trial","R. Buckely","2011","Long-Term Injection-Free Subcutaneous Delivery of Exenatide via ITCA 650 Improves Compliance and Controls Glycemic Parameters and Weight","MD Conference Express","CLOCKSS Archive","10.1177/155989771108006","https://doi.org/10.1177/155989771108006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00943917"],["1","R0048071","R0048071.pdf","paywalled","randomized_trial","Robert E. Buckley","2011","Liraglutide Reduces Insulin Dose without Affecting Glycemic Control in T1DM","MD Conference Express","CLOCKSS Archive","10.1177/155989771111012","https://doi.org/10.1177/155989771111012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00993720"],["1","R0020417","R0020417.pdf","paywalled","randomized_trial","Bergenstal RM","2010","Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(10)60590-9","https://doi.org/10.1016/s0140-6736(10)60590-9","20580422","https://pubmed.ncbi.nlm.nih.gov/20580422/",null,"ClinicalTrials.gov:NCT00637273"],["1","R0023279","R0023279.pdf","paywalled","randomized_trial","Kaku K","2010","Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01194.x","https://doi.org/10.1111/j.1463-1326.2009.01194.x","20380655","https://pubmed.ncbi.nlm.nih.gov/20380655/",null,null],["1","R0024648","R0024648.pdf","paywalled","randomized_trial","Seino Y","2010","Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1185/03007991003672551","https://doi.org/10.1185/03007991003672551","20199137","https://pubmed.ncbi.nlm.nih.gov/20199137/",null,"ClinicalTrials.gov:NCT00393718"],["1","R0025739","R0025739.pdf","paywalled","randomized_trial","Pratley RE","2010","Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(10)60307-8","https://doi.org/10.1016/s0140-6736(10)60307-8","20417856","https://pubmed.ncbi.nlm.nih.gov/20417856/",null,"ClinicalTrials.gov:NCT00700817"],["1","R0027049","R0027049.pdf","paywalled","randomized_trial","Schwartz EA","2010","Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2010.05.028","https://doi.org/10.1016/j.atherosclerosis.2010.05.028","20557887","https://pubmed.ncbi.nlm.nih.gov/20557887/",null,"ClinicalTrials.gov:NCT00974272"],["1","R0027273","R0027273.pdf","paywalled","randomized_trial","Diamant M","2010","Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(10)60406-0","https://doi.org/10.1016/s0140-6736(10)60406-0","20609969","https://pubmed.ncbi.nlm.nih.gov/20609969/",null,"ClinicalTrials.gov:NCT00641056"],["1","R0027314","R0027314.pdf","paywalled","randomized_trial","Bunck MC","2010","One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2010.04.024","https://doi.org/10.1016/j.atherosclerosis.2010.04.024","20494360","https://pubmed.ncbi.nlm.nih.gov/20494360/",null,"ClinicalTrials.gov:NCT00097500"],["1","R0020147","R0020147.pdf","paywalled","randomized_trial","White J","2009","Efficacy and safety of incretin based therapies: clinical trial data.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1331/japha.2009.09079","https://doi.org/10.1331/japha.2009.09079","19801363","https://pubmed.ncbi.nlm.nih.gov/19801363/",null,null],["1","R0020382","R0020382.pdf","paywalled","randomized_trial","Buse JB","2009","Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(09)60659-0","https://doi.org/10.1016/s0140-6736(09)60659-0","19515413","https://pubmed.ncbi.nlm.nih.gov/19515413/",null,"ClinicalTrials.gov:NCT00518882"],["1","R0022254","R0022254.pdf","paywalled","randomized_trial","McGill JB","2009","Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2009.05.1998","https://doi.org/10.3810/pgm.2009.05.1998","19491536","https://pubmed.ncbi.nlm.nih.gov/19491536/",null,null],["1","R0024741","R0024741.pdf","paywalled","randomized_trial","Seino Y","2009","Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.","Current medical research and opinion","Informa UK Limited","10.1185/03007990903372999","https://doi.org/10.1185/03007990903372999","19863477","https://pubmed.ncbi.nlm.nih.gov/19863477/",null,"ClinicalTrials.gov:NCT00530309"],["1","R0027086","R0027086.pdf","paywalled","randomized_trial","Malloy J","2009","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2009.04.005","https://doi.org/10.1016/j.clinthera.2009.04.005","19446153","https://pubmed.ncbi.nlm.nih.gov/19446153/",null,"ClinicalTrials.gov:NCT00254254"],["1","R0027240","R0027240.pdf","paywalled","randomized_trial","Gao Y","2009","Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2008.09.037","https://doi.org/10.1016/j.diabres.2008.09.037","19019476","https://pubmed.ncbi.nlm.nih.gov/19019476/",null,"ClinicalTrials.gov:NCT00324363"],["1","R0027293","R0027293.pdf","paywalled","randomized_trial","Astrup A","2009","Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(09)61375-1","https://doi.org/10.1016/s0140-6736(09)61375-1","19853906","https://pubmed.ncbi.nlm.nih.gov/19853906/",null,"ClinicalTrials.gov:NCT00422058"],["1","R0027365","R0027365.pdf","paywalled","randomized_trial","Bergenstal R","2009","Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.","Current medical research and opinion","Informa UK Limited","10.1185/03007990802597951","https://doi.org/10.1185/03007990802597951","19210140","https://pubmed.ncbi.nlm.nih.gov/19210140/",null,"ClinicalTrials.gov:NCT00097877"],["1","R0027526","R0027526.pdf","paywalled","randomized_trial","Garber A","2009","Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(08)61246-5","https://doi.org/10.1016/s0140-6736(08)61246-5","18819705","https://pubmed.ncbi.nlm.nih.gov/18819705/",null,"ClinicalTrials.gov:NCT00294723"],["1","R0027548","R0027548.pdf","paywalled","randomized_trial","Nauck M","2009","Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2009.05.1997","https://doi.org/10.3810/pgm.2009.05.1997","19491535","https://pubmed.ncbi.nlm.nih.gov/19491535/",null,"ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461"],["1","R0022965","R0022965.pdf","paywalled","randomized_trial","Vilsbøll T","2008","Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2007.02333.x","https://doi.org/10.1111/j.1464-5491.2007.02333.x","18201212","https://pubmed.ncbi.nlm.nih.gov/18201212/",null,null],["1","R0024969","R0024969.pdf","paywalled","randomized_trial","Irie S","2008","Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cpp46273","https://doi.org/10.5414/cpp46273","18541123","https://pubmed.ncbi.nlm.nih.gov/18541123/",null,null],["1","R0025313","R0025313.pdf","paywalled","randomized_trial","Drucker DJ","2008","Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(08)61206-4","https://doi.org/10.1016/s0140-6736(08)61206-4","18782641","https://pubmed.ncbi.nlm.nih.gov/18782641/",null,"ClinicalTrials.gov:NCT00308139"],["1","R0025632","R0025632.pdf","paywalled","randomized_trial","Seino Y","2008","Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2008.03.018","https://doi.org/10.1016/j.diabres.2008.03.018","18495285","https://pubmed.ncbi.nlm.nih.gov/18495285/",null,null],["1","R0025642","R0025642.pdf","paywalled","randomized_trial","DeFronzo RA","2008","Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.","Current medical research and opinion","Informa UK Limited","10.1185/03007990802418851","https://doi.org/10.1185/03007990802418851","18786299","https://pubmed.ncbi.nlm.nih.gov/18786299/",null,"ClinicalTrials.gov:NCT00477581"],["1","R0027392","R0027392.pdf","paywalled","randomized_trial","Moretto TJ","2008","Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2008.08.006","https://doi.org/10.1016/j.clinthera.2008.08.006","18803987","https://pubmed.ncbi.nlm.nih.gov/18803987/",null,null],["1","R0027566","R0027566.pdf","paywalled","randomized_trial","Forti A","2008","Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.","Current medical research and opinion","Informa Healthcare","10.1185/03007990802282398","https://doi.org/10.1185/03007990802282398","18662495","https://pubmed.ncbi.nlm.nih.gov/18662495/",null,"ClinicalTrials.gov:NCT00359879"],["1","R0025690","R0025690.pdf","paywalled","randomized_trial","Nelson P","2007","The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2006.0024","https://doi.org/10.1089/dia.2006.0024","17705687","https://pubmed.ncbi.nlm.nih.gov/17705687/",null,"ClinicalTrials.gov:NCT00044694; ClinicalTrials.gov:NCT00085969; ClinicalTrials.gov:NCT00111540"],["1","R0026490","R0026490.pdf","paywalled","randomized_trial","Buse JB","2007","Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2007.01.015","https://doi.org/10.1016/j.clinthera.2007.01.015","17379054","https://pubmed.ncbi.nlm.nih.gov/17379054/",null,null],["1","R0027482","R0027482.pdf","paywalled","randomized_trial","Zinman B","2007","The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-146-7-200704030-00003","https://doi.org/10.7326/0003-4819-146-7-200704030-00003","17404349","https://pubmed.ncbi.nlm.nih.gov/17404349/",null,"ClinicalTrials.gov:NCT00099320"],["1","R0030559","R0030559.pdf","paywalled","randomized_trial","Basu A","2007","Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00373.2007","https://doi.org/10.1152/ajpendo.00373.2007","17711996","https://pubmed.ncbi.nlm.nih.gov/17711996/",null,null],["1","R0025008","R0025008.pdf","paywalled","randomized_trial","Nauck MA","2006","Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-2006-924230","https://doi.org/10.1055/s-2006-924230","17039422","https://pubmed.ncbi.nlm.nih.gov/17039422/",null,null],["1","R0026056","R0026056.pdf","paywalled","randomized_trial","Mari A","2006","Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/s-2006-956505","https://doi.org/10.1055/s-2006-956505","17163361","https://pubmed.ncbi.nlm.nih.gov/17163361/",null,null],["1","R0022664","R0022664.pdf","paywalled","randomized_trial","DeFronzo RA","2005","Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/diacare.28.5.1092","https://doi.org/10.2337/diacare.28.5.1092","15855572","https://pubmed.ncbi.nlm.nih.gov/15855572/",null,null],["1","R0024019","R0024019.pdf","paywalled","randomized_trial","Kendall DM","2005","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","Diabetes care","American Diabetes Association","10.2337/diacare.28.5.1083","https://doi.org/10.2337/diacare.28.5.1083","15855571","https://pubmed.ncbi.nlm.nih.gov/15855571/",null,null],["1","R0027640","R0027640.pdf","paywalled","randomized_trial","Heine RJ","2005","Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-143-8-200510180-00006","https://doi.org/10.7326/0003-4819-143-8-200510180-00006","16230722","https://pubmed.ncbi.nlm.nih.gov/16230722/",null,"ClinicalTrials.gov:NCT00082381"],["1","R0027230","R0027230.pdf","paywalled","randomized_trial","Elbrønd B","2002","Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.","Diabetes care","American Diabetes Association","10.2337/diacare.25.8.1398","https://doi.org/10.2337/diacare.25.8.1398","12145241","https://pubmed.ncbi.nlm.nih.gov/12145241/",null,null],["1","R0031504","R0031504.pdf","paywalled","randomized_trial",null,"1995","Crystal chemistry of higher tungsten oxides","Metal Powder Report","Auricle Global Society of Education and Research","10.1016/0026-0657(95)93258-5","https://doi.org/10.1016/0026-0657(95)93258-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01237119"],["1","R0031521","R0031521.pdf","paywalled","randomized_trial",null,"1995","High density processing of ferrous alloys by supersolidus liquid phase sintering","Metal Powder Report","Auricle Global Society of Education and Research","10.1016/0026-0657(95)93284-4","https://doi.org/10.1016/0026-0657(95)93284-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01237119"],["1","R0031769","R0031769.pdf","paywalled","randomized_trial",null,"1995","Correlation of particle size distribution with process parameters in gas-atomization","Metal Powder Report","Auricle Global Society of Education and Research","10.1016/0026-0657(95)93260-7","https://doi.org/10.1016/0026-0657(95)93260-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01237119"],["1","R0042154","R0042154.pdf","paywalled","randomized_trial",null,"1995","New mechanical 500 ton compacting press for production of advanced PM parts","Metal Powder Report","Auricle Global Society of Education and Research","10.1016/0026-0657(95)93286-0","https://doi.org/10.1016/0026-0657(95)93286-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01237119"],["1","R0055747","R0055747.pdf","paywalled","randomized_trial","Fox, Claudia K",null,"Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.",null,null,"10.48620/76208","https://doi.org/10.48620/76208",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04775082"],["1","R0002643","R0002643.pdf","open_download_failed","randomized_trial","Ostrominski JW","2026","Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.","JAMA cardiology","American Medical Association (AMA)","10.1001/jamacardio.2026.3566","https://doi.org/10.1001/jamacardio.2026.3566","42747817","https://pubmed.ncbi.nlm.nih.gov/42747817/","https://pubmed.ncbi.nlm.nih.gov/42747817/","ClinicalTrials.gov:NCT03574597"],["1","R0003693","R0003693.pdf","open_download_failed","randomized_trial","Atieh O","2026","Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Oxford University Press (OUP)","10.1093/cid/ciaf577","https://doi.org/10.1093/cid/ciaf577","41098140","https://pubmed.ncbi.nlm.nih.gov/41098140/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13189676/","ClinicalTrials.gov:NCT04019197"],["1","R0003798","R0003798.pdf","open_download_failed","randomized_trial","Giorgino F","2026","Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2026.9512","https://doi.org/10.1001/jama.2026.9512","42251769","https://pubmed.ncbi.nlm.nih.gov/42251769/","https://pubmed.ncbi.nlm.nih.gov/42251769/","ClinicalTrials.gov:NCT06109311"],["1","R0003816","R0003816.pdf","free_to_read","randomized_trial","Sattar N","2026","Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.04.044","https://doi.org/10.1016/j.jacc.2026.04.044","42233927","https://pubmed.ncbi.nlm.nih.gov/42233927/","https://doi.org/10.1016/j.jacc.2026.04.044","ClinicalTrials.gov:NCT04184622"],["1","R0004173","R0004173.pdf","open_download_failed","randomized_trial","Sass MR","2026","Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2025.3639","https://doi.org/10.1001/jamapsychiatry.2025.3639","41335431","https://pubmed.ncbi.nlm.nih.gov/41335431/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12676471/","ClinicalTrials.gov:NCT04892199"],["1","R0004331","R0004331.pdf","open_download_failed","randomized_trial","Borlaug BA","2026","Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2026.103218","https://doi.org/10.1016/j.jchf.2026.103218","42417681","https://pubmed.ncbi.nlm.nih.gov/42417681/","https://pubmed.ncbi.nlm.nih.gov/42417681/","ClinicalTrials.gov:NCT04847557"],["1","R0004549","R0004549.pdf","open_download_failed","randomized_trial","Heerspink HJL","2026","Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001051","https://doi.org/10.2215/cjn.0000001051","42308057","https://pubmed.ncbi.nlm.nih.gov/42308057/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13379112/","ClinicalTrials.gov:NCT04889183"],["1","R0007327","R0007327.pdf","open_download_failed","randomized_trial","He K","2026","Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71218","https://doi.org/10.1111/dom.71218","42764407","https://pubmed.ncbi.nlm.nih.gov/42764407/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71218","ClinicalTrials.gov:NCT05152277"],["1","R0007404","R0007404.pdf","open_download_failed","randomized_trial","Klausen MK","2026","Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00305-3","https://doi.org/10.1016/s0140-6736(26)00305-3","42070571","https://pubmed.ncbi.nlm.nih.gov/42070571/","https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(26)00305-3.pdf","ClinicalTrials.gov:NCT05895643"],["1","R0008734","R0008734.pdf","open_download_failed","randomized_trial","Gill H","2026","Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2026.0594","https://doi.org/10.1001/jamapsychiatry.2026.0594","42054055","https://pubmed.ncbi.nlm.nih.gov/42054055/","https://pubmed.ncbi.nlm.nih.gov/42054055/","ClinicalTrials.gov:NCT04466345"],["1","R0009056","R0009056.pdf","free_to_read","randomized_trial","Daher J","2026","Effects of semaglutide on subclinical cardiovascular health in people with HIV.","AIDS (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/qad.0000000000004624","https://doi.org/10.1097/qad.0000000000004624","42752515","https://pubmed.ncbi.nlm.nih.gov/42752515/","https://doi.org/10.1097/qad.0000000000004624","ClinicalTrials.gov:NCT04019197"],["1","R0009090","R0009090.pdf","free_to_read","randomized_trial","Loomba R","2026","Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(26)00123-8","https://doi.org/10.1016/s2468-1253(26)00123-8","42456707","https://pubmed.ncbi.nlm.nih.gov/42456707/","https://doi.org/10.1016/s2468-1253(26)00123-8","ClinicalTrials.gov:NCT05016882"],["1","R0010279","R0010279.pdf","open_download_failed","randomized_trial","Gao L","2026","Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2026.8142","https://doi.org/10.1001/jama.2026.8142","42251595","https://pubmed.ncbi.nlm.nih.gov/42251595/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13244275/","ClinicalTrials.gov:NCT06164873"],["1","R0010697","R0010697.pdf","free_to_read","randomized_trial","Cummings JL","2026","Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00459-9","https://doi.org/10.1016/s0140-6736(26)00459-9","41865758","https://pubmed.ncbi.nlm.nih.gov/41865758/","https://doi.org/10.1016/s0140-6736(26)00459-9","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0011443","R0011443.pdf","open_download_failed","randomized_trial","Al Ozairi E","2026","Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease - A randomised, controlled pilot study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.113066","https://doi.org/10.1016/j.diabres.2025.113066","41435968","https://pubmed.ncbi.nlm.nih.gov/41435968/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)01081-2/pdf","ClinicalTrials.gov:NCT05390307"],["1","R0012383","R0012383.pdf","open_download_failed","randomized_trial","Hjelmesæth J","2026","Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71323","https://doi.org/10.1111/dom.71323","42764399","https://pubmed.ncbi.nlm.nih.gov/42764399/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71323","ClinicalTrials.gov:NCT05646706"],["1","R0012620","R0012620.pdf","free_to_read","randomized_trial","Davies MJ","2026","Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00748-8","https://doi.org/10.1016/s0140-6736(26)00748-8","42259337","https://pubmed.ncbi.nlm.nih.gov/42259337/","https://doi.org/10.1016/s0140-6736(26)00748-8","ClinicalTrials.gov:NCT06579092"],["1","R0013416","R0013416.pdf","free_to_read","randomized_trial","Inzucchi SE","2026","Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag290","https://doi.org/10.1210/clinem/dgag290","42478869","https://pubmed.ncbi.nlm.nih.gov/42478869/","https://doi.org/10.1210/clinem/dgag290","ClinicalTrials.gov:NCT03914326"],["1","R0013891","R0013891.pdf","free_to_read","randomized_trial","Kanu C","2026","Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses.","Sleep","Oxford University Press (OUP)","10.1093/sleep/zsag184","https://doi.org/10.1093/sleep/zsag184","42412744","https://pubmed.ncbi.nlm.nih.gov/42412744/","https://doi.org/10.1093/sleep/zsag184","ClinicalTrials.gov:NCT05412004"],["1","R0014151","R0014151.pdf","free_to_read","randomized_trial","Rutter MK","2026","SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70247","https://doi.org/10.1002/oby.70247","42297568","https://pubmed.ncbi.nlm.nih.gov/42297568/","https://doi.org/10.1002/oby.70247","ClinicalTrials.gov:NCT07247084"],["1","R0015191","R0015191.pdf","free_to_read","randomized_trial","Tuttle KR","2026","Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.5125","https://doi.org/10.1016/j.jacc.2026.02.5125","42233552","https://pubmed.ncbi.nlm.nih.gov/42233552/","https://doi.org/10.1016/j.jacc.2026.02.5125","ClinicalTrials.gov:NCT03819153"],["1","R0029336","R0029336.pdf","free_to_read","randomized_trial","Cavender MA","2026","Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).","American heart journal","Elsevier BV","10.1016/j.ahj.2026.107626","https://doi.org/10.1016/j.ahj.2026.107626","42838477","https://pubmed.ncbi.nlm.nih.gov/42838477/","https://doi.org/10.1016/j.ahj.2026.107626","ClinicalTrials.gov:NCT05669755"],["1","R0029885","R0029885.pdf","free_to_read","randomized_trial","Zhou Z","2026","UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2026.09.021","https://doi.org/10.1016/j.cmet.2026.09.021","42843337","https://pubmed.ncbi.nlm.nih.gov/42843337/","https://doi.org/10.1016/j.cmet.2026.09.021","ClinicalTrials.gov:NCT07177469"],["1","R0045473","R0045473.pdf","free_to_read","randomized_trial","Joseph D Abraham","2026","Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity","Journal of Cachexia Sarcopenia and Muscle","Wiley","10.1002/jcsm.70298","https://doi.org/10.1002/jcsm.70298","42046455","https://pubmed.ncbi.nlm.nih.gov/42046455/","https://doi.org/10.1002/jcsm.70298","ClinicalTrials.gov:NCT06282458"],["1","R0050940","R0050940.pdf","free_to_read","randomized_trial","Naga Chalasani","2026","Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001792","https://doi.org/10.1097/hep.0000000000001792","42127430","https://pubmed.ncbi.nlm.nih.gov/42127430/","https://doi.org/10.1097/hep.0000000000001792","ClinicalTrials.gov:NCT04767529; ClinicalTrials.gov:NCT05039450"],["1","R0052933","R0052933.pdf","free_to_read","randomized_trial","Hao Wang","2026","ABSTRACT NUMBER: ESOC2026LT58 LT58 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN ACUTE LARGE VESSEL OCCLUSION STROKE TREATED BY REPERFUSION THERAPIES (GALLOP-2) – A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED END-POINT TRIAL","European Stroke Journal","Oxford University Press (OUP)","10.1093/esj/aakag023.1868","https://doi.org/10.1093/esj/aakag023.1868",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/esj/aakag023.1868","ClinicalTrials.gov:NCT06788626"],["1","R0056125","R0056125.pdf","free_to_read","randomized_trial","Ruth O. Adekunle","2026","Durability of semaglutide effects after treatment discontinuation in HIV-associated lipohypertrophy: a randomized, double-blind, placebo-controlled phase IIb clinical trial","Open Forum Infectious Diseases","Oxford University Press (OUP)","10.1093/ofid/ofag631","https://doi.org/10.1093/ofid/ofag631",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ofid/ofag631","ClinicalTrials.gov:NCT04019197"],["1","R0057005","R0057005.pdf","open_download_failed","randomized_trial","Ahmad AI","2026","Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2026.0027","https://doi.org/10.1001/jamainternmed.2026.0027","41837981","https://pubmed.ncbi.nlm.nih.gov/41837981/","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2846278/jamainternal_ahmad_2026_oi_260003_1773176596.00531.pdf","ClinicalTrials.gov:NCT06533527"],["1","R0004489","R0004489.pdf","free_to_read","randomized_trial","Harrison SA","2025","Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2024.02.022","https://doi.org/10.1016/j.cgh.2024.02.022","38447814","https://pubmed.ncbi.nlm.nih.gov/38447814/","https://doi.org/10.1016/j.cgh.2024.02.022","ClinicalTrials.gov:NCT05039450"],["1","R0006026","R0006026.pdf","free_to_read","randomized_trial","Sanyal AJ","2025","Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2413258","https://doi.org/10.1056/nejmoa2413258","40305708","https://pubmed.ncbi.nlm.nih.gov/40305708/","https://hdl.handle.net/2318/2092070","ClinicalTrials.gov:NCT04822181"],["1","R0006183","R0006183.pdf","open_download_failed","randomized_trial","Kadowaki T","2025","Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2025.3599","https://doi.org/10.1001/jamainternmed.2025.3599","40758358","https://pubmed.ncbi.nlm.nih.gov/40758358/","https://pubmed.ncbi.nlm.nih.gov/40758358/","ClinicalTrials.gov:NCT05132088"],["1","R0006311","R0006311.pdf","free_to_read","randomized_trial","James S","2025","Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2025.05.001","https://doi.org/10.1016/j.ahj.2025.05.001","40345413","https://pubmed.ncbi.nlm.nih.gov/40345413/","https://doi.org/10.1016/j.ahj.2025.05.001","ClinicalTrials.gov:NCT04032197"],["1","R0006315","R0006315.pdf","free_to_read","randomized_trial","Borlaug BA","2025","Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.04.059","https://doi.org/10.1016/j.jacc.2025.04.059","40701669","https://pubmed.ncbi.nlm.nih.gov/40701669/","https://doi.org/10.1016/j.jacc.2025.04.059","ClinicalTrials.gov:NCT04847557"],["1","R0006421","R0006421.pdf","free_to_read","randomized_trial","McGuire DK","2025","Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2501006","https://doi.org/10.1056/nejmoa2501006","40162642","https://pubmed.ncbi.nlm.nih.gov/40162642/","https://pure.amsterdamumc.nl/en/publications/218fc235-c260-48e4-8f8b-23f1e331f03c","ClinicalTrials.gov:NCT03914326"],["1","R0006489","R0006489.pdf","open_download_failed","randomized_trial","Ganeshalingam AA","2025","Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2025.2332","https://doi.org/10.1001/jamapsychiatry.2025.2332","40900607","https://pubmed.ncbi.nlm.nih.gov/40900607/","https://pmc.ncbi.nlm.nih.gov/articles/instance/12409653/bin/jamapsychiatry-e252332-s001.pdf","ClinicalTrials.gov:NCT05193578"],["1","R0008020","R0008020.pdf","open_download_failed","randomized_trial","Luchsinger JA","2025","Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2025.1189","https://doi.org/10.1001/jamainternmed.2025.1189","40388190","https://pubmed.ncbi.nlm.nih.gov/40388190/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12090067/","ClinicalTrials.gov:NCT01794143"],["1","R0008687","R0008687.pdf","free_to_read","randomized_trial","Packer M","2025","Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.06.058","https://doi.org/10.1016/j.jacc.2025.06.058","40903131","https://pubmed.ncbi.nlm.nih.gov/40903131/","https://doi.org/10.1016/j.jacc.2025.06.058","ClinicalTrials.gov:NCT04847557"],["1","R0009598","R0009598.pdf","free_to_read","randomized_trial","Vijiaratnam N","2025","Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)02808-3","https://doi.org/10.1016/s0140-6736(24)02808-3","39919773","https://pubmed.ncbi.nlm.nih.gov/39919773/","https://doi.org/10.1016/s0140-6736(24)02808-3","ClinicalTrials.gov:NCT04232969; EudraCT:2018-003028-35"],["1","R0010671","R0010671.pdf","free_to_read","randomized_trial","Beck J","2025","Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf055","https://doi.org/10.1093/eurjpc/zwaf055","40037282","https://pubmed.ncbi.nlm.nih.gov/40037282/","https://doi.org/10.1093/eurjpc/zwaf055","ClinicalTrials.gov:NCT03204396"],["1","R0010879","R0010879.pdf","free_to_read","randomized_trial","Aronne LJ","2025","Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2416394","https://doi.org/10.1056/nejmoa2416394","40353578","https://pubmed.ncbi.nlm.nih.gov/40353578/","https://hdl.handle.net/1813/117699","ClinicalTrials.gov:NCT05822830"],["1","R0010888","R0010888.pdf","open_download_failed","randomized_trial","Harrison SA","2025","Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2024.07.006","https://doi.org/10.1016/j.jhep.2024.07.006","39002641","https://pubmed.ncbi.nlm.nih.gov/39002641/","http://www.journal-of-hepatology.eu/article/S0168827824023626/pdf","ClinicalTrials.gov:NCT05006885"],["1","R0011011","R0011011.pdf","open_download_failed","randomized_trial","Malhotra A","2025","Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.","Sleep medicine","Elsevier BV","10.1016/j.sleep.2025.106853","https://doi.org/10.1016/j.sleep.2025.106853","41135142","https://pubmed.ncbi.nlm.nih.gov/41135142/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12723708/","ClinicalTrials.gov:NCT05412004"],["1","R0011293","R0011293.pdf","open_download_failed","randomized_trial","Hepprich M","2025","Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvaf153","https://doi.org/10.1093/ejendo/lvaf153","40747712","https://pubmed.ncbi.nlm.nih.gov/40747712/","https://academic.oup.com/ejendo/advance-article-pdf/doi/10.1093/ejendo/lvaf153/63906396/lvaf153.pdf","ClinicalTrials.gov:NCT04909333"],["1","R0011419","R0011419.pdf","open_download_failed","randomized_trial","Yu H","2025","Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70093","https://doi.org/10.1002/bcp.70093","40344607","https://pubmed.ncbi.nlm.nih.gov/40344607/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70093","ClinicalTrials.gov:NCT04515849"],["1","R0013432","R0013432.pdf","free_to_read","randomized_trial","Packer M","2025","Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.03.009","https://doi.org/10.1016/j.jacc.2025.03.009","40162940","https://pubmed.ncbi.nlm.nih.gov/40162940/","https://doi.org/10.1016/j.jacc.2025.03.009","ClinicalTrials.gov:NCT04847557"],["1","R0015625","R0015625.pdf","free_to_read","randomized_trial","Pandey A","2025","Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2025.102610","https://doi.org/10.1016/j.jchf.2025.102610","40956259","https://pubmed.ncbi.nlm.nih.gov/40956259/","https://doi.org/10.1016/j.jchf.2025.102610","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0015844","R0015844.pdf","open_download_failed","randomized_trial","Borlaug BA","2025","Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2025.102660","https://doi.org/10.1016/j.jchf.2025.102660","41045908","https://pubmed.ncbi.nlm.nih.gov/41045908/","https://www.jacc.org/doi/pdf/10.1016/j.jchf.2025.102660?download=true","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0016482","R0016482.pdf","free_to_read","randomized_trial","Sattar N","2025","Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00027-0","https://doi.org/10.1016/s2213-8587(25)00027-0","40318682","https://pubmed.ncbi.nlm.nih.gov/40318682/","https://doi.org/10.1016/s2213-8587(25)00027-0","ClinicalTrials.gov:NCT03882970"],["1","R0016846","R0016846.pdf","open_download_failed","randomized_trial","Deanfield J","2025","Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)01375-3","https://doi.org/10.1016/s0140-6736(25)01375-3","41138739","https://pubmed.ncbi.nlm.nih.gov/41138739/","https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(25)01375-3.pdf","ClinicalTrials.gov:NCT03574597"],["1","R0017051","R0017051.pdf","open_download_failed","randomized_trial","Pop-Busui R","2025","Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.","Diabetes care","American Diabetes Association","10.2337/dc25-1087","https://doi.org/10.2337/dc25-1087","40986645","https://pubmed.ncbi.nlm.nih.gov/40986645/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12583396/",null],["1","R0017452","R0017452.pdf","free_to_read","randomized_trial","Kadowaki T","2025","Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.03.003","https://doi.org/10.1016/j.orcp.2025.03.003","40189961","https://pubmed.ncbi.nlm.nih.gov/40189961/","https://doi.org/10.1016/j.orcp.2025.03.003","ClinicalTrials.gov:NCT03811574"],["1","R0018491","R0018491.pdf","open_download_failed","randomized_trial","Hsia DS","2025","Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.","Diabetes care","American Diabetes Association","10.2337/dc24-2839","https://doi.org/10.2337/dc24-2839","40424051","https://pubmed.ncbi.nlm.nih.gov/40424051/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc24-2839/811057/dc242839.pdf",null],["1","R0018719","R0018719.pdf","free_to_read","randomized_trial","Apperloo EM","2025","Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-024-03327-6","https://doi.org/10.1038/s41591-024-03327-6","39455729","https://pubmed.ncbi.nlm.nih.gov/39455729/","https://research.rug.nl/en/publications/9cb420f1-ab6a-42e6-b834-5cbef5330368","ClinicalTrials.gov:NCT04889183"],["1","R0018972","R0018972.pdf","open_download_failed","randomized_trial","Davies MJ","2025","Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(24)00304-8","https://doi.org/10.1016/s2213-8587(24)00304-8","39848268","https://pubmed.ncbi.nlm.nih.gov/39848268/","https://research.rug.nl/files/1289784568/1-s2.0-S2213858724003048-main.pdf","ClinicalTrials.gov:NCT04916470"],["1","R0019604","R0019604.pdf","open_download_failed","randomized_trial","Shah VN","2025","Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241305647","https://doi.org/10.1177/19322968241305647","39717993","https://pubmed.ncbi.nlm.nih.gov/39717993/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669135/pdf/10.1177_19322968241305647.pdf","ClinicalTrials.gov:NCT01836523; ClinicalTrials.gov:NCT02098395"],["1","R0019659","R0019659.pdf","open_download_failed","randomized_trial","Wexler DJ","2025","Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc24-2825","https://doi.org/10.2337/dc24-2825","40267365","https://pubmed.ncbi.nlm.nih.gov/40267365/","https://pubmed.ncbi.nlm.nih.gov/40267365/",null],["1","R0020582","R0020582.pdf","open_download_failed","randomized_trial","Youovop J","2025","Dichrostachys glomerata and Cissus quadrangularis Extracts Enhance GLP-1 Secretion and Inhibit DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial","Authorea Preprints","Wiley","10.22541/au.175664716.64802840/v1","https://doi.org/10.22541/au.175664716.64802840/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175664716.64802840/v1","ClinicalTrials.gov:NCT06827002"],["1","R0021775","R0021775.pdf","open_download_failed","randomized_trial","Utzschneider KM","2025","Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc24-2419","https://doi.org/10.2337/dc24-2419","39998948","https://pubmed.ncbi.nlm.nih.gov/39998948/","https://pubmed.ncbi.nlm.nih.gov/39998948/",null],["1","R0041454","R0041454.pdf","no_doi","randomized_trial","Steve Bain","2025","Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03914326"],["1","R0042126","R0042126.pdf","no_doi","randomized_trial","WD Strain (14423826)","2025","Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomised SUSTAIN 6 & PIONEER 6","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["1","R0042191","R0042191.pdf","no_doi","randomized_trial","Melanie Davies (20342379)","2025","Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04916470"],["1","R0043652","R0043652.pdf","no_doi","randomized_trial","Stenlid, Rasmus","2025","Cardiovascular Risk Factors and Aspects of GLP-1 Treatment in Pediatric Obesity","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02794402"],["1","R0043856","R0043856.pdf","no_doi","randomized_trial","Dinkla, Lauren","2025","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND BONE HEALTH: RESULTS FROM A PILOT RANDOMIZED CONTROLLED TRIAL","WakeSpace Scholarship (Wake Forest University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05786521"],["1","R0043934","R0043934.pdf","open_download_failed","randomized_trial","Svenja Leibnitz","2025","SAT-064 Copeptin Levels at Baseline and in Response to Short-Acting GLP-1 Receptor Agonists in Patients with Endogenous Hyperinsulinemic Hypoglycemia and Healthy Controls - A Secondary Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1546","https://doi.org/10.1210/jendso/bvaf149.1546",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1546/64864978/bvaf149.1546.pdf","ClinicalTrials.gov:NCT04909333"],["1","R0045712","R0045712.pdf","free_to_read","randomized_trial","Vanita R. Aroda","2025","High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight/obesity: a randomized, placebo-controlled, phase 2 trial",null,"American Diabetes Association","10.2337/figshare.28544267.v1","https://doi.org/10.2337/figshare.28544267.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28544267.v1","ClinicalTrials.gov:NCT05486065"],["1","R0003419","R0003419.pdf","free_to_read","randomized_trial","Georgianos PI","2024","The glucagon-like peptide-1 receptor agonist semaglutide in diabetic kidney disease: A new kid on the block to afford maximal kidney protection.","European journal of clinical investigation","Wiley","10.1111/eci.14284","https://doi.org/10.1111/eci.14284","38979836","https://pubmed.ncbi.nlm.nih.gov/38979836/","https://doi.org/10.1111/eci.14284","ClinicalTrials.gov:NCT04865770"],["1","R0003688","R0003688.pdf","open_download_failed","randomized_trial","Gilbert MP","2024","Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15479","https://doi.org/10.1111/dom.15479","38317618","https://pubmed.ncbi.nlm.nih.gov/38317618/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15479","ClinicalTrials.gov:NCT02465515"],["1","R0003722","R0003722.pdf","open_download_failed","randomized_trial","Buckeridge C","2024","Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15643","https://doi.org/10.1111/dom.15643","38751362","https://pubmed.ncbi.nlm.nih.gov/38751362/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15643","ClinicalTrials.gov:NCT04305587; ClinicalTrials.gov:NCT05158244"],["1","R0003953","R0003953.pdf","open_download_failed","randomized_trial","Locatelli JC","2024","Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?","Diabetes care","American Diabetes Association","10.2337/dci23-0100","https://doi.org/10.2337/dci23-0100","38687506","https://pubmed.ncbi.nlm.nih.gov/38687506/","https://diabetesjournals.org/care/article-pdf/47/10/1718/783542/dci230100.pdf",null],["1","R0006125","R0006125.pdf","open_download_failed","randomized_trial","Xie P","2024","A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15624","https://doi.org/10.1111/dom.15624","38808476","https://pubmed.ncbi.nlm.nih.gov/38808476/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15624","ClinicalTrials.gov:NCT04016974"],["1","R0007788","R0007788.pdf","open_download_failed","randomized_trial","Gonzalez JS","2024","Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc23-2459","https://doi.org/10.2337/dc23-2459","38416773","https://pubmed.ncbi.nlm.nih.gov/38416773/","https://diabetesjournals.org/care/article-pdf/47/4/610/751798/dc232459.pdf",null],["1","R0007867","R0007867.pdf","free_to_read","randomized_trial","Pratley RE","2024","Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.08.004","https://doi.org/10.1016/j.jacc.2024.08.004","39217553","https://pubmed.ncbi.nlm.nih.gov/39217553/","https://doi.org/10.1016/j.jacc.2024.08.004","ClinicalTrials.gov:NCT03819153"],["1","R0007916","R0007916.pdf","free_to_read","randomized_trial","Petrie MC","2024","Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.04.022","https://doi.org/10.1016/j.jacc.2024.04.022","38819334","https://pubmed.ncbi.nlm.nih.gov/38819334/","https://www.sciencedirect.com/science/article/pii/S0735109724070207/pdf",null],["1","R0008321","R0008321.pdf","open_download_failed","randomized_trial","Cirnigliaro CM","2024","Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.","The journal of spinal cord medicine","Informa UK Limited","10.1080/10790268.2023.2207064","https://doi.org/10.1080/10790268.2023.2207064","37158751","https://pubmed.ncbi.nlm.nih.gov/37158751/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11218576/pdf/YSCM_47_2207064.pdf","ClinicalTrials.gov:NCT03292315"],["1","R0008914","R0008914.pdf","open_download_failed","randomized_trial","Chowdhary A","2024","Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.04.064","https://doi.org/10.1016/j.jacc.2024.04.064","39084829","https://pubmed.ncbi.nlm.nih.gov/39084829/","https://doi.org/10.1016/j.jacc.2024.04.064","ClinicalTrials.gov:NCT04657939"],["1","R0009933","R0009933.pdf","open_download_failed","randomized_trial","Herfarth H","2024","Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000002801","https://doi.org/10.14309/ajg.0000000000002801","38668926","https://pubmed.ncbi.nlm.nih.gov/38668926/","https://doi.org/10.14309/ajg.0000000000002801",null],["1","R0010286","R0010286.pdf","open_download_failed","randomized_trial","Selvarajah V","2024","A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.","Kidney international","Elsevier BV","10.1016/j.kint.2024.08.023","https://doi.org/10.1016/j.kint.2024.08.023","39218393","https://pubmed.ncbi.nlm.nih.gov/39218393/","http://www.kidney-international.org/article/S008525382400629X/pdf",null],["1","R0010504","R0010504.pdf","free_to_read","randomized_trial","Gabe MBN","2024","Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15951","https://doi.org/10.1111/dom.15951","39279639","https://pubmed.ncbi.nlm.nih.gov/39279639/","https://doi.org/10.1111/dom.15951","ClinicalTrials.gov:NCT05804162"],["1","R0011292","R0011292.pdf","open_download_failed","randomized_trial","Punthakee Z","2024","Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15926","https://doi.org/10.1111/dom.15926","39239702","https://pubmed.ncbi.nlm.nih.gov/39239702/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15926","ClinicalTrials.gov:NCT03862716"],["1","R0013589","R0013589.pdf","open_download_failed","randomized_trial","Liu M","2024","The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15724","https://doi.org/10.1111/dom.15724","38922731","https://pubmed.ncbi.nlm.nih.gov/38922731/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15724","ClinicalTrials.gov:NCT05413369"],["1","R0015327","R0015327.pdf","open_download_failed","randomized_trial","Eckard AR","2024","Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(24)00150-5","https://doi.org/10.1016/s2213-8587(24)00150-5","38964353","https://pubmed.ncbi.nlm.nih.gov/38964353/","https://doi.org/10.1016/s2213-8587(24)00150-5","ClinicalTrials.gov:NCT04019197"],["1","R0015817","R0015817.pdf","free_to_read","randomized_trial","McGowan BM","2024","Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(24)00182-7","https://doi.org/10.1016/s2213-8587(24)00182-7","39089293","https://pubmed.ncbi.nlm.nih.gov/39089293/","http://hdl.handle.net/10138/592784","ClinicalTrials.gov:NCT05040971"],["1","R0015897","R0015897.pdf","free_to_read","randomized_trial","Sanyal AJ","2024","A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2401755","https://doi.org/10.1056/nejmoa2401755","38847460","https://pubmed.ncbi.nlm.nih.gov/38847460/","https://research.birmingham.ac.uk/en/publications/f24ca898-be1b-40ab-ae5c-39434d3ee051","ClinicalTrials.gov:NCT04771273; EudraCT:2020-002723-11"],["1","R0015980","R0015980.pdf","free_to_read","randomized_trial","Deanfield J","2024","Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)01498-3","https://doi.org/10.1016/s0140-6736(24)01498-3","39181597","https://pubmed.ncbi.nlm.nih.gov/39181597/","https://doi.org/10.1016/s0140-6736(24)01498-3","ClinicalTrials.gov:NCT03574597"],["1","R0016007","R0016007.pdf","open_download_failed","randomized_trial","Golubic R","2024","Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15579","https://doi.org/10.1111/dom.15579","38562018","https://pubmed.ncbi.nlm.nih.gov/38562018/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15579","ClinicalTrials.gov:NCT03596177"],["1","R0016750","R0016750.pdf","free_to_read","randomized_trial","Shankar SS","2024","Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2024.04.017","https://doi.org/10.1016/j.cgh.2024.04.017","38729399","https://pubmed.ncbi.nlm.nih.gov/38729399/","https://doi.org/10.1016/j.cgh.2024.04.017","ClinicalTrials.gov:NCT04019561"],["1","R0016793","R0016793.pdf","open_download_failed","randomized_trial","Butler J","2024","Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)00469-0","https://doi.org/10.1016/s0140-6736(24)00469-0","38599221","https://pubmed.ncbi.nlm.nih.gov/38599221/","https://researchprofiles.ku.dk/da/publications/f3a281ad-c536-43dc-a9a4-3ed3a1d77d8a","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0017539","R0017539.pdf","open_download_failed","randomized_trial","Morioka T","2024","A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15644","https://doi.org/10.1111/dom.15644","38715179","https://pubmed.ncbi.nlm.nih.gov/38715179/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15644","ClinicalTrials.gov:NCT04809220"],["1","R0018279","R0018279.pdf","open_download_failed","randomized_trial","Zhao L","2024","Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2024.9217","https://doi.org/10.1001/jama.2024.9217","38819983","https://pubmed.ncbi.nlm.nih.gov/38819983/","https://pmc.ncbi.nlm.nih.gov/articles/instance/11337071/bin/jama-e249217-s001.pdf","ClinicalTrials.gov:NCT05024032"],["1","R0018369","R0018369.pdf","free_to_read","randomized_trial","Solomon SD","2024","Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.08.021","https://doi.org/10.1016/j.jacc.2024.08.021","39217567","https://pubmed.ncbi.nlm.nih.gov/39217567/","https://doi.org/10.1016/j.jacc.2024.08.021","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0018379","R0018379.pdf","free_to_read","randomized_trial","Scirica BM","2024","The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.08.007","https://doi.org/10.1016/j.jacc.2024.08.007","39217559","https://pubmed.ncbi.nlm.nih.gov/39217559/","https://doi.org/10.1016/j.jacc.2024.08.007","ClinicalTrials.gov:NCT03574597"],["1","R0018703","R0018703.pdf","free_to_read","randomized_trial","Schou M","2024","Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.04.038","https://doi.org/10.1016/j.jacc.2024.04.038","38913004","https://pubmed.ncbi.nlm.nih.gov/38913004/","https://doi.org/10.1016/j.jacc.2024.04.038","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0018819","R0018819.pdf","open_download_failed","randomized_trial","Gabe MBN","2024","Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15802","https://doi.org/10.1111/dom.15802","39082206","https://pubmed.ncbi.nlm.nih.gov/39082206/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15802",null],["1","R0018941","R0018941.pdf","open_download_failed","randomized_trial","Aronne LJ","2024","Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.24945","https://doi.org/10.1001/jama.2023.24945","38078870","https://pubmed.ncbi.nlm.nih.gov/38078870/","https://pmc.ncbi.nlm.nih.gov/articles/instance/10714284/bin/jama-e2324945-s001.pdf","ClinicalTrials.gov:NCT04660643"],["1","R0018977","R0018977.pdf","open_download_failed","randomized_trial","Malhotra A","2024","Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2404881","https://doi.org/10.1056/nejmoa2404881","38912654","https://pubmed.ncbi.nlm.nih.gov/38912654/","https://escholarship.org/content/qt5xf6509x/qt5xf6509x.pdf","ClinicalTrials.gov:NCT05412004"],["1","R0019167","R0019167.pdf","free_to_read","randomized_trial","Verma S","2024","Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.06.001","https://doi.org/10.1016/j.jacc.2024.06.001","38913003","https://pubmed.ncbi.nlm.nih.gov/38913003/","https://doi.org/10.1016/j.jacc.2024.06.001","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0019395","R0019395.pdf","free_to_read","randomized_trial","Verma S","2024","Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.08.028","https://doi.org/10.1016/j.jacc.2024.08.028","39217564","https://pubmed.ncbi.nlm.nih.gov/39217564/","https://www.sciencedirect.com/science/article/pii/S0735109724082342/pdf","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["1","R0019504","R0019504.pdf","open_download_failed","randomized_trial","Hankosky ER","2024","Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15318","https://doi.org/10.1111/dom.15318","37932236","https://pubmed.ncbi.nlm.nih.gov/37932236/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15318",null],["1","R0019870","R0019870.pdf","open_download_failed","randomized_trial","Rubino D","2024","Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15620","https://doi.org/10.1111/dom.15620","38698650","https://pubmed.ncbi.nlm.nih.gov/38698650/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15620","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987"],["1","R0020223","R0020223.pdf","free_to_read","randomized_trial","Kosiborod MN","2024","Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2313917","https://doi.org/10.1056/nejmoa2313917","38587233","https://pubmed.ncbi.nlm.nih.gov/38587233/","https://pure.amsterdamumc.nl/en/publications/05f2e856-9ac1-415b-9c69-de80b43f68c7","ClinicalTrials.gov:NCT04916470"],["1","R0020412","R0020412.pdf","open_download_failed","randomized_trial","Mather KJ","2024","Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15365","https://doi.org/10.1111/dom.15365","37989596","https://pubmed.ncbi.nlm.nih.gov/37989596/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15365","ClinicalTrials.gov:NCT05556512; ClinicalTrials.gov:NCT04255433"],["1","R0020516","R0020516.pdf","open_download_failed","randomized_trial","Cherrington AL","2024","Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc23-1648","https://doi.org/10.2337/dc23-1648","38190625","https://pubmed.ncbi.nlm.nih.gov/38190625/","https://diabetesjournals.org/care/article-pdf/47/4/603/751713/dc231648.pdf",null],["1","R0020853","R0020853.pdf","open_download_failed","randomized_trial","Gragnano F","2024","FLOW trial stopped early due to evidence of renal protection with semaglutide.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad080","https://doi.org/10.1093/ehjcvp/pvad080","37934595","https://pubmed.ncbi.nlm.nih.gov/37934595/","https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvad080/53402056/pvad080.pdf","ClinicalTrials.gov:NCT03819153"],["1","R0021172","R0021172.pdf","open_download_failed","randomized_trial","Kobo O","2024","Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15396","https://doi.org/10.1111/dom.15396","38082468","https://pubmed.ncbi.nlm.nih.gov/38082468/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15396","ClinicalTrials.gov:NCT01720446"],["1","R0021754","R0021754.pdf","open_download_failed","randomized_trial","Green JB","2024","Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.123.066604","https://doi.org/10.1161/circulationaha.123.066604","38344820","https://pubmed.ncbi.nlm.nih.gov/38344820/","https://escholarship.org/content/qt5hw2n6sr/qt5hw2n6sr.pdf","ClinicalTrials.gov:NCT01794143"],["1","R0022156","R0022156.pdf","open_download_failed","randomized_trial","Kirkman MS","2024","Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc23-1332","https://doi.org/10.2337/dc23-1332","38194519","https://pubmed.ncbi.nlm.nih.gov/38194519/","https://diabetesjournals.org/care/article-pdf/47/4/594/751727/dc231332.pdf",null],["1","R0022160","R0022160.pdf","open_download_failed","randomized_trial","Rasouli N","2024","Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc23-1070","https://doi.org/10.2337/dc23-1070","38211595","https://pubmed.ncbi.nlm.nih.gov/38211595/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10973918/pdf/dc231070.pdf",null],["1","R0022309","R0022309.pdf","open_download_failed","randomized_trial","Utzschneider KM","2024","Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.","Diabetes care","American Diabetes Association","10.2337/dc23-1059","https://doi.org/10.2337/dc23-1059","38190619","https://pubmed.ncbi.nlm.nih.gov/38190619/","https://diabetesjournals.org/care/article-pdf/47/4/571/751718/dc231059.pdf",null],["1","R0023016","R0023016.pdf","open_download_failed","randomized_trial","Garvey WT","2024","Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc23-1782","https://doi.org/10.2337/dc23-1782","38285957","https://pubmed.ncbi.nlm.nih.gov/38285957/","https://diabetesjournals.org/care/article-pdf/47/4/562/751814/dc231782.pdf",null],["1","R0023025","R0023025.pdf","open_download_failed","randomized_trial","Hollander PA","2024","The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc23-0516","https://doi.org/10.2337/dc23-0516","37756542","https://pubmed.ncbi.nlm.nih.gov/37756542/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10973913/pdf/dc230516.pdf",null],["1","R0032846","R0032846.pdf","free_to_read","randomized_trial","STUDY GROUP PB-718","2024","768-P: A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity","Diabetes","American Diabetes Association","10.2337/db24-768-p","https://doi.org/10.2337/db24-768-p",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2337/db24-768-p","ClinicalTrials.gov:NCT06147544"],["1","R0041799","R0041799.pdf","open_download_failed","randomized_trial","Stefan Agewall","2024","Prevention is the key","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvae090","https://doi.org/10.1093/ehjcvp/pvae090","39797531","https://pubmed.ncbi.nlm.nih.gov/39797531/","https://academic.oup.com/ehjcvp/article-pdf/10/8/649/61412109/pvae090.pdf","ClinicalTrials.gov:NCT04560998"],["1","R0041831","R0041831.pdf","open_download_failed","randomized_trial","Ronald R. Grunstein","2024","O064 Tirzepatide reduced sleep apnea severity in adults with obstructive sleep apnea and obesity: results from the SURMOUNT-OSA trial","SLEEP Advances","Oxford University Press (OUP)","10.1093/sleepadvances/zpae070.064","https://doi.org/10.1093/sleepadvances/zpae070.064",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleepadvances/article-pdf/5/Supplement_1/A23/60938788/zpae070.064.pdf","ClinicalTrials.gov:NCT05412004"],["1","R0042508","R0042508.pdf","no_doi","randomized_trial","J Deanfield (7667639)","2024","Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","Aston Publications Explorer (Aston University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03574597"],["1","R0044283","R0044283.pdf","no_doi","randomized_trial","Cliona P O'Donnell","2024","Evaluating a new treatment approach for obstructive sleep apnoea in adults with obesity and without diabetes: a proof-of-concept study investigating the effects of glucagon-like-peptide-1 agonist-mediated weight loss versus CPAP or both in combination, on metabolic, cardiovascular and quality of life outcomes","Research Repository UCD (University College Dublin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04186494"],["1","R0048854","R0048854.pdf","free_to_read","randomized_trial","Philip Scheltens","2024","Preliminary baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer’s disease","Arquivos de Neuro-Psiquiatria","Zeppelini Editorial e Comunicação","10.5327/cbn241336","https://doi.org/10.5327/cbn241336",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5327/cbn241336","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0052533","R0052533.pdf","open_download_failed","randomized_trial","Carel Wynand le Roux","2024","6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight/Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.033","https://doi.org/10.1210/jendso/bvae163.033",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.033/59607593/bvae163.033.pdf","ClinicalTrials.gov:NCT04667377"],["1","R0053377","R0053377.pdf","open_download_failed","randomized_trial","Wiesje M. van der Flier","2024","Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease","Alzheimer s & Dementia","Wiley","10.1002/alz.088793","https://doi.org/10.1002/alz.088793",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.088793","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409"],["1","R0055574","R0055574.pdf","open_download_failed","randomized_trial","M Jensterle Sever","2024","6468 Once-Weekly Semaglutide and Taste Perception in Women with Obesity","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.013","https://doi.org/10.1210/jendso/bvae163.013",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.013/59607287/bvae163.013.pdf","ClinicalTrials.gov:NCT04263415"],["1","R0006193","R0006193.pdf","open_download_failed","randomized_trial","Gerstein HC","2023","Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.122.063716","https://doi.org/10.1161/circulationaha.122.063716","36802715","https://pubmed.ncbi.nlm.nih.gov/36802715/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.122.063716","ClinicalTrials.gov:NCT03496298"],["1","R0007238","R0007238.pdf","open_download_failed","randomized_trial","Saxena AR","2023","Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15168","https://doi.org/10.1111/dom.15168","37311722","https://pubmed.ncbi.nlm.nih.gov/37311722/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15168","ClinicalTrials.gov:NCT04617275"],["1","R0008053","R0008053.pdf","open_download_failed","randomized_trial","Kelly AS","2023","Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23808","https://doi.org/10.1002/oby.23808","37196421","https://pubmed.ncbi.nlm.nih.gov/37196421/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23808","ClinicalTrials.gov:NCT04102189"],["1","R0008618","R0008618.pdf","free_to_read","randomized_trial","Frias JP","2023","Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(23)01163-7","https://doi.org/10.1016/s0140-6736(23)01163-7","37364590","https://pubmed.ncbi.nlm.nih.gov/37364590/","https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_co-administered_once-weekly_cagrilintide_2_4_mg_with_once-weekly_semaglutide_2_4_mg_in_type_2_diabetes_a_multicentre_randomised_double-blind_active-controlled_phase_2_trial/24182493","ClinicalTrials.gov:NCT04982575"],["1","R0008796","R0008796.pdf","open_download_failed","randomized_trial","Romero-Gómez M","2023","Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.17598","https://doi.org/10.1111/apt.17598","37328931","https://pubmed.ncbi.nlm.nih.gov/37328931/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.17598","ClinicalTrials.gov:NCT02970942"],["1","R0009070","R0009070.pdf","open_download_failed","randomized_trial","Romero-Gómez M","2023","A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2023.05.013","https://doi.org/10.1016/j.jhep.2023.05.013","37355043","https://pubmed.ncbi.nlm.nih.gov/37355043/","http://www.journal-of-hepatology.eu/article/S0168827823003422/pdf","ClinicalTrials.gov:NCT04944992; EudraCT:2020-005136-30"],["1","R0009442","R0009442.pdf","open_download_failed","randomized_trial","Angelidi AM","2023","Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2022.155346","https://doi.org/10.1016/j.metabol.2022.155346","36375643","https://pubmed.ncbi.nlm.nih.gov/36375643/","https://www.metabolismjournal.com/article/S0026-0495(22)00224-4/pdf","ClinicalTrials.gov:NCT03851874; ClinicalTrials.gov:NCT01562678; ClinicalTrials.gov:NCT02944500"],["1","R0009666","R0009666.pdf","open_download_failed","randomized_trial","Rosenstock J","2023","Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.20294","https://doi.org/10.1001/jama.2023.20294","37786396","https://pubmed.ncbi.nlm.nih.gov/37786396/","https://jamanetwork.com/journals/jama/articlepdf/2810386/jama_rosenstock_2023_oi_230119_1698789079.88265.pdf","ClinicalTrials.gov:NCT04537923"],["1","R0010585","R0010585.pdf","open_download_failed","randomized_trial","Guo X","2023","iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15074","https://doi.org/10.1111/dom.15074","36999231","https://pubmed.ncbi.nlm.nih.gov/36999231/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15074","ClinicalTrials.gov:NCT03798054; ClinicalTrials.gov:NCT03798080"],["1","R0011239","R0011239.pdf","open_download_failed","randomized_trial","Pagidipati NJ","2023","Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.2854","https://doi.org/10.1001/jama.2023.2854","36877177","https://pubmed.ncbi.nlm.nih.gov/36877177/","https://www.ncbi.nlm.nih.gov/pmc/articles/9989955","ClinicalTrials.gov:NCT03936660"],["1","R0011858","R0011858.pdf","free_to_read","randomized_trial","Gao L","2023","Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-023-02344-1","https://doi.org/10.1038/s41591-023-02344-1","37231074","https://pubmed.ncbi.nlm.nih.gov/37231074/",null,"ClinicalTrials.gov:NCT04093752"],["1","R0011935","R0011935.pdf","open_download_failed","randomized_trial","Takahashi Y","2023","Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14998","https://doi.org/10.1111/dom.14998","36722623","https://pubmed.ncbi.nlm.nih.gov/36722623/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14998",null],["1","R0016220","R0016220.pdf","open_download_failed","randomized_trial","Caruso P","2023","Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3627","https://doi.org/10.1002/dmrr.3627","36812501","https://pubmed.ncbi.nlm.nih.gov/36812501/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.3627","ClinicalTrials.gov:NCT04560998; ClinicalTrials.gov:NCT04146155; ClinicalTrials.gov:NCT04881110"],["1","R0017381","R0017381.pdf","open_download_failed","randomized_trial","Hamilton GS","2023","The potential impact of GLP-1 agonists on obstructive sleep apnoea.","Respirology (Carlton, Vic.)","Wiley","10.1111/resp.14545","https://doi.org/10.1111/resp.14545","37419864","https://pubmed.ncbi.nlm.nih.gov/37419864/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/resp.14545","ClinicalTrials.gov:NCT05412004"],["1","R0017762","R0017762.pdf","open_download_failed","randomized_trial","Asano M","2023","Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double-blind, placebo-controlled study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15107","https://doi.org/10.1111/dom.15107","37337366","https://pubmed.ncbi.nlm.nih.gov/37337366/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15107","ClinicalTrials.gov:NCT04208620"],["1","R0019180","R0019180.pdf","open_download_failed","randomized_trial","Urva S","2023","The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15167","https://doi.org/10.1111/dom.15167","37311727","https://pubmed.ncbi.nlm.nih.gov/37311727/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15167","ClinicalTrials.gov:NCT04143802"],["1","R0019477","R0019477.pdf","open_download_failed","randomized_trial","Hankosky ER","2023","Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15269","https://doi.org/10.1111/dom.15269","37700443","https://pubmed.ncbi.nlm.nih.gov/37700443/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15269","ClinicalTrials.gov:NCT04184622"],["1","R0019926","R0019926.pdf","open_download_failed","randomized_trial","Wilkinson L","2023","Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23842","https://doi.org/10.1002/oby.23842","37605636","https://pubmed.ncbi.nlm.nih.gov/37605636/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23842","ClinicalTrials.gov:NCT03548987; ClinicalTrials.gov:NCT03693430"],["1","R0020386","R0020386.pdf","open_download_failed","randomized_trial","Butler J","2023","Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2023.09.811","https://doi.org/10.1016/j.jacc.2023.09.811","37993201","https://pubmed.ncbi.nlm.nih.gov/37993201/","https://doi.org/10.1016/j.jacc.2023.09.811","ClinicalTrials.gov:NCT04788511"],["1","R0020837","R0020837.pdf","open_download_failed","randomized_trial","Kosiborod MN","2023","Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2306963","https://doi.org/10.1056/nejmoa2306963","37622681","https://pubmed.ncbi.nlm.nih.gov/37622681/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2306963","ClinicalTrials.gov:NCT04788511"],["1","R0021078","R0021078.pdf","open_download_failed","randomized_trial","Wharton S","2023","Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23673","https://doi.org/10.1002/oby.23673","36655300","https://pubmed.ncbi.nlm.nih.gov/36655300/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23673",null],["1","R0021243","R0021243.pdf","open_download_failed","randomized_trial","McGowan BM","2023","Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23732","https://doi.org/10.1002/oby.23732","36876594","https://pubmed.ncbi.nlm.nih.gov/36876594/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23732","ClinicalTrials.gov:NCT03548935"],["1","R0021620","R0021620.pdf","free_to_read","randomized_trial","Aroda VR","2023","Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(23)01127-3","https://doi.org/10.1016/s0140-6736(23)01127-3","37385279","https://pubmed.ncbi.nlm.nih.gov/37385279/",null,"ClinicalTrials.gov:NCT04707469; EudraCT:2020-000299-39"],["1","R0022330","R0022330.pdf","open_download_failed","randomized_trial","Verma S","2023","Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15081","https://doi.org/10.1111/dom.15081","37016488","https://pubmed.ncbi.nlm.nih.gov/37016488/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15081","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["1","R0024626","R0024626.pdf","open_download_failed","randomized_trial","Wexler DJ","2023","Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2023.1487","https://doi.org/10.1001/jamainternmed.2023.1487","37213109","https://pubmed.ncbi.nlm.nih.gov/37213109/","https://www.ncbi.nlm.nih.gov/pmc/articles/10203973","ClinicalTrials.gov:NCT01794143"],["1","R0030139","R0030139.pdf","free_to_read","randomized_trial","Jin J","2023","Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/j.ejps.2023.106448","https://doi.org/10.1016/j.ejps.2023.106448","37062422","https://pubmed.ncbi.nlm.nih.gov/37062422/","https://doi.org/10.1016/j.ejps.2023.106448","ClinicalTrials.gov:NCT03990090"],["1","R0042144","R0042144.pdf","no_doi","randomized_trial","Melanie J Davies (7258691)","2023","Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >= 8%, >= 64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058147"],["1","R0047034","R0047034.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","Tirzepatide maintained significant weight loss when treatment was continued in a follow‐up study","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.79","https://doi.org/10.1002/doi2.79",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.79","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643"],["1","R0050208","R0050208.pdf","open_download_failed","randomized_trial","Nikolaus Marx","2023","Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2751","https://doi.org/10.1093/eurheartj/ehad655.2751",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2751/53608373/ehad655.2751.pdf","ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT03819153"],["1","R0050551","R0050551.pdf","free_to_read","randomized_trial","Susan Leanne Samson","2023","THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.1134","https://doi.org/10.1210/jendso/bvad114.1134",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.1134","ClinicalTrials.gov:NCT02060383"],["1","R0052091","R0052091.pdf","open_download_failed","randomized_trial","Katherine R. Tuttle","2023","#4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfad063b_4441","https://doi.org/10.1093/ndt/gfad063b_4441",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/38/Supplement_1/gfad063b_4441/50674821/gfad063b_4441.pdf","ClinicalTrials.gov:NCT01720446"],["1","R0052122","R0052122.pdf","open_download_failed","randomized_trial","John Eric Deanfield","2023","Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2752","https://doi.org/10.1093/eurheartj/ehad655.2752",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2752/53608370/ehad655.2752.pdf","ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT03819153"],["1","R0052993","R0052993.pdf","open_download_failed","randomized_trial","Petar M Seferovic","2023","No such thing as an innocent bystander: the conundrum of obesity, diabetes, and heart failure with preserved ejection fraction","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad226","https://doi.org/10.1093/eurjpc/zwad226","37421379","https://pubmed.ncbi.nlm.nih.gov/37421379/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwad226/50896522/zwad226.pdf","ClinicalTrials.gov:NCT04847557"],["1","R0006214","R0006214.pdf","open_download_failed","randomized_trial","Vukajlovic T","2022","Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgac063","https://doi.org/10.1210/clinem/dgac063","35134170","https://pubmed.ncbi.nlm.nih.gov/35134170/","https://academic.oup.com/jcem/article-pdf/107/6/e2581/43739001/dgac063.pdf","ClinicalTrials.gov:NCT03141632; ClinicalTrials.gov:NCT02770885"],["1","R0007808","R0007808.pdf","free_to_read","randomized_trial","Pirro V","2022","Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgab722","https://doi.org/10.1210/clinem/dgab722","34608929","https://pubmed.ncbi.nlm.nih.gov/34608929/",null,"ClinicalTrials.gov:NCT03131687"],["1","R0009387","R0009387.pdf","open_download_failed","randomized_trial","López-Cano C","2022","Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.","Diabetes","American Diabetes Association","10.2337/db21-0688","https://doi.org/10.2337/db21-0688","34737187","https://pubmed.ncbi.nlm.nih.gov/34737187/","https://diabetesjournals.org/diabetes/article-pdf/71/2/315/640899/db210688.pdf","ClinicalTrials.gov:NCT02889510"],["1","R0009964","R0009964.pdf","open_download_failed","randomized_trial","Weghuber D","2022","Once-Weekly Semaglutide in Adolescents with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2208601","https://doi.org/10.1056/nejmoa2208601","36322838","https://pubmed.ncbi.nlm.nih.gov/36322838/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208601?articleTools=true","ClinicalTrials.gov:NCT04102189"],["1","R0010336","R0010336.pdf","open_download_failed","randomized_trial","Arslanian SA","2022","Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2204601","https://doi.org/10.1056/nejmoa2204601","35658022","https://pubmed.ncbi.nlm.nih.gov/35658022/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204601?articleTools=true","ClinicalTrials.gov:NCT02963766"],["1","R0010626","R0010626.pdf","open_download_failed","randomized_trial","GRADE Study Research Group","2022","Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2200433","https://doi.org/10.1056/nejmoa2200433","36129996","https://pubmed.ncbi.nlm.nih.gov/36129996/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433?articleTools=true","ClinicalTrials.gov:NCT01794143"],["1","R0010987","R0010987.pdf","open_download_failed","randomized_trial","Jastreboff AM","2022","Tirzepatide Once Weekly for the Treatment of Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2206038","https://doi.org/10.1056/nejmoa2206038","35658024","https://pubmed.ncbi.nlm.nih.gov/35658024/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206038?articleTools=true","ClinicalTrials.gov:NCT04184622"],["1","R0011197","R0011197.pdf","free_to_read","randomized_trial","Alkhouri N","2022","Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2022.04.003","https://doi.org/10.1016/j.jhep.2022.04.003","35439567","https://pubmed.ncbi.nlm.nih.gov/35439567/","https://doi.org/10.1016/j.jhep.2022.04.003","ClinicalTrials.gov:NCT03987074"],["1","R0012480","R0012480.pdf","open_download_failed","randomized_trial","Dahl D","2022","Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2022.0078","https://doi.org/10.1001/jama.2022.0078","35133415","https://pubmed.ncbi.nlm.nih.gov/35133415/","https://jamanetwork.com/journals/jama/articlepdf/2788781/jama_dahl_2022_oi_220003_1644261864.35143.pdf","ClinicalTrials.gov:NCT04039503"],["1","R0012580","R0012580.pdf","free_to_read","randomized_trial","Inagaki N","2022","Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00188-7","https://doi.org/10.1016/s2213-8587(22)00188-7","35914543","https://pubmed.ncbi.nlm.nih.gov/35914543/","https://doi.org/10.1016/s2213-8587(22)00188-7","ClinicalTrials.gov:NCT03861052"],["1","R0013321","R0013321.pdf","open_download_failed","randomized_trial","Yang W","2022","Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14722","https://doi.org/10.1111/dom.14722","35441412","https://pubmed.ncbi.nlm.nih.gov/35441412/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14722","ClinicalTrials.gov:NCT03798054"],["1","R0014535","R0014535.pdf","open_download_failed","randomized_trial","Rubino DM","2022","Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2021.23619","https://doi.org/10.1001/jama.2021.23619","35015037","https://pubmed.ncbi.nlm.nih.gov/35015037/","https://jamanetwork.com/journals/jama/articlepdf/2787907/jama_rubino_2022_oi_210142_1641310203.77797.pdf","ClinicalTrials.gov:NCT04074161"],["1","R0016746","R0016746.pdf","open_download_failed","randomized_trial","Maselli D","2022","Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23481","https://doi.org/10.1002/oby.23481","35894080","https://pubmed.ncbi.nlm.nih.gov/35894080/","https://www.ncbi.nlm.nih.gov/pmc/articles/9335902","ClinicalTrials.gov:NCT02647944"],["1","R0016965","R0016965.pdf","open_download_failed","randomized_trial","Tommerdahl KL","2022","The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.00020122","https://doi.org/10.2215/cjn.00020122","35396319","https://pubmed.ncbi.nlm.nih.gov/35396319/","https://www.ncbi.nlm.nih.gov/pmc/articles/9269664","ClinicalTrials.gov:NCT04865770; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT04889157; ClinicalTrials.gov:NCT05048719"],["1","R0018699","R0018699.pdf","free_to_read","randomized_trial","Heerspink HJL","2022","Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00243-1","https://doi.org/10.1016/s2213-8587(22)00243-1","36152639","https://pubmed.ncbi.nlm.nih.gov/36152639/","https://hdl.handle.net/11370/9fd182d5-8590-4916-a1a3-8301509299bf","ClinicalTrials.gov:NCT03730662"],["1","R0020654","R0020654.pdf","free_to_read","randomized_trial","Elkind-Hirsch KE","2022","Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.","Fertility and sterility","Elsevier BV","10.1016/j.fertnstert.2022.04.027","https://doi.org/10.1016/j.fertnstert.2022.04.027","35710599","https://pubmed.ncbi.nlm.nih.gov/35710599/","https://doi.org/10.1016/j.fertnstert.2022.04.027","ClinicalTrials.gov:NCT03480022"],["1","R0021705","R0021705.pdf","open_download_failed","randomized_trial","Zenz S","2022","Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgac369","https://doi.org/10.1210/clinem/dgac369","35833597","https://pubmed.ncbi.nlm.nih.gov/35833597/","https://academic.oup.com/jcem/article-pdf/107/9/e3583/45476783/dgac369.pdf","ClinicalTrials.gov:NCT02408705"],["1","R0021733","R0021733.pdf","open_download_failed","randomized_trial","Fox CK","2022","Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23395","https://doi.org/10.1002/oby.23395","35403350","https://pubmed.ncbi.nlm.nih.gov/35403350/","https://www.ncbi.nlm.nih.gov/pmc/articles/9050846","ClinicalTrials.gov:NCT02496611"],["1","R0022282","R0022282.pdf","free_to_read","randomized_trial","Kadowaki T","2022","Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00187-5","https://doi.org/10.1016/s2213-8587(22)00187-5","35914542","https://pubmed.ncbi.nlm.nih.gov/35914542/","https://doi.org/10.1016/s2213-8587(22)00187-5","ClinicalTrials.gov:NCT03861039"],["1","R0022403","R0022403.pdf","open_download_failed","randomized_trial","Cheng H","2022","Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.","Diabetes care","American Diabetes Association","10.2337/dc21-2064","https://doi.org/10.2337/dc21-2064","35263425","https://pubmed.ncbi.nlm.nih.gov/35263425/","https://diabetesjournals.org/care/article-pdf/45/5/1201/678659/dc212064.pdf","ClinicalTrials.gov:NCT03961659"],["1","R0024390","R0024390.pdf","open_download_failed","randomized_trial","Farokhnia M","2022","The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.","Addiction biology","Wiley","10.1111/adb.13211","https://doi.org/10.1111/adb.13211","36001436","https://pubmed.ncbi.nlm.nih.gov/36001436/","https://www.ncbi.nlm.nih.gov/pmc/articles/12258501",null],["1","R0024560","R0024560.pdf","open_download_failed","randomized_trial","GRADE Study Research Group","2022","Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2200436","https://doi.org/10.1056/nejmoa2200436","36129997","https://pubmed.ncbi.nlm.nih.gov/36129997/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200436?articleTools=true","ClinicalTrials.gov:NCT01794143"],["1","R0026310","R0026310.pdf","open_download_failed","randomized_trial","Utzschneider KM","2022","Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23475","https://doi.org/10.1002/oby.23475","35894078","https://pubmed.ncbi.nlm.nih.gov/35894078/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10849844/pdf/nihms-1850826.pdf","ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01763346"],["1","R0026326","R0026326.pdf","open_download_failed","randomized_trial","Toftgaard Pedersen A","2022","Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients.","Scandinavian cardiovascular journal : SCJ","Informa UK Limited","10.1080/14017431.2022.2074093","https://doi.org/10.1080/14017431.2022.2074093","35546563","https://pubmed.ncbi.nlm.nih.gov/35546563/","https://www.tandfonline.com/doi/pdf/10.1080/14017431.2022.2074093?needAccess=true","ClinicalTrials.gov:NCT02442791"],["1","R0028935","R0028935.pdf","open_download_failed","randomized_trial","Friedman AN","2022","Obesity in CKD: A Promising Path Forward.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.09150822","https://doi.org/10.2215/cjn.09150822","36126996","https://pubmed.ncbi.nlm.nih.gov/36126996/","https://www.ncbi.nlm.nih.gov/pmc/articles/9718013","ClinicalTrials.gov:NCT04626323; ClinicalTrials.gov:NCT03819153"],["1","R0043672","R0043672.pdf","open_download_failed","randomized_trial","Linong Ji","2022","ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.026","https://doi.org/10.1210/jendso/bvac150.026",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A12/46729022/bvac150.026.pdf","ClinicalTrials.gov:NCT04440345"],["1","R0044357","R0044357.pdf","free_to_read","randomized_trial","Sri Khaerani Rahman","2022","Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342311","https://doi.org/10.4103/2230-8210.342311",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342311","ClinicalTrials.gov:NCT03552757"],["1","R0046993","R0046993.pdf","free_to_read","randomized_trial","D Shabeer","2022","Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342139","https://doi.org/10.4103/2230-8210.342139",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342139","ClinicalTrials.gov:NCT02863328"],["1","R0049234","R0049234.pdf","open_download_failed","randomized_trial","Kenneth W. Mahaffey","2022","Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.2617","https://doi.org/10.1093/eurheartj/ehac544.2617",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/43/Supplement_2/ehac544.2617/46361479/ehac544.2617.pdf","ClinicalTrials.gov:NCT03819153"],["1","R0050401","R0050401.pdf","free_to_read","randomized_trial","Swaroop H Suresh","2022","Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342310","https://doi.org/10.4103/2230-8210.342310",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342310","ClinicalTrials.gov:NCT03548935"],["1","R0051271","R0051271.pdf","free_to_read","randomized_trial","Prashanth S Prakash","2022","Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342148","https://doi.org/10.4103/2230-8210.342148",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342148","ClinicalTrials.gov:NCT02863328"],["1","R0008332","R0008332.pdf","open_download_failed","randomized_trial","Yammine L","2021","Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.","Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","Oxford University Press (OUP)","10.1093/ntr/ntab066","https://doi.org/10.1093/ntr/ntab066","33831213","https://pubmed.ncbi.nlm.nih.gov/33831213/","https://www.ncbi.nlm.nih.gov/pmc/articles/8517504","ClinicalTrials.gov:NCT02975297"],["1","R0009838","R0009838.pdf","open_download_failed","randomized_trial","Koska J","2021","The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study.","Diabetes care","American Diabetes Association","10.2337/dc20-2014","https://doi.org/10.2337/dc20-2014","33495294","https://pubmed.ncbi.nlm.nih.gov/33495294/","https://www.ncbi.nlm.nih.gov/pmc/articles/8247511","ClinicalTrials.gov:NCT02162550"],["1","R0011702","R0011702.pdf","open_download_failed","randomized_trial","Dekkers IA","2021","The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.","Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation","Elsevier BV","10.1053/j.jrn.2020.09.006","https://doi.org/10.1053/j.jrn.2020.09.006","33293204","https://pubmed.ncbi.nlm.nih.gov/33293204/","http://www.jrnjournal.org/article/S1051227620302685/pdf","ClinicalTrials.gov:NCT01761318; ClinicalTrials.gov:NCT02660047"],["1","R0011738","R0011738.pdf","open_download_failed","randomized_trial","Elkind-Hirsch KE","2021","Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgab408","https://doi.org/10.1210/clinem/dgab408","34097062","https://pubmed.ncbi.nlm.nih.gov/34097062/","https://academic.oup.com/jcem/article-pdf/106/10/3019/41098088/dgab408.pdf","ClinicalTrials.gov:NCT02635386"],["1","R0012449","R0012449.pdf","open_download_failed","randomized_trial","Newsome PN","2021","A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2028395","https://doi.org/10.1056/nejmoa2028395","33185364","https://pubmed.ncbi.nlm.nih.gov/33185364/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028395?articleTools=true","ClinicalTrials.gov:NCT02970942"],["1","R0013102","R0013102.pdf","open_download_failed","randomized_trial","Rubino D","2021","Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2021.3224","https://doi.org/10.1001/jama.2021.3224","33755728","https://pubmed.ncbi.nlm.nih.gov/33755728/","https://jamanetwork.com/journals/jama/articlepdf/2777886/jama_rubino_2021_oi_210023_1618250221.55359.pdf","ClinicalTrials.gov:NCT03548987"],["1","R0013656","R0013656.pdf","free_to_read","randomized_trial","Frías JP","2021","Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2107519","https://doi.org/10.1056/nejmoa2107519","34170647","https://pubmed.ncbi.nlm.nih.gov/34170647/","https://figshare.com/articles/journal_contribution/Tirzepatide_versus_Semaglutide_Once_Weekly_in_Patients_with_Type_2_Diabetes/16972132","ClinicalTrials.gov:NCT03987919"],["1","R0014471","R0014471.pdf","open_download_failed","randomized_trial","Billings LK","2021","The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296820906888","https://doi.org/10.1177/1932296820906888","32107930","https://pubmed.ncbi.nlm.nih.gov/32107930/","https://www.ncbi.nlm.nih.gov/pmc/articles/8120051","ClinicalTrials.gov:NCT02420262"],["1","R0014754","R0014754.pdf","open_download_failed","randomized_trial","Gerstein HC","2021","Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2108269","https://doi.org/10.1056/nejmoa2108269","34215025","https://pubmed.ncbi.nlm.nih.gov/34215025/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2108269?articleTools=true","ClinicalTrials.gov:NCT03496298"],["1","R0016542","R0016542.pdf","open_download_failed","randomized_trial","Smits MM","2021","Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2021.101223","https://doi.org/10.1016/j.diabet.2021.101223","33429063","https://pubmed.ncbi.nlm.nih.gov/33429063/","https://www.sciencedirect.com/science/article/pii/S126236362100001X/pdf","ClinicalTrials.gov:NCT01744236"],["1","R0018616","R0018616.pdf","free_to_read","randomized_trial","Bajaj HS","2021","Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(21)00115-7","https://doi.org/10.1016/s2213-8587(21)00115-7","34153269","https://pubmed.ncbi.nlm.nih.gov/34153269/","https://repositorio.udes.edu.co/handle/001/6141","ClinicalTrials.gov:NCT01394952"],["1","R0020651","R0020651.pdf","free_to_read","randomized_trial","Davies M","2021","Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)00213-0","https://doi.org/10.1016/s0140-6736(21)00213-0","33667417","https://pubmed.ncbi.nlm.nih.gov/33667417/","https://figshare.com/articles/journal_contribution/Semaglutide_2_4_mg_once_a_week_in_adults_with_overweight_or_obesity_and_type_2_diabetes_STEP_2_a_randomised_doubleblind_double-dummy_placebo-controlled_phase_3_trial/14510538","ClinicalTrials.gov:NCT03552757"],["1","R0023498","R0023498.pdf","open_download_failed","randomized_trial","Lundgren JR","2021","Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa2028198","https://doi.org/10.1056/nejmoa2028198","33951361","https://pubmed.ncbi.nlm.nih.gov/33951361/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028198?articleTools=true","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32"],["1","R0023506","R0023506.pdf","open_download_failed","randomized_trial","Wadden TA","2021","Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2021.1831","https://doi.org/10.1001/jama.2021.1831","33625476","https://pubmed.ncbi.nlm.nih.gov/33625476/","https://jamanetwork.com/journals/jama/articlepdf/2777025/jama_wadden_2021_oi_210014_1618250237.04792.pdf","ClinicalTrials.gov:NCT03611582"],["1","R0023750","R0023750.pdf","free_to_read","randomized_trial","Gudbergsen H","2021","Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial.","The American journal of clinical nutrition","Elsevier BV","10.1093/ajcn/nqaa328","https://doi.org/10.1093/ajcn/nqaa328","33471039","https://pubmed.ncbi.nlm.nih.gov/33471039/","https://doi.org/10.1093/ajcn/nqaa328","ClinicalTrials.gov:NCT02905864"],["1","R0023832","R0023832.pdf","open_download_failed","randomized_trial","von Herrath M","2021","Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(21)00019-x","https://doi.org/10.1016/s2213-8587(21)00019-x","33662334","https://pubmed.ncbi.nlm.nih.gov/33662334/","http://www.thelancet.com/article/S221385872100019X/pdf","ClinicalTrials.gov:NCT02443155"],["1","R0025681","R0025681.pdf","open_download_failed","randomized_trial","Tao T","2021","Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa692","https://doi.org/10.1210/clinem/dgaa692","32995892","https://pubmed.ncbi.nlm.nih.gov/32995892/","https://www.ncbi.nlm.nih.gov/pmc/articles/8244122","ClinicalTrials.gov:NCT03352869"],["1","R0026084","R0026084.pdf","open_download_failed","randomized_trial","Abdul-Ghani M","2021","Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.","Diabetes care","American Diabetes Association","10.2337/dc20-0978","https://doi.org/10.2337/dc20-0978","33273042","https://pubmed.ncbi.nlm.nih.gov/33273042/","https://www.ncbi.nlm.nih.gov/pmc/articles/7818318","ClinicalTrials.gov:NCT01107717"],["1","R0027303","R0027303.pdf","open_download_failed","randomized_trial","Kahn SE","2021","Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study.","Diabetes care","American Diabetes Association","10.2337/dc21-0461","https://doi.org/10.2337/dc21-0461","34135015","https://pubmed.ncbi.nlm.nih.gov/34135015/","https://diabetesjournals.org/care/article-pdf/44/9/1948/633210/dc210461.pdf","ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01779375; ClinicalTrials.gov:NCT01763346"],["1","R0040401","R0040401.pdf","free_to_read","randomized_trial","Rajaa Nahra","2021","Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes Mellitus: A 54-Week Randomized Phase 2b Study",null,"American Diabetes Association","10.2337/figshare.14272955.v1","https://doi.org/10.2337/figshare.14272955.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.14272955.v1","ClinicalTrials.gov:NCT03235050"],["1","R0044061","R0044061.pdf","no_doi","randomized_trial","Victoria E Parker (16613325)","2021","Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03550378"],["1","R0047600","R0047600.pdf","open_download_failed","randomized_trial","Emilie H. Zobel","2021","FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfab144.001","https://doi.org/10.1093/ndt/gfab144.001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/36/Supplement_1/gfab144.001/38382357/gfab144.001.pdf","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446"],["1","R0055269","R0055269.pdf","no_doi","randomized_trial","Wharton, S","2021","Two-year Effect of Semaglutide 2.4 mg on Control of Eating in Adults with Overweight/Obesity: STEP 5","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03693430"],["1","R0006583","R0006583.pdf","open_download_failed","randomized_trial","Gaborit B","2020","Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgz069","https://doi.org/10.1210/clinem/dgz069","31589290","https://pubmed.ncbi.nlm.nih.gov/31589290/","https://academic.oup.com/jcem/article-pdf/105/4/e1549/33110446/dgz069.pdf","ClinicalTrials.gov:NCT02686177; ClinicalTrials.gov:NCT02671864"],["1","R0007679","R0007679.pdf","free_to_read","randomized_trial","Quast DR","2020","Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc20-0720","https://doi.org/10.2337/dc20-0720","32647054","https://pubmed.ncbi.nlm.nih.gov/32647054/",null,"ClinicalTrials.gov:NCT02231658"],["1","R0011561","R0011561.pdf","open_download_failed","randomized_trial","Bethel MA","2020","Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.119.043353","https://doi.org/10.1161/circulationaha.119.043353","32098501","https://pubmed.ncbi.nlm.nih.gov/32098501/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.043353?download=true","ClinicalTrials.gov:NCT01144338"],["1","R0012692","R0012692.pdf","open_download_failed","randomized_trial","Mann JFE","2020","Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.11881019","https://doi.org/10.2215/cjn.11881019","32132141","https://pubmed.ncbi.nlm.nih.gov/32132141/","https://www.ncbi.nlm.nih.gov/pmc/articles/7133133","ClinicalTrials.gov:NCT01179048"],["1","R0012962","R0012962.pdf","open_download_failed","randomized_trial","Marso SP","2020","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2019.12.063","https://doi.org/10.1016/j.jacc.2019.12.063","32164886","https://pubmed.ncbi.nlm.nih.gov/32164886/","https://www.sciencedirect.com/science/article/pii/S0735109720302485/pdf","ClinicalTrials.gov:NCT01179048"],["1","R0015927","R0015927.pdf","free_to_read","randomized_trial","DeSouza C","2020","Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgz072","https://doi.org/10.1210/clinem/dgz072","31769496","https://pubmed.ncbi.nlm.nih.gov/31769496/","https://zenodo.org/record/4979739","ClinicalTrials.gov:NCT02054897; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT02305381; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02648204"],["1","R0015952","R0015952.pdf","open_download_failed","randomized_trial","Yamada Y","2020","Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(20)30075-9","https://doi.org/10.1016/s2213-8587(20)30075-9","32333875","https://pubmed.ncbi.nlm.nih.gov/32333875/","http://www.thelancet.com/article/S2213858720300759/pdf","ClinicalTrials.gov:NCT03018028"],["1","R0018464","R0018464.pdf","open_download_failed","randomized_trial","Pozzilli P","2020","Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa149","https://doi.org/10.1210/clinem/dgaa149","32219329","https://pubmed.ncbi.nlm.nih.gov/32219329/","https://academic.oup.com/jcem/article-pdf/105/6/e2192/41829538/jcem_105_6_e2192.pdf","ClinicalTrials.gov:NCT02284009"],["1","R0018886","R0018886.pdf","open_download_failed","randomized_trial","Cannon AJ","2020","Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.19035","https://doi.org/10.18553/jmcp.2019.19035","31856636","https://pubmed.ncbi.nlm.nih.gov/31856636/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.19035","ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT02420262"],["1","R0019135","R0019135.pdf","open_download_failed","randomized_trial","Kadouh H","2020","GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgz140","https://doi.org/10.1210/clinem/dgz140","31665455","https://pubmed.ncbi.nlm.nih.gov/31665455/","https://www.ncbi.nlm.nih.gov/pmc/articles/7105351","ClinicalTrials.gov:NCT02647944"],["1","R0019428","R0019428.pdf","open_download_failed","randomized_trial","Hamidi V","2020","Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2019.0102","https://doi.org/10.1089/met.2019.0102","32228379","https://pubmed.ncbi.nlm.nih.gov/32228379/","https://www.ncbi.nlm.nih.gov/pmc/articles/7262649","ClinicalTrials.gov:NCT02104739"],["1","R0020309","R0020309.pdf","free_to_read","randomized_trial","Cukierman-Yaffe T","2020","Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.","The Lancet. Neurology","Elsevier BV","10.1016/s1474-4422(20)30173-3","https://doi.org/10.1016/s1474-4422(20)30173-3","32562683","https://pubmed.ncbi.nlm.nih.gov/32562683/","https://repositorio.ufro.cl/s/repositorio-ufro/item/9904","ClinicalTrials.gov:NCT01394952"],["1","R0021071","R0021071.pdf","free_to_read","randomized_trial","Gerstein HC","2020","The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30423-1","https://doi.org/10.1016/s2213-8587(19)30423-1","31924562","https://pubmed.ncbi.nlm.nih.gov/31924562/","https://repositorio.udes.edu.co/handle/001/5715","ClinicalTrials.gov:NCT01394952"],["1","R0021115","R0021115.pdf","open_download_failed","randomized_trial","Parker VER","2020","Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgz047","https://doi.org/10.1210/clinem/dgz047","31608926","https://pubmed.ncbi.nlm.nih.gov/31608926/","https://academic.oup.com/jcem/article-pdf/105/3/803/41824281/jcem_105_3_803.pdf","ClinicalTrials.gov:NCT03244800"],["1","R0022945","R0022945.pdf","free_to_read","randomized_trial","Sahay R","2020","Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108148","https://doi.org/10.1016/j.diabres.2020.108148","32302665","https://pubmed.ncbi.nlm.nih.gov/32302665/","https://doi.org/10.1016/j.diabres.2020.108148","ClinicalTrials.gov:NCT02941367"],["1","R0023247","R0023247.pdf","open_download_failed","randomized_trial","Jabbour SA","2020","Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc19-1350","https://doi.org/10.2337/dc19-1350","32816874","https://pubmed.ncbi.nlm.nih.gov/32816874/","https://www.ncbi.nlm.nih.gov/pmc/articles/7510043","ClinicalTrials.gov:NCT02229396"],["1","R0023489","R0023489.pdf","open_download_failed","randomized_trial","Cherney DZ","2020","Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.01260120","https://doi.org/10.2215/cjn.01260120","32149722","https://pubmed.ncbi.nlm.nih.gov/32149722/","https://www.ncbi.nlm.nih.gov/pmc/articles/7133122","ClinicalTrials.gov:NCT00696657"],["1","R0023922","R0023922.pdf","open_download_failed","randomized_trial","Kelly AS","2020","A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1916038","https://doi.org/10.1056/nejmoa1916038","32233338","https://pubmed.ncbi.nlm.nih.gov/32233338/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1916038?articleTools=true","ClinicalTrials.gov:NCT02918279"],["1","R0023961","R0023961.pdf","open_download_failed","randomized_trial","Redouane B","2020","Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.","Circulation. Heart failure","Ovid Technologies (Wolters Kluwer Health)","10.1161/circheartfailure.119.006758","https://doi.org/10.1161/circheartfailure.119.006758","32362166","https://pubmed.ncbi.nlm.nih.gov/32362166/","https://www.ncbi.nlm.nih.gov/pmc/articles/7906045","ClinicalTrials.gov:NCT01800968"],["1","R0024499","R0024499.pdf","open_download_failed","randomized_trial","Tronieri JS","2020","Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-019-0348-6","https://doi.org/10.1038/s41366-019-0348-6","30926955","https://pubmed.ncbi.nlm.nih.gov/30926955/","https://www.ncbi.nlm.nih.gov/pmc/articles/6766432","ClinicalTrials.gov:NCT02911818"],["1","R0024676","R0024676.pdf","open_download_failed","randomized_trial","Reed SD","2020","Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Diabetes care","American Diabetes Association","10.2337/dc19-0950","https://doi.org/10.2337/dc19-0950","31806653","https://pubmed.ncbi.nlm.nih.gov/31806653/","https://www.ncbi.nlm.nih.gov/pmc/articles/7210004","ClinicalTrials.gov:NCT01144338"],["1","R0049459","R0049459.pdf","open_download_failed","randomized_trial","William David Strain","2020","Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.2424","https://doi.org/10.1093/ehjci/ehaa946.2424",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.2424/34515909/ehaa946.2424.pdf","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["1","R0052247","R0052247.pdf","no_doi","randomized_trial","Robert F. Kushner","2020","Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP 1–5 Randomized Trials","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987; ClinicalTrials.gov:NCT03693430"],["1","R0013006","R0013006.pdf","open_download_failed","randomized_trial","Bethel MA","2019","Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).","Diabetes care","American Diabetes Association","10.2337/dc18-2028","https://doi.org/10.2337/dc18-2028","31010875","https://pubmed.ncbi.nlm.nih.gov/31010875/","https://www.ncbi.nlm.nih.gov/pmc/articles/6973544","ClinicalTrials.gov:NCT01144338"],["1","R0013053","R0013053.pdf","open_download_failed","randomized_trial","Zinman B","2019","Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.","Diabetes care","American Diabetes Association","10.2337/dc19-0898","https://doi.org/10.2337/dc19-0898","31530667","https://pubmed.ncbi.nlm.nih.gov/31530667/","https://www.ncbi.nlm.nih.gov/pmc/articles/7364672","ClinicalTrials.gov:NCT03021187"],["1","R0013782","R0013782.pdf","open_download_failed","randomized_trial","Husain M","2019","Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1901118","https://doi.org/10.1056/nejmoa1901118","31185157","https://pubmed.ncbi.nlm.nih.gov/31185157/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901118?articleTools=true","ClinicalTrials.gov:NCT02692716"],["1","R0015588","R0015588.pdf","open_download_failed","randomized_trial","Rosenstock J","2019","Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2019.2942","https://doi.org/10.1001/jama.2019.2942","30903796","https://pubmed.ncbi.nlm.nih.gov/30903796/","https://jamanetwork.com/journals/jama/articlepdf/2729339/jama_rosenstock_2019_oi_190026.pdf","ClinicalTrials.gov:NCT02607865"],["1","R0018256","R0018256.pdf","open_download_failed","randomized_trial","Rodbard HW","2019","Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.","Diabetes care","American Diabetes Association","10.2337/dc19-0883","https://doi.org/10.2337/dc19-0883","31530666","https://pubmed.ncbi.nlm.nih.gov/31530666/","https://care.diabetesjournals.org/content/diacare/42/12/2272.full.pdf","ClinicalTrials.gov:NCT02863328"],["1","R0018373","R0018373.pdf","free_to_read","randomized_trial","Aroda VR","2019","PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc19-0749","https://doi.org/10.2337/dc19-0749","31186300","https://pubmed.ncbi.nlm.nih.gov/31186300/","https://doi.org/10.2337/dc19-0749","ClinicalTrials.gov:NCT02906930"],["1","R0018537","R0018537.pdf","free_to_read","randomized_trial","Gerstein HC","2019","Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(19)31149-3","https://doi.org/10.1016/s0140-6736(19)31149-3","31189511","https://pubmed.ncbi.nlm.nih.gov/31189511/","https://repositorio.udes.edu.co/handle/001/5694","ClinicalTrials.gov:NCT01394952"],["1","R0018694","R0018694.pdf","free_to_read","randomized_trial","Gerstein HC","2019","Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(19)31150-x","https://doi.org/10.1016/s0140-6736(19)31150-x","31189509","https://pubmed.ncbi.nlm.nih.gov/31189509/","https://repositorio.udes.edu.co/handle/001/5693","ClinicalTrials.gov:NCT01394952"],["1","R0019398","R0019398.pdf","open_download_failed","randomized_trial","Lingvay I","2019","Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30311-0","https://doi.org/10.1016/s2213-8587(19)30311-0","31540867","https://pubmed.ncbi.nlm.nih.gov/31540867/","http://www.thelancet.com/article/S2213858719303110/pdf","ClinicalTrials.gov:NCT03136484"],["1","R0020392","R0020392.pdf","open_download_failed","randomized_trial","Pieber TR","2019","Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30194-9","https://doi.org/10.1016/s2213-8587(19)30194-9","31189520","https://pubmed.ncbi.nlm.nih.gov/31189520/","http://www.thelancet.com/article/S2213858719301949/pdf","ClinicalTrials.gov:NCT02849080; EudraCT:2015-005593-38"],["1","R0020471","R0020471.pdf","open_download_failed","randomized_trial","Mullins RJ","2019","A Pilot Study of Exenatide Actions in Alzheimer's Disease.","Current Alzheimer research","Bentham Science Publishers Ltd.","10.2174/1567205016666190913155950","https://doi.org/10.2174/1567205016666190913155950","31518224","https://pubmed.ncbi.nlm.nih.gov/31518224/","https://www.ncbi.nlm.nih.gov/pmc/articles/7476877","ClinicalTrials.gov:NCT01255163"],["1","R0021224","R0021224.pdf","free_to_read","randomized_trial","Muskiet MHA","2019","Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.05.001","https://doi.org/10.1016/j.diabres.2019.05.001","31078666","https://pubmed.ncbi.nlm.nih.gov/31078666/","https://dspace.library.uu.nl/handle/1874/440579","ClinicalTrials.gov:NCT00097500"],["1","R0021335","R0021335.pdf","open_download_failed","randomized_trial","Mosenzon O","2019","Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30192-5","https://doi.org/10.1016/s2213-8587(19)30192-5","31189517","https://pubmed.ncbi.nlm.nih.gov/31189517/","http://www.thelancet.com/article/S2213858719301925/pdf","ClinicalTrials.gov:NCT02827708; EudraCT:2015-005326-19"],["1","R0023902","R0023902.pdf","open_download_failed","randomized_trial","Fayfman M","2019","A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc18-1760","https://doi.org/10.2337/dc18-1760","30679302","https://pubmed.ncbi.nlm.nih.gov/30679302/","https://care.diabetesjournals.org/content/diacare/42/3/450.full.pdf","ClinicalTrials.gov:NCT02455076"],["1","R0024015","R0024015.pdf","open_download_failed","randomized_trial","Tronieri JS","2019","Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2019.03.005","https://doi.org/10.1016/j.metabol.2019.03.005","30902750","https://pubmed.ncbi.nlm.nih.gov/30902750/","https://www.ncbi.nlm.nih.gov/pmc/articles/6571049","ClinicalTrials.gov:NCT02911818"],["1","R0024236","R0024236.pdf","open_download_failed","randomized_trial","Athauda D","2019","Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.","JAMA neurology","American Medical Association (AMA)","10.1001/jamaneurol.2018.4304","https://doi.org/10.1001/jamaneurol.2018.4304","30640362","https://pubmed.ncbi.nlm.nih.gov/30640362/","https://jamanetwork.com/journals/jamaneurology/articlepdf/2719822/jamaneurology_athauda_2019_oi_180098.pdf",null],["1","R0024583","R0024583.pdf","free_to_read","randomized_trial","Nauck MA","2019","Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc19-0415","https://doi.org/10.2337/dc19-0415","31399438","https://pubmed.ncbi.nlm.nih.gov/31399438/",null,"ClinicalTrials.gov:NCT01179048"],["1","R0024642","R0024642.pdf","open_download_failed","randomized_trial","Philis-Tsimikas A","2019","Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2018.11.012","https://doi.org/10.1016/j.jdiacomp.2018.11.012","30600137","https://pubmed.ncbi.nlm.nih.gov/30600137/","https://www.sciencedirect.com/science/article/pii/S1056872718308821/pdf","ClinicalTrials.gov:NCT00308139"],["1","R0024688","R0024688.pdf","open_download_failed","randomized_trial","Verma S","2019","Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.","JAMA cardiology","American Medical Association (AMA)","10.1001/jamacardio.2019.3080","https://doi.org/10.1001/jamacardio.2019.3080","31721979","https://pubmed.ncbi.nlm.nih.gov/31721979/","https://jamanetwork.com/journals/jamacardiology/articlepdf/2754760/jamacardiology_verma_2019_oi_190052.pdf","ClinicalTrials.gov:NCT01179048"],["1","R0024737","R0024737.pdf","open_download_failed","randomized_trial","Tamborlane WV","2019","Liraglutide in Children and Adolescents with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1903822","https://doi.org/10.1056/nejmoa1903822","31034184","https://pubmed.ncbi.nlm.nih.gov/31034184/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1903822?articleTools=true","ClinicalTrials.gov:NCT01541215"],["1","R0024864","R0024864.pdf","open_download_failed","randomized_trial","Wadden TA","2019","Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.22359","https://doi.org/10.1002/oby.22359","30421856","https://pubmed.ncbi.nlm.nih.gov/30421856/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.22359","ClinicalTrials.gov:NCT02911818"],["1","R0025136","R0025136.pdf","open_download_failed","randomized_trial","Fudim M","2019","Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.119.041659","https://doi.org/10.1161/circulationaha.119.041659","31542942","https://pubmed.ncbi.nlm.nih.gov/31542942/","https://www.ncbi.nlm.nih.gov/pmc/articles/6924268","ClinicalTrials.gov:NCT01144338"],["1","R0025599","R0025599.pdf","open_download_failed","randomized_trial","RISE Consortium","2019","Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc19-0556","https://doi.org/10.2337/dc19-0556","31178434","https://pubmed.ncbi.nlm.nih.gov/31178434/","https://www.ncbi.nlm.nih.gov/pmc/articles/6702605","ClinicalTrials.gov:NCT01779362"],["1","R0025869","R0025869.pdf","open_download_failed","randomized_trial","Hassanein MM","2019","Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.01.035","https://doi.org/10.1016/j.diabres.2019.01.035","30772385","https://pubmed.ncbi.nlm.nih.gov/30772385/","http://www.diabetesresearchclinicalpractice.com/article/S0168822719300129/pdf","ClinicalTrials.gov:NCT02941367"],["1","R0028588","R0028588.pdf","open_download_failed","randomized_trial","Kolotkin RL","2019","Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.","Clinical obesity","Wiley","10.1111/cob.12310","https://doi.org/10.1111/cob.12310","30993900","https://pubmed.ncbi.nlm.nih.gov/30993900/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12310","ClinicalTrials.gov:NCT02453711; ClinicalTrials.gov:NCT02906930"],["1","R0044140","R0044140.pdf","no_doi","randomized_trial","J Rosenstock (7710920)","2019","Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02607865"],["1","R0048875","R0048875.pdf","free_to_read","randomized_trial","Jena Shaw Tronieri","2019","SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/js.2019-sat-105","https://doi.org/10.1210/js.2019-sat-105",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/js.2019-sat-105","ClinicalTrials.gov:NCT02963935"],["1","R0051746","R0051746.pdf","free_to_read","randomized_trial","Jena Shaw Tronieri","2019","SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT","Journal of the Endocrine Society","The Endocrine Society","10.1210/js.2019-sat-097","https://doi.org/10.1210/js.2019-sat-097",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/js.2019-sat-097","ClinicalTrials.gov:NCT02963935"],["1","R0012223","R0012223.pdf","open_download_failed","randomized_trial","Hernandez AF","2018","Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(18)32261-x","https://doi.org/10.1016/s0140-6736(18)32261-x","30291013","https://pubmed.ncbi.nlm.nih.gov/30291013/","http://www.thelancet.com/article/S014067361832261X/pdf","ClinicalTrials.gov:NCT02465515"],["1","R0015574","R0015574.pdf","free_to_read","randomized_trial","Rosenstock J","2018","Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.","Diabetes care","American Diabetes Association","10.2337/dc17-1306","https://doi.org/10.2337/dc17-1306","29242349","https://pubmed.ncbi.nlm.nih.gov/29242349/","https://doi.org/10.17615/yejd-1542","ClinicalTrials.gov:NCT01455857"],["1","R0018041","R0018041.pdf","free_to_read","randomized_trial","Billings LK","2018","Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc17-1114","https://doi.org/10.2337/dc17-1114","29483185","https://pubmed.ncbi.nlm.nih.gov/29483185/","http://hdl.handle.net/11268/7251","ClinicalTrials.gov:NCT02420262"],["1","R0019667","R0019667.pdf","open_download_failed","randomized_trial","Bækdal TA","2018","A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.","Expert opinion on drug metabolism & toxicology","Informa UK Limited","10.1080/17425255.2018.1488965","https://doi.org/10.1080/17425255.2018.1488965","29897249","https://pubmed.ncbi.nlm.nih.gov/29897249/","https://www.tandfonline.com/doi/pdf/10.1080/17425255.2018.1488965?needAccess=true&role=button",null],["1","R0020570","R0020570.pdf","open_download_failed","randomized_trial","Mather KJ","2018","Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2018-00712","https://doi.org/10.1210/jc.2018-00712","30020461","https://pubmed.ncbi.nlm.nih.gov/30020461/","https://academic.oup.com/jcem/article-pdf/103/9/3456/25685951/jc.2018-00712.pdf","ClinicalTrials.gov:NCT01232946"],["1","R0021448","R0021448.pdf","free_to_read","randomized_trial","Gerstein HC","2018","Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13028","https://doi.org/10.1111/dom.13028","28573765","https://pubmed.ncbi.nlm.nih.gov/28573765/","https://repositorio.udes.edu.co/handle/001/6095","ClinicalTrials.gov:NCT01394952"],["1","R0021473","R0021473.pdf","open_download_failed","randomized_trial","Athauda D","2018","What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-181329","https://doi.org/10.3233/jpd-181329","29843254","https://pubmed.ncbi.nlm.nih.gov/29843254/","https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd181329?id=journal-of-parkinsons-disease%2Fjpd181329",null],["1","R0023885","R0023885.pdf","open_download_failed","randomized_trial","Shankar SS","2018","Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.","Diabetes","American Diabetes Association","10.2337/db17-1331","https://doi.org/10.2337/db17-1331","29545266","https://pubmed.ncbi.nlm.nih.gov/29545266/","https://diabetesjournals.org/diabetes/article-pdf/67/6/1105/538435/db171331.pdf","ClinicalTrials.gov:NCT01055340; ClinicalTrials.gov:NCT01373450"],["1","R0024478","R0024478.pdf","open_download_failed","randomized_trial","Jabbour SA","2018","Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc18-0680","https://doi.org/10.2337/dc18-0680","30082326","https://pubmed.ncbi.nlm.nih.gov/30082326/","https://www.ncbi.nlm.nih.gov/pmc/articles/6150435","ClinicalTrials.gov:NCT02229396"],["1","R0024838","R0024838.pdf","open_download_failed","randomized_trial","Dandona P","2018","Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-02343","https://doi.org/10.1210/jc.2017-02343","29346597","https://pubmed.ncbi.nlm.nih.gov/29346597/","https://academic.oup.com/jcem/article-pdf/103/3/1180/24262887/jc.2017-02343.pdf","ClinicalTrials.gov:NCT01154933"],["1","R0024940","R0024940.pdf","open_download_failed","randomized_trial","Basolo A","2018","Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2018.03.017","https://doi.org/10.1016/j.metabol.2018.03.017","29596853","https://pubmed.ncbi.nlm.nih.gov/29596853/","https://doi.org/10.1016/j.metabol.2018.03.017","ClinicalTrials.gov:NCT00856609"],["1","R0025004","R0025004.pdf","free_to_read","randomized_trial","Hegedüs L","2018","No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.","Diabetes care","American Diabetes Association","10.2337/dc17-1956","https://doi.org/10.2337/dc17-1956","29279300","https://pubmed.ncbi.nlm.nih.gov/29279300/",null,"ClinicalTrials.gov:NCT01179048"],["1","R0025075","R0025075.pdf","open_download_failed","randomized_trial","Nauck MA","2018","Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc17-1825","https://doi.org/10.2337/dc17-1825","29898902","https://pubmed.ncbi.nlm.nih.gov/29898902/","https://www.ncbi.nlm.nih.gov/pmc/articles/6463597","ClinicalTrials.gov:NCT01179048"],["1","R0025408","R0025408.pdf","free_to_read","randomized_trial","Zinman B","2018","Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.","Diabetes care","American Diabetes Association","10.2337/dc17-2677","https://doi.org/10.2337/dc17-2677","29903847","https://pubmed.ncbi.nlm.nih.gov/29903847/","https://doi.org/10.17615/k65w-3s34","ClinicalTrials.gov:NCT01179048"],["1","R0025668","R0025668.pdf","open_download_failed","randomized_trial","Verma S","2018","Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.036862","https://doi.org/10.1161/circulationaha.118.036862","30354517","https://pubmed.ncbi.nlm.nih.gov/30354517/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.036862","ClinicalTrials.gov:NCT01179048"],["1","R0025753","R0025753.pdf","open_download_failed","randomized_trial","Verma S","2018","Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.033898","https://doi.org/10.1161/circulationaha.118.033898","29760228","https://pubmed.ncbi.nlm.nih.gov/29760228/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.033898","ClinicalTrials.gov:NCT01179048"],["1","R0028596","R0028596.pdf","open_download_failed","randomized_trial","Foltynie T","2018","Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.","Movement disorders clinical practice","Wiley","10.1002/mdc3.12611","https://doi.org/10.1002/mdc3.12611","30800701","https://pubmed.ncbi.nlm.nih.gov/30800701/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12611","ClinicalTrials.gov:NCT02953665; ClinicalTrials.gov:NCT01843075"],["1","R0049736","R0049736.pdf","open_download_failed","randomized_trial","Richard E. Pratley","2018","Implications of cardiovascular outcome trials with injectable antidiabetic agents","Journal of Diabetes","Wiley","10.1111/1753-0407.12792","https://doi.org/10.1111/1753-0407.12792","29971941","https://pubmed.ncbi.nlm.nih.gov/29971941/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12792","ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01455896; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT00069784"],["1","R0010213","R0010213.pdf","open_download_failed","randomized_trial","Ishøy P","2017","SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity","Schizophrenia bulletin","Oxford University Press (OUP)","10.1093/schbul/sbx024.017","https://doi.org/10.1093/schbul/sbx024.017",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ncbi.nlm.nih.gov/pmc/articles/5476046","ClinicalTrials.gov:NCT01794429"],["1","R0012723","R0012723.pdf","open_download_failed","randomized_trial","Mentz RJ","2017","Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","American heart journal","Elsevier BV","10.1016/j.ahj.2017.02.005","https://doi.org/10.1016/j.ahj.2017.02.005","28454792","https://pubmed.ncbi.nlm.nih.gov/28454792/","https://www.ncbi.nlm.nih.gov/pmc/articles/9849915","ClinicalTrials.gov:NCT01144338"],["1","R0012790","R0012790.pdf","free_to_read","randomized_trial","Kumarathurai P","2017","Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.","Diabetes care","American Diabetes Association","10.2337/dc16-1580","https://doi.org/10.2337/dc16-1580","27797930","https://pubmed.ncbi.nlm.nih.gov/27797930/",null,"ClinicalTrials.gov:NCT01595789"],["1","R0015700","R0015700.pdf","open_download_failed","randomized_trial","Frias JP","2017","The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2017.07.011","https://doi.org/10.1016/j.cmet.2017.07.011","28768173","https://pubmed.ncbi.nlm.nih.gov/28768173/","http://www.cell.com/article/S1550413117304321/pdf",null],["1","R0016720","R0016720.pdf","open_download_failed","randomized_trial","Larsen JR","2017","Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2017.1220","https://doi.org/10.1001/jamapsychiatry.2017.1220","28601891","https://pubmed.ncbi.nlm.nih.gov/28601891/","https://www.ncbi.nlm.nih.gov/pmc/articles/5710254","ClinicalTrials.gov:NCT01845259"],["1","R0017701","R0017701.pdf","free_to_read","randomized_trial","Muskiet MHA","2017","GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.","Nature reviews. Nephrology","Springer Science and Business Media LLC","10.1038/nrneph.2017.123","https://doi.org/10.1038/nrneph.2017.123","28869249","https://pubmed.ncbi.nlm.nih.gov/28869249/","https://dspace.library.uu.nl/handle/1874/360319",null],["1","R0019235","R0019235.pdf","open_download_failed","randomized_trial","Nylander M","2017","Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.","Reproductive biomedicine online","Elsevier BV","10.1016/j.rbmo.2017.03.023","https://doi.org/10.1016/j.rbmo.2017.03.023","28479118","https://pubmed.ncbi.nlm.nih.gov/28479118/","http://www.rbmojournal.com/article/S1472648317301943/pdf",null],["1","R0020665","R0020665.pdf","open_download_failed","randomized_trial","Tonneijck L","2017","Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12985","https://doi.org/10.1111/dom.12985","28449402","https://pubmed.ncbi.nlm.nih.gov/28449402/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12985","ClinicalTrials.gov:NCT02276196"],["1","R0021512","R0021512.pdf","open_download_failed","randomized_trial","Mann JFE","2017","Liraglutide and Renal Outcomes in Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1616011","https://doi.org/10.1056/nejmoa1616011","28854085","https://pubmed.ncbi.nlm.nih.gov/28854085/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1616011?articleTools=true","ClinicalTrials.gov:NCT01179048"],["1","R0021691","R0021691.pdf","free_to_read","randomized_trial","Lipš M","2017","Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13029","https://doi.org/10.1111/dom.13029","28581209","https://pubmed.ncbi.nlm.nih.gov/28581209/","https://pure.amsterdamumc.nl/en/publications/78fa410e-58d2-44d7-a77c-8b1ef857770f","ClinicalTrials.gov:NCT01373216"],["1","R0022177","R0022177.pdf","free_to_read","randomized_trial","Aroda VR","2017","Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(17)30085-2","https://doi.org/10.1016/s2213-8587(17)30085-2","28344112","https://pubmed.ncbi.nlm.nih.gov/28344112/",null,"ClinicalTrials.gov:NCT02128932"],["1","R0022440","R0022440.pdf","free_to_read","randomized_trial","Sorli C","2017","Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(17)30013-x","https://doi.org/10.1016/s2213-8587(17)30013-x","28110911","https://pubmed.ncbi.nlm.nih.gov/28110911/",null,"ClinicalTrials.gov:NCT02054897"],["1","R0022561","R0022561.pdf","open_download_failed","randomized_trial","Athauda D","2017","Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(17)31585-4","https://doi.org/10.1016/s0140-6736(17)31585-4","28781108","https://pubmed.ncbi.nlm.nih.gov/28781108/","https://www.ncbi.nlm.nih.gov/pmc/articles/5831666","ClinicalTrials.gov:NCT01971242"],["1","R0022731","R0022731.pdf","open_download_failed","randomized_trial","Davies M","2017","Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2017.14752","https://doi.org/10.1001/jama.2017.14752","29049653","https://pubmed.ncbi.nlm.nih.gov/29049653/","https://jamanetwork.com/journals/jama/articlepdf/2657376/jama_davies_2017_oi_170116.pdf","ClinicalTrials.gov:NCT01923181"],["1","R0025087","R0025087.pdf","open_download_failed","randomized_trial","le Roux C","2017","Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.","Obesity facts","S. Karger AG","10.1159/000478099","https://doi.org/10.1159/000478099","29145215","https://pubmed.ncbi.nlm.nih.gov/29145215/","https://doi.org/10.1159/000478099",null],["1","R0025311","R0025311.pdf","open_download_failed","randomized_trial","Holman RR","2017","Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1612917","https://doi.org/10.1056/nejmoa1612917","28910237","https://pubmed.ncbi.nlm.nih.gov/28910237/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1612917?articleTools=true","ClinicalTrials.gov:NCT01144338"],["1","R0025365","R0025365.pdf","free_to_read","randomized_trial","Steinberg WM","2017","Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.","Diabetes care","American Diabetes Association","10.2337/dc16-2684","https://doi.org/10.2337/dc16-2684","28473337","https://pubmed.ncbi.nlm.nih.gov/28473337/","https://pure.amsterdamumc.nl/en/publications/a98835a8-82a7-4a07-b627-b23ce270a481",null],["1","R0025431","R0025431.pdf","open_download_failed","randomized_trial","Iacobellis G","2017","Liraglutide causes large and rapid epicardial fat reduction.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.21718","https://doi.org/10.1002/oby.21718","28124506","https://pubmed.ncbi.nlm.nih.gov/28124506/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.21718","ClinicalTrials.gov:NCT02014740"],["1","R0025434","R0025434.pdf","free_to_read","randomized_trial","Steinberg WM","2017","Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-2747","https://doi.org/10.2337/dc16-2747","28476871","https://pubmed.ncbi.nlm.nih.gov/28476871/",null,"ClinicalTrials.gov:NCT01179048"],["1","R0025639","R0025639.pdf","open_download_failed","randomized_trial","Kramer CK","2017","Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-00928","https://doi.org/10.1210/jc.2017-00928","28472325","https://pubmed.ncbi.nlm.nih.gov/28472325/","https://academic.oup.com/jcem/article-pdf/102/8/2729/19452832/jc.2017-00928.pdf","ClinicalTrials.gov:NCT01270789"],["1","R0025826","R0025826.pdf","open_download_failed","randomized_trial","Danne T","2017","Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.","The Journal of pediatrics","Elsevier BV","10.1016/j.jpeds.2016.10.076","https://doi.org/10.1016/j.jpeds.2016.10.076","27979579","https://pubmed.ncbi.nlm.nih.gov/27979579/","http://www.jpeds.com/article/S0022347616312100/pdf","ClinicalTrials.gov:NCT01789086"],["1","R0028699","R0028699.pdf","open_download_failed","randomized_trial","Wolsk E","2017","Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.117.029503","https://doi.org/10.1161/circulationaha.117.029503","29038210","https://pubmed.ncbi.nlm.nih.gov/29038210/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.117.029503?download=true","ClinicalTrials.gov:NCT01147250"],["1","R0043293","R0043293.pdf","free_to_read","randomized_trial","Paul D. Rosenblit","2017","The emergence of cardiodiabetology","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000117","https://doi.org/10.1097/xce.0000000000000117","31646112","https://pubmed.ncbi.nlm.nih.gov/31646112/","https://www.ncbi.nlm.nih.gov/pmc/articles/6768527","ClinicalTrials.gov:NCT01032629; ClinicalTrials.gov:NCT01730534; ClinicalTrials.gov:NCT01986881; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01394952"],["1","R0043842","R0043842.pdf","free_to_read","randomized_trial","wharton sean","2017","Early responders to liraglutide 3.0 mg as adjunct to diet and exercise from the SCALE Maintenance trial",null,"Morressier","10.26226/morressier.59d51844d462b80296ca36ec","https://doi.org/10.26226/morressier.59d51844d462b80296ca36ec",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/cde2ce05-fe9d-482d-93e3-614b224ea7e8","ClinicalTrials.gov:NCT00781937"],["1","R0044406","R0044406.pdf","free_to_read","randomized_trial","Bowden Georgina","2017","Low incidence of gastrointestinal adverse events over time with a combination of insulin glargine and lixisenatide",null,"Morressier","10.26226/morressier.59d51845d462b80296ca34a6","https://doi.org/10.26226/morressier.59d51845d462b80296ca34a6",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/4b52d50b-9b4f-4a8f-b986-a78b2a6ac790","ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147"],["1","R0055239","R0055239.pdf","open_download_failed","randomized_trial","Thompson, G.J.","2017","Poster Viewing Session I","Journal of Cerebral Blood Flow & Metabolism","SAGE Publications","10.1177/0271678x17695982","https://doi.org/10.1177/0271678x17695982","28366130","https://pubmed.ncbi.nlm.nih.gov/28366130/","https://journals.sagepub.com/doi/pdf/10.1177/0271678X17695982","ClinicalTrials.gov:NCT01469351"],["1","R0055328","R0055328.pdf","free_to_read","randomized_trial","O. Henriksen","2017","Poster Viewing Session II","Journal of Cerebral Blood Flow & Metabolism","SAGE Publications","10.1177/0271678x17695989","https://doi.org/10.1177/0271678x17695989","28366134","https://pubmed.ncbi.nlm.nih.gov/28366134/","https://www.ncbi.nlm.nih.gov/pmc/articles/5441166","ClinicalTrials.gov:NCT01469351"],["1","R0055624","R0055624.pdf","open_download_failed","randomized_trial","Wong, D.F.","2017","The Niels Lassen Award Session and Oral Sessions","Journal of Cerebral Blood Flow & Metabolism","SAGE Publications","10.1177/0271678x17695978","https://doi.org/10.1177/0271678x17695978","28366133","https://pubmed.ncbi.nlm.nih.gov/28366133/","https://journals.sagepub.com/doi/pdf/10.1177/0271678X17695978","ClinicalTrials.gov:NCT01469351"],["1","R0012058","R0012058.pdf","free_to_read","randomized_trial","Thazhath SS","2016","The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.","Diabetes","American Diabetes Association","10.2337/db15-0893","https://doi.org/10.2337/db15-0893","26470783","https://pubmed.ncbi.nlm.nih.gov/26470783/",null,"ANZCTR:ACTRN12608000428369"],["1","R0013657","R0013657.pdf","open_download_failed","randomized_trial","Nauck MA","2016","A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc15-0165","https://doi.org/10.2337/dc15-0165","26358288","https://pubmed.ncbi.nlm.nih.gov/26358288/","https://care.diabetesjournals.org/content/diacare/39/2/231.full.pdf","ClinicalTrials.gov:NCT00696657"],["1","R0014435","R0014435.pdf","open_download_failed","randomized_trial","Yabe D","2016","Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.05.018","https://doi.org/10.1016/j.jdiacomp.2016.05.018","27267268","https://pubmed.ncbi.nlm.nih.gov/27267268/","https://www.sciencedirect.com/science/article/pii/S1056872716301714/pdf","ClinicalTrials.gov:NCT00712673; ClinicalTrials.gov:NCT00713830"],["1","R0015548","R0015548.pdf","free_to_read","randomized_trial","Rosenstock J","2016","Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0014","https://doi.org/10.2337/dc16-0014","27222510","https://pubmed.ncbi.nlm.nih.gov/27222510/",null,"ClinicalTrials.gov:NCT01768559"],["1","R0016476","R0016476.pdf","open_download_failed","randomized_trial","Wiberg S","2016","Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.116.024088","https://doi.org/10.1161/circulationaha.116.024088","27838646","https://pubmed.ncbi.nlm.nih.gov/27838646/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.024088","ClinicalTrials.gov:NCT02442791"],["1","R0017299","R0017299.pdf","open_download_failed","randomized_trial","Vanderheiden A","2016","Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2016.1540","https://doi.org/10.1001/jamainternmed.2016.1540","27273731","https://pubmed.ncbi.nlm.nih.gov/27273731/","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2526669/ioi160025.pdf","ClinicalTrials.gov:NCT01505673"],["1","R0017964","R0017964.pdf","free_to_read","randomized_trial","Rosenstock J","2016","Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0917","https://doi.org/10.2337/dc16-0917","27527848","https://pubmed.ncbi.nlm.nih.gov/27527848/","https://figshare.com/articles/journal_contribution/Benefits_of_LixiLan_a_Titratable_Fixed-Ratio_Combination_of_Insulin_Glargine_Plus_Lixisenatide_Versus_Insulin_Glargine_and_Lixisenatide_Monocomponents_in_Type_2_Diabetes_Inadequately_Controlled_on_Oral_Agents_The_LixiLan-O_Randomized_Trial_/10206770","ClinicalTrials.gov:NCT02058147"],["1","R0020866","R0020866.pdf","free_to_read","randomized_trial","Nauck M","2016","Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc15-2479","https://doi.org/10.2337/dc15-2479","27311491","https://pubmed.ncbi.nlm.nih.gov/27311491/","https://www.openaccessrepository.it/record/181334","ClinicalTrials.gov:NCT01973231"],["1","R0021191","R0021191.pdf","open_download_failed","randomized_trial","Lepore JJ","2016","Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2016.01.008","https://doi.org/10.1016/j.jchf.2016.01.008","27039125","https://pubmed.ncbi.nlm.nih.gov/27039125/","https://www.sciencedirect.com/science/article/pii/S2213177916000226/pdf","ClinicalTrials.gov:NCT01357850"],["1","R0021603","R0021603.pdf","open_download_failed","randomized_trial","Margulies KB","2016","Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2016.10260","https://doi.org/10.1001/jama.2016.10260","27483064","https://pubmed.ncbi.nlm.nih.gov/27483064/","https://jamanetwork.com/journals/jama/articlepdf/2540402/joi160085.pdf","ClinicalTrials.gov:NCT01800968"],["1","R0022060","R0022060.pdf","open_download_failed","randomized_trial","Marso SP","2016","Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1603827","https://doi.org/10.1056/nejmoa1603827","27295427","https://pubmed.ncbi.nlm.nih.gov/27295427/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827?articleTools=true","ClinicalTrials.gov:NCT01179048"],["1","R0022200","R0022200.pdf","free_to_read","randomized_trial","Armstrong MJ","2016","Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(15)00803-x","https://doi.org/10.1016/s0140-6736(15)00803-x","26608256","https://pubmed.ncbi.nlm.nih.gov/26608256/","http://eprints.nottingham.ac.uk/39309/","ClinicalTrials.gov:NCT01237119"],["1","R0022278","R0022278.pdf","open_download_failed","randomized_trial","Marso SP","2016","Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1607141","https://doi.org/10.1056/nejmoa1607141","27633186","https://pubmed.ncbi.nlm.nih.gov/27633186/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607141?articleTools=true","ClinicalTrials.gov:NCT01720446"],["1","R0022406","R0022406.pdf","free_to_read","randomized_trial","Tonneijck L","2016","Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-1371","https://doi.org/10.2337/dc16-1371","27585605","https://pubmed.ncbi.nlm.nih.gov/27585605/","https://pure.amsterdamumc.nl/en/publications/9d415e05-2cc0-43fb-a56f-f7d402ed993b","ClinicalTrials.gov:NCT01744236"],["1","R0025093","R0025093.pdf","free_to_read","randomized_trial","Wysham CH","2016","Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0238","https://doi.org/10.2337/dc16-0238","27436275","https://pubmed.ncbi.nlm.nih.gov/27436275/",null,"ClinicalTrials.gov:NCT01104701"],["1","R0025614","R0025614.pdf","free_to_read","randomized_trial","Ahrén B","2016","Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0690","https://doi.org/10.2337/dc16-0690","27493132","https://pubmed.ncbi.nlm.nih.gov/27493132/","https://doi.org/10.17615/6xvf-j016","ClinicalTrials.gov:NCT02098395"],["1","R0025853","R0025853.pdf","free_to_read","randomized_trial","FLAT-SUGAR Trial Investigators","2016","Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.","Diabetes care","American Diabetes Association","10.2337/dc15-2782","https://doi.org/10.2337/dc15-2782","27208320","https://pubmed.ncbi.nlm.nih.gov/27208320/",null,null],["1","R0026025","R0026025.pdf","free_to_read","randomized_trial","Davies MJ","2016","Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.","Diabetes care","American Diabetes Association","10.2337/dc14-2883","https://doi.org/10.2337/dc14-2883","26681713","https://pubmed.ncbi.nlm.nih.gov/26681713/","https://figshare.com/articles/journal_contribution/Efficacy_and_Safety_of_Liraglutide_versus_Placebo_as_Add-on_to_Glucose_Lowering_Therapy_in_Patients_with_Type_2_Diabetes_and_Moderate_Renal_Impairment_LIRA-RENAL_A_Randomized_Clinical_Trial/10153496","ClinicalTrials.gov:NCT01620489"],["1","R0026106","R0026106.pdf","free_to_read","randomized_trial","Idorn T","2016","Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc15-1025","https://doi.org/10.2337/dc15-1025","26283739","https://pubmed.ncbi.nlm.nih.gov/26283739/",null,"ClinicalTrials.gov:NCT01394341"],["1","R0026291","R0026291.pdf","open_download_failed","randomized_trial","Kuhadiya ND","2016","Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.","Diabetes care","American Diabetes Association","10.2337/dc15-1136","https://doi.org/10.2337/dc15-1136","27208343","https://pubmed.ncbi.nlm.nih.gov/27208343/","https://www.ncbi.nlm.nih.gov/pmc/articles/5864130","ClinicalTrials.gov:NCT01722266"],["1","R0026455","R0026455.pdf","open_download_failed","randomized_trial","Ten Kulve JS","2016","Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.","The Journal of endocrinology","Bioscientifica","10.1530/joe-15-0461","https://doi.org/10.1530/joe-15-0461","26769912","https://pubmed.ncbi.nlm.nih.gov/26769912/","https://joe.bioscientifica.com/downloadpdf/journals/joe/229/1/1.pdf",null],["1","R0026692","R0026692.pdf","open_download_failed","randomized_trial","Kuhadiya ND","2016","Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2016-1451","https://doi.org/10.1210/jc.2016-1451","27490915","https://pubmed.ncbi.nlm.nih.gov/27490915/","https://academic.oup.com/jcem/article-pdf/101/9/3506/10528911/jcem3506.pdf","ClinicalTrials.gov:NCT02518945"],["1","R0027538","R0027538.pdf","open_download_failed","randomized_trial","Oster G","2016","Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2016.1241663","https://doi.org/10.1080/00325481.2016.1241663","27690710","https://pubmed.ncbi.nlm.nih.gov/27690710/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2016.1241663?needAccess=true&role=button","ClinicalTrials.gov:NCT02451137"],["1","R0012750","R0012750.pdf","open_download_failed","randomized_trial","Buse JB","2015","Is insulin the most effective injectable antihyperglycaemic therapy?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12402","https://doi.org/10.1111/dom.12402","25323312","https://pubmed.ncbi.nlm.nih.gov/25323312/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12402",null],["1","R0012831","R0012831.pdf","free_to_read","randomized_trial","Bentley-Lewis R","2015","Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.","American heart journal","Elsevier BV","10.1016/j.ahj.2015.02.002","https://doi.org/10.1016/j.ahj.2015.02.002","25965710","https://pubmed.ncbi.nlm.nih.gov/25965710/","https://figshare.com/articles/journal_contribution/Rationale_design_and_baseline_characteristics_in_Evaluation_of_LIXisenatide_in_Acute_Coronary_Syndrome_a_long-term_cardiovascular_end_point_trial_of_lixisenatide_versus_placebo/20641314","ClinicalTrials.gov:NCT01147250"],["1","R0014347","R0014347.pdf","free_to_read","randomized_trial","Kapitza C","2015","Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.","Journal of clinical pharmacology","Wiley","10.1002/jcph.549","https://doi.org/10.1002/jcph.549","25998481","https://pubmed.ncbi.nlm.nih.gov/25998481/","https://doi.org/10.1002/jcph.549",null],["1","R0015384","R0015384.pdf","open_download_failed","randomized_trial","Pfeffer MA","2015","Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1509225","https://doi.org/10.1056/nejmoa1509225","26630143","https://pubmed.ncbi.nlm.nih.gov/26630143/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1509225?articleTools=true","ClinicalTrials.gov:NCT01147250"],["1","R0016839","R0016839.pdf","open_download_failed","randomized_trial","Daniele G","2015","Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.","Diabetes","American Diabetes Association","10.2337/db14-1718","https://doi.org/10.2337/db14-1718","26116695","https://pubmed.ncbi.nlm.nih.gov/26116695/","https://www.ncbi.nlm.nih.gov/pmc/articles/6908417","ClinicalTrials.gov:NCT01588418"],["1","R0019403","R0019403.pdf","open_download_failed","randomized_trial","van Bloemendaal L","2015","Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.21200","https://doi.org/10.1002/oby.21200","26331843","https://pubmed.ncbi.nlm.nih.gov/26331843/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.21200",null],["1","R0020535","R0020535.pdf","open_download_failed","randomized_trial","Lüdemann J","2015","Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.","Therapeutic advances in endocrinology and metabolism","SAGE Publications","10.1177/2042018815595584","https://doi.org/10.1177/2042018815595584","26301063","https://pubmed.ncbi.nlm.nih.gov/26301063/","https://journals.sagepub.com/doi/pdf/10.1177/2042018815595584",null],["1","R0020700","R0020700.pdf","open_download_failed","randomized_trial","Jaiswal M","2015","Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.07.013","https://doi.org/10.1016/j.jdiacomp.2015.07.013","26264399","https://pubmed.ncbi.nlm.nih.gov/26264399/","https://www.ncbi.nlm.nih.gov/pmc/articles/4656068","ClinicalTrials.gov:NCT00855439"],["1","R0022927","R0022927.pdf","open_download_failed","randomized_trial","Pi-Sunyer X","2015","A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1411892","https://doi.org/10.1056/nejmoa1411892","26132939","https://pubmed.ncbi.nlm.nih.gov/26132939/","https://www.nejm.org/doi/pdf/10.1056/NEJMoa1411892?articleTools=true","ClinicalTrials.gov:NCT01272219"],["1","R0023657","R0023657.pdf","open_download_failed","randomized_trial","Ingwersen SH","2015","Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.01.001","https://doi.org/10.1016/j.diabres.2015.01.001","25684604","https://pubmed.ncbi.nlm.nih.gov/25684604/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(15)00007-8/pdf",null],["1","R0025468","R0025468.pdf","free_to_read","randomized_trial","FLAT-SUGAR Trial Investigators","2015","Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc14-2689","https://doi.org/10.2337/dc14-2689","26068865","https://pubmed.ncbi.nlm.nih.gov/26068865/",null,"ClinicalTrials.gov:NCT01524705"],["1","R0025767","R0025767.pdf","open_download_failed","randomized_trial","Seino Y","2015","Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.07.003","https://doi.org/10.1016/j.jdiacomp.2015.07.003","26342556","https://pubmed.ncbi.nlm.nih.gov/26342556/","https://www.sciencedirect.com/science/article/pii/S1056872715002718/pdf",null],["1","R0025894","R0025894.pdf","open_download_failed","randomized_trial","Davies MJ","2015","Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2015.9676","https://doi.org/10.1001/jama.2015.9676","26284720","https://pubmed.ncbi.nlm.nih.gov/26284720/","http://hdl.handle.net/2381/36026","ClinicalTrials.gov:NCT01272232"],["1","R0026080","R0026080.pdf","free_to_read","randomized_trial","Frandsen CS","2015","Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.","Diabetes care","American Diabetes Association","10.2337/dc15-1037","https://doi.org/10.2337/dc15-1037","26486191","https://pubmed.ncbi.nlm.nih.gov/26486191/",null,"ClinicalTrials.gov:NCT02092896"],["1","R0026331","R0026331.pdf","open_download_failed","randomized_trial","Xu W","2015","Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).","Journal of internal medicine","Wiley","10.1111/joim.12293","https://doi.org/10.1111/joim.12293","25039675","https://pubmed.ncbi.nlm.nih.gov/25039675/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/joim.12293",null],["1","R0026378","R0026378.pdf","free_to_read","randomized_trial","Kramer CK","2015","The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-2725","https://doi.org/10.1210/jc.2015-2725","26230296","https://pubmed.ncbi.nlm.nih.gov/26230296/",null,"ClinicalTrials.gov:NCT01270789"],["1","R0040990","R0040990.pdf","no_doi","randomized_trial","Controlled Trial","2015","Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00765817"],["1","R0042435","R0042435.pdf","no_doi","randomized_trial","Melanie J. Davies (7155500)","2015","Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272232"],["1","R0015972","R0015972.pdf","free_to_read","randomized_trial","Yu Pan C","2014","Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2541","https://doi.org/10.1002/dmrr.2541","24639432","https://pubmed.ncbi.nlm.nih.gov/24639432/","https://doi.org/10.1002/dmrr.2541","ClinicalTrials.gov:NCT01169779"],["1","R0016300","R0016300.pdf","free_to_read","randomized_trial","Pratley RE","2014","Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(13)70214-6","https://doi.org/10.1016/s2213-8587(13)70214-6","24703047","https://pubmed.ncbi.nlm.nih.gov/24703047/",null,"ClinicalTrials.gov:NCT01128894"],["1","R0016788","R0016788.pdf","free_to_read","randomized_trial","Diamant M","2014","Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/dc14-0876","https://doi.org/10.2337/dc14-0876","25011946","https://pubmed.ncbi.nlm.nih.gov/25011946/",null,"ClinicalTrials.gov:NCT00960661"],["1","R0017904","R0017904.pdf","free_to_read","randomized_trial","Østoft SH","2014","Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.","Diabetes care","American Diabetes Association","10.2337/dc13-3007","https://doi.org/10.2337/dc13-3007","24929431","https://pubmed.ncbi.nlm.nih.gov/24929431/","https://doi.org/10.2337/dc13-3007","ClinicalTrials.gov:NCT01610934; EudraCT:2012-000592-17"],["1","R0022904","R0022904.pdf","open_download_failed","randomized_trial","Skrivanek Z","2014","Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12305","https://doi.org/10.1111/dom.12305","24762094","https://pubmed.ncbi.nlm.nih.gov/24762094/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12305","ClinicalTrials.gov:NCT00734474"],["1","R0023956","R0023956.pdf","open_download_failed","randomized_trial","Gu N","2014","Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2013.12.002","https://doi.org/10.1016/j.clinthera.2013.12.002","24373998","https://pubmed.ncbi.nlm.nih.gov/24373998/","http://www.clinicaltherapeutics.com/article/S0149291813011107/pdf","ClinicalTrials.gov:NCT00964262"],["1","R0025645","R0025645.pdf","open_download_failed","randomized_trial","Rosenstock J","2014","Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2014.01.012","https://doi.org/10.1016/j.jdiacomp.2014.01.012","24650952","https://pubmed.ncbi.nlm.nih.gov/24650952/","https://www.sciencedirect.com/science/article/pii/S1056872714000130/pdf","ClinicalTrials.gov:NCT00713830"],["1","R0025670","R0025670.pdf","free_to_read","randomized_trial","Seino Y","2014","A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2014.896327","https://doi.org/10.1185/03007995.2014.896327","24552155","https://pubmed.ncbi.nlm.nih.gov/24552155/","https://figshare.com/articles/journal_contribution/A_randomized_dose-finding_study_demonstrating_the_efficacy_and_tolerability_of_albiglutide_in_Japanese_patients_with_type_2_diabetes_mellitus/11830233","ClinicalTrials.gov:NCT01098461"],["1","R0025701","R0025701.pdf","open_download_failed","randomized_trial","Ahrén B","2014","Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2014.05.012","https://doi.org/10.1016/j.jdiacomp.2014.05.012","25012990","https://pubmed.ncbi.nlm.nih.gov/25012990/","https://www.sciencedirect.com/science/article/pii/S1056872714001512/pdf",null],["1","R0025963","R0025963.pdf","open_download_failed","randomized_trial","Bolli GB","2014","Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12328","https://doi.org/10.1111/dme.12328","24117597","https://pubmed.ncbi.nlm.nih.gov/24117597/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.12328","ClinicalTrials.gov:NCT00763451"],["1","R0026175","R0026175.pdf","open_download_failed","randomized_trial","Mathieu C","2014","A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12262","https://doi.org/10.1111/dom.12262","24443830","https://pubmed.ncbi.nlm.nih.gov/24443830/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12262",null],["1","R0026554","R0026554.pdf","open_download_failed","randomized_trial","Aviles-Olmos I","2014","Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-140364","https://doi.org/10.3233/jpd-140364","24662192","https://pubmed.ncbi.nlm.nih.gov/24662192/","https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd140364?id=journal-of-parkinsons-disease%2Fjpd140364",null],["1","R0026607","R0026607.pdf","open_download_failed","randomized_trial","Fonseca VA","2014","Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2014.01.009","https://doi.org/10.1016/j.jdiacomp.2014.01.009","24561125","https://pubmed.ncbi.nlm.nih.gov/24561125/","https://www.sciencedirect.com/science/article/pii/S1056872714000105/pdf","ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461; ClinicalTrials.gov:NCT00331851; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00518882"],["1","R0026677","R0026677.pdf","open_download_failed","randomized_trial","Kim SH","2014","Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-013-3134-3","https://doi.org/10.1007/s00125-013-3134-3","24326527","https://pubmed.ncbi.nlm.nih.gov/24326527/","https://www.ncbi.nlm.nih.gov/pmc/articles/5072364","ClinicalTrials.gov:NCT01784965"],["1","R0026795","R0026795.pdf","open_download_failed","randomized_trial","Klein DJ","2014","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2013.0366","https://doi.org/10.1089/dia.2013.0366","25036533","https://pubmed.ncbi.nlm.nih.gov/25036533/","https://doi.org/10.1089/dia.2013.0366","ClinicalTrials.gov:NCT00943501"],["1","R0048972","R0048972.pdf","free_to_read","randomized_trial","Alan Charles Moses","2014","Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer","Pancreas","Ovid Technologies (Wolters Kluwer Health)","10.1097/mpa.0000000000000037","https://doi.org/10.1097/mpa.0000000000000037","24713674","https://pubmed.ncbi.nlm.nih.gov/24713674/","https://www.ncbi.nlm.nih.gov/pmc/articles/4206353","ClinicalTrials.gov:NCT01179048"],["1","R0013363","R0013363.pdf","open_download_failed","randomized_trial","Kelly AS","2013","The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.","JAMA pediatrics","American Medical Association (AMA)","10.1001/jamapediatrics.2013.1045","https://doi.org/10.1001/jamapediatrics.2013.1045","23380890","https://pubmed.ncbi.nlm.nih.gov/23380890/","https://www.ncbi.nlm.nih.gov/pmc/articles/4010226","ClinicalTrials.gov:NCT01237197"],["1","R0014538","R0014538.pdf","open_download_failed","randomized_trial","Henry RR","2013","A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2013.03.011","https://doi.org/10.1016/j.clinthera.2013.03.011","23578605","https://pubmed.ncbi.nlm.nih.gov/23578605/","http://www.clinicaltherapeutics.com/article/S0149291813001239/pdf","ClinicalTrials.gov:NCT01798264"],["1","R0026296","R0026296.pdf","open_download_failed","randomized_trial","Woo JS","2013","Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.","Arteriosclerosis, thrombosis, and vascular biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvbaha.113.301586","https://doi.org/10.1161/atvbaha.113.301586","23868944","https://pubmed.ncbi.nlm.nih.gov/23868944/","https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.113.301586","ClinicalTrials.gov:NCT01580514"],["1","R0026610","R0026610.pdf","open_download_failed","randomized_trial","Aviles-Olmos I","2013","Exenatide and the treatment of patients with Parkinson's disease.","The Journal of clinical investigation","American Society for Clinical Investigation","10.1172/jci68295","https://doi.org/10.1172/jci68295","23728174","https://pubmed.ncbi.nlm.nih.gov/23728174/","https://www.ncbi.nlm.nih.gov/pmc/articles/3668846","ClinicalTrials.gov:NCT01174810"],["1","R0026674","R0026674.pdf","open_download_failed","randomized_trial","Langer J","2013","Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2013.19.3.237","https://doi.org/10.18553/jmcp.2013.19.3.237","23537458","https://pubmed.ncbi.nlm.nih.gov/23537458/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10438006/pdf/jmcp.2013.19.3.237.pdf","ClinicalTrials.gov:NCT00700817"],["1","R0026793","R0026793.pdf","open_download_failed","randomized_trial","Hermansen K","2013","Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12133","https://doi.org/10.1111/dom.12133","23683069","https://pubmed.ncbi.nlm.nih.gov/23683069/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12133","ClinicalTrials.gov:NCT00993304"],["1","R0027038","R0027038.pdf","open_download_failed","randomized_trial","Marso SP","2013","Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2013.07.012","https://doi.org/10.1016/j.ahj.2013.07.012","24176437","https://pubmed.ncbi.nlm.nih.gov/24176437/","https://www.sciencedirect.com/science/article/pii/S000287031300450X/pdf",null],["1","R0027281","R0027281.pdf","open_download_failed","randomized_trial","Rosenstock J","2013","One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2013.04.008","https://doi.org/10.1016/j.jdiacomp.2013.04.008","23746555","https://pubmed.ncbi.nlm.nih.gov/23746555/","https://www.sciencedirect.com/science/article/pii/S1056872713001037/pdf",null],["1","R0021573","R0021573.pdf","free_to_read","randomized_trial","Gejl M","2012","Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-3456","https://doi.org/10.1210/jc.2011-3456","22544917","https://pubmed.ncbi.nlm.nih.gov/22544917/",null,"ClinicalTrials.gov:NCT00747968"],["1","R0023502","R0023502.pdf","free_to_read","randomized_trial","Lønborg J","2012","Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehr309","https://doi.org/10.1093/eurheartj/ehr309","21920963","https://pubmed.ncbi.nlm.nih.gov/21920963/",null,"ClinicalTrials.gov:NCT00835848"],["1","R0024231","R0024231.pdf","open_download_failed","randomized_trial","Mendis B","2012","Investigation of the haemodynamic effects of exenatide in healthy male subjects.","British journal of clinical pharmacology","Wiley","10.1111/j.1365-2125.2012.04214.x","https://doi.org/10.1111/j.1365-2125.2012.04214.x","22320349","https://pubmed.ncbi.nlm.nih.gov/22320349/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2012.04214.x",null],["1","R0026878","R0026878.pdf","open_download_failed","randomized_trial","Chaudhuri A","2012","Exenatide exerts a potent antiinflammatory effect.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-1508","https://doi.org/10.1210/jc.2011-1508","22013105","https://pubmed.ncbi.nlm.nih.gov/22013105/","https://academic.oup.com/jcem/article-pdf/97/1/198/10746399/jcem0198.pdf",null],["1","R0026946","R0026946.pdf","open_download_failed","randomized_trial","Lønborg J","2012","Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.","Circulation. Cardiovascular interventions","Ovid Technologies (Wolters Kluwer Health)","10.1161/circinterventions.112.968388","https://doi.org/10.1161/circinterventions.112.968388","22496084","https://pubmed.ncbi.nlm.nih.gov/22496084/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.112.968388","ClinicalTrials.gov:NCT00835848"],["1","R0026950","R0026950.pdf","open_download_failed","randomized_trial","Kelly AS","2012","Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.","Obesity (Silver Spring, Md.)","Wiley","10.1038/oby.2011.337","https://doi.org/10.1038/oby.2011.337","22076596","https://pubmed.ncbi.nlm.nih.gov/22076596/","https://www.ncbi.nlm.nih.gov/pmc/articles/3684414","ClinicalTrials.gov:NCT00886626"],["1","R0027814","R0027814.pdf","open_download_failed","randomized_trial","Stevens JE","2012","The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.","Alimentary pharmacology & therapeutics","Wiley","10.1111/j.1365-2036.2012.05198.x","https://doi.org/10.1111/j.1365-2036.2012.05198.x","22738299","https://pubmed.ncbi.nlm.nih.gov/22738299/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2012.05198.x","ClinicalTrials.gov:NCT00501657"],["1","R0027069","R0027069.pdf","free_to_read","randomized_trial","Buse JB","2011","Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-154-2-201101180-00300","https://doi.org/10.7326/0003-4819-154-2-201101180-00300","21138825","https://pubmed.ncbi.nlm.nih.gov/21138825/",null,"ClinicalTrials.gov:NCT00765817"],["1","R0043692","R0043692.pdf","free_to_read","randomized_trial","Shailesh Pitale","2011","Fetal origin of vascular aging","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.86971","https://doi.org/10.4103/2230-8210.86971","22145131","https://pubmed.ncbi.nlm.nih.gov/22145131/","https://doi.org/10.4103/2230-8210.86971","ClinicalTrials.gov:NCT04255433"],["1","R0045813","R0045813.pdf","free_to_read","randomized_trial","Vikas Chaudhary","2011","Imaging of the pituitary: Recent advances","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.84871","https://doi.org/10.4103/2230-8210.84871","22029027","https://pubmed.ncbi.nlm.nih.gov/22029027/","https://doi.org/10.4103/2230-8210.84871","ClinicalTrials.gov:NCT04255433"],["1","R0024803","R0024803.pdf","open_download_failed","randomized_trial","Okerson T","2010","Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.","American journal of hypertension","Oxford University Press (OUP)","10.1038/ajh.2009.245","https://doi.org/10.1038/ajh.2009.245","20019672","https://pubmed.ncbi.nlm.nih.gov/20019672/","https://academic.oup.com/ajh/article-pdf/23/3/334/6631929/23_3_334.pdf",null],["1","R0026970","R0026970.pdf","open_download_failed","randomized_trial","Liutkus J","2010","A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01251.x","https://doi.org/10.1111/j.1463-1326.2010.01251.x","20977576","https://pubmed.ncbi.nlm.nih.gov/20977576/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2010.01251.x",null],["1","R0023385","R0023385.pdf","open_download_failed","randomized_trial","Jendle J","2009","Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01158.x","https://doi.org/10.1111/j.1463-1326.2009.01158.x","19930006","https://pubmed.ncbi.nlm.nih.gov/19930006/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2009.01158.x",null],["1","R0024980","R0024980.pdf","free_to_read","randomized_trial","Chatterjee DJ","2009","Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.","Journal of clinical pharmacology","Wiley","10.1177/0091270009339189","https://doi.org/10.1177/0091270009339189","19737980","https://pubmed.ncbi.nlm.nih.gov/19737980/",null,null],["1","R0025460","R0025460.pdf","open_download_failed","randomized_trial","Timmers L","2009","Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2008.10.033","https://doi.org/10.1016/j.jacc.2008.10.033","19195607","https://pubmed.ncbi.nlm.nih.gov/19195607/","https://www.sciencedirect.com/science/article/pii/S0735109708036760/pdf",null],["1","R0028017","R0028017.pdf","open_download_failed","randomized_trial","Elkind-Hirsch K","2008","Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2008-0115","https://doi.org/10.1210/jc.2008-0115","18460557","https://pubmed.ncbi.nlm.nih.gov/18460557/","https://academic.oup.com/jcem/article-pdf/93/7/2670/9058346/jcem2670.pdf","ClinicalTrials.gov:NCT00344851"],["1","R0022988","R0022988.pdf","open_download_failed","randomized_trial","Mari A","2007","Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.","Diabetes care","American Diabetes Association","10.2337/dc07-0310","https://doi.org/10.2337/dc07-0310","17468345","https://pubmed.ncbi.nlm.nih.gov/17468345/","https://diabetesjournals.org/care/article-pdf/30/8/2032/596797/zdc00807002032.pdf",null],["1","R0023309","R0023309.pdf","open_download_failed","randomized_trial","Vilsbøll T","2007","Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/dc06-2593","https://doi.org/10.2337/dc06-2593","17372153","https://pubmed.ncbi.nlm.nih.gov/17372153/","https://diabetesjournals.org/care/article-pdf/30/6/1608/598008/zdc00607001608.pdf","ClinicalTrials.gov:NCT00154401"],["1","R0027445","R0027445.pdf","free_to_read","randomized_trial","Davis SN","2007","Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.","Diabetes care","American Diabetes Association","10.2337/dc06-2532","https://doi.org/10.2337/dc06-2532","17595353","https://pubmed.ncbi.nlm.nih.gov/17595353/",null,"ClinicalTrials.gov:NCT00099333"],["1","R0025778","R0025778.pdf","free_to_read","randomized_trial","Ratner RE","2006","Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2006.00589.x","https://doi.org/10.1111/j.1463-1326.2006.00589.x","16776749","https://pubmed.ncbi.nlm.nih.gov/16776749/",null,null],["1","R0025957","R0025957.pdf","open_download_failed","randomized_trial","Blonde L","2006","Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2006.00602.x","https://doi.org/10.1111/j.1463-1326.2006.00602.x","16776751","https://pubmed.ncbi.nlm.nih.gov/16776751/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2006.00602.x",null],["1","R0023484","R0023484.pdf","open_download_failed","randomized_trial","Feinglos MN","2005","Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2005.01567.x","https://doi.org/10.1111/j.1464-5491.2005.01567.x","16026367","https://pubmed.ncbi.nlm.nih.gov/16026367/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-5491.2005.01567.x",null],["1","R0043174","R0043174.pdf","free_to_read","randomized_trial","Zosia Kmietowicz","2005","Too many heart patients discharged without follow-up care","BMJ","BMJ","10.1136/bmj.330.7504.1346-a","https://doi.org/10.1136/bmj.330.7504.1346-a","15947381","https://pubmed.ncbi.nlm.nih.gov/15947381/","https://www.ncbi.nlm.nih.gov/pmc/articles/558312","ClinicalTrials.gov:NCT02905864"],["1","R0022827","R0022827.pdf","open_download_failed","randomized_trial","Buse JB","2004","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/diacare.27.11.2628","https://doi.org/10.2337/diacare.27.11.2628","15504997","https://pubmed.ncbi.nlm.nih.gov/15504997/","https://diabetesjournals.org/care/article-pdf/27/11/2628/562462/zdc01104002628.pdf",null],["1","R0025482","R0025482.pdf","open_download_failed","randomized_trial","Degn KB","2004","Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.","Diabetes","American Diabetes Association","10.2337/diabetes.53.9.2397","https://doi.org/10.2337/diabetes.53.9.2397","15331551","https://pubmed.ncbi.nlm.nih.gov/15331551/","https://diabetesjournals.org/diabetes/article-pdf/53/9/2397/654007/zdb00904002397.pdf",null],["1","R0026486","R0026486.pdf","open_download_failed","randomized_trial","Degn KB","2004","One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.","Diabetes","American Diabetes Association","10.2337/diabetes.53.5.1187","https://doi.org/10.2337/diabetes.53.5.1187","15111485","https://pubmed.ncbi.nlm.nih.gov/15111485/","https://diabetesjournals.org/diabetes/article-pdf/53/5/1187/647136/zdb00504001187.pdf",null],["1","R0026652","R0026652.pdf","open_download_failed","randomized_trial","Harder H","2004","The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/diacare.27.8.1915","https://doi.org/10.2337/diacare.27.8.1915","15277417","https://pubmed.ncbi.nlm.nih.gov/15277417/","https://diabetesjournals.org/care/article-pdf/27/8/1915/651570/zdc00804001915.pdf",null],["1","R0027309","R0027309.pdf","free_to_read","randomized_trial","Chang AM","2003","The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.","Diabetes","American Diabetes Association","10.2337/diabetes.52.7.1786","https://doi.org/10.2337/diabetes.52.7.1786","12829647","https://pubmed.ncbi.nlm.nih.gov/12829647/",null,null],["1","R0027611","R0027611.pdf","open_download_failed","randomized_trial","Juhl CB","2002","Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.","Diabetes","American Diabetes Association","10.2337/diabetes.51.2.424","https://doi.org/10.2337/diabetes.51.2.424","11812750","https://pubmed.ncbi.nlm.nih.gov/11812750/","https://diabetesjournals.org/diabetes/article-pdf/51/2/424/644183/db0202000424.pdf",null],["1","R0036399","R0036399.pdf","no_doi","randomized_trial","Vijiaratnam N",null,"Exenatide once a week versus placebo as a potential disease modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","Newcastle University ePrints (Newcastle Univesity)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04232969; EudraCT:2018-003028-35"],["2","R0000057","R0000057.pdf","paywalled","randomized_trial","De Filippo O","2026","Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.","Journal of cardiovascular pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001862","https://doi.org/10.1097/fjc.0000000000001862","42520399","https://pubmed.ncbi.nlm.nih.gov/42520399/",null,null],["2","R0000066","R0000066.pdf","paywalled","randomized_trial","Trudeau M","2026","Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis.","The Orthopedic clinics of North America","Elsevier BV","10.1016/j.ocl.2026.05.004","https://doi.org/10.1016/j.ocl.2026.05.004","42692567","https://pubmed.ncbi.nlm.nih.gov/42692567/",null,null],["2","R0000108","R0000108.pdf","paywalled","randomized_trial","Kong AP","2026","Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2026.08.005","https://doi.org/10.1016/j.pcd.2026.08.005","42697752","https://pubmed.ncbi.nlm.nih.gov/42697752/",null,null],["2","R0000303","R0000303.pdf","paywalled","randomized_trial","Baldwin K","2026","Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.","Journal of dual diagnosis","Informa UK Limited","10.1080/15504263.2026.2720402","https://doi.org/10.1080/15504263.2026.2720402","42636272","https://pubmed.ncbi.nlm.nih.gov/42636272/",null,null],["2","R0000353","R0000353.pdf","paywalled","randomized_trial","Bala S","2026","Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know.","Survey of ophthalmology","Elsevier BV","10.1016/j.survophthal.2025.12.007","https://doi.org/10.1016/j.survophthal.2025.12.007","41482136","https://pubmed.ncbi.nlm.nih.gov/41482136/",null,null],["2","R0000372","R0000372.pdf","paywalled","randomized_trial","Chen H","2026","Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000004193","https://doi.org/10.1227/neu.0000000000004193","42599090","https://pubmed.ncbi.nlm.nih.gov/42599090/",null,null],["2","R0000378","R0000378.pdf","paywalled","randomized_trial","Pigeyre M","2026","Cardiovascular Risk Reduction With GLP-1 RA Drugs.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.126.079319","https://doi.org/10.1161/circulationaha.126.079319","42406865","https://pubmed.ncbi.nlm.nih.gov/42406865/",null,null],["2","R0000449","R0000449.pdf","paywalled","randomized_trial","Neumiller JJ","2026","Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2026.04.007","https://doi.org/10.1053/j.ajkd.2026.04.007","42302979","https://pubmed.ncbi.nlm.nih.gov/42302979/",null,null],["2","R0000472","R0000472.pdf","paywalled","randomized_trial","Singh P","2026","Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series.","Clinical nephrology","Dustri-Verlag Dr. Karl Feistle","10.5414/cn111893","https://doi.org/10.5414/cn111893","41841288","https://pubmed.ncbi.nlm.nih.gov/41841288/",null,null],["2","R0000487","R0000487.pdf","paywalled","randomized_trial","Gregory JM","2026","GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2026.04.010","https://doi.org/10.1016/j.ecl.2026.04.010","42526996","https://pubmed.ncbi.nlm.nih.gov/42526996/",null,null],["2","R0000509","R0000509.pdf","paywalled","randomized_trial","Ramadan A","2026","Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Disease: Redefining Therapy Through Cardiometabolic Substrate Modification.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001322","https://doi.org/10.1097/crd.0000000000001322","42307757","https://pubmed.ncbi.nlm.nih.gov/42307757/",null,null],["2","R0000523","R0000523.pdf","paywalled","randomized_trial","Hatzis G","2026","The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review.","Postgraduate medical journal","Oxford University Press (OUP)","10.1093/postmj/qgag044","https://doi.org/10.1093/postmj/qgag044","42059880","https://pubmed.ncbi.nlm.nih.gov/42059880/",null,null],["2","R0000535","R0000535.pdf","paywalled","randomized_trial","Wang T","2026","Real-World and Randomized Controlled Trial Evidence Converge: Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Safety.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.07.001","https://doi.org/10.1016/j.eprac.2026.07.001","42413660","https://pubmed.ncbi.nlm.nih.gov/42413660/",null,null],["2","R0000586","R0000586.pdf","paywalled","randomized_trial","Micha JP","2026","The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.","Expert review of anticancer therapy","Informa UK Limited","10.1080/14737140.2026.2691887","https://doi.org/10.1080/14737140.2026.2691887","42308159","https://pubmed.ncbi.nlm.nih.gov/42308159/",null,null],["2","R0000587","R0000587.pdf","paywalled","randomized_trial","Massay R","2026","Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis.","Current opinion in rheumatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/bor.0000000000001153","https://doi.org/10.1097/bor.0000000000001153","41782546","https://pubmed.ncbi.nlm.nih.gov/41782546/",null,null],["2","R0000612","R0000612.pdf","paywalled","randomized_trial","Potluru A","2026","Expanding the dermatological horizon of glucagon-like peptide-1 receptor agonists: response to 'Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study'.","Clinical and experimental dermatology","Oxford University Press (OUP)","10.1093/ced/llag025","https://doi.org/10.1093/ced/llag025","41549421","https://pubmed.ncbi.nlm.nih.gov/41549421/",null,null],["2","R0000636","R0000636.pdf","paywalled","randomized_trial","Savas M","2026","Beyond weight loss: multisystem benefits of obesity medications.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00100-2","https://doi.org/10.1016/s2213-8587(26)00100-2","42208956","https://pubmed.ncbi.nlm.nih.gov/42208956/",null,null],["2","R0000659","R0000659.pdf","paywalled","randomized_trial","Hardvik Åkerström J","2026","Glucagon-Like Peptide-1 Receptor Agonist Treatment and Risk of Esophageal Cancer.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003885","https://doi.org/10.14309/ajg.0000000000003885","41384845","https://pubmed.ncbi.nlm.nih.gov/41384845/",null,null],["2","R0000703","R0000703.pdf","paywalled","randomized_trial","Beniwal-Patel P","2026","The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izag151","https://doi.org/10.1093/ibd/izag151","42593078","https://pubmed.ncbi.nlm.nih.gov/42593078/",null,null],["2","R0000721","R0000721.pdf","paywalled","randomized_trial","Roy JM","2026","Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus.","Journal of neurosurgery","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2025.12.jns251072","https://doi.org/10.3171/2025.12.jns251072","41962156","https://pubmed.ncbi.nlm.nih.gov/41962156/",null,null],["2","R0000742","R0000742.pdf","paywalled","randomized_trial","Karpinski S","2026","Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001208","https://doi.org/10.2215/cjn.0000001208","42640716","https://pubmed.ncbi.nlm.nih.gov/42640716/",null,null],["2","R0000766","R0000766.pdf","paywalled","randomized_trial","Dalpiaz H","2026","Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice.","Heart (British Cardiac Society)","BMJ","10.1136/heartjnl-2024-324847","https://doi.org/10.1136/heartjnl-2024-324847","40664497","https://pubmed.ncbi.nlm.nih.gov/40664497/",null,null],["2","R0000786","R0000786.pdf","paywalled","randomized_trial","Renehan AG","2026","Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?","Cancer prevention research (Philadelphia, Pa.)","American Association for Cancer Research (AACR)","10.1158/1940-6207.capr-26-0018","https://doi.org/10.1158/1940-6207.capr-26-0018","41918364","https://pubmed.ncbi.nlm.nih.gov/41918364/",null,null],["2","R0000814","R0000814.pdf","paywalled","randomized_trial","Brogaard E","2026","Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.","Expert opinion on therapeutic targets","Informa UK Limited","10.1080/14728222.2026.2738341","https://doi.org/10.1080/14728222.2026.2738341","42779274","https://pubmed.ncbi.nlm.nih.gov/42779274/",null,null],["2","R0000915","R0000915.pdf","paywalled","randomized_trial","Friedman AN","2026","Weight Loss-Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2026.03.037","https://doi.org/10.1053/j.ajkd.2026.03.037","42140342","https://pubmed.ncbi.nlm.nih.gov/42140342/",null,null],["2","R0000922","R0000922.pdf","paywalled","randomized_trial","Vyas K","2026","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005187","https://doi.org/10.1097/dss.0000000000005187","42210887","https://pubmed.ncbi.nlm.nih.gov/42210887/",null,null],["2","R0000968","R0000968.pdf","paywalled","randomized_trial","McIntyre RS","2026","Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2026.2574","https://doi.org/10.1001/jamapsychiatry.2026.2574","42647034","https://pubmed.ncbi.nlm.nih.gov/42647034/",null,null],["2","R0000987","R0000987.pdf","paywalled","randomized_trial","Raja NP","2026","GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far.","Current oncology reports","Springer Science and Business Media LLC","10.1007/s11912-026-01825-z","https://doi.org/10.1007/s11912-026-01825-z","42645635","https://pubmed.ncbi.nlm.nih.gov/42645635/",null,null],["2","R0000998","R0000998.pdf","paywalled","randomized_trial","Liang Y","2026","Commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity'.","European journal of heart failure","Oxford University Press (OUP)","10.1093/ejhf/xuaf022","https://doi.org/10.1093/ejhf/xuaf022","41771083","https://pubmed.ncbi.nlm.nih.gov/41771083/",null,null],["2","R0001024","R0001024.pdf","paywalled","randomized_trial","Siddiqi TJ","2026","Reply to commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular kidney-metabolic comorbidity'.","European journal of heart failure","Oxford University Press (OUP)","10.1093/ejhf/xuaf004","https://doi.org/10.1093/ejhf/xuaf004","41771103","https://pubmed.ncbi.nlm.nih.gov/41771103/",null,null],["2","R0001027","R0001027.pdf","paywalled","randomized_trial","Elawa Z","2026","GLP-1 receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional optimization.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113332","https://doi.org/10.1016/j.diabres.2026.113332","42155603","https://pubmed.ncbi.nlm.nih.gov/42155603/",null,null],["2","R0001064","R0001064.pdf","paywalled","randomized_trial","Pan JY","2026","GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes.","Journal of general internal medicine","Springer Science and Business Media LLC","10.1007/s11606-026-10515-2","https://doi.org/10.1007/s11606-026-10515-2","42151525","https://pubmed.ncbi.nlm.nih.gov/42151525/",null,null],["2","R0001079","R0001079.pdf","paywalled","randomized_trial","Wang Y","2026","40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys.","Regulatory toxicology and pharmacology : RTP","Elsevier BV","10.1016/j.yrtph.2026.106192","https://doi.org/10.1016/j.yrtph.2026.106192","42532462","https://pubmed.ncbi.nlm.nih.gov/42532462/",null,null],["2","R0001080","R0001080.pdf","paywalled","randomized_trial","Xie WH","2026","[Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy].","Zhonghua yi xue za zhi",null,"10.3760/cma.j.cn112137-20260312-00692","https://doi.org/10.3760/cma.j.cn112137-20260312-00692","42706128","https://pubmed.ncbi.nlm.nih.gov/42706128/",null,null],["2","R0001098","R0001098.pdf","paywalled","randomized_trial","Koren A","2026","The pancreatic signal of GLP-1 receptor agonists: A biliary phenomenon rather than direct toxicity.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70512","https://doi.org/10.1002/bcp.70512","41786617","https://pubmed.ncbi.nlm.nih.gov/41786617/",null,null],["2","R0001123","R0001123.pdf","paywalled","randomized_trial","Kumar V","2026","Glucagon-like Peptide-1 Receptor Agonists as a Dual-target Strategy for Depression and Metabolic Health: A Narrative Review.","Annals of African medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/aam.aam_546_25","https://doi.org/10.4103/aam.aam_546_25","41568621","https://pubmed.ncbi.nlm.nih.gov/41568621/",null,null],["2","R0001140","R0001140.pdf","paywalled","randomized_trial","Mannucci E","2026","Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown.","Nature reviews. Clinical oncology","Springer Science and Business Media LLC","10.1038/s41571-026-01135-0","https://doi.org/10.1038/s41571-026-01135-0","41803464","https://pubmed.ncbi.nlm.nih.gov/41803464/",null,null],["2","R0001176","R0001176.pdf","paywalled","randomized_trial","Sheth S","2026","The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.","JAMA dermatology","American Medical Association (AMA)","10.1001/jamadermatol.2026.0859","https://doi.org/10.1001/jamadermatol.2026.0859","42054048","https://pubmed.ncbi.nlm.nih.gov/42054048/",null,null],["2","R0001228","R0001228.pdf","paywalled","randomized_trial","Ahuja AS","2026","Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2025.10.021","https://doi.org/10.1016/j.ajo.2025.10.021","41130371","https://pubmed.ncbi.nlm.nih.gov/41130371/",null,null],["2","R0001243","R0001243.pdf","paywalled","randomized_trial","Macanian J","2026","GLP-1 RAs in Substance Use Disorders: Emerging Evidence and Future Directions.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001319","https://doi.org/10.1097/crd.0000000000001319","42219586","https://pubmed.ncbi.nlm.nih.gov/42219586/",null,null],["2","R0001255","R0001255.pdf","paywalled","randomized_trial","Schmidt S","2026","Counting days: Cardiovascular and kidney event postponement with glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70589","https://doi.org/10.1111/dom.70589","41733076","https://pubmed.ncbi.nlm.nih.gov/41733076/",null,null],["2","R0001295","R0001295.pdf","paywalled","randomized_trial","McCann CJ","2026","GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.","British journal of sports medicine","BMJ","10.1136/bjsports-2025-111225","https://doi.org/10.1136/bjsports-2025-111225","42321007","https://pubmed.ncbi.nlm.nih.gov/42321007/",null,null],["2","R0001303","R0001303.pdf","paywalled","randomized_trial","Verma R","2026","Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001323","https://doi.org/10.1097/hco.0000000000001323","42388102","https://pubmed.ncbi.nlm.nih.gov/42388102/",null,null],["2","R0001444","R0001444.pdf","paywalled","randomized_trial","Merhi Z","2026","GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research.","Sexual medicine reviews","Oxford University Press (OUP)","10.1093/sxmrev/qeag015","https://doi.org/10.1093/sxmrev/qeag015","41870138","https://pubmed.ncbi.nlm.nih.gov/41870138/",null,null],["2","R0001471","R0001471.pdf","paywalled","randomized_trial","Ramadurgum P","2026","GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-026-02356-6","https://doi.org/10.1007/s11886-026-02356-6","41880122","https://pubmed.ncbi.nlm.nih.gov/41880122/",null,null],["2","R0001533","R0001533.pdf","paywalled","randomized_trial","Dong W","2026","Advances in Incretin-Based Therapies for MAFLD: Mechanisms and Clinical Evidence.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.70131","https://doi.org/10.1002/cpt.70131","41243582","https://pubmed.ncbi.nlm.nih.gov/41243582/",null,null],["2","R0001546","R0001546.pdf","paywalled","randomized_trial","Bruno A","2026","Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05805-3","https://doi.org/10.1007/s00266-026-05805-3","41944875","https://pubmed.ncbi.nlm.nih.gov/41944875/",null,null],["2","R0001559","R0001559.pdf","paywalled","randomized_trial","Kunutsor SK","2026","Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-025-02263-0","https://doi.org/10.1007/s40265-025-02263-0","41351656","https://pubmed.ncbi.nlm.nih.gov/41351656/",null,null],["2","R0001596","R0001596.pdf","paywalled","randomized_trial","Mourtzos MA","2026","Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113345","https://doi.org/10.1016/j.diabres.2026.113345","42208664","https://pubmed.ncbi.nlm.nih.gov/42208664/",null,null],["2","R0001678","R0001678.pdf","paywalled","randomized_trial","Shah E","2026","Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70713","https://doi.org/10.1111/dom.70713","41889156","https://pubmed.ncbi.nlm.nih.gov/41889156/",null,null],["2","R0001740","R0001740.pdf","paywalled","randomized_trial","Panou T","2026","Tirzepatide in type 1 diabetes: beyond mere weight loss.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2026.2685653","https://doi.org/10.1080/17512433.2026.2685653","42240053","https://pubmed.ncbi.nlm.nih.gov/42240053/",null,null],["2","R0001754","R0001754.pdf","paywalled","randomized_trial","Wang Y","2026","Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70495","https://doi.org/10.1111/dom.70495","41555840","https://pubmed.ncbi.nlm.nih.gov/41555840/",null,null],["2","R0001893","R0001893.pdf","paywalled","randomized_trial","Narla S","2026","JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.12.116","https://doi.org/10.1016/j.jaad.2025.12.116","41698604","https://pubmed.ncbi.nlm.nih.gov/41698604/",null,null],["2","R0001923","R0001923.pdf","paywalled","randomized_trial","Shroff GR","2026","Evidence-Based Cardiovascular-Kidney-Metabolic Therapies in Kidney Transplant Recipients.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001195","https://doi.org/10.2215/cjn.0000001195","42522128","https://pubmed.ncbi.nlm.nih.gov/42522128/",null,null],["2","R0001936","R0001936.pdf","paywalled","randomized_trial","Rahman E","2026","Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.","Toxicon : official journal of the International Society on Toxinology","Elsevier BV","10.1016/j.toxicon.2025.108638","https://doi.org/10.1016/j.toxicon.2025.108638","41173332","https://pubmed.ncbi.nlm.nih.gov/41173332/",null,null],["2","R0001990","R0001990.pdf","paywalled","randomized_trial","Tanquilut E","2026","Adapting Glucagon-Like Peptide-1 Receptor Agonists for Innovative Psoriasis Therapy.","Journal of cutaneous medicine and surgery","SAGE Publications","10.1177/12034754261428062","https://doi.org/10.1177/12034754261428062","41847997","https://pubmed.ncbi.nlm.nih.gov/41847997/",null,null],["2","R0002081","R0002081.pdf","paywalled","randomized_trial","Cassataro G","2026","Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.","Internal and emergency medicine","Springer Science and Business Media LLC","10.1007/s11739-026-04468-x","https://doi.org/10.1007/s11739-026-04468-x","42493728","https://pubmed.ncbi.nlm.nih.gov/42493728/",null,null],["2","R0002164","R0002164.pdf","paywalled","randomized_trial","Curtis LH","2026","Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.","Annals of internal medicine","American College of Physicians","10.7326/annals-26-00202","https://doi.org/10.7326/annals-26-00202","42372277","https://pubmed.ncbi.nlm.nih.gov/42372277/",null,null],["2","R0002257","R0002257.pdf","paywalled","randomized_trial","Daniel E","2026","Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1177/10815589251393978","https://doi.org/10.1177/10815589251393978","41137196","https://pubmed.ncbi.nlm.nih.gov/41137196/",null,null],["2","R0002260","R0002260.pdf","paywalled","randomized_trial","Lisante TA","2026","A Novel Cosmetic Anti-inflammatory Peptide With Firming and Lifting Benefits: The Potential for Adjunctive Care for Skin Laxity Associated With Weight Loss.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005181","https://doi.org/10.1097/dss.0000000000005181","42210882","https://pubmed.ncbi.nlm.nih.gov/42210882/",null,null],["2","R0002296","R0002296.pdf","paywalled","randomized_trial","Cornelio CK","2026","Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.","Pharmacotherapy","Wiley","10.1002/phar.70130","https://doi.org/10.1002/phar.70130","41801847","https://pubmed.ncbi.nlm.nih.gov/41801847/",null,null],["2","R0002323","R0002323.pdf","paywalled","randomized_trial","Kaur RJ","2026","Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study.","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","Springer Science and Business Media LLC","10.1007/s12664-025-01891-4","https://doi.org/10.1007/s12664-025-01891-4","41639322","https://pubmed.ncbi.nlm.nih.gov/41639322/",null,null],["2","R0002344","R0002344.pdf","paywalled","randomized_trial","Prabhakaran S","2026","Neoadjuvant Glucagon-Like Peptide-1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review.","World journal of surgery","Wiley","10.1002/wjs.70260","https://doi.org/10.1002/wjs.70260","41653161","https://pubmed.ncbi.nlm.nih.gov/41653161/",null,null],["2","R0002453","R0002453.pdf","paywalled","randomized_trial","Zhang Z","2026","Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag179","https://doi.org/10.1093/ndt/gfag179","42570222","https://pubmed.ncbi.nlm.nih.gov/42570222/",null,null],["2","R0002483","R0002483.pdf","paywalled","randomized_trial","Yoon JP","2026","GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model.","Journal of shoulder and elbow surgery","Elsevier BV","10.1016/j.jse.2025.12.019","https://doi.org/10.1016/j.jse.2025.12.019","41644032","https://pubmed.ncbi.nlm.nih.gov/41644032/",null,null],["2","R0002495","R0002495.pdf","paywalled","randomized_trial","Büyükcavlak M","2026","Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.","Journal of anesthesia","Springer Science and Business Media LLC","10.1007/s00540-026-03813-w","https://doi.org/10.1007/s00540-026-03813-w","42377486","https://pubmed.ncbi.nlm.nih.gov/42377486/",null,null],["2","R0002575","R0002575.pdf","paywalled","randomized_trial","Wu H","2026","GLP-1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70847","https://doi.org/10.1111/dom.70847","42098911","https://pubmed.ncbi.nlm.nih.gov/42098911/",null,null],["2","R0002595","R0002595.pdf","paywalled","randomized_trial","King AC","2026","GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.","Journal of addiction medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/adm.0000000000001565","https://doi.org/10.1097/adm.0000000000001565","40792626","https://pubmed.ncbi.nlm.nih.gov/40792626/",null,null],["2","R0002764","R0002764.pdf","paywalled","randomized_trial","Hajibandeh S","2026","Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2026.103117","https://doi.org/10.1016/j.japh.2026.103117","42025961","https://pubmed.ncbi.nlm.nih.gov/42025961/",null,null],["2","R0002797","R0002797.pdf","paywalled","randomized_trial","Dorjee T","2026","Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001170","https://doi.org/10.2215/cjn.0000001170","42545745","https://pubmed.ncbi.nlm.nih.gov/42545745/",null,null],["2","R0002869","R0002869.pdf","paywalled","randomized_trial","Gutierrez de Piñeres V","2026","Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113113","https://doi.org/10.1016/j.diabres.2026.113113","41571048","https://pubmed.ncbi.nlm.nih.gov/41571048/",null,null],["2","R0002893","R0002893.pdf","paywalled","randomized_trial","Rahman E","2026","Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05990-1","https://doi.org/10.1007/s00266-026-05990-1","42414642","https://pubmed.ncbi.nlm.nih.gov/42414642/",null,null],["2","R0003094","R0003094.pdf","paywalled","randomized_trial","Capon IM","2026","Emerging Cardiorenal Protective Therapies in Lupus Nephritis.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-026-02337-7","https://doi.org/10.1007/s40265-026-02337-7","42133281","https://pubmed.ncbi.nlm.nih.gov/42133281/",null,null],["2","R0003144","R0003144.pdf","paywalled","randomized_trial","Hung KC","2026","Preoperative GLP-1 Receptor Agonists Exposure and Risk of Postoperative Acute Kidney Injury after Metabolic and Bariatric Surgery: A Retrospective Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08436-w","https://doi.org/10.1007/s11695-025-08436-w","41405672","https://pubmed.ncbi.nlm.nih.gov/41405672/",null,null],["2","R0003298","R0003298.pdf","paywalled","randomized_trial","Leiter LA","2026","Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.","Diabetes care","American Diabetes Association","10.2337/dc26-0847","https://doi.org/10.2337/dc26-0847","42251764","https://pubmed.ncbi.nlm.nih.gov/42251764/",null,null],["2","R0003316","R0003316.pdf","paywalled","randomized_trial","Xie J","2026","A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70794","https://doi.org/10.1111/dom.70794","42010360","https://pubmed.ncbi.nlm.nih.gov/42010360/",null,"ClinicalTrials.gov:NCT06547775"],["2","R0003369","R0003369.pdf","paywalled","randomized_trial","Arslan S","2026","Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2026.103305","https://doi.org/10.1016/j.clnesp.2026.103305","42036071","https://pubmed.ncbi.nlm.nih.gov/42036071/",null,null],["2","R0003399","R0003399.pdf","paywalled","randomized_trial","Yahya R","2026","Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag154","https://doi.org/10.1093/ndt/gfag154","42397155","https://pubmed.ncbi.nlm.nih.gov/42397155/",null,null],["2","R0003654","R0003654.pdf","paywalled","randomized_trial","Samuel AH","2026","GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes.","Annales d'endocrinologie","Elsevier BV","10.1016/j.ando.2026.102494","https://doi.org/10.1016/j.ando.2026.102494","41713726","https://pubmed.ncbi.nlm.nih.gov/41713726/",null,null],["2","R0003750","R0003750.pdf","paywalled","randomized_trial","Subramanian V","2026","Screening and Treatment Using a Risk-Based Approach With NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2026.103153","https://doi.org/10.1016/j.jchf.2026.103153","42233896","https://pubmed.ncbi.nlm.nih.gov/42233896/",null,null],["2","R0003889","R0003889.pdf","paywalled","randomized_trial","Natarajan K","2026","Comparative Use Human Factors Study of a Manual vs. A Partially Automated Pen Injector for GLP-1 Receptor Agonist Delivery.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.70295","https://doi.org/10.1002/cpt.70295","41997744","https://pubmed.ncbi.nlm.nih.gov/41997744/",null,null],["2","R0004021","R0004021.pdf","paywalled","randomized_trial","Krychtiuk KA","2026","Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwae379","https://doi.org/10.1093/eurjpc/zwae379","39602568","https://pubmed.ncbi.nlm.nih.gov/39602568/",null,null],["2","R0004254","R0004254.pdf","paywalled","randomized_trial","Reaume M","2026","Remission in diabetic kidney disease: current evidence and future directions.","Current opinion in nephrology and hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/mnh.0000000000001197","https://doi.org/10.1097/mnh.0000000000001197","42077164","https://pubmed.ncbi.nlm.nih.gov/42077164/",null,null],["2","R0004269","R0004269.pdf","paywalled","randomized_trial","Zine-Eddine H","2026","Obesity and Atrial Fibrillation: Epidemiology, Mechanisms, and Therapeutic Implications in the Era of Metabolic Therapies.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001332","https://doi.org/10.1097/crd.0000000000001332","42269002","https://pubmed.ncbi.nlm.nih.gov/42269002/",null,null],["2","R0004341","R0004341.pdf","paywalled","randomized_trial","Gao F","2026","Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70429","https://doi.org/10.1111/dom.70429","41492234","https://pubmed.ncbi.nlm.nih.gov/41492234/",null,null],["2","R0004429","R0004429.pdf","paywalled","randomized_trial","Gurumurthy G","2026","Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis.","Seminars in thrombosis and hemostasis","Georg Thieme Verlag KG","10.1055/a-2712-3534","https://doi.org/10.1055/a-2712-3534","41092960","https://pubmed.ncbi.nlm.nih.gov/41092960/",null,null],["2","R0004697","R0004697.pdf","paywalled","randomized_trial","da Silva AMP","2026","Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109306","https://doi.org/10.1016/j.jdiacomp.2026.109306","41825212","https://pubmed.ncbi.nlm.nih.gov/41825212/",null,null],["2","R0004718","R0004718.pdf","paywalled","randomized_trial","Rahman E","2026","A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05973-2","https://doi.org/10.1007/s00266-026-05973-2","42310090","https://pubmed.ncbi.nlm.nih.gov/42310090/",null,null],["2","R0004774","R0004774.pdf","paywalled","randomized_trial","Tuttle Z","2026","Glucagon-like peptide-1 analogues in the management of high output stoma in adult patients: A narrative review.","JPEN. Journal of parenteral and enteral nutrition","Wiley","10.1002/jpen.70131","https://doi.org/10.1002/jpen.70131","42533381","https://pubmed.ncbi.nlm.nih.gov/42533381/",null,null],["2","R0004784","R0004784.pdf","paywalled","randomized_trial","Retnakaran R","2026","Glucose-lowering in type 2 diabetes may be mediated by improved proinsulin processing without better β-cell compensation.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00163.2026","https://doi.org/10.1152/ajpendo.00163.2026","42721371","https://pubmed.ncbi.nlm.nih.gov/42721371/",null,null],["2","R0004814","R0004814.pdf","paywalled","randomized_trial","Maheshwari A","2026","Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG).","Journal of human hypertension","Springer Science and Business Media LLC","10.1038/s41371-026-01150-9","https://doi.org/10.1038/s41371-026-01150-9","42056284","https://pubmed.ncbi.nlm.nih.gov/42056284/",null,null],["2","R0004849","R0004849.pdf","paywalled","randomized_trial","Siddiqi A","2026","Perioperative Nutritional Optimization in Total Joint Arthroplasty: From Screening to Supplementation.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2026.03.088","https://doi.org/10.1016/j.arth.2026.03.088","41951067","https://pubmed.ncbi.nlm.nih.gov/41951067/",null,null],["2","R0004941","R0004941.pdf","paywalled","randomized_trial","Villegas Meza AD","2026","Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","JBJS reviews","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.rvw.26.00027","https://doi.org/10.2106/jbjs.rvw.26.00027","42160466","https://pubmed.ncbi.nlm.nih.gov/42160466/",null,null],["2","R0005115","R0005115.pdf","paywalled","randomized_trial","Gutierrez de Piñeres V","2026","Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70313","https://doi.org/10.1111/dom.70313","41287185","https://pubmed.ncbi.nlm.nih.gov/41287185/",null,null],["2","R0005256","R0005256.pdf","paywalled","randomized_trial","Kitsios K","2026","Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261486127","https://doi.org/10.1177/15209156261486127","42695140","https://pubmed.ncbi.nlm.nih.gov/42695140/",null,null],["2","R0005585","R0005585.pdf","paywalled","randomized_trial","Blitshteyn S","2026","Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.","Immunopharmacology and immunotoxicology","Informa UK Limited","10.1080/08923973.2026.2731357","https://doi.org/10.1080/08923973.2026.2731357","42703003","https://pubmed.ncbi.nlm.nih.gov/42703003/",null,null],["2","R0005627","R0005627.pdf","paywalled","randomized_trial","Palazzuoli A","2026","Dapagliflozin effect on pericardial fat deposition: lessons from the DAPA EAT.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-026-10607-5","https://doi.org/10.1007/s10741-026-10607-5","41806003","https://pubmed.ncbi.nlm.nih.gov/41806003/",null,null],["2","R0005709","R0005709.pdf","paywalled","randomized_trial","O'Brien H","2026","GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads.","Current opinion in pulmonary medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcp.0000000000001249","https://doi.org/10.1097/mcp.0000000000001249","41664500","https://pubmed.ncbi.nlm.nih.gov/41664500/",null,null],["2","R0005883","R0005883.pdf","paywalled","randomized_trial","Koutouratsas T","2026","GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study.","Age and ageing","Oxford University Press (OUP)","10.1093/ageing/afag281","https://doi.org/10.1093/ageing/afag281","42765724","https://pubmed.ncbi.nlm.nih.gov/42765724/",null,null],["2","R0006127","R0006127.pdf","paywalled","randomized_trial","Costa TA","2026","Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001284","https://doi.org/10.1097/hco.0000000000001284","41802118","https://pubmed.ncbi.nlm.nih.gov/41802118/",null,null],["2","R0006637","R0006637.pdf","paywalled","randomized_trial","Al Rashid S","2026","Evaluating the Impact of SGLT-2 Inhibitors on Frailty in Older Adults: A Clinical Review.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/0115748863365749250519051710","https://doi.org/10.2174/0115748863365749250519051710","40454499","https://pubmed.ncbi.nlm.nih.gov/40454499/",null,null],["2","R0007080","R0007080.pdf","paywalled","randomized_trial","Thirugnanam AM","2026","Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.","Cardiovascular revascularization medicine : including molecular interventions","Elsevier BV","10.1016/j.carrev.2026.03.011","https://doi.org/10.1016/j.carrev.2026.03.011","42000295","https://pubmed.ncbi.nlm.nih.gov/42000295/",null,null],["2","R0007114","R0007114.pdf","paywalled","randomized_trial","Chen JJ","2026","Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2025.12.011","https://doi.org/10.1016/j.amjmed.2025.12.011","41419094","https://pubmed.ncbi.nlm.nih.gov/41419094/",null,null],["2","R0007328","R0007328.pdf","paywalled","randomized_trial","Song K","2026","Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology.","Current obesity reports","Springer Science and Business Media LLC","10.1007/s13679-026-00726-3","https://doi.org/10.1007/s13679-026-00726-3","42274840","https://pubmed.ncbi.nlm.nih.gov/42274840/",null,null],["2","R0007445","R0007445.pdf","paywalled","randomized_trial","Ojeda-Fernández L","2026","Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-025-02674-9","https://doi.org/10.1007/s00392-025-02674-9","40358690","https://pubmed.ncbi.nlm.nih.gov/40358690/",null,null],["2","R0007535","R0007535.pdf","paywalled","randomized_trial","Maggioni AP","2026","From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2026.134646","https://doi.org/10.1016/j.ijcard.2026.134646","42361988","https://pubmed.ncbi.nlm.nih.gov/42361988/",null,null],["2","R0007731","R0007731.pdf","paywalled","randomized_trial","Khalil I","2026","Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-026-11122-3","https://doi.org/10.1007/s12072-026-11122-3","42397506","https://pubmed.ncbi.nlm.nih.gov/42397506/",null,null],["2","R0008055","R0008055.pdf","paywalled","randomized_trial","Farokhnia M","2026","Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2025.4308","https://doi.org/10.1001/jamapsychiatry.2025.4308","41563749","https://pubmed.ncbi.nlm.nih.gov/41563749/",null,null],["2","R0008338","R0008338.pdf","paywalled","randomized_trial","Bhaduri G","2026","Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-025-02636-7","https://doi.org/10.1007/s00592-025-02636-7","41504921","https://pubmed.ncbi.nlm.nih.gov/41504921/",null,null],["2","R0008396","R0008396.pdf","paywalled","randomized_trial","Chopra HK","2026","National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.74.1375","https://doi.org/10.59556/japi.74.1375","41818087","https://pubmed.ncbi.nlm.nih.gov/41818087/",null,null],["2","R0008599","R0008599.pdf","paywalled","randomized_trial","Rosen CJ","2026","GLP-1 Receptor Agonists.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmra2500106","https://doi.org/10.1056/nejmra2500106","41931049","https://pubmed.ncbi.nlm.nih.gov/41931049/",null,null],["2","R0008936","R0008936.pdf","paywalled","randomized_trial","Qin H","2026","Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2026.01.008","https://doi.org/10.1016/j.cmet.2026.01.008","41666927","https://pubmed.ncbi.nlm.nih.gov/41666927/",null,"ChiCTR:ChiCTR2200066291"],["2","R0009038","R0009038.pdf","paywalled","randomized_trial","Chen MH","2026","Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100954","https://doi.org/10.1016/j.medj.2025.100954","41519115","https://pubmed.ncbi.nlm.nih.gov/41519115/",null,null],["2","R0009292","R0009292.pdf","paywalled","randomized_trial","Dong S","2026","Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity.","Medicinal research reviews","Wiley","10.1002/med.70049","https://doi.org/10.1002/med.70049","41923370","https://pubmed.ncbi.nlm.nih.gov/41923370/",null,null],["2","R0009523","R0009523.pdf","paywalled","randomized_trial","Sun R","2026","Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-025-03467-2","https://doi.org/10.1007/s12325-025-03467-2","41498879","https://pubmed.ncbi.nlm.nih.gov/41498879/",null,"ClinicalTrials.gov:NCT06605287"],["2","R0009735","R0009735.pdf","paywalled","randomized_trial","Wang CY","2026","Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70618","https://doi.org/10.1111/dom.70618","41749445","https://pubmed.ncbi.nlm.nih.gov/41749445/",null,null],["2","R0009953","R0009953.pdf","paywalled","randomized_trial","Fozouni L","2026","Editorial: Two for the Price of One-GLP-1 Receptor Agonists Could Be More Effective Than MAUD in Patients With AUD and Metabolic Dysfunction.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70655","https://doi.org/10.1111/apt.70655","41933385","https://pubmed.ncbi.nlm.nih.gov/41933385/",null,null],["2","R0009985","R0009985.pdf","paywalled","randomized_trial","Neves JS","2026","Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-025-06637-7","https://doi.org/10.1007/s00125-025-06637-7","41419618","https://pubmed.ncbi.nlm.nih.gov/41419618/",null,null],["2","R0010234","R0010234.pdf","paywalled","randomized_trial","Ahmadizar F","2026","Toward Precision Secondary Prevention After Myocardial Infarction and Stroke With GLP-1 Receptor Agonists.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag068","https://doi.org/10.1093/eurjpc/zwag068","41605254","https://pubmed.ncbi.nlm.nih.gov/41605254/",null,null],["2","R0010509","R0010509.pdf","paywalled","randomized_trial","Papaetis GS","2026","Prevalence, Glycemic Efficacy, and Safety of Four Non-Insulin Antidiabetic Drug Combinations in Patients with Type 2 Diabetes.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/0118715303402479251129144029","https://doi.org/10.2174/0118715303402479251129144029","41582388","https://pubmed.ncbi.nlm.nih.gov/41582388/",null,null],["2","R0011805","R0011805.pdf","paywalled","randomized_trial","Wespiser M","2026","Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.","Cancer treatment reviews","Elsevier BV","10.1016/j.ctrv.2026.103200","https://doi.org/10.1016/j.ctrv.2026.103200","42556070","https://pubmed.ncbi.nlm.nih.gov/42556070/",null,null],["2","R0012636","R0012636.pdf","paywalled","randomized_trial","Zhang Z","2026","An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.113055","https://doi.org/10.1016/j.diabres.2025.113055","41401898","https://pubmed.ncbi.nlm.nih.gov/41401898/",null,null],["2","R0012926","R0012926.pdf","paywalled","randomized_trial","Solini A","2026","Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors.","Handbook of experimental pharmacology","Springer Berlin Heidelberg","10.1007/164_2026_847","https://doi.org/10.1007/164_2026_847","42778649","https://pubmed.ncbi.nlm.nih.gov/42778649/",null,null],["2","R0012963","R0012963.pdf","paywalled","randomized_trial","Huang B","2026","Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.","Pediatric research","Springer Science and Business Media LLC","10.1038/s41390-025-04293-6","https://doi.org/10.1038/s41390-025-04293-6","40897883","https://pubmed.ncbi.nlm.nih.gov/40897883/",null,null],["2","R0013183","R0013183.pdf","paywalled","randomized_trial","Sun R","2026","Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70262","https://doi.org/10.1111/dom.70262","41208635","https://pubmed.ncbi.nlm.nih.gov/41208635/",null,null],["2","R0013636","R0013636.pdf","paywalled","randomized_trial","Jagtap N","2026","Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study.","Endoscopy","Georg Thieme Verlag KG","10.1055/a-2891-4165","https://doi.org/10.1055/a-2891-4165","42259388","https://pubmed.ncbi.nlm.nih.gov/42259388/",null,null],["2","R0013726","R0013726.pdf","paywalled","randomized_trial","Polsky S","2026","Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261468108","https://doi.org/10.1177/15209156261468108","42452840","https://pubmed.ncbi.nlm.nih.gov/42452840/",null,null],["2","R0013809","R0013809.pdf","paywalled","randomized_trial","Sørensen KK","2026","Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.","Clinical trials (London, England)","SAGE Publications","10.1177/17407745261449668","https://doi.org/10.1177/17407745261449668","42227113","https://pubmed.ncbi.nlm.nih.gov/42227113/",null,null],["2","R0013961","R0013961.pdf","paywalled","randomized_trial","Chumakova-Orin M","2026","GLP-1 receptor agonists and bariatric surgery: complement, not competition: An integrated framework for contemporary obesity management: a narrative review.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.07.021","https://doi.org/10.1016/j.soard.2026.07.021","42823265","https://pubmed.ncbi.nlm.nih.gov/42823265/",null,null],["2","R0014362","R0014362.pdf","paywalled","randomized_trial","Akturk HK","2026","Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156251398060","https://doi.org/10.1177/15209156251398060","41804540","https://pubmed.ncbi.nlm.nih.gov/41804540/",null,null],["2","R0014774","R0014774.pdf","paywalled","randomized_trial","Tardov MV","2026","[Pharmacological treatment of obstructive sleep apnea syndrome].","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","Media Sphere Publishing House","10.17116/jnevro202612605248","https://doi.org/10.17116/jnevro202612605248","42268272","https://pubmed.ncbi.nlm.nih.gov/42268272/",null,null],["2","R0015201","R0015201.pdf","paywalled","randomized_trial","Llach J","2026","The role of endoscopic therapies for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).","Expert review of gastroenterology & hepatology","Informa UK Limited","10.1080/17474124.2026.2632873","https://doi.org/10.1080/17474124.2026.2632873","41688294","https://pubmed.ncbi.nlm.nih.gov/41688294/",null,null],["2","R0015351","R0015351.pdf","paywalled","randomized_trial","Li S","2026","Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.","Diabetes care","American Diabetes Association","10.2337/dc26-0265","https://doi.org/10.2337/dc26-0265","42160606","https://pubmed.ncbi.nlm.nih.gov/42160606/",null,null],["2","R0015369","R0015369.pdf","paywalled","randomized_trial","Fernandes M","2026","Tirzepatide Combined With Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnoea Syndrome With Comorbid Obesity: Effects on Weight, Daytime Sleepiness, and Cognitive Performance.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70604","https://doi.org/10.1111/dom.70604","41757398","https://pubmed.ncbi.nlm.nih.gov/41757398/",null,null],["2","R0015387","R0015387.pdf","paywalled","randomized_trial","Mann JFE","2026","Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.","Diabetes care","American Diabetes Association","10.2337/dci26-0039","https://doi.org/10.2337/dci26-0039","42160596","https://pubmed.ncbi.nlm.nih.gov/42160596/",null,null],["2","R0015425","R0015425.pdf","paywalled","randomized_trial","Erdem BK","2026","Mechanisms and Current Therapeutic Targets of Podocyte Damage in Diabetic Kidney Disease.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/0115733998492007260723100211","https://doi.org/10.2174/0115733998492007260723100211","42613708","https://pubmed.ncbi.nlm.nih.gov/42613708/",null,null],["2","R0015496","R0015496.pdf","paywalled","randomized_trial","Rombach J","2026","Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes.","Osteoarthritis and cartilage","Elsevier BV","10.1016/j.joca.2026.09.007","https://doi.org/10.1016/j.joca.2026.09.007","42767324","https://pubmed.ncbi.nlm.nih.gov/42767324/",null,null],["2","R0015522","R0015522.pdf","paywalled","randomized_trial","Calderon Martinez E","2026","The Role of Bariatric Surgery in Kidney Disease: Evidence, Controversies, and Future Needs.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08901-0","https://doi.org/10.1007/s11695-026-08901-0","42627475","https://pubmed.ncbi.nlm.nih.gov/42627475/",null,null],["2","R0015768","R0015768.pdf","paywalled","randomized_trial","Huang YS","2026","Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08748-5","https://doi.org/10.1007/s11695-026-08748-5","42174244","https://pubmed.ncbi.nlm.nih.gov/42174244/",null,null],["2","R0015986","R0015986.pdf","paywalled","randomized_trial","Pasqua MR","2026","Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2025.10.175","https://doi.org/10.1016/j.jcjd.2025.10.175","41175929","https://pubmed.ncbi.nlm.nih.gov/41175929/",null,null],["2","R0016043","R0016043.pdf","paywalled","randomized_trial","Prati F","2026","Coronary inflammation: Identification, clinical impact and possible therapeutical solutions.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2026.134229","https://doi.org/10.1016/j.ijcard.2026.134229","41662913","https://pubmed.ncbi.nlm.nih.gov/41662913/",null,null],["2","R0016321","R0016321.pdf","paywalled","randomized_trial","Li D","2026","Semaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/0118715303422692260617052555","https://doi.org/10.2174/0118715303422692260617052555","42405390","https://pubmed.ncbi.nlm.nih.gov/42405390/",null,null],["2","R0016498","R0016498.pdf","paywalled","randomized_trial","Zhao YT","2026","Letter by Zhao Regarding Article, \"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.125.076451","https://doi.org/10.1161/circulationaha.125.076451","41525434","https://pubmed.ncbi.nlm.nih.gov/41525434/",null,null],["2","R0016537","R0016537.pdf","paywalled","randomized_trial","Haugen CE","2026","Anti-obesity Pharmacotherapy for Transplant Recipients.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-026-01388-1","https://doi.org/10.1007/s11883-026-01388-1","41575672","https://pubmed.ncbi.nlm.nih.gov/41575672/",null,null],["2","R0016916","R0016916.pdf","paywalled","randomized_trial","Andersen ES","2026","Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus-Results from a randomised controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70286","https://doi.org/10.1111/dom.70286","41208570","https://pubmed.ncbi.nlm.nih.gov/41208570/",null,null],["2","R0016970","R0016970.pdf","paywalled","randomized_trial","Weinreich AA","2026","Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70208","https://doi.org/10.1111/dom.70208","41098062","https://pubmed.ncbi.nlm.nih.gov/41098062/",null,null],["2","R0017312","R0017312.pdf","paywalled","randomized_trial","Xie C","2026","Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.","Diabetes","American Diabetes Association","10.2337/db25-0980","https://doi.org/10.2337/db25-0980","41591292","https://pubmed.ncbi.nlm.nih.gov/41591292/",null,null],["2","R0017327","R0017327.pdf","paywalled","randomized_trial","Iuliano S","2026","Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer.","Current opinion in oncology","Ovid Technologies (Wolters Kluwer Health)","10.1097/cco.0000000000001202","https://doi.org/10.1097/cco.0000000000001202","41222548","https://pubmed.ncbi.nlm.nih.gov/41222548/",null,null],["2","R0017841","R0017841.pdf","paywalled","randomized_trial","Arisha R","2026","The future of PCOS management: Disease modification through regenerative, metabolic, and digital therapeutics.","Pathology, research and practice","Elsevier BV","10.1016/j.prp.2026.156397","https://doi.org/10.1016/j.prp.2026.156397","41666555","https://pubmed.ncbi.nlm.nih.gov/41666555/",null,null],["2","R0019257","R0019257.pdf","paywalled","randomized_trial","Yuan M","2026","Systemic medications and their impact on age-related macular degeneration development and progression: a review of current evidence.","Current opinion in ophthalmology","Ovid Technologies (Wolters Kluwer Health)","10.1097/icu.0000000000001198","https://doi.org/10.1097/icu.0000000000001198","41481850","https://pubmed.ncbi.nlm.nih.gov/41481850/",null,null],["2","R0025699","R0025699.pdf","paywalled","randomized_trial","Lin J","2026","[Mechanism of electroacupuncture on improving insulin resistance and intestinal mucosal barrier injury via the GLP-1R/PKA signaling pathway in type 2 diabetes mellitus rats].","Zhongguo zhen jiu = Chinese acupuncture & moxibustion",null,"10.13703/j.0255-2930.20250312-k0002","https://doi.org/10.13703/j.0255-2930.20250312-k0002","41741988","https://pubmed.ncbi.nlm.nih.gov/41741988/",null,null],["2","R0029253","R0029253.pdf","paywalled","randomized_trial","Maiolino G","2026","Rethinking Obstructive Sleep Apnea Care in Obesity: Continuous Positive Airway Pressure, Incretin-Based Therapy, or Both?","Obesity reviews : an official journal of the International Association for the Study of Obesity",null,"10.1111/obr.70238","https://doi.org/10.1111/obr.70238","42862012","https://pubmed.ncbi.nlm.nih.gov/42862012/",null,null],["2","R0029311","R0029311.pdf","paywalled","randomized_trial","Schlaich MP","2026","Beyond the 4 pillars: aldosterone synthase inhibition as a fifth frontier in chronic kidney disease management.","American journal of hypertension","Oxford University Press (OUP)","10.1093/ajh/hpag090","https://doi.org/10.1093/ajh/hpag090","42847218","https://pubmed.ncbi.nlm.nih.gov/42847218/",null,null],["2","R0029332","R0029332.pdf","paywalled","randomized_trial","Gao L","2026","Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71354","https://doi.org/10.1111/dom.71354","42839752","https://pubmed.ncbi.nlm.nih.gov/42839752/",null,null],["2","R0029368","R0029368.pdf","paywalled","randomized_trial","Ostojic SM","2026","Creatine for glucagon-like peptide-1-associated muscle loss.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2026.106805","https://doi.org/10.1016/j.clnu.2026.106805","42800365","https://pubmed.ncbi.nlm.nih.gov/42800365/",null,null],["2","R0029385","R0029385.pdf","paywalled","randomized_trial","Biondi F","2026","Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2026.121898","https://doi.org/10.1016/j.atherosclerosis.2026.121898","42696840","https://pubmed.ncbi.nlm.nih.gov/42696840/",null,null],["2","R0029468","R0029468.pdf","paywalled","randomized_trial","Foer D","2026","Type 2 Diabetes and the Lung - Cause and Consequence.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-026-01625-6","https://doi.org/10.1007/s11892-026-01625-6","42095998","https://pubmed.ncbi.nlm.nih.gov/42095998/",null,null],["2","R0029585","R0029585.pdf","paywalled","randomized_trial","Horiuchi Y","2026","Real-world data and its clinical relevance: Complementing randomized controlled trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133971","https://doi.org/10.1016/j.ijcard.2025.133971","41110660","https://pubmed.ncbi.nlm.nih.gov/41110660/",null,null],["2","R0029631","R0029631.pdf","paywalled","randomized_trial","Luu S","2026","Clinical perspective on non-sleepy obstructive sleep apnea; to treat or not to treat?","Expert review of respiratory medicine","Informa UK Limited","10.1080/17476348.2025.2539542","https://doi.org/10.1080/17476348.2025.2539542","40704845","https://pubmed.ncbi.nlm.nih.gov/40704845/",null,null],["2","R0029651","R0029651.pdf","paywalled","randomized_trial","Yang GP","2026","Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71327","https://doi.org/10.1111/dom.71327","42712041","https://pubmed.ncbi.nlm.nih.gov/42712041/",null,"ChiCTR:ChiCTR2600116148; ChiCTR:ChiCTR2600123803"],["2","R0029689","R0029689.pdf","paywalled","randomized_trial","Chang YC","2026","EPR26-152: GLP-1 and Dual Agonists and the Incidence of Skin Cancer: Evidence from Randomized Controlled Trials.","Journal of the National Comprehensive Cancer Network : JNCCN","Harborside Press, LLC","10.6004/jnccn.2025.7464","https://doi.org/10.6004/jnccn.2025.7464","42066808","https://pubmed.ncbi.nlm.nih.gov/42066808/",null,null],["2","R0029954","R0029954.pdf","paywalled","randomized_trial","Xu H","2026","HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70160","https://doi.org/10.1002/oby.70160","41803652","https://pubmed.ncbi.nlm.nih.gov/41803652/",null,null],["2","R0030145","R0030145.pdf","paywalled","randomized_trial","Venter WDF","2026","Weight gain in people with HIV in Africa and Asia: a review of causes, consequences, and management implications.","Current opinion in HIV and AIDS","Ovid Technologies (Wolters Kluwer Health)","10.1097/coh.0000000000001074","https://doi.org/10.1097/coh.0000000000001074","42817201","https://pubmed.ncbi.nlm.nih.gov/42817201/",null,null],["2","R0032604","R0032604.pdf","paywalled","randomized_trial","Mercy Latricia","2026","GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management","IAA Journal of Biological Sciences","International Digital Organization for Scientific Research","10.59298/iaajb/2026/14145454","https://doi.org/10.59298/iaajb/2026/14145454",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032619","R0032619.pdf","paywalled","randomized_trial","SAIMSARA","2026","Peripheral Artery Disease and Medical Therapy: Scoping Review with ☸SAIMSARA","SAIMSARA Journal","ML in Health Science","10.62487/saimsara3b5bca76","https://doi.org/10.62487/saimsara3b5bca76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032643","R0032643.pdf","paywalled","randomized_trial","Giovana Pereira Lopes","2026","USO DE ANÁLOGOS DE GLP-1 COMO FATOR PROTETOR CARDIOVASCULAR E RENAL",null,"Editora Caminhos & Vozes","10.66396/pontes.c32.2026","https://doi.org/10.66396/pontes.c32.2026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032657","R0032657.pdf","paywalled","randomized_trial","Priti Jethlia","2026","THE EVOLVING PLACE OF GLP-1 THERAPY IN THE TREATMENT ALGORITHM: FROM SECOND LINE TO FIRST LINE AND COMBINATION STRATEGIES – A REVIEW","International Journal of Medicine and Public Health","Pink Petals Publications Pvt Ltd","10.70034/ijmedph.2026.1.306","https://doi.org/10.70034/ijmedph.2026.1.306",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032725","R0032725.pdf","paywalled","randomized_trial","Marco Vinícios de Oliveira Santana","2026","Gut Microbiota as a Determinant of Therapeutic Response in Chronic Diseases: From Systemic Dysbiosis to Microbiome-Guided Precision Medicine","Middle East Research Journal of Medical Sciences","SASPR Edu International Pvt. Ltd","10.36348/merjms.2026.v06i02.007","https://doi.org/10.36348/merjms.2026.v06i02.007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032731","R0032731.pdf","paywalled","randomized_trial","S Siddenthi","2026","B80-3-05 Comparative Effects of Glp-1 Receptor Agonists and Atomoxetine-antimuscarinic Combinations (oxybutynin and Aroxybutynin) on Obstructive Sleep Apnea: A Scoping Review","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.6390","https://doi.org/10.1093/ajrccm/aamag162.6390",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032740","R0032740.pdf","paywalled","randomized_trial","Ernest Nsubuga","2026","Dual GLP-1/GIP Agonists for Weight Reduction and Cardiovascular Outcomes in Type 2 Diabetes","International Academic Association Journal of Scientific Research.","International Digital Organization for Scientific Research","10.59298/iaajsr/2026/1316570","https://doi.org/10.59298/iaajsr/2026/1316570",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032743","R0032743.pdf","paywalled","randomized_trial","Anna Aleksandra Szwankowska","2026","Metformin or GLP 1 Receptor Agonists? Current Views on the Management of Polycystic Ovary Syndrome","Archiv Euromedica","European Scientific Society","10.35630/2026/16/iss.2.9","https://doi.org/10.35630/2026/16/iss.2.9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032985","R0032985.pdf","paywalled","randomized_trial","Mercy Latricia","2026","GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications","IAA Journal of Biological Sciences","International Digital Organization for Scientific Research","10.59298/iaajb/2026/1415559","https://doi.org/10.59298/iaajb/2026/1415559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032995","R0032995.pdf","paywalled","randomized_trial","João Carlos Mendes Maia","2026","SEMAGLUTIDA E O RISCO CARDIOVASCULAR NA OBESIDADE: A RELAÇÃO CRÍTICA ENTRE TOLERABILIDADE, ADESÃO E A SUSTENTAÇÃO DO BENEFÍCIO CLÍNICO","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/pa10202601181008","https://doi.org/10.69849/revistaft/pa10202601181008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033081","R0033081.pdf","paywalled","randomized_trial","YOUNGHWAN PARK","2026","2631-P: Phase 1 Study and Modelling of a Novel Drug Delivery System for GLP-1RA with Lower Adverse Events and Higher Efficacy","Diabetes","American Diabetes Association","10.2337/db26-2631-p","https://doi.org/10.2337/db26-2631-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033096","R0033096.pdf","paywalled","randomized_trial","ANNA KATRINA J. GRADEL","2026","2548-P: Petrelintide Elicits Distinct Effects on Eating Pattern and Maintains Locomotor Activity Compared with Semaglutide in Rats with Diet-Induced Obesity","Diabetes","American Diabetes Association","10.2337/db26-2548-p","https://doi.org/10.2337/db26-2548-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033101","R0033101.pdf","paywalled","randomized_trial","WEIPING JIA","2026","2827-LB: First-in-Human Study of Oral GLP-1 Receptor Agonist RDSY1801","Diabetes","American Diabetes Association","10.2337/db26-2827-lb","https://doi.org/10.2337/db26-2827-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033111","R0033111.pdf","paywalled","randomized_trial","Ling Feng Zhang","2026","2505-P: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk","Diabetes","American Diabetes Association","10.2337/db26-2505-p","https://doi.org/10.2337/db26-2505-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033117","R0033117.pdf","paywalled","randomized_trial","CAROL WYSHAM","2026","1666-P: Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial","Diabetes","American Diabetes Association","10.2337/db26-1666-p","https://doi.org/10.2337/db26-1666-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033128","R0033128.pdf","paywalled","randomized_trial","Jingjing Li","2026","1815-P: Efficacy and Safety of the GlP-1/GIP Dual Agonist HRS9531 in Overweight/Obese Chinese Patients with Polycystic Ovary Syndrome","Diabetes","American Diabetes Association","10.2337/db26-1815-p","https://doi.org/10.2337/db26-1815-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033131","R0033131.pdf","paywalled","randomized_trial","Evelyn Yandle","2026","1676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide","Diabetes","American Diabetes Association","10.2337/db26-1676-p","https://doi.org/10.2337/db26-1676-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033136","R0033136.pdf","paywalled","randomized_trial","JONAH J.C. THOMAS","2026","2202-P: The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist in a Trial Inspired, and Wider, Population Individuals Living with Type 2 Diabetes: A Target Trial Emulation Study in CPRD","Diabetes","American Diabetes Association","10.2337/db26-2202-p","https://doi.org/10.2337/db26-2202-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033143","R0033143.pdf","paywalled","randomized_trial","LINONG JI","2026","2608-P: Efficacy and Safety of DA-302168S, a Novel Oral GLP-1 Receptor Agonist, in Chinese Adults with Overweight or Obesity: A Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db26-2608-p","https://doi.org/10.2337/db26-2608-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033146","R0033146.pdf","paywalled","randomized_trial","LINE ZACHARIASSEN","2026","2577-P: Differential Effects of Semaglutide, Tirzepatide, and Survodutide on Energy Expenditure in Obese Mice under Thermoneutrality","Diabetes","American Diabetes Association","10.2337/db26-2577-p","https://doi.org/10.2337/db26-2577-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033147","R0033147.pdf","paywalled","randomized_trial","JINZI J. WU","2026","1672-P: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity","Diabetes","American Diabetes Association","10.2337/db26-1672-p","https://doi.org/10.2337/db26-1672-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033152","R0033152.pdf","paywalled","randomized_trial","Huan Zhou","2026","1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults","Diabetes","American Diabetes Association","10.2337/db26-1690-p","https://doi.org/10.2337/db26-1690-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07134127; ClinicalTrials.gov:NCT07170319"],["2","R0033156","R0033156.pdf","paywalled","randomized_trial","Juan P. Frías","2026","2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis","Diabetes","American Diabetes Association","10.2337/db26-2857-lb","https://doi.org/10.2337/db26-2857-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033174","R0033174.pdf","paywalled","randomized_trial","Jonadab dos Santos Silva","2026","Synergistic and Distinct Central Effects of Dapagliflozin and Exenatide on Brain Networks Intrinsic Connectivity in Obesity and Type 2 Diabetes: A Randomized Controlled Trial (P1-13.001)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000217682","https://doi.org/10.1212/wnl.0000000000217682",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033238","R0033238.pdf","paywalled","randomized_trial",null,"2026","Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31414","https://doi.org/10.1002/pu.31414",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033329","R0033329.pdf","paywalled","randomized_trial","Bruno Sander","2026","PEPTÍDEOS BIOATIVOS E REGULAÇÃO DO METABOLISMO ENERGÉTICO: EVIDÊNCIAS SOBRE CONTROLE DO PESO E SENSIBILIDADE À INSULINA – REVISÃO SISTEMÁTICA","Revista Científica Ipedss","IPEDSS - Instituto de Pesquisa e Determinacao Social da Saude Ltda","10.55703/27644006060205","https://doi.org/10.55703/27644006060205",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033404","R0033404.pdf","paywalled","randomized_trial","Danilo Gustavo Gonçalves Ferreira Romanelli","2026","AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE","Revista Científica Ipedss","IPEDSS - Instituto de Pesquisa e Determinacao Social da Saude Ltda","10.55703/27644006060208","https://doi.org/10.55703/27644006060208",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033542","R0033542.pdf","paywalled","randomized_trial","1Saad Suleman, 2Mario Gergis Azez Awed Awadala, 3Rashedul Hoq, 4Bibi Iram Hadi, 5Ufaq Hamid, 6Alabi Damilola, 7Muhammad Khaliq, 8Arshad Ali Zia, 9Mahmuda Kabir Humu, 10Dr. Nitesh Mandal, 11Nafiz Tareq Hasnain, 12*Husnain Ramzan","2026","SGLT2 INHIBITORS AND GLP-1 AGONISTS IN HEART FAILURE: SHARED AND DISTINCT MECHANISMS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20691867","https://doi.org/10.5281/zenodo.20691867",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033720","R0033720.pdf","paywalled","randomized_trial","Dr. Mohammed Riyaz2 Dr. Mohammed Muzammil*1","2026","BEYOND METFORMIN: A DECADAL REVIEW OF EMERGING ORAL HYPOGLYCAEMICS AND THEIR REAL-WORLD IMPACT ON GLYCEMIC CONTROL","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20465454","https://doi.org/10.5281/zenodo.20465454",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033878","R0033878.pdf","paywalled","randomized_trial","Gareth Davies","2026","Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20570202","https://doi.org/10.5281/zenodo.20570202",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033943","R0033943.pdf","paywalled","randomized_trial","S M Nazmuz Sakib","2026","A Comprehensive Textbook of Community Medicine And Public Health Science","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19667680","https://doi.org/10.5281/zenodo.19667680",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034231","R0034231.pdf","paywalled","randomized_trial","Samuel Adu-Agyei","2026","Perspectives and Insights on GLP-1 Receptor Agonist Drugs: From Development to Submission of a New Drug Application in the United States and a New Drug Submission in Canada","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21312611","https://doi.org/10.5281/zenodo.21312611",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034240","R0034240.pdf","paywalled","randomized_trial","И. Ф. Тимербулатов","2026","GLP-1 receptor agonists in the therapy of alcohol use disorder: current state of the evidence base, mechanisms of action, and unresolved issues (a narrative review)","Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery)","PANORAMA Publishing House","10.33920/med-01-2603-01","https://doi.org/10.33920/med-01-2603-01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034314","R0034314.pdf","paywalled","randomized_trial","1*Alabi Damilola, 2Fatima Zehra, 3Mohsin Babar, 4Chad Barker, 5Muhammad Ahsan Shaikh MBBS, MD, 6Syeddah Saiqa Gillani, 7Hirak Trivedi, 8Humaira Kousar, 9Surriya Kousar","2026","GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW OF THEIR ROLE ACROSS MULTIPLE ORGAN SYSTEMS BEYOND WEIGHT MANAGEMENT","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20465519","https://doi.org/10.5281/zenodo.20465519",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034627","R0034627.pdf","paywalled","randomized_trial","Gunjan Malhotra","2026","Sa2112 COMPARATIVE EFFICACY OF GLP-1 AGONISTS AND LIFESTYLE INTERVENTIONS ON METABOLIC DYSFUNCTIONAL-ASSOCIATED STEATOHEPATITIS: EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03578-9","https://doi.org/10.1016/s0016-5107(26)03578-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034831","R0034831.pdf","paywalled","randomized_trial","Prathamesh Shikhare","2026","Herbal Remedies in Metabolic Syndrome: Evidence and Limitations","Research Journal of Pharmacognosy and Phytochemistry","A and V Publications","10.52711/0975-4385.2026.00041","https://doi.org/10.52711/0975-4385.2026.00041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034850","R0034850.pdf","paywalled","randomized_trial","P Sudha Kumari","2026","ASSESSING THE POTENTIAL OF GLP-1 RECEPTOR AGONISTS IN IMPROVING OUTCOMES FOR POLYCYSTIC OVARY SYNDROME PATIENTS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21512535","https://doi.org/10.5281/zenodo.21512535",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034855","R0034855.pdf","paywalled","randomized_trial","Dr. Rahul Gaikwad","2026","RECENT ADVANCES IN SGLT2 INHIBITORS",null,"Iterative International Publishers (IIP)","10.58532/nbennuamsib7p2c2","https://doi.org/10.58532/nbennuamsib7p2c2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035016","R0035016.pdf","paywalled","randomized_trial","Youqi Yang","2026","Data Integration for Estimating Subgroup-Specific Conditional Average Treatment Effects (CATEs) Using Coarsened External Information in Randomized Trials","arXiv (Cornell University)",null,"10.48550/arxiv.2604.20667","https://doi.org/10.48550/arxiv.2604.20667",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035186","R0035186.pdf","paywalled","randomized_trial","Helene C. W. Rytgaard","2026","Estimation of treatment effects in presence of differential use of post-randomization concomitant medication with time-to-event outcomes","arXiv (Cornell University)",null,"10.48550/arxiv.2605.05859","https://doi.org/10.48550/arxiv.2605.05859",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035269","R0035269.pdf","paywalled","randomized_trial","Danilo Gustavo Gonçalves Ferreira Romanelli","2026","NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA","Revista Científica Ipedss","IPEDSS - Instituto de Pesquisa e Determinacao Social da Saude Ltda","10.55703/27644006060304","https://doi.org/10.55703/27644006060304",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035333","R0035333.pdf","paywalled","randomized_trial","Diego Almodiel","2026","Coadministration of Dendrimer-Tesaglitazar with Semaglutide Increases Therapeutic Benefit and Blunts Weight Regain After GLP-1 Receptor Agonist Termination","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2300197","https://doi.org/10.1152/physiol.2026.41.s1.2300197",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035794","R0035794.pdf","paywalled","randomized_trial","D M Macdonald","2026","B24-04 SGLT2 Inhibitors Are Associated With Decreased Risk of 30-Day Readmission in Diabetic Individuals Hospitalized for Acute Exacerbations of COPD: A Retrospective Cohort Analysis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1763","https://doi.org/10.1093/ajrccm/aamag162.1763",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035812","R0035812.pdf","paywalled","randomized_trial","Christopher Broomhead","2026","Clinical and Experiential Evaluation of Retatrutide for Advanced Weight and Neurobehavioral Optimization","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18372551","https://doi.org/10.5281/zenodo.18372551",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035889","R0035889.pdf","paywalled","randomized_trial","Albert H. Chao","2026","Plastic and Reconstructive Surgery Highlights: Plastic Surgery Focus","Plastic & Reconstructive Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012956","https://doi.org/10.1097/prs.0000000000012956","42340838","https://pubmed.ncbi.nlm.nih.gov/42340838/",null,null],["2","R0035906","R0035906.pdf","paywalled","randomized_trial",null,"2026","GLP-1 RA Use in Children With Obesity or Type 2 Diabetes","AAP Grand Rounds","American Academy of Pediatrics (AAP)","10.1542/gr.55-1-04","https://doi.org/10.1542/gr.55-1-04",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035933","R0035933.pdf","paywalled","randomized_trial",null,"2026","Knee","Bone and Joint 360","British Editorial Society of Bone & Joint Surgery","10.1302/2048-0105.154.360356","https://doi.org/10.1302/2048-0105.154.360356",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036031","R0036031.pdf","paywalled","randomized_trial","Jessy Jayakumar1, Chandini2, Marka Sheshi3, Srujana Rani Kasoju4,Talla Sairam Goud5","2026","Meta Analysis of FDA Approved Weight Loss Drugs in Obesity","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21771494","https://doi.org/10.5281/zenodo.21771494",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036042","R0036042.pdf","paywalled","randomized_trial","V Quagliariello","2026","GLP1 receptor agonism attenuates anthracycline and HER2 targeted therapy induced cardiac dysfunction and systemic inflammation in non-diabetic models","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suag097.004","https://doi.org/10.1093/eurheartjsupp/suag097.004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036113","R0036113.pdf","paywalled","randomized_trial","Brian P. Kilgore","2026","Cardiovascular Outcomes and Cardioprotective Mechanisms of GLP-1 Receptor Agonists: What Is Established in Humans, What Is Shown in Animal and Cell Models, and What Remains Contested","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21782646","https://doi.org/10.5281/zenodo.21782646",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036207","R0036207.pdf","paywalled","randomized_trial","Mohammed El Amin Bouchelit","2026","Beyond Body Weight","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21841035","https://doi.org/10.5281/zenodo.21841035",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036238","R0036238.pdf","paywalled","randomized_trial","Mohammed El Amin Bouchelit","2026","Beyond Body Weight","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21841034","https://doi.org/10.5281/zenodo.21841034",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036254","R0036254.pdf","paywalled","randomized_trial","Mohammed Alkhanafsa","2026","Metabolic Dysfunction-Associated Steatotic Liver Disease in General Medicine: From Incidental Fatty Liver to Cardiometabolic Risk Stratification","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.22037/aab.v17i1.52378","https://doi.org/10.22037/aab.v17i1.52378",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036406","R0036406.pdf","paywalled","randomized_trial","Charmaine Marcus-Paiva","2026","A Research Proposal to Examine the Semaglutide-Sarcopenia Paradox in Geriatric Care Among Older Adults in Ontario, Canada","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21877870","https://doi.org/10.5281/zenodo.21877870",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036465","R0036465.pdf","paywalled","randomized_trial","Vikram Kumar Dr. Rao","2026","THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON METABOLIC AND REPRODUCTIVE OUTCOMES IN POLYCYSTIC OVARY SYNDROME","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21890518","https://doi.org/10.5281/zenodo.21890518",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036466","R0036466.pdf","paywalled","randomized_trial","R Sumithra, Arun Kumar K, Manoj Irappa K, Ananda S, Mohammad Saqib Wani, Jiji K","2026","Impact of Semaglutide on Obesity and Cardio Metabolic Risk Factors in Non-Diabetic Adult","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21891387","https://doi.org/10.5281/zenodo.21891387",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036476","R0036476.pdf","paywalled","randomized_trial","Fulvio Cacciapuoti","2026","The cardiometabolic triad: obesity, sleep-disordered breathing, and epicardial adipose tissue","Minerva Cardiology and Angiology","Edizioni Minerva Medica","10.23736/s2724-5683.26.07120-6","https://doi.org/10.23736/s2724-5683.26.07120-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036598","R0036598.pdf","paywalled","randomized_trial","Abubakar A. Abubakar","2026","Carotid Intima-Media Thickness in Patients with Type II Diabetes Mellitus: A Narrative Review","Afrischolar Discovery",null,"10.60787/sjhrs.vol1no1.14","https://doi.org/10.60787/sjhrs.vol1no1.14",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036609","R0036609.pdf","paywalled","randomized_trial","Cade Shadbolt","2026","Landscape of randomised clinical trials of interventions to reduce perioperative aspiration risk in patients taking GLP-1 receptor agonists","Open Science Framework",null,"10.17605/osf.io/y7h5u","https://doi.org/10.17605/osf.io/y7h5u",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036614","R0036614.pdf","paywalled","randomized_trial","Cade Shadbolt","2026","Tirzepatide versus placebo in adults with back pain and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Open Science Framework",null,"10.17605/osf.io/bwuer","https://doi.org/10.17605/osf.io/bwuer",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036656","R0036656.pdf","paywalled","randomized_trial","Cade Shadbolt","2026","Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Open Science Framework",null,"10.17605/osf.io/3s4jv","https://doi.org/10.17605/osf.io/3s4jv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036877","R0036877.pdf","paywalled","randomized_trial","K.V. Shanmukhi Saisree*","2026","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: A COMPREHENSIVE COMPARATIVE REVIEW OF CLINICAL EVIDENCE","World Journal of Pharmaceutical Research",null,"10.5281/zenodo.20679044","https://doi.org/10.5281/zenodo.20679044",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037008","R0037008.pdf","paywalled","randomized_trial","Raymond Fuller","2026","The role of weight loss drugs in the management of patients scheduled for hip and knee joint replacement","Royal College of Surgeons in Ireland",null,"10.25419/rcsi.30551213","https://doi.org/10.25419/rcsi.30551213",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037052","R0037052.pdf","paywalled","randomized_trial","Rajamannar Thennati","2026","1700-P: Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status","Diabetes","American Diabetes Association","10.2337/db26-1700-p","https://doi.org/10.2337/db26-1700-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037097","R0037097.pdf","paywalled","randomized_trial","LIANQIN CHEN","2026","1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights","Diabetes","American Diabetes Association","10.2337/db26-1732-p","https://doi.org/10.2337/db26-1732-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037253","R0037253.pdf","paywalled","randomized_trial","Kuan Tian","2026","2580-P: Multimodal Imaging Reveals Organ- and Depot-Specific Adipose Tissue and Lean Mass Changes upon Weight-Loss Pharmacotherapy in NHPs","Diabetes","American Diabetes Association","10.2337/db26-2580-p","https://doi.org/10.2337/db26-2580-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037459","R0037459.pdf","paywalled","randomized_trial","JANINNE ORTEGA MONTIEL","2026","2375-P: Trends in Utilization of Glucose Lowering Medications among Patients with Type 1 Diabetes in the United States","Diabetes","American Diabetes Association","10.2337/db26-2375-p","https://doi.org/10.2337/db26-2375-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037501","R0037501.pdf","paywalled","randomized_trial","Dawit Hailemariam Yesho","2026","GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.628","https://doi.org/10.1200/jco.2026.44.16_suppl.628",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037567","R0037567.pdf","paywalled","randomized_trial","A Villarreal Rizzo","2026","Tirzepatide use in patients with heart failure with preserved ejection fraction and obesity in clinical practice","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.093","https://doi.org/10.1093/ejhf/xuag193.093",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037577","R0037577.pdf","paywalled","randomized_trial","METTE HØY JENSEN","2026","1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys","Diabetes","American Diabetes Association","10.2337/db26-1713-p","https://doi.org/10.2337/db26-1713-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037585","R0037585.pdf","paywalled","randomized_trial","Clare Brown","2026","A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide once weekly versus dapagliflozin alone in obese patients with Type 2 diabetes mellitus (RESILIENT).","University of Liverpool",null,"10.17638/03198911","https://doi.org/10.17638/03198911",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037723","R0037723.pdf","paywalled","randomized_trial","Yuliang Xiang","2026","Comparative Effectiveness of SGLT-2 Inhibitors versus GLP-1 Receptor Agonists on Recurrent Cardiovascular Events in Patients with Type 2 Diabetes After Acute Ischemic Stroke: A Target Trial Emulation Using Chinese Insurance Claims Data","Open Science Framework",null,"10.17605/osf.io/a3yht","https://doi.org/10.17605/osf.io/a3yht",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037805","R0037805.pdf","paywalled","randomized_trial","YIMING MU","2026","1218-OR: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HDM1002) in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Diet and Exercise or Metformin","Diabetes","American Diabetes Association","10.2337/db26-1218-or","https://doi.org/10.2337/db26-1218-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037987","R0037987.pdf","paywalled","randomized_trial","PETER ROSSING","2026","2700-LB: High-Dose Semaglutide Is Associated with Preservation of Kidney Function in People Living with Obesity without Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2700-lb","https://doi.org/10.2337/db26-2700-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038027","R0038027.pdf","paywalled","randomized_trial","LINONG JI","2026","1681-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Metformin (Met) with/without One Other Oral Antidiabetic Drug (OAD)","Diabetes","American Diabetes Association","10.2337/db26-1681-p","https://doi.org/10.2337/db26-1681-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038112","R0038112.pdf","paywalled","randomized_trial","Nicola Maurea","2026","Semaglutide preserves myocardial function in a murine model of sequential anthracycline trastuzumab induced early cardiotoxicity: insights from speckle tracking echocardiography","European Heart Journal - Cardiovascular Imaging","Oxford University Press (OUP)","10.1093/ehjci/jeaf367.267","https://doi.org/10.1093/ehjci/jeaf367.267",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038163","R0038163.pdf","paywalled","randomized_trial","RAJAMANNAR THENNATI","2026","2833-LB: Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)","Diabetes","American Diabetes Association","10.2337/db26-2833-lb","https://doi.org/10.2337/db26-2833-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038177","R0038177.pdf","paywalled","randomized_trial","Philip Haaf","2026","Sauna therapy in HFpEF: more than just heat?","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag093","https://doi.org/10.1093/ejhf/xuag093","41889337","https://pubmed.ncbi.nlm.nih.gov/41889337/",null,null],["2","R0038225","R0038225.pdf","paywalled","randomized_trial","Mazen Noureddin","2026","LBP-029 Weight loss–independent Glucagon effect led to rapid, clinically significant reductions in MASH severity, including steatosis and liver stiffness, during a 48-week randomized controlled trial of dual agonist DD01","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00444-7","https://doi.org/10.1016/s0168-8278(26)00444-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038252","R0038252.pdf","paywalled","randomized_trial","Lingge Feng","2026","1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice","Diabetes","American Diabetes Association","10.2337/db26-1322-or","https://doi.org/10.2337/db26-1322-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038388","R0038388.pdf","paywalled","randomized_trial","Jamy Ard","2026","2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial","Diabetes","American Diabetes Association","10.2337/db26-2846-lb","https://doi.org/10.2337/db26-2846-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038419","R0038419.pdf","paywalled","randomized_trial","JING YANG","2026","1106-OR: Prevention of Weight Rebound and Restoration of Muscle Mass after Semaglutide Withdrawal Using Bc-006, an INHBE siRNA, in a Nonhuman Primate Obesity Model","Diabetes","American Diabetes Association","10.2337/db26-1106-or","https://doi.org/10.2337/db26-1106-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038782","R0038782.pdf","paywalled","randomized_trial","NIKOLAJ BAK","2026","1035-OR: Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db26-1035-or","https://doi.org/10.2337/db26-1035-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038885","R0038885.pdf","paywalled","randomized_trial","A Elbayomy","2026","E-029 Semaglutide (Ozempic) use and mortality in acute ischemic stroke: insights from nationwide and institutional data",null,"BMJ Publishing Group Ltd.","10.1136/jnis-2026-snis.133","https://doi.org/10.1136/jnis-2026-snis.133",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039038","R0039038.pdf","paywalled","randomized_trial","DINESH KUMAR","2026","1659-P: Early Metabolic and Hepatic Benefits of Tirzepatide in Indian Adults with Type 2 Diabetes: Insights from Real-World Practice","Diabetes","American Diabetes Association","10.2337/db26-1659-p","https://doi.org/10.2337/db26-1659-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039145","R0039145.pdf","paywalled","randomized_trial","V Quagliariello","2026","The GLP-1 receptor agonist Semaglutide preserves cardiac function, reduces inflammation-driven cardiotoxicity with cardio-renal benefits in non-diabetic models exposed to anthracyclines and HER2 block","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.1327","https://doi.org/10.1093/ejhf/xuag193.1327",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039271","R0039271.pdf","paywalled","randomized_trial","DAVID M. D'ALESSIO","2026","1005-OR: The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy","Diabetes","American Diabetes Association","10.2337/db26-1005-or","https://doi.org/10.2337/db26-1005-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039279","R0039279.pdf","paywalled","randomized_trial","Charles‐Henri Malbert","2026","2456-P: Restoration of Impaired Portal Glucose Signaling Using Low-Dose Dihydrotestosterone Reprograms Brain Networks in Experimental Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2456-p","https://doi.org/10.2337/db26-2456-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039283","R0039283.pdf","paywalled","randomized_trial","Tim Oliver","2026","Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.7_suppl.401","https://doi.org/10.1200/jco.2026.44.7_suppl.401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ISRCTN:ISRCTN91422391"],["2","R0039300","R0039300.pdf","paywalled","randomized_trial","Mazen Noureddin","2026","OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00326-0","https://doi.org/10.1016/s0168-8278(26)00326-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039303","R0039303.pdf","paywalled","randomized_trial","Beverly G. Tchang","2026","TOS / OMA / OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action","Obesity","Wiley","10.1002/oby.70170","https://doi.org/10.1002/oby.70170","41782449","https://pubmed.ncbi.nlm.nih.gov/41782449/",null,null],["2","R0039331","R0039331.pdf","paywalled","randomized_trial","JENS ABERLE","2026","2835-LB: Greater Combined A1C Reductions and Weight Loss with 25 mg and 50 mg vs. 14 mg Oral Semaglutide in Adults with T2D: Evidence from PIONEER PLUS","Diabetes","American Diabetes Association","10.2337/db26-2835-lb","https://doi.org/10.2337/db26-2835-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039335","R0039335.pdf","paywalled","randomized_trial","Anayat Ullah","2026","A literature review of GLP-1 agonists for the urologist: What do we know so far?","Journal of Clinical Urology","SAGE Publications","10.1177/20514158261454811","https://doi.org/10.1177/20514158261454811",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039413","R0039413.pdf","paywalled","randomized_trial","Naim Alkhouri","2026","LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00451-4","https://doi.org/10.1016/s0168-8278(26)00451-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039544","R0039544.pdf","paywalled","randomized_trial","B Jazayeri","2026","1235 “From Waistline to Wound Healing: Do GLP-1 Receptor Agonists Improve Peri- and Post-Operative Outcomes After Major Weight-Bearing Joint and Spine Surgery in Overweight and Obese Adults?","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag063.495","https://doi.org/10.1093/bjs/znag063.495",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039644","R0039644.pdf","paywalled","randomized_trial","Prof. Ajay Kumar Duseja","2026","FRI-155 Efficacy of oral semaglutide in overweight- obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD) related compensated advanced chronic liver disease (cACLD) - Results of first randomized controlled trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01899-4","https://doi.org/10.1016/s0168-8278(26)01899-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039748","R0039748.pdf","paywalled","randomized_trial","Jeffrey A. Gusenoff","2026","Body of Work: Reflections on Body Contouring Surgery Innovation and 30 Years of Aesthetic Surgery Journal","Aesthetic Surgery Journal","Oxford University Press (OUP)","10.1093/asj/sjag034","https://doi.org/10.1093/asj/sjag034","42298944","https://pubmed.ncbi.nlm.nih.gov/42298944/",null,null],["2","R0039898","R0039898.pdf","paywalled","randomized_trial","L Ludwig","2026","Orforglipron is associated with improvements in markers of beta-cell function and insulin sensitivity when used as monotherapy in participants with type 2 diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819875","https://doi.org/10.1055/s-0046-1819875",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039964","R0039964.pdf","paywalled","randomized_trial","Ragen Chastain","2026","GLP-1 medications for weight-loss: a triumph of marketing over patient care","Figshare",null,"10.6084/m9.figshare.31942107.v1","https://doi.org/10.6084/m9.figshare.31942107.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039990","R0039990.pdf","paywalled","randomized_trial","Marlene Concepción Espínola Zárate","2026","GLP-1 en trastornos por uso de sustancias: Neurobiología, evidencia clínica y agenda de investigación","Dialnet (Universidad de la Rioja)",null,"10.5281/zenodo.20580232","https://doi.org/10.5281/zenodo.20580232",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039998","R0039998.pdf","paywalled","randomized_trial","Neha Shewale*, Manashri Ahire, Jubershaha Fakir, Chandrashekhar Patil","2026","GLP-1 Receptor Agonists: Expanding Pharmacological Horizons Beyond Metabolic Disease","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22044573","https://doi.org/10.5281/zenodo.22044573",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040189","R0040189.pdf","paywalled","randomized_trial","Dipesh Kumar","2026","Neuroprotective Potential of Semaglutide in Parkinson's Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22059804","https://doi.org/10.5281/zenodo.22059804",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041526","R0041526.pdf","paywalled","randomized_trial","Surov A.I. Surov","2026","Glucagon-like peptide-1 receptor agonists in combination therapy of gonarthrosis in patients with metabolic syndrome: Results of a 24-week prospective randomized study","Therapy","Bionika Media","10.18565/therapy.2026.1.14-23","https://doi.org/10.18565/therapy.2026.1.14-23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042090","R0042090.pdf","paywalled","randomized_trial","Hartur Fontes Assis de Sousa","2026","The efficacy of liraglutide in reducing major adverse cardiovascular events (MACE) in individuals with overweight or obesity without a diagnosis of type 2 diabetes mellitus.",null,null,"10.17605/osf.io/xgzs2","https://doi.org/10.17605/osf.io/xgzs2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042092","R0042092.pdf","paywalled","randomized_trial","Qin-Wen Liu","2026","Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk: Clinical Effectiveness and Human Urinary Lithogenic Phenotype Triangulation, with GLP-1-Based Therapies as an Active Comparator and Mechanistic Contrast",null,null,"10.17605/osf.io/k5wh4","https://doi.org/10.17605/osf.io/k5wh4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261491376"],["2","R0042145","R0042145.pdf","paywalled","randomized_trial","Marcin Kutek","2026","The comparison of GLP-1RA therapy with non-pharmacological interventions on Th1, Th2, Th17 cytokine profile and atherosclerosis markers in patients suffering from obesity",null,null,"10.17605/osf.io/n9jds","https://doi.org/10.17605/osf.io/n9jds",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042201","R0042201.pdf","paywalled","randomized_trial","Athena Flores Miranda","2026","Metabolic Adaptation to Weight Loss In Response to a Behavioural Lifestyle Program with or without Semaglutide in Adolescents with Obesity",null,null,"10.71548/2209","https://doi.org/10.71548/2209",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042525","R0042525.pdf","paywalled","randomized_trial","YAN BI","2026","2816-LB: Efficacy and Safety of Oral Ribupatide (HRS9531) in Adults with Obesity: A Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db26-2816-lb","https://doi.org/10.2337/db26-2816-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042752","R0042752.pdf","paywalled","randomized_trial","Gianna Wilkie","2026","Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial","California Digital Library",null,"10.48321/d1989d6a3a","https://doi.org/10.48321/d1989d6a3a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042792","R0042792.pdf","paywalled","randomized_trial","Achyuth P. Jakka","2026","The Endocrine Impact of Obstructive Sleep Apnea: Mechanisms, Hormonal Dysregulation, and Emerging Therapeutic Strategies","IFR journal of medicine and surgery.","International Federation of Research and Discovery","10.70146/msv03i03.002","https://doi.org/10.70146/msv03i03.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043055","R0043055.pdf","paywalled","randomized_trial","Hannon TS","2026","Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial","Yearbook of pediatric endocrinology","Bioscientifica","10.1530/ey.23.12.5","https://doi.org/10.1530/ey.23.12.5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043300","R0043300.pdf","paywalled","randomized_trial","Dominic Lynch","2026","Research Synthesis: Liraglutide Biomarker Effects — full paper",null,null,"10.17605/osf.io/c9uat","https://doi.org/10.17605/osf.io/c9uat",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043301","R0043301.pdf","paywalled","randomized_trial","Johannes F E Mann","2026","Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/zxjx-5p49","https://doi.org/10.17615/zxjx-5p49",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043512","R0043512.pdf","paywalled","randomized_trial","Sarah Albishri","2026","Efficacy and Safety of Basal Insulin Combined with GLP-1 Receptors Agonists versus Intensified Conventional Insulin Regimens in Type 2 Diabetes: A Meta Analysis of Randomized Controlled Trials","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1785039096","https://doi.org/10.24911/ijmdc.51-1785039096",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261443671"],["2","R0043513","R0043513.pdf","paywalled","randomized_trial","Muhindo Anitah","2026","Long-Acting GLP-1 Receptor Agonists for Weight and Glycaemic Control in Adolescents with Type 2 Diabetes","IDOSR JOURNAL OF SCIENTIFIC RESEARCH","International Digital Organization for Scientific Research","10.59298/idosrjsr/2026/11.2.2327","https://doi.org/10.59298/idosrjsr/2026/11.2.2327",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043606","R0043606.pdf","paywalled","randomized_trial","Oliver Freudenreich","2026","Schizophrenia: Does Semaglutide Outperform Liraglutide for Antipsychotic Weight Gain?",null,"Psychopharmacology Institute","10.64239/pi-qt9102","https://doi.org/10.64239/pi-qt9102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043634","R0043634.pdf","paywalled","randomized_trial","Hameed Alhashmi","2026","GLP-1–Based Pharmacotherapies and Migraine Outcomes: A Scoping Review of Human Clinical Evidence",null,null,"10.17605/osf.io/9xqgc","https://doi.org/10.17605/osf.io/9xqgc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043731","R0043731.pdf","paywalled","randomized_trial","Terri-Ann Burke","2026","Effect of Nutrition Education on Outcomes After Initiation of Glucagon-like Peptide-1 in Adults with Diabetes",null,null,"10.57709/347","https://doi.org/10.57709/347",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043919","R0043919.pdf","paywalled","randomized_trial","Ana Larissa Alves Rodrigues Melo","2026","The use of GLP-1 analogues in the treatment of patients with type 1 diabetes mellitus and obesity: a scoping review\"",null,null,"10.17605/osf.io/fkzs3","https://doi.org/10.17605/osf.io/fkzs3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044414","R0044414.pdf","paywalled","randomized_trial","Andy Young","2026","The Gut, Hormone, Skin Axis in Skin Health and Ageing: A Scoping Review and Integrative Dermatological Perspective",null,null,"10.17605/osf.io/k9jrg","https://doi.org/10.17605/osf.io/k9jrg",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044571","R0044571.pdf","paywalled","randomized_trial","Sidário Rodrigues Malheiros-junior","2026","Neurological symptoms during incretin receptor agonist therapy: current evidence for metabolic and fluid-electrolyte mechanisms and testable hypotheses","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21612596","https://doi.org/10.5281/zenodo.21612596",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044579","R0044579.pdf","paywalled","randomized_trial","V Quagliariello","2026","THE GLP–1 RECEPTOR AGONIST SEMAGLUTIDE PRESERVES CARDIAC FUNCTION, REDUCES INFLAMMATION–DRIVEN CARDIOTOXICITY WITH CARDIO–RENAL BENEFITS IN NON–DIABETIC MODELS EXPOSED TO ANTHRACYCLINES AND HER2 BLOCKADE","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suag058.049","https://doi.org/10.1093/eurheartjsupp/suag058.049",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045102","R0045102.pdf","paywalled","randomized_trial","Carina Sun","2026","Uncoupling weight regain and glycemic control: post-cessation effects of alternate-day fasting and semaglutide treatment in MS-NASH mice","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2299519","https://doi.org/10.1152/physiol.2026.41.s1.2299519",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045205","R0045205.pdf","paywalled","randomized_trial","Olivia Cory","2026","Racial and Ethnic Representation in Phase 3 RCTs of FDA-Approved GLP-1 Receptor Agonists (2021–2026)",null,null,"10.17605/osf.io/njkme","https://doi.org/10.17605/osf.io/njkme",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045217","R0045217.pdf","paywalled","randomized_trial","Anne Sofie Laulund","2026","High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.","UNC Libraries",null,"10.17615/vghg-6244","https://doi.org/10.17615/vghg-6244",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045255","R0045255.pdf","paywalled","randomized_trial","Maria Dermit","2026","1711-P: Menopausal Hormonal Status and Estradiol Use Modulate Semaglutide-Associated Weight Loss in Women: Analyses from STEP1 and SELECT","Diabetes","American Diabetes Association","10.2337/db26-1711-p","https://doi.org/10.2337/db26-1711-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045326","R0045326.pdf","paywalled","randomized_trial","Zuzanna Gąsior","2026","The Role of Semaglutide in Obesity Treatment: Effectiveness and Safety Based on Current Evidence","Archiv Euromedica","European Scientific Society","10.35630/2026/16/iss.1.007","https://doi.org/10.35630/2026/16/iss.1.007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045412","R0045412.pdf","paywalled","randomized_trial","Dawid Głaz","2026","GLP-1 receptor agonists and depression in obesity: current evidence","Archiv Euromedica","European Scientific Society","10.35630/2026/16/iss.1.005","https://doi.org/10.35630/2026/16/iss.1.005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045423","R0045423.pdf","paywalled","randomized_trial","Sabine Kahl","2026","OS-020 Effect of empagliflozin alone or combined with low-dose semaglutide on metabolic dysfunction-associated steatohepatitis and type 2 diabetes – a histology-based randomized, placebocontrolled, double-blind phase 4 trial (COMBAT_T2_NASH)","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00330-2","https://doi.org/10.1016/s0168-8278(26)00330-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045429","R0045429.pdf","paywalled","randomized_trial","Yerong Yu","2026","2844-LB: Safety, Tolerability, PK, and PD of Elecoglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults Living with Obesity or Overweight With or Without Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2844-lb","https://doi.org/10.2337/db26-2844-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045450","R0045450.pdf","paywalled","randomized_trial","ABSALON D. GUTIERREZ","2026","3057-LB: GLP-1 Receptor Agonist Treatment Promotes IL6-Dependent Activation of Brown Adipogenesis Program and Glucose Uptake in Adipose Tissue of Insulin-Resistant Humans","Diabetes","American Diabetes Association","10.2337/db26-3057-lb","https://doi.org/10.2337/db26-3057-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045539","R0045539.pdf","paywalled","randomized_trial","Ruofei Li","2026","Exercise Interventions During GLP-1–Based Obesity Treatment: A Scoping Review of Muscle Health, Physical Fitness, and Implementation Characteristics","Open Science Framework",null,"10.17605/osf.io/gnmwc","https://doi.org/10.17605/osf.io/gnmwc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045553","R0045553.pdf","paywalled","randomized_trial","DONGYANG LIU","2026","1805-P: Safety, Tolerability, and Pharmacokinetic Characteristics of GZR102 Injection Compared with GZR4 or Bofanglutide","Diabetes","American Diabetes Association","10.2337/db26-1805-p","https://doi.org/10.2337/db26-1805-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045574","R0045574.pdf","paywalled","randomized_trial","A M Alzahrani","2026","Efficacy of GLP-1 Receptor Agonists in Reducing Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21617085","https://doi.org/10.5281/zenodo.21617085",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045607","R0045607.pdf","paywalled","randomized_trial","Mauro Riccardi","2026","Effect of contemporary HFpEF therapies on diuretic management: decongestive role or disease modification?","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag074","https://doi.org/10.1093/ejhf/xuag074","41802271","https://pubmed.ncbi.nlm.nih.gov/41802271/",null,null],["2","R0045624","R0045624.pdf","paywalled","randomized_trial","Kendra Terrell","2026","1715-P: Health-Related Quality of Life (HRQOL) in People with Type 2 Diabetes (T2D) Receiving the Once-Daily, Oral, Nonpeptide GLP-1RA Orforglipron in ACHIEVE-2 and -3","Diabetes","American Diabetes Association","10.2337/db26-1715-p","https://doi.org/10.2337/db26-1715-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045630","R0045630.pdf","paywalled","randomized_trial","LIMING CHEN","2026","1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4)","Diabetes","American Diabetes Association","10.2337/db26-1752-p","https://doi.org/10.2337/db26-1752-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045635","R0045635.pdf","paywalled","randomized_trial","Sean Wharton","2026","Plain Language Summary of the Manuscript: Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.32034918.v1","https://doi.org/10.60915/boehringer-figshare.32034918.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045781","R0045781.pdf","paywalled","randomized_trial","Awadhesh Kumar Singh","2026","Strengths and Limitations of Synthetic Versus Reference Semaglutide in Indian Adults With Type 2 Diabetes and Obesity: A Systematic Critical Appraisal of the Published Phase III Evidence",null,null,"10.17605/osf.io/49gfn","https://doi.org/10.17605/osf.io/49gfn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045835","R0045835.pdf","paywalled","randomized_trial","Yu. A. Trusov","2026","Risk of cardiovascular disease development in metabolically associated fatty liver disease (MAFLD): risk stratification and current therapeutic strategies","Russian Medicine","ECO-Vector LLC (Publications)","10.17816/medjrf704126","https://doi.org/10.17816/medjrf704126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045852","R0045852.pdf","paywalled","randomized_trial","Nitin Kapoor","2026","Additional file 2 of Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)","Figshare",null,"10.6084/m9.figshare.32087491","https://doi.org/10.6084/m9.figshare.32087491",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045939","R0045939.pdf","paywalled","randomized_trial","LINONG JI","2026","1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis","Diabetes","American Diabetes Association","10.2337/db26-1725-p","https://doi.org/10.2337/db26-1725-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046025","R0046025.pdf","paywalled","randomized_trial","Sunil Dhungel","2026","Systematic Literature Review on Efficacy and Safety of Glucagon-Like Peptide (GLP-1) Agonists in Asian Adults Living with Type 2 Diabetes Mellitus.","Open Science Framework",null,"10.17605/osf.io/6z92t","https://doi.org/10.17605/osf.io/6z92t",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046076","R0046076.pdf","paywalled","randomized_trial","Illiasul K Ibad","2026","Difficult‐To‐Treat Psoriatic Arthritis: An Evolving Clinical Construct","International Journal of Rheumatic Diseases","Wiley","10.1111/1756-185x.70632","https://doi.org/10.1111/1756-185x.70632","41906347","https://pubmed.ncbi.nlm.nih.gov/41906347/",null,null],["2","R0046149","R0046149.pdf","paywalled","randomized_trial","Nitin Kapoor","2026","Additional file 1 of Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)","Figshare",null,"10.6084/m9.figshare.32087488.v1","https://doi.org/10.6084/m9.figshare.32087488.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046332","R0046332.pdf","paywalled","randomized_trial","Jordan Hart","2026","GLP-1/GIP-1 Agonism improves metabolic dysfunction and delays renal injury in an experimental model of Systemic Lupus Erythematosus","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2301118","https://doi.org/10.1152/physiol.2026.41.s1.2301118",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046430","R0046430.pdf","paywalled","randomized_trial","WEI HU","2026","1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study","Diabetes","American Diabetes Association","10.2337/db26-1721-p","https://doi.org/10.2337/db26-1721-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046525","R0046525.pdf","paywalled","randomized_trial","LINONG JI","2026","2620-P: MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity","Diabetes","American Diabetes Association","10.2337/db26-2620-p","https://doi.org/10.2337/db26-2620-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046562","R0046562.pdf","paywalled","randomized_trial","CHARLOTTE S. ULRIK","2026","1723-P: Semaglutide Reduces Asthma-Related Adverse Outcomes in Patients with Comorbid Asthma and Obesity: A Post Hoc Analysis of the SELECT Trial","Diabetes","American Diabetes Association","10.2337/db26-1723-p","https://doi.org/10.2337/db26-1723-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046573","R0046573.pdf","paywalled","randomized_trial","Usra Ghanem","2026","Nutritional Management and Monitoring of Adolescents on GLP-1 Receptor Agonist Therapy: A Scoping Review","Open Science Framework",null,"10.17605/osf.io/3dtyz","https://doi.org/10.17605/osf.io/3dtyz",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046621","R0046621.pdf","paywalled","randomized_trial","PISIT (DUKE) PITUKCHEEWANONT","2026","2589-P: Combination LUM-201 and Semaglutide Enhances Weight Loss and Preserves Lean Mass in Diet-Induced Obesity: Translational Rationale for a Phase 2 Study in Adults with Obesity","Diabetes","American Diabetes Association","10.2337/db26-2589-p","https://doi.org/10.2337/db26-2589-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046839","R0046839.pdf","paywalled","randomized_trial","BENJAMIN SCIRICA","2026","1696-P: Effect of Semaglutide on COVID-19–Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials","Diabetes","American Diabetes Association","10.2337/db26-1696-p","https://doi.org/10.2337/db26-1696-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047064","R0047064.pdf","paywalled","randomized_trial","Julio Rosenstock","2026","1032-OR: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight","Diabetes","American Diabetes Association","10.2337/db26-1032-or","https://doi.org/10.2337/db26-1032-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047378","R0047378.pdf","paywalled","randomized_trial","Dilorom Kamardinovna Najmutdinova","2026","CHARACTERISTICS OF THE COURSE AND TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC LIVER DISEASE","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20566967","https://doi.org/10.5281/zenodo.20566967",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047479","R0047479.pdf","paywalled","randomized_trial","Colton Jones","2026","Real-world analysis on the impact of GLP-1 receptor agonists on survival and metastatic risk in colorectal cancer.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.62","https://doi.org/10.1200/jco.2026.44.2_suppl.62",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047744","R0047744.pdf","paywalled","randomized_trial","Randee Sedaka","2026","Semaglutide reduces kidney disease severity and improves vascular endothelial function in mice with polycystic kidney disease in a diet-dependent manner","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2300525","https://doi.org/10.1152/physiol.2026.41.s1.2300525",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047814","R0047814.pdf","paywalled","randomized_trial","KRISTINA BOYE","2026","1667-P: Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results after Two Years of Treatment in SURPASS-EARLY","Diabetes","American Diabetes Association","10.2337/db26-1667-p","https://doi.org/10.2337/db26-1667-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047874","R0047874.pdf","paywalled","randomized_trial","Mackenzie Petie","2026","When ‘Quick Fixes’ Go Viral: The Impact of GLP-1 Misinformation on Younger Females' Body Dissatisfaction and Disordered Eating Behaviours","Open Science Framework",null,"10.17605/osf.io/kqgns","https://doi.org/10.17605/osf.io/kqgns",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047908","R0047908.pdf","paywalled","randomized_trial","Shelby A. Sullivan","2026","642 DUODENAL MUCOSAL RESURFACING PREVENTS WEIGHT REGAIN AFTER TIRZEPATIDE WITHDRAWAL: REMAIN-1 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED CLINICAL TRIAL - MIDPOINT COHORT RESULTS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04725-5","https://doi.org/10.1016/s0016-5107(26)04725-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048138","R0048138.pdf","paywalled","randomized_trial","Puneet S. Arora","2026","2643-P: Preliminary Data on Continuing Weight Loss at 52 Weeks and Durable Weight Loss Off Therapy with Nimacimab, a CB1R Antibody, in Combination with Semaglutide","Diabetes","American Diabetes Association","10.2337/db26-2643-p","https://doi.org/10.2337/db26-2643-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048176","R0048176.pdf","paywalled","randomized_trial","Panagiotis I. Georgianos","2026","Better cardiorenal protection for patients with CKD and type 1 diabetes","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfag076","https://doi.org/10.1093/ndt/gfag076","41910194","https://pubmed.ncbi.nlm.nih.gov/41910194/",null,"ClinicalTrials.gov:NCT06217302"],["2","R0048338","R0048338.pdf","paywalled","randomized_trial","Roland E. Schmieder","2026","Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1820049","https://doi.org/10.1055/s-0046-1820049",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048563","R0048563.pdf","paywalled","randomized_trial","Navneet Gupta","2026","B15-07 Beyond Weight Loss: GLP-1 Agonists Improve Outcomes in COPD-OSA Overlap—A Trinetx Network Analysis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1752","https://doi.org/10.1093/ajrccm/aamag162.1752",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048588","R0048588.pdf","paywalled","randomized_trial","Lee M Kaplan","2026","Publication Alert: Survodutide in adults with obesity and metabolic dysfunction–associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial, Ph III Primary results","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.32993774.v1","https://doi.org/10.60915/boehringer-figshare.32993774.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048829","R0048829.pdf","paywalled","randomized_trial","Pablo F. Mora","2026","1730-P: Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D","Diabetes","American Diabetes Association","10.2337/db26-1730-p","https://doi.org/10.2337/db26-1730-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048918","R0048918.pdf","paywalled","randomized_trial","Anastasia Searle","2026","Behavioural and lifestyle components used alongside GLP-1RAs in interventions for adults with obesity: a systematic scoping review of randomised controlled trials.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19484486","https://doi.org/10.5281/zenodo.19484486",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049132","R0049132.pdf","paywalled","randomized_trial","Mohammed A. Abdelsaid","2026","Abstract TP098: GLP-1 Agonist Improves VCID by Preventing Mitochondrial Dysgenesis in Diabetic Mice.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.57.suppl_1.tp098","https://doi.org/10.1161/str.57.suppl_1.tp098",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049169","R0049169.pdf","paywalled","randomized_trial","Destiny R Underwood","2026","IMPACT OF COMBINED TIRZEPATIDE (MOUNJARO®/ZEPBOUND®) AND RESISTANCE EXERCISE (T-REX) ON AEROBIC FITNESS IN OVERWEIGHT AND OBESE OLDER ADULTS.","Journal of Clinical Exercise Physiology","Clinical Exercise Physiology Association","10.31189/2165-7629-15-s2.250","https://doi.org/10.31189/2165-7629-15-s2.250",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049202","R0049202.pdf","paywalled","randomized_trial","João Lucas Souza Ferreira Almeida","2026","DEPRESSÃO, ANSIEDADE E IDEAÇÃO SUICIDA EM PACIENTES EM USO DE AGONISTAS DO RECEPTOR GLP-1: UMA REVISÃO SISTEMÁTICA DAS EVIDÊNCIAS CLÍNICAS E DOS MECANISMOS NEUROBIOLÓGICOS ENVOLVIDOS","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/dt10202602171027","https://doi.org/10.69849/revistaft/dt10202602171027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049216","R0049216.pdf","paywalled","randomized_trial","Roland E. Schmieder","2026","Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1820050","https://doi.org/10.1055/s-0046-1820050",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049276","R0049276.pdf","paywalled","randomized_trial","A Buckley","2026","The Hidden Burden of International Gastric Balloon Tourism: A Five-Year Analysis of Removal Procedures Performed at Homerton University Hospital an NHS Bariatric Centre in London, UK","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1821213","https://doi.org/10.1055/s-0046-1821213",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049379","R0049379.pdf","paywalled","randomized_trial","Nico-al Paolo Gotera","2026","GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10520","https://doi.org/10.1200/jco.2026.44.16_suppl.10520",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049527","R0049527.pdf","paywalled","randomized_trial","Charlotte Gibson","2026","Abstract 3623: Effects of the anti-obesity medication tirzepatide on the tumor microenvironment in a mouse model of obesity-associated, hormone-dependent breast cancer","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2026-3623","https://doi.org/10.1158/1538-7445.am2026-3623",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049573","R0049573.pdf","paywalled","randomized_trial","David C. Van Riper","2026","Lab Grown Paper","Open Science Framework",null,"10.17605/osf.io/etq39","https://doi.org/10.17605/osf.io/etq39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050497","R0050497.pdf","paywalled","randomized_trial","Rohit Seth Loomba","2026","WED-140 AI based cell free DNA methylation blood test for semaglutide response in patients with at-risk MASH: Results from SAMARA randomized control trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01682-x","https://doi.org/10.1016/s0168-8278(26)01682-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050535","R0050535.pdf","paywalled","randomized_trial","Amanda Dolores Abramowicz","2026","GLP-1 Receptor Agonists in Pediatric Obesity: Evidence, Knowledge Gaps, and Clinical Implications","Archiv Euromedica","European Scientific Society","10.35630/2026/16/iss.2.8","https://doi.org/10.35630/2026/16/iss.2.8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051573","R0051573.pdf","paywalled","randomized_trial","olivia jullian parra","2026","Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation","arXiv (Cornell University)",null,"10.48550/arxiv.2605.05125","https://doi.org/10.48550/arxiv.2605.05125",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051706","R0051706.pdf","paywalled","randomized_trial","Fayaz Khan","2026","Abstract PS1-10-12: Impact of Glucagon-like peptide-1 receptor agonists Use on Survival and Metabolic Outcomes in Metastatic Estrogen Receptor Positive Breast Cancer: A Real-World Cohort Study","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps1-10-12","https://doi.org/10.1158/1557-3265.sabcs25-ps1-10-12",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051946","R0051946.pdf","paywalled","randomized_trial","Lance Sloan","2026","1219-OR: Effects of Mifepristone in People with Difficult-to-Control T2D and Hypercortisolism on GLP-1RAs","Diabetes","American Diabetes Association","10.2337/db26-1219-or","https://doi.org/10.2337/db26-1219-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052146","R0052146.pdf","paywalled","randomized_trial","Lalantha Leelarathna","2026","1174-OR: Continuous Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: Subgroup Analysis from the FreeDM2 Trial","Diabetes","American Diabetes Association","10.2337/db26-1174-or","https://doi.org/10.2337/db26-1174-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05944432"],["2","R0052516","R0052516.pdf","paywalled","randomized_trial","R Gul","2026","A36-20 The Hidden Weight of Severe Asthma: Linking Metabolic Disease to Poor Control and New Solutions","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.345","https://doi.org/10.1093/ajrccm/aamag162.345",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052921","R0052921.pdf","paywalled","randomized_trial","I Ikonomidis","2026","Impact of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on myocardial work and coronary flow in liver steatosis and diabetes","European Heart Journal - Cardiovascular Imaging","Oxford University Press (OUP)","10.1093/ehjci/jeaf367.057","https://doi.org/10.1093/ehjci/jeaf367.057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053333","R0053333.pdf","paywalled","randomized_trial","SEOA KIM","2026","2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects","Diabetes","American Diabetes Association","10.2337/db26-2837-lb","https://doi.org/10.2337/db26-2837-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053412","R0053412.pdf","paywalled","randomized_trial","Jeffrey L. Cummings","2026","Top-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer’s Disease (P6-12.006)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000216975","https://doi.org/10.1212/wnl.0000000000216975",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053464","R0053464.pdf","paywalled","randomized_trial","Lawrence Leiter","2026","1247-OR: Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial","Diabetes","American Diabetes Association","10.2337/db26-1247-or","https://doi.org/10.2337/db26-1247-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053542","R0053542.pdf","paywalled","randomized_trial","Constanza Arancibia","2026","Weight management interventions before IVF in overweight and obese women: a scoping review","Figshare",null,"10.6084/m9.figshare.c.8471011.v1","https://doi.org/10.6084/m9.figshare.c.8471011.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053571","R0053571.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22116606","https://doi.org/10.5281/zenodo.22116606",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053572","R0053572.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22116607","https://doi.org/10.5281/zenodo.22116607",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053597","R0053597.pdf","paywalled","randomized_trial","Ms.Ruchika A Gupta","2026","Cardiometabolic Benefits and Weight-Loss Efficacy of the Oral GLP-1 Agonist Orforglipron in Non-Diabetic Adults","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21103425","https://doi.org/10.5281/zenodo.21103425",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053616","R0053616.pdf","paywalled","randomized_trial","THINLEY Y. WANGDEN","2026","1810-P: Time-to-Event Nonadditive Analysis Identifies Novel Genetic Variants Associated with Treatment Response and Weight Loss in the GRADE Clinical Trial","Diabetes","American Diabetes Association","10.2337/db26-1810-p","https://doi.org/10.2337/db26-1810-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053690","R0053690.pdf","paywalled","randomized_trial","TAMARA OSER","2026","1170-OR: CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db26-1170-or","https://doi.org/10.2337/db26-1170-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053744","R0053744.pdf","paywalled","randomized_trial","Mark David Orland","2026","Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.3143","https://doi.org/10.1200/jco.2026.44.16_suppl.3143",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053861","R0053861.pdf","paywalled","randomized_trial","Geoff Cook","2026","Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.104227","https://doi.org/10.2196/preprints.104227",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053969","R0053969.pdf","paywalled","randomized_trial","S Jacob","2026","Oral vs. Injectable Semaglutide: An Indirect Treatment Comparison of Weight Loss Outcomes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819894","https://doi.org/10.1055/s-0046-1819894",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053982","R0053982.pdf","paywalled","randomized_trial","Samantha S Moe","2026","Top studies of 2025 relevant to primary care: From the PEER team.","PubMed",null,"10.46747/cfp.7205308","https://doi.org/10.46747/cfp.7205308","42128641","https://pubmed.ncbi.nlm.nih.gov/42128641/",null,null],["2","R0054032","R0054032.pdf","paywalled","randomized_trial","HUSAM A. GHANIM","2026","2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial","Diabetes","American Diabetes Association","10.2337/db26-2876-lb","https://doi.org/10.2337/db26-2876-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054049","R0054049.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22116782","https://doi.org/10.5281/zenodo.22116782",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054137","R0054137.pdf","paywalled","randomized_trial","D D’Alessio","2026","Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide (SURPASS-CVOT)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819979","https://doi.org/10.1055/s-0046-1819979",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054141","R0054141.pdf","paywalled","randomized_trial","L Laffin","2026","IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS BY BODY WEIGHT REDUCTION WITH TIRZEPATIDE IN ADULTS WITH OBESITY AND PREDIABETES: A POST HOC ANALYSIS OF THE 3–YEAR SURMOUNT–1 STUDY","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suag058.163","https://doi.org/10.1093/eurheartjsupp/suag058.163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054146","R0054146.pdf","paywalled","randomized_trial","Ayna Baladi Nejad","2026","1228-OR: First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity","Diabetes","American Diabetes Association","10.2337/db26-1228-or","https://doi.org/10.2337/db26-1228-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054147","R0054147.pdf","paywalled","randomized_trial","Iga Machała","2026","Effects of GLP-1 receptor agonists and dual GIP/GLP-1 agonist on muscle mass and bone health during obesity treatment — a narrative review","Forum Leczenia Otyłości","VM Media Group sp. z o.o","10.5603/flo.112937","https://doi.org/10.5603/flo.112937",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054176","R0054176.pdf","paywalled","randomized_trial","Yu Mi Kang","2026","1217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b","Diabetes","American Diabetes Association","10.2337/db26-1217-or","https://doi.org/10.2337/db26-1217-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054194","R0054194.pdf","paywalled","randomized_trial","Meir Schechter","2026","1309-OR: Dementia Progression with GLP-1 Receptor Agonists in People with Type 2 Diabetes and Mild Cognitive Impairment: Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1309-or","https://doi.org/10.2337/db26-1309-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054233","R0054233.pdf","paywalled","randomized_trial","M Cameira","2026","(119) Exploring the Impact of GLP-1 Analogues on Libido and Sexual Function","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag118.105","https://doi.org/10.1093/jsxmed/qdag118.105",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054257","R0054257.pdf","paywalled","randomized_trial","WEIKAI C. FANG","2026","3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results","Diabetes","American Diabetes Association","10.2337/db26-3102-lb","https://doi.org/10.2337/db26-3102-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06252220"],["2","R0054289","R0054289.pdf","paywalled","randomized_trial","Peter Katzmarzyk","2026","Abstract WE445: Effects of a Weight Management Program Integrated with Continuous Glucose Monitoring on Cardiometabolic Risk Factors: A Randomized Controlled Trial in Patients with Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.we445","https://doi.org/10.1161/cir.153.suppl_1.we445",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054380","R0054380.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22122281","https://doi.org/10.5281/zenodo.22122281",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054389","R0054389.pdf","paywalled","randomized_trial","F Sommer","2026","(470) Preservation of Lean Mass under GLP-1/GIP-Based Pharmacotherapy: Effects of Testosterone and Resistance Training – A Five-Arm, Randomized, Open-Label Parallel-Group Study in Obese Men","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag118.413","https://doi.org/10.1093/jsxmed/qdag118.413",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054517","R0054517.pdf","paywalled","randomized_trial","Dylan M. Belmont-Rausch","2026","1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT","Diabetes","American Diabetes Association","10.2337/db26-1702-p","https://doi.org/10.2337/db26-1702-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054564","R0054564.pdf","paywalled","randomized_trial","ROBERTA A. JAMES","2026","2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP)","Diabetes","American Diabetes Association","10.2337/db26-2820-lb","https://doi.org/10.2337/db26-2820-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054565","R0054565.pdf","paywalled","randomized_trial","Patrick Strollo","2026","0589 Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep Apnea","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0588","https://doi.org/10.1093/sleep/zsag091.0588",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05813275; ClinicalTrials.gov:NCT05811247"],["2","R0054578","R0054578.pdf","paywalled","randomized_trial","Vincenzo Quagliariello","2026","Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted therapy–induced cardiac dysfunction and systemic inflammation in non-diabetic preclinical models.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e12524","https://doi.org/10.1200/jco.2026.44.16_suppl.e12524",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054635","R0054635.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22116705","https://doi.org/10.5281/zenodo.22116705",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054666","R0054666.pdf","paywalled","randomized_trial","LINONG JI","2026","1227-OR: RAY1225, a Biweekly Biased GLP-1/GIP RA for Weight Management: A Phase 2 Trial in Chinese Overweight/Obese Adults (REBUILDING-1)","Diabetes","American Diabetes Association","10.2337/db26-1227-or","https://doi.org/10.2337/db26-1227-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054773","R0054773.pdf","paywalled","randomized_trial","LIMING CHEN","2026","1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin","Diabetes","American Diabetes Association","10.2337/db26-1712-p","https://doi.org/10.2337/db26-1712-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054890","R0054890.pdf","paywalled","randomized_trial","Colton Jones","2026","From risk to reward: Redefining the role of GLP-1 receptor agonist in pancreatic cancer primary prevention.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e16449","https://doi.org/10.1200/jco.2026.44.16_suppl.e16449",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055027","R0055027.pdf","paywalled","randomized_trial","Jesse Chao","2026","1230-OR: Lean Mass Effects of Anti-GDF8 (Trevogrumab) ± Anti-Activin A (Garetosmab) in People Living with Obesity Treated with Semaglutide with or without Low Lean Mass at Baseline","Diabetes","American Diabetes Association","10.2337/db26-1230-or","https://doi.org/10.2337/db26-1230-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055063","R0055063.pdf","paywalled","randomized_trial","DOMENICA RUBINO","2026","2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class","Diabetes","American Diabetes Association","10.2337/db26-2838-lb","https://doi.org/10.2337/db26-2838-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055072","R0055072.pdf","paywalled","randomized_trial","J. Williams","2026","P172 Weight management and GLP-1 receptor agonists in psoriatic disease: insights from a survey of rheumatology and dermatology professionals","Lara D. Veeken","Oxford University Press (OUP)","10.1093/rheumatology/keag121.205","https://doi.org/10.1093/rheumatology/keag121.205",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055078","R0055078.pdf","paywalled","randomized_trial","Arshak Asefi","2026","Perioperative Management of GLP-1 Receptor Agonists: Pathophysiology, Clinical Evidence, and Guideline Synthesis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21641413","https://doi.org/10.5281/zenodo.21641413",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055159","R0055159.pdf","paywalled","randomized_trial","Anne Peters","2026","1258-OR: Performance of a Next-Generation Algorithm for Omnipod in Adults with Type 2 Diabetes: Findings from the STRIVE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db26-1258-or","https://doi.org/10.2337/db26-1258-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055211","R0055211.pdf","paywalled","randomized_trial","ILDIKO LINGVAY","2026","2637-P: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial","Diabetes","American Diabetes Association","10.2337/db26-2637-p","https://doi.org/10.2337/db26-2637-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055305","R0055305.pdf","paywalled","randomized_trial","SeungHwan Lee","2026","1682-P: ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment","Diabetes","American Diabetes Association","10.2337/db26-1682-p","https://doi.org/10.2337/db26-1682-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06635226"],["2","R0055337","R0055337.pdf","paywalled","randomized_trial","LI GONG","2026","2568-P: Obese Rhesus Monkeys Recapitulate Human Efficacy Profiles of Semaglutide, Bimagrumab, and Retatrutide","Diabetes","American Diabetes Association","10.2337/db26-2568-p","https://doi.org/10.2337/db26-2568-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055360","R0055360.pdf","paywalled","randomized_trial","LLOYD KLICKSTEIN","2026","2648-P: A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db26-2648-p","https://doi.org/10.2337/db26-2648-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055385","R0055385.pdf","paywalled","randomized_trial","Concetta Irace","2026","1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4.","Diabetes","American Diabetes Association","10.2337/db26-1753-p","https://doi.org/10.2337/db26-1753-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055419","R0055419.pdf","paywalled","randomized_trial","RACHEL L. HUYNH","2026","1265-OR: Tirzepatide: Effect on Insulin Resistance and Human Fat Cells","Diabetes","American Diabetes Association","10.2337/db26-1265-or","https://doi.org/10.2337/db26-1265-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055427","R0055427.pdf","paywalled","randomized_trial","Helena Orehovački","2026","MULTIDISCIPLINARY COMPREHENSIVE MEDICATION MANAGEMENT OPTIMIZES CARDIOMETABOLIC OUTCOMES IN CARDIO-RENAL-METABOLIC DISEASE","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001196596.57903.71","https://doi.org/10.1097/01.hjh.0001196596.57903.71",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055441","R0055441.pdf","paywalled","randomized_trial","Edward Leatham","2026","Ten Minutes Hard","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22122590","https://doi.org/10.5281/zenodo.22122590",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055493","R0055493.pdf","paywalled","randomized_trial","Dr SANJAY KALRA","2026","Pragmatic Considerations in Switching to Semaglutide for Obesity Management: Real- World Perspectives",null,null,"10.59793/bzsxq840","https://doi.org/10.59793/bzsxq840",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055524","R0055524.pdf","paywalled","randomized_trial","Telmo Eduardo Salas Joya","2026","SÍNDROME CARDIOVASCULAR–RIÑÓN–METABOLISMO (CKM): AVANCES EN LA PREVENCIÓN Y EL MANEJO INTEGRAL BASADOS EN EVIDENCIA CIENTÍFICA","VitalyScience Revista Científica Multidisciplinaria","InvestiGO","10.56519/mjmh0g15","https://doi.org/10.56519/mjmh0g15",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055562","R0055562.pdf","paywalled","randomized_trial","Thorsten Kliem","2026","REDUCTION OF PULSE PRESSURE BY TREATMENT WITH GLP-1 RECEPTOR AGONIST SEMAGLUTIDE IS ASSOCIATED WITH REDUCTION IN BMI: ANALYSIS OF A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED STUDY","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001195672.80545.cb","https://doi.org/10.1097/01.hjh.0001195672.80545.cb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055697","R0055697.pdf","paywalled","randomized_trial","MYUNG-JOO CHOI","2026","2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db26-2847-lb","https://doi.org/10.2337/db26-2847-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055698","R0055698.pdf","paywalled","randomized_trial","S Jacob","2026","Control of eating with semaglutide 7.2 mg in adults with obesity: The STEP UP trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819891","https://doi.org/10.1055/s-0046-1819891",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055754","R0055754.pdf","paywalled","randomized_trial","Jiandong Yuan","2026","2845-LB: Safety, Pharmacokinetics, and Weight Loss Effects of the Oral GLP-1/GIP Dual Agonist BGM0504 in Healthy and Overweight or Obese Adults: A Phase 1 Multiple-Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db26-2845-lb","https://doi.org/10.2337/db26-2845-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055756","R0055756.pdf","paywalled","randomized_trial","Sidra Saif","2026","Beyond BMI and Reflux: Metabolic Phenotypes and Metabolic Change as Modifiers of Barrett’s Esophagus Progression — A Scoping Review","Open Science Framework",null,"10.17605/osf.io/kpnqs","https://doi.org/10.17605/osf.io/kpnqs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055761","R0055761.pdf","paywalled","randomized_trial","Noémie Roland","2026","Use of GLP-1RA and risk of major adverse cardiovascular events in women with PMOS","Open Science Framework",null,"10.17605/osf.io/h4z9c","https://doi.org/10.17605/osf.io/h4z9c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055975","R0055975.pdf","paywalled","randomized_trial","Icy Ballentine","2026","Weight Regain and Maintenance After Discontinuation of Anti-Obesity Medications: A Scoping Review","Open Science Framework",null,"10.17605/osf.io/w5me8","https://doi.org/10.17605/osf.io/w5me8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056064","R0056064.pdf","paywalled","randomized_trial","Swaliha Sulfi*1, Shifana S.2, Ameen Labba N.3, Dr. Rincy Robinson","2026","SGLT2 INHIBITORS AND GLP-1 RAS: REAL-WORLD CARDIOVASCULAR OUTCOMES","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23031244","https://doi.org/10.5281/zenodo.23031244",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056138","R0056138.pdf","paywalled","randomized_trial","Md Siam Hayat","2026","Type 2 Diabetes Mellitus in Kyrgyzstan: Epidemiology, Risk Factors, Complications, and Clinical Management Challenges in a Resource-Limited Central Asian Setting — A Comprehensive Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23192682","https://doi.org/10.5281/zenodo.23192682",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056159","R0056159.pdf","paywalled","randomized_trial","Lee M Kaplan","2026","Plain Language Summary of the Manuscript: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.34012725","https://doi.org/10.60915/boehringer-figshare.34012725",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056275","R0056275.pdf","paywalled","randomized_trial","Raj Patel","2026","Beyond Telogen Effluvium: Alopecia Phenotypes Associated With GLP-1 Receptor Agonists and a Dermatologist-Led Management Framework (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.113526","https://doi.org/10.2196/preprints.113526",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056349","R0056349.pdf","paywalled","randomized_trial","Meilinda Ayu Saputri","2026","Efektivitas dan Keamanan Pengobatan Farmakologis pada Pasien Diabetes Melitus Tipe 2: Systematic Literature Review","Jurnal Lantera Ilmiah Keperawatan",null,"10.52120/p1w10b74","https://doi.org/10.52120/p1w10b74",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056412","R0056412.pdf","paywalled","randomized_trial","Lee M. Kaplan","2026","Graphical Abstract: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.33995691","https://doi.org/10.60915/boehringer-figshare.33995691",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056420","R0056420.pdf","paywalled","randomized_trial","Mateusz Stefański","2026","Emerging and Disease-Modifying Treatments for Alzheimer’s Disease: Current Evidence, Safety, and Future Directions","African Journal of Biomedical Research",null,"10.69980/p3pezf52","https://doi.org/10.69980/p3pezf52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056441","R0056441.pdf","paywalled","randomized_trial","Hazim Bozeyeh","2026","Metabolic Syndrome in Patients Treated with Second-Generation Antipsychotics: Prevention, Monitoring and Management","African Journal of Biomedical Research",null,"10.69980/ajbr.v29i1s.9727","https://doi.org/10.69980/ajbr.v29i1s.9727",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056569","R0056569.pdf","paywalled","randomized_trial","Marta Śliwińska","2026","Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: Metabolic Preconditioning and Reproductive Implications","African Journal of Biomedical Research",null,"10.53555/ajbr.v29i1s.9334","https://doi.org/10.53555/ajbr.v29i1s.9334",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056581","R0056581.pdf","paywalled","randomized_trial","Paula Biernat","2026","The Impact of GLP-1 Receptor Agonists on the Gut-Brain Axis: Adverse Effects or Therapeutic Mechanism? A Narrative Review","African Journal of Biomedical Research",null,"10.69980/ajbr.v29i1s.9889","https://doi.org/10.69980/ajbr.v29i1s.9889",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056652","R0056652.pdf","paywalled","randomized_trial","MUHAMMAD SULTHAN ARYA RASYAD","2026","GLP-1 Receptor Agonist as Modulators of Immunometabolic Pathways in Inflammatory Skin Diseases: A Scoping Review of Omics, Immune Regulation, and Exercise-Technology Interplay","Open Science Framework",null,"10.17605/osf.io/sg78j","https://doi.org/10.17605/osf.io/sg78j",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056658","R0056658.pdf","paywalled","randomized_trial","Rahul Garg","2026","Body Weight is Not Enough to Monitor Incretin Therapy in India","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23301837","https://doi.org/10.5281/zenodo.23301837",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056687","R0056687.pdf","paywalled","randomized_trial","Cline L","2026","Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study.","The Journal of cardiovascular nursing","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcn.0000000000001370","https://doi.org/10.1097/jcn.0000000000001370","42864707","https://pubmed.ncbi.nlm.nih.gov/42864707/",null,null],["2","R0056718","R0056718.pdf","paywalled","randomized_trial","Dr. Depti Bellani1*, Dr. Anish Desai1, Dr. Sunaina Anand1, Dr. Shivani Mishra1, Dr. Srishti Priya Maldahiar1","2026","WEIGHT REBOUND AFTER GLP-1 DISCONTINUATION IN INDIA: A HIGH-RISK CARDIOMETABOLIC TRANSITION","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23275960","https://doi.org/10.5281/zenodo.23275960",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0057008","R0057008.pdf","paywalled","randomized_trial","Paccou J","2026","Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000962","https://doi.org/10.1097/med.0000000000000962","42083415","https://pubmed.ncbi.nlm.nih.gov/42083415/",null,null],["2","R0001248","R0001248.pdf","paywalled","randomized_trial","Gupta P","2025","Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112434","https://doi.org/10.1016/j.diabres.2025.112434","40849048","https://pubmed.ncbi.nlm.nih.gov/40849048/",null,null],["2","R0001391","R0001391.pdf","paywalled","randomized_trial","He X","2025","Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.","European journal of medicinal chemistry","Elsevier BV","10.1016/j.ejmech.2025.118163","https://doi.org/10.1016/j.ejmech.2025.118163","40975962","https://pubmed.ncbi.nlm.nih.gov/40975962/",null,null],["2","R0001646","R0001646.pdf","paywalled","randomized_trial","Wu Y","2025","Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.","Current heart failure reports","Springer Science and Business Media LLC","10.1007/s11897-025-00722-z","https://doi.org/10.1007/s11897-025-00722-z","41160296","https://pubmed.ncbi.nlm.nih.gov/41160296/",null,null],["2","R0001699","R0001699.pdf","paywalled","randomized_trial","Shirani A","2025","Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2587277","https://doi.org/10.1080/13543784.2025.2587277","41196232","https://pubmed.ncbi.nlm.nih.gov/41196232/",null,null],["2","R0001750","R0001750.pdf","paywalled","randomized_trial","Atiquzzaman N","2025","GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-025-03898-4","https://doi.org/10.1007/s00228-025-03898-4","40835981","https://pubmed.ncbi.nlm.nih.gov/40835981/",null,null],["2","R0001758","R0001758.pdf","paywalled","randomized_trial","Rosenstock J","2025","Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70022","https://doi.org/10.1111/dom.70022","40808573","https://pubmed.ncbi.nlm.nih.gov/40808573/",null,null],["2","R0001804","R0001804.pdf","paywalled","randomized_trial","Wu JY","2025","Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study.","Journal of the American Medical Directors Association","Elsevier BV","10.1016/j.jamda.2025.105901","https://doi.org/10.1016/j.jamda.2025.105901","41075815","https://pubmed.ncbi.nlm.nih.gov/41075815/",null,null],["2","R0002239","R0002239.pdf","paywalled","randomized_trial","Maher S","2025","GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.9062","https://doi.org/10.36849/jdd.9062","41329148","https://pubmed.ncbi.nlm.nih.gov/41329148/",null,null],["2","R0002308","R0002308.pdf","paywalled","randomized_trial","Dal-Ré R","2025","Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.","Annals of the New York Academy of Sciences","Wiley","10.1111/nyas.70025","https://doi.org/10.1111/nyas.70025","40760786","https://pubmed.ncbi.nlm.nih.gov/40760786/",null,null],["2","R0002312","R0002312.pdf","paywalled","randomized_trial","Costa TA","2025","Advances in the management of obesity and heart failure: latest evidence from clinical trials.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001214","https://doi.org/10.1097/hco.0000000000001214","39998461","https://pubmed.ncbi.nlm.nih.gov/39998461/",null,null],["2","R0002466","R0002466.pdf","paywalled","randomized_trial","Inoue K","2025","Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-02648","https://doi.org/10.7326/annals-24-02648","40690769","https://pubmed.ncbi.nlm.nih.gov/40690769/",null,null],["2","R0002605","R0002605.pdf","paywalled","randomized_trial","Samanta A","2025","Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.","International ophthalmology clinics","Ovid Technologies (Wolters Kluwer Health)","10.1097/iio.0000000000000541","https://doi.org/10.1097/iio.0000000000000541","39710901","https://pubmed.ncbi.nlm.nih.gov/39710901/",null,null],["2","R0002753","R0002753.pdf","paywalled","randomized_trial","Kim BI","2025","Utilization of Glucagon-Like Peptide-1 Receptor Agonist at the Time of Total Hip Arthroplasty for Patients Who Have Morbid Obesity.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.12.008","https://doi.org/10.1016/j.arth.2024.12.008","39662850","https://pubmed.ncbi.nlm.nih.gov/39662850/",null,null],["2","R0002787","R0002787.pdf","paywalled","randomized_trial","Lehenbauer KS","2025","The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-025-10579-y","https://doi.org/10.1007/s10741-025-10579-y","41370018","https://pubmed.ncbi.nlm.nih.gov/41370018/",null,null],["2","R0003045","R0003045.pdf","paywalled","randomized_trial","Nadeem N","2025","In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2025.07.002","https://doi.org/10.1016/j.jcjd.2025.07.002","40712696","https://pubmed.ncbi.nlm.nih.gov/40712696/",null,null],["2","R0003155","R0003155.pdf","paywalled","randomized_trial","Targher G","2025","Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.","Gut","BMJ","10.1136/gutjnl-2024-334023","https://doi.org/10.1136/gutjnl-2024-334023","39592207","https://pubmed.ncbi.nlm.nih.gov/39592207/",null,null],["2","R0003274","R0003274.pdf","paywalled","randomized_trial","Saeed ZI","2025","Noninsulin Therapies in Management of Type 1 Diabetes.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.06.027","https://doi.org/10.1016/j.eprac.2025.06.027","40618954","https://pubmed.ncbi.nlm.nih.gov/40618954/",null,null],["2","R0003469","R0003469.pdf","paywalled","randomized_trial","Salama L","2025","On the front lines of cardiovascular-kidney-metabolic syndrome: Review of GLP-1 and Dual GLP-1/GIP receptor agonists in CV and kidney health.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxaf053","https://doi.org/10.1093/ajhp/zxaf053","40197714","https://pubmed.ncbi.nlm.nih.gov/40197714/",null,null],["2","R0003522","R0003522.pdf","paywalled","randomized_trial","Paccou J","2025","Effects of weight-loss interventions on bone health in people living with obesity.","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","Oxford University Press (OUP)","10.1093/jbmr/zjaf135","https://doi.org/10.1093/jbmr/zjaf135","41042228","https://pubmed.ncbi.nlm.nih.gov/41042228/",null,null],["2","R0003807","R0003807.pdf","paywalled","randomized_trial","O'Leary S","2025","Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study.","Journal of neurosurgery","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2025.1.jns242357","https://doi.org/10.3171/2025.1.jns242357","40344770","https://pubmed.ncbi.nlm.nih.gov/40344770/",null,null],["2","R0003833","R0003833.pdf","paywalled","randomized_trial","Bilgin E","2025","Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions.","Autoimmunity reviews","Elsevier BV","10.1016/j.autrev.2025.103864","https://doi.org/10.1016/j.autrev.2025.103864","40617296","https://pubmed.ncbi.nlm.nih.gov/40617296/",null,null],["2","R0003987","R0003987.pdf","paywalled","randomized_trial","Zheng L","2025","Phase I study of the oral GLP-1 receptor agonist DA-302168S: Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70159","https://doi.org/10.1111/dom.70159","40994059","https://pubmed.ncbi.nlm.nih.gov/40994059/",null,null],["2","R0004143","R0004143.pdf","paywalled","randomized_trial","Kim BI","2025","Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA.","The Journal of bone and joint surgery. American volume","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.24.00468","https://doi.org/10.2106/jbjs.24.00468","39719003","https://pubmed.ncbi.nlm.nih.gov/39719003/",null,null],["2","R0004155","R0004155.pdf","paywalled","randomized_trial","Arraf A","2025","Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2601050","https://doi.org/10.1080/14656566.2025.2601050","41406130","https://pubmed.ncbi.nlm.nih.gov/41406130/",null,null],["2","R0004165","R0004165.pdf","paywalled","randomized_trial","Yammine L","2025","Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.","Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","Oxford University Press (OUP)","10.1093/ntr/ntaf005","https://doi.org/10.1093/ntr/ntaf005","39780397","https://pubmed.ncbi.nlm.nih.gov/39780397/",null,null],["2","R0004507","R0004507.pdf","paywalled","randomized_trial","Malas K","2025","The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2504702","https://doi.org/10.1080/14656566.2025.2504702","40340589","https://pubmed.ncbi.nlm.nih.gov/40340589/",null,null],["2","R0004559","R0004559.pdf","paywalled","randomized_trial","Wang Q","2025","Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16452","https://doi.org/10.1111/dom.16452","40470753","https://pubmed.ncbi.nlm.nih.gov/40470753/",null,null],["2","R0004565","R0004565.pdf","paywalled","randomized_trial","Henney AE","2025","Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1513/annalsats.202409-923oc","https://doi.org/10.1513/annalsats.202409-923oc","40590655","https://pubmed.ncbi.nlm.nih.gov/40590655/",null,null],["2","R0004652","R0004652.pdf","paywalled","randomized_trial","Yaron S","2025","Adherence and Effectiveness of Liraglutide in Adolescents with Obesity.","Childhood obesity (Print)","SAGE Publications","10.1177/21532176251385715","https://doi.org/10.1177/21532176251385715","41047941","https://pubmed.ncbi.nlm.nih.gov/41047941/",null,null],["2","R0004933","R0004933.pdf","paywalled","randomized_trial","Bussetty A","2025","Current and Future Implications of Weight Loss Drugs on Liver Disease.","Clinics in liver disease","Elsevier BV","10.1016/j.cld.2025.06.005","https://doi.org/10.1016/j.cld.2025.06.005","41109700","https://pubmed.ncbi.nlm.nih.gov/41109700/",null,null],["2","R0005107","R0005107.pdf","paywalled","randomized_trial","Buch A","2025","Novel oral agents in anti-obesity pharmacotherapy: A narrative review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16618","https://doi.org/10.1111/dom.16618","40662383","https://pubmed.ncbi.nlm.nih.gov/40662383/",null,null],["2","R0005117","R0005117.pdf","paywalled","randomized_trial","Lisik D","2025","Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea.","Sleep medicine clinics","Elsevier BV","10.1016/j.jsmc.2024.10.002","https://doi.org/10.1016/j.jsmc.2024.10.002","39894591","https://pubmed.ncbi.nlm.nih.gov/39894591/",null,null],["2","R0005330","R0005330.pdf","paywalled","randomized_trial","Albini A","2025","Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives.","Seminars in cancer biology","Elsevier BV","10.1016/j.semcancer.2025.07.008","https://doi.org/10.1016/j.semcancer.2025.07.008","40701453","https://pubmed.ncbi.nlm.nih.gov/40701453/",null,null],["2","R0005406","R0005406.pdf","paywalled","randomized_trial","Luo Y","2025","Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-025-02665-7","https://doi.org/10.1007/s40618-025-02665-7","40719951","https://pubmed.ncbi.nlm.nih.gov/40719951/",null,"ChiCTR:ChiCTR1800015914"],["2","R0005787","R0005787.pdf","paywalled","randomized_trial","Chen JJ","2025","Treatment and Monitoring of Idiopathic Intracranial Hypertension.","Continuum (Minneapolis, Minn.)","Ovid Technologies (Wolters Kluwer Health)","10.1212/cont.0000000000001586","https://doi.org/10.1212/cont.0000000000001586","40459312","https://pubmed.ncbi.nlm.nih.gov/40459312/",null,null],["2","R0006393","R0006393.pdf","paywalled","randomized_trial","Blum MF","2025","Risk-directed management of chronic kidney disease.","Nature reviews. Nephrology","Springer Science and Business Media LLC","10.1038/s41581-025-00931-8","https://doi.org/10.1038/s41581-025-00931-8","39885336","https://pubmed.ncbi.nlm.nih.gov/39885336/",null,null],["2","R0006564","R0006564.pdf","paywalled","randomized_trial","Zou Y","2025","Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16080","https://doi.org/10.1111/dom.16080","39618170","https://pubmed.ncbi.nlm.nih.gov/39618170/",null,null],["2","R0007555","R0007555.pdf","paywalled","randomized_trial","Cowart K","2025","Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109116","https://doi.org/10.1016/j.jdiacomp.2025.109116","40614622","https://pubmed.ncbi.nlm.nih.gov/40614622/",null,null],["2","R0008460","R0008460.pdf","paywalled","randomized_trial","Alnagar A","2025","Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review.","Current obesity reports","Springer Science and Business Media LLC","10.1007/s13679-025-00640-0","https://doi.org/10.1007/s13679-025-00640-0","40407960","https://pubmed.ncbi.nlm.nih.gov/40407960/",null,null],["2","R0009020","R0009020.pdf","paywalled","randomized_trial","Aslam B","2025","Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.23.04101-5","https://doi.org/10.23736/s2724-6507.23.04101-5","38127407","https://pubmed.ncbi.nlm.nih.gov/38127407/",null,null],["2","R0009059","R0009059.pdf","paywalled","randomized_trial","Acosta-Madiedo AS","2025","An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.9569","https://doi.org/10.36849/jdd.9569","41329144","https://pubmed.ncbi.nlm.nih.gov/41329144/",null,null],["2","R0009549","R0009549.pdf","paywalled","randomized_trial","Jia W","2025","Efficacy and safety of Efsubaglutide Alfa in \"overrun\" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70112","https://doi.org/10.1111/dom.70112","40977363","https://pubmed.ncbi.nlm.nih.gov/40977363/",null,null],["2","R0009755","R0009755.pdf","paywalled","randomized_trial","Jensterle M","2025","Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf278","https://doi.org/10.1210/clinem/dgaf278","40341357","https://pubmed.ncbi.nlm.nih.gov/40341357/",null,null],["2","R0010207","R0010207.pdf","paywalled","randomized_trial","Sun M","2025","Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101623","https://doi.org/10.1016/j.diabet.2025.101623","39952607","https://pubmed.ncbi.nlm.nih.gov/39952607/",null,null],["2","R0010467","R0010467.pdf","paywalled","randomized_trial","Wu JY","2025","Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112279","https://doi.org/10.1016/j.diabres.2025.112279","40412626","https://pubmed.ncbi.nlm.nih.gov/40412626/",null,null],["2","R0011137","R0011137.pdf","paywalled","randomized_trial","Iacobellis G","2025","Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2024.08.019","https://doi.org/10.1016/j.numecd.2024.08.019","39277531","https://pubmed.ncbi.nlm.nih.gov/39277531/",null,null],["2","R0011779","R0011779.pdf","paywalled","randomized_trial","Ozatik FY","2025","The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.","Journal of molecular histology","Springer Science and Business Media LLC","10.1007/s10735-025-10440-4","https://doi.org/10.1007/s10735-025-10440-4","40341588","https://pubmed.ncbi.nlm.nih.gov/40341588/",null,null],["2","R0012250","R0012250.pdf","paywalled","randomized_trial","Feng P","2025","The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177972","https://doi.org/10.1016/j.ejphar.2025.177972","40683437","https://pubmed.ncbi.nlm.nih.gov/40683437/",null,null],["2","R0012496","R0012496.pdf","paywalled","randomized_trial","Theodorakopoulou M","2025","SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfae207","https://doi.org/10.1093/ndt/gfae207","39304535","https://pubmed.ncbi.nlm.nih.gov/39304535/",null,null],["2","R0012502","R0012502.pdf","paywalled","randomized_trial","Vidal J","2025","What is the evidence regarding the safety of new obesity pharmacotherapies.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01488-5","https://doi.org/10.1038/s41366-024-01488-5","38336863","https://pubmed.ncbi.nlm.nih.gov/38336863/",null,null],["2","R0012810","R0012810.pdf","paywalled","randomized_trial","Kanellis C","2025","The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system.","The Medical journal of Australia","Wiley","10.5694/mja2.52582","https://doi.org/10.5694/mja2.52582","39789665","https://pubmed.ncbi.nlm.nih.gov/39789665/",null,null],["2","R0012925","R0012925.pdf","paywalled","randomized_trial","Kelly DN","2025","Gastric point-of-care ultrasound in the GLP-1 receptor agonist era: clinical impact and competency.","Anaesthesia","Wiley","10.1111/anae.16548","https://doi.org/10.1111/anae.16548","39815651","https://pubmed.ncbi.nlm.nih.gov/39815651/",null,null],["2","R0013004","R0013004.pdf","paywalled","randomized_trial","Zhang H","2025","Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001003","https://doi.org/10.1097/crd.0000000000001003","40679509","https://pubmed.ncbi.nlm.nih.gov/40679509/",null,null],["2","R0013152","R0013152.pdf","paywalled","randomized_trial","Nelson AJ","2025","Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.","American heart journal","Elsevier BV","10.1016/j.ahj.2024.12.006","https://doi.org/10.1016/j.ahj.2024.12.006","39716628","https://pubmed.ncbi.nlm.nih.gov/39716628/",null,null],["2","R0015298","R0015298.pdf","paywalled","randomized_trial","Zhang W","2025","Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.","Current gastroenterology reports","Springer Science and Business Media LLC","10.1007/s11894-025-01026-x","https://doi.org/10.1007/s11894-025-01026-x","41258558","https://pubmed.ncbi.nlm.nih.gov/41258558/",null,null],["2","R0015647","R0015647.pdf","paywalled","randomized_trial","Niu S","2025","[Effect of semaglutide on serum metabolomics in obese patients with type 2 diabetes mellitus complicated with metabolic-associated fatty liver disease].","Zhonghua nei ke za zhi",null,"10.3760/cma.j.cn112138-20250424-00235","https://doi.org/10.3760/cma.j.cn112138-20250424-00235","41338557","https://pubmed.ncbi.nlm.nih.gov/41338557/",null,null],["2","R0015722","R0015722.pdf","paywalled","randomized_trial","Wang R","2025","The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177827","https://doi.org/10.1016/j.ejphar.2025.177827","40516844","https://pubmed.ncbi.nlm.nih.gov/40516844/",null,null],["2","R0015725","R0015725.pdf","paywalled","randomized_trial","Frey S","2025","Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70003","https://doi.org/10.1002/oby.70003","40898674","https://pubmed.ncbi.nlm.nih.gov/40898674/",null,null],["2","R0016066","R0016066.pdf","paywalled","randomized_trial","Tian J","2025","Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.","Hormones (Athens, Greece)","Springer Science and Business Media LLC","10.1007/s42000-025-00649-z","https://doi.org/10.1007/s42000-025-00649-z","40214965","https://pubmed.ncbi.nlm.nih.gov/40214965/",null,null],["2","R0016377","R0016377.pdf","paywalled","randomized_trial","Garg SK","2025","Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0481","https://doi.org/10.1089/dia.2024.0481","40098470","https://pubmed.ncbi.nlm.nih.gov/40098470/",null,null],["2","R0016749","R0016749.pdf","paywalled","randomized_trial","Nigro S","2025","Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08155-2","https://doi.org/10.1007/s11695-025-08155-2","40779281","https://pubmed.ncbi.nlm.nih.gov/40779281/",null,null],["2","R0016963","R0016963.pdf","paywalled","randomized_trial","Vergallo R","2025","Weekly Journal Scan: semaglutide in patients with peripheral artery disease and diabetes-a real STRIDE in their management?","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf535","https://doi.org/10.1093/eurheartj/ehaf535","40910353","https://pubmed.ncbi.nlm.nih.gov/40910353/",null,null],["2","R0017000","R0017000.pdf","paywalled","randomized_trial","Guerdjikova AI","2025","Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.","International journal of psychiatry in clinical practice","Informa UK Limited","10.1080/13651501.2025.2549307","https://doi.org/10.1080/13651501.2025.2549307","40849800","https://pubmed.ncbi.nlm.nih.gov/40849800/",null,null],["2","R0017247","R0017247.pdf","paywalled","randomized_trial","Liuzzo G","2025","Weekly Journal Scan: The ESSENCE of metabolic risk: targeting metabolic dysfunction-associated steatohepatitis with semaglutide.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf420","https://doi.org/10.1093/eurheartj/ehaf420","40679608","https://pubmed.ncbi.nlm.nih.gov/40679608/",null,null],["2","R0017253","R0017253.pdf","paywalled","randomized_trial","Lahooti A","2025","A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07671-5","https://doi.org/10.1007/s11695-025-07671-5","39885064","https://pubmed.ncbi.nlm.nih.gov/39885064/",null,null],["2","R0017428","R0017428.pdf","paywalled","randomized_trial","Pena C","2025","Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review.","Minerva medica","Edizioni Minerva Medica","10.23736/s0026-4806.25.09607-7","https://doi.org/10.23736/s0026-4806.25.09607-7","40146047","https://pubmed.ncbi.nlm.nih.gov/40146047/",null,null],["2","R0017494","R0017494.pdf","paywalled","randomized_trial","Nomoto H","2025","Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae213","https://doi.org/10.1210/clinem/dgae213","38695547","https://pubmed.ncbi.nlm.nih.gov/38695547/",null,null],["2","R0017779","R0017779.pdf","paywalled","randomized_trial","Golub IS","2025","The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2025.104036","https://doi.org/10.1016/j.numecd.2025.104036","40287313","https://pubmed.ncbi.nlm.nih.gov/40287313/",null,null],["2","R0017936","R0017936.pdf","paywalled","randomized_trial","Günther M","2025","[Renal replacement therapy in Germany: An overview with a clinical focus].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/a-2261-3753","https://doi.org/10.1055/a-2261-3753","39809432","https://pubmed.ncbi.nlm.nih.gov/39809432/",null,null],["2","R0018029","R0018029.pdf","paywalled","randomized_trial","Eldor R","2025","Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.","Diabetes care","American Diabetes Association","10.2337/dc25-0690","https://doi.org/10.2337/dc25-0690","40673973","https://pubmed.ncbi.nlm.nih.gov/40673973/",null,null],["2","R0018107","R0018107.pdf","paywalled","randomized_trial","Khalifa AK","2025","Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1-7/MasR signaling in male albino rats: in vivo and in silico study.","International immunopharmacology","Elsevier BV","10.1016/j.intimp.2025.115261","https://doi.org/10.1016/j.intimp.2025.115261","40706208","https://pubmed.ncbi.nlm.nih.gov/40706208/",null,null],["2","R0018308","R0018308.pdf","paywalled","randomized_trial","Ji L","2025","Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70036","https://doi.org/10.1111/dom.70036","40859882","https://pubmed.ncbi.nlm.nih.gov/40859882/",null,null],["2","R0018835","R0018835.pdf","paywalled","randomized_trial","Tavares Bello C","2025","Liraglutide in the management of obesity: real world data (Portugal).","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.24.04161-7","https://doi.org/10.23736/s2724-6507.24.04161-7","39012306","https://pubmed.ncbi.nlm.nih.gov/39012306/",null,null],["2","R0020560","R0020560.pdf","paywalled","randomized_trial","Fox CK","2025","Current and future state of pharmacological management of pediatric obesity.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01465-y","https://doi.org/10.1038/s41366-024-01465-y","38321079","https://pubmed.ncbi.nlm.nih.gov/38321079/",null,null],["2","R0020604","R0020604.pdf","paywalled","randomized_trial","Skov Breum M","2025","Estimation of Interventional Effects in Clinical Trials With a Repeatedly Measured Mediator.","Statistics in medicine","Wiley","10.1002/sim.70305","https://doi.org/10.1002/sim.70305","41201167","https://pubmed.ncbi.nlm.nih.gov/41201167/",null,null],["2","R0021427","R0021427.pdf","paywalled","randomized_trial","Harby SA","2025","Liraglutide and denatonium benzoate attenuate T2DM-induced metabolic, neurological, and testicular changes in rats: Targeting oxidative stress, inflammation, and BCRP transporter.","Journal of molecular histology","Springer Science and Business Media LLC","10.1007/s10735-025-10355-0","https://doi.org/10.1007/s10735-025-10355-0","39881033","https://pubmed.ncbi.nlm.nih.gov/39881033/",null,null],["2","R0029038","R0029038.pdf","paywalled","randomized_trial","Qin YF","2025","A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2500303","https://doi.org/10.1080/13543784.2025.2500303","40328758","https://pubmed.ncbi.nlm.nih.gov/40328758/",null,null],["2","R0029561","R0029561.pdf","paywalled","randomized_trial","Marx N","2025","The SOUL trial: another important study for the reduction of CV risk in individuals with type 2 diabetes.","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvaf216","https://doi.org/10.1093/cvr/cvaf216","41364656","https://pubmed.ncbi.nlm.nih.gov/41364656/",null,null],["2","R0029597","R0029597.pdf","paywalled","randomized_trial","Pack AI","2025","Is COMISA another opportunity for use of incretin drugs?","Sleep","Oxford University Press (OUP)","10.1093/sleep/zsaf254","https://doi.org/10.1093/sleep/zsaf254","40971532","https://pubmed.ncbi.nlm.nih.gov/40971532/",null,null],["2","R0029621","R0029621.pdf","paywalled","randomized_trial","Crutchlow M","2025","Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70014","https://doi.org/10.1111/dom.70014","40767101","https://pubmed.ncbi.nlm.nih.gov/40767101/",null,null],["2","R0029970","R0029970.pdf","paywalled","randomized_trial","Shanti Vaidya S","2025","Glucagon-Like Peptide-1 Agonists and Pediatric Obesity.","Pediatrics in review","American Academy of Pediatrics (AAP)","10.1542/pir.2024-006455","https://doi.org/10.1542/pir.2024-006455","39889784","https://pubmed.ncbi.nlm.nih.gov/39889784/",null,null],["2","R0030138","R0030138.pdf","paywalled","randomized_trial","Sun CC","2025","Risk and Protective Factors for Ocular Surface Disease in Patients with Type 2 Diabetic Mellitus: A Retrospective Cohort Study.","Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","SAGE Publications","10.1089/jop.2024.0175","https://doi.org/10.1089/jop.2024.0175","40485291","https://pubmed.ncbi.nlm.nih.gov/40485291/",null,null],["2","R0030232","R0030232.pdf","paywalled","randomized_trial","Hemmati MA","2025","Glp-1 mimetic of sitagliptin improved oxidative stress and liver function tests via suppressing NOX-4 enzyme in hepatic tissues of diabetic rats.","Biochemical and biophysical research communications","Elsevier BV","10.1016/j.bbrc.2025.151455","https://doi.org/10.1016/j.bbrc.2025.151455","39923462","https://pubmed.ncbi.nlm.nih.gov/39923462/",null,null],["2","R0031251","R0031251.pdf","paywalled","randomized_trial",null,"2025","Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.374505","https://doi.org/10.1211/pj.2025.1.374505",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031825","R0031825.pdf","paywalled","randomized_trial","Dr Shoaib Ahmed khan,Almas Khan,Dr. Sajid Usman Shah","2025","ROLE OF GLP-1 AGONISTS IN THE TREATMENT OF OBESITY-RELATED GASTROINTESTINAL DISORDERS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.16949195","https://doi.org/10.5281/zenodo.16949195",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032147","R0032147.pdf","paywalled","randomized_trial","Dr.Salve M.T Tarate K.M","2025","A Study on Weight Loss Cause as per the Side Effect of Liraglutide","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18074704","https://doi.org/10.5281/zenodo.18074704",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032638","R0032638.pdf","paywalled","randomized_trial","Rodrigo Rodrigues Pache","2025","EFICÁCIA E SEGURANÇA DA LIRAGLUTIDA NA OBESIDADE EM CRIANÇAS E ADOLESCENTES: UMA REVISÃO INTEGRATIVA","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/dt10202505221516","https://doi.org/10.69849/revistaft/dt10202505221516",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032669","R0032669.pdf","paywalled","randomized_trial","JINZI JASON WU","2025","750-P: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db25-750-p","https://doi.org/10.2337/db25-750-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032691","R0032691.pdf","paywalled","randomized_trial","Jennifer E. Below","2025","2167-LB: Proteomic Changes in Mexican-Americans before and after Meals in Response to Semaglutide Therapy","Diabetes","American Diabetes Association","10.2337/db25-2167-lb","https://doi.org/10.2337/db25-2167-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032717","R0032717.pdf","paywalled","randomized_trial","Robert M. Stoekenbroek","2025","788-P: A Twelve-Week Trial of MET097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db25-788-p","https://doi.org/10.2337/db25-788-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032718","R0032718.pdf","paywalled","randomized_trial","Lynda Tussey","2025","1708-P: Development of a Needle-Free, Self-Applied Microarray Patch for GLP-1 Delivery","Diabetes","American Diabetes Association","10.2337/db25-1708-p","https://doi.org/10.2337/db25-1708-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032790","R0032790.pdf","paywalled","randomized_trial","Hui Wang","2025","1616-P: Effect of Mazdutide on MASH Fibrosis—Targeting the Liver–Gut Axis and Microbiome","Diabetes","American Diabetes Association","10.2337/db25-1616-p","https://doi.org/10.2337/db25-1616-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032913","R0032913.pdf","paywalled","randomized_trial","Cibele Cardoso Amaro","2025","TIRZEPATIDA: A REVOLUÇÃO NO MANEJO DA DIABETES TIPO 2 E OBESIDADE- AVANÇOS E PERSPECTIVAS","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/ra10202506112238","https://doi.org/10.69849/revistaft/ra10202506112238",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032914","R0032914.pdf","paywalled","randomized_trial","In‐Gyu Je","2025","1983-LB: A Phase 1 Study of ID110521156, a Small Molecule Glucagon-Like Peptide 1 Receptor Agonist, in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db25-1983-lb","https://doi.org/10.2337/db25-1983-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06063291; ClinicalTrials.gov:NCT06635226"],["2","R0032983","R0032983.pdf","paywalled","randomized_trial","Mary Baun","2025","GLP-1 Agonists and Orthopedic Surgery: A Review of Their Impact on Bone Metabolism, Wound Healing, and Surgical Outcomes","Journal of the American Osteopathic Academy of Orthopedics","American Osteopathic Academy of Orthopedics","10.70709/r2fykae2uu","https://doi.org/10.70709/r2fykae2uu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033034","R0033034.pdf","paywalled","randomized_trial","BANSHI D. SABOO","2025","27-PUB: Enhanced Glycemic Control and Weight Benefits of Insulin Glargine plus lixisenatide vs. Insulin Glargine in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-27-pub","https://doi.org/10.2337/db25-27-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033206","R0033206.pdf","paywalled","randomized_trial",null,"2025","High-Impact Clinical Trials and Studies","Journal of the American College of Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.1097/xcs.0000000000001600","https://doi.org/10.1097/xcs.0000000000001600",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03636893; ClinicalTrials.gov:NCT04616131; ClinicalTrials.gov:NCT01022567"],["2","R0033265","R0033265.pdf","paywalled","randomized_trial","Juliana Lopez de Oliveira","2025","Liraglutide, a GLP-1 Receptor Agonist, Improves Metabolic Profile and Kidney Function in a Rat Model of Obesity-Induced Kidney Injury","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025z514be0y","https://doi.org/10.1681/asn.2025z514be0y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033285","R0033285.pdf","paywalled","randomized_trial","Candy Goulette","2025","GLP-1RAs Improve Lung Cancer Outcomes and Tumor Growth Control","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000000000000234","https://doi.org/10.1097/01.cot.0000000000000234",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033486","R0033486.pdf","paywalled","randomized_trial","W Le Roux, Carel","2025","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial”","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29063129","https://doi.org/10.60915/boehringer-figshare.29063129",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033516","R0033516.pdf","paywalled","randomized_trial","Tejasaradhya N","2025","Advancing Diabetes Care: A Comprehensive Review of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus – Addressing Efficacy, Safety, and Future Perspectives","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17777792","https://doi.org/10.5281/zenodo.17777792",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033566","R0033566.pdf","paywalled","randomized_trial","Challa Venku Reddy*","2025","PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD): A COMPREHENSIVE REVIEW","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17368244","https://doi.org/10.5281/zenodo.17368244",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033593","R0033593.pdf","paywalled","randomized_trial","Sarkani, Amir","2025","Glucagon-Like Peptide 1 Based Pharmacotherapy for Obesity: Clinical Benefits, Risks, and Access Challenges","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17457951","https://doi.org/10.5281/zenodo.17457951",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033848","R0033848.pdf","paywalled","randomized_trial","Acanfora, Matteo","2025","Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17101109","https://doi.org/10.5281/zenodo.17101109",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033918","R0033918.pdf","paywalled","randomized_trial","Birkenfeld, Andreas L.","2025","Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","Universitätsbibliothek Tübingen",null,"10.15496/publikation-111217","https://doi.org/10.15496/publikation-111217",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034415","R0034415.pdf","paywalled","randomized_trial","Su, Wilber W.","2025","Editorial introductions","Current Opinion in Cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001266","https://doi.org/10.1097/hco.0000000000001266",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034573","R0034573.pdf","paywalled","randomized_trial","Pranay Marlecha","2025","Abstract 4369713: Peripheral Artery Disease Outcomes in GLP-1RA Trials: Meta-Regression of SBP, HbA1c, and Weight.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4369713","https://doi.org/10.1161/circ.152.suppl_3.4369713",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034695","R0034695.pdf","paywalled","randomized_trial","Matthias Hepprich","2025","Exenatide for diagnosing endogenous hyperinsulinemic hypoglycaemia - a randomised placebo-controlled, double-blind, cross-over proof-of-principle study - fast study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p896","https://doi.org/10.1530/endoabs.110.p896",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034880","R0034880.pdf","paywalled","randomized_trial","Su, Zehao","2025","Improving precision of cumulative incidence estimates in randomized controlled trials with external controls","Research at the University of Copenhagen (University of Copenhagen)",null,"10.48550/arxiv.2506.18415","https://doi.org/10.48550/arxiv.2506.18415",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035919","R0035919.pdf","paywalled","randomized_trial","Chris Bannon","2025","INVESTIGATING ENTEROENDOCRINE HORMONE LEVELS IN CHRONIC DIARRHOEA AND OBESITY","Apollo (University of Cambridge)",null,"10.17863/cam.130523","https://doi.org/10.17863/cam.130523",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036543","R0036543.pdf","paywalled","randomized_trial","Cade Shadbolt","2025","Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Open Science Framework",null,"10.17605/osf.io/vsg6f","https://doi.org/10.17605/osf.io/vsg6f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036563","R0036563.pdf","paywalled","randomized_trial","Borghi, Rodrigo Nogueira","2025","Reward Dysregulation, Delay Aversion and Rewarded Perseveration in Adult ADHD: A Two-Arm Neuroimaging and GLP-1 Modulation Study of Habenular Circuits","Open Science Framework",null,"10.17605/osf.io/zxr8b","https://doi.org/10.17605/osf.io/zxr8b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036580","R0036580.pdf","paywalled","randomized_trial","Krüger, Nils","2025","Comparative effectiveness of the glucose-lowering agents semaglutide and tirzepatide vs sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients with peripheral vascular disease","Open Science Framework",null,"10.17605/osf.io/z4rxt","https://doi.org/10.17605/osf.io/z4rxt",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036846","R0036846.pdf","paywalled","randomized_trial","Alison Knopf","2025","RCT: Semaglutide reduces alcohol craving and consumption","Alcoholism & Drug Abuse Weekly","Wiley","10.1002/adaw.34470","https://doi.org/10.1002/adaw.34470",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037118","R0037118.pdf","paywalled","randomized_trial","Jobanputra, Rishi","2025","Exploring the interplay of pharmacotherapy and dietary weight loss interventions with whole body health including physical activity, physical function and body composition","University of Leicester",null,"10.25392/leicester.data.28333928","https://doi.org/10.25392/leicester.data.28333928",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037154","R0037154.pdf","paywalled","randomized_trial","Brandon Berman","2025","Abstract 4363248: GLP1 Receptor Agonist Use in Obstructive Sleep Apnea and the Risk of Developing Atrial Fibrillation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363248","https://doi.org/10.1161/circ.152.suppl_3.4363248",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037157","R0037157.pdf","paywalled","randomized_trial","Dalong Zhu","2025","306-OR: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)","Diabetes","American Diabetes Association","10.2337/db25-306-or","https://doi.org/10.2337/db25-306-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037293","R0037293.pdf","paywalled","randomized_trial","Erick Eduardo López Santos","2025","Cambio de Paradigma en la Insuficiencia Cardíaca con Fracción de Eyección Preservada: De la Nihilidad Terapéutica a la Medicina de Precisión","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18022384","https://doi.org/10.5281/zenodo.18022384",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037325","R0037325.pdf","paywalled","randomized_trial","Dhan Bahadur Shrestha","2025","Polypill: Shifting Paradigm from Concept to Practice in the Prevention of Myocardial Infarction","Cardiology","S. Karger AG","10.1159/000547098","https://doi.org/10.1159/000547098","40701142","https://pubmed.ncbi.nlm.nih.gov/40701142/",null,null],["2","R0037332","R0037332.pdf","paywalled","randomized_trial","Nisar Amin","2025","S5671 A Rare Case of Tirzepatide Induced Cholestatic Hepatitis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001150144.16302.ac","https://doi.org/10.14309/01.ajg.0001150144.16302.ac",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037591","R0037591.pdf","paywalled","randomized_trial","Jiaqiang Zhou","2025","874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes","Diabetes","American Diabetes Association","10.2337/db25-874-p","https://doi.org/10.2337/db25-874-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037838","R0037838.pdf","paywalled","randomized_trial","Bowen Tang","2025","Investigating drug effects on aging and alzheimer's disease using causal inference approaches",null,"Karolinska Institutet","10.69622/27889941","https://doi.org/10.69622/27889941",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037887","R0037887.pdf","paywalled","randomized_trial","Priyanka Pradhan","2025","S2765 Beyond Diabetes: The Role of Glucagon-Like Peptide-1 Receptor Agonists in Non-Diabetic NASH","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138520.35616.33","https://doi.org/10.14309/01.ajg.0001138520.35616.33",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038012","R0038012.pdf","paywalled","randomized_trial","Yongliang Fang","2025","LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebocontrolled, double-blind, multi-center trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)00422-2","https://doi.org/10.1016/s0168-8278(25)00422-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038025","R0038025.pdf","paywalled","randomized_trial","A Bhatty","2025","Standards of care in relation to diabetes status in patients with st-elevation myocardial infarction in 2023 - the european unified registries on heart care evaluation and randomized trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.2131","https://doi.org/10.1093/eurheartj/ehaf784.2131",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038069","R0038069.pdf","paywalled","randomized_trial","Linong Ji","2025","795-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Type 2 Diabetes (SHINING-1)","Diabetes","American Diabetes Association","10.2337/db25-795-p","https://doi.org/10.2337/db25-795-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038132","R0038132.pdf","paywalled","randomized_trial","SARAH OLKKOLA","2025","1692-P: Metabolic Assessment of Semaglutide (a GLP-1R Agonist) and Tirzepatide (a GLP-1R/GIPR Coagonist) in Diet-Induced Obese (DIO) Mice","Diabetes","American Diabetes Association","10.2337/db25-1692-p","https://doi.org/10.2337/db25-1692-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038192","R0038192.pdf","paywalled","randomized_trial","Jiandong Yuan","2025","303-OR: Efficacy and Safety of BGM0504 in Chinese Patients with Type 2 Diabetes—A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Semaglutide Positive-Controlled Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db25-303-or","https://doi.org/10.2337/db25-303-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038262","R0038262.pdf","paywalled","randomized_trial",null,"2025","Research","Bone and Joint 360","British Editorial Society of Bone & Joint Surgery","10.1302/2048-0105.143.360247","https://doi.org/10.1302/2048-0105.143.360247",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038347","R0038347.pdf","paywalled","randomized_trial","Silva, Thaiz","2025","EFFICACY AND SAFETY OF SEMAGLUTIDE FOR WEIGHT LOSS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17815944","https://doi.org/10.5281/zenodo.17815944",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038430","R0038430.pdf","paywalled","randomized_trial","Shahzeb Saeed","2025","Abstract 4364905: Beyond Glycemic Control: Cardiovascular Benefits of GLP-1 Receptor Agonists in Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4364905","https://doi.org/10.1161/circ.152.suppl_3.4364905",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038509","R0038509.pdf","paywalled","randomized_trial","Hoang Nhat Pham","2025","Abstract 4365569: GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Undergoing TAVI: A Real-World Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365569","https://doi.org/10.1161/circ.152.suppl_3.4365569",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038668","R0038668.pdf","paywalled","randomized_trial","Stine Maarbjerg","2025","141-OR: Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist","Diabetes","American Diabetes Association","10.2337/db25-141-or","https://doi.org/10.2337/db25-141-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038752","R0038752.pdf","paywalled","randomized_trial","Alkhouri, Naim","2025","Poster presented at AASLD 2025: Survodutide improved liver histology in people with MASH and moderate-to-severe fibrosis regardless of age, sex, ethnicity, or type 2 diabetes: Subgroup analysis of a randomized phase 2 trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.30437114","https://doi.org/10.60915/boehringer-figshare.30437114",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038838","R0038838.pdf","paywalled","randomized_trial","Isaac Tejeji","2025","787-P: GLP-1 Receptor Agonists as Monotherapy Lowered BMI Z-Score in Youth Newly Diagnosed with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-787-p","https://doi.org/10.2337/db25-787-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038909","R0038909.pdf","paywalled","randomized_trial","Ali Reza Rahmani","2025","Abstract 4367733: Dual Therapy With Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Is Associated With Improved Outcomes in Patients With Heart Failure: A Real-World Propensity-Matched Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367733","https://doi.org/10.1161/circ.152.suppl_3.4367733",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039087","R0039087.pdf","paywalled","randomized_trial","Domenica Rubino","2025","Treating obesity to optimize women’s health outcomes","Menopause The Journal of The North American Menopause Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/gme.0000000000002595","https://doi.org/10.1097/gme.0000000000002595","40446319","https://pubmed.ncbi.nlm.nih.gov/40446319/",null,null],["2","R0039093","R0039093.pdf","paywalled","randomized_trial","Brandon Berman","2025","Abstract 4370988: Outcomes Associated with GLP1 Receptor Agonist Use in Hypertrophic Cardiomyopathy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370988","https://doi.org/10.1161/circ.152.suppl_3.4370988",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039131","R0039131.pdf","paywalled","randomized_trial","A R Rahmani","2025","Newer GLP-1 receptor agonists and clinical outcomes in heart failure with reduced ejection fraction: a real-world comparative study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1530","https://doi.org/10.1093/eurheartj/ehaf784.1530",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039241","R0039241.pdf","paywalled","randomized_trial","Kara Eileen Rieth","2025","S2567 Insurance Coverage for GLP-1 Receptor Antagonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Analysis of the Top US Insurers","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137728.22009.20","https://doi.org/10.14309/01.ajg.0001137728.22009.20",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039273","R0039273.pdf","paywalled","randomized_trial","Saylor McFarland","2025","When the Shot Stops: A Scoping Review of Weight Trajectory and Metabolic Outcomes After Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Discontinuation","Open Science Framework",null,"10.17605/osf.io/6w2kh","https://doi.org/10.17605/osf.io/6w2kh",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039302","R0039302.pdf","paywalled","randomized_trial","Aihua Wu","2025","1857-LB: GLP-1 Receptor Agonist and GLP-1GIP Dual Agonist in Diabetic Kidney Disease","Diabetes","American Diabetes Association","10.2337/db25-1857-lb","https://doi.org/10.2337/db25-1857-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039385","R0039385.pdf","paywalled","randomized_trial","J Ling","2025","1973-LB: Glucagon-Like Peptide 1 Receptor Agonist with Basal Insulin vs. Basal-Bolus Regimen on Glycemic Variability and Time-in-Range in Type 2 Diabetes Patients with Chronic Kidney Disease—A Randomised Controlled Trial","Diabetes","American Diabetes Association","10.2337/db25-1973-lb","https://doi.org/10.2337/db25-1973-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039529","R0039529.pdf","paywalled","randomized_trial",null,"2025","Research","Bone and Joint 360","British Editorial Society of Bone & Joint Surgery","10.1302/2048-0105.145.360271","https://doi.org/10.1302/2048-0105.145.360271",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039584","R0039584.pdf","paywalled","randomized_trial","Sunny Kumar","2025","S1297 Endoscopic Gastric Remodeling Plus GLP-1 Receptor Agonist versus Endoscopic Gastric Remodeling Alone for Weight Loss","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132648.71698.3d","https://doi.org/10.14309/01.ajg.0001132648.71698.3d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039677","R0039677.pdf","paywalled","randomized_trial","Shaheen Tomah","2025","748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide","Diabetes","American Diabetes Association","10.2337/db25-748-p","https://doi.org/10.2337/db25-748-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039689","R0039689.pdf","paywalled","randomized_trial","Filippo Crea","2025","Focus on old and emerging risk factors: familial hypercholesterolaemia, lipoprotein(a), and skeletal muscle adiposity","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf124","https://doi.org/10.1093/eurheartj/ehaf124","40123524","https://pubmed.ncbi.nlm.nih.gov/40123524/",null,null],["2","R0039739","R0039739.pdf","paywalled","randomized_trial","François Briand","2025","1704-P: Survodutide Improves Heart Failure with Preserved Ejection Fraction and Dyslipidemia in a Diet-Induced Obese Hamster Model","Diabetes","American Diabetes Association","10.2337/db25-1704-p","https://doi.org/10.2337/db25-1704-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039755","R0039755.pdf","paywalled","randomized_trial","Lixin Guo","2025","837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin","Diabetes","American Diabetes Association","10.2337/db25-837-p","https://doi.org/10.2337/db25-837-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039832","R0039832.pdf","paywalled","randomized_trial","Benoît J. Arsenault","2025","Building a healthier future to prevent aortic stenosis","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf229","https://doi.org/10.1093/eurjpc/zwaf229","40685648","https://pubmed.ncbi.nlm.nih.gov/40685648/",null,null],["2","R0039881","R0039881.pdf","paywalled","randomized_trial","Muir, Kelsey","2025","Semaglutide Augments Vascular Proliferation and Cardiac Performance in a Large Animal Model of Ischemic Cardiomyopathy","Figshare",null,"10.6084/m9.figshare.30801743.v1","https://doi.org/10.6084/m9.figshare.30801743.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039947","R0039947.pdf","paywalled","randomized_trial","PENG  Hongye, LU  Chunli","2025","The Current Status and Challenges of Integrative Chinese and Western Medicine in the Treatment and Management of Prediabetes from a Proactive Health Perspective","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12114/j.issn.1007-9572.2024.0242","https://doi.org/10.12114/j.issn.1007-9572.2024.0242",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040583","R0040583.pdf","paywalled","randomized_trial","Gundtoft Uhrenholt, Nicolai","2025","Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia","University of Southern Denmark Research Portal (University of Southern Denmark)",null,"10.21996/a7ff50a6-55c8-451c-92d9-57b5688247d6","https://doi.org/10.21996/a7ff50a6-55c8-451c-92d9-57b5688247d6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041787","R0041787.pdf","paywalled","randomized_trial","Surov A.I. Surov","2025","The effect of glucagon-like peptide-1 receptor agonists on the course of gonarthrosis in obese patients with metabolic syndrome: a pilot randomized study","Фарматека","Bionika Media","10.18565/pharmateca.2025.8.80-88","https://doi.org/10.18565/pharmateca.2025.8.80-88",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042050","R0042050.pdf","paywalled","randomized_trial","Alicia Pacilio","2025","Target Trial Emulation Study of GLP-1 RAs for Depression-Related Outcomes in the All of US Cohort",null,null,"10.17605/osf.io/shbjv","https://doi.org/10.17605/osf.io/shbjv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042052","R0042052.pdf","paywalled","randomized_trial","Moiz, Areesha","2025","Glucagon-like peptide-1 receptor agonists and co-agonists for weight loss among individuals without diabetes","eScholarship@McGill (McGill)",null,"10.82308/2683","https://doi.org/10.82308/2683",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042117","R0042117.pdf","paywalled","randomized_trial","Evans, Mark","2025","Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes","Apollo (University of Cambridge)",null,"10.17863/cam.118841","https://doi.org/10.17863/cam.118841",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044479","R0044479.pdf","paywalled","randomized_trial","Krüger, Nils","2025","Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data","Open Science Framework",null,"10.17605/osf.io/ajnek","https://doi.org/10.17605/osf.io/ajnek",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044740","R0044740.pdf","paywalled","randomized_trial","Almazam, Saleh Ali M","2025","Can serious adverse event rates be used as a metric of trial representativeness for pharmacological interventions? Glucagon-like peptide-1 receptor agonist trials as an exemplar","Enlighten: Theses (The University of Glasgow)",null,"10.5525/gla.thesis.84908","https://doi.org/10.5525/gla.thesis.84908",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045052","R0045052.pdf","paywalled","randomized_trial","Atul Malhotra","2025","Change in Peripheral Apnea-Hypopnea Index (pAHI), and Body Weight in Participants With Moderate-to-Severe OSA With Obesity From Surmount-OSA","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a5288","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a5288",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045395","R0045395.pdf","paywalled","randomized_trial","Linong Ji","2025","164-OR: A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity","Diabetes","American Diabetes Association","10.2337/db25-164-or","https://doi.org/10.2337/db25-164-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045480","R0045480.pdf","paywalled","randomized_trial","KRISTINA BOYE","2025","227-OR: Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical Trial","Diabetes","American Diabetes Association","10.2337/db25-227-or","https://doi.org/10.2337/db25-227-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045511","R0045511.pdf","paywalled","randomized_trial","Heinz Drexel","2025","Clinical Science at the Intersection of Cardiovascular, Metabolic, and Renal Diseases: New Approaches","Cardiology","S. Karger AG","10.1159/000547405","https://doi.org/10.1159/000547405","40790846","https://pubmed.ncbi.nlm.nih.gov/40790846/",null,null],["2","R0045541","R0045541.pdf","paywalled","randomized_trial","ABSALON D. GUTIERREZ","2025","1678-P: Weight-Independent GLP-1RA Effects on Adipose Tissue PGC1-α and TERT in Insulin-Resistant Humans","Diabetes","American Diabetes Association","10.2337/db25-1678-p","https://doi.org/10.2337/db25-1678-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045599","R0045599.pdf","paywalled","randomized_trial","J Nordanstig","2025","Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3030","https://doi.org/10.1093/eurheartj/ehaf784.3030",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045616","R0045616.pdf","paywalled","randomized_trial","Hiddo J.L. Heerspink","2025","103-OR: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks","Diabetes","American Diabetes Association","10.2337/db25-103-or","https://doi.org/10.2337/db25-103-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045623","R0045623.pdf","paywalled","randomized_trial","Simone Magnisio","2025","P22 Perspectives of clinical trial site staff on recruitment and retention barriers at UK centres participating in the ESSENCE trial",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-basl.38","https://doi.org/10.1136/gutjnl-2025-basl.38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045709","R0045709.pdf","paywalled","randomized_trial","LINONG JI","2025","745-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Obesity or Overweight (REBUILDING-1)","Diabetes","American Diabetes Association","10.2337/db25-745-p","https://doi.org/10.2337/db25-745-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045761","R0045761.pdf","paywalled","randomized_trial","Winifred Chijioke","2025","Is Hair Loss a Class Effect of GLP-1 Receptor Agonists? A Structured Review of Semaglutide and Related Therapies",null,"WiiWoo LLC","10.64709/v1i101","https://doi.org/10.64709/v1i101",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045882","R0045882.pdf","paywalled","randomized_trial","Omar Bahamdan","2025","To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1737107151","https://doi.org/10.24911/ijmdc.51-1737107151",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045966","R0045966.pdf","paywalled","randomized_trial","Fanxing Du","2025","Abstract 4371250: The association between GLP-1 RA initiation and cardiovascular events among patients treated with direct oral anticoagulants: A target trial emulation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371250","https://doi.org/10.1161/circ.152.suppl_3.4371250",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046010","R0046010.pdf","paywalled","randomized_trial","LIXIN GUO","2025","730-P: Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes (SURPASS-CN-INS)","Diabetes","American Diabetes Association","10.2337/db25-730-p","https://doi.org/10.2337/db25-730-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046080","R0046080.pdf","paywalled","randomized_trial","Melissa‐Rosina Pasqua","2025","Changes to Insulin Requirements Over Time With Semaglutide in Adults With Type 1 Diabetes on Insulin Pump Therapy: A Post-Hoc Analysis of a Double-Blinded, Randomized, Crossover Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2025.10.134","https://doi.org/10.1016/j.jcjd.2025.10.134",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046189","R0046189.pdf","paywalled","randomized_trial","Julio Rosenstock","2025","Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improved Markers of Pancreatic Beta Cell Function and Insulin Sensitivity","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807451","https://doi.org/10.1055/s-0045-1807451",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046267","R0046267.pdf","paywalled","randomized_trial","J Plutzky","2025","Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4243","https://doi.org/10.1093/eurheartj/ehaf784.4243",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046295","R0046295.pdf","paywalled","randomized_trial","John W. Ostrominski","2025","223-OR: Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)","Diabetes","American Diabetes Association","10.2337/db25-223-or","https://doi.org/10.2337/db25-223-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046353","R0046353.pdf","paywalled","randomized_trial","Yulong Xu","2025","739-P: Post Hoc Analysis of Efsubaglutide Alfa Monotherapy and Combined Therapy with Metformin in T2D Patients by Baseline Characteristics","Diabetes","American Diabetes Association","10.2337/db25-739-p","https://doi.org/10.2337/db25-739-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046444","R0046444.pdf","paywalled","randomized_trial","B S Prado","2025","Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnoea: A real-world propensity score-matched study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3899","https://doi.org/10.1093/eurheartj/ehaf784.3899",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046475","R0046475.pdf","paywalled","randomized_trial","И.Р. ГАЙСИН","2025","НОВЫЙ, КАРДИОГЕПАТОРЕНАЛЬНЫЙ, КОНТИНУУМ: ЧАСТЬ II","Health demography ecology of finno-ugric peoples","Izhevsk State Medical Academy","10.64111/1994-8921.2025.51.4.009","https://doi.org/10.64111/1994-8921.2025.51.4.009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046680","R0046680.pdf","paywalled","randomized_trial","LINONG JI","2025","743-P: Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity","Diabetes","American Diabetes Association","10.2337/db25-743-p","https://doi.org/10.2337/db25-743-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046696","R0046696.pdf","paywalled","randomized_trial","Jiandong Yuan","2025","744-P: Efficacy and Safety of BGM0504 in Chinese Patients with Obesity—A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db25-744-p","https://doi.org/10.2337/db25-744-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046898","R0046898.pdf","paywalled","randomized_trial","DAN HESSE","2025","1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial","Diabetes","American Diabetes Association","10.2337/db25-1773-p","https://doi.org/10.2337/db25-1773-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046978","R0046978.pdf","paywalled","randomized_trial","Hiya Banerjee","2025","Abstract 4360716: An Artificial Intelligence Model for Clinical Event Adjudication in Cardiovascular Clinical Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4360716","https://doi.org/10.1161/circ.152.suppl_3.4360716",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047015","R0047015.pdf","paywalled","randomized_trial","Hongrong Xu","2025","737-P: HDM1002 in Chinese Adults with Overweight or Obesity—A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study","Diabetes","American Diabetes Association","10.2337/db25-737-p","https://doi.org/10.2337/db25-737-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047122","R0047122.pdf","paywalled","randomized_trial","Ayush Ayush","2025","S2404 Use of Oral Semaglutide in the Management of MASLD in Failures of Standard Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137076.03754.89","https://doi.org/10.14309/01.ajg.0001137076.03754.89",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047135","R0047135.pdf","paywalled","randomized_trial","Peter Hanlon","2025","2836 Age differences in efficacy of newer glucose lowering treatments for type 2 diabetes","Age and Ageing","Oxford University Press (OUP)","10.1093/ageing/afae277.076","https://doi.org/10.1093/ageing/afae277.076",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047164","R0047164.pdf","paywalled","randomized_trial","Coral Oghenerukevwe Omene","2025","Abstract P2-08-25: FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive/HER2 negative breast cancer","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs24-p2-08-25","https://doi.org/10.1158/1557-3265.sabcs24-p2-08-25",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047203","R0047203.pdf","paywalled","randomized_trial","Bernardino Alcázar Navarrete","2025","S102 The potential effect of glucagon-like peptide 1 receptor agonists (GLP1s) on chronic obstructive pulmonary disease (COPD) exacerbations, a case control analyses",null,"BMJ Publishing Group Ltd and British Thoracic Society","10.1136/thorax-2025-btsabstracts.108","https://doi.org/10.1136/thorax-2025-btsabstracts.108",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047227","R0047227.pdf","paywalled","randomized_trial","Vikash Jaiswal","2025","Abstract 52: Glucagon-like peptide-1 receptor agonists use and outcomes in Cardiac Amyloidosis patients: A Propensity Matched Analysis","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.56.suppl_1.52","https://doi.org/10.1161/str.56.suppl_1.52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047234","R0047234.pdf","paywalled","randomized_trial","Amara Sarwal","2025","ESKD in Veterans with Type 2 Diabetes: Comparative Effectiveness of Valproic Acid and Lamotrigine","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20257cq92try","https://doi.org/10.1681/asn.20257cq92try",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047315","R0047315.pdf","paywalled","randomized_trial","Abdulraheem Hassan","2025","Abstract 4371433: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonists in Obese Adults Without Diabetes: A Propensity-Matched Real-World Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371433","https://doi.org/10.1161/circ.152.suppl_3.4371433",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047353","R0047353.pdf","paywalled","randomized_trial","Keerthenan Raveendra","2025","Primary prevention of heart failure with glucagon-like peptide-1 receptor agonist","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1408","https://doi.org/10.1093/eurheartj/ehaf784.1408",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047373","R0047373.pdf","paywalled","randomized_trial","RAJIV AGARWAL","2025","1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1863-lb","https://doi.org/10.2337/db25-1863-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047677","R0047677.pdf","paywalled","randomized_trial","Vera Reber","2025","Effects of dulaglutide on oxytocin plasma levels in healthy men: a secondary analysis of a randomized, double-blind, placebo-controlled crossover study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p930","https://doi.org/10.1530/endoabs.110.p930",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047723","R0047723.pdf","paywalled","randomized_trial","Jeffrey S. Gonzalez","2025","681-P: Medication Adherence in the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) Study","Diabetes","American Diabetes Association","10.2337/db25-681-p","https://doi.org/10.2337/db25-681-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047836","R0047836.pdf","paywalled","randomized_trial","Asfand Yar Cheema","2025","Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications","Blood","American Society of Hematology","10.1182/blood-2025-2970","https://doi.org/10.1182/blood-2025-2970",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047912","R0047912.pdf","paywalled","randomized_trial","Clayton A. Dehn","2025","772-P: Cognitive Outcomes in Adults Treated with GLP-1 Receptor Agonists Compared with Nonusers—A Retrospective Chart Review","Diabetes","American Diabetes Association","10.2337/db25-772-p","https://doi.org/10.2337/db25-772-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047951","R0047951.pdf","paywalled","randomized_trial","Elisabetta Marchetti","2025","GLUCAGON–LIKE PEPTIDE–1 RECEPTOR AGONISTS REDUCE THE RISK OF COMPLETE ATRIOVENTRICULAR BLOCK IN PATIENTS WITH TYPE 2 DIABETES","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suaf076.357","https://doi.org/10.1093/eurheartjsupp/suaf076.357",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047987","R0047987.pdf","paywalled","randomized_trial","Sujatha Reddy","2025","90-OR: Effects of Glucagon-Like Peptide 1 (GLP-1) Agonist Therapy on Islet Function in Adults with Pancreatic-Insufficient Cystic Fibrosis ( PI-CF) and Abnormal Glucose Tolerance (AGT)—Preliminary Results","Diabetes","American Diabetes Association","10.2337/db25-90-or","https://doi.org/10.2337/db25-90-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048060","R0048060.pdf","paywalled","randomized_trial","Lin Zhao","2025","853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes—Up to 52-Week Treatment","Diabetes","American Diabetes Association","10.2337/db25-853-p","https://doi.org/10.2337/db25-853-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048162","R0048162.pdf","paywalled","randomized_trial","Reina Nakamura","2025","What’s New in Orthopaedic Rehabilitation","Journal of Bone and Joint Surgery","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.25.00796","https://doi.org/10.2106/jbjs.25.00796","40938971","https://pubmed.ncbi.nlm.nih.gov/40938971/",null,null],["2","R0048327","R0048327.pdf","paywalled","randomized_trial","JOHANNES F.E. MANN","2025","1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial","Diabetes","American Diabetes Association","10.2337/db25-1971-lb","https://doi.org/10.2337/db25-1971-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048532","R0048532.pdf","paywalled","randomized_trial","Rachel Neff","2025","Abstract 4371452: Viscous Soluble Fiber Supplement Improves Glycemic Control but not Novel Cardiometabolic Markers in Type 2 Diabetes; A Randomized Control Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371452","https://doi.org/10.1161/circ.152.suppl_3.4371452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048558","R0048558.pdf","paywalled","randomized_trial","Jiajun Zhao","2025","126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks","Diabetes","American Diabetes Association","10.2337/db25-126-or","https://doi.org/10.2337/db25-126-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048573","R0048573.pdf","paywalled","randomized_trial","Cara Nelson","2025","767-P: No Effect of Food or Proton Pump Inhibitor on the Pharmacokinetics of TERN-601, an Oral Small Molecule GLP-1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db25-767-p","https://doi.org/10.2337/db25-767-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048593","R0048593.pdf","paywalled","randomized_trial","Deborah Bade Horn","2025","2202-LB: Time to Reach Weight Reduction Thresholds with Tirzepatide vs. Semaglutide—A Post Hoc Analysis of SURMOUNT-5","Diabetes","American Diabetes Association","10.2337/db25-2202-lb","https://doi.org/10.2337/db25-2202-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048689","R0048689.pdf","paywalled","randomized_trial","Samuel Edward Weinberg","2025","GLP-1 Receptor Agonists, Glomerular Filtration Rates, and Survival in Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025cxg82ram","https://doi.org/10.1681/asn.2025cxg82ram",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048774","R0048774.pdf","paywalled","randomized_trial","Verena Parzer","2025","1759-P: Effect of Meal Replacement Compared with Liraglutide 3.0 mg on Weight Loss and Hepatic Steatosis before Bariatric Surgery—A Randomised Study","Diabetes","American Diabetes Association","10.2337/db25-1759-p","https://doi.org/10.2337/db25-1759-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049004","R0049004.pdf","paywalled","randomized_trial","Nooshin Mohebali","2025","Evaluation of potential therapeutic effects of GLP-1 receptor agonists on the state of secondary bile acid loss in mice","Zeitschrift für Gastroenterologie","Georg Thieme Verlag KG","10.1055/s-0045-1810790","https://doi.org/10.1055/s-0045-1810790",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049100","R0049100.pdf","paywalled","randomized_trial","Sharon L. Mulvagh","2025","Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4313","https://doi.org/10.1093/eurheartj/ehaf784.4313",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049147","R0049147.pdf","paywalled","randomized_trial","Akanksha Togra","2025","S2477 Limited Approvals in MASLD Highlight the Need to Reevaluate FDA Guidance for Outcome Measures","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137368.57872.32","https://doi.org/10.14309/01.ajg.0001137368.57872.32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049210","R0049210.pdf","paywalled","randomized_trial","Phyllis Thangaraj","2025","Abstract 4360925: A phenomapping-informed machine learning tool estimates individualized cardiometabolic effects from Tirzepatide and generalizes to a new population.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4360925","https://doi.org/10.1161/circ.152.suppl_3.4360925",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049530","R0049530.pdf","paywalled","randomized_trial","Karen M. Modesto","2025","Abstract 4367152: VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367152","https://doi.org/10.1161/circ.152.suppl_3.4367152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049611","R0049611.pdf","paywalled","randomized_trial","H Wightman","2025","2834 Frailty in randomised controlled trials of glucose-lowering therapies for type 2 diabetes","Age and Ageing","Oxford University Press (OUP)","10.1093/ageing/afae277.077","https://doi.org/10.1093/ageing/afae277.077",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049723","R0049723.pdf","paywalled","randomized_trial","Sammudeen Ibrahim","2025","Cardiovascular Outcomes Of Glucagon Like Peptide 1 Receptor Agonist Irrespective Of Diabetes Status: A Meta Analysis Of Randomized Controlled Trials","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2024.10.352","https://doi.org/10.1016/j.cardfail.2024.10.352",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049888","R0049888.pdf","paywalled","randomized_trial","JASMINE SWAGEL","2025","2168-LB: Metabolic and Physiological Effects of Survodutide in Polygenic Type 2 Diabetic Mice (NZO/HILtJ) under Thermoneutral Conditions","Diabetes","American Diabetes Association","10.2337/db25-2168-lb","https://doi.org/10.2337/db25-2168-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049930","R0049930.pdf","paywalled","randomized_trial","Laura Hohenstein","2025","Body fat reduction as a predictor for liver steatosis regression in obese patients: An interim analysis of the DocWeight 2.3 behavioral weight loss program","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807497","https://doi.org/10.1055/s-0045-1807497",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050035","R0050035.pdf","paywalled","randomized_trial","Reshmi Srinath","2025","1772-P: Baseline Characteristics of Participants Who Achieved Normal BMI—Surmount-1 Three-Year Study Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db25-1772-p","https://doi.org/10.2337/db25-1772-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050039","R0050039.pdf","paywalled","randomized_trial","Tim Heise","2025","A Long-acting Glucose-dependent Insulinotropic Polypeptide Receptor Agonist Improved Insulin Sensitivity and Beta-Cell Function in Participants with Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807435","https://doi.org/10.1055/s-0045-1807435",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050077","R0050077.pdf","paywalled","randomized_trial","Concetta Irace","2025","830-P: CGM-Based Outcomes in Adults with T2D Receiving IcoSema vs. Comparators—Post Hoc Analysis of COMBINE 1 and 3","Diabetes","American Diabetes Association","10.2337/db25-830-p","https://doi.org/10.2337/db25-830-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050079","R0050079.pdf","paywalled","randomized_trial","Mohammad Qasim Minhas","2025","We are what we eat","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000004097","https://doi.org/10.1097/hjh.0000000000004097","40910610","https://pubmed.ncbi.nlm.nih.gov/40910610/",null,null],["2","R0050147","R0050147.pdf","paywalled","randomized_trial","Thomas W. Fredrick","2025","Su2057: A GENETIC RISK SCORE ASSOCIATED WITH NAUSEA RESULTING FROM GLP-1 RECEPTOR AGONIST TREATMENT: A POST-HOC ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL OF LIRAGLUTIDE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03109-9","https://doi.org/10.1016/s0016-5085(25)03109-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050187","R0050187.pdf","paywalled","randomized_trial","Julio Rosenstock","2025","Orforglipron Improved Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807434","https://doi.org/10.1055/s-0045-1807434",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050227","R0050227.pdf","paywalled","randomized_trial","Haiya Wu","2025","752-P: Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D","Diabetes","American Diabetes Association","10.2337/db25-752-p","https://doi.org/10.2337/db25-752-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050415","R0050415.pdf","paywalled","randomized_trial","JUSTIN A. DOWER","2025","2206-LB: Weight Conversations—Examining Clinicians' Approaches to Discussing Weight during Routine Diabetes Care","Diabetes","American Diabetes Association","10.2337/db25-2206-lb","https://doi.org/10.2337/db25-2206-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05553912"],["2","R0050506","R0050506.pdf","paywalled","randomized_trial","Luke Joseph Laffin","2025","Abstract 4343615: Improvements in Cardiometabolic Risk Factors by Body Weight Reduction with Tirzepatide in Adults with Obesity and Prediabetes: A Post Hoc Analysis of the 3-year SURMOUNT-1 study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4343615","https://doi.org/10.1161/circ.152.suppl_3.4343615",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050684","R0050684.pdf","paywalled","randomized_trial","Katarzyna A. Stefanska","2025","Incretin-based weight loss therapies and heart failure with preserved ejection fraction: guideline impactful results, but mechanisms unclear","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaf001","https://doi.org/10.1093/cvr/cvaf001","39887081","https://pubmed.ncbi.nlm.nih.gov/39887081/",null,null],["2","R0050694","R0050694.pdf","paywalled","randomized_trial","Mahmoud H. Elbatreek","2025","Abstract 4359390: Low-Dose Semaglutide Attenuates Coronary Artery Pathology and Improves Vascular Function Independent of Weight Loss in a Porcine Model of Cardiometabolic HFpEF","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4359390","https://doi.org/10.1161/circ.152.suppl_3.4359390",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050724","R0050724.pdf","paywalled","randomized_trial","Hiddo J.L. Heerspink","2025","Effect of Tirzepatide on Kidney Parameters in People with Excess Body Weight and Type 2 Diabetes: A Post-Hoc Analysis of the SURMOUNT-2 Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807554","https://doi.org/10.1055/s-0045-1807554",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050835","R0050835.pdf","paywalled","randomized_trial","Matthew A. Cavender","2025","Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4319","https://doi.org/10.1093/eurheartj/ehaf784.4319",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050926","R0050926.pdf","paywalled","randomized_trial","Rahul Tripathi","2025","S767 Head-to-Head Comparison of Tirzepatide and Semaglutide: A Dose-Stratified Review of 2 Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130528.82045.8d","https://doi.org/10.14309/01.ajg.0001130528.82045.8d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051072","R0051072.pdf","paywalled","randomized_trial","MARJAN REZAEI","2025","762-P: Semaglutide Improves Intestinal Barrier Function in T2D—A Double-Blind Randomized Controlled Trial (RCT)","Diabetes","American Diabetes Association","10.2337/db25-762-p","https://doi.org/10.2337/db25-762-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051081","R0051081.pdf","paywalled","randomized_trial","Rodica Pop-Busui","2025","Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4317","https://doi.org/10.1093/eurheartj/ehaf784.4317",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051108","R0051108.pdf","paywalled","randomized_trial","Johannes F.E. Mann","2025","Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025vd9epqq7","https://doi.org/10.1681/asn.2025vd9epqq7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051124","R0051124.pdf","paywalled","randomized_trial","Jörn Markus Schattenberg","2025","Effect of resmetirom or placebo in NASH (MASH) fibrosis patients with<5% or≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52-week serial liver biopsy study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807552","https://doi.org/10.1055/s-0045-1807552",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03900429"],["2","R0051140","R0051140.pdf","paywalled","randomized_trial","Julio Rosenstock","2025","785-P: First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study","Diabetes","American Diabetes Association","10.2337/db25-785-p","https://doi.org/10.2337/db25-785-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06277934"],["2","R0051244","R0051244.pdf","paywalled","randomized_trial","Wei Hu","2025","797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study","Diabetes","American Diabetes Association","10.2337/db25-797-p","https://doi.org/10.2337/db25-797-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051385","R0051385.pdf","paywalled","randomized_trial","Richard A. Larson","2025","271-OR: Randomized Phase 1 Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-271-or","https://doi.org/10.2337/db25-271-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051432","R0051432.pdf","paywalled","randomized_trial","Alberto O. Chávez","2025","162-OR: Beta-Cell Preservation with Early Oral Antidiabetic Medications in Prediabetes (PreDM)","Diabetes","American Diabetes Association","10.2337/db25-162-or","https://doi.org/10.2337/db25-162-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051443","R0051443.pdf","paywalled","randomized_trial","Shobha Bhattachar","2025","882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept","Diabetes","American Diabetes Association","10.2337/db25-882-p","https://doi.org/10.2337/db25-882-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06230523"],["2","R0051478","R0051478.pdf","paywalled","randomized_trial","RAJAMANNAR THENNATI","2025","759-P: Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study","Diabetes","American Diabetes Association","10.2337/db25-759-p","https://doi.org/10.2337/db25-759-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051526","R0051526.pdf","paywalled","randomized_trial","Martijn Fenaux","2025","734-P: VRB101 Is a Potent Oral GLP-1 Tablet with Once-Weekly Dosing Potential","Diabetes","American Diabetes Association","10.2337/db25-734-p","https://doi.org/10.2337/db25-734-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051619","R0051619.pdf","paywalled","randomized_trial","C. Wysham","2025","Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807442","https://doi.org/10.1055/s-0045-1807442",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051662","R0051662.pdf","paywalled","randomized_trial","Ashok Ainkaran Ganeshalingam","2025","Effect of semaglutide vs placebo on HbA1c, weight, mental health and SF-36: a randomized clinical trial in people with pre-diabetes, obesity and schizophrenia","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p316","https://doi.org/10.1530/endoabs.110.p316",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051729","R0051729.pdf","paywalled","randomized_trial","Cara Nelson","2025","307-OR: Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight—A First-in-Human Study","Diabetes","American Diabetes Association","10.2337/db25-307-or","https://doi.org/10.2337/db25-307-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051747","R0051747.pdf","paywalled","randomized_trial","Mads Marstrand Helsted","2025","1979-LB: GIP Alone or with GLP-1RA Had No Detectable Effect on Glucose Levels in Individuals with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1979-lb","https://doi.org/10.2337/db25-1979-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051765","R0051765.pdf","paywalled","randomized_trial","Mahmoud H. Elbatreek","2025","Abstract 4359480: GLP-1 Agonist Therapy Attenuates Circulating Gut-Derived Trimethylamine N-Oxide (TMAO) and Improves Cardiac Function and Exercise Performance in Cardiometabolic HFpEF","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4359480","https://doi.org/10.1161/circ.152.suppl_3.4359480",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051770","R0051770.pdf","paywalled","randomized_trial","KATHRYN A. ESCHETE","2025","2169-LB: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity","Diabetes","American Diabetes Association","10.2337/db25-2169-lb","https://doi.org/10.2337/db25-2169-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051825","R0051825.pdf","paywalled","randomized_trial","John J. Suschak","2025","228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight","Diabetes","American Diabetes Association","10.2337/db25-228-or","https://doi.org/10.2337/db25-228-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051952","R0051952.pdf","paywalled","randomized_trial","Agnieszka Latosińska","2025","#1817 An application of urinary peptidomics and in silico methods to guide multifactorial intervention in chronic kidney disease","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.0516","https://doi.org/10.1093/ndt/gfaf116.0516",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052137","R0052137.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2025","Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025fdqxb4qe","https://doi.org/10.1681/asn.2025fdqxb4qe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052202","R0052202.pdf","paywalled","randomized_trial","Mahmoud H. Elbatreek","2025","Abstract 4359454: Low-Dose Semaglutide Attenuates Cardiac Lipid Content and Hepatic Steatosis in Cardiometabolic HFpEF: Weight Loss Independent Actions of GLP-1 Receptor Activation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4359454","https://doi.org/10.1161/circ.152.suppl_3.4359454",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052343","R0052343.pdf","paywalled","randomized_trial","Hongchao Pan","2025","Abstract GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs24-gs2-09","https://doi.org/10.1158/1557-3265.sabcs24-gs2-09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052580","R0052580.pdf","paywalled","randomized_trial","Elke Platz","2025","Abstract 4365838: Survodutide for the Treatment of Obesity: Baseline characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365838","https://doi.org/10.1161/circ.152.suppl_3.4365838",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052601","R0052601.pdf","paywalled","randomized_trial","Naveed A. Sattar","2025","Shift in Body Mass Index Category and Associated Cardiometabolic Risk Factors: A Post Hoc Analysis from the SURMOUNT-4 Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807556","https://doi.org/10.1055/s-0045-1807556",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052824","R0052824.pdf","paywalled","randomized_trial","Xiaoying Li","2025","727-P: A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-727-p","https://doi.org/10.2337/db25-727-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052903","R0052903.pdf","paywalled","randomized_trial","Bruno Linetzky","2025","Acute Dip in eGFR in Patients Treated with Tirzepatide: A Post Hoc Analysis of Long-Term Clinical Trials of Tirzepatide Treatment","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025gxmxsbre","https://doi.org/10.1681/asn.2025gxmxsbre",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052905","R0052905.pdf","paywalled","randomized_trial","Wen Li","2025","769-P: Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D","Diabetes","American Diabetes Association","10.2337/db25-769-p","https://doi.org/10.2337/db25-769-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052907","R0052907.pdf","paywalled","randomized_trial","Raffaele De Caterina","2025","Optimal medical therapy for initial management of stable angina: a call to action","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf596","https://doi.org/10.1093/eurheartj/ehaf596","40878861","https://pubmed.ncbi.nlm.nih.gov/40878861/",null,null],["2","R0052938","R0052938.pdf","paywalled","randomized_trial","Arvind Bussetty","2025","S730 Assessing the Risk of Recurrent Pancreatitis in Patients on GLP-1 Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130380.47233.e9","https://doi.org/10.14309/01.ajg.0001130380.47233.e9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052989","R0052989.pdf","paywalled","randomized_trial","Rodica Pop‐Busui","2025","2094-LB: Electrocardiogram Abnormalities in Relatively Early Type 2 Diabetes—Prevalence and Incidence in the Glycemia Reduction Approaches in Diabetes (GRADE) Cohort","Diabetes","American Diabetes Association","10.2337/db25-2094-lb","https://doi.org/10.2337/db25-2094-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052994","R0052994.pdf","paywalled","randomized_trial","Cassie D. Turner","2025","Low-carbohydrate nutrition counseling with continuous glucose monitoring to improve metabolic health among Veterans with type 2 diabetes: a pilot quality improvement initiative (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.75672","https://doi.org/10.2196/preprints.75672",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053170","R0053170.pdf","paywalled","randomized_trial","ALEJANDRA MACIAS PULIDO","2025","1980-LB: Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study","Diabetes","American Diabetes Association","10.2337/db25-1980-lb","https://doi.org/10.2337/db25-1980-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053336","R0053336.pdf","paywalled","randomized_trial","Michael Shechter","2025","Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4244","https://doi.org/10.1093/eurheartj/ehaf784.4244",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053538","R0053538.pdf","paywalled","randomized_trial","Anthony W. P. Flynn","2025","CURE Asthma: a unique opportunity for Australia","The Medical Journal of Australia","Wiley","10.5694/mja2.70093","https://doi.org/10.5694/mja2.70093","41241857","https://pubmed.ncbi.nlm.nih.gov/41241857/",null,"ClinicalTrials.gov:NCT02760329"],["2","R0053930","R0053930.pdf","paywalled","randomized_trial","Rajamannar Thennati","2025","Abstract 4345579: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4345579","https://doi.org/10.1161/circ.152.suppl_3.4345579",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054053","R0054053.pdf","paywalled","randomized_trial","Abhinav Sharma","2025","Abstract 4345655: Sodium–Glucose Cotransporter 2 Inhibitors are Cost-Effective and Dominate Glucagon-Like Peptide-1 Receptor Agonists for Patients with Type 2 Diabetes and High Cardiorenal Risk in Canada","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4345655","https://doi.org/10.1161/circ.152.suppl_3.4345655",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054107","R0054107.pdf","paywalled","randomized_trial","Tripdatabase","2025","What are the results of a comparative randomized controlled trial of oral hypoglycemics in type 2 diabetes in the UK?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17689315","https://doi.org/10.5281/zenodo.17689315",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054253","R0054253.pdf","paywalled","randomized_trial","O Levi","2025","Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4757","https://doi.org/10.1093/eurheartj/ehaf784.4757",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054379","R0054379.pdf","paywalled","randomized_trial","Yogish C. Kudva","2025","A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes","Obstetrical & Gynecological Survey","Ovid Technologies (Wolters Kluwer Health)","10.1097/ogx.0000000000001463","https://doi.org/10.1097/ogx.0000000000001463","41194356","https://pubmed.ncbi.nlm.nih.gov/41194356/",null,null],["2","R0054530","R0054530.pdf","paywalled","randomized_trial","Mark Stroh","2025","753-P: Safety, Tolerability, PK, and Efficacy of MET097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management","Diabetes","American Diabetes Association","10.2337/db25-753-p","https://doi.org/10.2337/db25-753-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054655","R0054655.pdf","paywalled","randomized_trial","Sarvesh Sankar Dass","2025","Fragility Index of SGLT2 Inhibitor, GLP-1 Receptor Agonist, and Nonsteroidal Mineralocorticoid Receptor Antagonist (nsMRA) Clinical Trials for Kidney and Cardiovascular Protection","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025tk01943m","https://doi.org/10.1681/asn.2025tk01943m",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054819","R0054819.pdf","paywalled","randomized_trial","Catherine G. Derington","2025","Comparative Effectiveness of Liraglutide, Semaglutide, and Dulaglutide on Kidney Outcomes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.202533kyg5gr","https://doi.org/10.1681/asn.202533kyg5gr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054917","R0054917.pdf","paywalled","randomized_trial","Hem prajapati","2025","Abstract 4371834: Targeting Cerebrovascular Risk in Diabetes: GLP-1 Receptor Agonists as Neuroprotective Agents","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371834","https://doi.org/10.1161/circ.152.suppl_3.4371834",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054942","R0054942.pdf","paywalled","randomized_trial","Weijun Gu","2025","865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes","Diabetes","American Diabetes Association","10.2337/db25-865-p","https://doi.org/10.2337/db25-865-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055248","R0055248.pdf","paywalled","randomized_trial","Abdul-Rahaman Adedolapo Ottun","2025","Abstract 4364820: Impact of GLP-1 Agonists on Cardiovascular Outcomes in Patients with Heart failure with Preserved Ejection Fraction: Analysis of Real-world studies","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4364820","https://doi.org/10.1161/circ.152.suppl_3.4364820",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055379","R0055379.pdf","paywalled","randomized_trial","Abdul-Rahaman Adedolapo Ottun","2025","Abstract 4373350: Efficacy of GLP-1 Receptor Agonists VS SGLT2 Inhibitors on Cardiovascular Outcomes in Women with Type 2 Diabetes and Premature Coronary Artery Disease: A Propensity Score Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4373350","https://doi.org/10.1161/circ.152.suppl_3.4373350",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055392","R0055392.pdf","paywalled","randomized_trial","William Alazawi","2025","P5 Pegozafermin treatment demonstrates long-term benefit in subjects with metabolic dysfunction-associated steatohepatitis and fibrosis: results from the Phase 2b ENLIVEN clinical trial",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-basl.22","https://doi.org/10.1136/gutjnl-2025-basl.22",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055651","R0055651.pdf","paywalled","randomized_trial","Sarah Torp Yttergren","2025","Cardiorenal Protective Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20252580qcqf","https://doi.org/10.1681/asn.20252580qcqf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0003418","R0003418.pdf","paywalled","randomized_trial","Maher M","2024","In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-02849-jc","https://doi.org/10.7326/annals-24-02849-jc","39496174","https://pubmed.ncbi.nlm.nih.gov/39496174/",null,null],["2","R0003440","R0003440.pdf","paywalled","randomized_trial","Doğan ŞE","2024","Case Series: Exposure to Glucagon-like Peptide-1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/0118715303252109231023115112","https://doi.org/10.2174/0118715303252109231023115112","37937565","https://pubmed.ncbi.nlm.nih.gov/37937565/",null,null],["2","R0003718","R0003718.pdf","paywalled","randomized_trial","Lavu MS","2024","Reply to the Letter to the Editor: Why Did the \"Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists\" Differ From the Previous Randomized Controlled Study?","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.08.036","https://doi.org/10.1016/j.arth.2024.08.036","39523050","https://pubmed.ncbi.nlm.nih.gov/39523050/",null,null],["2","R0003812","R0003812.pdf","paywalled","randomized_trial","Scheen AJ","2024","GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-024-02090-9","https://doi.org/10.1007/s40265-024-02090-9","39342059","https://pubmed.ncbi.nlm.nih.gov/39342059/",null,null],["2","R0004042","R0004042.pdf","paywalled","randomized_trial","Wu J","2024","Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15383","https://doi.org/10.1111/dom.15383","38100147","https://pubmed.ncbi.nlm.nih.gov/38100147/",null,null],["2","R0005670","R0005670.pdf","paywalled","randomized_trial","Popovic DS","2024","Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2024.2418398","https://doi.org/10.1080/17512433.2024.2418398","39429118","https://pubmed.ncbi.nlm.nih.gov/39429118/",null,null],["2","R0005738","R0005738.pdf","paywalled","randomized_trial","Rizzi A","2024","Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2023.12.012","https://doi.org/10.1016/j.numecd.2023.12.012","38336546","https://pubmed.ncbi.nlm.nih.gov/38336546/",null,null],["2","R0005802","R0005802.pdf","paywalled","randomized_trial","Rizzi A","2024","Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.102945","https://doi.org/10.1016/j.dsx.2024.102945","38262118","https://pubmed.ncbi.nlm.nih.gov/38262118/",null,null],["2","R0005947","R0005947.pdf","paywalled","randomized_trial","Georgianos PI","2024","Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-024-02091-8","https://doi.org/10.1007/s40265-024-02091-8","39259460","https://pubmed.ncbi.nlm.nih.gov/39259460/",null,null],["2","R0006048","R0006048.pdf","paywalled","randomized_trial","Scheen AJ","2024","Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2023.101508","https://doi.org/10.1016/j.diabet.2023.101508","38158077","https://pubmed.ncbi.nlm.nih.gov/38158077/",null,null],["2","R0006111","R0006111.pdf","paywalled","randomized_trial","Park B","2024","GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.","American journal of physiology. Heart and circulatory physiology","American Physiological Society","10.1152/ajpheart.00257.2024","https://doi.org/10.1152/ajpheart.00257.2024","38874618","https://pubmed.ncbi.nlm.nih.gov/38874618/",null,"ClinicalTrials.gov:NCT05253521"],["2","R0006831","R0006831.pdf","paywalled","randomized_trial","Dotan I","2024","Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000004945","https://doi.org/10.1097/tp.0000000000004945","38361246","https://pubmed.ncbi.nlm.nih.gov/38361246/",null,null],["2","R0006845","R0006845.pdf","paywalled","randomized_trial","Eghbali M","2024","Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-023-02761-1","https://doi.org/10.1007/s12325-023-02761-1","38172377","https://pubmed.ncbi.nlm.nih.gov/38172377/",null,null],["2","R0007184","R0007184.pdf","paywalled","randomized_trial","Karacabeyli D","2024","Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review.","Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","Ovid Technologies (Wolters Kluwer Health)","10.1097/rhu.0000000000001949","https://doi.org/10.1097/rhu.0000000000001949","36870080","https://pubmed.ncbi.nlm.nih.gov/36870080/",null,null],["2","R0007693","R0007693.pdf","paywalled","randomized_trial","Htoo PT","2024","Stratified analysis in comparative effectiveness studies that emulate randomized trials.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5716","https://doi.org/10.1002/pds.5716","37876341","https://pubmed.ncbi.nlm.nih.gov/37876341/",null,null],["2","R0007993","R0007993.pdf","paywalled","randomized_trial","Long JJ","2024","The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.07.008","https://doi.org/10.1016/j.eprac.2024.07.008","39025300","https://pubmed.ncbi.nlm.nih.gov/39025300/",null,null],["2","R0008015","R0008015.pdf","paywalled","randomized_trial","Feldman JM","2024","Ninerafaxstat in the Treatment of Diabetic Cardiomyopathy and Nonobstructive Hypertrophic Cardiomyopathy.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000776","https://doi.org/10.1097/crd.0000000000000776","39194232","https://pubmed.ncbi.nlm.nih.gov/39194232/",null,null],["2","R0008253","R0008253.pdf","paywalled","randomized_trial","Foghsgaard S","2024","Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15306","https://doi.org/10.1111/dom.15306","37846555","https://pubmed.ncbi.nlm.nih.gov/37846555/",null,null],["2","R0008298","R0008298.pdf","paywalled","randomized_trial","Pratley R","2024","Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","Current opinion in gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mog.0000000000001057","https://doi.org/10.1097/mog.0000000000001057","38967917","https://pubmed.ncbi.nlm.nih.gov/38967917/",null,null],["2","R0009410","R0009410.pdf","paywalled","randomized_trial","Lobkovich A","2024","Incretin Analogs for Weight Management in Adults Without Diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280231190089","https://doi.org/10.1177/10600280231190089","37522468","https://pubmed.ncbi.nlm.nih.gov/37522468/",null,null],["2","R0009924","R0009924.pdf","paywalled","randomized_trial","Gupta K","2024","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-024-01218-2","https://doi.org/10.1007/s11883-024-01218-2","38829515","https://pubmed.ncbi.nlm.nih.gov/38829515/",null,null],["2","R0010839","R0010839.pdf","paywalled","randomized_trial","Kitsios K","2024","Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials-A Short Review.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2024.0059","https://doi.org/10.1089/met.2024.0059","39088384","https://pubmed.ncbi.nlm.nih.gov/39088384/",null,null],["2","R0010893","R0010893.pdf","paywalled","randomized_trial","Essop T","2024","Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-024-01554-2","https://doi.org/10.1007/s11892-024-01554-2","39325334","https://pubmed.ncbi.nlm.nih.gov/39325334/",null,null],["2","R0011132","R0011132.pdf","paywalled","randomized_trial","Chan JSF","2024","Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.","The Journal of endocrinology","Bioscientifica","10.1530/joe-24-0032","https://doi.org/10.1530/joe-24-0032","38860519","https://pubmed.ncbi.nlm.nih.gov/38860519/",null,null],["2","R0011407","R0011407.pdf","paywalled","randomized_trial","Chan PYW","2024","Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.","JBJS reviews","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.rvw.23.00167","https://doi.org/10.2106/jbjs.rvw.23.00167","38181103","https://pubmed.ncbi.nlm.nih.gov/38181103/",null,null],["2","R0012353","R0012353.pdf","paywalled","randomized_trial","Garg SK","2024","Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2023.0490","https://doi.org/10.1089/dia.2023.0490","38444317","https://pubmed.ncbi.nlm.nih.gov/38444317/",null,null],["2","R0013062","R0013062.pdf","paywalled","randomized_trial","Gudzune KA","2024","Medications for Obesity: A Review.","JAMA","American Medical Association (AMA)","10.1001/jama.2024.10816","https://doi.org/10.1001/jama.2024.10816","39037780","https://pubmed.ncbi.nlm.nih.gov/39037780/",null,null],["2","R0013318","R0013318.pdf","paywalled","randomized_trial","Abdulrazeq H","2024","In Reply: GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003206","https://doi.org/10.1227/neu.0000000000003206","39360844","https://pubmed.ncbi.nlm.nih.gov/39360844/",null,null],["2","R0014355","R0014355.pdf","paywalled","randomized_trial","Irfan H","2024","Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2023.102060","https://doi.org/10.1016/j.cpcardiol.2023.102060","37640171","https://pubmed.ncbi.nlm.nih.gov/37640171/",null,null],["2","R0014845","R0014845.pdf","paywalled","randomized_trial","Tobaiqy M","2024","A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.","Pharmacological reports : PR","Springer Science and Business Media LLC","10.1007/s43440-024-00629-x","https://doi.org/10.1007/s43440-024-00629-x","39093550","https://pubmed.ncbi.nlm.nih.gov/39093550/",null,null],["2","R0015355","R0015355.pdf","paywalled","randomized_trial","Pham LN","2024","Patient honesty about NPO status in the era of GLP-1 agonists and liberal ERAS protocols: A randomized response technique study.","Journal of clinical anesthesia","Elsevier BV","10.1016/j.jclinane.2024.111650","https://doi.org/10.1016/j.jclinane.2024.111650","39388831","https://pubmed.ncbi.nlm.nih.gov/39388831/",null,null],["2","R0017263","R0017263.pdf","paywalled","randomized_trial","Bjornstad P","2024","Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.","Diabetes care","American Diabetes Association","10.2337/dc24-0322","https://doi.org/10.2337/dc24-0322","38954432","https://pubmed.ncbi.nlm.nih.gov/38954432/",null,null],["2","R0017512","R0017512.pdf","paywalled","randomized_trial","Attia SM","2024","Dulaglutide rescues the elevated testicular dysfunction in a mouse model of high-fat diet-induced obesity.","Mutation research. Genetic toxicology and environmental mutagenesis","Elsevier BV","10.1016/j.mrgentox.2024.503805","https://doi.org/10.1016/j.mrgentox.2024.503805","39147447","https://pubmed.ncbi.nlm.nih.gov/39147447/",null,null],["2","R0018122","R0018122.pdf","paywalled","randomized_trial","Merzeban DH","2024","Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.","Journal of molecular histology","Springer Science and Business Media LLC","10.1007/s10735-024-10326-x","https://doi.org/10.1007/s10735-024-10326-x","39704859","https://pubmed.ncbi.nlm.nih.gov/39704859/",null,null],["2","R0018759","R0018759.pdf","paywalled","randomized_trial","Scheen AJ","2024","[Underuse of SGLT2 inhibitors in clinical practice].","Revue medicale suisse","Médecine et Hygiène","10.53738/revmed.2024.20.884.1498","https://doi.org/10.53738/revmed.2024.20.884.1498","39219393","https://pubmed.ncbi.nlm.nih.gov/39219393/",null,null],["2","R0018954","R0018954.pdf","paywalled","randomized_trial","Garg SK","2024","Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0050","https://doi.org/10.1089/dia.2024.0050","38512447","https://pubmed.ncbi.nlm.nih.gov/38512447/",null,null],["2","R0018994","R0018994.pdf","paywalled","randomized_trial","Wittert G","2024","Testosterone and the prevention of type 2 diabetes mellitus: therapeutic implications from recent trials.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000884","https://doi.org/10.1097/med.0000000000000884","39285839","https://pubmed.ncbi.nlm.nih.gov/39285839/",null,null],["2","R0019005","R0019005.pdf","paywalled","randomized_trial","Zhao S","2024","Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102921","https://doi.org/10.1016/j.dsx.2023.102921","38128261","https://pubmed.ncbi.nlm.nih.gov/38128261/",null,null],["2","R0019580","R0019580.pdf","paywalled","randomized_trial","Katsarou A","2024","Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease.","Hormones (Athens, Greece)","Springer Science and Business Media LLC","10.1007/s42000-024-00588-1","https://doi.org/10.1007/s42000-024-00588-1","39112786","https://pubmed.ncbi.nlm.nih.gov/39112786/",null,null],["2","R0019753","R0019753.pdf","paywalled","randomized_trial","Pedicino D","2024","Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae429","https://doi.org/10.1093/eurheartj/ehae429","38985093","https://pubmed.ncbi.nlm.nih.gov/38985093/",null,null],["2","R0019755","R0019755.pdf","paywalled","randomized_trial","Herrington WG","2024","Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejme2406408","https://doi.org/10.1056/nejme2406408","38986062","https://pubmed.ncbi.nlm.nih.gov/38986062/",null,null],["2","R0019809","R0019809.pdf","paywalled","randomized_trial","Bagherzadeh-Rahmani B","2024","Tirzepatide and exercise training in obesity.","Clinical hemorheology and microcirculation","SAGE Publications","10.3233/ch-242134","https://doi.org/10.3233/ch-242134","38640145","https://pubmed.ncbi.nlm.nih.gov/38640145/",null,null],["2","R0019833","R0019833.pdf","paywalled","randomized_trial","Lyons D","2024","Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life.","The British journal of dermatology","Oxford University Press (OUP)","10.1093/bjd/ljae216","https://doi.org/10.1093/bjd/ljae216","38771673","https://pubmed.ncbi.nlm.nih.gov/38771673/",null,null],["2","R0019912","R0019912.pdf","paywalled","randomized_trial","Lovato A","2024","Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double‑Blind Single‑Centre Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07463-3","https://doi.org/10.1007/s11695-024-07463-3","39167150","https://pubmed.ncbi.nlm.nih.gov/39167150/",null,null],["2","R0020280","R0020280.pdf","paywalled","randomized_trial","Custódio G","2024","Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial.","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/lvt.0000000000000298","https://doi.org/10.1097/lvt.0000000000000298","37938130","https://pubmed.ncbi.nlm.nih.gov/37938130/",null,null],["2","R0020597","R0020597.pdf","paywalled","randomized_trial","Alabduljabbar K","2024","Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-023-03534-0","https://doi.org/10.1007/s12020-023-03534-0","37735340","https://pubmed.ncbi.nlm.nih.gov/37735340/",null,null],["2","R0020896","R0020896.pdf","paywalled","randomized_trial","Gopalasingam N","2024","Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.124.069732","https://doi.org/10.1161/circulationaha.124.069732","39162035","https://pubmed.ncbi.nlm.nih.gov/39162035/",null,"ClinicalTrials.gov:NCT05236335"],["2","R0021022","R0021022.pdf","paywalled","randomized_trial","Mathur W","2024","Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-023-06975-8","https://doi.org/10.1007/s11695-023-06975-8","38091192","https://pubmed.ncbi.nlm.nih.gov/38091192/",null,null],["2","R0021402","R0021402.pdf","paywalled","randomized_trial","Weisser B","2024","Neuroprotective Effects of Anti-diabetic Drugs in the Treatment of Patients with Diabetes and Glaucoma or at High Risk for Glaucoma.","Klinische Monatsblatter fur Augenheilkunde","Georg Thieme Verlag KG","10.1055/a-2066-3389","https://doi.org/10.1055/a-2066-3389","37336238","https://pubmed.ncbi.nlm.nih.gov/37336238/",null,null],["2","R0021480","R0021480.pdf","paywalled","randomized_trial","Grannell A","2024","Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.","Clinical obesity","Wiley","10.1111/cob.12622","https://doi.org/10.1111/cob.12622","37615384","https://pubmed.ncbi.nlm.nih.gov/37615384/",null,null],["2","R0026711","R0026711.pdf","paywalled","randomized_trial","Vinciguerra F","2024","Pharmacological treatment of non-responders following bariatric surgery.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.21.03311-3","https://doi.org/10.23736/s2724-6507.21.03311-3","33792233","https://pubmed.ncbi.nlm.nih.gov/33792233/",null,null],["2","R0029143","R0029143.pdf","paywalled","randomized_trial","Crea F","2024","The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae586","https://doi.org/10.1093/eurheartj/ehae586","39276017","https://pubmed.ncbi.nlm.nih.gov/39276017/",null,"PROSPERO:CRD42022353297"],["2","R0029163","R0029163.pdf","paywalled","randomized_trial","Hansen LS","2024","The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvae095","https://doi.org/10.1093/ejendo/lvae095","39049802","https://pubmed.ncbi.nlm.nih.gov/39049802/",null,"ClinicalTrials.gov:NCT03246451"],["2","R0029232","R0029232.pdf","paywalled","randomized_trial","Ray S","2024","An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2024.2330468","https://doi.org/10.1080/17512433.2024.2330468","38471973","https://pubmed.ncbi.nlm.nih.gov/38471973/",null,null],["2","R0029769","R0029769.pdf","paywalled","randomized_trial","Li Y","2024","Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15407","https://doi.org/10.1111/dom.15407","38105342","https://pubmed.ncbi.nlm.nih.gov/38105342/",null,null],["2","R0032105","R0032105.pdf","paywalled","randomized_trial",null,"2024","Semaglutide lowers risk of kidney failure and cardiovascular death in patients with type 2 diabetes and CKD, study results show","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2024.1.317079","https://doi.org/10.1211/pj.2024.1.317079",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032750","R0032750.pdf","paywalled","randomized_trial","SEUNGHOON HAN","2024","1859-LB: PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling","Diabetes","American Diabetes Association","10.2337/db24-1859-lb","https://doi.org/10.2337/db24-1859-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032955","R0032955.pdf","paywalled","randomized_trial","MARSEL KOCI","2024","745-P: Effects of Liraglutide on GLP-1, GIP, and Glucagon Concentrations in Persons with Type 2 Diabetes with Multiple Daily Insulin Injections during a 24-Week Period","Diabetes","American Diabetes Association","10.2337/db24-745-p","https://doi.org/10.2337/db24-745-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033009","R0033009.pdf","paywalled","randomized_trial","Yuanyuan Zhang","2024","119-OR: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db24-119-or","https://doi.org/10.2337/db24-119-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033040","R0033040.pdf","paywalled","randomized_trial","Jiandong Yuan","2024","849-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects—A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db24-849-p","https://doi.org/10.2337/db24-849-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033181","R0033181.pdf","paywalled","randomized_trial","Gary Enos","2024","Findings on weight‐loss drugs offer hope, but caution needed","Alcoholism & Drug Abuse Weekly","Wiley","10.1002/adaw.34334","https://doi.org/10.1002/adaw.34334",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033224","R0033224.pdf","paywalled","randomized_trial","Warren Froelich","2024","Tirzepatide","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0001026248.04310.16","https://doi.org/10.1097/01.cot.0001026248.04310.16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033260","R0033260.pdf","paywalled","randomized_trial",null,"2024","Science, Medicine, and the Anesthesiologist","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000005193","https://doi.org/10.1097/aln.0000000000005193",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033434","R0033434.pdf","paywalled","randomized_trial","Amalia, Ashcroft","2024","New FDA Approved Weight Loss: Drug Zepbound, a Wegovy and Ozempic Rival!","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12749457","https://doi.org/10.5281/zenodo.12749457",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033484","R0033484.pdf","paywalled","randomized_trial","Eli Lilly Demo","2024","Phase 3 trial: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled Phase 3 trial","Kudos Innovations Ltd",null,"10.26303/rhc0-e598","https://doi.org/10.26303/rhc0-e598",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033584","R0033584.pdf","paywalled","randomized_trial","Koychev, Ivan","2024","Additional file 2 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Figshare",null,"10.6084/m9.figshare.27157898","https://doi.org/10.6084/m9.figshare.27157898",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033617","R0033617.pdf","paywalled","randomized_trial","Koychev, Ivan","2024","Additional file 1 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Figshare",null,"10.6084/m9.figshare.27157895","https://doi.org/10.6084/m9.figshare.27157895",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033628","R0033628.pdf","paywalled","randomized_trial","Georgea, Strong","2024","Trulicity weight loss. Does it work and who can take it?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12787502","https://doi.org/10.5281/zenodo.12787502",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033725","R0033725.pdf","paywalled","randomized_trial","Ahmad, Ehtasham","2024","Use of novel glucose-lowering therapies in novel populations with type 2 diabetes","University of Leicester",null,"10.25392/leicester.data.27043756","https://doi.org/10.25392/leicester.data.27043756",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033734","R0033734.pdf","paywalled","randomized_trial","cgglswtdirf","2024","ozempic spanish pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.11952893","https://doi.org/10.5281/zenodo.11952893",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033787","R0033787.pdf","paywalled","randomized_trial","Wei, Ran","2024","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients","Figshare",null,"10.6084/m9.figshare.c.6797377","https://doi.org/10.6084/m9.figshare.c.6797377",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033795","R0033795.pdf","paywalled","randomized_trial","J. Sanyal, Arun","2024","Plain Language Summary of the Manuscript: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine.","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.27720072.v1","https://doi.org/10.60915/boehringer-figshare.27720072.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033810","R0033810.pdf","paywalled","randomized_trial","twiaqafvl","2024","Wegovy information pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12300022","https://doi.org/10.5281/zenodo.12300022",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033909","R0033909.pdf","paywalled","randomized_trial","ruwniklg","2024","diabetes guide pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.11884919","https://doi.org/10.5281/zenodo.11884919",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033941","R0033941.pdf","paywalled","randomized_trial","J. Sanyal, Arun","2024","Plain Language Summary of the Manuscript: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.27720072","https://doi.org/10.60915/boehringer-figshare.27720072",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033945","R0033945.pdf","paywalled","randomized_trial","Koychev, Ivan","2024","Additional file 3 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Figshare",null,"10.6084/m9.figshare.27157901","https://doi.org/10.6084/m9.figshare.27157901",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033956","R0033956.pdf","paywalled","randomized_trial","pnoumayodz","2024","Wegovy information pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.11707115","https://doi.org/10.5281/zenodo.11707115",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033980","R0033980.pdf","paywalled","randomized_trial","Johnes, Holmes","2024","Victoza Weight Loss: Does It work? - Advanced BMI Lebanon","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12793440","https://doi.org/10.5281/zenodo.12793440",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034087","R0034087.pdf","paywalled","randomized_trial","Koychev, Ivan","2024","Additional file 4 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Figshare",null,"10.6084/m9.figshare.27157907","https://doi.org/10.6084/m9.figshare.27157907",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035875","R0035875.pdf","paywalled","randomized_trial",null,"2024","Interventions for Weight Management in Children and Adolescents","AAP Grand Rounds","American Academy of Pediatrics (AAP)","10.1542/gr.52-4-43","https://doi.org/10.1542/gr.52-4-43",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036068","R0036068.pdf","paywalled","randomized_trial","Julio Rosenstock","2024","Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785381","https://doi.org/10.1055/s-0044-1785381",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036667","R0036667.pdf","paywalled","randomized_trial","Becker, Ezra Daniel","2024","Post Hoc Control Group Selection Methods","University of Illinois Chicago",null,"10.25417/uic.26108041","https://doi.org/10.25417/uic.26108041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036759","R0036759.pdf","paywalled","randomized_trial","Sohn, Minji","2024","Additional file 1 of Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","Figshare",null,"10.6084/m9.figshare.26157034","https://doi.org/10.6084/m9.figshare.26157034",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036804","R0036804.pdf","paywalled","randomized_trial","Terri D’Arrigo","2024","MedCheck: High-Dose Naloxone, Tavapadon, Tirzepatide, and Lumateperone","Psychiatric News","American Psychiatric Association Publishing","10.1176/appi.pn.2024.06.6.1","https://doi.org/10.1176/appi.pn.2024.06.6.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037175","R0037175.pdf","paywalled","randomized_trial","Adham Mottalib","2024","132-OR: Structured Medical Nutrition Therapy Improves Glycemia, Reduces Percentage Body Fat while Maintaining Fat-Free Mass in Individuals with Overweight/Obesity and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-132-or","https://doi.org/10.2337/db24-132-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037232","R0037232.pdf","paywalled","randomized_trial","MONICA BODENSTAB","2024","795-P: Balancing the Scales—The Effect of Tirzepatide on Lean Body Mass and Fat Mass","Diabetes","American Diabetes Association","10.2337/db24-795-p","https://doi.org/10.2337/db24-795-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037310","R0037310.pdf","paywalled","randomized_trial","W. le Roux, Carel","2024","Plain Language Summary of the Manuscript: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.27720057","https://doi.org/10.60915/boehringer-figshare.27720057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037326","R0037326.pdf","paywalled","randomized_trial","Diana Julia Tedesco","2024","SHOCK SYNOPSIS APRIL 2024","Shock","Ovid Technologies (Wolters Kluwer Health)","10.1097/shk.0000000000002368","https://doi.org/10.1097/shk.0000000000002368","38604132","https://pubmed.ncbi.nlm.nih.gov/38604132/",null,null],["2","R0037612","R0037612.pdf","paywalled","randomized_trial","Hiddo J.L. Heerspink","2024","264-OR: Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes—A Post-Hoc Analysis of the SURMOUNT-2 Trial","Diabetes","American Diabetes Association","10.2337/db24-264-or","https://doi.org/10.2337/db24-264-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037667","R0037667.pdf","paywalled","randomized_trial","John J. Suschak","2024","228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids","Diabetes","American Diabetes Association","10.2337/db24-228-or","https://doi.org/10.2337/db24-228-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037749","R0037749.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2024","266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity","Diabetes","American Diabetes Association","10.2337/db24-266-or","https://doi.org/10.2337/db24-266-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037908","R0037908.pdf","paywalled","randomized_trial","Πασχάλης Ι. Γκορτσίλας","2024","Πρωτόκολλο τυχαιοποιημένης ελεγχόμενης κλινικής μελέτης για την αξιολόγηση της αποτελεσματικότητας και ασφάλειας της σεμαγλουτίδης έναντι της μετφορμίνης σε ασθενείς με διαβήτη Τύπου 2","University of Thessaly Institutional Repository (University of Thessaly)",null,"10.26253/heal.uth.39614","https://doi.org/10.26253/heal.uth.39614",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037923","R0037923.pdf","paywalled","randomized_trial","Marco Tozzi","2024","1642-P: Metabolic Effects of Semaglutide and Resmetirom at Thermoneutrality in the Diet-Induced Obese Mouse","Diabetes","American Diabetes Association","10.2337/db24-1642-p","https://doi.org/10.2337/db24-1642-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037961","R0037961.pdf","paywalled","randomized_trial","Lingvay, Ildiko","2024","Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","Figshare",null,"10.6084/m9.figshare.c.6593632.v1","https://doi.org/10.6084/m9.figshare.c.6593632.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038126","R0038126.pdf","paywalled","randomized_trial",null,"2024","This Month in Anesthesiology","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000005270","https://doi.org/10.1097/aln.0000000000005270","39715501","https://pubmed.ncbi.nlm.nih.gov/39715501/",null,null],["2","R0038181","R0038181.pdf","paywalled","randomized_trial","Ihsan Almarzooqi","2024","1865-LB: Exploring Incretin-Based Therapies as Adjunctive Treatment for Type 1 Diabetes—Real-World Insights and Future Directions","Diabetes","American Diabetes Association","10.2337/db24-1865-lb","https://doi.org/10.2337/db24-1865-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038427","R0038427.pdf","paywalled","randomized_trial","Chungsoo Kim","2024","Abstract P137: Real-World Impact of Semaglutide on Cardiometabolic Risk Factors in Patients without Diabetes: A Multi-Center Analysis of Electronic Health Records","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.81.suppl_1.p137","https://doi.org/10.1161/hyp.81.suppl_1.p137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038432","R0038432.pdf","paywalled","randomized_trial","Matheus Henrique de Sousa Macêdo","2024","Endocrinologia: efeitos da terapia combinada com metformina e agonistas do GLP-1 na redução do peso corporal em pacientes com diabetes tipo 2","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)",null,"10.18378/rebes.v14i3.10839","https://doi.org/10.18378/rebes.v14i3.10839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038474","R0038474.pdf","paywalled","randomized_trial","LLOYD L. TRAN","2024","2081-LB: Efficacy and Safety of Semaglutide and Tirzepatide—A Comparative Analysis of Clinical Trials","Diabetes","American Diabetes Association","10.2337/db24-2081-lb","https://doi.org/10.2337/db24-2081-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038973","R0038973.pdf","paywalled","randomized_trial","Peabody, John W.","2024","Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial","Figshare",null,"10.6084/m9.figshare.c.6739593.v1","https://doi.org/10.6084/m9.figshare.c.6739593.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05237271"],["2","R0039102","R0039102.pdf","paywalled","randomized_trial","Ang Li","2024","893-P: Real-World Effectiveness of Finerenone in Chinese Patients with Type 2 Diabetes Mellitus (T2MD) and Chronic Kidney Disease (CKD)","Diabetes","American Diabetes Association","10.2337/db24-893-p","https://doi.org/10.2337/db24-893-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039462","R0039462.pdf","paywalled","randomized_trial","XIAO YAN XIN","2024","2072-LB: Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease","Diabetes","American Diabetes Association","10.2337/db24-2072-lb","https://doi.org/10.2337/db24-2072-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039633","R0039633.pdf","paywalled","randomized_trial",null,"2024","Science, Medicine, and the Anesthesiologist (October 2024): Erratum","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000005251","https://doi.org/10.1097/aln.0000000000005251","39530723","https://pubmed.ncbi.nlm.nih.gov/39530723/",null,null],["2","R0039684","R0039684.pdf","paywalled","randomized_trial","Linong Ji","2024","751-P: Benefits of HR17031, a Fixed-Ratio Combination of INS068 and SHR20004, vs. Its Components Alone in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Oral Antidiabetic Drug(s) (OADs)","Diabetes","American Diabetes Association","10.2337/db24-751-p","https://doi.org/10.2337/db24-751-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039691","R0039691.pdf","paywalled","randomized_trial","ZHIYI ZHU","2024","1871-LB: Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide","Diabetes","American Diabetes Association","10.2337/db24-1871-lb","https://doi.org/10.2337/db24-1871-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039910","R0039910.pdf","paywalled","randomized_trial","ZUNYUAN YANG","2024","1652-P: The Effectiveness of Semaglutide on Glucose Tolerance and Body Composition in Obese Diabetic Rhesus Monkeys","Diabetes","American Diabetes Association","10.2337/db24-1652-p","https://doi.org/10.2337/db24-1652-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040750","R0040750.pdf","paywalled","randomized_trial","Yuhao Deng","2024","Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials with Time-to-Event Outcomes under ICH E9 (R1)","arXiv (Cornell University)",null,"10.48550/arxiv.2401.14684","https://doi.org/10.48550/arxiv.2401.14684",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041405","R0041405.pdf","paywalled","randomized_trial","Lin, Diaozhu","2024","Additional file 1 of Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study","Figshare",null,"10.6084/m9.figshare.25918869","https://doi.org/10.6084/m9.figshare.25918869",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041528","R0041528.pdf","paywalled","randomized_trial","Jonathan Tjerkaski","2024","The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3311","https://doi.org/10.1093/eurheartj/ehae666.3311",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041564","R0041564.pdf","paywalled","randomized_trial","Athar Nawab","2024","Impact of Sglt-2 Inhibitors on Sickle Cell Disease Patients with Type 2 Diabetes: A Retrospective Matched Cohort Study","Blood","American Society of Hematology","10.1182/blood-2024-209371","https://doi.org/10.1182/blood-2024-209371",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041571","R0041571.pdf","paywalled","randomized_trial","Liang Peng","2024","Incretins for obstructive sleep apnea: effects mediated fully by weight loss?","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsae232","https://doi.org/10.1093/sleep/zsae232","39431950","https://pubmed.ncbi.nlm.nih.gov/39431950/",null,null],["2","R0041604","R0041604.pdf","paywalled","randomized_trial","Stefan Agewall","2024","Special focus on the new anti-diabetic drugs","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvae039","https://doi.org/10.1093/ehjcvp/pvae039","39012214","https://pubmed.ncbi.nlm.nih.gov/39012214/",null,null],["2","R0041659","R0041659.pdf","paywalled","randomized_trial","N Del-Cuerpo-Salinas","2024","Heart failure and renal outcomes in patient treated with GLP1 agonists","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.1036","https://doi.org/10.1093/eurheartj/ehae666.1036",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042072","R0042072.pdf","paywalled","randomized_trial","Grilo, Carlos","2024","Semaglutide and Behavioral Treatment for Binge-Eating Disorder Comorbid with Obesity","California Digital Library",null,"10.48321/d16d0a1e42","https://doi.org/10.48321/d16d0a1e42",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042267","R0042267.pdf","paywalled","randomized_trial","Yeung‐Ae Park","2024","Successful use of empagliflozin in medically refractory post‐bariatric surgery hypoglycaemia","Internal Medicine Journal","Wiley","10.1111/imj.16401","https://doi.org/10.1111/imj.16401","38757202","https://pubmed.ncbi.nlm.nih.gov/38757202/",null,"ClinicalTrials.gov:NCT05036317"],["2","R0042391","R0042391.pdf","paywalled","randomized_trial","Eugene Braunwald","2024","From cardiorenal to cardiovascular–kidney–metabolic syndromes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae775","https://doi.org/10.1093/eurheartj/ehae775","39699246","https://pubmed.ncbi.nlm.nih.gov/39699246/",null,null],["2","R0043206","R0043206.pdf","paywalled","randomized_trial","Wanning Wang","2024","Emulating randomized controlled trials using real-world evidence: The case of long-acting insulins among patients with type 2 diabetes","eScholarship@McGill (McGill)",null,"10.82308/35693","https://doi.org/10.82308/35693",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043402","R0043402.pdf","paywalled","randomized_trial","Buse J.B","2024","Case Study of Semaglutide and Cardiovascular Outcomes: An Application of the Causal Roadmap to a Hybrid Design for Augmenting an RCT Control Arm with Real-World Data","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/dzjx-xy02","https://doi.org/10.17615/dzjx-xy02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043543","R0043543.pdf","paywalled","randomized_trial","Sanaz Gabery","2024","Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/bf32-7709","https://doi.org/10.17615/bf32-7709",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043792","R0043792.pdf","paywalled","randomized_trial","Iatridi, Fotini","2024","A commentary from the European Renal Best Practice (ERBP) on the Kidney Disease Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in children and adults","Zurich Open Repository and Archive (University of Zurich)",null,"10.5167/uzh-264449","https://doi.org/10.5167/uzh-264449",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044879","R0044879.pdf","paywalled","randomized_trial","Filippo Crea","2024","Focus on the European Society of Cardiology: Guidelines on hypertension, Atlas of cardiovascular disease statistics, and Consensus statement on obesity","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae664","https://doi.org/10.1093/eurheartj/ehae664","39374627","https://pubmed.ncbi.nlm.nih.gov/39374627/",null,null],["2","R0044939","R0044939.pdf","paywalled","randomized_trial","Filippo Crea","2024","Heart failure and ischaemic heart disease: new challenges and opportunities","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae497","https://doi.org/10.1093/eurheartj/ehae497","39121015","https://pubmed.ncbi.nlm.nih.gov/39121015/",null,null],["2","R0045364","R0045364.pdf","paywalled","randomized_trial","Subodh Verma","2024","Abstract 4141117: Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4141117","https://doi.org/10.1161/circ.150.suppl_1.4141117",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045547","R0045547.pdf","paywalled","randomized_trial","Peter Novodvorský","2024","782-P: Insulin Therapy Deintensification with iGlarLixi—The IDEAL Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db24-782-p","https://doi.org/10.2337/db24-782-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045664","R0045664.pdf","paywalled","randomized_trial","Linong Ji","2024","752-P: Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics—Post Hoc Analysis of PIONEER 11 and 12","Diabetes","American Diabetes Association","10.2337/db24-752-p","https://doi.org/10.2337/db24-752-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045812","R0045812.pdf","paywalled","randomized_trial","M. Carel W. Le Roux","2024","A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight/obesity","Metabolism","Elsevier BV","10.1016/j.metabol.2024.155848","https://doi.org/10.1016/j.metabol.2024.155848",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045872","R0045872.pdf","paywalled","randomized_trial","Dalong Zhu","2024","742-P: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-742-p","https://doi.org/10.2337/db24-742-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046340","R0046340.pdf","paywalled","randomized_trial","Peter Novodvorský","2024","747-P: Insulin Therapy Deintensification with iGlarLixi (IDEAL) Randomized Controlled Trial—CGM-Related Outcomes","Diabetes","American Diabetes Association","10.2337/db24-747-p","https://doi.org/10.2337/db24-747-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046357","R0046357.pdf","paywalled","randomized_trial","Tamer Coşkun","2024","Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785379","https://doi.org/10.1055/s-0044-1785379",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046398","R0046398.pdf","paywalled","randomized_trial","Ania M. Jastreboff","2024","Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785389","https://doi.org/10.1055/s-0044-1785389",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046646","R0046646.pdf","paywalled","randomized_trial","Melissa‐Rosina Pasqua","2024","Subcutaneous Weekly Semaglutide as Adjunct to Automated Insulin Delivery: A Double-blinded, Randomized, Crossover Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.022","https://doi.org/10.1016/j.jcjd.2024.09.022",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046798","R0046798.pdf","paywalled","randomized_trial","Alison M. Bjornson","2024","1682-P: Weight Endpoints in Randomized Controlled Trials (Rcts) of Adults Eligible for Antiobesity Medications (AOM)—A Systematic Literature Review (SLR)","Diabetes","American Diabetes Association","10.2337/db24-1682-p","https://doi.org/10.2337/db24-1682-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047241","R0047241.pdf","paywalled","randomized_trial","Brett Thomas Phillips","2024","Spotlight in Plastic Surgery: October 2024","Plastic & Reconstructive Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000011591","https://doi.org/10.1097/prs.0000000000011591","39314108","https://pubmed.ncbi.nlm.nih.gov/39314108/",null,null],["2","R0047311","R0047311.pdf","paywalled","randomized_trial","Temitope Olasehinde","2024","S472 Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031256.48901.46","https://doi.org/10.14309/01.ajg.0001031256.48901.46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047352","R0047352.pdf","paywalled","randomized_trial","Scott R. Anderson","2024","S1086 Weight Loss and Safety of Glucagon-like Peptide-1 Agonists in Inflammatory Bowel Disease Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033712.16587.dd","https://doi.org/10.14309/01.ajg.0001033712.16587.dd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047366","R0047366.pdf","paywalled","randomized_trial","Hiddo Jan L. Heerspink","2024","Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20242wv2xw41","https://doi.org/10.1681/asn.20242wv2xw41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047472","R0047472.pdf","paywalled","randomized_trial","RAJAMANNAR THENNATI","2024","121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db24-121-or","https://doi.org/10.2337/db24-121-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047529","R0047529.pdf","paywalled","randomized_trial","Andrea Pozzi","2024","ADVERSE EVENTS ASSOCIATED WITH GLP1–RECEPTOR AGONISTS TREATMENT IN DIABETIC PATIENTS WITH HIGH CARDIOVASCULAR RISK: A META–ANALYSIS","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suae036.288","https://doi.org/10.1093/eurheartjsupp/suae036.288",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047580","R0047580.pdf","paywalled","randomized_trial","Hans H. Herfarth","2024","Su1752 EFFICACY AND SAFETY OF LIRAGLUTIDE IN PATIENTS WITH PATIENTS WITH AN ILEAL -POUCH-ANAL ANASTOMOSIS (IPAA) AND CHRONIC HIGH BOWEL FREQUENCY – PLACEBO-CONTROLLED, CROSSOVER, PROOF OF CONCEPT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)02316-3","https://doi.org/10.1016/s0016-5085(24)02316-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047644","R0047644.pdf","paywalled","randomized_trial","Julia Beck","2024","BLOOD PRESSURE CHANGES DURING SMOKING CESSATION ON DULAGLUTIDE AND PLACEBO TREATMENT – A SECONDARY ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED SKIP TRIAL","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001021732.82658.1f","https://doi.org/10.1097/01.hjh.0001021732.82658.1f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047709","R0047709.pdf","paywalled","randomized_trial","Kahn S.E","2024","Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/2s2m-qy50","https://doi.org/10.17615/2s2m-qy50",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047933","R0047933.pdf","paywalled","randomized_trial","Shahzad Hassan","2024","Abstract 4146888: Safety report from a remote disease management program to improve sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonist prescribing in Type 2 diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4146888","https://doi.org/10.1161/circ.150.suppl_1.4146888",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047966","R0047966.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2024","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on carotid intima-media thickness","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2280","https://doi.org/10.1093/eurheartj/ehae666.2280",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047992","R0047992.pdf","paywalled","randomized_trial","Sulman Khan","2024","S2308 Predictive Value of Gastric Myoelectrical Activity in Patient Satisfaction after Gastric Per-Oral Myotomy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038600.00193.18","https://doi.org/10.14309/01.ajg.0001038600.00193.18",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048218","R0048218.pdf","paywalled","randomized_trial","Juan P. Frías","2024","Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785387","https://doi.org/10.1055/s-0044-1785387",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048243","R0048243.pdf","paywalled","randomized_trial","Alice Liou Fitzpatrick","2024","261-OR: ADA Presidents' Select Abstract: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity","Diabetes","American Diabetes Association","10.2337/db24-261-or","https://doi.org/10.2337/db24-261-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048249","R0048249.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2024","The effect of the combined treatment with dulaglutide and dapagliflozin in arterial elasticity, cardiac function, albuminuria and endothelial thickness in type 2 diabetes mellitus after 12 months","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3265","https://doi.org/10.1093/eurheartj/ehae666.3265",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048303","R0048303.pdf","paywalled","randomized_trial","Jack Bowden","2024","Instrumental Variable methods to target Hypothetical Estimands with longitudinal repeated measures data: Application to the STEP 1 trial","arXiv (Cornell University)",null,"10.48550/arxiv.2407.02902","https://doi.org/10.48550/arxiv.2407.02902",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048442","R0048442.pdf","paywalled","randomized_trial","Helen Martina Colhoun","2024","Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2792","https://doi.org/10.1093/eurheartj/ehae666.2792",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048463","R0048463.pdf","paywalled","randomized_trial","Engelmann M.D.M","2024","Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/aayt-4b73","https://doi.org/10.17615/aayt-4b73",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048505","R0048505.pdf","paywalled","randomized_trial","NITSAN SHACHAM","2024","1182-P: GLP-1 Agonist Therapy in Adolescents and Young Adults with Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1182-p","https://doi.org/10.2337/db24-1182-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048574","R0048574.pdf","paywalled","randomized_trial","Chisom Kanu","2024","753-P: Eating Behavior in Adults with Type 2 Diabetes from a Phase 2 Study of Retatrutide","Diabetes","American Diabetes Association","10.2337/db24-753-p","https://doi.org/10.2337/db24-753-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048705","R0048705.pdf","paywalled","randomized_trial","Millie D. Long","2024","Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/vnc4-px11","https://doi.org/10.17615/vnc4-px11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048791","R0048791.pdf","paywalled","randomized_trial","Tummas Ternhamar","2024","Abstract 4141127: Combined use of cardioprotective glucose-lowering drugs and statins in individuals with type 2 diabetes is associated with the lowest risk of all-cause mortality","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4141127","https://doi.org/10.1161/circ.150.suppl_1.4141127",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048925","R0048925.pdf","paywalled","randomized_trial","Ramesh Nadarajah","2024","204 Machine learning for incident cardio-renal-metabolic disease and cardiovascular death: the optimise study",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2024-bcs.199","https://doi.org/10.1136/heartjnl-2024-bcs.199",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048946","R0048946.pdf","paywalled","randomized_trial","Talal Almas","2024","Abstract 4147387: Outcomes of Heart Failure with Preserved Ejection Fraction with GLP1RA plus SGLT2i vs SGLT2i alone: A Propensity-Matched Nationwide Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4147387","https://doi.org/10.1161/circ.150.suppl_1.4147387",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048967","R0048967.pdf","paywalled","randomized_trial","Wretlind, Asger","2024","Additional file 1 of Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","Figshare",null,"10.6084/m9.figshare.26619862","https://doi.org/10.6084/m9.figshare.26619862",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049007","R0049007.pdf","paywalled","randomized_trial","Stephen James Nicholls","2024","Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.1501","https://doi.org/10.1093/eurheartj/ehae666.1501",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049086","R0049086.pdf","paywalled","randomized_trial","Ying Chen","2024","1672-P: Weight Changes after Tirzepatide Cessation in Chinese Adults with Overweight/Obesity—A Real-World Follow-up Study of SURMOUNT-CN Trial","Diabetes","American Diabetes Association","10.2337/db24-1672-p","https://doi.org/10.2337/db24-1672-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049190","R0049190.pdf","paywalled","randomized_trial","Thim Prætorius","2024","192-OR: Effect of Video Conferences between Endocrinologists and Family Doctors on Levels of Recommended Medication among Persons with Type 2 Diabetes—Pragmatic RCT","Diabetes","American Diabetes Association","10.2337/db24-192-or","https://doi.org/10.2337/db24-192-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049486","R0049486.pdf","paywalled","randomized_trial","Cormac Kennedy","2024","The expanding role of semaglutide in cardiovascular disease and its the effect on blood pressure","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2591","https://doi.org/10.1093/eurheartj/ehae666.2591",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049556","R0049556.pdf","paywalled","randomized_trial","Edward John Pratt","2024","A Long-Acting Glucose Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss Without Nausea or Vomiting","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785388","https://doi.org/10.1055/s-0044-1785388",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049559","R0049559.pdf","paywalled","randomized_trial","Kristina Secnik Boye","2024","Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785382","https://doi.org/10.1055/s-0044-1785382",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049563","R0049563.pdf","paywalled","randomized_trial","Owen Thomas Carmichael","2024","263-OR: Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain","Diabetes","American Diabetes Association","10.2337/db24-263-or","https://doi.org/10.2337/db24-263-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049614","R0049614.pdf","paywalled","randomized_trial","Naveed A. Sattar","2024","Abstract 4120229: Shift in body mass index category and associated cardiometabolic risk factors: a post hoc analysis from the SURMOUNT-4 trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4120229","https://doi.org/10.1161/circ.150.suppl_1.4120229",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049704","R0049704.pdf","paywalled","randomized_trial","Landon W Trost","2024","Update to the Testosterone Guideline","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/ju.0000000000003855","https://doi.org/10.1097/ju.0000000000003855","38456434","https://pubmed.ncbi.nlm.nih.gov/38456434/",null,null],["2","R0049706","R0049706.pdf","paywalled","randomized_trial","Jeffrey Crawford","2024","2067-LB: Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials","Diabetes","American Diabetes Association","10.2337/db24-2067-lb","https://doi.org/10.2337/db24-2067-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049761","R0049761.pdf","paywalled","randomized_trial","Daniel L. Edmonston","2024","912-P: Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-912-p","https://doi.org/10.2337/db24-912-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049782","R0049782.pdf","paywalled","randomized_trial","Janet K. Snell‐Bergeon","2024","739-P: Efficacy and Safety of Tirzepatide in Overweight (OW) and Obese (OB) Patients with Type 1 Diabetes (T1D)","Diabetes","American Diabetes Association","10.2337/db24-739-p","https://doi.org/10.2337/db24-739-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049814","R0049814.pdf","paywalled","randomized_trial","SHARVIL S. GADVE","2024","877-P: Effect of Lobeglitazone, a Novel Thiazolidinedione, on Liver Fat in Patients with Type 2 Diabetes and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)—A Randomized Controlled Trial (Lobe-MASLD Trial)","Diabetes","American Diabetes Association","10.2337/db24-877-p","https://doi.org/10.2337/db24-877-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049859","R0049859.pdf","paywalled","randomized_trial","Cormac Kennedy","2024","Semaglutide for the treatment of resistant hypertension","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2590","https://doi.org/10.1093/eurheartj/ehae666.2590",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049880","R0049880.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2024","229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-229-or","https://doi.org/10.2337/db24-229-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049936","R0049936.pdf","paywalled","randomized_trial","Buse J.B","2024","Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/2d2s-yg87","https://doi.org/10.17615/2d2s-yg87",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050201","R0050201.pdf","paywalled","randomized_trial","Svenja Leibnitz","2024","Effects of Glucagon-like Peptide-1 Receptor Agonists on Copeptin in healthy volunteers and patients with primary polydipsia-A secondary analysis of the randomized, double-blind, placebo-controlled, crossover GOLD & GATE trials","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.99.oc5.1","https://doi.org/10.1530/endoabs.99.oc5.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050359","R0050359.pdf","paywalled","randomized_trial","Louis J. Aronne","2024","262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial","Diabetes","American Diabetes Association","10.2337/db24-262-or","https://doi.org/10.2337/db24-262-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050494","R0050494.pdf","paywalled","randomized_trial","Linong Ji","2024","1858-LB: A Novel GLP-1 Analog, GZR18, Induced an 18.6% Weight Reduction in Subjects with Obesity in a Phase Ib/IIa Trial","Diabetes","American Diabetes Association","10.2337/db24-1858-lb","https://doi.org/10.2337/db24-1858-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050532","R0050532.pdf","paywalled","randomized_trial","Filip Krag Knop","2024","A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785380","https://doi.org/10.1055/s-0044-1785380",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050653","R0050653.pdf","paywalled","randomized_trial","Louis J. Aronne","2024","Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785403","https://doi.org/10.1055/s-0044-1785403",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050661","R0050661.pdf","paywalled","randomized_trial","Abdul-Rahman Fadi Diab","2024","S1509 Bariatric Endoscopic Gastric Remodeling (BEGR) With Versus Without Pharmacotherapy With Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RAs): An Analysis of 985 Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035404.34681.f8","https://doi.org/10.14309/01.ajg.0001035404.34681.f8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051003","R0051003.pdf","paywalled","randomized_trial","Thomas W. Fredrick","2024","S2080 Analysis of Provider Preferences for AI-Generated Responses to Anti-Obesity Treatments","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037688.24010.4d","https://doi.org/10.14309/01.ajg.0001037688.24010.4d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051018","R0051018.pdf","paywalled","randomized_trial","Sean Wharton","2024","Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785400","https://doi.org/10.1055/s-0044-1785400",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051020","R0051020.pdf","paywalled","randomized_trial","Richard E. Pratley","2024","Effect of Semaglutide on Mortality Outcomes in the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20249xpc35vs","https://doi.org/10.1681/asn.20249xpc35vs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051087","R0051087.pdf","paywalled","randomized_trial","Philip Noel Newsome","2024","SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01771-9","https://doi.org/10.1016/s0168-8278(24)01771-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051135","R0051135.pdf","paywalled","randomized_trial","Cyrill Muller","2024","Effects of glucagon-like peptide-1 analogs on prolactin: a randomized, double-blind, placebo-controlled crossover trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.99.p549","https://doi.org/10.1530/endoabs.99.p549",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051175","R0051175.pdf","paywalled","randomized_trial","Naim Alkhouri","2024","WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01555-1","https://doi.org/10.1016/s0168-8278(24)01555-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051334","R0051334.pdf","paywalled","randomized_trial","Marwa R. Al-Badri","2024","14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists","Diabetes","American Diabetes Association","10.2337/db24-14-pub","https://doi.org/10.2337/db24-14-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051384","R0051384.pdf","paywalled","randomized_trial","Linda-Marie Ustaris Lavenburg","2024","Impact of Population Health Management to Modify Disparate Use of SGLT2 Inhibitors/Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs)","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024hfarrmfb","https://doi.org/10.1681/asn.2024hfarrmfb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051453","R0051453.pdf","paywalled","randomized_trial","Elaine M. Glenny","2024","Abstract 2189: Tirzepatide mitigates obesity-associated metabolic dysregulation and tumor progression in a mouse model of triple-negative breast cancer","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2024-2189","https://doi.org/10.1158/1538-7445.am2024-2189",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051474","R0051474.pdf","paywalled","randomized_trial","Ahmad Abdulraheem","2024","S2653 The Role of GLP-1 Agonist in Acute Cholecystitis After a Routine Colonoscopy: A Case Report","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001039980.58080.a2","https://doi.org/10.14309/01.ajg.0001039980.58080.a2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051562","R0051562.pdf","paywalled","randomized_trial","Irina Jouravskaya","2024","1675-P: Patient Experiences with Tirzepatide in SURMOUNT-4","Diabetes","American Diabetes Association","10.2337/db24-1675-p","https://doi.org/10.2337/db24-1675-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051569","R0051569.pdf","paywalled","randomized_trial","CAROL H. WYSHAM","2024","743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-743-p","https://doi.org/10.2337/db24-743-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051618","R0051618.pdf","paywalled","randomized_trial","Niharika Katkam","2024","Insulin Glargine and SGLT2 Inhibitors Have Higher Risk of Major Adverse Cardiovascular Events (MACE) Compared with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in a National Cohort of Veterans with Type 2 Diabetes (T2D) and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024sdjbfbv4","https://doi.org/10.1681/asn.2024sdjbfbv4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051696","R0051696.pdf","paywalled","randomized_trial","Michael F. Coleman","2024","Abstract 2188: Tirzepatide treatment restores antitumor immunity in a model of obesity-driven cancer","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2024-2188","https://doi.org/10.1158/1538-7445.am2024-2188",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051795","R0051795.pdf","paywalled","randomized_trial","Jesse E. Otero","2024","What’s New in Musculoskeletal Infection","Journal of Bone and Joint Surgery","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.24.00230","https://doi.org/10.2106/jbjs.24.00230","38781349","https://pubmed.ncbi.nlm.nih.gov/38781349/",null,null],["2","R0051865","R0051865.pdf","paywalled","randomized_trial","Ryan P. Chang","2024","Weight-Loss Interventions in Patients with Overweight/Obesity and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024a0855adb","https://doi.org/10.1681/asn.2024a0855adb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051974","R0051974.pdf","paywalled","randomized_trial","Francisca M. Acosta","2024","812-P: Safety and Efficacy of Early Initiation of GLP1RA and SGLT2 inhibitors, in Post–Kidney Transplant Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-812-p","https://doi.org/10.2337/db24-812-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052027","R0052027.pdf","paywalled","randomized_trial","Marso S.P","2024","Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/c7mx-4407","https://doi.org/10.17615/c7mx-4407",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052060","R0052060.pdf","paywalled","randomized_trial","Phyo Than Htoo","2024","Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/5s0p-d104","https://doi.org/10.17615/5s0p-d104",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052128","R0052128.pdf","paywalled","randomized_trial","Valentina Pirro","2024","117-OR: Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity","Diabetes","American Diabetes Association","10.2337/db24-117-or","https://doi.org/10.2337/db24-117-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052275","R0052275.pdf","paywalled","randomized_trial","Corby K. Martin","2024","Effects of Tirzepatide on Eating Behaviour: A Phase 1 Study in People Living with Obesity","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785402","https://doi.org/10.1055/s-0044-1785402",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052472","R0052472.pdf","paywalled","randomized_trial","Lin Zhao","2024","1861-LB: Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults—A Phase 2 Trial","Diabetes","American Diabetes Association","10.2337/db24-1861-lb","https://doi.org/10.2337/db24-1861-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052640","R0052640.pdf","paywalled","randomized_trial","Arun J. Sanyal","2024","GS-006 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)00430-6","https://doi.org/10.1016/s0168-8278(24)00430-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052692","R0052692.pdf","paywalled","randomized_trial","Sabina M. Sorondo","2024","Abstract 4141929: Genetic Evidence for GIP as a Therapeutic Target for Peripheral Artery Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4141929","https://doi.org/10.1161/circ.150.suppl_1.4141929",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052703","R0052703.pdf","paywalled","randomized_trial","H. v. Lilienfeld-Toal","2024","Weight reduction course boosts impact of GLP-1 agonist","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785371","https://doi.org/10.1055/s-0044-1785371",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052722","R0052722.pdf","paywalled","randomized_trial","Neda Rasouli","2024","784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial","Diabetes","American Diabetes Association","10.2337/db24-784-p","https://doi.org/10.2337/db24-784-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052754","R0052754.pdf","paywalled","randomized_trial","Shira Zelber‐Sagi","2024","Is curcumin the new kid on the block for the treatment of MASH?","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000949","https://doi.org/10.1097/hep.0000000000000949","38937942","https://pubmed.ncbi.nlm.nih.gov/38937942/",null,null],["2","R0052922","R0052922.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2024","Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024bjyvcgfe","https://doi.org/10.1681/asn.2024bjyvcgfe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053033","R0053033.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2024","Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2925","https://doi.org/10.1093/eurheartj/ehae666.2925",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053105","R0053105.pdf","paywalled","randomized_trial","Thomas A. Wadden","2024","Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785401","https://doi.org/10.1055/s-0044-1785401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053113","R0053113.pdf","paywalled","randomized_trial","Arun Jayant Sanyal","2024","O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: results from a randomised, double-blind, placebo-controlled phase 2 trial",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2024-basl.5","https://doi.org/10.1136/gutjnl-2024-basl.5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053126","R0053126.pdf","paywalled","randomized_trial","Helen Martina Colhoun","2024","#2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfae069.692","https://doi.org/10.1093/ndt/gfae069.692",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053340","R0053340.pdf","paywalled","randomized_trial","Cho Y.M","2024","Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/7bmd-2j28","https://doi.org/10.17615/7bmd-2j28",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053345","R0053345.pdf","paywalled","randomized_trial","Ajay Singh","2024","Finerenone in Patients with Type 2 Diabetes and CKD by SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists Receptor Agonist Use: A FIDELITY Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024z6zpnkzd","https://doi.org/10.1681/asn.2024z6zpnkzd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053547","R0053547.pdf","paywalled","randomized_trial","Zubin Punthakee","2024","1870-LB: Evaluating Remission of Type 2 Diabetes Using a Metabolic Intervention Including Fixed-Ratio Insulin Degludec and Liraglutide—A Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db24-1870-lb","https://doi.org/10.2337/db24-1870-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053586","R0053586.pdf","paywalled","randomized_trial","Rajamannar Thennati","2024","Abstract 4116298: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 × 450 µg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4116298","https://doi.org/10.1161/circ.150.suppl_1.4116298",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053654","R0053654.pdf","paywalled","randomized_trial","Liam Byrne","2024","Long-Term Follow-Up of GLP-1 receptor agonist therapy for type 2 diabetes mellitus","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22812604","https://doi.org/10.5281/zenodo.22812604",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054473","R0054473.pdf","paywalled","randomized_trial","Maria Luiza Caramori","2024","Characteristics of Patients with Type 1 Diabetes (T1D) and CKD Receiving Novel Kidney Protective Therapies (KPT)","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20241gdh8x5e","https://doi.org/10.1681/asn.20241gdh8x5e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054561","R0054561.pdf","paywalled","randomized_trial","Vincent Lingzhi Chen","2024","Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001112","https://doi.org/10.1097/hep.0000000000001112","39422487","https://pubmed.ncbi.nlm.nih.gov/39422487/",null,null],["2","R0054683","R0054683.pdf","paywalled","randomized_trial","Morag Nelson","2024","Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.114","https://doi.org/10.1016/j.orcp.2024.09.114",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054759","R0054759.pdf","paywalled","randomized_trial","Haluzik, Martin","2024","Insulin therapy DE-intensificAtion with iGlarLixi: the IDEAL randomised controlled trial","Diabetologia",null,"10.5281/zenodo.14235366","https://doi.org/10.5281/zenodo.14235366",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0003958","R0003958.pdf","paywalled","randomized_trial","Teague M","2023","Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2023.02.003","https://doi.org/10.1016/j.clinthera.2023.02.003","36872170","https://pubmed.ncbi.nlm.nih.gov/36872170/",null,null],["2","R0004760","R0004760.pdf","paywalled","randomized_trial","Jalleh RJ","2023","Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists.","Annals of internal medicine","American College of Physicians","10.7326/m23-2019","https://doi.org/10.7326/m23-2019","37931267","https://pubmed.ncbi.nlm.nih.gov/37931267/",null,null],["2","R0004939","R0004939.pdf","paywalled","randomized_trial","Clemens KK","2023","Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2023.03.023","https://doi.org/10.1016/j.numecd.2023.03.023","37100640","https://pubmed.ncbi.nlm.nih.gov/37100640/",null,null],["2","R0004986","R0004986.pdf","paywalled","randomized_trial","Yammine L","2023","Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.","Journal of addiction medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/adm.0000000000001147","https://doi.org/10.1097/adm.0000000000001147","37579116","https://pubmed.ncbi.nlm.nih.gov/37579116/",null,"ClinicalTrials.gov:NCT04941521"],["2","R0005214","R0005214.pdf","paywalled","randomized_trial","Kimura T","2023","Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15258","https://doi.org/10.1111/dom.15258","37646192","https://pubmed.ncbi.nlm.nih.gov/37646192/",null,null],["2","R0005381","R0005381.pdf","paywalled","randomized_trial","Kim SQ","2023","Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.","Biochemical and biophysical research communications","Elsevier BV","10.1016/j.bbrc.2023.149164","https://doi.org/10.1016/j.bbrc.2023.149164","37951155","https://pubmed.ncbi.nlm.nih.gov/37951155/",null,null],["2","R0005551","R0005551.pdf","paywalled","randomized_trial","Carriazo S","2023","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Annals of internal medicine","American College of Physicians","10.7326/l23-0005","https://doi.org/10.7326/l23-0005","37068289","https://pubmed.ncbi.nlm.nih.gov/37068289/",null,null],["2","R0005555","R0005555.pdf","paywalled","randomized_trial","Hanna C","2023","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Annals of internal medicine","American College of Physicians","10.7326/l23-0006","https://doi.org/10.7326/l23-0006","37068293","https://pubmed.ncbi.nlm.nih.gov/37068293/",null,null],["2","R0005712","R0005712.pdf","paywalled","randomized_trial","Richards JR","2023","Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.","The Journal of clinical psychiatry","Physicians Postgraduate Press, Inc","10.4088/jcp.23m15068","https://doi.org/10.4088/jcp.23m15068","38019594","https://pubmed.ncbi.nlm.nih.gov/38019594/",null,null],["2","R0005741","R0005741.pdf","paywalled","randomized_trial","Zhang J","2023","Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102804","https://doi.org/10.1016/j.dsx.2023.102804","37315473","https://pubmed.ncbi.nlm.nih.gov/37315473/",null,null],["2","R0006094","R0006094.pdf","paywalled","randomized_trial","Liarakos AL","2023","Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108390","https://doi.org/10.1016/j.jdiacomp.2022.108390","36610322","https://pubmed.ncbi.nlm.nih.gov/36610322/",null,null],["2","R0006253","R0006253.pdf","paywalled","randomized_trial","Scheen AJ","2023","Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2023.2279193","https://doi.org/10.1080/17512433.2023.2279193","37919944","https://pubmed.ncbi.nlm.nih.gov/37919944/",null,null],["2","R0006256","R0006256.pdf","paywalled","randomized_trial","Scheen AJ","2023","Clinical pharmacology of antidiabetic drugs: What can be expected of their use?","Presse medicale (Paris, France : 1983)","Elsevier BV","10.1016/j.lpm.2022.104158","https://doi.org/10.1016/j.lpm.2022.104158","36565754","https://pubmed.ncbi.nlm.nih.gov/36565754/",null,null],["2","R0006379","R0006379.pdf","paywalled","randomized_trial","Lim LL","2023","Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/s41574-022-00776-2","https://doi.org/10.1038/s41574-022-00776-2","36446898","https://pubmed.ncbi.nlm.nih.gov/36446898/",null,null],["2","R0006548","R0006548.pdf","paywalled","randomized_trial","Bai S","2023","Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2023.01.008","https://doi.org/10.1016/j.ejim.2023.01.008","36628824","https://pubmed.ncbi.nlm.nih.gov/36628824/",null,null],["2","R0007050","R0007050.pdf","paywalled","randomized_trial","Popovic DS","2023","The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2023.2274988","https://doi.org/10.1080/17512433.2023.2274988","37864783","https://pubmed.ncbi.nlm.nih.gov/37864783/",null,null],["2","R0007205","R0007205.pdf","paywalled","randomized_trial","Michaud L","2023","Safety and cardiometabolic efficacy of novel antidiabetic drugs.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2023.2188190","https://doi.org/10.1080/14740338.2023.2188190","36877138","https://pubmed.ncbi.nlm.nih.gov/36877138/",null,null],["2","R0007628","R0007628.pdf","paywalled","randomized_trial","Munoz Pena JM","2023","Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad395","https://doi.org/10.1210/clinem/dgad395","37410930","https://pubmed.ncbi.nlm.nih.gov/37410930/",null,null],["2","R0008513","R0008513.pdf","paywalled","randomized_trial","Wang N","2023","Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes.","Presse medicale (Paris, France : 1983)","Elsevier BV","10.1016/j.lpm.2022.104160","https://doi.org/10.1016/j.lpm.2022.104160","36565752","https://pubmed.ncbi.nlm.nih.gov/36565752/",null,null],["2","R0009068","R0009068.pdf","paywalled","randomized_trial","Popovic DS","2023","Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-2019-1111","https://doi.org/10.1055/a-2019-1111","36693416","https://pubmed.ncbi.nlm.nih.gov/36693416/",null,null],["2","R0009297","R0009297.pdf","paywalled","randomized_trial","Feng S","2023","A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.1187","https://doi.org/10.1002/cpdd.1187","36648126","https://pubmed.ncbi.nlm.nih.gov/36648126/",null,"ChiCTR:ChiCTR2100043348"],["2","R0010061","R0010061.pdf","paywalled","randomized_trial","Lexchin J","2023","Semaglutide: a new drug for the treatment of obesity.","Drug and therapeutics bulletin","BMJ","10.1136/dtb.2023.000007","https://doi.org/10.1136/dtb.2023.000007","37879878","https://pubmed.ncbi.nlm.nih.gov/37879878/",null,null],["2","R0011108","R0011108.pdf","paywalled","randomized_trial","Sciacqua A","2023","Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-021-10182-x","https://doi.org/10.1007/s10741-021-10182-x","34859336","https://pubmed.ncbi.nlm.nih.gov/34859336/",null,null],["2","R0013091","R0013091.pdf","paywalled","randomized_trial","Bradley CL","2023","Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280221134127","https://doi.org/10.1177/10600280221134127","36367094","https://pubmed.ncbi.nlm.nih.gov/36367094/",null,null],["2","R0013174","R0013174.pdf","paywalled","randomized_trial","Stenlid R","2023","Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.","Annals of nutrition & metabolism","S. Karger AG","10.1159/000534725","https://doi.org/10.1159/000534725","37883939","https://pubmed.ncbi.nlm.nih.gov/37883939/",null,null],["2","R0013628","R0013628.pdf","paywalled","randomized_trial","Jiang Y","2023","A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-023-01255-w","https://doi.org/10.1007/s40261-023-01255-w","36943659","https://pubmed.ncbi.nlm.nih.gov/36943659/",null,null],["2","R0015067","R0015067.pdf","paywalled","randomized_trial","Xie Y","2023","Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(23)00171-7","https://doi.org/10.1016/s2213-8587(23)00171-7","37499675","https://pubmed.ncbi.nlm.nih.gov/37499675/",null,null],["2","R0015154","R0015154.pdf","paywalled","randomized_trial","Zhang Q","2023","Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.","Expert opinion on biological therapy","Informa UK Limited","10.1080/14712598.2023.2189009","https://doi.org/10.1080/14712598.2023.2189009","36880118","https://pubmed.ncbi.nlm.nih.gov/36880118/",null,"ChiCTR:ChiCTR2200066519"],["2","R0016454","R0016454.pdf","paywalled","randomized_trial","Markey K","2023","Idiopathic intracranial hypertension: expanding our understanding.","Current opinion in neurology","Ovid Technologies (Wolters Kluwer Health)","10.1097/wco.0000000000001209","https://doi.org/10.1097/wco.0000000000001209","37865852","https://pubmed.ncbi.nlm.nih.gov/37865852/",null,null],["2","R0016987","R0016987.pdf","paywalled","randomized_trial","Bechlioulis A","2023","The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2023.108436","https://doi.org/10.1016/j.jdiacomp.2023.108436","36842186","https://pubmed.ncbi.nlm.nih.gov/36842186/",null,null],["2","R0018013","R0018013.pdf","paywalled","randomized_trial","Erdogan MA","2023","The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties.","Neurochemical research","Springer Science and Business Media LLC","10.1007/s11064-022-03736-4","https://doi.org/10.1007/s11064-022-03736-4","36040609","https://pubmed.ncbi.nlm.nih.gov/36040609/",null,null],["2","R0019885","R0019885.pdf","paywalled","randomized_trial","Lee EY","2023","Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110884","https://doi.org/10.1016/j.diabres.2023.110884","37595844","https://pubmed.ncbi.nlm.nih.gov/37595844/",null,"KCT:KCT0006157"],["2","R0020271","R0020271.pdf","paywalled","randomized_trial","Oe Y","2023","Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02327-7","https://doi.org/10.1007/s12325-022-02327-7","36306064","https://pubmed.ncbi.nlm.nih.gov/36306064/",null,null],["2","R0020344","R0020344.pdf","paywalled","randomized_trial","Kawaguchi Y","2023","Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02328-6","https://doi.org/10.1007/s12325-022-02328-6","36261771","https://pubmed.ncbi.nlm.nih.gov/36261771/",null,null],["2","R0020460","R0020460.pdf","paywalled","randomized_trial","Davidson MB","2023","In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.","Annals of internal medicine","American College of Physicians","10.7326/j23-0089","https://doi.org/10.7326/j23-0089","37931265","https://pubmed.ncbi.nlm.nih.gov/37931265/",null,null],["2","R0020509","R0020509.pdf","paywalled","randomized_trial","Sun W","2023","Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.","Current medical science","Springer Science and Business Media LLC","10.1007/s11596-023-2776-8","https://doi.org/10.1007/s11596-023-2776-8","37594676","https://pubmed.ncbi.nlm.nih.gov/37594676/",null,null],["2","R0020718","R0020718.pdf","paywalled","randomized_trial","Leventhal-Perek S","2023","Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.","Family practice","Oxford University Press (OUP)","10.1093/fampra/cmac141","https://doi.org/10.1093/fampra/cmac141","36477550","https://pubmed.ncbi.nlm.nih.gov/36477550/",null,null],["2","R0020752","R0020752.pdf","paywalled","randomized_trial","Alsayed Hasan M","2023","An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-023-06758-1","https://doi.org/10.1007/s11695-023-06758-1","37530920","https://pubmed.ncbi.nlm.nih.gov/37530920/",null,null],["2","R0021249","R0021249.pdf","paywalled","randomized_trial","Thivolet C","2023","Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2023.101433","https://doi.org/10.1016/j.diabet.2023.101433","36781064","https://pubmed.ncbi.nlm.nih.gov/36781064/",null,null],["2","R0021839","R0021839.pdf","paywalled","randomized_trial","Snaith JR","2023","Once-Weekly Semaglutide in Adolescents with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2300510","https://doi.org/10.1056/nejmc2300510","36947474","https://pubmed.ncbi.nlm.nih.gov/36947474/",null,null],["2","R0022225","R0022225.pdf","paywalled","randomized_trial","Meng XM","2023","[Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].","Zhonghua yi xue za zhi",null,"10.3760/cma.j.cn112137-20220924-02018","https://doi.org/10.3760/cma.j.cn112137-20220924-02018","37150681","https://pubmed.ncbi.nlm.nih.gov/37150681/",null,null],["2","R0022262","R0022262.pdf","paywalled","randomized_trial","Chandran L","2023","Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset Autoimmune Diabetes in Adults: A Concise Review.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399818666220324095918","https://doi.org/10.2174/1573399818666220324095918","35331118","https://pubmed.ncbi.nlm.nih.gov/35331118/",null,null],["2","R0022426","R0022426.pdf","paywalled","randomized_trial","Strokov IA","2023","[Efficacy and safety of Cytoflavin in the treatment of diabetic polyneuropathy: results of a multicenter, double-blind, placebo-controlled, randomized CYLINDER study].","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","Media Sphere Publishing House","10.17116/jnevro2023123051100","https://doi.org/10.17116/jnevro2023123051100","37315248","https://pubmed.ncbi.nlm.nih.gov/37315248/",null,null],["2","R0026343","R0026343.pdf","paywalled","randomized_trial","Retnakaran R","2023","Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15073","https://doi.org/10.1111/dom.15073","37380623","https://pubmed.ncbi.nlm.nih.gov/37380623/",null,null],["2","R0028889","R0028889.pdf","paywalled","randomized_trial","Milloh-Raz H","2023","Protecting the Brains of People With Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad191","https://doi.org/10.1210/clinem/dgad191","37009694","https://pubmed.ncbi.nlm.nih.gov/37009694/",null,null],["2","R0031665","R0031665.pdf","paywalled","randomized_trial","Ahmed Hossain","2023","Short-term and low-dose liraglutide plus metformin decreased body mass index and insulin resistance more than metformin alone in obese women with polycystic ovary syndrome: An open-label randomized controlled study","Greater South Information System",null,"10.60692/d2w4w-3se76","https://doi.org/10.60692/d2w4w-3se76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032681","R0032681.pdf","paywalled","randomized_trial","Barrie Chubb","2023","790-P: An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-790-p","https://doi.org/10.2337/db23-790-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032804","R0032804.pdf","paywalled","randomized_trial","Yuqin Zhang","2023","111-OR: Effect of Dulaglutide plus Calorie-Restricted Diet vs. Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome—A Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db23-111-or","https://doi.org/10.2337/db23-111-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032851","R0032851.pdf","paywalled","randomized_trial","Shafi Malik","2023","Cardiovascular Disease, Hypertension, and Diabetes (Part A)",null,"Oxford University PressOxford","10.1093/oso/9780192844163.003.0006","https://doi.org/10.1093/oso/9780192844163.003.0006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033225","R0033225.pdf","paywalled","randomized_trial",null,"2023","FDA Approving Drugs After Fewer Trials With Less Public Disclosure","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000978992.77433.22","https://doi.org/10.1097/01.cot.0000978992.77433.22",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033244","R0033244.pdf","paywalled","randomized_trial","Xunrong Luo","2023","Research Highlights","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000004547","https://doi.org/10.1097/tp.0000000000004547",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033587","R0033587.pdf","paywalled","randomized_trial","Santos-Pardo, Irene","2023","Additional file 1 of Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study","Figshare",null,"10.6084/m9.figshare.24779232","https://doi.org/10.6084/m9.figshare.24779232",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033805","R0033805.pdf","paywalled","randomized_trial","Dietsche, Katrina","2023","Glycemia and Gluconeogenesis in Youth-onset Type 2 diabetes: A Randomized Controlled Trial","Figshare",null,"10.6084/m9.figshare.24492187","https://doi.org/10.6084/m9.figshare.24492187",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033947","R0033947.pdf","paywalled","randomized_trial","Hussein, Humaira","2023","Comparative Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Randomised and Real-World Evidence","University of Leicester",null,"10.25392/leicester.data.23977146","https://doi.org/10.25392/leicester.data.23977146",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034080","R0034080.pdf","paywalled","randomized_trial","Adis Journalson Behalf Of","2023","Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects","Figshare",null,"10.6084/m9.figshare.23304206","https://doi.org/10.6084/m9.figshare.23304206",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036574","R0036574.pdf","paywalled","randomized_trial","Rives-Lange, Claire","2023","Nutritional assessment in registered randomized clinical trials evaluating the efficacy of incretin-based therapy in people living with overweight or obesity (PWO)","Open Science Framework",null,"10.17605/osf.io/yun2v","https://doi.org/10.17605/osf.io/yun2v",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036758","R0036758.pdf","paywalled","randomized_trial","Sandsdal, Rasmus M.","2023","Additional file 1 of Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","Figshare",null,"10.6084/m9.figshare.22615322","https://doi.org/10.6084/m9.figshare.22615322",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037214","R0037214.pdf","paywalled","randomized_trial","Rana Assaly","2023","Abstract 15257: The “Free Choice” Diet-Induced Obese Nonalcoholic Steatohepatitis Hamster, a Clinically Relevant Model for Evaluating Drugs Targeting Heart Failure With Preserved Ejection Fraction","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15257","https://doi.org/10.1161/circ.148.suppl_1.15257",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037586","R0037586.pdf","paywalled","randomized_trial",null,"2023","Obesity-related hypertension","The Nurse Practitioner","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.npr.0000000000000064","https://doi.org/10.1097/01.npr.0000000000000064","37227310","https://pubmed.ncbi.nlm.nih.gov/37227310/",null,null],["2","R0038101","R0038101.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2023","750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-750-p","https://doi.org/10.2337/db23-750-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038123","R0038123.pdf","paywalled","randomized_trial","Ivo Boškoski","2023","The liver adventures of bariatric endoscopy","Endoscopy","Georg Thieme Verlag KG","10.1055/a-2160-1581","https://doi.org/10.1055/a-2160-1581","37699426","https://pubmed.ncbi.nlm.nih.gov/37699426/",null,null],["2","R0038129","R0038129.pdf","paywalled","randomized_trial","ZHIYI ZHU","2023","79-LB: An Open-Label, Active-Controlled Phase 2 Evaluation of Novel GLP-1 Analog Ecnoglutide in Adults with Obesity","Diabetes","American Diabetes Association","10.2337/db23-79-lb","https://doi.org/10.2337/db23-79-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038190","R0038190.pdf","paywalled","randomized_trial","Hummel, Julia","2023","Determinants and pharmacologic modulation of fasting substrate oxidation in humans","Universitätsbibliothek Tübingen",null,"10.15496/publikation-83524","https://doi.org/10.15496/publikation-83524",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038259","R0038259.pdf","paywalled","randomized_trial","Ridwan Alam","2023","PD34-08 SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS ARE ASSOCIATED WITH A DECREASED RISK OF UROLITHIASIS COMPARED TO OTHER ANTIHYPERGLYCEMICS AMONG STONE-NAIVE DIABETICS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/ju.0000000000003327.08","https://doi.org/10.1097/ju.0000000000003327.08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038508","R0038508.pdf","paywalled","randomized_trial","Jean‐François Yale","2023","797-P: Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D","Diabetes","American Diabetes Association","10.2337/db23-797-p","https://doi.org/10.2337/db23-797-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038648","R0038648.pdf","paywalled","randomized_trial",null,"2023","Category Index","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000582","https://doi.org/10.1097/hep.0000000000000582","38227906","https://pubmed.ncbi.nlm.nih.gov/38227906/",null,null],["2","R0038788","R0038788.pdf","paywalled","randomized_trial","Blai Coll","2023","754-P: A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers","Diabetes","American Diabetes Association","10.2337/db23-754-p","https://doi.org/10.2337/db23-754-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038888","R0038888.pdf","paywalled","randomized_trial","Aishwarya Krishnaraj","2023","792-P: GLP-1 RA Therapy Increases Circulating Vascular Regenerative Cell Content and Decreases Inflammatory Burden in People with T2D","Diabetes","American Diabetes Association","10.2337/db23-792-p","https://doi.org/10.2337/db23-792-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039449","R0039449.pdf","paywalled","randomized_trial","ALICE Y. CHENG","2023","788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi","Diabetes","American Diabetes Association","10.2337/db23-788-p","https://doi.org/10.2337/db23-788-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039620","R0039620.pdf","paywalled","randomized_trial","GAO  Zhe, DUAN  Kaixin, LYU  Xiuqin, MA  Huijuan, ZHANG  Zhimei, SONG  Guangyao","2023","Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12114/j.issn.1007-9572.2023.0062","https://doi.org/10.12114/j.issn.1007-9572.2023.0062",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040766","R0040766.pdf","paywalled","randomized_trial","Αρτέμιος Γ. Καραγιαννίδης","2023","Αξιολόγηση της επίδρασης της τιρζεπατίδης στα νεφρικά εκβάματα σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και διαβητική νεφρική νόσο (RENT-DKD): πρωτόκολλο μιας τυχαιοποιημένης, διπλά-τυφλής, ελεγχόμενης με εικονικό φάρμακο κλινικής δοκιμής","University of Thessaly Institutional Repository (University of Thessaly)",null,"10.26253/heal.uth.39000","https://doi.org/10.26253/heal.uth.39000",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041657","R0041657.pdf","paywalled","randomized_trial","Michael Mæng","2023","Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2538","https://doi.org/10.1093/eurheartj/ehad655.2538",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041682","R0041682.pdf","paywalled","randomized_trial","Jennifer L. Strande","2023","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity","Metabolism","Elsevier BV","10.1016/j.metabol.2023.155433","https://doi.org/10.1016/j.metabol.2023.155433",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041762","R0041762.pdf","paywalled","randomized_trial","Mark L. Jewell","2023","Commentary on: Aesthetic Surgery Journal Articles on Injectable Weight Loss Medications and Their Role in Plastic Surgery","Aesthetic Surgery Journal","Oxford University Press (OUP)","10.1093/asj/sjad263","https://doi.org/10.1093/asj/sjad263","37610239","https://pubmed.ncbi.nlm.nih.gov/37610239/",null,null],["2","R0041763","R0041763.pdf","paywalled","randomized_trial","Ahmed R. Ahmed","2023","Innovating in the field of weight loss","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znad025","https://doi.org/10.1093/bjs/znad025","36745552","https://pubmed.ncbi.nlm.nih.gov/36745552/",null,null],["2","R0043862","R0043862.pdf","paywalled","randomized_trial","Stephen A. Harrison","2023","Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)00517-2","https://doi.org/10.1016/s0168-8278(23)00517-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044428","R0044428.pdf","paywalled","randomized_trial","Alvaro Serrano","2023","Semaglutide in Routine Obesity Care: Effectiveness Outside the Trial Population","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22258300","https://doi.org/10.5281/zenodo.22258300",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044950","R0044950.pdf","paywalled","randomized_trial","Steven E. Nissen","2023","Comparative Effectiveness of Diabetes Drugs: The Use and Misuse of Observational Research","Annals of Internal Medicine","American College of Physicians","10.7326/m23-0958","https://doi.org/10.7326/m23-0958","37155989","https://pubmed.ncbi.nlm.nih.gov/37155989/",null,null],["2","R0045220","R0045220.pdf","paywalled","randomized_trial","Manu V. Chakravarthy","2023","774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-774-p","https://doi.org/10.2337/db23-774-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045294","R0045294.pdf","paywalled","randomized_trial","Marine Jullien","2023","Diabetes mellitus and fertility","Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie","JLE","10.1684/mte.2023.0969","https://doi.org/10.1684/mte.2023.0969",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045918","R0045918.pdf","paywalled","randomized_trial","YUKA TAKAHASHI","2023","786-P: Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Metabolic Parameters in Older People with Type 2 Diabetes Mellitus—SWITCH-SEMA1 Subgroup Analysis","Diabetes","American Diabetes Association","10.2337/db23-786-p","https://doi.org/10.2337/db23-786-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"jRCT:jRCTs1011200008"],["2","R0045964","R0045964.pdf","paywalled","randomized_trial","KRISTINA BOYE","2023","753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6)","Diabetes","American Diabetes Association","10.2337/db23-753-p","https://doi.org/10.2337/db23-753-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045965","R0045965.pdf","paywalled","randomized_trial","MARTIN HALUZIK","2023","800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial","Diabetes","American Diabetes Association","10.2337/db23-800-p","https://doi.org/10.2337/db23-800-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045971","R0045971.pdf","paywalled","randomized_trial","Tomohiko Kimura","2023","748-P: GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes—Randomized, Parallel-Group, Multicenter, Open-Label Trial","Diabetes","American Diabetes Association","10.2337/db23-748-p","https://doi.org/10.2337/db23-748-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046051","R0046051.pdf","paywalled","randomized_trial","Juan P. Frías","2023","761-P: Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-761-p","https://doi.org/10.2337/db23-761-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046108","R0046108.pdf","paywalled","randomized_trial","Sean Wharton","2023","52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study","Diabetes","American Diabetes Association","10.2337/db23-52-or","https://doi.org/10.2337/db23-52-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046300","R0046300.pdf","paywalled","randomized_trial","CORBY K. MARTIN","2023","128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity","Diabetes","American Diabetes Association","10.2337/db23-128-or","https://doi.org/10.2337/db23-128-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046404","R0046404.pdf","paywalled","randomized_trial","XIAOSU MA","2023","769-P: Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Orforglipron (LY3502970), an Oral, Nonpeptide GLP-1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db23-769-p","https://doi.org/10.2337/db23-769-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046424","R0046424.pdf","paywalled","randomized_trial","Philippe Casassus","2023","Au fil de la presse","Médecine","JLE","10.1684/med.2023.903","https://doi.org/10.1684/med.2023.903",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046656","R0046656.pdf","paywalled","randomized_trial","Éric Ravussin","2023","127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity","Diabetes","American Diabetes Association","10.2337/db23-127-or","https://doi.org/10.2337/db23-127-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046921","R0046921.pdf","paywalled","randomized_trial","Ravi R. Retnakaran","2023","180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function","Diabetes","American Diabetes Association","10.2337/db23-180-or","https://doi.org/10.2337/db23-180-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047313","R0047313.pdf","paywalled","randomized_trial","Guang Wang","2023","756-P: A Phase 1c Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Weight Loss in Adults with Overweight and Obesity","Diabetes","American Diabetes Association","10.2337/db23-756-p","https://doi.org/10.2337/db23-756-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047629","R0047629.pdf","paywalled","randomized_trial","RAJAMANNAR THENNATI","2023","766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study","Diabetes","American Diabetes Association","10.2337/db23-766-p","https://doi.org/10.2337/db23-766-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047703","R0047703.pdf","paywalled","randomized_trial","Melanie R. Weltman","2023","Use of Guideline-Recommended Medication Therapy in a High-Risk CKD Population in the Kidney CHAMP Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1804d","https://doi.org/10.1681/asn.20233411s1804d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047844","R0047844.pdf","paywalled","randomized_trial","Paloma Rodriguez","2023","74-LB: Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)—A Prospective Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db23-74-lb","https://doi.org/10.2337/db23-74-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047882","R0047882.pdf","paywalled","randomized_trial","RAJAMANNAR THENNATI","2023","765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes","Diabetes","American Diabetes Association","10.2337/db23-765-p","https://doi.org/10.2337/db23-765-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048282","R0048282.pdf","paywalled","randomized_trial","Tadej Battelino","2023","225-OR: The Effect of Tirzepatide vs. Insulin Degludec on Post-meal Glucose Control in Patients with Type 2 Diabetes (SURPASS-3 CGM)","Diabetes","American Diabetes Association","10.2337/db23-225-or","https://doi.org/10.2337/db23-225-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048778","R0048778.pdf","paywalled","randomized_trial","Madona Azar","2023","IMPACT OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ON METABOLIC SYNDROME IN THE 2-YEAR, RANDOMIZED CONTROLLED STEP 5 TRIAL","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2023.06.393","https://doi.org/10.1016/j.cjca.2023.06.393",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049158","R0049158.pdf","paywalled","randomized_trial","Shweta Urva","2023","LY3437943 (LY), A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2D after 12 Weeks of Treatment","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767868","https://doi.org/10.1055/s-0043-1767868",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049288","R0049288.pdf","paywalled","randomized_trial","Amrit Chowdhary","2023","168 Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a glucagon like peptide-1 receptor agonist (liraglutide)- a randomised, single centre, open label, cross-over drug trial",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2023-bcs.168","https://doi.org/10.1136/heartjnl-2023-bcs.168",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049356","R0049356.pdf","paywalled","randomized_trial","Amrit Chowdhary","2023","Abstract 12365: Liraglutide Improves Myocardial Stress Perfusion and Energetics in Patients With Type 2 Diabetes- A Randomised, Single Centre, Open Label, Cross-Over Drug Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.12365","https://doi.org/10.1161/circ.148.suppl_1.12365",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049517","R0049517.pdf","paywalled","randomized_trial","Thomas Rudolf Pieber","2023","129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-129-or","https://doi.org/10.2337/db23-129-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049657","R0049657.pdf","paywalled","randomized_trial","Laurent Castéra","2023","Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)02279-1","https://doi.org/10.1016/s0168-8278(23)02279-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049695","R0049695.pdf","paywalled","randomized_trial","Teayoun Kim","2023","1648-P: Triagonism Targeting GCGR/GLP-1/GIP-1 Receptors Improves Insulin Sensitivity in Obese Mice","Diabetes","American Diabetes Association","10.2337/db23-1648-p","https://doi.org/10.2337/db23-1648-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050011","R0050011.pdf","paywalled","randomized_trial","Sophia Lengsfeld","2023","Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.90.p69","https://doi.org/10.1530/endoabs.90.p69",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050141","R0050141.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2023","179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1","Diabetes","American Diabetes Association","10.2337/db23-179-or","https://doi.org/10.2337/db23-179-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04460885"],["2","R0050225","R0050225.pdf","paywalled","randomized_trial","Arslanian SA","2023","Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","Yearbook of pediatric endocrinology","Bioscientifica","10.1530/ey.20.10.4","https://doi.org/10.1530/ey.20.10.4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050235","R0050235.pdf","paywalled","randomized_trial","Ali Lahooti","2023","701 A RANDOMIZED, DOUBLE-BLIND, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY OF LIRAGLUTIDE TREATMENT IN PATIENTS UNDERGOING TRANSORAL OUTLET REDUCTION ENDOSCOPY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)01308-2","https://doi.org/10.1016/s0016-5085(23)01308-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050380","R0050380.pdf","paywalled","randomized_trial","Lauren Eyler Dang","2023","A Causal Roadmap for Hybrid Randomized and Real-World Data Designs: Case Study of Semaglutide and Cardiovascular Outcomes","arXiv (Cornell University)",null,"10.48550/arxiv.2305.07647","https://doi.org/10.48550/arxiv.2305.07647",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050537","R0050537.pdf","paywalled","randomized_trial","Frederik Persson","2023","Renal Effects of Empagliflozin Alone or in Combination with Semaglutide in Albuminuric Type 2 Diabetes: A Randomized, Placebo-Controlled Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s116c","https://doi.org/10.1681/asn.20233411s116c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050553","R0050553.pdf","paywalled","randomized_trial","Alberto O. Chávez","2023","68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)","Diabetes","American Diabetes Association","10.2337/db23-68-lb","https://doi.org/10.2337/db23-68-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050927","R0050927.pdf","paywalled","randomized_trial","Αndrew Xanthopoulos","2023","Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a randomized study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.794","https://doi.org/10.1093/eurheartj/ehad655.794",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051033","R0051033.pdf","paywalled","randomized_trial","Stephen Douglas Anton","2023","Preventing Weight Regain after Weight Loss",null,"CRC Press","10.1201/9781003432807-28","https://doi.org/10.1201/9781003432807-28",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051065","R0051065.pdf","paywalled","randomized_trial","Tim Heise","2023","Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767865","https://doi.org/10.1055/s-0043-1767865",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051180","R0051180.pdf","paywalled","randomized_trial","Fabienne Baur","2023","Gender differences in smoking cessation? Results of a randomized controlled trial of dulaglutide-assisted smoking cessation","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.90.p65","https://doi.org/10.1530/endoabs.90.p65",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051241","R0051241.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2023","751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials","Diabetes","American Diabetes Association","10.2337/db23-751-p","https://doi.org/10.2337/db23-751-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051354","R0051354.pdf","paywalled","randomized_trial","Juan M. Maldonado","2023","771-P: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function—Post Hoc Analysis from SURPASS-1 and SURPASS-2","Diabetes","American Diabetes Association","10.2337/db23-771-p","https://doi.org/10.2337/db23-771-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051363","R0051363.pdf","paywalled","randomized_trial","Louis J. Aronne","2023","Tirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767938","https://doi.org/10.1055/s-0043-1767938",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051673","R0051673.pdf","paywalled","randomized_trial","MEDHA MUNSHI","2023","775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis","Diabetes","American Diabetes Association","10.2337/db23-775-p","https://doi.org/10.2337/db23-775-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052052","R0052052.pdf","paywalled","randomized_trial","Kristoffer Kjærgaard","2023","P42 Semaglutide Reduces Cognitive Dysfunction in Experimental Non-Alcoholic Steatohepatitis Through Anti-Inflammatory and Neuroprotective Effects","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000948452.01988.0c","https://doi.org/10.14309/01.ajg.0000948452.01988.0c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052077","R0052077.pdf","paywalled","randomized_trial","Anita Y. M. Kwan","2023","Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767995","https://doi.org/10.1055/s-0043-1767995",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052175","R0052175.pdf","paywalled","randomized_trial","Abraham Michael Lincoff","2023","Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2023 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2023","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.0000000000001200","https://doi.org/10.1161/cir.0000000000001200",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052199","R0052199.pdf","paywalled","randomized_trial","Manuel Romero‐Gómez","2023","A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with non-alcoholic fatty liver disease","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)00514-7","https://doi.org/10.1016/s0168-8278(23)00514-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052205","R0052205.pdf","paywalled","randomized_trial","Dalong Zhu","2023","755-P: A Phase 2 Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Glycemic Control in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-755-p","https://doi.org/10.2337/db23-755-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052230","R0052230.pdf","paywalled","randomized_trial","Josephine H. Li","2023","1466-P: Genome-Wide Association Studies in the GRADE Study Identify Genetic Variation Influencing the Response to Pharmacotherapy for Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-1466-p","https://doi.org/10.2337/db23-1466-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052344","R0052344.pdf","paywalled","randomized_trial","Hiddo J.L. Heerspink","2023","Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s141b","https://doi.org/10.1681/asn.20233411s141b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052446","R0052446.pdf","paywalled","randomized_trial","W. TIMOTHY GARVEY","2023","747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5","Diabetes","American Diabetes Association","10.2337/db23-747-p","https://doi.org/10.2337/db23-747-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052549","R0052549.pdf","paywalled","randomized_trial","Amalia Gastaldelli","2023","Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in Patients with Type 2 Diabetes (SURPASS-3 MRI)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767866","https://doi.org/10.1055/s-0043-1767866",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052704","R0052704.pdf","paywalled","randomized_trial","Blandine Gatta‐Cherifi","2023","Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the Cranioexe randomized placebo-controlled trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.90.p369","https://doi.org/10.1530/endoabs.90.p369",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052726","R0052726.pdf","paywalled","randomized_trial","Jörn Markus Schattenberg","2023","Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)02269-9","https://doi.org/10.1016/s0168-8278(23)02269-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052838","R0052838.pdf","paywalled","randomized_trial","Emily R. Hankosky","2023","70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial","Diabetes","American Diabetes Association","10.2337/db23-70-lb","https://doi.org/10.2337/db23-70-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052878","R0052878.pdf","paywalled","randomized_trial","IRENE M. HRAMIAK","2023","799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis","Diabetes","American Diabetes Association","10.2337/db23-799-p","https://doi.org/10.2337/db23-799-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052999","R0052999.pdf","paywalled","randomized_trial","Oluwaseun Anyiam","2023","278-LB: The Effect of Combining Very-Low-Calorie Diet with Semaglutide on Beta-Cell Function in Individuals with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-278-lb","https://doi.org/10.2337/db23-278-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053332","R0053332.pdf","paywalled","randomized_trial","Djordje S. Popovic","2023","Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes","Annals of Internal Medicine","American College of Physicians","10.7326/l23-0227","https://doi.org/10.7326/l23-0227","37722122","https://pubmed.ncbi.nlm.nih.gov/37722122/",null,null],["2","R0054003","R0054003.pdf","paywalled","randomized_trial","Manu V. Chakravarthy","2023","75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults","Diabetes","American Diabetes Association","10.2337/db23-75-lb","https://doi.org/10.2337/db23-75-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054788","R0054788.pdf","paywalled","randomized_trial","C. Anthony Burton","2023","Do statins increase the risk for the development of diabetes?","Evidence-Based Practice","Ovid Technologies (Wolters Kluwer Health)","10.1097/ebp.0000000000001990","https://doi.org/10.1097/ebp.0000000000001990",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056730","R0056730.pdf","paywalled","randomized_trial","Andrea Mari","2023","Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","Newcastle University ePrints (Newcastle Univesity)",null,"10.25405/ncl.34464717","https://doi.org/10.25405/ncl.34464717",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0005740","R0005740.pdf","paywalled","randomized_trial","Sassenrath K","2022","Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900211010678","https://doi.org/10.1177/08971900211010678","33926305","https://pubmed.ncbi.nlm.nih.gov/33926305/",null,null],["2","R0007107","R0007107.pdf","paywalled","randomized_trial","Joshi SR","2022","The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102508","https://doi.org/10.1016/j.dsx.2022.102508","35653929","https://pubmed.ncbi.nlm.nih.gov/35653929/",null,null],["2","R0008360","R0008360.pdf","paywalled","randomized_trial","Li XY","2022","Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202211_30153","https://doi.org/10.26355/eurrev_202211_30153","36394750","https://pubmed.ncbi.nlm.nih.gov/36394750/",null,null],["2","R0008738","R0008738.pdf","paywalled","randomized_trial","Phillips A","2022","Clinical review of subcutaneous semaglutide for obesity.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13574","https://doi.org/10.1111/jcpt.13574","34964141","https://pubmed.ncbi.nlm.nih.gov/34964141/",null,null],["2","R0008916","R0008916.pdf","paywalled","randomized_trial","Zhang J","2022","Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1136/jim-2021-002237","https://doi.org/10.1136/jim-2021-002237","35725020","https://pubmed.ncbi.nlm.nih.gov/35725020/",null,null],["2","R0009269","R0009269.pdf","paywalled","randomized_trial","Scheen AJ","2022","Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2022.101390","https://doi.org/10.1016/j.diabet.2022.101390","36170946","https://pubmed.ncbi.nlm.nih.gov/36170946/",null,null],["2","R0009437","R0009437.pdf","paywalled","randomized_trial","Lin L","2022","Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.","The Journal of dermatological treatment","Informa UK Limited","10.1080/09546634.2020.1826392","https://doi.org/10.1080/09546634.2020.1826392","32962477","https://pubmed.ncbi.nlm.nih.gov/32962477/",null,null],["2","R0009775","R0009775.pdf","paywalled","randomized_trial","Novodvorský P","2022","An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2021.1978974","https://doi.org/10.1080/14740338.2021.1978974","34641742","https://pubmed.ncbi.nlm.nih.gov/34641742/",null,null],["2","R0009848","R0009848.pdf","paywalled","randomized_trial","Wyne KL","2022","JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2022.03.007","https://doi.org/10.1016/j.jacl.2022.03.007","35430025","https://pubmed.ncbi.nlm.nih.gov/35430025/",null,null],["2","R0010906","R0010906.pdf","paywalled","randomized_trial","Timmermans M","2022","The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.21.03296-x","https://doi.org/10.23736/s2724-6507.21.03296-x","33759444","https://pubmed.ncbi.nlm.nih.gov/33759444/",null,null],["2","R0011579","R0011579.pdf","paywalled","randomized_trial","Møller M","2022","Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.","CNS spectrums","Cambridge University Press (CUP)","10.1017/s1092852920002217","https://doi.org/10.1017/s1092852920002217","33308348","https://pubmed.ncbi.nlm.nih.gov/33308348/",null,null],["2","R0012123","R0012123.pdf","paywalled","randomized_trial","Cosmi F","2022","[Process to insulin for type 2 diabetes mellitus therapy].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/3715.37063","https://doi.org/10.1714/3715.37063","34985463","https://pubmed.ncbi.nlm.nih.gov/34985463/",null,null],["2","R0014436","R0014436.pdf","paywalled","randomized_trial","Scheen AJ","2022","Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2022.101405","https://doi.org/10.1016/j.diabet.2022.101405","36334794","https://pubmed.ncbi.nlm.nih.gov/36334794/",null,null],["2","R0015746","R0015746.pdf","paywalled","randomized_trial","Singh AK","2022","Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102436","https://doi.org/10.1016/j.dsx.2022.102436","35245858","https://pubmed.ncbi.nlm.nih.gov/35245858/",null,null],["2","R0017317","R0017317.pdf","paywalled","randomized_trial","Kauffman RP","2022","In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.","Annals of internal medicine","American College of Physicians","10.7326/j22-0023","https://doi.org/10.7326/j22-0023","35500264","https://pubmed.ncbi.nlm.nih.gov/35500264/",null,null],["2","R0019069","R0019069.pdf","paywalled","randomized_trial","Lokeshwar SD","2022","Re: Sperm Count is Increased by Diet-induced Weight Loss and Maintained by Exercise or GLP-1 Analogue Treatment: A Randomized Controlled Trial.","European urology","Elsevier BV","10.1016/j.eururo.2022.08.016","https://doi.org/10.1016/j.eururo.2022.08.016","36058803","https://pubmed.ncbi.nlm.nih.gov/36058803/",null,null],["2","R0021763","R0021763.pdf","paywalled","randomized_trial","Branch KRH","2022","Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.2719","https://doi.org/10.1002/ejhf.2719","36224326","https://pubmed.ncbi.nlm.nih.gov/36224326/",null,null],["2","R0022608","R0022608.pdf","paywalled","randomized_trial","Singh M","2022","In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk.","Annals of internal medicine","American College of Physicians","10.7326/j22-0009","https://doi.org/10.7326/j22-0009","35226523","https://pubmed.ncbi.nlm.nih.gov/35226523/",null,null],["2","R0022629","R0022629.pdf","paywalled","randomized_trial","Hammerman A","2022","Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2022.01.027","https://doi.org/10.1016/j.amjcard.2022.01.027","35197207","https://pubmed.ncbi.nlm.nih.gov/35197207/",null,null],["2","R0022867","R0022867.pdf","paywalled","randomized_trial","Bradley CL","2022","High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280211053867","https://doi.org/10.1177/10600280211053867","34706581","https://pubmed.ncbi.nlm.nih.gov/34706581/",null,null],["2","R0023774","R0023774.pdf","paywalled","randomized_trial","He ST","2022","HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB.","Journal of investigative surgery : the official journal of the Academy of Surgical Research","Informa UK Limited","10.1080/08941939.2021.1989729","https://doi.org/10.1080/08941939.2021.1989729","34670452","https://pubmed.ncbi.nlm.nih.gov/34670452/",null,null],["2","R0023835","R0023835.pdf","paywalled","randomized_trial","Middleton TL","2022","Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14621","https://doi.org/10.1111/dom.14621","34882926","https://pubmed.ncbi.nlm.nih.gov/34882926/",null,null],["2","R0024057","R0024057.pdf","paywalled","randomized_trial","Visentin R","2022","A software interface for in silico testing of type 2 diabetes treatments.","Computer methods and programs in biomedicine","Elsevier BV","10.1016/j.cmpb.2022.106973","https://doi.org/10.1016/j.cmpb.2022.106973","35792365","https://pubmed.ncbi.nlm.nih.gov/35792365/",null,null],["2","R0024535","R0024535.pdf","paywalled","randomized_trial","Bergenstal RM","2022","Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2021.108106","https://doi.org/10.1016/j.jdiacomp.2021.108106","35131155","https://pubmed.ncbi.nlm.nih.gov/35131155/",null,null],["2","R0025438","R0025438.pdf","paywalled","randomized_trial","Xiao Y","2022","Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2022.0014","https://doi.org/10.1089/met.2022.0014","35925752","https://pubmed.ncbi.nlm.nih.gov/35925752/",null,null],["2","R0028972","R0028972.pdf","paywalled","randomized_trial","Vrablik M","2022","Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-022-00983-2","https://doi.org/10.1007/s11883-022-00983-2","35174437","https://pubmed.ncbi.nlm.nih.gov/35174437/",null,null],["2","R0029743","R0029743.pdf","paywalled","randomized_trial","Gabe MBN","2022","GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2022.106058","https://doi.org/10.1016/j.phrs.2022.106058","34995796","https://pubmed.ncbi.nlm.nih.gov/34995796/",null,null],["2","R0031733","R0031733.pdf","paywalled","randomized_trial","Frias JP","2022","Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","Yearbook of pediatric endocrinology","Bioscientifica","10.1530/ey.19.15.1","https://doi.org/10.1530/ey.19.15.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032332","R0032332.pdf","paywalled","randomized_trial","María Ximena Rojas Reyes","2022","Living Evidence Synthesis Updated Report. Instituto Aragonés de Ciencias de la Salud-IACS. LE-IHD.","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/c9yf8","https://doi.org/10.17605/osf.io/c9yf8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032611","R0032611.pdf","paywalled","randomized_trial","ANRAN MA","2022","93-LB: A Randomized Clinical Trial of Safety, Pharmacokinetics, and Pharmacodynamics of Weekly Dosing Supagutide in Healthy Chinese Subjects","Diabetes","American Diabetes Association","10.2337/db22-93-lb","https://doi.org/10.2337/db22-93-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032704","R0032704.pdf","paywalled","randomized_trial","MARK A. PIRNER","2022","724-P: A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects","Diabetes","American Diabetes Association","10.2337/db22-724-p","https://doi.org/10.2337/db22-724-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032775","R0032775.pdf","paywalled","randomized_trial","Anne Lautenbach","2022","1422-P: The Potential of Semaglutide Once-Weekly in Patients without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss after Bariatric Surgery","Diabetes","American Diabetes Association","10.2337/db22-1422-p","https://doi.org/10.2337/db22-1422-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032908","R0032908.pdf","paywalled","randomized_trial","YUE ZHOU","2022","88-LB: Safety, PK, PD, and Efficacy of Weekly Dosing Supaglutide in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db22-88-lb","https://doi.org/10.2337/db22-88-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032947","R0032947.pdf","paywalled","randomized_trial","Yik Tian Akira Wu","2022","Expert Insights for PCPs in Managing CKD in T2DM","The Singapore Family Physician","College of Family Physicians Singapore","10.33591/sfp.48.3.u5","https://doi.org/10.33591/sfp.48.3.u5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032999","R0032999.pdf","paywalled","randomized_trial","CAROLINA M. CASELLINI","2022","459-P: Effects of Liraglutide on Somatic Nerve Function in Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-459-p","https://doi.org/10.2337/db22-459-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033940","R0033940.pdf","paywalled","randomized_trial","Mosenzon, Ofri","2022","Additional file 1 of Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","Figshare",null,"10.6084/m9.figshare.20882123","https://doi.org/10.6084/m9.figshare.20882123",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034003","R0034003.pdf","paywalled","randomized_trial","Endocrine Society 2022","2022","Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2","Underline Science Inc.",null,"10.48448/4rdf-9v24","https://doi.org/10.48448/4rdf-9v24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034008","R0034008.pdf","paywalled","randomized_trial","Bröckelmann, Nils","2022","Additional file 1 of An empirical evaluation of the impact scenario of pooling bodies of evidence from randomized controlled trials and cohort studies in medical research","Figshare",null,"10.6084/m9.figshare.21385915","https://doi.org/10.6084/m9.figshare.21385915",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034051","R0034051.pdf","paywalled","randomized_trial","Endocrine Society 2022","2022","Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis","Underline Science Inc.",null,"10.48448/t2qy-py24","https://doi.org/10.48448/t2qy-py24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034089","R0034089.pdf","paywalled","randomized_trial","Endocrine Society 2022","2022","Empagliflozin and the risk of nephrolithiasis","Underline Science Inc.",null,"10.48448/p4qp-zj44","https://doi.org/10.48448/p4qp-zj44",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034405","R0034405.pdf","paywalled","randomized_trial","Ronen Arbel","2022","Abstract 13050: Tirzepatide versus Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients Over the Age of 65 With Type 2 Diabetes Mellitus-Value per Money Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.13050","https://doi.org/10.1161/circ.146.suppl_1.13050",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036589","R0036589.pdf","paywalled","randomized_trial","Martin Torp Rahbek","2022","Association of glucagon-like peptide 1 receptor agonists and treatment for bile acid diarrhea","Open Science Framework",null,"10.17605/osf.io/854ts","https://doi.org/10.17605/osf.io/854ts",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037077","R0037077.pdf","paywalled","randomized_trial","Silmara A O Leite","2022","704-P: Time in Range and Time Below Range in Insulin-Treated Older Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-704-p","https://doi.org/10.2337/db22-704-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037150","R0037150.pdf","paywalled","randomized_trial","MARK A. PIRNER","2022","94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-94-lb","https://doi.org/10.2337/db22-94-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037155","R0037155.pdf","paywalled","randomized_trial","PHILIP HOME","2022","845-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI","Diabetes","American Diabetes Association","10.2337/db22-845-p","https://doi.org/10.2337/db22-845-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0037358","R0037358.pdf","paywalled","randomized_trial","SAMUEL KLEIN","2022","334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db22-334-or","https://doi.org/10.2337/db22-334-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038035","R0038035.pdf","paywalled","randomized_trial","W. TIMOTHY GARVEY","2022","2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db22-2-lb","https://doi.org/10.2337/db22-2-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038801","R0038801.pdf","paywalled","randomized_trial","Ewan R. Pearson","2022","258-OR: Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","Diabetes","American Diabetes Association","10.2337/db22-258-or","https://doi.org/10.2337/db22-258-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039426","R0039426.pdf","paywalled","randomized_trial","Justin Oveyssi","2022","Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000004374","https://doi.org/10.1097/tp.0000000000004374","36525549","https://pubmed.ncbi.nlm.nih.gov/36525549/",null,null],["2","R0039728","R0039728.pdf","paywalled","randomized_trial","PHILIP HOME","2022","846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function","Diabetes","American Diabetes Association","10.2337/db22-846-p","https://doi.org/10.2337/db22-846-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0039957","R0039957.pdf","paywalled","randomized_trial","Ivan Schmidt","2022","Clinical Evaluation of Novel Antidiabetic Molecules","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19511451","https://doi.org/10.5281/zenodo.19511451",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040711","R0040711.pdf","paywalled","randomized_trial","Gullaksen, Søren; id_orcid 0000-0001-8275-1278","2022","Effects of treatment with semaglutide, empagliflozin and the combination on kidney function in type 2 diabetes: impact of oxygenation and perfusion",null,null,"10.1007/s00125-022-05755-w#sec15","https://doi.org/10.1007/s00125-022-05755-w#sec15",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043589","R0043589.pdf","paywalled","randomized_trial","Martin, William Patrick","2022","Multi-Omic Characterisation of Renal Responses to Intentional Weight Loss in Diabetic Kidney Disease","Research Repository UCD (University College Dublin)",null,"10.13140/rg.2.2.23464.65286","https://doi.org/10.13140/rg.2.2.23464.65286",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045105","R0045105.pdf","paywalled","randomized_trial","Kieren J. Mather","2022","714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism","Diabetes","American Diabetes Association","10.2337/db22-714-p","https://doi.org/10.2337/db22-714-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045163","R0045163.pdf","paywalled","randomized_trial","SHWETA URVA","2022","340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment","Diabetes","American Diabetes Association","10.2337/db22-340-or","https://doi.org/10.2337/db22-340-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045325","R0045325.pdf","paywalled","randomized_trial","Ailbhe King","2022","The effect of the GLP-1 analogue Liraglutide on intermittent hypoxia-induced systemic insulin resistance in vivo",null,"European Respiratory Society","10.1183/13993003.congress-2022.2182","https://doi.org/10.1183/13993003.congress-2022.2182",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045606","R0045606.pdf","paywalled","randomized_trial","Nauck, Michael A.","2022","Additional file 1 of Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","Figshare",null,"10.6084/m9.figshare.20782257.v1","https://doi.org/10.6084/m9.figshare.20782257.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046037","R0046037.pdf","paywalled","randomized_trial","RODOLFO J. GALINDO","2022","217-OR: A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira vs. Basal Bolus in Patients with Poorly Controlled Type 2 Diabetes and Very High HbA1c (>9%–15%) : IDegLira HIGH Trial","Diabetes","American Diabetes Association","10.2337/db22-217-or","https://doi.org/10.2337/db22-217-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046388","R0046388.pdf","paywalled","randomized_trial","MARTIN HALUZIK","2022","730-P: Effectiveness of iGlarLixi (Insulin Glargine-Lixisenatide) in People with Type 2 Diabetes According to the Time of Administration through the Day","Diabetes","American Diabetes Association","10.2337/db22-730-p","https://doi.org/10.2337/db22-730-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046632","R0046632.pdf","paywalled","randomized_trial","TIM HEISE","2022","338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D","Diabetes","American Diabetes Association","10.2337/db22-338-or","https://doi.org/10.2337/db22-338-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047145","R0047145.pdf","paywalled","randomized_trial","Ahmed A. Kolkailah","2022","Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwac056.042","https://doi.org/10.1093/eurjpc/zwac056.042",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047222","R0047222.pdf","paywalled","randomized_trial","Bryan Haddock","2022","231-LB: GLP-1 Promotes Cortical and Medullary Perfusion in Human Kidney and Maintains Tissue Oxygenation during Na Loading","Diabetes","American Diabetes Association","10.2337/db22-231-lb","https://doi.org/10.2337/db22-231-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047285","R0047285.pdf","paywalled","randomized_trial","José M. Rodriguez‐Valadez","2022","871-P: Weight Change as Mediator for Cardiovascular Benefits of Novel Diabetes Medications: A Meta-Regression Analysis","Diabetes","American Diabetes Association","10.2337/db22-871-p","https://doi.org/10.2337/db22-871-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047503","R0047503.pdf","paywalled","randomized_trial","Dimitrios Patoulias","2022","CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETICS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000837336.21736.d6","https://doi.org/10.1097/01.hjh.0000837336.21736.d6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047549","R0047549.pdf","paywalled","randomized_trial","José M. Rodriguez‐Valadez","2022","872-P: Cardiovascular Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Meta-Regression Analysis of 17 Randomized Trials","Diabetes","American Diabetes Association","10.2337/db22-872-p","https://doi.org/10.2337/db22-872-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047680","R0047680.pdf","paywalled","randomized_trial","Eric D. Goldstein","2022","Abstract 144: Glucagon-like Peptide-1 Receptor Agonists Reduce The Risk Of Ischemic Stroke","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.53.suppl_1.144","https://doi.org/10.1161/str.53.suppl_1.144",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047701","R0047701.pdf","paywalled","randomized_trial","Mette Q. Ludwig","2022","A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human Alzheimer’s disease, and the Glucagon‐Like Peptide‐1 receptor agonist semaglutide attenuates neuroinflammation in this model","Alzheimer s & Dementia","Wiley","10.1002/alz.063862","https://doi.org/10.1002/alz.063862",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047816","R0047816.pdf","paywalled","randomized_trial","Stefano Del Prato","2022","Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746267","https://doi.org/10.1055/s-0042-1746267",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047867","R0047867.pdf","paywalled","randomized_trial","Hamed Kianmehr","2022","817-P: Identifying Modulators of Treatment Benefits of Albiglutide (GLP-1 RA) in Preventing Major Adverse Cardiovascular Events (MACE) among Individuals with Type 2 Diabetes in the HARMONY Trial Using Machine Learning","Diabetes","American Diabetes Association","10.2337/db22-817-p","https://doi.org/10.2337/db22-817-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047886","R0047886.pdf","paywalled","randomized_trial","Julio Cesar Nunes","2022","Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14832","https://doi.org/10.1111/dom.14832","35938182","https://pubmed.ncbi.nlm.nih.gov/35938182/",null,null],["2","R0047931","R0047931.pdf","paywalled","randomized_trial","Tarek Mahmoud","2022","412.4: Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors And Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000887616.86686.ae","https://doi.org/10.1097/01.tp.0000887616.86686.ae",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047957","R0047957.pdf","paywalled","randomized_trial","Ritwika Mallik","2022","Safety and Efficacy of Long-Term Use of GLP-1RA in Post-Transplant Diabetes Mellitus (PTDM): Analysis of Dulaglutide vs. Liraglutide","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1558b","https://doi.org/10.1681/asn.20223311s1558b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047983","R0047983.pdf","paywalled","randomized_trial","James A. de Lemos","2022","Abstract 10370: Effects of Tirzepatide on 24-Hour Ambulatory Blood Pressure and Heart Rate in Adults With Obesity - Results From the SURMOUNT-1 Ambulatory Blood Pressure Monitoring Sub-Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.10370","https://doi.org/10.1161/circ.146.suppl_1.10370",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047996","R0047996.pdf","paywalled","randomized_trial","Sophia Lengsfeld","2022","Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP - a randomised controlled study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.81.p76","https://doi.org/10.1530/endoabs.81.p76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048044","R0048044.pdf","paywalled","randomized_trial","Tarek Mahmoud","2022","Safety of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1544c","https://doi.org/10.1681/asn.20223311s1544c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048078","R0048078.pdf","paywalled","randomized_trial","Daniel L. Edmonston","2022","Abstract 13779: Metabolic Profiles Identify Distinct Cardiorenal Risk Factors in People With Diabetes Mellitus: Insights From the EXSCEL Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.13779","https://doi.org/10.1161/circ.146.suppl_1.13779",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048123","R0048123.pdf","paywalled","randomized_trial","Juan P. Frías","2022","Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746269","https://doi.org/10.1055/s-0042-1746269",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048699","R0048699.pdf","paywalled","randomized_trial","Andrea Mari","2022","DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746270","https://doi.org/10.1055/s-0042-1746270",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048815","R0048815.pdf","paywalled","randomized_trial","Anthony E. Peters","2022","Abstract 13166: Proteomic Pathways Across Ejection Fraction Categories in Heart Failure: An Exscel Substudy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.13166","https://doi.org/10.1161/circ.146.suppl_1.13166",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048880","R0048880.pdf","paywalled","randomized_trial","ARIAN W. PLAT","2022","720-P: Change in Body Weight from Baseline with Tirzepatide: Sex Subgroup Analysis of the SURPASS Studies","Diabetes","American Diabetes Association","10.2337/db22-720-p","https://doi.org/10.2337/db22-720-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049010","R0049010.pdf","paywalled","randomized_trial","Julio Rosenstock","2022","Efficacy and Safety of Once Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist Versus Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746287","https://doi.org/10.1055/s-0042-1746287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049413","R0049413.pdf","paywalled","randomized_trial","Mohamad Bassam Kassab","2022","Abstract 15480: Liraglutide Inhibits Atherosclerotic Plaque Progression in Rabbits Through the Downregulation of Multiple Inflammatory and Metabolic Pathways","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.15480","https://doi.org/10.1161/circ.146.suppl_1.15480",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049543","R0049543.pdf","paywalled","randomized_trial","Lauren Eyler Dang","2022","Experiment-selector cross-validated targeted maximum likelihood estimator for hybrid RCT-external data studies","arXiv (Cornell University)",null,"10.48550/arxiv.2210.05802","https://doi.org/10.48550/arxiv.2210.05802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049769","R0049769.pdf","paywalled","randomized_trial","Peter R Rossing","2022","22-OR: Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use","Diabetes","American Diabetes Association","10.2337/db22-22-or","https://doi.org/10.2337/db22-22-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049906","R0049906.pdf","paywalled","randomized_trial","Luiz Sérgio Fernandes de Carvalho","2022","Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.14830","https://doi.org/10.1161/circ.146.suppl_1.14830",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050189","R0050189.pdf","paywalled","randomized_trial","Giulia Ferrannini","2022","Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.2400","https://doi.org/10.1093/eurheartj/ehac544.2400",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050318","R0050318.pdf","paywalled","randomized_trial","ANITA KWAN","2022","719-P: Tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies","Diabetes","American Diabetes Association","10.2337/db22-719-p","https://doi.org/10.2337/db22-719-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050776","R0050776.pdf","paywalled","randomized_trial","KATRINA B. DIETSCHE","2022","991-P: Metformin Plasma Concentration as a Biomarker of Treatment Responsiveness in Youth-Onset Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-991-p","https://doi.org/10.2337/db22-991-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050852","R0050852.pdf","paywalled","randomized_trial","Shweta Urva","2022","Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First in Human Dose Study in Healthy Subjects","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746266","https://doi.org/10.1055/s-0042-1746266",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051154","R0051154.pdf","paywalled","randomized_trial","Rohit Seth Loomba","2022","Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(22)00440-8","https://doi.org/10.1016/s0168-8278(22)00440-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051753","R0051753.pdf","paywalled","randomized_trial","Stephen A. Harrison","2022","Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(22)00570-0","https://doi.org/10.1016/s0168-8278(22)00570-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051896","R0051896.pdf","paywalled","randomized_trial","Athena Philis‐Tsimikas","2022","806-P: Correlation of Derived Time in Range (dTIR) and Time in Range (TIR) in People with Type 2 Diabetes (T2D) Treated with IDegLira (IDL) , Degludec, or Liraglutide: A Post Hoc Analysis of the DUAL I Trial","Diabetes","American Diabetes Association","10.2337/db22-806-p","https://doi.org/10.2337/db22-806-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051958","R0051958.pdf","paywalled","randomized_trial","Marie Oertel","2022","Effects of a combinatory treatment with semaglutide and a selective PYY-Y2 receptor analogue in diet-induced obese rats: Surpassing bariatric surgery? (#64)","Adipositas - Ursachen Folgeerkrankungen Therapie","Georg Thieme Verlag KG","10.1055/s-0042-1755715","https://doi.org/10.1055/s-0042-1755715",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052025","R0052025.pdf","paywalled","randomized_trial","Silva A Arslanian","2022","5-LB: Dulaglutide in Youth with Type 2 Diabetes (T2D) —Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial","Diabetes","American Diabetes Association","10.2337/db22-5-lb","https://doi.org/10.2337/db22-5-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052108","R0052108.pdf","paywalled","randomized_trial","Susan M. Jenks","2022","Weight Loss From Bariatric Surgery Lowers Risk of Cancer & Death","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000872276.40830.dd","https://doi.org/10.1097/01.cot.0000872276.40830.dd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052207","R0052207.pdf","paywalled","randomized_trial","Rachel M. Ostroff","2022","Abstract 11650: Cardiometabolic Disease Protein Signatures and Response to GLP-1 Receptor Agonist in the EXSCEL Clinical Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.11650","https://doi.org/10.1161/circ.146.suppl_1.11650",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052302","R0052302.pdf","paywalled","randomized_trial","Enzo Bonora","2022","Higher doses of dulaglutide induce weight loss in patients with type 2 diabetes (T2D) regardless of baseline BMI: post hoc analysis of AWARD-11","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746329","https://doi.org/10.1055/s-0042-1746329",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052434","R0052434.pdf","paywalled","randomized_trial","Neda Rasouli","2022","1324-P: Short-Term Effects of Glycemia-Lowering Medications on ß-Cell Function in the GRADE Study","Diabetes","American Diabetes Association","10.2337/db22-1324-p","https://doi.org/10.2337/db22-1324-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052670","R0052670.pdf","paywalled","randomized_trial","Wissam Ghusn","2022","S1455 Real World Weight Loss Outcomes of Semaglutide in Patients With Overweight and Obesity After Bariatric Surgery","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000862460.34172.fc","https://doi.org/10.14309/01.ajg.0000862460.34172.fc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053052","R0053052.pdf","paywalled","randomized_trial","Michael Søberg Christensen","2022","MO069: Therapeutic Effects of Semaglutide as Mono and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac063.021","https://doi.org/10.1093/ndt/gfac063.021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053092","R0053092.pdf","paywalled","randomized_trial","Dominik B. Dahl","2022","Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746273","https://doi.org/10.1055/s-0042-1746273",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053539","R0053539.pdf","paywalled","randomized_trial","Henrik Maagensen","2022","182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series","Diabetes","American Diabetes Association","10.2337/db22-182-or","https://doi.org/10.2337/db22-182-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053543","R0053543.pdf","paywalled","randomized_trial","JULIO ROSENSTOCK","2022","1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)","Diabetes","American Diabetes Association","10.2337/db22-1413-p","https://doi.org/10.2337/db22-1413-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053718","R0053718.pdf","paywalled","randomized_trial","Bernhard H. Ludvik","2022","EFFICACY AND SAFETY OF TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR AGONIST, COMPARED TO INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746289","https://doi.org/10.1055/s-0042-1746289",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054001","R0054001.pdf","paywalled","randomized_trial","Cormac Ryan","2022","Comparative Analysis of GLP-1 receptor agonist therapy versus Standard Care in gestational diabetes","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22812581","https://doi.org/10.5281/zenodo.22812581",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054017","R0054017.pdf","paywalled","randomized_trial","Ryosuke Ono","2022","339-OR: Oral Small-Molecule GLP-1R Agonist Danuglipron Robustly Reduces Plasma Glucose and Body Weight after Eight Weeks in Japanese Adults with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db22-339-or","https://doi.org/10.2337/db22-339-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055151","R0055151.pdf","paywalled","randomized_trial","Camille Malatt","2022","Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9-11.005)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.98.18_supplement.3068","https://doi.org/10.1212/wnl.98.18_supplement.3068",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055647","R0055647.pdf","paywalled","randomized_trial","Andrea Mari","2022","722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function","Diabetes","American Diabetes Association","10.2337/db22-722-p","https://doi.org/10.2337/db22-722-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0006929","R0006929.pdf","paywalled","randomized_trial","Lehmann EW","2021","Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvab249","https://doi.org/10.1093/cvr/cvab249","34448813","https://pubmed.ncbi.nlm.nih.gov/34448813/",null,null],["2","R0007071","R0007071.pdf","paywalled","randomized_trial","Volpe M","2021","A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab550","https://doi.org/10.1093/eurheartj/ehab550","34355764","https://pubmed.ncbi.nlm.nih.gov/34355764/",null,null],["2","R0007079","R0007079.pdf","paywalled","randomized_trial","Iqbal AM","2021","Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/1574886315999201208212356","https://doi.org/10.2174/1574886315999201208212356","33292155","https://pubmed.ncbi.nlm.nih.gov/33292155/",null,null],["2","R0007212","R0007212.pdf","paywalled","randomized_trial","Heinla K","2021","A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-1498-7098","https://doi.org/10.1055/a-1498-7098","34154031","https://pubmed.ncbi.nlm.nih.gov/34154031/",null,null],["2","R0007368","R0007368.pdf","paywalled","randomized_trial","Ertuglu LA","2021","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.","Transplant international : official journal of the European Society for Organ Transplantation","Frontiers Media SA","10.1111/tri.13883","https://doi.org/10.1111/tri.13883","33880815","https://pubmed.ncbi.nlm.nih.gov/33880815/",null,null],["2","R0007961","R0007961.pdf","paywalled","randomized_trial","Clements JN","2021","Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-020-00951-6","https://doi.org/10.1007/s40262-020-00951-6","33108617","https://pubmed.ncbi.nlm.nih.gov/33108617/",null,null],["2","R0008573","R0008573.pdf","paywalled","randomized_trial","Papazafiropoulou AK","2021","Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612826666200909142126","https://doi.org/10.2174/1381612826666200909142126","32912116","https://pubmed.ncbi.nlm.nih.gov/32912116/",null,null],["2","R0008875","R0008875.pdf","paywalled","randomized_trial","Bojer AS","2021","Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14480","https://doi.org/10.1111/dom.14480","34189832","https://pubmed.ncbi.nlm.nih.gov/34189832/",null,null],["2","R0009078","R0009078.pdf","paywalled","randomized_trial","Ahmad E","2021","Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14343","https://doi.org/10.1111/dom.14343","33565691","https://pubmed.ncbi.nlm.nih.gov/33565691/",null,null],["2","R0009169","R0009169.pdf","paywalled","randomized_trial","Pawaskar M","2021","Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2021.88728","https://doi.org/10.37765/ajmc.2021.88728","34460181","https://pubmed.ncbi.nlm.nih.gov/34460181/",null,null],["2","R0009611","R0009611.pdf","paywalled","randomized_trial","Giugliano D","2021","Simplification of complex insulin therapy: a story of dogma and therapeutic resignation.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108958","https://doi.org/10.1016/j.diabres.2021.108958","34280468","https://pubmed.ncbi.nlm.nih.gov/34280468/",null,null],["2","R0009778","R0009778.pdf","paywalled","randomized_trial","Shuai Y","2021","Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14198","https://doi.org/10.1111/dom.14198","32965075","https://pubmed.ncbi.nlm.nih.gov/32965075/",null,null],["2","R0010499","R0010499.pdf","paywalled","randomized_trial","Maagensen H","2021","Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.","Psychiatry research","Elsevier BV","10.1016/j.psychres.2020.113670","https://doi.org/10.1016/j.psychres.2020.113670","33373806","https://pubmed.ncbi.nlm.nih.gov/33373806/",null,null],["2","R0011572","R0011572.pdf","paywalled","randomized_trial","Joubert M","2021","Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14225","https://doi.org/10.1111/dom.14225","33043591","https://pubmed.ncbi.nlm.nih.gov/33043591/",null,null],["2","R0012689","R0012689.pdf","paywalled","randomized_trial","Lisco G","2021","Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871530320666200705211224","https://doi.org/10.2174/1871530320666200705211224","32628602","https://pubmed.ncbi.nlm.nih.gov/32628602/",null,null],["2","R0013600","R0013600.pdf","paywalled","randomized_trial","Joshi PH","2021","Diagnosis and Management of Stable Angina: A Review.","JAMA","American Medical Association (AMA)","10.1001/jama.2021.1527","https://doi.org/10.1001/jama.2021.1527","33944871","https://pubmed.ncbi.nlm.nih.gov/33944871/",null,null],["2","R0015200","R0015200.pdf","paywalled","randomized_trial","Tanner M","2021","In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.","Annals of internal medicine","American College of Physicians","10.7326/acpj202106150-067","https://doi.org/10.7326/acpj202106150-067","34058114","https://pubmed.ncbi.nlm.nih.gov/34058114/",null,null],["2","R0015753","R0015753.pdf","paywalled","randomized_trial","Boggild MK","2021","Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM.","Annals of internal medicine","American College of Physicians","10.7326/acpj202109210-106","https://doi.org/10.7326/acpj202109210-106","34487441","https://pubmed.ncbi.nlm.nih.gov/34487441/",null,null],["2","R0017157","R0017157.pdf","paywalled","randomized_trial","Yamada S","2021","Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.","Clinical and experimental nephrology","Springer Science and Business Media LLC","10.1007/s10157-020-02007-2","https://doi.org/10.1007/s10157-020-02007-2","33409761","https://pubmed.ncbi.nlm.nih.gov/33409761/",null,null],["2","R0017278","R0017278.pdf","paywalled","randomized_trial","Östlund Papadogeorgos N","2021","Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.","Microcirculation (New York, N.Y. : 1994)","Wiley","10.1111/micc.12670","https://doi.org/10.1111/micc.12670","33151597","https://pubmed.ncbi.nlm.nih.gov/33151597/",null,"EudraCT:2008-008367-95"],["2","R0017478","R0017478.pdf","paywalled","randomized_trial","Song X","2021","Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.","Stem cells and development","SAGE Publications","10.1089/scd.2020.0137","https://doi.org/10.1089/scd.2020.0137","33677993","https://pubmed.ncbi.nlm.nih.gov/33677993/",null,null],["2","R0018366","R0018366.pdf","paywalled","randomized_trial","Jensterle M","2021","Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108935","https://doi.org/10.1016/j.diabres.2021.108935","34217774","https://pubmed.ncbi.nlm.nih.gov/34217774/",null,null],["2","R0018836","R0018836.pdf","paywalled","randomized_trial","Ramadan NM","2021","Liraglutide Effect on Ventricular Transient Outward K +  Channel and Connexin-43 Protein Expression.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-1162-8196","https://doi.org/10.1055/a-1162-8196","32559789","https://pubmed.ncbi.nlm.nih.gov/32559789/",null,null],["2","R0019351","R0019351.pdf","paywalled","randomized_trial","Chen X","2021","Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2021.03.015","https://doi.org/10.1016/j.eprac.2021.03.015","33831552","https://pubmed.ncbi.nlm.nih.gov/33831552/",null,null],["2","R0019513","R0019513.pdf","paywalled","randomized_trial","Perakakis N","2021","Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.14888","https://doi.org/10.1111/liv.14888","33788377","https://pubmed.ncbi.nlm.nih.gov/33788377/",null,null],["2","R0019865","R0019865.pdf","paywalled","randomized_trial","Persano M","2021","Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202101_24661","https://doi.org/10.26355/eurrev_202101_24661","33577047","https://pubmed.ncbi.nlm.nih.gov/33577047/",null,null],["2","R0020294","R0020294.pdf","paywalled","randomized_trial","Badurdeen D","2021","Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-020-05117-8","https://doi.org/10.1007/s11695-020-05117-8","33211267","https://pubmed.ncbi.nlm.nih.gov/33211267/",null,null],["2","R0020335","R0020335.pdf","paywalled","randomized_trial","Navabi R","2021","Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.","Life sciences","Elsevier BV","10.1016/j.lfs.2021.119374","https://doi.org/10.1016/j.lfs.2021.119374","33745896","https://pubmed.ncbi.nlm.nih.gov/33745896/",null,null],["2","R0020421","R0020421.pdf","paywalled","randomized_trial","Asano M","2021","Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14412","https://doi.org/10.1111/dom.14412","33908687","https://pubmed.ncbi.nlm.nih.gov/33908687/",null,null],["2","R0023142","R0023142.pdf","paywalled","randomized_trial","Bizino MB","2021","Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-020-01635-0","https://doi.org/10.1007/s00592-020-01635-0","33399989","https://pubmed.ncbi.nlm.nih.gov/33399989/",null,null],["2","R0023466","R0023466.pdf","paywalled","randomized_trial","Lau D","2021","In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.","Annals of internal medicine","American College of Physicians","10.7326/acpj202108170-088","https://doi.org/10.7326/acpj202108170-088","34339232","https://pubmed.ncbi.nlm.nih.gov/34339232/",null,null],["2","R0023693","R0023693.pdf","paywalled","randomized_trial","Lee SE","2021","Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients.","Psychiatry research","Elsevier BV","10.1016/j.psychres.2021.113830","https://doi.org/10.1016/j.psychres.2021.113830","33677189","https://pubmed.ncbi.nlm.nih.gov/33677189/",null,null],["2","R0023996","R0023996.pdf","paywalled","randomized_trial","Yu DN","2021","[The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].","Zhonghua nei ke za zhi",null,"10.3760/cma.j.cn112138-20210205-00105","https://doi.org/10.3760/cma.j.cn112138-20210205-00105","34689519","https://pubmed.ncbi.nlm.nih.gov/34689519/",null,null],["2","R0024047","R0024047.pdf","paywalled","randomized_trial","Whicher CA","2021","The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14334","https://doi.org/10.1111/dom.14334","33528914","https://pubmed.ncbi.nlm.nih.gov/33528914/",null,null],["2","R0024833","R0024833.pdf","paywalled","randomized_trial","Birudaraju D","2021","Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107840","https://doi.org/10.1016/j.jdiacomp.2020.107840","33419635","https://pubmed.ncbi.nlm.nih.gov/33419635/",null,null],["2","R0024913","R0024913.pdf","paywalled","randomized_trial","Alba M","2021","Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.","Clinical obesity","Wiley","10.1111/cob.12432","https://doi.org/10.1111/cob.12432","33475255","https://pubmed.ncbi.nlm.nih.gov/33475255/",null,null],["2","R0027312","R0027312.pdf","paywalled","randomized_trial","Hallström S","2021","Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2020.0577","https://doi.org/10.1089/dia.2020.0577","33416422","https://pubmed.ncbi.nlm.nih.gov/33416422/",null,null],["2","R0028463","R0028463.pdf","paywalled","randomized_trial","Redmond IP","2021","Use of Weight Loss Medications in Patients after Bariatric Surgery.","Current obesity reports","Springer Science and Business Media LLC","10.1007/s13679-021-00425-1","https://doi.org/10.1007/s13679-021-00425-1","33492629","https://pubmed.ncbi.nlm.nih.gov/33492629/",null,null],["2","R0028986","R0028986.pdf","paywalled","randomized_trial","Romero A","2021","Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2021.11.031","https://doi.org/10.1016/j.endien.2021.11.031","34924163","https://pubmed.ncbi.nlm.nih.gov/34924163/",null,null],["2","R0028996","R0028996.pdf","paywalled","randomized_trial","Safouris A","2021","Emerging agents for the treatment and prevention of stroke: progress in clinical trials.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2021.1985463","https://doi.org/10.1080/13543784.2021.1985463","34555978","https://pubmed.ncbi.nlm.nih.gov/34555978/",null,null],["2","R0029764","R0029764.pdf","paywalled","randomized_trial","Di Prospero NA","2021","Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.","Clinical obesity","Wiley","10.1111/cob.12433","https://doi.org/10.1111/cob.12433","33475251","https://pubmed.ncbi.nlm.nih.gov/33475251/",null,null],["2","R0029919","R0029919.pdf","paywalled","randomized_trial","Ding Y","2021","Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2021.2008906","https://doi.org/10.1080/13543784.2021.2008906","34793265","https://pubmed.ncbi.nlm.nih.gov/34793265/",null,"ChiCTR:ChiCTR-IPC-15007190"],["2","R0030962","R0030962.pdf","paywalled","randomized_trial","Allan S. Brett","2021","Semaglutide for Obesity: A Randomized Trial","Journal watch",null,"10.1056/nejm-jw.na53218","https://doi.org/10.1056/nejm-jw.na53218",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031418","R0031418.pdf","paywalled","randomized_trial",null,"2021","Complications of Youth-Onset Type 2 Diabetes","AAP Grand Rounds","American Academy of Pediatrics (AAP)","10.1542/gr.46-5-51","https://doi.org/10.1542/gr.46-5-51",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031616","R0031616.pdf","paywalled","randomized_trial","Vanita R. Aroda","2021","663-P: Achievement of Near-Normal HbA1c with Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1","Diabetes","American Diabetes Association","10.2337/db21-663-p","https://doi.org/10.2337/db21-663-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031740","R0031740.pdf","paywalled","randomized_trial","Leigh Perreault","2021","82-OR: Effect of Semaglutide 2.4 mg on Glucose Metabolism and Body Weight in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Diabetes","American Diabetes Association","10.2337/db21-82-or","https://doi.org/10.2337/db21-82-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031742","R0031742.pdf","paywalled","randomized_trial","Tanja Kongerslev Thorning","2021","688-P: Effect of Probenecid and Cyclosporin on the Pharmacokinetics of SNAC in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db21-688-p","https://doi.org/10.2337/db21-688-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031892","R0031892.pdf","paywalled","randomized_trial","Hongwei� Jiang","2021","667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity","Diabetes","American Diabetes Association","10.2337/db21-667-p","https://doi.org/10.2337/db21-667-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033561","R0033561.pdf","paywalled","randomized_trial","Kumarathurai, Preman","2021","Additional file 1 of Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study","Figshare",null,"10.6084/m9.figshare.13545530","https://doi.org/10.6084/m9.figshare.13545530",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033591","R0033591.pdf","paywalled","randomized_trial","Endocrine Society 2021","2021","Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH","Underline Science Inc.",null,"10.48448/ebg3-jq20","https://doi.org/10.48448/ebg3-jq20",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033777","R0033777.pdf","paywalled","randomized_trial","Kumarathurai, Preman","2021","Additional file 2 of Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study","Figshare",null,"10.6084/m9.figshare.13545533","https://doi.org/10.6084/m9.figshare.13545533",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033864","R0033864.pdf","paywalled","randomized_trial","Endocrine Society 2021","2021","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Underline Science Inc.",null,"10.48448/hm3x-8s87","https://doi.org/10.48448/hm3x-8s87",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034367","R0034367.pdf","paywalled","randomized_trial","Mojca Jensterle","2021","Semaglutide reduces fat accumulation in the tongue of obese women with polycystic ovary syndrome: A randomized, placebo-controlled prospective study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.73.aep163","https://doi.org/10.1530/endoabs.73.aep163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034493","R0034493.pdf","paywalled","randomized_trial","Prof. Wenying Yang","2021","Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study",null,"Morressier","10.26226/morressier.617c37307c09fc044a97516d","https://doi.org/10.26226/morressier.617c37307c09fc044a97516d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034608","R0034608.pdf","paywalled","randomized_trial","Aya Shiraki","2021","GLP-1 ANALOG LIRAGLUTIDE INDUCED CARDIAC DYSFUNCTION DUE TO ENERGETIC STARVATION IN HEART FAILURE WITH NON-DIABETIC DILATED CARDIOMYOPATHY IN HAMSTERS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000745372.65932.fd","https://doi.org/10.1097/01.hjh.0000745372.65932.fd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035781","R0035781.pdf","paywalled","randomized_trial","Rowan Hillson","2021","The gallbladder in diabetes","Practical Diabetes","Wiley","10.1002/pdi.2323","https://doi.org/10.1002/pdi.2323",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035899","R0035899.pdf","paywalled","randomized_trial",null,"2021","Semaglutide effective for weight loss in non-diabetic adults, research suggests","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2021.20208793","https://doi.org/10.1211/pj.2021.20208793",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036085","R0036085.pdf","paywalled","randomized_trial","Ulrich Dischinger","2021","Effects of liraglutide plus PYY3-36 vs. Roux-en-Y gastric bypass on hypothalamic gene expression","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727385","https://doi.org/10.1055/s-0041-1727385",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036581","R0036581.pdf","paywalled","randomized_trial","Hannah Syed","2021","Changing the way type 2 diabetes is managed","Journal of Prescribing Practice","Mark Allen Group","10.12968/jprp.2021.3.10.412","https://doi.org/10.12968/jprp.2021.3.10.412",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036801","R0036801.pdf","paywalled","randomized_trial","Myat, Aung","2021","Additional file 1 of Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial","Figshare",null,"10.6084/m9.figshare.13979203","https://doi.org/10.6084/m9.figshare.13979203",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037201","R0037201.pdf","paywalled","randomized_trial","János Tibor Kis","2021","637-P: Effectiveness of Fixed Ratio Combination of IGlarLixi in People with Type 2 Diabetes Mellitus: Experience from Routine Clinical Practice","Diabetes","American Diabetes Association","10.2337/db21-637-p","https://doi.org/10.2337/db21-637-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038661","R0038661.pdf","paywalled","randomized_trial","Dorrin Zarrin Khat","2021","Abstract 13142: Combined Treatment With Dapagliflozin and Exenatide is More Cardioprotective Than Either Agent Alone in a Non-Diabetic Mouse Model of Ischemia-Reperfusion Injury","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.13142","https://doi.org/10.1161/circ.144.suppl_1.13142",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039195","R0039195.pdf","paywalled","randomized_trial","Ulrich Dischinger","2021","Effects of liraglutide + / - PYY3-36 vs. Roux-en-Y gastric bypass on non-alcoholic fatty liver disease","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727388","https://doi.org/10.1055/s-0041-1727388",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039488","R0039488.pdf","paywalled","randomized_trial","Murphy, Mark","2021","Management of Suboptimally Controlled Type 2 Diabetes Mellitus in General Practice","Royal College of Surgeons in Ireland",null,"10.25419/rcsi.15035628","https://doi.org/10.25419/rcsi.15035628",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039749","R0039749.pdf","paywalled","randomized_trial","Riccardo Candido","2021","110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study","Diabetes","American Diabetes Association","10.2337/db21-110-lb","https://doi.org/10.2337/db21-110-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040374","R0040374.pdf","paywalled","randomized_trial","Of, Adis Journals On Behalf","2021","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Figshare",null,"10.6084/m9.figshare.13360163.v2","https://doi.org/10.6084/m9.figshare.13360163.v2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041551","R0041551.pdf","paywalled","randomized_trial","Filippo Crea","2021","The growing complexity of the number one killer: ischaemic heart disease","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab414","https://doi.org/10.1093/eurheartj/ehab414","34244748","https://pubmed.ncbi.nlm.nih.gov/34244748/",null,null],["2","R0041620","R0041620.pdf","paywalled","randomized_trial","Alina M. Allen","2021","The Importance of Glycemic Equipoise in NASH","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.31866","https://doi.org/10.1002/hep.31866","33901304","https://pubmed.ncbi.nlm.nih.gov/33901304/",null,null],["2","R0041768","R0041768.pdf","paywalled","randomized_trial","Giovanna Liuzzo","2021","FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab725","https://doi.org/10.1093/eurheartj/ehab725","34905601","https://pubmed.ncbi.nlm.nih.gov/34905601/",null,null],["2","R0041797","R0041797.pdf","paywalled","randomized_trial","Terence J. Quinn","2021","Can we re‐purpose drugs from the cardiology medicine cabinet? Should we look in the rheumatology, metabolic and hematology cabinets as well?","Alzheimer s & Dementia","Wiley","10.1002/alz.050163","https://doi.org/10.1002/alz.050163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043253","R0043253.pdf","paywalled","randomized_trial","Sø. Rasmussen","2021","Occurence of First and Recurrent Major Adverse Cardiovascular Events with Liraglutide Treatment among Patients with Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/t4wn-b146","https://doi.org/10.17615/t4wn-b146",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043538","R0043538.pdf","paywalled","randomized_trial","Peter K. Honig","2021","Real‐World Evidence and the Regulation of Medicines","Clinical Pharmacology & Therapeutics","Wiley","10.1002/cpt.2230","https://doi.org/10.1002/cpt.2230","33870489","https://pubmed.ncbi.nlm.nih.gov/33870489/",null,null],["2","R0043612","R0043612.pdf","paywalled","randomized_trial","Soo Lim","2021","Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14627","https://doi.org/10.1111/dom.14627","34908220","https://pubmed.ncbi.nlm.nih.gov/34908220/",null,null],["2","R0045455","R0045455.pdf","paywalled","randomized_trial","Seung Jae Baek","2021","102-OR: Efficacy and Safety of Once-Weekly Efpeglenatide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (AMPLITUDE-M)","Diabetes","American Diabetes Association","10.2337/db21-102-or","https://doi.org/10.2337/db21-102-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045738","R0045738.pdf","paywalled","randomized_trial","William V. Tamborlane","2021","91-LB: Once-Weekly Exenatide in Youth with Type 2 Diabetes: A Pivotal Phase III Randomized Study","Diabetes","American Diabetes Association","10.2337/db21-91-lb","https://doi.org/10.2337/db21-91-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045764","R0045764.pdf","paywalled","randomized_trial","Shweta Urva","2021","104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db21-104-or","https://doi.org/10.2337/db21-104-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046546","R0046546.pdf","paywalled","randomized_trial","Denis Nößler","2021","Typ-2-Diabetes – was nach Metformin kommt und die Niere schützen kann","EvidenzUpdate",null,"10.69156/pod.001/2021.02.00058","https://doi.org/10.69156/pod.001/2021.02.00058",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046667","R0046667.pdf","paywalled","randomized_trial","Lai‐San Tham","2021","106-OR: A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db21-106-or","https://doi.org/10.2337/db21-106-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046819","R0046819.pdf","paywalled","randomized_trial","Luis‐Emilio García‐Pérez","2021","673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial","Diabetes","American Diabetes Association","10.2337/db21-673-p","https://doi.org/10.2337/db21-673-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046883","R0046883.pdf","paywalled","randomized_trial","Julio Rosenstock","2021","234-OR: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with IGlarLixi vs. Premix 70/30 in the SoliMix Trial","Diabetes","American Diabetes Association","10.2337/db21-234-or","https://doi.org/10.2337/db21-234-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0047029","R0047029.pdf","paywalled","randomized_trial","Martin Lund Kårhus","2021","103-OR: The Glucagon-Like Peptide-1 Analog, Liraglutide Is a Safe and Effective Treatment of Bile Acid Malabsorption: A Proof of Concept Study","Diabetes","American Diabetes Association","10.2337/db21-103-or","https://doi.org/10.2337/db21-103-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047032","R0047032.pdf","paywalled","randomized_trial","Nadia A. Akawi","2021","Abstract 13393: Liraglutide Improves Myocardial Redox State in Humans by Regulating the Adipose Tissue-Derived Long-Chain Ceramides","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_2.13393","https://doi.org/10.1161/circ.144.suppl_2.13393",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047141","R0047141.pdf","paywalled","randomized_trial","Dominik B. Dahl","2021","80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)","Diabetes","American Diabetes Association","10.2337/db21-80-lb","https://doi.org/10.2337/db21-80-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047184","R0047184.pdf","paywalled","randomized_trial","Peter R Rossing","2021","406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment","Diabetes","American Diabetes Association","10.2337/db21-406-p","https://doi.org/10.2337/db21-406-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02540993"],["2","R0047204","R0047204.pdf","paywalled","randomized_trial","Jean‐Jacques Mourad","2021","FRAGILITY INDEX OF VARIOUS GLP1 AGONISTS ON CARDIOVASCULAR OUTCOMES IN PLACEBO CONTROLLED TRIALS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000746812.65674.1a","https://doi.org/10.1097/01.hjh.0000746812.65674.1a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047420","R0047420.pdf","paywalled","randomized_trial","Annemie Stege Bojer","2021","Metabolic improvement during short-term treatment with a GLP-1 receptor agonist does not improve cardiac diastolic function in patients type 2 diabetes: a randomized double-blind placebo-controlled trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2619","https://doi.org/10.1093/eurheartj/ehab724.2619",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047455","R0047455.pdf","paywalled","randomized_trial","A. Kavyasree","2021","A Review: Comparison of Efficacy of Liraglutide Versus Sitagliptin add-on-to Metformin in Type 2 Diabetes Mellitus patients","Research Journal of Pharmacy and Technology","A and V Publications","10.52711/0974-360x.2021.00405","https://doi.org/10.52711/0974-360x.2021.00405",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047664","R0047664.pdf","paywalled","randomized_trial","Bernhard H. Ludvik","2021","78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)","Diabetes","American Diabetes Association","10.2337/db21-78-lb","https://doi.org/10.2337/db21-78-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047665","R0047665.pdf","paywalled","randomized_trial","Peter R Rossing","2021","405-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment","Diabetes","American Diabetes Association","10.2337/db21-405-p","https://doi.org/10.2337/db21-405-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02540993"],["2","R0047731","R0047731.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2021","Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727305","https://doi.org/10.1055/s-0041-1727305",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047955","R0047955.pdf","paywalled","randomized_trial","Bettina Felicitas Winzeler","2021","The GLP-1 receptor agonist dulaglutide reduces fluid intake in primary polydipsia: A randomised controlled trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.73.aep467","https://doi.org/10.1530/endoabs.73.aep467",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048202","R0048202.pdf","paywalled","randomized_trial","Leigh Perreault","2021","81-OR: Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial","Diabetes","American Diabetes Association","10.2337/db21-81-or","https://doi.org/10.2337/db21-81-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048641","R0048641.pdf","paywalled","randomized_trial","ALICE Y.Y. CHENG","2021","748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe","Diabetes","American Diabetes Association","10.2337/db21-748-p","https://doi.org/10.2337/db21-748-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0048811","R0048811.pdf","paywalled","randomized_trial","Bernard Zinman","2021","Efficacy of Semaglutide by Background Sodium–Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727320","https://doi.org/10.1055/s-0041-1727320",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048909","R0048909.pdf","paywalled","randomized_trial","Kristina Secnik Boye","2021","81-LB: Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Placebo (SURPASS-1)","Diabetes","American Diabetes Association","10.2337/db21-81-lb","https://doi.org/10.2337/db21-81-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049150","R0049150.pdf","paywalled","randomized_trial","Joanna T Van","2021","680-P: Once-Weekly Dulaglutide 3 mg and 4.5 mg Gastrointestinal Tolerability: Post-hoc Analysis of Incidence and Prevalence in Award-11","Diabetes","American Diabetes Association","10.2337/db21-680-p","https://doi.org/10.2337/db21-680-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049280","R0049280.pdf","paywalled","randomized_trial","William H. Polonsky","2021","747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial","Diabetes","American Diabetes Association","10.2337/db21-747-p","https://doi.org/10.2337/db21-747-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0049461","R0049461.pdf","paywalled","randomized_trial","Eleni T. Pappa","2021","297-OR: Triglyceride Reduction and Effect on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus Receiving Fixed-Dose Combination of Insulin Degludec and Liraglutide","Diabetes","American Diabetes Association","10.2337/db21-297-or","https://doi.org/10.2337/db21-297-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049524","R0049524.pdf","paywalled","randomized_trial","Ian J. Neeland","2021","221-LB: Effects of Liraglutide on Visceral and Ectopic Fat in Adults with Overweight/Obesity at High Cardiovascular Risk: A Randomized Clinical Trial","Diabetes","American Diabetes Association","10.2337/db21-221-lb","https://doi.org/10.2337/db21-221-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049609","R0049609.pdf","paywalled","randomized_trial","Eleni-Margarita Tzouganatou","2021","THE EFFECT OF ADD-ON THERAPY OF LIRAGLUTIDE AND EMPAGLIFLOZIN ON AMBULATORY BLOOD PRESSURE IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES MELLITUS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000746872.52004.bf","https://doi.org/10.1097/01.hjh.0000746872.52004.bf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049977","R0049977.pdf","paywalled","randomized_trial","James Mitchell","2021","2 IIH Pressure – a randomised, controlled, double blind physiology study of the effect of Exenatide on intracranial pressure","BMJ Military Health","BMJ","10.1136/bmjmilitary-2021-rsmabstracts.2","https://doi.org/10.1136/bmjmilitary-2021-rsmabstracts.2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050190","R0050190.pdf","paywalled","randomized_trial","Bryan Haddock","2021","GLP-1's Effect on Renal Perfusion and Oxygenation Measured with Quantitative MRI: A Potential Renoprotective Pathway in the Human GLP-1-Renal Axis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1256b","https://doi.org/10.1681/asn.20213210s1256b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050223","R0050223.pdf","paywalled","randomized_trial","CAROLINA M. CASELLINI","2021","420-P: Effects of Liraglutide on Sudomotor Function in Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-420-p","https://doi.org/10.2337/db21-420-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050764","R0050764.pdf","paywalled","randomized_trial","Rory J. McCrimmon","2021","1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial","Diabetes","American Diabetes Association","10.2337/db21-1-lb","https://doi.org/10.2337/db21-1-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050767","R0050767.pdf","paywalled","randomized_trial","Emilie Skytte Andersen","2021","10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out","Diabetes","American Diabetes Association","10.2337/db21-10-or","https://doi.org/10.2337/db21-10-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051274","R0051274.pdf","paywalled","randomized_trial","Daniel Barry Maselli","2021","160 IMPACT OF GASTRIC EMPTYING AND GENETIC VARIANTS RELATED TO GLP-1 ON WEIGHT LOSS WITH LIRAGLUTIDE IN TREATMENT OF OBESITY: A 16-WEEK, SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN 76 PATIENTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(21)00837-4","https://doi.org/10.1016/s0016-5085(21)00837-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051339","R0051339.pdf","paywalled","randomized_trial","M Asano","2021","659-P: Cotadutide (MEDI0382) Is Well Tolerated at Doses Up to 600 µG with Blood Glucose-Lowering Activity in Japanese Patients with T2DM","Diabetes","American Diabetes Association","10.2337/db21-659-p","https://doi.org/10.2337/db21-659-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051435","R0051435.pdf","paywalled","randomized_trial","Jessica A. Regan","2021","Abstract 11459: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in Individuals with Type 2 Diabetes Mellitus: An Exscel Biomarker Substudy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.11459","https://doi.org/10.1161/circ.144.suppl_1.11459",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051516","R0051516.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2021","The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2959","https://doi.org/10.1093/eurheartj/ehab724.2959",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051836","R0051836.pdf","paywalled","randomized_trial","Robert F. Kushner","2021","80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis","Diabetes","American Diabetes Association","10.2337/db21-80-or","https://doi.org/10.2337/db21-80-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051847","R0051847.pdf","paywalled","randomized_trial","Vandana S. Raman","2021","Metformin Treatment of Pediatric Obesity","PEDIATRICS","American Academy of Pediatrics (AAP)","10.1542/peds.2020-044982","https://doi.org/10.1542/peds.2020-044982","33608414","https://pubmed.ncbi.nlm.nih.gov/33608414/",null,null],["2","R0051950","R0051950.pdf","paywalled","randomized_trial","Richard E. Pratley","2021","Maintaining Operational Excellence During the COVID-19 Pandemic in the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1b6a","https://doi.org/10.1681/asn.20213210s1b6a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052053","R0052053.pdf","paywalled","randomized_trial","Vivian Andrew Fonseca","2021","749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe","Diabetes","American Diabetes Association","10.2337/db21-749-p","https://doi.org/10.2337/db21-749-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0052064","R0052064.pdf","paywalled","randomized_trial","Julio Rosenstock","2021","100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)","Diabetes","American Diabetes Association","10.2337/db21-100-or","https://doi.org/10.2337/db21-100-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052357","R0052357.pdf","paywalled","randomized_trial","Juan P. Frías","2021","84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)","Diabetes","American Diabetes Association","10.2337/db21-84-lb","https://doi.org/10.2337/db21-84-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052525","R0052525.pdf","paywalled","randomized_trial","Kamyar Kalantar‐Zadeh","2021","Association of SGLT2 Inhibitors and DPP-4 Inhibitors vs. GLP-1 Agonists with Incident CKD in US Veterans","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1697d","https://doi.org/10.1681/asn.20213210s1697d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052717","R0052717.pdf","paywalled","randomized_trial","Athena Philis‐Tsimikas","2021","606-P: Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db21-606-p","https://doi.org/10.2337/db21-606-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052721","R0052721.pdf","paywalled","randomized_trial","Kristin Gonzales","2021","Incretin‐Based Therapy for the Management of Type 2 Diabetes",null,"Wiley","10.1002/9781119603207.ch12","https://doi.org/10.1002/9781119603207.ch12",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052743","R0052743.pdf","paywalled","randomized_trial","Michelle E. Hauser","2021","Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727309","https://doi.org/10.1055/s-0041-1727309",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052857","R0052857.pdf","paywalled","randomized_trial","Rory J. McCrimmon","2021","746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial","Diabetes","American Diabetes Association","10.2337/db21-746-p","https://doi.org/10.2337/db21-746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["2","R0052931","R0052931.pdf","paywalled","randomized_trial","Rajna Golubić","2021","105-OR: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Cotadutide on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db21-105-or","https://doi.org/10.2337/db21-105-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053114","R0053114.pdf","paywalled","randomized_trial","Gilbert H. Daniels","2021","Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/4ena-v672","https://doi.org/10.17615/4ena-v672",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053138","R0053138.pdf","paywalled","randomized_trial","Enzo Bonora","2021","Efficacy of investigational dulaglutide doses overall and by baseline HbA1c and Body Mass Index (BMI): exploratory subgroup analyses of the AWARD-11 trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727332","https://doi.org/10.1055/s-0041-1727332",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053150","R0053150.pdf","paywalled","randomized_trial","Dhiran Verghese","2021","Association of Cardio-Ankle Vascular Index (CAVI) and Duration of Diabetes Mellitus in the STOP (Semaglutide Treatment on Coronary Plaque Progression) Randomized Control Trial","American Heart Journal","Elsevier BV","10.1016/j.ahj.2021.10.061","https://doi.org/10.1016/j.ahj.2021.10.061",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053217","R0053217.pdf","paywalled","randomized_trial","Thomas Simon James Crabtree","2021","686-P: The Association of British Clinical Diabetologists (ABCD) United Kingdom Nationwide Semaglutide Audit","Diabetes","American Diabetes Association","10.2337/db21-686-p","https://doi.org/10.2337/db21-686-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053288","R0053288.pdf","paywalled","randomized_trial","Enzo Bonora","2021","651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11","Diabetes","American Diabetes Association","10.2337/db21-651-p","https://doi.org/10.2337/db21-651-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053392","R0053392.pdf","paywalled","randomized_trial","Natalia McInnes","2021","677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db21-677-p","https://doi.org/10.2337/db21-677-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053506","R0053506.pdf","paywalled","randomized_trial","Patrick H. Griffin","2021","S1368 The Pharmacokinetics of Long-Acting GLP-1 Analogue (NM-002) in Patients With Short Bowel Syndrome","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000779004.80713.37","https://doi.org/10.14309/01.ajg.0000779004.80713.37",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054190","R0054190.pdf","paywalled","randomized_trial","Debora de Melo Behrens","2021","Most Clinical Studies Do Not Report FDA Recommendations For Endpoints In NAFLD/NASH","Medicine & Science in Sports & Exercise","Ovid Technologies (Wolters Kluwer Health)","10.1249/01.mss.0000764484.54799.31","https://doi.org/10.1249/01.mss.0000764484.54799.31",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0007919","R0007919.pdf","paywalled","randomized_trial","Yandrapalli S","2020","Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000308","https://doi.org/10.1097/crd.0000000000000308","32282393","https://pubmed.ncbi.nlm.nih.gov/32282393/",null,null],["2","R0008194","R0008194.pdf","paywalled","randomized_trial","Khan MS","2020","Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.120.045888","https://doi.org/10.1161/circulationaha.120.045888","32955939","https://pubmed.ncbi.nlm.nih.gov/32955939/",null,null],["2","R0008693","R0008693.pdf","paywalled","randomized_trial","Winzeler B","2020","Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-020-02394-2","https://doi.org/10.1007/s12020-020-02394-2","32623637","https://pubmed.ncbi.nlm.nih.gov/32623637/",null,null],["2","R0009148","R0009148.pdf","paywalled","randomized_trial","Gao F","2020","Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14163","https://doi.org/10.1111/dom.14163","32744358","https://pubmed.ncbi.nlm.nih.gov/32744358/",null,null],["2","R0009603","R0009603.pdf","paywalled","randomized_trial","Yandrapalli S","2020","Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000311","https://doi.org/10.1097/crd.0000000000000311","32271194","https://pubmed.ncbi.nlm.nih.gov/32271194/",null,null],["2","R0010315","R0010315.pdf","paywalled","randomized_trial","Johansen NJ","2020","Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14078","https://doi.org/10.1111/dom.14078","32543021","https://pubmed.ncbi.nlm.nih.gov/32543021/",null,null],["2","R0011010","R0011010.pdf","paywalled","randomized_trial","Page LC","2020","Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.","Current obesity reports","Springer Science and Business Media LLC","10.1007/s13679-020-00409-7","https://doi.org/10.1007/s13679-020-00409-7","33085056","https://pubmed.ncbi.nlm.nih.gov/33085056/",null,null],["2","R0011227","R0011227.pdf","paywalled","randomized_trial","Papaetis GS","2020","Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-020-00942-2","https://doi.org/10.1007/s40261-020-00942-2","32583294","https://pubmed.ncbi.nlm.nih.gov/32583294/",null,null],["2","R0011926","R0011926.pdf","paywalled","randomized_trial","Cernea S","2020","Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-020-01393-x","https://doi.org/10.1007/s40265-020-01393-x","32930957","https://pubmed.ncbi.nlm.nih.gov/32930957/",null,null],["2","R0012002","R0012002.pdf","paywalled","randomized_trial","Athyros VG","2020","Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161117666190405164313","https://doi.org/10.2174/1570161117666190405164313","30961499","https://pubmed.ncbi.nlm.nih.gov/30961499/",null,null],["2","R0012194","R0012194.pdf","paywalled","randomized_trial","Hygum K","2020","Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.","Bone","Elsevier BV","10.1016/j.bone.2019.115197","https://doi.org/10.1016/j.bone.2019.115197","31870634","https://pubmed.ncbi.nlm.nih.gov/31870634/",null,null],["2","R0012197","R0012197.pdf","paywalled","randomized_trial","Patoulias D","2020","Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161117666190426162746","https://doi.org/10.2174/1570161117666190426162746","32013815","https://pubmed.ncbi.nlm.nih.gov/32013815/",null,null],["2","R0012200","R0012200.pdf","paywalled","randomized_trial","Napoli R","2020","Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2020.07.012","https://doi.org/10.1016/j.numecd.2020.07.012","32928628","https://pubmed.ncbi.nlm.nih.gov/32928628/",null,null],["2","R0012230","R0012230.pdf","paywalled","randomized_trial","Abdul-Ghani M","2020","Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14153","https://doi.org/10.1111/dom.14153","32729222","https://pubmed.ncbi.nlm.nih.gov/32729222/",null,null],["2","R0012346","R0012346.pdf","paywalled","randomized_trial","Abdelhafiz AH","2020","Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107639","https://doi.org/10.1016/j.jdiacomp.2020.107639","32595017","https://pubmed.ncbi.nlm.nih.gov/32595017/",null,null],["2","R0012388","R0012388.pdf","paywalled","randomized_trial","Chien CL","2020","Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2020.1815686","https://doi.org/10.1080/03007995.2020.1815686","32851879","https://pubmed.ncbi.nlm.nih.gov/32851879/",null,null],["2","R0012579","R0012579.pdf","paywalled","randomized_trial","Koufakis T","2020","Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all.","Journal of diabetes","Wiley","10.1111/1753-0407.12982","https://doi.org/10.1111/1753-0407.12982","31449359","https://pubmed.ncbi.nlm.nih.gov/31449359/",null,null],["2","R0014135","R0014135.pdf","paywalled","randomized_trial","Jones KL","2020","Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13956","https://doi.org/10.1111/dom.13956","31903712","https://pubmed.ncbi.nlm.nih.gov/31903712/",null,null],["2","R0016173","R0016173.pdf","paywalled","randomized_trial","Rayner CK","2020","Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc20-0190","https://doi.org/10.2337/dc20-0190","32471908","https://pubmed.ncbi.nlm.nih.gov/32471908/",null,"ANZCTR:ACTRN12616001059459"],["2","R0016824","R0016824.pdf","paywalled","randomized_trial","Foltynie T","2020","Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.","Progress in brain research","Elsevier","10.1016/bs.pbr.2019.10.008","https://doi.org/10.1016/bs.pbr.2019.10.008","32247373","https://pubmed.ncbi.nlm.nih.gov/32247373/",null,null],["2","R0021389","R0021389.pdf","paywalled","randomized_trial","Yang J","2020","Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-020-01510-y","https://doi.org/10.1007/s00592-020-01510-y","32206903","https://pubmed.ncbi.nlm.nih.gov/32206903/",null,"ChiCTR:ChiCTR-IPR-15006558"],["2","R0022036","R0022036.pdf","paywalled","randomized_trial","Siasos G","2020","Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612826666201109110107","https://doi.org/10.2174/1381612826666201109110107","33167826","https://pubmed.ncbi.nlm.nih.gov/33167826/",null,null],["2","R0022703","R0022703.pdf","paywalled","randomized_trial","Hotta Y","2020","Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.","Neurourology and urodynamics","Wiley","10.1002/nau.24449","https://doi.org/10.1002/nau.24449","32725853","https://pubmed.ncbi.nlm.nih.gov/32725853/",null,null],["2","R0023264","R0023264.pdf","paywalled","randomized_trial","Mann JFE","2020","Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(20)30313-2","https://doi.org/10.1016/s2213-8587(20)30313-2","32971040","https://pubmed.ncbi.nlm.nih.gov/32971040/",null,null],["2","R0023356","R0023356.pdf","paywalled","randomized_trial","Cui H","2020","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.","European journal of drug metabolism and pharmacokinetics","Springer Science and Business Media LLC","10.1007/s13318-020-00605-9","https://doi.org/10.1007/s13318-020-00605-9","32006325","https://pubmed.ncbi.nlm.nih.gov/32006325/",null,"ClinicalTrials.gov:NCT02084251"],["2","R0023620","R0023620.pdf","paywalled","randomized_trial","Ghanim H","2020","Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14090","https://doi.org/10.1111/dom.14090","32424935","https://pubmed.ncbi.nlm.nih.gov/32424935/",null,null],["2","R0023647","R0023647.pdf","paywalled","randomized_trial","Romera I","2020","Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107575","https://doi.org/10.1016/j.jdiacomp.2020.107575","32220551","https://pubmed.ncbi.nlm.nih.gov/32220551/",null,null],["2","R0023669","R0023669.pdf","paywalled","randomized_trial","Guo W","2020","Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108487","https://doi.org/10.1016/j.diabres.2020.108487","33035599","https://pubmed.ncbi.nlm.nih.gov/33035599/",null,null],["2","R0023733","R0023733.pdf","paywalled","randomized_trial","Liu L","2020","Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3292","https://doi.org/10.1002/dmrr.3292","31955491","https://pubmed.ncbi.nlm.nih.gov/31955491/",null,null],["2","R0023889","R0023889.pdf","paywalled","randomized_trial","Eid TJ","2020","Exenatide ER-induced eosinophilia.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxaa105","https://doi.org/10.1093/ajhp/zxaa105","32470112","https://pubmed.ncbi.nlm.nih.gov/32470112/",null,null],["2","R0024035","R0024035.pdf","paywalled","randomized_trial","Dubé MC","2020","Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14050","https://doi.org/10.1111/dom.14050","32250534","https://pubmed.ncbi.nlm.nih.gov/32250534/",null,null],["2","R0024159","R0024159.pdf","paywalled","randomized_trial","Zhang LY","2020","Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2020.01.007","https://doi.org/10.1016/j.clinre.2020.01.007","32113823","https://pubmed.ncbi.nlm.nih.gov/32113823/",null,null],["2","R0024401","R0024401.pdf","paywalled","randomized_trial","Mabilleau G","2020","Update on: effects of anti-diabetic drugs on bone metabolism.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2020.1831911","https://doi.org/10.1080/17446651.2020.1831911","33059497","https://pubmed.ncbi.nlm.nih.gov/33059497/",null,null],["2","R0024701","R0024701.pdf","paywalled","randomized_trial","Yang G","2020","Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cp203730","https://doi.org/10.5414/cp203730","32729820","https://pubmed.ncbi.nlm.nih.gov/32729820/",null,null],["2","R0025028","R0025028.pdf","paywalled","randomized_trial","Vadini F","2020","Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-020-0535-5","https://doi.org/10.1038/s41366-020-0535-5","31965072","https://pubmed.ncbi.nlm.nih.gov/31965072/",null,null],["2","R0026092","R0026092.pdf","paywalled","randomized_trial","Ferrari F","2020","Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-020-01334-1","https://doi.org/10.1007/s40618-020-01334-1","32594453","https://pubmed.ncbi.nlm.nih.gov/32594453/",null,null],["2","R0026494","R0026494.pdf","paywalled","randomized_trial","Ferrannini E","2020","Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13870","https://doi.org/10.1111/dom.13870","31469220","https://pubmed.ncbi.nlm.nih.gov/31469220/",null,null],["2","R0030376","R0030376.pdf","paywalled","randomized_trial","Elharram M","2020","Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2020.03.025","https://doi.org/10.1016/j.ijcard.2020.03.025","32303419","https://pubmed.ncbi.nlm.nih.gov/32303419/",null,null],["2","R0033014","R0033014.pdf","paywalled","randomized_trial","Hongrong Deng","2020","962-P: Impacts of Different Hypoglycemic Agents on Adipokines and Inflammatory Markers in Newly Diagnosed T2D Patients","Diabetes","American Diabetes Association","10.2337/db20-962-p","https://doi.org/10.2337/db20-962-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033019","R0033019.pdf","paywalled","randomized_trial","Tsung-Hui Wu","2020","937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia","Diabetes","American Diabetes Association","10.2337/db20-937-p","https://doi.org/10.2337/db20-937-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033208","R0033208.pdf","paywalled","randomized_trial","Shohei Yamada","2020","Renoprotective Effect of a GLP-1 Receptor Agonist, Liraglutide, in an Early Phase of Diabetic Kidney Disease in Spontaneously Diabetic Tori Fatty Rats","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1317d","https://doi.org/10.1681/asn.20203110s1317d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033463","R0033463.pdf","paywalled","randomized_trial","Husain, Mansoor","2020","Additional file 4 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Figshare",null,"10.6084/m9.figshare.13031555","https://doi.org/10.6084/m9.figshare.13031555",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033581","R0033581.pdf","paywalled","randomized_trial","Zhang, Yi","2020","Exenatide, metformin, or both for prediabetes in PCOS: A randomized, open-labeled, parallel-group controlled study","Figshare",null,"10.6084/m9.figshare.12894080","https://doi.org/10.6084/m9.figshare.12894080",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034398","R0034398.pdf","paywalled","randomized_trial","Joseph Azuri","2020","Abstract 14615: Empagliflozin Provides More Value for Money Than Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.14615","https://doi.org/10.1161/circ.142.suppl_3.14615",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034484","R0034484.pdf","paywalled","randomized_trial","Sposito, Andrei C.","2020","Additional file 1 of Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","Figshare",null,"10.6084/m9.figshare.7794971","https://doi.org/10.6084/m9.figshare.7794971",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035782","R0035782.pdf","paywalled","randomized_trial",null,"2020","Infectious complications of newer agents in the fight against diabetes","The Nurse Practitioner","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.npr.0000722048.34837.83","https://doi.org/10.1097/01.npr.0000722048.34837.83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035868","R0035868.pdf","paywalled","randomized_trial","Nuno Borges","2020","Current Pharmacological Approaches in Obesity Treatment","Recent advances in obesity research","BENTHAM SCIENCE PUBLISHERS","10.2174/9789811442636120010011","https://doi.org/10.2174/9789811442636120010011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036734","R0036734.pdf","paywalled","randomized_trial","Zhang, Jie","2020","Additional file 1 of Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial","Figshare",null,"10.6084/m9.figshare.12197088","https://doi.org/10.6084/m9.figshare.12197088",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037355","R0037355.pdf","paywalled","randomized_trial","D Cazorla-Morallon","2020","Stroke and myocardial infarction prevention with GLP1 analogues in high or very-high cardiovascular risk diabetic patients","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.2967","https://doi.org/10.1093/ehjci/ehaa946.2967",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037368","R0037368.pdf","paywalled","randomized_trial","John B. Buse","2020","957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Diabetes","American Diabetes Association","10.2337/db20-957-p","https://doi.org/10.2337/db20-957-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037929","R0037929.pdf","paywalled","randomized_trial","Of, Adis Journals On Behalf","2020","Effect of Oral Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Figshare",null,"10.6084/m9.figshare.13360163.v1","https://doi.org/10.6084/m9.figshare.13360163.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037968","R0037968.pdf","paywalled","randomized_trial","Esteban Jódar","2020","1056-P: Effect of Dulaglutide on Glycemic Variability: Post Hoc Analysis of the AWARD Studies","Diabetes","American Diabetes Association","10.2337/db20-1056-p","https://doi.org/10.2337/db20-1056-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038028","R0038028.pdf","paywalled","randomized_trial","Hilla Knobler","2020","Letter to the Editor from Knobler and Toledano: “Validation of the Swedish Diabetes Regrouping Scheme in Adult-Onset Diabetes in China”","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgaa827","https://doi.org/10.1210/clinem/dgaa827","33164090","https://pubmed.ncbi.nlm.nih.gov/33164090/",null,null],["2","R0038175","R0038175.pdf","paywalled","randomized_trial","Nish Chaturvedi","2020","Prescribing by Ethnicity: (Im)precision Medicine?","Diabetes Care","American Diabetes Association","10.2337/dci20-0015","https://doi.org/10.2337/dci20-0015","33539313","https://pubmed.ncbi.nlm.nih.gov/33539313/",null,null],["2","R0038329","R0038329.pdf","paywalled","randomized_trial","Esteban Jódar","2020","1055-P: Glycemic Variability with Dulaglutide vs. Basal Insulin Glargine","Diabetes","American Diabetes Association","10.2337/db20-1055-p","https://doi.org/10.2337/db20-1055-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038369","R0038369.pdf","paywalled","randomized_trial","Massimo Volpe","2020","Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaa334","https://doi.org/10.1093/cvr/cvaa334","33231613","https://pubmed.ncbi.nlm.nih.gov/33231613/",null,null],["2","R0038524","R0038524.pdf","paywalled","randomized_trial","Giuseppe Mancia","2020","Highlights of the March issue","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000002357","https://doi.org/10.1097/hjh.0000000000002357","32028512","https://pubmed.ncbi.nlm.nih.gov/32028512/",null,null],["2","R0038534","R0038534.pdf","paywalled","randomized_trial","Sean Wharton","2020","141-OR: Efficacy and Safety of Naltrexone/Bupropion as Add-On to Incretin Agents in Patients with Obesity and T2DM","Diabetes","American Diabetes Association","10.2337/db20-141-or","https://doi.org/10.2337/db20-141-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038595","R0038595.pdf","paywalled","randomized_trial","Hirokazu Takahashi","2020","31-OR: Ipragliflozin Ameliorated Overweight and Pathological Liver Fibrosis in Diabetic Patients with Nonalcoholic Fatty Liver Disease in a Multicenter Randomized Controlled Trial","Diabetes","American Diabetes Association","10.2337/db20-31-or","https://doi.org/10.2337/db20-31-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038779","R0038779.pdf","paywalled","randomized_trial","Darren B. Taichman","2020","Annals for Educators - 18 August 2020","Annals of Internal Medicine","American College of Physicians","10.7326/awed202008180","https://doi.org/10.7326/awed202008180","32805170","https://pubmed.ncbi.nlm.nih.gov/32805170/",null,null],["2","R0039180","R0039180.pdf","paywalled","randomized_trial","Of, Adis Journals On Behalf","2020","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Figshare",null,"10.6084/m9.figshare.13360163","https://doi.org/10.6084/m9.figshare.13360163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039806","R0039806.pdf","paywalled","randomized_trial","Nikolaus Marx","2020","Prescribing Paradigm Shift? Damned If You Do, Damned If You Don’t","Diabetes Care","American Diabetes Association","10.2337/dci20-0027","https://doi.org/10.2337/dci20-0027","32910774","https://pubmed.ncbi.nlm.nih.gov/32910774/",null,null],["2","R0039927","R0039927.pdf","paywalled","randomized_trial","Susan Sam","2020","1779-P: Liraglutide + Metformin Delays Worsening of Glycemia in Adults with Impaired Glucose Tolerance (IGT) or Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db20-1779-p","https://doi.org/10.2337/db20-1779-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041748","R0041748.pdf","paywalled","randomized_trial","Rajaa Nahra","2020","Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(20)30655-3","https://doi.org/10.1016/s0168-8278(20)30655-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041963","R0041963.pdf","paywalled","randomized_trial","Clara Odilia Sailer","2020","Primary polydipsia in the medical and psychiatric patients","edoc (University of Basel)",null,"10.5451/unibas-007218396","https://doi.org/10.5451/unibas-007218396",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043033","R0043033.pdf","paywalled","randomized_trial","Manal F. Abdelmalek","2020","HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(20)30765-0","https://doi.org/10.1016/s0168-8278(20)30765-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043182","R0043182.pdf","paywalled","randomized_trial","R. Roginski Rea","2020","Effect of liraglutide on cardiovascular outcomes in elderly patients: A post hoc analysis of a randomized controlled trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/8t49-rn46","https://doi.org/10.17615/8t49-rn46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043211","R0043211.pdf","paywalled","randomized_trial","Ling, Yong Yong","2020","Effects of gut hormones, glucagon-like peptide-1 and desacyl ghrelin, on eating behaviour in obesity and ex-smokers",null,null,"10.25560/108169","https://doi.org/10.25560/108169",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043219","R0043219.pdf","paywalled","randomized_trial","S.P. Marso","2020","Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the leader trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/14f1-fy23","https://doi.org/10.17615/14f1-fy23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043238","R0043238.pdf","paywalled","randomized_trial","M. Donsmark","2020","Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/6xz3-t923","https://doi.org/10.17615/6xz3-t923",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043296","R0043296.pdf","paywalled","randomized_trial","S.C. Gough","2020","IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/q14z-kk30","https://doi.org/10.17615/q14z-kk30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043323","R0043323.pdf","paywalled","randomized_trial","J. Rosenstock","2020","Efficacy and safety of ITCA 650, a novel drug-Device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/yejd-1542","https://doi.org/10.17615/yejd-1542",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043353","R0043353.pdf","paywalled","randomized_trial","W. E. Schmidt","2020","Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/bnt5-cj47","https://doi.org/10.17615/bnt5-cj47",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043386","R0043386.pdf","paywalled","randomized_trial","K. Brown-Frandsen","2020","Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/tazj-ry27","https://doi.org/10.17615/tazj-ry27",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043405","R0043405.pdf","paywalled","randomized_trial","K. L. Taylor","2020","DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/nqmf-re91","https://doi.org/10.17615/nqmf-re91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043424","R0043424.pdf","paywalled","randomized_trial","Buse,","2020","Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/cz52-x169","https://doi.org/10.17615/cz52-x169",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043431","R0043431.pdf","paywalled","randomized_trial","P. Raskin","2020","Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/cn5s-c680","https://doi.org/10.17615/cn5s-c680",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043466","R0043466.pdf","paywalled","randomized_trial","N. Poulter","2020","Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/7zxp-j706","https://doi.org/10.17615/7zxp-j706",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043488","R0043488.pdf","paywalled","randomized_trial","A. C. Moses","2020","LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/7bvq-pf76","https://doi.org/10.17615/7bvq-pf76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044647","R0044647.pdf","paywalled","randomized_trial","W.M. Steinberg","2020","Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treatedwith liraglutide: Results from the LEADER randomized trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/w55w-c869","https://doi.org/10.17615/w55w-c869",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044855","R0044855.pdf","paywalled","randomized_trial","Ian H. de Boer","2020","Liraglutide and Renal Outcomes in Type 2 Diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/p8r3-g815","https://doi.org/10.17615/p8r3-g815",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044856","R0044856.pdf","paywalled","randomized_trial","M.A. Nauck","2020","Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care 2019;42:1912-1920","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/hmrw-yb89","https://doi.org/10.17615/hmrw-yb89",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044876","R0044876.pdf","paywalled","randomized_trial","M.A. Nauck","2020","Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/1h1y-s837","https://doi.org/10.17615/1h1y-s837",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044883","R0044883.pdf","paywalled","randomized_trial","S.T. Hoff","2020","Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PioNEER 8 trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/1bzn-7t47","https://doi.org/10.17615/1bzn-7t47",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045357","R0045357.pdf","paywalled","randomized_trial","Márcio Galindo Kiuchi","2020","Is the sympathetic hyperactivity a confounding factor for the outcomes of atrial fibrillation ablation?","EP Europace","Oxford University Press (OUP)","10.1093/europace/euaa089","https://doi.org/10.1093/europace/euaa089","32531031","https://pubmed.ncbi.nlm.nih.gov/32531031/",null,null],["2","R0045875","R0045875.pdf","paywalled","randomized_trial","Renyuan Li","2020","1341-P: Comparison of the Effects of Metformin and Exenatide on Pregnancy Rate and Outcomes in Overweight or Obese PCOS Women","Diabetes","American Diabetes Association","10.2337/db20-1341-p","https://doi.org/10.2337/db20-1341-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046781","R0046781.pdf","paywalled","randomized_trial","Steve Chaplin","2020","ESC/EASD guideline sheds light on diabetes and cardiovascular disease management","Practical Diabetes","Wiley","10.1002/pdi.2256","https://doi.org/10.1002/pdi.2256",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046840","R0046840.pdf","paywalled","randomized_trial","Xiangyu Wang","2020","26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study","Diabetes","American Diabetes Association","10.2337/db20-26-lb","https://doi.org/10.2337/db20-26-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047009","R0047009.pdf","paywalled","randomized_trial","Rory J. McCrimmon","2020","960-P: Characteristics of U.S. Patients with Type 2 Diabetes Prescribed GLP-1RA+SGLT2i in Combination during 2018","Diabetes","American Diabetes Association","10.2337/db20-960-p","https://doi.org/10.2337/db20-960-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047051","R0047051.pdf","paywalled","randomized_trial","Gregory Desrosiers","2020","Abstract 13544: Cardiologist Underutilization of New Antihyperglycemic Medications in Diabetic Patients With Cardiovascular Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.13544","https://doi.org/10.1161/circ.142.suppl_3.13544",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047114","R0047114.pdf","paywalled","randomized_trial","Olga Lavrynenko","2020","184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM","Diabetes","American Diabetes Association","10.2337/db20-184-or","https://doi.org/10.2337/db20-184-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047317","R0047317.pdf","paywalled","randomized_trial","Christine M. Laine","2020","Annals for Educators - 3 November 2020","Annals of Internal Medicine","American College of Physicians","10.7326/awed202011030","https://doi.org/10.7326/awed202011030","33137267","https://pubmed.ncbi.nlm.nih.gov/33137267/",null,null],["2","R0047740","R0047740.pdf","paywalled","randomized_trial","Charlotte Janus","2020","139-OR: Superior Effect of 1-Year Treatment with GLP-1 Receptor Agonist and Exercise on Weight Loss Maintenance and Body Composition after a Very Low-Calorie Diet: The S-LITE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db20-139-or","https://doi.org/10.2337/db20-139-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048144","R0048144.pdf","paywalled","randomized_trial","Hassan B. Awal","2020","Abstract 16844: Effect of Canagliflozin on Gene Expression and CD34+ Function on Type 2 Diabetes Subjects","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.16844","https://doi.org/10.1161/circ.142.suppl_3.16844",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048238","R0048238.pdf","paywalled","randomized_trial","Stephen C. L. Gough","2020","One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/y8b3-er87","https://doi.org/10.17615/y8b3-er87",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048352","R0048352.pdf","paywalled","randomized_trial","Massimiliano Caprio","2020","From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvaa019","https://doi.org/10.1093/ehjcvp/pvaa019","32298414","https://pubmed.ncbi.nlm.nih.gov/32298414/",null,null],["2","R0048500","R0048500.pdf","paywalled","randomized_trial","Cyrus V Desouza","2020","930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Diabetes","American Diabetes Association","10.2337/db20-930-p","https://doi.org/10.2337/db20-930-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048744","R0048744.pdf","paywalled","randomized_trial","CARLOS A. ALVAREZ","2020","1596-P: Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System","Diabetes","American Diabetes Association","10.2337/db20-1596-p","https://doi.org/10.2337/db20-1596-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048841","R0048841.pdf","paywalled","randomized_trial","Joseph Bailey","2020","Abstract 39: GLP-1 Agonists Improve Cerebrovascular Integrity and Vascular Induced Cognitive Impairment and Dementia Beyond Glycemic Control via Restoration of Brain Pericytes Functions in Diabetic Mice","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.51.suppl_1.39","https://doi.org/10.1161/str.51.suppl_1.39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048915","R0048915.pdf","paywalled","randomized_trial","Géza Hálasz","2020","Editors’ presentation: Focus on diabetes mellitus and diet","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1177/2047487320969012","https://doi.org/10.1177/2047487320969012","33200629","https://pubmed.ncbi.nlm.nih.gov/33200629/",null,null],["2","R0048924","R0048924.pdf","paywalled","randomized_trial","Jonathan Edward Shaw","2020","356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","Diabetes","American Diabetes Association","10.2337/db20-356-or","https://doi.org/10.2337/db20-356-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049358","R0049358.pdf","paywalled","randomized_trial","Francisco J. Pasquel","2020","963-P: A Randomized Controlled Trial Comparing Liraglutide vs. Glargine Insulin for the Management of Patients with Type 2 Diabetes after Hospital Discharge","Diabetes","American Diabetes Association","10.2337/db20-963-p","https://doi.org/10.2337/db20-963-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049447","R0049447.pdf","paywalled","randomized_trial","SIMON JENSEN","2020","686-P: Exercise Alone and in Combination with Liraglutide Exert Clinically Relevant Improvements in Cardiorespiratory Fitness during 1-Year Weight Loss Maintenance: The S-LITE Randomized Trial","Diabetes","American Diabetes Association","10.2337/db20-686-p","https://doi.org/10.2337/db20-686-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049654","R0049654.pdf","paywalled","randomized_trial","Ahmed Elhussein","2020","37-OR: Racial and Socioeconomic Disparities in the Use of Newer Classes of Diabetes Medications","Diabetes","American Diabetes Association","10.2337/db20-37-or","https://doi.org/10.2337/db20-37-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049690","R0049690.pdf","paywalled","randomized_trial","Charalambos V. Vlachopoulos","2020","Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa1022","https://doi.org/10.1093/eurheartj/ehaa1022","33374009","https://pubmed.ncbi.nlm.nih.gov/33374009/",null,null],["2","R0049757","R0049757.pdf","paywalled","randomized_trial","Thomas Felix Lüscher","2020","Frontiers of acute coronary syndromes: primary PCI time window, 15-year outcomes, bleeding and MINOCA","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa105","https://doi.org/10.1093/eurheartj/ehaa105","33216912","https://pubmed.ncbi.nlm.nih.gov/33216912/",null,null],["2","R0049811","R0049811.pdf","paywalled","randomized_trial","Avivit Cahn","2020","1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58","Diabetes","American Diabetes Association","10.2337/db20-1101-p","https://doi.org/10.2337/db20-1101-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049913","R0049913.pdf","paywalled","randomized_trial","Linong Ji","2020","961-P: Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial","Diabetes","American Diabetes Association","10.2337/db20-961-p","https://doi.org/10.2337/db20-961-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049926","R0049926.pdf","paywalled","randomized_trial","Bo Åhrén","2020","Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/6xvf-j016","https://doi.org/10.17615/6xvf-j016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050354","R0050354.pdf","paywalled","randomized_trial","HARPREET SINGH BAJAJ","2020","65 - Randomized Comparison of Initiating Insulin Glargine or Iglarlixi in South Asian Canadians With Type 2 Diabetes: VARIATION 2 SA Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.071","https://doi.org/10.1016/j.jcjd.2020.08.071",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050356","R0050356.pdf","paywalled","randomized_trial","Kyriaki Michailidou","2020","A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/dvr3-xw57","https://doi.org/10.17615/dvr3-xw57",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050609","R0050609.pdf","paywalled","randomized_trial","Nete Tofte","2020","P1006IMPACT OF GLUCOSE-LOWERING AND ANTIHYPERTENSIVE MEDICATIONS ON DEVELOPMENT OF MICROALBUMINURIA IN SUBJECTS WITH TYPE 2 DIATETES AND NORMOALBUMINURIA IN THE PRIORITY STUDY","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa142.p1006","https://doi.org/10.1093/ndt/gfaa142.p1006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050627","R0050627.pdf","paywalled","randomized_trial","Mary Angelyn Bethel","2020","Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the Exenatide study of Cardiovascular Event Lowering (EXSCEL)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/qvey-hf80","https://doi.org/10.17615/qvey-hf80",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050816","R0050816.pdf","paywalled","randomized_trial","Victoria Parker","2020","Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1348b","https://doi.org/10.1681/asn.20203110s1348b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050910","R0050910.pdf","paywalled","randomized_trial","Kathleen Marie Dungan","2020","964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","Diabetes","American Diabetes Association","10.2337/db20-964-p","https://doi.org/10.2337/db20-964-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051078","R0051078.pdf","paywalled","randomized_trial","Jonathan Edward Shaw","2020","Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1348a","https://doi.org/10.1681/asn.20203110s1348a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051641","R0051641.pdf","paywalled","randomized_trial","Jacob Kildevang Jensen","2020","The GLP-1 receptor agonist Semaglutide decreases vascular inflammation in a rabbit model of advanced atherosclerosis","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.0287","https://doi.org/10.1093/ehjci/ehaa946.0287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051756","R0051756.pdf","paywalled","randomized_trial","Juan P. Frías","2020","357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11","Diabetes","American Diabetes Association","10.2337/db20-357-or","https://doi.org/10.2337/db20-357-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051931","R0051931.pdf","paywalled","randomized_trial","Simran Grewal","2020","Abstract 15526: Glucagon-like Peptide-1 Receptor Agonists Reduce Adverse Cardiovascular Disease (CVD) Events in Patients With Type 2 Diabetes: An Assessment of Heterogeneity Among CVD Outcomes and a Meta-regression Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.15526","https://doi.org/10.1161/circ.142.suppl_3.15526",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051979","R0051979.pdf","paywalled","randomized_trial","Darren C. Robertson","2020","354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content","Diabetes","American Diabetes Association","10.2337/db20-354-or","https://doi.org/10.2337/db20-354-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051981","R0051981.pdf","paywalled","randomized_trial","Anna R. Kahkoska","2020","2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-2160-pub","https://doi.org/10.2337/db20-2160-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052016","R0052016.pdf","paywalled","randomized_trial","Theocharis Koufakis","2020","Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?","Journal of Diabetes","Wiley","10.1111/1753-0407.13105","https://doi.org/10.1111/1753-0407.13105","32886864","https://pubmed.ncbi.nlm.nih.gov/32886864/",null,null],["2","R0052213","R0052213.pdf","paywalled","randomized_trial","Melanie R. Weltman","2020","Uptake of Evidence-Based Recommendations to Improve Care for CKD Patients in the Kidney Coordinated Health Management Partnership (Kidney CHAMP) Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1226b","https://doi.org/10.1681/asn.20203110s1226b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052400","R0052400.pdf","paywalled","randomized_trial","David A. Ehrmann","2020","1782-P: Impact of Treatment with Medication vs. Laparoscopic Gastric Banding (GB) on ß-Cell Function in Adults with Impaired Glucose Tolerance (IGT) or Type 2 Diabetes (T2D) in the Restoring Insulin Secretion (RISE) Study","Diabetes","American Diabetes Association","10.2337/db20-1782-p","https://doi.org/10.2337/db20-1782-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052416","R0052416.pdf","paywalled","randomized_trial","Hawkins C. Gay","2020","Abstract 14678: Prevalence Of Sglt2 Inhibitor And Glp-1 Receptor Agonist Prescriptions In Patients With Comorbid Diabetes And Cardiovascular Disease In An Integrated Academic Health System","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.14678","https://doi.org/10.1161/circ.142.suppl_3.14678",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052421","R0052421.pdf","paywalled","randomized_trial","Mariam Alatrach","2020","1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-1136-p","https://doi.org/10.2337/db20-1136-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052441","R0052441.pdf","paywalled","randomized_trial","Oksana Logvinova","2020","Прогнозирование раннего ответа на терапию агонистом рецепторов глюкагоноподобного пептида-1 лираглутидом у пациентов с экзогенно-конституциональным ожирением",null,null,"10.14341/omet12274-9554","https://doi.org/10.14341/omet12274-9554",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052918","R0052918.pdf","paywalled","randomized_trial","Nicklas Järvelä Johansen","2020","1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial","Diabetes","American Diabetes Association","10.2337/db20-1094-p","https://doi.org/10.2337/db20-1094-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052935","R0052935.pdf","paywalled","randomized_trial","William M. Steinberg","2020","LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/1j3p-pt08","https://doi.org/10.17615/1j3p-pt08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053051","R0053051.pdf","paywalled","randomized_trial","Aditi R. Saxena","2020","353-OR: Oral Small Molecule GLP-1R Agonist PF-06882961 Robustly Reduces Plasma Glucose and Body Weight after 28 Days in Adults with T2DM","Diabetes","American Diabetes Association","10.2337/db20-353-or","https://doi.org/10.2337/db20-353-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053280","R0053280.pdf","paywalled","randomized_trial","Darren C. Robertson","2020","951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM","Diabetes","American Diabetes Association","10.2337/db20-951-p","https://doi.org/10.2337/db20-951-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053313","R0053313.pdf","paywalled","randomized_trial","Mariam Alatrach","2020","352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study","Diabetes","American Diabetes Association","10.2337/db20-352-or","https://doi.org/10.2337/db20-352-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054859","R0054859.pdf","paywalled","randomized_trial","Clive G. Ballard","2020","Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes","Alzheimer s & Dementia","Wiley","10.1002/alz.042909","https://doi.org/10.1002/alz.042909",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0009338","R0009338.pdf","paywalled","randomized_trial","De Cosmo S","2019","Impact of CVOTs in primary and secondary prevention of kidney disease.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.107907","https://doi.org/10.1016/j.diabres.2019.107907","31676332","https://pubmed.ncbi.nlm.nih.gov/31676332/",null,null],["2","R0009926","R0009926.pdf","paywalled","randomized_trial","Makino H","2019","Addition of low-dose liraglutide to insulin therapy is useful for glycaemic control during the peri-operative period: effect of glucagon-like peptide-1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery (GLOLIA study).","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14084","https://doi.org/10.1111/dme.14084","31335979","https://pubmed.ncbi.nlm.nih.gov/31335979/",null,null],["2","R0010397","R0010397.pdf","paywalled","randomized_trial","Abreu M","2019","A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13794","https://doi.org/10.1111/dom.13794","31144435","https://pubmed.ncbi.nlm.nih.gov/31144435/",null,null],["2","R0011351","R0011351.pdf","paywalled","randomized_trial","Hupfeld C","2019","Navigating the \"MACE\" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13740","https://doi.org/10.1111/dom.13740","30957945","https://pubmed.ncbi.nlm.nih.gov/30957945/",null,null],["2","R0012401","R0012401.pdf","paywalled","randomized_trial","Jones KL","2019","Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13633","https://doi.org/10.1111/dom.13633","30623563","https://pubmed.ncbi.nlm.nih.gov/30623563/",null,null],["2","R0012445","R0012445.pdf","paywalled","randomized_trial","O'Keefe JH","2019","The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.","Progress in cardiovascular diseases","Elsevier BV","10.1016/j.pcad.2019.08.001","https://doi.org/10.1016/j.pcad.2019.08.001","31408637","https://pubmed.ncbi.nlm.nih.gov/31408637/",null,null],["2","R0013283","R0013283.pdf","paywalled","randomized_trial","Anholm C","2019","Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2019.07.007","https://doi.org/10.1016/j.atherosclerosis.2019.07.007","31326727","https://pubmed.ncbi.nlm.nih.gov/31326727/",null,null],["2","R0013579","R0013579.pdf","paywalled","randomized_trial","Bokvist K","2019","Gastrin analogue administration adds no significant glycaemic benefit to a glucagon-like peptide-1 receptor agonist acutely or after washout of both analogues.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13695","https://doi.org/10.1111/dom.13695","30848033","https://pubmed.ncbi.nlm.nih.gov/30848033/",null,null],["2","R0013620","R0013620.pdf","paywalled","randomized_trial","Liakos A","2019","Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13541","https://doi.org/10.1111/dom.13541","30242948","https://pubmed.ncbi.nlm.nih.gov/30242948/",null,null],["2","R0014022","R0014022.pdf","paywalled","randomized_trial","Shin JI","2019","Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-019-1171-0","https://doi.org/10.1007/s11892-019-1171-0","31286271","https://pubmed.ncbi.nlm.nih.gov/31286271/",null,null],["2","R0014082","R0014082.pdf","paywalled","randomized_trial","Nassif ME","2019","A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2019.10.025","https://doi.org/10.1016/j.amjcard.2019.10.025","31741435","https://pubmed.ncbi.nlm.nih.gov/31741435/",null,null],["2","R0015006","R0015006.pdf","paywalled","randomized_trial","Pablo Frias J","2019","Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1541316","https://doi.org/10.1080/03007995.2018.1541316","30360647","https://pubmed.ncbi.nlm.nih.gov/30360647/",null,null],["2","R0015310","R0015310.pdf","paywalled","randomized_trial","Packer M","2019","Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2019.09.002","https://doi.org/10.1016/j.cardfail.2019.09.002","31541742","https://pubmed.ncbi.nlm.nih.gov/31541742/",null,null],["2","R0016259","R0016259.pdf","paywalled","randomized_trial","Cusi K","2019","Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.30670","https://doi.org/10.1002/hep.30670","31006135","https://pubmed.ncbi.nlm.nih.gov/31006135/",null,null],["2","R0017856","R0017856.pdf","paywalled","randomized_trial","Cheng JWM","2019","Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028018816466","https://doi.org/10.1177/1060028018816466","30516068","https://pubmed.ncbi.nlm.nih.gov/30516068/",null,null],["2","R0018106","R0018106.pdf","paywalled","randomized_trial","Sarafidis P","2019","SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfy407","https://doi.org/10.1093/ndt/gfy407","30753708","https://pubmed.ncbi.nlm.nih.gov/30753708/",null,null],["2","R0020097","R0020097.pdf","paywalled","randomized_trial","Frias JP","2019","Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13764","https://doi.org/10.1111/dom.13764","31050143","https://pubmed.ncbi.nlm.nih.gov/31050143/",null,null],["2","R0020524","R0020524.pdf","paywalled","randomized_trial","Lipscombe LL","2019","In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.","Annals of internal medicine","American College of Physicians","10.7326/acpj201909170-029","https://doi.org/10.7326/acpj201909170-029","31525763","https://pubmed.ncbi.nlm.nih.gov/31525763/",null,null],["2","R0020611","R0020611.pdf","paywalled","randomized_trial","Athauda D","2019","Post hoc analysis of the Exenatide-PD trial-Factors that predict response.","The European journal of neuroscience","Wiley","10.1111/ejn.14096","https://doi.org/10.1111/ejn.14096","30070753","https://pubmed.ncbi.nlm.nih.gov/30070753/",null,null],["2","R0021045","R0021045.pdf","paywalled","randomized_trial","Zhao T","2019","Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.","Acta biochimica et biophysica Sinica","China Science Publishing & Media Ltd.","10.1093/abbs/gmy177","https://doi.org/10.1093/abbs/gmy177","30883649","https://pubmed.ncbi.nlm.nih.gov/30883649/",null,null],["2","R0021059","R0021059.pdf","paywalled","randomized_trial","Lemos NE","2019","Renal effects of exendin-4 in an animal model of brain death.","Molecular biology reports","Springer Science and Business Media LLC","10.1007/s11033-019-04674-1","https://doi.org/10.1007/s11033-019-04674-1","30759298","https://pubmed.ncbi.nlm.nih.gov/30759298/",null,null],["2","R0021099","R0021099.pdf","paywalled","randomized_trial","Geyer MC","2019","Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13544","https://doi.org/10.1111/dom.13544","30259623","https://pubmed.ncbi.nlm.nih.gov/30259623/",null,null],["2","R0021266","R0021266.pdf","paywalled","randomized_trial","Mikhail N","2019","Cardiovascular Effects of Liraglutide.","Current hypertension reviews","Bentham Science Publishers Ltd.","10.2174/1573402114666180507152620","https://doi.org/10.2174/1573402114666180507152620","29737256","https://pubmed.ncbi.nlm.nih.gov/29737256/",null,null],["2","R0022191","R0022191.pdf","paywalled","randomized_trial","Wägner AM","2019","Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2018.08.010","https://doi.org/10.1016/j.diabet.2018.08.010","30223083","https://pubmed.ncbi.nlm.nih.gov/30223083/",null,null],["2","R0022347","R0022347.pdf","paywalled","randomized_trial","Carlson AL","2019","EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0177","https://doi.org/10.4158/ep-2018-0177","30995433","https://pubmed.ncbi.nlm.nih.gov/30995433/",null,null],["2","R0022418","R0022418.pdf","paywalled","randomized_trial","Braga T","2019","Treating prediabetes: why and how should we do it?","Minerva medica","Edizioni Minerva Medica","10.23736/s0026-4806.18.05897-4","https://doi.org/10.23736/s0026-4806.18.05897-4","30371047","https://pubmed.ncbi.nlm.nih.gov/30371047/",null,null],["2","R0023075","R0023075.pdf","paywalled","randomized_trial","Kaneko M","2019","Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-019-00770-z","https://doi.org/10.1007/s40261-019-00770-z","30887418","https://pubmed.ncbi.nlm.nih.gov/30887418/",null,null],["2","R0023436","R0023436.pdf","paywalled","randomized_trial","Guo NF","2019","Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_201905_17832","https://doi.org/10.26355/eurrev_201905_17832","31115031","https://pubmed.ncbi.nlm.nih.gov/31115031/",null,null],["2","R0023571","R0023571.pdf","paywalled","randomized_trial","McGuire DK","2019","FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13645","https://doi.org/10.1111/dom.13645","30690856","https://pubmed.ncbi.nlm.nih.gov/30690856/",null,null],["2","R0023662","R0023662.pdf","paywalled","randomized_trial","Athyros VG","2019","Understanding the cardiovascular risk with non-insulin antidiabetic drugs.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2019.1586881","https://doi.org/10.1080/14740338.2019.1586881","30810055","https://pubmed.ncbi.nlm.nih.gov/30810055/",null,null],["2","R0024093","R0024093.pdf","paywalled","randomized_trial","DeFronzo RA","2019","Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164118825376","https://doi.org/10.1177/1479164118825376","30706731","https://pubmed.ncbi.nlm.nih.gov/30706731/",null,null],["2","R0024263","R0024263.pdf","paywalled","randomized_trial","Lipscombe LL","2019","In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.","Annals of internal medicine","American College of Physicians","10.7326/acpj201909170-027","https://doi.org/10.7326/acpj201909170-027","31525761","https://pubmed.ncbi.nlm.nih.gov/31525761/",null,null],["2","R0024292","R0024292.pdf","paywalled","randomized_trial","Chao AM","2019","Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.","Clinical obesity","Wiley","10.1111/cob.12340","https://doi.org/10.1111/cob.12340","31691531","https://pubmed.ncbi.nlm.nih.gov/31691531/",null,null],["2","R0025056","R0025056.pdf","paywalled","randomized_trial","Lipscombe LL","2019","In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.","Annals of internal medicine","American College of Physicians","10.7326/acpj201908200-016","https://doi.org/10.7326/acpj201908200-016","31426059","https://pubmed.ncbi.nlm.nih.gov/31426059/",null,null],["2","R0025072","R0025072.pdf","paywalled","randomized_trial","Watson KT","2019","Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.","Behavioural brain research","Elsevier BV","10.1016/j.bbr.2018.08.006","https://doi.org/10.1016/j.bbr.2018.08.006","30099030","https://pubmed.ncbi.nlm.nih.gov/30099030/",null,null],["2","R0025134","R0025134.pdf","paywalled","randomized_trial","Øhrstrøm CC","2019","Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13796","https://doi.org/10.1111/dom.13796","31144430","https://pubmed.ncbi.nlm.nih.gov/31144430/",null,null],["2","R0025161","R0025161.pdf","paywalled","randomized_trial","Suliman M","2019","Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13672","https://doi.org/10.1111/dom.13672","30768836","https://pubmed.ncbi.nlm.nih.gov/30768836/",null,null],["2","R0025643","R0025643.pdf","paywalled","randomized_trial","Upala S","2019","Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.30551","https://doi.org/10.1002/hep.30551","30734333","https://pubmed.ncbi.nlm.nih.gov/30734333/",null,null],["2","R0025648","R0025648.pdf","paywalled","randomized_trial","Khoo J","2019","Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.14065","https://doi.org/10.1111/liv.14065","30721572","https://pubmed.ncbi.nlm.nih.gov/30721572/",null,"ClinicalTrials.gov:NCT02654665"],["2","R0027853","R0027853.pdf","paywalled","randomized_trial","Larsen JR","2019","High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.","CNS spectrums","Cambridge University Press (CUP)","10.1017/s1092852918001311","https://doi.org/10.1017/s1092852918001311","30596361","https://pubmed.ncbi.nlm.nih.gov/30596361/",null,null],["2","R0028595","R0028595.pdf","paywalled","randomized_trial","Quiñones M","2019","Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.","Expert opinion on drug discovery","Informa UK Limited","10.1080/17460441.2019.1583642","https://doi.org/10.1080/17460441.2019.1583642","30821530","https://pubmed.ncbi.nlm.nih.gov/30821530/",null,null],["2","R0030767","R0030767.pdf","paywalled","randomized_trial","Xueqin Yan","2019","Effects of liraglutide combined with metformin on glucose and lipid metabolism, islet beta cell function and body fat in obesity with type 2 diabetes mellitus","Chin J Cell Stem Cell (Electronic Edition)",null,"10.3877/cma.j.issn.2095-1221.2019.05.004","https://doi.org/10.3877/cma.j.issn.2095-1221.2019.05.004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031047","R0031047.pdf","paywalled","randomized_trial","Allan S. Brett","2019","Oral Semaglutide for Type 2 Diabetic Patients at High Cardiovascular Risk","Journal watch",null,"10.1056/nejm-jw.na49344","https://doi.org/10.1056/nejm-jw.na49344",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032055","R0032055.pdf","paywalled","randomized_trial",null,"2019","Science, Medicine, and the Anesthesiologist","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000003013","https://doi.org/10.1097/aln.0000000000003013",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032966","R0032966.pdf","paywalled","randomized_trial","Jeehee Yoon","2019","2314-PUB: No Clinical Factors, Except Baseline HbA1c, Can Predict Glycemic Response to Dulaglutide: Real-World Data in Korean Patients","Diabetes","American Diabetes Association","10.2337/db19-2314-pub","https://doi.org/10.2337/db19-2314-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033744","R0033744.pdf","paywalled","randomized_trial","Ahmad Moolla","2019","Novel non-invasive markers, imaging and interventions for the diagnosis, characterisation and treatment of non-alcoholic fatty liver disease","Oxford University Research Archive (ORA) (University of Oxford)",null,"10.5287/ora-rjorg9k8b","https://doi.org/10.5287/ora-rjorg9k8b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033781","R0033781.pdf","paywalled","randomized_trial","Peradze, Natia","2019","MOESM2 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Figshare",null,"10.6084/m9.figshare.10117193","https://doi.org/10.6084/m9.figshare.10117193",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033834","R0033834.pdf","paywalled","randomized_trial","Peradze, Natia","2019","MOESM3 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Figshare",null,"10.6084/m9.figshare.10117199","https://doi.org/10.6084/m9.figshare.10117199",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033838","R0033838.pdf","paywalled","randomized_trial","Peradze, Natia","2019","MOESM1 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Figshare",null,"10.6084/m9.figshare.10117184","https://doi.org/10.6084/m9.figshare.10117184",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034564","R0034564.pdf","paywalled","randomized_trial","Sposito, Andrei","2019","MOESM1 of Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","Figshare",null,"10.6084/m9.figshare.7794971.v1","https://doi.org/10.6084/m9.figshare.7794971.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036771","R0036771.pdf","paywalled","randomized_trial","Nick Zagorski","2019","Journal Digest","Psychiatric News","American Psychiatric Association Publishing","10.1176/appi.pn.2019.1a5","https://doi.org/10.1176/appi.pn.2019.1a5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037180","R0037180.pdf","paywalled","randomized_trial","Vanita R. Aroda","2019","147-OR: DUAL VIII: Significantly Longer Time to Treatment Intensification with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) in a 104-Week (Wk) Randomized Trial Mirroring Clinical Practice","Diabetes","American Diabetes Association","10.2337/db19-147-or","https://doi.org/10.2337/db19-147-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037671","R0037671.pdf","paywalled","randomized_trial","Jingyan Chen","2019","1033-P: Effects of Benaglutide on Weight Loss, Metabolic Changes, and Sexual Hormones in PCOS","Diabetes","American Diabetes Association","10.2337/db19-1033-p","https://doi.org/10.2337/db19-1033-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037774","R0037774.pdf","paywalled","randomized_trial","Danijela Gašević","2019","The modulating effect of differences in cardiovascular risk factors on major cardiovascular outcomes in glucose-lowering trials","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000002181","https://doi.org/10.1097/hjh.0000000000002181","31464860","https://pubmed.ncbi.nlm.nih.gov/31464860/",null,null],["2","R0037803","R0037803.pdf","paywalled","randomized_trial","Maya Fayfman","2019","382-P: Insulin Requirements after Hospital Discharge in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-382-p","https://doi.org/10.2337/db19-382-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037850","R0037850.pdf","paywalled","randomized_trial","Darren B. Taichman","2019","Annals for Educators - 5 February 2019","Annals of Internal Medicine","American College of Physicians","10.7326/awed201902050","https://doi.org/10.7326/awed201902050","30716759","https://pubmed.ncbi.nlm.nih.gov/30716759/",null,null],["2","R0038518","R0038518.pdf","paywalled","randomized_trial","M. Ahsan Siraj","2019","P5997GLP-1(28-36) prevents progression of ischemic heart failure in mice","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz746.0718","https://doi.org/10.1093/eurheartj/ehz746.0718",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038740","R0038740.pdf","paywalled","randomized_trial","Yoshinobu Kondo","2019","994-P: Effects of Dulaglutide and Trelagliptin on ß-Cell Function after One Year in Patients with Type 2 Diabetes: DUET-Beta Extension Study","Diabetes","American Diabetes Association","10.2337/db19-994-p","https://doi.org/10.2337/db19-994-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038952","R0038952.pdf","paywalled","randomized_trial","Chuanan Shen","2019","113 Effects of Exendin-4 on Pancreatic Islets Function in Treating Hyperglycemia Post Severe Scald Injury in Rats","Journal of Burn Care & Research","Oxford University Press (OUP)","10.1093/jbcr/irz013.114","https://doi.org/10.1093/jbcr/irz013.114",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039060","R0039060.pdf","paywalled","randomized_trial","Hirotatsu Nakaguchi","2019","113-LB: Effects of Liraglutide and Empagliflozin Add-On to Insulin Therapy in Patients with Type 2 Diabetes: ELLENA-IT, a Randomized Controlled Study","Diabetes","American Diabetes Association","10.2337/db19-113-lb","https://doi.org/10.2337/db19-113-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039637","R0039637.pdf","paywalled","randomized_trial","Chintan V. Dave","2019","Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections","Annals of Internal Medicine","American College of Physicians","10.7326/l19-0671","https://doi.org/10.7326/l19-0671","31842209","https://pubmed.ncbi.nlm.nih.gov/31842209/",null,null],["2","R0039799","R0039799.pdf","paywalled","randomized_trial","Husam Ghanim","2019","1034-P: Liraglutide and Dapagliflozin Induce an Increase in Plasma GLP-1 and GLP-2 Concentrations","Diabetes","American Diabetes Association","10.2337/db19-1034-p","https://doi.org/10.2337/db19-1034-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044292","R0044292.pdf","paywalled","randomized_trial","Jemima E. Mellerio","2019","Enduring support for the case report","British Journal of Dermatology","Oxford University Press (OUP)","10.1111/bjd.17500","https://doi.org/10.1111/bjd.17500","31475346","https://pubmed.ncbi.nlm.nih.gov/31475346/",null,null],["2","R0044500","R0044500.pdf","paywalled","randomized_trial","Terri D’Arrigo","2019","Med Check: Loperamide; SPN-810; BNC210; Aducanumab; Reyvow; Trulicity","Psychiatric News","American Psychiatric Association Publishing","10.1176/appi.pn.2019.12a5","https://doi.org/10.1176/appi.pn.2019.12a5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045117","R0045117.pdf","paywalled","randomized_trial","NEIL SKOLNIK","2019","1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents","Diabetes","American Diabetes Association","10.2337/db19-1134-p","https://doi.org/10.2337/db19-1134-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045542","R0045542.pdf","paywalled","randomized_trial","Kenji Ohwaki","2019","1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM","Diabetes","American Diabetes Association","10.2337/db19-1024-p","https://doi.org/10.2337/db19-1024-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045899","R0045899.pdf","paywalled","randomized_trial","Hitoshi Kuwata","2019","1018-P: Comparison of Short- and Long-Acting Glucagon-Like Peptide-1 Receptor Agonist Effects on Postprandial Glucose and Lipid Excursion via Gastric Emptying","Diabetes","American Diabetes Association","10.2337/db19-1018-p","https://doi.org/10.2337/db19-1018-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046792","R0046792.pdf","paywalled","randomized_trial","Hideaki Kaneto","2019","1032-P: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM","Diabetes","American Diabetes Association","10.2337/db19-1032-p","https://doi.org/10.2337/db19-1032-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047132","R0047132.pdf","paywalled","randomized_trial","Joseph Proietto","2019","Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI <35 vs ≥35 kg/m2 in the SCALE Obesity and Prediabetes 56-week randomized, double-blind, placebo-controlled trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2016.10.266","https://doi.org/10.1016/j.orcp.2016.10.266",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047171","R0047171.pdf","paywalled","randomized_trial","Carmen Valcarce","2019","1015-P: Effects of the Oral, Small Molecule GLP-1R Agonist TTP273 on Patients with Stage 2 Hypertension: Results from a Post Hoc Analysis of the Phase 2 Logra Study","Diabetes","American Diabetes Association","10.2337/db19-1015-p","https://doi.org/10.2337/db19-1015-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047301","R0047301.pdf","paywalled","randomized_trial","Trisha O'Moore‐Sullivan","2019","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in individuals with prediabetes and obesity or overweight from the SCALE Obesity and prediabetes randomised, double-blind, placebo-controlled trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2016.10.259","https://doi.org/10.1016/j.orcp.2016.10.259",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047395","R0047395.pdf","paywalled","randomized_trial","Caroline Christfort Øhrstrøm","2019","2073-P: Are Early Dumping and Postprandial Hypoglycemia after Roux-en-Y Gastric Bypass Related Events?","Diabetes","American Diabetes Association","10.2337/db19-2073-p","https://doi.org/10.2337/db19-2073-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048050","R0048050.pdf","paywalled","randomized_trial","Malak Ghazi Almutairi","2019","GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes","ERA: Education and Research Archive (University of Alberta)",null,"10.7939/r3-fhr3-cr50","https://doi.org/10.7939/r3-fhr3-cr50",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048127","R0048127.pdf","paywalled","randomized_trial","Marek Bolanowski","2019","A multicentre, randomized, open-label, Phase IV study investigating management of pasireotide-associated hyperglycaemia with incretin-based therapy or insulin in patients with acromegaly or Cushing's disease (CD)","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.63.p737","https://doi.org/10.1530/endoabs.63.p737",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048284","R0048284.pdf","paywalled","randomized_trial","Stephan Jacob","2019","Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688352","https://doi.org/10.1055/s-0039-1688352",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048745","R0048745.pdf","paywalled","randomized_trial","Abraham H. Hulst","2019","56-OR: Liraglutide for Perioperative Management of Hyperglycaemia in Cardiac Surgery Patients (GLOBE): A Multicentre, Prospective, Superiority Randomised Trial","Diabetes","American Diabetes Association","10.2337/db19-56-or","https://doi.org/10.2337/db19-56-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048968","R0048968.pdf","paywalled","randomized_trial","Darren C. Robertson","2019","988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time","Diabetes","American Diabetes Association","10.2337/db19-988-p","https://doi.org/10.2337/db19-988-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048985","R0048985.pdf","paywalled","randomized_trial","Melissa K. Thomas","2019","980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients","Diabetes","American Diabetes Association","10.2337/db19-980-p","https://doi.org/10.2337/db19-980-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048991","R0048991.pdf","paywalled","randomized_trial","Manjiri D. Pawaskar","2019","1275-P: Cost Effectiveness of Using DPP-4i and SGLT2i Combination Therapy vs. Switching to GLP-1 Therapy for the Management of Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1275-p","https://doi.org/10.2337/db19-1275-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049466","R0049466.pdf","paywalled","randomized_trial","Jae Duk Choi","2019","982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects","Diabetes","American Diabetes Association","10.2337/db19-982-p","https://doi.org/10.2337/db19-982-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049500","R0049500.pdf","paywalled","randomized_trial","Thomas Fremming Dejgaard","2019","59-OR: Liraglutide Preserved Insulin Secretion in Adults with Newly Diagnosed Type 1 Diabetes: The NewLira Trial","Diabetes","American Diabetes Association","10.2337/db19-59-or","https://doi.org/10.2337/db19-59-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049759","R0049759.pdf","paywalled","randomized_trial","Tania Markovic","2019","Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight, but without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2016.10.079","https://doi.org/10.1016/j.orcp.2016.10.079",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049898","R0049898.pdf","paywalled","randomized_trial","Darren C. Robertson","2019","989-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity: Safety Study in Subjects of Japanese and Chinese Descent","Diabetes","American Diabetes Association","10.2337/db19-989-p","https://doi.org/10.2337/db19-989-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049965","R0049965.pdf","paywalled","randomized_trial","Abraham H. Hulst","2019","Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients - A multicentre, prospective, randomised superiority trial","Journal of Cardiothoracic and Vascular Anesthesia","Elsevier BV","10.1053/j.jvca.2019.07.101","https://doi.org/10.1053/j.jvca.2019.07.101",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050298","R0050298.pdf","paywalled","randomized_trial","Victoria E R Parker","2019","1010-P: Effects of MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, on Amino Acids, Ketones, and Free Fatty Acids","Diabetes","American Diabetes Association","10.2337/db19-1010-p","https://doi.org/10.2337/db19-1010-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050412","R0050412.pdf","paywalled","randomized_trial","Richard E. Pratley","2019","1000-P: Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7","Diabetes","American Diabetes Association","10.2337/db19-1000-p","https://doi.org/10.2337/db19-1000-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050692","R0050692.pdf","paywalled","randomized_trial","Vlado Perkovic","2019","SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfz101.sao010","https://doi.org/10.1093/ndt/gfz101.sao010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050783","R0050783.pdf","paywalled","randomized_trial","Ken Y Thong","2019","1201-P: Characteristics and Treatment Outcomes of Patients Treated with Empagliflozin in the ABCD Nationwide Empagliflozin Audit","Diabetes","American Diabetes Association","10.2337/db19-1201-p","https://doi.org/10.2337/db19-1201-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050844","R0050844.pdf","paywalled","randomized_trial","Juan P. Frías","2019","128-LB: Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Basal Insulins (BI) in Insulin-Naïve Type 2 Diabetes (T2D) Patients (Pts) With and Without Cardiovascular Disease (CVD): Outcomes of the Randomized Pragmatic Real-Life Clinical Trial ACHIEVE Control","Diabetes","American Diabetes Association","10.2337/db19-128-lb","https://doi.org/10.2337/db19-128-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050918","R0050918.pdf","paywalled","randomized_trial","Katherine R. Tuttle","2019","233-OR: Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) vs. Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7","Diabetes","American Diabetes Association","10.2337/db19-233-or","https://doi.org/10.2337/db19-233-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051074","R0051074.pdf","paywalled","randomized_trial","Bernard Zinman","2019","986-P: Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9","Diabetes","American Diabetes Association","10.2337/db19-986-p","https://doi.org/10.2337/db19-986-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051123","R0051123.pdf","paywalled","randomized_trial","Evanthia Bletsa","2019","P2483Differential effects of novel antidiabetics on arterial stiffness in patients with type 2 diabetes mellitus","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz748.0813","https://doi.org/10.1093/eurheartj/ehz748.0813",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051340","R0051340.pdf","paywalled","randomized_trial","Wolfgang Ekkehard Schmidt","2019","Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688354","https://doi.org/10.1055/s-0039-1688354",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051961","R0051961.pdf","paywalled","randomized_trial","Mark L. Hartman","2019","134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db19-134-or","https://doi.org/10.2337/db19-134-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051972","R0051972.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2019","P4991Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz746.0169","https://doi.org/10.1093/eurheartj/ehz746.0169",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052118","R0052118.pdf","paywalled","randomized_trial","Maya Fayfman","2019","1007-P: Incretin Therapy with DPP-4-I and GLP1-RA for the Hospital Management of Elderly Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1007-p","https://doi.org/10.2337/db19-1007-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052266","R0052266.pdf","paywalled","randomized_trial","Cyrus V Desouza","2019","P6271The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz746.0870","https://doi.org/10.1093/eurheartj/ehz746.0870",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052298","R0052298.pdf","paywalled","randomized_trial","Juan P. Frías","2019","993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-993-p","https://doi.org/10.2337/db19-993-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052462","R0052462.pdf","paywalled","randomized_trial","Christopher Bladin","2019","Abstract TP285: Ongoing Clinical Trial: Treatment With Exenatide in Acute Ischaemic Stroke (TEXAIS) Trial: Prospective, Randomised, Open Label, Blinded End-point Study of Exenatide vs. Standard Care in Post Stroke Hyperglycaemia","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.50.suppl_1.tp285","https://doi.org/10.1161/str.50.suppl_1.tp285",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052846","R0052846.pdf","paywalled","randomized_trial","Michael Albrecht Nauck","2019","Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs. exenatide and dulaglutide in type 2 diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688353","https://doi.org/10.1055/s-0039-1688353",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053882","R0053882.pdf","paywalled","randomized_trial","MISUN BYUN","2019","114-LB: GX-G6, a Novel Long-Acting Glucagon-Like Peptide Receptor Agonist: Result of Phase I Study in Healthy Volunteers","Diabetes","American Diabetes Association","10.2337/db19-114-lb","https://doi.org/10.2337/db19-114-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03651466"],["2","R0055121","R0055121.pdf","paywalled","randomized_trial","Stephen Charles Bain","2019","An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063–1071","Diabetic Medicine","Wiley","10.1111/dme.14172","https://doi.org/10.1111/dme.14172","31691349","https://pubmed.ncbi.nlm.nih.gov/31691349/",null,null],["2","R0056954","R0056954.pdf","paywalled","randomized_trial","Rehfeld JF","2019","Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?","Scandinavian journal of gastroenterology","Informa UK Limited","10.1080/00365521.2019.1690673","https://doi.org/10.1080/00365521.2019.1690673","31725337","https://pubmed.ncbi.nlm.nih.gov/31725337/",null,null],["2","R0008408","R0008408.pdf","paywalled","randomized_trial","Kaneko M","2018","Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028018757407","https://doi.org/10.1177/1060028018757407","29424239","https://pubmed.ncbi.nlm.nih.gov/29424239/",null,null],["2","R0010874","R0010874.pdf","paywalled","randomized_trial","Coon SA","2018","Semaglutide once-weekly: improved efficacy with a new safety warning.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2018.1534201","https://doi.org/10.1080/17512433.2018.1534201","30296182","https://pubmed.ncbi.nlm.nih.gov/30296182/",null,null],["2","R0011069","R0011069.pdf","paywalled","randomized_trial","Giugliano D","2018","Type 2 diabetes and cardiovascular prevention: the dogmas disputed.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-017-1418-y","https://doi.org/10.1007/s12020-017-1418-y","28895030","https://pubmed.ncbi.nlm.nih.gov/28895030/",null,null],["2","R0011945","R0011945.pdf","paywalled","randomized_trial","Petite SE","2018","Noninsulin medication therapy for hospitalized patients with diabetes mellitus.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.2146/ajhp170869","https://doi.org/10.2146/ajhp170869","30190293","https://pubmed.ncbi.nlm.nih.gov/30190293/",null,null],["2","R0012695","R0012695.pdf","paywalled","randomized_trial","Aroda VR","2018","A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13162","https://doi.org/10.1111/dom.13162","29364586","https://pubmed.ncbi.nlm.nih.gov/29364586/",null,null],["2","R0012890","R0012890.pdf","paywalled","randomized_trial","Lupsa BC","2018","Diabetes medications and cardiovascular disease: at long last progress.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000400","https://doi.org/10.1097/med.0000000000000400","29369916","https://pubmed.ncbi.nlm.nih.gov/29369916/",null,null],["2","R0014372","R0014372.pdf","paywalled","randomized_trial","Kaneko S","2018","GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.","European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes","S. Karger AG","10.1159/000494768","https://doi.org/10.1159/000494768","30537714","https://pubmed.ncbi.nlm.nih.gov/30537714/",null,null],["2","R0015313","R0015313.pdf","paywalled","randomized_trial","Nassif M","2018","Effect of glucose-lowering therapies on heart failure.","Nature reviews. Cardiology","Springer Science and Business Media LLC","10.1038/nrcardio.2017.211","https://doi.org/10.1038/nrcardio.2017.211","29368701","https://pubmed.ncbi.nlm.nih.gov/29368701/",null,null],["2","R0016346","R0016346.pdf","paywalled","randomized_trial","Henry R","2018","Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13133","https://doi.org/10.1111/dom.13133","29053202","https://pubmed.ncbi.nlm.nih.gov/29053202/",null,null],["2","R0018250","R0018250.pdf","paywalled","randomized_trial","Li D","2018","Effects of Exendin-4 on pancreatic islets function in treating hyperglycemia post severe scald injury in rats.","The journal of trauma and acute care surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/ta.0000000000002066","https://doi.org/10.1097/ta.0000000000002066","30211851","https://pubmed.ncbi.nlm.nih.gov/30211851/",null,null],["2","R0018975","R0018975.pdf","paywalled","randomized_trial","Elbelt U","2018","[Diabetes Mellitus Type 2: Recent Publications and New Drugs].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0043-117490","https://doi.org/10.1055/s-0043-117490","29807374","https://pubmed.ncbi.nlm.nih.gov/29807374/",null,null],["2","R0020951","R0020951.pdf","paywalled","randomized_trial","Siskind DJ","2018","Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13167","https://doi.org/10.1111/dom.13167","29194917","https://pubmed.ncbi.nlm.nih.gov/29194917/",null,null],["2","R0021103","R0021103.pdf","paywalled","randomized_trial","Pozzilli P","2018","Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13237","https://doi.org/10.1111/dom.13237","29377522","https://pubmed.ncbi.nlm.nih.gov/29377522/",null,null],["2","R0021513","R0021513.pdf","paywalled","randomized_trial","Bekiari E","2018","In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2018-168-8-046","https://doi.org/10.7326/acpjc-2018-168-8-046","29677253","https://pubmed.ncbi.nlm.nih.gov/29677253/",null,null],["2","R0022454","R0022454.pdf","paywalled","randomized_trial","Guthrie R","2018","Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2018.1430446","https://doi.org/10.1080/00325481.2018.1430446","29350569","https://pubmed.ncbi.nlm.nih.gov/29350569/",null,null],["2","R0023056","R0023056.pdf","paywalled","randomized_trial","Eleftheriadou I","2018","Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0929867324666170530075533","https://doi.org/10.2174/0929867324666170530075533","28554326","https://pubmed.ncbi.nlm.nih.gov/28554326/",null,null],["2","R0025098","R0025098.pdf","paywalled","randomized_trial","Bassi N","2018","Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-018-1050-3","https://doi.org/10.1007/s11886-018-1050-3","30259198","https://pubmed.ncbi.nlm.nih.gov/30259198/",null,null],["2","R0025368","R0025368.pdf","paywalled","randomized_trial","Abdul-Ghani M","2018","Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13189","https://doi.org/10.1111/dom.13189","29227578","https://pubmed.ncbi.nlm.nih.gov/29227578/",null,null],["2","R0025369","R0025369.pdf","paywalled","randomized_trial","Jiang LL","2018","The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-017-0765-0","https://doi.org/10.1007/s40618-017-0765-0","29032494","https://pubmed.ncbi.nlm.nih.gov/29032494/",null,null],["2","R0025578","R0025578.pdf","paywalled","randomized_trial","Koska J","2018","Effect of liraglutide on dietary lipid-induced insulin resistance in humans.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13037","https://doi.org/10.1111/dom.13037","28605158","https://pubmed.ncbi.nlm.nih.gov/28605158/",null,null],["2","R0027697","R0027697.pdf","paywalled","randomized_trial","Imprialos KP","2018","Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161115666170609101502","https://doi.org/10.2174/1570161115666170609101502","28595561","https://pubmed.ncbi.nlm.nih.gov/28595561/",null,null],["2","R0028647","R0028647.pdf","paywalled","randomized_trial","Van Name MA","2018","The present and future treatment of pediatric type 2 diabetes.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2018.1499467","https://doi.org/10.1080/17446651.2018.1499467","30063424","https://pubmed.ncbi.nlm.nih.gov/30063424/",null,null],["2","R0031938","R0031938.pdf","paywalled","randomized_trial",null,"2018","Type 2 diabetes drug aids weight loss, study finds","Clinical pharmacist","Royal Pharmaceutical Society","10.1211/cp.2018.20205053","https://doi.org/10.1211/cp.2018.20205053",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032834","R0032834.pdf","paywalled","randomized_trial","Wenhuan Feng","2018","Effect of Liraglutide, Metformin, and Gliclazide on Body Composition in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease—A Randomised Trial","Diabetes","American Diabetes Association","10.2337/db18-1344-p","https://doi.org/10.2337/db18-1344-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037264","R0037264.pdf","paywalled","randomized_trial","Nobutoshi Fushimi","2018","Dulaglutide-Combined Conventional Insulin Therapy Contributes to Ideal Glycemic Control in Noncritically Ill Hospitalized Patients","Diabetes","American Diabetes Association","10.2337/db18-1087-p","https://doi.org/10.2337/db18-1087-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037278","R0037278.pdf","paywalled","randomized_trial","Linjawi, Sultan","2018","The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial","Figshare",null,"10.6084/m9.figshare.6205676","https://doi.org/10.6084/m9.figshare.6205676",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037349","R0037349.pdf","paywalled","randomized_trial","Yoshinobu Kondo","2018","Effects of Dulaglutide and Trelagliptin on Beta-Cell Function in Patients with Type 2 Diabetes—The DUET-Beta Study","Diabetes","American Diabetes Association","10.2337/db18-1080-p","https://doi.org/10.2337/db18-1080-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037403","R0037403.pdf","paywalled","randomized_trial","Yin, Ting-Ting","2018","Comparison of Glycemic Variability in Chinese T2DM Patient Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial","Figshare",null,"10.6084/m9.figshare.5982262.v2","https://doi.org/10.6084/m9.figshare.5982262.v2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037621","R0037621.pdf","paywalled","randomized_trial","Yu Mi Kang","2018","Identification of Subpopulations Exhibiting the Greatest Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide-1 Receptor Agonists—A Combined Analysis of Large Cardiovascular Outcome Trials","Diabetes","American Diabetes Association","10.2337/db18-1064-p","https://doi.org/10.2337/db18-1064-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037716","R0037716.pdf","paywalled","randomized_trial","Munenori Hiromura","2018","Actions of Liraglutide on Vascular Endothelial Cells Play a Central Role in the Suppression of Atherosclerosis in Diabetic Mice","Diabetes","American Diabetes Association","10.2337/db18-487-p","https://doi.org/10.2337/db18-487-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037992","R0037992.pdf","paywalled","randomized_trial","Megumi Inoue","2018","Effect of Single Dose of Insulin Glargine/Lixisenatide Fixed-Ratio Combination (IGlarLixi) on Postprandial Glucodynamic Response in Japanese Patients with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db18-1075-p","https://doi.org/10.2337/db18-1075-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038321","R0038321.pdf","paywalled","randomized_trial","Li, Feng-fei","2018","Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial","Figshare",null,"10.6084/m9.figshare.6189518","https://doi.org/10.6084/m9.figshare.6189518",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038434","R0038434.pdf","paywalled","randomized_trial","Xinhua Xiao","2018","Achieving Composite Endpoint of A1C <7.0% without Weight Gain or Hypoglycemia with Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes—Post-Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db18-1069-p","https://doi.org/10.2337/db18-1069-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038606","R0038606.pdf","paywalled","randomized_trial","Yin, Ting-Ting","2018","Comparison of Glycemic Variability of Exenatide and Insulin Glargine Treatment in Chinese T2DM Patients: A Randomized Controlled Trial","Figshare",null,"10.6084/m9.figshare.5982262.v1","https://doi.org/10.6084/m9.figshare.5982262.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038697","R0038697.pdf","paywalled","randomized_trial","Absalon Gutierrez","2018","Exenatide and Saxagliptin Do Not Attenuate NFkB-Induced Inflammation in Prediabetic Humans","Diabetes","American Diabetes Association","10.2337/db18-1954-p","https://doi.org/10.2337/db18-1954-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038871","R0038871.pdf","paywalled","randomized_trial","Masakazu Koshibu","2018","Liraglutide Suppresses Atherosclerosis via AMP-Activated Protein Kinase Dependent and Independent Mechanisms in Diabetic Apolipoprotein Enull Mice","Diabetes","American Diabetes Association","10.2337/db18-289-or","https://doi.org/10.2337/db18-289-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039151","R0039151.pdf","paywalled","randomized_trial","F Juntao","2018","26 Exenatide alleviate adriamycin-induced cardiac injury",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2018-ics.26","https://doi.org/10.1136/heartjnl-2018-ics.26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039294","R0039294.pdf","paywalled","randomized_trial","Claudio Borghi","2018","Decrease mortality in type II diabetes mellitus","Journal of Cardiovascular Medicine","Ovid Technologies (Wolters Kluwer Health)","10.2459/jcm.0000000000000586","https://doi.org/10.2459/jcm.0000000000000586","29538138","https://pubmed.ncbi.nlm.nih.gov/29538138/",null,null],["2","R0039938","R0039938.pdf","paywalled","randomized_trial","Andrej Janež","2018","GLP-1 Receptor Agonist Liraglutide Increased IVF Pregnancy Rates in Obese Women with PCOS and Previous Poor Response to First-Line Reproductive Treatments","Diabetes","American Diabetes Association","10.2337/db18-1465-p","https://doi.org/10.2337/db18-1465-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043771","R0043771.pdf","paywalled","randomized_trial","Angus Stirling","2018","Torasemide","Practical Diabetes","Wiley","10.1002/pdi.2174","https://doi.org/10.1002/pdi.2174",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044318","R0044318.pdf","paywalled","randomized_trial","Zachary T. Bloomgarden","2018","Evolution of type 2 diabetes mellitus treatment approaches","Journal of Diabetes","Wiley","10.1111/1753-0407.12854","https://doi.org/10.1111/1753-0407.12854","30204296","https://pubmed.ncbi.nlm.nih.gov/30204296/",null,null],["2","R0044863","R0044863.pdf","paywalled","randomized_trial","Edgar D. Torres Fernandez","2018","Metabolic Syndrome and the Role of GLP‐1 Receptor Agonists in a Model of Postmenopausal PCOS","The FASEB Journal","Wiley","10.1096/fasebj.2018.32.1_supplement.766.2","https://doi.org/10.1096/fasebj.2018.32.1_supplement.766.2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045152","R0045152.pdf","paywalled","randomized_trial","Allen M. Andres","2018","Abstract 523: Pioglitazone and Glucagon-like Peptide 1 Receptor Agonist Stimulate Mitochondrial Turnover in the Heart When Administered After the Infarct in Obese Mice","Circulation Research","Ovid Technologies (Wolters Kluwer Health)","10.1161/res.123.suppl_1.523","https://doi.org/10.1161/res.123.suppl_1.523",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045555","R0045555.pdf","paywalled","randomized_trial","В. В. Салухов","2018","Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований","Сахарный диабет",null,"10.14341/dm9570-7290","https://doi.org/10.14341/dm9570-7290",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046527","R0046527.pdf","paywalled","randomized_trial","Huisheng Xiao","2018","Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial",null,null,"10.3760/cma.j.issn.1000-6699.2018.04.015","https://doi.org/10.3760/cma.j.issn.1000-6699.2018.04.015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046901","R0046901.pdf","paywalled","randomized_trial","IRENE M. HRAMIAK","2018","Semaglutide Consistently Reduces Cardiovascular Events in Both Male and Female Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1085-p","https://doi.org/10.2337/db18-1085-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047346","R0047346.pdf","paywalled","randomized_trial","Athena Philis‐Tsimikas","2018","Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial","Diabetes","American Diabetes Association","10.2337/db18-127-or","https://doi.org/10.2337/db18-127-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047667","R0047667.pdf","paywalled","randomized_trial","Caroline Christfort Øhrstrøm","2018","Acarbose and Pasireotide Reduce Hypoglycemia in Roux-en-Y Gastric Bypass Operated Subjects","Diabetes","American Diabetes Association","10.2337/db18-2046-p","https://doi.org/10.2337/db18-2046-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047746","R0047746.pdf","paywalled","randomized_trial","Francesco Cosentino","2018","Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy677","https://doi.org/10.1093/eurheartj/ehy677","30445605","https://pubmed.ncbi.nlm.nih.gov/30445605/",null,null],["2","R0048058","R0048058.pdf","paywalled","randomized_trial","Steve C Bain","2018","P1878Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p1878","https://doi.org/10.1093/eurheartj/ehy565.p1878",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048129","R0048129.pdf","paywalled","randomized_trial","Francesco Giorgino","2018","iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin: A Post-Hoc Analysis From the LixiLan-L Study","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2018.08.128","https://doi.org/10.1016/j.jcjd.2018.08.128",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048172","R0048172.pdf","paywalled","randomized_trial","Deborah J. Wexler","2018","Baseline Characteristics of Participants in the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness Study (GRADE)","Diabetes","American Diabetes Association","10.2337/db18-1182-p","https://doi.org/10.2337/db18-1182-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048522","R0048522.pdf","paywalled","randomized_trial","Lise Kjems","2018","Efficacy and Safety of ITCA 650, an Injection-Free GLP-1RA, in T2D Patients—A Pooled Analysis of Phase 3 Studies","Diabetes","American Diabetes Association","10.2337/db18-1103-p","https://doi.org/10.2337/db18-1103-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048647","R0048647.pdf","paywalled","randomized_trial","William Donald Leslie","2018","Pharmacovigilance in the Real World","Annals of Internal Medicine","American College of Physicians","10.7326/m18-3550","https://doi.org/10.7326/m18-3550","30597488","https://pubmed.ncbi.nlm.nih.gov/30597488/",null,null],["2","R0048767","R0048767.pdf","paywalled","randomized_trial","Mary Angelyn Bethel","2018","Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","Diabetes","American Diabetes Association","10.2337/db18-522-p","https://doi.org/10.2337/db18-522-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048804","R0048804.pdf","paywalled","randomized_trial","Juan P. Frías","2018","Efficacy and Safety of an Expanded Dulaglutide Dose Range—A Phase 2, Placebo-Controlled Trial in T2D Patients on Metformin","Diabetes","American Diabetes Association","10.2337/db18-126-or","https://doi.org/10.2337/db18-126-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048859","R0048859.pdf","paywalled","randomized_trial","Srilaxmi Kalavalapalli","2018","Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH)","Diabetes","American Diabetes Association","10.2337/db18-1846-p","https://doi.org/10.2337/db18-1846-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049073","R0049073.pdf","paywalled","randomized_trial","Ignatios Ikonomidis","2018","4324Effects of the glucagon like peptide-1 receptor agonist on arterial stiffness, LV myocardial deformation and oxidative stress in newly diagnosed type 2 diabetes after 6-month treatment","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy563.4324","https://doi.org/10.1093/eurheartj/ehy563.4324",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049256","R0049256.pdf","paywalled","randomized_trial","Timothy J Wilt","2018","Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy","Annals of Internal Medicine","American College of Physicians","10.7326/l18-0373","https://doi.org/10.7326/l18-0373","30285195","https://pubmed.ncbi.nlm.nih.gov/30285195/",null,null],["2","R0049388","R0049388.pdf","paywalled","randomized_trial","Shuqian Jing","2018","A Phase 1b/2a Study of Glutazumab for the Treatment of Type 2 Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db18-2298-pub","https://doi.org/10.2337/db18-2298-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049772","R0049772.pdf","paywalled","randomized_trial","A.M. El-Hassan","2018","Medication Compliance on Glycemic Control in Patients with Elevated HbA1c","Diabetes","American Diabetes Association","10.2337/db18-1077-p","https://doi.org/10.2337/db18-1077-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050085","R0050085.pdf","paywalled","randomized_trial","Muhammad A. Abdul-Ghani","2018","Effect of Combination Therapy with Liraglutide plus Canagliflozin on HGP and HbA1c vs. Each Therapy Alone in T2DM","Diabetes","American Diabetes Association","10.2337/db18-109-or","https://doi.org/10.2337/db18-109-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050196","R0050196.pdf","paywalled","randomized_trial","Neda Rasouli","2018","Exploring Two Dose Regimens of ITCA 650 to Switch from Stable Liraglutide Therapy in Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db18-1102-p","https://doi.org/10.2337/db18-1102-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050261","R0050261.pdf","paywalled","randomized_trial","Dragana Lovre","2018","The Effect of Liraglutide on 24-Hour Ambulatory Blood Pressure in Patients with T2DM—A Pilot Study","Diabetes","American Diabetes Association","10.2337/db18-16-lb","https://doi.org/10.2337/db18-16-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050479","R0050479.pdf","paywalled","randomized_trial","Meryl I. Brod","2018","Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial","Diabetes","American Diabetes Association","10.2337/db18-101-lb","https://doi.org/10.2337/db18-101-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050549","R0050549.pdf","paywalled","randomized_trial","Julio Rosenstock","2018","Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies","Diabetes","American Diabetes Association","10.2337/db18-1111-p","https://doi.org/10.2337/db18-1111-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050576","R0050576.pdf","paywalled","randomized_trial","Dilan S. Athauda","2018","Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial","Yearbook of pediatric endocrinology","Bioscientifica","10.1530/ey.15.14.17","https://doi.org/10.1530/ey.15.14.17",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050933","R0050933.pdf","paywalled","randomized_trial","Muhammad A Abdul‐Ghani","2018","Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study","Diabetes","American Diabetes Association","10.2337/db18-123-or","https://doi.org/10.2337/db18-123-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051167","R0051167.pdf","paywalled","randomized_trial","Michelle Beaton","2018","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH","Diabetes","American Diabetes Association","10.2337/db18-1841-p","https://doi.org/10.2337/db18-1841-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051235","R0051235.pdf","paywalled","randomized_trial","George Grunberger","2018","Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study—All Randomized Population","Diabetes","American Diabetes Association","10.2337/db18-351-or","https://doi.org/10.2337/db18-351-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02561078"],["2","R0051251","R0051251.pdf","paywalled","randomized_trial","Paresh Dandona","2018","Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial","Diabetes","American Diabetes Association","10.2337/db18-3-lb","https://doi.org/10.2337/db18-3-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051499","R0051499.pdf","paywalled","randomized_trial","Stephen Charles Bain","2018","P2859Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p2859","https://doi.org/10.1093/eurheartj/ehy565.p2859",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051598","R0051598.pdf","paywalled","randomized_trial","Maya Fayfman","2018","Safety and Efficacy of Exenatide Therapy for the Management of Hospitalized Patients with Type 2 Diabetes—Exenatide Hospital Trial","Diabetes","American Diabetes Association","10.2337/db18-1078-p","https://doi.org/10.2337/db18-1078-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051639","R0051639.pdf","paywalled","randomized_trial","Muhammad A Abdul‐Ghani","2018","Durability of Combination Therapy with Exenatide and Pioglitazone vs. Basal Bolus Insulin in Poorly Controlled T2DM Patients—Three-Year Follow-Up of the QATAR Study","Diabetes","American Diabetes Association","10.2337/db18-1062-p","https://doi.org/10.2337/db18-1062-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051693","R0051693.pdf","paywalled","randomized_trial","Cheli Melzer Cohen","2018","Persistence to Liraglutide Therapy Is Associated with Good Glycemic and Body Weight Control in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-2295-pub","https://doi.org/10.2337/db18-2295-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051717","R0051717.pdf","paywalled","randomized_trial","George Grunberger","2018","Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study, Primary Population","Diabetes","American Diabetes Association","10.2337/db18-1011-p","https://doi.org/10.2337/db18-1011-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02561078"],["2","R0052063","R0052063.pdf","paywalled","randomized_trial","Marconi Abreu","2018","Comparing Treatment Strategies for Patients with Very Elevated HbA1c—A Randomized Trial","Diabetes","American Diabetes Association","10.2337/db18-124-or","https://doi.org/10.2337/db18-124-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052103","R0052103.pdf","paywalled","randomized_trial","Kirstine Brown‐Frandsen","2018","Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis","Diabetes","American Diabetes Association","10.2337/db18-1065-p","https://doi.org/10.2337/db18-1065-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01959529"],["2","R0052105","R0052105.pdf","paywalled","randomized_trial","Ellen R. Thiel","2018","A Real-World Evaluation of the Association between Cardiovascular Outcomes and T2D Therapy","Diabetes","American Diabetes Association","10.2337/db18-1493-p","https://doi.org/10.2337/db18-1493-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052451","R0052451.pdf","paywalled","randomized_trial","Lindsay E. Clegg","2018","Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group","Diabetes","American Diabetes Association","10.2337/db18-130-lb","https://doi.org/10.2337/db18-130-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052586","R0052586.pdf","paywalled","randomized_trial","Prakash Prabhakar","2018","ITCA 650 Provides Consistent Efficacy in T2D Irrespective of Baseline Characteristics—Results of a Pooled Subgroup Analysis","Diabetes","American Diabetes Association","10.2337/db18-1061-p","https://doi.org/10.2337/db18-1061-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052592","R0052592.pdf","paywalled","randomized_trial","Philip Noel Newsome","2018","The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: Data from a randomised Phase 2 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(18)31421-1","https://doi.org/10.1016/s0168-8278(18)31421-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053107","R0053107.pdf","paywalled","randomized_trial","Thomas Felix Lüscher","2018","Prevention: From Lifestyle Changes to Medication","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy371","https://doi.org/10.1093/eurheartj/ehy371","30052950","https://pubmed.ncbi.nlm.nih.gov/30052950/",null,null],["2","R0055000","R0055000.pdf","paywalled","randomized_trial","Mikhail Kosiborod","2018","Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.117.031847","https://doi.org/10.1161/circulationaha.117.031847","29483180","https://pubmed.ncbi.nlm.nih.gov/29483180/",null,"ClinicalTrials.gov:NCT01730534"],["2","R0010791","R0010791.pdf","paywalled","randomized_trial","Ji Q","2017","Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2017.03.013","https://doi.org/10.1016/j.clinthera.2017.03.013","28526416","https://pubmed.ncbi.nlm.nih.gov/28526416/",null,null],["2","R0012180","R0012180.pdf","paywalled","randomized_trial","Chawla H","2017","Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-017-0215-6","https://doi.org/10.1007/s40256-017-0215-6","28197977","https://pubmed.ncbi.nlm.nih.gov/28197977/",null,null],["2","R0012318","R0012318.pdf","paywalled","randomized_trial","Frandsen CS","2017","Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12830","https://doi.org/10.1111/dom.12830","27868372","https://pubmed.ncbi.nlm.nih.gov/27868372/",null,null],["2","R0013203","R0013203.pdf","paywalled","randomized_trial","Nauck MA","2017","Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12802","https://doi.org/10.1111/dom.12802","27709794","https://pubmed.ncbi.nlm.nih.gov/27709794/",null,null],["2","R0014195","R0014195.pdf","paywalled","randomized_trial","Carls GS","2017","Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc16-2725","https://doi.org/10.2337/dc16-2725","28801475","https://pubmed.ncbi.nlm.nih.gov/28801475/",null,null],["2","R0014823","R0014823.pdf","paywalled","randomized_trial","Sönmez A","2017","Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0042-120708","https://doi.org/10.1055/s-0042-120708","28201828","https://pubmed.ncbi.nlm.nih.gov/28201828/",null,null],["2","R0015414","R0015414.pdf","paywalled","randomized_trial","Seggelke SA","2017","Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-017-0884-1","https://doi.org/10.1007/s11892-017-0884-1","28699089","https://pubmed.ncbi.nlm.nih.gov/28699089/",null,null],["2","R0018988","R0018988.pdf","paywalled","randomized_trial","Cheng JWM","2017","Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2017.1284052","https://doi.org/10.1080/03007995.2017.1284052","28097882","https://pubmed.ncbi.nlm.nih.gov/28097882/",null,null],["2","R0019106","R0019106.pdf","paywalled","randomized_trial","Chen X","2017","Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients.","Journal of diabetes","Wiley","10.1111/1753-0407.12397","https://doi.org/10.1111/1753-0407.12397","26989888","https://pubmed.ncbi.nlm.nih.gov/26989888/",null,null],["2","R0019425","R0019425.pdf","paywalled","randomized_trial","LeBras MH","2017","Cardiovascular safety outcomes of new antidiabetic therapies.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.2146/ajhp160279","https://doi.org/10.2146/ajhp160279","28483748","https://pubmed.ncbi.nlm.nih.gov/28483748/",null,null],["2","R0019652","R0019652.pdf","paywalled","randomized_trial","Kramer CK","2017","Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12858","https://doi.org/10.1111/dom.12858","28181363","https://pubmed.ncbi.nlm.nih.gov/28181363/",null,null],["2","R0021693","R0021693.pdf","paywalled","randomized_trial","Caballero AE","2017","Long-term studies of treatments for type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2017.1265417","https://doi.org/10.1080/00325481.2017.1265417","27882816","https://pubmed.ncbi.nlm.nih.gov/27882816/",null,null],["2","R0022581","R0022581.pdf","paywalled","randomized_trial","Anholm C","2017","Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12891","https://doi.org/10.1111/dom.12891","28124822","https://pubmed.ncbi.nlm.nih.gov/28124822/",null,null],["2","R0022854","R0022854.pdf","paywalled","randomized_trial","Kyhl K","2017","Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction.","Peptides","Elsevier BV","10.1016/j.peptides.2017.04.009","https://doi.org/10.1016/j.peptides.2017.04.009","28460895","https://pubmed.ncbi.nlm.nih.gov/28460895/",null,null],["2","R0023288","R0023288.pdf","paywalled","randomized_trial","Eberhardt O","2017","Neurological outcomes of antidiabetic therapy: What the neurologist should know.","Clinical neurology and neurosurgery","Elsevier BV","10.1016/j.clineuro.2017.04.014","https://doi.org/10.1016/j.clineuro.2017.04.014","28477558","https://pubmed.ncbi.nlm.nih.gov/28477558/",null,null],["2","R0023670","R0023670.pdf","paywalled","randomized_trial","Shi L","2017","Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2017.01.003","https://doi.org/10.1016/j.orcp.2017.01.003","28161303","https://pubmed.ncbi.nlm.nih.gov/28161303/",null,"ChiCTR:ChiCTR-OPC-16008152"],["2","R0024435","R0024435.pdf","paywalled","randomized_trial","Meier JJ","2017","Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12968","https://doi.org/10.1111/dom.12968","28407415","https://pubmed.ncbi.nlm.nih.gov/28407415/",null,null],["2","R0024541","R0024541.pdf","paywalled","randomized_trial","Lei Y","2017","Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2017.05.062","https://doi.org/10.1016/j.ijcard.2017.05.062","28549747","https://pubmed.ncbi.nlm.nih.gov/28549747/",null,null],["2","R0025049","R0025049.pdf","paywalled","randomized_trial","Seko Y","2017","Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.","Hepatology research : the official journal of the Japan Society of Hepatology","Wiley","10.1111/hepr.12837","https://doi.org/10.1111/hepr.12837","27917557","https://pubmed.ncbi.nlm.nih.gov/27917557/",null,null],["2","R0025077","R0025077.pdf","paywalled","randomized_trial","Besch G","2017","Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial.","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000001838","https://doi.org/10.1097/aln.0000000000001838","28820780","https://pubmed.ncbi.nlm.nih.gov/28820780/",null,null],["2","R0025204","R0025204.pdf","paywalled","randomized_trial","Wolverton D","2017","Fracture risk associated with common medications used in treating type 2 diabetes mellitus.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.2146/ajhp160319","https://doi.org/10.2146/ajhp160319","28743778","https://pubmed.ncbi.nlm.nih.gov/28743778/",null,null],["2","R0025281","R0025281.pdf","paywalled","randomized_trial","de la Peña A","2017","Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12847","https://doi.org/10.1111/dom.12847","27976833","https://pubmed.ncbi.nlm.nih.gov/27976833/",null,null],["2","R0025366","R0025366.pdf","paywalled","randomized_trial","Gu S","2017","Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12991","https://doi.org/10.1111/dom.12991","28452095","https://pubmed.ncbi.nlm.nih.gov/28452095/",null,null],["2","R0025385","R0025385.pdf","paywalled","randomized_trial","Feng W","2017","Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.","Journal of diabetes","Wiley","10.1111/1753-0407.12555","https://doi.org/10.1111/1753-0407.12555","28332301","https://pubmed.ncbi.nlm.nih.gov/28332301/",null,null],["2","R0025493","R0025493.pdf","paywalled","randomized_trial","Lipscombe LL","2017","Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2017-167-12-067","https://doi.org/10.7326/acpjc-2017-167-12-067","29255857","https://pubmed.ncbi.nlm.nih.gov/29255857/",null,null],["2","R0025513","R0025513.pdf","paywalled","randomized_trial","Pokala N","2017","The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12939","https://doi.org/10.1111/dom.12939","28608447","https://pubmed.ncbi.nlm.nih.gov/28608447/",null,null],["2","R0025711","R0025711.pdf","paywalled","randomized_trial","Dejgaard TF","2017","Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12841","https://doi.org/10.1111/dom.12841","27935240","https://pubmed.ncbi.nlm.nih.gov/27935240/",null,null],["2","R0025737","R0025737.pdf","paywalled","randomized_trial","von Scholten BJ","2017","Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12884","https://doi.org/10.1111/dom.12884","28105731","https://pubmed.ncbi.nlm.nih.gov/28105731/",null,null],["2","R0025810","R0025810.pdf","paywalled","randomized_trial","Arturi F","2017","Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-016-1166-4","https://doi.org/10.1007/s12020-016-1166-4","27830456","https://pubmed.ncbi.nlm.nih.gov/27830456/",null,null],["2","R0025844","R0025844.pdf","paywalled","randomized_trial","Ferjan S","2017","Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2017.0095","https://doi.org/10.1089/met.2017.0095","29064743","https://pubmed.ncbi.nlm.nih.gov/29064743/",null,null],["2","R0025893","R0025893.pdf","paywalled","randomized_trial","Abdelsameea AA","2017","Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-016-1330-7","https://doi.org/10.1007/s00210-016-1330-7","27986979","https://pubmed.ncbi.nlm.nih.gov/27986979/",null,null],["2","R0025952","R0025952.pdf","paywalled","randomized_trial","Lipscombe LL","2017","Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2017-167-12-066","https://doi.org/10.7326/acpjc-2017-167-12-066","29255856","https://pubmed.ncbi.nlm.nih.gov/29255856/",null,null],["2","R0026045","R0026045.pdf","paywalled","randomized_trial","Khoo J","2017","Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13007","https://doi.org/10.1111/dom.13007","28503750","https://pubmed.ncbi.nlm.nih.gov/28503750/",null,null],["2","R0026286","R0026286.pdf","paywalled","randomized_trial","Pappachan JM","2017","Medical Management of Diabesity: Do We Have Realistic Targets?","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-017-0828-9","https://doi.org/10.1007/s11892-017-0828-9","28101792","https://pubmed.ncbi.nlm.nih.gov/28101792/",null,null],["2","R0027300","R0027300.pdf","paywalled","randomized_trial","Tsioufis C","2017","Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161114666161208150642","https://doi.org/10.2174/1570161114666161208150642","27928947","https://pubmed.ncbi.nlm.nih.gov/27928947/",null,null],["2","R0027646","R0027646.pdf","paywalled","randomized_trial","Kasher-Meron M","2017","Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2909","https://doi.org/10.1002/dmrr.2909","28544499","https://pubmed.ncbi.nlm.nih.gov/28544499/",null,null],["2","R0027664","R0027664.pdf","paywalled","randomized_trial","Gadde KM","2017","Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-017-0859-2","https://doi.org/10.1007/s11892-017-0859-2","28378293","https://pubmed.ncbi.nlm.nih.gov/28378293/",null,null],["2","R0027854","R0027854.pdf","paywalled","randomized_trial","Macut D","2017","MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-16-1063","https://doi.org/10.1530/eje-16-1063","28694246","https://pubmed.ncbi.nlm.nih.gov/28694246/",null,null],["2","R0027887","R0027887.pdf","paywalled","randomized_trial","Polyzos SA","2017","Adipose tissue, obesity and non-alcoholic fatty liver disease.","Minerva endocrinologica","Edizioni Minerva Medica","10.23736/s0391-1977.16.02563-3","https://doi.org/10.23736/s0391-1977.16.02563-3","27711029","https://pubmed.ncbi.nlm.nih.gov/27711029/",null,null],["2","R0028715","R0028715.pdf","paywalled","randomized_trial","Portron A","2017","Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13025","https://doi.org/10.1111/dom.13025","28741871","https://pubmed.ncbi.nlm.nih.gov/28741871/",null,null],["2","R0028717","R0028717.pdf","paywalled","randomized_trial","Schmitt C","2017","Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13024","https://doi.org/10.1111/dom.13024","28730694","https://pubmed.ncbi.nlm.nih.gov/28730694/",null,null],["2","R0028729","R0028729.pdf","paywalled","randomized_trial","Grunberger G","2017","Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-017-0853-8","https://doi.org/10.1007/s11892-017-0853-8","28293908","https://pubmed.ncbi.nlm.nih.gov/28293908/",null,null],["2","R0030648","R0030648.pdf","paywalled","randomized_trial","Zhiyu Zhang","2017","Randomized controlled trials of liraglutide and sitagliptin in obese patients with inadequately controlled type 2 diabetes with insulin therapy","Central Plains Medical Journal",null,"10.3760/cma.j.issn.1674-4756.2017.08.010","https://doi.org/10.3760/cma.j.issn.1674-4756.2017.08.010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030766","R0030766.pdf","paywalled","randomized_trial","Allan S. Brett","2017","Liraglutide and Renal Outcomes in Patients with Longstanding Type 2 Diabetes","Journal watch",null,"10.1056/nejm-jw.na44837","https://doi.org/10.1056/nejm-jw.na44837",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031044","R0031044.pdf","paywalled","randomized_trial","Руяткина Людмила Александровна","2017","Новые возможности достижения целевого гликемического контроля у пациентов с сахарным диабетом 2 типа с использованием комбинированной терапии лираглутидом и инсулином детемир: основания для альянса","Сахарный диабет",null,"10.14341/dm8296-6397","https://doi.org/10.14341/dm8296-6397",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031885","R0031885.pdf","paywalled","randomized_trial",null,"2017","Diabetes drug has positive effects on symptoms of Parkinson’s disease","Clinical pharmacist","Royal Pharmaceutical Society","10.1211/cp.2017.20203466","https://doi.org/10.1211/cp.2017.20203466",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031909","R0031909.pdf","paywalled","randomized_trial","David H. Wesorick","2017","Annals for Hospitalists - 18 April 2017","Annals of Internal Medicine","American College of Physicians","10.7326/afho201704180","https://doi.org/10.7326/afho201704180",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032387","R0032387.pdf","paywalled","randomized_trial","Suzuki, Shuichi","2017","Additional file 1: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Figshare",null,"10.6084/m9.figshare.c.3801541_d1","https://doi.org/10.6084/m9.figshare.c.3801541_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032392","R0032392.pdf","paywalled","randomized_trial","Suzuki, Shuichi","2017","Additional file 3: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Figshare",null,"10.6084/m9.figshare.c.3801541_d3","https://doi.org/10.6084/m9.figshare.c.3801541_d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032398","R0032398.pdf","paywalled","randomized_trial","Suzuki, Shuichi","2017","Additional file 4: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Figshare",null,"10.6084/m9.figshare.c.3801541_d4","https://doi.org/10.6084/m9.figshare.c.3801541_d4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032403","R0032403.pdf","paywalled","randomized_trial","Suzuki, Shuichi","2017","Additional file 2: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Figshare",null,"10.6084/m9.figshare.c.3801541_d2","https://doi.org/10.6084/m9.figshare.c.3801541_d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034736","R0034736.pdf","paywalled","randomized_trial","Knop Filip","2017","A randomised trial of the effects of liraglutide on gallbladder emptying in adults with overweight or obesity",null,"Morressier","10.26226/morressier.59d51844d462b80296ca3914","https://doi.org/10.26226/morressier.59d51844d462b80296ca3914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037338","R0037338.pdf","paywalled","randomized_trial","Peter M. Nilsson","2017","Hemodynamic effects by glucagon-like peptide-1 receptor analogues","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000001315","https://doi.org/10.1097/hjh.0000000000001315","28353547","https://pubmed.ncbi.nlm.nih.gov/28353547/",null,null],["2","R0038541","R0038541.pdf","paywalled","randomized_trial","Fernanda Cerqueira Barroso Oliveira","2017","Liraglutide Promotes Browning of White Adipose Tissue in Mice with Diet Induced Obesity","The FASEB Journal","Wiley","10.1096/fasebj.31.1_supplement.886.1","https://doi.org/10.1096/fasebj.31.1_supplement.886.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039310","R0039310.pdf","paywalled","randomized_trial","Janette Panhuis","2017","The Population Health Research Institute","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehx608","https://doi.org/10.1093/eurheartj/ehx608","29145659","https://pubmed.ncbi.nlm.nih.gov/29145659/",null,null],["2","R0039785","R0039785.pdf","paywalled","randomized_trial","Alberto Zanchetti","2017","Problems of antihypertensive management","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000001334","https://doi.org/10.1097/hjh.0000000000001334","28244898","https://pubmed.ncbi.nlm.nih.gov/28244898/",null,null],["2","R0041446","R0041446.pdf","paywalled","randomized_trial","M. J. Davies (7604990)","2017","Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.","Figshare",null,"10.1111/dom.13125/abstract","https://doi.org/10.1111/dom.13125/abstract",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043730","R0043730.pdf","paywalled","randomized_trial",null,"2017","Impact of Lixisenatide On Phase 1 and Phase 2 Glucose-Stimulated insulin Secretion During An intravenous Glucose Tolerance Test in Type 2 Diabetes : a Model-Based Assessment","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8158e668b9000b9f8e24","https://doi.org/10.26226/morressier.5c3c8158e668b9000b9f8e24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043750","R0043750.pdf","paywalled","randomized_trial",null,"2017","EFFECT OF DULAGLUTIDE VERSUS LIRAGLUTIDE ON GLUCOSE VARIABILITY AND OXIDATIVE STRESS AND ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES PATIENTS","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8159e668b9000b9f8d98","https://doi.org/10.26226/morressier.5c3c8159e668b9000b9f8d98",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044267","R0044267.pdf","paywalled","randomized_trial",null,"2017","EFFECT OF THE GLP-1 RECEPTOR AGONIST EXENATIDE ON AWARENESS OF HYPOGLYCAEMIA IN PATIENTS WITH TYPE 1 DIABETES AND IMPAIRED AWARENESS OF HYPOGLYCAEMIA","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8158e668b9000b9f8e2a","https://doi.org/10.26226/morressier.5c3c8158e668b9000b9f8e2a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046626","R0046626.pdf","paywalled","randomized_trial","Steve Chaplin","2017","Primary care diabetes prescribing rates: latest analysis shows continued rise in volume and cost","Practical Diabetes","Wiley","10.1002/pdi.2075","https://doi.org/10.1002/pdi.2075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047183","R0047183.pdf","paywalled","randomized_trial","Esteban Jódar","2017","Once-weekly dulaglutide (DU) vs. insulin glargine in the control of fasting serum glucose and hypoglycaemia rate in the first 20 weeks in patients with type 2 diabetes mellitus on metformin and glimepiride","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0037-1601745","https://doi.org/10.1055/s-0037-1601745",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047422","R0047422.pdf","paywalled","randomized_trial","Esteban Jódar","2017","3910SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehx504.3910","https://doi.org/10.1093/eurheartj/ehx504.3910",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047602","R0047602.pdf","paywalled","randomized_trial","Disha Khemani","2017","Effects of Liraglutide on Gastric Emptying, Gastric Accommodation, Satiation and Satiety after 16 Weeks' Treatment: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients","Gastroenterology","Elsevier BV","10.1016/s0016-5085(17)32245-x","https://doi.org/10.1016/s0016-5085(17)32245-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047833","R0047833.pdf","paywalled","randomized_trial","Hermione Clare Price","2017","Effects of once weekly dulaglutide 1.5 mg on glycaemic control, weight and hypoglycaemia in patients with Type 2 diabetes in the AWARD-1 and AWARD-2 clinical trials","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0037-1601748","https://doi.org/10.1055/s-0037-1601748",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047904","R0047904.pdf","paywalled","randomized_trial","Barbara M. McGowan","2017","Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.48.p1","https://doi.org/10.1530/endoabs.48.p1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050124","R0050124.pdf","paywalled","randomized_trial","Barbara M. McGowan","2017","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.48.p11","https://doi.org/10.1530/endoabs.48.p11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050761","R0050761.pdf","paywalled","randomized_trial","Hoda C. Kadouh","2017","A Single-Center, Randomized, Placebo-Controlled, 16-Week Trial of Effects of Liraglutide on Weight Loss and Relationship to Change in Gastric Emptying in Obese Patients","Gastroenterology","Elsevier BV","10.1016/s0016-5085(17)32248-5","https://doi.org/10.1016/s0016-5085(17)32248-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052098","R0052098.pdf","paywalled","randomized_trial","Disha Khemani","2017","Effect of Liraglutide on Gastric Emptying at 5 and 16 Weeks: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients","Gastroenterology","Elsevier BV","10.1016/s0016-5085(17)30625-x","https://doi.org/10.1016/s0016-5085(17)30625-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052457","R0052457.pdf","paywalled","randomized_trial","V. Demmel","2017","P5349Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehx493.p5349","https://doi.org/10.1093/eurheartj/ehx493.p5349",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052491","R0052491.pdf","paywalled","randomized_trial","Derek John Hausenloy","2017","Combination Therapy to Target Reperfusion Injury After ST-Segment–Elevation Myocardial Infarction","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.117.029859","https://doi.org/10.1161/circulationaha.117.029859","28874421","https://pubmed.ncbi.nlm.nih.gov/28874421/",null,"ClinicalTrials.gov:NCT01398384"],["2","R0053085","R0053085.pdf","paywalled","randomized_trial","Qing Tian","2017","Efficacy and safety of domestic exenatide injection in treating type 2 diabetes: A multicenter, randomized, controlled, and non-inferiority trial","Zhonghua neifenmi daixie zazhi",null,"10.3760/cma.j.issn.1000-6699.2017.04.006","https://doi.org/10.3760/cma.j.issn.1000-6699.2017.04.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0010063","R0010063.pdf","paywalled","randomized_trial","Leiter LA","2016","Gastrointestinal safety across the albiglutide development programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12679","https://doi.org/10.1111/dom.12679","27097971","https://pubmed.ncbi.nlm.nih.gov/27097971/",null,null],["2","R0010522","R0010522.pdf","paywalled","randomized_trial","Davies ML","2016","GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.","Pharmacotherapy","Wiley","10.1002/phar.1792","https://doi.org/10.1002/phar.1792","27340935","https://pubmed.ncbi.nlm.nih.gov/27340935/",null,null],["2","R0011766","R0011766.pdf","paywalled","randomized_trial","Mari A","2016","Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12671","https://doi.org/10.1111/dom.12671","27059816","https://pubmed.ncbi.nlm.nih.gov/27059816/",null,null],["2","R0012239","R0012239.pdf","paywalled","randomized_trial","Consoli A","2016","[Incretin therapies and multifactorial clinical approach to cardiometabolic patients].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/2206.23818","https://doi.org/10.1714/2206.23818","27030119","https://pubmed.ncbi.nlm.nih.gov/27030119/",null,null],["2","R0012862","R0012862.pdf","paywalled","randomized_trial","Jendle J","2016","Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12705","https://doi.org/10.1111/dom.12705","27279266","https://pubmed.ncbi.nlm.nih.gov/27279266/",null,null],["2","R0014252","R0014252.pdf","paywalled","randomized_trial","Dejgaard TF","2016","Liraglutide for treating type 1 diabetes.","Expert opinion on biological therapy","Informa Healthcare","10.1517/14712598.2016.1160050","https://doi.org/10.1517/14712598.2016.1160050","26926662","https://pubmed.ncbi.nlm.nih.gov/26926662/",null,null],["2","R0014331","R0014331.pdf","paywalled","randomized_trial","Davidson JA","2016","EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep161337.or","https://doi.org/10.4158/ep161337.or","27540883","https://pubmed.ncbi.nlm.nih.gov/27540883/",null,null],["2","R0016108","R0016108.pdf","paywalled","randomized_trial","Smith JD","2016","Treatment of Pediatric Type 2 Diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028016655179","https://doi.org/10.1177/1060028016655179","27307414","https://pubmed.ncbi.nlm.nih.gov/27307414/",null,null],["2","R0016412","R0016412.pdf","paywalled","randomized_trial","Savvidou S","2016","Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.12.003","https://doi.org/10.1016/j.diabres.2015.12.003","26803355","https://pubmed.ncbi.nlm.nih.gov/26803355/",null,null],["2","R0019963","R0019963.pdf","paywalled","randomized_trial","Skov J","2016","Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12651","https://doi.org/10.1111/dom.12651","26910107","https://pubmed.ncbi.nlm.nih.gov/26910107/",null,null],["2","R0023197","R0023197.pdf","paywalled","randomized_trial","Li HT","2016","Exendin-4 Enhances Motor Function Recovery via Promotion of Autophagy and Inhibition of Neuronal Apoptosis After Spinal Cord Injury in Rats.","Molecular neurobiology","Springer Science and Business Media LLC","10.1007/s12035-015-9327-7","https://doi.org/10.1007/s12035-015-9327-7","26198566","https://pubmed.ncbi.nlm.nih.gov/26198566/",null,null],["2","R0023209","R0023209.pdf","paywalled","randomized_trial","Nakatani Y","2016","Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability.","Diabetes care","American Diabetes Association","10.2337/dc15-1437","https://doi.org/10.2337/dc15-1437","26681718","https://pubmed.ncbi.nlm.nih.gov/26681718/",null,null],["2","R0023213","R0023213.pdf","paywalled","randomized_trial","Dutour A","2016","Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12680","https://doi.org/10.1111/dom.12680","27106272","https://pubmed.ncbi.nlm.nih.gov/27106272/",null,null],["2","R0025341","R0025341.pdf","paywalled","randomized_trial","Kyhl K","2016","A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction.","EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology","Europa Digital & Publishing","10.4244/eijv12i4a78","https://doi.org/10.4244/eijv12i4a78","27436599","https://pubmed.ncbi.nlm.nih.gov/27436599/",null,null],["2","R0025707","R0025707.pdf","paywalled","randomized_trial","Tawfik MK","2016","Exenatide suppresses 1,2-dimethylhydrazine-induced colon cancer in diabetic mice: Effect on tumor angiogenesis and cell proliferation.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2016.05.005","https://doi.org/10.1016/j.biopha.2016.05.005","27470345","https://pubmed.ncbi.nlm.nih.gov/27470345/",null,null],["2","R0025972","R0025972.pdf","paywalled","randomized_trial","Filion KB","2016","A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmoa1506115","https://doi.org/10.1056/nejmoa1506115","27007958","https://pubmed.ncbi.nlm.nih.gov/27007958/",null,"ClinicalTrials.gov:NCT02456428"],["2","R0025997","R0025997.pdf","paywalled","randomized_trial","Ferrario MG","2016","Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2015.10.002","https://doi.org/10.1016/j.pcd.2015.10.002","26546244","https://pubmed.ncbi.nlm.nih.gov/26546244/",null,null],["2","R0026217","R0026217.pdf","paywalled","randomized_trial","Tanner M","2016","In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2016-165-12-064","https://doi.org/10.7326/acpjc-2016-165-12-064","27992920","https://pubmed.ncbi.nlm.nih.gov/27992920/",null,null],["2","R0026267","R0026267.pdf","paywalled","randomized_trial","Gonzales K","2016","In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2016-165-8-040","https://doi.org/10.7326/acpjc-2016-165-8-040","27750300","https://pubmed.ncbi.nlm.nih.gov/27750300/",null,null],["2","R0027287","R0027287.pdf","paywalled","randomized_trial","Connelly KA","2016","Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.","Journal of diabetes","Wiley","10.1111/1753-0407.12258","https://doi.org/10.1111/1753-0407.12258","25565455","https://pubmed.ncbi.nlm.nih.gov/25565455/",null,null],["2","R0027759","R0027759.pdf","paywalled","randomized_trial","Chen P","2016","[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].","Zhonghua nei ke za zhi",null,"10.3760/cma.j.issn.0578-1426.2016.05.004","https://doi.org/10.3760/cma.j.issn.0578-1426.2016.05.004","27143183","https://pubmed.ncbi.nlm.nih.gov/27143183/",null,"ClinicalTrials.gov:NCT01954147"],["2","R0027868","R0027868.pdf","paywalled","randomized_trial","Galindo RJ","2016","HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep151039.ra","https://doi.org/10.4158/ep151039.ra","26720253","https://pubmed.ncbi.nlm.nih.gov/26720253/",null,null],["2","R0028761","R0028761.pdf","paywalled","randomized_trial","Abdulsalim S","2016","New fixed dose chemical combinations: the way forward for better diabetes type II management?","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2016.1241235","https://doi.org/10.1080/14656566.2016.1241235","27700188","https://pubmed.ncbi.nlm.nih.gov/27700188/",null,null],["2","R0028770","R0028770.pdf","paywalled","randomized_trial","Lovre D","2016","What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-016-0788-5","https://doi.org/10.1007/s11892-016-0788-5","27541296","https://pubmed.ncbi.nlm.nih.gov/27541296/",null,null],["2","R0028815","R0028815.pdf","paywalled","randomized_trial","Montori VM","2016","The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.","Annals of internal medicine","American College of Physicians","10.7326/m15-2610","https://doi.org/10.7326/m15-2610","26641027","https://pubmed.ncbi.nlm.nih.gov/26641027/",null,null],["2","R0030628","R0030628.pdf","paywalled","randomized_trial","Paul S. Mueller","2016","GLP-1 Analogues and Risk for Breast Cancer","Journal watch",null,"10.1056/nejm-jw.na42648","https://doi.org/10.1056/nejm-jw.na42648",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030931","R0030931.pdf","paywalled","randomized_trial","Lunpan Mou","2016","Efficacy and safety of liraglutide versus sitagliptin in obese patients with inadequately controlled type 2 diabetes with insulin therapy","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2016.01.008","https://doi.org/10.3760/cma.j.issn.1674-5809.2016.01.008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031004","R0031004.pdf","paywalled","randomized_trial","Allan S. Brett","2016","A Fixed Combination of Long-Acting Insulin and GLP-1 Receptor Agonist","Journal watch",null,"10.1056/nejm-jw.na40646","https://doi.org/10.1056/nejm-jw.na40646",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031133","R0031133.pdf","paywalled","randomized_trial","Allan S. Brett","2016","Liraglutide and Cardiovascular Outcomes in Patients with Long-Standing Type 2 Diabetes","Journal watch",null,"10.1056/nejm-jw.na41592","https://doi.org/10.1056/nejm-jw.na41592",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031147","R0031147.pdf","paywalled","randomized_trial","Paul S. Mueller","2016","Cardiovascular Outcomes with Newer Antidiabetes Drugs","Journal watch",null,"10.1056/nejm-jw.na43024","https://doi.org/10.1056/nejm-jw.na43024",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031468","R0031468.pdf","paywalled","randomized_trial","So Hun Kim","2016","Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials","Journal of Korean Diabetes","Korean Diabetes Association","10.4093/jkd.2016.17.1.1","https://doi.org/10.4093/jkd.2016.17.1.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032404","R0032404.pdf","paywalled","randomized_trial","Preman Kumarathurai","2016","MOESM1 of Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study","Figshare",null,"10.6084/m9.figshare.c.3617195_d1","https://doi.org/10.6084/m9.figshare.c.3617195_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034779","R0034779.pdf","paywalled","randomized_trial","Thuy Pham","2016","Cohort Analysis of Randomized Clinical Trials on long acting GLP-1 receptor agonists versus DPP4 inhibitors","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.43.oc32","https://doi.org/10.1530/endoabs.43.oc32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034927","R0034927.pdf","paywalled","randomized_trial","Preman Kumarathurai","2016","[OP.4A.09] THE EFFECT OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE ON 24-H BLOOD PRESSURE VARIATION","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000491445.66874.a8","https://doi.org/10.1097/01.hjh.0000491445.66874.a8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035804","R0035804.pdf","paywalled","randomized_trial","Gaurav Kaithwas","2016","PS 16-29 GLP-1 RECEPTOR AGONISTIC AND ANTIDIABETIC ACTIVITY OF MEFLOQUINE AGAINST STZ-NA INDUCED DIABETES IN ALBINO WISTAR RATS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000501260.52383.7b","https://doi.org/10.1097/01.hjh.0000501260.52383.7b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039398","R0039398.pdf","paywalled","randomized_trial","Alberto Zanchetti","2016","Prediction, diagnosis and treatment of hypertension","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000000939","https://doi.org/10.1097/hjh.0000000000000939","27088637","https://pubmed.ncbi.nlm.nih.gov/27088637/",null,null],["2","R0042044","R0042044.pdf","paywalled","randomized_trial","Sony S. Thazhath","2016","Gastrointestinal mediation of glucose homeostasis and postprandial cardiovascular risk","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,"10.4225/55/58ae4f68c1232","https://doi.org/10.4225/55/58ae4f68c1232",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047734","R0047734.pdf","paywalled","randomized_trial","Caroline Kaercher Kramer","2016","Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehw158","https://doi.org/10.1093/eurheartj/ehw158","27153862","https://pubmed.ncbi.nlm.nih.gov/27153862/",null,null],["2","R0048462","R0048462.pdf","paywalled","randomized_trial","Christian Labenz","2016","NASH – Ist die Zeit für eine medikamentöse Therapie gekommen?","Zeitschrift für Gastroenterologie","Georg Thieme Verlag KG","10.1055/s-0042-118409","https://doi.org/10.1055/s-0042-118409","27919110","https://pubmed.ncbi.nlm.nih.gov/27919110/",null,null],["2","R0048546","R0048546.pdf","paywalled","randomized_trial","Jens Aberle","2016","Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580948","https://doi.org/10.1055/s-0036-1580948",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048896","R0048896.pdf","paywalled","randomized_trial","Matthias Blueher","2016","Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580953","https://doi.org/10.1055/s-0036-1580953",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049072","R0049072.pdf","paywalled","randomized_trial","Bo Åhrén","2016","Abstract #299: Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Type 1 Diabetes, the Adjunct Two Randomized Trial","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)45007-4","https://doi.org/10.1016/s1530-891x(20)45007-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049127","R0049127.pdf","paywalled","randomized_trial","David C.W. Lau","2016","Reduction in the Risk of Developing Type 2 Diabetes (T2D) with Liraglutide 3.0 mg in People with Prediabetes from the SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2016.08.100","https://doi.org/10.1016/j.jcjd.2016.08.100",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049181","R0049181.pdf","paywalled","randomized_trial","Raffaella Gentilella","2016","Consistency of treatment effect across the range of baseline HbA1c in patients with type 2 diabetes mellitus (T2DM) treated with once-weekly dulaglutide or comparators in AWARD-1, -5 and -6","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580999","https://doi.org/10.1055/s-0036-1580999",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050047","R0050047.pdf","paywalled","randomized_trial","Massimo Francesco Piepoli","2016","The year in cardiology 2016: prevention","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehw637","https://doi.org/10.1093/eurheartj/ehw637","28043976","https://pubmed.ncbi.nlm.nih.gov/28043976/",null,null],["2","R0050260","R0050260.pdf","paywalled","randomized_trial","Wolfgang Kern","2016","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580798","https://doi.org/10.1055/s-0036-1580798",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050362","R0050362.pdf","paywalled","randomized_trial","Chantal Mathieu","2016","Abstract #291: Efficacy and Safety of Liraglutide Addded to Insulin Treatment in Type 1 Diabetes, The Adjunct One Treat-Totarget Randomized Trial","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)44999-7","https://doi.org/10.1016/s1530-891x(20)44999-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051320","R0051320.pdf","paywalled","randomized_trial","Nitesh D Kuhadiya","2016","Abstract #213: Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients with Type 1 Diabetes. A Randomized Clinical Trial","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)44921-3","https://doi.org/10.1016/s1530-891x(20)44921-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051346","R0051346.pdf","paywalled","randomized_trial","Tobias Keck","2016","Metabolic Syndrome: An Interdisciplinary Approach","Visceral Medicine","S. Karger AG","10.1159/000452140","https://doi.org/10.1159/000452140",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052759","R0052759.pdf","paywalled","randomized_trial","Damir Boras","2016","Switching from Sitagliptin to Liraglutide in Subjects with Type 2 Diabetes (T2D): Analysis of Composite Endpoints from the LIRA-SWITCH Randomized Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2016.08.112","https://doi.org/10.1016/j.jcjd.2016.08.112",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054243","R0054243.pdf","paywalled","randomized_trial","Dennis Khodasevich","2016","Evidence Shows Few Drugs Cause Acute Pancreatitis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/00000434-201610001-00030","https://doi.org/10.14309/00000434-201610001-00030",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0013125","R0013125.pdf","paywalled","randomized_trial","Syed YY","2015","Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-015-0420-z","https://doi.org/10.1007/s40265-015-0420-z","26071140","https://pubmed.ncbi.nlm.nih.gov/26071140/",null,null],["2","R0013581","R0013581.pdf","paywalled","randomized_trial","Tanaka K","2015","Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-015-0331-5","https://doi.org/10.1007/s40261-015-0331-5","26369653","https://pubmed.ncbi.nlm.nih.gov/26369653/",null,"UMIN:UMIN000004243"],["2","R0013858","R0013858.pdf","paywalled","randomized_trial","Faurschou A","2015","Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.12629","https://doi.org/10.1111/jdv.12629","25139195","https://pubmed.ncbi.nlm.nih.gov/25139195/",null,null],["2","R0016368","R0016368.pdf","paywalled","randomized_trial","Burness CB","2015","Dulaglutide: A Review in Type 2 Diabetes.","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","Springer Science and Business Media LLC","10.1007/s40259-015-0143-4","https://doi.org/10.1007/s40259-015-0143-4","26423061","https://pubmed.ncbi.nlm.nih.gov/26423061/",null,null],["2","R0017165","R0017165.pdf","paywalled","randomized_trial","von Scholten BJ","2015","Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12594","https://doi.org/10.1111/dme.12594","25251901","https://pubmed.ncbi.nlm.nih.gov/25251901/",null,null],["2","R0017743","R0017743.pdf","paywalled","randomized_trial","Goldman-Levine JD","2015","Combination therapy when metformin is not an option for type 2 diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028015572653","https://doi.org/10.1177/1060028015572653","25770115","https://pubmed.ncbi.nlm.nih.gov/25770115/",null,null],["2","R0017812","R0017812.pdf","paywalled","randomized_trial","Gan Y","2015","GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0035-1548797","https://doi.org/10.1055/s-0035-1548797","25962403","https://pubmed.ncbi.nlm.nih.gov/25962403/",null,null],["2","R0019836","R0019836.pdf","paywalled","randomized_trial","Clements JN","2015","Liraglutide: an injectable option for the management of obesity.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028015586806","https://doi.org/10.1177/1060028015586806","25986009","https://pubmed.ncbi.nlm.nih.gov/25986009/",null,null],["2","R0020974","R0020974.pdf","paywalled","randomized_trial","Usborne A","2015","An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.","Toxicologic pathology","SAGE Publications","10.1177/0192623315596857","https://doi.org/10.1177/0192623315596857","26269615","https://pubmed.ncbi.nlm.nih.gov/26269615/",null,null],["2","R0022049","R0022049.pdf","paywalled","randomized_trial","Sturm-Pellanda C","2015","Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.08.022","https://doi.org/10.1016/j.clinthera.2015.08.022","26412802","https://pubmed.ncbi.nlm.nih.gov/26412802/",null,null],["2","R0024136","R0024136.pdf","paywalled","randomized_trial","Popovic DS","2015","GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/0929867322666151006142224","https://doi.org/10.2174/0929867322666151006142224","26438316","https://pubmed.ncbi.nlm.nih.gov/26438316/",null,null],["2","R0024520","R0024520.pdf","paywalled","randomized_trial","von Scholten BJ","2015","The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.08.007","https://doi.org/10.1016/j.jdiacomp.2015.08.007","26345339","https://pubmed.ncbi.nlm.nih.gov/26345339/",null,null],["2","R0024732","R0024732.pdf","paywalled","randomized_trial","Lin J","2015","GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12533","https://doi.org/10.1111/dom.12533","26179090","https://pubmed.ncbi.nlm.nih.gov/26179090/",null,"ClinicalTrials.gov:NCT01545570"],["2","R0025029","R0025029.pdf","paywalled","randomized_trial","Yang GR","2015","Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes.","Journal of clinical pharmacology","Wiley","10.1002/jcph.386","https://doi.org/10.1002/jcph.386","25167840","https://pubmed.ncbi.nlm.nih.gov/25167840/",null,null],["2","R0025857","R0025857.pdf","paywalled","randomized_trial","Ma Z","2015","Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cp202415","https://doi.org/10.5414/cp202415","26365337","https://pubmed.ncbi.nlm.nih.gov/26365337/",null,null],["2","R0026089","R0026089.pdf","paywalled","randomized_trial","Boland CL","2015","Pharmacological management of obesity in pediatric patients.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028014557859","https://doi.org/10.1177/1060028014557859","25366340","https://pubmed.ncbi.nlm.nih.gov/25366340/",null,null],["2","R0026338","R0026338.pdf","paywalled","randomized_trial","Inoue Y","2015","A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.","Journal of clinical pharmacology","Wiley","10.1002/jcph.483","https://doi.org/10.1002/jcph.483","25677642","https://pubmed.ncbi.nlm.nih.gov/25677642/",null,null],["2","R0026395","R0026395.pdf","paywalled","randomized_trial","Li D","2015","Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.05.051","https://doi.org/10.1016/j.diabres.2015.05.051","26376464","https://pubmed.ncbi.nlm.nih.gov/26376464/",null,null],["2","R0026448","R0026448.pdf","paywalled","randomized_trial","Rigato M","2015","Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-015-0385-5","https://doi.org/10.1007/s40618-015-0385-5","26328783","https://pubmed.ncbi.nlm.nih.gov/26328783/",null,null],["2","R0026551","R0026551.pdf","paywalled","randomized_trial","Soe K","2015","Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants.","Evidence-based medicine","BMJ","10.1136/ebmed-2015-110273","https://doi.org/10.1136/ebmed-2015-110273","26385492","https://pubmed.ncbi.nlm.nih.gov/26385492/",null,null],["2","R0026647","R0026647.pdf","paywalled","randomized_trial","Mayor S","2015","Liraglutide improves weight loss in people who are overweight or obese, study shows.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.h3545","https://doi.org/10.1136/bmj.h3545","26138725","https://pubmed.ncbi.nlm.nih.gov/26138725/",null,null],["2","R0026780","R0026780.pdf","paywalled","randomized_trial","Li R","2015","Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-015-0792-2","https://doi.org/10.1007/s00592-015-0792-2","26249206","https://pubmed.ncbi.nlm.nih.gov/26249206/",null,null],["2","R0026796","R0026796.pdf","paywalled","randomized_trial","Lapolla A","2015","Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2014.11.015","https://doi.org/10.1016/j.clinthera.2014.11.015","25626486","https://pubmed.ncbi.nlm.nih.gov/25626486/",null,null],["2","R0026874","R0026874.pdf","paywalled","randomized_trial","Tang A","2015","Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.","Diabetes care","American Diabetes Association","10.2337/dc15-1091","https://doi.org/10.2337/dc15-1091","26294785","https://pubmed.ncbi.nlm.nih.gov/26294785/",null,null],["2","R0027097","R0027097.pdf","paywalled","randomized_trial","Cotugno M","2015","Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-014-0644-5","https://doi.org/10.1007/s00592-014-0644-5","25218924","https://pubmed.ncbi.nlm.nih.gov/25218924/",null,null],["2","R0027915","R0027915.pdf","paywalled","randomized_trial","Lønborg JT","2015","Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype?","Heart (British Cardiac Society)","BMJ","10.1136/heartjnl-2015-307804","https://doi.org/10.1136/heartjnl-2015-307804","26130664","https://pubmed.ncbi.nlm.nih.gov/26130664/",null,null],["2","R0028197","R0028197.pdf","paywalled","randomized_trial","Kramer CK","2015","Response to the Letter by Kalra S. et al.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-3553","https://doi.org/10.1210/jc.2015-3553","26544664","https://pubmed.ncbi.nlm.nih.gov/26544664/",null,null],["2","R0030654","R0030654.pdf","paywalled","randomized_trial","Binbin Liu","2015","Liraglutide treatment promotes beta cells proliferation via regulation of microRNA expression","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2012.06.008","https://doi.org/10.3760/cma.j.issn.1674-5809.2012.06.008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030883","R0030883.pdf","paywalled","randomized_trial","Atif Zaman","2015","Promising Early Results for Liraglutide in the Treatment of NASH","Journal watch",null,"10.1056/nejm-jw.na39715","https://doi.org/10.1056/nejm-jw.na39715",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033350","R0033350.pdf","paywalled","randomized_trial","X Pi-Sunyer","2015","Adipositas – Liraglutid kann Gewichtsabnahme unterstützen","Aktuelle Ernährungsmedizin","Georg Thieme Verlag KG","10.1055/s-0035-1552442","https://doi.org/10.1055/s-0035-1552442",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034242","R0034242.pdf","paywalled","randomized_trial","Tsuyoshi Nozue","2015","Abstract 11806: Not Glycemic Control Using Sitagliptin But Lipid Control is Associated With Change in Coronary Atherosclerosis in Patients With Type 2 Diabetes -A Serial Integrated Backscatter Intravascular Ultrasound Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.132.suppl_3.11806","https://doi.org/10.1161/circ.132.suppl_3.11806",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035716","R0035716.pdf","paywalled","randomized_trial","M. Cunningham","2015","Neutral Results Obtained in the ELIXA Trial","MD Conference Express","CLOCKSS Archive","10.1177/1559897715611120","https://doi.org/10.1177/1559897715611120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035783","R0035783.pdf","paywalled","randomized_trial","Andrew J. Krentz","2015","Conference report","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000070","https://doi.org/10.1097/xce.0000000000000070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036003","R0036003.pdf","paywalled","randomized_trial","J Baeumler","2015","Indirect comparisons (ICs) of once weekly dulaglutide (DU) plus metformin (MET) versus sulphonylureas (SU) plus MET in patients with type 2 diabetes (T2D) from AWARD-5","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549664","https://doi.org/10.1055/s-0035-1549664",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038455","R0038455.pdf","paywalled","randomized_trial","Peter M. Nilsson","2015","DPP-4 inhibition and blood pressure lowering in perspective","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000000814","https://doi.org/10.1097/hjh.0000000000000814","26682784","https://pubmed.ncbi.nlm.nih.gov/26682784/",null,"ClinicalTrials.gov:NCT01897532"],["2","R0038686","R0038686.pdf","paywalled","randomized_trial","Savvoula Savvidou","2015","P0996 : The effects of short-term exenatide on circulating adiponectin levels in patients with type 2 diabetes mellitus (DMT2) with or without non-alcoholic fatty liver disease (NAFLD): a randomized, open-label, controlled intervention trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(15)31197-1","https://doi.org/10.1016/s0168-8278(15)31197-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039160","R0039160.pdf","paywalled","randomized_trial","The Editors","2015","Discrepancies Between Prespecified and Reported Outcomes","Annals of Internal Medicine","American College of Physicians","10.7326/l15-0615","https://doi.org/10.7326/l15-0615","26720499","https://pubmed.ncbi.nlm.nih.gov/26720499/",null,null],["2","R0044209","R0044209.pdf","paywalled","randomized_trial","Paula Cristina Cardoso Teixeira","2015","Psoriasis patients with obesity and type 2 biabetes: the effect of glucagon-like peptide 1 (GLP-1) receptor agonists","Open Repository of the University of Porto (University of Porto)",null,"10.34626/x485-j713","https://doi.org/10.34626/x485-j713",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048032","R0048032.pdf","paywalled","randomized_trial","O Adetunji","2015","Percentage of patients with type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly AdministRation of dulaglutide in Diabetes (AWARD)-1 and -5 studies","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549748","https://doi.org/10.1055/s-0035-1549748",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049753","R0049753.pdf","paywalled","randomized_trial","Piya Sen Gupta","2015","OC-072 Does endoscopic duodenal-jejunal exclusion improve non-alcoholic fatty liver disease (nafld) in patients with diabesity?",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2015-309861.72","https://doi.org/10.1136/gutjnl-2015-309861.72",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049829","R0049829.pdf","paywalled","randomized_trial","Thomas M. Forst","2015","The 2 week fasting blood glucose (FBG) level as a predictor of HbA1c treatment response (HbA1c-TR) to once weekly dulaglutide 1.5 mg in patients with type 2 diabetes (T2DM)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549749","https://doi.org/10.1055/s-0035-1549749",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050215","R0050215.pdf","paywalled","randomized_trial","Frank L. Greenway","2015","Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomized trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1556575","https://doi.org/10.1055/s-0035-1556575",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050779","R0050779.pdf","paywalled","randomized_trial","David C.W. Lau","2015","Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.183","https://doi.org/10.1016/j.jcjd.2015.01.183",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051465","R0051465.pdf","paywalled","randomized_trial","Sue D. Pedersen","2015","Effects of Liraglutide 3.0 mg and 1.8 mg on Body Weight and Cardiometabolic Risk Factors in Adults with Overweight or Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.141","https://doi.org/10.1016/j.jcjd.2015.01.141",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051928","R0051928.pdf","paywalled","randomized_trial","David C.W. Lau","2015","Additional Analyses of the Weight-lowering Efficacy of Liraglutide 3.0 mg in Adults with Overweight and Obesity: The SCALE Obesity and Prediabetes Randomized Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.182","https://doi.org/10.1016/j.jcjd.2015.01.182",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053037","R0053037.pdf","paywalled","randomized_trial","Joanne Liutkus","2015","Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.142","https://doi.org/10.1016/j.jcjd.2015.01.142",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053329","R0053329.pdf","paywalled","randomized_trial","Sean Wharton","2015","Weight Loss with Liraglutide 3.0 mg is Associated with Improved Health-related Quality of Life (HRQoL) and Treatment Satisfaction in Adults with Overweight/Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.140","https://doi.org/10.1016/j.jcjd.2015.01.140",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054687","R0054687.pdf","paywalled","randomized_trial","Matthew James Armstrong","2015","G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(15)30002-7","https://doi.org/10.1016/s0168-8278(15)30002-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056892","R0056892.pdf","paywalled","randomized_trial","Arcopinto M","2015","Hormone replacement therapy in heart failure.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000166","https://doi.org/10.1097/hco.0000000000000166","25807222","https://pubmed.ncbi.nlm.nih.gov/25807222/",null,null],["2","R0056893","R0056893.pdf","paywalled","randomized_trial","Ye Z","2015","Soluble dietary fiber (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a meal.","Nutrition research (New York, N.Y.)","Elsevier BV","10.1016/j.nutres.2015.03.004","https://doi.org/10.1016/j.nutres.2015.03.004","25823991","https://pubmed.ncbi.nlm.nih.gov/25823991/",null,"ClinicalTrials.gov:NCT01305291"],["2","R0009910","R0009910.pdf","paywalled","randomized_trial","Ferdinand KC","2014","Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.","Hypertension (Dallas, Tex. : 1979)","Ovid Technologies (Wolters Kluwer Health)","10.1161/hypertensionaha.114.03062","https://doi.org/10.1161/hypertensionaha.114.03062","24980665","https://pubmed.ncbi.nlm.nih.gov/24980665/",null,null],["2","R0010816","R0010816.pdf","paywalled","randomized_trial","Umpierrez GE","2014","Use of incretin-based therapy in hospitalized patients with hyperglycemia.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep13471.ra","https://doi.org/10.4158/ep13471.ra","25100362","https://pubmed.ncbi.nlm.nih.gov/25100362/",null,null],["2","R0010866","R0010866.pdf","paywalled","randomized_trial","Ametov AS","2014","[Cardioprotective effects of glucagon-like peptide 1 receptor agonists].","Kardiologiia","Bionika Media","10.18565/cardio.2014.7.92-96","https://doi.org/10.18565/cardio.2014.7.92-96","25177820","https://pubmed.ncbi.nlm.nih.gov/25177820/",null,null],["2","R0010947","R0010947.pdf","paywalled","randomized_trial","Bolli GB","2014","Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12253","https://doi.org/10.1111/dom.12253","24373190","https://pubmed.ncbi.nlm.nih.gov/24373190/",null,null],["2","R0011017","R0011017.pdf","paywalled","randomized_trial","de Heer J","2014","Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?","Expert opinion on drug safety","Informa Healthcare","10.1517/14740338.2014.955013","https://doi.org/10.1517/14740338.2014.955013","25270593","https://pubmed.ncbi.nlm.nih.gov/25270593/",null,null],["2","R0012815","R0012815.pdf","paywalled","randomized_trial","Faurschou A","2014","Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-011-0359-9","https://doi.org/10.1007/s00592-011-0359-9","22160246","https://pubmed.ncbi.nlm.nih.gov/22160246/",null,null],["2","R0013431","R0013431.pdf","paywalled","randomized_trial","Reusch J","2014","Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12382","https://doi.org/10.1111/dom.12382","25155146","https://pubmed.ncbi.nlm.nih.gov/25155146/",null,null],["2","R0014300","R0014300.pdf","paywalled","randomized_trial","Lane W","2014","The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12286","https://doi.org/10.1111/dom.12286","24589127","https://pubmed.ncbi.nlm.nih.gov/24589127/",null,null],["2","R0014799","R0014799.pdf","paywalled","randomized_trial","Suarez EA","2014","Incretin-mimetic therapies and pancreatic disease: a review of observational data.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2014.960515","https://doi.org/10.1185/03007995.2014.960515","25180611","https://pubmed.ncbi.nlm.nih.gov/25180611/",null,null],["2","R0016326","R0016326.pdf","paywalled","randomized_trial","O'Connor-Semmes RL","2014","GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.","Clinical pharmacology and therapeutics","Wiley","10.1038/clpt.2014.187","https://doi.org/10.1038/clpt.2014.187","25238251","https://pubmed.ncbi.nlm.nih.gov/25238251/",null,null],["2","R0018806","R0018806.pdf","paywalled","randomized_trial","Carris NW","2014","Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-014-0325-2","https://doi.org/10.1007/s40265-014-0325-2","25414121","https://pubmed.ncbi.nlm.nih.gov/25414121/",null,null],["2","R0019905","R0019905.pdf","paywalled","randomized_trial","Wysham C","2014","Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).","Diabetes care","American Diabetes Association","10.2337/dc13-2760","https://doi.org/10.2337/dc13-2760","24879836","https://pubmed.ncbi.nlm.nih.gov/24879836/",null,null],["2","R0021386","R0021386.pdf","paywalled","randomized_trial","Gastaldelli A","2014","A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12192","https://doi.org/10.1111/dom.12192","23911196","https://pubmed.ncbi.nlm.nih.gov/23911196/",null,null],["2","R0022164","R0022164.pdf","paywalled","randomized_trial","Mikhail N","2014","Effects of incretin-based therapy in patients with heart failure and myocardial infarction.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0175-4","https://doi.org/10.1007/s12020-014-0175-4","24493030","https://pubmed.ncbi.nlm.nih.gov/24493030/",null,null],["2","R0022675","R0022675.pdf","paywalled","randomized_trial","Brady EM","2014","A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12249","https://doi.org/10.1111/dom.12249","24373063","https://pubmed.ncbi.nlm.nih.gov/24373063/",null,null],["2","R0023132","R0023132.pdf","paywalled","randomized_trial","Novelli M","2014","Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2014.01.071","https://doi.org/10.1016/j.ejphar.2014.01.071","24530416","https://pubmed.ncbi.nlm.nih.gov/24530416/",null,null],["2","R0023133","R0023133.pdf","paywalled","randomized_trial","Foltynie T","2014","Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.","Alzheimer's & dementia : the journal of the Alzheimer's Association","Wiley","10.1016/j.jalz.2013.12.005","https://doi.org/10.1016/j.jalz.2013.12.005","24529524","https://pubmed.ncbi.nlm.nih.gov/24529524/",null,null],["2","R0023144","R0023144.pdf","paywalled","randomized_trial","Morey-Vargas OL","2014","ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-161-10-201411180-02009","https://doi.org/10.7326/0003-4819-161-10-201411180-02009","25402542","https://pubmed.ncbi.nlm.nih.gov/25402542/",null,null],["2","R0023516","R0023516.pdf","paywalled","randomized_trial","Distiller LA","2014","A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep14067.or","https://doi.org/10.4158/ep14067.or","24936555","https://pubmed.ncbi.nlm.nih.gov/24936555/",null,null],["2","R0023639","R0023639.pdf","paywalled","randomized_trial","Einarson TR","2014","Composite endpoints in trials of type-2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12226","https://doi.org/10.1111/dom.12226","24148209","https://pubmed.ncbi.nlm.nih.gov/24148209/",null,null],["2","R0024107","R0024107.pdf","paywalled","randomized_trial","Lutz SZ","2014","Antihyperglycaemic therapies and cancer risk.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164114549553","https://doi.org/10.1177/1479164114549553","25231191","https://pubmed.ncbi.nlm.nih.gov/25231191/",null,null],["2","R0024363","R0024363.pdf","paywalled","randomized_trial","Raccah D","2014","Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2013.10.003","https://doi.org/10.1016/j.jdiacomp.2013.10.003","24246441","https://pubmed.ncbi.nlm.nih.gov/24246441/",null,null],["2","R0024513","R0024513.pdf","paywalled","randomized_trial","Jayawardene D","2014","New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2014.05.007","https://doi.org/10.1016/j.hlc.2014.05.007","24996388","https://pubmed.ncbi.nlm.nih.gov/24996388/",null,null],["2","R0024620","R0024620.pdf","paywalled","randomized_trial","Hage C","2014","The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164114533355","https://doi.org/10.1177/1479164114533355","24845072","https://pubmed.ncbi.nlm.nih.gov/24845072/",null,null],["2","R0024945","R0024945.pdf","paywalled","randomized_trial","Ahrén B","2014","HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.","Diabetes care","American Diabetes Association","10.2337/dc14-0024","https://doi.org/10.2337/dc14-0024","24898304","https://pubmed.ncbi.nlm.nih.gov/24898304/",null,null],["2","R0026118","R0026118.pdf","paywalled","randomized_trial","Bi Y","2014","Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-014-0638-3","https://doi.org/10.1007/s00592-014-0638-3","25118999","https://pubmed.ncbi.nlm.nih.gov/25118999/",null,null],["2","R0026463","R0026463.pdf","paywalled","randomized_trial","Gurkan E","2014","Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2014.09.046","https://doi.org/10.1016/j.diabres.2014.09.046","25458329","https://pubmed.ncbi.nlm.nih.gov/25458329/",null,null],["2","R0026517","R0026517.pdf","paywalled","randomized_trial","Li CJ","2014","Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0034-1374586","https://doi.org/10.1055/s-0034-1374586","24838155","https://pubmed.ncbi.nlm.nih.gov/24838155/",null,null],["2","R0027074","R0027074.pdf","paywalled","randomized_trial","Plosker GL","2014","Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-013-0169-1","https://doi.org/10.1007/s40265-013-0169-1","24407560","https://pubmed.ncbi.nlm.nih.gov/24407560/",null,null],["2","R0027111","R0027111.pdf","paywalled","randomized_trial","Breitschaft A","2014","Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2013.12.011","https://doi.org/10.1016/j.diabres.2013.12.011","24461109","https://pubmed.ncbi.nlm.nih.gov/24461109/",null,null],["2","R0027553","R0027553.pdf","paywalled","randomized_trial","Banerji MA","2014","Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2014.05.2761","https://doi.org/10.3810/pgm.2014.05.2761","24918797","https://pubmed.ncbi.nlm.nih.gov/24918797/",null,null],["2","R0027727","R0027727.pdf","paywalled","randomized_trial","Heise T","2014","Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12304","https://doi.org/10.1111/dom.12304","24720741","https://pubmed.ncbi.nlm.nih.gov/24720741/",null,"ClinicalTrials.gov:NCT01680328"],["2","R0028255","R0028255.pdf","paywalled","randomized_trial","Papazafiropoulou A","2014","Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399810666140217114848","https://doi.org/10.2174/1573399810666140217114848","24527734","https://pubmed.ncbi.nlm.nih.gov/24527734/",null,null],["2","R0034315","R0034315.pdf","paywalled","randomized_trial","Linnéa Eriksson","2014","Abstract 515: Effects of the Glucagon-Like Peptide-1 Analog Exendin-4 on Reendothelialization and Intimal Hyperplasia Formation in an Animal Model of Vascular Injury","Arteriosclerosis Thrombosis and Vascular Biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvb.34.suppl_1.515","https://doi.org/10.1161/atvb.34.suppl_1.515",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035788","R0035788.pdf","paywalled","randomized_trial","Andrew J. Krentz","2014","Conference report","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000041","https://doi.org/10.1097/xce.0000000000000041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035797","R0035797.pdf","paywalled","randomized_trial","David Carty","2014","Glucose in the coronary care unit","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000034","https://doi.org/10.1097/xce.0000000000000034",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037337","R0037337.pdf","paywalled","randomized_trial","Jens Jordan","2014","Antihypertensive treatments in obese patients","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000000245","https://doi.org/10.1097/hjh.0000000000000245","24984176","https://pubmed.ncbi.nlm.nih.gov/24984176/",null,null],["2","R0038421","R0038421.pdf","paywalled","randomized_trial","Rebekka Faber","2014","Abstract 13697: Glucagon-like Peptide-1 Analogue Liraglutide Does Not Improve Microvascular Myocardial Function in Patients With Type 2 Diabetes - a Randomized, Single-blinded Cross Over Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.130.suppl_2.13697","https://doi.org/10.1161/circ.130.suppl_2.13697",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043890","R0043890.pdf","paywalled","randomized_trial","Craig J. Currie","2014","Optimizing clinical outcomes resulting from glucose‐lowering therapies in type 2 diabetes: increased confidence about the DPP ‐4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.12349","https://doi.org/10.1111/dom.12349","25040702","https://pubmed.ncbi.nlm.nih.gov/25040702/",null,null],["2","R0045323","R0045323.pdf","paywalled","randomized_trial","Fan Liu","2014","Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus","Intern J Endocrinol Metab",null,"10.3760/cma.j.issn.1673-4157.2014.04.006","https://doi.org/10.3760/cma.j.issn.1673-4157.2014.04.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045460","R0045460.pdf","paywalled","randomized_trial","Wen Guo","2014","Efficacy and safety of liraglutide compared with insulin glargine in patients with type 2 diabetes mellitus inadequately controlled with metformin","Zhonghua neifenmi daixie zazhi",null,"10.3760/cma.j.issn.1000-6699.2014.12.011","https://doi.org/10.3760/cma.j.issn.1000-6699.2014.12.011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045558","R0045558.pdf","paywalled","randomized_trial","Richard E. Gilbert","2014","Heart failure in SAVOR‐TIMI 53: The hindsight of diabetic retinopathySAVOR‐TIMI 53研究中的心脏衰竭：糖尿病视网膜病变的后尘","Journal of Diabetes","Wiley","10.1111/1753-0407.12249","https://doi.org/10.1111/1753-0407.12249","25443633","https://pubmed.ncbi.nlm.nih.gov/25443633/",null,null],["2","R0045703","R0045703.pdf","paywalled","randomized_trial","Rui Chen","2014","Comparison of efficacy and safety between liraglutide and sitagliptin in overweight and obese type 2 diabetes patients","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2014.03.005","https://doi.org/10.3760/cma.j.issn.1674-5809.2014.03.005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046350","R0046350.pdf","paywalled","randomized_trial","Zejun Ma","2014","Evaluation of efficacy and safety of liraglutide in newly diagnosed type 2 diabetic patients with continuous glucose monitoring system","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2014.12.011","https://doi.org/10.3760/cma.j.issn.1674-5809.2014.12.011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047210","R0047210.pdf","paywalled","randomized_trial","Gary Wittert","2014","Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2014.10.211","https://doi.org/10.1016/j.orcp.2014.10.211",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047275","R0047275.pdf","paywalled","randomized_trial","O Adetunji","2014","A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0034-1374980","https://doi.org/10.1055/s-0034-1374980",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047662","R0047662.pdf","paywalled","randomized_trial","Christopher JL Kueh","2014","Taspoglutide","Practical Diabetes","Wiley","10.1002/pdi.1911","https://doi.org/10.1002/pdi.1911",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048407","R0048407.pdf","paywalled","randomized_trial","Matthew James Armstrong","2014","Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial","The Lancet","Elsevier BV","10.1016/s0140-6736(14)60284-1","https://doi.org/10.1016/s0140-6736(14)60284-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048530","R0048530.pdf","paywalled","randomized_trial","James Conway","2014","Efficacy and Safety of Liraglutide vs. Placebo When Added to Basal Insulin Analogues in Subjects with Type 2 Diabetes (LIRA-ADD2BASAL): A Randomized, Placebo-Controlled Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2014.07.017","https://doi.org/10.1016/j.jcjd.2014.07.017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049120","R0049120.pdf","paywalled","randomized_trial","Chantal Mathieu","2014","OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/s0168-8227(14)70266-9","https://doi.org/10.1016/s0168-8227(14)70266-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049581","R0049581.pdf","paywalled","randomized_trial","Natalia N. Rudovich","2014","Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance","Diabetes Care","American Diabetes Association","10.2337/dc14-1452","https://doi.org/10.2337/dc14-1452","25538323","https://pubmed.ncbi.nlm.nih.gov/25538323/",null,null],["2","R0049788","R0049788.pdf","paywalled","randomized_trial","Robert Charles Andrews","2014","‘Bariatric surgery for type 2 diabetes always produces a good outcome’","Practical Diabetes","Wiley","10.1002/pdi.1907","https://doi.org/10.1002/pdi.1907",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050004","R0050004.pdf","paywalled","randomized_trial","John Reyes Ussher","2014","Deciphering ventricular GLP-1 action: time for a change of heart","American Journal of Physiology-Heart and Circulatory Physiology","American Physiological Society","10.1152/ajpheart.00680.2014","https://doi.org/10.1152/ajpheart.00680.2014","25260609","https://pubmed.ncbi.nlm.nih.gov/25260609/",null,null],["2","R0050183","R0050183.pdf","paywalled","randomized_trial","Andrew Ahmann","2014","PO410 EFFICACY AND SAFETY OF LIRAGLUTIDE VS PLACEBO WHEN ADDED TO BASAL INSULIN ANALOGUES IN SUBJECTS WITH TYPE 2 DIABETES (LIRA-ADD2BASAL): A RANDOMISED, PLACEBO-CONTROLLED TRIAL","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/s0168-8227(14)70704-1","https://doi.org/10.1016/s0168-8227(14)70704-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051198","R0051198.pdf","paywalled","randomized_trial","Shireene Ratna Vethakkan","2014","The Incretin Response After Successful Islet Transplantation","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000437565.15965.67","https://doi.org/10.1097/01.tp.0000437565.15965.67","24434489","https://pubmed.ncbi.nlm.nih.gov/24434489/",null,null],["2","R0051975","R0051975.pdf","paywalled","randomized_trial","Carol Wysham","2014","Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167","Diabetes Care","American Diabetes Association","10.2337/dc14-er10","https://doi.org/10.2337/dc14-er10",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051997","R0051997.pdf","paywalled","randomized_trial","Joseph Proietto","2014","Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2014.10.210","https://doi.org/10.1016/j.orcp.2014.10.210",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056879","R0056879.pdf","paywalled","randomized_trial","Heruc GA","2014","Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00370.2014","https://doi.org/10.1152/ajpendo.00370.2014","25231186","https://pubmed.ncbi.nlm.nih.gov/25231186/",null,null],["2","R0022959","R0022959.pdf","paywalled","randomized_trial","Boland CL","2013","Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1r444","https://doi.org/10.1345/aph.1r444","23548652","https://pubmed.ncbi.nlm.nih.gov/23548652/",null,null],["2","R0024336","R0024336.pdf","paywalled","randomized_trial","Wysham C","2013","Once weekly exenatide: efficacy, tolerability and place in therapy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12084","https://doi.org/10.1111/dom.12084","23425609","https://pubmed.ncbi.nlm.nih.gov/23425609/",null,null],["2","R0024668","R0024668.pdf","paywalled","randomized_trial","Scheen A","2013","Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.","Expert opinion on drug safety","Informa Healthcare","10.1517/14740338.2013.793671","https://doi.org/10.1517/14740338.2013.793671","23621381","https://pubmed.ncbi.nlm.nih.gov/23621381/",null,null],["2","R0025014","R0025014.pdf","paywalled","randomized_trial","Khan MA","2013","Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-012-9318-y","https://doi.org/10.1007/s10741-012-9318-y","22570104","https://pubmed.ncbi.nlm.nih.gov/22570104/",null,null],["2","R0025052","R0025052.pdf","paywalled","randomized_trial","Pratley RE","2013","Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12009","https://doi.org/10.1111/dom.12009","22958426","https://pubmed.ncbi.nlm.nih.gov/22958426/",null,null],["2","R0025121","R0025121.pdf","paywalled","randomized_trial","Hollander P","2013","Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.20042","https://doi.org/10.1002/oby.20042","23404788","https://pubmed.ncbi.nlm.nih.gov/23404788/",null,null],["2","R0026580","R0026580.pdf","paywalled","randomized_trial","Derosa G","2013","Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.","Pharmacotherapy","Wiley","10.1002/phar.1301","https://doi.org/10.1002/phar.1301","23744726","https://pubmed.ncbi.nlm.nih.gov/23744726/",null,null],["2","R0026706","R0026706.pdf","paywalled","randomized_trial","Derosa G","2013","Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.","Canadian journal of physiology and pharmacology","Canadian Science Publishing","10.1139/cjpp-2012-0300","https://doi.org/10.1139/cjpp-2012-0300","23984793","https://pubmed.ncbi.nlm.nih.gov/23984793/",null,null],["2","R0026790","R0026790.pdf","paywalled","randomized_trial","Christensen ST","2013","Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.","Journal of patient safety","Ovid Technologies (Wolters Kluwer Health)","10.1097/pts.0000000000000054","https://doi.org/10.1097/pts.0000000000000054","24257065","https://pubmed.ncbi.nlm.nih.gov/24257065/",null,null],["2","R0027057","R0027057.pdf","paywalled","randomized_trial","Campbell-Scherer DL","2013","Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride.","Evidence-based medicine","BMJ","10.1136/eb-2013-101248","https://doi.org/10.1136/eb-2013-101248","23474698","https://pubmed.ncbi.nlm.nih.gov/23474698/",null,null],["2","R0027122","R0027122.pdf","paywalled","randomized_trial","Idris I","2013","Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea.","Journal of sleep research","Wiley","10.1111/j.1365-2869.2012.01030.x","https://doi.org/10.1111/j.1365-2869.2012.01030.x","22716195","https://pubmed.ncbi.nlm.nih.gov/22716195/",null,null],["2","R0027698","R0027698.pdf","paywalled","randomized_trial","Liang Z","2013","Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2013.04.005","https://doi.org/10.1016/j.diabres.2013.04.005","23706413","https://pubmed.ncbi.nlm.nih.gov/23706413/",null,null],["2","R0027856","R0027856.pdf","paywalled","randomized_trial","Herrmann BL","2013","Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0033-1334905","https://doi.org/10.1055/s-0033-1334905","23512415","https://pubmed.ncbi.nlm.nih.gov/23512415/",null,null],["2","R0027897","R0027897.pdf","paywalled","randomized_trial","Grimm M","2013","Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2013.09.2704","https://doi.org/10.3810/pgm.2013.09.2704","24113668","https://pubmed.ncbi.nlm.nih.gov/24113668/",null,null],["2","R0028028","R0028028.pdf","paywalled","randomized_trial","Aviles-Olmos I","2013","Parkinson's disease, insulin resistance and novel agents of neuroprotection.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/aws009","https://doi.org/10.1093/brain/aws009","22344583","https://pubmed.ncbi.nlm.nih.gov/22344583/",null,null],["2","R0030478","R0030478.pdf","paywalled","randomized_trial","George P","2013","Potential role of non-insulin adjunct therapy in Type 1 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03744.x","https://doi.org/10.1111/j.1464-5491.2012.03744.x","22804102","https://pubmed.ncbi.nlm.nih.gov/22804102/",null,null],["2","R0031038","R0031038.pdf","paywalled","randomized_trial","Yuanxing Yang","2013","Effect of glucagon-like peptide-1 agonist on expression of glucose transporter 4 in the skeletal muscle of rats with impaired glucose tolerance","Chin J Endocr Surg",null,"10.3760/cma.j.issn.1674-6090.2013.03.004","https://doi.org/10.3760/cma.j.issn.1674-6090.2013.03.004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031057","R0031057.pdf","paywalled","randomized_trial","Rui Chen","2013","Efficacy and safety of liraglutide versus insulin in overweight and obese patients with type 2 diabetes mellitus","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2013.05.005","https://doi.org/10.3760/cma.j.issn.1674-5809.2013.05.005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031527","R0031527.pdf","paywalled","randomized_trial","Jeffrey S. Freeman","2013","Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies","Osteopathic Family Physician","The American College of Osteopathic Family Physicians - ACOFP","10.1016/j.osfp.2012.11.001","https://doi.org/10.1016/j.osfp.2012.11.001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035819","R0035819.pdf","paywalled","randomized_trial","Andrew J. Krentz","2013","Diabetes UK, March 2013, Manchester, UK","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0b013e328361ec9b","https://doi.org/10.1097/xce.0b013e328361ec9b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ISRCTN:ISRCTN34875079"],["2","R0043674","R0043674.pdf","paywalled","randomized_trial","Manu V. Venkat","2013","Journal of Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12094","https://doi.org/10.1111/1753-0407.12094","24112456","https://pubmed.ncbi.nlm.nih.gov/24112456/",null,null],["2","R0047159","R0047159.pdf","paywalled","randomized_trial","Robert R. Henry","2013","Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36:2559–2565","Diabetes Care","American Diabetes Association","10.2337/dc14-er01b","https://doi.org/10.2337/dc14-er01b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047555","R0047555.pdf","paywalled","randomized_trial","John B. Buse","2013","1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR)","Nederlands Tijdschrift voor Diabetologie","Springer Science and Business Media LLC","10.1007/s12467-013-0026-6","https://doi.org/10.1007/s12467-013-0026-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050324","R0050324.pdf","paywalled","randomized_trial","Jessica K. Devin","2013","Abstract 95: Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.62.suppl_1.a95","https://doi.org/10.1161/hyp.62.suppl_1.a95",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050744","R0050744.pdf","paywalled","randomized_trial","David Carty","2013","Cardiovascular safety and GLP‐1 receptor agonists","Practical Diabetes","Wiley","10.1002/pdi.1785","https://doi.org/10.1002/pdi.1785",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052286","R0052286.pdf","paywalled","randomized_trial","Ulrik Madvig Mogensen","2013","DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/eht311.5929","https://doi.org/10.1093/eurheartj/eht311.5929",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052648","R0052648.pdf","paywalled","randomized_trial","Wayne Kuznar","2013","Fixed-Ratio Combination of Insulin Degludec and Liraglutide Improves Glycemic Control in Type 2 Diabetes","MD Conference Express","CLOCKSS Archive","10.1177/155989771317015","https://doi.org/10.1177/155989771317015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053327","R0053327.pdf","paywalled","randomized_trial","Camilla Hage","2013","The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/eht309.p4289","https://doi.org/10.1093/eurheartj/eht309.p4289",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054745","R0054745.pdf","paywalled","randomized_trial","Julio Rosenstock","2013","Cardiovascular Effects of Diabetes Drugs: Making the Dark Ages Brighter With CAROLINA","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-158-6-201303190-00017","https://doi.org/10.7326/0003-4819-158-6-201303190-00017","23553039","https://pubmed.ncbi.nlm.nih.gov/23553039/",null,null],["2","R0056855","R0056855.pdf","paywalled","randomized_trial","González-Ortiz M","2013","Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2013.0020","https://doi.org/10.1089/dia.2013.0020","23617250","https://pubmed.ncbi.nlm.nih.gov/23617250/",null,null],["2","R0014109","R0014109.pdf","paywalled","randomized_trial","Consoli A","2012","[Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/1203.13333","https://doi.org/10.1714/1203.13333","23258125","https://pubmed.ncbi.nlm.nih.gov/23258125/",null,null],["2","R0016673","R0016673.pdf","paywalled","randomized_trial","Keller J","2012","Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.","Regulatory peptides","Elsevier BV","10.1016/j.regpep.2012.08.005","https://doi.org/10.1016/j.regpep.2012.08.005","22960288","https://pubmed.ncbi.nlm.nih.gov/22960288/",null,null],["2","R0016784","R0016784.pdf","paywalled","randomized_trial","Tzefos M","2012","Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1q379","https://doi.org/10.1345/aph.1q379","22232377","https://pubmed.ncbi.nlm.nih.gov/22232377/",null,null],["2","R0017605","R0017605.pdf","paywalled","randomized_trial","Jendle J","2012","Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.","Expert opinion on investigational drugs","Informa Healthcare","10.1517/13543784.2012.707190","https://doi.org/10.1517/13543784.2012.707190","22799463","https://pubmed.ncbi.nlm.nih.gov/22799463/",null,null],["2","R0026586","R0026586.pdf","paywalled","randomized_trial","Moreno JL","2012","Exenatide as a novel weight loss modality in patients without diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1r372","https://doi.org/10.1345/aph.1r372","23191935","https://pubmed.ncbi.nlm.nih.gov/23191935/",null,null],["2","R0026672","R0026672.pdf","paywalled","randomized_trial","Derosa G","2012","Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03699.x","https://doi.org/10.1111/j.1464-5491.2012.03699.x","22540883","https://pubmed.ncbi.nlm.nih.gov/22540883/",null,null],["2","R0026763","R0026763.pdf","paywalled","randomized_trial","Murphy CE","2012","Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1q722","https://doi.org/10.1345/aph.1q722","22669803","https://pubmed.ncbi.nlm.nih.gov/22669803/",null,null],["2","R0026956","R0026956.pdf","paywalled","randomized_trial","Shi S","2012","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.","Arzneimittel-Forschung","Georg Thieme Verlag KG","10.1055/s-0031-1295484","https://doi.org/10.1055/s-0031-1295484","22344551","https://pubmed.ncbi.nlm.nih.gov/22344551/",null,null],["2","R0027079","R0027079.pdf","paywalled","randomized_trial","Ha SJ","2012","Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.","Arteriosclerosis, thrombosis, and vascular biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvbaha.110.222653","https://doi.org/10.1161/atvbaha.110.222653","22155457","https://pubmed.ncbi.nlm.nih.gov/22155457/",null,null],["2","R0027101","R0027101.pdf","paywalled","randomized_trial","Pencek R","2012","Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep11306.or","https://doi.org/10.4158/ep11306.or","22446132","https://pubmed.ncbi.nlm.nih.gov/22446132/",null,null],["2","R0027886","R0027886.pdf","paywalled","randomized_trial","Pencek R","2012","Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2012.07.2568","https://doi.org/10.3810/pgm.2012.07.2568","22913892","https://pubmed.ncbi.nlm.nih.gov/22913892/",null,null],["2","R0028059","R0028059.pdf","paywalled","randomized_trial","Keating GM","2012","Insulin detemir: a review of its use in the management of diabetes mellitus.","Drugs","Springer Science and Business Media LLC","10.2165/11470200-000000000-00000","https://doi.org/10.2165/11470200-000000000-00000","23110609","https://pubmed.ncbi.nlm.nih.gov/23110609/",null,null],["2","R0028318","R0028318.pdf","paywalled","randomized_trial","Hausenloy DJ","2012","Taking lizard saliva to heart.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehr382","https://doi.org/10.1093/eurheartj/ehr382","21992997","https://pubmed.ncbi.nlm.nih.gov/21992997/",null,null],["2","R0030812","R0030812.pdf","paywalled","randomized_trial","Allan S. Brett","2012","Once-Weekly Exenatide for Type 2 Diabetes","Journal watch",null,"10.1056/jw201202160000002","https://doi.org/10.1056/jw201202160000002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030898","R0030898.pdf","paywalled","randomized_trial","Allan S. Brett","2012","Once-Weekly Exenatide: An 84-Week Study","Journal watch",null,"10.1056/jw201204260000003","https://doi.org/10.1056/jw201204260000003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034554","R0034554.pdf","paywalled","randomized_trial","Dongjuan Wang","2012","Abstract 8993: Protective Effects of Glucagon-like Peptide-1 on Cardiac Microvessels Injury via cAMP/PKA/Rho Dependent Pathway in Diabetic Rats","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.126.suppl_21.a8993","https://doi.org/10.1161/circ.126.suppl_21.a8993",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035798","R0035798.pdf","paywalled","randomized_trial","Gerardo Sarno","2012","Tailored Antidiabetic Therapy","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0b013e318260b218","https://doi.org/10.1097/tp.0b013e318260b218",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01002339; ClinicalTrials.gov:NCT01265537"],["2","R0035822","R0035822.pdf","paywalled","randomized_trial",null,"2012","All you need to read in the other general journals","BMJ","BMJ","10.1136/bmj.e4055","https://doi.org/10.1136/bmj.e4055",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041125","R0041125.pdf","paywalled","randomized_trial","Richard P. Shannon","2012","Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartj/sus001","https://doi.org/10.1093/eurheartj/sus001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043192","R0043192.pdf","paywalled","randomized_trial","Elaine Hui","2012","Evaluation of glycaemic control and diabetes treatment strategies during the religious fasting period of Ramadan","Spiral (Imperial College London)",null,"10.25560/13695","https://doi.org/10.25560/13695",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044791","R0044791.pdf","paywalled","randomized_trial","Michael S. Lauer","2012","Lemons for Obesity","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-157-2-201207170-00438","https://doi.org/10.7326/0003-4819-157-2-201207170-00438","22801677","https://pubmed.ncbi.nlm.nih.gov/22801677/",null,null],["2","R0048063","R0048063.pdf","paywalled","randomized_trial","Zin Zin Htike","2012","Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors","Clinical Practice","OMICS Publishing Group","10.2217/cpr.11.132","https://doi.org/10.2217/cpr.11.132",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049317","R0049317.pdf","paywalled","randomized_trial","Muhammad A Abdul‐Ghani","2012","How to treat diabetes in Arabs: A rational approach based upon the pathogenesis of the disease","Qatar Foundation Annual Research Forum Volume 2012 Issue 1","Hamad bin Khalifa University Press (HBKU Press)","10.5339/qfarf.2012.bmo1","https://doi.org/10.5339/qfarf.2012.bmo1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051371","R0051371.pdf","paywalled","randomized_trial","David B Haslam","2012","Management of diabesity in primary care: individualisation of care","Practical Diabetes","Wiley","10.1002/pdi.1717","https://doi.org/10.1002/pdi.1717",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052278","R0052278.pdf","paywalled","randomized_trial","William M. Steinberg","2012","Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide","Gastroenterology","Elsevier BV","10.1016/s0016-5085(12)63296-x","https://doi.org/10.1016/s0016-5085(12)63296-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0018333","R0018333.pdf","paywalled","randomized_trial","Linnebjerg H","2011","A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cp201462","https://doi.org/10.5414/cp201462","21961484","https://pubmed.ncbi.nlm.nih.gov/21961484/",null,null],["2","R0018585","R0018585.pdf","paywalled","randomized_trial","Fadini GP","2011","The metabolic syndrome influences the response to incretin-based therapies.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-011-0296-7","https://doi.org/10.1007/s00592-011-0296-7","21574000","https://pubmed.ncbi.nlm.nih.gov/21574000/",null,null],["2","R0019618","R0019618.pdf","paywalled","randomized_trial","Charbonnel B","2011","Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01317.x","https://doi.org/10.1111/j.1463-1326.2010.01317.x","21199262","https://pubmed.ncbi.nlm.nih.gov/21199262/",null,null],["2","R0019995","R0019995.pdf","paywalled","randomized_trial","Neumiller JJ","2011","Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.04.024","https://doi.org/10.1016/j.clinthera.2011.04.024","21665041","https://pubmed.ncbi.nlm.nih.gov/21665041/",null,null],["2","R0021013","R0021013.pdf","paywalled","randomized_trial","Ryan GJ","2011","Review of the therapeutic uses of liraglutide.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.06.004","https://doi.org/10.1016/j.clinthera.2011.06.004","21741090","https://pubmed.ncbi.nlm.nih.gov/21741090/",null,null],["2","R0021931","R0021931.pdf","paywalled","randomized_trial","Anagnostis P","2011","Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01345.x","https://doi.org/10.1111/j.1463-1326.2010.01345.x","21205117","https://pubmed.ncbi.nlm.nih.gov/21205117/",null,null],["2","R0021979","R0021979.pdf","paywalled","randomized_trial","Hellström PM","2011","GLP-1 playing the role of a gut regulatory compound.","Acta physiologica (Oxford, England)","Wiley","10.1111/j.1748-1716.2010.02150.x","https://doi.org/10.1111/j.1748-1716.2010.02150.x","20518750","https://pubmed.ncbi.nlm.nih.gov/20518750/",null,null],["2","R0022082","R0022082.pdf","paywalled","randomized_trial","Perry CM","2011","Liraglutide: a review of its use in the management of type 2 diabetes mellitus.","Drugs","Springer Science and Business Media LLC","10.2165/11208110-000000000-00000","https://doi.org/10.2165/11208110-000000000-00000","22085389","https://pubmed.ncbi.nlm.nih.gov/22085389/",null,null],["2","R0022263","R0022263.pdf","paywalled","randomized_trial","Bunck MC","2011","Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01355.x","https://doi.org/10.1111/j.1463-1326.2010.01355.x","21205127","https://pubmed.ncbi.nlm.nih.gov/21205127/",null,null],["2","R0023569","R0023569.pdf","paywalled","randomized_trial","Wilding JP","2011","Glucagon-like peptide-1 analogues for type 2 diabetes.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.d410","https://doi.org/10.1136/bmj.d410","21325387","https://pubmed.ncbi.nlm.nih.gov/21325387/",null,null],["2","R0023649","R0023649.pdf","paywalled","randomized_trial","Lee WC","2011","Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2011.559444","https://doi.org/10.1185/03007995.2011.559444","21348806","https://pubmed.ncbi.nlm.nih.gov/21348806/",null,null],["2","R0023946","R0023946.pdf","paywalled","randomized_trial","Umpierrez GE","2011","The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01366.x","https://doi.org/10.1111/j.1463-1326.2011.01366.x","21251180","https://pubmed.ncbi.nlm.nih.gov/21251180/",null,null],["2","R0024260","R0024260.pdf","paywalled","randomized_trial","Goodall G","2011","[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","Elsevier BV","10.1016/j.endonu.2011.04.005","https://doi.org/10.1016/j.endonu.2011.04.005","21719364","https://pubmed.ncbi.nlm.nih.gov/21719364/",null,null],["2","R0025444","R0025444.pdf","paywalled","randomized_trial","Viereck C","2011","An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2011.01.009","https://doi.org/10.1016/j.cct.2011.01.009","21266202","https://pubmed.ncbi.nlm.nih.gov/21266202/",null,null],["2","R0025470","R0025470.pdf","paywalled","randomized_trial","DeFronzo RA","2011","Preservation of β-cell function: the key to diabetes prevention.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-0246","https://doi.org/10.1210/jc.2011-0246","21697254","https://pubmed.ncbi.nlm.nih.gov/21697254/",null,null],["2","R0026724","R0026724.pdf","paywalled","randomized_trial","Hirsch IB","2011","Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep11014.or","https://doi.org/10.4158/ep11014.or","21856602","https://pubmed.ncbi.nlm.nih.gov/21856602/",null,null],["2","R0026759","R0026759.pdf","paywalled","randomized_trial","Gilor C","2011","The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.","Domestic animal endocrinology","Elsevier BV","10.1016/j.domaniend.2011.03.001","https://doi.org/10.1016/j.domaniend.2011.03.001","21645806","https://pubmed.ncbi.nlm.nih.gov/21645806/",null,null],["2","R0026805","R0026805.pdf","paywalled","randomized_trial","Linnebjerg H","2011","Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cp201361","https://doi.org/10.5414/cp201361","21255526","https://pubmed.ncbi.nlm.nih.gov/21255526/",null,null],["2","R0026918","R0026918.pdf","paywalled","randomized_trial","Derosa G","2011","Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2011.05.051","https://doi.org/10.1016/j.ejphar.2011.05.051","21645507","https://pubmed.ncbi.nlm.nih.gov/21645507/",null,null],["2","R0027133","R0027133.pdf","paywalled","randomized_trial","Wu JD","2011","Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2010.0048","https://doi.org/10.1089/dia.2010.0048","21284481","https://pubmed.ncbi.nlm.nih.gov/21284481/",null,null],["2","R0027581","R0027581.pdf","paywalled","randomized_trial","Gustavson SM","2011","Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01479.x","https://doi.org/10.1111/j.1463-1326.2011.01479.x","21812891","https://pubmed.ncbi.nlm.nih.gov/21812891/",null,null],["2","R0028332","R0028332.pdf","paywalled","randomized_trial","Nathan DM","2011","Time for clinically relevant comparative effectiveness studies in type 2 diabetes.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-154-2-201101180-00303","https://doi.org/10.7326/0003-4819-154-2-201101180-00303","21135287","https://pubmed.ncbi.nlm.nih.gov/21135287/",null,null],["2","R0030842","R0030842.pdf","paywalled","randomized_trial","Jianjia Jiang","2011","Efficacy and safety of exenatide versus insulin in patients with inadequately glycemic controlled obese type 2 diabetes with oral antidiabetic agents","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2011.04.008","https://doi.org/10.3760/cma.j.issn.1674-5809.2011.04.008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031053","R0031053.pdf","paywalled","randomized_trial","Xiaoli Li","2011","Effects of glucagon-like peptide-1 receptor agonists on apoptosis of pancreatic β cells in impaired glucose tolerance rats","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2011.06.009","https://doi.org/10.3760/cma.j.issn.1674-5809.2011.06.009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031089","R0031089.pdf","paywalled","randomized_trial","Wenying Yang","2011","Comparison of efficacy and safety of liraglutide and glimepiride in combination with metformin in type 2 diabetes","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2011.06.004","https://doi.org/10.3760/cma.j.issn.1674-5809.2011.06.004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031507","R0031507.pdf","paywalled","randomized_trial","Wendy L. Bennett","2011","An Update on Comparative Effectiveness and Safety of Medications for Type 2 Diabetes","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-155-8-201110180-00021","https://doi.org/10.7326/0003-4819-155-8-201110180-00021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036486","R0036486.pdf","paywalled","randomized_trial","Hidekatsu Yanai","2011","Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes","Journal of Endocrinology and Metabolism",null,"10.4021/jem.v1i3.38","https://doi.org/10.4021/jem.v1i3.38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037140","R0037140.pdf","paywalled","randomized_trial","Robert E. J. Ryder","2011","Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes","The British Journal of Diabetes","SAGE Publications","10.1177/1474651411412658","https://doi.org/10.1177/1474651411412658",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037239","R0037239.pdf","paywalled","randomized_trial","Yutaka Seino","2011","Understanding the Incretin Effect","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/jc.2011-0329","https://doi.org/10.1210/jc.2011-0329","21474688","https://pubmed.ncbi.nlm.nih.gov/21474688/",null,null],["2","R0046465","R0046465.pdf","paywalled","randomized_trial","M‐F Kong","2011","‘Insulin should be prescribed at the outset of diagnosis of type 2 diabetes’","Practical Diabetes","Wiley","10.1002/pdi.1564","https://doi.org/10.1002/pdi.1564",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050813","R0050813.pdf","paywalled","randomized_trial","Samia Barbouch","2011","Réaction chronique du greffon contre l’hôte et atteinte rénale","Néphrologie & Thérapeutique","JLE","10.1016/j.nephro.2011.07.391","https://doi.org/10.1016/j.nephro.2011.07.391",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051996","R0051996.pdf","paywalled","randomized_trial","J. K. Dowman","2011","The diagnosis of non‐alcoholic fatty liver disease: authors' reply","Alimentary Pharmacology & Therapeutics","Wiley","10.1111/j.1365-2036.2011.04917.x","https://doi.org/10.1111/j.1365-2036.2011.04917.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052228","R0052228.pdf","paywalled","randomized_trial","Benjamin M. Kozak","2011","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/j.1753-0407.2011.00180.x","https://doi.org/10.1111/j.1753-0407.2011.00180.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052734","R0052734.pdf","paywalled","randomized_trial","PHILIP A. LEVIN","2011","Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting","F1000Research",null,"10.7490/f1000research.1089301.1","https://doi.org/10.7490/f1000research.1089301.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053352","R0053352.pdf","paywalled","randomized_trial","D Lee","2011","Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, 2 and 3","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0031-1277484","https://doi.org/10.1055/s-0031-1277484",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053716","R0053716.pdf","paywalled","randomized_trial","Mathijs C. M. Bunck","2011","Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on β-cell disposition index in metformin treated patients with type 2 diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0031-1277490","https://doi.org/10.1055/s-0031-1277490",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0016409","R0016409.pdf","paywalled","randomized_trial","Drab SR","2010","Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.","Pharmacotherapy","Wiley","10.1592/phco.30.6.609","https://doi.org/10.1592/phco.30.6.609","20500049","https://pubmed.ncbi.nlm.nih.gov/20500049/",null,null],["2","R0023270","R0023270.pdf","paywalled","randomized_trial","Derosa G","2010","Exenatide versus glibenclamide in patients with diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2009.0141","https://doi.org/10.1089/dia.2009.0141","20151774","https://pubmed.ncbi.nlm.nih.gov/20151774/",null,null],["2","R0026903","R0026903.pdf","paywalled","randomized_trial","Blevins T","2010","Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2010.05.2149","https://doi.org/10.3810/pgm.2010.05.2149","20463421","https://pubmed.ncbi.nlm.nih.gov/20463421/",null,null],["2","R0027244","R0027244.pdf","paywalled","randomized_trial","Apovian CM","2010","Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2009.11.019","https://doi.org/10.1016/j.amjmed.2009.11.019","20399326","https://pubmed.ncbi.nlm.nih.gov/20399326/",null,null],["2","R0027382","R0027382.pdf","paywalled","randomized_trial","Kress S","2010","[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0030-1253676","https://doi.org/10.1055/s-0030-1253676","20425675","https://pubmed.ncbi.nlm.nih.gov/20425675/",null,null],["2","R0031729","R0031729.pdf","paywalled","randomized_trial","Sven Schinner","2010","Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","Yearbook of Endocrinology","Elsevier BV","10.1016/s0084-3741(10)79449-x","https://doi.org/10.1016/s0084-3741(10)79449-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039481","R0039481.pdf","paywalled","randomized_trial",null,"2010","Liraglutide: A Review of its Use in the Treatment of Diabetes Mellitus","Clinical Medicine Reviews in Vascular Health","Portico","10.4137/cmrvh.s1652","https://doi.org/10.4137/cmrvh.s1652",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039532","R0039532.pdf","paywalled","randomized_trial","Matthew C. Riddle","2010","More Reasons to Say Goodbye to Glyburide","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/jc.2010-1972","https://doi.org/10.1210/jc.2010-1972","21051583","https://pubmed.ncbi.nlm.nih.gov/21051583/",null,null],["2","R0048488","R0048488.pdf","paywalled","randomized_trial","Abd A. Tahrani","2010","Liraglutide, a new diabetes treatment approved by NICE","Practical Diabetes","Wiley","10.1002/pdi.1526","https://doi.org/10.1002/pdi.1526",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048919","R0048919.pdf","paywalled","randomized_trial","Benjamin M. Kozak","2010","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/j.1753-0407.2010.00104.x","https://doi.org/10.1111/j.1753-0407.2010.00104.x","21138543","https://pubmed.ncbi.nlm.nih.gov/21138543/",null,null],["2","R0049740","R0049740.pdf","paywalled","randomized_trial","Patrick J Kenny","2010","Exenatide in the Treatment of Diabetic Patients with Non-Alcoholic Steatohepatitis - A Pilot Study: 2010 Presidential Poster","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/00000434-201010001-00242","https://doi.org/10.14309/00000434-201010001-00242",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049837","R0049837.pdf","paywalled","randomized_trial","Eric M. Chang","2010","Journal of Diabetes News","Journal of Diabetes","Wiley","10.1111/j.1753-0407.2010.00075.x","https://doi.org/10.1111/j.1753-0407.2010.00075.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051206","R0051206.pdf","paywalled","randomized_trial","Karen T. Chang","2010","Diabetes Medication Choice cards improve patient knowledge and involvement in decision-making, but do not improve medication adherence or glycaemic control","Evidence-Based Nursing","BMJ","10.1136/ebn1023","https://doi.org/10.1136/ebn1023","20179069","https://pubmed.ncbi.nlm.nih.gov/20179069/",null,null],["2","R0052469","R0052469.pdf","paywalled","randomized_trial","Rosane Ness-Abramof","2010","Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","Yearbook of Endocrinology","Elsevier BV","10.1016/s0084-3741(10)79555-x","https://doi.org/10.1016/s0084-3741(10)79555-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0023251","R0023251.pdf","paywalled","randomized_trial","Kapitza C","2009","Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2009.02854.x","https://doi.org/10.1111/j.1464-5491.2009.02854.x","19929995","https://pubmed.ncbi.nlm.nih.gov/19929995/",null,null],["2","R0025883","R0025883.pdf","paywalled","randomized_trial","Hellström PM","2009","Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.","Alimentary pharmacology & therapeutics","Wiley","10.1111/j.1365-2036.2008.03870.x","https://doi.org/10.1111/j.1365-2036.2008.03870.x","18945254","https://pubmed.ncbi.nlm.nih.gov/18945254/",null,null],["2","R0026730","R0026730.pdf","paywalled","randomized_trial","Bush MA","2009","Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2008.00992.x","https://doi.org/10.1111/j.1463-1326.2008.00992.x","19187286","https://pubmed.ncbi.nlm.nih.gov/19187286/",null,null],["2","R0027272","R0027272.pdf","paywalled","randomized_trial","Linnebjerg H","2009","The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cpp47651","https://doi.org/10.5414/cpp47651","19840529","https://pubmed.ncbi.nlm.nih.gov/19840529/",null,null],["2","R0027311","R0027311.pdf","paywalled","randomized_trial","Sullivan SD","2009","A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.","Pharmacotherapy","Wiley","10.1592/phco.29.11.1280","https://doi.org/10.1592/phco.29.11.1280","19873688","https://pubmed.ncbi.nlm.nih.gov/19873688/",null,null],["2","R0027377","R0027377.pdf","paywalled","randomized_trial","Mittendorf T","2009","Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01099.x","https://doi.org/10.1111/j.1463-1326.2009.01099.x","19732121","https://pubmed.ncbi.nlm.nih.gov/19732121/",null,null],["2","R0027385","R0027385.pdf","paywalled","randomized_trial","Kazda C","2009","The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01091.x","https://doi.org/10.1111/j.1463-1326.2009.01091.x","19758357","https://pubmed.ncbi.nlm.nih.gov/19758357/",null,null],["2","R0027668","R0027668.pdf","paywalled","randomized_trial","Brixner DI","2009","Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01081.x","https://doi.org/10.1111/j.1463-1326.2009.01081.x","19930004","https://pubmed.ncbi.nlm.nih.gov/19930004/",null,null],["2","R0027941","R0027941.pdf","paywalled","randomized_trial","Neumiller JJ","2009","Pharmacologic management of the older patient with type 2 diabetes mellitus.","The American journal of geriatric pharmacotherapy","Elsevier BV","10.1016/j.amjopharm.2009.12.002","https://doi.org/10.1016/j.amjopharm.2009.12.002","20129254","https://pubmed.ncbi.nlm.nih.gov/20129254/",null,null],["2","R0028003","R0028003.pdf","paywalled","randomized_trial","Lerche S","2009","No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.","Clinical endocrinology","Wiley","10.1111/j.1365-2265.2008.03510.x","https://doi.org/10.1111/j.1365-2265.2008.03510.x","19094067","https://pubmed.ncbi.nlm.nih.gov/19094067/",null,"ClinicalTrials.gov:NCT00285896"],["2","R0028362","R0028362.pdf","paywalled","randomized_trial","Adler AI","2009","Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.b1668","https://doi.org/10.1136/bmj.b1668","19465464","https://pubmed.ncbi.nlm.nih.gov/19465464/",null,null],["2","R0030442","R0030442.pdf","paywalled","randomized_trial","Clement S","2009","What are the best options for controlling prandial glycemia?","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-009-0056-z","https://doi.org/10.1007/s11892-009-0056-z","19793505","https://pubmed.ncbi.nlm.nih.gov/19793505/",null,null],["2","R0045726","R0045726.pdf","paywalled","randomized_trial","George Hall","2009","Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?","Anesthesia & Analgesia","Ovid Technologies (Wolters Kluwer Health)","10.1213/ane.0b013e3181a6ad5c","https://doi.org/10.1213/ane.0b013e3181a6ad5c","19448192","https://pubmed.ncbi.nlm.nih.gov/19448192/",null,null],["2","R0048104","R0048104.pdf","paywalled","randomized_trial","Thozhukat Sathyapalan","2009","Effect of rimonabant and metformin on glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 in obese women with polycystic ovary syndrome","Clinical Endocrinology","Wiley","10.1111/j.1365-2265.2009.03643.x","https://doi.org/10.1111/j.1365-2265.2009.03643.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056811","R0056811.pdf","paywalled","randomized_trial","Schirra J","2009","GLP-1 regulates gastroduodenal motility involving cholinergic pathways.","Neurogastroenterology and motility","Wiley","10.1111/j.1365-2982.2008.01246.x","https://doi.org/10.1111/j.1365-2982.2008.01246.x","19220754","https://pubmed.ncbi.nlm.nih.gov/19220754/",null,null],["2","R0019863","R0019863.pdf","paywalled","randomized_trial","Pi-Sunyer FX","2008","The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2008.07.1785","https://doi.org/10.3810/pgm.2008.07.1785","18654064","https://pubmed.ncbi.nlm.nih.gov/18654064/",null,null],["2","R0024252","R0024252.pdf","paywalled","randomized_trial","Aguilar D","2008","Management of type 2 diabetes in patients with heart failure.","Current treatment options in cardiovascular medicine","Springer Science and Business Media LLC","10.1007/s11936-008-0039-4","https://doi.org/10.1007/s11936-008-0039-4","19026177","https://pubmed.ncbi.nlm.nih.gov/19026177/",null,null],["2","R0025349","R0025349.pdf","paywalled","randomized_trial","Schwartz S","2008","Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.","Current medical research and opinion","Informa Healthcare","10.1185/03007990802390795","https://doi.org/10.1185/03007990802390795","18828960","https://pubmed.ncbi.nlm.nih.gov/18828960/",null,null],["2","R0025862","R0025862.pdf","paywalled","randomized_trial","Klonoff DC","2008","Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.","Current medical research and opinion","Informa UK Limited","10.1185/030079908x253870","https://doi.org/10.1185/030079908x253870","18053320","https://pubmed.ncbi.nlm.nih.gov/18053320/",null,null],["2","R0027249","R0027249.pdf","paywalled","randomized_trial","Linnebjerg H","2008","Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.","Regulatory peptides","Elsevier BV","10.1016/j.regpep.2008.07.003","https://doi.org/10.1016/j.regpep.2008.07.003","18675854","https://pubmed.ncbi.nlm.nih.gov/18675854/",null,null],["2","R0027396","R0027396.pdf","paywalled","randomized_trial","Zhao X","2008","Exenatide pharmacokinetics in healthy Chinese subjects.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cpp46459","https://doi.org/10.5414/cpp46459","18793576","https://pubmed.ncbi.nlm.nih.gov/18793576/",null,null],["2","R0027535","R0027535.pdf","paywalled","randomized_trial","Glass LC","2008","Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.","Current medical research and opinion","Informa Healthcare","10.1185/030079908x260862","https://doi.org/10.1185/030079908x260862","18218179","https://pubmed.ncbi.nlm.nih.gov/18218179/",null,null],["2","R0027577","R0027577.pdf","paywalled","randomized_trial","Schwartz SL","2008","Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2008.05.004","https://doi.org/10.1016/j.clinthera.2008.05.004","18555933","https://pubmed.ncbi.nlm.nih.gov/18555933/",null,null],["2","R0027807","R0027807.pdf","paywalled","randomized_trial","Halimi S","2008","[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].","La Revue de medecine interne","Elsevier BV","10.1016/j.revmed.2008.05.011","https://doi.org/10.1016/j.revmed.2008.05.011","18722695","https://pubmed.ncbi.nlm.nih.gov/18722695/",null,null],["2","R0036749","R0036749.pdf","paywalled","randomized_trial","Vasudevan A. Raghavan","2008","Postprandial Hyperglycemia","Humana Press eBooks","Humana Press","10.1007/978-1-60327-043-4_7","https://doi.org/10.1007/978-1-60327-043-4_7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046088","R0046088.pdf","paywalled","randomized_trial","Milan K. Piya","2008","NICE gives rimonabant the green light","Practical Diabetes","Wiley","10.1002/pdi.1284","https://doi.org/10.1002/pdi.1284",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049229","R0049229.pdf","paywalled","randomized_trial","Per M. Hellström","2008","T1388 GTP-010 As a Therapeutic Tool in IBS Pain Relief: Prospective, Randomized, Placebo-Controlled Study of a GLP-1 Analog","Gastroenterology","Elsevier BV","10.1016/s0016-5085(08)62542-1","https://doi.org/10.1016/s0016-5085(08)62542-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055259","R0055259.pdf","paywalled","randomized_trial","Bernard Zinman","2008","Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind Placebo- Controlled Trial.","Canadian Journal of Diabetes","Elsevier BV","10.1016/s1499-2671(08)24115-8","https://doi.org/10.1016/s1499-2671(08)24115-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0023810","R0023810.pdf","paywalled","randomized_trial","Cvetković RS","2007","Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).","Drugs","Springer Science and Business Media LLC","10.2165/00003495-200767060-00008","https://doi.org/10.2165/00003495-200767060-00008","17428109","https://pubmed.ncbi.nlm.nih.gov/17428109/",null,null],["2","R0024753","R0024753.pdf","paywalled","randomized_trial","Sicat BL","2007","New therapeutic options for the management of diabetes.","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","American Society of Consultant Pharmacists","10.4140/tcp.n.2007.45","https://doi.org/10.4140/tcp.n.2007.45","17367252","https://pubmed.ncbi.nlm.nih.gov/17367252/",null,null],["2","R0027409","R0027409.pdf","paywalled","randomized_trial","Kothare PA","2007","Exenatide effects on statin pharmacokinetics and lipid response.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cpp45114","https://doi.org/10.5414/cpp45114","17323791","https://pubmed.ncbi.nlm.nih.gov/17323791/",null,null],["2","R0027571","R0027571.pdf","paywalled","randomized_trial","Barnett AH","2007","Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2007.11.006","https://doi.org/10.1016/j.clinthera.2007.11.006","18158075","https://pubmed.ncbi.nlm.nih.gov/18158075/",null,null],["2","R0027758","R0027758.pdf","paywalled","randomized_trial","Malozowski S","2007","Exenatide in combination therapy: small study, big market, and many unanswered questions.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-146-7-200704030-00009","https://doi.org/10.7326/0003-4819-146-7-200704030-00009","17404355","https://pubmed.ncbi.nlm.nih.gov/17404355/",null,null],["2","R0028060","R0028060.pdf","paywalled","randomized_trial","Vinik A","2007","Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2007.07.005","https://doi.org/10.1016/j.clinthera.2007.07.005","18036387","https://pubmed.ncbi.nlm.nih.gov/18036387/",null,null],["2","R0044987","R0044987.pdf","paywalled","randomized_trial","Cynthia D. Mulrow","2007","Rosiglitazone: A Thunderstorm from Scarce and Fragile Data","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-147-8-200710160-00013","https://doi.org/10.7326/0003-4819-147-8-200710160-00013","17938398","https://pubmed.ncbi.nlm.nih.gov/17938398/",null,null],["2","R0045861","R0045861.pdf","paywalled","randomized_trial","Richard E. Gilbert","2007","Rosiglitazone","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.03470807","https://doi.org/10.2215/cjn.03470807","17928463","https://pubmed.ncbi.nlm.nih.gov/17928463/",null,null],["2","R0048615","R0048615.pdf","paywalled","randomized_trial","LEONARD M. POGACH","2007","“Doctor, How Certain Are We That This Diabetes Medication Is Best for Me?”","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-147-6-200709180-00181","https://doi.org/10.7326/0003-4819-147-6-200709180-00181","17652707","https://pubmed.ncbi.nlm.nih.gov/17652707/",null,null],["2","R0024718","R0024718.pdf","paywalled","randomized_trial","Lam S","2006","Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.crd.0000223655.16253.e4","https://doi.org/10.1097/01.crd.0000223655.16253.e4","16788334","https://pubmed.ncbi.nlm.nih.gov/16788334/",null,null],["2","R0025984","R0025984.pdf","paywalled","randomized_trial","Linnebjerg H","2006","Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2006.01800.x","https://doi.org/10.1111/j.1464-5491.2006.01800.x","16492205","https://pubmed.ncbi.nlm.nih.gov/16492205/",null,null],["2","R0026802","R0026802.pdf","paywalled","randomized_trial","Penfornis A","2006","Immunosuppressive drug-induced diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/s1262-3636(06)72809-9","https://doi.org/10.1016/s1262-3636(06)72809-9","17130815","https://pubmed.ncbi.nlm.nih.gov/17130815/",null,null],["2","R0027495","R0027495.pdf","paywalled","randomized_trial","Yoo BK","2006","Exenatide: a new option for the treatment of type 2 diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1h060","https://doi.org/10.1345/aph.1h060","16985091","https://pubmed.ncbi.nlm.nih.gov/16985091/",null,null],["2","R0027661","R0027661.pdf","paywalled","randomized_trial","Riddle MC","2006","Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.646","https://doi.org/10.1002/dmrr.646","16634116","https://pubmed.ncbi.nlm.nih.gov/16634116/",null,null],["2","R0031234","R0031234.pdf","paywalled","randomized_trial","J.L. Leahy","2006","Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized Trial","Yearbook of Medicine","Elsevier BV","10.1016/s0084-3873(08)70593-5","https://doi.org/10.1016/s0084-3873(08)70593-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046908","R0046908.pdf","paywalled","randomized_trial","Prajakti A. Kothare","2006","PII-39Effects of exenatide on statin single-dose pharmacokinetics and 30-week lipid response","Clinical Pharmacology & Therapeutics","Wiley","10.1016/j.clpt.2005.12.164","https://doi.org/10.1016/j.clpt.2005.12.164",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0022517","R0022517.pdf","paywalled","randomized_trial","Blase E","2005","Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.","Journal of clinical pharmacology","Wiley","10.1177/0091270004274432","https://doi.org/10.1177/0091270004274432","15831781","https://pubmed.ncbi.nlm.nih.gov/15831781/",null,null],["2","R0022751","R0022751.pdf","paywalled","randomized_trial","Calara F","2005","A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2005.02.008","https://doi.org/10.1016/j.clinthera.2005.02.008","15811484","https://pubmed.ncbi.nlm.nih.gov/15811484/",null,null],["2","R0025985","R0025985.pdf","paywalled","randomized_trial","Poon T","2005","Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2005.7.467","https://doi.org/10.1089/dia.2005.7.467","15929678","https://pubmed.ncbi.nlm.nih.gov/15929678/",null,null],["2","R0030536","R0030536.pdf","paywalled","randomized_trial","Roges OA","2005","The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.","Expert opinion on investigational drugs","Informa UK Limited","10.1517/13543784.14.6.705","https://doi.org/10.1517/13543784.14.6.705","16004598","https://pubmed.ncbi.nlm.nih.gov/16004598/",null,null],["2","R0044848","R0044848.pdf","paywalled","randomized_trial","Richard J. Comi","2005","Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-143-8-200510180-00012","https://doi.org/10.7326/0003-4819-143-8-200510180-00012","16230728","https://pubmed.ncbi.nlm.nih.gov/16230728/",null,null],["2","R0052910","R0052910.pdf","paywalled","randomized_trial","Prajakti A. Kothare","2005","Effect of exenatide on lisinopril pharmacodynamics in patients treated for hypertension","Clinical Pharmacology & Therapeutics","Wiley","10.1016/j.clpt.2004.11.056","https://doi.org/10.1016/j.clpt.2004.11.056",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0021304","R0021304.pdf","paywalled","randomized_trial","&NA;","2004","Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.","Drugs in R&D","Springer Science and Business Media LLC","10.2165/00126839-200405010-00007","https://doi.org/10.2165/00126839-200405010-00007","14725490","https://pubmed.ncbi.nlm.nih.gov/14725490/",null,null],["2","R0024149","R0024149.pdf","paywalled","randomized_trial","Fineman MS","2004","Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.499","https://doi.org/10.1002/dmrr.499","15343588","https://pubmed.ncbi.nlm.nih.gov/15343588/",null,null],["2","R0052531","R0052531.pdf","paywalled","randomized_trial","Federico B. Calara","2004","Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4)","Clinical Pharmacology & Therapeutics","Wiley","10.1016/j.clpt.2003.11.221","https://doi.org/10.1016/j.clpt.2003.11.221",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039120","R0039120.pdf","paywalled","randomized_trial","John A. Wagner","2002","Early Clinical Development of Pharmaceuticals for Type 2 Diabetes Mellitus: From Preclinical Models to Human Investigation","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/jc.2002-020910","https://doi.org/10.1210/jc.2002-020910","12466321","https://pubmed.ncbi.nlm.nih.gov/12466321/",null,null],["2","R0031316","R0031316.pdf","paywalled","randomized_trial","Ralph A. DeFronzo","2000","Pharmacologic Therapy for Type 2 Diabetes Mellitus","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-133-1-200007040-00016","https://doi.org/10.7326/0003-4819-133-1-200007040-00016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0028176","R0028176.pdf","paywalled","randomized_trial","Wettergren A","1994","Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.","Scandinavian journal of gastroenterology","Informa UK Limited","10.3109/00365529409092462","https://doi.org/10.3109/00365529409092462","7915853","https://pubmed.ncbi.nlm.nih.gov/7915853/",null,null],["2","R0040646","R0040646.pdf","paywalled","randomized_trial","M Spittle","1981","Breast cancer trials--a new initiative.","BMJ","BMJ","10.1136/bmj.282.6257.68-b","https://doi.org/10.1136/bmj.282.6257.68-b","6778570","https://pubmed.ncbi.nlm.nih.gov/6778570/",null,"PROSPERO:CRD42021271647"],["2","R0039902","R0039902.pdf","paywalled","randomized_trial","William B. Kannel","1964","Risk Factors in Coronary Heart Disease","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-61-5-888","https://doi.org/10.7326/0003-4819-61-5-888","14233810","https://pubmed.ncbi.nlm.nih.gov/14233810/",null,null],["2","R0034154","R0034154.pdf","paywalled","randomized_trial","Mojca Jensterle Sever",null,"Semaglutide and taste in women with obesity and polycystic ovary syndrome","dCOBISS.SI Digital Repository",null,"10.1210/clinem/dgaf278/8127627?redirectedfrom=fulltext#no-access-message","https://doi.org/10.1210/clinem/dgaf278/8127627?redirectedfrom=fulltext#no-access-message",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044572","R0044572.pdf","paywalled","randomized_trial","光彦 奈良",null,"糖尿病性腎臓病のための自己管理支援システム「DialBetesPlus」の有用性に関する無作為化比較試験","Institutional Repositories DataBase (IRDB)",null,"10.20569/0002002064","https://doi.org/10.20569/0002002064",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054948","R0054948.pdf","paywalled","randomized_trial","Antwi, Kwadwo",null,"Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.",null,null,"10.7892/boris.70209","https://doi.org/10.7892/boris.70209",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055186","R0055186.pdf","paywalled","randomized_trial","Shah, Viral N",null,"Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.","Open Access CRIS of the University of Bern",null,"10.48620/77469","https://doi.org/10.48620/77469",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0000010","R0000010.pdf","free_to_read","randomized_trial","Loblundo C","2026","Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","Wiley","10.1002/ohn.70407","https://doi.org/10.1002/ohn.70407","42611692","https://pubmed.ncbi.nlm.nih.gov/42611692/","https://doi.org/10.1002/ohn.70407",null],["2","R0000087","R0000087.pdf","free_to_read","randomized_trial","Zheng C","2026","Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.","Surgery","Elsevier BV","10.1016/j.surg.2026.110369","https://doi.org/10.1016/j.surg.2026.110369","42386418","https://pubmed.ncbi.nlm.nih.gov/42386418/","https://doi.org/10.1016/j.surg.2026.110369",null],["2","R0000112","R0000112.pdf","open_download_failed","randomized_trial","Cutrona M","2026","GLP-1 receptor agonists in psoriasis management.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.09.037","https://doi.org/10.1016/j.clindermatol.2026.09.037","42822650","https://pubmed.ncbi.nlm.nih.gov/42822650/","https://www.sciencedirect.com/science/article/pii/S0738081X26002853/pdf",null],["2","R0000115","R0000115.pdf","free_to_read","randomized_trial","Sulter GA","2026","Glucagon-Like Peptide-1 Receptor Agonists in Chronic Migraine: A Convergent Disease-Modification Hypothesis","Preprints.org","MDPI AG","10.20944/preprints202605.0916.v1","https://doi.org/10.20944/preprints202605.0916.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202605.0916.v1",null],["2","R0000142","R0000142.pdf","open_download_failed","randomized_trial","Silberzweig A","2026","Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Hidradenitis Suppurativa: A Narrative Review of Emerging Evidence.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.09.029","https://doi.org/10.1016/j.clindermatol.2026.09.029","42790605","https://pubmed.ncbi.nlm.nih.gov/42790605/","https://www.sciencedirect.com/science/article/pii/S0738081X26002774/pdf",null],["2","R0000233","R0000233.pdf","free_to_read","randomized_trial","Vergniory-Trueba O","2026","Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy Study","Preprints.org","MDPI AG","10.20944/preprints202608.0314.v1","https://doi.org/10.20944/preprints202608.0314.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202608.0314.v1",null],["2","R0000263","R0000263.pdf","free_to_read","randomized_trial","Rouse M","2026","Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.05.027","https://doi.org/10.1016/j.soard.2026.05.027","42342489","https://pubmed.ncbi.nlm.nih.gov/42342489/","https://doi.org/10.1016/j.soard.2026.05.027",null],["2","R0000278","R0000278.pdf","free_to_read","randomized_trial","Vilsbøll T","2026","Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.","The British journal of ophthalmology","BMJ","10.1136/bjo-2025-328729","https://doi.org/10.1136/bjo-2025-328729","42049287","https://pubmed.ncbi.nlm.nih.gov/42049287/","https://doi.org/10.1136/bjo-2025-328729",null],["2","R0000306","R0000306.pdf","free_to_read","randomized_trial","Lipska D","2026","Glucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetes","medRxiv","openRxiv","10.64898/2026.07.22.26358565","https://doi.org/10.64898/2026.07.22.26358565",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.07.22.26358565",null],["2","R0000334","R0000334.pdf","free_to_read","randomized_trial","Rajan LT","2026","Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag135","https://doi.org/10.1093/ejendo/lvag135","42541759","https://pubmed.ncbi.nlm.nih.gov/42541759/","https://doi.org/10.1093/ejendo/lvag135",null],["2","R0000362","R0000362.pdf","free_to_read","randomized_trial","Al-Ali D","2026","GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.","Experimental gerontology","Elsevier BV","10.1016/j.exger.2026.113325","https://doi.org/10.1016/j.exger.2026.113325","42735804","https://pubmed.ncbi.nlm.nih.gov/42735804/","https://doi.org/10.1016/j.exger.2026.113325",null],["2","R0000399","R0000399.pdf","free_to_read","randomized_trial","Klausen MK","2026","Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence.","Biological psychiatry","Elsevier BV","10.1016/j.biopsych.2026.07.010","https://doi.org/10.1016/j.biopsych.2026.07.010","42486217","https://pubmed.ncbi.nlm.nih.gov/42486217/","https://doi.org/10.1016/j.biopsych.2026.07.010",null],["2","R0000448","R0000448.pdf","open_download_failed","randomized_trial","Mohsen M","2026","Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag163","https://doi.org/10.1210/clinem/dgag163","41973867","https://pubmed.ncbi.nlm.nih.gov/41973867/","https://pubmed.ncbi.nlm.nih.gov/41973867/",null],["2","R0000524","R0000524.pdf","free_to_read","randomized_trial",null,"2026","Tirzepatide (Mounjaro): Indication: For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: Reimbursement Recommendation","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","42771745","https://pubmed.ncbi.nlm.nih.gov/42771745/",null,null],["2","R0000584","R0000584.pdf","free_to_read","randomized_trial","Schrage B","2026","Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.01.055","https://doi.org/10.1016/j.jacc.2026.01.055","41811277","https://pubmed.ncbi.nlm.nih.gov/41811277/","https://doi.org/10.1016/j.jacc.2026.01.055",null],["2","R0000585","R0000585.pdf","free_to_read","randomized_trial","Cunanan ALP","2026","GLP-1 Receptor Agonists in Eating Disorder Recovery","Preprints.org","MDPI AG","10.20944/preprints202609.2026.v1","https://doi.org/10.20944/preprints202609.2026.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.2026.v1",null],["2","R0000589","R0000589.pdf","free_to_read","randomized_trial","Fioretti F","2026","Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.5086","https://doi.org/10.1016/j.jacc.2026.02.5086","42017554","https://pubmed.ncbi.nlm.nih.gov/42017554/","https://eprints.gla.ac.uk/view/author/14153.html>",null],["2","R0000609","R0000609.pdf","open_download_failed","randomized_trial","Volkow ND","2026","Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review.","Biological psychiatry","Elsevier BV","10.1016/j.biopsych.2026.03.1002","https://doi.org/10.1016/j.biopsych.2026.03.1002","41932372","https://pubmed.ncbi.nlm.nih.gov/41932372/","https://pubmed.ncbi.nlm.nih.gov/41932372/",null],["2","R0000628","R0000628.pdf","open_download_failed","randomized_trial","Kennedy KP","2026","GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.","The Journal of clinical psychiatry","Physicians Postgraduate Press, Inc","10.4088/jcp.25m16212","https://doi.org/10.4088/jcp.25m16212","42474323","https://pubmed.ncbi.nlm.nih.gov/42474323/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13527612/",null],["2","R0000645","R0000645.pdf","free_to_read","randomized_trial","Negida Y","2026","Pre-stroke glucagon-like peptide-1 receptor agonist use and outcomes after acute ischemic stroke: a propensity score-matched retrospective cohort study","medRxiv","openRxiv","10.64898/2026.04.29.26352109","https://doi.org/10.64898/2026.04.29.26352109",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.04.29.26352109",null],["2","R0000654","R0000654.pdf","free_to_read","randomized_trial","Danesh-Meyer HV","2026","Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.","Clinical & experimental ophthalmology","Wiley","10.1111/ceo.70096","https://doi.org/10.1111/ceo.70096","42020100","https://pubmed.ncbi.nlm.nih.gov/42020100/","https://doi.org/10.1111/ceo.70096",null],["2","R0000753","R0000753.pdf","open_download_failed","randomized_trial","Alexander GC","2026","Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70076","https://doi.org/10.1002/oby.70076","41271442","https://pubmed.ncbi.nlm.nih.gov/41271442/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70076",null],["2","R0000881","R0000881.pdf","open_download_failed","randomized_trial","Morales JK","2026","The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.","The Journal of clinical and aesthetic dermatology",null,null,"https://doi.org/","41890772","https://pubmed.ncbi.nlm.nih.gov/41890772/",null,null],["2","R0000954","R0000954.pdf","open_download_failed","randomized_trial","Salim H","2026","Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71375","https://doi.org/10.1111/dom.71375","42802242","https://pubmed.ncbi.nlm.nih.gov/42802242/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71375",null],["2","R0001035","R0001035.pdf","free_to_read","randomized_trial","Khan MQ","2026","Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study.","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/lvt.0000000000000917","https://doi.org/10.1097/lvt.0000000000000917","42208060","https://pubmed.ncbi.nlm.nih.gov/42208060/","https://doi.org/10.48620/98268",null],["2","R0001104","R0001104.pdf","free_to_read","randomized_trial","Marwaha A","2026","Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic Burden","Preprints.org","MDPI AG","10.20944/preprints202607.2217.v1","https://doi.org/10.20944/preprints202607.2217.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.2217.v1",null],["2","R0001165","R0001165.pdf","open_download_failed","randomized_trial","Liu D","2026","Pharmacological intersections between type 2 diabetes and cancer: Metabolic crosstalk, antidiabetic therapies and clinical implications.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2026.108456","https://doi.org/10.1016/j.phrs.2026.108456","42753877","https://pubmed.ncbi.nlm.nih.gov/42753877/","https://www.sciencedirect.com/science/article/pii/S1043661826003713/pdf",null],["2","R0001193","R0001193.pdf","free_to_read","randomized_trial","Schmitz SH","2026","GLP-1 receptor agonists for kidney transplant recipients.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfaf199","https://doi.org/10.1093/ndt/gfaf199","41026089","https://pubmed.ncbi.nlm.nih.gov/41026089/","https://ecommons.cornell.edu/items/33caa3f4-dcdc-497f-8c60-907ba71a5a90/request-a-copy?bitstream=801c0449-dd92-4cb4-877e-060506c29251",null],["2","R0001270","R0001270.pdf","open_download_failed","randomized_trial","Prokopidis K","2026","Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.","British journal of pharmacology","Wiley","10.1111/bph.70355","https://doi.org/10.1111/bph.70355","41577337","https://pubmed.ncbi.nlm.nih.gov/41577337/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bph.70355",null],["2","R0001312","R0001312.pdf","open_download_failed","randomized_trial","Singh B","2026","SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2026.122407","https://doi.org/10.1016/j.jad.2026.122407","42632571","https://pubmed.ncbi.nlm.nih.gov/42632571/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13561641/pdf/nihms-2206372.pdf",null],["2","R0001375","R0001375.pdf","open_download_failed","randomized_trial","Sattar N","2026","From adiposity to multisystem morbidity: the case for weight loss as disease modification.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00186-5","https://doi.org/10.1016/s2213-8587(26)00186-5","42660161","https://pubmed.ncbi.nlm.nih.gov/42660161/","https://eprints.gla.ac.uk/390329/1/390329.pdf",null],["2","R0001438","R0001438.pdf","open_download_failed","randomized_trial","Mao C","2026","Glucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review.","The Journal of surgical research","Elsevier BV","10.1016/j.jss.2026.03.080","https://doi.org/10.1016/j.jss.2026.03.080","41990642","https://pubmed.ncbi.nlm.nih.gov/41990642/","https://www.journalofsurgicalresearch.com/article/S0022-4804(26)00192-7/pdf",null],["2","R0001500","R0001500.pdf","free_to_read","randomized_trial","Mah JSY","2026","The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in chronic obstructive pulmonary disease.","Expert review of clinical immunology","Informa UK Limited","10.1080/1744666x.2026.2625967","https://doi.org/10.1080/1744666x.2026.2625967","41640042","https://pubmed.ncbi.nlm.nih.gov/41640042/","https://doi.org/10.1080/1744666x.2026.2625967",null],["2","R0001541","R0001541.pdf","free_to_read","randomized_trial","Yousafzai O","2026","GLP-1 Receptor Agonists as a Potential Fifth Pillar of GDMT in HFrEF (NYHA II–IV): A Multicenter Real-World Propensity-Matched Analysis","medRxiv","openRxiv","10.64898/2026.04.13.26350824","https://doi.org/10.64898/2026.04.13.26350824",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.04.13.26350824",null],["2","R0001572","R0001572.pdf","open_download_failed","randomized_trial","Almazan E","2026","Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000004048","https://doi.org/10.14309/ajg.0000000000004048","42117589","https://pubmed.ncbi.nlm.nih.gov/42117589/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13428635/pdf/nihms-2199266.pdf",null],["2","R0001606","R0001606.pdf","open_download_failed","randomized_trial","Shimada H","2026","Comparative cardiovascular effectiveness of GLP-1RAs versus DPP-4is in dialysis patients with type 2 diabetes: a target trial emulation.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101760","https://doi.org/10.1016/j.diabet.2026.101760","41974347","https://pubmed.ncbi.nlm.nih.gov/41974347/","https://repository.kulib.kyoto-u.ac.jp/bitstreams/44f4fb23-b3ba-4f03-b85b-61ef49fa7833/download",null],["2","R0001671","R0001671.pdf","free_to_read","randomized_trial","Hendershot CS","2026","Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.","Biological psychiatry","Elsevier BV","10.1016/j.biopsych.2026.04.002","https://doi.org/10.1016/j.biopsych.2026.04.002","41967661","https://pubmed.ncbi.nlm.nih.gov/41967661/","https://doi.org/10.1016/j.biopsych.2026.04.002",null],["2","R0001759","R0001759.pdf","free_to_read","randomized_trial","Wang SSY","2026","Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead.","Singapore medical journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/singaporemedj.smj-2025-240","https://doi.org/10.4103/singaporemedj.smj-2025-240","42496362","https://pubmed.ncbi.nlm.nih.gov/42496362/","https://doi.org/10.4103/singaporemedj.smj-2025-240",null],["2","R0001803","R0001803.pdf","free_to_read","randomized_trial","Hassan SM","2026","Oral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Study","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-10712752/v1","https://doi.org/10.21203/rs.3.rs-10712752/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-10712752/v1",null],["2","R0001837","R0001837.pdf","free_to_read","randomized_trial","Lum J","2026","Cardiovascular Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes or Obesity Undergoing Surgical Aortic Valve Replacement","medRxiv","openRxiv","10.64898/2026.06.02.26354773","https://doi.org/10.64898/2026.06.02.26354773",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.06.02.26354773",null],["2","R0001854","R0001854.pdf","open_download_failed","randomized_trial","Fan Y","2026","SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156678","https://doi.org/10.1016/j.metabol.2026.156678","42289243","https://pubmed.ncbi.nlm.nih.gov/42289243/","https://www.metabolismjournal.com/article/S0026-0495(26)00188-5/pdf",null],["2","R0001956","R0001956.pdf","open_download_failed","randomized_trial","Hung CT","2026","Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study.","Pharmacotherapy","Wiley","10.1002/phar.70194","https://doi.org/10.1002/phar.70194","42618217","https://pubmed.ncbi.nlm.nih.gov/42618217/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13489788/pdf/PHAR-46-0.pdf",null],["2","R0002069","R0002069.pdf","free_to_read","randomized_trial","Seijas-Amigo J","2026","GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.","Progress in neuro-psychopharmacology & biological psychiatry","Elsevier BV","10.1016/j.pnpbp.2026.111802","https://doi.org/10.1016/j.pnpbp.2026.111802","42364723","https://pubmed.ncbi.nlm.nih.gov/42364723/","https://doi.org/10.1016/j.pnpbp.2026.111802",null],["2","R0002369","R0002369.pdf","open_download_failed","randomized_trial","Cui H","2026","Geroprotective potential of anti-diabetic medications: Bridging type 2 diabetes and accelerated aging.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2026.108443","https://doi.org/10.1016/j.phrs.2026.108443","42710703","https://pubmed.ncbi.nlm.nih.gov/42710703/","https://www.sciencedirect.com/science/article/pii/S1043661826003580/pdf",null],["2","R0002432","R0002432.pdf","open_download_failed","randomized_trial","Wilkinson T","2026","Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2734645","https://doi.org/10.1080/03007995.2026.2734645","42806732","https://pubmed.ncbi.nlm.nih.gov/42806732/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2026.2734645?needAccess=true",null],["2","R0002763","R0002763.pdf","open_download_failed","randomized_trial","Younis A","2026","Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113083","https://doi.org/10.1016/j.diabres.2026.113083","41544899","https://pubmed.ncbi.nlm.nih.gov/41544899/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00002-1/pdf",null],["2","R0002923","R0002923.pdf","free_to_read","randomized_trial","Leehey DJ","2026","Is There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2025.09.030","https://doi.org/10.1053/j.ajkd.2025.09.030","41866016","https://pubmed.ncbi.nlm.nih.gov/41866016/","https://doi.org/10.1053/j.ajkd.2025.09.030",null],["2","R0002963","R0002963.pdf","open_download_failed","randomized_trial","Vesole AS","2026","Reduction of Cerebrospinal Fluid Leaks in Idiopathic Intracranial Hypertension with Glucagon-like Peptide-1 Receptor Agonist Use.","Journal of neurological surgery. Part B, Skull base","Georg Thieme Verlag KG","10.1055/a-2678-8331","https://doi.org/10.1055/a-2678-8331","42404189","https://pubmed.ncbi.nlm.nih.gov/42404189/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13331668/",null],["2","R0002973","R0002973.pdf","free_to_read","randomized_trial","Chan JCN","2026","Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113173","https://doi.org/10.1016/j.diabres.2026.113173","41722868","https://pubmed.ncbi.nlm.nih.gov/41722868/","https://doi.org/10.1016/j.diabres.2026.113173",null],["2","R0003098","R0003098.pdf","open_download_failed","randomized_trial","Schacht JP","2026","Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.","The American journal of psychiatry","American Psychiatric Association Publishing","10.1176/appi.ajp.20260003","https://doi.org/10.1176/appi.ajp.20260003","42522065","https://pubmed.ncbi.nlm.nih.gov/42522065/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13567346/pdf/nihms-2200559.pdf",null],["2","R0003203","R0003203.pdf","open_download_failed","randomized_trial","Karanxha J","2026","Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2026.134773","https://doi.org/10.1016/j.ijcard.2026.134773","42710812","https://pubmed.ncbi.nlm.nih.gov/42710812/","https://www.internationaljournalofcardiology.com/article/S0167-5273(26)00623-6/pdf",null],["2","R0003258","R0003258.pdf","open_download_failed","randomized_trial","Kröger K","2026","The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease.","Deutsches Arzteblatt international","Deutscher Arzte-Verlag GmbH","10.3238/arztebl.m2026.0055","https://doi.org/10.3238/arztebl.m2026.0055","42059101","https://pubmed.ncbi.nlm.nih.gov/42059101/","https://pubmed.ncbi.nlm.nih.gov/42059101/",null],["2","R0003503","R0003503.pdf","open_download_failed","randomized_trial","Jensen SK","2026","SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2025.7409","https://doi.org/10.1001/jamainternmed.2025.7409","41557360","https://pubmed.ncbi.nlm.nih.gov/41557360/","https://pubmed.ncbi.nlm.nih.gov/41557360/",null],["2","R0003581","R0003581.pdf","open_download_failed","randomized_trial","Morello CM","2026","Emerging and Off-Label Uses Of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and Dual GIP/GLP1-RAs.","Journal of the American Board of Family Medicine : JABFM","American Board of Family Medicine (ABFM)","10.3122/jabfm.2025.250158r1","https://doi.org/10.3122/jabfm.2025.250158r1","42049507","https://pubmed.ncbi.nlm.nih.gov/42049507/","https://doi.org/10.3122/jabfm.2025.250158r1",null],["2","R0003729","R0003729.pdf","free_to_read","randomized_trial","Varra F","2026","Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction","Preprints.org","MDPI AG","10.20944/preprints202605.1774.v1","https://doi.org/10.20944/preprints202605.1774.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202605.1774.v1",null],["2","R0003796","R0003796.pdf","free_to_read","randomized_trial","Kyriazi N","2026","Antiobesity medications in rheumatology. Quo vadis?","Annals of the rheumatic diseases","Elsevier BV","10.1016/j.ard.2025.08.013","https://doi.org/10.1016/j.ard.2025.08.013","40946026","https://pubmed.ncbi.nlm.nih.gov/40946026/","https://doi.org/10.1016/j.ard.2025.08.013",null],["2","R0003858","R0003858.pdf","free_to_read","randomized_trial","Uhrenholt N","2026","Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.","Schizophrenia research","Elsevier BV","10.1016/j.schres.2026.02.009","https://doi.org/10.1016/j.schres.2026.02.009","41702353","https://pubmed.ncbi.nlm.nih.gov/41702353/","https://doi.org/10.1016/j.schres.2026.02.009",null],["2","R0004224","R0004224.pdf","free_to_read","randomized_trial","Taipale H","2026","Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.","The lancet. Psychiatry","Elsevier BV","10.1016/s2215-0366(26)00014-3","https://doi.org/10.1016/s2215-0366(26)00014-3","41862258","https://pubmed.ncbi.nlm.nih.gov/41862258/","https://doi.org/10.1016/s2215-0366(26)00014-3",null],["2","R0004284","R0004284.pdf","open_download_failed","randomized_trial","Mercado F","2026","Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025)","Preprints.org","MDPI AG","10.20944/preprints202601.2404.v1","https://doi.org/10.20944/preprints202601.2404.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/f33f0277c17fe8b74cae2ae75b48b27b/download_pub",null],["2","R0004442","R0004442.pdf","free_to_read","randomized_trial","Geiger N","2026","PYY3-36 potentiates semaglutide-mediated mitochondrial modulation in MASLD.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00036.2026","https://doi.org/10.1152/ajpendo.00036.2026","42526426","https://pubmed.ncbi.nlm.nih.gov/42526426/","https://doi.org/10.1152/ajpendo.00036.2026",null],["2","R0004496","R0004496.pdf","free_to_read","randomized_trial","Rodríguez-Velásquez F","2026","Multimodal Strategies for Obesity Management: Integration and Combination of GLP-1/GIP Therapies, Bariatric Endoscopy, and Metabolic Surgery: A Scoping Review","Preprints.org","MDPI AG","10.20944/preprints202607.2380.v1","https://doi.org/10.20944/preprints202607.2380.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.2380.v1",null],["2","R0004501","R0004501.pdf","open_download_failed","randomized_trial","Kittipibul V","2026","Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.","American heart journal","Elsevier BV","10.1016/j.ahj.2026.107475","https://doi.org/10.1016/j.ahj.2026.107475","42102896","https://pubmed.ncbi.nlm.nih.gov/42102896/","https://eprints.gla.ac.uk/387099/1/387099.pdf",null],["2","R0004598","R0004598.pdf","free_to_read","randomized_trial","Cherney DZI","2026","Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2026.01.010","https://doi.org/10.1016/j.mayocp.2026.01.010","42017862","https://pubmed.ncbi.nlm.nih.gov/42017862/","https://doi.org/10.1016/j.mayocp.2026.01.010",null],["2","R0004822","R0004822.pdf","open_download_failed","randomized_trial","Viquez Burboa GU","2026","GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.","Skin appendage disorders","S. Karger AG","10.1159/000552598","https://doi.org/10.1159/000552598","42454220","https://pubmed.ncbi.nlm.nih.gov/42454220/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13368244/",null],["2","R0004878","R0004878.pdf","open_download_failed","randomized_trial","Bellos I","2026","Sex in CKD trials: representation and treatment effects of cardiorenoprotective therapies.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag199","https://doi.org/10.1093/ndt/gfag199","42671242","https://pubmed.ncbi.nlm.nih.gov/42671242/","https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfag199/70881948/gfag199.pdf",null],["2","R0004903","R0004903.pdf","free_to_read","randomized_trial","Leibnitz S","2026","Effects of GLP-1 receptor agonists on copeptin in euvolemic participants.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag005","https://doi.org/10.1093/ejendo/lvag005","41525326","https://pubmed.ncbi.nlm.nih.gov/41525326/","https://doi.org/10.1093/ejendo/lvag005",null],["2","R0005600","R0005600.pdf","free_to_read","randomized_trial","Mann JFE","2026","Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00134-8","https://doi.org/10.1016/s2213-8587(26)00134-8","42567173","https://pubmed.ncbi.nlm.nih.gov/42567173/","https://eprints.gla.ac.uk/view/journal_volume/Lancet_Diabetes_and_Endocrinology.html>,",null],["2","R0006139","R0006139.pdf","open_download_failed","randomized_trial","Qian F","2026","Integrated approaches to preventing macrovascular complications in type 2 diabetes mellitus: Advances in secondary prevention.","Pakistan journal of pharmaceutical sciences","Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","10.36721/pjps.2026.39.3.reg.15014.1","https://doi.org/10.36721/pjps.2026.39.3.reg.15014.1","41620898","https://pubmed.ncbi.nlm.nih.gov/41620898/","https://doi.org/10.36721/pjps.2026.39.3.reg.15014.1",null],["2","R0006163","R0006163.pdf","free_to_read","randomized_trial","Venkatakrishnan A","2026","Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities","Preprints.org","MDPI AG","10.20944/preprints202609.0311.v1","https://doi.org/10.20944/preprints202609.0311.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.0311.v1",null],["2","R0006252","R0006252.pdf","free_to_read","randomized_trial",null,"2026","Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","42771753","https://pubmed.ncbi.nlm.nih.gov/42771753/",null,null],["2","R0006260","R0006260.pdf","open_download_failed","randomized_trial","Khalil I","2026","Comparative Efficacy of GLP-1 RAs Versus SGLT2 Inhibitors in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter Propensity Score-Matched Real-World Study.","Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","Wiley","10.1002/ccd.70668","https://doi.org/10.1002/ccd.70668","42219874","https://pubmed.ncbi.nlm.nih.gov/42219874/","https://pubmed.ncbi.nlm.nih.gov/42219874/",null],["2","R0006827","R0006827.pdf","open_download_failed","randomized_trial","Muir KC","2026","Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.","American journal of physiology. Heart and circulatory physiology","American Physiological Society","10.1152/ajpheart.00828.2025","https://doi.org/10.1152/ajpheart.00828.2025","41553720","https://pubmed.ncbi.nlm.nih.gov/41553720/","https://doi.org/10.1152/ajpheart.00828.2025",null],["2","R0006833","R0006833.pdf","open_download_failed","randomized_trial","Avogaro A","2026","Discontinuation of incretin-based therapies in obesity: the complexity of a breakup.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2026.106833","https://doi.org/10.1016/j.ejim.2026.106833","41833473","https://pubmed.ncbi.nlm.nih.gov/41833473/","https://www.ejinme.com/article/S0953-6205(26)00138-X/pdf",null],["2","R0007403","R0007403.pdf","open_download_failed","randomized_trial","Butt JH","2026","Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf635","https://doi.org/10.1093/eurheartj/ehaf635","40888808","https://pubmed.ncbi.nlm.nih.gov/40888808/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehaf635/64171801/ehaf635.pdf",null],["2","R0008022","R0008022.pdf","open_download_failed","randomized_trial","Fang E","2026","Effects of the Short-Acting GLP-1 Analogue Beinaglutide on Liver Fat and Visceral Adiposity in T2DM with MASLD: A 24-Week Single-Arm Exploratory Pilot Study","Authorea Preprints","Wiley","10.22541/au.177036320.04416099/v1","https://doi.org/10.22541/au.177036320.04416099/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.177036320.04416099",null],["2","R0008161","R0008161.pdf","free_to_read","randomized_trial","Zafar W","2026","Impact of Smartphone-Enabled Home Urinary Albumin-Creatinine Ratio Testing on Albuminuria Screening and Management.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2025.09.019","https://doi.org/10.1053/j.ajkd.2025.09.019","41360254","https://pubmed.ncbi.nlm.nih.gov/41360254/","https://doi.org/10.1053/j.ajkd.2025.09.019",null],["2","R0008943","R0008943.pdf","free_to_read","randomized_trial","Pearson MJ","2026","Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag201","https://doi.org/10.1210/clinem/dgag201","42135195","https://pubmed.ncbi.nlm.nih.gov/42135195/","https://doi.org/10.1210/clinem/dgag201",null],["2","R0009344","R0009344.pdf","free_to_read","randomized_trial","Tentolouris A","2026","Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2026.01.003","https://doi.org/10.1016/j.pcd.2026.01.003","41565568","https://pubmed.ncbi.nlm.nih.gov/41565568/","https://doi.org/10.1016/j.pcd.2026.01.003",null],["2","R0009698","R0009698.pdf","free_to_read","randomized_trial","Zoungas S","2026","A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00032-x","https://doi.org/10.1016/s2213-8587(26)00032-x","42114520","https://pubmed.ncbi.nlm.nih.gov/42114520/","https://doi.org/10.1016/s2213-8587(26)00032-x",null],["2","R0009727","R0009727.pdf","free_to_read","randomized_trial","Wilmot EG","2026","Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00076-8","https://doi.org/10.1016/s2213-8587(26)00076-8","42035781","https://pubmed.ncbi.nlm.nih.gov/42035781/","https://doi.org/10.1016/s2213-8587(26)00076-8","ClinicalTrials.gov:NCT05944432"],["2","R0009781","R0009781.pdf","open_download_failed","randomized_trial","Inoue K","2026","GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation?","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.126.078150","https://doi.org/10.1161/circulationaha.126.078150","41973838","https://pubmed.ncbi.nlm.nih.gov/41973838/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13134813/pdf/nihms-2154218.pdf",null],["2","R0009834","R0009834.pdf","free_to_read","randomized_trial","Doğan A","2026","Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.","The Journal of pharmacy and pharmacology","Oxford University Press (OUP)","10.1093/jpp/rgag065","https://doi.org/10.1093/jpp/rgag065","42341220","https://pubmed.ncbi.nlm.nih.gov/42341220/","https://doi.org/10.1093/jpp/rgag065",null],["2","R0010081","R0010081.pdf","open_download_failed","randomized_trial","Parikh M","2026","Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag033","https://doi.org/10.1210/clinem/dgag033","41604435","https://pubmed.ncbi.nlm.nih.gov/41604435/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13271809/",null],["2","R0010140","R0010140.pdf","free_to_read","randomized_trial","Sattar N","2026","Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag408","https://doi.org/10.1093/eurjpc/zwag408","42572119","https://pubmed.ncbi.nlm.nih.gov/42572119/","https://doi.org/10.1093/eurjpc/zwag408",null],["2","R0010196","R0010196.pdf","free_to_read","randomized_trial","Diniz CG","2026","Title: Gene expression, neuroinflammation, and neural plasticity in type 2 diabetes: Translational insights from exercise and cognitive modulation.","Neuroscience and biobehavioral reviews","Elsevier BV","10.1016/j.neubiorev.2026.106922","https://doi.org/10.1016/j.neubiorev.2026.106922","42648513","https://pubmed.ncbi.nlm.nih.gov/42648513/","https://doi.org/10.1016/j.neubiorev.2026.106922",null],["2","R0010278","R0010278.pdf","open_download_failed","randomized_trial","Akcan T","2026","Use of High-Potency GLP-1 Receptor Agonists With OpenAPS Automated Insulin Dosing Algorithm Eliminates Need for Meal Announcements to Achieve Glycemic Goals.","Diabetes care","American Diabetes Association","10.2337/dc25-2569","https://doi.org/10.2337/dc25-2569","41511751","https://pubmed.ncbi.nlm.nih.gov/41511751/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2569/853614/dc252569.pdf",null],["2","R0010331","R0010331.pdf","open_download_failed","randomized_trial","Long W","2026","Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.","Pakistan journal of pharmaceutical sciences","Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","10.36721/pjps.2026.39.7.204.1","https://doi.org/10.36721/pjps.2026.39.7.204.1","42170981","https://pubmed.ncbi.nlm.nih.gov/42170981/","https://doi.org/10.36721/pjps.2026.39.7.204.1",null],["2","R0010501","R0010501.pdf","free_to_read","randomized_trial","Lange AH","2026","Circulating levels of PYY are increased in individuals with bile acid diarrhoea.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag295","https://doi.org/10.1210/clinem/dgag295","42496159","https://pubmed.ncbi.nlm.nih.gov/42496159/","https://doi.org/10.1210/clinem/dgag295",null],["2","R0010576","R0010576.pdf","open_download_failed","randomized_trial","Post SM","2026","Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity.","Stigma and health","American Psychological Association (APA)","10.1037/sah0000689","https://doi.org/10.1037/sah0000689","42181798","https://pubmed.ncbi.nlm.nih.gov/42181798/","https://doi.org/10.1037/sah0000689",null],["2","R0010739","R0010739.pdf","open_download_failed","randomized_trial","Horváth G","2026","[The role of obesity and weight reduction in obstructive sleep apnea].","Orvosi hetilap","Akademiai Kiado Zrt.","10.1556/650.2026.33589","https://doi.org/10.1556/650.2026.33589","42365594","https://pubmed.ncbi.nlm.nih.gov/42365594/","https://www.akjournals.com/downloadpdf/view/journals/650/167/26/article-p1011.pdf",null],["2","R0010853","R0010853.pdf","open_download_failed","randomized_trial","Newsome JS","2026","Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","SAGE Publications","10.1177/87551225261466571","https://doi.org/10.1177/87551225261466571","42483637","https://pubmed.ncbi.nlm.nih.gov/42483637/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13385150/",null],["2","R0011146","R0011146.pdf","open_download_failed","randomized_trial","Sattar N","2026","Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.","Annals of the rheumatic diseases","Elsevier BV","10.1016/j.ard.2025.10.009","https://doi.org/10.1016/j.ard.2025.10.009","41198460","https://pubmed.ncbi.nlm.nih.gov/41198460/","https://ard.eular.org/article/S0003-4967(25)04448-6/pdf",null],["2","R0011320","R0011320.pdf","open_download_failed","randomized_trial","Platz E","2026","Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.01.013","https://doi.org/10.1016/j.jacc.2026.01.013","41811272","https://pubmed.ncbi.nlm.nih.gov/41811272/","https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=7520&context=baylor_docs",null],["2","R0011547","R0011547.pdf","open_download_failed","randomized_trial","Amrein K","2026","Mini-review. Vitamin D for the prevention of type 2 diabetes: Evidence and implications.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156566","https://doi.org/10.1016/j.metabol.2026.156566","41707752","https://pubmed.ncbi.nlm.nih.gov/41707752/","https://www.metabolismjournal.com/article/S0026-0495(26)00076-4/pdf",null],["2","R0012282","R0012282.pdf","open_download_failed","randomized_trial","Lingvay I","2026","Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial.","Diabetes care","American Diabetes Association","10.2337/dc26-0784","https://doi.org/10.2337/dc26-0784","42782193","https://pubmed.ncbi.nlm.nih.gov/42782193/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc26-0784/896196/dc260784.pdf",null],["2","R0012772","R0012772.pdf","free_to_read","randomized_trial","Rosenthal MH","2026","Compounding stigma: An experimental study comparing perceptions of an individual using Ozempic, bariatric surgery, or behavior modification.","Social science & medicine (1982)","Elsevier BV","10.1016/j.socscimed.2026.119710","https://doi.org/10.1016/j.socscimed.2026.119710","42612445","https://pubmed.ncbi.nlm.nih.gov/42612445/","https://doi.org/10.1016/j.socscimed.2026.119710",null],["2","R0012785","R0012785.pdf","free_to_read","randomized_trial","Yin Y","2026","Novel treatments for Parkinson's disease.","Chinese medical journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000004163","https://doi.org/10.1097/cm9.0000000000004163","42366511","https://pubmed.ncbi.nlm.nih.gov/42366511/","https://doi.org/10.1097/cm9.0000000000004163",null],["2","R0012806","R0012806.pdf","free_to_read","randomized_trial","Pérez-Pevida B","2026","Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2026.105005","https://doi.org/10.1016/j.clnesp.2026.105005","42542297","https://pubmed.ncbi.nlm.nih.gov/42542297/","https://doi.org/10.1016/j.clnesp.2026.105005",null],["2","R0012818","R0012818.pdf","open_download_failed","randomized_trial","Chen L","2026","Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX.","Diabetes care","American Diabetes Association","10.2337/dc26-0540","https://doi.org/10.2337/dc26-0540","42765971","https://pubmed.ncbi.nlm.nih.gov/42765971/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc26-0540/896161/dc260540.pdf",null],["2","R0012823","R0012823.pdf","open_download_failed","randomized_trial","Huang C","2026","Pharmacokinetics and Food Effect of HDM1002, a Novel Oral Small-Molecule GLP-1 Receptor Agonist, in Healthy Chinese Volunteers: A Bioequivalence Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70931","https://doi.org/10.1111/dom.70931","42310909","https://pubmed.ncbi.nlm.nih.gov/42310909/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448887/pdf/DOM-28-8136.pdf","ChiCTR:ChiCTR2500111569"],["2","R0013067","R0013067.pdf","free_to_read","randomized_trial","Krüger N","2026","Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-100011","https://doi.org/10.1136/bmj-2026-100011","42556854","https://pubmed.ncbi.nlm.nih.gov/42556854/","https://doi.org/10.1136/bmj-2026-100011","ClinicalTrials.gov:NCT07203677"],["2","R0013127","R0013127.pdf","open_download_failed","randomized_trial","Amioka M","2026","Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71162","https://doi.org/10.1111/dom.71162","42521631","https://pubmed.ncbi.nlm.nih.gov/42521631/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538803/pdf/DOM-28-9395.pdf",null],["2","R0013215","R0013215.pdf","open_download_failed","randomized_trial","Waki H","2026","Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.09.006","https://doi.org/10.1016/j.eprac.2026.09.006","42762980","https://pubmed.ncbi.nlm.nih.gov/42762980/","https://www.endocrinepractice.org/article/S1530-891X(26)01148-1/pdf",null],["2","R0013357","R0013357.pdf","free_to_read","randomized_trial","Gullaksen S","2026","Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109397","https://doi.org/10.1016/j.jdiacomp.2026.109397","42679726","https://pubmed.ncbi.nlm.nih.gov/42679726/","https://doi.org/10.1016/j.jdiacomp.2026.109397","EudraCT:2019-000781-38"],["2","R0013493","R0013493.pdf","open_download_failed","randomized_trial","Zhou Z","2026","Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71305","https://doi.org/10.1111/dom.71305","42750649","https://pubmed.ncbi.nlm.nih.gov/42750649/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71305",null],["2","R0013613","R0013613.pdf","open_download_failed","randomized_trial","Choujaa Goudira S","2026","The Risk of Retinal Vascular Events in Patients Using Semaglutide: A Scoping Review.","Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde","S. Karger AG","10.1159/000553235","https://doi.org/10.1159/000553235","42348481","https://pubmed.ncbi.nlm.nih.gov/42348481/","https://karger.com/oph/article-pdf/doi/10.1159/000553235/4554127/000553235.pdf",null],["2","R0013930","R0013930.pdf","free_to_read","randomized_trial","Kim B","2026","Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease","Preprints.org","MDPI AG","10.20944/preprints202609.0768.v1","https://doi.org/10.20944/preprints202609.0768.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.0768.v1",null],["2","R0014465","R0014465.pdf","free_to_read","randomized_trial","Tchang BG","2026","Tirzepatide Heralds the Hope of Chronic Disease Eradication.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf444","https://doi.org/10.1210/clinem/dgaf444","40754464","https://pubmed.ncbi.nlm.nih.gov/40754464/","https://hdl.handle.net/1813/118201",null],["2","R0014966","R0014966.pdf","open_download_failed","randomized_trial","Kostev K","2026","Epidemiological Studies on Type 2 Diabetes Using the German Disease Analyser Database: A Narrative Review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71089","https://doi.org/10.1111/dom.71089","42410298","https://pubmed.ncbi.nlm.nih.gov/42410298/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538734/pdf/DOM-28-8795.pdf",null],["2","R0015375","R0015375.pdf","open_download_failed","randomized_trial","Ajmera V","2026","Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70516","https://doi.org/10.1111/apt.70516","41527269","https://pubmed.ncbi.nlm.nih.gov/41527269/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70516",null],["2","R0015442","R0015442.pdf","free_to_read","randomized_trial","Liu Y","2026","Single-dose pharmacokinetics of sublingual semaglutide in rats.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/j.ejps.2025.107406","https://doi.org/10.1016/j.ejps.2025.107406","41386332","https://pubmed.ncbi.nlm.nih.gov/41386332/","https://doi.org/10.1016/j.ejps.2025.107406",null],["2","R0015489","R0015489.pdf","free_to_read","randomized_trial","Martínez JJL","2026","Causal Inference in Non-Allergic Asthma Associated with Obesity: Application of the Bradford Hill Viewpoints to a Complex Epidemiological Association","Preprints.org","MDPI AG","10.20944/preprints202606.0451.v1","https://doi.org/10.20944/preprints202606.0451.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0451.v1",null],["2","R0015526","R0015526.pdf","open_download_failed","randomized_trial","Sarabhai T","2026","Diabetes Mellitus and Osteoporosis After Organ Transplantation: Frequency, Clinical Features, and Treatment.","Deutsches Arzteblatt international","Deutscher Arzte-Verlag GmbH","10.3238/arztebl.m2026.0019","https://doi.org/10.3238/arztebl.m2026.0019","41711448","https://pubmed.ncbi.nlm.nih.gov/41711448/","https://pubmed.ncbi.nlm.nih.gov/41711448/",null],["2","R0016560","R0016560.pdf","open_download_failed","randomized_trial","Bergenstal RM","2026","Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.","Diabetes care","American Diabetes Association","10.2337/dc25-3055","https://doi.org/10.2337/dc25-3055","41925680","https://pubmed.ncbi.nlm.nih.gov/41925680/","https://pubmed.ncbi.nlm.nih.gov/41925680/",null],["2","R0016755","R0016755.pdf","no_doi","randomized_trial","Kashmoola IO","2026","Adipokine dysregulation and oxidative stress in type 2 diabetes: Implications for neurodegeneration and neuroprotective eff ects of antidiabetic therapies.","Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology",null,null,"https://doi.org/","42389857","https://pubmed.ncbi.nlm.nih.gov/42389857/",null,null],["2","R0016796","R0016796.pdf","free_to_read","randomized_trial","Baldassarre MPA","2026","Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109273","https://doi.org/10.1016/j.jdiacomp.2026.109273","41621217","https://pubmed.ncbi.nlm.nih.gov/41621217/","https://doi.org/10.1016/j.jdiacomp.2026.109273",null],["2","R0016842","R0016842.pdf","free_to_read","randomized_trial","Kitsios K","2026","Automated Insulin Delivery for Patients with Type 2 Diabetes: A Narrative Review.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/0115733998418695251203105337","https://doi.org/10.2174/0115733998418695251203105337","41788003","https://pubmed.ncbi.nlm.nih.gov/41788003/","https://doi.org/10.2174/0115733998418695251203105337",null],["2","R0020455","R0020455.pdf","open_download_failed","randomized_trial","Vogel JM","2026","Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID","medRxiv","openRxiv","10.64898/2026.08.19.26360832","https://doi.org/10.64898/2026.08.19.26360832",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/08/22/2026.08.19.26360832.full.pdf",null],["2","R0021936","R0021936.pdf","free_to_read","randomized_trial","Li T","2026","Inflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-02084-2","https://doi.org/10.1007/s40200-026-02084-2","42787324","https://pubmed.ncbi.nlm.nih.gov/42787324/","https://pubmed.ncbi.nlm.nih.gov/42787324/",null],["2","R0022559","R0022559.pdf","open_download_failed","randomized_trial","Kahn SE","2026","Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Diabetes care","American Diabetes Association","10.2337/dc25-2186","https://doi.org/10.2337/dc25-2186","41432725","https://pubmed.ncbi.nlm.nih.gov/41432725/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2186/852301/dc252186.pdf",null],["2","R0025229","R0025229.pdf","free_to_read","randomized_trial","Mayar S","2026","Agreement of an AI tool for joint space width measurement in radiographic knee osteoarthritis: data from the LOSEIT trial","medRxiv","openRxiv","10.64898/2026.06.11.26355242","https://doi.org/10.64898/2026.06.11.26355242",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.06.11.26355242",null],["2","R0029261","R0029261.pdf","free_to_read","randomized_trial","O'Callaghan M","2026","GLP-1-based therapies in lung diseases.","The European respiratory journal","European Respiratory Society (ERS)","10.1183/13993003.00643-2026","https://doi.org/10.1183/13993003.00643-2026","42860278","https://pubmed.ncbi.nlm.nih.gov/42860278/","https://doi.org/10.1183/13993003.00643-2026",null],["2","R0029291","R0029291.pdf","open_download_failed","randomized_trial","Ueda P","2026","GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.","Journal of internal medicine","Wiley","10.1111/joim.70170","https://doi.org/10.1111/joim.70170","42851139","https://pubmed.ncbi.nlm.nih.gov/42851139/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/joim.70170",null],["2","R0029370","R0029370.pdf","free_to_read","randomized_trial","Jerjes W","2026","Beyond Prescribing: GLP-1 Care and Obesity Prevention in Primary Care.","Journal of primary care & community health","SAGE Publications","10.1177/21501319261494129","https://doi.org/10.1177/21501319261494129","42789525","https://pubmed.ncbi.nlm.nih.gov/42789525/","https://doi.org/10.1177/21501319261494129",null],["2","R0029389","R0029389.pdf","open_download_failed","randomized_trial","Belury MA","2026","Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71237","https://doi.org/10.1111/dom.71237","42677730","https://pubmed.ncbi.nlm.nih.gov/42677730/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71237","ClinicalTrials.gov:NCT05199948"],["2","R0029461","R0029461.pdf","open_download_failed","randomized_trial","Tanaka A","2026","Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD.","Kidney international reports","Elsevier BV","10.1016/j.ekir.2026.106546","https://doi.org/10.1016/j.ekir.2026.106546","42180819","https://pubmed.ncbi.nlm.nih.gov/42180819/","https://www.kireports.org/article/S2468-0249(26)02778-6/pdf",null],["2","R0029465","R0029465.pdf","open_download_failed","randomized_trial","Renke G","2026","Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","International journal of molecular sciences","MDPI AG","10.3390/ijms27093890","https://doi.org/10.3390/ijms27093890","42123471","https://pubmed.ncbi.nlm.nih.gov/42123471/","https://www.mdpi.com/1422-0067/27/9/3890/pdf?version=1777382973",null],["2","R0029491","R0029491.pdf","free_to_read","randomized_trial","Gouda P","2026","Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity-JACC: Advances Expert Panel.","JACC. Advances","Elsevier BV","10.1016/j.jacadv.2026.102713","https://doi.org/10.1016/j.jacadv.2026.102713","41931082","https://pubmed.ncbi.nlm.nih.gov/41931082/","https://doi.org/10.1016/j.jacadv.2026.102713",null],["2","R0029503","R0029503.pdf","free_to_read","randomized_trial","Younglove C","2026","Clinical review: Menopause hormone therapy in weight management.","Obesity pillars","Elsevier BV","10.1016/j.obpill.2026.100258","https://doi.org/10.1016/j.obpill.2026.100258","41883510","https://pubmed.ncbi.nlm.nih.gov/41883510/","https://doi.org/10.1016/j.obpill.2026.100258",null],["2","R0029568","R0029568.pdf","free_to_read","randomized_trial","McMath A","2026","Understanding Impact of Anti-Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70041","https://doi.org/10.1111/obr.70041","41287517","https://pubmed.ncbi.nlm.nih.gov/41287517/","https://doi.org/10.1111/obr.70041",null],["2","R0032424","R0032424.pdf","no_doi","randomized_trial","Erika Alexandra Jami Tonato","2026","Manejo integral del síndrome de ovario poliquístico: revisión sistemática de estrategias terapéuticas farmacológicas","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032528","R0032528.pdf","free_to_read","randomized_trial","Mayur Madhav Mayabhate","2026","Bridging Innovation and Access: Randomized, Single-Dose, Open-Label, Parallel-Group Bioequivalence Study of Generic and Innovator Injection Semaglutide in India","American Journal of Pharmacology and Toxicology","Science Publications","10.3844/ajptsp.2026.9.15","https://doi.org/10.3844/ajptsp.2026.9.15",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3844/ajptsp.2026.9.15",null],["2","R0032909","R0032909.pdf","free_to_read","randomized_trial","Lucas Caseri Câmara","2026","Beyond weight loss: Clinical anabolism to reduce muscle mass loss and physical function decline in patients undergoing pharmacological treatment for obesity","Revista fisio&terapia.","Revista ft Ltda","10.69849/g2hbtt18","https://doi.org/10.69849/g2hbtt18",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69849/g2hbtt18",null],["2","R0033011","R0033011.pdf","free_to_read","randomized_trial","Ana Clara Fernandes Cassimiro","2026","AGONISTAS DE GLP-1 NA ONCOLOGIA: ONDE ESTAMOS?",null,"Editora Caminhos & Vozes","10.66396/pontes.c21.2026","https://doi.org/10.66396/pontes.c21.2026",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.66396/pontes.c21.2026",null],["2","R0033063","R0033063.pdf","no_doi","randomized_trial","Sean Bannister","2026","Glucagon-Like Peptide-1 Receptor Agonist Therapy for Failed Weight Loss Surgery","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033163","R0033163.pdf","free_to_read","randomized_trial","Sanjin Bajgoric","2026","Comparative Effectiveness of GLP-1 Agonists Versus Continuous Positive Airway Pressure in Reducing Symptoms and Improving Outcomes for Adults with Obstructive Sleep Apnoea: A Literature Review","SAS Journal of Medicine","SASPR Edu International Pvt. Ltd","10.36347/sasjm.2026.v12i06.005","https://doi.org/10.36347/sasjm.2026.v12i06.005",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36347/sasjm.2026.v12i06.005",null],["2","R0033166","R0033166.pdf","free_to_read","randomized_trial","A.Z. Ismailova","2026","Cardiometabolic Features of Remodeling of the Cardiovascular System when Using Semaglutide in Patients with Obesity and Diabetes Mellitus Type 2","Effective Pharmacotherapy","Medforum","10.33978/2307-3586-2026-22-11-34-38","https://doi.org/10.33978/2307-3586-2026-22-11-34-38",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.33978/2307-3586-2026-22-11-34-38",null],["2","R0033167","R0033167.pdf","free_to_read","randomized_trial","M.V. Makarovskaya","2026","Cardiovascular Complications in Type 2 Diabetes Mellitus: Current Possibilities of Cardioprotective Therapy","Effective Pharmacotherapy","Medforum","10.33978/2307-3586-2026-22-11-50-57","https://doi.org/10.33978/2307-3586-2026-22-11-50-57",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.33978/2307-3586-2026-22-11-50-57",null],["2","R0033270","R0033270.pdf","free_to_read","randomized_trial","Ahmad Alam","2026","Tirzepatide versus Dulaglutide in Type 2 Diabetes Mellitus: Cardiovascular Insights from SURPASS-CVOT and Relevance to South Asian Populations","Bangladesh Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/bjem.bjem_11_26","https://doi.org/10.4103/bjem.bjem_11_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bjem.bjem_11_26",null],["2","R0034190","R0034190.pdf","free_to_read","randomized_trial","Sandip Kumar Bhowmick","2026","Pharmacological Management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)","Faridpur Medical College Journal","Bangladesh Academy of Sciences","10.3329/fmcj.v21i2.90822","https://doi.org/10.3329/fmcj.v21i2.90822",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3329/fmcj.v21i2.90822",null],["2","R0034280","R0034280.pdf","free_to_read","randomized_trial","Himat ALI Faiaz","2026","A-94 | Efficacy and Safety of CagriSema compared with Semaglutide or Placebo: A Systemic Review and Updated Meta Analysis of Randomized Controlled Trials","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104585","https://doi.org/10.1016/j.jscai.2026.104585",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104585",null],["2","R0034345","R0034345.pdf","free_to_read","randomized_trial","Adam Caplin","2026","Glucagon-like Peptide-1 Receptor Agonists and Their Potential Role in the Treatment of Substance Use Disorders: A Narrative Review","The Canadian Journal of Addiction","Ovid Technologies (Wolters Kluwer Health)","10.1097/cxa.0000000000000268","https://doi.org/10.1097/cxa.0000000000000268",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/cxa.0000000000000268",null],["2","R0034453","R0034453.pdf","free_to_read","randomized_trial","A. B. M. Kamrul-Hasan","2026","Role of Sodium-glucose Cotransporter-2 Inhibitors in Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes","Bangladesh Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/bjem.bjem_2_26","https://doi.org/10.4103/bjem.bjem_2_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bjem.bjem_2_26",null],["2","R0034628","R0034628.pdf","free_to_read","randomized_trial","Alexander Weiss","2026","Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide","Brain Circulation","Ovid Technologies (Wolters Kluwer Health)","10.4103/bc.bc_210_25","https://doi.org/10.4103/bc.bc_210_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bc.bc_210_25",null],["2","R0034758","R0034758.pdf","free_to_read","randomized_trial","Vanishri Ganakumar","2026","Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching","World Journal of Diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.116477","https://doi.org/10.4239/wjd.116477",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4239/wjd.116477",null],["2","R0035915","R0035915.pdf","free_to_read","randomized_trial","Dr. Partha Pratim Adak","2026","Endocrinology, Diabetes, and Metabolic Disorders",null,"Cerebral Publication Private Limited","10.66715/cerebral/2026.edmd","https://doi.org/10.66715/cerebral/2026.edmd",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.66715/cerebral/2026.edmd",null],["2","R0036130","R0036130.pdf","no_doi","randomized_trial","Carolina McGuane","2026","Nutritional Care for Adults with Obesity Treated with GLP-1and Dual GIP/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036131","R0036131.pdf","no_doi","randomized_trial","Anne W Shand","2026","Implementation of GLP-1 Receptor Agonists for Perioperative Weight Loss","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036181","R0036181.pdf","no_doi","randomized_trial","Rimi Saloum","2026","Injekcinio semagliutido, dulagliutido ir tirzepatido veiksmingumas ir saugumas metaboliniams rodikliams suaugusiesiems, sergantiems 2 tipo cukriniu diabetu","Lithuanian University of Health Sciences",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036222","R0036222.pdf","no_doi","randomized_trial","Patricia J Quartin","2026","Beyond Skin: Adjunctive GLP-1 Receptor Agonist Therapy for Psoriasis and Metabolic Dysfunction","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036242","R0036242.pdf","no_doi","randomized_trial","Daniela Lizbeth Avilez","2026","GLP-1 Receptor Agonists in Diabetic Foot and Ankle Care: Skeletal Liability or a Blessing in Disguise? A Scoping Review","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036262","R0036262.pdf","no_doi","randomized_trial","Bryanna A Bhakta","2026","Analysis of the dose-dependent risk factors of the GLP-1 receptor agonist and the societal normalization of the drug for cosmetic use","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036304","R0036304.pdf","no_doi","randomized_trial","Saul Villalobos Escorza","2026","Evaluating GLP-1 Receptor Agonist in the Treatment of Type 2 Diabetes: A Comparison of Medication Efficacy and Cost","ScholarsArchive  (Brigham Young University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036355","R0036355.pdf","no_doi","randomized_trial","Ryan Gomes Pedrosa de Siqueira","2026","GLP-1 RAs in AD","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036389","R0036389.pdf","no_doi","randomized_trial","Yurydia Jorge","2026","Semaglutide Treatment in Children and Adolescent with Obesity: A Scoping Review of clinical evidence, safety and Ongoing trials","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036437","R0036437.pdf","no_doi","randomized_trial","Graziela Torres Blanch","2026","The efficacy of liraglutide in reducing major adverse cardiovascular events (MACE) in individuals with overweight or obesity without a diagnosis of type 2 diabetes mellitus.","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036652","R0036652.pdf","free_to_read","randomized_trial","Nasser Mikhail","2026","Clinical Implications of The Direct Comparison of Dulaglutide Versus Tirzepatide","General medicine and Clinical Practice","Auctores Publishing LLC","10.31579/2639-4162/330","https://doi.org/10.31579/2639-4162/330",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31579/2639-4162/330",null],["2","R0036793","R0036793.pdf","no_doi","randomized_trial","Lindsey Roos","2026","“Beyond Weight Loss: Evaluating the Anti-Inflammatory Potential of GLP-1 Receptor Agonists in Hidradenitis Suppurativa”","ValpoScholar (Valparaiso University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037167","R0037167.pdf","free_to_read","randomized_trial","Kishore Kumar Shil","2026","Challenge following discontinuation of incretin-based anti-obesity drugs: weight relapse and prevention strategies","European journal of medical research","Springer Science and Business Media LLC","10.1186/s40001-026-04862-3","https://doi.org/10.1186/s40001-026-04862-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s40001-026-04862-3",null],["2","R0037170","R0037170.pdf","free_to_read","randomized_trial","G Fazio","2026","Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.275","https://doi.org/10.1093/eurjpc/zwag249.275",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.275",null],["2","R0037345","R0037345.pdf","open_download_failed","randomized_trial",null,"2026","4134 PREOPERATIVE SEMAGLUTIDE BEFORE SLEEVE GASTRECTOMY IS ASSOCIATED WITH GREATER SHORT-TERM WEIGHT LOSS AND DYSLIPIDEMIA REMISSION: A PROSPECTIVE NON-RANDOMIZED CONTROLLED TRIAL","Surgery for Obesity and Related Diseases","Elsevier BV","10.1016/j.soard.2026.02.202","https://doi.org/10.1016/j.soard.2026.02.202",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.soard.org/article/S1550-7289(26)00357-6/pdf",null],["2","R0037696","R0037696.pdf","free_to_read","randomized_trial","Yung‐Chih Chen","2026","GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2–4: a target trial emulation","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02266-1","https://doi.org/10.1186/s13098-026-02266-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02266-1",null],["2","R0037862","R0037862.pdf","free_to_read","randomized_trial","Maria Chantal Ponziani","2026","Diabetes prevention while treating obesity: STEP by STEP analysis of an apparently inSURMOUNTable problem","Obesity and Endocrinology","Oxford University Press (OUP)","10.1093/obendo/wjag002","https://doi.org/10.1093/obendo/wjag002",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/obendo/wjag002",null],["2","R0037865","R0037865.pdf","free_to_read","randomized_trial","Giulio Equitani","2026","Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity","Obesity and Endocrinology","Oxford University Press (OUP)","10.1093/obendo/wjag009","https://doi.org/10.1093/obendo/wjag009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/obendo/wjag009",null],["2","R0038528","R0038528.pdf","no_doi","randomized_trial","Çetiner S.","2026","Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038543","R0038543.pdf","free_to_read","randomized_trial","Chao Xue","2026","Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists","iNew Medicine","Wiley","10.1002/inm3.70048","https://doi.org/10.1002/inm3.70048",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/inm3.70048",null],["2","R0038570","R0038570.pdf","free_to_read","randomized_trial","Hao Wang","2026","Glucagon-like Peptide-1 Receptor Agonist in Large Vessel Occlusion Treated by Endovascular Therapy (GALLOP-2): A Multicentre, Prospective, Randomised, Open-label, Blinded Endpoint Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6724402","https://doi.org/10.2139/ssrn.6724402",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6724402",null],["2","R0038880","R0038880.pdf","free_to_read","randomized_trial","Giovanni Musso","2026","Dysfunctional Lipid‐Induced Secretion of Glucagon‐Like Peptide‐2(GLP‐2), but Not of Incretins Glucagon‐Like Peptide‐1(GLP‐1)/Glucose‐Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia","MedComm","Wiley","10.1002/mco2.70323","https://doi.org/10.1002/mco2.70323","41948456","https://pubmed.ncbi.nlm.nih.gov/41948456/","https://doi.org/10.1002/mco2.70323",null],["2","R0039230","R0039230.pdf","open_download_failed","randomized_trial","SAIMSARA","2026","GLP-1 Receptor Agonists and Cardiovascular Effects: Scoping Review with ☸SAIMSARA","SAIMSARA Journal","ML in Health Science","10.62487/saimsarafcc6e977","https://doi.org/10.62487/saimsarafcc6e977",null,"https://pubmed.ncbi.nlm.nih.gov//","https://saimsara.com/sessions/glp-cardiovascular-20260219-101232-fcc6e977/saimsara_paper_20260219_120042_17f935.pdf",null],["2","R0039370","R0039370.pdf","open_download_failed","randomized_trial","Jeyatheepan Jeyatheepan Jeyaretnam","2026","The Rising Burden of Obesity and the Emerging Role of Injectable Weight-Loss Therapies: A Systematic Literature Review","Journal of Diseases Disorders & Treatments","Scientific Research and Community Ltd","10.47363/jddt/2026(6)142","https://doi.org/10.47363/jddt/2026(6)142",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47363/jddt/2026(6)142",null],["2","R0039524","R0039524.pdf","free_to_read","randomized_trial","Pérez-Macías JP","2026","Eosinophilic Esophagitis induced by semaglutide use: A case report","Journal of Surgery and Research","Fortune Journals","10.26502/jsr.10020482","https://doi.org/10.26502/jsr.10020482",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/jsr.10020482",null],["2","R0039569","R0039569.pdf","free_to_read","randomized_trial","Gniewko Więckiewicz","2026","GLP-1 Receptor Agonists in Addiction Psychiatry—Neurobiological Rationale, Emerging Clinical Evidence, and Cautions for Practice: A Narrative Review","Psychiatry International","MDPI AG","10.3390/psychiatryint7030130","https://doi.org/10.3390/psychiatryint7030130",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/psychiatryint7030130",null],["2","R0039717","R0039717.pdf","free_to_read","randomized_trial","Zhuoran Jia","2026","Convergent and complementary cardiorenal protective mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease within the CKM framework","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02284-z","https://doi.org/10.1186/s13098-026-02284-z",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02284-z",null],["2","R0040065","R0040065.pdf","open_download_failed","randomized_trial","Gaetano Leto","2026","Diabetes and Gastroparesis: New Concepts and Insights","Diabetology","MDPI AG","10.3390/diabetology7050093","https://doi.org/10.3390/diabetology7050093",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/7/5/93/pdf?version=1778144564",null],["2","R0040178","R0040178.pdf","no_doi","randomized_trial","Bethany A. Johnson","2026","The Benefits of Glucagon-Like Peptide 1 Agonists in Adult Women with Polycystic Ovary Syndrome","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040725","R0040725.pdf","open_download_failed","randomized_trial","Writing Task Force | ICARDIO-Alliance","2026","Draft Document for Public Consultation: What is new and what has changed in the 2026 Global Heart Failure Implementation Guidelines and why","Global Cardiology","PAGEPress Publications","10.4081/cardio.2026.111","https://doi.org/10.4081/cardio.2026.111",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.globalcardiology.info/site/article/download/111/252",null],["2","R0041597","R0041597.pdf","no_doi","randomized_trial","Brandon Thomas Mysliwiec","2026","Wanting, Liking, Effort and Interoception: Dissociable Reward Constructs in Incretin Pharmacology, and the Limits of Cross-Domain Generalisation","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041611","R0041611.pdf","free_to_read","randomized_trial","Xuancheng Zhou","2026","Effects of Antidiabetic Drugs on Longevity and Healthspan: Evidence and Controversies From Glucose-Lowering Therapy to Anti-Aging Intervention","Cytotherapy and Longevity","ICJN Publishing","10.66729/cl202606044","https://doi.org/10.66729/cl202606044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.66729/cl202606044",null],["2","R0041880","R0041880.pdf","open_download_failed","randomized_trial","A Pucci","2026","DB17 Switching from oral semaglutide to tirzepatide in patients with type 2 diabetes: a real-world retrospective cohort study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag128.018","https://doi.org/10.1093/ejendo/lvag128.018",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_2/lvag128.018/70769641/lvag128.018.pdf",null],["2","R0041883","R0041883.pdf","no_doi","randomized_trial","Saharsh Satheesh","2026","GLP-1 Receptor Agonists and Ocular Risk","The Medicine Forum",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041900","R0041900.pdf","free_to_read","randomized_trial","Dr. Yogesh Harwani","2026","Antiobesity Medicines: How Far Can We Go?","Journal of Digestive Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1828823","https://doi.org/10.1055/s-0046-1828823",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0046-1828823",null],["2","R0041943","R0041943.pdf","free_to_read","randomized_trial","Jessica Atieh","2026","Weight-loss interventions in gastrointestinal and liver diseases: a narrative review of GLP-1 based therapies, bariatric surgery, and endoscopic approaches","BMC Gastroenterology","Springer Science and Business Media LLC","10.1186/s12876-026-05264-9","https://doi.org/10.1186/s12876-026-05264-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12876-026-05264-9",null],["2","R0042249","R0042249.pdf","open_download_failed","randomized_trial","Penglin Zhou","2026","Cost-utility of injectable and oral GLP-1RAs for type 2 diabetes mellitus inadequately controlled with metformin: A Markov model analysis","Pharmacoeconomics and Policy","Elsevier BV","10.1016/j.pharp.2026.08.004","https://doi.org/10.1016/j.pharp.2026.08.004",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2950266726000510/pdf",null],["2","R0042670","R0042670.pdf","free_to_read","randomized_trial","Adela-Georgiana Buciuc","2026","Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence","Addiction & Prevention","MDPI AG","10.3390/addictprev1010007","https://doi.org/10.3390/addictprev1010007",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/addictprev1010007",null],["2","R0043299","R0043299.pdf","free_to_read","randomized_trial","Yu‐Ping Hsiao","2026","The expanding role of dermatologists in the era of glucagon-like peptide-1 receptor agonist therapies","Dermatologica Sinica","Ovid Technologies (Wolters Kluwer Health)","10.4103/ds.ds_v44-2_editorial","https://doi.org/10.4103/ds.ds_v44-2_editorial",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ds.ds_v44-2_editorial",null],["2","R0043320","R0043320.pdf","open_download_failed","randomized_trial","Lamis Jomaa","2026","Exploring Gaps in Infant and Young Child Feeding Practices and Emerging Initiatives Within Collective Shelters for Displaced Children in Lebanon","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2026.108587","https://doi.org/10.1016/j.cdnut.2026.108587",null,"https://pubmed.ncbi.nlm.nih.gov//","https://cdn.nutrition.org/article/S2475-2991(26)00952-2/pdf",null],["2","R0043472","R0043472.pdf","free_to_read","randomized_trial","Guna Sai Vallapuri","2026","A Retrospective Real-world Study of Oral Semaglutide in Obesity-related Heart Failure with Preserved Ejection Fraction in India","Journal of the Practice of Cardiovascular Sciences","Ovid Technologies (Wolters Kluwer Health)","10.4103/jpcs.jpcs_92_25","https://doi.org/10.4103/jpcs.jpcs_92_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jpcs.jpcs_92_25",null],["2","R0043482","R0043482.pdf","free_to_read","randomized_trial","A. L. Tibilova","2026","Clinical and economic aspects of semaglutide use in the treatment of obesity","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","IRBIS","10.17749/2070-4909/farmakoekonomika.2026.369","https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.369",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.369",null],["2","R0043740","R0043740.pdf","no_doi","randomized_trial","Rawan Al Marrawi","2026","Effekten av tirzepatid jämfört medliraglutid på viktminskning hos vuxnamed fetma : En litteraturstudie","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043947","R0043947.pdf","no_doi","randomized_trial","Emilia Uddenbjörk","2026","The effect of tirzepatide compared with semaglutide on weight loss in adults with obesity : A literature review","DiVA (Linnaeus University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044116","R0044116.pdf","no_doi","randomized_trial","Mojca Jensterle Sever","2026","Semaglutide delays 4-hour gastric emptying in women with PCOS and obesity","DiRROS repository (University of Maribor)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044281","R0044281.pdf","no_doi","randomized_trial","Steve Bain","2026","Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044306","R0044306.pdf","free_to_read","randomized_trial","Sri V. Madhu","2026","The Indian Obesity Paradox- Low in Muscle, High in Fat","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_245_26","https://doi.org/10.4103/ijem.ijem_245_26","42238564","https://pubmed.ncbi.nlm.nih.gov/42238564/","https://doi.org/10.4103/ijem.ijem_245_26",null],["2","R0044410","R0044410.pdf","no_doi","randomized_trial","Israa J. Mohammad","2026","A Clinical Study on the Metabolic and Hormonal Effects of Terzepate in Women With Polycystic Ovary Syndrome and Obesity","Umsida Repository (Universitas Muhammadiyah Sidoarjo)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044538","R0044538.pdf","open_download_failed","randomized_trial","G Fanelli","2026","729. From metabolic dysregulation and shared genetic etiology to suicidality: the psychiatric promise and safety debate of GLP-1 receptor agonists","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyag040.499","https://doi.org/10.1093/ijnp/pyag040.499",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ijnp/article-pdf/29/Supplement_1/i266/71009394/pyag040.499.pdf",null],["2","R0044553","R0044553.pdf","free_to_read","randomized_trial","H Taipale","2026","548. Glucagon-like peptide-1 agonists and their association with worsening mental illness in individuals with depression and anxiety. Results from a nationwide cohort study from Sweden","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyag040.159","https://doi.org/10.1093/ijnp/pyag040.159",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ijnp/pyag040.159",null],["2","R0044557","R0044557.pdf","open_download_failed","randomized_trial","M Taylor","2026","758. Use of glucagon-like peptide 1 receptor agonists and the associated outcomes in bipolar disorder, from a nationwide cohort, 2009-2024","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyag040.166","https://doi.org/10.1093/ijnp/pyag040.166",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ijnp/article-pdf/29/Supplement_1/i91/71009215/pyag040.166.pdf",null],["2","R0044591","R0044591.pdf","open_download_failed","randomized_trial","Simon Kloock","2026","P71 - ECE_1542 - Beneficial for weight, detrimental for bone: semaglutide and PYY3-36 exacerbate metabolic osteoporosis (MetOP) in a novel two-hit MetOP rat model","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.274","https://doi.org/10.1093/ejendo/lvag096.274",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.274/70597476/lvag096.274.pdf",null],["2","R0044600","R0044600.pdf","free_to_read","randomized_trial","Ursula Winterfeld","2026","S2.4 - GLP1 induced weight loss and pregnancy","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.014","https://doi.org/10.1093/ejendo/lvag096.014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.014",null],["2","R0044603","R0044603.pdf","open_download_failed","randomized_trial","Tabinda Dugal","2026","EP1778 - LBA_ECE_1292 - GLP-1 receptor agonist therapy in “double diabetes”: a case demonstrating arked improvement in glycaemic control and insulin requirements in type 1 diabetes","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1823","https://doi.org/10.1093/ejendo/lvag096.1823",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1823/70540672/lvag096.1823.pdf",null],["2","R0044660","R0044660.pdf","open_download_failed","randomized_trial","Felix Wiegand","2026","EP423 - ECE_1970 - Anti-inflammatory & anti-fibrotic effects of semaglutide in a rat model for metabolic kidney disease","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.933","https://doi.org/10.1093/ejendo/lvag096.933",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.933/70594019/lvag096.933.pdf",null],["2","R0044661","R0044661.pdf","open_download_failed","randomized_trial","Niklas Geiger","2026","EP500 - ECE_1831 - Semaglutide rewires thyroid transcriptional programs in obesity through sex-specific modulation of adiponectin signaling and mTOR–RET pathways","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.991","https://doi.org/10.1093/ejendo/lvag096.991",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.991/70593485/lvag096.991.pdf",null],["2","R0044712","R0044712.pdf","open_download_failed","randomized_trial","M Ferrua Trucco","2026","ROLE OF GLP1 AGONIST AFTER TAVI: INSIGHTS FROM MOTIVE REGISTRY","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suag058.061","https://doi.org/10.1093/eurheartjsupp/suag058.061",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartjsupp/article-pdf/28/Supplement_6/suag058.061/68233935/suag058.061.pdf",null],["2","R0044720","R0044720.pdf","open_download_failed","randomized_trial","Maja Navodnik Preložnik","2026","P149 - ECE_2587 - Semaglutide and empagliflozin improve glycaemic control and body composition in type 1 diabetes (T1DM): results from the ENDIS trial","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.337","https://doi.org/10.1093/ejendo/lvag096.337",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.337/70597596/lvag096.337.pdf",null],["2","R0044729","R0044729.pdf","open_download_failed","randomized_trial","Hurjahan Banu","2026","P475 - LBA_ECE_1057 - Clinical outcome and safety profile of combination therapy with low-dose semaglutide and metformin vs metformin alone in polycystic ovary syndrome with obesity","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.591","https://doi.org/10.1093/ejendo/lvag096.591",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.591/70596919/lvag096.591.pdf",null],["2","R0044899","R0044899.pdf","free_to_read","randomized_trial","Ghassan Ahmed","2026","Comparative effectiveness of semaglutide and tirzepatide in patients with type 2 diabetes mellitus","Tropical Journal of Pharmaceutical Research","African Journals Online (AJOL)","10.4314/tjpr.v25i8.13","https://doi.org/10.4314/tjpr.v25i8.13",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4314/tjpr.v25i8.13",null],["2","R0044918","R0044918.pdf","free_to_read","randomized_trial","Xiaoyang Ruan","2026","Current status of anti-obesity medications and performance, an EHR based survey","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02423-7","https://doi.org/10.1186/s12902-026-02423-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02423-7",null],["2","R0045000","R0045000.pdf","free_to_read","randomized_trial","Marco Lombardi","2026","Is thirst the missing physiological link between SGLT2 inhibitors and reduced nephrolithiasis risk?","Clinical Kidney Journal","Oxford University Press (OUP)","10.1093/ckj/sfag133","https://doi.org/10.1093/ckj/sfag133","42147789","https://pubmed.ncbi.nlm.nih.gov/42147789/","https://doi.org/10.1093/ckj/sfag133",null],["2","R0045051","R0045051.pdf","free_to_read","randomized_trial","Jerzy Darmoń","2026","From GLP-1 Agonism to Triple-Receptor Therapy. Narrative Review of Semaglutide, Tirzepatide, and Retatrutide in Obesity Management.","Quality in Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/qs.2026.54.70772","https://doi.org/10.12775/qs.2026.54.70772",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12775/qs.2026.54.70772",null],["2","R0045057","R0045057.pdf","free_to_read","randomized_trial","Marriam Abid","2026","Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial","DOAJ (DOAJ: Directory of Open Access Journals)","Link Medical Institute","10.61919/061x6w21","https://doi.org/10.61919/061x6w21",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.61919/061x6w21",null],["2","R0045233","R0045233.pdf","free_to_read","randomized_trial","Javed Imran","2026","Efficacy of Empagliflozin in Fibrosis Progression in Patients with Type 2 Diabetes Mellitus Having Metabolic Dysfunction-Associated Steatotic Liver Disease","Bangladesh Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/bjem.bjem_31_25","https://doi.org/10.4103/bjem.bjem_31_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bjem.bjem_31_25",null],["2","R0045265","R0045265.pdf","open_download_failed","randomized_trial","João Pedro Henriques","2026","Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review","Neurology and Clinical Neuroscience","Wiley","10.1002/ncn3.70165","https://doi.org/10.1002/ncn3.70165",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ncn3.70165",null],["2","R0045308","R0045308.pdf","free_to_read","randomized_trial","Bartosz Nowak","2026","GLP-1 RECEPTOR AGONISTS AND COLORECTAL CANCER: BIOLOGICAL PLAUSIBILITY AND CURRENT EVIDENCE","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.1(49).2026.4822","https://doi.org/10.31435/ijitss.1(49).2026.4822",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.1(49).2026.4822",null],["2","R0045388","R0045388.pdf","free_to_read","randomized_trial","Maria Evangelia Koloutsou","2026","EP670 - ECE_2372 - Liraglutide versus tirzepatide: real-world effects on lipid and carbohydrate metabolism in adults with class III obesity","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1087","https://doi.org/10.1093/ejendo/lvag096.1087",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.1087","ClinicalTrials.gov:NCT07094568"],["2","R0045419","R0045419.pdf","free_to_read","randomized_trial","Andrea Carugno","2026","Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives","Sage Open Chronic Disease","SAGE Publications","10.1177/27558428261449178","https://doi.org/10.1177/27558428261449178",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/27558428261449178",null],["2","R0045476","R0045476.pdf","no_doi","randomized_trial","Bryan Alcazar","2026","The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study","Dove Medical Press (Taylor and Francis Group)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045644","R0045644.pdf","free_to_read","randomized_trial","Guido Gembillo","2026","Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions","World Journal of Diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.v17.i4.115058","https://doi.org/10.4239/wjd.v17.i4.115058",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4239/wjd.v17.i4.115058",null],["2","R0045838","R0045838.pdf","free_to_read","randomized_trial","Emilia Lenkiewicz","2026","BERBERINE IN METABOLIC DISORDERS: THE “NATURE’S OZEMPIC” PHENOMENON - A NARRATIVE REVIEW","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.2(50).2026.5247","https://doi.org/10.31435/ijitss.2(50).2026.5247",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.2(50).2026.5247",null],["2","R0045915","R0045915.pdf","free_to_read","randomized_trial","Nina Polek","2026","GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: A NARRATIVE REVIEW OF THERAPEUTIC POTENTIAL AND WELL-BEING OUTCOMES","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.2(50).2026.5584","https://doi.org/10.31435/ijitss.2(50).2026.5584",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.2(50).2026.5584",null],["2","R0045995","R0045995.pdf","open_download_failed","randomized_trial","Michelle Raja","2026","GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders","Journal of Community Hospital Internal Medicine Perspectives","Greater Baltimore Medical Center","10.55729/2000-9666.1651","https://doi.org/10.55729/2000-9666.1651",null,"https://pubmed.ncbi.nlm.nih.gov//","https://scholarlycommons.gbmc.org/cgi/viewcontent.cgi?article=1651&context=jchimp",null],["2","R0046207","R0046207.pdf","no_doi","randomized_trial","Nimet Yılmaz","2026","Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations","Dove Medical Press (Taylor and Francis Group)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046326","R0046326.pdf","free_to_read","randomized_trial","Sarah Baumann","2026","Potential effect of the short-acting GLP-1 agonist exenatide on copeptin in healthy adults","Obesity and Endocrinology","Oxford University Press (OUP)","10.1093/obendo/wjag006","https://doi.org/10.1093/obendo/wjag006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/obendo/wjag006",null],["2","R0046427","R0046427.pdf","no_doi","randomized_trial","Roberta Lamptey","2026","Systematic Literature Review on Efficacy and Safety of Glucagon-Like Peptide (GLP-1) Agonists in Asian Adults Living with Type 2 Diabetes Mellitus.","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046589","R0046589.pdf","no_doi","randomized_trial","Jean-Francois Dartigues","2026","BiblioDem 2026 23 (4)","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046662","R0046662.pdf","free_to_read","randomized_trial","Fádi Fakhouri","2026","Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000001093","https://doi.org/10.1681/asn.0000001093","41842947","https://pubmed.ncbi.nlm.nih.gov/41842947/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13337175/",null],["2","R0046827","R0046827.pdf","free_to_read","randomized_trial","Т. S. Zaikina","2026","CARDIOPROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A REVIEW OF RANDOMIZED CLINICAL TRIALS","Bulletin of Problems Biology and Medicine","Poltava State Medical University","10.29254/2077-4214-2026-2-181-62-67","https://doi.org/10.29254/2077-4214-2026-2-181-62-67",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.29254/2077-4214-2026-2-181-62-67",null],["2","R0046869","R0046869.pdf","open_download_failed","randomized_trial","Sarina Ailawadi","2026","GLP-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.733","https://doi.org/10.1200/jco.2026.44.2_suppl.733",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.2_suppl.733",null],["2","R0048037","R0048037.pdf","open_download_failed","randomized_trial","Colton Jones","2026","GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.18","https://doi.org/10.1200/jco.2026.44.2_suppl.18",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ascopubs.org/doi/pdf/10.1200/JCO.2026.44.2_suppl.18",null],["2","R0048834","R0048834.pdf","open_download_failed","randomized_trial","Inge Nobbenhuis","2026","P294 - ECE_2059 - Oral semaglutide—a novel stimulant for the hypothalamic-pituitary-adrenal axis?","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.449","https://doi.org/10.1093/ejendo/lvag096.449",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.449/70596790/lvag096.449.pdf",null],["2","R0049362","R0049362.pdf","free_to_read","randomized_trial","Christodoula Kourtidou","2026","A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy","Journal of Atherosclerosis Prevention and Treatment","Ovid Technologies (Wolters Kluwer Health)","10.4103/aptj.aptj_27_26","https://doi.org/10.4103/aptj.aptj_27_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aptj.aptj_27_26",null],["2","R0050030","R0050030.pdf","free_to_read","randomized_trial","Obiageri Ihuarulam Okeoma","2026","From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity","Journal of international research in medical and pharmaceutical sciences","IK Press","10.56557/jirmeps/2026/v21i310654","https://doi.org/10.56557/jirmeps/2026/v21i310654",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.56557/jirmeps/2026/v21i310654",null],["2","R0050139","R0050139.pdf","free_to_read","randomized_trial","Ashok Ainkaran Ganeshalingam","2026","Semaglutide effects on insulin sensitivity and beta-cell function in patients with schizophrenia, prediabetes, and obesity treated with second generation antipsychotics",null,"American Diabetes Association","10.2337/figshare.31298458","https://doi.org/10.2337/figshare.31298458",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.31298458",null],["2","R0050398","R0050398.pdf","open_download_failed","randomized_trial","Grazia Piras","2026","GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?","Diabetology","MDPI AG","10.3390/diabetology7030050","https://doi.org/10.3390/diabetology7030050",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/7/3/50/pdf?version=1772530474",null],["2","R0050444","R0050444.pdf","open_download_failed","randomized_trial","Nour Ghostine","2026","Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists","JEADV Clinical Practice","Wiley","10.1002/jvc2.70266","https://doi.org/10.1002/jvc2.70266",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jvc2.70266",null],["2","R0050467","R0050467.pdf","free_to_read","randomized_trial","Anna Homeniuk","2026","Glucagon-like peptide-1 receptor agonist initiation and subsequent risk of gallbladder and biliary tract cancers in type 2 diabetes","Journal of Medicine Surgery and Public Health","Elsevier BV","10.1016/j.glmedi.2026.100234","https://doi.org/10.1016/j.glmedi.2026.100234",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.glmedi.2026.100234",null],["2","R0051131","R0051131.pdf","free_to_read","randomized_trial","N. Balaji","2026","A review of Non-Alcoholic Fatty Liver Disease (NAFLD) clinical trials registered in the clinical trials registry of India","Perspectives in Clinical Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/picr.picr_391_25","https://doi.org/10.4103/picr.picr_391_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/picr.picr_391_25",null],["2","R0051327","R0051327.pdf","free_to_read","randomized_trial","Nisha Ravindran","2026","Connecting the Dots: The Mind–Body Interplay within Metabolic and Cardiovascular Health","Heart and Mind","Ovid Technologies (Wolters Kluwer Health)","10.4103/hm.hm-d-26-00025","https://doi.org/10.4103/hm.hm-d-26-00025",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/hm.hm-d-26-00025",null],["2","R0051349","R0051349.pdf","free_to_read","randomized_trial","Ametov As","2026","Comparative analysis of bioequivalence, safety, and tolerability of semaglutide (tablets): results of an open-label randomized crossover comparative study","Pharmacy & Pharmacology","Volgograd State Medical University","10.19163/2307-9266-2026-14-4-387-409","https://doi.org/10.19163/2307-9266-2026-14-4-387-409",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.19163/2307-9266-2026-14-4-387-409",null],["2","R0051431","R0051431.pdf","free_to_read","randomized_trial","JEFFREY S. GONZALEZ","2026","Medication Adherence and Glycemia Reduction in Type 2 Diabetes: a Subanalysis from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study",null,"American Diabetes Association","10.2337/figshare.30657905","https://doi.org/10.2337/figshare.30657905",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30657905",null],["2","R0052636","R0052636.pdf","free_to_read","randomized_trial","Ahmed A. Abdelmoaty","2026","GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions","Clinical review for general practice","MediaMedica - MMA Limited Liability Company","10.47407/kr2026.7.4.00822","https://doi.org/10.47407/kr2026.7.4.00822",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47407/kr2026.7.4.00822",null],["2","R0053298","R0053298.pdf","open_download_failed","randomized_trial","Samir H. Assaad-Khalil","2026","Simplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations","Diabetology","MDPI AG","10.3390/diabetology7050090","https://doi.org/10.3390/diabetology7050090",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/7/5/90/pdf?version=1778056880",null],["2","R0053428","R0053428.pdf","free_to_read","randomized_trial","J N Julio Nunez","2026","Small left ventricular volume in HFpEF: from phenotype to clinical implications","ESC Heart Failure","Oxford University Press (OUP)","10.1093/eschf/xvag080","https://doi.org/10.1093/eschf/xvag080","41832742","https://pubmed.ncbi.nlm.nih.gov/41832742/","https://doi.org/10.1093/eschf/xvag080","ClinicalTrials.gov:NCT04745013; ClinicalTrials.gov:NCT06099891"],["2","R0053451","R0053451.pdf","open_download_failed","randomized_trial","Unnikrishnan Gopalkrishnan","2026","EP403 - ECE_3269 - Efficacy and safety of semaglutide injection in weight management: a subgroup analysis in patients based on Waist circumference","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.919","https://doi.org/10.1093/ejendo/lvag096.919",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.919/70594199/lvag096.919.pdf","CTRI:CTRI/2025/04/085487"],["2","R0053481","R0053481.pdf","free_to_read","randomized_trial","Jaideep Khare","2026","Real World Evidences and Identifying the Gaps and Future Prospects with Incretin Therapy in India","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_28_26","https://doi.org/10.4103/ijdt.ijdt_28_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_28_26",null],["2","R0053484","R0053484.pdf","open_download_failed","randomized_trial","Dipesh Sonawane","2026","EP596 - ECE_2764 - A subgroup analysis of phase 3 study of semaglutide injection in type 2 diabetes mellitus patients aged <40 years, 40 to <50 years and ≥50 years","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1042","https://doi.org/10.1093/ejendo/lvag096.1042",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1042/70599257/lvag096.1042.pdf","CTRI:CTRI/2025/02/080592"],["2","R0053537","R0053537.pdf","free_to_read","randomized_trial","Tatiana Palotta Minari","2026","Dietary Approaches to Obstructive Sleep Apnea: Translating Mechanistic Pathways into Clinical Practice","Clocks & Sleep","MDPI AG","10.3390/clockssleep8040058","https://doi.org/10.3390/clockssleep8040058",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/clockssleep8040058",null],["2","R0053582","R0053582.pdf","open_download_failed","randomized_trial","Judith A. Hsia","2026","Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.04.014","https://doi.org/10.1016/j.aed.2026.04.014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.endocrinologydiabetes.org/article/S3050-9157(26)00089-5/pdf",null],["2","R0053606","R0053606.pdf","open_download_failed","randomized_trial","Dipesh Sonawane","2026","EP788 - ECE_3157 - Efficacy and safety of semaglutide injection in type 2 diabetes mellitus: a subgroup analysis of patients with mild renal impairment","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1146","https://doi.org/10.1093/ejendo/lvag096.1146",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1146/70599024/lvag096.1146.pdf","CTRI:CTRI/2025/02/080592"],["2","R0053624","R0053624.pdf","open_download_failed","randomized_trial","Miguel A. Sierra-Duque","2026","Body Contouring Surgery in the Era of GLP–1 Receptor Agonists: A Narrative Review","Indian Journal of Plastic Surgery","Georg Thieme Verlag KG","10.1055/s-0046-1824526","https://doi.org/10.1055/s-0046-1824526",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0046-1824526.pdf",null],["2","R0053689","R0053689.pdf","free_to_read","randomized_trial","Paweł Jan Kuna","2026","GLP1 receptor agonists and their role in the therapy of neurodegenerative diseases - a literature review","Quality in Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/qs.2026.51.68584","https://doi.org/10.12775/qs.2026.51.68584",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12775/qs.2026.51.68584",null],["2","R0053706","R0053706.pdf","free_to_read","randomized_trial","Kavita Batra","2026","Psychiatric Safety of GLP-1 Receptor Agonists Across Type 2 Diabetes and Obesity: An Integrative Review","Diabetology","MDPI AG","10.3390/diabetology7080144","https://doi.org/10.3390/diabetology7080144",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7080144",null],["2","R0053812","R0053812.pdf","open_download_failed","randomized_trial","Kleopatra Alexiadou","2026","EP430 - ECE_3900 - Early changes in circulating immune cell populations following GLP-1 receptor agonist therapy in obesity","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.939","https://doi.org/10.1093/ejendo/lvag096.939",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.939/70593919/lvag096.939.pdf",null],["2","R0053858","R0053858.pdf","free_to_read","randomized_trial","Sedat Arslan","2026","GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications","Academia oncology.","Academia.edu Journals","10.20935/acadonco8234","https://doi.org/10.20935/acadonco8234",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20935/acadonco8234",null],["2","R0053964","R0053964.pdf","open_download_failed","randomized_trial","Unnikrishnan Gopalkrishnan","2026","EP640 - ECE_3474 - Correlation of weight loss and SF-36 physical function score in weight management with semaglutide injection: post-hoc analysis of phase 3 Study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1070","https://doi.org/10.1093/ejendo/lvag096.1070",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1070/70599034/lvag096.1070.pdf","CTRI:CTRI/2025/04/085487"],["2","R0054024","R0054024.pdf","free_to_read","randomized_trial","Abdul Malik","2026","Beyond Glycaemic Control: The Expanding Role of GLP-1 Receptor Agonists in Obesity, Obstructive Sleep Apnoea, Cardiovascular Disease, and Steatohepatitis: A Narrative Review","Journal of Health Wellness and Community Research","Link Medical Institute","10.61919/7n09x564","https://doi.org/10.61919/7n09x564",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.61919/7n09x564",null],["2","R0054174","R0054174.pdf","free_to_read","randomized_trial","Mads Bank Lynggaard","2026","Sustained improvements of bile acid diarrhoea symptoms upon statin treatment","Gastroenterology report","Oxford University Press (OUP)","10.1093/gastro/goag076","https://doi.org/10.1093/gastro/goag076","42483431","https://pubmed.ncbi.nlm.nih.gov/42483431/","https://doi.org/10.1093/gastro/goag076",null],["2","R0054266","R0054266.pdf","free_to_read","randomized_trial","Julia Pająk","2026","GLP-1 RECEPTOR AGONISTS AND THE RISK OF CHOLELITHIASIS: A LITERATURE REVIEW","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.1(49).2026.5421","https://doi.org/10.31435/ijitss.1(49).2026.5421",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.1(49).2026.5421",null],["2","R0054435","R0054435.pdf","open_download_failed","randomized_trial","Unnikrishnan Gopalkrishnan","2026","EP509 - ECE_3401 - Effect of semaglutide injection in physical function: a post-hoc analysis of a phase III study of in weight management","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.996","https://doi.org/10.1093/ejendo/lvag096.996",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.996/70594374/lvag096.996.pdf","CTRI:CTRI/2025/04/085487"],["2","R0054457","R0054457.pdf","open_download_failed","randomized_trial","Niklas Geiger","2026","RC11.1 - ECE_1833 - Additive effects of semaglutide and peptide YY3-36 dual agonism on HFpEF: focus on mitochondrial function in obese rats","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.203","https://doi.org/10.1093/ejendo/lvag096.203",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.203/70597159/lvag096.203.pdf",null],["2","R0054514","R0054514.pdf","open_download_failed","randomized_trial","Jessica Abou Chaaya","2026","Tirzepatide Use in Overweight and Obese Middle Eastern Patients With Type 1 Diabetes Mellitus","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.04.003","https://doi.org/10.1016/j.aed.2026.04.003",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.endocrinologydiabetes.org/article/S3050-9157(26)00078-0/pdf",null],["2","R0054515","R0054515.pdf","open_download_failed","randomized_trial","Unnikrishnan Gopalkrishnan","2026","EP639 - ECE_3171 - Efficacy and safety of semaglutide injection in weight management: a subgroup analysis in mild renal impairment patients","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1069","https://doi.org/10.1093/ejendo/lvag096.1069",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1069/70599183/lvag096.1069.pdf","CTRI:CTRI/2025/04/085487"],["2","R0054532","R0054532.pdf","open_download_failed","randomized_trial","Dipesh Sonawane","2026","EP636 - ECE_3154 - A subgroup analysis of Phase 3 study of Semaglutide Injection in Type 2 Diabetes Mellitus patients based on BMI: <23 kg/m2, 23 to <25 kg/m2 and ≥25 kg/m2","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1066","https://doi.org/10.1093/ejendo/lvag096.1066",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1066/70599282/lvag096.1066.pdf","CTRI:CTRI/2025/02/080592"],["2","R0054563","R0054563.pdf","free_to_read","randomized_trial","Ahmad Alam","2026","Sarcopenia in Asian Patients in the Era of SGLT2i and GLP-1RA: A Clinical Concern?","Bangladesh Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/bjem.bjem_30_26","https://doi.org/10.4103/bjem.bjem_30_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bjem.bjem_30_26",null],["2","R0054649","R0054649.pdf","free_to_read","randomized_trial","Chunqin Hu","2026","Glucagon-like peptide-1 receptor agonists and the risk of ventricular arrhythmia in patients with acute myocardial infarction and type 2 diabetes mellitus: a propensity score-matched cohort study","BMC Cardiovascular Disorders","Springer Science and Business Media LLC","10.1186/s12872-026-06354-y","https://doi.org/10.1186/s12872-026-06354-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12872-026-06354-y",null],["2","R0054736","R0054736.pdf","open_download_failed","randomized_trial","Unnikrishnan Gopalkrishnanl","2026","EP689 - ECE_2790 - Efficacy and Safety of Semaglutide Injection in Weight management: A subgroup analysis of patients based on BMI","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1097","https://doi.org/10.1093/ejendo/lvag096.1097",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1097/70599247/lvag096.1097.pdf","CTRI:CTRI/2025/04/085487"],["2","R0054799","R0054799.pdf","open_download_failed","randomized_trial","Zaid Muthana A. Abdelkarim","2026","Comparative Efficacy of various GLP-1 Receptor Agonists in the Managamenet of type 2 Diabetes Mellitus","Fortune Journal of Health Sciences","Fortune Journals","10.26502/fjhs.399","https://doi.org/10.26502/fjhs.399",null,"https://pubmed.ncbi.nlm.nih.gov//","https://cdn.fortunejournals.com/articles/comparative-efficacy-of-various-glp-1-receptor-agonists-in-the-managamenet-of-type-2-d-6595.pdf",null],["2","R0054983","R0054983.pdf","free_to_read","randomized_trial","Y. S. Rudyk","2026","Features of treatment of heart failure in patients with metabolic dysfunction-associated steatotic liver disease. Literature review","Ukrainian Therapeutical Journal","Publishing Company VIT-A-POL","10.30978/utj2026-1-74","https://doi.org/10.30978/utj2026-1-74",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.30978/utj2026-1-74",null],["2","R0055092","R0055092.pdf","free_to_read","randomized_trial","Tomáš Bolek","2026","P363 - ECE_1283 - The effect of submaximal doses of semaglutide with metformin on fertility outcomes in obese PCOS patients: a prospective observational study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.504","https://doi.org/10.1093/ejendo/lvag096.504",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.504",null],["2","R0055128","R0055128.pdf","free_to_read","randomized_trial","Ryota Usui","2026","The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model: Sub‐Analysis of an Exploratory Randomised Controlled Trial","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.70693","https://doi.org/10.1111/dom.70693","41853858","https://pubmed.ncbi.nlm.nih.gov/41853858/","https://doi.org/10.1111/dom.70693","jRCT:jRCTs051220075"],["2","R0055171","R0055171.pdf","free_to_read","randomized_trial","Jiayang Lin","2026","Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis","Journal of Diabetes","Wiley","10.1111/1753-0407.70206","https://doi.org/10.1111/1753-0407.70206","41793082","https://pubmed.ncbi.nlm.nih.gov/41793082/","https://doi.org/10.1111/1753-0407.70206",null],["2","R0055193","R0055193.pdf","free_to_read","randomized_trial","Aleksandra Płusa","2026","Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome and Women’s Reproductive Health: Metabolic and Reproductive Effects and Preconception Strategies","Reproductive and Developmental Medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/rd9.0000000000000178","https://doi.org/10.1097/rd9.0000000000000178",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/rd9.0000000000000178",null],["2","R0055266","R0055266.pdf","open_download_failed","randomized_trial","Valentina Gavazova","2026","EP600 - ECE_2544 - Metabolic-reproductive restoration in obese women with polycystic ovary syndrome treated with tirzepatide: a one-year single-arm interventional study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1044","https://doi.org/10.1093/ejendo/lvag096.1044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1044/70599271/lvag096.1044.pdf",null],["2","R0055339","R0055339.pdf","free_to_read","randomized_trial","Raphael Ijeokwu","2026","Scope and Efficacy of Semaglutide in Metabolic Dysfunction-associated Steatohepatitis: A Critical Review of Recent Evidences","Journal of Advances in Medicine and Medical Research","Sciencedomain International","10.9734/jammr/2026/v38i86177","https://doi.org/10.9734/jammr/2026/v38i86177",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9734/jammr/2026/v38i86177",null],["2","R0055354","R0055354.pdf","open_download_failed","randomized_trial","Mirjeta Guni","2026","EP1787 - LBA_ECE_1348 - Real-world treatment persistence and metabolic outcomes with a GLP-1 receptor agonist (tirzepatide) in adults with obesity: an observational cohort study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1827","https://doi.org/10.1093/ejendo/lvag096.1827",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_1/lvag096.1827/70541116/lvag096.1827.pdf",null],["2","R0055393","R0055393.pdf","free_to_read","randomized_trial","Lena Apanowicz","2026","Comparative Efficacy and Safety of Semaglutide and Tirzepatide in Obesity Management: A Literature Review","Polish Journal of Sports Medicine","Index Copernicus","10.5604/01.3001.0055.8587","https://doi.org/10.5604/01.3001.0055.8587",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5604/01.3001.0055.8587",null],["2","R0055450","R0055450.pdf","open_download_failed","randomized_trial","Hiroki Shimada","2026","WCN26-3459 COMPARATIVE CARDIOVASCULAR EFFECTIVENESS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN DIALYSIS PATIENTS WITH TYPE 2 DIABETES MELLITUS: A TARGET TRIAL EMULATION","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2026.104604","https://doi.org/10.1016/j.ekir.2026.104604",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.kireports.org/article/S2468-0249(26)00835-1/pdf",null],["2","R0055500","R0055500.pdf","free_to_read","randomized_trial","R.A. Kroken","2026","Stabil-nor: an interventional, multi-center, randomized, double blinded, placebo-controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2025.106788","https://doi.org/10.1016/j.nsa.2025.106788",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2025.106788",null],["2","R0055507","R0055507.pdf","open_download_failed","randomized_trial","Sayat Oraz","2026","GLYMPHATIC RESERVE AS A DETERMINANT OF RESPONSIVENESS NEURO-METABOLIC REHABILITATION DRIVEN BY GLP-1 RECEPTOR AGONISTS: A NOVEL PARADIGM FOR MANAGING ALZHEIMER’S DISEASE AS TYPE 3 DIABETES IN CENTRAL ASIA","Central Asian Journal of Medical Hypotheses and Ethics","South Kazakhstan Medical Academy","10.47316/cajmhe.2026.7.2.03","https://doi.org/10.47316/cajmhe.2026.7.2.03",null,"https://pubmed.ncbi.nlm.nih.gov//","https://cajmhe.com/index.php/journal/article/download/615/218",null],["2","R0055517","R0055517.pdf","free_to_read","randomized_trial","Mirembe Katabaazi Lillian","2026","Artificial Intelligence in the Optimisation of Glucagon-Like Peptide-1 Receptor agonist Therapy for Obesity and Type 2 Diabetes: A Critical Narrative Review of Treatment Monitoring and Clinical Decision Support","Journal of Medicine and Health Research","IK Press","10.56557/jomahr/2026/v11i210991","https://doi.org/10.56557/jomahr/2026/v11i210991",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.56557/jomahr/2026/v11i210991",null],["2","R0055544","R0055544.pdf","no_doi","randomized_trial","Gellért Horváth","2026","Az elhízás és a testsúlycsökkentés szerepe obstruktív alvási apnoéban = The role of obesity and weight reduction in obstructive sleep apnea","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055599","R0055599.pdf","free_to_read","randomized_trial","Unnikrishnan Gopalkrishnan","2026","EP565 - ECE_3436 - Correlation between weight loss and reduction in waist circumference in weight management with semaglutide injection: post-hoc analysis of phase 3 study","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1026","https://doi.org/10.1093/ejendo/lvag096.1026",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.1026","CTRI:CTRI/2025/04/085487"],["2","R0055675","R0055675.pdf","no_doi","randomized_trial","Ю. С. Рудик","2026","Особливості лікування серцевої недостатності в пацієнтів із метаболічно-асоційованою стеатотичною хворобою печінки. Огляд літератури","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055713","R0055713.pdf","open_download_failed","randomized_trial","Arpan B. Patel","2026","Nutritional Assessment and Management in MASLD: A Practical Guide for Primary Care","Livers","MDPI AG","10.3390/livers6040069","https://doi.org/10.3390/livers6040069",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4389/6/4/69/pdf?version=1784039668",null],["2","R0055757","R0055757.pdf","free_to_read","randomized_trial","Karolina Ciołkosz","2026","Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications","Nutrients","MDPI AG","10.3390/nu18193131","https://doi.org/10.3390/nu18193131",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/nu18193131",null],["2","R0055852","R0055852.pdf","open_download_failed","randomized_trial","Mariia Hataliak","2026","Weight Regain After Bariatric Surgery: Anatomical, Metabolic, and Behavioral Mechanisms and the Role of GLP-1/GIP Therapy","European Journal of Medical and Health Research","AMO Publisher","10.59324/ejmhr.2026.4(5).21","https://doi.org/10.59324/ejmhr.2026.4(5).21",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ejmhr.com/index.php/journal/article/download/1045/688",null],["2","R0055862","R0055862.pdf","no_doi","randomized_trial","Sajjad Ahmed Khan","2026","Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Multicenter Propensity-Matched Cohort Study","International Journal of Medical Students",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055863","R0055863.pdf","free_to_read","randomized_trial","Hubert Krzewiński","2026","MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15197540","https://doi.org/10.3390/jcm15197540",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15197540",null],["2","R0055946","R0055946.pdf","no_doi","randomized_trial","Mayur Agrawal","2026","Efficacy of SlimSEB® in enhancing health-related quality of life and weight regulation among GLP-1 treated type 2 Diabetes patients: A single-arm, placebo-controlled, sequential, pilot study","Journal of Clinical Trials and Experimental Investigations",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055995","R0055995.pdf","open_download_failed","randomized_trial",null,"2026","Open‐label extension trial of ketamine for depression shows short‐term benefit","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31512","https://doi.org/10.1002/pu.31512",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pu.31512",null],["2","R0056043","R0056043.pdf","free_to_read","randomized_trial","Rhea Sibal","2026","Do Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy","Medicina","MDPI AG","10.3390/medicina62101916","https://doi.org/10.3390/medicina62101916",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/medicina62101916",null],["2","R0056109","R0056109.pdf","free_to_read","randomized_trial","Beata Tekieli","2026","GLP-1 AND DUAL GLP-1/GIP RECEPTOR AGONISTS AS NEUROPROTECTIVE AGENTS: MECHANISMS, CLINICAL EVIDENCE, AND TRANSLATIONAL PERSPECTIVES","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.3(51).2026.6110","https://doi.org/10.31435/ijitss.3(51).2026.6110",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.3(51).2026.6110",null],["2","R0056118","R0056118.pdf","free_to_read","randomized_trial","Boknyun Kim","2026","Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review","Pharmaceuticals","MDPI AG","10.3390/ph19101572","https://doi.org/10.3390/ph19101572",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/ph19101572",null],["2","R0056131","R0056131.pdf","free_to_read","randomized_trial","Jacqueline Afua Yeboah","2026","Effects of Blueberry and Collard Greens Dietary Intervention on Metabolic and Inflammatory Biomarkers in Zucker Obese Rats","Nutrients","MDPI AG","10.3390/nu18193246","https://doi.org/10.3390/nu18193246",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/nu18193246",null],["2","R0056144","R0056144.pdf","free_to_read","randomized_trial","Dini Aulia Cahya","2026","Type 2 Diabetes and Central Obesity in the Cardiovascular Kidney–Metabolic Continuum: A Critical Narrative Review","Biomedical & Pharmacology Journal","Oriental Scientific Publishing Company","10.13005/bpj/3489","https://doi.org/10.13005/bpj/3489",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.13005/bpj/3489",null],["2","R0056154","R0056154.pdf","no_doi","randomized_trial","Satish Chandra","2026","Effect of Antidiabetic Medications on Cancer Risk: Mechanisms and Clinical Evidence","Journal of chemical health risks",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056156","R0056156.pdf","no_doi","randomized_trial","Tatjana Svjetlanovic","2026","Role of GLP-1 Receptor Agonist Medications in Substance Use Disorders","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056158","R0056158.pdf","no_doi","randomized_trial","Ashok Pingoliya","2026","Prevalence of Obstructive Sleep Apnea (Osa), Risk and Associated Factors among Patients with Type-2 Diabetes Mellitus: A Comprehensive Narrative Review","Journal of chemical health risks",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056246","R0056246.pdf","free_to_read","randomized_trial","Olatz Vergniory-Trueba","2026","Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study","Healthcare","MDPI AG","10.3390/healthcare14193355","https://doi.org/10.3390/healthcare14193355",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/healthcare14193355",null],["2","R0056248","R0056248.pdf","no_doi","randomized_trial","Sidi Mohammed Medjadi","2026","The Nutritional Impact of the Expansion of GLP-1 Receptor Agonists: The Role of Food Biotechnology","International Journal of Nutrition and Biotechnology Advancements",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056289","R0056289.pdf","no_doi","randomized_trial","Florencia Aranguren","2026","Nefropatía y albuminuria: la entrada al riesgo cardiovascular. Uso de ISRAA y fármacos nefroprotectores","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056290","R0056290.pdf","no_doi","randomized_trial","Natalia Nardelli","2026","Obesidad y síndrome metabólico: de la doble diabetes al riesgo aterosclerótico","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056294","R0056294.pdf","no_doi","randomized_trial","Santiago Lima","2026","Complicaciones oculares y nuevos tratamientos para la diabetes: ¿qué sabemos hoy?","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056296","R0056296.pdf","no_doi","randomized_trial","Pilar Cean","2026","Adultos: fármacos aprobados y su aplicación en la práctica clínica","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056322","R0056322.pdf","free_to_read","randomized_trial","Julien Paccou","2026","Musculoskeletal health in people living with obesity and the effects of glucagon-like peptide-1 receptor agonists on bone, muscle, and joints: a narrative review","Therapeutic Advances in Musculoskeletal Disease","SAGE Publications","10.1177/1759720x261460301","https://doi.org/10.1177/1759720x261460301",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/1759720x261460301",null],["2","R0056358","R0056358.pdf","no_doi","randomized_trial","Gustavo Lavenia","2026","Terapia combinada con GLP-1 e iSGLT2: ¿mayor impacto cardiorrenal?","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056364","R0056364.pdf","free_to_read","randomized_trial","Andrea Boccatonda","2026","From Adipose Tissue Dysfunction to Venous Thromboembolism","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15197500","https://doi.org/10.3390/jcm15197500",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15197500",null],["2","R0056385","R0056385.pdf","free_to_read","randomized_trial","Luz Adriana López González","2026","Modulation of the inflammatory profile and metabolic endotoxemia by passiflora ligularis juss in adults with obesity","Cahiers de Nutrition et de Diététique","Elsevier BV","10.1016/j.cnd.2026.08.044","https://doi.org/10.1016/j.cnd.2026.08.044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cnd.2026.08.044",null],["2","R0056414","R0056414.pdf","free_to_read","randomized_trial","Elena Popa","2026","GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review","International Journal of Molecular Sciences","MDPI AG","10.3390/ijms27198738","https://doi.org/10.3390/ijms27198738",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/ijms27198738",null],["2","R0056426","R0056426.pdf","open_download_failed","randomized_trial","Sebastian Guerrero L ́ópez","2026","Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP‐1 Receptor Agonists and Tirzepatide","Dermatologic Therapy","Wiley","10.1155/dth/5742100","https://doi.org/10.1155/dth/5742100",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/5742100",null],["2","R0056442","R0056442.pdf","free_to_read","randomized_trial","Guido Gembillo","2026","Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia","Medicina","MDPI AG","10.3390/medicina62101855","https://doi.org/10.3390/medicina62101855",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/medicina62101855",null],["2","R0056516","R0056516.pdf","free_to_read","randomized_trial","Obiageri Ihuarulam Okeoma","2026","Hormonal Dysregulation of Energy Expenditure and Adipose Tissue Metabolism in Non-Diabetic Adults with Obesity: Implications for Metabolic Inflammation and Weight-Loss Resistance","Journal of Medicine and Health Research","IK Press","10.56557/jomahr/2026/v11i211157","https://doi.org/10.56557/jomahr/2026/v11i211157",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.56557/jomahr/2026/v11i211157",null],["2","R0056558","R0056558.pdf","free_to_read","randomized_trial","Justin A. Dower","2026","Examining clinicians’ approaches to discussing weight during routine diabetes care: an observational study","BMC Family Practice","Springer Science and Business Media LLC","10.1186/s12875-026-03588-9","https://doi.org/10.1186/s12875-026-03588-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12875-026-03588-9","ClinicalTrials.gov:NCT05553912"],["2","R0056562","R0056562.pdf","free_to_read","randomized_trial","Hamid Nasri","2026","Dyslipidemia–Renin–Angiotensin System Crosstalk in Diabetic Kidney Disease: A Critical Narrative Review of Experimental Mechanisms and Clinical Evidence","Bratislavské lekárske listy/Bratislava medical journal","Springer Science and Business Media LLC","10.1007/s44411-026-00884-9","https://doi.org/10.1007/s44411-026-00884-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1007/s44411-026-00884-9",null],["2","R0056570","R0056570.pdf","free_to_read","randomized_trial","Abdul Qadeer","2026","Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study","Clinical Medicine Insights Cardiology","SAGE Publications","10.1177/11795468261496357","https://doi.org/10.1177/11795468261496357",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/11795468261496357",null],["2","R0056617","R0056617.pdf","free_to_read","randomized_trial","Luiza Barseghyan","2026","Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15207834","https://doi.org/10.3390/jcm15207834",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15207834",null],["2","R0056682","R0056682.pdf","free_to_read","randomized_trial","Robert P. Matson","2026","Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin-Dose Reduction, Metabolic Outcomes and Safety Assessment","Diabetology","MDPI AG","10.3390/diabetology7100189","https://doi.org/10.3390/diabetology7100189",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7100189",null],["2","R0056683","R0056683.pdf","open_download_failed","randomized_trial","Dmytro Fedkov","2026","CONTEMPORARY REHABILITATION IN HIP AND KNEE OSTEOARTHRITIS: EXERCISE PRESCRIPTION, MUSCLE HEALTH, WEIGHT MANAGEMENT, AND PERSONALIZED CARE","Anti-Aging Eastern Europe","Medical Center &quot;Edem Medical&quot; LLC","10.56543/aaeeu.2026.5.3.02","https://doi.org/10.56543/aaeeu.2026.5.3.02",null,"https://pubmed.ncbi.nlm.nih.gov//","https://antiagingeeu.com/index.php/journal/article/download/179/160",null],["2","R0056689","R0056689.pdf","free_to_read","randomized_trial","Michelle Look","2026","Orforglipron Improved Physical and Psychosocial Functioning in Adults with Obesity: Results from ATTAIN Phase 3 Randomized Trials","Obesity Pillars","Elsevier BV","10.1016/j.obpill.2026.100347","https://doi.org/10.1016/j.obpill.2026.100347",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obpill.2026.100347",null],["2","R0056709","R0056709.pdf","free_to_read","randomized_trial","Paulina Bigda","2026","BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.3(51).2026.6153","https://doi.org/10.31435/ijitss.3(51).2026.6153",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.3(51).2026.6153",null],["2","R0056713","R0056713.pdf","open_download_failed","randomized_trial","Ryan Buchanan","2026","O5 A multi-centre randomised controlled trial with nested cost-effectiveness evaluation ofscreening for liver disease in people living with type 2 diabetes in primary caref",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2026-basl.3","https://doi.org/10.1136/gutjnl-2026-basl.3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://gut.bmj.com/content/gutjnl/75/Suppl_3/A2.full.pdf",null],["2","R0056719","R0056719.pdf","free_to_read","randomized_trial","Hamed Mirzaei","2026","Non-prescription dispensing of injectable weight-loss medicines in iran: regulatory, ethical, and patient-safety concerns","Journal of the Iranian Scientific Association of Medical Ethics","InkVista Publishing House","10.66224/jirme.2.3.61","https://doi.org/10.66224/jirme.2.3.61",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.66224/jirme.2.3.61",null],["2","R0056744","R0056744.pdf","free_to_read","randomized_trial","Andrea Matteucci","2026","Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation","Journal of Cardiovascular Development and Disease","MDPI AG","10.3390/jcdd13100512","https://doi.org/10.3390/jcdd13100512",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcdd13100512",null],["2","R0057016","R0057016.pdf","free_to_read","randomized_trial","Singh S","2026","When weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder.","Annals of medicine and surgery (2012)",null,"10.1097/ms9.0000000000005709","https://doi.org/10.1097/ms9.0000000000005709","42866353","https://pubmed.ncbi.nlm.nih.gov/42866353/",null,null],["2","R0001221","R0001221.pdf","free_to_read","randomized_trial","Bucciarelli L","2025","Psychotropic effects of GLP-1R agonists.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2025.108036","https://doi.org/10.1016/j.phrs.2025.108036","41253199","https://pubmed.ncbi.nlm.nih.gov/41253199/","https://doi.org/10.1016/j.phrs.2025.108036",null],["2","R0001385","R0001385.pdf","free_to_read","randomized_trial","Cao H","2025","Efficacy and safety of glucagon-like peptide-1 receptor agonist liraglutide in new-onset diabetes after kidney transplantation: An open-label, parallel-group, randomized controlled trial.","Chinese medical journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000003880","https://doi.org/10.1097/cm9.0000000000003880","41267184","https://pubmed.ncbi.nlm.nih.gov/41267184/","https://doi.org/10.1097/cm9.0000000000003880","ChiCTR:ChiCTR2300078600"],["2","R0001440","R0001440.pdf","open_download_failed","randomized_trial","Ahuja AS","2025","Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.","JAMA ophthalmology","American Medical Association (AMA)","10.1001/jamaophthalmol.2025.3821","https://doi.org/10.1001/jamaophthalmol.2025.3821","41129133","https://pubmed.ncbi.nlm.nih.gov/41129133/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12550735/",null],["2","R0001587","R0001587.pdf","free_to_read","randomized_trial","Scheen AJ","2025","Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16453","https://doi.org/10.1111/dom.16453","40364515","https://pubmed.ncbi.nlm.nih.gov/40364515/","https://orbi.uliege.be/handle/2268/340416",null],["2","R0001717","R0001717.pdf","open_download_failed","randomized_trial","Yammine L","2025","The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence.","Current addiction reports","Springer Science and Business Media LLC","10.1007/s40429-025-00657-4","https://doi.org/10.1007/s40429-025-00657-4","41347181","https://pubmed.ncbi.nlm.nih.gov/41347181/","https://pubmed.ncbi.nlm.nih.gov/41347181/",null],["2","R0001969","R0001969.pdf","free_to_read","randomized_trial","Afrin LB","2025","Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.","The American journal of the medical sciences","Elsevier BV","10.1016/j.amjms.2025.07.006","https://doi.org/10.1016/j.amjms.2025.07.006","40675372","https://pubmed.ncbi.nlm.nih.gov/40675372/","https://doi.org/10.1016/j.amjms.2025.07.006",null],["2","R0002040","R0002040.pdf","free_to_read","randomized_trial","Bailey CJ","2025","Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.","Peptides","Elsevier BV","10.1016/j.peptides.2025.171380","https://doi.org/10.1016/j.peptides.2025.171380","40081498","https://pubmed.ncbi.nlm.nih.gov/40081498/","https://doi.org/10.1016/j.peptides.2025.171380",null],["2","R0002051","R0002051.pdf","open_download_failed","randomized_trial","D'Annibale DA","2025","Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea.","Current opinion in pulmonary medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcp.0000000000001208","https://doi.org/10.1097/mcp.0000000000001208","40855981","https://pubmed.ncbi.nlm.nih.gov/40855981/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12538296/pdf/nihms-2107079.pdf",null],["2","R0002129","R0002129.pdf","no_doi","randomized_trial","Scheen A","2025","[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].","Revue medicale de Liege",null,null,"https://doi.org/","41069298","https://pubmed.ncbi.nlm.nih.gov/41069298/",null,null],["2","R0002447","R0002447.pdf","open_download_failed","randomized_trial","Shah VN","2025","Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241291512","https://doi.org/10.1177/19322968241291512","39517127","https://pubmed.ncbi.nlm.nih.gov/39517127/","https://journals.sagepub.com/doi/pdf/10.1177/19322968241291512?download=true",null],["2","R0002777","R0002777.pdf","free_to_read","randomized_trial","Deo SV","2025","Promising results but caution needed in GLP-1RA large scale epidemiology.","Trends in endocrinology and metabolism: TEM","Elsevier BV","10.1016/j.tem.2025.03.015","https://doi.org/10.1016/j.tem.2025.03.015","40280862","https://pubmed.ncbi.nlm.nih.gov/40280862/","https://doi.org/10.1016/j.tem.2025.03.015",null],["2","R0002926","R0002926.pdf","free_to_read","randomized_trial","Scheen AJ","2025","Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101612","https://doi.org/10.1016/j.diabet.2025.101612","39818408","https://pubmed.ncbi.nlm.nih.gov/39818408/","https://orbi.uliege.be/handle/2268/340983",null],["2","R0003052","R0003052.pdf","open_download_failed","randomized_trial","Liu X","2025","RE: Glucagon-like peptide 1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","Journal of the National Cancer Institute","Oxford University Press (OUP)","10.1093/jnci/djae324","https://doi.org/10.1093/jnci/djae324","39658267","https://pubmed.ncbi.nlm.nih.gov/39658267/","https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djae324/61022328/djae324.pdf",null],["2","R0004091","R0004091.pdf","free_to_read","randomized_trial","Lee Y","2025","Review of Acetazolamide and Novel Medical Paradigms for Idiopathic Intracranial Hypertension Treatment.","Ear, nose, & throat journal","SAGE Publications","10.1177/01455613251358629","https://doi.org/10.1177/01455613251358629","40801435","https://pubmed.ncbi.nlm.nih.gov/40801435/","https://doi.org/10.1177/01455613251358629",null],["2","R0004531","R0004531.pdf","open_download_failed","randomized_trial","Kowalczyk NS","2025","Mitigating heart failure risk in patients with diabetes and chronic kidney disease.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001208","https://doi.org/10.1097/hco.0000000000001208","39998480","https://pubmed.ncbi.nlm.nih.gov/39998480/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13528586/",null],["2","R0004532","R0004532.pdf","free_to_read","randomized_trial","Scheen AJ","2025","Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2024.101594","https://doi.org/10.1016/j.diabet.2024.101594","39608670","https://pubmed.ncbi.nlm.nih.gov/39608670/","https://doi.org/10.1016/j.diabet.2024.101594",null],["2","R0004840","R0004840.pdf","free_to_read","randomized_trial","Seijas-Amigo J","2025","Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103312","https://doi.org/10.1016/j.dsx.2025.103312","41129847","https://pubmed.ncbi.nlm.nih.gov/41129847/","https://doi.org/10.1016/j.dsx.2025.103312","ClinicalTrials.gov:NCT05136287"],["2","R0004865","R0004865.pdf","open_download_failed","randomized_trial","Kalyani RR","2025","Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review.","JAMA","American Medical Association (AMA)","10.1001/jama.2025.5956","https://doi.org/10.1001/jama.2025.5956","40549398","https://pubmed.ncbi.nlm.nih.gov/40549398/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13014273/pdf/nihms-2149201.pdf",null],["2","R0005079","R0005079.pdf","open_download_failed","randomized_trial","M","2025","Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework","Authorea Preprints","Wiley","10.22541/au.175762014.42205498/v1","https://doi.org/10.22541/au.175762014.42205498/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175762014.42205498/v1",null],["2","R0005219","R0005219.pdf","free_to_read","randomized_trial","Sarkar S","2025","CROI 2025: Metabolic and Other Complications of HIV Infection.","Topics in antiviral medicine",null,null,"https://doi.org/","40802984","https://pubmed.ncbi.nlm.nih.gov/40802984/",null,null],["2","R0005816","R0005816.pdf","free_to_read","randomized_trial","Wei L","2025","Cardiorenal interactions: an update and review of treatment options","Authorea Preprints","Wiley","10.22541/au.174072853.34697252/v1","https://doi.org/10.22541/au.174072853.34697252/v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0005996","R0005996.pdf","open_download_failed","randomized_trial","Zhu D","2025","The prevention and management of chronic kidney disease among patients with metabolic syndrome.","Kidney international","Elsevier BV","10.1016/j.kint.2024.12.021","https://doi.org/10.1016/j.kint.2024.12.021","39986466","https://pubmed.ncbi.nlm.nih.gov/39986466/","https://www.kidney-international.org/article/S0085-2538(25)00141-3/pdf",null],["2","R0006031","R0006031.pdf","free_to_read","randomized_trial","Mashayekhi M","2025","RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.","The Journal of endocrinology","Bioscientifica","10.1530/joe-25-0174","https://doi.org/10.1530/joe-25-0174","41042549","https://pubmed.ncbi.nlm.nih.gov/41042549/",null,null],["2","R0006345","R0006345.pdf","free_to_read","randomized_trial","Lee CH","2025","Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16049","https://doi.org/10.1111/dom.16049","39497579","https://pubmed.ncbi.nlm.nih.gov/39497579/","https://hub.hku.hk/handle/10722/353997",null],["2","R0007288","R0007288.pdf","free_to_read","randomized_trial","Siskind D","2025","Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.","The lancet. Psychiatry","Elsevier BV","10.1016/s2215-0366(25)00129-4","https://doi.org/10.1016/s2215-0366(25)00129-4","40506208","https://pubmed.ncbi.nlm.nih.gov/40506208/","https://hdl.handle.net/10072/438504","ANZCTR:ACTRN12621001539820"],["2","R0008610","R0008610.pdf","open_download_failed","randomized_trial","Kim M","2025","Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US.","JAMA surgery","American Medical Association (AMA)","10.1001/jamasurg.2025.3089","https://doi.org/10.1001/jamasurg.2025.3089","40864458","https://pubmed.ncbi.nlm.nih.gov/40864458/","https://pmc.ncbi.nlm.nih.gov/articles/instance/12392147/bin/jamasurg-e253089-s001.pdf",null],["2","R0009126","R0009126.pdf","open_download_failed","randomized_trial","Bonnesen K","2025","Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.70276","https://doi.org/10.1002/pds.70276","41334697","https://pubmed.ncbi.nlm.nih.gov/41334697/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.70276",null],["2","R0009519","R0009519.pdf","free_to_read","randomized_trial","Rodriguez N","2025","Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.","Pharmacological reviews","Elsevier BV","10.1016/j.pharmr.2025.100058","https://doi.org/10.1016/j.pharmr.2025.100058","40554267","https://pubmed.ncbi.nlm.nih.gov/40554267/","https://doi.org/10.1016/j.pharmr.2025.100058",null],["2","R0011024","R0011024.pdf","open_download_failed","randomized_trial","Yarmolinsky J","2025","GLP-1 receptor agonists: an emerging tool for obesity-related cancer prevention?","Journal of the National Cancer Institute","Oxford University Press (OUP)","10.1093/jnci/djaf212","https://doi.org/10.1093/jnci/djaf212","40901707","https://pubmed.ncbi.nlm.nih.gov/40901707/","https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djaf212/64200573/djaf212.pdf",null],["2","R0011372","R0011372.pdf","open_download_failed","randomized_trial","O'Connor PJ","2025","Incretin Mimetics and Cardiovascular Events-The Evolving Comparative Effectiveness Landscape.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2025.37304","https://doi.org/10.1001/jamanetworkopen.2025.37304","41082236","https://pubmed.ncbi.nlm.nih.gov/41082236/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2840017/oconnor_2025_ic_250253_1759522488.63854.pdf",null],["2","R0011482","R0011482.pdf","open_download_failed","randomized_trial","Mather KJ","2025","Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16159","https://doi.org/10.1111/dom.16159","39762971","https://pubmed.ncbi.nlm.nih.gov/39762971/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16159",null],["2","R0011620","R0011620.pdf","free_to_read","randomized_trial","Dennis JM","2025","A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)02617-5","https://doi.org/10.1016/s0140-6736(24)02617-5","40020703","https://pubmed.ncbi.nlm.nih.gov/40020703/","https://doi.org/10.1016/s0140-6736(24)02617-5","ClinicalTrials.gov:NCT00622284; ClinicalTrials.gov:NCT01167881"],["2","R0011645","R0011645.pdf","open_download_failed","randomized_trial","Wang W","2025","Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.","Journal of Alzheimer's disease : JAD","SAGE Publications","10.1177/13872877251351329","https://doi.org/10.1177/13872877251351329","40552638","https://pubmed.ncbi.nlm.nih.gov/40552638/","https://www.ncbi.nlm.nih.gov/pmc/articles/12262134",null],["2","R0012255","R0012255.pdf","open_download_failed","randomized_trial","Ahmed A","2025","Helospectin from Heloderma Venom: A VIP‐Like Vasodilatory Peptide for Erectile Dysfunction and Clitoral Engorgement—A Theoretical Preclinical Proposal","Preprints.org","MDPI AG","10.20944/preprints202512.0658.v1","https://doi.org/10.20944/preprints202512.0658.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/a0fe235f09e6c68878065b8ecc3335d3/download_pub",null],["2","R0012321","R0012321.pdf","open_download_failed","randomized_trial","Pitton Rissardo J","2025","Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical Pipeline","Preprints.org","MDPI AG","10.20944/preprints202512.2271.v1","https://doi.org/10.20944/preprints202512.2271.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/4a3ddcc1fbf01a050ff9b7b434e054c4/download_pub",null],["2","R0012804","R0012804.pdf","open_download_failed","randomized_trial","Fan Y","2025","The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16203","https://doi.org/10.1111/dom.16203","39840511","https://pubmed.ncbi.nlm.nih.gov/39840511/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16203",null],["2","R0012829","R0012829.pdf","free_to_read","randomized_trial","Aamir MB","2025","Zepbound: A novel pharmacological approach to Obstructive Sleep Apnoea management.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.30330","https://doi.org/10.47391/jpma.30330","41418157","https://pubmed.ncbi.nlm.nih.gov/41418157/","https://doi.org/10.47391/jpma.30330",null],["2","R0014004","R0014004.pdf","open_download_failed","randomized_trial","Branch KRH","2025","Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial.","Diabetes care","American Diabetes Association","10.2337/dc24-2629","https://doi.org/10.2337/dc24-2629","40489260","https://pubmed.ncbi.nlm.nih.gov/40489260/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc24-2629/822817/dc242629.pdf",null],["2","R0014023","R0014023.pdf","free_to_read","randomized_trial","Hernández-Flandes R","2025","Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs Obesity and Type 2 Diabetes Treated with Liraglutide","Preprints.org","MDPI AG","10.20944/preprints202503.0855.v1","https://doi.org/10.20944/preprints202503.0855.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202503.0855.v1",null],["2","R0014043","R0014043.pdf","free_to_read","randomized_trial","Motso A","2025","GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.","Cell","Elsevier BV","10.1016/j.cell.2025.05.042","https://doi.org/10.1016/j.cell.2025.05.042","40555230","https://pubmed.ncbi.nlm.nih.gov/40555230/","https://doi.org/10.1016/j.cell.2025.05.042",null],["2","R0014049","R0014049.pdf","open_download_failed","randomized_trial","Candels LS","2025","Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70010","https://doi.org/10.1111/apt.70010","40019269","https://pubmed.ncbi.nlm.nih.gov/40019269/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70010",null],["2","R0014207","R0014207.pdf","free_to_read","randomized_trial","Cheung KS","2025","Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001034","https://doi.org/10.1097/hep.0000000000001034","39047080","https://pubmed.ncbi.nlm.nih.gov/39047080/","https://hub.hku.hk/handle/10722/350802",null],["2","R0014463","R0014463.pdf","open_download_failed","randomized_trial","Gao R","2025","Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus.","Pakistan journal of pharmaceutical sciences","Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","10.36721/pjps.2025.38.6.reg.13419.1","https://doi.org/10.36721/pjps.2025.38.6.reg.13419.1","41241797","https://pubmed.ncbi.nlm.nih.gov/41241797/","https://doi.org/10.36721/pjps.2025.38.6.reg.13419.1",null],["2","R0015224","R0015224.pdf","open_download_failed","randomized_trial","Gosavi R","2025","Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence.","European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","Elsevier BV","10.1016/j.ejso.2025.110358","https://doi.org/10.1016/j.ejso.2025.110358","40818296","https://pubmed.ncbi.nlm.nih.gov/40818296/","https://www.ejso.com/article/S0748-7983(25)00786-3/pdf",null],["2","R0015545","R0015545.pdf","free_to_read","randomized_trial","Ribeiro AL","2025","Pipeline treatments on psoriatic disease.","Best practice & research. Clinical rheumatology","Elsevier BV","10.1016/j.berh.2025.102090","https://doi.org/10.1016/j.berh.2025.102090","40987667","https://pubmed.ncbi.nlm.nih.gov/40987667/","https://doi.org/10.5167/uzh-280523",null],["2","R0015665","R0015665.pdf","free_to_read","randomized_trial","Talha M","2025","Prospecting the use of tirzepatide in combating obesity in Pakistan.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.30598","https://doi.org/10.47391/jpma.30598","41418149","https://pubmed.ncbi.nlm.nih.gov/41418149/","https://doi.org/10.47391/jpma.30598",null],["2","R0016192","R0016192.pdf","open_download_failed","randomized_trial","Zhao L","2025","Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16439","https://doi.org/10.1111/dom.16439","40329666","https://pubmed.ncbi.nlm.nih.gov/40329666/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16439",null],["2","R0016471","R0016471.pdf","free_to_read","randomized_trial","Sokary S","2025","The promise of tirzepatide: A narrative review of metabolic benefits.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2025.03.008","https://doi.org/10.1016/j.pcd.2025.03.008","40221292","https://pubmed.ncbi.nlm.nih.gov/40221292/","https://doi.org/10.1016/j.pcd.2025.03.008",null],["2","R0016926","R0016926.pdf","open_download_failed","randomized_trial","Hullon D","2025","Medical Management of Coronary Artery Disease: An Update.","The International journal of angiology : official publication of the International College of Angiology, Inc","Georg Thieme Verlag KG","10.1055/a-2645-8838","https://doi.org/10.1055/a-2645-8838","41210669","https://pubmed.ncbi.nlm.nih.gov/41210669/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12591713/pdf/10-1055-a-2645-8838.pdf",null],["2","R0016944","R0016944.pdf","open_download_failed","randomized_trial","Kukanti C","2025","Tirzepatide for Obstructive Sleep Apnea: A Novel Therapeutic Promise and the Perioperative Considerations.","Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India","Springer Science and Business Media LLC","10.1007/s12070-025-05485-6","https://doi.org/10.1007/s12070-025-05485-6","40420878","https://pubmed.ncbi.nlm.nih.gov/40420878/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12103393/pdf/12070_2025_Article_5485.pdf",null],["2","R0016958","R0016958.pdf","open_download_failed","randomized_trial","Watve M","2025","Resilience Selection: A Grave Potential Bias in Clinical Trials","Preprints.org","MDPI AG","10.20944/preprints202501.2344.v1","https://doi.org/10.20944/preprints202501.2344.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/91804e628ffdee077069d91a892ae896/download_pub",null],["2","R0017029","R0017029.pdf","free_to_read","randomized_trial","Luu S","2025","Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials.","Sleep medicine reviews","Elsevier BV","10.1016/j.smrv.2025.102169","https://doi.org/10.1016/j.smrv.2025.102169","40974973","https://pubmed.ncbi.nlm.nih.gov/40974973/","https://doi.org/10.1016/j.smrv.2025.102169",null],["2","R0017522","R0017522.pdf","free_to_read","randomized_trial","Gullaksen S","2025","Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109039","https://doi.org/10.1016/j.jdiacomp.2025.109039","40239470","https://pubmed.ncbi.nlm.nih.gov/40239470/","https://doi.org/10.1016/j.jdiacomp.2025.109039",null],["2","R0017689","R0017689.pdf","open_download_failed","randomized_trial","Wang Y","2025","EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.","Acta endocrinologica (Bucharest, Romania : 2005)","ACTA Endocrinologica Foundation","10.4183/aeb.2025.207","https://doi.org/10.4183/aeb.2025.207","42569730","https://pubmed.ncbi.nlm.nih.gov/42569730/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13450665/",null],["2","R0017760","R0017760.pdf","open_download_failed","randomized_trial","Rennert-May E","2025","Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2024.09.025","https://doi.org/10.1016/j.cjca.2024.09.025","39772331","https://pubmed.ncbi.nlm.nih.gov/39772331/","http://onlinecjc.ca/article/S0828282X24010055/pdf",null],["2","R0018127","R0018127.pdf","open_download_failed","randomized_trial","Giese S","2025","Use of Semaglutide for Successful Weight Loss and Maintenance in a Non-Obese Population: An Observational Study","Preprints.org","MDPI AG","10.20944/preprints202506.1737.v1","https://doi.org/10.20944/preprints202506.1737.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/8fba92a7e3226b96fc1ec1bc560e074a/download_pub",null],["2","R0018187","R0018187.pdf","open_download_failed","randomized_trial","Lofton HF","2025","A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2024.08.037","https://doi.org/10.1016/j.soard.2024.08.037","39401933","https://pubmed.ncbi.nlm.nih.gov/39401933/","https://www.soard.org/article/S1550-7289(24)00800-1/pdf",null],["2","R0018272","R0018272.pdf","no_doi","randomized_trial","Jin Y","2025","Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.","Alternative therapies in health and medicine",null,null,"https://doi.org/","38814610","https://pubmed.ncbi.nlm.nih.gov/38814610/",null,null],["2","R0018287","R0018287.pdf","open_download_failed","randomized_trial","Pu J","2025","First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16610","https://doi.org/10.1111/dom.16610","40662378","https://pubmed.ncbi.nlm.nih.gov/40662378/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16610",null],["2","R0018413","R0018413.pdf","open_download_failed","randomized_trial","Apperloo EM","2025","Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.","Diabetes care","American Diabetes Association","10.2337/dc24-2244","https://doi.org/10.2337/dc24-2244","39792380","https://pubmed.ncbi.nlm.nih.gov/39792380/","https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc24-2244/794467/dc242244.pdf",null],["2","R0018496","R0018496.pdf","open_download_failed","randomized_trial","Goodman J","2025","Dual agonism at the GLP-1 and glucagon receptor -- haemodynamic effects in healthy male volunteers","Authorea Preprints","Wiley","10.22541/au.174134885.55958956/v1","https://doi.org/10.22541/au.174134885.55958956/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.174134885.55958956",null],["2","R0018862","R0018862.pdf","open_download_failed","randomized_trial","Maddaloni E","2025","Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112125","https://doi.org/10.1016/j.diabres.2025.112125","40154887","https://pubmed.ncbi.nlm.nih.gov/40154887/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00139-1/pdf",null],["2","R0020098","R0020098.pdf","open_download_failed","randomized_trial","Orozco-Beltran D","2025","Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.12.002","https://doi.org/10.1016/j.pcd.2024.12.002","39741072","https://pubmed.ncbi.nlm.nih.gov/39741072/","https://www.primary-care-diabetes.com/article/S1751-9918(24)00237-7/pdf",null],["2","R0020118","R0020118.pdf","open_download_failed","randomized_trial","Akturk HK","2025","Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968231223991","https://doi.org/10.1177/19322968231223991","38317405","https://pubmed.ncbi.nlm.nih.gov/38317405/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11571402/pdf/10.1177_19322968231223991.pdf",null],["2","R0020909","R0020909.pdf","free_to_read","randomized_trial","Maddaloni E","2025","Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.","Diabetes care","American Diabetes Association","10.2337/dc24-1455","https://doi.org/10.2337/dc24-1455","39576722","https://pubmed.ncbi.nlm.nih.gov/39576722/",null,null],["2","R0022157","R0022157.pdf","open_download_failed","randomized_trial","Cifuentes L","2025","Genetic and physiological insights into satiation variability predict responses to obesity treatment.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2025.05.008","https://doi.org/10.1016/j.cmet.2025.05.008","40482646","https://pubmed.ncbi.nlm.nih.gov/40482646/","https://doi.org/10.1016/j.cmet.2025.05.008",null],["2","R0022353","R0022353.pdf","open_download_failed","randomized_trial","Deng Y","2025","Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).","Statistics in medicine","Wiley","10.1002/sim.70091","https://doi.org/10.1002/sim.70091","40386918","https://pubmed.ncbi.nlm.nih.gov/40386918/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sim.70091",null],["2","R0023421","R0023421.pdf","open_download_failed","randomized_trial","Dell'Isola A","2025","Osteoarthritis year in review 2025: Epidemiology and therapy.","Osteoarthritis and cartilage","Elsevier BV","10.1016/j.joca.2025.08.015","https://doi.org/10.1016/j.joca.2025.08.015","40914550","https://pubmed.ncbi.nlm.nih.gov/40914550/","https://www.oarsijournal.com/article/S1063-4584(25)01127-6/pdf",null],["2","R0024922","R0024922.pdf","open_download_failed","randomized_trial","Brosnahan N","2025","Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2025.08.009","https://doi.org/10.1016/j.clnu.2025.08.009","40934815","https://pubmed.ncbi.nlm.nih.gov/40934815/","https://www.clinicalnutritionjournal.com/article/S0261-5614(25)00223-7/pdf","ClinicalTrials.gov:NCT02683798"],["2","R0029072","R0029072.pdf","free_to_read","randomized_trial","Dhingra NK","2025","Generalizability of SELECT to Cardiac Surgical Patients: Analysis of the TRICS III Randomized Trial.","JACC. Advances","Elsevier BV","10.1016/j.jacadv.2025.101597","https://doi.org/10.1016/j.jacadv.2025.101597","39954345","https://pubmed.ncbi.nlm.nih.gov/39954345/","https://doi.org/10.1016/j.jacadv.2025.101597",null],["2","R0029608","R0029608.pdf","open_download_failed","randomized_trial","Borlaug BA","2025","HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf663","https://doi.org/10.1093/eurheartj/ehaf663","40886160","https://pubmed.ncbi.nlm.nih.gov/40886160/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehaf663/64164445/ehaf663.pdf","ClinicalTrials.gov:NCT05592275"],["2","R0030109","R0030109.pdf","open_download_failed","randomized_trial","Moe SS","2025","Top studies of 2024 relevant to primary care: From the PEER team.","Canadian family physician Medecin de famille canadien","The College of Family Physicians of Canada","10.46747/cfp.7105309","https://doi.org/10.46747/cfp.7105309","40368626","https://pubmed.ncbi.nlm.nih.gov/40368626/","https://www.cfp.ca/content/cfp/71/5/309.full.pdf",null],["2","R0031454","R0031454.pdf","free_to_read","randomized_trial","Rajeev Gupta","2025","Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century","RUHS Journal of Health Science","Rajasthan University of Health Sciences","10.37821/ruhsjhs.10.2.2025.869","https://doi.org/10.37821/ruhsjhs.10.2.2025.869",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.37821/ruhsjhs.10.2.2025.869",null],["2","R0032342","R0032342.pdf","open_download_failed","randomized_trial","Fleurimond Cemelus, Madge, PA-C","2025","The Role of GLP-1RAs in Depression among Patients with Metabolic Conditions","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","University of Lynchburg","10.63932/3067-7106.1037","https://doi.org/10.63932/3067-7106.1037",null,"https://pubmed.ncbi.nlm.nih.gov//","https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=1037&context=jms",null],["2","R0032347","R0032347.pdf","no_doi","randomized_trial","Oliver, Abir","2025","GLP-1 vs Gastric Bypass in Treating Obesity and Type 2 Diabetes","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032352","R0032352.pdf","no_doi","randomized_trial","Graczyk, Nicole A","2025","Expanding the Role of GLP-1 Receptor Agonists: Cardiovascular, Renal, and Metabolic Outcomes Beyond Glycemic Control","Florida International University Digital Commons (Florida International University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032357","R0032357.pdf","no_doi","randomized_trial","Nasser, PharmD, Sukeina","2025","Strengths, Gaps, and Opportunities in the Evidence Base For GLP-1 Receptor Agonists: Implications for Market Access Strategy","The Medicine Forum",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032363","R0032363.pdf","no_doi","randomized_trial","António Luís Martins Coutinho Cabral e Lopes","2025","SGLT2i and GLP1RA: Safety and Effectiveness Profiles Evaluation using Real-World Patient Data","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032367","R0032367.pdf","no_doi","randomized_trial","Luiza Paulsen Rodrigues","2025","Target Trial Emulation: A Rigorous Framework for Causal Inference in Real-World Data Studies (Motivated by the OneFlorida+ Study on GLP-1RA and SGLT2i Use and Dementia Risk in Type 2 Diabetes by Tang et al.)","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032369","R0032369.pdf","no_doi","randomized_trial","Zabel, Debbie","2025","Pharmacological Treatment Options for Nonalcoholic Steatohepatitis: Resmetirom vs GLP- 1 Receptor Agonists","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032371","R0032371.pdf","no_doi","randomized_trial","Oliver, Abir","2025","Comparing the Efficacy and Safety of GLP-1 Receptor Agonists Versus Gastric Bypass Surgery in the Treatment of Obesity and Type 2 Diabetes","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032380","R0032380.pdf","no_doi","randomized_trial","Fischer, Ellie","2025","Efficacy of GLP-1 Receptor Agonists in Women with Polycystic Ovary Syndrome","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032616","R0032616.pdf","free_to_read","randomized_trial","Roland Gál","2025","The Year in Hungarian Cardiology 2024: Heart failure","Cardiologia Hungarica","Cardiologia Hungarica","10.26430/chungarica.2025.55.5.335","https://doi.org/10.26430/chungarica.2025.55.5.335",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26430/chungarica.2025.55.5.335",null],["2","R0033242","R0033242.pdf","free_to_read","randomized_trial","Demosthenes Panagiotakos","2025","Metabolic Liver Disease and Obesity at a Therapeutic Crossroads: From Lifestyle Interventions to Incretin-based Pharmacotherapy","Journal of Atherosclerosis Prevention and Treatment","Ovid Technologies (Wolters Kluwer Health)","10.4103/aptj.aptj_26_26","https://doi.org/10.4103/aptj.aptj_26_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aptj.aptj_26_26",null],["2","R0033262","R0033262.pdf","free_to_read","randomized_trial",null,"2025","AAPS 2025 Annual Meeting Abstracts Supplement Table of Contents","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/gox.0000000000006712","https://doi.org/10.1097/gox.0000000000006712",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/gox.0000000000006712",null],["2","R0034279","R0034279.pdf","free_to_read","randomized_trial","Pawanindra Lal","2025","Anti Obesity Drugs and Bariatric Surgery: Complementary Noncompeting Strategies in Obesity Management","Journal of Bariatric Surgery","Ovid Technologies (Wolters Kluwer Health)","10.4103/jbs.jbs_1_26","https://doi.org/10.4103/jbs.jbs_1_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jbs.jbs_1_26",null],["2","R0034428","R0034428.pdf","free_to_read","randomized_trial","Ashwani Mehta","2025","Editorial comment on “The effect of cardiovascular–kidney–metabolic disease on pulse pressure in patients with type II diabetes”","Journal of current cardiology.","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcc.jcc_9_25","https://doi.org/10.4103/jcc.jcc_9_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcc.jcc_9_25",null],["2","R0035942","R0035942.pdf","no_doi","randomized_trial","Velazquez Hernandez, Maite","2025","Semaglutide Injection for Weight Reduction in Non-Diabetic Adults with Overweight and Obesity","JMU Scholoraly Commons (James Madison University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036220","R0036220.pdf","no_doi","randomized_trial","Jakob German","2025","Geneettiseen tietoon perustuva reaalimaailman näyttö ja tutkimuksen suunnittelu","Työväentutkimus Vuosikirja",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036285","R0036285.pdf","no_doi","randomized_trial","Bar, Orian","2025","Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity","Digital Commons - Gardner-Webb University (Gardner–Webb University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036386","R0036386.pdf","no_doi","randomized_trial","Sabet, Oliver G","2025","Examining the Molecular Mechanisms of Glucagon-like Peptide-1 Receptor Agonists in Cancer Cell Biology","OpenCommons - UConn (University of Connecticut)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036443","R0036443.pdf","no_doi","randomized_trial","Shirley Wang Ph.D.","2025","Comparative effectiveness of the glucose-lowering agents semaglutide and tirzepatide vs sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients with peripheral vascular disease","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036947","R0036947.pdf","free_to_read","randomized_trial","Qamar mohammed kashmoola","2025","TIRZEPATIDE USE IN SPECIAL POPULATIONS: ELDERLY, PREGNANT WOMEN, AND ADOLESCENTS WITH TYPE 2 DIABETES","Journal of Population Therapeutics and Clinical Pharmacology","Green Publication","10.53555/0cqhb709","https://doi.org/10.53555/0cqhb709",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53555/0cqhb709",null],["2","R0036997","R0036997.pdf","no_doi","randomized_trial","Hiromi Okuyama, Agnês","2025","O uso de semaglutida no tratamento de obesidade e sobrepeso: uma revisão integrativa","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037445","R0037445.pdf","no_doi","randomized_trial","Victor Galvão","2025","Target trial emulation to reduce confounding in therapy effectiveness assessment - (Based on the Cohort Study by Wang et al. on Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder)","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037875","R0037875.pdf","free_to_read","randomized_trial",null,"2025","Title Index","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.jcma.0001177672.68128.57","https://doi.org/10.1097/01.jcma.0001177672.68128.57","41449607","https://pubmed.ncbi.nlm.nih.gov/41449607/","https://doi.org/10.1097/01.jcma.0001177672.68128.57",null],["2","R0038076","R0038076.pdf","open_download_failed","randomized_trial","Angimar Uriepero","2025","Cardiovascular outcomes in CLL patients receiving GLP-1 agonists and BTK inhibitors: A global propensity-matched study","Blood","American Society of Hematology","10.1182/blood-2025-2774","https://doi.org/10.1182/blood-2025-2774",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ashpublications.org/blood/article-pdf/146/Supplement 1/2774/2450097/blood-5521-main.pdf",null],["2","R0038131","R0038131.pdf","open_download_failed","randomized_trial","Filippo Crea","2025","New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf271","https://doi.org/10.1093/eurheartj/ehaf271","40364752","https://pubmed.ncbi.nlm.nih.gov/40364752/","https://academic.oup.com/eurheartj/article-pdf/46/19/1777/63173029/ehaf271.pdf",null],["2","R0038275","R0038275.pdf","no_doi","randomized_trial","Zhang An-na","2025","Molecular mechanism of Haikun Shenxi Capsules as adjuvant therapy for diabetic kidney disease through the interleukin-23/interleukin-17 inflammatory axis","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038362","R0038362.pdf","open_download_failed","randomized_trial","Armin Farahvash","2025","A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT","Journal of the Canadian Association of Gastroenterology","Oxford University Press (OUP)","10.1093/jcag/gwae059.085","https://doi.org/10.1093/jcag/gwae059.085",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jcag/article-pdf/8/Supplement_1/i33/61814133/gwae059.085.pdf",null],["2","R0038372","R0038372.pdf","free_to_read","randomized_trial","Stefan Agewall","2025","Lipid treatment","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvaf009","https://doi.org/10.1093/ehjcvp/pvaf009","40079901","https://pubmed.ncbi.nlm.nih.gov/40079901/","https://doi.org/10.1093/ehjcvp/pvaf009",null],["2","R0038836","R0038836.pdf","free_to_read","randomized_trial","Joshua J. Neumiller","2025","Real-World Data","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000000989","https://doi.org/10.34067/kid.0000000989","41264407","https://pubmed.ncbi.nlm.nih.gov/41264407/","https://doi.org/10.34067/kid.0000000989",null],["2","R0039144","R0039144.pdf","open_download_failed","randomized_trial","Sam Schulman","2025","Recent Advances in Thrombosis and Hemostasis—Part XII","Seminars in Thrombosis and Hemostasis","Georg Thieme Verlag KG","10.1055/s-0045-1809697","https://doi.org/10.1055/s-0045-1809697","40940012","https://pubmed.ncbi.nlm.nih.gov/40940012/","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0045-1809697.pdf",null],["2","R0039330","R0039330.pdf","free_to_read","randomized_trial","Justyna Daniek","2025","Neuroendocrine modulation in addiction: clinical perspectives on GLP-1R agonists","MEDICAL SCIENCE PULSE","Index Copernicus","10.5604/01.3001.0055.3402","https://doi.org/10.5604/01.3001.0055.3402",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5604/01.3001.0055.3402",null],["2","R0039521","R0039521.pdf","no_doi","randomized_trial","Чернявський, Володимир","2025","Вплив ліраглутиду та дапагліфлозину на серцево-судинний ризик у пацієнтів зі стеатотичною хворобою печінки, асоційованою з метаболічною дисфункцією","Scientific periodicals of Ukraine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039651","R0039651.pdf","open_download_failed","randomized_trial","Mallory Mandel","2025","Reaching for Individualized Medicine in Diabetic Kidney Disease","JAMA Network Open","American Medical Association (AMA)","10.1001/jamanetworkopen.2025.1702","https://doi.org/10.1001/jamanetworkopen.2025.1702","40126484","https://pubmed.ncbi.nlm.nih.gov/40126484/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2831873/mandel_2025_ic_250034_1742234480.28594.pdf",null],["2","R0039872","R0039872.pdf","open_download_failed","randomized_trial","Mashal Shahzadi","2025","PHARMACOLOGICAL MODULATORS OF APPETITE AND METABOLISM IN OBESITY MANAGEMENT","Biology and Biotechnology Communications","Synapse Educational Research Institute (SMC-Private) Limited","10.67079/bbc.0232","https://doi.org/10.67079/bbc.0232",null,"https://pubmed.ncbi.nlm.nih.gov//","https://biotech-journal.com/index.php/BBCJ/article/download/32/35",null],["2","R0039946","R0039946.pdf","no_doi","randomized_trial","Jessica Mok","2025","The role of glucagon-like-peptide 1 in patients with suboptimal weight loss following bariatric surgery","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039961","R0039961.pdf","open_download_failed","randomized_trial","Jonathan M. Kalman","2025","Knowledge gaps in the 2024 consensus statement on atrial fibrillation ablation","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf175","https://doi.org/10.1093/eurheartj/ehaf175","40325605","https://pubmed.ncbi.nlm.nih.gov/40325605/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehaf175/63057972/ehaf175.pdf",null],["2","R0040009","R0040009.pdf","open_download_failed","randomized_trial",null,"2025","Weekly semaglutide reduces craving in adults with alcohol use disorder","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31307","https://doi.org/10.1002/pu.31307",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pu.31307",null],["2","R0040025","R0040025.pdf","open_download_failed","randomized_trial","Stefan Agewall","2025","Bleeding and thrombosis","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvaf017","https://doi.org/10.1093/ehjcvp/pvaf017","40314444","https://pubmed.ncbi.nlm.nih.gov/40314444/","https://academic.oup.com/ehjcvp/article-pdf/11/3/211/63043982/pvaf017.pdf",null],["2","R0040168","R0040168.pdf","open_download_failed","randomized_trial","Konstantinos C. Koskinas","2025","European Society of Cardiology clinical consensus statement on obesity and cardiovascular disease: 10 key points","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf177","https://doi.org/10.1093/eurheartj/ehaf177","40838297","https://pubmed.ncbi.nlm.nih.gov/40838297/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehaf177/64099320/ehaf177.pdf",null],["2","R0040212","R0040212.pdf","open_download_failed","randomized_trial",null,"2025","Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial","Texila international journal of academic research","Texila International Marketing Management","10.21522/tijar.2014.12.02.art012","https://doi.org/10.21522/tijar.2014.12.02.art012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.texilajournal.com/adminlogin/download.php?category=article&file=12_TJ3533.pdf",null],["2","R0040281","R0040281.pdf","no_doi","randomized_trial","Brady Park","2025","Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040458","R0040458.pdf","open_download_failed","randomized_trial","Dipti Gothi","2025","Tirzepatide as an Emerging Modality for Management of Obstructive Sleep Apnea","Indian Journal of Sleep Medicine","Jaypee Brothers Medical Publishing","10.5005/jp-journals-10069-0151","https://doi.org/10.5005/jp-journals-10069-0151",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5005/jp-journals-10069-0151",null],["2","R0040470","R0040470.pdf","no_doi","randomized_trial","Hartej Gill","2025","The Effect of Adjunctive Semaglutide Treatment on Cognition and Reward Based Decision Making in Patients with Major Depressive Disorder","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040543","R0040543.pdf","open_download_failed","randomized_trial","E. Wynn Jones","2025","Let food be thy medicine: anti-inflammatory diets and the hidden properties of coronary plaque","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaf115","https://doi.org/10.1093/cvr/cvaf115","40667871","https://pubmed.ncbi.nlm.nih.gov/40667871/","https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvaf115/63775371/cvaf115.pdf",null],["2","R0040607","R0040607.pdf","open_download_failed","randomized_trial","Sunny Ssu‐Yu Chen","2025","Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke: Statistical and Methodological Suggestions While Exploring Outcomes",null,"Wiley","10.22541/au.173921621.11534712/v1","https://doi.org/10.22541/au.173921621.11534712/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.173921621.11534712",null],["2","R0040941","R0040941.pdf","open_download_failed","randomized_trial","Filippo Crea","2025","Heart failure: focus on genes, kidney, and sudden death","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf872","https://doi.org/10.1093/eurheartj/ehaf872","41232809","https://pubmed.ncbi.nlm.nih.gov/41232809/","https://academic.oup.com/eurheartj/article-pdf/46/43/4449/65280652/ehaf872.pdf",null],["2","R0041404","R0041404.pdf","free_to_read","randomized_trial","Phillipe Abreu","2025","Should Kidney Transplantation be Offered to Patients with Body Mass Index >40?: Commentary","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000000954","https://doi.org/10.34067/kid.0000000954","40779321","https://pubmed.ncbi.nlm.nih.gov/40779321/","https://doi.org/10.34067/kid.0000000954",null],["2","R0041802","R0041802.pdf","free_to_read","randomized_trial","Xin Zhang","2025","MASLD/MASH—New mechanisms and treatments","Hepatology Communications","Ovid Technologies (Wolters Kluwer Health)","10.1097/hc9.0000000000000770","https://doi.org/10.1097/hc9.0000000000000770","40694379","https://pubmed.ncbi.nlm.nih.gov/40694379/","https://doi.org/10.1097/hc9.0000000000000770",null],["2","R0042045","R0042045.pdf","free_to_read","randomized_trial","Robert Gerard Memelink","2025","Keep the muscles, lose the fat",null,"VU E-Publishing","10.5463/thesis.1193","https://doi.org/10.5463/thesis.1193",null,"https://pubmed.ncbi.nlm.nih.gov//","https://research.vu.nl/en/publications/e5b87826-4eaf-42a8-8c78-0ce17fe80a5d",null],["2","R0042083","R0042083.pdf","no_doi","randomized_trial","Nitish K Dhingra (14832449)","2025","Generalizability of SELECT to cardiac surgical patients: analysis of the TRICS III randomized trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042110","R0042110.pdf","no_doi","randomized_trial","Ricky Le (13082112)","2025","The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042183","R0042183.pdf","no_doi","randomized_trial","Bahareh Kheiri","2025","Evaluating the Impact of Missing Data on Treatment Effect Evaluating the Impact of Missing Data on Treatment Effect Estimation in Simulated Pragmatic Trials: A Methodological Study in Type 2 Diabetes","Scholarship@Western (Western University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042291","R0042291.pdf","open_download_failed","randomized_trial","Sylvia Peña","2025","GLP-1 medications for kids: do they work, and at what price?","Evidence-Based Nursing","BMJ","10.1136/ebnurs-2025-104495","https://doi.org/10.1136/ebnurs-2025-104495","41475770","https://pubmed.ncbi.nlm.nih.gov/41475770/","https://epublications.marquette.edu/cgi/viewcontent.cgi?article=2090&context=nursing_fac",null],["2","R0042337","R0042337.pdf","free_to_read","randomized_trial","Vo Van Kha","2025","P03 | Role of GLP-1 RAs on bone metabolism in patients with type 2 diabetes mellitus: longitudinal study","Italian Journal of Medicine","PAGEPress Publications","10.4081/itjm.2025.2209","https://doi.org/10.4081/itjm.2025.2209",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4081/itjm.2025.2209",null],["2","R0042595","R0042595.pdf","free_to_read","randomized_trial","Sami, Nafiseh","2025","Antidiabetic Agents and Stroke Risk in Type 2 Diabetes: A Narrative Review of Mechanisms, Evidence, and Clinical Implications",null,"DoNotEdit","10.32592/smmr.202501.05.06","https://doi.org/10.32592/smmr.202501.05.06",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.32592/smmr.202501.05.06",null],["2","R0043325","R0043325.pdf","free_to_read","randomized_trial","Sawera Haider","2025","Glucagon-like Peptide-1 Receptor Agonists: Multifaceted Agents for Cardiovascular Risk Reduction in Diabetes","The Journal of Medical Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/jmr.jmr_48_25","https://doi.org/10.4103/jmr.jmr_48_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jmr.jmr_48_25",null],["2","R0043414","R0043414.pdf","free_to_read","randomized_trial","Mansi Srivastava","2025","Advancing Type 2 Diabetes Management with Semaglutide: Clinical and Real-World Insights","medtigo Journal of Medicine","Medtigo","10.63096/medtigo3061238","https://doi.org/10.63096/medtigo3061238",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.63096/medtigo3061238",null],["2","R0043422","R0043422.pdf","free_to_read","randomized_trial","Ahmad Alam","2025","GLP-1 Receptor Agonists for Obesity in Asians: Evidence From East Asia and Research Gaps in South Asia","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_164_25","https://doi.org/10.4103/jod.jod_164_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_164_25",null],["2","R0043445","R0043445.pdf","free_to_read","randomized_trial","Suman Bhandari","2025","Recent trials with a “High impact” on current daily practice: A 360° journal search","Journal of current cardiology.","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcc.jcc_3_25","https://doi.org/10.4103/jcc.jcc_3_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcc.jcc_3_25","ClinicalTrials.gov:NCT04275726"],["2","R0043468","R0043468.pdf","free_to_read","randomized_trial",null,"2025","Abstract of Oral Papers presented at the OSSICON 2026, the 23rd Annual Conference of the Obesity and Metabolic Surgery Society of India (OSSI), February 25–28, 2026, Ahmedabad, India","Journal of Bariatric Surgery","Ovid Technologies (Wolters Kluwer Health)","10.4103/jbs.jbs_4_26","https://doi.org/10.4103/jbs.jbs_4_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jbs.jbs_4_26",null],["2","R0043492","R0043492.pdf","free_to_read","randomized_trial","Natalia Halpern","2025","Critically Appraised Topic: Weight Gain Following Discontinuation Of Semaglutide In Nondiabetic Patients","Michigan Journal of Medicine","University of Michigan Library","10.3998/mjm.7687","https://doi.org/10.3998/mjm.7687",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3998/mjm.7687",null],["2","R0043532","R0043532.pdf","open_download_failed","randomized_trial","Xin Li","2025","Dapagliflozin restores odor‐induced functional integration of POC circuit, but not local olfactory neural activation in patients with type 2 diabetes: a 16‐week randomized parallel comparative study","Alzheimer s & Dementia","Wiley","10.1002/alz70859_097012","https://doi.org/10.1002/alz70859_097012","41446977","https://pubmed.ncbi.nlm.nih.gov/41446977/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz70859_097012",null],["2","R0043548","R0043548.pdf","open_download_failed","randomized_trial","Tracey McLaughlin","2025","MON-734 TIrzepatide Reverses Insulin Resistance Independent of Weight Loss in Individuals Without Diabetes","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.067","https://doi.org/10.1210/jendso/bvaf149.067",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.067/64862718/bvaf149.067.pdf",null],["2","R0043605","R0043605.pdf","open_download_failed","randomized_trial","Roshaneh Ali","2025","MON-702 Semaglutide as a Potential Tool in Pre-Lung Transplant Weight Loss Optimization","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.040","https://doi.org/10.1210/jendso/bvaf149.040",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.040/64864228/bvaf149.040.pdf",null],["2","R0043627","R0043627.pdf","free_to_read","randomized_trial","Nikola Todorović","2025","Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1α for improved metabolism","Medical Gas Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/mgr.medgasres-d-24-00146","https://doi.org/10.4103/mgr.medgasres-d-24-00146","40251025","https://pubmed.ncbi.nlm.nih.gov/40251025/","https://doi.org/10.4103/mgr.medgasres-d-24-00146",null],["2","R0043654","R0043654.pdf","no_doi","randomized_trial","Marta Lecina Arranz","2025","Effect of semaglutide combined with lifestyle intervention on ovulation rate, androgen excess and metabolic outcomes in adolescent and young adult women with polycystic ovary syndrome: an open-label randomized clinical trial","Universitat de Girona Digital Repository (Universitat de Girona)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043657","R0043657.pdf","open_download_failed","randomized_trial","Mahvish Ayman","2025","SAT-725 Impact of Ozempic (Semaglutide) on Reducing Total Knee Replacement Procedures in Patients with Osteoarthritis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.582","https://doi.org/10.1210/jendso/bvaf149.582",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.582/64862950/bvaf149.582.pdf",null],["2","R0043673","R0043673.pdf","free_to_read","randomized_trial","Giuseppe Marano","2025","Narrative review on glucagon-like peptide-1 receptor agonists and late-life depression: A new frontier in geriatric psychiatry?","Aging advances.","Ovid Technologies (Wolters Kluwer Health)","10.4103/agingadv.agingadv-d-25-00027","https://doi.org/10.4103/agingadv.agingadv-d-25-00027",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/agingadv.agingadv-d-25-00027",null],["2","R0043804","R0043804.pdf","open_download_failed","randomized_trial","Jo-Ching Chen","2025","MON-684 Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.023","https://doi.org/10.1210/jendso/bvaf149.023",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.023/64863978/bvaf149.023.pdf",null],["2","R0043831","R0043831.pdf","no_doi","randomized_trial","David Owens","2025","An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043949","R0043949.pdf","free_to_read","randomized_trial","Xia Gu","2025","Prostaglandins supplementation enhances the efficacy of standard care on renal outcomes in patients with diabetic kidney disease","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000003740","https://doi.org/10.1097/cm9.0000000000003740","40898398","https://pubmed.ncbi.nlm.nih.gov/40898398/","https://doi.org/10.1097/cm9.0000000000003740","ClinicalTrials.gov:NCT00968812; ChiCTR:ChiCTR2000040170"],["2","R0043977","R0043977.pdf","no_doi","randomized_trial","Steve Bain","2025","Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044026","R0044026.pdf","free_to_read","randomized_trial","Haoyi Zheng","2025","Cardiovascular effects of anti-obesity medications: the perils and promise","Cardiology Plus","Ovid Technologies (Wolters Kluwer Health)","10.1097/cp9.0000000000000114","https://doi.org/10.1097/cp9.0000000000000114",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/cp9.0000000000000114",null],["2","R0044366","R0044366.pdf","no_doi","randomized_trial","Herman, Rok","2025","Effect of tirzepatide-induced weight loss on adipose tissue in obesity","DiRROS repository (University of Maribor)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044522","R0044522.pdf","no_doi","randomized_trial","D'AMBROSIO, MELISSA","2025","Semaglutide per il trattamento dell'obesità: valutazione di efficacia in un contesto di vita reale","Electronic Theses and Dissertations Repository (University of Pisa)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044589","R0044589.pdf","free_to_read","randomized_trial","Asbjørn Seenithamby Poulsen","2025","Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteo-arthritis: Secondary analyses of a randomized controlled trial","Osteoarthritis and Cartilage","Elsevier BV","10.1016/j.joca.2025.02.024","https://doi.org/10.1016/j.joca.2025.02.024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.joca.2025.02.024",null],["2","R0044844","R0044844.pdf","open_download_failed","randomized_trial","Salem Beshyah","2025","Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses","Ibnosina Journal of Medicine and Biomedical Sciences","Georg Thieme Verlag KG","10.1055/s-0045-1811568","https://doi.org/10.1055/s-0045-1811568",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0045-1811568.pdf",null],["2","R0045239","R0045239.pdf","open_download_failed","randomized_trial","Anvesh Dasari","2025","MON-691 Oral Delivery Of A Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) Via A Robotic Pill (RT-114) Achieves Bioequivalence To Subcutaneous Injection In Canines","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.029","https://doi.org/10.1210/jendso/bvaf149.029",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.029/64862934/bvaf149.029.pdf",null],["2","R0045464","R0045464.pdf","open_download_failed","randomized_trial","Hsing‐Yuan Li","2025","Comparing GLP-1 agonists versus other weight loss interventions on atrial fibrillation recurrence after catheter ablation: a meta-regression analysis","EP Europace","Oxford University Press (OUP)","10.1093/europace/euaf085.330","https://doi.org/10.1093/europace/euaf085.330",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/europace/article-pdf/27/Supplement_1/euaf085.330/63305074/euaf085.330.pdf",null],["2","R0045519","R0045519.pdf","free_to_read","randomized_trial","Roy Eldor","2025","Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled open label pilot study examining a 16-week flexible titration regimen vs. label-recommended 8-week semaglutide titration regimen",null,"American Diabetes Association","10.2337/figshare.29425454.v1","https://doi.org/10.2337/figshare.29425454.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.29425454.v1",null],["2","R0045691","R0045691.pdf","open_download_failed","randomized_trial","Pshysical and Rehabilitation medicine 2 , IRCSS istituto ortopedico Rizzoli, Bologna , Italy","2025","The Role of GLP-1 Receptor Agonists In Rheumatic Diseases and Osteoarthritis: A Literature Review","˜The œjournal of clinical medicine.","Directive Publications","10.52338/tjocm.2025.5014","https://doi.org/10.52338/tjocm.2025.5014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52338/tjocm.2025.5014",null],["2","R0046169","R0046169.pdf","free_to_read","randomized_trial","Ravishankar Asokkumar","2025","Recent advances in bariatric endoscopy for obesity management: expanding the therapeutic spectrum","Singapore Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/singaporemedj.smj-2025-121","https://doi.org/10.4103/singaporemedj.smj-2025-121","40833753","https://pubmed.ncbi.nlm.nih.gov/40833753/","https://doi.org/10.4103/singaporemedj.smj-2025-121",null],["2","R0046320","R0046320.pdf","no_doi","randomized_trial","Ainul Mardhiah Irfan","2025","Meal replacement plans in managing adolescent obesity: a systematic literature review","The International Islamic University Malaysia Repository (The International Islamic University Malaysia)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046330","R0046330.pdf","no_doi","randomized_trial","Vanesa Berati","2025","The Safety of Chance GLP-1RA Exposure in Pregnancy","Scholarship@Western (Western University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046799","R0046799.pdf","no_doi","randomized_trial","Masashi Hasebe","2025","Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists isproportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0046856","R0046856.pdf","open_download_failed","randomized_trial","Priyamvada Singh","2025","Largest, Five-Year Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Kidney Transplant Recipients a Retrospective Single-Center Study","American Journal of Transplantation","Elsevier BV","10.1016/j.ajt.2025.07.914","https://doi.org/10.1016/j.ajt.2025.07.914",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.amjtransplant.org/article/S1600-6135(25)01293-6/pdf",null],["2","R0047078","R0047078.pdf","free_to_read","randomized_trial","Dimitrios Patoulias","2025","Effects of Long-Term Use of Sodium–Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 Pandemic","Saudi Journal of Kidney Diseases and Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.4103/sjkdt.sjkdt_605_21","https://doi.org/10.4103/sjkdt.sjkdt_605_21","41431916","https://pubmed.ncbi.nlm.nih.gov/41431916/","https://doi.org/10.4103/sjkdt.sjkdt_605_21","ISRCTN:ISRCTN88851713"],["2","R0047308","R0047308.pdf","open_download_failed","randomized_trial","Niklas Geiger","2025","OC21 - Additive effects of semaglutide and peptide YY3-36 dual agonism on HFpEF: focus on excitation-contraction coupling and mitochondrial function in obese rats","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvaf168.040","https://doi.org/10.1093/ejendo/lvaf168.040",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/193/Supplement_1/lvaf168.040/64341012/lvaf168.040.pdf",null],["2","R0047381","R0047381.pdf","open_download_failed","randomized_trial","Amanda L. Kucinskas","2025","SAT-291 Impact of the Incretin Mimetic Drug Tirzepatide on Obesity-Associated Breast Cancer Growth: Findings from a Preclinical Model","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.2433","https://doi.org/10.1210/jendso/bvaf149.2433",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.2433/64862134/bvaf149.2433.pdf",null],["2","R0047413","R0047413.pdf","open_download_failed","randomized_trial","Sandesh J. Marathe","2025","661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 immunotherapy in a preclinical model of pancreatic cancer","Regular and Young Investigator Award Abstracts","BMJ Publishing Group Ltd","10.1136/jitc-2025-sitc2025.0661","https://doi.org/10.1136/jitc-2025-sitc2025.0661",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jitc.bmj.com/content/13/Suppl_2/A752.full.pdf",null],["2","R0047474","R0047474.pdf","open_download_failed","randomized_trial","Dan J. Siskind","2025","206. EFFECTS OF SEMAGLUTIDE ON BODY WEIGHT IN CLOZAPINE-TREATED INDIVIDUALS WITH SCHIZOPHRENIA AND OBESITY: A RANDOMIZED CONTROLLED TRIAL","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyaf052.020","https://doi.org/10.1093/ijnp/pyaf052.020",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ijnp/article-pdf/28/Supplement_2/ii11/64072341/pyaf052.020.pdf",null],["2","R0047588","R0047588.pdf","open_download_failed","randomized_trial","William Blad","2025","P0653 Patients with ileo-anal J-Pouch display altered, higher pouch contractility than controls as measured with motility MRI","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjae190.0827","https://doi.org/10.1093/ecco-jcc/jjae190.0827",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ecco-jcc/article-pdf/19/Supplement_1/i1278/61545473/jjae190.0827.pdf",null],["2","R0047611","R0047611.pdf","open_download_failed","randomized_trial","Konstantinos Stefanakis","2025","OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.072","https://doi.org/10.1210/jendso/bvaf149.072",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.072/64863968/bvaf149.072.pdf",null],["2","R0047692","R0047692.pdf","free_to_read","randomized_trial","Steven E. Kahn","2025","DIFFERENTIAL LONGITUDINAL EFFECTS OF GLUCOSE-LOWERING MEDICATIONS ON GLUCAGON AND C-PEPTIDE RESPONSES IN THE GLYCEMIA REDUCTION APPROACHES IN DIABETES: A COMPARATIVE EFFECTIVENESS (GRADE) STUDY",null,"American Diabetes Association","10.2337/figshare.30659303","https://doi.org/10.2337/figshare.30659303",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30659303",null],["2","R0047773","R0047773.pdf","open_download_failed","randomized_trial","Phyllis Thangaraj","2025","EVALUATING PARTICIPANT-LEVEL EFFECTS OF TIRZEPATIDE ACROSS SURPASS RANDOMIZED CLINICAL TRIALS USING A MULTIDIMENSIONAL COMPUTATIONAL PHENOMAPPING APPROACH","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)01187-8","https://doi.org/10.1016/s0735-1097(25)01187-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2901187-8?download=true",null],["2","R0047821","R0047821.pdf","open_download_failed","randomized_trial","Christian Ludwig Roth","2025","MON-665 Experiences And Observations With Acquired Hypothalamic Obesity: A Qualitative Interview Sub-study","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.005","https://doi.org/10.1210/jendso/bvaf149.005",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.005/64862938/bvaf149.005.pdf","ClinicalTrials.gov:NCT05774756"],["2","R0047920","R0047920.pdf","free_to_read","randomized_trial","Casper K. Nielsen","2025","Dapiglutide, a Dual GLP-1 and GLP-2 Receptor Agonist, for Obesity: A Randomised, Double-Blind, Placebo-Controlled Parallel-Group, Proof-of-Concept Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5395622","https://doi.org/10.2139/ssrn.5395622",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5395622",null],["2","R0048025","R0048025.pdf","free_to_read","randomized_trial","M.W. Brejnebøl","2025","THE EFFECT OF WEIGHT LOSS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON STRUCTURAL CHANGES IN KNEE OSTEOARTHRITIS: SECONDARY ANALYSIS OF THE RANDOMISED, PLACEBO-CONTROLLED LOSEIT TRIAL","Osteoarthritis Imaging","Elsevier BV","10.1016/j.ostima.2025.100280","https://doi.org/10.1016/j.ostima.2025.100280",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ostima.2025.100280",null],["2","R0048417","R0048417.pdf","open_download_failed","randomized_trial","Andy Higgs","2025","Distinguishing prophylactic and therapeutic cricoid force","Anaesthesia","Wiley","10.1111/anae.16714","https://doi.org/10.1111/anae.16714","40689685","https://pubmed.ncbi.nlm.nih.gov/40689685/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/anae.16714",null],["2","R0048432","R0048432.pdf","free_to_read","randomized_trial","Elpis Athina Vlachopapadopoulou","2025","Editorial: Endocrine and metabolic consequences of childhood obesity, volume III","Frontiers in Endocrinology","Frontiers Media SA","10.3389/fendo.2025.1546470","https://doi.org/10.3389/fendo.2025.1546470","40196461","https://pubmed.ncbi.nlm.nih.gov/40196461/","https://doi.org/10.3389/fendo.2025.1546470",null],["2","R0048452","R0048452.pdf","free_to_read","randomized_trial","Peter R Rossing","2025","Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Pre-Specified Secondary Analysis",null,"American Diabetes Association","10.2337/figshare.29469482.v1","https://doi.org/10.2337/figshare.29469482.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.29469482.v1",null],["2","R0048785","R0048785.pdf","free_to_read","randomized_trial","Michelle W J Heijman","2025","POS0565 Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.947","https://doi.org/10.1016/j.ard.2025.05.947",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.947",null],["2","R0049095","R0049095.pdf","open_download_failed","randomized_trial","Thomas J. Schnitzer","2025","SAT-736 Post-hoc analysis of weight reduction and physical function in participants with obesity or overweight and osteoarthritis in SURMOUNT-1","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.592","https://doi.org/10.1210/jendso/bvaf149.592",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.592/64863080/bvaf149.592.pdf",null],["2","R0049099","R0049099.pdf","open_download_failed","randomized_trial","Karolina Bohdan","2025","0990 Effect of Semaglutide on Apnea Hypopnea Index in Female Adolescents with Polycystic Ovary Syndrome and Obesity","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsaf090.0990","https://doi.org/10.1093/sleep/zsaf090.0990",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleep/article-pdf/48/Supplement_1/A429/63222795/zsaf090.0990.pdf",null],["2","R0049168","R0049168.pdf","free_to_read","randomized_trial","M.W. Brejnebøl","2025","OP0223 THE EFFECT OF WEIGHT LOSS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON STRUCTURAL CHANGES IN KNEE OSTEOARTHRITIS: SECONDARY ANALYSIS OF THE RANDOMISED, PLACEBO-CONTROLLED LOSEIT TRIAL","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.234","https://doi.org/10.1016/j.ard.2025.05.234",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.234",null],["2","R0049419","R0049419.pdf","open_download_failed","randomized_trial","V.V. Cherniavskyi","2025","Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study","GASTROENTEROLOGY","Publishing House Zaslavsky","10.22141/2308-2097.59.4.2025.705","https://doi.org/10.22141/2308-2097.59.4.2025.705",null,"https://pubmed.ncbi.nlm.nih.gov//","https://gastro-journal.com/index.php/journal/article/download/705/891",null],["2","R0049441","R0049441.pdf","open_download_failed","randomized_trial","Scott A. Reule","2025","Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes","Diabetology","MDPI AG","10.3390/diabetology6120161","https://doi.org/10.3390/diabetology6120161",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/6/12/161/pdf",null],["2","R0049555","R0049555.pdf","open_download_failed","randomized_trial","Steven Luu","2025","P018 Pharmacotherapy for OSA: a critical review of randomised placebo-controlled trials","SLEEP Advances","Oxford University Press (OUP)","10.1093/sleepadvances/zpaf053.078","https://doi.org/10.1093/sleepadvances/zpaf053.078",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleepadvances/article-pdf/6/Supplement_1/A29/64479775/zpaf053.078.pdf",null],["2","R0049796","R0049796.pdf","free_to_read","randomized_trial","Lauren Eyler Dang","2025","Experiment-selector cross-validated targeted maximum likelihood estimator for hybrid RCT-external data studies","Journal of Causal Inference","Walter de Gruyter GmbH","10.1515/jci-2024-0041","https://doi.org/10.1515/jci-2024-0041",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1515/jci-2024-0041",null],["2","R0050598","R0050598.pdf","free_to_read","randomized_trial","Nouran Eshak","2025","OP0281 EXPLORING GLP-1 AGONISTS EFFECTS IN FIBROMYALGIA PATIENTS: A PROPENSITY MATCHED ANALYSIS USING TriNetX DATABASE","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.291","https://doi.org/10.1016/j.ard.2025.05.291",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.291",null],["2","R0050681","R0050681.pdf","free_to_read","randomized_trial","Krishna S. Upadhye","2025","HbA1c reduction strategies: An overview of pharmacological interventions","National Journal of Pharmacology and Therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.4103/njpt.njpt_72_24","https://doi.org/10.4103/njpt.njpt_72_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/njpt.njpt_72_24",null],["2","R0050747","R0050747.pdf","open_download_failed","randomized_trial","Andrea F. Attanasio","2025","Quality of care and clinical outcomes in clinical pharmacotherapy","European Heart Journal - Quality of Care and Clinical Outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcaf132","https://doi.org/10.1093/ehjqcco/qcaf132","41412163","https://pubmed.ncbi.nlm.nih.gov/41412163/","https://academic.oup.com/ehjqcco/article-pdf/11/8/1207/65996003/qcaf132.pdf",null],["2","R0051030","R0051030.pdf","free_to_read","randomized_trial","Deborah J. Wexler","2025","Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in type 2 diabetes patients independent of diabetes medication in the GRADE Randomized Controlled Trial",null,"American Diabetes Association","10.2337/figshare.28611941.v1","https://doi.org/10.2337/figshare.28611941.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28611941.v1",null],["2","R0051080","R0051080.pdf","free_to_read","randomized_trial","Daniel S. Hsia","2025","Association of Hospitalizations with Randomized Glycemia-Lowering Treatment in the GRADE Study",null,"American Diabetes Association","10.2337/figshare.28898609","https://doi.org/10.2337/figshare.28898609",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28898609",null],["2","R0051739","R0051739.pdf","free_to_read","randomized_trial","Nazeen Morelli","2025","Weight Loss Via Oral Semaglutide or Diet Intervention in Adolescent Females with Obesity and Polycystic Ovary Syndrome: Treating Pcos with Semaglutide vs Active Lifestyle Intervention (Teal) Study, a Randomized, Open-Label, Phase 3 Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5368696","https://doi.org/10.2139/ssrn.5368696",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5368696",null],["2","R0051744","R0051744.pdf","open_download_failed","randomized_trial","Susan S Redline","2025","O045 Participants with OSA severity improvement following treatment: SURMOUNT-OSA post-hoc analyses","SLEEP Advances","Oxford University Press (OUP)","10.1093/sleepadvances/zpaf053.045","https://doi.org/10.1093/sleepadvances/zpaf053.045",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleepadvances/article-pdf/6/Supplement_1/A17/64479753/zpaf053.045.pdf",null],["2","R0051788","R0051788.pdf","open_download_failed","randomized_trial","Joshua C. Toliver","2025","SAT-694 Association Between Engagement With The WeGoTogether Digital Self-support App And Weight Loss In A Real-world Setting","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.127","https://doi.org/10.1210/jendso/bvaf149.127",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.127/64865980/bvaf149.127.pdf",null],["2","R0051859","R0051859.pdf","free_to_read","randomized_trial","Kristin K. Clemens","2025","Steps Forward for Cardio-Kidney-Metabolic Research in Transplant Recipients","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000000796","https://doi.org/10.34067/kid.0000000796","40440455","https://pubmed.ncbi.nlm.nih.gov/40440455/","https://doi.org/10.34067/kid.0000000796",null],["2","R0052206","R0052206.pdf","free_to_read","randomized_trial","Sebastian Badulescu","2025","Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Clinical Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5164525","https://doi.org/10.2139/ssrn.5164525",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5164525",null],["2","R0052216","R0052216.pdf","open_download_failed","randomized_trial","Susan S Redline","2025","0776 Participants with Improvement in OSA Severity Following Treatment: A Post Hoc Analysis of SURMOUNT-OSA Studies","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsaf090.0776","https://doi.org/10.1093/sleep/zsaf090.0776",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleep/article-pdf/48/Supplement_1/A336/63223055/zsaf090.0776.pdf",null],["2","R0052287","R0052287.pdf","open_download_failed","randomized_trial","Merve Çelik Güler","2025","SUN-645 Leptin- And Incretin-based Combination Therapy In Lipodystrophy: A Promising Metabolic Strategy?","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.155","https://doi.org/10.1210/jendso/bvaf149.155",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.155/64866735/bvaf149.155.pdf",null],["2","R0052714","R0052714.pdf","open_download_failed","randomized_trial","Svenja Leibnitz","2025","SAT-065 Comparison of Long-Acting and Short-Acting GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants - A Secondary Analysis of Three Prospective Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1547","https://doi.org/10.1210/jendso/bvaf149.1547",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1547/64864976/bvaf149.1547.pdf",null],["2","R0052730","R0052730.pdf","open_download_failed","randomized_trial","Rohan Shad Arora","2025","(197) Peptides in Practice: Evaluating Efficacy and Safety in Men’s Health","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf320.196","https://doi.org/10.1093/jsxmed/qdaf320.196",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_4/qdaf320.196/65819443/qdaf320.196.pdf",null],["2","R0052756","R0052756.pdf","open_download_failed","randomized_trial","Hadir Aljohani","2025","RWD76 POTENTIAL RISK OF ACUTE PANCREATITIS WITH GLP-1 RECEPTOR AGONISTS","Value in Health Regional Issues","Elsevier BV","10.1016/j.vhri.2025.101306","https://doi.org/10.1016/j.vhri.2025.101306",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.valuehealthregionalissues.com/article/S2212-1099(25)00232-8/pdf",null],["2","R0052945","R0052945.pdf","free_to_read","randomized_trial","Kagan Karakus","2025","Effect of semaglutide on insulin dose requirements in adults with type 1 diabetes and obesity using automated insulin delivery systems: ADJUST-T1D post-hoc analysis",null,"American Diabetes Association","10.2337/figshare.30727271.v1","https://doi.org/10.2337/figshare.30727271.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30727271.v1",null],["2","R0053156","R0053156.pdf","free_to_read","randomized_trial","Ricardo S. Pietrobon","2025","Target trial emulation to reduce confounding in therapy effectiveness assessment - (Based on the Cohort Study by Wang et al. on Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder)",null,"Center for Open Science","10.31219/osf.io/mwthq_v1","https://doi.org/10.31219/osf.io/mwthq_v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31219/osf.io/mwthq_v1",null],["2","R0053549","R0053549.pdf","open_download_failed","randomized_trial","Reza Ghalamghash","2025","The Role of Neuropharmacology in Obesity Treatment: A Comprehensive Scientific Review",null,"Wiley","10.22541/au.175312428.81257507/v1","https://doi.org/10.22541/au.175312428.81257507/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175312428.81257507",null],["2","R0053608","R0053608.pdf","open_download_failed","randomized_trial","Martin Halle","2025","Multimodal management of the cardiometabolic syndrome: the essential triad of nutrition, exercise, and obesity-specific pharmacotherapy to reduce cardiovascular risk","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf522","https://doi.org/10.1093/eurjpc/zwaf522","40889141","https://pubmed.ncbi.nlm.nih.gov/40889141/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwaf522/64172096/zwaf522.pdf",null],["2","R0053752","R0053752.pdf","free_to_read","randomized_trial","Yu. A. Dolgikh","2025","РМЖ. Медицинское обозрение. T. 9, № 10, 2025 / Russian Medical Inquiry. Vol. 9, № 10, 2025 Эндокринология / Endocrinology743 Обзоры / Review Articles Сахарный диабет 2 типа и неалкогольная жировая болезнь печени: протективные эффекты сахароснижающих препаратов Ю.А. Долгих, С.В. Булгакова, Л.А. Шаронова, О.В. Косарева, Е.В. Тренева, П.Я. Мерзлова, Д.П. Курмаев ФГБОУ ВО СамГМУ Минздрава России, Самара, Российская Федерация РЕЗЮМЕ Сочетание неалкогольной жировой болезни печени (НАЖБП) и сахарного диабета 2 типа (СД2) является достаточно распространен- ным, так как ожирение и резистентность к инсулину служат общими патологическими предикторами этих заболеваний. Для успешного лечения как СД2, так и НАЖБП необходимо влияние на инсулинорезистентность, уровень гликемии и массу тела пациента. Сахаросни- жающие препараты, используемые при СД2, могут также быть эффективными и при лечении НАЖБП. В данном обзоре обсуждают- ся гепатопротективные свойства метформина, агонистов глюкагоноподобного пептида 1 (ГПП1) и ингибиторов натрийглюкозного котранспортера 2го типа ( НГЛТ2). Применение данных групп препаратов приводит к снижению массы тела, уровней трансаминаз и уменьшению количества жира в печени. Лираглутид приводил к разрешению стеатогепатита и уменьшал прогрессирование фиброза. Семаглутид у пациентов с СД2 и умеренным или выраженным фиброзом печени также улучшал гистологические показатели. Активно изучается влияние на состояние печени нового комбинированного препарата тирзепатида. На фоне его применения отмечалось раз- решение НАЖБП и уменьшение фиброза. Ингибиторы НГЛТ2 продемонстрировали снижение уровня трансаминаз и процента жира в печени. Внимания также заслуживает препарат ипраглифлозин. Его длительное применение уменьшает фиброз печени у пациен- тов с НАЖБП. По данным многоцентрового рандомизированного клинического исследования, ипраглифлозин привел к уменьшению фиброза печени в 57,1% случаев и баллонной дистрофии гепатоцитов в 52,4% случаев (по данным парных биопсий печени). Кроме того, ингибиторы НГЛТ2 показали себя более эффективными в отношении снижения уровня трансаминаз по сравнению с агонистами ГПП1. Таким образом, при назначении сахароснижающей терапии стоит учитывать влияние препаратов на состояние печени и отда- вать предпочтение лекарственным средствам, имеющим гепатопротективные свойства. КЛЮЧЕВЫЕ СЛОВА: метформин, агонисты глюкагоноподобного пептида 1, ингибиторы натрийглюкозного котранспортера 2 типа, фиброз, стеатогепатит, инсулинорезистентность. ДЛЯ ЦИТИРОВАНИЯ: Долгих Ю.А., Булгакова С.В., Шаронова Л.А., Косарева О.В., Тренева Е.В., Мерзлова П.Я., Курмаев Д.П. Са- харный диабет 2 типа и неалкогольная жировая болезнь печени: протективные эффекты сахароснижающих препаратов. РМЖ. Медицинское обозрение. 2025;9(10):743–748. DOI: 10.32364/2587-6821-2025-9-10-7 Type 2 diabetes mellitus and NAFLD: the protective effects of glucose-lowering drugs","Russian Medical Inquiry","LLC Russian Medical Journal","10.32364/2587-6821-2025-9-10-7","https://doi.org/10.32364/2587-6821-2025-9-10-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.32364/2587-6821-2025-9-10-7",null],["2","R0053998","R0053998.pdf","open_download_failed","randomized_trial","Benjamin Bearss","2025","Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models","Blood","American Society of Hematology","10.1182/blood-2025-1127","https://doi.org/10.1182/blood-2025-1127",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ashpublications.org/blood/article-pdf/146/Supplement 1/1127/2460176/blood-3874-main.pdf",null],["2","R0054140","R0054140.pdf","free_to_read","randomized_trial","Tahsin Jahan","2025","‘Efficacy of GLP-1 Receptor Agonists’ in Hypertriglyceridemia: A Systemic Review and Meta Analysis","Asian Journal of Medicine and Health","Sciencedomain International","10.9734/ajmah/2025/v23i41205","https://doi.org/10.9734/ajmah/2025/v23i41205",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9734/ajmah/2025/v23i41205",null],["2","R0054151","R0054151.pdf","open_download_failed","randomized_trial","Yousra Naz","2025","Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS)","Indus journal of bioscience research.","Indus Publishers","10.70749/ijbr.v3i3.818","https://doi.org/10.70749/ijbr.v3i3.818",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijbr.com.pk/IJBR/article/download/818/803",null],["2","R0054593","R0054593.pdf","free_to_read","randomized_trial","Arya Singh","2025","Tirzepatide and Obesity: A Narrative Review","Advances in Human Biology","Ovid Technologies (Wolters Kluwer Health)","10.4103/aihb.aihb_244_25","https://doi.org/10.4103/aihb.aihb_244_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aihb.aihb_244_25",null],["2","R0054603","R0054603.pdf","open_download_failed","randomized_trial","Peter Novodvorský","2025","Insulin therapy de-intensification with iGlarLixi in people with type 2 diabetes: the IDEAL randomised controlled trial","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2025.112854","https://doi.org/10.1016/j.diabres.2025.112854",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00868-X/pdf",null],["2","R0054617","R0054617.pdf","open_download_failed","randomized_trial","Ana Rita Leite","2025","OR19-05 Efficacy of Tirzepatide versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: a post hoc analysis of SURPASS-2 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1025","https://doi.org/10.1210/jendso/bvaf149.1025",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1025/64865412/bvaf149.1025.pdf",null],["2","R0054659","R0054659.pdf","open_download_failed","randomized_trial","Nathan Zou","2025","Association Between GLP-1 Agonist Use and Site-Specific Fracture Risk: A Retrospective Cohort Analysis","Stony Brook Orthopaedic and Musculoskeletal Journal","Stony Brook University","10.31259/3065-2677.1035","https://doi.org/10.31259/3065-2677.1035",null,"https://pubmed.ncbi.nlm.nih.gov//","https://commons.library.stonybrook.edu/cgi/viewcontent.cgi?article=1035&context=orthomusculoskeletaljournal",null],["2","R0054662","R0054662.pdf","free_to_read","randomized_trial","Lucian Petrescu","2025","Are current systemic endothelial anti-inflammatory therapies effective/safe, and only in secondary prophylaxis?","Romanian Journal of Cardiology","Walter de Gruyter GmbH","10.2478/rjc-2025-0029","https://doi.org/10.2478/rjc-2025-0029",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2478/rjc-2025-0029",null],["2","R0054779","R0054779.pdf","free_to_read","randomized_trial","Rajesh Rajput","2025","Expert Opinion on Cardio-Renal-Metabolic Approach to Management of Adults with Type 2 Diabetes Mellitus Using Oral Semaglutide: An Indian Perspective","Clinical Diabetology","VM Media Group sp. z o.o","10.5603/cd.103785","https://doi.org/10.5603/cd.103785",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5603/cd.103785",null],["2","R0054919","R0054919.pdf","free_to_read","randomized_trial","Effrosyni Blathra","2025","The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review","Journal of Atherosclerosis Prevention and Treatment","Ovid Technologies (Wolters Kluwer Health)","10.4103/aptj.aptj_16_25","https://doi.org/10.4103/aptj.aptj_16_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aptj.aptj_16_25",null],["2","R0055048","R0055048.pdf","open_download_failed","randomized_trial","Denise Deo Dias","2025","Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review","Obesities","MDPI AG","10.3390/obesities5040088","https://doi.org/10.3390/obesities5040088",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4168/5/4/88/pdf?version=1764669579",null],["2","R0055085","R0055085.pdf","open_download_failed","randomized_trial","Ricardo S. Pietrobon","2025","Target Trial Emulation: A Rigorous Framework for Causal Inference in Real-World Data Studies (Motivated by the OneFlorida+ Study on GLP-1RA and SGLT2i Use and Dementia Risk in Type 2 Diabetes by Tang et al.)",null,"Center for Open Science","10.31219/osf.io/yfpt8_v1","https://doi.org/10.31219/osf.io/yfpt8_v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://osf.io/yfpt8_v1/download",null],["2","R0055442","R0055442.pdf","free_to_read","randomized_trial","Adam Solarz","2025","TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.4(48).2025.4143","https://doi.org/10.31435/ijitss.4(48).2025.4143",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.4(48).2025.4143",null],["2","R0055453","R0055453.pdf","no_doi","randomized_trial","Riddhita De","2025","The Effect of Antipsychotic-Induced Weight Gain in Individuals with Severe Mental Illness: Understanding the Impact and Looking at a Novel Pharmacological Intervention","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055592","R0055592.pdf","free_to_read","randomized_trial","Victoria L. Walker","2025","The Endoscopic Optimization for Obesity in Patients Undergoing Abdominal Wall Reconstruction","Journal of Abdominal Wall Surgery","Frontiers Media SA","10.3389/jaws.2025.15383","https://doi.org/10.3389/jaws.2025.15383","41209724","https://pubmed.ncbi.nlm.nih.gov/41209724/","https://doi.org/10.3389/jaws.2025.15383",null],["2","R0055715","R0055715.pdf","free_to_read","randomized_trial","Roosa Perämäki","2025","Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2025.100596","https://doi.org/10.1016/j.obmed.2025.100596",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obmed.2025.100596",null],["2","R0055986","R0055986.pdf","no_doi","randomized_trial","Karla Scorsatto dos Santos","2025","Avaliação do efeito da tirzepatida na perda de peso: revisão sistemática","Revista brasileira de obesidade, nutrição e emagrecimento",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056006","R0056006.pdf","no_doi","randomized_trial","Lin Liao","2025","The culprit of chronic complications of diabetes-from glucose to insulin resistance","International Health Sciences Journal (online)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056074","R0056074.pdf","no_doi","randomized_trial","Ilham Hariaji","2025","Effectiveness of Metformin in Management Latest Type 2 Diabetes Mellitus : A Literature Study","Buletin Farmatera",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056140","R0056140.pdf","no_doi","randomized_trial","Jirawan Vienghirun","2025","ประสทธภาพของยากลมยากระตนตวรบเปปไทดตวเหมอนกลคากอนชนดท 1 ตอ ดชนมวลกายและเสนรอบเอวในผปวยโรคอวนหรอนำหนกตวเกน: การทบทวนวรรณกรรมอยางเปนระบบและการวเคราะหอภมานเครอขาย","Thai Journal of Pharmacy Practice",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056367","R0056367.pdf","no_doi","randomized_trial","Ellen Cristina Ribeiro da Silva","2025","USE OF OZEMPIC FOR WEIGHT LOSS IN NON-DIABETIC INDIVIDUALS: ETHICAL AND HEALTH IMPLICATIONS","CIPEEX",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056522","R0056522.pdf","no_doi","randomized_trial","Uzma Dost Muhammad Rajar","2025","Effects of Liraglutide on Thyroid Stimulating Hormone and Level of Depression: Liraglutide Effects on TSH and Depression","Annals of Punjab Medical College",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0003209","R0003209.pdf","open_download_failed","randomized_trial","Haluzík M","2024","Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15811","https://doi.org/10.1111/dom.15811","39245809","https://pubmed.ncbi.nlm.nih.gov/39245809/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15811",null],["2","R0003664","R0003664.pdf","free_to_read","randomized_trial","Ling J","2024","Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2024.06.010","https://doi.org/10.1016/j.medj.2024.06.010","39127031","https://pubmed.ncbi.nlm.nih.gov/39127031/","https://doi.org/10.1016/j.medj.2024.06.010",null],["2","R0003730","R0003730.pdf","free_to_read","randomized_trial","Scheen AJ","2024","Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2024.2354885","https://doi.org/10.1080/14740338.2024.2354885","38738549","https://pubmed.ncbi.nlm.nih.gov/38738549/","https://orbi.uliege.be/handle/2268/340413",null],["2","R0003781","R0003781.pdf","open_download_failed","randomized_trial","Ni D","2024","Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usae311","https://doi.org/10.1093/milmed/usae311","38870042","https://pubmed.ncbi.nlm.nih.gov/38870042/","https://academic.oup.com/milmed/advance-article-pdf/doi/10.1093/milmed/usae311/58229687/usae311.pdf",null],["2","R0004383","R0004383.pdf","open_download_failed","randomized_trial","Dash S","2024","Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15829","https://doi.org/10.1111/dom.15829","39157881","https://pubmed.ncbi.nlm.nih.gov/39157881/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15829",null],["2","R0004451","R0004451.pdf","open_download_failed","randomized_trial","Lau D","2024","Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15459","https://doi.org/10.1111/dom.15459","38229461","https://pubmed.ncbi.nlm.nih.gov/38229461/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15459",null],["2","R0004480","R0004480.pdf","open_download_failed","randomized_trial","Giorgino F","2024","Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111604","https://doi.org/10.1016/j.diabres.2024.111604","38447911","https://pubmed.ncbi.nlm.nih.gov/38447911/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724000883/pdf",null],["2","R0004590","R0004590.pdf","free_to_read","randomized_trial","Yeh JG","2024","Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000768","https://doi.org/10.1097/hep.0000000000000768","38345826","https://pubmed.ncbi.nlm.nih.gov/38345826/",null,null],["2","R0004695","R0004695.pdf","open_download_failed","randomized_trial","Raven LM","2024","Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists.","The Medical journal of Australia","Wiley","10.5694/mja2.52170","https://doi.org/10.5694/mja2.52170","38009941","https://pubmed.ncbi.nlm.nih.gov/38009941/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.5694/mja2.52170",null],["2","R0004699","R0004699.pdf","free_to_read","randomized_trial","Ferreira JP","2024","Response to Letter to Editor From Banerjee et al: \"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure\".","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad507","https://doi.org/10.1210/clinem/dgad507","37623824","https://pubmed.ncbi.nlm.nih.gov/37623824/",null,null],["2","R0004828","R0004828.pdf","open_download_failed","randomized_trial","Palecek EJ","2024","Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1177/10815589241270427","https://doi.org/10.1177/10815589241270427","39075666","https://pubmed.ncbi.nlm.nih.gov/39075666/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11581925/pdf/nihms-2016420.pdf",null],["2","R0004846","R0004846.pdf","no_doi","randomized_trial","Scheen A","2024","[GLP-1 receptor agonists in type 2 diabetes : paradoxical real-life underuse in patients with atherosclerotic cardiovascular disease].","Revue medicale de Liege",null,null,"https://doi.org/","38487908","https://pubmed.ncbi.nlm.nih.gov/38487908/",null,null],["2","R0004917","R0004917.pdf","open_download_failed","randomized_trial","Nguyen A","2024","Glucagon-like-peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association.","Clinical obesity","Wiley","10.1111/cob.12676","https://doi.org/10.1111/cob.12676","38778795","https://pubmed.ncbi.nlm.nih.gov/38778795/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12676",null],["2","R0005322","R0005322.pdf","free_to_read","randomized_trial","Harrington J","2024","Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-023-02016-z","https://doi.org/10.1007/s11886-023-02016-z","38551786","https://pubmed.ncbi.nlm.nih.gov/38551786/","https://eprints.gla.ac.uk/324317/",null],["2","R0005590","R0005590.pdf","no_doi","randomized_trial","Scheen A","2024","[New outcome studies with injectable semaglutide in different at risk populations].","Revue medicale de Liege",null,null,"https://doi.org/","39397557","https://pubmed.ncbi.nlm.nih.gov/39397557/",null,null],["2","R0005867","R0005867.pdf","open_download_failed","randomized_trial","Bensignor MO","2024","Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.","Pediatric obesity","Wiley","10.1111/ijpo.13105","https://doi.org/10.1111/ijpo.13105","38339799","https://pubmed.ncbi.nlm.nih.gov/38339799/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.13105",null],["2","R0005998","R0005998.pdf","open_download_failed","randomized_trial","Bonnet F","2024","A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15710","https://doi.org/10.1111/dom.15710","38899425","https://pubmed.ncbi.nlm.nih.gov/38899425/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15710",null],["2","R0006105","R0006105.pdf","open_download_failed","randomized_trial","Dejgaard TF","2024","Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15889","https://doi.org/10.1111/dom.15889","39192527","https://pubmed.ncbi.nlm.nih.gov/39192527/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15889",null],["2","R0006108","R0006108.pdf","open_download_failed","randomized_trial","Post SM","2024","Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.","Annals of behavioral medicine : a publication of the Society of Behavioral Medicine","Oxford University Press (OUP)","10.1093/abm/kaae063","https://doi.org/10.1093/abm/kaae063","39427238","https://pubmed.ncbi.nlm.nih.gov/39427238/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568355/pdf/kaae063.pdf",null],["2","R0006141","R0006141.pdf","free_to_read","randomized_trial","Sarkar S","2024","CROI 2024: Metabolic and Other Complications of HIV Infection.","Topics in antiviral medicine",null,null,"https://doi.org/","39142292","https://pubmed.ncbi.nlm.nih.gov/39142292/",null,null],["2","R0006243","R0006243.pdf","open_download_failed","randomized_trial","Munshi M","2024","Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15377","https://doi.org/10.1111/dom.15377","38082473","https://pubmed.ncbi.nlm.nih.gov/38082473/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15377",null],["2","R0006254","R0006254.pdf","free_to_read","randomized_trial","Lisco G","2024","Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study.","Andrology","Wiley","10.1111/andr.13519","https://doi.org/10.1111/andr.13519","37615353","https://pubmed.ncbi.nlm.nih.gov/37615353/","https://doi.org/10.1111/andr.13519",null],["2","R0006407","R0006407.pdf","free_to_read","randomized_trial","Singh AK","2024","Clinical trial designs of emerging therapies for diabetic kidney disease (DKD).","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2024.2377529","https://doi.org/10.1080/00325481.2024.2377529","39045637","https://pubmed.ncbi.nlm.nih.gov/39045637/","https://doi.org/10.1080/00325481.2024.2377529",null],["2","R0006539","R0006539.pdf","open_download_failed","randomized_trial","Rubino D","2024","Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24042","https://doi.org/10.1002/oby.24042","38932728","https://pubmed.ncbi.nlm.nih.gov/38932728/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24042",null],["2","R0006644","R0006644.pdf","free_to_read","randomized_trial","Januzzi JL","2024","Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.03.380","https://doi.org/10.1016/j.jacc.2024.03.380","38597864","https://pubmed.ncbi.nlm.nih.gov/38597864/","https://doi.org/10.1016/j.jacc.2024.03.380","ClinicalTrials.gov:NCT04083339"],["2","R0006660","R0006660.pdf","open_download_failed","randomized_trial","Anyiam O","2024","Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2024.06.034","https://doi.org/10.1016/j.clnu.2024.06.034","38996661","https://pubmed.ncbi.nlm.nih.gov/38996661/","http://www.clinicalnutritionjournal.com/article/S0261561424002267/pdf",null],["2","R0007086","R0007086.pdf","open_download_failed","randomized_trial","Post SM","2024","The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01516-4","https://doi.org/10.1038/s41366-024-01516-4","38561488","https://pubmed.ncbi.nlm.nih.gov/38561488/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12439114/pdf/nihms-2108681.pdf","OSF:osf.io/xme4w"],["2","R0007111","R0007111.pdf","open_download_failed","randomized_trial","Chen GL","2024","Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15441","https://doi.org/10.1111/dom.15441","38287130","https://pubmed.ncbi.nlm.nih.gov/38287130/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15441","ChiCTR:ChiCTR2100049732"],["2","R0007192","R0007192.pdf","open_download_failed","randomized_trial","Khera R","2024","Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.05.069","https://doi.org/10.1016/j.jacc.2024.05.069","39197980","https://pubmed.ncbi.nlm.nih.gov/39197980/","https://doi.org/10.1016/j.jacc.2024.05.069",null],["2","R0007732","R0007732.pdf","open_download_failed","randomized_trial","Rahbek MT","2024","A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5673","https://doi.org/10.1002/pds.5673","37559355","https://pubmed.ncbi.nlm.nih.gov/37559355/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.5673",null],["2","R0007743","R0007743.pdf","open_download_failed","randomized_trial","Vernstrøm L","2024","Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15464","https://doi.org/10.1111/dom.15464","38240066","https://pubmed.ncbi.nlm.nih.gov/38240066/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15464",null],["2","R0007801","R0007801.pdf","open_download_failed","randomized_trial","Eissing T","2024","Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15387","https://doi.org/10.1111/dom.15387","38037539","https://pubmed.ncbi.nlm.nih.gov/38037539/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15387",null],["2","R0007844","R0007844.pdf","open_download_failed","randomized_trial","Krychtiuk KA","2024","Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvae006","https://doi.org/10.1093/ehjcvp/pvae006","38271596","https://pubmed.ncbi.nlm.nih.gov/38271596/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13031111/",null],["2","R0008084","R0008084.pdf","open_download_failed","randomized_trial","Sivalingam S","2024","Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15287","https://doi.org/10.1111/dom.15287","37722966","https://pubmed.ncbi.nlm.nih.gov/37722966/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15287",null],["2","R0008095","R0008095.pdf","open_download_failed","randomized_trial","Chao TH","2024","2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II.","Acta Cardiologica Sinica",null,"10.6515/acs.202411_40(6).20240724b","https://doi.org/10.6515/acs.202411_40(6).20240724b","39582845","https://pubmed.ncbi.nlm.nih.gov/39582845/",null,null],["2","R0008347","R0008347.pdf","open_download_failed","randomized_trial","Mashayekhi M","2024","Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.","Diabetes","American Diabetes Association","10.2337/db23-0356","https://doi.org/10.2337/db23-0356","37874653","https://pubmed.ncbi.nlm.nih.gov/37874653/","https://www.ncbi.nlm.nih.gov/pmc/articles/10784656",null],["2","R0009131","R0009131.pdf","free_to_read","randomized_trial","Hsiao FY","2024","Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.","The lancet. Healthy longevity","Elsevier BV","10.1016/j.lanhl.2024.07.004","https://doi.org/10.1016/j.lanhl.2024.07.004","39284334","https://pubmed.ncbi.nlm.nih.gov/39284334/","https://doi.org/10.1016/j.lanhl.2024.07.004",null],["2","R0009266","R0009266.pdf","open_download_failed","randomized_trial","Holliday MW","2024","Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.","Current opinion in nephrology and hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/mnh.0000000000000976","https://doi.org/10.1097/mnh.0000000000000976","38411162","https://pubmed.ncbi.nlm.nih.gov/38411162/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11126299/pdf/nihms-1967784.pdf",null],["2","R0010306","R0010306.pdf","no_doi","randomized_trial","Grad R","2024","Top 20 Research Studies of 2023 for Primary Care Physicians.","American family physician",null,null,"https://doi.org/","39028784","https://pubmed.ncbi.nlm.nih.gov/39028784/",null,null],["2","R0013645","R0013645.pdf","open_download_failed","randomized_trial","Osonoi T","2024","Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15296","https://doi.org/10.1111/dom.15296","37794628","https://pubmed.ncbi.nlm.nih.gov/37794628/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15296",null],["2","R0013689","R0013689.pdf","free_to_read","randomized_trial","Ng K","2024","Why Did the \"Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists\" Differ From Previous Randomized Controlled Study?","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.08.035","https://doi.org/10.1016/j.arth.2024.08.035","39523049","https://pubmed.ncbi.nlm.nih.gov/39523049/","https://orbi.uliege.be/handle/2268/324689",null],["2","R0014157","R0014157.pdf","open_download_failed","randomized_trial","Lupianez-Merly C","2024","Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.17856","https://doi.org/10.1111/apt.17856","38169126","https://pubmed.ncbi.nlm.nih.gov/38169126/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.17856",null],["2","R0014830","R0014830.pdf","open_download_failed","randomized_trial","Krishnan K","2024","Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.111034","https://doi.org/10.1016/j.diabres.2023.111034","38061446","https://pubmed.ncbi.nlm.nih.gov/38061446/","http://www.diabetesresearchclinicalpractice.com/article/S0168822723007970/pdf","CTRI:CTRI/2022/02/040261"],["2","R0014896","R0014896.pdf","open_download_failed","randomized_trial","Cohen JB","2024","Quantifying antihypertensive effects of GLP-1 agonists.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae520","https://doi.org/10.1093/eurheartj/ehae520","39217501","https://pubmed.ncbi.nlm.nih.gov/39217501/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae520/58970321/ehae520.pdf",null],["2","R0015177","R0015177.pdf","free_to_read","randomized_trial","O’Connor E","2024","Interventions for High Body Mass Index in Children and Adolescents: An Evidence Update for the U.S. Preventive Services Task Force","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","38913817","https://pubmed.ncbi.nlm.nih.gov/38913817/",null,null],["2","R0015294","R0015294.pdf","open_download_failed","randomized_trial","Rosenstock J","2024","Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15339","https://doi.org/10.1111/dom.15339","37935463","https://pubmed.ncbi.nlm.nih.gov/37935463/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15339",null],["2","R0015636","R0015636.pdf","open_download_failed","randomized_trial","Patel H","2024","Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15333","https://doi.org/10.1111/dom.15333","37853960","https://pubmed.ncbi.nlm.nih.gov/37853960/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15333",null],["2","R0015858","R0015858.pdf","free_to_read","randomized_trial","Lim WH","2024","\"Heart\" Outcome in Organ Transplant Recipients With Diabetes: Is GLP-1-RA the Leader of the Pack?","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000005045","https://doi.org/10.1097/tp.0000000000005045","38644532","https://pubmed.ncbi.nlm.nih.gov/38644532/","https://doi.org/10.1097/TP.0000000000005045",null],["2","R0016068","R0016068.pdf","open_download_failed","randomized_trial","Chen K","2024","Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15360","https://doi.org/10.1111/dom.15360","37945546","https://pubmed.ncbi.nlm.nih.gov/37945546/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15360","ChiCTR:ChiCTR1900023428"],["2","R0016538","R0016538.pdf","free_to_read","randomized_trial","Lawitz EJ","2024","Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2024.06.003","https://doi.org/10.1016/j.jhep.2024.06.003","38857788","https://pubmed.ncbi.nlm.nih.gov/38857788/","https://doi.org/10.1016/j.jhep.2024.06.003","ClinicalTrials.gov:NCT05296733"],["2","R0017550","R0017550.pdf","open_download_failed","randomized_trial","Kondo Y","2024","Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-024-00717-6","https://doi.org/10.1007/s13340-024-00717-6","39101164","https://pubmed.ncbi.nlm.nih.gov/39101164/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11291836/pdf/13340_2024_Article_717.pdf",null],["2","R0017700","R0017700.pdf","open_download_failed","randomized_trial","García-Vega D","2024","Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2024.04.032","https://doi.org/10.1016/j.amjmed.2024.04.032","38729592","https://pubmed.ncbi.nlm.nih.gov/38729592/","http://www.amjmed.com/article/S0002934324002766/pdf",null],["2","R0017722","R0017722.pdf","open_download_failed","randomized_trial","Kong W","2024","Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.","Gynecologic oncology","Elsevier BV","10.1016/j.ygyno.2024.10.004","https://doi.org/10.1016/j.ygyno.2024.10.004","39388742","https://pubmed.ncbi.nlm.nih.gov/39388742/","https://www.gynecologiconcology-online.net/article/S0090-8258(24)01154-5/pdf",null],["2","R0017766","R0017766.pdf","open_download_failed","randomized_trial","Fan Y","2024","Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15359","https://doi.org/10.1111/dom.15359","37975640","https://pubmed.ncbi.nlm.nih.gov/37975640/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15359",null],["2","R0017848","R0017848.pdf","free_to_read","randomized_trial","Kadowaki T","2024","Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.01.002","https://doi.org/10.1016/j.orcp.2025.01.002","39824696","https://pubmed.ncbi.nlm.nih.gov/39824696/","https://doi.org/10.1016/j.orcp.2025.01.002",null],["2","R0018374","R0018374.pdf","open_download_failed","randomized_trial","Liuzzo G","2024","Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae568","https://doi.org/10.1093/eurheartj/ehae568","39302811","https://pubmed.ncbi.nlm.nih.gov/39302811/","https://academic.oup.com/eurheartj/article-pdf/45/45/4870/60834460/ehae568.pdf",null],["2","R0018731","R0018731.pdf","free_to_read","randomized_trial","Manubolu VS","2024","Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.05.065","https://doi.org/10.1016/j.jacc.2024.05.065","39168573","https://pubmed.ncbi.nlm.nih.gov/39168573/","https://doi.org/10.1016/j.jacc.2024.05.065",null],["2","R0018747","R0018747.pdf","open_download_failed","randomized_trial","Mu Y","2024","The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15857","https://doi.org/10.1111/dom.15857","39157869","https://pubmed.ncbi.nlm.nih.gov/39157869/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15857",null],["2","R0018812","R0018812.pdf","open_download_failed","randomized_trial","Wang J","2024","Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15860","https://doi.org/10.1111/dom.15860","39188242","https://pubmed.ncbi.nlm.nih.gov/39188242/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15860",null],["2","R0018815","R0018815.pdf","open_download_failed","randomized_trial","Bensignor MO","2024","Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.","Current opinion in pediatrics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mop.0000000000001365","https://doi.org/10.1097/mop.0000000000001365","38774967","https://pubmed.ncbi.nlm.nih.gov/38774967/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11222026/pdf/nihms-1992186.pdf",null],["2","R0019148","R0019148.pdf","open_download_failed","randomized_trial","Yale JF","2024","Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15794","https://doi.org/10.1111/dom.15794","39118222","https://pubmed.ncbi.nlm.nih.gov/39118222/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15794",null],["2","R0019272","R0019272.pdf","no_doi","randomized_trial","Ma J","2024","Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.","Alternative therapies in health and medicine",null,null,"https://doi.org/","38294744","https://pubmed.ncbi.nlm.nih.gov/38294744/",null,null],["2","R0019389","R0019389.pdf","open_download_failed","randomized_trial","Vergallo R","2024","Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae567","https://doi.org/10.1093/eurheartj/ehae567","39228366","https://pubmed.ncbi.nlm.nih.gov/39228366/","https://academic.oup.com/eurheartj/article-pdf/45/44/4769/60750998/ehae567.pdf",null],["2","R0019577","R0019577.pdf","free_to_read","randomized_trial","Dearos Sanchis M","2024","[Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].","Nutricion hospitalaria","ARAN Ediciones","10.20960/nh.04995","https://doi.org/10.20960/nh.04995","38450509","https://pubmed.ncbi.nlm.nih.gov/38450509/","https://doi.org/10.20960/nh.04995",null],["2","R0019718","R0019718.pdf","open_download_failed","randomized_trial","Oosterom-Eijmael MJP","2024","Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.","Journal of cardiothoracic and vascular anesthesia","Elsevier BV","10.1053/j.jvca.2024.06.015","https://doi.org/10.1053/j.jvca.2024.06.015","38977382","https://pubmed.ncbi.nlm.nih.gov/38977382/","https://www.jcvaonline.com/article/S1053-0770(24)00385-9/pdf",null],["2","R0019758","R0019758.pdf","open_download_failed","randomized_trial","Liuzzo G","2024","Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae076","https://doi.org/10.1093/eurheartj/ehae076","38365916","https://pubmed.ncbi.nlm.nih.gov/38365916/","https://academic.oup.com/eurheartj/article-pdf/45/16/1392/57295268/ehae076.pdf",null],["2","R0020049","R0020049.pdf","open_download_failed","randomized_trial","Furusawa S","2024","Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15393","https://doi.org/10.1111/dom.15393","38073422","https://pubmed.ncbi.nlm.nih.gov/38073422/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15393",null],["2","R0020108","R0020108.pdf","open_download_failed","randomized_trial","Kushner RF","2024","Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23946","https://doi.org/10.1002/oby.23946","37989717","https://pubmed.ncbi.nlm.nih.gov/37989717/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23946",null],["2","R0020668","R0020668.pdf","open_download_failed","randomized_trial","Liuzzo G","2024","Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad823","https://doi.org/10.1093/eurheartj/ehad823","38103177","https://pubmed.ncbi.nlm.nih.gov/38103177/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehad823/54548070/ehad823.pdf",null],["2","R0020687","R0020687.pdf","open_download_failed","randomized_trial","O'Donnell C","2024","GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24126","https://doi.org/10.1002/oby.24126","39169732","https://pubmed.ncbi.nlm.nih.gov/39169732/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24126",null],["2","R0020714","R0020714.pdf","open_download_failed","randomized_trial","Ji L","2024","Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15309","https://doi.org/10.1111/dom.15309","37822270","https://pubmed.ncbi.nlm.nih.gov/37822270/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15309",null],["2","R0020790","R0020790.pdf","free_to_read","randomized_trial","Gullaksen S","2024","The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2023.108673","https://doi.org/10.1016/j.jdiacomp.2023.108673","38219335","https://pubmed.ncbi.nlm.nih.gov/38219335/","https://doi.org/10.1016/j.jdiacomp.2023.108673","EudraCT:2019-000781-38"],["2","R0020923","R0020923.pdf","open_download_failed","randomized_trial","Lincoff AM","2024","The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad097","https://doi.org/10.1093/ehjcvp/pvad097","38066700","https://pubmed.ncbi.nlm.nih.gov/38066700/","https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvad097/54693506/pvad097.pdf",null],["2","R0021246","R0021246.pdf","open_download_failed","randomized_trial","Kuswanto W","2024","Repurposing drugs for the treatment of osteoarthritis.","Osteoarthritis and cartilage","Elsevier BV","10.1016/j.joca.2024.05.008","https://doi.org/10.1016/j.joca.2024.05.008","38821468","https://pubmed.ncbi.nlm.nih.gov/38821468/","https://www.oarsijournal.com/article/S1063-4584(24)01207-X/pdf",null],["2","R0021321","R0021321.pdf","open_download_failed","randomized_trial","Dietsche KB","2024","Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad669","https://doi.org/10.1210/clinem/dgad669","37967247","https://pubmed.ncbi.nlm.nih.gov/37967247/","https://www.ncbi.nlm.nih.gov/pmc/articles/11031226",null],["2","R0022042","R0022042.pdf","open_download_failed","randomized_trial","Winther JB","2024","Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15693","https://doi.org/10.1111/dom.15693","38853300","https://pubmed.ncbi.nlm.nih.gov/38853300/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15693",null],["2","R0022249","R0022249.pdf","free_to_read","randomized_trial","Goodman J","2024","Dual agonism at the glucagon and GLP-1 receptor -- haemodynamic effects in healthy male volunteers","Authorea Preprints","Wiley","10.22541/au.171861520.06708642/v1","https://doi.org/10.22541/au.171861520.06708642/v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0022285","R0022285.pdf","free_to_read","randomized_trial","Vuppalanchi R","2024","Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.18042","https://doi.org/10.1111/apt.18042","38768298","https://pubmed.ncbi.nlm.nih.gov/38768298/","https://doi.org/10.1111/apt.18042",null],["2","R0022840","R0022840.pdf","open_download_failed","randomized_trial","Konstantinidou SK","2024","Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15642","https://doi.org/10.1111/dom.15642","38757729","https://pubmed.ncbi.nlm.nih.gov/38757729/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15642",null],["2","R0023350","R0023350.pdf","open_download_failed","randomized_trial","Du Y","2024","A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.","Statistics in medicine","Wiley","10.1002/sim.10064","https://doi.org/10.1002/sim.10064","38742595","https://pubmed.ncbi.nlm.nih.gov/38742595/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sim.10064",null],["2","R0025546","R0025546.pdf","open_download_failed","randomized_trial","Tronieri J","2024","Use of pharmacotherapy to improve weight loss in early non-responders to behavioral treatment","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.pex-2526/v1","https://doi.org/10.21203/rs.3.pex-2526/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.researchsquare.com/article/pex-2526/latest.pdf",null],["2","R0029093","R0029093.pdf","open_download_failed","randomized_trial","Nilsson MI","2024","Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management.","Nutrients","MDPI AG","10.3390/nu16244407","https://doi.org/10.3390/nu16244407","39771028","https://pubmed.ncbi.nlm.nih.gov/39771028/","https://www.mdpi.com/2072-6643/16/24/4407/pdf?version=1734920898",null],["2","R0029136","R0029136.pdf","open_download_failed","randomized_trial","LeBlanc ES","2024","Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae655","https://doi.org/10.1210/clinem/dgae655","39312230","https://pubmed.ncbi.nlm.nih.gov/39312230/","https://academic.oup.com/jcem/article-pdf/109/12/e2167/60680362/dgae655.pdf",null],["2","R0029140","R0029140.pdf","free_to_read","randomized_trial","Santamaria A","2024","Effect of surgical, medical, and behavioral weight loss on hormonal and sexual function in men: a contemporary narrative review.","Therapeutic advances in urology","SAGE Publications","10.1177/17562872241279648","https://doi.org/10.1177/17562872241279648","39285942","https://pubmed.ncbi.nlm.nih.gov/39285942/","https://doi.org/10.1177/17562872241279648",null],["2","R0029141","R0029141.pdf","open_download_failed","randomized_trial","Aharon-Hananel G","2024","Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15942","https://doi.org/10.1111/dom.15942","39267254","https://pubmed.ncbi.nlm.nih.gov/39267254/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15942",null],["2","R0029235","R0029235.pdf","open_download_failed","randomized_trial","Alhenc-Gelas F","2024","Young-Onset Type 2 Diabetes: When Gluconeogenesis Is Overfueled and Out of Control.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae123","https://doi.org/10.1210/clinem/dgae123","38441504","https://pubmed.ncbi.nlm.nih.gov/38441504/","https://academic.oup.com/jcem/article-pdf/109/10/e1940/59135767/dgae123.pdf",null],["2","R0029714","R0029714.pdf","open_download_failed","randomized_trial","Hope DCD","2024","Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15448","https://doi.org/10.1111/dom.15448","38229453","https://pubmed.ncbi.nlm.nih.gov/38229453/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15448",null],["2","R0030270","R0030270.pdf","free_to_read","randomized_trial","Navas-Acien A","2024","Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).","American heart journal","Elsevier BV","10.1016/j.ahj.2024.04.005","https://doi.org/10.1016/j.ahj.2024.04.005","38621575","https://pubmed.ncbi.nlm.nih.gov/38621575/","https://doi.org/10.1016/j.ahj.2024.04.005","ClinicalTrials.gov:NCT02733185"],["2","R0030334","R0030334.pdf","open_download_failed","randomized_trial","Quast DR","2024","Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15736","https://doi.org/10.1111/dom.15736","38951936","https://pubmed.ncbi.nlm.nih.gov/38951936/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15736",null],["2","R0033183","R0033183.pdf","free_to_read","randomized_trial","Tanvi Bindal","2024","Journal Scan","Asian Journal of Pediatric Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ajpn.ajpn_22_24","https://doi.org/10.4103/ajpn.ajpn_22_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ajpn.ajpn_22_24","ClinicalTrials.gov:NCT04564339; ClinicalTrials.gov:NCT06291376"],["2","R0033284","R0033284.pdf","free_to_read","randomized_trial","Kayalvizhi Jayaraman","2024","Gastroenterology Elsewhere","Gastroenterology Hepatology and Endoscopy Practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/ghep.ghep_17_24","https://doi.org/10.4103/ghep.ghep_17_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ghep.ghep_17_24",null],["2","R0036197","R0036197.pdf","no_doi","randomized_trial","Fagg, Ellington","2024","Effects of Nonpharmacological and Pharmacological Interventions on the Management of Polycystic Ovarian Syndrome","Journal of the Arkansas Academy of Science",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036313","R0036313.pdf","no_doi","randomized_trial","Getahun, BSN, RN, CCRN, Hana","2024","An Evidence Based Practice Educational Module Utilizing a Risk Stratification Algorithm for Surgical Patients on GLP-1 Agonists","Florida International University Digital Commons (Florida International University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037046","R0037046.pdf","free_to_read","randomized_trial","Suman Bhandari","2024","Recent trials with a “High Impact” on current daily practice: A 360° journal search","Journal of current cardiology.","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcc.jcc_35_24","https://doi.org/10.4103/jcc.jcc_35_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcc.jcc_35_24",null],["2","R0038285","R0038285.pdf","open_download_failed","randomized_trial","F. Keli","2024","Therapeutic effects of glucagon-like peptide -1 receptor agonist in adult overweight and obese women with polycystic ovary syndrome: a narrative review","Journal of Kenya Assocation of Physicians","African Journals Online (AJOL)","10.4314/jkap.v6i2.19a","https://doi.org/10.4314/jkap.v6i2.19a",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ajol.info/index.php/jkap/article/download/282301/265992",null],["2","R0040466","R0040466.pdf","free_to_read","randomized_trial","С. М. Ткач","2024","Glucagon-like peptide 1 receptor agonists in the treatment of patients with type 2 diabetes and metabolically-associated steatosic liver disease. Review","Clinical endocrinology and endocrine surgery","Publishing Company VIT-A-POL","10.30978/cees-2024-1-44","https://doi.org/10.30978/cees-2024-1-44",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.30978/cees-2024-1-44",null],["2","R0040936","R0040936.pdf","no_doi","randomized_trial","Santos Pardo, Irene","2024","On cardiovascular complications in people with type 2 diabetes : Aspects of incretin-based therapy and glycemic control","Open Archive (Karolinska Institutet)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041483","R0041483.pdf","open_download_failed","randomized_trial","N Del-Cuerpo-Salinas","2024","Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2775","https://doi.org/10.1093/eurheartj/ehae666.2775",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.2775/60050851/ehae666.2775.pdf",null],["2","R0041608","R0041608.pdf","open_download_failed","randomized_trial","Lloyd Tran","2024","Associations Between Alzheimer’s Disease and Stroke: Clinical Studies of NA‐831 for AD and NA‐911 for Stroke","Alzheimer s & Dementia","Wiley","10.1002/alz.095736","https://doi.org/10.1002/alz.095736",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.095736",null],["2","R0041689","R0041689.pdf","open_download_failed","randomized_trial","Antoine Christiaens","2024","From burden to benefits: new promises of glucose-lowering treatments in older adults","Age and Ageing","Oxford University Press (OUP)","10.1093/ageing/afae265","https://doi.org/10.1093/ageing/afae265","39656766","https://pubmed.ncbi.nlm.nih.gov/39656766/","https://academic.oup.com/ageing/article-pdf/53/12/afae265/60936671/afae265.pdf",null],["2","R0041690","R0041690.pdf","free_to_read","randomized_trial","Marco Zuin","2024","Heart failure treatment and mortality in older people: beyond clinical trials","The Lancet Healthy Longevity","Elsevier BV","10.1016/s2666-7568(24)00060-6","https://doi.org/10.1016/s2666-7568(24)00060-6","38705148","https://pubmed.ncbi.nlm.nih.gov/38705148/","https://doi.org/10.1016/s2666-7568(24)00060-6",null],["2","R0041719","R0041719.pdf","open_download_failed","randomized_trial","N. Dhingra","2024","Generalizability of SELECT to a contemporary cohort of cardiac surgical patients: analysis of the TRICS III Randomized Trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2492","https://doi.org/10.1093/eurheartj/ehae666.2492",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.2492/60055475/ehae666.2492.pdf",null],["2","R0042132","R0042132.pdf","free_to_read","randomized_trial","Eugen Javor","2024","Metabolic Syndrome and Pharmacological Interventions in Clinical Development","Diabetology","MDPI AG","10.3390/diabetology5030023","https://doi.org/10.3390/diabetology5030023",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology5030023",null],["2","R0042159","R0042159.pdf","no_doi","randomized_trial","Helf, Megan","2024","A Clinical Review of Adult Obesity and Weight Management in the United States","RIT Scholar Works (Rochester Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042382","R0042382.pdf","free_to_read","randomized_trial","Hailing Zhao","2024","Gut Microbiota-derived Metabolites: A New Perspective of Traditional Chinese Medicine Against Diabetic Kidney Disease","Integrative Medicine in Nephrology and Andrology","Ovid Technologies (Wolters Kluwer Health)","10.1097/imna-d-23-00024","https://doi.org/10.1097/imna-d-23-00024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/imna-d-23-00024",null],["2","R0042735","R0042735.pdf","free_to_read","randomized_trial","Dora Gašparini","2024","Oral semaglutide improves glycemic control and lowers blood lipids: evidence from a real-world study","Cardiovascular Endocrinology & Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000312","https://doi.org/10.1097/xce.0000000000000312",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1097/xce.0000000000000312",null],["2","R0042929","R0042929.pdf","open_download_failed","randomized_trial","Tim Kambič","2024","Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad856","https://doi.org/10.1093/eurheartj/ehad856","38190431","https://pubmed.ncbi.nlm.nih.gov/38190431/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehad856/55145465/ehad856.pdf",null],["2","R0043417","R0043417.pdf","no_doi","randomized_trial","Steve Bain","2024","Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043436","R0043436.pdf","open_download_failed","randomized_trial","Richard Imrich","2024","Effects of GLP-1 Receptor Agonist on Chronic Axonal Damage, Neurodegeneration, and Cognitive Function in Relapsing-remitting MS (MSGLP): Exploratory, Open Label, Randomized Controlled Trial","Neurotherapeutics","Elsevier BV","10.1016/j.neurot.2024.e00403","https://doi.org/10.1016/j.neurot.2024.e00403",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.neurotherapeuticsjournal.org/article/S1878-7479(24)00089-8/pdf",null],["2","R0043550","R0043550.pdf","free_to_read","randomized_trial","Т. Н. Маркова","2024","The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus","Diabetes Mellitus","Endocrinology Research Centre","10.14341/dm13106","https://doi.org/10.14341/dm13106",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.14341/dm13106",null],["2","R0043552","R0043552.pdf","no_doi","randomized_trial","Owen Carmichael (707539)","2024","Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043833","R0043833.pdf","no_doi","randomized_trial","Hachat, Lindsay","2024","Patient Compliance Through Education for Type 2 Diabetics on New Medications: SGLT-2 Inhibitors and GLP-1 Analogues","Scholarly Commons - Ouachita Research, Creative Work, and Archives (Ouachita Baptist University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043906","R0043906.pdf","no_doi","randomized_trial","Steve Bain","2024","Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043912","R0043912.pdf","free_to_read","randomized_trial","Nkechinyere Mary Harry","2024","Potential Role of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in the Treatment of Bulimia Nervosa","Journal of Advances in Medicine and Medical Research","Sciencedomain International","10.9734/jammr/2024/v36i75514","https://doi.org/10.9734/jammr/2024/v36i75514",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9734/jammr/2024/v36i75514",null],["2","R0043935","R0043935.pdf","free_to_read","randomized_trial","Qi Pan","2024","First study with positive cardiovascular outcome in obesity: Reflections on SELECT","Aging Medicine","Wiley","10.1002/agm2.12300","https://doi.org/10.1002/agm2.12300","38975303","https://pubmed.ncbi.nlm.nih.gov/38975303/","https://doi.org/10.1002/agm2.12300",null],["2","R0044004","R0044004.pdf","no_doi","randomized_trial","Irene Santos Pardo (18663229)","2024","On cardiovascular complications in people with type 2 diabetes : Aspects of incretin-based therapy and glycemic control","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044082","R0044082.pdf","free_to_read","randomized_trial","Roland Gál","2024","The Year in Hungarian Cardiology 2023: Heart failure","Cardiologia Hungarica","Cardiologia Hungarica","10.26430/chungarica.2024.54.3.177","https://doi.org/10.26430/chungarica.2024.54.3.177",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.26430/chungarica.2024.54.3.177",null],["2","R0044718","R0044718.pdf","free_to_read","randomized_trial","K Raveendra","2024","Primary prevention of atrial fibrillation with pharmacological therapy","EP Europace","Oxford University Press (OUP)","10.1093/europace/euae102.829","https://doi.org/10.1093/europace/euae102.829",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/europace/euae102.829",null],["2","R0044878","R0044878.pdf","open_download_failed","randomized_trial","Giuseppe Biondi‐Zoccai","2024","Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001636","https://doi.org/10.1097/fjc.0000000000001636","39326052","https://pubmed.ncbi.nlm.nih.gov/39326052/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11969339/pdf/nihms-2065904.pdf",null],["2","R0044885","R0044885.pdf","open_download_failed","randomized_trial","Filippo Crea","2024","New light shed on the treatment of heart failure and on novel therapeutic targets","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae643","https://doi.org/10.1093/eurheartj/ehae643","39367734","https://pubmed.ncbi.nlm.nih.gov/39367734/","https://academic.oup.com/eurheartj/article-pdf/45/37/3775/59616535/ehae643.pdf",null],["2","R0044938","R0044938.pdf","open_download_failed","randomized_trial","Daniela Pedicino","2024","Weekly Journal Scan: a ‘thousand-mile’ journey in obesity-related heart failure treatment begins with a few STEPs","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae427","https://doi.org/10.1093/eurheartj/ehae427","38985014","https://pubmed.ncbi.nlm.nih.gov/38985014/","https://academic.oup.com/eurheartj/article-pdf/45/37/3787/59616462/ehae427.pdf",null],["2","R0045250","R0045250.pdf","open_download_failed","randomized_trial","Jamie Talan","2024","A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease","Neurology Today","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.nt.0001017612.54350.b4","https://doi.org/10.1097/01.nt.0001017612.54350.b4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://neurologytoday.aan.com/doi/pdf/10.1097/01.NT.0001017612.54350.b4",null],["2","R0045373","R0045373.pdf","open_download_failed","randomized_trial","Theresa Marie Gibble","2024","9229 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.043","https://doi.org/10.1210/jendso/bvae163.043",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.043/59608318/bvae163.043.pdf",null],["2","R0045404","R0045404.pdf","open_download_failed","randomized_trial","Andrew G. Renehan","2024","Diabetes and cancer: Doubts of a causal link","International Journal of Cancer","Wiley","10.1002/ijc.34862","https://doi.org/10.1002/ijc.34862","38450768","https://pubmed.ncbi.nlm.nih.gov/38450768/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.34862",null],["2","R0045559","R0045559.pdf","open_download_failed","randomized_trial","Teodora Mitrovic","2024","Review of current therapeutic approaches for polycystic ovary syndrome","Medicinski pregled","National Library of Serbia","10.2298/mpns2412309m","https://doi.org/10.2298/mpns2412309m",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.doiserbia.nb.rs/ft.aspx?id=0025-81052412309M",null],["2","R0045870","R0045870.pdf","open_download_failed","randomized_trial","Ronald R. Grunstein","2024","0620 Effect of Tirzepatide on Weight Loss in Patients with Obstructive Sleep Apnea and Obesity from SURMOUNT-1","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsae067.0620","https://doi.org/10.1093/sleep/zsae067.0620",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleep/article-pdf/47/Supplement_1/A264/57288766/zsae067.0620.pdf",null],["2","R0046751","R0046751.pdf","open_download_failed","randomized_trial","Gerald F. Watts","2024","Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwae095","https://doi.org/10.1093/eurjpc/zwae095","38446991","https://pubmed.ncbi.nlm.nih.gov/38446991/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwae095/56975380/zwae095.pdf","ClinicalTrials.gov:NCT05610280"],["2","R0046948","R0046948.pdf","open_download_failed","randomized_trial","Jwan A. Naser","2024","Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.124.069479","https://doi.org/10.1161/circulationaha.124.069479","38885297","https://pubmed.ncbi.nlm.nih.gov/38885297/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11185269/pdf/nihms-1990609.pdf","ClinicalTrials.gov:NCT04730947"],["2","R0047021","R0047021.pdf","free_to_read","randomized_trial","Ariane Jullien","2024","Regional heterogeneity of the results of glucagon-like peptide-1 receptor agonists trials in type 2 diabetes: a reanalysis of individual participant data",null,"American Diabetes Association","10.2337/figshare.26528158","https://doi.org/10.2337/figshare.26528158",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.26528158",null],["2","R0047054","R0047054.pdf","free_to_read","randomized_trial","Kristina M. Utzschneider","2024","Impact of insulin sensitivity and β-cell function over time on glycemic outcomes in the GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) Study: differential treatment effects of dual therapy.",null,"American Diabetes Association","10.2337/figshare.24324946.v1","https://doi.org/10.2337/figshare.24324946.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.24324946.v1",null],["2","R0047168","R0047168.pdf","free_to_read","randomized_trial","Henrik Maagensen","2024","Clinical effects of SGLT2 inhibitors in seven persons with HNF1A ‐ MODY ( MODY3 )","Diabetic Medicine","Wiley","10.1111/dme.15387","https://doi.org/10.1111/dme.15387","38875310","https://pubmed.ncbi.nlm.nih.gov/38875310/","https://doi.org/10.1111/dme.15387","CTIS:2023-503760-17-00"],["2","R0047242","R0047242.pdf","open_download_failed","randomized_trial","T M Gibble","2024","5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.044","https://doi.org/10.1210/jendso/bvae163.044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.044/59608316/bvae163.044.pdf",null],["2","R0047272","R0047272.pdf","open_download_failed","randomized_trial","Naim Alkhouri","2024","SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)05018-2","https://doi.org/10.1016/s0016-5085(24)05018-2",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.gastrojournal.org/article/S0016508524050182/pdf",null],["2","R0047387","R0047387.pdf","open_download_failed","randomized_trial","Carel Wynand le Roux","2024","Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2895","https://doi.org/10.1093/eurheartj/ehae666.2895",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.2895/60048570/ehae666.2895.pdf",null],["2","R0047412","R0047412.pdf","open_download_failed","randomized_trial","Luis Miguel Ruilope","2024","Hypertension and the kidney: an update","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad896","https://doi.org/10.1093/eurheartj/ehad896","38326985","https://pubmed.ncbi.nlm.nih.gov/38326985/","https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehad896/56619341/ehad896.pdf",null],["2","R0047426","R0047426.pdf","free_to_read","randomized_trial","Sunder R. Mudaliar","2024","Diabetes Remission - The Holy Grail in Diabetes Management","Chronicle of Diabetes Research and Practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/cdrp.cdrp_15_23","https://doi.org/10.4103/cdrp.cdrp_15_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/cdrp.cdrp_15_23",null],["2","R0047551","R0047551.pdf","open_download_failed","randomized_trial","Henning Bliddal","2024","Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial","Osteoarthritis and Cartilage","Elsevier BV","10.1016/j.joca.2024.03.003","https://doi.org/10.1016/j.joca.2024.03.003",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.oarsijournal.com/article/S1063-4584(24)01017-3/pdf",null],["2","R0047633","R0047633.pdf","free_to_read","randomized_trial","Marian Sue Kirkman","2024","Comparative effects of randomized second-line therapy for type 2 diabetes on a composite outcome incorporating glycemic control, body weight, and hypoglycemia: An analysis of the Glycemia Reduction Approaches in Type 2 Diabetes - A Comparative Effectiveness (GRADE) Study",null,"American Diabetes Association","10.2337/figshare.24534463","https://doi.org/10.2337/figshare.24534463",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.24534463",null],["2","R0047713","R0047713.pdf","free_to_read","randomized_trial","Seán Coleman","2024","OBESITY Medication Self-Injection Education Using “Digital Clinicians”: A Feasibility Randomised Controlled Trial (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.63503","https://doi.org/10.2196/preprints.63503",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.63503",null],["2","R0047748","R0047748.pdf","free_to_read","randomized_trial","Husam Ghanim","2024","12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.019","https://doi.org/10.1210/jendso/bvae163.019",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.019",null],["2","R0047864","R0047864.pdf","free_to_read","randomized_trial","Andrea Cherrington","2024","Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes (GRADE) Study: A Comparative Effectiveness Randomized Clinical Trial",null,"American Diabetes Association","10.2337/figshare.24653628","https://doi.org/10.2337/figshare.24653628",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.24653628",null],["2","R0047865","R0047865.pdf","free_to_read","randomized_trial","Ita Fitzgerald","2024","Metformin in the management of antipsychotic-induced weight gain – why the ‘weight’?","Frontiers in Psychiatry","Frontiers Media SA","10.3389/fpsyt.2024.1491417","https://doi.org/10.3389/fpsyt.2024.1491417","39600786","https://pubmed.ncbi.nlm.nih.gov/39600786/","https://doi.org/10.3389/fpsyt.2024.1491417",null],["2","R0047889","R0047889.pdf","free_to_read","randomized_trial","André Jacques Scheen","2024","Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2024.100197","https://doi.org/10.1016/j.deman.2024.100197",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2024.100197",null],["2","R0048021","R0048021.pdf","free_to_read","randomized_trial","S. M. Noskov","2024","Semaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/ms2024-346","https://doi.org/10.21518/ms2024-346",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21518/ms2024-346",null],["2","R0048137","R0048137.pdf","free_to_read","randomized_trial","Franziska Sophie Ulrich","2024","Real-World Effectiveness of Semaglutide and Liraglutide for Weight Management in Overweight or Obese Adults with or Without Type-2 Diabetes Mellitus: Emulation of Randomised Clinical Trials Using UK Electronic Medical Records","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4785364","https://doi.org/10.2139/ssrn.4785364",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4785364",null],["2","R0048334","R0048334.pdf","open_download_failed","randomized_trial","Ashraf Barakat Said","2024","Biochemical Evaluation of Metformin and GLP-1 Therapy in Amelioration Metabolic Disturbance in Rats Induced Type II Diabetes","Suez Canal Veterinary Medicine Journal SCVMJ","Egyptian Knowledge Bank","10.21608/scvmj.2024.394171","https://doi.org/10.21608/scvmj.2024.394171",null,"https://pubmed.ncbi.nlm.nih.gov//","https://scvmj.journals.ekb.eg/article_394171_5f87e277fa2bc5c2685130211affd49d.pdf",null],["2","R0048402","R0048402.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2024","Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP ‐1 analogue","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.70003","https://doi.org/10.1002/doi2.70003",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.70003",null],["2","R0048412","R0048412.pdf","free_to_read","randomized_trial","Ildiko Lingvay","2024","Semaglutide and Cardiovascular Outcomes by Baseline and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT",null,"American Diabetes Association","10.2337/figshare.25777446","https://doi.org/10.2337/figshare.25777446",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2337/figshare.25777446",null],["2","R0048415","R0048415.pdf","free_to_read","randomized_trial","Ebaa Al‐Ozairi","2024","Combining Glucagon-Like Peptide 1 Analogues with Sodium-Glucose Cotransporter 2 Inhibitors to Treat Patients with Type 1 Diabetes, BMI > 25 Kg/M2, and Chronic Kidney Disease – a Randomised, Controlled Pilot Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4735625","https://doi.org/10.2139/ssrn.4735625",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4735625",null],["2","R0048492","R0048492.pdf","free_to_read","randomized_trial","Venkat Sanjay Manubolu","2024","EFFECT OF SEMAGLUTIDE ON EPICARDIAL ADIPOSE TISSUE VOLUME AND DENSITY IN TYPE 2 DIABETES: INSIGHTS FROM THE STOP RANDOMIZED TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03154-1","https://doi.org/10.1016/s0735-1097(24)03154-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03154-1",null],["2","R0048544","R0048544.pdf","open_download_failed","randomized_trial","SHARVIL S. GADVE","2024","#1772053 Oral Semaglutide plus metformin vs. Myoinositol plus metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.387","https://doi.org/10.1016/j.eprac.2024.03.387",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.endocrinepractice.org/article/S1530891X24004701/pdf",null],["2","R0048788","R0048788.pdf","open_download_failed","randomized_trial","Michel Y. Jadoul","2024","The era of combination of nephroprotective agents in CKD is there","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfae260","https://doi.org/10.1093/ndt/gfae260","39907537","https://pubmed.ncbi.nlm.nih.gov/39907537/","https://academic.oup.com/ndt/article-pdf/40/Supplement_1/i1/61766375/gfae260.pdf",null],["2","R0048958","R0048958.pdf","open_download_failed","randomized_trial","Mary P. Miles","2024","Impacts of Cottonseed and Extra Virgin Olive Oil Intake on Plasma Arachidonic Acid and Eicosanoids: A Randomized Controlled Trial","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2024.102588","https://doi.org/10.1016/j.cdnut.2024.102588",null,"https://pubmed.ncbi.nlm.nih.gov//","https://cdn.nutrition.org/article/S2475-2991(24)00522-5/pdf",null],["2","R0049016","R0049016.pdf","free_to_read","randomized_trial","R. Maan","2024","8707 Are We Adequately Prescribing Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) Or Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) In Patients With Type 2 Diabetes Mellitus (T2DM) And Established Atherosclerotic Cardiovascular Disease (ASCVD) Or Chronic Kidney Disease (CKD) In An Outpatient Setting: A Community Center Experience","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.1032","https://doi.org/10.1210/jendso/bvae163.1032",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.1032",null],["2","R0049023","R0049023.pdf","free_to_read","randomized_trial","Sachin Chittawar","2024","Real-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_31_24","https://doi.org/10.4103/ijdt.ijdt_31_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_31_24",null],["2","R0049096","R0049096.pdf","free_to_read","randomized_trial","Jeffrey S. Gonzalez","2024","Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in GRADE: A Randomized Clinical Trial",null,"American Diabetes Association","10.2337/figshare.25075580","https://doi.org/10.2337/figshare.25075580",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2337/figshare.25075580",null],["2","R0049331","R0049331.pdf","open_download_failed","randomized_trial","Rüdiger Landgraf","2024","Therapy of Type 2 Diabetes","Experimental and Clinical Endocrinology & Diabetes","Georg Thieme Verlag KG","10.1055/a-2166-6755","https://doi.org/10.1055/a-2166-6755","38599610","https://pubmed.ncbi.nlm.nih.gov/38599610/","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2166-6755.pdf",null],["2","R0049376","R0049376.pdf","free_to_read","randomized_trial","Ametov As","2024","Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide","Pharmacy & Pharmacology","Volgograd State Medical University","10.19163/2307-9266-2023-11-4-324-346","https://doi.org/10.19163/2307-9266-2023-11-4-324-346",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.19163/2307-9266-2023-11-4-324-346",null],["2","R0049430","R0049430.pdf","free_to_read","randomized_trial","William Timothy Garvey","2024","The Association of Baseline Factors with Glycemic Outcomes in the GRADE Study: A Comparative Effectiveness Randomized Clinical Trial",null,"American Diabetes Association","10.2337/figshare.24543754","https://doi.org/10.2337/figshare.24543754",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.24543754",null],["2","R0049622","R0049622.pdf","free_to_read","randomized_trial","Ramesh Nadarajah","2024","Machine learning to identify community-dwelling individuals at higher risk of incident cardio-renal-metabolic diseases and death","Future Healthcare Journal","Elsevier BV","10.1016/j.fhj.2024.100109","https://doi.org/10.1016/j.fhj.2024.100109",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.fhj.2024.100109",null],["2","R0049780","R0049780.pdf","open_download_failed","randomized_trial","TIFFANY M. CORTES","2024","EFFECT OF SEMAGLUTIDE ON PHYSICAL FUNCTION, BODY COMPOSITION, AND BIOMARKERS OF AGING IN OLDER ADULTS","Innovation in Aging","Oxford University Press (OUP)","10.1093/geroni/igae098.1054","https://doi.org/10.1093/geroni/igae098.1054",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/innovateage/article-pdf/8/Supplement_1/322/61305500/igae098.1054.pdf",null],["2","R0050001","R0050001.pdf","open_download_failed","randomized_trial","Ricardo Caballero","2024","News in cardiovascular pharmacotherapy from the ACC.24 Meeting","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvae034","https://doi.org/10.1093/ehjcvp/pvae034","38907602","https://pubmed.ncbi.nlm.nih.gov/38907602/","https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvae034/58304490/pvae034.pdf",null],["2","R0050213","R0050213.pdf","open_download_failed","randomized_trial","T M Gibble","2024","5183 Tirzepatide Improved Health-Related Quality of Life in People with Obesity or Overweight: Results from SURMOUNT-4 Phase 3 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.042","https://doi.org/10.1210/jendso/bvae163.042",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.042/59608524/bvae163.042.pdf",null],["2","R0050236","R0050236.pdf","open_download_failed","randomized_trial","Jaime P. Almandoz","2024","Response to the Letter to the Editor by Athinarayanan","Obesity","Wiley","10.1002/oby.24191","https://doi.org/10.1002/oby.24191","39675924","https://pubmed.ncbi.nlm.nih.gov/39675924/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24191",null],["2","R0050605","R0050605.pdf","open_download_failed","randomized_trial","Howard Feldman","2024","Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2","Alzheimer s & Dementia","Wiley","10.1002/alz.083684","https://doi.org/10.1002/alz.083684",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.083684",null],["2","R0050659","R0050659.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2024","Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on mitochondrial-derived peptide-c and on markers of neurohumoral activation","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2915","https://doi.org/10.1093/eurheartj/ehae666.2915",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.2915/60047975/ehae666.2915.pdf",null],["2","R0050818","R0050818.pdf","open_download_failed","randomized_trial","Simon Kok Jensen","2024","#462 Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfae069.111","https://doi.org/10.1093/ndt/gfae069.111",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/39/Supplement_1/gfae069-0111-462/57792088/gfae069-0111-462.pdf",null],["2","R0050906","R0050906.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2024","The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.70001","https://doi.org/10.1002/doi2.70001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.70001",null],["2","R0051289","R0051289.pdf","open_download_failed","randomized_trial","Rasimcan Meral","2024","7255 Tirzepatide Helps Achieve Glycemic Control and Lower Triglycerides in Seven Patients with Lipodystrophy","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.041","https://doi.org/10.1210/jendso/bvae163.041",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.041/59608526/bvae163.041.pdf",null],["2","R0051692","R0051692.pdf","open_download_failed","randomized_trial","Mattía Galli","2024","2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvae069","https://doi.org/10.1093/ehjcvp/pvae069","39289001","https://pubmed.ncbi.nlm.nih.gov/39289001/","https://academic.oup.com/ehjcvp/article-pdf/10/7/572/60456899/pvae069.pdf",null],["2","R0051734","R0051734.pdf","open_download_failed","randomized_trial","Ananda Mohan Chakraborty","2024","8613 Diabetes remission: experience from a randomized control trial conducted in a tertiary care hospital in India","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.731","https://doi.org/10.1210/jendso/bvae163.731",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.731/59610298/bvae163.731.pdf",null],["2","R0051835","R0051835.pdf","open_download_failed","randomized_trial","Clara Odilia Sailer","2024","7625 Functional and structural neuronal changes of dulaglutide compared to placebo during smoking cessation - a randomized placebo-controlled trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.1217","https://doi.org/10.1210/jendso/bvae163.1217",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.1217/59608302/bvae163.1217.pdf",null],["2","R0051913","R0051913.pdf","open_download_failed","randomized_trial","Cormac Kennedy","2024","Blood pressure effect of semaglutide in patients with hypertension: an individual patient data analysis of randomised controlled trials","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwae175.172","https://doi.org/10.1093/eurjpc/zwae175.172",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurjpc/article-pdf/31/Supplement_1/zwae175.172/58221620/zwae175.172.pdf",null],["2","R0052096","R0052096.pdf","open_download_failed","randomized_trial","T H Gibble","2024","8366 Weight Reduction is Associated with Improved Quality of Life in Patients in SURMOUNT-3","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.053","https://doi.org/10.1210/jendso/bvae163.053",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.053/59609098/bvae163.053.pdf",null],["2","R0052179","R0052179.pdf","open_download_failed","randomized_trial","Eric N. Kramer","2024","Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain","American Journal of Psychiatry","American Psychiatric Association Publishing","10.1176/appi.ajp.20240111","https://doi.org/10.1176/appi.ajp.20240111","39350623","https://pubmed.ncbi.nlm.nih.gov/39350623/","https://psychiatryonline.org/doi/pdf/10.1176/appi.ajp.20240111?download=true",null],["2","R0052675","R0052675.pdf","free_to_read","randomized_trial","Varsha G. Vimalananda","2024","6851 Rapidly Increasing Use of Anti-Obesity Medications among Veterans in the Veterans Health Administration (VA)","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.024","https://doi.org/10.1210/jendso/bvae163.024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.024",null],["2","R0052826","R0052826.pdf","free_to_read","randomized_trial","Marc P. Bonaca","2024","EFFECTS OF 1 MG ONCE-WEEKLY SEMAGLUTIDE ON FUNCTIONAL CAPACITY IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERIAL DISEASE: TRIAL DESIGN AND BASELINE CHARACTERISTICS FROM STRIDE A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)04221-9","https://doi.org/10.1016/s0735-1097(24)04221-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)04221-9",null],["2","R0052896","R0052896.pdf","open_download_failed","randomized_trial","Bilal Bin Mukhtar","2024","SEMAGLUTIDE (OZEMPIC) A POTENT WEAPON IN THE FIGHT AGAINST OBESITY","Pakistan Postgraduate Medical Journal","Postgraduate Medical Institute, Lahore General Hospital","10.51642/ppmj.v35i01.694","https://doi.org/10.51642/ppmj.v35i01.694",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ppmj.org.pk/index.php/ppmj/article/download/694/467",null],["2","R0053020","R0053020.pdf","open_download_failed","randomized_trial","Subodh Verma","2024","Baseline patient reported outcomes in patients with peripheral artery disease and type 2 diabetes from STRIDE: a phase 3, 52-week, randomised, double-blind, placebo-controlled trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2287","https://doi.org/10.1093/eurheartj/ehae666.2287",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.2287/60051769/ehae666.2287.pdf",null],["2","R0053320","R0053320.pdf","free_to_read","randomized_trial","Jubbin Jagan Jacob","2024","Gut–Brain Hormone Analogues and Metabolic Magic Wand","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_460_24","https://doi.org/10.4103/ijem.ijem_460_24","39676777","https://pubmed.ncbi.nlm.nih.gov/39676777/","https://doi.org/10.4103/ijem.ijem_460_24",null],["2","R0054246","R0054246.pdf","open_download_failed","randomized_trial","Louis A Talay","2024","Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.15513","https://doi.org/10.1111/dom.15513","38379435","https://pubmed.ncbi.nlm.nih.gov/38379435/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15513",null],["2","R0054347","R0054347.pdf","open_download_failed","randomized_trial","Ramreddy Godela","2024","Estimation of Lexisinatide in Bulk and Tablets by RP‐UPLC Method Developed by Quality by Design Concept","Macromolecular Symposia","Wiley","10.1002/masy.202300142","https://doi.org/10.1002/masy.202300142",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/masy.202300142",null],["2","R0054590","R0054590.pdf","open_download_failed","randomized_trial","Ying Lü","2024","Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.15822","https://doi.org/10.1111/dom.15822","39075921","https://pubmed.ncbi.nlm.nih.gov/39075921/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15822",null],["2","R0055318","R0055318.pdf","no_doi","randomized_trial","E.G.I. Clementi","2024","THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE","Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056021","R0056021.pdf","no_doi","randomized_trial","Afifa Khaleelullah","2024","The Use of GLP-Receptor Agonists for Improving Fertility in PCOS Patients","Journal of Asian Medical Students Association",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056025","R0056025.pdf","no_doi","randomized_trial","冯晓青","2024","CiteSpace-based Visualization of Xanthone Capsule for Diabetic Nephropathy Treatment","Journal of Theory and Practice in Clinical Sciences",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056291","R0056291.pdf","no_doi","randomized_trial","Lina Paola Villamil Castañeda","2024","Safety and efficacy of the insulin Degludec/Liraglutide co-formulation compared to multiple daily insulin injections in the transition from hospital to uutpatient management in patients with type 2 diabetes, evaluated by continuous glucose monitoring : the DELI-transition trial","Repositorio Institucional (Pontificia Universidad Javeriana)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056356","R0056356.pdf","no_doi","randomized_trial","Susana Gutt","2024","Relación con la conducta ingestiva y elección del tratamiento farmacológico","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0056583","R0056583.pdf","no_doi","randomized_trial","Thomas Simon James Crabtree","2024","Individualisation of HbA1c targets and treatment strategies in people with diabetes: real-world observational studies","Nottingham ePrints (University of Nottingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0003338","R0003338.pdf","open_download_failed","randomized_trial","Pratt E","2023","Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15150","https://doi.org/10.1111/dom.15150","37264711","https://pubmed.ncbi.nlm.nih.gov/37264711/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15150",null],["2","R0004359","R0004359.pdf","open_download_failed","randomized_trial","Pratt E","2023","Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15184","https://doi.org/10.1111/dom.15184","37344954","https://pubmed.ncbi.nlm.nih.gov/37344954/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15184",null],["2","R0004626","R0004626.pdf","free_to_read","randomized_trial","Rasalam R","2023","Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14953","https://doi.org/10.1111/dom.14953","36541153","https://pubmed.ncbi.nlm.nih.gov/36541153/","https://doi.org/10.1111/dom.14953",null],["2","R0004830","R0004830.pdf","open_download_failed","randomized_trial","Sabouret P","2023","What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad632","https://doi.org/10.1093/eurheartj/ehad632","37793139","https://pubmed.ncbi.nlm.nih.gov/37793139/","https://academic.oup.com/eurheartj/article-pdf/44/43/4499/53403712/ehad632.pdf",null],["2","R0005325","R0005325.pdf","open_download_failed","randomized_trial","Liu M","2023","The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad032","https://doi.org/10.1093/eurjpc/zwad032","36740456","https://pubmed.ncbi.nlm.nih.gov/36740456/","https://academic.oup.com/eurjpc/article-pdf/30/8/656/50496561/zwad032.pdf",null],["2","R0005384","R0005384.pdf","open_download_failed","randomized_trial","Mahmoud T","2023","Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.","Clinical transplantation","Wiley","10.1111/ctr.15144","https://doi.org/10.1111/ctr.15144","37755118","https://pubmed.ncbi.nlm.nih.gov/37755118/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ctr.15144",null],["2","R0005419","R0005419.pdf","open_download_failed","randomized_trial","Seijas-Amigo J","2023","Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2023.05.004","https://doi.org/10.1016/j.pcd.2023.05.004","37230813","https://pubmed.ncbi.nlm.nih.gov/37230813/","http://www.primary-care-diabetes.com/article/S1751991823000955/pdf",null],["2","R0005704","R0005704.pdf","open_download_failed","randomized_trial","Shou X","2023","Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2022.101194","https://doi.org/10.1016/j.cpcardiol.2022.101194","35395332","https://pubmed.ncbi.nlm.nih.gov/35395332/","https://www.sciencedirect.com/science/article/pii/S0146280622000913/pdf",null],["2","R0005781","R0005781.pdf","open_download_failed","randomized_trial","Minis E","2023","Glucagon-like peptide-1 receptor agonists and safety in the preconception period.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000835","https://doi.org/10.1097/med.0000000000000835","37678163","https://pubmed.ncbi.nlm.nih.gov/37678163/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10615799/pdf/nihms-1934964.pdf",null],["2","R0005863","R0005863.pdf","open_download_failed","randomized_trial","Aroda VR","2023","Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15079","https://doi.org/10.1111/dom.15079","37013892","https://pubmed.ncbi.nlm.nih.gov/37013892/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15079",null],["2","R0006082","R0006082.pdf","open_download_failed","randomized_trial","Silver HJ","2023","Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15113","https://doi.org/10.1111/dom.15113","37188932","https://pubmed.ncbi.nlm.nih.gov/37188932/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10544709/pdf/nihms-1933225.pdf",null],["2","R0007104","R0007104.pdf","open_download_failed","randomized_trial","Yazawa R","2023","A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15064","https://doi.org/10.1111/dom.15064","36974349","https://pubmed.ncbi.nlm.nih.gov/36974349/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15064",null],["2","R0008032","R0008032.pdf","open_download_failed","randomized_trial","Lingvay I","2023","Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14943","https://doi.org/10.1111/dom.14943","36514843","https://pubmed.ncbi.nlm.nih.gov/36514843/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14943",null],["2","R0008546","R0008546.pdf","open_download_failed","randomized_trial","Jensen SBK","2023","Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23715","https://doi.org/10.1002/oby.23715","36942420","https://pubmed.ncbi.nlm.nih.gov/36942420/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23715",null],["2","R0008912","R0008912.pdf","free_to_read","randomized_trial","Aroda VR","2023","Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14990","https://doi.org/10.1111/dom.14990","36700417","https://pubmed.ncbi.nlm.nih.gov/36700417/","https://doi.org/10.1111/dom.14990",null],["2","R0009167","R0009167.pdf","open_download_failed","randomized_trial","Dihoum A","2023","Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2023.2196010","https://doi.org/10.1080/13543784.2023.2196010","36972373","https://pubmed.ncbi.nlm.nih.gov/36972373/","https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2196010?download=true",null],["2","R0010143","R0010143.pdf","open_download_failed","randomized_trial","Jendle J","2023","Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15087","https://doi.org/10.1111/dom.15087","37046364","https://pubmed.ncbi.nlm.nih.gov/37046364/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15087",null],["2","R0010334","R0010334.pdf","free_to_read","randomized_trial","Chen C","2023","Stroke and Diabetes in Adults","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)",null,null,"https://doi.org/","41370623","https://pubmed.ncbi.nlm.nih.gov/41370623/",null,null],["2","R0011015","R0011015.pdf","free_to_read","randomized_trial","Shao H","2023","Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15112","https://doi.org/10.1111/dme.15112","37035994","https://pubmed.ncbi.nlm.nih.gov/37035994/","https://doi.org/10.1111/dme.15112",null],["2","R0011404","R0011404.pdf","open_download_failed","randomized_trial","McInnes N","2023","Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15234","https://doi.org/10.1111/dom.15234","37580972","https://pubmed.ncbi.nlm.nih.gov/37580972/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15234",null],["2","R0013671","R0013671.pdf","free_to_read","randomized_trial","Kalyani RR","2023","Heart Disease and Diabetes","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)",null,null,"https://doi.org/","38117924","https://pubmed.ncbi.nlm.nih.gov/38117924/",null,null],["2","R0013849","R0013849.pdf","free_to_read","randomized_trial","Tayyaba","2023","Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.7685","https://doi.org/10.47391/jpma.7685","37218275","https://pubmed.ncbi.nlm.nih.gov/37218275/","http://dx.doi.org/10.47391/jpma.7685",null],["2","R0013864","R0013864.pdf","open_download_failed","randomized_trial","Dawed AY","2023","Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(22)00340-0","https://doi.org/10.1016/s2213-8587(22)00340-0","36528349","https://pubmed.ncbi.nlm.nih.gov/36528349/","http://www.thelancet.com/article/S2213858722003400/pdf",null],["2","R0015208","R0015208.pdf","open_download_failed","randomized_trial","Kato ET","2023","GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad072","https://doi.org/10.1093/ehjcvp/pvad072","37777847","https://pubmed.ncbi.nlm.nih.gov/37777847/","https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvad072/52173747/pvad072.pdf",null],["2","R0015486","R0015486.pdf","open_download_failed","randomized_trial","Galindo RJ","2023","A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.","Diabetes care","American Diabetes Association","10.2337/dc22-2426","https://doi.org/10.2337/dc22-2426","37459574","https://pubmed.ncbi.nlm.nih.gov/37459574/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10465828/pdf/dc222426.pdf",null],["2","R0017796","R0017796.pdf","open_download_failed","randomized_trial","Frechtel G","2023","Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15125","https://doi.org/10.1111/dom.15125","37253689","https://pubmed.ncbi.nlm.nih.gov/37253689/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15125","EudraCT:2017-003370-13"],["2","R0018824","R0018824.pdf","open_download_failed","randomized_trial","Wang W","2023","Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15263","https://doi.org/10.1111/dom.15263","37732487","https://pubmed.ncbi.nlm.nih.gov/37732487/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15263",null],["2","R0019543","R0019543.pdf","free_to_read","randomized_trial","Volpe M","2023","How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2023.03.054","https://doi.org/10.1016/j.ijcard.2023.03.054","37001648","https://pubmed.ncbi.nlm.nih.gov/37001648/","https://doi.org/10.1016/j.ijcard.2023.03.054",null],["2","R0020134","R0020134.pdf","open_download_failed","randomized_trial","van der Aart-van der Beek AB","2023","Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15033","https://doi.org/10.1111/dom.15033","36843215","https://pubmed.ncbi.nlm.nih.gov/36843215/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15033",null],["2","R0020628","R0020628.pdf","free_to_read","randomized_trial","Gullaksen S","2023","Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2023.108472","https://doi.org/10.1016/j.jdiacomp.2023.108472","37062189","https://pubmed.ncbi.nlm.nih.gov/37062189/","https://doi.org/10.1016/j.jdiacomp.2023.108472","EudraCT:2019-000781-38"],["2","R0021110","R0021110.pdf","free_to_read","randomized_trial","Kolotkin RL","2023","Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.","Clinical obesity","Wiley","10.1111/cob.12589","https://doi.org/10.1111/cob.12589","36905345","https://pubmed.ncbi.nlm.nih.gov/36905345/","https://doi.org/10.1111/cob.12589",null],["2","R0021232","R0021232.pdf","open_download_failed","randomized_trial","Mochel J","2023","A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control","Authorea Preprints","Wiley","10.22541/au.170022092.29999283/v1","https://doi.org/10.22541/au.170022092.29999283/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.170022092.29999283",null],["2","R0021318","R0021318.pdf","free_to_read","randomized_trial","Habiba U","2023","Tirzepatide - A major breakthrough in the fight against obesity.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.7552","https://doi.org/10.47391/jpma.7552","36932808","https://pubmed.ncbi.nlm.nih.gov/36932808/","https://doi.org/10.47391/jpma.7552",null],["2","R0021356","R0021356.pdf","open_download_failed","randomized_trial","Bjorner JB","2023","The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15090","https://doi.org/10.1111/dom.15090","37055712","https://pubmed.ncbi.nlm.nih.gov/37055712/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15090",null],["2","R0021417","R0021417.pdf","free_to_read","randomized_trial","Nerild HH","2023","Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15017","https://doi.org/10.1111/dom.15017","36781820","https://pubmed.ncbi.nlm.nih.gov/36781820/","https://doi.org/10.1111/dom.15017",null],["2","R0021437","R0021437.pdf","open_download_failed","randomized_trial","Grunstein RR","2023","Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?","Sleep","Oxford University Press (OUP)","10.1093/sleep/zsad224","https://doi.org/10.1093/sleep/zsad224","37668448","https://pubmed.ncbi.nlm.nih.gov/37668448/","https://academic.oup.com/sleep/article-pdf/46/10/zsad224/51943118/zsad224.pdf",null],["2","R0021609","R0021609.pdf","free_to_read","randomized_trial","Jensterle M","2023","Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14944","https://doi.org/10.1111/dom.14944","36511825","https://pubmed.ncbi.nlm.nih.gov/36511825/","https://doi.org/10.1111/dom.14944",null],["2","R0021657","R0021657.pdf","free_to_read","randomized_trial","Aguilar Salinas CA","2023","Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad017","https://doi.org/10.1210/clinem/dgad017","36638011","https://pubmed.ncbi.nlm.nih.gov/36638011/",null,null],["2","R0021807","R0021807.pdf","free_to_read","randomized_trial","Povar-Echeverría M","2023","Prognostic impact of metformin in patients with type 2 diabetes mellitus and acute heart failure: Combined analysis of the EAHFE and RICA registries.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2023.09.007","https://doi.org/10.1016/j.rceng.2023.09.007","37717921","https://pubmed.ncbi.nlm.nih.gov/37717921/","https://doi.org/10.1016/j.rceng.2023.09.007",null],["2","R0022318","R0022318.pdf","open_download_failed","randomized_trial","Sannaa W","2023","Factors associated with successful weight loss after liraglutide treatment for obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14880","https://doi.org/10.1111/dom.14880","36193713","https://pubmed.ncbi.nlm.nih.gov/36193713/","https://www.ncbi.nlm.nih.gov/pmc/articles/9812862",null],["2","R0022410","R0022410.pdf","open_download_failed","randomized_trial","Long X","2023","Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","Informa UK Limited","10.1080/09513590.2023.2223648","https://doi.org/10.1080/09513590.2023.2223648","37406658","https://pubmed.ncbi.nlm.nih.gov/37406658/","https://www.tandfonline.com/doi/pdf/10.1080/09513590.2023.2223648?needAccess=true&role=button","ChiCTR:ChiCTR1900024384"],["2","R0022791","R0022791.pdf","open_download_failed","randomized_trial","Wauters L","2023","Treatment of short bowel syndrome: Breaking the therapeutic ceiling?","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","Wiley","10.1002/ncp.10974","https://doi.org/10.1002/ncp.10974","37115030","https://pubmed.ncbi.nlm.nih.gov/37115030/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ncp.10974",null],["2","R0022831","R0022831.pdf","open_download_failed","randomized_trial","Green JB","2023","Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14993","https://doi.org/10.1111/dom.14993","36700460","https://pubmed.ncbi.nlm.nih.gov/36700460/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14993",null],["2","R0022846","R0022846.pdf","free_to_read","randomized_trial","Khalaf MM","2023","A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.","International immunopharmacology","Elsevier BV","10.1016/j.intimp.2023.110170","https://doi.org/10.1016/j.intimp.2023.110170","37075673","https://pubmed.ncbi.nlm.nih.gov/37075673/","https://doi.org/10.1016/j.intimp.2023.110170",null],["2","R0024875","R0024875.pdf","open_download_failed","randomized_trial","Peters AE","2023","Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2023.05.16.23288273","https://doi.org/10.1101/2023.05.16.23288273","37293003","https://pubmed.ncbi.nlm.nih.gov/37293003/","https://www.medrxiv.org/content/medrxiv/early/2023/05/16/2023.05.16.23288273.full.pdf",null],["2","R0024976","R0024976.pdf","open_download_failed","randomized_trial","Camilleri M","2023","New Developments in Bile Acid Diarrhea.","Gastroenterology & hepatology",null,null,"https://doi.org/","37771793","https://pubmed.ncbi.nlm.nih.gov/37771793/",null,null],["2","R0030166","R0030166.pdf","open_download_failed","randomized_trial","Corbin KD","2023","Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23633","https://doi.org/10.1002/oby.23633","36695055","https://pubmed.ncbi.nlm.nih.gov/36695055/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23633",null],["2","R0030237","R0030237.pdf","open_download_failed","randomized_trial","Pokoly B","2023","[Rediscovery of pioglitazone].","Orvosi hetilap","Akademiai Kiado Zrt.","10.1556/650.2023.32783","https://doi.org/10.1556/650.2023.32783","37393546","https://pubmed.ncbi.nlm.nih.gov/37393546/","https://akjournals.com/downloadpdf/journals/650/164/26/article-p1012.pdf",null],["2","R0030261","R0030261.pdf","open_download_failed","randomized_trial","Luijken K","2023","Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5620","https://doi.org/10.1002/pds.5620","36946319","https://pubmed.ncbi.nlm.nih.gov/36946319/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.5620",null],["2","R0032442","R0032442.pdf","no_doi","randomized_trial","Burke, McKenzie","2023","Liraglutide versus Semaglutide: Long Term Weight Loss Management in Obese Individuals","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032841","R0032841.pdf","free_to_read","randomized_trial","Abbas Mohsin Younus","2023","Obesity between 13 to 16 Years Students Visiting General Hospital \"Cross-Sectional Study\"","Himalayan Journal of Applied Medical Sciences and Research","International Academic and Research Consortium","10.47310/hjamsr.2023.v04i01.019","https://doi.org/10.47310/hjamsr.2023.v04i01.019",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47310/hjamsr.2023.v04i01.019",null],["2","R0033193","R0033193.pdf","free_to_read","randomized_trial","Burhanuddin Sohail Rangwala","2023","Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD)","International Journal of Surgery Global Health","Ovid Technologies (Wolters Kluwer Health)","10.1097/gh9.0000000000000168","https://doi.org/10.1097/gh9.0000000000000168",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1097/gh9.0000000000000168",null],["2","R0033197","R0033197.pdf","free_to_read","randomized_trial",null,"2023","Keyword Index","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.jcma.0000998236.52367.df","https://doi.org/10.1097/01.jcma.0000998236.52367.df",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/01.jcma.0000998236.52367.df",null],["2","R0036463","R0036463.pdf","free_to_read","randomized_trial","Nasser Mikhail","2023","Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes","Clinical Research and Clinical Trials","Auctores Publishing LLC","10.31579/2693-4779/154","https://doi.org/10.31579/2693-4779/154",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31579/2693-4779/154",null],["2","R0036930","R0036930.pdf","free_to_read","randomized_trial","Ammar Rasoul Mohammad","2023","Protective Effect of Ipragliflozin on Acute Brain Injury Induced by Endotoxemia in Mice","مجله طب جانباز","Varlik Publishing Group","10.58209/ijwph.15.3.225","https://doi.org/10.58209/ijwph.15.3.225",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.58209/ijwph.15.3.225",null],["2","R0037973","R0037973.pdf","free_to_read","randomized_trial",null,"2023","Title Index","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.jcma.0000998240.92275.b3","https://doi.org/10.1097/01.jcma.0000998240.92275.b3","40460871","https://pubmed.ncbi.nlm.nih.gov/40460871/","https://doi.org/10.1097/01.jcma.0000998240.92275.b3",null],["2","R0038159","R0038159.pdf","free_to_read","randomized_trial","Jun-Zhang Chen","2023","Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000000000230","https://doi.org/10.1681/asn.0000000000000230","38039089","https://pubmed.ncbi.nlm.nih.gov/38039089/","https://www.ncbi.nlm.nih.gov/pmc/articles/10881182",null],["2","R0038342","R0038342.pdf","open_download_failed","randomized_trial","Sadaf Afraz","2023","Endocrinology for the hepatologist","Clinical Liver Disease","Ovid Technologies (Wolters Kluwer Health)","10.1097/cld.0000000000000037","https://doi.org/10.1097/cld.0000000000000037","37521181","https://pubmed.ncbi.nlm.nih.gov/37521181/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10378804/pdf/xcl-22-01.pdf",null],["2","R0040106","R0040106.pdf","free_to_read","randomized_trial","Danisha Dhirani","2023","A new kind of diabetes medication approved by the FDA: is there hope for obesity?","International Journal of Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000000044","https://doi.org/10.1097/js9.0000000000000044","36799809","https://pubmed.ncbi.nlm.nih.gov/36799809/","https://doi.org/10.1097/js9.0000000000000044",null],["2","R0040475","R0040475.pdf","no_doi","randomized_trial","Eyk, H.J. van","2023","GLP-1 receptor agonism to improve cardiometabolic health","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040559","R0040559.pdf","free_to_read","randomized_trial","Mehmet İlkin Naharcı","2023","Comment on the article titled “Association of the triglyceride‐glucose index with subclinical left ventricular dysfunction in type 2 diabetes mellitus patients: A retrospective cross‐sectional study”","Journal of Diabetes Investigation","Wiley","10.1111/jdi.14093","https://doi.org/10.1111/jdi.14093","37864283","https://pubmed.ncbi.nlm.nih.gov/37864283/","http://dx.doi.org/10.1111/jdi.14093",null],["2","R0040863","R0040863.pdf","no_doi","randomized_trial","AL-Salman, Jasmine","2023","Effekten av liraglutid som monoterapi eller i kombination med metformin vid behandling av fetma och övervikt hos kvinnor med polycystiskt ovarialt syndrom","DiVA (Linkoping University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041488","R0041488.pdf","open_download_failed","randomized_trial","Irene Santos‐Pardo","2023","Effects on re-endothelialisation with Bydureon treatment add on to insulin versus insulin alone, both in combination with metformin in type 2 diabetic subjects: Rebuild study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.1328","https://doi.org/10.1093/eurheartj/ehad655.1328",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.1328/53592708/ehad655.1328.pdf",null],["2","R0041658","R0041658.pdf","open_download_failed","randomized_trial","Ivo Boškoski","2023","Small intestine is a big player!","Digestive Endoscopy","Wiley","10.1111/den.14624","https://doi.org/10.1111/den.14624","37492017","https://pubmed.ncbi.nlm.nih.gov/37492017/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/den.14624",null],["2","R0041733","R0041733.pdf","open_download_failed","randomized_trial","Isca Hershkowitz","2023","Prescription patterns in people who are frail","The Lancet Healthy Longevity","Elsevier BV","10.1016/s2666-7568(23)00177-0","https://doi.org/10.1016/s2666-7568(23)00177-0","37734396","https://pubmed.ncbi.nlm.nih.gov/37734396/","http://www.thelancet.com/article/S2666756823001770/pdf",null],["2","R0041757","R0041757.pdf","open_download_failed","randomized_trial","Felice Gragnano","2023","The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad043","https://doi.org/10.1093/ehjcvp/pvad043","37358273","https://pubmed.ncbi.nlm.nih.gov/37358273/","https://academic.oup.com/ehjcvp/article-pdf/9/6/499/51686177/pvad043.pdf",null],["2","R0041811","R0041811.pdf","open_download_failed","randomized_trial","Kris G. Vargas","2023","Assessing the potential for precision medicine of glucose-lowering drugs in type 2 diabetes mellitus: a meta-regression analysis considering body weight variability from 120 randomized trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2994","https://doi.org/10.1093/eurheartj/ehad655.2994",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2994/53608244/ehad655.2994.pdf",null],["2","R0041821","R0041821.pdf","open_download_failed","randomized_trial","Abderrahim Oulhaj","2023","The incorporation of repeated measurements of risk factors at current and previous visits improves the accuracy of cardiovascular risk assessment: an analysis of the EXSCEL trial","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad125.029","https://doi.org/10.1093/eurjpc/zwad125.029",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurjpc/article-pdf/30/Supplement_1/zwad125.029/50458332/zwad125.029.pdf",null],["2","R0042212","R0042212.pdf","no_doi","randomized_trial","Scott, Russell","2023","Prevention and Delayed Progression of Diabetic Nephropathy","OpenSIUC (Southern Illinois University Carbondale)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042369","R0042369.pdf","open_download_failed","randomized_trial","Hyeong Kyu Park","2023","THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.723","https://doi.org/10.1210/jendso/bvad114.723",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/7/Supplement_1/bvad114.723/51890147/bvad114.723.pdf",null],["2","R0042384","R0042384.pdf","no_doi","randomized_trial","Dang, Lauren Elizabeth Eyler","2023","Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator","eScholarship (California Digital Library)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042421","R0042421.pdf","open_download_failed","randomized_trial","Nora Abrahimi","2023","THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.820","https://doi.org/10.1210/jendso/bvad114.820",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/7/Supplement_1/bvad114.820/51900753/bvad114.820.pdf",null],["2","R0042462","R0042462.pdf","no_doi","randomized_trial","Sankar D Navaneethan (8335614)","2023","Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042680","R0042680.pdf","open_download_failed","randomized_trial","Özlem Zeynep Akyay","2023","Evaluation of Exenatide Versus Insulin Glargine Treatment’s Impact on Brown Adipose Tissue Markers and Epicardial Adipose Tissue","Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy","Galenos Yayinevi","10.4274/bmj.galenos.2023.2023.6-5","https://doi.org/10.4274/bmj.galenos.2023.2023.6-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4274/bmj.galenos.2023.2023.6-5",null],["2","R0042684","R0042684.pdf","open_download_failed","randomized_trial","Massimo Volpe","2023","The promise of a new orally active body weight reducer","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad470","https://doi.org/10.1093/eurheartj/ehad470","37525544","https://pubmed.ncbi.nlm.nih.gov/37525544/","https://academic.oup.com/eurheartj/article-pdf/44/36/3403/51722308/ehad470.pdf",null],["2","R0042945","R0042945.pdf","open_download_failed","randomized_trial",null,"2023","Science, Medicine, and the Anesthesiologist","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000004792","https://doi.org/10.1097/aln.0000000000004792",null,"https://pubmed.ncbi.nlm.nih.gov//","https://pubs.asahq.org/anesthesiology/article-pdf/139/6/A15/696973/20231200.0-00004.pdf",null],["2","R0042957","R0042957.pdf","open_download_failed","randomized_trial","Chunxiao Yang","2023","A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy","Proceedings of Anticancer Research","Bio-Byword Scientific Publishing, Pty. Ltd.","10.26689/par.v7i6.5566","https://doi.org/10.26689/par.v7i6.5566",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ojs.bbwpublisher.com/index.php/PAR/article/download/5566/4843",null],["2","R0043156","R0043156.pdf","open_download_failed","randomized_trial","Giovanna Liuzzo","2023","Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad674","https://doi.org/10.1093/eurheartj/ehad674","37879100","https://pubmed.ncbi.nlm.nih.gov/37879100/","https://academic.oup.com/eurheartj/article-pdf/44/46/4829/54041791/ehad674.pdf",null],["2","R0043165","R0043165.pdf","open_download_failed","randomized_trial","Felice Gragnano","2023","What's new in pharmacotherapy at ESC Congress 2023?","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad064","https://doi.org/10.1093/ehjcvp/pvad064","37682522","https://pubmed.ncbi.nlm.nih.gov/37682522/","https://academic.oup.com/ehjcvp/article-pdf/9/7/597/52629689/pvad064.pdf",null],["2","R0043758","R0043758.pdf","free_to_read","randomized_trial","Anna Arefeva","2023","Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/ms2023-312","https://doi.org/10.21518/ms2023-312",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21518/ms2023-312",null],["2","R0043932","R0043932.pdf","open_download_failed","randomized_trial","Shintaro Ide","2023","Updates on dyslipidemia in patients with diabetes","Journal of Diabetes Investigation","Wiley","10.1111/jdi.14042","https://doi.org/10.1111/jdi.14042","37347218","https://pubmed.ncbi.nlm.nih.gov/37347218/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.14042",null],["2","R0044099","R0044099.pdf","no_doi","randomized_trial","Anna Isayeva","2023","The Effectiveness of the use of Liraglutide 3.0mg in Obesity Services (The STRIVE Study)","Research Repository UCD (University College Dublin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044250","R0044250.pdf","no_doi","randomized_trial","Giulia Ferrannini (18679255)","2023","Dysglycaemia and cardiovascular disease. Aspects on screening, management, and prognosis","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044302","R0044302.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2023","Pulmonary disease in diabetes","Journal of Diabetes","Wiley","10.1111/1753-0407.13509","https://doi.org/10.1111/1753-0407.13509","38156437","https://pubmed.ncbi.nlm.nih.gov/38156437/","https://doi.org/10.1111/1753-0407.13509",null],["2","R0044336","R0044336.pdf","open_download_failed","randomized_trial","Rachel Mauchlen","2023","Finerenone","Practical Diabetes","Wiley","10.1002/pdi.2471","https://doi.org/10.1002/pdi.2471",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2471",null],["2","R0044771","R0044771.pdf","open_download_failed","randomized_trial","Y.-T. Lee","2023","Commentary on glucose reduction in type 2 diabetes ( GRADE )","Journal of Diabetes Investigation","Wiley","10.1111/jdi.13994","https://doi.org/10.1111/jdi.13994","36799078","https://pubmed.ncbi.nlm.nih.gov/36799078/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.13994",null],["2","R0044852","R0044852.pdf","open_download_failed","randomized_trial","Gisle Langslet","2023","Is prediabetes a cardiovascular risk factor in patients with coronary artery disease?","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad097","https://doi.org/10.1093/eurjpc/zwad097","37036914","https://pubmed.ncbi.nlm.nih.gov/37036914/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwad097/49807958/zwad097.pdf",null],["2","R0044871","R0044871.pdf","free_to_read","randomized_trial","Dinah Foer","2023","Reply to Li et al.","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/rccm.202310-1721le","https://doi.org/10.1164/rccm.202310-1721le","37855723","https://pubmed.ncbi.nlm.nih.gov/37855723/","http://dx.doi.org/10.1164/rccm.202310-1721le",null],["2","R0044874","R0044874.pdf","open_download_failed","randomized_trial","Tracey G. Simon","2023","Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.15052","https://doi.org/10.1111/dom.15052","36938914","https://pubmed.ncbi.nlm.nih.gov/36938914/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15052",null],["2","R0045797","R0045797.pdf","open_download_failed","randomized_trial","David Chen","2023","Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application","Statistics in Biopharmaceutical Research","Informa UK Limited","10.1080/19466315.2023.2173644","https://doi.org/10.1080/19466315.2023.2173644",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.tandfonline.com/doi/pdf/10.1080/19466315.2023.2173644?needAccess=true&role=button",null],["2","R0047006","R0047006.pdf","open_download_failed","randomized_trial","Paul Edison","2023","MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE","Alzheimer s & Dementia","Wiley","10.1002/alz.080538","https://doi.org/10.1002/alz.080538",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.080538",null],["2","R0047137","R0047137.pdf","open_download_failed","randomized_trial","Anne L. Peters","2023","THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.731","https://doi.org/10.1210/jendso/bvad114.731",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/7/Supplement_1/bvad114.731/51901248/bvad114.731.pdf",null],["2","R0047400","R0047400.pdf","open_download_failed","randomized_trial","Grace A. McComsey","2023","1984. Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy","Open Forum Infectious Diseases","Oxford University Press (OUP)","10.1093/ofid/ofad500.111","https://doi.org/10.1093/ofid/ofad500.111",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.111/53762767/ofad500.111.pdf",null],["2","R0047533","R0047533.pdf","free_to_read","randomized_trial","ISKANDAR RAUF IDRIS","2023","Semaglutide 2.4 mg shown to reduce heart failure with preserved ejection fraction in overweight/obese people without diabetes","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.74","https://doi.org/10.1002/doi2.74",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/doi2.74",null],["2","R0047603","R0047603.pdf","open_download_failed","randomized_trial","Viknesh Selvarajah","2023","#3000 EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfad063a_3000","https://doi.org/10.1093/ndt/gfad063a_3000",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/38/Supplement_1/gfad063a_3000/50672862/gfad063a_3000.pdf",null],["2","R0047607","R0047607.pdf","no_doi","randomized_trial","Gullaksen, Søren; id_orcid 0000-0001-8275-1278","2023","Effects of 32 weeks treatment with semaglutide and empagliflozin on magnetic resonance imaging derived kidney parameters and on retinal function in people with type 2 diabetes:data from a randomised trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047855","R0047855.pdf","free_to_read","randomized_trial","Mohammed Altigani Abdalla","2023","Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_16_23","https://doi.org/10.4103/jod.jod_16_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_16_23",null],["2","R0047858","R0047858.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","High dose semaglutide 2.4 mg (once weekly) shown to reduce the risks of cardiovascular events in people without diabetes","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.82","https://doi.org/10.1002/doi2.82",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.82",null],["2","R0047915","R0047915.pdf","open_download_failed","randomized_trial","Samuel Zachary Goldhaber","2023","Obesity and Pulmonary Embolism: Can We Dismantle the “Obesity Paradox”","Thrombosis and Haemostasis","Georg Thieme Verlag KG","10.1055/a-2187-0966","https://doi.org/10.1055/a-2187-0966","37802123","https://pubmed.ncbi.nlm.nih.gov/37802123/","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2187-0966.pdf",null],["2","R0048014","R0048014.pdf","free_to_read","randomized_trial","Frank Chip Brosius","2023","Treatment of Nondiabetic Kidney Diseases with Sodium-Glucose Cotransporter-2 Inhibitors","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000000000000194","https://doi.org/10.2215/cjn.0000000000000194","37831467","https://pubmed.ncbi.nlm.nih.gov/37831467/","https://www.ncbi.nlm.nih.gov/pmc/articles/10578631",null],["2","R0048287","R0048287.pdf","free_to_read","randomized_trial","Tom Crabtree","2023","factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2023.418","https://doi.org/10.15277/bjd.2023.418",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2023.418",null],["2","R0048348","R0048348.pdf","open_download_failed","randomized_trial","Lakshmi Sankaran","2023","Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight","Practical Diabetes","Wiley","10.1002/pdi.2432","https://doi.org/10.1002/pdi.2432",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2432",null],["2","R0048466","R0048466.pdf","open_download_failed","randomized_trial","Rahaf Wardeh","2023","Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence","Journal of Diabetes and Endocrine Practice","Georg Thieme Verlag KG","10.1055/s-0043-1775966","https://doi.org/10.1055/s-0043-1775966",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0043-1775966.pdf",null],["2","R0048598","R0048598.pdf","free_to_read","randomized_trial","Reshmi Srinath","2023","SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.108","https://doi.org/10.1210/jendso/bvad114.108",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.108",null],["2","R0048752","R0048752.pdf","open_download_failed","randomized_trial","Robert J. Weber","2023","1274 Infliximab for decompensated diabetes following immune checkpoint inhibitor therapy","Regular and Young Investigator Award Abstracts","BMJ Publishing Group Ltd","10.1136/jitc-2023-sitc2023.1274","https://doi.org/10.1136/jitc-2023-sitc2023.1274",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jitc.bmj.com/content/jitc/11/Suppl_1/1411.full.pdf",null],["2","R0048819","R0048819.pdf","open_download_failed","randomized_trial","Mona Mashayekhi","2023","Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes",null,"American Diabetes Association","10.2337/figshare.24375271","https://doi.org/10.2337/figshare.24375271",null,"https://pubmed.ncbi.nlm.nih.gov//","https://diabetesjournals.figshare.com/articles/figure/Weight_Loss-Independent_Effect_of_Liraglutide_on_Insulin_Sensitivity_in_Individuals_with_Obesity_and_Pre-Diabetes/24375271/1/files/42788359.pdf",null],["2","R0048851","R0048851.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","Cardio‐renal benefits of newer glucose lowering agents may be less effective in Black people","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.76","https://doi.org/10.1002/doi2.76",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.76",null],["2","R0048989","R0048989.pdf","free_to_read","randomized_trial","Morten Steen Hansen","2023","The Effect of Semaglutide on Bone Turnover in Adults with Increased Fracture Risk: A Randomised, Double-Blinded, Placebo-Controlled Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4647909","https://doi.org/10.2139/ssrn.4647909",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4647909",null],["2","R0049079","R0049079.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2023","Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2560","https://doi.org/10.1093/eurheartj/ehad655.2560",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2560/53608492/ehad655.2560.pdf",null],["2","R0049103","R0049103.pdf","free_to_read","randomized_trial","Sanbao Chai","2023","Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000002520","https://doi.org/10.1097/cm9.0000000000002520","36723862","https://pubmed.ncbi.nlm.nih.gov/36723862/","https://doi.org/10.1097/cm9.0000000000002520",null],["2","R0049350","R0049350.pdf","free_to_read","randomized_trial","Marina Povar-Echeverría","2023","Impacto pronóstico de metformina en pacientes con diabetes mellitus tipo 2 e insuficiencia cardiaca aguda. Análisis combinado de los registros EAHFE y RICA","Revista Clínica Española","Elsevier BV","10.1016/j.rce.2023.07.007","https://doi.org/10.1016/j.rce.2023.07.007",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.rce.2023.07.007",null],["2","R0049501","R0049501.pdf","free_to_read","randomized_trial","Leila Probst","2023","THU122 Effects Of A GLP-1 Agonist On Consumption Of Alcohol In Patients Treated For Smoking Cessation","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.1200","https://doi.org/10.1210/jendso/bvad114.1200",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.1200",null],["2","R0049677","R0049677.pdf","open_download_failed","randomized_trial","Mitja Lainščak","2023","Protecting women heart in Type 2 diabetes mellitus: why, how, and when?","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad335","https://doi.org/10.1093/eurjpc/zwad335","37897497","https://pubmed.ncbi.nlm.nih.gov/37897497/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwad335/54126765/zwad335.pdf",null],["2","R0049702","R0049702.pdf","free_to_read","randomized_trial","Fabienne Baur","2023","FRI068 Gender Differences In Smoking Cessation? Results Of A Randomized Controlled Trial Of Dulaglutide-assisted Smoking Cessation","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.078","https://doi.org/10.1210/jendso/bvad114.078",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.078",null],["2","R0049908","R0049908.pdf","free_to_read","randomized_trial","Priscilla A. Hollander","2023","The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes (GRADE) Study",null,"American Diabetes Association","10.2337/figshare.23800437.v1","https://doi.org/10.2337/figshare.23800437.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.23800437.v1",null],["2","R0050320","R0050320.pdf","open_download_failed","randomized_trial","Géza Hálasz","2023","Issue 30.08 focus on diabetes mellitus and cardiometabolic disorders","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad135","https://doi.org/10.1093/eurjpc/zwad135","37258061","https://pubmed.ncbi.nlm.nih.gov/37258061/","https://academic.oup.com/eurjpc/article-pdf/30/8/621/50496576/zwad135.pdf",null],["2","R0050388","R0050388.pdf","free_to_read","randomized_trial","Jiat Ling Poon","2023","OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.011","https://doi.org/10.1210/jendso/bvad114.011",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.011",null],["2","R0050613","R0050613.pdf","open_download_failed","randomized_trial","James P. Daniels","2023","The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?","JNCI Journal of the National Cancer Institute","Oxford University Press (OUP)","10.1093/jnci/djad140","https://doi.org/10.1093/jnci/djad140","37587090","https://pubmed.ncbi.nlm.nih.gov/37587090/","https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djad140/51119470/djad140.pdf",null],["2","R0050677","R0050677.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","Effects of bariatric surgery to induce weight loss and HbA1c reduction shown to persist at 12 years","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.71","https://doi.org/10.1002/doi2.71",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.71",null],["2","R0050709","R0050709.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2023","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on markers of neurohumoral activation and left atrial strain","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2571","https://doi.org/10.1093/eurheartj/ehad655.2571",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2571/53608703/ehad655.2571.pdf",null],["2","R0051040","R0051040.pdf","open_download_failed","randomized_trial","Amrit Chowdhary","2023","Improvement in myocardial energetics and perfusion with Liraglutide in patients with type 2 diabetes- A randomised, single centre, open label, cross-over drug trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.1810","https://doi.org/10.1093/eurheartj/ehad655.1810",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.1810/53607593/ehad655.1810.pdf",null],["2","R0051057","R0051057.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2023","Association of GDF15, NTpoBNP and PLGF with subclinical cardiac dysfunction in type 2 diabetes: effects of novel antidiabetic treatment","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2558","https://doi.org/10.1093/eurheartj/ehad655.2558",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2558/53608945/ehad655.2558.pdf",null],["2","R0051073","R0051073.pdf","open_download_failed","randomized_trial","Lilly ChunHong Gu","2023","Not just skin deep: Association of acne with elevated hemoglobin A1c levels in a retrospective case–control study of 1098 patients at an academic center","Journal of Cosmetic Dermatology","Wiley","10.1111/jocd.15851","https://doi.org/10.1111/jocd.15851","37313617","https://pubmed.ncbi.nlm.nih.gov/37313617/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.15851",null],["2","R0051286","R0051286.pdf","open_download_failed","randomized_trial","Naveed A. Sattar","2023","Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvac186","https://doi.org/10.1093/cvr/cvac186","36683167","https://pubmed.ncbi.nlm.nih.gov/36683167/","https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvac186/48820643/cvac186.pdf",null],["2","R0051568","R0051568.pdf","free_to_read","randomized_trial","Ametov As","2023","Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide","Pharmacy & Pharmacology","Volgograd State Medical University","10.19163/2307-9266-2023-11-3-255-276","https://doi.org/10.19163/2307-9266-2023-11-3-255-276",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.19163/2307-9266-2023-11-3-255-276",null],["2","R0051707","R0051707.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","Real world study on the Clinical and Safety Outcomes With GLP ‐1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.28","https://doi.org/10.1002/doi2.28",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.28",null],["2","R0051723","R0051723.pdf","open_download_failed","randomized_trial","Konstantinos Katogiannis","2023","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on left atrial strain and arterial function","European Heart Journal - Cardiovascular Imaging","Oxford University Press (OUP)","10.1093/ehjci/jead119.163","https://doi.org/10.1093/ehjci/jead119.163",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ehjcimaging/article-pdf/24/Supplement_1/jead119.163/50622598/jead119.163.pdf",null],["2","R0051904","R0051904.pdf","free_to_read","randomized_trial","Norberto Perico","2023","Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000000000231","https://doi.org/10.1681/asn.0000000000000231","38039090","https://pubmed.ncbi.nlm.nih.gov/38039090/","https://www.ncbi.nlm.nih.gov/pmc/articles/10881181",null],["2","R0051953","R0051953.pdf","open_download_failed","randomized_trial","Ofer M. Kobo","2023","Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2568","https://doi.org/10.1093/eurheartj/ehad655.2568",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2568/53608641/ehad655.2568.pdf",null],["2","R0052106","R0052106.pdf","open_download_failed","randomized_trial","Sasha A. S. Kjeldsen","2023","SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.900","https://doi.org/10.1210/jendso/bvad114.900",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/7/Supplement_1/bvad114.900/51901142/bvad114.900.pdf",null],["2","R0052121","R0052121.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2023","Efficacy of a non‐peptide GLP ‐1 analogue, orfoglipton to induce weight loss reported in a phase 2 study","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.67","https://doi.org/10.1002/doi2.67",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.67",null],["2","R0052211","R0052211.pdf","open_download_failed","randomized_trial","Amrit Chowdhary","2023","C Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a Glucagon like peptide-1 receptor agonist (Liraglutide)- A randomised, single centre, open label, cross-over drug trial",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2023-bcs.301","https://doi.org/10.1136/heartjnl-2023-bcs.301",null,"https://pubmed.ncbi.nlm.nih.gov//","https://heart.bmj.com/content/heartjnl/109/Suppl_3/A310.full.pdf",null],["2","R0052352","R0052352.pdf","free_to_read","randomized_trial","André Jacques Scheen","2023","Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2023.100135","https://doi.org/10.1016/j.deman.2023.100135",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2023.100135",null],["2","R0052870","R0052870.pdf","free_to_read","randomized_trial","André Jacques Scheen","2023","Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2023.100179","https://doi.org/10.1016/j.deman.2023.100179",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2023.100179",null],["2","R0052887","R0052887.pdf","open_download_failed","randomized_trial","Carolyn G. Ahlers","2023","Obesity management for the pre–liver transplant and post–liver transplant patient","Clinical Liver Disease","Ovid Technologies (Wolters Kluwer Health)","10.1097/cld.0000000000000039","https://doi.org/10.1097/cld.0000000000000039","37361255","https://pubmed.ncbi.nlm.nih.gov/37361255/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10287134/pdf/xcl-21-165.pdf",null],["2","R0053054","R0053054.pdf","free_to_read","randomized_trial","Emily R. Hankosky","2023","SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.106","https://doi.org/10.1210/jendso/bvad114.106",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.106",null],["2","R0053186","R0053186.pdf","free_to_read","randomized_trial","David Tyler Broome","2023","SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.951","https://doi.org/10.1210/jendso/bvad114.951",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.951",null],["2","R0053282","R0053282.pdf","open_download_failed","randomized_trial","Bradley Scott Miller","2023","Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgad095","https://doi.org/10.1210/clinem/dgad095","36869702","https://pubmed.ncbi.nlm.nih.gov/36869702/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgad095/49496598/dgad095.pdf",null],["2","R0053322","R0053322.pdf","no_doi","randomized_trial","Sudipa Sarkar","2023","CROI 2023: Metabolic and Other Complications of HIV Infection.","PubMed",null,null,"https://doi.org/","37704199","https://pubmed.ncbi.nlm.nih.gov/37704199/",null,null],["2","R0053450","R0053450.pdf","open_download_failed","randomized_trial","Naoise Rasmussen","2023","The effectiveness of the glucagon‐like peptide 1 receptor agonist in improving cognitive function","Alzheimer s & Dementia","Wiley","10.1002/alz.076717","https://doi.org/10.1002/alz.076717",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.076717","PROSPERO:CRD42022366254"],["2","R0054292","R0054292.pdf","open_download_failed","randomized_trial","Debarati Bhar","2023","Incretin-based Antidiabetic Therapy and Pancreatitis: A Case Series","Bengal Physician Journal","Jaypee Brothers Medical Publishing","10.5005/jp-journals-10070-8012","https://doi.org/10.5005/jp-journals-10070-8012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5005/jp-journals-10070-8012",null],["2","R0056157","R0056157.pdf","no_doi","randomized_trial","Clémentine Beucher","2023","Étude STEP 8 : essai clinique à répartition aléatoire comparant le sémaglutide au liraglutide par voie sous-cutanée pour la perte de poids chez les patients non diabétiques en surpoids ou obèses","Pharmactuel",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0006685","R0006685.pdf","open_download_failed","randomized_trial","Yates T","2022","Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.","Diabetes care","American Diabetes Association","10.2337/dc22-0888","https://doi.org/10.2337/dc22-0888","35984425","https://pubmed.ncbi.nlm.nih.gov/35984425/","https://diabetesjournals.org/care/article-pdf/45/11/2749/690174/dc220888.pdf",null],["2","R0008711","R0008711.pdf","open_download_failed","randomized_trial","Shoemaker AH","2022","Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-021-01043-6","https://doi.org/10.1038/s41366-021-01043-6","34975146","https://pubmed.ncbi.nlm.nih.gov/34975146/","https://www.ncbi.nlm.nih.gov/pmc/articles/8881399",null],["2","R0008882","R0008882.pdf","free_to_read","randomized_trial","Ferreira JP","2022","Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.2660","https://doi.org/10.1002/ejhf.2660","36053803","https://pubmed.ncbi.nlm.nih.gov/36053803/",null,null],["2","R0008884","R0008884.pdf","free_to_read","randomized_trial","Johansen NJ","2022","Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14568","https://doi.org/10.1111/dom.14568","34617375","https://pubmed.ncbi.nlm.nih.gov/34617375/","https://researchprofiles.ku.dk/da/publications/b20654fd-de95-4ca5-9428-dd7011b65414",null],["2","R0009469","R0009469.pdf","open_download_failed","randomized_trial","Choi JG","2022","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.","Annals of internal medicine","American College of Physicians","10.7326/m21-2941","https://doi.org/10.7326/m21-2941","36191315","https://pubmed.ncbi.nlm.nih.gov/36191315/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10155215/pdf/nihms-1891477.pdf",null],["2","R0010722","R0010722.pdf","free_to_read","randomized_trial","Doycheva I","2022","Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.","Fertility and sterility","Elsevier BV","10.1016/j.fertnstert.2022.03.020","https://doi.org/10.1016/j.fertnstert.2022.03.020","35512974","https://pubmed.ncbi.nlm.nih.gov/35512974/","https://doi.org/10.1016/j.fertnstert.2022.03.020",null],["2","R0011285","R0011285.pdf","open_download_failed","randomized_trial","van Ruiten CC","2022","Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.","Psychoneuroendocrinology","Elsevier BV","10.1016/j.psyneuen.2022.105667","https://doi.org/10.1016/j.psyneuen.2022.105667","35033928","https://pubmed.ncbi.nlm.nih.gov/35033928/","https://www.sciencedirect.com/science/article/pii/S0306453022000087/pdf",null],["2","R0012932","R0012932.pdf","no_doi","randomized_trial","Seijas-Amigo J","2022","Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study.","Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria",null,null,"https://doi.org/","36520578","https://pubmed.ncbi.nlm.nih.gov/36520578/",null,null],["2","R0016025","R0016025.pdf","free_to_read","randomized_trial","Akyay OZ","2022","Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.","Nigerian journal of clinical practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/njcp.njcp_1640_21","https://doi.org/10.4103/njcp.njcp_1640_21","35859471","https://pubmed.ncbi.nlm.nih.gov/35859471/","https://doi.org/10.4103/njcp.njcp_1640_21",null],["2","R0018478","R0018478.pdf","open_download_failed","randomized_trial","Valenzuela-Vallejo L","2022","Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2022.155237","https://doi.org/10.1016/j.metabol.2022.155237","35700837","https://pubmed.ncbi.nlm.nih.gov/35700837/","https://www.ncbi.nlm.nih.gov/pmc/articles/11426964",null],["2","R0021171","R0021171.pdf","free_to_read","randomized_trial","Branch KRH","2022","Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.2670","https://doi.org/10.1002/ejhf.2670","36073143","https://pubmed.ncbi.nlm.nih.gov/36073143/","https://repositorio.ufro.cl/s/repositorio-ufro/item/4801",null],["2","R0021606","R0021606.pdf","free_to_read","randomized_trial","Raubenheimer PJ","2022","Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14634","https://doi.org/10.1111/dom.14634","34984808","https://pubmed.ncbi.nlm.nih.gov/34984808/","https://repositorio.ufro.cl/s/repositorio-ufro/item/6921",null],["2","R0021919","R0021919.pdf","free_to_read","randomized_trial","Ferreira JP","2022","Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.2694","https://doi.org/10.1002/ejhf.2694","36114733","https://pubmed.ncbi.nlm.nih.gov/36114733/",null,null],["2","R0022112","R0022112.pdf","open_download_failed","randomized_trial","Schernthaner G","2022","Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2022.155160","https://doi.org/10.1016/j.metabol.2022.155160","35143848","https://pubmed.ncbi.nlm.nih.gov/35143848/","http://www.metabolismjournal.com/article/S0026049522000385/pdf",null],["2","R0022229","R0022229.pdf","free_to_read","randomized_trial","Loganathan J","2022","A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108188","https://doi.org/10.1016/j.jdiacomp.2022.108188","35382966","https://pubmed.ncbi.nlm.nih.gov/35382966/","https://figshare.com/articles/journal_contribution/A_pilot_clinical_study_to_Evaluate_Liraglutide-mediated_Anti-platelet_activity_in_patients_with_type-2_Diabetes_ELAID_study_/20587287",null],["2","R0022630","R0022630.pdf","open_download_failed","randomized_trial","Schmidt S","2022","Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14567","https://doi.org/10.1111/dom.14567","34595827","https://pubmed.ncbi.nlm.nih.gov/34595827/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14567",null],["2","R0023104","R0023104.pdf","no_doi","randomized_trial","Ou T","2022","Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.","Alternative therapies in health and medicine",null,null,"https://doi.org/","35751892","https://pubmed.ncbi.nlm.nih.gov/35751892/",null,null],["2","R0023114","R0023114.pdf","open_download_failed","randomized_trial","Samms RJ","2022","FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00050.2022","https://doi.org/10.1152/ajpendo.00050.2022","35723225","https://pubmed.ncbi.nlm.nih.gov/35723225/","https://www.ncbi.nlm.nih.gov/pmc/articles/9291413",null],["2","R0023211","R0023211.pdf","free_to_read","randomized_trial","Shaikh TG","2022","Is liraglutide the solution for weight loss in women with polycystic ovarian syndrome?","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.11-4370","https://doi.org/10.47391/jpma.11-4370","35099475","https://pubmed.ncbi.nlm.nih.gov/35099475/","https://doi.org/10.47391/jpma.11-4370",null],["2","R0023682","R0023682.pdf","open_download_failed","randomized_trial","Nyirjesy SC","2022","Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.","Diabetes","American Diabetes Association","10.2337/db22-0399","https://doi.org/10.2337/db22-0399","35796669","https://pubmed.ncbi.nlm.nih.gov/35796669/","https://diabetesjournals.org/diabetes/article-pdf/71/10/2153/688400/db220399.pdf","ClinicalTrials.gov:NCT01851694"],["2","R0023702","R0023702.pdf","open_download_failed","randomized_trial","Deng Y","2022","Emulating the GRADE Trial Using Real-World Data","medRxiv","openRxiv","10.1101/2022.05.23.22275392","https://doi.org/10.1101/2022.05.23.22275392",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/05/25/2022.05.23.22275392.full.pdf",null],["2","R0023868","R0023868.pdf","free_to_read","randomized_trial","Ahmed M","2022","Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-022-01145-6","https://doi.org/10.1007/s40200-022-01145-6","36404821","https://pubmed.ncbi.nlm.nih.gov/36404821/","https://www.ncbi.nlm.nih.gov/pmc/articles/9672258",null],["2","R0024238","R0024238.pdf","free_to_read","randomized_trial","Brady C","2022","Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.","Archives of disease in childhood. Education and practice edition","BMJ","10.1136/archdischild-2020-319807","https://doi.org/10.1136/archdischild-2020-319807","32988963","https://pubmed.ncbi.nlm.nih.gov/32988963/","https://eprints.gla.ac.uk/323425/",null],["2","R0027248","R0027248.pdf","free_to_read","randomized_trial","Calderon G","2022","Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-021-01019-6","https://doi.org/10.1038/s41366-021-01019-6","34811486","https://pubmed.ncbi.nlm.nih.gov/34811486/","https://www.ncbi.nlm.nih.gov/pmc/articles/8881310",null],["2","R0028930","R0028930.pdf","free_to_read","randomized_trial","Hurt RT","2022","Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial.","Mayo Clinic proceedings. Innovations, quality & outcomes","Elsevier BV","10.1016/j.mayocpiqo.2022.01.004","https://doi.org/10.1016/j.mayocpiqo.2022.01.004","36160639","https://pubmed.ncbi.nlm.nih.gov/36160639/","https://doi.org/10.1016/j.mayocpiqo.2022.01.004","ClinicalTrials.gov:NCT02412631"],["2","R0029726","R0029726.pdf","free_to_read","randomized_trial","Kim ER","2022","A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.32235","https://doi.org/10.1002/hep.32235","34773257","https://pubmed.ncbi.nlm.nih.gov/34773257/","https://ir.ymlib.yonsei.ac.kr/handle/22282913/189505",null],["2","R0029739","R0029739.pdf","open_download_failed","randomized_trial","Friedrichsen M","2022","Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues","medRxiv","openRxiv","10.1101/2022.06.02.22275920","https://doi.org/10.1101/2022.06.02.22275920",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/06/03/2022.06.02.22275920.full.pdf",null],["2","R0030048","R0030048.pdf","open_download_failed","randomized_trial","Liuzzo G","2022","Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac384","https://doi.org/10.1093/eurheartj/ehac384","35866301","https://pubmed.ncbi.nlm.nih.gov/35866301/","https://academic.oup.com/eurheartj/article-pdf/43/35/3288/45748328/ehac384.pdf",null],["2","R0030062","R0030062.pdf","free_to_read","randomized_trial","Stensen S","2022","Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14736","https://doi.org/10.1111/dom.14736","35491518","https://pubmed.ncbi.nlm.nih.gov/35491518/","https://researchprofiles.ku.dk/da/publications/de62de24-acb3-4249-811e-c276b8f850dd",null],["2","R0032300","R0032300.pdf","no_doi","randomized_trial","Geyer, Myfanwy Clare","2022","Targeting postprandial hyperglycaemia with exenatide in young people with cystic fibrosis","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036278","R0036278.pdf","no_doi","randomized_trial","Frankwick, Katelyn M","2022","Trimming the Fat: GLP-1 Agonists in Treatment of NASH","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036393","R0036393.pdf","no_doi","randomized_trial","Chowdhary, Amrit","2022","The role of Magnetic Resonance Imaging and Spectroscopy in the Assessment of Disease Pathophysiology in Patients with Type 2 Diabetes Mellitus","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036410","R0036410.pdf","no_doi","randomized_trial","Putri, Nanda Elmaiyana","2022","Kajian pustaka efektivitas dan keamanan semaglutide injeksi pada pasien diabetes melitus tipe 2 dengan obesitas","Widya Mandala Catholic University Surabaya Repository (Widya Mandala Catholic University Surabaya)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036994","R0036994.pdf","free_to_read","randomized_trial",null,"2022","JPEF Abstracts 2022","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/2949-8457.369062","https://doi.org/10.4103/2949-8457.369062",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2949-8457.369062",null],["2","R0037122","R0037122.pdf","free_to_read","randomized_trial","Akanksha Kulhari","2022","Abstract 115","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.363618","https://doi.org/10.4103/2230-8210.363618",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.363618",null],["2","R0037517","R0037517.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2022","The world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )","Journal of Diabetes","Wiley","10.1111/1753-0407.13260","https://doi.org/10.1111/1753-0407.13260","35191189","https://pubmed.ncbi.nlm.nih.gov/35191189/","https://doi.org/10.1111/1753-0407.13260",null],["2","R0037989","R0037989.pdf","no_doi","randomized_trial","Mitchell, James Lee","2022","Human physiology of intra-cranial pressure and the biological role of GLP-1 agonists","University of Birmingham Institutional Research Archive (University of Birmingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039229","R0039229.pdf","no_doi","randomized_trial","Gao Rui-chao","2022","Regulating effect of empagliflozin plus liraglutide on glucose/lipid metabolism and serum levels of SFRP5， Irisin and tAPN in obese type 2 diabetics","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039277","R0039277.pdf","free_to_read","randomized_trial","Manoj Chawla","2022","Glycemic Treatment Effect of Oral Semaglutide Plus Other Antidiabetic Medications","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_71_22","https://doi.org/10.4103/jod.jod_71_22",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_71_22",null],["2","R0039925","R0039925.pdf","free_to_read","randomized_trial","D Shabeer","2022","Abstract 171","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.363677","https://doi.org/10.4103/2230-8210.363677",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.363677",null],["2","R0040089","R0040089.pdf","free_to_read","randomized_trial","Rafael Simó","2022","Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration","Neural Regeneration Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/1673-5374.353492","https://doi.org/10.4103/1673-5374.353492","37843198","https://pubmed.ncbi.nlm.nih.gov/37843198/","https://doi.org/10.4103/1673-5374.353492",null],["2","R0040418","R0040418.pdf","open_download_failed","randomized_trial","C. Possidente","2022","The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2022.100485","https://doi.org/10.1016/j.nsa.2022.100485",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2772408522004860/pdf",null],["2","R0040978","R0040978.pdf","free_to_read","randomized_trial","Amanda J. Vinson","2022","Premature Death in Kidney Transplant Recipients: The Time for Trials is Now","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2021111517","https://doi.org/10.1681/asn.2021111517","35292438","https://pubmed.ncbi.nlm.nih.gov/35292438/","https://www.ncbi.nlm.nih.gov/pmc/articles/8970447",null],["2","R0041496","R0041496.pdf","open_download_failed","randomized_trial","Lucas M. Donovan","2022","Approaching sleep apnea management in the setting of uncertainty","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsac234","https://doi.org/10.1093/sleep/zsac234","36149838","https://pubmed.ncbi.nlm.nih.gov/36149838/","https://academic.oup.com/sleep/article-pdf/45/12/zsac234/47762460/zsac234.pdf",null],["2","R0041497","R0041497.pdf","open_download_failed","randomized_trial",null,"2022","Corrigendum","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14846","https://doi.org/10.1111/dom.14846","36004610","https://pubmed.ncbi.nlm.nih.gov/36004610/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10117583/pdf/DOM-24-2280.pdf",null],["2","R0041645","R0041645.pdf","open_download_failed","randomized_trial","Filippo Crea","2022","Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab905","https://doi.org/10.1093/eurheartj/ehab905","35100343","https://pubmed.ncbi.nlm.nih.gov/35100343/","https://academic.oup.com/eurheartj/article-pdf/43/4/245/42351981/ehab905.pdf",null],["2","R0041992","R0041992.pdf","no_doi","randomized_trial","Bizino, M.B.","2022","Metabolic and functional evaluation of diabetic cardiomyopathy using MR Spectroscopy and MR Imaging","Data Archiving and Networked Services (DANS)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042133","R0042133.pdf","no_doi","randomized_trial","Webster, Chelsi","2022","Behavioral and hormonal measures of hunger, satiety, and energy intake to predict weight-loss response to Liraglutide","ThinkTech (Texas Tech University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042575","R0042575.pdf","open_download_failed","randomized_trial","Stefan Agewall","2022","Pharmacological treatment of CVD","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvac068","https://doi.org/10.1093/ehjcvp/pvac068","36519600","https://pubmed.ncbi.nlm.nih.gov/36519600/","https://academic.oup.com/ehjcvp/article-pdf/9/1/1/49254001/pvac068.pdf",null],["2","R0042972","R0042972.pdf","open_download_failed","randomized_trial","Federico Bernardini","2022","548 ROLE OF NEW ANTIDIABETIC DRUGS IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN DIABETIC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suac121.499","https://doi.org/10.1093/eurheartjsupp/suac121.499",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartjsupp/article-pdf/24/Supplement_K/suac121.499/47966127/suac121.499.pdf",null],["2","R0042975","R0042975.pdf","open_download_failed","randomized_trial","Simon O’Neill","2022","Update on technologies, medicines and treatments","Diabetic Medicine","Wiley","10.1111/dme.15004","https://doi.org/10.1111/dme.15004",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15004",null],["2","R0043615","R0043615.pdf","open_download_failed","randomized_trial","Young Min Cho","2022","Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes","Journal of Diabetes Investigation","Wiley","10.1111/jdi.13953","https://doi.org/10.1111/jdi.13953","36449020","https://pubmed.ncbi.nlm.nih.gov/36449020/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.13953",null],["2","R0043642","R0043642.pdf","open_download_failed","randomized_trial","Jaap Seelig","2022","New-onset atrial fibrillation during critical illness: another piece of the puzzle","EP Europace","Oxford University Press (OUP)","10.1093/europace/euac197","https://doi.org/10.1093/europace/euac197","36352552","https://pubmed.ncbi.nlm.nih.gov/36352552/","https://academic.oup.com/europace/article-pdf/25/2/249/49230737/euac197.pdf",null],["2","R0043666","R0043666.pdf","open_download_failed","randomized_trial","Alimitha M Kodali","2022","RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.887","https://doi.org/10.1210/jendso/bvac150.887",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A426/47383084/bvac150.887.pdf",null],["2","R0043785","R0043785.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2022","The 5th Annual Heart in Diabetes Conference (part 2)","Journal of Diabetes","Wiley","10.1111/1753-0407.13251","https://doi.org/10.1111/1753-0407.13251","35075783","https://pubmed.ncbi.nlm.nih.gov/35075783/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13251",null],["2","R0043839","R0043839.pdf","no_doi","randomized_trial","Brendan Moran","2022","Examining the Efficacy of a Home Sleep Apnoea Testing Kit and the Effect of liraglutide 3.0mg on Parameters of Sleep Apnoea and Metrics of Health and Obesity","Research Repository UCD (University College Dublin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043855","R0043855.pdf","free_to_read","randomized_trial","S Parthasarathy","2022","The battle against perioperative glycaemic control: Hard to win?","Indian Journal of Anaesthesia","Ovid Technologies (Wolters Kluwer Health)","10.4103/ija.ija_923_22","https://doi.org/10.4103/ija.ija_923_22","36590185","https://pubmed.ncbi.nlm.nih.gov/36590185/","https://doi.org/10.4103/ija.ija_923_22",null],["2","R0043910","R0043910.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2022","Small steps forward: Adjunctive therapy for T1D","Journal of Diabetes","Wiley","10.1111/1753-0407.13326","https://doi.org/10.1111/1753-0407.13326","36205524","https://pubmed.ncbi.nlm.nih.gov/36205524/","https://doi.org/10.1111/1753-0407.13326",null],["2","R0044072","R0044072.pdf","open_download_failed","randomized_trial","Travis Goettemoeller","2022","PSUN113 Evaluating The Efficacy Of Anti-Obesity Medications In a Multidisciplinary Weight Management Clinic At a VA Medical Center","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.045","https://doi.org/10.1210/jendso/bvac150.045",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A21/46730054/bvac150.045.pdf",null],["2","R0044127","R0044127.pdf","open_download_failed","randomized_trial","Priyadarshini Balasubramanian","2022","RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.878","https://doi.org/10.1210/jendso/bvac150.878",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A422/47383520/bvac150.878.pdf",null],["2","R0044174","R0044174.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2022","Learning by reading: A review of recent diabetes articles","Journal of Diabetes","Wiley","10.1111/1753-0407.13272","https://doi.org/10.1111/1753-0407.13272","35606898","https://pubmed.ncbi.nlm.nih.gov/35606898/","https://doi.org/10.1111/1753-0407.13272",null],["2","R0044355","R0044355.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2022","Diabetes update: What's new, what's interesting","Journal of Diabetes","Wiley","10.1111/1753-0407.13308","https://doi.org/10.1111/1753-0407.13308","36040202","https://pubmed.ncbi.nlm.nih.gov/36040202/","https://doi.org/10.1111/1753-0407.13308",null],["2","R0044372","R0044372.pdf","open_download_failed","randomized_trial","Mojca Jensterle","2022","RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.070","https://doi.org/10.1210/jendso/bvac150.070",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A33/46730987/bvac150.070.pdf",null],["2","R0044384","R0044384.pdf","open_download_failed","randomized_trial","Brian D. Benneyworth","2022","OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.738","https://doi.org/10.1210/jendso/bvac150.738",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A355/47384468/bvac150.738.pdf",null],["2","R0044392","R0044392.pdf","free_to_read","randomized_trial","Zachary T. Bloomgarden","2022","The 2022 American Diabetes Association Meeting","Journal of Diabetes","Wiley","10.1111/1753-0407.13297","https://doi.org/10.1111/1753-0407.13297","35841236","https://pubmed.ncbi.nlm.nih.gov/35841236/","https://doi.org/10.1111/1753-0407.13297",null],["2","R0044794","R0044794.pdf","free_to_read","randomized_trial","Nini de Boer","2022","Antipsychotic‐induced weight gain: Is the weight over? New guidelines needed","Acta Psychiatrica Scandinavica","Wiley","10.1111/acps.13485","https://doi.org/10.1111/acps.13485","35951775","https://pubmed.ncbi.nlm.nih.gov/35951775/","https://dspace.library.uu.nl/handle/1874/447046",null],["2","R0044814","R0044814.pdf","open_download_failed","randomized_trial","Mainak Banerjee","2022","Letter to the Editor from Banerjee and Mondal: “Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline”","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgac478","https://doi.org/10.1210/clinem/dgac478","35962775","https://pubmed.ncbi.nlm.nih.gov/35962775/","https://academic.oup.com/jcem/article-pdf/107/10/e4272/46112720/dgac478.pdf",null],["2","R0045158","R0045158.pdf","open_download_failed","randomized_trial","Nattapol Sathavarodom","2022","ODP222 Liragluitde Increased IL-1RA Concentrations in Obese Type 2 Diabetes: A Small Randomized Controlled Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.673","https://doi.org/10.1210/jendso/bvac150.673",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A325/46734058/bvac150.673.pdf",null],["2","R0046913","R0046913.pdf","free_to_read","randomized_trial","Elliot J. Hogg","2022","A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4212371","https://doi.org/10.2139/ssrn.4212371",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4212371",null],["2","R0047031","R0047031.pdf","open_download_failed","randomized_trial","Husam Ghanim","2022","LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.592","https://doi.org/10.1210/jendso/bvac150.592",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A287/46734461/bvac150.592.pdf",null],["2","R0047143","R0047143.pdf","open_download_failed","randomized_trial","Elo Andersen","2022","O-018 Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomised controlled trial","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deac104.018","https://doi.org/10.1093/humrep/deac104.018",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/humrep/article-pdf/37/Supplement_1/deac104.018/44305879/deac104.018.pdf",null],["2","R0047336","R0047336.pdf","free_to_read","randomized_trial","K B Sharan Kumar","2022","Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342129","https://doi.org/10.4103/2230-8210.342129",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342129",null],["2","R0047435","R0047435.pdf","free_to_read","randomized_trial","Huilin Tang","2022","Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials","Journal of the American Geriatrics Society","Wiley","10.1111/jgs.17895","https://doi.org/10.1111/jgs.17895","35612586","https://pubmed.ncbi.nlm.nih.gov/35612586/","https://www.ncbi.nlm.nih.gov/pmc/articles/9489613",null],["2","R0047831","R0047831.pdf","open_download_failed","randomized_trial","Syeda Shamim Fatima","2022","LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.002","https://doi.org/10.1210/jendso/bvac150.002",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A1/46729522/bvac150.002.pdf","ClinicalTrials.gov:NCT04883346"],["2","R0048041","R0048041.pdf","free_to_read","randomized_trial","Devin Abrahami","2022","Sodium-Glucose Co-Transporter 2 inhibitors and the Short-term Risk of Bladder Cancer: An International Multi-Site Cohort Study",null,"American Diabetes Association","10.2337/figshare.21040987.v1","https://doi.org/10.2337/figshare.21040987.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.21040987.v1",null],["2","R0048045","R0048045.pdf","free_to_read","randomized_trial","Varun Garg","2022","Abstract 122","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.363626","https://doi.org/10.4103/2230-8210.363626",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.363626",null],["2","R0048077","R0048077.pdf","open_download_failed","randomized_trial","Wenli Yang","2022","IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2022.109271","https://doi.org/10.1016/j.diabres.2022.109271",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.diabetesresearchclinicalpractice.com/article/S0168822722000833/pdf",null],["2","R0048759","R0048759.pdf","open_download_failed","randomized_trial","Alice  Y. Yau","2022","PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.831","https://doi.org/10.1210/jendso/bvac150.831",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A399/46733135/bvac150.831.pdf",null],["2","R0048783","R0048783.pdf","open_download_failed","randomized_trial","Rasmus Moeskjær Schwarz","2022","Improving functioning in affective disorders, a randomized controlled multimodule intervention design, presentation of a currently ongoing study","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2022.100486","https://doi.org/10.1016/j.nsa.2022.100486",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2772408522004872/pdf",null],["2","R0049009","R0049009.pdf","open_download_failed","randomized_trial","Cihan Atila","2022","RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.536","https://doi.org/10.1210/jendso/bvac150.536",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A261/46729579/bvac150.536.pdf",null],["2","R0049057","R0049057.pdf","free_to_read","randomized_trial","Ahmad Aly","2022","Bariatric surgery: a call for greater access to coordinated surgical and specialist care in the public health system","The Medical Journal of Australia","Wiley","10.5694/mja2.51673","https://doi.org/10.5694/mja2.51673","35964266","https://pubmed.ncbi.nlm.nih.gov/35964266/","https://doi.org/10.5694/mja2.51673",null],["2","R0049135","R0049135.pdf","free_to_read","randomized_trial","Jasmine Gujral","2022","Pediatric diabetes update","Journal of Diabetes","Wiley","10.1111/1753-0407.13317","https://doi.org/10.1111/1753-0407.13317","36114692","https://pubmed.ncbi.nlm.nih.gov/36114692/","https://doi.org/10.1111/1753-0407.13317",null],["2","R0049301","R0049301.pdf","open_download_failed","randomized_trial","Mona Mashayekhi","2022","LBSUN306 Effects Of Glp-1 Receptor Agonism, Dpp4 Inhibition, And Hypocaloric Diet On Metabolic Parameters In Obese Pre-diabetic Individuals: A Randomized-controlled Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.603","https://doi.org/10.1210/jendso/bvac150.603",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A292/46734439/bvac150.603.pdf",null],["2","R0049429","R0049429.pdf","free_to_read","randomized_trial","Kunal Srivastava","2022","Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.342263","https://doi.org/10.4103/2230-8210.342263",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.342263",null],["2","R0049513","R0049513.pdf","free_to_read","randomized_trial","Evan M. Zeitler","2022","Toward Guideline-Directed Medical Therapy in Nephrology","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.12401022","https://doi.org/10.2215/cjn.12401022","36414317","https://pubmed.ncbi.nlm.nih.gov/36414317/","https://www.ncbi.nlm.nih.gov/pmc/articles/9718011",null],["2","R0049760","R0049760.pdf","open_download_failed","randomized_trial","Bea C. M. Campforts","2022","Management of obesity with semaglutide in antipsychotic-induced weight gain (MOSA) - a non-randomized open-label pilot study: research proposal","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2022.100336","https://doi.org/10.1016/j.nsa.2022.100336",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2772408522003362/pdf",null],["2","R0049993","R0049993.pdf","free_to_read","randomized_trial","Makka R. Azimova","2022","Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus","Systemic Hypertension","Intermedservice Ltd","10.38109/2075-082x-2022-1-39-48","https://doi.org/10.38109/2075-082x-2022-1-39-48",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.38109/2075-082x-2022-1-39-48",null],["2","R0050233","R0050233.pdf","free_to_read","randomized_trial","Janani Rangaswami","2022","Changing the Trajectory of Heart Failure and Kidney Disease","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.00470122","https://doi.org/10.2215/cjn.00470122","35232819","https://pubmed.ncbi.nlm.nih.gov/35232819/","https://www.ncbi.nlm.nih.gov/pmc/articles/9269572",null],["2","R0050579","R0050579.pdf","free_to_read","randomized_trial","Thomas E. Yates","2022","The initiation of new glucose lowering therapies may act to reduce physical activity levels: pooled analysis from three randomised trials",null,"American Diabetes Association","10.2337/figshare.20409372.v1","https://doi.org/10.2337/figshare.20409372.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.20409372.v1",null],["2","R0050704","R0050704.pdf","open_download_failed","randomized_trial","Theocharis Koufakis","2022","Antiatherosclerotic Effects of Sodium-Glucose Cotransporter 2 Inhibitors: An Underrecognized Piece of the Big Puzzle?","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgac116","https://doi.org/10.1210/clinem/dgac116","35245937","https://pubmed.ncbi.nlm.nih.gov/35245937/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgac116/42978601/dgac116.pdf",null],["2","R0051044","R0051044.pdf","open_download_failed","randomized_trial","Joey Ward","2022","Testing for association between exonic glucagon‐like peptide 1 receptor mutation with physical and brain health traits in UK Biobank","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14879","https://doi.org/10.1111/dom.14879","36181450","https://pubmed.ncbi.nlm.nih.gov/36181450/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14879",null],["2","R0051669","R0051669.pdf","open_download_failed","randomized_trial","Konstantinos Kitsios","2022","Type 1 diabetes mellitus and cardiovascular risk: A short review","Journal of Atherosclerosis Prevention and Treatment","Ovid Technologies (Wolters Kluwer Health)","10.53590/japt.02.1039","https://doi.org/10.53590/japt.02.1039",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.japt.gr/wp-content/uploads/2022/12/03_Kitsios_Review.pdf",null],["2","R0051933","R0051933.pdf","free_to_read","randomized_trial","Rayaz Ahmed Malik","2022","Corneal confocal microscopy for the assessment of diabetic neuropathy and beyond in Brazil","Arquivos de Neuro-Psiquiatria","Georg Thieme Verlag KG","10.1055/s-0042-1756169","https://doi.org/10.1055/s-0042-1756169","36252583","https://pubmed.ncbi.nlm.nih.gov/36252583/","https://doi.org/10.1055/s-0042-1756169",null],["2","R0052011","R0052011.pdf","free_to_read","randomized_trial","Yu. Sh. Khalimov","2022","Obesity and COVID-19: Insights from Two Pandemics","Doctor Ru","NP Rusmedical Group","10.31550/1727-2378-2022-21-2-59-66","https://doi.org/10.31550/1727-2378-2022-21-2-59-66",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31550/1727-2378-2022-21-2-59-66",null],["2","R0052018","R0052018.pdf","free_to_read","randomized_trial","Gabriela Piovezani Ramos","2022","Diagnosis and Management of Gastroparesis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000002003","https://doi.org/10.14309/ajg.0000000000002003","36114770","https://pubmed.ncbi.nlm.nih.gov/36114770/","https://www.ncbi.nlm.nih.gov/pmc/articles/9722580",null],["2","R0052496","R0052496.pdf","open_download_failed","randomized_trial","Muhammad Hafizh Husain","2022","Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.1939","https://doi.org/10.1093/eurheartj/ehac544.1939",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/43/Supplement_2/ehac544.1939/46366049/ehac544.1939.pdf",null],["2","R0052554","R0052554.pdf","open_download_failed","randomized_trial","Francesco Zaccardi","2022","Ethnicity and risks of severe COVID ‐19 outcomes associated with glucose‐lowering medications: A cohort study","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14872","https://doi.org/10.1111/dom.14872","36099041","https://pubmed.ncbi.nlm.nih.gov/36099041/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14872",null],["2","R0052753","R0052753.pdf","free_to_read","randomized_trial","Amanda Jean Vinson","2022","Underrepresentation of Women in Recent Landmark Kidney Trials: The Gender Gap Prevails","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2022.08.022","https://doi.org/10.1016/j.ekir.2022.08.022","36531883","https://pubmed.ncbi.nlm.nih.gov/36531883/","https://doi.org/10.1016/j.ekir.2022.08.022",null],["2","R0055303","R0055303.pdf","open_download_failed","randomized_trial","Lauren Ferris","2022","Management of obesity in pregnancy","Australian and New Zealand Journal of Obstetrics and Gynaecology","Wiley","10.1111/ajo.13610","https://doi.org/10.1111/ajo.13610","36250401","https://pubmed.ncbi.nlm.nih.gov/36250401/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajo.13610","ANZCTR:ACTRN12620001238965; ANZCTR:ACTRN12621000128897"],["2","R0056390","R0056390.pdf","no_doi","randomized_trial","Ricardo J. Samms","2022","FGF21 Contributes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes","UEF eRepo (University of Eastern Finland)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0004441","R0004441.pdf","open_download_failed","randomized_trial","Quast DR","2021","Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14477","https://doi.org/10.1111/dom.14477","34189834","https://pubmed.ncbi.nlm.nih.gov/34189834/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14477",null],["2","R0006631","R0006631.pdf","free_to_read","randomized_trial","Marathe CS","2021","Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.","Diabetes care","American Diabetes Association","10.2337/dc20-2987","https://doi.org/10.2337/dc20-2987","34670789","https://pubmed.ncbi.nlm.nih.gov/34670789/",null,null],["2","R0006673","R0006673.pdf","open_download_failed","randomized_trial","Patorno E","2021","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Annals of internal medicine","American College of Physicians","10.7326/m21-0893","https://doi.org/10.7326/m21-0893","34570599","https://pubmed.ncbi.nlm.nih.gov/34570599/","https://www.ncbi.nlm.nih.gov/pmc/articles/8969214",null],["2","R0006682","R0006682.pdf","open_download_failed","randomized_trial","Rosenstock J","2021","Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.","Diabetes care","American Diabetes Association","10.2337/dci21-0004","https://doi.org/10.2337/dci21-0004","34670790","https://pubmed.ncbi.nlm.nih.gov/34670790/","https://diabetesjournals.org/care/article-pdf/44/11/e196/631728/dci210004.pdf",null],["2","R0006977","R0006977.pdf","open_download_failed","randomized_trial","Eberly LA","2021","Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.","JAMA health forum","American Medical Association (AMA)","10.1001/jamahealthforum.2021.4182","https://doi.org/10.1001/jamahealthforum.2021.4182","35977298","https://pubmed.ncbi.nlm.nih.gov/35977298/","https://doi.org/10.1001/jamahealthforum.2021.4182",null],["2","R0007428","R0007428.pdf","open_download_failed","randomized_trial","Perez FA","2021","MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14366","https://doi.org/10.1111/dom.14366","33651438","https://pubmed.ncbi.nlm.nih.gov/33651438/","https://www.ncbi.nlm.nih.gov/pmc/articles/8353597",null],["2","R0007673","R0007673.pdf","open_download_failed","randomized_trial","Patorno E","2021","Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.","Diabetes care","American Diabetes Association","10.2337/dc20-1464","https://doi.org/10.2337/dc20-1464","33495295","https://pubmed.ncbi.nlm.nih.gov/33495295/","https://www.ncbi.nlm.nih.gov/pmc/articles/7896266",null],["2","R0007737","R0007737.pdf","open_download_failed","randomized_trial","Liao M","2021","Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial","Authorea Preprints","Wiley","10.22541/au.163570984.48793962/v1","https://doi.org/10.22541/au.163570984.48793962/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.163570984.48793962",null],["2","R0007881","R0007881.pdf","open_download_failed","randomized_trial","Albogami Y","2021","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc20-1794","https://doi.org/10.2337/dc20-1794","33875487","https://pubmed.ncbi.nlm.nih.gov/33875487/","https://www.ncbi.nlm.nih.gov/pmc/articles/8247488",null],["2","R0008152","R0008152.pdf","open_download_failed","randomized_trial","Roth CL","2021","A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14224","https://doi.org/10.1111/dom.14224","33026160","https://pubmed.ncbi.nlm.nih.gov/33026160/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14224",null],["2","R0009166","R0009166.pdf","open_download_failed","randomized_trial","Chowdhury TA","2021","Diabetes and the kidney.","Clinical medicine (London, England)","Elsevier BV","10.7861/clinmed.2021-0144","https://doi.org/10.7861/clinmed.2021-0144","35192470","https://pubmed.ncbi.nlm.nih.gov/35192470/","https://www.rcpjournals.org/content/clinmedicine/21/4/e318.full.pdf",null],["2","R0010172","R0010172.pdf","open_download_failed","randomized_trial","Gautier T","2021","The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296819891170","https://doi.org/10.1177/1932296819891170","31810389","https://pubmed.ncbi.nlm.nih.gov/31810389/","https://www.ncbi.nlm.nih.gov/pmc/articles/8256059",null],["2","R0010747","R0010747.pdf","open_download_failed","randomized_trial","van Baar ACG","2021","Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2020.12.021","https://doi.org/10.1016/j.gie.2020.12.021","33359437","https://pubmed.ncbi.nlm.nih.gov/33359437/","http://www.giejournal.org/article/S0016510720351002/pdf",null],["2","R0011299","R0011299.pdf","open_download_failed","randomized_trial","Pasquel FJ","2021","Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14347","https://doi.org/10.1111/dom.14347","33591621","https://pubmed.ncbi.nlm.nih.gov/33591621/","https://www.ncbi.nlm.nih.gov/pmc/articles/8571803",null],["2","R0011631","R0011631.pdf","free_to_read","randomized_trial","Andreasen CR","2021","Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14500","https://doi.org/10.1111/dom.14500","34519400","https://pubmed.ncbi.nlm.nih.gov/34519400/",null,null],["2","R0013226","R0013226.pdf","open_download_failed","randomized_trial","Longwell CK","2021","Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.","ACS chemical biology","American Chemical Society (ACS)","10.1021/acschembio.0c00722","https://doi.org/10.1021/acschembio.0c00722","33307682","https://pubmed.ncbi.nlm.nih.gov/33307682/","https://pubs.acs.org/doi/pdf/10.1021/acschembio.0c00722",null],["2","R0014979","R0014979.pdf","open_download_failed","randomized_trial","Malkin SJP","2021","The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108759","https://doi.org/10.1016/j.diabres.2021.108759","33744377","https://pubmed.ncbi.nlm.nih.gov/33744377/","http://www.diabetesresearchclinicalpractice.com/article/S0168822721001121/pdf",null],["2","R0015085","R0015085.pdf","open_download_failed","randomized_trial","Kim SH","2021","Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14242","https://doi.org/10.1111/dom.14242","33140542","https://pubmed.ncbi.nlm.nih.gov/33140542/","https://www.ncbi.nlm.nih.gov/pmc/articles/7856054",null],["2","R0017126","R0017126.pdf","open_download_failed","randomized_trial","Gribble FM","2021","Obesity therapeutics: The end of the beginning.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2021.03.012","https://doi.org/10.1016/j.cmet.2021.03.012","33826913","https://pubmed.ncbi.nlm.nih.gov/33826913/","http://www.cell.com/article/S1550413121001194/pdf",null],["2","R0018613","R0018613.pdf","free_to_read","randomized_trial","Ferrannini G","2021","Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa777","https://doi.org/10.1093/eurheartj/ehaa777","33197271","https://pubmed.ncbi.nlm.nih.gov/33197271/","https://repositorio.udes.edu.co/handle/001/6070",null],["2","R0018745","R0018745.pdf","free_to_read","randomized_trial","Rydén L","2021","Is cardioprotection with GLP-1 receptor agonists a class effect?","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaa103","https://doi.org/10.1093/eurjpc/zwaa103","33623981","https://pubmed.ncbi.nlm.nih.gov/33623981/",null,null],["2","R0019016","R0019016.pdf","open_download_failed","randomized_trial","Aso Y","2021","Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.","International journal of clinical practice","Wiley","10.1111/ijcp.13734","https://doi.org/10.1111/ijcp.13734","33099848","https://pubmed.ncbi.nlm.nih.gov/33099848/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13734",null],["2","R0019687","R0019687.pdf","free_to_read","randomized_trial","Bain EK","2021","Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14487","https://doi.org/10.1111/dom.14487","34324260","https://pubmed.ncbi.nlm.nih.gov/34324260/",null,null],["2","R0021004","R0021004.pdf","open_download_failed","randomized_trial","Dave CV","2021","Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.120.047965","https://doi.org/10.1161/circulationaha.120.047965","33302723","https://pubmed.ncbi.nlm.nih.gov/33302723/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047965",null],["2","R0022737","R0022737.pdf","free_to_read","randomized_trial","Rasmussen IKB","2021","Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14516","https://doi.org/10.1111/dom.14516","34387408","https://pubmed.ncbi.nlm.nih.gov/34387408/","https://researchprofiles.ku.dk/da/publications/520f775e-7496-4264-90d5-09064d6468d4",null],["2","R0023397","R0023397.pdf","open_download_failed","randomized_trial","Haase CL","2021","Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.","Obesity facts","S. Karger AG","10.1159/000518325","https://doi.org/10.1159/000518325","34515194","https://pubmed.ncbi.nlm.nih.gov/34515194/","https://www.karger.com/Article/Pdf/518325",null],["2","R0023416","R0023416.pdf","open_download_failed","randomized_trial","Katsiki N","2021","Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.14833","https://doi.org/10.1111/ijcp.14833","34510676","https://pubmed.ncbi.nlm.nih.gov/34510676/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.14833",null],["2","R0023666","R0023666.pdf","free_to_read","randomized_trial","Bagger JI","2021","Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects.","Diabetes","American Diabetes Association","10.2337/db20-0998","https://doi.org/10.2337/db20-0998","33722838","https://pubmed.ncbi.nlm.nih.gov/33722838/",null,"ClinicalTrials.gov:NCT01507597"],["2","R0023937","R0023937.pdf","open_download_failed","randomized_trial","Patikorn C","2021","Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.","Annals of hepatology","Elsevier BV","10.1016/j.aohep.2021.100315","https://doi.org/10.1016/j.aohep.2021.100315","33515800","https://pubmed.ncbi.nlm.nih.gov/33515800/","https://www.sciencedirect.com/science/article/pii/S1665268121000144/pdf",null],["2","R0025034","R0025034.pdf","open_download_failed","randomized_trial","Fuentes B","2021","Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.","Neurologia","Elsevier BV","10.1016/j.nrl.2020.04.030","https://doi.org/10.1016/j.nrl.2020.04.030","32981775","https://pubmed.ncbi.nlm.nih.gov/32981775/","https://www.sciencedirect.com/science/article/pii/S0213485320302243/pdf",null],["2","R0025122","R0025122.pdf","open_download_failed","randomized_trial","Tuttle KR","2021","Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0005852020","https://doi.org/10.34067/kid.0005852020","35373017","https://pubmed.ncbi.nlm.nih.gov/35373017/","https://doi.org/10.34067/kid.0005852020",null],["2","R0025420","R0025420.pdf","open_download_failed","randomized_trial","Clark M","2021","Feline comorbidities: Pathophysiology and management of the obese diabetic cat.","Journal of feline medicine and surgery","SAGE Publications","10.1177/1098612x211021540","https://doi.org/10.1177/1098612x211021540","34167340","https://pubmed.ncbi.nlm.nih.gov/34167340/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10812123/pdf/10.1177_1098612X211021540.pdf",null],["2","R0025624","R0025624.pdf","open_download_failed","randomized_trial","Halimi JM","2021","[SGLT2 inhibitors: A new era for our patients].","Nephrologie & therapeutique","JLE","10.1016/j.nephro.2020.12.006","https://doi.org/10.1016/j.nephro.2020.12.006","33773943","https://pubmed.ncbi.nlm.nih.gov/33773943/","https://stm.cairn.info/article/NDT_1703_0143/pdf?lang=fr",null],["2","R0027070","R0027070.pdf","open_download_failed","randomized_trial","Abdelgani S","2021","Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgab403","https://doi.org/10.1210/clinem/dgab403","34343296","https://pubmed.ncbi.nlm.nih.gov/34343296/","https://academic.oup.com/jcem/article-pdf/106/12/3497/42264021/dgab403.pdf",null],["2","R0027372","R0027372.pdf","open_download_failed","randomized_trial","Abdelgani S","2021","Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14383","https://doi.org/10.1111/dom.14383","33852204","https://pubmed.ncbi.nlm.nih.gov/33852204/","https://www.ncbi.nlm.nih.gov/pmc/articles/8238899",null],["2","R0028095","R0028095.pdf","free_to_read","randomized_trial","Jonas DE","2021","Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","34554661","https://pubmed.ncbi.nlm.nih.gov/34554661/",null,null],["2","R0029019","R0029019.pdf","free_to_read","randomized_trial","Scholz O","2021","Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets.","Cell chemical biology","Elsevier BV","10.1016/j.chembiol.2021.05.011","https://doi.org/10.1016/j.chembiol.2021.05.011","34118188","https://pubmed.ncbi.nlm.nih.gov/34118188/","https://doi.org/10.1016/j.chembiol.2021.05.011",null],["2","R0030159","R0030159.pdf","free_to_read","randomized_trial","Galiuto L","2021","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab356","https://doi.org/10.1093/eurheartj/ehab356","34160039","https://pubmed.ncbi.nlm.nih.gov/34160039/","https://www.openaccessrepository.it/record/149712",null],["2","R0032829","R0032829.pdf","free_to_read","randomized_trial","Mohammed Ghani","2021","A case study of liraglutide in an obese diabetic patient in a District General Hospital",null,"Unified Citation Journals Ltd","10.52402/diabetes7001","https://doi.org/10.52402/diabetes7001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52402/diabetes7001",null],["2","R0034947","R0034947.pdf","no_doi","randomized_trial","Hye Jin Kim","2021","Focused Issue : Glucagon-Like Peptide 1 수용체작용제 최신지견",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035924","R0035924.pdf","free_to_read","randomized_trial","Se-Eun Kim","2021","Anti-Diabetic Drugs in Cardiovascular Disease","Korean Journal of Medicine","Korean Association of Internal Medicine","10.3904/kjm.2021.96.2.85","https://doi.org/10.3904/kjm.2021.96.2.85",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3904/kjm.2021.96.2.85",null],["2","R0036166","R0036166.pdf","no_doi","randomized_trial","Ho‐Jin Shin","2021","Evaluating novel glucose-lowering therapies in first-line treatment for type 2 diabetes","Digital Access to Scholarship at Harvard (DASH) (Harvard University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036206","R0036206.pdf","no_doi","randomized_trial","Edgar Gerardo Dorsey-Treviño","2021","Association of GLP1R polymorphisms with the incretin response: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)","Digital Access to Scholarship at Harvard (DASH) (Harvard University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036441","R0036441.pdf","no_doi","randomized_trial","Wittmann, István","2021","A glukagonszerű-peptid-1-receptoragonisták anyagcsere-, ér- és vesehatása, a kénhidrogén lehetséges szerepe [Metabolic, vascular and renal effect of glucagon-like peptide-1 receptor agonist; the possible role of hydrogen sulfide]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036682","R0036682.pdf","no_doi","randomized_trial","Nilsson, Natalié","2021","Farmakologisk behandling vid fetma : Semaglutid versus liraglutid","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037655","R0037655.pdf","free_to_read","randomized_trial",null,"2021","Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity","International Journal of Diabetes & Metabolic Disorders","Opast Group LLC","10.33140/ijdmd.06.02.03","https://doi.org/10.33140/ijdmd.06.02.03",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.33140/ijdmd.06.02.03",null],["2","R0038937","R0038937.pdf","no_doi","randomized_trial","van Baar, Anna C. G.","2021","Endoscopic duodenal hydrothermal ablation for the treatment of type 2 diabetes mellitus","Data Archiving and Networked Services (DANS)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039334","R0039334.pdf","no_doi","randomized_trial","O'Rielly, Rebecca Jane","2021","Dietary, Lifestyle and Pharmaceutical Interventions for the Treatment of Metabolic Diseases","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039594","R0039594.pdf","free_to_read","randomized_trial","Sulin Cheng","2021","Translational Medicine and Exercise Prescription (TMEP): Advancing the Era of Exercise Medicine","Translational Medicine and Exercise Prescription","Scilight Press Pty Ltd","10.53941/tmep.v1i1.27","https://doi.org/10.53941/tmep.v1i1.27",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53941/tmep.v1i1.27",null],["2","R0042007","R0042007.pdf","no_doi","randomized_trial","Yadav, Shaina","2021","Is liraglutide effective for weight loss in adults who are overweight or obese compared to placebo?","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042357","R0042357.pdf","free_to_read","randomized_trial","Rudolf Chlup","2021","Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020","IntechOpen eBooks","IntechOpen","10.5772/intechopen.96237","https://doi.org/10.5772/intechopen.96237",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5772/intechopen.96237",null],["2","R0042527","R0042527.pdf","open_download_failed","randomized_trial","Unlu, Y","2021","Oral Abstracts","Obesity","Wiley","10.1002/oby.23328","https://doi.org/10.1002/oby.23328","34874110","https://pubmed.ncbi.nlm.nih.gov/34874110/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23328",null],["2","R0042742","R0042742.pdf","open_download_failed","randomized_trial","László Bajnok","2021","A súlyfelesleg és annak csökkentése kardiovaszkuláris szempontból","Cardiologia Hungarica","Cardiologia Hungarica","10.26430/chungarica.2021.51.5.331","https://doi.org/10.26430/chungarica.2021.51.5.331",null,"https://pubmed.ncbi.nlm.nih.gov//","http://cardiologia.hungarica.eu/wp-content/uploads/2021/12/Bajnok-Laszlo-1.pdf",null],["2","R0043766","R0043766.pdf","no_doi","randomized_trial","Domenica Rubino (8951612)","2021","Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043770","R0043770.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2021","Presentations at the 81st scientific sessions of the American Diabetes Association ( ADA ), Part 1","Journal of Diabetes","Wiley","10.1111/1753-0407.13211","https://doi.org/10.1111/1753-0407.13211","34251079","https://pubmed.ncbi.nlm.nih.gov/34251079/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13211",null],["2","R0043951","R0043951.pdf","open_download_failed","randomized_trial","Miles Fisher","2021","Clinical relevance of recent outcome trials with antidiabetic drugs","Practical Diabetes","Wiley","10.1002/pdi.2363","https://doi.org/10.1002/pdi.2363",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2363",null],["2","R0043952","R0043952.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2021","Use of HbA1c in clinical practice: New insights","Journal of Diabetes","Wiley","10.1111/1753-0407.13155","https://doi.org/10.1111/1753-0407.13155","33427383","https://pubmed.ncbi.nlm.nih.gov/33427383/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13155",null],["2","R0044134","R0044134.pdf","no_doi","randomized_trial","Thomas A Wadden (8951606)","2021","Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044229","R0044229.pdf","no_doi","randomized_trial","Marco Trevisan","2021","Drug safety and effectiveness in relation to kidney function : a pharmacoepidemiological approach","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044234","R0044234.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2021","Developments in type 1 and type 2 diabetes","Journal of Diabetes","Wiley","10.1111/1753-0407.13186","https://doi.org/10.1111/1753-0407.13186","33855791","https://pubmed.ncbi.nlm.nih.gov/33855791/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13186",null],["2","R0044257","R0044257.pdf","free_to_read","randomized_trial","Charlotte K. Boughton","2021","Fully closed-loop insulin delivery—are we nearly there yet?","The Lancet Digital Health","Elsevier BV","10.1016/s2589-7500(21)00218-1","https://doi.org/10.1016/s2589-7500(21)00218-1","34580054","https://pubmed.ncbi.nlm.nih.gov/34580054/","https://doi.org/10.1016/s2589-7500(21)00218-1",null],["2","R0044322","R0044322.pdf","open_download_failed","randomized_trial","Michael E. Nassif","2021","Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials","European Journal of Heart Failure","Oxford University Press (OUP)","10.1002/ejhf.2193","https://doi.org/10.1002/ejhf.2193","33880841","https://pubmed.ncbi.nlm.nih.gov/33880841/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2193",null],["2","R0044790","R0044790.pdf","no_doi","randomized_trial","Whicher, Clare Alexandra","2021","Evaluation of the feasibility and acceptability of liraglutide 3.0mg as a management of overweight and obesity in people with severe mental illness (LOSE Weight trial)","ePrints Soton (University of Southampton)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047148","R0047148.pdf","free_to_read","randomized_trial","Carolina López‐Cano","2021","Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Cross-Over LIRALUNG Study",null,"American Diabetes Association","10.2337/figshare.16915396.v1","https://doi.org/10.2337/figshare.16915396.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.16915396.v1",null],["2","R0047406","R0047406.pdf","free_to_read","randomized_trial","Peter M. Wolfgram","2021","Youth Along the T2D Risk Continuum Remain Concerningly Refractory to Therapeutic Interventions","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgab292","https://doi.org/10.1210/clinem/dgab292","33942103","https://pubmed.ncbi.nlm.nih.gov/33942103/","https://www.ncbi.nlm.nih.gov/pmc/articles/8208664",null],["2","R0047453","R0047453.pdf","open_download_failed","randomized_trial","Rafael Ferraz Bannitz","2021","Bariatric Surgery: It’s Not Just Incretins!","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgab694","https://doi.org/10.1210/clinem/dgab694","34543416","https://pubmed.ncbi.nlm.nih.gov/34543416/","https://academic.oup.com/jcem/article-pdf/107/2/e883/42224476/dgab694.pdf",null],["2","R0047501","R0047501.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2021","Effects of glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors on myocardial deformation and work index in type 2 diabetes: 1 year follow up","European Heart Journal - Cardiovascular Imaging","Oxford University Press (OUP)","10.1093/ehjci/jeaa356.143","https://doi.org/10.1093/ehjci/jeaa356.143",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ehjcimaging/article-pdf/22/Supplement_1/jeaa356.143/36214534/jeaa356.143.pdf",null],["2","R0047786","R0047786.pdf","open_download_failed","randomized_trial","Heba Mohamed Atif Ismail","2021","Potential Role for the Use of Gliptins in Cystic Fibrosis-related Diabetes","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgab442","https://doi.org/10.1210/clinem/dgab442","34139767","https://pubmed.ncbi.nlm.nih.gov/34139767/","https://academic.oup.com/jcem/article-pdf/106/11/e4786/41378572/dgab442.pdf","ClinicalTrials.gov:NCT01851694"],["2","R0047989","R0047989.pdf","free_to_read","randomized_trial","Jovanna Tsoutsouki","2021","A year in diabetic nephropathy","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2021.293","https://doi.org/10.15277/bjd.2021.293",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2021.293",null],["2","R0048755","R0048755.pdf","open_download_failed","randomized_trial","Gautam Chandra Das","2021","Liraglutide for overweight and obesity","Practical Diabetes","Wiley","10.1002/pdi.2313","https://doi.org/10.1002/pdi.2313",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2313",null],["2","R0048914","R0048914.pdf","open_download_failed","randomized_trial","Cecilie Rødgaard Bartholdy","2021","Changes in physical activity during a one-year weight loss trial with liraglutide in participants with knee osteoarthritis: secondary analyses of a randomised trial","Osteoarthritis and Cartilage","Elsevier BV","10.1016/j.joca.2021.02.554","https://doi.org/10.1016/j.joca.2021.02.554",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.oarsijournal.com/article/S1063458421006099/pdf",null],["2","R0049437","R0049437.pdf","free_to_read","randomized_trial","Abdulrahman Jameel A Sehly","2021","Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes","International Journal of Pharmaceutical and Phytopharmacological Research","Polaris","10.51847/skbdqro7ng","https://doi.org/10.51847/skbdqro7ng",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.51847/skbdqro7ng",null],["2","R0049510","R0049510.pdf","free_to_read","randomized_trial","Guang Ning","2021","Chinese Guideline on the Primary Prevention of Cardiovascular Diseases: Time to Start Better Cardiovascular Primary Prevention","Cardiology Discovery","Ovid Technologies (Wolters Kluwer Health)","10.1097/cd9.0000000000000024","https://doi.org/10.1097/cd9.0000000000000024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/cd9.0000000000000024",null],["2","R0050897","R0050897.pdf","open_download_failed","randomized_trial","Yu. Sh. Khalimov","2021","Glucagon-like Peptide-1 Receptor Agonists and New Opportunities in Primary Prevention of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus","Doctor Ru","NP Rusmedical Group","10.31550/1727-2378-2021-20-2-21-29","https://doi.org/10.31550/1727-2378-2021-20-2-21-29",null,"https://pubmed.ncbi.nlm.nih.gov//","https://journaldoctor.ru/upload/iblock/b74/Doctor.Ru_Endocrinology_Vol20_2_2021_3.pdf",null],["2","R0051427","R0051427.pdf","no_doi","randomized_trial","Annemie Stege Bojer","2021","Short-term treatment with liraglutide does not improve cardiac diastolic function in patients with type 2 diabetes: a randomised double-blind placebo-controlled trial","University of Southern Denmark Research Portal (University of Southern Denmark)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051501","R0051501.pdf","open_download_failed","randomized_trial","Panagiota K. Stampouloglou","2021","Differential effect of novel antidiabetic agents on the arterial stiffness and endothelial function in patients with type 2 diabetes mellitus","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2962","https://doi.org/10.1093/eurheartj/ehab724.2962",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2962/41052255/ehab724.2962.pdf",null],["2","R0051580","R0051580.pdf","open_download_failed","randomized_trial","Francesco Cosentino","2021","Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2650","https://doi.org/10.1093/eurheartj/ehab724.2650",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2650/41056018/ehab724.2650.pdf",null],["2","R0051708","R0051708.pdf","free_to_read","randomized_trial","Xiang Ming Xu","2021","New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks","Journal of Evidence-Based Medicine","Wiley","10.1111/jebm.12452","https://doi.org/10.1111/jebm.12452","34724335","https://pubmed.ncbi.nlm.nih.gov/34724335/","https://doi.org/10.1111/jebm.12452",null],["2","R0052117","R0052117.pdf","open_download_failed","randomized_trial","Luca Di Ienno","2021","Glucagon-like peptide-1 receptor agonist and the relation between metabolic effects and cardiovascular outcomes: insight into mechanisms of action","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2956","https://doi.org/10.1093/eurheartj/ehab724.2956",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2956/41052272/ehab724.2956.pdf",null],["2","R0052332","R0052332.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2021","Effect ofglucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on left atrial strain and arterial function","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2652","https://doi.org/10.1093/eurheartj/ehab724.2652",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2652/41056012/ehab724.2652.pdf",null],["2","R0052542","R0052542.pdf","open_download_failed","randomized_trial","M. V. Martianova","2021","Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis","Экспериментальная и клиническая гастроэнтерология","LLC Global Media Technology","10.31146/1682-8658-ecg-194-10-82-90","https://doi.org/10.31146/1682-8658-ecg-194-10-82-90",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.nogr.org/jour/article/download/1763/1620",null],["2","R0052625","R0052625.pdf","free_to_read","randomized_trial","Blanca Fuentes","2021","Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group","Neurología (English Edition)","Elsevier BV","10.1016/j.nrleng.2020.04.022","https://doi.org/10.1016/j.nrleng.2020.04.022",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nrleng.2020.04.022",null],["2","R0052917","R0052917.pdf","free_to_read","randomized_trial","Claudia K. Fox","2021","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvab048.128","https://doi.org/10.1210/jendso/bvab048.128",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvab048.128",null],["2","R0054278","R0054278.pdf","open_download_failed","randomized_trial","Davide Maurício Carvalho","2021","A LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TREATMENTS FOR TYPE 2 DIABETES IN PORTUGAL: ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS ONCE-DAILY EMPAGLIFLOZIN 25 MG","Revista Portuguesa de Endocrinologia Diabetes e Metabolismo","S. Karger AG","10.26497/ao200073","https://doi.org/10.26497/ao200073",null,"https://pubmed.ncbi.nlm.nih.gov//","https://karger.com/eni/article-pdf/16/1-2/13/4339186/000544577.pdf",null],["2","R0054794","R0054794.pdf","free_to_read","randomized_trial","Shuoming Luo","2021","A long and winding road to understand latent autoimmune diabetes in adults","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000001321","https://doi.org/10.1097/cm9.0000000000001321","33395070","https://pubmed.ncbi.nlm.nih.gov/33395070/","https://doi.org/10.1097/cm9.0000000000001321",null],["2","R0005446","R0005446.pdf","open_download_failed","randomized_trial","Honigberg MC","2020","Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.","JAMA cardiology","American Medical Association (AMA)","10.1001/jamacardio.2020.1966","https://doi.org/10.1001/jamacardio.2020.1966","32584928","https://pubmed.ncbi.nlm.nih.gov/32584928/","https://www.ncbi.nlm.nih.gov/pmc/articles/7744318",null],["2","R0008737","R0008737.pdf","open_download_failed","randomized_trial","Arnott C","2020","The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2020.06.011","https://doi.org/10.1016/j.ijcard.2020.06.011","32569700","https://pubmed.ncbi.nlm.nih.gov/32569700/","http://www.internationaljournalofcardiology.com/article/S0167527320333891/pdf",null],["2","R0008969","R0008969.pdf","open_download_failed","randomized_trial","Nielsen R","2020","The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14135","https://doi.org/10.1111/dom.14135","32627271","https://pubmed.ncbi.nlm.nih.gov/32627271/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14135",null],["2","R0009837","R0009837.pdf","free_to_read","randomized_trial","Lavernia F","2020","Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1798638","https://doi.org/10.1080/00325481.2020.1798638","32815436","https://pubmed.ncbi.nlm.nih.gov/32815436/","https://doi.org/10.1080/00325481.2020.1798638",null],["2","R0010724","R0010724.pdf","open_download_failed","randomized_trial","Webb DR","2020","A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14023","https://doi.org/10.1111/dom.14023","32157772","https://pubmed.ncbi.nlm.nih.gov/32157772/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14023",null],["2","R0011212","R0011212.pdf","open_download_failed","randomized_trial","Ehrhardt N","2020","Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes.","Diabetes spectrum : a publication of the American Diabetes Association","American Diabetes Association","10.2337/ds19-0025","https://doi.org/10.2337/ds19-0025","32425456","https://pubmed.ncbi.nlm.nih.gov/32425456/","https://www.ncbi.nlm.nih.gov/pmc/articles/7228818",null],["2","R0011323","R0011323.pdf","open_download_failed","randomized_trial","Wegeberg AL","2020","Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.","United European gastroenterology journal","Wiley","10.1177/2050640620925968","https://doi.org/10.1177/2050640620925968","32390563","https://pubmed.ncbi.nlm.nih.gov/32390563/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1177/2050640620925968",null],["2","R0011382","R0011382.pdf","open_download_failed","randomized_trial","Meier JJ","2020","Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13935","https://doi.org/10.1111/dom.13935","31793165","https://pubmed.ncbi.nlm.nih.gov/31793165/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13935",null],["2","R0011817","R0011817.pdf","open_download_failed","randomized_trial","Wang X","2020","Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.","American journal of nephrology","S. Karger AG","10.1159/000510255","https://doi.org/10.1159/000510255","32966971","https://pubmed.ncbi.nlm.nih.gov/32966971/","https://doi.org/10.1159/000510255",null],["2","R0012055","R0012055.pdf","open_download_failed","randomized_trial","de Boer IH","2020","Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.","Kidney international","Elsevier BV","10.1016/j.kint.2020.06.024","https://doi.org/10.1016/j.kint.2020.06.024","32653403","https://pubmed.ncbi.nlm.nih.gov/32653403/","http://www.kidney-international.org/article/S0085253820307985/pdf",null],["2","R0014406","R0014406.pdf","free_to_read","randomized_trial","Siskind D","2020","Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).","Journal of psychiatric research","Elsevier BV","10.1016/j.jpsychires.2020.02.015","https://doi.org/10.1016/j.jpsychires.2020.02.015","32087425","https://pubmed.ncbi.nlm.nih.gov/32087425/","http://hdl.handle.net/10072/397012",null],["2","R0014514","R0014514.pdf","open_download_failed","randomized_trial","Morieri ML","2020","Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa204","https://doi.org/10.1210/clinem/dgaa204","32301492","https://pubmed.ncbi.nlm.nih.gov/32301492/","https://academic.oup.com/jcem/article-pdf/105/7/e2617/33555275/dgaa204.pdf",null],["2","R0014551","R0014551.pdf","open_download_failed","randomized_trial","Leehey DJ","2020","Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0001252019","https://doi.org/10.34067/kid.0001252019","35372914","https://pubmed.ncbi.nlm.nih.gov/35372914/","https://doi.org/10.34067/kid.0001252019",null],["2","R0015705","R0015705.pdf","open_download_failed","randomized_trial","Glotfelty EJ","2020","Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2020.1764534","https://doi.org/10.1080/13543784.2020.1764534","32412796","https://pubmed.ncbi.nlm.nih.gov/32412796/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10477949/pdf/nihms-1923973.pdf",null],["2","R0017177","R0017177.pdf","free_to_read","randomized_trial","Nyland JE","2020","Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study","SSRN","Elsevier BV","10.2139/ssrn.3725612","https://doi.org/10.2139/ssrn.3725612",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.3725612",null],["2","R0018383","R0018383.pdf","free_to_read","randomized_trial","Antwi K","2020","Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.","Clinical nuclear medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/rlu.0000000000003124","https://doi.org/10.1097/rlu.0000000000003124","32558709","https://pubmed.ncbi.nlm.nih.gov/32558709/","https://boris.unibe.ch/148290/",null],["2","R0019362","R0019362.pdf","open_download_failed","randomized_trial","Herold KC","2020","Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14121","https://doi.org/10.1111/dom.14121","32573927","https://pubmed.ncbi.nlm.nih.gov/32573927/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14121",null],["2","R0019851","R0019851.pdf","free_to_read","randomized_trial","Marx N","2020","Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa174","https://doi.org/10.1093/eurheartj/ehaa174","32227240","https://pubmed.ncbi.nlm.nih.gov/32227240/",null,null],["2","R0019961","R0019961.pdf","open_download_failed","randomized_trial","Redondo MJ","2020","GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa314","https://doi.org/10.1210/clinem/dgaa314","32485735","https://pubmed.ncbi.nlm.nih.gov/32485735/","https://www.ncbi.nlm.nih.gov/pmc/articles/7316204",null],["2","R0020319","R0020319.pdf","open_download_failed","randomized_trial","Moschovaki Filippidou F","2020","Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation.","The American journal of pathology","Elsevier BV","10.1016/j.ajpath.2019.10.008","https://doi.org/10.1016/j.ajpath.2019.10.008","31759969","https://pubmed.ncbi.nlm.nih.gov/31759969/","http://ajp.amjpathol.org/article/S0002944019308065/pdf",null],["2","R0020507","R0020507.pdf","free_to_read","randomized_trial","Marx N","2020","Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz853","https://doi.org/10.1093/eurheartj/ehz853","31800036","https://pubmed.ncbi.nlm.nih.gov/31800036/",null,null],["2","R0020592","R0020592.pdf","open_download_failed","randomized_trial","Weghuber D","2020","A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.","Pediatric obesity","Wiley","10.1111/ijpo.12624","https://doi.org/10.1111/ijpo.12624","32062862","https://pubmed.ncbi.nlm.nih.gov/32062862/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.12624",null],["2","R0022660","R0022660.pdf","free_to_read","randomized_trial","Cusi K","2020","A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.14350","https://doi.org/10.1111/liv.14350","32077613","https://pubmed.ncbi.nlm.nih.gov/32077613/",null,null],["2","R0023124","R0023124.pdf","free_to_read","randomized_trial","Davies MJ","2020","Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2020.154242","https://doi.org/10.1016/j.metabol.2020.154242","32315698","https://pubmed.ncbi.nlm.nih.gov/32315698/","https://figshare.com/articles/journal_contribution/Use_of_incretin-based_medications_what_do_current_international_recommendations_suggest_with_respect_to_GLP-1_receptor_agonists_and_DPP-4_inhibitors_/12155466",null],["2","R0023257","R0023257.pdf","open_download_failed","randomized_trial","Chia CW","2020","Incretins in obesity and diabetes.","Annals of the New York Academy of Sciences","Wiley","10.1111/nyas.14211","https://doi.org/10.1111/nyas.14211","31392745","https://pubmed.ncbi.nlm.nih.gov/31392745/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10131087/pdf/nihms-1889843.pdf",null],["2","R0023840","R0023840.pdf","open_download_failed","randomized_trial","Tougaard RS","2020","Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.","Scandinavian cardiovascular journal : SCJ","Informa UK Limited","10.1080/14017431.2020.1751873","https://doi.org/10.1080/14017431.2020.1751873","32292074","https://pubmed.ncbi.nlm.nih.gov/32292074/","https://www.tandfonline.com/doi/pdf/10.1080/14017431.2020.1751873?needAccess=true&role=button",null],["2","R0023860","R0023860.pdf","free_to_read","randomized_trial","Rena G","2020","Metformin: still the sweet spot for CV protection in diabetes?","Current opinion in pharmacology","Elsevier BV","10.1016/j.coph.2020.10.018","https://doi.org/10.1016/j.coph.2020.10.018","33271428","https://pubmed.ncbi.nlm.nih.gov/33271428/","https://discovery.dundee.ac.uk/en/publications/40c71416-a68d-437d-8e47-d76c398e07a0",null],["2","R0024023","R0024023.pdf","open_download_failed","randomized_trial","Tronieri JS","2020","Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.","Obesity facts","S. Karger AG","10.1159/000511130","https://doi.org/10.1159/000511130","33197917","https://pubmed.ncbi.nlm.nih.gov/33197917/","https://www.karger.com/Article/Pdf/511130",null],["2","R0024387","R0024387.pdf","open_download_failed","randomized_trial","Tronieri JS","2020","Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.","Behaviour research and therapy","Elsevier BV","10.1016/j.brat.2020.103639","https://doi.org/10.1016/j.brat.2020.103639","32450367","https://pubmed.ncbi.nlm.nih.gov/32450367/","https://www.ncbi.nlm.nih.gov/pmc/articles/7336389",null],["2","R0024491","R0024491.pdf","free_to_read","randomized_trial","Vukotic R","2020","The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series.","Annals of internal medicine","American College of Physicians","10.7326/l20-0041","https://doi.org/10.7326/l20-0041","32449885","https://pubmed.ncbi.nlm.nih.gov/32449885/","http://hdl.handle.net/11380/1237320",null],["2","R0024606","R0024606.pdf","open_download_failed","randomized_trial","Sabouret P","2020","The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvaa051","https://doi.org/10.1093/ehjcvp/pvaa051","32402065","https://pubmed.ncbi.nlm.nih.gov/32402065/","https://academic.oup.com/ehjcvp/article-pdf/6/6/394/34333947/pvaa051.pdf",null],["2","R0024987","R0024987.pdf","open_download_failed","randomized_trial","Chen C","2020","Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with Polycystic ovary syndrome: a retrospective study","Research Square","Research Square Platform LLC","10.21203/rs.3.rs-22460/v1","https://doi.org/10.21203/rs.3.rs-22460/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://assets.researchsquare.com/files/rs-22460/v1/liraglutideandmetforminleadtoasignificantweightloss.pdf","ChiCTR:ChiCTR1900024384"],["2","R0025160","R0025160.pdf","open_download_failed","randomized_trial","Chao AM","2020","The risk of cardiovascular complications with current obesity drugs.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2020.1806234","https://doi.org/10.1080/14740338.2020.1806234","32750250","https://pubmed.ncbi.nlm.nih.gov/32750250/","https://www.ncbi.nlm.nih.gov/pmc/articles/7554173",null],["2","R0025233","R0025233.pdf","free_to_read","randomized_trial","Skelin M","2020","Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.","Diabetes care","American Diabetes Association","10.2337/dc19-2039","https://doi.org/10.2337/dc19-2039","31959649","https://pubmed.ncbi.nlm.nih.gov/31959649/",null,null],["2","R0026543","R0026543.pdf","open_download_failed","randomized_trial","Cataldi M","2020","Cardiovascular effects of antiobesity drugs: are the new medicines all the same?","International journal of obesity supplements","Springer Science and Business Media LLC","10.1038/s41367-020-0015-3","https://doi.org/10.1038/s41367-020-0015-3","32714509","https://pubmed.ncbi.nlm.nih.gov/32714509/","https://www.nature.com/articles/s41367-020-0015-3.pdf",null],["2","R0027341","R0027341.pdf","open_download_failed","randomized_trial","Asakura T","2020","Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analysis.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2020.1739636","https://doi.org/10.1080/03007995.2020.1739636","32141343","https://pubmed.ncbi.nlm.nih.gov/32141343/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1739636?needAccess=true",null],["2","R0027484","R0027484.pdf","open_download_failed","randomized_trial","Van Name M","2020","Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2019.0448","https://doi.org/10.1089/dia.2019.0448","31859529","https://pubmed.ncbi.nlm.nih.gov/31859529/","https://www.ncbi.nlm.nih.gov/pmc/articles/7869879",null],["2","R0027764","R0027764.pdf","free_to_read","randomized_trial","Wang Y","2020","Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2020.109914","https://doi.org/10.1016/j.biopha.2020.109914","32035395","https://pubmed.ncbi.nlm.nih.gov/32035395/","https://doi.org/10.1016/j.biopha.2020.109914",null],["2","R0028477","R0028477.pdf","open_download_failed","randomized_trial","Sukkar L","2020","How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?","Kidney & blood pressure research","S. Karger AG","10.1159/000511214","https://doi.org/10.1159/000511214","33271545","https://pubmed.ncbi.nlm.nih.gov/33271545/","https://www.karger.com/Article/Pdf/511214",null],["2","R0028520","R0028520.pdf","free_to_read","randomized_trial","Gadde KM","2020","The limits and challenges of antiobesity pharmacotherapy.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2020.1748599","https://doi.org/10.1080/14656566.2020.1748599","32292094","https://pubmed.ncbi.nlm.nih.gov/32292094/","https://www.ncbi.nlm.nih.gov/pmc/articles/7523877",null],["2","R0028528","R0028528.pdf","free_to_read","randomized_trial","Gelosa P","2020","Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?","Biochemical pharmacology","Elsevier BV","10.1016/j.bcp.2020.113894","https://doi.org/10.1016/j.bcp.2020.113894","32142728","https://pubmed.ncbi.nlm.nih.gov/32142728/","http://hdl.handle.net/2434/722900",null],["2","R0028543","R0028543.pdf","open_download_failed","randomized_trial","Gujral J","2020","Update: Pediatric Diabetes.","Journal of diabetes","Wiley","10.1111/1753-0407.13012","https://doi.org/10.1111/1753-0407.13012","31837125","https://pubmed.ncbi.nlm.nih.gov/31837125/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13012",null],["2","R0030599","R0030599.pdf","no_doi","randomized_trial","Syed Raza","2020","Underuse and Misuse of Newer Antidiabetic Medication with Established Positive Cardiovascular Outcome","Angiology Open Access",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030853","R0030853.pdf","no_doi","randomized_trial","Nasser Mikhail","2020","Treatment of Type 2 Diabetes with SodiumGlucose Co-Transporter 2 Inhibitors plus Glucagon-Like Peptide-1 Receptor Agonists","Insights in Biomedicine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036821","R0036821.pdf","no_doi","randomized_trial","del Olmo García, María Isabel","2020","Alteraciones del metabolismo hidrocarbonado en el paciene con síndrome coronario agudo. Beneficios del tratamiento con agonistas del receptor de GLP1","Repository of Digital Objects for Teaching Research and Culture (University of Valencia)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037726","R0037726.pdf","open_download_failed","randomized_trial","Neda Rasouli","2020","An Escape From Diabetes","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgaa401","https://doi.org/10.1210/clinem/dgaa401","32597475","https://pubmed.ncbi.nlm.nih.gov/32597475/","https://academic.oup.com/jcem/article-pdf/105/9/e3460/33769857/dgaa401.pdf",null],["2","R0038014","R0038014.pdf","free_to_read","randomized_trial","Yoshimasa Aso","2020","2186-PUB: Comparison of Insulin Degludec (IDeg)/Insulin Aspart (IAsp) Coformulation Therapy Twice Daily with Free Combination of GLP-1 Receptor Agonist Liraglutide plus Insulin Degludec in Tochigi: IDEAL Trial","Diabetes","American Diabetes Association","10.2337/db20-2186-pub","https://doi.org/10.2337/db20-2186-pub",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/db20-2186-pub",null],["2","R0038497","R0038497.pdf","free_to_read","randomized_trial","Julio Rosenstock","2020","Impact of a Weekly GLP-1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial",null,"American Diabetes Association","10.2337/figshare.12469121.v1","https://doi.org/10.2337/figshare.12469121.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.12469121.v1",null],["2","R0039747","R0039747.pdf","free_to_read","randomized_trial","Yaping Luo","2020","Decreased 68Ga-NOTA-exendin-4 renal uptake in patients pretreated with Gelofusine infusion: a randomized controlled study","Journal of Pancreatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/jp9.0000000000000053","https://doi.org/10.1097/jp9.0000000000000053",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/jp9.0000000000000053",null],["2","R0041854","R0041854.pdf","open_download_failed","randomized_trial",null,"2020","An Important Dose‐response study for tirzepatide, a novel dual (GIP and GLP‐1) Agonist (https://doi.org/10.1111/dom.13979)","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.00007","https://doi.org/10.1002/doi2.00007",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.00007",null],["2","R0041917","R0041917.pdf","open_download_failed","randomized_trial","Giuseppe Biondi‐Zoccai","2020","Clinical Conundrum: Three Management Strategies for Three-Vessel Coronary Artery Disease?","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000000900","https://doi.org/10.1097/fjc.0000000000000900","32826412","https://pubmed.ncbi.nlm.nih.gov/32826412/","http://hdl.handle.net/11573/1473421",null],["2","R0041960","R0041960.pdf","no_doi","randomized_trial","Elvina Gunawan","2020","Literature review efektivitas dan keamanan liraglutide sebagai terapi kombinasi pada pasien diabetes melitus","Widya Mandala Catholic University Surabaya Repository (Widya Mandala Catholic University Surabaya)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041962","R0041962.pdf","no_doi","randomized_trial","Terán Chávez, Pier André","2020","Relación entre el uso de inhibidores SGLT2 y agonistas GLP-1 con desenlaces cardiovasculares en pacientes con Diabetes Mellitus tipo 2: Una Revisión sistemática y Metaanálisis","renati",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041981","R0041981.pdf","no_doi","randomized_trial","Joseph Bailey","2020","GLP-1R AGONISTS IMPROVE CEREBROVASCULAR INTEGRITY AND VASCULAR COGNITIVE IMPAIRMENT AND DEMENTIA (VCID) BEYOND GLYCEMIC CONTROL VIA RECOVERY OF BRAIN PERICYTE FUNCTION IN DIABETIC MICE","Mercer University Libraries (Mercer University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042262","R0042262.pdf","open_download_failed","randomized_trial",null,"2020","LIRA‐ADD2SGLT2i – New Evidence on Combing GLP‐1 RA and SGLT2i Therapies (https://doi.org/10.1111/dom.13978)","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.00008","https://doi.org/10.1002/doi2.00008",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.00008",null],["2","R0042436","R0042436.pdf","no_doi","randomized_trial","David Webb (294780)","2020","A randomised, open label, active comparator trial assessing the effects of 26 weeks of Liraglutide or Sitagliptin on cardiovascular function in young obese adults with Type 2 diabetes","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042469","R0042469.pdf","open_download_failed","randomized_trial","Brian A. Bergmark","2020","Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.119.044819","https://doi.org/10.1161/circulationaha.119.044819","31986098","https://pubmed.ncbi.nlm.nih.gov/31986098/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044819",null],["2","R0042633","R0042633.pdf","open_download_failed","randomized_trial","Pasquale Simeone","2020","Baseline interleukin1beta expression in peripheral blood monocytes predicts the extent of weight loss and nonalcoholic fatty liver improvement in obese subjects with prediabetes or type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3033","https://doi.org/10.1093/ehjci/ehaa946.3033",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.3033/34522201/ehaa946.3033.pdf",null],["2","R0042847","R0042847.pdf","open_download_failed","randomized_trial","Stefan Agewall","2020","Focus on blood pressure and risk factor intervention","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvaa130","https://doi.org/10.1093/ehjcvp/pvaa130","33197927","https://pubmed.ncbi.nlm.nih.gov/33197927/","https://academic.oup.com/ehjcvp/article-pdf/6/6/339/34333935/pvaa130.pdf",null],["2","R0044057","R0044057.pdf","free_to_read","randomized_trial","Efstratios Koutroumpakis","2020","Diabetes and Cardiovascular Disease in Women: Current Challenges and New Hope","Texas Heart Institute Journal","Texas Heart Institute Journal","10.14503/thij-19-7068","https://doi.org/10.14503/thij-19-7068","32603448","https://pubmed.ncbi.nlm.nih.gov/32603448/","https://doi.org/10.14503/thij-19-7068",null],["2","R0044135","R0044135.pdf","open_download_failed","randomized_trial","Stephanie O. Omokaro","2020","The regulatory state of nonalcoholic steatohepatitis and metabolism","Endocrinology Diabetes & Metabolism","Wiley","10.1002/edm2.113","https://doi.org/10.1002/edm2.113","33102795","https://pubmed.ncbi.nlm.nih.gov/33102795/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/edm2.113",null],["2","R0044371","R0044371.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2020","The ADA 2020 virtual poster hall","Journal of Diabetes","Wiley","10.1111/1753-0407.13103","https://doi.org/10.1111/1753-0407.13103","32755033","https://pubmed.ncbi.nlm.nih.gov/32755033/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.13103",null],["2","R0044379","R0044379.pdf","open_download_failed","randomized_trial","Malik Elharram","2020","The Intersecting Role of Glycaemia and Cardiac Function in the Development of Heart Failure Among Patients with Type 2 Diabetes Mellitus After an Acute Coronary Syndrome","European Journal of Heart Failure","Oxford University Press (OUP)","10.1002/ejhf.1845","https://doi.org/10.1002/ejhf.1845","32353172","https://pubmed.ncbi.nlm.nih.gov/32353172/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.1845",null],["2","R0044385","R0044385.pdf","free_to_read","randomized_trial","Antonio Ceriello","2020","Is it time to ban sulfonylureas?","Journal of Diabetes","Wiley","10.1111/1753-0407.13095","https://doi.org/10.1111/1753-0407.13095","32767650","https://pubmed.ncbi.nlm.nih.gov/32767650/","https://www.openaccessrepository.it/record/103281",null],["2","R0045675","R0045675.pdf","open_download_failed","randomized_trial","Hirotaka Watada","2020","Efficacy and Safety of 1:1 Fixed Ratio Combination of Insulin Glargine/Lixisenatide (iGlarLixi) versus Lixisenatide in Japanese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial",null,"American Diabetes Association","10.2337/dc20-1234/suppl.12016425.v1","https://doi.org/10.2337/dc20-1234/suppl.12016425.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://diabetesjournals.figshare.com/articles/figure/Efficacy_and_Safety_of_1_1_Fixed_Ratio_Combination_of_Insulin_Glargine_Lixisenatide_iGlarLixi_versus_Lixisenatide_in_Japanese_Patients_with_Type_2_Diabetes_Mellitus_Inadequately_Controlled_on_Oral_Antidiabetic_Drugs_The_LixiLan_JP-O1_Random/12016425/files/22078662.pdf",null],["2","R0046302","R0046302.pdf","open_download_failed","randomized_trial","Yoshimasa Aso","2020","Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin deguldec in Tochigi: IDEAL Trial",null,"Wiley","10.22541/au.159129005.57065700","https://doi.org/10.22541/au.159129005.57065700",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.159129005.57065700",null],["2","R0046511","R0046511.pdf","free_to_read","randomized_trial","Yu. Sh. Khalimov","2020","Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/2079-701x-2019-21-189-197","https://doi.org/10.21518/2079-701x-2019-21-189-197",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21518/2079-701x-2019-21-189-197",null],["2","R0047138","R0047138.pdf","open_download_failed","randomized_trial","Sun H. Kim","2020","MON-591 Effect of Liraglutide Treatment on Proglucagon-Derived Peptides","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaa046.1288","https://doi.org/10.1210/jendso/bvaa046.1288",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/4/Supplement_1/MON-591/33188291/bvaa046.1288.pdf",null],["2","R0047162","R0047162.pdf","open_download_failed","randomized_trial","Ninian N. Lang","2020","Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaa247","https://doi.org/10.1093/cvr/cvaa247","32980877","https://pubmed.ncbi.nlm.nih.gov/32980877/","https://academic.oup.com/cardiovascres/article-pdf/116/12/e152/33796028/cvaa247.pdf",null],["2","R0047324","R0047324.pdf","no_doi","randomized_trial","Caroline A. Mulvaney","2020","GLP-1 receptor agonists for Parkinson's disease (Review)","Lancaster EPrints (Lancaster University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047857","R0047857.pdf","free_to_read","randomized_trial","Oksana Logvinova","2020","Prediction of early response to liraglutide therapy in patients with obesity","Obesity and metabolism","Endocrinology Research Centre","10.14341/omet12274","https://doi.org/10.14341/omet12274",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14341/omet12274",null],["2","R0048592","R0048592.pdf","open_download_failed","randomized_trial","Signe Abitz Winther","2020","TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgaa428","https://doi.org/10.1210/clinem/dgaa428","32701146","https://pubmed.ncbi.nlm.nih.gov/32701146/","https://academic.oup.com/jcem/article-pdf/105/12/e4958/41829118/dgaa428.pdf",null],["2","R0049696","R0049696.pdf","open_download_failed","randomized_trial","Giacomo Ruotolo","2020","Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3056","https://doi.org/10.1093/ehjci/ehaa946.3056",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.3056/34522771/ehaa946.3056.pdf",null],["2","R0049751","R0049751.pdf","free_to_read","randomized_trial","Mohammad Shafi Kuchay","2020","Effect of Dulaglutide on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial (D-LIFT Trial)","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.3582791","https://doi.org/10.2139/ssrn.3582791",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.3582791",null],["2","R0049882","R0049882.pdf","open_download_failed","randomized_trial","Thorsten Martin Leucker","2020","Highlights from the first ever virtual American College of Cardiology World Congress of Cardiology 2020 (ACC.20/WCC)","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaa099","https://doi.org/10.1093/cvr/cvaa099","32406489","https://pubmed.ncbi.nlm.nih.gov/32406489/","https://academic.oup.com/cardiovascres/article-pdf/116/7/e75/33640949/cvaa099.pdf",null],["2","R0050102","R0050102.pdf","open_download_failed","randomized_trial","Athanasia K. Papazafiropoulou","2020","Cardiorenal effects of newer antidiabetic agents","Journal of Atherosclerosis Prevention and Treatment","Ovid Technologies (Wolters Kluwer Health)","10.53590/japt.02.1010","https://doi.org/10.53590/japt.02.1010",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.japt.gr/wp-content/uploads/2020/07/02_Papazafiropoulou_review.pdf",null],["2","R0050130","R0050130.pdf","free_to_read","randomized_trial","Kausik Kumar Ray","2020","Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.1425","https://doi.org/10.1093/ehjci/ehaa946.1425",null,"https://pubmed.ncbi.nlm.nih.gov//","https://escholarship.org/uc/item/9cp4g40c",null],["2","R0050143","R0050143.pdf","open_download_failed","randomized_trial","Helen Martina Colhoun","2020","Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3350","https://doi.org/10.1093/ehjci/ehaa946.3350",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.3350/34519884/ehaa946.3350.pdf",null],["2","R0050426","R0050426.pdf","free_to_read","randomized_trial","Taufiq Salahuddin","2020","POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(20)32463-3","https://doi.org/10.1016/s0735-1097(20)32463-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(20)32463-3",null],["2","R0050714","R0050714.pdf","open_download_failed","randomized_trial","ISKANDAR RAUF IDRIS","2020","Early evidence for a GLP‐receptor antagonist for the pharmacological management of post bariatric surgery reactive hypoglycaemia","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.00014","https://doi.org/10.1002/doi2.00014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/doi2.00014",null],["2","R0050771","R0050771.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2020","Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.2376","https://doi.org/10.1093/ehjci/ehaa946.2376",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.2376/34514467/ehaa946.2376.pdf",null],["2","R0051022","R0051022.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2020","Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.0115","https://doi.org/10.1093/ehjci/ehaa946.0115",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.0115/34515527/ehaa946.0115.pdf",null],["2","R0051129","R0051129.pdf","open_download_failed","randomized_trial","Маниге Кониг","2020","OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaa046.071","https://doi.org/10.1210/jendso/bvaa046.071",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/4/Supplement_1/OR30-06/33186332/bvaa046.071.pdf",null],["2","R0051208","R0051208.pdf","open_download_failed","randomized_trial","Giulia Ferrannini","2020","Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3353","https://doi.org/10.1093/ehjci/ehaa946.3353",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.3353/34519965/ehaa946.3353.pdf",null],["2","R0051258","R0051258.pdf","open_download_failed","randomized_trial","JaeDuk Choi","2020","A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(20)31393-3","https://doi.org/10.1016/s0168-8278(20)31393-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0168-8278(20)31393-3",null],["2","R0051978","R0051978.pdf","open_download_failed","randomized_trial","Gautam Chandra Das","2020","SGLT inhibitors for type 1 diabetes","Practical Diabetes","Wiley","10.1002/pdi.2273","https://doi.org/10.1002/pdi.2273",null,"https://pubmed.ncbi.nlm.nih.gov//","https://wchh.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2273","ClinicalTrials.gov:NCT02139943"],["2","R0051983","R0051983.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2020","Effects of glucagon like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on vascular function and myocardial work index in patient with type-2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.3066","https://doi.org/10.1093/ehjci/ehaa946.3066",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.3066/34522884/ehaa946.3066.pdf",null],["2","R0052437","R0052437.pdf","open_download_failed","randomized_trial","Kristian Zobbe","2020","OP0172 EFFECT OF WEIGHT LOSS AND LIRAGLUTIDE ON SERUM URATE LEVELS AMONG OBESE KNEE OSTEOARTHRITIS PATIENTS: SECONDARY ANALYSIS OF A RANDOMISED CONTROLLED TRIAL","Annals of the Rheumatic Diseases","Elsevier BV","10.1136/annrheumdis-2020-eular.3088","https://doi.org/10.1136/annrheumdis-2020-eular.3088",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ard.bmj.com/content/annrheumdis/79/Suppl_1/107.1.full.pdf",null],["2","R0052807","R0052807.pdf","open_download_failed","randomized_trial","Xia Li","2020","Response to Letter to the Editor from Knobler et al: “Validation of the Swedish Diabetes Regrouping Scheme in Adult-Onset Diabetes in China”","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/clinem/dgaa828","https://doi.org/10.1210/clinem/dgaa828","33164083","https://pubmed.ncbi.nlm.nih.gov/33164083/","https://academic.oup.com/jcem/article-pdf/106/2/e1068/41849627/dgaa828.pdf",null],["2","R0052860","R0052860.pdf","free_to_read","randomized_trial","Jakub Tomasik","2020","Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients","Schizophrenia Bulletin Open","Oxford University Press (OUP)","10.1093/schizbullopen/sgaa044","https://doi.org/10.1093/schizbullopen/sgaa044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/schizbullopen/sgaa044",null],["2","R0053824","R0053824.pdf","free_to_read","randomized_trial","Eiichi Araki","2020","Japanese Clinical Practice Guideline for Diabetes 2019","Journal of Diabetes Investigation","Wiley","10.1111/jdi.13306","https://doi.org/10.1111/jdi.13306",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1111/jdi.13306",null],["2","R0054130","R0054130.pdf","open_download_failed","randomized_trial","György Jermendy","2020","GLP1-receptor-agonisták: antidiabetikumok kardiovaszkuláris előnnyel","Cardiologia Hungarica","Cardiologia Hungarica","10.26430/chungarica.2020.50.4.283","https://doi.org/10.26430/chungarica.2020.50.4.283",null,"https://pubmed.ncbi.nlm.nih.gov//","http://cardiologia.hungarica.eu/wp-content/uploads/2020/10/jermendy_gyorgy.pdf",null],["2","R0054790","R0054790.pdf","free_to_read","randomized_trial","Jinghang Xu","2020","Management of chronic liver diseases and cirrhosis: current status and future directions","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000001084","https://doi.org/10.1097/cm9.0000000000001084","32925282","https://pubmed.ncbi.nlm.nih.gov/32925282/","https://doi.org/10.1097/cm9.0000000000001084",null],["2","R0005833","R0005833.pdf","open_download_failed","randomized_trial","Andrikou E","2019","GLP-1 receptor agonists and cardiovascular outcome trials: An update.","Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese","Elsevier BV","10.1016/j.hjc.2018.11.008","https://doi.org/10.1016/j.hjc.2018.11.008","30528435","https://pubmed.ncbi.nlm.nih.gov/30528435/","https://www.sciencedirect.com/science/article/pii/S1109966618304081/pdf",null],["2","R0007265","R0007265.pdf","open_download_failed","randomized_trial","Mata-Cases M","2019","Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2019.1618806","https://doi.org/10.1080/03007995.2019.1618806","31081693","https://pubmed.ncbi.nlm.nih.gov/31081693/","https://figshare.com/articles/Glucagon-like_peptide-1_receptor_agonists_in_patients_with_type_2_diabetes_real-world_evidence_from_a_Mediterranean_area/8282942",null],["2","R0008245","R0008245.pdf","open_download_failed","randomized_trial","Guerci B","2019","Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2019.01.006","https://doi.org/10.1016/j.diabet.2019.01.006","30677504","https://pubmed.ncbi.nlm.nih.gov/30677504/","https://www.sciencedirect.com/science/article/am/pii/S1262363619300217?via%3Dihub",null],["2","R0008478","R0008478.pdf","no_doi","randomized_trial","Wen S","2019","Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats.","Sheng li xue bao : [Acta physiologica Sinica]",null,null,"https://doi.org/","31440748","https://pubmed.ncbi.nlm.nih.gov/31440748/",null,null],["2","R0008774","R0008774.pdf","open_download_failed","randomized_trial","Eriksson R","2019","O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS","Schizophrenia bulletin","Oxford University Press (OUP)","10.1093/schbul/sbz021.268","https://doi.org/10.1093/schbul/sbz021.268",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ncbi.nlm.nih.gov/pmc/articles/6455238",null],["2","R0009047","R0009047.pdf","free_to_read","randomized_trial","Gyorffy JB","2019","THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2019-0023","https://doi.org/10.4158/ep-2019-0023","31170363","https://pubmed.ncbi.nlm.nih.gov/31170363/","https://digitalcommons.unmc.edu/com_hosp_articles/28",null],["2","R0010076","R0010076.pdf","open_download_failed","randomized_trial","Winzeler B","2019","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2018-01420","https://doi.org/10.1210/jc.2018-01420","30272170","https://pubmed.ncbi.nlm.nih.gov/30272170/","https://academic.oup.com/jcem/article-pdf/104/1/202/27059798/jc.2018-01420.pdf",null],["2","R0010162","R0010162.pdf","open_download_failed","randomized_trial","Larsson M","2019","Prehospital exenatide in hyperglycemic stroke-A randomized trial.","Acta neurologica Scandinavica","Wiley","10.1111/ane.13166","https://doi.org/10.1111/ane.13166","31518433","https://pubmed.ncbi.nlm.nih.gov/31518433/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ane.13166",null],["2","R0011366","R0011366.pdf","free_to_read","randomized_trial","van Meijel LA","2019","Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2019-00087","https://doi.org/10.1210/jc.2019-00087","30958544","https://pubmed.ncbi.nlm.nih.gov/30958544/",null,null],["2","R0012420","R0012420.pdf","free_to_read","randomized_trial","Smits MM","2019","GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.","Nutrition (Burbank, Los Angeles County, Calif.)","Elsevier BV","10.1016/j.nut.2019.06.005","https://doi.org/10.1016/j.nut.2019.06.005","31415908","https://pubmed.ncbi.nlm.nih.gov/31415908/","https://pure.amsterdamumc.nl/en/publications/4756fe96-e8f2-4d66-a7b7-53fba2ff19d1",null],["2","R0012771","R0012771.pdf","open_download_failed","randomized_trial","Svensson CK","2019","One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.","Acta psychiatrica Scandinavica","Wiley","10.1111/acps.12982","https://doi.org/10.1111/acps.12982","30374965","https://pubmed.ncbi.nlm.nih.gov/30374965/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acps.12982",null],["2","R0013015","R0013015.pdf","open_download_failed","randomized_trial","Thomsen M","2019","Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.","Psychopharmacology","Springer Science and Business Media LLC","10.1007/s00213-018-5089-z","https://doi.org/10.1007/s00213-018-5089-z","30382353","https://pubmed.ncbi.nlm.nih.gov/30382353/","https://www.ncbi.nlm.nih.gov/pmc/articles/6428196",null],["2","R0015523","R0015523.pdf","free_to_read","randomized_trial","Almby KE","2019","Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-19-0171","https://doi.org/10.1530/eje-19-0171","31176298","https://pubmed.ncbi.nlm.nih.gov/31176298/",null,null],["2","R0017888","R0017888.pdf","open_download_failed","randomized_trial","Fang S","2019","[Exendin-4 alleviates oxidative stress and liver fibrosis by activating Nrf2/HO-1 in streptozotocin-induced diabetic mice].","Nan fang yi ke da xue xue bao = Journal of Southern Medical University",null,"10.12122/j.issn.1673-4254.2019.04.13","https://doi.org/10.12122/j.issn.1673-4254.2019.04.13","31068291","https://pubmed.ncbi.nlm.nih.gov/31068291/",null,null],["2","R0019902","R0019902.pdf","open_download_failed","randomized_trial","Anholm C","2019","Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13761","https://doi.org/10.1111/dom.13761","31050161","https://pubmed.ncbi.nlm.nih.gov/31050161/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13761",null],["2","R0021049","R0021049.pdf","free_to_read","randomized_trial","Miras AD","2019","Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30157-3","https://doi.org/10.1016/s2213-8587(19)30157-3","31174993","https://pubmed.ncbi.nlm.nih.gov/31174993/","http://hdl.handle.net/10044/1/85812","ISRCTN:ISRCTN13643081; EudraCT:2014-003923-23"],["2","R0021492","R0021492.pdf","open_download_failed","randomized_trial","Farr OM","2019","Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13827","https://doi.org/10.1111/dom.13827","31282006","https://pubmed.ncbi.nlm.nih.gov/31282006/","https://www.ncbi.nlm.nih.gov/pmc/articles/6800581",null],["2","R0022173","R0022173.pdf","open_download_failed","randomized_trial","Singh A","2019","Diet Composition and Host Genetics Interact to Modulate Gut Microbiota and Predisposition to Metabolic Syndrome in Spontaneously Hypertensive Stroke-Prone Rats (P08-023-19)","Current developments in nutrition","Elsevier BV","10.1093/cdn/nzz044.p08-023-19","https://doi.org/10.1093/cdn/nzz044.p08-023-19",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2475299123153327/pdf",null],["2","R0024119","R0024119.pdf","open_download_failed","randomized_trial","Chao AM","2019","Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.22653","https://doi.org/10.1002/oby.22653","31746553","https://pubmed.ncbi.nlm.nih.gov/31746553/","https://www.ncbi.nlm.nih.gov/pmc/articles/6873814",null],["2","R0024317","R0024317.pdf","open_download_failed","randomized_trial","Vellanki P","2019","Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13587","https://doi.org/10.1111/dom.13587","30456796","https://pubmed.ncbi.nlm.nih.gov/30456796/","https://www.ncbi.nlm.nih.gov/pmc/articles/7231260",null],["2","R0024829","R0024829.pdf","open_download_failed","randomized_trial","Wijkman MO","2019","Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.","Journal of clinical hypertension (Greenwich, Conn.)","Wiley","10.1111/jch.13447","https://doi.org/10.1111/jch.13447","30515978","https://pubmed.ncbi.nlm.nih.gov/30515978/","https://www.ncbi.nlm.nih.gov/pmc/articles/8030426",null],["2","R0025831","R0025831.pdf","free_to_read","randomized_trial","Giblett JP","2019","The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2019.05.013","https://doi.org/10.1016/j.ahj.2019.05.013","31277053","https://pubmed.ncbi.nlm.nih.gov/31277053/","https://www.repository.cam.ac.uk/handle/1810/295369","ClinicalTrials.gov:NCT02127996"],["2","R0026897","R0026897.pdf","free_to_read","randomized_trial","Rossello X","2019","Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome.","European heart journal. Acute cardiovascular care","Oxford University Press (OUP)","10.1177/2048872619845283","https://doi.org/10.1177/2048872619845283","31172789","https://pubmed.ncbi.nlm.nih.gov/31172789/","http://hdl.handle.net/20.500.12105/9483",null],["2","R0028565","R0028565.pdf","open_download_failed","randomized_trial","Vansteelandt S","2019","Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.","Statistics in medicine","Wiley","10.1002/sim.8336","https://doi.org/10.1002/sim.8336","31411779","https://pubmed.ncbi.nlm.nih.gov/31411779/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sim.8336",null],["2","R0031313","R0031313.pdf","no_doi","randomized_trial","Johan Farngren","2019","Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy","Lund University Publications (Lund University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031694","R0031694.pdf","no_doi","randomized_trial","Ludovica F. S. Grasso","2019","PASIREOTIDE-INDUCED HYPERGLYCEMIA INACROMEGALY PATIENTS: EVALUATION OF PATHOPHISIOLOGICAL MECHANISMS AND EFFICACY OF ANTIDIABETIC TREATMENT",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034653","R0034653.pdf","no_doi","randomized_trial","Juraj Koška","2019","Abstract 14727: The Effect of Exenatide Once-Weekly on Carotid Atherosclerosis and Endothelial Function in Persons With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034873","R0034873.pdf","open_download_failed","randomized_trial",null,"2019","Highlights","JAMA","American Medical Association (AMA)","10.1001/jama.2018.15289","https://doi.org/10.1001/jama.2018.15289",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jamanetwork.com/journals/jama/articlepdf/2730602/jama_2019_ii_190015.pdf",null],["2","R0035925","R0035925.pdf","no_doi","randomized_trial","Eyk, H.J. van","2019","A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036144","R0036144.pdf","no_doi","randomized_trial",null,"2019","Efficacy and safety of liraglutide vs placebo in children and adolescents with type 2 diabetes: the ellipse randomised trial results","Dspace Repository (Marmara Üniversitesi)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037756","R0037756.pdf","no_doi","randomized_trial","Jermendy, György","2019","Szemaglutid és a kardiovaszkuláris kockázat – a SUSTAIN-6 vizsgálat eredményei [Semaglutide and cardiovascular risk – results from the SUSTAIN-6 clinical trial]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041968","R0041968.pdf","no_doi","randomized_trial","Barrett, T.","2019","Efficacy and safety of liraglutide vs placebo in children and adolescents with type 2 diabetes: the ellipse randomised trial results","Dspace Repository (Marmara Üniversitesi)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041988","R0041988.pdf","no_doi","randomized_trial","Maurice B. Bizino","2019","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus : randomized placebo-controlled trial (vol 18, pg 55, 2019)","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042229","R0042229.pdf","no_doi","randomized_trial","Suematsu, Natsu","2019","Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study","Kobe University Repository Kernel (Kobe University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042763","R0042763.pdf","open_download_failed","randomized_trial","I‐Ching Cheng","2019","Low‐molecular‐weight fucoidan and high‐stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease—A double‐blind, randomized controlled trial","Advances in digestive medicine","Wiley","10.1002/aid2.13125","https://doi.org/10.1002/aid2.13125",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/aid2.13125",null],["2","R0042867","R0042867.pdf","open_download_failed","randomized_trial","Mrugank Parmar","2019","REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION","International Research Journal of Pharmacy","Moksha Publishing House","10.7897/2230-8407.0912297","https://doi.org/10.7897/2230-8407.0912297",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.7897/2230-8407.0912297",null],["2","R0043032","R0043032.pdf","open_download_failed","randomized_trial",null,"2019","Clinical care and other categories posters: Incretin therapies","Diabetic Medicine","Wiley","10.1111/dme.31_13883","https://doi.org/10.1111/dme.31_13883",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.31_13883",null],["2","R0043194","R0043194.pdf","no_doi","randomized_trial","Guillaume Grenet","2019","Challenges in personalized evidence-based medicine, applications in type 2 diabetes","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043727","R0043727.pdf","open_download_failed","randomized_trial","Natália A. Rocha","2019","Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes","Journal of Diabetes","Wiley","10.1111/1753-0407.12918","https://doi.org/10.1111/1753-0407.12918","31044534","https://pubmed.ncbi.nlm.nih.gov/31044534/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12918",null],["2","R0043776","R0043776.pdf","open_download_failed","randomized_trial","Ko Hanai","2019","CREDENCE: A silver lining in the dark cloud of diabetic nephropathy","Journal of Diabetes Investigation","Wiley","10.1111/jdi.13175","https://doi.org/10.1111/jdi.13175","31705732","https://pubmed.ncbi.nlm.nih.gov/31705732/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.13175",null],["2","R0044030","R0044030.pdf","free_to_read","randomized_trial","Ravinder Goswami","2019","Diabetes mellitus, vitamin D & osteoporosis","The Indian Journal of Medical Research","Scientific Scholar","10.4103/ijmr.ijmr_1920_19","https://doi.org/10.4103/ijmr.ijmr_1920_19","31939384","https://pubmed.ncbi.nlm.nih.gov/31939384/","https://doi.org/10.4103/ijmr.ijmr_1920_19",null],["2","R0044101","R0044101.pdf","no_doi","randomized_trial","Martin Larsson","2019","Save the brain! ; studies on GLP-1-mediated neuroprotection","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044133","R0044133.pdf","no_doi","randomized_trial","Abd El Aziz, Mirna Safia (Dr. med.)","2019","Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies","Dokumentenrepositorium der RUB (Ruhr University Bochum)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044187","R0044187.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2019","The heart in diabetes meeting","Journal of Diabetes","Wiley","10.1111/1753-0407.12973","https://doi.org/10.1111/1753-0407.12973","31373114","https://pubmed.ncbi.nlm.nih.gov/31373114/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12973",null],["2","R0044192","R0044192.pdf","open_download_failed","randomized_trial","Mark Richards","2019","How Does Neprilysin Inhibition in Heart Failure Work?","European Journal of Heart Failure","Oxford University Press (OUP)","10.1002/ejhf.1454","https://doi.org/10.1002/ejhf.1454","30884077","https://pubmed.ncbi.nlm.nih.gov/30884077/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.1454",null],["2","R0044423","R0044423.pdf","open_download_failed","randomized_trial","Matthew R. Weir","2019","Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies","Journal of Diabetes","Wiley","10.1111/1753-0407.12929","https://doi.org/10.1111/1753-0407.12929","31066238","https://pubmed.ncbi.nlm.nih.gov/31066238/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12929",null],["2","R0044705","R0044705.pdf","open_download_failed","randomized_trial","Thomas Schmid","2019","Analogues du GLP-1 : un traitement oral bientôt disponible ?","Revue Médicale Suisse","Medecine et Hygiene","10.53738/revmed.2019.15.666.1840","https://doi.org/10.53738/revmed.2019.15.666.1840",null,"https://pubmed.ncbi.nlm.nih.gov//","https://access.archive-ouverte.unige.ch/access/metadata/b7e803c2-d9be-4177-9e45-873b16f08379/download",null],["2","R0046649","R0046649.pdf","open_download_failed","randomized_trial","Arne Janssen","2019","Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1177/2047487319891783","https://doi.org/10.1177/2047487319891783","31801050","https://pubmed.ncbi.nlm.nih.gov/31801050/","https://academic.oup.com/eurjpc/article-pdf/27/10/1059/34256491/eurjpc1059.pdf",null],["2","R0046977","R0046977.pdf","open_download_failed","randomized_trial","Rhiannon E. Austin","2019","P44 Type 2 diabetes mellitus in children: non-insulin medication, where are we up to?","Archives of Disease in Childhood","BMJ","10.1136/archdischild-2019-esdppp.82","https://doi.org/10.1136/archdischild-2019-esdppp.82",null,"https://pubmed.ncbi.nlm.nih.gov//","https://adc.bmj.com/content/archdischild/104/6/e35.2.full.pdf",null],["2","R0048458","R0048458.pdf","open_download_failed","randomized_trial","Henrik Gudbergsen","2019","OP0011 EFFECT OF LIRAGLUTIDE ON BODY WEIGHT AND PAIN IN THE TREATMENT OF OVERWEIGHT AND KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1136/annrheumdis-2019-eular.1375","https://doi.org/10.1136/annrheumdis-2019-eular.1375",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ard.bmj.com/content/annrheumdis/78/Suppl_2/71.full.pdf",null],["2","R0049036","R0049036.pdf","free_to_read","randomized_trial","Chioma N. Izzi‐Engbeaya","2019","SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men","Journal of the Endocrine Society","The Endocrine Society","10.1210/js.2019-sun-lb044","https://doi.org/10.1210/js.2019-sun-lb044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/js.2019-sun-lb044",null],["2","R0049475","R0049475.pdf","open_download_failed","randomized_trial","David Topitz","2019","Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfz244","https://doi.org/10.1093/ndt/gfz244","31803915","https://pubmed.ncbi.nlm.nih.gov/31803915/","https://academic.oup.com/ndt/article-pdf/35/3/544/34305505/gfz244.pdf","ClinicalTrials.gov:NCT03507829"],["2","R0050019","R0050019.pdf","free_to_read","randomized_trial","Kausik Kumar Ray","2019","P4608BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz745.0991","https://doi.org/10.1093/eurheartj/ehz745.0991",null,"https://pubmed.ncbi.nlm.nih.gov//","https://escholarship.org/uc/item/2x48f7s7",null],["2","R0050020","R0050020.pdf","free_to_read","randomized_trial","Joshua J. Neumiller","2019","How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.05340419","https://doi.org/10.2215/cjn.05340419","31575617","https://pubmed.ncbi.nlm.nih.gov/31575617/","https://www.ncbi.nlm.nih.gov/pmc/articles/6832045",null],["2","R0051291","R0051291.pdf","free_to_read","randomized_trial","Thomas Felix Lüscher","2019","Novel insights into body fat distribution and cardiometabolic risk","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz634","https://doi.org/10.1093/eurheartj/ehz634","31539907","https://pubmed.ncbi.nlm.nih.gov/31539907/","https://www.zora.uzh.ch/handle/20.500.14742/164595",null],["2","R0052818","R0052818.pdf","free_to_read","randomized_trial","Vasiliki K. Katsi","2019","Cardiologist as a cardiometabolic specialist","Journal of Clinical Hypertension","Wiley","10.1111/jch.13636","https://doi.org/10.1111/jch.13636","31355513","https://pubmed.ncbi.nlm.nih.gov/31355513/","https://www.ncbi.nlm.nih.gov/pmc/articles/8030368",null],["2","R0052908","R0052908.pdf","open_download_failed","randomized_trial","Gemma D. Banham","2019","Belimumab in kidney transplantation – Authors' reply","The Lancet","Elsevier BV","10.1016/s0140-6736(18)33066-6","https://doi.org/10.1016/s0140-6736(18)33066-6","30837145","https://pubmed.ncbi.nlm.nih.gov/30837145/","http://www.thelancet.com/article/S0140673618330666/pdf",null],["2","R0053021","R0053021.pdf","free_to_read","randomized_trial","Dan J. Siskind","2019","Metabolic Outcome 12 months Following the end of a Randomised Controlled Trial of Exenatide for Clozapine Associated Obesity and Diabetes",null,"Morressier","10.26226/morressier.5d1a037957558b317a14099e","https://doi.org/10.26226/morressier.5d1a037957558b317a14099e",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/9f116fc1-04c2-4244-999e-8487944d29d6",null],["2","R0053208","R0053208.pdf","free_to_read","randomized_trial","Xiao Zhang","2019","Geographic Variation in Prevalence of Adult Obesity in China: Results From the 2013–2014 National Chronic Disease and Risk Factor Surveillance","Annals of Internal Medicine","American College of Physicians","10.7326/m19-0477","https://doi.org/10.7326/m19-0477","31658469","https://pubmed.ncbi.nlm.nih.gov/31658469/","https://research.utwente.nl/en/publications/a5bb2cdf-6f6f-4fff-834f-9a738543175f",null],["2","R0054124","R0054124.pdf","free_to_read","randomized_trial","Xiaoling Cai","2019","Treatment response between Asian and non-Asian patients with type 2 diabetes","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000000012","https://doi.org/10.1097/cm9.0000000000000012","30628952","https://pubmed.ncbi.nlm.nih.gov/30628952/","https://doi.org/10.1097/cm9.0000000000000012",null],["2","R0054589","R0054589.pdf","open_download_failed","randomized_trial","Abdul Rahim Samad","2019","Effect Of Withania Coagulans And Liraglutide On Serum Glp-1, Postprandial And Fasting Blood Glucose In Streptozotocin Induced Diabetic Rats","Journal of Bahria University Medical and Dental College","Bahria University Medical and Dental College","10.51985/jbumdc2018125","https://doi.org/10.51985/jbumdc2018125",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jbumdc.bahria.edu.pk/index.php/ojs/article/download/353/328",null],["2","R0054860","R0054860.pdf","free_to_read","randomized_trial","Alan S. Kliger","2019","Preserving Kidney Function Instead of Replacing It","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.07820719","https://doi.org/10.2215/cjn.07820719","31594804","https://pubmed.ncbi.nlm.nih.gov/31594804/","https://www.ncbi.nlm.nih.gov/pmc/articles/6946074",null],["2","R0056780","R0056780.pdf","open_download_failed","randomized_trial","Blicher, Thalia Marie","2019","Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","Repository@Hull (Worktribe) (University of Hull)","Elsevier BV","10.1016/s2213-8587%2819%2930192-5","https://doi.org/10.1016/s2213-8587%2819%2930192-5",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thelancet.com/article/S2213858719301925/pdf",null],["2","R0008899","R0008899.pdf","free_to_read","randomized_trial","Knudsen JS","2018","Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.","Diabetes care","American Diabetes Association","10.2337/dc18-0999","https://doi.org/10.2337/dc18-0999","30002200","https://pubmed.ncbi.nlm.nih.gov/30002200/","https://portal.findresearcher.sdu.dk/da/publications/36ac4635-24cb-4c56-bc78-62b6d92d16ab",null],["2","R0011254","R0011254.pdf","free_to_read","randomized_trial","Henry RR","2018","Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.","Diabetes care","American Diabetes Association","10.2337/dc17-1519","https://doi.org/10.2337/dc17-1519","29301824","https://pubmed.ncbi.nlm.nih.gov/29301824/",null,"ClinicalTrials.gov:NCT01785771"],["2","R0011765","R0011765.pdf","free_to_read","randomized_trial","Zaccardi F","2018","Epidemiology of hypoglycaemia : trends, risk factors and outcomes","University of Leicester",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0012037","R0012037.pdf","no_doi","randomized_trial","Pareek M","2018","[Novel antidiabetic drugs and cardiovascular complications].","Ugeskrift for laeger",null,null,"https://doi.org/","29429477","https://pubmed.ncbi.nlm.nih.gov/29429477/",null,null],["2","R0012805","R0012805.pdf","open_download_failed","randomized_trial","Mills EP","2018","Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.","Therapeutic advances in endocrinology and metabolism","SAGE Publications","10.1177/2042018817741852","https://doi.org/10.1177/2042018817741852","29344336","https://pubmed.ncbi.nlm.nih.gov/29344336/","https://www.ncbi.nlm.nih.gov/pmc/articles/5761952",null],["2","R0013009","R0013009.pdf","open_download_failed","randomized_trial","Tonneijck L","2018","Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.","Hypertension (Dallas, Tex. : 1979)","Ovid Technologies (Wolters Kluwer Health)","10.1161/hypertensionaha.117.10740","https://doi.org/10.1161/hypertensionaha.117.10740","29915021","https://pubmed.ncbi.nlm.nih.gov/29915021/","https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.117.10740?download=true",null],["2","R0020232","R0020232.pdf","free_to_read","randomized_trial","Antwi K","2018","Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.","European journal of nuclear medicine and molecular imaging","Springer Science and Business Media LLC","10.1007/s00259-018-4101-5","https://doi.org/10.1007/s00259-018-4101-5","30054698","https://pubmed.ncbi.nlm.nih.gov/30054698/","https://boris.unibe.ch/125775/","ClinicalTrials.gov:NCT02127541"],["2","R0020488","R0020488.pdf","open_download_failed","randomized_trial","Ipsen DH","2018","Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.","Basic & clinical pharmacology & toxicology","Wiley","10.1111/bcpt.13082","https://doi.org/10.1111/bcpt.13082","29953740","https://pubmed.ncbi.nlm.nih.gov/29953740/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcpt.13082",null],["2","R0020715","R0020715.pdf","open_download_failed","randomized_trial","Murphy CF","2018","Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?","Annals of translational medicine","AME Publishing Company","10.21037/atm.2018.03.06","https://doi.org/10.21037/atm.2018.03.06","29951508","https://pubmed.ncbi.nlm.nih.gov/29951508/","https://atm.amegroups.com/article/viewFile/18783/pdf",null],["2","R0020732","R0020732.pdf","free_to_read","randomized_trial","Packer M","2018","Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.1047","https://doi.org/10.1002/ejhf.1047","29082598","https://pubmed.ncbi.nlm.nih.gov/29082598/",null,null],["2","R0021820","R0021820.pdf","open_download_failed","randomized_trial","Ambery PD","2018","MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.","British journal of clinical pharmacology","Wiley","10.1111/bcp.13688","https://doi.org/10.1111/bcp.13688","29926478","https://pubmed.ncbi.nlm.nih.gov/29926478/","https://www.ncbi.nlm.nih.gov/pmc/articles/6138475",null],["2","R0024287","R0024287.pdf","free_to_read","randomized_trial","Ahmed HM","2018","Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehx668","https://doi.org/10.1093/eurheartj/ehx668","29236983","https://pubmed.ncbi.nlm.nih.gov/29236983/",null,null],["2","R0024379","R0024379.pdf","open_download_failed","randomized_trial","Asakura T","2018","Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1448260","https://doi.org/10.1080/03007995.2018.1448260","29504812","https://pubmed.ncbi.nlm.nih.gov/29504812/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1448260?needAccess=true&role=button",null],["2","R0025002","R0025002.pdf","free_to_read","randomized_trial","Su K","2018","Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000000431","https://doi.org/10.1097/mjt.0000000000000431","26844723","https://pubmed.ncbi.nlm.nih.gov/26844723/","https://doi.org/10.1097/mjt.0000000000000431",null],["2","R0025023","R0025023.pdf","open_download_failed","randomized_trial","Mentz RJ","2018","Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.036811","https://doi.org/10.1161/circulationaha.118.036811","30571356","https://pubmed.ncbi.nlm.nih.gov/30571356/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.036811",null],["2","R0025141","R0025141.pdf","open_download_failed","randomized_trial","Gajos G","2018","Diabetes and cardiovascular disease: from new mechanisms to new therapies.","Polish archives of internal medicine","Medycyna Praktyczna","10.20452/pamw.4227","https://doi.org/10.20452/pamw.4227","29579035","https://pubmed.ncbi.nlm.nih.gov/29579035/","https://www.mp.pl/paim/en/node/4227/pdf",null],["2","R0025405","R0025405.pdf","open_download_failed","randomized_trial","Capristo E","2018","Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2017.12.007","https://doi.org/10.1016/j.diabet.2017.12.007","29398254","https://pubmed.ncbi.nlm.nih.gov/29398254/","https://kclpure.kcl.ac.uk/portal/files/84186889/Intensive_lifestyle_modifications_with_CAPRISTO_Firstonline29December2017_GREEN_AAM_CC_BY_NC_ND_.pdf",null],["2","R0025475","R0025475.pdf","open_download_failed","randomized_trial","Polderman JAW","2018","Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial.","Anaesthesia","Wiley","10.1111/anae.14180","https://doi.org/10.1111/anae.14180","29230803","https://pubmed.ncbi.nlm.nih.gov/29230803/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/anae.14180",null],["2","R0025501","R0025501.pdf","open_download_failed","randomized_trial","Tran S","2018","Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00374.2017","https://doi.org/10.1152/ajpendo.00374.2017","29183873","https://pubmed.ncbi.nlm.nih.gov/29183873/","https://www.physiology.org/doi/pdf/10.1152/ajpendo.00374.2017",null],["2","R0026234","R0026234.pdf","free_to_read","randomized_trial","Ibrahim M","2018","Global status of diabetes prevention and prospects for action: A consensus statement.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3021","https://doi.org/10.1002/dmrr.3021","29757486","https://pubmed.ncbi.nlm.nih.gov/29757486/",null,null],["2","R0026948","R0026948.pdf","free_to_read","randomized_trial","Gawrieh S","2018","Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.","Clinics in liver disease","Elsevier BV","10.1016/j.cld.2017.08.013","https://doi.org/10.1016/j.cld.2017.08.013","29128056","https://pubmed.ncbi.nlm.nih.gov/29128056/",null,null],["2","R0026986","R0026986.pdf","free_to_read","randomized_trial","Yamamoto S","2018","Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.03.032","https://doi.org/10.1016/j.diabres.2018.03.032","29588170","https://pubmed.ncbi.nlm.nih.gov/29588170/","https://doi.org/10.1016/j.diabres.2018.03.032","UMIN:UMIN000028313"],["2","R0027172","R0027172.pdf","open_download_failed","randomized_trial","Martinez R","2018","Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.","Diabetes","American Diabetes Association","10.2337/db17-1278","https://doi.org/10.2337/db17-1278","29602791","https://pubmed.ncbi.nlm.nih.gov/29602791/","https://www.ncbi.nlm.nih.gov/pmc/articles/7301339",null],["2","R0028683","R0028683.pdf","open_download_failed","randomized_trial","MacIsaac RJ","2018","Effects of Diabetes Medications Targeting the Incretin System on the Kidney.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.10380917","https://doi.org/10.2215/cjn.10380917","29321176","https://pubmed.ncbi.nlm.nih.gov/29321176/","https://www.ncbi.nlm.nih.gov/pmc/articles/5967437",null],["2","R0031117","R0031117.pdf","no_doi","randomized_trial","Juan Carlos Palma","2018","Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study","Journal of Clinical and Molecular Endocrinology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031374","R0031374.pdf","no_doi","randomized_trial","Simona Ferjan","2018","THE IMPACT OF DEGRADATION INHIBITOR OF GLUCAGON LIKE POLYPEPTIDE 1 ON BODY WEIGHT AND BETA-CELL FUNCTION IN OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME","Repository of the University of Ljubljana (University of Ljubljana)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035198","R0035198.pdf","no_doi","randomized_trial","Hyun Jin Kim","2018","특집 : 제2형 당뇨병 약제치료 지침 2017 개정안: Glucagon-Like Peptide-1 수용체작용제",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035724","R0035724.pdf","free_to_read","randomized_trial",null,"2018","Liraglutide Effects on Gallbladder Emptying: A Randomized Trial in Adults with Overweight or Obesity","International Journal of Nutrology","Thieme Revinter Publicações Ltda","10.1055/s-0038-1674813","https://doi.org/10.1055/s-0038-1674813",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0038-1674813",null],["2","R0036229","R0036229.pdf","no_doi","randomized_trial","Shazia Ali Abdul Samad","2018","Comparison of Postprandial Insulin Levels in Withania Coagulans and Liraglutide Treated Diabetic Rats","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036409","R0036409.pdf","no_doi","randomized_trial","Winkler, Gábor","2018","Új antidiabetikum-csoportok cardiovascularis biztonságossága 2-es típusú diabetesben [Cardiovascular safety of newer antidiabetic compounds in type 2 diabetes]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037885","R0037885.pdf","no_doi","randomized_trial","Chlup, Rudolf","2018","Pathophysiologic Approach to Type 2 Diabetes Management : One Centre Experience 1980‚Äì2020","BiblioBoard Library Catalog (Open Research Library)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040042","R0040042.pdf","no_doi","randomized_trial","Nasser M. Aldekhail","2018","Pharmacotherapy and weight management: efficacy and clinical effectiveness in patients with obesity and type 2 diabetes","Enlighten: Theses (The University of Glasgow)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042656","R0042656.pdf","open_download_failed","randomized_trial",null,"2018","Highlights","JAMA","American Medical Association (AMA)","10.1001/jama.2017.12328","https://doi.org/10.1001/jama.2017.12328",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jamanetwork.com/journals/jama/articlepdf/2678601/jama_2018_ii_180015.pdf",null],["2","R0042974","R0042974.pdf","open_download_failed","randomized_trial",null,"2018","Highlights","JAMA Internal Medicine","American Medical Association (AMA)","10.1001/jamainternmed.2017.5229","https://doi.org/10.1001/jamainternmed.2017.5229",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2698354/jamainternal_2018_ii_180009.pdf",null],["2","R0043354","R0043354.pdf","free_to_read","randomized_trial","Mahima Charan","2018","24. A case of necrotising autoimmune myopathy with recent statin use","Rheumatology Advances in Practice","Oxford University Press (OUP)","10.1093/rap/rky033.015","https://doi.org/10.1093/rap/rky033.015",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/rap/rky033.015",null],["2","R0043567","R0043567.pdf","no_doi","randomized_trial","EM Miller (7814318)","2018","The clinical benefits of IDegLira in DUAL VII were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043819","R0043819.pdf","open_download_failed","randomized_trial","Leona Courtney","2018","Dietetic input is important when starting a GLP‐1 analogue","Practical Diabetes","Wiley","10.1002/pdi.2175","https://doi.org/10.1002/pdi.2175",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2175",null],["2","R0044090","R0044090.pdf","open_download_failed","randomized_trial","Milton Packer","2018","Are Physicians Neglecting the Risk of Heart Failure in Diabetic Patients who are Receiving Sulfonylureas? Lessons from the TOSCA.IT Trial","European Journal of Heart Failure","Oxford University Press (OUP)","10.1002/ejhf.1093","https://doi.org/10.1002/ejhf.1093","29388338","https://pubmed.ncbi.nlm.nih.gov/29388338/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.1093",null],["2","R0044207","R0044207.pdf","open_download_failed","randomized_trial","Miles Fisher","2018","More cardiovascular outcomes trials in people with diabetes: time to change the NICE guidelines","Practical Diabetes","Wiley","10.1002/pdi.2193","https://doi.org/10.1002/pdi.2193",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2193",null],["2","R0044364","R0044364.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2018","Adherence and diabetes","Journal of Diabetes","Wiley","10.1111/1753-0407.12786","https://doi.org/10.1111/1753-0407.12786","29808586","https://pubmed.ncbi.nlm.nih.gov/29808586/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12786",null],["2","R0044442","R0044442.pdf","no_doi","randomized_trial","Jorinde A. W. Polderman","2018","Perioperative hyperglycaemia and its treatment in patients with diabetes mellitus","UvA-DARE (University of Amsterdam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044881","R0044881.pdf","free_to_read","randomized_trial","Kendall R. McEachron","2018","Sitagliptin treatment increases GLP-1 without improving diabetes outcomes after total pancreatectomy with islet autotransplantation","American Journal of Transplantation","Elsevier BV","10.1111/ajt.15119","https://doi.org/10.1111/ajt.15119","30230221","https://pubmed.ncbi.nlm.nih.gov/30230221/","https://doi.org/10.1111/ajt.15119",null],["2","R0045172","R0045172.pdf","free_to_read","randomized_trial","Maurice B. Bizino","2018","Randomised Placebo Controlled Trial to Assess the Effect of Liraglutide on Cardiac Function in Type 2 Diabetes Mellitus Patients","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.3204722","https://doi.org/10.2139/ssrn.3204722",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.3204722",null],["2","R0046986","R0046986.pdf","open_download_failed","randomized_trial","Elaine W. Butterly","2018","ITCA 650","Practical Diabetes","Wiley","10.1002/pdi.2165","https://doi.org/10.1002/pdi.2165",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2165",null],["2","R0047125","R0047125.pdf","free_to_read","randomized_trial","Domenica Rubino","2018","Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials","International Journal of Nutrology","Thieme Revinter Publicações Ltda","10.1055/s-0038-1674366","https://doi.org/10.1055/s-0038-1674366",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0038-1674366",null],["2","R0047165","R0047165.pdf","no_doi","randomized_trial","Dan J. Siskind","2018","Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX): a pilot randomised controlled trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048246","R0048246.pdf","open_download_failed","randomized_trial","Tobias Bomholt","2018","SP426HYPOGLYCAEMIC EPISODES EVALUATED BY CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES AND DIALYSIS-DEPENDENT END-STAGE RENAL DISEASE RANDOMISED TO 12-WEEK LIRAGLUTIDE OR PLACEBO TREATMENT","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfy104.sp426","https://doi.org/10.1093/ndt/gfy104.sp426",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/33/suppl_1/i492/24824571/gfy104.sp426.pdf",null],["2","R0049125","R0049125.pdf","open_download_failed","randomized_trial","Anna S. Pogorelova","2018","Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/2079-701x-2018-4-36-41","https://doi.org/10.21518/2079-701x-2018-4-36-41",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.med-sovet.pro/jour/article/download/2329/2324",null],["2","R0050003","R0050003.pdf","free_to_read","randomized_trial","Estelle Amandine Well","2018","Short term effects of liraglutide versus vildagliptin on insulin secretion and sensitivity in type 2 diabetes (Liravis study)","Pan African Medical Journal Conference Proceedings","Pan African Medical Journal","10.11604/pamj.cp.2017.2.16.46","https://doi.org/10.11604/pamj.cp.2017.2.16.46",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.11604/pamj.cp.2017.2.16.46",null],["2","R0050009","R0050009.pdf","open_download_failed","randomized_trial","В. В. Салухов","2018","Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies","Diabetes Mellitus","Endocrinology Research Centre","10.14341/dm9570","https://doi.org/10.14341/dm9570",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.dia-endojournals.ru/jour/article/download/9570/7290",null],["2","R0050662","R0050662.pdf","open_download_failed","randomized_trial","Chinmay S. Marathe","2018","Gastric Emptying and the Personalized Management of Type 1 Diabetes","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/jc.2018-00849","https://doi.org/10.1210/jc.2018-00849","29788123","https://pubmed.ncbi.nlm.nih.gov/29788123/","https://academic.oup.com/jcem/article-pdf/103/9/3503/25685996/jc.2018-00849.pdf",null],["2","R0051273","R0051273.pdf","free_to_read","randomized_trial","Christina Brock","2018","26-Week Treatment with Liraglutide Reduced Inflammatory Markers But Did Not Reverse Severe Polyneuropathy in Adults with Type 1 Diabetes: A Randomised, Double-Blind, Placebo-Controlled Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.3218713","https://doi.org/10.2139/ssrn.3218713",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.3218713",null],["2","R0052519","R0052519.pdf","open_download_failed","randomized_trial","Ignatios Ikonomidis","2018","P2522The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p2522","https://doi.org/10.1093/eurheartj/ehy565.p2522",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/39/suppl_1/ehy565.P2522/25570955/ehy565.p2522.pdf",null],["2","R0052784","R0052784.pdf","no_doi","randomized_trial","Jakob Schöllhammer Knudsen","2018","Differences between randomized clinical trial patients and real-world initiators of liraglutide","University of Southern Denmark Research Portal (University of Southern Denmark)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0053314","R0053314.pdf","open_download_failed","randomized_trial","Ian A Scott","2018","Selected state of the art research in internal medicine, 2017","Internal Medicine Journal","Wiley","10.1111/imj.13820","https://doi.org/10.1111/imj.13820","29898274","https://pubmed.ncbi.nlm.nih.gov/29898274/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imj.13820",null],["2","R0054739","R0054739.pdf","no_doi","randomized_trial","Manan Pareek","2018","Nye antidiabetiske lægemidler og kardiovaskulære komplikationer","VBN Forskningsportal (Aalborg Universitet)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0010548","R0010548.pdf","free_to_read","randomized_trial","Jørgensen PG","2017","Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12900","https://doi.org/10.1111/dom.12900","28188972","https://pubmed.ncbi.nlm.nih.gov/28188972/",null,null],["2","R0011653","R0011653.pdf","open_download_failed","randomized_trial","Thazhath SS","2017","Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164116666761","https://doi.org/10.1177/1479164116666761","27941058","https://pubmed.ncbi.nlm.nih.gov/27941058/","https://journals.sagepub.com/doi/pdf/10.1177/1479164116666761",null],["2","R0012718","R0012718.pdf","free_to_read","randomized_trial","Kaul S","2017","Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.","Diabetes care","American Diabetes Association","10.2337/dc17-0291","https://doi.org/10.2337/dc17-0291","28637887","https://pubmed.ncbi.nlm.nih.gov/28637887/",null,null],["2","R0014963","R0014963.pdf","free_to_read","randomized_trial","Pozzilli P","2017","Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12937","https://doi.org/10.1111/dom.12937","28294499","https://pubmed.ncbi.nlm.nih.gov/28294499/","http://hdl.handle.net/11268/7191",null],["2","R0015777","R0015777.pdf","free_to_read","randomized_trial","Wang N","2017","Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","S. Karger AG","10.1159/000485776","https://doi.org/10.1159/000485776","29216639","https://pubmed.ncbi.nlm.nih.gov/29216639/","https://doi.org/10.1159/000485776",null],["2","R0016202","R0016202.pdf","open_download_failed","randomized_trial","Smits MM","2017","Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-16-0507","https://doi.org/10.1530/eje-16-0507","27777261","https://pubmed.ncbi.nlm.nih.gov/27777261/","https://eje.bioscientifica.com/downloadpdf/journals/eje/176/1/77.pdf",null],["2","R0017214","R0017214.pdf","open_download_failed","randomized_trial","Salehi P","2017","Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.","Pediatric obesity","Wiley","10.1111/ijpo.12131","https://doi.org/10.1111/ijpo.12131","27071367","https://pubmed.ncbi.nlm.nih.gov/27071367/","https://www.ncbi.nlm.nih.gov/pmc/articles/5288290",null],["2","R0018040","R0018040.pdf","free_to_read","randomized_trial","Secrest MH","2017","The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.","Trends in cardiovascular medicine","Elsevier BV","10.1016/j.tcm.2017.01.009","https://doi.org/10.1016/j.tcm.2017.01.009","28291655","https://pubmed.ncbi.nlm.nih.gov/28291655/","https://escholarship.mcgill.ca/concern/articles/2f75rd450",null],["2","R0018141","R0018141.pdf","open_download_failed","randomized_trial","Ma LL","2017","Letter by Ma et al Regarding Article, \"Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.116.027072","https://doi.org/10.1161/circulationaha.116.027072","28507254","https://pubmed.ncbi.nlm.nih.gov/28507254/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.027072",null],["2","R0018163","R0018163.pdf","free_to_read","randomized_trial","Wiberg S","2017","Response by Wiberg et al to Letter Regarding Article, \"Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.117.027774","https://doi.org/10.1161/circulationaha.117.027774","28507255","https://pubmed.ncbi.nlm.nih.gov/28507255/",null,null],["2","R0019550","R0019550.pdf","open_download_failed","randomized_trial","Jorsal A","2017","Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.657","https://doi.org/10.1002/ejhf.657","27790809","https://pubmed.ncbi.nlm.nih.gov/27790809/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.657",null],["2","R0020414","R0020414.pdf","open_download_failed","randomized_trial","Ekström K","2017","Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.","Scandinavian cardiovascular journal : SCJ","Informa UK Limited","10.1080/14017431.2016.1197417","https://doi.org/10.1080/14017431.2016.1197417","27309633","https://pubmed.ncbi.nlm.nih.gov/27309633/","https://www.tandfonline.com/doi/pdf/10.1080/14017431.2016.1197417?needAccess=true&role=button",null],["2","R0020662","R0020662.pdf","open_download_failed","randomized_trial","Smits MM","2017","The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2016.12.011","https://doi.org/10.1016/j.diabres.2016.12.011","28086201","https://pubmed.ncbi.nlm.nih.gov/28086201/","http://www.diabetesresearchclinicalpractice.com/article/S0168822716303825/pdf",null],["2","R0020775","R0020775.pdf","open_download_failed","randomized_trial","Siskind D","2017","SA47. RCT of Exenatide for Clozapine-Associated Obesity","Schizophrenia bulletin","Oxford University Press (OUP)","10.1093/schbul/sbx023.046","https://doi.org/10.1093/schbul/sbx023.046",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ncbi.nlm.nih.gov/pmc/articles/5475939",null],["2","R0021124","R0021124.pdf","free_to_read","randomized_trial","Scheen AJ","2017","Pharmacological management of type 2 diabetes: what's new in 2017?","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2017.1376652","https://doi.org/10.1080/17512433.2017.1376652","28879786","https://pubmed.ncbi.nlm.nih.gov/28879786/","https://orbi.uliege.be/handle/2268/216142",null],["2","R0021649","R0021649.pdf","open_download_failed","randomized_trial","Santilli F","2017","Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc17-0589","https://doi.org/10.2337/dc17-0589","28912305","https://pubmed.ncbi.nlm.nih.gov/28912305/","https://care.diabetesjournals.org/content/diacare/40/11/1556.full.pdf",null],["2","R0021695","R0021695.pdf","open_download_failed","randomized_trial","Kajiwara M","2017","Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.","Journal of cardiology","Elsevier BV","10.1016/j.jjcc.2016.10.009","https://doi.org/10.1016/j.jjcc.2016.10.009","27894787","https://pubmed.ncbi.nlm.nih.gov/27894787/","http://www.journal-of-cardiology.com/article/S0914508716302684/pdf","UMIN:UMIN000006817"],["2","R0022142","R0022142.pdf","open_download_failed","randomized_trial","Athauda D","2017","Is Exenatide a Treatment for Parkinson's Disease?","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-171192","https://doi.org/10.3233/jpd-171192","28777758","https://pubmed.ncbi.nlm.nih.gov/28777758/","https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd171192?id=journal-of-parkinsons-disease%2Fjpd171192",null],["2","R0022536","R0022536.pdf","open_download_failed","randomized_trial","Scalzo RL","2017","Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.10.003","https://doi.org/10.1016/j.jdiacomp.2016.10.003","27884660","https://pubmed.ncbi.nlm.nih.gov/27884660/","https://www.ncbi.nlm.nih.gov/pmc/articles/5787373",null],["2","R0022926","R0022926.pdf","open_download_failed","randomized_trial","Smits MM","2017","Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.","Diabetes care","American Diabetes Association","10.2337/dc16-0836","https://doi.org/10.2337/dc16-0836","27998910","https://pubmed.ncbi.nlm.nih.gov/27998910/","https://care.diabetesjournals.org/content/diacare/40/3/301.full.pdf",null],["2","R0024372","R0024372.pdf","open_download_failed","randomized_trial","Busch RS","2017","Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.","International journal of clinical practice","Wiley","10.1111/ijcp.13029","https://doi.org/10.1111/ijcp.13029","29044860","https://pubmed.ncbi.nlm.nih.gov/29044860/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13029",null],["2","R0024770","R0024770.pdf","open_download_failed","randomized_trial","Trautmann ME","2017","Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2017.06.004","https://doi.org/10.1016/j.jdiacomp.2017.06.004","28669463","https://pubmed.ncbi.nlm.nih.gov/28669463/","https://www.sciencedirect.com/science/article/pii/S1056872717300351/pdf",null],["2","R0024817","R0024817.pdf","open_download_failed","randomized_trial","Yaşar HY","2017","THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.","Acta endocrinologica (Bucharest, Romania : 2005)","ACTA Endocrinologica Foundation","10.4183/aeb.2017.447","https://doi.org/10.4183/aeb.2017.447","31149215","https://pubmed.ncbi.nlm.nih.gov/31149215/","https://www.ncbi.nlm.nih.gov/pmc/articles/6516540",null],["2","R0025406","R0025406.pdf","open_download_failed","randomized_trial","Garg M","2017","Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12944","https://doi.org/10.1111/dom.12944","28304146","https://pubmed.ncbi.nlm.nih.gov/28304146/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12944",null],["2","R0025852","R0025852.pdf","free_to_read","randomized_trial","Abdul-Ghani M","2017","Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2016-3423","https://doi.org/10.1210/jc.2016-3423","28324038","https://pubmed.ncbi.nlm.nih.gov/28324038/",null,null],["2","R0026053","R0026053.pdf","open_download_failed","randomized_trial","Komajda M","2017","Liraglutide in heart failure: caution is needed.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.707","https://doi.org/10.1002/ejhf.707","28052548","https://pubmed.ncbi.nlm.nih.gov/28052548/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.707",null],["2","R0026112","R0026112.pdf","open_download_failed","randomized_trial","Campbell-Scherer D","2017","Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.","Evidence-based medicine","BMJ","10.1136/ebmed-2016-110652","https://doi.org/10.1136/ebmed-2016-110652","28270434","https://pubmed.ncbi.nlm.nih.gov/28270434/","https://ebm.bmj.com/content/ebmed/22/2/57.full.pdf",null],["2","R0026309","R0026309.pdf","open_download_failed","randomized_trial","Umpierrez GE","2017","Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12930","https://doi.org/10.1111/dom.12930","28256054","https://pubmed.ncbi.nlm.nih.gov/28256054/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12930",null],["2","R0027966","R0027966.pdf","open_download_failed","randomized_trial","Rahelić D","2017","Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.","Annals of medicine","Informa UK Limited","10.1080/07853890.2016.1226514","https://doi.org/10.1080/07853890.2016.1226514","27535028","https://pubmed.ncbi.nlm.nih.gov/27535028/","https://www.tandfonline.com/doi/pdf/10.1080/07853890.2016.1226514?needAccess=true&role=button",null],["2","R0028749","R0028749.pdf","open_download_failed","randomized_trial","Marathe PH","2017","Obesity Week 2016 Annual Meeting.","Journal of diabetes","Wiley","10.1111/1753-0407.12509","https://doi.org/10.1111/1753-0407.12509","27883282","https://pubmed.ncbi.nlm.nih.gov/27883282/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12509",null],["2","R0028751","R0028751.pdf","free_to_read","randomized_trial","Green BP","2017","Metabolic, endocrine and appetite-related responses to acute and daily milk snack consumption in healthy, adolescent males.","Appetite","Elsevier BV","10.1016/j.appet.2016.09.029","https://doi.org/10.1016/j.appet.2016.09.029","27686820","https://pubmed.ncbi.nlm.nih.gov/27686820/","https://doi.org/10.25405/ncl.34297485",null],["2","R0030246","R0030246.pdf","open_download_failed","randomized_trial","Khan F","2017","Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy.","QJM : monthly journal of the Association of Physicians","Oxford University Press (OUP)","10.1093/qjmed/hcx125","https://doi.org/10.1093/qjmed/hcx125","28673015","https://pubmed.ncbi.nlm.nih.gov/28673015/","https://academic.oup.com/qjmed/article-pdf/110/12/853/22866084/hcx125.pdf",null],["2","R0033048","R0033048.pdf","open_download_failed","randomized_trial",null,"2017","This Month in: Anesthesiology","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000001924","https://doi.org/10.1097/aln.0000000000001924",null,"https://pubmed.ncbi.nlm.nih.gov//","https://pubs.asahq.org/anesthesiology/article-pdf/127/5/A1/379914/20171100_0-00003.pdf",null],["2","R0038296","R0038296.pdf","free_to_read","randomized_trial","Lili Tong","2017","Diabetic Kidney Disease","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.04650417","https://doi.org/10.2215/cjn.04650417","29046291","https://pubmed.ncbi.nlm.nih.gov/29046291/","https://www.ncbi.nlm.nih.gov/pmc/articles/5967422",null],["2","R0039761","R0039761.pdf","open_download_failed","randomized_trial","Juan Carlos Palma","2017","Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study","Revista Médica Del Hospital General De México","Elsevier BV","10.1016/j.hgmx.2017.03.001","https://doi.org/10.1016/j.hgmx.2017.03.001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S0185106317300094/pdf",null],["2","R0042478","R0042478.pdf","no_doi","randomized_trial","Ruifeng Li","2017","To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children","Biomedical Research-tokyo",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042545","R0042545.pdf","open_download_failed","randomized_trial","Dirk von Lewinski","2017","Antidiabetics and Heart Failure - Large Trials but Little Mechanistic Insight","Journal of Clinical and Molecular Endocrinology","Scitechnol Biosoft Pvt. Ltd.","10.21767/2572-5432.100037","https://doi.org/10.21767/2572-5432.100037",null,"https://pubmed.ncbi.nlm.nih.gov//","http://clinical-and-molecular-endocrinology.imedpub.com/antidiabetics-and-heart-failure--large-trials-but-little-mechanistic-insight.pdf",null],["2","R0042571","R0042571.pdf","open_download_failed","randomized_trial",null,"2017","Highlights","JAMA","American Medical Association (AMA)","10.1001/jama.2016.13355","https://doi.org/10.1001/jama.2016.13355",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jamanetwork.com/journals/jama/articlepdf/2657362/jama_2017_ii_170039.pdf",null],["2","R0042609","R0042609.pdf","open_download_failed","randomized_trial","Evangelos K. Oikonomou","2017","Clinical and translational science in cardiovascular research: highlights from the American Heart Association Scientific Sessions 2017","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvx233","https://doi.org/10.1093/cvr/cvx233","29202178","https://pubmed.ncbi.nlm.nih.gov/29202178/","https://academic.oup.com/cardiovascres/article-pdf/114/1/e6/30033906/cvx233.pdf",null],["2","R0042857","R0042857.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2017","Non‐alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control","Journal of Diabetes","Wiley","10.1111/1753-0407.12566","https://doi.org/10.1111/1753-0407.12566","28513098","https://pubmed.ncbi.nlm.nih.gov/28513098/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12566",null],["2","R0043441","R0043441.pdf","free_to_read","randomized_trial","Andrew J. Krentz","2017","Metformin: new insights into an archetypal cardiometabolic drug","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000129","https://doi.org/10.1097/xce.0000000000000129","31646125","https://pubmed.ncbi.nlm.nih.gov/31646125/","https://www.ncbi.nlm.nih.gov/pmc/articles/6768509",null],["2","R0043597","R0043597.pdf","open_download_failed","randomized_trial","Iona Galloway","2017","Omarigliptin","Practical Diabetes","Wiley","10.1002/pdi.2086","https://doi.org/10.1002/pdi.2086",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2086",null],["2","R0043608","R0043608.pdf","free_to_read","randomized_trial","Yu Maria","2017","Improved treatment satisfaction with dulaglutide and insulin glargine in patients with T2D and chronic kidney disease",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3bda","https://doi.org/10.26226/morressier.59d51846d462b80296ca3bda",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/d60a3e05-298f-461d-97a9-eb99cc92dea2",null],["2","R0043709","R0043709.pdf","free_to_read","randomized_trial","Maja Baretić","2017","The hunger games: taste, GLP-1 and female gender involved",null,"Morressier","10.26226/morressier.59d51846d462b80296ca2e52","https://doi.org/10.26226/morressier.59d51846d462b80296ca2e52",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/5c05b709-c289-4c5b-b2a2-abd7ecaf0efa",null],["2","R0043769","R0043769.pdf","no_doi","randomized_trial","Melanie Davies (545715)","2017","Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","The Medicine Forum",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043782","R0043782.pdf","free_to_read","randomized_trial","Jeroen Hermanides","2017","A randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in patients with diabetes – PILGRIM trial",null,"Morressier","10.26226/morressier.58f5b033d462b80296c9ddb3","https://doi.org/10.26226/morressier.58f5b033d462b80296c9ddb3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/cc7a50f4-9ef1-47ba-b93a-519e2f6171e0",null],["2","R0043791","R0043791.pdf","free_to_read","randomized_trial","Bowden Georgina","2017","Characteristics and glycemic outcomes of T2D patients titrated to 60 U/day iGlarLixi vs insulin in the LixiLan-L trial",null,"Morressier","10.26226/morressier.59d51845d462b80296ca34ab","https://doi.org/10.26226/morressier.59d51845d462b80296ca34ab",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/997932cc-bb95-445d-9c67-2c89d368d81c",null],["2","R0043802","R0043802.pdf","open_download_failed","randomized_trial","Chih Wong","2017","Inconclusive effects of once‐weekly exenatide on cardiovascular outcomes in type 2 diabetes","Practical Diabetes","Wiley","10.1002/pdi.2140","https://doi.org/10.1002/pdi.2140",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2140",null],["2","R0043943","R0043943.pdf","free_to_read","randomized_trial","ueno shinji","2017","Comparison of short- and long-acting GLP-1RA on glucose excursion, insulin/glucagon secretions and gastric emptying",null,"Morressier","10.26226/morressier.59d51845d462b80296ca346f","https://doi.org/10.26226/morressier.59d51845d462b80296ca346f",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/4d38529e-7060-4e89-bb66-bc31349733a2",null],["2","R0043995","R0043995.pdf","free_to_read","randomized_trial","Altamash Shaikh","2017","Sulfonylureas: Scoring beyond START STUDY","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_322_17","https://doi.org/10.4103/ijem.ijem_322_17","29285461","https://pubmed.ncbi.nlm.nih.gov/29285461/","https://doi.org/10.4103/ijem.ijem_322_17",null],["2","R0044047","R0044047.pdf","no_doi","randomized_trial","Uchenna Anyanwagu","2017","Cardiovascular and metabolic outcomes associated with insulin use in type 2 diabetes : evidence from insulin users in the UK primary care","Nottingham ePrints (University of Nottingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044246","R0044246.pdf","free_to_read","randomized_trial","Kumkum Patel","2017","Hormonal Management of Small Bowel Failure","Clinical and Translational Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1038/ctg.2017.32","https://doi.org/10.1038/ctg.2017.32","28662020","https://pubmed.ncbi.nlm.nih.gov/28662020/","https://doi.org/10.1038/ctg.2017.32",null],["2","R0044415","R0044415.pdf","open_download_failed","randomized_trial","Clare Shaban","2017","‘What sort of diabetes have I got?’ The importance of a label","Practical Diabetes","Wiley","10.1002/pdi.2114","https://doi.org/10.1002/pdi.2114",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2114",null],["2","R0044488","R0044488.pdf","free_to_read","randomized_trial","J. Hans DeVries","2017","DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!","Diabetes Care","American Diabetes Association","10.2337/dci16-0035","https://doi.org/10.2337/dci16-0035","28108536","https://pubmed.ncbi.nlm.nih.gov/28108536/","https://pure.amsterdamumc.nl/en/publications/0059aafa-78e6-4a8d-a90d-2317ec67d79f",null],["2","R0044895","R0044895.pdf","open_download_failed","randomized_trial","William T. Cefalu","2017","Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201","Diabetes Care","American Diabetes Association","10.2337/dci16-0036","https://doi.org/10.2337/dci16-0036","28108540","https://pubmed.ncbi.nlm.nih.gov/28108540/","https://care.diabetesjournals.org/content/diacare/40/2/e23.full.pdf",null],["2","R0045274","R0045274.pdf","free_to_read","randomized_trial","New John","2017","Effectiveness and safety of ITCA 650 vs currently available GLP-1 RAs in type 2 diabetes: a phase IIIb, pragmatic RCT",null,"Morressier","10.26226/morressier.59d5184ed462b80296ca2ba0","https://doi.org/10.26226/morressier.59d5184ed462b80296ca2ba0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/1e9d6a34-be39-42db-9ac4-175a946a0ff1",null],["2","R0047237","R0047237.pdf","open_download_failed","randomized_trial","Thomas Andersen Schmidt","2017","Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: is there hope?","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvx026","https://doi.org/10.1093/ehjcvp/pvx026","29315396","https://pubmed.ncbi.nlm.nih.gov/29315396/","https://academic.oup.com/ehjcvp/article-pdf/4/1/4/23029167/pvx026.pdf",null],["2","R0047267","R0047267.pdf","no_doi","randomized_trial","D Tsanova","2017","Мрежов метаанализ разход/ефективност на неинсулиновите антидиабетни препарати","Conference proceedings - IEEE Instrumentation/Measurement Technology Conference",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047274","R0047274.pdf","open_download_failed","randomized_trial","Abigail E. Dove","2017","35th Annual J . P . M organ healthcare conference","Journal of Diabetes","Wiley","10.1111/1753-0407.12532","https://doi.org/10.1111/1753-0407.12532","28111923","https://pubmed.ncbi.nlm.nih.gov/28111923/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12532",null],["2","R0048754","R0048754.pdf","open_download_failed","randomized_trial","Rasmus Stilling Tougaard","2017","247The glucagon-like peptide 1 agonist liraglutide increases heart rate in heart failure patients","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehx501.247","https://doi.org/10.1093/eurheartj/ehx501.247",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/38/suppl_1/ehx501.247/19618686/ehx501.247.pdf",null],["2","R0051610","R0051610.pdf","open_download_failed","randomized_trial","Justin Adrian Ezekowitz","2017","Diabetes and Heart Failure in the Crosshairs: Where is the Target?","European Journal of Heart Failure","Oxford University Press (OUP)","10.1002/ejhf.703","https://doi.org/10.1002/ejhf.703","28052547","https://pubmed.ncbi.nlm.nih.gov/28052547/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.703",null],["2","R0008016","R0008016.pdf","open_download_failed","randomized_trial","Waldrop G","2016","Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2015.12.058","https://doi.org/10.1016/j.jacc.2015.12.058","27012410","https://pubmed.ncbi.nlm.nih.gov/27012410/","https://www.sciencedirect.com/science/article/pii/S073510971600320X/pdf",null],["2","R0013069","R0013069.pdf","open_download_failed","randomized_trial","Ten Kulve JS","2016","Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc15-0772","https://doi.org/10.2337/dc15-0772","26283736","https://pubmed.ncbi.nlm.nih.gov/26283736/","https://care.diabetesjournals.org/content/diacare/39/2/214.full.pdf",null],["2","R0014167","R0014167.pdf","free_to_read","randomized_trial","Farngren J","2016","Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc15-1274","https://doi.org/10.2337/dc15-1274","26537183","https://pubmed.ncbi.nlm.nih.gov/26537183/","https://lup.lub.lu.se/record/8243127","ClinicalTrials.gov:NCT02020629"],["2","R0014847","R0014847.pdf","open_download_failed","randomized_trial","Roos ST","2016","No benefit of additional treatment with exenatide in patients with an acute myocardial infarction.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2016.06.283","https://doi.org/10.1016/j.ijcard.2016.06.283","27394978","https://pubmed.ncbi.nlm.nih.gov/27394978/","http://www.internationaljournalofcardiology.com/article/S0167527316312906/pdf",null],["2","R0016180","R0016180.pdf","free_to_read","randomized_trial","Fulcher G","2016","Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12589","https://doi.org/10.1111/dom.12589","26450639","https://pubmed.ncbi.nlm.nih.gov/26450639/","https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_canagliflozin_when_used_in_conjunction_with_incretin-mimetic_therapy_in_patients_with_type_2_diabetes/20641320",null],["2","R0017831","R0017831.pdf","free_to_read","randomized_trial","Flory JH","2016","Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-016-0633-y","https://doi.org/10.1007/s11883-016-0633-y","27817160","https://pubmed.ncbi.nlm.nih.gov/27817160/","https://www.ncbi.nlm.nih.gov/pmc/articles/5509052",null],["2","R0018695","R0018695.pdf","no_doi","randomized_trial",null,"2016","liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.","Prescrire international",null,null,"https://doi.org/","26942248","https://pubmed.ncbi.nlm.nih.gov/26942248/",null,null],["2","R0018907","R0018907.pdf","free_to_read","randomized_trial","Sharaf SE","2016","The effect of exercise in NAFLD and a GLP-1 receptor agonist in type 2 diabetes on lipid metabolism","University of Surrey",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0019526","R0019526.pdf","open_download_failed","randomized_trial","Farr OM","2016","Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2016.03.009","https://doi.org/10.1016/j.metabol.2016.03.009","27282865","https://pubmed.ncbi.nlm.nih.gov/27282865/","https://www.ncbi.nlm.nih.gov/pmc/articles/4902873",null],["2","R0021287","R0021287.pdf","open_download_failed","randomized_trial","Lu HI","2016","Exendin-4 therapy still offered an additional benefit on reducing transverse aortic constriction-induced cardiac hypertrophy-caused myocardial damage in DPP-4 deficient rats.","American journal of translational research",null,null,"https://doi.org/","27158369","https://pubmed.ncbi.nlm.nih.gov/27158369/",null,null],["2","R0021472","R0021472.pdf","free_to_read","randomized_trial","Jermendy G","2016","[Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].","Orvosi hetilap","Akademiai Kiado Zrt.","10.1556/650.2016.30409","https://doi.org/10.1556/650.2016.30409","27017851","https://pubmed.ncbi.nlm.nih.gov/27017851/",null,null],["2","R0023954","R0023954.pdf","open_download_failed","randomized_trial","van Raalte DH","2016","Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-16-0286","https://doi.org/10.1530/eje-16-0286","27466218","https://pubmed.ncbi.nlm.nih.gov/27466218/","https://eje.bioscientifica.com/downloadpdf/journals/eje/175/4/345.pdf",null],["2","R0024578","R0024578.pdf","free_to_read","randomized_trial","Monnier L","2016","Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981.","Diabetes care","American Diabetes Association","10.2337/dc16-1133","https://doi.org/10.2337/dc16-1133","27660130","https://pubmed.ncbi.nlm.nih.gov/27660130/",null,null],["2","R0024590","R0024590.pdf","free_to_read","randomized_trial","O'Brien KD","2016","Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981.","Diabetes care","American Diabetes Association","10.2337/dci16-0021","https://doi.org/10.2337/dci16-0021","27660131","https://pubmed.ncbi.nlm.nih.gov/27660131/",null,null],["2","R0025187","R0025187.pdf","free_to_read","randomized_trial","de Lapertosa SB","2016","The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2016.10.001","https://doi.org/10.1016/j.diabres.2016.10.001","27776251","https://pubmed.ncbi.nlm.nih.gov/27776251/","https://doi.org/10.1016/j.diabres.2016.10.001",null],["2","R0025259","R0025259.pdf","free_to_read","randomized_trial","Bolen S","2016","Diabetes Medications for Adults With Type 2 Diabetes: An Update","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","27227214","https://pubmed.ncbi.nlm.nih.gov/27227214/",null,null],["2","R0025523","R0025523.pdf","open_download_failed","randomized_trial","Azoulay L","2016","Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2016.1522","https://doi.org/10.1001/jamainternmed.2016.1522","27479930","https://pubmed.ncbi.nlm.nih.gov/27479930/","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2540537/ioi160023.pdf",null],["2","R0025878","R0025878.pdf","open_download_failed","randomized_trial","Ilkowitz JT","2016","Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296816647976","https://doi.org/10.1177/1932296816647976","27184690","https://pubmed.ncbi.nlm.nih.gov/27184690/","https://www.ncbi.nlm.nih.gov/pmc/articles/5032955",null],["2","R0025913","R0025913.pdf","open_download_failed","randomized_trial","de Wit HM","2016","Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.","Journal of internal medicine","Wiley","10.1111/joim.12447","https://doi.org/10.1111/joim.12447","26553486","https://pubmed.ncbi.nlm.nih.gov/26553486/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/joim.12447",null],["2","R0026282","R0026282.pdf","open_download_failed","randomized_trial","Roussel R","2016","Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2015.1100998","https://doi.org/10.3111/13696998.2015.1100998","26413789","https://pubmed.ncbi.nlm.nih.gov/26413789/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1100998?needAccess=true&role=button",null],["2","R0026504","R0026504.pdf","open_download_failed","randomized_trial","Cegla J","2016","Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study.","Annals of clinical biochemistry","SAGE Publications","10.1177/0004563216648250","https://doi.org/10.1177/0004563216648250","28071092","https://pubmed.ncbi.nlm.nih.gov/28071092/","https://journals.sagepub.com/doi/pdf/10.1177/0004563216648250",null],["2","R0027229","R0027229.pdf","free_to_read","randomized_trial","Jermendy G","2016","[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].","Orvosi hetilap","Akademiai Kiado Zrt.","10.1556/650.2016.30416","https://doi.org/10.1556/650.2016.30416","27063427","https://pubmed.ncbi.nlm.nih.gov/27063427/",null,null],["2","R0028752","R0028752.pdf","open_download_failed","randomized_trial","Clayton DJ","2016","Effect of 24-h severe energy restriction on appetite regulation and ad libitum energy intake in lean men and women.","The American journal of clinical nutrition","Elsevier BV","10.3945/ajcn.116.136937","https://doi.org/10.3945/ajcn.116.136937","27806971","https://pubmed.ncbi.nlm.nih.gov/27806971/","https://academic.oup.com/ajcn/article-pdf/104/6/1545/23774198/ajcn136937.pdf","ClinicalTrials.gov:NCT02696772"],["2","R0028768","R0028768.pdf","open_download_failed","randomized_trial","Steg PG","2016","Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.116.021914","https://doi.org/10.1161/circulationaha.116.021914","27550966","https://pubmed.ncbi.nlm.nih.gov/27550966/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.021914?download=true",null],["2","R0028801","R0028801.pdf","open_download_failed","randomized_trial","Bloomgarden Z","2016","Glycemic control and the heart: it matters how you get there.","Journal of diabetes","Wiley","10.1111/1753-0407.12398","https://doi.org/10.1111/1753-0407.12398","26990043","https://pubmed.ncbi.nlm.nih.gov/26990043/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12398",null],["2","R0030295","R0030295.pdf","open_download_failed","randomized_trial","Scott RA","2016","A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.","Science translational medicine","American Association for the Advancement of Science (AAAS)","10.1126/scitranslmed.aad3744","https://doi.org/10.1126/scitranslmed.aad3744","27252175","https://pubmed.ncbi.nlm.nih.gov/27252175/","https://www.research.ed.ac.uk/files/29263256/Genomic_approach_to_therapeutic_target_validation.pdf",null],["2","R0030633","R0030633.pdf","no_doi","randomized_trial","Omorogieva Ojo","2016","The role of Exenatide in managing cardiovascular risks and complications in patients with type 2 diabetes","Journal of Diabetes & Metabolism",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031096","R0031096.pdf","no_doi","randomized_trial","Adnan Zaina","2016","Diabetic Patients Fasting During Ramadan: Ten Years Overview","Diabetes Management",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034211","R0034211.pdf","no_doi","randomized_trial","Yaping Luo","2016","Gelofusine is effective in reducing renal uptake of 68Ga-exendin-4 and contributes to better quantification of pancreatic β cell mass","Journal of Nuclear Medicine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035138","R0035138.pdf","no_doi","randomized_trial","김소헌","2016","시론 : 당뇨병 약제들의 심혈관계 효과와 그와 관련된 대규모 임상연구에 대한 고찰",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036903","R0036903.pdf","free_to_read","randomized_trial","Nae‐Yun Heo","2016","Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?","Korean Journal of Gastroenterology","The Korean Society of Gastroenterology","10.4166/kjg.2016.67.5.286","https://doi.org/10.4166/kjg.2016.67.5.286",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4166/kjg.2016.67.5.286",null],["2","R0037215","R0037215.pdf","free_to_read","randomized_trial","Ian H. de Boer","2016","SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2016060650","https://doi.org/10.1681/asn.2016060650","27539605","https://pubmed.ncbi.nlm.nih.gov/27539605/","https://www.ncbi.nlm.nih.gov/pmc/articles/5198295","ClinicalTrials.gov:NCT02065791"],["2","R0038924","R0038924.pdf","free_to_read","randomized_trial","AlokKumar Singh","2016","Journal watch","Heart India","Ovid Technologies (Wolters Kluwer Health)","10.4103/2321-449x.190756","https://doi.org/10.4103/2321-449x.190756",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2321-449x.190756",null],["2","R0040642","R0040642.pdf","no_doi","randomized_trial","Stephen C. Bain","2016","REVIEW The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040648","R0040648.pdf","no_doi","randomized_trial","Y. Seino","2016","in a l a",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040650","R0040650.pdf","no_doi","randomized_trial","An Investigator-initiated","2016","OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040691","R0040691.pdf","no_doi","randomized_trial","David Russell-jones Md","2016","Efficacy and Safety of Exenatide Once WeeklyVersusMetformin,Pioglitazone, and Sitagliptin Used asMonotherapy in Drug-Naive PatientsWith Type 2 Diabetes (DURATION-4)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040721","R0040721.pdf","no_doi","randomized_trial","Exocrine Pancreas Dysplasia","2016","Diabetes 2013;62:2595–2604",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040732","R0040732.pdf","no_doi","randomized_trial","Julio Rosenstock Md","2016","TheFateofTaspoglutide,aWeeklyGLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2Diabetes The T-emerge 2 trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040733","R0040733.pdf","no_doi","randomized_trial","A -week","2016","AddingOnce-DailyLixisenatideforType2 Diabetes Inadequately ControlledWith Newly Initiated and Continuously Titrated Basal Insulin Glargine",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040770","R0040770.pdf","no_doi","randomized_trial",null,"2016","Objectives",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040781","R0040781.pdf","no_doi","randomized_trial","Javier Escalada-san","2016","ORIGINAL RESEARCH Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040811","R0040811.pdf","no_doi","randomized_trial","Thomas Fremming Dejgaard","2016","The Lira-1 study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040833","R0040833.pdf","no_doi","randomized_trial","Matthew C. Riddle","2016","Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040850","R0040850.pdf","no_doi","randomized_trial","Matteo Monami","2016","Word count: 2,442 Address for correspondence:",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040862","R0040862.pdf","no_doi","randomized_trial",null,"2016","OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040885","R0040885.pdf","no_doi","randomized_trial","Liraglutidereduces Insulindosewithout","2016","Loss of Glycemic Control in Type 1 Diabetic PatientsWith andWithout Residual b-Cell Function URD KIELGAST, MD1,2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040920","R0040920.pdf","no_doi","randomized_trial","Thomas Fremming Dejgaard","2016","The Lira-1 study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040921","R0040921.pdf","no_doi","randomized_trial",null,"2016","a Randomized Controlled Trial (AWARD-5) Diabetes Care 2014;37:2149–2158 | DOI: 10.2337/dc13-2761 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040923","R0040923.pdf","no_doi","randomized_trial",null,"2016","Objectives",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040976","R0040976.pdf","no_doi","randomized_trial","The T-emerge Trial","2016","TheFateofTaspoglutide,aWeeklyGLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040979","R0040979.pdf","no_doi","randomized_trial","Matthew C. Riddle","2016","Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by EstablishedBasal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040982","R0040982.pdf","no_doi","randomized_trial","Tanya Simunia","2016","Commentary Is Exenatide the Next Big Thing in Parkinson’s Disease?",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040995","R0040995.pdf","no_doi","randomized_trial","Annette Horstmann","2016","Exenatide-Induced Reduction in Energy Intake Is AssociatedWith Increase in Hypothalamic Connectivity",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041004","R0041004.pdf","no_doi","randomized_trial","Itamar Raz Md","2016","Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24Weeks of Treatment Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041012","R0041012.pdf","no_doi","randomized_trial","Richard E. Pratley","2016","PatientsWith Type 2 Diabetes A randomized, open-label trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041038","R0041038.pdf","no_doi","randomized_trial","Ole Schmitz","2016","INTERNATIONAL STUDY GROUP",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041070","R0041070.pdf","no_doi","randomized_trial","Individualswith Prediabetes","2016","Benefits of Liraglutide Treatment in Overweight and Obese Older",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041071","R0041071.pdf","no_doi","randomized_trial","Jean-francois Gautier","2016","ORIGINAL RESEARCH Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041080","R0041080.pdf","no_doi","randomized_trial","Haiko Schlögl Md","2016","Exenatide-Induced Reduction in Energy Intake Is AssociatedWith Increase in Hypothalamic Connectivity",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041081","R0041081.pdf","no_doi","randomized_trial","Lise L Gluud","2016","Correspondence to",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041097","R0041097.pdf","no_doi","randomized_trial","Helle Harder","2016","Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041104","R0041104.pdf","no_doi","randomized_trial","Diabetes Mellitus","2016","Clinical Study Study of Postprandial Lipaemia in Type 2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041106","R0041106.pdf","no_doi","randomized_trial",null,"2016","Press Release",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041107","R0041107.pdf","no_doi","randomized_trial",null,"2016","Exploratory Trial of Intranasal Administration of Glucagon-Like Peptide-1 in Japanese Patients With Type 2 Diabetes Diabetes Care 2014;37:2024–2027 | DOI: 10.2337/dc13-0690 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041183","R0041183.pdf","no_doi","randomized_trial","Monotherapy Versusmetformin In","2016","Controlled Trial (AWARD-3) DOI: 10.2337/dc13-2759 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041193","R0041193.pdf","no_doi","randomized_trial","Arina Miyoshi","2016","RESEARCH ARTICLE A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041199","R0041199.pdf","no_doi","randomized_trial","A Randomized Trial","2016","Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041200","R0041200.pdf","no_doi","randomized_trial",null,"2016","Objectives",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041215","R0041215.pdf","no_doi","randomized_trial","Controlled Trial","2016","One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041249","R0041249.pdf","no_doi","randomized_trial",null,"2016","Objectives",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041275","R0041275.pdf","no_doi","randomized_trial","Samit Ghosal","2016","Review Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041297","R0041297.pdf","no_doi","randomized_trial","Weight Loss","2016","OBJECTIVE — In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study,",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041333","R0041333.pdf","no_doi","randomized_trial",null,"2016","Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041339","R0041339.pdf","no_doi","randomized_trial","Monotherapy Versusmetformin In","2016","Controlled Trial (AWARD-3) Diabetes Care 2014;37:2168–2176 | DOI: 10.2337/dc13-2759 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041345","R0041345.pdf","no_doi","randomized_trial",null,"2016","Exploratory Trial of Intranasal Administration of Glucagon-like Peptide-1 in Japanese Patients With Type 2 Diabetes OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042573","R0042573.pdf","open_download_failed","randomized_trial","Basil S. Lewis","2016","Cardiovascular pharmacotherapy—2015 was a good year","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvw020","https://doi.org/10.1093/ehjcvp/pvw020","27600902","https://pubmed.ncbi.nlm.nih.gov/27600902/","https://academic.oup.com/ehjcvp/article-pdf/2/4/209/6722463/pvw020.pdf",null],["2","R0042924","R0042924.pdf","open_download_failed","randomized_trial","Rowan Hillson","2016","NICE : type 2 diabetes in adults, 2015","Practical Diabetes","Wiley","10.1002/pdi.1989","https://doi.org/10.1002/pdi.1989",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1989",null],["2","R0042941","R0042941.pdf","no_doi","randomized_trial",null,"2016","DOI 10.1186/s13098-015-0116-2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043147","R0043147.pdf","open_download_failed","randomized_trial",null,"2016","Highlights","JAMA","American Medical Association (AMA)","10.1001/jama.2015.14406","https://doi.org/10.1001/jama.2015.14406",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jamanetwork.com/journals/jama/articlepdf/2540384/jii160030.pdf",null],["2","R0043275","R0043275.pdf","free_to_read","randomized_trial","Margaret K. Yu","2016","Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.10361016","https://doi.org/10.2215/cjn.10361016","27827307","https://pubmed.ncbi.nlm.nih.gov/27827307/","https://www.ncbi.nlm.nih.gov/pmc/articles/5142075",null],["2","R0043342","R0043342.pdf","open_download_failed","randomized_trial",null,"2016","Erratum","Journal of Diabetes Investigation","Wiley","10.1111/jdi.12470","https://doi.org/10.1111/jdi.12470","27042283","https://pubmed.ncbi.nlm.nih.gov/27042283/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.12470",null],["2","R0043641","R0043641.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2016","Treatment: Concepts and new developments","Journal of Diabetes","Wiley","10.1111/1753-0407.12381","https://doi.org/10.1111/1753-0407.12381","26854013","https://pubmed.ncbi.nlm.nih.gov/26854013/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12381",null],["2","R0043715","R0043715.pdf","open_download_failed","randomized_trial","Rachel Livingstone","2016","LEADER and the new ‘cardiovascular’ glucose‐lowering agents","Practical Diabetes","Wiley","10.1002/pdi.2033","https://doi.org/10.1002/pdi.2033",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.2033",null],["2","R0043873","R0043873.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2016","Dipeptidyl peptidase‐4 inhibitor approaches","Journal of Diabetes","Wiley","10.1111/1753-0407.12476","https://doi.org/10.1111/1753-0407.12476","27576300","https://pubmed.ncbi.nlm.nih.gov/27576300/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12476",null],["2","R0043882","R0043882.pdf","free_to_read","randomized_trial","Awadhesh Kumar Singh","2016","Efficacy and safety of teneligliptin","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.193163","https://doi.org/10.4103/2230-8210.193163","28217491","https://pubmed.ncbi.nlm.nih.gov/28217491/","https://doi.org/10.4103/2230-8210.193163",null],["2","R0043965","R0043965.pdf","free_to_read","randomized_trial","Sergey V. Kakorin","2016","Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)","Diabetes Mellitus","Endocrinology Research Centre","10.14341/dm2003422-27","https://doi.org/10.14341/dm2003422-27",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14341/dm2003422-27",null],["2","R0044259","R0044259.pdf","open_download_failed","randomized_trial","Helen X. Gao","2016","10th International conference on advanced technologies & treatments for diabetes","Journal of Diabetes","Wiley","10.1111/1753-0407.12415","https://doi.org/10.1111/1753-0407.12415","27100744","https://pubmed.ncbi.nlm.nih.gov/27100744/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12415",null],["2","R0044780","R0044780.pdf","no_doi","randomized_trial",null,"2016","The role of Exenatide in managing cardiovascular risks and complications in patients with type 2 diabetes","Greenwich Academic Literature Archive (University of Greenwich)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047847","R0047847.pdf","no_doi","randomized_trial","Per Lundkvist","2016","Metabolic effects of dapagliflozin QD and exenatide QW in obese adults without diabetes : a 24-week randomised placebo-controlled phase 2 study","Diabetologia",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0047873","R0047873.pdf","open_download_failed","randomized_trial","Weena Jing Yan Chen","2016","EFFECTS OF EXENATIDE ON CARDIAC FUNCTION, PERFUSION, AND ENERGETICS IN TYPE 2 DIABETIC PATIENTS WITH CARDIOMYOPATHY: A RANDOMIZED CONTROLLED TRIAL AGAINST INSULIN GLARGINE","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(16)31353-5","https://doi.org/10.1016/s0735-1097(16)31353-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S0735109716313535/pdf",null],["2","R0048316","R0048316.pdf","free_to_read","randomized_trial","Lyudmila Alexandrovna Ruyatkina","2016","Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/2079-701x-2016-4-100-109","https://doi.org/10.21518/2079-701x-2016-4-100-109",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21518/2079-701x-2016-4-100-109",null],["2","R0048430","R0048430.pdf","free_to_read","randomized_trial","Aldo Pietro Maggioni","2016","The year in cardiology 2016: heart failure","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehw638","https://doi.org/10.1093/eurheartj/ehw638","28043977","https://pubmed.ncbi.nlm.nih.gov/28043977/","https://www.zora.uzh.ch/handle/20.500.14742/140819",null],["2","R0049283","R0049283.pdf","free_to_read","randomized_trial","Thomas Felix Lüscher","2016","Acute coronary syndromes: mechanisms, reperfusion injury, antithrombotic therapy, and current outcomes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehw142","https://doi.org/10.1093/eurheartj/ehw142","27102807","https://pubmed.ncbi.nlm.nih.gov/27102807/","https://www.zora.uzh.ch/handle/20.500.14742/127930",null],["2","R0049515","R0049515.pdf","no_doi","randomized_trial","Shari Danielle Bolen","2016","Table 24, Randomized controlled trials comparing a combination of metformin plus a sulfonylurea with a combination of metformin plus a GLP-1 receptor agonist on all-cause mortality",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050099","R0050099.pdf","open_download_failed","randomized_trial","Abigail E. Dove","2016","Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12451","https://doi.org/10.1111/1753-0407.12451","27427410","https://pubmed.ncbi.nlm.nih.gov/27427410/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12451",null],["2","R0051909","R0051909.pdf","free_to_read","randomized_trial","Natalya A. Koziolova","2016","The choice of antihyperglycemic agents in patients with type 2 diabetes mellitus and very high cardiovascular risk (part 2)","Arterial’naya Gipertenziya (Arterial Hypertension)","Arterialnaya Gipertenziya","10.18705/1607-419x-2016-22-5-441-455","https://doi.org/10.18705/1607-419x-2016-22-5-441-455",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18705/1607-419x-2016-22-5-441-455",null],["2","R0055628","R0055628.pdf","free_to_read","randomized_trial","Sanjay Kalra","2016","Glycemic equipoise","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.194361","https://doi.org/10.4103/2230-8210.194361","28217492","https://pubmed.ncbi.nlm.nih.gov/28217492/","https://doi.org/10.4103/2230-8210.194361",null],["2","R0014687","R0014687.pdf","free_to_read","randomized_trial","Fisher M","2015","Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12380","https://doi.org/10.1111/dom.12380","25155010","https://pubmed.ncbi.nlm.nih.gov/25155010/",null,null],["2","R0015708","R0015708.pdf","free_to_read","randomized_trial","Home PD","2015","Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12414","https://doi.org/10.1111/dom.12414","25406730","https://pubmed.ncbi.nlm.nih.gov/25406730/","https://doi.org/10.25405/ncl.34244883",null],["2","R0016229","R0016229.pdf","open_download_failed","randomized_trial","Iepsen EW","2015","GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-1176","https://doi.org/10.1210/jc.2015-1176","26043228","https://pubmed.ncbi.nlm.nih.gov/26043228/","https://academic.oup.com/jcem/article-pdf/100/8/2909/17636148/jcem2909.pdf","ClinicalTrials.gov:NCT02094183"],["2","R0016344","R0016344.pdf","no_doi","randomized_trial","George CM","2015","Management of Blood Glucose with Noninsulin Therapies in Type 2 Diabetes.","American family physician",null,null,"https://doi.org/","26132124","https://pubmed.ncbi.nlm.nih.gov/26132124/",null,null],["2","R0016455","R0016455.pdf","no_doi","randomized_trial","Østoft SH","2015","Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.","Danish medical journal",null,null,"https://doi.org/","26324089","https://pubmed.ncbi.nlm.nih.gov/26324089/",null,null],["2","R0016814","R0016814.pdf","open_download_failed","randomized_trial","Rotz ME","2015","Implications of incretin-based therapies on cardiovascular disease.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.12572","https://doi.org/10.1111/ijcp.12572","25363540","https://pubmed.ncbi.nlm.nih.gov/25363540/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.12572",null],["2","R0017284","R0017284.pdf","open_download_failed","randomized_trial","Takebayashi K","2015","Effect of proton pump inhibitors on glycemic control in patients with diabetes.","World journal of diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.v6.i10.1122","https://doi.org/10.4239/wjd.v6.i10.1122","26322158","https://pubmed.ncbi.nlm.nih.gov/26322158/","https://www.wjgnet.com/1948-9358/full/v6/i10/1122.htm",null],["2","R0017805","R0017805.pdf","no_doi","randomized_trial","Scheen AJ","2015","[Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].","Revue medicale de Liege",null,null,"https://doi.org/","26054173","https://pubmed.ncbi.nlm.nih.gov/26054173/",null,null],["2","R0018874","R0018874.pdf","open_download_failed","randomized_trial","Desouza CV","2015","Cardiometabolic Effects of a New Class of Antidiabetic Agents.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.02.016","https://doi.org/10.1016/j.clinthera.2015.02.016","25754876","https://pubmed.ncbi.nlm.nih.gov/25754876/","http://www.clinicaltherapeutics.com/article/S0149291815000867/pdf",null],["2","R0020076","R0020076.pdf","free_to_read","randomized_trial","Bacci S","2015","The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2015.06.056","https://doi.org/10.1016/j.ejphar.2015.06.056","26164788","https://pubmed.ncbi.nlm.nih.gov/26164788/","http://hdl.handle.net/2158/1003297",null],["2","R0020377","R0020377.pdf","open_download_failed","randomized_trial","Doggrell SA","2015","Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1586/17446651.2015.995629","https://doi.org/10.1586/17446651.2015.995629","30298769","https://pubmed.ncbi.nlm.nih.gov/30298769/","https://www.tandfonline.com/doi/pdf/10.1586/17446651.2015.995629?download=true",null],["2","R0022557","R0022557.pdf","no_doi","randomized_trial","Yan L","2015","[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].","Zhonghua nei ke za zhi",null,null,"https://doi.org/","26268058","https://pubmed.ncbi.nlm.nih.gov/26268058/",null,null],["2","R0023278","R0023278.pdf","free_to_read","randomized_trial","Carlessi R","2015","Exendin-4 attenuates brain death-induced liver damage in the rat.","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","Ovid Technologies (Wolters Kluwer Health)","10.1002/lt.24317","https://doi.org/10.1002/lt.24317","26334443","https://pubmed.ncbi.nlm.nih.gov/26334443/",null,null],["2","R0023819","R0023819.pdf","no_doi","randomized_trial","Wang XH","2015","[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].","Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition",null,null,"https://doi.org/","26480664","https://pubmed.ncbi.nlm.nih.gov/26480664/",null,null],["2","R0025600","R0025600.pdf","open_download_failed","randomized_trial","Lehrskov-Schmidt L","2015","The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2014-4244","https://doi.org/10.1210/jc.2014-4244","25675385","https://pubmed.ncbi.nlm.nih.gov/25675385/","https://academic.oup.com/jcem/article-pdf/100/4/E616/17636399/jcemE616.pdf","ClinicalTrials.gov:NCT01347801"],["2","R0025684","R0025684.pdf","free_to_read","randomized_trial","Raccah D","2015","Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2588","https://doi.org/10.1002/dmrr.2588","25115916","https://pubmed.ncbi.nlm.nih.gov/25115916/","https://doi.org/10.1002/dmrr.2588",null],["2","R0026240","R0026240.pdf","free_to_read","randomized_trial","Naderpoor N","2015","Obesity and polycystic ovary syndrome.","Minerva endocrinologica","S. Karger AG","10.1159/000194971","https://doi.org/10.1159/000194971","25411807","https://pubmed.ncbi.nlm.nih.gov/25411807/","https://www.ncbi.nlm.nih.gov/pmc/articles/6444522",null],["2","R0026241","R0026241.pdf","open_download_failed","randomized_trial","Deng J","2015","Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2015.1067622","https://doi.org/10.3111/13696998.2015.1067622","26134916","https://pubmed.ncbi.nlm.nih.gov/26134916/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1067622?needAccess=true&role=button",null],["2","R0026246","R0026246.pdf","open_download_failed","randomized_trial","D'Alessio D","2015","Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12406","https://doi.org/10.1111/dom.12406","25359159","https://pubmed.ncbi.nlm.nih.gov/25359159/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12406",null],["2","R0026442","R0026442.pdf","free_to_read","randomized_trial",null,"2015","Dulaglutide -- Benefit Assessment According to §35a Social Code Book V","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany",null,null,"https://doi.org/","27905789","https://pubmed.ncbi.nlm.nih.gov/27905789/",null,null],["2","R0026558","R0026558.pdf","free_to_read","randomized_trial","Davenport C","2015","The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-14-1137","https://doi.org/10.1530/eje-14-1137","26036811","https://pubmed.ncbi.nlm.nih.gov/26036811/",null,null],["2","R0026860","R0026860.pdf","open_download_failed","randomized_trial","Shan PF","2015","Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.","Diabetes care","American Diabetes Association","10.2337/dc15-0887","https://doi.org/10.2337/dc15-0887","26294784","https://pubmed.ncbi.nlm.nih.gov/26294784/","https://diabetesjournals.org/care/article-pdf/38/9/e148/625193/dc150887.pdf",null],["2","R0026963","R0026963.pdf","free_to_read","randomized_trial","Retnakaran R","2015","Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.","Diabetes care","American Diabetes Association","10.2337/dc14-2586","https://doi.org/10.2337/dc14-2586","25614699","https://pubmed.ncbi.nlm.nih.gov/25614699/",null,null],["2","R0027121","R0027121.pdf","open_download_failed","randomized_trial","Abdul-Ghani MA","2015","Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12417","https://doi.org/10.1111/dom.12417","25425451","https://pubmed.ncbi.nlm.nih.gov/25425451/","https://www.ncbi.nlm.nih.gov/pmc/articles/5577982",null],["2","R0027700","R0027700.pdf","free_to_read","randomized_trial","Plummer MP","2015","Hyperglycemia potentiates the slowing of gastric emptying induced by exogenous GLP-1.","Diabetes care","American Diabetes Association","10.2337/dc14-3091","https://doi.org/10.2337/dc14-3091","25784665","https://pubmed.ncbi.nlm.nih.gov/25784665/",null,"ANZCTR:ACTRN12613001384741"],["2","R0027972","R0027972.pdf","open_download_failed","randomized_trial","Lang UE","2015","Nutritional aspects of depression.","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","S. Karger AG","10.1159/000430229","https://doi.org/10.1159/000430229","26402520","https://pubmed.ncbi.nlm.nih.gov/26402520/","https://www.karger.com/Article/Pdf/430229",null],["2","R0031437","R0031437.pdf","no_doi","randomized_trial","井上 雄一郎","2015","A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031834","R0031834.pdf","no_doi","randomized_trial","AgonistsJ Chilton","2015","Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035286","R0035286.pdf","no_doi","randomized_trial","Kohzo","2015","Effect of proton pump inhibitors on glycemic control in patients with diabetes","Acta Scientiarum Naturalium Universitatis Sunyatseni",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035888","R0035888.pdf","free_to_read","randomized_trial","Signe Frossing Malin Nylander","2015","The LIPT-Study: On Risk Markers of Vascular Thrombosis in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Liraglutide","Journal of Obesity & Weight loss Therapy","OMICS Publishing Group","10.4172/2165-7904.1000254","https://doi.org/10.4172/2165-7904.1000254",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4172/2165-7904.1000254",null],["2","R0036464","R0036464.pdf","free_to_read","randomized_trial","Yang Yu","2015","Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study","Journal of Endocrinology and Metabolism","Elmer Press, Inc.","10.14740/jem304w","https://doi.org/10.14740/jem304w",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14740/jem304w",null],["2","R0037958","R0037958.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2015","Approaches to treatment 1: How is type 2 diabetes actually treated?","Journal of Diabetes","Wiley","10.1111/1753-0407.12329","https://doi.org/10.1111/1753-0407.12329","26211568","https://pubmed.ncbi.nlm.nih.gov/26211568/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12329",null],["2","R0038573","R0038573.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2015","Sodium–glucose cotransporter 2 inhibitors and renal function钠‐葡萄糖共转运体2抑制剂与肾功能","Journal of Diabetes","Wiley","10.1111/1753-0407.12268","https://doi.org/10.1111/1753-0407.12268","25565352","https://pubmed.ncbi.nlm.nih.gov/25565352/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12268","ClinicalTrials.gov:NCT02065791; ClinicalTrials.gov:NCT01131676"],["2","R0040618","R0040618.pdf","no_doi","randomized_trial",null,"2015","ARTICLE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040629","R0040629.pdf","no_doi","randomized_trial","Weijian Ke","2015","Clinical Study Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040749","R0040749.pdf","no_doi","randomized_trial","John B. Buse","2015","FOR THE LIRAGLUTIDE EFFECT ACTION IN DIABETES (LEAD)-6 STUDY GROUP*",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040830","R0040830.pdf","no_doi","randomized_trial","David M. Kendall","2015","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040838","R0040838.pdf","no_doi","randomized_trial","Vedtofte L","2015","private correspondence",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040896","R0040896.pdf","no_doi","randomized_trial","Hiroki Yokoyama","2015","Japanese Clinical Medicine Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiab",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040988","R0040988.pdf","no_doi","randomized_trial",null,"2015","Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041002","R0041002.pdf","no_doi","randomized_trial","Prajakti A Kothare","2015","RESEARCH ARTICLE Open Access Effect",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041074","R0041074.pdf","no_doi","randomized_trial","Antonio Nicolucci","2015","Maintaining an adequat...",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041092","R0041092.pdf","no_doi","randomized_trial","Ralph A. Defronzo","2015","Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041865","R0041865.pdf","no_doi","randomized_trial","M. Odawara","2015","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041921","R0041921.pdf","no_doi","randomized_trial","Susanne Andréasson","2015","A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT","Epsilon Archive for Student Projects (University of Southampton)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043146","R0043146.pdf","open_download_failed","randomized_trial","Ma'en Al‐Mrayat","2015","The diabetes clinic consultation: and one more question?","Practical Diabetes","Wiley","10.1002/pdi.1922","https://doi.org/10.1002/pdi.1922",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1922",null],["2","R0043703","R0043703.pdf","open_download_failed","randomized_trial","Emily E. Regier","2015","Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12328","https://doi.org/10.1111/1753-0407.12328","26223410","https://pubmed.ncbi.nlm.nih.gov/26223410/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12328",null],["2","R0044323","R0044323.pdf","open_download_failed","randomized_trial","Miles Fisher","2015","Recent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!","Practical Diabetes","Wiley","10.1002/pdi.1980","https://doi.org/10.1002/pdi.1980",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1980",null],["2","R0044873","R0044873.pdf","free_to_read","randomized_trial","Yong‐ho Lee","2015","Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?","Diabetes & Metabolism Journal","Korean Diabetes Association","10.4093/dmj.2015.39.3.204","https://doi.org/10.4093/dmj.2015.39.3.204","26124990","https://pubmed.ncbi.nlm.nih.gov/26124990/","https://doi.org/10.4093/dmj.2015.39.3.204",null],["2","R0046249","R0046249.pdf","free_to_read","randomized_trial","Nihal Thomas","2015","Impact of oral antidiabetic agents on bone metabolism","The Indian Journal of Medical Research","Scientific Scholar","10.4103/0971-5916.159244","https://doi.org/10.4103/0971-5916.159244","26112838","https://pubmed.ncbi.nlm.nih.gov/26112838/","https://doi.org/10.4103/0971-5916.159244",null],["2","R0049944","R0049944.pdf","open_download_failed","randomized_trial","Yanbing Li","2015","Beta-Cell Function and Its Underlying Mechanism 2015","Journal of Diabetes Research","Hindawi Limited","10.1155/2016/7638120","https://doi.org/10.1155/2016/7638120","26783538","https://pubmed.ncbi.nlm.nih.gov/26783538/","https://downloads.hindawi.com/journals/jdr/2016/7638120.pdf",null],["2","R0050841","R0050841.pdf","open_download_failed","randomized_trial","Heather Daly","2015","Development of a self‐management education module for those with type 2 diabetes on injectable therapies","Practical Diabetes","Wiley","10.1002/pdi.1979","https://doi.org/10.1002/pdi.1979",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1979",null],["2","R0054781","R0054781.pdf","no_doi","randomized_trial","Kirsten Madsen Hølmkjær","2015","ESVE-O-8 A PLACEBO-CONTROLLED STUDY ON THE EFFECT OF THE GLP-1 ANALOGUE, EXENATIDE, ON BODY COMPOSITION, LEPTIN AND ADIPONECTIN IN OBESE, CLIENTOWNED CATS","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055529","R0055529.pdf","free_to_read","randomized_trial","Marina Vladimirovna Shestakova","2015","Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies","Diabetes Mellitus","Endocrinology Research Centre","10.14341/dm20151s1-112","https://doi.org/10.14341/dm20151s1-112",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14341/dm20151s1-112",null],["2","R0012980","R0012980.pdf","open_download_failed","randomized_trial","Stauder U","2014","Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296813511733","https://doi.org/10.1177/1932296813511733","24876548","https://pubmed.ncbi.nlm.nih.gov/24876548/","https://journals.sagepub.com/doi/pdf/10.1177/1932296813511733",null],["2","R0013525","R0013525.pdf","open_download_failed","randomized_trial","Simuni T","2014","Is exenatide the next big thing in Parkinson's disease?","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-149001","https://doi.org/10.3233/jpd-149001","24748153","https://pubmed.ncbi.nlm.nih.gov/24748153/","https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd149001?id=journal-of-parkinsons-disease%2Fjpd149001",null],["2","R0015892","R0015892.pdf","open_download_failed","randomized_trial","Wu S","2014","The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.","Journal of clinical pharmacy and therapeutics","Hindawi Limited","10.1111/jcpt.12102","https://doi.org/10.1111/jcpt.12102","24127768","https://pubmed.ncbi.nlm.nih.gov/24127768/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcpt.12102",null],["2","R0019800","R0019800.pdf","open_download_failed","randomized_trial","Connelly KA","2014","Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease.","Clinical and investigative medicine. Medecine clinique et experimentale","University of Toronto Press Inc. (UTPress)","10.25011/cim.v37i3.21384","https://doi.org/10.25011/cim.v37i3.21384","24895991","https://pubmed.ncbi.nlm.nih.gov/24895991/","https://cimonline.ca/index.php/cim/article/download/21384/17411",null],["2","R0020543","R0020543.pdf","open_download_failed","randomized_trial","Smolen HJ","2014","The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2014.20.9.968","https://doi.org/10.18553/jmcp.2014.20.9.968","25166296","https://pubmed.ncbi.nlm.nih.gov/25166296/","http://www.jmcp.org/doi/pdf/10.18553/jmcp.2014.20.9.968",null],["2","R0020965","R0020965.pdf","open_download_failed","randomized_trial","Henry RR","2014","Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2013.12.009","https://doi.org/10.1016/j.jdiacomp.2013.12.009","24631129","https://pubmed.ncbi.nlm.nih.gov/24631129/","https://www.sciencedirect.com/science/article/pii/S1056872713003358/pdf",null],["2","R0021436","R0021436.pdf","open_download_failed","randomized_trial","Renukuntla VS","2014","Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296814542153","https://doi.org/10.1177/1932296814542153","25030181","https://pubmed.ncbi.nlm.nih.gov/25030181/","https://www.ncbi.nlm.nih.gov/pmc/articles/4455387",null],["2","R0022864","R0022864.pdf","free_to_read","randomized_trial","Leiter LA","2014","Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.","Diabetes care","American Diabetes Association","10.2337/dc13-2855","https://doi.org/10.2337/dc13-2855","25048383","https://pubmed.ncbi.nlm.nih.gov/25048383/",null,null],["2","R0023859","R0023859.pdf","free_to_read","randomized_trial","Clemmensen C","2014","GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.","Diabetes","American Diabetes Association","10.2337/db13-1609","https://doi.org/10.2337/db13-1609","24379349","https://pubmed.ncbi.nlm.nih.gov/24379349/","https://doi.org/10.2337/db13-1609",null],["2","R0024114","R0024114.pdf","open_download_failed","randomized_trial","Holmberg FE","2014","Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.","Scandinavian cardiovascular journal : SCJ","Informa UK Limited","10.3109/14017431.2014.923930","https://doi.org/10.3109/14017431.2014.923930","24852515","https://pubmed.ncbi.nlm.nih.gov/24852515/","https://www.tandfonline.com/doi/pdf/10.3109/14017431.2014.923930?download=true",null],["2","R0025487","R0025487.pdf","free_to_read","randomized_trial","van Genugten RE","2014","Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-13-0610","https://doi.org/10.1530/eje-13-0610","24297090","https://pubmed.ncbi.nlm.nih.gov/24297090/",null,"ClinicalTrials.gov:NCT00721552"],["2","R0025656","R0025656.pdf","free_to_read","randomized_trial",null,"2014","Albiglutide -- Benefit Assessment According to §35a Social Code Book V","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany",null,null,"https://doi.org/","27905781","https://pubmed.ncbi.nlm.nih.gov/27905781/",null,null],["2","R0025904","R0025904.pdf","free_to_read","randomized_trial","Raz I","2014","Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.","Diabetes care","American Diabetes Association","10.2337/dc13-2546","https://doi.org/10.2337/dc13-2546","24914244","https://pubmed.ncbi.nlm.nih.gov/24914244/",null,null],["2","R0026226","R0026226.pdf","free_to_read","randomized_trial","Carvalho AF","2014","Cognitive dysfunction in depression - pathophysiology and novel targets.","CNS & neurological disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871527313666141130203627","https://doi.org/10.2174/1871527313666141130203627","25470397","https://pubmed.ncbi.nlm.nih.gov/25470397/","https://figshare.com/articles/journal_contribution/Cognitive_dysfunction_in_depression_-_pathophysiology_and_novel_targets/20917759",null],["2","R0026323","R0026323.pdf","open_download_failed","randomized_trial","Kim J","2014","Cardiovascular effects of incretin therapy in diabetes care.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2014.0035","https://doi.org/10.1089/met.2014.0035","24842063","https://pubmed.ncbi.nlm.nih.gov/24842063/","https://www.ncbi.nlm.nih.gov/pmc/articles/4162447",null],["2","R0026345","R0026345.pdf","free_to_read","randomized_trial","Lønborg J","2014","Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.","Diabetes","American Diabetes Association","10.2337/db13-1849","https://doi.org/10.2337/db13-1849","24584550","https://pubmed.ncbi.nlm.nih.gov/24584550/","https://doi.org/10.2337/db13-1849",null],["2","R0026464","R0026464.pdf","open_download_failed","randomized_trial","Gastaldelli A","2014","The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes.","Clinical endocrinology","Wiley","10.1111/cen.12199","https://doi.org/10.1111/cen.12199","23574529","https://pubmed.ncbi.nlm.nih.gov/23574529/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cen.12199",null],["2","R0027215","R0027215.pdf","open_download_failed","randomized_trial","Quinn CC","2014","Mobile Diabetes Intervention for Glycemic Control: Impact on Physician Prescribing.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296813514503","https://doi.org/10.1177/1932296813514503","24876589","https://pubmed.ncbi.nlm.nih.gov/24876589/","https://www.ncbi.nlm.nih.gov/pmc/articles/4455407",null],["2","R0027490","R0027490.pdf","free_to_read","randomized_trial","Armstrong MJ","2014","Glucagon-like peptide-1 in nonalcoholic steatohepatitis","University of Birmingham",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0028014","R0028014.pdf","open_download_failed","randomized_trial","Manning S","2014","Pharmacotherapy for obesity: novel agents and paradigms.","Therapeutic advances in chronic disease","SAGE Publications","10.1177/2040622314522848","https://doi.org/10.1177/2040622314522848","24790728","https://pubmed.ncbi.nlm.nih.gov/24790728/","https://www.ncbi.nlm.nih.gov/pmc/articles/3992824",null],["2","R0028235","R0028235.pdf","open_download_failed","randomized_trial","Tenner S","2014","Drug induced acute pancreatitis: does it exist?","World journal of gastroenterology","Baishideng Publishing Group Inc.","10.3748/wjg.v20.i44.16529","https://doi.org/10.3748/wjg.v20.i44.16529","25469020","https://pubmed.ncbi.nlm.nih.gov/25469020/","https://www.wjgnet.com/1007-9327/full/v20/i44/16529.htm",null],["2","R0030385","R0030385.pdf","open_download_failed","randomized_trial","Liu Y","2014","Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.","World journal of gastroenterology","Baishideng Publishing Group Inc.","10.3748/wjg.v20.i27.9090","https://doi.org/10.3748/wjg.v20.i27.9090","25083081","https://pubmed.ncbi.nlm.nih.gov/25083081/","https://doi.org/10.3748/wjg.v20.i27.9090",null],["2","R0030658","R0030658.pdf","no_doi","randomized_trial","Svetlana Podzchina","2014","Poster Session：PS 0177 ; Endocrinology : Achieving Target Blood Pressure in Type 2 Diabetes Therapy Optimization","대한내과학회 추계학술발표논문집",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030700","R0030700.pdf","no_doi","randomized_trial","LI Ju-fe","2014","Liraglutide protects endothelial cells from oxidative damage induced by fluctuating glucose","Zhongguo tangniaobing zazhi",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031140","R0031140.pdf","no_doi","randomized_trial","Yan Niu","2014","Outcomes of Obese Patients with Type 2 Diabetes Following Treatment with Insulin Alone or in Combination with Liraglutide","Zhongguo quanke yixue",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031282","R0031282.pdf","no_doi","randomized_trial","Sheetal Kalra","2014","Choosing an insulin regime: a developing country perspective",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031830","R0031830.pdf","no_doi","randomized_trial","Springer-Verlag Italia","2014","Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032011","R0032011.pdf","no_doi","randomized_trial","Sowjanya Naha","2014","Hypertension in Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032311","R0032311.pdf","no_doi","randomized_trial","D. Klein","2014","Liraglutide's safety, tolerability, pharmaokinetics, and pharmacodynamics in pediatric type 2 diabetes : a randomized, double-blind, placebo-controlled trial.","VUBIR (Vrije Universiteit Brussel)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0033054","R0033054.pdf","open_download_failed","randomized_trial",null,"2014","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/1753-0407.12219","https://doi.org/10.1111/1753-0407.12219",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12219",null],["2","R0035114","R0035114.pdf","no_doi","randomized_trial","Xiangyang Ye","2014","Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease","Acta Scientiarum Naturalium Universitatis Sunyatseni",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036924","R0036924.pdf","open_download_failed","randomized_trial",null,"2014","Journal of Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12247","https://doi.org/10.1111/1753-0407.12247",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12247",null],["2","R0039296","R0039296.pdf","open_download_failed","randomized_trial",null,"2014","Obesity, Type 2 diabetes and NAFLD","Diabetic Medicine","Wiley","10.1111/dme.12377_1","https://doi.org/10.1111/dme.12377_1","24593688","https://pubmed.ncbi.nlm.nih.gov/24593688/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.12377_1",null],["2","R0040228","R0040228.pdf","open_download_failed","randomized_trial",null,"2014","In This Issue of Diabetes Care","Diabetes Care","American Diabetes Association","10.2337/dc14-ti10","https://doi.org/10.2337/dc14-ti10",null,"https://pubmed.ncbi.nlm.nih.gov//","https://diabetesjournals.org/care/article-pdf/37/10/2663/618939/2663.pdf",null],["2","R0040260","R0040260.pdf","open_download_failed","randomized_trial","Chen Weiren","2014","GW25-e0235 Effects of Liraglutide on Glycemic Control and Left Ventricular Function in Patients with Acute Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled Clinical Trial","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2014.06.611","https://doi.org/10.1016/j.jacc.2014.06.611",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S0735109714035153/pdf",null],["2","R0040702","R0040702.pdf","no_doi","randomized_trial","Ole Schmitz","2014","ON BEHALF OF THE NN2211-1310",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040783","R0040783.pdf","no_doi","randomized_trial","Kumarathurai P","2014","To cite: Anholm C,",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041033","R0041033.pdf","no_doi","randomized_trial","Anthony Heymann","2014","ORIGINAL RESEARCH Efficacy of Liraglutide in a Real-Life Cohort",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041057","R0041057.pdf","no_doi","randomized_trial","Diabetes Centre","2014","Correspondence to:",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044227","R0044227.pdf","free_to_read","randomized_trial","Seung‐Hwan Lee","2014","Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J2014;38:211-9)","Diabetes & Metabolism Journal","Korean Diabetes Association","10.4093/dmj.2014.38.4.317","https://doi.org/10.4093/dmj.2014.38.4.317","25215279","https://pubmed.ncbi.nlm.nih.gov/25215279/","https://doi.org/10.4093/dmj.2014.38.4.317",null],["2","R0045667","R0045667.pdf","free_to_read","randomized_trial","Dae Ho Lee","2014","Dipeptidyl Peptidase-4 Inhibitor","Korean Journal of Medicine","Korean Association of Internal Medicine","10.3904/kjm.2014.87.1.1","https://doi.org/10.3904/kjm.2014.87.1.1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3904/kjm.2014.87.1.1",null],["2","R0045972","R0045972.pdf","no_doi","randomized_trial","Kunihiro Suzuki","2014","Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048410","R0048410.pdf","free_to_read","randomized_trial","Sanjay Kalra","2014","Can cardiac autonomic neuropathy be a predictor of cardiovascular outcomes in diabetes?","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.145795","https://doi.org/10.4103/2230-8210.145795","25729680","https://pubmed.ncbi.nlm.nih.gov/25729680/","https://doi.org/10.4103/2230-8210.145795",null],["2","R0052899","R0052899.pdf","open_download_failed","randomized_trial","A. Collier","2014","S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial","Thorax","BMJ","10.1136/thoraxjnl-2014-206260.34","https://doi.org/10.1136/thoraxjnl-2014-206260.34",null,"https://pubmed.ncbi.nlm.nih.gov//","https://thorax.bmj.com/content/thoraxjnl/69/Suppl_2/A16.2.full.pdf",null],["2","R0053287","R0053287.pdf","open_download_failed","randomized_trial","Jonathan Edward Shaw","2014","Individualizing therapy: Do we have the tools to do it? 个体化治疗：我们有具体的执行方法吗？","Journal of Diabetes","Wiley","10.1111/1753-0407.12218","https://doi.org/10.1111/1753-0407.12218","25209957","https://pubmed.ncbi.nlm.nih.gov/25209957/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12218",null],["2","R0054493","R0054493.pdf","free_to_read","randomized_trial","Sanjay Kalra","2014","Untapped diamonds for untamed diabetes: The α-glucosidase inhibitors","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.129102","https://doi.org/10.4103/2230-8210.129102","24741507","https://pubmed.ncbi.nlm.nih.gov/24741507/","https://doi.org/10.4103/2230-8210.129102",null],["2","R0016630","R0016630.pdf","open_download_failed","randomized_trial","Lorenz M","2013","Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.","Regulatory peptides","Elsevier BV","10.1016/j.regpep.2013.04.001","https://doi.org/10.1016/j.regpep.2013.04.001","23665027","https://pubmed.ncbi.nlm.nih.gov/23665027/","https://www.sciencedirect.com/science/article/pii/S0167011513000773/pdf",null],["2","R0024364","R0024364.pdf","open_download_failed","randomized_trial","Abegg K","2013","Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass.","Physiology & behavior","Elsevier BV","10.1016/j.physbeh.2013.03.027","https://doi.org/10.1016/j.physbeh.2013.03.027","23562866","https://pubmed.ncbi.nlm.nih.gov/23562866/","https://www.zora.uzh.ch/id/eprint/80566/1/Abegg_Physiol_Behav_2013.pdf",null],["2","R0026613","R0026613.pdf","open_download_failed","randomized_trial","Lu CH","2013","Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.","Journal of the Formosan Medical Association = Taiwan yi zhi","Elsevier BV","10.1016/j.jfma.2012.02.027","https://doi.org/10.1016/j.jfma.2012.02.027","23473527","https://pubmed.ncbi.nlm.nih.gov/23473527/","https://www.sciencedirect.com/science/article/pii/S0929664612002318/pdf",null],["2","R0028106","R0028106.pdf","free_to_read","randomized_trial","Hartmann KE","2013","Primary Care Management of Abnormal Uterine Bleeding","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","23617013","https://pubmed.ncbi.nlm.nih.gov/23617013/",null,null],["2","R0030673","R0030673.pdf","no_doi","randomized_trial","Yali Fu","2013","The clinic observation of exenatide therapy for patients with obese T2DM","Zhongguo tangniaobing zazhi",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031130","R0031130.pdf","no_doi","randomized_trial","Li Yang","2013","Effect of liraglutide on serum AGEs and inflammatory factors in IGT-OLETF rats","Jiefangjun yixue zazhi",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031801","R0031801.pdf","no_doi","randomized_trial","Patricia S Juang","2013","Figure 16, Changes from Baseline A1C Patients Randomized to Exenatide or Placebo",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034130","R0034130.pdf","no_doi","randomized_trial",null,"2013","Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes","Queen Margaret University Publications Repository (Queen Margaret University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036373","R0036373.pdf","no_doi","randomized_trial","Anonymous,","2013","Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes","Queen Margaret University eTheses Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039888","R0039888.pdf","open_download_failed","randomized_trial",null,"2013","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/1753-0407.12109","https://doi.org/10.1111/1753-0407.12109",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12109",null],["2","R0040060","R0040060.pdf","open_download_failed","randomized_trial","Chao Deng","2013","Biologic therapies in type 1 diabetes: how far are they from us?","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.3760/cma.j.issn.0366-6999.20132375","https://doi.org/10.3760/cma.j.issn.0366-6999.20132375","24229664","https://pubmed.ncbi.nlm.nih.gov/24229664/","https://mednexus.org/doi/pdf/10.3760/cma.j.issn.0366-6999.20132375?download=true","ClinicalTrials.gov:NCT01773707; ClinicalTrials.gov:NCT01785108"],["2","R0040616","R0040616.pdf","no_doi","randomized_trial",null,"2013","ORIGINAL PAPER",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040634","R0040634.pdf","no_doi","randomized_trial","Benjamin C. T. Field","2013","ORIGINAL ARTICLE PYY 3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040664","R0040664.pdf","no_doi","randomized_trial","John B. Buse","2013","A 2004 Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes 53(Suppl 2):A82 (Abstract 352-OR) Endocrinology is published monthly by The Endocrine Society (http://www.en",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040683","R0040683.pdf","no_doi","randomized_trial",null,"2013","original article Diabetes, Obesity and Metabolism 12: 604–612, 2010.",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040692","R0040692.pdf","no_doi","randomized_trial",null,"2013","Treatment of antipsychotic-associated",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040698","R0040698.pdf","no_doi","randomized_trial","Glucocorticoid-induced Glucose","2013","Intolerance and Islet-Cell Dysfunction in Humans",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040752","R0040752.pdf","no_doi","randomized_trial","Kristina I. Rother","2013","Effects of Exenatide Alone and in Combination With Daclizumab on -Cell Function in Long-Standing Type 1 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040755","R0040755.pdf","no_doi","randomized_trial","Michael Nauck","2013","Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040775","R0040775.pdf","no_doi","randomized_trial","Raquel N. Faradji","2013","CELL THERAPY AND ISLET TRANSPLANTATION Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040824","R0040824.pdf","no_doi","randomized_trial","Anne Gill","2013","CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040829","R0040829.pdf","no_doi","randomized_trial","Barbara Fruci","2013","Review Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040861","R0040861.pdf","no_doi","randomized_trial","Diabetes Metab J","2013","Understanding the Cardiovascular Effects of Incretin",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040956","R0040956.pdf","no_doi","randomized_trial","Michael Böhmer","2013","BAPTIST GALLWITZ, MD 1",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040983","R0040983.pdf","no_doi","randomized_trial","Insulin Glargine","2013","Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041035","R0041035.pdf","no_doi","randomized_trial","Juraj Koska Md","2013","Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041040","R0041040.pdf","no_doi","randomized_trial","Gabriel A Mecott","2013","RESEARCH Open Access The use of exenatide in severely burned pediatric patients",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041044","R0041044.pdf","no_doi","randomized_trial",null,"2013","Efficacy and Safety of the Once- Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study DOI: 10.2337/dc13-2855 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041048","R0041048.pdf","no_doi","randomized_trial",null,"2013","Efficacy and Safety of the Once- Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study Diabetes Care 2014;37:2723–2730 | DOI: 10.2337/dc13-2855 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041130","R0041130.pdf","no_doi","randomized_trial","Ralph A. Defronzo","2013","Effects of Exenatide Plus Rosiglitazone on �-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041163","R0041163.pdf","no_doi","randomized_trial","Romilla Yogesh Bijlani","2013","Efficacy of GLP-1 Infusion in Congestive Heart Failure Patients on Myocardial Function",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041296","R0041296.pdf","no_doi","randomized_trial","Bernard Zinman","2013","Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met�TZD)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041315","R0041315.pdf","no_doi","randomized_trial","Gavin J Bush","2013","GLP-1 Infusions in the setting of Acute Myocardial Infarction Improve Myocardial Function and Reduce Morbidity and Mortality",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043309","R0043309.pdf","no_doi","randomized_trial","Mark H. Ebell","2013","Top 20 Research Studies of 2023 for Primary Care Physicians.","PubMed",null,null,"https://doi.org/","24134045","https://pubmed.ncbi.nlm.nih.gov/24134045/",null,null],["2","R0043469","R0043469.pdf","no_doi","randomized_trial","Glenn R. Cunningham","2013","Diabetes and cardiovascular disease: what have we learned in 2012?","PubMed",null,null,"https://doi.org/","23914022","https://pubmed.ncbi.nlm.nih.gov/23914022/",null,null],["2","R0043712","R0043712.pdf","open_download_failed","randomized_trial","Ma'en Al‐Mrayat","2013","Dapagliflozin: NICE guidance for use in combination therapy for the treatment of type 2 diabetes","Practical Diabetes","Wiley","10.1002/pdi.1779","https://doi.org/10.1002/pdi.1779",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1779",null],["2","R0043810","R0043810.pdf","open_download_failed","randomized_trial","Koichi Yokono","2013","New therapeutic strategy for Alzheimer's disease using antidiabetes agents","Journal of Diabetes Investigation","Wiley","10.1111/jdi.12031","https://doi.org/10.1111/jdi.12031","24843645","https://pubmed.ncbi.nlm.nih.gov/24843645/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdi.12031",null],["2","R0043814","R0043814.pdf","open_download_failed","randomized_trial","Zachary T. Bloomgarden","2013","Cardiovascular safety trials: Be careful what you wish for (心血管安全性研究：当心你许的愿)","Journal of Diabetes","Wiley","10.1111/1753-0407.12092","https://doi.org/10.1111/1753-0407.12092","24103189","https://pubmed.ncbi.nlm.nih.gov/24103189/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12092",null],["2","R0043909","R0043909.pdf","free_to_read","randomized_trial","Alexandra E. Butler","2013","Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604","Diabetes","American Diabetes Association","10.2337/db13-0996","https://doi.org/10.2337/db13-0996","24065800","https://pubmed.ncbi.nlm.nih.gov/24065800/","https://doi.org/10.2337/db13-0996",null],["2","R0047235","R0047235.pdf","open_download_failed","randomized_trial","Bob Ryder","2013","ABCD position statement on GLP‐1 based therapies and pancreatic damage","Practical Diabetes","Wiley","10.1002/pdi.1816","https://doi.org/10.1002/pdi.1816",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1816",null],["2","R0047642","R0047642.pdf","open_download_failed","randomized_trial","William V. Tamborlane","2013","Crisis in Care: Limited Treatment Options for Type 2 Diabetes in Adolescents and Youth","Diabetes Care","American Diabetes Association","10.2337/dc13-0743","https://doi.org/10.2337/dc13-0743","23704679","https://pubmed.ncbi.nlm.nih.gov/23704679/","https://care.diabetesjournals.org/content/diacare/36/6/1777.full.pdf",null],["2","R0048761","R0048761.pdf","no_doi","randomized_trial","Matthew James Armstrong","2013","Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial","Hepatology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0049446","R0049446.pdf","no_doi","randomized_trial","QU Geng-r","2013","Efficacy comparison between liraglutide and insulin glargine in treatment of type 2 diabetic patients","Chinese Journal of New Drugs and Clinical Remedies",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0018641","R0018641.pdf","open_download_failed","randomized_trial","Geiger MJ","2012","An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.","Journal of diabetes science and technology","SAGE Publications","10.1177/193229681200600610","https://doi.org/10.1177/193229681200600610","23294776","https://pubmed.ncbi.nlm.nih.gov/23294776/","https://www.ncbi.nlm.nih.gov/pmc/articles/3570871",null],["2","R0019665","R0019665.pdf","open_download_failed","randomized_trial","Skrivanek Z","2012","Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.","Journal of diabetes science and technology","SAGE Publications","10.1177/193229681200600609","https://doi.org/10.1177/193229681200600609","23294775","https://pubmed.ncbi.nlm.nih.gov/23294775/","https://www.ncbi.nlm.nih.gov/pmc/articles/3570870",null],["2","R0020573","R0020573.pdf","open_download_failed","randomized_trial","Nauck MA","2012","The design of the liraglutide clinical trial programme.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01573.x","https://doi.org/10.1111/j.1463-1326.2012.01573.x","22405264","https://pubmed.ncbi.nlm.nih.gov/22405264/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2012.01573.x",null],["2","R0021901","R0021901.pdf","no_doi","randomized_trial","van der Klauw MM","2012","The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.","The Netherlands journal of medicine",null,null,"https://doi.org/","23230012","https://pubmed.ncbi.nlm.nih.gov/23230012/",null,null],["2","R0023059","R0023059.pdf","free_to_read","randomized_trial","Kela R","2012","Treatment evaluation of liraglutide in type 2 diabetes.","Expert opinion on biological therapy","Informa Healthcare","10.1517/14712598.2012.716823","https://doi.org/10.1517/14712598.2012.716823","22897447","https://pubmed.ncbi.nlm.nih.gov/22897447/",null,null],["2","R0023066","R0023066.pdf","no_doi","randomized_trial","Yuan GH","2012","Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.","Chinese medical journal",null,null,"https://doi.org/","22931974","https://pubmed.ncbi.nlm.nih.gov/22931974/",null,null],["2","R0023156","R0023156.pdf","open_download_failed","randomized_trial","Stranges P","2012","Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.","Therapeutic advances in drug safety","SAGE Publications","10.1177/2042098612454290","https://doi.org/10.1177/2042098612454290","25083236","https://pubmed.ncbi.nlm.nih.gov/25083236/","https://www.ncbi.nlm.nih.gov/pmc/articles/4110849",null],["2","R0024055","R0024055.pdf","free_to_read","randomized_trial","Jendle J","2012","Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2012.703633","https://doi.org/10.3111/13696998.2012.703633","22853443","https://pubmed.ncbi.nlm.nih.gov/22853443/",null,null],["2","R0025046","R0025046.pdf","free_to_read","randomized_trial","Henry RR","2012","Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-3253","https://doi.org/10.1210/jc.2011-3253","22539590","https://pubmed.ncbi.nlm.nih.gov/22539590/",null,null],["2","R0027117","R0027117.pdf","no_doi","randomized_trial","Guo N","2012","[Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats].","Nan fang yi ke da xue xue bao = Journal of Southern Medical University",null,null,"https://doi.org/","22699075","https://pubmed.ncbi.nlm.nih.gov/22699075/",null,null],["2","R0030808","R0030808.pdf","no_doi","randomized_trial","Guo Qing-hu","2012","Effects of exendin-4 on expression of endoplasmic reticulum stress marker C/EBP homologous protein in hepatocyte of rats with impaired glucose tolerance","Chinese Remedies & Clinics",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031358","R0031358.pdf","no_doi","randomized_trial","Z.F. Zin","2012","A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0037499","R0037499.pdf","open_download_failed","randomized_trial","Benjamin M. Kozak","2012","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/j.1753-0407.2012.00197.x","https://doi.org/10.1111/j.1753-0407.2012.00197.x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1753-0407.2012.00197.x",null],["2","R0037872","R0037872.pdf","open_download_failed","randomized_trial","Katya B. Rubinow","2012","The Author's Reply: Testosterone, oestradiol, and insulin sensitivity in men","Clinical Endocrinology","Wiley","10.1111/j.1365-2265.2012.04367.x","https://doi.org/10.1111/j.1365-2265.2012.04367.x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2265.2012.04367.x",null],["2","R0039001","R0039001.pdf","no_doi","randomized_trial","Maffioli P","2012","Optimizing glycemic control: clinical utility of exenatide prolonged release injection","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039440","R0039440.pdf","no_doi","randomized_trial","Haber, Harry","2012","Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks","Hispana",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0039772","R0039772.pdf","open_download_failed","randomized_trial","Giuseppe Derosa","2012","Optimizing glycemic control: clinical utility of exenatide prolonged release injection","Dove Medical Press (Taylor and Francis Group)","Informa UK Limited","10.2147/rred.s24237","https://doi.org/10.2147/rred.s24237",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.dovepress.com/getfile.php?fileID=14066",null],["2","R0040821","R0040821.pdf","no_doi","randomized_trial","Linong Ji","2012","Clinical Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042376","R0042376.pdf","no_doi","randomized_trial","RE Pratley (7631600)","2012","Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042624","R0042624.pdf","open_download_failed","randomized_trial","D Carrick","2012","Prognostic importance of myocardial infarct characteristics","European Heart Journal - Cardiovascular Imaging","Oxford University Press (OUP)","10.1093/ehjci/jes296","https://doi.org/10.1093/ehjci/jes296","23248208","https://pubmed.ncbi.nlm.nih.gov/23248208/","https://academic.oup.com/ehjcimaging/article-pdf/14/4/313/9706598/jes296.pdf","ClinicalTrials.gov:NCT01388504"],["2","R0043004","R0043004.pdf","open_download_failed","randomized_trial","Dongjuan Wang","2012","PROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 VIA CAMP/PKA/RHO DEPENDENT PATHWAY ON CARDIAC MICROVESSELS INJURY IN DIABETES MELLITUS","Heart","BMJ","10.1136/heartjnl-2012-302920a.1","https://doi.org/10.1136/heartjnl-2012-302920a.1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://heart.bmj.com/content/heartjnl/98/Suppl_2/E1.1.full.pdf",null],["2","R0043648","R0043648.pdf","free_to_read","randomized_trial","Т. В. Саприна","2012","The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus","Problems of Endocrinology","Endocrinology Research Centre","10.14341/probl201258575-79","https://doi.org/10.14341/probl201258575-79",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14341/probl201258575-79",null],["2","R0043895","R0043895.pdf","open_download_failed","randomized_trial","Satish K. Garg","2012","New medications for the treatment of diabetes","International Journal of Clinical Practice","Wiley","10.1111/j.1742-1241.2011.02859.x","https://doi.org/10.1111/j.1742-1241.2011.02859.x","22308994","https://pubmed.ncbi.nlm.nih.gov/22308994/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2011.02859.x",null],["2","R0043980","R0043980.pdf","free_to_read","randomized_trial","Vishal Mundra","2012","Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.103040","https://doi.org/10.4103/2230-8210.103040","23226666","https://pubmed.ncbi.nlm.nih.gov/23226666/","https://doi.org/10.4103/2230-8210.103040",null],["2","R0048737","R0048737.pdf","no_doi","randomized_trial","Icíar Avilés-Olmos","2012","An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054642","R0054642.pdf","free_to_read","randomized_trial","Adrian V Vella","2012","Mechanism of Action of DPP-4 Inhibitors—New Insights","The Journal of Clinical Endocrinology & Metabolism","The Endocrine Society","10.1210/jc.2012-2396","https://doi.org/10.1210/jc.2012-2396","22869847","https://pubmed.ncbi.nlm.nih.gov/22869847/","https://www.ncbi.nlm.nih.gov/pmc/articles/3410278",null],["2","R0019049","R0019049.pdf","no_doi","randomized_trial","Bode B","2011","Liraglutide: a review of the first once-daily GLP-1 receptor agonist.","The American journal of managed care",null,null,"https://doi.org/","21517658","https://pubmed.ncbi.nlm.nih.gov/21517658/",null,null],["2","R0026971","R0026971.pdf","free_to_read","randomized_trial","Pinelli NR","2011","Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.","Journal of clinical pharmacology","Wiley","10.1177/0091270010367653","https://doi.org/10.1177/0091270010367653","20484613","https://pubmed.ncbi.nlm.nih.gov/20484613/",null,null],["2","R0027222","R0027222.pdf","open_download_failed","randomized_trial","Beaudet A","2011","Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2011.579213","https://doi.org/10.3111/13696998.2011.579213","21563878","https://pubmed.ncbi.nlm.nih.gov/21563878/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2011.579213?needAccess=true",null],["2","R0027858","R0027858.pdf","free_to_read","randomized_trial","Bennett WL","2011","Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","21735563","https://pubmed.ncbi.nlm.nih.gov/21735563/",null,null],["2","R0030481","R0030481.pdf","open_download_failed","randomized_trial","Hedrington MS","2011","Basal insulin treatment in type 2 diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2011.0062","https://doi.org/10.1089/dia.2011.0062","21668335","https://pubmed.ncbi.nlm.nih.gov/21668335/","https://doi.org/10.1089/dia.2011.0062",null],["2","R0030661","R0030661.pdf","no_doi","randomized_trial","Muhammad Owais Khan","2011","DIABETES AND ITS TREATMENT BY GLUCAGON- LIKE PEPTIDE 1 ANALOGS AND DI-PEPTIDYL PEPTIDASE 4 INHIBITORS","Journal of Postgraduate Medical Institute",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0030737","R0030737.pdf","no_doi","randomized_trial","Haiqin Rong","2011","Progress on antidiabetic mechanism and clinical application of exenatide","Chinese Journal of New Drugs and Clinical Remedies",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031173","R0031173.pdf","no_doi","randomized_trial","Wang Chang-jun Yuan Feng-shan","2011","The Therapeutic Effect of the Induced Insulin Secreting Cells on Rat Diabetes","Zhongguo shengwu gongcheng zazhi",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034139","R0034139.pdf","no_doi","randomized_trial","McDougall, Claire","2011","Drugs for diabetes: part 6 GLP-1 receptor agonists","ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034881","R0034881.pdf","no_doi","randomized_trial","Э. А. Войчик","2011","Виктоза: опыт клинического применения у больных сахарным диабетом 2-го типа","CyberLeninK (CyberLeninka)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041230","R0041230.pdf","no_doi","randomized_trial","J. K. Berg","2011","measures: a randomized, double-blind, crossover study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041281","R0041281.pdf","no_doi","randomized_trial","Zin Z. Htike","2011","REVIEW A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041328","R0041328.pdf","no_doi","randomized_trial","W. E. Schmidt","2011","Article: Treatment",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042829","R0042829.pdf","open_download_failed","randomized_trial","M. Bannon","2011","Which oral agent to use when metformin is no longer effective?","QJM","Oxford University Press (OUP)","10.1093/qjmed/hcr015","https://doi.org/10.1093/qjmed/hcr015","21330402","https://pubmed.ncbi.nlm.nih.gov/21330402/","https://academic.oup.com/qjmed/article-pdf/104/3/183/4472957/hcr015.pdf",null],["2","R0043790","R0043790.pdf","open_download_failed","randomized_trial","Kathleen E. Corey","2011","Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.24696","https://doi.org/10.1002/hep.24696","21953015","https://pubmed.ncbi.nlm.nih.gov/21953015/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24696",null],["2","R0044161","R0044161.pdf","free_to_read","randomized_trial","Vishvas Garg","2011","Health economic evaluation of dipeptidyl peptidase-4 inhibitors","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.83049","https://doi.org/10.4103/2230-8210.83049","21847463","https://pubmed.ncbi.nlm.nih.gov/21847463/","https://doi.org/10.4103/2230-8210.83049",null],["2","R0050266","R0050266.pdf","no_doi","randomized_trial","Wendy L. Bennett","2011","Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet]",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050342","R0050342.pdf","open_download_failed","randomized_trial","Stuart R. Maudsley","2011","To Be or Not To Be—Obese","Endocrinology","The Endocrine Society","10.1210/en.2011-1615","https://doi.org/10.1210/en.2011-1615","21937750","https://pubmed.ncbi.nlm.nih.gov/21937750/","https://academic.oup.com/endo/article-pdf/152/10/3592/9010250/endo3592.pdf",null],["2","R0053574","R0053574.pdf","no_doi","randomized_trial","Michael E. J. Lean","2011","Incidence and effects of nausea on weight loss and quality of life with the glp-1 analogue liraglutide:a 52 week randomised trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0018773","R0018773.pdf","no_doi","randomized_trial","Campbell RK","2010","Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.","The Journal of family practice",null,null,"https://doi.org/","20824235","https://pubmed.ncbi.nlm.nih.gov/20824235/",null,null],["2","R0020748","R0020748.pdf","no_doi","randomized_trial","Mannucci E","2010","[Glucagon-like peptide-1 analogues and cardiovascular risk factors: evidence from clinical trials].","Giornale italiano di cardiologia (2006)",null,null,"https://doi.org/","21361053","https://pubmed.ncbi.nlm.nih.gov/21361053/",null,null],["2","R0023783","R0023783.pdf","no_doi","randomized_trial",null,"2010","Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.","Prescrire international",null,null,"https://doi.org/","20738033","https://pubmed.ncbi.nlm.nih.gov/20738033/",null,null],["2","R0027257","R0027257.pdf","open_download_failed","randomized_trial","Gallwitz B","2010","Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.","International journal of clinical practice","Hindawi Limited","10.1111/j.1742-1241.2009.02265.x","https://doi.org/10.1111/j.1742-1241.2009.02265.x","19925617","https://pubmed.ncbi.nlm.nih.gov/19925617/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2009.02265.x",null],["2","R0027606","R0027606.pdf","free_to_read","randomized_trial","Tsai AG","2010","Randomised controlled trial: Liraglutide for weight loss: more research is needed.","Evidence-based medicine","BMJ","10.1136/ebm1041","https://doi.org/10.1136/ebm1041","20436119","https://pubmed.ncbi.nlm.nih.gov/20436119/",null,null],["2","R0027617","R0027617.pdf","free_to_read","randomized_trial","Koh A","2010","Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0b013e3181bcdbe8","https://doi.org/10.1097/tp.0b013e3181bcdbe8","20145529","https://pubmed.ncbi.nlm.nih.gov/20145529/","https://archive-ouverte.unige.ch/unige:20693",null],["2","R0027695","R0027695.pdf","free_to_read","randomized_trial","Fonseca V","2010","Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone.","Evidence-based medicine","BMJ","10.1136/ebm1098","https://doi.org/10.1136/ebm1098","20610447","https://pubmed.ncbi.nlm.nih.gov/20610447/",null,null],["2","R0027741","R0027741.pdf","free_to_read","randomized_trial","McAdam-Marx C","2010","Contemporary management of patients with Type 2 diabetes.","Expert review of cardiovascular therapy","Informa UK Limited","10.1586/erc.10.62","https://doi.org/10.1586/erc.10.62","20528633","https://pubmed.ncbi.nlm.nih.gov/20528633/",null,null],["2","R0027934","R0027934.pdf","open_download_failed","randomized_trial","Edholm T","2010","Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.","Neurogastroenterology and motility","Wiley","10.1111/j.1365-2982.2010.01554.x","https://doi.org/10.1111/j.1365-2982.2010.01554.x","20584260","https://pubmed.ncbi.nlm.nih.gov/20584260/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2982.2010.01554.x",null],["2","R0031852","R0031852.pdf","no_doi","randomized_trial","Robert E. Ratner","2010","Original Article: Treatment Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0031859","R0031859.pdf","no_doi","randomized_trial","Sarah Elizabeth Withycombe","2010","A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032317","R0032317.pdf","no_doi","randomized_trial","Lean, MEJ","2010","Sustained Weight Loss and Acceptable Tolerability With the GLP-1 Analogue Liraglutide in Obese Non-Diabetic Adults: A 2-Year Randomized Trial","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0032423","R0032423.pdf","no_doi","randomized_trial","Schloegl, H.","2010","Exenatide Increases Hypothalamic Connectivity in Obese Men: First Evidence of Central appetite modulating Effects in fMRI Analyzed With Eigenvector Centrality Mapping","MPG.PuRe (Max Planck Society)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034683","R0034683.pdf","no_doi","randomized_trial","A. Rissanen","2010","Weight loss with liraglutide in obese adults is primarily due to a reduction in fat tissue:a subgroup analysis of a 20-week randomised placebo-controlled trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038051","R0038051.pdf","open_download_failed","randomized_trial","Raffaele De Caterina","2010","Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehp589","https://doi.org/10.1093/eurheartj/ehp589","20418342","https://pubmed.ncbi.nlm.nih.gov/20418342/","https://academic.oup.com/eurheartj/article-pdf/31/10/1159/1317335/ehp589.pdf",null],["2","R0040787","R0040787.pdf","no_doi","randomized_trial",null,"2010","DIABETICMedicine Original Article: Treatment",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040865","R0040865.pdf","no_doi","randomized_trial","Karen Chang","2010","doi: 10.1136/ebn1023",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043419","R0043419.pdf","open_download_failed","randomized_trial","Deepak Bhatnagar","2010","New treatments and new choices for type 2 diabetes mellitus","The Journal of the Royal College of Physicians of Edinburgh","SAGE Publications","10.4997/jrcpe.2010.424","https://doi.org/10.4997/jrcpe.2010.424","21132140","https://pubmed.ncbi.nlm.nih.gov/21132140/","https://doi.org/10.4997/jrcpe.2010.424",null],["2","R0043863","R0043863.pdf","open_download_failed","randomized_trial","David P. Steensma","2010","AJH Hematology Crossword Puzzle, August 2010","American Journal of Hematology","Wiley","10.1002/ajh.21778","https://doi.org/10.1002/ajh.21778",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21778",null],["2","R0044240","R0044240.pdf","no_doi","randomized_trial","David Nathanson","2010","Studies on Incretins and Cardiovascular Function","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045902","R0045902.pdf","open_download_failed","randomized_trial","Melva Louisa","2010","Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials","Medical Journal of Indonesia","Faculty of Medicine, Universitas Indonesia","10.13181/mji.v19i3.406","https://doi.org/10.13181/mji.v19i3.406",null,"https://pubmed.ncbi.nlm.nih.gov//","http://mji.ui.ac.id/journal/index.php/mji/article/download/406/399",null],["2","R0049762","R0049762.pdf","free_to_read","randomized_trial","Matt Armstrong","2010","OP03 Effects of two years of liraglutide treatment on fatty liver disease in patients with type 2 diabetes: analysis of the Liraglutide Effect and Action in Diabetes-2 extension trial","Gut","BMJ","10.1136/gut.2010.223362.3","https://doi.org/10.1136/gut.2010.223362.3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1136/gut.2010.223362.3",null],["2","R0050672","R0050672.pdf","open_download_failed","randomized_trial","Charles J. Fox","2010","‘New therapies for type 2 diabetes have added little to improve glycaemic control compared to conventional therapies’","Practical Diabetes","Wiley","10.1002/pdi.1449","https://doi.org/10.1002/pdi.1449",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1449",null],["2","R0051773","R0051773.pdf","no_doi","randomized_trial","Lean, Michael E. J.","2010","Sustained weight loss and acceptable tolerability with the GLP-1 analogue Liraglutided in obese non-diabetic adults:a 2-year randomized trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051841","R0051841.pdf","no_doi","randomized_trial","Bong Ki Cha","2010","S1316 Patient Willingness to use ROSE-010: A Subcutaneous (SC) GLP-1 Analogue for IBS Pain Episodes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054092","R0054092.pdf","open_download_failed","randomized_trial","Gerit-Holger Schernthaner","2010","Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfq199","https://doi.org/10.1093/ndt/gfq199","20388630","https://pubmed.ncbi.nlm.nih.gov/20388630/","https://academic.oup.com/ndt/article-pdf/25/7/2044/5291156/gfq199.pdf",null],["2","R0021773","R0021773.pdf","no_doi","randomized_trial","Rossi MC","2009","Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.","Acta bio-medica : Atenei Parmensis",null,null,"https://doi.org/","19848045","https://pubmed.ncbi.nlm.nih.gov/19848045/",null,null],["2","R0025342","R0025342.pdf","open_download_failed","randomized_trial","Faradji RN","2009","Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.","Cell transplantation","SAGE Publications","10.3727/096368909x474456","https://doi.org/10.3727/096368909x474456","20003758","https://pubmed.ncbi.nlm.nih.gov/20003758/","https://journals.sagepub.com/doi/pdf/10.3727/096368909X474456","ClinicalTrials.gov:NCT00306098; ClinicalTrials.gov:NCT00315588"],["2","R0027181","R0027181.pdf","open_download_failed","randomized_trial","Smith CC","2009","Effects of exenatide on plasma glucose and insulin concentrations in alpacas.","Journal of veterinary internal medicine","Oxford University Press (OUP)","10.1111/j.1939-1676.2009.0335.x","https://doi.org/10.1111/j.1939-1676.2009.0335.x","19566854","https://pubmed.ncbi.nlm.nih.gov/19566854/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1939-1676.2009.0335.x",null],["2","R0027237","R0027237.pdf","free_to_read","randomized_trial","Brändle M","2009","Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cpp47501","https://doi.org/10.5414/cpp47501","19640359","https://pubmed.ncbi.nlm.nih.gov/19640359/","https://doi.org/10.5167/uzh-31208",null],["2","R0027537","R0027537.pdf","free_to_read","randomized_trial","Rickels MR","2009","Exenatide use in islet transplantation: words of caution.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0b013e318191eb48","https://doi.org/10.1097/tp.0b013e318191eb48","19136906","https://pubmed.ncbi.nlm.nih.gov/19136906/",null,null],["2","R0027562","R0027562.pdf","open_download_failed","randomized_trial","Froud T","2009","Exenatide Use in Islet Transplantation - Reasons to Remain Optimistic.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0b013e318191ebe9","https://doi.org/10.1097/tp.0b013e318191ebe9","20737025","https://pubmed.ncbi.nlm.nih.gov/20737025/","https://www.ncbi.nlm.nih.gov/pmc/articles/2925279",null],["2","R0032000","R0032000.pdf","no_doi","randomized_trial","Luc F. Van Gaal","2009","Long-term outcome of placental-site trophoblastic tumours",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034291","R0034291.pdf","no_doi","randomized_trial","Nick Finer","2009","The once-daily human GLP-1 analog liraglutide reduces the prevalence of prediabetes and improves systolci blood pressure in obese non-diabetic subjects:a 52-week randomized placebo controlled trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0035088","R0035088.pdf","no_doi","randomized_trial","Peipei Li","2009","Effects of exendin-4 on the expression of IRS-2 of pancreatic β cells in STZ diabetic rat islet","Acta Academiae Medicinae Xuzhou",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040699","R0040699.pdf","no_doi","randomized_trial","Michael A Nauck","2009","Corresponding author:",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040715","R0040715.pdf","no_doi","randomized_trial","Julio Rosenstock","2009","Albiglutide dose regimen study The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing Running title: Albiglutide dose regimen study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040999","R0040999.pdf","no_doi","randomized_trial","Royal Guildford Hospital","2009","ARTICLE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041266","R0041266.pdf","no_doi","randomized_trial","John B Buse","2009","Articles",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041267","R0041267.pdf","no_doi","randomized_trial",null,"2009","DIABETICMedicine Original Article: Treatment Improved treatment satisfaction and weight-related",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0043144","R0043144.pdf","open_download_failed","randomized_trial","Wroe Cd","2009","Autumn 2008 Meeting of the Association of British Clinical Diabetologists","Practical Diabetes","Wiley","10.1002/pdi.1363","https://doi.org/10.1002/pdi.1363",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1363",null],["2","R0048330","R0048330.pdf","no_doi","randomized_trial","Nick Finer","2009","Liraglutide, a once-daily human GLP-1 analog, reverses indices of prediabetes in obese subjects: A randomized placebo-controlled 20-week trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048680","R0048680.pdf","no_doi","randomized_trial","Nick Finer","2009","Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050442","R0050442.pdf","no_doi","randomized_trial","Arne Vernon Astrup","2009","Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0050914","R0050914.pdf","no_doi","randomized_trial","Arne Vernon Astrup","2009","Tolerability and weight loss effects of liraglutide in obese adults: a 104-week randomised trial","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0051600","R0051600.pdf","no_doi","randomized_trial","Julio Rosenstock","2009","The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing Running title: Albiglutide dose regimen study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0052709","R0052709.pdf","no_doi","randomized_trial","Nick Finer","2009","The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0055909","R0055909.pdf","no_doi","randomized_trial","M. C. Rossi","2009","Liraglutide in type 2 diabetes: from pharmacological development toclinical practice","Acta bio-medica dell'Ateneo parmense/Acta biomedica",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0026746","R0026746.pdf","open_download_failed","randomized_trial","Matthews JE","2008","Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2008-1518","https://doi.org/10.1210/jc.2008-1518","18812476","https://pubmed.ncbi.nlm.nih.gov/18812476/","https://academic.oup.com/jcem/article-pdf/93/12/4810/9055024/jcem4810.pdf",null],["2","R0027255","R0027255.pdf","free_to_read","randomized_trial","Kothare PA","2008","Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.","Journal of clinical pharmacology","Wiley","10.1177/0091270008323750","https://doi.org/10.1177/0091270008323750","19047364","https://pubmed.ncbi.nlm.nih.gov/19047364/",null,null],["2","R0027913","R0027913.pdf","open_download_failed","randomized_trial","Faradji RN","2008","Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0b013e31818fe448","https://doi.org/10.1097/tp.0b013e31818fe448","19104401","https://pubmed.ncbi.nlm.nih.gov/19104401/","https://www.ncbi.nlm.nih.gov/pmc/articles/2759384",null],["2","R0027976","R0027976.pdf","open_download_failed","randomized_trial","Bharucha AE","2008","Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.","American journal of physiology. Regulatory, integrative and comparative physiology","American Physiological Society","10.1152/ajpregu.00153.2008","https://doi.org/10.1152/ajpregu.00153.2008","18596108","https://pubmed.ncbi.nlm.nih.gov/18596108/","https://www.ncbi.nlm.nih.gov/pmc/articles/2536850",null],["2","R0031066","R0031066.pdf","no_doi","randomized_trial","Zhufang Shen","2008","Recent progress on exendin-4,a novel therapeutic drug for diabetes","The Chinese Journal of Clinical Pharmacology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0038773","R0038773.pdf","open_download_failed","randomized_trial",null,"2008","Latest news and product developments","Prescriber","Wiley","10.1002/psb.250","https://doi.org/10.1002/psb.250",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psb.250",null],["2","R0039669","R0039669.pdf","free_to_read","randomized_trial","Wenying Yang","2008","Mission: halt diabetes momentum and stop growing epidemic","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/00029330-200811010-00001","https://doi.org/10.1097/00029330-200811010-00001","19080168","https://pubmed.ncbi.nlm.nih.gov/19080168/","https://doi.org/10.1097/00029330-200811010-00001",null],["2","R0041309","R0041309.pdf","no_doi","randomized_trial",null,"2008","Articles",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044095","R0044095.pdf","open_download_failed","randomized_trial","Barry J. Goldstein","2008","Inflammatory Signaling: Another Drug Target to Improve Glycemic Control in Type 2 Diabetes","Clinical and Translational Science","Wiley","10.1111/j.1752-8062.2008.00011.x","https://doi.org/10.1111/j.1752-8062.2008.00011.x","19468293","https://pubmed.ncbi.nlm.nih.gov/19468293/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1752-8062.2008.00011.x",null],["2","R0046140","R0046140.pdf","free_to_read","randomized_trial","Lawrence S. Phillips","2008","It's Time to Overcome Clinical Inertia","Annals of Internal Medicine","American College of Physicians","10.7326/0003-4819-148-10-200805200-00011","https://doi.org/10.7326/0003-4819-148-10-200805200-00011","18490691","https://pubmed.ncbi.nlm.nih.gov/18490691/","https://www.ncbi.nlm.nih.gov/pmc/articles/3685435",null],["2","R0054112","R0054112.pdf","no_doi","randomized_trial","Nauck, M.A.; Diabetes Center, Bad Lauterberg im Harz, Niemcy","2008","Porównanie skuteczności eksenatydu stosowanego dwa razy na dobę i dwufazowej insuliny aspart u chorych na cukrzycę typu 2 leczonych wcześniej z umiarkowanym efektem pochodnymi sulfonylomocznika i metforminą: badanie nie mniejszej skuteczności (non-inferiority)","Via Medica Journals",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0054609","R0054609.pdf","no_doi","randomized_trial","Arne Astrup","2008","Liraglutide, a once-daily human GLP-1 analogue, reduces body weight and improves obesity-related risk factors in obese non-diabetic subjects: A randomised placebo-controlled trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0023962","R0023962.pdf","free_to_read","randomized_trial","Raun K","2007","Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.","Diabetes","American Diabetes Association","10.2337/db06-0565","https://doi.org/10.2337/db06-0565","17192459","https://pubmed.ncbi.nlm.nih.gov/17192459/",null,null],["2","R0027320","R0027320.pdf","no_doi","randomized_trial",null,"2007","Exenatide: new drug. Type 2 diabetes for some overweight patients.","Prescrire international",null,null,"https://doi.org/","18087791","https://pubmed.ncbi.nlm.nih.gov/18087791/",null,null],["2","R0027375","R0027375.pdf","open_download_failed","randomized_trial","Herman RE","2007","The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7.","The Journal of biological chemistry","Elsevier BV","10.1074/jbc.m610722200","https://doi.org/10.1074/jbc.m610722200","17264074","https://pubmed.ncbi.nlm.nih.gov/17264074/","http://www.jbc.org/article/S0021925819336373/pdf",null],["2","R0027422","R0027422.pdf","no_doi","randomized_trial","Féry F","2007","[The incretin effect: a new therapeutic target in type 2 diabetes].","Revue medicale de Bruxelles",null,null,"https://doi.org/","17958029","https://pubmed.ncbi.nlm.nih.gov/17958029/",null,null],["2","R0027492","R0027492.pdf","open_download_failed","randomized_trial","Kim D","2007","Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/dc06-2375","https://doi.org/10.2337/dc06-2375","17353504","https://pubmed.ncbi.nlm.nih.gov/17353504/","https://diabetesjournals.org/care/article-pdf/30/6/1487/598085/zdc00607001487.pdf",null],["2","R0027523","R0027523.pdf","open_download_failed","randomized_trial","Andrews CN","2007","Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.","Neurogastroenterology and motility","Wiley","10.1111/j.1365-2982.2007.00923.x","https://doi.org/10.1111/j.1365-2982.2007.00923.x","17727392","https://pubmed.ncbi.nlm.nih.gov/17727392/","https://www.ncbi.nlm.nih.gov/pmc/articles/2538797",null],["2","R0027578","R0027578.pdf","free_to_read","randomized_trial","Ray JA","2007","Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.","Current medical research and opinion","Informa UK Limited","10.1185/030079907x178685","https://doi.org/10.1185/030079907x178685","17355742","https://pubmed.ncbi.nlm.nih.gov/17355742/","https://figshare.com/articles/journal_contribution/Exenatide_versus_insulin_glargine_in_patients_with_type_2_diabetes_in_the_UK_a_model_of_long-term_clinical_and_cost_outcomes/22887470",null],["2","R0031153","R0031153.pdf","no_doi","randomized_trial","Zheng Jing-che","2007","Eexperimental study of exendin-4 for weight reduction in obese rats","Medical Journal of the Chinese People's Armed Police Forces",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0034184","R0034184.pdf","no_doi","randomized_trial","Fery, Françoise","2007","L'effet incrétine: Une nouvelle cible thérapeutique dans le diabète de type 2","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0048208","R0048208.pdf","open_download_failed","randomized_trial","Marion C. Devers","2007","Type 2 diabetes: getting off to a good start","Practical Diabetes","Wiley","10.1002/pdi.1033","https://doi.org/10.1002/pdi.1033",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.1033",null],["2","R0022821","R0022821.pdf","open_download_failed","randomized_trial","Bond A","2006","Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.","Proceedings (Baylor University. Medical Center)","Informa UK Limited","10.1080/08998280.2006.11928181","https://doi.org/10.1080/08998280.2006.11928181","17252050","https://pubmed.ncbi.nlm.nih.gov/17252050/","https://www.tandfonline.com/doi/pdf/10.1080/08998280.2006.11928181?needAccess=true&role=button",null],["2","R0040910","R0040910.pdf","no_doi","randomized_trial","Vivian Fonseca","2006","Email correspondence",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0042725","R0042725.pdf","open_download_failed","randomized_trial","Charles D Wroe","2006","41st Annual Meeting of the European Association for the study of Diabetes","Practical Diabetes","Wiley","10.1002/pdi.905","https://doi.org/10.1002/pdi.905",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pdi.905",null],["2","R0027682","R0027682.pdf","free_to_read","randomized_trial","Kolterman OG","2005","Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/62.2.173","https://doi.org/10.1093/ajhp/62.2.173","15700891","https://pubmed.ncbi.nlm.nih.gov/15700891/",null,null],["2","R0023713","R0023713.pdf","free_to_read","randomized_trial","Madsbad S","2004","Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.","Diabetes care","American Diabetes Association","10.2337/diacare.27.6.1335","https://doi.org/10.2337/diacare.27.6.1335","15161785","https://pubmed.ncbi.nlm.nih.gov/15161785/",null,null],["2","R0026162","R0026162.pdf","no_doi","randomized_trial","Scheen AJ","2004","[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].","Revue medicale de Liege",null,null,"https://doi.org/","15346979","https://pubmed.ncbi.nlm.nih.gov/15346979/",null,null],["2","R0042636","R0042636.pdf","open_download_failed","randomized_trial",null,"2004","Algoritmos para determinar el umbral de alerta ante epidemias de malaria","Revista Panamericana de Salud Pública","FapUNIFESP (SciELO)","10.1590/s1020-49892004000800012","https://doi.org/10.1590/s1020-49892004000800012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://scielosp.org/article/ssm/content/raw/?resource_ssm_path=/media/assets/rpsp/v16n2/22251.pdf",null],["2","R0021871","R0021871.pdf","open_download_failed","randomized_trial","Fineman MS","2003","Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.","Diabetes care","American Diabetes Association","10.2337/diacare.26.8.2370","https://doi.org/10.2337/diacare.26.8.2370","12882864","https://pubmed.ncbi.nlm.nih.gov/12882864/","https://diabetesjournals.org/care/article-pdf/26/8/2370/660914/dc0803002370.pdf",null],["2","R0027413","R0027413.pdf","open_download_failed","randomized_trial","Larsen PJ","2001","Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.","Diabetes","American Diabetes Association","10.2337/diabetes.50.11.2530","https://doi.org/10.2337/diabetes.50.11.2530","11679431","https://pubmed.ncbi.nlm.nih.gov/11679431/","https://diabetesjournals.org/diabetes/article-pdf/50/11/2530/339488/db1101002530.pdf",null],["2","R0017479","R0017479.pdf","free_to_read","randomized_trial","Feingold KR","2000","Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease in Patients with Diabetes","MDText.com, Inc., South Dartmouth (MA)",null,null,"https://doi.org/","25905182","https://pubmed.ncbi.nlm.nih.gov/25905182/",null,null],["2","R0030093","R0030093.pdf","free_to_read","randomized_trial","Feingold KR","2000","Dyslipidemia in Patients with Diabetes","MDText.com, Inc., South Dartmouth (MA)",null,null,"https://doi.org/","26247092","https://pubmed.ncbi.nlm.nih.gov/26247092/",null,null],["2","R0030338","R0030338.pdf","free_to_read","randomized_trial","Naha S","2000","Hypertension in Diabetes","MDText.com, Inc., South Dartmouth (MA)",null,null,"https://doi.org/","25905256","https://pubmed.ncbi.nlm.nih.gov/25905256/",null,null],["2","R0029847","R0029847.pdf","free_to_read","randomized_trial","Wolfhagen MJ","1990","Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.","Antimicrobial agents and chemotherapy","American Society for Microbiology","10.1128/aac.34.3.409","https://doi.org/10.1128/aac.34.3.409","2110437","https://pubmed.ncbi.nlm.nih.gov/2110437/","https://www.ncbi.nlm.nih.gov/pmc/articles/171606",null],["2","R0029859","R0029859.pdf","free_to_read","randomized_trial","Weidekamm E","1987","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.","Antimicrobial agents and chemotherapy","American Society for Microbiology","10.1128/aac.31.12.1909","https://doi.org/10.1128/aac.31.12.1909","3125788","https://pubmed.ncbi.nlm.nih.gov/3125788/","https://www.ncbi.nlm.nih.gov/pmc/articles/175826",null],["2","R0032488","R0032488.pdf","no_doi","randomized_trial","雄一郎 井上",null,"A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0036439","R0036439.pdf","no_doi","randomized_trial","Martin Torp Rahbek",null,"Association of glucagon-like peptide 1 receptor agonists and treatment for bile acid diarrhea","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040409","R0040409.pdf","no_doi","randomized_trial","裕達 中口",null,"Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0040600","R0040600.pdf","no_doi","randomized_trial","弘江 長池",null,"Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0041874","R0041874.pdf","no_doi","randomized_trial","咲 山本",null,"Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0044785","R0044785.pdf","no_doi","randomized_trial","匡彦 宮城",null,"Up-titration strategy after DPP-4 inhibitor-based oral therapy for type 2 diabetes: A randomized controlled trial shifting to a single-dose GLP-1 enhancer versus adding a variable basal insulin algorithm","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["2","R0045138","R0045138.pdf","no_doi","randomized_trial","Takahiro Iijima",null,"Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0000007","R0000007.pdf","paywalled","systematic_review","Zhong X","2026","Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-2923-3830","https://doi.org/10.1055/a-2923-3830","42600634","https://pubmed.ncbi.nlm.nih.gov/42600634/",null,null],["3","R0000008","R0000008.pdf","paywalled","systematic_review","Moiz A","2026","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-05519","https://doi.org/10.7326/annals-25-05519","42673585","https://pubmed.ncbi.nlm.nih.gov/42673585/",null,"PROSPERO:CRD42024505558"],["3","R0000014","R0000014.pdf","paywalled","systematic_review","Abomohsen M","2026","Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2026.04.001","https://doi.org/10.1016/j.jcjd.2026.04.001","41967797","https://pubmed.ncbi.nlm.nih.gov/41967797/",null,null],["3","R0000165","R0000165.pdf","paywalled","systematic_review","Muthu S","2026","Can glucagon-like peptide-1 receptor agonists affect outcomes after spine surgery? A systematic review and meta-analysis.","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Springer Science and Business Media LLC","10.1007/s00586-026-10205-x","https://doi.org/10.1007/s00586-026-10205-x","42471496","https://pubmed.ncbi.nlm.nih.gov/42471496/",null,null],["3","R0000202","R0000202.pdf","paywalled","systematic_review","Hung TH","2026","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Human psychopharmacology","Wiley","10.1002/hup.70041","https://doi.org/10.1002/hup.70041","41914576","https://pubmed.ncbi.nlm.nih.gov/41914576/",null,"PROSPERO:CRD42024566217"],["3","R0000206","R0000206.pdf","paywalled","systematic_review","Wachiraphansakul N","2026","Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70884","https://doi.org/10.1111/dom.70884","42209204","https://pubmed.ncbi.nlm.nih.gov/42209204/",null,null],["3","R0000313","R0000313.pdf","paywalled","systematic_review","Sobral MVS","2026","Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.","Schizophrenia research","Elsevier BV","10.1016/j.schres.2026.06.025","https://doi.org/10.1016/j.schres.2026.06.025","42497473","https://pubmed.ncbi.nlm.nih.gov/42497473/",null,"PROSPERO:CRD420251177261"],["3","R0000340","R0000340.pdf","paywalled","systematic_review","Dhivagaran T","2026","Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000214864","https://doi.org/10.1212/wnl.0000000000214864","42060879","https://pubmed.ncbi.nlm.nih.gov/42060879/",null,null],["3","R0000358","R0000358.pdf","paywalled","systematic_review","Yu X","2026","GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Springer Science and Business Media LLC","10.1007/s00586-026-10293-9","https://doi.org/10.1007/s00586-026-10293-9","42635669","https://pubmed.ncbi.nlm.nih.gov/42635669/",null,null],["3","R0000368","R0000368.pdf","paywalled","systematic_review","Yang N","2026","Glucagon-like peptide-1 receptor agonists and bowel preparation: methodological and clinical considerations for meta-analysis.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2026.03.005","https://doi.org/10.1016/j.gie.2026.03.005","42601135","https://pubmed.ncbi.nlm.nih.gov/42601135/",null,null],["3","R0000393","R0000393.pdf","paywalled","systematic_review","Joy B","2026","Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-025-04494-3","https://doi.org/10.1007/s12020-025-04494-3","41489846","https://pubmed.ncbi.nlm.nih.gov/41489846/",null,null],["3","R0000397","R0000397.pdf","paywalled","systematic_review","Basile C","2026","Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf560","https://doi.org/10.1093/eurjpc/zwaf560","40899050","https://pubmed.ncbi.nlm.nih.gov/40899050/",null,null],["3","R0000413","R0000413.pdf","paywalled","systematic_review","Phutinart S","2026","Visual and Neurological Outcomes Following Glucagon-Like Peptide-1 Receptor Agonist Therapy and Bariatric Surgery in Idiopathic Intracranial Hypertension: A Network Meta-Analysis.","Metabolic syndrome and related disorders","SAGE Publications","10.1177/15578518261442833","https://doi.org/10.1177/15578518261442833","41973746","https://pubmed.ncbi.nlm.nih.gov/41973746/",null,null],["3","R0000415","R0000415.pdf","paywalled","systematic_review","Sajjad M","2026","GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.","Multiple sclerosis and related disorders","Elsevier BV","10.1016/j.msard.2026.107388","https://doi.org/10.1016/j.msard.2026.107388","42470876","https://pubmed.ncbi.nlm.nih.gov/42470876/",null,"PROSPERO:CRD420261385854"],["3","R0000423","R0000423.pdf","paywalled","systematic_review","Cheng PL","2026","Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113333","https://doi.org/10.1016/j.diabres.2026.113333","42155605","https://pubmed.ncbi.nlm.nih.gov/42155605/",null,null],["3","R0000427","R0000427.pdf","paywalled","systematic_review","Soliman AT","2026","GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113400","https://doi.org/10.1016/j.diabres.2026.113400","42365860","https://pubmed.ncbi.nlm.nih.gov/42365860/",null,null],["3","R0000473","R0000473.pdf","paywalled","systematic_review","Chan YC","2026","Glucagon-Like Peptide-1 Receptor Agonists, Readmission, and Postoperative Complications in Arthroplasty: A Systematic Review and Meta-Analysis.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.11.036","https://doi.org/10.1016/j.arth.2025.11.036","41276236","https://pubmed.ncbi.nlm.nih.gov/41276236/",null,null],["3","R0000497","R0000497.pdf","paywalled","systematic_review",null,"2026","Summary for Patients: An Updated Systematic Review on Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-05519-ps","https://doi.org/10.7326/annals-25-05519-ps","42673597","https://pubmed.ncbi.nlm.nih.gov/42673597/",null,null],["3","R0000511","R0000511.pdf","paywalled","systematic_review","Barone M","2026","Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05820-4","https://doi.org/10.1007/s00266-026-05820-4","42162206","https://pubmed.ncbi.nlm.nih.gov/42162206/",null,null],["3","R0000536","R0000536.pdf","paywalled","systematic_review","Moubarak ES","2026","Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811261478625","https://doi.org/10.1177/02698811261478625","42746999","https://pubmed.ncbi.nlm.nih.gov/42746999/",null,null],["3","R0000543","R0000543.pdf","paywalled","systematic_review","Ahmed M","2026","Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcag079","https://doi.org/10.1093/ehjqcco/qcag079","42142362","https://pubmed.ncbi.nlm.nih.gov/42142362/",null,null],["3","R0000577","R0000577.pdf","paywalled","systematic_review","Wajid MA","2026","Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","International journal of psychiatry in medicine","SAGE Publications","10.1177/00912174261479866","https://doi.org/10.1177/00912174261479866","42628005","https://pubmed.ncbi.nlm.nih.gov/42628005/",null,null],["3","R0000599","R0000599.pdf","paywalled","systematic_review","Chiappa GR","2026","Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70572","https://doi.org/10.1111/dom.70572","41725443","https://pubmed.ncbi.nlm.nih.gov/41725443/",null,null],["3","R0000621","R0000621.pdf","paywalled","systematic_review","Srisurapanont M","2026","Response to Letter to the Editor: Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","International journal of psychiatry in medicine","SAGE Publications","10.1177/00912174261480243","https://doi.org/10.1177/00912174261480243","42633966","https://pubmed.ncbi.nlm.nih.gov/42633966/",null,null],["3","R0000661","R0000661.pdf","paywalled","systematic_review","Deameh MG","2026","Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.","The journal of sexual medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf381","https://doi.org/10.1093/jsxmed/qdaf381","41498523","https://pubmed.ncbi.nlm.nih.gov/41498523/",null,null],["3","R0000710","R0000710.pdf","paywalled","systematic_review","Lauri G","2026","Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis.","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Elsevier BV","10.1016/j.pan.2026.04.005","https://doi.org/10.1016/j.pan.2026.04.005","41991368","https://pubmed.ncbi.nlm.nih.gov/41991368/",null,null],["3","R0000737","R0000737.pdf","paywalled","systematic_review","Saadat S","2026","Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Obesity-Associated Asthma: A Systematic Review of Clinical Outcomes and Translational Mechanisms.","The journal of allergy and clinical immunology. In practice","Elsevier BV","10.1016/j.jaip.2026.05.010","https://doi.org/10.1016/j.jaip.2026.05.010","42167405","https://pubmed.ncbi.nlm.nih.gov/42167405/",null,null],["3","R0000831","R0000831.pdf","paywalled","systematic_review","Sun SP","2026","GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-026-11132-1","https://doi.org/10.1007/s12072-026-11132-1","42509395","https://pubmed.ncbi.nlm.nih.gov/42509395/",null,"PROSPERO:CRD420261287573"],["3","R0000840","R0000840.pdf","paywalled","systematic_review","Nogueira A","2026","Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis.","Diabetes care","American Diabetes Association","10.2337/dc25-1238","https://doi.org/10.2337/dc25-1238","41498755","https://pubmed.ncbi.nlm.nih.gov/41498755/",null,null],["3","R0000875","R0000875.pdf","paywalled","systematic_review","Ateiwi YA","2026","Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113158","https://doi.org/10.1016/j.diabres.2026.113158","41722869","https://pubmed.ncbi.nlm.nih.gov/41722869/",null,null],["3","R0000895","R0000895.pdf","paywalled","systematic_review","Srisurapanont M","2026","Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.","International journal of psychiatry in medicine","SAGE Publications","10.1177/00912174261422822","https://doi.org/10.1177/00912174261422822","41618880","https://pubmed.ncbi.nlm.nih.gov/41618880/",null,null],["3","R0000907","R0000907.pdf","paywalled","systematic_review","Pham TP","2026","Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70635","https://doi.org/10.1111/dom.70635","41804851","https://pubmed.ncbi.nlm.nih.gov/41804851/",null,"PROSPERO:CRD42024592825"],["3","R0000916","R0000916.pdf","paywalled","systematic_review","M A","2026","Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2026.125953","https://doi.org/10.1016/j.jns.2026.125953","42176522","https://pubmed.ncbi.nlm.nih.gov/42176522/",null,null],["3","R0000919","R0000919.pdf","paywalled","systematic_review","Wang L","2026","Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-026-04015-9","https://doi.org/10.1007/s00228-026-04015-9","41811375","https://pubmed.ncbi.nlm.nih.gov/41811375/",null,null],["3","R0000950","R0000950.pdf","paywalled","systematic_review","White RT","2026","Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.","Pharmacotherapy","Wiley","10.1002/phar.70135","https://doi.org/10.1002/phar.70135","41947645","https://pubmed.ncbi.nlm.nih.gov/41947645/",null,"PROSPERO:CRD42024615851"],["3","R0000956","R0000956.pdf","paywalled","systematic_review","Cao B","2026","Comment on \"The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis\".","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-026-02700-w","https://doi.org/10.1007/s00592-026-02700-w","42089955","https://pubmed.ncbi.nlm.nih.gov/42089955/",null,null],["3","R0001105","R0001105.pdf","paywalled","systematic_review","Srinivasan N","2026","Comment on \"efficacy of glucagon-like Peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2026.125877","https://doi.org/10.1016/j.jns.2026.125877","41955853","https://pubmed.ncbi.nlm.nih.gov/41955853/",null,null],["3","R0001125","R0001125.pdf","paywalled","systematic_review","Lee S","2026","The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.09.054","https://doi.org/10.1016/j.arth.2025.09.054","41072556","https://pubmed.ncbi.nlm.nih.gov/41072556/",null,null],["3","R0001142","R0001142.pdf","paywalled","systematic_review","Chan YC","2026","Reply to the Letter to the Editor on \"The Association Between Glucagon-like Peptide-1 Receptor Agonists and Postoperative Complications after Arthroplasty: A Systematic Review and Meta-Analysis\".","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.12.010","https://doi.org/10.1016/j.arth.2025.12.010","41881605","https://pubmed.ncbi.nlm.nih.gov/41881605/",null,null],["3","R0001145","R0001145.pdf","paywalled","systematic_review","Zhang M","2026","Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2026.125867","https://doi.org/10.1016/j.jns.2026.125867","41826174","https://pubmed.ncbi.nlm.nih.gov/41826174/",null,null],["3","R0001151","R0001151.pdf","paywalled","systematic_review","Rivero-Moreno Y","2026","Comparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients.","Journal of laparoendoscopic & advanced surgical techniques. Part A","SAGE Publications","10.1177/10926429261469272","https://doi.org/10.1177/10926429261469272","42452903","https://pubmed.ncbi.nlm.nih.gov/42452903/",null,null],["3","R0001152","R0001152.pdf","paywalled","systematic_review","Falcão L","2026","Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","Headache","Wiley","10.1111/head.70131","https://doi.org/10.1111/head.70131","42619634","https://pubmed.ncbi.nlm.nih.gov/42619634/",null,null],["3","R0001174","R0001174.pdf","paywalled","systematic_review","Farmakis D","2026","The role of glucagon-like peptide-1 receptor agonists in cancer therapy-related cardiovascular disease: a meta-analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf730","https://doi.org/10.1093/eurjpc/zwaf730","41253686","https://pubmed.ncbi.nlm.nih.gov/41253686/",null,null],["3","R0001189","R0001189.pdf","paywalled","systematic_review","Zheng X","2026","Comment on: Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.12.009","https://doi.org/10.1016/j.soard.2025.12.009","41946634","https://pubmed.ncbi.nlm.nih.gov/41946634/",null,null],["3","R0001210","R0001210.pdf","paywalled","systematic_review","Francisco C","2026","Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Springer Science and Business Media LLC","10.1007/s00417-026-07430-x","https://doi.org/10.1007/s00417-026-07430-x","42541561","https://pubmed.ncbi.nlm.nih.gov/42541561/",null,"PROSPERO:CRD420251237987"],["3","R0001222","R0001222.pdf","paywalled","systematic_review","Parekh RS","2026","GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102150","https://doi.org/10.1016/j.disamonth.2026.102150","42215399","https://pubmed.ncbi.nlm.nih.gov/42215399/",null,null],["3","R0001249","R0001249.pdf","paywalled","systematic_review","Berardicurti A","2026","Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis.","Internal and emergency medicine","Springer Science and Business Media LLC","10.1007/s11739-026-04384-0","https://doi.org/10.1007/s11739-026-04384-0","42141180","https://pubmed.ncbi.nlm.nih.gov/42141180/",null,"PROSPERO:CRD420251162316"],["3","R0001278","R0001278.pdf","paywalled","systematic_review","Guevel B","2026","Letter Regarding \"The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis (Chan et al., J Arthroplasty, 2025)\".","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.11.050","https://doi.org/10.1016/j.arth.2025.11.050","41881604","https://pubmed.ncbi.nlm.nih.gov/41881604/",null,null],["3","R0001279","R0001279.pdf","paywalled","systematic_review","Gadelmawla AF","2026","CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.02.030","https://doi.org/10.1016/j.amjcard.2026.02.030","41759565","https://pubmed.ncbi.nlm.nih.gov/41759565/",null,null],["3","R0001359","R0001359.pdf","paywalled","systematic_review","Bhaduri G","2026","GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04559-x","https://doi.org/10.1007/s12020-026-04559-x","41697556","https://pubmed.ncbi.nlm.nih.gov/41697556/",null,null],["3","R0001366","R0001366.pdf","paywalled","systematic_review","Barreto EF","2026","SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.","Pharmacotherapy","Wiley","10.1002/phar.70137","https://doi.org/10.1002/phar.70137","41947629","https://pubmed.ncbi.nlm.nih.gov/41947629/",null,null],["3","R0001415","R0001415.pdf","paywalled","systematic_review","AbdelMagid AM","2026","Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis.","Pharmacotherapy","Wiley","10.1002/phar.70142","https://doi.org/10.1002/phar.70142","41947610","https://pubmed.ncbi.nlm.nih.gov/41947610/",null,null],["3","R0001420","R0001420.pdf","paywalled","systematic_review","Ko A","2026","Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-02237","https://doi.org/10.7326/annals-25-02237","41359966","https://pubmed.ncbi.nlm.nih.gov/41359966/",null,"PROSPERO:CRD42024608365"],["3","R0001453","R0001453.pdf","paywalled","systematic_review","Xu H","2026","The Efficacy of Glucagon-like Peptide-1 Receptor Agonists on Different Cognitive Domains: A Meta-analysis of Randomized Controlled Trials.","Current neuropharmacology","Bentham Science Publishers Ltd.","10.2174/011570159x439787260312090015","https://doi.org/10.2174/011570159x439787260312090015","42163663","https://pubmed.ncbi.nlm.nih.gov/42163663/",null,null],["3","R0001515","R0001515.pdf","paywalled","systematic_review","Ozbek L","2026","Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70699","https://doi.org/10.1111/dom.70699","41885132","https://pubmed.ncbi.nlm.nih.gov/41885132/",null,null],["3","R0001532","R0001532.pdf","paywalled","systematic_review","Guo M","2026","Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70134","https://doi.org/10.1002/dmrr.70134","41668634","https://pubmed.ncbi.nlm.nih.gov/41668634/",null,null],["3","R0001567","R0001567.pdf","paywalled","systematic_review","Parekh DS","2026","GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102151","https://doi.org/10.1016/j.disamonth.2026.102151","42285803","https://pubmed.ncbi.nlm.nih.gov/42285803/",null,null],["3","R0001577","R0001577.pdf","paywalled","systematic_review","Zhou L","2026","The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-026-02697-2","https://doi.org/10.1007/s00592-026-02697-2","42101662","https://pubmed.ncbi.nlm.nih.gov/42101662/",null,"PROSPERO:CRD420251034203"],["3","R0001588","R0001588.pdf","paywalled","systematic_review","Song J","2026","Potential therapeutic role of GLP-1 receptor agonists in Idiopathic intracranial hypertension: a systematic review and meta-analysis.","Neurological research","Informa UK Limited","10.1080/01616412.2026.2640121","https://doi.org/10.1080/01616412.2026.2640121","41776834","https://pubmed.ncbi.nlm.nih.gov/41776834/",null,null],["3","R0001589","R0001589.pdf","paywalled","systematic_review","Cordova F","2026","Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.11.024","https://doi.org/10.1016/j.soard.2025.11.024","41506923","https://pubmed.ncbi.nlm.nih.gov/41506923/",null,null],["3","R0001609","R0001609.pdf","paywalled","systematic_review","Sayed MS","2026","Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000002069","https://doi.org/10.1097/mjt.0000000000002069","41656069","https://pubmed.ncbi.nlm.nih.gov/41656069/",null,null],["3","R0001657","R0001657.pdf","paywalled","systematic_review","Sun WT","2026","Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71094","https://doi.org/10.1111/dom.71094","42426564","https://pubmed.ncbi.nlm.nih.gov/42426564/",null,null],["3","R0001666","R0001666.pdf","paywalled","systematic_review",null,"2026","Annals Video Summary - Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-04736-vs","https://doi.org/10.7326/annals-25-04736-vs","41359969","https://pubmed.ncbi.nlm.nih.gov/41359969/",null,null],["3","R0001697","R0001697.pdf","paywalled","systematic_review","Delgado LM","2026","Metabolic Bariatric Surgery versus GLP-1 Receptor Agonists for Obesity Management: A Systematic Review and Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08551-2","https://doi.org/10.1007/s11695-026-08551-2","41826529","https://pubmed.ncbi.nlm.nih.gov/41826529/",null,null],["3","R0001753","R0001753.pdf","paywalled","systematic_review","Lampsas S","2026","Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Springer Science and Business Media LLC","10.1007/s00417-026-07291-4","https://doi.org/10.1007/s00417-026-07291-4","42201355","https://pubmed.ncbi.nlm.nih.gov/42201355/",null,"PROSPERO:CRD420251155026"],["3","R0001818","R0001818.pdf","paywalled","systematic_review","Zhou Y","2026","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261420209","https://doi.org/10.1177/15209156261420209","41640116","https://pubmed.ncbi.nlm.nih.gov/41640116/",null,"PROSPERO:CRD420251107996"],["3","R0001841","R0001841.pdf","paywalled","systematic_review","Banerjee M","2026","Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04752-y","https://doi.org/10.1007/s12020-026-04752-y","42616235","https://pubmed.ncbi.nlm.nih.gov/42616235/",null,null],["3","R0001995","R0001995.pdf","paywalled","systematic_review","Ouyang C","2026","Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2026.121452","https://doi.org/10.1016/j.jad.2026.121452","41713610","https://pubmed.ncbi.nlm.nih.gov/41713610/",null,null],["3","R0002000","R0002000.pdf","paywalled","systematic_review","O'Mara A","2026","The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-025-08602-z","https://doi.org/10.1007/s10072-025-08602-z","41524953","https://pubmed.ncbi.nlm.nih.gov/41524953/",null,null],["3","R0002031","R0002031.pdf","paywalled","systematic_review","Stefanou MI","2026","Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109271","https://doi.org/10.1016/j.jdiacomp.2026.109271","41619622","https://pubmed.ncbi.nlm.nih.gov/41619622/",null,null],["3","R0002033","R0002033.pdf","paywalled","systematic_review","Škudar S","2026","Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.","The International journal of eating disorders","Wiley","10.1002/eat.70145","https://doi.org/10.1002/eat.70145","42223191","https://pubmed.ncbi.nlm.nih.gov/42223191/",null,null],["3","R0002087","R0002087.pdf","paywalled","systematic_review","Li HY","2026","GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials.","Diabetes care","American Diabetes Association","10.2337/dc25-1929","https://doi.org/10.2337/dc25-1929","41587563","https://pubmed.ncbi.nlm.nih.gov/41587563/",null,null],["3","R0002167","R0002167.pdf","paywalled","systematic_review","Xu S","2026","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Obese or Diabetic Patients With Obstructive Sleep Apnea Syndrome: A Meta-Analysis.","Nutrition reviews","Oxford University Press (OUP)","10.1093/nutrit/nuaf115","https://doi.org/10.1093/nutrit/nuaf115","40700548","https://pubmed.ncbi.nlm.nih.gov/40700548/",null,"PROSPERO:CRD42024599675"],["3","R0002223","R0002223.pdf","paywalled","systematic_review","Yuan Y","2026","GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-026-02380-4","https://doi.org/10.1007/s40265-026-02380-4","42791433","https://pubmed.ncbi.nlm.nih.gov/42791433/",null,"PROSPERO:CRD420251079970"],["3","R0002268","R0002268.pdf","paywalled","systematic_review","Gamal I","2026","Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001465","https://doi.org/10.1097/crd.0000000000001465","42693519","https://pubmed.ncbi.nlm.nih.gov/42693519/",null,null],["3","R0002356","R0002356.pdf","paywalled","systematic_review","Liu C","2026","Efficacy of preoperative GLP-1 receptor agonists on the perioperative outcomes of bariatric surgery: a systematic review and meta-analysis.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.02.019","https://doi.org/10.1016/j.soard.2026.02.019","41887957","https://pubmed.ncbi.nlm.nih.gov/41887957/",null,null],["3","R0002388","R0002388.pdf","paywalled","systematic_review","Visan MA","2026","A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.","American journal of clinical dermatology","Springer Science and Business Media LLC","10.1007/s40257-026-01049-8","https://doi.org/10.1007/s40257-026-01049-8","42295612","https://pubmed.ncbi.nlm.nih.gov/42295612/",null,"PROSPERO:CRD420251110220"],["3","R0002427","R0002427.pdf","paywalled","systematic_review","Damen JAA","2026","Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-03764","https://doi.org/10.7326/annals-24-03764","42296503","https://pubmed.ncbi.nlm.nih.gov/42296503/",null,"PROSPERO:CRD42023491646"],["3","R0002567","R0002567.pdf","paywalled","systematic_review","Quan AT","2026","Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2026.103466","https://doi.org/10.1016/j.dsx.2026.103466","42508090","https://pubmed.ncbi.nlm.nih.gov/42508090/",null,null],["3","R0002582","R0002582.pdf","paywalled","systematic_review","Alfehaid L","2026","Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2465870","https://doi.org/10.1080/14740338.2025.2465870","39964295","https://pubmed.ncbi.nlm.nih.gov/39964295/",null,"PROSPERO:CRD42024585971"],["3","R0002598","R0002598.pdf","paywalled","systematic_review","Abdallah AK","2026","Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-026-09238-3","https://doi.org/10.1007/s10072-026-09238-3","42432163","https://pubmed.ncbi.nlm.nih.gov/42432163/",null,null],["3","R0002664","R0002664.pdf","paywalled","systematic_review","Zhao H","2026","Efficacy of SGLT2i and GLP-1RA in Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0109298673349221251203101854","https://doi.org/10.2174/0109298673349221251203101854","42099143","https://pubmed.ncbi.nlm.nih.gov/42099143/",null,null],["3","R0002672","R0002672.pdf","paywalled","systematic_review","Khan BW","2026","Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-026-05809-5","https://doi.org/10.1007/s00210-026-05809-5","42608559","https://pubmed.ncbi.nlm.nih.gov/42608559/",null,null],["3","R0002747","R0002747.pdf","paywalled","systematic_review","Shekouh D","2026","Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08500-z","https://doi.org/10.1007/s11695-026-08500-z","41644868","https://pubmed.ncbi.nlm.nih.gov/41644868/",null,null],["3","R0002780","R0002780.pdf","paywalled","systematic_review","Zhang J","2026","GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2025.156433","https://doi.org/10.1016/j.metabol.2025.156433","41207615","https://pubmed.ncbi.nlm.nih.gov/41207615/",null,"PROSPERO:CRD420251088042"],["3","R0002812","R0002812.pdf","paywalled","systematic_review","Han S","2026","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70692","https://doi.org/10.1111/dom.70692","41852258","https://pubmed.ncbi.nlm.nih.gov/41852258/",null,"PROSPERO:CRD42024546896"],["3","R0002875","R0002875.pdf","paywalled","systematic_review","Ahmed Z","2026","Bowel preparation quality in patients using glucagon-like peptide-1 agonists: a systematic review and meta-analysis.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2025.08.027","https://doi.org/10.1016/j.gie.2025.08.027","40846241","https://pubmed.ncbi.nlm.nih.gov/40846241/",null,null],["3","R0002880","R0002880.pdf","paywalled","systematic_review","Gunasekaran P","2026","Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102113","https://doi.org/10.1016/j.disamonth.2026.102113","41991422","https://pubmed.ncbi.nlm.nih.gov/41991422/",null,null],["3","R0002998","R0002998.pdf","paywalled","systematic_review","de Oliveira HM","2026","Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.","Headache","Wiley","10.1111/head.70005","https://doi.org/10.1111/head.70005","41246926","https://pubmed.ncbi.nlm.nih.gov/41246926/",null,"PROSPERO:CRD420251058602"],["3","R0003024","R0003024.pdf","paywalled","systematic_review","Carminati M","2026","Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.","International clinical psychopharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/yic.0000000000000595","https://doi.org/10.1097/yic.0000000000000595","40577093","https://pubmed.ncbi.nlm.nih.gov/40577093/",null,null],["3","R0003064","R0003064.pdf","paywalled","systematic_review","Tristan CD","2026","Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-026-00812-w","https://doi.org/10.1007/s40256-026-00812-w","42429894","https://pubmed.ncbi.nlm.nih.gov/42429894/",null,"PROSPERO:CRD420261320840"],["3","R0003129","R0003129.pdf","paywalled","systematic_review","Birda CL","2026","Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review.","Autoimmunity reviews","Elsevier BV","10.1016/j.autrev.2025.103936","https://doi.org/10.1016/j.autrev.2025.103936","41077375","https://pubmed.ncbi.nlm.nih.gov/41077375/",null,"OSF:osf.io/jvmz6"],["3","R0003161","R0003161.pdf","paywalled","systematic_review","Shuja SH","2026","GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2025.09.039","https://doi.org/10.1016/j.amjcard.2025.09.039","41022246","https://pubmed.ncbi.nlm.nih.gov/41022246/",null,null],["3","R0003173","R0003173.pdf","paywalled","systematic_review","Tahir M","2026","Weight Loss Outcomes Between GLP-1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta-Analysis and Meta-Regression.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70676","https://doi.org/10.1111/dom.70676","41873009","https://pubmed.ncbi.nlm.nih.gov/41873009/",null,null],["3","R0003207","R0003207.pdf","paywalled","systematic_review","Passos PRC","2026","Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.","Diabetes care","American Diabetes Association","10.2337/dc26-0336","https://doi.org/10.2337/dc26-0336","41973508","https://pubmed.ncbi.nlm.nih.gov/41973508/",null,null],["3","R0003324","R0003324.pdf","paywalled","systematic_review","Michaelsen MK","2026","GLP-1 Receptor Agonists as Treatment of Nondiabetic Ischemic Stroke: A Systematic Review and Meta-Analysis.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.125.053075","https://doi.org/10.1161/strokeaha.125.053075","41263069","https://pubmed.ncbi.nlm.nih.gov/41263069/",null,null],["3","R0003417","R0003417.pdf","paywalled","systematic_review","Batista PG","2026","GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-026-00809-5","https://doi.org/10.1007/s40256-026-00809-5","42387250","https://pubmed.ncbi.nlm.nih.gov/42387250/",null,"PROSPERO:CRD420251270326"],["3","R0003482","R0003482.pdf","paywalled","systematic_review","Marino G","2026","Cardiovascular Outcomes in Diabetic Patients Treated with Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist: A Systematic Review and Meta-Analysis.","Cardiology",null,"10.1159/000551686","https://doi.org/10.1159/000551686","41979993","https://pubmed.ncbi.nlm.nih.gov/41979993/",null,"PROSPERO:CRD420261306111"],["3","R0003497","R0003497.pdf","paywalled","systematic_review","Caldeira Gaelzer G","2026","Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2025.103194","https://doi.org/10.1016/j.cpcardiol.2025.103194","41173128","https://pubmed.ncbi.nlm.nih.gov/41173128/",null,null],["3","R0003528","R0003528.pdf","paywalled","systematic_review","Cesaro A","2026","Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag077","https://doi.org/10.1093/eurjpc/zwag077","41662383","https://pubmed.ncbi.nlm.nih.gov/41662383/",null,null],["3","R0003862","R0003862.pdf","paywalled","systematic_review","Lei D","2026","Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","Urologic oncology","Elsevier BV","10.1016/j.urolonc.2026.05.024","https://doi.org/10.1016/j.urolonc.2026.05.024","42314323","https://pubmed.ncbi.nlm.nih.gov/42314323/",null,"PROSPERO:CRD420251149266"],["3","R0003961","R0003961.pdf","paywalled","systematic_review","Abreu M","2026","SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.09.007","https://doi.org/10.1016/j.eprac.2026.09.007","42810621","https://pubmed.ncbi.nlm.nih.gov/42810621/",null,null],["3","R0003978","R0003978.pdf","paywalled","systematic_review","Yang J","2026","Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001695","https://doi.org/10.1097/hep.0000000000001695","41609749","https://pubmed.ncbi.nlm.nih.gov/41609749/",null,null],["3","R0004188","R0004188.pdf","paywalled","systematic_review","Abdelaal A","2026","Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2026.02.013","https://doi.org/10.1016/j.ophtha.2026.02.013","41692115","https://pubmed.ncbi.nlm.nih.gov/41692115/",null,"PROSPERO:CRD420251107346"],["3","R0004390","R0004390.pdf","paywalled","systematic_review","Khan S","2026","Glucagon-Like Peptide-1 Receptor Agonists vs. Bariatric Endoscopy: A Systematic Review and Meta Analysis of Efficacy, Safety, and Metabolic Outcomes.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08588-3","https://doi.org/10.1007/s11695-026-08588-3","41954719","https://pubmed.ncbi.nlm.nih.gov/41954719/",null,null],["3","R0004481","R0004481.pdf","paywalled","systematic_review","Abbas N","2026","Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.","Journal of clinical psychopharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcp.0000000000002234","https://doi.org/10.1097/jcp.0000000000002234","42503999","https://pubmed.ncbi.nlm.nih.gov/42503999/",null,"PROSPERO:CRD420251248437"],["3","R0004605","R0004605.pdf","paywalled","systematic_review","Pack SJJ","2026","Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.","Heart (British Cardiac Society)","BMJ","10.1136/heartjnl-2026-327872","https://doi.org/10.1136/heartjnl-2026-327872","42571647","https://pubmed.ncbi.nlm.nih.gov/42571647/",null,"PROSPERO:CRD42025631539"],["3","R0004650","R0004650.pdf","paywalled","systematic_review","Eisa N","2026","Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70666","https://doi.org/10.1111/dom.70666","41877354","https://pubmed.ncbi.nlm.nih.gov/41877354/",null,null],["3","R0004905","R0004905.pdf","paywalled","systematic_review","Giugliano D","2026","GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70454","https://doi.org/10.1111/dom.70454","41508745","https://pubmed.ncbi.nlm.nih.gov/41508745/",null,null],["3","R0005163","R0005163.pdf","paywalled","systematic_review","Ahmed M","2026","Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70667","https://doi.org/10.1111/dom.70667","41834765","https://pubmed.ncbi.nlm.nih.gov/41834765/",null,null],["3","R0005286","R0005286.pdf","paywalled","systematic_review","Thompson K","2026","Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2026.102784","https://doi.org/10.1016/j.clinre.2026.102784","41679467","https://pubmed.ncbi.nlm.nih.gov/41679467/",null,null],["3","R0005357","R0005357.pdf","paywalled","systematic_review","Tong J","2026","The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.06.012","https://doi.org/10.1016/j.soard.2026.06.012","42442963","https://pubmed.ncbi.nlm.nih.gov/42442963/",null,null],["3","R0005379","R0005379.pdf","paywalled","systematic_review","Zhou XY","2026","Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2026.104859","https://doi.org/10.1016/j.numecd.2026.104859","42469143","https://pubmed.ncbi.nlm.nih.gov/42469143/",null,null],["3","R0005398","R0005398.pdf","paywalled","systematic_review","Vienghirun J","2026","GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70698","https://doi.org/10.1111/dom.70698","41872986","https://pubmed.ncbi.nlm.nih.gov/41872986/",null,"PROSPERO:CRD42024539634"],["3","R0005564","R0005564.pdf","paywalled","systematic_review","Dutta D","2026","Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.07.018","https://doi.org/10.1016/j.eprac.2026.07.018","42551699","https://pubmed.ncbi.nlm.nih.gov/42551699/",null,null],["3","R0005746","R0005746.pdf","paywalled","systematic_review","Shegena EA","2026","Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70200","https://doi.org/10.1111/obr.70200","42503568","https://pubmed.ncbi.nlm.nih.gov/42503568/",null,null],["3","R0005763","R0005763.pdf","paywalled","systematic_review","AlAraibi AJ","2026","The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2026.104994","https://doi.org/10.1016/j.numecd.2026.104994","42772984","https://pubmed.ncbi.nlm.nih.gov/42772984/",null,null],["3","R0005828","R0005828.pdf","paywalled","systematic_review","Jayathilaka NS","2026","Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.1624","https://doi.org/10.1002/cpdd.1624","41238444","https://pubmed.ncbi.nlm.nih.gov/41238444/",null,null],["3","R0005965","R0005965.pdf","paywalled","systematic_review","Yang H","2026","GLP-1 Receptor Agonist-Based Prandial Insulin De-Intensification in Outpatients With Type 2 Diabetes Receiving Basal-Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71359","https://doi.org/10.1111/dom.71359","42736042","https://pubmed.ncbi.nlm.nih.gov/42736042/",null,null],["3","R0005985","R0005985.pdf","paywalled","systematic_review","Pascale S","2026","Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Antipsychotic-Induced Weight Gain.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280251414107","https://doi.org/10.1177/10600280251414107","41723102","https://pubmed.ncbi.nlm.nih.gov/41723102/",null,null],["3","R0006064","R0006064.pdf","paywalled","systematic_review","Ahmed HM","2026","Divergent Efficacy of GLP-1 Receptor Agonists in HFpEF Versus HFrEF: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.04.046","https://doi.org/10.1016/j.amjcard.2026.04.046","42069283","https://pubmed.ncbi.nlm.nih.gov/42069283/",null,"PROSPERO:CRD420251138529"],["3","R0006302","R0006302.pdf","paywalled","systematic_review","Zhu C","2026","Association Between Preoperative GLP-1 Receptor Agonists Use and Perioperative Complications in Metabolic Bariatric Surgery: A Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08629-x","https://doi.org/10.1007/s11695-026-08629-x","41951956","https://pubmed.ncbi.nlm.nih.gov/41951956/",null,null],["3","R0006459","R0006459.pdf","paywalled","systematic_review","Benny O","2026","Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Elsevier BV","10.1016/j.pan.2026.03.021","https://doi.org/10.1016/j.pan.2026.03.021","41927408","https://pubmed.ncbi.nlm.nih.gov/41927408/",null,null],["3","R0006466","R0006466.pdf","paywalled","systematic_review","Kassira NR","2026","The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review.","Cutis","Frontline Medical Communications, Inc.","10.12788/cutis.1385","https://doi.org/10.12788/cutis.1385","42411880","https://pubmed.ncbi.nlm.nih.gov/42411880/",null,null],["3","R0006494","R0006494.pdf","paywalled","systematic_review","Gonzales-Uribe A","2026","Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-025-02710-8","https://doi.org/10.1007/s00392-025-02710-8","40637782","https://pubmed.ncbi.nlm.nih.gov/40637782/",null,null],["3","R0006565","R0006565.pdf","paywalled","systematic_review","Dos Santos Barbosa LA","2026","Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).","Therapeutic innovation & regulatory science","Springer Science and Business Media LLC","10.1007/s43441-025-00875-y","https://doi.org/10.1007/s43441-025-00875-y","40993341","https://pubmed.ncbi.nlm.nih.gov/40993341/",null,null],["3","R0006680","R0006680.pdf","paywalled","systematic_review","Rajab I","2026","Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-026-05257-1","https://doi.org/10.1007/s00210-026-05257-1","41879841","https://pubmed.ncbi.nlm.nih.gov/41879841/",null,null],["3","R0006735","R0006735.pdf","paywalled","systematic_review","Silva CFXCA","2026","GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70864","https://doi.org/10.1111/dom.70864","42115753","https://pubmed.ncbi.nlm.nih.gov/42115753/",null,null],["3","R0006829","R0006829.pdf","paywalled","systematic_review","Zhao S","2026","Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.","Internal and emergency medicine","Springer Science and Business Media LLC","10.1007/s11739-026-04326-w","https://doi.org/10.1007/s11739-026-04326-w","41917519","https://pubmed.ncbi.nlm.nih.gov/41917519/",null,"ClinicalTrials.gov:NCT04166773; ClinicalTrials.gov:NCT04849728; ClinicalTrials.gov:NCT03900429; ClinicalTrials.gov:NCT04197479; ClinicalTrials.gov:NCT04951219; PROSPERO:CRD42025637054"],["3","R0007222","R0007222.pdf","paywalled","systematic_review","Sebastian SA","2026","Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102099","https://doi.org/10.1016/j.disamonth.2026.102099","41862384","https://pubmed.ncbi.nlm.nih.gov/41862384/",null,"PROSPERO:CRD420251170117"],["3","R0007493","R0007493.pdf","paywalled","systematic_review","Osborne D","2026","Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-02002-1","https://doi.org/10.1038/s41366-025-02002-1","41491273","https://pubmed.ncbi.nlm.nih.gov/41491273/",null,null],["3","R0007597","R0007597.pdf","paywalled","systematic_review","Rangraze IR","2026","Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/0115748863330434241015125302","https://doi.org/10.2174/0115748863330434241015125302","39484756","https://pubmed.ncbi.nlm.nih.gov/39484756/",null,null],["3","R0007618","R0007618.pdf","paywalled","systematic_review","Zeng L","2026","Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1093/annalsats/aaoag177","https://doi.org/10.1093/annalsats/aaoag177","42479131","https://pubmed.ncbi.nlm.nih.gov/42479131/",null,null],["3","R0007754","R0007754.pdf","paywalled","systematic_review","Romariz LM","2026","GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials.","Pediatric research","Springer Science and Business Media LLC","10.1038/s41390-025-04228-1","https://doi.org/10.1038/s41390-025-04228-1","40588554","https://pubmed.ncbi.nlm.nih.gov/40588554/",null,null],["3","R0007761","R0007761.pdf","paywalled","systematic_review","Alam A","2026","Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.","Wiener medizinische Wochenschrift (1946)","Springer Science and Business Media LLC","10.1007/s10354-025-01108-5","https://doi.org/10.1007/s10354-025-01108-5","40900212","https://pubmed.ncbi.nlm.nih.gov/40900212/",null,null],["3","R0007773","R0007773.pdf","paywalled","systematic_review","Chen QX","2026","Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04757-7","https://doi.org/10.1007/s12020-026-04757-7","42603240","https://pubmed.ncbi.nlm.nih.gov/42603240/",null,null],["3","R0007816","R0007816.pdf","paywalled","systematic_review","Batsis JA","2026","Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-00478","https://doi.org/10.7326/annals-25-00478","41996180","https://pubmed.ncbi.nlm.nih.gov/41996180/",null,"OSF:osf.io/s3a5e"],["3","R0008129","R0008129.pdf","paywalled","systematic_review","Milori PH","2026","Incidence of dementia in patients with type 2 diabetes using SGLT2 inhibitors versus GLP-1 receptor agonists or DPP-4 inhibitors: A systematic review and meta-analysis of cohort studies.","Journal of Alzheimer's disease : JAD","SAGE Publications","10.1177/13872877251395086","https://doi.org/10.1177/13872877251395086","41252314","https://pubmed.ncbi.nlm.nih.gov/41252314/",null,null],["3","R0008209","R0008209.pdf","paywalled","systematic_review","Roessler J","2026","Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Diabetes care","American Diabetes Association","10.2337/dc26-1127","https://doi.org/10.2337/dc26-1127","42627353","https://pubmed.ncbi.nlm.nih.gov/42627353/",null,null],["3","R0008317","R0008317.pdf","paywalled","systematic_review","Renna NF","2026","Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000004158","https://doi.org/10.1097/hjh.0000000000004158","41230897","https://pubmed.ncbi.nlm.nih.gov/41230897/",null,null],["3","R0008439","R0008439.pdf","paywalled","systematic_review","Jia IT","2026","Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-026-12940-0","https://doi.org/10.1007/s00464-026-12940-0","42260171","https://pubmed.ncbi.nlm.nih.gov/42260171/",null,null],["3","R0008581","R0008581.pdf","paywalled","systematic_review","Simental-Mendía LE","2026","Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Springer Science and Business Media LLC","10.1007/s40292-026-00812-6","https://doi.org/10.1007/s40292-026-00812-6","42371360","https://pubmed.ncbi.nlm.nih.gov/42371360/",null,null],["3","R0008656","R0008656.pdf","paywalled","systematic_review","Hammad N","2026","Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261420404","https://doi.org/10.1177/15209156261420404","41640110","https://pubmed.ncbi.nlm.nih.gov/41640110/",null,null],["3","R0008851","R0008851.pdf","paywalled","systematic_review","Alper A","2026","Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Springer Science and Business Media LLC","10.1007/s40292-026-00814-4","https://doi.org/10.1007/s40292-026-00814-4","42458197","https://pubmed.ncbi.nlm.nih.gov/42458197/",null,null],["3","R0009258","R0009258.pdf","paywalled","systematic_review","Goldenberg RM","2026","Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70859","https://doi.org/10.1111/dom.70859","42115707","https://pubmed.ncbi.nlm.nih.gov/42115707/",null,null],["3","R0009430","R0009430.pdf","paywalled","systematic_review","Horne MP","2026","Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.","Journal of the American Association of Nurse Practitioners","Ovid Technologies (Wolters Kluwer Health)","10.1097/jxx.0000000000001303","https://doi.org/10.1097/jxx.0000000000001303","42250233","https://pubmed.ncbi.nlm.nih.gov/42250233/",null,null],["3","R0009536","R0009536.pdf","paywalled","systematic_review","Elganyny MKE","2026","Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.","La Clinica terapeutica",null,"10.7417/ct.2026.2083","https://doi.org/10.7417/ct.2026.2083","42340790","https://pubmed.ncbi.nlm.nih.gov/42340790/",null,null],["3","R0009822","R0009822.pdf","paywalled","systematic_review","Banerjee M","2026","Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70187","https://doi.org/10.1111/dom.70187","41063381","https://pubmed.ncbi.nlm.nih.gov/41063381/",null,null],["3","R0009929","R0009929.pdf","paywalled","systematic_review","Eisa N","2026","Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70161","https://doi.org/10.1111/obr.70161","42140745","https://pubmed.ncbi.nlm.nih.gov/42140745/",null,null],["3","R0009937","R0009937.pdf","paywalled","systematic_review","Zufry H","2026","Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2026.02.002","https://doi.org/10.1016/j.orcp.2026.02.002","41723034","https://pubmed.ncbi.nlm.nih.gov/41723034/",null,null],["3","R0009971","R0009971.pdf","paywalled","systematic_review","Gadelmawla AF","2026","Therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-026-08843-6","https://doi.org/10.1007/s10072-026-08843-6","41772331","https://pubmed.ncbi.nlm.nih.gov/41772331/",null,null],["3","R0010128","R0010128.pdf","paywalled","systematic_review","Souza M","2026","Impact of GLP-1 Receptor Agonist Discontinuation on Liver-Related Parameters: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70642","https://doi.org/10.1111/dom.70642","41804222","https://pubmed.ncbi.nlm.nih.gov/41804222/",null,null],["3","R0010142","R0010142.pdf","paywalled","systematic_review","Chan ZH","2026","Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001209","https://doi.org/10.1097/crd.0000000000001209","41711462","https://pubmed.ncbi.nlm.nih.gov/41711462/",null,null],["3","R0010266","R0010266.pdf","paywalled","systematic_review","Jamal A","2026","Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-025-02635-8","https://doi.org/10.1007/s00592-025-02635-8","41498807","https://pubmed.ncbi.nlm.nih.gov/41498807/",null,null],["3","R0010332","R0010332.pdf","paywalled","systematic_review","Masson W","2026","Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.","Reviews in endocrine & metabolic disorders","Springer Science and Business Media LLC","10.1007/s11154-025-09991-4","https://doi.org/10.1007/s11154-025-09991-4","41032183","https://pubmed.ncbi.nlm.nih.gov/41032183/",null,null],["3","R0010686","R0010686.pdf","paywalled","systematic_review","Kilic ME","2026","GLP-1 receptor agonist therapy is associated with reduced atrial fibrillation recurrence after catheter ablation: a meta-analysis.","Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","Springer Science and Business Media LLC","10.1007/s10840-025-02233-2","https://doi.org/10.1007/s10840-025-02233-2","41493516","https://pubmed.ncbi.nlm.nih.gov/41493516/",null,null],["3","R0010946","R0010946.pdf","paywalled","systematic_review","Jenniskens K","2026","Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-03766","https://doi.org/10.7326/annals-24-03766","42296505","https://pubmed.ncbi.nlm.nih.gov/42296505/",null,"PROSPERO:CRD42023491646"],["3","R0011052","R0011052.pdf","paywalled","systematic_review","Araújo de Lucena L","2026","Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-026-01619-4","https://doi.org/10.1007/s11892-026-01619-4","41806022","https://pubmed.ncbi.nlm.nih.gov/41806022/",null,"PROSPERO:CRD420251083622"],["3","R0011134","R0011134.pdf","paywalled","systematic_review","Eisa N","2026","Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.04.014","https://doi.org/10.1016/j.eprac.2026.04.014","42061648","https://pubmed.ncbi.nlm.nih.gov/42061648/",null,null],["3","R0011448","R0011448.pdf","paywalled","systematic_review","Yang YT","2026","Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.","Respiratory medicine","Elsevier BV","10.1016/j.rmed.2026.108671","https://doi.org/10.1016/j.rmed.2026.108671","41616874","https://pubmed.ncbi.nlm.nih.gov/41616874/",null,"PROSPERO:CRD420251165267"],["3","R0011562","R0011562.pdf","paywalled","systematic_review","Leikin JB","2026","Forward for: Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102112","https://doi.org/10.1016/j.disamonth.2026.102112","41936525","https://pubmed.ncbi.nlm.nih.gov/41936525/",null,null],["3","R0011571","R0011571.pdf","paywalled","systematic_review","Moews LD","2026","GLP-1 receptor agonist therapy is not associated with adverse events following shoulder surgery: a systematic review and meta-analysis.","Journal of shoulder and elbow surgery","Elsevier BV","10.1016/j.jse.2025.12.005","https://doi.org/10.1016/j.jse.2025.12.005","41619919","https://pubmed.ncbi.nlm.nih.gov/41619919/",null,null],["3","R0011600","R0011600.pdf","paywalled","systematic_review","Azam MH","2026","Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70643","https://doi.org/10.1111/dom.70643","41804840","https://pubmed.ncbi.nlm.nih.gov/41804840/",null,null],["3","R0011630","R0011630.pdf","paywalled","systematic_review","Huang J","2026","Refining Meta-Analyses of GLP-1RA Safety: Sparse Event Data, Confounding, and Sex Differences.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2025.06.039","https://doi.org/10.1053/j.gastro.2025.06.039","41422838","https://pubmed.ncbi.nlm.nih.gov/41422838/",null,null],["3","R0011707","R0011707.pdf","paywalled","systematic_review","Alamoudi A","2026","Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis.","Eye (London, England)","Springer Science and Business Media LLC","10.1038/s41433-026-04904-4","https://doi.org/10.1038/s41433-026-04904-4","42786281","https://pubmed.ncbi.nlm.nih.gov/42786281/",null,"PROSPERO:CRD420251077729"],["3","R0011745","R0011745.pdf","paywalled","systematic_review","Hughes A","2026","Pancreaticobiliary side effects of GLP-1 agonists: a meta-analysis of published randomized control trials and a real-world pharmacovigilance profile.","The British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag022","https://doi.org/10.1093/bjs/znag022","41783935","https://pubmed.ncbi.nlm.nih.gov/41783935/",null,"PROSPERO:CRD420251018806"],["3","R0012339","R0012339.pdf","paywalled","systematic_review","Kumar A","2026","Comparison of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Atrial Fibrillation in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001968","https://doi.org/10.1097/mjt.0000000000001968","40304630","https://pubmed.ncbi.nlm.nih.gov/40304630/",null,null],["3","R0012367","R0012367.pdf","paywalled","systematic_review","Kamrul-Hasan ABM","2026","Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.11.010","https://doi.org/10.1016/j.eprac.2025.11.010","41297885","https://pubmed.ncbi.nlm.nih.gov/41297885/",null,null],["3","R0012507","R0012507.pdf","paywalled","systematic_review","Pardeshi G","2026","Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.","Clinical obesity","Wiley","10.1111/cob.70042","https://doi.org/10.1111/cob.70042","40832978","https://pubmed.ncbi.nlm.nih.gov/40832978/",null,"PROSPERO:CRD42024614466"],["3","R0012574","R0012574.pdf","paywalled","systematic_review","Spiazzi BF","2026","Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113431","https://doi.org/10.1016/j.diabres.2026.113431","42442557","https://pubmed.ncbi.nlm.nih.gov/42442557/",null,null],["3","R0012837","R0012837.pdf","paywalled","systematic_review","Chattopadhyay K","2026","Harnessing Herbal Power: A Systematic Review of Phytopharmaceuticals in Type 2 Diabetes Management.","Journal of the American Nutrition Association","Informa UK Limited","10.1080/27697061.2026.2650457","https://doi.org/10.1080/27697061.2026.2650457","42008388","https://pubmed.ncbi.nlm.nih.gov/42008388/",null,null],["3","R0013022","R0013022.pdf","paywalled","systematic_review","Alhazmi AM","2026","From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2026.103423","https://doi.org/10.1016/j.cpcardiol.2026.103423","42586458","https://pubmed.ncbi.nlm.nih.gov/42586458/",null,null],["3","R0013438","R0013438.pdf","paywalled","systematic_review","Ananthesh L","2026","Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.","Journal of racial and ethnic health disparities","Springer Science and Business Media LLC","10.1007/s40615-025-02410-z","https://doi.org/10.1007/s40615-025-02410-z","40259185","https://pubmed.ncbi.nlm.nih.gov/40259185/",null,null],["3","R0013528","R0013528.pdf","paywalled","systematic_review","Kamrul-Hasan ABM","2026","Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.","Postgraduate medical journal","Oxford University Press (OUP)","10.1093/postmj/qgaf238","https://doi.org/10.1093/postmj/qgaf238","41536268","https://pubmed.ncbi.nlm.nih.gov/41536268/",null,null],["3","R0014859","R0014859.pdf","paywalled","systematic_review","Leikin JB","2026","Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102098","https://doi.org/10.1016/j.disamonth.2026.102098","41862385","https://pubmed.ncbi.nlm.nih.gov/41862385/",null,null],["3","R0014932","R0014932.pdf","paywalled","systematic_review","Abomohsen M","2026","Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis.","Heart rhythm","Elsevier BV","10.1016/j.hrthm.2026.05.048","https://doi.org/10.1016/j.hrthm.2026.05.048","42217600","https://pubmed.ncbi.nlm.nih.gov/42217600/",null,null],["3","R0015002","R0015002.pdf","paywalled","systematic_review","Wood E","2026","Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70314","https://doi.org/10.1111/dom.70314","41365848","https://pubmed.ncbi.nlm.nih.gov/41365848/",null,null],["3","R0015491","R0015491.pdf","paywalled","systematic_review","Liu X","2026","Pharmacological Treatment for Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of 71 Randomised Controlled Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70823","https://doi.org/10.1111/dom.70823","42082193","https://pubmed.ncbi.nlm.nih.gov/42082193/",null,null],["3","R0015493","R0015493.pdf","paywalled","systematic_review","Zhang S","2026","Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2026.178587","https://doi.org/10.1016/j.ejphar.2026.178587","41580006","https://pubmed.ncbi.nlm.nih.gov/41580006/",null,null],["3","R0015616","R0015616.pdf","paywalled","systematic_review","Liu Z","2026","Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2025.12.022","https://doi.org/10.1016/j.ophtha.2025.12.022","41475544","https://pubmed.ncbi.nlm.nih.gov/41475544/",null,null],["3","R0015663","R0015663.pdf","paywalled","systematic_review","Dong J","2026","Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.","Pediatric research","Springer Science and Business Media LLC","10.1038/s41390-025-04537-5","https://doi.org/10.1038/s41390-025-04537-5","41184626","https://pubmed.ncbi.nlm.nih.gov/41184626/",null,null],["3","R0015827","R0015827.pdf","paywalled","systematic_review","Kong W","2026","Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70301","https://doi.org/10.1111/dom.70301","41321175","https://pubmed.ncbi.nlm.nih.gov/41321175/",null,null],["3","R0016158","R0016158.pdf","paywalled","systematic_review","Chen H","2026","Recurrent Weight Gain after Weight Loss Induced by Lifestyle Intervention, Metabolic and Bariatric Surgery, or Semaglutide in Adults with Obesity: A Systematic Review of Randomized Controlled Trials.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08415-1","https://doi.org/10.1007/s11695-025-08415-1","41483046","https://pubmed.ncbi.nlm.nih.gov/41483046/",null,null],["3","R0016654","R0016654.pdf","paywalled","systematic_review","Eisa N","2026","Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.11.018","https://doi.org/10.1016/j.eprac.2025.11.018","41419187","https://pubmed.ncbi.nlm.nih.gov/41419187/",null,null],["3","R0016792","R0016792.pdf","paywalled","systematic_review","Liu CI","2026","Efficacy of pharmacological and nutritional interventions for glucose dysfunction in schizophrenia-A systematic review and network meta-analysis.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811261443680","https://doi.org/10.1177/02698811261443680","42104950","https://pubmed.ncbi.nlm.nih.gov/42104950/",null,null],["3","R0016862","R0016862.pdf","paywalled","systematic_review","Mansour MEM","2026","Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811251399544","https://doi.org/10.1177/02698811251399544","41439550","https://pubmed.ncbi.nlm.nih.gov/41439550/",null,"PROSPERO:CRD42024599597"],["3","R0017271","R0017271.pdf","paywalled","systematic_review","Violante-Cumpa JR","2026","Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.11.002","https://doi.org/10.1016/j.eprac.2025.11.002","41513086","https://pubmed.ncbi.nlm.nih.gov/41513086/",null,null],["3","R0018002","R0018002.pdf","paywalled","systematic_review","Hegazy MA","2026","Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-026-02408-x","https://doi.org/10.1007/s11886-026-02408-x","42714692","https://pubmed.ncbi.nlm.nih.gov/42714692/",null,"PROSPERO:CRD42025644064"],["3","R0018100","R0018100.pdf","paywalled","systematic_review","Timsit MO","2026","Kidney transplantation in adult candidates with obesity: Guidelines by the Association Française d'Urologie and Société Francophone de Transplantation.","The French journal of urology","Elsevier BV","10.1016/j.fjurol.2026.103100","https://doi.org/10.1016/j.fjurol.2026.103100","41912112","https://pubmed.ncbi.nlm.nih.gov/41912112/",null,null],["3","R0019952","R0019952.pdf","paywalled","systematic_review","Murtaza S","2026","Evaluating the Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Management of Obstructive Sleep Apnea; a Systematic Review and Meta-Analysis.","Journal of sleep research","Wiley","10.1111/jsr.70196","https://doi.org/10.1111/jsr.70196","40974185","https://pubmed.ncbi.nlm.nih.gov/40974185/",null,null],["3","R0021403","R0021403.pdf","paywalled","systematic_review","Liao Y","2026","Gegen Qinlian decoction ameliorates insulin resistance in type 2 diabetes: A systematic review and meta-analysis of RCTs with mechanistic insights into SIRT1/AMPK pathway activation.","Journal of ethnopharmacology","Elsevier BV","10.1016/j.jep.2025.120960","https://doi.org/10.1016/j.jep.2025.120960","41297722","https://pubmed.ncbi.nlm.nih.gov/41297722/",null,null],["3","R0029251","R0029251.pdf","paywalled","systematic_review","Hassan D","2026","GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.","Annals of cardiac anaesthesia",null,"10.4103/aca.aca_307_25","https://doi.org/10.4103/aca.aca_307_25","42862661","https://pubmed.ncbi.nlm.nih.gov/42862661/",null,null],["3","R0029274","R0029274.pdf","paywalled","systematic_review","Inban P","2026","Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.","Disease-a-month : DM","Elsevier BV","10.1016/j.disamonth.2026.102231","https://doi.org/10.1016/j.disamonth.2026.102231","42855378","https://pubmed.ncbi.nlm.nih.gov/42855378/",null,null],["3","R0029295","R0029295.pdf","paywalled","systematic_review","Jędrasek A","2026","GLP-1 Receptor Agonist Therapy for Glucocorticoid-Induced Dysglycaemia: A Systematic Review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71418","https://doi.org/10.1111/dom.71418","42850058","https://pubmed.ncbi.nlm.nih.gov/42850058/",null,"PROSPERO:CRD420251183082"],["3","R0029326","R0029326.pdf","paywalled","systematic_review","Chu AH","2026","Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-026-02431-y","https://doi.org/10.1007/s11886-026-02431-y","42842171","https://pubmed.ncbi.nlm.nih.gov/42842171/",null,null],["3","R0029343","R0029343.pdf","paywalled","systematic_review","Carvalhal G","2026","GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.","Sleep & breathing = Schlaf & Atmung","Springer Science and Business Media LLC","10.1007/s11325-026-03826-5","https://doi.org/10.1007/s11325-026-03826-5","42837024","https://pubmed.ncbi.nlm.nih.gov/42837024/",null,"PROSPERO:CRD42024564018"],["3","R0029447","R0029447.pdf","paywalled","systematic_review","Simental-Mendía LE","2026","Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1177/10815589261460894","https://doi.org/10.1177/10815589261460894","42257390","https://pubmed.ncbi.nlm.nih.gov/42257390/",null,null],["3","R0032479","R0032479.pdf","paywalled","systematic_review","Cheng-Hao Lai","2026","Skeletal Effects of GLP-1 Receptor Agonist Therapy in Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.3.0076","https://doi.org/10.37766/inplasy2026.3.0076",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032525","R0032525.pdf","paywalled","systematic_review","Rong Huang","2026","Effect of GLP-1 Receptor Agonists on Body Weight and Albuminuria in Patients With and Without Type 2 Diabetes: A Protocol for a Systematic Review and Meta-Analysis",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.5.0012","https://doi.org/10.37766/inplasy2026.5.0012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032667","R0032667.pdf","paywalled","systematic_review","Hosam Awaji","2026","The impact of semaglutide in body weight reduction: a systematic review and meta-analysis","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1765515744","https://doi.org/10.24911/ijmdc.51-1765515744",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032679","R0032679.pdf","paywalled","systematic_review","Jefferson Lorençoni de Morais","2026","Dual Incretin Agonism in Type 2 Diabetes and Obesity: Systematic Review of Tirzepatide Mechanisms and Clinical Outcomes","International Journal of Research in Pharmacy and Allied Science","Ideal Publication","10.71431/ijrpas.2026.5309","https://doi.org/10.71431/ijrpas.2026.5309",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033108","R0033108.pdf","paywalled","systematic_review","JOSE M. ZALDUMBIDE","2026","1751-P: Efficacy and Safety of GLP-1 Receptor Agonists as Add-On Therapy to Insulin-Based Regimens in Adults with Type 1 Diabetes: A Systematic Review and Meta-Analysis","Diabetes","American Diabetes Association","10.2337/db26-1751-p","https://doi.org/10.2337/db26-1751-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033142","R0033142.pdf","paywalled","systematic_review","PAULAMI DESHMUKH","2026","13-PUB: Semaglutide Reduces Risk of Adverse Limb Events among Patients with Diabetes and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis","Diabetes","American Diabetes Association","10.2337/db26-13-pub","https://doi.org/10.2337/db26-13-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251182802"],["3","R0033287","R0033287.pdf","paywalled","systematic_review","Miran Kamil","2026","The Neuroprotective Potential of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Cognition and Dementia: A Comprehensive Systematic Review and Meta-Analysis",null,null,"10.13140/rg.2.2.25321.25448","https://doi.org/10.13140/rg.2.2.25321.25448",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033321","R0033321.pdf","paywalled","systematic_review","RAYAN F. Alataa","2026","1115 EFFECTS OF GLP-1 RECEPTOR AGONISTS ON GASTROINTESTINAL TRANSIT AND CAPSULE ENDOSCOPY OUTCOMES: SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05669-5","https://doi.org/10.1016/s0016-5107(26)05669-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033652","R0033652.pdf","paywalled","systematic_review","Miguel Valdebenito Barraza","2026","Effects of Glycemic Control and Antidiabetic Therapies on Erectile Function in Men With Type 2 Diabetes: A Systematic Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20249934","https://doi.org/10.5281/zenodo.20249934",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034228","R0034228.pdf","paywalled","systematic_review","Mahnoor Shahzad,Maham Noor,Haadia Arooj,Jannat Yaqoob,Hafsa Tahir,Fahad Niaz","2026","EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL HEALTH, ORAL WOUND HEALING, AND PERIODONTAL REGENERATION: A SYSTEMATIC REVIEW OF PRECLINICAL EVIDENCE","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21305320","https://doi.org/10.5281/zenodo.21305320",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034275","R0034275.pdf","paywalled","systematic_review","Adarsh Vardhan Tangella","2026","GLP-1 receptor agonists and pancreatic cancer risk: A meta-analysis of real-world and trial evidence.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.712","https://doi.org/10.1200/jco.2026.44.2_suppl.712",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034282","R0034282.pdf","paywalled","systematic_review","Casey Moffitt","2026","Oral Contraceptive Failure With GLP-1 and Dual GLP-1/GIP Therapies: A Case Report and Systematic Review of Incretin–COC Interactions [ID 3414]","Obstetrics and Gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aog.0000000000006265.09","https://doi.org/10.1097/aog.0000000000006265.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034301","R0034301.pdf","paywalled","systematic_review","Anmol Mohan","2026","Mo1827 LONG-TERM GLP-1 RA EXPOSURE AND CANCER RISK IN OBESITY MANAGEMENT: SYSTEMATIC REVIEW AND META-ANALYTIC EVIDENCE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04891-1","https://doi.org/10.1016/s0016-5107(26)04891-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034390","R0034390.pdf","paywalled","systematic_review","Ravi Jandhyala","2026","Time-Dependent Effects of GLP-1 Receptor Agonists on Weight Loss: A Systematic Review and Meta-Analysis of Phase 3 Trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21025119","https://doi.org/10.5281/zenodo.21025119",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034429","R0034429.pdf","paywalled","systematic_review","Chia-Ta Wu","2026","GLP-1 receptor agonists for organ protection in sepsis: a protocol for a systematic review and meta-analysis of preclinical and clinical evidence",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.5.0167","https://doi.org/10.37766/inplasy2026.5.0167",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034435","R0034435.pdf","paywalled","systematic_review","NASEEM ALTHUBAITI","2026","1734-P: Dual Incretin Therapy vs. GLP-1 Monotherapy: Meta-Analysis of Tirzepatide and Semaglutide in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1734-p","https://doi.org/10.2337/db26-1734-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034463","R0034463.pdf","paywalled","systematic_review","Ibrahim Shanti","2026","Mo1919 ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE WITH RISK OF CHOLELITHIASIS AND CHOLECYSTITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)00467-0","https://doi.org/10.1016/s0016-5107(26)00467-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034518","R0034518.pdf","paywalled","systematic_review","Aamir Saeed","2026","Tu1598 SAFETY AND EFFICACY OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS (GLP-1RAS) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03216-5","https://doi.org/10.1016/s0016-5107(26)03216-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034553","R0034553.pdf","paywalled","systematic_review","Luiz Felippe Mendes Caquetti","2026","RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS","INTERNATIONAL BLEST SCIENTIFIC","Editora Blest","10.65671/7z5zjv05","https://doi.org/10.65671/7z5zjv05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034634","R0034634.pdf","paywalled","systematic_review","Yiwen Zhang","2026","Additional file 1 of Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.31367664","https://doi.org/10.6084/m9.figshare.31367664",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034703","R0034703.pdf","paywalled","systematic_review","Fernando Ortiz López","2026","Sa1833 REAL-WORLD RISK OF ACUTE PANCREATITIS AND BILIARY DISEASE WITH GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW AND META- ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05060-1","https://doi.org/10.1016/s0016-5107(26)05060-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034730","R0034730.pdf","paywalled","systematic_review","Vishal Chandel","2026","Mo1823 EFFECTIVENESS OF GLP1RA BASED TREATMENT MODALITIES IN CHANGING BODY COMPOSITION AND LEAN BODY MASS : A METAANALYSIS OF RANDOMIZED CLINICAL STUDIES","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04887-x","https://doi.org/10.1016/s0016-5107(26)04887-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034772","R0034772.pdf","paywalled","systematic_review","Ishaan Vohra","2026","Mo1815 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND TIRZEPATIDE FOR WEIGHT LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04879-0","https://doi.org/10.1016/s0016-5107(26)04879-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034787","R0034787.pdf","paywalled","systematic_review","Rubela Ray","2026","Sa2115 COMPARATIVE EFFICACY OF TIRZEPATIDE VS SEMAGLUTIDE FOR REDUCTION OF HEPATIC STEATOSIS IN NAFLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03581-9","https://doi.org/10.1016/s0016-5107(26)03581-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034840","R0034840.pdf","paywalled","systematic_review","Jasmin Kaur Bhullar","2026","Additional file 1 of A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction","Figshare",null,"10.6084/m9.figshare.33056137","https://doi.org/10.6084/m9.figshare.33056137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035693","R0035693.pdf","paywalled","systematic_review","Minahil Rasul","2026","Underlying and Extended Data for: Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21649808","https://doi.org/10.5281/zenodo.21649808",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035776","R0035776.pdf","paywalled","systematic_review","Harshitha G.*1, Surendra Vada2, P. Aswathy3, K. Keerthana4","2026","Rybelsus (Semaglutide): Revolutionizing Type 2 Diabetes Therapy - A Systematic Review Of Clinical Evidence And Future Prospects","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21671030","https://doi.org/10.5281/zenodo.21671030",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036151","R0036151.pdf","paywalled","systematic_review","Sandro La Vignera","2026","Impact of Endocrine Comorbidities on the Clinical Response to Semaglutide and Tirzepatide: A Systematic Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21818802","https://doi.org/10.5281/zenodo.21818802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036317","R0036317.pdf","paywalled","systematic_review","Dr. Nada Zainalabden Tawfeeq, Khalil Ibrahim Bo grain, Amal Abdullah Alhayek, Fatimah Mossa Alahmad, Hawra Mohammed Bu hulayqah, Zainab Abdulrzzak Aldajani, Sakainh Waleed Abdraboh, Yara Waleed Alsaeed, Sara Abdullah Alali, Hawraa Ayesh Al-Ibrahim, Maryam Abdulmonem Bukhamsin","2026","UPDATES ON SAFETY AND EFFECTIVENESS OF SEMAGLUTIDE IN WEIGHT LOSS AMONG OBESE PATIENTS WITHOUT DIABETES: A SYSTEMATIC REVIEW","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21825441","https://doi.org/10.5281/zenodo.21825441",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036337","R0036337.pdf","paywalled","systematic_review","Gülçin Türkmen Sarıyıldız","2026","Efficacy and Safety of Tirzepatide for Weight Management in Adults with Overweight or Obesity, with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21773036","https://doi.org/10.5281/zenodo.21773036",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036516","R0036516.pdf","paywalled","systematic_review","Αναστασία Χ. Σταματίου","2026","Weight loss interventions for overweight or obese individuals with chronic kidney disease (CKD): a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.372860","https://doi.org/10.26262/heal.auth.ir.372860",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036639","R0036639.pdf","paywalled","systematic_review","Dr. Daniyal Khan","2026","Patient-Centred Outcomes with Incretin-Based Therapies and SGLT2 Inhibitors in Obesity-Related HFpEF: A Programme-Level Systematic Review and Meta-Analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/naqrg","https://doi.org/10.17605/osf.io/naqrg",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036668","R0036668.pdf","paywalled","systematic_review","Fathur Agita Raihan","2026","SGLT2 Inhibitors versus GLP-1 Receptor Agonists for Chronic Kidney Disease Progression in Asian Populations with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/2ued3","https://doi.org/10.17605/osf.io/2ued3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036699","R0036699.pdf","paywalled","systematic_review","Hazem Ayesh","2026","Comparative Effectiveness of Orforglipron and Oral Semaglutide in the Management of Overweight and Obesity: Network Meta-analysis of Randomized Clinical Trials.","Open Science Framework",null,"10.17605/osf.io/56tah","https://doi.org/10.17605/osf.io/56tah",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036824","R0036824.pdf","paywalled","systematic_review","Chenran Tang","2026","Data extraction dataset for a network meta-analysis of GLP-1 receptor agonists in women with polycystic ovary syndrome","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21961648","https://doi.org/10.5281/zenodo.21961648",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036827","R0036827.pdf","paywalled","systematic_review","Shalini Y1, Rashmi H R2*, Akshay B3","2026","GLP-1 Receptor Agonist Withholding Interval and Residual Gastric Contents before Anaesthesia: A Systematic Review and Meta-analysis","International Journal of Medical Science in Clinical Research and Review",null,"10.5281/zenodo.21960925","https://doi.org/10.5281/zenodo.21960925",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037096","R0037096.pdf","paywalled","systematic_review","Shu Yu Lim","2026","IBC Oxford Poster Abstract 1 - Effectiveness of liraglutide in managing recurrent weight gain and suboptimal clinical response after bariatric surgery: a meta-analysis","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znaf288.065","https://doi.org/10.1093/bjs/znaf288.065",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251053386"],["3","R0037424","R0037424.pdf","paywalled","systematic_review","Elhaitham Yasir Awad Musa","2026","Additional file 1 of GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs","Figshare",null,"10.6084/m9.figshare.32227353.v1","https://doi.org/10.6084/m9.figshare.32227353.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037545","R0037545.pdf","paywalled","systematic_review","A Colicchio","2026","6ER-018 Therapeutic strategies in cardio-renal-metabolic syndrome: a systematic review",null,"British Medical Journal Publishing Group","10.1136/ejhpharm-2026-eahp.618","https://doi.org/10.1136/ejhpharm-2026-eahp.618",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037635","R0037635.pdf","paywalled","systematic_review","Brandon Berman","2026","Outcomes Associated With GLP1 Receptor Agonist Use In Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review And Meta Analysis Of Randomized Control Trials","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2025.11.075","https://doi.org/10.1016/j.cardfail.2025.11.075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037659","R0037659.pdf","paywalled","systematic_review","O Benny","2026","409 Dose–Response Analysis of Tirzepatide and Acute Pancreatitis: An International Systematic Review and Quantitative Meta-Analysis of Randomised Trials","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag063.671","https://doi.org/10.1093/bjs/znag063.671",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037930","R0037930.pdf","paywalled","systematic_review","Luca Sgarra","2026","Impact of GLP1Ra and SGLT2i on Atrial Fibrillation in Overweight, Non-Diabetic Patients: A Meta-Analysis of Randomized Evidence - search string","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21215992","https://doi.org/10.5281/zenodo.21215992",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037982","R0037982.pdf","paywalled","systematic_review","Saif Al Basri","2026","1684-P: Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db26-1684-p","https://doi.org/10.2337/db26-1684-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038098","R0038098.pdf","paywalled","systematic_review","N. Blampied","2026","L26/O-010 Glucagon-like peptide-1 receptor agonists (GLP-1’s) for the improvement of cardiometabolic outcomes in women with polycystic ovarian syndrome (PCOS): a systematic review and network meta-analysis (NMA)","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.010","https://doi.org/10.1093/humrep/deag083.010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038315","R0038315.pdf","paywalled","systematic_review","Waqar Khan","2026","Real-World Comparative Effectiveness and Treatment Persistence of Tirzepatide versus Semaglutide in Middle Eastern Populations: A Systematic Review and Meta-Analysis (2020–2026)","Journal of Medical Research and Reviews","ScopeMed","10.5455/jmrr.20260526050512","https://doi.org/10.5455/jmrr.20260526050512",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42026019344"],["3","R0038461","R0038461.pdf","paywalled","systematic_review","F. Oliveira","2026","L26/P-755 Comparative efficacy of GLP-1 receptor agonists and DPP-4 inhibitors versus metformin for insulin resistance in PCOS: a systematic review and meta-analysis","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.1082","https://doi.org/10.1093/humrep/deag083.1082",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251129333"],["3","R0038470","R0038470.pdf","paywalled","systematic_review","Shahzeb Saeed","2026","Comparative Efficacy Of GLP-1 Receptor Agonists, Mineralocorticoid Receptor Antagonists, And SGLT2 Inhibitors In HFpEF: A Meta-analysis Of Cardiovascular Outcomes","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2025.11.197","https://doi.org/10.1016/j.cardfail.2025.11.197",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038743","R0038743.pdf","paywalled","systematic_review",null,"2026","Wernicke Encephalopathy in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists: A Comprehensive Systematic Review","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.059","https://doi.org/10.1016/j.eprac.2026.03.059",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038911","R0038911.pdf","paywalled","systematic_review","JIA YAO","2026","2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis","Diabetes","American Diabetes Association","10.2337/db26-2732-lb","https://doi.org/10.2337/db26-2732-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038969","R0038969.pdf","paywalled","systematic_review","Hasan Munshi","2026","26-A-13345-ACC EFFECT OF GLP-1 RECEPTOR AGONISTS ON INFARCT SIZE AND CARDIAC FUNCTION IN ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2111","https://doi.org/10.1016/j.jacc.2026.02.2111",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039095","R0039095.pdf","paywalled","systematic_review","Gerald Chi","2026","26-A-13454-ACC TIME TO SUSTAINED CARDIOVASCULAR BENEFIT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HIGH-RISK PATIENTS: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.483","https://doi.org/10.1016/j.jacc.2026.02.483",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039216","R0039216.pdf","paywalled","systematic_review","Mrinal Bhandari","2026","26-A-14626-ACC HARMONIZED META-ANALYSIS OF GLP-1 RECEPTOR AGONIST CARDIOVASCULAR OUTCOME TRIALS: CONSISTENT REDUCTION IN 3-POINT MACE","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.683","https://doi.org/10.1016/j.jacc.2026.02.683",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039244","R0039244.pdf","paywalled","systematic_review",null,"2026","Tirzepatide Versus Semaglutide for Glycemic Control and Weight Loss: Updated Network Meta-analysis of Phase 3 Trials Incorporating 2025 SURMOUNT-5 Data","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.157","https://doi.org/10.1016/j.eprac.2026.01.157",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039367","R0039367.pdf","paywalled","systematic_review","Diego Pichardo-Rojas","2026","559 Efficacy of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_559","https://doi.org/10.1227/neu.0000000000003964_559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039538","R0039538.pdf","paywalled","systematic_review","SI-YAN CHEN","2026","1722-P: Effect of Tirzepatide on Cardiac Arrhythmia in Adults with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis","Diabetes","American Diabetes Association","10.2337/db26-1722-p","https://doi.org/10.2337/db26-1722-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251237091"],["3","R0039602","R0039602.pdf","paywalled","systematic_review","Brandon Berman","2026","Outcomes Associated With GLP1 Receptor Agonist Use In Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review And Meta Analysis Of Randomized Control Trials","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2025.11.417","https://doi.org/10.1016/j.cardfail.2025.11.417",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039668","R0039668.pdf","paywalled","systematic_review",null,"2026","Impact of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists on Diabetic Macular Edema: A Systematic Review and Meta-Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.039","https://doi.org/10.1016/j.eprac.2026.03.039",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039725","R0039725.pdf","paywalled","systematic_review",null,"2026","Association Between Semaglutide Treatment and Suicide in Patients With Obesity: Systematic Review and Meta-analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.327","https://doi.org/10.1016/j.eprac.2026.01.327",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039849","R0039849.pdf","paywalled","systematic_review","M J Primo","2026","Semaglutide and atrial fibrillation: a systematic review and meta-analysis","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.1364","https://doi.org/10.1093/ejhf/xuag193.1364",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039877","R0039877.pdf","paywalled","systematic_review","I Di Cesare","2026","6ER-007 Cost-effectiveness of novel therapies in cardio-renal-metabolic syndrome: a systematic review",null,"British Medical Journal Publishing Group","10.1136/ejhpharm-2026-eahp.607","https://doi.org/10.1136/ejhpharm-2026-eahp.607",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039882","R0039882.pdf","paywalled","systematic_review","Alexandra Peary","2026","3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db26-3092-lb","https://doi.org/10.2337/db26-3092-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0040054","R0040054.pdf","paywalled","systematic_review","Tae Hyuk Kim","2026","Glucagon-like peptide-1 receptor agonists and the incidence of medullary thyroid cancer: A systematic review and meta-analysis of rare events","Vivli",null,"10.25934/pr00012972","https://doi.org/10.25934/pr00012972",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0040919","R0040919.pdf","paywalled","systematic_review","Khalil Bograin","2026","Risk of pancreatitis with semaglutide (Ozempic) use for weight reduction: a systematic review","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1782826605","https://doi.org/10.24911/ijmdc.51-1782826605",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041037","R0041037.pdf","paywalled","systematic_review","Yohei Doi","2026","Effects of Tirzepatide on Erythropoiesis in People with Obesity: An Individual Patient Data Meta-analysis of the SURMOUNT Trials","Vivli",null,"10.25934/pr00011648","https://doi.org/10.25934/pr00011648",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041078","R0041078.pdf","paywalled","systematic_review","Wiku Andonotopo","2026","Periconception Discontinuation of GLP-1 Receptor Agonists and GLP-1/GIP Dual Agonists: Contraception Reliability, Metabolic Rebound, and Early Pregnancy Outcomes-A Systematic Review with a Clinical Transition Pathway",null,null,"10.13140/rg.2.2.24567.69287","https://doi.org/10.13140/rg.2.2.24567.69287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041381","R0041381.pdf","paywalled","systematic_review","Advait Teli","2026","Comparative Efficacy and Safety of GLP-1 Receptor Agonists vs SGLT2 Inhibitors on the Risk of Alzheimer’s Disease and Related Dementia: A Systematic Review and Meta-analysis (P4-13.002)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000216824","https://doi.org/10.1212/wnl.0000000000216824",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042025","R0042025.pdf","paywalled","systematic_review","Georgios Kostopoulos","2026","Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of real-world studies","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.119.ps2-09-02","https://doi.org/10.1530/endoabs.119.ps2-09-02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042065","R0042065.pdf","paywalled","systematic_review","Junhui Bai","2026","Decomposing the cardiovascular benefit of GLP-1 receptor agonists: a multi-state network meta-analysis of cardiovascular outcome trials",null,null,"10.17605/osf.io/sqezd","https://doi.org/10.17605/osf.io/sqezd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042071","R0042071.pdf","paywalled","systematic_review",null,"2026","Corrigendum to ’Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis’ [AACE Endocrinology and Diabetes. 2026;13(2):259-269]","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.08.013","https://doi.org/10.1016/j.aed.2026.08.013",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042100","R0042100.pdf","paywalled","systematic_review","Piyush Puri","2026","Cardioprotective pharmacotherapy during immune checkpoint inhibitor therapy and cardiovascular outcomes: a systematic review and meta-analysis.",null,null,"10.17605/osf.io/bwtd5","https://doi.org/10.17605/osf.io/bwtd5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042112","R0042112.pdf","paywalled","systematic_review","QINGKE HE","2026","Semaglutide, Tirzepatide, and Muscle-Related Adverse Events: A Systematic Review of Published Cases",null,null,"10.17605/osf.io/kwfzb","https://doi.org/10.17605/osf.io/kwfzb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042164","R0042164.pdf","paywalled","systematic_review","Eva Brahmbhatt","2026","Pharmacokinetic Variability, Bioavailability, and Gastrointestinal Adverse Events of SNAC-Formulated Oral Semaglutide versus Subcutaneous Semaglutide: A Systematic Review and Meta-Analysis of Clinical Studies",null,null,"10.17605/osf.io/7kg9z","https://doi.org/10.17605/osf.io/7kg9z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042194","R0042194.pdf","paywalled","systematic_review","Yiwei Shang","2026","Semaglutide as a bridge to kidney transplantation in adults with obesity and kidney failure: a systematic review and exploratory meta-analysis",null,null,"10.17605/osf.io/6uj2r","https://doi.org/10.17605/osf.io/6uj2r",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042206","R0042206.pdf","paywalled","systematic_review","Yaqeen M. Al-Jaradeen","2026","Cardiovascular Remodeling and Myocardial Fibrosis Outcomes of Dual GIP/GLP-1 Receptor Agonism With Tirzepatide in Obesity and Heart Failure: A Systematic Review and Meta-Analysis of Clinical Trials",null,null,"10.17605/osf.io/26sbq","https://doi.org/10.17605/osf.io/26sbq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042277","R0042277.pdf","paywalled","systematic_review","Choudhary Ahmed Hasan Maqbool","2026","Mol826 EFFICACY AND SAFETY OF ORAL GLP-l RECEPTOR AGONIST ORFORGLIPRON FOR WEIGHT MANAGEMENT IN ADULTS WITH OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04890-x","https://doi.org/10.1016/s0016-5107(26)04890-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042348","R0042348.pdf","paywalled","systematic_review","MOHAMED ABDALLA SELIM MEKKAWI","2026","GLP-1 Receptor Agonist Drugs, Gastric Emptying, and Fatal Perioperative Pulmonary Aspiration: A Systematic Review and Meta-Analysis",null,null,"10.17605/osf.io/26yse","https://doi.org/10.17605/osf.io/26yse",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261374130"],["3","R0042414","R0042414.pdf","paywalled","systematic_review","He Liu","2026","GLP-1-based therapies and functional ageing: post-completion protocol and audit archive for a systematic review and evidence-gap map",null,null,"10.17605/osf.io/2fcdm","https://doi.org/10.17605/osf.io/2fcdm",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042498","R0042498.pdf","paywalled","systematic_review","Prasannakumar Pedapudi","2026","Cardiometabolic Outcomes of Glucagon-Like Peptide-1 Receptor Agonists and Incretin-Based Co-Agonists in Adults with Diabesity: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/yntgw","https://doi.org/10.17605/osf.io/yntgw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042539","R0042539.pdf","paywalled","systematic_review","Samit Ghosal","2026","Data and Reproducibility Code for the VAT Meta-analysis of Lifestyle and GLP-1RA-Based Interventions","Figshare",null,"10.6084/m9.figshare.33437314","https://doi.org/10.6084/m9.figshare.33437314",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043023","R0043023.pdf","paywalled","systematic_review","XIAO MA","2026","Is the excess of serious biliary events with incretin-based therapies determined by the magnitude of weight loss rather than by drug identity? A network meta-analysis and dose–response meta-regression of individually enumerated adverse events from mandated trial-registry reporting","Open Science Framework",null,"10.17605/osf.io/b4ufj","https://doi.org/10.17605/osf.io/b4ufj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043228","R0043228.pdf","paywalled","systematic_review","Bárbara Moema Peixoto Frazão","2026","GLP-1 Receptor Agonists for MASH in Non-Diabetic Adults: A Systematic Review",null,null,"10.17605/osf.io/4rt95","https://doi.org/10.17605/osf.io/4rt95",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043505","R0043505.pdf","paywalled","systematic_review","Gautham Bonny Natesan","2026","TIRZEPATIDE VERSUS SEMAGLUTIDE ON ATHEROGENIC LIPID PROFILES AND WEIGHT LOSS IN OBESITY: A SYSTEMATIC REVIEW","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2026.121452","https://doi.org/10.1016/j.atherosclerosis.2026.121452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043520","R0043520.pdf","paywalled","systematic_review","Yehya Tlaiss","2026","Ocular Adverse Events of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide versus Selective GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis",null,null,"10.17605/osf.io/wnfqb","https://doi.org/10.17605/osf.io/wnfqb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043558","R0043558.pdf","paywalled","systematic_review","Marianne Legault","2026","Impact of lifestyle habits on the risk of sarcopenia when using incretin hormones therapies: a systematic review",null,null,"10.17605/osf.io/38vb7","https://doi.org/10.17605/osf.io/38vb7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043694","R0043694.pdf","paywalled","systematic_review","Piyush Puri","2026","Cardioprotective Pharmacotherapy During ICI Therapy and Cardiovascular Outcomes: Systematic Review and Meta-Analysis Protocol",null,null,"10.17605/osf.io/kcteq","https://doi.org/10.17605/osf.io/kcteq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044011","R0044011.pdf","paywalled","systematic_review","Julia Follmann","2026","GLP-1 Receptor Agonist Plastic Surgery Meta-Analysis: Extracted Event Count Dataset",null,null,"10.17605/osf.io/xkubr","https://doi.org/10.17605/osf.io/xkubr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261376776"],["3","R0044271","R0044271.pdf","paywalled","systematic_review","Ahmed Amr Ahmed Hegazy Morsy","2026","Efficacy and Safety of Glucagon Receptor Agonists and Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-Analysis with Harmonised Hepatic Endpoints.","Open Science Framework",null,"10.17605/osf.io/7f2p6","https://doi.org/10.17605/osf.io/7f2p6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044696","R0044696.pdf","paywalled","systematic_review","Eyasu Daba Dugasa*, Md Ahmadunnisa, Mohammad Al-Haddad, Ali Al Salami","2026","Cardiovascular–Kidney Outcome Concordance with Tirzepatide in Type 2 Diabetes: A Design-Stratified Systematic Review and Exploratory Meta-analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22770210","https://doi.org/10.5281/zenodo.22770210",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261436184"],["3","R0044853","R0044853.pdf","paywalled","systematic_review","Leah Thomas","2026","Antidiabetic Pharmacotherapy in Psoriatic Disease: A Comprehensive Systematic Review Across Five Drug Classes","Open Science Framework",null,"10.17605/osf.io/9trnu","https://doi.org/10.17605/osf.io/9trnu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044931","R0044931.pdf","paywalled","systematic_review","Peichen Zhang","2026","Cardiovascular and kidney outcomes of semaglutide and the annual eGFR slope in adults with and without type 2 diabetes: data extraction sheet, analysis code and search records for a systematic review and meta-analysis of randomised controlled trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22841839","https://doi.org/10.5281/zenodo.22841839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261496524"],["3","R0044947","R0044947.pdf","paywalled","systematic_review","Mina Ashraf Tawfik Goher","2026","GLP-1 Receptor Agonists and the Risk of Upper Gastrointestinal Tract Disorders: Protocol for a Systematic Review of Observational Studies","Open Science Framework",null,"10.17605/osf.io/udp26","https://doi.org/10.17605/osf.io/udp26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044958","R0044958.pdf","paywalled","systematic_review","Saad Masood","2026","Sa2109 TRIPLE AND DUAL INCRETIN CO-AGONISTS DEMONSTRATE SUPERIOR HISTOLOGIC AND RADIOGRAPHIC EFFICACY COMPARED TO GLP-1 MONO-AGONISTS IN MASLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03644-9","https://doi.org/10.1016/s0016-5085(26)03644-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044974","R0044974.pdf","paywalled","systematic_review","Mohamed Saad Sayed","2026","Outcomes with GLP-1RAs in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-analysis. (S20.007)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000217270","https://doi.org/10.1212/wnl.0000000000217270",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045007","R0045007.pdf","paywalled","systematic_review","Kezia Peter","2026","Additional file 1 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.32142834.v1","https://doi.org/10.6084/m9.figshare.32142834.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045031","R0045031.pdf","paywalled","systematic_review","Kezia Peter","2026","Additional file 2 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.32142840","https://doi.org/10.6084/m9.figshare.32142840",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045032","R0045032.pdf","paywalled","systematic_review","Ahmad Hassan","2026","Efficacy and Dataset and PRISMA checklist for Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21447435","https://doi.org/10.5281/zenodo.21447435",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045151","R0045151.pdf","paywalled","systematic_review","Marina Wenn","2026","Weight Reduction in Adolescents with Obesity: A Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists and Metabolic-Bariatric Surgery",null,null,"10.17605/osf.io/ptyhu","https://doi.org/10.17605/osf.io/ptyhu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045161","R0045161.pdf","paywalled","systematic_review","Arveen Shokravi","2026","Additional file 1 of Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.31937673","https://doi.org/10.6084/m9.figshare.31937673",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045165","R0045165.pdf","paywalled","systematic_review","Paul‐Yang Lin","2026","Additional file 1 of Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants","Figshare",null,"10.6084/m9.figshare.31976059.v1","https://doi.org/10.6084/m9.figshare.31976059.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045301","R0045301.pdf","paywalled","systematic_review","Dimo Dimitrov","2026","Su1182 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND RISK OF GASTROESOPHAGEAL REFLUX DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01998-x","https://doi.org/10.1016/s0016-5107(26)01998-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045305","R0045305.pdf","paywalled","systematic_review","Kezia Peter","2026","Additional file 4 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.32142846.v1","https://doi.org/10.6084/m9.figshare.32142846.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045306","R0045306.pdf","paywalled","systematic_review","Kezia Peter","2026","Additional file 3 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.32142843","https://doi.org/10.6084/m9.figshare.32142843",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045335","R0045335.pdf","paywalled","systematic_review","Minahil Rasul","2026","Dataset for: Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21546594","https://doi.org/10.5281/zenodo.21546594",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045368","R0045368.pdf","paywalled","systematic_review","Abdulrahman Al‐Majmuei","2026","Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes in Adults with Obesity Undergoing Elective Non-Bariatric Surgery: A Systematic Review","SN Comprehensive Clinical Medicine","Springer Science and Business Media LLC","10.1007/s42399-026-02671-7","https://doi.org/10.1007/s42399-026-02671-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045515","R0045515.pdf","paywalled","systematic_review","Binayak Sinha","2026","The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.c.8245119.v1","https://doi.org/10.6084/m9.figshare.c.8245119.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251045294"],["3","R0045516","R0045516.pdf","paywalled","systematic_review","Adam Gędek","2026","Efficacy and safety of GLP-1 receptor agonists for metabolic outcomes in patients with schizophrenia spectrum disorders treated with second-generation antipsychotics: a systematic review and meta-analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/zbc98","https://doi.org/10.17605/osf.io/zbc98",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045563","R0045563.pdf","paywalled","systematic_review","Luke M. Yaldo","2026","Association between GLP-1 receptor agonist use and glaucoma risk: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.31435727.v1","https://doi.org/10.6084/m9.figshare.31435727.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045568","R0045568.pdf","paywalled","systematic_review","Sharath Kommu","2026","26-A-19079-ACC EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.703","https://doi.org/10.1016/j.jacc.2026.02.703",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045578","R0045578.pdf","paywalled","systematic_review","Adir Alper","2026","Additional file 1 of Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials","Figshare",null,"10.6084/m9.figshare.33413240.v1","https://doi.org/10.6084/m9.figshare.33413240.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045582","R0045582.pdf","paywalled","systematic_review","Binayak Sinha","2026","Additional file 1 of The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.31075797","https://doi.org/10.6084/m9.figshare.31075797",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045648","R0045648.pdf","paywalled","systematic_review","Carlos E. Builes-Montaño","2026","Association Between Incretin-Based Therapies and Ocular Outcomes in Adults: A Systematic Review with Qualitative Synthesis",null,null,"10.17605/osf.io/28uz4","https://doi.org/10.17605/osf.io/28uz4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045692","R0045692.pdf","paywalled","systematic_review","Hui Zheng","2026","Weight Regain After Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists in Adults with Obesity or Overweight: A Systematic Review and Meta-Analysis Integrating Randomized Controlled Trials and Real-World Evidence",null,null,"10.17605/osf.io/w86gy","https://doi.org/10.17605/osf.io/w86gy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045704","R0045704.pdf","paywalled","systematic_review","Ehab sharyan","2026","Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/qcg3y","https://doi.org/10.17605/osf.io/qcg3y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045730","R0045730.pdf","paywalled","systematic_review","Rishikesh R Magaji","2026","Mo1810 ASSESSING THE ROLE OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH): A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04874-1","https://doi.org/10.1016/s0016-5107(26)04874-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045748","R0045748.pdf","paywalled","systematic_review","Medhansh Biradar","2026","Mo1822 EFFICACY OF ORFORGLIPRON FOR WEIGHT REDUCTION IN OBESITY AND GLYCEMIC CONTROL: A DOSE STRATIFIED SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04955-3","https://doi.org/10.1016/s0016-5085(26)04955-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045779","R0045779.pdf","paywalled","systematic_review","Nicole Ann Tesoro","2026","26-A-12430-ACC EFFECTS OF GLP-1 RECEPTOR AGONISTS AND DUAL AGONISTS ON ALCOHOL USE DISORDER: A META-ANALYSIS AND SYSTEMATIC REVIEW","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.466","https://doi.org/10.1016/j.jacc.2026.02.466",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045842","R0045842.pdf","paywalled","systematic_review","Muna Salah","2026","26-A-13364-ACC IMPACT OF INCRETIN-BASED THERAPIES ON ATRIAL FIBRILLATION AND FLUTTER: A META-ANALYSIS OF RANDOMIZED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.086","https://doi.org/10.1016/j.jacc.2026.02.086",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045889","R0045889.pdf","paywalled","systematic_review","Abdulrahman Alanazi","2026","GLP-1 Receptor Agonist-Based Pharmacotherapy for Weight Management in Adults with Obesity or Overweight Compared with Placebo or Active Comparator: A Protocol for a Systematic Review and Network Meta-Analysis of Randomised Controlled Trials",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.5.0153","https://doi.org/10.37766/inplasy2026.5.0153",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045922","R0045922.pdf","paywalled","systematic_review","Ballakur D. Rao","2026","Tu1791 ROUX-EN-Y IS MORE EFFECTIVE THAN GLP-1 RECEPTOR AGONISTS AT ACHIEVING WEIGHT LOSS WITHOUT INCREASED SAFETY CONCERNS AT 52 WEEKS: RESULTS OF A NETWORK META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04918-7","https://doi.org/10.1016/s0016-5107(26)04918-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046044","R0046044.pdf","paywalled","systematic_review","Luigi Angelo Z. Borlongan","2026","Impact of luseogliflozin on metabolic health, lipid profiles, and cardiovascular outcomes in patients with type II diabetes: A systematic review and network meta‐analysis","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.70482","https://doi.org/10.1111/dom.70482","41582558","https://pubmed.ncbi.nlm.nih.gov/41582558/",null,"PROSPERO:CRD42024605191"],["3","R0046085","R0046085.pdf","paywalled","systematic_review","Bara M. Hammadeh","2026","26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.652","https://doi.org/10.1016/j.jacc.2026.02.652",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046201","R0046201.pdf","paywalled","systematic_review","Claire Williams","2026","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences",null,null,"10.17605/osf.io/e3qyd","https://doi.org/10.17605/osf.io/e3qyd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046229","R0046229.pdf","paywalled","systematic_review","Brajan Budini","2026","Trajectory of weight regain after cessation of glucagon-like-peptide-1 receptor agonists: a systematic review and nonlinear meta-regression","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.117.p102","https://doi.org/10.1530/endoabs.117.p102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420250631751"],["3","R0046254","R0046254.pdf","paywalled","systematic_review","Wachirawit Angkatavanich","2026","Weight loss efficacy of high-dose semaglutide regimens in adults with type 2 diabetes and obesity: a systematic review with quantitative synthesis",null,null,"10.17605/osf.io/7wzu5","https://doi.org/10.17605/osf.io/7wzu5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046268","R0046268.pdf","paywalled","systematic_review","Gabriele Volucke","2026","26-A-19380-ACC CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.401","https://doi.org/10.1016/j.jacc.2026.02.401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046304","R0046304.pdf","paywalled","systematic_review","Varathpavee Bhuriveth","2026","Mo1818 SEMAGLUTIDE AND RISK OF NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION): AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF OVER 3 MILLION ADULTS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04882-0","https://doi.org/10.1016/s0016-5107(26)04882-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046307","R0046307.pdf","paywalled","systematic_review","Grace Kim","2026","Perioperative Glucagon-Like Peptide-1 Receptor Agonist Use in Orthopaedic Surgery: A Systematic Review of Surgical Outcomes","Journal of the American Osteopathic Academy of Orthopedics","American Osteopathic Academy of Orthopedics","10.70709/pmiw7lkpkareon","https://doi.org/10.70709/pmiw7lkpkareon",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046311","R0046311.pdf","paywalled","systematic_review","Philip Branigan","2026","Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing GLP-1 Receptor Agonists and SGLT2 Inhibitors","Open Science Framework",null,"10.17605/osf.io/prnya","https://doi.org/10.17605/osf.io/prnya",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046317","R0046317.pdf","paywalled","systematic_review","Roy Novri Ramadhan","2026","Perioperative Cardioprotective Effects of GLP-1 Receptor Agonists in Patients Undergoing Cardiac Surgery: A Systematic Review",null,null,"10.17605/osf.io/26pwr","https://doi.org/10.17605/osf.io/26pwr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046342","R0046342.pdf","paywalled","systematic_review","Abdulrahman Alanazi","2026","Subcutaneous Tirzepatide Versus Semaglutide and Emerging Incretin Agents in Type 2 Diabetes: A Comprehensive Frequentist Network Meta-Analysis of 42 Trials Through May 2026",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.6.0011","https://doi.org/10.37766/inplasy2026.6.0011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046360","R0046360.pdf","paywalled","systematic_review","Subhendu Mandal","2026","26-A-10033-ACC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN THE POST ACUTE MYOCARDIAL INFARCTION SETTING: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2053","https://doi.org/10.1016/j.jacc.2026.02.2053",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046411","R0046411.pdf","paywalled","systematic_review","Tamer Hodrob","2026","Comparative Effectiveness of Semaglutide, Orforglipron, Phentermine–Topiramate, and Naltrexone–Bupropion for the Management of Overweight and Obesity: A Network Meta-analysis of Randomized Clinical Trials",null,null,"10.17605/osf.io/g8jmy","https://doi.org/10.17605/osf.io/g8jmy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046421","R0046421.pdf","paywalled","systematic_review","W. Vollebregt","2026","L26/O-314 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) during preconception and pregnancy: a systematic review and meta-analysis of obstetric and neonatal outcomes","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.312","https://doi.org/10.1093/humrep/deag083.312",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046503","R0046503.pdf","paywalled","systematic_review","David Savage-Lobeck","2026","26-A-13074-ACC CARDIO-RENAL OUTCOMES OF GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: AN UMBRELLA REVIEW OF META-ANALYSES AND DEVELOPING A CARDIO-RENAL GUIDELINE FRAMEWORK","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.674","https://doi.org/10.1016/j.jacc.2026.02.674",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046518","R0046518.pdf","paywalled","systematic_review","Syed Muhammad Rayyan","2026","Reproducible analysis code and data for Efficacy and safety of mazdutide in overweight, obesity, and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21427643","https://doi.org/10.5281/zenodo.21427643",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046529","R0046529.pdf","paywalled","systematic_review","Kaushal Jatti","2026","Impact of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Patient-Reported Quality of Life in Adults: A Systematic Review Protocol",null,null,"10.17605/osf.io/yxtg8","https://doi.org/10.17605/osf.io/yxtg8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046681","R0046681.pdf","paywalled","systematic_review","Abdulrahman Alanazi","2026","Dual Cardiorenal Coverage in Type 2 Diabetes: A Comprehensive Systematic Review and Meta-Analysis of GLP-1 Receptor Agonist and SGLT-2 Inhibitor Combination Therapy Versus Monotherapy Across Cardiovascular, Renal, and Metabolic Endpoints",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2026.6.0007","https://doi.org/10.37766/inplasy2026.6.0007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046786","R0046786.pdf","paywalled","systematic_review","Lorenzo Bianchi","2026","26-A-13687-ACC SAFETY AND EFFICACY OF GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED AND MILDLY REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1890","https://doi.org/10.1016/j.jacc.2026.02.1890",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046871","R0046871.pdf","paywalled","systematic_review","Carlos M. Patiño","2026","26-A-16654-ACC REDUCED RISK OF SINUS NODE DYSFUNCTION WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: EVIDENCE FROM A SYSTEMATIC REVIEW OF CLINICAL TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.154","https://doi.org/10.1016/j.jacc.2026.02.154",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047303","R0047303.pdf","paywalled","systematic_review","Jayesh Srivastava","2026","2870-LB: Glucagon-Like Peptide 1 Receptor Agonists for Antipsychotic-Associated Metabolic Dysfunctions In Patients with Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db26-2870-lb","https://doi.org/10.2337/db26-2870-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047689","R0047689.pdf","paywalled","systematic_review","Param Darpan Sheth","2026","26-A-11744-ACC GLP-1 AGONISTS VS DPP-4 INHIBITORS AND ATRIAL FIBRILLATION: A HEAD-TO-HEAD META-ANALYSIS OF RANDOMIZED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.347","https://doi.org/10.1016/j.jacc.2026.02.347",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047876","R0047876.pdf","paywalled","systematic_review","C L Birda","2026","P1064 Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjaf231.1245","https://doi.org/10.1093/ecco-jcc/jjaf231.1245",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048024","R0048024.pdf","paywalled","systematic_review","Maximiliano Lang","2026","26-A-14486-ACC CARDIOVASCULAR OUTCOMES OF GLP-1 RECEPTOR AGONISTS ADDED TO SGLT2 INHIBITORS VERSUS SGLT2 INHIBITORS ALONE IN TYPE 2 DIABETES MELLITUS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.682","https://doi.org/10.1016/j.jacc.2026.02.682",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048046","R0048046.pdf","paywalled","systematic_review","Omer A. Raheem","2026","(O-11) Effects of GLP-1 Receptor Agonists on Semen Quality in Men: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag062.018","https://doi.org/10.1093/jsxmed/qdag062.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048132","R0048132.pdf","paywalled","systematic_review","G Chilingarashvili","2026","A28-03 Protective Role of GLP-1 Receptor Agonists in Sepsis-associated Acute Lung Injury: A Systematic Review of Mechanistic and Clinical Evidence","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.035","https://doi.org/10.1093/ajrccm/aamag162.035",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048589","R0048589.pdf","paywalled","systematic_review","Nida Abraitytė","2026","Weight Regain After GLP-1 Receptor Agonist Discontinuation and the Role of Tapering and Maintenance Strategies: A Systematic Review",null,null,"10.17605/osf.io/wpt7m","https://doi.org/10.17605/osf.io/wpt7m",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048695","R0048695.pdf","paywalled","systematic_review","Omer Farooq Mohammed","2026","Comparative Effects of Tirzepatide and Other Glucose-Lowering Therapies on Fasting Lipid Parameters: A Random-Effects Network Meta-analysis of Randomized Controlled Trials","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2026.05.023","https://doi.org/10.1016/j.jacl.2026.05.023",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048979","R0048979.pdf","paywalled","systematic_review","Adir Alper","2026","Additional file 1 of Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review","Figshare",null,"10.6084/m9.figshare.31374977.v1","https://doi.org/10.6084/m9.figshare.31374977.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049058","R0049058.pdf","paywalled","systematic_review","O Raheem","2026","(368) Effects of GLP-1 Receptor Agonists on Male Reproductive Hormones, Semen Parameters, and Metabolic Outcomes: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag118.332","https://doi.org/10.1093/jsxmed/qdag118.332",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049397","R0049397.pdf","paywalled","systematic_review","S Jugnundan","2026","Obesity Management and Health Outcomes: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1822009","https://doi.org/10.1055/s-0046-1822009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049405","R0049405.pdf","paywalled","systematic_review","Yanchenhan Hao","2026","The Efficacy and Safety of GLP-1 Receptor Agonists in the Treatment of Chronic Heart Failure with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials","MEDS Clinical Medicine","Clausius Scientific Press, Inc.","10.23977/medsc.2026.070316","https://doi.org/10.23977/medsc.2026.070316",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050106","R0050106.pdf","paywalled","systematic_review","Abdulrahman A. Azab","2026","Semaglutide 2.4 mg for weight loss in overweight adolescents and adults without diabetes: an updated systematic review and meta-analysis of randomized controlled trials","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1766048131","https://doi.org/10.24911/ijmdc.51-1766048131",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050461","R0050461.pdf","paywalled","systematic_review","Bijay Mukesh Jeswani","2026","26-A-21545-ACC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1943","https://doi.org/10.1016/j.jacc.2026.02.1943",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050464","R0050464.pdf","paywalled","systematic_review","Omar Kherad","2026","Systematic review and meta-analysis of glucagon-like peptide 1 receptor agonists (GLP1-RAs) safety and efficacy in patients with inflammatory bowel disease","Frontline Gastroenterology","BMJ","10.1136/flgastro-2026-103640","https://doi.org/10.1136/flgastro-2026-103640",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261350546"],["3","R0051053","R0051053.pdf","paywalled","systematic_review","Aasim Ali","2026","Early GLP-1 Receptor Agonist Therapy in Acute Ischemic Stroke and High-Risk TIA: A Systematic Review and Meta-analysis of Randomized Trials",null,null,"10.17605/osf.io/9ut8r","https://doi.org/10.17605/osf.io/9ut8r",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051528","R0051528.pdf","paywalled","systematic_review","Laura Chiavaroli","2026","Glucagon-Like Peptide-1 (GLP-1) Therapies Combined with Structured Lifestyle Interventions in Adults with Type 2 Diabetes: A Systematic Review Protocol",null,null,"10.17605/osf.io/fgh9z","https://doi.org/10.17605/osf.io/fgh9z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051532","R0051532.pdf","paywalled","systematic_review","Lissette Haydee García-Mena","2026","26-A-17035-ACC A META-ANALYSIS OF EFFECTIVENESS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN PATIENTS WITH OBESITY AND HEART FAILURE WITH PRESERVED EJECTION FRACTION","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1915","https://doi.org/10.1016/j.jacc.2026.02.1915",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052260","R0052260.pdf","paywalled","systematic_review","Maurice Tiotsop","2026","Cardiovascular and Cardiorenal Outcomes of GLP-1 Receptor Agonists and Dual Incretin Therapies: Systematic Review and Meta-analysis",null,null,"10.17605/osf.io/y2j3n","https://doi.org/10.17605/osf.io/y2j3n",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052466","R0052466.pdf","paywalled","systematic_review","Arkansh Sharma","2026","Drug-specific Effects of GLP-1 Receptor Agonists on Dementia Risk: A Network Meta-analysis (P3-13.008)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000216715","https://doi.org/10.1212/wnl.0000000000216715",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053349","R0053349.pdf","paywalled","systematic_review","Adithya Chandran","2026","Comparative Cardiovascular Effectiveness of GLP-1 Receptor Agonists in Type 2 Diabetes and ASCVD: A Bayesian Network Meta-Analysis",null,null,"10.13140/rg.2.2.27575.28325","https://doi.org/10.13140/rg.2.2.27575.28325",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053497","R0053497.pdf","paywalled","systematic_review","Leigh Perreault","2026","1691-P: A Meta-Analysis of Persistence and Adherence to Glucagon-Like Peptide 1-Based Treatments among Patients with Type 2 Diabetes in the United States","Diabetes","American Diabetes Association","10.2337/db26-1691-p","https://doi.org/10.2337/db26-1691-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053592","R0053592.pdf","paywalled","systematic_review","Levi Da Silva","2026","GLP-1 Receptor Agonists vs. SGLT2 Inhibitors and the Risk of Alzheimer’s Disease in Type 2 Diabetes: A Systematic Review and Meta-Analysis (N3.002)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000215416","https://doi.org/10.1212/wnl.0000000000215416",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053735","R0053735.pdf","paywalled","systematic_review","Paulami Deshmukh","2026","Abstract Wed133: Title: Comparative Efficacy of GLP-1RAs Among Individuals With PAD And Type 2 Diabetes: A Network Meta-analysis of Randomized Controlled Trials","Arteriosclerosis Thrombosis and Vascular Biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvb.46.suppl_1.wed133","https://doi.org/10.1161/atvb.46.suppl_1.wed133",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053879","R0053879.pdf","paywalled","systematic_review","J J E Wong","2026","1325 GLP-1 Agonists in Lymphedema: A Systematic Review of Clinical Evidence","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag063.695","https://doi.org/10.1093/bjs/znag063.695",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053942","R0053942.pdf","paywalled","systematic_review","Gustavo Adolfo Vásquez-Tirado","2026","Effectiveness of combined intragastric balloon therapy and GLP-1 receptor agonists for weight loss in adults with obesity: a systematic review and meta-analysis","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2026.100697","https://doi.org/10.1016/j.obmed.2026.100697",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054349","R0054349.pdf","paywalled","systematic_review","Yi Zhou","2026","1886-P: Efficacy and Safety Noninsulin Hypoglycemic Drugs as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","Diabetes","American Diabetes Association","10.2337/db26-1886-p","https://doi.org/10.2337/db26-1886-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054409","R0054409.pdf","paywalled","systematic_review","Divya Pathak","2026","Current and Innovative Molecular Targets in Diabetes Mellitus Therapy: A Systematic Review","Current Signal Transduction Therapy","Bentham Science Publishers Ltd.","10.2174/0115743624488705260825073021","https://doi.org/10.2174/0115743624488705260825073021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054559","R0054559.pdf","paywalled","systematic_review","Neda Rasouli","2026","20-PUB: A Meta-Analysis of Real-World Effectiveness of Glucagon-Like Peptide 1s among Patients with Type 2 Diabetes in the United States","Diabetes","American Diabetes Association","10.2337/db26-20-pub","https://doi.org/10.2337/db26-20-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054669","R0054669.pdf","paywalled","systematic_review","Omer Raheem","2026","(O-10) Impact of GLP-1 Receptor Agonists on Testosterone and Gonadotropin Profiles in Men: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag062.017","https://doi.org/10.1093/jsxmed/qdag062.017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054719","R0054719.pdf","paywalled","systematic_review","Nwachukwu O Nwachukwu","2026","THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS ON LIPID METABOLISM: A NEW AVENUE FOR CARDIOVASCULAR DISEASE PREVENTION—A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS","Postgraduate Medical Journal","Oxford University Press (OUP)","10.1093/postmj/qgag039.008","https://doi.org/10.1093/postmj/qgag039.008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055059","R0055059.pdf","paywalled","systematic_review","Troy B Puga","2026","Outcomes of glucagon-like-peptide-1 receptor agonists and patients undergoing total shoulder arthroplasty: a systematic review and meta-analysis","Seminars in Arthroplasty JSES","Elsevier BV","10.1016/j.sart.2026.151583","https://doi.org/10.1016/j.sart.2026.151583",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055230","R0055230.pdf","paywalled","systematic_review","Shohinee Sarma","2026","3089-LB: Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db26-3089-lb","https://doi.org/10.2337/db26-3089-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055457","R0055457.pdf","paywalled","systematic_review","Gautham Kolla","2026","Efficacy and safety of once-weekly IcoSema compared to active comparators in adults with type 2 diabetes: A systematic review and comparator-stratified quantitative synthesis of randomized controlled trials","International Journal of Diabetes in Developing Countries","Springer Science and Business Media LLC","10.1007/s13410-026-01648-5","https://doi.org/10.1007/s13410-026-01648-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055511","R0055511.pdf","paywalled","systematic_review","FAROUQ B.F. ALAHMED","2026","1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence","Diabetes","American Diabetes Association","10.2337/db26-1683-p","https://doi.org/10.2337/db26-1683-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261278843"],["3","R0055573","R0055573.pdf","paywalled","systematic_review","Ishaque Hameed","2026","1200.07 Comparison Of the Efficacy of Oral and Subcutaneous Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2026.01.182","https://doi.org/10.1016/j.jcin.2026.01.182",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055758","R0055758.pdf","paywalled","systematic_review","Shreya Mittal","2026","A Systematic Review: What is the current evidence on the use of point-of-care gastric ultrasound to risk-stratify patients taking GLP-1 receptor agonists pre-procedurally?","Open Science Framework",null,"10.17605/osf.io/bxhf8","https://doi.org/10.17605/osf.io/bxhf8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055778","R0055778.pdf","paywalled","systematic_review","Yara El Deghel","2026","Preconception GLP-1 Receptor Agonist Therapy and Reproductive Outcomes in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/c3jax","https://doi.org/10.17605/osf.io/c3jax",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055788","R0055788.pdf","paywalled","systematic_review","Ana Carolina Ferreira Vianet Ribeiro","2026","Glucagon-like peptide-1 receptor agonists versus insulin and the risk of diabetic retinopathy complications and other ocular disorders in type 2 diabetes: a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/qmjr6","https://doi.org/10.17605/osf.io/qmjr6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261349536"],["3","R0055821","R0055821.pdf","paywalled","systematic_review","Minesh","2026","Meta-Analysis of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention","Open Science Framework",null,"10.17605/osf.io/vqtpx","https://doi.org/10.17605/osf.io/vqtpx",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055823","R0055823.pdf","paywalled","systematic_review","Hiva","2026","Periprocedural Risk Mitigation in Patients Receiving GLP-1–Based Therapies: Effects of Drug Interruption, Fasting Strategies, and Clinical Risk Modifiers on Residual Gastric Content—An Updated Systematic Review and Meta-analysis","Open Science Framework",null,"10.17605/osf.io/3uwdy","https://doi.org/10.17605/osf.io/3uwdy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055945","R0055945.pdf","paywalled","systematic_review","Indra Narayan Shrestha","2026","Efficacy, Safety, and Implementation of Alternative Smoking Interventions: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/zd635","https://doi.org/10.17605/osf.io/zd635",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055954","R0055954.pdf","paywalled","systematic_review","Shamama Niaz","2026","Efficacy of SGLT2 Inhibitors and GLP-1/GIP Agonists in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Network Meta-Analysis Protocol.","Open Science Framework",null,"10.17605/osf.io/6mnzr","https://doi.org/10.17605/osf.io/6mnzr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055989","R0055989.pdf","paywalled","systematic_review","Han Sang Kim","2026","Comparator and time-alignment sensitivity of associations between GLP-1 receptor agonists and incident cancer: a systematic review and meta-research study of within-cohort design contrasts","Open Science Framework",null,"10.17605/osf.io/u5cef","https://doi.org/10.17605/osf.io/u5cef",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056026","R0056026.pdf","paywalled","systematic_review","Yara El Deghel","2026","Urologic Adverse Events Associated with GLP-1 Receptor Agonist Use: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/fxacp","https://doi.org/10.17605/osf.io/fxacp",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056110","R0056110.pdf","paywalled","systematic_review","Tripdatabase","2026","What meta-analysis and systematic review evidence supports the use of semaglutide for improving metabolism and treating obesity?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23049925","https://doi.org/10.5281/zenodo.23049925",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056160","R0056160.pdf","paywalled","systematic_review","XIAO MA","2026","Is non-response real? True between-patient heterogeneity in weight-loss response to incretin-based anti-obesity medications: a systematic review and dose-response network meta-analysis of variability, with an evaluation of early stopping rules","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/c598r","https://doi.org/10.17605/osf.io/c598r",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056218","R0056218.pdf","paywalled","systematic_review","Jack Michael Birch","2026","PROTOCOL How can waiting times and prioritisation of eligibility for weight loss drugs be effectively communicated to patients? A rapid systematic review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23236919","https://doi.org/10.5281/zenodo.23236919",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056312","R0056312.pdf","paywalled","systematic_review","Zaid Nabeel Alkhalidi","2026","GLP-1 Receptor Agonists for Prevention of Stroke and Ischaemic Cerebrovascular Events in Type 2 Diabetes Mellitus: A Trial-Level Meta-analysis","SN Comprehensive Clinical Medicine","Springer Science and Business Media LLC","10.1007/s42399-026-02747-4","https://doi.org/10.1007/s42399-026-02747-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056327","R0056327.pdf","paywalled","systematic_review","Mukesh Kumar Sharma","2026","Efficacy and Safety of Oral GLP-1 Receptor Agonists for Weight Loss in Adults Without Diabetes: An Updated Meta-Analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/fker5","https://doi.org/10.17605/osf.io/fker5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056332","R0056332.pdf","paywalled","systematic_review","Ekaterina Chepeleva","2026","Neuroprotective efficacy of semaglutide in preclinical in vivo rodent models: a systematic review and quantitative meta-analysis","Open Science Framework",null,"10.17605/osf.io/ht6xe","https://doi.org/10.17605/osf.io/ht6xe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056382","R0056382.pdf","paywalled","systematic_review","Danilo Ferreira de Sousa","2026","Quality and sustainability of weight loss with injectable incretin therapies in adults with obesity: an umbrella review of systematic reviews and meta analyses","Journal of Social Issues and Health Sciences (JSIHS)",null,"10.5281/zenodo.22207914","https://doi.org/10.5281/zenodo.22207914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056402","R0056402.pdf","paywalled","systematic_review","Katarzyna Marut","2026","Metabolic Implications of Obesity in Polycystic Ovary Syndrome: A Systematic Review of Current Evidence and Therapeutic Strategies","African Journal of Biomedical Research",null,"10.69980/8vsmth73","https://doi.org/10.69980/8vsmth73",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056469","R0056469.pdf","paywalled","systematic_review","A. Shokravi","2026","P214 DO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION? A SYSTEMATIC REVIEW AND META-ANALYSIS","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2026.07.204","https://doi.org/10.1016/j.cjca.2026.07.204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056503","R0056503.pdf","paywalled","systematic_review","Maria Sultana","2026","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss and Cardiovascular Protection in Obesity and Type2 Diabetes: A Systematic Review and Meta-Analysis","Journal of Diabetes Research Review & Reports",null,"10.47363/pstgch08","https://doi.org/10.47363/pstgch08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056544","R0056544.pdf","paywalled","systematic_review","Yuvraj Jadhav","2026","Comparative Efficacy and Safety of Novel Pharmacological Interventions for MASH: A Systematic Review and Network Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/gct74","https://doi.org/10.17605/osf.io/gct74",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056606","R0056606.pdf","paywalled","systematic_review","Eisa N","2026","Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag284","https://doi.org/10.1210/clinem/dgag284","42867450","https://pubmed.ncbi.nlm.nih.gov/42867450/",null,"PROSPERO:CRD42026137255"],["3","R0056640","R0056640.pdf","paywalled","systematic_review","Junhui Bai","2026","GLP-1 receptor agonists multi-state network meta-analysis: analysis code and data","Open Science Framework",null,"10.17605/osf.io/cyjfp","https://doi.org/10.17605/osf.io/cyjfp",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056710","R0056710.pdf","paywalled","systematic_review","Sarah Dib","2026","Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement","The Lancet Obstetrics Gynaecology & Women s Health","Elsevier BV","10.1016/s3050-5038(26)00266-9","https://doi.org/10.1016/s3050-5038(26)00266-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056759","R0056759.pdf","paywalled","systematic_review","Károly Szili","2026","Incretin-Based Agents and Reproduction, Fertility and Pregnancy: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/rthdu","https://doi.org/10.17605/osf.io/rthdu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0057006","R0057006.pdf","paywalled","systematic_review","Sha H","2026","GLP-1 and its derivatives are associated with the reduction of macrophage infiltration and inflammation in systemic chronic inflammatory diseases: a systematic review and meta-analysis of animal models.","Immunologic research","Springer Science and Business Media LLC","10.1007/s12026-026-09764-4","https://doi.org/10.1007/s12026-026-09764-4","41843040","https://pubmed.ncbi.nlm.nih.gov/41843040/",null,null],["3","R0000174","R0000174.pdf","paywalled","systematic_review","Xu Y","2025","Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112954","https://doi.org/10.1016/j.diabres.2025.112954","42618994","https://pubmed.ncbi.nlm.nih.gov/42618994/",null,null],["3","R0000236","R0000236.pdf","paywalled","systematic_review","Ravikulan R","2025","Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.70085","https://doi.org/10.1002/ejhf.70085","41216984","https://pubmed.ncbi.nlm.nih.gov/41216984/",null,null],["3","R0000256","R0000256.pdf","paywalled","systematic_review","Patel S","2025","GLP-1 receptor agonists and alcohol use disorder: a systematic review.","Alcohol and alcoholism (Oxford, Oxfordshire)",null,"10.1093/alcalc/agaf069","https://doi.org/10.1093/alcalc/agaf069","41273789","https://pubmed.ncbi.nlm.nih.gov/41273789/",null,null],["3","R0000539","R0000539.pdf","paywalled","systematic_review","Fu W","2025","Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16581","https://doi.org/10.1111/dom.16581","40613325","https://pubmed.ncbi.nlm.nih.gov/40613325/",null,null],["3","R0000652","R0000652.pdf","paywalled","systematic_review","Wang Y","2025","Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf336","https://doi.org/10.1210/clinem/dgaf336","40489581","https://pubmed.ncbi.nlm.nih.gov/40489581/",null,null],["3","R0001263","R0001263.pdf","paywalled","systematic_review","Esparham A","2025","Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08137-4","https://doi.org/10.1007/s11695-025-08137-4","40782272","https://pubmed.ncbi.nlm.nih.gov/40782272/",null,null],["3","R0001392","R0001392.pdf","paywalled","systematic_review","Khalil I","2025","Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.06.005","https://doi.org/10.1016/j.eprac.2025.06.005","40553959","https://pubmed.ncbi.nlm.nih.gov/40553959/",null,null],["3","R0001526","R0001526.pdf","paywalled","systematic_review","Yonatan ER","2025","Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis.","Journal of gastrointestinal cancer","Springer Science and Business Media LLC","10.1007/s12029-025-01330-9","https://doi.org/10.1007/s12029-025-01330-9","41075111","https://pubmed.ncbi.nlm.nih.gov/41075111/",null,"PROSPERO:CRD42025641616"],["3","R0001545","R0001545.pdf","paywalled","systematic_review","Celsa C","2025","Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.","Gut","BMJ","10.1136/gutjnl-2024-334591","https://doi.org/10.1136/gutjnl-2024-334591","40015951","https://pubmed.ncbi.nlm.nih.gov/40015951/",null,null],["3","R0001580","R0001580.pdf","paywalled","systematic_review","Karakasis P","2025","Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2024.156113","https://doi.org/10.1016/j.metabol.2024.156113","39719170","https://pubmed.ncbi.nlm.nih.gov/39719170/",null,null],["3","R0001763","R0001763.pdf","paywalled","systematic_review","Zamanian N","2025","The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177966","https://doi.org/10.1016/j.ejphar.2025.177966","40680981","https://pubmed.ncbi.nlm.nih.gov/40680981/",null,"PROSPERO:CRD42024603661"],["3","R0001781","R0001781.pdf","paywalled","systematic_review","Zhang S","2025","Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0533","https://doi.org/10.1089/dia.2024.0533","39911047","https://pubmed.ncbi.nlm.nih.gov/39911047/",null,null],["3","R0001863","R0001863.pdf","paywalled","systematic_review","Ahmad B","2025","Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety.","Semergen","Elsevier BV","10.1016/j.semerg.2025.102628","https://doi.org/10.1016/j.semerg.2025.102628","41223488","https://pubmed.ncbi.nlm.nih.gov/41223488/",null,null],["3","R0001884","R0001884.pdf","paywalled","systematic_review","Beran A","2025","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003362","https://doi.org/10.14309/ajg.0000000000003362","39933910","https://pubmed.ncbi.nlm.nih.gov/39933910/",null,null],["3","R0001929","R0001929.pdf","paywalled","systematic_review","Sedenho-Prado LG","2025","Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-01790-w","https://doi.org/10.1038/s41366-025-01790-w","40269110","https://pubmed.ncbi.nlm.nih.gov/40269110/",null,"PROSPERO:CRD42024532845"],["3","R0001974","R0001974.pdf","paywalled","systematic_review","Yeh JA","2025","Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson's disease in patients with type 2 diabetes: A propensity score-matched cohort study with meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112914","https://doi.org/10.1016/j.diabres.2025.112914","40976497","https://pubmed.ncbi.nlm.nih.gov/40976497/",null,null],["3","R0001999","R0001999.pdf","paywalled","systematic_review","An X","2025","Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16228","https://doi.org/10.1111/dom.16228","39910752","https://pubmed.ncbi.nlm.nih.gov/39910752/",null,null],["3","R0002050","R0002050.pdf","paywalled","systematic_review","Nie Y","2025","Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07733-8","https://doi.org/10.1007/s11695-025-07733-8","39948306","https://pubmed.ncbi.nlm.nih.gov/39948306/",null,null],["3","R0002099","R0002099.pdf","paywalled","systematic_review","Perencin A","2025","Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.","Minerva medica","Edizioni Minerva Medica","10.23736/s0026-4806.25.09709-5","https://doi.org/10.23736/s0026-4806.25.09709-5","40932602","https://pubmed.ncbi.nlm.nih.gov/40932602/",null,null],["3","R0002222","R0002222.pdf","paywalled","systematic_review","Sánchez-Feliciano A","2025","Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: A systematic review.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.06.077","https://doi.org/10.1016/j.jaad.2025.06.077","40706684","https://pubmed.ncbi.nlm.nih.gov/40706684/",null,null],["3","R0002254","R0002254.pdf","paywalled","systematic_review","Younus I","2025","Are GLP-1 Receptor Agonists Safe in Spine Surgery: A Systematic Review.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005466","https://doi.org/10.1097/brs.0000000000005466","40719010","https://pubmed.ncbi.nlm.nih.gov/40719010/",null,null],["3","R0002317","R0002317.pdf","paywalled","systematic_review","Mahalingasivam AA","2025","Headline: Fracture Risk in Type 2 Diabetes: Systematic Review of Cardiovascular Outcome Trials with Glucagon Like Peptide Receptor Agonists.","Current osteoporosis reports","Springer Science and Business Media LLC","10.1007/s11914-025-00937-y","https://doi.org/10.1007/s11914-025-00937-y","41026248","https://pubmed.ncbi.nlm.nih.gov/41026248/",null,null],["3","R0002328","R0002328.pdf","paywalled","systematic_review","Lee V","2025","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes in Arthroplasty: A Systematic Review.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.07.015","https://doi.org/10.1016/j.arth.2025.07.015","40675511","https://pubmed.ncbi.nlm.nih.gov/40675511/",null,null],["3","R0002331","R0002331.pdf","paywalled","systematic_review","Goldenberg RM","2025","Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta-analysis of observational studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70013","https://doi.org/10.1111/dom.70013","40757429","https://pubmed.ncbi.nlm.nih.gov/40757429/",null,null],["3","R0002354","R0002354.pdf","paywalled","systematic_review","Abdulraheem A","2025","Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-11962-4","https://doi.org/10.1007/s00464-025-11962-4","40634731","https://pubmed.ncbi.nlm.nih.gov/40634731/",null,null],["3","R0002469","R0002469.pdf","paywalled","systematic_review","Chiu YT","2025","The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy - a systematic review and meta-analysis.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Elsevier BV","10.1016/j.dld.2025.03.004","https://doi.org/10.1016/j.dld.2025.03.004","40121157","https://pubmed.ncbi.nlm.nih.gov/40121157/",null,null],["3","R0002487","R0002487.pdf","paywalled","systematic_review","Chiang CH","2025","Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2025.06.003","https://doi.org/10.1053/j.gastro.2025.06.003","40499738","https://pubmed.ncbi.nlm.nih.gov/40499738/",null,null],["3","R0002503","R0002503.pdf","paywalled","systematic_review","Baig MU","2025","Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.12.019","https://doi.org/10.1016/j.gie.2024.12.019","39694296","https://pubmed.ncbi.nlm.nih.gov/39694296/",null,"PROSPERO:CRD42024556732"],["3","R0002577","R0002577.pdf","paywalled","systematic_review","de Faria Moraes B","2025","Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis.","Drug and alcohol dependence","Elsevier BV","10.1016/j.drugalcdep.2025.112840","https://doi.org/10.1016/j.drugalcdep.2025.112840","40845737","https://pubmed.ncbi.nlm.nih.gov/40845737/",null,null],["3","R0002602","R0002602.pdf","paywalled","systematic_review","Duchemin L","2025","Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16504","https://doi.org/10.1111/dom.16504","40468864","https://pubmed.ncbi.nlm.nih.gov/40468864/",null,null],["3","R0002661","R0002661.pdf","paywalled","systematic_review","Garagoli F","2025","Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2025.501562","https://doi.org/10.1016/j.endien.2025.501562","40413013","https://pubmed.ncbi.nlm.nih.gov/40413013/",null,"PROSPERO:CRD42024565567"],["3","R0002709","R0002709.pdf","paywalled","systematic_review","Wen Z","2025","Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.111999","https://doi.org/10.1016/j.diabres.2025.111999","39828025","https://pubmed.ncbi.nlm.nih.gov/39828025/",null,null],["3","R0002717","R0002717.pdf","paywalled","systematic_review","Siranart N","2025","Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.","Journal of Crohn's & colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjaf193","https://doi.org/10.1093/ecco-jcc/jjaf193","41212197","https://pubmed.ncbi.nlm.nih.gov/41212197/",null,null],["3","R0002732","R0002732.pdf","paywalled","systematic_review","Kang YM","2025","Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16424","https://doi.org/10.1111/dom.16424","40342232","https://pubmed.ncbi.nlm.nih.gov/40342232/",null,null],["3","R0002820","R0002820.pdf","paywalled","systematic_review","Zhang Z","2025","Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2025.119509","https://doi.org/10.1016/j.jad.2025.119509","40447157","https://pubmed.ncbi.nlm.nih.gov/40447157/",null,null],["3","R0002831","R0002831.pdf","paywalled","systematic_review","Chen W","2025","Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2025.10.006","https://doi.org/10.1016/j.clnu.2025.10.006","41187492","https://pubmed.ncbi.nlm.nih.gov/41187492/",null,null],["3","R0002841","R0002841.pdf","paywalled","systematic_review","Moiz A","2025","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-01590","https://doi.org/10.7326/annals-24-01590","39761578","https://pubmed.ncbi.nlm.nih.gov/39761578/",null,"PROSPERO:CRD42024505558"],["3","R0002846","R0002846.pdf","paywalled","systematic_review","Singh S","2025","Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.10.011","https://doi.org/10.1016/j.gie.2024.10.011","39401599","https://pubmed.ncbi.nlm.nih.gov/39401599/",null,null],["3","R0002896","R0002896.pdf","paywalled","systematic_review","Zhang Y","2025","Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Journal of neurology","Springer Science and Business Media LLC","10.1007/s00415-025-13301-y","https://doi.org/10.1007/s00415-025-13301-y","40760123","https://pubmed.ncbi.nlm.nih.gov/40760123/",null,null],["3","R0003051","R0003051.pdf","paywalled","systematic_review","Chan YC","2025","The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.06.083","https://doi.org/10.1016/j.arth.2025.06.083","40617546","https://pubmed.ncbi.nlm.nih.gov/40617546/",null,null],["3","R0003105","R0003105.pdf","paywalled","systematic_review","Talavera A","2025","Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70102","https://doi.org/10.1111/dom.70102","40937512","https://pubmed.ncbi.nlm.nih.gov/40937512/",null,null],["3","R0003220","R0003220.pdf","paywalled","systematic_review","Wong HJ","2025","Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000003903","https://doi.org/10.1097/hjh.0000000000003903","39445607","https://pubmed.ncbi.nlm.nih.gov/39445607/",null,null],["3","R0003256","R0003256.pdf","paywalled","systematic_review","Lu J","2025","The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177885","https://doi.org/10.1016/j.ejphar.2025.177885","40615102","https://pubmed.ncbi.nlm.nih.gov/40615102/",null,null],["3","R0003358","R0003358.pdf","paywalled","systematic_review","Rivera FB","2025","Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2024.2442027","https://doi.org/10.1080/03007995.2024.2442027","39666879","https://pubmed.ncbi.nlm.nih.gov/39666879/",null,null],["3","R0003668","R0003668.pdf","paywalled","systematic_review","Alammari N","2025","Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16476","https://doi.org/10.1111/dom.16476","40390279","https://pubmed.ncbi.nlm.nih.gov/40390279/",null,null],["3","R0003691","R0003691.pdf","paywalled","systematic_review","Bramlage P","2025","Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70010","https://doi.org/10.1111/dom.70010","40798873","https://pubmed.ncbi.nlm.nih.gov/40798873/",null,null],["3","R0003702","R0003702.pdf","paywalled","systematic_review","Xu R","2025","Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.11.017","https://doi.org/10.1016/j.eprac.2024.11.017","39701283","https://pubmed.ncbi.nlm.nih.gov/39701283/",null,null],["3","R0003770","R0003770.pdf","paywalled","systematic_review","Wong HJ","2025","Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16136","https://doi.org/10.1111/dom.16136","39726212","https://pubmed.ncbi.nlm.nih.gov/39726212/",null,null],["3","R0003773","R0003773.pdf","paywalled","systematic_review","Badran AS","2025","From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-025-08411-4","https://doi.org/10.1007/s10072-025-08411-4","40835782","https://pubmed.ncbi.nlm.nih.gov/40835782/",null,null],["3","R0003794","R0003794.pdf","paywalled","systematic_review","Li W","2025","Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70084","https://doi.org/10.1111/dom.70084","40936218","https://pubmed.ncbi.nlm.nih.gov/40936218/",null,null],["3","R0003830","R0003830.pdf","paywalled","systematic_review","Kamarullah W","2025","Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-024-00695-9","https://doi.org/10.1007/s40256-024-00695-9","39616304","https://pubmed.ncbi.nlm.nih.gov/39616304/",null,null],["3","R0003842","R0003842.pdf","paywalled","systematic_review","Wong HJ","2025","Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.","Diabetes care","American Diabetes Association","10.2337/dc24-1678","https://doi.org/10.2337/dc24-1678","39841962","https://pubmed.ncbi.nlm.nih.gov/39841962/",null,null],["3","R0003951","R0003951.pdf","paywalled","systematic_review","Song R","2025","Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.","Postgraduate medical journal","Oxford University Press (OUP)","10.1093/postmj/qgae148","https://doi.org/10.1093/postmj/qgae148","39487697","https://pubmed.ncbi.nlm.nih.gov/39487697/",null,null],["3","R0003952","R0003952.pdf","paywalled","systematic_review","Sharma N","2025","Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-024-04266-4","https://doi.org/10.1007/s11255-024-04266-4","39495435","https://pubmed.ncbi.nlm.nih.gov/39495435/",null,null],["3","R0003954","R0003954.pdf","paywalled","systematic_review","Cooper DH","2025","Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review.","Respiratory medicine","Elsevier BV","10.1016/j.rmed.2025.108197","https://doi.org/10.1016/j.rmed.2025.108197","40480531","https://pubmed.ncbi.nlm.nih.gov/40480531/",null,null],["3","R0004027","R0004027.pdf","paywalled","systematic_review","Yeh JA","2025","SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112088","https://doi.org/10.1016/j.diabres.2025.112088","40057043","https://pubmed.ncbi.nlm.nih.gov/40057043/",null,null],["3","R0004171","R0004171.pdf","paywalled","systematic_review","Liu L","2025","Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70084","https://doi.org/10.1111/jgh.70084","41025363","https://pubmed.ncbi.nlm.nih.gov/41025363/",null,null],["3","R0004303","R0004303.pdf","paywalled","systematic_review","Yang Y","2025","Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases.","Journal of autoimmunity","Elsevier BV","10.1016/j.jaut.2025.103414","https://doi.org/10.1016/j.jaut.2025.103414","40174283","https://pubmed.ncbi.nlm.nih.gov/40174283/",null,null],["3","R0004337","R0004337.pdf","paywalled","systematic_review","Pak KY","2025","GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.","Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mao.0000000000004373","https://doi.org/10.1097/mao.0000000000004373","39666743","https://pubmed.ncbi.nlm.nih.gov/39666743/",null,null],["3","R0004404","R0004404.pdf","paywalled","systematic_review","Siddiqui HF","2025","The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-025-10523-0","https://doi.org/10.1007/s10741-025-10523-0","40399552","https://pubmed.ncbi.nlm.nih.gov/40399552/",null,null],["3","R0004432","R0004432.pdf","paywalled","systematic_review","Katz G","2025","Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-2569-7315","https://doi.org/10.1055/a-2569-7315","40409279","https://pubmed.ncbi.nlm.nih.gov/40409279/",null,null],["3","R0004466","R0004466.pdf","paywalled","systematic_review","Zhang Y","2025","Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.","Bone","Elsevier BV","10.1016/j.bone.2024.117338","https://doi.org/10.1016/j.bone.2024.117338","39603373","https://pubmed.ncbi.nlm.nih.gov/39603373/",null,null],["3","R0004544","R0004544.pdf","paywalled","systematic_review","Borooghani H","2025","Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.","Iranian journal of kidney diseases",null,"10.61882/zwq4sh57","https://doi.org/10.61882/zwq4sh57","42234904","https://pubmed.ncbi.nlm.nih.gov/42234904/",null,null],["3","R0004609","R0004609.pdf","paywalled","systematic_review","Zhou XL","2025","[A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].","Zhonghua yi xue za zhi",null,"10.3760/cma.j.cn112137-20250416-00945","https://doi.org/10.3760/cma.j.cn112137-20250416-00945","41218895","https://pubmed.ncbi.nlm.nih.gov/41218895/",null,null],["3","R0004634","R0004634.pdf","paywalled","systematic_review","Bacha Z","2025","Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001057","https://doi.org/10.1097/crd.0000000000001057","40968407","https://pubmed.ncbi.nlm.nih.gov/40968407/",null,null],["3","R0004656","R0004656.pdf","paywalled","systematic_review","Lin J","2025","The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-025-03899-3","https://doi.org/10.1007/s00228-025-03899-3","40788386","https://pubmed.ncbi.nlm.nih.gov/40788386/",null,"PROSPERO:CRD420251068833"],["3","R0004680","R0004680.pdf","paywalled","systematic_review","Tan Y","2025","Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Elsevier BV","10.1016/j.dld.2025.03.002","https://doi.org/10.1016/j.dld.2025.03.002","40133086","https://pubmed.ncbi.nlm.nih.gov/40133086/",null,null],["3","R0004870","R0004870.pdf","paywalled","systematic_review","Feldman-Billard S","2025","What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101664","https://doi.org/10.1016/j.diabet.2025.101664","40383371","https://pubmed.ncbi.nlm.nih.gov/40383371/",null,null],["3","R0004895","R0004895.pdf","paywalled","systematic_review","Ammar A","2025","Updates in chronic kidney disease management: A systematic review.","Pharmacotherapy","Wiley","10.1002/phar.70014","https://doi.org/10.1002/phar.70014","40152479","https://pubmed.ncbi.nlm.nih.gov/40152479/",null,null],["3","R0005038","R0005038.pdf","paywalled","systematic_review","Chen QQ","2025","Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.11.013","https://doi.org/10.1016/j.eprac.2024.11.013","39638244","https://pubmed.ncbi.nlm.nih.gov/39638244/",null,null],["3","R0005091","R0005091.pdf","paywalled","systematic_review","Arrowaili A","2025","Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07856-y","https://doi.org/10.1007/s11695-025-07856-y","40237975","https://pubmed.ncbi.nlm.nih.gov/40237975/",null,null],["3","R0005121","R0005121.pdf","paywalled","systematic_review","Zhang M","2025","One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16078","https://doi.org/10.1111/dom.16078","39568391","https://pubmed.ncbi.nlm.nih.gov/39568391/",null,null],["3","R0005515","R0005515.pdf","paywalled","systematic_review","Miranda S","2025","Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177953","https://doi.org/10.1016/j.ejphar.2025.177953","40675357","https://pubmed.ncbi.nlm.nih.gov/40675357/",null,"PROSPERO:CRD42025100858"],["3","R0005696","R0005696.pdf","paywalled","systematic_review","Otmani Z","2025","Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000925","https://doi.org/10.1097/crd.0000000000000925","40310127","https://pubmed.ncbi.nlm.nih.gov/40310127/",null,null],["3","R0005760","R0005760.pdf","paywalled","systematic_review","Gomes DA","2025","Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-024-07547-3","https://doi.org/10.1007/s10557-024-07547-3","38214869","https://pubmed.ncbi.nlm.nih.gov/38214869/",null,null],["3","R0005873","R0005873.pdf","paywalled","systematic_review","Zufry H","2025","Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70073","https://doi.org/10.1111/dom.70073","40859897","https://pubmed.ncbi.nlm.nih.gov/40859897/",null,null],["3","R0006334","R0006334.pdf","paywalled","systematic_review","Al-Qudah AA","2025","Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis.","The journal of obstetrics and gynaecology research","Wiley","10.1111/jog.16296","https://doi.org/10.1111/jog.16296","40301112","https://pubmed.ncbi.nlm.nih.gov/40301112/",null,null],["3","R0006385","R0006385.pdf","paywalled","systematic_review","Armstrong BBS","2025","Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis.","Journal of gynecology obstetrics and human reproduction","Elsevier BV","10.1016/j.jogoh.2025.103046","https://doi.org/10.1016/j.jogoh.2025.103046","41052543","https://pubmed.ncbi.nlm.nih.gov/41052543/",null,null],["3","R0006467","R0006467.pdf","paywalled","systematic_review","Wu R","2025","Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-025-08680-z","https://doi.org/10.1007/s10072-025-08680-z","41402646","https://pubmed.ncbi.nlm.nih.gov/41402646/",null,null],["3","R0006483","R0006483.pdf","paywalled","systematic_review","Ihnat JMH","2025","A systematic review of the use of GLP-1 receptor agonists in surgery.","American journal of surgery","Elsevier BV","10.1016/j.amjsurg.2024.116119","https://doi.org/10.1016/j.amjsurg.2024.116119","39615284","https://pubmed.ncbi.nlm.nih.gov/39615284/",null,null],["3","R0006536","R0006536.pdf","paywalled","systematic_review","Pessoa-Gonçalves YM","2025","Evaluating the neuroprotective effect of GLP-1 receptor agonists in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-025-08568-y","https://doi.org/10.1007/s10072-025-08568-y","41077616","https://pubmed.ncbi.nlm.nih.gov/41077616/",null,null],["3","R0006551","R0006551.pdf","paywalled","systematic_review","Tanashat M","2025","The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-025-00726-z","https://doi.org/10.1007/s40256-025-00726-z","40246808","https://pubmed.ncbi.nlm.nih.gov/40246808/",null,"PROSPERO:CRD42024498538"],["3","R0006596","R0006596.pdf","paywalled","systematic_review","Osorio Manyari AA","2025","Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08414-2","https://doi.org/10.1007/s11695-025-08414-2","41313431","https://pubmed.ncbi.nlm.nih.gov/41313431/",null,null],["3","R0006850","R0006850.pdf","paywalled","systematic_review","Au HCT","2025","A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2024.11.019","https://doi.org/10.1016/j.jad.2024.11.019","39515485","https://pubmed.ncbi.nlm.nih.gov/39515485/",null,null],["3","R0007270","R0007270.pdf","paywalled","systematic_review","Amaral DC","2025","GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2024.12.024","https://doi.org/10.1016/j.ajo.2024.12.024","39732312","https://pubmed.ncbi.nlm.nih.gov/39732312/",null,null],["3","R0007388","R0007388.pdf","paywalled","systematic_review","Sun Y","2025","Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103186","https://doi.org/10.1016/j.dsx.2025.103186","39793280","https://pubmed.ncbi.nlm.nih.gov/39793280/",null,null],["3","R0008034","R0008034.pdf","paywalled","systematic_review","Waqas SA","2025","Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.","Archives of gerontology and geriatrics","Elsevier BV","10.1016/j.archger.2025.105981","https://doi.org/10.1016/j.archger.2025.105981","40812084","https://pubmed.ncbi.nlm.nih.gov/40812084/",null,null],["3","R0008689","R0008689.pdf","paywalled","systematic_review","Kellett J","2025","The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07723-w","https://doi.org/10.1007/s11695-025-07723-w","39910018","https://pubmed.ncbi.nlm.nih.gov/39910018/",null,null],["3","R0008804","R0008804.pdf","paywalled","systematic_review","Qi-Chang W","2025","Diagnostic Performance of Exendin-4 PET/CT in Localizing Insulinomas: A Systematic Review and Meta-analysis.","Academic radiology","Elsevier BV","10.1016/j.acra.2025.09.020","https://doi.org/10.1016/j.acra.2025.09.020","41033966","https://pubmed.ncbi.nlm.nih.gov/41033966/",null,null],["3","R0009189","R0009189.pdf","paywalled","systematic_review","Zhao Y","2025","Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis.","Reproductive sciences (Thousand Oaks, Calif.)","Springer Science and Business Media LLC","10.1007/s43032-025-01788-9","https://doi.org/10.1007/s43032-025-01788-9","39881036","https://pubmed.ncbi.nlm.nih.gov/39881036/",null,null],["3","R0010171","R0010171.pdf","paywalled","systematic_review","Beshr MS","2025","Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-Analysis.","Cardiology in review",null,"10.1097/crd.0000000000000915","https://doi.org/10.1097/crd.0000000000000915","40243299","https://pubmed.ncbi.nlm.nih.gov/40243299/",null,null],["3","R0010348","R0010348.pdf","paywalled","systematic_review","Arpan","2025","Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India.","The Journal of the Association of Physicians of India",null,"10.59556/japi.73.1184","https://doi.org/10.59556/japi.73.1184","41100333","https://pubmed.ncbi.nlm.nih.gov/41100333/",null,null],["3","R0010775","R0010775.pdf","paywalled","systematic_review","Golzarand M","2025","Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-01807-4","https://doi.org/10.1038/s41366-025-01807-4","40382437","https://pubmed.ncbi.nlm.nih.gov/40382437/",null,null],["3","R0011113","R0011113.pdf","paywalled","systematic_review","Tan Y","2025","Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-025-02468-5","https://doi.org/10.1007/s00592-025-02468-5","39985672","https://pubmed.ncbi.nlm.nih.gov/39985672/",null,null],["3","R0011370","R0011370.pdf","paywalled","systematic_review","Jia IT","2025","Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-12086-5","https://doi.org/10.1007/s00464-025-12086-5","41028671","https://pubmed.ncbi.nlm.nih.gov/41028671/",null,null],["3","R0011536","R0011536.pdf","paywalled","systematic_review","Singh A","2025","Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103212","https://doi.org/10.1016/j.dsx.2025.103212","40086043","https://pubmed.ncbi.nlm.nih.gov/40086043/",null,null],["3","R0011718","R0011718.pdf","paywalled","systematic_review","Sharma A","2025","Comment on: \"Efficacy and safety of GLP-1 receptor agonists in obstructive sleep apnea - a systematic review and meta-analysis\" by Kow et al.","Sleep medicine","Elsevier BV","10.1016/j.sleep.2025.106708","https://doi.org/10.1016/j.sleep.2025.106708","40763546","https://pubmed.ncbi.nlm.nih.gov/40763546/",null,null],["3","R0011943","R0011943.pdf","paywalled","systematic_review","Breit S","2025","Response to \"Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review\".","Psychoneuroendocrinology","Elsevier BV","10.1016/j.psyneuen.2025.107572","https://doi.org/10.1016/j.psyneuen.2025.107572","40803162","https://pubmed.ncbi.nlm.nih.gov/40803162/",null,null],["3","R0011953","R0011953.pdf","paywalled","systematic_review","Kow CS","2025","Response to comment on \"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials\".","Sleep medicine","Elsevier BV","10.1016/j.sleep.2025.106709","https://doi.org/10.1016/j.sleep.2025.106709","40795454","https://pubmed.ncbi.nlm.nih.gov/40795454/",null,null],["3","R0012073","R0012073.pdf","paywalled","systematic_review","Garbaccio NC","2025","Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-025-05112-3","https://doi.org/10.1007/s00266-025-05112-3","40835770","https://pubmed.ncbi.nlm.nih.gov/40835770/",null,null],["3","R0012162","R0012162.pdf","paywalled","systematic_review","Goodarzi S","2025","SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.","International ophthalmology","Springer Science and Business Media LLC","10.1007/s10792-025-03768-z","https://doi.org/10.1007/s10792-025-03768-z","41042286","https://pubmed.ncbi.nlm.nih.gov/41042286/",null,null],["3","R0012276","R0012276.pdf","paywalled","systematic_review","Pedrosa MR","2025","GLP-1 Receptor Agonists and Cardiac Health: Insights from a Systematic Review.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-025-07680-7","https://doi.org/10.1007/s10557-025-07680-7","40088397","https://pubmed.ncbi.nlm.nih.gov/40088397/",null,null],["3","R0013234","R0013234.pdf","paywalled","systematic_review","Teperikidis L","2025","Validating ChatGPT's role in systematic reviews and meta-analyses: A case study on GLP-1 receptor agonists and all-cause mortality.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2024.10.017","https://doi.org/10.1016/j.ejim.2024.10.017","39613702","https://pubmed.ncbi.nlm.nih.gov/39613702/",null,null],["3","R0013531","R0013531.pdf","paywalled","systematic_review","Cleto AS","2025","Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01646-9","https://doi.org/10.1038/s41366-024-01646-9","39396098","https://pubmed.ncbi.nlm.nih.gov/39396098/",null,null],["3","R0013632","R0013632.pdf","paywalled","systematic_review","Lu TT","2025","Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-01719-3","https://doi.org/10.1038/s41366-025-01719-3","39865161","https://pubmed.ncbi.nlm.nih.gov/39865161/",null,null],["3","R0013955","R0013955.pdf","paywalled","systematic_review","Xiao YJ","2025","Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70105","https://doi.org/10.1111/dom.70105","40922121","https://pubmed.ncbi.nlm.nih.gov/40922121/",null,null],["3","R0013987","R0013987.pdf","paywalled","systematic_review","Misra S","2025","Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.","Journal of basic and clinical physiology and pharmacology","Walter de Gruyter GmbH","10.1515/jbcpp-2025-0113","https://doi.org/10.1515/jbcpp-2025-0113","40728138","https://pubmed.ncbi.nlm.nih.gov/40728138/",null,null],["3","R0014064","R0014064.pdf","paywalled","systematic_review","Poshtdar S","2025","The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2025.2491404","https://doi.org/10.1080/17446651.2025.2491404","40214160","https://pubmed.ncbi.nlm.nih.gov/40214160/",null,null],["3","R0014124","R0014124.pdf","paywalled","systematic_review","Aubignat M","2025","Concerns regarding the inclusion of a preprint in a meta-analysis on GLP-1 agonists in Parkinson's Disease.","Parkinsonism & related disorders","Elsevier BV","10.1016/j.parkreldis.2025.107798","https://doi.org/10.1016/j.parkreldis.2025.107798","40122718","https://pubmed.ncbi.nlm.nih.gov/40122718/",null,null],["3","R0014274","R0014274.pdf","paywalled","systematic_review","Wang J","2025","Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16585","https://doi.org/10.1111/dom.16585","40600452","https://pubmed.ncbi.nlm.nih.gov/40600452/",null,null],["3","R0014973","R0014973.pdf","paywalled","systematic_review","Tewari J","2025","Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2025.2450254","https://doi.org/10.1080/17512433.2025.2450254","39817343","https://pubmed.ncbi.nlm.nih.gov/39817343/",null,"PROSPERO:CRD42024566153"],["3","R0015036","R0015036.pdf","paywalled","systematic_review","Li J","2025","Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-025-04207-w","https://doi.org/10.1007/s12020-025-04207-w","40011373","https://pubmed.ncbi.nlm.nih.gov/40011373/",null,null],["3","R0015378","R0015378.pdf","paywalled","systematic_review","He YM","2025","Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70097","https://doi.org/10.1002/dmrr.70097","41100405","https://pubmed.ncbi.nlm.nih.gov/41100405/",null,"PROSPERO:CRD42024620051"],["3","R0015419","R0015419.pdf","paywalled","systematic_review","Abuali A","2025","Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-2737-6110","https://doi.org/10.1055/a-2737-6110","41187775","https://pubmed.ncbi.nlm.nih.gov/41187775/",null,null],["3","R0015535","R0015535.pdf","paywalled","systematic_review","Cerchi E","2025","Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-01920-4","https://doi.org/10.1038/s41366-025-01920-4","41015578","https://pubmed.ncbi.nlm.nih.gov/41015578/",null,null],["3","R0015765","R0015765.pdf","paywalled","systematic_review","Norris Q","2025","Management of Type 2 Diabetes Mellitus in Native Americans and Alaska Natives: A Systematic Review.","Journal of racial and ethnic health disparities","Springer Science and Business Media LLC","10.1007/s40615-025-02668-3","https://doi.org/10.1007/s40615-025-02668-3","40971128","https://pubmed.ncbi.nlm.nih.gov/40971128/",null,null],["3","R0016045","R0016045.pdf","paywalled","systematic_review","Natali LD","2025","Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease: A systematic review and meta analysis of randomized controlled trials.","Heart & lung : the journal of critical care","Elsevier BV","10.1016/j.hrtlng.2025.07.009","https://doi.org/10.1016/j.hrtlng.2025.07.009","40682989","https://pubmed.ncbi.nlm.nih.gov/40682989/",null,null],["3","R0016405","R0016405.pdf","paywalled","systematic_review","Bao Y","2025","SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16107","https://doi.org/10.1111/dom.16107","39639835","https://pubmed.ncbi.nlm.nih.gov/39639835/",null,null],["3","R0016743","R0016743.pdf","paywalled","systematic_review","Kamrul-Hasan ABM","2025","Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.12.005","https://doi.org/10.1016/j.eprac.2024.12.005","39672540","https://pubmed.ncbi.nlm.nih.gov/39672540/",null,null],["3","R0016902","R0016902.pdf","paywalled","systematic_review","Jamialahamdi T","2025","Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07848-y","https://doi.org/10.1007/s11695-025-07848-y","40418526","https://pubmed.ncbi.nlm.nih.gov/40418526/",null,null],["3","R0016981","R0016981.pdf","paywalled","systematic_review","Li Y","2025","Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-025-00738-9","https://doi.org/10.1007/s40256-025-00738-9","40493329","https://pubmed.ncbi.nlm.nih.gov/40493329/",null,null],["3","R0017371","R0017371.pdf","paywalled","systematic_review","Espinet-Coll E","2025","Endoscopic sleeve gastroplasty (ESG) ‒ A semi-systematic review of current evidence, metabolic impact, special populations, and comparative strategies.","Revista espanola de enfermedades digestivas","Sociedad Espanola de Patologia Digestiva (SEPD)","10.17235/reed.2025.11719/2025","https://doi.org/10.17235/reed.2025.11719/2025","41410254","https://pubmed.ncbi.nlm.nih.gov/41410254/",null,null],["3","R0017902","R0017902.pdf","paywalled","systematic_review","Kamrul-Hasan ABM","2025","Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.12.017","https://doi.org/10.1016/j.eprac.2024.12.017","39733942","https://pubmed.ncbi.nlm.nih.gov/39733942/",null,null],["3","R0017949","R0017949.pdf","paywalled","systematic_review","Hamayal M","2025","Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-025-00727-y","https://doi.org/10.1007/s40256-025-00727-y","40106161","https://pubmed.ncbi.nlm.nih.gov/40106161/",null,"PROSPERO:CRD42024580784"],["3","R0017962","R0017962.pdf","paywalled","systematic_review","Hu X","2025","Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-025-04179-x","https://doi.org/10.1007/s12020-025-04179-x","39955702","https://pubmed.ncbi.nlm.nih.gov/39955702/",null,"PROSPERO:CRD42023493235"],["3","R0018275","R0018275.pdf","paywalled","systematic_review","Sobral MVS","2025","Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-025-00721-4","https://doi.org/10.1007/s40256-025-00721-4","39907981","https://pubmed.ncbi.nlm.nih.gov/39907981/",null,null],["3","R0018299","R0018299.pdf","paywalled","systematic_review","Chen B","2025","Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2025.01.056","https://doi.org/10.1016/j.clnesp.2025.01.056","39892787","https://pubmed.ncbi.nlm.nih.gov/39892787/",null,null],["3","R0018417","R0018417.pdf","paywalled","systematic_review","Ala M","2025","The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-024-02459-3","https://doi.org/10.1007/s40618-024-02459-3","39347905","https://pubmed.ncbi.nlm.nih.gov/39347905/",null,null],["3","R0019566","R0019566.pdf","paywalled","systematic_review","Ayesh H","2025","Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysis.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001808","https://doi.org/10.1097/mjt.0000000000001808","39297757","https://pubmed.ncbi.nlm.nih.gov/39297757/",null,null],["3","R0019590","R0019590.pdf","paywalled","systematic_review","Raja A","2025","Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus, With or Without Cardiovascular Disease: A Systematic Review and Meta-Analysis of 10,013 Patients.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001828","https://doi.org/10.1097/mjt.0000000000001828","40338694","https://pubmed.ncbi.nlm.nih.gov/40338694/",null,null],["3","R0019858","R0019858.pdf","paywalled","systematic_review","Satapathy P","2025","Impact of SGLT-2i on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101646","https://doi.org/10.1016/j.diabet.2025.101646","40220861","https://pubmed.ncbi.nlm.nih.gov/40220861/",null,null],["3","R0021294","R0021294.pdf","paywalled","systematic_review","Jiao R","2025","Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16012","https://doi.org/10.1111/dom.16012","39431379","https://pubmed.ncbi.nlm.nih.gov/39431379/",null,null],["3","R0023975","R0023975.pdf","paywalled","systematic_review","Benedictus B","2025","Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.12.013","https://doi.org/10.1016/j.clinthera.2024.12.013","39843265","https://pubmed.ncbi.nlm.nih.gov/39843265/",null,null],["3","R0029681","R0029681.pdf","paywalled","systematic_review","Drager LF","2025","A meta-analysis of glucagon-like peptide 1 receptor and dual agonists for the treatment of obstructive sleep apnea: end of the story or just the beginning?","Sleep","Oxford University Press (OUP)","10.1093/sleep/zsaf004","https://doi.org/10.1093/sleep/zsaf004","39758029","https://pubmed.ncbi.nlm.nih.gov/39758029/",null,null],["3","R0030134","R0030134.pdf","paywalled","systematic_review","Kidess GG","2025","The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Atrial Fibrillation Burden in Diabetic Patients.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2025.03.002","https://doi.org/10.1016/j.amjcard.2025.03.002","40058622","https://pubmed.ncbi.nlm.nih.gov/40058622/",null,null],["3","R0031453","R0031453.pdf","paywalled","systematic_review","Patricio Castro Suarez","2025","Comparative Effect of Glucagon-Like Peptide-1 Receptor Agonists vs Other Antidiabetic Drugs on Dementia Risk: A Systematic Review and Meta-Analysis (P1-3.014)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000212675","https://doi.org/10.1212/wnl.0000000000212675",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0031598","R0031598.pdf","paywalled","systematic_review","Fang Zhao","2025","The Effects of GLP-1 Receptor Agonists on Metabolic Inflammatory Markers in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2025.4.0020","https://doi.org/10.37766/inplasy2025.4.0020",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0031860","R0031860.pdf","paywalled","systematic_review","Parvataneni, Tarun","2025","Role of liraglutide and other newer diabetic drugs in the improvement of the apnea-hypopnea index and sleepiness scale amongst OSA patients with standard care - a meta-analysis",null,null,"10.13140/rg.2.2.20675.52009","https://doi.org/10.13140/rg.2.2.20675.52009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032151","R0032151.pdf","paywalled","systematic_review","Majd Aldin Oudeh,Esra Mhd. Nour Barodi,Yara Mohamed,Moubaraka EL Boukhari,Nada Ahmed said,Heba Intabli,Kiran khan,Maryam Sabah,Saja Elamin Omer Elamin,Mehreen Nawaz Khan,Rana Anees Ur Rehman,Owais Mudassir","2025","GLP-1 RECEPTOR AGONISTS AND NON-ALCOHOLIC FATTY LIVER DISEASE: EFFICACY IN STEATOSIS RESOLUTION - A SYSTEMATIC REVIEW AND META-ANALYSIS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18162095","https://doi.org/10.5281/zenodo.18162095",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032524","R0032524.pdf","paywalled","systematic_review","Fahad Ali Alsahli","2025","Tirzepatide and Diabetic Retinopathy: A Systematic Review of Effects on Incidence, Progression, and Retinal Outcomes in Adults with Type 2 Diabetes","Genetics and Molecular Research","Open Access Text Pvt, Ltd.","10.4238/syvpp340","https://doi.org/10.4238/syvpp340",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032651","R0032651.pdf","paywalled","systematic_review","Valeria Gazzotti","2025","ANTI–INFLAMMATORY PROPERTIES OF SEMAGLUTIDE: A SYSTEMATIC REVIEW AND META–ANALYSIS","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suaf076.378","https://doi.org/10.1093/eurheartjsupp/suaf076.378",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032901","R0032901.pdf","paywalled","systematic_review","Eling Felix","2025","A Comprehensive Systematic Review of Belly Fats: Pathophysiology, Clinical Implications, and Intervention Strategies","International Journal of Research and Innovation in Social Science","RSIS International","10.47772/ijriss.2025.9020319","https://doi.org/10.47772/ijriss.2025.9020319",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033232","R0033232.pdf","paywalled","systematic_review","Sul A Lee","2025","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: Systematic Review and Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025pqbtg0tr","https://doi.org/10.1681/asn.2025pqbtg0tr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033248","R0033248.pdf","paywalled","systematic_review","Samveg Shah","2025","GLP-1 Receptor Agonists and Serious Adverse Events of Hyperkalemia/Hypokalemia: Systematic Review and Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025wm57tqrv","https://doi.org/10.1681/asn.2025wm57tqrv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033491","R0033491.pdf","paywalled","systematic_review","Shokravi, Arveen","2025","Additional file 1 of Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.30254184","https://doi.org/10.6084/m9.figshare.30254184",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033501","R0033501.pdf","paywalled","systematic_review","He, hebinghong","2025","Comparative Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: A Bayesian Network Meta-Analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.14958369","https://doi.org/10.5281/zenodo.14958369",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033792","R0033792.pdf","paywalled","systematic_review","Sidhu, Nav","2025","Association between glucagon-like peptide-1 receptor agonists, residual gastric content, and bronchopulmonary aspiration after fasting: an ongoing systematic review and meta-analysis","University of Auckland Data Repository",null,"10.17608/k6.auckland.28537307.v1","https://doi.org/10.17608/k6.auckland.28537307.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033828","R0033828.pdf","paywalled","systematic_review","Synthory AI","2025","Diabetes as a Risk Factor for Neurodegenerative Diseases: A Systematic Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15299456","https://doi.org/10.5281/zenodo.15299456",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033907","R0033907.pdf","paywalled","systematic_review","Myo, Elaine","2025","Comparison of subcutaneous GLP-1 receptor agonists, semaglutide and dulaglutide, on HbA1c and weight loss outcomes: A systematic review","University of Kent",null,"10.22024/unikent/03/ajpp.1365","https://doi.org/10.22024/unikent/03/ajpp.1365",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033928","R0033928.pdf","paywalled","systematic_review","Raj Kumar*, Pardeep Kumar, Leena Thakur","2025","A Systematic Review on Management of Type 2 Diabetes Mellitus: Conventional Treatment Strategies v/s Phyto-Alkaloids as Natural Alternatives","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17053155","https://doi.org/10.5281/zenodo.17053155",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034031","R0034031.pdf","paywalled","systematic_review","Isca Evidence","2025","GLP-1 RAs for weight loss: the quantity, quality and findings of network meta-analyses evaluating their effectiveness.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18759111","https://doi.org/10.5281/zenodo.18759111",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034261","R0034261.pdf","paywalled","systematic_review","H.S., Siddalingaiah","2025","Network Meta-Analysis of Drug Class Sequencing for Optimizing Glycemic Control, Cardiovascular, and Renal Outcomes in Type 2 Diabetes Mellitus","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17334010","https://doi.org/10.5281/zenodo.17334010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034285","R0034285.pdf","paywalled","systematic_review","Nicole Fernanda Penteado","2025","GLP-1 and neuroprotection in Alzheimer’s disease: a systematic review of randomized clinical trials",null,"Zeppelini Editorial e Comunicação","10.5327/1516-3180.cpn.1784","https://doi.org/10.5327/1516-3180.cpn.1784",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034287","R0034287.pdf","paywalled","systematic_review","Chrzanowski, Jędrzej","2025","Semaglutide-associated risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17885011","https://doi.org/10.5281/zenodo.17885011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034319","R0034319.pdf","paywalled","systematic_review","Samit Ghosal","2025","Comparative efficacy of lifestyle and GLP-1RA-based interventions for visceral adipose tissue reduction: meta-analysis of 36 randomised controlled trials","Obesity Abstracts","Bioscientifica","10.1530/obabs.05.p1","https://doi.org/10.1530/obabs.05.p1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034379","R0034379.pdf","paywalled","systematic_review","Kan, Ranran","2025","Additional file 2 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Figshare",null,"10.6084/m9.figshare.30703259","https://doi.org/10.6084/m9.figshare.30703259",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034381","R0034381.pdf","paywalled","systematic_review","Zhong, Ying","2025","Additional file 1 of Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","Figshare",null,"10.6084/m9.figshare.29972422","https://doi.org/10.6084/m9.figshare.29972422",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034386","R0034386.pdf","paywalled","systematic_review","Kan, Ranran","2025","Additional file 5 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Figshare",null,"10.6084/m9.figshare.30703268","https://doi.org/10.6084/m9.figshare.30703268",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034411","R0034411.pdf","paywalled","systematic_review","Kan, Ranran","2025","Additional file 1 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Figshare",null,"10.6084/m9.figshare.30703256","https://doi.org/10.6084/m9.figshare.30703256",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034439","R0034439.pdf","paywalled","systematic_review","Tseng, Ping-Tao","2025","Additional file 2 of The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","Figshare",null,"10.6084/m9.figshare.30736691","https://doi.org/10.6084/m9.figshare.30736691",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034547","R0034547.pdf","paywalled","systematic_review","Kan, Ranran","2025","Additional file 4 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Figshare",null,"10.6084/m9.figshare.30703265","https://doi.org/10.6084/m9.figshare.30703265",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034574","R0034574.pdf","paywalled","systematic_review","Tseng, Ping-Tao","2025","Additional file 1 of The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","Figshare",null,"10.6084/m9.figshare.30736685","https://doi.org/10.6084/m9.figshare.30736685",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034746","R0034746.pdf","paywalled","systematic_review","Huang, Zhilong","2025","Glucagon-like peptide-1 receptor agonists and risk of prostatic cancer: A systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.27600966","https://doi.org/10.6084/m9.figshare.27600966",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034769","R0034769.pdf","paywalled","systematic_review","The Pharmaceutical Society Of Korea","2025","Efficacy and Safety of GLP-1 Receptor Agonist for Adults with Overweight and Obesity: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials","Yakhak Hoeji","The Pharmaceutical Society of Korea","10.17480/psk.2025.69.3.240","https://doi.org/10.17480/psk.2025.69.3.240",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024522544"],["3","R0034806","R0034806.pdf","paywalled","systematic_review","Kan, Ranran","2025","Additional file 3 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Figshare",null,"10.6084/m9.figshare.30703262","https://doi.org/10.6084/m9.figshare.30703262",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036518","R0036518.pdf","paywalled","systematic_review","Ayesh, Hazem","2025","The Use Of Oral Small-Molecule Glucagon-Like Peptide-1 And Metabolic Outcomes In DMT2 And Obesity: Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/3cy6e","https://doi.org/10.17605/osf.io/3cy6e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036519","R0036519.pdf","paywalled","systematic_review","Taro Kishi","2025","Glucagon-like peptide-1 Receptor Agonists for Weight Management in Mental Illness: A Network Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/e89uf","https://doi.org/10.17605/osf.io/e89uf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036525","R0036525.pdf","paywalled","systematic_review","Ayesh, Hazem","2025","Comparative Analysis of GLP-1 Agonists vs Metformin vs Inositol in the Treatment of PCOS: Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/zyhws","https://doi.org/10.17605/osf.io/zyhws",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036530","R0036530.pdf","paywalled","systematic_review","Latif, Rabia","2025","Comparative efficacy of Tirzepatide vs Semaglutide in reducing body weight in humans; A systematic review and metanalysis","Open Science Framework",null,"10.17605/osf.io/mjt9p","https://doi.org/10.17605/osf.io/mjt9p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036531","R0036531.pdf","paywalled","systematic_review","Laiba Nasir","2025","Evaluating the Impact of Semaglutide on Stroke Risk Reduction in Cardiovascular High-Risk Populations: A Systematic Review and Meta-analysis","Open Science Framework",null,"10.17605/osf.io/mbwgq","https://doi.org/10.17605/osf.io/mbwgq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036532","R0036532.pdf","paywalled","systematic_review","Ayesh, Hazem","2025","Comparative Effectiveness of Long-Term Weight Loss Maintenance Post Sleeve Gastrectomy and Glucagon-Like Peptide-1 Receptor Agonist Treatment: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/ysq4z","https://doi.org/10.17605/osf.io/ysq4z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036545","R0036545.pdf","paywalled","systematic_review","Karakasis, Paschalis","2025","GLP-1 receptor agonists and co-agonists for the prevention of atrial fibrillation in overweight or obesity: A meta-analysis of randomized controlled trials","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/2qd5p","https://doi.org/10.17605/osf.io/2qd5p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036547","R0036547.pdf","paywalled","systematic_review","Farooqui, Maryam","2025","Evaluating the Impact of Semaglutide on Stroke Risk Reduction in Cardiovascular High-Risk Populations: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/hf583","https://doi.org/10.17605/osf.io/hf583",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036553","R0036553.pdf","paywalled","systematic_review","Makarand Prasad Nadendla","2025","Dietary Guidance for Managing Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","Open Science Framework",null,"10.17605/osf.io/6s4dj","https://doi.org/10.17605/osf.io/6s4dj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036559","R0036559.pdf","paywalled","systematic_review","Yu, Oriana Hoi Yun","2025","Glucagon-Like Peptide-1 Receptor Agonists for the Prevention of Genitourinary Cancers: A Systematic Review of Observational Studies","Open Science Framework",null,"10.17605/osf.io/fgbc9","https://doi.org/10.17605/osf.io/fgbc9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036568","R0036568.pdf","paywalled","systematic_review","Mentz, Robert","2025","Temporal and Racial Differences in Outcomes of Treatment of Myocardial Infarction-Associated Heart: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/ehj4x","https://doi.org/10.17605/osf.io/ehj4x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036579","R0036579.pdf","paywalled","systematic_review","Tsironikos, Georgios","2025","Effectiveness of GLP-1 RAs in reversing patients with prediabetes to normoglycemia: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/ebxch","https://doi.org/10.17605/osf.io/ebxch",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036593","R0036593.pdf","paywalled","systematic_review","Tsavdaris, Dimitrios","2025","Comparative Effectiveness of GLP-1 Receptor Agonists Alone vs. in Combination with Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: Protocol for Systematic Review and Network Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/muazq","https://doi.org/10.17605/osf.io/muazq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036599","R0036599.pdf","paywalled","systematic_review","Hooper, Joanna","2025","A scoping systematic review on the effect of GLP-1 analogue therapy for obesity management on vitamin and micronutrient levels.","Open Science Framework",null,"10.17605/osf.io/qj35d","https://doi.org/10.17605/osf.io/qj35d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036631","R0036631.pdf","paywalled","systematic_review","Van Alebeek, Remigius","2025","Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/zn3aq","https://doi.org/10.17605/osf.io/zn3aq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036638","R0036638.pdf","paywalled","systematic_review","Erul, Enes","2025","Glucagon-Like Peptide Therapies and Cancer Risk: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/enjtb","https://doi.org/10.17605/osf.io/enjtb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036641","R0036641.pdf","paywalled","systematic_review","Bayoumy, Ahmed","2025","Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review","Open Science Framework",null,"10.17605/osf.io/wabe5","https://doi.org/10.17605/osf.io/wabe5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036645","R0036645.pdf","paywalled","systematic_review","Tsavdaris, Dimitrios","2025","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in People With HIV: A Systematic Review and Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/72ymp","https://doi.org/10.17605/osf.io/72ymp",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036655","R0036655.pdf","paywalled","systematic_review","Salhab, Ahmad","2025","Comparative Efficacy of Retatrutide versus Tirzepatide in Achieving Weight Loss: A Network Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/pqdwk","https://doi.org/10.17605/osf.io/pqdwk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036666","R0036666.pdf","paywalled","systematic_review","Patil, Shruti","2025","GLP-1 Receptor Agonists in Substance Use Disorders: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/x76sn","https://doi.org/10.17605/osf.io/x76sn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036677","R0036677.pdf","paywalled","systematic_review","Liangjun Zhong","2025","Efficacy of GLP-1 Receptor Agonists on Alveolar Bone Regeneration, Osseointegration, and Inflammation: A Preclinical Systematic Review and Meta-analysis","Open Science Framework",null,"10.17605/osf.io/tx63s","https://doi.org/10.17605/osf.io/tx63s",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036684","R0036684.pdf","paywalled","systematic_review","Habis, Yousef","2025","Semaglutide Versus Tirzepatide in Heart Failure with Preserved Ejection Fraction and Obesity: A Meta-Analysis and Systematic Review","Open Science Framework",null,"10.17605/osf.io/2uhzp","https://doi.org/10.17605/osf.io/2uhzp",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036696","R0036696.pdf","paywalled","systematic_review","Rangraze, Imran","2025","Reassessing Cancer Risk with GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Gastrointestinal Malignancies","Open Science Framework",null,"10.17605/osf.io/3rv6d","https://doi.org/10.17605/osf.io/3rv6d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036700","R0036700.pdf","paywalled","systematic_review","Lehia, Ayah Freih Abu","2025","Comparative Efficacy of Survodutide, Cotadutide, Retatrutide, and Mazdutide on Weight Loss: A Network Meta-Analysis of randomized control trial","Open Science Framework",null,"10.17605/osf.io/ek5nu","https://doi.org/10.17605/osf.io/ek5nu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036701","R0036701.pdf","paywalled","systematic_review","Mantovani, Alessandro","2025","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of MASLD: An Updated Meta-Analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/hgvs4","https://doi.org/10.17605/osf.io/hgvs4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036776","R0036776.pdf","paywalled","systematic_review","Shokravi, Arveen","2025","Additional file 1 of Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","Figshare",null,"10.6084/m9.figshare.30816974","https://doi.org/10.6084/m9.figshare.30816974",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036797","R0036797.pdf","paywalled","systematic_review","Tseng, Ping-Tao","2025","Additional file 1 of The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis","Figshare",null,"10.6084/m9.figshare.28738874","https://doi.org/10.6084/m9.figshare.28738874",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036798","R0036798.pdf","paywalled","systematic_review","Wu, Rui","2025","Additional file 1 of Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.30026680","https://doi.org/10.6084/m9.figshare.30026680",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036876","R0036876.pdf","paywalled","systematic_review","Salvador, Rui","2025","Efficacy and safety of semaglutide for obesity: A systematic review of phase 3 clinical trials","Science Letters",null,"10.48797/sl.2025.374","https://doi.org/10.48797/sl.2025.374",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036892","R0036892.pdf","paywalled","systematic_review","Santosh Yadav","2025","Systematic Review of Tirzepatide's Dual Action on Glycemic Control and Hepatic Biomarkers in Adults with Type 2 Diabetes","International journal for current research and techniques.",null,"10.5281/zenodo.15796120","https://doi.org/10.5281/zenodo.15796120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036901","R0036901.pdf","paywalled","systematic_review","Isabel Ralha de Abreu","2025","GLP‑1 Receptor Agonists in Non‑Diabetic Chronic Kidney Disease: A Systematic Review","Portuguese Kidney Journal (PKJ)",null,"10.71749/pkj.120","https://doi.org/10.71749/pkj.120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037124","R0037124.pdf","paywalled","systematic_review","Chen, rulong","2025","Figures of Efficacy and Safety of Modern Renoprotective Therapies for Non-Diabetic Kidney Disease: Insights from a Network Meta-Analysis","Figshare",null,"10.6084/m9.figshare.29649545.v1","https://doi.org/10.6084/m9.figshare.29649545.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037194","R0037194.pdf","paywalled","systematic_review",null,"2025","Cardiometabolic Outcomes of Novel Therapy Tirzepatide: A Systematic Review","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.564","https://doi.org/10.1016/j.eprac.2025.05.564",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037207","R0037207.pdf","paywalled","systematic_review","Ghosal, Samit","2025","Optimizing GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM","Figshare",null,"10.6084/m9.figshare.29918414","https://doi.org/10.6084/m9.figshare.29918414",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037576","R0037576.pdf","paywalled","systematic_review","Israni, Jake","2025","Lower risk of long-term adverse clinical outcomes of Glucagon-like peptide-1 receptor agonist and/or Sodium–glucose cotransporter-2 inhibitor treatment among patients with Metabolic dysfunction associated steatotic liver disease: a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/7ubcn","https://doi.org/10.17605/osf.io/7ubcn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037615","R0037615.pdf","paywalled","systematic_review","Monica Gaurdian","2025","S768 Efficacy and Safety of Tirzepatide for the Management of Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130532.17598.29","https://doi.org/10.14309/01.ajg.0001130532.17598.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037620","R0037620.pdf","paywalled","systematic_review","Aria Khan","2025","S2827 Comparative Efficacy of GLP-1 Receptor Agonists in the Treatment of Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138768.29025.a3","https://doi.org/10.14309/01.ajg.0001138768.29025.a3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037824","R0037824.pdf","paywalled","systematic_review","Vishal Singh Chandel","2025","Su2071: RISK OF SUICIDE AND SELF HARM BEHAVIOR IN PATIENTS ON GLP-1 RECEPTOR AGONISTS: SYSTEMATIC REVIEW OF DISPROPORTIONALITY ANALYSIS AND A META-ANALYSIS OF PUBLISHED STUDIES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03123-3","https://doi.org/10.1016/s0016-5085(25)03123-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037854","R0037854.pdf","paywalled","systematic_review","Roaa Haddad","2025","Effects of GLP-1RAs on the course of IBD and clinical outcomes in IBD patients, A systematic review article.",null,null,"10.13140/rg.2.2.14206.70727","https://doi.org/10.13140/rg.2.2.14206.70727",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037902","R0037902.pdf","paywalled","systematic_review","Samit Ghosal","2025","Comparative Efficacy of Lifestyle Modification and GLP-1RA-Based Interventions for Visceral Adipose Tissue Reduction: Meta-Analysis of 36 Randomised Controlled Trials","Figshare",null,"10.6084/m9.figshare.29875070","https://doi.org/10.6084/m9.figshare.29875070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037909","R0037909.pdf","paywalled","systematic_review",null,"2025","GLP-1 Receptor Agonists for the Treatment of Obesity in Children and Adolescents: A Systematic Review and Updated Meta-Analysis of Randomized Controlled Trials","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.521","https://doi.org/10.1016/j.eprac.2025.05.521",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038053","R0038053.pdf","paywalled","systematic_review","XIUQI QIAO","2025","890-P: Efficacy of Antiobesity Agents on Fat Distribution—A Systematic Review and Network Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db25-890-p","https://doi.org/10.2337/db25-890-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038073","R0038073.pdf","paywalled","systematic_review","Vikash Jaiswal","2025","Abstract 4373476: Disparities in Major Adverse Cardiovascular Outcomes Based on Body Mass Index and Estimated Glomerular Filtration Rate in Glucagon-like Peptide-1 Receptor Agonists Users Among Patients With and Without Diabetes Mellitus: A Meta-analysis of 9 Randomized Controlled trials.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4373476","https://doi.org/10.1161/circ.152.suppl_3.4373476",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038289","R0038289.pdf","paywalled","systematic_review","Hayder Alamily","2025","S1317 Effect of GLP-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132728.40130.cb","https://doi.org/10.14309/01.ajg.0001132728.40130.cb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038451","R0038451.pdf","paywalled","systematic_review","MA  Panpan, WANG  Sijing, YOU  Na, DING  Dafa, LU  Yibing","2025","Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12114/j.issn.1007-9572.2024.0484","https://doi.org/10.12114/j.issn.1007-9572.2024.0484",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038476","R0038476.pdf","paywalled","systematic_review","Mohamed A. B. Elnaggar","2025","S2463 Targeting Liver and Glucose: Comparative Efficacy of SGLT2i and GLP-1RA in NAFLD Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137312.65504.8c","https://doi.org/10.14309/01.ajg.0001137312.65504.8c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038481","R0038481.pdf","paywalled","systematic_review","Mylavarapu, Maneeth","2025","Semaglutide in Patients with Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review & Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/k6hzv","https://doi.org/10.17605/osf.io/k6hzv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038638","R0038638.pdf","paywalled","systematic_review","Panagiotis G. Doukas","2025","102 The Impact of GLP-1 Receptor Agonists on IBD Outcomes – A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001172832.03359.d6","https://doi.org/10.14309/01.ajg.0001172832.03359.d6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038651","R0038651.pdf","paywalled","systematic_review","Panda, Shivani","2025","Impacts of Glucagon-like Peptide-1 Receptor-Agonists (GLP-1 RAs) Treatment for Metabolic Disturbances & Weight Gain in Patients on Clozapine/Olanzapine: A Systematic Review","Open Science Framework",null,"10.17605/osf.io/8fpzk","https://doi.org/10.17605/osf.io/8fpzk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038659","R0038659.pdf","paywalled","systematic_review","Kimberly Ho","2025","S2461 Demographic and Regional Disparities in GLP-1 Receptor Agonist Clinical Trials for Weight Loss: A Comparative Meta-Analysis of US and International RCTs","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137304.74762.c2","https://doi.org/10.14309/01.ajg.0001137304.74762.c2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038708","R0038708.pdf","paywalled","systematic_review","Remus Ballotin, Vinicius","2025","A Multimodal Approach to Optimizing Semaglutide Suspension Timing Before Surgery: A Systematic Review and Meta-Analysis","Figshare",null,"10.6084/m9.figshare.30450836.v1","https://doi.org/10.6084/m9.figshare.30450836.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024609601"],["3","R0038723","R0038723.pdf","paywalled","systematic_review","Yash Verma","2025","Su2046: GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OBESE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03098-7","https://doi.org/10.1016/s0016-5085(25)03098-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038774","R0038774.pdf","paywalled","systematic_review","Fnu Payal","2025","S3044 The Double-Edged Sword of GLP-1 Receptor Agonists: Metabolic Benefits and GI Risks – A Systematic Review","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001139636.52094.23","https://doi.org/10.14309/01.ajg.0001139636.52094.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038857","R0038857.pdf","paywalled","systematic_review","Lima, João Pedro","2025","OphthoEvidence Report: Protocol for a systematic review and meta-analysis on glucagon-like peptide-1 receptor agonists and eye-related outcomes","Open Science Framework",null,"10.17605/osf.io/9zmp7","https://doi.org/10.17605/osf.io/9zmp7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038923","R0038923.pdf","paywalled","systematic_review","Ghosal, Samit","2025","Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modelling","Figshare",null,"10.6084/m9.figshare.30162679.v1","https://doi.org/10.6084/m9.figshare.30162679.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024567890"],["3","R0039055","R0039055.pdf","paywalled","systematic_review","Xin Ya See","2025","Glucagon-Like Peptide-1 Receptor Agonists and Respiratory Diseases: A Systematic Review and Meta-Analysis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a6561","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a6561",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039110","R0039110.pdf","paywalled","systematic_review","Jafar, Uzair","2025","Glucagon-like peptide-1 and glucagon receptor dual agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.30643241","https://doi.org/10.6084/m9.figshare.30643241",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039176","R0039176.pdf","paywalled","systematic_review","Emeka S. Obi","2025","S1307 Examining the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Residual Gastric Contents During Upper Endoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132688.69299.45","https://doi.org/10.14309/01.ajg.0001132688.69299.45",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039208","R0039208.pdf","paywalled","systematic_review","Rubab Fatimaa","2025","Abstract 4371746: Comparative Study of Cardiovascular Safety of GLP-1 Receptor Agonists Across Indications: A Meta-Analysis of Randomized Controlled Trials in Type 2 Diabetes and Obesity","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371746","https://doi.org/10.1161/circ.152.suppl_3.4371746",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039215","R0039215.pdf","paywalled","systematic_review","Christopher C. Thompson","2025","Sa1586: REVERSE OF LIVER PATHOLOGY IN MASH PATIENTS WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST MEDICATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04806-1","https://doi.org/10.1016/s0016-5085(25)04806-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039298","R0039298.pdf","paywalled","systematic_review","Vikash Jaiswal","2025","Abstract 51: Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Prevention of Stroke among Patients with Type 2 Diabetes Mellitus, Heart Failure, or Obesity: A Meta-Analysis of 12 Randomized Controlled Trials.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.56.suppl_1.51","https://doi.org/10.1161/str.56.suppl_1.51",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039315","R0039315.pdf","paywalled","systematic_review","Rahul Tripathi","2025","S2660 Efficacy of GLP-1 Receptor Agonists in MASH Resolution and Fibrosis Reduction: A Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138100.63129.02","https://doi.org/10.14309/01.ajg.0001138100.63129.02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039459","R0039459.pdf","paywalled","systematic_review","Claudine Feliciano","2025","IDDF2025-ABS-0014 Effectiveness of semaglutide in non-alcoholic steatohepatitis resolution a meta-analysis and systematic review",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-iddf.135","https://doi.org/10.1136/gutjnl-2025-iddf.135",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039483","R0039483.pdf","paywalled","systematic_review","Vikash Jaiswal","2025","Abstract 4373642: Efficacy of GLP-1 Receptor Agonists in Patients with Established Cardiovascular Disease: A Meta-Analysis of Nine Randomized controlled trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4373642","https://doi.org/10.1161/circ.152.suppl_3.4373642",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039502","R0039502.pdf","paywalled","systematic_review","Calvin Ke","2025","Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials","Vivli",null,"10.25934/pr00010843","https://doi.org/10.25934/pr00010843",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039535","R0039535.pdf","paywalled","systematic_review","F Alnajjar","2025","Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson's Disease: An Updated Systematic Review and Meta-Analysis",null,null,"10.13140/rg.2.2.10233.94563","https://doi.org/10.13140/rg.2.2.10233.94563",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039559","R0039559.pdf","paywalled","systematic_review","El-Hagrasy, Ahmed Mohsen","2025","Efficacy of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss in Non-Diabetic Children & Adolescents with Overweight or Obesity: A Systematic Review & Meta-Analysis",null,null,"10.13140/rg.2.2.31161.07520","https://doi.org/10.13140/rg.2.2.31161.07520",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039672","R0039672.pdf","paywalled","systematic_review","ZONGLIN LI","2025","433-P: Comparative Evaluation of Current Therapeutic Agents for Heart Failure with Preserved Ejection Fraction (HFPEF)—A Systematic Review and Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db25-433-p","https://doi.org/10.2337/db25-433-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039724","R0039724.pdf","paywalled","systematic_review","X Zou","2025","Pharmacological treatments in adults with chronic heart failure: a systematic review and component network meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1303","https://doi.org/10.1093/eurheartj/ehaf784.1303",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039759","R0039759.pdf","paywalled","systematic_review","Saqr Alsakarneh","2025","S473 GLP-1 Receptor Agonists Worsen Colonoscopy Quality Indicators: A Meta-Analysis of 18,805 Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129352.20930.36","https://doi.org/10.14309/01.ajg.0001129352.20930.36",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039762","R0039762.pdf","paywalled","systematic_review","Mohammad Tanshat","2025","S2858 Efficacy and Safety of Semaglutide in Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138892.42646.d3","https://doi.org/10.14309/01.ajg.0001138892.42646.d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251045059"],["3","R0041442","R0041442.pdf","paywalled","systematic_review","Gaetano Lauri","2025","Association Between Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Pancreatic Cancer: A Systematic Review and Meta-Analysis","Pancreatology","Elsevier BV","10.1016/j.pan.2025.07.187","https://doi.org/10.1016/j.pan.2025.07.187",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041489","R0041489.pdf","paywalled","systematic_review","Krishnarjun Banerjee","2025","Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.409","https://doi.org/10.1093/eurheartj/ehaf784.409",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042041","R0042041.pdf","paywalled","systematic_review","Amanda Rigdon","2025","S2435 Incretin-Based Therapies in MASH: A Meta-Analysis of Hepatic and Metabolic Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137200.19766.2f","https://doi.org/10.14309/01.ajg.0001137200.19766.2f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042078","R0042078.pdf","paywalled","systematic_review","Kannan Sridharan","2025","A Systematic Review and Network Meta-Analysis: Efficacy and Safety of Pharmacotherapy for Weight Management Following Bariatric Surgery",null,null,"10.17605/osf.io/kxvy5","https://doi.org/10.17605/osf.io/kxvy5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042217","R0042217.pdf","paywalled","systematic_review","Hamarsheh, Sultan","2025","Comparative Effectiveness of CagriSegma, semaglutide, cagrilintide and Tirzepatide in the Management of Overweight and Obesity: Network Meta-analysis of Randomized Clinical Trials.",null,null,"10.17605/osf.io/bfh6s","https://doi.org/10.17605/osf.io/bfh6s",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042313","R0042313.pdf","paywalled","systematic_review","Mads Bobjerg Kirkhoff Larsen","2025","Protocol GLP-1 RA's effect on oxidative stress in humans. A systematic review.",null,null,"10.17605/osf.io/w6f8e","https://doi.org/10.17605/osf.io/w6f8e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042315","R0042315.pdf","paywalled","systematic_review","Ghosal, Samit","2025","Risk-Based Cardio–Renal Benefits of GLP-1 Receptor Agonists and SGLT-2 Inhibitors: A Systematic Review, Meta-analysis, and Decision-Support Tool","Figshare",null,"10.6084/m9.figshare.30071938.v1","https://doi.org/10.6084/m9.figshare.30071938.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251142103"],["3","R0042450","R0042450.pdf","paywalled","systematic_review","Maryam Moghbel Baerz","2025","Systematic Review of the Efficacy and Safety of GLP-1 Agonists in the Treatment of Idiopathic Intracranial Hypertension (IIH)","Open Science Framework",null,"10.17605/osf.io/y2s5g","https://doi.org/10.17605/osf.io/y2s5g",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044303","R0044303.pdf","paywalled","systematic_review","Mamta Panwar","2025","The Role of GLP-1 Receptor Agonists (e.g., Ozempic) in Decreasing Disparities in Diabetes and Obesity Care: A Systematic Review of Efficacy, Access, and Public Health Equity Implications","Journal of the National Medical Association","Elsevier BV","10.1016/j.jnma.2025.08.017","https://doi.org/10.1016/j.jnma.2025.08.017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044846","R0044846.pdf","paywalled","systematic_review","Amauri De Vargas Junior","2025","GLP-1 Receptor Agonists for Smoking Cessation: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22820471","https://doi.org/10.5281/zenodo.22820471",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251104504"],["3","R0045063","R0045063.pdf","paywalled","systematic_review","I Khalil","2025","Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4321","https://doi.org/10.1093/eurheartj/ehaf784.4321",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045166","R0045166.pdf","paywalled","systematic_review","Geraldine de Melo","2025","Abstract 4353895: The effectiveness of the GLP-1 receptors agonists in improving obesity-related heart failure events: A systematic review and meta-analysis of randomized clinical trials.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4353895","https://doi.org/10.1161/circ.152.suppl_3.4353895",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045167","R0045167.pdf","paywalled","systematic_review","Smruti Karale","2025","S728 Meta-Analysis of Survodutide: Impact on Satiety, Appetite, Gastrointestinal Adverse Effects, and Drug Discontinuation","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130372.83275.a5","https://doi.org/10.14309/01.ajg.0001130372.83275.a5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045173","R0045173.pdf","paywalled","systematic_review","Hazem Ayesh","2025","Comparative Dose–Response Effects of Liraglutide, Metformin, and Their Combination in Polycystic Ovary Syndrome: A Network Meta-Analysis","Open Science Framework",null,"10.17605/osf.io/7njuw","https://doi.org/10.17605/osf.io/7njuw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045190","R0045190.pdf","paywalled","systematic_review","A. N. Das","2025","S788 Oral Super-Absorbent Hydrogel Capsules Double Clinically Meaningful Weight Loss Without Added Serious or GI Adverse Events: A Systematic Review and Meta Analysis of Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130612.88952.c3","https://doi.org/10.14309/01.ajg.0001130612.88952.c3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045207","R0045207.pdf","paywalled","systematic_review","C. Celsa","2025","OC.10.2 USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IS ASSOCIATED WITH REDUCED RISK OF MAJOR LIVER-RELATED EVENTS: A META-ANALYSIS","Digestive and Liver Disease","Elsevier BV","10.1016/s1590-8658(25)00470-0","https://doi.org/10.1016/s1590-8658(25)00470-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045232","R0045232.pdf","paywalled","systematic_review","Hazem Ayesh","2025","Comparative efficacy, safety, and treatment burden of injectable intensification strategies after basal insulin in type 2 diabetes: a network meta-analysis","Open Science Framework",null,"10.17605/osf.io/us2dq","https://doi.org/10.17605/osf.io/us2dq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045238","R0045238.pdf","paywalled","systematic_review","Moulika Kari","2025","S1561 Evaluating Effectiveness and Safety of a GLP-1 Agonist in Obese Patients With Inflammatory Bowel Disease: A Systematic Review","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133704.32389.16","https://doi.org/10.14309/01.ajg.0001133704.32389.16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045522","R0045522.pdf","paywalled","systematic_review","Jacinthe Khater","2025","Efficacy and safety of GLP-1 agonists in obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized placebo-controlled trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1283","https://doi.org/10.1093/eurheartj/ehaf784.1283",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045619","R0045619.pdf","paywalled","systematic_review","CHI-HAN CHENG","2025","21-OR: Systematic Review and Meta-analysis of the Association of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Dementia in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-21-or","https://doi.org/10.2337/db25-21-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045673","R0045673.pdf","paywalled","systematic_review","Kyriacos Ioannou","2025","MSR93 Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.3378","https://doi.org/10.1016/j.jval.2025.09.3378",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045687","R0045687.pdf","paywalled","systematic_review","Ahmad Abdulraheem","2025","CLINICAL IMPACT OF GLP-1 RECEPTOR AGONISTS ON COLONOSCOPY: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2025.03.603","https://doi.org/10.1016/j.gie.2025.03.603",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045717","R0045717.pdf","paywalled","systematic_review","Ibrahim Khalil","2025","COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS IN OBSTRUCTIVE SLEEP APNEA MANAGEMENT: A COMPREHENSIVE BAYESIAN NETWORK META-ANALYSIS WITH INTERVENTION RANKING","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3942","https://doi.org/10.1016/j.chest.2025.07.3942",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045804","R0045804.pdf","paywalled","systematic_review","CHU LIN","2025","1730-P: The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db25-1730-p","https://doi.org/10.2337/db25-1730-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045948","R0045948.pdf","paywalled","systematic_review","Ibrahim Khalil","2025","COMPARATIVE EVALUATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THEIR ASSOCIATION WITH THE RISK OF ASTHMA INCIDENCE: A COMPREHENSIVE BAYESIAN NETWORK META-ANALYSIS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3063","https://doi.org/10.1016/j.chest.2025.07.3063",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045987","R0045987.pdf","paywalled","systematic_review","Madhu Babu Adusumilli","2025","S2654 Semaglutide’s Dose Dependent Effect on MASH Resolution: Updated Meta-Analysis of 5 RCTs With Histologic and Metabolic Improvements","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138076.63959.68","https://doi.org/10.14309/01.ajg.0001138076.63959.68",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046072","R0046072.pdf","paywalled","systematic_review","Lawrence Willis Chinn","2025","Perioperative Management of GLP-1 Receptor Agonists and SGLT2 Inhibitors and the Risk of Aspiration, Ketoacidosis, and Major Complications: A Systematic Review and Meta-analysis",null,null,"10.17605/osf.io/rvdpw","https://doi.org/10.17605/osf.io/rvdpw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046094","R0046094.pdf","paywalled","systematic_review","Lin Luo","2025","771-P: Meta-analysis of hsCRP's Effect on Cardiovascular Outcome among GLP-1RAs–Based Clinical Trials","Diabetes","American Diabetes Association","10.2337/db25-771-p","https://doi.org/10.2337/db25-771-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046135","R0046135.pdf","paywalled","systematic_review","Ibrahim Khalil","2025","Abstract 4359705: Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Dementia Risk in Type 2 Diabetes: A Comprehensive Bayesian Network Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4359705","https://doi.org/10.1161/circ.152.suppl_3.4359705",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046239","R0046239.pdf","paywalled","systematic_review","Ahmed J. AlAraibi","2025","The Effects of Tirzepatide and Semaglutide on Clinical and Metabolic Outcomes in Patients With Heart Failure and Obesity or Metabolic Syndrome: A systematic review",null,null,"10.13140/rg.2.2.36009.45928","https://doi.org/10.13140/rg.2.2.36009.45928",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046373","R0046373.pdf","paywalled","systematic_review","C Rodrigues Rosa","2025","GLP-1 receptor agonists for obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1248","https://doi.org/10.1093/eurheartj/ehaf784.1248",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046490","R0046490.pdf","paywalled","systematic_review","Vaishnavi Sabesan","2025","Abstract 071: Comparative Antihypertensive Effects of Emerging Cardiorenal Therapies in Chronic Kidney Disease: A Network Meta-Analysis of SGLT2 Inhibitors, MRAs, and GLP-1 Receptor Agonists","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.82.suppl_1.071","https://doi.org/10.1161/hyp.82.suppl_1.071",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046565","R0046565.pdf","paywalled","systematic_review","Christopher Aquino Pereira Lima","2025","Semaglutide as a cardioprotective factor in patients with type 2 diabetes mellitus: a meta-analysis",null,null,"10.13140/rg.2.2.27407.85922","https://doi.org/10.13140/rg.2.2.27407.85922",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046605","R0046605.pdf","paywalled","systematic_review","C. Celsa","2025","Use of Glucagon-like Peptide-1 Receptor Agonist is associated with reduced risk of major liver-related events: a meta-analysis","Digestive and Liver Disease","Elsevier BV","10.1016/j.dld.2025.01.124","https://doi.org/10.1016/j.dld.2025.01.124",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046627","R0046627.pdf","paywalled","systematic_review","GAGAN DEEP REDDY CHITIKI","2025","21-PUB: A Real-World Adverse Event Profile of Tirzepatide—A Pilot Systematic Review and Meta-analysis of Observational Studies","Diabetes","American Diabetes Association","10.2337/db25-21-pub","https://doi.org/10.2337/db25-21-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046772","R0046772.pdf","paywalled","systematic_review","Mazhar Shapoo","2025","S2756 GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Efficacy and Safety","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138484.16960.b7","https://doi.org/10.14309/01.ajg.0001138484.16960.b7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046918","R0046918.pdf","paywalled","systematic_review","E. Radha Krishnan","2025","6.35 Exploring Semaglutide as a Potential Treatment for Eating Disorders: A Systematic Review and Meta-Analysis","Journal of the American Academy of Child & Adolescent Psychiatry","Elsevier BV","10.1016/j.jaac.2025.08.511","https://doi.org/10.1016/j.jaac.2025.08.511",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046935","R0046935.pdf","paywalled","systematic_review","Hassan Waseem","2025","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials (P11-5.012)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000211906","https://doi.org/10.1212/wnl.0000000000211906",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047070","R0047070.pdf","paywalled","systematic_review","Ryan YanZhe Lim","2025","SAT-452 GLP1 agonist and metabolic dysfunction-associated steatohepatitis (MASH): systematic review and meta-analysis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01708-8","https://doi.org/10.1016/s0168-8278(25)01708-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047169","R0047169.pdf","paywalled","systematic_review","Selome F. Yewedalsew","2025","Su1101: IMPACT OF GLP-1 RA ON GASTRIC EMPTYING AT TIME OF ENDOSCOPY; A SYSTEMATIC REVIEW","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02531-4","https://doi.org/10.1016/s0016-5085(25)02531-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047280","R0047280.pdf","paywalled","systematic_review","Renuka Verma","2025","Su1097: IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BOWEL PREPARATION FOR COLONOSCOPY; A META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02527-2","https://doi.org/10.1016/s0016-5085(25)02527-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047394","R0047394.pdf","paywalled","systematic_review","I Hecker","2025","Glucagon-like peptide 1 based treatments preserve left ventricular diastolic function irrespective of body weight changes - a systematic review and meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.935","https://doi.org/10.1093/eurheartj/ehaf784.935",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047594","R0047594.pdf","paywalled","systematic_review","Sudheer Dhoop","2025","S2864 Efficacy and Safety of GLP-1 Receptor Agonists in Metabolic-Associated Steatohepatitis With Significant Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138916.35861.29","https://doi.org/10.14309/01.ajg.0001138916.35861.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047672","R0047672.pdf","paywalled","systematic_review","Javad Heshmati","2025","P304 GLP-1 AGONISTS AND SMOKING CESSATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2025.08.294","https://doi.org/10.1016/j.cjca.2025.08.294",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047738","R0047738.pdf","paywalled","systematic_review","J. Ruiz","2025","Abstract 4341436: Semaglutide as an effective therapy for heart failure: Evidence from a meta-analysis of 6,479 patients","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4341436","https://doi.org/10.1161/circ.152.suppl_3.4341436",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047859","R0047859.pdf","paywalled","systematic_review","Xinyan Jia","2025","1994-LB: Effects of Switching Glucagon-Like Peptide 1 Receptor Agonists on HbA1c, Body Weight, and Treatment Satisfaction among Patients with Type 2 Diabetes—A Meta-analysis","Diabetes","American Diabetes Association","10.2337/db25-1994-lb","https://doi.org/10.2337/db25-1994-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047918","R0047918.pdf","paywalled","systematic_review","Hasan Jaber","2025","Tu1841: EVALUATING THE OUTCOMES OF GLP-1 RECEPTOR AGONIST USE IN INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04370-7","https://doi.org/10.1016/s0016-5085(25)04370-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048290","R0048290.pdf","paywalled","systematic_review","Erin Frazee Barreto","2025","SGLT2 Inhibitors and GLP-1 Receptor Agonists and the Risk for Adverse Outcomes After AKI or Acute Kidney Disease: Systematic Review and Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025mck1neet","https://doi.org/10.1681/asn.2025mck1neet",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024607838"],["3","R0048418","R0048418.pdf","paywalled","systematic_review","Gurjot Singh","2025","S420 Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) on Colonoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129140.58869.18","https://doi.org/10.14309/01.ajg.0001129140.58869.18",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048537","R0048537.pdf","paywalled","systematic_review","Haji Abdul Rehman Akhter","2025","Abstract 4367751: Cardiovascular Outcomes of Oral Semaglutide in High Risk Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367751","https://doi.org/10.1161/circ.152.suppl_3.4367751",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048717","R0048717.pdf","paywalled","systematic_review","MIAN MUHAMMAD SALMAN ASLAM","2025","1745-P: Long-Term Safety and Efficacy of Once-Weekly Dosage of 2.4 mg Semaglutide for Weight Loss in Patients with and without Diabetes—An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db25-1745-p","https://doi.org/10.2337/db25-1745-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024532538"],["3","R0048810","R0048810.pdf","paywalled","systematic_review","Areesha Moiz","2025","Abstract 4365415: Comparative Efficacy of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists for Weight Loss Among Patients Without Diabetes: A Network Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365415","https://doi.org/10.1161/circ.152.suppl_3.4365415",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049195","R0049195.pdf","paywalled","systematic_review","Midori Torpoco Rivers","2025","Abstract 4357466: Effect of Combination Therapy With GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes and ASCVD: A Systematic Review and Meta-analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4357466","https://doi.org/10.1161/circ.152.suppl_3.4357466",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049295","R0049295.pdf","paywalled","systematic_review","Avinash Vangara","2025","Effects of GLP-1 Receptor Agonists on Kidney Function: Meta-Analysis of Laboratory Biomarkers","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.202589m6mbq2","https://doi.org/10.1681/asn.202589m6mbq2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049578","R0049578.pdf","paywalled","systematic_review","Haakim Waraich","2025","S236 Comparison of Safety and Efficacy of Endoscopic Biliary Stents for Malignant Biliary Strictures: A Systemic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127404.19651.2f","https://doi.org/10.14309/01.ajg.0001127404.19651.2f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049593","R0049593.pdf","paywalled","systematic_review","Faseeh Haider","2025","S2411 Safety and Efficacy of Semaglutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137104.21208.7e","https://doi.org/10.14309/01.ajg.0001137104.21208.7e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049693","R0049693.pdf","paywalled","systematic_review","Hatem Yaser","2025","A network meta-analysis of various pharmacotherapeutics for obstructive sleep apnea",null,"European Respiratory Society","10.1183/13993003.congress-2025.pa3565","https://doi.org/10.1183/13993003.congress-2025.pa3565",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049749","R0049749.pdf","paywalled","systematic_review","Niharika Katkam","2025","SGLT2 Inhibitors Rather Than GLP-1 Receptor Agonists Lower the Risk of Kidney Failure: A Systematic Review and Network Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025ys83adxw","https://doi.org/10.1681/asn.2025ys83adxw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049792","R0049792.pdf","paywalled","systematic_review","Ibrahim Khalil","2025","Abstract 4357452: Glucagon-Like Peptide-1 Receptor Agonists Show Varied Impact on Venous Thromboembolism Risk: A Comprehensive Bayesian Network Meta-Analysis of Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4357452","https://doi.org/10.1161/circ.152.suppl_3.4357452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050000","R0050000.pdf","paywalled","systematic_review","Piyush Ratan","2025","834-P: A Meta-analysis of Novel Glucose-Lowering Therapies in Kidney Transplant Recipients with Diabetes","Diabetes","American Diabetes Association","10.2337/db25-834-p","https://doi.org/10.2337/db25-834-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050164","R0050164.pdf","paywalled","systematic_review","Cindy Ho","2025","1972-LB: Glucagon-Like Peptide 1 Receptor Agonists and NAION—A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db25-1972-lb","https://doi.org/10.2337/db25-1972-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050253","R0050253.pdf","paywalled","systematic_review","Amit Dang","2025","CO37 Cardiovascular Effects of Semaglutide in Patients With Obesity, With or Without Type 2 Diabetes (T2DM): An Umbrella Review","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.139","https://doi.org/10.1016/j.jval.2025.09.139",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050288","R0050288.pdf","paywalled","systematic_review","Xavier C. Zonna","2025","S2790 A Meta-Analysis of Type 2 Diabetes Mellitus Treatments for MASLD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138620.38612.9c","https://doi.org/10.14309/01.ajg.0001138620.38612.9c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050584","R0050584.pdf","paywalled","systematic_review","AMANDA R. PURCELL","2025","1977-LB: Glucometabolic Outcomes in Patients with Concurrent Overweight/Obesity and Type 1 Diabetes following Prolonged Glucagon-Like Peptide 1 Receptor Agonist Treatment—A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db25-1977-lb","https://doi.org/10.2337/db25-1977-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050649","R0050649.pdf","paywalled","systematic_review","Avneet Kaur","2025","S1810 Impact of GLP-1 Receptor Agonists on IBD Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001134700.23465.86","https://doi.org/10.14309/01.ajg.0001134700.23465.86",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050675","R0050675.pdf","paywalled","systematic_review","Carlos M. Patiño","2025","Abstract 4362806: Effect of Glucagon-like peptide-1 Receptor Agonists on Cardiac Arrhythmias: Systematic Review and Meta-analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4362806","https://doi.org/10.1161/circ.152.suppl_3.4362806",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050828","R0050828.pdf","paywalled","systematic_review","Muhammad Faizan Ali","2025","Abstract 4371988: Cardiovascular Outcomes of Oral Incretin-Based Therapies in Type 2 Diabetes: A Systematic Review and Meta-Analysis of 62,821 Patients","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371988","https://doi.org/10.1161/circ.152.suppl_3.4371988",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050838","R0050838.pdf","paywalled","systematic_review","Ahmed Ahmed","2025","501. A Systematic Review Exploring the Neuropsychiatric Safety of GLP-1 Receptor Agonists in Patients Taking Second-Generation Antipsychotics","Biological Psychiatry","Elsevier BV","10.1016/j.biopsych.2025.02.740","https://doi.org/10.1016/j.biopsych.2025.02.740",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050946","R0050946.pdf","paywalled","systematic_review","Benjamin Douglas Xun Liu","2025","Sa1107: INTERIM RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROINTESTINAL MOTILITY RELEVANT SYMPTOMS IN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST-BASED RANDOMIZED CONTROLLED TRIALS.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)01757-3","https://doi.org/10.1016/s0016-5085(25)01757-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051171","R0051171.pdf","paywalled","systematic_review","Lakshmi Sai Meghana Kodali","2025","Abstract 4371548: GLP-1 Receptor Agonists Use in Pregnant Women Reduce Adverse Maternal and Fetal Outcomes: A Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371548","https://doi.org/10.1161/circ.152.suppl_3.4371548",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051214","R0051214.pdf","paywalled","systematic_review","Maitri Shah","2025","S736 Gastrointestinal Tolerability of Tirzepatide Compared With GLP-1 Receptor Agonists, Insulin and Placebo in Obesity: A Meta-Analysis of 11,000+ Subjects","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130404.86228.5e","https://doi.org/10.14309/01.ajg.0001130404.86228.5e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051616","R0051616.pdf","paywalled","systematic_review","Tanishq Kesani","2025","S244 Beyond the Triad: Diagnostic Delays and the Role of Biomarkers in Atypical Acute Cholangitis: A Systematic Review","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127436.10004.af","https://doi.org/10.14309/01.ajg.0001127436.10004.af",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051643","R0051643.pdf","paywalled","systematic_review","Ashesh Kumar Das","2025","SODIUM GLUCOSE CO-TRANSPORTER-2 INHIBITORS VS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A META-ANALYSIS OF BENEFITS AND RISKS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.240","https://doi.org/10.1016/j.chest.2025.07.240",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052297","R0052297.pdf","paywalled","systematic_review","Fariha Hasan","2025","Mo1273: IMPACT OF GLP-1 RECEPTOR AGONISTS ON BOWEL PREPARATION QUALITY FOR COLONOSCOPY: A META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03386-4","https://doi.org/10.1016/s0016-5085(25)03386-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052564","R0052564.pdf","paywalled","systematic_review","Ahmad Alhomaid","2025","SAFETY OF ENDOSCOPIC PROCEDURES IN PATIENTS ON GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2025.03.267","https://doi.org/10.1016/j.gie.2025.03.267",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052605","R0052605.pdf","paywalled","systematic_review","Daniel A. Guifarro","2025","S764 Effectiveness of Early vs Delayed GLP-1 Receptor Agonist Initiation Following Bariatric Procedures: A Meta-Analysis of Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130516.83820.d3","https://doi.org/10.14309/01.ajg.0001130516.83820.d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052865","R0052865.pdf","paywalled","systematic_review","Aparajita Tyagi","2025","CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.106","https://doi.org/10.1016/j.jval.2025.09.106",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052904","R0052904.pdf","paywalled","systematic_review","Piyush Ratan","2025","897-P: Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors on Solid Organ Transplant Recipients with Diabetes—A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db25-897-p","https://doi.org/10.2337/db25-897-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053382","R0053382.pdf","paywalled","systematic_review","R. Ravikulan","2025","Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1032","https://doi.org/10.1093/eurheartj/ehaf784.1032",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053449","R0053449.pdf","paywalled","systematic_review","Samit Ghosal","2025","Comparative Efficacy of Lifestyle and GLP-1RA-Based Interventions for Visceral Adipose Tissue Reduction: Meta-Analysis of 40 Randomized Controlled Trials","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.09.171","https://doi.org/10.1016/j.eprac.2025.09.171",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053470","R0053470.pdf","paywalled","systematic_review","Tripdatabase","2025","What are the findings from randomized controlled trials, systematic reviews, or guidelines on the use of glucose-lowering drugs in managing fasting plasma glucose levels?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18019838","https://doi.org/10.5281/zenodo.18019838",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053514","R0053514.pdf","paywalled","systematic_review","E Mansouri","2025","Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3817","https://doi.org/10.1093/eurheartj/ehaf784.3817",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053660","R0053660.pdf","paywalled","systematic_review","Jafar Aljazeeri","2025","GLP-1 Receptor Agonists for Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a2901","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a2901",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053698","R0053698.pdf","paywalled","systematic_review","M Galli","2025","GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4322","https://doi.org/10.1093/eurheartj/ehaf784.4322",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054168","R0054168.pdf","paywalled","systematic_review","Anne M. May","2025","Impact of GLP-1 agonists on heart failure with preserved ejection fraction in obese patients: a meta-analysis of cardiometabolic and functional outcomes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1048","https://doi.org/10.1093/eurheartj/ehaf784.1048",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054326","R0054326.pdf","paywalled","systematic_review","Tripdatabase","2025","What is the impact of glucose-lowering medications on fasting blood glucose as demonstrated in randomized controlled trials, systematic reviews, or guidelines?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18158464","https://doi.org/10.5281/zenodo.18158464",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054397","R0054397.pdf","paywalled","systematic_review","Mohamed, S. Imam","2025","Impact of agonists of glucagon-like peptide-1 receptor in individuals with type 2 diabetes: A meta-analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17906204","https://doi.org/10.5281/zenodo.17906204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054494","R0054494.pdf","paywalled","systematic_review","Abdullah Afridi","2025","“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2025.100605","https://doi.org/10.1016/j.obmed.2025.100605",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054861","R0054861.pdf","paywalled","systematic_review","Muhammad Waseem Tahir","2025","Abstract 4367191: Cardiovascular Safety of Semaglutide: An Updated Systematic Review and Meta-analysis with Focus on Sex, Race, and Renal Function","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367191","https://doi.org/10.1161/circ.152.suppl_3.4367191",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420251066136"],["3","R0054981","R0054981.pdf","paywalled","systematic_review","Jahanvi Kasodariya","2025","Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368175","https://doi.org/10.1161/circ.152.suppl_3.4368175",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055096","R0055096.pdf","paywalled","systematic_review","Jiandra da Luz","2025","64792 Impact of GLP-1 Receptor Agonists on Psoriasis: A Systematic Review and Single-arm Meta-Analysis","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.05.219","https://doi.org/10.1016/j.jaad.2025.05.219",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055202","R0055202.pdf","paywalled","systematic_review","Samit Ghosal","2025","Impact of Baseline Characteristics and Medications on GLP-1RA Cardiovascular Outcomes: A Meta-Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.09.142","https://doi.org/10.1016/j.eprac.2025.09.142",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055370","R0055370.pdf","paywalled","systematic_review","Rishabh Dev Pandey","2025","CO27 Bayesian Network Meta-Analysis of Weight Loss Efficacy for GLP-1 Receptor Agonists and Tirzepatide","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.129","https://doi.org/10.1016/j.jval.2025.09.129",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055495","R0055495.pdf","paywalled","systematic_review","Aymen Arain","2025","Abstract 4368319: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Endothelial Function and Cardiometabolic Outcomes in Polycystic Ovary Syndrome: A Systematic Review","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368319","https://doi.org/10.1161/circ.152.suppl_3.4368319",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055610","R0055610.pdf","paywalled","systematic_review","Ibrahim Khalil","2025","Comparative Effectiveness of GLP-1 Receptor Agonists in Patients with Heart Failure with Preserved or Minimally Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.049","https://doi.org/10.1016/j.ahj.2025.07.049",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055639","R0055639.pdf","paywalled","systematic_review","Arya Aminorroaya","2025","Abstract 4361308: Tirzepatide Reduces the Risk of Major Adverse Cardiovascular Events: An Individual Participant Data Meta-analysis of Phase 3 Randomized Clinical Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4361308","https://doi.org/10.1161/circ.152.suppl_3.4361308",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056262","R0056262.pdf","paywalled","systematic_review","Luiza Marinho Lopes","2025","Efficacy and Safety of Oral Glucagon-like peptide 1 Receptor Agonists in Obesity and Overweight: a Systematic Review and Meta-analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/84ch9","https://doi.org/10.17605/osf.io/84ch9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056351","R0056351.pdf","paywalled","systematic_review","Moamen Abdelfadil Ismail, Ali Khalifah Alkhalifah, Ayman Fahad Alshammari, Fay Fahad Aljumah, Shouq Waleed Almgamsi5, Razan Saud Alshalawi, Maram Abdullah Almatrafi","2025","The Effect Of Metformin On Clinical And Metabolic Outcomes In Women With Polycystic Ovary Syndrome: A Systematic Review And Meta-Analysis","The Review of Diabetic Studies",null,"10.70082/6aq1as96","https://doi.org/10.70082/6aq1as96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056421","R0056421.pdf","paywalled","systematic_review","Moamen Abdelfadil Ismail, Hadeel Abdullah Al-Rashidi, Asmaa Y. Alotaibi, Shadin Abdullah Albebi, Razan Abdulmohsen Alqarni, Abdulaziz Yousef Alfredi, Afnan Ahmed Alsahli","2025","Efficacy And Safety Of GLP-1 Receptor Agonists In The Management Of Obesity Among Saudi Adults: A Systematic Review","The Review of Diabetic Studies",null,"10.70082/9dsp4e91","https://doi.org/10.70082/9dsp4e91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056507","R0056507.pdf","paywalled","systematic_review","Beenish Khurshid","2025","EFFICACY AND RISKS PROFILES OF “GLP-1 RECEPTOR AGONISTS” IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS","Review journal of neurological & medical sciences review.",null,"10.63075/fmkjkn28","https://doi.org/10.63075/fmkjkn28",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056519","R0056519.pdf","paywalled","systematic_review","Beenish Khurshid","2025","Comparison of the GLP-1 Receptor Agonists with other anti-obesity/anti-diabetic medicines: a systematic review","Review journal of neurological & medical sciences review.",null,"10.63075/w16p9p55","https://doi.org/10.63075/w16p9p55",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0001087","R0001087.pdf","paywalled","systematic_review","Goldenberg RM","2024","A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15381","https://doi.org/10.1111/dom.15381","38016705","https://pubmed.ncbi.nlm.nih.gov/38016705/",null,null],["3","R0002221","R0002221.pdf","paywalled","systematic_review","Tsukamoto S","2024","Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15312","https://doi.org/10.1111/dom.15312","37828829","https://pubmed.ncbi.nlm.nih.gov/37828829/",null,null],["3","R0002451","R0002451.pdf","paywalled","systematic_review","Jullien A","2024","Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data.","Diabetes care","American Diabetes Association","10.2337/dca24-0034","https://doi.org/10.2337/dca24-0034","39190488","https://pubmed.ncbi.nlm.nih.gov/39190488/",null,null],["3","R0002475","R0002475.pdf","paywalled","systematic_review","Kramer CK","2024","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae176","https://doi.org/10.1210/clinem/dgae176","38488042","https://pubmed.ncbi.nlm.nih.gov/38488042/",null,null],["3","R0002628","R0002628.pdf","paywalled","systematic_review","Shamim MA","2024","Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15777","https://doi.org/10.1111/dom.15777","39044306","https://pubmed.ncbi.nlm.nih.gov/39044306/",null,null],["3","R0002901","R0002901.pdf","paywalled","systematic_review","Jiao BL","2024","Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202404_36023","https://doi.org/10.26355/eurrev_202404_36023","38708466","https://pubmed.ncbi.nlm.nih.gov/38708466/",null,null],["3","R0003212","R0003212.pdf","paywalled","systematic_review","Xie Z","2024","Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2024.156038","https://doi.org/10.1016/j.metabol.2024.156038","39305981","https://pubmed.ncbi.nlm.nih.gov/39305981/",null,null],["3","R0003478","R0003478.pdf","paywalled","systematic_review","Yanto TA","2024","Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103069","https://doi.org/10.1016/j.dsx.2024.103069","38963997","https://pubmed.ncbi.nlm.nih.gov/38963997/",null,null],["3","R0003529","R0003529.pdf","paywalled","systematic_review","Johnson CE","2024","Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15809","https://doi.org/10.1111/dom.15809","39044308","https://pubmed.ncbi.nlm.nih.gov/39044308/",null,null],["3","R0003932","R0003932.pdf","paywalled","systematic_review","Liu P","2024","Is polyethylene glycol loxenatide 100 μg the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202403_35731","https://doi.org/10.26355/eurrev_202403_35731","38567590","https://pubmed.ncbi.nlm.nih.gov/38567590/",null,null],["3","R0004031","R0004031.pdf","paywalled","systematic_review","Ku SC","2024","Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis.","Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","Wiley","10.1111/ddg.15431","https://doi.org/10.1111/ddg.15431","38824670","https://pubmed.ncbi.nlm.nih.gov/38824670/",null,null],["3","R0004157","R0004157.pdf","paywalled","systematic_review","Rivera FB","2024","Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials.","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2024.03.011","https://doi.org/10.1016/j.jacl.2024.03.011","38906751","https://pubmed.ncbi.nlm.nih.gov/38906751/",null,null],["3","R0004286","R0004286.pdf","paywalled","systematic_review","Weng J","2024","Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.","Journal of evidence-based medicine","Wiley","10.1111/jebm.12620","https://doi.org/10.1111/jebm.12620","38858300","https://pubmed.ncbi.nlm.nih.gov/38858300/",null,"PROSPERO:CRD42023409585"],["3","R0004306","R0004306.pdf","paywalled","systematic_review","Singh S","2024","Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2024.102403","https://doi.org/10.1016/j.cpcardiol.2024.102403","38237815","https://pubmed.ncbi.nlm.nih.gov/38237815/",null,null],["3","R0004385","R0004385.pdf","paywalled","systematic_review","Wong SY","2024","Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-022-07360-w","https://doi.org/10.1007/s10557-022-07360-w","35819544","https://pubmed.ncbi.nlm.nih.gov/35819544/",null,"PROSPERO:CRD42021259661"],["3","R0004401","R0004401.pdf","paywalled","systematic_review","Fang L","2024","Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.03.005","https://doi.org/10.1016/j.pcd.2024.03.005","38555202","https://pubmed.ncbi.nlm.nih.gov/38555202/",null,"PROSPERO:CRD42023390735"],["3","R0004471","R0004471.pdf","paywalled","systematic_review","Xie W","2024","Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108743","https://doi.org/10.1016/j.jdiacomp.2024.108743","38688179","https://pubmed.ncbi.nlm.nih.gov/38688179/",null,null],["3","R0004668","R0004668.pdf","paywalled","systematic_review","Dutta D","2024","Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07175-8","https://doi.org/10.1007/s11695-024-07175-8","38502519","https://pubmed.ncbi.nlm.nih.gov/38502519/",null,"PROSPERO:CRD42023473991"],["3","R0004686","R0004686.pdf","paywalled","systematic_review","Pan XH","2024","Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24002","https://doi.org/10.1002/oby.24002","38413012","https://pubmed.ncbi.nlm.nih.gov/38413012/",null,null],["3","R0004824","R0004824.pdf","paywalled","systematic_review","Tong X","2024","Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.","Archives of physiology and biochemistry","Informa UK Limited","10.1080/13813455.2024.2380422","https://doi.org/10.1080/13813455.2024.2380422","39084250","https://pubmed.ncbi.nlm.nih.gov/39084250/",null,null],["3","R0004899","R0004899.pdf","paywalled","systematic_review","Yang Y","2024","Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15342","https://doi.org/10.1111/dom.15342","37860884","https://pubmed.ncbi.nlm.nih.gov/37860884/",null,"PROSPERO:CRD42023418551"],["3","R0004920","R0004920.pdf","paywalled","systematic_review","Wang JY","2024","The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13686","https://doi.org/10.1111/obr.13686","38204284","https://pubmed.ncbi.nlm.nih.gov/38204284/",null,null],["3","R0004929","R0004929.pdf","paywalled","systematic_review","Zhang Y","2024","The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15557","https://doi.org/10.1111/dom.15557","38528818","https://pubmed.ncbi.nlm.nih.gov/38528818/",null,null],["3","R0005130","R0005130.pdf","paywalled","systematic_review","Ansari HUH","2024","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2023.11.007","https://doi.org/10.1016/j.eprac.2023.11.007","38029929","https://pubmed.ncbi.nlm.nih.gov/38029929/",null,null],["3","R0005363","R0005363.pdf","paywalled","systematic_review","Barbagelata L","2024","Semaglutide and heart failure: Updated meta-analysis.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2024.102721","https://doi.org/10.1016/j.cpcardiol.2024.102721","38908729","https://pubmed.ncbi.nlm.nih.gov/38908729/",null,null],["3","R0005421","R0005421.pdf","paywalled","systematic_review","Lin RT","2024","Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2024.156043","https://doi.org/10.1016/j.metabol.2024.156043","39357599","https://pubmed.ncbi.nlm.nih.gov/39357599/",null,null],["3","R0005519","R0005519.pdf","paywalled","systematic_review","Karakasis P","2024","Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-024-02959-x","https://doi.org/10.1007/s12325-024-02959-x","39141282","https://pubmed.ncbi.nlm.nih.gov/39141282/",null,null],["3","R0005572","R0005572.pdf","paywalled","systematic_review","Pereira M","2024","Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07486-w","https://doi.org/10.1007/s11695-024-07486-w","39215779","https://pubmed.ncbi.nlm.nih.gov/39215779/",null,null],["3","R0005757","R0005757.pdf","paywalled","systematic_review","Banerjee M","2024","GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.102943","https://doi.org/10.1016/j.dsx.2024.102943","38211482","https://pubmed.ncbi.nlm.nih.gov/38211482/",null,"PROSPERO:CRD42022337559"],["3","R0005907","R0005907.pdf","paywalled","systematic_review","Kilickap M","2024","GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.","Angiology","SAGE Publications","10.1177/00033197231183229","https://doi.org/10.1177/00033197231183229","37326223","https://pubmed.ncbi.nlm.nih.gov/37326223/",null,null],["3","R0005972","R0005972.pdf","paywalled","systematic_review","Liu Y","2024","IDegLira for type 2 diabetes: a systematic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-023-03543-z","https://doi.org/10.1007/s12020-023-03543-z","37768513","https://pubmed.ncbi.nlm.nih.gov/37768513/",null,null],["3","R0006104","R0006104.pdf","paywalled","systematic_review","Banerjee M","2024","Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-023-07432-5","https://doi.org/10.1007/s10557-023-07432-5","36696050","https://pubmed.ncbi.nlm.nih.gov/36696050/",null,"PROSPERO:CRD42022367633"],["3","R0006295","R0006295.pdf","paywalled","systematic_review","Wang DH","2024","A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-024-02289-y","https://doi.org/10.1007/s00592-024-02289-y","38714558","https://pubmed.ncbi.nlm.nih.gov/38714558/",null,null],["3","R0006312","R0006312.pdf","paywalled","systematic_review","Zhang MQ","2024","The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.","Biomedical and environmental sciences : BES",null,"10.3967/bes2024.067","https://doi.org/10.3967/bes2024.067","38988111","https://pubmed.ncbi.nlm.nih.gov/38988111/",null,null],["3","R0006403","R0006403.pdf","paywalled","systematic_review","Pan SY","2024","Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials.","Age and ageing","Oxford University Press (OUP)","10.1093/ageing/afae175","https://doi.org/10.1093/ageing/afae175","39137064","https://pubmed.ncbi.nlm.nih.gov/39137064/",null,null],["3","R0006611","R0006611.pdf","paywalled","systematic_review","Bikou A","2024","A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2024.2343092","https://doi.org/10.1080/14656566.2024.2343092","38629387","https://pubmed.ncbi.nlm.nih.gov/38629387/",null,null],["3","R0006635","R0006635.pdf","paywalled","systematic_review","Yang W","2024","Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13725","https://doi.org/10.1111/obr.13725","38346789","https://pubmed.ncbi.nlm.nih.gov/38346789/",null,null],["3","R0006694","R0006694.pdf","paywalled","systematic_review","Zhang HD","2024","Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103067","https://doi.org/10.1016/j.dsx.2024.103067","38955095","https://pubmed.ncbi.nlm.nih.gov/38955095/",null,null],["3","R0007081","R0007081.pdf","paywalled","systematic_review","Kim H","2024","Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2024.117490","https://doi.org/10.1016/j.atherosclerosis.2024.117490","38452432","https://pubmed.ncbi.nlm.nih.gov/38452432/",null,null],["3","R0007097","R0007097.pdf","paywalled","systematic_review","Dréant A","2024","Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07127-2","https://doi.org/10.1007/s11695-024-07127-2","38436920","https://pubmed.ncbi.nlm.nih.gov/38436920/",null,null],["3","R0007322","R0007322.pdf","paywalled","systematic_review","Tsai HR","2024","Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3739","https://doi.org/10.1002/dmrr.3739","37862117","https://pubmed.ncbi.nlm.nih.gov/37862117/",null,null],["3","R0007436","R0007436.pdf","paywalled","systematic_review","Song ZH","2024","The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.","Therapeutic innovation & regulatory science","Springer Science and Business Media LLC","10.1007/s43441-024-00633-6","https://doi.org/10.1007/s43441-024-00633-6","38683419","https://pubmed.ncbi.nlm.nih.gov/38683419/",null,null],["3","R0007451","R0007451.pdf","paywalled","systematic_review","Rizos EC","2024","The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108781","https://doi.org/10.1016/j.jdiacomp.2024.108781","38833853","https://pubmed.ncbi.nlm.nih.gov/38833853/",null,null],["3","R0007819","R0007819.pdf","paywalled","systematic_review","Tuersun A","2024","Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.","The American journal of the medical sciences","Elsevier BV","10.1016/j.amjms.2024.07.011","https://doi.org/10.1016/j.amjms.2024.07.011","38977245","https://pubmed.ncbi.nlm.nih.gov/38977245/",null,null],["3","R0009107","R0009107.pdf","paywalled","systematic_review","de Oliveira Almeida G","2024","Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-024-00647-3","https://doi.org/10.1007/s40256-024-00647-3","38734847","https://pubmed.ncbi.nlm.nih.gov/38734847/",null,"PROSPERO:CRD42023475226"],["3","R0009132","R0009132.pdf","paywalled","systematic_review","Villaschi A","2024","GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-023-02362-6","https://doi.org/10.1007/s00392-023-02362-6","38252145","https://pubmed.ncbi.nlm.nih.gov/38252145/",null,"PROSPERO:CRD42022371264"],["3","R0009579","R0009579.pdf","paywalled","systematic_review","Li Y","2024","The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.","European journal of clinical investigation","Wiley","10.1111/eci.14125","https://doi.org/10.1111/eci.14125","37950521","https://pubmed.ncbi.nlm.nih.gov/37950521/",null,null],["3","R0010096","R0010096.pdf","paywalled","systematic_review","Shi Q","2024","Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)00351-9","https://doi.org/10.1016/s0140-6736(24)00351-9","38582569","https://pubmed.ncbi.nlm.nih.gov/38582569/",null,"PROSPERO:CRD42021245678"],["3","R0010631","R0010631.pdf","paywalled","systematic_review","Douros JD","2024","The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.","The Journal of endocrinology","Bioscientifica","10.1530/joe-23-0226","https://doi.org/10.1530/joe-23-0226","38451873","https://pubmed.ncbi.nlm.nih.gov/38451873/",null,null],["3","R0010908","R0010908.pdf","paywalled","systematic_review","Alsaqaaby MS","2024","Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(24)00098-6","https://doi.org/10.1016/s2213-8587(24)00098-6","38723646","https://pubmed.ncbi.nlm.nih.gov/38723646/",null,null],["3","R0011300","R0011300.pdf","paywalled","systematic_review","Ayesh H","2024","Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001756","https://doi.org/10.1097/mjt.0000000000001756","39292847","https://pubmed.ncbi.nlm.nih.gov/39292847/",null,null],["3","R0012051","R0012051.pdf","paywalled","systematic_review","Ayesh H","2024","Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001743","https://doi.org/10.1097/mjt.0000000000001743","38976545","https://pubmed.ncbi.nlm.nih.gov/38976545/",null,null],["3","R0012618","R0012618.pdf","paywalled","systematic_review","Lalić NM","2024","Glucose lowering drug or strategy dependent impact of weight reduction on the prevention of CVD outcomes in Type 2 diabetes: a systematic review of CVOTs.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111816","https://doi.org/10.1016/j.diabres.2024.111816","39147102","https://pubmed.ncbi.nlm.nih.gov/39147102/",null,null],["3","R0012688","R0012688.pdf","paywalled","systematic_review","Drake T","2024","Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.","Annals of internal medicine","American College of Physicians","10.7326/m23-1490","https://doi.org/10.7326/m23-1490","38639549","https://pubmed.ncbi.nlm.nih.gov/38639549/",null,"PROSPERO:CRD42022322129"],["3","R0013258","R0013258.pdf","paywalled","systematic_review","Deng B","2024","Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-03857-6","https://doi.org/10.1007/s12020-024-03857-6","38740695","https://pubmed.ncbi.nlm.nih.gov/38740695/",null,null],["3","R0013505","R0013505.pdf","paywalled","systematic_review","Liu Y","2024","iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-03868-3","https://doi.org/10.1007/s12020-024-03868-3","38740694","https://pubmed.ncbi.nlm.nih.gov/38740694/",null,null],["3","R0014453","R0014453.pdf","paywalled","systematic_review","Ntentakis DP","2024","Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Springer Science and Business Media LLC","10.1007/s00417-023-06236-5","https://doi.org/10.1007/s00417-023-06236-5","37728754","https://pubmed.ncbi.nlm.nih.gov/37728754/",null,null],["3","R0015374","R0015374.pdf","paywalled","systematic_review","Asiabar AS","2024","The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-024-03755-w","https://doi.org/10.1007/s00228-024-03755-w","39254692","https://pubmed.ncbi.nlm.nih.gov/39254692/",null,null],["3","R0015854","R0015854.pdf","paywalled","systematic_review","Mao T","2024","Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-024-02474-7","https://doi.org/10.1007/s00392-024-02474-7","38916609","https://pubmed.ncbi.nlm.nih.gov/38916609/",null,null],["3","R0016937","R0016937.pdf","paywalled","systematic_review","O'Connor EA","2024","Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","JAMA","American Medical Association (AMA)","10.1001/jama.2024.6739","https://doi.org/10.1001/jama.2024.6739","38888913","https://pubmed.ncbi.nlm.nih.gov/38888913/",null,null],["3","R0017001","R0017001.pdf","paywalled","systematic_review","Austregésilo de Athayde De Hollanda Morais B","2024","The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108834","https://doi.org/10.1016/j.jdiacomp.2024.108834","39178623","https://pubmed.ncbi.nlm.nih.gov/39178623/",null,null],["3","R0018182","R0018182.pdf","paywalled","systematic_review","Sheng L","2024","The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111617","https://doi.org/10.1016/j.diabres.2024.111617","38490492","https://pubmed.ncbi.nlm.nih.gov/38490492/",null,null],["3","R0018394","R0018394.pdf","paywalled","systematic_review","Wang Y","2024","Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-024-02015-6","https://doi.org/10.1007/s40265-024-02015-6","38478331","https://pubmed.ncbi.nlm.nih.gov/38478331/",null,"PROSPERO:CRD42023404309"],["3","R0018511","R0018511.pdf","paywalled","systematic_review","Muhammed A","2024","Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2023.2284992","https://doi.org/10.1080/14740338.2023.2284992","37986140","https://pubmed.ncbi.nlm.nih.gov/37986140/",null,null],["3","R0018520","R0018520.pdf","paywalled","systematic_review","Rivera FB","2024","Evaluating the safety profile of semaglutide: an updated meta-analysis.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2024.2383731","https://doi.org/10.1080/03007995.2024.2383731","39046272","https://pubmed.ncbi.nlm.nih.gov/39046272/",null,null],["3","R0018672","R0018672.pdf","paywalled","systematic_review","Popovic DS","2024","Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111758","https://doi.org/10.1016/j.diabres.2024.111758","38925294","https://pubmed.ncbi.nlm.nih.gov/38925294/",null,null],["3","R0018701","R0018701.pdf","paywalled","systematic_review","Ala M","2024","Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01621-4","https://doi.org/10.1038/s41366-024-01621-4","39210008","https://pubmed.ncbi.nlm.nih.gov/39210008/",null,null],["3","R0018712","R0018712.pdf","paywalled","systematic_review","Kamrul-Hasan ABM","2024","Hepatobiliary effects and safety of tirzepatide: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15948","https://doi.org/10.1111/dom.15948","39268951","https://pubmed.ncbi.nlm.nih.gov/39268951/",null,null],["3","R0019039","R0019039.pdf","paywalled","systematic_review","Meir J","2024","The vascular complications of diabetes: a review of their management, pathogenesis, and prevention.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2023.2279533","https://doi.org/10.1080/17446651.2023.2279533","37947481","https://pubmed.ncbi.nlm.nih.gov/37947481/",null,null],["3","R0019075","R0019075.pdf","paywalled","systematic_review","Zhang K","2024","Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-024-01449-1","https://doi.org/10.1007/s40262-024-01449-1","39549228","https://pubmed.ncbi.nlm.nih.gov/39549228/",null,null],["3","R0019108","R0019108.pdf","paywalled","systematic_review","Singh AK","2024","Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103024","https://doi.org/10.1016/j.dsx.2024.103024","38718449","https://pubmed.ncbi.nlm.nih.gov/38718449/",null,null],["3","R0019131","R0019131.pdf","paywalled","systematic_review","Masson W","2024","Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2024.03.012","https://doi.org/10.1016/j.endien.2024.03.012","38555109","https://pubmed.ncbi.nlm.nih.gov/38555109/",null,null],["3","R0019574","R0019574.pdf","paywalled","systematic_review","de Moraes FCA","2024","Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07384-1","https://doi.org/10.1007/s11695-024-07384-1","38987454","https://pubmed.ncbi.nlm.nih.gov/38987454/",null,null],["3","R0019627","R0019627.pdf","paywalled","systematic_review","Conte C","2024","Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07445-5","https://doi.org/10.1007/s11695-024-07445-5","39126592","https://pubmed.ncbi.nlm.nih.gov/39126592/",null,null],["3","R0019650","R0019650.pdf","paywalled","systematic_review","Ayesh H","2024","Efficacy and Safety of FGF21 Versus Semaglutide in the Management of Metabolic-Associated Steatotic Liver Disease: A Network Meta-analysis.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001814","https://doi.org/10.1097/mjt.0000000000001814","39297747","https://pubmed.ncbi.nlm.nih.gov/39297747/",null,null],["3","R0019808","R0019808.pdf","paywalled","systematic_review","Dorneles G","2024","Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-2303-8558","https://doi.org/10.1055/a-2303-8558","38599612","https://pubmed.ncbi.nlm.nih.gov/38599612/",null,null],["3","R0019818","R0019818.pdf","paywalled","systematic_review","Yuan D","2024","A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2024.102736","https://doi.org/10.1016/j.cpcardiol.2024.102736","38944224","https://pubmed.ncbi.nlm.nih.gov/38944224/",null,null],["3","R0021076","R0021076.pdf","paywalled","systematic_review","Alsanea S","2024","Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.05.009","https://doi.org/10.1016/j.eprac.2024.05.009","38782201","https://pubmed.ncbi.nlm.nih.gov/38782201/",null,null],["3","R0021279","R0021279.pdf","paywalled","systematic_review","Salvi V","2024","Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.","Schizophrenia research","Elsevier BV","10.1016/j.schres.2024.09.008","https://doi.org/10.1016/j.schres.2024.09.008","39265262","https://pubmed.ncbi.nlm.nih.gov/39265262/",null,null],["3","R0022486","R0022486.pdf","paywalled","systematic_review","Scragg J","2024","Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.","Annals of internal medicine","American College of Physicians","10.7326/m23-3179","https://doi.org/10.7326/m23-3179","39496172","https://pubmed.ncbi.nlm.nih.gov/39496172/",null,"PROSPERO:CRD42022367488"],["3","R0025283","R0025283.pdf","paywalled","systematic_review","Hegde NC","2024","Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.","General hospital psychiatry","Elsevier BV","10.1016/j.genhosppsych.2024.06.003","https://doi.org/10.1016/j.genhosppsych.2024.06.003","38878592","https://pubmed.ncbi.nlm.nih.gov/38878592/",null,null],["3","R0029173","R0029173.pdf","paywalled","systematic_review","Ashraf MT","2024","Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001689","https://doi.org/10.1097/mjt.0000000000001689","38976535","https://pubmed.ncbi.nlm.nih.gov/38976535/",null,null],["3","R0030154","R0030154.pdf","paywalled","systematic_review","Schousboe JT","2024","Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.","Annals of internal medicine","American College of Physicians","10.7326/m23-1492","https://doi.org/10.7326/m23-1492","38639547","https://pubmed.ncbi.nlm.nih.gov/38639547/",null,"PROSPERO:CRD42022382315"],["3","R0031567","R0031567.pdf","paywalled","systematic_review",null,"2024","Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis","Egyptian Society of Diabetes and Lipidology Journal","Egyptian Knowledge Bank","10.21608/esdlj.2024.456243","https://doi.org/10.21608/esdlj.2024.456243",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032413","R0032413.pdf","paywalled","systematic_review","Mark Jason D. C. Milan","2024","Efficacy of retatrutide for weight reduction and its cardiometabolic effects among adults: A systematic review and meta-analysis","Clinical Nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2024.07.467","https://doi.org/10.1016/j.clnesp.2024.07.467",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032625","R0032625.pdf","paywalled","systematic_review","CHAOCHAO YANG","2024","1472-P: Low CRP Alleles in HNF1A Are Associated with Increased Risk of Cardiovascular Disease—A Meta-analysis","Diabetes","American Diabetes Association","10.2337/db24-1472-p","https://doi.org/10.2337/db24-1472-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033236","R0033236.pdf","paywalled","systematic_review","Whitney B. Sussman","2024","Medication Adherence to SGLT2 Inhibitors vs. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20245w2bgaw1","https://doi.org/10.1681/asn.20245w2bgaw1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033868","R0033868.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.c.6689993.v1","https://doi.org/10.6084/m9.figshare.c.6689993.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034237","R0034237.pdf","paywalled","systematic_review","Vikash Jaiswal","2024","Abstract 4145802: Association between Glucagon-like peptide-1 receptor agonists and risk of Arrhythmias or Heart Failure among patients with Type 2 Diabetes: A Meta-Analysis of 29 Randomized Controlled Trials.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145802","https://doi.org/10.1161/circ.150.suppl_1.4145802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034333","R0034333.pdf","paywalled","systematic_review","Immanuel, Surya Sinaga","2024","The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonist in Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials",null,null,"10.13140/rg.2.2.10696.12803","https://doi.org/10.13140/rg.2.2.10696.12803",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034357","R0034357.pdf","paywalled","systematic_review","Ze-jin Liao","2024","Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.3969/j.issn.1671-2390.2024.12.003","https://doi.org/10.3969/j.issn.1671-2390.2024.12.003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034383","R0034383.pdf","paywalled","systematic_review","Gu, Xia","2024","Additional file 2 of Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.24987936","https://doi.org/10.6084/m9.figshare.24987936",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034395","R0034395.pdf","paywalled","systematic_review","Hu, Yan","2024","Additional file 2 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26641015","https://doi.org/10.6084/m9.figshare.26641015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034418","R0034418.pdf","paywalled","systematic_review","Gu, Xia","2024","Additional file 1 of Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.24987804","https://doi.org/10.6084/m9.figshare.24987804",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034480","R0034480.pdf","paywalled","systematic_review","Ahmad, Aftab","2024","Additional file 1 of Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","Figshare",null,"10.6084/m9.figshare.26695038","https://doi.org/10.6084/m9.figshare.26695038",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034487","R0034487.pdf","paywalled","systematic_review","Ahmad, Aftab","2024","Additional file 2 of Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","Figshare",null,"10.6084/m9.figshare.26695041","https://doi.org/10.6084/m9.figshare.26695041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034498","R0034498.pdf","paywalled","systematic_review","Yu, Meixin","2024","Additional file 1 of The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.26606593","https://doi.org/10.6084/m9.figshare.26606593",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034549","R0034549.pdf","paywalled","systematic_review","Wu, Sijin","2024","Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.c.6577411.v1","https://doi.org/10.6084/m9.figshare.c.6577411.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42022339389"],["3","R0034558","R0034558.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Additional file 8 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.26595992","https://doi.org/10.6084/m9.figshare.26595992",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034570","R0034570.pdf","paywalled","systematic_review","Zhou, Qian","2024","Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.c.6905587","https://doi.org/10.6084/m9.figshare.c.6905587",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034625","R0034625.pdf","paywalled","systematic_review","Frederick Berro Rivera","2024","Abstract 4134308: Re-evaluating the safety profile of Semaglutide: An updated meta-analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4134308","https://doi.org/10.1161/circ.150.suppl_1.4134308",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034626","R0034626.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Additional file 6 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.26595986","https://doi.org/10.6084/m9.figshare.26595986",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034638","R0034638.pdf","paywalled","systematic_review","Hu, Yan","2024","Additional file 1 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26641012","https://doi.org/10.6084/m9.figshare.26641012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034712","R0034712.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Additional file 5 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.26595983","https://doi.org/10.6084/m9.figshare.26595983",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034739","R0034739.pdf","paywalled","systematic_review","Myasoedova, Veronika A.","2024","Additional file 2 of Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26565300","https://doi.org/10.6084/m9.figshare.26565300",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034745","R0034745.pdf","paywalled","systematic_review","Hu, Yan","2024","Additional file 3 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26641018","https://doi.org/10.6084/m9.figshare.26641018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034748","R0034748.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Additional file 4 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.26595980","https://doi.org/10.6084/m9.figshare.26595980",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034800","R0034800.pdf","paywalled","systematic_review","Huang, Yi-lin","2024","Additional file 7 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.26595989","https://doi.org/10.6084/m9.figshare.26595989",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036506","R0036506.pdf","paywalled","systematic_review","Mengying Wang","2024","Glucagon-like peptide-1 receptor agonists on outcomes in osteoarthritis among persons with obesity: a protocol for systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/8y457","https://doi.org/10.17605/osf.io/8y457",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036526","R0036526.pdf","paywalled","systematic_review","Teperikidis, Lefteris","2024","Validating the Role of Chatgpt in Automatic Systematic Reviews and Meta-Analysis: a Case Study Focusing on Mortality Benefits of Glucagon-Like Peptide-1 Receptor Agonists","Open Science Framework",null,"10.17605/osf.io/x6n8b","https://doi.org/10.17605/osf.io/x6n8b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036537","R0036537.pdf","paywalled","systematic_review","Thomaz Alexandre Costa","2024","\"Incretin-Based Therapies for Patients with Overweight or Obesity and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/3w4cs","https://doi.org/10.17605/osf.io/3w4cs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036540","R0036540.pdf","paywalled","systematic_review","Thomaz Alexandre Costa","2024","Glucagon-Like Peptide 1 Receptor Agonist for Patients with Obesity and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/5a26b","https://doi.org/10.17605/osf.io/5a26b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036562","R0036562.pdf","paywalled","systematic_review","Collins, Clare","2024","Reporting of diet quality and intake in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of RCTs","Open Science Framework",null,"10.17605/osf.io/gcmxw","https://doi.org/10.17605/osf.io/gcmxw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036573","R0036573.pdf","paywalled","systematic_review","Dadkhah, Parisa Alsadat","2024","Comparative effectiveness of semaglutide versus liraglutide/dulaglutide or tirzepatide: a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/xkhvq","https://doi.org/10.17605/osf.io/xkhvq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036587","R0036587.pdf","paywalled","systematic_review","Belal, Mohamed Mohamed","2024","Safety and efficacy of Retatrutide in treatment of obesity : a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/ex2ud","https://doi.org/10.17605/osf.io/ex2ud",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036592","R0036592.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Comparative Efficacy of FGF21 Analogues and Semaglutide in the Management of MASLD: A Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/7fng3","https://doi.org/10.17605/osf.io/7fng3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036618","R0036618.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","GLP-1 Agonist vs SGLT-2 Inhibitor in the Management of MASLD: A Network Meta-analysis","Open Science Framework",null,"10.17605/osf.io/3uyxv","https://doi.org/10.17605/osf.io/3uyxv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036623","R0036623.pdf","paywalled","systematic_review","Han, Chin Yip","2024","EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN MYOCARDIAL INFARCTION PREVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/7vxn5","https://doi.org/10.17605/osf.io/7vxn5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036628","R0036628.pdf","paywalled","systematic_review","Mihai-Teodor Georgescu","2024","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies","Open Science Framework",null,"10.17605/osf.io/n3hxf","https://doi.org/10.17605/osf.io/n3hxf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036636","R0036636.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Comparative Analysis of Resmetirom vs GLP-1 Agonist vs SGLT-2 Inhibitor in MASLD and MASH: Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/2pqhm","https://doi.org/10.17605/osf.io/2pqhm",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036649","R0036649.pdf","paywalled","systematic_review","Ρέμπελου, Ελένη Ιωάννη","2024","Effect of glucagon-like peptide-1 receptor agonists as add-on therapy to insulin on metabolic outcomes in type 1 diabetes mellitus: a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.359931","https://doi.org/10.26262/heal.auth.ir.359931",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036657","R0036657.pdf","paywalled","systematic_review","Abdelaziz Awad","2024","Safety and efficacy of the Glucagon and GLP-1 receptor dual agonist survodutide in treatment of obesity : a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/gb39w","https://doi.org/10.17605/osf.io/gb39w",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036665","R0036665.pdf","paywalled","systematic_review","Karakasis, Paschalis","2024","Effect of tirzepatide on the risk for malignancy among individuals with type 2 diabetes: a meta-analysis.","Open Science Framework",null,"10.17605/osf.io/8j9yd","https://doi.org/10.17605/osf.io/8j9yd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036670","R0036670.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Comparative Analysis of Resmetirom vs FGF21 Agonists vs GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/hxvp3","https://doi.org/10.17605/osf.io/hxvp3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036678","R0036678.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Enhanced Reduction of Albuminuria with Combined SGLT-2 and GLP-1 Therapy: A Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/ug3ed","https://doi.org/10.17605/osf.io/ug3ed",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036688","R0036688.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Comparative Efficacy and Safety of Resmetirom vs Semaglutide in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Network Meta-analysis of Randomized Clinical Trials","Open Science Framework",null,"10.17605/osf.io/ec6df","https://doi.org/10.17605/osf.io/ec6df",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036694","R0036694.pdf","paywalled","systematic_review","Ayesh, Hazem","2024","Comparative Efficacy of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Reducing Albuminuria: A Network Meta-Analysis of Clinical Trials","Open Science Framework",null,"10.17605/osf.io/e7cmx","https://doi.org/10.17605/osf.io/e7cmx",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036698","R0036698.pdf","paywalled","systematic_review","Reis, Victor Hugo Palhares Flavio Dos","2024","Evaluating the efficacy of GLP-1 receptor agonists for Parkinson's Disease: a systematic review and meta-analysis","Open Science Framework",null,"10.17605/osf.io/bdrwf","https://doi.org/10.17605/osf.io/bdrwf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036752","R0036752.pdf","paywalled","systematic_review","Zhou, Qian","2024","Additional file 1 of Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.26633796","https://doi.org/10.6084/m9.figshare.26633796",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036774","R0036774.pdf","paywalled","systematic_review","Yugar, Louise Buonalumi Tacito","2024","Additional file 1 of The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis","Figshare",null,"10.6084/m9.figshare.25687387","https://doi.org/10.6084/m9.figshare.25687387",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036781","R0036781.pdf","paywalled","systematic_review","Wu, Sijin","2024","Additional file 1 of Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.26557475","https://doi.org/10.6084/m9.figshare.26557475",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036790","R0036790.pdf","paywalled","systematic_review","Zhou, Lingling","2024","Additional file 1 of Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","Figshare",null,"10.6084/m9.figshare.26637207","https://doi.org/10.6084/m9.figshare.26637207",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036800","R0036800.pdf","paywalled","systematic_review","Salamah, Hazem Mohamed","2024","Additional file 1 of Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.26733807","https://doi.org/10.6084/m9.figshare.26733807",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037056","R0037056.pdf","paywalled","systematic_review","Raseen Tariq","2024","S855 Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Endoscopy Outcomes: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032788.29188.60","https://doi.org/10.14309/01.ajg.0001032788.29188.60",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037178","R0037178.pdf","paywalled","systematic_review","Yu, Meixin","2024","The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.c.6759424.v1","https://doi.org/10.6084/m9.figshare.c.6759424.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42023396138"],["3","R0037234","R0037234.pdf","paywalled","systematic_review","PHILIP HOME","2024","1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin—A Systemic Literature Review and Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db24-1880-lb","https://doi.org/10.2337/db24-1880-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037250","R0037250.pdf","paywalled","systematic_review","Zhou, Lingling","2024","Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","Figshare",null,"10.6084/m9.figshare.c.6921447","https://doi.org/10.6084/m9.figshare.c.6921447",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037575","R0037575.pdf","paywalled","systematic_review","Boulmpou, Aristi","2024","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","Figshare",null,"10.6084/m9.figshare.27231628","https://doi.org/10.6084/m9.figshare.27231628",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038121","R0038121.pdf","paywalled","systematic_review","Nicole Felix","2024","KIDNEY PROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS",null,"Sociedade Brasileira de Nefrologia","10.65034/bjnabstract-cbn240726","https://doi.org/10.65034/bjnabstract-cbn240726",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038207","R0038207.pdf","paywalled","systematic_review","Hu, Yan","2024","Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.c.6935175.v1","https://doi.org/10.6084/m9.figshare.c.6935175.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038261","R0038261.pdf","paywalled","systematic_review","Chananard Siritanetdachatorn","2024","The Effects of Liraglutide on Cardiovascular Outcomes in Patients with Diabetes Type 2. A Systematic Review and Meta-Analysis",null,null,"10.13140/rg.2.2.21778.26562","https://doi.org/10.13140/rg.2.2.21778.26562",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038614","R0038614.pdf","paywalled","systematic_review","Ellebedy, Mohamed","2024","TIRZEPATIDE VERSUS LONG-ACTING INSULIN IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META ANALYSIS",null,null,"10.13140/rg.2.2.29401.74081","https://doi.org/10.13140/rg.2.2.29401.74081",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038631","R0038631.pdf","paywalled","systematic_review","Myasoedova, Veronika A.","2024","Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.c.6586522.v1","https://doi.org/10.6084/m9.figshare.c.6586522.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038646","R0038646.pdf","paywalled","systematic_review","Zenel Qenami","2024","160 Pharmacotherapies in improving functional capacity in heart failure with preserved ejection fraction: a combined bayesian and frequentist network meta-analysis","Heart failure","BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2024-bcs.157","https://doi.org/10.1136/heartjnl-2024-bcs.157",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039694","R0039694.pdf","paywalled","systematic_review","Alsharif, Fatima R","2024","Efficacy of GLP-1 agonists in the achievement of remission-level HbA1c in type 2 diabetes: A systematic review and meta-analysis",null,null,"10.13140/rg.2.2.33101.55521","https://doi.org/10.13140/rg.2.2.33101.55521",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039757","R0039757.pdf","paywalled","systematic_review","Frederick Berro Rivera","2024","Abstract 4129733: Glucagon-like Peptide 1 Receptor Agonists Effect on Low-Density Lipoprotein Cholesterol and Total Cholesterol Levels Independent of Weight Reduction: A Meta-analysis and Meta-regression of Placebo-controlled Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4129733","https://doi.org/10.1161/circ.150.suppl_1.4129733",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041389","R0041389.pdf","paywalled","systematic_review","Mohammed K. Aldosari","2024","COMPARATIVE ANALYSIS OF INSULIN VARIETIES IN THE MANAGEMENT OF OBESITY: A COMPREHENSIVE SYSTEMATIC REVIEW","International Journal of Advanced Research","International Journal Of Advanced Research","10.21474/ijar01/19391","https://doi.org/10.21474/ijar01/19391",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042325","R0042325.pdf","paywalled","systematic_review","Vincent Dang","2024","The effect of the GLP -1 receptor agonist on brain responses to reward-related cues and emotional cues? Protocol for a systematic review",null,null,"10.17605/osf.io/jbpv7","https://doi.org/10.17605/osf.io/jbpv7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042457","R0042457.pdf","paywalled","systematic_review","Silva, Catarina Columbano Paulino","2024","GLP-1 analogues in post-operative bariatric surgery patients: a systematic review and meta-analysis","Open Repository of the University of Porto (University of Porto)",null,"10.34626/1f8k-th73","https://doi.org/10.34626/1f8k-th73",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042549","R0042549.pdf","paywalled","systematic_review","Kevin Gracia Pratama","2024","Glucagon-like peptide-1 receptor agonists for post-bariatric surgery weight regain and insufficient weight loss: A systematic review","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2024.100533","https://doi.org/10.1016/j.obmed.2024.100533",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043526","R0043526.pdf","paywalled","systematic_review","Stanford, Jordan","2024","Reporting of diet quality and intake in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of RCTs","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/xpngy","https://doi.org/10.17605/osf.io/xpngy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043653","R0043653.pdf","paywalled","systematic_review","Zhenwu Wang","2024","Sa1572 COMPARATIVE EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS WITH DIFFERENT TREATMENT DURATIONS PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A NETWORK META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01575-0","https://doi.org/10.1016/s0016-5085(24)01575-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044015","R0044015.pdf","paywalled","systematic_review","Karakasis, Paschalis","2024","Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis of propensity score-matched studies","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/zgw26","https://doi.org/10.17605/osf.io/zgw26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044042","R0044042.pdf","paywalled","systematic_review","Ravi Teja Pasam","2024","Sa1965 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BODY COMPOSITION - A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01842-0","https://doi.org/10.1016/s0016-5085(24)01842-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044043","R0044043.pdf","paywalled","systematic_review","Karakasis, Paschalis","2024","Effect of glucagon-like peptide-1 receptor agonists and co-agonists dose on body mass composition: systematic review and network meta-analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/su5hc","https://doi.org/10.17605/osf.io/su5hc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044103","R0044103.pdf","paywalled","systematic_review","Karakasis, Paschalis","2024","Effects of glucagon-like peptide-1 receptor agonists on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/bx368","https://doi.org/10.17605/osf.io/bx368",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045336","R0045336.pdf","paywalled","systematic_review","Noppachai Siranart","2024","S2117 Combination Therapy of Glucagon-Like-Peptide-1 Receptor Agonists and Endoscopic Gastric Plication in Obesity Population: A Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037836.98748.24","https://doi.org/10.14309/01.ajg.0001037836.98748.24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045414","R0045414.pdf","paywalled","systematic_review","do Nascimento, Tatiana S.","2024","Additional file 2 of The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26752561","https://doi.org/10.6084/m9.figshare.26752561",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045505","R0045505.pdf","paywalled","systematic_review","Albalushi, Sarvinoz","2024","A meta-analysis preliminary result: Effectiveness and Safety of Oral Semaglutide vs. Injectable Semaglutide in Weight Loss in General Population Indifferent of Diabetic Status","Digital Access to Scholarship at Harvard (DASH) (Harvard University)",null,"10.53901/tjbs.2024.03.art03","https://doi.org/10.53901/tjbs.2024.03.art03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045810","R0045810.pdf","paywalled","systematic_review","Spyridon Peppas","2024","S918 The Impact of GLP-1 Receptor Agonists on Upper and Lower GI Endoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033040.94957.e9","https://doi.org/10.14309/01.ajg.0001033040.94957.e9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045998","R0045998.pdf","paywalled","systematic_review","do Nascimento, Tatiana S.","2024","Additional file 1 of The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.26752558","https://doi.org/10.6084/m9.figshare.26752558",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046147","R0046147.pdf","paywalled","systematic_review","Nazanin Mozaffari","2024","Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials","PharmaNutrition","Elsevier BV","10.1016/j.phanu.2024.100409","https://doi.org/10.1016/j.phanu.2024.100409",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046182","R0046182.pdf","paywalled","systematic_review","Nancy Nakhoul","2024","Abstract #1902451 The Efficacy of Glucagon-Like Peptide-1 Receptor Agonists as Adjunct Therapy to Insulin in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.09.044","https://doi.org/10.1016/j.eprac.2024.09.044",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046215","R0046215.pdf","paywalled","systematic_review","FARDAD MOSHTAGH SISAN","2024","Evaluating the Pulmonary Impact of Semaglutide in Patients With Diabetes: A Meta-analysis of Randomized Clinical Trials",null,"American Thoracic Society","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5957","https://doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5957",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046434","R0046434.pdf","paywalled","systematic_review","YUHANG MA","2024","937-P: Efficacy and Safety of SGLT2i vs. Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes—A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db24-937-p","https://doi.org/10.2337/db24-937-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046757","R0046757.pdf","paywalled","systematic_review","Jacob Itkin","2024","S2328 The Effect of GLP-1 RA Use on Gastric Emptying and Gastroparesis Symptoms in Patients With Diabetic Gastroparesis: A Systematic Review","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038680.08387.b9","https://doi.org/10.14309/01.ajg.0001038680.08387.b9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046934","R0046934.pdf","paywalled","systematic_review","Abdulrhman M. Khaity","2024","SEMAGLUTIDE IN OBESE PATIENTS: AN UPDATED META-ANALYSIS OF 11930 PATIENTS","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2024.118709","https://doi.org/10.1016/j.atherosclerosis.2024.118709",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046965","R0046965.pdf","paywalled","systematic_review","Jena Velji-Ibrahim","2024","Sa1953 COMPARATIVE EFFECTIVENESS OF GLP-1 AGONISTS FOR OBESITY MANAGEMENT IN ADULTS WITHOUT DIABETES: A NETWORK META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01830-4","https://doi.org/10.1016/s0016-5085(24)01830-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046966","R0046966.pdf","paywalled","systematic_review","Mahmoud Mahdi","2024","S1981 A Systematic Review Comparing GLP-Agonists and Resmetirom for Improving Fibrosis among Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037292.83414.fb","https://doi.org/10.14309/01.ajg.0001037292.83414.fb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047464","R0047464.pdf","paywalled","systematic_review","Raj H. Patel","2024","Mo1942 ASSESSING THE IMPACT OF GLP-1 AGONISTS ON WEIGHT REGAIN FOR POST-BARIATRIC SURGERY PATIENTS: A SYSTEMATIC REVIEW","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)03177-9","https://doi.org/10.1016/s0016-5085(24)03177-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047792","R0047792.pdf","paywalled","systematic_review","Dimitrios Patoulias","2024","EFFECT OF TIRZEPATIDE ON OFFICE BLOOD PRESSURE LEVELS IN OVERWEIGHT OR OBESE INDIVIDUALS WITHOUT TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001021832.58477.b1","https://doi.org/10.1097/01.hjh.0001021832.58477.b1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048361","R0048361.pdf","paywalled","systematic_review","Masayuki Akabane","2024","Abstract 4145254: Effects Of Semaglutide On Safety Outcomes In Patients With Type 2 Diabetes Mellitus And High Cardiovascular Risk: A Meta-Analysis Of Randomized Controlled Trials And Systematic Review","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145254","https://doi.org/10.1161/circ.150.suppl_1.4145254",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048453","R0048453.pdf","paywalled","systematic_review","Nihal Ijaz I. Khan","2024","S2085 Comparing the Efficacy of Endoscopic Bariatric Interventions and GLP-1 Agonists to Endoscopic Bariatric Interventions Alone in Weight Loss; A Systematic Review and Meta-analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037708.99179.76","https://doi.org/10.14309/01.ajg.0001037708.99179.76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048694","R0048694.pdf","paywalled","systematic_review","Eleazar Enrique. Montalvan-Sanchez","2024","S893 The Impact of GLP-1 Receptor Agonists on Retained Gastric Contents, Aborted Procedures, and Aspiration During Esophagogastroduodenoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032940.79412.4b","https://doi.org/10.14309/01.ajg.0001032940.79412.4b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048950","R0048950.pdf","paywalled","systematic_review","G Costa","2024","Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.442","https://doi.org/10.1093/eurheartj/ehae666.442",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048997","R0048997.pdf","paywalled","systematic_review","Maneeth Mylavarapu","2024","Abstract 4143622: Efficacy of Semaglutide in Patients with Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review&Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4143622","https://doi.org/10.1161/circ.150.suppl_1.4143622",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049246","R0049246.pdf","paywalled","systematic_review","Atheer Alshutayli","2024","The effect of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists in nonalcoholic fatty liver disease in type 2 diabetic patients: a systematic review and meta-analysis","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1725216272","https://doi.org/10.24911/ijmdc.51-1725216272",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049336","R0049336.pdf","paywalled","systematic_review","Lizeth Cifuentes","2024","Tu1032 EXAMINING DEMOGRAPHIC DISPARITIES IN RECRUITMENT FOR CLINICAL TRIALS AMONG ADULTS WITH OVERWEIGHT AND OBESITY TREATED WITH GLP-1 RA OR DUAL GIP AND GLP-1 RA: A COMPREHENSIVE SYSTEMATIC REVIEW","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)03276-1","https://doi.org/10.1016/s0016-5085(24)03276-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049986","R0049986.pdf","paywalled","systematic_review","Syed Hamaad Rahman","2024","S349 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001030764.09309.1d","https://doi.org/10.14309/01.ajg.0001030764.09309.1d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050778","R0050778.pdf","paywalled","systematic_review","Syed Hamaad Rahman","2024","S921 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use on Retained Gastric Contents and Adverse Events With Upper Endoscopy: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033052.14494.cb","https://doi.org/10.14309/01.ajg.0001033052.14494.cb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050865","R0050865.pdf","paywalled","systematic_review","Yahya Alsawaf","2024","S848 Perioperative GLP-1 Receptor Agonist Impact on Endoscopy and Colonoscopy Outcomes: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032760.30423.11","https://doi.org/10.14309/01.ajg.0001032760.30423.11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051165","R0051165.pdf","paywalled","systematic_review","M. A. Khan","2024","Abstract 4145358: Cardiovascular Outcomes of Glucagon-Like Peptide 1 Receptor Agonists in Patients with or without Diabetes Mellitus, A Meta-Analysis of Randomized Controlled Trials:","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145358","https://doi.org/10.1161/circ.150.suppl_1.4145358",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051247","R0051247.pdf","paywalled","systematic_review","Anna Jansson","2024","Reporting of dietary intake and dietary quality in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of phase 3 and 4 randomised controlled trials","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.023","https://doi.org/10.1016/j.orcp.2024.09.023",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051278","R0051278.pdf","paywalled","systematic_review","Kaveh Hosseini","2024","Abstract 4139045: Suicide and Self-Harm with GLP-1 Receptor Agonists: A Meta-Analysis of Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4139045","https://doi.org/10.1161/circ.150.suppl_1.4139045",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051400","R0051400.pdf","paywalled","systematic_review","Buse J.B","2024","Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: A meta-analysis of cardiovascular outcome trials in type 2 diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/7330-b938","https://doi.org/10.17615/7330-b938",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051593","R0051593.pdf","paywalled","systematic_review","Luís Lobo","2024","Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2917","https://doi.org/10.1093/eurheartj/ehae666.2917",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051812","R0051812.pdf","paywalled","systematic_review","Muhammad Aaqib Shamim","2024","802-P: A New Dawn beyond Basal Insulin? Dose-Response Meta-analysis for Efficacy and Safety of Tirzepatide Compared with Basal Insulin in Uncontrolled Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db24-802-p","https://doi.org/10.2337/db24-802-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42023450278"],["3","R0051864","R0051864.pdf","paywalled","systematic_review","Daryl Ramai","2024","S877 Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis of 84,065 Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032876.50941.e0","https://doi.org/10.14309/01.ajg.0001032876.50941.e0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051899","R0051899.pdf","paywalled","systematic_review","Dimitrios Patoulias","2024","EFFECT OF GLP-1 RECEPTOR AGONISTS ON OFFICE BLOOD PRESSURE LEVELS AMONG OVERWEIGHT OR OBESE SUBJECTS TREATED WITH ANTIPSYCHOTIC DRUGS: A META-ANALYSIS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001021828.69534.09","https://doi.org/10.1097/01.hjh.0001021828.69534.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051919","R0051919.pdf","paywalled","systematic_review","Zina Otmani","2024","SEMAGLUTIDE AND HEART FAILURE IN DIABETIC PATIENTS: A META-ANALYSIS","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2024.118835","https://doi.org/10.1016/j.atherosclerosis.2024.118835",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051951","R0051951.pdf","paywalled","systematic_review","Cecelia Barry","2024","Efficacy and Safety of Novel Diabetes Drugs for Stroke Prevention: Systematic Review, Meta-analysis, and Meta-regression (P1-5.017)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000205339","https://doi.org/10.1212/wnl.0000000000205339",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052320","R0052320.pdf","paywalled","systematic_review","Lizeth Cifuentes","2024","S2114 Association of GLP-1 RA Or Dual GIP and GLP-1 RA for Obesity And Gastrointestinal Adverse Events: A Systematic Review","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037824.19003.ab","https://doi.org/10.14309/01.ajg.0001037824.19003.ab",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42023458537"],["3","R0052507","R0052507.pdf","paywalled","systematic_review","Muhammad Aaqib Shamim","2024","801-P: TRIM—Teen Obesity and GLP-1 Receptor Agonists—Insights from a Systematic Review, Meta-analysis, and Drug-Wise Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db24-801-p","https://doi.org/10.2337/db24-801-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052808","R0052808.pdf","paywalled","systematic_review","Mahmoud Mahdi","2024","Su1568 A SYSTEMATIC REVIEW ON THE IMPACT OF GLP-1 AGONISTS ON NAFLD: A PROMISING NNT THAT CALLS FOR EARLY SCREENING AND TREATMENT","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)04237-9","https://doi.org/10.1016/s0016-5085(24)04237-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052973","R0052973.pdf","paywalled","systematic_review","Dimitrios Patoulias","2024","EFFECT OF SEMAGLUTIDE VERSUS OTHER GLP-1 RECEPTOR AGONISTS ON OFFICE BLOOD PRESSURE LEVELS AMONG SUBJECTS WITH TYPE 2 DIABETES: A META-ANALYSIS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001020820.64485.c0","https://doi.org/10.1097/01.hjh.0001020820.64485.c0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052974","R0052974.pdf","paywalled","systematic_review","Asma Mousavi","2024","Abstract 4140276: Safety, Efficacy and Cardiovascular Benefits of Combination Therapy with Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4140276","https://doi.org/10.1161/circ.150.suppl_1.4140276",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053134","R0053134.pdf","paywalled","systematic_review","Jena Velji-Ibrahim","2024","S2061 Comparative Efficacy and Safety of Bariatric Surgery, Bariatric Endoscopy, and GLP-1 Receptor Agonists in Obesity Management: A Network Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037612.78551.4e","https://doi.org/10.14309/01.ajg.0001037612.78551.4e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053238","R0053238.pdf","paywalled","systematic_review","Jeffrey Crawford","2024","2066-LB: Potential to Optimize Weight Loss with Enobosarm—Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat","Diabetes","American Diabetes Association","10.2337/db24-2066-lb","https://doi.org/10.2337/db24-2066-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054009","R0054009.pdf","paywalled","systematic_review","Silvia Tempia Valenta","2024","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Current Treatment Options in Psychiatry","Springer Science and Business Media LLC","10.1007/s40501-024-00331-y","https://doi.org/10.1007/s40501-024-00331-y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0002214","R0002214.pdf","paywalled","systematic_review","Jiao X","2023","Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-023-01319-x","https://doi.org/10.1007/s40261-023-01319-x","37938535","https://pubmed.ncbi.nlm.nih.gov/37938535/",null,"PROSPERO:CRD42023413199"],["3","R0002597","R0002597.pdf","paywalled","systematic_review","Alkhezi OS","2023","Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13543","https://doi.org/10.1111/obr.13543","36579723","https://pubmed.ncbi.nlm.nih.gov/36579723/",null,null],["3","R0004087","R0004087.pdf","paywalled","systematic_review","Kan M","2023","Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15219","https://doi.org/10.1111/dom.15219","37529870","https://pubmed.ncbi.nlm.nih.gov/37529870/",null,null],["3","R0004204","R0004204.pdf","paywalled","systematic_review","Kapoor I","2023","GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.","Survey of ophthalmology","Elsevier BV","10.1016/j.survophthal.2023.07.002","https://doi.org/10.1016/j.survophthal.2023.07.002","37454782","https://pubmed.ncbi.nlm.nih.gov/37454782/",null,null],["3","R0004443","R0004443.pdf","paywalled","systematic_review","Wang W","2023","Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3680","https://doi.org/10.1002/dmrr.3680","37356073","https://pubmed.ncbi.nlm.nih.gov/37356073/",null,null],["3","R0004444","R0004444.pdf","paywalled","systematic_review","Watkins AR","2023","Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.","Future cardiology","Informa UK Limited","10.2217/fca-2022-0093","https://doi.org/10.2217/fca-2022-0093","36975720","https://pubmed.ncbi.nlm.nih.gov/36975720/",null,null],["3","R0004705","R0004705.pdf","paywalled","systematic_review","Patoulias D","2023","Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2023.108529","https://doi.org/10.1016/j.jdiacomp.2023.108529","37301063","https://pubmed.ncbi.nlm.nih.gov/37301063/",null,null],["3","R0005013","R0005013.pdf","paywalled","systematic_review","Karakasis P","2023","Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2023.155710","https://doi.org/10.1016/j.metabol.2023.155710","37852529","https://pubmed.ncbi.nlm.nih.gov/37852529/",null,null],["3","R0005068","R0005068.pdf","paywalled","systematic_review","Nreu B","2023","Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.20.03219-8","https://doi.org/10.23736/s2724-6507.20.03219-8","32720500","https://pubmed.ncbi.nlm.nih.gov/32720500/",null,null],["3","R0005342","R0005342.pdf","paywalled","systematic_review","Banerjee M","2023","GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad076","https://doi.org/10.1210/clinem/dgad076","36800286","https://pubmed.ncbi.nlm.nih.gov/36800286/",null,"PROSPERO:CRD42022331547"],["3","R0005405","R0005405.pdf","paywalled","systematic_review","Shridharani SM","2023","The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjad240","https://doi.org/10.1093/asj/sjad240","37493261","https://pubmed.ncbi.nlm.nih.gov/37493261/",null,null],["3","R0005653","R0005653.pdf","paywalled","systematic_review","Obata S","2023","Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials.","Journal of cardiovascular medicine (Hagerstown, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.2459/jcm.0000000000001430","https://doi.org/10.2459/jcm.0000000000001430","36583981","https://pubmed.ncbi.nlm.nih.gov/36583981/",null,null],["3","R0005724","R0005724.pdf","paywalled","systematic_review","Scheen AJ","2023","Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2023.101474","https://doi.org/10.1016/j.diabet.2023.101474","37678760","https://pubmed.ncbi.nlm.nih.gov/37678760/",null,null],["3","R0005780","R0005780.pdf","paywalled","systematic_review","Lavalle Cobo A","2023","Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2023.101940","https://doi.org/10.1016/j.cpcardiol.2023.101940","37422042","https://pubmed.ncbi.nlm.nih.gov/37422042/",null,null],["3","R0006115","R0006115.pdf","paywalled","systematic_review","Merza N","2023","The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2023.101602","https://doi.org/10.1016/j.cpcardiol.2023.101602","36682393","https://pubmed.ncbi.nlm.nih.gov/36682393/",null,null],["3","R0006364","R0006364.pdf","paywalled","systematic_review","Nagendra L","2023","Semaglutide and cancer: A systematic review and meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102834","https://doi.org/10.1016/j.dsx.2023.102834","37531876","https://pubmed.ncbi.nlm.nih.gov/37531876/",null,null],["3","R0006728","R0006728.pdf","paywalled","systematic_review","Tan B","2023","Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-023-01321-5","https://doi.org/10.1038/s41366-023-01321-5","37253796","https://pubmed.ncbi.nlm.nih.gov/37253796/",null,null],["3","R0006863","R0006863.pdf","paywalled","systematic_review","Yang XY","2023","Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202308_33290","https://doi.org/10.26355/eurrev_202308_33290","37606127","https://pubmed.ncbi.nlm.nih.gov/37606127/",null,null],["3","R0007121","R0007121.pdf","paywalled","systematic_review","Zhao H","2023","Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-023-01932-2","https://doi.org/10.1007/s40265-023-01932-2","37639180","https://pubmed.ncbi.nlm.nih.gov/37639180/",null,"PROSPERO:CRD42022357886"],["3","R0007191","R0007191.pdf","paywalled","systematic_review","Boulmpou A","2023","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias.","Acta cardiologica","Informa UK Limited","10.1080/00015385.2022.2087839","https://doi.org/10.1080/00015385.2022.2087839","35699112","https://pubmed.ncbi.nlm.nih.gov/35699112/",null,null],["3","R0007512","R0007512.pdf","paywalled","systematic_review","Diallo A","2023","Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-023-02154-4","https://doi.org/10.1007/s00592-023-02154-4","37439858","https://pubmed.ncbi.nlm.nih.gov/37439858/",null,"PROSPERO:CRD42023400899"],["3","R0007533","R0007533.pdf","paywalled","systematic_review","de Mesquita YLL","2023","Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-023-01337-x","https://doi.org/10.1038/s41366-023-01337-x","37460681","https://pubmed.ncbi.nlm.nih.gov/37460681/",null,"PROSPERO:CRD42022348576"],["3","R0008137","R0008137.pdf","paywalled","systematic_review","Guo N","2023","Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-023-03561-w","https://doi.org/10.1007/s00228-023-03561-w","37682287","https://pubmed.ncbi.nlm.nih.gov/37682287/",null,"PROSPERO:CRD42023429701"],["3","R0008186","R0008186.pdf","paywalled","systematic_review","Hidayat K","2023","A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5550","https://doi.org/10.1002/pds.5550","36224724","https://pubmed.ncbi.nlm.nih.gov/36224724/",null,null],["3","R0008812","R0008812.pdf","paywalled","systematic_review","Sun X","2023","Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence.","Dermatology (Basel, Switzerland)","S. Karger AG","10.1159/000528026","https://doi.org/10.1159/000528026","36623489","https://pubmed.ncbi.nlm.nih.gov/36623489/",null,null],["3","R0009060","R0009060.pdf","paywalled","systematic_review","Yang Q","2023","Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110592","https://doi.org/10.1016/j.diabres.2023.110592","36842477","https://pubmed.ncbi.nlm.nih.gov/36842477/",null,"PROSPERO:CRD42022343601"],["3","R0009856","R0009856.pdf","paywalled","systematic_review","Sabouret P","2023","Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.","Minerva cardiology and angiology","Edizioni Minerva Medica","10.23736/s2724-5683.22.05900-2","https://doi.org/10.23736/s2724-5683.22.05900-2","35195376","https://pubmed.ncbi.nlm.nih.gov/35195376/",null,null],["3","R0010155","R0010155.pdf","paywalled","systematic_review","Ruan Z","2023","Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2023.2174099","https://doi.org/10.1080/17512433.2023.2174099","36706368","https://pubmed.ncbi.nlm.nih.gov/36706368/",null,"PROSPERO:CRD42022306164"],["3","R0011003","R0011003.pdf","paywalled","systematic_review","Forbes AK","2023","Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15111","https://doi.org/10.1111/dom.15111","37202870","https://pubmed.ncbi.nlm.nih.gov/37202870/",null,null],["3","R0011246","R0011246.pdf","paywalled","systematic_review","Kodama S","2023","Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1177/10815589221149188","https://doi.org/10.1177/10815589221149188","36695427","https://pubmed.ncbi.nlm.nih.gov/36695427/",null,null],["3","R0012212","R0012212.pdf","paywalled","systematic_review","Cooper DH","2023","Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.","Journal of psychiatric research","Elsevier BV","10.1016/j.jpsychires.2023.05.041","https://doi.org/10.1016/j.jpsychires.2023.05.041","37331261","https://pubmed.ncbi.nlm.nih.gov/37331261/",null,null],["3","R0013199","R0013199.pdf","paywalled","systematic_review","Jiao R","2023","The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2181693","https://doi.org/10.1080/14656566.2023.2181693","36799287","https://pubmed.ncbi.nlm.nih.gov/36799287/",null,null],["3","R0014319","R0014319.pdf","paywalled","systematic_review","Tian S","2023","Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3673","https://doi.org/10.1002/dmrr.3673","37302139","https://pubmed.ncbi.nlm.nih.gov/37302139/",null,"PROSPERO:CRD42022347280"],["3","R0015557","R0015557.pdf","paywalled","systematic_review","Li A","2023","Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110605","https://doi.org/10.1016/j.diabres.2023.110605","36871874","https://pubmed.ncbi.nlm.nih.gov/36871874/",null,null],["3","R0019116","R0019116.pdf","paywalled","systematic_review","Li J","2023","Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108362","https://doi.org/10.1016/j.jdiacomp.2022.108362","36462459","https://pubmed.ncbi.nlm.nih.gov/36462459/",null,"PROSPERO:CRD42022326382"],["3","R0019414","R0019414.pdf","paywalled","systematic_review","Li Y","2023","Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","European journal of gastroenterology & hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/meg.0000000000002471","https://doi.org/10.1097/meg.0000000000002471","36468565","https://pubmed.ncbi.nlm.nih.gov/36468565/",null,null],["3","R0019593","R0019593.pdf","paywalled","systematic_review","Kanbay M","2023","Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15272","https://doi.org/10.1111/dom.15272","37700437","https://pubmed.ncbi.nlm.nih.gov/37700437/",null,null],["3","R0020390","R0020390.pdf","paywalled","systematic_review","Gou H","2023","Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.","European journal of pediatrics","Springer Science and Business Media LLC","10.1007/s00431-023-05186-8","https://doi.org/10.1007/s00431-023-05186-8","37672063","https://pubmed.ncbi.nlm.nih.gov/37672063/",null,null],["3","R0020738","R0020738.pdf","paywalled","systematic_review","Morsali M","2023","Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2023.06.003","https://doi.org/10.1016/j.clinthera.2023.06.003","37400324","https://pubmed.ncbi.nlm.nih.gov/37400324/",null,null],["3","R0021262","R0021262.pdf","paywalled","systematic_review","Xiao Y","2023","Letter to the Editor regarding \"Semaglutide and cancer: A systematic review and meta-analysis\" by Nagendra L et al.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102895","https://doi.org/10.1016/j.dsx.2023.102895","39491072","https://pubmed.ncbi.nlm.nih.gov/39491072/",null,null],["3","R0021339","R0021339.pdf","paywalled","systematic_review","He F","2023","Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14908","https://doi.org/10.1111/dom.14908","36314246","https://pubmed.ncbi.nlm.nih.gov/36314246/",null,null],["3","R0021383","R0021383.pdf","paywalled","systematic_review","Bandyopadhyay S","2023","Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102849","https://doi.org/10.1016/j.dsx.2023.102849","37717295","https://pubmed.ncbi.nlm.nih.gov/37717295/",null,null],["3","R0022180","R0022180.pdf","paywalled","systematic_review","Long Y","2023","Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.","Irish journal of medical science","Springer Science and Business Media LLC","10.1007/s11845-023-03337-2","https://doi.org/10.1007/s11845-023-03337-2","37036569","https://pubmed.ncbi.nlm.nih.gov/37036569/",null,null],["3","R0023530","R0023530.pdf","paywalled","systematic_review","Kovalic AJ","2023","Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","European journal of gastroenterology & hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/meg.0000000000002463","https://doi.org/10.1097/meg.0000000000002463","36468574","https://pubmed.ncbi.nlm.nih.gov/36468574/",null,null],["3","R0023847","R0023847.pdf","paywalled","systematic_review","Masson R","2023","Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.7325","https://doi.org/10.36849/jdd.7325","37556513","https://pubmed.ncbi.nlm.nih.gov/37556513/",null,null],["3","R0030148","R0030148.pdf","paywalled","systematic_review","Xie Y","2023","Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-023-06965-9","https://doi.org/10.1007/s10072-023-06965-9","37500992","https://pubmed.ncbi.nlm.nih.gov/37500992/",null,null],["3","R0032100","R0032100.pdf","paywalled","systematic_review",null,"2023","Tirzepatide more effective in blood sugar control and weight loss than semaglutide, meta-analysis finds","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2023.1.197201","https://doi.org/10.1211/pj.2023.1.197201",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033908","R0033908.pdf","paywalled","systematic_review","Frutuoso, João Francisco da Cunha","2023","Effectiveness and safety of liraglutide for weight loss failure after bariatric interventions - a systematic review","Universidade do Porto",null,"10.34626/apd3-wq34","https://doi.org/10.34626/apd3-wq34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034306","R0034306.pdf","paywalled","systematic_review","Sharath Kommu","2023","Abstract 13756: The Role of Glucagon Like Peptide-1 Receptor Agonists on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure: A Meta-Analysis From Cardiovascular Outcome Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.13756","https://doi.org/10.1161/circ.148.suppl_1.13756",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034699","R0034699.pdf","paywalled","systematic_review","Sohn, Minji","2023","Additional file 1 of Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","Figshare",null,"10.6084/m9.figshare.23597476","https://doi.org/10.6084/m9.figshare.23597476",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034726","R0034726.pdf","paywalled","systematic_review","Yang Liu","2023","Abstract 13450: Clinical Outcomes With GLP-1 Receptor Agonists in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.13450","https://doi.org/10.1161/circ.148.suppl_1.13450",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034803","R0034803.pdf","paywalled","systematic_review","Giuseppe Lisco","2023","The dual GIP/GLP-1 receptor co-agonist Tirzepatide vs GLP-1 receptor agonists as add-on to basal insulin in uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.90.p61","https://doi.org/10.1530/endoabs.90.p61",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036548","R0036548.pdf","paywalled","systematic_review","Abouelmagd, Alaa Abdrabou","2023","Orforglipron different doses effect on body weight : A systematic review and network meta-analysis of randomized clinical trials","Open Science Framework",null,"10.17605/osf.io/nmaq5","https://doi.org/10.17605/osf.io/nmaq5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036570","R0036570.pdf","paywalled","systematic_review","Areesha Moiz","2023","Efficacy and Safety of Once-Weekly Semaglutide Use for Weight Loss Among Patients without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Open Science Framework",null,"10.17605/osf.io/6g7j4","https://doi.org/10.17605/osf.io/6g7j4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036591","R0036591.pdf","paywalled","systematic_review","Foy, Colleen","2023","Clinical Effects of GLP1RA Based Treatments on DXA-Acquired Musculoskeletal Health Outcomes: A meta-analysis","Open Science Framework",null,"10.17605/osf.io/4yafm","https://doi.org/10.17605/osf.io/4yafm",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036627","R0036627.pdf","paywalled","systematic_review","Yu, Oriana Hoi Yun","2023","Replicating cardiovascular outcome trials for type 2 diabetes using real-world evidence: protocol for a systematic review of observational studies.","Open Science Framework",null,"10.17605/osf.io/g8erw","https://doi.org/10.17605/osf.io/g8erw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036632","R0036632.pdf","paywalled","systematic_review","Alwafi, Hassan","2023","UntitledThe safety of glp-1 agonists in patients with type 2 diabetes and patients with obesity, a systematic review","Open Science Framework",null,"10.17605/osf.io/58vd7","https://doi.org/10.17605/osf.io/58vd7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036674","R0036674.pdf","paywalled","systematic_review","Πανάς, Παντελεήμων Αλέξανδρος Χαράλαμπου","2023","Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on controlled attenuation parameter in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.344903","https://doi.org/10.26262/heal.auth.ir.344903",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036802","R0036802.pdf","paywalled","systematic_review","Hu, Shanshan","2023","Additional file 1 of Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.24452492","https://doi.org/10.6084/m9.figshare.24452492",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037697","R0037697.pdf","paywalled","systematic_review","Sabran, Mohammad Zuhriansyah","2023","Tirzepatide, Suatu Dual GIP dan GLP1-RA pada Diabetes Mellitus Tipe 2, Efektifkah? : Systematic Review",null,null,"10.13140/rg.2.2.16038.50247","https://doi.org/10.13140/rg.2.2.16038.50247",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037986","R0037986.pdf","paywalled","systematic_review","Salaar Ahmed","2023","The Effect of Tirzepatide on Lipid Metabolism: A Systematic Review and Meta-Analysis",null,null,"10.13140/rg.2.2.18297.03682","https://doi.org/10.13140/rg.2.2.18297.03682",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038678","R0038678.pdf","paywalled","systematic_review","Muhammad, Asif","2023","Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials","Figshare",null,"10.6084/m9.figshare.24597757.v1","https://doi.org/10.6084/m9.figshare.24597757.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038832","R0038832.pdf","paywalled","systematic_review","Kai Zhu","2023","S1562 Efficacy and Safety of Semaglutide in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000955888.05905.21","https://doi.org/10.14309/01.ajg.0000955888.05905.21",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038922","R0038922.pdf","paywalled","systematic_review","Vikash Jaiswal","2023","Abstract 12095: Efficacy, Safety, and Cardio-Protective Effect of GLP-1 Receptor Agonists Among Patients With Diabetes Mellitus: A Meta-Analysis and Meta-Regression","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.12095","https://doi.org/10.1161/circ.148.suppl_1.12095",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041697","R0041697.pdf","paywalled","systematic_review","Minji Sohn","2023","Baseline Body Mass Index anticipating the Efficacy of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: A Meta-analysis Study","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2023.08.012","https://doi.org/10.1016/j.orcp.2023.08.012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041833","R0041833.pdf","paywalled","systematic_review","Saurabh Aggarwal","2023","Effects of Semaglutide on Metabolic Syndrome Parameters in Non-Diabetics: A Meta-analysis of Randomized Controlled Trials","Metabolism","Elsevier BV","10.1016/j.metabol.2023.155462","https://doi.org/10.1016/j.metabol.2023.155462",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043314","R0043314.pdf","paywalled","systematic_review","Shi, L.","2023","Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/0ytp-fq60","https://doi.org/10.17615/0ytp-fq60",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043530","R0043530.pdf","paywalled","systematic_review","Karakasis, Paschalis","2023","Efficacy and safety of oral small-molecule GLP-1RAs in type 2 diabetes mellitus, obesity or both: A systematic review and meta-analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/rmu7q","https://doi.org/10.17605/osf.io/rmu7q",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043733","R0043733.pdf","paywalled","systematic_review","Patoulias, Dimitrios","2023","Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/k3fvx","https://doi.org/10.17605/osf.io/k3fvx",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043905","R0043905.pdf","paywalled","systematic_review","Jean M. Chalhoub","2023","Tu1605 EFFICACY AND SAFETY OF SEMAGLUTIDE IN NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)03453-4","https://doi.org/10.1016/s0016-5085(23)03453-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047249","R0047249.pdf","paywalled","systematic_review","Daniel Robert Quast","2023","Inkretin-basierte Glukose-senkende Therapie versus Basalinsulin: Eine Meta-Analyse klinischer Studien unter Berücksichtigung kürzlich entwickelter GLP-1 Rezeptoragonisten und dem GIP/GLP-1 Rezeptor Co-Agonisten Tirzepatide","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767841","https://doi.org/10.1055/s-0043-1767841",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048089","R0048089.pdf","paywalled","systematic_review","Pajaree Krisanapan","2023","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) Among Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced CKD and ESKD: A Systematic Review and Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1854b","https://doi.org/10.1681/asn.20233411s1854b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42023398452"],["3","R0048421","R0048421.pdf","paywalled","systematic_review","YASMIN L.L. MESQUITA","2023","1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db23-1704-p","https://doi.org/10.2337/db23-1704-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048582","R0048582.pdf","paywalled","systematic_review","Gabriel Torbahn","2023","Pharmakologische Interventionen zum Management von Kindern und Jugendlichen mit Adipositas – ein Update eines Cochrane Reviews mit Metaanalysen","Adipositas - Ursachen Folgeerkrankungen Therapie","Georg Thieme Verlag KG","10.1055/s-0043-1771593","https://doi.org/10.1055/s-0043-1771593",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050113","R0050113.pdf","paywalled","systematic_review","Jena Velji-Ibrahim","2023","S1628 GLP-1 Agonists and Their Efficacy for Weight Loss: Unraveling the Best Option Through Network Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956152.75833.3b","https://doi.org/10.14309/01.ajg.0000956152.75833.3b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050256","R0050256.pdf","paywalled","systematic_review","Areesha Moiz","2023","Abstract 15741: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Individuals With Obesity or Overweight but Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15741","https://doi.org/10.1161/circ.148.suppl_1.15741",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050466","R0050466.pdf","paywalled","systematic_review","Jonathan Vincent Lee","2023","58. Blood Pressure Reduction Effect of Dapagliflozin in Patients with Type 2 Diabetes Mellitus: a Systematic Review","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000935612.24932.1d","https://doi.org/10.1097/01.hjh.0000935612.24932.1d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050616","R0050616.pdf","paywalled","systematic_review","Muhammad Ayyan","2023","S1669 Efficacy and Safety of Tirzepatide for the Management of Obesity in People With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956316.34865.87","https://doi.org/10.14309/01.ajg.0000956316.34865.87",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052142","R0052142.pdf","paywalled","systematic_review","Khushboo Gala","2023","S1658 Use of Antiobesity Medications With Endoscopic Bariatric Therapies: A Systematic Review and Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956272.22940.8a","https://doi.org/10.14309/01.ajg.0000956272.22940.8a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052680","R0052680.pdf","paywalled","systematic_review","HUILIN TANG","2023","484-P: Newer Glucose-Lowering Drugs and Risk of Parkinson’s Disease—A Meta-analysis of Randomized Outcome Trials","Diabetes","American Diabetes Association","10.2337/db23-484-p","https://doi.org/10.2337/db23-484-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0005941","R0005941.pdf","paywalled","systematic_review","Iqbal J","2022","Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13435","https://doi.org/10.1111/obr.13435","35194917","https://pubmed.ncbi.nlm.nih.gov/35194917/",null,null],["3","R0006189","R0006189.pdf","paywalled","systematic_review","Goldenberg RM","2022","Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108285","https://doi.org/10.1016/j.jdiacomp.2022.108285","35998555","https://pubmed.ncbi.nlm.nih.gov/35998555/",null,null],["3","R0006353","R0006353.pdf","paywalled","systematic_review","Scheen AJ","2022","Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2022.101325","https://doi.org/10.1016/j.diabet.2022.101325","35121148","https://pubmed.ncbi.nlm.nih.gov/35121148/",null,null],["3","R0006509","R0006509.pdf","paywalled","systematic_review","Ferrari F","2022","Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-021-00515-4","https://doi.org/10.1007/s40256-021-00515-4","34958423","https://pubmed.ncbi.nlm.nih.gov/34958423/",null,null],["3","R0006762","R0006762.pdf","paywalled","systematic_review","Patoulias D","2022","Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2021.12.040","https://doi.org/10.1016/j.amjcard.2021.12.040","35045931","https://pubmed.ncbi.nlm.nih.gov/35045931/",null,null],["3","R0007060","R0007060.pdf","paywalled","systematic_review","Patoulias D","2022","Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2021.12.001","https://doi.org/10.1016/j.amjcard.2021.12.001","34974899","https://pubmed.ncbi.nlm.nih.gov/34974899/",null,null],["3","R0007252","R0007252.pdf","paywalled","systematic_review","Xu L","2022","Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.11.006","https://doi.org/10.1016/j.pcd.2021.11.006","34953749","https://pubmed.ncbi.nlm.nih.gov/34953749/",null,null],["3","R0007604","R0007604.pdf","paywalled","systematic_review","Yang S","2022","The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-022-01779-z","https://doi.org/10.1007/s40265-022-01779-z","36129662","https://pubmed.ncbi.nlm.nih.gov/36129662/",null,"PROSPERO:CRD42021248314"],["3","R0007716","R0007716.pdf","paywalled","systematic_review","Shetty R","2022","Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102427","https://doi.org/10.1016/j.dsx.2022.102427","35217468","https://pubmed.ncbi.nlm.nih.gov/35217468/",null,null],["3","R0007804","R0007804.pdf","paywalled","systematic_review","Li X","2022","Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2022.101366","https://doi.org/10.1016/j.diabet.2022.101366","35760374","https://pubmed.ncbi.nlm.nih.gov/35760374/",null,null],["3","R0007944","R0007944.pdf","paywalled","systematic_review","Ng CH","2022","Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2021.09.013","https://doi.org/10.1016/j.eprac.2021.09.013","34606980","https://pubmed.ncbi.nlm.nih.gov/34606980/",null,null],["3","R0008141","R0008141.pdf","paywalled","systematic_review","Sarma S","2022","Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23563","https://doi.org/10.1002/oby.23563","36321278","https://pubmed.ncbi.nlm.nih.gov/36321278/",null,null],["3","R0008199","R0008199.pdf","paywalled","systematic_review","Zafar Y","2022","Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2022.101970","https://doi.org/10.1016/j.clinre.2022.101970","35659603","https://pubmed.ncbi.nlm.nih.gov/35659603/",null,null],["3","R0008676","R0008676.pdf","paywalled","systematic_review","Cui H","2022","Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2022.106094","https://doi.org/10.1016/j.phrs.2022.106094","35074527","https://pubmed.ncbi.nlm.nih.gov/35074527/",null,null],["3","R0008695","R0008695.pdf","paywalled","systematic_review","Wang A","2022","Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109080","https://doi.org/10.1016/j.diabres.2021.109080","34626677","https://pubmed.ncbi.nlm.nih.gov/34626677/",null,null],["3","R0008704","R0008704.pdf","paywalled","systematic_review","Simental-Mendía M","2022","Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomized controlled trials.","British journal of clinical pharmacology","Wiley","10.1111/bcp.15304","https://doi.org/10.1111/bcp.15304","35277985","https://pubmed.ncbi.nlm.nih.gov/35277985/",null,null],["3","R0009303","R0009303.pdf","paywalled","systematic_review","Li W","2022","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.","Journal of cardiovascular pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001197","https://doi.org/10.1097/fjc.0000000000001197","34935705","https://pubmed.ncbi.nlm.nih.gov/34935705/",null,null],["3","R0009320","R0009320.pdf","paywalled","systematic_review","Du Y","2022","Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.12.007","https://doi.org/10.1016/j.pcd.2021.12.007","34930687","https://pubmed.ncbi.nlm.nih.gov/34930687/",null,null],["3","R0009360","R0009360.pdf","paywalled","systematic_review","Ruan Z","2022","Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.","Expert review of pharmacoeconomics & outcomes research","Informa UK Limited","10.1080/14737167.2022.2042255","https://doi.org/10.1080/14737167.2022.2042255","35152812","https://pubmed.ncbi.nlm.nih.gov/35152812/",null,null],["3","R0009665","R0009665.pdf","paywalled","systematic_review","Ding C","2022","Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-021-01830-7","https://doi.org/10.1007/s00592-021-01830-7","34988690","https://pubmed.ncbi.nlm.nih.gov/34988690/",null,null],["3","R0009996","R0009996.pdf","paywalled","systematic_review","Wang F","2022","Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-021-01110-w","https://doi.org/10.1007/s40261-021-01110-w","34894326","https://pubmed.ncbi.nlm.nih.gov/34894326/",null,null],["3","R0010121","R0010121.pdf","paywalled","systematic_review","Qiu M","2022","Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwab221","https://doi.org/10.1093/eurjpc/zwab221","34939100","https://pubmed.ncbi.nlm.nih.gov/34939100/",null,null],["3","R0011279","R0011279.pdf","paywalled","systematic_review","Sim R","2022","Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14780","https://doi.org/10.1111/dme.14780","34962662","https://pubmed.ncbi.nlm.nih.gov/34962662/",null,"PROSPERO:CRD42020168322"],["3","R0011429","R0011429.pdf","paywalled","systematic_review","Huang CJ","2022","Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14819","https://doi.org/10.1111/dom.14819","35848464","https://pubmed.ncbi.nlm.nih.gov/35848464/",null,null],["3","R0011784","R0011784.pdf","paywalled","systematic_review","Zheng H","2022","Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3515","https://doi.org/10.1002/dmrr.3515","34951928","https://pubmed.ncbi.nlm.nih.gov/34951928/",null,null],["3","R0012525","R0012525.pdf","paywalled","systematic_review","Berg G","2022","Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102562","https://doi.org/10.1016/j.dsx.2022.102562","35816950","https://pubmed.ncbi.nlm.nih.gov/35816950/",null,null],["3","R0013315","R0013315.pdf","paywalled","systematic_review","Gracia-Ramos AE","2022","Incretin-based therapy for glycemic control of hospitalized patients with type 2 diabetes: a systematic review.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2021.09.003","https://doi.org/10.1016/j.rceng.2021.09.003","34872879","https://pubmed.ncbi.nlm.nih.gov/34872879/",null,null],["3","R0013361","R0013361.pdf","paywalled","systematic_review","Shi Q","2022","Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(21)01640-8","https://doi.org/10.1016/s0140-6736(21)01640-8","34895470","https://pubmed.ncbi.nlm.nih.gov/34895470/",null,"PROSPERO:CRD42021245678"],["3","R0013808","R0013808.pdf","paywalled","systematic_review","Zaazouee MS","2022","Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102511","https://doi.org/10.1016/j.dsx.2022.102511","35623229","https://pubmed.ncbi.nlm.nih.gov/35623229/",null,null],["3","R0015206","R0015206.pdf","paywalled","systematic_review","Chang G","2022","Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.","The Journal of dermatological treatment","Informa UK Limited","10.1080/09546634.2021.1882658","https://doi.org/10.1080/09546634.2021.1882658","33934692","https://pubmed.ncbi.nlm.nih.gov/33934692/",null,null],["3","R0015427","R0015427.pdf","paywalled","systematic_review","Winquist RJ","2022","Cardiovascular effects of GLP-1 receptor agonism.","Advances in pharmacology (San Diego, Calif.)","Elsevier","10.1016/bs.apha.2022.02.005","https://doi.org/10.1016/bs.apha.2022.02.005","35659373","https://pubmed.ncbi.nlm.nih.gov/35659373/",null,null],["3","R0015709","R0015709.pdf","paywalled","systematic_review","Permana H","2022","Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102640","https://doi.org/10.1016/j.dsx.2022.102640","36274410","https://pubmed.ncbi.nlm.nih.gov/36274410/",null,null],["3","R0016879","R0016879.pdf","paywalled","systematic_review","Shibuki K","2022","Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102474","https://doi.org/10.1016/j.dsx.2022.102474","35378386","https://pubmed.ncbi.nlm.nih.gov/35378386/",null,"PROSPERO:CRD42021178888"],["3","R0016883","R0016883.pdf","paywalled","systematic_review","Ng NBH","2022","The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.","Clinical endocrinology","Wiley","10.1111/cen.14583","https://doi.org/10.1111/cen.14583","34448208","https://pubmed.ncbi.nlm.nih.gov/34448208/",null,null],["3","R0017601","R0017601.pdf","paywalled","systematic_review","Zhang X","2022","Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2021.12.007","https://doi.org/10.1016/j.eprac.2021.12.007","34922031","https://pubmed.ncbi.nlm.nih.gov/34922031/",null,null],["3","R0018092","R0018092.pdf","paywalled","systematic_review","Li X","2022","The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review.","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2021-0533","https://doi.org/10.1515/jpem-2021-0533","36315979","https://pubmed.ncbi.nlm.nih.gov/36315979/",null,null],["3","R0019390","R0019390.pdf","paywalled","systematic_review","Zhao G","2022","Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2022.2117152","https://doi.org/10.1080/17512433.2022.2117152","36039827","https://pubmed.ncbi.nlm.nih.gov/36039827/",null,null],["3","R0020082","R0020082.pdf","paywalled","systematic_review","Qiu M","2022","Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-021-03261-3","https://doi.org/10.1007/s00228-021-03261-3","34860262","https://pubmed.ncbi.nlm.nih.gov/34860262/",null,null],["3","R0020776","R0020776.pdf","paywalled","systematic_review","Abdelhaleem IA","2022","Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14602","https://doi.org/10.1111/dom.14602","34766431","https://pubmed.ncbi.nlm.nih.gov/34766431/",null,null],["3","R0021925","R0021925.pdf","paywalled","systematic_review","Lin Q","2022","Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2022.2130760","https://doi.org/10.1080/17512433.2022.2130760","36180402","https://pubmed.ncbi.nlm.nih.gov/36180402/",null,null],["3","R0021969","R0021969.pdf","paywalled","systematic_review","Patoulias D","2022","Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2022.07.003","https://doi.org/10.1016/j.amjcard.2022.07.003","35977865","https://pubmed.ncbi.nlm.nih.gov/35977865/",null,null],["3","R0022275","R0022275.pdf","paywalled","systematic_review","Zhong P","2022","Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-021-02945-1","https://doi.org/10.1007/s12020-021-02945-1","34981419","https://pubmed.ncbi.nlm.nih.gov/34981419/",null,null],["3","R0022599","R0022599.pdf","paywalled","systematic_review","Patoulias D","2022","Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2022.03.042","https://doi.org/10.1016/j.amjcard.2022.03.042","35459459","https://pubmed.ncbi.nlm.nih.gov/35459459/",null,null],["3","R0022789","R0022789.pdf","paywalled","systematic_review","Ge JJ","2022","The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-021-01666-6","https://doi.org/10.1007/s40618-021-01666-6","34455568","https://pubmed.ncbi.nlm.nih.gov/34455568/",null,null],["3","R0022902","R0022902.pdf","paywalled","systematic_review","Patoulias D","2022","Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2022.04.030","https://doi.org/10.1016/j.amjcard.2022.04.030","35599190","https://pubmed.ncbi.nlm.nih.gov/35599190/",null,null],["3","R0023166","R0023166.pdf","paywalled","systematic_review","Tian D","2022","Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.","Minerva medica","Edizioni Minerva Medica","10.23736/s0026-4806.21.07085-3","https://doi.org/10.23736/s0026-4806.21.07085-3","33555153","https://pubmed.ncbi.nlm.nih.gov/33555153/",null,null],["3","R0023225","R0023225.pdf","paywalled","systematic_review","Arastu N","2022","Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.","International journal of clinical pharmacy","Springer Science and Business Media LLC","10.1007/s11096-022-01428-1","https://doi.org/10.1007/s11096-022-01428-1","35715543","https://pubmed.ncbi.nlm.nih.gov/35715543/",null,null],["3","R0023255","R0023255.pdf","paywalled","systematic_review","He K","2022","Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14612","https://doi.org/10.1111/dom.14612","34866313","https://pubmed.ncbi.nlm.nih.gov/34866313/",null,"PROSPERO:CRD42021259374"],["3","R0023312","R0023312.pdf","paywalled","systematic_review","Dutta D","2022","Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102539","https://doi.org/10.1016/j.dsx.2022.102539","35709586","https://pubmed.ncbi.nlm.nih.gov/35709586/",null,null],["3","R0028936","R0028936.pdf","paywalled","systematic_review","Tsai WH","2022","Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.110082","https://doi.org/10.1016/j.diabres.2022.110082","36122867","https://pubmed.ncbi.nlm.nih.gov/36122867/",null,null],["3","R0031244","R0031244.pdf","paywalled","systematic_review","Mohammed Ashraf Ali","2022","Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Greater South Information System",null,"10.60692/jy4g6-nhn57","https://doi.org/10.60692/jy4g6-nhn57",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42021257670"],["3","R0031355","R0031355.pdf","paywalled","systematic_review","Tauqeer Hussain Mallhi","2022","Relationship between the use of drugs and changes in body weight among patients: A systematic review and meta-analysis","Greater South Information System",null,"10.60692/rhss6-a7k83","https://doi.org/10.60692/rhss6-a7k83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032752","R0032752.pdf","paywalled","systematic_review","WEN HSUAN TSAI","2022","181-LB: Fracture Risk of Antidiabetic Agents in Type 2 Diabetes—A Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db22-181-lb","https://doi.org/10.2337/db22-181-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032981","R0032981.pdf","paywalled","systematic_review","HONGWEI CAO","2022","393-P: SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db22-393-p","https://doi.org/10.2337/db22-393-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033003","R0033003.pdf","paywalled","systematic_review","Shohinee Sarma","2022","1433-P: Comparative Weight Loss with GLP-1 Receptor Agonists vs. Bariatric Surgery in Obesity: A Systematic Review and Pair-Wise Meta-analysis","Diabetes","American Diabetes Association","10.2337/db22-1433-p","https://doi.org/10.2337/db22-1433-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034363","R0034363.pdf","paywalled","systematic_review","Ikechukwu R Ogbu","2022","Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonist based on race, ethnicity, and gender: A systematic review and meta-analysis of randomized trials","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.5904341","https://doi.org/10.5281/zenodo.5904341",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034399","R0034399.pdf","paywalled","systematic_review","Ali, Mahmoud M.","2022","Additional file 1 of Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Figshare",null,"10.6084/m9.figshare.19686997","https://doi.org/10.6084/m9.figshare.19686997",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036624","R0036624.pdf","paywalled","systematic_review","Siafis, Spyridon","2022","Antipsychotic-induced metabolic side-effects: a systematic review and meta-analysis of rodent models","Open Science Framework",null,"10.17605/osf.io/m8vc3","https://doi.org/10.17605/osf.io/m8vc3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036653","R0036653.pdf","paywalled","systematic_review","Filion, Kristian","2022","Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Open Science Framework",null,"10.17605/osf.io/epv6t","https://doi.org/10.17605/osf.io/epv6t",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036743","R0036743.pdf","paywalled","systematic_review","Giugliano, Dario","2022","Additional file 1 of The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","Figshare",null,"10.6084/m9.figshare.19373457","https://doi.org/10.6084/m9.figshare.19373457",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039049","R0039049.pdf","paywalled","systematic_review","Pérez Pérez, Diana","2022","Systematic review of the study of cell therapy on pancreatic marker expression for β-cell regeneration.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.7293622","https://doi.org/10.5281/zenodo.7293622",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041525","R0041525.pdf","paywalled","systematic_review","Georg Wolff","2022","Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.2686","https://doi.org/10.1093/eurheartj/ehac544.2686",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041544","R0041544.pdf","paywalled","systematic_review","Manar Ahmed Kamal","2022","Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades","Metabolism","Elsevier BV","10.1016/j.metabol.2021.154997","https://doi.org/10.1016/j.metabol.2021.154997",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041603","R0041603.pdf","paywalled","systematic_review","Manar Ahmed Kamal","2022","Efficacy of Liraglutide Versus Gliclazide in Treatment of Patients with Type II Diabetes Mellitus: Systematic Review and Meta-Analysis","American Heart Journal","Elsevier BV","10.1016/j.ahj.2022.10.016","https://doi.org/10.1016/j.ahj.2022.10.016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041705","R0041705.pdf","paywalled","systematic_review","Ivana Beatrice Paulus","2022","IDF21-0072 Safety and Efficacy of Insulin IGlarLixi versus IDegLira: A Meta-Analysis of Fifteen studies","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2022.109606","https://doi.org/10.1016/j.diabres.2022.109606",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042377","R0042377.pdf","paywalled","systematic_review","Laura Lizeth Trujillo Vargas","2022","Effectiveness and safety of GLP-1 receptor analogues vs. rapid-acting insulin added to basal insulin therapy in patients with type 2 diabetes mellitus: a living systematic review",null,null,"10.17605/osf.io/zvq7c","https://doi.org/10.17605/osf.io/zvq7c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045290","R0045290.pdf","paywalled","systematic_review","Muhammad Usman","2022","Abstract 15922: Effect of Glp-1 Receptor Agonists on Systolic Blood Pressure in Patients With Overweight or Obesity: A Network Meta-Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.15922","https://doi.org/10.1161/circ.146.suppl_1.15922",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046502","R0046502.pdf","paywalled","systematic_review","Zhengrong Ye","2022","The effects and safety of Exenatide on reproductive function in PCOS:A Meta-Analysis",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2022.5.0105","https://doi.org/10.37766/inplasy2022.5.0105",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047086","R0047086.pdf","paywalled","systematic_review","SATORU KODAMA","2022","378-P: Network Meta-analysis of Hypoglycemic Treatment Regimens with Potential Risk of Hypoglycemia in Terms of Glycemic Control and Severe Hypoglycemia","Diabetes","American Diabetes Association","10.2337/db22-378-p","https://doi.org/10.2337/db22-378-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048578","R0048578.pdf","paywalled","systematic_review","Dimitrios Patoulias","2022","CARDIOVASCULAR EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000837316.89812.46","https://doi.org/10.1097/01.hjh.0000837316.89812.46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049667","R0049667.pdf","paywalled","systematic_review","Shota Obata","2022","Abstract 10770: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Patients With or Without Heart Failure: A Meta-Analysis of Randomized Control Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.10770","https://doi.org/10.1161/circ.146.suppl_1.10770",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050723","R0050723.pdf","paywalled","systematic_review","Mark Peter Maskery","2022","033 GLP-1RAs reduce stroke incidence in patients with type 2 diabetes mellitus: a meta-analysis","Journal of Neurology Neurosurgery & Psychiatry","BMJ","10.1136/jnnp-2022-abn.358","https://doi.org/10.1136/jnnp-2022-abn.358",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051325","R0051325.pdf","paywalled","systematic_review","Dimitrios Patoulias","2022","META-ANALYSIS ASSESSING THE IMPACT OF PRIOR HEART FAILURE AND CHRONIC KIDNEY DISEASE ON THE CARDIOVASCULAR EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000837320.01511.6f","https://doi.org/10.1097/01.hjh.0000837320.01511.6f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052144","R0052144.pdf","paywalled","systematic_review","Dimitrios Patoulias","2022","META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000838652.68523.bc","https://doi.org/10.1097/01.hjh.0000838652.68523.bc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04255433"],["3","R0052309","R0052309.pdf","paywalled","systematic_review","Alessandro Villaschi","2022","192 GLP1-RA AND HEART FAILURE-RELATED OUTCOMES IN PATIENTS WITH AND WITHOUT HISTORY OF HEART FAILURE: A SYSTEMATIC REVIEW AND METANALYSIS","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suac121.489","https://doi.org/10.1093/eurheartjsupp/suac121.489",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053381","R0053381.pdf","paywalled","systematic_review","Dimitrios Patoulias","2022","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT DECREASE THE RISK FOR CORONARY REVASCULARIZATION IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000837028.88430.4f","https://doi.org/10.1097/01.hjh.0000837028.88430.4f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053453","R0053453.pdf","paywalled","systematic_review","HUILIN TANG","2022","870-P: Newer Glucose-Lowering Drugs and Risk of Dementia: A Meta-analysis of Cardiovascular Outcome Trials","Diabetes","American Diabetes Association","10.2337/db22-870-p","https://doi.org/10.2337/db22-870-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055432","R0055432.pdf","paywalled","systematic_review","HUILIN TANG","2022","438-P: Cardiorenal Benefits of Newer Glucose-Lowering Drugs by Hispanic Ethnicity: A Meta-analysis of Results from Randomized Outcome Trials in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-438-p","https://doi.org/10.2337/db22-438-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0005633","R0005633.pdf","paywalled","systematic_review","Simental-Mendía LE","2021","Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108899","https://doi.org/10.1016/j.diabres.2021.108899","34098057","https://pubmed.ncbi.nlm.nih.gov/34098057/",null,null],["3","R0005888","R0005888.pdf","paywalled","systematic_review","Qiu M","2021","Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.","Journal of cardiovascular pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000000916","https://doi.org/10.1097/fjc.0000000000000916","33136765","https://pubmed.ncbi.nlm.nih.gov/33136765/",null,null],["3","R0005948","R0005948.pdf","paywalled","systematic_review","Wei XB","2021","Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2020.08.017","https://doi.org/10.1016/j.pcd.2020.08.017","32912710","https://pubmed.ncbi.nlm.nih.gov/32912710/",null,null],["3","R0006126","R0006126.pdf","paywalled","systematic_review","Patoulias D","2021","The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis.","Blood pressure monitoring","Ovid Technologies (Wolters Kluwer Health)","10.1097/mbp.0000000000000537","https://doi.org/10.1097/mbp.0000000000000537","33741774","https://pubmed.ncbi.nlm.nih.gov/33741774/",null,null],["3","R0006299","R0006299.pdf","paywalled","systematic_review","Risebrough NA","2021","Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2021.08.015","https://doi.org/10.1016/j.clinthera.2021.08.015","34728099","https://pubmed.ncbi.nlm.nih.gov/34728099/",null,null],["3","R0006446","R0006446.pdf","paywalled","systematic_review","Xia L","2021","Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108904","https://doi.org/10.1016/j.diabres.2021.108904","34102249","https://pubmed.ncbi.nlm.nih.gov/34102249/",null,null],["3","R0006450","R0006450.pdf","paywalled","systematic_review","Alkhezi OS","2021","Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.04.005","https://doi.org/10.1016/j.pcd.2021.04.005","33926837","https://pubmed.ncbi.nlm.nih.gov/33926837/",null,null],["3","R0006492","R0006492.pdf","paywalled","systematic_review","Lavalle-Cobo A","2021","Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Springer Science and Business Media LLC","10.1007/s40292-021-00479-1","https://doi.org/10.1007/s40292-021-00479-1","34705249","https://pubmed.ncbi.nlm.nih.gov/34705249/",null,"PROSPERO:CRD42021260040"],["3","R0006500","R0006500.pdf","paywalled","systematic_review","Simental-Mendía LE","2021","Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.","British journal of clinical pharmacology","Wiley","10.1111/bcp.14855","https://doi.org/10.1111/bcp.14855","33835520","https://pubmed.ncbi.nlm.nih.gov/33835520/",null,null],["3","R0006502","R0006502.pdf","paywalled","systematic_review","Weeda ER","2021","Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.","International journal of clinical practice","Wiley","10.1111/ijcp.14060","https://doi.org/10.1111/ijcp.14060","33527605","https://pubmed.ncbi.nlm.nih.gov/33527605/",null,null],["3","R0006696","R0006696.pdf","paywalled","systematic_review","Updike WH","2021","Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?","Drugs","Springer Science and Business Media LLC","10.1007/s40265-021-01525-x","https://doi.org/10.1007/s40265-021-01525-x","33929717","https://pubmed.ncbi.nlm.nih.gov/33929717/",null,null],["3","R0006736","R0006736.pdf","paywalled","systematic_review","Ida S","2021","Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-020-09936-w","https://doi.org/10.1007/s10741-020-09936-w","32080782","https://pubmed.ncbi.nlm.nih.gov/32080782/",null,null],["3","R0006993","R0006993.pdf","paywalled","systematic_review","Patoulias D","2021","Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2021.08.009","https://doi.org/10.1016/j.amjcard.2021.08.009","34497008","https://pubmed.ncbi.nlm.nih.gov/34497008/",null,null],["3","R0007148","R0007148.pdf","paywalled","systematic_review","Li L","2021","Meta-Analysis of the Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Patients With Polycystic Ovary Syndrome.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001418","https://doi.org/10.1097/mjt.0000000000001418","34224428","https://pubmed.ncbi.nlm.nih.gov/34224428/",null,null],["3","R0007311","R0007311.pdf","paywalled","systematic_review","Jianping W","2021","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000001556","https://doi.org/10.1097/mcg.0000000000001556","34039937","https://pubmed.ncbi.nlm.nih.gov/34039937/",null,null],["3","R0007570","R0007570.pdf","paywalled","systematic_review","Nowrouzi-Sohrabi P","2021","The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2020.173823","https://doi.org/10.1016/j.ejphar.2020.173823","33352183","https://pubmed.ncbi.nlm.nih.gov/33352183/",null,null],["3","R0007696","R0007696.pdf","paywalled","systematic_review","Li J","2021","Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108656","https://doi.org/10.1016/j.diabres.2021.108656","33434602","https://pubmed.ncbi.nlm.nih.gov/33434602/",null,null],["3","R0007845","R0007845.pdf","paywalled","systematic_review","Baviera M","2021","Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14361","https://doi.org/10.1111/dom.14361","33606897","https://pubmed.ncbi.nlm.nih.gov/33606897/",null,null],["3","R0007960","R0007960.pdf","paywalled","systematic_review","Zafeiropoulos S","2021","Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612827666210119103153","https://doi.org/10.2174/1381612827666210119103153","33463455","https://pubmed.ncbi.nlm.nih.gov/33463455/",null,null],["3","R0008093","R0008093.pdf","paywalled","systematic_review","Dougherty JA","2021","A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028020935105","https://doi.org/10.1177/1060028020935105","32571083","https://pubmed.ncbi.nlm.nih.gov/32571083/",null,null],["3","R0008175","R0008175.pdf","paywalled","systematic_review","Grewal S","2021","Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2021.05.043","https://doi.org/10.1016/j.amjcard.2021.05.043","34266665","https://pubmed.ncbi.nlm.nih.gov/34266665/",null,null],["3","R0008591","R0008591.pdf","paywalled","systematic_review","Karagiannis T","2021","GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108737","https://doi.org/10.1016/j.diabres.2021.108737","33705820","https://pubmed.ncbi.nlm.nih.gov/33705820/",null,null],["3","R0009298","R0009298.pdf","paywalled","systematic_review","Xu J","2021","Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13398","https://doi.org/10.1111/jcpt.13398","33675117","https://pubmed.ncbi.nlm.nih.gov/33675117/",null,null],["3","R0009538","R0009538.pdf","paywalled","systematic_review","Ida S","2021","Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399816666200705210006","https://doi.org/10.2174/1573399816666200705210006","32628589","https://pubmed.ncbi.nlm.nih.gov/32628589/",null,null],["3","R0009674","R0009674.pdf","paywalled","systematic_review","Mishriky BM","2021","Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2020.05.002","https://doi.org/10.1016/j.diabet.2020.05.002","32439471","https://pubmed.ncbi.nlm.nih.gov/32439471/",null,null],["3","R0009979","R0009979.pdf","paywalled","systematic_review","Masson W","2021","Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaa074","https://doi.org/10.1093/eurjpc/zwaa074","33606884","https://pubmed.ncbi.nlm.nih.gov/33606884/",null,null],["3","R0010247","R0010247.pdf","paywalled","systematic_review","Wei JP","2021","Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs.","The clinical respiratory journal","Wiley","10.1111/crj.13372","https://doi.org/10.1111/crj.13372","33825329","https://pubmed.ncbi.nlm.nih.gov/33825329/",null,null],["3","R0010339","R0010339.pdf","paywalled","systematic_review","Wang Y","2021","Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811211035391","https://doi.org/10.1177/02698811211035391","34311625","https://pubmed.ncbi.nlm.nih.gov/34311625/",null,null],["3","R0010366","R0010366.pdf","paywalled","systematic_review","Tsapas A","2021","GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108921","https://doi.org/10.1016/j.diabres.2021.108921","34144086","https://pubmed.ncbi.nlm.nih.gov/34144086/",null,null],["3","R0010898","R0010898.pdf","paywalled","systematic_review","Qiu M","2021","Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107803","https://doi.org/10.1016/j.jdiacomp.2020.107803","33293207","https://pubmed.ncbi.nlm.nih.gov/33293207/",null,null],["3","R0010934","R0010934.pdf","paywalled","systematic_review","Shi W","2021","Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.","Heart rhythm","Elsevier BV","10.1016/j.hrthm.2021.03.007","https://doi.org/10.1016/j.hrthm.2021.03.007","33684547","https://pubmed.ncbi.nlm.nih.gov/33684547/",null,null],["3","R0011028","R0011028.pdf","paywalled","systematic_review","Escobar C","2021","SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14502","https://doi.org/10.1111/dme.14502","33368612","https://pubmed.ncbi.nlm.nih.gov/33368612/",null,null],["3","R0011163","R0011163.pdf","paywalled","systematic_review","Anderson S","2021","Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028020951955","https://doi.org/10.1177/1060028020951955","32795145","https://pubmed.ncbi.nlm.nih.gov/32795145/",null,null],["3","R0011862","R0011862.pdf","paywalled","systematic_review","Ruan Z","2021","The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.","Expert review of pharmacoeconomics & outcomes research","Informa UK Limited","10.1080/14737167.2021.1860022","https://doi.org/10.1080/14737167.2021.1860022","33317348","https://pubmed.ncbi.nlm.nih.gov/33317348/",null,null],["3","R0013030","R0013030.pdf","paywalled","systematic_review","Oikonomaki D","2021","Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108604","https://doi.org/10.1016/j.diabres.2020.108604","33338553","https://pubmed.ncbi.nlm.nih.gov/33338553/",null,null],["3","R0013676","R0013676.pdf","paywalled","systematic_review","Buchan TA","2021","Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.","Heart (British Cardiac Society)","BMJ","10.1136/heartjnl-2021-319243","https://doi.org/10.1136/heartjnl-2021-319243","33833070","https://pubmed.ncbi.nlm.nih.gov/33833070/",null,"PROSPERO:CRD42020168351"],["3","R0015747","R0015747.pdf","paywalled","systematic_review","Shah R","2021","Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.","Clinical endocrinology","Wiley","10.1111/cen.14406","https://doi.org/10.1111/cen.14406","33386617","https://pubmed.ncbi.nlm.nih.gov/33386617/",null,null],["3","R0016670","R0016670.pdf","paywalled","systematic_review","Jia S","2021","Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-020-01542-4","https://doi.org/10.1007/s00592-020-01542-4","32514989","https://pubmed.ncbi.nlm.nih.gov/32514989/",null,null],["3","R0017626","R0017626.pdf","paywalled","systematic_review","Tandon S","2021","The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14221","https://doi.org/10.1111/dom.14221","33026152","https://pubmed.ncbi.nlm.nih.gov/33026152/",null,null],["3","R0017939","R0017939.pdf","paywalled","systematic_review","Tsapas A","2021","Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14451","https://doi.org/10.1111/dom.14451","34047443","https://pubmed.ncbi.nlm.nih.gov/34047443/",null,null],["3","R0020844","R0020844.pdf","paywalled","systematic_review","Avgerinos I","2021","Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14291","https://doi.org/10.1111/dom.14291","33300282","https://pubmed.ncbi.nlm.nih.gov/33300282/",null,null],["3","R0022439","R0022439.pdf","paywalled","systematic_review","Kumar J","2021","Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Elsevier BV","10.1016/j.dld.2020.08.021","https://doi.org/10.1016/j.dld.2020.08.021","32912770","https://pubmed.ncbi.nlm.nih.gov/32912770/",null,null],["3","R0023406","R0023406.pdf","paywalled","systematic_review","Kalogirou MS","2021","Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2020.10.012","https://doi.org/10.1016/j.clinre.2020.10.012","33309563","https://pubmed.ncbi.nlm.nih.gov/33309563/",null,null],["3","R0023488","R0023488.pdf","paywalled","systematic_review","Hamad F","2021","Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399816999200821164129","https://doi.org/10.2174/1573399816999200821164129","32867644","https://pubmed.ncbi.nlm.nih.gov/32867644/",null,null],["3","R0023931","R0023931.pdf","paywalled","systematic_review","Wang L","2021","Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2021.105765","https://doi.org/10.1016/j.phrs.2021.105765","34252552","https://pubmed.ncbi.nlm.nih.gov/34252552/",null,null],["3","R0023947","R0023947.pdf","paywalled","systematic_review",null,"2021","Withdrawal: \"Efficacy and safety of liraglutide 3.0 mg in obese diabetic and non-diabetic patients-A systematic review and meta-analysis of randomised controlled trials\" Mahanjit Konwar, Renju Ravi, Miteshkumar Maurya, Debdipta Bose, Sanjeet kumar Jaiswal.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.14367","https://doi.org/10.1111/ijcp.14367","33998106","https://pubmed.ncbi.nlm.nih.gov/33998106/",null,null],["3","R0024556","R0024556.pdf","paywalled","systematic_review","Subrahmanyan NA","2021","Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/1574886315999200819150544","https://doi.org/10.2174/1574886315999200819150544","32819262","https://pubmed.ncbi.nlm.nih.gov/32819262/",null,null],["3","R0024685","R0024685.pdf","paywalled","systematic_review","Maringwa J","2021","Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.2130","https://doi.org/10.1002/cpt.2130","33280092","https://pubmed.ncbi.nlm.nih.gov/33280092/",null,null],["3","R0025433","R0025433.pdf","paywalled","systematic_review","Mannucci E","2021","Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2020.12.030","https://doi.org/10.1016/j.numecd.2020.12.030","33618919","https://pubmed.ncbi.nlm.nih.gov/33618919/",null,null],["3","R0025525","R0025525.pdf","paywalled","systematic_review","Rados DV","2021","All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108688","https://doi.org/10.1016/j.diabres.2021.108688","33549676","https://pubmed.ncbi.nlm.nih.gov/33549676/",null,"PROSPERO:CRD42018087336"],["3","R0028489","R0028489.pdf","paywalled","systematic_review","Chi CC","2021","Effects of antidiabetic drugs on psoriasis: A meta-analysis.","European journal of clinical investigation","Wiley","10.1111/eci.13377","https://doi.org/10.1111/eci.13377","32914429","https://pubmed.ncbi.nlm.nih.gov/32914429/",null,null],["3","R0029002","R0029002.pdf","paywalled","systematic_review","Qiu M","2021","Comment on \"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies\".","Pharmacological research","Elsevier BV","10.1016/j.phrs.2021.105862","https://doi.org/10.1016/j.phrs.2021.105862","34481073","https://pubmed.ncbi.nlm.nih.gov/34481073/",null,null],["3","R0030586","R0030586.pdf","paywalled","systematic_review","Bruce Soloway","2021","Meta-Analysis Clarifies Differing Benefits and Risks for SGLT-2 Inhibitors and GLP-1 Receptor Agonists","Journal watch",null,"10.1056/nejm-jw.na53083","https://doi.org/10.1056/nejm-jw.na53083",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0031770","R0031770.pdf","paywalled","systematic_review","Manov, Andrey Emanuilov","2021","Comparison of adverse effects among different GLP-1 receptor agonists added to basal insulin, and between GLP-1 receptor agonists and basal insulin versus Basal-plus or basal-bolus insulin in type 2 diabetes: A meta-analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.5030763","https://doi.org/10.5281/zenodo.5030763",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034461","R0034461.pdf","paywalled","systematic_review","Ivana Beatrice Paulus","2021","Safety and Efficacy of Insulin IGlarLixi versus IDegLira: A Meta-Analysis of Fifteen studies",null,"Morressier","10.26226/morressier.617c37317c09fc044a9751b3","https://doi.org/10.26226/morressier.617c37317c09fc044a9751b3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036501","R0036501.pdf","paywalled","systematic_review","Raed Aldahash","2021","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in the Weight Loss Among Obese Individuals: A Systematic Review","Journal of Endocrinology and Metabolism",null,"10.14740/jem.v0i0.745","https://doi.org/10.14740/jem.v0i0.745",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036761","R0036761.pdf","paywalled","systematic_review","Yamada, Takayuki","2021","Additional file 1 of Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","Figshare",null,"10.6084/m9.figshare.13545484","https://doi.org/10.6084/m9.figshare.13545484",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036782","R0036782.pdf","paywalled","systematic_review","Yang, Chen-Yi","2021","Additional file 1 of Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review","Figshare",null,"10.6084/m9.figshare.13612565","https://doi.org/10.6084/m9.figshare.13612565",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037416","R0037416.pdf","paywalled","systematic_review","Of, Adis Journals On Behalf","2021","Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies","Figshare",null,"10.6084/m9.figshare.13667132","https://doi.org/10.6084/m9.figshare.13667132",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038104","R0038104.pdf","paywalled","systematic_review","abdalla, mohammed","2021","Impact of pharmacological Interventions on insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials: supplementary materials","Figshare",null,"10.6084/m9.figshare.14748921","https://doi.org/10.6084/m9.figshare.14748921",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038454","R0038454.pdf","paywalled","systematic_review","Adis Journals On Behalf Of","2021","Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Figshare",null,"10.6084/m9.figshare.14519067","https://doi.org/10.6084/m9.figshare.14519067",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039808","R0039808.pdf","paywalled","systematic_review","Of, Adis Journals On Behalf","2021","Once-Daily Oral Semaglutide Versus Injectable Glp 1 RAs in People With Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-Analysis","Figshare",null,"10.6084/m9.figshare.13953326","https://doi.org/10.6084/m9.figshare.13953326",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042155","R0042155.pdf","paywalled","systematic_review","Alessandro Mantovani","2021","Systematic Review on efficacy of newer antihyperglycemic agents for treatment of NAFLD/NASH",null,null,"10.17605/osf.io/ckphb","https://doi.org/10.17605/osf.io/ckphb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042480","R0042480.pdf","paywalled","systematic_review","Thomas Karagiannis","2021","Tirzepatide for type 2 diabetes. Systematic review and meta-analysis",null,null,"10.17605/osf.io/kjysc","https://doi.org/10.17605/osf.io/kjysc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048489","R0048489.pdf","paywalled","systematic_review","Dimitrios Patoulias","2021","META-ANALYSIS EVALUATING THE RISK OF ATRIAL FIBRILLATION WITH NEWER ANTIDIABETICS ACROSS THE CARDIOVASCULAR AND RENAL OUTCOME TRIALS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000745428.72000.19","https://doi.org/10.1097/01.hjh.0000745428.72000.19",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049711","R0049711.pdf","paywalled","systematic_review","Haoran Peng","2021","Sa378 EFFECTIVENESS OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST IN NON-ALCOHOLIC FATTY LIVER DISEASE WITH COEXISTING TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(21)02737-2","https://doi.org/10.1016/s0016-5085(21)02737-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049922","R0049922.pdf","paywalled","systematic_review","Dimitrios Patoulias","2021","The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2950","https://doi.org/10.1093/eurheartj/ehab724.2950",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050053","R0050053.pdf","paywalled","systematic_review","Philip Home","2021","118-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp: Systematic Review and Indirect Treatment Comparison (ITC)","Diabetes","American Diabetes Association","10.2337/db21-118-lb","https://doi.org/10.2337/db21-118-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051353","R0051353.pdf","paywalled","systematic_review","Dimitrios Patoulias","2021","EFFECT OF A GLP-1 RECEPTOR AGONIST AND SGLT-2 INHIBITOR COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 INHIBITOR ALONE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000746848.72715.67","https://doi.org/10.1097/01.hjh.0000746848.72715.67",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051587","R0051587.pdf","paywalled","systematic_review","Dimitrios Patoulias","2021","UPDATED META-ANALYSIS OF TRIALS ASSESSING THE CARDIOVASCULAR EFFICACY OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN BLACK PATIENTS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000746888.24529.47","https://doi.org/10.1097/01.hjh.0000746888.24529.47",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051845","R0051845.pdf","paywalled","systematic_review","Chloe Wong","2021","Sa375 A META-ANALYSIS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(21)02734-7","https://doi.org/10.1016/s0016-5085(21)02734-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051954","R0051954.pdf","paywalled","systematic_review","Ryan S. Johnson","2021","777-P: Efficacy of SGLT2 Inhibitors and GLP1-Receptor Agonists in Asians with Type 2 Diabetes: A Systemic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db21-777-p","https://doi.org/10.2337/db21-777-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052960","R0052960.pdf","paywalled","systematic_review","Andrey Manov","2021","Comparison of the effect on Hyperglycemia and the Adverse Effects among Different GLP-1 Receptor Agonists Added to Basal Insulin and between GLP-1 Receptor Agonists and Basal Insulin Versus Basal-Plus or Basal-Bolus Insulin in Type 2 Diabetes: A Meta-Analysis","Book Publisher International (a part of SCIENCEDOMAIN International)","Book Publisher International (a part of SCIENCEDOMAIN International)","10.9734/bpi/nfmmr/v10/4105f","https://doi.org/10.9734/bpi/nfmmr/v10/4105f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056961","R0056961.pdf","paywalled","systematic_review","Melo FJ","2021","The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izaa324","https://doi.org/10.1093/ibd/izaa324","33295607","https://pubmed.ncbi.nlm.nih.gov/33295607/",null,null],["3","R0005344","R0005344.pdf","paywalled","systematic_review","Nreu B","2020","Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2020.03.013","https://doi.org/10.1016/j.numecd.2020.03.013","32448716","https://pubmed.ncbi.nlm.nih.gov/32448716/",null,"PROSPERO:CRD42018115577"],["3","R0007302","R0007302.pdf","paywalled","systematic_review","Mantsiou C","2020","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14108","https://doi.org/10.1111/dom.14108","32476254","https://pubmed.ncbi.nlm.nih.gov/32476254/",null,null],["3","R0007505","R0007505.pdf","paywalled","systematic_review","Patoulias D","2020","Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2020.04.001","https://doi.org/10.1016/j.diabet.2020.04.001","32437914","https://pubmed.ncbi.nlm.nih.gov/32437914/",null,null],["3","R0007763","R0007763.pdf","paywalled","systematic_review","Bellastella G","2020","Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.119.027557","https://doi.org/10.1161/strokeaha.119.027557","31813360","https://pubmed.ncbi.nlm.nih.gov/31813360/",null,null],["3","R0008003","R0008003.pdf","paywalled","systematic_review","Qie S","2020","Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-020-02193-9","https://doi.org/10.1007/s12020-020-02193-9","31927749","https://pubmed.ncbi.nlm.nih.gov/31927749/",null,null],["3","R0008009","R0008009.pdf","paywalled","systematic_review","Patoulias D","2020","Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2020.10.004","https://doi.org/10.1016/j.amjcard.2020.10.004","33045202","https://pubmed.ncbi.nlm.nih.gov/33045202/",null,null],["3","R0008226","R0008226.pdf","paywalled","systematic_review","Morieri ML","2020","Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2020.154190","https://doi.org/10.1016/j.metabol.2020.154190","32109448","https://pubmed.ncbi.nlm.nih.gov/32109448/",null,null],["3","R0008269","R0008269.pdf","paywalled","systematic_review","Mannucci E","2020","Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13888","https://doi.org/10.1111/dom.13888","31595657","https://pubmed.ncbi.nlm.nih.gov/31595657/",null,null],["3","R0008336","R0008336.pdf","paywalled","systematic_review","Xu L","2020","Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.","Biomedical and environmental sciences : BES",null,"10.3967/bes2020.005","https://doi.org/10.3967/bes2020.005","32029057","https://pubmed.ncbi.nlm.nih.gov/32029057/",null,null],["3","R0008381","R0008381.pdf","paywalled","systematic_review","Cao C","2020","GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-020-02223-6","https://doi.org/10.1007/s12020-020-02223-6","32103407","https://pubmed.ncbi.nlm.nih.gov/32103407/",null,null],["3","R0008431","R0008431.pdf","paywalled","systematic_review","Jin Y","2020","The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-020-01529-1","https://doi.org/10.1007/s00592-020-01529-1","32300876","https://pubmed.ncbi.nlm.nih.gov/32300876/",null,"PROSPERO:CRD42019138777"],["3","R0009446","R0009446.pdf","paywalled","systematic_review","Tsapas A","2020","Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/m20-0864","https://doi.org/10.7326/m20-0864","32598218","https://pubmed.ncbi.nlm.nih.gov/32598218/",null,"PROSPERO:CRD42019122043"],["3","R0009478","R0009478.pdf","paywalled","systematic_review","Pulipati VP","2020","Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1177/2047487320903638","https://doi.org/10.1177/2047487320903638","32089007","https://pubmed.ncbi.nlm.nih.gov/32089007/",null,null],["3","R0009777","R0009777.pdf","paywalled","systematic_review","Singh AK","2020","Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2020.04.051","https://doi.org/10.1016/j.dsx.2020.04.051","32470852","https://pubmed.ncbi.nlm.nih.gov/32470852/",null,null],["3","R0010007","R0010007.pdf","paywalled","systematic_review","Nreu B","2020","Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108087","https://doi.org/10.1016/j.diabres.2020.108087","32084455","https://pubmed.ncbi.nlm.nih.gov/32084455/",null,null],["3","R0010208","R0010208.pdf","paywalled","systematic_review","Singh AK","2020","Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2020.02.012","https://doi.org/10.1016/j.dsx.2020.02.012","32142999","https://pubmed.ncbi.nlm.nih.gov/32142999/",null,null],["3","R0010668","R0010668.pdf","paywalled","systematic_review","Elnour AA","2020","Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399816666200522214554","https://doi.org/10.2174/1573399816666200522214554","32442089","https://pubmed.ncbi.nlm.nih.gov/32442089/",null,null],["3","R0011059","R0011059.pdf","paywalled","systematic_review","Singh AK","2020","Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2020.1736041","https://doi.org/10.1080/17512433.2020.1736041","32129106","https://pubmed.ncbi.nlm.nih.gov/32129106/",null,null],["3","R0011548","R0011548.pdf","paywalled","systematic_review","Giugliano D","2020","Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14047","https://doi.org/10.1111/dom.14047","32250550","https://pubmed.ncbi.nlm.nih.gov/32250550/",null,null],["3","R0011887","R0011887.pdf","paywalled","systematic_review","Zhou Y","2020","Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3223","https://doi.org/10.1002/dmrr.3223","31642583","https://pubmed.ncbi.nlm.nih.gov/31642583/",null,null],["3","R0011963","R0011963.pdf","paywalled","systematic_review","Yoshida Y","2020","A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-020-1292-5","https://doi.org/10.1007/s11892-020-1292-5","32166504","https://pubmed.ncbi.nlm.nih.gov/32166504/",null,null],["3","R0012189","R0012189.pdf","paywalled","systematic_review","Avgerinos I","2020","Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13899","https://doi.org/10.1111/dom.13899","31637820","https://pubmed.ncbi.nlm.nih.gov/31637820/",null,null],["3","R0013063","R0013063.pdf","paywalled","systematic_review","Schneider R","2020","GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-020-04750-7","https://doi.org/10.1007/s11695-020-04750-7","32500274","https://pubmed.ncbi.nlm.nih.gov/32500274/",null,null],["3","R0013541","R0013541.pdf","paywalled","systematic_review","Katsanos AH","2020","New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.","JAMA neurology","American Medical Association (AMA)","10.1001/jamaneurol.2020.2494","https://doi.org/10.1001/jamaneurol.2020.2494","32716473","https://pubmed.ncbi.nlm.nih.gov/32716473/",null,null],["3","R0014307","R0014307.pdf","paywalled","systematic_review","Zhu J","2020","Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30422-x","https://doi.org/10.1016/s2213-8587(19)30422-x","32006518","https://pubmed.ncbi.nlm.nih.gov/32006518/",null,null],["3","R0014389","R0014389.pdf","paywalled","systematic_review","Lin C","2020","Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-020-02376-4","https://doi.org/10.1007/s12020-020-02376-4","32533507","https://pubmed.ncbi.nlm.nih.gov/32533507/",null,null],["3","R0015710","R0015710.pdf","paywalled","systematic_review","Malhotra K","2020","GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.","Journal of neurology","Springer Science and Business Media LLC","10.1007/s00415-020-09813-4","https://doi.org/10.1007/s00415-020-09813-4","32246253","https://pubmed.ncbi.nlm.nih.gov/32246253/",null,null],["3","R0018914","R0018914.pdf","paywalled","systematic_review","Chewcharat A","2020","Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-020-02520-z","https://doi.org/10.1007/s11255-020-02520-z","32524495","https://pubmed.ncbi.nlm.nih.gov/32524495/",null,null],["3","R0019802","R0019802.pdf","paywalled","systematic_review","Guo M","2020","The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-019-02175-6","https://doi.org/10.1007/s12020-019-02175-6","31900793","https://pubmed.ncbi.nlm.nih.gov/31900793/",null,null],["3","R0022577","R0022577.pdf","paywalled","systematic_review","Fralick M","2020","Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107704","https://doi.org/10.1016/j.jdiacomp.2020.107704","32888788","https://pubmed.ncbi.nlm.nih.gov/32888788/",null,null],["3","R0023194","R0023194.pdf","paywalled","systematic_review","Men P","2020","Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13871","https://doi.org/10.1111/dom.13871","31469217","https://pubmed.ncbi.nlm.nih.gov/31469217/",null,null],["3","R0024111","R0024111.pdf","paywalled","systematic_review","Zhao D","2020","Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.","Clinical and experimental hypertension (New York, N.Y. : 1993)","Informa UK Limited","10.1080/10641963.2019.1676771","https://doi.org/10.1080/10641963.2019.1676771","31610701","https://pubmed.ncbi.nlm.nih.gov/31610701/",null,null],["3","R0024196","R0024196.pdf","paywalled","systematic_review","Dimitrios P","2020","Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399815666190614141918","https://doi.org/10.2174/1573399815666190614141918","31203802","https://pubmed.ncbi.nlm.nih.gov/31203802/",null,null],["3","R0025200","R0025200.pdf","paywalled","systematic_review","Yang X","2020","Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.","Herz","Springer Science and Business Media LLC","10.1007/s00059-018-4748-5","https://doi.org/10.1007/s00059-018-4748-5","30467578","https://pubmed.ncbi.nlm.nih.gov/30467578/",null,null],["3","R0025534","R0025534.pdf","paywalled","systematic_review","Aschner P","2020","Insulin Therapy in Type 2 Diabetes.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001088","https://doi.org/10.1097/mjt.0000000000001088","31567175","https://pubmed.ncbi.nlm.nih.gov/31567175/",null,null],["3","R0026179","R0026179.pdf","paywalled","systematic_review","Khalil H","2020","Pharmacological Treatment for Obesity in Adults: An Umbrella Review.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028019898912","https://doi.org/10.1177/1060028019898912","31958967","https://pubmed.ncbi.nlm.nih.gov/31958967/",null,null],["3","R0026883","R0026883.pdf","paywalled","systematic_review","Ghosh-Swaby OR","2020","Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(20)30038-3","https://doi.org/10.1016/s2213-8587(20)30038-3","32333878","https://pubmed.ncbi.nlm.nih.gov/32333878/",null,null],["3","R0027330","R0027330.pdf","paywalled","systematic_review","Singh AK","2020","Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2020.1698291","https://doi.org/10.1080/17512433.2020.1698291","31770497","https://pubmed.ncbi.nlm.nih.gov/31770497/",null,null],["3","R0028498","R0028498.pdf","paywalled","systematic_review","Berra C","2020","Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2020.105052","https://doi.org/10.1016/j.phrs.2020.105052","32650058","https://pubmed.ncbi.nlm.nih.gov/32650058/",null,null],["3","R0031091","R0031091.pdf","paywalled","systematic_review","Young Ho Lee","2020","The Associations Between Liraglutide and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes : A Meta-analysis","Journal of Korean Society of Health-System Pharmacists",null,"10.32429/jkshp.2020.37.4.006","https://doi.org/10.32429/jkshp.2020.37.4.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0031848","R0031848.pdf","paywalled","systematic_review",null,"2020","CAN PRECAUTIONS BE CONSIDERED IN PRESCRIBING EXENDIN-4 TO DIABETIC PATIENTS?: A SYSTEMATIC META-ANALYSIS","Journal of Xidian University","Engineering Skill Development","10.37896/jxu14.12/029","https://doi.org/10.37896/jxu14.12/029",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033420","R0033420.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 2 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12544994","https://doi.org/10.6084/m9.figshare.12544994",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033585","R0033585.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 1 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12544985","https://doi.org/10.6084/m9.figshare.12544985",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033665","R0033665.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 3 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12545000","https://doi.org/10.6084/m9.figshare.12545000",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033672","R0033672.pdf","paywalled","systematic_review","Chang, Kai-Cheng","2020","Additional file 1 of Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis","Figshare",null,"10.6084/m9.figshare.13076588","https://doi.org/10.6084/m9.figshare.13076588",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033861","R0033861.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 5 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12545018","https://doi.org/10.6084/m9.figshare.12545018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033964","R0033964.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 4 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12545009","https://doi.org/10.6084/m9.figshare.12545009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034020","R0034020.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 7 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12545036","https://doi.org/10.6084/m9.figshare.12545036",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034044","R0034044.pdf","paywalled","systematic_review","Alfayez, Osamah M.","2020","Additional file 6 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Figshare",null,"10.6084/m9.figshare.12545027","https://doi.org/10.6084/m9.figshare.12545027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034262","R0034262.pdf","paywalled","systematic_review","Acharya, Yogesh","2020","Efficacy and safety of basal insulin plus glucagon-like peptide-1 receptor agonist versus basal-bolus insulin in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials",null,null,"10.13140/rg.2.2.15642.47043","https://doi.org/10.13140/rg.2.2.15642.47043",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034805","R0034805.pdf","paywalled","systematic_review","Osamah M. Alfayez","2020","974-P: Network Meta-analysis of Once Weekly Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Cardiovascular Safety and Mortality","Diabetes","American Diabetes Association","10.2337/db20-974-p","https://doi.org/10.2337/db20-974-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036661","R0036661.pdf","paywalled","systematic_review","Pare, Aurelie","2020","The Use of GLP-1 Agonists Following Bariatric Surgery: A Systematic Review","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/rwv9z","https://doi.org/10.17605/osf.io/rwv9z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036680","R0036680.pdf","paywalled","systematic_review","Mantovani, Alessandro","2020","GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: An updated meta-analysis of RCTs","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/qtuc7","https://doi.org/10.17605/osf.io/qtuc7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039304","R0039304.pdf","paywalled","systematic_review","Osamah M. Alfayez","2020","445-P: Network Meta-analysis of Seven Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Cardiovascular Outcome Trials Data","Diabetes","American Diabetes Association","10.2337/db20-445-p","https://doi.org/10.2337/db20-445-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042354","R0042354.pdf","paywalled","systematic_review","NING DING","2020","Acupuncture for patients with GLP-1 RAs-induced nausea and vomiting: a systematic review protocol",null,null,"10.17605/osf.io/3fgu8","https://doi.org/10.17605/osf.io/3fgu8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042438","R0042438.pdf","paywalled","systematic_review","Stefanos Zafeiropoulos","2020","Cardio-protective effects of glucagon-like peptide-1 receptor agonists: An overview of systematic reviews",null,null,"10.17605/osf.io/tprvn","https://doi.org/10.17605/osf.io/tprvn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042485","R0042485.pdf","paywalled","systematic_review","Paulo Victor dos Santos Lima Paim","2020","EFFICACY OF GLP-1 RECEPTOR ANALOGS IN NON-ALCOHOLIC FAT LIVER DISEASE: A SYSTEMATIC REVIEW",null,null,"10.17605/osf.io/3b7um","https://doi.org/10.17605/osf.io/3b7um",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043426","R0043426.pdf","paywalled","systematic_review","Sooyeun Choi","2020","Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/32vd-ce81","https://doi.org/10.17615/32vd-ce81",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046208","R0046208.pdf","paywalled","systematic_review","Simin Fan","2020","Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: a protocol for a systematic review and meta-analysis",null,"INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols","10.37766/inplasy2020.5.0045","https://doi.org/10.37766/inplasy2020.5.0045",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049538","R0049538.pdf","paywalled","systematic_review","D.N Afaga","2020","Glucagon-like peptide-1 receptor agonists (GLP-1 RA) as adjunct to standard treatment in diabetic patients with chronic heart failure: a systematic review & meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/ehjci/ehaa946.1046","https://doi.org/10.1093/ehjci/ehaa946.1046",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049779","R0049779.pdf","paywalled","systematic_review","Theodora Oikonomaki","2020","P1014INCRETIN BASED THERAPIES IN DIABETIC KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa142.p1014","https://doi.org/10.1093/ndt/gfaa142.p1014",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049935","R0049935.pdf","paywalled","systematic_review","Jason T. Alexander","2020","420-P: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db20-420-p","https://doi.org/10.2337/db20-420-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053460","R0053460.pdf","paywalled","systematic_review","Christine G. Lee","2020","The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?","Annals of Internal Medicine","American College of Physicians","10.7326/m20-4266","https://doi.org/10.7326/m20-4266","32598225","https://pubmed.ncbi.nlm.nih.gov/32598225/",null,null],["3","R0054346","R0054346.pdf","paywalled","systematic_review","Takayuki Yamada","2020","Cardiovascular Outcomes with SGLT-2 Inhibitors vs. GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and CKD: A Systematic Review and Network Meta-Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1346c","https://doi.org/10.1681/asn.20203110s1346c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0007914","R0007914.pdf","paywalled","systematic_review","Patoulias D","2019","Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.107927","https://doi.org/10.1016/j.diabres.2019.107927","31733280","https://pubmed.ncbi.nlm.nih.gov/31733280/",null,null],["3","R0008058","R0008058.pdf","paywalled","systematic_review","Mishriky BM","2019","Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2018.09.002","https://doi.org/10.1016/j.diabet.2018.09.002","30243806","https://pubmed.ncbi.nlm.nih.gov/30243806/",null,null],["3","R0008067","R0008067.pdf","paywalled","systematic_review","Siskind D","2019","Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13522","https://doi.org/10.1111/dom.13522","30187620","https://pubmed.ncbi.nlm.nih.gov/30187620/",null,null],["3","R0008519","R0008519.pdf","paywalled","systematic_review","Cheng L","2019","Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3168","https://doi.org/10.1002/dmrr.3168","30974033","https://pubmed.ncbi.nlm.nih.gov/30974033/",null,null],["3","R0008562","R0008562.pdf","paywalled","systematic_review","Giugliano D","2019","GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13847","https://doi.org/10.1111/dom.13847","31373167","https://pubmed.ncbi.nlm.nih.gov/31373167/",null,null],["3","R0009073","R0009073.pdf","paywalled","systematic_review","Wu S","2019","The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13613","https://doi.org/10.1111/dom.13613","30536884","https://pubmed.ncbi.nlm.nih.gov/30536884/",null,null],["3","R0009239","R0009239.pdf","paywalled","systematic_review","Avgerinos I","2019","Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13484","https://doi.org/10.1111/dom.13484","30058208","https://pubmed.ncbi.nlm.nih.gov/30058208/",null,null],["3","R0009361","R0009361.pdf","paywalled","systematic_review","Alfayez OM","2019","Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2019.04.003","https://doi.org/10.1016/j.jcjd.2019.04.003","31175007","https://pubmed.ncbi.nlm.nih.gov/31175007/",null,null],["3","R0009983","R0009983.pdf","paywalled","systematic_review","Hidayat K","2019","Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Springer Science and Business Media LLC","10.1007/s00198-019-04968-x","https://doi.org/10.1007/s00198-019-04968-x","31134305","https://pubmed.ncbi.nlm.nih.gov/31134305/",null,null],["3","R0010681","R0010681.pdf","paywalled","systematic_review","Barkas F","2019","Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.","European journal of neurology","Wiley","10.1111/ene.13905","https://doi.org/10.1111/ene.13905","30629331","https://pubmed.ncbi.nlm.nih.gov/30629331/",null,null],["3","R0010723","R0010723.pdf","paywalled","systematic_review","Maloney A","2019","A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.1307","https://doi.org/10.1002/cpt.1307","30457671","https://pubmed.ncbi.nlm.nih.gov/30457671/",null,null],["3","R0011313","R0011313.pdf","paywalled","systematic_review","Mishriky BM","2019","Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13805","https://doi.org/10.1111/dom.13805","31168889","https://pubmed.ncbi.nlm.nih.gov/31168889/",null,null],["3","R0011601","R0011601.pdf","paywalled","systematic_review","Maiorino MI","2019","The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.06.009","https://doi.org/10.1016/j.diabres.2019.06.009","31238059","https://pubmed.ncbi.nlm.nih.gov/31238059/",null,null],["3","R0011749","R0011749.pdf","paywalled","systematic_review","Castellana M","2019","GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3082","https://doi.org/10.1002/dmrr.3082","30270567","https://pubmed.ncbi.nlm.nih.gov/30270567/",null,"PROSPERO:CRD42017079547"],["3","R0011826","R0011826.pdf","paywalled","systematic_review","Giugliano D","2019","Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-019-01931-y","https://doi.org/10.1007/s12020-019-01931-y","31028667","https://pubmed.ncbi.nlm.nih.gov/31028667/",null,null],["3","R0013197","R0013197.pdf","paywalled","systematic_review","Giugliano D","2019","Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-019-01047-0","https://doi.org/10.1007/s40618-019-01047-0","30955180","https://pubmed.ncbi.nlm.nih.gov/30955180/",null,null],["3","R0013249","R0013249.pdf","paywalled","systematic_review","Cao C","2019","GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-019-02055-z","https://doi.org/10.1007/s12020-019-02055-z","31420784","https://pubmed.ncbi.nlm.nih.gov/31420784/",null,null],["3","R0016207","R0016207.pdf","paywalled","systematic_review","Wang H","2019","Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2019.01.001","https://doi.org/10.1016/j.clinthera.2019.01.001","30711143","https://pubmed.ncbi.nlm.nih.gov/30711143/",null,"PROSPERO:CRD42018089761"],["3","R0016841","R0016841.pdf","paywalled","systematic_review","Han Y","2019","GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.","Reproductive biomedicine online","Elsevier BV","10.1016/j.rbmo.2019.04.017","https://doi.org/10.1016/j.rbmo.2019.04.017","31229399","https://pubmed.ncbi.nlm.nih.gov/31229399/",null,null],["3","R0017002","R0017002.pdf","paywalled","systematic_review","Zelniker TA","2019","Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.038868","https://doi.org/10.1161/circulationaha.118.038868","30786725","https://pubmed.ncbi.nlm.nih.gov/30786725/",null,null],["3","R0018435","R0018435.pdf","paywalled","systematic_review","Bonora BM","2019","Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-019-01347-0","https://doi.org/10.1007/s00592-019-01347-0","30993527","https://pubmed.ncbi.nlm.nih.gov/30993527/",null,null],["3","R0020692","R0020692.pdf","paywalled","systematic_review","Alfayez OM","2019","Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2019.01.003","https://doi.org/10.1016/j.pcd.2019.01.003","30713085","https://pubmed.ncbi.nlm.nih.gov/30713085/",null,null],["3","R0022947","R0022947.pdf","paywalled","systematic_review","Hong D","2019","Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-019-00774-9","https://doi.org/10.1007/s40273-019-00774-9","30854589","https://pubmed.ncbi.nlm.nih.gov/30854589/",null,null],["3","R0024874","R0024874.pdf","paywalled","systematic_review","Pastor R","2019","Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612825666190701155737","https://doi.org/10.2174/1381612825666190701155737","31267857","https://pubmed.ncbi.nlm.nih.gov/31267857/",null,null],["3","R0025165","R0025165.pdf","paywalled","systematic_review","Peng Y","2019","Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.","Journal of cellular physiology","Wiley","10.1002/jcp.27097","https://doi.org/10.1002/jcp.27097","30145806","https://pubmed.ncbi.nlm.nih.gov/30145806/",null,null],["3","R0025436","R0025436.pdf","paywalled","systematic_review","Rashid F","2019","A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2019.02.005","https://doi.org/10.1016/j.dsx.2019.02.005","31336501","https://pubmed.ncbi.nlm.nih.gov/31336501/",null,null],["3","R0026671","R0026671.pdf","paywalled","systematic_review","Pozzi M","2019","A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on \"Translational and Neuroscience Studies in Affective Disorders\". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2019.05.044","https://doi.org/10.1016/j.jad.2019.05.044","31153593","https://pubmed.ncbi.nlm.nih.gov/31153593/",null,null],["3","R0026683","R0026683.pdf","paywalled","systematic_review","Finkelstein EA","2019","Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.","Clinical obesity","Wiley","10.1111/cob.12294","https://doi.org/10.1111/cob.12294","30677252","https://pubmed.ncbi.nlm.nih.gov/30677252/",null,null],["3","R0027525","R0027525.pdf","paywalled","systematic_review","Gaisl T","2019","Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis.","Sleep medicine reviews","Elsevier BV","10.1016/j.smrv.2019.04.009","https://doi.org/10.1016/j.smrv.2019.04.009","31075665","https://pubmed.ncbi.nlm.nih.gov/31075665/",null,"PROSPERO:CRD42018086446"],["3","R0027769","R0027769.pdf","paywalled","systematic_review","Billeter AT","2019","Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2019.04.029","https://doi.org/10.1016/j.soard.2019.04.029","31201113","https://pubmed.ncbi.nlm.nih.gov/31201113/",null,null],["3","R0028598","R0028598.pdf","paywalled","systematic_review","Sinha B","2019","Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.02.014","https://doi.org/10.1016/j.diabres.2019.02.014","30794833","https://pubmed.ncbi.nlm.nih.gov/30794833/",null,null],["3","R0028658","R0028658.pdf","paywalled","systematic_review","Rix I","2019","Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.","Clinical physiology and functional imaging","Wiley","10.1111/cpf.12526","https://doi.org/10.1111/cpf.12526","29808958","https://pubmed.ncbi.nlm.nih.gov/29808958/",null,null],["3","R0031917","R0031917.pdf","paywalled","systematic_review","Abd El Aziz","2019","Metaanalyse von direkten Vergleichsstudien zwischen GLP-1 Rezeptor-Agonisten und Insulin in der Therapie des Typ 2 Diabetes","Dokumentenrepositorium der RUB (Ruhr University Bochum)",null,"10.13154/294-6304","https://doi.org/10.13154/294-6304",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032848","R0032848.pdf","paywalled","systematic_review","Yoon Ji Kim","2019","148-LB: Efficacy and Safety of Adding an Oral Hypoglycemic Agent or a GLP-1 Receptor Agonist to Insulin in Patients with Type 1 Diabetes: A Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db19-148-lb","https://doi.org/10.2337/db19-148-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032936","R0032936.pdf","paywalled","systematic_review","Man Guo","2019","2300-PUB: The Efficacy and Safety of Combinations of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db19-2300-pub","https://doi.org/10.2337/db19-2300-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034512","R0034512.pdf","paywalled","systematic_review","Efstratios Koutroumpakis","2019","Abstract P077: Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.139.suppl_1.p077","https://doi.org/10.1161/circ.139.suppl_1.p077",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035024","R0035024.pdf","paywalled","systematic_review","Yi Han","2019","Efficacy and safety of glucagon-like peptide-1 receptor agonists for treating polycystic ovary syndrome: a Meta-analysis","Chin J Reprod Contracep",null,"10.3760/cma.j.issn.2096-2916.2019.02.006","https://doi.org/10.3760/cma.j.issn.2096-2916.2019.02.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036527","R0036527.pdf","paywalled","systematic_review","Δημήτριος Ιωάννη Πατουλιάς","2019","Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.305942","https://doi.org/10.26262/heal.auth.ir.305942",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036605","R0036605.pdf","paywalled","systematic_review","Θεόδωρος Γεωργίου Μιχαηλίδης","2019","The efficacy and safety of liraglutide for the management of obesity in individuals without diabetes: Systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.305898","https://doi.org/10.26262/heal.auth.ir.305898",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036611","R0036611.pdf","paywalled","systematic_review","Καλογήρου, Μαρία-Στυλιανή Βασιλείου","2019","Safety and efficacy of liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.306639","https://doi.org/10.26262/heal.auth.ir.306639",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037334","R0037334.pdf","paywalled","systematic_review","Maskery, Mark P","2019","Glucagon like peptide-1 receptor agonists as neuroprotective agents for stroke: a systematic review of pre-clinical studies",null,null,"10.13140/rg.2.2.32974.00326","https://doi.org/10.13140/rg.2.2.32974.00326",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037712","R0037712.pdf","paywalled","systematic_review","Αγγελούδη, Ελένη Μιχαήλ","2019","Effect of GLP-1 receptor agonists on obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.305070","https://doi.org/10.26262/heal.auth.ir.305070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039886","R0039886.pdf","paywalled","systematic_review","Maskery, Mark P","2019","Systematic review of stroke outcomes during clinical studies of glucagon like peptide-1 receptor agonists (GLP-1RAs)",null,null,"10.13140/rg.2.2.19552.23045","https://doi.org/10.13140/rg.2.2.19552.23045",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042468","R0042468.pdf","paywalled","systematic_review","Chrysanthi Mantsiou","2019","Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/73fj5","https://doi.org/10.17605/osf.io/73fj5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043233","R0043233.pdf","paywalled","systematic_review","Jordan M. Kautz","2019","A systematic review of the efficacy and safety of triple therapy in patients with type 2 diabetes mellitus not achieving target Ale goals despite existing dual therapy (metformin plus a sulfonylurea)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/0965-cd05","https://doi.org/10.17615/0965-cd05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047438","R0047438.pdf","paywalled","systematic_review","Olivia R. Ghosh‐Swaby","2019","4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz745.0117","https://doi.org/10.1093/eurheartj/ehz745.0117",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049739","R0049739.pdf","paywalled","systematic_review","Basem M. Mishriky","2019","242-OR: Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African-American Patients with Type 2 Diabetes? A Meta-analysis","Diabetes","American Diabetes Association","10.2337/db19-242-or","https://doi.org/10.2337/db19-242-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050666","R0050666.pdf","paywalled","systematic_review","Yan Lin","2019","P6268Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz746.0867","https://doi.org/10.1093/eurheartj/ehz746.0867",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052114","R0052114.pdf","paywalled","systematic_review","Alistair Roddick","2019","4111Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz745.0115","https://doi.org/10.1093/eurheartj/ehz745.0115",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052326","R0052326.pdf","paywalled","systematic_review","Fotios Barkas","2019","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes: A Systematic Review And Meta-Analysis","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2019.06.336","https://doi.org/10.1016/j.atherosclerosis.2019.06.336",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0007186","R0007186.pdf","paywalled","systematic_review","Zhang YS","2018","Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Springer Science and Business Media LLC","10.1007/s00198-018-4649-8","https://doi.org/10.1007/s00198-018-4649-8","30083774","https://pubmed.ncbi.nlm.nih.gov/30083774/",null,"PROSPERO:CRD42018094433"],["3","R0007697","R0007697.pdf","paywalled","systematic_review","Peterson SC","2018","Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399813666170414101450","https://doi.org/10.2174/1573399813666170414101450","28413990","https://pubmed.ncbi.nlm.nih.gov/28413990/",null,null],["3","R0008988","R0008988.pdf","paywalled","systematic_review","Maciel MG","2018","The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.05.034","https://doi.org/10.1016/j.diabres.2018.05.034","29857094","https://pubmed.ncbi.nlm.nih.gov/29857094/",null,null],["3","R0009234","R0009234.pdf","paywalled","systematic_review","Waldrop G","2018","Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.08.018","https://doi.org/10.1016/j.jdiacomp.2016.08.018","29074120","https://pubmed.ncbi.nlm.nih.gov/29074120/",null,null],["3","R0010163","R0010163.pdf","paywalled","systematic_review","Andreadis P","2018","Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13361","https://doi.org/10.1111/dom.13361","29756388","https://pubmed.ncbi.nlm.nih.gov/29756388/",null,null],["3","R0010531","R0010531.pdf","paywalled","systematic_review","Jia X","2018","GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-018-6773-2","https://doi.org/10.1007/s10557-018-6773-2","29445896","https://pubmed.ncbi.nlm.nih.gov/29445896/",null,null],["3","R0011773","R0011773.pdf","paywalled","systematic_review","Al Yami MS","2018","Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2018.03.018","https://doi.org/10.1016/j.hlc.2018.03.018","29887418","https://pubmed.ncbi.nlm.nih.gov/29887418/",null,null],["3","R0012991","R0012991.pdf","paywalled","systematic_review","Fei Y","2018","Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2017.12.039","https://doi.org/10.1016/j.ijcard.2017.12.039","29277321","https://pubmed.ncbi.nlm.nih.gov/29277321/",null,null],["3","R0013034","R0013034.pdf","paywalled","systematic_review","Li X","2018","The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-018-1708-z","https://doi.org/10.1007/s12020-018-1708-z","30101378","https://pubmed.ncbi.nlm.nih.gov/30101378/",null,null],["3","R0013240","R0013240.pdf","paywalled","systematic_review","Maiorino MI","2018","Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13343","https://doi.org/10.1111/dom.13343","29732679","https://pubmed.ncbi.nlm.nih.gov/29732679/",null,null],["3","R0020299","R0020299.pdf","paywalled","systematic_review","Okere AN","2018","An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399813666170724113240","https://doi.org/10.2174/1573399813666170724113240","28738763","https://pubmed.ncbi.nlm.nih.gov/28738763/",null,null],["3","R0021037","R0021037.pdf","paywalled","systematic_review","Garg A","2018","Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/1574886313666180601082412","https://doi.org/10.2174/1574886313666180601082412","29852875","https://pubmed.ncbi.nlm.nih.gov/29852875/",null,null],["3","R0021908","R0021908.pdf","paywalled","systematic_review","Bifari F","2018","Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).","Pharmacological research","Elsevier BV","10.1016/j.phrs.2018.09.025","https://doi.org/10.1016/j.phrs.2018.09.025","30359962","https://pubmed.ncbi.nlm.nih.gov/30359962/",null,null],["3","R0022362","R0022362.pdf","paywalled","systematic_review","Raffort J","2018","Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?","Biochimie","Elsevier BV","10.1016/j.biochi.2018.06.026","https://doi.org/10.1016/j.biochi.2018.06.026","30103898","https://pubmed.ncbi.nlm.nih.gov/30103898/",null,null],["3","R0022566","R0022566.pdf","paywalled","systematic_review","Luo Y","2018","The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-018-0707-4","https://doi.org/10.1007/s40261-018-0707-4","30255388","https://pubmed.ncbi.nlm.nih.gov/30255388/",null,null],["3","R0022679","R0022679.pdf","paywalled","systematic_review","Wang Q","2018","Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.06.009","https://doi.org/10.1016/j.diabres.2018.06.009","29935211","https://pubmed.ncbi.nlm.nih.gov/29935211/",null,null],["3","R0025734","R0025734.pdf","paywalled","systematic_review","Avranas K","2018","Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.","Cardiovascular & hematological disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871529x18666180206160838","https://doi.org/10.2174/1871529x18666180206160838","29412124","https://pubmed.ncbi.nlm.nih.gov/29412124/",null,null],["3","R0027481","R0027481.pdf","paywalled","systematic_review","Cao B","2018","Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13373","https://doi.org/10.1111/dom.13373","29790638","https://pubmed.ncbi.nlm.nih.gov/29790638/",null,"PROSPERO:CRD42018085967"],["3","R0028700","R0028700.pdf","paywalled","systematic_review","Campbell JM","2018","Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.","Burns : journal of the International Society for Burn Injuries","Elsevier BV","10.1016/j.burns.2017.09.013","https://doi.org/10.1016/j.burns.2017.09.013","29029859","https://pubmed.ncbi.nlm.nih.gov/29029859/",null,null],["3","R0034269","R0034269.pdf","paywalled","systematic_review","Osamah M. Alfayez","2018","Update in Cardiovascular Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes—A Mixed Treatment Comparison Meta-analysis of Randomized Controlled Trials","Diabetes","American Diabetes Association","10.2337/db18-414-p","https://doi.org/10.2337/db18-414-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034337","R0034337.pdf","paywalled","systematic_review","Li, Ling","2018","Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Open Collections",null,"10.14288/1.0367018","https://doi.org/10.14288/1.0367018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034346","R0034346.pdf","paywalled","systematic_review","Zhang, Xiaowen","2018","Additional file 2: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Figshare",null,"10.6084/m9.figshare.7096853","https://doi.org/10.6084/m9.figshare.7096853",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034637","R0034637.pdf","paywalled","systematic_review","Zhang, Xiaowen","2018","Additional file 1: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Figshare",null,"10.6084/m9.figshare.7096841","https://doi.org/10.6084/m9.figshare.7096841",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034798","R0034798.pdf","paywalled","systematic_review","Zhang, Xiaowen","2018","Additional file 3: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Figshare",null,"10.6084/m9.figshare.7096865","https://doi.org/10.6084/m9.figshare.7096865",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036582","R0036582.pdf","paywalled","systematic_review","Ανδρεάδης, Παναγιώτης Αλέξανδρου","2018","Semaglutide for type 2 diabetes: a systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.299033","https://doi.org/10.26262/heal.auth.ir.299033",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037816","R0037816.pdf","paywalled","systematic_review","Πιέτρη, Αικατερίνη Χρήστου","2018","Weight loss effect of Glucagon-like peptide-1 receptor agonists in obese, non- diabetic patients: A systematic review and meta-analysis","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.298390","https://doi.org/10.26262/heal.auth.ir.298390",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037938","R0037938.pdf","paywalled","systematic_review","Wang, Weihao","2018","Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Figshare",null,"10.6084/m9.figshare.6050624","https://doi.org/10.6084/m9.figshare.6050624",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038022","R0038022.pdf","paywalled","systematic_review","Chen, Han","2018","Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials","Figshare",null,"10.6084/m9.figshare.6210794","https://doi.org/10.6084/m9.figshare.6210794",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038243","R0038243.pdf","paywalled","systematic_review","Shu, Hua","2018","Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis","Figshare",null,"10.6084/m9.figshare.6210710","https://doi.org/10.6084/m9.figshare.6210710",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038266","R0038266.pdf","paywalled","systematic_review","M M Satti","2018","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus—A Systematic Review and Meta-analysis","Diabetes","American Diabetes Association","10.2337/db18-1108-p","https://doi.org/10.2337/db18-1108-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038586","R0038586.pdf","paywalled","systematic_review","Mannucci, Edoardo","2018","Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials","Figshare",null,"10.6084/m9.figshare.6450422","https://doi.org/10.6084/m9.figshare.6450422",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038776","R0038776.pdf","paywalled","systematic_review","G. Lozano-Ortega","2018","Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea","Figshare",null,"10.6084/m9.figshare.6865667","https://doi.org/10.6084/m9.figshare.6865667",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038849","R0038849.pdf","paywalled","systematic_review","Lorenzi, Maria","2018","Liraglutide vs SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis","Figshare",null,"10.6084/m9.figshare.6210485","https://doi.org/10.6084/m9.figshare.6210485",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047627","R0047627.pdf","paywalled","systematic_review","Julio Rosenstock","2018","Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis","Diabetes","American Diabetes Association","10.2337/db18-1081-p","https://doi.org/10.2337/db18-1081-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047973","R0047973.pdf","paywalled","systematic_review","Brenda W. C. Bongaerts","2018","Mortality Risk of Noninsulin Glucose-Lowering Drugs in Type 2 Diabetes—A Network Meta-analysis of Observational Trials","Diabetes","American Diabetes Association","10.2337/db18-1139-p","https://doi.org/10.2337/db18-1139-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048969","R0048969.pdf","paywalled","systematic_review","ANN MARIE MCNEILL","2018","Type 2 Diabetes Mellitus (T2DM) Patients with Inadequate A1C Control on Metformin (MET) + DPP-4i—A Network Meta-analysis (NMA) of the Efficacy and Safety of SGLT2i, GLP-1 Analogs, and Insulin","Diabetes","American Diabetes Association","10.2337/db18-1161-p","https://doi.org/10.2337/db18-1161-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049263","R0049263.pdf","paywalled","systematic_review","Sean L. Zheng","2018","66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of 127,731 individuals",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2018-bcs.66","https://doi.org/10.1136/heartjnl-2018-bcs.66",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051554","R0051554.pdf","paywalled","systematic_review","Alistair Roddick","2018","Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists—A Network Meta-analysis","Diabetes","American Diabetes Association","10.2337/db18-427-p","https://doi.org/10.2337/db18-427-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052885","R0052885.pdf","paywalled","systematic_review","Sean L. Zheng","2018","P2519Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 studies","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p2519","https://doi.org/10.1093/eurheartj/ehy565.p2519",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053141","R0053141.pdf","paywalled","systematic_review","H.J. Milionis","2018","Glucagon-like peptide 1 receptor agonists and protection against stroke: a systematic review and meta-analysis","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2018.06.170","https://doi.org/10.1016/j.atherosclerosis.2018.06.170",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0006973","R0006973.pdf","paywalled","systematic_review","Storgaard H","2017","Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12885","https://doi.org/10.1111/dom.12885","28105738","https://pubmed.ncbi.nlm.nih.gov/28105738/",null,null],["3","R0007009","R0007009.pdf","paywalled","systematic_review","Liakopoulou P","2017","Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-017-1293-6","https://doi.org/10.1007/s12020-017-1293-6","28401444","https://pubmed.ncbi.nlm.nih.gov/28401444/",null,null],["3","R0007416","R0007416.pdf","paywalled","systematic_review","Monami M","2017","Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12926","https://doi.org/10.1111/dom.12926","28244632","https://pubmed.ncbi.nlm.nih.gov/28244632/",null,null],["3","R0007532","R0007532.pdf","paywalled","systematic_review","Dicembrini I","2017","Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-017-1031-9","https://doi.org/10.1007/s00592-017-1031-9","28748377","https://pubmed.ncbi.nlm.nih.gov/28748377/",null,null],["3","R0008100","R0008100.pdf","paywalled","systematic_review","Monami M","2017","Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-017-0698-7","https://doi.org/10.1007/s40618-017-0698-7","28569363","https://pubmed.ncbi.nlm.nih.gov/28569363/",null,null],["3","R0008343","R0008343.pdf","paywalled","systematic_review","Monami M","2017","Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-017-1054-2","https://doi.org/10.1007/s00592-017-1054-2","28932989","https://pubmed.ncbi.nlm.nih.gov/28932989/",null,null],["3","R0008749","R0008749.pdf","paywalled","systematic_review","Monami M","2017","Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2017.03.163","https://doi.org/10.1016/j.ijcard.2017.03.163","28501352","https://pubmed.ncbi.nlm.nih.gov/28501352/",null,null],["3","R0009127","R0009127.pdf","paywalled","systematic_review","Wysham CH","2017","Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2017.1297669","https://doi.org/10.1080/00325481.2017.1297669","28294702","https://pubmed.ncbi.nlm.nih.gov/28294702/",null,null],["3","R0010189","R0010189.pdf","paywalled","systematic_review","Dong Y","2017","Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2016.11.009","https://doi.org/10.1016/j.clinre.2016.11.009","28065744","https://pubmed.ncbi.nlm.nih.gov/28065744/",null,null],["3","R0010330","R0010330.pdf","paywalled","systematic_review","Trujillo JM","2017","Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.","Pharmacotherapy","Wiley","10.1002/phar.1962","https://doi.org/10.1002/phar.1962","28556176","https://pubmed.ncbi.nlm.nih.gov/28556176/",null,null],["3","R0011157","R0011157.pdf","paywalled","systematic_review","Cai X","2017","Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2017.1400011","https://doi.org/10.1080/14656566.2017.1400011","29090600","https://pubmed.ncbi.nlm.nih.gov/29090600/",null,"PROSPERO:CRD42017053952"],["3","R0011638","R0011638.pdf","paywalled","systematic_review","Abd El Aziz MS","2017","A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12804","https://doi.org/10.1111/dom.12804","27717195","https://pubmed.ncbi.nlm.nih.gov/27717195/",null,null],["3","R0012185","R0012185.pdf","paywalled","systematic_review","Maiorino MI","2017","Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Diabetes care","American Diabetes Association","10.2337/dc16-1957","https://doi.org/10.2337/dc16-1957","28325801","https://pubmed.ncbi.nlm.nih.gov/28325801/",null,null],["3","R0012565","R0012565.pdf","paywalled","systematic_review","Broglio F","2017","Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12810","https://doi.org/10.1111/dom.12810","27762096","https://pubmed.ncbi.nlm.nih.gov/27762096/",null,null],["3","R0012882","R0012882.pdf","paywalled","systematic_review","Wu S","2017","Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2017.07.036","https://doi.org/10.1016/j.clinthera.2017.07.036","28827024","https://pubmed.ncbi.nlm.nih.gov/28827024/",null,null],["3","R0014468","R0014468.pdf","paywalled","systematic_review","Raccah D","2017","Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2016.11.007","https://doi.org/10.1016/j.diabet.2016.11.007","28169086","https://pubmed.ncbi.nlm.nih.gov/28169086/",null,null],["3","R0018960","R0018960.pdf","paywalled","systematic_review","Barakat AF","2017","Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2017.01.144","https://doi.org/10.1016/j.ijcard.2017.01.144","28560966","https://pubmed.ncbi.nlm.nih.gov/28560966/",null,null],["3","R0019260","R0019260.pdf","paywalled","systematic_review","Mahmoud AN","2017","Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2016.12.113","https://doi.org/10.1016/j.ijcard.2016.12.113","28043676","https://pubmed.ncbi.nlm.nih.gov/28043676/",null,null],["3","R0020276","R0020276.pdf","paywalled","systematic_review","Yang XL","2017","Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.","Journal of cellular biochemistry","Wiley","10.1002/jcb.26115","https://doi.org/10.1002/jcb.26115","28471499","https://pubmed.ncbi.nlm.nih.gov/28471499/",null,null],["3","R0020983","R0020983.pdf","paywalled","systematic_review","Wang W","2017","Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.05.007","https://doi.org/10.1016/j.diabres.2017.05.007","28552612","https://pubmed.ncbi.nlm.nih.gov/28552612/",null,null],["3","R0023216","R0023216.pdf","paywalled","systematic_review","Gargiulo P","2017","Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2017.09.006","https://doi.org/10.1016/j.numecd.2017.09.006","29113708","https://pubmed.ncbi.nlm.nih.gov/29113708/",null,null],["3","R0026177","R0026177.pdf","paywalled","systematic_review","Ayers D","2017","Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2017.1345730","https://doi.org/10.1080/03007995.2017.1345730","28635331","https://pubmed.ncbi.nlm.nih.gov/28635331/",null,null],["3","R0026524","R0026524.pdf","paywalled","systematic_review","Grenet G","2017","Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design.","Fundamental & clinical pharmacology","Wiley","10.1111/fcp.12263","https://doi.org/10.1111/fcp.12263","28036112","https://pubmed.ncbi.nlm.nih.gov/28036112/",null,null],["3","R0026728","R0026728.pdf","paywalled","systematic_review","Katsi V","2017","Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612823666170519144841","https://doi.org/10.2174/1381612823666170519144841","28741456","https://pubmed.ncbi.nlm.nih.gov/28741456/",null,null],["3","R0027002","R0027002.pdf","paywalled","systematic_review","Wang LG","2017","A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2017.05.002","https://doi.org/10.1016/j.biopha.2017.05.002","28586742","https://pubmed.ncbi.nlm.nih.gov/28586742/",null,null],["3","R0027080","R0027080.pdf","paywalled","systematic_review","Plock N","2017","Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.","Journal of clinical pharmacology","Wiley","10.1002/jcph.781","https://doi.org/10.1002/jcph.781","27277818","https://pubmed.ncbi.nlm.nih.gov/27277818/",null,null],["3","R0030406","R0030406.pdf","paywalled","systematic_review","Neff LM","2017","Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.","Clinical obesity","Wiley","10.1111/cob.12213","https://doi.org/10.1111/cob.12213","28891142","https://pubmed.ncbi.nlm.nih.gov/28891142/",null,null],["3","R0034243","R0034243.pdf","paywalled","systematic_review","Fotios Barkas","2017","GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Atherosclerosis","Morressier","10.26226/morressier.58e389add462b802923855fd","https://doi.org/10.26226/morressier.58e389add462b802923855fd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034534","R0034534.pdf","paywalled","systematic_review","Kanters Steve","2017","Semaglutide is more efficacious than SGLT-2is in patients inadequately controlled on metformin: a network meta-analysis",null,"Morressier","10.26226/morressier.59d51840d462b80296ca2d25","https://doi.org/10.26226/morressier.59d51840d462b80296ca2d25",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034583","R0034583.pdf","paywalled","systematic_review","Kanters Steve","2017","Semaglutide is more efficacious than SGLT-2is in patients inadequately controlled on 1-2 OADs: a network meta-analysis",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3be4","https://doi.org/10.26226/morressier.59d51847d462b80296ca3be4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034620","R0034620.pdf","paywalled","systematic_review","Qing Tian","2017","Incretin drugs and pancreatic cancer risk in patients with type 2 diabetes: Meta-analysis of randomized controlled trials","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2017.12.005","https://doi.org/10.3760/cma.j.issn.1674-5809.2017.12.005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034698","R0034698.pdf","paywalled","systematic_review","Kidd Catherine","2017","Efficacy and safety of fixed-ratio combination of GLP-1 RAs plus basal insulin in T2D: a network meta-analysis",null,"Morressier","10.26226/morressier.59d51845d462b80296ca363c","https://doi.org/10.26226/morressier.59d51845d462b80296ca363c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034767","R0034767.pdf","paywalled","systematic_review","Sayre Tobias","2017","Network meta-analysis of iGlarLixi, a fixed-ratio combination GLP-1 RA and basal insulin, versus insulin premix",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3bc1","https://doi.org/10.26226/morressier.59d51847d462b80296ca3bc1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037643","R0037643.pdf","paywalled","systematic_review","Raju Panta","2017","Abstract #216: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Use of GLP1 Receptor Agonists in Type 1 Diabetes Mellitus","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)44336-8","https://doi.org/10.1016/s1530-891x(20)44336-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038800","R0038800.pdf","paywalled","systematic_review","Ayers, Dieter","2017","Network meta-analysis of liraglutide versus DPP-4 inhibitors for the treatment of Type 2 diabetes in Japanese patients.","Figshare",null,"10.6084/m9.figshare.5132680.v1","https://doi.org/10.6084/m9.figshare.5132680.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044078","R0044078.pdf","paywalled","systematic_review","Filippas-Ntekouan, Sempastian","2017","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes : A Systematic Review And Meta-Analysis","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5cc04c44c66852000b5aee26","https://doi.org/10.26226/morressier.5cc04c44c66852000b5aee26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044156","R0044156.pdf","paywalled","systematic_review","Barkas, Fotios","2017","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke in Patients With Diabetes : a Systematic Review and Meta-Analysis of 5 Randomized Controlled Trials","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5cb58cffc668520010b56f27","https://doi.org/10.26226/morressier.5cb58cffc668520010b56f27",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051982","R0051982.pdf","paywalled","systematic_review","Suetonia C. Palmer","2017","SP427GLUCOSE-LOWERING DRUGS ADDED TO EXISTING THERAPIES AND RISKS OF MORTALITY AND CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES: NETWORK META-ANALYSIS OF RANDOMIZED TRIALS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfx149.sp427","https://doi.org/10.1093/ndt/gfx149.sp427",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0007707","R0007707.pdf","paywalled","systematic_review","Zaccardi F","2016","Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/m15-1432","https://doi.org/10.7326/m15-1432","26642233","https://pubmed.ncbi.nlm.nih.gov/26642233/",null,null],["3","R0007996","R0007996.pdf","paywalled","systematic_review","Guo X","2016","Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-016-0389-8","https://doi.org/10.1007/s40261-016-0389-8","26979594","https://pubmed.ncbi.nlm.nih.gov/26979594/",null,null],["3","R0011592","R0011592.pdf","paywalled","systematic_review","Carbone LJ","2016","Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.13026","https://doi.org/10.1111/jgh.13026","26111358","https://pubmed.ncbi.nlm.nih.gov/26111358/",null,null],["3","R0014469","R0014469.pdf","paywalled","systematic_review","Bihan H","2016","Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2016.08.011","https://doi.org/10.1016/j.diabres.2016.08.011","27622682","https://pubmed.ncbi.nlm.nih.gov/27622682/",null,null],["3","R0014509","R0014509.pdf","paywalled","systematic_review","Tang W","2016","Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2713","https://doi.org/10.1002/dmrr.2713","26381272","https://pubmed.ncbi.nlm.nih.gov/26381272/",null,null],["3","R0017205","R0017205.pdf","paywalled","systematic_review","Zhang X","2016","Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000000782","https://doi.org/10.1097/hjh.0000000000000782","26682782","https://pubmed.ncbi.nlm.nih.gov/26682782/",null,null],["3","R0020758","R0020758.pdf","paywalled","systematic_review","Niafar M","2016","A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.","Archives of gynecology and obstetrics","Springer Science and Business Media LLC","10.1007/s00404-015-3976-7","https://doi.org/10.1007/s00404-015-3976-7","26660657","https://pubmed.ncbi.nlm.nih.gov/26660657/",null,null],["3","R0021100","R0021100.pdf","paywalled","systematic_review","Su N","2016","Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2016.06.028","https://doi.org/10.1016/j.ijcard.2016.06.028","27343423","https://pubmed.ncbi.nlm.nih.gov/27343423/",null,null],["3","R0021500","R0021500.pdf","paywalled","systematic_review","Cimmaruta D","2016","Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2016.1221402","https://doi.org/10.1080/14740338.2016.1221402","27875915","https://pubmed.ncbi.nlm.nih.gov/27875915/",null,null],["3","R0024386","R0024386.pdf","paywalled","systematic_review","Maruthur NM","2016","Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/m15-2650","https://doi.org/10.7326/m15-2650","27088241","https://pubmed.ncbi.nlm.nih.gov/27088241/",null,null],["3","R0024498","R0024498.pdf","paywalled","systematic_review","Lozano-Ortega G","2016","Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2015.1135110","https://doi.org/10.1185/03007995.2015.1135110","26700585","https://pubmed.ncbi.nlm.nih.gov/26700585/",null,null],["3","R0025809","R0025809.pdf","paywalled","systematic_review","Terauchi Y","2016","Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2015.08.008","https://doi.org/10.1016/j.dsx.2015.08.008","26341928","https://pubmed.ncbi.nlm.nih.gov/26341928/",null,null],["3","R0026741","R0026741.pdf","paywalled","systematic_review","Cai X","2016","Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2016.1202921","https://doi.org/10.1080/14656566.2016.1202921","27322963","https://pubmed.ncbi.nlm.nih.gov/27322963/",null,null],["3","R0028804","R0028804.pdf","paywalled","systematic_review","Thompson JC","2016","Importance and methods of searching for E-publications ahead of print in systematic reviews.","Evidence-based medicine","BMJ","10.1136/ebmed-2015-110374","https://doi.org/10.1136/ebmed-2015-110374","26912572","https://pubmed.ncbi.nlm.nih.gov/26912572/",null,null],["3","R0030419","R0030419.pdf","paywalled","systematic_review","Ding S","2016","Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2016.07.199","https://doi.org/10.1016/j.ijcard.2016.07.199","27526367","https://pubmed.ncbi.nlm.nih.gov/27526367/",null,null],["3","R0034264","R0034264.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d1","https://doi.org/10.6084/m9.figshare.c.3633269_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034331","R0034331.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 1: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d6","https://doi.org/10.6084/m9.figshare.c.3633269_d6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034361","R0034361.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 2: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d2","https://doi.org/10.6084/m9.figshare.c.3633269_d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034505","R0034505.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 4: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d7","https://doi.org/10.6084/m9.figshare.c.3633269_d7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034690","R0034690.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 5: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d8","https://doi.org/10.6084/m9.figshare.c.3633269_d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034711","R0034711.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 8: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d5","https://doi.org/10.6084/m9.figshare.c.3633269_d5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034743","R0034743.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 7: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d3","https://doi.org/10.6084/m9.figshare.c.3633269_d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034766","R0034766.pdf","paywalled","systematic_review","Ferdinand, Keith","2016","MOESM1 of Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events","Figshare",null,"10.6084/m9.figshare.c.3608609_d1","https://doi.org/10.6084/m9.figshare.c.3608609_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034802","R0034802.pdf","paywalled","systematic_review","Li, Ling","2016","Additional file 6: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.c.3633269_d4","https://doi.org/10.6084/m9.figshare.c.3633269_d4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036103","R0036103.pdf","paywalled","systematic_review","Mohammed Aziz","2016","Metaanalyse von direkten Vergleichsstudien zwischen Therapie mit GLP-1 Rezeptor-Agonisten oder Insulin: Unterschied für kurz- und lang-wirksame Medikamente?","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1584101","https://doi.org/10.1055/s-0036-1584101",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047255","R0047255.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 7: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430720.v1","https://doi.org/10.6084/m9.figshare.4430720.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047783","R0047783.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 6: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430744.v1","https://doi.org/10.6084/m9.figshare.4430744.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048023","R0048023.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 8: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430768","https://doi.org/10.6084/m9.figshare.4430768",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048712","R0048712.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 4: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430798.v1","https://doi.org/10.6084/m9.figshare.4430798.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050385","R0050385.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430678.v1","https://doi.org/10.6084/m9.figshare.4430678.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050739","R0050739.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 5: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430819.v1","https://doi.org/10.6084/m9.figshare.4430819.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0050890","R0050890.pdf","paywalled","systematic_review","Thomas R. McCarty","2016","Efficacy and Safety of Non-surgical Bariatric Therapies for Non-alcoholic Steatohepatitis and Metabolic Syndrome: A Comparative Meta-Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/00000434-201610001-00844","https://doi.org/10.14309/00000434-201610001-00844",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051417","R0051417.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 2: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430699.v1","https://doi.org/10.6084/m9.figshare.4430699.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051533","R0051533.pdf","paywalled","systematic_review","Ling Li","2016","Additional file 1: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Figshare",null,"10.6084/m9.figshare.4430780","https://doi.org/10.6084/m9.figshare.4430780",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0009301","R0009301.pdf","paywalled","systematic_review","Karagiannis T","2015","Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12541","https://doi.org/10.1111/dom.12541","26395850","https://pubmed.ncbi.nlm.nih.gov/26395850/",null,null],["3","R0010756","R0010756.pdf","paywalled","systematic_review","Su B","2015","Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0361-4","https://doi.org/10.1007/s12020-014-0361-4","25074632","https://pubmed.ncbi.nlm.nih.gov/25074632/",null,null],["3","R0011034","R0011034.pdf","paywalled","systematic_review","Sun F","2015","Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2014.11.008","https://doi.org/10.1016/j.clinthera.2014.11.008","25554560","https://pubmed.ncbi.nlm.nih.gov/25554560/",null,null],["3","R0011091","R0011091.pdf","paywalled","systematic_review","Seshasai SR","2015","Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12448","https://doi.org/10.1111/dom.12448","25656522","https://pubmed.ncbi.nlm.nih.gov/25656522/",null,null],["3","R0011441","R0011441.pdf","paywalled","systematic_review","Sun F","2015","Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0373-0","https://doi.org/10.1007/s12020-014-0373-0","25115635","https://pubmed.ncbi.nlm.nih.gov/25115635/",null,null],["3","R0011644","R0011644.pdf","paywalled","systematic_review","Sun F","2015","Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.07.015","https://doi.org/10.1016/j.diabres.2015.07.015","26358202","https://pubmed.ncbi.nlm.nih.gov/26358202/",null,null],["3","R0013642","R0013642.pdf","paywalled","systematic_review","Zhang F","2015","Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.","Journal of diabetes","Wiley","10.1111/1753-0407.12198","https://doi.org/10.1111/1753-0407.12198","25043423","https://pubmed.ncbi.nlm.nih.gov/25043423/",null,null],["3","R0013981","R0013981.pdf","paywalled","systematic_review","Liu FP","2015","Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.","Journal of diabetes","Wiley","10.1111/1753-0407.12200","https://doi.org/10.1111/1753-0407.12200","25047138","https://pubmed.ncbi.nlm.nih.gov/25047138/",null,null],["3","R0014048","R0014048.pdf","paywalled","systematic_review","Giorda CB","2015","Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0386-8","https://doi.org/10.1007/s12020-014-0386-8","25146552","https://pubmed.ncbi.nlm.nih.gov/25146552/",null,null],["3","R0014419","R0014419.pdf","paywalled","systematic_review","Zhong X","2015","Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.05.048","https://doi.org/10.1016/j.diabres.2015.05.048","26233934","https://pubmed.ncbi.nlm.nih.gov/26233934/",null,null],["3","R0015830","R0015830.pdf","paywalled","systematic_review","Fisher M","2015","Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(15)00233-8","https://doi.org/10.1016/s2213-8587(15)00233-8","26276240","https://pubmed.ncbi.nlm.nih.gov/26276240/",null,null],["3","R0020743","R0020743.pdf","paywalled","systematic_review","Roshanov PS","2015","Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.10.014","https://doi.org/10.1016/j.diabres.2015.10.014","26643128","https://pubmed.ncbi.nlm.nih.gov/26643128/",null,null],["3","R0020753","R0020753.pdf","paywalled","systematic_review","Wang T","2015","Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12386","https://doi.org/10.1111/dom.12386","25200423","https://pubmed.ncbi.nlm.nih.gov/25200423/",null,null],["3","R0025267","R0025267.pdf","paywalled","systematic_review","Gamble JM","2015","Incretin-based medications for type 2 diabetes: an overview of reviews.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12465","https://doi.org/10.1111/dom.12465","25772666","https://pubmed.ncbi.nlm.nih.gov/25772666/",null,"PROSPERO:CRD42013005149"],["3","R0027359","R0027359.pdf","paywalled","systematic_review","Mearns ES","2015","Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12837","https://doi.org/10.1111/dme.12837","26104021","https://pubmed.ncbi.nlm.nih.gov/26104021/",null,null],["3","R0031060","R0031060.pdf","paywalled","systematic_review","Jamaluddin Moloo","2015","Once-Weekly GLP-1 Receptor Agonists Compared: A Network Meta-Analysis","Journal watch",null,"10.1056/nejm-jw.na39810","https://doi.org/10.1056/nejm-jw.na39810",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033416","R0033416.pdf","paywalled","systematic_review","Dooley, Gordon","2015","Incretin-based therapies and bone fractures in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","York",null,"10.15124/crd42015020399","https://doi.org/10.15124/crd42015020399",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033869","R0033869.pdf","paywalled","systematic_review","Dooley, Gordon","2015","Incretin-based therapies and risk of cancer in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","York",null,"10.15124/crd42015020401","https://doi.org/10.15124/crd42015020401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034055","R0034055.pdf","paywalled","systematic_review","Dooley, Gordon","2015","The potential risks of pancreatitis and pancreatic cancer with incretin-based therapies in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","York",null,"10.15124/crd42015020398","https://doi.org/10.15124/crd42015020398",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039548","R0039548.pdf","paywalled","systematic_review","Dooley, Gordon","2015","Effect of incretin-based therapies on cardiovascular risk in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","York",null,"10.15124/crd42015020395","https://doi.org/10.15124/crd42015020395",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044022","R0044022.pdf","paywalled","systematic_review","Laura J. Gray (7605071)","2015","Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis","Figshare",null,"10.1111/dom.12462/abstract","https://doi.org/10.1111/dom.12462/abstract",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045472","R0045472.pdf","paywalled","systematic_review","Na Su","2015","Safety of liraglutide treatment for obesity or overweight:a Meta-analysis","药物不良反应杂志",null,"10.3760/cma.j.issn.1008-5734.2015.02.012","https://doi.org/10.3760/cma.j.issn.1008-5734.2015.02.012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048965","R0048965.pdf","paywalled","systematic_review","Carlos Alves","2015","ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.25756/rpf.v4i3.66","https://doi.org/10.25756/rpf.v4i3.66",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052809","R0052809.pdf","paywalled","systematic_review","Stanley Yakubov","2015","Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Risk of Acute Pancreatitis: A Meta-analysis of Randomized Clinical Trial and Review of Literature","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/00000434-201510001-00020","https://doi.org/10.14309/00000434-201510001-00020",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0008098","R0008098.pdf","paywalled","systematic_review","Monami M","2014","Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2014.01.010","https://doi.org/10.1016/j.diabres.2014.01.010","24485345","https://pubmed.ncbi.nlm.nih.gov/24485345/",null,null],["3","R0013136","R0013136.pdf","paywalled","systematic_review","Monami M","2014","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12175","https://doi.org/10.1111/dom.12175","23829656","https://pubmed.ncbi.nlm.nih.gov/23829656/",null,null],["3","R0015207","R0015207.pdf","paywalled","systematic_review","Giorda CB","2014","Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0179-0","https://doi.org/10.1007/s12020-014-0179-0","24510630","https://pubmed.ncbi.nlm.nih.gov/24510630/",null,null],["3","R0016181","R0016181.pdf","paywalled","systematic_review","Hanefeld M","2014","Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-014-0146-4","https://doi.org/10.1007/s12325-014-0146-4","25143188","https://pubmed.ncbi.nlm.nih.gov/25143188/",null,null],["3","R0016924","R0016924.pdf","paywalled","systematic_review","Eng C","2014","Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(14)61335-0","https://doi.org/10.1016/s0140-6736(14)61335-0","25220191","https://pubmed.ncbi.nlm.nih.gov/25220191/",null,null],["3","R0017526","R0017526.pdf","paywalled","systematic_review","Schmidt LJ","2014","A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12269","https://doi.org/10.1111/dom.12269","24476092","https://pubmed.ncbi.nlm.nih.gov/24476092/",null,null],["3","R0018795","R0018795.pdf","paywalled","systematic_review","Tölle S","2014","[GLP-1 analogues in treatment of type 1 diabetes mellitus].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0034-1387304","https://doi.org/10.1055/s-0034-1387304","25289919","https://pubmed.ncbi.nlm.nih.gov/25289919/",null,null],["3","R0019354","R0019354.pdf","paywalled","systematic_review","Goldenberg R","2014","Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2013.852078","https://doi.org/10.1185/03007995.2013.852078","24106875","https://pubmed.ncbi.nlm.nih.gov/24106875/",null,null],["3","R0020200","R0020200.pdf","paywalled","systematic_review","Kim YG","2014","Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12293","https://doi.org/10.1111/dom.12293","24655583","https://pubmed.ncbi.nlm.nih.gov/24655583/",null,null],["3","R0020577","R0020577.pdf","paywalled","systematic_review","Ahrén B","2014","Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12290","https://doi.org/10.1111/dom.12290","24641271","https://pubmed.ncbi.nlm.nih.gov/24641271/",null,null],["3","R0021057","R0021057.pdf","paywalled","systematic_review","Katout M","2014","Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.","American journal of hypertension","Oxford University Press (OUP)","10.1093/ajh/hpt196","https://doi.org/10.1093/ajh/hpt196","24263424","https://pubmed.ncbi.nlm.nih.gov/24263424/",null,null],["3","R0025212","R0025212.pdf","paywalled","systematic_review","Zueger PM","2014","Cost effectiveness of liraglutide in type II diabetes: a systematic review.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-014-0192-4","https://doi.org/10.1007/s40273-014-0192-4","25052903","https://pubmed.ncbi.nlm.nih.gov/25052903/",null,null],["3","R0026030","R0026030.pdf","paywalled","systematic_review","Dai X","2014","The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2014.921608","https://doi.org/10.1185/03007995.2014.921608","24805140","https://pubmed.ncbi.nlm.nih.gov/24805140/",null,null],["3","R0026242","R0026242.pdf","paywalled","systematic_review","Du Q","2014","Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-014-0164-2","https://doi.org/10.1007/s12325-014-0164-2","25388240","https://pubmed.ncbi.nlm.nih.gov/25388240/",null,null],["3","R0026614","R0026614.pdf","paywalled","systematic_review","Goring S","2014","Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12239","https://doi.org/10.1111/dom.12239","24237939","https://pubmed.ncbi.nlm.nih.gov/24237939/",null,null],["3","R0027035","R0027035.pdf","paywalled","systematic_review","Giorda CB","2014","A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12297","https://doi.org/10.1111/dom.12297","24702687","https://pubmed.ncbi.nlm.nih.gov/24702687/",null,null],["3","R0027505","R0027505.pdf","paywalled","systematic_review","Esposito K","2014","A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-012-0370-9","https://doi.org/10.1007/s00592-012-0370-9","24809070","https://pubmed.ncbi.nlm.nih.gov/24809070/",null,null],["3","R0027524","R0027524.pdf","paywalled","systematic_review","Zintzaras E","2014","Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2014.06.035","https://doi.org/10.1016/j.clinthera.2014.06.035","25109773","https://pubmed.ncbi.nlm.nih.gov/25109773/",null,null],["3","R0033456","R0033456.pdf","paywalled","systematic_review","Dooley, Gordon","2014","A systematic review of the placebo effect of GLP-1 receptor agonists versus new class oral glucose-lowering agents in type 2 diabetes","York",null,"10.15124/crd42014014134","https://doi.org/10.15124/crd42014014134",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033737","R0033737.pdf","paywalled","systematic_review","Dooley, Gordon","2014","Comparative efficacy and acceptability of glucagon-like peptide-1 receptor agonists for glycemic control among patients with type 2 diabetes: a systematic review with trial sequential analysis and network meta-analysis","York",null,"10.15124/crd42014015328","https://doi.org/10.15124/crd42014015328",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0033813","R0033813.pdf","paywalled","systematic_review","Dooley, Gordon","2014","Impact of GLP-1 receptor agonists on heart rate, blood pressure and hypertension among type 2 diabetes: a systematic review and network meta-analysis","York",null,"10.15124/crd42014009019","https://doi.org/10.15124/crd42014009019",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038307","R0038307.pdf","paywalled","systematic_review","Dooley, Gordon","2014","Efficacy of glucagon-like peptide-1 receptor agonist and basal insulin combination therapy for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","York",null,"10.15124/crd42014010688","https://doi.org/10.15124/crd42014010688",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0012316","R0012316.pdf","paywalled","systematic_review","Wang B","2013","Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12085","https://doi.org/10.1111/dom.12085","23433305","https://pubmed.ncbi.nlm.nih.gov/23433305/",null,null],["3","R0014496","R0014496.pdf","paywalled","systematic_review","Scott DA","2013","A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12007","https://doi.org/10.1111/dom.12007","22958381","https://pubmed.ncbi.nlm.nih.gov/22958381/",null,null],["3","R0021039","R0021039.pdf","paywalled","systematic_review","Abdul-Ghani MA","2013","Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis.","Journal of endocrinological investigation",null,"10.3275/8367","https://doi.org/10.3275/8367","22522662","https://pubmed.ncbi.nlm.nih.gov/22522662/",null,null],["3","R0022839","R0022839.pdf","paywalled","systematic_review","Rizos EC","2013","Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/15701611113119990103","https://doi.org/10.2174/15701611113119990103","22724475","https://pubmed.ncbi.nlm.nih.gov/22724475/",null,null],["3","R0027373","R0027373.pdf","paywalled","systematic_review","Ryder RE","2013","The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12301","https://doi.org/10.1111/dme.12301","24073725","https://pubmed.ncbi.nlm.nih.gov/24073725/",null,null],["3","R0033519","R0033519.pdf","paywalled","systematic_review","Dooley, Gordon","2013","Risk of pancreatic complication events associated with the use of GLP-1 receptor agonist and DPP-4 inhibitor drugs: a systematic review and meta-analysis","York",null,"10.15124/crd42013004742","https://doi.org/10.15124/crd42013004742",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035795","R0035795.pdf","paywalled","systematic_review","Ellen Dombrowski","2013","The effect of nutrition and exercise in addition to hypoglycemic medications on HbA1C in patients with type 2 diabetes mellitus: a systematic review protocol","The JBI Database of Systematic Reviews and Implementation Reports","Ovid Technologies (Wolters Kluwer Health)","10.11124/jbisrir-2013-954","https://doi.org/10.11124/jbisrir-2013-954",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035800","R0035800.pdf","paywalled","systematic_review","Laura Garza-Gongora","2013","The Effect of Vitamin D Supplementation on Glycemic Control and Body Mass Index in the Obese, Vitamin D Deficient Adult with Type 2 Diabetes Mellitus: A Systematic Review Protocol","The JBI Database of Systematic Reviews and Implementation Reports","Ovid Technologies (Wolters Kluwer Health)","10.11124/01938924-201311020-00006","https://doi.org/10.11124/01938924-201311020-00006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051091","R0051091.pdf","paywalled","systematic_review","MJ Armstrong","2013","Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme","The Lancet","Elsevier BV","10.1016/s0140-6736(13)60460-2","https://doi.org/10.1016/s0140-6736(13)60460-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051352","R0051352.pdf","paywalled","systematic_review","Ronald Goldenberg","2013","Meta-Analysis of Randomized Controlled Trials of Lixisenatide as Add On to Basal Insulin and/or Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes Mellitus","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2013.08.106","https://doi.org/10.1016/j.jcjd.2013.08.106",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0011681","R0011681.pdf","paywalled","systematic_review","Cornell S","2012","Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.","Journal of clinical pharmacy and therapeutics","Hindawi Limited","10.1111/j.1365-2710.2012.01342.x","https://doi.org/10.1111/j.1365-2710.2012.01342.x","22436069","https://pubmed.ncbi.nlm.nih.gov/22436069/",null,null],["3","R0011846","R0011846.pdf","paywalled","systematic_review","Deacon CF","2012","Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01603.x","https://doi.org/10.1111/j.1463-1326.2012.01603.x","22471248","https://pubmed.ncbi.nlm.nih.gov/22471248/",null,null],["3","R0014186","R0014186.pdf","paywalled","systematic_review","Sun F","2012","Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2012.09.004","https://doi.org/10.1016/j.diabres.2012.09.004","23020934","https://pubmed.ncbi.nlm.nih.gov/23020934/",null,null],["3","R0018720","R0018720.pdf","paywalled","systematic_review","Mannucci E","2012","[Incretin-based therapies and cardiovascular outcome: analyses, pooled analyses and meta-analyses].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/1203.13331","https://doi.org/10.1714/1203.13331","23258123","https://pubmed.ncbi.nlm.nih.gov/23258123/",null,null],["3","R0020069","R0020069.pdf","paywalled","systematic_review","Alves C","2012","A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2012.09.008","https://doi.org/10.1016/j.diabres.2012.09.008","23010561","https://pubmed.ncbi.nlm.nih.gov/23010561/",null,null],["3","R0022006","R0022006.pdf","paywalled","systematic_review","Zinman B","2012","Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01493.x","https://doi.org/10.1111/j.1463-1326.2011.01493.x","21883806","https://pubmed.ncbi.nlm.nih.gov/21883806/",null,null],["3","R0025880","R0025880.pdf","paywalled","systematic_review","Esposito K","2012","Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01512.x","https://doi.org/10.1111/j.1463-1326.2011.01512.x","21958121","https://pubmed.ncbi.nlm.nih.gov/21958121/",null,null],["3","R0025922","R0025922.pdf","paywalled","systematic_review","Liu SC","2012","Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01606.x","https://doi.org/10.1111/j.1463-1326.2012.01606.x","22486990","https://pubmed.ncbi.nlm.nih.gov/22486990/",null,null],["3","R0049451","R0049451.pdf","paywalled","systematic_review","Peter A. Boyle","2012","Abstract P4-13-07: Meta-analysis of epidemiological studies of Insulin Glargine and Breast Cancer Risk","Cancer Research","American Association for Cancer Research (AACR)","10.1158/0008-5472.sabcs12-p4-13-07","https://doi.org/10.1158/0008-5472.sabcs12-p4-13-07",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0052258","R0052258.pdf","paywalled","systematic_review","Xin Sun","2012","Abstract 9654: Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Meta-analyses Oof Randomized Controlled Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.126.suppl_21.a9654","https://doi.org/10.1161/circ.126.suppl_21.a9654",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0010690","R0010690.pdf","paywalled","systematic_review","Pinelli NR","2011","Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1q024","https://doi.org/10.1345/aph.1q024","21730278","https://pubmed.ncbi.nlm.nih.gov/21730278/",null,null],["3","R0015198","R0015198.pdf","paywalled","systematic_review","Wang Y","2011","Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01436.x","https://doi.org/10.1111/j.1463-1326.2011.01436.x","21651690","https://pubmed.ncbi.nlm.nih.gov/21651690/",null,null],["3","R0017255","R0017255.pdf","paywalled","systematic_review","Esposito K","2011","GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2011.590127","https://doi.org/10.1185/03007995.2011.590127","21663496","https://pubmed.ncbi.nlm.nih.gov/21663496/",null,null],["3","R0020407","R0020407.pdf","paywalled","systematic_review","Campbell RK","2011","Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.04.015","https://doi.org/10.1016/j.clinthera.2011.04.015","21665040","https://pubmed.ncbi.nlm.nih.gov/21665040/",null,null],["3","R0025876","R0025876.pdf","paywalled","systematic_review","Henry RR","2011","Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep.17.6.906","https://doi.org/10.4158/ep.17.6.906","22193143","https://pubmed.ncbi.nlm.nih.gov/22193143/",null,null],["3","R0027134","R0027134.pdf","paywalled","systematic_review","Davidson JA","2011","Mild renal impairment and the efficacy and safety of liraglutide.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep10215.ra","https://doi.org/10.4158/ep10215.ra","21700561","https://pubmed.ncbi.nlm.nih.gov/21700561/",null,null],["3","R0030530","R0030530.pdf","paywalled","systematic_review","Gross JL","2011","Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.","Annals of internal medicine","American College of Physicians","10.7326/0003-4819-154-10-201105170-00007","https://doi.org/10.7326/0003-4819-154-10-201105170-00007","21576535","https://pubmed.ncbi.nlm.nih.gov/21576535/",null,null],["3","R0030987","R0030987.pdf","paywalled","systematic_review","Songtao Tang","2011","Efficacy and safety of liraglutide on glycaemic control in patients with type 2 diabetes: a systematic review","Chin J Diabetes Mellitus",null,"10.3760/cma.j.issn.1674-5809.2011.06.003","https://doi.org/10.3760/cma.j.issn.1674-5809.2011.06.003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0021816","R0021816.pdf","paywalled","systematic_review","Fakhoury WK","2010","A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.","Pharmacology","S. Karger AG","10.1159/000314690","https://doi.org/10.1159/000314690","20616619","https://pubmed.ncbi.nlm.nih.gov/20616619/",null,null],["3","R0055658","R0055658.pdf","paywalled","systematic_review","Igho Onakpoya","2010","Food Supplements for Body Weight Reduction: A Systematic Review of Systematic Reviews","Obesity","Wiley","10.1038/oby.2010.185","https://doi.org/10.1038/oby.2010.185","20814412","https://pubmed.ncbi.nlm.nih.gov/20814412/",null,null],["3","R0027195","R0027195.pdf","paywalled","systematic_review","Norris SL","2009","Exenatide efficacy and safety: a systematic review.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2009.02790.x","https://doi.org/10.1111/j.1464-5491.2009.02790.x","19719703","https://pubmed.ncbi.nlm.nih.gov/19719703/",null,null],["3","R0027755","R0027755.pdf","paywalled","systematic_review","Plutzky J","2009","Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis.","Canadian journal of diabetes","Elsevier BV","10.1016/s1499-2671(09)33072-5","https://doi.org/10.1016/s1499-2671(09)33072-5","25998594","https://pubmed.ncbi.nlm.nih.gov/25998594/",null,null],["3","R0046941","R0046941.pdf","paywalled","systematic_review","Richard E. Pratley","2009","adding liraglutide to existing therapy improves glycaemic control: evidence from a meta-analysis of six large randomised clinical trials","Canadian Journal of Diabetes","Elsevier BV","10.1016/s1499-2671(09)33266-9","https://doi.org/10.1016/s1499-2671(09)33266-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0027473","R0027473.pdf","paywalled","systematic_review","Eleftheriadou I","2008","The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/157339908786241133","https://doi.org/10.2174/157339908786241133","18991602","https://pubmed.ncbi.nlm.nih.gov/18991602/",null,null],["3","R0023824","R0023824.pdf","paywalled","systematic_review","Amori RE","2007","Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","JAMA","American Medical Association (AMA)","10.1001/jama.298.2.194","https://doi.org/10.1001/jama.298.2.194","17622601","https://pubmed.ncbi.nlm.nih.gov/17622601/",null,null],["3","R0028385","R0028385.pdf","paywalled","systematic_review","Bottomley JM","2007","Pharmaco-economic issues for diabetes therapy.","Best practice & research. Clinical endocrinology & metabolism","Elsevier BV","10.1016/j.beem.2007.08.002","https://doi.org/10.1016/j.beem.2007.08.002","18054741","https://pubmed.ncbi.nlm.nih.gov/18054741/",null,null],["3","R0045333","R0045333.pdf","paywalled","systematic_review","Olivia Benny",null,"Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.","Open Access CRIS of the University of Bern",null,"10.48620/97703","https://doi.org/10.48620/97703",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053727","R0053727.pdf","paywalled","systematic_review","Breit, Sigrid",null,"Response to \"Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review\".","Open Access CRIS of the University of Bern",null,"10.48620/90875","https://doi.org/10.48620/90875",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055581","R0055581.pdf","paywalled","systematic_review","Breit, Sigrid",null,"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review.","Open Access CRIS of the University of Bern",null,"10.48620/87415","https://doi.org/10.48620/87415",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0000081","R0000081.pdf","open_download_failed","systematic_review","Kanbay M","2026","Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71106","https://doi.org/10.1111/dom.71106","42449480","https://pubmed.ncbi.nlm.nih.gov/42449480/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538776/pdf/DOM-28-9002.pdf","PROSPERO:CRD420261321430"],["3","R0000118","R0000118.pdf","open_download_failed","systematic_review","Hakim J","2026","Neonatal and obstetric outcomes following periconceptional exposure to glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","American journal of obstetrics and gynecology","Elsevier BV","10.1016/j.ajog.2026.04.037","https://doi.org/10.1016/j.ajog.2026.04.037","42061782","https://pubmed.ncbi.nlm.nih.gov/42061782/","https://www.ajog.org/article/S0002-9378(26)00222-X/pdf",null],["3","R0000227","R0000227.pdf","free_to_read","systematic_review","Bihelek N","2026","Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag121","https://doi.org/10.1093/ajhp/zxag121","42033237","https://pubmed.ncbi.nlm.nih.gov/42033237/","https://doi.org/10.1093/ajhp/zxag121",null],["3","R0000255","R0000255.pdf","open_download_failed","systematic_review","Al-Burak SA","2026","Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review.","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","Elsevier BV","10.1016/j.jcjo.2026.05.010","https://doi.org/10.1016/j.jcjo.2026.05.010","42242290","https://pubmed.ncbi.nlm.nih.gov/42242290/","https://www.canadianjournalofophthalmology.ca/article/S0008-4182(26)00205-X/pdf","PROSPERO:CRD420251183938"],["3","R0000388","R0000388.pdf","free_to_read","systematic_review","Li Y","2026","GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2026.108333","https://doi.org/10.1016/j.phrs.2026.108333","42401410","https://pubmed.ncbi.nlm.nih.gov/42401410/","https://doi.org/10.1016/j.phrs.2026.108333",null],["3","R0000409","R0000409.pdf","free_to_read","systematic_review","Brucar LR","2026","Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies.","Neuroscience and biobehavioral reviews","Elsevier BV","10.1016/j.neubiorev.2026.106990","https://doi.org/10.1016/j.neubiorev.2026.106990","42762879","https://pubmed.ncbi.nlm.nih.gov/42762879/","https://doi.org/10.1016/j.neubiorev.2026.106990",null],["3","R0000476","R0000476.pdf","free_to_read","systematic_review","Ortiz-Seller A","2026","Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials.","Survey of ophthalmology","Elsevier BV","10.1016/j.survophthal.2026.08.007","https://doi.org/10.1016/j.survophthal.2026.08.007","42612754","https://pubmed.ncbi.nlm.nih.gov/42612754/","https://doi.org/10.1016/j.survophthal.2026.08.007",null],["3","R0000488","R0000488.pdf","free_to_read","systematic_review","Lim M","2026","Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70169","https://doi.org/10.1002/oby.70169","41936548","https://pubmed.ncbi.nlm.nih.gov/41936548/","https://doi.org/10.1002/oby.70169",null],["3","R0000741","R0000741.pdf","open_download_failed","systematic_review","Alexander GC","2026","Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2025.8222","https://doi.org/10.1001/jamainternmed.2025.8222","41770554","https://pubmed.ncbi.nlm.nih.gov/41770554/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12954602/",null],["3","R0000770","R0000770.pdf","free_to_read","systematic_review","Xu T","2026","Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: A systematic review.","Asian journal of psychiatry","Elsevier BV","10.1016/j.ajp.2026.104870","https://doi.org/10.1016/j.ajp.2026.104870","41619567","https://pubmed.ncbi.nlm.nih.gov/41619567/","https://doi.org/10.1016/j.ajp.2026.104870",null],["3","R0000798","R0000798.pdf","open_download_failed","systematic_review","Hertzer LA","2026","The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.","Childhood obesity (Print)","SAGE Publications","10.1177/21532176251413898","https://doi.org/10.1177/21532176251413898","41715277","https://pubmed.ncbi.nlm.nih.gov/41715277/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13191177/",null],["3","R0000820","R0000820.pdf","open_download_failed","systematic_review","Nunns M","2026","The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.","Health technology assessment (Winchester, England)","National Institute for Health and Care Research","10.3310/skht8119","https://doi.org/10.3310/skht8119","40580049","https://pubmed.ncbi.nlm.nih.gov/40580049/","https://doi.org/10.3310/skht8119",null],["3","R0000921","R0000921.pdf","free_to_read","systematic_review","Lee S","2026","Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811261456190","https://doi.org/10.1177/02698811261456190","42312633","https://pubmed.ncbi.nlm.nih.gov/42312633/","https://doi.org/10.1177/02698811261456190","PROSPERO:CRD420251118829"],["3","R0000937","R0000937.pdf","free_to_read","systematic_review","Santos Dantas R","2026","Effects of GLP-1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review.","The FEBS journal","Wiley","10.1111/febs.70656","https://doi.org/10.1111/febs.70656","42625391","https://pubmed.ncbi.nlm.nih.gov/42625391/","https://doi.org/10.1111/febs.70656",null],["3","R0000939","R0000939.pdf","open_download_failed","systematic_review","Silva JPMRJ","2026","Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71051","https://doi.org/10.1111/dom.71051","42410309","https://pubmed.ncbi.nlm.nih.gov/42410309/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13449074/pdf/DOM-28-8627.pdf","PROSPERO:CRD420261354941"],["3","R0000943","R0000943.pdf","open_download_failed","systematic_review","Bilal AR","2026","Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-02000-8","https://doi.org/10.1007/s40200-026-02000-8","42422116","https://pubmed.ncbi.nlm.nih.gov/42422116/","https://pubmed.ncbi.nlm.nih.gov/42422116/",null],["3","R0000953","R0000953.pdf","open_download_failed","systematic_review","Lee O","2026","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71325","https://doi.org/10.1111/dom.71325","42723273","https://pubmed.ncbi.nlm.nih.gov/42723273/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71325",null],["3","R0001021","R0001021.pdf","free_to_read","systematic_review","Yi YT","2026","The effect of GLP-1 receptor agonists on anxiety: A systematic review.","Psychoneuroendocrinology","Elsevier BV","10.1016/j.psyneuen.2026.107844","https://doi.org/10.1016/j.psyneuen.2026.107844","41931929","https://pubmed.ncbi.nlm.nih.gov/41931929/","https://doi.org/10.1016/j.psyneuen.2026.107844",null],["3","R0001068","R0001068.pdf","open_download_failed","systematic_review","Lu D","2026","Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.","Clinical obesity","Wiley","10.1111/cob.70112","https://doi.org/10.1111/cob.70112","42733128","https://pubmed.ncbi.nlm.nih.gov/42733128/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13572569/pdf/COB-16-e70112.pdf",null],["3","R0001070","R0001070.pdf","free_to_read","systematic_review","Siranart N","2026","Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials.","Hepatology communications","Ovid Technologies (Wolters Kluwer Health)","10.1097/hc9.0000000000000871","https://doi.org/10.1097/hc9.0000000000000871","41543478","https://pubmed.ncbi.nlm.nih.gov/41543478/","https://doi.org/10.1097/hc9.0000000000000871",null],["3","R0001159","R0001159.pdf","open_download_failed","systematic_review","Al-Burak SA","2026","Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis.","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","Elsevier BV","10.1016/j.jcjo.2026.05.004","https://doi.org/10.1016/j.jcjo.2026.05.004","42242293","https://pubmed.ncbi.nlm.nih.gov/42242293/","https://www.canadianjournalofophthalmology.ca/article/S0008-4182(26)00206-1/pdf","PROSPERO:CRD420251176164"],["3","R0001161","R0001161.pdf","open_download_failed","systematic_review","Perry F","2026","Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71337","https://doi.org/10.1111/dom.71337","42733137","https://pubmed.ncbi.nlm.nih.gov/42733137/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71337","PROSPERO:CRD420261352699"],["3","R0001172","R0001172.pdf","free_to_read","systematic_review","Danielli M","2026","GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression","medRxiv","openRxiv","10.64898/2026.09.18.26363449","https://doi.org/10.64898/2026.09.18.26363449",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261305938"],["3","R0001175","R0001175.pdf","free_to_read","systematic_review","Ahmed W","2026","Response to \"Comment on 'efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis'\".","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2026.125866","https://doi.org/10.1016/j.jns.2026.125866","41833129","https://pubmed.ncbi.nlm.nih.gov/41833129/","https://ecommons.aku.edu/pakistan_fhs_mc_mc/625",null],["3","R0001177","R0001177.pdf","free_to_read","systematic_review","Ahmed W","2026","Response to comment by Srinivasan et al. on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2026.125876","https://doi.org/10.1016/j.jns.2026.125876","41916123","https://pubmed.ncbi.nlm.nih.gov/41916123/","https://ecommons.aku.edu/pakistan_fhs_mc_mc/611",null],["3","R0001233","R0001233.pdf","open_download_failed","systematic_review","Shubietah A","2026","Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis.","Pacing and clinical electrophysiology : PACE","Wiley","10.1111/pace.70262","https://doi.org/10.1111/pace.70262","42033283","https://pubmed.ncbi.nlm.nih.gov/42033283/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13456437/pdf/PACE-49-1086.pdf",null],["3","R0001373","R0001373.pdf","free_to_read","systematic_review","Belančić A","2026","Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70492","https://doi.org/10.1002/bcp.70492","41703425","https://pubmed.ncbi.nlm.nih.gov/41703425/","https://doi.org/10.1002/bcp.70492","PROSPERO:CRD42024609736"],["3","R0001401","R0001401.pdf","open_download_failed","systematic_review","Bhaduri G","2026","Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.","Clinical obesity","Wiley","10.1111/cob.70105","https://doi.org/10.1111/cob.70105","42584177","https://pubmed.ncbi.nlm.nih.gov/42584177/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13464048/",null],["3","R0001467","R0001467.pdf","free_to_read","systematic_review","D'Antonio F","2026","GLP-1 receptor agonist exposure in the periconceptional period and adverse obstetric outcomes: A systematic review and meta-analysis.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101267","https://doi.org/10.1016/j.medj.2026.101267","42810337","https://pubmed.ncbi.nlm.nih.gov/42810337/","https://doi.org/10.1016/j.medj.2026.101267",null],["3","R0001492","R0001492.pdf","free_to_read","systematic_review","Ahmed W","2026","Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","Journal of the neurological sciences","Elsevier BV","10.1016/j.jns.2025.125711","https://doi.org/10.1016/j.jns.2025.125711","41468715","https://pubmed.ncbi.nlm.nih.gov/41468715/","https://doi.org/10.1016/j.jns.2025.125711",null],["3","R0001543","R0001543.pdf","open_download_failed","systematic_review","Kateel R","2026","Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113270","https://doi.org/10.1016/j.diabres.2026.113270","42105869","https://pubmed.ncbi.nlm.nih.gov/42105869/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00189-0/pdf",null],["3","R0001548","R0001548.pdf","free_to_read","systematic_review","Corcoran E","2026","The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.","Molecular and cellular neurosciences","Elsevier BV","10.1016/j.mcn.2026.104091","https://doi.org/10.1016/j.mcn.2026.104091","42014236","https://pubmed.ncbi.nlm.nih.gov/42014236/","https://doi.org/10.1016/j.mcn.2026.104091","PROSPERO:CRD420251029748"],["3","R0001700","R0001700.pdf","free_to_read","systematic_review","Anaspure OS","2026","\"Examining the impact of perioperative glucagon-like-peptide-1 use within foot and ankle surgery: A systematic review of comparative studies\".","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2026.07.011","https://doi.org/10.1053/j.jfas.2026.07.011","42508720","https://pubmed.ncbi.nlm.nih.gov/42508720/","https://doi.org/10.1053/j.jfas.2026.07.011",null],["3","R0001789","R0001789.pdf","open_download_failed","systematic_review","Bakker L","2026","GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis","medRxiv","openRxiv","10.64898/2026.03.19.26348844","https://doi.org/10.64898/2026.03.19.26348844",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/03/23/2026.03.19.26348844.full.pdf",null],["3","R0001948","R0001948.pdf","open_download_failed","systematic_review","Tsironikos GI","2026","Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70114","https://doi.org/10.1002/dmrr.70114","41398448","https://pubmed.ncbi.nlm.nih.gov/41398448/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.70114",null],["3","R0002008","R0002008.pdf","free_to_read","systematic_review","Choudhury I","2026","Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2026.02.010","https://doi.org/10.1016/j.clinthera.2026.02.010","41862354","https://pubmed.ncbi.nlm.nih.gov/41862354/","https://doi.org/10.1016/j.clinthera.2026.02.010","PROSPERO:CRD420251025534"],["3","R0002019","R0002019.pdf","free_to_read","systematic_review","Campbell C","2026","The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.07.012","https://doi.org/10.1016/j.soard.2026.07.012","42660781","https://pubmed.ncbi.nlm.nih.gov/42660781/","https://doi.org/10.1016/j.soard.2026.07.012",null],["3","R0002140","R0002140.pdf","open_download_failed","systematic_review","Nong K","2026","Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-372161","https://doi.org/10.1136/bmj-2026-372161","42419792","https://pubmed.ncbi.nlm.nih.gov/42419792/","https://www.bmj.com/content/bmj/394/bmj-2026-372161.full.pdf","PROSPERO:CRD42024507993"],["3","R0002213","R0002213.pdf","open_download_failed","systematic_review","Omeh Z","2026","Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2026.2656247","https://doi.org/10.1080/17446651.2026.2656247","41968780","https://pubmed.ncbi.nlm.nih.gov/41968780/","https://www.tandfonline.com/doi/pdf/10.1080/17446651.2026.2656247","PROSPERO:CRD420251016726"],["3","R0002235","R0002235.pdf","open_download_failed","systematic_review","Cavalcante Lima Chagas G","2026","Contemporary Initial Glucose-Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71397","https://doi.org/10.1111/dom.71397","42811398","https://pubmed.ncbi.nlm.nih.gov/42811398/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71397","PROSPERO:CRD420251178714"],["3","R0002460","R0002460.pdf","open_download_failed","systematic_review","Akande R","2026","Meta-analysis of sodium glucose transport 2 inhibitors versus other glucose-lowering agents on the progression of diabetic retinopathy and diabetic macular edema.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113429","https://doi.org/10.1016/j.diabres.2026.113429","42425328","https://pubmed.ncbi.nlm.nih.gov/42425328/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00349-9/pdf",null],["3","R0002462","R0002462.pdf","open_download_failed","systematic_review","Amjad MM","2026","Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71400","https://doi.org/10.1111/dom.71400","42811393","https://pubmed.ncbi.nlm.nih.gov/42811393/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71400","PROSPERO:CRD420261456447"],["3","R0002539","R0002539.pdf","free_to_read","systematic_review","Lee SA","2026","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000005496","https://doi.org/10.1097/tp.0000000000005496","40702593","https://pubmed.ncbi.nlm.nih.gov/40702593/","https://pure.eur.nl/en/publications/504363be-f15a-4ecb-9346-82f315bc84b6",null],["3","R0002542","R0002542.pdf","open_download_failed","systematic_review","Waqas SA","2026","Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in patients without obesity: a systematic review and meta-analysis of randomized controlled trials.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-01969-6","https://doi.org/10.1007/s40200-026-01969-6","42299230","https://pubmed.ncbi.nlm.nih.gov/42299230/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13264643/",null],["3","R0002593","R0002593.pdf","open_download_failed","systematic_review","Zhou L","2026","Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis.","Journal of general internal medicine","Springer Science and Business Media LLC","10.1007/s11606-025-09950-4","https://doi.org/10.1007/s11606-025-09950-4","41249646","https://pubmed.ncbi.nlm.nih.gov/41249646/","https://pubmed.ncbi.nlm.nih.gov/41249646/",null],["3","R0002737","R0002737.pdf","free_to_read","systematic_review","Forslund M","2026","GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag033","https://doi.org/10.1093/ejendo/lvag033","41701618","https://pubmed.ncbi.nlm.nih.gov/41701618/","https://doi.org/10.1093/ejendo/lvag033","PROSPERO:CRD42024535096"],["3","R0002786","R0002786.pdf","open_download_failed","systematic_review","Boccatonda A","2026","GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113271","https://doi.org/10.1016/j.diabres.2026.113271","42009258","https://pubmed.ncbi.nlm.nih.gov/42009258/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00190-7/pdf",null],["3","R0002815","R0002815.pdf","free_to_read","systematic_review","Labate AM","2026","<span data-teams=\"true\">Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs","Preprints.org","MDPI AG","10.20944/preprints202609.1706.v1","https://doi.org/10.20944/preprints202609.1706.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.1706.v1",null],["3","R0002932","R0002932.pdf","free_to_read","systematic_review","Nybo PF","2026","Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.70346","https://doi.org/10.1111/dme.70346","42036870","https://pubmed.ncbi.nlm.nih.gov/42036870/","https://doi.org/10.1111/dme.70346",null],["3","R0002991","R0002991.pdf","free_to_read","systematic_review","Karakasis P","2026","Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2025.156463","https://doi.org/10.1016/j.metabol.2025.156463","41349790","https://pubmed.ncbi.nlm.nih.gov/41349790/","https://doi.org/10.1016/j.metabol.2025.156463",null],["3","R0003049","R0003049.pdf","free_to_read","systematic_review","Rudran B","2026","Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis.","The bone & joint journal","British Editorial Society of Bone & Joint Surgery","10.1302/0301-620x.108b8.bjj-2025-1486.r2","https://doi.org/10.1302/0301-620x.108b8.bjj-2025-1486.r2","42538001","https://pubmed.ncbi.nlm.nih.gov/42538001/","https://research-information.bris.ac.uk/en/publications/6c49deab-2847-4591-8dd0-47c00fc5d7dc",null],["3","R0003109","R0003109.pdf","open_download_failed","systematic_review","Abdel-Rahman SM","2026","Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70506","https://doi.org/10.1111/dom.70506","41605813","https://pubmed.ncbi.nlm.nih.gov/41605813/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70506",null],["3","R0003162","R0003162.pdf","open_download_failed","systematic_review","Viquez Burboa GU","2026","GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.","Skin appendage disorders","S. Karger AG","10.1159/000553070","https://doi.org/10.1159/000553070","42621629","https://pubmed.ncbi.nlm.nih.gov/42621629/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13489628/","PROSPERO:CRD420261335458"],["3","R0003472","R0003472.pdf","open_download_failed","systematic_review","Rakhsha SS","2026","Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70957","https://doi.org/10.1111/dom.70957","42304171","https://pubmed.ncbi.nlm.nih.gov/42304171/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13449080/pdf/DOM-28-7689.pdf",null],["3","R0003475","R0003475.pdf","open_download_failed","systematic_review","Chen Y","2026","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70111","https://doi.org/10.1002/dmrr.70111","41331723","https://pubmed.ncbi.nlm.nih.gov/41331723/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.70111",null],["3","R0003494","R0003494.pdf","open_download_failed","systematic_review","Ceravolo R","2026","Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.06.015","https://doi.org/10.1016/j.amjcard.2026.06.015","42342009","https://pubmed.ncbi.nlm.nih.gov/42342009/","https://www.ajconline.org/article/S0002-9149(26)00418-2/pdf",null],["3","R0003616","R0003616.pdf","free_to_read","systematic_review","Sibal R","2026","Nonhormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review.","Journal of pediatric and adolescent gynecology","Elsevier BV","10.1016/j.jpag.2026.01.001","https://doi.org/10.1016/j.jpag.2026.01.001","41506442","https://pubmed.ncbi.nlm.nih.gov/41506442/","https://doi.org/10.1016/j.jpag.2026.01.001",null],["3","R0003845","R0003845.pdf","free_to_read","systematic_review","Faheem MSB","2026","Safety and efficacy of semaglutide for non-alcoholic fatty liver disease: A meta-analysis of clinical outcomes","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9176897/v1","https://doi.org/10.21203/rs.3.rs-9176897/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9176897/v1",null],["3","R0003914","R0003914.pdf","free_to_read","systematic_review","Spiazzi BF","2026","Time to Benefit of Incretin-Based Therapies in Adiposity-Related Heart Failure With Mildly Reduced or Preserved Ejection Fraction: a Systematic Review and Meta-Analysis.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2026.06.025","https://doi.org/10.1016/j.cardfail.2026.06.025","42401228","https://pubmed.ncbi.nlm.nih.gov/42401228/","https://doi.org/10.1016/j.cardfail.2026.06.025",null],["3","R0003944","R0003944.pdf","open_download_failed","systematic_review","Puga TB","2026","Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.","The Iowa orthopaedic journal",null,null,"https://doi.org/","42488294","https://pubmed.ncbi.nlm.nih.gov/42488294/",null,null],["3","R0004004","R0004004.pdf","open_download_failed","systematic_review","Silva LL","2026","GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis","medRxiv","openRxiv","10.64898/2026.07.22.26358702","https://doi.org/10.64898/2026.07.22.26358702",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/07/24/2026.07.22.26358702.full.pdf",null],["3","R0004079","R0004079.pdf","free_to_read","systematic_review","Rao Y","2026","Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.11.017","https://doi.org/10.1016/j.eprac.2025.11.017","41419174","https://pubmed.ncbi.nlm.nih.gov/41419174/","https://doi.org/10.1016/j.eprac.2025.11.017",null],["3","R0004340","R0004340.pdf","free_to_read","systematic_review","Ahmed A","2026","Beyond Cardiology's Pillars: A Network Meta-Analysis Comparing the Recombinant Zoster Vaccine (Shingrix/RZV) with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Prevention of Major Adverse Cardiovascular Events and Dementia in Adults Aged ≥50 Years","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9727771/v1","https://doi.org/10.21203/rs.3.rs-9727771/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9727771/v1",null],["3","R0004438","R0004438.pdf","open_download_failed","systematic_review","Mandal L","2026","Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.","European journal of obstetrics, gynecology, and reproductive biology","Elsevier BV","10.1016/j.ejogrb.2025.114836","https://doi.org/10.1016/j.ejogrb.2025.114836","41313865","https://pubmed.ncbi.nlm.nih.gov/41313865/","https://www.ejog.org/article/S0301-2115(25)01112-1/pdf",null],["3","R0004738","R0004738.pdf","free_to_read","systematic_review","Mısırlıoğlu PE","2026","Appetite Dysregulation as a Driver of Weight Regain After GLP-1 Receptor Agonist-Induced Weight Loss: A Systematic Review","Preprints.org","MDPI AG","10.20944/preprints202604.1938.v1","https://doi.org/10.20944/preprints202604.1938.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202604.1938.v1",null],["3","R0004779","R0004779.pdf","free_to_read","systematic_review","Musso G","2026","Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100959","https://doi.org/10.1016/j.medj.2025.100959","41610839","https://pubmed.ncbi.nlm.nih.gov/41610839/","https://www.sciencedirect.com/science/article/pii/S2666634025003861/pdf",null],["3","R0004811","R0004811.pdf","open_download_failed","systematic_review","Kaur R","2026","Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71031","https://doi.org/10.1111/dom.71031","42337824","https://pubmed.ncbi.nlm.nih.gov/42337824/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448877/",null],["3","R0004831","R0004831.pdf","open_download_failed","systematic_review","Wan S","2026","Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70201","https://doi.org/10.1111/dom.70201","41104525","https://pubmed.ncbi.nlm.nih.gov/41104525/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70201",null],["3","R0005125","R0005125.pdf","free_to_read","systematic_review","Alaycı B","2026","DXA-Measured Body Composition Effects of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adults with Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis of Phase 3 Randomized Trials","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9973131/v1","https://doi.org/10.21203/rs.3.rs-9973131/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9973131/v1","PROSPERO:CRD420261323497"],["3","R0005198","R0005198.pdf","open_download_failed","systematic_review","Wan KW","2026","Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.","JAMA pediatrics","American Medical Association (AMA)","10.1001/jamapediatrics.2026.2248","https://doi.org/10.1001/jamapediatrics.2026.2248","42329656","https://pubmed.ncbi.nlm.nih.gov/42329656/","https://pubmed.ncbi.nlm.nih.gov/42329656/",null],["3","R0005215","R0005215.pdf","free_to_read","systematic_review","Jayathilaka NS","2026","Enteroendocrine hormones and gut microbiota in obesity: a systematic review from mechanistic insight to precision metabolic care.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-01887-7","https://doi.org/10.1007/s40200-026-01887-7","41743894","https://pubmed.ncbi.nlm.nih.gov/41743894/","https://pubmed.ncbi.nlm.nih.gov/41743894/",null],["3","R0005385","R0005385.pdf","free_to_read","systematic_review","Yang L","2026","Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.","The journal of sexual medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag272","https://doi.org/10.1093/jsxmed/qdag272","42704281","https://pubmed.ncbi.nlm.nih.gov/42704281/","https://doi.org/10.1093/jsxmed/qdag272",null],["3","R0005465","R0005465.pdf","open_download_failed","systematic_review","Rao H","2026","Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-01942-3","https://doi.org/10.1007/s40200-026-01942-3","42180166","https://pubmed.ncbi.nlm.nih.gov/42180166/","https://pubmed.ncbi.nlm.nih.gov/42180166/",null],["3","R0005812","R0005812.pdf","free_to_read","systematic_review","Campos García FJ","2026","GLP-1 Receptor Agonists and Dual GIP/GLP-1 and Reduction in Major Cardiovascular Events: A Systematic Review and Network Meta-Analysis","Preprints.org","MDPI AG","10.20944/preprints202610.0314.v1","https://doi.org/10.20944/preprints202610.0314.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202610.0314.v1",null],["3","R0005949","R0005949.pdf","open_download_failed","systematic_review","Kato S","2026","Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70182","https://doi.org/10.1111/dom.70182","41126557","https://pubmed.ncbi.nlm.nih.gov/41126557/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70182","UMIN:UMIN000042499"],["3","R0006337","R0006337.pdf","open_download_failed","systematic_review","Jansson AK","2026","A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70077","https://doi.org/10.1111/obr.70077","41491340","https://pubmed.ncbi.nlm.nih.gov/41491340/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.70077","OSF:osf.io/xpngy"],["3","R0006524","R0006524.pdf","open_download_failed","systematic_review","Zeng BS","2026","The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis.","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","Elsevier BV","10.1016/j.cmi.2026.01.014","https://doi.org/10.1016/j.cmi.2026.01.014","41610949","https://pubmed.ncbi.nlm.nih.gov/41610949/","https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(26)00019-4/pdf",null],["3","R0007286","R0007286.pdf","open_download_failed","systematic_review","Marassi M","2026","Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2026.104714","https://doi.org/10.1016/j.numecd.2026.104714","41997798","https://pubmed.ncbi.nlm.nih.gov/41997798/","https://www.nmcd-journal.com/article/S0939-4753(26)00176-6/pdf",null],["3","R0007324","R0007324.pdf","free_to_read","systematic_review","Chen KY","2026","Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.","Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)","Elsevier BV","10.1016/j.apjo.2025.100245","https://doi.org/10.1016/j.apjo.2025.100245","40962119","https://pubmed.ncbi.nlm.nih.gov/40962119/","https://doi.org/10.1016/j.apjo.2025.100245",null],["3","R0007331","R0007331.pdf","free_to_read","systematic_review","Ciudin A","2026","A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Update","medRxiv","openRxiv","10.64898/2026.04.19.26351196","https://doi.org/10.64898/2026.04.19.26351196",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0007472","R0007472.pdf","free_to_read","systematic_review","Andersson A","2026","Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2025.03.003","https://doi.org/10.1016/j.cgh.2025.03.003","40220846","https://pubmed.ncbi.nlm.nih.gov/40220846/","https://doi.org/10.1016/j.cgh.2025.03.003",null],["3","R0007494","R0007494.pdf","open_download_failed","systematic_review","Stamatiou A","2026","Effects of Weight-Loss Interventions on Kidney, Cardiometabolic and Anthropometric Outcomes in Adults With CKD and Overweight or Obesity: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70997","https://doi.org/10.1111/dom.70997","42331714","https://pubmed.ncbi.nlm.nih.gov/42331714/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448983/pdf/DOM-28-8266.pdf",null],["3","R0007603","R0007603.pdf","free_to_read","systematic_review","Rashid M","2026","Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70198","https://doi.org/10.1111/obr.70198","42483841","https://pubmed.ncbi.nlm.nih.gov/42483841/","https://doi.org/10.1111/obr.70198",null],["3","R0007622","R0007622.pdf","open_download_failed","systematic_review","Shah N","2026","Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Journal of general internal medicine","Springer Science and Business Media LLC","10.1007/s11606-026-10178-z","https://doi.org/10.1007/s11606-026-10178-z","41838266","https://pubmed.ncbi.nlm.nih.gov/41838266/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13421548/",null],["3","R0007718","R0007718.pdf","free_to_read","systematic_review","Ballum H","2026","The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2026.121310","https://doi.org/10.1016/j.jad.2026.121310","41621451","https://pubmed.ncbi.nlm.nih.gov/41621451/","https://doi.org/10.1016/j.jad.2026.121310",null],["3","R0008407","R0008407.pdf","open_download_failed","systematic_review","Kamrul-Hasan ABM","2026","Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71058","https://doi.org/10.1111/dom.71058","42410325","https://pubmed.ncbi.nlm.nih.gov/42410325/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538747/pdf/DOM-28-8777.pdf",null],["3","R0008574","R0008574.pdf","open_download_failed","systematic_review","Chuang SM","2026","The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70915","https://doi.org/10.1111/dom.70915","42219271","https://pubmed.ncbi.nlm.nih.gov/42219271/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13341365/pdf/DOM-28-7137.pdf",null],["3","R0008880","R0008880.pdf","open_download_failed","systematic_review","Stogios N","2026","Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2026.1814","https://doi.org/10.1001/jamapsychiatry.2026.1814","42418179","https://pubmed.ncbi.nlm.nih.gov/42418179/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13347271/",null],["3","R0009284","R0009284.pdf","free_to_read","systematic_review","Shabil M","2026","Impact of antidiabetic agents on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","Diabetes & vascular disease research","SAGE Publications","10.1177/14791641261487590","https://doi.org/10.1177/14791641261487590","42821775","https://pubmed.ncbi.nlm.nih.gov/42821775/","https://doi.org/10.1177/14791641261487590",null],["3","R0009820","R0009820.pdf","open_download_failed","systematic_review","Barer Y","2026","Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.","Parkinsonism & related disorders","Elsevier BV","10.1016/j.parkreldis.2025.108171","https://doi.org/10.1016/j.parkreldis.2025.108171","41468681","https://pubmed.ncbi.nlm.nih.gov/41468681/","https://www.prd-journal.com/article/S1353-8020(25)00920-4/pdf",null],["3","R0009839","R0009839.pdf","open_download_failed","systematic_review","Luo L","2026","Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70986","https://doi.org/10.1111/dom.70986","42310900","https://pubmed.ncbi.nlm.nih.gov/42310900/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448963/",null],["3","R0010131","R0010131.pdf","open_download_failed","systematic_review","Hoffmann K","2026","The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2586703","https://doi.org/10.1080/14740338.2025.2586703","41200927","https://pubmed.ncbi.nlm.nih.gov/41200927/","https://www.tandfonline.com/doi/pdf/10.1080/14740338.2025.2586703",null],["3","R0010995","R0010995.pdf","open_download_failed","systematic_review","Li C","2026","Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70054","https://doi.org/10.1002/oby.70054","41189318","https://pubmed.ncbi.nlm.nih.gov/41189318/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13535721/pdf/OBY-34-16.pdf",null],["3","R0011149","R0011149.pdf","free_to_read","systematic_review","Wang B","2026","On \"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use a network meta-analysis of 68 randomized controlled trials\" - correspondence.","International journal of surgery (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000003969","https://doi.org/10.1097/js9.0000000000003969","41222906","https://pubmed.ncbi.nlm.nih.gov/41222906/","https://doi.org/10.1097/js9.0000000000003969",null],["3","R0012065","R0012065.pdf","open_download_failed","systematic_review","Mansouri ES","2026","Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.125.044249","https://doi.org/10.1161/jaha.125.044249","42714458","https://pubmed.ncbi.nlm.nih.gov/42714458/","https://www.ahajournals.org/doi/pdf/10.1161/JAHA.125.044249?download=true",null],["3","R0012733","R0012733.pdf","open_download_failed","systematic_review","Khani E","2026","Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.","Journal of clinical pharmacology","Wiley","10.1002/jcph.70248","https://doi.org/10.1002/jcph.70248","42612051","https://pubmed.ncbi.nlm.nih.gov/42612051/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13485131/","PROSPERO:CRD42025649542"],["3","R0012792","R0012792.pdf","open_download_failed","systematic_review","Gerardi C","2026","Pharmacological interventions for the treatment of obesity in children and adolescents.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd015986","https://doi.org/10.1002/14651858.cd015986","42125960","https://pubmed.ncbi.nlm.nih.gov/42125960/","https://pubmed.ncbi.nlm.nih.gov/42125960/","PROSPERO:CRD42023433123"],["3","R0012867","R0012867.pdf","free_to_read","systematic_review","Bai L","2026","Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/0115733998359708250822102217","https://doi.org/10.2174/0115733998359708250822102217","40947681","https://pubmed.ncbi.nlm.nih.gov/40947681/","https://doi.org/10.2174/0115733998359708250822102217",null],["3","R0012914","R0012914.pdf","free_to_read","systematic_review","Remiro-Azócar A","2026","Incorporating estimands into meta-analyses of clinical trials.","Research synthesis methods","Cambridge University Press (CUP)","10.1017/rsm.2026.10107","https://doi.org/10.1017/rsm.2026.10107","42527984","https://pubmed.ncbi.nlm.nih.gov/42527984/","https://doi.org/10.1017/rsm.2026.10107",null],["3","R0013155","R0013155.pdf","open_download_failed","systematic_review","Dutta D","2026","Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70391","https://doi.org/10.1111/dom.70391","41424191","https://pubmed.ncbi.nlm.nih.gov/41424191/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70391",null],["3","R0013164","R0013164.pdf","free_to_read","systematic_review","Marroquín JJ","2026","Comparative efficacy and safety of non-insulin antihyperglycemic agents versus insulin in patients over 65 years with type 2 diabetes and advanced or end-stage chronic kidney disease on dialysis: a systematic review of studies published in the last 10 years.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-01928-1","https://doi.org/10.1007/s40200-026-01928-1","41822052","https://pubmed.ncbi.nlm.nih.gov/41822052/","https://pubmed.ncbi.nlm.nih.gov/41822052/",null],["3","R0013521","R0013521.pdf","open_download_failed","systematic_review","Chiang CH","2026","Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70980","https://doi.org/10.1111/dom.70980","42297743","https://pubmed.ncbi.nlm.nih.gov/42297743/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13449091/pdf/DOM-28-8693.pdf",null],["3","R0013713","R0013713.pdf","open_download_failed","systematic_review","Eisa N","2026","The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70992","https://doi.org/10.1111/dom.70992","42297754","https://pubmed.ncbi.nlm.nih.gov/42297754/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448870/",null],["3","R0013905","R0013905.pdf","open_download_failed","systematic_review","Peng TR","2026","Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70629","https://doi.org/10.1002/bcp.70629","42273973","https://pubmed.ncbi.nlm.nih.gov/42273973/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13420891/","PROSPERO:CRD420261288562"],["3","R0013945","R0013945.pdf","open_download_failed","systematic_review","Spary-Kainz U","2026","Long-term effects of weight-reducing drugs in people with hypertension.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd007654.pub6","https://doi.org/10.1002/14651858.cd007654.pub6","42318855","https://pubmed.ncbi.nlm.nih.gov/42318855/","https://pubmed.ncbi.nlm.nih.gov/42318855/",null],["3","R0014344","R0014344.pdf","open_download_failed","systematic_review","Schmidt PHS","2026","Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70529","https://doi.org/10.1111/dom.70529","41705736","https://pubmed.ncbi.nlm.nih.gov/41705736/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70529",null],["3","R0014590","R0014590.pdf","free_to_read","systematic_review","Bennett KA","2026","Systematic review and synthesis without meta-analysis (SWiM) reveals lack of clinical studies and weak preclinical evidence for interaction between glucose regulating drugs and environmental contaminant exposure.","Biochemical pharmacology","Elsevier BV","10.1016/j.bcp.2025.117575","https://doi.org/10.1016/j.bcp.2025.117575","41330518","https://pubmed.ncbi.nlm.nih.gov/41330518/","https://doi.org/10.1016/j.bcp.2025.117575",null],["3","R0014804","R0014804.pdf","open_download_failed","systematic_review","Yu H","2026","Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70267","https://doi.org/10.1002/oby.70267","42644866","https://pubmed.ncbi.nlm.nih.gov/42644866/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70267",null],["3","R0015227","R0015227.pdf","open_download_failed","systematic_review","Nordvall LM","2026","Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology. 2026;133;589-598).","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2026.05.017","https://doi.org/10.1016/j.ophtha.2026.05.017","42283648","https://pubmed.ncbi.nlm.nih.gov/42283648/","https://www.aaojournal.org/article/S0161-6420(26)00365-9/pdf",null],["3","R0015324","R0015324.pdf","open_download_failed","systematic_review","Lu YT","2026","Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70452","https://doi.org/10.1111/dom.70452","41508932","https://pubmed.ncbi.nlm.nih.gov/41508932/","https://www.authorea.com/doi/pdf/10.22541/au.174919687.75586804/v1",null],["3","R0015397","R0015397.pdf","open_download_failed","systematic_review","Soliman A","2026","Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-01880-0","https://doi.org/10.1007/s40200-026-01880-0","41883513","https://pubmed.ncbi.nlm.nih.gov/41883513/","https://pubmed.ncbi.nlm.nih.gov/41883513/","PROSPERO:CRD42025633998"],["3","R0016083","R0016083.pdf","open_download_failed","systematic_review","Agon HC","2026","Effects of Glucose-Lowering Medications on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70087","https://doi.org/10.1111/obr.70087","41622606","https://pubmed.ncbi.nlm.nih.gov/41622606/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.70087",null],["3","R0016371","R0016371.pdf","open_download_failed","systematic_review","Spagnolo M","2026","Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf358","https://doi.org/10.1093/eurjpc/zwaf358","40567168","https://pubmed.ncbi.nlm.nih.gov/40567168/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwaf358/63587062/zwaf358.pdf",null],["3","R0016562","R0016562.pdf","open_download_failed","systematic_review","Souza M","2026","Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70565","https://doi.org/10.1111/apt.70565","41645601","https://pubmed.ncbi.nlm.nih.gov/41645601/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70565",null],["3","R0016565","R0016565.pdf","open_download_failed","systematic_review","Bajorek B","2026","Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70286","https://doi.org/10.1002/bcp.70286","41126794","https://pubmed.ncbi.nlm.nih.gov/41126794/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70286",null],["3","R0016586","R0016586.pdf","free_to_read","systematic_review","Wagner E","2026","Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.","The lancet. Psychiatry","Elsevier BV","10.1016/s2215-0366(25)00332-3","https://doi.org/10.1016/s2215-0366(25)00332-3","41506273","https://pubmed.ncbi.nlm.nih.gov/41506273/","https://doi.org/10.1016/s2215-0366(25)00332-3",null],["3","R0017013","R0017013.pdf","open_download_failed","systematic_review","Koh B","2026","Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001028","https://doi.org/10.1097/hep.0000000000001028","39028914","https://pubmed.ncbi.nlm.nih.gov/39028914/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11913421/pdf/nihms-2047761.pdf",null],["3","R0017057","R0017057.pdf","free_to_read","systematic_review","Wong S","2026","The association between depressive symptom severity and metabolic disturbances in major depressive and bipolar disorders: A systematic review and meta-analysis.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2025.120783","https://doi.org/10.1016/j.jad.2025.120783","41318004","https://pubmed.ncbi.nlm.nih.gov/41318004/","https://doi.org/10.1016/j.jad.2025.120783",null],["3","R0017443","R0017443.pdf","free_to_read","systematic_review","Luo P","2026","Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2026.108420","https://doi.org/10.1016/j.phrs.2026.108420","42668074","https://pubmed.ncbi.nlm.nih.gov/42668074/","https://doi.org/10.1016/j.phrs.2026.108420",null],["3","R0029555","R0029555.pdf","open_download_failed","systematic_review","Morrow S","2026","Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.70247","https://doi.org/10.1111/jdv.70247","41416383","https://pubmed.ncbi.nlm.nih.gov/41416383/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70247",null],["3","R0030113","R0030113.pdf","free_to_read","systematic_review","Tsutsumi T","2026","Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101077","https://doi.org/10.1016/j.medj.2026.101077","41946364","https://pubmed.ncbi.nlm.nih.gov/41946364/","https://www.research.ed.ac.uk/files/633843160/Med_Manuscript_production_Jonathan_Fallowfield.pdf",null],["3","R0032526","R0032526.pdf","free_to_read","systematic_review","Paul E. Hernández-Montes","2026","Clinical outcomes with GLP-1 receptor agonists in obese HFpEF: systematic review and meta- analysis","Revista Médica Del Hospital General De México","Publicidad Permanyer, SLU","10.24875/hgmx.25000035","https://doi.org/10.24875/hgmx.25000035",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.24875/hgmx.25000035",null],["3","R0036288","R0036288.pdf","no_doi","systematic_review","Sérgio Oliveira Pires [UNIFESP] Teixeira","2026","Semaglutide and tirzepatide – comparison of weight regain after treatment discontinuation: a systematic review","UNIFESP Institutional Repository (Universidade Federal de São Paulo)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036307","R0036307.pdf","no_doi","systematic_review","Rolanda Willacy","2026","GLP-1 Agonists and Total Knee Arthroplasty Outcomes: A Systematic Review","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036358","R0036358.pdf","no_doi","systematic_review","Catherine Homer","2026","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036361","R0036361.pdf","no_doi","systematic_review","Marie Balfour","2026","Metabolic Dysfunction-Associated Steatohepatitis Systematic Review and Meta-Analysis: From Diagnosis to Newest Available Medications and Outcomes","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036379","R0036379.pdf","no_doi","systematic_review","Kalliopi Tsapa","2026","Comparative effects of GLP-1 receptor agonist–based therapies approved for weight management worldwide in adults with overweight or obesity: protocol for a global systematic review and network meta-analysis","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037863","R0037863.pdf","free_to_read","systematic_review","Jin‐Yi Wan","2026","Symptom-Level Gastrointestinal Adverse Event Profiles of GLP-1 Receptor Agonists: A Network Meta-Analysis to Inform Initial Agent Selection","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6836584","https://doi.org/10.2139/ssrn.6836584",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6836584",null],["3","R0037969","R0037969.pdf","open_download_failed","systematic_review","D.J. Halim","2026","232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis","ESMO Open","Elsevier BV","10.1016/j.esmoop.2026.107864","https://doi.org/10.1016/j.esmoop.2026.107864",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.esmoopen.com/article/S2059-7029(26)01806-5/pdf",null],["3","R0038063","R0038063.pdf","free_to_read","systematic_review","Xiao Liu","2026","Efficacy of SGLT2i and GLP-1RA in acute myocardial infarction: A meta-analysis of randomized controlled trials","Journal of Molecular and Cellular Cardiology Plus","Elsevier BV","10.1016/j.jmccpl.2025.100630","https://doi.org/10.1016/j.jmccpl.2025.100630",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jmccpl.2025.100630",null],["3","R0038452","R0038452.pdf","free_to_read","systematic_review","Juana Sophiya Ariza Garcia","2026","WCN26-1902 KIDNEY OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2026.104587","https://doi.org/10.1016/j.ekir.2026.104587",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2026.104587",null],["3","R0038827","R0038827.pdf","free_to_read","systematic_review","S U N G E Makawa","2026","Female participation in cardiovascular trials of antidiabetic medications: a SAGER-Guided systematic review","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.411","https://doi.org/10.1093/eurjpc/zwag249.411",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.411",null],["3","R0039838","R0039838.pdf","free_to_read","systematic_review","Jiaqi Duan","2026","GLP-1 Receptor Agonists Across Different Levels of Physical Activity and Lifestyle: A Bayesian Network Meta-Analysis in Adults Who Are Overweight or Obese","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7205699","https://doi.org/10.2139/ssrn.7205699",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7205699",null],["3","R0040526","R0040526.pdf","open_download_failed","systematic_review","Grace Vanderheyden","2026","Efficacy and Safety of GLP-1 Receptor Agonists in Adults with Overweight/Obesity: A Systematic Review","Journal of Food Studies","Macrothink Institute, Inc.","10.5296/jfs.v15i1.23736","https://doi.org/10.5296/jfs.v15i1.23736",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.macrothink.org/journal/index.php/jfs/article/download/23736/18325",null],["3","R0040881","R0040881.pdf","open_download_failed","systematic_review","S. Sathiyapal","2026","The Impact of GLP-1 Receptor Agonists on Lipid Subfractions and Cardiometabolic Risk in Non-Diabetic Adults: A Systematic Review and Meta-Analysis","Heart Lung and Circulation","Elsevier BV","10.1016/j.hlc.2026.07.573","https://doi.org/10.1016/j.hlc.2026.07.573",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.heartlungcirc.org/article/S1443-9506(26)01075-9/pdf",null],["3","R0043212","R0043212.pdf","open_download_failed","systematic_review","Ronald Watema-Lord","2026","Cost-utility of semaglutide in the management of obesity or overweight: A systematic review","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2026.100744","https://doi.org/10.1016/j.obmed.2026.100744",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S245184762600062X/pdf",null],["3","R0043274","R0043274.pdf","free_to_read","systematic_review","Pedro Robson Costa Passos","2026","Hepatic Events Prevention by Anti-Hyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-Analysis",null,"American Diabetes Association","10.2337/figshare.31795342.v1","https://doi.org/10.2337/figshare.31795342.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.31795342.v1",null],["3","R0043780","R0043780.pdf","free_to_read","systematic_review","Sara Eltirafi","2026","ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES","European Stroke Journal","Oxford University Press (OUP)","10.1093/esj/aakag023.1061","https://doi.org/10.1093/esj/aakag023.1061",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/esj/aakag023.1061",null],["3","R0043849","R0043849.pdf","open_download_failed","systematic_review","Jazzaa Hammad Mutlaq Alshammari","2026","Efficacy of Semaglutide in Reducing Visceral Adipose Tissue and Ectopic Fat Deposition: A Systematic Review of Clinical Trials","Journal of Clinical Practice and Medical Research","AMO Publisher","10.59324/jcpmr.2026.2(4).16","https://doi.org/10.59324/jcpmr.2026.2(4).16",null,"https://pubmed.ncbi.nlm.nih.gov//","https://jcpmr.com/index.php/journal/article/download/167/128",null],["3","R0043942","R0043942.pdf","no_doi","systematic_review","Mariana Resendiz Chavez","2026","Evaluation of the Influence of Route of Administration and Patient Covariates on a Pharmacokinetics and Pharmacodynamics Model: A Model-Based Meta-Analysis of Oral versus Subcutaneous Semaglutide","Uppsala University Publications (Uppsala University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044068","R0044068.pdf","no_doi","systematic_review","Alesia Isamar Julca Malca","2026","Efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RA) in primary prevention of cardiovascular events in patients with type 2 diabetes mellitus without established cardiovascular disease: a systematic review and meta-analysis of randomized clinical trials","Universidad Peruana Cayetano Heredia Institutional Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044145","R0044145.pdf","no_doi","systematic_review","Lilio <1993> Hu","2026","Impact of GLP-1 receptor agonists on renal function and weight loss in patients with chronic kidney disease and obesity: a systematic review and meta-analysis","AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044431","R0044431.pdf","no_doi","systematic_review","María Icíar Lloréns Martín","2026","Efficacy of new obesity treatments GLP-1ar (semaglutide) and dual agonists GLP-1 + GIPar (tirzepatide) in the treatment of weight regain and insufficient weight loss after bariatric-metabolic surgery: a systematic review and meta-analysis","e_Buah",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044554","R0044554.pdf","open_download_failed","systematic_review","L. Priestley-Barnham","2026","Distribution of Lipoprotein(a) Concentrations in Children and Young People with Familial Hypercholesterolemia (FH) compared to those without FH: A Systematic Review and Narrative Synthesis","Atherosclerosis Plus","Elsevier BV","10.1016/j.athplu.2026.100596","https://doi.org/10.1016/j.athplu.2026.100596",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S2667089526000519/pdf",null],["3","R0045049","R0045049.pdf","open_download_failed","systematic_review","L Mlaćo Skenderi","2026","DB20 Maintenance strategies following GLP-1/GIP-based obesity pharmacotherapy: a systematic review and exploratory meta-analysis","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag128.028","https://doi.org/10.1093/ejendo/lvag128.028",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_2/lvag128.028/70769639/lvag128.028.pdf","PROSPERO:CRD420261411350"],["3","R0045198","R0045198.pdf","free_to_read","systematic_review","Johann Roessler","2026","Cardiometabolic effects of dual GLP-1 and glucagon receptor agonists: a systematic review and meta-analysis of randomised controlled trials",null,"American Diabetes Association","10.2337/figshare.33167144.v1","https://doi.org/10.2337/figshare.33167144.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.33167144.v1","PROSPERO:CRD420261295754"],["3","R0045218","R0045218.pdf","free_to_read","systematic_review","Rachel M. Slaton","2026","Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials","JAPhA Pharmacotherapy","Elsevier BV","10.1016/j.japhar.2026.100032","https://doi.org/10.1016/j.japhar.2026.100032",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.japhar.2026.100032",null],["3","R0045245","R0045245.pdf","free_to_read","systematic_review","Minahil Rasul","2026","Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies","Therapeutic Advances in Psychopharmacology","SAGE Publications","10.1177/20451253261473919","https://doi.org/10.1177/20451253261473919",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/20451253261473919",null],["3","R0045312","R0045312.pdf","free_to_read","systematic_review","Omer Mohammed","2026","A-109 | Cardiovascular outcomes with tirzepatide versus GLP-1 RA in patients with type 2 diabetes mellitus: a systematic review and meta-analysis post-SURPASS-CVOT trial","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104600","https://doi.org/10.1016/j.jscai.2026.104600",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104600",null],["3","R0045466","R0045466.pdf","open_download_failed","systematic_review","Ishtiaq Ahmad","2026","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss and Cardiovascular Protection in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analysis","Journal of Diabetes Research Review & Reports","Scientific Research and Community Ltd","10.47363/jdrr/2026(8)209","https://doi.org/10.47363/jdrr/2026(8)209",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47363/jdrr/2026(8)209",null],["3","R0045586","R0045586.pdf","free_to_read","systematic_review","Reza Amani‐Beni","2026","Comparative effects of glucagon-like peptide-1-based regimens on peripheral arterial and limb events in type 2 diabetes: a network meta-analysis of randomized trials","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02271-4","https://doi.org/10.1186/s13098-026-02271-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02271-4","PROSPERO:CRD420251244166"],["3","R0045678","R0045678.pdf","free_to_read","systematic_review","Muhammad Hassan","2026","Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02248-3","https://doi.org/10.1186/s13098-026-02248-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02248-3",null],["3","R0045790","R0045790.pdf","open_download_failed","systematic_review","Muhammad Sharjeel Abbas","2026","26-A-13162-ACC USE OF ECNOGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2913","https://doi.org/10.1016/j.jacc.2026.02.2913",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/j.jacc.2026.02.2913?download=true",null],["3","R0046071","R0046071.pdf","open_download_failed","systematic_review","Gianmarco Adinolfi","2026","Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis","Endocrines","MDPI AG","10.3390/endocrines7010009","https://doi.org/10.3390/endocrines7010009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-396X/7/1/9/pdf?version=1772628656",null],["3","R0046170","R0046170.pdf","open_download_failed","systematic_review","Flávio Henrique Figueiredo de Macêdo Andrade","2026","Comparative clinical outcomes and metabolomic considerations of the use of tirzepatide and retatrutide in the treatment of obesity: a systematic and umbrella review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn26107","https://doi.org/10.54448/ijn26107",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/538/473",null],["3","R0046212","R0046212.pdf","free_to_read","systematic_review","Ehab Al Mashtoub","2026","Glucagon-like peptide-1-based incretin agonists in obesity-related heart failure with preserved ejection fraction: A systematic review and meta-analysis","World Journal of Meta-Analysis","Baishideng Publishing Group Inc.","10.13105/wjma.v14.i2.119849","https://doi.org/10.13105/wjma.v14.i2.119849",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.13105/wjma.v14.i2.119849",null],["3","R0046530","R0046530.pdf","free_to_read","systematic_review","Mohammed A. Elbahloul","2026","Dual GLP-1/glucagon receptor agonists in metabolic dysfunction–associated steatotic liver disease: a meta-analysis of randomized controlled trials","BMC Gastroenterology","Springer Science and Business Media LLC","10.1186/s12876-026-05324-0","https://doi.org/10.1186/s12876-026-05324-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12876-026-05324-0",null],["3","R0046531","R0046531.pdf","free_to_read","systematic_review","Chia Siang Kow","2026","Efficacy and safety of GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of randomized controlled trials","Proceedings of Singapore Healthcare","SAGE Publications","10.1177/20101058261424018","https://doi.org/10.1177/20101058261424018",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/20101058261424018",null],["3","R0046596","R0046596.pdf","open_download_failed","systematic_review","A. Cai","2026","Comparative Effectiveness of GLP-1 RAs Versus SGLT2 Inhibitors in Patients With Heart Failure With Preserved Ejection Fraction: A Network Meta-Analysis of Cardiovascular Outcomes, Mortality, and Hospitalisations","Heart Lung and Circulation","Elsevier BV","10.1016/j.hlc.2026.07.279","https://doi.org/10.1016/j.hlc.2026.07.279",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.heartlungcirc.org/article/S1443-9506(26)00781-X/pdf",null],["3","R0046668","R0046668.pdf","no_doi","systematic_review","Alexandria Ratzki-Leewing","2026","Impact of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Patient-Reported Quality of Life in Adults: A Systematic Review Protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046679","R0046679.pdf","open_download_failed","systematic_review","Ravi Venkata Sai Krishna Medarametla","2026","26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.688","https://doi.org/10.1016/j.jacc.2026.02.688",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/j.jacc.2026.02.688?download=true",null],["3","R0046732","R0046732.pdf","free_to_read","systematic_review","Pedram Pirmoradian","2026","GLP-1 receptor agonists in patients with alcohol use disorder and related liver disease: a systematic review and meta-analysis","European journal of medical research","Springer Science and Business Media LLC","10.1186/s40001-026-04867-y","https://doi.org/10.1186/s40001-026-04867-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s40001-026-04867-y",null],["3","R0046823","R0046823.pdf","free_to_read","systematic_review","Dorsa Shekouh","2026","Association of glucagon-like peptide-1 receptor agonist therapy with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02268-z","https://doi.org/10.1186/s13098-026-02268-z",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02268-z",null],["3","R0046835","R0046835.pdf","free_to_read","systematic_review","Rafał Bednarczyk","2026","TIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.1(49).2026.4671","https://doi.org/10.31435/ijitss.1(49).2026.4671",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.1(49).2026.4671",null],["3","R0046995","R0046995.pdf","open_download_failed","systematic_review","Sebastián Eustaquio Martín Pérez","2026","Glucagon-like Peptide-1 Receptor Agonists as Modulators of Pain-Related Mechanisms: A Systematic Review of Experimental and Translational Evidence","Rheumato","MDPI AG","10.3390/rheumato6030016","https://doi.org/10.3390/rheumato6030016",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2674-0621/6/3/16/pdf?version=1783569053","PROSPERO:CRD420261367538"],["3","R0047684","R0047684.pdf","open_download_failed","systematic_review","Nicole Ann Tesoro","2026","26-A-12618-ACC IMPACT OF GLP-1 RECEPTOR AGONISTS AND DUAL AGONISTS ON LIVER ENZYMES AND IMAGING OUTCOMES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.473","https://doi.org/10.1016/j.jacc.2026.02.473",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/j.jacc.2026.02.473?download=true",null],["3","R0047735","R0047735.pdf","free_to_read","systematic_review","Emre Adalier","2026","Perioperative anesthesia and aspiration-related outcomes in patients receiving GLP-1 receptor agonists undergoing urgent and elective procedures: a systematic review","Trends in Anaesthesia and Critical Care","Elsevier BV","10.1016/j.tacc.2026.101660","https://doi.org/10.1016/j.tacc.2026.101660",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.tacc.2026.101660","PROSPERO:CRD420261334646"],["3","R0047991","R0047991.pdf","free_to_read","systematic_review","Vinícius Ricieri Ferraz","2026","GLP-1 Receptor Agonists in Elective Spine Surgery: A Systematic Review of Fusion Outcomes, Perioperative Safety, and Procedure-Specific Risk","North American Spine Society Journal (NASSJ)","Elsevier BV","10.1016/j.xnsj.2026.100942","https://doi.org/10.1016/j.xnsj.2026.100942",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.xnsj.2026.100942",null],["3","R0048331","R0048331.pdf","free_to_read","systematic_review","Maurice Tiotsop","2026","Incretin-Based Therapy for Cardiovascular and Cardiorenal Risk Reduction: A Systematic Review and Meta-Analysis of GLP-1 Receptor Agonist and Dual Incretin Randomized Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7028058","https://doi.org/10.2139/ssrn.7028058",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7028058",null],["3","R0048420","R0048420.pdf","free_to_read","systematic_review","Tasneem Hetta","2026","ABSTRACT NUMBER: ESOC2026A1557 EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON STROKE RISK AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS","European Stroke Journal","Oxford University Press (OUP)","10.1093/esj/aakag023.742","https://doi.org/10.1093/esj/aakag023.742",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/esj/aakag023.742",null],["3","R0048723","R0048723.pdf","free_to_read","systematic_review","Ellice Caldwell-Dunn","2026","Dose Equivalence across GLP-1 Receptor Agonists: A Dose Response Meta-Analysis and Digital Tool Development","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6509069","https://doi.org/10.2139/ssrn.6509069",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6509069",null],["3","R0048898","R0048898.pdf","free_to_read","systematic_review","Sima Ahadieh","2026","Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis",null,"International Society of Pharmacometrics","10.70534/gfse7218","https://doi.org/10.70534/gfse7218",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.70534/gfse7218",null],["3","R0049005","R0049005.pdf","no_doi","systematic_review","Conor Corbett","2026","Commentary and Critical Appraisal of a Systematic Review of GLP-1 Receptor Agonists and Bone Health in Type 2 Diabetes","CLOK (University of Central Lancashire)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0049623","R0049623.pdf","free_to_read","systematic_review","Saaed Abunada","2026","Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02250-9","https://doi.org/10.1186/s13098-026-02250-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02250-9",null],["3","R0050231","R0050231.pdf","free_to_read","systematic_review","Baoqi Zeng","2026","Characteristics of meta-analyses of multi-indication drugs: a systematic review of systematic reviews","BMC Medical Research Methodology","Springer Science and Business Media LLC","10.1186/s12874-026-03018-5","https://doi.org/10.1186/s12874-026-03018-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12874-026-03018-5",null],["3","R0050898","R0050898.pdf","free_to_read","systematic_review","Nabeel M. Abdo","2026","Pharmacological Modifiers of Atrial Fibrillation Recurrence After Catheter Ablation: An Umbrella Review of Meta-Analyses","Heart Rhythm O2","Elsevier BV","10.1016/j.hroo.2026.08.149","https://doi.org/10.1016/j.hroo.2026.08.149",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.hroo.2026.08.149","PROSPERO:CRD420261361247"],["3","R0052505","R0052505.pdf","free_to_read","systematic_review","Mateusz Zwierz","2026","Endogenous oxyntomodulin in metabolic homeostasis and clinical utility as a prognostic biomarker: a systematic review","BMC Medicine","Springer Science and Business Media LLC","10.1186/s12916-026-05184-1","https://doi.org/10.1186/s12916-026-05184-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12916-026-05184-1","PROSPERO:CRD420261308863"],["3","R0052661","R0052661.pdf","no_doi","systematic_review","Utsab Panta","2026","Incretin-based therapy for cardiovascular and cardiorenal risk reduction: a systematic review and meta-analysis of GLP-1 receptor agonist and dual incretin randomized trials","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0053374","R0053374.pdf","free_to_read","systematic_review","S Christoforou","2026","Assessing the efficacy of large language models in data extraction for a meta-analysis on the role of glucagon-like peptide-1 receptor agonists in heart failure","European Heart Journal - Digital Health","Oxford University Press (OUP)","10.1093/ehjdh/ztaf143.012","https://doi.org/10.1093/ehjdh/ztaf143.012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ehjdh/ztaf143.012",null],["3","R0053422","R0053422.pdf","free_to_read","systematic_review","Rasha Mahmoud","2026","Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review","Cureus","Springer Science and Business Media LLC","10.7759/cureus.116733","https://doi.org/10.7759/cureus.116733",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.7759/cureus.116733",null],["3","R0053558","R0053558.pdf","open_download_failed","systematic_review","J P C Lima","2026","(040) Can Glucagon-Like Peptide-1 Receptor Agonists Be Used in Men with Type 2 Diabetes Mellitus or Obesity Who Complain of Erectile Dysfunction? A Systematic Review and Meta-Analysis","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag118.035","https://doi.org/10.1093/jsxmed/qdag118.035",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/23/Supplement_4/qdag118.035/68472380/qdag118.035.pdf",null],["3","R0053615","R0053615.pdf","free_to_read","systematic_review","Joseph D. Giacalone","2026","Comparative post-operative outcomes in glucagon-like peptide-1 receptor agonist users vs. non-users following total shoulder arthroplasty: a systematic review and meta-analysis","Seminars in Arthroplasty JSES","Elsevier BV","10.1016/j.sart.2026.151594","https://doi.org/10.1016/j.sart.2026.151594",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.sart.2026.151594",null],["3","R0053652","R0053652.pdf","open_download_failed","systematic_review","I Sirbegovic","2026","RP06 Effects of GLP-1 receptor agonists on ovulatory function and reproductive hormonal parameters in women with polyendocrine metabolic ovarian syndrome: a systematic review","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag128.074","https://doi.org/10.1093/ejendo/lvag128.074",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ejendo/article-pdf/195/Supplement_2/lvag128.074/70769682/lvag128.074.pdf",null],["3","R0053746","R0053746.pdf","free_to_read","systematic_review","Anastasia Tereshchenko","2026","Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus","Therapeutic Advances in Endocrinology and Metabolism","SAGE Publications","10.1177/20420188261474093","https://doi.org/10.1177/20420188261474093",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/20420188261474093","PROSPERO:CRD420251014217"],["3","R0053919","R0053919.pdf","open_download_failed","systematic_review","Naseem Eisa","2026","Efficacy of GLP-1 Receptor Agonists for Fibrosis Regression in Patients with MASH and F2-F3 Fibrosis: A Systematic Review and Meta-Analysis","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.06.006","https://doi.org/10.1016/j.aed.2026.06.006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.endocrinologydiabetes.org/article/S3050-9157(26)00125-6/pdf",null],["3","R0054335","R0054335.pdf","free_to_read","systematic_review","Yao Li","2026","GLP-1 Receptor Agonist Therapy in Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6752746","https://doi.org/10.2139/ssrn.6752746",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6752746",null],["3","R0054454","R0054454.pdf","free_to_read","systematic_review","Aristomenis G. Alevizopoulos","2026","Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context","Therapeutic Advances in Psychopharmacology","SAGE Publications","10.1177/20451253261457548","https://doi.org/10.1177/20451253261457548",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/20451253261457548",null],["3","R0054665","R0054665.pdf","free_to_read","systematic_review","Rana A. Alotaibi","2026","Liraglutide on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review","Journal of Advanced Trends in Medical Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/atmr.atmr_146_25","https://doi.org/10.4103/atmr.atmr_146_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/atmr.atmr_146_25",null],["3","R0054996","R0054996.pdf","free_to_read","systematic_review","Isobel Emptage","2026","The Effectiveness and Safety of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Binge Eating in Patients with Obesity: A Systematic Review and Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6176554","https://doi.org/10.2139/ssrn.6176554",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6176554",null],["3","R0055114","R0055114.pdf","no_doi","systematic_review","Sarah Dib","2026","Preconception, pregnancy and postnatal use of GLP-1RA based therapies in diabetes: a systematic review and international expert consensus statement on clinical need and human safety data in women with type 1, type 2 or gestational diabetes","Research Portal (King's College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055206","R0055206.pdf","free_to_read","systematic_review","Vinicius Remus Ballotin","2026","Residual gastric content and aspiration-related outcomes in perioperative patients treated with semaglutide: A systematic review and meta-analysis","World Journal of Gastrointestinal Surgery","Baishideng Publishing Group Inc.","10.4240/wjgs.121449","https://doi.org/10.4240/wjgs.121449",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4240/wjgs.121449",null],["3","R0055498","R0055498.pdf","free_to_read","systematic_review","Guanglan Zou","2026","Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trials","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02264-3","https://doi.org/10.1186/s13098-026-02264-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02264-3","PROSPERO:CRD420251067874"],["3","R0055518","R0055518.pdf","free_to_read","systematic_review","Adili Tuersun","2026","Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists Versus either Agent Alone in Type 2 Diabetes: A Network Meta-Analysis with An Exploratory Analysis of Treatment Initiation Design","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7256960","https://doi.org/10.2139/ssrn.7256960",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7256960",null],["3","R0055597","R0055597.pdf","free_to_read","systematic_review","L. T. Savin","2026","Side effects of androgen deprivation in prostate cancer and their correction: Systematic review","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/ms2026-151","https://doi.org/10.21518/ms2026-151",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21518/ms2026-151",null],["3","R0055767","R0055767.pdf","free_to_read","systematic_review","Ella A. Kovaleva","2026","Efficacy and safety of liraglutide and semaglutide in obese children and adolescents: a systematic review","Medical Technologies Assessment and Choice","Media Sphere Publishing House","10.17116/medtech202648031110","https://doi.org/10.17116/medtech202648031110",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17116/medtech202648031110",null],["3","R0055779","R0055779.pdf","free_to_read","systematic_review","Sabrina Schlesinger","2026","Efficacy of Incretin Agonists in MASH: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7511460","https://doi.org/10.2139/ssrn.7511460",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7511460",null],["3","R0055783","R0055783.pdf","free_to_read","systematic_review","Yavuz Ayar","2026","Cardiorenal effects of SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes: a systematic review and meta-analysis","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02586-3","https://doi.org/10.1186/s12902-026-02586-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02586-3",null],["3","R0055795","R0055795.pdf","no_doi","systematic_review","Harry Claireaux","2026","Glucagon-like peptide-1 receptor agonists for osteoarthritis: a systematic review","Spiral (Imperial College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055809","R0055809.pdf","open_download_failed","systematic_review","Linge Jian","2026","Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis","Open Research (University of Surrey)","Wiley","10.1002/viw2.70204","https://doi.org/10.1002/viw2.70204",null,"https://pubmed.ncbi.nlm.nih.gov//","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/viw2.70204",null],["3","R0055959","R0055959.pdf","open_download_failed","systematic_review","Pischetola A","2026","Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review.","Translational andrology and urology","AME Publishing Company","10.21037/tau-2026-0541","https://doi.org/10.21037/tau-2026-0541","42866845","https://pubmed.ncbi.nlm.nih.gov/42866845/","https://doi.org/10.21037/tau-2026-0541","PROSPERO:CRD420261366483"],["3","R0056175","R0056175.pdf","free_to_read","systematic_review","Ye-xin Chen","2026","Metformin and GLP-1 receptor agonists for antipsychotic-induced metabolic disturbances: a systematic review and network meta-analysis","BMC Medicine","Springer Science and Business Media LLC","10.1186/s12916-026-05280-2","https://doi.org/10.1186/s12916-026-05280-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12916-026-05280-2",null],["3","R0056189","R0056189.pdf","free_to_read","systematic_review","Jin Peng","2026","Effects of approved anti-obesity medications on depression symptoms, psychiatric adverse events, and quality of life in adults who are overweight or obesity: a systematic review and Bayesian network meta-analysis","BMC Psychiatry","Springer Science and Business Media LLC","10.1186/s12888-026-08721-7","https://doi.org/10.1186/s12888-026-08721-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12888-026-08721-7","PROSPERO:CRD420261400491"],["3","R0056198","R0056198.pdf","no_doi","systematic_review","Adesh D. Mishra","2026","Comparative Effectiveness of GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review","Journal of chemical health risks",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056230","R0056230.pdf","no_doi","systematic_review","Antonio Maria Labate","2026","Semaglutide across cardiovascular and kidney outcome trials: a systematic review and stratified synthesis","Romanian Journal of Diabetes Nutrition and Metabolic Diseases",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD420261441534"],["3","R0056277","R0056277.pdf","free_to_read","systematic_review","Aditya Kumar Gupta","2026","Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review","Medical Sciences","MDPI AG","10.3390/medsci14060652","https://doi.org/10.3390/medsci14060652",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/medsci14060652",null],["3","R0056297","R0056297.pdf","free_to_read","systematic_review","Saad Alhumaid","2026","Effects of glucagon-like peptide-1 receptor agonists on asthma outcomes in patients with obesity and/or metabolic comorbidities: a systematic review of observational cohort studies","BMC Pulmonary Medicine","Springer Science and Business Media LLC","10.1186/s12890-026-04798-8","https://doi.org/10.1186/s12890-026-04798-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12890-026-04798-8","PROSPERO:CRD420261361548"],["3","R0056398","R0056398.pdf","free_to_read","systematic_review","Angela Marie Abbatecola","2026","Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Nutrients","MDPI AG","10.3390/nu18203312","https://doi.org/10.3390/nu18203312",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/nu18203312",null],["3","R0056434","R0056434.pdf","open_download_failed","systematic_review","Sophie Awad","2026","Long-Term Effects of GLP-1 and GIP Receptor Agonists on Quality of Life: A Systematic Review","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2026.109114","https://doi.org/10.1016/j.cdnut.2026.109114",null,"https://pubmed.ncbi.nlm.nih.gov//","https://cdn.nutrition.org/article/S2475-2991(26)01479-4/pdf",null],["3","R0056458","R0056458.pdf","free_to_read","systematic_review","Arianna Pischetola","2026","SGLT2 inhibitors versus GLP-1 receptor agonists and DPP-4 inhibitors for incident and recurrent nephrolithiasis: An EAU Endourology Systematic Review","European Urology Open Science","Elsevier BV","10.1016/s2666-1683(26)01909-9","https://doi.org/10.1016/s2666-1683(26)01909-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s2666-1683(26)01909-9",null],["3","R0056471","R0056471.pdf","open_download_failed","systematic_review","González-Cruz DC","2026","Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.","BMJ medicine","BMJ","10.1136/bmjmed-2026-002780","https://doi.org/10.1136/bmjmed-2026-002780","42866418","https://pubmed.ncbi.nlm.nih.gov/42866418/","https://bmjmedicine.bmj.com/content/5/1/e002780.full.pdf","PROSPERO:CRD42023429170"],["3","R0056482","R0056482.pdf","no_doi","systematic_review","Ángel Augusto Naranjo-Ramos","2026","GASTRIC ULTRASOUND FOR ASPIRATION-RISK STRATIFICATION IN PATIENTS RECEIVING GLP-1 RECEPTOR AGONISTS: AN INTEGRATED SYSTEMATIC REVIEW AND EVIDENCE UPDATE OF ULTRASONOGRAPHIC, ENDOSCOPIC, AND ANESTHETIC OUTCOMES","REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056528","R0056528.pdf","free_to_read","systematic_review","Marco Marchetti","2026","Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review","Metabolites","MDPI AG","10.3390/metabo16100757","https://doi.org/10.3390/metabo16100757",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/metabo16100757",null],["3","R0056534","R0056534.pdf","free_to_read","systematic_review","Ahmed Elazab","2026","Cardiovascular and functional outcomes of glucagon-like peptide−1 receptor agonists in heart failure with preserved or mildly reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials","European journal of medical research","Springer Science and Business Media LLC","10.1186/s40001-026-05199-7","https://doi.org/10.1186/s40001-026-05199-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s40001-026-05199-7",null],["3","R0056557","R0056557.pdf","free_to_read","systematic_review","Indrajit Banerjee","2026","Liraglutide plus Metformin versus Metformin alone in women living with Polyendocrine metabolic ovarian syndrome (PMOS): A Systematic Review and Meta-analysis of Randomized Controlled Trials","Nepal Journal of Epidemiology","Nepal Journals Online (JOL)","10.3126/nje.v16i3.99703","https://doi.org/10.3126/nje.v16i3.99703",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3126/nje.v16i3.99703",null],["3","R0056560","R0056560.pdf","no_doi","systematic_review","Claire Williams","2026","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences [abstract only]","SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056568","R0056568.pdf","no_doi","systematic_review","Fiona McGinnes","2026","GLP-1 Receptor Agonists in Paediatric obesity: An Umbrella Review [abstract only]","SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056576","R0056576.pdf","no_doi","systematic_review","Kateryna Nohejlova","2026","Neuroprotective efficacy of semaglutide in preclinical in vivo rodent models: a systematic review and quantitative meta-analysis","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056605","R0056605.pdf","free_to_read","systematic_review","Massimo Nardone","2026","Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials","EClinicalMedicine","Elsevier BV","10.1016/j.eclinm.2026.104251","https://doi.org/10.1016/j.eclinm.2026.104251",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.eclinm.2026.104251","PROSPERO:CRD420251146441"],["3","R0056607","R0056607.pdf","open_download_failed","systematic_review","Sun SP","2026","GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.","Frontiers in medicine","Frontiers Media SA","10.3389/fmed.2026.1800909","https://doi.org/10.3389/fmed.2026.1800909","42865473","https://pubmed.ncbi.nlm.nih.gov/42865473/","https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1800909/pdf","PROSPERO:CRD420261287573"],["3","R0056648","R0056648.pdf","free_to_read","systematic_review","Razan Suliman Alhumayed","2026","Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02641-z","https://doi.org/10.1186/s12902-026-02641-z",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02641-z","PROSPERO:CRD420261296560"],["3","R0056669","R0056669.pdf","free_to_read","systematic_review","Yiwei Shang","2026","Semaglutide in adults receiving dialysis: anthropometric outcomes and transplant-access milestones in a systematic review with exploratory meta‑analysis","BMC Nephrology","Springer Science and Business Media LLC","10.1186/s12882-026-05448-1","https://doi.org/10.1186/s12882-026-05448-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12882-026-05448-1",null],["3","R0056697","R0056697.pdf","open_download_failed","systematic_review","Zouina Sarfraz","2026","Should oncology teams reassess GLP-1 receptor agonist management during cancer care? A meta-analysis.","JCO Oncology Practice","American Society of Clinical Oncology (ASCO)","10.1200/op.2026.22.10_suppl.533","https://doi.org/10.1200/op.2026.22.10_suppl.533",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ascopubs.org/doi/pdfdirect/10.1200/OP.2026.22.10_suppl.533",null],["3","R0057009","R0057009.pdf","free_to_read","systematic_review","Gaskin PS","2026","Low Weight Loss Response to Incretin Analogs: A Systematic Review.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70145","https://doi.org/10.1111/obr.70145","42083728","https://pubmed.ncbi.nlm.nih.gov/42083728/","https://doi.org/10.1111/obr.70145",null],["3","R0000576","R0000576.pdf","open_download_failed","systematic_review","Berg S","2025","Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13929","https://doi.org/10.1111/obr.13929","40186344","https://pubmed.ncbi.nlm.nih.gov/40186344/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13929",null],["3","R0000626","R0000626.pdf","open_download_failed","systematic_review","Chou OHI","2025","Differential effects of glucagon-like peptide-1 receptor agonist classes on blood pressure: a systematic review and network meta-analysis of randomised controlled trials with meta-regression","medRxiv","openRxiv","10.1101/2025.07.05.25330933","https://doi.org/10.1101/2025.07.05.25330933",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/07/06/2025.07.05.25330933.full.pdf",null],["3","R0000878","R0000878.pdf","free_to_read","systematic_review","Di Stefano R","2025","Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103238","https://doi.org/10.1016/j.dsx.2025.103238","40388845","https://pubmed.ncbi.nlm.nih.gov/40388845/","https://doi.org/10.1016/j.dsx.2025.103238",null],["3","R0001147","R0001147.pdf","open_download_failed","systematic_review","Galli M","2025","Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.08.027","https://doi.org/10.1016/j.jacc.2025.08.027","40892610","https://pubmed.ncbi.nlm.nih.gov/40892610/","https://www.jacc.org/doi/pdf/10.1016/j.jacc.2025.08.027?download=true","PROSPERO:CRD420251032222"],["3","R0001681","R0001681.pdf","open_download_failed","systematic_review","Chen X","2025","The impact of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) on anesthetic risk in patients undergoing surgery or esophagogastroduodenoscopy: A systematic review and meta-Analysis","Authorea Preprints","Wiley","10.22541/au.176719154.49976277/v1","https://doi.org/10.22541/au.176719154.49976277/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176719154.49976277/v1",null],["3","R0001747","R0001747.pdf","free_to_read","systematic_review",null,"2025","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in MASH Resolution and Fibrosis Reduction: A Meta-Analysis.","Gastroenterology & hepatology",null,null,"https://doi.org/","41658349","https://pubmed.ncbi.nlm.nih.gov/41658349/",null,null],["3","R0001757","R0001757.pdf","free_to_read","systematic_review","Chiang CH","2025","Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.","Journal of thrombosis and haemostasis : JTH","Elsevier BV","10.1016/j.jtha.2025.06.020","https://doi.org/10.1016/j.jtha.2025.06.020","40602613","https://pubmed.ncbi.nlm.nih.gov/40602613/","https://pure.eur.nl/en/publications/6d85e0af-141c-4d02-a014-366ea2f5a7fe",null],["3","R0002077","R0002077.pdf","open_download_failed","systematic_review","Oprea AD","2025","Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2025.04.001","https://doi.org/10.1016/j.bja.2025.04.001","40379536","https://pubmed.ncbi.nlm.nih.gov/40379536/","https://doi.org/10.1016/j.bja.2025.04.001","PROSPERO:CRD42023438624"],["3","R0002144","R0002144.pdf","open_download_failed","systematic_review","Albanese GM","2025","Ocular Effects of GLP-1 Receptor Agonists: A Systematic Review of Current Evidence and Safety Concerns","Preprints.org","MDPI AG","10.20944/preprints202508.0031.v1","https://doi.org/10.20944/preprints202508.0031.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/54ea2af045764a069fb1306909bd5419/download_pub",null],["3","R0002150","R0002150.pdf","open_download_failed","systematic_review","Li M","2025","Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.","Sleep","Oxford University Press (OUP)","10.1093/sleep/zsae280","https://doi.org/10.1093/sleep/zsae280","39626095","https://pubmed.ncbi.nlm.nih.gov/39626095/","https://academic.oup.com/sleep/advance-article-pdf/doi/10.1093/sleep/zsae280/60921870/zsae280.pdf",null],["3","R0002200","R0002200.pdf","open_download_failed","systematic_review","Ghose K","2025","Efficacy and Safety of Tirzepatide  for the Management of Obesity: A Systematic Review and Meta-analysis of Randomized  Controlled Trials (RCTs)            ","Authorea Preprints","Wiley","10.22541/au.176402391.10613553/v1","https://doi.org/10.22541/au.176402391.10613553/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176402391.10613553",null],["3","R0002391","R0002391.pdf","open_download_failed","systematic_review","Mendonça L","2025","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000000584","https://doi.org/10.2215/cjn.0000000584","39480988","https://pubmed.ncbi.nlm.nih.gov/39480988/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11835157/","ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT04865770"],["3","R0002425","R0002425.pdf","open_download_failed","systematic_review","Lee MMY","2025","Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.","Diabetes care","American Diabetes Association","10.2337/dc24-1533","https://doi.org/10.2337/dc24-1533","39977628","https://pubmed.ncbi.nlm.nih.gov/39977628/","https://diabetesjournals.org/care/article-pdf/48/3/489/800086/dc241533.pdf",null],["3","R0002490","R0002490.pdf","free_to_read","systematic_review","Valentino K","2025","The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.","Journal of psychiatric research","Elsevier BV","10.1016/j.jpsychires.2025.02.008","https://doi.org/10.1016/j.jpsychires.2025.02.008","39956093","https://pubmed.ncbi.nlm.nih.gov/39956093/","https://doi.org/10.1016/j.jpsychires.2025.02.008",null],["3","R0002703","R0002703.pdf","open_download_failed","systematic_review","Chang YT","2025","Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","Diabetes care","American Diabetes Association","10.2337/dc25-0896","https://doi.org/10.2337/dc25-0896","40834250","https://pubmed.ncbi.nlm.nih.gov/40834250/","https://diabetesjournals.org/care/article-pdf/48/9/e107/839757/dc250896.pdf",null],["3","R0002729","R0002729.pdf","open_download_failed","systematic_review","Lee MMY","2025","Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","Diabetes care","American Diabetes Association","10.2337/dci25-0060","https://doi.org/10.2337/dci25-0060","40834256","https://pubmed.ncbi.nlm.nih.gov/40834256/","https://diabetesjournals.org/care/article-pdf/48/9/e109/839804/dci250060.pdf",null],["3","R0002939","R0002939.pdf","free_to_read","systematic_review","Li S","2025","Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Elsevier BV","10.1016/j.euroneuro.2025.08.002","https://doi.org/10.1016/j.euroneuro.2025.08.002","40925272","https://pubmed.ncbi.nlm.nih.gov/40925272/","https://doi.org/10.1016/j.euroneuro.2025.08.002",null],["3","R0003026","R0003026.pdf","open_download_failed","systematic_review","Sinha B","2025","Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24360","https://doi.org/10.1002/oby.24360","40685589","https://pubmed.ncbi.nlm.nih.gov/40685589/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24360",null],["3","R0003362","R0003362.pdf","open_download_failed","systematic_review","Waqas SA","2025","Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2025.01.022","https://doi.org/10.1016/j.cardfail.2025.01.022","39993464","https://pubmed.ncbi.nlm.nih.gov/39993464/","https://onlinejcf.com/article/S1071-9164(25)00091-0/pdf",null],["3","R0003387","R0003387.pdf","open_download_failed","systematic_review","Ebrahimi P","2025","Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2025.0091","https://doi.org/10.1001/jamapsychiatry.2025.0091","40105856","https://pubmed.ncbi.nlm.nih.gov/40105856/","https://pubmed.ncbi.nlm.nih.gov/40105856/",null],["3","R0003398","R0003398.pdf","free_to_read","systematic_review","Fan S","2025","Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis.","Journal of neurochemistry","Wiley","10.1111/jnc.16242","https://doi.org/10.1111/jnc.16242","39453834","https://pubmed.ncbi.nlm.nih.gov/39453834/",null,null],["3","R0003479","R0003479.pdf","free_to_read","systematic_review","Facciorusso A","2025","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2024.07.021","https://doi.org/10.1016/j.cgh.2024.07.021","39142543","https://pubmed.ncbi.nlm.nih.gov/39142543/","https://doi.org/10.1016/j.cgh.2024.07.021",null],["3","R0003623","R0003623.pdf","free_to_read","systematic_review","Kow CS","2025","Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials.","Sleep medicine","Elsevier BV","10.1016/j.sleep.2025.02.010","https://doi.org/10.1016/j.sleep.2025.02.010","39978242","https://pubmed.ncbi.nlm.nih.gov/39978242/","https://pure.hud.ac.uk/en/publications/99704d2c-dd74-4999-bb6a-4c080698fa95",null],["3","R0003625","R0003625.pdf","open_download_failed","systematic_review","Ren Y","2025","The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16366","https://doi.org/10.1111/dom.16366","40230207","https://pubmed.ncbi.nlm.nih.gov/40230207/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16366",null],["3","R0003757","R0003757.pdf","open_download_failed","systematic_review","Kapoor I","2025","Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome.","Clinical & experimental ophthalmology","Wiley","10.1111/ceo.14445","https://doi.org/10.1111/ceo.14445","39327045","https://pubmed.ncbi.nlm.nih.gov/39327045/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ceo.14445",null],["3","R0003772","R0003772.pdf","open_download_failed","systematic_review","Duhan S","2025","GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133604","https://doi.org/10.1016/j.ijcard.2025.133604","40623630","https://pubmed.ncbi.nlm.nih.gov/40623630/","https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00647-3/pdf",null],["3","R0003865","R0003865.pdf","free_to_read","systematic_review","Mashayekhi Y","2025","Impact of glucagon-like peptide-1 receptor agonists on postoperative complications after total joint arthroplasty: A systematic review and meta-analysis.","Journal of orthopaedic surgery (Hong Kong)","SAGE Publications","10.1177/10225536251391959","https://doi.org/10.1177/10225536251391959","41233973","https://pubmed.ncbi.nlm.nih.gov/41233973/","https://doi.org/10.1177/10225536251391959",null],["3","R0003969","R0003969.pdf","open_download_failed","systematic_review","Passos PRC","2025","Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.16752","https://doi.org/10.1111/jgh.16752","39322970","https://pubmed.ncbi.nlm.nih.gov/39322970/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.16752",null],["3","R0004062","R0004062.pdf","free_to_read","systematic_review","Bardóczi A","2025","Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","Sleep medicine reviews","Elsevier BV","10.1016/j.smrv.2025.102119","https://doi.org/10.1016/j.smrv.2025.102119","40633481","https://pubmed.ncbi.nlm.nih.gov/40633481/","https://doi.org/10.1016/j.smrv.2025.102119",null],["3","R0004228","R0004228.pdf","open_download_failed","systematic_review","Han S","2025","Association of glucagon-like peptide-1 receptor agonist use with risk of infections: A systematic review and meta-analysis.","The Journal of infection","Elsevier BV","10.1016/j.jinf.2025.106645","https://doi.org/10.1016/j.jinf.2025.106645","41173399","https://pubmed.ncbi.nlm.nih.gov/41173399/","https://www.journalofinfection.com/article/S0163-4453(25)00245-2/pdf",null],["3","R0004281","R0004281.pdf","open_download_failed","systematic_review","Kokkorakis M","2025","Emerging pharmacotherapies for obesity: A systematic review.","Pharmacological reviews","Elsevier BV","10.1124/pharmrev.123.001045","https://doi.org/10.1124/pharmrev.123.001045","39952695","https://pubmed.ncbi.nlm.nih.gov/39952695/","https://pharmrev.aspetjournals.org/article/S0031-6997(24)00002-4/pdf","ClinicalTrials.gov:NCT01351753; ClinicalTrials.gov:NCT05579977; ClinicalTrials.gov:NCT01540864; ClinicalTrials.gov:NCT03051451"],["3","R0004446","R0004446.pdf","open_download_failed","systematic_review","Cesaro A","2025","Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf257","https://doi.org/10.1093/eurjpc/zwaf257","40294206","https://pubmed.ncbi.nlm.nih.gov/40294206/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwaf257/63023508/zwaf257.pdf",null],["3","R0004483","R0004483.pdf","open_download_failed","systematic_review","Wang Y","2025","Comparison of the Effects of SGLT-2i Versus GLP-1RA on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes, Based on Baseline Renal Function.","Diabetes","American Diabetes Association","10.2337/db24-0688","https://doi.org/10.2337/db24-0688","39932725","https://pubmed.ncbi.nlm.nih.gov/39932725/","https://diabetesjournals.org/diabetes/article-pdf/doi/10.2337/db24-0688/797988/db240688.pdf",null],["3","R0004616","R0004616.pdf","open_download_failed","systematic_review","Nong K","2025","Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2024-083039","https://doi.org/10.1136/bmj-2024-083039","40813122","https://pubmed.ncbi.nlm.nih.gov/40813122/","https://www.bmj.com/content/bmj/390/bmj-2024-083039.full.pdf","PROSPERO:CRD42022325948"],["3","R0004640","R0004640.pdf","open_download_failed","systematic_review","Pierret ACS","2025","Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2025.0679","https://doi.org/10.1001/jamapsychiatry.2025.0679","40366681","https://pubmed.ncbi.nlm.nih.gov/40366681/","https://www.research.ed.ac.uk/en/publications/af25f74f-ef88-4559-acde-3a7196799262",null],["3","R0004742","R0004742.pdf","open_download_failed","systematic_review","Lu Y","2025","Efficacy of Liraglutide on Metabolic and Reproductive Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis","Authorea Preprints","Wiley","10.22541/au.174919687.75586804/v1","https://doi.org/10.22541/au.174919687.75586804/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.174919687.75586804/v1",null],["3","R0004945","R0004945.pdf","open_download_failed","systematic_review","Chtatbi A","2025","The Hidden Costs of GLP-1 Agonists: A Meta-Analysis of Sarcopenia, Psychiatric Risks, and Long-Term Health Implications","Authorea Preprints","Wiley","10.22541/au.175641359.91480737/v1","https://doi.org/10.22541/au.175641359.91480737/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175641359.91480737",null],["3","R0004960","R0004960.pdf","open_download_failed","systematic_review","Kotecha P","2025","Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","JAMA pediatrics","American Medical Association (AMA)","10.1001/jamapediatrics.2025.3243","https://doi.org/10.1001/jamapediatrics.2025.3243","40952752","https://pubmed.ncbi.nlm.nih.gov/40952752/","https://pmc.ncbi.nlm.nih.gov/articles/instance/12439189/bin/jamapediatr-e253243-s001.pdf",null],["3","R0005212","R0005212.pdf","open_download_failed","systematic_review","Tang H","2025","Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16147","https://doi.org/10.1111/dom.16147","39723481","https://pubmed.ncbi.nlm.nih.gov/39723481/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16147",null],["3","R0005228","R0005228.pdf","open_download_failed","systematic_review","Zhang H","2025","Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70077","https://doi.org/10.1002/dmrr.70077","40847599","https://pubmed.ncbi.nlm.nih.gov/40847599/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.70077",null],["3","R0005238","R0005238.pdf","open_download_failed","systematic_review","Hansen LMH","2025","Impact of Semaglutide Exposure on Neonatal Outcomes in Pregnant Women: A Systematic Review","Authorea Preprints","Wiley","10.22541/au.175023393.36965849/v1","https://doi.org/10.22541/au.175023393.36965849/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175023393.36965849/v1",null],["3","R0005302","R0005302.pdf","open_download_failed","systematic_review","Ramteke HD","2025","Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","medRxiv","openRxiv","10.1101/2025.09.01.25334855","https://doi.org/10.1101/2025.09.01.25334855",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/09/02/2025.09.01.25334855.full.pdf",null],["3","R0005371","R0005371.pdf","open_download_failed","systematic_review","Laguna MAS","2025","Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis","Authorea Preprints","Wiley","10.22541/au.176361875.58584436/v1","https://doi.org/10.22541/au.176361875.58584436/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176361875.58584436/v1","PROSPERO:CRD420251128528"],["3","R0005615","R0005615.pdf","open_download_failed","systematic_review","Beavers KM","2025","GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24172","https://doi.org/10.1002/oby.24172","39710882","https://pubmed.ncbi.nlm.nih.gov/39710882/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24172",null],["3","R0005726","R0005726.pdf","free_to_read","systematic_review","Baxter SM","2025","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study.","Thyroid : official journal of the American Thyroid Association","SAGE Publications","10.1089/thy.2024.0387","https://doi.org/10.1089/thy.2024.0387","39772758","https://pubmed.ncbi.nlm.nih.gov/39772758/","https://pure.qub.ac.uk/en/publications/1b014ff3-2a95-40da-8cf9-e7a4a5230e9d",null],["3","R0006084","R0006084.pdf","open_download_failed","systematic_review","Bracchiglione J","2025","Semaglutide for adults living with obesity.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd015092.pub2","https://doi.org/10.1002/14651858.cd015092.pub2","41161683","https://pubmed.ncbi.nlm.nih.gov/41161683/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12571522/","PROSPERO:CRD420250654193"],["3","R0006156","R0006156.pdf","open_download_failed","systematic_review","Meza N","2025","Liraglutide for adults living with obesity.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd016017","https://doi.org/10.1002/14651858.cd016017","41161684","https://pubmed.ncbi.nlm.nih.gov/41161684/","https://pubmed.ncbi.nlm.nih.gov/41161684/","PROSPERO:CRD420250654193"],["3","R0006632","R0006632.pdf","open_download_failed","systematic_review","Al Nofal A","2025","A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf289","https://doi.org/10.1210/clinem/dgaf289","40652449","https://pubmed.ncbi.nlm.nih.gov/40652449/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgaf289/63724356/dgaf289.pdf",null],["3","R0006945","R0006945.pdf","open_download_failed","systematic_review","Wang Y","2025","Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16599","https://doi.org/10.1111/dom.16599","40642833","https://pubmed.ncbi.nlm.nih.gov/40642833/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16599",null],["3","R0007369","R0007369.pdf","open_download_failed","systematic_review","Franco JV","2025","Tirzepatide for adults living with obesity.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd016018","https://doi.org/10.1002/14651858.cd016018","41161687","https://pubmed.ncbi.nlm.nih.gov/41161687/","https://pubmed.ncbi.nlm.nih.gov/41161687/","PROSPERO:CRD420250654193"],["3","R0007461","R0007461.pdf","open_download_failed","systematic_review","Mantovani A","2025","Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies.","Diabetes care","American Diabetes Association","10.2337/dc25-0282","https://doi.org/10.2337/dc25-0282","40392994","https://pubmed.ncbi.nlm.nih.gov/40392994/","https://diabetesjournals.org/care/article-pdf/48/6/1042/810952/dc250282.pdf",null],["3","R0007676","R0007676.pdf","open_download_failed","systematic_review","Yang C","2025","Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular Disease.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae602","https://doi.org/10.1210/clinem/dgae602","39210612","https://pubmed.ncbi.nlm.nih.gov/39210612/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae602/58968868/dgae602.pdf",null],["3","R0008357","R0008357.pdf","open_download_failed","systematic_review","Awad AA","2025","Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.","Proceedings (Baylor University. Medical Center)","Informa UK Limited","10.1080/08998280.2025.2480512","https://doi.org/10.1080/08998280.2025.2480512","40557198","https://pubmed.ncbi.nlm.nih.gov/40557198/","https://www.ncbi.nlm.nih.gov/pmc/articles/12184113",null],["3","R0008499","R0008499.pdf","open_download_failed","systematic_review","Aminorroaya A","2025","Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.03.516","https://doi.org/10.1016/j.jacc.2025.03.516","40368575","https://pubmed.ncbi.nlm.nih.gov/40368575/","https://www.jacc.org/doi/pdf/10.1016/j.jacc.2025.03.516?download=true",null],["3","R0008628","R0008628.pdf","free_to_read","systematic_review","Veronese N","2025","Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103303","https://doi.org/10.1016/j.dsx.2025.103303","41151201","https://pubmed.ncbi.nlm.nih.gov/41151201/","https://doi.org/10.1016/j.dsx.2025.103303","PROSPERO:CRD42025649619"],["3","R0008891","R0008891.pdf","free_to_read","systematic_review","Chen W","2025","Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","Informa UK Limited","10.1080/09513590.2025.2553052","https://doi.org/10.1080/09513590.2025.2553052","40960939","https://pubmed.ncbi.nlm.nih.gov/40960939/","https://doi.org/10.1080/09513590.2025.2553052",null],["3","R0009595","R0009595.pdf","free_to_read","systematic_review","Chen JY","2025","Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2024.11.013","https://doi.org/10.1053/j.ajkd.2024.11.013","39863261","https://pubmed.ncbi.nlm.nih.gov/39863261/","https://doi.org/10.1053/j.ajkd.2024.11.013","PROSPERO:CRD42023449059"],["3","R0010237","R0010237.pdf","open_download_failed","systematic_review","Natale P","2025","Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd015849.pub2","https://doi.org/10.1002/14651858.cd015849.pub2","39963952","https://pubmed.ncbi.nlm.nih.gov/39963952/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11834151/","ClinicalTrials.gov:NCT03496298; ClinicalTrials.gov:NCT01621178; ClinicalTrials.gov:NCT02963766; ClinicalTrials.gov:NCT01761318; ClinicalTrials.gov:NCT02660047; ClinicalTrials.gov:NCT01336023; ClinicalTrials.gov:NCT01392573; ClinicalTrials.gov:NCT01676116; ClinicalTrials.gov:NCT01618162; ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT01798706; ClinicalTrials.gov:NCT01794143; ClinicalTrials.gov:NCT02465515; ClinicalTrials.gov:NCT01394341; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01098539; ClinicalTrials.gov:NCT02730377; ClinicalTrials.gov:NCT01620489; ClinicalTrials.gov:NCT00097500; ClinicalTrials.gov:NCT01847313; ClinicalTrials.gov:NCT03550378; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02692716; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT04515849; ClinicalTrials.gov:NCT04061200; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT03136484; ClinicalTrials.gov:NCT03824002; ClinicalTrials.gov:NCT02545738; ClinicalTrials.gov:NCT02690883; ClinicalTrials.gov:NCT00712673; ClinicalTrials.gov:NCT00763451; ClinicalTrials.gov:NCT00707031; ClinicalTrials.gov:NCT05536804; ClinicalTrials.gov:NCT06182891; ClinicalTrials.gov:NCT06555146; ClinicalTrials.gov:NCT04865770"],["3","R0010450","R0010450.pdf","open_download_failed","systematic_review","Khan LA","2025","A systematic review and meta-analysis comparing the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists in type 2 diabetes.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-025-01741-2","https://doi.org/10.1007/s40200-025-01741-2","41084518","https://pubmed.ncbi.nlm.nih.gov/41084518/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12515190/",null],["3","R0010484","R0010484.pdf","open_download_failed","systematic_review","Albuquerque MB","2025","GLP-1 receptor agonists for Parkinson's disease: An updated meta-analysis.","Parkinsonism & related disorders","Elsevier BV","10.1016/j.parkreldis.2024.107220","https://doi.org/10.1016/j.parkreldis.2024.107220","39642803","https://pubmed.ncbi.nlm.nih.gov/39642803/","https://www.prd-journal.com/article/S1353-8020(24)01232-X/pdf",null],["3","R0011229","R0011229.pdf","open_download_failed","systematic_review","Natale P","2025","Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd015906.pub2","https://doi.org/10.1002/14651858.cd015906.pub2","41263251","https://pubmed.ncbi.nlm.nih.gov/41263251/","https://pubmed.ncbi.nlm.nih.gov/41263251/",null],["3","R0011486","R0011486.pdf","open_download_failed","systematic_review","Abdu E","2025","Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","medRxiv","openRxiv","10.64898/2025.12.22.25342824","https://doi.org/10.64898/2025.12.22.25342824",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/12/23/2025.12.22.25342824.full.pdf",null],["3","R0011647","R0011647.pdf","free_to_read","systematic_review","Breit S","2025","The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review.","Psychoneuroendocrinology","Elsevier BV","10.1016/j.psyneuen.2025.107415","https://doi.org/10.1016/j.psyneuen.2025.107415","40138849","https://pubmed.ncbi.nlm.nih.gov/40138849/","https://doi.org/10.1016/j.psyneuen.2025.107415",null],["3","R0011898","R0011898.pdf","open_download_failed","systematic_review","Neves JS","2025","Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16603","https://doi.org/10.1111/dom.16603","40654219","https://pubmed.ncbi.nlm.nih.gov/40654219/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16603",null],["3","R0012041","R0012041.pdf","free_to_read","systematic_review","Neves JS","2025","GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction: Meta-Analysis of Randomized Clinical Trials.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2025.03.035","https://doi.org/10.1016/j.jchf.2025.03.035","40434323","https://pubmed.ncbi.nlm.nih.gov/40434323/","https://doi.org/10.1016/j.jchf.2025.03.035",null],["3","R0012127","R0012127.pdf","free_to_read","systematic_review","Ristori Costa G","2025","The Effect of GLP-1RA on the Motor Function of Patients With Parkinson Disease: A Systematic Review and Meta-Analysis.","Neurology. Clinical practice","Ovid Technologies (Wolters Kluwer Health)","10.1212/cpj.0000000000200548","https://doi.org/10.1212/cpj.0000000000200548","41089206","https://pubmed.ncbi.nlm.nih.gov/41089206/",null,null],["3","R0012155","R0012155.pdf","open_download_failed","systematic_review","Rebelo TG","2025","Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133683","https://doi.org/10.1016/j.ijcard.2025.133683","40752805","https://pubmed.ncbi.nlm.nih.gov/40752805/","https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00726-0/pdf",null],["3","R0012159","R0012159.pdf","free_to_read","systematic_review","Schmidt PHS","2025","Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.01.009","https://doi.org/10.1016/j.orcp.2025.01.009","39904668","https://pubmed.ncbi.nlm.nih.gov/39904668/","https://repositorio.ufsc.br/handle/123456789/265732",null],["3","R0012320","R0012320.pdf","free_to_read","systematic_review","Wang W","2025","Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies.","Journal of clinical epidemiology","Elsevier BV","10.1016/j.jclinepi.2025.111872","https://doi.org/10.1016/j.jclinepi.2025.111872","40550404","https://pubmed.ncbi.nlm.nih.gov/40550404/","https://doi.org/10.1016/j.jclinepi.2025.111872",null],["3","R0012706","R0012706.pdf","open_download_failed","systematic_review","Huang J","2025","Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","Diabetes care","American Diabetes Association","10.2337/dc25-0267","https://doi.org/10.2337/dc25-0267","40392995","https://pubmed.ncbi.nlm.nih.gov/40392995/","https://diabetesjournals.org/care/article-pdf/48/6/e85/810910/dc250267.pdf",null],["3","R0012749","R0012749.pdf","open_download_failed","systematic_review","Wong HJ","2025","Response to Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","Diabetes care","American Diabetes Association","10.2337/dci25-0023","https://doi.org/10.2337/dci25-0023","40392996","https://pubmed.ncbi.nlm.nih.gov/40392996/","https://diabetesjournals.org/care/article-pdf/48/6/e86/810879/dci250023.pdf",null],["3","R0013113","R0013113.pdf","open_download_failed","systematic_review","Ren Q","2025","Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta-Analysis.","Journal of evidence-based medicine","Wiley","10.1111/jebm.70021","https://doi.org/10.1111/jebm.70021","40229658","https://pubmed.ncbi.nlm.nih.gov/40229658/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jebm.70021",null],["3","R0013739","R0013739.pdf","open_download_failed","systematic_review","Moetaz I","2025","The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials.","Clinical obesity","Wiley","10.1111/cob.70030","https://doi.org/10.1111/cob.70030","40530685","https://pubmed.ncbi.nlm.nih.gov/40530685/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.70030",null],["3","R0014407","R0014407.pdf","free_to_read","systematic_review","Goetz-Kundera Z","2025","Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.","Comprehensive psychiatry","Elsevier BV","10.1016/j.comppsych.2025.152632","https://doi.org/10.1016/j.comppsych.2025.152632","40934730","https://pubmed.ncbi.nlm.nih.gov/40934730/","https://doi.org/10.1016/j.comppsych.2025.152632",null],["3","R0015410","R0015410.pdf","open_download_failed","systematic_review","Abdrabou Abouelmagd A","2025","Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.","Proceedings (Baylor University. Medical Center)","Informa UK Limited","10.1080/08998280.2025.2456441","https://doi.org/10.1080/08998280.2025.2456441","40291085","https://pubmed.ncbi.nlm.nih.gov/40291085/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/pdf/UBMC_38_2456441.pdf",null],["3","R0015504","R0015504.pdf","open_download_failed","systematic_review","Drygalski K","2025","Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.","Polish archives of internal medicine","&quot;Medycyna Praktyczna&quot; Spolka Jawna","10.20452/pamw.17141","https://doi.org/10.20452/pamw.17141","41117588","https://pubmed.ncbi.nlm.nih.gov/41117588/","https://www.mp.pl/paim/en/node/17141/pdf","PROSPERO:CRD420251017953"],["3","R0015821","R0015821.pdf","open_download_failed","systematic_review","Giorelli G","2025","Body Composition Changes with Semaglutide: A Systematic Review and Meta-Analysis","medRxiv","openRxiv","10.1101/2025.09.29.25336760","https://doi.org/10.1101/2025.09.29.25336760",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/10/03/2025.09.29.25336760.full.pdf",null],["3","R0016121","R0016121.pdf","open_download_failed","systematic_review","Wang JY","2025","Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.","Clinical obesity","Wiley","10.1111/cob.70036","https://doi.org/10.1111/cob.70036","40685889","https://pubmed.ncbi.nlm.nih.gov/40685889/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.70036",null],["3","R0016399","R0016399.pdf","open_download_failed","systematic_review","Natividade GR","2025","Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.","JAMA ophthalmology","American Medical Association (AMA)","10.1001/jamaophthalmol.2025.2489","https://doi.org/10.1001/jamaophthalmol.2025.2489","40810985","https://pubmed.ncbi.nlm.nih.gov/40810985/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12355393/",null],["3","R0017577","R0017577.pdf","open_download_failed","systematic_review","Wang Y","2025","Efficacy and safety of liraglutide plus acarbose in obese patients with type 2 diabetes mellitus: A meta-analysis","Authorea Preprints","Wiley","10.22541/au.174625036.66012183/v1","https://doi.org/10.22541/au.174625036.66012183/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.174625036.66012183/v1",null],["3","R0018305","R0018305.pdf","open_download_failed","systematic_review","Armani MN","2025","Efficacy and Safety of Pharmacologic Therapies in HFpEF: A Systematic Review and Network Meta-Analysis","medRxiv","openRxiv","10.1101/2025.09.17.25335973","https://doi.org/10.1101/2025.09.17.25335973",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/09/18/2025.09.17.25335973.full.pdf",null],["3","R0019949","R0019949.pdf","open_download_failed","systematic_review","Albon E","2025","Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis.","Health technology assessment (Winchester, England)","National Institute for Health and Care Research","10.3310/pwkq2310","https://doi.org/10.3310/pwkq2310","41424377","https://pubmed.ncbi.nlm.nih.gov/41424377/","https://doi.org/10.3310/pwkq2310","PROSPERO:CRD42022302942"],["3","R0020053","R0020053.pdf","free_to_read","systematic_review","De Luca M","2025","Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16352","https://doi.org/10.1111/dom.16352","40197859","https://pubmed.ncbi.nlm.nih.gov/40197859/","https://hdl.handle.net/20.500.11768/183376",null],["3","R0020106","R0020106.pdf","open_download_failed","systematic_review","Faghfouri AH","2025","Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13946","https://doi.org/10.1111/obr.13946","40437653","https://pubmed.ncbi.nlm.nih.gov/40437653/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13946",null],["3","R0023830","R0023830.pdf","open_download_failed","systematic_review","Chen AS","2025","Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24160","https://doi.org/10.1002/oby.24160","39725567","https://pubmed.ncbi.nlm.nih.gov/39725567/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12198421/pdf/nihms-2023403.pdf",null],["3","R0023926","R0023926.pdf","free_to_read","systematic_review","Zehtabian K","2025","Hormonal Dysregulation in Major Depressive Disorder: A Systematic Review","PsyArXiv","Center for Open Science","10.31234/osf.io/y897m_v1","https://doi.org/10.31234/osf.io/y897m_v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31234/osf.io/y897m_v1",null],["3","R0029572","R0029572.pdf","free_to_read","systematic_review","Alizargar J","2025","Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target.","Journal of clinical orthopaedics and trauma","Elsevier BV","10.1016/j.jcot.2025.103256","https://doi.org/10.1016/j.jcot.2025.103256","41245346","https://pubmed.ncbi.nlm.nih.gov/41245346/",null,"PROSPERO:CRD420251177348"],["3","R0029598","R0029598.pdf","open_download_failed","systematic_review","Romero-Vélez F","2025","Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.","Animals : an open access journal from MDPI","MDPI AG","10.3390/ani15172561","https://doi.org/10.3390/ani15172561","40941356","https://pubmed.ncbi.nlm.nih.gov/40941356/","https://www.mdpi.com/2076-2615/15/17/2561/pdf?version=1756630499",null],["3","R0032815","R0032815.pdf","free_to_read","systematic_review","Gana Ali Ahmad Tahmaz","2025","Comparative Outcomes of Newer Antidiabetic Agents in Preventing Diabetic Nephropathy: A Meta-Analysis","Fortune Journal of Health Sciences","Fortune Journals","10.26502/fjhs.262","https://doi.org/10.26502/fjhs.262",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/fjhs.262",null],["3","R0034258","R0034258.pdf","no_doi","systematic_review","Thiago Moreira Trindade","2025","GLP-1 eficcacy in severely obese people: systematic review of individual patient data of clinical trials","Arca - Repositório Institucional da Fiocruz",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034316","R0034316.pdf","no_doi","systematic_review","Kannan Sridharan","2025","Meta-analysis of SGLT2 inhibitors and GLP-1 agonists in treating PCOS","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034344","R0034344.pdf","free_to_read","systematic_review","Nathaniel Eraikhuemen","2025","Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies","Journal of Clinical Ophthalmology and Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcor.jcor_148_24","https://doi.org/10.4103/jcor.jcor_148_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcor.jcor_148_24",null],["3","R0034557","R0034557.pdf","free_to_read","systematic_review","Rajat Bhatt","2025","Utility of Glucagon like peptide-1 analogues in patients of acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials","Indian Heart Journal","Elsevier BV","10.1016/j.ihj.2025.11.012","https://doi.org/10.1016/j.ihj.2025.11.012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ihj.2025.11.012",null],["3","R0034577","R0034577.pdf","free_to_read","systematic_review","Princee Kaur","2025","Use of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5929268","https://doi.org/10.2139/ssrn.5929268",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5929268",null],["3","R0035918","R0035918.pdf","open_download_failed","systematic_review","Selena Gong","2025","GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.5_suppl.374","https://doi.org/10.1200/jco.2025.43.5_suppl.374",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2025.43.5_suppl.374",null],["3","R0035978","R0035978.pdf","free_to_read","systematic_review","Zhou Xiao-yu","2025","Comparative Cardiovascular Benefits of Semaglutide Versus Tirzepatide in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5359752","https://doi.org/10.2139/ssrn.5359752",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5359752",null],["3","R0036023","R0036023.pdf","free_to_read","systematic_review","Rui Zhang","2025","Evaluation and Comparison of Efficacy and Safety of SGLT-2 Inhibitors, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease: A Bayesian Network Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5213389","https://doi.org/10.2139/ssrn.5213389",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5213389",null],["3","R0036094","R0036094.pdf","free_to_read","systematic_review","Ning Lan","2025","Association of Glucagon-Like Peptide-1 Receptor Agonists with Diabetic Retinopathy and Other Ocular Diseases in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5364609","https://doi.org/10.2139/ssrn.5364609",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5364609",null],["3","R0036200","R0036200.pdf","no_doi","systematic_review","Mirajkar, Nikita","2025","Determining Minimal Dosage Thresholds for Gastroparesis Development in GLP-1 Receptor Agonist Therapy: A Comprehensive Systematic Review and Meta-Analysis","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036348","R0036348.pdf","no_doi","systematic_review","Dominik Diefenbach","2025","Dietary Guidance for Managing Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036396","R0036396.pdf","no_doi","systematic_review","Tara Brigham","2025","Search Strategies for: \"Evaluating the Efficacy of GLP-1 Receptor Agonists in Metabolic Liver Diseases: A Systematic Review and Network Meta-Analysis.\"","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036889","R0036889.pdf","free_to_read","systematic_review","Hui-Ling Huang","2025","Clinical management strategies for type 2 diabetes mellitus with metabolic dysfunction-associated fatty liver disease: an umbrella review of systematic reviews and meta-analyses","Exploration of Endocrine and Metabolic Diseases","Open Exploration Publishing","10.37349/eemd.2025.101443","https://doi.org/10.37349/eemd.2025.101443",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.37349/eemd.2025.101443",null],["3","R0036958","R0036958.pdf","free_to_read","systematic_review","Jiarong Liu","2025","Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP‐1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta‐analysis","Rheumatology & autoimmunity","Wiley","10.1002/rai2.12172","https://doi.org/10.1002/rai2.12172",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/rai2.12172",null],["3","R0037286","R0037286.pdf","free_to_read","systematic_review","Lu Li","2025","SAT-416 The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01679-4","https://doi.org/10.1016/s0168-8278(25)01679-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0168-8278(25)01679-4",null],["3","R0037616","R0037616.pdf","free_to_read","systematic_review","Ziyun Liu","2025","Cost Effectiveness of Semaglutide Compared to Other Anti-Diabetic Medication in Treating Type 2 Diabetes – A Comprehensive Systematic Review and Meta-Analysis",null,"American Diabetes Association","10.2337/figshare.28570043.v1","https://doi.org/10.2337/figshare.28570043.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28570043.v1",null],["3","R0037798","R0037798.pdf","free_to_read","systematic_review","Zhiqiang Ma","2025","Body mass index-dependent therapeutic efficacy in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction: A systematic review and network meta-analysis","Asian Heart Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/ah9.0000000000000024","https://doi.org/10.1097/ah9.0000000000000024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/ah9.0000000000000024","PROSPERO:CRD420251022550"],["3","R0038231","R0038231.pdf","open_download_failed","systematic_review","Luís Gustavo Menegardo Siqueira De Oliveira","2025","CARDIOMETABOLIC EFFECTS OF SEMAGLUTIDE IN OBESE AND OVERWEIGHT PATIENTS WITH PREEXISTING CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)00865-4","https://doi.org/10.1016/s0735-1097(25)00865-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2900865-4?download=true",null],["3","R0038736","R0038736.pdf","open_download_failed","systematic_review","Arya Aminorroaya","2025","CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)00899-x","https://doi.org/10.1016/s0735-1097(25)00899-x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2900899-X?download=true",null],["3","R0038814","R0038814.pdf","free_to_read","systematic_review","Matthew M.Y. Lee","2025","Comparative efficacy of glucagon-like peptide-1 receptor agonists for cardiovascular outcomes in Asian versus White persons: systematic review and meta-analyses of randomized trials with and without type 2 diabetes and/or overweight/obesity",null,"American Diabetes Association","10.2337/figshare.28074674.v1","https://doi.org/10.2337/figshare.28074674.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28074674.v1","PROSPERO:CRD42024493010"],["3","R0038864","R0038864.pdf","free_to_read","systematic_review","Arya Aminorroaya","2025","EFFICACY OF TIRZEPATIDE IN TREATING METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 10 RANDOMIZED CLINICAL TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)05174-5","https://doi.org/10.1016/s0735-1097(25)05174-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(25)05174-5",null],["3","R0038976","R0038976.pdf","open_download_failed","systematic_review","B Steinberg","2025","(248) Exploring the Effects of GLP-1 Agonists on Male Fertility: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf320.244","https://doi.org/10.1093/jsxmed/qdaf320.244",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_4/qdaf320.244/65819831/qdaf320.244.pdf",null],["3","R0040043","R0040043.pdf","free_to_read","systematic_review","Chun-I Liu","2025","EXAMINING THE EFFECTS OF PHARMACOLOGICAL AND NUTRITIONAL INTERVENTIONS ON METABOLIC SYNDROME ASSOCIATED WITH ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyae059.622","https://doi.org/10.1093/ijnp/pyae059.622",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ijnp/pyae059.622",null],["3","R0040142","R0040142.pdf","open_download_failed","systematic_review",null,"2025","Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists","Journal of diabetology research.","Directive Publications","10.52338/jodr.2025.4833","https://doi.org/10.52338/jodr.2025.4833",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52338/jodr.2025.4833",null],["3","R0040169","R0040169.pdf","open_download_failed","systematic_review",null,"2025","CME Exam 1: Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","Gastroenterology","Elsevier BV","10.1053/j.gastro.2025.08.035","https://doi.org/10.1053/j.gastro.2025.08.035",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.gastrojournal.org/article/S0016-5085(25)05977-3/pdf",null],["3","R0040245","R0040245.pdf","open_download_failed","systematic_review",null,"2025","GLP-1 Receptor Agonists for the Treatment of Obstructive Sleep Apnea and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.505","https://doi.org/10.1016/j.eprac.2025.05.505",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.endocrinepractice.org/article/S1530-891X(25)00647-0/pdf",null],["3","R0040444","R0040444.pdf","open_download_failed","systematic_review","G Rastrelli","2025","IMPACT OF DIABETIC MEDICATIONS ON ERECTILE FUNCTION: A META-ANALYSIS","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf077.056","https://doi.org/10.1093/jsxmed/qdaf077.056",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_2/qdaf077.056/63137624/qdaf077.056.pdf",null],["3","R0040515","R0040515.pdf","open_download_failed","systematic_review","Velimir Altabas","2025","Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review","Diabetology","MDPI AG","10.3390/diabetology6060052","https://doi.org/10.3390/diabetology6060052",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/6/6/52/pdf?version=1749107255",null],["3","R0040523","R0040523.pdf","open_download_failed","systematic_review","Xiaoyu Wu","2025","#1700 Heterogeneity in characteristics of target population and definitions of renal outcome on evaluating the renoprotective effect of GLP-1RA in patients with diabetes: a systematic review and meta-analysis of observational studies versus randomized controlled trials","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.0920","https://doi.org/10.1093/ndt/gfaf116.0920",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/40/Supplement_3/gfaf116.0920/64842767/gfaf116.0920.pdf",null],["3","R0040533","R0040533.pdf","open_download_failed","systematic_review","Yanping Bao","2025","MACE With GLP-1RAs in Patients With Type 2 Diabetes—A Systematic Review and Meta-Analysis of Randomised Controlled Trials","Heart Lung and Circulation","Elsevier BV","10.1016/j.hlc.2025.06.887","https://doi.org/10.1016/j.hlc.2025.06.887",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.heartlungcirc.org/article/S1443-9506(25)01376-9/pdf",null],["3","R0041742","R0041742.pdf","open_download_failed","systematic_review","Bruna Marmett","2025","Anti-obesity drugs alone or combined with exercise training in the management of obesity: a systematic review with meta-analysis","Translational Exercise Biomedicine","Walter de Gruyter GmbH","10.1515/teb-2024-0039","https://doi.org/10.1515/teb-2024-0039",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.degruyterbrill.com/document/doi/10.1515/teb-2024-0039/pdf",null],["3","R0041903","R0041903.pdf","free_to_read","systematic_review","Gabriela Masiero Marcon","2025","Medicines for the management of overweight and obesity: A systematic review with network meta-analysis","Brazilian Journal of Pharmaceutical Sciences","FapUNIFESP (SciELO)","10.1590/s2175-97902025e24177","https://doi.org/10.1590/s2175-97902025e24177",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1590/s2175-97902025e24177","PROSPERO:CRD42023423308"],["3","R0043575","R0043575.pdf","free_to_read","systematic_review","Ghazala S. Virk","2025","Efficacy of Lifestyle Intervention Versus Pharmacotherapy in the Progression of Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","Journal of Advances in Medicine and Medical Research","Sciencedomain International","10.9734/jammr/2025/v37i15712","https://doi.org/10.9734/jammr/2025/v37i15712",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9734/jammr/2025/v37i15712",null],["3","R0043644","R0043644.pdf","open_download_failed","systematic_review","Ahmad Salhab","2025","SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.169","https://doi.org/10.1210/jendso/bvaf149.169",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.169/64863008/bvaf149.169.pdf",null],["3","R0043755","R0043755.pdf","open_download_failed","systematic_review","Konstantinos Pamporis","2025","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis","EP Europace","Oxford University Press (OUP)","10.1093/europace/euaf085.236","https://doi.org/10.1093/europace/euaf085.236",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/europace/article-pdf/27/Supplement_1/euaf085.236/63304323/euaf085.236.pdf",null],["3","R0043765","R0043765.pdf","open_download_failed","systematic_review","Ashraf Ahmed","2025","SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.163","https://doi.org/10.1210/jendso/bvaf149.163",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.163/64865636/bvaf149.163.pdf",null],["3","R0043834","R0043834.pdf","open_download_failed","systematic_review","Adnan Ezici","2025","SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1998","https://doi.org/10.1210/jendso/bvaf149.1998",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1998/64863284/bvaf149.1998.pdf","PROSPERO:CRD42025640594"],["3","R0043948","R0043948.pdf","no_doi","systematic_review","Ligia Patricia Laverde Jimenez","2025","Effect of GLP-1 receptor agonists at doses for obesity management on muscle health : systematic review of the literature and meta-analysis","Repositorio Institucional (Pontificia Universidad Javeriana)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044152","R0044152.pdf","open_download_failed","systematic_review","Jahnavi Udaikumar","2025","The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review","Pharmacoepidemiology","MDPI AG","10.3390/pharma4030014","https://doi.org/10.3390/pharma4030014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2813-0618/4/3/14/pdf?version=1751113445",null],["3","R0044443","R0044443.pdf","no_doi","systematic_review","Emily Elizabeth Douglas","2025","Lifestyle Interventions to Mitigate Muscle and Bone Loss During GLP-1RA Use in Diabetes and Obesity: A Systematic Review & Meta-Analysis","Scholarship@Western (Western University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044970","R0044970.pdf","free_to_read","systematic_review","Ghinwa M. Barakat","2025","AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.86960","https://doi.org/10.2196/preprints.86960",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.86960",null],["3","R0045072","R0045072.pdf","open_download_failed","systematic_review","Júlia Cremonini Bernardi","2025","WHO WINS THE WAR AGAINST DIABETES? COMPARATIVE EFFICACY OF TIRZEPATIDE, SEMAGLUTIDE, AND PLACEBO IN DIABETES CONTROL: A NETWORK META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)01067-8","https://doi.org/10.1016/s0735-1097(25)01067-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2901067-8?download=true",null],["3","R0045090","R0045090.pdf","open_download_failed","systematic_review","Abuzar Mahmood","2025","(272) GLP-1 Agonists and Testosterone Deficiency: A Systematic Review of Clinical and Preclinical Evidence","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf320.268","https://doi.org/10.1093/jsxmed/qdaf320.268",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_4/qdaf320.268/65820208/qdaf320.268.pdf",null],["3","R0045092","R0045092.pdf","open_download_failed","systematic_review","G Corona","2025","ROLE OF GLUCAGON-LIKE PEPTIDE TYPE 1 ANALOGUES ON HYPOTHALAMUS-PITUITARY TESTIS AXIS AND SEXUAL FUNCTION IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf077.063","https://doi.org/10.1093/jsxmed/qdaf077.063",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_2/qdaf077.063/63137584/qdaf077.063.pdf",null],["3","R0045110","R0045110.pdf","open_download_failed","systematic_review","Jia Shi","2025","Evaluating novel therapeutics in type 2 diabetes: a systematic review and meta-analysis of bexagliflozin and tirzepatide","Turkish Journal of Biochemistry","Walter de Gruyter GmbH","10.1515/tjb-2024-0393","https://doi.org/10.1515/tjb-2024-0393",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.degruyterbrill.com/document/doi/10.1515/tjb-2024-0393/pdf",null],["3","R0045135","R0045135.pdf","free_to_read","systematic_review","Mohamed Ahmed Abu-Alsaud","2025","Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_213_24","https://doi.org/10.4103/jod.jod_213_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_213_24",null],["3","R0045206","R0045206.pdf","open_download_failed","systematic_review","Barbara Vanzelli de Oliveira","2025","Investigation of clinical outcomes on the oral or injectable use of semaglutide and cardiovascular risks: a systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn25207","https://doi.org/10.54448/ijn25207",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/422/388",null],["3","R0045330","R0045330.pdf","open_download_failed","systematic_review","Celina R Andonie","2025","SAT-655 Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.091","https://doi.org/10.1210/jendso/bvaf149.091",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.091/64865570/bvaf149.091.pdf",null],["3","R0045500","R0045500.pdf","open_download_failed","systematic_review","Ayah Abulehia","2025","SUN-654 Comparative Efficacy and Safety of Glucagon Receptor Agonists in Metabolic Outcomes: A Network Meta-Analysis of Randomized Controlled Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.164","https://doi.org/10.1210/jendso/bvaf149.164",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.164/64864382/bvaf149.164.pdf",null],["3","R0045697","R0045697.pdf","open_download_failed","systematic_review","Daniah Rizwan","2025","MON-641 Effectiveness Of Semaglutide On Renal Outcomes In Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1001","https://doi.org/10.1210/jendso/bvaf149.1001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1001/64865988/bvaf149.1001.pdf","PROSPERO:CRD42024603838"],["3","R0045702","R0045702.pdf","open_download_failed","systematic_review","Priya Hotwani","2025","EFFECTIVENESS OF SEMAGLUTIDE FOR OBESITY MANAGEMENT IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A SYSTEMATIC REVIEW AND A META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)01927-8","https://doi.org/10.1016/s0735-1097(25)01927-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2901927-8?download=true",null],["3","R0045768","R0045768.pdf","open_download_failed","systematic_review","Júlia Cremonini Bernardi","2025","COMPARATIVE EFFICACY OF TIRZEPATIDE, SEMAGLUTIDE, AND PLACEBO IN WEIGHT MANAGEMENT: A NOVEL NETWORK META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)01093-9","https://doi.org/10.1016/s0735-1097(25)01093-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2901093-9?download=true",null],["3","R0045843","R0045843.pdf","free_to_read","systematic_review","Xincheng Li","2025","Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis","Precision medication.","Elsevier BV","10.1016/j.prmedi.2025.100064","https://doi.org/10.1016/j.prmedi.2025.100064",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.prmedi.2025.100064",null],["3","R0045885","R0045885.pdf","open_download_failed","systematic_review","Helena Ramalho Arvate","2025","Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn25102","https://doi.org/10.54448/ijn25102",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/400/370",null],["3","R0045911","R0045911.pdf","open_download_failed","systematic_review","Camila Barreto Maciel","2025","Visual disturbances due to semaglutide: A systematic review of the literature","International Journal of Neurology","South American Publishing","10.62486/ijn2025247","https://doi.org/10.62486/ijn2025247",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.ageditor.uy/index.php/ijn/article/download/247/51",null],["3","R0046284","R0046284.pdf","free_to_read","systematic_review","Asad Omarion","2025","SUN-114 Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol in Managing Polycystic Ovary Syndrome: A Network Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.2048","https://doi.org/10.1210/jendso/bvaf149.2048",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvaf149.2048",null],["3","R0046690","R0046690.pdf","open_download_failed","systematic_review","Christian Basile","2025","Effect of glucagon-like peptide-1 receptor agonists on blood pressure: a systematic review and meta-analysis","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf236.127","https://doi.org/10.1093/eurjpc/zwaf236.127",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurjpc/article-pdf/32/Supplement_1/zwaf236.127/63229487/zwaf236.127.pdf",null],["3","R0047421","R0047421.pdf","free_to_read","systematic_review","Sang‐Cheol Lee","2025","Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Agonist in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis","American Journal of Transplantation","Elsevier BV","10.1016/j.ajt.2025.07.1001","https://doi.org/10.1016/j.ajt.2025.07.1001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajt.2025.07.1001",null],["3","R0047423","R0047423.pdf","open_download_failed","systematic_review","Sanchit Duhan","2025","300.04 GLP-1 Agonists Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Updated Meta-Analysis of SUMMIT, SELECT, STEP-HFpEF, STEP-HFpEF DM, and FLOW Trials","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2025.01.225","https://doi.org/10.1016/j.jcin.2025.01.225",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/j.jcin.2025.01.225?download=true",null],["3","R0047822","R0047822.pdf","open_download_failed","systematic_review","Aureliane C. S. Pierret","2025","SUN-665 Meta-Analysis of Psychiatric and Quality of Life Outcomes in Patients With Obesity and Diabetes Treated With Glucagon-Like Peptide 1 Receptor Agonists","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.175","https://doi.org/10.1210/jendso/bvaf149.175",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.175/64862554/bvaf149.175.pdf",null],["3","R0047958","R0047958.pdf","open_download_failed","systematic_review","Antony Gonzales-Uribe","2025","IMPACT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF): A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)02152-7","https://doi.org/10.1016/s0735-1097(25)02152-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2902152-7?download=true",null],["3","R0048097","R0048097.pdf","open_download_failed","systematic_review","Robert F. Kushner","2025","Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects","Obesities","MDPI AG","10.3390/obesities5020029","https://doi.org/10.3390/obesities5020029",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4168/5/2/29/pdf?version=1745504017",null],["3","R0048111","R0048111.pdf","free_to_read","systematic_review","Dharmendra Kumar Gupta","2025","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Cognitive Decline and Dementia Prevention: A Systematic Review and Semiquantitative Synthesis","Journal of Mental Health and Human Behaviour","Ovid Technologies (Wolters Kluwer Health)","10.4103/jmhhb.jmhhb_71_25","https://doi.org/10.4103/jmhhb.jmhhb_71_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jmhhb.jmhhb_71_25",null],["3","R0048457","R0048457.pdf","free_to_read","systematic_review","Awwatf S. R. Alshammari","2025","The Use of Liraglutide Compared to Lifestyle Modifications in Weight Reduction in Lifestyle Clinic Patients: A Systematic Review","Scientia. Technology, science and society.","AMO Publisher","10.59324/stss.2025.2(3).01","https://doi.org/10.59324/stss.2025.2(3).01",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.59324/stss.2025.2(3).01",null],["3","R0049089","R0049089.pdf","open_download_failed","systematic_review","Abuzar Mahmood","2025","(189) Effects of GLP-1 Receptor Agonists on Erectile Function and Ejaculation: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf320.188","https://doi.org/10.1093/jsxmed/qdaf320.188",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_4/qdaf320.188/65820763/qdaf320.188.pdf",null],["3","R0049192","R0049192.pdf","free_to_read","systematic_review","SN Notta","2025","2 Cardiovascular outcomes of GLP-1 receptor agonists in patients with coronary artery disease and heart failure: a meta-analysis","The American Journal of the Medical Sciences","Elsevier BV","10.1016/s0002-9629(25)00011-4","https://doi.org/10.1016/s0002-9629(25)00011-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0002-9629(25)00011-4",null],["3","R0049207","R0049207.pdf","free_to_read","systematic_review","Hon Jen Wong","2025","Efficacy of GLP-1 receptor agonists on weight loss, body mass index and waist circumference for obese or overweight patients: A systematic review, meta-analysis and meta-regression of 47 randomized-controlled trials",null,"American Diabetes Association","10.2337/figshare.27890331.v1","https://doi.org/10.2337/figshare.27890331.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.27890331.v1",null],["3","R0049411","R0049411.pdf","open_download_failed","systematic_review","George G. Kidess","2025","SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ARE ASSOCIATED WITH A LOWER RISK OF ATRIAL FIBRILLATION COMPARED TO GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A DIRECT METAANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)00661-8","https://doi.org/10.1016/s0735-1097(25)00661-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2900661-8?download=true",null],["3","R0049607","R0049607.pdf","open_download_failed","systematic_review","Reema Salman Alfadliah","2025","Semaglutide for Weight Loss in Diabetic and Non-Diabetic Patients: A Comprehensive Systematic Review of Efficacy and Safety","Scientia. Technology, science and society.","AMO Publisher","10.59324/stss.2025.2(4).06","https://doi.org/10.59324/stss.2025.2(4).06",null,"https://pubmed.ncbi.nlm.nih.gov//","https://scientia-tss.com/index.php/journal/article/download/64/68",null],["3","R0049653","R0049653.pdf","open_download_failed","systematic_review","Stanley Wong","2025","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Psychiatry International","MDPI AG","10.3390/psychiatryint6030111","https://doi.org/10.3390/psychiatryint6030111",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-5318/6/3/111/pdf?version=1757493055","PROSPERO:CRD42024537280"],["3","R0049698","R0049698.pdf","free_to_read","systematic_review","Matthew M.Y. Lee","2025","Cardiovascular, Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide-1 Receptor Agonists in Persons With Type 2 Diabetes – a Systematic Review and Meta-Analyses of Randomized Trials",null,"American Diabetes Association","10.2337/figshare.28473485","https://doi.org/10.2337/figshare.28473485",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28473485","PROSPERO:CRD42024607253"],["3","R0049843","R0049843.pdf","open_download_failed","systematic_review","Stanley Sau Ching Wong","2025","0774 Glucagon-Like Peptide 1 Receptor Agonists for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsaf090.0774","https://doi.org/10.1093/sleep/zsaf090.0774",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/sleep/article-pdf/48/Supplement_1/A335/63222821/zsaf090.0774.pdf",null],["3","R0050104","R0050104.pdf","open_download_failed","systematic_review","Nisarg B. Shah","2025","MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1291","https://doi.org/10.1210/jendso/bvaf149.1291",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1291/64865222/bvaf149.1291.pdf",null],["3","R0050474","R0050474.pdf","open_download_failed","systematic_review","Wanxiang Yao","2025","GLP-1 Receptor Agonists Reduce All-Cause Mortality and Non-Fatal Myocardial Infarction in Overweight and Obese Adults Without Diabetes Mellitus: Results of a Systematic Review and Meta-Analysis","Heart Lung and Circulation","Elsevier BV","10.1016/j.hlc.2025.06.872","https://doi.org/10.1016/j.hlc.2025.06.872",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.heartlungcirc.org/article/S1443-9506(25)01361-7/pdf",null],["3","R0050476","R0050476.pdf","free_to_read","systematic_review","Muhammad Uzair","2025","INSIGHT INTO PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS AND THERAPEUTIC ROLE OF GLP-1 AND SGLT INHIBITORS: A SYSTEMATIC REVIEW","Insights-Journal of Health and Rehabilitation","Health and Research Insights","10.71000/mph7kz17","https://doi.org/10.71000/mph7kz17",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.71000/mph7kz17",null],["3","R0051115","R0051115.pdf","open_download_failed","systematic_review","Takaya Sasaki","2025","#01842 The effect of GLP-1 receptor agonists on renal outcomes:a systematic review and meta-analysis","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.0511","https://doi.org/10.1093/ndt/gfaf116.0511",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/40/Supplement_3/gfaf116.0511/64841245/gfaf116.0511.pdf",null],["3","R0051296","R0051296.pdf","open_download_failed","systematic_review","Aurélie Phan","2025","Effect of antidiabetic drugs on gut endocrine function after metabolic and bariatric surgery: a systematic review","Obesity and Endocrinology","Oxford University Press (OUP)","10.1093/obendo/wjaf012","https://doi.org/10.1093/obendo/wjaf012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/obendo/advance-article-pdf/doi/10.1093/obendo/wjaf012/65378390/wjaf012.pdf",null],["3","R0051421","R0051421.pdf","open_download_failed","systematic_review","Zina Otmani","2025","300.21 Semaglutide in Patients With Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-Analysis of Randomized Controlled Trials","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2025.01.230","https://doi.org/10.1016/j.jcin.2025.01.230",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/j.jcin.2025.01.230?download=true",null],["3","R0051689","R0051689.pdf","free_to_read","systematic_review","O. Raheem","2025","166 - Effects of GLP-1 Receptor Agonists on Testosterone Levels and Semen Parameters in Men: A Systematic Review","Continence","Elsevier BV","10.1016/j.cont.2025.102090","https://doi.org/10.1016/j.cont.2025.102090",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cont.2025.102090",null],["3","R0051704","R0051704.pdf","free_to_read","systematic_review","Joseph Chu","2025","Efficacy of GLP-1 Receptor Agonists Combined with Lifestyle Modification on Weight and Cardiovascular Metabolic Biomarkers for the Treatment of Overweight and Obesity: Meta-Analysis of Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5172447","https://doi.org/10.2139/ssrn.5172447",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5172447",null],["3","R0051858","R0051858.pdf","free_to_read","systematic_review","Ahmed B. Bayoumy","2025","Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5246533","https://doi.org/10.2139/ssrn.5246533",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5246533",null],["3","R0051995","R0051995.pdf","free_to_read","systematic_review","Dena Osama Khawandanah","2025","Glucagon-like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Saudi Journal of Clinical Pharmacy","Ovid Technologies (Wolters Kluwer Health)","10.4103/sjcp.sjcp_22_25","https://doi.org/10.4103/sjcp.sjcp_22_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/sjcp.sjcp_22_25",null],["3","R0052082","R0052082.pdf","free_to_read","systematic_review","Jirawan Vienghirun","2025","Efficacy and Safety of Subcutaneous and Oral GLP-1 Receptor/Dual Agonists on Weight Loss: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5372118","https://doi.org/10.2139/ssrn.5372118",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5372118",null],["3","R0052532","R0052532.pdf","open_download_failed","systematic_review","Sarah Morrow","2025","P050 Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis","British Journal of Dermatology","Oxford University Press (OUP)","10.1093/bjd/ljaf085.078","https://doi.org/10.1093/bjd/ljaf085.078",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/bjd/article-pdf/193/Supplement_1/ljaf085.078/63486810/ljaf085.078.pdf",null],["3","R0053262","R0053262.pdf","open_download_failed","systematic_review","Radhika Gulhar","2025","Efficacy and safety of semaglutide in patients with obesity-related heart failure: a meta-analysis of randomized clinical trials","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf236.265","https://doi.org/10.1093/eurjpc/zwaf236.265",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurjpc/article-pdf/32/Supplement_1/zwaf236.265/63229930/zwaf236.265.pdf",null],["3","R0053880","R0053880.pdf","free_to_read","systematic_review","Shifa Taj","2025","CO39 Risk of Cutaneous Adverse Drug Reactions with GLP-1 Receptor Agonists: Insights from FAERS and Systematic Review","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.124","https://doi.org/10.1016/j.jval.2025.04.124",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.124",null],["3","R0054019","R0054019.pdf","open_download_failed","systematic_review","Sher Bano","2025","Mitochondrial Dysfunction, Genetic Predisposition, and Targeted Interventions in Neurodegenerative Diseases and Cognitive Decline: A Meta-Analysis of Mechanisms and Treatments","Indus journal of bioscience research.","Indus Publishers","10.70749/ijbr.v3i3.715","https://doi.org/10.70749/ijbr.v3i3.715",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijbr.com.pk/IJBR/article/download/715/712",null],["3","R0054021","R0054021.pdf","open_download_failed","systematic_review","Tiago Loureiro","2025","Clinical outcome of off-label drugs for weight loss: a systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn25s310","https://doi.org/10.54448/ijn25s310",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/459/418",null],["3","R0054231","R0054231.pdf","open_download_failed","systematic_review","Mohammad Ghassab Deameh","2025","(152) Effects of GLP-1 Receptor Agonists on Male Reproductive Hormones, Semen Parameters, and Metabolic Outcomes: A Systematic Review","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdaf320.152","https://doi.org/10.1093/jsxmed/qdaf320.152",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jsm/article-pdf/22/Supplement_4/qdaf320.152/65820766/qdaf320.152.pdf",null],["3","R0054249","R0054249.pdf","open_download_failed","systematic_review","Karan Varshney","2025","Impacts of Glucagon-like Peptide-1 Receptor-Agonist (GLP-1 RA) Treatment for Metabolic Disturbances and Weight Gain in Patients on Clozapine/Olanzapine: A Systematic Review","Obesities","MDPI AG","10.3390/obesities5040072","https://doi.org/10.3390/obesities5040072",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4168/5/4/72/pdf?version=1759992126",null],["3","R0054285","R0054285.pdf","no_doi","systematic_review","Shadman Newaz","2025","Risk of hepatocellular carcinoma in adults exposed to oral antidiabetic drugs: a systematic review","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0054317","R0054317.pdf","free_to_read","systematic_review","Mohammed Muzammil","2025","A Comprehensive Meta-analysis of Efficacy, Cardiovascular Protection, and Emerging Therapeutic Innovations of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus","Telangana journal of IMA.","Ovid Technologies (Wolters Kluwer Health)","10.4103/tjima.tjima_31_25","https://doi.org/10.4103/tjima.tjima_31_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/tjima.tjima_31_25",null],["3","R0054432","R0054432.pdf","open_download_failed","systematic_review","C.C. Soekamto","2025","Potential effect of GLP-1 RA in reducing arterial stiffness in diabetic patients: a systematic review and meta-analysis","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2025.112542","https://doi.org/10.1016/j.diabres.2025.112542",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00556-X/pdf",null],["3","R0054604","R0054604.pdf","open_download_failed","systematic_review","Aminah Abrão Fauaz Ritter Lima","2025","SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1227","https://doi.org/10.1210/jendso/bvaf149.1227",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1227/64863952/bvaf149.1227.pdf",null],["3","R0054706","R0054706.pdf","open_download_failed","systematic_review","Azhar M. Al Ibrahem","2025","Efficacy and Safety of Oral Semaglutide (Rybelsus) for Weight Reduction in Individuals with Obesity and Type 2 Diabetes: A Systematic Review","Journal of Healthcare Sciences","Research Establishment for Electronic Publication","10.52533/johs.2025.50101","https://doi.org/10.52533/johs.2025.50101",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52533/johs.2025.50101",null],["3","R0054817","R0054817.pdf","free_to_read","systematic_review","Mohammed Riyaz","2025","The Impact of Oral Hypoglycemic Agents on Elderly Patients: A Meta-analysis (2000–2025)","Telangana journal of IMA.","Ovid Technologies (Wolters Kluwer Health)","10.4103/tjima.tjima_21_25","https://doi.org/10.4103/tjima.tjima_21_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/tjima.tjima_21_25",null],["3","R0054883","R0054883.pdf","free_to_read","systematic_review","Eleftherios Teperikidis","2025","Comparative Effectiveness of GLP-1 Receptor Agonists: A Network Meta-Analysis Using Chatgpt","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5103748","https://doi.org/10.2139/ssrn.5103748",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5103748",null],["3","R0054933","R0054933.pdf","no_doi","systematic_review","César Luis González-Cuello","2025","Effect of weight-loss medications on obstructive sleep apnea. Systematic review","Gredos (University of Salamanca)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055008","R0055008.pdf","open_download_failed","systematic_review","Hideki Zimermann Kamitani","2025","MON-241 Efficacy and Safety of Liraglutide in Managing Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1715","https://doi.org/10.1210/jendso/bvaf149.1715",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1715/64864522/bvaf149.1715.pdf",null],["3","R0055023","R0055023.pdf","open_download_failed","systematic_review","Faizan Ahmed","2025","MON-516 Effectiveness of Semaglutide on Cardiovascular Outcomes in Chronic Kidney Disease (CKD) Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.884","https://doi.org/10.1210/jendso/bvaf149.884",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.884/64864244/bvaf149.884.pdf","PROSPERO:CRD42024617222"],["3","R0055133","R0055133.pdf","open_download_failed","systematic_review","Natanael de Paula Portilho","2025","EFFECTS OF GLP-1 AGONISTS IN PATIENTS WITH CHRONIC HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)02078-9","https://doi.org/10.1016/s0735-1097(25)02078-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2825%2902078-9?download=true",null],["3","R0055160","R0055160.pdf","open_download_failed","systematic_review","Deep Dutta","2025","Impact of 1-Year Tirzepatide Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis","Diabetes Technology and Obesity Medicine","SAGE Publications","10.1089/dtom.2025.0048","https://doi.org/10.1089/dtom.2025.0048",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.liebertpub.com/doi/pdf/10.1089/dtom.2025.0048?download=true",null],["3","R0055218","R0055218.pdf","open_download_failed","systematic_review","Muhammad Faizan Ali","2025","E-107 | Role of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2025.103368","https://doi.org/10.1016/j.jscai.2025.103368",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jscai.org/article/S2772-9303(25)00810-5/pdf",null],["3","R0055325","R0055325.pdf","open_download_failed","systematic_review","Nidhi Lanka","2025","MON-183 Effect of GLP-1 Receptor Agonists on Anthropometric, Metabolic and Fertility Parameters in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1915","https://doi.org/10.1210/jendso/bvaf149.1915",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1915/64862186/bvaf149.1915.pdf",null],["3","R0055401","R0055401.pdf","open_download_failed","systematic_review","Luisa Montejano","2025","SUN-031 Efficacy Of The Glp-1 Agonists In The Treatment Of Idiopathic Intracranial Hypertension: A Systematic Review And Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.1620","https://doi.org/10.1210/jendso/bvaf149.1620",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.1620/64864378/bvaf149.1620.pdf",null],["3","R0055587","R0055587.pdf","free_to_read","systematic_review","Yash Verma","2025","A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the Canadian Association of Gastroenterology","Oxford University Press (OUP)","10.1093/jcag/gwae059.081","https://doi.org/10.1093/jcag/gwae059.081",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/jcag/gwae059.081",null],["3","R0055595","R0055595.pdf","free_to_read","systematic_review","Chun-Chiao Yu","2025","Impact of glucagon-like peptide-1 receptor agonists on cutaneous events: A systematic review and meta-analysis","JAAD reviews.","Elsevier BV","10.1016/j.jdrv.2025.04.009","https://doi.org/10.1016/j.jdrv.2025.04.009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jdrv.2025.04.009",null],["3","R0055707","R0055707.pdf","open_download_failed","systematic_review","Elizabeth Caroline Palaparthi","2025","SUN-676 Impact Of Once-weekly Semaglutide On Heart Failure Hospitalizations And Weight Loss In Obese Patients With Preserved Ejection Fraction (Hfpef): A Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.186","https://doi.org/10.1210/jendso/bvaf149.186",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/9/Supplement_1/bvaf149.186/64863914/bvaf149.186.pdf",null],["3","R0055944","R0055944.pdf","no_doi","systematic_review","MOAMEN ABDELFADIL ISMAIL, MAJED MOHAMMED ALANAZI, BUSHRA F. ALQURASHI, RUBA M. ABUTALEB, YOUSEF FAHAD ALRESHOODI, RIYADH T. IZZZULDEEN,","2025","THE EFFICACY AND SAFETY OF SEMAGLUTIDE IN GLYCEMIC CONTROL, WEIGHT REDUCTION, AND CARDIOVASCULAR RISK MANAGEMENT IN TYPE 2 DIABETES PATIENTS: A SYSTEMATIC REVIEW","TPM Testing, psychometrics, methodology in applied psychology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055973","R0055973.pdf","no_doi","systematic_review","MOHAMMED SAAD ALNAWMASI","2025","CARDIOVASCULAR RISK IN TIRZEPATIDE MANAGEMENT FOR OBESITY IN TYPE 2 DIABETES PATIENTS: A SYSTEMATIC REVIEW","TPM Testing, psychometrics, methodology in applied psychology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056240","R0056240.pdf","no_doi","systematic_review","MOAMEN ABDELFADIL ISMAIL, ALI MUSAAD ALGHAMDI, ABDULLAH S. ALMOHAMMED, MARYAM ALI ALANAZI, RAZAN IBRAHIM SANGOURA, JANA WAEL ALGHAMDI","2025","PHARMACOLOGICAL MECHANISMS AND CLINICAL EFFICACY OF GLP-1 RECEPTOR AGONISTS IN APPETITE REGULATION AND GLYCEMIC CONTROL: A SYSTEMATIC REVIEW IN OBESE PATIENTS WITH INSULIN RESISTANCE","TPM Testing, psychometrics, methodology in applied psychology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056244","R0056244.pdf","no_doi","systematic_review","S.Emrani","2025","Efficacy of GLP-1 Receptor Agonists on Major Adverse Cardiovascular Events in Type 2 Diabetes: A Systematic Review","Medical Education in The United States and Canada",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056470","R0056470.pdf","no_doi","systematic_review","DR. SHRINIDHI B","2025","UNDERSTANDING THE ADOPTION AND PERCEPTIONS OF TIRZEPATIDE IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC REVIEW","TPM Testing, psychometrics, methodology in applied psychology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0000904","R0000904.pdf","open_download_failed","systematic_review","Ndubuisi J","2024","Efficacy and Safety of GLP-1RAs including Tirzepatide, in the Management of Obesity in Nondiabetic Patients: A Systematic Review","Preprints.org","MDPI AG","10.20944/preprints202407.2397.v1","https://doi.org/10.20944/preprints202407.2397.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/2e9eae5f7bef4e7478750e99025ffd21/download_pub",null],["3","R0001294","R0001294.pdf","open_download_failed","systematic_review","Ramalan MA","2024","Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and meta-analysis of randomized clinical trials","medRxiv","openRxiv","10.1101/2024.07.18.24310630","https://doi.org/10.1101/2024.07.18.24310630",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/07/18/2024.07.18.24310630.full.pdf",null],["3","R0001862","R0001862.pdf","free_to_read","systematic_review","Elkin J","2024","Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis","medRxiv","openRxiv","10.1101/2024.11.10.24317070","https://doi.org/10.1101/2024.11.10.24317070",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2024.11.10.24317070",null],["3","R0002692","R0002692.pdf","open_download_failed","systematic_review","Rivera FB","2024","Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15529","https://doi.org/10.1111/dom.15529","38505997","https://pubmed.ncbi.nlm.nih.gov/38505997/","https://www.medrxiv.org/content/medrxiv/early/2024/01/30/2024.01.29.24301971.full.pdf",null],["3","R0002929","R0002929.pdf","free_to_read","systematic_review","Saglietto A","2024","Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.","European journal of clinical investigation","Wiley","10.1111/eci.14292","https://doi.org/10.1111/eci.14292","39058274","https://pubmed.ncbi.nlm.nih.gov/39058274/","https://doi.org/10.1111/eci.14292",null],["3","R0003270","R0003270.pdf","open_download_failed","systematic_review","Ng VWW","2024","The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.","Clinical obesity","Wiley","10.1111/cob.12642","https://doi.org/10.1111/cob.12642","38273176","https://pubmed.ncbi.nlm.nih.gov/38273176/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12642",null],["3","R0003388","R0003388.pdf","open_download_failed","systematic_review","Kim HJ","2024","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3843","https://doi.org/10.1002/dmrr.3843","39311048","https://pubmed.ncbi.nlm.nih.gov/39311048/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.3843",null],["3","R0003412","R0003412.pdf","open_download_failed","systematic_review","Menon T","2024","A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.","CNS spectrums","Cambridge University Press (CUP)","10.1017/s1092852924000531","https://doi.org/10.1017/s1092852924000531","39582175","https://pubmed.ncbi.nlm.nih.gov/39582175/","https://www.cambridge.org/core/services/aop-cambridge-core/content/view/48801F4A9CE25AE46D43F26B8847E8EB/S1092852924000531a.pdf/div-class-title-a-systematic-review-on-the-efficacy-of-glp-1-receptor-agonists-in-mitigating-psychotropic-drug-related-weight-gain-div.pdf",null],["3","R0003677","R0003677.pdf","free_to_read","systematic_review","Badulescu S","2024","Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review.","Physiology & behavior","Elsevier BV","10.1016/j.physbeh.2024.114622","https://doi.org/10.1016/j.physbeh.2024.114622","38945189","https://pubmed.ncbi.nlm.nih.gov/38945189/","https://doi.org/10.1016/j.physbeh.2024.114622",null],["3","R0003686","R0003686.pdf","open_download_failed","systematic_review","Silverii GA","2024","Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15382","https://doi.org/10.1111/dom.15382","38018310","https://pubmed.ncbi.nlm.nih.gov/38018310/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15382",null],["3","R0003717","R0003717.pdf","open_download_failed","systematic_review","Karakasis P","2024","Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15979","https://doi.org/10.1111/dom.15979","39344842","https://pubmed.ncbi.nlm.nih.gov/39344842/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15979",null],["3","R0003732","R0003732.pdf","open_download_failed","systematic_review","Stefanou MI","2024","Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.","European stroke journal","Oxford University Press (OUP)","10.1177/23969873241234238","https://doi.org/10.1177/23969873241234238","38400569","https://pubmed.ncbi.nlm.nih.gov/38400569/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11418422/pdf/10.1177_23969873241234238.pdf",null],["3","R0004241","R0004241.pdf","open_download_failed","systematic_review","Anson M","2024","Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15576","https://doi.org/10.1111/dom.15576","38558280","https://pubmed.ncbi.nlm.nih.gov/38558280/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15576",null],["3","R0004257","R0004257.pdf","open_download_failed","systematic_review","Espinosa De Ycaza AE","2024","Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.","Thyroid : official journal of the American Thyroid Association","SAGE Publications","10.1089/thy.2023.0530","https://doi.org/10.1089/thy.2023.0530","38343381","https://pubmed.ncbi.nlm.nih.gov/38343381/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10998705/pdf/thy.2023.0530.pdf",null],["3","R0004347","R0004347.pdf","open_download_failed","systematic_review","Silverii GA","2024","Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15538","https://doi.org/10.1111/dom.15538","38449004","https://pubmed.ncbi.nlm.nih.gov/38449004/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15538",null],["3","R0004364","R0004364.pdf","open_download_failed","systematic_review","Goldenberg RM","2024","A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15588","https://doi.org/10.1111/dom.15588","38576082","https://pubmed.ncbi.nlm.nih.gov/38576082/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15588",null],["3","R0004457","R0004457.pdf","open_download_failed","systematic_review","Adamou A","2024","Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.","International journal of stroke : official journal of the International Stroke Society","SAGE Publications","10.1177/17474930241253988","https://doi.org/10.1177/17474930241253988","38676552","https://pubmed.ncbi.nlm.nih.gov/38676552/","https://journals.sagepub.com/doi/pdf/10.1177/17474930241253988?download=true",null],["3","R0004615","R0004615.pdf","free_to_read","systematic_review","Figlioli G","2024","Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2024.107401","https://doi.org/10.1016/j.phrs.2024.107401","39251099","https://pubmed.ncbi.nlm.nih.gov/39251099/","https://doi.org/10.1016/j.phrs.2024.107401","PROSPERO:CRD42023476762"],["3","R0005237","R0005237.pdf","free_to_read","systematic_review","Asifa F","2024","SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Reducing Heart Failure Hospitalizations in Type-2 Diabetes. A Systematic Review and Meta-Analysis","Preprints.org","MDPI AG","10.20944/preprints202410.0929.v1","https://doi.org/10.20944/preprints202410.0929.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202410.0929.v1",null],["3","R0005539","R0005539.pdf","open_download_failed","systematic_review","Wahi G","2024","Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.","Pediatric obesity","Wiley","10.1111/ijpo.13169","https://doi.org/10.1111/ijpo.13169","39238400","https://pubmed.ncbi.nlm.nih.gov/39238400/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.13169",null],["3","R0005655","R0005655.pdf","open_download_failed","systematic_review","Wang A","2024","Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.04.013","https://doi.org/10.1016/j.clinthera.2024.04.013","38796335","https://pubmed.ncbi.nlm.nih.gov/38796335/","https://www.clinicaltherapeutics.com/article/S0149-2918(24)00105-X/pdf",null],["3","R0005772","R0005772.pdf","open_download_failed","systematic_review","Kunutsor SK","2024","Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials.","Scandinavian cardiovascular journal : SCJ","Informa UK Limited","10.1080/14017431.2024.2418086","https://doi.org/10.1080/14017431.2024.2418086","39425977","https://pubmed.ncbi.nlm.nih.gov/39425977/","https://www.tandfonline.com/doi/pdf/10.1080/14017431.2024.2418086?needAccess=true",null],["3","R0005795","R0005795.pdf","free_to_read","systematic_review","Chen X","2024","The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","Elsevier BV","10.1016/j.jagp.2023.08.010","https://doi.org/10.1016/j.jagp.2023.08.010","37684186","https://pubmed.ncbi.nlm.nih.gov/37684186/","https://doi.org/10.1016/j.jagp.2023.08.010",null],["3","R0005866","R0005866.pdf","free_to_read","systematic_review","Chae Y","2024","Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2024.2363838","https://doi.org/10.1080/17512433.2024.2363838","38832475","https://pubmed.ncbi.nlm.nih.gov/38832475/","https://figshare.com/articles/journal_contribution/Lipid_profile_changes_induced_by_glucagon-like_peptide-1_receptor_agonists_in_patients_with_type_2_diabetes_a_systematic_review_and_network_meta-analysis/25983261","PROSPERO:CRD42021282668"],["3","R0005871","R0005871.pdf","open_download_failed","systematic_review","Au H","2024","Examining the Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Human Gut Microbiome: A Systematic Review","Authorea Preprints","Wiley","10.22541/au.173199831.11097717/v1","https://doi.org/10.22541/au.173199831.11097717/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.173199831.11097717",null],["3","R0006206","R0006206.pdf","free_to_read","systematic_review","Martinelli S","2024","Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.","Drug and alcohol dependence","Elsevier BV","10.1016/j.drugalcdep.2024.112424","https://doi.org/10.1016/j.drugalcdep.2024.112424","39288591","https://pubmed.ncbi.nlm.nih.gov/39288591/","https://doi.org/10.1016/j.drugalcdep.2024.112424",null],["3","R0006369","R0006369.pdf","free_to_read","systematic_review","Kunutsor SK","2024","Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.09.007","https://doi.org/10.1016/j.pcd.2024.09.007","39366881","https://pubmed.ncbi.nlm.nih.gov/39366881/","https://doi.org/10.1016/j.pcd.2024.09.007","PROSPERO:CRD42024498939"],["3","R0006806","R0006806.pdf","free_to_read","systematic_review","Malandris K","2024","Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.16559","https://doi.org/10.1111/jgh.16559","38627972","https://pubmed.ncbi.nlm.nih.gov/38627972/","https://doi.org/10.1111/jgh.16559",null],["3","R0006830","R0006830.pdf","free_to_read","systematic_review","Wang R","2024","Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3752","https://doi.org/10.1002/dmrr.3752","38013215","https://pubmed.ncbi.nlm.nih.gov/38013215/",null,null],["3","R0006942","R0006942.pdf","open_download_failed","systematic_review","Kunutsor SK","2024","Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15500","https://doi.org/10.1111/dom.15500","38379094","https://pubmed.ncbi.nlm.nih.gov/38379094/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15500",null],["3","R0007062","R0007062.pdf","free_to_read","systematic_review","Neuen BL","2024","Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.124.071689","https://doi.org/10.1161/circulationaha.124.071689","39210781","https://pubmed.ncbi.nlm.nih.gov/39210781/","https://research.rug.nl/files/1176160241/neuen-et-al-2024-cardiovascular-kidney-and-safety-outcomes-with-glp-1-receptor-agonists-alone-and-in-combination-with.pdf","PROSPERO:CRD42024565765"],["3","R0007310","R0007310.pdf","open_download_failed","systematic_review","Igweokpala S","2024","Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15367","https://doi.org/10.1111/dom.15367","38031234","https://pubmed.ncbi.nlm.nih.gov/38031234/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15367",null],["3","R0007442","R0007442.pdf","open_download_failed","systematic_review","Moiz A","2024","Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2024.04.041","https://doi.org/10.1016/j.amjcard.2024.04.041","38679221","https://pubmed.ncbi.nlm.nih.gov/38679221/","http://www.ajconline.org/article/S0002914924003199/pdf",null],["3","R0007511","R0007511.pdf","free_to_read","systematic_review","Li H","2024","Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2024.116150","https://doi.org/10.1016/j.biopha.2024.116150","38242040","https://pubmed.ncbi.nlm.nih.gov/38242040/","https://doi.org/10.1016/j.biopha.2024.116150",null],["3","R0007598","R0007598.pdf","open_download_failed","systematic_review","Esparham A","2024","Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13811","https://doi.org/10.1111/obr.13811","39134066","https://pubmed.ncbi.nlm.nih.gov/39134066/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13811",null],["3","R0007758","R0007758.pdf","free_to_read","systematic_review","Müllertz ALO","2024","Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13717","https://doi.org/10.1111/obr.13717","38463003","https://pubmed.ncbi.nlm.nih.gov/38463003/","https://doi.org/10.1111/obr.13717",null],["3","R0007771","R0007771.pdf","open_download_failed","systematic_review","Kuate Defo A","2024","Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15331","https://doi.org/10.1111/dom.15331","37869901","https://pubmed.ncbi.nlm.nih.gov/37869901/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15331",null],["3","R0008838","R0008838.pdf","open_download_failed","systematic_review","Vargas KG","2024","Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15519","https://doi.org/10.1111/dom.15519","38425176","https://pubmed.ncbi.nlm.nih.gov/38425176/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15519",null],["3","R0009506","R0009506.pdf","open_download_failed","systematic_review","Bak M","2024","Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.","Acta psychiatrica Scandinavica","Wiley","10.1111/acps.13734","https://doi.org/10.1111/acps.13734","39048532","https://pubmed.ncbi.nlm.nih.gov/39048532/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acps.13734",null],["3","R0009789","R0009789.pdf","free_to_read","systematic_review","Njei B","2024","Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials","Authorea Preprints","Wiley","10.22541/au.171585503.34303032/v1","https://doi.org/10.22541/au.171585503.34303032/v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0010289","R0010289.pdf","open_download_failed","systematic_review","Hiramoto B","2024","Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000002820","https://doi.org/10.14309/ajg.0000000000002820","38634551","https://pubmed.ncbi.nlm.nih.gov/38634551/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150091/pdf/nihms-1986549.pdf",null],["3","R0012989","R0012989.pdf","open_download_failed","systematic_review","Qazi SU","2024","Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-024-01409-3","https://doi.org/10.1007/s40200-024-01409-3","38932865","https://pubmed.ncbi.nlm.nih.gov/38932865/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11196538/pdf/40200_2024_Article_1409.pdf",null],["3","R0013631","R0013631.pdf","open_download_failed","systematic_review","Natale P","2024","Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd015588.pub2","https://doi.org/10.1002/14651858.cd015588.pub2","38770818","https://pubmed.ncbi.nlm.nih.gov/38770818/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11106805/pdf/CD015588.pdf","ClinicalTrials.gov:NCT02836873; ClinicalTrials.gov:NCT01032629; ClinicalTrials.gov:NCT01989754; ClinicalTrials.gov:NCT03242018; ClinicalTrials.gov:NCT02532855; ClinicalTrials.gov:NCT02065791; ClinicalTrials.gov:NCT03036150; ClinicalTrials.gov:NCT03036124; ClinicalTrials.gov:NCT04350593; ClinicalTrials.gov:NCT01730534; ClinicalTrials.gov:NCT02547935; ClinicalTrials.gov:NCT02268214; ClinicalTrials.gov:NCT02460978; ClinicalTrials.gov:NCT02413398; ClinicalTrials.gov:NCT03594110; ClinicalTrials.gov:NCT01370005; ClinicalTrials.gov:NCT01159600; ClinicalTrials.gov:NCT01177813; ClinicalTrials.gov:NCT01131676; ClinicalTrials.gov:NCT01210001; ClinicalTrials.gov:NCT01164501; ClinicalTrials.gov:NCT03057951; ClinicalTrials.gov:NCT03057977; ClinicalTrials.gov:NCT03078101; ClinicalTrials.gov:NCT01193218; ClinicalTrials.gov:NCT01294423; ClinicalTrials.gov:NCT00663260; ClinicalTrials.gov:NCT01316094; ClinicalTrials.gov:NCT01646320; ClinicalTrials.gov:NCT01137474; ClinicalTrials.gov:NCT02682563; ClinicalTrials.gov:NCT00683878; ClinicalTrials.gov:NCT03315143; ClinicalTrials.gov:NCT03521934; ClinicalTrials.gov:NCT01381887; ClinicalTrials.gov:NCT01986881; ClinicalTrials.gov:NCT01986855; ClinicalTrials.gov:NCT03436693; ClinicalTrials.gov:NCT01195662; ClinicalTrials.gov:NCT00673231; ClinicalTrials.gov:NCT01555008; ClinicalTrials.gov:NCT00528879; ClinicalTrials.gov:NCT00855166; ClinicalTrials.gov:NCT00968812; ClinicalTrials.gov:NCT01031680; ClinicalTrials.gov:NCT00528372; ClinicalTrials.gov:NCT00688701; ClinicalTrials.gov:NCT01512849; ClinicalTrials.gov:NCT00984867; ClinicalTrials.gov:NCT01042977; ClinicalTrials.gov:NCT04243850; ClinicalTrials.gov:NCT02096705; ClinicalTrials.gov:NCT05359263; ClinicalTrials.gov:NCT04662723; ClinicalTrials.gov:NCT04061200; ClinicalTrials.gov:NCT04238702; ClinicalTrials.gov:NCT01167881"],["3","R0013669","R0013669.pdf","open_download_failed","systematic_review","Wang W","2024","Replicating cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: A systematic review of observational studies","medRxiv","openRxiv","10.1101/2024.11.28.24317099","https://doi.org/10.1101/2024.11.28.24317099",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/11/29/2024.11.28.24317099.full.pdf",null],["3","R0014128","R0014128.pdf","open_download_failed","systematic_review","Zhang L","2024","Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.","Journal of clinical pharmacology","Wiley","10.1002/jcph.2483","https://doi.org/10.1002/jcph.2483","38874130","https://pubmed.ncbi.nlm.nih.gov/38874130/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcph.2483",null],["3","R0014781","R0014781.pdf","open_download_failed","systematic_review","Goldberg A","2024","Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13704","https://doi.org/10.1111/obr.13704","38355887","https://pubmed.ncbi.nlm.nih.gov/38355887/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13704",null],["3","R0015350","R0015350.pdf","open_download_failed","systematic_review","Karagiannis T","2024","A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc23-0925","https://doi.org/10.2337/dc23-0925","38241493","https://pubmed.ncbi.nlm.nih.gov/38241493/","https://diabetesjournals.org/care/article-pdf/47/2/184/745785/dc230925.pdf",null],["3","R0017030","R0017030.pdf","open_download_failed","systematic_review","Karakasis P","2024","Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15410","https://doi.org/10.1111/dom.15410","38116693","https://pubmed.ncbi.nlm.nih.gov/38116693/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15410",null],["3","R0017907","R0017907.pdf","open_download_failed","systematic_review","Khanmohammadi S","2024","Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15437","https://doi.org/10.1111/dme.15437","39340770","https://pubmed.ncbi.nlm.nih.gov/39340770/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15437",null],["3","R0018167","R0018167.pdf","free_to_read","systematic_review","Ayesh H","2024","Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15725","https://doi.org/10.1111/dom.15725","38923379","https://pubmed.ncbi.nlm.nih.gov/38923379/","https://doi.org/10.1111/dom.15725","OSF:osf.io/gd67x"],["3","R0018508","R0018508.pdf","free_to_read","systematic_review","Hanlon P","2024","Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data","medRxiv","openRxiv","10.1101/2024.06.23.24309242","https://doi.org/10.1101/2024.06.23.24309242",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2024.06.23.24309242",null],["3","R0019022","R0019022.pdf","free_to_read","systematic_review","Kommu S","2024","Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13792","https://doi.org/10.1111/obr.13792","38923272","https://pubmed.ncbi.nlm.nih.gov/38923272/","https://doi.org/10.1111/obr.13792",null],["3","R0019132","R0019132.pdf","open_download_failed","systematic_review","Wang H","2024","Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13727","https://doi.org/10.1111/obr.13727","38509775","https://pubmed.ncbi.nlm.nih.gov/38509775/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13727",null],["3","R0019385","R0019385.pdf","open_download_failed","systematic_review","Rangwala HS","2024","Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-024-01412-8","https://doi.org/10.1007/s40200-024-01412-8","38932909","https://pubmed.ncbi.nlm.nih.gov/38932909/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11196572/pdf/40200_2024_Article_1412.pdf",null],["3","R0019661","R0019661.pdf","open_download_failed","systematic_review","Di Ciaula A","2024","Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2024.07.008","https://doi.org/10.1016/j.ejim.2024.07.008","39069430","https://pubmed.ncbi.nlm.nih.gov/39069430/","https://www.ejinme.com/article/S0953-6205(24)00291-7/pdf",null],["3","R0020618","R0020618.pdf","open_download_failed","systematic_review","Qin W","2024","Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15386","https://doi.org/10.1111/dom.15386","38016699","https://pubmed.ncbi.nlm.nih.gov/38016699/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15386",null],["3","R0020704","R0020704.pdf","free_to_read","systematic_review","Tlili NE","2024","A systematic review of the value of clinical decision support systems in the prescription of antidiabetic drugs.","International journal of medical informatics","Elsevier BV","10.1016/j.ijmedinf.2024.105581","https://doi.org/10.1016/j.ijmedinf.2024.105581","39106772","https://pubmed.ncbi.nlm.nih.gov/39106772/","https://doi.org/10.1016/j.ijmedinf.2024.105581",null],["3","R0021195","R0021195.pdf","free_to_read","systematic_review","Ding Y","2024","Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2023.107031","https://doi.org/10.1016/j.phrs.2023.107031","38061595","https://pubmed.ncbi.nlm.nih.gov/38061595/","https://doi.org/10.1016/j.phrs.2023.107031",null],["3","R0021989","R0021989.pdf","free_to_read","systematic_review","Abedi-yekta A","2024","Effect of Obesity Pharmacotherapy on anthropometrics, metabolic parameters and blood pressure in patients with obesity or overweight: An umbrella review of systematic reviews and meta-analyses of randomized clinical trials","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-5522253/v1","https://doi.org/10.21203/rs.3.rs-5522253/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.21203/rs.3.rs-5522253/v1",null],["3","R0023023","R0023023.pdf","open_download_failed","systematic_review","Peck KH","2024","Intentional weight loss in overweight and obese patients with heart failure: A systematic review.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.3270","https://doi.org/10.1002/ejhf.3270","38752254","https://pubmed.ncbi.nlm.nih.gov/38752254/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.3270",null],["3","R0023404","R0023404.pdf","free_to_read","systematic_review","Amaro-Álvarez L","2024","Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.","Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","Elsevier BV","10.1016/j.farma.2023.12.004","https://doi.org/10.1016/j.farma.2023.12.004","38341366","https://pubmed.ncbi.nlm.nih.gov/38341366/","https://doi.org/10.1016/j.farma.2023.12.004",null],["3","R0024512","R0024512.pdf","free_to_read","systematic_review","Aghebat-Bekheir S","2024","Discovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.","Human & experimental toxicology","SAGE Publications","10.1177/09603271241290922","https://doi.org/10.1177/09603271241290922","39378909","https://pubmed.ncbi.nlm.nih.gov/39378909/","https://doi.org/10.1177/09603271241290922",null],["3","R0025593","R0025593.pdf","open_download_failed","systematic_review","Johns JR","2024","The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review.","The British journal of dermatology","Oxford University Press (OUP)","10.1093/bjd/ljae228","https://doi.org/10.1093/bjd/ljae228","38819233","https://pubmed.ncbi.nlm.nih.gov/38819233/","https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae228/58031711/ljae228.pdf",null],["3","R0025760","R0025760.pdf","open_download_failed","systematic_review","Torbahn G","2024","Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.","Pediatric obesity","Wiley","10.1111/ijpo.13113","https://doi.org/10.1111/ijpo.13113","38454737","https://pubmed.ncbi.nlm.nih.gov/38454737/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.13113",null],["3","R0034515","R0034515.pdf","free_to_read","systematic_review","Regina Carneiro Leão","2024","Impact of glucagon-like-peptide-1 receptor agonists on non-motor symptoms in Parkinson’s disease: a systematic review and meta-analysis","Arquivos de Neuro-Psiquiatria","Zeppelini Editorial e Comunicação","10.5327/cbn240922","https://doi.org/10.5327/cbn240922",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5327/cbn240922",null],["3","R0034670","R0034670.pdf","free_to_read","systematic_review","Yago Marcos Pessoa-Gonçalves","2024","Effectiveness of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis","Arquivos de Neuro-Psiquiatria","Zeppelini Editorial e Comunicação","10.5327/cbn240615","https://doi.org/10.5327/cbn240615",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5327/cbn240615",null],["3","R0034715","R0034715.pdf","no_doi","systematic_review","Tara Brigham","2024","Systematic review and consensus statement for the preoperative management of GLP 1 agonists","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036514","R0036514.pdf","free_to_read","systematic_review","Jogimahanti Arjun","2024","The Effect of SGLT-2i and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Journal of Cardiology and Cardiovascular Medicine","Heighten Science Publications Corporation","10.29328/journal.jccm.1001173","https://doi.org/10.29328/journal.jccm.1001173",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.29328/journal.jccm.1001173",null],["3","R0036902","R0036902.pdf","free_to_read","systematic_review","Ioannis Bellos","2024","Comparative efficacy and safety of cardio-renoprotective pharmacological interventions in chronic kidney disease: an umbrella review of network meta-analyses and a multicriteria decision analysis v1",null,"Springer Science and Business Media LLC","10.17504/protocols.io.81wgbrdx3lpk/v1","https://doi.org/10.17504/protocols.io.81wgbrdx3lpk/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17504/protocols.io.81wgbrdx3lpk/v1",null],["3","R0036980","R0036980.pdf","free_to_read","systematic_review","Ali Rahnama Sisakht","2024","The effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis","Journal of Renal Injury Prevention","Maad Rayan Publishing Company","10.34172/jrip.2024.32292","https://doi.org/10.34172/jrip.2024.32292",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.34172/jrip.2024.32292","PROSPERO:CRD42023483132"],["3","R0037019","R0037019.pdf","free_to_read","systematic_review","Koo Thai Hau","2024","Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_80_24","https://doi.org/10.4103/jod.jod_80_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_80_24",null],["3","R0037828","R0037828.pdf","free_to_read","systematic_review","Raed Aldahash","2024","Evaluation of Insulin and Glucagon-like peptide-1 Receptor Agonists Combination for Type 2 Diabetes Mellitus: An Updated Meta-analysis","Majmaah Journal of Health Sciences","ScopeMed","10.5455/mjhs.2024.03.015","https://doi.org/10.5455/mjhs.2024.03.015",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5455/mjhs.2024.03.015",null],["3","R0037932","R0037932.pdf","free_to_read","systematic_review","Roger Rafael Porto Ro","2024","Off-label pharmacotherapy of obesity: a systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn24s304","https://doi.org/10.54448/ijn24s304",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.54448/ijn24s304",null],["3","R0038965","R0038965.pdf","free_to_read","systematic_review","Talha Tariq","2024","Effectiveness of different anti-diabetic medications in managing cardiovascular outcomes in patients with type 2 diabetes: A meta-analysis",null,"Institute for Advanced Studies","10.48047/hm.10.2.2024.1102-1115","https://doi.org/10.48047/hm.10.2.2024.1102-1115",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.48047/hm.10.2.2024.1102-1115",null],["3","R0039084","R0039084.pdf","free_to_read","systematic_review","Aisha Alyassi","2024","GLP-1 RECEPTOR AGONISTS AS A BREAKTHROUGH THERAPY FOR OBESITY AND METABOLIC SYNDROME: A SYSTEMATIC REVIEW OF EFFICACY AND LONG-TERM OUTCOMES","Journal of Population Therapeutics and Clinical Pharmacology","Green Publication","10.53555/6tdd8g65","https://doi.org/10.53555/6tdd8g65",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53555/6tdd8g65",null],["3","R0039456","R0039456.pdf","free_to_read","systematic_review","Iqbal Saeed Shaikh","2024","RENAL PROTECTIVE COMPARISON BETWEEN SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW","Journal of Population Therapeutics and Clinical Pharmacology","Green Publication","10.53555/jptcp.v31i6.6423","https://doi.org/10.53555/jptcp.v31i6.6423",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.53555/jptcp.v31i6.6423",null],["3","R0041443","R0041443.pdf","no_doi","systematic_review","Anson , Matthew","2024","Effect of combination pioglitazone with SGLT2i or GLP-1 RA on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database","Research Explorer (The University of Manchester)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041557","R0041557.pdf","free_to_read","systematic_review","Aline Levy Sitnoveter","2024","12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.788","https://doi.org/10.1210/jendso/bvae163.788",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.788",null],["3","R0041580","R0041580.pdf","open_download_failed","systematic_review","Su‐Chi Ku","2024","Wirksamkeit von Glucagon‐like Peptide‐1‐Rezeptor‐Agonisten bei Psoriasis: Eine aktualisierte systematische Übersicht und Metaanalyse","JDDG Journal der Deutschen Dermatologischen Gesellschaft","Wiley","10.1111/ddg.15431_g","https://doi.org/10.1111/ddg.15431_g","39105246","https://pubmed.ncbi.nlm.nih.gov/39105246/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.15431_g",null],["3","R0041624","R0041624.pdf","open_download_failed","systematic_review","Michelle Panol Del Rosario","2024","5185 A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.648","https://doi.org/10.1210/jendso/bvae163.648",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.648/59608092/bvae163.648.pdf",null],["3","R0041669","R0041669.pdf","open_download_failed","systematic_review","RJ. Ahiwale","2024","CO34 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists - Efficacy, Safety, and Cost-Effectiveness in Obesity Management: A Systematic Review","Value in Health","Elsevier BV","10.1016/j.jval.2024.03.123","https://doi.org/10.1016/j.jval.2024.03.123",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.valueinhealthjournal.com/article/S1098301524002389/pdf",null],["3","R0041819","R0041819.pdf","open_download_failed","systematic_review","Dan Wei","2024","RWD164 Association Between GLP-1 Receptor Agonists and Suicidal Ideation in Type 2 Diabetes and Obesity: A Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2024.10.3721","https://doi.org/10.1016/j.jval.2024.10.3721",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.valueinhealthjournal.com/article/S1098-3015(24)06606-3/pdf",null],["3","R0042393","R0042393.pdf","open_download_failed","systematic_review","Tiange Wang","2024","7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.957","https://doi.org/10.1210/jendso/bvae163.957",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.957/59607841/bvae163.957.pdf",null],["3","R0042610","R0042610.pdf","open_download_failed","systematic_review","Ramin Haghighi","2024","Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis","Journal of Renal Injury Prevention","Maad Rayan Publishing Company","10.34172/jrip.2024.32276","https://doi.org/10.34172/jrip.2024.32276",null,"https://pubmed.ncbi.nlm.nih.gov//","https://journalrip.com/Inpress/jrip-32276.pdf","PROSPERO:CRD42023479548"],["3","R0045359","R0045359.pdf","free_to_read","systematic_review","Arjun V. Jogimahanti","2024","The Effect of SGLT-2i and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Cardiology and Cardiovascular Medicine","Fortune Journals","10.26502/fccm.92920359","https://doi.org/10.26502/fccm.92920359",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/fccm.92920359",null],["3","R0045597","R0045597.pdf","free_to_read","systematic_review","Luís Fernando Ferreira Cavalcante","2024","The effect of GLP-1 analogs on the motor function of patients with Parkinson’s disease: a systematic review and meta-analysis","Arquivos de Neuro-Psiquiatria","Zeppelini Editorial e Comunicação","10.5327/cbn241606","https://doi.org/10.5327/cbn241606",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5327/cbn241606",null],["3","R0045932","R0045932.pdf","open_download_failed","systematic_review","Hongda Zhang","2024","PO-03-076 SEMAGLUTIDE FOR THE PREVENTION OF ATRIAL FIBRILLATION: A SYSTEMIC REVIEW AND META-ANALYSIS","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2024.03.1077","https://doi.org/10.1016/j.hrthm.2024.03.1077",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.heartrhythmjournal.com/article/S1547-5271(24)01450-4/pdf",null],["3","R0046185","R0046185.pdf","open_download_failed","systematic_review","D C Lopez","2024","7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.749","https://doi.org/10.1210/jendso/bvae163.749",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.749/59608044/bvae163.749.pdf",null],["3","R0046726","R0046726.pdf","free_to_read","systematic_review","Maria Abi Azar","2024","12624 The Efficacy Of Glp1 Receptor Agonists As Adjunct Therapy To Insulin In Patients With Type 1 Diabetes: A Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.958","https://doi.org/10.1210/jendso/bvae163.958",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.958",null],["3","R0046758","R0046758.pdf","open_download_failed","systematic_review","Francinny Alves Kelly","2024","SAT-631 Glucagon-Like Peptide-1 Receptor Agonist Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.2289","https://doi.org/10.1210/jendso/bvae163.2289",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.2289/63033483/bvae163.2289.pdf",null],["3","R0047005","R0047005.pdf","open_download_failed","systematic_review","Andreea Ciudin","2024","CO133 Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients With Obesity: A Bayesian Network Meta-Analysis of GLP-1 RCTs","Value in Health","Elsevier BV","10.1016/j.jval.2024.10.209","https://doi.org/10.1016/j.jval.2024.10.209",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.valueinhealthjournal.com/article/S1098-3015(24)03072-9/pdf",null],["3","R0047063","R0047063.pdf","open_download_failed","systematic_review","Mohamed Abouzid","2024","The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32,884 patients","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3279","https://doi.org/10.1093/eurheartj/ehae666.3279",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.3279/60060330/ehae666.3279.pdf",null],["3","R0047250","R0047250.pdf","open_download_failed","systematic_review","B.K.H. Tan","2024","Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3313","https://doi.org/10.1093/eurheartj/ehae666.3313",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.3313/60058557/ehae666.3313.pdf",null],["3","R0047467","R0047467.pdf","open_download_failed","systematic_review","Al Anoud Al Garzaie","2024","Effect of Subcutaneous Semaglutide on Diabetic Retinopathy among Adults with Type 2 Diabetes in Saudi Arabia. A Systematic Review","European Journal of Medical and Health Research","AMO Publisher","10.59324/ejmhr.2024.2(5).07","https://doi.org/10.59324/ejmhr.2024.2(5).07",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ejmhr.com/index.php/journal/article/download/279/186",null],["3","R0047488","R0047488.pdf","free_to_read","systematic_review","Caique M P Ternes","2024","GLP-1 RECEPTOR AGONISTS RISING ROLE IN HEART FAILURE MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)02381-7","https://doi.org/10.1016/s0735-1097(24)02381-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)02381-7",null],["3","R0047767","R0047767.pdf","free_to_read","systematic_review","Pranjal Sharma","2024","Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects","Endocrines","MDPI AG","10.3390/endocrines5030023","https://doi.org/10.3390/endocrines5030023",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/endocrines5030023",null],["3","R0048436","R0048436.pdf","free_to_read","systematic_review","Yashendra Sethi","2024","ONE DRUG FOR MULTIMORBID HYPERTENSION AND TYPE 2 DIABETES? A DOSE-WISE NETWORK META-ANALYSIS OF TIRZEPATIDE","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03722-7","https://doi.org/10.1016/s0735-1097(24)03722-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03722-7",null],["3","R0048468","R0048468.pdf","free_to_read","systematic_review","Pranjal Sharma","2024","Glucagon Like Peptide-1 Receptor Agonists: Is It As Good as It Seems? A Systematic Review of Severe Adverse Effects","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4780856","https://doi.org/10.2139/ssrn.4780856",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2139/ssrn.4780856",null],["3","R0049552","R0049552.pdf","free_to_read","systematic_review","Gustavo Yudi Orikassa de Oliveira","2024","CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WHO ARE OBESE OR OVERWEIGHT: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03838-5","https://doi.org/10.1016/s0735-1097(24)03838-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03838-5",null],["3","R0049577","R0049577.pdf","free_to_read","systematic_review","Sharath Kommu","2024","THE EFFECT OF TRIPLE-HORMONE-RECEPTOR AGONIST RETATRUTIDE, A NOVEL MEDICATION FOR WEIGHT LOSS, ON BLOOD PRESSURE - A META-ANALYSIS OF RANDOMIZED CONTROLLED PHASE 2 TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03870-1","https://doi.org/10.1016/s0735-1097(24)03870-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03870-1",null],["3","R0049764","R0049764.pdf","open_download_failed","systematic_review","Vanessa Lins de Menezes","2024","MON-301 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.2380","https://doi.org/10.1210/jendso/bvae163.2380",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.2380/63033382/bvae163.2380.pdf","PROSPERO:CRD42023482279"],["3","R0049910","R0049910.pdf","open_download_failed","systematic_review","Pedro Henrique Carvalho Leite Romeiro","2024","8007 The Effect of Glucagon-Like Peptide-1 Receptor Agonists in Reducing Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.950","https://doi.org/10.1210/jendso/bvae163.950",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.950/59607855/bvae163.950.pdf",null],["3","R0049984","R0049984.pdf","free_to_read","systematic_review","Anna Maria Klasa","2024","Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review","MEDICAL SCIENCE PULSE","Index Copernicus","10.5604/01.3001.0055.0721","https://doi.org/10.5604/01.3001.0055.0721",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5604/01.3001.0055.0721",null],["3","R0050875","R0050875.pdf","free_to_read","systematic_review","B Austregesilo Athayde H Morais","2024","8687 The Efficacy of GLP1 Receptor Agonists in Obese Women with PCOS in Promoting Weight Loss and Hormonal Regulation: A Systematic Review and Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.1073","https://doi.org/10.1210/jendso/bvae163.1073",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.1073",null],["3","R0051049","R0051049.pdf","free_to_read","systematic_review","Brendon Lange Neuen","2024","EFFECTS OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES WITH AND WITHOUT BASELINE USE OF GLP-1 RECEPTOR AGONISTS: A SMART-C COLLABORATIVE META-ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03898-1","https://doi.org/10.1016/s0735-1097(24)03898-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03898-1",null],["3","R0051479","R0051479.pdf","free_to_read","systematic_review","Lora Petrova","2024","Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus","Pharmacia","Pensoft Publishers","10.3897/pharmacia.71.e132148","https://doi.org/10.3897/pharmacia.71.e132148",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3897/pharmacia.71.e132148",null],["3","R0051815","R0051815.pdf","open_download_failed","systematic_review","Fran Kelly","2024","8699 Efficacy of Glucagon-like Peptide-1 Analogs In Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.1536","https://doi.org/10.1210/jendso/bvae163.1536",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/8/Supplement_1/bvae163.1536/59611124/bvae163.1536.pdf",null],["3","R0052934","R0052934.pdf","open_download_failed","systematic_review","Anna Hodgson","2024","Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.15571","https://doi.org/10.1111/dom.15571","38558251","https://pubmed.ncbi.nlm.nih.gov/38558251/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15571","PROSPERO:CRD42022325598"],["3","R0053091","R0053091.pdf","open_download_failed","systematic_review","Leonor Amaro","2024","4CPS-055 Pharmacogenetics and its applications in personalised medicine: a systematic review","Section 4: Clinical pharmacy services","British Medical Journal Publishing Group","10.1136/ejhpharm-2024-eahp.159","https://doi.org/10.1136/ejhpharm-2024-eahp.159",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ejhp.bmj.com/content/ejhpharm/31/Suppl_1/A78.full.pdf",null],["3","R0055255","R0055255.pdf","no_doi","systematic_review","Laura Răducu","2024","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0055271","R0055271.pdf","open_download_failed","systematic_review","Abrar Abdullateef Soqati","2024","Tirzepatide Safety and Efficacy in Managing Type 2 Diabetes and Obesity: A Systemic Review and Meta-Analysis","Journal of Healthcare Sciences","Research Establishment for Electronic Publication","10.52533/johs.2024.40902","https://doi.org/10.52533/johs.2024.40902",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52533/johs.2024.40902",null],["3","R0055490","R0055490.pdf","free_to_read","systematic_review","xiaoye hu","2024","Effect of Semaglutide in Individuals with Obesity or Overweight Without Diabetes: An Umbrella Review of Systematic Reviews","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4959966","https://doi.org/10.2139/ssrn.4959966",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2139/ssrn.4959966",null],["3","R0055516","R0055516.pdf","free_to_read","systematic_review","Aisha Alyassi","2024","META-ANALYSIS OF CARDIOPROTECTIVE EFFECTS OF COMBINED SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS VS. MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE: IMPACT ON MORTALITY AND HOSPITALIZATION OUTCOMES","Insights-Journal of Health and Rehabilitation","Health and Research Insights","10.71000/ijhr139","https://doi.org/10.71000/ijhr139",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.71000/ijhr139",null],["3","R0055565","R0055565.pdf","open_download_failed","systematic_review","Pranab M. Barman","2024","CO14 Glycaemic Control, Obesity Management, and Cardiovascular Outcomes of Semaglutide for Type 2 Diabetes Mellitus Patients: An Umbrella Review of Meta-Analyses of Randomized Clinical Trials","Value in Health","Elsevier BV","10.1016/j.jval.2024.10.091","https://doi.org/10.1016/j.jval.2024.10.091",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.valueinhealthjournal.com/article/S1098-3015(24)02954-1/pdf",null],["3","R0055992","R0055992.pdf","no_doi","systematic_review","W.Epstein","2024","Efficacy of Semaglutide for Weight Management in Individuals with Obesity but without Diabetes: A Meta-Analysis","Medical Education in The United States and Canada",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056018","R0056018.pdf","no_doi","systematic_review","Ammar Saeed Mohammad Alqahtani, Hamoud Sulaiman Hamoud Alharbi, Marzouq Munaji Abdan Alotaibi, Bandar Bader Malawi Alanazi, Naif Mutlaq Hammod Alotaibi, Muayad nasser saad almutaiwea, Turki Mansour Mutlaq Alosaimi, Khaled Sattam Sultan Alota","2024","Twin Cretins as Potential Therapy for Type 2 Diabetes Mellitus; Systematic Review","The International Journal of Multiphysics",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0056983","R0056983.pdf","free_to_read","systematic_review","Wang J","2024","The optimal second-line therapy for older adults with type 2 diabetes mellitus: protocol for a systematic review and network meta-analysis using individual participant data (IPD).","Systematic reviews","Springer Science and Business Media LLC","10.1186/s13643-024-02558-5","https://doi.org/10.1186/s13643-024-02558-5","38872216","https://pubmed.ncbi.nlm.nih.gov/38872216/","https://doi.org/10.1186/s13643-024-02558-5","PROSPERO:CRD42021272686"],["3","R0056989","R0056989.pdf","open_download_failed","systematic_review","Jeyakumar Y","2024","Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps.","BMJ global health","BMJ","10.1136/bmjgh-2024-017177","https://doi.org/10.1136/bmjgh-2024-017177","39608857","https://pubmed.ncbi.nlm.nih.gov/39608857/","https://gh.bmj.com/content/9/11/e017177.full.pdf",null],["3","R0002775","R0002775.pdf","open_download_failed","systematic_review","Stretton B","2023","Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.","Internal medicine journal","Wiley","10.1111/imj.16126","https://doi.org/10.1111/imj.16126","37189293","https://pubmed.ncbi.nlm.nih.gov/37189293/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imj.16126",null],["3","R0003451","R0003451.pdf","free_to_read","systematic_review","Visolyi GÁ","2023","Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2023.03.002","https://doi.org/10.1016/j.jcjd.2023.03.002","36963632","https://pubmed.ncbi.nlm.nih.gov/36963632/","https://doi.org/10.1016/j.jcjd.2023.03.002",null],["3","R0004645","R0004645.pdf","open_download_failed","systematic_review","Guo X","2023","Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15043","https://doi.org/10.1111/dom.15043","36864658","https://pubmed.ncbi.nlm.nih.gov/36864658/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15043",null],["3","R0004669","R0004669.pdf","free_to_read","systematic_review","Liu Y","2023","The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.","The American journal of clinical nutrition","Elsevier BV","10.1016/j.ajcnut.2023.04.017","https://doi.org/10.1016/j.ajcnut.2023.04.017","37661106","https://pubmed.ncbi.nlm.nih.gov/37661106/","https://doi.org/10.1016/j.ajcnut.2023.04.017",null],["3","R0004805","R0004805.pdf","free_to_read","systematic_review","Huixing L","2023","Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2022.12.006","https://doi.org/10.1016/j.clinthera.2022.12.006","36604209","https://pubmed.ncbi.nlm.nih.gov/36604209/","https://doi.org/10.1016/j.clinthera.2022.12.006","PROSPERO:CRD42021226231"],["3","R0006165","R0006165.pdf","open_download_failed","systematic_review","Nguyen BN","2023","Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15009","https://doi.org/10.1111/dom.15009","36751968","https://pubmed.ncbi.nlm.nih.gov/36751968/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15009",null],["3","R0006968","R0006968.pdf","open_download_failed","systematic_review","Sohn M","2023","Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15251","https://doi.org/10.1111/dom.15251","37649320","https://pubmed.ncbi.nlm.nih.gov/37649320/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15251",null],["3","R0007152","R0007152.pdf","open_download_failed","systematic_review","Ahmad E","2023","Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15083","https://doi.org/10.1111/dme.15083","36905324","https://pubmed.ncbi.nlm.nih.gov/36905324/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15083",null],["3","R0007453","R0007453.pdf","open_download_failed","systematic_review","Bi Z","2023","Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer's disease: A systematic review and meta-analysis.","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","Wroclaw Medical University","10.17219/acem/161734","https://doi.org/10.17219/acem/161734","37077141","https://pubmed.ncbi.nlm.nih.gov/37077141/","https://advances.umw.edu.pl/ahead-of-print/161734.pdf",null],["3","R0007590","R0007590.pdf","open_download_failed","systematic_review","Mannucci E","2023","Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15226","https://doi.org/10.1111/dom.15226","37529868","https://pubmed.ncbi.nlm.nih.gov/37529868/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15226",null],["3","R0007821","R0007821.pdf","open_download_failed","systematic_review","Rodriguez-Valadez JM","2023","Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.","Diabetes care","American Diabetes Association","10.2337/dc22-0772","https://doi.org/10.2337/dc22-0772","37220263","https://pubmed.ncbi.nlm.nih.gov/37220263/","https://diabetesjournals.org/care/article-pdf/46/6/1300/704600/dc220772.pdf",null],["3","R0007856","R0007856.pdf","free_to_read","systematic_review","Yu D","2023","Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2023.06.008","https://doi.org/10.1016/j.clinthera.2023.06.008","37455226","https://pubmed.ncbi.nlm.nih.gov/37455226/","https://doi.org/10.1016/j.clinthera.2023.06.008",null],["3","R0008104","R0008104.pdf","free_to_read","systematic_review","Neves JS","2023","GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2023.05.048","https://doi.org/10.1016/j.jacc.2023.05.048","37532422","https://pubmed.ncbi.nlm.nih.gov/37532422/","https://doi.org/10.1016/j.jacc.2023.05.048",null],["3","R0008110","R0008110.pdf","open_download_failed","systematic_review","Ferreira JP","2023","Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14997","https://doi.org/10.1111/dom.14997","36722252","https://pubmed.ncbi.nlm.nih.gov/36722252/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14997",null],["3","R0008362","R0008362.pdf","free_to_read","systematic_review","Albert SG","2023","Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102696","https://doi.org/10.1016/j.dsx.2022.102696","36596264","https://pubmed.ncbi.nlm.nih.gov/36596264/","https://doi.org/10.1016/j.dsx.2022.102696",null],["3","R0008389","R0008389.pdf","open_download_failed","systematic_review","Tang H","2023","Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.","Movement disorders clinical practice","Wiley","10.1002/mdc3.13893","https://doi.org/10.1002/mdc3.13893","37982117","https://pubmed.ncbi.nlm.nih.gov/37982117/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10654811/pdf/MDC3-10-1659.pdf",null],["3","R0008827","R0008827.pdf","open_download_failed","systematic_review","Tang H","2023","Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.","Journal of the American Geriatrics Society","Wiley","10.1111/jgs.18306","https://doi.org/10.1111/jgs.18306","36821780","https://pubmed.ncbi.nlm.nih.gov/36821780/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgs.18306",null],["3","R0009062","R0009062.pdf","open_download_failed","systematic_review","Zou CY","2023","Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2022.102053","https://doi.org/10.1016/j.clinre.2022.102053","36403941","https://pubmed.ncbi.nlm.nih.gov/36403941/","https://www.sciencedirect.com/science/article/pii/S2210740122001863/pdf",null],["3","R0010614","R0010614.pdf","open_download_failed","systematic_review","Park J","2023","Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad471","https://doi.org/10.1210/clinem/dgad471","37561012","https://pubmed.ncbi.nlm.nih.gov/37561012/","https://academic.oup.com/jcem/article-pdf/109/1/279/54731659/dgad471.pdf",null],["3","R0011340","R0011340.pdf","open_download_failed","systematic_review","Stumpf MAM","2023","Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad280","https://doi.org/10.1093/eurjpc/zwad280","37648659","https://pubmed.ncbi.nlm.nih.gov/37648659/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwad280/51369828/zwad280.pdf",null],["3","R0011696","R0011696.pdf","free_to_read","systematic_review","Nauck MA","2023","Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14988","https://doi.org/10.1111/dom.14988","36700380","https://pubmed.ncbi.nlm.nih.gov/36700380/","https://doi.org/10.1111/dom.14988",null],["3","R0012796","R0012796.pdf","open_download_failed","systematic_review","Akoumianakis I","2023","GLP-1 analogs and regional adiposity: A systematic review and meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13574","https://doi.org/10.1111/obr.13574","37191219","https://pubmed.ncbi.nlm.nih.gov/37191219/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13574",null],["3","R0013191","R0013191.pdf","open_download_failed","systematic_review","Brønden A","2023","Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15157","https://doi.org/10.1111/dme.15157","37249579","https://pubmed.ncbi.nlm.nih.gov/37249579/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15157",null],["3","R0015336","R0015336.pdf","free_to_read","systematic_review","Gu Y","2023","Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.","Expert review of gastroenterology & hepatology","Informa UK Limited","10.1080/17474124.2023.2172397","https://doi.org/10.1080/17474124.2023.2172397","36689199","https://pubmed.ncbi.nlm.nih.gov/36689199/","https://figshare.com/articles/journal_contribution/Comparative_efficacy_of_glucagon-like_peptide_1_GLP-1_receptor_agonists_pioglitazone_and_vitamin_E_for_liver_histology_among_patients_with_nonalcoholic_fatty_liver_disease_systematic_review_and_pilot_network_meta-analysis_of_randomized_cont/22015822",null],["3","R0016436","R0016436.pdf","free_to_read","systematic_review","Neves JS","2023","Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2023.03.017","https://doi.org/10.1016/j.cardfail.2023.03.017","37028749","https://pubmed.ncbi.nlm.nih.gov/37028749/","https://doi.org/10.1016/j.cardfail.2023.03.017",null],["3","R0020877","R0020877.pdf","open_download_failed","systematic_review","BouSaba J","2023","Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.","Pharmacogenomics","Informa UK Limited","10.2217/pgs-2022-0192","https://doi.org/10.2217/pgs-2022-0192","36999540","https://pubmed.ncbi.nlm.nih.gov/36999540/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10152409/pdf/pgs-24-283.pdf",null],["3","R0021062","R0021062.pdf","open_download_failed","systematic_review","Zhan K","2023","Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280221133577","https://doi.org/10.1177/10600280221133577","36314281","https://pubmed.ncbi.nlm.nih.gov/36314281/","https://www.ncbi.nlm.nih.gov/pmc/articles/9618918",null],["3","R0021633","R0021633.pdf","open_download_failed","systematic_review","Finkelstein EA","2023","A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23760","https://doi.org/10.1002/oby.23760","37231621","https://pubmed.ncbi.nlm.nih.gov/37231621/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23760",null],["3","R0021707","R0021707.pdf","open_download_failed","systematic_review","Jobanputra R","2023","The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13553","https://doi.org/10.1111/obr.13553","36721366","https://pubmed.ncbi.nlm.nih.gov/36721366/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13553",null],["3","R0022419","R0022419.pdf","open_download_failed","systematic_review","Iannone A","2023","Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15138","https://doi.org/10.1111/dom.15138","37254688","https://pubmed.ncbi.nlm.nih.gov/37254688/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15138",null],["3","R0023732","R0023732.pdf","open_download_failed","systematic_review","Lee SWH","2023","Interventions for people with type 2 diabetes mellitus fasting during Ramadan.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd013178.pub2","https://doi.org/10.1002/14651858.cd013178.pub2","37435938","https://pubmed.ncbi.nlm.nih.gov/37435938/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10355254/pdf/CD013178.pdf","ClinicalTrials.gov:NCT01131182; ClinicalTrials.gov:NCT01340768; ClinicalTrials.gov:NCT01917656; ClinicalTrials.gov:NCT01758380; ClinicalTrials.gov:NCT02648217; ClinicalTrials.gov:NCT02941367; ClinicalTrials.gov:NCT02189135; ClinicalTrials.gov:NCT03314246; ClinicalTrials.gov:NCT02694263"],["3","R0025843","R0025843.pdf","no_doi","systematic_review","Veerman SRT","2023","[Prevention and treatment of antipsychotic induced weight gain].","Tijdschrift voor psychiatrie",null,null,"https://doi.org/","37323046","https://pubmed.ncbi.nlm.nih.gov/37323046/",null,null],["3","R0028873","R0028873.pdf","open_download_failed","systematic_review","Bril F","2023","Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad356","https://doi.org/10.1210/clinem/dgad356","37329216","https://pubmed.ncbi.nlm.nih.gov/37329216/","https://academic.oup.com/jcem/article-pdf/109/1/10/54731358/dgad356.pdf",null],["3","R0028884","R0028884.pdf","open_download_failed","systematic_review","Wilson RB","2023","Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.","International journal of molecular sciences","MDPI AG","10.3390/ijms24076192","https://doi.org/10.3390/ijms24076192","37047163","https://pubmed.ncbi.nlm.nih.gov/37047163/","https://www.mdpi.com/1422-0067/24/7/6192/pdf?version=1679901790",null],["3","R0028890","R0028890.pdf","open_download_failed","systematic_review","Mahmoud F","2023","Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.","European journal of clinical investigation","Wiley","10.1111/eci.13997","https://doi.org/10.1111/eci.13997","37002856","https://pubmed.ncbi.nlm.nih.gov/37002856/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/eci.13997",null],["3","R0030220","R0030220.pdf","open_download_failed","systematic_review","Service CA","2023","The impact of obesity and metabolic health on male fertility: a systematic review.","Fertility and sterility","Elsevier BV","10.1016/j.fertnstert.2023.10.017","https://doi.org/10.1016/j.fertnstert.2023.10.017","37839720","https://pubmed.ncbi.nlm.nih.gov/37839720/","http://www.fertstert.org/article/S0015028223019350/pdf",null],["3","R0034524","R0034524.pdf","no_doi","systematic_review","Abdelaziz Awad","2023","Orforglipron different doses effect on body weight : A systematic review and network meta-analysis of randomized clinical trials","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037506","R0037506.pdf","no_doi","systematic_review","Visolyi, Gergely Á","2023","Comparison of the efficacy and safety of commercially available fixed ratio combinations of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) - a network meta-analysis","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038325","R0038325.pdf","free_to_read","systematic_review","Yong Yang","2023","Dose-Response Relationship of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4618777","https://doi.org/10.2139/ssrn.4618777",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4618777",null],["3","R0039233","R0039233.pdf","free_to_read","systematic_review","Xihong Li","2023","Exenatide for obesity in children and adolescents: Systematic Review and Meta-analysis (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.48486","https://doi.org/10.2196/preprints.48486",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2196/preprints.48486","PROSPERO:CRD42023413706"],["3","R0039541","R0039541.pdf","free_to_read","systematic_review","Xinyu Zhang","2023","Effect of Glucagon-like Peptide-1 Receptor Agonist on Cardiac Structure and Function in Patients with Heart Failure: A Systematic Review and Meta-analysis","International Journal of Drug Discovery and Pharmacology","Scilight Press Pty Ltd","10.53941/ijddp.2023.100010","https://doi.org/10.53941/ijddp.2023.100010",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53941/ijddp.2023.100010",null],["3","R0039828","R0039828.pdf","free_to_read","systematic_review","Qingxing Xie","2023","Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000002778","https://doi.org/10.1097/cm9.0000000000002778","37464470","https://pubmed.ncbi.nlm.nih.gov/37464470/","https://doi.org/10.1097/cm9.0000000000002778",null],["3","R0041032","R0041032.pdf","no_doi","systematic_review","Petrova, L.","2023","Efficacy and safety of GLP-1 receptor agonists in patients with diabetes mellitus - systematic review",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041606","R0041606.pdf","open_download_failed","systematic_review","Samit Ghosal","2023","#3484 A NETWORK META-ANALYSIS COMPARING INTENSIVE GLYCEMIC CONTROL AND SGLT-2 INHIBITORS IN PREVENTING RENAL OUTCOMES","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfad063c_3484","https://doi.org/10.1093/ndt/gfad063c_3484",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/38/Supplement_1/gfad063c_3484/50673111/gfad063c_3484.pdf",null],["3","R0042483","R0042483.pdf","free_to_read","systematic_review","Caroliny Hellen Silva","2023","FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.077","https://doi.org/10.1210/jendso/bvad114.077",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.077",null],["3","R0042524","R0042524.pdf","open_download_failed","systematic_review","Mobina Oladghaffari","2023","Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","International Journal of Drug Research in Clinics","Maad Rayan Publishing Company","10.34172/ijdrc.2023.e19","https://doi.org/10.34172/ijdrc.2023.e19",null,"https://pubmed.ncbi.nlm.nih.gov//","http://ijdrug.com/PDF/ijdrc-1-e19.pdf",null],["3","R0042900","R0042900.pdf","open_download_failed","systematic_review","Elvira Meni Maria Gkrinia","2023","A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes","Diabetology","MDPI AG","10.3390/diabetology4040038","https://doi.org/10.3390/diabetology4040038",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.mdpi.com/2673-4540/4/4/38/pdf?version=1697182972",null],["3","R0043000","R0043000.pdf","open_download_failed","systematic_review","D Gomes","2023","Association between intensity of glycemic control with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: a systematic review and meta-regression","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2542","https://doi.org/10.1093/eurheartj/ehad655.2542",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2542/53608951/ehad655.2542.pdf",null],["3","R0043046","R0043046.pdf","open_download_failed","systematic_review","Bander J. Alshehri","2023","Glucagon-like Peptide 1 Receptor Agonists for the Treatment of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Journal of Pharmaceutical Research International","Sciencedomain International","10.9734/jpri/2023/v35i127361","https://doi.org/10.9734/jpri/2023/v35i127361",null,"https://pubmed.ncbi.nlm.nih.gov//","https://journaljpri.com/index.php/JPRI/article/download/7361/14701",null],["3","R0043850","R0043850.pdf","no_doi","systematic_review","M Nunns (21855728)","2023","What is the quantity, quality and scope of recent network meta-analyses evaluating the effectiveness of Glucagon-like peptide-1 receptor agonists for weight loss in obese adults? Protocol for a scoping review of network meta-analyses","Open Research Exeter (University of Exeter)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044121","R0044121.pdf","open_download_failed","systematic_review","Giulia Biagi Furlan","2023","Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn23105","https://doi.org/10.54448/ijn23105",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/262/249",null],["3","R0044687","R0044687.pdf","free_to_read","systematic_review","Xia Yu","2023","Risk factors for stroke recurrence in young patients with first-ever ischemic stroke: A meta-analysis","World Journal of Clinical Cases","Baishideng Publishing Group Inc.","10.12998/wjcc.v11.i26.6122","https://doi.org/10.12998/wjcc.v11.i26.6122","37731567","https://pubmed.ncbi.nlm.nih.gov/37731567/","https://doi.org/10.12998/wjcc.v11.i26.6122",null],["3","R0046927","R0046927.pdf","open_download_failed","systematic_review","Faisal Inayat","2023","Drug-induced liver injury associated with liraglutide use: a systematic review of detection, severity, causality assessment, and clinical outcomes","Journal of Clinical and Translational Research","AccScience Publishing","10.18053/jctres.09.202303.004","https://doi.org/10.18053/jctres.09.202303.004",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.jctres.com/media/downloads/jctres09202303004/jclintranslres-2023-9-3-168.pdf",null],["3","R0048321","R0048321.pdf","free_to_read","systematic_review","Xin‐Hui Pan","2023","EFFICACY AND SAFETY OF TIRZEPATIDE IN IMPROVING CARDIOMETABOLIC OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(23)02218-0","https://doi.org/10.1016/s0735-1097(23)02218-0",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1016/s0735-1097(23)02218-0",null],["3","R0050138","R0050138.pdf","free_to_read","systematic_review","Maarten Bak","2023","GLP-1 agonists for weight management in antipsychotic-induced weight gain: systematic review and meta-analysis","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2023.103085","https://doi.org/10.1016/j.nsa.2023.103085",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2023.103085",null],["3","R0050508","R0050508.pdf","free_to_read","systematic_review","Nishant Babubhai Prajapati","2023","Efficacy of anti-obesity agents: a systematic review and network meta-analysis of randomized controlled trials","PERSPECTIVES IN MEDICAL RESEARCH","Prathima Institute of Medical Sciences","10.47799/pimr.1103.03","https://doi.org/10.47799/pimr.1103.03",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47799/pimr.1103.03","PROSPERO:CRD42023465989"],["3","R0053123","R0053123.pdf","free_to_read","systematic_review","Muhammad Aaqib Shamim","2023","TRIM: Teen Obesity and GLP-1 Receptor Agonists - Insights from a Systematic Review, Meta-Analysis, and Drug-Wise Network Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4654257","https://doi.org/10.2139/ssrn.4654257",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4654257",null],["3","R0053963","R0053963.pdf","open_download_failed","systematic_review","Fabrício Bastos Fernandes","2023","Major evidence of the GLP-1 analog (liraglutide) in the treatment of obesity: a systematic review","International Journal of Nutrology","Zotarelli-Filho Scientific Works","10.54448/ijn23211","https://doi.org/10.54448/ijn23211",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/download/285/273",null],["3","R0054997","R0054997.pdf","free_to_read","systematic_review","Irene Caruso","2023","Glucometabolic Outcomes of GLP-1RA-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4442851","https://doi.org/10.2139/ssrn.4442851",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4442851",null],["3","R0005011","R0005011.pdf","open_download_failed","systematic_review","Guo X","2022","The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-1844-1176","https://doi.org/10.1055/a-1844-1176","35512849","https://pubmed.ncbi.nlm.nih.gov/35512849/","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1844-1176.pdf","PROSPERO:CRD42020173199"],["3","R0005549","R0005549.pdf","open_download_failed","systematic_review","He L","2022","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2022.0338","https://doi.org/10.1001/jamainternmed.2022.0338","35344001","https://pubmed.ncbi.nlm.nih.gov/35344001/","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2790392/jamainternal_he_2022_oi_220009_1650900276.01193.pdf","PROSPERO:CRD42021271599"],["3","R0005859","R0005859.pdf","free_to_read","systematic_review","Leite AR","2022","Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14707","https://doi.org/10.1111/dom.14707","35373878","https://pubmed.ncbi.nlm.nih.gov/35373878/",null,"ClinicalTrials.gov:NCT03574597"],["3","R0006037","R0006037.pdf","open_download_failed","systematic_review","Najafi S","2022","The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.","British journal of clinical pharmacology","Wiley","10.1111/bcp.15344","https://doi.org/10.1111/bcp.15344","35384008","https://pubmed.ncbi.nlm.nih.gov/35384008/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15344",null],["3","R0006177","R0006177.pdf","free_to_read","systematic_review","Yoshida Y","2022","Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108255","https://doi.org/10.1016/j.jdiacomp.2022.108255","35817678","https://pubmed.ncbi.nlm.nih.gov/35817678/","https://doi.org/10.1016/j.jdiacomp.2022.108255",null],["3","R0006625","R0006625.pdf","free_to_read","systematic_review","Ali MU","2022","The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2022.05.011","https://doi.org/10.1016/j.cjca.2022.05.011","35961756","https://pubmed.ncbi.nlm.nih.gov/35961756/",null,null],["3","R0006899","R0006899.pdf","open_download_failed","systematic_review","Wright AK","2022","Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc21-1113","https://doi.org/10.2337/dc21-1113","35100355","https://pubmed.ncbi.nlm.nih.gov/35100355/","https://diabetesjournals.org/care/article-pdf/45/4/909/672215/dc211113.pdf",null],["3","R0006924","R0006924.pdf","open_download_failed","systematic_review","Borodavkin P","2022","Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14565","https://doi.org/10.1111/dom.14565","34605124","https://pubmed.ncbi.nlm.nih.gov/34605124/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14565",null],["3","R0006996","R0006996.pdf","open_download_failed","systematic_review","Yoshiji S","2022","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14666","https://doi.org/10.1111/dom.14666","35137511","https://pubmed.ncbi.nlm.nih.gov/35137511/","https://www.medrxiv.org/content/medrxiv/early/2022/02/21/2021.10.14.21264803.full.pdf",null],["3","R0007087","R0007087.pdf","free_to_read","systematic_review","Avogaro A","2022","The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2022.03.032","https://doi.org/10.1016/j.ijcard.2022.03.032","35306033","https://pubmed.ncbi.nlm.nih.gov/35306033/","https://www.sciencedirect.com/science/article/pii/S0167527322003916",null],["3","R0007099","R0007099.pdf","free_to_read","systematic_review","Mantovani A","2022","Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(21)00261-2","https://doi.org/10.1016/s2468-1253(21)00261-2","35030323","https://pubmed.ncbi.nlm.nih.gov/35030323/",null,null],["3","R0007594","R0007594.pdf","open_download_failed","systematic_review","Alexander JT","2022","The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.","Journal of general internal medicine","Springer Science and Business Media LLC","10.1007/s11606-021-07105-9","https://doi.org/10.1007/s11606-021-07105-9","34508290","https://pubmed.ncbi.nlm.nih.gov/34508290/","https://www.ncbi.nlm.nih.gov/pmc/articles/8810987","PROSPERO:CRD42018090506"],["3","R0007709","R0007709.pdf","free_to_read","systematic_review","Tang H","2022","Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.","Diabetes care","American Diabetes Association","10.2337/dc21-1722","https://doi.org/10.2337/dc21-1722","35349656","https://pubmed.ncbi.nlm.nih.gov/35349656/",null,null],["3","R0007899","R0007899.pdf","free_to_read","systematic_review","Kawai Y","2022","Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109146","https://doi.org/10.1016/j.diabres.2021.109146","34780865","https://pubmed.ncbi.nlm.nih.gov/34780865/","https://doi.org/10.1016/j.diabres.2021.109146",null],["3","R0008035","R0008035.pdf","free_to_read","systematic_review","Lee MMY","2022","Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2021.102382","https://doi.org/10.1016/j.dsx.2021.102382","35030451","https://pubmed.ncbi.nlm.nih.gov/35030451/","https://eprints.gla.ac.uk/264196/",null],["3","R0008469","R0008469.pdf","open_download_failed","systematic_review","Ma H","2022","Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","medRxiv","openRxiv","10.1101/2022.02.06.22270446","https://doi.org/10.1101/2022.02.06.22270446",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/02/10/2022.02.06.22270446.full.pdf",null],["3","R0008792","R0008792.pdf","free_to_read","systematic_review","Soto-Chávez MJ","2022","Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: Systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.110019","https://doi.org/10.1016/j.diabres.2022.110019","35931222","https://pubmed.ncbi.nlm.nih.gov/35931222/","https://doi.org/10.1016/j.diabres.2022.110019",null],["3","R0011867","R0011867.pdf","open_download_failed","systematic_review","Binet Q","2022","Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?","Acta gastro-enterologica Belgica","Universa BV","10.51821/85.2.9775","https://doi.org/10.51821/85.2.9775","35709779","https://pubmed.ncbi.nlm.nih.gov/35709779/","https://www.ageb.be/Articles/Volume 85 (2022)/Fasc2/13-Binet.pdf",null],["3","R0012292","R0012292.pdf","free_to_read","systematic_review","Galaviz KI","2022","Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.","American journal of preventive medicine","Elsevier BV","10.1016/j.amepre.2021.10.020","https://doi.org/10.1016/j.amepre.2021.10.020","35151523","https://pubmed.ncbi.nlm.nih.gov/35151523/","https://doi.org/10.1016/j.amepre.2021.10.020",null],["3","R0019032","R0019032.pdf","free_to_read","systematic_review","Kacimi SEO","2022","Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis","medRxiv","openRxiv","10.1101/2022.05.28.22275730","https://doi.org/10.1101/2022.05.28.22275730",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2022.05.28.22275730",null],["3","R0019521","R0019521.pdf","open_download_failed","systematic_review","Lee K","2022","A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.","General hospital psychiatry","Elsevier BV","10.1016/j.genhosppsych.2022.07.006","https://doi.org/10.1016/j.genhosppsych.2022.07.006","35863294","https://pubmed.ncbi.nlm.nih.gov/35863294/","https://www.sciencedirect.com/science/article/pii/S0163834322000895/pdf",null],["3","R0021470","R0021470.pdf","open_download_failed","systematic_review","Liao XX","2022","Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13588","https://doi.org/10.1111/jcpt.13588","34939679","https://pubmed.ncbi.nlm.nih.gov/34939679/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcpt.13588",null],["3","R0021729","R0021729.pdf","open_download_failed","systematic_review","Chalmoukou K","2022","Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2021.12.018","https://doi.org/10.1016/j.ejim.2021.12.018","34953655","https://pubmed.ncbi.nlm.nih.gov/34953655/","http://www.ejinme.com/article/S0953620521004283/pdf",null],["3","R0024967","R0024967.pdf","free_to_read","systematic_review","Byrne J","2022","Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta-ethnography.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14678","https://doi.org/10.1111/dme.14678","34432914","https://pubmed.ncbi.nlm.nih.gov/34432914/","https://figshare.com/articles/journal_contribution/Individual_healthcare_professional_and_system-level_barriers_and_facilitators_to_initiation_and_adherence_to_injectable_therapies_for_type_2_diabetes_A_systematic_review_and_meta-ethnography_/16595606",null],["3","R0025066","R0025066.pdf","free_to_read","systematic_review","Abdalla MA","2022","Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.","Clinical endocrinology","Wiley","10.1111/cen.14623","https://doi.org/10.1111/cen.14623","34713480","https://pubmed.ncbi.nlm.nih.gov/34713480/","https://doi.org/10.1111/cen.14623",null],["3","R0028989","R0028989.pdf","free_to_read","systematic_review","Evans M","2022","Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14603","https://doi.org/10.1111/dom.14603","34779107","https://pubmed.ncbi.nlm.nih.gov/34779107/","https://doi.org/10.1111/dom.14603",null],["3","R0030331","R0030331.pdf","open_download_failed","systematic_review","Seisa MO","2022","A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgac277","https://doi.org/10.1210/clinem/dgac277","35690929","https://pubmed.ncbi.nlm.nih.gov/35690929/","https://academic.oup.com/jcem/article-pdf/107/8/2139/44886347/dgac277.pdf",null],["3","R0032495","R0032495.pdf","no_doi","systematic_review","Sho Kinguchi","2022","Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034297","R0034297.pdf","free_to_read","systematic_review","Rui Zhang","2022","Efficacy and Safety of Subcutaneous Semaglutide in Overweight or Obese Adults: A Subgroup Meta-Analysis of Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4249801","https://doi.org/10.2139/ssrn.4249801",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4249801",null],["3","R0034477","R0034477.pdf","free_to_read","systematic_review","Jing-yi Kang","2022","The Effects of Glucagon-Like Peptide-1 Receptor Agonists of Liraglutide on Bone Turnover Makers Among Type 2 Diabetes Mellitus Patients: A Meta-Analysis of Randomized Controlled Trials","Archives of Clinical and Biomedical Research","Fortune Journals","10.26502/acbr.50170231","https://doi.org/10.26502/acbr.50170231",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/acbr.50170231",null],["3","R0034565","R0034565.pdf","no_doi","systematic_review","Angie Santafe Garcia","2022","Effectiveness and safety of GLP-1 receptor analogues vs. rapid-acting insulin added to basal insulin therapy in patients with type 2 diabetes mellitus: a living systematic review","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037069","R0037069.pdf","free_to_read","systematic_review","Minjeong Park","2022","Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Thiazolidinediones for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Network Meta-Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4049630","https://doi.org/10.2139/ssrn.4049630",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4049630",null],["3","R0037629","R0037629.pdf","free_to_read","systematic_review","Fudan Zhang","2022","Efficacy and Safety of Weekly Glucagon-Like Receptor Agonist (GLP-1RA) Versus Daily Glucagon-Like Receptor Agonist (GLP-1RA) for Type 2 Diabetes: A Meta-Analysis of Data from Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4007186","https://doi.org/10.2139/ssrn.4007186",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4007186",null],["3","R0041655","R0041655.pdf","open_download_failed","systematic_review","O Kuss","2022","Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.2685","https://doi.org/10.1093/eurheartj/ehac544.2685",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/43/Supplement_2/ehac544.2685/46363649/ehac544.2685.pdf",null],["3","R0042287","R0042287.pdf","no_doi","systematic_review","Alhassane Diallo","2022","Blood pressure lowering in type 2 diabetes for preventing of cardiovascular events and death: a meta-analysis of SGLT2 inhibitors and GLP-1 receptor agonists trials","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043334","R0043334.pdf","free_to_read","systematic_review","A Naveen","2022","A Systematic Review On Novel Twincretin; Tirzepatide in Treatment of Type-II Diabetes Mellitus.","International Journal of Pharma and Bio Sciences","Lapin Press Publications (LPP)","10.22376/ijpbs.2022.13.4.p7-15","https://doi.org/10.22376/ijpbs.2022.13.4.p7-15",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.22376/ijpbs.2022.13.4.p7-15",null],["3","R0043714","R0043714.pdf","open_download_failed","systematic_review","Nam Nhat Nguyen","2022","ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.718","https://doi.org/10.1210/jendso/bvac150.718",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A345/46734280/bvac150.718.pdf",null],["3","R0043988","R0043988.pdf","open_download_failed","systematic_review","Zheng Zhu","2022","ODP240 Routine Glucose-lowering Therapies and Risk of Adverse Outcomes in COVID-19 Patients with Diabetes: a Network Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.689","https://doi.org/10.1210/jendso/bvac150.689",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A332/46734026/bvac150.689.pdf",null],["3","R0044697","R0044697.pdf","free_to_read","systematic_review","Mohammed Al‐Sadawi","2022","THE EFFECT OF ONCE-WEEKLY OF HIGH DOSE SEMAGLUTIDE ON BODY WEIGHT AND PHYSICAL ACTIVITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(22)02537-2","https://doi.org/10.1016/s0735-1097(22)02537-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(22)02537-2",null],["3","R0044734","R0044734.pdf","free_to_read","systematic_review","Debra Winberg","2022","EE227 Systematic Review on Cost-Effectiveness of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists","Value in Health","Elsevier BV","10.1016/j.jval.2022.04.475","https://doi.org/10.1016/j.jval.2022.04.475",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2022.04.475",null],["3","R0046057","R0046057.pdf","free_to_read","systematic_review","Kia Vosoughi","2022","Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(22)61976-0","https://doi.org/10.1016/s0016-5085(22)61976-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ncbi.nlm.nih.gov/pmc/articles/9212452",null],["3","R0049364","R0049364.pdf","open_download_failed","systematic_review","Jeayoung Park","2022","PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvac150.782","https://doi.org/10.1210/jendso/bvac150.782",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/6/Supplement_1/A376/47383660/bvac150.782.pdf",null],["3","R0050435","R0050435.pdf","free_to_read","systematic_review","Huilin Tang","2022","Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials",null,"American Diabetes Association","10.2337/figshare.18057245","https://doi.org/10.2337/figshare.18057245",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.18057245",null],["3","R0050956","R0050956.pdf","free_to_read","systematic_review","Mohammed Al‐Sadawi","2022","THE EFFECT OF GLP-1 AGONISTS IN PATIENTS WITH TYPE 2 DIABETES ON ALL-CAUSE MORTALITY AND CARDIOVASCULAR MORTALITY: AN UPDATED META-ANALYSIS OF 44 RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(22)02533-5","https://doi.org/10.1016/s0735-1097(22)02533-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(22)02533-5",null],["3","R0051792","R0051792.pdf","free_to_read","systematic_review","Mohammed Al‐Sadawi","2022","ASSOCIATION OF GLP-1 AGONISTS WITH ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF 27 RANDOMIZED CONTROLLED TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(22)02516-5","https://doi.org/10.1016/s0735-1097(22)02516-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(22)02516-5",null],["3","R0052594","R0052594.pdf","open_download_failed","systematic_review","Feras A. Mahmoud","2022","Obesity association with antidiabetic drugs’ prescription among patients with type 2 diabetes mellitus: a systematic review and meta-analysis","International Journal of Pharmacy Practice","Oxford University Press (OUP)","10.1093/ijpp/riac021.016","https://doi.org/10.1093/ijpp/riac021.016",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ijpp/article-pdf/30/Supplement_1/i11/43226668/riac021.016.pdf",null],["3","R0053247","R0053247.pdf","free_to_read","systematic_review","Susan P. Mollan","2022","Letter: Cerebrospinal Fluid Shunting for Idiopathic Intracranial Hypertension: A Systematic Review, Meta-Analysis, and Implications for a Modern Management Protocol","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000002316","https://doi.org/10.1227/neu.0000000000002316","36700758","https://pubmed.ncbi.nlm.nih.gov/36700758/","https://research.birmingham.ac.uk/en/publications/acad5693-5284-4b5b-a10c-c7c02e8154b1",null],["3","R0055219","R0055219.pdf","free_to_read","systematic_review","Kia Vosoughi","2022","Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2022.100456","https://doi.org/10.1016/j.obmed.2022.100456",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obmed.2022.100456",null],["3","R0005783","R0005783.pdf","open_download_failed","systematic_review","Widiarti W","2021","Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2021.04.005","https://doi.org/10.1016/j.dsx.2021.04.005","33866119","https://pubmed.ncbi.nlm.nih.gov/33866119/","https://www.sciencedirect.com/science/article/pii/S187140212100117X",null],["3","R0006573","R0006573.pdf","free_to_read","systematic_review","Qian W","2021","Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13502","https://doi.org/10.1111/jcpt.13502","34355405","https://pubmed.ncbi.nlm.nih.gov/34355405/",null,null],["3","R0007059","R0007059.pdf","open_download_failed","systematic_review","Yoshiji S","2021","Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis","medRxiv","openRxiv","10.1101/2021.10.14.21264803","https://doi.org/10.1101/2021.10.14.21264803",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/02/21/2021.10.14.21264803.full.pdf",null],["3","R0007361","R0007361.pdf","open_download_failed","systematic_review","Fitch A","2021","Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1845534","https://doi.org/10.1080/00325481.2020.1845534","33151791","https://pubmed.ncbi.nlm.nih.gov/33151791/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2020.1845534?needAccess=true",null],["3","R0007721","R0007721.pdf","open_download_failed","systematic_review","Bray JJH","2021","Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14399","https://doi.org/10.1111/dom.14399","33830637","https://pubmed.ncbi.nlm.nih.gov/33830637/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14399",null],["3","R0009434","R0009434.pdf","open_download_failed","systematic_review","Ryan PM","2021","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis.","The Journal of pediatrics","Elsevier BV","10.1016/j.jpeds.2021.05.009","https://doi.org/10.1016/j.jpeds.2021.05.009","33984333","https://pubmed.ncbi.nlm.nih.gov/33984333/","https://www.jpeds.com/article/S0022-3476(21)00432-7/pdf","PROSPERO:CRD42020195869"],["3","R0010123","R0010123.pdf","free_to_read","systematic_review","Lee MMY","2021","Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc20-3007","https://doi.org/10.2337/dc20-3007","33707305","https://pubmed.ncbi.nlm.nih.gov/33707305/","https://eprints.gla.ac.uk/view/author/36910.html>",null],["3","R0011646","R0011646.pdf","open_download_failed","systematic_review","Kanie T","2021","Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd013650.pub2","https://doi.org/10.1002/14651858.cd013650.pub2","34693515","https://pubmed.ncbi.nlm.nih.gov/34693515/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013650.pub2/pdf/full","ClinicalTrials.gov:NCT03619213; ClinicalTrials.gov:NCT03087773; ClinicalTrials.gov:NCT03485222; ClinicalTrials.gov:NCT03057951; ClinicalTrials.gov:NCT04146155; ClinicalTrials.gov:NCT02917031; ClinicalTrials.gov:NCT02397421; ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03485092"],["3","R0012832","R0012832.pdf","open_download_failed","systematic_review","Cowart K","2021","Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.","Journal of clinical pharmacy and therapeutics","Hindawi Limited","10.1111/jcpt.13270","https://doi.org/10.1111/jcpt.13270","33067896","https://pubmed.ncbi.nlm.nih.gov/33067896/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcpt.13270",null],["3","R0012966","R0012966.pdf","open_download_failed","systematic_review","Cintra RM","2021","Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgab428","https://doi.org/10.1210/clinem/dgab428","34125217","https://pubmed.ncbi.nlm.nih.gov/34125217/","https://academic.oup.com/jcem/article-pdf/106/10/3060/41098115/dgab428.pdf",null],["3","R0014322","R0014322.pdf","open_download_failed","systematic_review","Lazzaroni E","2021","Anti-diabetic drugs and weight loss in patients with type 2 diabetes.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2021.105782","https://doi.org/10.1016/j.phrs.2021.105782","34302978","https://pubmed.ncbi.nlm.nih.gov/34302978/","https://ars.els-cdn.com/content/image/1-s2.0-S1043661821003662-ga1_lrg.jpg",null],["3","R0015666","R0015666.pdf","free_to_read","systematic_review","Chadda KR","2021","GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13177","https://doi.org/10.1111/obr.13177","33354917","https://pubmed.ncbi.nlm.nih.gov/33354917/",null,null],["3","R0018334","R0018334.pdf","open_download_failed","systematic_review","Kamdar A","2021","Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis.","Reviews in cardiovascular medicine","IMR Press","10.31083/j.rcm2204152","https://doi.org/10.31083/j.rcm2204152","34957787","https://pubmed.ncbi.nlm.nih.gov/34957787/","https://rcm.imrpress.com/EN/article/downloadArticleFile.do?attachType=PDF&id=10300","PROSPERO:CRD42021268563"],["3","R0018411","R0018411.pdf","free_to_read","systematic_review","Cotter G","2021","Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.","American heart journal","Elsevier BV","10.1016/j.ahj.2021.06.001","https://doi.org/10.1016/j.ahj.2021.06.001","34107289","https://pubmed.ncbi.nlm.nih.gov/34107289/","https://doi.org/10.1016/j.ahj.2021.06.001",null],["3","R0018559","R0018559.pdf","open_download_failed","systematic_review","Li S","2021","SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.n1091","https://doi.org/10.1136/bmj.n1091","33975892","https://pubmed.ncbi.nlm.nih.gov/33975892/","https://www.bmj.com/content/bmj/373/bmj.n1091.full.pdf",null],["3","R0019466","R0019466.pdf","open_download_failed","systematic_review","Kadowaki T","2021","Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2021.1898585","https://doi.org/10.1080/14740338.2021.1898585","33706621","https://pubmed.ncbi.nlm.nih.gov/33706621/","https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1898585?needAccess=true",null],["3","R0020160","R0020160.pdf","open_download_failed","systematic_review","Cha AS","2021","Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa894","https://doi.org/10.1210/clinem/dgaa894","33248440","https://pubmed.ncbi.nlm.nih.gov/33248440/","https://academic.oup.com/jcem/article-pdf/106/4/1225/36736062/dgaa894.pdf",null],["3","R0021360","R0021360.pdf","open_download_failed","systematic_review","Majzoub AM","2021","Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.16583","https://doi.org/10.1111/apt.16583","34435378","https://pubmed.ncbi.nlm.nih.gov/34435378/","https://www.ncbi.nlm.nih.gov/pmc/articles/8711247",null],["3","R0025290","R0025290.pdf","open_download_failed","systematic_review","Gad H","2021","Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108562","https://doi.org/10.1016/j.diabres.2020.108562","33271228","https://pubmed.ncbi.nlm.nih.gov/33271228/","http://www.diabetesresearchclinicalpractice.com/article/S0168822720308196/pdf",null],["3","R0026978","R0026978.pdf","open_download_failed","systematic_review","Maski K","2021","Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","Springer Science and Business Media LLC","10.5664/jcsm.9326","https://doi.org/10.5664/jcsm.9326","34743790","https://pubmed.ncbi.nlm.nih.gov/34743790/","https://jcsm.aasm.org/doi/pdf/10.5664/jcsm.9326",null],["3","R0027438","R0027438.pdf","open_download_failed","systematic_review","Panunzi S","2021","Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14304","https://doi.org/10.1111/dom.14304","33368954","https://pubmed.ncbi.nlm.nih.gov/33368954/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14304",null],["3","R0027866","R0027866.pdf","open_download_failed","systematic_review","Taghavi SA","2021","Pharmacological and non-pharmacological strategies for obese women with subfertility.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012650.pub2","https://doi.org/10.1002/14651858.cd012650.pub2","33765343","https://pubmed.ncbi.nlm.nih.gov/33765343/","https://www.ncbi.nlm.nih.gov/pmc/articles/8094444",null],["3","R0028050","R0028050.pdf","free_to_read","systematic_review","Siebenhofer A","2021","Long-term effects of weight-reducing drugs in people with hypertension.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd007654.pub5","https://doi.org/10.1002/14651858.cd007654.pub5","33454957","https://pubmed.ncbi.nlm.nih.gov/33454957/",null,null],["3","R0028976","R0028976.pdf","free_to_read","systematic_review","Zhao LM","2021","Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.","Frontiers in endocrinology","Frontiers Media SA","10.3389/fendo.2021.825100","https://doi.org/10.3389/fendo.2021.825100","35082762","https://pubmed.ncbi.nlm.nih.gov/35082762/","https://doi.org/10.3389/fendo.2021.825100",null],["3","R0030301","R0030301.pdf","open_download_failed","systematic_review","O'Keefe EL","2021","Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2021.08.042","https://doi.org/10.1016/j.amjcard.2021.08.042","34583808","https://pubmed.ncbi.nlm.nih.gov/34583808/","http://www.ajconline.org/article/S0002914921008274/pdf",null],["3","R0034559","R0034559.pdf","no_doi","systematic_review","Rados, Dimitris Rucks Varvaki","2021","All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus : asystematic review with meta-analysis and trial sequential analysis","Lume (Universidade Federal do Rio Grande do Sul)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42018087336"],["3","R0036153","R0036153.pdf","no_doi","systematic_review","Hatch, Kelly","2021","Incretin-Based Medications for Type 2 Diabetes: An Overview of Reviews","Scholarship@Western (Western University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42013005149"],["3","R0042803","R0042803.pdf","open_download_failed","systematic_review","Kulvinder Kochar Kaur","2021","The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity & Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic & Therapeutic Purposes-A Systematic Review","Journal of Endocrinology Research","Bilingual Publishing Co.","10.30564/jer.v3i2.3520","https://doi.org/10.30564/jer.v3i2.3520",null,"https://pubmed.ncbi.nlm.nih.gov//","https://ojs.bilpublishing.com/index.php/jer/article/download/3520/3118",null],["3","R0043408","R0043408.pdf","free_to_read","systematic_review","Najla Shamsi","2021","The Cardiovascular Events in Metabolic Surgery Compared to the New Classes of Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus: A Systematic Review With Narrative Synthesis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvab048.977","https://doi.org/10.1210/jendso/bvab048.977",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvab048.977",null],["3","R0049682","R0049682.pdf","open_download_failed","systematic_review","Cheng Han Ng","2021","IDDF2021-ABS-0096 Selecting anti-diabetic medications for type 2 diabetics with non-alcoholic fatty liver disease. Evidence from a network meta-analysis",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2021-iddf.89","https://doi.org/10.1136/gutjnl-2021-iddf.89",null,"https://pubmed.ncbi.nlm.nih.gov//","https://gut.bmj.com/content/gutjnl/70/Suppl_2/A83.full.pdf",null],["3","R0050289","R0050289.pdf","free_to_read","systematic_review","Cláudia Matta-Coelho","2021","Pharmacotherapy for weight loss in adults with type 2 diabetes: a systematic review of randomised controlled trials","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2021.281","https://doi.org/10.15277/bjd.2021.281",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2021.281",null],["3","R0050550","R0050550.pdf","free_to_read","systematic_review","Limin Zhao","2021","Letter Regarding “Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR”","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2021.09.014","https://doi.org/10.1016/j.ekir.2021.09.014","34805647","https://pubmed.ncbi.nlm.nih.gov/34805647/","https://doi.org/10.1016/j.ekir.2021.09.014",null],["3","R0050713","R0050713.pdf","free_to_read","systematic_review","Davy Vancampfort","2021","The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials","FOCUS The Journal of Lifelong Learning in Psychiatry","American Psychiatric Association Publishing","10.1176/appi.focus.19103","https://doi.org/10.1176/appi.focus.19103","34483776","https://pubmed.ncbi.nlm.nih.gov/34483776/","https://research.manchester.ac.uk/en/publications/eceb008a-8394-4184-aca8-62f932cb0911",null],["3","R0051645","R0051645.pdf","no_doi","systematic_review","Niamh McGuckin","2021","The Use of Incretin-Based Therapies and Cancer-Specific Risk in Type 2 Diabetes Mellitus Patients: A Systematic Review","Research Portal (Queen's University Belfast)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051665","R0051665.pdf","free_to_read","systematic_review","William David Strain","2021","A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2021.292","https://doi.org/10.15277/bjd.2021.292",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2021.292",null],["3","R0051794","R0051794.pdf","free_to_read","systematic_review","Poobalan Naidoo","2021","Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review","World Journal of Meta-Analysis","Baishideng Publishing Group Inc.","10.13105/wjma.v9.i3.297","https://doi.org/10.13105/wjma.v9.i3.297",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.13105/wjma.v9.i3.297",null],["3","R0052171","R0052171.pdf","open_download_failed","systematic_review","Aristi Boulmpou","2021","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.2952","https://doi.org/10.1093/eurheartj/ehab724.2952",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2952/41052286/ehab724.2952.pdf",null],["3","R0056185","R0056185.pdf","no_doi","systematic_review","W.Weinberg","2021","Management of Non-alcoholic Steatohepatitis (NASH): A Systematic Review of Pharmacological Therapies","Medical Education in The United States and Canada",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0005536","R0005536.pdf","open_download_failed","systematic_review","Home PD","2020","Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14136","https://doi.org/10.1111/dom.14136","32627297","https://pubmed.ncbi.nlm.nih.gov/32627297/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14136",null],["3","R0007624","R0007624.pdf","free_to_read","systematic_review","Morales J","2020","Practical guidance for use of oral semaglutide in primary care: a narrative review.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1788340","https://doi.org/10.1080/00325481.2020.1788340","32643514","https://pubmed.ncbi.nlm.nih.gov/32643514/","https://doi.org/10.1080/00325481.2020.1788340",null],["3","R0007680","R0007680.pdf","open_download_failed","systematic_review","Davies MJ","2020","Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14066","https://doi.org/10.1111/dom.14066","32372425","https://pubmed.ncbi.nlm.nih.gov/32372425/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14066",null],["3","R0007838","R0007838.pdf","free_to_read","systematic_review","Hussein H","2020","Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14008","https://doi.org/10.1111/dom.14008","32077218","https://pubmed.ncbi.nlm.nih.gov/32077218/","https://figshare.com/articles/journal_contribution/Efficacy_and_tolerability_of_sodium_glucose_co_transporter_2_inhibitors_and_glucagon_like_peptide_1_receptor_agonists_A_systematic_review_and_network_meta_analysis/11902209","PROSPERO:CRD42018091306"],["3","R0008096","R0008096.pdf","free_to_read","systematic_review","Fan S","2020","The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","Revista espanola de enfermedades digestivas","Sociedad Espanola de Patologia Digestiva (SEPD)","10.17235/reed.2020.6392/2019","https://doi.org/10.17235/reed.2020.6392/2019","32496108","https://pubmed.ncbi.nlm.nih.gov/32496108/",null,null],["3","R0008197","R0008197.pdf","open_download_failed","systematic_review","Herrera Comoglio R","2020","Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.","International journal of clinical practice","Wiley","10.1111/ijcp.13553","https://doi.org/10.1111/ijcp.13553","32452094","https://pubmed.ncbi.nlm.nih.gov/32452094/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13553",null],["3","R0008270","R0008270.pdf","free_to_read","systematic_review","Huthmacher JA","2020","Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.","Diabetes care","American Diabetes Association","10.2337/dc20-0498","https://doi.org/10.2337/dc20-0498","32910778","https://pubmed.ncbi.nlm.nih.gov/32910778/",null,null],["3","R0008514","R0008514.pdf","open_download_failed","systematic_review","Chen C","2020","The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","Informa UK Limited","10.1080/09513590.2019.1703943","https://doi.org/10.1080/09513590.2019.1703943","31858859","https://pubmed.ncbi.nlm.nih.gov/31858859/","https://figshare.com/articles/The_effect_of_dipeptidyl_peptidase-4_inhibitor_and_glucagon-like_peptide-1_receptor_agonist_in_gestational_diabetes_mellitus_a_systematic_review/11417589",null],["3","R0009704","R0009704.pdf","open_download_failed","systematic_review","Marsico F","2020","Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa082","https://doi.org/10.1093/eurheartj/ehaa082","32077924","https://pubmed.ncbi.nlm.nih.gov/32077924/","https://academic.oup.com/eurheartj/article-pdf/41/35/3346/33856018/ehaa082.pdf",null],["3","R0010653","R0010653.pdf","open_download_failed","systematic_review","Zhao M","2020","Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.11220720","https://doi.org/10.2215/cjn.11220720","33376101","https://pubmed.ncbi.nlm.nih.gov/33376101/","https://www.ncbi.nlm.nih.gov/pmc/articles/7792639",null],["3","R0011122","R0011122.pdf","open_download_failed","systematic_review","Al-Mashhadi Z","2020","Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.","Current osteoporosis reports","Springer Science and Business Media LLC","10.1007/s11914-020-00638-8","https://doi.org/10.1007/s11914-020-00638-8","33165875","https://pubmed.ncbi.nlm.nih.gov/33165875/","https://link.springer.com/content/pdf/10.1007/s11914-020-00638-8.pdf",null],["3","R0011142","R0011142.pdf","free_to_read","systematic_review","Pinto LC","2020","Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa534","https://doi.org/10.1210/clinem/dgaa534","32797182","https://pubmed.ncbi.nlm.nih.gov/32797182/",null,"PROSPERO:CRD42019132807"],["3","R0011894","R0011894.pdf","free_to_read","systematic_review","Rigato M","2020","Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa178","https://doi.org/10.1210/clinem/dgaa178","32271381","https://pubmed.ncbi.nlm.nih.gov/32271381/",null,null],["3","R0013925","R0013925.pdf","open_download_failed","systematic_review","Home P","2020","Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14148","https://doi.org/10.1111/dom.14148","32700442","https://pubmed.ncbi.nlm.nih.gov/32700442/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14148",null],["3","R0014185","R0014185.pdf","open_download_failed","systematic_review","Yan C","2020","Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.","Hypertension (Dallas, Tex. : 1979)","Ovid Technologies (Wolters Kluwer Health)","10.1161/hypertensionaha.120.14791","https://doi.org/10.1161/hypertensionaha.120.14791","32639887","https://pubmed.ncbi.nlm.nih.gov/32639887/","https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.120.14791",null],["3","R0014421","R0014421.pdf","free_to_read","systematic_review","Sacre JW","2020","Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.","Diabetes care","American Diabetes Association","10.2337/dc20-0654","https://doi.org/10.2337/dc20-0654","32958618","https://pubmed.ncbi.nlm.nih.gov/32958618/",null,null],["3","R0016766","R0016766.pdf","open_download_failed","systematic_review","Mulvaney CA","2020","GLP-1 receptor agonists for Parkinson's disease.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012990.pub2","https://doi.org/10.1002/14651858.cd012990.pub2","32700772","https://pubmed.ncbi.nlm.nih.gov/32700772/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012990.pub2/pdf/full",null],["3","R0019748","R0019748.pdf","open_download_failed","systematic_review","Abd El Aziz M","2020","Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13924","https://doi.org/10.1111/dom.13924","31750601","https://pubmed.ncbi.nlm.nih.gov/31750601/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13924",null],["3","R0021211","R0021211.pdf","open_download_failed","systematic_review","Singh AK","2020","Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","Diabetes care","American Diabetes Association","10.2337/dc20-1950","https://doi.org/10.2337/dc20-1950","33218984","https://pubmed.ncbi.nlm.nih.gov/33218984/","https://diabetesjournals.org/care/article-pdf/43/12/e200/530948/dc201950.pdf",null],["3","R0021475","R0021475.pdf","open_download_failed","systematic_review","Gorgojo-Martínez JJ","2020","Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2019.1681436","https://doi.org/10.1080/13696998.2019.1681436","31613199","https://pubmed.ncbi.nlm.nih.gov/31613199/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1681436?needAccess=true&role=button",null],["3","R0022673","R0022673.pdf","open_download_failed","systematic_review","Ferreira GS","2020","Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2020.173153","https://doi.org/10.1016/j.ejphar.2020.173153","32360835","https://pubmed.ncbi.nlm.nih.gov/32360835/","https://www.sciencedirect.com/science/article/pii/S0014299920302454/pdf",null],["3","R0022762","R0022762.pdf","open_download_failed","systematic_review","Zhou JB","2020","Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2020.154265","https://doi.org/10.1016/j.metabol.2020.154265","32446679","https://pubmed.ncbi.nlm.nih.gov/32446679/","http://www.metabolismjournal.com/article/S0026049520301293/pdf",null],["3","R0024857","R0024857.pdf","open_download_failed","systematic_review","Gnesin F","2020","Metformin monotherapy for adults with type 2 diabetes mellitus.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012906.pub2","https://doi.org/10.1002/14651858.cd012906.pub2","32501595","https://pubmed.ncbi.nlm.nih.gov/32501595/","https://www.ncbi.nlm.nih.gov/pmc/articles/7386876","ClinicalTrials.gov:NCT00679939; ClinicalTrials.gov:NCT00279045; ClinicalTrials.gov:NCT00327015; ClinicalTrials.gov:NCT00099866; ClinicalTrials.gov:NCT00138567; ClinicalTrials.gov:NCT01126580; ClinicalTrials.gov:NCT00103857; ClinicalTrials.gov:NCT00035568; ClinicalTrials.gov:NCT03010683; ClinicalTrials.gov:NCT00373178; ClinicalTrials.gov:NCT00396851; ClinicalTrials.gov:NCT01001962; ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT02853630; ClinicalTrials.gov:NCT03982381"],["3","R0025074","R0025074.pdf","free_to_read","systematic_review","Muñoz-Jiménez M","2020","Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.","Dementia and geriatric cognitive disorders","S. Karger AG","10.1159/000510677","https://doi.org/10.1159/000510677","33080602","https://pubmed.ncbi.nlm.nih.gov/33080602/","http://hdl.handle.net/10668/16457",null],["3","R0026369","R0026369.pdf","open_download_failed","systematic_review","Dambha-Miller H","2020","Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review","medRxiv","openRxiv","10.1101/2020.05.19.20106856","https://doi.org/10.1101/2020.05.19.20106856",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2020/05/26/2020.05.19.20106856.full.pdf",null],["3","R0027875","R0027875.pdf","open_download_failed","systematic_review","Lo C","2020","Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd009966.pub3","https://doi.org/10.1002/14651858.cd009966.pub3","32803882","https://pubmed.ncbi.nlm.nih.gov/32803882/","http://hdl.handle.net/1959.4/unsworks_74804","ClinicalTrials.gov:NCT03157414; ClinicalTrials.gov:NCT00980356; ClinicalTrials.gov:NCT00609986; ClinicalTrials.gov:NCT01643382; ClinicalTrials.gov:NCT00740363; ClinicalTrials.gov:NCT00598013; ClinicalTrials.gov:NCT00830297; ClinicalTrials.gov:NCT01680185; ClinicalTrials.gov:NCT01148680; ClinicalTrials.gov:NCT01346254; ClinicalTrials.gov:NCT00507494; ClinicalTrials.gov:NCT03642184"],["3","R0036351","R0036351.pdf","no_doi","systematic_review","Linzhi LI","2020","Acupuncture for patients with GLP-1 RAs-induced nausea and vomiting: a systematic review protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039523","R0039523.pdf","free_to_read","systematic_review","Sushrima Gan","2020","Efficacy of Modern Diabetes Treatments- Dpp-4i, Sglt-2i, Glp-1ra- in White and Asian Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials",null,"American Diabetes Association","10.2337/figshare.12003276","https://doi.org/10.2337/figshare.12003276",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.12003276",null],["3","R0039887","R0039887.pdf","open_download_failed","systematic_review","Nadia Sarween","2020","P1011CARDIOVASCULAR OUTCOME TRIALS (CVOT) USING NEW ANTI-DIABETIC AGENTS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa142.p1011","https://doi.org/10.1093/ndt/gfaa142.p1011",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/ndt/article-pdf/35/Supplement_3/gfaa142.P1011/33359901/gfaa142.p1011.pdf",null],["3","R0040929","R0040929.pdf","no_doi","systematic_review","賴妘薇","2020","Efficacy and safety of glucagon-like peptide 1 analogs for prediabetes: A systematic review and meta-analyses","Taipei Medical University Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043888","R0043888.pdf","open_download_failed","systematic_review","Soo Lim","2020","SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaa046.1636","https://doi.org/10.1210/jendso/bvaa046.1636",null,"https://pubmed.ncbi.nlm.nih.gov//","https://academic.oup.com/jes/article-pdf/4/Supplement_1/SAT-662/33185576/bvaa046.1636.pdf",null],["3","R0044294","R0044294.pdf","no_doi","systematic_review","Terán Chávez, Pier André","2020","Cardiovascular outcomes and harmful effects of SGLT-2 inhibitors and GLP-1 agonists in patients with type 2 diabetes mellitus: A systematic review and metaanalysis","Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044309","R0044309.pdf","no_doi","systematic_review","Al Oneze, Ameera","2020","Is Liraglutide a Safe and Effective Medication to Treat Hyperglycaemia?: A Systematic Review","Repository@Nottingham (University of Nottingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0046161","R0046161.pdf","open_download_failed","systematic_review","Katherine Fazioli","2020","PDB9 THE COMPARATIVE EFFICACY OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA)","Value in Health","Elsevier BV","10.1016/j.jval.2020.04.198","https://doi.org/10.1016/j.jval.2020.04.198",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.valueinhealthjournal.com/article/S1098301520303867/pdf",null],["3","R0046715","R0046715.pdf","open_download_failed","systematic_review","J.Y. Ye","2020","PDB5 Effectiveness of Dulaglutide and Liraglutide in Glycemic Control, Weight Loss and Blood Pressure Reduction: A Systematic Review and Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2020.08.602","https://doi.org/10.1016/j.jval.2020.08.602",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.valueinhealthjournal.com/article/S1098301520328588/pdf",null],["3","R0047409","R0047409.pdf","no_doi","systematic_review","Bogdan Apan","2020","THE EFFECTS OF EXENATIDE ON SERUM CRP LEVELS IN PATIENTS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047460","R0047460.pdf","free_to_read","systematic_review","Jessica Annalena Huthmacher","2020","Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: A meta-analysis",null,"American Diabetes Association","10.2337/figshare.12272840.v1","https://doi.org/10.2337/figshare.12272840.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.12272840.v1",null],["3","R0049658","R0049658.pdf","open_download_failed","systematic_review","Carina Kirstine Klarskov","2020","Oral treatment of glucocorticoid‐induced diabetes mellitus: A systematic review","International Journal of Clinical Practice","Wiley","10.1111/ijcp.13529","https://doi.org/10.1111/ijcp.13529","32392375","https://pubmed.ncbi.nlm.nih.gov/32392375/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13529",null],["3","R0052641","R0052641.pdf","free_to_read","systematic_review","Francesco Zaccardi","2020","Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes","Diabetes Care","American Diabetes Association","10.2337/dc20-2080","https://doi.org/10.2337/dc20-2080","33334809","https://pubmed.ncbi.nlm.nih.gov/33334809/","https://www.ncbi.nlm.nih.gov/pmc/articles/8441544",null],["3","R0052911","R0052911.pdf","no_doi","systematic_review","Ameera Khaled Al Onezei","2020","Is Liraglutide a Safe and Effective Medication to Treat Hyperglycaemia? A Systematic Review",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0009680","R0009680.pdf","free_to_read","systematic_review","Hussein H","2019","Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13898","https://doi.org/10.1111/dme.13898","30653708","https://pubmed.ncbi.nlm.nih.gov/30653708/","https://figshare.com/articles/journal_contribution/Cardiovascular_efficacy_and_safety_of_sodium-glucose_co-transporter-2_inhibitors_and_glucagon-like_peptide-1_receptor_agonists_a_systematic_review_and_network_meta-analysis/10236623",null],["3","R0009738","R0009738.pdf","open_download_failed","systematic_review","Inoue H","2019","Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.","British journal of clinical pharmacology","Wiley","10.1111/bcp.13807","https://doi.org/10.1111/bcp.13807","30394576","https://pubmed.ncbi.nlm.nih.gov/30394576/","https://www.ncbi.nlm.nih.gov/pmc/articles/6339993",null],["3","R0012365","R0012365.pdf","free_to_read","systematic_review","Kristensen SL","2019","Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30249-9","https://doi.org/10.1016/s2213-8587(19)30249-9","31422062","https://pubmed.ncbi.nlm.nih.gov/31422062/","http://eprints.gla.ac.uk/view/author/31665.html>,",null],["3","R0012544","R0012544.pdf","open_download_failed","systematic_review","Brunchmann A","2019","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.","Physiology & behavior","Elsevier BV","10.1016/j.physbeh.2019.03.029","https://doi.org/10.1016/j.physbeh.2019.03.029","30946836","https://pubmed.ncbi.nlm.nih.gov/30946836/","https://www.ncbi.nlm.nih.gov/pmc/articles/6520118",null],["3","R0013491","R0013491.pdf","open_download_failed","systematic_review","Domecq JP","2019","Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2019-01269","https://doi.org/10.1210/jc.2019-01269","31365088","https://pubmed.ncbi.nlm.nih.gov/31365088/","https://academic.oup.com/jcem/article-pdf/104/9/3986/29027704/jc.2019-01269.pdf",null],["3","R0016533","R0016533.pdf","open_download_failed","systematic_review","Vancampfort D","2019","The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.","World psychiatry : official journal of the World Psychiatric Association (WPA)","Wiley","10.1002/wps.20614","https://doi.org/10.1002/wps.20614","30600626","https://pubmed.ncbi.nlm.nih.gov/30600626/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/wps.20614",null],["3","R0019373","R0019373.pdf","open_download_failed","systematic_review","Fralick M","2019","Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.","Annals of internal medicine","American College of Physicians","10.7326/m18-0567","https://doi.org/10.7326/m18-0567","30597484","https://pubmed.ncbi.nlm.nih.gov/30597484/","https://www.ncbi.nlm.nih.gov/pmc/articles/6602870",null],["3","R0024596","R0024596.pdf","open_download_failed","systematic_review","Zhang Y","2019","The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.","The heart surgery forum","IMR Press","10.1532/hsf.2513","https://doi.org/10.1532/hsf.2513","31895026","https://pubmed.ncbi.nlm.nih.gov/31895026/","https://journal.hsforum.com/index.php/HSF/article/download/2513/3913",null],["3","R0027951","R0027951.pdf","open_download_failed","systematic_review","Madsen KS","2019","Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012368.pub2","https://doi.org/10.1002/14651858.cd012368.pub2","30998259","https://pubmed.ncbi.nlm.nih.gov/30998259/",null,null],["3","R0030420","R0030420.pdf","open_download_failed","systematic_review","Choi SE","2019","Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.","Medical decision making : an international journal of the Society for Medical Decision Making","SAGE Publications","10.1177/0272989x19829735","https://doi.org/10.1177/0272989x19829735","30767632","https://pubmed.ncbi.nlm.nih.gov/30767632/","https://www.ncbi.nlm.nih.gov/pmc/articles/6469997",null],["3","R0034797","R0034797.pdf","no_doi","systematic_review","Yeong-Min Lee","2019","Abstract 12808: Cardiovascular Outcomes With Glucagon-Like Peptide 1 Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes: A Meta-Analysis","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037127","R0037127.pdf","free_to_read","systematic_review","Edoardo Mannucci","2019","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.3424204","https://doi.org/10.2139/ssrn.3424204",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.3424204",null],["3","R0041495","R0041495.pdf","no_doi","systematic_review","David Preiss","2019","Cardiovascular, mortality and renal outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes – a systematic review and meta-analysis of randomised trials","The Lancet Diabetes & Endocrinology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041829","R0041829.pdf","open_download_failed","systematic_review","David Aguilar","2019","CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(19)30847-2","https://doi.org/10.1016/s0735-1097(19)30847-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S0735109719308472/pdf",null],["3","R0044738","R0044738.pdf","free_to_read","systematic_review","P. Men","2019","PDB59 LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS","Value in Health","Elsevier BV","10.1016/j.jval.2019.04.608","https://doi.org/10.1016/j.jval.2019.04.608",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2019.04.608",null],["3","R0048151","R0048151.pdf","free_to_read","systematic_review","Dongzhe Hong","2019","PDB37 COST EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: A SYSTEMATIC REVIEW","Value in Health","Elsevier BV","10.1016/j.jval.2019.04.587","https://doi.org/10.1016/j.jval.2019.04.587",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2019.04.587",null],["3","R0055375","R0055375.pdf","open_download_failed","systematic_review","Kulvinder Kochar Kaur","2019","Targeting Orexin Neurons for Treatment of Obesity is It Feasible in Human Being-A Systematic Review","Journal of Neurology Research Review & Reports","Scientific Research and Community Ltd","10.47363/jnrrr/2019(1)104","https://doi.org/10.47363/jnrrr/2019(1)104",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47363/jnrrr/2019(1)104",null],["3","R0009725","R0009725.pdf","free_to_read","systematic_review","Bethel MA","2018","Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(17)30412-6","https://doi.org/10.1016/s2213-8587(17)30412-6","29221659","https://pubmed.ncbi.nlm.nih.gov/29221659/","http://hdl.handle.net/10044/1/61644",null],["3","R0009747","R0009747.pdf","free_to_read","systematic_review","Tran S","2018","Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13137","https://doi.org/10.1111/dom.13137","29364587","https://pubmed.ncbi.nlm.nih.gov/29364587/",null,"PROSPERO:CRD42017057115"],["3","R0010354","R0010354.pdf","open_download_failed","systematic_review","Eggert S","2018","Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2018.1444882","https://doi.org/10.1080/14656566.2018.1444882","29471700","https://pubmed.ncbi.nlm.nih.gov/29471700/","https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1444882?needAccess=true&role=button",null],["3","R0010419","R0010419.pdf","free_to_read","systematic_review","Chatterjee S","2018","What have we learnt from \"real world\" data, observational studies and meta-analyses.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13178","https://doi.org/10.1111/dom.13178","29364585","https://pubmed.ncbi.nlm.nih.gov/29364585/","https://figshare.com/articles/journal_contribution/What_have_we_learnt_from_real_world_data_observational_studies_and_meta_analyses/10199870",null],["3","R0012385","R0012385.pdf","free_to_read","systematic_review","Valencia WM","2018","Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-018-1052-y","https://doi.org/10.1007/s11892-018-1052-y","30187176","https://pubmed.ncbi.nlm.nih.gov/30187176/",null,null],["3","R0013680","R0013680.pdf","free_to_read","systematic_review","Zaccardi F","2018","Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13185","https://doi.org/10.1111/dom.13185","29205774","https://pubmed.ncbi.nlm.nih.gov/29205774/","https://figshare.com/articles/journal_contribution/Comparison_of_glucose_lowering_agents_after_dual_therapy_failure_in_type_2_diabetes_A_systematic_review_and_network_meta_analysis_of_randomized_controlled_trials/10226729",null],["3","R0013745","R0013745.pdf","free_to_read","systematic_review","Wu S","2018","The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2018.1424826","https://doi.org/10.1080/14740338.2018.1424826","29320889","https://pubmed.ncbi.nlm.nih.gov/29320889/",null,null],["3","R0014654","R0014654.pdf","free_to_read","systematic_review","Marlet IR","2018","Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies.","Basic & clinical pharmacology & toxicology","Wiley","10.1111/bcpt.12974","https://doi.org/10.1111/bcpt.12974","29411931","https://pubmed.ncbi.nlm.nih.gov/29411931/",null,null],["3","R0014991","R0014991.pdf","open_download_failed","systematic_review","McGovern A","2018","Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13160","https://doi.org/10.1111/dom.13160","29135080","https://pubmed.ncbi.nlm.nih.gov/29135080/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13160",null],["3","R0017533","R0017533.pdf","free_to_read","systematic_review","Dumbrill JL","2018","Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2017.06.009","https://doi.org/10.1016/j.pcd.2017.06.009","28732654","https://pubmed.ncbi.nlm.nih.gov/28732654/","https://kclpure.kcl.ac.uk/portal/en/publications/813a570e-0252-4ca0-b3c2-d1ea8e8bba49",null],["3","R0018776","R0018776.pdf","free_to_read","systematic_review","Wang H","2018","Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13177","https://doi.org/10.1111/dom.13177","29193572","https://pubmed.ncbi.nlm.nih.gov/29193572/","http://hdl.handle.net/10138/325808",null],["3","R0023071","R0023071.pdf","no_doi","systematic_review","Malik J","2018","GLP-1, a powerful physiological incretin: an update.","Journal of biological regulators and homeostatic agents",null,null,"https://doi.org/","30334409","https://pubmed.ncbi.nlm.nih.gov/30334409/",null,null],["3","R0023327","R0023327.pdf","open_download_failed","systematic_review","Zheng SL","2018","Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","JAMA","American Medical Association (AMA)","10.1001/jama.2018.3024","https://doi.org/10.1001/jama.2018.3024","29677303","https://pubmed.ncbi.nlm.nih.gov/29677303/","https://jamanetwork.com/journals/jama/articlepdf/2678616/jama_zheng_2018_oi_180031.pdf",null],["3","R0023445","R0023445.pdf","open_download_failed","systematic_review","Kramer CK","2018","Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2018.05.021","https://doi.org/10.1016/j.jchf.2018.05.021","30196071","https://pubmed.ncbi.nlm.nih.gov/30196071/","https://www.sciencedirect.com/science/article/pii/S2213177918304475/pdf",null],["3","R0023610","R0023610.pdf","free_to_read","systematic_review","Moulton CD","2018","Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.","Psychoneuroendocrinology","Elsevier BV","10.1016/j.psyneuen.2018.05.010","https://doi.org/10.1016/j.psyneuen.2018.05.010","29775878","https://pubmed.ncbi.nlm.nih.gov/29775878/","https://kclpure.kcl.ac.uk/portal/en/publications/6584d05b-4888-44bd-a17e-5c882c12f39b",null],["3","R0024009","R0024009.pdf","open_download_failed","systematic_review","Lo C","2018","Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd011798.pub2","https://doi.org/10.1002/14651858.cd011798.pub2","30246878","https://pubmed.ncbi.nlm.nih.gov/30246878/","https://www.ncbi.nlm.nih.gov/pmc/articles/6513625",null],["3","R0024752","R0024752.pdf","open_download_failed","systematic_review","Tang H","2018","Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13232","https://doi.org/10.1111/dom.13232","29369494","https://pubmed.ncbi.nlm.nih.gov/29369494/","https://doi.org/10.17615/0ytp-fq60",null],["3","R0025308","R0025308.pdf","free_to_read","systematic_review","Wang FF","2018","Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.12720","https://doi.org/10.1111/obr.12720","30066361","https://pubmed.ncbi.nlm.nih.gov/30066361/",null,"PROSPERO:CRD42017076625"],["3","R0025617","R0025617.pdf","free_to_read","systematic_review","Sharma R","2018","Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1476332","https://doi.org/10.1080/03007995.2018.1476332","29764222","https://pubmed.ncbi.nlm.nih.gov/29764222/","https://figshare.com/articles/journal_contribution/Comparative_efficacy_of_once-weekly_semaglutide_and_SGLT-2_inhibitors_in_type_2_diabetic_patients_inadequately_controlled_with_metformin_monotherapy_a_systematic_literature_review_and_network_meta-analysis/6272540",null],["3","R0025932","R0025932.pdf","open_download_failed","systematic_review","Skelin M","2018","The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.","International journal of clinical practice","Wiley","10.1111/ijcp.13274","https://doi.org/10.1111/ijcp.13274","30295381","https://pubmed.ncbi.nlm.nih.gov/30295381/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13274",null],["3","R0027595","R0027595.pdf","free_to_read","systematic_review","Khera R","2018","Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2017.12.024","https://doi.org/10.1053/j.gastro.2017.12.024","29305933","https://pubmed.ncbi.nlm.nih.gov/29305933/","https://www.ncbi.nlm.nih.gov/pmc/articles/5880739","PROSPERO:CRD42016039486"],["3","R0028119","R0028119.pdf","free_to_read","systematic_review","LeBlanc EL","2018","Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force","Agency for Healthcare Research and Quality (US), Rockville (MD)",null,null,"https://doi.org/","30354042","https://pubmed.ncbi.nlm.nih.gov/30354042/",null,null],["3","R0030860","R0030860.pdf","no_doi","systematic_review","Shimaa Elsayad Ahmed","2018","Liraglutide 3.0 mg for weight loss, is it more effective in diabetic or non-diabetic patients? A systematic review and meta-analysis","American Journal of Pharmacology and Pharmacotherapeutics",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032816","R0032816.pdf","free_to_read","systematic_review","Lana Catani Ferreira Pinto","2018","Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer—A Meta-analysis with Trial Sequential Analysis","Diabetes","American Diabetes Association","10.2337/db18-1086-p","https://doi.org/10.2337/db18-1086-p",null,"https://pubmed.ncbi.nlm.nih.gov//","http://hdl.handle.net/10183/218669",null],["3","R0042392","R0042392.pdf","no_doi","systematic_review","H Hussein (7790060)","2018","Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protoco","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42018091306"],["3","R0043997","R0043997.pdf","free_to_read","systematic_review","Abraham H. Hulst","2018","01 / Incretins and the anaesthetist: a systematic review",null,"Morressier","10.26226/morressier.5aeb0ac607b0d6001a79a15b","https://doi.org/10.26226/morressier.5aeb0ac607b0d6001a79a15b",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/de6356e4-2777-4a81-8451-37f2281f2f53",null],["3","R0044654","R0044654.pdf","free_to_read","systematic_review","P Men","2018","Comparative Efficacy and Safety of Lixisenatide and Insulin Regimens in the Treatment of Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Basal Insulin: A Systematic Review and Network Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2018.07.269","https://doi.org/10.1016/j.jval.2018.07.269",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.07.269",null],["3","R0044667","R0044667.pdf","free_to_read","systematic_review","Amit Pagada","2018","A Meta-Analysis of Randomized Controlled Trials Comparing Once-Weekly Semaglutide to Control Therapy for the Treatment of Type 2 Diabetes","Value in Health","Elsevier BV","10.1016/j.jval.2018.07.268","https://doi.org/10.1016/j.jval.2018.07.268",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.07.268",null],["3","R0045378","R0045378.pdf","open_download_failed","systematic_review","Wei Lin","2018","Efficacy and safety of semaglutide in type 2 diabetes compared with sitagliptin, exenatide ER, insulin glargine, basal insulin and placebo: a systematic review","Pharmaceutical Sciences Asia","Faculty of Pharmacy, Mahidol University","10.29090/psa.2018.03.123","https://doi.org/10.29090/psa.2018.03.123",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.29090/psa.2018.03.123",null],["3","R0056938","R0056938.pdf","open_download_failed","systematic_review","Huang CJ","2018","Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13342","https://doi.org/10.1111/dom.13342","29722116","https://pubmed.ncbi.nlm.nih.gov/29722116/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13342",null],["3","R0006363","R0006363.pdf","open_download_failed","systematic_review","Htike ZZ","2017","Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12849","https://doi.org/10.1111/dom.12849","27981757","https://pubmed.ncbi.nlm.nih.gov/27981757/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12849",null],["3","R0014739","R0014739.pdf","open_download_failed","systematic_review","Mazidi M","2017","Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.05.022","https://doi.org/10.1016/j.jdiacomp.2016.05.022","28479155","https://pubmed.ncbi.nlm.nih.gov/28479155/","http://sro.sussex.ac.uk/id/eprint/61270/1/ADVMS_147%20gf.pdf","PROSPERO:CRD42016036868"],["3","R0014815","R0014815.pdf","open_download_failed","systematic_review","Driessen JH","2017","The use of incretins and fractures - a meta-analysis on population-based real life data.","British journal of clinical pharmacology","Wiley","10.1111/bcp.13167","https://doi.org/10.1111/bcp.13167","27780288","https://pubmed.ncbi.nlm.nih.gov/27780288/","https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13167",null],["3","R0018191","R0018191.pdf","open_download_failed","systematic_review","Hemmingsen B","2017","Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012204.pub2","https://doi.org/10.1002/14651858.cd012204.pub2","28489279","https://pubmed.ncbi.nlm.nih.gov/28489279/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/full",null],["3","R0021457","R0021457.pdf","free_to_read","systematic_review","Baptista A","2017","The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.","The European journal of health economics : HEPAC : health economics in prevention and care","Springer Science and Business Media LLC","10.1007/s10198-016-0837-7","https://doi.org/10.1007/s10198-016-0837-7","27752788","https://pubmed.ncbi.nlm.nih.gov/27752788/",null,null],["3","R0022939","R0022939.pdf","free_to_read","systematic_review","Home P","2017","Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12842","https://doi.org/10.1111/dom.12842","27935230","https://pubmed.ncbi.nlm.nih.gov/27935230/","https://doi.org/10.25405/ncl.34298799",null],["3","R0025816","R0025816.pdf","open_download_failed","systematic_review","Huang M","2017","Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.","Annals of medicine","Informa UK Limited","10.1080/07853890.2017.1306653","https://doi.org/10.1080/07853890.2017.1306653","28286967","https://pubmed.ncbi.nlm.nih.gov/28286967/","https://www.tandfonline.com/doi/pdf/10.1080/07853890.2017.1306653?needAccess=true&role=button","ClinicalTrials.gov:NCT02001363; ClinicalTrials.gov:NCT00835848; ClinicalTrials.gov:NCT01254123; ClinicalTrials.gov:NCT01580514"],["3","R0028010","R0028010.pdf","open_download_failed","systematic_review","Tieu J","2017","Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd010211.pub3","https://doi.org/10.1002/14651858.cd010211.pub3","28836274","https://pubmed.ncbi.nlm.nih.gov/28836274/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010211.pub3/pdf/full",null],["3","R0030433","R0030433.pdf","free_to_read","systematic_review","Bain S","2017","Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12821","https://doi.org/10.1111/dom.12821","27862902","https://pubmed.ncbi.nlm.nih.gov/27862902/","http://eprints.nottingham.ac.uk/43902/",null],["3","R0038626","R0038626.pdf","no_doi","systematic_review","Mcgovern, Andrew","2017","Comparison of medication adherence and persistence \\nin type 2 diabetes: A systematic review and meta-analysis","Surrey Research Insight Open Access (The University of Surrey)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043568","R0043568.pdf","free_to_read","systematic_review","Dr Muhammad Umar Wahab","2017","Efficacy and cardiovascular effects of dipeptidyl peptidase-4 (DPP4) inhibitors: a systematic review",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3bd0","https://doi.org/10.26226/morressier.59d51846d462b80296ca3bd0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/338dc46a-7521-4271-ad98-9f284447691c",null],["3","R0044685","R0044685.pdf","free_to_read","systematic_review","Naichuan Su","2017","Exenatide In Obese Or Overweight Patients Without Diabetes: A Systematic Review And Meta-Analyses Of Randomized Controlled Trials","Value in Health","Elsevier BV","10.1016/j.jval.2017.08.2822","https://doi.org/10.1016/j.jval.2017.08.2822",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2017.08.2822",null],["3","R0007309","R0007309.pdf","open_download_failed","systematic_review","Xue X","2016","Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.12847","https://doi.org/10.1111/ijcp.12847","27456750","https://pubmed.ncbi.nlm.nih.gov/27456750/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.12847",null],["3","R0007949","R0007949.pdf","no_doi","systematic_review","Li ZX","2016","[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].","Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences",null,null,"https://doi.org/","27318907","https://pubmed.ncbi.nlm.nih.gov/27318907/",null,null],["3","R0009048","R0009048.pdf","free_to_read","systematic_review","Evans M","2016","A systematic review of the safety of incretin-based therapies in type 2 diabetes.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1586/17446651.2015.1057502","https://doi.org/10.1586/17446651.2015.1057502","30058866","https://pubmed.ncbi.nlm.nih.gov/30058866/","https://figshare.com/articles/journal_contribution/A_systematic_review_of_the_safety_of_incretin_based_therapies_in_type_2_diabetes/2138974",null],["3","R0011860","R0011860.pdf","free_to_read","systematic_review","Howse PM","2016","Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2016.06.014","https://doi.org/10.1053/j.ajkd.2016.06.014","27528374","https://pubmed.ncbi.nlm.nih.gov/27528374/","https://doi.org/10.1053/j.ajkd.2016.06.014",null],["3","R0012795","R0012795.pdf","open_download_failed","systematic_review","Davidson JA","2016","Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12653","https://doi.org/10.1111/dom.12653","26936426","https://pubmed.ncbi.nlm.nih.gov/26936426/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12653",null],["3","R0013651","R0013651.pdf","open_download_failed","systematic_review","Twigg SM","2016","Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.","Journal of diabetes","Wiley","10.1111/1753-0407.12372","https://doi.org/10.1111/1753-0407.12372","26729046","https://pubmed.ncbi.nlm.nih.gov/26729046/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12372",null],["3","R0016556","R0016556.pdf","open_download_failed","systematic_review","Fahrbach JL","2016","Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.12775","https://doi.org/10.1111/ijcp.12775","26916354","https://pubmed.ncbi.nlm.nih.gov/26916354/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.12775",null],["3","R0017212","R0017212.pdf","open_download_failed","systematic_review","Wang T","2016","Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2804","https://doi.org/10.1002/dmrr.2804","27037787","https://pubmed.ncbi.nlm.nih.gov/27037787/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.2804",null],["3","R0017368","R0017368.pdf","open_download_failed","systematic_review","de Wit HM","2016","The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.","British journal of clinical pharmacology","Wiley","10.1111/bcp.12925","https://doi.org/10.1111/bcp.12925","26935973","https://pubmed.ncbi.nlm.nih.gov/26935973/","https://www.ncbi.nlm.nih.gov/pmc/articles/4917794",null],["3","R0026757","R0026757.pdf","open_download_failed","systematic_review","Khera R","2016","Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.","JAMA","American Medical Association (AMA)","10.1001/jama.2016.7602","https://doi.org/10.1001/jama.2016.7602","27299618","https://pubmed.ncbi.nlm.nih.gov/27299618/","https://jamanetwork.com/journals/jama/articlepdf/2528211/joi160066.pdf",null],["3","R0027477","R0027477.pdf","open_download_failed","systematic_review","Palmer SC","2016","Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.","JAMA","American Medical Association (AMA)","10.1001/jama.2016.9400","https://doi.org/10.1001/jama.2016.9400","27434443","https://pubmed.ncbi.nlm.nih.gov/27434443/","https://jamanetwork.com/journals/jama/articlepdf/2533506/jama_palmer_2016_oi_160080.pdf",null],["3","R0027771","R0027771.pdf","free_to_read","systematic_review","Siebenhofer A","2016","Long-term effects of weight-reducing drugs in people with hypertension.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd007654.pub4","https://doi.org/10.1002/14651858.cd007654.pub4","26934640","https://pubmed.ncbi.nlm.nih.gov/26934640/","https://www.ncbi.nlm.nih.gov/pmc/articles/8094237",null],["3","R0028116","R0028116.pdf","open_download_failed","systematic_review","Mead E","2016","Drug interventions for the treatment of obesity in children and adolescents.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd012436","https://doi.org/10.1002/14651858.cd012436","27899001","https://pubmed.ncbi.nlm.nih.gov/27899001/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/pdf/full",null],["3","R0031287","R0031287.pdf","no_doi","systematic_review","P M Howse","2016","Original Investigation Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0031700","R0031700.pdf","free_to_read","systematic_review","Shao Hong","2016","Incretin-based therapies for type 2 diabetes with nonalcoholic fatty liver disease: a systematic review and meta-analysis","Journal of Chinese Pharmaceutical Sciences","Journal of Chinese Pharmaceutical Sciences","10.5246/jcps.2016.03.025","https://doi.org/10.5246/jcps.2016.03.025",null,"https://pubmed.ncbi.nlm.nih.gov//","http://doi.org/10.5246/jcps.2016.03.025",null],["3","R0036201","R0036201.pdf","no_doi","systematic_review","Ana Paula Martins","2016","Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037918","R0037918.pdf","open_download_failed","systematic_review","Shanshan Wu","2016","Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","The Lancet Diabetes & Endocrinology","Elsevier BV","10.1016/s2213-8587(16)30373-4","https://doi.org/10.1016/s2213-8587(16)30373-4",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thelancet.com/article/S2213858716303734/pdf",null],["3","R0040878","R0040878.pdf","no_doi","systematic_review",null,"2016","A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0040937","R0040937.pdf","no_doi","systematic_review","Feng Sun","2016","Review Article Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041203","R0041203.pdf","no_doi","systematic_review","Carlo M. Rotella","2016","doi:10.1155/2012/672658 Research Article Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0041890","R0041890.pdf","no_doi","systematic_review","Bellman, Susan Marie","2016","The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044256","R0044256.pdf","no_doi","systematic_review","ZZ Htike (7774208)","2016","Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0044742","R0044742.pdf","free_to_read","systematic_review","JG Bayona","2016","SYSTEMATIC REVIEW OF EFFICACY AND SAFETY OF DULAGLUTIDE COMPARED WITH OTHER ANTIDIABETIC DRUGS","Value in Health","Elsevier BV","10.1016/j.jval.2016.03.1320","https://doi.org/10.1016/j.jval.2016.03.1320",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.03.1320",null],["3","R0044774","R0044774.pdf","free_to_read","systematic_review","Raju Kanukula","2016","EFFICACY AND SAFETY OF DULAGLUTIDE IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Value in Health","Elsevier BV","10.1016/j.jval.2016.03.1319","https://doi.org/10.1016/j.jval.2016.03.1319",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.03.1319",null],["3","R0047119","R0047119.pdf","free_to_read","systematic_review","Ify R. Mordi","2016","P20 A comparison of the cardiovascular effects of empagliflozin and liraglutide: a systematic review and meta-analysis",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2016-310696.24","https://doi.org/10.1136/heartjnl-2016-310696.24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1136/heartjnl-2016-310696.24",null],["3","R0051688","R0051688.pdf","free_to_read","systematic_review","Michelle Elaine Orme","2016","GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH ONCE-WEEKLY GLP-1RAS: COMPARISON OF A NETWORK META-ANALYSIS WITH A DIRECT ANALYSIS OF PLACEBO-CONTROLLED TRIALS","Value in Health","Elsevier BV","10.1016/j.jval.2016.03.1313","https://doi.org/10.1016/j.jval.2016.03.1313",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.03.1313",null],["3","R0009836","R0009836.pdf","open_download_failed","systematic_review","Sun F","2015","Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2014.0188","https://doi.org/10.1089/dia.2014.0188","25375397","https://pubmed.ncbi.nlm.nih.gov/25375397/","https://www.ncbi.nlm.nih.gov/pmc/articles/4290796",null],["3","R0017441","R0017441.pdf","open_download_failed","systematic_review","Saulsberry WJ","2015","Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.","International journal of clinical practice","Wiley","10.1111/ijcp.12698","https://doi.org/10.1111/ijcp.12698","26215321","https://pubmed.ncbi.nlm.nih.gov/26215321/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.12698",null],["3","R0023112","R0023112.pdf","free_to_read","systematic_review","Gray LJ","2015","Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12462","https://doi.org/10.1111/dom.12462","25777247","https://pubmed.ncbi.nlm.nih.gov/25777247/",null,null],["3","R0023483","R0023483.pdf","free_to_read","systematic_review","Jensen TM","2015","Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.","Diabetes care","American Diabetes Association","10.2337/dc13-1210","https://doi.org/10.2337/dc13-1210","25504028","https://pubmed.ncbi.nlm.nih.gov/25504028/",null,null],["3","R0026427","R0026427.pdf","open_download_failed","systematic_review","Li H","2015","Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.","Journal of pharmacological sciences","Elsevier BV","10.1016/j.jphs.2014.12.004","https://doi.org/10.1016/j.jphs.2014.12.004","25727954","https://pubmed.ncbi.nlm.nih.gov/25727954/","https://www.sciencedirect.com/science/article/pii/S1347861314000255/pdf",null],["3","R0027019","R0027019.pdf","open_download_failed","systematic_review","Domecq JP","2015","Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2014-3421","https://doi.org/10.1210/jc.2014-3421","25590213","https://pubmed.ncbi.nlm.nih.gov/25590213/","https://www.ncbi.nlm.nih.gov/pmc/articles/5393509",null],["3","R0030798","R0030798.pdf","no_doi","systematic_review","Liang Jing-jin","2015","A Meta-analysis on Sitagliptin and Other Antidiabetic Drugs in the Treatment of Type 2 Diabetes","Medical Recapitulate",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0034738","R0034738.pdf","free_to_read","systematic_review","Hasan M Shihab","2015","Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials","World Journal of Meta-Analysis","Baishideng Publishing Group Inc.","10.13105/wjma.v3.i6.254","https://doi.org/10.13105/wjma.v3.i6.254",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.13105/wjma.v3.i6.254",null],["3","R0040223","R0040223.pdf","open_download_failed","systematic_review","Zhirong Yang","2015","GW26-e4793 Comparative efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes: a systematic review and network meta-analysis","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2015.06.493","https://doi.org/10.1016/j.jacc.2015.06.493",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.sciencedirect.com/science/article/pii/S073510971503346X/pdf",null],["3","R0041285","R0041285.pdf","no_doi","systematic_review","Walid K. H","2015","A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0043613","R0043613.pdf","no_doi","systematic_review","Melanie J. Davies (7155500)","2015","Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments. A systematic review and network meta-analysis","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045352","R0045352.pdf","free_to_read","systematic_review","Suzy Van Sanden","2015","Bayesian Network Meta-Analysis (Nma) to Assess Relative Efficacy of Canagliflozin (Cana) Versus Glucagon-Like Peptide-1 (Glp-1) Agonists in Dual and Triple Therapy In Patients with type 2 Diabetes Mellitus (T2dm)","Value in Health","Elsevier BV","10.1016/j.jval.2015.03.319","https://doi.org/10.1016/j.jval.2015.03.319",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.03.319",null],["3","R0046996","R0046996.pdf","open_download_failed","systematic_review","Sheena Kayaniyil","2015","Exenatide Once Weekly Plus Metformin for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomised Controlled Trials","Value in Health","Elsevier BV","10.1016/j.jval.2015.09.2044","https://doi.org/10.1016/j.jval.2015.09.2044",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.valueinhealthjournal.com/article/S1098301515041200/pdf",null],["3","R0049955","R0049955.pdf","free_to_read","systematic_review","Maria F. Lorenzi","2015","Liraglutide vs Other Daily GLP-1 Analogues in People with Type 2 Diabetes: A Network Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2015.09.2049","https://doi.org/10.1016/j.jval.2015.09.2049",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.09.2049",null],["3","R0053379","R0053379.pdf","no_doi","systematic_review","A Baptista","2015","The Place of DPP-4 Inhibitors in the Treatment Algorithm of Diabetes Type 2: a Systematic Review of Cost-effectiveness Studies","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0012389","R0012389.pdf","free_to_read","systematic_review","Mabilleau G","2014","Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.","Journal of diabetes","Wiley","10.1111/1753-0407.12102","https://doi.org/10.1111/1753-0407.12102","24164867","https://pubmed.ncbi.nlm.nih.gov/24164867/","https://univ-angers.hal.science/hal-03262091",null],["3","R0012432","R0012432.pdf","open_download_failed","systematic_review","Liatis S","2014","Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12213","https://doi.org/10.1111/dom.12213","24495116","https://pubmed.ncbi.nlm.nih.gov/24495116/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12213",null],["3","R0015881","R0015881.pdf","free_to_read","systematic_review","Raccah D","2014","Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2548","https://doi.org/10.1002/dmrr.2548","24687427","https://pubmed.ncbi.nlm.nih.gov/24687427/","https://doi.org/10.1002/dmrr.2548",null],["3","R0020590","R0020590.pdf","free_to_read","systematic_review","Hawkins N","2014","Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2014.08.641","https://doi.org/10.1016/j.jval.2014.08.641","27200592","https://pubmed.ncbi.nlm.nih.gov/27200592/","https://doi.org/10.1016/j.jval.2014.08.641",null],["3","R0022245","R0022245.pdf","open_download_failed","systematic_review","Charbonnel B","2014","Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2014.07.007","https://doi.org/10.1016/j.jdiacomp.2014.07.007","25130920","https://pubmed.ncbi.nlm.nih.gov/25130920/","https://www.sciencedirect.com/science/article/pii/S1056872714002074/pdf","ClinicalTrials.gov:NCT00715624; ClinicalTrials.gov:NCT00899958; ClinicalTrials.gov:NCT00975286"],["3","R0024475","R0024475.pdf","free_to_read","systematic_review","Sun F","2014","Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2014.08.010","https://doi.org/10.1016/j.jval.2014.08.010","27202544","https://pubmed.ncbi.nlm.nih.gov/27202544/","https://doi.org/10.1016/j.jval.2014.08.010",null],["3","R0025744","R0025744.pdf","free_to_read","systematic_review","García-Casares N","2014","[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].","Revista de neurologia","IMR Press","10.33588/rn.5911.2014023","https://doi.org/10.33588/rn.5911.2014023","25418147","https://pubmed.ncbi.nlm.nih.gov/25418147/",null,null],["3","R0030937","R0030937.pdf","no_doi","systematic_review","VC Echebiri","2014","A systematic review of the effectiveness of Liraglutide for the treatment of type 2 diabetes","International Journal of Community Research",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0035873","R0035873.pdf","free_to_read","systematic_review","Barnett Ah","2014","Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes","Internal Medicine Open Access","OMICS Publishing Group","10.4172/2165-8048.s6-006","https://doi.org/10.4172/2165-8048.s6-006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4172/2165-8048.s6-006",null],["3","R0055043","R0055043.pdf","free_to_read","systematic_review","Susan M. Bellman","2014","The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review protocol","The JBI Database of Systematic Reviews and Implementation Reports","Ovid Technologies (Wolters Kluwer Health)","10.11124/jbisrir-2014-1858","https://doi.org/10.11124/jbisrir-2014-1858",null,"https://pubmed.ncbi.nlm.nih.gov//","http://hdl.handle.net/2440/94153",null],["3","R0023827","R0023827.pdf","open_download_failed","systematic_review","Armstrong MJ","2013","Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.12149","https://doi.org/10.1111/apt.12149","23163663","https://pubmed.ncbi.nlm.nih.gov/23163663/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.12149",null],["3","R0030548","R0030548.pdf","free_to_read","systematic_review","Zinsmeister AR","2013","Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-012-2369-z","https://doi.org/10.1007/s10620-012-2369-z","22918691","https://pubmed.ncbi.nlm.nih.gov/22918691/","https://www.ncbi.nlm.nih.gov/pmc/articles/3529760",null],["3","R0035473","R0035473.pdf","no_doi","systematic_review","Wan Li-ya","2013","Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus:a meta-analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0040967","R0040967.pdf","no_doi","systematic_review","Matteo Monami","2013","doi:10.1155/2011/215764 Research Article Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0042686","R0042686.pdf","open_download_failed","systematic_review",null,"2013","Kombinationstherapie bei Typ-2-Diabetes - Metaanalyse bestätigt synergistische Effekte","Diabetes aktuell","Georg Thieme Verlag KG","10.1055/s-0033-1337655","https://doi.org/10.1055/s-0033-1337655",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1337655.pdf",null],["3","R0051549","R0051549.pdf","open_download_failed","systematic_review","IRENE M. HRAMIAK","2013","Meta-Analysis of GLP-1 Receptor Agonist Lixisenatide Use in Patients Insufficiently Controlled with Oral Antihyperglycemic Agents","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2013.08.109","https://doi.org/10.1016/j.jcjd.2013.08.109",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.canadianjournalofdiabetes.com/article/S1499267113010575/pdf",null],["3","R0011327","R0011327.pdf","free_to_read","systematic_review","Aroda VR","2012","Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.04.013","https://doi.org/10.1016/j.clinthera.2012.04.013","22608780","https://pubmed.ncbi.nlm.nih.gov/22608780/","https://doi.org/10.1016/j.clinthera.2012.04.013",null],["3","R0024853","R0024853.pdf","open_download_failed","systematic_review","Karagiannis T","2012","Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.e1369","https://doi.org/10.1136/bmj.e1369","22411919","https://pubmed.ncbi.nlm.nih.gov/22411919/","https://www.bmj.com/content/bmj/344/bmj.e1369.full.pdf",null],["3","R0026965","R0026965.pdf","free_to_read","systematic_review","Best JH","2012","The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01533.x","https://doi.org/10.1111/j.1463-1326.2011.01533.x","22074017","https://pubmed.ncbi.nlm.nih.gov/22074017/",null,null],["3","R0027729","R0027729.pdf","open_download_failed","systematic_review","Gorter KJ","2012","Diabetes: glycaemic control in type 2 (drug treatments).","BMJ clinical evidence",null,null,"https://doi.org/","23862772","https://pubmed.ncbi.nlm.nih.gov/23862772/",null,null],["3","R0027933","R0027933.pdf","open_download_failed","systematic_review","Bennett WL","2012","AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2012.18.s1-a.1","https://doi.org/10.18553/jmcp.2012.18.s1-a.1","22313233","https://pubmed.ncbi.nlm.nih.gov/22313233/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2012.18.S1-A.1?download=true",null],["3","R0030957","R0030957.pdf","no_doi","systematic_review","Shi Lu-we","2012","Cardiovascular safety of antidiabetic agents including GLP-1 receptor agonist reviewed systematically by Network Meta-analysis","Chinese Journal of Evidence-Based Cardiovascular Medicine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032056","R0032056.pdf","no_doi","systematic_review","Louise Robinson","2012","For peer review only Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta- analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0032321","R0032321.pdf","no_doi","systematic_review","MONAMI, MATTEO","2012","Effects of\\nglucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","Florence Research (University of Florence)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036368","R0036368.pdf","no_doi","systematic_review","Arif Al-Attar, Delman Mohammed Raoof","2012","Effects of Liraglutide on body weight in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Queen Margaret University eTheses Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039504","R0039504.pdf","no_doi","systematic_review","Anonymous,","2012","Clinical Efficacy and Safety of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","Queen Margaret University eTheses Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0039802","R0039802.pdf","open_download_failed","systematic_review","Q. Ye","2012","PDB5 Efficacy and Safety of Liraglutide 1.2Mg and Exenatide 10Mcg Twice Daily in Type 2 Diabetes Mellitus: A Systemtic Review and Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2012.03.926","https://doi.org/10.1016/j.jval.2012.03.926",null,"https://pubmed.ncbi.nlm.nih.gov//","http://www.valueinhealthjournal.com/article/S1098301512009916/pdf",null],["3","R0044669","R0044669.pdf","free_to_read","systematic_review","J.J. Fadipe","2012","PRM40 Efficacy of Liraglutide Compared to Exenatide and Insulin Glargine in Patients With Diabetes Type 2: A Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2012.08.1504","https://doi.org/10.1016/j.jval.2012.08.1504",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2012.08.1504",null],["3","R0044737","R0044737.pdf","free_to_read","systematic_review","Qiuyan Ye","2012","PDB7 Efficacy and Safety of Liraglutide 1.2Mg Once Daily in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2012.03.928","https://doi.org/10.1016/j.jval.2012.03.928",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2012.03.928",null],["3","R0050367","R0050367.pdf","free_to_read","systematic_review","Jakob J. Langer","2012","PDB14 Assessing Treatment Success of Diabetes Therapies - Number Needed to Treat to Reach a Clinically Relevant Composite Endpoint: Using a Meta-Analysis of the Liraglutide Clinical Trial Program","Value in Health","Elsevier BV","10.1016/j.jval.2012.03.935","https://doi.org/10.1016/j.jval.2012.03.935",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2012.03.935",null],["3","R0018897","R0018897.pdf","open_download_failed","systematic_review","Shyangdan DS","2011","Glucagon-like peptide analogues for type 2 diabetes mellitus.","The Cochrane database of systematic reviews","Wiley","10.1002/14651858.cd006423.pub2","https://doi.org/10.1002/14651858.cd006423.pub2","21975753","https://pubmed.ncbi.nlm.nih.gov/21975753/","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006423.pub2/pdf/full",null],["3","R0027182","R0027182.pdf","open_download_failed","systematic_review","Shyangdan D","2011","Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.","Health technology assessment (Winchester, England)","National Institute for Health and Care Research","10.3310/hta15380","https://doi.org/10.3310/hta15380","22059955","https://pubmed.ncbi.nlm.nih.gov/22059955/","https://njl-admin.nihr.ac.uk/document/download/2002125",null],["3","R0036300","R0036300.pdf","no_doi","systematic_review","Henry RR","2011","Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.","IRIS Research product catalog (Sapienza University of Rome)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045017","R0045017.pdf","no_doi","systematic_review","Tang Yao","2011","Safety of exenatide for type 2 diabetes: a systematic review","Chinese Journal of Hospital Pharmacy",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0048108","R0048108.pdf","open_download_failed","systematic_review","Pooneh Salari","2011","No Superiority of Exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis","International Journal of Pharmacology","IMR Press","10.3923/ijp.2011.749.756","https://doi.org/10.3923/ijp.2011.749.756",null,"https://pubmed.ncbi.nlm.nih.gov//","https://scialert.net/qredirect.php?doi=ijp.2011.749.756&linkid=pdf",null],["3","R0016391","R0016391.pdf","open_download_failed","systematic_review","Li WX","2010","Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","Current therapeutic research, clinical and experimental","Elsevier BV","10.1016/j.curtheres.2010.08.003","https://doi.org/10.1016/j.curtheres.2010.08.003","24688145","https://pubmed.ncbi.nlm.nih.gov/24688145/","https://www.sciencedirect.com/science/article/pii/S0011393X10000640/pdf",null],["3","R0023176","R0023176.pdf","no_doi","systematic_review","Kleefstra N","2010","[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].","Nederlands tijdschrift voor geneeskunde",null,null,"https://doi.org/","20298625","https://pubmed.ncbi.nlm.nih.gov/20298625/",null,null],["3","R0025849","R0025849.pdf","free_to_read","systematic_review","Waugh N","2010","Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.","Health technology assessment (Winchester, England)","National Institute for Health and Care Research","10.3310/hta14360","https://doi.org/10.3310/hta14360","20646668","https://pubmed.ncbi.nlm.nih.gov/20646668/","https://doi.org/10.3310/hta14360",null],["3","R0027650","R0027650.pdf","free_to_read","systematic_review","Phung OJ","2010","Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.","JAMA","American Medical Association (AMA)","10.1001/jama.2010.405","https://doi.org/10.1001/jama.2010.405","20388897","https://pubmed.ncbi.nlm.nih.gov/20388897/",null,null],["3","R0034274","R0034274.pdf","no_doi","systematic_review","Jonathan T. Rowell","2010","Meta-Analysis of Exenatide, the Sitagliptin, and Pramlintide Compared to Placebo for Treatment of Type II Diabetes.","UA Campus Repository (The University of Arizona)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0038348","R0038348.pdf","no_doi","systematic_review","Alvaro Ramos","2010","A Systematic Review of Exenatide in Glycemic Control","CommonKnowledge Research Repository (Pacific University Oregon)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0045670","R0045670.pdf","no_doi","systematic_review","Tang Yao","2010","Systematic Review of Exenatide for Type 2 Diabetes","Zhongguo yaofang",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0047755","R0047755.pdf","no_doi","systematic_review","Matthew James Armstrong","2010","High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program","Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0051685","R0051685.pdf","no_doi","systematic_review","Matthew James Armstrong","2010","High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program","Diabetologia",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0014956","R0014956.pdf","free_to_read","systematic_review","Monami M","2009","Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-09-0101","https://doi.org/10.1530/eje-09-0101","19318378","https://pubmed.ncbi.nlm.nih.gov/19318378/","https://www.openaccessrepository.it/record/162322",null],["3","R0027378","R0027378.pdf","free_to_read","systematic_review","Pinelli NR","2008","Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1l198","https://doi.org/10.1345/aph.1l198","18957626","https://pubmed.ncbi.nlm.nih.gov/18957626/",null,null],["3","R0036405","R0036405.pdf","no_doi","systematic_review","Victoria Clifton",null,"Systematic review and consensus statement for the preoperative management of GLP 1 agonists","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036407","R0036407.pdf","no_doi","systematic_review","Areesha Moiz",null,"Efficacy and Safety of Once-Weekly Semaglutide Use for Weight Loss Among Patients without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0036453","R0036453.pdf","no_doi","systematic_review","Paschalis Karakasis",null,"Efficacy and safety of oral small-molecule GLP-1RAs in type 2 diabetes mellitus, obesity or both: A systematic review and meta-analysis","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0037115","R0037115.pdf","no_doi","systematic_review","González González, José Gerardo",null,"Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review","El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["3","R0040503","R0040503.pdf","no_doi","systematic_review","貴之 山田",null,"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000002","R0000002.pdf","paywalled","nonrandomized_study","Yeh KH","2026","Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2026.06.008","https://doi.org/10.1016/j.cgh.2026.06.008","42309434","https://pubmed.ncbi.nlm.nih.gov/42309434/",null,null],["4","R0000004","R0000004.pdf","paywalled","nonrandomized_study","Elgindi D","2026","Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.08.012","https://doi.org/10.1016/j.clindermatol.2026.08.012","42692277","https://pubmed.ncbi.nlm.nih.gov/42692277/",null,null],["4","R0000015","R0000015.pdf","paywalled","nonrandomized_study","Stump K","2026","Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched Analysis.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000002145","https://doi.org/10.1097/bsd.0000000000002145","42683541","https://pubmed.ncbi.nlm.nih.gov/42683541/",null,null],["4","R0000028","R0000028.pdf","paywalled","nonrandomized_study","Ammendolia I","2026","Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-026-05813-9","https://doi.org/10.1007/s00210-026-05813-9","42629417","https://pubmed.ncbi.nlm.nih.gov/42629417/",null,null],["4","R0000029","R0000029.pdf","paywalled","nonrandomized_study","Mateo-Kubach P","2026","Glucagon-like peptide-1 receptor agonist and post-operative opioid consumption in gynecologic surgery.","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","Elsevier BV","10.1016/j.ijgc.2026.104803","https://doi.org/10.1016/j.ijgc.2026.104803","42447684","https://pubmed.ncbi.nlm.nih.gov/42447684/",null,null],["4","R0000031","R0000031.pdf","paywalled","nonrandomized_study","Boukind A","2026","Abdominoplasty After Bariatric Surgery and GLP-1 Receptor Agonists: Independent vs Combined Complication Risks.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjaf244","https://doi.org/10.1093/asj/sjaf244","41403207","https://pubmed.ncbi.nlm.nih.gov/41403207/",null,null],["4","R0000039","R0000039.pdf","paywalled","nonrandomized_study","Liu TH","2026","Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71353","https://doi.org/10.1111/dom.71353","42736027","https://pubmed.ncbi.nlm.nih.gov/42736027/",null,null],["4","R0000053","R0000053.pdf","paywalled","nonrandomized_study","Miller LB","2026","Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usag316","https://doi.org/10.1093/milmed/usag316","42424303","https://pubmed.ncbi.nlm.nih.gov/42424303/",null,null],["4","R0000056","R0000056.pdf","paywalled","nonrandomized_study","Almukhadeb E","2026","Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.","International journal of dermatology","Wiley","10.1111/ijd.70346","https://doi.org/10.1111/ijd.70346","41729201","https://pubmed.ncbi.nlm.nih.gov/41729201/",null,null],["4","R0000058","R0000058.pdf","paywalled","nonrandomized_study","Cross-Najafi AA","2026","Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.","The Journal of surgical research","Elsevier BV","10.1016/j.jss.2026.08.047","https://doi.org/10.1016/j.jss.2026.08.047","42767161","https://pubmed.ncbi.nlm.nih.gov/42767161/",null,null],["4","R0000068","R0000068.pdf","paywalled","nonrandomized_study","Mirfakhraee S","2026","Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1.","Respiratory medicine","Elsevier BV","10.1016/j.rmed.2026.109137","https://doi.org/10.1016/j.rmed.2026.109137","42685881","https://pubmed.ncbi.nlm.nih.gov/42685881/",null,null],["4","R0000079","R0000079.pdf","paywalled","nonrandomized_study","Carlson K","2026","A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetes.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2726017","https://doi.org/10.1080/03007995.2026.2726017","42712138","https://pubmed.ncbi.nlm.nih.gov/42712138/",null,null],["4","R0000088","R0000088.pdf","paywalled","nonrandomized_study","Orandi BJ","2026","Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026.","Pediatrics","American Academy of Pediatrics (AAP)","10.1542/peds.2026-077048","https://doi.org/10.1542/peds.2026-077048","42692477","https://pubmed.ncbi.nlm.nih.gov/42692477/",null,null],["4","R0000103","R0000103.pdf","paywalled","nonrandomized_study","Kakkar AK","2026","Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70952","https://doi.org/10.1111/dom.70952","42259643","https://pubmed.ncbi.nlm.nih.gov/42259643/",null,null],["4","R0000110","R0000110.pdf","paywalled","nonrandomized_study","Wartko PD","2026","Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113504","https://doi.org/10.1016/j.diabres.2026.113504","42624330","https://pubmed.ncbi.nlm.nih.gov/42624330/",null,null],["4","R0000120","R0000120.pdf","paywalled","nonrandomized_study","Wang AL","2026","Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000002395","https://doi.org/10.1097/mcg.0000000000002395","42133868","https://pubmed.ncbi.nlm.nih.gov/42133868/",null,null],["4","R0000126","R0000126.pdf","paywalled","nonrandomized_study","Zhang T","2026","Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.","The international journal of lower extremity wounds","SAGE Publications","10.1177/15347346261487722","https://doi.org/10.1177/15347346261487722","42726083","https://pubmed.ncbi.nlm.nih.gov/42726083/",null,null],["4","R0000143","R0000143.pdf","paywalled","nonrandomized_study","Wright EE","2026","Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261489904","https://doi.org/10.1177/15209156261489904","42762166","https://pubmed.ncbi.nlm.nih.gov/42762166/",null,null],["4","R0000148","R0000148.pdf","paywalled","nonrandomized_study","Brooks JK","2026","Potential oral and maxillofacial adverse events associated with glucagon-like peptide-1 receptor agonist administration: a narrative review.","Quintessence international (Berlin, Germany : 1985)",null,"10.3290/j.qi.b7034788","https://doi.org/10.3290/j.qi.b7034788","42334501","https://pubmed.ncbi.nlm.nih.gov/42334501/",null,null],["4","R0000163","R0000163.pdf","paywalled","nonrandomized_study","Raghunathan R","2026","Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second \"epidemic\" of thyroid cancer overdiagnosis?","Surgery","Elsevier BV","10.1016/j.surg.2025.109868","https://doi.org/10.1016/j.surg.2025.109868","41371825","https://pubmed.ncbi.nlm.nih.gov/41371825/",null,null],["4","R0000175","R0000175.pdf","paywalled","nonrandomized_study","Kutler RB","2026","Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","Wiley","10.1002/ohn.70231","https://doi.org/10.1002/ohn.70231","41979383","https://pubmed.ncbi.nlm.nih.gov/41979383/",null,null],["4","R0000183","R0000183.pdf","paywalled","nonrandomized_study","Ali Akbar U","2026","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.05.004","https://doi.org/10.1016/j.amjcard.2026.05.004","42103200","https://pubmed.ncbi.nlm.nih.gov/42103200/",null,null],["4","R0000185","R0000185.pdf","paywalled","nonrandomized_study","Avram GM","2026","GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","Wiley","10.1002/ksa.70557","https://doi.org/10.1002/ksa.70557","42546112","https://pubmed.ncbi.nlm.nih.gov/42546112/",null,null],["4","R0000192","R0000192.pdf","paywalled","nonrandomized_study","Dong Z","2026","Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-026-13121-9","https://doi.org/10.1007/s00464-026-13121-9","42426387","https://pubmed.ncbi.nlm.nih.gov/42426387/",null,null],["4","R0000194","R0000194.pdf","paywalled","nonrandomized_study","Singh V","2026","Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000002396","https://doi.org/10.1097/mcg.0000000000002396","42183591","https://pubmed.ncbi.nlm.nih.gov/42183591/",null,null],["4","R0000195","R0000195.pdf","paywalled","nonrandomized_study","Lipska KJ","2026","Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-05216","https://doi.org/10.7326/annals-25-05216","42441965","https://pubmed.ncbi.nlm.nih.gov/42441965/",null,null],["4","R0000201","R0000201.pdf","paywalled","nonrandomized_study","Frey C","2026","Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.","Obstetrics and gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aog.0000000000006367","https://doi.org/10.1097/aog.0000000000006367","42424619","https://pubmed.ncbi.nlm.nih.gov/42424619/",null,null],["4","R0000203","R0000203.pdf","paywalled","nonrandomized_study","Hobai IA","2026","Coming full circle: could glucagon-like peptide-1 receptor agonists confer a net perioperative benefit?","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2025.10.003","https://doi.org/10.1016/j.bja.2025.10.003","41162254","https://pubmed.ncbi.nlm.nih.gov/41162254/",null,null],["4","R0000208","R0000208.pdf","paywalled","nonrandomized_study","Tu CY","2026","Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113573","https://doi.org/10.1016/j.diabres.2026.113573","42764072","https://pubmed.ncbi.nlm.nih.gov/42764072/",null,null],["4","R0000209","R0000209.pdf","paywalled","nonrandomized_study","Cathey JM","2026","Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture.","Injury","Elsevier BV","10.1016/j.injury.2026.113456","https://doi.org/10.1016/j.injury.2026.113456","42314528","https://pubmed.ncbi.nlm.nih.gov/42314528/",null,null],["4","R0000210","R0000210.pdf","paywalled","nonrandomized_study","Amiri A","2026","Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-026-01632-7","https://doi.org/10.1007/s11892-026-01632-7","42262435","https://pubmed.ncbi.nlm.nih.gov/42262435/",null,null],["4","R0000215","R0000215.pdf","paywalled","nonrandomized_study","Hyung B","2026","Perioperative Desaturation and Postoperative Nausea or Vomiting Requiring Antiemetic Administration in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Ambulatory Ophthalmic Surgery Under Mild-To-Moderate Sedation: A Large Retrospective Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70955","https://doi.org/10.1111/dom.70955","42259623","https://pubmed.ncbi.nlm.nih.gov/42259623/",null,null],["4","R0000219","R0000219.pdf","paywalled","nonrandomized_study","Joo JH","2026","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2025.12.014","https://doi.org/10.1016/j.oret.2025.12.014","41443408","https://pubmed.ncbi.nlm.nih.gov/41443408/",null,null],["4","R0000244","R0000244.pdf","paywalled","nonrandomized_study","Bitar ER","2026","Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.","Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","Elsevier BV","10.1016/j.gassur.2026.102497","https://doi.org/10.1016/j.gassur.2026.102497","42447648","https://pubmed.ncbi.nlm.nih.gov/42447648/",null,null],["4","R0000246","R0000246.pdf","paywalled","nonrandomized_study","Zheng YQ","2026","[Association between the initiation of glucagon-like peptide-1 receptor agonist use and the risk of incident diabetic retinopathy in patients with type 2 diabetes mellitus].","Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi",null,"10.3760/cma.j.cn112338-20260105-00013","https://doi.org/10.3760/cma.j.cn112338-20260105-00013","42618485","https://pubmed.ncbi.nlm.nih.gov/42618485/",null,null],["4","R0000252","R0000252.pdf","paywalled","nonrandomized_study","Oyewole SO","2026","Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study.","Oral surgery, oral medicine, oral pathology and oral radiology","Elsevier BV","10.1016/j.oooo.2026.06.002","https://doi.org/10.1016/j.oooo.2026.06.002","42463344","https://pubmed.ncbi.nlm.nih.gov/42463344/",null,null],["4","R0000257","R0000257.pdf","paywalled","nonrandomized_study","Alqinai B","2026","GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izag167","https://doi.org/10.1093/ibd/izag167","42627215","https://pubmed.ncbi.nlm.nih.gov/42627215/",null,null],["4","R0000262","R0000262.pdf","paywalled","nonrandomized_study","Bea S","2026","Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.","Diabetes care","American Diabetes Association","10.2337/dc26-0757","https://doi.org/10.2337/dc26-0757","42684335","https://pubmed.ncbi.nlm.nih.gov/42684335/",null,null],["4","R0000300","R0000300.pdf","paywalled","nonrandomized_study","Haidar L","2026","Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.","Current opinion in HIV and AIDS","Ovid Technologies (Wolters Kluwer Health)","10.1097/coh.0000000000001059","https://doi.org/10.1097/coh.0000000000001059","42467949","https://pubmed.ncbi.nlm.nih.gov/42467949/",null,null],["4","R0000308","R0000308.pdf","paywalled","nonrandomized_study","Badalian H","2026","GLP-1 Receptor Agonists in the Male Aesthetic Practice: Opportunities for the Dermatologic Surgeon.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005158","https://doi.org/10.1097/dss.0000000000005158","42210890","https://pubmed.ncbi.nlm.nih.gov/42210890/",null,null],["4","R0000312","R0000312.pdf","paywalled","nonrandomized_study","Lee JJ","2026","Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2026.08.029","https://doi.org/10.1016/j.oret.2026.08.029","42692107","https://pubmed.ncbi.nlm.nih.gov/42692107/",null,null],["4","R0000317","R0000317.pdf","paywalled","nonrandomized_study","Fat MN","2026","Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.9448","https://doi.org/10.36849/jdd.9448","41493256","https://pubmed.ncbi.nlm.nih.gov/41493256/",null,null],["4","R0000333","R0000333.pdf","paywalled","nonrandomized_study","Choi UE","2026","Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis.","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000006326","https://doi.org/10.1097/aln.0000000000006326","42585629","https://pubmed.ncbi.nlm.nih.gov/42585629/",null,null],["4","R0000380","R0000380.pdf","paywalled","nonrandomized_study","Basri T","2026","Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2026.07.014","https://doi.org/10.1016/j.mayocp.2026.07.014","42486225","https://pubmed.ncbi.nlm.nih.gov/42486225/",null,null],["4","R0000381","R0000381.pdf","paywalled","nonrandomized_study","DeCoster M","2026","Where the future lies: GLP-1 receptor agonists as therapeutics for dermatologic comorbidities.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.08.013","https://doi.org/10.1016/j.clindermatol.2026.08.013","42685919","https://pubmed.ncbi.nlm.nih.gov/42685919/",null,null],["4","R0000384","R0000384.pdf","paywalled","nonrandomized_study","Lishinsky-Fischer N","2026","Beyond Weight Loss: Association Between Glucagon-like peptide-1 Receptor Agonist Therapy and Incidence of Facial and Oculoplastic Procedures.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000013108","https://doi.org/10.1097/prs.0000000000013108","41945654","https://pubmed.ncbi.nlm.nih.gov/41945654/",null,null],["4","R0000398","R0000398.pdf","paywalled","nonrandomized_study","Zhang T","2026","Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study.","Nature metabolism","Springer Science and Business Media LLC","10.1038/s42255-026-01567-z","https://doi.org/10.1038/s42255-026-01567-z","42426287","https://pubmed.ncbi.nlm.nih.gov/42426287/",null,null],["4","R0000424","R0000424.pdf","paywalled","nonrandomized_study","Said J","2026","GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review.","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2026-0227","https://doi.org/10.1515/jpem-2026-0227","42732089","https://pubmed.ncbi.nlm.nih.gov/42732089/",null,null],["4","R0000425","R0000425.pdf","paywalled","nonrandomized_study","Hwang SY","2026","Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.","European journal of gastroenterology & hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/meg.0000000000003162","https://doi.org/10.1097/meg.0000000000003162","41784422","https://pubmed.ncbi.nlm.nih.gov/41784422/",null,null],["4","R0000437","R0000437.pdf","paywalled","nonrandomized_study","Pennycuff JE","2026","Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonist Receptor Agonists on Postoperative Pain Management in Patients Undergoing Cancer Surgery: A Retrospective Study.","Anesthesia and analgesia","Ovid Technologies (Wolters Kluwer Health)","10.1213/ane.0000000000007967","https://doi.org/10.1213/ane.0000000000007967","41698178","https://pubmed.ncbi.nlm.nih.gov/41698178/",null,null],["4","R0000440","R0000440.pdf","paywalled","nonrandomized_study","Liao KM","2026","Associations Between Glucagon-like Peptide-1 Receptor Agonists and Respiratory Outcomes in Chronic Obstructive pulmonary disease and Diabetes.","QJM : monthly journal of the Association of Physicians","Oxford University Press (OUP)","10.1093/qjmed/hcag217","https://doi.org/10.1093/qjmed/hcag217","42606949","https://pubmed.ncbi.nlm.nih.gov/42606949/",null,null],["4","R0000461","R0000461.pdf","paywalled","nonrandomized_study","DeParis SW","2026","Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2026.04.008","https://doi.org/10.1016/j.ophtha.2026.04.008","42132708","https://pubmed.ncbi.nlm.nih.gov/42132708/",null,null],["4","R0000470","R0000470.pdf","paywalled","nonrandomized_study","Horvit A","2026","Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index.","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","Elsevier BV","10.1016/j.jcf.2025.10.006","https://doi.org/10.1016/j.jcf.2025.10.006","41109836","https://pubmed.ncbi.nlm.nih.gov/41109836/",null,null],["4","R0000482","R0000482.pdf","paywalled","nonrandomized_study","Divya A","2026","Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study.","ASAIO journal (American Society for Artificial Internal Organs : 1992)","Ovid Technologies (Wolters Kluwer Health)","10.1097/mat.0000000000002804","https://doi.org/10.1097/mat.0000000000002804","42497207","https://pubmed.ncbi.nlm.nih.gov/42497207/",null,null],["4","R0000514","R0000514.pdf","paywalled","nonrandomized_study","Li L","2026","Signal thresholds and causal inference in pharmacovigilance studies of glucagon-like Peptide-1 receptor agonists.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2026.106731","https://doi.org/10.1016/j.clnu.2026.106731","42520369","https://pubmed.ncbi.nlm.nih.gov/42520369/",null,null],["4","R0000517","R0000517.pdf","paywalled","nonrandomized_study","Bridges AG","2026","Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.09.017","https://doi.org/10.1016/j.clindermatol.2026.09.017","42767469","https://pubmed.ncbi.nlm.nih.gov/42767469/",null,null],["4","R0000521","R0000521.pdf","paywalled","nonrandomized_study","Bridges AG","2026","GLP-1 receptor agonists in dermatology: Prescribing frameworks, access, and the emerging pipeline.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.09.018","https://doi.org/10.1016/j.clindermatol.2026.09.018","42777891","https://pubmed.ncbi.nlm.nih.gov/42777891/",null,null],["4","R0000528","R0000528.pdf","paywalled","nonrandomized_study","Ahmad O","2026","Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.134042","https://doi.org/10.1016/j.ijcard.2025.134042","41297711","https://pubmed.ncbi.nlm.nih.gov/41297711/",null,null],["4","R0000549","R0000549.pdf","paywalled","nonrandomized_study","Shah J","2026","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2026.04.021","https://doi.org/10.1016/j.ajo.2026.04.021","42025665","https://pubmed.ncbi.nlm.nih.gov/42025665/",null,null],["4","R0000556","R0000556.pdf","paywalled","nonrandomized_study","Kayali H","2026","Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Fusion Outcomes After First Metatarsophalangeal Arthrodesis in Patients With Type 2 Diabetes Mellitus.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-26-00153","https://doi.org/10.5435/jaaos-d-26-00153","42200664","https://pubmed.ncbi.nlm.nih.gov/42200664/",null,null],["4","R0000557","R0000557.pdf","paywalled","nonrandomized_study","Issaka Y","2026","Glucagon-Like Peptide-1 Receptor Agonists and Heart Failure Hospitalization in a Real-World Cardiometabolic Population.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.03.055","https://doi.org/10.1016/j.amjcard.2026.03.055","41895359","https://pubmed.ncbi.nlm.nih.gov/41895359/",null,null],["4","R0000588","R0000588.pdf","paywalled","nonrandomized_study","Khouri C","2026","Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.","American journal of respiratory and critical care medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag474","https://doi.org/10.1093/ajrccm/aamag474","42745463","https://pubmed.ncbi.nlm.nih.gov/42745463/",null,null],["4","R0000597","R0000597.pdf","paywalled","nonrandomized_study","Scannell C","2026","Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2026.89983","https://doi.org/10.37765/ajmc.2026.89983","42640207","https://pubmed.ncbi.nlm.nih.gov/42640207/",null,null],["4","R0000601","R0000601.pdf","paywalled","nonrandomized_study","Kuryłowicz A","2026","Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71226","https://doi.org/10.1111/dom.71226","42634284","https://pubmed.ncbi.nlm.nih.gov/42634284/",null,null],["4","R0000607","R0000607.pdf","paywalled","nonrandomized_study","Allan KC","2026","Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2025.10.020","https://doi.org/10.1016/j.oret.2025.10.020","41197713","https://pubmed.ncbi.nlm.nih.gov/41197713/",null,null],["4","R0000611","R0000611.pdf","paywalled","nonrandomized_study","Ueda P","2026","Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-02096","https://doi.org/10.7326/annals-25-02096","42441962","https://pubmed.ncbi.nlm.nih.gov/42441962/",null,null],["4","R0000627","R0000627.pdf","paywalled","nonrandomized_study","Wilson PR","2026","Glucagon-like peptide-1 receptor agonists and retained gastric contents on endoscopy: a prospective observational study.","Canadian journal of anaesthesia = Journal canadien d'anesthesie","Springer Science and Business Media LLC","10.1007/s12630-026-03186-4","https://doi.org/10.1007/s12630-026-03186-4","42618723","https://pubmed.ncbi.nlm.nih.gov/42618723/",null,null],["4","R0000640","R0000640.pdf","paywalled","nonrandomized_study","Ostrovsky D","2026","Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Incident Atrial Fibrillation in Type 2 Diabetes: A Population-Based Target Trial Emulation.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag478","https://doi.org/10.1093/eurjpc/zwag478","42700963","https://pubmed.ncbi.nlm.nih.gov/42700963/",null,null],["4","R0000643","R0000643.pdf","paywalled","nonrandomized_study","Vadini V","2026","Impact of GLP-1 Receptor Agonists on Bone Metabolism.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag323","https://doi.org/10.1210/clinem/dgag323","42563411","https://pubmed.ncbi.nlm.nih.gov/42563411/",null,null],["4","R0000646","R0000646.pdf","paywalled","nonrandomized_study","Kokura Y","2026","Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113404","https://doi.org/10.1016/j.diabres.2026.113404","42385946","https://pubmed.ncbi.nlm.nih.gov/42385946/",null,null],["4","R0000668","R0000668.pdf","paywalled","nonrandomized_study","Wada Y","2026","Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity.","Clinical and experimental nephrology","Springer Science and Business Media LLC","10.1007/s10157-026-02845-6","https://doi.org/10.1007/s10157-026-02845-6","41838277","https://pubmed.ncbi.nlm.nih.gov/41838277/",null,null],["4","R0000671","R0000671.pdf","paywalled","nonrandomized_study","Lev D","2026","Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2025.106571","https://doi.org/10.1016/j.clnu.2025.106571","41534460","https://pubmed.ncbi.nlm.nih.gov/41534460/",null,null],["4","R0000682","R0000682.pdf","paywalled","nonrandomized_study","Koshizaka M","2026","Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71209","https://doi.org/10.1111/dom.71209","42581431","https://pubmed.ncbi.nlm.nih.gov/42581431/",null,null],["4","R0000688","R0000688.pdf","paywalled","nonrandomized_study","Iglesias P","2026","Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04587-7","https://doi.org/10.1007/s12020-026-04587-7","41803337","https://pubmed.ncbi.nlm.nih.gov/41803337/",null,null],["4","R0000693","R0000693.pdf","paywalled","nonrandomized_study","Ramadan A","2026","Effect of glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors alone and in combination on AF recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation.","Heart rhythm","Elsevier BV","10.1016/j.hrthm.2026.09.018","https://doi.org/10.1016/j.hrthm.2026.09.018","42753998","https://pubmed.ncbi.nlm.nih.gov/42753998/",null,null],["4","R0000696","R0000696.pdf","paywalled","nonrandomized_study","Song BG","2026","Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101776","https://doi.org/10.1016/j.diabet.2026.101776","42349715","https://pubmed.ncbi.nlm.nih.gov/42349715/",null,null],["4","R0000708","R0000708.pdf","paywalled","nonrandomized_study","Cheng X","2026","Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-025-02712-3","https://doi.org/10.1007/s40618-025-02712-3","41021211","https://pubmed.ncbi.nlm.nih.gov/41021211/",null,null],["4","R0000712","R0000712.pdf","paywalled","nonrandomized_study","Motamedi S","2026","GLP-1 Receptor Agonists and Oral-Facial Aesthetics: The Intersection of Dentistry and Dermatologic Surgery.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005161","https://doi.org/10.1097/dss.0000000000005161","42210894","https://pubmed.ncbi.nlm.nih.gov/42210894/",null,null],["4","R0000717","R0000717.pdf","paywalled","nonrandomized_study","Debiec JC","2026","Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study.","Journal of neurointerventional surgery","BMJ","10.1136/jnis-2025-024139","https://doi.org/10.1136/jnis-2025-024139","40987589","https://pubmed.ncbi.nlm.nih.gov/40987589/",null,null],["4","R0000718","R0000718.pdf","paywalled","nonrandomized_study","Stump K","2026","Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes.","Hand surgery & rehabilitation","Elsevier BV","10.1016/j.hansur.2026.102589","https://doi.org/10.1016/j.hansur.2026.102589","41619807","https://pubmed.ncbi.nlm.nih.gov/41619807/",null,null],["4","R0000730","R0000730.pdf","paywalled","nonrandomized_study","Khadija HA","2026","Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101794","https://doi.org/10.1016/j.diabet.2026.101794","42785671","https://pubmed.ncbi.nlm.nih.gov/42785671/",null,null],["4","R0000745","R0000745.pdf","paywalled","nonrandomized_study","Singh N","2026","Comment on Puga et al. : Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study.","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","Elsevier BV","10.1016/j.jos.2026.03.010","https://doi.org/10.1016/j.jos.2026.03.010","42431801","https://pubmed.ncbi.nlm.nih.gov/42431801/",null,null],["4","R0000750","R0000750.pdf","paywalled","nonrandomized_study","Kwon S","2026","GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy.","Clinical genitourinary cancer","Elsevier BV","10.1016/j.clgc.2026.102630","https://doi.org/10.1016/j.clgc.2026.102630","42613293","https://pubmed.ncbi.nlm.nih.gov/42613293/",null,null],["4","R0000765","R0000765.pdf","paywalled","nonrandomized_study","Reynolds KR","2026","Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-00860","https://doi.org/10.7326/annals-25-00860","42441967","https://pubmed.ncbi.nlm.nih.gov/42441967/",null,null],["4","R0000772","R0000772.pdf","paywalled","nonrandomized_study","Yen FS","2026","Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156790","https://doi.org/10.1016/j.metabol.2026.156790","42810614","https://pubmed.ncbi.nlm.nih.gov/42810614/",null,null],["4","R0000776","R0000776.pdf","paywalled","nonrandomized_study","Lee H","2026","The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists.","Diabetes care","American Diabetes Association","10.2337/dc26-0662","https://doi.org/10.2337/dc26-0662","42561183","https://pubmed.ncbi.nlm.nih.gov/42561183/",null,null],["4","R0000796","R0000796.pdf","paywalled","nonrandomized_study","Wu HL","2026","Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: target trial emulation with active comparators. Response to Br J Anaesth 2026; 137: 877-8.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2026.06.055","https://doi.org/10.1016/j.bja.2026.06.055","42601296","https://pubmed.ncbi.nlm.nih.gov/42601296/",null,null],["4","R0000797","R0000797.pdf","paywalled","nonrandomized_study","Essibayi MA","2026","Commentary: Glucagon-Like Peptide-1 Receptor Agonists and Outcomes After Intracerebral Hemorrhage in Patients With Type 2 Diabetes: A Propensity-Matched Cohort Study.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000004122","https://doi.org/10.1227/neu.0000000000004122","42283470","https://pubmed.ncbi.nlm.nih.gov/42283470/",null,null],["4","R0000823","R0000823.pdf","paywalled","nonrandomized_study","Wang B","2026","Reassessing the role of GLP-1 receptor agonists in colorectal cancer Care.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101742","https://doi.org/10.1016/j.diabet.2026.101742","41698477","https://pubmed.ncbi.nlm.nih.gov/41698477/",null,null],["4","R0000828","R0000828.pdf","paywalled","nonrandomized_study","Noh Y","2026","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc25-2577","https://doi.org/10.2337/dc25-2577","41701611","https://pubmed.ncbi.nlm.nih.gov/41701611/",null,null],["4","R0000838","R0000838.pdf","paywalled","nonrandomized_study","Vemulapalli V","2026","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy.","American journal of clinical oncology","Ovid Technologies (Wolters Kluwer Health)","10.1097/coc.0000000000001358","https://doi.org/10.1097/coc.0000000000001358","42574286","https://pubmed.ncbi.nlm.nih.gov/42574286/",null,null],["4","R0000839","R0000839.pdf","paywalled","nonrandomized_study","Zayed MF","2026","An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/0113816128375766250720234005","https://doi.org/10.2174/0113816128375766250720234005","40798976","https://pubmed.ncbi.nlm.nih.gov/40798976/",null,null],["4","R0000846","R0000846.pdf","paywalled","nonrandomized_study","Gautam R","2026","Interpretable machine learning for rare events: an inverse probability weighted application to understanding glucagon-like peptide-1 receptor agonists use and incident alcohol-related disorder.","Alcohol and alcoholism (Oxford, Oxfordshire)","Oxford University Press (OUP)","10.1093/alcalc/agag045","https://doi.org/10.1093/alcalc/agag045","42322639","https://pubmed.ncbi.nlm.nih.gov/42322639/",null,null],["4","R0000854","R0000854.pdf","paywalled","nonrandomized_study","Puga T","2026","Reply to letter to the editor by Singh et al.","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","Elsevier BV","10.1016/j.jos.2026.06.008","https://doi.org/10.1016/j.jos.2026.06.008","42420094","https://pubmed.ncbi.nlm.nih.gov/42420094/",null,null],["4","R0000864","R0000864.pdf","paywalled","nonrandomized_study","Hanke CW","2026","Commentary: Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005173","https://doi.org/10.1097/dss.0000000000005173","42210893","https://pubmed.ncbi.nlm.nih.gov/42210893/",null,null],["4","R0000874","R0000874.pdf","paywalled","nonrandomized_study","Diab AR","2026","Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort study.","Hip international : the journal of clinical and experimental research on hip pathology and therapy","SAGE Publications","10.1177/11207000261476202","https://doi.org/10.1177/11207000261476202","42725550","https://pubmed.ncbi.nlm.nih.gov/42725550/",null,null],["4","R0000898","R0000898.pdf","paywalled","nonrandomized_study","Wyles S","2026","Reduced Epidermal p21 Expression Is Identified in Some Subjects on Systemic GLP-1 Receptor Agonists: A Hypothesis-Generating Pilot Study of Metabolic Modulation in Human Skin Senescence.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005186","https://doi.org/10.1097/dss.0000000000005186","42210884","https://pubmed.ncbi.nlm.nih.gov/42210884/",null,null],["4","R0000900","R0000900.pdf","paywalled","nonrandomized_study","Abbas MT","2026","The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","Elsevier BV","10.1016/j.healun.2026.01.003","https://doi.org/10.1016/j.healun.2026.01.003","41520801","https://pubmed.ncbi.nlm.nih.gov/41520801/",null,null],["4","R0000910","R0000910.pdf","paywalled","nonrandomized_study","Tawfik F","2026","GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.","Journal of neurology","Springer Science and Business Media LLC","10.1007/s00415-026-14127-y","https://doi.org/10.1007/s00415-026-14127-y","42704495","https://pubmed.ncbi.nlm.nih.gov/42704495/",null,null],["4","R0000926","R0000926.pdf","paywalled","nonrandomized_study","Kazi MAI","2026","Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network.","Journal of gastrointestinal cancer","Springer Science and Business Media LLC","10.1007/s12029-026-01523-w","https://doi.org/10.1007/s12029-026-01523-w","42745130","https://pubmed.ncbi.nlm.nih.gov/42745130/",null,null],["4","R0000930","R0000930.pdf","paywalled","nonrandomized_study","Jeon M","2026","Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113091","https://doi.org/10.1016/j.diabres.2026.113091","41513044","https://pubmed.ncbi.nlm.nih.gov/41513044/",null,null],["4","R0000942","R0000942.pdf","paywalled","nonrandomized_study","Tribhuvan M","2026","Comment on \"Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis\".","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-026-05217-x","https://doi.org/10.1007/s11255-026-05217-x","42189463","https://pubmed.ncbi.nlm.nih.gov/42189463/",null,null],["4","R0000951","R0000951.pdf","paywalled","nonrandomized_study","Rapp H","2026","Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2026.32.10.1167","https://doi.org/10.18553/jmcp.2026.32.10.1167","42808548","https://pubmed.ncbi.nlm.nih.gov/42808548/",null,null],["4","R0000952","R0000952.pdf","paywalled","nonrandomized_study","Atencia Goñi J","2026","Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated With Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Experience.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.09.005","https://doi.org/10.1016/j.eprac.2026.09.005","42762981","https://pubmed.ncbi.nlm.nih.gov/42762981/",null,null],["4","R0000971","R0000971.pdf","paywalled","nonrandomized_study","Mousavi T","2026","Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy.","Expert opinion on drug metabolism & toxicology","Informa UK Limited","10.1080/17425255.2026.2729203","https://doi.org/10.1080/17425255.2026.2729203","42709045","https://pubmed.ncbi.nlm.nih.gov/42709045/",null,null],["4","R0000977","R0000977.pdf","paywalled","nonrandomized_study","Kuo KC","2026","Sepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies.","Expert review of respiratory medicine","Informa UK Limited","10.1080/17476348.2026.2713233","https://doi.org/10.1080/17476348.2026.2713233","42543031","https://pubmed.ncbi.nlm.nih.gov/42543031/",null,null],["4","R0000982","R0000982.pdf","paywalled","nonrandomized_study","Javaid SS","2026","GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.06.008","https://doi.org/10.1016/j.amjcard.2026.06.008","42264283","https://pubmed.ncbi.nlm.nih.gov/42264283/",null,null],["4","R0000990","R0000990.pdf","paywalled","nonrandomized_study","Weitzner AS","2026","Perioperative and Renal Outcomes After Nephrectomy in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists: A Pilot Study.","Urology practice","Ovid Technologies (Wolters Kluwer Health)","10.1097/upj.0000000000001007","https://doi.org/10.1097/upj.0000000000001007","41886402","https://pubmed.ncbi.nlm.nih.gov/41886402/",null,null],["4","R0000991","R0000991.pdf","paywalled","nonrandomized_study","Malka RE","2026","GLP-1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis.","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","Wiley","10.1002/ohn.70327","https://doi.org/10.1002/ohn.70327","42405847","https://pubmed.ncbi.nlm.nih.gov/42405847/",null,null],["4","R0000994","R0000994.pdf","paywalled","nonrandomized_study","Dotan I","2026","GLP-1 Receptor Agonist Exposure and Malignancy Risk in Patients With Endogenous Cushing's Syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag223","https://doi.org/10.1210/clinem/dgag223","42233686","https://pubmed.ncbi.nlm.nih.gov/42233686/",null,null],["4","R0001005","R0001005.pdf","paywalled","nonrandomized_study","Park MJ","2026","Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag086","https://doi.org/10.1093/ajhp/zxag086","41870187","https://pubmed.ncbi.nlm.nih.gov/41870187/",null,null],["4","R0001013","R0001013.pdf","paywalled","nonrandomized_study","Lee WT","2026","GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag032","https://doi.org/10.1093/ndt/gfag032","41697144","https://pubmed.ncbi.nlm.nih.gov/41697144/",null,null],["4","R0001014","R0001014.pdf","paywalled","nonrandomized_study","Lakhani DA","2026","Association of GLP-1 receptor agonist use with long-term outcomes in patients with opioid use disorder.","Journal of addictive diseases","Informa UK Limited","10.1080/10550887.2026.2653228","https://doi.org/10.1080/10550887.2026.2653228","42116696","https://pubmed.ncbi.nlm.nih.gov/42116696/",null,null],["4","R0001023","R0001023.pdf","paywalled","nonrandomized_study","Mahmoud AK","2026","GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2026.134588","https://doi.org/10.1016/j.ijcard.2026.134588","42203003","https://pubmed.ncbi.nlm.nih.gov/42203003/",null,null],["4","R0001033","R0001033.pdf","paywalled","nonrandomized_study","Urbina J","2026","Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.","Clinical obesity","Wiley","10.1111/cob.70070","https://doi.org/10.1111/cob.70070","41549912","https://pubmed.ncbi.nlm.nih.gov/41549912/",null,null],["4","R0001042","R0001042.pdf","paywalled","nonrandomized_study","Ruchika F","2026","Glucagon-Like Peptide-1 Receptor Agonists and Outcomes After Intracerebral Hemorrhage in Patients With Type 2 Diabetes: A Propensity-Matched Cohort Study.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000004079","https://doi.org/10.1227/neu.0000000000004079","42084373","https://pubmed.ncbi.nlm.nih.gov/42084373/",null,null],["4","R0001077","R0001077.pdf","paywalled","nonrandomized_study","Tseng TC","2026","Prior GLP-1RA or tirzepatide use and early cardiorenal outcomes after metabolic and bariatric surgery.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2026.09.010","https://doi.org/10.1016/j.amjmed.2026.09.010","42735883","https://pubmed.ncbi.nlm.nih.gov/42735883/",null,null],["4","R0001089","R0001089.pdf","paywalled","nonrandomized_study","Albanese R","2026","Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-06232-0","https://doi.org/10.1007/s00266-026-06232-0","42716982","https://pubmed.ncbi.nlm.nih.gov/42716982/",null,null],["4","R0001090","R0001090.pdf","paywalled","nonrandomized_study","Hundal J","2026","Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications.","JCO oncology practice","American Society of Clinical Oncology (ASCO)","10.1200/op-26-00061","https://doi.org/10.1200/op-26-00061","42385128","https://pubmed.ncbi.nlm.nih.gov/42385128/",null,null],["4","R0001095","R0001095.pdf","paywalled","nonrandomized_study","DI Marzio B","2026","Impact of hypoglycemic agents on glycemic control and cognitive decline in older adults with type 2 diabetes: real-world evidence on glucagon like peptide 1 receptor agonists.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.26.04501-x","https://doi.org/10.23736/s2724-6507.26.04501-x","41925713","https://pubmed.ncbi.nlm.nih.gov/41925713/",null,null],["4","R0001099","R0001099.pdf","paywalled","nonrandomized_study","Oates PL","2026","Glucagon Like Peptide-1 Receptor Agonist Use Not Related With Gastric Volume After Preoperative Fasting: A Prospective Observational Study.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usaf510","https://doi.org/10.1093/milmed/usaf510","41168658","https://pubmed.ncbi.nlm.nih.gov/41168658/",null,null],["4","R0001111","R0001111.pdf","paywalled","nonrandomized_study","Kasher Meron M","2026","GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag056","https://doi.org/10.1210/clinem/dgag056","41665888","https://pubmed.ncbi.nlm.nih.gov/41665888/",null,null],["4","R0001116","R0001116.pdf","paywalled","nonrandomized_study","Collier M","2026","Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a French nationwide population-based study.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-026-06882-4","https://doi.org/10.1007/s00125-026-06882-4","42809004","https://pubmed.ncbi.nlm.nih.gov/42809004/",null,null],["4","R0001118","R0001118.pdf","paywalled","nonrandomized_study","Robertson CM","2026","Cup-To-Disc Ratio in Glucagon-Like Peptide 1 Receptor Agonist-Associated Nonarteritic Anterior Ischemic Optic Neuropathy.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2026.07.036","https://doi.org/10.1016/j.ophtha.2026.07.036","42556433","https://pubmed.ncbi.nlm.nih.gov/42556433/",null,null],["4","R0001133","R0001133.pdf","paywalled","nonrandomized_study","Pomenti S","2026","Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70450","https://doi.org/10.1111/apt.70450","41215723","https://pubmed.ncbi.nlm.nih.gov/41215723/",null,null],["4","R0001141","R0001141.pdf","paywalled","nonrandomized_study","Sundar Sah S","2026","Comment on \"Exploratory real-world experience with glucagon-like peptide 1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study\".","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2025-0664","https://doi.org/10.1515/jpem-2025-0664","42034966","https://pubmed.ncbi.nlm.nih.gov/42034966/",null,null],["4","R0001162","R0001162.pdf","paywalled","nonrandomized_study","Sardana S","2026","GLP-1 receptor agonist use and aspiration pneumonia risk following endovascular thrombectomy.","Journal of neurointerventional surgery","BMJ","10.1136/jnis-2026-025486","https://doi.org/10.1136/jnis-2026-025486","42248677","https://pubmed.ncbi.nlm.nih.gov/42248677/",null,null],["4","R0001183","R0001183.pdf","paywalled","nonrandomized_study","Gougol A","2026","Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70596","https://doi.org/10.1111/apt.70596","41813606","https://pubmed.ncbi.nlm.nih.gov/41813606/",null,null],["4","R0001205","R0001205.pdf","paywalled","nonrandomized_study","Desai A","2026","Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izaf301","https://doi.org/10.1093/ibd/izaf301","41365321","https://pubmed.ncbi.nlm.nih.gov/41365321/",null,null],["4","R0001206","R0001206.pdf","paywalled","nonrandomized_study","Shabanowitz S","2026","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients.","Pharmacotherapy","Wiley","10.1002/phar.70123","https://doi.org/10.1002/phar.70123","41800749","https://pubmed.ncbi.nlm.nih.gov/41800749/",null,null],["4","R0001212","R0001212.pdf","paywalled","nonrandomized_study","Costa M","2026","Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study.","Journal of neurosurgery","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2025.5.jns25786","https://doi.org/10.3171/2025.5.jns25786","41043189","https://pubmed.ncbi.nlm.nih.gov/41043189/",null,null],["4","R0001213","R0001213.pdf","paywalled","nonrandomized_study","Singh A","2026","Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis.","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","Elsevier BV","10.1016/j.jcf.2026.05.009","https://doi.org/10.1016/j.jcf.2026.05.009","42151007","https://pubmed.ncbi.nlm.nih.gov/42151007/",null,null],["4","R0001226","R0001226.pdf","paywalled","nonrandomized_study","Gallagher M","2026","Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis.","Journal of robotic surgery","Springer Science and Business Media LLC","10.1007/s11701-026-03454-x","https://doi.org/10.1007/s11701-026-03454-x","42213238","https://pubmed.ncbi.nlm.nih.gov/42213238/",null,null],["4","R0001230","R0001230.pdf","paywalled","nonrandomized_study","Mansory EM","2026","Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/0115748863468899260323094036","https://doi.org/10.2174/0115748863468899260323094036","42227478","https://pubmed.ncbi.nlm.nih.gov/42227478/",null,null],["4","R0001235","R0001235.pdf","paywalled","nonrandomized_study","Hoying D","2026","Assessing the Impact of GLP-1R Agonists in Post-sinus Surgery Management.","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","Wiley","10.1002/ohn.70072","https://doi.org/10.1002/ohn.70072","41353729","https://pubmed.ncbi.nlm.nih.gov/41353729/",null,null],["4","R0001240","R0001240.pdf","paywalled","nonrandomized_study","Islam MM","2026","Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113346","https://doi.org/10.1016/j.diabres.2026.113346","42214559","https://pubmed.ncbi.nlm.nih.gov/42214559/",null,null],["4","R0001271","R0001271.pdf","paywalled","nonrandomized_study","Ohyama K","2026","Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.","International journal of clinical pharmacology and therapeutics","Dustri-Verlag Dr. Karl Feistle","10.5414/cp204789","https://doi.org/10.5414/cp204789","41122011","https://pubmed.ncbi.nlm.nih.gov/41122011/",null,null],["4","R0001277","R0001277.pdf","paywalled","nonrandomized_study","Calvo Arbeloa M","2026","Semaglutide-associated agranulocytosis requiring hospitalisation and granulocyte colony-stimulating factor: a case report.","European journal of hospital pharmacy : science and practice","BMJ","10.1136/ejhpharm-2026-005049","https://doi.org/10.1136/ejhpharm-2026-005049","42638077","https://pubmed.ncbi.nlm.nih.gov/42638077/",null,null],["4","R0001281","R0001281.pdf","paywalled","nonrandomized_study","Hong AT","2026","Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2026.02.002","https://doi.org/10.1016/j.oret.2026.02.002","41655764","https://pubmed.ncbi.nlm.nih.gov/41655764/",null,null],["4","R0001286","R0001286.pdf","paywalled","nonrandomized_study","Li SY","2026","GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study.","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","Elsevier BV","10.1016/j.jocn.2026.111905","https://doi.org/10.1016/j.jocn.2026.111905","41671787","https://pubmed.ncbi.nlm.nih.gov/41671787/",null,null],["4","R0001287","R0001287.pdf","paywalled","nonrandomized_study","Ukita K","2026","Comparative cardiovascular outcomes of GLP-1 receptor agonists vs. SGLT2 inhibitors in type 2 diabetes: a large-scale real-world cohort analysis.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-026-02970-y","https://doi.org/10.1007/s00392-026-02970-y","42307748","https://pubmed.ncbi.nlm.nih.gov/42307748/",null,null],["4","R0001293","R0001293.pdf","paywalled","nonrandomized_study","Kelleher S","2026","Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study.","Clinical neurology and neurosurgery","Elsevier BV","10.1016/j.clineuro.2026.109372","https://doi.org/10.1016/j.clineuro.2026.109372","41832796","https://pubmed.ncbi.nlm.nih.gov/41832796/",null,null],["4","R0001299","R0001299.pdf","paywalled","nonrandomized_study","Ghusn W","2026","Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000007064","https://doi.org/10.1097/sla.0000000000007064","42002851","https://pubmed.ncbi.nlm.nih.gov/42002851/",null,null],["4","R0001314","R0001314.pdf","paywalled","nonrandomized_study","Marzook FA","2026","Preoperative Use of GLP-1 Receptor Agonists Is Associated With Reduced Risk of Postoperative DVT and Mortality in Patients Undergoing Lumbar Laminectomy.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000002113","https://doi.org/10.1097/bsd.0000000000002113","42397280","https://pubmed.ncbi.nlm.nih.gov/42397280/",null,null],["4","R0001339","R0001339.pdf","paywalled","nonrandomized_study","Teke E","2026","Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08698-y","https://doi.org/10.1007/s11695-026-08698-y","42026424","https://pubmed.ncbi.nlm.nih.gov/42026424/",null,null],["4","R0001345","R0001345.pdf","paywalled","nonrandomized_study","Banerjee M","2026","Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70853","https://doi.org/10.1111/dom.70853","42098901","https://pubmed.ncbi.nlm.nih.gov/42098901/",null,null],["4","R0001361","R0001361.pdf","paywalled","nonrandomized_study","Pinto LF","2026","GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications.","Seizure","Elsevier BV","10.1016/j.seizure.2026.05.013","https://doi.org/10.1016/j.seizure.2026.05.013","42202441","https://pubmed.ncbi.nlm.nih.gov/42202441/",null,null],["4","R0001367","R0001367.pdf","paywalled","nonrandomized_study","Baur AJ","2026","Preoperative GLP-1 receptor agonist use is not associated with increased risk of pseudoarthrosis following midfoot fusion: a propensity-matched analysis.","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2026.05.015","https://doi.org/10.1053/j.jfas.2026.05.015","42217565","https://pubmed.ncbi.nlm.nih.gov/42217565/",null,null],["4","R0001382","R0001382.pdf","paywalled","nonrandomized_study","Dao MQ","2026","Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.","Burns : journal of the International Society for Burn Injuries","Elsevier BV","10.1016/j.burns.2025.107848","https://doi.org/10.1016/j.burns.2025.107848","41581262","https://pubmed.ncbi.nlm.nih.gov/41581262/",null,null],["4","R0001386","R0001386.pdf","paywalled","nonrandomized_study","Kristensen FPB","2026","Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease : An Emulated Target Trial.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-01262","https://doi.org/10.7326/annals-25-01262","41490509","https://pubmed.ncbi.nlm.nih.gov/41490509/",null,null],["4","R0001395","R0001395.pdf","paywalled","nonrandomized_study","El Khatib O","2026","Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","Baskent University","10.6002/ect.2025.0180","https://doi.org/10.6002/ect.2025.0180","41808646","https://pubmed.ncbi.nlm.nih.gov/41808646/",null,null],["4","R0001404","R0001404.pdf","paywalled","nonrandomized_study","Sisodia A","2026","Predicting GLP-1 Discontinuation From Pharmacy Claims.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2026.89993","https://doi.org/10.37765/ajmc.2026.89993","42663544","https://pubmed.ncbi.nlm.nih.gov/42663544/",null,"ClinicalTrials.gov:NCT03574597"],["4","R0001418","R0001418.pdf","paywalled","nonrandomized_study","Zaher A","2026","A Retrospective Analysis of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation Efficacy in Colonoscopies.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001964","https://doi.org/10.1097/mjt.0000000000001964","41505167","https://pubmed.ncbi.nlm.nih.gov/41505167/",null,null],["4","R0001419","R0001419.pdf","paywalled","nonrandomized_study","Ovsak GG","2026","Managing patients taking glucagon-like peptide-1 receptor agonists: proceed with caution.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2025.10.004","https://doi.org/10.1016/j.bja.2025.10.004","41162256","https://pubmed.ncbi.nlm.nih.gov/41162256/",null,null],["4","R0001427","R0001427.pdf","paywalled","nonrandomized_study","Feghali J","2026","Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.125.053599","https://doi.org/10.1161/strokeaha.125.053599","41492776","https://pubmed.ncbi.nlm.nih.gov/41492776/",null,null],["4","R0001449","R0001449.pdf","paywalled","nonrandomized_study","Den J","2026","GLP-1 Receptor Agonists versus Bariatric Surgery in Breast Cancer: A Comparative Study of Oncologic Outcomes.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000007121","https://doi.org/10.1097/sla.0000000000007121","42298328","https://pubmed.ncbi.nlm.nih.gov/42298328/",null,null],["4","R0001473","R0001473.pdf","paywalled","nonrandomized_study","Barkmeier AJ","2026","Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2025.07.019","https://doi.org/10.1016/j.oret.2025.07.019","40774571","https://pubmed.ncbi.nlm.nih.gov/40774571/",null,null],["4","R0001481","R0001481.pdf","paywalled","nonrandomized_study","Rajan T","2026","History of GLP-1 receptor agonists confer no improvement for Achilles tendon repairs: A national, propensity-matched comparison.","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2026.05.005","https://doi.org/10.1053/j.jfas.2026.05.005","42128170","https://pubmed.ncbi.nlm.nih.gov/42128170/",null,null],["4","R0001497","R0001497.pdf","paywalled","nonrandomized_study","Panou T","2026","Retatrutide in type 2 diabetes mellitus and obesity: an overview.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2026.2642415","https://doi.org/10.1080/17512433.2026.2642415","41785010","https://pubmed.ncbi.nlm.nih.gov/41785010/",null,null],["4","R0001498","R0001498.pdf","paywalled","nonrandomized_study","van Klei WA","2026","Risk of periprocedural regurgitation of gastric contents in patients on glucagon-like peptide-1 receptor agonists: a two-centre nested case-control study.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2025.12.033","https://doi.org/10.1016/j.bja.2025.12.033","41547617","https://pubmed.ncbi.nlm.nih.gov/41547617/",null,null],["4","R0001504","R0001504.pdf","paywalled","nonrandomized_study","Benavidez MC","2026","Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.09.010","https://doi.org/10.1016/j.soard.2025.09.010","41162242","https://pubmed.ncbi.nlm.nih.gov/41162242/",null,null],["4","R0001520","R0001520.pdf","paywalled","nonrandomized_study","Wang R","2026","Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005773","https://doi.org/10.1097/brs.0000000000005773","42348793","https://pubmed.ncbi.nlm.nih.gov/42348793/",null,null],["4","R0001538","R0001538.pdf","paywalled","nonrandomized_study","Jain H","2026","Glucagon-like Peptide-1 Receptor Agonist Use and Outcomes in Peripartum Cardiomyopathy: A Propensity-Score Matched Analysis.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2025.12.047","https://doi.org/10.1016/j.cjca.2025.12.047","41482149","https://pubmed.ncbi.nlm.nih.gov/41482149/",null,null],["4","R0001550","R0001550.pdf","paywalled","nonrandomized_study","Lemas DJ","2026","Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70221","https://doi.org/10.1002/oby.70221","42120704","https://pubmed.ncbi.nlm.nih.gov/42120704/",null,null],["4","R0001558","R0001558.pdf","paywalled","nonrandomized_study","Chu C","2026","Use of Second-line Diabetes Mellitus Medications and Adverse Events Among Older Adults After the Introduction of Glucagon-like Peptide-1 Receptor Agonists in Ontario, Canada: A Retrospective Cohort Study.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2025.12.009","https://doi.org/10.1016/j.jcjd.2025.12.009","41418910","https://pubmed.ncbi.nlm.nih.gov/41418910/",null,null],["4","R0001561","R0001561.pdf","paywalled","nonrandomized_study","Khalil I","2026","Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score-Matched Real-World Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.03.009","https://doi.org/10.1016/j.eprac.2026.03.009","41895690","https://pubmed.ncbi.nlm.nih.gov/41895690/",null,null],["4","R0001579","R0001579.pdf","paywalled","nonrandomized_study","Muayad J","2026","Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease.","Ophthalmic plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/iop.0000000000003222","https://doi.org/10.1097/iop.0000000000003222","41949435","https://pubmed.ncbi.nlm.nih.gov/41949435/",null,null],["4","R0001584","R0001584.pdf","paywalled","nonrandomized_study","Pan SY","2026","GLP-1 receptor agonists and age-related macular degeneration risk in diabetes or non-diabetic obesity: A retrospective cohort study.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2026.06.023","https://doi.org/10.1016/j.amjmed.2026.06.023","42379510","https://pubmed.ncbi.nlm.nih.gov/42379510/",null,null],["4","R0001585","R0001585.pdf","paywalled","nonrandomized_study","Liang J","2026","Trends in preoperative weight loss modalities among patients receiving body contouring surgery.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.08.008","https://doi.org/10.1016/j.soard.2026.08.008","42686475","https://pubmed.ncbi.nlm.nih.gov/42686475/",null,null],["4","R0001599","R0001599.pdf","paywalled","nonrandomized_study","Ha J","2026","GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.","Journal of reconstructive microsurgery","Georg Thieme Verlag KG","10.1055/a-2858-3774","https://doi.org/10.1055/a-2858-3774","42013898","https://pubmed.ncbi.nlm.nih.gov/42013898/",null,null],["4","R0001604","R0001604.pdf","paywalled","nonrandomized_study","Liu TH","2026","Effectiveness of GLP-1RA vs metformin for diabetes prevention in antipsychotic-treated patients.","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Elsevier BV","10.1016/j.euroneuro.2026.112853","https://doi.org/10.1016/j.euroneuro.2026.112853","42068648","https://pubmed.ncbi.nlm.nih.gov/42068648/",null,null],["4","R0001608","R0001608.pdf","paywalled","nonrandomized_study","Islam Z","2026","Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Reduced Disease Severity and Pain in Hidradenitis Suppurativa: A Retrospective Study.","International journal of dermatology","Wiley","10.1111/ijd.70191","https://doi.org/10.1111/ijd.70191","41366828","https://pubmed.ncbi.nlm.nih.gov/41366828/",null,null],["4","R0001619","R0001619.pdf","paywalled","nonrandomized_study","Olbrich H","2026","Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.","The British journal of dermatology","Oxford University Press (OUP)","10.1093/bjd/ljaf346","https://doi.org/10.1093/bjd/ljaf346","40897378","https://pubmed.ncbi.nlm.nih.gov/40897378/",null,null],["4","R0001630","R0001630.pdf","paywalled","nonrandomized_study","Salameh A","2026","Cannabis use and cardiovascular, renal, and mortality outcomes in patients with type 2 diabetes receiving GLP-1 receptor agonists: A propensity score-matched cohort study.","Drug and alcohol dependence","Elsevier BV","10.1016/j.drugalcdep.2026.113296","https://doi.org/10.1016/j.drugalcdep.2026.113296","42546368","https://pubmed.ncbi.nlm.nih.gov/42546368/",null,null],["4","R0001636","R0001636.pdf","paywalled","nonrandomized_study","Jurin I","2026","GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry.","Cardiology","S. Karger AG","10.1159/000551964","https://doi.org/10.1159/000551964","41979990","https://pubmed.ncbi.nlm.nih.gov/41979990/",null,null],["4","R0001649","R0001649.pdf","paywalled","nonrandomized_study","Hung CH","2026","Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.05.010","https://doi.org/10.1016/j.eprac.2026.05.010","42142623","https://pubmed.ncbi.nlm.nih.gov/42142623/",null,null],["4","R0001652","R0001652.pdf","paywalled","nonrandomized_study","Hernández-Pérez JG","2026","GLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag197","https://doi.org/10.1093/ndt/gfag197","42644757","https://pubmed.ncbi.nlm.nih.gov/42644757/",null,null],["4","R0001655","R0001655.pdf","paywalled","nonrandomized_study","Abughazaleh S","2026","Impact of GLP-1 Receptor Agonist on Atrial Fibrillation Recurrence After Catheter Ablation in Non-Obese Patients.","Pacing and clinical electrophysiology : PACE","Wiley","10.1111/pace.70317","https://doi.org/10.1111/pace.70317","42261786","https://pubmed.ncbi.nlm.nih.gov/42261786/",null,null],["4","R0001691","R0001691.pdf","paywalled","nonrandomized_study","Tepetes NI","2026","Improved Survival With Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000002139","https://doi.org/10.1097/mjt.0000000000002139","42090713","https://pubmed.ncbi.nlm.nih.gov/42090713/",null,null],["4","R0001704","R0001704.pdf","paywalled","nonrandomized_study","Yang CC","2026","Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113206","https://doi.org/10.1016/j.diabres.2026.113206","41802676","https://pubmed.ncbi.nlm.nih.gov/41802676/",null,null],["4","R0001712","R0001712.pdf","paywalled","nonrandomized_study","Fan Y","2026","Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71313","https://doi.org/10.1111/dom.71313","42712110","https://pubmed.ncbi.nlm.nih.gov/42712110/",null,null],["4","R0001744","R0001744.pdf","paywalled","nonrandomized_study","Seika P","2026","Glucagon-like Peptide-1 Receptor Agonists Are Associated With a Lower Risk of Peptic Ulcer Disease: A Nationwide Cohort Study.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2025.08.015","https://doi.org/10.1016/j.cgh.2025.08.015","40865627","https://pubmed.ncbi.nlm.nih.gov/40865627/",null,null],["4","R0001774","R0001774.pdf","paywalled","nonrandomized_study","Rai C","2026","Association of GLP-1 receptor agonists with post-operative outcomes after achilles tendon repair in obese patients.","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2026.02.007","https://doi.org/10.1053/j.jfas.2026.02.007","41690504","https://pubmed.ncbi.nlm.nih.gov/41690504/",null,null],["4","R0001787","R0001787.pdf","paywalled","nonrandomized_study","Niu C","2026","Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003760","https://doi.org/10.14309/ajg.0000000000003760","40900093","https://pubmed.ncbi.nlm.nih.gov/40900093/",null,null],["4","R0001795","R0001795.pdf","paywalled","nonrandomized_study","Hussain T","2026","Association of GLP-1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70867","https://doi.org/10.1111/dom.70867","42150869","https://pubmed.ncbi.nlm.nih.gov/42150869/",null,null],["4","R0001814","R0001814.pdf","paywalled","nonrandomized_study","Mendez-Pino L","2026","Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study.","Canadian journal of anaesthesia = Journal canadien d'anesthesie","Springer Science and Business Media LLC","10.1007/s12630-026-03187-3","https://doi.org/10.1007/s12630-026-03187-3","42618722","https://pubmed.ncbi.nlm.nih.gov/42618722/",null,null],["4","R0001820","R0001820.pdf","paywalled","nonrandomized_study","Constantine E","2026","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-24-01505","https://doi.org/10.5435/jaaos-d-24-01505","41429015","https://pubmed.ncbi.nlm.nih.gov/41429015/",null,null],["4","R0001823","R0001823.pdf","paywalled","nonrandomized_study","Hsiao YW","2026","Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis is associated with a decreased risk of psoriatic arthritis: A retrospective cohort study using the TriNetX database.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.12.035","https://doi.org/10.1016/j.jaad.2025.12.035","41390127","https://pubmed.ncbi.nlm.nih.gov/41390127/",null,null],["4","R0001860","R0001860.pdf","paywalled","nonrandomized_study","Llach CD","2026","Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence.","Molecular psychiatry","Springer Science and Business Media LLC","10.1038/s41380-025-03261-0","https://doi.org/10.1038/s41380-025-03261-0","40940560","https://pubmed.ncbi.nlm.nih.gov/40940560/",null,null],["4","R0001866","R0001866.pdf","paywalled","nonrandomized_study","Wu JY","2026","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113273","https://doi.org/10.1016/j.diabres.2026.113273","42009260","https://pubmed.ncbi.nlm.nih.gov/42009260/",null,null],["4","R0001868","R0001868.pdf","paywalled","nonrandomized_study","Zhang Z","2026","Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.07.013","https://doi.org/10.1016/j.eprac.2025.07.013","40706753","https://pubmed.ncbi.nlm.nih.gov/40706753/",null,null],["4","R0001879","R0001879.pdf","paywalled","nonrandomized_study","Xu Y","2026","Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.125.075157","https://doi.org/10.1161/circulationaha.125.075157","41732861","https://pubmed.ncbi.nlm.nih.gov/41732861/",null,null],["4","R0001883","R0001883.pdf","paywalled","nonrandomized_study","Bank NC","2026","The association of GLP-1 receptor agonists and outcomes following midfoot arthrodesis.","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2026.01.011","https://doi.org/10.1053/j.jfas.2026.01.011","41565054","https://pubmed.ncbi.nlm.nih.gov/41565054/",null,null],["4","R0001892","R0001892.pdf","paywalled","nonrandomized_study","Liang J","2026","Massive Weight Loss with Bariatric Surgery and GLP-1RA Therapy Predicts Postoperative Complications Following Abdominal Body Contouring.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000013015","https://doi.org/10.1097/prs.0000000000013015","42054101","https://pubmed.ncbi.nlm.nih.gov/42054101/",null,null],["4","R0001899","R0001899.pdf","paywalled","nonrandomized_study","McIntyre RS","2026","Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2024.2430306","https://doi.org/10.1080/14740338.2024.2430306","39552465","https://pubmed.ncbi.nlm.nih.gov/39552465/",null,null],["4","R0001905","R0001905.pdf","paywalled","nonrandomized_study","Ikonomidis I","2026","Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000004311","https://doi.org/10.1097/hjh.0000000000004311","42201656","https://pubmed.ncbi.nlm.nih.gov/42201656/",null,null],["4","R0001910","R0001910.pdf","paywalled","nonrandomized_study","Matsushita T","2026","Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes.","Hypertension research : official journal of the Japanese Society of Hypertension","Springer Science and Business Media LLC","10.1038/s41440-026-02695-5","https://doi.org/10.1038/s41440-026-02695-5","42243292","https://pubmed.ncbi.nlm.nih.gov/42243292/",null,null],["4","R0001913","R0001913.pdf","paywalled","nonrandomized_study","Hong AT","2026","Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2025.12.003","https://doi.org/10.1016/j.ajo.2025.12.003","41360342","https://pubmed.ncbi.nlm.nih.gov/41360342/",null,null],["4","R0001928","R0001928.pdf","paywalled","nonrandomized_study","Mathew RO","2026","Obesity and Cardio-Metabolic Health in Kidney Disease: Implications for Kidney Health, Risk Stratification, and Management.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001233","https://doi.org/10.2215/cjn.0000001233","42726513","https://pubmed.ncbi.nlm.nih.gov/42726513/",null,null],["4","R0001932","R0001932.pdf","paywalled","nonrandomized_study","Lewin Z","2026","Glucagon-Like Peptide-1 Receptor Agonists among Pregnancies with Pregestational Diabetes and Its Relationship with Congenital Malformations.","American journal of perinatology","Georg Thieme Verlag KG","10.1055/a-2716-1639","https://doi.org/10.1055/a-2716-1639","41052622","https://pubmed.ncbi.nlm.nih.gov/41052622/",null,null],["4","R0001933","R0001933.pdf","paywalled","nonrandomized_study","Hsu J","2026","Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.","Journal of vascular surgery","Elsevier BV","10.1016/j.jvs.2026.02.003","https://doi.org/10.1016/j.jvs.2026.02.003","41654037","https://pubmed.ncbi.nlm.nih.gov/41654037/",null,null],["4","R0001935","R0001935.pdf","paywalled","nonrandomized_study","Kazi MAI","2026","Protective Impact of GLP-1 Therapy on Post-ERCP Outcomes: A TriNetX Retrospective Cohort Analysis.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000002374","https://doi.org/10.1097/mcg.0000000000002374","42084951","https://pubmed.ncbi.nlm.nih.gov/42084951/",null,null],["4","R0001937","R0001937.pdf","paywalled","nonrandomized_study","Boukind A","2026","Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients.","The British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag048","https://doi.org/10.1093/bjs/znag048","42003114","https://pubmed.ncbi.nlm.nih.gov/42003114/",null,null],["4","R0001938","R0001938.pdf","paywalled","nonrandomized_study","Moh'd Mari AA","2026","GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps.","The American journal of the medical sciences","Elsevier BV","10.1016/j.amjms.2026.02.002","https://doi.org/10.1016/j.amjms.2026.02.002","41698506","https://pubmed.ncbi.nlm.nih.gov/41698506/",null,null],["4","R0001973","R0001973.pdf","paywalled","nonrandomized_study","Lee S","2026","Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-25-00982","https://doi.org/10.5435/jaaos-d-25-00982","41805656","https://pubmed.ncbi.nlm.nih.gov/41805656/",null,null],["4","R0001976","R0001976.pdf","paywalled","nonrandomized_study","Yen FS","2026","Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2026.01.035","https://doi.org/10.1016/j.mayocp.2026.01.035","42012433","https://pubmed.ncbi.nlm.nih.gov/42012433/",null,null],["4","R0001998","R0001998.pdf","paywalled","nonrandomized_study","Liu L","2026","Letter to the Editor Regarding \"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease\": A BMI-Stratified Retrospective Study.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005577","https://doi.org/10.1097/brs.0000000000005577","41284919","https://pubmed.ncbi.nlm.nih.gov/41284919/",null,null],["4","R0002073","R0002073.pdf","paywalled","nonrandomized_study","Comisi JC","2026","Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.","Clinical oral investigations","Springer Science and Business Media LLC","10.1007/s00784-026-07135-9","https://doi.org/10.1007/s00784-026-07135-9","42734711","https://pubmed.ncbi.nlm.nih.gov/42734711/",null,null],["4","R0002074","R0002074.pdf","paywalled","nonrandomized_study","Bahdi F","2026","The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000002414","https://doi.org/10.1097/mcg.0000000000002414","42348290","https://pubmed.ncbi.nlm.nih.gov/42348290/",null,null],["4","R0002119","R0002119.pdf","paywalled","nonrandomized_study","Huang CW","2026","Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag028","https://doi.org/10.1093/ndt/gfag028","41665869","https://pubmed.ncbi.nlm.nih.gov/41665869/",null,null],["4","R0002139","R0002139.pdf","paywalled","nonrandomized_study","McCall KL","2026","Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2499670","https://doi.org/10.1080/14740338.2025.2499670","40285721","https://pubmed.ncbi.nlm.nih.gov/40285721/",null,null],["4","R0002156","R0002156.pdf","paywalled","nonrandomized_study","Good CB","2026","Medication use for patients with obesity: trends and characteristics for US employees.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2026.89920","https://doi.org/10.37765/ajmc.2026.89920","42044422","https://pubmed.ncbi.nlm.nih.gov/42044422/",null,null],["4","R0002176","R0002176.pdf","paywalled","nonrandomized_study","Maroufi SF","2026","Bariatric Surgery Versus GLP-1RAs in Idiopathic Intracranial Hypertension: A Propensity Matched Multi-Institutional Cohort.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000004099","https://doi.org/10.1227/neu.0000000000004099","42159383","https://pubmed.ncbi.nlm.nih.gov/42159383/",null,null],["4","R0002198","R0002198.pdf","paywalled","nonrandomized_study","Hung KC","2026","Preoperative GLP-1 Receptor Agonist (GLP-1 RA) Exposure Is Associated With Postoperative Initiation of GLP-1 RA Following Metabolic Bariatric Surgery: A Multicenter Cohort Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08671-9","https://doi.org/10.1007/s11695-026-08671-9","41965452","https://pubmed.ncbi.nlm.nih.gov/41965452/",null,null],["4","R0002219","R0002219.pdf","paywalled","nonrandomized_study","McCoy RG","2026","Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.01.012","https://doi.org/10.1016/j.eprac.2026.01.012","41638310","https://pubmed.ncbi.nlm.nih.gov/41638310/",null,null],["4","R0002258","R0002258.pdf","paywalled","nonrandomized_study","Chen YR","2026","Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation.","GeroScience","Springer Science and Business Media LLC","10.1007/s11357-026-02300-0","https://doi.org/10.1007/s11357-026-02300-0","42101745","https://pubmed.ncbi.nlm.nih.gov/42101745/",null,null],["4","R0002290","R0002290.pdf","paywalled","nonrandomized_study","Go CC","2026","GLP-1 Receptor Agonist Use Is Associated with Venous Ulcer Healing and Fewer Wound Infections.","Annals of vascular surgery","Elsevier BV","10.1016/j.avsg.2026.03.023","https://doi.org/10.1016/j.avsg.2026.03.023","41895589","https://pubmed.ncbi.nlm.nih.gov/41895589/",null,null],["4","R0002291","R0002291.pdf","paywalled","nonrandomized_study","Box M","2026","Association of GLP-1 receptor agonist use with outcomes after surgical fixation of femoral neck fracture in patients with type 2 diabetes: a propensity score-matched analysis.","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","Springer Science and Business Media LLC","10.1007/s00590-026-04720-2","https://doi.org/10.1007/s00590-026-04720-2","41870668","https://pubmed.ncbi.nlm.nih.gov/41870668/",null,null],["4","R0002309","R0002309.pdf","paywalled","nonrandomized_study","Patel Y","2026","A single-center retrospective review of food retention during upper endoscopy following GLP-1 receptor agonist usage and introduction of the Tampa Intraluminal Gastric Residue (TiGR) grading scale.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-026-12640-9","https://doi.org/10.1007/s00464-026-12640-9","41772229","https://pubmed.ncbi.nlm.nih.gov/41772229/",null,null],["4","R0002353","R0002353.pdf","paywalled","nonrandomized_study","Yahyavi A","2026","Benefits of glucagon-like peptide (GLP)-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia.","Vascular medicine (London, England)","SAGE Publications","10.1177/1358863x251393107","https://doi.org/10.1177/1358863x251393107","41410071","https://pubmed.ncbi.nlm.nih.gov/41410071/",null,null],["4","R0002368","R0002368.pdf","paywalled","nonrandomized_study","Zhang JZ","2026","GLP-1 receptor agonist use and surgical outcomes following diabetic foot reconstruction: A propensity score-matched retrospective cohort study.","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Elsevier BV","10.1016/j.bjps.2026.03.001","https://doi.org/10.1016/j.bjps.2026.03.001","41880708","https://pubmed.ncbi.nlm.nih.gov/41880708/",null,null],["4","R0002393","R0002393.pdf","paywalled","nonrandomized_study","Nieto LM","2026","Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003525","https://doi.org/10.14309/ajg.0000000000003525","40358430","https://pubmed.ncbi.nlm.nih.gov/40358430/",null,null],["4","R0002402","R0002402.pdf","paywalled","nonrandomized_study","Do D","2026","Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.","The journal of behavioral health services & research","Springer Science and Business Media LLC","10.1007/s11414-025-09950-6","https://doi.org/10.1007/s11414-025-09950-6","40439835","https://pubmed.ncbi.nlm.nih.gov/40439835/",null,null],["4","R0002410","R0002410.pdf","paywalled","nonrandomized_study","Aksan F","2026","Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-025-04745-0","https://doi.org/10.1007/s00210-025-04745-0","41143957","https://pubmed.ncbi.nlm.nih.gov/41143957/",null,null],["4","R0002445","R0002445.pdf","paywalled","nonrandomized_study","Ramos S","2026","Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.","Clinical lymphoma, myeloma & leukemia","Elsevier BV","10.1016/j.clml.2026.06.007","https://doi.org/10.1016/j.clml.2026.06.007","42471299","https://pubmed.ncbi.nlm.nih.gov/42471299/",null,null],["4","R0002472","R0002472.pdf","paywalled","nonrandomized_study","Pai SL","2026","Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists Before Anesthesia.","Anesthesia and analgesia","Ovid Technologies (Wolters Kluwer Health)","10.1213/ane.0000000000007764","https://doi.org/10.1213/ane.0000000000007764","41032460","https://pubmed.ncbi.nlm.nih.gov/41032460/",null,null],["4","R0002479","R0002479.pdf","paywalled","nonrandomized_study","Mahiny D","2026","Media Coverage of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) After Semaglutide Use: A Content Analysis of News Reporting Accuracy and Framing.","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/wno.0000000000002454","https://doi.org/10.1097/wno.0000000000002454","41870413","https://pubmed.ncbi.nlm.nih.gov/41870413/",null,null],["4","R0002492","R0002492.pdf","paywalled","nonrandomized_study","Lee IO","2026","Outcomes of Maternal Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review of Evidence and Reporting Trends.","Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC","Elsevier BV","10.1016/j.jogc.2025.103191","https://doi.org/10.1016/j.jogc.2025.103191","41319953","https://pubmed.ncbi.nlm.nih.gov/41319953/",null,null],["4","R0002506","R0002506.pdf","paywalled","nonrandomized_study","Garg S","2026","All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156251403555","https://doi.org/10.1177/15209156251403555","41468099","https://pubmed.ncbi.nlm.nih.gov/41468099/",null,null],["4","R0002512","R0002512.pdf","paywalled","nonrandomized_study","Daggolu J","2026","Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults.","Journal of clinical psychopharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcp.0000000000002145","https://doi.org/10.1097/jcp.0000000000002145","41676872","https://pubmed.ncbi.nlm.nih.gov/41676872/",null,null],["4","R0002514","R0002514.pdf","paywalled","nonrandomized_study","Li XY","2026","Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP-1 receptor agonists: A prospective observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70537","https://doi.org/10.1111/dom.70537","41635113","https://pubmed.ncbi.nlm.nih.gov/41635113/",null,null],["4","R0002554","R0002554.pdf","paywalled","nonrandomized_study","Li Y","2026","Sodium-Glucose Cotransporter 2 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes Mellitus: An Active Comparator, New-User Cohort Study.","International journal of cancer","Wiley","10.1002/ijc.70642","https://doi.org/10.1002/ijc.70642","42538609","https://pubmed.ncbi.nlm.nih.gov/42538609/",null,null],["4","R0002564","R0002564.pdf","paywalled","nonrandomized_study","Mazzola A","2026","Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2026.102899","https://doi.org/10.1016/j.clinre.2026.102899","42562072","https://pubmed.ncbi.nlm.nih.gov/42562072/",null,null],["4","R0002566","R0002566.pdf","paywalled","nonrandomized_study","Sa B","2026","Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.","Journal of psychiatric research","Elsevier BV","10.1016/j.jpsychires.2026.01.042","https://doi.org/10.1016/j.jpsychires.2026.01.042","41616750","https://pubmed.ncbi.nlm.nih.gov/41616750/",null,null],["4","R0002572","R0002572.pdf","paywalled","nonrandomized_study","Lin BH","2026","Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cataract.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2025.12.025","https://doi.org/10.1016/j.ajo.2025.12.025","41456709","https://pubmed.ncbi.nlm.nih.gov/41456709/",null,null],["4","R0002589","R0002589.pdf","paywalled","nonrandomized_study","Xu Y","2026","Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes.","Kidney international","Elsevier BV","10.1016/j.kint.2026.06.041","https://doi.org/10.1016/j.kint.2026.06.041","42498061","https://pubmed.ncbi.nlm.nih.gov/42498061/",null,null],["4","R0002599","R0002599.pdf","paywalled","nonrandomized_study","Saxena A","2026","Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.74.1507","https://doi.org/10.59556/japi.74.1507","42543940","https://pubmed.ncbi.nlm.nih.gov/42543940/",null,null],["4","R0002621","R0002621.pdf","paywalled","nonrandomized_study","Braud SC","2026","GLP-1 Receptor Agonists versus Bariatric Surgery: A Global Health Network Analysis of Panniculectomy Outcomes.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012955","https://doi.org/10.1097/prs.0000000000012955","41729134","https://pubmed.ncbi.nlm.nih.gov/41729134/",null,null],["4","R0002625","R0002625.pdf","paywalled","nonrandomized_study","Liu R","2026","Comparison of non-insulin glucose-lowering therapies on coronary atherosclerotic plaque progression in diabetes.","La Radiologia medica","Springer Science and Business Media LLC","10.1007/s11547-026-02237-6","https://doi.org/10.1007/s11547-026-02237-6","42496918","https://pubmed.ncbi.nlm.nih.gov/42496918/",null,null],["4","R0002713","R0002713.pdf","paywalled","nonrandomized_study","Chen TH","2026","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Facial Landmarks.","Ophthalmic plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/iop.0000000000003070","https://doi.org/10.1097/iop.0000000000003070","41022041","https://pubmed.ncbi.nlm.nih.gov/41022041/",null,null],["4","R0002725","R0002725.pdf","paywalled","nonrandomized_study","Khan SA","2026","Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-026-10171-w","https://doi.org/10.1007/s10620-026-10171-w","42570075","https://pubmed.ncbi.nlm.nih.gov/42570075/",null,null],["4","R0002726","R0002726.pdf","paywalled","nonrandomized_study","Cheng CY","2026","Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000214509","https://doi.org/10.1212/wnl.0000000000214509","41370744","https://pubmed.ncbi.nlm.nih.gov/41370744/",null,null],["4","R0002736","R0002736.pdf","paywalled","nonrandomized_study","Morieri ML","2026","The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70445","https://doi.org/10.1111/dom.70445","41480667","https://pubmed.ncbi.nlm.nih.gov/41480667/",null,null],["4","R0002758","R0002758.pdf","paywalled","nonrandomized_study","Strickler I","2026","Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-25-01571","https://doi.org/10.5435/jaaos-d-25-01571","41930687","https://pubmed.ncbi.nlm.nih.gov/41930687/",null,null],["4","R0002759","R0002759.pdf","paywalled","nonrandomized_study","Lieberman RA","2026","Semaglutide Decreases Risk of Non-Arteritic Anterior Ischemic Optic Neuroapthy in Type 2 Diabetic Patients.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usaf522","https://doi.org/10.1093/milmed/usaf522","41217382","https://pubmed.ncbi.nlm.nih.gov/41217382/",null,null],["4","R0002766","R0002766.pdf","paywalled","nonrandomized_study","Woo KA","2026","GLP1R expression and Parkinson's disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/awag130","https://doi.org/10.1093/brain/awag130","41967915","https://pubmed.ncbi.nlm.nih.gov/41967915/",null,null],["4","R0002802","R0002802.pdf","paywalled","nonrandomized_study","Lee CC","2026","Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012703","https://doi.org/10.1097/prs.0000000000012703","41364427","https://pubmed.ncbi.nlm.nih.gov/41364427/",null,null],["4","R0002833","R0002833.pdf","paywalled","nonrandomized_study","Zaman W","2026","Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2026.2676109","https://doi.org/10.1080/14656566.2026.2676109","42138103","https://pubmed.ncbi.nlm.nih.gov/42138103/",null,null],["4","R0002834","R0002834.pdf","paywalled","nonrandomized_study","Sharma A","2026","Short-Term Complications of Preoperative Weight Loss Strategies in Total Knee Arthroplasty: Bariatric Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.08.073","https://doi.org/10.1016/j.arth.2025.08.073","40912337","https://pubmed.ncbi.nlm.nih.gov/40912337/",null,null],["4","R0002850","R0002850.pdf","paywalled","nonrandomized_study","Box MW","2026","Association of preoperative GLP‑1 receptor agonist use with outcomes after primary total knee arthroplasty.","The Knee","Elsevier BV","10.1016/j.knee.2025.10.026","https://doi.org/10.1016/j.knee.2025.10.026","41241648","https://pubmed.ncbi.nlm.nih.gov/41241648/",null,null],["4","R0002863","R0002863.pdf","paywalled","nonrandomized_study","Daggolu J","2026","Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70555","https://doi.org/10.1111/dom.70555","41669827","https://pubmed.ncbi.nlm.nih.gov/41669827/",null,null],["4","R0002872","R0002872.pdf","paywalled","nonrandomized_study","Lago Garma J","2026","Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2026.501713","https://doi.org/10.1016/j.endien.2026.501713","41651756","https://pubmed.ncbi.nlm.nih.gov/41651756/",null,null],["4","R0003013","R0003013.pdf","paywalled","nonrandomized_study","Sheth MS","2026","Neighborhood-Level Material Resources and Risk of Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2026.06.027","https://doi.org/10.1016/j.cjca.2026.06.027","42398733","https://pubmed.ncbi.nlm.nih.gov/42398733/",null,null],["4","R0003070","R0003070.pdf","paywalled","nonrandomized_study","Lin LY","2026","Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.70087","https://doi.org/10.1002/cpt.70087","41074575","https://pubmed.ncbi.nlm.nih.gov/41074575/",null,null],["4","R0003090","R0003090.pdf","paywalled","nonrandomized_study","O'Brien EM","2026","Delayed gastric emptying in adolescent patients on GLP-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2026.07.016","https://doi.org/10.1016/j.bja.2026.07.016","42711215","https://pubmed.ncbi.nlm.nih.gov/42711215/",null,null],["4","R0003142","R0003142.pdf","paywalled","nonrandomized_study","Bonnet JB","2026","GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study.","Diabetes care","American Diabetes Association","10.2337/dc25-2120","https://doi.org/10.2337/dc25-2120","41615296","https://pubmed.ncbi.nlm.nih.gov/41615296/",null,null],["4","R0003295","R0003295.pdf","paywalled","nonrandomized_study","Al Hayek A","2026","Flash Glucose Monitoring System Enhances Glycemic Control and Metabolic Health in People with Type 2 Diabetes on GLP-1RA-Based Therapy: Real-World Evidence.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-026-03495-6","https://doi.org/10.1007/s12325-026-03495-6","41718943","https://pubmed.ncbi.nlm.nih.gov/41718943/",null,null],["4","R0003449","R0003449.pdf","paywalled","nonrandomized_study","Allaham L","2026","GLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge Gaps.","Lung","Springer Science and Business Media LLC","10.1007/s00408-026-00939-2","https://doi.org/10.1007/s00408-026-00939-2","42747605","https://pubmed.ncbi.nlm.nih.gov/42747605/",null,null],["4","R0003452","R0003452.pdf","paywalled","nonrandomized_study","Stirpe C","2026","Impact of GLP-1 dose intensity on perioperative and long-term fusion outcomes following ACDF.","The spine journal : official journal of the North American Spine Society","Elsevier BV","10.1016/j.spinee.2026.08.009","https://doi.org/10.1016/j.spinee.2026.08.009","42705550","https://pubmed.ncbi.nlm.nih.gov/42705550/",null,null],["4","R0003456","R0003456.pdf","paywalled","nonrandomized_study","Htoo PT","2026","Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70195","https://doi.org/10.1111/dom.70195","41090391","https://pubmed.ncbi.nlm.nih.gov/41090391/",null,null],["4","R0003520","R0003520.pdf","paywalled","nonrandomized_study","Kalathiya UN","2026","Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.09.004","https://doi.org/10.1016/j.eprac.2025.09.004","40945659","https://pubmed.ncbi.nlm.nih.gov/40945659/",null,null],["4","R0003526","R0003526.pdf","paywalled","nonrandomized_study","Butensky SD","2026","Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08645-x","https://doi.org/10.1007/s11695-026-08645-x","41912836","https://pubmed.ncbi.nlm.nih.gov/41912836/",null,null],["4","R0003530","R0003530.pdf","paywalled","nonrandomized_study","Chang CI","2026","Association of sodium-glucose cotransporter 2 inhibitors with the risk of incident anxiety and insomnia: a retrospective cohort study using the TriNetX database.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103373","https://doi.org/10.1016/j.dsx.2025.103373","41477924","https://pubmed.ncbi.nlm.nih.gov/41477924/",null,null],["4","R0003543","R0003543.pdf","paywalled","nonrandomized_study","Liu CY","2026","Long-term risk of total joint replacement associated with second-line glucose-lowering therapies in type 2 diabetes: A population-based retrospective cohort study.","Seminars in arthritis and rheumatism","Elsevier BV","10.1016/j.semarthrit.2026.152995","https://doi.org/10.1016/j.semarthrit.2026.152995","42139974","https://pubmed.ncbi.nlm.nih.gov/42139974/",null,null],["4","R0003605","R0003605.pdf","paywalled","nonrandomized_study","Hundal J","2026","Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health.","American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","American Society of Clinical Oncology (ASCO)","10.1200/edbk-26-517396","https://doi.org/10.1200/edbk-26-517396","42127339","https://pubmed.ncbi.nlm.nih.gov/42127339/",null,null],["4","R0003631","R0003631.pdf","paywalled","nonrandomized_study","Chinn JO","2026","The impact of preoperative antiobesity medications on weight loss in adolescents undergoing metabolic and bariatric surgery - a COSMIC study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.10.014","https://doi.org/10.1016/j.soard.2025.10.014","41353013","https://pubmed.ncbi.nlm.nih.gov/41353013/",null,null],["4","R0003637","R0003637.pdf","paywalled","nonrandomized_study","Zhou B","2026","Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration.","Expert opinion on drug discovery","Informa UK Limited","10.1080/17460441.2026.2635492","https://doi.org/10.1080/17460441.2026.2635492","41805144","https://pubmed.ncbi.nlm.nih.gov/41805144/",null,null],["4","R0003647","R0003647.pdf","paywalled","nonrandomized_study","Corrêa LMA","2026","Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.","Transplantation reviews (Orlando, Fla.)","Elsevier BV","10.1016/j.trre.2026.101003","https://doi.org/10.1016/j.trre.2026.101003","41707409","https://pubmed.ncbi.nlm.nih.gov/41707409/",null,null],["4","R0003650","R0003650.pdf","paywalled","nonrandomized_study","Bcharah H","2026","Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.08.035","https://doi.org/10.1016/j.amjcard.2026.08.035","42727630","https://pubmed.ncbi.nlm.nih.gov/42727630/",null,null],["4","R0003661","R0003661.pdf","paywalled","nonrandomized_study","Talay L","2026","AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71181","https://doi.org/10.1111/dom.71181","42575845","https://pubmed.ncbi.nlm.nih.gov/42575845/",null,null],["4","R0003671","R0003671.pdf","paywalled","nonrandomized_study","Malighetti ME","2026","Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.25.04376-3","https://doi.org/10.23736/s2724-6507.25.04376-3","41307513","https://pubmed.ncbi.nlm.nih.gov/41307513/",null,null],["4","R0003684","R0003684.pdf","paywalled","nonrandomized_study","Puga T","2026","Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study.","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","Elsevier BV","10.1016/j.jos.2026.02.002","https://doi.org/10.1016/j.jos.2026.02.002","41735126","https://pubmed.ncbi.nlm.nih.gov/41735126/",null,null],["4","R0003687","R0003687.pdf","paywalled","nonrandomized_study","Kageyama M","2026","Temporal trends and clinical factors associated with hypoglycemia-related hospitalization of patients with type 2 diabetes: a large-scale claims database study in Japan.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113539","https://doi.org/10.1016/j.diabres.2026.113539","42660202","https://pubmed.ncbi.nlm.nih.gov/42660202/",null,null],["4","R0003734","R0003734.pdf","paywalled","nonrandomized_study","Tripathy M","2026","The Association of Diabetes and Atherosclerosis: Understanding the Molecular Mechanism of the Double Burden.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0109298673435173260213113630","https://doi.org/10.2174/0109298673435173260213113630","42316498","https://pubmed.ncbi.nlm.nih.gov/42316498/",null,null],["4","R0003797","R0003797.pdf","paywalled","nonrandomized_study","Mera-Carreiro S","2026","Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08954-1","https://doi.org/10.1007/s11695-026-08954-1","42802300","https://pubmed.ncbi.nlm.nih.gov/42802300/",null,null],["4","R0003799","R0003799.pdf","paywalled","nonrandomized_study","Bcharah G","2026","Preoperative Glucagon-Like Peptide-1 Agonist Use Is Associated With Decreased Complications Compared to Bariatric Surgery Following Primary Total Hip Arthroplasty.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2026.04.032","https://doi.org/10.1016/j.arth.2026.04.032","42001909","https://pubmed.ncbi.nlm.nih.gov/42001909/",null,null],["4","R0003814","R0003814.pdf","paywalled","nonrandomized_study","Dombrowski SK","2026","Medication adherence and persistence of newly initiated medications in older adults with diabetes.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2026.103075","https://doi.org/10.1016/j.japh.2026.103075","41850681","https://pubmed.ncbi.nlm.nih.gov/41850681/",null,null],["4","R0003818","R0003818.pdf","paywalled","nonrandomized_study","Salingaros S","2026","Active GLP-1 RA Use Is Associated With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters.","Annals of plastic surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sap.0000000000004657","https://doi.org/10.1097/sap.0000000000004657","41687055","https://pubmed.ncbi.nlm.nih.gov/41687055/",null,null],["4","R0003856","R0003856.pdf","paywalled","nonrandomized_study","Avogaro A","2026","Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.","European journal of clinical investigation","Wiley","10.1111/eci.70184","https://doi.org/10.1111/eci.70184","41653035","https://pubmed.ncbi.nlm.nih.gov/41653035/",null,null],["4","R0003861","R0003861.pdf","paywalled","nonrandomized_study","Khan S","2026","GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital.","General hospital psychiatry","Elsevier BV","10.1016/j.genhosppsych.2026.08.002","https://doi.org/10.1016/j.genhosppsych.2026.08.002","42594759","https://pubmed.ncbi.nlm.nih.gov/42594759/",null,null],["4","R0003926","R0003926.pdf","paywalled","nonrandomized_study","Yen FS","2026","Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.","Epilepsia","Wiley","10.1002/epi.70369","https://doi.org/10.1002/epi.70369","42397685","https://pubmed.ncbi.nlm.nih.gov/42397685/",null,null],["4","R0003928","R0003928.pdf","paywalled","nonrandomized_study","Mishra NK","2026","Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2026.103260","https://doi.org/10.1016/j.clnesp.2026.103260","41933725","https://pubmed.ncbi.nlm.nih.gov/41933725/",null,null],["4","R0003931","R0003931.pdf","paywalled","nonrandomized_study","Dacon C","2026","Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900261449175","https://doi.org/10.1177/08971900261449175","42084545","https://pubmed.ncbi.nlm.nih.gov/42084545/",null,null],["4","R0003968","R0003968.pdf","paywalled","nonrandomized_study","Lakavath B","2026","Beyond intraocular pressure: vascular and metabolic modifiers of optic nerve vulnerability in glaucoma.","International ophthalmology","Springer Science and Business Media LLC","10.1007/s10792-026-04189-2","https://doi.org/10.1007/s10792-026-04189-2","42484773","https://pubmed.ncbi.nlm.nih.gov/42484773/",null,null],["4","R0003988","R0003988.pdf","paywalled","nonrandomized_study","Shlomov T","2026","Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes.","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","Elsevier BV","10.1016/j.jcjo.2026.01.010","https://doi.org/10.1016/j.jcjo.2026.01.010","41620207","https://pubmed.ncbi.nlm.nih.gov/41620207/",null,null],["4","R0003991","R0003991.pdf","paywalled","nonrandomized_study","Evola V","2026","Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","Springer Science and Business Media LLC","10.1007/s00011-025-02166-6","https://doi.org/10.1007/s00011-025-02166-6","41504939","https://pubmed.ncbi.nlm.nih.gov/41504939/",null,null],["4","R0004020","R0004020.pdf","paywalled","nonrandomized_study","Kim HS","2026","Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.","Clinical endocrinology","Wiley","10.1111/cen.70078","https://doi.org/10.1111/cen.70078","41387176","https://pubmed.ncbi.nlm.nih.gov/41387176/",null,null],["4","R0004089","R0004089.pdf","paywalled","nonrandomized_study","Khalil I","2026","Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.06.004","https://doi.org/10.1016/j.eprac.2026.06.004","42320716","https://pubmed.ncbi.nlm.nih.gov/42320716/",null,null],["4","R0004098","R0004098.pdf","paywalled","nonrandomized_study","Biasin M","2026","Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.","Journal of cardiovascular medicine (Hagerstown, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.2459/jcm.0000000000001837","https://doi.org/10.2459/jcm.0000000000001837","41703411","https://pubmed.ncbi.nlm.nih.gov/41703411/",null,null],["4","R0004099","R0004099.pdf","paywalled","nonrandomized_study","Airhart AE","2026","Temporal trends in patient demographics and postoperative outcomes in metabolic and bariatric surgery: a longitudinal analysis of the MBSAQIP database in the GLP-1 era.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.05.029","https://doi.org/10.1016/j.soard.2026.05.029","42336702","https://pubmed.ncbi.nlm.nih.gov/42336702/",null,null],["4","R0004109","R0004109.pdf","paywalled","nonrandomized_study","Riesemann S","2026","Perioperative anesthesia care for patients with diabetes mellitus: a review of current literature with focus on oral antidiabetic medication.","Current opinion in anaesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aco.0000000000001644","https://doi.org/10.1097/aco.0000000000001644","41885293","https://pubmed.ncbi.nlm.nih.gov/41885293/",null,null],["4","R0004138","R0004138.pdf","paywalled","nonrandomized_study","Silva D","2026","Could Glucagon-Like Peptide-1 (GLP-1) receptor antagonists be used to treat obstructive sleep apnoea in children and adolescents with obesity?","Paediatric respiratory reviews","Elsevier BV","10.1016/j.prrv.2025.08.001","https://doi.org/10.1016/j.prrv.2025.08.001","40887408","https://pubmed.ncbi.nlm.nih.gov/40887408/",null,null],["4","R0004222","R0004222.pdf","paywalled","nonrandomized_study","Katz A","2026","Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study.","Dermatitis : contact, atopic, occupational, drug","SAGE Publications","10.1177/17103568251410211","https://doi.org/10.1177/17103568251410211","41649183","https://pubmed.ncbi.nlm.nih.gov/41649183/",null,null],["4","R0004253","R0004253.pdf","paywalled","nonrandomized_study","Borissov Borissov M","2026","GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus.","Sleep & breathing = Schlaf & Atmung","Springer Science and Business Media LLC","10.1007/s11325-026-03748-2","https://doi.org/10.1007/s11325-026-03748-2","42363996","https://pubmed.ncbi.nlm.nih.gov/42363996/",null,null],["4","R0004268","R0004268.pdf","paywalled","nonrandomized_study","Wang YH","2026","Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-025-01623-9","https://doi.org/10.1007/s40264-025-01623-9","41123870","https://pubmed.ncbi.nlm.nih.gov/41123870/",null,null],["4","R0004290","R0004290.pdf","paywalled","nonrandomized_study","Choi J","2026","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Reduced Hepatocellular Carcinoma Risk in Patients With Type 2 Diabetes.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003889","https://doi.org/10.14309/ajg.0000000000003889","41400268","https://pubmed.ncbi.nlm.nih.gov/41400268/",null,null],["4","R0004291","R0004291.pdf","paywalled","nonrandomized_study","Hsieh TYJ","2026","Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.","Gynecologic oncology","Elsevier BV","10.1016/j.ygyno.2026.03.010","https://doi.org/10.1016/j.ygyno.2026.03.010","42000371","https://pubmed.ncbi.nlm.nih.gov/42000371/",null,null],["4","R0004302","R0004302.pdf","paywalled","nonrandomized_study","Heo KY","2026","Glucagon-like peptide-1 receptor agonist use and perioperative outcomes after anterior cervical discectomy and fusion: a propensity-matched cohort study.","The spine journal : official journal of the North American Spine Society","Elsevier BV","10.1016/j.spinee.2025.12.019","https://doi.org/10.1016/j.spinee.2025.12.019","41482188","https://pubmed.ncbi.nlm.nih.gov/41482188/",null,null],["4","R0004417","R0004417.pdf","paywalled","nonrandomized_study","Angelopoulos N","2026","A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-025-01986-0","https://doi.org/10.1038/s41366-025-01986-0","41354867","https://pubmed.ncbi.nlm.nih.gov/41354867/",null,"ANZCTR:ACTRN12625000071426"],["4","R0004427","R0004427.pdf","paywalled","nonrandomized_study","Kishan A","2026","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005494","https://doi.org/10.1097/brs.0000000000005494","40905270","https://pubmed.ncbi.nlm.nih.gov/40905270/",null,null],["4","R0004475","R0004475.pdf","paywalled","nonrandomized_study","Nicolau J","2026","Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study.","Clinical and experimental dermatology","Oxford University Press (OUP)","10.1093/ced/llaf473","https://doi.org/10.1093/ced/llaf473","41137591","https://pubmed.ncbi.nlm.nih.gov/41137591/",null,null],["4","R0004484","R0004484.pdf","paywalled","nonrandomized_study","Milanov V","2026","Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists versus SGLT2 Inhibitors: A Real-World Active Comparator Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.09.013","https://doi.org/10.1016/j.eprac.2026.09.013","42810620","https://pubmed.ncbi.nlm.nih.gov/42810620/",null,null],["4","R0004515","R0004515.pdf","paywalled","nonrandomized_study","Mushtaq M","2026","Does Preoperative GLP-1 Therapy Improve Postoperative Bariatric Surgery Outcomes? A Single-Centre Retrospective Observational Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08525-4","https://doi.org/10.1007/s11695-026-08525-4","41686318","https://pubmed.ncbi.nlm.nih.gov/41686318/",null,null],["4","R0004563","R0004563.pdf","paywalled","nonrandomized_study","Jebeile H","2026","GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70049","https://doi.org/10.1111/obr.70049","41340366","https://pubmed.ncbi.nlm.nih.gov/41340366/",null,null],["4","R0004573","R0004573.pdf","paywalled","nonrandomized_study","Ng MK","2026","Semaglutide Use Is Associated With Decreased Length of Stay and Hospital Costs in Patients Undergoing Anterior Lumbar Interbody Fusion: A Retrospective Cohort Study.","Orthopedics","SLACK, Inc.","10.3928/01477447-20251219-01","https://doi.org/10.3928/01477447-20251219-01","41636429","https://pubmed.ncbi.nlm.nih.gov/41636429/",null,null],["4","R0004595","R0004595.pdf","paywalled","nonrandomized_study","Smith JE","2026","Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05861-9","https://doi.org/10.1007/s00266-026-05861-9","41991800","https://pubmed.ncbi.nlm.nih.gov/41991800/",null,null],["4","R0004613","R0004613.pdf","paywalled","nonrandomized_study","Maynard S","2026","Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.","The International journal of eating disorders","Wiley","10.1002/eat.24575","https://doi.org/10.1002/eat.24575","41139846","https://pubmed.ncbi.nlm.nih.gov/41139846/",null,null],["4","R0004631","R0004631.pdf","paywalled","nonrandomized_study","Katzman J","2026","Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?","Archives of orthopaedic and trauma surgery","Springer Science and Business Media LLC","10.1007/s00402-025-06167-2","https://doi.org/10.1007/s00402-025-06167-2","41718773","https://pubmed.ncbi.nlm.nih.gov/41718773/",null,null],["4","R0004671","R0004671.pdf","paywalled","nonrandomized_study","Palmisano T","2026","Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.","Heart rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.1940","https://doi.org/10.1016/j.hrthm.2026.03.1940","42029362","https://pubmed.ncbi.nlm.nih.gov/42029362/",null,null],["4","R0004689","R0004689.pdf","paywalled","nonrandomized_study","Casper J","2026","Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag198","https://doi.org/10.1093/ndt/gfag198","42658186","https://pubmed.ncbi.nlm.nih.gov/42658186/",null,null],["4","R0004717","R0004717.pdf","paywalled","nonrandomized_study","Rivero-Moreno Y","2026","Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08627-z","https://doi.org/10.1007/s11695-026-08627-z","41906069","https://pubmed.ncbi.nlm.nih.gov/41906069/",null,null],["4","R0004723","R0004723.pdf","paywalled","nonrandomized_study","Holler E","2026","Preoperative GLP-1 Receptor Agonist Use and Weight Loss Outcomes Following Bariatric Surgery.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000007042","https://doi.org/10.1097/sla.0000000000007042","41772757","https://pubmed.ncbi.nlm.nih.gov/41772757/",null,null],["4","R0004761","R0004761.pdf","paywalled","nonrandomized_study","Katsura M","2026","Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70721","https://doi.org/10.1111/dom.70721","41891334","https://pubmed.ncbi.nlm.nih.gov/41891334/",null,null],["4","R0004771","R0004771.pdf","paywalled","nonrandomized_study","Mahmoud AK","2026","Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcag051","https://doi.org/10.1093/ehjqcco/qcag051","41910632","https://pubmed.ncbi.nlm.nih.gov/41910632/",null,null],["4","R0004973","R0004973.pdf","paywalled","nonrandomized_study","Wu KA","2026","Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis.","The Knee","Elsevier BV","10.1016/j.knee.2026.104639","https://doi.org/10.1016/j.knee.2026.104639","42727208","https://pubmed.ncbi.nlm.nih.gov/42727208/",null,null],["4","R0004974","R0004974.pdf","paywalled","nonrandomized_study","Deas C","2026","Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.","Journal of health care for the poor and underserved","Project MUSE","10.1353/hpu.2026.a982969","https://doi.org/10.1353/hpu.2026.a982969","42766517","https://pubmed.ncbi.nlm.nih.gov/42766517/",null,null],["4","R0004979","R0004979.pdf","paywalled","nonrandomized_study","Spitery A","2026","Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2026.89952","https://doi.org/10.37765/ajmc.2026.89952","42335260","https://pubmed.ncbi.nlm.nih.gov/42335260/",null,null],["4","R0004987","R0004987.pdf","paywalled","nonrandomized_study","Angelopoulos N","2026","Short-term effect of tirzepatide on serum calcitonin in adults with obesity.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04655-y","https://doi.org/10.1007/s12020-026-04655-y","42081121","https://pubmed.ncbi.nlm.nih.gov/42081121/",null,null],["4","R0005001","R0005001.pdf","paywalled","nonrandomized_study","Lambadiari V","2026","Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.02.014","https://doi.org/10.1016/j.eprac.2026.02.014","41713690","https://pubmed.ncbi.nlm.nih.gov/41713690/",null,null],["4","R0005036","R0005036.pdf","paywalled","nonrandomized_study","Le Y","2026","Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.","Foot & ankle specialist","SAGE Publications","10.1177/19386400261471652","https://doi.org/10.1177/19386400261471652","42609010","https://pubmed.ncbi.nlm.nih.gov/42609010/",null,null],["4","R0005081","R0005081.pdf","paywalled","nonrandomized_study","Qaisar R","2026","Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70253","https://doi.org/10.1002/bcp.70253","40855709","https://pubmed.ncbi.nlm.nih.gov/40855709/",null,null],["4","R0005084","R0005084.pdf","paywalled","nonrandomized_study","Tseng YY","2026","Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes.","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Oxford University Press (OUP)","10.1093/ndt/gfag175","https://doi.org/10.1093/ndt/gfag175","42566276","https://pubmed.ncbi.nlm.nih.gov/42566276/",null,null],["4","R0005097","R0005097.pdf","paywalled","nonrandomized_study","Kozato A","2026","Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-026-13147-z","https://doi.org/10.1007/s00464-026-13147-z","42467193","https://pubmed.ncbi.nlm.nih.gov/42467193/",null,null],["4","R0005123","R0005123.pdf","paywalled","nonrandomized_study","Forst E","2026","Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair:An Analysis of 1,092 Patients.","Orthopedics","SLACK, Inc.","10.3928/01477447-20260811-01","https://doi.org/10.3928/01477447-20260811-01","42673608","https://pubmed.ncbi.nlm.nih.gov/42673608/",null,null],["4","R0005124","R0005124.pdf","paywalled","nonrandomized_study","Barton A","2026","[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].","Zeitschrift fur Gastroenterologie","Georg Thieme Verlag KG","10.1055/a-2894-7716","https://doi.org/10.1055/a-2894-7716","42777699","https://pubmed.ncbi.nlm.nih.gov/42777699/",null,null],["4","R0005144","R0005144.pdf","paywalled","nonrandomized_study","Alpert Z","2026","Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.08.068","https://doi.org/10.1016/j.arth.2025.08.068","40907673","https://pubmed.ncbi.nlm.nih.gov/40907673/",null,null],["4","R0005161","R0005161.pdf","paywalled","nonrandomized_study","Podder V","2026","Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.","Clinical cancer research : an official journal of the American Association for Cancer Research","American Association for Cancer Research (AACR)","10.1158/1078-0432.ccr-25-2819","https://doi.org/10.1158/1078-0432.ccr-25-2819","41329840","https://pubmed.ncbi.nlm.nih.gov/41329840/",null,null],["4","R0005201","R0005201.pdf","paywalled","nonrandomized_study","Saad-Omer S","2026","Examining the association of dipeptidyl peptidase-4 inhibitors with autoimmune blistering disorders in the U.S. Military veterans.","Cutaneous and ocular toxicology","Informa UK Limited","10.1080/15569527.2026.2672618","https://doi.org/10.1080/15569527.2026.2672618","42189844","https://pubmed.ncbi.nlm.nih.gov/42189844/",null,null],["4","R0005251","R0005251.pdf","paywalled","nonrandomized_study","Papadakis Z","2026","Exercise as a Cornerstone Therapy for Cardiovascular-Kidney-Metabolic Syndrome: A Stage-Informed, Mechanistic, and Integrative Framework.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.03.103","https://doi.org/10.1016/j.eprac.2026.03.103","41921667","https://pubmed.ncbi.nlm.nih.gov/41921667/",null,null],["4","R0005291","R0005291.pdf","paywalled","nonrandomized_study","Xie Z","2026","Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70065","https://doi.org/10.1002/oby.70065","41266832","https://pubmed.ncbi.nlm.nih.gov/41266832/",null,null],["4","R0005347","R0005347.pdf","paywalled","nonrandomized_study","Solpari K","2026","Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.70580","https://doi.org/10.1111/liv.70580","41823026","https://pubmed.ncbi.nlm.nih.gov/41823026/",null,null],["4","R0005440","R0005440.pdf","paywalled","nonrandomized_study","Polyzos SA","2026","Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment Considerations.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/0115701611414052251127074106","https://doi.org/10.2174/0115701611414052251127074106","41582340","https://pubmed.ncbi.nlm.nih.gov/41582340/",null,null],["4","R0005443","R0005443.pdf","paywalled","nonrandomized_study","Falcetta P","2026","Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP-1 Receptor Agonists: A Machine Learning-Based Analysis of a Large Real World Cohort.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70648","https://doi.org/10.1111/dom.70648","41804217","https://pubmed.ncbi.nlm.nih.gov/41804217/",null,null],["4","R0005456","R0005456.pdf","paywalled","nonrandomized_study","Biswas S","2026","Differential Effects of GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-on Therapy on Outcomes Following Cardiac Surgery: A Propensity Score-Matched Analysis.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001393","https://doi.org/10.1097/crd.0000000000001393","42487161","https://pubmed.ncbi.nlm.nih.gov/42487161/",null,null],["4","R0005497","R0005497.pdf","paywalled","nonrandomized_study","Sun M","2026","GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70459","https://doi.org/10.1111/dom.70459","41582696","https://pubmed.ncbi.nlm.nih.gov/41582696/",null,null],["4","R0005520","R0005520.pdf","paywalled","nonrandomized_study","Nguefang GL","2026","Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08864-2","https://doi.org/10.1007/s11695-026-08864-2","42471527","https://pubmed.ncbi.nlm.nih.gov/42471527/",null,null],["4","R0005547","R0005547.pdf","paywalled","nonrandomized_study","Ternhamar T","2026","Combination of cardioprotective glucose-lowering drugs and statins on cardiovascular mortality in diabetes: a nationwide cohort study.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag085","https://doi.org/10.1093/eurjpc/zwag085","41733203","https://pubmed.ncbi.nlm.nih.gov/41733203/",null,null],["4","R0005636","R0005636.pdf","paywalled","nonrandomized_study","D'Arcy SJ","2026","Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.","Head & neck","Wiley","10.1002/hed.70286","https://doi.org/10.1002/hed.70286","42003032","https://pubmed.ncbi.nlm.nih.gov/42003032/",null,null],["4","R0005679","R0005679.pdf","paywalled","nonrandomized_study","Friedman O","2026","Abdominoplasty Outcomes after GLP-1 Agonist-Induced versus Postbariatric Massive Weight Loss: A Retrospective Comparative Case Series.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012523","https://doi.org/10.1097/prs.0000000000012523","41118524","https://pubmed.ncbi.nlm.nih.gov/41118524/",null,null],["4","R0005682","R0005682.pdf","paywalled","nonrandomized_study","Ghusn W","2026","Mapping the continuum of procedural bariatric care: real-world weight loss after endoscopic and surgical interventions.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-026-12933-z","https://doi.org/10.1007/s00464-026-12933-z","42277424","https://pubmed.ncbi.nlm.nih.gov/42277424/",null,null],["4","R0005731","R0005731.pdf","paywalled","nonrandomized_study","Camilleri M","2026","Gastroparesis: A Review.","JAMA","American Medical Association (AMA)","10.1001/jama.2026.12181","https://doi.org/10.1001/jama.2026.12181","42485161","https://pubmed.ncbi.nlm.nih.gov/42485161/",null,null],["4","R0005736","R0005736.pdf","paywalled","nonrandomized_study","Hsiao CC","2026","Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113115","https://doi.org/10.1016/j.diabres.2026.113115","41611096","https://pubmed.ncbi.nlm.nih.gov/41611096/",null,null],["4","R0005743","R0005743.pdf","paywalled","nonrandomized_study","Singh H","2026","Type 2 Diabetes and Vascular Complications: Current Perspectives on Pathophysiology and Management Strategies.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/0113816128415070251009170250","https://doi.org/10.2174/0113816128415070251009170250","41735213","https://pubmed.ncbi.nlm.nih.gov/41735213/",null,null],["4","R0005836","R0005836.pdf","paywalled","nonrandomized_study","Koenig ZA","2026","Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012405","https://doi.org/10.1097/prs.0000000000012405","40875227","https://pubmed.ncbi.nlm.nih.gov/40875227/",null,null],["4","R0005886","R0005886.pdf","paywalled","nonrandomized_study","Mehta MKS","2026","GLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects.","Journal of neurosurgery. Spine","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2026.4.spine26216","https://doi.org/10.3171/2026.4.spine26216","42664518","https://pubmed.ncbi.nlm.nih.gov/42664518/",null,null],["4","R0005889","R0005889.pdf","paywalled","nonrandomized_study","Bach P","2026","Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.","The lancet. Psychiatry","Elsevier BV","10.1016/s2215-0366(26)00172-0","https://doi.org/10.1016/s2215-0366(26)00172-0","42456704","https://pubmed.ncbi.nlm.nih.gov/42456704/",null,null],["4","R0005902","R0005902.pdf","paywalled","nonrandomized_study","Stryelkina M","2026","Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-025-09307-1","https://doi.org/10.1007/s10620-025-09307-1","40783459","https://pubmed.ncbi.nlm.nih.gov/40783459/",null,null],["4","R0005906","R0005906.pdf","paywalled","nonrandomized_study","Dallal RM","2026","Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.12.007","https://doi.org/10.1016/j.soard.2025.12.007","41672790","https://pubmed.ncbi.nlm.nih.gov/41672790/",null,null],["4","R0005911","R0005911.pdf","paywalled","nonrandomized_study","Kędzierska-Kapuza K","2026","Real-World Incretin-Based Therapy for Obesity After Solid Organ Transplantation: A Single-Centre Retrospective Study From Poland.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71222","https://doi.org/10.1111/dom.71222","42634580","https://pubmed.ncbi.nlm.nih.gov/42634580/",null,null],["4","R0005923","R0005923.pdf","paywalled","nonrandomized_study","Esmann FVL","2026","Anabolic androgenic steroid use and risk of diabetes mellitus in males.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70283","https://doi.org/10.1111/dom.70283","41208464","https://pubmed.ncbi.nlm.nih.gov/41208464/",null,null],["4","R0005946","R0005946.pdf","paywalled","nonrandomized_study","Le Y","2026","Five-Year Incidence of Progression to Ankle Osteoarthritis in Patients with and without Glucagon-like Peptide-1 Receptor Agonist Therapy.","Foot & ankle specialist","SAGE Publications","10.1177/19386400261427898","https://doi.org/10.1177/19386400261427898","41805465","https://pubmed.ncbi.nlm.nih.gov/41805465/",null,null],["4","R0005966","R0005966.pdf","paywalled","nonrandomized_study","Mao X","2026","GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001771","https://doi.org/10.1097/hep.0000000000001771","42029657","https://pubmed.ncbi.nlm.nih.gov/42029657/",null,null],["4","R0006042","R0006042.pdf","paywalled","nonrandomized_study","Chauhan I","2026","What obgyns need to know about GLP-1 receptor agonists.","Current opinion in obstetrics & gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/gco.0000000000001116","https://doi.org/10.1097/gco.0000000000001116","42108205","https://pubmed.ncbi.nlm.nih.gov/42108205/",null,null],["4","R0006145","R0006145.pdf","paywalled","nonrandomized_study","Wang SF","2026","Cardiovascular benefits of early sodium-glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70416","https://doi.org/10.1002/bcp.70416","41392024","https://pubmed.ncbi.nlm.nih.gov/41392024/",null,null],["4","R0006152","R0006152.pdf","paywalled","nonrandomized_study","Tobin MJ","2026","Body Mass Index, Comorbidities, and the New Lancet Obesity Definition: Implications for Risk Analysis in Plastic and Reconstructive Surgery.","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000012830","https://doi.org/10.1097/prs.0000000000012830","41557524","https://pubmed.ncbi.nlm.nih.gov/41557524/",null,null],["4","R0006195","R0006195.pdf","paywalled","nonrandomized_study","Mazzeo L","2026","Metabolic and renal effects of combined SGLT-2 inhibitors and GLP1-R agonists therapy in type 2 diabetes: a real-world analysis across DKD and non-DKD patients.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-025-02756-5","https://doi.org/10.1007/s40618-025-02756-5","41452441","https://pubmed.ncbi.nlm.nih.gov/41452441/",null,null],["4","R0006224","R0006224.pdf","paywalled","nonrandomized_study","Gregory EF","2026","Characteristics of Youth Treated With GLP-1RAs at an Integrated Weight Management Clinic.","Pediatrics","American Academy of Pediatrics (AAP)","10.1542/peds.2025-074094","https://doi.org/10.1542/peds.2025-074094","41765353","https://pubmed.ncbi.nlm.nih.gov/41765353/",null,null],["4","R0006267","R0006267.pdf","paywalled","nonrandomized_study","Nguyen XT","2026","Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(25)00395-x","https://doi.org/10.1016/s2213-8587(25)00395-x","41763234","https://pubmed.ncbi.nlm.nih.gov/41763234/",null,null],["4","R0006289","R0006289.pdf","paywalled","nonrandomized_study","Marassi M","2026","GLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2026.2640982","https://doi.org/10.1080/14740338.2026.2640982","41773040","https://pubmed.ncbi.nlm.nih.gov/41773040/",null,null],["4","R0006419","R0006419.pdf","paywalled","nonrandomized_study","Brown A","2026","Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-12403-y","https://doi.org/10.1007/s00464-025-12403-y","41326727","https://pubmed.ncbi.nlm.nih.gov/41326727/",null,null],["4","R0006679","R0006679.pdf","paywalled","nonrandomized_study","Taha MME","2026","Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-025-04574-1","https://doi.org/10.1007/s00210-025-04574-1","40900331","https://pubmed.ncbi.nlm.nih.gov/40900331/",null,null],["4","R0006720","R0006720.pdf","paywalled","nonrandomized_study","Abdul Fasi M","2026","Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.","Expert opinion on therapeutic patents","Informa UK Limited","10.1080/13543776.2026.2645812","https://doi.org/10.1080/13543776.2026.2645812","41820018","https://pubmed.ncbi.nlm.nih.gov/41820018/",null,null],["4","R0006759","R0006759.pdf","paywalled","nonrandomized_study","Cromer SJ","2026","Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study.","Diabetes care","American Diabetes Association","10.2337/dca26-0039","https://doi.org/10.2337/dca26-0039","42765974","https://pubmed.ncbi.nlm.nih.gov/42765974/",null,null],["4","R0006841","R0006841.pdf","paywalled","nonrandomized_study","Goyal A","2026","Cardiovascular Outcomes With GLP-1 Receptor Agonists in Patients With Diabetes or Obesity Undergoing Transcatheter Aortic Valve Replacement.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2026.04.003","https://doi.org/10.1016/j.cjca.2026.04.003","42019817","https://pubmed.ncbi.nlm.nih.gov/42019817/",null,null],["4","R0006880","R0006880.pdf","paywalled","nonrandomized_study","Fabi S","2026","Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005166","https://doi.org/10.1097/dss.0000000000005166","42210883","https://pubmed.ncbi.nlm.nih.gov/42210883/",null,null],["4","R0006928","R0006928.pdf","paywalled","nonrandomized_study","Markoutsaki V","2026","Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus.","Hormones (Athens, Greece)","Springer Science and Business Media LLC","10.1007/s42000-025-00743-2","https://doi.org/10.1007/s42000-025-00743-2","41417204","https://pubmed.ncbi.nlm.nih.gov/41417204/",null,null],["4","R0006989","R0006989.pdf","paywalled","nonrandomized_study","Corrado RL","2026","Prevalence of Obesity Medications in the Military Health System: An Update from 2022.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usag142","https://doi.org/10.1093/milmed/usag142","41894608","https://pubmed.ncbi.nlm.nih.gov/41894608/",null,null],["4","R0007174","R0007174.pdf","paywalled","nonrandomized_study","Valdez Y","2026","Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2026-0335","https://doi.org/10.1515/jpem-2026-0335","42576608","https://pubmed.ncbi.nlm.nih.gov/42576608/",null,null],["4","R0007253","R0007253.pdf","paywalled","nonrandomized_study","Nicolau J","2026","Semaglutide in patients with hidradenitis suppurativa and obesity.","Medicina clinica","Elsevier BV","10.1016/j.medcli.2026.107405","https://doi.org/10.1016/j.medcli.2026.107405","41832804","https://pubmed.ncbi.nlm.nih.gov/41832804/",null,null],["4","R0007282","R0007282.pdf","paywalled","nonrandomized_study","Bassatne A","2026","Medical Treatments for Obesity: What Does the Future Have in Store?","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag274","https://doi.org/10.1210/clinem/dgag274","42444567","https://pubmed.ncbi.nlm.nih.gov/42444567/",null,null],["4","R0007354","R0007354.pdf","paywalled","nonrandomized_study","Maruyama F","2026","Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70734","https://doi.org/10.1111/dom.70734","41944182","https://pubmed.ncbi.nlm.nih.gov/41944182/",null,null],["4","R0007409","R0007409.pdf","paywalled","nonrandomized_study","Prado BS","2026","Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1093/annalsats/aaoaf071","https://doi.org/10.1093/annalsats/aaoaf071","41915565","https://pubmed.ncbi.nlm.nih.gov/41915565/",null,null],["4","R0007498","R0007498.pdf","paywalled","nonrandomized_study","Chang Y","2026","Association between glucagon-like peptide-1 receptor agonists and nonfusion risk after single-level anterior cervical discectomy and fusion.","The spine journal : official journal of the North American Spine Society","Elsevier BV","10.1016/j.spinee.2025.07.010","https://doi.org/10.1016/j.spinee.2025.07.010","40633588","https://pubmed.ncbi.nlm.nih.gov/40633588/",null,null],["4","R0007720","R0007720.pdf","paywalled","nonrandomized_study","Ghusn W","2026","Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2026.02.006","https://doi.org/10.1016/j.mayocp.2026.02.006","42383938","https://pubmed.ncbi.nlm.nih.gov/42383938/",null,null],["4","R0007723","R0007723.pdf","paywalled","nonrandomized_study","Yadav Y","2026","Septic Shock and Glucagon-Like Peptide-1 Analog Association in Real World: A Propensity Score Matched Analysis.","Chest","Elsevier BV","10.1016/j.chest.2026.06.016","https://doi.org/10.1016/j.chest.2026.06.016","42320668","https://pubmed.ncbi.nlm.nih.gov/42320668/",null,null],["4","R0007739","R0007739.pdf","paywalled","nonrandomized_study","Banerjee M","2026","Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70277","https://doi.org/10.1002/oby.70277","42618523","https://pubmed.ncbi.nlm.nih.gov/42618523/",null,null],["4","R0007828","R0007828.pdf","paywalled","nonrandomized_study","Benyamini B","2026","1-year patient-reported outcomes in patients with a documented GLP-1 agonist prescription history prior to total hip arthroplasty: a retrospective cohort study.","Hip international : the journal of clinical and experimental research on hip pathology and therapy","SAGE Publications","10.1177/11207000261450078","https://doi.org/10.1177/11207000261450078","42274387","https://pubmed.ncbi.nlm.nih.gov/42274387/",null,null],["4","R0008103","R0008103.pdf","paywalled","nonrandomized_study","Wang L","2026","Association between hemoglobin glycation index and carotid plaques in non-dialysis CKD stage 3-5 patients: a retrospective cross-sectional study.","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-025-04728-3","https://doi.org/10.1007/s11255-025-04728-3","40813550","https://pubmed.ncbi.nlm.nih.gov/40813550/",null,null],["4","R0008149","R0008149.pdf","paywalled","nonrandomized_study","El Zibaoui R","2026","Real-world experience with GLP-1 receptor agonists in adults with epilepsy following a modified atkins diet.","Epilepsy research","Elsevier BV","10.1016/j.eplepsyres.2026.107896","https://doi.org/10.1016/j.eplepsyres.2026.107896","42617503","https://pubmed.ncbi.nlm.nih.gov/42617503/",null,null],["4","R0008210","R0008210.pdf","paywalled","nonrandomized_study","Akbar UA","2026","Interpreting Real-World Cardiovascular Outcomes With GLP-1 Receptor Agonists.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.08.028","https://doi.org/10.1016/j.amjcard.2026.08.028","42686051","https://pubmed.ncbi.nlm.nih.gov/42686051/",null,null],["4","R0008280","R0008280.pdf","paywalled","nonrandomized_study","Janić M","2026","Tirzepatide data: safety first is safety always!","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2026.2681511","https://doi.org/10.1080/14740338.2026.2681511","42201797","https://pubmed.ncbi.nlm.nih.gov/42201797/",null,null],["4","R0008335","R0008335.pdf","paywalled","nonrandomized_study","Feng Z","2026","Potential Associations Between GLP-1 Receptor Agonists and Polyendocrine Metabolic Ovarian Syndrome: Triangulation of Genetic and Pharmacovigilance Evidence.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71348","https://doi.org/10.1111/dom.71348","42736040","https://pubmed.ncbi.nlm.nih.gov/42736040/",null,null],["4","R0008532","R0008532.pdf","paywalled","nonrandomized_study","Akturk HK","2026","Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156261423903","https://doi.org/10.1177/15209156261423903","41804758","https://pubmed.ncbi.nlm.nih.gov/41804758/",null,null],["4","R0008586","R0008586.pdf","paywalled","nonrandomized_study","Yu CC","2026","Clarifying cohort design in a study of GLP-1 receptor agonist use and metabolic outcomes following radical cystectomy.","Urologic oncology","Elsevier BV","10.1016/j.urolonc.2026.05.008","https://doi.org/10.1016/j.urolonc.2026.05.008","42618167","https://pubmed.ncbi.nlm.nih.gov/42618167/",null,null],["4","R0008741","R0008741.pdf","paywalled","nonrandomized_study","Vosburg RW","2026","American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2026.04.002","https://doi.org/10.1016/j.soard.2026.04.002","42150970","https://pubmed.ncbi.nlm.nih.gov/42150970/",null,null],["4","R0008753","R0008753.pdf","paywalled","nonrandomized_study","Habib H","2026","Response to letter to the editor: \"GLP-1RAs for pouchitis in obesity: what the current study does not tell us\".","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izag128","https://doi.org/10.1093/ibd/izag128","42424310","https://pubmed.ncbi.nlm.nih.gov/42424310/",null,null],["4","R0008758","R0008758.pdf","paywalled","nonrandomized_study","Tang Y","2026","An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product.","Pharmaceutical research","Springer Science and Business Media LLC","10.1007/s11095-026-04178-1","https://doi.org/10.1007/s11095-026-04178-1","42687068","https://pubmed.ncbi.nlm.nih.gov/42687068/",null,null],["4","R0008833","R0008833.pdf","paywalled","nonrandomized_study","Pantazopoulos D","2026","GLP-1 Receptor Agonists to Reduce Mortality in Patients with Diabetic Foot Ulcers: Insights from a Recent Nationwide Observational Study.","The international journal of lower extremity wounds","SAGE Publications","10.1177/15347346261474199","https://doi.org/10.1177/15347346261474199","42523126","https://pubmed.ncbi.nlm.nih.gov/42523126/",null,null],["4","R0008872","R0008872.pdf","paywalled","nonrandomized_study","Cotrik E","2026","Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.","International clinical psychopharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/yic.0000000000000636","https://doi.org/10.1097/yic.0000000000000636","42542974","https://pubmed.ncbi.nlm.nih.gov/42542974/",null,null],["4","R0008913","R0008913.pdf","paywalled","nonrandomized_study","Hafez A","2026","GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Hypertrophic Cardiomyopathy With Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.07.025","https://doi.org/10.1016/j.amjcard.2026.07.025","42526673","https://pubmed.ncbi.nlm.nih.gov/42526673/",null,null],["4","R0008915","R0008915.pdf","paywalled","nonrandomized_study","Banerjee M","2026","Prepregnancy GLP-1 Receptor Agonist Use: Unaccounted Pretreatment BMI May Distort Obstetric Outcome Signals in Real-World Studies.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70286","https://doi.org/10.1002/oby.70286","42575725","https://pubmed.ncbi.nlm.nih.gov/42575725/",null,null],["4","R0008941","R0008941.pdf","paywalled","nonrandomized_study","Lemas DJ","2026","Response to \"Prepregnancy GLP-1 Receptor Agonist Use: Unaccounted Pretreatment BMI May Distort Obstetric Outcome Signals in Real-World Studies\".","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70287","https://doi.org/10.1002/oby.70287","42578724","https://pubmed.ncbi.nlm.nih.gov/42578724/",null,null],["4","R0008965","R0008965.pdf","paywalled","nonrandomized_study","Zickler CL","2026","GLP-1 agonists versus bariatric surgery: Which management carries heavier weight prior to total knee arthroplasty?","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","Wiley","10.1002/ksa.70473","https://doi.org/10.1002/ksa.70473","42240558","https://pubmed.ncbi.nlm.nih.gov/42240558/",null,null],["4","R0008987","R0008987.pdf","paywalled","nonrandomized_study","AlTaweel MO","2026","Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.","Expert review of cardiovascular therapy","Informa UK Limited","10.1080/14779072.2026.2713476","https://doi.org/10.1080/14779072.2026.2713476","42535667","https://pubmed.ncbi.nlm.nih.gov/42535667/",null,null],["4","R0009055","R0009055.pdf","paywalled","nonrandomized_study","Beyene E","2026","Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.","Clinics and research in hepatology and gastroenterology","Elsevier BV","10.1016/j.clinre.2026.102760","https://doi.org/10.1016/j.clinre.2026.102760","41500355","https://pubmed.ncbi.nlm.nih.gov/41500355/",null,null],["4","R0009124","R0009124.pdf","paywalled","nonrandomized_study","Htoo PT","2026","Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001244","https://doi.org/10.2215/cjn.0000001244","42809365","https://pubmed.ncbi.nlm.nih.gov/42809365/",null,null],["4","R0009125","R0009125.pdf","paywalled","nonrandomized_study","Leslie DB","2026","1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(26)00030-6","https://doi.org/10.1016/s2213-8587(26)00030-6","42309121","https://pubmed.ncbi.nlm.nih.gov/42309121/",null,null],["4","R0009160","R0009160.pdf","paywalled","nonrandomized_study","Hsu HY","2026","Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113186","https://doi.org/10.1016/j.diabres.2026.113186","41740927","https://pubmed.ncbi.nlm.nih.gov/41740927/",null,null],["4","R0009252","R0009252.pdf","paywalled","nonrandomized_study","Cestari M","2026","Peripheral neuropathic symptoms with GLP-1 receptor agonists: Insights from a large real-world cohort.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag077","https://doi.org/10.1093/ajhp/zxag077","41824639","https://pubmed.ncbi.nlm.nih.gov/41824639/",null,null],["4","R0009339","R0009339.pdf","paywalled","nonrandomized_study","Mariscal Vázquez S","2026","Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2026.502562","https://doi.org/10.1016/j.rceng.2026.502562","42061608","https://pubmed.ncbi.nlm.nih.gov/42061608/",null,null],["4","R0009368","R0009368.pdf","paywalled","nonrandomized_study","Talmy T","2026","Risk of postoperative respiratory complications in adults treated with GLP-1 receptor agonists: a propensity-matched population-based study.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2026.04.051","https://doi.org/10.1016/j.bja.2026.04.051","42215372","https://pubmed.ncbi.nlm.nih.gov/42215372/",null,null],["4","R0009374","R0009374.pdf","paywalled","nonrandomized_study","Boujenah J","2026","GLP-1 Receptor Agonists, Gestational Weight Gain, and Pregnancy Outcomes.","JAMA","American Medical Association (AMA)","10.1001/jama.2026.2648","https://doi.org/10.1001/jama.2026.2648","42008281","https://pubmed.ncbi.nlm.nih.gov/42008281/",null,null],["4","R0009438","R0009438.pdf","paywalled","nonrandomized_study","Zhang Y","2026","Letter to the Editor regarding \"The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study\".","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Springer Science and Business Media LLC","10.1007/s00198-026-08068-5","https://doi.org/10.1007/s00198-026-08068-5","42201384","https://pubmed.ncbi.nlm.nih.gov/42201384/",null,null],["4","R0009441","R0009441.pdf","paywalled","nonrandomized_study","Ni H","2026","Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2026.2723583","https://doi.org/10.1080/14656566.2026.2723583","42638087","https://pubmed.ncbi.nlm.nih.gov/42638087/",null,null],["4","R0009453","R0009453.pdf","paywalled","nonrandomized_study","Ciaffi J","2026","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Rheumatology (Oxford, England)","Oxford University Press (OUP)","10.1093/rheumatology/keag350","https://doi.org/10.1093/rheumatology/keag350","42384173","https://pubmed.ncbi.nlm.nih.gov/42384173/",null,null],["4","R0009463","R0009463.pdf","paywalled","nonrandomized_study","Bruno A","2026","Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-05978-x","https://doi.org/10.1007/s00266-026-05978-x","42286330","https://pubmed.ncbi.nlm.nih.gov/42286330/",null,null],["4","R0009472","R0009472.pdf","paywalled","nonrandomized_study","Jones GB","2026","Editorial on \"GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated lip(a) levels: A multicenter retrospective study\" IJCJOURNAL-D-26-01993R1.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2026.134632","https://doi.org/10.1016/j.ijcard.2026.134632","42331181","https://pubmed.ncbi.nlm.nih.gov/42331181/",null,null],["4","R0009596","R0009596.pdf","paywalled","nonrandomized_study","Jha AK","2026","Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.74.1508","https://doi.org/10.59556/japi.74.1508","42543936","https://pubmed.ncbi.nlm.nih.gov/42543936/",null,null],["4","R0009613","R0009613.pdf","paywalled","nonrandomized_study","Kvist AV","2026","Author response to OSIN-D-26-00705 Comment on: The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Springer Science and Business Media LLC","10.1007/s00198-026-08071-w","https://doi.org/10.1007/s00198-026-08071-w","42201385","https://pubmed.ncbi.nlm.nih.gov/42201385/",null,null],["4","R0009664","R0009664.pdf","paywalled","nonrandomized_study","Muzurović E","2026","Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156494","https://doi.org/10.1016/j.metabol.2026.156494","41564595","https://pubmed.ncbi.nlm.nih.gov/41564595/",null,null],["4","R0009691","R0009691.pdf","paywalled","nonrandomized_study","Pasquariello T","2026","Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review.","Nephron","S. Karger AG","10.1159/nef/adtag006","https://doi.org/10.1159/nef/adtag006","42743093","https://pubmed.ncbi.nlm.nih.gov/42743093/",null,null],["4","R0009700","R0009700.pdf","paywalled","nonrandomized_study","Kvist AV","2026","Author response to OSIN-D-26-00775 Letter to the Editor regarding \"The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study\".","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Springer Science and Business Media LLC","10.1007/s00198-026-08069-4","https://doi.org/10.1007/s00198-026-08069-4","42201383","https://pubmed.ncbi.nlm.nih.gov/42201383/",null,null],["4","R0009752","R0009752.pdf","paywalled","nonrandomized_study","Eshak N","2026","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform: reply.","Rheumatology (Oxford, England)","Oxford University Press (OUP)","10.1093/rheumatology/keag255","https://doi.org/10.1093/rheumatology/keag255","42143728","https://pubmed.ncbi.nlm.nih.gov/42143728/",null,null],["4","R0009783","R0009783.pdf","paywalled","nonrandomized_study","Jiang C","2026","Re-evaluating GLP-1 receptor agonist-associated changes in copeptin.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag065","https://doi.org/10.1093/ejendo/lvag065","41986882","https://pubmed.ncbi.nlm.nih.gov/41986882/",null,null],["4","R0009814","R0009814.pdf","paywalled","nonrandomized_study","Pham HN","2026","GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcaf135","https://doi.org/10.1093/ehjqcco/qcaf135","41206745","https://pubmed.ncbi.nlm.nih.gov/41206745/",null,null],["4","R0009826","R0009826.pdf","paywalled","nonrandomized_study","St-Pierre J","2026","Letter: From Safety to Precision-Optimising the Use of GLP-1 Receptor Agonists in Gastroenterology.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70538","https://doi.org/10.1111/apt.70538","41856913","https://pubmed.ncbi.nlm.nih.gov/41856913/",null,null],["4","R0009858","R0009858.pdf","paywalled","nonrandomized_study","Pomenti S","2026","Letter: From Safety to Precision-Optimising the Use of GLP-1 Receptor Agonists in Gastroenterology: Authors' Reply.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70547","https://doi.org/10.1111/apt.70547","41874346","https://pubmed.ncbi.nlm.nih.gov/41874346/",null,null],["4","R0009907","R0009907.pdf","paywalled","nonrandomized_study","Hong AT","2026","Response to Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care 2025;48:1728-1736.","Diabetes care","American Diabetes Association","10.2337/dci26-0037","https://doi.org/10.2337/dci26-0037","42160602","https://pubmed.ncbi.nlm.nih.gov/42160602/",null,null],["4","R0009908","R0009908.pdf","paywalled","nonrandomized_study","Velasco Á","2026","Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2026.502455","https://doi.org/10.1016/j.rceng.2026.502455","41520703","https://pubmed.ncbi.nlm.nih.gov/41520703/",null,null],["4","R0009928","R0009928.pdf","paywalled","nonrandomized_study","Cheng R","2026","Implementation or Intrinsic Efficacy? Interpreting Real-World Comparisons of GLP-1 Receptor Agonists.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70174","https://doi.org/10.1002/oby.70174","41792037","https://pubmed.ncbi.nlm.nih.gov/41792037/",null,null],["4","R0009945","R0009945.pdf","paywalled","nonrandomized_study","AlTaweel M","2026","BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2692167","https://doi.org/10.1080/03007995.2026.2692167","42381378","https://pubmed.ncbi.nlm.nih.gov/42381378/",null,null],["4","R0009958","R0009958.pdf","paywalled","nonrandomized_study","Wang J","2026","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Rheumatology (Oxford, England)","Oxford University Press (OUP)","10.1093/rheumatology/keag151","https://doi.org/10.1093/rheumatology/keag151","41923358","https://pubmed.ncbi.nlm.nih.gov/41923358/",null,null],["4","R0009969","R0009969.pdf","paywalled","nonrandomized_study","Hornick MA","2026","The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-026-02120-4","https://doi.org/10.1038/s41366-026-02120-4","42225949","https://pubmed.ncbi.nlm.nih.gov/42225949/",null,null],["4","R0010041","R0010041.pdf","paywalled","nonrandomized_study","Ferrulli A","2026","Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70105","https://doi.org/10.1002/oby.70105","41451880","https://pubmed.ncbi.nlm.nih.gov/41451880/",null,"ClinicalTrials.gov:NCT03009695"],["4","R0010104","R0010104.pdf","paywalled","nonrandomized_study","Zubairi R","2026","Combination GLP-1 RA Plus SGLT2i Therapy in MASLD and Type 2 Diabetes: Methodological Considerations for the Three Pairwise Target Trial Emulations.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70703","https://doi.org/10.1111/jgh.70703","42638155","https://pubmed.ncbi.nlm.nih.gov/42638155/",null,null],["4","R0010111","R0010111.pdf","paywalled","nonrandomized_study","Karim A","2026","Re: GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70681","https://doi.org/10.1111/jgh.70681","42610485","https://pubmed.ncbi.nlm.nih.gov/42610485/",null,null],["4","R0010216","R0010216.pdf","paywalled","nonrandomized_study","Alkuwaiti MA","2026","Reply to Letter to the Editor About the Article \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70698","https://doi.org/10.1111/jgh.70698","42638184","https://pubmed.ncbi.nlm.nih.gov/42638184/",null,null],["4","R0010311","R0010311.pdf","paywalled","nonrandomized_study","D'Anna G","2026","Comments on \"Abdominoplasty Outcomes After GLP-1 Agonist-Induced Versus Postbariatric Massive Weight Loss: A Retrospective Comparative Case Series\".","Plastic and reconstructive surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000013427","https://doi.org/10.1097/prs.0000000000013427","42695811","https://pubmed.ncbi.nlm.nih.gov/42695811/",null,null],["4","R0010349","R0010349.pdf","paywalled","nonrandomized_study","Jean SS","2026","Methodological concerns regarding \"Alopecia after GLP-1 agonist therapy: A TriNetX database active comparator retrospective cohort study\".","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.06.154","https://doi.org/10.1016/j.jaad.2026.06.154","42641691","https://pubmed.ncbi.nlm.nih.gov/42641691/",null,null],["4","R0010386","R0010386.pdf","paywalled","nonrandomized_study","Sánchez VMA","2026","Comment On: Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists; An Examination of the FAERS Database.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2026.01.042","https://doi.org/10.1016/j.ajo.2026.01.042","41672365","https://pubmed.ncbi.nlm.nih.gov/41672365/",null,null],["4","R0010394","R0010394.pdf","paywalled","nonrandomized_study","Naude J","2026","Response to concerns with the statistical analysis in \"Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study\".","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-026-02135-x","https://doi.org/10.1038/s41366-026-02135-x","42509259","https://pubmed.ncbi.nlm.nih.gov/42509259/",null,null],["4","R0010411","R0010411.pdf","paywalled","nonrandomized_study","Murray M","2026","Reply to Comment on: \"Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS Database\".","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2026.02.004","https://doi.org/10.1016/j.ajo.2026.02.004","41679369","https://pubmed.ncbi.nlm.nih.gov/41679369/",null,null],["4","R0010458","R0010458.pdf","paywalled","nonrandomized_study","Khang J","2026","Tolerability and safety of concomitant GLP-1 receptor agonist and biologic therapy: A retrospective chart review.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.01.016","https://doi.org/10.1016/j.jaad.2026.01.016","41571150","https://pubmed.ncbi.nlm.nih.gov/41571150/",null,null],["4","R0010648","R0010648.pdf","paywalled","nonrandomized_study","Liu S","2026","Comment on \"Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients\".","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-025-07812-z","https://doi.org/10.1007/s10557-025-07812-z","41240220","https://pubmed.ncbi.nlm.nih.gov/41240220/",null,null],["4","R0010734","R0010734.pdf","paywalled","nonrandomized_study","D'Souza RS","2026","Step-by-step: GLP-1 agonist use is associated with lower risk of knee replacement.","Regional anesthesia and pain medicine","BMJ","10.1136/rapm-2026-108024","https://doi.org/10.1136/rapm-2026-108024","42336491","https://pubmed.ncbi.nlm.nih.gov/42336491/",null,null],["4","R0010833","R0010833.pdf","paywalled","nonrandomized_study","Almeida OP","2026","No causal link between the supply of GLP-1 receptor agonists and antidepressants: Real-world evidence from the Australian Pharmaceutical Benefits Scheme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70376","https://doi.org/10.1111/dom.70376","41369009","https://pubmed.ncbi.nlm.nih.gov/41369009/",null,null],["4","R0010891","R0010891.pdf","paywalled","nonrandomized_study","Ceriello A","2026","Causes and consequences of discontinuation of GLP1RAs or tirzepatide.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/s41574-026-01258-5","https://doi.org/10.1038/s41574-026-01258-5","42168641","https://pubmed.ncbi.nlm.nih.gov/42168641/",null,null],["4","R0010912","R0010912.pdf","paywalled","nonrandomized_study","Tomaselli F","2026","Correspondence on: \"Breast implant explantation with mastopexy in patients using GLP-1 receptor agonists: A retrospective comparative analysis\".","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Elsevier BV","10.1016/j.bjps.2025.11.014","https://doi.org/10.1016/j.bjps.2025.11.014","41273948","https://pubmed.ncbi.nlm.nih.gov/41273948/",null,null],["4","R0010940","R0010940.pdf","paywalled","nonrandomized_study","Kır Y","2026","Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-026-03024-w","https://doi.org/10.1007/s40618-026-03024-w","42611111","https://pubmed.ncbi.nlm.nih.gov/42611111/",null,null],["4","R0011051","R0011051.pdf","paywalled","nonrandomized_study","Bergstein VE","2026","Response to Cromer and Alkabbani regarding: \"GLP-1 agonist use increases the incidence of adhesive capsulitis and odds of requiring operative management in type 2 diabetes patients: a matched propensity score analysis\".","Journal of shoulder and elbow surgery","Elsevier BV","10.1016/j.jse.2026.07.003","https://doi.org/10.1016/j.jse.2026.07.003","42468772","https://pubmed.ncbi.nlm.nih.gov/42468772/",null,null],["4","R0011055","R0011055.pdf","paywalled","nonrandomized_study","Fite J","2026","The impact of GLP-1 receptor agonists on clinical outcomes and healthcare utilization in hidradenitis suppurativa patients: A retrospective cohort study using TriNetX.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.11.017","https://doi.org/10.1016/j.jaad.2025.11.017","41223997","https://pubmed.ncbi.nlm.nih.gov/41223997/",null,null],["4","R0011153","R0011153.pdf","paywalled","nonrandomized_study","Huang B","2026","Fracture-Centred Skeletal Reporting Profiles of Glucose-Lowering Drug Classes in FAERS and JADER: Cross-Database and Regional Reporting-Context Analyses.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71319","https://doi.org/10.1111/dom.71319","42734024","https://pubmed.ncbi.nlm.nih.gov/42734024/",null,null],["4","R0011498","R0011498.pdf","paywalled","nonrandomized_study","Chapani MS","2026","Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0109298673480116260915111102","https://doi.org/10.2174/0109298673480116260915111102","42813623","https://pubmed.ncbi.nlm.nih.gov/42813623/",null,null],["4","R0011542","R0011542.pdf","paywalled","nonrandomized_study","Mancinetti F","2026","Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.","European geriatric medicine","Springer Science and Business Media LLC","10.1007/s41999-025-01271-3","https://doi.org/10.1007/s41999-025-01271-3","40624450","https://pubmed.ncbi.nlm.nih.gov/40624450/",null,null],["4","R0011546","R0011546.pdf","paywalled","nonrandomized_study","Alawami F","2026","The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.","Irish journal of medical science","Springer Science and Business Media LLC","10.1007/s11845-025-04194-x","https://doi.org/10.1007/s11845-025-04194-x","41283946","https://pubmed.ncbi.nlm.nih.gov/41283946/",null,null],["4","R0011550","R0011550.pdf","paywalled","nonrandomized_study","Rivera NM","2026","The Impact of GLP-1 Receptor Agonists on Outcomes in Nondiabetic Patients Undergoing Posterior Cervical Spine Surgery: A Retrospective Analysis.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000002064","https://doi.org/10.1097/bsd.0000000000002064","42615893","https://pubmed.ncbi.nlm.nih.gov/42615893/",null,null],["4","R0011741","R0011741.pdf","paywalled","nonrandomized_study","Qin Y","2026","Comparison of SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single-center retrospective cohort study.","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-025-04748-z","https://doi.org/10.1007/s11255-025-04748-z","40911179","https://pubmed.ncbi.nlm.nih.gov/40911179/",null,null],["4","R0011962","R0011962.pdf","paywalled","nonrandomized_study","Noemi Torres I","2026","Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.","Substance use & addiction journal","SAGE Publications","10.1177/29767342251351111","https://doi.org/10.1177/29767342251351111","40765170","https://pubmed.ncbi.nlm.nih.gov/40765170/",null,null],["4","R0011979","R0011979.pdf","paywalled","nonrandomized_study","Chou PP","2026","GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.20874","https://doi.org/10.1111/jdv.20874","40693677","https://pubmed.ncbi.nlm.nih.gov/40693677/",null,null],["4","R0012069","R0012069.pdf","paywalled","nonrandomized_study","Goldstein AR","2026","Trimming the Fat: Does GLP-1 Receptor Agonist Therapy Impact Clinical and Functional Results After Tibial Plateau Fracture Fixation?","The journal of knee surgery","Georg Thieme Verlag KG","10.1055/a-2851-0573","https://doi.org/10.1055/a-2851-0573","41985491","https://pubmed.ncbi.nlm.nih.gov/41985491/",null,null],["4","R0012092","R0012092.pdf","paywalled","nonrandomized_study","Schnieder M","2026","[Advances in Anti-Dementia Therapies in Older Adults].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/a-2676-7649","https://doi.org/10.1055/a-2676-7649","42214359","https://pubmed.ncbi.nlm.nih.gov/42214359/",null,null],["4","R0012139","R0012139.pdf","paywalled","nonrandomized_study","Portillo-Canales S","2026","Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.01.003","https://doi.org/10.1016/j.eprac.2026.01.003","41544705","https://pubmed.ncbi.nlm.nih.gov/41544705/",null,null],["4","R0012213","R0012213.pdf","paywalled","nonrandomized_study","Murphy F","2026","Obesity versus China: how Ozempic is complicating the world's largest weight loss campaign.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-523232","https://doi.org/10.1136/bmj-2026-523232","42297440","https://pubmed.ncbi.nlm.nih.gov/42297440/",null,null],["4","R0012253","R0012253.pdf","paywalled","nonrandomized_study","Alkabbani W","2026","Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70963","https://doi.org/10.1111/dom.70963","42244136","https://pubmed.ncbi.nlm.nih.gov/42244136/",null,null],["4","R0012317","R0012317.pdf","paywalled","nonrandomized_study","Aburumman R","2026","Comparative Outcomes of GLP-1 Therapy vs. Bariatric Surgery in Patients with Cirrhosis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08823-x","https://doi.org/10.1007/s11695-026-08823-x","42348118","https://pubmed.ncbi.nlm.nih.gov/42348118/",null,null],["4","R0012334","R0012334.pdf","paywalled","nonrandomized_study","Khan MAUH","2026","Comment on: Comparison of SGLT‑2i and GLP‑1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single‑center retrospective cohort study.","International urology and nephrology","Springer Science and Business Media LLC","10.1007/s11255-025-04828-0","https://doi.org/10.1007/s11255-025-04828-0","41065935","https://pubmed.ncbi.nlm.nih.gov/41065935/",null,null],["4","R0012854","R0012854.pdf","paywalled","nonrandomized_study","Finer N","2026","Recommendations for real-world evidence of efficacy and safety of GLP-1 agonists in Prader-Willi syndrome: Report of a workshop held by the Foundation for Prader-Willi Research and International Prader Willi Syndrome Organisation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70282","https://doi.org/10.1111/dom.70282","41243595","https://pubmed.ncbi.nlm.nih.gov/41243595/",null,null],["4","R0012918","R0012918.pdf","paywalled","nonrandomized_study","Beck H","2026","Considerations and challenges in microdosing of GLP-1-based receptor agonists.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2026.2740393","https://doi.org/10.1080/14656566.2026.2740393","42788826","https://pubmed.ncbi.nlm.nih.gov/42788826/",null,null],["4","R0012949","R0012949.pdf","paywalled","nonrandomized_study","Ruderman SA","2026","Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV.","AIDS (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/qad.0000000000004596","https://doi.org/10.1097/qad.0000000000004596","42558050","https://pubmed.ncbi.nlm.nih.gov/42558050/",null,null],["4","R0012952","R0012952.pdf","paywalled","nonrandomized_study","Akinci B","2026","Letter to the editor from Akinci and Oral: \"Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy\".","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag362","https://doi.org/10.1210/clinem/dgag362","42770910","https://pubmed.ncbi.nlm.nih.gov/42770910/",null,null],["4","R0013121","R0013121.pdf","paywalled","nonrandomized_study","Manueli Laos EG","2026","Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights.","Clinical obesity","Wiley","10.1111/cob.70084","https://doi.org/10.1111/cob.70084","42145153","https://pubmed.ncbi.nlm.nih.gov/42145153/",null,null],["4","R0013213","R0013213.pdf","paywalled","nonrandomized_study","Lund N","2026","Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-026-01659-4","https://doi.org/10.1007/s40273-026-01659-4","42722807","https://pubmed.ncbi.nlm.nih.gov/42722807/",null,null],["4","R0013268","R0013268.pdf","paywalled","nonrandomized_study","Sacks GI","2026","Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Springer Science and Business Media LLC","10.1007/s00586-026-10099-9","https://doi.org/10.1007/s00586-026-10099-9","42315695","https://pubmed.ncbi.nlm.nih.gov/42315695/",null,null],["4","R0013339","R0013339.pdf","paywalled","nonrandomized_study","Fuentes-Mendoza JM","2026","Beyond metabolism: sexual dysfunction and weight-loss drugs.","Sexual medicine reviews","Oxford University Press (OUP)","10.1093/sxmrev/qeaf074","https://doi.org/10.1093/sxmrev/qeaf074","41427954","https://pubmed.ncbi.nlm.nih.gov/41427954/",null,null],["4","R0013475","R0013475.pdf","paywalled","nonrandomized_study","Vagios S","2026","Distinct metabolomic profiles in lean and non-lean polyendocrine metabolic ovarian syndrome.","Journal of assisted reproduction and genetics","Springer Science and Business Media LLC","10.1007/s10815-026-04015-9","https://doi.org/10.1007/s10815-026-04015-9","42658451","https://pubmed.ncbi.nlm.nih.gov/42658451/",null,null],["4","R0013665","R0013665.pdf","paywalled","nonrandomized_study","Tseng TC","2026","Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.08.006","https://doi.org/10.1016/j.eprac.2026.08.006","42580629","https://pubmed.ncbi.nlm.nih.gov/42580629/",null,null],["4","R0013778","R0013778.pdf","paywalled","nonrandomized_study","Angelopoulos N","2026","Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.","Nutrition (Burbank, Los Angeles County, Calif.)","Elsevier BV","10.1016/j.nut.2026.113286","https://doi.org/10.1016/j.nut.2026.113286","42275945","https://pubmed.ncbi.nlm.nih.gov/42275945/",null,null],["4","R0013798","R0013798.pdf","paywalled","nonrandomized_study","Mehdizadeh M","2026","Rebuilding After Weight Loss: A Nationwide Retrospective Cohort Study on the Outcomes of Autologous Breast Reconstruction in Post-Bariatric Patients.","Annals of plastic surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sap.0000000000004698","https://doi.org/10.1097/sap.0000000000004698","41838092","https://pubmed.ncbi.nlm.nih.gov/41838092/",null,null],["4","R0013833","R0013833.pdf","paywalled","nonrandomized_study","Frey C","2026","Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.05.036","https://doi.org/10.1016/j.eprac.2026.05.036","42248357","https://pubmed.ncbi.nlm.nih.gov/42248357/",null,null],["4","R0013874","R0013874.pdf","paywalled","nonrandomized_study","Vlaeminck N","2026","Gastric content and aspiration risk after semaglutide cessation: a reply.","Anaesthesia","Wiley","10.1111/anae.70328","https://doi.org/10.1111/anae.70328","42601802","https://pubmed.ncbi.nlm.nih.gov/42601802/",null,null],["4","R0013895","R0013895.pdf","paywalled","nonrandomized_study","Balata M","2026","Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-025-02694-5","https://doi.org/10.1007/s00392-025-02694-5","40493069","https://pubmed.ncbi.nlm.nih.gov/40493069/",null,null],["4","R0013993","R0013993.pdf","paywalled","nonrandomized_study","Sato T","2026","Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70710","https://doi.org/10.1002/bcp.70710","42516042","https://pubmed.ncbi.nlm.nih.gov/42516042/",null,null],["4","R0014068","R0014068.pdf","paywalled","nonrandomized_study","Mortada I","2026","Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.03.020","https://doi.org/10.1016/j.amjcard.2026.03.020","41862113","https://pubmed.ncbi.nlm.nih.gov/41862113/",null,null],["4","R0014173","R0014173.pdf","paywalled","nonrandomized_study","Angelopoulos N","2026","Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70810","https://doi.org/10.1111/dom.70810","42037110","https://pubmed.ncbi.nlm.nih.gov/42037110/",null,"ANZCTR:ACTRN12625000071426"],["4","R0014405","R0014405.pdf","paywalled","nonrandomized_study","Huang X","2026","Comment on \"Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes\".","Medicina clinica","Elsevier BV","10.1016/j.medcli.2026.107573","https://doi.org/10.1016/j.medcli.2026.107573","42520650","https://pubmed.ncbi.nlm.nih.gov/42520650/",null,null],["4","R0014477","R0014477.pdf","paywalled","nonrandomized_study","Jia Q","2026","Advances in proteomics research related to semaglutide: evidence from humans and animals.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-026-02989-y","https://doi.org/10.1007/s40618-026-02989-y","42489869","https://pubmed.ncbi.nlm.nih.gov/42489869/",null,null],["4","R0014502","R0014502.pdf","paywalled","nonrandomized_study","Zhang L","2026","Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response.","Journal of visualized experiments : JoVE","MyJove Corporation","10.3791/70462","https://doi.org/10.3791/70462","42507607","https://pubmed.ncbi.nlm.nih.gov/42507607/",null,null],["4","R0014528","R0014528.pdf","paywalled","nonrandomized_study","Powell WJB","2026","Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.","Clinical obesity","Wiley","10.1111/cob.70076","https://doi.org/10.1111/cob.70076","41830068","https://pubmed.ncbi.nlm.nih.gov/41830068/",null,null],["4","R0014546","R0014546.pdf","paywalled","nonrandomized_study","Cornet NC","2026","Diabetic Status, Advanced Age, and Hispanic Ethnicity Predict Poorer Weight Loss in Patients With Obesity Receiving Semaglutide.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.05.029","https://doi.org/10.1016/j.eprac.2026.05.029","42248359","https://pubmed.ncbi.nlm.nih.gov/42248359/",null,null],["4","R0014591","R0014591.pdf","paywalled","nonrandomized_study","Matsunuma S","2026","Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.","International journal of clinical pharmacology and therapeutics","Dustri-Verlag Dr. Karl Feistle","10.5414/cp204899","https://doi.org/10.5414/cp204899","41582648","https://pubmed.ncbi.nlm.nih.gov/41582648/",null,null],["4","R0014741","R0014741.pdf","paywalled","nonrandomized_study","Hussain SM","2026","Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000005711","https://doi.org/10.1097/tp.0000000000005711","41952049","https://pubmed.ncbi.nlm.nih.gov/41952049/",null,null],["4","R0014748","R0014748.pdf","paywalled","nonrandomized_study","Shah J","2026","Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2026.01.013","https://doi.org/10.1016/j.ophtha.2026.01.013","41577258","https://pubmed.ncbi.nlm.nih.gov/41577258/",null,null],["4","R0014901","R0014901.pdf","paywalled","nonrandomized_study","Liu TH","2026","Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Elsevier BV","10.1016/j.euroneuro.2025.11.016","https://doi.org/10.1016/j.euroneuro.2025.11.016","41389474","https://pubmed.ncbi.nlm.nih.gov/41389474/",null,null],["4","R0014997","R0014997.pdf","paywalled","nonrandomized_study","Wu JY","2026","Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1093/annalsats/aaoaf070","https://doi.org/10.1093/annalsats/aaoaf070","41915556","https://pubmed.ncbi.nlm.nih.gov/41915556/",null,null],["4","R0015105","R0015105.pdf","paywalled","nonrandomized_study","Weissmann S","2026","Is Maternal Diabetes Mellitus Type 2 a Protective Factor for Atopic Dermatitis in Children? A Nationwide Retrospective Cohort Study.","Dermatitis : contact, atopic, occupational, drug","SAGE Publications","10.1177/17103568261454831","https://doi.org/10.1177/17103568261454831","42249778","https://pubmed.ncbi.nlm.nih.gov/42249778/",null,null],["4","R0015112","R0015112.pdf","paywalled","nonrandomized_study","Xie H","2026","Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2469273","https://doi.org/10.1080/14740338.2025.2469273","40049721","https://pubmed.ncbi.nlm.nih.gov/40049721/",null,null],["4","R0015258","R0015258.pdf","paywalled","nonrandomized_study","Da Porto A","2026","When Sex Shapes Diabetes Care: Evidence from the AMD Annals Registry.","Journal of women's health (2002)","SAGE Publications","10.1177/15409996261479909","https://doi.org/10.1177/15409996261479909","42596603","https://pubmed.ncbi.nlm.nih.gov/42596603/",null,null],["4","R0015359","R0015359.pdf","paywalled","nonrandomized_study","Sami MM","2026","Semaglutide for Aboriginal and Torres Strait Islander cardiovascular care: equity, cost and real-world hurdles.","Internal medicine journal","Wiley","10.1111/imj.70387","https://doi.org/10.1111/imj.70387","41943227","https://pubmed.ncbi.nlm.nih.gov/41943227/",null,null],["4","R0015381","R0015381.pdf","paywalled","nonrandomized_study","Tichy EM","2026","National trends in prescription drug expenditures and projections for 2026.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag115","https://doi.org/10.1093/ajhp/zxag115","42059345","https://pubmed.ncbi.nlm.nih.gov/42059345/",null,null],["4","R0015459","R0015459.pdf","paywalled","nonrandomized_study","Cheng H","2026","Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70153","https://doi.org/10.1002/oby.70153","41736232","https://pubmed.ncbi.nlm.nih.gov/41736232/",null,"ChiCTR:ChiCTR1900022948"],["4","R0015513","R0015513.pdf","paywalled","nonrandomized_study","Nicolau J","2026","Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.","Medicina clinica","Elsevier BV","10.1016/j.medcli.2026.107364","https://doi.org/10.1016/j.medcli.2026.107364","41722140","https://pubmed.ncbi.nlm.nih.gov/41722140/",null,null],["4","R0015533","R0015533.pdf","paywalled","nonrandomized_study","Salama M","2026","Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity-Related Genes.","Pediatric obesity","Wiley","10.1111/ijpo.70091","https://doi.org/10.1111/ijpo.70091","41667135","https://pubmed.ncbi.nlm.nih.gov/41667135/",null,null],["4","R0015562","R0015562.pdf","paywalled","nonrandomized_study","Doan TT","2026","Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.","Childhood obesity (Print)","SAGE Publications","10.1177/21532176261454487","https://doi.org/10.1177/21532176261454487","42233337","https://pubmed.ncbi.nlm.nih.gov/42233337/",null,null],["4","R0015586","R0015586.pdf","paywalled","nonrandomized_study","Wu JY","2026","Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf663","https://doi.org/10.1093/eurjpc/zwaf663","41123417","https://pubmed.ncbi.nlm.nih.gov/41123417/",null,null],["4","R0015730","R0015730.pdf","paywalled","nonrandomized_study","Yu Y","2026","Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure.","Obstetrics and gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aog.0000000000006325","https://doi.org/10.1097/aog.0000000000006325","42208070","https://pubmed.ncbi.nlm.nih.gov/42208070/",null,null],["4","R0015812","R0015812.pdf","paywalled","nonrandomized_study","Tan MC","2026","Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2025.09.018","https://doi.org/10.1016/j.amjmed.2025.09.018","40998187","https://pubmed.ncbi.nlm.nih.gov/40998187/",null,null],["4","R0016036","R0016036.pdf","paywalled","nonrandomized_study","Savvidou S","2026","Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Metabolic syndrome and related disorders","SAGE Publications","10.1177/15578518251409025","https://doi.org/10.1177/15578518251409025","41944572","https://pubmed.ncbi.nlm.nih.gov/41944572/",null,null],["4","R0016167","R0016167.pdf","paywalled","nonrandomized_study","Cowart K","2026","Association of oral semaglutide with cardiovascular outcomes in a real-world primary prevention population.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70412","https://doi.org/10.1111/dom.70412","41457323","https://pubmed.ncbi.nlm.nih.gov/41457323/",null,null],["4","R0016235","R0016235.pdf","paywalled","nonrandomized_study","Xu JJ","2026","The Effect of Body Mass Index on the Efficacy of Semaglutide Use at the Time of Total Knee Arthroplasty.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.09.056","https://doi.org/10.1016/j.arth.2025.09.056","41072554","https://pubmed.ncbi.nlm.nih.gov/41072554/",null,null],["4","R0016264","R0016264.pdf","paywalled","nonrandomized_study","Gorard L","2026","Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?","Current opinion in gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mog.0000000000001169","https://doi.org/10.1097/mog.0000000000001169","41866997","https://pubmed.ncbi.nlm.nih.gov/41866997/",null,null],["4","R0016271","R0016271.pdf","paywalled","nonrandomized_study","Minsky NC","2026","Effect of semaglutide add-on therapy for people living with type 1 diabetes and excess weight.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70389","https://doi.org/10.1111/dom.70389","41417475","https://pubmed.ncbi.nlm.nih.gov/41417475/",null,null],["4","R0016296","R0016296.pdf","paywalled","nonrandomized_study","Baumann AN","2026","Independent Risk Factors for Sacral Fracture After Lumbosacral Fusion in Adults: A Cox Proportional Hazards Retrospective Analysis.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000001999","https://doi.org/10.1097/bsd.0000000000001999","41538249","https://pubmed.ncbi.nlm.nih.gov/41538249/",null,null],["4","R0016363","R0016363.pdf","paywalled","nonrandomized_study","Zhao Y","2026","Commentary on \"Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study\".","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-025-10958-5","https://doi.org/10.1007/s12072-025-10958-5","41222619","https://pubmed.ncbi.nlm.nih.gov/41222619/",null,null],["4","R0016390","R0016390.pdf","paywalled","nonrandomized_study","Brunet-Manquat L","2026","Design Differences and Usability Risks in GLP-1 Pen Injectors: A Comparative Study of a Generic and Reference Device.","PDA journal of pharmaceutical science and technology","Parenteral Drug Association, Inc.","10.5731/pdajpst.2025-000043.1","https://doi.org/10.5731/pdajpst.2025-000043.1","41698692","https://pubmed.ncbi.nlm.nih.gov/41698692/",null,null],["4","R0016414","R0016414.pdf","paywalled","nonrandomized_study","Ramon-Granés M","2026","Clinical trends in Catalonia's Primary Care Setting (2018-2023) in Elderly (≥75 years) and Frail Adults with Type 2 Diabetes.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2026.03.010","https://doi.org/10.1016/j.pcd.2026.03.010","41916804","https://pubmed.ncbi.nlm.nih.gov/41916804/",null,null],["4","R0016681","R0016681.pdf","paywalled","nonrandomized_study","Hasan I","2026","Association of GLP-1 inhibitors with cardiovascular outcomes in patients undergoing coronary artery bypass surgery.","The Journal of thoracic and cardiovascular surgery","Elsevier BV","10.1016/j.jtcvs.2026.02.005","https://doi.org/10.1016/j.jtcvs.2026.02.005","41713699","https://pubmed.ncbi.nlm.nih.gov/41713699/",null,null],["4","R0016704","R0016704.pdf","paywalled","nonrandomized_study","Torales J","2026","Treatment-refractory Addictions: Clinical Characterization and an Operational Model for Integrated Management.","Current drug research reviews","Bentham Science Publishers Ltd.","10.2174/0125899775434631260211074804","https://doi.org/10.2174/0125899775434631260211074804","41941316","https://pubmed.ncbi.nlm.nih.gov/41941316/",null,null],["4","R0016739","R0016739.pdf","paywalled","nonrandomized_study","Tourtourikov I","2026","GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.","Pharmacogenetics and genomics","Ovid Technologies (Wolters Kluwer Health)","10.1097/fpc.0000000000000577","https://doi.org/10.1097/fpc.0000000000000577","40996853","https://pubmed.ncbi.nlm.nih.gov/40996853/",null,null],["4","R0016881","R0016881.pdf","paywalled","nonrandomized_study","Petrakis V","2026","The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-2737-6227","https://doi.org/10.1055/a-2737-6227","41187787","https://pubmed.ncbi.nlm.nih.gov/41187787/",null,null],["4","R0016980","R0016980.pdf","paywalled","nonrandomized_study","Chow A","2026","Comparison of Type 2 Diabetes Mellitus Management by an Ambulatory Care Pharmacist vs Usual Care in a Medically Underserved Population.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900261450730","https://doi.org/10.1177/08971900261450730","42117347","https://pubmed.ncbi.nlm.nih.gov/42117347/",null,null],["4","R0017014","R0017014.pdf","paywalled","nonrandomized_study","Tchang B","2026","Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70120","https://doi.org/10.1002/oby.70120","41367196","https://pubmed.ncbi.nlm.nih.gov/41367196/",null,null],["4","R0017159","R0017159.pdf","paywalled","nonrandomized_study","Ponzo M","2026","Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-026-06002-y","https://doi.org/10.1007/s00266-026-06002-y","42310082","https://pubmed.ncbi.nlm.nih.gov/42310082/",null,null],["4","R0017370","R0017370.pdf","paywalled","nonrandomized_study","Pasam RT","2026","Impact of Endoscopic Bariatric and Metabolic Therapies on Chronic Kidney Disease in Patients with Impaired Glycemic Control.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-026-08583-8","https://doi.org/10.1007/s11695-026-08583-8","41832390","https://pubmed.ncbi.nlm.nih.gov/41832390/",null,null],["4","R0017403","R0017403.pdf","paywalled","nonrandomized_study","Loizidis G","2026","GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.","Clinical rheumatology","Springer Science and Business Media LLC","10.1007/s10067-026-08212-w","https://doi.org/10.1007/s10067-026-08212-w","42274932","https://pubmed.ncbi.nlm.nih.gov/42274932/",null,null],["4","R0017434","R0017434.pdf","paywalled","nonrandomized_study","Oo HH","2026","Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea.","Sleep & breathing = Schlaf & Atmung","Springer Science and Business Media LLC","10.1007/s11325-026-03667-2","https://doi.org/10.1007/s11325-026-03667-2","41925927","https://pubmed.ncbi.nlm.nih.gov/41925927/",null,null],["4","R0017650","R0017650.pdf","paywalled","nonrandomized_study","Fushimi Y","2026","Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-026-02662-z","https://doi.org/10.1007/s00592-026-02662-z","41661272","https://pubmed.ncbi.nlm.nih.gov/41661272/",null,null],["4","R0017769","R0017769.pdf","paywalled","nonrandomized_study","Labate AM","2026","Reporting on the real-world safety and effectiveness of oral semaglutide in improving glycemic control and reducing cardiovascular risk: a letter to the editor.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.25.04395-7","https://doi.org/10.23736/s2724-6507.25.04395-7","40599046","https://pubmed.ncbi.nlm.nih.gov/40599046/",null,null],["4","R0017940","R0017940.pdf","paywalled","nonrandomized_study","Huang L","2026","Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2026.103112","https://doi.org/10.1016/j.japh.2026.103112","41962807","https://pubmed.ncbi.nlm.nih.gov/41962807/",null,null],["4","R0018205","R0018205.pdf","paywalled","nonrandomized_study","Wu JY","2026","Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-025-11021-z","https://doi.org/10.1007/s12072-025-11021-z","41535629","https://pubmed.ncbi.nlm.nih.gov/41535629/",null,null],["4","R0018887","R0018887.pdf","paywalled","nonrandomized_study","Mertens J","2026","Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1177/15209156251362497","https://doi.org/10.1177/15209156251362497","40712645","https://pubmed.ncbi.nlm.nih.gov/40712645/",null,null],["4","R0018989","R0018989.pdf","paywalled","nonrandomized_study","Zhang P","2026","Disparities in Antidiabetic Medication Discontinuation Between Non-Hispanic White and Black Beneficiaries in Medicare Across Diabetes Belt and Surrounding Area.","Journal of racial and ethnic health disparities","Springer Science and Business Media LLC","10.1007/s40615-025-02388-8","https://doi.org/10.1007/s40615-025-02388-8","40088385","https://pubmed.ncbi.nlm.nih.gov/40088385/",null,null],["4","R0019757","R0019757.pdf","paywalled","nonrandomized_study","Xia A","2026","Atypical Antipsychotics-Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention.","Journal of applied toxicology : JAT","Wiley","10.1002/jat.70036","https://doi.org/10.1002/jat.70036","41387116","https://pubmed.ncbi.nlm.nih.gov/41387116/",null,null],["4","R0020403","R0020403.pdf","paywalled","nonrandomized_study","Mantz L","2026","Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue.","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","Elsevier BV","10.1016/j.jtho.2026.104078","https://doi.org/10.1016/j.jtho.2026.104078","42419484","https://pubmed.ncbi.nlm.nih.gov/42419484/",null,null],["4","R0021873","R0021873.pdf","paywalled","nonrandomized_study","Du P","2026","Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70790","https://doi.org/10.1111/dom.70790","42010884","https://pubmed.ncbi.nlm.nih.gov/42010884/",null,null],["4","R0022953","R0022953.pdf","paywalled","nonrandomized_study","Desai A","2026","Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","Springer Science and Business Media LLC","10.1007/s12664-025-01835-y","https://doi.org/10.1007/s12664-025-01835-y","40682732","https://pubmed.ncbi.nlm.nih.gov/40682732/",null,null],["4","R0023430","R0023430.pdf","paywalled","nonrandomized_study","Xie F","2026","Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2025.08.019","https://doi.org/10.1016/j.jval.2025.08.019","40939703","https://pubmed.ncbi.nlm.nih.gov/40939703/",null,null],["4","R0029250","R0029250.pdf","paywalled","nonrandomized_study","Jurin I","2026","Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.","Cardiology",null,"10.1159/crd/absag023","https://doi.org/10.1159/crd/absag023","42862749","https://pubmed.ncbi.nlm.nih.gov/42862749/",null,null],["4","R0029252","R0029252.pdf","paywalled","nonrandomized_study","Yang W","2026","Cardiorenal Protective Glucose-Lowering Treatment Patterns in Type 2 Diabetes Mellitus Based on a Real-World Study: A Clinical Phenotype Cluster Analysis.","Advances in therapy",null,"10.1007/s12325-026-03826-7","https://doi.org/10.1007/s12325-026-03826-7","42862437","https://pubmed.ncbi.nlm.nih.gov/42862437/",null,"ChiCTR:ChiCTR230007376"],["4","R0029277","R0029277.pdf","paywalled","nonrandomized_study","Dziewierz A","2026","Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.","Advances in medical sciences","Elsevier BV","10.1016/j.advms.2026.10.005","https://doi.org/10.1016/j.advms.2026.10.005","42854961","https://pubmed.ncbi.nlm.nih.gov/42854961/",null,null],["4","R0029278","R0029278.pdf","paywalled","nonrandomized_study","Pace H","2026","A stewardship framework for incretin-based therapies in weight management.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2026.103547","https://doi.org/10.1016/j.japh.2026.103547","42854871","https://pubmed.ncbi.nlm.nih.gov/42854871/",null,null],["4","R0029293","R0029293.pdf","paywalled","nonrandomized_study","Manueli Laos EG","2026","Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.","Clinical obesity","Wiley","10.1111/cob.70116","https://doi.org/10.1111/cob.70116","42850698","https://pubmed.ncbi.nlm.nih.gov/42850698/",null,null],["4","R0029303","R0029303.pdf","paywalled","nonrandomized_study","Singh B","2026","GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease.","The Journal of clinical psychiatry","Physicians Postgraduate Press, Inc","10.4088/jcp.26m16392","https://doi.org/10.4088/jcp.26m16392","42848524","https://pubmed.ncbi.nlm.nih.gov/42848524/",null,null],["4","R0029324","R0029324.pdf","paywalled","nonrandomized_study","Gilligan G","2026","Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights.","Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","Wiley","10.1111/jop.70191","https://doi.org/10.1111/jop.70191","42843413","https://pubmed.ncbi.nlm.nih.gov/42843413/",null,null],["4","R0029328","R0029328.pdf","paywalled","nonrandomized_study","Duan X","2026","GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04808-z","https://doi.org/10.1007/s12020-026-04808-z","42842067","https://pubmed.ncbi.nlm.nih.gov/42842067/",null,null],["4","R0029334","R0029334.pdf","paywalled","nonrandomized_study","Peymani P","2026","Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015-2023.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2026.10.001","https://doi.org/10.1016/j.orcp.2026.10.001","42838854","https://pubmed.ncbi.nlm.nih.gov/42838854/",null,null],["4","R0029341","R0029341.pdf","paywalled","nonrandomized_study","Villalva CR","2026","Incretin Mimetics for Patients Living with Type 2 Diabetes in a Predominantly Hispanic/Latino Population: Analysis of Prescribing Frequency and Predictors of Use.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag321","https://doi.org/10.1093/ajhp/zxag321","42837617","https://pubmed.ncbi.nlm.nih.gov/42837617/",null,null],["4","R0029351","R0029351.pdf","paywalled","nonrandomized_study","Korman A","2026","Cardiometabolic benefits after adrenalectomy for mild autonomous cortisol secretion.","Surgery","Elsevier BV","10.1016/j.surg.2026.110600","https://doi.org/10.1016/j.surg.2026.110600","42833940","https://pubmed.ncbi.nlm.nih.gov/42833940/",null,null],["4","R0029353","R0029353.pdf","paywalled","nonrandomized_study","Liu C","2026","Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.","Peptides","Elsevier BV","10.1016/j.peptides.2026.171524","https://doi.org/10.1016/j.peptides.2026.171524","42833423","https://pubmed.ncbi.nlm.nih.gov/42833423/",null,null],["4","R0029372","R0029372.pdf","paywalled","nonrandomized_study","Söderbom G","2026","Parkinson's disease-Crucial advances and on-going challenges.","International review of neurobiology","Elsevier","10.1016/bs.irn.2026.08.019","https://doi.org/10.1016/bs.irn.2026.08.019","42767720","https://pubmed.ncbi.nlm.nih.gov/42767720/",null,null],["4","R0029379","R0029379.pdf","paywalled","nonrandomized_study","McCraw CD","2026","Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study.","Expert review of respiratory medicine","Informa UK Limited","10.1080/17476348.2026.2730537","https://doi.org/10.1080/17476348.2026.2730537","42733229","https://pubmed.ncbi.nlm.nih.gov/42733229/",null,null],["4","R0029403","R0029403.pdf","paywalled","nonrandomized_study","Hill MA","2026","GLP-1 and GLP-1/GIP agonists in psoriasis: A real-world cohort study on healthcare resource usage.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.70678","https://doi.org/10.1111/jdv.70678","42627149","https://pubmed.ncbi.nlm.nih.gov/42627149/",null,null],["4","R0029420","R0029420.pdf","paywalled","nonrandomized_study","Eisa N","2026","Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment-Resistant Non-Diabetic Obesity: A Retrospective Pilot Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71161","https://doi.org/10.1111/dom.71161","42503493","https://pubmed.ncbi.nlm.nih.gov/42503493/",null,null],["4","R0029425","R0029425.pdf","paywalled","nonrandomized_study","Milardović TM","2026","Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2026.2706660","https://doi.org/10.1080/17512433.2026.2706660","42467408","https://pubmed.ncbi.nlm.nih.gov/42467408/",null,null],["4","R0029477","R0029477.pdf","paywalled","nonrandomized_study","Patel M","2026","Selected 2025 Highlights in Congenital Cardiac Anesthesia.","Journal of cardiothoracic and vascular anesthesia","Elsevier BV","10.1053/j.jvca.2026.03.037","https://doi.org/10.1053/j.jvca.2026.03.037","42002501","https://pubmed.ncbi.nlm.nih.gov/42002501/",null,null],["4","R0029485","R0029485.pdf","paywalled","nonrandomized_study","Stark JE","2026","Response to Cestari et al.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag079","https://doi.org/10.1093/ajhp/zxag079","41955518","https://pubmed.ncbi.nlm.nih.gov/41955518/",null,null],["4","R0029518","R0029518.pdf","paywalled","nonrandomized_study","Pandey A","2026","Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70597","https://doi.org/10.1111/dom.70597","41804205","https://pubmed.ncbi.nlm.nih.gov/41804205/",null,null],["4","R0029529","R0029529.pdf","paywalled","nonrandomized_study","Hill MA","2026","Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.02.049","https://doi.org/10.1016/j.jaad.2026.02.049","41713592","https://pubmed.ncbi.nlm.nih.gov/41713592/",null,null],["4","R0029533","R0029533.pdf","paywalled","nonrandomized_study","Kalamaras H","2026","Association of incretin therapy with self-harm behaviors in people with psychiatric conditions: A retrospective cohort study.","Journal of psychopharmacology (Oxford, England)","SAGE Publications","10.1177/02698811261416077","https://doi.org/10.1177/02698811261416077","41693095","https://pubmed.ncbi.nlm.nih.gov/41693095/",null,null],["4","R0029673","R0029673.pdf","paywalled","nonrandomized_study","Montastier E","2026","[Changes in obesity management: The clinician's perspective].","Biologie aujourd'hui","EDP Sciences","10.1051/jbio/2026002","https://doi.org/10.1051/jbio/2026002","42536829","https://pubmed.ncbi.nlm.nih.gov/42536829/",null,null],["4","R0029722","R0029722.pdf","paywalled","nonrandomized_study","Barenbaum SR","2026","Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf641","https://doi.org/10.1210/clinem/dgaf641","41314250","https://pubmed.ncbi.nlm.nih.gov/41314250/",null,null],["4","R0029887","R0029887.pdf","paywalled","nonrandomized_study","Thawkar SA","2026","Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study.","Clinical nutrition ESPEN",null,"10.1016/j.clnesp.2026.105169","https://doi.org/10.1016/j.clnesp.2026.105169","42863671","https://pubmed.ncbi.nlm.nih.gov/42863671/",null,null],["4","R0029890","R0029890.pdf","paywalled","nonrandomized_study","Lo SW","2026","GLP-1 Receptor Agonists and Thromboembolic Risk in Patients With Atrial Fibrillation or Flutter and Type 2 Diabetes: A Propensity Score-Matched Cohort Study.","Diabetes, obesity & metabolism",null,"10.1111/dom.71443","https://doi.org/10.1111/dom.71443","42864268","https://pubmed.ncbi.nlm.nih.gov/42864268/",null,null],["4","R0029909","R0029909.pdf","paywalled","nonrandomized_study","Lauck KC","2026","Response to Jean et al, \"Alopecia after glucagon-like peptide-1 agonist therapy: A TriNetX Database active comparator retrospective cohort study\".","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.08.074","https://doi.org/10.1016/j.jaad.2026.08.074","42637046","https://pubmed.ncbi.nlm.nih.gov/42637046/",null,null],["4","R0029916","R0029916.pdf","paywalled","nonrandomized_study","Ong TE","2026","Five-year outcomes of glucagon-like peptide-1 agonists in hypertrophic cardiomyopathy: A population-based retrospective study.","Journal of cardiology","Elsevier BV","10.1016/j.jjcc.2026.06.015","https://doi.org/10.1016/j.jjcc.2026.06.015","42349649","https://pubmed.ncbi.nlm.nih.gov/42349649/",null,null],["4","R0029958","R0029958.pdf","paywalled","nonrandomized_study","Weng CH","2026","Comment on: Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-025-01617-7","https://doi.org/10.1007/s40264-025-01617-7","41003919","https://pubmed.ncbi.nlm.nih.gov/41003919/",null,null],["4","R0029962","R0029962.pdf","paywalled","nonrandomized_study","Mansi IA","2026","Authors' Response to Weng et al.'s Comment on \"Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study\".","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-025-01616-8","https://doi.org/10.1007/s40264-025-01616-8","41003918","https://pubmed.ncbi.nlm.nih.gov/41003918/",null,null],["4","R0030086","R0030086.pdf","paywalled","nonrandomized_study","Velez-Valle E","2026","Exploring BMI Classification Changes and Disparities Upon Incarceration in U.S. Federal Prisons.","Journal of correctional health care : the official journal of the National Commission on Correctional Health Care","SAGE Publications","10.1177/10783458261485713","https://doi.org/10.1177/10783458261485713","42766498","https://pubmed.ncbi.nlm.nih.gov/42766498/",null,null],["4","R0030149","R0030149.pdf","paywalled","nonrandomized_study","Patel N","2026","Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2025.01.003","https://doi.org/10.1016/j.mayocp.2025.01.003","41099677","https://pubmed.ncbi.nlm.nih.gov/41099677/",null,null],["4","R0032580","R0032580.pdf","paywalled","nonrandomized_study","Indunil Karunarathna","2026","Pediatric Obesity: From Pathophysiology to Family-Centered Care—A Clinical Synthesis for the Practicing Clinician","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20139194","https://doi.org/10.5281/zenodo.20139194",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032733","R0032733.pdf","paywalled","nonrandomized_study",null,"2026","Research","Bone and Joint 360","British Editorial Society of Bone & Joint Surgery","10.1302/2048-0105.152.360318","https://doi.org/10.1302/2048-0105.152.360318",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032820","R0032820.pdf","paywalled","nonrandomized_study","L F Drager","2026","B80-3-03 Cpap Use in the Era of Glp-1 and Dual Agonists in Patients With Obstructive Sleep Apnea: A Real-World Study","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.6388","https://doi.org/10.1093/ajrccm/aamag162.6388",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032838","R0032838.pdf","paywalled","nonrandomized_study","MR Imbroane","2026","Preconception Glucagon-like Peptide-1 Receptor Agonist Use Associated With Decreased Risk of Adverse Obstetrical Outcomes","Obstetrical & Gynecological Survey","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ogx.0001181216.66623.98","https://doi.org/10.1097/01.ogx.0001181216.66623.98",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032902","R0032902.pdf","paywalled","nonrandomized_study","Mugisha Emmanuel K.","2026","Targeted Nanocarriers for Insulin and Incretin Delivery: Overcoming Barriers in Type 2 Diabetes Management","Research Output Journal of Biological and Applied Science","International Digital Organization for Scientific Research","10.59298/rojbas/2026/611118","https://doi.org/10.59298/rojbas/2026/611118",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033033","R0033033.pdf","paywalled","nonrandomized_study","E. Glenn","2026","ASSOCIATION OF SEMAGLUTIDE WITH ORTHOPAEDIC OUTCOMES IN PATIENTS WITH SIGNIFICANT ADIPOSITY AND TYPE 2 DIABETES MELLITUS","Orthopaedic Proceedings","British Editorial Society of Bone & Joint Surgery","10.1302/1358-992x.2026.2.034","https://doi.org/10.1302/1358-992x.2026.2.034",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033049","R0033049.pdf","paywalled","nonrandomized_study","J Marta Moreno","2026","The Ozempic Phenomenon: Linguistic Representations of Weight Issues in the Spanish Press","Journal of Language and Discrimination","University of Toronto Press Inc. (UTPress)","10.3138/jld-2025-0013","https://doi.org/10.3138/jld-2025-0013",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033060","R0033060.pdf","paywalled","nonrandomized_study","Cordelia Ko","2026","A Shot in the Dark: The Paradoxical Effects of GLP-1 Receptor Agonists on Rotator Cuff Disease and Surgical Outcomes","Galter Health Sciences Library, Northwestern University",null,"10.18131/tt7z0-7bx51","https://doi.org/10.18131/tt7z0-7bx51",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033067","R0033067.pdf","paywalled","nonrandomized_study","SAIMSARA","2026","Substandard and Falsified Medical Products, Devices, and Online Pharmacy Supply-Chain Security: Scoping Review with ☸SAIMSARA","SAIMSARA Journal","ML in Health Science","10.62487/saimsarab2913b49","https://doi.org/10.62487/saimsarab2913b49",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033073","R0033073.pdf","paywalled","nonrandomized_study","Khalid Ahmed","2026","PREVALENCE AND CARDIO–KIDNEY–METABOLIC PROFILES ACROSS AHA 2025 BLOOD PRESSURE CATEGORIES IN 32,046 ADULTS WITH TYPE 2 DIABETES IN A HIGH-RISK POPULATION","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001197524.73701.cb","https://doi.org/10.1097/01.hjh.0001197524.73701.cb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033087","R0033087.pdf","paywalled","nonrandomized_study","SHALMALI S. BANE","2026","2149-P: The Association between GLP-1 and GIP Hormone Levels in Early Pregnancy and Subsequent Gestational Weight Gain","Diabetes","American Diabetes Association","10.2337/db26-2149-p","https://doi.org/10.2337/db26-2149-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033094","R0033094.pdf","paywalled","nonrandomized_study","REEM ALSHAREEF","2026","1879-P: Beyond Insulin Alone: One-Year CGM Outcomes of Adjunctive Incretin-Based and SGLT2 Inhibitors Therapy in Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems","Diabetes","American Diabetes Association","10.2337/db26-1879-p","https://doi.org/10.2337/db26-1879-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033098","R0033098.pdf","paywalled","nonrandomized_study","Thaer Idrees","2026","1710-P: Fragility Fracture Risk among Patients with Type 2 Diabetes Initiating Treatment with GLP-1 Receptor Agonists vs. Sulfonylureas","Diabetes","American Diabetes Association","10.2337/db26-1710-p","https://doi.org/10.2337/db26-1710-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033114","R0033114.pdf","paywalled","nonrandomized_study","PURVI CHAWLA","2026","2659-P: Effect of GLP-1RA and Dual GIP/GLP-1 Agonist on Metabolic Parameters in Patients with Severe Obesity: Indian Real-World Evidence","Diabetes","American Diabetes Association","10.2337/db26-2659-p","https://doi.org/10.2337/db26-2659-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033127","R0033127.pdf","paywalled","nonrandomized_study","Erika Choi","2026","2949-LB: Glucagon-like Peptide 1 Receptor Agonist Use in Youth with Type 1 Diabetes Mellitus at an Academic Pediatric Medical Center","Diabetes","American Diabetes Association","10.2337/db26-2949-lb","https://doi.org/10.2337/db26-2949-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033133","R0033133.pdf","paywalled","nonrandomized_study","JAIME ALMANDOZ","2026","1665-P: Real-World HbA1c and Weight Change after 6 and 12 Months by GLP-1 Treatment Persistence in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1665-p","https://doi.org/10.2337/db26-1665-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033139","R0033139.pdf","paywalled","nonrandomized_study","SAVANNAH LIN","2026","19-PUB: Real-World Outcomes of Adjunct GLP-1 Receptor Agonist Therapy in Adults with Type 1 Diabetes: A Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-19-pub","https://doi.org/10.2337/db26-19-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033140","R0033140.pdf","paywalled","nonrandomized_study","HENG YEH","2026","2049-P: Longitudinal Changes in Diabetes Care Delivery Before and During the COVID-19 Pandemic","Diabetes","American Diabetes Association","10.2337/db26-2049-p","https://doi.org/10.2337/db26-2049-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033145","R0033145.pdf","paywalled","nonrandomized_study","ARCHANA R. SADHU","2026","1392-P: Metabolic Benefits of GLP-1RA and SGLT2i after Kidney Transplantation: A Real-World Experience","Diabetes","American Diabetes Association","10.2337/db26-1392-p","https://doi.org/10.2337/db26-1392-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033150","R0033150.pdf","paywalled","nonrandomized_study","HUILIN TANG","2026","1714-P: Semaglutide, Tirzepatide, and Risk of Alcohol Use Disorder in Type 2 Diabetes: A Target Trial Emulation","Diabetes","American Diabetes Association","10.2337/db26-1714-p","https://doi.org/10.2337/db26-1714-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033154","R0033154.pdf","paywalled","nonrandomized_study","Morgan Brinson","2026","4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations","Diabetes","American Diabetes Association","10.2337/db26-4-pub","https://doi.org/10.2337/db26-4-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033155","R0033155.pdf","paywalled","nonrandomized_study","BRANDON PODYMA","2026","1709-P: Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists Compared with Leptin in a Retrospective Study of Patients with Partial Lipodystrophy","Diabetes","American Diabetes Association","10.2337/db26-1709-p","https://doi.org/10.2337/db26-1709-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033171","R0033171.pdf","paywalled","nonrandomized_study","Seerat Sachdeva","2026","GLP-1 Receptor Agonists and Neurological Outcomes in Patients With Brain Tumors: A Real-world Propensity-matched Cohort Study (S28.010)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000217764","https://doi.org/10.1212/wnl.0000000000217764",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033172","R0033172.pdf","paywalled","nonrandomized_study","Karl Heward","2026","GLP-1 Receptor Agonist Use Associated With Greater Physical Activity and Improved Patientreported Outcomes in Multiple Sclerosis: A Single-site Retrospective Cohort Study (P1-20.009)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000215503","https://doi.org/10.1212/wnl.0000000000215503",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033173","R0033173.pdf","paywalled","nonrandomized_study","Michelle Nguyen","2026","GLP-1 Receptor Agonists in Migraine: Variable Clinical Outcomes in a Retrospective Cohort (P10-15.018)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000213258","https://doi.org/10.1212/wnl.0000000000213258",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033241","R0033241.pdf","paywalled","nonrandomized_study","Leon Gussow","2026","GLP-1 Drug and Ethanol Interactions Much More Complicated Than Imagined","Emergency Medicine News","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.eem.0000000000000205","https://doi.org/10.1097/01.eem.0000000000000205",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033295","R0033295.pdf","paywalled","nonrandomized_study","Saqr Alsakarneh","2026","583 ASSOCIATION BETWEEN GLP-1 ANALOGUE USE AND RISK OF SMALL INTESTINAL BACTERIAL OVERGROWTH: A LARGE U.S. MULTI-CENTER PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05634-8","https://doi.org/10.1016/s0016-5107(26)05634-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033296","R0033296.pdf","paywalled","nonrandomized_study","Krishna Kothamasu","2026","554 COMPARATIVE MICRONUTRIENT DEFICIENCY RISKS AFTER BARIATRIC SURGERY VERSUS GLP-1 RA THERAPY: A MULTICENTER RETROSPECTIVE COHORT ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04719-x","https://doi.org/10.1016/s0016-5107(26)04719-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033297","R0033297.pdf","paywalled","nonrandomized_study","Balkrishna Sapariya","2026","559 REAL WORLD GI SAFETY COMPARISON OF SEMAGLUTIDE AND TIRZEPATIDE: A PHARMACOVIGILANCE STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04724-3","https://doi.org/10.1016/s0016-5107(26)04724-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033302","R0033302.pdf","paywalled","nonrandomized_study","Rubela Ray","2026","Sul8l4 ENDOSCOPIC MANAGEMENT OF OBESITY: COMPARATIVE OUTCOMES OF ENDOSCOPIC SLEEVE GASTROPLASTY, SEMAGLUTIDE, AND TIRZEPATIDE IN A MULTICENTER COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04830-3","https://doi.org/10.1016/s0016-5107(26)04830-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033303","R0033303.pdf","paywalled","nonrandomized_study","Eshan Nanda","2026","553 COMPARATIVE RISK OF INTESTINAL OBSTRUCTION AND INTUSSUSCEPTION WITH GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS: A 984,000-PATIENT PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04271-9","https://doi.org/10.1016/s0016-5107(26)04271-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033306","R0033306.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2026","186 EXPANDING GLP-1 THERAPY TO LIVER DISEASE: POPULATION-BASED ESTIMATES OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ELIGIBILITY IN THE FRAMINGHAM HEART STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03313-4","https://doi.org/10.1016/s0016-5107(26)03313-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033307","R0033307.pdf","paywalled","nonrandomized_study","C Ikwu","2026","B101-09 GLP1 Receptor Agonists and Respiratory Outcomes in Obese Adults With Asthma and Obstructive Sleep Apnea","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.514","https://doi.org/10.1093/ajrccm/aamag162.514",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033314","R0033314.pdf","paywalled","nonrandomized_study","Thomas W. Fredrick","2026","556 REAL-WORLD ANALYSIS OF SEMAGLUTIDE SIDE EFFECTS SHOWS CONSTIPATION IS ASSOCIATED WITH GREATER 12-MONTH BODY WEIGHT LOSS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04721-8","https://doi.org/10.1016/s0016-5107(26)04721-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033315","R0033315.pdf","paywalled","nonrandomized_study","ibrahim abduljabbar","2026","GLP-1 Receptor Agonist Use is Associated with Reduced Post-stroke Mortality and Dementia: A National Matched Cohort Study (P8-13.003)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000217181","https://doi.org/10.1212/wnl.0000000000217181",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033319","R0033319.pdf","paywalled","nonrandomized_study","Ayah Matar","2026","970 GLP-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH AN INCREASED INCIDENCE OF GERD: RESULTS OF A 1:1 PROPENSITY MATCHED STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01787-6","https://doi.org/10.1016/s0016-5107(26)01787-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033331","R0033331.pdf","paywalled","nonrandomized_study","Nooraldin Merza","2026","808 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED NEOPLASTIC PROGRESSION IN BARRETT’S ESOPHAGUS: INSIGHTS FROM A LARGE MULTICENTER TRINETX PROPENSITY-MATCHED COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01760-8","https://doi.org/10.1016/s0016-5107(26)01760-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033334","R0033334.pdf","paywalled","nonrandomized_study","Mohammad Alabbas","2026","498 CARDIOVASCULAR AND HEPATIC OUTCOMES WITH URSODEOXYCHOLIC ACID PLUS GLP-1 RECEPTOR AGONISTS IN PRIMARY BILIARY CHOLANGITIS PATIENTS: A PROPENSITY-MATCHED COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03342-0","https://doi.org/10.1016/s0016-5107(26)03342-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033338","R0033338.pdf","paywalled","nonrandomized_study","S. Ricci","2026","Pre-Transplant GLP-1 Receptor Agonist Use Associates with Lower 30- and 90-Day Mortality and Graft Failure After Kidney Transplant: A Multicenter Propensity-Matched Analysis","American Journal of Transplantation","Elsevier BV","10.1016/j.ajt.2026.05.315","https://doi.org/10.1016/j.ajt.2026.05.315",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033376","R0033376.pdf","paywalled","nonrandomized_study","A Piagnani","2026","Effectiveness of Different Split-Dose Bowel Preparation Regimens in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists: preliminary results of The GLPreparation Study","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1821797","https://doi.org/10.1055/s-0046-1821797",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033423","R0033423.pdf","paywalled","nonrandomized_study","*Aryan Srivastava, Surabhi Dwivedi, Asheesh Pratap Singh","2026","A COMPREHENSIVE OVERVIEW OF ANTIDIABETIC DRUG'S SAFETY PROFILE USING WHO – UMC SCALE","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20643184","https://doi.org/10.5281/zenodo.20643184",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033512","R0033512.pdf","paywalled","nonrandomized_study","Dr. Shivaraj D. R.1*, Dr. Nagarjuna D.2, Dr. R. S. Meghasri3, Varshini J.4, Gowthami L.5, Bharath Gowda H. G.6","2026","Injectable Semaglutide (Ozempic) For Type 2 Diabetes in India; Traslating Global Evidence into Real-World Practice After Recent Market Entry","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18485151","https://doi.org/10.5281/zenodo.18485151",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033565","R0033565.pdf","paywalled","nonrandomized_study","Muhammad Usman Malik","2026","N-K Sciences Report. Gila Monster Venom Derivative (Ozempic/Semaglutide) — Phase Offset Analysis Reveals Mechanism of Pancreatic Cancer · GM3 (Abb-e-Hayaat) as the Universal Phase-Coherent Cure","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19648497","https://doi.org/10.5281/zenodo.19648497",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033619","R0033619.pdf","paywalled","nonrandomized_study","Chih-Hsuan Wang","2026","Additional file 1 of Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation","Figshare",null,"10.6084/m9.figshare.32210496.v1","https://doi.org/10.6084/m9.figshare.32210496.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033667","R0033667.pdf","paywalled","nonrandomized_study","Gayatri S. Bansode. Rupal R.Walke","2026","THE EXPANDING THERAPEUTIC LANDSCAPE OF GLP-1 RECEPTOR AGONISTS BEYOND DIABETES","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18524936","https://doi.org/10.5281/zenodo.18524936",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033705","R0033705.pdf","paywalled","nonrandomized_study","Ricardo ET Navarrete","2026","Adjuvant Dapagliflozin in Kidney Transplant Recipients with Diabetes and Heart Failure – A Real-World Data Exploratory Study","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19446326","https://doi.org/10.5281/zenodo.19446326",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033714","R0033714.pdf","paywalled","nonrandomized_study","kasula sharath","2026","Clinical Trial vs Real-World Adverse Event Divergence: A Semaglutide Case Study Using FAERS Data","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19502666","https://doi.org/10.5281/zenodo.19502666",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033724","R0033724.pdf","paywalled","nonrandomized_study","Kumud Madan","2026","DIABETES MELLITUS: PATHOPHYSIOLOGY, DIAGNOSIS, AND THERAPEUTIC ADVANCES","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20444364","https://doi.org/10.5281/zenodo.20444364",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033731","R0033731.pdf","paywalled","nonrandomized_study","Hector M. Virgen-Ayala","2026","FDEP-TP framework — Article A3: Methodological and translational foundations (Lancet Diabetes & Endocrinology submission package)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20102987","https://doi.org/10.5281/zenodo.20102987",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"OSF:osf.io/3czre"],["4","R0033776","R0033776.pdf","paywalled","nonrandomized_study","Wiktoria Marta Rybak2 Emilia Piaszczyńska1*","2026","From Scalpel to Syringe: Can Tirzepatide Bridge the Gap Between Pharmacotherapy and Bariatric Surgery?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19695495","https://doi.org/10.5281/zenodo.19695495",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033789","R0033789.pdf","paywalled","nonrandomized_study","Luigi Usai","2026","In Silico Generation of Absolute Biomedical Discoveries: Topological Inference of Post-Translational Modification Cascades and PubMed Automated Cross-Referencing","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20736025","https://doi.org/10.5281/zenodo.20736025",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033911","R0033911.pdf","paywalled","nonrandomized_study","Mamarasul Kyzy Minura","2026","Diagnosis and Treatment of Endocrine Diseases in Outpatient Settings: Type II Diabetes Mellitus","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19667581","https://doi.org/10.5281/zenodo.19667581",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034027","R0034027.pdf","paywalled","nonrandomized_study","James E. Dunn","2026","Cryo-Coupling Trial Framework: Independent Phased Validation of T1-Guided Cancer Intervention","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19223725","https://doi.org/10.5281/zenodo.19223725",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034218","R0034218.pdf","paywalled","nonrandomized_study","Sagar Sagar","2026","Orforglipron for Type 2 Diabetes Mellitus: Current Evidence, Clinical Benefits, and Future Prospects","International Scientific Journal of Engineering and Management","Edtech Publishers (OPC) Private Limited","10.55041/isjem08155","https://doi.org/10.55041/isjem08155",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034238","R0034238.pdf","paywalled","nonrandomized_study","Sahil Sethi","2026","Tu1688 RISK OF SEVERE GI MOTILITY COMPLICATIONS GLP-1 AGONIST INITIATION IN PATIENTS WITH PRIOR ABDOMINAL SURGERY OR OBSTRUCTION: A RETROSPECTIVE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04618-3","https://doi.org/10.1016/s0016-5107(26)04618-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034239","R0034239.pdf","paywalled","nonrandomized_study","Eshan Nanda","2026","Sa1276 GLP-1 RECEPTOR AGONISTS DO NOT INCREASE CELIAC DISEASE RISK: A 675,000-PATIENT PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD TESTING AND BIOPSY OUTCOMES","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05707-x","https://doi.org/10.1016/s0016-5107(26)05707-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034254","R0034254.pdf","paywalled","nonrandomized_study","Bireera Muzaffar","2026","Su1708 GASTROPARESIS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS: A FAERS DATABASE RETROSPECTIVE PHARMACOVIGILANCE ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04413-5","https://doi.org/10.1016/s0016-5107(26)04413-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034256","R0034256.pdf","paywalled","nonrandomized_study","Anna C. Hoff","2026","Su1800 METABOLIC REMISSION AFTER COMBINED ENDOSCOPIC SLEEVE GASTROPLASTY AND EARLY TIRZEPATIDE THERAPY: FIRST PROSPECTIVE SIX-MONTH OUTCOMES FROM A 77-PATIENT COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04816-9","https://doi.org/10.1016/s0016-5107(26)04816-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034281","R0034281.pdf","paywalled","nonrandomized_study","Mustafa Habib","2026","Sa2106 ASSOCIATIONS BETWEEN GLP-1 RECEPTOR AGONISTS AND LIVER FUNCTION IN TYPE 2 DIABETES: A PROPENSITY SCORE-MATCHED STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03572-8","https://doi.org/10.1016/s0016-5107(26)03572-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034296","R0034296.pdf","paywalled","nonrandomized_study","Yavuz Özden","2026","Su2217 INCREASED RESIDUAL GASTRIC CONTENT BUT NO ASPIRATION IN GLP-1 RECEPTOR AGONIST USERS UNDERGOING ELECTIVE ENDOSCOPY: A PROSPECTIVE MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01502-6","https://doi.org/10.1016/s0016-5107(26)01502-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034298","R0034298.pdf","paywalled","nonrandomized_study","Jessica Atieh","2026","Mo1813 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH DELAYED COLONIC TRANSIT: A PROPENSITY SCORE-WEIGHTED RETROSPECTIVE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04877-7","https://doi.org/10.1016/s0016-5107(26)04877-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034299","R0034299.pdf","paywalled","nonrandomized_study","Richard Maradiaga","2026","Mo1781 COMPARISON OF ADVANCED CONSTIPATION PHARMACOTHERAPY BETWEEN ADULTS WITH OBESITY ON GLP-1RA VS NOT INITIATING GLP-1RA: A PROPENSITY-MATCHED REAL-WORLD COHORT ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04590-6","https://doi.org/10.1016/s0016-5107(26)04590-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034300","R0034300.pdf","paywalled","nonrandomized_study","Regis Lee","2026","Su2089 RESMETIROM VS SEMAGLUTIDE IN MASH: A REAL-WORLD ASSESSMENT OF CLINICAL OUTCOMES, SAFETY EVENTS, AND BIOCHEMICAL TRAJECTORIES","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03718-1","https://doi.org/10.1016/s0016-5107(26)03718-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034336","R0034336.pdf","paywalled","nonrandomized_study","Sima Fansa","2026","Tu2126 FEASIBILITY, SAFETY, AND METABOLIC EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS IN LIVER TRANSPLANTATION: A REAL-WORLD COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04148-9","https://doi.org/10.1016/s0016-5107(26)04148-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034362","R0034362.pdf","paywalled","nonrandomized_study","Yussif Issaka","2026","Tu1654 CARDIOMETABOLIC AND RENAL OUTCOMES OF GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS IN IBD WITH OBESITY OR MASLD: A REAL-WORLD PROPENSITY-MATCHED STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03272-4","https://doi.org/10.1016/s0016-5107(26)03272-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034372","R0034372.pdf","paywalled","nonrandomized_study","Shree A. Patel","2026","Mo1137 GLP-1 RECEPTOR AGONISTS INCREASE THE INCIDENCE OF BARRETT’S ESOPHAGUS IN A LARGE PROPENSITY MATCHED COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02057-2","https://doi.org/10.1016/s0016-5107(26)02057-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034380","R0034380.pdf","paywalled","nonrandomized_study","S.E Lee","2026","P0759 The association between GLP-1 and dual GIP/GLP-1 agonists and severe urolithiasis requiring surgery: A global real-world cohort study","European Urology","Elsevier BV","10.1016/s0302-2838(26)01627-1","https://doi.org/10.1016/s0302-2838(26)01627-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034391","R0034391.pdf","paywalled","nonrandomized_study","Sarpong Boateng","2026","Sa1287 CLINICAL OUTCOMES OF GLP-1 RECEPTOR AGONIST THERAPY IN ADULTS WITH CELIAC DISEASE: A PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05718-4","https://doi.org/10.1016/s0016-5107(26)05718-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034437","R0034437.pdf","paywalled","nonrandomized_study","Anika Azam","2026","Mo1337 BMI-DEPENDENT EFFECT MODIFICATION OF GLP-1 RECEPTOR AGONIST THERAPY ON BOWEL PREPARATION QUALITY: A RETROSPECTIVE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01006-0","https://doi.org/10.1016/s0016-5107(26)01006-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034443","R0034443.pdf","paywalled","nonrandomized_study","Ila Sruti","2026","GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.11017","https://doi.org/10.1200/jco.2026.44.16_suppl.11017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034458","R0034458.pdf","paywalled","nonrandomized_study","Luxi Chen","2026","Abstract PD8-10: Glp-1 receptor agonist in combination with radiotherapy significantly delays tumor growth and improves overall survival in a murine model of triple negative breast cancer","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-10","https://doi.org/10.1158/1557-3265.sabcs25-pd8-10",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034478","R0034478.pdf","paywalled","nonrandomized_study","Thomas W Fredrick","2026","Tu1770 A VALIDATED PROCESS USING LARGE LANGUAGE MODELS TO ENSURE ACCURACY OF REAL-WORLD DATASETS AND CLINICAL UTILITY WITH SEMAGLUTIDE IMPROVES SPECIFICITY COMPARED TO TRADITIONAL METHODS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04897-2","https://doi.org/10.1016/s0016-5107(26)04897-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034502","R0034502.pdf","paywalled","nonrandomized_study","Souvik Saha","2026","Su1575 REAL-WORLD TRENDS IN GLP-1 AND GLP-1 + GIP DUAL AGONIST PRESCRIBING AMONG PATIENTS WITH METABOLIC RISK AND INFLAMMATORY BOWEL DISEASE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02713-6","https://doi.org/10.1016/s0016-5107(26)02713-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034504","R0034504.pdf","paywalled","nonrandomized_study","Faryal Akhtar","2026","Comparative efficacy of GLP-1 RA vs. SGLT2 inhibitors in slowing chronic kidney disease (CKD) progression - a retrospective study done in northern hospital in pakistan","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.117.p119","https://doi.org/10.1530/endoabs.117.p119",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034517","R0034517.pdf","paywalled","nonrandomized_study","Magda Elamin","2026","Mo1589 IMPACT OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE: A POPULATION BASED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02959-7","https://doi.org/10.1016/s0016-5107(26)02959-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034521","R0034521.pdf","paywalled","nonrandomized_study","J.Y. Hsu","2026","P0491 Increased risk of erectile and testicular dysfunction among young men with type 2 diabetes treated with semaglutide: A global trinetx cohort analysis","European Urology","Elsevier BV","10.1016/s0302-2838(26)01377-1","https://doi.org/10.1016/s0302-2838(26)01377-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034522","R0034522.pdf","paywalled","nonrandomized_study","Jashanveer S. Johal","2026","Mo1098 ESOPHAGEAL DYSMOTILITY AND REFLUX OUTCOMES IN TYPE 2 DIABETES PATIENTS TREATED WITH VERSUS WITHOUT GLP-1 RECEPTOR AGONISTS: A PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02018-3","https://doi.org/10.1016/s0016-5107(26)02018-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034530","R0034530.pdf","paywalled","nonrandomized_study","Niven Wang","2026","Mo1811 GASTROINTESTINAL OUTCOMES ASSOCIATED WITH GLP-1 RECEPTOR AGONIST USE IN NON-DIABETIC PATIENTS WITH OBESITY: A LARGE MULTICENTER PROPENSITY MATCHED ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04875-3","https://doi.org/10.1016/s0016-5107(26)04875-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034533","R0034533.pdf","paywalled","nonrandomized_study","Yousef Ateiwi","2026","Incretin-based therapies and all-cause mortality and progression to multiple myeloma in patients with MGUS and type 2 diabetes: A real-world cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.7572","https://doi.org/10.1200/jco.2026.44.16_suppl.7572",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034589","R0034589.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2026","Su1960 PROPENSITY-MATCHED REAL-WORLD COMPARATIVE RISK OF BILIARY AND PANCREATIC EVENTS WITH TIRZEPATIDE, SEMAGLUTIDE, AND NON-GLP-1 THERAPIES IN OBESITY AND DIABETES","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)00444-x","https://doi.org/10.1016/s0016-5107(26)00444-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034600","R0034600.pdf","paywalled","nonrandomized_study","Hsien Yao Yang","2026","Mo1806 ASSOCIATION OF GLP-1 RECEPTOR AGONIST USE WITH ACUTE BILIARY AND PANCREATIC EVENTS IN ADULTS WITH OBESITY: A PROPENSITY-MATCHED COHORT STRATIFIED BY BASELINE CHOLELITHIASIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04870-4","https://doi.org/10.1016/s0016-5107(26)04870-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034614","R0034614.pdf","paywalled","nonrandomized_study","E.T. Carey","2026","Evaluating the impact of GLP-1 receptor agonists on glycaemic control and weight in patients with type 1 diabetes: a retrospective multi-centre study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.115.ep39","https://doi.org/10.1530/endoabs.115.ep39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034640","R0034640.pdf","paywalled","nonrandomized_study","Joshua Chen","2026","Mo1586 REAL-WORLD COMPARATIVE OUTCOMES OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS AND BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE: A MULTI-CENTER COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02956-1","https://doi.org/10.1016/s0016-5107(26)02956-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034673","R0034673.pdf","paywalled","nonrandomized_study","Chloe Jian","2026","Mo1552 GLP-1 RECEPTOR AGONISTS AND INFLAMMATORY BOWEL DISEASE SEVERITY: A TARGET TRIAL EMULATION USING MERATIVE™ MARKETSCAN® DATABASE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)02922-6","https://doi.org/10.1016/s0016-5107(26)02922-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034702","R0034702.pdf","paywalled","nonrandomized_study","Meghana Kakarla","2026","Sa2077 REAL-WORLD MULTI-CENTER COMPARISON OF DEMENTIA OUTCOMES AFTER BARIATRIC SURGERY AND GLP-1 THERAPY IN MASLD","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03543-1","https://doi.org/10.1016/s0016-5107(26)03543-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034704","R0034704.pdf","paywalled","nonrandomized_study","Benyamin Yaniv","2026","Association of GLP-1 receptor agonist therapy with BCG response in high-risk non–muscle invasive bladder cancer.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.4620","https://doi.org/10.1200/jco.2026.44.16_suppl.4620",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034706","R0034706.pdf","paywalled","nonrandomized_study","Sobia Laique","2026","Sa2079 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND TIRZEPATIDE IN MASLD: HIGH DISCONTINUATION RATES LIMIT CLINICAL POTENTIAL","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03545-5","https://doi.org/10.1016/s0016-5107(26)03545-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034707","R0034707.pdf","paywalled","nonrandomized_study","Jamie L. C. Wong","2026","Analysis code for: Digital-first delivery of GLP-1 receptor agonist therapy in a large real-world cohort of women","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18821944","https://doi.org/10.5281/zenodo.18821944",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034716","R0034716.pdf","paywalled","nonrandomized_study","Yan Sun","2026","Sa1143 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH INCREASED RISK FOR PHARYNGOESOPHAGEAL DYSPHAGIA: A LARGE, REAL-WORLD COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01895-x","https://doi.org/10.1016/s0016-5107(26)01895-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034751","R0034751.pdf","paywalled","nonrandomized_study","Eshan Nanda","2026","Su1127 GLP-1 RECEPTOR AGONIST EXPOSURE PRIOR TO BARRETT’S ESOPHAGUS DIAGNOSIS IS ASSOCIATED WITH REDUCED PROGRESSION TO HIGH-GRADE DYSPLASIA AND ESOPHAGEAL CANCER: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01943-7","https://doi.org/10.1016/s0016-5107(26)01943-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034752","R0034752.pdf","paywalled","nonrandomized_study","Tania Siu Xiao","2026","Sa2096 REAL-WORLD COMPARATIVE EFFECTIVENESS OF TIRZEPATIDE VERSUS SEMAGLUTIDE ON CARDIOVASCULAR AND HEPATIC OUTCOMES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03562-5","https://doi.org/10.1016/s0016-5107(26)03562-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034788","R0034788.pdf","paywalled","nonrandomized_study","Ibrahim Reyaz","2026","Su2199 SILENT DANGER OR FALSE ALARM? A PHARMACOVIGILANCE ANALYSIS OF PULMONARY ASPIRATION RISK WITH GLP-1 RECEPTOR AGONISTS AMIDST CONFLICTING SOCIETY GUIDELINES","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)01484-7","https://doi.org/10.1016/s0016-5107(26)01484-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034790","R0034790.pdf","paywalled","nonrandomized_study","Prasun K. Jalal","2026","Mo2139 SAFETY OF CONCOMITANT RIFAXIMIN AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST USE: A REAL-WORLD DATABASE ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03958-1","https://doi.org/10.1016/s0016-5107(26)03958-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034791","R0034791.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2026","Su1823 COMPARATIVE EFFECTS OF TIRZEPATIDE, SEMAGLUTIDE, AND NON-GLP-1 THERAPIES ON DE NOVO ARRHYTHMIA RISK IN ADULTS WITH OBESITY AND DIABETES: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04839-x","https://doi.org/10.1016/s0016-5107(26)04839-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034792","R0034792.pdf","paywalled","nonrandomized_study","Ammara Ghaffar","2026","Tu1955 COMPARATIVE ANALYSIS OF BILIARY ADVERSE EVENTS ASSOCIATED WITH TIRZEPATIDE VERSUS SEMAGLUTIDE: A REAL-WORLD PHARMACOVIGILANCE STUDY USING THE FAERS DATABASE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)00580-8","https://doi.org/10.1016/s0016-5107(26)00580-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034824","R0034824.pdf","paywalled","nonrandomized_study","Karina Protti De Mattos","2026","From Behavioral Failure to Biological Control: Obesity as an Institutional Blind Spot","Academy of Management Proceedings","Academy of Management","10.5465/amproc.2026.15917abstract","https://doi.org/10.5465/amproc.2026.15917abstract",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034854","R0034854.pdf","paywalled","nonrandomized_study","Arkadeep Dhali","2026","Additional file 1 of Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study","Figshare",null,"10.6084/m9.figshare.33076002","https://doi.org/10.6084/m9.figshare.33076002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034858","R0034858.pdf","paywalled","nonrandomized_study","Yury Sharafanovich","2026","Interpreting an Observed Association Between GLP-1 Receptor Agonists and Breast Cancer in an Imaging Cohort: A Methodological Research Note","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21533265","https://doi.org/10.5281/zenodo.21533265",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034868","R0034868.pdf","paywalled","nonrandomized_study","Hyojung Jang","2026","Privacy-preserving causal mediation analysis using distributed electronic health record networks","arXiv (Cornell University)",null,"10.48550/arxiv.2607.17958","https://doi.org/10.48550/arxiv.2607.17958",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035449","R0035449.pdf","paywalled","nonrandomized_study",null,"2026","GLP-1 therapy: gastrointestinal burden examined in real-world study","Reactions Weekly","Springer Science and Business Media LLC","10.1007/s40278-026-96480-5","https://doi.org/10.1007/s40278-026-96480-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035469","R0035469.pdf","paywalled","nonrandomized_study",null,"2026","GLP-1RA-related cancers identified in FAERS","Reactions Weekly","Springer Science and Business Media LLC","10.1007/s40278-026-93393-2","https://doi.org/10.1007/s40278-026-93393-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035508","R0035508.pdf","paywalled","nonrandomized_study","Bruno Sander","2026","TERAPIAS BASEADAS EM PEPTÍDEOS NA MEDICINA MODERNA: APLICAÇÕES CLÍNICAS E DESAFIOS NA ESTABILIDADE E BIODISPONIBILIDADE – REVISÃO SISTEMÁTICA","Revista Científica Ipedss","IPEDSS - Instituto de Pesquisa e Determinacao Social da Saude Ltda","10.55703/27644006060301","https://doi.org/10.55703/27644006060301",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035635","R0035635.pdf","paywalled","nonrandomized_study","Shelley Edwards","2026","Paradoxical Increase In Cubital Tunnel Syndrome Risk Among Glp-1 Agonist Users Despite Obesity As An Independent Risk Factor","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20064784","https://doi.org/10.5281/zenodo.20064784",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035639","R0035639.pdf","paywalled","nonrandomized_study","Berk Ozmen","2026","Glp-1 Receptor Agonists Mitigate Lymphedema Risk Following Axillary Node Dissection And Lumpectomy","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20079155","https://doi.org/10.5281/zenodo.20079155",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035662","R0035662.pdf","paywalled","nonrandomized_study","Nathan Booth","2026","GLP-1 Receptor Agonist Effect On Wound Healing In Breast Reduction Surgery","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20064021","https://doi.org/10.5281/zenodo.20064021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035696","R0035696.pdf","paywalled","nonrandomized_study","Kumaran. R","2026","A Deep Reinforcement Learning (DRL) Agent for Optimizing Tirzepatide Dosing Schedules to Minimize Gastrointestinal Side Effects",null,"IEEE","10.1109/raeeucci67649.2026.11504461","https://doi.org/10.1109/raeeucci67649.2026.11504461",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035715","R0035715.pdf","paywalled","nonrandomized_study","Yash Mehta","2026","Influence Of Glucagon-like Peptide-1 Receptor Agonists On Implant-based Breast Surgery Infection Risk","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20064500","https://doi.org/10.5281/zenodo.20064500",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035765","R0035765.pdf","paywalled","nonrandomized_study","Sidário Rodrigues Malheiros-junior","2026","Incretin Receptor Agonists: Pharmacovigilance Implications of Rational Molecular Design","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21612597","https://doi.org/10.5281/zenodo.21612597",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035785","R0035785.pdf","paywalled","nonrandomized_study","K -M Liao","2026","B99-08 Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.6756","https://doi.org/10.1093/ajrccm/aamag162.6756",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035947","R0035947.pdf","paywalled","nonrandomized_study","Oksana Janik Lozano Ramírez M.D.","2026","Six-month total weight loss after sleeve gastrectomy versus roux-en-y gastric bypass and the adjunctive effect of glp-1 receptor agonists: A retrospective cohort study","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21763156","https://doi.org/10.5281/zenodo.21763156",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035962","R0035962.pdf","paywalled","nonrandomized_study","N Jagtap","2026","Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1820792","https://doi.org/10.1055/s-0046-1820792",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036114","R0036114.pdf","paywalled","nonrandomized_study",null,"2026","Trends in Drug Discovery in Diabetes and Obesity",null,"Wiley","10.1002/9783527845408","https://doi.org/10.1002/9783527845408",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036224","R0036224.pdf","paywalled","nonrandomized_study","Cai Fengyi","2026","Research on living clinical practice guidelines in diabetes mellitus II: summary of key evidence in the development of drug treatment strategies for type 2 diabetes mellitus","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12173/j.issn.1004-5511.202508056","https://doi.org/10.12173/j.issn.1004-5511.202508056",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036339","R0036339.pdf","paywalled","nonrandomized_study","D. Urueta Portillo","2026","Abstract PS3-11-29: Impact of GLP-1 Receptor Agonist Use on Pathologic Complete Response in HER2-Positive Breast Cancer Treated with Neoadjuvant TCHP","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps3-11-29","https://doi.org/10.1158/1557-3265.sabcs25-ps3-11-29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036472","R0036472.pdf","paywalled","nonrandomized_study","Jasmine Kelley","2026","848: PRIOR GLP-1 USAGE MAY BE ASSOCIATED WITH REDUCED MORTALITY IN SEPTIC SURGICAL PATIENTS WITH OBESITY","Critical Care Medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ccm.0001185388.05241.50","https://doi.org/10.1097/01.ccm.0001185388.05241.50",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036510","R0036510.pdf","paywalled","nonrandomized_study","Satya Manasa Kota","2026","SDOH, GLP-1 Prescription Patterns and MASLD-associated Liver Disease in a Real World Population","University of Illinois Chicago",null,"10.25417/uic.32991914.v1","https://doi.org/10.25417/uic.32991914.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036586","R0036586.pdf","paywalled","nonrandomized_study","Γεώργιος Η. Βουρνάς","2026","Discrepancy between guidelines and clinical practice regarding the use of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and established cardiovascular disease","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.372857","https://doi.org/10.26262/heal.auth.ir.372857",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036697","R0036697.pdf","paywalled","nonrandomized_study","Adnan Agha","2026","Usability and educational impact of GLiMPSE, a pharmacovigilance-aware GLP-1 prescribing simulator: a prospective single-group mixed-methods study","Open Science Framework",null,"10.17605/osf.io/6q5pa","https://doi.org/10.17605/osf.io/6q5pa",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036704","R0036704.pdf","paywalled","nonrandomized_study","R. Terekhov","2026","EFFECT OF DIHYDROQUERCETIN ON THE WEIGHT OF EXPERIMENTAL ANIMALS: REVIEW","Problems of Biological Medical and Pharmaceutical Chemistry","Russian Vrach, Publishing House Ltd.","10.29296/25877313-2026-04-14","https://doi.org/10.29296/25877313-2026-04-14",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036720","R0036720.pdf","paywalled","nonrandomized_study","Nino Vreča","2026","REAL-WORLD DETERMINANTS OF BLOOD PRESSURE CONTROL AND SHORT-TERM BLOOD PRESSURE CHANGES IN PATIENTS WITH CHRONIC KIDNEY DISEASE","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001196668.98605.01","https://doi.org/10.1097/01.hjh.0001196668.98605.01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036732","R0036732.pdf","paywalled","nonrandomized_study",null,"2026","GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin","Cancer Discovery","American Association for Cancer Research (AACR)","10.1158/2159-8290.cd-nw2026-0002","https://doi.org/10.1158/2159-8290.cd-nw2026-0002","41543505","https://pubmed.ncbi.nlm.nih.gov/41543505/",null,null],["4","R0036808","R0036808.pdf","paywalled","nonrandomized_study","Mukthiyar Ahamed*","2026","REAL-WORLD SAFETY PROFILE OF TIRZEPATIDE: A DESCRIPTIVE ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21949709","https://doi.org/10.5281/zenodo.21949709",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036925","R0036925.pdf","paywalled","nonrandomized_study","Dr. Lal Prasanth ML. Dr. Sebin Tharique K.*","2026","The Metabolic-Cognitive Link: Exploring the Association Between Diabetes and Alzheimer's Disease","International Journal of Medical & Pharmaceutical Sciences",null,"10.5281/zenodo.18128851","https://doi.org/10.5281/zenodo.18128851",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036951","R0036951.pdf","paywalled","nonrandomized_study","Rikin Shah","2026","Real-world Evidence of Injection Semaglutide 2.4 mg in Indian Adults with Obesity: Effects on Weight Loss and Metabolic Outcomes","International journal of scientific study",null,"10.5281/zenodo.19451528","https://doi.org/10.5281/zenodo.19451528",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036972","R0036972.pdf","paywalled","nonrandomized_study","Shisode Shweta*, Kelgaonkar Prajakta, Dhamshetti Nikita, Kadbe Mansi, Aishwarya Mehtre","2026","Ozempic (Semaglutide): Beyond Diabetes-An Emerging Role in Weight Loss","International Journal of Medical & Pharmaceutical Sciences",null,"10.5281/zenodo.21860169","https://doi.org/10.5281/zenodo.21860169",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036987","R0036987.pdf","paywalled","nonrandomized_study","J. Song","2026","Abstract PS1-05-22: Characteristics and weight loss outcomes in patients with breast cancer prescribed semaglutide","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps1-05-22","https://doi.org/10.1158/1557-3265.sabcs25-ps1-05-22",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037031","R0037031.pdf","paywalled","nonrandomized_study","Ιωάννης Κορκολής Ανέστης Μάριος","2026","Study of the physiological and pharmacological actions of GLP-1 and GLP-1 receptor antagonists in appetite regulation","Harokopio University",null,"10.26258/heal.hua.7732","https://doi.org/10.26258/heal.hua.7732",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037035","R0037035.pdf","paywalled","nonrandomized_study","D. Urueta Portillo","2026","Abstract PD8-09: Revisiting the GLP-1-pCR Link in TNBC: Contrasting Outcomes in a High-BMI, Majority-Hispanic Cohort","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-09","https://doi.org/10.1158/1557-3265.sabcs25-pd8-09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037061","R0037061.pdf","paywalled","nonrandomized_study","Aseed Mestarihi","2026","CE-534538-004 GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND INCIDENCE OF ATRIAL FIBRILLATION IN OBESE ADULTS WITHOUT DIABETES: A PROPENSITY-MATCHED COHORT STUDY","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.017","https://doi.org/10.1016/j.hrthm.2026.03.017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037183","R0037183.pdf","paywalled","nonrandomized_study","Devin M. Dishong","2026","IP15-19 ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 AGONIST USE AND ESCALATION TO SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA: A NATIONWIDE CLAIMS DATABASE STUDY","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191356.52697.6d.19","https://doi.org/10.1097/01.ju.0001191356.52697.6d.19",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037240","R0037240.pdf","paywalled","nonrandomized_study","Thomas Syphan","2026","IP18-24 DO GLP-1 RECEPTOR AGONISTS PROTECT AGAINST KIDNEY STONES IN DIABETES? REAL-WORLD INSIGHTS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191368.71794.72.24","https://doi.org/10.1097/01.ju.0001191368.71794.72.24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037258","R0037258.pdf","paywalled","nonrandomized_study","G Fazio","2026","Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvag092.061","https://doi.org/10.1093/cvr/cvag092.061",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037277","R0037277.pdf","paywalled","nonrandomized_study","Leah Vaikutis","2026","26-A-13994-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS IN WOMEN UNDERGOING CARDIAC REHABILITATION: A TRINETX RETROSPECTIVE COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1895","https://doi.org/10.1016/j.jacc.2026.02.1895",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037296","R0037296.pdf","paywalled","nonrandomized_study","Philip Grandoff","2026","298. Association of glucagon-like peptide-1 receptor agonist use with complications following spinal fracture: a propensity-matched analysis of 14,000 patients","The Spine Journal","Elsevier BV","10.1016/j.spinee.2026.06.318","https://doi.org/10.1016/j.spinee.2026.06.318",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037346","R0037346.pdf","paywalled","nonrandomized_study","Mark William McGiffin","2026","IMPROVING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE MANAGEMENT IN TYPE 2 DIABETES:","Purdue",null,"10.25394/pgs.32076660","https://doi.org/10.25394/pgs.32076660",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037370","R0037370.pdf","paywalled","nonrandomized_study","Federica Sileo","2026","2473-P: Does Visceral Fat Reduction Drive Steatosis Improvement Regardless of Weight-Loss Method? A Single-Center Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-2473-p","https://doi.org/10.2337/db26-2473-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037379","R0037379.pdf","paywalled","nonrandomized_study","Joshua Chen","2026","Real-world comparative outcomes of glucagon like peptide-1 receptor agonists and bariatric surgery in inflammatory bowel disease: A multi-center cohort study","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2026.100727","https://doi.org/10.1016/j.obmed.2026.100727",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037389","R0037389.pdf","paywalled","nonrandomized_study","Husnain Abid","2026","56 Adherence to NICE guidance for GLP-1 receptor agonist prescribing in patients with severe aortic stenosis and elevated body mass index",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2026-bcs.6","https://doi.org/10.1136/heartjnl-2026-bcs.6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037398","R0037398.pdf","paywalled","nonrandomized_study","Andrea Foppiani","2026","1033-OR: Early Weight Loss Velocity Guides Precision Escalation in Obesity Treatment","Diabetes","American Diabetes Association","10.2337/db26-1033-or","https://doi.org/10.2337/db26-1033-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037504","R0037504.pdf","paywalled","nonrandomized_study","Harsh Agarwal","2026","26-A-13496-ACC ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY WITH CLINICAL OUTCOMES IN CARDIAC ALLOGRAFT VASCULOPATHY: A PROPENSITY-MATCHED MULTICENTER COHORT","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1804","https://doi.org/10.1016/j.jacc.2026.02.1804",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037525","R0037525.pdf","paywalled","nonrandomized_study","Lauren Broffman","2026","2604-P: Sleep-Related Outcomes in Patients with OSA Treated with Tirzepatide for Obesity or Overweight via Telehealth","Diabetes","American Diabetes Association","10.2337/db26-2604-p","https://doi.org/10.2337/db26-2604-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037542","R0037542.pdf","paywalled","nonrandomized_study","SHANSHAN WANG","2026","1798-P: Combined Semaglutide and Sodium–Glucose Cotransporter 2 Inhibitors in Real-World Clinical Practice in China: Scholar Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db26-1798-p","https://doi.org/10.2337/db26-1798-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06351748"],["4","R0037559","R0037559.pdf","paywalled","nonrandomized_study","Geoffroy A. Napon","2026","PO-03-100 GLP-1 AGONISTS AFTER AF ABLATION AND RISK OF RECURRENT ATRIAL FIBRILLATION: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.839","https://doi.org/10.1016/j.hrthm.2026.03.839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037568","R0037568.pdf","paywalled","nonrandomized_study","SUN  Xia, SHEN  Wen, TANG  Xiang, ZHONG  Wei, WANG  Kailin, DAI  Zhiyin, ZHANG  Chaopu, YUAN  Wei, YUAN  Guoyue","2026","Analysis of Clinical Characteristics in Dilated Cardiomyopathy Patients with Different Weight Statuses and the Influence of Weight Management on the Prognosis","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12114/j.issn.1007-9572.2025.0352","https://doi.org/10.12114/j.issn.1007-9572.2025.0352",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037608","R0037608.pdf","paywalled","nonrandomized_study","Ammad Naeem","2026","26-A-13902-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS VS. SGLT2 INHIBITORS IN OBESE PATIENTS WITH HFPEF: A PROPENSITY-MATCHED ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1894","https://doi.org/10.1016/j.jacc.2026.02.1894",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037626","R0037626.pdf","paywalled","nonrandomized_study","VANESSA WILLIAMS","2026","2034-P: Glycemic Outcomes for Patients with Type 2 Diabetes Mellitus (DM2) and Hemoglobin A1c ≥10% Managed in Primary Care and Endocrinology Clinics and Indications for Endocrinology Referral","Diabetes","American Diabetes Association","10.2337/db26-2034-p","https://doi.org/10.2337/db26-2034-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037638","R0037638.pdf","paywalled","nonrandomized_study","Eli Kasheri","2026","73985 Association of GLP-1 Therapy with Reduced Biologic Initiation in Hidradenitis Suppurativa: A Retrospective Cohort Study","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.268","https://doi.org/10.1016/j.jaad.2026.04.268",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037662","R0037662.pdf","paywalled","nonrandomized_study","D Pohl","2026","(716) Divergent Trends in Testosterone and GLP-1 Prescribing Across the United States: A State-Level Analysis of Medicare Part D Data (2013–2025)","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag118.624","https://doi.org/10.1093/jsxmed/qdag118.624",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037677","R0037677.pdf","paywalled","nonrandomized_study","JOYCE Y-C. LEE","2026","1680-P: Prescribing Pattern of GLP-1 Receptor Agonists among People with Newly Diagnosed Type 2 Diabetes: A Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1680-p","https://doi.org/10.2337/db26-1680-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037700","R0037700.pdf","paywalled","nonrandomized_study",null,"2026","Comparative Cardiometabolic and Hepatic Outcomes with Tirzepatide vs Semaglutide in Noncirrhotic Nonalcoholic Steatohepatitis: A Global Real-World TriNetX Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.310","https://doi.org/10.1016/j.eprac.2026.01.310",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037764","R0037764.pdf","paywalled","nonrandomized_study","Shruti Chandra","2026","Tirzepatide — A Twin cretin in Obesity Patients: A Comprehensive Review & Recent updates","International Journal of Drug Delivery Technology","Dr. Yashwant Research Labs Pvt. Ltd.","10.25258/ijddt.16.35s.70","https://doi.org/10.25258/ijddt.16.35s.70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037802","R0037802.pdf","paywalled","nonrandomized_study","Amanda Johnson","2026","GLUCAGON-LIKE 1 RECEPTOR AGONIST USE WAS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LARGE REAL-WORLD DATABASE STUDY","Inflammatory Bowel Diseases","Oxford University Press (OUP)","10.1093/ibd/izag006.159","https://doi.org/10.1093/ibd/izag006.159",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037815","R0037815.pdf","paywalled","nonrandomized_study","Tetiana Kutsyba","2026","Pancreatic and Gallbladder safety profile of Tirzepatide in Obesity Management: A Scoping Review of Clinical and Real-World Evidence.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21095264","https://doi.org/10.5281/zenodo.21095264",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037820","R0037820.pdf","paywalled","nonrandomized_study","Caden Rowan","2026","Effect of glucagon-like peptide 1 receptor agonism on exercise blood pressure: genome-wide association and mendelian randomization analyses","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2300122","https://doi.org/10.1152/physiol.2026.41.s1.2300122",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037822","R0037822.pdf","paywalled","nonrandomized_study","Mary Rooney","2026","Abstract MPTU11: Prediabetes Progression In Young American Adults: A Pooling Project","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.mptu11","https://doi.org/10.1161/cir.153.suppl_1.mptu11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037830","R0037830.pdf","paywalled","nonrandomized_study",null,"2026","40 | Does Tirzepatide Lead to an Improvement in Joint Symptoms Among Patients With Inflammatory Arthropathies? A Retrospective Analysis","International Journal of Rheumatic Diseases","Wiley","10.1111/1756-185x.70608_53","https://doi.org/10.1111/1756-185x.70608_53",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037856","R0037856.pdf","paywalled","nonrandomized_study","Ngo Cheung","2026","Precision Treatment of Metabolic Subtypes in Major Depressive Disorder – Multi-Tissue Transcriptome-Wide Association Reveals Mitochondrial-NAD-Insulin Axis Drivers of Symptom Heterogeneity","Figshare",null,"10.6084/m9.figshare.31939008.v1","https://doi.org/10.6084/m9.figshare.31939008.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037883","R0037883.pdf","paywalled","nonrandomized_study","Nicole Turk","2026","1363-P: Glucagon-Like Peptide 1 Receptor Agonists Slow Gastric Emptying but Do Not Prevent Hypoglycemia in Patients with Post-Bariatric Hypoglycemia","Diabetes","American Diabetes Association","10.2337/db26-1363-p","https://doi.org/10.2337/db26-1363-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037890","R0037890.pdf","paywalled","nonrandomized_study","M.W. Hayama","2026","0469 Skin excision complications following glucagon-like peptide-1 receptor agonist use: A retrospective cohort analysis","Journal of Investigative Dermatology","Elsevier BV","10.1016/j.jid.2026.06.500","https://doi.org/10.1016/j.jid.2026.06.500",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037897","R0037897.pdf","paywalled","nonrandomized_study","Daniel O. Umoru","2026","RWD3 REAL-WORLD SAFETY TRENDS OF GLP-1 RECEPTOR AGONISTS IN THE UNITED STATES: ANALYSIS OF FAERS REPORTS (2015-2025)","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.1992","https://doi.org/10.1016/j.jval.2026.03.1992",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037928","R0037928.pdf","paywalled","nonrandomized_study","HUYNH GIA BAO","2026","AFTER THE UNIVERSAL MORTALITY PREMISE: What Every Discipline Must Reconstruct When Death Becomes a Class Variable","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20790802","https://doi.org/10.5281/zenodo.20790802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037993","R0037993.pdf","paywalled","nonrandomized_study","Anna Brackenridge","2026","MANAGEMENT OF HYPEROSMOLAR HYPERGLYCAEMIC STATE","Postgraduate Medical Journal","Oxford University Press (OUP)","10.1093/postmj/qgag042.009","https://doi.org/10.1093/postmj/qgag042.009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037994","R0037994.pdf","paywalled","nonrandomized_study","Pushan Aggarwal","2026","26-A-8886-ACC GLP1 AGONISTS IN PATIENTS WITH DIABETES: EVALUATING INCIDENT PULMONARY HYPERTENSION WITH REAL WORLD DATA","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2395","https://doi.org/10.1016/j.jacc.2026.02.2395",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038046","R0038046.pdf","paywalled","nonrandomized_study","Pamela Senesi","2026","1444-P: The Relationship between Diabetic Retinopathy and Glucose-Lowering Therapy in Type 2 Diabetes: Results of an Observational Retrospective Study","Diabetes","American Diabetes Association","10.2337/db26-1444-p","https://doi.org/10.2337/db26-1444-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038143","R0038143.pdf","paywalled","nonrandomized_study","Leah Vaikutis","2026","26-A-14016-ACC GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS UNDERGOING CARDIAC REHABILITATION: A REAL-WORLD COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1897","https://doi.org/10.1016/j.jacc.2026.02.1897",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038166","R0038166.pdf","paywalled","nonrandomized_study","Xinyan Jia","2026","2859-LB: Fracture Risk with Combined SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Target Trial Emulation","Diabetes","American Diabetes Association","10.2337/db26-2859-lb","https://doi.org/10.2337/db26-2859-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038167","R0038167.pdf","paywalled","nonrandomized_study","Murray Coetzee","2026","Association of GLP-1 Receptor Agonist Exposure and Device-Detected Ventricular Arrhythmic Events.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20584169","https://doi.org/10.5281/zenodo.20584169",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038184","R0038184.pdf","paywalled","nonrandomized_study","Sungho Bea","2026","1778-P: Opioids and Risk of Gastrointestinal Outcomes among Patients Receiving GLP-1RAs","Diabetes","American Diabetes Association","10.2337/db26-1778-p","https://doi.org/10.2337/db26-1778-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038191","R0038191.pdf","paywalled","nonrandomized_study","H Kamal","2026","B54-10 Association of Glucagon-Like Peptide-1 Agonist Use With Pulmonary and Infectious Complications in Non-Alcoholic Steatohepatitis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.4253","https://doi.org/10.1093/ajrccm/aamag162.4253",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038210","R0038210.pdf","paywalled","nonrandomized_study","Justin Haloot","2026","26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.160","https://doi.org/10.1016/j.jacc.2026.02.160",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038228","R0038228.pdf","paywalled","nonrandomized_study","Mohab Elnashar","2026","26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.516","https://doi.org/10.1016/j.jacc.2026.02.516",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038233","R0038233.pdf","paywalled","nonrandomized_study","Mushgan Nassiri","2026","1800-P: GLP-1 Use in Type 1 Diabetes Patients: Assessing Changes in HbA1c, Body Weight, and Cardiovascular Disease Risk Reduction","Diabetes","American Diabetes Association","10.2337/db26-1800-p","https://doi.org/10.2337/db26-1800-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038236","R0038236.pdf","paywalled","nonrandomized_study","Sungho Bea","2026","1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders","Diabetes","American Diabetes Association","10.2337/db26-1657-p","https://doi.org/10.2337/db26-1657-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038239","R0038239.pdf","paywalled","nonrandomized_study","Temiloluwa Oladeji","2026","GLP-1 RECEPTOR AGONISTS IMPROVE MENSTRUAL REGULARITY IN POLYCYSTIC OVARY SYNDROME: A RETROSPECTIVE COHORT STUDY","Fertility and Sterility","Elsevier BV","10.1016/j.fertnstert.2026.05.065","https://doi.org/10.1016/j.fertnstert.2026.05.065",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038245","R0038245.pdf","paywalled","nonrandomized_study","KATARINA VUKELIC","2026","1827-P: Add-On Semaglutide in the Treatment of Elderly with Type 2 Diabetes May Offer the Potential Benefits","Diabetes","American Diabetes Association","10.2337/db26-1827-p","https://doi.org/10.2337/db26-1827-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038345","R0038345.pdf","paywalled","nonrandomized_study","KRISTEN KULASA","2026","2755-LB: Education and Implementation to Improve Prescription of Guideline-Based Cardiorenal Protective Medications","Diabetes","American Diabetes Association","10.2337/db26-2755-lb","https://doi.org/10.2337/db26-2755-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038350","R0038350.pdf","paywalled","nonrandomized_study","Rachna Rana","2026","RWD78 SOCIAL MEDIA CONVERSATIONS ON GLP-1 THERAPIES FOR OBESITY: REAL-WORLD EXPERIENCES AND TREATMENT NARRATIVES","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2066","https://doi.org/10.1016/j.jval.2026.03.2066",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038361","R0038361.pdf","paywalled","nonrandomized_study","ADITYA JAIN","2026","1727-P: Tirzepatide Induced Cardiometabolic Transformation in Indian Patients with Obesity: A Prospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1727-p","https://doi.org/10.2337/db26-1727-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038380","R0038380.pdf","paywalled","nonrandomized_study","HUGO A. TORRES","2026","2906-LB: Utilization of GLP-1RA and SGLT2i Medication Classes in Medicaid: Results from an Academic Health System","Diabetes","American Diabetes Association","10.2337/db26-2906-lb","https://doi.org/10.2337/db26-2906-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038382","R0038382.pdf","paywalled","nonrandomized_study","Kevin Cowart","2026","1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease","Diabetes","American Diabetes Association","10.2337/db26-1282-or","https://doi.org/10.2337/db26-1282-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038391","R0038391.pdf","paywalled","nonrandomized_study","Preet Doshi","2026","Abstract 03: Impact of SGLT 2 inhibitors and GLP-1 receptor agonists dual therapy on Cardiovascular Outcomes in patients with Heart Failure with Reduced Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Propensity-Matched Cohort","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.03","https://doi.org/10.1161/cir.153.suppl_1.03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038440","R0038440.pdf","paywalled","nonrandomized_study","Ure K Eziyi","2026","26-A-19426-ACC GLP-1 RECEPTOR AGONISTS AND OUTCOMES IN TAKOTSUBO SYNDROME: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1673","https://doi.org/10.1016/j.jacc.2026.02.1673",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038448","R0038448.pdf","paywalled","nonrandomized_study","Muhammad Aaqib Shamim","2026","Finerenone in Type 1 Diabetes and Chronic Kidney Disease","New England Journal of Medicine","Massachusetts Medical Society","10.1056/nejmc2604395","https://doi.org/10.1056/nejmc2604395","42235021","https://pubmed.ncbi.nlm.nih.gov/42235021/",null,null],["4","R0038450","R0038450.pdf","paywalled","nonrandomized_study","HANS JOHNSON","2026","1662-P: Digital Programme Engagement Overcomes Weight Loss Resistance in Women with PCOS Treated with GLP-1 Receptor Agonists","Diabetes","American Diabetes Association","10.2337/db26-1662-p","https://doi.org/10.2337/db26-1662-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038472","R0038472.pdf","paywalled","nonrandomized_study",null,"2026","Evaluating the Synergistic Effect of Glucagon-like Peptide-1 Receptor Agonists and Lipid- Lowering Therapy on Apolipoprotein B in Diabetic Patients: A Retrospective Study Using TriNetX Database","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.282","https://doi.org/10.1016/j.eprac.2026.01.282",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038475","R0038475.pdf","paywalled","nonrandomized_study","Thomas Syphan","2026","IP12-11 GLP-1 RECEPTOR AGONISTS REDUCE KIDNEY STONE EVENTS IN OBESE PATIENTS: EVIDENCE FROM A REAL-WORLD COHORT","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191328.95269.a6.11","https://doi.org/10.1097/01.ju.0001191328.95269.a6.11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038486","R0038486.pdf","paywalled","nonrandomized_study","LIJUN DUAN","2026","1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1755-p","https://doi.org/10.2337/db26-1755-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038489","R0038489.pdf","paywalled","nonrandomized_study","Pareeta Kotecha","2026","2170-P: Association of Newer Glucose-Lowering Drugs with Incident Parkinsonian Disorders in Older Adults with REM Sleep Behavior Disorder and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2170-p","https://doi.org/10.2337/db26-2170-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038521","R0038521.pdf","paywalled","nonrandomized_study",null,"2026","Impact of GLP-1 Receptor Agonists on End-Organ Complications in Type 1 Diabetes: A Retrospective Cohort Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.132","https://doi.org/10.1016/j.eprac.2026.01.132",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038620","R0038620.pdf","paywalled","nonrandomized_study","Zhouzhou Chu","2026","RWD148 MACHINE LEARNING MODELS FOR PREDICTING SERIOUS ADVERSE EVENT REPORTS IN GLP-1 RECEPTOR AGONISTS USING FAERS, 2015-2025","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2136","https://doi.org/10.1016/j.jval.2026.03.2136",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038622","R0038622.pdf","paywalled","nonrandomized_study","Muhammad Usman Malik","2026","N‑K SCIENCES COMPLETE DRUG RESPONSE SIMULATION BY BLOOD TYPE: Antibiotics, Cardiovascular Drugs, Analgesics, and More — Organ‑Specific Effects on Kidneys, Liver, Heart, Brain, and Pancreas Subtitle From First Principles — Using Only Four Divine Axioms — No Empirical Fitting — 60+ Drugs, 8 Blood Types, 5 Major Organs — The First Blood Type‑Stratified Pharmacological Simulation in Medical History","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20482487","https://doi.org/10.5281/zenodo.20482487",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038642","R0038642.pdf","paywalled","nonrandomized_study","Koji Kashima","2026","1838-P: Individualized Slope Analysis: Optimizing Reno-Protective Pillars of Therapy","Diabetes","American Diabetes Association","10.2337/db26-1838-p","https://doi.org/10.2337/db26-1838-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038710","R0038710.pdf","paywalled","nonrandomized_study","CHHAVI G. MEHRA","2026","1677-P: Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db26-1677-p","https://doi.org/10.2337/db26-1677-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038728","R0038728.pdf","paywalled","nonrandomized_study","Arshi Syal","2026","Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: A propensity score–matched analysis from a global federated health research network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.7548","https://doi.org/10.1200/jco.2026.44.16_suppl.7548",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038733","R0038733.pdf","paywalled","nonrandomized_study","A Munawwar","2026","From referral to therapy: opportunities for treatment optimisation in heart failure with preserved ejection fraction across care settings","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.545","https://doi.org/10.1093/ejhf/xuag193.545",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038741","R0038741.pdf","paywalled","nonrandomized_study","Kiara Patino","2026","Impact of GLP-1 receptor agonists in hormone receptor–positive breast cancer patients receiving CDK4/6 inhibitors.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.1100","https://doi.org/10.1200/jco.2026.44.16_suppl.1100",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038755","R0038755.pdf","paywalled","nonrandomized_study","Hala Yousef","2026","Evaluating the Synergistic Effect of GLP-1 Agonists and Lipid- Lowering Therapy on Apolipoprotein B in Diabetic Patient: A Retrospective Study Using TriNetX Database",null,null,"10.13140/rg.2.2.11750.38722","https://doi.org/10.13140/rg.2.2.11750.38722",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038781","R0038781.pdf","paywalled","nonrandomized_study","Jie Zhang (64655)","2026","2875-LB: Effectiveness and Safety of Adjunctive Therapy in Classic Type 1 Diabetes: A Real-World Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-2875-lb","https://doi.org/10.2337/db26-2875-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038784","R0038784.pdf","paywalled","nonrandomized_study","Reina Tonegawa‐Kuji","2026","PO-04-251 OBESITY-DEPENDENT BENEFITS OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS ON ATRIAL FIBRILLATION RISK: A LARGE-SCALE ELECTRONIC HEALTH RECORD-BASED TARGET TRIAL EMULATION","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.1249","https://doi.org/10.1016/j.hrthm.2026.03.1249",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038799","R0038799.pdf","paywalled","nonrandomized_study","Arash Fattahi","2026","O03 Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review","British Journal of Dermatology","Oxford University Press (OUP)","10.1093/bjd/ljag086.018","https://doi.org/10.1093/bjd/ljag086.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038844","R0038844.pdf","paywalled","nonrandomized_study","A. Y. Khan","2026","Abstract PD8-08: Glp-1 receptor agonists are associated with improved breast cancer outcomes in dcis patients on hormonal therapy: a real-world cohort study","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-08","https://doi.org/10.1158/1557-3265.sabcs25-pd8-08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038851","R0038851.pdf","paywalled","nonrandomized_study","ABIGAEL FINKLE","2026","2150-P: Association between GLP-1 Receptor Agonist Use during Pregnancy and Adverse Birth Outcomes","Diabetes","American Diabetes Association","10.2337/db26-2150-p","https://doi.org/10.2337/db26-2150-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038886","R0038886.pdf","paywalled","nonrandomized_study","JAIME ALMANDOZ","2026","2324-P: GLP-1RA Discontinuation in People with Obesity: Real-World Insights across Disease Burden Subgroups","Diabetes","American Diabetes Association","10.2337/db26-2324-p","https://doi.org/10.2337/db26-2324-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038917","R0038917.pdf","paywalled","nonrandomized_study","Aakash Srikanth","2026","Abstract Fri042: Association of GLP-1 Receptor Agonist Use With Carotid Revascularization, Cerebrovascular Events, and Mortality in Patients With Type 2 Diabetes: A Real-World Analysis","Arteriosclerosis Thrombosis and Vascular Biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvb.46.suppl_1.fri042","https://doi.org/10.1161/atvb.46.suppl_1.fri042",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038949","R0038949.pdf","paywalled","nonrandomized_study","JAIME LUCOVE","2026","45-PUB: Glycemia in Perimenopausal vs. Preperimenopausal Age Groups in Women with Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-45-pub","https://doi.org/10.2337/db26-45-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038955","R0038955.pdf","paywalled","nonrandomized_study","Yun-Yu Chen","2026","PO-02-162 IMPACT OF SGLT2 INHIBITORS, GLP-1 RECEPTOR AGONISTS, AND SGLT2I–GLP-1RA COMBINATION THERAPY ON VENTRICULAR ARRHYTHMIAS AND MORTALITY IN STAGE 4 CKM SYNDROME: A GLOBAL TRINETX COHORT ANALYSIS","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.553","https://doi.org/10.1016/j.hrthm.2026.03.553",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039012","R0039012.pdf","paywalled","nonrandomized_study","Margaret Crawford","2026","1914-P: From Data to Action: Early Real-World Evidence on Behavioral Change and Feature Engagement with Stelo","Diabetes","American Diabetes Association","10.2337/db26-1914-p","https://doi.org/10.2337/db26-1914-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039013","R0039013.pdf","paywalled","nonrandomized_study","LAURA NGUYEN","2026","2023-P: From Guidelines to Practice: System-Level Adherence to Guideline-Directed Diabetes Therapies in Real-World Academic Practice","Diabetes","American Diabetes Association","10.2337/db26-2023-p","https://doi.org/10.2337/db26-2023-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039027","R0039027.pdf","paywalled","nonrandomized_study","Nicole Levin","2026","74372 Do GLP-1s SCAR? A FAERS Disproportionality Analysis of Severe Cutaneous Adverse Reactions to GLP-1 Receptor Agonists","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.672","https://doi.org/10.1016/j.jaad.2026.04.672",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039039","R0039039.pdf","paywalled","nonrandomized_study","Jordan Mallette","2026","Modeling the role of semaglutide treatment in patients with obesity and kidney disease","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2300865","https://doi.org/10.1152/physiol.2026.41.s1.2300865",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039088","R0039088.pdf","paywalled","nonrandomized_study",null,"2026","Real-World Experience With Tirzepatide in Nondiabetic Obese Indian Adults - An Early Interim Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.318","https://doi.org/10.1016/j.eprac.2026.01.318",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039122","R0039122.pdf","paywalled","nonrandomized_study","Rajeev Chawla","2026","Metabolic and hepatic effects of tirzepatide in adults with type 2 diabetes: A 4-month real-world evaluation","International Journal of Diabetes in Developing Countries","Springer Science and Business Media LLC","10.1007/s13410-026-01645-8","https://doi.org/10.1007/s13410-026-01645-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039161","R0039161.pdf","paywalled","nonrandomized_study","HANS JOHNSON","2026","1661-P: Digital Programme Engagement Enhances GLP-1 Receptor Agonist Weight Loss Outcomes in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1661-p","https://doi.org/10.2337/db26-1661-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039221","R0039221.pdf","paywalled","nonrandomized_study",null,"2026","Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.290","https://doi.org/10.1016/j.eprac.2026.01.290",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039224","R0039224.pdf","paywalled","nonrandomized_study","A Walker","2026","4 Prospective Audit and Observational Study of GLP-1 Receptor Agonist Use in a Surgical Patient Cohort","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag080.002","https://doi.org/10.1093/bjs/znag080.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039235","R0039235.pdf","paywalled","nonrandomized_study","Christopher James","2026","100.69 Pre-Procedural GLP-1 Receptor Agonist Use and Risk of Contrast-Induced Acute Kidney Injury After PCI: A Single-Center Cohort Study","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2026.01.072","https://doi.org/10.1016/j.jcin.2026.01.072",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039252","R0039252.pdf","paywalled","nonrandomized_study","ELIZABETH MITCHELL","2026","1177-OR: Informing Medicare Prescription Drug Subsidy Expansion: A Cost Sensitivity Analysis of Income-Related Heterogeneity in Discontinuation of GLP-1 Receptor Agonists and SGLT2 Inhibitors","Diabetes","American Diabetes Association","10.2337/db26-1177-or","https://doi.org/10.2337/db26-1177-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039268","R0039268.pdf","paywalled","nonrandomized_study","Amanda Gronniger","2026","1236 Impact of Pharmacy Support on Tirzepatide Management in Patients with Obstructive Sleep Apnea or Obesity","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.1235","https://doi.org/10.1093/sleep/zsag091.1235",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039272","R0039272.pdf","paywalled","nonrandomized_study","Giada Rossi","2026","1811-P: Therapeutic Transition to Weekly Basal Insulin Icodec plus Tirzepatide in Type 2 Diabetes: An Early Real-World Experience","Diabetes","American Diabetes Association","10.2337/db26-1811-p","https://doi.org/10.2337/db26-1811-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039288","R0039288.pdf","paywalled","nonrandomized_study","Pal Ramesh","2026","EVALUATING POUCH RELATED OUTCOMES WITH GLUCAGON LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS IN PATIENTS WITH ILEAL POUCH ANAL ANASTOMOSIS—A DATABASE STUDY IN THE UNITED STATES","Inflammatory Bowel Diseases","Oxford University Press (OUP)","10.1093/ibd/izag006.048","https://doi.org/10.1093/ibd/izag006.048",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039301","R0039301.pdf","paywalled","nonrandomized_study","Nicholas Stucky","2026","Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study","UNC Libraries",null,"10.17615/0qep-j968","https://doi.org/10.17615/0qep-j968",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039305","R0039305.pdf","paywalled","nonrandomized_study","Henry Herrera","2026","75371 Risk of New-Onset Hair Loss with Semaglutide and Tirzepatide: A Retrospective Cohort Study","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.1557","https://doi.org/10.1016/j.jaad.2026.04.1557",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039332","R0039332.pdf","paywalled","nonrandomized_study","JOSEPH HERGES","2026","2860-LB: Clinical Inertia in the Treatment of Hypertension for Individuals with Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2860-lb","https://doi.org/10.2337/db26-2860-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039359","R0039359.pdf","paywalled","nonrandomized_study","Pareeta Kotecha","2026","2069-P: Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study","Diabetes","American Diabetes Association","10.2337/db26-2069-p","https://doi.org/10.2337/db26-2069-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039388","R0039388.pdf","paywalled","nonrandomized_study","Fnu Ruchika","2026","2158 Comparative Outcomes of GLP-1 Receptor Agonists versus Glyburide in ICH Patients With Type 2 Diabetes: A Real-World Analysis Using the TriNetX Live Database","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_2158","https://doi.org/10.1227/neu.0000000000003964_2158",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039391","R0039391.pdf","paywalled","nonrandomized_study","R Leguizamon","2026","A39-23 Association Between GLP 1 Receptor Agonists Use and Interstitial Lung Disease Incidence in Rheumatoid Arthritis With Type 2 Diabetes: A Real-world Cohort Analysis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.2246","https://doi.org/10.1093/ajrccm/aamag162.2246",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039402","R0039402.pdf","paywalled","nonrandomized_study",null,"2026","Safety of GLP-1 and GIP/GLP-1 Receptor Agonists in Patients With Prior Alcohol-induced Pancreatitis: A Multicenter Real-World Cohort Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.216","https://doi.org/10.1016/j.eprac.2026.01.216",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039452","R0039452.pdf","paywalled","nonrandomized_study","H Wei","2026","Tirzepatide and the prevention of heart failure in patients with obesity and atrial fibrillation: a multicenter real-world cohort study","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.730","https://doi.org/10.1093/ejhf/xuag193.730",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039493","R0039493.pdf","paywalled","nonrandomized_study","H Alaws","2026","B45-05 Association Between Glp-1 Receptor Agonist Use and Mortality Among Patients With Bronchiectasis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1233","https://doi.org/10.1093/ajrccm/aamag162.1233",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039519","R0039519.pdf","paywalled","nonrandomized_study","G Severini","2026","Potential role of CPAP treatment on right ventricular function in patients with heart failure and OSA","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.767","https://doi.org/10.1093/ejhf/xuag193.767",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039556","R0039556.pdf","paywalled","nonrandomized_study","I Marín Espinosa","2026","4CPS-306 Semaglutide in obese haemodialysis patients with chronic kidney disease: a case series","Section 4: Clinical pharmacy services","British Medical Journal Publishing Group","10.1136/ejhpharm-2026-eahp.403","https://doi.org/10.1136/ejhpharm-2026-eahp.403",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039646","R0039646.pdf","paywalled","nonrandomized_study","RISHAB TANDON","2026","1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM","Diabetes","American Diabetes Association","10.2337/db26-1965-p","https://doi.org/10.2337/db26-1965-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039667","R0039667.pdf","paywalled","nonrandomized_study",null,"2026","Cardiovascular, Metabolic, and Mortality Outcomes With Semaglutide Versus Tirzepatide in Obese Patients With Hypothyroidism: A Real-World Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.054","https://doi.org/10.1016/j.eprac.2026.03.054",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039682","R0039682.pdf","paywalled","nonrandomized_study",null,"2026","G-361 GLP-1 Receptor Agonist Utilization in a National Cohort of Maintenance Dialysis Patients","American Journal of Kidney Diseases","Elsevier BV","10.1053/j.ajkd.2026.02.362","https://doi.org/10.1053/j.ajkd.2026.02.362",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039700","R0039700.pdf","paywalled","nonrandomized_study","Yun-Yu Chen","2026","CE-534538-005 COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS, GLP-1 RECEPTOR AGONISTS, AND THEIR COMBINATION ON THE RISK OF ATRIAL FIBRILLATION AND STROKE IN STAGE 4 CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME: A TRINETX GLOBAL COHORT STUDY","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.018","https://doi.org/10.1016/j.hrthm.2026.03.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039718","R0039718.pdf","paywalled","nonrandomized_study","Muhammed Hammad","2026","IP22-12 GLP-1 RECEPTOR AGONISTS ASSOCIATED WITH REDUCE PELVIC COMPLICATIONS IN POSTPARTUM WOMEN: A GLOBAL REAL-WORLD MATCHED COHORT STUDY","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191396.05243.57.12","https://doi.org/10.1097/01.ju.0001191396.05243.57.12",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039750","R0039750.pdf","paywalled","nonrandomized_study","Jasmine S. Sukumar","2026","Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.629","https://doi.org/10.1200/jco.2026.44.16_suppl.629",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039777","R0039777.pdf","paywalled","nonrandomized_study",null,"2026","Comprehensive Metabolic and Hepatic Benefits of Tirzepatide in Type 2 Diabetes: A 4-Month Real-World Evaluation in 132 Patients","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.211","https://doi.org/10.1016/j.eprac.2026.01.211",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039791","R0039791.pdf","paywalled","nonrandomized_study","Dhiraj J. Pangal","2026","343. GLP-1 receptor agonist use is associated with reduced systemic complications but increased pseudarthrosis following lumbar spine surgery: a national cohort study","The Spine Journal","Elsevier BV","10.1016/j.spinee.2026.06.363","https://doi.org/10.1016/j.spinee.2026.06.363",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039804","R0039804.pdf","paywalled","nonrandomized_study","A Obeidat","2026","B24-09 Glp-1 Receptor Agonist Use Is Associated With Improved Survival and Reduced Hospitalizations in COPD Patients With Obesity","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1768","https://doi.org/10.1093/ajrccm/aamag162.1768",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039810","R0039810.pdf","paywalled","nonrandomized_study","Travis E. Adamson","2026","Abstract PD8-02: Evaluating weight loss outcomes in patients with hormone receptor-positive breast cancer on endocrine therapy receiving concurrent weight loss medications","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-02","https://doi.org/10.1158/1557-3265.sabcs25-pd8-02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039823","R0039823.pdf","paywalled","nonrandomized_study","Muneeb Asad","2026","GLP-1 receptor agonist therapy and cancer risk and mortality in patients with moderate CKD: A national matched cohort study of 58,000 patients.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10583","https://doi.org/10.1200/jco.2026.44.16_suppl.10583",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039824","R0039824.pdf","paywalled","nonrandomized_study","XIXI ZHU","2026","1737-P: Efficacy, Glycemic Variability, and Safety of Insulin Icodec Combined with Semaglutide in Simplifying Complex Polypharmacy for Uncontrolled Type 2 Diabetes: A Retrospective Study","Diabetes","American Diabetes Association","10.2337/db26-1737-p","https://doi.org/10.2337/db26-1737-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039833","R0039833.pdf","paywalled","nonrandomized_study","Koji Kashima","2026","21-PUB: GLP-1 Receptor Agonist–Based Therapy in Early Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-21-pub","https://doi.org/10.2337/db26-21-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039896","R0039896.pdf","paywalled","nonrandomized_study",null,"2026","Early Real-World Sex-Stratified Phenotypic Patterns of GLP-1 Receptor Agonist Initiation Following Recent Launch in India","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.021","https://doi.org/10.1016/j.eprac.2026.03.021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039936","R0039936.pdf","paywalled","nonrandomized_study","Henry Herrera","2026","75345 GLP-1 Receptor Agonists and Treatment Utilization in Cicatricial Alopecia: A Retrospective Cohort Study","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.952","https://doi.org/10.1016/j.jaad.2026.04.952",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039942","R0039942.pdf","paywalled","nonrandomized_study","W Fernando Trigoso","2026","1688-P: Addition of GLP-1 Analogs to DM1 Patients Using Automatic Insulin Delivery (AID) (MiniMed 780G): A Retrospective Real-Life Study","Diabetes","American Diabetes Association","10.2337/db26-1688-p","https://doi.org/10.2337/db26-1688-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040015","R0040015.pdf","paywalled","nonrandomized_study","Sidário Rodrigues Malheiros-junior","2026","Suppressed tonic glucagon, depleted substrate and attenuated warning: hypoglycaemia risk with incretin receptor agonists outside diabetes","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22018963","https://doi.org/10.5281/zenodo.22018963",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041352","R0041352.pdf","paywalled","nonrandomized_study","Sidário Rodrigues Malheiros-junior","2026","Metabolic and neurological warning phenotypes during tirzepatide treatment: a clinical pharmacology and pharmacovigilance review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22105183","https://doi.org/10.5281/zenodo.22105183",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041361","R0041361.pdf","paywalled","nonrandomized_study","Cho Han Chiang","2026","Glucagon-like peptide-1 receptor agonists and risk of pancreatic cancer in high-risk individuals: A multicenter real-world analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.19_suppl.126","https://doi.org/10.1200/jco.2026.44.19_suppl.126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041382","R0041382.pdf","paywalled","nonrandomized_study","Ilana Graetz","2026","Trends and factors associated with glucagon-like peptide 1 receptor agonists prescription for cancer populations with type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.11181","https://doi.org/10.1200/jco.2026.44.16_suppl.11181",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041386","R0041386.pdf","paywalled","nonrandomized_study","Cho Han Chiang","2026","Safety of glucagon-like peptide-1 receptor agonists in patients with breast cancer: A real-world multicenter cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.11139","https://doi.org/10.1200/jco.2026.44.16_suppl.11139",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041407","R0041407.pdf","paywalled","nonrandomized_study","Nikitha Vobugari","2026","Association of SGLT2 inhibitors and GLP-1 receptor agonists or DPP-4 inhibitors with incident cancer in patients with type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10590","https://doi.org/10.1200/jco.2026.44.16_suppl.10590",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041427","R0041427.pdf","paywalled","nonrandomized_study","Jeevin Sandhu","2026","2607-P: Dynamics of Noninvasive Tests, LIVERFASt (LFASt), FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), during Monitoring Therapy with THR-beta Agonist Resmetirom (RT) in Patients with MASH: Update","Diabetes","American Diabetes Association","10.2337/db26-2607-p","https://doi.org/10.2337/db26-2607-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041432","R0041432.pdf","paywalled","nonrandomized_study","Shih‐Syuan Wang","2026","Tirzepatide and Reduced Initial Ischemic Stroke Risk in Adults with Type 2 Diabetes: A Target Trial Emulation (N3.001)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000213029","https://doi.org/10.1212/wnl.0000000000213029",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041481","R0041481.pdf","paywalled","nonrandomized_study","Camilo Fernández Bravo","2026","Multiscale Mathematical and Computational Systems Biology Frameworks That Explicitly Couple Molecular Clock Gene Networks Across Multiple Tissues, Pulsatile Neuroendocrine Generators, Autonomic Flux Balance, and Stochastic Hormonal Noise to Predict Individual Dawn Phenomenon Severity and to Identify Optimal, Personalized Circadian Therapeutic Windows: A Theoretical and Predictive Architecture Whose Construction and Experimental Validation Remain at an Embryonic Stage in the International Literature","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22133364","https://doi.org/10.5281/zenodo.22133364",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041506","R0041506.pdf","paywalled","nonrandomized_study","Tomas Pødenphant Lund","2026","Pressure, Hysteresis, and Experience: A Friction-Theoretic Framework for Clinical Intervention","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22132990","https://doi.org/10.5281/zenodo.22132990",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041852","R0041852.pdf","paywalled","nonrandomized_study","Rotana M. Radwan","2026","PT37 EFFECTIVENESS AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH WEIGHT RECURRENCE AFTER BARIATRIC SURGERY: A REAL-WORLD STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.295","https://doi.org/10.1016/j.jval.2026.03.295",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042003","R0042003.pdf","paywalled","nonrandomized_study","Nneoma Ubah","2026","POSTER: MPN-1689: Impact of GLP-1 Agonists on Clinical Outcomes in Patients With Essential Thrombocythemia: A Propensity-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01005-0","https://doi.org/10.1016/s2152-2650(26)01005-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042006","R0042006.pdf","paywalled","nonrandomized_study","Dhriti Sood","2026","POSTER: MM-1350: GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01449-7","https://doi.org/10.1016/s2152-2650(26)01449-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042012","R0042012.pdf","paywalled","nonrandomized_study","Nnamdi Omenuko","2026","POSTER: MM-857: Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01376-5","https://doi.org/10.1016/s2152-2650(26)01376-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042014","R0042014.pdf","paywalled","nonrandomized_study","Nneoma Ubah","2026","MPN-1689: Impact of GLP-1 Agonists on Clinical Outcomes in Patients With Essential Thrombocythemia: A Propensity-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02436-5","https://doi.org/10.1016/s2152-2650(26)02436-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042019","R0042019.pdf","paywalled","nonrandomized_study","Colton Jones","2026","MM-626: GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02903-4","https://doi.org/10.1016/s2152-2650(26)02903-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042034","R0042034.pdf","paywalled","nonrandomized_study","The Pharmaceutical Society Of Korea","2026","Indication-Specific Adverse Event Patterns of Tirzepatide: An Updated FAERS Pharmacovigilance Study","Yakhak Hoeji","The Pharmaceutical Society of Korea","10.17480/psk.2026.70.4.347","https://doi.org/10.17480/psk.2026.70.4.347",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042037","R0042037.pdf","paywalled","nonrandomized_study","Colton Jones","2026","POSTER: MM-626: GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01336-4","https://doi.org/10.1016/s2152-2650(26)01336-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042039","R0042039.pdf","paywalled","nonrandomized_study","Dhriti Sood","2026","MM-1350: GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)03031-4","https://doi.org/10.1016/s2152-2650(26)03031-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042040","R0042040.pdf","paywalled","nonrandomized_study","Muluken Megiso","2026","POSTER: MPN-1144: GLP-1 Receptor Agonists and Major Clinical Outcomes in Adults With Classic Myeloproliferative Neoplasms and Type 2 Diabetes and/or Obesity: A Global Propensity Score-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)00983-3","https://doi.org/10.1016/s2152-2650(26)00983-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042063","R0042063.pdf","paywalled","nonrandomized_study","Leonardo Neves","2026","Pain in studies of glucagon-like peptide-1 receptor agonists is measured with instruments that cannot locate it: a scoping review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.17605/osf.io/kq7pb","https://doi.org/10.17605/osf.io/kq7pb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042104","R0042104.pdf","paywalled","nonrandomized_study","Nitin Mohaniraj Patankar","2026","Real-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy","Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.74.1627","https://doi.org/10.59556/japi.74.1627",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042111","R0042111.pdf","paywalled","nonrandomized_study","Solomon Chih‐Cheng Chen","2026","Cardiorenal Outcomes of Tirzepatide versus Semaglutide in Adults with Type 2 Diabetes and Established Chronic Kidney Disease: A Multi-National Target Trial Emulation in the TriNetX Global Network",null,null,"10.17605/osf.io/9au65","https://doi.org/10.17605/osf.io/9au65",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042118","R0042118.pdf","paywalled","nonrandomized_study","Augusto Sassi-Baldizan","2026","GLP-1 receptor agonists in women with polycystic ovary syndrome and mental health, quality of life, and psychosocial outcomes: a scoping review",null,null,"10.17605/osf.io/ef3j5","https://doi.org/10.17605/osf.io/ef3j5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042122","R0042122.pdf","paywalled","nonrandomized_study","Rahmah Sameh Shaheen","2026","Comparative Effects of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors on Lipid Profiles: A Large Real-World Propensity-Matched Analysis",null,null,"10.17605/osf.io/p9be4","https://doi.org/10.17605/osf.io/p9be4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042140","R0042140.pdf","paywalled","nonrandomized_study","Yunchao Huang","2026","Biologics, GLP-1 Receptor Agonists and Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease: A Scoping Review of Evidence Isolation",null,null,"10.17605/osf.io/8tfrq","https://doi.org/10.17605/osf.io/8tfrq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042161","R0042161.pdf","paywalled","nonrandomized_study","Alexander Gyenis","2026","Pharmacological and biologically active interventions to improve dental implant osseointegration and wound healing in diabetic patients: A scoping review",null,null,"10.17605/osf.io/4ekzv","https://doi.org/10.17605/osf.io/4ekzv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042179","R0042179.pdf","paywalled","nonrandomized_study","Xiyi Lu","2026","Real-world safety signals of resmetirom in FAERS: a disproportionality study with GLP-1 comparator and MAESTRO-NASH benchmarking",null,null,"10.17605/osf.io/fpg84","https://doi.org/10.17605/osf.io/fpg84",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042193","R0042193.pdf","paywalled","nonrandomized_study","Valentin","2026","Real-World Weight Loss with GLP-1 Receptor Agonists versus SGLT2 Inhibitors in a Diverse US Cohort: An Active Comparator New-User Study",null,null,"10.17605/osf.io/xb8th","https://doi.org/10.17605/osf.io/xb8th",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042196","R0042196.pdf","paywalled","nonrandomized_study","Alexxai V. Kravitz","2026","Dopaminergic control of obesity in mice","California Digital Library",null,"10.48321/d174a1d243","https://doi.org/10.48321/d174a1d243",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042198","R0042198.pdf","paywalled","nonrandomized_study","Md. Shadin","2026","Glucagon-like Peptide-1 Receptor Agonists in Essential Tremor and Cerebellar Neurodegeneration: Mechanistic Rationale, Pharmacovigilance Paradox, and the Case for Targeted Investigation",null,null,"10.17605/osf.io/rscd2","https://doi.org/10.17605/osf.io/rscd2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042204","R0042204.pdf","paywalled","nonrandomized_study","Abdullah Bokhary","2026","Population-level oral health implications of GLP-1 receptor agonists: a scoping review of emerging evidence and public health preparedness",null,null,"10.17605/osf.io/93ehj","https://doi.org/10.17605/osf.io/93ehj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042214","R0042214.pdf","paywalled","nonrandomized_study","Fang Li","2026","GLP-1 Receptor Agonists and Risk of Substance Use Disorders Among Adults with Type 2 Diabetes: An Active Comparator New User Study in a Diverse US Population",null,null,"10.17605/osf.io/5r2sb","https://doi.org/10.17605/osf.io/5r2sb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042224","R0042224.pdf","paywalled","nonrandomized_study","Valentin","2026","Clinical Predictors of GLP-1 Receptor Agonist Weight Loss Response in Real-World Practice: An Exploratory Analysis from the All of Us Research Program",null,null,"10.17605/osf.io/um8jh","https://doi.org/10.17605/osf.io/um8jh",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042239","R0042239.pdf","paywalled","nonrandomized_study","Nicholas Stanley","2026","The Five-Gate Framework: A Two-Axis Evidence-Governance Instrument for Peptide Therapeutics in Pre-Consensus Use. Specification, Calibration on an Approved Anchor, and an Applied Monograph on BPC-157","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22260110","https://doi.org/10.5281/zenodo.22260110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042251","R0042251.pdf","paywalled","nonrandomized_study","Donna Maria Abboud","2026","Sal339 REDUCED RISK OF CLOSTRIDIOIDES DIFFICILE INFECTION WITH GLP-1 RECEPTOR AGONISTS COMPARED WITH DPP-4 INHIBITORS IN ADULTS WITH DIABETES: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)00825-5","https://doi.org/10.1016/s0016-5085(26)00825-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042259","R0042259.pdf","paywalled","nonrandomized_study","Shubham Sharma","2026","Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies","Open Science Framework",null,"10.17605/osf.io/ng7mu","https://doi.org/10.17605/osf.io/ng7mu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042394","R0042394.pdf","paywalled","nonrandomized_study","Barbara Alicja Rymanowska","2026","“Ozempic personality” — anxious patient or happier patient? A narrative review of GLP-1 receptor agonists and mood disorder","Forum Leczenia Otyłości","VM Media Group sp. z o.o","10.5603/flo.113152","https://doi.org/10.5603/flo.113152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042562","R0042562.pdf","paywalled","nonrandomized_study","Linda Van Le","2026","Comment on “GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases”","Obstetrical & Gynecological Survey","Ovid Technologies (Wolters Kluwer Health)","10.1097/ogx.0000000000001626","https://doi.org/10.1097/ogx.0000000000001626",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043070","R0043070.pdf","paywalled","nonrandomized_study","Ryan Lu","2026","Impact of Ozempic (Semaglutide) on Post-Cataract Surgery Complications in Diabetic Patients: A Retrospective Cohort Analysis",null,null,"10.13140/rg.2.2.14152.89600","https://doi.org/10.13140/rg.2.2.14152.89600",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043089","R0043089.pdf","paywalled","nonrandomized_study","H. Tezel-Yalcin","2026","P31-05 Safety Evaluation of GLP-1 Receptor Agonists in the Pediatric Population: A Multi-Method Disproportionality Analysis of Real-World Data from the FDA Adverse Event Monitoring System","Toxicology Letters","Elsevier BV","10.1016/j.toxlet.2026.112858","https://doi.org/10.1016/j.toxlet.2026.112858",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043090","R0043090.pdf","paywalled","nonrandomized_study","lingyan xu","2026","Temporary interruption and safe reinitiation of cardiometabolic medications during acute illness and peri-procedural fasting in adults: a scoping review of risk triggers, restart criteria, patient education and clinical responsibility","Open Science Framework",null,"10.17605/osf.io/u28qs","https://doi.org/10.17605/osf.io/u28qs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043927","R0043927.pdf","paywalled","nonrandomized_study","P.C. Liu","2026","P0976 GLP-1 receptor agonists and male genitourinary infections: A 3-year TriNetX comparative cohort study","European Urology","Elsevier BV","10.1016/s0302-2838(26)01827-0","https://doi.org/10.1016/s0302-2838(26)01827-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044149","R0044149.pdf","paywalled","nonrandomized_study","Ahmed Salem","2026","High-Risk Coronary Plaques and Cardiovascular Prevention: Insights from Coronary Computed Tomography Angiography and Real-World Data",null,"Swansea University","10.23889/suthesis.72008","https://doi.org/10.23889/suthesis.72008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044368","R0044368.pdf","paywalled","nonrandomized_study","P-H. Lee","2026","P0758 Comparative risk of nephrolithiasis in obesity pharmacotherapy: A real-world analysis of semaglutide, tirzepatide, and orlistat in type 2 diabetes","European Urology","Elsevier BV","10.1016/s0302-2838(26)01626-x","https://doi.org/10.1016/s0302-2838(26)01626-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044481","R0044481.pdf","paywalled","nonrandomized_study","abdullah talab","2026","Reporting of lithium toxicity with GLP-1 receptor agonists and tirzepatide in FAERS: how much of an apparent interaction signal is made of duplicated literature reports?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22704855","https://doi.org/10.5281/zenodo.22704855",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044529","R0044529.pdf","paywalled","nonrandomized_study","Bartosz Krawczyk-Demczuk","2026","Food noise in adults with obesity treated with GLP-1 receptor agonists: scoping review","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/cm8tr","https://doi.org/10.17605/osf.io/cm8tr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044558","R0044558.pdf","paywalled","nonrandomized_study","Fatima Arif","2026","Glp-1 Usage As Novel Treatment For Lower And Upper Extremity Lymphedema","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20086839","https://doi.org/10.5281/zenodo.20086839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044590","R0044590.pdf","paywalled","nonrandomized_study","Vanessa Bolchis","2026","Beyond Glycemic Control: Periodontal, Salivary, and Oral Mi-crobiome Effects of GLP 1 Receptor Agonists—A Scoping Re-view of Clinical and Preclinical Evidence","Open Science Framework",null,"10.17605/osf.io/mhk9u","https://doi.org/10.17605/osf.io/mhk9u",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044620","R0044620.pdf","paywalled","nonrandomized_study","Majd A. AbuAlrob","2026","GLP-1 Receptor Agonists and Neurological Outcomes in Multiple Sclerosis: A TriNetX Retrospective Cohort Study","Multiple Sclerosis and Related Disorders","Elsevier BV","10.1016/j.msard.2026.107630","https://doi.org/10.1016/j.msard.2026.107630",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044933","R0044933.pdf","paywalled","nonrandomized_study","NCMR Congress","2026","Abstract Book of 1st Neuro-Cell Molecular Research Congress-Oral Presentations","Neuro-Cell Molecular Research","Neuro-Cell Molecular Research","10.66588/ncmr.3.sp1.2","https://doi.org/10.66588/ncmr.3.sp1.2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044934","R0044934.pdf","paywalled","nonrandomized_study","Sulaiman Alahmad","2026","Clinical outcomes of overweight and obese patients in a lifestyle medicine clinic at PHCC, Riyadh, Saudi Arabia, December 2024: a retrospective observational study","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1754435066","https://doi.org/10.24911/ijmdc.51-1754435066",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044935","R0044935.pdf","paywalled","nonrandomized_study","Camilo Fernández Bravo","2026","NEW AUDIO INTERVIEW - Camilo Fernández Bravo, MD/PhD/FACC, Editor in Chief, on the Future of Clinical and Translational Cardiology","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22845623","https://doi.org/10.5281/zenodo.22845623",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044961","R0044961.pdf","paywalled","nonrandomized_study","Yazan Al Jabiri","2026","Sa2089 EFFECT OF STATIN USE ON THE CLINICAL EFFECTIVENESS OF SEMAGLUTIDE IN MASLD/MASH: A PROPENSITY SCORE-MATCHED ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03555-8","https://doi.org/10.1016/s0016-5107(26)03555-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044964","R0044964.pdf","paywalled","nonrandomized_study","Yussif Issaka","2026","594 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS SLEEVE GASTRECTOMY FOR MORBID OBESITY: A TARGET TRIAL EMULATION STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05966-4","https://doi.org/10.1016/s0016-5085(26)05966-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044967","R0044967.pdf","paywalled","nonrandomized_study","George Hatzis","2026","Abstract TH929: GLP-1 Receptor Agonist Medication Use Persistence in the All of Us Research Program","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th929","https://doi.org/10.1161/cir.153.suppl_1.th929",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044972","R0044972.pdf","paywalled","nonrandomized_study","Kai‐Cheng Chang","2026","P8 COMPARATIVE EFFECTIVENESS OF GLP-1RA AND SGLT2I IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A TARGET TRIAL EMULATION","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.023","https://doi.org/10.1016/j.jval.2026.03.023",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045005","R0045005.pdf","paywalled","nonrandomized_study","Rishi Chowdhary","2026","Su1129 ASSOCIATION OF GLP-1 RECEPTOR AGONISTS WITH ACCELERATED PROGRESSION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS: A POPULATION-LEVEL RETROSPECTIVE MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)02014-7","https://doi.org/10.1016/s0016-5085(26)02014-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045042","R0045042.pdf","paywalled","nonrandomized_study","Ying Liu","2026","44-PUB: Evaluation and Care of Double Diabetes in Asian American Patients","Diabetes","American Diabetes Association","10.2337/db26-44-pub","https://doi.org/10.2337/db26-44-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045047","R0045047.pdf","paywalled","nonrandomized_study","Diane Saab","2026","Surgical Outcomes Of Patients Receiving GLP-1 Receptor Agonists Undergoing Breast Reduction Surgery: A Propensity Score-matching Analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20087075","https://doi.org/10.5281/zenodo.20087075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045078","R0045078.pdf","paywalled","nonrandomized_study","Igor Eduardo","2026","GLP-1 FAERS Pharmacovigilance Pre-registration 2024","Open Science Framework",null,"10.17605/osf.io/hrcn6","https://doi.org/10.17605/osf.io/hrcn6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045113","R0045113.pdf","paywalled","nonrandomized_study","K. Shoba and B. C. Surekha Merwin Paul. R","2026","A Convolutional Neural Network (CNN) Analysis of Liver Histology Images to Predict Response to GLP-1 Agonists in NASH",null,"IEEE","10.1109/icmsci67830.2026.11469554","https://doi.org/10.1109/icmsci67830.2026.11469554",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045122","R0045122.pdf","paywalled","nonrandomized_study","Eric Wu","2026","Abstract TH854: Digital Twins Powered by Generative Artificial Intelligence Support Long-Term Evaluation of Obesity and Cardiometabolic Outcomes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th854","https://doi.org/10.1161/cir.153.suppl_1.th854",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045123","R0045123.pdf","paywalled","nonrandomized_study","Budoor Alqinai","2026","Tu1478 IMPACT OF GLP-1 RECEPTOR AGONISTS ON SYMPTOMATIC REMISSION IN ULCERATIVE COLITIS: A RETROSPECTIVE COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03166-5","https://doi.org/10.1016/s0016-5085(26)03166-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045125","R0045125.pdf","paywalled","nonrandomized_study","Asifa Manzoor","2026","185 LONG TERM OUTCOMES OF GLP1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS IN PATIENTS WITH MASLD: A REAL WORLD MULTINATIONAL COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03381-0","https://doi.org/10.1016/s0016-5085(26)03381-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045128","R0045128.pdf","paywalled","nonrandomized_study","Yong Eun","2026","Semaglutide Reduces the Risk of Adult-onset Epilepsy in Type 2 Diabetes: A Target Trial Emulation and Mediation Analysis (S5.004)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000216020","https://doi.org/10.1212/wnl.0000000000216020",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045145","R0045145.pdf","paywalled","nonrandomized_study","SURVEEN SINGH","2026","The Double-Edged Sword: Bidirectional Oral Health Implications of GLP-1 Receptor Agonists and the Unpreparedness of Modern Dental Practice",null,null,"10.17605/osf.io/56bj3","https://doi.org/10.17605/osf.io/56bj3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045154","R0045154.pdf","paywalled","nonrandomized_study","MAGDALENA SEVILLA-GONZALEZ","2026","1261-OR: Molecular Risk Scores Enhance Type 2 Diabetes (T2D) Prediction beyond Hemoglobin A1c (HbA1c) and Body Mass Index (BMI) across Diverse Clinical Contexts","Diabetes","American Diabetes Association","10.2337/db26-1261-or","https://doi.org/10.2337/db26-1261-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045211","R0045211.pdf","paywalled","nonrandomized_study","Eshan Nanda","2026","Tu1594 GLP-1 RECEPTOR AGONISTS DO NOT INCREASE IBD FLARES OR HOSPITAL UTILIZATION IN OBESE PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03281-6","https://doi.org/10.1016/s0016-5085(26)03281-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045212","R0045212.pdf","paywalled","nonrandomized_study","Guy Nguefang","2026","1082 IMPACT OF GLP-1 RECEPTOR AGONIST USE IN ADULTS WITH SICKLE CELL DISEASE AND TYPE 2 DIABETES: A REAL-WORLD COHORT ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04748-6","https://doi.org/10.1016/s0016-5107(26)04748-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045248","R0045248.pdf","paywalled","nonrandomized_study","Afnan Chaudhry","2026","400.05 Long-term Survival Benefit of GLP-1 Agonists In Heart-Transplant Recipients: A Propensity-matched Real-World Analysis","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2026.01.142","https://doi.org/10.1016/j.jcin.2026.01.142",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045254","R0045254.pdf","paywalled","nonrandomized_study","Melina I. Manolas","2026","1427-P: Fibrosis-4 Index Is Associated with ASCVD Burden, MACE, and Mortality in Real-World Type 2 Diabetes Cohort","Diabetes","American Diabetes Association","10.2337/db26-1427-p","https://doi.org/10.2337/db26-1427-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045261","R0045261.pdf","paywalled","nonrandomized_study","Mohammad Alnuman","2026","2603-P: Body Mass Index and Blood Pressure Changes During and After Antiobesity Medication Use","Diabetes","American Diabetes Association","10.2337/db26-2603-p","https://doi.org/10.2337/db26-2603-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045262","R0045262.pdf","paywalled","nonrandomized_study","Yumeng Wang","2026","EPH123 PREOPERATIVE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS)AND SHORT-TERM POSTOPERATIVE OUTCOMES AFTER BARIATRIC SURGERY: A RETROSPECTIVE COHORT STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.955","https://doi.org/10.1016/j.jval.2026.03.955",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045266","R0045266.pdf","paywalled","nonrandomized_study","Zachary Smith","2026","GLP1-PANC: Risk of Acute Pancreatitis Among Patients With Obesity Treated With GLP-1 Receptor Agonists: A Target Trial Emulation Using National EHR-Claims Data","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/4mkqz","https://doi.org/10.17605/osf.io/4mkqz",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045271","R0045271.pdf","paywalled","nonrandomized_study","Gang Fang","2026","2834-LB: Cardiometabolic Outcomes in Adults with T2D Treated with 1 mg Semaglutide Who Titrate to 2 mg Semaglutide vs. Switch to Tirzepatide","Diabetes","American Diabetes Association","10.2337/db26-2834-lb","https://doi.org/10.2337/db26-2834-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045275","R0045275.pdf","paywalled","nonrandomized_study","Pooja Khatiwala","2026","Sa2092 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE HEPATIC AND METABOLIC OUTCOMES IN PATIENTS WITH MASLD: A RETROSPECTIVE STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03558-3","https://doi.org/10.1016/s0016-5107(26)03558-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045276","R0045276.pdf","paywalled","nonrandomized_study","Alina McCue","2026","Prescribing Patterns for Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Chronic Kidney Disease: Retrospective Analysis at an Academic Family Medicine Center","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/4c3a-z128","https://doi.org/10.17615/4c3a-z128",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045277","R0045277.pdf","paywalled","nonrandomized_study","Muhammad Ali Ibrahim Kazi","2026","Sa1274 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN ADULTS WITH CELIAC DISEASE: A MULTI-INSTITUTIONAL COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05774-4","https://doi.org/10.1016/s0016-5085(26)05774-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045318","R0045318.pdf","paywalled","nonrandomized_study","Mariam Chalhoub","2026","513 RISK OF POST-ERCP PANCREATITIS IN GLP-1 RECEPTOR AGONIST USERS: A REAL-WORLD PROPENSITY-MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05043-2","https://doi.org/10.1016/s0016-5085(26)05043-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045339","R0045339.pdf","paywalled","nonrandomized_study","Eleonora Castellana","2026","5PSQ-043 Rare adverse event monitoring: nonarteritic anterior ischaemic optic neuropathy associated with tirzepatide – a pharmacovigilance disproportionality study","Section 5: Patient safety and quality assurance","British Medical Journal Publishing Group","10.1136/ejhpharm-2026-eahp.470","https://doi.org/10.1136/ejhpharm-2026-eahp.470",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045381","R0045381.pdf","paywalled","nonrandomized_study","ELAMIN ABDELGADIR","2026","2817-LB: Semaglutide in Kidney Transplant Recipients: Real-World Evidence on Safety and Efficacy","Diabetes","American Diabetes Association","10.2337/db26-2817-lb","https://doi.org/10.2337/db26-2817-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045389","R0045389.pdf","paywalled","nonrandomized_study","Kevin Nguyen","2026","Mo1738 COMPARATIVE RISK OF ESOPHAGEAL DYSFUNCTION AMONG GLP-1 RECEPTOR AGONIST USERS VERSUS NON–GLP-1 USERS IN A LARGE MULTICENTER PROPENSITY-MATCHED COHORT","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04616-0","https://doi.org/10.1016/s0016-5085(26)04616-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045398","R0045398.pdf","paywalled","nonrandomized_study","Vitória Acar","2026","GLP-1 Receptor Agonists and Chronic Migraine: A Real-world Cohort Study of Healthcare Utilization and Preventive Escalation (P10-15.017)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000215109","https://doi.org/10.1212/wnl.0000000000215109",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045451","R0045451.pdf","paywalled","nonrandomized_study","Gagandeep Sukhija","2026","P073 GLP-1 agonists, weight-loss and systemic autoimmune rheumatic diseases: functional outcomes and real-world safety experience","Lara D. Veeken","Oxford University Press (OUP)","10.1093/rheumatology/keag121.109","https://doi.org/10.1093/rheumatology/keag121.109",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045475","R0045475.pdf","paywalled","nonrandomized_study","Youxin Tan","2026","Clonal hematopoiesis of indeterminate potential (CHIP) as a pre-specified effect modifier of GLP-1 receptor agonist cardiovascular benefit in type 2 diabetes: a target trial emulation",null,null,"10.17605/osf.io/tnq8x","https://doi.org/10.17605/osf.io/tnq8x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045484","R0045484.pdf","paywalled","nonrandomized_study","Rama Nanah","2026","Tu1779 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) USE IS ASSOCIATED WITH LOWER RATES OF GASTROINTESTINAL MALIGNANCIES IN OBESE PATIENTS. NATIONWIDE DATA ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04975-9","https://doi.org/10.1016/s0016-5085(26)04975-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045488","R0045488.pdf","paywalled","nonrandomized_study","Mustafa Naveed","2026","Su1689 GASTROINTESTINAL EVENTS ASSOCIATED WITH CONCURRENT PPI AND GLP-1 RECEPTOR AGONIST THERAPY: A NATIONAL RETROSPECTIVE MULTICENTER COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04394-4","https://doi.org/10.1016/s0016-5107(26)04394-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045498","R0045498.pdf","paywalled","nonrandomized_study","Hira Khan","2026","Su1985 GLP-1 RECEPTOR AGONIST USE AND MAJOR FRACTURE RISK IN METABOLIC DYSFUNCTION-ASSOCIATED: A PROPENSITY-MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03683-8","https://doi.org/10.1016/s0016-5085(26)03683-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045514","R0045514.pdf","paywalled","nonrandomized_study","Samantha N. Hart","2026","BARIATRIC SURGERY IMPACTS IMMUNE CELL METABOLISM AND FUNCTION DEPENDENT ON METABOLIC STATUS","UKnowledge (University of Kentucky)",null,"10.13023/etd.2025.574","https://doi.org/10.13023/etd.2025.574",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045529","R0045529.pdf","paywalled","nonrandomized_study","Charles L. Nelson","2026","IMPACT OF GLP-1 AGONISTS AND SOCIAL DETERMINANTS OF HEALTH ON OUTCOMES FOLLOWING TOTAL KNEE ARTHROPLASTY","Orthopaedic Proceedings","British Editorial Society of Bone & Joint Surgery","10.1302/1358-992x.2026.6.018","https://doi.org/10.1302/1358-992x.2026.6.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045536","R0045536.pdf","paywalled","nonrandomized_study","ABSALON D. GUTIERREZ","2026","3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis","Diabetes","American Diabetes Association","10.2337/db26-3058-lb","https://doi.org/10.2337/db26-3058-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045545","R0045545.pdf","paywalled","nonrandomized_study","Abdullah Sohail","2026","WED-512-YI Safety and outcomes of glp-1 receptor agonists in patients with cirrhosis: a meld-matched real-world cohort study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00780-4","https://doi.org/10.1016/s0168-8278(26)00780-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045549","R0045549.pdf","paywalled","nonrandomized_study","Amandeep Kaur","2026","Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists","Glucolipid metabolic disorders","Bentham Science Publishers Ltd.","10.2174/0129499011491956260906185203","https://doi.org/10.2174/0129499011491956260906185203",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045575","R0045575.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2026","MPN-1634: Targeting Metabolic-Inflammatory Signaling in Chronic Myelomonocytic Leukemia: Association of GLP-1 Receptor Agonist Therapy With Improved Real-World Outcomes","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02429-8","https://doi.org/10.1016/s2152-2650(26)02429-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045577","R0045577.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2026","POSTER: MPN-1634: Targeting Metabolic-Inflammatory Signaling in Chronic Myelomonocytic Leukemia: Association of GLP-1 Receptor Agonist Therapy With Improved Real-World Outcomes","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01000-1","https://doi.org/10.1016/s2152-2650(26)01000-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045580","R0045580.pdf","paywalled","nonrandomized_study","Guy Nguefang","2026","Sa1973 OUTCOMES OF GLP-1 RECEPTOR AGONIST THERAPY AFTER LIVER TRANSPLANTATION IN PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03508-0","https://doi.org/10.1016/s0016-5085(26)03508-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045587","R0045587.pdf","paywalled","nonrandomized_study","Charbel Nakhoul","2026","26-A-14698-ACC GLP-1 RECEPTOR AGONISTS AND CLINICAL OUTCOMES IN HEART FAILURE PATIENTS: A REAL-WORLD MATCHED COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1902","https://doi.org/10.1016/j.jacc.2026.02.1902",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045603","R0045603.pdf","paywalled","nonrandomized_study","YUNWEN XU","2026","1222-OR: Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study","Diabetes","American Diabetes Association","10.2337/db26-1222-or","https://doi.org/10.2337/db26-1222-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045605","R0045605.pdf","paywalled","nonrandomized_study","Jason N. Chen","2026","Additional file 2 of Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease","Figshare",null,"10.6084/m9.figshare.31911393","https://doi.org/10.6084/m9.figshare.31911393",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045626","R0045626.pdf","paywalled","nonrandomized_study","Yongtai Cho","2026","2154-P: Second-Line Antidiabetic Exposure in Early Pregnancy and Risk of Spontaneous Abortion: A Nationwide Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-2154-p","https://doi.org/10.2337/db26-2154-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045629","R0045629.pdf","paywalled","nonrandomized_study","Colton Jones","2026","Glucagon-like peptide-1 receptor agonist for primary prevention of hepatocellular carcinoma in high-risk patients: A real-world analysis across metabolic, viral, alcoholic, and hereditary liver disease.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10522","https://doi.org/10.1200/jco.2026.44.16_suppl.10522",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045632","R0045632.pdf","paywalled","nonrandomized_study","Gautam Maddineni","2026","Su1732 COMPARATIVE RISK OF ASPIRATION PNEUMONITIS ACROSS GLP-1 RECEPTOR AGONISTS AND TIRZEPATIDE: A LARGE REAL-WORLD TRINETX ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04506-3","https://doi.org/10.1016/s0016-5085(26)04506-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045633","R0045633.pdf","paywalled","nonrandomized_study","Michael K. Wang","2026","IP59-23 INFLUENCE OF GLP1 RECEPTOR AGONIST ON RENAL CELL CARCINOMA INCIDENCE AND OVERALL SURVIVAL, A PROPENSITY SCORE MATCHED ANALYSIS USING THE OPTUMLABS DATA WAREHOUSE","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191632.79764.15.23","https://doi.org/10.1097/01.ju.0001191632.79764.15.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045649","R0045649.pdf","paywalled","nonrandomized_study","Rohit Goyal","2026","1113 EXPOSURE TO GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH SIGNIFICANT REDUCTION IN BLEEDING EVENTS, TRANSFUSIONS, AND ENDOSCOPIC UTILIZATION IN PATIENTS WITH GASTROINTESTINAL ARTERIOVENOUS MALFORMATIONS: A REAL-WORLD PROPENSITY-SCORE MATCHED ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05736-7","https://doi.org/10.1016/s0016-5085(26)05736-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045668","R0045668.pdf","paywalled","nonrandomized_study","Nakul Ganju","2026","Mo1572 GLP-1 RECEPTOR AGONIST THERAPY IS ASSOCIATED WITH REDUCED CORTICOSTEROID DEPENDENCE AND IMPROVED LONG-TERM OUTCOMES IN ADULTS WITH CROHN’S DISEASE: A MULTICENTER REAL-WORLD COHORT STUDY.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03011-8","https://doi.org/10.1016/s0016-5085(26)03011-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045685","R0045685.pdf","paywalled","nonrandomized_study","Antonia Karina Silva Azevedo","2026","MANIFESTATION OF GLP-1 RECEPTOR AGONISTS IN THE ORAL AND MAXILLOFACIAL REGION: A SCOPING REVIEW","Open Science Framework",null,"10.17605/osf.io/7fs5t","https://doi.org/10.17605/osf.io/7fs5t",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045722","R0045722.pdf","paywalled","nonrandomized_study","Muhammad Hanif","2026","26-A-13149-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN THE PREVENTION OF LUPUS NEPHRITIS AMONG PATIENTS WITH TYPE 2 DIABETES AND SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM REAL WORLD GLOBAL DATA","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.478","https://doi.org/10.1016/j.jacc.2026.02.478",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045725","R0045725.pdf","paywalled","nonrandomized_study","Islam Rajab","2026","Sa2110 NOVEL REAL-WORLD HEAD-TO-HEAD COMPARISON OF SEMAGLUTIDE VS RESMETIROM IN MASLD: A PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03576-5","https://doi.org/10.1016/s0016-5107(26)03576-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045817","R0045817.pdf","paywalled","nonrandomized_study","LIN XIE","2026","1708-P: Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)","Diabetes","American Diabetes Association","10.2337/db26-1708-p","https://doi.org/10.2337/db26-1708-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045845","R0045845.pdf","paywalled","nonrandomized_study","Adam Cardenas","2026","74974 Evaluating GLP-1 agonist dialogue within the field of dermatology across conditions, attitudes, regions, and time: a retrospective review","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.833","https://doi.org/10.1016/j.jaad.2026.04.833",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045857","R0045857.pdf","paywalled","nonrandomized_study","Kevin Nguyen","2026","Sa1850 GLP-1 RECEPTOR AGONIST EXPOSURE AND ACUTE PANCREATITIS OUTCOMES: A PROPENSITY-MATCHED MULTICENTER COHORT ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05077-7","https://doi.org/10.1016/s0016-5107(26)05077-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045866","R0045866.pdf","paywalled","nonrandomized_study","Jonathan Ghobrial","2026","Mo1807 COMPARATIVE RISK OF ATRIAL FIBRILLATION AMONG PATIENTS WITH OBESITY TREATED WITH GLP-1 RECEPTOR AGONISTS: A RETROSPECTIVE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04871-6","https://doi.org/10.1016/s0016-5107(26)04871-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045896","R0045896.pdf","paywalled","nonrandomized_study","Brooks Han","2026","Renegade AI: The Catalyst for the Evolution of Human Cognition","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21887749","https://doi.org/10.5281/zenodo.21887749",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045956","R0045956.pdf","paywalled","nonrandomized_study","Arkadeep Dhali","2026","Su1831 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND PANCREATIC OUTCOMES IN CHRONIC PANCREATITIS: A REAL-WORLD COHORT STUDY USING THE TRINETX RESEARCH NETWORK","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05198-x","https://doi.org/10.1016/s0016-5085(26)05198-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045959","R0045959.pdf","paywalled","nonrandomized_study","Zixuan He","2026","Abstract TH930: Potential overtreatment of older adults with diabetes and dementia: a real-world study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th930","https://doi.org/10.1161/cir.153.suppl_1.th930",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045980","R0045980.pdf","paywalled","nonrandomized_study","Lauren Broffman","2026","2605-P: Comparing Adverse Event Rates among GLP-1/GIP Therapy Switchers vs. Continuous Use Groups in a Real-World Telehealth Cohort","Diabetes","American Diabetes Association","10.2337/db26-2605-p","https://doi.org/10.2337/db26-2605-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046005","R0046005.pdf","paywalled","nonrandomized_study","Hasan Kamal","2026","637: PULMONARY OUTCOMES IN DIABETIC GASTROPARESIS: A PROPENSITY-MATCHED STUDY OF GLP-1 AGONIST USE","Critical Care Medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ccm.0001184544.61601.14","https://doi.org/10.1097/01.ccm.0001184544.61601.14",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046013","R0046013.pdf","paywalled","nonrandomized_study","Dylan Wambold","2026","76672 Impact of GLP-1 and Dual GLP-1/GIP Receptor Agonists on Inflammatory Outcomes in Atopic Dermatitis: A Real-World Cohort Study","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.1033","https://doi.org/10.1016/j.jaad.2026.04.1033",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046015","R0046015.pdf","paywalled","nonrandomized_study","Yuqing Fan","2026","CO170 COMPARATIVE CARDIOVASCULAR AND KIDNEY EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD STUDY IN CHINA","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.265","https://doi.org/10.1016/j.jval.2026.03.265",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046056","R0046056.pdf","paywalled","nonrandomized_study","Kibum Kim","2026","2007-P: Obesity Prevalence in the Patient Neighborhood and Outcomes of Antiobesity Medication Mediated by Treatment Continuation: Structured Equation Modeling Approach","Diabetes","American Diabetes Association","10.2337/db26-2007-p","https://doi.org/10.2337/db26-2007-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046060","R0046060.pdf","paywalled","nonrandomized_study","Lijuan Zeng","2026","Abstract TH826: Impact of Glucagon-Like Peptide-1 Receptor Agonists on Asthma Exacerbations Among Individuals with Type 2 Diabetes and Asthma: A Target Trial Emulation Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th826","https://doi.org/10.1161/cir.153.suppl_1.th826",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046112","R0046112.pdf","paywalled","nonrandomized_study","Madeleine Chang","2026","Mo1821 RISK OF NEW-ONSET CONSTIPATION ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1) USE: RESULTS FROM A NATIONWIDE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04885-6","https://doi.org/10.1016/s0016-5107(26)04885-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046124","R0046124.pdf","paywalled","nonrandomized_study","Gerardo Uriel Viquez Burboa","2026","GLP-1 Receptor Agonists in People Living with HIV and Overweight or Obesity Associated with Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide: A JBI Scoping Review",null,null,"10.17605/osf.io/nqhwe","https://doi.org/10.17605/osf.io/nqhwe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046126","R0046126.pdf","paywalled","nonrandomized_study","Prerna Ashok Kherajani","2026","GLP-1 receptor agonist therapy and risk of small intestinal neoplasms: Real-world evidence from a global network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e16499","https://doi.org/10.1200/jco.2026.44.16_suppl.e16499",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046128","R0046128.pdf","paywalled","nonrandomized_study","Catherine Shen","2026","73447 Risk of Bullous Pemphigoid in Patients Treated With GLP-1 Receptor Agonists and Other Diabetes Medications: A Retrospective Cohort Study","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.1549","https://doi.org/10.1016/j.jaad.2026.04.1549",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046150","R0046150.pdf","paywalled","nonrandomized_study","Lilah Khoja","2026","2602-P: Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use","Diabetes","American Diabetes Association","10.2337/db26-2602-p","https://doi.org/10.2337/db26-2602-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046151","R0046151.pdf","paywalled","nonrandomized_study","Johannes Thrul","2026","Glucagon-Like Peptide-1 and Glucagon-Like Peptide-2 Receptor Agonists and Their Association With Cannabis: A Scoping Review",null,null,"10.17605/osf.io/evxfy","https://doi.org/10.17605/osf.io/evxfy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046156","R0046156.pdf","paywalled","nonrandomized_study","Sai Sushrutha Mudupula Vemula","2026","Association of GLP-1 receptor agonist exposure with mortality, infectious, and hematologic outcomes in chronic lymphocytic leukemia: A real-world retrospective TriNetX study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e18591","https://doi.org/10.1200/jco.2026.44.16_suppl.e18591",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046199","R0046199.pdf","paywalled","nonrandomized_study","Sumi Akter","2026","GLP-1 Receptor Agonists versus Metformin and Incident Dementia After Delirium in Adults ≥ 65 years With Type 2 Diabetes Mellitus: A Real-World Retrospective Cohort Study",null,null,"10.13140/rg.2.2.30038.61762","https://doi.org/10.13140/rg.2.2.30038.61762",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046203","R0046203.pdf","paywalled","nonrandomized_study","Kriti Soni","2026","26-A-18326-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN TRANSTHYRETINAMYLOID CARDIOMYOPATHY WITH DIABETES MELLITUS: A PROPENSITY-SCORE MATCHEDANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1654","https://doi.org/10.1016/j.jacc.2026.02.1654",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046204","R0046204.pdf","paywalled","nonrandomized_study","Manthan Suthar","2026","From Insulin Resistance to Neurodegeneration: Exploring the Link Between Type 2 Diabetes and Alzheimer’s Disease as Type 3 Diabetes","Current Signal Transduction Therapy","Bentham Science Publishers Ltd.","10.2174/0115743624420375251212124953","https://doi.org/10.2174/0115743624420375251212124953",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046213","R0046213.pdf","paywalled","nonrandomized_study","Zachary Flamholz","2026","Patient foundation model for risk stratification in low-risk overweight patients","arXiv (Cornell University)",null,"10.48550/arxiv.2602.09079","https://doi.org/10.48550/arxiv.2602.09079",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046219","R0046219.pdf","paywalled","nonrandomized_study","S E Niedermeyer","2026","A65-06 Glucagon-Like Peptide-1 Receptor Agonist Use in Patients With Pulmonary Arterial Hypertension","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.5568","https://doi.org/10.1093/ajrccm/aamag162.5568",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046242","R0046242.pdf","paywalled","nonrandomized_study","Ekow Pinkrah","2026","POSTER: MM-837: GLP-1 Receptor Agonists Are Associated With Significantly Reduced All-Cause Mortality, Hospitalization, and Sepsis in Patients With Multiple Myeloma and Type 2 Diabetes: A Propensity Score–Matched Analysis of the TriNetX Global Collaborative Network","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01370-4","https://doi.org/10.1016/s2152-2650(26)01370-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046260","R0046260.pdf","paywalled","nonrandomized_study","Fnu Alvina","2026","Sa2105 BILIARY SAFETY SIGNALS WITH RESMETIROM IN MASH: REAL-WORLD COMPARISON AGAINST GLP-1 RECEPTOR AGONISTS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03571-6","https://doi.org/10.1016/s0016-5107(26)03571-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046285","R0046285.pdf","paywalled","nonrandomized_study","Yassine Kilani","2026","Mo2040 COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS NALTREXONE IN THE TREATMENT OF ALCOHOL USE DISORDER: A REAL-WORLD ANALYSIS OF 9,360 PATIENTS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03859-9","https://doi.org/10.1016/s0016-5107(26)03859-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046331","R0046331.pdf","paywalled","nonrandomized_study","Rob Walker","2026","Abstract TH822: Characteristics of Glucagon-like Peptide-1 Receptor Agonist Initiators and Temporal Trends in Prescriptions by Diabetes Status; MarketScan 2016-2023","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th822","https://doi.org/10.1161/cir.153.suppl_1.th822",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046381","R0046381.pdf","paywalled","nonrandomized_study","Jason N. Chen","2026","Additional file 1 of Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease","Figshare",null,"10.6084/m9.figshare.31911390","https://doi.org/10.6084/m9.figshare.31911390",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046383","R0046383.pdf","paywalled","nonrandomized_study","Silvia Fisch","2026","2824-LB: Indication-Specific Adverse Event Profiles of Semaglutide and Liraglutide: A FAERS Disproportionality Analysis","Diabetes","American Diabetes Association","10.2337/db26-2824-lb","https://doi.org/10.2337/db26-2824-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046417","R0046417.pdf","paywalled","nonrandomized_study","Ayesha Malik","2026","A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000004250","https://doi.org/10.1097/hjh.0000000000004250","41744241","https://pubmed.ncbi.nlm.nih.gov/41744241/",null,null],["4","R0046429","R0046429.pdf","paywalled","nonrandomized_study","Kevin Eid","2026","Sa2095 REAL-WORLD LIVER-RELATED OUTCOMES AFTER INITIATION OF RESMETIROM VS GLP-1 RECEPTOR AGONISTS IN MASH: A PROPENSITY SCORE-MATCHED COHORT ANALYSIS HIGHLIGHTING THE IMPACT OF FIBROSIS CODING.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03630-9","https://doi.org/10.1016/s0016-5085(26)03630-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046435","R0046435.pdf","paywalled","nonrandomized_study","J Glowala","2026","C75-11 Evaluation of Diaphragmatic Weakness - Lessons From a Dedicated Clinic at a Tertiary Care Center","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.5337","https://doi.org/10.1093/ajrccm/aamag162.5337",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046436","R0046436.pdf","paywalled","nonrandomized_study","Gwen Aubrac","2026","Abstract 06: Comparative Effectiveness of Semaglutide and Tirzepatide on Cardiovascular Outcomes among Patients with Obesity and Established Cardiovascular Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.06","https://doi.org/10.1161/cir.153.suppl_1.06",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046438","R0046438.pdf","paywalled","nonrandomized_study","Claire Hines","2026","75730 Evaluating GLP-1 Agonists and Weight Loss in Hidradenitis Suppurativa: A Retrospective Analysis and Patient Survey","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.834","https://doi.org/10.1016/j.jaad.2026.04.834",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046439","R0046439.pdf","paywalled","nonrandomized_study","Ferdous Ara Joty","2026","Glycemic Control and Dosage Form Preference Following the Transition from Weekly-once Injectable to Daily Oral Semaglutide in Type 2 Diabetes Mellitus","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21864297","https://doi.org/10.5281/zenodo.21864297",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046448","R0046448.pdf","paywalled","nonrandomized_study","Christina S. Han","2026","Comment on: “Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation”","Obstetrical & Gynecological Survey","Ovid Technologies (Wolters Kluwer Health)","10.1097/ogx.0000000000001543","https://doi.org/10.1097/ogx.0000000000001543",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046451","R0046451.pdf","paywalled","nonrandomized_study","SALMA ELNOUR","2026","2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease","Diabetes","American Diabetes Association","10.2337/db26-2818-lb","https://doi.org/10.2337/db26-2818-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046458","R0046458.pdf","paywalled","nonrandomized_study","Priyanka Boettger","2026","Beyond weight loss in hypertrophic cardiomyopathy: metabolic therapy and the evolving treatment paradigm","European Heart Journal - Quality of Care and Clinical Outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcag064","https://doi.org/10.1093/ehjqcco/qcag064","42017238","https://pubmed.ncbi.nlm.nih.gov/42017238/",null,null],["4","R0046459","R0046459.pdf","paywalled","nonrandomized_study","Johnny Bou Saba","2026","PO-03-087 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) THERAPY ON RECURRENCE OF TACHYARRHYTHMIAS IN DIABETIC PATIENTS: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.826","https://doi.org/10.1016/j.hrthm.2026.03.826",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046471","R0046471.pdf","paywalled","nonrandomized_study","Arunkumar Krishnan","2026","TOP-162 Glucagon-like peptide-1 receptor agonists and long-term liver outcomes in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a large real-world analysis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01884-2","https://doi.org/10.1016/s0168-8278(26)01884-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046482","R0046482.pdf","paywalled","nonrandomized_study","Julio Zúñiga Cisneros","2026","Mol808 GASTROINTESTINAL ADVERSE EFFECTS AND MOTILITY ALTERATIONS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS: ANALYSIS FROM LARGE TERTIARY CARE COHORT.","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04872-8","https://doi.org/10.1016/s0016-5107(26)04872-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046483","R0046483.pdf","paywalled","nonrandomized_study","Luis Antonio Diaz","2026","Alcohol use dominates determining liver-related events in steatotic liver disease: Rethinking the role of metabolic dysfunction","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001687","https://doi.org/10.1097/hep.0000000000001687","41563877","https://pubmed.ncbi.nlm.nih.gov/41563877/",null,null],["4","R0046494","R0046494.pdf","paywalled","nonrandomized_study","Akter Sraboni","2026","Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review","Journal of Biochemistry Pharmacology and Public Health","KMF Publishers","10.64907/xkmf.v4.i1.jbpph.1","https://doi.org/10.64907/xkmf.v4.i1.jbpph.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046499","R0046499.pdf","paywalled","nonrandomized_study","Sarit Polsky","2026","1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year","Diabetes","American Diabetes Association","10.2337/db26-1293-or","https://doi.org/10.2337/db26-1293-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046507","R0046507.pdf","paywalled","nonrandomized_study","Yassine Kilani","2026","Tu1773 TIRZEPATIDE AND SEMAGLUTIDE AND CANCER RISK: A PROPENSITY SCORE-MATCHED ANALYSIS OF 92,284 PATIENTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04969-3","https://doi.org/10.1016/s0016-5085(26)04969-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046517","R0046517.pdf","paywalled","nonrandomized_study","Demir C. Uslu","2026","RWD133 GLP-1 RECEPTOR AGONIST-ASSOCIATED THROMBOCYTOPENIA: A NOVEL/EXTENSIVE PHARMACOVIGILANCE EVALUATION FROM SOUTHERN NETWORK ON ADVERSE REACTIONS (SONAR-AI)","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2121","https://doi.org/10.1016/j.jval.2026.03.2121",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046536","R0046536.pdf","paywalled","nonrandomized_study","OZI IYALOMHE","2026","2065-P: Trends in Metabolic Medication Use among Youth Receiving Antipsychotics, 2016–2024","Diabetes","American Diabetes Association","10.2337/db26-2065-p","https://doi.org/10.2337/db26-2065-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046543","R0046543.pdf","paywalled","nonrandomized_study","Yasaman Navari","2026","26-A-18263-ACC CARDIOVASCULAR OUTCOMES IN ATRIAL FIBRILLATION PATIENTS ON SEMIGLUTIDE VS LIRAGLUTIDE: A PROPENSITY-MATCHED GLOBAL COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.191","https://doi.org/10.1016/j.jacc.2026.02.191",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046561","R0046561.pdf","paywalled","nonrandomized_study","Kory Mack","2026","0653 Integration of GLP-1 Receptor Agonists into Treatment Protocols for Obstructive Sleep Apnea","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0652","https://doi.org/10.1093/sleep/zsag091.0652",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046586","R0046586.pdf","paywalled","nonrandomized_study","Michael K. Wang","2026","IP35-11 INFLUENCE OF GLP1 RECEPTOR AGONIST ON BLADDER CANCER INCIDENCE AND OVERALL SURVIVAL, A PROPENSITY SCORE MATCHED ANALYSIS USING THE OPTUMLABS DATA WAREHOUSE","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191484.59024.a0.11","https://doi.org/10.1097/01.ju.0001191484.59024.a0.11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046609","R0046609.pdf","paywalled","nonrandomized_study","Raslina Shrestha","2026","2281-P: Metformin and GLP-1RA Use in Adults with Hidradenitis Suppurativa: A Population-Based Study","Diabetes","American Diabetes Association","10.2337/db26-2281-p","https://doi.org/10.2337/db26-2281-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046619","R0046619.pdf","paywalled","nonrandomized_study","Jungae Lee","2026","Abstract TU207: Independent and Joint Association of GLP-1 Therapy and Physical Activity with Weight Loss: Real-World Evidence from All of Us","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.tu207","https://doi.org/10.1161/cir.153.suppl_1.tu207",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046640","R0046640.pdf","paywalled","nonrandomized_study","Furkan Bahar","2026","Liraglutide may be associated with increased skin cancer risk: A propensity score-matched analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e21504","https://doi.org/10.1200/jco.2026.44.16_suppl.e21504",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046699","R0046699.pdf","paywalled","nonrandomized_study","Ameera Syed","2026","Glucagon-like peptide 1 receptor agonists and the risk of developing malignancies of the liver.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.525","https://doi.org/10.1200/jco.2026.44.2_suppl.525",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046706","R0046706.pdf","paywalled","nonrandomized_study","Arunkumar Krishnan","2026","Impact of concomitant GLP-1 receptor agonist use on overall survival and chemotherapy-related adverse events in colorectal cancer: A real-world pharmacoepidemiologic cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.3661","https://doi.org/10.1200/jco.2026.44.16_suppl.3661",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046713","R0046713.pdf","paywalled","nonrandomized_study","Oleksandr Shumeiko","2026","Mo1262 ENDOSCOPIC FINDINGS IN PATIENTS ON GLP-1 RECEPTOR AGONISTS PRESENTING WITH DYSPEPSIA: A PROPENSITY-MATCHED COHORT ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)06240-2","https://doi.org/10.1016/s0016-5085(26)06240-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046727","R0046727.pdf","paywalled","nonrandomized_study","Vrushabh P. Ladage","2026","HSD80 GLP-1 THERAPY IMPROVES GLYCEMIC CONTROL WITH NO DIFFERENCE IN MEDICAL SPENDING: A REAL-WORLD EFFECTIVENESS STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.1317","https://doi.org/10.1016/j.jval.2026.03.1317",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046738","R0046738.pdf","paywalled","nonrandomized_study","Johnson Y. Osei","2026","2008-P: Association between ZIP-Code Level, Obesity Prevalence, and Antiobesity Medication Persistence","Diabetes","American Diabetes Association","10.2337/db26-2008-p","https://doi.org/10.2337/db26-2008-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046771","R0046771.pdf","paywalled","nonrandomized_study","Ekow Pinkrah","2026","MM-837: GLP-1 Receptor Agonists Are Associated With Significantly Reduced All-Cause Mortality, Hospitalization, and Sepsis in Patients With Multiple Myeloma and Type 2 Diabetes: A Propensity Score–Matched Analysis of the TriNetX Global Collaborative Network","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02939-3","https://doi.org/10.1016/s2152-2650(26)02939-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046779","R0046779.pdf","paywalled","nonrandomized_study","S Störk","2026","Beyond phenogroups: towards a continuous biology of HFpEF","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag130","https://doi.org/10.1093/ejhf/xuag130","42008131","https://pubmed.ncbi.nlm.nih.gov/42008131/",null,null],["4","R0046784","R0046784.pdf","paywalled","nonrandomized_study","K. Shoba and B. C. Surekha Merwin Paul. R","2026","A Graph Convolutional Network (GCN) Framework to Identify Patients at High Risk for GLP-1 Agonist Discontinuation",null,"IEEE","10.1109/icmsci67830.2026.11469215","https://doi.org/10.1109/icmsci67830.2026.11469215",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046787","R0046787.pdf","paywalled","nonrandomized_study","Babak J. Orandi","2026","203.8: Metabolic bariatric surgery vs GLP-1 receptor agonists in dialysis patients with diabetes and obesity: A target trial emulation study.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0001249444.65141.3e","https://doi.org/10.1097/01.tp.0001249444.65141.3e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046790","R0046790.pdf","paywalled","nonrandomized_study","Aslesha Deshraju","2026","TPW 6.14 Effect of Saxenda on Pre-operative Bariatric Patients for Weight Reduction","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag087.367","https://doi.org/10.1093/bjs/znag087.367",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046807","R0046807.pdf","paywalled","nonrandomized_study","Ethan Cannon","2026","Abstract MPTU08: Semaglutide versus liraglutide and incidence of diabetes and cardiovascular disease: a target trial emulation using real-world data","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.mptu08","https://doi.org/10.1161/cir.153.suppl_1.mptu08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046809","R0046809.pdf","paywalled","nonrandomized_study","Akter Sraboni","2026","Emerging Role of Dual Agonists in Metabolic Disease Management: Clinical Outcomes and Safety Considerations – A Review Study","Review of Medicine Surgery and Dentistry","KMF Publishers","10.64907/xkmf.v5.i1.rmsd.1","https://doi.org/10.64907/xkmf.v5.i1.rmsd.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046815","R0046815.pdf","paywalled","nonrandomized_study","Y. J. Kim","2026","L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.1087","https://doi.org/10.1093/humrep/deag083.1087",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046841","R0046841.pdf","paywalled","nonrandomized_study","C M Duty","2026","P1039 Effectiveness and Safety of GLP-1 Receptor Agonists in Reducing Ostomy Output Among IBD Patients with Ileostomies","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjaf231.1220","https://doi.org/10.1093/ecco-jcc/jjaf231.1220",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046853","R0046853.pdf","paywalled","nonrandomized_study","Dustin Bastaich","2026","Propensity Score Matching Accounting for Longitudinal Trends Before Baseline with Group-based Trajectory Modeling","VCU Scholars Compass (Virginia Commonwealth University)",null,"10.25772/ptqt-xf74","https://doi.org/10.25772/ptqt-xf74",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046910","R0046910.pdf","paywalled","nonrandomized_study","Gangadhar Dhulipala","2026","Agricultural Technology: Reconciling Food Abundance and Public Health Through Integrated Pharmacotherapy Policies","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19554469","https://doi.org/10.5281/zenodo.19554469",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046915","R0046915.pdf","paywalled","nonrandomized_study","Emily Noelle Kinsey","2026","Relationship between GLP-1 receptor agonists on cancer recurrence and survival of patients with stage I-III colorectal cancer: A retrospective cohort study using the TriNetX database.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.3636","https://doi.org/10.1200/jco.2026.44.16_suppl.3636",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047023","R0047023.pdf","paywalled","nonrandomized_study","Sarina Ailawadi","2026","GLP-1 receptor agonist use and colorectal cancer risk in patients with inflammatory bowel disease.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.19_suppl.138","https://doi.org/10.1200/jco.2026.44.19_suppl.138",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047042","R0047042.pdf","paywalled","nonrandomized_study","Shawn Wang","2026","26-A-19195-ACC INCREMENTAL CARDIOVASCULAR BENEFITS OF GLP1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE ON SGLT2 INHIBITORS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION: A REAL-WORLD COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.5044","https://doi.org/10.1016/j.jacc.2026.02.5044",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047069","R0047069.pdf","paywalled","nonrandomized_study","Nadean F Alnajjar","2026","72819 Evaluation of GLP1-Receptor Agonist Use in Patients with Idiopathic Inflammatory Myopathies: A Retrospective Analysis","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.866","https://doi.org/10.1016/j.jaad.2026.04.866",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047212","R0047212.pdf","paywalled","nonrandomized_study","M Moukhtar Hammad","2026","(010) Vulvar Tissue Changes in Non-diabetic Women Receiving GLP-1 Receptor Agonists: A Global Federated Cohort Analysis","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag063.010","https://doi.org/10.1093/jsxmed/qdag063.010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047256","R0047256.pdf","paywalled","nonrandomized_study","Joanna Mary Roy","2026","401 Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Moyamoya Disease","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_401","https://doi.org/10.1227/neu.0000000000003964_401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047295","R0047295.pdf","paywalled","nonrandomized_study","Yasemin Bahar","2026","26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.678","https://doi.org/10.1016/j.jacc.2026.02.678",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047368","R0047368.pdf","paywalled","nonrandomized_study","Lakshmi Prasanna Vaishnavi Kattamuri","2026","Recent Advances in the Management of Heart Failure, Including the Role of AI and Advances in Gene Therapy","International Journal of Angiology","Georg Thieme Verlag KG","10.1055/a-2904-8847","https://doi.org/10.1055/a-2904-8847",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047383","R0047383.pdf","paywalled","nonrandomized_study","R. Nelson","2026","Abstract PS5-11-16: Impact of GLP-1 Receptor Agonist Exposure on the Long-Term Survival in Breast Cancer Patients","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps5-11-16","https://doi.org/10.1158/1557-3265.sabcs25-ps5-11-16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047392","R0047392.pdf","paywalled","nonrandomized_study","Guy Nguefang","2026","494 IMPACT OF GLP-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN AUTOIMMUNE HEPATITIS: A PROPENSITY SCORE-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03338-9","https://doi.org/10.1016/s0016-5107(26)03338-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047451","R0047451.pdf","paywalled","nonrandomized_study","Wei‐Han Chen","2026","Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.6592","https://doi.org/10.1200/jco.2026.44.16_suppl.6592",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047480","R0047480.pdf","paywalled","nonrandomized_study","Peng Li","2026","Abstract 6785: Evasion of hepatic ILC1 immunosurveillance drives breast cancer liver metastasis","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2026-6785","https://doi.org/10.1158/1538-7445.am2026-6785",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047482","R0047482.pdf","paywalled","nonrandomized_study","E. Robert McDonald","2026","Association of GLP-1 agonists with breast cancer incidence in women.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10506","https://doi.org/10.1200/jco.2026.44.16_suppl.10506",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047484","R0047484.pdf","paywalled","nonrandomized_study","Waasay Hassan Khan","2026","26-A-13332-ACC GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH AORTIC STENOSIS: A PROPENSITY-MATCHED ANALYSIS FROM A GLOBAL REAL-WORLD COHORT","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.4986","https://doi.org/10.1016/j.jacc.2026.02.4986",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047536","R0047536.pdf","paywalled","nonrandomized_study","Abdi Khalif","2026","96. GLP-1 receptor agonist use is associated with increased risk of bone loss and thoracolumbar compression fractures: a national cohort study","The Spine Journal","Elsevier BV","10.1016/j.spinee.2026.06.115","https://doi.org/10.1016/j.spinee.2026.06.115",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047628","R0047628.pdf","paywalled","nonrandomized_study","Olivia O’Mahony","2026","Pharmacist-Led Interventions to Optimize Guideline-Directed Medical Therapy in Diabetic Kidney Disease in Primary Care: A Scoping Review",null,null,"10.17605/osf.io/954gb","https://doi.org/10.17605/osf.io/954gb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047649","R0047649.pdf","paywalled","nonrandomized_study","Shide Zhang","2026","0629 Characterizing and Predicting Hypoglossal Nerve Stimulator Outcomes: Updated Analysis from an Urban Sleep Clinic","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0628","https://doi.org/10.1093/sleep/zsag091.0628",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047739","R0047739.pdf","paywalled","nonrandomized_study","Yajur Arya","2026","Real world outcomes comparing the use of GLP-1 agonists in patients with renal cell carcinoma (RCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.7_suppl.484","https://doi.org/10.1200/jco.2026.44.7_suppl.484",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047800","R0047800.pdf","paywalled","nonrandomized_study","Mahesh M. Umapathysivam","2026","Additional file 1 of Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists","Figshare",null,"10.6084/m9.figshare.32004906","https://doi.org/10.6084/m9.figshare.32004906",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047828","R0047828.pdf","paywalled","nonrandomized_study","Kevin Bowers","2026","The use of GLP-1 receptor agonist therapy in patients with type 1 diabetes, a retrospective cohort study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.115.p32","https://doi.org/10.1530/endoabs.115.p32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047868","R0047868.pdf","paywalled","nonrandomized_study","Carlo El Khoury","2026","PO-FPI-025 GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS AFTER CARDIAC ARREST IN PATIENTS WITH DIABETES: A PROPENSITY-MATCHED EHR COHORT","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2026.03.307","https://doi.org/10.1016/j.hrthm.2026.03.307",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047942","R0047942.pdf","paywalled","nonrandomized_study","JUAN J. GORGOJO-MARTINEZ","2026","1846-P: Effects of Intensification of Canagliflozin from 100 mg to 300 mg Daily on Insulin Initiation in the INTENSIFY Study","Diabetes","American Diabetes Association","10.2337/db26-1846-p","https://doi.org/10.2337/db26-1846-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048006","R0048006.pdf","paywalled","nonrandomized_study","Yajur Arya","2026","Real-world outcomes comparing the use of GLP-1 agonists in patients with colon cancer and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.83","https://doi.org/10.1200/jco.2026.44.2_suppl.83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048066","R0048066.pdf","paywalled","nonrandomized_study","Bernard Bright Davies-Teye","2026","PT38 REAL-WORLD ADHERENCE TO GLP-1RA AND DUAL GIP-GLP-1RA AMONG COMMERCIALLY INSURED US PATIENTS WITH TYPE 2 DIABETES AND OBESITY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.1988","https://doi.org/10.1016/j.jval.2026.03.1988",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048072","R0048072.pdf","paywalled","nonrandomized_study","Emmanuel Arega","2026","26-A-15070-ACC THE ANTIARRHYTHMIC EFFECTS OF ADD-ON GLP-1 RECEPTOR AGONISTS VERSUS OTHER ANTIDIABETIC THERAPIES: A NATIONWIDE COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.358","https://doi.org/10.1016/j.jacc.2026.02.358",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048141","R0048141.pdf","paywalled","nonrandomized_study","Emily Parker","2026","Economic Burden of Parkinson's and Atypical Parkinsonism in the United States","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20705357","https://doi.org/10.5281/zenodo.20705357",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048195","R0048195.pdf","paywalled","nonrandomized_study","Akil E. Olliverrie","2026","Tu2068 A REAL-WORLD ANALYSIS ON MITIGATING ALL-CAUSE MORTALITY AND GASTROINTESTINAL COMPLICATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS WITH DIABETES: THE THERAPEUTIC ROLE OF GLP-1 AGONIST","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)04090-3","https://doi.org/10.1016/s0016-5107(26)04090-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048196","R0048196.pdf","paywalled","nonrandomized_study","M Rafiqul Islam","2026","Comparative Effectiveness of Tirzepatide versus SGLT2 Inhibitors on Cardiovascular, Renal, and Limb Outcomes in Adults With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A TriNetX Target-Trial Emulation",null,null,"10.17605/osf.io/xb7ty","https://doi.org/10.17605/osf.io/xb7ty",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048318","R0048318.pdf","paywalled","nonrandomized_study","Sophia Salingaros","2026","The Differing Impact Of Perioperative Glp-1RA Use On Surgical Outcomes In Diabetic Versus Nondiabetic Plastic Surgery Patients","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20087070","https://doi.org/10.5281/zenodo.20087070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048399","R0048399.pdf","paywalled","nonrandomized_study","Nneoma Ubah","2026","Impact of glucagon-like peptide-1 receptor agonists on clinical outcomes in pancreatic cancer: A large-scale real-world cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.688","https://doi.org/10.1200/jco.2026.44.2_suppl.688",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048429","R0048429.pdf","paywalled","nonrandomized_study","J. Hundal","2026","Abstract PS4-01-14: Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps4-01-14","https://doi.org/10.1158/1557-3265.sabcs25-ps4-01-14",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048467","R0048467.pdf","paywalled","nonrandomized_study","Ahmad Habbas","2026","Association of GLP-1 receptor agonist use with mortality and hospitalization in women with breast cancer and type 2 diabetes: A propensity score–matched cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e12731","https://doi.org/10.1200/jco.2026.44.16_suppl.e12731",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048628","R0048628.pdf","paywalled","nonrandomized_study","R George","2026","Improving Upper GI Endoscopy Safety and Success in Patients on GLP-1 Agonists","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1822114","https://doi.org/10.1055/s-0046-1822114",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048657","R0048657.pdf","paywalled","nonrandomized_study","Hussam Almasri","2026","Sa2085 COMPARATIVE BIOCHEMICAL RESPONSE AND SIDE EFFECTS OF RESMETIROM VERSUS GLP-1 RA IN PATIENTS WITH MASLD AND OBESITY: A REAL-WORLD DATA STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03620-6","https://doi.org/10.1016/s0016-5085(26)03620-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048663","R0048663.pdf","paywalled","nonrandomized_study","Maria Dermit","2026","1685-P: Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT","Diabetes","American Diabetes Association","10.2337/db26-1685-p","https://doi.org/10.2337/db26-1685-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048732","R0048732.pdf","paywalled","nonrandomized_study","Tasneem Jamal Al-Din","2026","Sa1836 SHOULD GLP-1 THERAPY BE STOPPED AFTER DEVELOPING ACUTE PANCREATITIS? RECURRENCE OUTCOMES FROM A REAL-WORLD COHORT","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)05063-7","https://doi.org/10.1016/s0016-5107(26)05063-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048865","R0048865.pdf","paywalled","nonrandomized_study","Jovan Milosavljevic","2026","1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care","Diabetes","American Diabetes Association","10.2337/db26-1169-or","https://doi.org/10.2337/db26-1169-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048866","R0048866.pdf","paywalled","nonrandomized_study","Álvaro Caballero Romero","2026","GLP-1 receptor agonists and plastic surgery: mapping the evidence on perioperative risks, anatomical changes, and surgical outcomes",null,null,"10.17605/osf.io/j8etr","https://doi.org/10.17605/osf.io/j8etr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048992","R0048992.pdf","paywalled","nonrandomized_study","Oscar A Hinojosa","2026","GLP-1 receptor agonists vs 5-alpha reductase inhibitors for prostate cancer primary prevention in high-risk men: A real-world head-to-head comparison.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e17134","https://doi.org/10.1200/jco.2026.44.16_suppl.e17134",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049038","R0049038.pdf","paywalled","nonrandomized_study","Carolina Vélez-Mejía","2026","Survival in patients with hepatobiliary and pancreatic cancers taking GLP-1 receptor agonist therapy.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e16276","https://doi.org/10.1200/jco.2026.44.16_suppl.e16276",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049122","R0049122.pdf","paywalled","nonrandomized_study","Chia-Yu Kuo","2026","PREOPERATIVE GLP-1 RECEPTOR AGONIST USE AND RISK OF POSTOPERATIVE PNEUMONIA IN OBESE PATIENTS UNDERGOING ERAS-BASED COLORECTAL SURGERY: A MULTI-INSTITUTIONAL COHORT STUDY","Clinical Nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2026.103543","https://doi.org/10.1016/j.clnesp.2026.103543",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049148","R0049148.pdf","paywalled","nonrandomized_study","Jacinda Tran","2026","RWD112 MPACT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS TO TREAT OBESITY ON NON-GLP-1 COSTS AMONG COMMERCIALLY INSURED MEMBERS WITHOUT DIABETES: A THREE-YEAR RETROSPECTIVE ANALYSIS","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2100","https://doi.org/10.1016/j.jval.2026.03.2100",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049154","R0049154.pdf","paywalled","nonrandomized_study","Regina Castaneda","2026","The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study","The Lancet Obstetrics Gynaecology & Women s Health","Elsevier BV","10.1016/s3050-5038(25)00145-1","https://doi.org/10.1016/s3050-5038(25)00145-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049183","R0049183.pdf","paywalled","nonrandomized_study","Ali Reza Rahmani","2026","Semaglutide And Clinical Outcomes In Patients With Heart Failure With Reduced Ejection Fraction And Obesity: A Retrospective Cohort Study Using Real World Data","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2025.11.149","https://doi.org/10.1016/j.cardfail.2025.11.149",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049367","R0049367.pdf","paywalled","nonrandomized_study","Sarina Ailawadi","2026","Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus statins and the risk of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with type 2 diabetes mellitus (T2DM).","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.19_suppl.139","https://doi.org/10.1200/jco.2026.44.19_suppl.139",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049540","R0049540.pdf","paywalled","nonrandomized_study","Sam Joseph King","2026","Impact of SGLT2i and GLP1 agonists on prostate cancer incidence and outcomes: A real-world propensity score–matched cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e17148","https://doi.org/10.1200/jco.2026.44.16_suppl.e17148",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049592","R0049592.pdf","paywalled","nonrandomized_study","Baqir Jafry","2026","Association of GLP-1 receptor agonist use with overall survival in patients with colorectal cancer and type 2 diabetes: A multicenter real-world study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e15556","https://doi.org/10.1200/jco.2026.44.16_suppl.e15556",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049617","R0049617.pdf","paywalled","nonrandomized_study","Maunil Mullick","2026","Perioperative GLP-1 Use Improves Pituitary Function Recovery After Endoscopic Resection","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0046-1818680","https://doi.org/10.1055/s-0046-1818680",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049642","R0049642.pdf","paywalled","nonrandomized_study","Bryan C. Kaps","2026","IP18-25 GLP-1 AGONIST USE IS ASSOCIATED WITH REDUCED RISK OF REPEAT KIDNEY STONE EVENTS IN A NATIONALLY REPRESENTATIVE COHORT","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191368.71794.72.25","https://doi.org/10.1097/01.ju.0001191368.71794.72.25",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049664","R0049664.pdf","paywalled","nonrandomized_study","Ana Maria Davila Morales","2026","FRI-151 Which comes first: GLP-1 RA vs resmetirom in MASH real world practice","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01895-7","https://doi.org/10.1016/s0168-8278(26)01895-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049678","R0049678.pdf","paywalled","nonrandomized_study","C. F. Jones","2026","Abstract PD8-06: Real-world Analysis on the Impact of GLP-1 Receptor Agonists on All-cause Mortality and Endocrine Therapy-Tolerability in Obese Breast Cancer Patients","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-06","https://doi.org/10.1158/1557-3265.sabcs25-pd8-06",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049697","R0049697.pdf","paywalled","nonrandomized_study","Karecia Byfield","2026","Tu1549 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY: A MULTICENTER REAL-WORLD ANALYSIS","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03167-6","https://doi.org/10.1016/s0016-5107(26)03167-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049713","R0049713.pdf","paywalled","nonrandomized_study","Abidemi O. Akinrinmade","2026","Su2120 SEX AND MENOPAUSAL STATUS AS DETERMINANTS OF HEPATIC AND CARDIOMETABOLIC OUTCOMES AFTER GLP-1-BASED THERAPY IN OBESE ADULTS WITH MASLD/MASH: A PROPENSITY-MATCHED REAL- WORLD COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03749-1","https://doi.org/10.1016/s0016-5107(26)03749-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049777","R0049777.pdf","paywalled","nonrandomized_study","Yi Xiao","2026","0591 Clinical and Societal Impact of Tirzepatide in Patients with Moderate-to-severe OSA and Obesity: A Lifetime Modelling Study in China","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0590","https://doi.org/10.1093/sleep/zsag091.0590",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049825","R0049825.pdf","paywalled","nonrandomized_study","MUHAMMAD T. YOUNAS","2026","1705-P: Effects of Tirzepatide in Obese Adults with Type 1 Diabetes on Hybrid Closed-Loop Continuous Subcutaneous Insulin Infusion: A 12-Month Observational Study","Diabetes","American Diabetes Association","10.2337/db26-1705-p","https://doi.org/10.2337/db26-1705-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049848","R0049848.pdf","paywalled","nonrandomized_study","Guy Nguefang","2026","Additional file 1 of Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis","Figshare",null,"10.6084/m9.figshare.31931931","https://doi.org/10.6084/m9.figshare.31931931",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049881","R0049881.pdf","paywalled","nonrandomized_study","Arshi Syal","2026","Real world outcomes comparing the use of GLP-1 agonists in patients with hepatocellular cancer (HCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.2_suppl.517","https://doi.org/10.1200/jco.2026.44.2_suppl.517",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049953","R0049953.pdf","paywalled","nonrandomized_study","Azhar Hussain","2026","Sa1834 PROTECTIVE ROLE OF GLP-1 RECEPTOR AGONISTS AGAINST RECURRENT ACUTE PANCREATITIS: A U.S. POPULATION-BASED PROPENSITY-MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)05130-9","https://doi.org/10.1016/s0016-5085(26)05130-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050056","R0050056.pdf","paywalled","nonrandomized_study","Zin Thawdar Oo","2026","Real-World Experience of Semaglutide (Wegovy) Effectiveness in Weight Loss in an NHS Tier-3 Weight Management Service","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.117.p150","https://doi.org/10.1530/endoabs.117.p150",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050123","R0050123.pdf","paywalled","nonrandomized_study","Muhammad Ali Khan","2026","Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.7_suppl.352","https://doi.org/10.1200/jco.2026.44.7_suppl.352",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050149","R0050149.pdf","paywalled","nonrandomized_study","Sean O'Connor","2026","Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e16462","https://doi.org/10.1200/jco.2026.44.16_suppl.e16462",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050178","R0050178.pdf","paywalled","nonrandomized_study","Om Prakash Patel","2026","P0319 Association of GLP-1 Receptor Agonist Use With Clinical Outcomes in Diabetic Patients With Inflammatory Bowel Disease Receiving Adalimumab: A Propensity-Matched Cohort Study","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjaf231.500","https://doi.org/10.1093/ecco-jcc/jjaf231.500",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050441","R0050441.pdf","paywalled","nonrandomized_study","Ariana N. Neely","2026","Clinical impact of GLP-1 receptor agonist use on lung cancer incidence in high-risk patients: A real-world analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10559","https://doi.org/10.1200/jco.2026.44.16_suppl.10559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050463","R0050463.pdf","paywalled","nonrandomized_study","Junaid Ali Khan","2026","Tu1610 IMPACT OF GLP-1 RECEPTOR AGONIST USE ON EXTRA-INTESTINAL AND INFECTIOUS OUTCOMES IN ULCERATIVE COLITIS: A PROPENSITYMATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/s0016-5107(26)03228-1","https://doi.org/10.1016/s0016-5107(26)03228-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050468","R0050468.pdf","paywalled","nonrandomized_study","Mahan Najhawan","2026","IP38-23 GLP-1 RECEPTOR AGONISTS REDUCE MORTALITY AND HOSPITALIZATION IN DIABETIC PATIENTS WITH UROLOGIC MALIGNANCIES: A RETROSPECTIVE COHORT STUDY","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191508.89690.7a.23","https://doi.org/10.1097/01.ju.0001191508.89690.7a.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050495","R0050495.pdf","paywalled","nonrandomized_study","Anica Lara Bošnjak","2026","Treatment of Obesity with GLP-1 Receptor Agonists - An Outcome Mapping Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20074060","https://doi.org/10.5281/zenodo.20074060",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050586","R0050586.pdf","paywalled","nonrandomized_study","Muhammed A.M. Hammad","2026","IP28-29 VULVAR TISSUE CHANGES IN NON-DIABETIC WOMEN RECEIVING GLP-1 RECEPTOR AGONISTS: A GLOBAL FEDERATED COHORT ANALYSIS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001191440.21691.12.29","https://doi.org/10.1097/01.ju.0001191440.21691.12.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050711","R0050711.pdf","paywalled","nonrandomized_study","Vagisha Sharma","2026","1200.05 Effect Of Semaglutide Formulations On QTc Interval: A Retrospective Comparison Of Wegovy And Ozempic In A Tertiary Care Hospital","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2026.01.180","https://doi.org/10.1016/j.jcin.2026.01.180",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050775","R0050775.pdf","paywalled","nonrandomized_study","Vinod Kumar Yakkala","2026","RWD80 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INDIVIDUALS INITIATING GLP-1 AGONISTS FOR OBESITY: A CLAIMS DATABASE ANALYSIS IN THE US","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2068","https://doi.org/10.1016/j.jval.2026.03.2068",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050815","R0050815.pdf","paywalled","nonrandomized_study","Amanda Koire","2026","Quick Take Vol. 91",null,"Psychopharmacology Institute","10.64239/pi-it-qt91","https://doi.org/10.64239/pi-it-qt91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050952","R0050952.pdf","paywalled","nonrandomized_study","Gnanasekaran Ashok","2026","Oral Insulin and GLP-1 Receptor Agonist Delivery Technological Advances and Physiological Barriers Toward Non-Invasive Diabetes Therapeutics","Integrative Biomedical Research","Eman Research Publishing LLC","10.25163/biomedical.10210939","https://doi.org/10.25163/biomedical.10210939",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050953","R0050953.pdf","paywalled","nonrandomized_study","Shuhan Yang","2026","Abstract TH935: Glucagon-Like Peptide-1 Receptor Agonists Are More Frequently Prescribed to Individuals at Lower Predicted Cardiovascular Risk Than Those at Higher Risk Among People Without Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th935","https://doi.org/10.1161/cir.153.suppl_1.th935",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050996","R0050996.pdf","paywalled","nonrandomized_study","Dhriti Sood","2026","Beyond cardio-renal outcomes with GLP-1RA and SGLT2i in anthracycline-treated diabetic women with breast cancer: A propensity score–matched analysis from Global Federated Health Research Network.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e23079","https://doi.org/10.1200/jco.2026.44.16_suppl.e23079",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051069","R0051069.pdf","paywalled","nonrandomized_study","Kelli M. Richardson","2026","2586-P: Real-World Weight Loss Outcomes of a Telehealth Medical Weight Management Program in Adults with Prediabetes or Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2586-p","https://doi.org/10.2337/db26-2586-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051086","R0051086.pdf","paywalled","nonrandomized_study","M Moukhtar Hammad","2026","(106) GLP-1 Receptor Agonists Associated With Reduced Pelvic Complications in Postpartum Women: A Global Real-World Matched Cohort Study","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdag063.098","https://doi.org/10.1093/jsxmed/qdag063.098",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051150","R0051150.pdf","paywalled","nonrandomized_study","Farhan Ullah Afridi","2026","26-A-17921-ACC TRENDS IN THE USE OF GLP-1 ANALOGS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: INSIGHTS FROM A 10-YEAR REAL-WORLD DATA","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1755","https://doi.org/10.1016/j.jacc.2026.02.1755",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051221","R0051221.pdf","paywalled","nonrandomized_study","Sergio Andres Segrera","2026","Preoperative GLP-1 Receptor Agonist Exposure And Postoperative Complications After Autologous Breast Reconstruction: A Real-world TriNetX Cohort Study","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20086419","https://doi.org/10.5281/zenodo.20086419",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051305","R0051305.pdf","paywalled","nonrandomized_study","Muhammad Ali Ibrahim Kazi","2026","Tu1523 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON POST-ERCP OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROPENSITY-MATCHED COHORT ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)03210-5","https://doi.org/10.1016/s0016-5085(26)03210-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051337","R0051337.pdf","paywalled","nonrandomized_study","Archana Sadhu","2026","P4.787: Metabolic benefits of GLP-1RA and SGLT2i use after kidney transplantation: A single center real-world experience.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0001254672.97257.77","https://doi.org/10.1097/01.tp.0001254672.97257.77",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051407","R0051407.pdf","paywalled","nonrandomized_study","Yixue Shao","2026","1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data","Diabetes","American Diabetes Association","10.2337/db26-1292-or","https://doi.org/10.2337/db26-1292-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051503","R0051503.pdf","paywalled","nonrandomized_study","JERA A. VADÉN","2026","1704-P: Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland","Diabetes","American Diabetes Association","10.2337/db26-1704-p","https://doi.org/10.2337/db26-1704-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051505","R0051505.pdf","paywalled","nonrandomized_study","Giovanni Petralli","2026","FRI-187 Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfuction-associated steatotic liver disease (MASLD)","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01925-2","https://doi.org/10.1016/s0168-8278(26)01925-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051621","R0051621.pdf","paywalled","nonrandomized_study","Christopher Roberts","2026","Rapid uptake of GLP-1 receptor agonists in patients with inflammatory bowel disease: a 14-month repeated cross-sectional survey","Frontline Gastroenterology","BMJ","10.1136/flgastro-2026-103717","https://doi.org/10.1136/flgastro-2026-103717",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051684","R0051684.pdf","paywalled","nonrandomized_study","Joshua Airgood","2026","GLP-1 Agonist–Associated Weight Loss: A Comparison by HIV Status in the MACS/WIHS Combined Cohort","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/sybt-dt02","https://doi.org/10.17615/sybt-dt02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051758","R0051758.pdf","paywalled","nonrandomized_study","Adrien Holzgreve","2026","[18F]FDG PET in the era of glucagon-like peptide-1 receptor agonists – A retrospective single-center study","Nuklearmedizin - NuclearMedicine","Georg Thieme Verlag KG","10.1055/s-0046-1818196","https://doi.org/10.1055/s-0046-1818196",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051805","R0051805.pdf","paywalled","nonrandomized_study","Marc Patricio-Liébana","2026","Active lupus nephritis is an orphan disease","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfag056","https://doi.org/10.1093/ndt/gfag056","41811967","https://pubmed.ncbi.nlm.nih.gov/41811967/",null,null],["4","R0051851","R0051851.pdf","paywalled","nonrandomized_study","Yesh Dhruva","2026","26-A-12216-ACC REAL-WORLD COMPARATIVE ANALYSIS OF GLP1 RECEPTOR AGONISTS ON CARDIOVASCULAR OUTCOMES","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2109","https://doi.org/10.1016/j.jacc.2026.02.2109",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051856","R0051856.pdf","paywalled","nonrandomized_study","Dominic Nunag","2026","1707-P: Association of GLP-1 Use and End-Stage Liver Disease (ESLD) Events in U.S. Adults with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)","Diabetes","American Diabetes Association","10.2337/db26-1707-p","https://doi.org/10.2337/db26-1707-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051918","R0051918.pdf","paywalled","nonrandomized_study","Amanda Koire","2026","Quick Take Vol. 91",null,"Psychopharmacology Institute","10.64239/pi-qt91","https://doi.org/10.64239/pi-qt91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051934","R0051934.pdf","paywalled","nonrandomized_study","Sean O'Leary","2026","432 Early GLP-1 Receptor Agonist Use Is Associated With Reduced Mortality and Neurologic Complications Following Traumatic Brain Injury: A Propensity Score Matched Cohort Study","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_432","https://doi.org/10.1227/neu.0000000000003964_432",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051947","R0051947.pdf","paywalled","nonrandomized_study","Andrew C. P. Sims","2026","Abstract TH817: Development of a new diabetes classification algorithm for epidemiological studies: The Jackson Heart Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th817","https://doi.org/10.1161/cir.153.suppl_1.th817",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051977","R0051977.pdf","paywalled","nonrandomized_study","Yoshinori Nishijima","2026","GLP-1 receptor agonists improve and preserve microvascular endothelial function - Focus on chemotherapy induced vascular damage","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2301196","https://doi.org/10.1152/physiol.2026.41.s1.2301196",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051980","R0051980.pdf","paywalled","nonrandomized_study","Marialaura Simonetto","2026","Abstract A075: Association of Glucagon-like Peptide-1 Receptor Agonist Use and Long-Term Mortality after Acute Ischemic Stroke","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.57.suppl_1.a075","https://doi.org/10.1161/str.57.suppl_1.a075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052045","R0052045.pdf","paywalled","nonrandomized_study","Ankitha Vanaparti","2026","1431-P: Synergistic Effect of GLP-1 Receptor Agonists and Opioids on Gastric Emptying and Symptom Burden: A Propensity-Matched Multicenter Analysis","Diabetes","American Diabetes Association","10.2337/db26-1431-p","https://doi.org/10.2337/db26-1431-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052100","R0052100.pdf","paywalled","nonrandomized_study","Khvaramze Shaverdashvili","2026","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on outcomes in metastatic non-small cell lung cancer (mNSCLC) patients treated with tyrosine kinase inhibitors (TKIs): Real-world retrospective analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.8636","https://doi.org/10.1200/jco.2026.44.16_suppl.8636",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052157","R0052157.pdf","paywalled","nonrandomized_study","Μargarita Papatheodoridi","2026","THU-172 Eligibility for resmetirom or semaglutide therapy in a real-life Greek cohort of patients with metabolic associated steatotic liver disease","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01564-3","https://doi.org/10.1016/s0168-8278(26)01564-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052166","R0052166.pdf","paywalled","nonrandomized_study","Abdelrahman Hafez Hafez","2026","26-A-15961-ACC BARIATRIC METABOLIC SURGERY VERSUS GLP-1 RECEPTOR AGONISTS AMONG ADULTS WITH OBESITY: A PROPENSITY-MATCHED COHORT STUDY OF LONG-TERM MORTALITY AND CARDIOVASCULAR OUTCOMES","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.517","https://doi.org/10.1016/j.jacc.2026.02.517",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052222","R0052222.pdf","paywalled","nonrandomized_study","Efeturi Maxwell Okorigba","2026","26-A-20853-ACC CARDIOVASCULAR OUTCOMES OF GLP-1 RA USE IN NON-OBESE DIABETIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A PROPENSITY MATCHED ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1939","https://doi.org/10.1016/j.jacc.2026.02.1939",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052224","R0052224.pdf","paywalled","nonrandomized_study","Zunairah Shah","2026","GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.10548","https://doi.org/10.1200/jco.2026.44.16_suppl.10548",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052300","R0052300.pdf","paywalled","nonrandomized_study","Matthew Dao","2026","The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Burn Recovery: Reduced Infection, Opioid Prescriptions, and Mortality","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20086786","https://doi.org/10.5281/zenodo.20086786",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052337","R0052337.pdf","paywalled","nonrandomized_study","Ghaith Khaleel","2026","Effectiveness of new generation incretin-based therapies in hypothalamic obesity: a single centre real-world experience","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.117.p286","https://doi.org/10.1530/endoabs.117.p286",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052341","R0052341.pdf","paywalled","nonrandomized_study","Sultan Samin","2026","Efficacy of GLP-1 Receptor Agonists in Patients with Prader-Willi Syndrome: A Retrospective Cohort Study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.117.op2.3","https://doi.org/10.1530/endoabs.117.op2.3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052348","R0052348.pdf","paywalled","nonrandomized_study","Emma J. Anisman","2026","Glucagon-Like Peptide-1 Receptor Agonist Use and Survival Outcomes in Skull Base and Head and Neck Tumors","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0046-1818751","https://doi.org/10.1055/s-0046-1818751",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052369","R0052369.pdf","paywalled","nonrandomized_study","Matias Luis Costa","2026","243 Early GLP-1 Receptor Agonist Use Is Associated With Reduced Mortality and Neurological Complications Following Spinal Cord Injury: A Propensity Score Matched Cohort Study","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_243","https://doi.org/10.1227/neu.0000000000003964_243",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052374","R0052374.pdf","paywalled","nonrandomized_study","Amin Tajerian","2026","One-year Heart Failure Outcomes On Glp1-ra Treatment And After Discontinuation: A Real-world Retrospective Cohort Study","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2025.11.082","https://doi.org/10.1016/j.cardfail.2025.11.082",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052394","R0052394.pdf","paywalled","nonrandomized_study","Khalid Sawalha","2026","26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.451","https://doi.org/10.1016/j.jacc.2026.02.451",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052678","R0052678.pdf","paywalled","nonrandomized_study","J. Hundal","2026","Abstract PS2-02-24: Comparative Effects of Semaglutide vs Tirzepatide on Weight Change and Cardiovascular Risk in Breast Cancer Survivors","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps2-02-24","https://doi.org/10.1158/1557-3265.sabcs25-ps2-02-24",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052706","R0052706.pdf","paywalled","nonrandomized_study","R. B. Halley","2026","Use of the dual GLP-1/GIP coagonist, tirzepatide, in patients with advanced metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: real-world data","Frontline Gastroenterology","BMJ","10.1136/flgastro-2026-103661","https://doi.org/10.1136/flgastro-2026-103661",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052718","R0052718.pdf","paywalled","nonrandomized_study","Brian Hyung","2026","2842-LB: Risk of Pulmonary Aspiration with Glucagon-Like Peptide 1 Receptor Agonists in Mild-to-Moderate Sedation","Diabetes","American Diabetes Association","10.2337/db26-2842-lb","https://doi.org/10.2337/db26-2842-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052998","R0052998.pdf","paywalled","nonrandomized_study","B Norton","2026","Economic evaluation of proximal intestinal mucosal ablation in insulin-requiring type 2 diabetes: cost-effectiveness and price threshold analysis from a UK NHS perspective with comparison to semaglutide","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1821211","https://doi.org/10.1055/s-0046-1821211",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053200","R0053200.pdf","paywalled","nonrandomized_study","M Alkharabsheh","2026","B45-18 Glp-1 Receptor Agonists Reduce Hospitalization, Respiratory Failure, and Mortality in Adults With Cystic Fibrosis and Diabetes: A Real-world Propensity-matched Study","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.2147","https://doi.org/10.1093/ajrccm/aamag162.2147",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053235","R0053235.pdf","paywalled","nonrandomized_study","Ruchi Patel","2026","Association between Glucagon-Like Peptide-1 Receptor Agonists and Asthma Exacerbations in Non-Diabetic Patients with Obesity: Cohort Study","Journal of Allergy and Clinical Immunology","Elsevier BV","10.1016/j.jaci.2025.12.553","https://doi.org/10.1016/j.jaci.2025.12.553",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053401","R0053401.pdf","paywalled","nonrandomized_study","Elvis Obomanu","2026","Abstract PD8-05: A Retrospective Cohort Study on Mitigating Chemotherapy Side Effects in Breast Cancer Patients: The Role of GLP-1 Agonists","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-pd8-05","https://doi.org/10.1158/1557-3265.sabcs25-pd8-05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053446","R0053446.pdf","paywalled","nonrandomized_study","James E. Dunn","2026","GLP-1 as Governance Architecture: The Three-Node Relay, Permeability Reinforcement, and Cancer Incidence (HLRP Paper #130)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19239705","https://doi.org/10.5281/zenodo.19239705",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053490","R0053490.pdf","paywalled","nonrandomized_study","Naomi Dillard","2026","2346-P: Access to GLP-1 Receptor Agonists (GLP-1RA) and Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) for Type 2 Diabetes Mellitus (T2DM) by Sociodemographic Factors in a Large Integrated Health System","Diabetes","American Diabetes Association","10.2337/db26-2346-p","https://doi.org/10.2337/db26-2346-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053518","R0053518.pdf","paywalled","nonrandomized_study","T. Lakshmi Prasanna","2026","Adverse Drug Reaction Monitoring of Semaglutide in India: Impact of Expanding Formulations and Generic Market Entry","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20951127","https://doi.org/10.5281/zenodo.20951127",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053519","R0053519.pdf","paywalled","nonrandomized_study","Iapunira Catarina Sant’Anna Aragão","2026","ENDOCRINOLOGIA DE PRECISÃO E RESISTÊNCIA À INSULINA – AVANÇOS EM BIOMARCADORES E TERAPIAS PERSONALIZADAS: REVISÃO SISTEMÁTICA COM ABORDAGEM DE METANÁLISE","Revista Científica Ipedss","IPEDSS - Instituto de Pesquisa e Determinacao Social da Saude Ltda","10.55703/27644006060123","https://doi.org/10.55703/27644006060123",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053671","R0053671.pdf","paywalled","nonrandomized_study","Aubree Seibert-Jeffrey","2026","RWD115 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND INCIDENT ALCOHOL USE DISORDER AMONG PATIENTS WITH DIABETES: A REAL-WORLD EVIDENCE STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2103","https://doi.org/10.1016/j.jval.2026.03.2103",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053676","R0053676.pdf","paywalled","nonrandomized_study","MD/ PhD/ FACC Camilo Fernández Bravo","2026","Precision Cardiometabolic Risk Stratification and Therapeutic Targeting in Patients with Cardiovascular-Kidney-Metabolic Syndrome Integrating Lipoprotein(a) Levels, Multi-Omics Biomarkers, Inflammatory Pathways, and Novel GLP-1/GIP Receptor Agonist Therapies to Mitilare Progression to Heart Failure with Preserved Eection Fraction - Results from Preserved Eection Fraction - Results from a Prospective Multi-Center Observational Cohort with Long-Term Composite Endpoint Analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18612727","https://doi.org/10.5281/zenodo.18612727",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053693","R0053693.pdf","paywalled","nonrandomized_study","RUPESH KUMAR","2026","\"Impact of GLP-1/GIP Receptor Agonist–Associated Delayed Gastric Emptying on Oral Drug Absorption and Pharmacokinetics\": A Narrative Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22102668","https://doi.org/10.5281/zenodo.22102668",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053708","R0053708.pdf","paywalled","nonrandomized_study","Kriti Soni","2026","26-A-18754-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN CARDIAC SARCOIDOSIS: A PROPENSITY-SCORE MATCHED ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1662","https://doi.org/10.1016/j.jacc.2026.02.1662",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053709","R0053709.pdf","paywalled","nonrandomized_study","Laura DeFina","2026","Abstract TU204: Glucagon-like Peptide-1 Receptor Agonists: Are They Associated With Increased Cardiorespiratory Fitness?","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.tu204","https://doi.org/10.1161/cir.153.suppl_1.tu204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053743","R0053743.pdf","paywalled","nonrandomized_study","Jay B. Lusk","2026","1671-P: Heterogeneity of Treatment Effect of Glucagon-Like Peptide 1 Receptor Agonists for Secondary Prevention of Cardiovascular Events in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1671-p","https://doi.org/10.2337/db26-1671-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053781","R0053781.pdf","paywalled","nonrandomized_study","Chidiebube Ugwu","2026","MM-1225: GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score–Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)03010-7","https://doi.org/10.1016/s2152-2650(26)03010-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053805","R0053805.pdf","paywalled","nonrandomized_study","Or Shaked","2026","RWD79 INITIATION WITH GLP-1 RECEPTOR AGONISTS TREATMENT FOR OBESITY IN PATIENTS WITH MENTAL HEALTH CONDITIONS - A REAL WORLD DATA RETROSPECTIVE STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.2067","https://doi.org/10.1016/j.jval.2026.03.2067",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053810","R0053810.pdf","paywalled","nonrandomized_study","Michela Palleschi","2026","Real-world survival benefit of glucagon-like peptide-1 receptor agonists (GLP-1 Ras) concomitant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy in hormone receptor-positive (HR+)/HER2− metastatic breast cancer: A large propensity-matched analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.1070","https://doi.org/10.1200/jco.2026.44.16_suppl.1070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053811","R0053811.pdf","paywalled","nonrandomized_study","Paula Mateo-Kubach","2026","Perioperative GLP-1 receptor agonist use and postoperative opioid consumption in gynecologic surgery: A retrospective cohort analysis","International Journal of Gynecological Cancer","Elsevier BV","10.1016/j.ijgc.2025.103656","https://doi.org/10.1016/j.ijgc.2025.103656",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053856","R0053856.pdf","paywalled","nonrandomized_study","Nnamdi Omenuko","2026","MM-857: Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02945-9","https://doi.org/10.1016/s2152-2650(26)02945-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053871","R0053871.pdf","paywalled","nonrandomized_study","YU N. WANG","2026","1968-P: Impact of GLP-1RA Initiation on Medical Expenditures in Medicare Beneficiaries with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1968-p","https://doi.org/10.2337/db26-1968-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053872","R0053872.pdf","paywalled","nonrandomized_study","Tardibuono Vincenza Adriana","2026","NP-009 Discontinuation and predictive factors in patients treated with GLP-1 receptor analogues: evidence from Sicilian distribution 'per conto' (DPC) data (2021-2024)",null,"British Medical Journal Publishing Group","10.1136/ejhpharm-2026-eahp.9","https://doi.org/10.1136/ejhpharm-2026-eahp.9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053889","R0053889.pdf","paywalled","nonrandomized_study","U Suresh","2026","B16-09 Attenuation of Respiratory Exacerbation Rate With GLP-1 Receptor Agonist Therapy in Patients With COPD","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1758","https://doi.org/10.1093/ajrccm/aamag162.1758",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053926","R0053926.pdf","paywalled","nonrandomized_study","Mohamed Shadi","2026","Comparative Economic Value of GLP-1 Obesity Medications Vs Standard Care in Egypt","International Journal of Research and Innovation in Social Science","RSIS International","10.47772/ijriss.2026.100400148","https://doi.org/10.47772/ijriss.2026.100400148",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053948","R0053948.pdf","paywalled","nonrandomized_study","F. Schiele","2026","Lower risk of MACE and all-cause death in patients initiated on semaglutide 2.4 mg in routine clinical care: Results from the score study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)","Archives of cardiovascular diseases","Elsevier BV","10.1016/j.acvd.2025.10.204","https://doi.org/10.1016/j.acvd.2025.10.204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053987","R0053987.pdf","paywalled","nonrandomized_study","Gideon Wolf","2026","Safety of glucagon-like peptide-1 receptor agonists in patients receiving chimeric antigen receptor T cell or bispecific T cell engager therapy.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e24016","https://doi.org/10.1200/jco.2026.44.16_suppl.e24016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053999","R0053999.pdf","paywalled","nonrandomized_study","M L Stanchina","2026","A79-05 The Impact of Tirzepatide Induced Weight Loss on Lung Hyperinflation and AHI Reduction in COPD-OSA Overlap Syndrome","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.6312","https://doi.org/10.1093/ajrccm/aamag162.6312",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054022","R0054022.pdf","paywalled","nonrandomized_study","Gajaram Sirvi","2026","From Pills to Injections: Comparing the Pharmacokinetics and Clinical Impact of Oral Semaglutide and Injectable GLP-1 Agonists","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21943336","https://doi.org/10.5281/zenodo.21943336",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054027","R0054027.pdf","paywalled","nonrandomized_study","Jacqueline Maya","2026","2167-P: Postpartum Weight Retention after Glucagon-Like Peptide 1 Receptor Agonist Discontinuation for Pregnancy","Diabetes","American Diabetes Association","10.2337/db26-2167-p","https://doi.org/10.2337/db26-2167-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054061","R0054061.pdf","paywalled","nonrandomized_study","Mohammmad Amer Al Tamimi","2026","Impact of GLP-1 receptor agonists on outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter propensity-matched real-world analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e16180","https://doi.org/10.1200/jco.2026.44.16_suppl.e16180",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054077","R0054077.pdf","paywalled","nonrandomized_study","F Monego","2026","HIGH PREVALENCE OF ADVANCED CARDIOVASCULAR–KIDNEY–METABOLIC SYNDROME IN CARDIAC REHABILITATION PATIENTS AND THERAPEUTIC IMPLICATIONS: A SINGLE–DAY OBSERVATIONAL STUDY","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suag058.459","https://doi.org/10.1093/eurheartjsupp/suag058.459",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054108","R0054108.pdf","paywalled","nonrandomized_study","RASHON LANE","2026","2363-P: A1C and BMI Changes by Sociodemographic Groups among Patients Using GLP-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors in a Large Integrated Health System","Diabetes","American Diabetes Association","10.2337/db26-2363-p","https://doi.org/10.2337/db26-2363-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054152","R0054152.pdf","paywalled","nonrandomized_study","WENJUN FAN","2026","2200-P: Real-World Effectiveness of Novel Antidiabetic Medications on Cardiovascular Outcomes among Medicare Beneficiaries by Race","Diabetes","American Diabetes Association","10.2337/db26-2200-p","https://doi.org/10.2337/db26-2200-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054212","R0054212.pdf","paywalled","nonrandomized_study","Glauco Messina","2026","Modulation of Shift-Work Induced Metabolic Chronodisruption and Neurovascular Risk in Healthcare Professionals: A Prospective Real-World Three-Arm Incretin Study","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20681849","https://doi.org/10.5281/zenodo.20681849",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054219","R0054219.pdf","paywalled","nonrandomized_study","MINGKAI PENG","2026","1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1344-or","https://doi.org/10.2337/db26-1344-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054228","R0054228.pdf","paywalled","nonrandomized_study","Madeline Carmain","2026","Perioperative Adverse Events in Women Taking GLP1-RAs in Gynecologic Surgery","Obstetrics and Gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aog.0000000000006204.2","https://doi.org/10.1097/aog.0000000000006204.2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054241","R0054241.pdf","paywalled","nonrandomized_study","F Da Canal","2026","Efficacy of GLP 1 Receptor Agonists in Managing Weight Regain Following Roux-en-Y Gastric Bypass: A Therapeutic Avenue to Restore Metabolic Control?","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znag055.002","https://doi.org/10.1093/bjs/znag055.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054320","R0054320.pdf","paywalled","nonrandomized_study","Abdalhakim R. M. Shubietah","2026","26-A-14458-ACC PROTECTIVE EFFECT OF GLP-1 RECEPTOR AGONISTS ON POST-TAVR CONDUCTION AND ARRHYTHMIC COMPLICATIONS: A RETROSPECTIVE COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.103","https://doi.org/10.1016/j.jacc.2026.02.103",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054332","R0054332.pdf","paywalled","nonrandomized_study","Arkadeep Dhali","2026","FP39 Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2026-bsg.115","https://doi.org/10.1136/gutjnl-2026-bsg.115",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054430","R0054430.pdf","paywalled","nonrandomized_study","Carol Levy","2026","1067-OR: A Multicenter Trial Assessing the Efficacy and Safety of the Novel Twiist Automated Insulin Delivery (AID) System in Adults with Insulin-Treated Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db26-1067-or","https://doi.org/10.2337/db26-1067-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054498","R0054498.pdf","paywalled","nonrandomized_study","A Chaaban","2026","A19-09 Comparative Cardiopulmonary Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Older Adults With Pulmonary Hypertension: A Real-world Propensity-matched Analysis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.5485","https://doi.org/10.1093/ajrccm/aamag162.5485",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054506","R0054506.pdf","paywalled","nonrandomized_study","GABRIELA M. SIEW","2026","1164-OR: Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class","Diabetes","American Diabetes Association","10.2337/db26-1164-or","https://doi.org/10.2337/db26-1164-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054598","R0054598.pdf","paywalled","nonrandomized_study","Yifat F. Hershcovitz","2026","1469-P: Real-World Weight Loss with Digital Health with and without GLP-1 Therapy","Diabetes","American Diabetes Association","10.2337/db26-1469-p","https://doi.org/10.2337/db26-1469-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054613","R0054613.pdf","paywalled","nonrandomized_study","Hanson Chan","2026","1679-P: Concurrent Ondansetron Use during Semaglutide Initiation Is Associated with Increased Biliary Complications in a Large Real-World Cohort","Diabetes","American Diabetes Association","10.2337/db26-1679-p","https://doi.org/10.2337/db26-1679-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054627","R0054627.pdf","paywalled","nonrandomized_study","Braeden Christopher Benedict","2026","1120 Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients With Obesity: A Pilot Study","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003964_1120","https://doi.org/10.1227/neu.0000000000003964_1120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054647","R0054647.pdf","paywalled","nonrandomized_study","WEI-HAN CHEN","2026","2841-LB: Glucagon-Like Peptide 1 Receptor Agonists Lower the Risk of Stroke and Vascular Dementia among Individuals with Obesity","Diabetes","American Diabetes Association","10.2337/db26-2841-lb","https://doi.org/10.2337/db26-2841-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054708","R0054708.pdf","paywalled","nonrandomized_study","Reny Mathew","2026","Abstract TP202: Quality Improvement Project of Increasing Utilization of Antihyperglycemic Medications with Cardiovascular Benefits in Patient with Diabetes admitted with Acute Ischemic Stroke","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.57.suppl_1.tp202","https://doi.org/10.1161/str.57.suppl_1.tp202",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054711","R0054711.pdf","paywalled","nonrandomized_study","HAO DAI","2026","2199-P: GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation","Diabetes","American Diabetes Association","10.2337/db26-2199-p","https://doi.org/10.2337/db26-2199-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054743","R0054743.pdf","paywalled","nonrandomized_study","Tim Prior","2026","Impact of GLP1 receptor agonists on survival of breast cancer patients.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.639","https://doi.org/10.1200/jco.2026.44.16_suppl.639",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054774","R0054774.pdf","paywalled","nonrandomized_study","Mostafa Eysha","2026","Abstract B041: GLP-1 receptor agonists associated with improved response to immune checkpoint inhibitors in solid tumors: a multi-institutional retrospective cohort study","Cancer Immunology Research","American Association for Cancer Research (AACR)","10.1158/2326-6074.io2026-b041","https://doi.org/10.1158/2326-6074.io2026-b041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054803","R0054803.pdf","paywalled","nonrandomized_study","B. M. Makkar","2026","1698-P: Three-Month Response Threshold as a Predictive Biomarker for Long-Term Weight Loss Sustainability in GLP-1 Receptor Agonist Therapy: A Real-World Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1698-p","https://doi.org/10.2337/db26-1698-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054841","R0054841.pdf","paywalled","nonrandomized_study","Shalin Rawal","2026","Association of concurrent GLP-1 receptor agonist use with survival outcomes in patients with metastatic colorectal cancer receiving immune checkpoint inhibitors.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.3605","https://doi.org/10.1200/jco.2026.44.16_suppl.3605",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054850","R0054850.pdf","paywalled","nonrandomized_study","S S Shama","2026","C104-17 Impact of Sglt2 Inhibitors on Mortality and Clinical Outcomes in Patients With Sarcoidosis: A Real-world Analysis From Trinetx","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.2831","https://doi.org/10.1093/ajrccm/aamag162.2831",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054864","R0054864.pdf","paywalled","nonrandomized_study","Aneeq Chaudhry","2026","Perioperative GLP-1 Analogue Exposure and Postoperative Outcomes in Mommy Makeover Surgical Procedures: A Nationwide Propensity-Matched Analysis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20086937","https://doi.org/10.5281/zenodo.20086937",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054895","R0054895.pdf","paywalled","nonrandomized_study","Ankitha Vanaparti","2026","2595-P: Tirzepatide vs. Semaglutide and the Risk of Incident Gastroparesis: A Propensity-Matched Analysis of 828,426 Patients","Diabetes","American Diabetes Association","10.2337/db26-2595-p","https://doi.org/10.2337/db26-2595-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054915","R0054915.pdf","paywalled","nonrandomized_study","J Johal","2026","P1050 Impact of GLP-1 receptor agonist therapy on clinical outcomes in diabetic patients with Inflammatory Bowel Disease treated with infliximab: a propensity-matched cohort study","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjaf231.1231","https://doi.org/10.1093/ecco-jcc/jjaf231.1231",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054934","R0054934.pdf","paywalled","nonrandomized_study","Chidiebube Ugwu","2026","POSTER: MM-1225: GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score–Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)01434-5","https://doi.org/10.1016/s2152-2650(26)01434-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054957","R0054957.pdf","paywalled","nonrandomized_study","Muluken Megiso","2026","MPN-1144: GLP-1 Receptor Agonists and Major Clinical Outcomes in Adults With Classic Myeloproliferative Neoplasms and Type 2 Diabetes and/or Obesity: A Global Propensity Score-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(26)02399-2","https://doi.org/10.1016/s2152-2650(26)02399-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054961","R0054961.pdf","paywalled","nonrandomized_study","Z Wright","2026","GLP-1 receptor agonist-induced post-procedural gastrointestinal and biliary complications in cardiothoracic surgery","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.1304","https://doi.org/10.1093/ejhf/xuag193.1304",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054974","R0054974.pdf","paywalled","nonrandomized_study","Hnin Oo","2026","0540 Varying Hypopnea Definitions and Missed Treatment Opportunities in Obstructive Sleep Apnea","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0539","https://doi.org/10.1093/sleep/zsag091.0539",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054977","R0054977.pdf","paywalled","nonrandomized_study","Wouter van der Pluijm","2026","EPH18 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST INITIATION AND ALCOHOL USE DISORDER AND ALCOHOL-RELATED MEDICAL CONDITIONS IN A U.S. ADMINISTRATIVE CLAIMS DATABASE","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.851","https://doi.org/10.1016/j.jval.2026.03.851",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055007","R0055007.pdf","paywalled","nonrandomized_study","VIVIAN FONSECA","2026","1706-P: Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals among Patients with Type 2 Diabetes: Quantifying an Opportunity to Improve Treatment Benefits","Diabetes","American Diabetes Association","10.2337/db26-1706-p","https://doi.org/10.2337/db26-1706-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055019","R0055019.pdf","paywalled","nonrandomized_study","Soad Al Osta","2026","26-A-17762-ACC GLP-1 RECEPTOR AGONISTS AND RISK OF CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANT: A MULTICENTER RETROSPECTIVE ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1918","https://doi.org/10.1016/j.jacc.2026.02.1918",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055024","R0055024.pdf","paywalled","nonrandomized_study","Jay B. Lusk","2026","1670-P: Heterogeneity of Treatment Effect of Glucagon-Like Peptide 1 Receptor Agonists for Primary Prevention of Cardiovascular Events in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1670-p","https://doi.org/10.2337/db26-1670-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055051","R0055051.pdf","paywalled","nonrandomized_study","Nicole Rangos","2026","2090-P: High Day-to-Day Glycemic Variability in Youth-Onset Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2090-p","https://doi.org/10.2337/db26-2090-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055094","R0055094.pdf","paywalled","nonrandomized_study","Chenxi Gao","2026","Metabolic Bariatric Surgery vs GLP-1 Receptor Agonists in Dialysis Patients with Diabetes and Obesity: A Target Trial Emulation Study","Surgery for Obesity and Related Diseases","Elsevier BV","10.1016/j.soard.2026.09.014","https://doi.org/10.1016/j.soard.2026.09.014",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055113","R0055113.pdf","paywalled","nonrandomized_study","Jyoti Jain","2026","26-A-19312-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN PERIPARTUM CARDIOMYOPATHY: A PROPENSITY-SCORE MATCHED ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2647","https://doi.org/10.1016/j.jacc.2026.02.2647",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055115","R0055115.pdf","paywalled","nonrandomized_study","Maria Cecilia Lansang","2026","Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022","Diabetes Obesity and Cardiometabolic CARE","American Diabetes Association","10.2337/doc26-0027","https://doi.org/10.2337/doc26-0027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055127","R0055127.pdf","paywalled","nonrandomized_study","Revanth Reddy Bandaru","2026","26-A-20019-ACC IMPACT OF GLP-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN PATIENTS WITH GROUP-2 PULMONARY HYPERTENSION: A REAL-WORLD EVIDENCE STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.1937","https://doi.org/10.1016/j.jacc.2026.02.1937",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055147","R0055147.pdf","paywalled","nonrandomized_study","ANNA NOWAK-SZWED","2026","1687-P: Circulating miRNAs as Predictors of Weight Reduction in Type 2 Diabetes Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial","Diabetes","American Diabetes Association","10.2337/db26-1687-p","https://doi.org/10.2337/db26-1687-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055154","R0055154.pdf","paywalled","nonrandomized_study","Nicolas Bakinde","2026","All obesity is not created equal: implications for NP-agnostic HFpEF enrichment using the HFpEF-ABA score","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag118","https://doi.org/10.1093/eurheartj/ehag118","41790459","https://pubmed.ncbi.nlm.nih.gov/41790459/",null,null],["4","R0055192","R0055192.pdf","paywalled","nonrandomized_study","Ahmed Ghanem","2026","Comparative Effects of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors on Lipid Profiles: A Large Real-World Propensity-Matched Analysis","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2026.05.172","https://doi.org/10.1016/j.jacl.2026.05.172",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055209","R0055209.pdf","paywalled","nonrandomized_study","Junmin Song","2026","Reevaluating the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA) vs aspirin for colorectal cancer prevention in type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e15690","https://doi.org/10.1200/jco.2026.44.16_suppl.e15690",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055241","R0055241.pdf","paywalled","nonrandomized_study","C Chinthammit","2026","Real-world effectiveness of tirzepatide among individuals with obesity or overweight","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819893","https://doi.org/10.1055/s-0046-1819893",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055242","R0055242.pdf","paywalled","nonrandomized_study","Muluken Megiso","2026","A real-world analysis on the management of post-mastectomy lymphedema in breast cancer patients: The therapeutic promise of glucagon-like peptide-1 receptor agonist.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.e12695","https://doi.org/10.1200/jco.2026.44.16_suppl.e12695",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055272","R0055272.pdf","paywalled","nonrandomized_study","Si Huang","2026","Structural Mass Spectrometry Resolves the Conformational Dynamics of Semaglutide Oligomerization","Journal of the American Chemical Society","American Chemical Society (ACS)","10.1021/jacs.6c12077","https://doi.org/10.1021/jacs.6c12077",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055294","R0055294.pdf","paywalled","nonrandomized_study","K.V.R. Hviid","2026","L26/O-097 Preconception GLP-1 receptor agonist exposure in couples and fertility outcomes: a danish nationwide cohort study","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.097","https://doi.org/10.1093/humrep/deag083.097",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055306","R0055306.pdf","paywalled","nonrandomized_study","Sharath Kasula","2026","AI-Assisted Pharmacovigilance via Multi-Source Data Integration: A Comparative Safety Signal Analysis of Semaglutide and Sertraline","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21286904","https://doi.org/10.5281/zenodo.21286904",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055319","R0055319.pdf","paywalled","nonrandomized_study","HANSEUL CHO","2026","2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-2201-p","https://doi.org/10.2337/db26-2201-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055330","R0055330.pdf","paywalled","nonrandomized_study","Liang-Yuan Lin","2026","CO12 REAL-WORLD WEIGHT OUTCOMES FOLLOWING INITIATION OF GLP-1 RECEPTOR AGONIST ANTI-OBESITY MEDICATIONS IN A MISSISSIPPI MEDICAID POPULATION","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.107","https://doi.org/10.1016/j.jval.2026.03.107",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055333","R0055333.pdf","paywalled","nonrandomized_study","Carlos González-Merino","2026","GLP-1 receptor expression in a molecularly characterized cohort of endometrial carcinoma: Results from the GEICO 163-T/SPECTRUM study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2026.44.16_suppl.5625","https://doi.org/10.1200/jco.2026.44.16_suppl.5625",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055343","R0055343.pdf","paywalled","nonrandomized_study","YESTLE KIM","2026","1776-P: Early Real-World Liver Biomarker Changes among Resmetirom-Treated MASH Patients, with and without Concomitant GLP-1 Use: A Descriptive Cohort Study","Diabetes","American Diabetes Association","10.2337/db26-1776-p","https://doi.org/10.2337/db26-1776-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055347","R0055347.pdf","paywalled","nonrandomized_study","Alin Kalayjian","2026","CO86 RISK OF SEVERE GASTROINTESTINAL EVENTS IN COMMERCIALLY INSURED PATIENTS INITIATING GLP-1RAS FOR DIABETES MELLITUS AND OBESITY: A TARGET TRIAL EMULATION STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.181","https://doi.org/10.1016/j.jval.2026.03.181",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055403","R0055403.pdf","paywalled","nonrandomized_study","C. J. Fabian","2026","Abstract PS3-01-28: Effects of 6 Months of Tirzepatide on Risk Biomarkers for Development of Breast Cancer","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs25-ps3-01-28","https://doi.org/10.1158/1557-3265.sabcs25-ps3-01-28",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055418","R0055418.pdf","paywalled","nonrandomized_study","FRANCESCA LIM","2026","2073-P: Cost-Effectiveness of Tirzepatide among Adolescents with Recent-Onset Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-2073-p","https://doi.org/10.2337/db26-2073-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055420","R0055420.pdf","paywalled","nonrandomized_study","忠才 陈","2026","2350-P: Unmet Need in Post-Stroke Antidiabetic Treatment Patterns among Individuals Newly Diagnosed with Type 2 Diabetes (T2D) during Ischemic Stroke Hospitalization","Diabetes","American Diabetes Association","10.2337/db26-2350-p","https://doi.org/10.2337/db26-2350-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055430","R0055430.pdf","paywalled","nonrandomized_study","Dr. Kailash Singh Bisht*","2026","REVIEW OF TIRZEPATIDE AND CHROMIUM PICOLINATE FOR GLYCEMIC CONTROL AND WEIGHT LOSS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19332956","https://doi.org/10.5281/zenodo.19332956",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055446","R0055446.pdf","paywalled","nonrandomized_study","James Kimpton","2026","E144 Using social media data to understand the lived experience of people with psoriatic arthritis receiving biologic therapies and weight management interventions","Lara D. Veeken","Oxford University Press (OUP)","10.1093/rheumatology/keag121.366","https://doi.org/10.1093/rheumatology/keag121.366",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055451","R0055451.pdf","paywalled","nonrandomized_study","Anwar Zahran","2026","26-A-18955-ACC COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS FOR SECONDARY PREVENTION IN PATIENTS WITH T2DM AND PERIPHERAL ARTERY DISEASE: A RETROSPECTIVE COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.548","https://doi.org/10.1016/j.jacc.2026.02.548",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055460","R0055460.pdf","paywalled","nonrandomized_study","Serena Jingchuan Guo","2026","2647-P: GLP-1 Receptor Agonists (GLP-1RAs) and Clinical Outcomes of Binge Eating Disorders","Diabetes","American Diabetes Association","10.2337/db26-2647-p","https://doi.org/10.2337/db26-2647-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055474","R0055474.pdf","paywalled","nonrandomized_study","Aayma Irfan","2026","Neuroprotective Potential of Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Retrospective Cohort Study Using TriNetX (P3-3.013)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000217904","https://doi.org/10.1212/wnl.0000000000217904",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055476","R0055476.pdf","paywalled","nonrandomized_study","Xavier Jacq","2026","1802-P: Myo-004 Induces Body-Weight Loss in DIO at Thermoneutrality by Switching Metabolism from Fat to Carbohydrate Oxidation","Diabetes","American Diabetes Association","10.2337/db26-1802-p","https://doi.org/10.2337/db26-1802-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055478","R0055478.pdf","paywalled","nonrandomized_study","Sammy Saab","2026","HSD105 REAL-WORLD CLINICAL CHARACTERISTICS AND FACTORS ASSOCIATED WITH CONCURRENT GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) THERAPY AMONG PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) PRESCRIBED RESMETIROM","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.1342","https://doi.org/10.1016/j.jval.2026.03.1342",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055510","R0055510.pdf","paywalled","nonrandomized_study","YU N. WANG","2026","1977-P: Medical Spending Before and After GLP-1RA Initiation among Commercially Insured Adults Aged 18–64 Years with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1977-p","https://doi.org/10.2337/db26-1977-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055515","R0055515.pdf","paywalled","nonrandomized_study","M Souto","2026","The Blockbuster Drug and the Sluggish Stomach: A Case of Mistaken Blame?","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1822575","https://doi.org/10.1055/s-0046-1822575",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055520","R0055520.pdf","paywalled","nonrandomized_study","Rashwan Alameddine","2026","76142 GLP-1 receptor agonists and reduced risk of melanoma and nonmelanoma skin cancer (NMSC): A retrospective cohort study of patients with obesity","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.04.951","https://doi.org/10.1016/j.jaad.2026.04.951",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055569","R0055569.pdf","paywalled","nonrandomized_study","Hala Zakaria","2026","2701-LB: Independent Prognostic Value of the Novel Early Biomarker uPTM-FetA/Ucr in Diabetic Kidney Disease: Overcoming Treatment Confounders in a Real-World Cohort","Diabetes","American Diabetes Association","10.2337/db26-2701-lb","https://doi.org/10.2337/db26-2701-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055571","R0055571.pdf","paywalled","nonrandomized_study","Sammudeen Ibrahim","2026","900.06 Impact Of GLP-1 Receptor Agonist Use on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Propensity-Matched Analysis from a Global Federated Network","JACC: Cardiovascular Interventions","Elsevier BV","10.1016/j.jcin.2026.01.216","https://doi.org/10.1016/j.jcin.2026.01.216",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055604","R0055604.pdf","paywalled","nonrandomized_study","H. Aldahham","2026","Exploring the Outcomes of Tirzepatide in a Cohort of Kidney Transplant Recipients","American Journal of Transplantation","Elsevier BV","10.1016/j.ajt.2026.05.1255","https://doi.org/10.1016/j.ajt.2026.05.1255",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055608","R0055608.pdf","paywalled","nonrandomized_study","Katelyn Brown","2026","Exploring the Role of Microbiome Dysregulation in PCOS: Pathophysiology, and Emerging Therapies Toward Targeted and Personalized Treatment","RVU Elevate",null,"10.82451/k51016","https://doi.org/10.82451/k51016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055609","R0055609.pdf","paywalled","nonrandomized_study","Warren Peters","2026","P6 REAL-WORLD COMPARATIVE EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG VERSUS OTHER COMMERCIALLY AVAILABLE MEDICATIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH OBESITY IN THE UNITED STATES: A PRAGMATIC CLINICAL STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.021","https://doi.org/10.1016/j.jval.2026.03.021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055617","R0055617.pdf","paywalled","nonrandomized_study","Alessia Mihich","2026","Pharmacovigilance of Semaglutide and Liraglutide: A Narrative Review of Safety Profiles, Emerging Signals, and Risk Management Strategies","Indian Journal of Clinical Biochemistry","Springer Science and Business Media LLC","10.1007/s12291-026-01421-9","https://doi.org/10.1007/s12291-026-01421-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055638","R0055638.pdf","paywalled","nonrandomized_study","Rachel Whooten","2026","Disparities in Medication Treatment of Type 2 Diabetes and Obesity","PEDIATRICS","American Academy of Pediatrics (AAP)","10.1542/peds.2025-074840","https://doi.org/10.1542/peds.2025-074840","41765354","https://pubmed.ncbi.nlm.nih.gov/41765354/",null,null],["4","R0055668","R0055668.pdf","paywalled","nonrandomized_study","AMANDA R. PURCELL","2026","1729-P: Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital","Diabetes","American Diabetes Association","10.2337/db26-1729-p","https://doi.org/10.2337/db26-1729-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055682","R0055682.pdf","paywalled","nonrandomized_study","Arkadeep Dhali","2026","O42 Comparative effectiveness and gastrointestinal safety of orlistat versus liraglutide in obesity and type 2 diabetes adults: a real-world cohort study",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2026-bsg.41","https://doi.org/10.1136/gutjnl-2026-bsg.41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055688","R0055688.pdf","paywalled","nonrandomized_study","Matthew H. Lanehart","2026","Association between GLP-1 receptor agonists and nonscarring hair loss: a population-based, propensity score matched cohort analysis","Archives of Dermatological Research","Springer Science and Business Media LLC","10.1007/s00403-026-04603-w","https://doi.org/10.1007/s00403-026-04603-w",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055729","R0055729.pdf","paywalled","nonrandomized_study","Saisree Gollapudi","2026","Exploring the Phytochemicals from Gardenia jasminoides Ellis with GLP-1 Receptor Activation","Physiology","American Physiological Society","10.1152/physiol.2026.41.s1.2297278","https://doi.org/10.1152/physiol.2026.41.s1.2297278",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055751","R0055751.pdf","paywalled","nonrandomized_study","A Lohana","2026","B24-21 Glucagon Like Peptide 1 Receptor Agonists and Outcomes in Obese Adults With COPD","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1093/ajrccm/aamag162.1780","https://doi.org/10.1093/ajrccm/aamag162.1780",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055802","R0055802.pdf","paywalled","nonrandomized_study","H. Markus","2026","GLP-1 Receptor Agonists and Radiation Toxicity in Prostate Cancer: A Propensity-Matched Cohort Analysis","International Journal of Radiation Oncology*Biology*Physics","Elsevier BV","10.1016/j.ijrobp.2026.06.1191","https://doi.org/10.1016/j.ijrobp.2026.06.1191",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055813","R0055813.pdf","paywalled","nonrandomized_study","Fayez Salahedin Alkhateeb","2026","Semaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementation","SN Comprehensive Clinical Medicine","Springer Science and Business Media LLC","10.1007/s42399-026-02716-x","https://doi.org/10.1007/s42399-026-02716-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055866","R0055866.pdf","paywalled","nonrandomized_study","William George Oliver Hinton","2026","Cardiorenal Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes: Observations from Real-World Clinical Practice","University of Surrey Open Research repository",null,"10.15126/thesis.902256","https://doi.org/10.15126/thesis.902256",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055926","R0055926.pdf","paywalled","nonrandomized_study","Yotsapon Thewjitcharoen","2026","Effect of Tirzepatide in prediabetes remission among Thai people with obesity and prediabetes: A real-world study from a tertiary care in Bangkok",null,null,"10.13140/rg.2.2.27715.16160","https://doi.org/10.13140/rg.2.2.27715.16160",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056032","R0056032.pdf","paywalled","nonrandomized_study","PAKISTAN JOURNAL OF MEDICAL AND CARDIOLOGICAL REVIEW","2026","Real-World Pharmacovigilance Analysis of Suicidal Ideation and Self-Injurious Behavior Associated with GLP-1 Receptor Agonists: Disproportionality and Mechanistic Insights","Pakistan Journal of Medical & Cardiological Review",null,"10.5281/zenodo.23010672","https://doi.org/10.5281/zenodo.23010672",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056047","R0056047.pdf","paywalled","nonrandomized_study","Natalija Karpichina","2026","Pre-registered mechanistic prediction: VK2735 in VANQUISH-2 (NCT07104383)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23044760","https://doi.org/10.5281/zenodo.23044760",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07104383"],["4","R0056048","R0056048.pdf","paywalled","nonrandomized_study","ELIANA PEREIRA DE ARAUJO","2026","Spectrum of dermatological effects associated with GLP-1 and GIP receptor agonists: a scoping review","Open Science Framework",null,"10.17605/osf.io/4w5u6","https://doi.org/10.17605/osf.io/4w5u6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056120","R0056120.pdf","paywalled","nonrandomized_study","Syed Muntasir Mamun","2026","GLP-1 Receptor Agonism and Artificial Intelligence in Reward System Modulation and Human Agency Review of Del Valle (2026)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22992360","https://doi.org/10.5281/zenodo.22992360",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056124","R0056124.pdf","paywalled","nonrandomized_study","Ameera Zulfiqar","2026","Comparative Pharmacovigilance of GLP-1, Dual GIP/GLP-1, and SGLT-2 Receptor Agonists: A Complete 3×3 FAERS Disproportionality Analysis of Pancreatitis, Gastroparesis, and Diabetic Ketoacidosis Signals","Figshare",null,"10.6084/m9.figshare.33977968","https://doi.org/10.6084/m9.figshare.33977968",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056165","R0056165.pdf","paywalled","nonrandomized_study","Ashwin Yadhav Kumar","2026","Modernizing the Regional Research Data Engine: A Zero-Trust Operating Model to Close the \"Data-When-Needed\" & DevEx Gaps in the South West Secure Data Environment (SWSDE)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23135137","https://doi.org/10.5281/zenodo.23135137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056180","R0056180.pdf","paywalled","nonrandomized_study","Seiji Nishikage","2026","Ketosis and ketoacidosis reported with tirzepatide and semaglutide in JADER: overall and non-approved or inappropriate use","Figshare",null,"10.6084/m9.figshare.34021683","https://doi.org/10.6084/m9.figshare.34021683",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056181","R0056181.pdf","paywalled","nonrandomized_study","Zachary L. Smith","2026","Pre-Procedural SGLT2 Inhibitor Use and the Risk of Post-ERCP Adverse Events Among Patients With Type 2 Diabetes: A Prevalent-User Target Trial Emulation (The SGLT2i-PEP Study)","Open Science Framework",null,"10.17605/osf.io/yuhsg","https://doi.org/10.17605/osf.io/yuhsg",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"OSF:osf.io/jv7qy"],["4","R0056226","R0056226.pdf","paywalled","nonrandomized_study","Aishwarya Yannamani","2026","Abstract Tue182: Cardiometabolic Outcomes in Polycystic Ovary Syndrome With GLP-1 Receptor Agonists Versus Metformin: A Propensity-Matched Analysis","Circulation Research","Ovid Technologies (Wolters Kluwer Health)","10.1161/res.139.suppl_1.tue182","https://doi.org/10.1161/res.139.suppl_1.tue182",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056249","R0056249.pdf","paywalled","nonrandomized_study","Aishwarya Yannamani","2026","Abstract Tue181: Sex-Specific Incident Cardiovascular Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Added to Statins in Patients With Obesity, Without Diabetes, and With Coronary Artery Disease: A Propensity-Matched Cohort Study","Circulation Research","Ovid Technologies (Wolters Kluwer Health)","10.1161/res.139.suppl_1.tue181","https://doi.org/10.1161/res.139.suppl_1.tue181",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056304","R0056304.pdf","paywalled","nonrandomized_study","M. Lakhani","2026","P173 GLP-1 THERAPIES AND CARDIOVASCULAR OUTCOMES IN YOUNG-ONSET TYPE 2 DIABETES: A GLOBAL TARGET TRIAL EMULATION ACROSS 275 MILLION PATIENTS","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2026.07.166","https://doi.org/10.1016/j.cjca.2026.07.166",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056338","R0056338.pdf","paywalled","nonrandomized_study","Yoga Prasetyo","2026","Efektivitas Obat Generasi Baru (Amylin-based, CagriSema) dalam Mengelola Obesitas sebagai Penyakit Kronis","MUARA KESEHATAN Jurnal Ilmiah Ilmu Kesehatan",null,"10.64365/murakes.v2i3.365","https://doi.org/10.64365/murakes.v2i3.365",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056342","R0056342.pdf","paywalled","nonrandomized_study","Qiyang Pan","2026","1.23 Pharmacovigilance Analysis of Psychiatric Adverse Events Associated With Semaglutide and Liraglutide","Journal of the American Academy of Child & Adolescent Psychiatry","Elsevier BV","10.1016/j.jaac.2026.08.057","https://doi.org/10.1016/j.jaac.2026.08.057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056359","R0056359.pdf","paywalled","nonrandomized_study","AlObaid Abdulrahman","2026","Global Research Landscape of Diabetes Mellitus Type 2 in the SGLT2 Inhibitors and GLP-1 Receptor Agonists Era: A Bibliometric Analysis of The Top 1000 Publications","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1786306992","https://doi.org/10.24911/ijmdc.51-1786306992",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056437","R0056437.pdf","paywalled","nonrandomized_study","Mohammad Hesham Hoshmand","2026","A Novel Approach to Mitigating the Systemic Health Impacts of Postprandial Hyperglycemia","Kateb Journal of Medical Sciences and Biotechnology",null,"10.66943/kjmsb.v4i1.69","https://doi.org/10.66943/kjmsb.v4i1.69",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056447","R0056447.pdf","paywalled","nonrandomized_study","A. Al-Ani","2026","P318 MICROVASCULAR ISCHEMIC RISK ASSOCIATED WITH SEMAGLUTIDE: A GLOBAL POPULATION-BASED ANALYSIS OF OVER 30 MILLION SAFETY REPORTS","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2026.07.292","https://doi.org/10.1016/j.cjca.2026.07.292",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056461","R0056461.pdf","paywalled","nonrandomized_study","NOEL BARENGO","2026","Advancing Knowledge, Collaboration, and Impact—Highlights from the FIU 2025 Diabetes Awareness Day",null,"Florida International University","10.25148/fiuir.156","https://doi.org/10.25148/fiuir.156",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056467","R0056467.pdf","paywalled","nonrandomized_study","Sedra T. Alabed","2026","Disproportionate Reporting of Optic Ischemic Neuropathy in FAERS with GLP-1-Based Therapies Compared with SGLT2 Inhibitors","Neuro-Ophthalmology","Informa UK Limited","10.1080/01658107.2026.2741570","https://doi.org/10.1080/01658107.2026.2741570",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056468","R0056468.pdf","paywalled","nonrandomized_study","Angela T.H. Kwan","2026","Reply - Letter to the Editor - Signal Thresholds and Causal Inference in Pharmacovigilance Studies of Glucagon-like Peptide-1 Receptor Agonists","Clinical Nutrition","Elsevier BV","10.1016/j.clnu.2026.106809","https://doi.org/10.1016/j.clnu.2026.106809",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056523","R0056523.pdf","paywalled","nonrandomized_study","Coy Steel","2026","Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series","Journal of Ophthalmology and Advance Research","Athenaeum Scientific Publishers","10.46889/joar.2026.7306","https://doi.org/10.46889/joar.2026.7306",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056566","R0056566.pdf","paywalled","nonrandomized_study","Jesper Eriksson","2026","Preoperative GLP-1 receptor agonist versus DPP-4 inhibitor use and 30-day outcomes after non-cardiac surgery in adults with type 2 diabetes: a Swedish nationwide active-comparator cohort study","Open Science Framework",null,"10.17605/osf.io/bvfju","https://doi.org/10.17605/osf.io/bvfju",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056567","R0056567.pdf","paywalled","nonrandomized_study","Eli D. Ehrenpreis","2026","Cascades from a Drug (CFADs): Characterization of a Newly Described Pharmacovigilance Process","Open Science Framework",null,"10.17605/osf.io/qztg9","https://doi.org/10.17605/osf.io/qztg9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056578","R0056578.pdf","paywalled","nonrandomized_study","Madison Hayes","2026","FAERS Signal Triangulation: Verify Live Data Before Trusting PRR ≥2, n ≥3 Screens","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23305411","https://doi.org/10.5281/zenodo.23305411",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056602","R0056602.pdf","paywalled","nonrandomized_study","Steven E Kahn","2026","Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.","UNC Libraries",null,"10.17615/t892-3m21","https://doi.org/10.17615/t892-3m21",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056613","R0056613.pdf","paywalled","nonrandomized_study","Xianwen Wang","2026","Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data","European Archives of Oto-Rhino-Laryngology","Springer Science and Business Media LLC","10.1007/s00405-026-10708-9","https://doi.org/10.1007/s00405-026-10708-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056615","R0056615.pdf","paywalled","nonrandomized_study","Olivia G. Leonovicz","2026","Comparative Outcomes of GLP-1 Receptor Agonist Users vs Nonusers in Obese Patients Undergoing Body Contouring Surgery: A Propensity-Matched Cohort of 4,352 Patients",null,null,"10.13140/rg.2.2.20237.50403","https://doi.org/10.13140/rg.2.2.20237.50403",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056619","R0056619.pdf","paywalled","nonrandomized_study","Jesús Hernández","2026","Comparative Effects of GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs on Kidney Cancer Risk: A Target Trial Emulation in Post-Bariatric Patients","Epidemiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ede.0001280296.77292.d8","https://doi.org/10.1097/01.ede.0001280296.77292.d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056662","R0056662.pdf","paywalled","nonrandomized_study","Colette Cooper","2026","Incident Inflammatory Skin Conditions After GLP-1 Receptor Agonist Initiation: A Propensity Score–Matched TriNetX Cohort Study",null,null,"10.13140/rg.2.2.28498.31687","https://doi.org/10.13140/rg.2.2.28498.31687",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056673","R0056673.pdf","paywalled","nonrandomized_study","Motohiko Adomi","2026","Real-world Evidence of GLP-1 receptor agonists and Cardiovascular Outcomes among Diabetes: A Target Trial Emulation","Epidemiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ede.0001280828.22914.1e","https://doi.org/10.1097/01.ede.0001280828.22914.1e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056679","R0056679.pdf","paywalled","nonrandomized_study","Louis A Talay","2026","Weight change following discontinuation of a medicated digital weight loss program: a retrospective cohort study from Australia and the United Kingdom (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.113195","https://doi.org/10.2196/preprints.113195",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056707","R0056707.pdf","paywalled","nonrandomized_study","Xia Qu","2026","Previous bariatric surgery before knee arthroplasty: A cautious interpretation","Knee Surgery Sports Traumatology Arthroscopy","Wiley","10.1002/ksa.70640","https://doi.org/10.1002/ksa.70640",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056714","R0056714.pdf","paywalled","nonrandomized_study","Megan Lau","2026","Cross-sectional retrospective analysis assessing the role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa","Archives of Dermatological Research","Springer Science and Business Media LLC","10.1007/s00403-026-04968-y","https://doi.org/10.1007/s00403-026-04968-y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056715","R0056715.pdf","paywalled","nonrandomized_study","Rafeya V. Raquib","2026","Target Trial Emulation of Semaglutide vs Tirzepatide on Cardiovascular Outcomes in Patients with Obesity and Established CVD","Epidemiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ede.0001280036.48687.e9","https://doi.org/10.1097/01.ede.0001280036.48687.e9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056753","R0056753.pdf","paywalled","nonrandomized_study","Jéssica Coutinho Furtado","2026","Evidence on the Use of GLP-1 Receptor Agonists to Dual GIP/GLP-1 Receptor Agonists in the Management of Obstructive Sleep Apnea: A Scoping Review","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/ns74u","https://doi.org/10.17605/osf.io/ns74u",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0057003","R0057003.pdf","paywalled","nonrandomized_study","Wasden K","2026","Disparities in Prescription of Long-Acting GLP-1s.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70152","https://doi.org/10.1002/oby.70152","41771653","https://pubmed.ncbi.nlm.nih.gov/41771653/",null,null],["4","R0000390","R0000390.pdf","paywalled","nonrandomized_study","Weng J","2025","Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-025-09344-w","https://doi.org/10.1007/s10620-025-09344-w","40830314","https://pubmed.ncbi.nlm.nih.gov/40830314/",null,null],["4","R0000452","R0000452.pdf","paywalled","nonrandomized_study","Gala K","2025","Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use.","Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus","Oxford University Press (OUP)","10.1093/dote/doaf109","https://doi.org/10.1093/dote/doaf109","41343723","https://pubmed.ncbi.nlm.nih.gov/41343723/",null,null],["4","R0000593","R0000593.pdf","paywalled","nonrandomized_study","Yau K","2025","Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease.","Diabetes care","American Diabetes Association","10.2337/dc24-2811","https://doi.org/10.2337/dc24-2811","40569823","https://pubmed.ncbi.nlm.nih.gov/40569823/",null,null],["4","R0000683","R0000683.pdf","paywalled","nonrandomized_study","Imbroane MR","2025","Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes.","American journal of obstetrics and gynecology","Elsevier BV","10.1016/j.ajog.2025.01.019","https://doi.org/10.1016/j.ajog.2025.01.019","39848396","https://pubmed.ncbi.nlm.nih.gov/39848396/",null,null],["4","R0000932","R0000932.pdf","paywalled","nonrandomized_study","Metoyer G","2025","Utilization and Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients.","Clinical transplantation","Wiley","10.1111/ctr.70354","https://doi.org/10.1111/ctr.70354","41123471","https://pubmed.ncbi.nlm.nih.gov/41123471/",null,null],["4","R0001003","R0001003.pdf","paywalled","nonrandomized_study","Khalil S","2025","Association of Glucagon-Like Peptide-1 Receptor Agonist with Incident Atrial Fibrillation.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-025-00751-y","https://doi.org/10.1007/s40256-025-00751-y","40682632","https://pubmed.ncbi.nlm.nih.gov/40682632/",null,null],["4","R0001182","R0001182.pdf","paywalled","nonrandomized_study","Liang J","2025","Postoperative Outcomes in Body Contouring Procedures Following Glucagon-Like Peptide-1 Receptor Agonist Use: A 10-Year Analysis.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjaf029","https://doi.org/10.1093/asj/sjaf029","39960861","https://pubmed.ncbi.nlm.nih.gov/39960861/",null,null],["4","R0001223","R0001223.pdf","paywalled","nonrandomized_study","Liu L","2025","GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy: What an Endocrinologist Needs to Know.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf541","https://doi.org/10.1210/clinem/dgaf541","41022666","https://pubmed.ncbi.nlm.nih.gov/41022666/",null,null],["4","R0001253","R0001253.pdf","paywalled","nonrandomized_study","Frazier RD","2025","Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms.","Expert review of gastroenterology & hepatology","Informa UK Limited","10.1080/17474124.2025.2579117","https://doi.org/10.1080/17474124.2025.2579117","41138239","https://pubmed.ncbi.nlm.nih.gov/41138239/",null,null],["4","R0001265","R0001265.pdf","paywalled","nonrandomized_study","Zhou J","2025","Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-04112-8","https://doi.org/10.1007/s12020-024-04112-8","39578328","https://pubmed.ncbi.nlm.nih.gov/39578328/",null,null],["4","R0001308","R0001308.pdf","paywalled","nonrandomized_study","Gupta N","2025","Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.8926","https://doi.org/10.36849/jdd.8926","40911751","https://pubmed.ncbi.nlm.nih.gov/40911751/",null,null],["4","R0001340","R0001340.pdf","paywalled","nonrandomized_study","Mondoh A","2025","Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2601060","https://doi.org/10.1080/14656566.2025.2601060","41351384","https://pubmed.ncbi.nlm.nih.gov/41351384/",null,null],["4","R0001371","R0001371.pdf","paywalled","nonrandomized_study","Elangovan A","2025","Rates of repeat EGD in nondiabetic adults with glucagon-like peptide-1 receptor agonist prescription: a retrospective matched cohort study.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.10.004","https://doi.org/10.1016/j.gie.2024.10.004","39389433","https://pubmed.ncbi.nlm.nih.gov/39389433/",null,null],["4","R0001406","R0001406.pdf","paywalled","nonrandomized_study","Panou T","2025","Orforglipron in type 2 diabetes mellitus and obesity: an overview.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2025.2594493","https://doi.org/10.1080/17512433.2025.2594493","41275408","https://pubmed.ncbi.nlm.nih.gov/41275408/",null,null],["4","R0001456","R0001456.pdf","paywalled","nonrandomized_study","Nielsen J","2025","Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izae276","https://doi.org/10.1093/ibd/izae276","39603814","https://pubmed.ncbi.nlm.nih.gov/39603814/",null,null],["4","R0001586","R0001586.pdf","paywalled","nonrandomized_study","Lahey AM","2025","Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus.","Pharmacotherapy","Wiley","10.1002/phar.70009","https://doi.org/10.1002/phar.70009","40108854","https://pubmed.ncbi.nlm.nih.gov/40108854/",null,null],["4","R0001602","R0001602.pdf","paywalled","nonrandomized_study","C Palmer R","2025","GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","Springer Science and Business Media LLC","10.1007/s00590-025-04604-x","https://doi.org/10.1007/s00590-025-04604-x","41351714","https://pubmed.ncbi.nlm.nih.gov/41351714/",null,null],["4","R0001735","R0001735.pdf","paywalled","nonrandomized_study","Hsu YH","2025","Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112995","https://doi.org/10.1016/j.diabres.2025.112995","41218687","https://pubmed.ncbi.nlm.nih.gov/41218687/",null,null],["4","R0001739","R0001739.pdf","paywalled","nonrandomized_study","Katzman JL","2025","Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.02.042","https://doi.org/10.1016/j.arth.2025.02.042","40087066","https://pubmed.ncbi.nlm.nih.gov/40087066/",null,null],["4","R0001776","R0001776.pdf","paywalled","nonrandomized_study","Dev B","2025","Low Rates of Aborted Endoscopy Due to Gastric Food Retention in Patients on Glucagon-Like-Peptide-1 Receptor Agonists.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-025-08915-1","https://doi.org/10.1007/s10620-025-08915-1","40021603","https://pubmed.ncbi.nlm.nih.gov/40021603/",null,null],["4","R0001809","R0001809.pdf","paywalled","nonrandomized_study","Al-Moussally F","2025","Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-025-02177-x","https://doi.org/10.1007/s40265-025-02177-x","40223043","https://pubmed.ncbi.nlm.nih.gov/40223043/",null,null],["4","R0001890","R0001890.pdf","paywalled","nonrandomized_study","Yen FS","2025","Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70034","https://doi.org/10.1111/dom.70034","40859767","https://pubmed.ncbi.nlm.nih.gov/40859767/",null,null],["4","R0002014","R0002014.pdf","paywalled","nonrandomized_study","Kuo CC","2025","Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-025-06453-z","https://doi.org/10.1007/s00125-025-06453-z","40471238","https://pubmed.ncbi.nlm.nih.gov/40471238/",null,null],["4","R0002175","R0002175.pdf","paywalled","nonrandomized_study","Blumenfeld L","2025","Use of glucagon-like peptide 1 receptor agonist to sustain patients off basal-bolus insulin regimens.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2024.102288","https://doi.org/10.1016/j.japh.2024.102288","39527981","https://pubmed.ncbi.nlm.nih.gov/39527981/",null,null],["4","R0002196","R0002196.pdf","paywalled","nonrandomized_study","Wiener JM","2025","Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005283","https://doi.org/10.1097/brs.0000000000005283","39895110","https://pubmed.ncbi.nlm.nih.gov/39895110/",null,null],["4","R0002230","R0002230.pdf","paywalled","nonrandomized_study","Siddiqi TJ","2025","Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.70048","https://doi.org/10.1002/ejhf.70048","40977256","https://pubmed.ncbi.nlm.nih.gov/40977256/",null,null],["4","R0002278","R0002278.pdf","paywalled","nonrandomized_study","Hanif M","2025","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 Diabetes.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2025.03.013","https://doi.org/10.1016/j.amjcard.2025.03.013","40107335","https://pubmed.ncbi.nlm.nih.gov/40107335/",null,null],["4","R0002332","R0002332.pdf","paywalled","nonrandomized_study","Hisada H","2025","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Retained Gastric Contents During Esophagogastroduodenoscopy: A Propensity Score-Matched Study.","Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","Wiley","10.1111/den.70016","https://doi.org/10.1111/den.70016","40819843","https://pubmed.ncbi.nlm.nih.gov/40819843/",null,null],["4","R0002345","R0002345.pdf","paywalled","nonrandomized_study","Wang JL","2025","GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112324","https://doi.org/10.1016/j.diabres.2025.112324","40505816","https://pubmed.ncbi.nlm.nih.gov/40505816/",null,null],["4","R0002355","R0002355.pdf","paywalled","nonrandomized_study","Yen FS","2025","Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112328","https://doi.org/10.1016/j.diabres.2025.112328","40532767","https://pubmed.ncbi.nlm.nih.gov/40532767/",null,null],["4","R0002357","R0002357.pdf","paywalled","nonrandomized_study","Milad C","2025","Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.","Medicina clinica","Elsevier BV","10.1016/j.medcli.2025.107153","https://doi.org/10.1016/j.medcli.2025.107153","40865274","https://pubmed.ncbi.nlm.nih.gov/40865274/",null,null],["4","R0002392","R0002392.pdf","paywalled","nonrandomized_study","Kelly CA","2025","Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae722","https://doi.org/10.1210/clinem/dgae722","39400117","https://pubmed.ncbi.nlm.nih.gov/39400117/",null,null],["4","R0002442","R0002442.pdf","paywalled","nonrandomized_study","Pérez López G","2025","GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.","Medicina clinica","Elsevier BV","10.1016/j.medcli.2025.107122","https://doi.org/10.1016/j.medcli.2025.107122","40716192","https://pubmed.ncbi.nlm.nih.gov/40716192/",null,null],["4","R0002463","R0002463.pdf","paywalled","nonrandomized_study","Chen WM","2025","GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112407","https://doi.org/10.1016/j.diabres.2025.112407","40803507","https://pubmed.ncbi.nlm.nih.gov/40803507/",null,null],["4","R0002520","R0002520.pdf","paywalled","nonrandomized_study","Go CC","2025","Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease.","Journal of vascular surgery","Elsevier BV","10.1016/j.jvs.2025.05.037","https://doi.org/10.1016/j.jvs.2025.05.037","40484062","https://pubmed.ncbi.nlm.nih.gov/40484062/",null,null],["4","R0002558","R0002558.pdf","paywalled","nonrandomized_study","Ahmed F","2025","Racial/ethnic differences in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for atherosclerotic cardiovascular disease (ASCVD) benefit in patients with type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2025.2606551","https://doi.org/10.1080/03007995.2025.2606551","41427774","https://pubmed.ncbi.nlm.nih.gov/41427774/",null,null],["4","R0002585","R0002585.pdf","paywalled","nonrandomized_study","Luo ZY","2025","Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2024.2419989","https://doi.org/10.1080/14740338.2024.2419989","39425661","https://pubmed.ncbi.nlm.nih.gov/39425661/",null,null],["4","R0002632","R0002632.pdf","paywalled","nonrandomized_study","Sontam T","2025","Glucagon-like peptide-1 receptor agonist use in patients with psoriasis is associated with lower incidence of atherosclerotic cardiovascular disease: A retrospective cohort study using TriNetX.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.06.022","https://doi.org/10.1016/j.jaad.2025.06.022","40513888","https://pubmed.ncbi.nlm.nih.gov/40513888/",null,null],["4","R0002647","R0002647.pdf","paywalled","nonrandomized_study","Pérez-Velasco MA","2025","Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.","Medicina clinica","Elsevier BV","10.1016/j.medcli.2025.107019","https://doi.org/10.1016/j.medcli.2025.107019","40466271","https://pubmed.ncbi.nlm.nih.gov/40466271/",null,null],["4","R0002653","R0002653.pdf","paywalled","nonrandomized_study","Liu BD","2025","Glucagon-like Peptide-1 Receptor Agonists Are Associated With Improved Survival and Reduced Liver-Related Events in Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease: A Large Real-World Retrospective Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.04.017","https://doi.org/10.1016/j.eprac.2025.04.017","40306364","https://pubmed.ncbi.nlm.nih.gov/40306364/",null,null],["4","R0002662","R0002662.pdf","paywalled","nonrandomized_study","Agarwal S","2025","Author's response to the Letter to the Editor \"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy\".","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109143","https://doi.org/10.1016/j.jdiacomp.2025.109143","40721363","https://pubmed.ncbi.nlm.nih.gov/40721363/",null,null],["4","R0002679","R0002679.pdf","paywalled","nonrandomized_study","Borrás-Blasco J","2025","Letter to the Editor \"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy\".","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109134","https://doi.org/10.1016/j.jdiacomp.2025.109134","40750509","https://pubmed.ncbi.nlm.nih.gov/40750509/",null,null],["4","R0002690","R0002690.pdf","paywalled","nonrandomized_study","Almeida OP","2025","Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Current opinion in psychiatry","Ovid Technologies (Wolters Kluwer Health)","10.1097/yco.0000000000001001","https://doi.org/10.1097/yco.0000000000001001","40009763","https://pubmed.ncbi.nlm.nih.gov/40009763/",null,null],["4","R0002699","R0002699.pdf","paywalled","nonrandomized_study","Abu-Freha N","2025","Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy.","Endoscopy","Georg Thieme Verlag KG","10.1055/a-2419-3875","https://doi.org/10.1055/a-2419-3875","39389565","https://pubmed.ncbi.nlm.nih.gov/39389565/",null,null],["4","R0002707","R0002707.pdf","paywalled","nonrandomized_study","Noh Y","2025","Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-03420","https://doi.org/10.7326/annals-24-03420","40658955","https://pubmed.ncbi.nlm.nih.gov/40658955/",null,null],["4","R0002734","R0002734.pdf","paywalled","nonrandomized_study","Trenas A","2025","Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2025.06.007","https://doi.org/10.1016/j.ejim.2025.06.007","40518344","https://pubmed.ncbi.nlm.nih.gov/40518344/",null,null],["4","R0002742","R0002742.pdf","paywalled","nonrandomized_study","Liu G","2025","Navigating compounded semaglutide: what health care providers need to know.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2025.89787","https://doi.org/10.37765/ajmc.2025.89787","40966636","https://pubmed.ncbi.nlm.nih.gov/40966636/",null,null],["4","R0002771","R0002771.pdf","paywalled","nonrandomized_study","Titus J","2025","Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-025-01558-1","https://doi.org/10.1007/s40264-025-01558-1","40587039","https://pubmed.ncbi.nlm.nih.gov/40587039/",null,null],["4","R0002779","R0002779.pdf","paywalled","nonrandomized_study","Morningstar J","2025","Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes following ankle fracture open reduction and internal fixation.","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Elsevier BV","10.1053/j.jfas.2025.05.002","https://doi.org/10.1053/j.jfas.2025.05.002","40345639","https://pubmed.ncbi.nlm.nih.gov/40345639/",null,null],["4","R0002849","R0002849.pdf","paywalled","nonrandomized_study","Sahi SS","2025","Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2025.02.020","https://doi.org/10.1016/j.eprac.2025.02.020","40054529","https://pubmed.ncbi.nlm.nih.gov/40054529/",null,null],["4","R0002891","R0002891.pdf","paywalled","nonrandomized_study","Luc G","2025","Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08258-w","https://doi.org/10.1007/s11695-025-08258-w","40931278","https://pubmed.ncbi.nlm.nih.gov/40931278/",null,null],["4","R0002918","R0002918.pdf","paywalled","nonrandomized_study","Xie Y","2025","Mapping the effectiveness and risks of GLP-1 receptor agonists.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-024-03412-w","https://doi.org/10.1038/s41591-024-03412-w","39833406","https://pubmed.ncbi.nlm.nih.gov/39833406/",null,null],["4","R0002928","R0002928.pdf","paywalled","nonrandomized_study","Chen JY","2025","Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112339","https://doi.org/10.1016/j.diabres.2025.112339","40581158","https://pubmed.ncbi.nlm.nih.gov/40581158/",null,null],["4","R0002937","R0002937.pdf","paywalled","nonrandomized_study","Ranson R","2025","GLP-1 agonists are protective against postoperative complications following total knee arthroplasty.","The Knee","Elsevier BV","10.1016/j.knee.2025.08.007","https://doi.org/10.1016/j.knee.2025.08.007","40834675","https://pubmed.ncbi.nlm.nih.gov/40834675/",null,null],["4","R0002957","R0002957.pdf","paywalled","nonrandomized_study","Maceroni M","2025","Non arteritic ischemic optic neuropathy in a patient taking semaglutide: Is there a relation? A case report and a review of the literature.","European journal of ophthalmology","SAGE Publications","10.1177/11206721251331655","https://doi.org/10.1177/11206721251331655","40183385","https://pubmed.ncbi.nlm.nih.gov/40183385/",null,null],["4","R0002986","R0002986.pdf","paywalled","nonrandomized_study","Khong J","2025","New Contours, Different Risks: A 9-Year Comparison of Trends and Postoperative Complications in Patients Undergoing Aesthetic Surgery With Previous Bariatric Surgery Vs Glucagon-Like Peptide 1 Receptor Agonist Use.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjaf131","https://doi.org/10.1093/asj/sjaf131","40692274","https://pubmed.ncbi.nlm.nih.gov/40692274/",null,null],["4","R0003005","R0003005.pdf","paywalled","nonrandomized_study","Adeniran O","2025","Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70001","https://doi.org/10.1002/oby.70001","40855971","https://pubmed.ncbi.nlm.nih.gov/40855971/",null,null],["4","R0003093","R0003093.pdf","paywalled","nonrandomized_study","Patel H","2025","Long-Term Impact of GLP-1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients.","Journal of cardiovascular electrophysiology","Wiley","10.1111/jce.16737","https://doi.org/10.1111/jce.16737","40406931","https://pubmed.ncbi.nlm.nih.gov/40406931/",null,null],["4","R0003124","R0003124.pdf","paywalled","nonrandomized_study","Odah T","2025","Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.07.014","https://doi.org/10.1016/j.gie.2024.07.014","39094916","https://pubmed.ncbi.nlm.nih.gov/39094916/",null,null],["4","R0003131","R0003131.pdf","paywalled","nonrandomized_study","Burke O","2025","Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.01.046","https://doi.org/10.1016/j.jaad.2025.01.046","39863171","https://pubmed.ncbi.nlm.nih.gov/39863171/",null,null],["4","R0003172","R0003172.pdf","paywalled","nonrandomized_study","Talebi R","2025","Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.","Retina (Philadelphia, Pa.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/iae.0000000000004507","https://doi.org/10.1097/iae.0000000000004507","40334190","https://pubmed.ncbi.nlm.nih.gov/40334190/",null,null],["4","R0003202","R0003202.pdf","paywalled","nonrandomized_study","Nassar M","2025","Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101613","https://doi.org/10.1016/j.diabet.2025.101613","39826595","https://pubmed.ncbi.nlm.nih.gov/39826595/",null,null],["4","R0003204","R0003204.pdf","paywalled","nonrandomized_study","Ghali A","2025","The Use of Semaglutide in Patients Undergoing Lumbar Fusion Does not Increase 90-Day Medical or 1-Year Implant Complications.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000001800","https://doi.org/10.1097/bsd.0000000000001800","40096579","https://pubmed.ncbi.nlm.nih.gov/40096579/",null,null],["4","R0003205","R0003205.pdf","paywalled","nonrandomized_study","Wu CC","2025","Reduced risks of colorectal cancer with GLP-1RAs in type 2 diabetes: A nationwide cohort study using a target trial emulation framework.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101695","https://doi.org/10.1016/j.diabet.2025.101695","40796052","https://pubmed.ncbi.nlm.nih.gov/40796052/",null,null],["4","R0003211","R0003211.pdf","paywalled","nonrandomized_study","Luna-Ceron E","2025","Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes.","Cardiovascular & hematological disorders drug targets","Bentham Science Publishers Ltd.","10.2174/011871529x421551250801194823","https://doi.org/10.2174/011871529x421551250801194823","40798974","https://pubmed.ncbi.nlm.nih.gov/40798974/",null,null],["4","R0003229","R0003229.pdf","paywalled","nonrandomized_study","Grosicki GJ","2025","Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16151","https://doi.org/10.1111/dom.16151","39743934","https://pubmed.ncbi.nlm.nih.gov/39743934/",null,null],["4","R0003282","R0003282.pdf","paywalled","nonrandomized_study","Clarke L","2025","Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-025-08964-6","https://doi.org/10.1007/s10620-025-08964-6","40069510","https://pubmed.ncbi.nlm.nih.gov/40069510/",null,null],["4","R0003308","R0003308.pdf","paywalled","nonrandomized_study","Cho SW","2025","Glucagon-like peptide-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men: A retrospective cohort study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.02.009","https://doi.org/10.1016/j.jaad.2025.02.009","39923849","https://pubmed.ncbi.nlm.nih.gov/39923849/",null,null],["4","R0003333","R0003333.pdf","paywalled","nonrandomized_study","Friesch M","2025","Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-11838-7","https://doi.org/10.1007/s00464-025-11838-7","40490579","https://pubmed.ncbi.nlm.nih.gov/40490579/",null,null],["4","R0003379","R0003379.pdf","paywalled","nonrandomized_study","Gala K","2025","Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.11.024","https://doi.org/10.1016/j.gie.2024.11.024","39557200","https://pubmed.ncbi.nlm.nih.gov/39557200/",null,null],["4","R0003394","R0003394.pdf","paywalled","nonrandomized_study","Pradhan R","2025","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc24-1903","https://doi.org/10.2337/dc24-1903","39774820","https://pubmed.ncbi.nlm.nih.gov/39774820/",null,null],["4","R0003415","R0003415.pdf","paywalled","nonrandomized_study","Postlethwaite R","2025","Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Elsevier BV","10.1016/j.pan.2025.06.018","https://doi.org/10.1016/j.pan.2025.06.018","40695708","https://pubmed.ncbi.nlm.nih.gov/40695708/",null,null],["4","R0003428","R0003428.pdf","paywalled","nonrandomized_study","Burke CA","2025","Colonoscopy preparation adequacy in glucagon-like peptide-1 receptor agonist users: the jury is still out.","Endoscopy","Georg Thieme Verlag KG","10.1055/a-2461-3899","https://doi.org/10.1055/a-2461-3899","39577846","https://pubmed.ncbi.nlm.nih.gov/39577846/",null,null],["4","R0003510","R0003510.pdf","paywalled","nonrandomized_study","Roberts DW","2025","Total Knee Arthroplasty and Morbid Obesity: Is There a Glimmer of Hope?: Commentary on an article by Billy I. Kim, MD, et al.: \"Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA\".","The Journal of bone and joint surgery. American volume","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.24.01050","https://doi.org/10.2106/jbjs.24.01050","39969496","https://pubmed.ncbi.nlm.nih.gov/39969496/",null,null],["4","R0003545","R0003545.pdf","paywalled","nonrandomized_study","Chen TH","2025","Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-024-02443-6","https://doi.org/10.1007/s00592-024-02443-6","39812791","https://pubmed.ncbi.nlm.nih.gov/39812791/",null,null],["4","R0003565","R0003565.pdf","paywalled","nonrandomized_study","Xiao Y","2025","Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-024-02415-w","https://doi.org/10.1007/s00592-024-02415-w","39556224","https://pubmed.ncbi.nlm.nih.gov/39556224/",null,null],["4","R0003670","R0003670.pdf","paywalled","nonrandomized_study","Yakubu I","2025","Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000005361","https://doi.org/10.1097/tp.0000000000005361","40128152","https://pubmed.ncbi.nlm.nih.gov/40128152/",null,null],["4","R0003769","R0003769.pdf","paywalled","nonrandomized_study","Ratzki-Leewing A","2025","FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16266","https://doi.org/10.1111/dom.16266","40117297","https://pubmed.ncbi.nlm.nih.gov/40117297/",null,null],["4","R0003848","R0003848.pdf","paywalled","nonrandomized_study","Saturnino A","2025","Searching the Crystal Ball for Tailored GLP-1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70017","https://doi.org/10.1002/dmrr.70017","39673731","https://pubmed.ncbi.nlm.nih.gov/39673731/",null,null],["4","R0003886","R0003886.pdf","paywalled","nonrandomized_study","Shan X","2025","GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2024.09.013","https://doi.org/10.1016/j.soard.2024.09.013","39482214","https://pubmed.ncbi.nlm.nih.gov/39482214/",null,null],["4","R0003915","R0003915.pdf","paywalled","nonrandomized_study","Quinn JA","2025","Perioperative glucagon-like peptide-1 receptor agonist use and retained gastric contents: A retrospective analysis of patients undergoing elective upper endoscopy.","Journal of clinical anesthesia","Elsevier BV","10.1016/j.jclinane.2025.111776","https://doi.org/10.1016/j.jclinane.2025.111776","39951938","https://pubmed.ncbi.nlm.nih.gov/39951938/",null,null],["4","R0004028","R0004028.pdf","paywalled","nonrandomized_study","Ferrara F","2025","Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-025-04319-0","https://doi.org/10.1007/s00210-025-04319-0","40515833","https://pubmed.ncbi.nlm.nih.gov/40515833/",null,null],["4","R0004030","R0004030.pdf","paywalled","nonrandomized_study","Triplett JD","2025","GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000213916","https://doi.org/10.1212/wnl.0000000000213916","40694751","https://pubmed.ncbi.nlm.nih.gov/40694751/",null,null],["4","R0004046","R0004046.pdf","paywalled","nonrandomized_study","Chen YT","2025","[Comparison of the effects of intensified lifestyle and glucagon-like peptide-1 receptor agonist combined with lifestyle intervention on body composition in adult patients with overweight or obesity].","Zhonghua yi xue za zhi",null,"10.3760/cma.j.cn112137-20250305-00530","https://doi.org/10.3760/cma.j.cn112137-20250305-00530","41083404","https://pubmed.ncbi.nlm.nih.gov/41083404/",null,null],["4","R0004069","R0004069.pdf","paywalled","nonrandomized_study","Maideen NMP","2025","Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/0115748863301925240507044637","https://doi.org/10.2174/0115748863301925240507044637","38766830","https://pubmed.ncbi.nlm.nih.gov/38766830/",null,null],["4","R0004082","R0004082.pdf","paywalled","nonrandomized_study","Grosicki GJ","2025","Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference.","American journal of physiology. Heart and circulatory physiology","American Physiological Society","10.1152/ajpheart.00809.2024","https://doi.org/10.1152/ajpheart.00809.2024","39705534","https://pubmed.ncbi.nlm.nih.gov/39705534/",null,null],["4","R0004113","R0004113.pdf","paywalled","nonrandomized_study","Daniel S","2025","A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.8605","https://doi.org/10.36849/jdd.8605","40196945","https://pubmed.ncbi.nlm.nih.gov/40196945/",null,null],["4","R0004276","R0004276.pdf","paywalled","nonrandomized_study","Nassar M","2025","Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-024-02466-4","https://doi.org/10.1007/s40618-024-02466-4","39302577","https://pubmed.ncbi.nlm.nih.gov/39302577/",null,null],["4","R0004299","R0004299.pdf","paywalled","nonrandomized_study","Wade FG","2025","Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation.","Clinical transplantation","Wiley","10.1111/ctr.70344","https://doi.org/10.1111/ctr.70344","41075262","https://pubmed.ncbi.nlm.nih.gov/41075262/",null,null],["4","R0004329","R0004329.pdf","paywalled","nonrandomized_study","Sudhoff H","2025","First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.","European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","Springer Science and Business Media LLC","10.1007/s00405-025-09604-5","https://doi.org/10.1007/s00405-025-09604-5","40721956","https://pubmed.ncbi.nlm.nih.gov/40721956/",null,null],["4","R0004361","R0004361.pdf","paywalled","nonrandomized_study","Yang X","2025","Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70144","https://doi.org/10.1111/dom.70144","40994081","https://pubmed.ncbi.nlm.nih.gov/40994081/",null,null],["4","R0004482","R0004482.pdf","paywalled","nonrandomized_study","Jeter AF","2025","Predictors of Use of Individual Insulin and GLP-1 RA Products Versus Fixed Ratio Insulin/GLP-1 RA Combinations in Medicare Beneficiaries.","The Senior care pharmacist","American Society of Consultant Pharmacists","10.4140/tcp.n.2025.97","https://doi.org/10.4140/tcp.n.2025.97","39891325","https://pubmed.ncbi.nlm.nih.gov/39891325/",null,null],["4","R0004506","R0004506.pdf","paywalled","nonrandomized_study","Lawand JJ","2025","Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty.","Journal of shoulder and elbow surgery","Elsevier BV","10.1016/j.jse.2024.09.012","https://doi.org/10.1016/j.jse.2024.09.012","39528042","https://pubmed.ncbi.nlm.nih.gov/39528042/",null,null],["4","R0004648","R0004648.pdf","paywalled","nonrandomized_study","Zhou J","2025","The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System.","British journal of clinical pharmacology","Wiley","10.1111/bcp.16354","https://doi.org/10.1111/bcp.16354","39658840","https://pubmed.ncbi.nlm.nih.gov/39658840/",null,null],["4","R0004662","R0004662.pdf","paywalled","nonrandomized_study","Tolkacheva EV","2025","\"Next-in-class\" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0109298673366258250710101146","https://doi.org/10.2174/0109298673366258250710101146","40873282","https://pubmed.ncbi.nlm.nih.gov/40873282/",null,null],["4","R0004665","R0004665.pdf","paywalled","nonrandomized_study","Rayman S","2025","Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2024.09.010","https://doi.org/10.1016/j.soard.2024.09.010","39516068","https://pubmed.ncbi.nlm.nih.gov/39516068/",null,null],["4","R0004666","R0004666.pdf","paywalled","nonrandomized_study","McLaughlin SA","2025","IMPACT OF GLP-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES MELLITUS ON THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION.","Retina (Philadelphia, Pa.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/iae.0000000000004616","https://doi.org/10.1097/iae.0000000000004616","40712124","https://pubmed.ncbi.nlm.nih.gov/40712124/",null,null],["4","R0004715","R0004715.pdf","paywalled","nonrandomized_study","Kumar A","2025","MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.73.1058","https://doi.org/10.59556/japi.73.1058","40836732","https://pubmed.ncbi.nlm.nih.gov/40836732/",null,null],["4","R0004745","R0004745.pdf","paywalled","nonrandomized_study","Saeed A","2025","Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-00775","https://doi.org/10.7326/annals-24-00775","40523289","https://pubmed.ncbi.nlm.nih.gov/40523289/",null,null],["4","R0004792","R0004792.pdf","paywalled","nonrandomized_study","Yun B","2025","Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP-1RA in CHB and T2DM Patients.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.70060","https://doi.org/10.1111/liv.70060","40257422","https://pubmed.ncbi.nlm.nih.gov/40257422/",null,null],["4","R0004793","R0004793.pdf","paywalled","nonrandomized_study","Rothman SM","2025","Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-025-01551-8","https://doi.org/10.1007/s40264-025-01551-8","40347221","https://pubmed.ncbi.nlm.nih.gov/40347221/",null,null],["4","R0004829","R0004829.pdf","paywalled","nonrandomized_study","Pourabhari Langroudi A","2025","Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-025-01061-2","https://doi.org/10.1038/s41443-025-01061-2","40240532","https://pubmed.ncbi.nlm.nih.gov/40240532/",null,null],["4","R0004844","R0004844.pdf","paywalled","nonrandomized_study","Hu Y","2025","Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-024-03082-7","https://doi.org/10.1007/s12325-024-03082-7","39680313","https://pubmed.ncbi.nlm.nih.gov/39680313/",null,null],["4","R0004932","R0004932.pdf","paywalled","nonrandomized_study","Muayad J","2025","Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2024.08.023","https://doi.org/10.1016/j.ophtha.2024.08.023","39182626","https://pubmed.ncbi.nlm.nih.gov/39182626/",null,null],["4","R0004995","R0004995.pdf","paywalled","nonrandomized_study","Haddy N","2025","Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","Springer Science and Business Media LLC","10.1007/s40259-024-00699-6","https://doi.org/10.1007/s40259-024-00699-6","39930059","https://pubmed.ncbi.nlm.nih.gov/39930059/",null,null],["4","R0005049","R0005049.pdf","paywalled","nonrandomized_study","Huo Y","2025","Data mining study on adverse events of tirzepatide based on FAERS database.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2024.2376686","https://doi.org/10.1080/14740338.2024.2376686","39007672","https://pubmed.ncbi.nlm.nih.gov/39007672/",null,null],["4","R0005113","R0005113.pdf","paywalled","nonrandomized_study","Anderson SR","2025","Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003208","https://doi.org/10.14309/ajg.0000000000003208","39717004","https://pubmed.ncbi.nlm.nih.gov/39717004/",null,null],["4","R0005158","R0005158.pdf","paywalled","nonrandomized_study","Fano A","2025","GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005598","https://doi.org/10.1097/brs.0000000000005598","41400023","https://pubmed.ncbi.nlm.nih.gov/41400023/",null,null],["4","R0005166","R0005166.pdf","paywalled","nonrandomized_study","Hu WS","2025","Effect of anti-diabetic agent on interstitial lung disease in patients with diabetes mellitus.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-024-03296-0","https://doi.org/10.1007/s00210-024-03296-0","39031184","https://pubmed.ncbi.nlm.nih.gov/39031184/",null,null],["4","R0005209","R0005209.pdf","paywalled","nonrandomized_study","Muayad J","2025","Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2024.12.006","https://doi.org/10.1016/j.oret.2024.12.006","39644923","https://pubmed.ncbi.nlm.nih.gov/39644923/",null,null],["4","R0005220","R0005220.pdf","paywalled","nonrandomized_study","Abdel-Bary M","2025","Treating class 2-3 obesity with glucagon-like peptide-1 agonists: A 2-year real-world cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16331","https://doi.org/10.1111/dom.16331","40104874","https://pubmed.ncbi.nlm.nih.gov/40104874/",null,null],["4","R0005264","R0005264.pdf","paywalled","nonrandomized_study","Singh H","2025","Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2025.2459720","https://doi.org/10.1080/17446651.2025.2459720","39873334","https://pubmed.ncbi.nlm.nih.gov/39873334/",null,null],["4","R0005355","R0005355.pdf","paywalled","nonrandomized_study","Yen FS","2025","Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112174","https://doi.org/10.1016/j.diabres.2025.112174","40228671","https://pubmed.ncbi.nlm.nih.gov/40228671/",null,null],["4","R0005464","R0005464.pdf","paywalled","nonrandomized_study","Xu B","2025","Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2595727","https://doi.org/10.1080/14740338.2025.2595727","41283794","https://pubmed.ncbi.nlm.nih.gov/41283794/",null,null],["4","R0005480","R0005480.pdf","paywalled","nonrandomized_study","Heo KY","2025","Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.10.099","https://doi.org/10.1016/j.arth.2024.10.099","39486470","https://pubmed.ncbi.nlm.nih.gov/39486470/",null,null],["4","R0005538","R0005538.pdf","paywalled","nonrandomized_study","Nusca A","2025","Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2025.01.007","https://doi.org/10.1016/j.amjcard.2025.01.007","39805357","https://pubmed.ncbi.nlm.nih.gov/39805357/",null,null],["4","R0005601","R0005601.pdf","paywalled","nonrandomized_study","Tiwari RK","2025","Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/0115733998294919240506044544","https://doi.org/10.2174/0115733998294919240506044544","38766831","https://pubmed.ncbi.nlm.nih.gov/38766831/",null,null],["4","R0005642","R0005642.pdf","paywalled","nonrandomized_study","Rai P","2025","Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis.","Journal of neurology","Springer Science and Business Media LLC","10.1007/s00415-025-13470-w","https://doi.org/10.1007/s00415-025-13470-w","41118000","https://pubmed.ncbi.nlm.nih.gov/41118000/",null,null],["4","R0005719","R0005719.pdf","paywalled","nonrandomized_study","Seddio AE","2025","As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.08.003","https://doi.org/10.1016/j.arth.2025.08.003","40784425","https://pubmed.ncbi.nlm.nih.gov/40784425/",null,null],["4","R0005796","R0005796.pdf","paywalled","nonrandomized_study","Wu JY","2025","Clinical Impact of Tirzepatide on Patients With OSA and Obesity.","Chest","Elsevier BV","10.1016/j.chest.2025.03.030","https://doi.org/10.1016/j.chest.2025.03.030","40254150","https://pubmed.ncbi.nlm.nih.gov/40254150/",null,null],["4","R0005904","R0005904.pdf","paywalled","nonrandomized_study","Nakhla M","2025","Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-024-07613-w","https://doi.org/10.1007/s10557-024-07613-w","39264502","https://pubmed.ncbi.nlm.nih.gov/39264502/",null,null],["4","R0005925","R0005925.pdf","paywalled","nonrandomized_study","Vatsia SK","2025","Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis.","Clinical spine surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/bsd.0000000000001775","https://doi.org/10.1097/bsd.0000000000001775","40042198","https://pubmed.ncbi.nlm.nih.gov/40042198/",null,null],["4","R0006025","R0006025.pdf","paywalled","nonrandomized_study","Chhabra P","2025","Unmasking Aspiration Risks: A Propensity-Matched Odyssey of GLP-1 Receptor Agonists and Colonoscopy.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70071","https://doi.org/10.1111/jgh.70071","40954421","https://pubmed.ncbi.nlm.nih.gov/40954421/",null,null],["4","R0006088","R0006088.pdf","paywalled","nonrandomized_study","Wang M","2025","Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2025.119670","https://doi.org/10.1016/j.jad.2025.119670","40523410","https://pubmed.ncbi.nlm.nih.gov/40523410/",null,null],["4","R0006191","R0006191.pdf","paywalled","nonrandomized_study","Guth MA","2025","Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis.","International journal of pharmaceutical compounding",null,"10.5281/zenodo.22017427","https://doi.org/10.5281/zenodo.22017427","39921911","https://pubmed.ncbi.nlm.nih.gov/39921911/",null,null],["4","R0006229","R0006229.pdf","paywalled","nonrandomized_study","Wu JY","2025","Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112083","https://doi.org/10.1016/j.diabres.2025.112083","40049522","https://pubmed.ncbi.nlm.nih.gov/40049522/",null,null],["4","R0006436","R0006436.pdf","paywalled","nonrandomized_study","Mahmoud AK","2025","The complementary effects of GLP-1 receptor agonists and SGLT2 inhibitors in transthyretin cardiac amyloidosis patients: A retrospective multicenter cohort study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133567","https://doi.org/10.1016/j.ijcard.2025.133567","40592407","https://pubmed.ncbi.nlm.nih.gov/40592407/",null,null],["4","R0006487","R0006487.pdf","paywalled","nonrandomized_study","Pardo Lozano F","2025","Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2025.501574","https://doi.org/10.1016/j.endien.2025.501574","40450456","https://pubmed.ncbi.nlm.nih.gov/40450456/",null,null],["4","R0006697","R0006697.pdf","paywalled","nonrandomized_study","Nazarenko N","2025","Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.","HIV medicine","Wiley","10.1111/hiv.13760","https://doi.org/10.1111/hiv.13760","39948235","https://pubmed.ncbi.nlm.nih.gov/39948235/",null,null],["4","R0006738","R0006738.pdf","paywalled","nonrandomized_study","Ren R","2025","The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108932","https://doi.org/10.1016/j.jdiacomp.2024.108932","39700591","https://pubmed.ncbi.nlm.nih.gov/39700591/",null,null],["4","R0006754","R0006754.pdf","paywalled","nonrandomized_study","Goldman V","2025","Obesity Management in Youth with Duchenne Muscular Dystrophy: A Review of Metformin and Alternative Pharmacotherapies.","Childhood obesity (Print)","SAGE Publications","10.1089/chi.2024.0297","https://doi.org/10.1089/chi.2024.0297","39392010","https://pubmed.ncbi.nlm.nih.gov/39392010/",null,null],["4","R0006787","R0006787.pdf","paywalled","nonrandomized_study","An J","2025","Understanding the erectile dysfunction-cardiovascular disease connection: clinical and pathophysiological insights.","Sexual medicine reviews","Oxford University Press (OUP)","10.1093/sxmrev/qeaf014","https://doi.org/10.1093/sxmrev/qeaf014","40153594","https://pubmed.ncbi.nlm.nih.gov/40153594/",null,null],["4","R0006822","R0006822.pdf","paywalled","nonrandomized_study","Mazzilli R","2025","Neuroendocrine tumors and diabetes mellitus: which treatment and which effect.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-04149-9","https://doi.org/10.1007/s12020-024-04149-9","39752043","https://pubmed.ncbi.nlm.nih.gov/39752043/",null,null],["4","R0006872","R0006872.pdf","paywalled","nonrandomized_study","Al Ashi S","2025","Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16657","https://doi.org/10.1111/dom.16657","40735942","https://pubmed.ncbi.nlm.nih.gov/40735942/",null,null],["4","R0006913","R0006913.pdf","paywalled","nonrandomized_study","Mavaddat H","2025","The effects of incretins as a double-edged sword on cancer.","Molecular biology reports","Springer Science and Business Media LLC","10.1007/s11033-025-11062-5","https://doi.org/10.1007/s11033-025-11062-5","41023473","https://pubmed.ncbi.nlm.nih.gov/41023473/",null,null],["4","R0007215","R0007215.pdf","paywalled","nonrandomized_study","Ernst K","2025","Collaboration to transition members to preferred formulary dipeptidyl-peptidase-4 inhibitor.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2025.89661","https://doi.org/10.37765/ajmc.2025.89661","39847784","https://pubmed.ncbi.nlm.nih.gov/39847784/",null,null],["4","R0007269","R0007269.pdf","paywalled","nonrandomized_study","Eng K","2025","Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2024.10.029","https://doi.org/10.1016/j.ajo.2024.10.029","39515454","https://pubmed.ncbi.nlm.nih.gov/39515454/",null,null],["4","R0007345","R0007345.pdf","paywalled","nonrandomized_study","Zeyfang A","2025","Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry.","Journal of the American Medical Directors Association","Elsevier BV","10.1016/j.jamda.2025.105724","https://doi.org/10.1016/j.jamda.2025.105724","40553729","https://pubmed.ncbi.nlm.nih.gov/40553729/",null,null],["4","R0007383","R0007383.pdf","paywalled","nonrandomized_study","Gras C","2025","Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.","European journal of clinical nutrition","Springer Science and Business Media LLC","10.1038/s41430-025-01653-7","https://doi.org/10.1038/s41430-025-01653-7","40908328","https://pubmed.ncbi.nlm.nih.gov/40908328/",null,null],["4","R0007491","R0007491.pdf","paywalled","nonrandomized_study","Khalid SI","2025","Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease.","Journal of neurosurgery. Spine","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2024.6.spine24141","https://doi.org/10.3171/2024.6.spine24141","39366019","https://pubmed.ncbi.nlm.nih.gov/39366019/",null,null],["4","R0007596","R0007596.pdf","paywalled","nonrandomized_study","Azab M","2025","Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.01.011","https://doi.org/10.1016/j.orcp.2025.01.011","39922760","https://pubmed.ncbi.nlm.nih.gov/39922760/",null,null],["4","R0007756","R0007756.pdf","paywalled","nonrandomized_study","De Cosmo S","2025","Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies.","Journal of nephrology","Oxford University Press (OUP)","10.1007/s40620-024-02171-8","https://doi.org/10.1007/s40620-024-02171-8","39676127","https://pubmed.ncbi.nlm.nih.gov/39676127/",null,null],["4","R0007767","R0007767.pdf","paywalled","nonrandomized_study","Balachandra S","2025","Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules.","The Journal of surgical research","Elsevier BV","10.1016/j.jss.2025.05.016","https://doi.org/10.1016/j.jss.2025.05.016","40578060","https://pubmed.ncbi.nlm.nih.gov/40578060/",null,null],["4","R0007902","R0007902.pdf","paywalled","nonrandomized_study","Shi J","2025","Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.","Experimental cell research","Elsevier BV","10.1016/j.yexcr.2025.114708","https://doi.org/10.1016/j.yexcr.2025.114708","40784419","https://pubmed.ncbi.nlm.nih.gov/40784419/",null,null],["4","R0007952","R0007952.pdf","paywalled","nonrandomized_study","Faran M","2025","Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08054-6","https://doi.org/10.1007/s11695-025-08054-6","40711700","https://pubmed.ncbi.nlm.nih.gov/40711700/",null,null],["4","R0008227","R0008227.pdf","paywalled","nonrandomized_study","Albanese R","2025","GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.","Aesthetic plastic surgery","Springer Science and Business Media LLC","10.1007/s00266-025-05015-3","https://doi.org/10.1007/s00266-025-05015-3","40603775","https://pubmed.ncbi.nlm.nih.gov/40603775/",null,null],["4","R0008258","R0008258.pdf","paywalled","nonrandomized_study","Garagoli F","2025","Breaking the weight of therapeutic inertia: obesity management in cardiology practice.","Medicina","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3778","https://doi.org/10.1093/eurheartj/ehaf784.3778","41109278","https://pubmed.ncbi.nlm.nih.gov/41109278/",null,null],["4","R0008292","R0008292.pdf","paywalled","nonrandomized_study","Alluri AA","2025","Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.","Journal of basic and clinical physiology and pharmacology","Walter de Gruyter GmbH","10.1515/jbcpp-2025-0031","https://doi.org/10.1515/jbcpp-2025-0031","40150960","https://pubmed.ncbi.nlm.nih.gov/40150960/",null,null],["4","R0008454","R0008454.pdf","paywalled","nonrandomized_study","Suresh J","2025","Blinded by the drug? A vigilyze signal linking semaglutide to NAION.","International ophthalmology","Springer Science and Business Media LLC","10.1007/s10792-025-03760-7","https://doi.org/10.1007/s10792-025-03760-7","41026313","https://pubmed.ncbi.nlm.nih.gov/41026313/",null,null],["4","R0008717","R0008717.pdf","paywalled","nonrandomized_study","Al Basri S","2025","[The weight-loss injection : An orthopaedic overview].","Orthopadie (Heidelberg, Germany)","Springer Science and Business Media LLC","10.1007/s00132-025-04609-8","https://doi.org/10.1007/s00132-025-04609-8","39900779","https://pubmed.ncbi.nlm.nih.gov/39900779/",null,null],["4","R0008752","R0008752.pdf","paywalled","nonrandomized_study","Chou OHI","2025","Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2024.101571","https://doi.org/10.1016/j.diabet.2024.101571","39182669","https://pubmed.ncbi.nlm.nih.gov/39182669/",null,null],["4","R0009002","R0009002.pdf","paywalled","nonrandomized_study","Al Hayek A","2025","Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109064","https://doi.org/10.1016/j.jdiacomp.2025.109064","40318459","https://pubmed.ncbi.nlm.nih.gov/40318459/",null,null],["4","R0009116","R0009116.pdf","paywalled","nonrandomized_study","Bhattacharyya S","2025","The Weight of the Matter in Diabetes Care.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.73.1201","https://doi.org/10.59556/japi.73.1201","41277213","https://pubmed.ncbi.nlm.nih.gov/41277213/",null,null],["4","R0009187","R0009187.pdf","paywalled","nonrandomized_study","Sharma RK","2025","Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","Wiley","10.1002/ohn.1209","https://doi.org/10.1002/ohn.1209","40407186","https://pubmed.ncbi.nlm.nih.gov/40407186/",null,null],["4","R0009236","R0009236.pdf","paywalled","nonrandomized_study","Ambulkar KS","2025","Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-2620-2931","https://doi.org/10.1055/a-2620-2931","40409292","https://pubmed.ncbi.nlm.nih.gov/40409292/",null,null],["4","R0009578","R0009578.pdf","paywalled","nonrandomized_study","Amen TB","2025","Glucagon-like peptide-1 Agonists and Common Hand Procedures: Perioperative and Postoperative Risks and Complications.","The Journal of hand surgery","Elsevier BV","10.1016/j.jhsa.2025.08.004","https://doi.org/10.1016/j.jhsa.2025.08.004","41055617","https://pubmed.ncbi.nlm.nih.gov/41055617/",null,null],["4","R0009588","R0009588.pdf","paywalled","nonrandomized_study","Matsushiro M","2025","Short-term outcomes of switching from GLP-1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16237","https://doi.org/10.1111/dom.16237","39895173","https://pubmed.ncbi.nlm.nih.gov/39895173/",null,null],["4","R0009621","R0009621.pdf","paywalled","nonrandomized_study","Zhang H","2025","Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.","European journal of nuclear medicine and molecular imaging","Springer Science and Business Media LLC","10.1007/s00259-025-07298-9","https://doi.org/10.1007/s00259-025-07298-9","40310561","https://pubmed.ncbi.nlm.nih.gov/40310561/",null,"ClinicalTrials.gov:NCT02560376"],["4","R0009670","R0009670.pdf","paywalled","nonrandomized_study","Martini ML","2025","Effects of glucagon-like peptide-1 agonist therapy on vertebral bone mineral density as measured by CT-based Hounsfield units.","Journal of neurosurgery. Spine","Journal of Neurosurgery Publishing Group (JNSPG)","10.3171/2025.7.spine25791","https://doi.org/10.3171/2025.7.spine25791","41270274","https://pubmed.ncbi.nlm.nih.gov/41270274/",null,null],["4","R0010055","R0010055.pdf","paywalled","nonrandomized_study","Fath AR","2025","Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133082","https://doi.org/10.1016/j.ijcard.2025.133082","39983877","https://pubmed.ncbi.nlm.nih.gov/39983877/",null,null],["4","R0010445","R0010445.pdf","paywalled","nonrandomized_study","Alluri AA","2025","Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration.","Minerva cardiology and angiology","Edizioni Minerva Medica","10.23736/s2724-5683.25.06846-2","https://doi.org/10.23736/s2724-5683.25.06846-2","40923921","https://pubmed.ncbi.nlm.nih.gov/40923921/",null,null],["4","R0010528","R0010528.pdf","paywalled","nonrandomized_study","Masrur MA","2025","Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-07712-z","https://doi.org/10.1007/s11695-025-07712-z","39875789","https://pubmed.ncbi.nlm.nih.gov/39875789/",null,null],["4","R0010636","R0010636.pdf","paywalled","nonrandomized_study","Das L","2025","Effect of Oral Semaglutide on Volumetric BMD and Bone Microarchitecture in Overweight/Obese Individuals with Type 2 Diabetes.","Calcified tissue international","Springer Science and Business Media LLC","10.1007/s00223-025-01417-2","https://doi.org/10.1007/s00223-025-01417-2","40782266","https://pubmed.ncbi.nlm.nih.gov/40782266/",null,null],["4","R0010766","R0010766.pdf","paywalled","nonrandomized_study","Kishimori T","2025","Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcaf065","https://doi.org/10.1093/ehjqcco/qcaf065","40676725","https://pubmed.ncbi.nlm.nih.gov/40676725/",null,null],["4","R0010836","R0010836.pdf","paywalled","nonrandomized_study","So JE","2025","The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70134","https://doi.org/10.1111/jgh.70134","41194677","https://pubmed.ncbi.nlm.nih.gov/41194677/",null,null],["4","R0010977","R0010977.pdf","paywalled","nonrandomized_study","Verhey JT","2025","GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2025.03.012","https://doi.org/10.1016/j.arth.2025.03.012","40081604","https://pubmed.ncbi.nlm.nih.gov/40081604/",null,null],["4","R0011312","R0011312.pdf","paywalled","nonrandomized_study","Levidy MF","2025","The Effects of Glucagon-Like Peptide-1 Agonist Therapy on Risk of Infection, Fracture, and Early Revision in Primary Total Joint Arthroplasty.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-24-01284","https://doi.org/10.5435/jaaos-d-24-01284","40397943","https://pubmed.ncbi.nlm.nih.gov/40397943/",null,null],["4","R0011343","R0011343.pdf","paywalled","nonrandomized_study","Brown A","2025","Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-11942-8","https://doi.org/10.1007/s00464-025-11942-8","40691334","https://pubmed.ncbi.nlm.nih.gov/40691334/",null,null],["4","R0011586","R0011586.pdf","paywalled","nonrandomized_study","Pourabhari Langroudi A","2025","Response to Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-025-01143-1","https://doi.org/10.1038/s41443-025-01143-1","40775124","https://pubmed.ncbi.nlm.nih.gov/40775124/",null,null],["4","R0011703","R0011703.pdf","paywalled","nonrandomized_study","Pozzi E","2025","Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-025-01126-2","https://doi.org/10.1038/s41443-025-01126-2","40681805","https://pubmed.ncbi.nlm.nih.gov/40681805/",null,null],["4","R0011735","R0011735.pdf","paywalled","nonrandomized_study","Kohn TP","2025","Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-025-01121-7","https://doi.org/10.1038/s41443-025-01121-7","40665040","https://pubmed.ncbi.nlm.nih.gov/40665040/",null,null],["4","R0011763","R0011763.pdf","paywalled","nonrandomized_study","Niccolai F","2025","Basal Insulin and GLP-1 Receptor Agonist Combination Therapy in Frail Older Inpatients: A Real-World Observational Study.","Drugs & aging","Springer Science and Business Media LLC","10.1007/s40266-025-01241-1","https://doi.org/10.1007/s40266-025-01241-1","40782292","https://pubmed.ncbi.nlm.nih.gov/40782292/",null,null],["4","R0011992","R0011992.pdf","paywalled","nonrandomized_study","Medhati P","2025","GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000006748","https://doi.org/10.1097/sla.0000000000006748","40334053","https://pubmed.ncbi.nlm.nih.gov/40334053/",null,null],["4","R0012077","R0012077.pdf","paywalled","nonrandomized_study","Kumar S","2025","Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-025-09218-1","https://doi.org/10.1007/s10620-025-09218-1","40629230","https://pubmed.ncbi.nlm.nih.gov/40629230/",null,null],["4","R0012099","R0012099.pdf","paywalled","nonrandomized_study","Siegel R","2025","GLP-1 Receptor Agonist Prescribing Practices in a Pediatric Weight Management Program.","Childhood obesity (Print)","SAGE Publications","10.1089/chi.2025.0004","https://doi.org/10.1089/chi.2025.0004","40465478","https://pubmed.ncbi.nlm.nih.gov/40465478/",null,null],["4","R0012100","R0012100.pdf","paywalled","nonrandomized_study","Procacci A","2025","Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.03.001","https://doi.org/10.1016/j.orcp.2025.03.001","40133108","https://pubmed.ncbi.nlm.nih.gov/40133108/",null,null],["4","R0012343","R0012343.pdf","paywalled","nonrandomized_study","Kong J","2025","Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study.","Archives of gerontology and geriatrics","Elsevier BV","10.1016/j.archger.2024.105656","https://doi.org/10.1016/j.archger.2024.105656","39447350","https://pubmed.ncbi.nlm.nih.gov/39447350/",null,null],["4","R0012428","R0012428.pdf","paywalled","nonrandomized_study","Ng MK","2025","Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.","The spine journal : official journal of the North American Spine Society","Elsevier BV","10.1016/j.spinee.2025.03.023","https://doi.org/10.1016/j.spinee.2025.03.023","40154624","https://pubmed.ncbi.nlm.nih.gov/40154624/",null,null],["4","R0012458","R0012458.pdf","paywalled","nonrandomized_study","Yen FS","2025","Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112357","https://doi.org/10.1016/j.diabres.2025.112357","40602532","https://pubmed.ncbi.nlm.nih.gov/40602532/",null,null],["4","R0012476","R0012476.pdf","paywalled","nonrandomized_study","Seddio AE","2025","Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair.","Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association","Wiley","10.1016/j.arthro.2024.09.057","https://doi.org/10.1016/j.arthro.2024.09.057","39490542","https://pubmed.ncbi.nlm.nih.gov/39490542/",null,null],["4","R0012535","R0012535.pdf","paywalled","nonrandomized_study","Thang CJ","2025","Response to Cho et al's \"GLP-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in non-diabetic obese women but not men: A retrospective cohort study\".","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.03.102","https://doi.org/10.1016/j.jaad.2025.03.102","40451302","https://pubmed.ncbi.nlm.nih.gov/40451302/",null,null],["4","R0012696","R0012696.pdf","paywalled","nonrandomized_study","Cho SW","2025","Response to Thang et al's \"Response to Cho et al's 'GLP-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in non-diabetic obese women but not men: A retrospective cohort study'\".","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.04.085","https://doi.org/10.1016/j.jaad.2025.04.085","40451305","https://pubmed.ncbi.nlm.nih.gov/40451305/",null,null],["4","R0012762","R0012762.pdf","paywalled","nonrandomized_study","Wantuch GA","2025","TikTok's take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2025.102384","https://doi.org/10.1016/j.japh.2025.102384","40049364","https://pubmed.ncbi.nlm.nih.gov/40049364/",null,null],["4","R0012864","R0012864.pdf","paywalled","nonrandomized_study","Cheung D","2025","Metabolic inflammation and cancer risk: A potential target with GLP-1 agonist or bariatric surgery?","Cancer","Wiley","10.1002/cncr.70124","https://doi.org/10.1002/cncr.70124","41091624","https://pubmed.ncbi.nlm.nih.gov/41091624/",null,null],["4","R0012877","R0012877.pdf","paywalled","nonrandomized_study","Gionfriddo MR","2025","An analysis of national news coverage of semaglutide for weight loss.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2024.102297","https://doi.org/10.1016/j.japh.2024.102297","39580054","https://pubmed.ncbi.nlm.nih.gov/39580054/",null,null],["4","R0013196","R0013196.pdf","paywalled","nonrandomized_study","Ramsha Azmat","2025","Letter to the Editor: Combination treatment of Sglt2i and Glp-1ra associated with improved cardiovascular outcomes in Type-2 diabetes patients with acute coronary syndrome: A propensity score-matched Cohort study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133660","https://doi.org/10.1016/j.ijcard.2025.133660","40706810","https://pubmed.ncbi.nlm.nih.gov/40706810/",null,null],["4","R0013221","R0013221.pdf","paywalled","nonrandomized_study","Zevin B","2025","Paired editorial for \"GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study\".","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2024.12.007","https://doi.org/10.1016/j.soard.2024.12.007","39743444","https://pubmed.ncbi.nlm.nih.gov/39743444/",null,null],["4","R0013374","R0013374.pdf","paywalled","nonrandomized_study","Bahdi F","2025","Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.","Clinical obesity","Wiley","10.1111/cob.70001","https://doi.org/10.1111/cob.70001","39909715","https://pubmed.ncbi.nlm.nih.gov/39909715/",null,null],["4","R0013477","R0013477.pdf","paywalled","nonrandomized_study","Seddio AE","2025","Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively.","The Journal of the American Academy of Orthopaedic Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaos-d-25-00439","https://doi.org/10.5435/jaaos-d-25-00439","40549942","https://pubmed.ncbi.nlm.nih.gov/40549942/",null,null],["4","R0013735","R0013735.pdf","paywalled","nonrandomized_study","Alfadda AA","2025","Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108910","https://doi.org/10.1016/j.jdiacomp.2024.108910","39675110","https://pubmed.ncbi.nlm.nih.gov/39675110/",null,"ClinicalTrials.gov:NCT05697991"],["4","R0013867","R0013867.pdf","paywalled","nonrandomized_study","Queiroz VNF","2025","Evaluation of gastric content in fasting patient during semaglutide use: an observational study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2024.08.039","https://doi.org/10.1016/j.soard.2024.08.039","39343660","https://pubmed.ncbi.nlm.nih.gov/39343660/",null,null],["4","R0013889","R0013889.pdf","paywalled","nonrandomized_study","Godfrey H","2025","Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.20197","https://doi.org/10.1111/jdv.20197","38925559","https://pubmed.ncbi.nlm.nih.gov/38925559/",null,null],["4","R0014033","R0014033.pdf","paywalled","nonrandomized_study","Tao X","2025","No Difference in Short-term Surgical Outcomes From Semaglutide Treatment for Type 2 Diabetes Mellitus After Cervical Decompression and Fusion: A Propensity Score-matched Analysis.","Spine","Ovid Technologies (Wolters Kluwer Health)","10.1097/brs.0000000000005099","https://doi.org/10.1097/brs.0000000000005099","39034750","https://pubmed.ncbi.nlm.nih.gov/39034750/",null,null],["4","R0014046","R0014046.pdf","paywalled","nonrandomized_study","Hvisdas CM","2025","Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.09.117","https://doi.org/10.1016/j.eprac.2024.09.117","39414234","https://pubmed.ncbi.nlm.nih.gov/39414234/",null,null],["4","R0014188","R0014188.pdf","paywalled","nonrandomized_study","Moka MK","2025","\"Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions\".","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-024-02363-5","https://doi.org/10.1007/s00592-024-02363-5","39254745","https://pubmed.ncbi.nlm.nih.gov/39254745/",null,null],["4","R0014371","R0014371.pdf","paywalled","nonrandomized_study","Kim MJ","2025","Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112978","https://doi.org/10.1016/j.diabres.2025.112978","41175980","https://pubmed.ncbi.nlm.nih.gov/41175980/",null,null],["4","R0014566","R0014566.pdf","paywalled","nonrandomized_study","Anderer S","2025","GLP-1 Agonists May Reduce Risk of Alcohol Use Disorder Hospitalizations.","JAMA","American Medical Association (AMA)","10.1001/jama.2024.25503","https://doi.org/10.1001/jama.2024.25503","39705025","https://pubmed.ncbi.nlm.nih.gov/39705025/",null,null],["4","R0015068","R0015068.pdf","paywalled","nonrandomized_study","Yu H","2025","Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.","European journal of nuclear medicine and molecular imaging","Springer Science and Business Media LLC","10.1007/s00259-025-07288-x","https://doi.org/10.1007/s00259-025-07288-x","40259061","https://pubmed.ncbi.nlm.nih.gov/40259061/",null,"ClinicalTrials.gov:NCT06690957; ClinicalTrials.gov:NCT06725693"],["4","R0015185","R0015185.pdf","paywalled","nonrandomized_study","Goldstein AR","2025","Slimming the risks: GLP-1 receptor agonist therapy may reduce in-hospital complications and hospital readmissions rates for hip fractures compared to obese patients not on these medications.","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","Springer Science and Business Media LLC","10.1007/s00590-025-04477-0","https://doi.org/10.1007/s00590-025-04477-0","40892123","https://pubmed.ncbi.nlm.nih.gov/40892123/",null,null],["4","R0015349","R0015349.pdf","paywalled","nonrandomized_study","Bergstein VE","2025","GLP-1 agonist use increases the incidence of adhesive capsulitis and odds of requiring operative management in type 2 diabetes patients: a matched propensity score analysis.","Journal of shoulder and elbow surgery","Elsevier BV","10.1016/j.jse.2024.11.041","https://doi.org/10.1016/j.jse.2024.11.041","39855332","https://pubmed.ncbi.nlm.nih.gov/39855332/",null,null],["4","R0015560","R0015560.pdf","paywalled","nonrandomized_study","Seddio AE","2025","Endoscopic and Open Carpal Tunnel Release in Patients With Type II Diabetes Mellitus: Influence of Preoperative Semaglutide Use on Postoperative Outcomes.","The Journal of hand surgery","Elsevier BV","10.1016/j.jhsa.2025.09.003","https://doi.org/10.1016/j.jhsa.2025.09.003","41105066","https://pubmed.ncbi.nlm.nih.gov/41105066/",null,null],["4","R0015585","R0015585.pdf","paywalled","nonrandomized_study","Seddio AE","2025","Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes.","The spine journal : official journal of the North American Spine Society","Elsevier BV","10.1016/j.spinee.2024.10.011","https://doi.org/10.1016/j.spinee.2024.10.011","39491749","https://pubmed.ncbi.nlm.nih.gov/39491749/",null,null],["4","R0015651","R0015651.pdf","paywalled","nonrandomized_study","Wu JY","2025","Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-025-10857-9","https://doi.org/10.1007/s12072-025-10857-9","40668509","https://pubmed.ncbi.nlm.nih.gov/40668509/",null,null],["4","R0015670","R0015670.pdf","paywalled","nonrandomized_study","Zahid MD","2025","Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease- A Growing Threat Beyond the Liver.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-025-01353-4","https://doi.org/10.1007/s11883-025-01353-4","41165963","https://pubmed.ncbi.nlm.nih.gov/41165963/",null,null],["4","R0015786","R0015786.pdf","paywalled","nonrandomized_study","Tsai KW","2025","Research Design Concerns in a TriNetX Study of Tirzepatide and Heart Failure Prevention in Obese Patients.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf721","https://doi.org/10.1093/eurjpc/zwaf721","41225710","https://pubmed.ncbi.nlm.nih.gov/41225710/",null,null],["4","R0015966","R0015966.pdf","paywalled","nonrandomized_study","Angelopoulos N","2025","Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109181","https://doi.org/10.1016/j.jdiacomp.2025.109181","41075711","https://pubmed.ncbi.nlm.nih.gov/41075711/",null,null],["4","R0016128","R0016128.pdf","paywalled","nonrandomized_study","Kermansaravi M","2025","Oral Semaglutide in Adults with Overweight or Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2515109","https://doi.org/10.1056/nejmc2515109","41370811","https://pubmed.ncbi.nlm.nih.gov/41370811/",null,null],["4","R0016212","R0016212.pdf","paywalled","nonrandomized_study","Wu JY","2025","Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112294","https://doi.org/10.1016/j.diabres.2025.112294","40456414","https://pubmed.ncbi.nlm.nih.gov/40456414/",null,null],["4","R0016462","R0016462.pdf","paywalled","nonrandomized_study","Mazzotti DR","2025","Tirzepatide, Mortality, Cardiovascular, and Renal Outcomes in Sleep Apnea: Evidence From Real World Data.","Chest","Elsevier BV","10.1016/j.chest.2025.05.019","https://doi.org/10.1016/j.chest.2025.05.019","40935542","https://pubmed.ncbi.nlm.nih.gov/40935542/",null,null],["4","R0016507","R0016507.pdf","paywalled","nonrandomized_study","Malapati SN","2025","Tirzepatide and Hydrochlorothiazide Coadministration in CKD: A Real-World Signal for Hypercalcemia Risk.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000002041","https://doi.org/10.1097/mjt.0000000000002041","40748859","https://pubmed.ncbi.nlm.nih.gov/40748859/",null,null],["4","R0016649","R0016649.pdf","paywalled","nonrandomized_study","Wu JY","2025","Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16353","https://doi.org/10.1111/dom.16353","40109063","https://pubmed.ncbi.nlm.nih.gov/40109063/",null,null],["4","R0016659","R0016659.pdf","paywalled","nonrandomized_study","Moka MK","2025","Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.11.015","https://doi.org/10.1016/j.clinthera.2024.11.015","39709252","https://pubmed.ncbi.nlm.nih.gov/39709252/",null,null],["4","R0016690","R0016690.pdf","paywalled","nonrandomized_study","Kanazawa K","2025","Effectiveness and predictors of weight reduction with low-dose tirzepatide in Japanese patients with type 2 diabetes: A pilot retrospective cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70062","https://doi.org/10.1111/dom.70062","40874299","https://pubmed.ncbi.nlm.nih.gov/40874299/",null,null],["4","R0016697","R0016697.pdf","paywalled","nonrandomized_study","Wasden K","2025","Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-11910-2","https://doi.org/10.1007/s00464-025-11910-2","40603615","https://pubmed.ncbi.nlm.nih.gov/40603615/",null,null],["4","R0016741","R0016741.pdf","paywalled","nonrandomized_study","Neubauer Z","2025","Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: A retrospective cohort TriNetX database study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.08.033","https://doi.org/10.1016/j.jaad.2025.08.033","40848975","https://pubmed.ncbi.nlm.nih.gov/40848975/",null,null],["4","R0016765","R0016765.pdf","paywalled","nonrandomized_study","He M","2025","Short-Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70006","https://doi.org/10.1002/oby.70006","40964805","https://pubmed.ncbi.nlm.nih.gov/40964805/",null,null],["4","R0016934","R0016934.pdf","paywalled","nonrandomized_study","Paribello G","2025","Semaglutide in overweight non-diabetic peritoneal dialysis patients: a real-world single-center experience.","Journal of nephrology","Oxford University Press (OUP)","10.1007/s40620-025-02453-9","https://doi.org/10.1007/s40620-025-02453-9","41060612","https://pubmed.ncbi.nlm.nih.gov/41060612/",null,null],["4","R0017288","R0017288.pdf","paywalled","nonrandomized_study","Limpijankit V","2025","Factors Associated With New-Onset Atrial Fibrillation in Thai Adults with Hypertension.","American journal of hypertension","Oxford University Press (OUP)","10.1093/ajh/hpaf149","https://doi.org/10.1093/ajh/hpaf149","40796195","https://pubmed.ncbi.nlm.nih.gov/40796195/",null,null],["4","R0017365","R0017365.pdf","paywalled","nonrandomized_study","Catalán V","2025","Oral semaglutide in HFpEF: Real-world evidence and causal considerations.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2025.07.024","https://doi.org/10.1016/j.ejim.2025.07.024","40716975","https://pubmed.ncbi.nlm.nih.gov/40716975/",null,null],["4","R0017396","R0017396.pdf","paywalled","nonrandomized_study","Chu C","2025","Effectiveness of an academic detailing service to support appropriate prescribing and care in patients with type 2 diabetes.","Family practice","Oxford University Press (OUP)","10.1093/fampra/cmaf101","https://doi.org/10.1093/fampra/cmaf101","41510816","https://pubmed.ncbi.nlm.nih.gov/41510816/",null,null],["4","R0017496","R0017496.pdf","paywalled","nonrandomized_study","El Khatib O","2025","Safety and Efficacy of Tirzepatide in Solid-Organ Transplant Recipients: Experience of a Quaternary Care Center in the Middle East.","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","Baskent University","10.6002/ect.2024.0284","https://doi.org/10.6002/ect.2024.0284","39918190","https://pubmed.ncbi.nlm.nih.gov/39918190/",null,null],["4","R0017497","R0017497.pdf","paywalled","nonrandomized_study","Baser O","2025","External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2518329","https://doi.org/10.1080/14656566.2025.2518329","40489337","https://pubmed.ncbi.nlm.nih.gov/40489337/",null,null],["4","R0017571","R0017571.pdf","paywalled","nonrandomized_study","Rivera Gutierrez R","2025","Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2024.07.006","https://doi.org/10.1016/j.mayocp.2024.07.006","39601745","https://pubmed.ncbi.nlm.nih.gov/39601745/",null,null],["4","R0017702","R0017702.pdf","paywalled","nonrandomized_study","Bhagavathula AS","2025","Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.","Annals of epidemiology","Elsevier BV","10.1016/j.annepidem.2025.09.003","https://doi.org/10.1016/j.annepidem.2025.09.003","40957545","https://pubmed.ncbi.nlm.nih.gov/40957545/",null,null],["4","R0017710","R0017710.pdf","paywalled","nonrandomized_study","Werge MP","2025","Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver disease.","Hepatology research : the official journal of the Japan Society of Hepatology","Wiley","10.1111/hepr.14148","https://doi.org/10.1111/hepr.14148","40317579","https://pubmed.ncbi.nlm.nih.gov/40317579/",null,null],["4","R0017784","R0017784.pdf","paywalled","nonrandomized_study","Caruso P","2025","Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16594","https://doi.org/10.1111/dom.16594","40620210","https://pubmed.ncbi.nlm.nih.gov/40620210/",null,null],["4","R0017789","R0017789.pdf","paywalled","nonrandomized_study","Coon SA","2025","Real-world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16349","https://doi.org/10.1111/dom.16349","40104893","https://pubmed.ncbi.nlm.nih.gov/40104893/",null,null],["4","R0017815","R0017815.pdf","paywalled","nonrandomized_study","Bismuth E","2025","Practical implementation of automated insulin delivery systems in 2025: A French position statement update.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101637","https://doi.org/10.1016/j.diabet.2025.101637","40073966","https://pubmed.ncbi.nlm.nih.gov/40073966/",null,null],["4","R0018043","R0018043.pdf","paywalled","nonrandomized_study","Brady VJ","2025","Racial and ethnic differences in prescribing antihyperglycemic medications to persons with type 2 diabetes: An all of us cohort study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2025.05.011","https://doi.org/10.1016/j.pcd.2025.05.011","40461295","https://pubmed.ncbi.nlm.nih.gov/40461295/",null,null],["4","R0018046","R0018046.pdf","paywalled","nonrandomized_study","Chen H","2025","Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2025.2468860","https://doi.org/10.1080/14740338.2025.2468860","40037695","https://pubmed.ncbi.nlm.nih.gov/40037695/",null,null],["4","R0018113","R0018113.pdf","paywalled","nonrandomized_study","Muschler K","2025","Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center.","Clinical toxicology (Philadelphia, Pa.)","Informa UK Limited","10.1080/15563650.2024.2444642","https://doi.org/10.1080/15563650.2024.2444642","39803696","https://pubmed.ncbi.nlm.nih.gov/39803696/",null,null],["4","R0018164","R0018164.pdf","paywalled","nonrandomized_study","Tichy EM","2025","National trends in prescription drug expenditures and projections for 2025.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxaf092","https://doi.org/10.1093/ajhp/zxaf092","40263109","https://pubmed.ncbi.nlm.nih.gov/40263109/",null,null],["4","R0018194","R0018194.pdf","paywalled","nonrandomized_study","Whipple MO","2025","Review of Article: Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112,083.","Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing","Elsevier BV","10.1016/j.jvn.2025.04.001","https://doi.org/10.1016/j.jvn.2025.04.001","40484580","https://pubmed.ncbi.nlm.nih.gov/40484580/",null,null],["4","R0018263","R0018263.pdf","paywalled","nonrandomized_study","Tan Y","2025","The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101680","https://doi.org/10.1016/j.diabet.2025.101680","40545031","https://pubmed.ncbi.nlm.nih.gov/40545031/",null,null],["4","R0018270","R0018270.pdf","paywalled","nonrandomized_study","Kuo CC","2025","Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.","Hepatology international","Springer Science and Business Media LLC","10.1007/s12072-024-10752-9","https://doi.org/10.1007/s12072-024-10752-9","39602049","https://pubmed.ncbi.nlm.nih.gov/39602049/",null,null],["4","R0018344","R0018344.pdf","paywalled","nonrandomized_study","Israel A","2025","Health disparities in diabetes treatment: The challenge of G6PD deficiency.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111965","https://doi.org/10.1016/j.diabres.2024.111965","39710070","https://pubmed.ncbi.nlm.nih.gov/39710070/",null,null],["4","R0018347","R0018347.pdf","paywalled","nonrandomized_study","Xie S","2025","Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-2618-7509","https://doi.org/10.1055/a-2618-7509","40473254","https://pubmed.ncbi.nlm.nih.gov/40473254/",null,null],["4","R0018370","R0018370.pdf","paywalled","nonrandomized_study","Gavriilidis S","2025","The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-04007-8","https://doi.org/10.1007/s12020-024-04007-8","39179734","https://pubmed.ncbi.nlm.nih.gov/39179734/",null,null],["4","R0018418","R0018418.pdf","paywalled","nonrandomized_study","Müller HL","2025","Long-term quality of life and hypothalamic dysfunction after craniopharyngioma.","Journal of neuro-oncology","Springer Science and Business Media LLC","10.1007/s11060-025-04987-1","https://doi.org/10.1007/s11060-025-04987-1","40097882","https://pubmed.ncbi.nlm.nih.gov/40097882/",null,null],["4","R0018484","R0018484.pdf","paywalled","nonrandomized_study","Conti M","2025","Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-024-02424-9","https://doi.org/10.1007/s00592-024-02424-9","39680131","https://pubmed.ncbi.nlm.nih.gov/39680131/",null,null],["4","R0018557","R0018557.pdf","paywalled","nonrandomized_study","Sansone D","2025","Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-025-02475-6","https://doi.org/10.1007/s00592-025-02475-6","40014091","https://pubmed.ncbi.nlm.nih.gov/40014091/",null,null],["4","R0018580","R0018580.pdf","paywalled","nonrandomized_study","Zhang L","2025","Reevaluating Semaglutide in Postbariatric Contouring Surgery: The Role of Undermined Immune Response and Nutritional Deficiency in Wound Complications.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjaf008","https://doi.org/10.1093/asj/sjaf008","39815693","https://pubmed.ncbi.nlm.nih.gov/39815693/",null,null],["4","R0018587","R0018587.pdf","paywalled","nonrandomized_study","Castellana E","2025","Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights.","European journal of hospital pharmacy : science and practice","BMJ","10.1136/ejhpharm-2024-004333","https://doi.org/10.1136/ejhpharm-2024-004333","39242186","https://pubmed.ncbi.nlm.nih.gov/39242186/",null,null],["4","R0018746","R0018746.pdf","paywalled","nonrandomized_study","Chun E","2025","Weight loss and body composition after compounded semaglutide treatment in a real world setting.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16162","https://doi.org/10.1111/dom.16162","39776038","https://pubmed.ncbi.nlm.nih.gov/39776038/",null,null],["4","R0018768","R0018768.pdf","paywalled","nonrandomized_study","Lassen MCH","2025","Forecasting cardiovascular risk reduction with semaglutide in overweight and obese with heart disease: a nationwide cohort study.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwae224","https://doi.org/10.1093/eurjpc/zwae224","39021164","https://pubmed.ncbi.nlm.nih.gov/39021164/",null,null],["4","R0018807","R0018807.pdf","paywalled","nonrandomized_study","Zhu H","2025","Re: Chou et al.: Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study (Ophthalmology. 2025:132:381-388).","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2025.02.024","https://doi.org/10.1016/j.ophtha.2025.02.024","40186600","https://pubmed.ncbi.nlm.nih.gov/40186600/",null,null],["4","R0018823","R0018823.pdf","paywalled","nonrandomized_study","Andò G","2025","STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven risk.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133058","https://doi.org/10.1016/j.ijcard.2025.133058","39954788","https://pubmed.ncbi.nlm.nih.gov/39954788/",null,null],["4","R0018898","R0018898.pdf","paywalled","nonrandomized_study","Cohen N","2025","Real-world experience of adjunct weekly semaglutide in Type 1 diabetes. Is it worth it?","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111979","https://doi.org/10.1016/j.diabres.2024.111979","39732202","https://pubmed.ncbi.nlm.nih.gov/39732202/",null,null],["4","R0018912","R0018912.pdf","paywalled","nonrandomized_study","Bashier A","2025","Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: Results of the PACT-MEA-UAE cohort.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112030","https://doi.org/10.1016/j.diabres.2025.112030","39909317","https://pubmed.ncbi.nlm.nih.gov/39909317/",null,null],["4","R0019084","R0019084.pdf","paywalled","nonrandomized_study","Iturralde-Iriso JM","2025","[Estimation of body fat in a diabetic population from a health area using the Clínica Universitaria de Navarra-Body Adiposity Estimator formula [CUN-BAE]].","Semergen","Elsevier BV","10.1016/j.semerg.2025.102548","https://doi.org/10.1016/j.semerg.2025.102548","40700844","https://pubmed.ncbi.nlm.nih.gov/40700844/",null,null],["4","R0019110","R0019110.pdf","paywalled","nonrandomized_study","Park J","2025","Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.","Annals of nutrition & metabolism","S. Karger AG","10.1159/000547347","https://doi.org/10.1159/000547347","40675139","https://pubmed.ncbi.nlm.nih.gov/40675139/",null,null],["4","R0019125","R0019125.pdf","paywalled","nonrandomized_study","Costa S","2025","Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16314","https://doi.org/10.1111/dom.16314","40045764","https://pubmed.ncbi.nlm.nih.gov/40045764/",null,null],["4","R0019152","R0019152.pdf","paywalled","nonrandomized_study","Hill MA","2025","Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2024.11.039","https://doi.org/10.1016/j.jaad.2024.11.039","39615553","https://pubmed.ncbi.nlm.nih.gov/39615553/",null,null],["4","R0019188","R0019188.pdf","paywalled","nonrandomized_study","Mustafa M","2025","The omics revolution in obesity: from molecularsignatures to clinical solutions.","Molecular omics","Oxford University Press (OUP)","10.1039/d5mo00074b","https://doi.org/10.1039/d5mo00074b","41133487","https://pubmed.ncbi.nlm.nih.gov/41133487/",null,null],["4","R0019265","R0019265.pdf","paywalled","nonrandomized_study","Able C","2025","Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-024-00895-6","https://doi.org/10.1038/s41443-024-00895-6","38778151","https://pubmed.ncbi.nlm.nih.gov/38778151/",null,null],["4","R0019429","R0019429.pdf","paywalled","nonrandomized_study","Korakas E","2025","\"Cardiometabolic outpatient clinics: evidence from collaborative academic tertiary centers-research article\".","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-025-04450-1","https://doi.org/10.1007/s12020-025-04450-1","41091292","https://pubmed.ncbi.nlm.nih.gov/41091292/",null,null],["4","R0019525","R0019525.pdf","paywalled","nonrandomized_study","Obermark AD","2025","Bariatric outcomes of high BMI patients with preoperative anti-obesity medications.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-025-11851-w","https://doi.org/10.1007/s00464-025-11851-w","40640624","https://pubmed.ncbi.nlm.nih.gov/40640624/",null,null],["4","R0019660","R0019660.pdf","paywalled","nonrandomized_study","Sommer WH","2025","Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.","Current topics in behavioral neurosciences","Springer Nature Switzerland","10.1007/7854_2025_586","https://doi.org/10.1007/7854_2025_586","40646424","https://pubmed.ncbi.nlm.nih.gov/40646424/",null,null],["4","R0020052","R0020052.pdf","paywalled","nonrandomized_study","Unal S","2025","Comment on: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study.","International journal of impotence research","Springer Science and Business Media LLC","10.1038/s41443-024-00960-0","https://doi.org/10.1038/s41443-024-00960-0","39122866","https://pubmed.ncbi.nlm.nih.gov/39122866/",null,null],["4","R0020463","R0020463.pdf","paywalled","nonrandomized_study","Neyer M","2025","Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16084","https://doi.org/10.1111/dom.16084","39604296","https://pubmed.ncbi.nlm.nih.gov/39604296/",null,null],["4","R0020468","R0020468.pdf","paywalled","nonrandomized_study","Zhao H","2025","Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.","Gynecologic and obstetric investigation","S. Karger AG","10.1159/000539039","https://doi.org/10.1159/000539039","38768579","https://pubmed.ncbi.nlm.nih.gov/38768579/",null,null],["4","R0021043","R0021043.pdf","paywalled","nonrandomized_study","Vu C","2025","Semaglutide Plus Metformin Versus Metformin Alone For Antipsychotic-Induced Weight Gain In Patients With Type 2 Diabetes Mellitus.","The Psychiatric quarterly","Springer Science and Business Media LLC","10.1007/s11126-025-10137-7","https://doi.org/10.1007/s11126-025-10137-7","40227520","https://pubmed.ncbi.nlm.nih.gov/40227520/",null,null],["4","R0021536","R0021536.pdf","paywalled","nonrandomized_study","Disse E","2025","Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101625","https://doi.org/10.1016/j.diabet.2025.101625","39971183","https://pubmed.ncbi.nlm.nih.gov/39971183/",null,null],["4","R0022429","R0022429.pdf","paywalled","nonrandomized_study","Garcia DE Lucas MD","2025","Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.23.03985-4","https://doi.org/10.23736/s2724-6507.23.03985-4","37337740","https://pubmed.ncbi.nlm.nih.gov/37337740/",null,null],["4","R0023013","R0023013.pdf","paywalled","nonrandomized_study","Junaid V","2025","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-025-01313-y","https://doi.org/10.1007/s11883-025-01313-y","40542886","https://pubmed.ncbi.nlm.nih.gov/40542886/",null,null],["4","R0023658","R0023658.pdf","paywalled","nonrandomized_study","Wu SN","2025","Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.177820","https://doi.org/10.1016/j.ejphar.2025.177820","40490170","https://pubmed.ncbi.nlm.nih.gov/40490170/",null,null],["4","R0023982","R0023982.pdf","paywalled","nonrandomized_study","Wharton S","2025","Healthcare utilization associated with obesity management in Ontario, Canada.","Clinical obesity","Wiley","10.1111/cob.12720","https://doi.org/10.1111/cob.12720","39582393","https://pubmed.ncbi.nlm.nih.gov/39582393/",null,null],["4","R0029035","R0029035.pdf","paywalled","nonrandomized_study","Wooster M","2025","Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.","Breast cancer research and treatment","Springer Science and Business Media LLC","10.1007/s10549-025-07714-6","https://doi.org/10.1007/s10549-025-07714-6","40360855","https://pubmed.ncbi.nlm.nih.gov/40360855/",null,null],["4","R0029554","R0029554.pdf","paywalled","nonrandomized_study","O'Gorman C","2025","Peripheral nerve complications of weight loss associated with novel antihyperglycemic agents: a cohort study.","Journal of neurology","Springer Science and Business Media LLC","10.1007/s00415-025-13566-3","https://doi.org/10.1007/s00415-025-13566-3","41417220","https://pubmed.ncbi.nlm.nih.gov/41417220/",null,null],["4","R0029576","R0029576.pdf","paywalled","nonrandomized_study","Besci O","2025","Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2025.2574318","https://doi.org/10.1080/17446651.2025.2574318","41191736","https://pubmed.ncbi.nlm.nih.gov/41191736/",null,null],["4","R0029600","R0029600.pdf","paywalled","nonrandomized_study","Chen CY","2025","Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08256-y","https://doi.org/10.1007/s11695-025-08256-y","40931277","https://pubmed.ncbi.nlm.nih.gov/40931277/",null,null],["4","R0030053","R0030053.pdf","paywalled","nonrandomized_study","Balshi A","2025","Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort.","Multiple sclerosis and related disorders","Elsevier BV","10.1016/j.msard.2024.106229","https://doi.org/10.1016/j.msard.2024.106229","39693702","https://pubmed.ncbi.nlm.nih.gov/39693702/",null,null],["4","R0030070","R0030070.pdf","paywalled","nonrandomized_study","Alosaimi DN","2025","Comment on \"Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis\".","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-025-08202-y","https://doi.org/10.1007/s11695-025-08202-y","40864374","https://pubmed.ncbi.nlm.nih.gov/40864374/",null,null],["4","R0030081","R0030081.pdf","paywalled","nonrandomized_study","Chiang CH","2025","Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.","European journal of cancer (Oxford, England : 1990)","Elsevier BV","10.1016/j.ejca.2024.115170","https://doi.org/10.1016/j.ejca.2024.115170","39709670","https://pubmed.ncbi.nlm.nih.gov/39709670/",null,null],["4","R0031384","R0031384.pdf","paywalled","nonrandomized_study","Osei, Samuel Prince","2025","Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database","Open Collections",null,"10.14288/1.0447722","https://doi.org/10.14288/1.0447722",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031406","R0031406.pdf","paywalled","nonrandomized_study",null,"2025","Eye disorder is a ‘very rare’ side effect of weight-loss drugs, concludes EMA review","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.359994","https://doi.org/10.1211/pj.2025.1.359994",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031434","R0031434.pdf","paywalled","nonrandomized_study",null,"2025","Study finds association between GLP-1 use and macular degeneration in diabetes","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.359651","https://doi.org/10.1211/pj.2025.1.359651",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031574","R0031574.pdf","paywalled","nonrandomized_study","Filipi Fim Andreão","2025","Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes and Obesity Using GLP-1 Receptor Agonists: A Cohort Study (S14.004)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000212637","https://doi.org/10.1212/wnl.0000000000212637",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031582","R0031582.pdf","paywalled","nonrandomized_study","R. Thibault","2025","Therapeutic effects of glucagon like peptide (GLP)-1 receptor agonists in hidradenitis suppurativa: A retrospective study","Clinical Nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2025.07.844","https://doi.org/10.1016/j.clnesp.2025.07.844",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031967","R0031967.pdf","paywalled","nonrandomized_study","Scott, Victoria","2025","Real-world data for tirzepatide treatment in type 2 diabetes mellitus (T2DM) to address HbA1c and obesity with consideration of atherosclerotic cardiovascular disease (ASCVD)",null,null,"10.13140/rg.2.2.16049.85607","https://doi.org/10.13140/rg.2.2.16049.85607",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032176","R0032176.pdf","paywalled","nonrandomized_study","Antsiferov M.B. Antsiferov","2025","Efficacy and safety of the russian GLP-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus in real-world clinical practice (“QUEENPROMIS” study)","Фарматека","Bionika Media","10.18565/pharmateca.2025.8.51-60","https://doi.org/10.18565/pharmateca.2025.8.51-60",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032558","R0032558.pdf","paywalled","nonrandomized_study","Baoting CHEN","2025","Assessment of the efficacy and safety of glucagon-like peptide-1 receptor agonists combined with insulin therapy for obese adults with type 2 diabetes mellitus","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12464/j.issn.0253-9802.2024-0370","https://doi.org/10.12464/j.issn.0253-9802.2024-0370",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032621","R0032621.pdf","paywalled","nonrandomized_study","Kibum Kim","2025","2197-LB: BMI Regain and Blood-Pressure Change after Discontinuation of Antiobesity Agents","Diabetes","American Diabetes Association","10.2337/db25-2197-lb","https://doi.org/10.2337/db25-2197-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032684","R0032684.pdf","paywalled","nonrandomized_study","Wei Lu","2025","1050-P: Revolutionary GLP-1 Weight Loss Medicine Semaglutide—To Cover or Not to Cover?","Diabetes","American Diabetes Association","10.2337/db25-1050-p","https://doi.org/10.2337/db25-1050-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032701","R0032701.pdf","paywalled","nonrandomized_study","Wilson Souza Neto","2025","TRATAMENTO DE OBESIDADE COM USO DE SEMAGLUTIDA: UMA REVISÃO DE LITERATURA","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/pa10202502262002","https://doi.org/10.69849/revistaft/pa10202502262002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032732","R0032732.pdf","paywalled","nonrandomized_study","AMIR HERMAN","2025","1495-P: Improved A1C in People with Non–Insulin-Treated T2D Using CGM in Primary Care—The Dexcom Global Registry","Diabetes","American Diabetes Association","10.2337/db25-1495-p","https://doi.org/10.2337/db25-1495-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06483945"],["4","R0032738","R0032738.pdf","paywalled","nonrandomized_study","Polina Kukhareva","2025","304-OR: Leveraging Real-World Evidence to Analyze Changes in Prescribing of GLP-1 Receptor Agonists in the United States","Diabetes","American Diabetes Association","10.2337/db25-304-or","https://doi.org/10.2337/db25-304-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032809","R0032809.pdf","paywalled","nonrandomized_study","Tugce Akcan","2025","944-P: Use of High-Potency GLP-1 Receptor Agonists with OpenAPS Automated Insulin Dosing Algorithm Eliminates Need for Meal Announcements to Achieve Glycemic Goals","Diabetes","American Diabetes Association","10.2337/db25-944-p","https://doi.org/10.2337/db25-944-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032856","R0032856.pdf","paywalled","nonrandomized_study","Jiabi Xue","2025","1785-P: Clinical Characteristics and Medication Use in Children and Young Adults with Obesity in the United States","Diabetes","American Diabetes Association","10.2337/db25-1785-p","https://doi.org/10.2337/db25-1785-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032943","R0032943.pdf","paywalled","nonrandomized_study","Weixia Sun","2025","850-P: Comparision of Efficacy on MASLD between GLP-1RA and SGLT2i—A Real-World Study","Diabetes","American Diabetes Association","10.2337/db25-850-p","https://doi.org/10.2337/db25-850-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032960","R0032960.pdf","paywalled","nonrandomized_study","Osama Albasheer","2025","Global Trends and Hotspots in Dulaglutide in the Fields of Diabetes, Obesity, and Cardiovascular Research: A Bibliometric Analysis","Current Bioactive Compounds","Bentham Science Publishers Ltd.","10.2174/0115734072353980250418211500","https://doi.org/10.2174/0115734072353980250418211500",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032973","R0032973.pdf","paywalled","nonrandomized_study","Alex Chelton","2025","GLP-1 Receptor Agonist Impact on Fracture Risk In Patients with Obesity","Journal of the American Osteopathic Academy of Orthopedics","American Osteopathic Academy of Orthopedics","10.70709/ellc5ccpa22","https://doi.org/10.70709/ellc5ccpa22",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032984","R0032984.pdf","paywalled","nonrandomized_study","SHU NIU","2025","1066-P: Cost-Effectiveness of SGLT2i plus GLP-1RAs vs. SGLT2i in Patients with Chronic Kidney Disease","Diabetes","American Diabetes Association","10.2337/db25-1066-p","https://doi.org/10.2337/db25-1066-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033027","R0033027.pdf","paywalled","nonrandomized_study","ISABELLA MARRANZINI RODRIGUEZ","2025","2068-LB: GLP-1RA Prescribing Patterns among Youth with T2DM at an Academic Pediatric Endocrinology Clinic","Diabetes","American Diabetes Association","10.2337/db25-2068-lb","https://doi.org/10.2337/db25-2068-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033180","R0033180.pdf","paywalled","nonrandomized_study","Wen-Teng Lee","2025","GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025rdy8v05v","https://doi.org/10.1681/asn.2025rdy8v05v",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033196","R0033196.pdf","paywalled","nonrandomized_study","Katia Hannah","2025","Association of Dexcom Continuous Glucose Monitor (CGM) Initiation with Improved Kidney Function in Adults with Diabetes and CKD on Insulin Therapy","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20250bjqr2tv","https://doi.org/10.1681/asn.20250bjqr2tv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033202","R0033202.pdf","paywalled","nonrandomized_study","Amara Sarwal","2025","Outcomes of Automatic E-Consults in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Rural Veterans with CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025ksby0c2g","https://doi.org/10.1681/asn.2025ksby0c2g",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033253","R0033253.pdf","paywalled","nonrandomized_study",null,"2025","An Assortment of Journal Abstracts to Enhance Oncology Care","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000000000000293","https://doi.org/10.1097/01.cot.0000000000000293",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033257","R0033257.pdf","paywalled","nonrandomized_study","Adriana M. Hung","2025","Target Emulation Trial of GLP-1 Receptor Agonists (GLP-1 RA), SGLT2 Inhibitors (SGLTi), or Dipeptidyl-Peptidase 4 Inhibitors (DPP4i) as Add-On Therapy in Primary Prevention of Kidney Outcomes Among Older Veterans","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025xn97dn13","https://doi.org/10.1681/asn.2025xn97dn13",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033258","R0033258.pdf","paywalled","nonrandomized_study","Genya Aharon‐Hananel","2025","Going with the FLOW: A Large Registry Study on Semaglutide and the Risk of Kidney Complications in Patients with Early Diabetic Kidney Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20254cepk3st","https://doi.org/10.1681/asn.20254cepk3st",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033261","R0033261.pdf","paywalled","nonrandomized_study","Szu‐Yu Pan","2025","Associations Between Antidiabetes Medications and Mortality in Patients on Dialysis: A National Study from Taiwan","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025940qe8e6","https://doi.org/10.1681/asn.2025940qe8e6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033266","R0033266.pdf","paywalled","nonrandomized_study",null,"2025","Ophthalmic Surgery","Journal of the American College of Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.1097/xcs.0000000000001562","https://doi.org/10.1097/xcs.0000000000001562",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033433","R0033433.pdf","paywalled","nonrandomized_study","Ragunathan Muthuswamy","2025","Evolution of Semaglutide as a Multifaceted Therapeutic Agent: Mechanism And Management To A Systematic Therapeutic Agent: A Comprehensive Review of Its Role beyond Type 2 Diabetes","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17447881","https://doi.org/10.5281/zenodo.17447881",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033469","R0033469.pdf","paywalled","nonrandomized_study","Anand Gupta*, Samir Raja, Fujail Ashraf, Khushi Kumari, Satyam Kumar, Sabreen Khatoon, Sakshi Kumari, Md. Rehan Sanwar, Shana Shabbir, Md. Saif","2025","A Study of Adverse Drug Reactions due to Anti-Obesity Drugs in Diabetic Patients in a Multispecialty Hospital","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17515585","https://doi.org/10.5281/zenodo.17515585",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033487","R0033487.pdf","paywalled","nonrandomized_study","American Medical Association 2025","2025","Short-Term Complications After TKA in Patients with Prior Bariatric Surgery or GLP-1 Agonist Use","Underline Science Inc.",null,"10.48448/3e9w-zr41","https://doi.org/10.48448/3e9w-zr41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033490","R0033490.pdf","paywalled","nonrandomized_study","Dr. S. Arthanareeswaran, Dr. R. Subashini*, R. Mounisha, R. Preethi, N. Preethika, S. Priyadharshini, T. Manisha","2025","Dual GIP/GLP-1 Receptor Agonism in Diabetes and Obesity: A Review of Tirzepatide's Efficacy and Safety","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17918417","https://doi.org/10.5281/zenodo.17918417",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033508","R0033508.pdf","paywalled","nonrandomized_study","American Medical Association 2025","2025","From Forum to Clinic: Transforming Patient Narratives into Clinical Insights Using Autonomous AI","Underline Science Inc.",null,"10.48448/v9y3-wm36","https://doi.org/10.48448/v9y3-wm36",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033510","R0033510.pdf","paywalled","nonrandomized_study","Navarrete, Ricardo ET","2025","Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17066370","https://doi.org/10.5281/zenodo.17066370",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033522","R0033522.pdf","paywalled","nonrandomized_study","Navarrete, Ricardo ET","2025","Adjuvant Dapagliflozin in Kidney Transplant Recipients with Diabetes and Heart Failure – A Real-World Data Exploratory Study","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17247451","https://doi.org/10.5281/zenodo.17247451",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033529","R0033529.pdf","paywalled","nonrandomized_study","Chawla Amit","2025","Diabetes: Status of disease in India and its Treatment policy","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15369509","https://doi.org/10.5281/zenodo.15369509",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033666","R0033666.pdf","paywalled","nonrandomized_study","Crespo, Javier","2025","Futurismo, presentismo y gestión clínica de la MASLD","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17854701","https://doi.org/10.5281/zenodo.17854701",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033713","R0033713.pdf","paywalled","nonrandomized_study","American Medical Association 2025","2025","Safety and Efficacy of Phentermine and Topiramate for Weight Loss in Obesity-Related HFpEF","Underline Science Inc.",null,"10.48448/trjm-gy02","https://doi.org/10.48448/trjm-gy02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033717","R0033717.pdf","paywalled","nonrandomized_study","Sumit Ghosh1, Yash Srivastav2, Shonu Jain3, Nilanjan Pahari4, Soni Singh5, Johny Lakra6, Sujit Kumar Panda7, Jayalakshmi M.8, Srinivas Venkatraman*9","2025","Polycystic Ovary Syndrome as a Multi-System Disorder: A Comprehensive Review of Hormonal, Metabolic, and Inflammatory Crosstalk at the Cellular and Molecular Level","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17047471","https://doi.org/10.5281/zenodo.17047471",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033727","R0033727.pdf","paywalled","nonrandomized_study","Giotas, Ilias","2025","GLP-1 Receptor Agonists and Cholelithiasis: A Comprehensive Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15303789","https://doi.org/10.5281/zenodo.15303789",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033752","R0033752.pdf","paywalled","nonrandomized_study","Che‐Yuan Wu","2025","Additional file 1 of Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","Figshare",null,"10.6084/m9.figshare.30970098.v1","https://doi.org/10.6084/m9.figshare.30970098.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033753","R0033753.pdf","paywalled","nonrandomized_study","Praveen Kumar Vuppula1* and Shiva Prasad Thoutu2","2025","THE HIDDEN SIDE OF MOUNJARO (TIRZEPATIDE) WEIGHT LOSS: NAVIGATING ADVERSE DRUG REACTIONS AND SOCIAL QUESTIONS","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17766991","https://doi.org/10.5281/zenodo.17766991",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033832","R0033832.pdf","paywalled","nonrandomized_study","Giotas, Ilias","2025","Retatrutide: Α triple incretin receptor agonist showing promise in obesity treatment","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15299219","https://doi.org/10.5281/zenodo.15299219",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033910","R0033910.pdf","paywalled","nonrandomized_study","Jaisawal, Sudheer","2025","Navigating the Perfect Storm: A Comprehensive Analysis of US Healthcare Industry Pain Points 2024-2025","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15598190","https://doi.org/10.5281/zenodo.15598190",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033975","R0033975.pdf","paywalled","nonrandomized_study","Chaiyakunapruk, Nathorn","2025","Additional file 1 of Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","Figshare",null,"10.6084/m9.figshare.28862501","https://doi.org/10.6084/m9.figshare.28862501",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034035","R0034035.pdf","paywalled","nonrandomized_study","Morieri, Mario Luca","2025","Additional file 1 of Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods","Figshare",null,"10.6084/m9.figshare.30390553","https://doi.org/10.6084/m9.figshare.30390553",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034241","R0034241.pdf","paywalled","nonrandomized_study","Payal Shelke*, Rutuja Ghumare, Vaishnavi Rakshe, Mansi Deshmukh, Bhakti Shirke, Vedika Aandhle, Priyanka Panmand","2025","A Narrative Review on Clinical Evidence of Tirzepatide's Role in Addressing Type 2 Diabetes and Obesity Management","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17570995","https://doi.org/10.5281/zenodo.17570995",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034348","R0034348.pdf","paywalled","nonrandomized_study","Jo-Ching Chen","2025","Comparative analysis of GLP-1 receptor agonists, traditional glucose-lowering medications and traditional anti-obesity medications on skeletal outcomes in obese individuals with and without type 2 diabetes: a five-year propensity-score matched cohort study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p684","https://doi.org/10.1530/endoabs.110.p684",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034349","R0034349.pdf","paywalled","nonrandomized_study","Katarina Štajer","2025","Real-world outcomes of liraglutide treatment in children with obesity: beyond weight loss","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p696","https://doi.org/10.1530/endoabs.110.p696",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034397","R0034397.pdf","paywalled","nonrandomized_study","Tusharbhai Patel","2025","Abstract 4366880: Rates of Atrial Fibrillation and Atrial Flutter in Non-diabetic Obese Adult Patients on Tirzepatide","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4366880","https://doi.org/10.1161/circ.152.suppl_3.4366880",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034427","R0034427.pdf","paywalled","nonrandomized_study","Lopez de Linares Lidia Urbon","2025","Real-world effect of tirzepatide: a prospective observational study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.ep967","https://doi.org/10.1530/endoabs.110.ep967",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034507","R0034507.pdf","paywalled","nonrandomized_study","Jessica Khoury","2025","Abstract Th0048: How do novel type 2 diabetes mellitus (T2DM) medications affect lipid parameters in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes","Arteriosclerosis Thrombosis and Vascular Biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atv.45.suppl_1.th0048","https://doi.org/10.1161/atv.45.suppl_1.th0048",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034659","R0034659.pdf","paywalled","nonrandomized_study","Harendra Kumar","2025","Abstract 4370717: Maternal GLP-1 Receptor Agonist Exposure and the Risk of Congenital Cardiovascular Defects: A Global Pharmacovigilance Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370717","https://doi.org/10.1161/circ.152.suppl_3.4370717",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034700","R0034700.pdf","paywalled","nonrandomized_study","Harendra Kumar","2025","Abstract 4368923: Impact of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy on Cardiovascular Events in Hospitalized Diabetic Patients: A National Inpatient Sample Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368923","https://doi.org/10.1161/circ.152.suppl_3.4368923",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034714","R0034714.pdf","paywalled","nonrandomized_study","Schaub, Jennifer A","2025","Analytic code for manuscript: The impact of SGLT2 inhibitors and GLP-1 receptor agonists on 24-hour urine parameters: a retrospective cohort study","University of Michigan Library",null,"10.7302/55an-x018","https://doi.org/10.7302/55an-x018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034747","R0034747.pdf","paywalled","nonrandomized_study","Po‐Huang Lee","2025","P263 – Glucagon-like peptide-1 agonist is associated with an increased risk of nephrolithiasis: A retrospective analysis of TriNetX data","European Urology","Elsevier BV","10.1016/j.eururo.2025.09.2712","https://doi.org/10.1016/j.eururo.2025.09.2712",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035890","R0035890.pdf","paywalled","nonrandomized_study","Diana Pinzón","2025","1743-P: Assessing Disparities in Diabetes Prevention and Obesity Pharmacotherapy Treatment Outcomes among Veterans—A Local Cohort Study","Diabetes","American Diabetes Association","10.2337/db25-1743-p","https://doi.org/10.2337/db25-1743-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035910","R0035910.pdf","paywalled","nonrandomized_study",null,"2025","EMA safety committee to review link between semaglutide and rare eye condition","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.344423","https://doi.org/10.1211/pj.2025.1.344423",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035948","R0035948.pdf","paywalled","nonrandomized_study","Arman Saeedi","2025","Evaluating the Role of Anti-Obesity Medications in Modifying Risks of Visual and CSF Complications in Idiopathic Intracranial Hypertension","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0045-1803092","https://doi.org/10.1055/s-0045-1803092",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036013","R0036013.pdf","paywalled","nonrandomized_study","M Füchtenbusch","2025","Treatment utilization patterns and characteristics of individuals using tirzepatide for type 2 diabetes in Germany","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807432","https://doi.org/10.1055/s-0045-1807432",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036126","R0036126.pdf","paywalled","nonrandomized_study","Anna Ferrulli","2025","760-P: Real-World Efficacy of Combined SGLT2i and GLP-1RA Therapy in Elderly Patients with Type 2 Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db25-760-p","https://doi.org/10.2337/db25-760-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036509","R0036509.pdf","paywalled","nonrandomized_study","Köhler-Forsberg, Ole","2025","Effect of GLP-1RA, SGLT2i, and DPP-4i on incident depression in individuals with type 2 diabetes: A Danish nationwide target trial emulation","Open Science Framework",null,"10.17605/osf.io/y67fg","https://doi.org/10.17605/osf.io/y67fg",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036529","R0036529.pdf","paywalled","nonrandomized_study","Mortensen, Ole Steen","2025","A nationwide target trial emulation evaluating whether initiation of GLP-1 receptor agonists reduces work disability among adults with low back pain","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/qd7ap","https://doi.org/10.17605/osf.io/qd7ap",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036538","R0036538.pdf","paywalled","nonrandomized_study","Pottegård, Anton","2025","Association between SGLT2 inhibitors use and risk of phimosis: A Norwegian cohort study","Open Science Framework",null,"10.17605/osf.io/yzrj3","https://doi.org/10.17605/osf.io/yzrj3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036556","R0036556.pdf","paywalled","nonrandomized_study","Κυρτσόπουλος, Μιχαήλ Γεωργίου","2025","Real-world evidence on the cardiovascular impact of GLP-1 RAs in diabetic patients with and without heart failure: Insights from longitudinal data of Greek tertiary hospitals","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.361792","https://doi.org/10.26262/heal.auth.ir.361792",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05176769"],["4","R0036569","R0036569.pdf","paywalled","nonrandomized_study","Kildegaard, Helene","2025","Impact of semaglutide introduction on the use of antimigraine medication: an interrupted-time series","Open Science Framework",null,"10.17605/osf.io/jum4z","https://doi.org/10.17605/osf.io/jum4z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036588","R0036588.pdf","paywalled","nonrandomized_study","Bykov, Katsiaryna","2025","Risk of Gastrointestinal Events Associated with Concomitant Use of Oxycodone, Hydrocodone, and Tramadol in Patients Receiving GLP-1RA","Open Science Framework",null,"10.17605/osf.io/spn5r","https://doi.org/10.17605/osf.io/spn5r",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036596","R0036596.pdf","paywalled","nonrandomized_study","Fraietta, Renato","2025","Effect of the use of GLP-1 analogues on sex hormones, seminal parameters and sperm function in obese men - A scoping review","Open Science Framework",null,"10.17605/osf.io/g9fbq","https://doi.org/10.17605/osf.io/g9fbq",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036607","R0036607.pdf","paywalled","nonrandomized_study","Elsworth, Rebecca","2025","Exploring perspectives on a novel weight loss device and on ecological momentary assessment as a tool to measure appetite in underserved communities","Open Science Framework",null,"10.17605/osf.io/t37ye","https://doi.org/10.17605/osf.io/t37ye",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036644","R0036644.pdf","paywalled","nonrandomized_study","Fuglsang, Nina Friis Bak","2025","Comparative effectiveness of GLP-1RA, SGLT2i, and DPP-4i on preventing the worsening of depression in comorbid patients with depression and type 2 diabetes: A Danish nationwide target trial emulation","Open Science Framework",null,"10.17605/osf.io/hws97","https://doi.org/10.17605/osf.io/hws97",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036669","R0036669.pdf","paywalled","nonrandomized_study","Θεοδωρίδου, Κωνσταντίνα Σπυρίδων","2025","Safety profile of glucagon-like peptide-1 agonists (GLP1) for weight loss, a scoping review","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.361756","https://doi.org/10.26262/heal.auth.ir.361756",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036689","R0036689.pdf","paywalled","nonrandomized_study","Hosam I. Taha","2025","Cardiovascular, Metabolic, and Hepatic Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease: Comparative Efficacy of Semaglutide versus Sodium–Glucose Cotransporter 2 Inhibitors","Open Science Framework",null,"10.17605/osf.io/fujyp","https://doi.org/10.17605/osf.io/fujyp",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036695","R0036695.pdf","paywalled","nonrandomized_study","Hammarberg, Anders","2025","Mapping Alcohol Use and Mental Health in Diabetes: An Explorative Study","Open Science Framework",null,"10.17605/osf.io/57wj9","https://doi.org/10.17605/osf.io/57wj9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036829","R0036829.pdf","paywalled","nonrandomized_study","Simranjeet Singh1, Ishrat Amin2, Bisma Ayoub3, Yasir Ahmad Dar4, Ananya5, Lovepreet Singh6","2025","Cardiovascular Implications of NAFLD: Pathophysiology, Risk Assessment, and Clinical Management Strategies","Journal of Pharmaceutical Sciences",null,"10.5281/zenodo.17662909","https://doi.org/10.5281/zenodo.17662909",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036851","R0036851.pdf","paywalled","nonrandomized_study","Anuja Bhosale, Jagruti Desale, Durgesh Chitte","2025","A Review on Pharmacovigilance in the Treatment of Diabetic Patients","Journal of Pharmaceutical Sciences",null,"10.5281/zenodo.17986502","https://doi.org/10.5281/zenodo.17986502",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036855","R0036855.pdf","paywalled","nonrandomized_study","Iyad Khalifah Ahmad Al-Domi","2025","A real-world observational study comparing cardiovascular outcomes in patients with type 2 diabetes initiating mixed insulin versus newer oral antidiabetic agents as first injectable therapy","International Journal of Science and Research Archive",null,"10.5281/zenodo.18337323","https://doi.org/10.5281/zenodo.18337323",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037065","R0037065.pdf","paywalled","nonrandomized_study","Varun Vemulapalli","2025","S3131 Effects of GLP-1RA Use on Upper GI Toxicity in Patients Receiving Platinum Analog-Based Chemotherapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001139984.75057.54","https://doi.org/10.14309/01.ajg.0001139984.75057.54",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037067","R0037067.pdf","paywalled","nonrandomized_study","Fariha Hasan","2025","S1911 Impact of GLP-1 Therapy on Disease Outcomes in Patients With Inflammatory Bowel Disease and Type 2 Diabetes: A Nationwide Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135104.41808.5b","https://doi.org/10.14309/01.ajg.0001135104.41808.5b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037093","R0037093.pdf","paywalled","nonrandomized_study","Danah Al-Deiri","2025","1984-LB: All-Cause Mortality and GI Adverse Effects in Adults with Type 1 Diabetes (T1D) on GLP-1RA","Diabetes","American Diabetes Association","10.2337/db25-1984-lb","https://doi.org/10.2337/db25-1984-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037184","R0037184.pdf","paywalled","nonrandomized_study","Lorenz Büchler","2025","Is It Beneficial to Delay Surgery for Weight Loss in Obese Patients Before THA?","Journal of Bone and Joint Surgery","Ovid Technologies (Wolters Kluwer Health)","10.2106/jbjs.24.01481","https://doi.org/10.2106/jbjs.24.01481","40237720","https://pubmed.ncbi.nlm.nih.gov/40237720/",null,null],["4","R0037197","R0037197.pdf","paywalled","nonrandomized_study","Vincent Dioguardi","2025","S1975 GLP1-RA in Patients With Crohn's Disease Independently Associated With Reduction in SEMA-CD Score","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135360.07354.89","https://doi.org/10.14309/01.ajg.0001135360.07354.89",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037198","R0037198.pdf","paywalled","nonrandomized_study","Cameron G. Gmehlin","2025","Retrospective Review of the Impact of Glucagon-like Peptide 1 Agonists on Gastrointestinal Motility and Outcomes in the Medical ICU","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a3800","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a3800",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037246","R0037246.pdf","paywalled","nonrandomized_study","SONALI A. PATANGE","2025","746-P: Time in Tight Range with Oral Semaglutide as an Add on to SGLT2i and Metformin Combination in People with Type 2DM—Real-World Evidence from India","Diabetes","American Diabetes Association","10.2337/db25-746-p","https://doi.org/10.2337/db25-746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037270","R0037270.pdf","paywalled","nonrandomized_study",null,"2025","Editors’ Selections from Relevant Scientific Publications","Cancer Prevention Research","American Association for Cancer Research (AACR)","10.1158/1940-6207.capr-18-11-hfl","https://doi.org/10.1158/1940-6207.capr-18-11-hfl","41178363","https://pubmed.ncbi.nlm.nih.gov/41178363/",null,null],["4","R0037295","R0037295.pdf","paywalled","nonrandomized_study","Kevin Lin","2025","S780 Predictors of Weight Loss Following Endoscopic Re-Suturing Post Endoscopic Sleeve Gastroplasty","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130580.58233.56","https://doi.org/10.14309/01.ajg.0001130580.58233.56",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037305","R0037305.pdf","paywalled","nonrandomized_study","Xiaocao Xu","2025","Glucagon-like peptide-1 receptor agonists and the risk of chemotherapy-induced peripheral neuropathy in patients with diabetes: A real-world study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.12133","https://doi.org/10.1200/jco.2025.43.16_suppl.12133",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037313","R0037313.pdf","paywalled","nonrandomized_study","Adis journals of behalf of","2025","Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study","Figshare",null,"10.6084/m9.figshare.29532950","https://doi.org/10.6084/m9.figshare.29532950",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037336","R0037336.pdf","paywalled","nonrandomized_study","Chidera Onwuzo","2025","S2605 GLP-1 Analogs Linked to Lower Ascites, Paracentesis, and SBP Rates in Cirrhosis: Insights From a Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137880.52226.7f","https://doi.org/10.14309/01.ajg.0001137880.52226.7f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037359","R0037359.pdf","paywalled","nonrandomized_study","Maria Elena Lunati","2025","22-PUB: Semaglutide Improves Metabolic Profile in Patients with LADA","Diabetes","American Diabetes Association","10.2337/db25-22-pub","https://doi.org/10.2337/db25-22-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037366","R0037366.pdf","paywalled","nonrandomized_study","Bowers, Cameron","2025","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Hip Arthroplasty: A Propensity Matched Comparison",null,null,"10.13140/rg.2.2.19455.52645","https://doi.org/10.13140/rg.2.2.19455.52645",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037477","R0037477.pdf","paywalled","nonrandomized_study","A R Rahmani","2025","The impact of GLP-1 receptor agonists on cognitive decline in heart failure patients: a retrospective cohort study using real world data","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1431","https://doi.org/10.1093/eurheartj/ehaf784.1431",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037513","R0037513.pdf","paywalled","nonrandomized_study","Stephen Shields","2025","S1593 Temporal Patterns of Body Mass Index, Health Care Resource Utilization, and Biomarkers in Patients With Ulcerative Colitis; A Descriptive Study of Electronic Health Records","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133832.70875.f5","https://doi.org/10.14309/01.ajg.0001133832.70875.f5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037641","R0037641.pdf","paywalled","nonrandomized_study","Harendra Kumar","2025","S2597 Semaglutide Use Is Associated With Lower Risk of Cirrhosis Among Hospitalized Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Analysis Using the National Inpatient Sample","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137848.14651.18","https://doi.org/10.14309/01.ajg.0001137848.14651.18",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037658","R0037658.pdf","paywalled","nonrandomized_study","Emily Shu-Yen Chan","2025","S2634 GLP-1 Receptor Agonist Use Is Associated With Lower Risks of Cardiovascular and Kidney Outcomes in Type 2 Diabetic Liver Transplant Recipients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137996.11428.4a","https://doi.org/10.14309/01.ajg.0001137996.11428.4a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037708","R0037708.pdf","paywalled","nonrandomized_study","Mona Abdel‐Bary","2025","Effects of Preoperative Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss After Bariatric Surgery","Bariatric Surgical Practice and Patient Care","SAGE Publications","10.1177/2168023x251389594","https://doi.org/10.1177/2168023x251389594",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037743","R0037743.pdf","paywalled","nonrandomized_study","journals on behalf of:, Adis","2025","Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients With Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study","Figshare",null,"10.6084/m9.figshare.30580040","https://doi.org/10.6084/m9.figshare.30580040",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037768","R0037768.pdf","paywalled","nonrandomized_study","Benjamin M. Moy","2025","S87 Early Signs of Pancreas Adenocarcinoma Are Often Missed on Cross-Sectional Imaging: Results From a Multicenter Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126808.04121.09","https://doi.org/10.14309/01.ajg.0001126808.04121.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037777","R0037777.pdf","paywalled","nonrandomized_study","Mohamed Ebrahim","2025","Su2051: ANALYZING THE GASTROINTESTINAL BURDEN OF GLP-1 AGONISTS: A RETROSPECTIVE FAERS ANALYSIS OF ADVERSE EVENTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03103-8","https://doi.org/10.1016/s0016-5085(25)03103-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037783","R0037783.pdf","paywalled","nonrandomized_study","Amin Tajerian","2025","One-year cardiovascular outcomes before and after GLP-1 ra discontinuation: a real-world retrospective cohort study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1624","https://doi.org/10.1093/eurheartj/ehaf784.1624",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037789","R0037789.pdf","paywalled","nonrandomized_study","Jose Villamarin","2025","S1890 Safety and Weight Loss Outcomes of Tirzepatide in Obesity Patients With Inflammatory Bowel Disease: A Matched-Control Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135020.04175.da","https://doi.org/10.14309/01.ajg.0001135020.04175.da",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037790","R0037790.pdf","paywalled","nonrandomized_study","Ahmed Abuhasna","2025","S2552 Semaglutide Versus Sodium-Glucose Cotransporter-2 Inhibitors for Liver and Cardiovascular Outcomes in Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score-Matched Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137668.83929.70","https://doi.org/10.14309/01.ajg.0001137668.83929.70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037800","R0037800.pdf","paywalled","nonrandomized_study","Kyle Scholten","2025","S1224 Double Trouble: The Effect of Opioid and GLP-1 Agonist Use on Peri- and Post-Operative Complications","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132356.72629.5e","https://doi.org/10.14309/01.ajg.0001132356.72629.5e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037801","R0037801.pdf","paywalled","nonrandomized_study","Robert Molina","2025","S1264 Comparison of Aspiration Risk in Patients Undergoing Upper Endoscopy vs Colonoscopy While on GLP-1 Agonist Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132516.80767.63","https://doi.org/10.14309/01.ajg.0001132516.80767.63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037808","R0037808.pdf","paywalled","nonrandomized_study","Z. Dhanani","2025","Assessing the Role of GLP-1 Receptor Agonists in Lung Transplantation: Risks and Benefits","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a1870","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a1870",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037835","R0037835.pdf","paywalled","nonrandomized_study","Gordon Hong","2025","S790 Risk of Neuroendocrine Neoplasms With Glucagon-Like-Petide-1 Receptor Agonist Use in Patients With Type 2 Diabetes Mellitus","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130620.01386.2d","https://doi.org/10.14309/01.ajg.0001130620.01386.2d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037836","R0037836.pdf","paywalled","nonrandomized_study",null,"2025","Comparative Risk of Pancreatitis and Related Outcomes in Diabetic Patients Using GLP-1 Receptor Agonists versus DPP-4 Inhibitors: A Propensity-matched Cohort Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.09.062","https://doi.org/10.1016/j.eprac.2025.09.062",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037841","R0037841.pdf","paywalled","nonrandomized_study","Bowers, Cameron","2025","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Knee Arthroplasty: A Propensity Matched Comparison",null,null,"10.13140/rg.2.2.21133.24802","https://doi.org/10.13140/rg.2.2.21133.24802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037927","R0037927.pdf","paywalled","nonrandomized_study","Jesus Lujan","2025","P30. Preoperative semaglutide use in patients undergoing single-level lumbar fusion results in lower infection and pseudoarthrosis rates: a propensity-matched retrospective cohort analysis","The Spine Journal","Elsevier BV","10.1016/j.spinee.2025.08.031","https://doi.org/10.1016/j.spinee.2025.08.031",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037948","R0037948.pdf","paywalled","nonrandomized_study","Wang, Joshua","2025","Impact of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Diabetic Macular Edema and Ophthalmic Outcomes: A Retrospective Cohort Analysis",null,null,"10.13140/rg.2.2.36543.21921","https://doi.org/10.13140/rg.2.2.36543.21921",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037962","R0037962.pdf","paywalled","nonrandomized_study","Ritu Singh","2025","SAT-415 Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01678-2","https://doi.org/10.1016/s0168-8278(25)01678-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037988","R0037988.pdf","paywalled","nonrandomized_study","Aun Muhammad","2025","S1603 GLP-1 Agonists in Inflammatory Bowel Disease: Does the Choice Between Semaglutide and Dulaglutide Matter?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133872.35314.33","https://doi.org/10.14309/01.ajg.0001133872.35314.33",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037997","R0037997.pdf","paywalled","nonrandomized_study",null,"2025","AMERICAN OTOLOGICAL SOCIETY PRELIMINARY PROGRAM 158th Annual Meeting May 16–18, 2025 New Orleans, LA","Otology & Neurotology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mao.0000000000004436","https://doi.org/10.1097/mao.0000000000004436","39951670","https://pubmed.ncbi.nlm.nih.gov/39951670/",null,null],["4","R0037999","R0037999.pdf","paywalled","nonrandomized_study","Adis Journals on behalf of","2025","Real-World Effectiveness of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study","Figshare",null,"10.6084/m9.figshare.30105244","https://doi.org/10.6084/m9.figshare.30105244",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038003","R0038003.pdf","paywalled","nonrandomized_study","Mohammad Abuassi","2025","S2264 Evaluating the Safety of GLP-1 Receptor Agonists in ERCP: A Propensity-Matched Analysis of Aspiration and Procedural Outcomes Before and After ASA Guideline Changes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136516.81245.bb","https://doi.org/10.14309/01.ajg.0001136516.81245.bb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038023","R0038023.pdf","paywalled","nonrandomized_study","Josue A. Davila","2025","S1632 GLP-1 Receptor Agonists Are Associated With Reduced IBD Exacerbations, Hospitalizations, and ER Visits: A Multicenter Observational Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133988.82754.9b","https://doi.org/10.14309/01.ajg.0001133988.82754.9b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038048","R0038048.pdf","paywalled","nonrandomized_study","O.P.Kovtun O.P.Kovtun","2025","Potential predictors of response to therapy in a cohort 24-week study of the efficacy and safety of liraglutide in obese adolescents aged 12–15 years old","Voprosy praktičeskoj pediatrii","Dynasty Publishing House","10.20953/1817-7646-2025-2-54-62","https://doi.org/10.20953/1817-7646-2025-2-54-62",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038057","R0038057.pdf","paywalled","nonrandomized_study","Rohan Raj","2025","S139 Sex-Related Disparities Observed in Acute Pancreatitis-Associated ARF/ARDS Mortality: A CDC WONDER Analysis (2018 to 2023)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127016.09366.b7","https://doi.org/10.14309/01.ajg.0001127016.09366.b7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038077","R0038077.pdf","paywalled","nonrandomized_study","Muaz Alsabbagh","2025","S3180 GLP-1 Receptor Agonist Use and Risk of Gastric Cancer: A Population-Based Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001140180.62996.32","https://doi.org/10.14309/01.ajg.0001140180.62996.32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038079","R0038079.pdf","paywalled","nonrandomized_study","Saud Alawad","2025","COMPARATIVE CARDIOPROTECTIVE EFFECTS OF GLP-1 RA VS SGLT2i INHIBITORS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM A LARGE-SCALE REAL-WORLD DATA ANALYSIS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3124","https://doi.org/10.1016/j.chest.2025.07.3124",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038092","R0038092.pdf","paywalled","nonrandomized_study",null,"2025","Literature Commentary","Journal of Neuro-Ophthalmology","Ovid Technologies (Wolters Kluwer Health)","10.1097/wno.0000000000002321","https://doi.org/10.1097/wno.0000000000002321","39879172","https://pubmed.ncbi.nlm.nih.gov/39879172/",null,null],["4","R0038111","R0038111.pdf","paywalled","nonrandomized_study","Tomomi Takeshima","2025","HSD7 Are Glucagon-Like Peptide-1 Receptor Agonists Prescribed for Weight Loss Slipping Through the Net of Japan’s Strict Guidelines? An Analysis of Health Insurance Claims Data","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.1668","https://doi.org/10.1016/j.jval.2025.09.1668",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038113","R0038113.pdf","paywalled","nonrandomized_study","P Gabert","2025","GLP-1 receptor agonists are associated with higher mitochondrial coupling efficiency in the human heart","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1252","https://doi.org/10.1093/eurheartj/ehaf784.1252",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038118","R0038118.pdf","paywalled","nonrandomized_study","Gicel J. Aguilar","2025","S2627 Metabolic Liver Disease in HCC: Underdiagnosis and Advanced Portal Hypertension in Patients With a MASH-Consistent Phenotype in a Diverse Southwestern Cohort","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137968.68500.bb","https://doi.org/10.14309/01.ajg.0001137968.68500.bb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038146","R0038146.pdf","paywalled","nonrandomized_study","Hassan Elsaygh","2025","Tu1754: THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON COLONIC ADENOMA INCIDENCE: A LARGE RETROSPECTIVE COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04283-0","https://doi.org/10.1016/s0016-5085(25)04283-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038185","R0038185.pdf","paywalled","nonrandomized_study","Varun Aitharaju","2025","S2554 Comparative Effectiveness of Initiating GLP-1 Receptor Agonists (GLP-1 RAs) vs SGLT-2 Inhibitors (SGLT2is) in Patients With Compensated MASLD Cirrhosis and Type 2 Diabetes: A Global Retrospective Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137676.76763.38","https://doi.org/10.14309/01.ajg.0001137676.76763.38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038205","R0038205.pdf","paywalled","nonrandomized_study","Ting‐Tai Yen","2025","Comparative effects of glucagon-like peptide-1 receptor agonists combined with hormone therapy on endometrial cancer risk among women with benign uterine or endometrial hyperplasia: A United States real-world retrospective study","Gynecologic Oncology","Elsevier BV","10.1016/j.ygyno.2025.04.029","https://doi.org/10.1016/j.ygyno.2025.04.029",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038223","R0038223.pdf","paywalled","nonrandomized_study","Wade N. O'Brien","2025","S171 The Over-Estimation of Pancreatic Cyst Malignant Transformation Rates: A Lesson From the EPIC Cosmos Database","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127144.37536.45","https://doi.org/10.14309/01.ajg.0001127144.37536.45",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038227","R0038227.pdf","paywalled","nonrandomized_study","Daiki Yoshiura","2025","Efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.910","https://doi.org/10.1093/eurheartj/ehaf784.910",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038257","R0038257.pdf","paywalled","nonrandomized_study","TAO-CHUN LEE","2025","409-P: The Prevalence and Factors Associated with CKD Remission in Patients with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db25-409-p","https://doi.org/10.2337/db25-409-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038269","R0038269.pdf","paywalled","nonrandomized_study","Ritu Singh","2025","SAT-414-YI Can non-diabetic patients with metabolic dysfunction associated steatotic liver disease benefit from glucagon-like peptide-1 analogs? A multicenter cohort study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01677-0","https://doi.org/10.1016/s0168-8278(25)01677-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038272","R0038272.pdf","paywalled","nonrandomized_study","Lina AlQirem","2025","S3058 Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001139692.64685.fa","https://doi.org/10.14309/01.ajg.0001139692.64685.fa",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038284","R0038284.pdf","paywalled","nonrandomized_study","Ruchir Paladiya","2025","P234 Glucagon-like-peptide-1 receptor agonists and cholecystitis incidence in type 2 diabetic mellitus and obesity: insights from the TriNetX database (2015–2024)",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-bsg.368","https://doi.org/10.1136/gutjnl-2025-bsg.368",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038288","R0038288.pdf","paywalled","nonrandomized_study","Aman Mohapatra","2025","S27 Detection of Ultra-High Risk Pancreatic Cancer Diagnoses Using a Custom NLP Pipeline Incorporating a Large Language Model: A Pilot Safety Net for Missed Diagnoses","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126568.63035.43","https://doi.org/10.14309/01.ajg.0001126568.63035.43",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038333","R0038333.pdf","paywalled","nonrandomized_study","Annie L. Wang","2025","S824 Impact of GLP-1 RA Therapy on Esophageal Motility Patterns","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130756.96696.bd","https://doi.org/10.14309/01.ajg.0001130756.96696.bd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038351","R0038351.pdf","paywalled","nonrandomized_study","Kermanjot Sidhu","2025","GLP-1 Receptor Agonists Associated With Reduced Surgical Interventions in Hidradenitis Suppurativa: A Propensity Score-Matched Analysis",null,null,"10.13140/rg.2.2.28313.68960","https://doi.org/10.13140/rg.2.2.28313.68960",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038365","R0038365.pdf","paywalled","nonrandomized_study","Abanoub J. Armanious","2025","Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.78391","https://doi.org/10.2196/preprints.78391",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038375","R0038375.pdf","paywalled","nonrandomized_study","Han Wu","2025","848-P: The Antidiabetic Medication Treatment Patterns in Chinese Patients with Type 2 Diabetes—Real-World Evidence from ICaReMe China Registry Study","Diabetes","American Diabetes Association","10.2337/db25-848-p","https://doi.org/10.2337/db25-848-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038446","R0038446.pdf","paywalled","nonrandomized_study","XIANG  Xinyue, ZHANG  Bingqing, OUYANG  Yuqin, TANG  Wenjuan, FENG  Wenhuan","2025","Impact of Short-term Medical Weight Loss on Atherosclerotic Cardiovascular Disease Risk in Patients with Obesity","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.12114/j.issn.1007-9572.2024.0652","https://doi.org/10.12114/j.issn.1007-9572.2024.0652",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038457","R0038457.pdf","paywalled","nonrandomized_study",null,"2025","Dose Initiation and the Risk of Semaglutide Discontinuation in Real-World Practice","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.501","https://doi.org/10.1016/j.eprac.2025.05.501",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038566","R0038566.pdf","paywalled","nonrandomized_study","Anders Holt","2025","Vagal activity related events and GLP-1 receptor agonists","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4315","https://doi.org/10.1093/eurheartj/ehaf784.4315",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038580","R0038580.pdf","paywalled","nonrandomized_study","Shawn Howell","2025","S2676 Effects of GLP-1 Agonists on Rates of Decompensated Liver Failure","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138164.34024.40","https://doi.org/10.14309/01.ajg.0001138164.34024.40",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038592","R0038592.pdf","paywalled","nonrandomized_study","Eli Malkovskiy","2025","152 GLP-1 Receptor Agonists are Associated With Reduced Fecal Calprotectin and Neutrophil Counts in Patients With Inflammatory Bowel Disease and Type 2 Diabetes Mellitus","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001173032.66112.39","https://doi.org/10.14309/01.ajg.0001173032.66112.39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038600","R0038600.pdf","paywalled","nonrandomized_study","Shreya Sakthivel","2025","Impact of SGLT2 Inhibitors and GLP-1 Agonists on Rheumatoid Arthritis Flares in Patients on DMARD Therapy: A Retrospective Study",null,null,"10.13140/rg.2.2.10947.57120","https://doi.org/10.13140/rg.2.2.10947.57120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038660","R0038660.pdf","paywalled","nonrandomized_study","Venket Rao","2025","1420-P: Adherence to ADA SOC Guidelines for CKD in Individuals with Diabetes at an Academic Primary Care Outpatient Practice","Diabetes","American Diabetes Association","10.2337/db25-1420-p","https://doi.org/10.2337/db25-1420-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038662","R0038662.pdf","paywalled","nonrandomized_study","NAVNEET GUPTA","2025","COMPARATIVE EFFECTIVENESS OF GLP-1 AGONISTS AND BARIATRIC SURGERY ON ASTHMA AND OBSTRUCTIVE SLEEP APNEA OUTCOMES: A PROPENSITY-MATCHED ANALYSIS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3050","https://doi.org/10.1016/j.chest.2025.07.3050",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038725","R0038725.pdf","paywalled","nonrandomized_study","Nicholas Noverati","2025","Tu1694: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THEIR EFFECTS ON GASTRIC EMPTYING SCANS: A RETROSPECTIVE REVIEW","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04259-3","https://doi.org/10.1016/s0016-5085(25)04259-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038729","R0038729.pdf","paywalled","nonrandomized_study","IRAKLI LEMONJAVA","2025","GLP-1 RECEPTOR AGONISTS AND RISK OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN TYPE 2 DIABETES: EVIDENCE FROM A LARGE, REAL-WORLD DATABASE ANALYSIS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3123","https://doi.org/10.1016/j.chest.2025.07.3123",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038751","R0038751.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2025","S1929 GLP-1 Receptor Agonists Decrease the Colorectal Cancer Rates in Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135176.67610.d3","https://doi.org/10.14309/01.ajg.0001135176.67610.d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038757","R0038757.pdf","paywalled","nonrandomized_study","Ikponmwosa Igbinigie","2025","Abstract 4367438: Evaluating Procedural Safety and Outcomes In GLP-1 Exposed Patients Undergoing TEE","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367438","https://doi.org/10.1161/circ.152.suppl_3.4367438",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038771","R0038771.pdf","paywalled","nonrandomized_study",null,"2025","Weight‐loss drugs improve outcomes in patients with alcohol use disorder","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31274","https://doi.org/10.1002/pu.31274",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038797","R0038797.pdf","paywalled","nonrandomized_study","Tina Yi Jin Hsieh","2025","Comparing the Effects of Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Events to Metformin in Patients With Polycystic Ovary Syndrome: A Real-World Multicenter Cohort Study Across the United States [ID 1078]","Obstetrics and Gynecology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aog.0000000000005917.021","https://doi.org/10.1097/aog.0000000000005917.021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038809","R0038809.pdf","paywalled","nonrandomized_study","CHUN JUI HUANG","2025","814-P: Efficacy and Safety of Switching to Iglarlixi from Premix Insulin Regimen in Patients with T2DM—Real-World Experience","Diabetes","American Diabetes Association","10.2337/db25-814-p","https://doi.org/10.2337/db25-814-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038833","R0038833.pdf","paywalled","nonrandomized_study","Pradhan Hariharan","2025","S2643 Racial Disparities in Prevalence of Cirrhosis and Extrahepatic Manifestations in Alcohol-Associated Liver Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138032.23327.33","https://doi.org/10.14309/01.ajg.0001138032.23327.33",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038898","R0038898.pdf","paywalled","nonrandomized_study","Chidera Onwuzo","2025","S2606 GLP-1 Analogs in Cirrhosis: Reduced Mortality and Fewer Complications in a National Cohort","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137884.89687.d4","https://doi.org/10.14309/01.ajg.0001137884.89687.d4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038916","R0038916.pdf","paywalled","nonrandomized_study","Tina Yi Jin Hsieh","2025","Effects of glucagon-like peptide-1 receptor agonists on incident gynecologic cancer outcomes in endometriosis patients compared to metformin: A real-world multicenter retrospective cohort study across the United States","Gynecologic Oncology","Elsevier BV","10.1016/j.ygyno.2025.04.222","https://doi.org/10.1016/j.ygyno.2025.04.222",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038928","R0038928.pdf","paywalled","nonrandomized_study","Bangwei Wu","2025","296-OR: Underutilization of High-Intensity Statin Therapy in Patients with Type 2 Diabetes and Elevated Coronary Artery Inflammation Detected on Coronary CT Angiography","Diabetes","American Diabetes Association","10.2337/db25-296-or","https://doi.org/10.2337/db25-296-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038940","R0038940.pdf","paywalled","nonrandomized_study","Hamzah Shariff","2025","S1493 Clinical Effectiveness and Safety of GLP1RA in Patients With IBD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133432.99448.b2","https://doi.org/10.14309/01.ajg.0001133432.99448.b2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038947","R0038947.pdf","paywalled","nonrandomized_study","Puneet Chhabra","2025","IDDF2025-ABS-0165 Unmasking aspiration risks: a propensity matched odyssey of GLP-1 receptor agonists and colonoscopy","Clinical Gastroenterology","BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-iddf.221","https://doi.org/10.1136/gutjnl-2025-iddf.221",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038968","R0038968.pdf","paywalled","nonrandomized_study","Jin Jung","2025","766-P: GLP-1RA, Oral Formulation and Its Preclinical Evaluations","Diabetes","American Diabetes Association","10.2337/db25-766-p","https://doi.org/10.2337/db25-766-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038980","R0038980.pdf","paywalled","nonrandomized_study",null,"2025","GLP-1 RA Initiation and Risk of Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.607","https://doi.org/10.1016/j.eprac.2025.05.607",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039057","R0039057.pdf","paywalled","nonrandomized_study",null,"2025","Comparative Effectiveness of GLP-1 Receptor Agonists and Phentermine-Topiramate for Weight Loss in Patients with Obesity With and Without Type 2 Diabetes: A Retrospective Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.613","https://doi.org/10.1016/j.eprac.2025.05.613",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039068","R0039068.pdf","paywalled","nonrandomized_study","Yue Li","2025","Translational 3D spatiomolecular imaging in health and disease",null,"Karolinska Institutet","10.69622/30108748","https://doi.org/10.69622/30108748",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039115","R0039115.pdf","paywalled","nonrandomized_study","Alzyood, Laith","2025","GLP-1 Receptor Agonists and Inflammatory Protein Profiles in Advanced CKD: Insights from Two Cohort Studies","Journal of the American Society of Nephrology",null,"10.13140/rg.2.2.24568.30729","https://doi.org/10.13140/rg.2.2.24568.30729",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039130","R0039130.pdf","paywalled","nonrandomized_study","Yong Liu","2025","P0116 The Protective Role of PYY in Intestinal Mucosal Defects Induced by SATB2 Deficiency in Inflammatory Bowel Disease","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjae190.0290","https://doi.org/10.1093/ecco-jcc/jjae190.0290",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039155","R0039155.pdf","paywalled","nonrandomized_study","Jyotirmoy Sarker","2025","859-P: GLP-1 Receptor Agonists vs. DPP-4 Inhibitors and SGLT2 Inhibitors on Liver Outcomes in Metabolic Dysfunction–Associated Steatotic Liver Disease","Diabetes","American Diabetes Association","10.2337/db25-859-p","https://doi.org/10.2337/db25-859-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039181","R0039181.pdf","paywalled","nonrandomized_study","Amit Dang","2025","CO217 Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.318","https://doi.org/10.1016/j.jval.2025.09.318",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039194","R0039194.pdf","paywalled","nonrandomized_study","Sarpong Boateng","2025","S2080 Antiretroviral Therapy Enhances the Cardioprotective Benefit of GLP-1 Receptor Agonists in People With HIV","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135780.83910.54","https://doi.org/10.14309/01.ajg.0001135780.83910.54",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039231","R0039231.pdf","paywalled","nonrandomized_study",null,"2025","Research","Bone and Joint 360","British Editorial Society of Bone & Joint Surgery","10.1302/2048-0105.144.360255","https://doi.org/10.1302/2048-0105.144.360255",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039250","R0039250.pdf","paywalled","nonrandomized_study","Jordan Barnett-Kradjian","2025","S1102 GLP-1 Receptor Agonist Use for Reducing Symptom Burden and Medication Utilization in Non-Obese Women With IBS-D: A Propensity Matched Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131868.76662.c6","https://doi.org/10.14309/01.ajg.0001131868.76662.c6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039281","R0039281.pdf","paywalled","nonrandomized_study","‪Yifat Fundoiano-Hershcovitz","2025","530-P: Evaluating the Role of a Digital Health Platform in Supporting GLP-1 Adherence and Sustained Outcomes Post-discontinuation","Diabetes","American Diabetes Association","10.2337/db25-530-p","https://doi.org/10.2337/db25-530-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039322","R0039322.pdf","paywalled","nonrandomized_study","Karthic Drishna Perumal","2025","S754 Investigating the Prescription Patterns of GLP-1 Receptor Agonist Medications in Patients With Chronic Pancreatitis and Obesity","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130476.20703.6b","https://doi.org/10.14309/01.ajg.0001130476.20703.6b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039342","R0039342.pdf","paywalled","nonrandomized_study","Debbiche, Khalid","2025","Heterogeneity in Cardiovascular Risk Among Patients with Type 2 Diabetes: Insights from a Large Cardiology Database","Figshare",null,"10.6084/m9.figshare.29485859","https://doi.org/10.6084/m9.figshare.29485859",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039393","R0039393.pdf","paywalled","nonrandomized_study","Aman Goyal","2025","TCT-751 Outcomes of GLP-1 Receptor Agonist Use in Transcatheter Mitral Valve Repair or Replacement: A Real-World Analysis","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.917","https://doi.org/10.1016/j.jacc.2025.09.917",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039399","R0039399.pdf","paywalled","nonrandomized_study","J U N Y A N Zhang","2025","Differential effects of glucose-lowering agents on atherosclerotic plaque progression in diabetic patients: a retrospective cohort study using serial coronary CT angiography","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1724","https://doi.org/10.1093/eurheartj/ehaf784.1724",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039425","R0039425.pdf","paywalled","nonrandomized_study","Saqr Alsakarneh","2025","S797 Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists Used for Weight Loss: A Real-World Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130648.55090.4f","https://doi.org/10.14309/01.ajg.0001130648.55090.4f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039428","R0039428.pdf","paywalled","nonrandomized_study","Wang, Xiaoxia (M.S. in pharmaceutical sciences)","2025","The comparison of outcomes between metabolic bariatric surgery and glucagon-like peptide 1 receptor agonists (GLP-1 RA) after three years","Texas Digital Library (University of Texas)",null,"10.26153/tsw/61703","https://doi.org/10.26153/tsw/61703",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039458","R0039458.pdf","paywalled","nonrandomized_study","C J Chen","2025","GLP-1 RA vs DPP4i in patients with prior major adverse limb evets","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3019","https://doi.org/10.1093/eurheartj/ehaf784.3019",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039479","R0039479.pdf","paywalled","nonrandomized_study","Ningjing Qian","2025","Dietary intake based leg muscle building and fat loss: reducing the cardiovascular-cause mortality","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3769","https://doi.org/10.1093/eurheartj/ehaf784.3769",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039489","R0039489.pdf","paywalled","nonrandomized_study","YICHEN E. FANG","2025","751-P: The Risk of Acute Pancreatitis and Biliary Events after Initiation of GLP-1RA, SGLT2i, or DPP-4i in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db25-751-p","https://doi.org/10.2337/db25-751-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039491","R0039491.pdf","paywalled","nonrandomized_study","Xiaoliang Wang","2025","S1594 Association Between SGLT2 Inhibitor Use and Inflammatory Bowel Disease in Non-Diabetic Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133836.48463.29","https://doi.org/10.14309/01.ajg.0001133836.48463.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039515","R0039515.pdf","paywalled","nonrandomized_study","Mohamed Nadeem","2025","S1885 Impact of GLP-1 Receptor Agonist or GIP/GLP-1 Receptor Agonist on Clinical Outcomes in Obese Patients With Inflammatory Bowel Disease: A Propensity-Matched Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135000.32511.d8","https://doi.org/10.14309/01.ajg.0001135000.32511.d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039537","R0039537.pdf","paywalled","nonrandomized_study","Ricardo Flores","2025","S1289 Peri-Operative Use of Glucagon-Like Peptide 1 (GLP-1) Agonists Is Associated with Retained Gastric Contents During Upper Endoscopy and Procedure Abortion, But Not With Procedural Complications","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132616.34609.d2","https://doi.org/10.14309/01.ajg.0001132616.34609.d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039547","R0039547.pdf","paywalled","nonrandomized_study","Nutchapon Xanthavanij","2025","Association Between GLP-1 Agonists/co-agonists and Thromboembolic Events in COPD Patients: A Retrospective Cohort Study","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a6152","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a6152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039554","R0039554.pdf","paywalled","nonrandomized_study","Hyunsuk Lee","2025","28-OR: GLP1R R131Q is a Gs-Biased Gain-of-Function Variant Associated with Preservation of β-Cell Function","Diabetes","American Diabetes Association","10.2337/db25-28-or","https://doi.org/10.2337/db25-28-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039603","R0039603.pdf","paywalled","nonrandomized_study","Schyler McBride","2025","S517 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) Significantly Impair Quality Metrics for Colonoscopy Preparations, Even When Held 7 Days Prior to Procedure","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129528.48929.23","https://doi.org/10.14309/01.ajg.0001129528.48929.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039628","R0039628.pdf","paywalled","nonrandomized_study","Sevag Hamamah","2025","S2243 Trends in Utilization and Outcomes After Endoscopic Bariatric Therapies: An MBSAQIP Database Analysis From 2016-2023","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136432.64243.30","https://doi.org/10.14309/01.ajg.0001136432.64243.30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039630","R0039630.pdf","paywalled","nonrandomized_study","NOHA EL YAMAN","2025","1158-P: Evolving Trends in GLP-1 Receptor Agonist Prescriptions for Pediatric Type 2 Diabetes—A Retrospective Analysis (2019–2024)","Diabetes","American Diabetes Association","10.2337/db25-1158-p","https://doi.org/10.2337/db25-1158-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039635","R0039635.pdf","paywalled","nonrandomized_study","Ali Akram Qureshi","2025","Abstract 4371168: Comparative Outcomes of GLP-1 Agonists vs SGLT2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure: A Propensity-Matched Multicenter Retrospective Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371168","https://doi.org/10.1161/circ.152.suppl_3.4371168",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039640","R0039640.pdf","paywalled","nonrandomized_study","Matthew Still","2025","S1757 Impact of Glucagon-Like Peptide-1 Receptor Agonists on Inflammatory Bowel Disease in Patients With and Without Type 2 Diabetes Mellitus","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001134488.18764.c4","https://doi.org/10.14309/01.ajg.0001134488.18764.c4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039658","R0039658.pdf","paywalled","nonrandomized_study","Raffaele Marfella","2025","Microplastics and nanoplastics: tiny threats for cardiovascular diseases?","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvaf143","https://doi.org/10.1093/cvr/cvaf143","40919846","https://pubmed.ncbi.nlm.nih.gov/40919846/",null,null],["4","R0039678","R0039678.pdf","paywalled","nonrandomized_study","Wajd Alkabbani","2025","768-P: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Motility-Related Gastrointestinal Adverse Events—A Cohort Study","Diabetes","American Diabetes Association","10.2337/db25-768-p","https://doi.org/10.2337/db25-768-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039688","R0039688.pdf","paywalled","nonrandomized_study","Orsolya Tímár","2025","Diabetes and prediabetes prevalence and guideline directed antidiabetic therapy in acute coronary syndrome and complex coronary interventions","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3658","https://doi.org/10.1093/eurheartj/ehaf784.3658",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039801","R0039801.pdf","paywalled","nonrandomized_study","Steven H J Hageman","2025","EPH84 Estimated Healthcare Resource Utilization and Costs Associated With Semaglutide Life Expectancy Gains in a Real-World Population With CVD and Overweight or Obesity in the United Kingdom","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.1213","https://doi.org/10.1016/j.jval.2025.09.1213",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039814","R0039814.pdf","paywalled","nonrandomized_study","Jason N. Chen","2025","S2613 Assessing the Effects of Glucagon-Like Peptide-1 Agonists and Lifestyle Changes on Fibrosis and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137912.22199.46","https://doi.org/10.14309/01.ajg.0001137912.22199.46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039856","R0039856.pdf","paywalled","nonrandomized_study","Nishani Wickramarachchi","2025","S2830 Alcohol Use Reduction With GLP-1 Agonist Use","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138780.07976.e4","https://doi.org/10.14309/01.ajg.0001138780.07976.e4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039861","R0039861.pdf","paywalled","nonrandomized_study","Bowers, Cameron","2025","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Shoulder Arthroplasty: A Propensity Matched Comparison",null,null,"10.13140/rg.2.2.10647.48808","https://doi.org/10.13140/rg.2.2.10647.48808",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039904","R0039904.pdf","paywalled","nonrandomized_study","William H. Polonsky","2025","786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA","Diabetes","American Diabetes Association","10.2337/db25-786-p","https://doi.org/10.2337/db25-786-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039918","R0039918.pdf","paywalled","nonrandomized_study","Katherine L. Gibbs","2025","CO205 Real-World Evidence on the Broader Benefits of GLP-1RA-Based Therapies: A Global Targeted Literature Review","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.306","https://doi.org/10.1016/j.jval.2025.09.306",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039923","R0039923.pdf","paywalled","nonrandomized_study","Shizuka Kaneko","2025","378-P: Enhanced Renal Protective Effects of Tirzepatide in T2D People","Diabetes","American Diabetes Association","10.2337/db25-378-p","https://doi.org/10.2337/db25-378-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040799","R0040799.pdf","paywalled","nonrandomized_study","Do, Kimchi","2025","Comparing management of cardio-metabolic risk in Diabetes Related Foot Disease: a retrospective audit","UNSWorks (University of New South Wales, Sydney, Australia)",null,"10.26190/unsworks/31417","https://doi.org/10.26190/unsworks/31417",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040813","R0040813.pdf","paywalled","nonrandomized_study","Elizabeth Mohney","2025","Propensity score matching in semaglutide retrospective studies","arXiv (Cornell University)",null,"10.48550/arxiv.2501.05533","https://doi.org/10.48550/arxiv.2501.05533",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041460","R0041460.pdf","paywalled","nonrandomized_study","Mouhand Mohamed","2025","57 Underutilization of Weight-Management Interventions in Patients With IBD and Obesity: A Propensity-Matched Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001172652.40278.4e","https://doi.org/10.14309/01.ajg.0001172652.40278.4e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042024","R0042024.pdf","paywalled","nonrandomized_study","S ARMSTRONG","2025","758-P: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset","Diabetes","American Diabetes Association","10.2337/db25-758-p","https://doi.org/10.2337/db25-758-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042189","R0042189.pdf","paywalled","nonrandomized_study","Emma Simonsen","2025","Real-World Use and Dosing Patterns of Semaglutide for Weight Management in Denmark 2022–2025",null,null,"10.17605/osf.io/twbu9","https://doi.org/10.17605/osf.io/twbu9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042218","R0042218.pdf","paywalled","nonrandomized_study","Rothman, Sonny","2025","Incretin-based drugs and the incidence of endometrial cancer among patients with type 2 diabetes","eScholarship@McGill (McGill)",null,"10.82308/49186","https://doi.org/10.82308/49186",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042281","R0042281.pdf","paywalled","nonrandomized_study","L. Parker Gregg","2025","Risk Assessment in Cardiovascular-Kidney-Metabolic Syndrome","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000000973","https://doi.org/10.2215/cjn.0000000973","41414951","https://pubmed.ncbi.nlm.nih.gov/41414951/",null,null],["4","R0042950","R0042950.pdf","paywalled","nonrandomized_study","Tara Shahrvini","2025","Abstract 4343038: Effects of cardiac rehabilitation on body composition changes in patients receiving GLP-1 receptor agonists","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4343038","https://doi.org/10.1161/circ.152.suppl_3.4343038",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043490","R0043490.pdf","paywalled","nonrandomized_study","Maxim Bird","2025","Determining the gastrointestinal stability of peptide therapeutics via chromatographic methods",null,null,"10.25560/128174","https://doi.org/10.25560/128174",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043556","R0043556.pdf","paywalled","nonrandomized_study","Rodrigues, Ana Clara Martins","2025","Efficacy and Safety of the Combined Use of Antidiabetic Drugs: Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2) and Glucagon-Like Peptide-1 Receptor Agonists (GLP 1): A Scoping Review","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/yf73j","https://doi.org/10.17605/osf.io/yf73j",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043829","R0043829.pdf","paywalled","nonrandomized_study","Alsuhibani, Ali","2025","Enhancing Post-Marketing Pharmacovigilance: An AI-Driven System Approach for Safety Signal Detection of Adverse Drug Events: A Case Study of Glucagon-Like Peptide-1 Receptor Agonists","VCU Scholars Compass (Virginia Commonwealth University)",null,"10.25772/btp3-ze96","https://doi.org/10.25772/btp3-ze96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043891","R0043891.pdf","paywalled","nonrandomized_study","Deo, Salil Vasudeo","2025","Guideline directed medical therapy for secondary prevention after coronary artery bypass grafting","Enlighten: Theses (The University of Glasgow)",null,"10.5525/gla.thesis.85379","https://doi.org/10.5525/gla.thesis.85379",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044025","R0044025.pdf","paywalled","nonrandomized_study","Donglan Zhang (702608)","2025","Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes","Figshare",null,"10.60929/nyulangone.28995647.v1","https://doi.org/10.60929/nyulangone.28995647.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044169","R0044169.pdf","paywalled","nonrandomized_study","Cardoso, Mariane","2025","“Oral Health and Adverse Oral Effects Associated with Semaglutide and Tirzepatide: A Scoping Review”","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/2vhc6","https://doi.org/10.17605/osf.io/2vhc6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044311","R0044311.pdf","paywalled","nonrandomized_study","Jones, Emily Paige","2025","Impact of Incretin Mimetics on Body Composition: A Systematic Literature Review","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/s3a5e","https://doi.org/10.17605/osf.io/s3a5e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044448","R0044448.pdf","paywalled","nonrandomized_study","Felix Trautmann","2025","GLP-1 Receptor Agonists and Muscle Mass: A Narrative Review of What Body Composition Data Do and Do Not Show","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22261251","https://doi.org/10.5281/zenodo.22261251",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044467","R0044467.pdf","paywalled","nonrandomized_study","Bashaaer Sharad","2025","Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3791","https://doi.org/10.1093/eurheartj/ehaf784.3791",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044991","R0044991.pdf","paywalled","nonrandomized_study","Yixue Shao","2025","1067-P: Trends in Medical Expenditures before and after Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Initiation in U.S. Adults Aged 18–64 Years with Type 2 Diabetes (T2D) and Commercial Insurance","Diabetes","American Diabetes Association","10.2337/db25-1067-p","https://doi.org/10.2337/db25-1067-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045070","R0045070.pdf","paywalled","nonrandomized_study","Thai Hau Koo","2025","Sa1437: GLP-1 RECEPTOR AGONIST IN ACUTE PANCREATITIS, CHRONIC PANCREATITIS AND PANCREATIC DUCTAL ADENOCARCINOMA: A POPULATION-BASED STUDY IN THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02015-3","https://doi.org/10.1016/s0016-5085(25)02015-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045168","R0045168.pdf","paywalled","nonrandomized_study","Muhammad Ali Ibrahim Kazi","2025","S48 Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients With Type 2 Diabetes and Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126652.27700.96","https://doi.org/10.14309/01.ajg.0001126652.27700.96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045186","R0045186.pdf","paywalled","nonrandomized_study","Rosaria Vincenza Giglio","2025","Effetti a lungo termine della liraglutide sui parametri glico-metabolici, sulle lipoproteine a bassa densità piccole e dense e sullo spessore medio intimale carotideo nei pazienti con diabete mellito di tipo 2: studio prospettico di 5 anni","Biochimica Clinica","Edizioni Minerva Medica","10.23736/s0393-0564.25.00059-7","https://doi.org/10.23736/s0393-0564.25.00059-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045244","R0045244.pdf","paywalled","nonrandomized_study","Bettina Achleitner","2025","Nutrition Support During GLP-1 Receptor Agonist Therapy: Protecting Lean Mass While Intake Falls","Journal of Clinical Nutrition and Health",null,"10.5281/zenodo.22302378","https://doi.org/10.5281/zenodo.22302378",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045264","R0045264.pdf","paywalled","nonrandomized_study","MAGDALENA NEYER","2025","423-P: Three Decades of Glucose-Lowering Therapy in Patients with Established Coronary Artery Disease—A Real-World Analysis","Diabetes","American Diabetes Association","10.2337/db25-423-p","https://doi.org/10.2337/db25-423-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045299","R0045299.pdf","paywalled","nonrandomized_study","Xin Ya See","2025","The Impact of GLP-1 Analogs on Thromboembolic Outcomes in Patients With Sarcoidosis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a1130","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a1130",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045307","R0045307.pdf","paywalled","nonrandomized_study","Mariana Letícia de Bastos Maximiano","2025","Tirzepatide versus Semaglutide in the Risk of Cerebral Infarction in Patients with Diagnosis of Type 2 Diabetes Mellitus: A Propensity Score Matching from a Global Federated Health Network Analysis (S30.005)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000212661","https://doi.org/10.1212/wnl.0000000000212661",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045439","R0045439.pdf","paywalled","nonrandomized_study","Yu Wang","2025","1052-P: Changes in Medical Expenditures Associated with GLP-1RA Initiation in Medicare Beneficiaries with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1052-p","https://doi.org/10.2337/db25-1052-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045504","R0045504.pdf","paywalled","nonrandomized_study","Hussein Baydoun","2025","Su2072: ASSESSMENT OF GASTROINTESTINAL ADVERSE EFFECTS OF TIRZEPATIDE VERSUS SEMAGLUTIDE: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS OF THE U.S. COLLABORATIVE NETWORK","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03124-5","https://doi.org/10.1016/s0016-5085(25)03124-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045689","R0045689.pdf","paywalled","nonrandomized_study","Xiaoling Cai","2025","440-P: Associated Factors with Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in iCaReMe China Registry","Diabetes","American Diabetes Association","10.2337/db25-440-p","https://doi.org/10.2337/db25-440-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045740","R0045740.pdf","paywalled","nonrandomized_study","Tiago Palmisano","2025","Abstract 4368472: Glucagon-Like Peptide 1 Mediated Reduction in Atrial Fibrillation Risk Is Independent of Weight Loss","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368472","https://doi.org/10.1161/circ.152.suppl_3.4368472",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045745","R0045745.pdf","paywalled","nonrandomized_study","Rebecca Richards","2025","Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.81912","https://doi.org/10.2196/preprints.81912",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045756","R0045756.pdf","paywalled","nonrandomized_study","P T Tonnesen","2025","5-year risk of progression to type 2 diabetes in patients with myocardial infarction and overweight or obesity: a cohort study of the preventive potential of semaglutide treatment","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3627","https://doi.org/10.1093/eurheartj/ehaf784.3627",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045759","R0045759.pdf","paywalled","nonrandomized_study","Kate Cooper","2025","983: SEMAGLUTIDE EXPOSURE IS ASSOCIATED WITH LOWER ODDS OF CIRRHOSIS IN NON-OBESE, NON-DIABETIC PATIENTS WITH STEATOTIC LIVER DISEASE: A GLOBAL DATABASE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04678-5","https://doi.org/10.1016/s0016-5085(25)04678-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045791","R0045791.pdf","paywalled","nonrandomized_study","SUPRATIK BHATTACHARYYA","2025","764-P: Long-Term (24-Month) Follow-up of Indian T2DM Patients on Oral Semaglutide","Diabetes","American Diabetes Association","10.2337/db25-764-p","https://doi.org/10.2337/db25-764-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045821","R0045821.pdf","paywalled","nonrandomized_study","Ashujot K. Dang","2025","S133 Etiology-Based Outcomes of Acute Pancreatitis: A Multi-Center Real-World Analysis From a Nationwide EMR Network","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126992.81811.48","https://doi.org/10.14309/01.ajg.0001126992.81811.48",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045822","R0045822.pdf","paywalled","nonrandomized_study","Zhijie Duan","2025","Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide","arXiv (Cornell University)",null,"10.48550/arxiv.2504.04346","https://doi.org/10.48550/arxiv.2504.04346",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045847","R0045847.pdf","paywalled","nonrandomized_study","Muhammad Soban Arif Maan","2025","783: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IS ASSOCIATED WITH ELEVATED RISK OF GALLBLADDER AND BILIARY TRACT DISEASE IN INDIVIDUALS WITH OVERWEIGHT OR OBESITY: A PROPENSITY MATCHED MULTI-INSTITUTIONAL NETWORK ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)01367-8","https://doi.org/10.1016/s0016-5085(25)01367-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045897","R0045897.pdf","paywalled","nonrandomized_study","Aleksandrina Ruseva","2025","1733-P: Two-Year Real-World Effectiveness of Semaglutide in Patients with Obesity or Overweight","Diabetes","American Diabetes Association","10.2337/db25-1733-p","https://doi.org/10.2337/db25-1733-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045905","R0045905.pdf","paywalled","nonrandomized_study","YUHANG MA","2025","397-P: Association of Visit-to-Visit Variability of Metabolic Indicators with the Progress of Proteinuria in Chinese Patients with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db25-397-p","https://doi.org/10.2337/db25-397-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045993","R0045993.pdf","paywalled","nonrandomized_study","Tim Mori","2025","898-P: SGLT2 Inhibitors or GLP-1 Receptor Agonists? Development of a Personalized Treatment Algorithm for Individuals with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-898-p","https://doi.org/10.2337/db25-898-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046026","R0046026.pdf","paywalled","nonrandomized_study","REGINA CASTANEDA","2025","1779-P: Cracking the Code—How the Individualized Metabolic Surgery Score Predicts Weight Loss with Tirzepatide in People with Type 2 Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db25-1779-p","https://doi.org/10.2337/db25-1779-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046041","R0046041.pdf","paywalled","nonrandomized_study","Yassine Kilani","2025","244: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED RISK OF LIVER DISEASE PROGRESSION IN PATIENTS WITH ALCOHOL USE DISORDER: A PROPENSITY SCORE MATCHED ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04621-9","https://doi.org/10.1016/s0016-5085(25)04621-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046047","R0046047.pdf","paywalled","nonrandomized_study","Mahmoud Y. Madi","2025","Sa1433: DECREASED RISK OF ACUTE PANCREATITIS IN CHRONIC PANCREATITIS PATIENTS ON GLP-1 RECEPTOR AGONISTS: A PROPENSITY MATCHED ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02011-6","https://doi.org/10.1016/s0016-5085(25)02011-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046089","R0046089.pdf","paywalled","nonrandomized_study","Panupong Hansrivijit","2025","1469-P: Risk of Diabetic Ketoacidosis in SGLT2i vs. GLP-1RA Initiators with Chronic Kidney Disease Stage 3–4 and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1469-p","https://doi.org/10.2337/db25-1469-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046101","R0046101.pdf","paywalled","nonrandomized_study","Camilo González","2025","Trends in New Antidiabetes Drug Dispensation in Colombia, 2015-2023","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20256maz5wje","https://doi.org/10.1681/asn.20256maz5wje",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046105","R0046105.pdf","paywalled","nonrandomized_study","B S Prado","2025","Is obstructive sleep apnoea more than an epiphenomenon in patients with obesity? A cardiovascular perspective from a real-world propensity score-matched study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3900","https://doi.org/10.1093/eurheartj/ehaf784.3900",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046134","R0046134.pdf","paywalled","nonrandomized_study","ADITYA KAICKER","2025","2021-LB: Sustained Weight and Metabolic Health following GLP-1 Deprescription for Type 2 Diabetes—Evaluating the Long-Term Impact of Breathe Well-Being’s Lifestyle Management Program","Diabetes","American Diabetes Association","10.2337/db25-2021-lb","https://doi.org/10.2337/db25-2021-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046160","R0046160.pdf","paywalled","nonrandomized_study","D Garcia Vega","2025","Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3972","https://doi.org/10.1093/eurheartj/ehaf784.3972",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046178","R0046178.pdf","paywalled","nonrandomized_study","A.S. Ananeva","2025","A review of the recent clinical studies on the treatment of patients with the chronic kidney disease et advanced stages","Russian Journal of Preventive Medicine","Media Sphere Publishing House","10.17116/profmed202528081110","https://doi.org/10.17116/profmed202528081110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046180","R0046180.pdf","paywalled","nonrandomized_study","K Soerensen","2025","Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4316","https://doi.org/10.1093/eurheartj/ehaf784.4316",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046195","R0046195.pdf","paywalled","nonrandomized_study","Imran Qureshi","2025","Sa1953: GLP-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION AND DOES NOT INCREASE THE NEED OF SURGERY: A PROPENSITY-MATCHED, MULTICENTER STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02315-7","https://doi.org/10.1016/s0016-5085(25)02315-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046209","R0046209.pdf","paywalled","nonrandomized_study","Jin‐Xiu Pan","2025","S1113 Long-Acting GLP-1 Receptor Agonists Are Associated With a Reduced Risk of Functional Lower Gastrointestinal Disorders in Obese Patients With or Without Diabetes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131912.61970.71","https://doi.org/10.14309/01.ajg.0001131912.61970.71",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046233","R0046233.pdf","paywalled","nonrandomized_study","Hiroyuki Hisada","2025","Su2100: IMPACT OF GLP-1 RECEPTOR AGONIST ON RETAINED GASTRIC CONTENTS DURING: A PROPENSITY SCORE MATCHED STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03132-4","https://doi.org/10.1016/s0016-5085(25)03132-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046282","R0046282.pdf","paywalled","nonrandomized_study","И.Р. Гайсин","2025","Ассоциированная с Метаболической дисфункцией стеатотическая болезнь печени (МасБП) и лишняя масса тела: обзор литературы","Health demography ecology of finno-ugric peoples","Izhevsk State Medical Academy","10.64111/1994-8921.2025.51.3.007","https://doi.org/10.64111/1994-8921.2025.51.3.007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046416","R0046416.pdf","paywalled","nonrandomized_study","Hatem Ahmed","2025","S2901 Comparative Outcomes of GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Patients With Cirrhosis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001139064.02867.85","https://doi.org/10.14309/01.ajg.0001139064.02867.85",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046548","R0046548.pdf","paywalled","nonrandomized_study","F Fussing","2025","Hemodynamic Changes in response to GLP-1 RA treatment in ICD and CRT patients: Insights from HeartLogic Sensor Data","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1228","https://doi.org/10.1093/eurheartj/ehaf784.1228",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046555","R0046555.pdf","paywalled","nonrandomized_study","P T Tonnesen","2025","Impact of body mass index and prediabetes on the risk of type 2 diabetes and cardiovascular events following a recent myocardial infarction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3467","https://doi.org/10.1093/eurheartj/ehaf784.3467",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046613","R0046613.pdf","paywalled","nonrandomized_study","Wojciech Losos","2025","Abstract 4361396: Cardiometabolic Therapy Reduces Electrocardiogram-Derived Biological Age: A Time-Weighted Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4361396","https://doi.org/10.1161/circ.152.suppl_3.4361396",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046659","R0046659.pdf","paywalled","nonrandomized_study","Francisca M. Acosta","2025","729-P: Retrospective Effects of GLP-1 Receptor Agonists with and without Concomitant SGLT2 Inhibitor Use in Diabetic Renal Transplant Recipients after 12 Months","Diabetes","American Diabetes Association","10.2337/db25-729-p","https://doi.org/10.2337/db25-729-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046848","R0046848.pdf","paywalled","nonrandomized_study","Laurence Salle","2025","Diabetes and cardiovascular prevention: bridging two epidemics","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf737","https://doi.org/10.1093/eurjpc/zwaf737","41493054","https://pubmed.ncbi.nlm.nih.gov/41493054/",null,null],["4","R0046870","R0046870.pdf","paywalled","nonrandomized_study","Zhiyao Luo","2025","GLP1 receptor agonist with add-on SGLT2 inhibitor therapy is associated with lower risks of major adverse cardiovascular events: a population-based and machine learning causal inference analysis","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.109.p110","https://doi.org/10.1530/endoabs.109.p110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046878","R0046878.pdf","paywalled","nonrandomized_study","Aleksandrina Ruseva","2025","1734-P: Reduction of the 10-Year ASCVD Risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care—A Real-World Study","Diabetes","American Diabetes Association","10.2337/db25-1734-p","https://doi.org/10.2337/db25-1734-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046897","R0046897.pdf","paywalled","nonrandomized_study","Pareeta Kotecha","2025","844-P: Association between Preoperative GLP-1RA Use and Postoperative Respiratory Complications in Real-World Patients Undergoing Elective Surgical Procedures—A Target Trial Emulation Study","Diabetes","American Diabetes Association","10.2337/db25-844-p","https://doi.org/10.2337/db25-844-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046930","R0046930.pdf","paywalled","nonrandomized_study","Yaman Jarrar","2025","Abstract 4361084: GLP-1 Receptor Agonists in Non-Diabetic Obese Adults: A Retrospective Cohort Study of Cardiovascular and Arrhythmia Outcomes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4361084","https://doi.org/10.1161/circ.152.suppl_3.4361084",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046936","R0046936.pdf","paywalled","nonrandomized_study","Mark D. Orland","2025","GLP‑1 receptor agonists and clonal hematopoiesis: Early human signals of anti‑inflammatory clone mitigation and lower MDS‑to‑AML progression","Blood","American Society of Hematology","10.1182/blood-2025-1385","https://doi.org/10.1182/blood-2025-1385",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046952","R0046952.pdf","paywalled","nonrandomized_study","Lean Alkhatib","2025","Potential of Triple Therapy in Diabetic Kidney Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025pt4vchxa","https://doi.org/10.1681/asn.2025pt4vchxa",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046956","R0046956.pdf","paywalled","nonrandomized_study","Hannah Wallace","2025","#944 Baseline analysis of the patterns of CKD care in an implementation trial using future health today in primary care","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.0583","https://doi.org/10.1093/ndt/gfaf116.0583",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ANZCTR:ACTRN12623001096640"],["4","R0046970","R0046970.pdf","paywalled","nonrandomized_study","Leslie K. Iverson","2025","Abstract 4367612: The Risk of Pancreatitis and Adverse Cardiovascular Events in Patients with Type 2 Diabetes and/or Overweight/Obesity with and without Hypertriglyceridemia when Prescribed GLP1RA: A Propensity Score-Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367612","https://doi.org/10.1161/circ.152.suppl_3.4367612",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046997","R0046997.pdf","paywalled","nonrandomized_study","Wenxin Guo","2025","Abstract 4367419: Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Lower Risk Of Cardiovascular Event Recurrence Compared With Use Of Bupropion-Naltrexone or Phentermine-Topiramate: A Nationwide Target Trial Emulation Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367419","https://doi.org/10.1161/circ.152.suppl_3.4367419",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047010","R0047010.pdf","paywalled","nonrandomized_study","Vikash Kumar","2025","S798 Endoscopic Sleeve Gastroplasty vs GLP-1 Receptor Agonists: Comparative Effectiveness in Obesity Management","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130652.47326.dc","https://doi.org/10.14309/01.ajg.0001130652.47326.dc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047022","R0047022.pdf","paywalled","nonrandomized_study","J Student","2025","773-P: Effect of Glucagon-Like Peptide 1 Receptor Agonists Compared with Basal Insulin in Severely Uncontrolled Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-773-p","https://doi.org/10.2337/db25-773-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047058","R0047058.pdf","paywalled","nonrandomized_study","Sarpong Boateng","2025","S90 Predictors of Biliary Malignancy Among GLP-1 Receptor Agonist Users","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126820.19690.23","https://doi.org/10.14309/01.ajg.0001126820.19690.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047090","R0047090.pdf","paywalled","nonrandomized_study","Noor Albusta","2025","S2338 GLP-1 Receptor Agonist Therapy in Obese Patients With Coexisting IBD and MASLD: Metabolic and Inflammatory Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136812.26450.d8","https://doi.org/10.14309/01.ajg.0001136812.26450.d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047108","R0047108.pdf","paywalled","nonrandomized_study","George Anthony Komatsoulis","2025","Semaglutide and cardiovascular outcomes in overweight or obesity without diabetes: A real-world cohort study","Next research.","Elsevier BV","10.1016/j.nexres.2025.100587","https://doi.org/10.1016/j.nexres.2025.100587",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047116","R0047116.pdf","paywalled","nonrandomized_study","Altaf GAUHAR Haji","2025","eP172 Tirzepatide Mimicking /Causing Acute Surgical Abdomen: A Two-Case Experience","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znaf166.438","https://doi.org/10.1093/bjs/znaf166.438",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047129","R0047129.pdf","paywalled","nonrandomized_study","Hasan Nassereldine","2025","Abstract 4365144: Glucagon-like-peptide-1 Receptor Agonists Are Associated with Lower Postoperative Complication Rates in Patients with Peripheral Artery Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365144","https://doi.org/10.1161/circ.152.suppl_3.4365144",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047130","R0047130.pdf","paywalled","nonrandomized_study","KRISTIN N. CASTORINO","2025","155-OR: Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D)—Analysis of the SECURE-T2D Study","Diabetes","American Diabetes Association","10.2337/db25-155-or","https://doi.org/10.2337/db25-155-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047133","R0047133.pdf","paywalled","nonrandomized_study","Reeti K. Gulati","2025","Sa1506: REAL WORLD DATA ASSESSING THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04726-2","https://doi.org/10.1016/s0016-5085(25)04726-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047153","R0047153.pdf","paywalled","nonrandomized_study","Leandro Sierra","2025","S2570 Underuse of GLP-1 Receptor Agonists Despite Promising Evidence in Managing Post-Liver Transplant Alcohol Recidivism in Alcohol Associated Liver Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137740.62046.3a","https://doi.org/10.14309/01.ajg.0001137740.62046.3a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047209","R0047209.pdf","paywalled","nonrandomized_study","Chungsoo Kim","2025","Abstract 4367801: Tirzepatide Achieves Greater Weight and Blood Pressure Reduction Than Semaglutide in Routine Clinical Practice","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367801","https://doi.org/10.1161/circ.152.suppl_3.4367801",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047228","R0047228.pdf","paywalled","nonrandomized_study","Abdulrahman Murshid","2025","Abstract 4370885: Outcomes of Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction: A Retrospective Cohort Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370885","https://doi.org/10.1161/circ.152.suppl_3.4370885",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047233","R0047233.pdf","paywalled","nonrandomized_study","Ahmad Muneer Alkhatib","2025","Abstract 4367416: GLP-1 Receptor Agonists and Mortality Outcomes in Patients with Left Ventricular Assist Devices: A Propensity-Matched Cohort Study from the TriNetX Global Network","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367416","https://doi.org/10.1161/circ.152.suppl_3.4367416",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047239","R0047239.pdf","paywalled","nonrandomized_study","ANWAR MOHAMMAD","2025","781-P: Structural Modeling of GLP-1R Variants Interactions with Tirzepatide Using AI Tools—A Precision Diabetes Management Method","Diabetes","American Diabetes Association","10.2337/db25-781-p","https://doi.org/10.2337/db25-781-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047262","R0047262.pdf","paywalled","nonrandomized_study","Nicholas Till Haddock","2025","Discussion: Metabolic Bridge Therapy before Microvascular Breast Reconstruction in Morbidly Obese Patients: A Proof-of-Concept Risk Analysis","Plastic & Reconstructive Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/prs.0000000000011866","https://doi.org/10.1097/prs.0000000000011866","40294309","https://pubmed.ncbi.nlm.nih.gov/40294309/",null,null],["4","R0047269","R0047269.pdf","paywalled","nonrandomized_study","James J. Amamoo","2025","732-P: Real-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)","Diabetes","American Diabetes Association","10.2337/db25-732-p","https://doi.org/10.2337/db25-732-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047286","R0047286.pdf","paywalled","nonrandomized_study","Agnieszka Brandt-Varma","2025","Clinical outcomes of GLP-1 receptor agonist therapy in paediatric patients in the thames valley: a retrospective audit","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.111.p143","https://doi.org/10.1530/endoabs.111.p143",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047342","R0047342.pdf","paywalled","nonrandomized_study","Ahmed Elbayomy","2025","O-018 Association between ozempic use and stroke risk: a nationwide emergency department analysis",null,"BMJ Publishing Group Ltd.","10.1136/jnis-2025-snis.18","https://doi.org/10.1136/jnis-2025-snis.18",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047345","R0047345.pdf","paywalled","nonrandomized_study","Anders L. Carlson","2025","945-P: Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin—Subanalysis of the SECURE-T2D Study","Diabetes","American Diabetes Association","10.2337/db25-945-p","https://doi.org/10.2337/db25-945-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047431","R0047431.pdf","paywalled","nonrandomized_study","Urja N Kalathiya","2025","780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk","Diabetes","American Diabetes Association","10.2337/db25-780-p","https://doi.org/10.2337/db25-780-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047446","R0047446.pdf","paywalled","nonrandomized_study","Sana Rabeeah","2025","S2397 Real-World Benefits of GLP-1RA Therapy in MASLD: Reductions in Cardiovascular, Renal, Hepatic, and Mortality Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137048.94451.f7","https://doi.org/10.14309/01.ajg.0001137048.94451.f7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047476","R0047476.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2025","POSTER: MDS-1221 Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)00847-x","https://doi.org/10.1016/s2152-2650(25)00847-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047614","R0047614.pdf","paywalled","nonrandomized_study","LUIS A. RODRIGUEZ","2025","1488-P: Indicators of Diabetes Remission in Six Integrated Health Care Systems—A Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db25-1488-p","https://doi.org/10.2337/db25-1488-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047682","R0047682.pdf","paywalled","nonrandomized_study","Ying Lü","2025","736-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Cancer Risk in Older Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-736-p","https://doi.org/10.2337/db25-736-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047705","R0047705.pdf","paywalled","nonrandomized_study","Hsien Yao Yang","2025","Tu1200: COMPARATIVE RISKS OF GERD, GASTRIC INTESTINAL METAPLASIA, AND UPPER GI CANCERS IN OBESITY PATIENTS: A PROPENSITY-MATCHED POPULATION-BASED STUDY OF BARIATRIC SURGERY VS GLP-1 RECEPTOR AGONISTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03992-7","https://doi.org/10.1016/s0016-5085(25)03992-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047710","R0047710.pdf","paywalled","nonrandomized_study","Himsikhar Khataniar","2025","S2360 Racial, Ethnic, and Sex-Based Disparities in Met-ALD: A 10-Year Propensity Score Matched Analysis Utilizing a National Database","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136900.25861.dd","https://doi.org/10.14309/01.ajg.0001136900.25861.dd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047722","R0047722.pdf","paywalled","nonrandomized_study","Lydia Vassiliadi","2025","Abstract 018: Semaglutide Use Associated with Lower Blood Pressure in Patients with Cardiometabolic Multimorbidity: Real-World Evidence from the All of Us Research Program","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.82.suppl_1.018","https://doi.org/10.1161/hyp.82.suppl_1.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047737","R0047737.pdf","paywalled","nonrandomized_study","Omar S. Obeidat","2025","Abstract 4368263: Use of Contemporary Cardiometabolic Therapies in Cardiac Amyloidosis Treated with Tafamidis: A Real-World Propensity-Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368263","https://doi.org/10.1161/circ.152.suppl_3.4368263",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047774","R0047774.pdf","paywalled","nonrandomized_study","Prerna Singh","2025","Personalized risk assessment for heart failure and atherosclerosis in diabetes: radiomic analysis of coronary calcium and epicardial adipose tissue on cardiac CT",null,"SPIE","10.1117/12.3047113","https://doi.org/10.1117/12.3047113",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047808","R0047808.pdf","paywalled","nonrandomized_study","Omer Sayed Ashruf","2025","Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.12027","https://doi.org/10.1200/jco.2025.43.16_suppl.12027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047813","R0047813.pdf","paywalled","nonrandomized_study","Nishanthi A. Vigneswaramoorthy","2025","Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367243","https://doi.org/10.1161/circ.152.suppl_3.4367243",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047818","R0047818.pdf","paywalled","nonrandomized_study","Ahmed Salem","2025","S791 Comparative Risk of Gastrointestinal Adverse Events Among GLP-1 Receptor Agonists: A Real-World Multicenter Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130624.52234.9c","https://doi.org/10.14309/01.ajg.0001130624.52234.9c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047848","R0047848.pdf","paywalled","nonrandomized_study","D T Zhang","2025","Effect of glucagon-like peptide-1 agonists on ventricular tachycardia ablation outcomes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.625","https://doi.org/10.1093/eurheartj/ehaf784.625",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047878","R0047878.pdf","paywalled","nonrandomized_study","Lim Ch","2025","S96 Weight management in patients with decompensated obesity hypoventilation syndrome: understanding the changing landscape in the era of weight loss injections",null,"BMJ Publishing Group Ltd and British Thoracic Society","10.1136/thorax-2025-btsabstracts.102","https://doi.org/10.1136/thorax-2025-btsabstracts.102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047879","R0047879.pdf","paywalled","nonrandomized_study","Regis Lee","2025","S2002 Association of Body Mass Index and GLP-1 in Outcomes in Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135468.57678.f3","https://doi.org/10.14309/01.ajg.0001135468.57678.f3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047880","R0047880.pdf","paywalled","nonrandomized_study","Ludovic Saba","2025","S2340 Semaglutide and Tirzepatide Show Comparable Hepatic Outcomes in MASLD: A Propensity-Matched Analysis of a Multi-Institutional EHR Database","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136820.07930.f5","https://doi.org/10.14309/01.ajg.0001136820.07930.f5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047885","R0047885.pdf","paywalled","nonrandomized_study","Joy Roy","2025","E-164 Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and moyamoya disease: a propensity-score matched study",null,"BMJ Publishing Group Ltd.","10.1136/jnis-2025-snis.279","https://doi.org/10.1136/jnis-2025-snis.279",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047891","R0047891.pdf","paywalled","nonrandomized_study","Mohanad Elchouemi","2025","The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.4559","https://doi.org/10.1200/jco.2025.43.16_suppl.4559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047911","R0047911.pdf","paywalled","nonrandomized_study","Venkatesh Kolli","2025","Evaluating Antidiabetic Modulatory Effects on Drug-induced Pulmonary Arterial Hypertension Using Real-world Data","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a4977","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a4977",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047917","R0047917.pdf","paywalled","nonrandomized_study","Jonah David Garry","2025","Abstract 4348998: Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary Hypertension","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4348998","https://doi.org/10.1161/circ.152.suppl_3.4348998",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047919","R0047919.pdf","paywalled","nonrandomized_study","Collin York","2025","Su2054: ASSOCIATION BETWEEN SEMAGLUTIDE AND SEVERE GASTROINTESTINAL ADVERSE EFFECTS IN ADULTS WITH AND WITHOUT DIABETES: A REAL-WORLD CLAIMS DATA STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03106-3","https://doi.org/10.1016/s0016-5085(25)03106-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047937","R0047937.pdf","paywalled","nonrandomized_study","Luìs Manuel de Almieda Nieto","2025","Su1572: CONCOMITANT USE OF IMMUNE CHECKPOINT INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR ACUTE PANCREATITIS: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02800-8","https://doi.org/10.1016/s0016-5085(25)02800-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047956","R0047956.pdf","paywalled","nonrandomized_study","Osman Suliman","2025","The impact of tirzepatide injection on weight loss in patients with obesity in the Al Madinah region","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1741855756","https://doi.org/10.24911/ijmdc.51-1741855756",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047962","R0047962.pdf","paywalled","nonrandomized_study","Ian Yahnke","2025","Abstract WP333: Population-based Study of Stroke Recurrence in Overweight or Obese Patients: Considerations for Future Prevention Trials","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.56.suppl_1.wp333","https://doi.org/10.1161/str.56.suppl_1.wp333",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047974","R0047974.pdf","paywalled","nonrandomized_study","Siddharth Agrawal","2025","Abstract 4367655: Comparative Cardiometabolic Outcomes of Tirzepatide Versus Semaglutide in Patients with HFpEF and Obesity: A Real-World Multicenter Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4367655","https://doi.org/10.1161/circ.152.suppl_3.4367655",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047979","R0047979.pdf","paywalled","nonrandomized_study","Kaitlyn Gernhard","2025","984: ADDRESSING THE GROWING EPIDEMIC OF OBESITY: BARIATRIC SURGERY OR GLP-1 AGONIST IN PATIENTS WITH MASLD? A RETROSPECTIVE COHORT ANALYSIS OVER A 6-YEAR PERIOD","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04679-7","https://doi.org/10.1016/s0016-5085(25)04679-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048000","R0048000.pdf","paywalled","nonrandomized_study","Joseph T. Kassab","2025","Abstract 4370534: Guideline-Directed Medical Therapy Prescribing Trends in Patients with Heart Failure with Preserved Ejection Fraction: A Nationwide Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370534","https://doi.org/10.1161/circ.152.suppl_3.4370534",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048019","R0048019.pdf","paywalled","nonrandomized_study","Suman Kumar Lama","2025","#3586 Demographics and comorbidities of dialysis patients using SGLT2 inhibitors and GLP-1 agonists","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.0393","https://doi.org/10.1093/ndt/gfaf116.0393",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048027","R0048027.pdf","paywalled","nonrandomized_study","Rafael Sousa Fava Nersessian","2025","Obesity may present challenges but does not preclude gastric ultrasound","Anaesthesia","Wiley","10.1111/anae.16587","https://doi.org/10.1111/anae.16587","40032613","https://pubmed.ncbi.nlm.nih.gov/40032613/",null,null],["4","R0048070","R0048070.pdf","paywalled","nonrandomized_study","Himsikhar Khataniar","2025","S842 Bariatric Surgery Nearly Doubles 5-Year Reflux and Barrett’s Risk versus GLP-1 Agonists: A Propensity-Matched 81,410-Patient Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130828.05754.4d","https://doi.org/10.14309/01.ajg.0001130828.05754.4d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048074","R0048074.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2025","Impact of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Kidney Failure Risk Prediction","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025b720vjd3","https://doi.org/10.1681/asn.2025b720vjd3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048091","R0048091.pdf","paywalled","nonrandomized_study","Harsimran Kalsi","2025","IMPACT OF GLP-1 AGONIST USE ON POST-PROCEDURAL OUTCOMES IN ELECTIVE UPPER AND LOWER ENDOSCOPIC PROCEDURES: A NATIONAL DATABASE STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2025.03.444","https://doi.org/10.1016/j.gie.2025.03.444",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048115","R0048115.pdf","paywalled","nonrandomized_study","Samantha E. Clark","2025","CO218 Semaglutide Weight Outcomes Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Real-World Setting","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.319","https://doi.org/10.1016/j.jval.2025.09.319",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048198","R0048198.pdf","paywalled","nonrandomized_study","Muhammad Sabri","2025","Abstract 072: Cardiovascular Outcomes in Hypertensive Adults Treated with GLP-1 Receptor Agonists: A Retrospective Cohort Study","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.82.suppl_1.072","https://doi.org/10.1161/hyp.82.suppl_1.072",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048206","R0048206.pdf","paywalled","nonrandomized_study","Amy Houghton Attaway","2025","Leptin Decline is Associated With Improvement in Lung Function and Body Composition in a Longitudinal Tobacco-exposed Cohort","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a2859","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a2859",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048262","R0048262.pdf","paywalled","nonrandomized_study","Mark Duncan Kilpatrick","2025","GLP-1 Receptor Agonists vs. Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors and Risk of Dementia in Patients with Diabetes Requiring Hemodialysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025x0hs2ah8","https://doi.org/10.1681/asn.2025x0hs2ah8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048268","R0048268.pdf","paywalled","nonrandomized_study","Aravinthan Vignarajah","2025","TCT-490 Long-term Outcomes of Glucagon-like Peptide-1 Agonist in Coronary Artery Disease and Obesity without Diabetes Mellitus: A Real-world Retrospective Cohort Study","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.619","https://doi.org/10.1016/j.jacc.2025.09.619",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048332","R0048332.pdf","paywalled","nonrandomized_study","Rodolfo Javier Galindo","2025","Differences in weight reduction efficacy of tirzepatide in adults without versus with type 2 diabetes with overweight or obesity in SURMOUNT 1 and 2","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807559","https://doi.org/10.1055/s-0045-1807559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048364","R0048364.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2025","Sa1646: GLP-1 AGONIST USE IS ASSOCIATED WITH OVERALL IMPROVEMENT OF SYMPTOMS IN PATIENTS WITH IBS-D AND OBESITY: A NATIONAL DATABASE ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02058-x","https://doi.org/10.1016/s0016-5085(25)02058-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048370","R0048370.pdf","paywalled","nonrandomized_study","Nadim Zaidan","2025","Effect of SGLT2 Inhibitor and GLP-1 Receptor Agonist Treatment on Urine and Plasma Parameters Involved in Lithogenesis in Patients with Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025e3yf1fnk","https://doi.org/10.1681/asn.2025e3yf1fnk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048373","R0048373.pdf","paywalled","nonrandomized_study","CAROLINA I. BATLLE","2025","1252-P: Glucagon-Like Peptide 1 Receptor Agonist Prescription prior to Pregnancy According to Health Insurance Type and Race/Ethnicity","Diabetes","American Diabetes Association","10.2337/db25-1252-p","https://doi.org/10.2337/db25-1252-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048389","R0048389.pdf","paywalled","nonrandomized_study","Beatriz Sánchez Álamo","2025","#3819 Comparative effects of GLP-1RAs on kidney transplant recipients and chronic kidney disease patients","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.1839","https://doi.org/10.1093/ndt/gfaf116.1839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048423","R0048423.pdf","paywalled","nonrandomized_study","KYAW LINN SU KHIN","2025","756-P: Real-World Data Comparing the Effectiveness of Injectable vs. Oral Semaglutide—Association of British Clinical Diabetologist (ABCD) National Audit","Diabetes","American Diabetes Association","10.2337/db25-756-p","https://doi.org/10.2337/db25-756-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048446","R0048446.pdf","paywalled","nonrandomized_study","Farirai Melania Marwizi","2025","S732 Cardiovascular and Hepatic Outcomes of Tirzepatide vs Aspirin in Patients With Obesity and Metabolic Dysfunction-Associated Steatohepatitis: A Real-World Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130388.39934.cf","https://doi.org/10.14309/01.ajg.0001130388.39934.cf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048448","R0048448.pdf","paywalled","nonrandomized_study","Adele Watfa","2025","Abstract 4368871: Impact of Glucagon-Like Peptide-1 Agonists on Ventricular Tachycardia Ablation Outcomes: a Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368871","https://doi.org/10.1161/circ.152.suppl_3.4368871",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048484","R0048484.pdf","paywalled","nonrandomized_study","Ashkan Yahyavi","2025","Abstract 4363968: Impact of Glucagon-Like Peptide-1 Receptor Agonists on 5-Year Risk of Major Amputation and Cardiovascular Outcomes in Diabetic Patients with Chronic Limb-Threatening Ischemia","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363968","https://doi.org/10.1161/circ.152.suppl_3.4363968",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048506","R0048506.pdf","paywalled","nonrandomized_study","Samuel Macedo Costa","2025","Are professionals familiar with glucagonlike peptide-1 receptor agonists and their effects in oral surgery? A national survey","Journal of the Brazilian College of Oral and Maxillofacial Surgery","Dental Press International","10.14436/2358-2782.11.2.e252521.oar","https://doi.org/10.14436/2358-2782.11.2.e252521.oar",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048536","R0048536.pdf","paywalled","nonrandomized_study","Sadaf Sadighian","2025","S593 Risk of SIBO and Colorectal Cancer Among Non-Obese Patients With Irritable Bowel Syndrome Treated With GLP-1 Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129832.69349.8c","https://doi.org/10.14309/01.ajg.0001129832.69349.8c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048571","R0048571.pdf","paywalled","nonrandomized_study","Jake Levine","2025","S1990 Effect of Dual GLP-1/GIP and GLP-1 Agonists on Inflammatory Bowel Disease Activity Among Patients With Obesity","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135420.11072.6d","https://doi.org/10.14309/01.ajg.0001135420.11072.6d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048576","R0048576.pdf","paywalled","nonrandomized_study","Layth Alzubaidy","2025","S594 Disparities in Colorectal Cancer Demographics, Mortality, and Survival: A SEER-Based Comparison of East Texas and the Rest of Texas (2017–2021)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129836.55082.bc","https://doi.org/10.14309/01.ajg.0001129836.55082.bc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048581","R0048581.pdf","paywalled","nonrandomized_study","Himaben Gohil","2025","S1468 Semaglutide and Tirzepatide Have the Most Clinical Benefit Compared to Most Weight Loss Medications in Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133332.90580.4f","https://doi.org/10.14309/01.ajg.0001133332.90580.4f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048600","R0048600.pdf","paywalled","nonrandomized_study","Arleen M. Delgado","2025","286: MENTAL HEALTH OUTCOMES IN PEDIATRIC PATIENTS WITH OBESITY TAKING GLP-1 RAS: A POPULATION-BASED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)01132-1","https://doi.org/10.1016/s0016-5085(25)01132-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048640","R0048640.pdf","paywalled","nonrandomized_study","Priya Kumari Maheshwari","2025","S132 Evaluating the Severity of Acute Pancreatitis in Type 2 Diabetes Patients Treated With Incretin-Based Therapies vs Insulin: A Multicenter Retrospective Analysis Using APACHE II","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126988.33169.a2","https://doi.org/10.14309/01.ajg.0001126988.33169.a2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048654","R0048654.pdf","paywalled","nonrandomized_study","Mohammed Najdat Seijari","2025","Abstract 4370404: Glucagon-Like Peptide-1 Receptor Agonists and Anthracycline Therapy in Breast Cancer: A Real-World Propensity-Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370404","https://doi.org/10.1161/circ.152.suppl_3.4370404",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048669","R0048669.pdf","paywalled","nonrandomized_study","Jonathan Mertens","2025","Real-world evidence of the effect of adjunctive semaglutide on weight change, glycaemic control, and metabolic dysfunction associated steatotic liver disease in people with type 1 diabetes","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.112.001","https://doi.org/10.1530/endoabs.112.001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048701","R0048701.pdf","paywalled","nonrandomized_study","Vishal Kumar Gupta","2025","30-PUB: Comparison of Effectiveness of Canagliflozin 300mg plus Gliptin vs. Oral Semaglutide plus SGLT2i on Cardiorenal Markers in T2DM Patients","Diabetes","American Diabetes Association","10.2337/db25-30-pub","https://doi.org/10.2337/db25-30-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048718","R0048718.pdf","paywalled","nonrandomized_study","Peter R Rossing","2025","782-P: Once-Weekly Semaglutide vs. Placebo for the Treatment of Type 2 Diabetes and Chronic Kidney Disease in Denmark—A Long-Term Cost-Effectiveness Analysis Based on Flow","Diabetes","American Diabetes Association","10.2337/db25-782-p","https://doi.org/10.2337/db25-782-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048735","R0048735.pdf","paywalled","nonrandomized_study","Ioannis Ntanasis‐Stathopoulos","2025","Clinical Outcomes of Patients with MGUS and Diabetes/Obesity on GLP-1 Receptor Agonists: A Real-World, Propensity-Matched Study","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)03827-3","https://doi.org/10.1016/s2152-2650(25)03827-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048738","R0048738.pdf","paywalled","nonrandomized_study","Varun Aitharaju","2025","Sa1536: MORTALITY REDUCTION IN PATIENTS WITH OBESITY AND MASLD CIRRHOSIS USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS): INSIGHTS FROM A GLOBAL RETROSPECTIVE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04756-0","https://doi.org/10.1016/s0016-5085(25)04756-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048765","R0048765.pdf","paywalled","nonrandomized_study","Medora Doris Rodrigues","2025","S26 Risk of Biliary Diseases in Patients Treated With GLP-1 vs GLP-1/GI Receptor Agonists: A Real-World Comparative Analysis of Semaglutide and Tirzepatide","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001126564.70811.7c","https://doi.org/10.14309/01.ajg.0001126564.70811.7c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048797","R0048797.pdf","paywalled","nonrandomized_study","Suria Devarapalli","2025","S784 Efficacy of Bowel Regimen on GLP1-RA-Induced Constipation","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130596.61749.e8","https://doi.org/10.14309/01.ajg.0001130596.61749.e8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048806","R0048806.pdf","paywalled","nonrandomized_study","Irhoboudu Dickson Atogwe","2025","S416 When the Checkpoint Fails: ICI Colitis as a Pathway to Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129124.16211.f4","https://doi.org/10.14309/01.ajg.0001129124.16211.f4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048882","R0048882.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2025","POSTER: MPN-642 Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)00892-4","https://doi.org/10.1016/s2152-2650(25)00892-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048908","R0048908.pdf","paywalled","nonrandomized_study","Shannon Lee","2025","Abstract 4372125: Elevated Peri-coronary Adipose Tissue attenuation association with Coronary Plaque Progression in Type 2 Diabetes Mellitus Patients","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4372125","https://doi.org/10.1161/circ.152.suppl_3.4372125",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048923","R0048923.pdf","paywalled","nonrandomized_study","THIERRY KOCHKARIAN","2025","Abstract 4370661: Cardiovascular Benefits of GLP-1 Receptor Agonists in Non-Obese Patients With Type 2 Diabetes, Chronic Kidney Disease, or Coronary Artery Disease: A Real-World TriNetX Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370661","https://doi.org/10.1161/circ.152.suppl_3.4370661",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048930","R0048930.pdf","paywalled","nonrandomized_study","Sarpong Boateng","2025","S738 Risk of Vision-Threatening Eye Complications Among GLP-1 Receptor Agonist Users: A Retrospective Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130412.76718.7d","https://doi.org/10.14309/01.ajg.0001130412.76718.7d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048959","R0048959.pdf","paywalled","nonrandomized_study","Mohammad A. Irshad","2025","MicroRNA expression profiling in type 2 diabetes patients treated with liraglutide","Journal of King Saud University - Science","Scientific Scholar","10.25259/jksus_103_2024","https://doi.org/10.25259/jksus_103_2024",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048966","R0048966.pdf","paywalled","nonrandomized_study","Ethan J. Cannon","2025","Abstract P3134: Semaglutide Versus Liraglutide and Incidence of Diabetes and Cardiovascular Disease: an Analysis of Real-World Data","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.151.suppl_1.p3134","https://doi.org/10.1161/cir.151.suppl_1.p3134",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049019","R0049019.pdf","paywalled","nonrandomized_study","Simon A. Berry","2025","305-OR: Tirzepatide in Type 1 Diabetes—Safety, Tolerability, and Clinical Outcomes—Real-World Experience from a Large UK Center","Diabetes","American Diabetes Association","10.2337/db25-305-or","https://doi.org/10.2337/db25-305-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049054","R0049054.pdf","paywalled","nonrandomized_study","Vaia Lambadiari","2025","1098-P: Tracking Treatment Outcomes Using the Semaglutide Patient Support Solution App","Diabetes","American Diabetes Association","10.2337/db25-1098-p","https://doi.org/10.2337/db25-1098-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049055","R0049055.pdf","paywalled","nonrandomized_study","Salvatore Crisafulli","2025","18-PUB: Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-18-pub","https://doi.org/10.2337/db25-18-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049065","R0049065.pdf","paywalled","nonrandomized_study","Suman Kumar Lama","2025","Effect of GLP-1 Receptor Agonists on Inflammatory Markers, Nutritional Markers, and Erythropoiesis-Stimulating Agent (ESA) Use in Patients on Hemodialysis: A Propensity Score-Matched Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025rqx87nvk","https://doi.org/10.1681/asn.2025rqx87nvk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049085","R0049085.pdf","paywalled","nonrandomized_study","Ahila Manivannan","2025","S2816 Identifying Screening Deficits for MASLD in the Diabetic Population at an Academic Endocrinology Clinic","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138724.42630.ab","https://doi.org/10.14309/01.ajg.0001138724.42630.ab",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049091","R0049091.pdf","paywalled","nonrandomized_study","Jonathan Mertens","2025","Real-world evidence of the effect of adjunctive semaglutide on weight change, liver steatosis and metabolic control in people with type 1 diabetes","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p418","https://doi.org/10.1530/endoabs.110.p418",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049105","R0049105.pdf","paywalled","nonrandomized_study","Ibrahim Shanti","2025","S243 Comparative Risk of Acute Pancreatitis in Hypertriglyceridemia Patients Treated With SGLT2 Inhibitors vs GLP-1 Receptor Agonists: A Propensity-Score Matched Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127432.56625.2e","https://doi.org/10.14309/01.ajg.0001127432.56625.2e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049118","R0049118.pdf","paywalled","nonrandomized_study","Harsimran Kalsi","2025","INFLUENCE OF ANESTHESIA TYPE ON POST-ENDOSCOPIC OUTCOMES IN GLP-1 RECEPTOR AGONIST USERS UNDERGOING ELECTIVE ENDOSCOPY: A NATIONAL DATABASE STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2025.03.264","https://doi.org/10.1016/j.gie.2025.03.264",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049134","R0049134.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2025","Tu1226: GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER USE OF PPI, ESOPHAGITIS AND ESOPHAGEAL STRICTURES IN PATIENTS WITH OBESITY AND GERD WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04018-1","https://doi.org/10.1016/s0016-5085(25)04018-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049137","R0049137.pdf","paywalled","nonrandomized_study","Armin E. Frie�","2025","S1268 Evaluating Glucagon-Like Peptide 1 Receptor Agonist Use and Retained Gastric Contents: Safety Implications for Upper Endoscopy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132532.13017.95","https://doi.org/10.14309/01.ajg.0001132532.13017.95",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049162","R0049162.pdf","paywalled","nonrandomized_study","Georgeina L Jarman","2025","P10 Evaluation of the metabolic profile of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis in anticipation of demand for future therapies",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2025-basl.27","https://doi.org/10.1136/gutjnl-2025-basl.27",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049170","R0049170.pdf","paywalled","nonrandomized_study","Mayur Sarangdhar","2025","Network Propagation Analysis to Uncover the Mechanisms of Antidiabetics as Therapeutic Candidates in Pulmonary Arterial Hypertension","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a4976","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a4976",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049209","R0049209.pdf","paywalled","nonrandomized_study","Francesco Fusco","2025","Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.4487","https://doi.org/10.1093/eurheartj/ehaf784.4487",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049286","R0049286.pdf","paywalled","nonrandomized_study","Imad Addin Brema","2025","477-P: Semaglutide Is Associated with Lower Risk of Diabetic Retinopathy in a Saudi Cohort with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-477-p","https://doi.org/10.2337/db25-477-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049296","R0049296.pdf","paywalled","nonrandomized_study","Aakash Desai","2025","S1565 Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Decreased Risk of Recurrent Pouchitis in Obese Patients With Ulcerative Colitis and IPAA: A Propensity-Matched Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133720.90877.e7","https://doi.org/10.14309/01.ajg.0001133720.90877.e7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049305","R0049305.pdf","paywalled","nonrandomized_study","Louise Thisted","2025","783-P: Elucidating the Benefit of Pump-Delivered Subcutaneous GLP-1R Agonist—Exploratory Study in the DIO Mouse","Diabetes","American Diabetes Association","10.2337/db25-783-p","https://doi.org/10.2337/db25-783-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049306","R0049306.pdf","paywalled","nonrandomized_study","Kristen A. Breslin","2025","1120-P: Use of Choice Architecture to Influence Inpatient A1C Ordering and Patient Outcomes","Diabetes","American Diabetes Association","10.2337/db25-1120-p","https://doi.org/10.2337/db25-1120-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049322","R0049322.pdf","paywalled","nonrandomized_study","Fouad H. Jaber","2025","Su2055: TIRZEPATIDE SHOWS LOWER RISK OF GASTROINTESTINAL SIDE EFFECTS COMPARED TO OTHER GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: A REAL-WORLD ANALYSIS OF OVER 1 MILLION PATIENTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03107-5","https://doi.org/10.1016/s0016-5085(25)03107-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049337","R0049337.pdf","paywalled","nonrandomized_study","Ruchir Damjibhai. Paladiya","2025","S421 System-Based and Culturally Responsive Interventions to Enhance CRC Screening Uptake in a Safety Net Clinic","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129144.65825.9b","https://doi.org/10.14309/01.ajg.0001129144.65825.9b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049359","R0049359.pdf","paywalled","nonrandomized_study","MARGARET ZUPA","2025","1059-P: Patterns of Telemedicine vs. In-Person Endocrinology Care for T2D","Diabetes","American Diabetes Association","10.2337/db25-1059-p","https://doi.org/10.2337/db25-1059-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049374","R0049374.pdf","paywalled","nonrandomized_study","Cristina Natha","2025","S427 Reduced Immunosuppression Requirements With GLP-1 Receptor Agonists Use in Patients Experiencing Immune-Mediated Diarrhea and Colitis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129168.17549.64","https://doi.org/10.14309/01.ajg.0001129168.17549.64",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049416","R0049416.pdf","paywalled","nonrandomized_study","Luìs Manuel de Almieda Nieto","2025","S799 Gastrointestial Outcomes in Patients With Concomitant Use of Immuno Checkpoint Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Study in the United States","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130656.38889.ff","https://doi.org/10.14309/01.ajg.0001130656.38889.ff",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049422","R0049422.pdf","paywalled","nonrandomized_study","Alexander Turchin","2025","415-P: Proteinuria and Progression of Kidney Disease in Patients with T2D Treated with SGLT2i and GLP-1RA—A Target Trial Emulation","Diabetes","American Diabetes Association","10.2337/db25-415-p","https://doi.org/10.2337/db25-415-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049425","R0049425.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2025","Kidney Failure Risk Modifies Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic (CKM) Events","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025gvpshbjk","https://doi.org/10.1681/asn.2025gvpshbjk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049443","R0049443.pdf","paywalled","nonrandomized_study","Jasmine Singh Sukumar","2025","Abstract PS15-03: Retrospective study of GLP-1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs24-ps15-03","https://doi.org/10.1158/1557-3265.sabcs24-ps15-03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049450","R0049450.pdf","paywalled","nonrandomized_study","Calyani Ganesan","2025","GLP-1 Receptor Agonist Semaglutide and Risk of Incident Urinary Stone Disease","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20253gqh8bva","https://doi.org/10.1681/asn.20253gqh8bva",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049455","R0049455.pdf","paywalled","nonrandomized_study","Cosmo Fowler","2025","ENHANCED SURVIVAL BENEFIT FOR GLP-1 RECEPTOR AGONIST PRESCRIPTION IN PATIENTS WITH COEXISTING TYPE 2 DIABETES AND SLEEP APNEA: A REAL-WORLD ANALYSIS OF 1.8 MILLION PATIENTS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3956","https://doi.org/10.1016/j.chest.2025.07.3956",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049460","R0049460.pdf","paywalled","nonrandomized_study","Maxwell W. Pickles","2025","Analysis of Glucagon-Like Peptide Agonist Use in Patients with Transsphenoidal Surgery of the Pituitary Adenoma over Time","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0045-1803738","https://doi.org/10.1055/s-0045-1803738",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049468","R0049468.pdf","paywalled","nonrandomized_study","Adel Hajj Ali","2025","Sa1535: GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04755-9","https://doi.org/10.1016/s0016-5085(25)04755-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049539","R0049539.pdf","paywalled","nonrandomized_study","M.B. Shaikh","2025","GLP-1 Agonists Do Not Increase Risk of Bacterial Pneumonia in Obese Patients: A Real-world Retrospective Multicenter Study","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a7725","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a7725",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049554","R0049554.pdf","paywalled","nonrandomized_study","Samuel Mensah","2025","Abstract 4363938: Combination Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapy Reduces Admissions and Death in Patients with Heart Failure with Reduced Ejection Fraction","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363938","https://doi.org/10.1161/circ.152.suppl_3.4363938",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049560","R0049560.pdf","paywalled","nonrandomized_study","PHYO T. HTOO","2025","329-OR: Cardiovascular Effectiveness of SGLT2i and GLP-1RA vs. Sulfonylureas by Socioeconomic Status—Analysis of U.S. and UK Health Care Systems","Diabetes","American Diabetes Association","10.2337/db25-329-or","https://doi.org/10.2337/db25-329-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049569","R0049569.pdf","paywalled","nonrandomized_study","Bright Chizitere Nwatamole","2025","S786 Comparative Gastrointestinal Safety of Tirzepatide vs Semaglutide: A Real-World Multicenter Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130604.96709.70","https://doi.org/10.14309/01.ajg.0001130604.96709.70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049594","R0049594.pdf","paywalled","nonrandomized_study","Ahmed Eltelbany","2025","S1936 Glucagon Like Peptide 1 Receptor Agonist Use Is Associated With Improved Clinical Outcomes in Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001135204.44495.0f","https://doi.org/10.14309/01.ajg.0001135204.44495.0f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049619","R0049619.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2025","MPN-642: Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)02129-9","https://doi.org/10.1016/s2152-2650(25)02129-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049646","R0049646.pdf","paywalled","nonrandomized_study","Jonathan Ghobrial","2025","S793 Reduced Risk of Iron Deficiency Anemia With GLP-1 Use in Celiac Disease Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130632.36905.cc","https://doi.org/10.14309/01.ajg.0001130632.36905.cc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049705","R0049705.pdf","paywalled","nonrandomized_study","Saqr Alsakarneh","2025","Tu1391: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH A LOWER RISK OF PANCREATIC CANCER COMPARED TO BARIATRIC SURGERY IN OBESE PATIENTS WITH DIABETES MELLITUS: A NATIONWIDE ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04143-5","https://doi.org/10.1016/s0016-5085(25)04143-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049708","R0049708.pdf","paywalled","nonrandomized_study","Iain Noel Encarnacion","2025","62064 The Role of GLP-1 Agonists in Overweight and Obese Hidradenitis Suppurativa Patients: A Retrospective Analysis","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.05.1277","https://doi.org/10.1016/j.jaad.2025.05.1277",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049729","R0049729.pdf","paywalled","nonrandomized_study","Kim G. E. Smolderen","2025","Abstract 4369118: Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4369118","https://doi.org/10.1161/circ.152.suppl_3.4369118",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049770","R0049770.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2025","Sex Differences in SGLT2 Inhibitor and GLP-1 Receptor Agonist Discontinuation in Patients with and Without CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20251ctrq6jw","https://doi.org/10.1681/asn.20251ctrq6jw",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049775","R0049775.pdf","paywalled","nonrandomized_study","Yaman Jarrar","2025","Abstract 4361120: Use Of Glucagon Like Peptide 1 Receptor Agonists In Non Diabetic Patients With Dilated Cardiomyopathy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4361120","https://doi.org/10.1161/circ.152.suppl_3.4361120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049785","R0049785.pdf","paywalled","nonrandomized_study","Alexander T. Hong","2025","260-OR: Differential Effect of GLP-1RA and SGLT2 Inhibitors on Lower Extremity Amputation Outcomes in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-260-or","https://doi.org/10.2337/db25-260-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049798","R0049798.pdf","paywalled","nonrandomized_study","Mauricio Franco Jin","2025","Sa1954: IMPACT OF GLP-1 RECEPTOR AGONISTS ON SEVERITY OF CLOSTRIDIUM DIFFICILE INFECTIONS: A PROPENSITY MATCHED COHORT ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02316-9","https://doi.org/10.1016/s0016-5085(25)02316-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049865","R0049865.pdf","paywalled","nonrandomized_study","Sabina M. Sorondo","2025","Abstract Th0029: Genetic Evidence for Glucose-dependent Insulinotropic Polypeptide as a Therapeutic Target for Peripheral Artery Disease","Arteriosclerosis Thrombosis and Vascular Biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atv.45.suppl_1.th0029","https://doi.org/10.1161/atv.45.suppl_1.th0029",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049919","R0049919.pdf","paywalled","nonrandomized_study","Aravinthan Vignarajah","2025","PO-07-068 IMPACT OF TIRZEPATIDE ON VENTRICULAR TACHYCARDIA: A PROPENSITY SCORE-MATCHED ANALYSIS","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2025.03.1828","https://doi.org/10.1016/j.hrthm.2025.03.1828",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049923","R0049923.pdf","paywalled","nonrandomized_study","Basil Jalamneh","2025","S2327 Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients With MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136768.40528.c9","https://doi.org/10.14309/01.ajg.0001136768.40528.c9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049949","R0049949.pdf","paywalled","nonrandomized_study","Osman K. Yousafzai","2025","TCT-499 Impact of GLP-1 Agonists on Cardiovascular Outcomes in Obese Adults with HFrEF receiving Guideline Directed Medical Therapy: A Propensity Score Matched Analysis","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.629","https://doi.org/10.1016/j.jacc.2025.09.629",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049957","R0049957.pdf","paywalled","nonrandomized_study","Himaben Gohil","2025","S1470 Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Comparison of Agent-Specific Outcomes in Type 2 Diabetes and Obese Inflammatory Bowel Disease Populations","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001133340.09329.f1","https://doi.org/10.14309/01.ajg.0001133340.09329.f1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049987","R0049987.pdf","paywalled","nonrandomized_study","Cristina Natha","2025","S428 Impact of Cardiovascular and Metabolic Comorbidities on Immune-Mediated Diarrhea and Colitis Severity and Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129172.13849.ff","https://doi.org/10.14309/01.ajg.0001129172.13849.ff",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050008","R0050008.pdf","paywalled","nonrandomized_study","Shriya Chunduri","2025","Abstract 4363403: The Effect of Tirzepatide versus Semaglutide on Post-Operative Outcomes in Type 2 Diabetics Following Coronary Artery Bypass Grafting","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363403","https://doi.org/10.1161/circ.152.suppl_3.4363403",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050014","R0050014.pdf","paywalled","nonrandomized_study","María‐José Sánchez","2025","1981-LB: Elevated BMI and Antiobesity Medication Prevalence in Adults with Type 1 Diabetes—Cross-Sectional Study of the Epic Cosmos Database","Diabetes","American Diabetes Association","10.2337/db25-1981-lb","https://doi.org/10.2337/db25-1981-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050021","R0050021.pdf","paywalled","nonrandomized_study","Ludovic Saba","2025","S2339 Semaglutide Reduces Incident Cirrhosis, Complications, and Mortality in MASLD Patients With Diabetes: A Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136816.79380.3d","https://doi.org/10.14309/01.ajg.0001136816.79380.3d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050052","R0050052.pdf","paywalled","nonrandomized_study","Asaf Ness","2025","Su1483: IMPROVEMENT IN HELICOBACTER PYLORI ERADICATION AMONG ADULTS RECEIVING SEMAGLUTIDE: A POPULATION-BASED PROPENSITY-SCORE-ADJUSTED ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02732-5","https://doi.org/10.1016/s0016-5085(25)02732-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050103","R0050103.pdf","paywalled","nonrandomized_study","Olanrewaju Felix Adeniran","2025","S2607 Real-World Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Aspirin in Patients With Metabolic Dysfunction-Associated Steatotic Liver Diseases and Obesity: A Propensity-Matched Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137888.44462.29","https://doi.org/10.14309/01.ajg.0001137888.44462.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050160","R0050160.pdf","paywalled","nonrandomized_study","Jessica C. Petrov","2025","S3043 Inpatient Video Capsule Endoscopy: Why the Incomplete Rates?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001139632.67794.91","https://doi.org/10.14309/01.ajg.0001139632.67794.91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050179","R0050179.pdf","paywalled","nonrandomized_study","Sami Mesgun","2025","Su2052: DOES WITHHOLDING GLP-1 RECEPTOR AGONISTS REDUCE ASPIRATION RISK IN ENDOSCOPY? A NATIONWIDE COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03104-x","https://doi.org/10.1016/s0016-5085(25)03104-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050200","R0050200.pdf","paywalled","nonrandomized_study","Eyad Gadour","2025","Long-term effects of re-sleeve endoscopic gastroplasty with GLP-1 agonists: weight reduction, liver function improvement, and insulin resistance insights over 24 months","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0045-1805402","https://doi.org/10.1055/s-0045-1805402",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050232","R0050232.pdf","paywalled","nonrandomized_study","Jasneet Gill","2025","S474 Epidemiological Characteristics and Risk Factor Associations of Colorectal Cancer in a Community Health Setting in the Appalachian Region (2020-2024)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129356.15858.1f","https://doi.org/10.14309/01.ajg.0001129356.15858.1f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050239","R0050239.pdf","paywalled","nonrandomized_study","Preston M. Carey","2025","Postoperative Complication Risk in Idiopathic Intracranial Hypertension Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0045-1803082","https://doi.org/10.1055/s-0045-1803082",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050264","R0050264.pdf","paywalled","nonrandomized_study","Spenser E. January","2025","Impact of GLP‐1 and GLP‐1/GIP Receptor Agonist Weight Loss Post‐Lung Transplant on Lung Allograft Function","Clinical Transplantation","Wiley","10.1111/ctr.70246","https://doi.org/10.1111/ctr.70246",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050274","R0050274.pdf","paywalled","nonrandomized_study","A Cordero","2025","Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3748","https://doi.org/10.1093/eurheartj/ehaf784.3748",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050291","R0050291.pdf","paywalled","nonrandomized_study","Margaux E. Wooster","2025","Abstract PS15-01: Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer","Clinical Cancer Research","American Association for Cancer Research (AACR)","10.1158/1557-3265.sabcs24-ps15-01","https://doi.org/10.1158/1557-3265.sabcs24-ps15-01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050302","R0050302.pdf","paywalled","nonrandomized_study","Ashkan Pourabhari Langroudi","2025","IP10-31 GLP-1 RECEPTOR AGONISTS: FROM METABOLIC BENEFITS TO SEXUAL HEALTH CONCERNS &NDASH; AN ANALYSIS OF US INSURANCE CLAIMS DATA","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001109900.23127.a9.31","https://doi.org/10.1097/01.ju.0001109900.23127.a9.31",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050319","R0050319.pdf","paywalled","nonrandomized_study","Ujjwal P. Dutta","2025","S740 Knowledge, Attitudes, and Practices Regarding Semaglutide Use in the US: A Nationwide Survey With Emphasis on Gastrointestinal Adverse Effects","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130420.15367.f2","https://doi.org/10.14309/01.ajg.0001130420.15367.f2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050386","R0050386.pdf","paywalled","nonrandomized_study","Timothy J. Kieffer","2025","1970-LB: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice","Diabetes","American Diabetes Association","10.2337/db25-1970-lb","https://doi.org/10.2337/db25-1970-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050402","R0050402.pdf","paywalled","nonrandomized_study","Fayaz Aijaz Ahmed Khan","2025","GLP-1 Receptor Agonist Use and Kidney Outcomes in Patients with Cancer and Type 2 Diabetes: Real-World Global Matched Cohort Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025cqzf6qh7","https://doi.org/10.1681/asn.2025cqzf6qh7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050417","R0050417.pdf","paywalled","nonrandomized_study","Shannon W. Finks","2025","Real‐world observations of using compounded GLP ‐1 ± GIP agonists within a clinical pharmacist‐managed cardiometabolic clinic","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","Wiley","10.1002/jac5.2071","https://doi.org/10.1002/jac5.2071",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050429","R0050429.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2025","Su2065: COMPARATIVE REAL-WORLD ANALYSIS OF WEIGHT LOSS OUTCOMES AND SIDE EFFECT PROFILES BETWEEN SEMAGLUTIDE AND TIRZEPATIDE: A MULTICENTERED STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03117-8","https://doi.org/10.1016/s0016-5085(25)03117-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050445","R0050445.pdf","paywalled","nonrandomized_study","Muhammad Saad Faisal","2025","S2740 Impact of Glucagon-Like Peptide-1 (GLP-1) Analogues Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138420.47997.52","https://doi.org/10.14309/01.ajg.0001138420.47997.52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050447","R0050447.pdf","paywalled","nonrandomized_study","Omer Sayed Ashruf","2025","Disparities in access of GLP-1 receptor agonists in cancer patients with obesity or type 2 diabetes: A cascade-of-care analysis across the semaglutide shortage timeline.","JCO Oncology Practice","American Society of Clinical Oncology (ASCO)","10.1200/op.2025.21.10_suppl.193","https://doi.org/10.1200/op.2025.21.10_suppl.193",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050449","R0050449.pdf","paywalled","nonrandomized_study","Xi Tan","2025","Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4351008","https://doi.org/10.1161/circ.152.suppl_3.4351008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050459","R0050459.pdf","paywalled","nonrandomized_study","Andrea Caudill","2025","Abstract 4345917: Trends in Atherosclerotic Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus: An Insurance Claims-Based Review","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4345917","https://doi.org/10.1161/circ.152.suppl_3.4345917",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050462","R0050462.pdf","paywalled","nonrandomized_study","Deepika Laddu","2025","Abstract P1072: Underutilization of Novel Guideline-Directed Medical Therapy in Patients with Heart Failure","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.151.suppl_1.p1072","https://doi.org/10.1161/cir.151.suppl_1.p1072",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050477","R0050477.pdf","paywalled","nonrandomized_study","Mia Lynch","2025","Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar","Blood","American Society of Hematology","10.1182/blood-2025-6581","https://doi.org/10.1182/blood-2025-6581",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050487","R0050487.pdf","paywalled","nonrandomized_study","ali h. osman","2025","S806 Comparative Effectiveness of Transoral Outlet Reduction (TORe) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Post-Bariatric Weight Regain: A Real-World Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130684.68009.47","https://doi.org/10.14309/01.ajg.0001130684.68009.47",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050527","R0050527.pdf","paywalled","nonrandomized_study","Erika Tsuchiyose","2025","S818 Nationwide Trends in GLP-1 Use: Examining Indications, Sociodemographics, and Cost Burden Using MEPS (2018-2022)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130732.54979.85","https://doi.org/10.14309/01.ajg.0001130732.54979.85",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050536","R0050536.pdf","paywalled","nonrandomized_study","Laith  D. Alomari","2025","Su1638: ASSESSING THE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON LONG-TERM OUTCOMES IN DIABETIC PATIENTS WITH ALCOHOLIC CIRRHOSIS: A RETROSPECTIVE COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02826-4","https://doi.org/10.1016/s0016-5085(25)02826-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050573","R0050573.pdf","paywalled","nonrandomized_study","Fredriikka Nurminen","2025","HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.1588","https://doi.org/10.1016/j.jval.2025.09.1588",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050581","R0050581.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2025","ORAL ABSTRACT: MPN-642 Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)00371-4","https://doi.org/10.1016/s2152-2650(25)00371-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050593","R0050593.pdf","paywalled","nonrandomized_study","Jessica Liu","2025","852-P: Factors Associated with the Use of Adjunct-to-Insulin Glucose-Lowering Agents in Patients with Type 1 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db25-852-p","https://doi.org/10.2337/db25-852-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050663","R0050663.pdf","paywalled","nonrandomized_study","Zainab Zaib Khan","2025","Abstract 4339657: Glucagon-Like Peptide-1 Receptor Agonists with Guideline Therapy Lower Mortality and Hospitalizations in HFpEF: A Propensity-Matched U.S. TriNetX Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4339657","https://doi.org/10.1161/circ.152.suppl_3.4339657",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050668","R0050668.pdf","paywalled","nonrandomized_study","Abdellatif Salah Ismail","2025","S744 Underutilization and Racial Disparities in Obesity Management in the United States","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130436.97057.db","https://doi.org/10.14309/01.ajg.0001130436.97057.db",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050738","R0050738.pdf","paywalled","nonrandomized_study","Chung‐Kan Peng","2025","Pulmonary Benefits of GLP-1 Analogs Versus SGLT-2 Inhibitors in COPD Patients With Coexisting Type 2 Diabetes","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a2855","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a2855",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050769","R0050769.pdf","paywalled","nonrandomized_study","Stacey M. Sklepinski","2025","308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-308-or","https://doi.org/10.2337/db25-308-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050780","R0050780.pdf","paywalled","nonrandomized_study","Delano Carty","2025","S2523 Long Term Cardiovascular Outcomes in Patients With MASLD Who Also Have Obesity and are Overweight Who Underwent Semaglutide Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137552.12187.09","https://doi.org/10.14309/01.ajg.0001137552.12187.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050806","R0050806.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2025","S811 Metabolic and Bariatric Surgery vs Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison of Cardiometabolic Risk Profiles","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130704.37750.31","https://doi.org/10.14309/01.ajg.0001130704.37750.31",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050808","R0050808.pdf","paywalled","nonrandomized_study","Jo Searles","2025","[ldquo]Real world[rdquo] experience[rdquo] of treatment with wegovy (semagluatide) and saxenda (liragluatide) in a paediatric population living with severe obesity","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.111.oc10.6","https://doi.org/10.1530/endoabs.111.oc10.6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050833","R0050833.pdf","paywalled","nonrandomized_study","Omar Al Ta’ani","2025","735: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH INCREASED RISK REDUCTION OF COLORECTAL CANCER WHEN COMPARED TO BARIATRIC SURGERY IN OBESE PATIENTS WITH DIABETES MELLITUS: A MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)01340-x","https://doi.org/10.1016/s0016-5085(25)01340-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050836","R0050836.pdf","paywalled","nonrandomized_study","Mohamed H. Eldesouki","2025","S1098 Increased Diagnoses of IBS and Functional Dyspepsia in Patients With Uncomplicated Diabetes Mellitus on GLP-1 Receptor Agonists: A Propensity-Matched Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131852.26831.fd","https://doi.org/10.14309/01.ajg.0001131852.26831.fd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050858","R0050858.pdf","paywalled","nonrandomized_study","Andrew M. Ford","2025","S720 Glucagon-Like Peptide 1 Receptor Agonists Reduce All-Cause Mortality and Healthcare Utilization in Patients With Type 1 Diabetes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130340.87475.cf","https://doi.org/10.14309/01.ajg.0001130340.87475.cf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050860","R0050860.pdf","paywalled","nonrandomized_study","THIERRY KOCHKARIAN","2025","Abstract 4370557: Cardiovascular Benefits of GLP-1 Receptor Agonists in Non-Obese Patients with Heart-Failure: A Real-World TriNetX Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370557","https://doi.org/10.1161/circ.152.suppl_3.4370557",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050878","R0050878.pdf","paywalled","nonrandomized_study","Mohammad Alqadi","2025","TCT-206 Impact of GLP-1 Receptor Agonist Use on Outcomes Following PCI in Acute Coronary Syndrome: A Multicenter Real-World Analysis","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.287","https://doi.org/10.1016/j.jacc.2025.09.287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050889","R0050889.pdf","paywalled","nonrandomized_study","Buu Minh Thanh Truong","2025","Abstract 4363148: Polygenic Modification of Weight Loss Response to GLP-1 Receptor Agonists","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363148","https://doi.org/10.1161/circ.152.suppl_3.4363148",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050892","R0050892.pdf","paywalled","nonrandomized_study","Joseph Kassab","2025","Liraglutide in patients with heart failure with preserved ejection fraction and obesity without diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.998","https://doi.org/10.1093/eurheartj/ehaf784.998",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050907","R0050907.pdf","paywalled","nonrandomized_study","Gloria Amoako","2025","Comparative Analysis of Mortality and Cardiometabolic Outcomes in Obese Patients with Type 2 Diabetes Treated with Semaglutide versus Tirzepatide: Insights from the TriNetX Database","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.066","https://doi.org/10.1016/j.ahj.2025.07.066",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050945","R0050945.pdf","paywalled","nonrandomized_study","HYE-JIN YOON","2025","1090-P: Achievement of Guideline-Directed Diabetes Management in Patients Treated by Cardiologists vs. Endocrinologists after Myocardial Infarction—A Nationwide Population-Based Study","Diabetes","American Diabetes Association","10.2337/db25-1090-p","https://doi.org/10.2337/db25-1090-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050979","R0050979.pdf","paywalled","nonrandomized_study","Cheryl Kalapura","2025","Abstract 4370283: Real-World Effectiveness of GLP-1 Receptor Agonists on Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370283","https://doi.org/10.1161/circ.152.suppl_3.4370283",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050982","R0050982.pdf","paywalled","nonrandomized_study","Danah Al-Deiri","2025","S332 Association Between ICI and Chronic Colon Mucosal Inflammation: IBD and Microscopic Colitis Risk","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001128788.87987.36","https://doi.org/10.14309/01.ajg.0001128788.87987.36",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050984","R0050984.pdf","paywalled","nonrandomized_study","Yaman Jarrar","2025","Abstract 4361086: GLP-1 Receptor Agonists and Clinical Outcomes in Non-Diabetic Patients with Peripartum Cardiomyopathy: A Propensity-Matched Retrospective Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4361086","https://doi.org/10.1161/circ.152.suppl_3.4361086",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051006","R0051006.pdf","paywalled","nonrandomized_study","Benjamin Douglas Xun Liu","2025","S938 Re-Examining the Association of Glucagon-Like Peptide-1 Receptor Agonists With Gastroesophageal Reflux Disease Through pH Impedance Testing","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131212.65698.cc","https://doi.org/10.14309/01.ajg.0001131212.65698.cc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051027","R0051027.pdf","paywalled","nonrandomized_study","Boniface Mensah","2025","S476 Unexpected Findings: GLP-1 Agonist Use Linked to Increased Colonic Polyp Risk in a Diverse U.S. Population","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129364.85006.f0","https://doi.org/10.14309/01.ajg.0001129364.85006.f0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051052","R0051052.pdf","paywalled","nonrandomized_study","Fouad H. Jaber","2025","Mo2067: GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED RISK OF GASTROINTESTINAL CANCERS: INSIGHTS FROM A NATIONWIDE REAL-WORLD ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03837-5","https://doi.org/10.1016/s0016-5085(25)03837-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051075","R0051075.pdf","paywalled","nonrandomized_study","Tinsae Anebo","2025","S2548 Clinical Outcomes of GLP-1 Agonists on Patients With Compensated Cirrhosis and Type 2 Diabetes Mellitus: A Propensity Score-Matched Study Demonstrating a Reduction in Decompensated Cirrhosis From a Multinetwork Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137652.00354.00","https://doi.org/10.14309/01.ajg.0001137652.00354.00",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051114","R0051114.pdf","paywalled","nonrandomized_study","Lina AlQirem","2025","S138 Comparative Risk of Pancreatic Pseudocyst Among Users of GLP-1 RAs: Findings From a Large-Scale EHR-Based Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127012.30891.29","https://doi.org/10.14309/01.ajg.0001127012.30891.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051136","R0051136.pdf","paywalled","nonrandomized_study","Dima Bechenati","2025","1757-P: The Rebound Effect—Weight Regain after Tirzepatide Discontinuation","Diabetes","American Diabetes Association","10.2337/db25-1757-p","https://doi.org/10.2337/db25-1757-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051148","R0051148.pdf","paywalled","nonrandomized_study","Aman Goyal","2025","Abstract 4364588: GLP-1 Receptor Agonist in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Impact on Outcomes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4364588","https://doi.org/10.1161/circ.152.suppl_3.4364588",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051177","R0051177.pdf","paywalled","nonrandomized_study","Matteo Rocco Reccia","2025","TO IMPROVE THE QUALITY OF SECONDARY PREVENTION STRATEGIES IN DIABETIC PATIENTS: THE BRING–UP PREVENTION STUDY RESULTS","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartjsupp/suaf076.075","https://doi.org/10.1093/eurheartjsupp/suaf076.075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051197","R0051197.pdf","paywalled","nonrandomized_study","Jacob Johnson","2025","Comparison of patients achieving treatment success with a glucagon‐like peptide‐1 receptor agonist for weight management between primary care provider and pharmacist co‐managed patients","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","Wiley","10.1002/jac5.70024","https://doi.org/10.1002/jac5.70024",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051240","R0051240.pdf","paywalled","nonrandomized_study","Qiaochu Xue","2025","2199-LB: Weight Loss Maintenance following Semaglutide Discontinuation—The Role of Concurrent Lifestyle Intervention","Diabetes","American Diabetes Association","10.2337/db25-2199-lb","https://doi.org/10.2337/db25-2199-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051246","R0051246.pdf","paywalled","nonrandomized_study","Xiaoliang Wang","2025","S1122 Association Between SGLT2 Inhibitors and Irritable Bowel Syndrome and Gastrointestinal Symptoms in Non-Diabetic Patients With Chronic Kidney Disease or Heart Failure","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131948.41098.23","https://doi.org/10.14309/01.ajg.0001131948.41098.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051266","R0051266.pdf","paywalled","nonrandomized_study","Thai Hau Koo","2025","S270 Impact of Prior Bariatric Surgery on the Outcomes of Acute Pancreatitis in Obese Adults: A TriNetX Database Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001128540.09683.02","https://doi.org/10.14309/01.ajg.0001128540.09683.02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051276","R0051276.pdf","paywalled","nonrandomized_study","Kim G. E. Smolderen","2025","Abstract 4369285: Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4369285","https://doi.org/10.1161/circ.152.suppl_3.4369285",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051279","R0051279.pdf","paywalled","nonrandomized_study","Julie Vanourek","2025","Abstract 4366502: Graduation from a Nurse Practitioner-led, Team-Based Cardiovascular-Kidney-Metabolic Clinic Improves Cardiovascular-Kidney-Metabolic Health and is Associated with Hospitalization Reduction: Initial Experience in an Academic Community Practice","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4366502","https://doi.org/10.1161/circ.152.suppl_3.4366502",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051345","R0051345.pdf","paywalled","nonrandomized_study","Klara Rachel Klein","2025","Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/fbay-4t58","https://doi.org/10.17615/fbay-4t58",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051369","R0051369.pdf","paywalled","nonrandomized_study","Asfand Yar Cheema","2025","MDS-1221: Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis","Clinical Lymphoma Myeloma & Leukemia","Elsevier BV","10.1016/s2152-2650(25)02069-5","https://doi.org/10.1016/s2152-2650(25)02069-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051372","R0051372.pdf","paywalled","nonrandomized_study","Jacqueline Maya","2025","1234-P: Glucagon-Like Peptide 1 Receptor Agonists Use prior to Pregnancy Is Not Associated with Abnormal Birthweight","Diabetes","American Diabetes Association","10.2337/db25-1234-p","https://doi.org/10.2337/db25-1234-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051381","R0051381.pdf","paywalled","nonrandomized_study","Jayson Mahalik","2025","S737 Risk of GERD and Psychological Symptoms in Patients Using GLP-1 Agonist and DPP-4 Antagonist vs Gastric Bypass Surgery Recipients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130408.88075.ff","https://doi.org/10.14309/01.ajg.0001130408.88075.ff",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051402","R0051402.pdf","paywalled","nonrandomized_study","Andrei Loghin","2025","Abstract 4369293: Clinical outcomes associated with utilization of Glucagon-like Peptide-1 Receptor Agonists in heart failure patients in the United States","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4369293","https://doi.org/10.1161/circ.152.suppl_3.4369293",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051439","R0051439.pdf","paywalled","nonrandomized_study","Djibril Mari Ba","2025","Mo1462: PRIOR GLP-1 RECEPTOR AGONISTS EXPOSURE AND NEW-ONSET DIABETES FOLLOWING PANCREATITIS: ANALYSIS OF LARGE US REAL-WORLD DATABASE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03534-6","https://doi.org/10.1016/s0016-5085(25)03534-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051448","R0051448.pdf","paywalled","nonrandomized_study","Ruchir Damjibhai. Paladiya","2025","S170 Incidence of Acute Pancreatitis With GLP-1 Receptor Agonists Use Across Obesity and Type 2 Diabetes Phenotypes: A Multi-Center Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127140.53940.27","https://doi.org/10.14309/01.ajg.0001127140.53940.27",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051458","R0051458.pdf","paywalled","nonrandomized_study","Emanuel Christ","2025","[68Ga]Ga-DOTA-exendin-4 PET/CT for the localization of insulinoma: results of an international, dual-center, retrospective, open-label real-world imaging study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.110.p468","https://doi.org/10.1530/endoabs.110.p468",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051495","R0051495.pdf","paywalled","nonrandomized_study","Matias Luis Costa","2025","O-070 Impact of GLP-1 agonists on stroke, SAH, and ICH: a propensity-matched multi-institutional cohort study",null,"BMJ Publishing Group Ltd.","10.1136/jnis-2025-snis.70","https://doi.org/10.1136/jnis-2025-snis.70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051508","R0051508.pdf","paywalled","nonrandomized_study","Katia L. Hannah","2025","973-P: Initiation of Dexcom CGM Is Associated with Improved Renal Outcomes in Adults with Chronic Kidney Disease (CKD) on Insulin Therapy","Diabetes","American Diabetes Association","10.2337/db25-973-p","https://doi.org/10.2337/db25-973-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051512","R0051512.pdf","paywalled","nonrandomized_study","Noor Albusta","2025","S2337 Illness Perception and Weight Loss Adherence in MASLD: A Retrospective Cohort Study With Psychological Profiling","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001136808.01427.6d","https://doi.org/10.14309/01.ajg.0001136808.01427.6d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051539","R0051539.pdf","paywalled","nonrandomized_study","Chung‐Kang Peng","2025","Comparison Between GIP/GLP-1 Co-agonists and GLP-1 Agonists on Pulmonary Outcomes in COPD Patients","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a3255","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a3255",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051555","R0051555.pdf","paywalled","nonrandomized_study","Efeturi Maxwell Okorigba","2025","Abstract 4371398: Glucagon Receptor Agonist Impact on Cardiac Amyloidosis. A Retrospective Propensity Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4371398","https://doi.org/10.1161/circ.152.suppl_3.4371398",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051565","R0051565.pdf","paywalled","nonrandomized_study","Ahmed Eltelbany","2025","602: TRENDS IN GLP-1 RECEPTOR AGONIST UTILIZATION AND BARIATRIC SURGERY RATES: A REAL-WORLD ANALYSIS FROM 2021-2024","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)05346-6","https://doi.org/10.1016/s0016-5085(25)05346-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051572","R0051572.pdf","paywalled","nonrandomized_study","Giuseppe Galati","2025","Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Under Renal Replacement Therapies: Bridging the Gap Between Cardiovascular and Systemic Benefit, From Heart Failure to Myocardial Infarction","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001677","https://doi.org/10.1097/fjc.0000000000001677","39913314","https://pubmed.ncbi.nlm.nih.gov/39913314/",null,null],["4","R0051584","R0051584.pdf","paywalled","nonrandomized_study","Omer Sayed Ashruf","2025","Tirzepatide vs semaglutide for metabolic optimization in patients with cancer: A target trial emulation study.","JCO Oncology Practice","American Society of Clinical Oncology (ASCO)","10.1200/op.2025.21.10_suppl.528","https://doi.org/10.1200/op.2025.21.10_suppl.528",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051631","R0051631.pdf","paywalled","nonrandomized_study","Yahya Alhalalmeh","2025","S269 Comparative Risk of Cholangiocarcinoma With GLP-1 Receptor Agonists and Bariatric Surgery in Patients With Diabetes and Obesity: A Matched Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001128536.23109.f4","https://doi.org/10.14309/01.ajg.0001128536.23109.f4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051682","R0051682.pdf","paywalled","nonrandomized_study","Qi Wu","2025","777-P: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation","Diabetes","American Diabetes Association","10.2337/db25-777-p","https://doi.org/10.2337/db25-777-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051686","R0051686.pdf","paywalled","nonrandomized_study","Ronan P. Allencherril","2025","S761 Combination Transoral Outlet Reduction (TORe) Plus Pharmacotherapy vs Transoral Outlet Reduction (TORe) Alone for Treatment of Weight Regain After Roux-en-Y Gastric Bypass","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130504.83877.35","https://doi.org/10.14309/01.ajg.0001130504.83877.35",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051733","R0051733.pdf","paywalled","nonrandomized_study","Virginia Milner","2025","S751 An Institutional Review of Upper Endoscopy Outcomes in Patients Taking Glucagon-Like Peptide-1 Receptor (Glp-1) Agonists: No Increased Risk of Aspiration or Retained Gastric Contents","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130464.09902.ee","https://doi.org/10.14309/01.ajg.0001130464.09902.ee",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051737","R0051737.pdf","paywalled","nonrandomized_study","Ahmed Elbayomy","2025","E-258 The impact of semaglutide (ozempic) on mortality and survival in patients with acute ischemic stroke: a nationwide and institutional retrospective analysis",null,"BMJ Publishing Group Ltd.","10.1136/jnis-2025-snis.373","https://doi.org/10.1136/jnis-2025-snis.373",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051751","R0051751.pdf","paywalled","nonrandomized_study","Ricardo Correa-Rotter","2025","Dosing, Treatment Patterns, Urine Albumin-to-Creatinine Ratio (UACR) Changes, and Safety with Finerenone Treatment in Routine Care: FINE-REAL Interim Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025nz0z1wct","https://doi.org/10.1681/asn.2025nz0z1wct",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05348733"],["4","R0051785","R0051785.pdf","paywalled","nonrandomized_study","Luìs Manuel de Almieda Nieto","2025","Su1529: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR RECURRENT ACUTE PANCREATITIS AND ARE NOT ASSOCIATED WITH LOCAL COMPLICATIONS IN PATIENTS WHO DEVELOP IT: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02757-x","https://doi.org/10.1016/s0016-5085(25)02757-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051800","R0051800.pdf","paywalled","nonrandomized_study","Johan Prevot","2025","Applying Artificial Intelligence to Measure Abdominal Adipose Metrics in Obstructive Sleep Apnea Before and After CPAP Therapy","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a4759","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a4759",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051803","R0051803.pdf","paywalled","nonrandomized_study","Jason N. Chen","2025","S796 Comparing Glucagon-Like Peptide-1 Agonists and Lifestyle Modifications on Weight Loss in a Predominantly Hispanic Population","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130644.66360.e0","https://doi.org/10.14309/01.ajg.0001130644.66360.e0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051811","R0051811.pdf","paywalled","nonrandomized_study","Aisha Siddiqah Ahmed","2025","THE RELATIONSHIP OF THE KDIGO HEAT MAP TO PULSE PRESSURE IN PATIENTS WITH TYPE II DIABETES","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001117008.46988.26","https://doi.org/10.1097/01.hjh.0001117008.46988.26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051817","R0051817.pdf","paywalled","nonrandomized_study","Abdulmalik Saleem","2025","S1093 Slowing Transit Without Consequence? Evaluating GLP-1 Agonist Use in Patients With IBS","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131832.84329.02","https://doi.org/10.14309/01.ajg.0001131832.84329.02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051911","R0051911.pdf","paywalled","nonrandomized_study","Laith Alomari","2025","S233 Impact of GLP-1 Receptor Agonists on Transplant-Free Survival and Hepatic Outcomes in Diabetic Patients With Primary Biliary Cholangitis: A Real-World Multicenter Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127392.18773.9a","https://doi.org/10.14309/01.ajg.0001127392.18773.9a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051924","R0051924.pdf","paywalled","nonrandomized_study","Budoor Alqinai","2025","S735 Psychiatric Risk in Obese vs Diabetic Non-Obese Patients on GLP-1 Receptor Agonists: A Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130400.06843.35","https://doi.org/10.14309/01.ajg.0001130400.06843.35",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051969","R0051969.pdf","paywalled","nonrandomized_study","Alexander K. Malik","2025","S765 Examining the Associations Between Treatments for Morbid Obesity and Superior Mesenteric Artery Syndrome","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130520.38322.ba","https://doi.org/10.14309/01.ajg.0001130520.38322.ba",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052065","R0052065.pdf","paywalled","nonrandomized_study","Mansur E. Shomali","2025","1060-P: A Novel Approach to Estimating Cost Savings and Return on Investment (ROI) for Weight/BMI Changes with Digital Health","Diabetes","American Diabetes Association","10.2337/db25-1060-p","https://doi.org/10.2337/db25-1060-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052073","R0052073.pdf","paywalled","nonrandomized_study","AVIK RAY","2025","757-P: Comparative Glycemic Effectiveness of Four Second-Line Glucose-Lowering Medications in Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db25-757-p","https://doi.org/10.2337/db25-757-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052090","R0052090.pdf","paywalled","nonrandomized_study","Jeong Hoon Kim","2025","S769 Trends in GLP-1 Receptor Agonist Therapy Post-Endoscopic Sleeve Gastroplasty","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001130536.81645.d8","https://doi.org/10.14309/01.ajg.0001130536.81645.d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052110","R0052110.pdf","paywalled","nonrandomized_study","Danial Nadeem","2025","S1242 Glucagon-Like Peptide-1 Receptor Agonists and Upper Endoscopy: A Data-Driven Approach to Pre-Procedural Optimization","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132428.81674.49","https://doi.org/10.14309/01.ajg.0001132428.81674.49",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052131","R0052131.pdf","paywalled","nonrandomized_study","Pushan Aggarwal","2025","Abstract 4366311: Cardiovascular-Kidney-Metabolic Syndrome: Comparing Outcomes between Sodium glucose co-transporter 2 inhibitor and Glucagon like petide 1 receptor analogue use - A Real world propensity Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4366311","https://doi.org/10.1161/circ.152.suppl_3.4366311",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052174","R0052174.pdf","paywalled","nonrandomized_study","Ying Lü","2025","735-P: Impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) on Survival among Cancer Survivors with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-735-p","https://doi.org/10.2337/db25-735-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052187","R0052187.pdf","paywalled","nonrandomized_study","Stacey M. Sklepinski","2025","779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk","Diabetes","American Diabetes Association","10.2337/db25-779-p","https://doi.org/10.2337/db25-779-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052212","R0052212.pdf","paywalled","nonrandomized_study","Matija Crnogorac","2025","#2003 Fine with finerenone in Croatia—advancing renal care for our diabetic chronic kidney disease patients","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.1928","https://doi.org/10.1093/ndt/gfaf116.1928",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052220","R0052220.pdf","paywalled","nonrandomized_study","Mohammad Kloub","2025","S190 Increased Risk of Gallbladder and Biliary Diseases With GLP-1 Receptor Agonists: A United States Collaborative Network Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127220.21310.63","https://doi.org/10.14309/01.ajg.0001127220.21310.63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052264","R0052264.pdf","paywalled","nonrandomized_study","PALWASHA ZAFAR","2025","EFFECT OF GLP-1 AGONISTS ON CLINICAL OUTCOMES IN OBESE AND DIABETIC PATIENTS WITH ASTHMA: A PROPENSITY MATCHED ANALYSIS","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.014","https://doi.org/10.1016/j.chest.2025.07.014",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052312","R0052312.pdf","paywalled","nonrandomized_study","Abdullah Sohail","2025","Tu1753: ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND REDUCED COLORECTAL CANCER INCIDENCE IN TYPE 2 DIABETES: A REAL-WORLD COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04282-9","https://doi.org/10.1016/s0016-5085(25)04282-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052377","R0052377.pdf","paywalled","nonrandomized_study","V Tsigkou","2025","Impact of multidisciplinary cardiometabolic clinics on cardiovascular risk management and therapeutic optimization in patients with type 2 diabetes mellitus","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3790","https://doi.org/10.1093/eurheartj/ehaf784.3790",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052383","R0052383.pdf","paywalled","nonrandomized_study","Lea Menz","2025","68Ga-DOTA-Exendin-4 PET/CT for the localization of insulinoma: Results of an international, dual-center, retrospective, open-label real-world imaging study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807555","https://doi.org/10.1055/s-0045-1807555",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052392","R0052392.pdf","paywalled","nonrandomized_study","Amy L. Shaver","2025","Use of GIP and GLP-1 receptor agonists in prostate cancer patients.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.5024","https://doi.org/10.1200/jco.2025.43.16_suppl.5024",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052395","R0052395.pdf","paywalled","nonrandomized_study","Patricia Y. Chu","2025","1163-P: Disparities in Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Utilization in Pediatric Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db25-1163-p","https://doi.org/10.2337/db25-1163-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052424","R0052424.pdf","paywalled","nonrandomized_study","Yan Leyfman","2025","Impact of incretin mimetic therapy on weight change in patients with cancer: A pan-cancer analysis from a single institutional cohort.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.10598","https://doi.org/10.1200/jco.2025.43.16_suppl.10598",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052465","R0052465.pdf","paywalled","nonrandomized_study","Amani K. Elshaer","2025","S2696 Glucagon-Like Peptide-1 Receptor Agonists Impact on Metabolic Dysfunction-Associated Liver Disease: A Retrospective Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138244.18055.5d","https://doi.org/10.14309/01.ajg.0001138244.18055.5d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052494","R0052494.pdf","paywalled","nonrandomized_study","Łukasz Szczerbiński","2025","333-OR: Genetic Variants Associated with Weight Change in Response to Glucose-Lowering Medications—Results from the GRADE Study","Diabetes","American Diabetes Association","10.2337/db25-333-or","https://doi.org/10.2337/db25-333-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052495","R0052495.pdf","paywalled","nonrandomized_study","Anthony J. Maristany","2025","197. Psychiatric Outcomes in Patients Treated With GLP-1 Receptor Agonists: A Retrospective Cohort Study","Journal of the Academy of Consultation-Liaison Psychiatry","Elsevier BV","10.1016/j.jaclp.2025.10.199","https://doi.org/10.1016/j.jaclp.2025.10.199",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052502","R0052502.pdf","paywalled","nonrandomized_study","Tarek Odah","2025","Su2060: INVESTIGATING THE ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THE RISK OF BOWEL OBSTRUCTION AND ILEUS: A LARGE POPULATION-BASED MATCHED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03112-9","https://doi.org/10.1016/s0016-5085(25)03112-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052524","R0052524.pdf","paywalled","nonrandomized_study","Nisar A. Amin","2025","S415 Impact of GLP1RA on Immune-Related Colitis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001129120.29209.0c","https://doi.org/10.14309/01.ajg.0001129120.29209.0c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052535","R0052535.pdf","paywalled","nonrandomized_study","Aisha Siddiqah Ahmed","2025","NON-PROTEINURIC KIDNEY DISEASE AND TYPE II DIABETES: CKM (CARDIO KIDNEY METABOLIC) PARAMETERS AND CURRENT RECOMMENDED TREATMENT MODALITIES","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001117004.86638.b8","https://doi.org/10.1097/01.hjh.0001117004.86638.b8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052551","R0052551.pdf","paywalled","nonrandomized_study","Oluwamisimi Mary Abib","2025","Abstract 4370759: Bariatric Surgery vs. GLP/GIP Agonists: A Real-World Comparative Analysis of Cardiovascular Outcomes in Over 2 Million Patients.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370759","https://doi.org/10.1161/circ.152.suppl_3.4370759",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052563","R0052563.pdf","paywalled","nonrandomized_study","Mona Abdel‐Bary","2025","Real-world weight change pattern after glucagon-like peptide-1 receptor agonist discontinuation: A 1-year observational study","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2025.100658","https://doi.org/10.1016/j.obmed.2025.100658",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052567","R0052567.pdf","paywalled","nonrandomized_study","Luìs Manuel de Almieda Nieto","2025","Su2049: GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER ALL-CAUSE HOSPITALIZATION AND DIVERTICULITIS IN PATIENTS WITH DIVERTICULAR DISEASE AND OBESITY WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03101-4","https://doi.org/10.1016/s0016-5085(25)03101-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052574","R0052574.pdf","paywalled","nonrandomized_study","Kaynat Khalid","2025","Tu1750: EXAMINING THE ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND DEVELOPMENT OF COLORECTAL CANCER: INSIGHTS FROM A GLOBAL DATABASE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)04279-9","https://doi.org/10.1016/s0016-5085(25)04279-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052604","R0052604.pdf","paywalled","nonrandomized_study","Vikash Jaiswal","2025","TCT-775 Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Cardiovascular and Limb Outcomes in Patients with Type 2 Diabetes and Peripheral Artery Disease: Findings from the TriNetX Database","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.945","https://doi.org/10.1016/j.jacc.2025.09.945",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052615","R0052615.pdf","paywalled","nonrandomized_study","Mohamad-Noor Abu-Hammour","2025","Mo1048: RACIAL DISPARITIES IN GLP-1 RECEPTOR AGONIST UTILIZATION IN PATIENTS WITH OBESITY: A U.S. COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)03209-3","https://doi.org/10.1016/s0016-5085(25)03209-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052616","R0052616.pdf","paywalled","nonrandomized_study","Jasmin Hundal","2025","Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2025.43.16_suppl.e13831","https://doi.org/10.1200/jco.2025.43.16_suppl.e13831",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052647","R0052647.pdf","paywalled","nonrandomized_study","Xuan‐Mai T. Nguyen","2025","Abstract 4362202: Combined associations of GLP-1 medications and healthy lifestyle with cardiovascular outcomes among individuals with diabetes: The Million Veteran Program","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4362202","https://doi.org/10.1161/circ.152.suppl_3.4362202",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052653","R0052653.pdf","paywalled","nonrandomized_study","Vikash Jaiswal","2025","TCT-1003 Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.1198","https://doi.org/10.1016/j.jacc.2025.09.1198",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052693","R0052693.pdf","paywalled","nonrandomized_study","Archana Sadhu","2025","1086-P: Disparities in GLP-1RA Prescription for Primary Prevention of ASCVD in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db25-1086-p","https://doi.org/10.2337/db25-1086-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052768","R0052768.pdf","paywalled","nonrandomized_study","JESSICA TANENBAUM","2025","1035-P: CGM Access in Primary Care—Feasibility Analysis of the First Six Months of an Urban Safety-Net Clinic Pilot Program","Diabetes","American Diabetes Association","10.2337/db25-1035-p","https://doi.org/10.2337/db25-1035-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052787","R0052787.pdf","paywalled","nonrandomized_study","Nabeela Siddeeque","2025","Evaluating the therapeutic potential of GLP-1 Agonists in Neurodegenerative Disorders (S25.006)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000208642","https://doi.org/10.1212/wnl.0000000000208642",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052796","R0052796.pdf","paywalled","nonrandomized_study","Shaina Ailawadi","2025","S235 GLP1-RA-Based Medications in Patients With Obesity and Chronic Pancreatitis Are Associated With Decreased Cardiac Events Without Increased Risk of Pancreatic Cancer","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001127400.60446.ac","https://doi.org/10.14309/01.ajg.0001127400.60446.ac",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052825","R0052825.pdf","paywalled","nonrandomized_study","Min Choon Tan","2025","PO-FP-056 EXPLORING THE EFFECTS OF TIRZEPATIDE IN ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED ANALYSIS","Heart Rhythm","Elsevier BV","10.1016/j.hrthm.2025.03.223","https://doi.org/10.1016/j.hrthm.2025.03.223",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052847","R0052847.pdf","paywalled","nonrandomized_study","Esteban Kosak Lopez","2025","Association of Glucagon-Like Peptide-1 Agonists and Mortality Among Patients With Idiopathic Pulmonary Fibrosis","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a1750","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a1750",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052864","R0052864.pdf","paywalled","nonrandomized_study","Sudheer Dhoop","2025","S2865 Hepatic Steatosis Is Associated With Amplified Hypoglycemia and Diabetic Ketoacidosis Risk in Type 2 Diabetes: A Multicenter Propensity-Matched Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001138920.86464.42","https://doi.org/10.14309/01.ajg.0001138920.86464.42",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052880","R0052880.pdf","paywalled","nonrandomized_study","Susan Thapa","2025","1002-P: HbA1c Improvement with the Addition of Continuous Glucose Monitoring to GLP-1 Agonist Therapy in People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1002-p","https://doi.org/10.2337/db25-1002-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052886","R0052886.pdf","paywalled","nonrandomized_study","Thitiphan Srikulmontri","2025","Abstract 4364028: Real-World Outcomes of Tirzepatide Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Peripheral Arterial Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4364028","https://doi.org/10.1161/circ.152.suppl_3.4364028",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052923","R0052923.pdf","paywalled","nonrandomized_study","Osman K. Yousafzai","2025","Abstract 4368969: Cardiovascular and Rhythm Benefits of GLP-1 Receptor Agonists in Obese Patients: A Real-World Multicenter Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368969","https://doi.org/10.1161/circ.152.suppl_3.4368969",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052972","R0052972.pdf","paywalled","nonrandomized_study","Eva Havers-Borgersen","2025","Women with polycystic ovarian syndrome are at increased associated risk of acute myocardial infarction and ischemic stroke","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3974","https://doi.org/10.1093/eurheartj/ehaf784.3974",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052978","R0052978.pdf","paywalled","nonrandomized_study","Varun Kumar Viswanath","2025","Abstract TMP104: Association of GLP-1 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.56.suppl_1.tmp104","https://doi.org/10.1161/str.56.suppl_1.tmp104",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052986","R0052986.pdf","paywalled","nonrandomized_study","Steven Quan","2025","Impact of GLP-1 Receptor Agonists on the Quality of Bowel Preparation in Screening Colonoscopies",null,null,"10.11575/prism/51849","https://doi.org/10.11575/prism/51849",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053003","R0053003.pdf","paywalled","nonrandomized_study","Benjamin Douglas Xun Liu","2025","S997 Examining the Effects of GLP-1 Receptor Agonist Therapy on Esophageal Motility Through High Resolution Esophageal Manometry (HREM)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131448.75516.0e","https://doi.org/10.14309/01.ajg.0001131448.75516.0e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053043","R0053043.pdf","paywalled","nonrandomized_study","Ali Lahooti","2025","PROPENSITY SCORE MATCHED COMPARISON OF HSI SCORE REDUCTION BETWEEN ESG + GLP-1 RA, ESG ALONE, AND GLP-1 RA ALONE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2025.03.119","https://doi.org/10.1016/j.gie.2025.03.119",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053059","R0053059.pdf","paywalled","nonrandomized_study","Kuan Yu Chi","2025","Abstract 4368981: Early GLP-1 Receptor Agonist Initiation Reduces Major Cardiac and Renal Events in Older Adults with Type 2 Diabetes Without Prior Cardiovascular or Renal Disease: A Target Trial Emulation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368981","https://doi.org/10.1161/circ.152.suppl_3.4368981",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053063","R0053063.pdf","paywalled","nonrandomized_study","Harsimran Kalsi","2025","S1241 Impact of GLP-1 Receptor Agonist Guidelines Change on Post-Endoscopic Complications: A Propensity-Matched Multi-Center Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001132424.22922.fd","https://doi.org/10.14309/01.ajg.0001132424.22922.fd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053067","R0053067.pdf","paywalled","nonrandomized_study","Thomas Schulte","2025","Social Circuitry: Wiring the ORganization – Highlights from the 2025 AACD Perioperative Leadership Summit","ASA Monitor","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.asm.0001118264.24641.dc","https://doi.org/10.1097/01.asm.0001118264.24641.dc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053072","R0053072.pdf","paywalled","nonrandomized_study","I Ikonomidis","2025","Effect of a 12-month treatment with liraglutide, empagliflozin and their combination on carotid intima-media thickness in patients with type 2 diabetes mellitus","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3038","https://doi.org/10.1093/eurheartj/ehaf784.3038",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053168","R0053168.pdf","paywalled","nonrandomized_study","Amanda Bingaman","2025","Analysis of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1-RA) Use in Patients with Idiopathic Intracranial Hypertension (IIH)","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0045-1803718","https://doi.org/10.1055/s-0045-1803718",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053236","R0053236.pdf","paywalled","nonrandomized_study","Ziad Arow","2025","Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3793","https://doi.org/10.1093/eurheartj/ehaf784.3793",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053257","R0053257.pdf","paywalled","nonrandomized_study","Jason H. Yan","2025","Abstract 4364791: GLP-1 Receptor Agonists Lower Readmission Rates Without Impacting Mortality After CABG in Adults with Congenital Heart Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4364791","https://doi.org/10.1161/circ.152.suppl_3.4364791",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053259","R0053259.pdf","paywalled","nonrandomized_study","Shawn Howell","2025","S972 GLP-1 Use in the Obese Population and the Development of Barrett's Esophagus in a Rural State","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001131348.38207.76","https://doi.org/10.14309/01.ajg.0001131348.38207.76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053279","R0053279.pdf","paywalled","nonrandomized_study","PURVI M. CHAWLA","2025","784-P: The First Real-World Experience of the Effectiveness and Safety of Tirzepatide in Improving Metabolic Parameters in Type 2 Diabetes—A Six-Month Observational Study from India","Diabetes","American Diabetes Association","10.2337/db25-784-p","https://doi.org/10.2337/db25-784-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053281","R0053281.pdf","paywalled","nonrandomized_study","Aleksandrina Ruseva","2025","Abstract 4368652: Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368652","https://doi.org/10.1161/circ.152.suppl_3.4368652",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053318","R0053318.pdf","paywalled","nonrandomized_study","DALIAN LETREN","2025","IMPACT OF SEMAGLUTIDE ON MORTALITY IN OBSTRUCTIVE SLEEP APNEA PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROPENSITY SCORE-MATCHED, RETROSPECTIVE COHORT STUDY","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3954","https://doi.org/10.1016/j.chest.2025.07.3954",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053325","R0053325.pdf","paywalled","nonrandomized_study","James J. Amamoo","2025","2005-LB: Changes in Clinical Measures among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Receiving Once-Weekly Semaglutide (sema OW) vs. Oral Antidiabetic Medications (ADMs)","Diabetes","American Diabetes Association","10.2337/db25-2005-lb","https://doi.org/10.2337/db25-2005-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053389","R0053389.pdf","paywalled","nonrandomized_study","James J. Amamoo","2025","838-P: Changes in Clinical Measures in U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Who Received Once-Weekly (OW) Semaglutide","Diabetes","American Diabetes Association","10.2337/db25-838-p","https://doi.org/10.2337/db25-838-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053475","R0053475.pdf","paywalled","nonrandomized_study","Bethany A. Kalich","2025","Abstract 4365696: Virtual Decentralized Study of Patient Nausea Experience on Anti-Obesity Medication (COSMOS-DIGITAL)","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365696","https://doi.org/10.1161/circ.152.suppl_3.4365696",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053516","R0053516.pdf","paywalled","nonrandomized_study","Taweesak Wannachalee","2025","CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.303","https://doi.org/10.1016/j.jval.2025.09.303",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053544","R0053544.pdf","paywalled","nonrandomized_study","Rayaz Ahmed Malik","2025","Real-world study evaluating long-term effectiveness of iGlarLixi in people with T2D in the USA: Soli-durability study","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2025.112564","https://doi.org/10.1016/j.diabres.2025.112564",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053579","R0053579.pdf","paywalled","nonrandomized_study","Mariana Ortiz","2025","1.47 GLP1-RA Use and Sustained Depressive Symptoms in Diabetic Children: A Retrospective Study","Journal of the American Academy of Child & Adolescent Psychiatry","Elsevier BV","10.1016/j.jaac.2025.08.076","https://doi.org/10.1016/j.jaac.2025.08.076",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053636","R0053636.pdf","paywalled","nonrandomized_study","Ekow Essien","2025","Comparative Cardiovascular Benefits of Semaglutide Adjunctive to Bariatric Surgery: A Real-World Analysis Using TriNetX","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.063","https://doi.org/10.1016/j.ahj.2025.07.063",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053687","R0053687.pdf","paywalled","nonrandomized_study","Mauro Gitto","2025","GLP1 receptor agonists and CAD regression in diabetic patients after ACS","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.1805","https://doi.org/10.1093/eurheartj/ehaf784.1805",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053723","R0053723.pdf","paywalled","nonrandomized_study","Avleen Dhody","2025","GLP-1 Medications: Redefining Food Choices and Industry Trends","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18014212","https://doi.org/10.5281/zenodo.18014212",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053877","R0053877.pdf","paywalled","nonrandomized_study","Mohamed Alzahrani","2025","EE708 The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.1088","https://doi.org/10.1016/j.jval.2025.09.1088",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053896","R0053896.pdf","paywalled","nonrandomized_study","Yong Hao Yeo","2025","Abstract 4370898: Long-Term Impact of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Patients Treated with Hematopoietic Stem Cell Transplantation: A Propensity-Score Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4370898","https://doi.org/10.1161/circ.152.suppl_3.4370898",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053929","R0053929.pdf","paywalled","nonrandomized_study","Argen Omurzakov","2025","Perioperative glucagon-like peptide-1 receptor agonist use is not associated with increased complications in obese patients undergoing total shoulder arthroplasty: a propensity-matched large database study","Seminars in Arthroplasty JSES","Elsevier BV","10.1053/j.sart.2025.06.001","https://doi.org/10.1053/j.sart.2025.06.001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053994","R0053994.pdf","paywalled","nonrandomized_study","Patrycja Ochman-Pasierbek","2025","From medication to movement: The role of physical activity in the treatment of obesity","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.16632878","https://doi.org/10.5281/zenodo.16632878",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054157","R0054157.pdf","paywalled","nonrandomized_study","Maxwell W. Pickles","2025","Risk of Postoperative Complications in Patients Who Underwent Transsphenoidal Pituitary Surgery Treated with Glucagon-Like Peptide Agonists (TRINETX)","Journal of Neurological Surgery Part B Skull Base","Georg Thieme Verlag KG","10.1055/s-0045-1803739","https://doi.org/10.1055/s-0045-1803739",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054181","R0054181.pdf","paywalled","nonrandomized_study","Manja Antonič","2025","Safety and Feasibility of Simultaneous and Gradual Initiation of Combination Renoprotective Therapy in Patients with Type 2 Diabetes and CKD: A Real-World Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20258z6ec0wf","https://doi.org/10.1681/asn.20258z6ec0wf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054262","R0054262.pdf","paywalled","nonrandomized_study","Rishav Adhikari","2025","National Trends in Use of CKD Guideline-Directed Medical Therapies","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025ejx8sf08","https://doi.org/10.1681/asn.2025ejx8sf08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054428","R0054428.pdf","paywalled","nonrandomized_study","Brianna M. Papoutsis","2025","5.22 Comparing Psychiatric Safety Profiles of Semaglutide and Metformin in Pediatric Patients: A Retrospective Study","Journal of the American Academy of Child & Adolescent Psychiatry","Elsevier BV","10.1016/j.jaac.2025.08.407","https://doi.org/10.1016/j.jaac.2025.08.407",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054449","R0054449.pdf","paywalled","nonrandomized_study","Ekow Essien","2025","Tirzepatide vs Semaglutide in Coronary Artery Disease and Obesity: Real-World Cardiovascular Outcomes Analysis from the TriNetX Research Network","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.060","https://doi.org/10.1016/j.ahj.2025.07.060",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054497","R0054497.pdf","paywalled","nonrandomized_study","Ekow Essien","2025","Cardiovascular Outcomes in Obese Patients with Sleep Apnea Treated with Tirzepatide Versus Bariatric Surgery: A Propensity-Matched Analysis Using the TriNetX Research Network","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.039","https://doi.org/10.1016/j.ahj.2025.07.039",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054586","R0054586.pdf","paywalled","nonrandomized_study","Muluken Megiso","2025","A real-world analysis on the impact of GLP-1 receptor agonist use on all-cause mortality and hematological outcomes in AML/CML patients with obesity","Blood","American Society of Hematology","10.1182/blood-2025-2857","https://doi.org/10.1182/blood-2025-2857",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054620","R0054620.pdf","paywalled","nonrandomized_study","Hossny Alaws","2025","P158 The association between GLP-1 receptor agonist use and mortality among COPD patients",null,"BMJ Publishing Group Ltd and British Thoracic Society","10.1136/thorax-2025-btsabstracts.339","https://doi.org/10.1136/thorax-2025-btsabstracts.339",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054679","R0054679.pdf","paywalled","nonrandomized_study","Ekow Essien","2025","Comparative Cardiovascular Outcomes of Tirzepatide vs Liraglutide in Obese Patients with Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network","American Heart Journal","Elsevier BV","10.1016/j.ahj.2025.07.038","https://doi.org/10.1016/j.ahj.2025.07.038",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054713","R0054713.pdf","paywalled","nonrandomized_study","Fionn Walsh","2025","A Retrospective Cohort Study of GLP-1 receptor agonist therapy in pregnant women with insulin resistance","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22812609","https://doi.org/10.5281/zenodo.22812609",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054742","R0054742.pdf","paywalled","nonrandomized_study","Junaid Khan","2025","S2455 Effects of Bariatric Surgery on Non-Invasive Markers of MASLD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001137280.23777.90","https://doi.org/10.14309/01.ajg.0001137280.23777.90",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054837","R0054837.pdf","paywalled","nonrandomized_study","Nishant P. Shah","2025","Abstract 4360264: Real World Evaluation of the Eligibility, Uptake, and Cardiometabolic Effects of Tirzepatide: An Analysis from the Platform for Evidence GeneraTion in CArdiometabolic HeaLth (PETAL) Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4360264","https://doi.org/10.1161/circ.152.suppl_3.4360264",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054887","R0054887.pdf","paywalled","nonrandomized_study","F Acquistapace","2025","Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland multicentre, prospective, observational study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3796","https://doi.org/10.1093/eurheartj/ehaf784.3796",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054946","R0054946.pdf","paywalled","nonrandomized_study","SAUD ALAWAD","2025","EXPLORING THE POTENTIAL BENEFITS OF GLP-1 RECEPTOR AGONISTS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM A LARGE DATABASE STUDY","CHEST Journal","Elsevier BV","10.1016/j.chest.2025.07.3690","https://doi.org/10.1016/j.chest.2025.07.3690",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055069","R0055069.pdf","paywalled","nonrandomized_study","Viveca Ritsinger","2025","Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the swedish AROS study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3760","https://doi.org/10.1093/eurheartj/ehaf784.3760",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055089","R0055089.pdf","paywalled","nonrandomized_study","Anna Rubinski","2025","RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.2916","https://doi.org/10.1016/j.jval.2025.09.2916",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055125","R0055125.pdf","paywalled","nonrandomized_study","Veerabahu Ramasamy Mohan","2025","iGlarLixi vs BIAsp 30 patient-reported outcomes in people with type 2 diabetes—SoliMix trial subanalysis in India cohort","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2025.112735","https://doi.org/10.1016/j.diabres.2025.112735",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055145","R0055145.pdf","paywalled","nonrandomized_study","Tze Ern Ong","2025","Abstract 4345595: Five-Year Outcomes of Glucagon-Like Peptide-1 Agonists in Obstructive Hypertrophic Cardiomyopathy: A Population-Based Retrospective Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4345595","https://doi.org/10.1161/circ.152.suppl_3.4345595",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055284","R0055284.pdf","paywalled","nonrandomized_study","Amer Muhyieddeen","2025","TCT-767 Clinical Outcomes of GLP-1 Receptor Agonist Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large-Scale Propensity-Matched Analysis","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.09.936","https://doi.org/10.1016/j.jacc.2025.09.936",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055304","R0055304.pdf","paywalled","nonrandomized_study","D. G. Ward","2025","Patients with normal spirometry results in community diagnostics: the role of BMI",null,"European Respiratory Society","10.1183/13993003.congress-2025.pa4137","https://doi.org/10.1183/13993003.congress-2025.pa4137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055312","R0055312.pdf","paywalled","nonrandomized_study","Sultana Jahan","2025","Abstract 4363572: Comparative Effectiveness of SGLT2 Inhibitors with and without GLP-1 Receptor Agonists in Patients with Heart Failure and Type 2 Diabetes Mellitus","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4363572","https://doi.org/10.1161/circ.152.suppl_3.4363572",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055363","R0055363.pdf","paywalled","nonrandomized_study","Randall W. Dick","2025","Recent Use Of Weight Loss Drugs - Exploring Patient Claims Data","Medicine & Science in Sports & Exercise","Ovid Technologies (Wolters Kluwer Health)","10.1249/01.mss.0001157904.83008.3b","https://doi.org/10.1249/01.mss.0001157904.83008.3b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055396","R0055396.pdf","paywalled","nonrandomized_study","Janis Casper","2025","GLP-1RA, SGLT2I AND RAASI COMBINATION THERAPY REDUCES MORTALITY AND KIDNEY EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0001115716.93531.61","https://doi.org/10.1097/01.hjh.0001115716.93531.61",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055509","R0055509.pdf","paywalled","nonrandomized_study","Jayakrishnan B.","2025","Multisystem Complications of Type 2 Diabetes: A Comprehensive Narrative Review","IFR Journal of Medical Science and Case Report","International Federation of Research and Discovery","10.70146/mscrv01i03.010","https://doi.org/10.70146/mscrv01i03.010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055519","R0055519.pdf","paywalled","nonrandomized_study","Vikash Jaiswal","2025","Abstract 4368269: Association between Glucagon-like peptide-1 receptor agonists and risk of Arrhythmias: A Contemporary Real-World Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4368269","https://doi.org/10.1161/circ.152.suppl_3.4368269",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055586","R0055586.pdf","paywalled","nonrandomized_study","P Sedova","2025","Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3655","https://doi.org/10.1093/eurheartj/ehaf784.3655",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055678","R0055678.pdf","paywalled","nonrandomized_study","Abdul Wali Khan","2025","Abstract 4365133: Impact of GLP-1 Analog Use on Clinical Outcomes Following Bariatric Surgery: A Propensity-Matched Retrospective Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365133","https://doi.org/10.1161/circ.152.suppl_3.4365133",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056250","R0056250.pdf","paywalled","nonrandomized_study","Rud machado varela","2025","Non-surgical techniques for managing skin laxity after abrupt weight loss: a scope review","Open Science Framework",null,"10.17605/osf.io/fkdva","https://doi.org/10.17605/osf.io/fkdva",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0002545","R0002545.pdf","paywalled","nonrandomized_study","Cazzola M","2024","Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.","The Journal of asthma : official journal of the Association for the Care of Asthma","Informa UK Limited","10.1080/02770903.2024.2372600","https://doi.org/10.1080/02770903.2024.2372600","38913778","https://pubmed.ncbi.nlm.nih.gov/38913778/",null,null],["4","R0002919","R0002919.pdf","paywalled","nonrandomized_study","Chapman MB","2024","Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.05.012","https://doi.org/10.1016/j.gie.2024.05.012","38759761","https://pubmed.ncbi.nlm.nih.gov/38759761/",null,null],["4","R0003104","R0003104.pdf","paywalled","nonrandomized_study","McIntyre RS","2024","The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2023.2295397","https://doi.org/10.1080/14740338.2023.2295397","38087976","https://pubmed.ncbi.nlm.nih.gov/38087976/",null,null],["4","R0003315","R0003315.pdf","paywalled","nonrandomized_study","Samuels SL","2024","Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15430","https://doi.org/10.1111/dom.15430","38229444","https://pubmed.ncbi.nlm.nih.gov/38229444/",null,null],["4","R0003328","R0003328.pdf","paywalled","nonrandomized_study","Joshi GP","2024","Preoperative Strategies for Patients on Glucagon-like Peptide-1 Receptor Agonists Navigating Current Controversies and Future Directions.","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000005222","https://doi.org/10.1097/aln.0000000000005222","39471348","https://pubmed.ncbi.nlm.nih.gov/39471348/",null,null],["4","R0003436","R0003436.pdf","paywalled","nonrandomized_study","Peng CY","2024","Association between Glucagon-like Peptide-1 Receptor Agonists and Aspiration Pneumonia during Endoscopic Procedures.","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000005174","https://doi.org/10.1097/aln.0000000000005174","39240542","https://pubmed.ncbi.nlm.nih.gov/39240542/",null,null],["4","R0003512","R0003512.pdf","paywalled","nonrandomized_study","Liu BD","2024","Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.","Gut","BMJ","10.1136/gutjnl-2023-329651","https://doi.org/10.1136/gutjnl-2023-329651","37739778","https://pubmed.ncbi.nlm.nih.gov/37739778/",null,null],["4","R0003575","R0003575.pdf","paywalled","nonrandomized_study","Wolff Sagy Y","2024","Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-024-03052-0","https://doi.org/10.1038/s41591-024-03052-0","38749475","https://pubmed.ncbi.nlm.nih.gov/38749475/",null,null],["4","R0003638","R0003638.pdf","paywalled","nonrandomized_study","Huang YN","2024","Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15869","https://doi.org/10.1111/dom.15869","39171569","https://pubmed.ncbi.nlm.nih.gov/39171569/",null,null],["4","R0003696","R0003696.pdf","paywalled","nonrandomized_study","Niazi S","2024","Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2024.03.004","https://doi.org/10.1016/j.ophtha.2024.03.004","38490274","https://pubmed.ncbi.nlm.nih.gov/38490274/",null,null],["4","R0003810","R0003810.pdf","paywalled","nonrandomized_study","Zheng K","2024","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15769","https://doi.org/10.1111/dom.15769","39056216","https://pubmed.ncbi.nlm.nih.gov/39056216/",null,null],["4","R0003823","R0003823.pdf","paywalled","nonrandomized_study","Mizubuti GB","2024","Perioperative management of patients on glucagon-like peptide-1 receptor agonists.","Current opinion in anaesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aco.0000000000001348","https://doi.org/10.1097/aco.0000000000001348","38390914","https://pubmed.ncbi.nlm.nih.gov/38390914/",null,null],["4","R0003883","R0003883.pdf","paywalled","nonrandomized_study","Yeo YH","2024","Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.","Annals of internal medicine","American College of Physicians","10.7326/m24-0019","https://doi.org/10.7326/m24-0019","39038291","https://pubmed.ncbi.nlm.nih.gov/39038291/",null,null],["4","R0003934","R0003934.pdf","paywalled","nonrandomized_study","Nigam A","2024","Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.72.0644","https://doi.org/10.59556/japi.72.0644","39291515","https://pubmed.ncbi.nlm.nih.gov/39291515/",null,null],["4","R0003977","R0003977.pdf","paywalled","nonrandomized_study","Yen FS","2024","Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD.","Thorax","BMJ","10.1136/thorax-2023-221040","https://doi.org/10.1136/thorax-2023-221040","39353727","https://pubmed.ncbi.nlm.nih.gov/39353727/",null,null],["4","R0004001","R0004001.pdf","paywalled","nonrandomized_study","Garza K","2024","Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000002777","https://doi.org/10.14309/ajg.0000000000002777","38534127","https://pubmed.ncbi.nlm.nih.gov/38534127/",null,null],["4","R0004060","R0004060.pdf","paywalled","nonrandomized_study","Yen FS","2024","Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2023.06.004","https://doi.org/10.1016/j.cgh.2023.06.004","37331413","https://pubmed.ncbi.nlm.nih.gov/37331413/",null,null],["4","R0004092","R0004092.pdf","paywalled","nonrandomized_study","Akhverdyan N","2024","Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2024.0115","https://doi.org/10.1089/met.2024.0115","38868900","https://pubmed.ncbi.nlm.nih.gov/38868900/",null,null],["4","R0004112","R0004112.pdf","paywalled","nonrandomized_study","Nassar M","2024","Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103116","https://doi.org/10.1016/j.dsx.2024.103116","39332263","https://pubmed.ncbi.nlm.nih.gov/39332263/",null,null],["4","R0004249","R0004249.pdf","paywalled","nonrandomized_study","Yen FS","2024","Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103099","https://doi.org/10.1016/j.dsx.2024.103099","39128378","https://pubmed.ncbi.nlm.nih.gov/39128378/",null,null],["4","R0004273","R0004273.pdf","paywalled","nonrandomized_study","Suissa S","2024","Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?","Gut","BMJ","10.1136/gutjnl-2024-331976","https://doi.org/10.1136/gutjnl-2024-331976","38499341","https://pubmed.ncbi.nlm.nih.gov/38499341/",null,null],["4","R0004379","R0004379.pdf","paywalled","nonrandomized_study","Iwamoto H","2024","Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15784","https://doi.org/10.1111/dom.15784","39039725","https://pubmed.ncbi.nlm.nih.gov/39039725/",null,null],["4","R0004458","R0004458.pdf","paywalled","nonrandomized_study","Ushakumari DS","2024","ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.","Anesthesiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/aln.0000000000004776","https://doi.org/10.1097/aln.0000000000004776","37982170","https://pubmed.ncbi.nlm.nih.gov/37982170/",null,null],["4","R0004459","R0004459.pdf","paywalled","nonrandomized_study","Su YC","2024","Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2024.101545","https://doi.org/10.1016/j.diabet.2024.101545","38777141","https://pubmed.ncbi.nlm.nih.gov/38777141/",null,null],["4","R0004508","R0004508.pdf","paywalled","nonrandomized_study","Wood M","2024","Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900241253661","https://doi.org/10.1177/08971900241253661","38720191","https://pubmed.ncbi.nlm.nih.gov/38720191/",null,null],["4","R0004555","R0004555.pdf","paywalled","nonrandomized_study","Lin DS","2024","Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15788","https://doi.org/10.1111/dom.15788","39030922","https://pubmed.ncbi.nlm.nih.gov/39030922/",null,null],["4","R0004690","R0004690.pdf","paywalled","nonrandomized_study","Tagliapietra GA","2024","Glucagon-like peptide receptor agonists and risk for depression.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.05.005","https://doi.org/10.1016/j.pcd.2024.05.005","38852027","https://pubmed.ncbi.nlm.nih.gov/38852027/",null,null],["4","R0004755","R0004755.pdf","paywalled","nonrandomized_study","Chen JJ","2024","Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.","Kidney international","Elsevier BV","10.1016/j.kint.2024.01.002","https://doi.org/10.1016/j.kint.2024.01.002","38388145","https://pubmed.ncbi.nlm.nih.gov/38388145/",null,null],["4","R0004821","R0004821.pdf","paywalled","nonrandomized_study","Su YC","2024","Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2024.101522","https://doi.org/10.1016/j.diabet.2024.101522","38341131","https://pubmed.ncbi.nlm.nih.gov/38341131/",null,null],["4","R0004841","R0004841.pdf","paywalled","nonrandomized_study","Bottanelli M","2024","Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV?","HIV medicine","Wiley","10.1111/hiv.13587","https://doi.org/10.1111/hiv.13587","37990373","https://pubmed.ncbi.nlm.nih.gov/37990373/",null,"ClinicalTrials.gov:NCT04174755; ClinicalTrials.gov:NCT04019197"],["4","R0005072","R0005072.pdf","paywalled","nonrandomized_study","Scheen AJ","2024","[Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk].","Revue medicale suisse","Médecine et Hygiène","10.53738/revmed.2024.20.884.1492","https://doi.org/10.53738/revmed.2024.20.884.1492","39219392","https://pubmed.ncbi.nlm.nih.gov/39219392/",null,null],["4","R0005105","R0005105.pdf","paywalled","nonrandomized_study","Hong B","2024","Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.","Annals of internal medicine","American College of Physicians","10.7326/m23-3220","https://doi.org/10.7326/m23-3220","39186787","https://pubmed.ncbi.nlm.nih.gov/39186787/",null,null],["4","R0005118","R0005118.pdf","paywalled","nonrandomized_study","Singh AK","2024","Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.72.0621","https://doi.org/10.59556/japi.72.0621","39163055","https://pubmed.ncbi.nlm.nih.gov/39163055/",null,null],["4","R0005361","R0005361.pdf","paywalled","nonrandomized_study","Haraguchi T","2024","Glucagon Stimulation Test and Insulin Secretory Capacity in the Clinical Assessment of Incretin-Based Therapy for Diabetes.","Diabetes","American Diabetes Association","10.2337/db24-0518","https://doi.org/10.2337/db24-0518","39196369","https://pubmed.ncbi.nlm.nih.gov/39196369/",null,null],["4","R0005427","R0005427.pdf","paywalled","nonrandomized_study","Bea S","2024","Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15292","https://doi.org/10.1111/dom.15292","37735822","https://pubmed.ncbi.nlm.nih.gov/37735822/",null,null],["4","R0005442","R0005442.pdf","paywalled","nonrandomized_study","Basile L","2024","Semaglutide and obesity: beyond the nutritional and lifestyle intervention?","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.23.04103-9","https://doi.org/10.23736/s2724-6507.23.04103-9","39028209","https://pubmed.ncbi.nlm.nih.gov/39028209/",null,null],["4","R0005470","R0005470.pdf","paywalled","nonrandomized_study","Cárdenas-Salas JJ","2024","REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108874","https://doi.org/10.1016/j.jdiacomp.2024.108874","39442257","https://pubmed.ncbi.nlm.nih.gov/39442257/",null,null],["4","R0005494","R0005494.pdf","paywalled","nonrandomized_study","Jalleh RJ","2024","Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(24)00188-2","https://doi.org/10.1016/s2468-1253(24)00188-2","39096914","https://pubmed.ncbi.nlm.nih.gov/39096914/",null,null],["4","R0005952","R0005952.pdf","paywalled","nonrandomized_study","Lin YH","2024","Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.01.016","https://doi.org/10.1016/j.eprac.2024.01.016","38325629","https://pubmed.ncbi.nlm.nih.gov/38325629/",null,null],["4","R0005956","R0005956.pdf","paywalled","nonrandomized_study","Yao R","2024","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000002564","https://doi.org/10.14309/ajg.0000000000002564","37856247","https://pubmed.ncbi.nlm.nih.gov/37856247/",null,null],["4","R0005986","R0005986.pdf","paywalled","nonrandomized_study","Holzhey M","2024","Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD.","European journal of gastroenterology & hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/meg.0000000000002656","https://doi.org/10.1097/meg.0000000000002656","37823453","https://pubmed.ncbi.nlm.nih.gov/37823453/",null,null],["4","R0006017","R0006017.pdf","paywalled","nonrandomized_study","Yang CT","2024","Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.","Journal of internal medicine","Wiley","10.1111/joim.13751","https://doi.org/10.1111/joim.13751","37994187","https://pubmed.ncbi.nlm.nih.gov/37994187/",null,null],["4","R0006167","R0006167.pdf","paywalled","nonrandomized_study","Choy K","2024","Weighing your options-intragastric balloon versus semaglutide.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-024-11169-z","https://doi.org/10.1007/s00464-024-11169-z","39138683","https://pubmed.ncbi.nlm.nih.gov/39138683/",null,null],["4","R0006325","R0006325.pdf","paywalled","nonrandomized_study","Maselli DB","2024","Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07278-2","https://doi.org/10.1007/s11695-024-07278-2","38753265","https://pubmed.ncbi.nlm.nih.gov/38753265/",null,null],["4","R0006348","R0006348.pdf","paywalled","nonrandomized_study","Rabbani SA","2024","Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2024.2395540","https://doi.org/10.1080/17446651.2024.2395540","39194153","https://pubmed.ncbi.nlm.nih.gov/39194153/",null,null],["4","R0006408","R0006408.pdf","paywalled","nonrandomized_study","Engström A","2024","Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000712","https://doi.org/10.1097/hep.0000000000000712","38085855","https://pubmed.ncbi.nlm.nih.gov/38085855/",null,null],["4","R0006674","R0006674.pdf","paywalled","nonrandomized_study","Arvanitakis K","2024","Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102935","https://doi.org/10.1016/j.dsx.2023.102935","38163417","https://pubmed.ncbi.nlm.nih.gov/38163417/",null,null],["4","R0006726","R0006726.pdf","paywalled","nonrandomized_study","Jirapinyo P","2024","Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07178-5","https://doi.org/10.1007/s11695-024-07178-5","38512644","https://pubmed.ncbi.nlm.nih.gov/38512644/",null,null],["4","R0006782","R0006782.pdf","paywalled","nonrandomized_study","Medhati P","2024","Outcomes and Management of Re-Establishing Bariatric Patients.","Journal of the American College of Surgeons","Ovid Technologies (Wolters Kluwer Health)","10.1097/xcs.0000000000001062","https://doi.org/10.1097/xcs.0000000000001062","38421026","https://pubmed.ncbi.nlm.nih.gov/38421026/",null,null],["4","R0007210","R0007210.pdf","paywalled","nonrandomized_study","Bandyopadhyay S","2024","An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review.","Hospital practice (1995)","Informa UK Limited","10.1080/21548331.2024.2412513","https://doi.org/10.1080/21548331.2024.2412513","39356238","https://pubmed.ncbi.nlm.nih.gov/39356238/",null,null],["4","R0007359","R0007359.pdf","paywalled","nonrandomized_study","Dave BP","2024","From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.","Molecular biology reports","Springer Science and Business Media LLC","10.1007/s11033-024-09793-y","https://doi.org/10.1007/s11033-024-09793-y","39042283","https://pubmed.ncbi.nlm.nih.gov/39042283/",null,null],["4","R0007411","R0007411.pdf","paywalled","nonrandomized_study","Fadini GP","2024","Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15554","https://doi.org/10.1111/dom.15554","38477183","https://pubmed.ncbi.nlm.nih.gov/38477183/",null,null],["4","R0007556","R0007556.pdf","paywalled","nonrandomized_study","Abu-Freha N","2024","The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111900","https://doi.org/10.1016/j.diabres.2024.111900","39433216","https://pubmed.ncbi.nlm.nih.gov/39433216/",null,null],["4","R0007852","R0007852.pdf","paywalled","nonrandomized_study","Hasselstrøm Jensen J","2024","Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/1574886318666230420084701","https://doi.org/10.2174/1574886318666230420084701","37078347","https://pubmed.ncbi.nlm.nih.gov/37078347/",null,null],["4","R0007887","R0007887.pdf","paywalled","nonrandomized_study","Salahuddin T","2024","Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021.","American heart journal","Elsevier BV","10.1016/j.ahj.2023.11.009","https://doi.org/10.1016/j.ahj.2023.11.009","37956920","https://pubmed.ncbi.nlm.nih.gov/37956920/",null,null],["4","R0008156","R0008156.pdf","paywalled","nonrandomized_study","Lee S","2024","Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111712","https://doi.org/10.1016/j.diabres.2024.111712","38768867","https://pubmed.ncbi.nlm.nih.gov/38768867/",null,null],["4","R0008286","R0008286.pdf","paywalled","nonrandomized_study","Betts KA","2024","Antihyperglycemic treatment patterns for chronic kidney disease and type 2 diabetes.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2024.89599","https://doi.org/10.37765/ajmc.2024.89599","39302264","https://pubmed.ncbi.nlm.nih.gov/39302264/",null,null],["4","R0008529","R0008529.pdf","paywalled","nonrandomized_study","Ramos Belinchón C","2024","Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.","Revista espanola de enfermedades digestivas","Sociedad Espanola de Patologia Digestiva (SEPD)","10.17235/reed.2024.10305/2024","https://doi.org/10.17235/reed.2024.10305/2024","38767015","https://pubmed.ncbi.nlm.nih.gov/38767015/",null,null],["4","R0008616","R0008616.pdf","paywalled","nonrandomized_study","Wilhite K","2024","Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280231205490","https://doi.org/10.1177/10600280231205490","37881914","https://pubmed.ncbi.nlm.nih.gov/37881914/",null,null],["4","R0008949","R0008949.pdf","paywalled","nonrandomized_study","Buddhiraju A","2024","Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.05.079","https://doi.org/10.1016/j.arth.2024.05.079","38823516","https://pubmed.ncbi.nlm.nih.gov/38823516/",null,null],["4","R0008957","R0008957.pdf","paywalled","nonrandomized_study","Zhang J","2024","Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15594","https://doi.org/10.1111/dom.15594","38618979","https://pubmed.ncbi.nlm.nih.gov/38618979/",null,null],["4","R0009143","R0009143.pdf","paywalled","nonrandomized_study","Docimo S","2024","A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-024-11191-1","https://doi.org/10.1007/s00464-024-11191-1","39285034","https://pubmed.ncbi.nlm.nih.gov/39285034/",null,null],["4","R0009648","R0009648.pdf","paywalled","nonrandomized_study","Kowall B","2024","Too good to be true: Are GLP-1 receptor agonists the new metformin?","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108851","https://doi.org/10.1016/j.jdiacomp.2024.108851","39236411","https://pubmed.ncbi.nlm.nih.gov/39236411/",null,null],["4","R0009771","R0009771.pdf","paywalled","nonrandomized_study","Chetty AK","2024","A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2023.12.010","https://doi.org/10.1016/j.eprac.2023.12.010","38122931","https://pubmed.ncbi.nlm.nih.gov/38122931/",null,null],["4","R0009930","R0009930.pdf","paywalled","nonrandomized_study","Abdelmannan D","2024","Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.111045","https://doi.org/10.1016/j.diabres.2023.111045","38070546","https://pubmed.ncbi.nlm.nih.gov/38070546/",null,null],["4","R0010618","R0010618.pdf","paywalled","nonrandomized_study","Agrawal V","2024","Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study.","Neurosurgery","Ovid Technologies (Wolters Kluwer Health)","10.1227/neu.0000000000003291","https://doi.org/10.1227/neu.0000000000003291","39589142","https://pubmed.ncbi.nlm.nih.gov/39589142/",null,null],["4","R0010753","R0010753.pdf","paywalled","nonrandomized_study","Baser O","2024","The impact of approved anti-obesity medications on osteoarthritis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2024.2391524","https://doi.org/10.1080/14656566.2024.2391524","39129529","https://pubmed.ncbi.nlm.nih.gov/39129529/",null,null],["4","R0011036","R0011036.pdf","paywalled","nonrandomized_study","Naude J","2024","Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-024-01526-2","https://doi.org/10.1038/s41366-024-01526-2","38724682","https://pubmed.ncbi.nlm.nih.gov/38724682/",null,null],["4","R0013372","R0013372.pdf","paywalled","nonrandomized_study","Montastruc JL","2024","GLP 1 receptor agonists and obesity-associated cancers: a disproportionality analysis in Vigibase®.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-024-03761-y","https://doi.org/10.1007/s00228-024-03761-y","39331139","https://pubmed.ncbi.nlm.nih.gov/39331139/",null,null],["4","R0013911","R0013911.pdf","paywalled","nonrandomized_study","Jamal M","2024","Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07137-0","https://doi.org/10.1007/s11695-024-07137-0","38430320","https://pubmed.ncbi.nlm.nih.gov/38430320/",null,null],["4","R0015241","R0015241.pdf","paywalled","nonrandomized_study","Nicolau J","2024","Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.","Journal of addictive diseases","Informa UK Limited","10.1080/10550887.2024.2315365","https://doi.org/10.1080/10550887.2024.2315365","38369467","https://pubmed.ncbi.nlm.nih.gov/38369467/",null,null],["4","R0015775","R0015775.pdf","paywalled","nonrandomized_study","Firkins SA","2024","Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-024-07181-w","https://doi.org/10.1007/s11695-024-07181-w","38512645","https://pubmed.ncbi.nlm.nih.gov/38512645/",null,null],["4","R0016291","R0016291.pdf","paywalled","nonrandomized_study","Rozani V","2024","Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.","Parkinsonism & related disorders","Elsevier BV","10.1016/j.parkreldis.2024.107132","https://doi.org/10.1016/j.parkreldis.2024.107132","39260107","https://pubmed.ncbi.nlm.nih.gov/39260107/",null,null],["4","R0016357","R0016357.pdf","paywalled","nonrandomized_study","Hu S","2024","Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15645","https://doi.org/10.1111/dom.15645","38738340","https://pubmed.ncbi.nlm.nih.gov/38738340/",null,null],["4","R0016466","R0016466.pdf","paywalled","nonrandomized_study","Edwards MA","2024","Out-of-Pocket Costs among Commercially Insured Individuals with type 2 Diabetes and Obesity: Comparison between Ozempic and Sleeve Gastrectomy.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000006353","https://doi.org/10.1097/sla.0000000000006353","38775477","https://pubmed.ncbi.nlm.nih.gov/38775477/",null,null],["4","R0016727","R0016727.pdf","paywalled","nonrandomized_study","Wehrman G","2024","Comparison of A1c Reduction, Weight Loss, and Changes in Insulin Requirements With Addition of GLP-1 Agonists vs SGLT-2 Inhibitors in Patients Using Multiple Daily Insulin Injections.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900221134174","https://doi.org/10.1177/08971900221134174","36227709","https://pubmed.ncbi.nlm.nih.gov/36227709/",null,null],["4","R0016890","R0016890.pdf","paywalled","nonrandomized_study","Siafarikas C","2024","Prevalence and Incidence of Medication-Treated Diabetes and Pattern of Glucose-Lowering Treatment During the COVID-19 Pandemic: Real-World Data from the Electronic Greek Prescription Database.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-2307-4631","https://doi.org/10.1055/a-2307-4631","38626912","https://pubmed.ncbi.nlm.nih.gov/38626912/",null,null],["4","R0016913","R0016913.pdf","paywalled","nonrandomized_study","Zhao Y","2024","Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study.","Progress in neuro-psychopharmacology & biological psychiatry","Elsevier BV","10.1016/j.pnpbp.2024.111128","https://doi.org/10.1016/j.pnpbp.2024.111128","39181309","https://pubmed.ncbi.nlm.nih.gov/39181309/",null,null],["4","R0018181","R0018181.pdf","paywalled","nonrandomized_study","Gallwitz B","2024","[Drug therapy of type-2-diabetes-is metformin dispensable now?].","Innere Medizin (Heidelberg, Germany)","Springer Science and Business Media LLC","10.1007/s00108-024-01755-7","https://doi.org/10.1007/s00108-024-01755-7","39167190","https://pubmed.ncbi.nlm.nih.gov/39167190/",null,null],["4","R0018214","R0018214.pdf","paywalled","nonrandomized_study","Corona G","2024","Advances in the treatment of functional male hypogonadism.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2023.2296022","https://doi.org/10.1080/17446651.2023.2296022","38117229","https://pubmed.ncbi.nlm.nih.gov/38117229/",null,null],["4","R0018335","R0018335.pdf","paywalled","nonrandomized_study","Gong J","2024","Pharmacist-initiated interventions using RxChange message communication with prescribers for electronic prescriptions: A retrospective descriptive study.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2024.102188","https://doi.org/10.1016/j.japh.2024.102188","39029625","https://pubmed.ncbi.nlm.nih.gov/39029625/",null,null],["4","R0018920","R0018920.pdf","paywalled","nonrandomized_study","Duong A","2024","Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280231199852","https://doi.org/10.1177/10600280231199852","37743669","https://pubmed.ncbi.nlm.nih.gov/37743669/",null,null],["4","R0019102","R0019102.pdf","paywalled","nonrandomized_study","da Hora Passos R","2024","Semaglutide for Chronic Kidney Disease in Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2410532","https://doi.org/10.1056/nejmc2410532","39504528","https://pubmed.ncbi.nlm.nih.gov/39504528/",null,null],["4","R0019204","R0019204.pdf","paywalled","nonrandomized_study","Lusk JB","2024","Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2024.05.007","https://doi.org/10.1016/j.ahj.2024.05.007","39182939","https://pubmed.ncbi.nlm.nih.gov/39182939/",null,null],["4","R0019387","R0019387.pdf","paywalled","nonrandomized_study","Mentias A","2024","Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity.","Circulation. Heart failure","Ovid Technologies (Wolters Kluwer Health)","10.1161/circheartfailure.122.010453","https://doi.org/10.1161/circheartfailure.122.010453","38275114","https://pubmed.ncbi.nlm.nih.gov/38275114/",null,null],["4","R0019607","R0019607.pdf","paywalled","nonrandomized_study","Crim J","2024","Editorial Comment: Retrospective Opportunistic CT for Assessment of Changes in Body Composition Related to Semaglutide Therapy.","AJR. American journal of roentgenology","American Roentgen Ray Society","10.2214/ajr.24.32063","https://doi.org/10.2214/ajr.24.32063","39320356","https://pubmed.ncbi.nlm.nih.gov/39320356/",null,null],["4","R0019709","R0019709.pdf","paywalled","nonrandomized_study","van Boxel EJ","2024","Semaglutide treatment for children with obesity: an observational study.","Archives of disease in childhood","BMJ","10.1136/archdischild-2023-326687","https://doi.org/10.1136/archdischild-2023-326687","38471743","https://pubmed.ncbi.nlm.nih.gov/38471743/",null,null],["4","R0019751","R0019751.pdf","paywalled","nonrandomized_study","Ghusn W","2024","The association between previous use of anti-obesity medication and semaglutide weight loss outcomes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15523","https://doi.org/10.1111/dom.15523","38469598","https://pubmed.ncbi.nlm.nih.gov/38469598/",null,null],["4","R0019763","R0019763.pdf","paywalled","nonrandomized_study","Ghusn W","2024","Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-023-01456-5","https://doi.org/10.1038/s41366-023-01456-5","38302591","https://pubmed.ncbi.nlm.nih.gov/38302591/",null,null],["4","R0020021","R0020021.pdf","paywalled","nonrandomized_study","Lan NSR","2024","Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2024.02.001","https://doi.org/10.1016/j.orcp.2024.02.001","38331597","https://pubmed.ncbi.nlm.nih.gov/38331597/",null,null],["4","R0020026","R0020026.pdf","paywalled","nonrandomized_study","Grassi BA","2024","Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111593","https://doi.org/10.1016/j.diabres.2024.111593","38403174","https://pubmed.ncbi.nlm.nih.gov/38403174/",null,null],["4","R0020257","R0020257.pdf","paywalled","nonrandomized_study","Magruder ML","2024","Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2023.12.023","https://doi.org/10.1016/j.arth.2023.12.023","38122837","https://pubmed.ncbi.nlm.nih.gov/38122837/",null,null],["4","R0020424","R0020424.pdf","paywalled","nonrandomized_study","Gupta P","2024","Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.","Current drug research reviews","Bentham Science Publishers Ltd.","10.2174/0125899775243787231103075804","https://doi.org/10.2174/0125899775243787231103075804","37966282","https://pubmed.ncbi.nlm.nih.gov/37966282/",null,null],["4","R0020501","R0020501.pdf","paywalled","nonrandomized_study","Bhatt AS","2024","Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2023.09.005","https://doi.org/10.1016/j.cardfail.2023.09.005","37757995","https://pubmed.ncbi.nlm.nih.gov/37757995/",null,null],["4","R0020655","R0020655.pdf","paywalled","nonrandomized_study","Romero-Secin AA","2024","Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients.","Semergen","Elsevier BV","10.1016/j.semerg.2024.102220","https://doi.org/10.1016/j.semerg.2024.102220","38554607","https://pubmed.ncbi.nlm.nih.gov/38554607/",null,null],["4","R0020817","R0020817.pdf","paywalled","nonrandomized_study","Li D","2024","Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.3139","https://doi.org/10.1002/cpt.3139","38069538","https://pubmed.ncbi.nlm.nih.gov/38069538/",null,null],["4","R0021131","R0021131.pdf","paywalled","nonrandomized_study","Wang J","2024","Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.","ACS nano","American Chemical Society (ACS)","10.1021/acsnano.4c11453","https://doi.org/10.1021/acsnano.4c11453","39681528","https://pubmed.ncbi.nlm.nih.gov/39681528/",null,null],["4","R0021789","R0021789.pdf","paywalled","nonrandomized_study","Ippolito B","2024","Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion.","Health affairs (Project Hope)","Health Affairs Publishing, LLC","10.1377/hlthaff.2024.00356","https://doi.org/10.1377/hlthaff.2024.00356","39146500","https://pubmed.ncbi.nlm.nih.gov/39146500/",null,null],["4","R0022899","R0022899.pdf","paywalled","nonrandomized_study",null,"2024","Literature Commentary.","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/wno.0000000000002285","https://doi.org/10.1097/wno.0000000000002285","40418702","https://pubmed.ncbi.nlm.nih.gov/40418702/",null,null],["4","R0024405","R0024405.pdf","paywalled","nonrandomized_study","Shaw L","2024","INTERACTIONS OF METFORMIN AND OTHER MEDICATIONS IN REDUCING THE ODDS OF AGE-RELATED MACULAR DEGENERATION IN A COHORT OF PATIENTS WITH DIABETES.","Retina (Philadelphia, Pa.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/iae.0000000000003949","https://doi.org/10.1097/iae.0000000000003949","37782954","https://pubmed.ncbi.nlm.nih.gov/37782954/",null,null],["4","R0024509","R0024509.pdf","paywalled","nonrandomized_study","Daniali M","2024","Advancements in pharmacotherapy options for treating diabetes ‎in children and adolescents.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2023.2290491","https://doi.org/10.1080/17446651.2023.2290491","38078451","https://pubmed.ncbi.nlm.nih.gov/38078451/",null,null],["4","R0024576","R0024576.pdf","paywalled","nonrandomized_study","Köhne S","2024","Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.","Expert opinion on emerging drugs","Informa UK Limited","10.1080/14728214.2024.2342951","https://doi.org/10.1080/14728214.2024.2342951","38606899","https://pubmed.ncbi.nlm.nih.gov/38606899/",null,null],["4","R0025250","R0025250.pdf","paywalled","nonrandomized_study","Tichy EM","2024","National trends in prescription drug expenditures and projections for 2024.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxae105","https://doi.org/10.1093/ajhp/zxae105","38656319","https://pubmed.ncbi.nlm.nih.gov/38656319/",null,null],["4","R0025884","R0025884.pdf","paywalled","nonrandomized_study","Ballister B","2024","Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900221144399","https://doi.org/10.1177/08971900221144399","36469659","https://pubmed.ncbi.nlm.nih.gov/36469659/",null,null],["4","R0026026","R0026026.pdf","paywalled","nonrandomized_study","Samuels JM","2024","High Prevalence of Positive Genetic Obesity Variants in Postoperative Bariatric Surgery Patients with Weight Regain Presenting for Medical Obesity Intervention.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-023-06952-1","https://doi.org/10.1007/s11695-023-06952-1","37996769","https://pubmed.ncbi.nlm.nih.gov/37996769/",null,null],["4","R0029204","R0029204.pdf","paywalled","nonrandomized_study","Frau T","2024","Emerging drugs for the treatment of short bowel syndrome.","Expert opinion on emerging drugs","Informa UK Limited","10.1080/14728214.2024.2357567","https://doi.org/10.1080/14728214.2024.2357567","38761162","https://pubmed.ncbi.nlm.nih.gov/38761162/",null,null],["4","R0030118","R0030118.pdf","paywalled","nonrandomized_study","Tran D","2024","Impact of glucagon-Like peptide-1 agonists in optimizing abdominal wall Reconstruction patients.","Hernia : the journal of hernias and abdominal wall surgery","Springer Science and Business Media LLC","10.1007/s10029-024-03214-6","https://doi.org/10.1007/s10029-024-03214-6","39549167","https://pubmed.ncbi.nlm.nih.gov/39549167/",null,null],["4","R0030188","R0030188.pdf","paywalled","nonrandomized_study","Villikudathil AT","2024","Computational approaches for clinical, genomic and proteomic markers of response to glucagon-like peptide-1 therapy in type-2 diabetes mellitus: An exploratory analysis with machine learning algorithms.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2024.103086","https://doi.org/10.1016/j.dsx.2024.103086","39067327","https://pubmed.ncbi.nlm.nih.gov/39067327/",null,null],["4","R0032126","R0032126.pdf","paywalled","nonrandomized_study",null,"2024","Suicidal ideation more commonly reported as reaction to semaglutide than for all other drugs, study finds","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2024.1.327710","https://doi.org/10.1211/pj.2024.1.327710",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032127","R0032127.pdf","paywalled","nonrandomized_study",null,"2024","Semaglutide linked to sight-threatening eye condition, study results suggest","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2024.1.322776","https://doi.org/10.1211/pj.2024.1.322776",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032416","R0032416.pdf","paywalled","nonrandomized_study","Armin Farahvash","2024","Pattern of Semaglutide Prescription in a Real-World Patient Cohort","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.102","https://doi.org/10.1016/j.jcjd.2024.09.102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032417","R0032417.pdf","paywalled","nonrandomized_study","Noppachai Siranart","2024","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) AND UPPER ENDOSCOPY: A REAL WORLD EXPERIENCE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2024.04.1219","https://doi.org/10.1016/j.gie.2024.04.1219",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032620","R0032620.pdf","paywalled","nonrandomized_study","Samaneh Dowlatshahi","2024","13-PUB: Safety and Efficacy of Tirzepatide in Patients with Solid-Organ Transplant","Diabetes","American Diabetes Association","10.2337/db24-13-pub","https://doi.org/10.2337/db24-13-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032760","R0032760.pdf","paywalled","nonrandomized_study","K K","2024","Regional Differences in GLP-1 Receptor Agonists Related Biliary Disease: A Pharmacovigilance Study of VigiBase®","Yakhak Hoeji","The Pharmaceutical Society of Korea","10.17480/psk.2024.68.2.112","https://doi.org/10.17480/psk.2024.68.2.112",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032872","R0032872.pdf","paywalled","nonrandomized_study","Michele Traverse","2024","Retrospective Analysis Comparing the Efficacy of GLP-1 Receptor Agonists Dulaglutide and Semaglutide","Guthrie Journal","University of Toronto Press Inc. (UTPress)","10.3138/guthrie-2024-0008","https://doi.org/10.3138/guthrie-2024-0008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032910","R0032910.pdf","paywalled","nonrandomized_study","Faidat Adeola Ishola","2024","746-P: GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-746-p","https://doi.org/10.2337/db24-746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032938","R0032938.pdf","paywalled","nonrandomized_study","QIAOCHU XUE","2024","36-OR: Modulation of Cardiorenal Benefits for GLP-1RAs Treatment by GLP1R Genetic Variants","Diabetes","American Diabetes Association","10.2337/db24-36-or","https://doi.org/10.2337/db24-36-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032958","R0032958.pdf","paywalled","nonrandomized_study","Jothydev Kesavadev","2024","803-P: How Effective Is Weight Loss by Oral Semaglutide on Glycemic Control in a Real-World Setting?","Diabetes","American Diabetes Association","10.2337/db24-803-p","https://doi.org/10.2337/db24-803-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033204","R0033204.pdf","paywalled","nonrandomized_study","Iqra Nawaz","2024","Safety Profile of SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in Patients with CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20244hrvkhs9","https://doi.org/10.1681/asn.20244hrvkhs9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033205","R0033205.pdf","paywalled","nonrandomized_study","Swetha Rani Kanduri","2024","Exposure to Glucagon-Like Peptide 1 Receptor Agonists Does Not Increase the Risk of AKI Associated with Anticancer Therapy","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024x8y8t8d2","https://doi.org/10.1681/asn.2024x8y8t8d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033210","R0033210.pdf","paywalled","nonrandomized_study",null,"2024","Study finds semaglutide not associated with higher risk of suicidality","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31149","https://doi.org/10.1002/pu.31149",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033246","R0033246.pdf","paywalled","nonrandomized_study","Emiko Otsuka","2024","Tirzepatide Improves Glycemic Control Better than Dulagutide in Patients Undergoing Hemodialysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20246zjscmkf","https://doi.org/10.1681/asn.20246zjscmkf",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033251","R0033251.pdf","paywalled","nonrandomized_study","Panupong Hansrivijit","2024","Utilization Trends of Tirzepatide, Glucose-Lowering Medications, and Anti-obesity Medications in Patients with CKD with and without Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024vtsjzr0s","https://doi.org/10.1681/asn.2024vtsjzr0s",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033418","R0033418.pdf","paywalled","nonrandomized_study","Werkman, Nikki C. C.","2024","The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","Figshare",null,"10.6084/m9.figshare.c.6721175","https://doi.org/10.6084/m9.figshare.c.6721175",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033437","R0033437.pdf","paywalled","nonrandomized_study","Chang, Kai-Cheng","2024","Additional file 1 of Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study","Figshare",null,"10.6084/m9.figshare.27253376","https://doi.org/10.6084/m9.figshare.27253376",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033438","R0033438.pdf","paywalled","nonrandomized_study","Oe, Yuki","2024","Additional file 2 of Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)","Figshare",null,"10.6084/m9.figshare.26368536","https://doi.org/10.6084/m9.figshare.26368536",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033462","R0033462.pdf","paywalled","nonrandomized_study","Wang, Wei","2024","Additional file 2 of hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair","Figshare",null,"10.6084/m9.figshare.26553779","https://doi.org/10.6084/m9.figshare.26553779",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033518","R0033518.pdf","paywalled","nonrandomized_study","Foss-Freitas, Maria","2024","The efficacy and safety of glucagon-like-peptide-1 agonists in patients with familial partial lipodystrophy","University of Michigan Library",null,"10.7302/25183","https://doi.org/10.7302/25183",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033524","R0033524.pdf","paywalled","nonrandomized_study","Zhou, Jianxing","2024","Additional file 1 of Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","Figshare",null,"10.6084/m9.figshare.26680684","https://doi.org/10.6084/m9.figshare.26680684",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033558","R0033558.pdf","paywalled","nonrandomized_study","Funck, Kristian Løkke","2024","Additional file 2 of Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","Figshare",null,"10.6084/m9.figshare.26552839","https://doi.org/10.6084/m9.figshare.26552839",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033608","R0033608.pdf","paywalled","nonrandomized_study","djjuwhueiby","2024","diabetes research paper pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.11878163","https://doi.org/10.5281/zenodo.11878163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033615","R0033615.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of","2024","PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide use in Adults with Type 2 Diabetes","Figshare",null,"10.6084/m9.figshare.26583082","https://doi.org/10.6084/m9.figshare.26583082",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033637","R0033637.pdf","paywalled","nonrandomized_study","Funck, Kristian Løkke","2024","Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","Figshare",null,"10.6084/m9.figshare.c.6584788","https://doi.org/10.6084/m9.figshare.c.6584788",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033647","R0033647.pdf","paywalled","nonrandomized_study","Lui, David Tak Wai","2024","Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong","Figshare",null,"10.6084/m9.figshare.c.6588533","https://doi.org/10.6084/m9.figshare.c.6588533",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033677","R0033677.pdf","paywalled","nonrandomized_study","Peng, Zi-Yang","2024","Additional file 1 of Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.26623015","https://doi.org/10.6084/m9.figshare.26623015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033688","R0033688.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of","2024","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study","Figshare",null,"10.6084/m9.figshare.26977636","https://doi.org/10.6084/m9.figshare.26977636",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033845","R0033845.pdf","paywalled","nonrandomized_study","Schechter, Meir","2024","Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence","Figshare",null,"10.6084/m9.figshare.c.6668267","https://doi.org/10.6084/m9.figshare.c.6668267",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033855","R0033855.pdf","paywalled","nonrandomized_study","Manobalan M, Selvabalaji S, Rashvin CV, Haribaskar R, NaveenKumar Mannar","2024","Role of Lifestyle Interventions in Diabetes Prevention and Management","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.11354003","https://doi.org/10.5281/zenodo.11354003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033954","R0033954.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2024","Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with T2D Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis","Figshare",null,"10.6084/m9.figshare.26977447","https://doi.org/10.6084/m9.figshare.26977447",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034026","R0034026.pdf","paywalled","nonrandomized_study","American Medical Association 2024","2024","Investigating the Association Between Ozempic Use and Psoriasis: An Analysis of FDA Adverse Event Reporting System Data from 2019-2024.","Underline Science Inc.",null,"10.48448/wezz-pk26","https://doi.org/10.48448/wezz-pk26",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034066","R0034066.pdf","paywalled","nonrandomized_study","Grauslund, Jakob","2024","Additional file 1 of Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","Figshare",null,"10.6084/m9.figshare.28058503","https://doi.org/10.6084/m9.figshare.28058503",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034246","R0034246.pdf","paywalled","nonrandomized_study","Giuseppe Lisco","2024","GLP-1RAs boost erectile function in men with type 2 diabetes and erectile dysfunction: results from a 1-year retrospective cohort study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.99.p268","https://doi.org/10.1530/endoabs.99.p268",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034500","R0034500.pdf","paywalled","nonrandomized_study","Yu‐Cheng Chang","2024","The impact of glucagon-like peptide-1 receptor agonists on proteasome inhibitor-associated cardiotoxicity in patients with multiple myeloma.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2024.42.16_suppl.e24008","https://doi.org/10.1200/jco.2024.42.16_suppl.e24008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034594","R0034594.pdf","paywalled","nonrandomized_study","Jill Libby","2024","Abstract TP51: Improving Prescriptions of Cardiovascular-Effective Anti-Diabetic Medications in Patients With Stroke and Type 2 Diabetes","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.55.suppl_1.tp51","https://doi.org/10.1161/str.55.suppl_1.tp51",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034897","R0034897.pdf","paywalled","nonrandomized_study",null,"2024","Semaglutide-related ADEs identified in FAERS","Reactions Weekly","Springer Science and Business Media LLC","10.1007/s40278-024-60246-1","https://doi.org/10.1007/s40278-024-60246-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035769","R0035769.pdf","paywalled","nonrandomized_study",null,"2024","Editors' Selections from Relevant Scientific Publications","Cancer Prevention Research","American Association for Cancer Research (AACR)","10.1158/1940-6207.capr-17-3-hfl","https://doi.org/10.1158/1940-6207.capr-17-3-hfl",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035914","R0035914.pdf","paywalled","nonrandomized_study","Monalisa Rout","2024","Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease","Current Drug Therapy","Bentham Science Publishers Ltd.","10.2174/0115748855332557240820054810","https://doi.org/10.2174/0115748855332557240820054810",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036338","R0036338.pdf","paywalled","nonrandomized_study","Cho‐Han Chiang","2024","The impact of glucagon-like peptide 1 agonists on anthracycline or human epidermal growth factor receptor 2 inhibitor-associated cardiotoxicity in patients with breast cancer and diabetes mellitus.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2024.42.16_suppl.12026","https://doi.org/10.1200/jco.2024.42.16_suppl.12026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036555","R0036555.pdf","paywalled","nonrandomized_study","Gudbergsen, Henrik","2024","TRIM","Open Science Framework",null,"10.17605/osf.io/65pxj","https://doi.org/10.17605/osf.io/65pxj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036635","R0036635.pdf","paywalled","nonrandomized_study","Pottegård, Anton","2024","Use of semaglutide and risk of anterior ischemic optic neuropathy: Danish nationwide observational studies","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/h3uv4","https://doi.org/10.17605/osf.io/h3uv4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036693","R0036693.pdf","paywalled","nonrandomized_study","Hoffman, Sarah Ruth","2024","Comparative safety and cardiovascular outcomes of glucagon-like peptide 1 receptor agonists (GLP-1-RAs) versus sodium glucose co-transporter 2 inhibitors (SGLT2-Is), naltrexone/bupropion, or phentermine/topiramate: a real-world data study.","Open Science Framework",null,"10.17605/osf.io/psy74","https://doi.org/10.17605/osf.io/psy74",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036754","R0036754.pdf","paywalled","nonrandomized_study","Balata, Mahmoud","2024","Additional file 1 of Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis","Figshare",null,"10.6084/m9.figshare.27312312","https://doi.org/10.6084/m9.figshare.27312312",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036756","R0036756.pdf","paywalled","nonrandomized_study","Li, Yukun","2024","Additional file 1 of Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study","Figshare",null,"10.6084/m9.figshare.26112931","https://doi.org/10.6084/m9.figshare.26112931",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036769","R0036769.pdf","paywalled","nonrandomized_study","Werkman, Nikki C. C.","2024","Additional file 1 of The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","Figshare",null,"10.6084/m9.figshare.26600980","https://doi.org/10.6084/m9.figshare.26600980",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036794","R0036794.pdf","paywalled","nonrandomized_study","Lui, David Tak Wai","2024","Additional file 1 of Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong","Figshare",null,"10.6084/m9.figshare.26571379","https://doi.org/10.6084/m9.figshare.26571379",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036894","R0036894.pdf","paywalled","nonrandomized_study","Yildirim, Duygu İlke","2024","Evaluation of the Effect of Liraglutide Used in Obesity Treatment on Quality of Life","Annals of Medical and Health Sciences Research",null,"10.5281/zenodo.14505266","https://doi.org/10.5281/zenodo.14505266",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037022","R0037022.pdf","paywalled","nonrandomized_study","Daniela Urueta Portillo","2024","Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: A comparative analysis.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2024.42.16_suppl.e13063","https://doi.org/10.1200/jco.2024.42.16_suppl.e13063",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037177","R0037177.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2024","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor","Figshare",null,"10.6084/m9.figshare.24610002","https://doi.org/10.6084/m9.figshare.24610002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037323","R0037323.pdf","paywalled","nonrandomized_study","of, Adis journals on behalf","2024","PIONEER REAL Sweden: a multicentre, prospective, real-world observational study of oral semaglutide use in adults with type 2 diabetes in Swedish clinical practice","Figshare",null,"10.6084/m9.figshare.26064211.v1","https://doi.org/10.6084/m9.figshare.26064211.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037339","R0037339.pdf","paywalled","nonrandomized_study","Charles G. Rickert","2024","Another Detrimental Effect of Immunosuppression: Metabolic Syndrome","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000005253","https://doi.org/10.1097/tp.0000000000005253","39466196","https://pubmed.ncbi.nlm.nih.gov/39466196/",null,null],["4","R0037343","R0037343.pdf","paywalled","nonrandomized_study","Madalyn Elliott","2024","S896 GLP-1 Receptor Agonists and Retained Gastric Content in Type 2 Diabetics: Insights From a Retrospective Endoscopic Analysis, A Preliminary Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032952.21205.89","https://doi.org/10.14309/01.ajg.0001032952.21205.89",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037481","R0037481.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2024","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","Figshare",null,"10.6084/m9.figshare.24807525","https://doi.org/10.6084/m9.figshare.24807525",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037492","R0037492.pdf","paywalled","nonrandomized_study","Lena R Kaisinger","2024","Abstract 4142589: GLP-1 receptor agonists slow the progression of subclinical cardiovascular risk as detected from 12-lead electrocardiograms","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4142589","https://doi.org/10.1161/circ.150.suppl_1.4142589",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037547","R0037547.pdf","paywalled","nonrandomized_study","SherylDF, rederick","2024","Rybelsus Weight Loss Weight Loss Options: Ozempic Alternatives for Australians Seek","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12780059","https://doi.org/10.5281/zenodo.12780059",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037583","R0037583.pdf","paywalled","nonrandomized_study","Jeremy A. Klein","2024","S1494 Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-Diabetic Patients With Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035344.73427.3c","https://doi.org/10.14309/01.ajg.0001035344.73427.3c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037627","R0037627.pdf","paywalled","nonrandomized_study","THOMAS S.J. CRABTREE","2024","791-P: The Impact of Age on Response to Injectable Semaglutide—Insights from the Association of British Clinical Diabetologists’ Audit Programme","Diabetes","American Diabetes Association","10.2337/db24-791-p","https://doi.org/10.2337/db24-791-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037710","R0037710.pdf","paywalled","nonrandomized_study","HENON GEBRE","2024","736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)","Diabetes","American Diabetes Association","10.2337/db24-736-p","https://doi.org/10.2337/db24-736-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037811","R0037811.pdf","paywalled","nonrandomized_study","Peng, Zi-Yang","2024","Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.c.6866379","https://doi.org/10.6084/m9.figshare.c.6866379",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037853","R0037853.pdf","paywalled","nonrandomized_study","Alan Abboud","2024","S1261 Benefits of Glucagon-Like Peptide-1 Agonists Use in Patients With Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001034412.42810.c5","https://doi.org/10.14309/01.ajg.0001034412.42810.c5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037867","R0037867.pdf","paywalled","nonrandomized_study","Noppachai Siranart","2024","S931 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Upper Endoscopy: A Real World Experience","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033092.86725.ca","https://doi.org/10.14309/01.ajg.0001033092.86725.ca",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037870","R0037870.pdf","paywalled","nonrandomized_study","Rohini Ghosh","2024","S2076 Trends in the Prescription of Weight Loss Medications in Patients With Obesity: A Nationwide Cross-Sectional Analysis, 1999-2018","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037672.94077.d8","https://doi.org/10.14309/01.ajg.0001037672.94077.d8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037904","R0037904.pdf","paywalled","nonrandomized_study","Daniel Rosa da Silva","2024","ORIENTAÇÃO FARMACÊUTICA E OS RISCOS DA SEMAGLUTIDA: NAVEGANDO COM SEGURANÇA NA PERDA DE PESO","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/ch102024111531","https://doi.org/10.69849/revistaft/ch102024111531",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037945","R0037945.pdf","paywalled","nonrandomized_study","ALAN BELTRAN","2024","1423-P: A Longitudinal Analysis of Changes in Therapies and Outcomes among People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1423-p","https://doi.org/10.2337/db24-1423-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038088","R0038088.pdf","paywalled","nonrandomized_study","Schechter, Meir","2024","Additional file 1 of Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence","Figshare",null,"10.6084/m9.figshare.26592413","https://doi.org/10.6084/m9.figshare.26592413",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038171","R0038171.pdf","paywalled","nonrandomized_study","Hor, Hui Min","2024","Are GLP-1 Receptor Agonists safe in Prader-Willi Syndrome? A detailed investigation on safety and efficacy with a focus on gastric emptying.","UNSWorks (University of New South Wales, Sydney, Australia)",null,"10.26190/unsworks/30386","https://doi.org/10.26190/unsworks/30386",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038195","R0038195.pdf","paywalled","nonrandomized_study","Kazuo Kobayashi","2024","427-P: Influence of Blood Pressure Management on the Renal Outcome in Patients Treated with SGLT2 Inhibitors and GLP1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db24-427-p","https://doi.org/10.2337/db24-427-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038332","R0038332.pdf","paywalled","nonrandomized_study","Daniel Staursky","2024","S809 Gastric Emptying Scintigraphy: Understanding Nuclear Medicine’s Real World Clinical Practice","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032604.58940.5f","https://doi.org/10.14309/01.ajg.0001032604.58940.5f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038340","R0038340.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2024","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study","Figshare",null,"10.6084/m9.figshare.25574685","https://doi.org/10.6084/m9.figshare.25574685",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038343","R0038343.pdf","paywalled","nonrandomized_study","Takeshi Horii","2024","1873-LB: Comparison of Adherence and Persistence between Oral Semaglutide and Once-Weekly Semaglutide Injection at 12-Month Follow-up in Japanese Real-World Data","Diabetes","American Diabetes Association","10.2337/db24-1873-lb","https://doi.org/10.2337/db24-1873-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038417","R0038417.pdf","paywalled","nonrandomized_study","RODOLFO J. GALINDO","2024","1926-LB: Use of Continuous Glucose Monitoring and Health Care Resource Utilization in Patients with Diabetes Treated with Sulfonylureas/Meglitinides","Diabetes","American Diabetes Association","10.2337/db24-1926-lb","https://doi.org/10.2337/db24-1926-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038506","R0038506.pdf","paywalled","nonrandomized_study","Tan, Xi","2024","Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Figshare",null,"10.6084/m9.figshare.c.6940274","https://doi.org/10.6084/m9.figshare.c.6940274",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038526","R0038526.pdf","paywalled","nonrandomized_study","Michael Nakhla","2024","Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4142154","https://doi.org/10.1161/circ.150.suppl_1.4142154",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038625","R0038625.pdf","paywalled","nonrandomized_study","Trombara, Filippo","2024","Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction","Figshare",null,"10.6084/m9.figshare.c.6580579","https://doi.org/10.6084/m9.figshare.c.6580579",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038640","R0038640.pdf","paywalled","nonrandomized_study","JAEWON CHOI","2024","863-P: Genetically Proxied GLP-1 Receptor Agonism Improves Kidney Function—A Mendelian Randomization Study","Diabetes","American Diabetes Association","10.2337/db24-863-p","https://doi.org/10.2337/db24-863-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038676","R0038676.pdf","paywalled","nonrandomized_study","Kim Boyd","2024","Abstract 4141434: Real-World Improvement of Cardiometabolic Risk Factors by Treating Obesity at Scale","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4141434","https://doi.org/10.1161/circ.150.suppl_1.4141434",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038685","R0038685.pdf","paywalled","nonrandomized_study","Sungho Bea","2024","1400-P: Hepatic Effectiveness of SGLT2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1400-p","https://doi.org/10.2337/db24-1400-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038727","R0038727.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","S1624 Glucagon-Like Peptide-1 Receptor Agonists Are Not Associated With Higher Risk of Intubation or Aspiration Pneumonia in Patients Who Underwent ERCP: A National Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035864.69509.0f","https://doi.org/10.14309/01.ajg.0001035864.69509.0f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038749","R0038749.pdf","paywalled","nonrandomized_study","Emiko Otsuka","2024","11-PUB: Transitioning from Dulaglutide to Tirzepatide Improves Glycemic Control in Patients Undergoing Hemodialysis with Type 2 Diabetes—An Assessment by Continuous Glucose Monitoring","Diabetes","American Diabetes Association","10.2337/db24-11-pub","https://doi.org/10.2337/db24-11-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038794","R0038794.pdf","paywalled","nonrandomized_study","YIFAT HERSHCOVITZ","2024","685-P: Digital Platform Users Taking GLP-1 and Managing Diabetes Adapt Lifestyle Behavior Change over Twelve Months","Diabetes","American Diabetes Association","10.2337/db24-685-p","https://doi.org/10.2337/db24-685-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038823","R0038823.pdf","paywalled","nonrandomized_study",null,"2024","Analysis suggests risk of suicidal ideation associated with semaglutide","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31236","https://doi.org/10.1002/pu.31236",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038892","R0038892.pdf","paywalled","nonrandomized_study","Annie L. Wang","2024","S645 Esophageal Motility Patterns in Patients Receiving GLP-1RA Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031948.81401.61","https://doi.org/10.14309/01.ajg.0001031948.81401.61",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039198","R0039198.pdf","paywalled","nonrandomized_study","Kate Hawke","2024","980-P: Automated Insulin Delivery Clamp Technology—Proof of Concept Study","Diabetes","American Diabetes Association","10.2337/db24-980-p","https://doi.org/10.2337/db24-980-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039238","R0039238.pdf","paywalled","nonrandomized_study","JOTHYDEV KESAVADEV","2024","1708-P: Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ≥25 kg/m2—A Six-Month Real-World Study","Diabetes","American Diabetes Association","10.2337/db24-1708-p","https://doi.org/10.2337/db24-1708-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039299","R0039299.pdf","paywalled","nonrandomized_study","Nicole Felix","2024","Abstract 4145444: GLP-1 Receptor Agonists And Clinical Events After Anthracycline-Based Chemotherapy: A Propensity Score-Matched Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145444","https://doi.org/10.1161/circ.150.suppl_1.4145444",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039408","R0039408.pdf","paywalled","nonrandomized_study","Samantha B. Shapiro","2024","1862-LB: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Suicide and Self-Harm among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1862-lb","https://doi.org/10.2337/db24-1862-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039509","R0039509.pdf","paywalled","nonrandomized_study","Jes Sebastian Denis Völker","2024","Semaglutide’s Neuropharmacological Effects: From Glycemic Regulation and Weight Loss to Potential Implications in Substance Use Disorders – A Narrative Review","Current Psychopharmacologye","Bentham Science Publishers Ltd.","10.2174/0122115560282952231218061257","https://doi.org/10.2174/0122115560282952231218061257",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039605","R0039605.pdf","paywalled","nonrandomized_study","Yuka Suganuma","2024","814-P: What Are the Early Selection Predictors of GLP-1 Receptor Agonists in Real-World Data for Japanese Individuals with Type 2 Diabetes?","Diabetes","American Diabetes Association","10.2337/db24-814-p","https://doi.org/10.2337/db24-814-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039623","R0039623.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2024","PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice","Figshare",null,"10.6084/m9.figshare.26064211","https://doi.org/10.6084/m9.figshare.26064211",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039661","R0039661.pdf","paywalled","nonrandomized_study","Lin, Yuan","2024","The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","Figshare",null,"10.6084/m9.figshare.c.6590636.v1","https://doi.org/10.6084/m9.figshare.c.6590636.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039722","R0039722.pdf","paywalled","nonrandomized_study","Aishwarya Krishnaraj","2024","755-P: GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular–Risk Individuals with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-755-p","https://doi.org/10.2337/db24-755-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039738","R0039738.pdf","paywalled","nonrandomized_study","Yousef Hreish","2024","S2482 Prescriber Beware: Rethinking the Routine Glucagon-Like Peptide-1 Receptor Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001039296.29354.19","https://doi.org/10.14309/01.ajg.0001039296.29354.19",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039766","R0039766.pdf","paywalled","nonrandomized_study","QIAOCHU XUE","2024","174-OR: Genetic Variation in GLP-1R Modify the Risk of Hypoglycemia in Response to Intensive Glycemic Control in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-174-or","https://doi.org/10.2337/db24-174-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039841","R0039841.pdf","paywalled","nonrandomized_study","Michael Cymbal","2024","S755 The Effect of GLP-1 Receptor Agonists on Whole Gut Gastrointestinal Motility Using Wireless Motility Capsule","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032388.64356.b1","https://doi.org/10.14309/01.ajg.0001032388.64356.b1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039863","R0039863.pdf","paywalled","nonrandomized_study","Takaya Matsushita","2024","860-P: Effects of the Combination Treatment with SGLT2 Inhibitors and GLP1 Receptor Agonists among Japanese Patients with Type 2 Diabetes Mellitus and Obesity","Diabetes","American Diabetes Association","10.2337/db24-860-p","https://doi.org/10.2337/db24-860-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040275","R0040275.pdf","paywalled","nonrandomized_study","Schmidt, Thomas Robert","2024","Cardiac magnetic resonance-based prediction of left atrial fibrosis as a feature of left atrial myopathy using left atrial epicardial adipose tissue volume quantification","Qucosa (Saxon State and University Library Dresden)",null,"10.13140/rg.2.2.20951.28324","https://doi.org/10.13140/rg.2.2.20951.28324",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041409","R0041409.pdf","paywalled","nonrandomized_study","Demetria M Bolden","2024","Abstract 4143220: Racial Differences in Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among US Veterans with Type 2 Diabetes and Coronary Artery Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4143220","https://doi.org/10.1161/circ.150.suppl_1.4143220",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041505","R0041505.pdf","paywalled","nonrandomized_study","Stephen V. McBrien","2024","Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3304","https://doi.org/10.1093/eurheartj/ehae666.3304",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041522","R0041522.pdf","paywalled","nonrandomized_study","Kathrine Vauvert Römmelmayer Hviid","2024","P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - A nationwide cohort study","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deae108.041","https://doi.org/10.1093/humrep/deae108.041",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041523","R0041523.pdf","paywalled","nonrandomized_study","Rajeev Chawla","2024","#1706873 Paradox in T2DM Management: Relative ineffectiveness of Oral Semaglutide in Overweight Patients - A Real-World Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.220","https://doi.org/10.1016/j.eprac.2024.03.220",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041573","R0041573.pdf","paywalled","nonrandomized_study","Alessandro Villaschi","2024","Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.1096","https://doi.org/10.1093/eurheartj/ehae666.1096",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041691","R0041691.pdf","paywalled","nonrandomized_study","Leeanne Macklin","2024","Optimizing heart failure services: a focus on patients with heart failure with preserved ejection fraction","European Journal of Cardiovascular Nursing","Oxford University Press (OUP)","10.1093/eurjcn/zvae140","https://doi.org/10.1093/eurjcn/zvae140","39446566","https://pubmed.ncbi.nlm.nih.gov/39446566/",null,null],["4","R0041692","R0041692.pdf","paywalled","nonrandomized_study","Mohammed Suki","2024","THU-194 Semaglutide links with improved survival and liver outcomes in MASLD patients, a large multicenter retrospective real-world cohort study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01667-2","https://doi.org/10.1016/s0168-8278(24)01667-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041696","R0041696.pdf","paywalled","nonrandomized_study","Novera Shahid","2024","#1783600 The Efficacy of GLP-1 RA Therapy in Patients with Type 1 Diabetes: A Real-world Observational Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.164","https://doi.org/10.1016/j.eprac.2024.03.164",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041770","R0041770.pdf","paywalled","nonrandomized_study","Akshaya Srikanth Bhagavathula","2024","Leveraging AI and NLP to Uncover real-world experiences with semaglutide for weight loss","Annals of Epidemiology","Elsevier BV","10.1016/j.annepidem.2024.07.054","https://doi.org/10.1016/j.annepidem.2024.07.054",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041785","R0041785.pdf","paywalled","nonrandomized_study","Hussein Al‐Sudani","2024","#1698349 Comparative Effectiveness of GLP-1 Analogues on BMI Reduction in Obese and Morbidly Obese Populations: A TriNetX Database Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.256","https://doi.org/10.1016/j.eprac.2024.03.256",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041801","R0041801.pdf","paywalled","nonrandomized_study","Yousif Arif","2024","S2087 Efficacy and Safety of Subcutaneous Semaglutide and Tirzepatide Injections in Elderly vs Younger Obese: A Case-Control Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037716.85106.62","https://doi.org/10.14309/01.ajg.0001037716.85106.62",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042029","R0042029.pdf","paywalled","nonrandomized_study","Gudbergsen, Henrik","2024","TRIM","Open Science Framework",null,"10.17605/osf.io/86kmc","https://doi.org/10.17605/osf.io/86kmc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042074","R0042074.pdf","paywalled","nonrandomized_study","Tina Yi Jin Hsieh","2024","Comparative analysis of GLP-1 receptor agonists versus metformin on cancer outcomes in patients with polycystic ovarian syndrome: A real-world multi-center cohort study in the United States.","JCO Oncology Practice","American Society of Clinical Oncology (ASCO)","10.1200/op.2024.20.10_suppl.402","https://doi.org/10.1200/op.2024.20.10_suppl.402",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042230","R0042230.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","S699 GLP-1 Receptor Agonists Are Associated With Decreased Esophageal Cancer Risk in Type 2 Diabetes Patients Compared to Other Anti-Diabetic Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032164.05931.aa","https://doi.org/10.14309/01.ajg.0001032164.05931.aa",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043200","R0043200.pdf","paywalled","nonrandomized_study","Wang, Tiansheng","2024","USING MACHINE LEARNING TECHNIQUES TO IDENTIFY AND ASSESS HETEROGENEOUS TREATMENT EFFECTS IN ADULTS WITH TYPE 2 DIABETES","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/0hkx-9a76","https://doi.org/10.17615/0hkx-9a76",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043562","R0043562.pdf","paywalled","nonrandomized_study",null,"2024","A500 The risk of progression of steatotic liver disease to hepatocellular carcinoma and cirrhosis with use of vitamin E, pioglitazone, and glucagon-like peptide 1 analogs: a large, multi-center cohort study","Surgery for Obesity and Related Diseases","Elsevier BV","10.1016/j.soard.2024.04.433","https://doi.org/10.1016/j.soard.2024.04.433",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043633","R0043633.pdf","paywalled","nonrandomized_study","Belinda P. Childs","2024","761-P: Use of Tirzepatide in Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-761-p","https://doi.org/10.2337/db24-761-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043975","R0043975.pdf","paywalled","nonrandomized_study","Hussein Al‐Sudani","2024","#1698348 Gender and Racial Disparities in the Utilization of GLP-1 Analogues in Obese Patients: A TriNetX Database Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.255","https://doi.org/10.1016/j.eprac.2024.03.255",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044051","R0044051.pdf","paywalled","nonrandomized_study","Pourya Medhati","2024","149 REAL-WORLD WEIGHT LOSS OUTCOMES OF SEMAGLUTIDE: COMPARATIVE ANALYSIS AMONG PATIENTS WITH AND WITHOUT METABOLIC/BARIATRIC SURGERY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)04574-8","https://doi.org/10.1016/s0016-5085(24)04574-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044084","R0044084.pdf","paywalled","nonrandomized_study","Kedson Melo","2024","FATORES RELACIONADOS AO USO DO MEDICAMENTO MOUNJARO (TIZERPATIDA) PARA O MANEJO DE COMORBIDADES, EXPONDO AS PERSPECTIVAS DE SUA UTILIZAÇÃO","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/ni10202408142114","https://doi.org/10.69849/revistaft/ni10202408142114",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044178","R0044178.pdf","paywalled","nonrandomized_study","Nguyen, Khang","2024","Factors Associated with the Serious Adverse Effects and Misuse of GLP-1 Receptor Agonists","Digital Archive @ GSU",null,"10.57709/37401983","https://doi.org/10.57709/37401983",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044202","R0044202.pdf","paywalled","nonrandomized_study","Gisele Marlene Maciag","2024","SEMAGLUTIDE : A THERAPEUTIC REVOLUTION IN THE MANAGEMENT OF OBESITY AND OVERWEIGHT IN TYPE 2 DIABETICS","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/ra10202411061804","https://doi.org/10.69849/revistaft/ra10202411061804",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044266","R0044266.pdf","paywalled","nonrandomized_study","Hadi, Karam","2024","A retrospective single-center study, evaluating the long-term effects of the roux-en-y gastric bypass on weight, metabolic health, and comorbidities","ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway)",null,"10.13025/29200","https://doi.org/10.13025/29200",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044328","R0044328.pdf","paywalled","nonrandomized_study","Wanderluci Rocha Ribeiro","2024","OS RISCOS E BENEFÍCIOS DO USO OFF-LABEL DA SEMAGLUTIDA (OZEMPIC) PARA EMAGRECIMENTO: UMA REVISÃO INTEGRATIVA","Revista fisio&terapia.","Revista ft Ltda","10.69849/revistaft/ar10202411151900","https://doi.org/10.69849/revistaft/ar10202411151900",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044575","R0044575.pdf","paywalled","nonrandomized_study","Linda M. Richmond","2024","Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show","Psychiatric News","American Psychiatric Association Publishing","10.1176/appi.pn.2024.06.6.38","https://doi.org/10.1176/appi.pn.2024.06.6.38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044994","R0044994.pdf","paywalled","nonrandomized_study","EILEEN HUANG","2024","1917-LB: Association of FreeStyle Libre Utilization and Glycemic Outcomes among People with Type 2 Diabetes Treated with Basal Insulin and GLP-1RAs","Diabetes","American Diabetes Association","10.2337/db24-1917-lb","https://doi.org/10.2337/db24-1917-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045026","R0045026.pdf","paywalled","nonrandomized_study","Vismaya S. Bachu","2024","S850 Bowel Preparation Quality and Colonoscopy Safety With Glucagon-Like Peptide 1 Receptor Agonists vs Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032768.58705.8c","https://doi.org/10.14309/01.ajg.0001032768.58705.8c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045028","R0045028.pdf","paywalled","nonrandomized_study","Omar Almetwali","2024","S1768 The Efficacy of GLP-1 Agonists in the Management of MASH in an Appalachian Cohort","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036440.35710.e8","https://doi.org/10.14309/01.ajg.0001036440.35710.e8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045079","R0045079.pdf","paywalled","nonrandomized_study","Blai Coll","2024","767-P: A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM)","Diabetes","American Diabetes Association","10.2337/db24-767-p","https://doi.org/10.2337/db24-767-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045130","R0045130.pdf","paywalled","nonrandomized_study","Victoria de Braal","2024","227 Improving the assessment of cardiovascular risk factors in patients with non-ST elevation acute coronary syndrome: a quality improvement project",null,"BMJ Publishing Group Ltd and British Cardiovascular Society","10.1136/heartjnl-2024-bcs.219","https://doi.org/10.1136/heartjnl-2024-bcs.219",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045148","R0045148.pdf","paywalled","nonrandomized_study","SUPRATIK BHATTACHARYYA","2024","809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up","Diabetes","American Diabetes Association","10.2337/db24-809-p","https://doi.org/10.2337/db24-809-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045193","R0045193.pdf","paywalled","nonrandomized_study","Irene Caruso","2024","783-P: Efficacy of GLP-1RA according to Type 2 Diabetes Phenotypes—A Monocentric Retrospective Study","Diabetes","American Diabetes Association","10.2337/db24-783-p","https://doi.org/10.2337/db24-783-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045194","R0045194.pdf","paywalled","nonrandomized_study","Tyler J. Dunn","2024","740-P: Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting","Diabetes","American Diabetes Association","10.2337/db24-740-p","https://doi.org/10.2337/db24-740-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045209","R0045209.pdf","paywalled","nonrandomized_study","AVIK RAY","2024","796-P: Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-796-p","https://doi.org/10.2337/db24-796-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045469","R0045469.pdf","paywalled","nonrandomized_study","XI TAN","2024","766-P: Long-Term Effectiveness Associated with Maintenance Doses of Once-Weekly Semaglutide in U.S. Adults with Poorly Controlled Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-766-p","https://doi.org/10.2337/db24-766-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045495","R0045495.pdf","paywalled","nonrandomized_study","D Garcia Vega","2024","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2932","https://doi.org/10.1093/eurheartj/ehae666.2932",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045576","R0045576.pdf","paywalled","nonrandomized_study","SARAH R. HOFFMAN","2024","1864-LB: Comparative Safety and Effectiveness of GLP-1RA and SGLT2i Use in Adults with Type 2 Diabetes in U.S. Clinical Practice","Diabetes","American Diabetes Association","10.2337/db24-1864-lb","https://doi.org/10.2337/db24-1864-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045752","R0045752.pdf","paywalled","nonrandomized_study","Kevin Pak","2024","“Winning the peace” against obesity in recipients of liver transplant","Liver Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/lvt.0000000000000430","https://doi.org/10.1097/lvt.0000000000000430","38963348","https://pubmed.ncbi.nlm.nih.gov/38963348/",null,null],["4","R0045793","R0045793.pdf","paywalled","nonrandomized_study","LIXIN GUO","2024","19-PUB: Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) in a Real-World Setting in China","Diabetes","American Diabetes Association","10.2337/db24-19-pub","https://doi.org/10.2337/db24-19-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05221580"],["4","R0045912","R0045912.pdf","paywalled","nonrandomized_study","Zheng Li","2024","Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000803","https://doi.org/10.1097/hep.0000000000000803","38373119","https://pubmed.ncbi.nlm.nih.gov/38373119/",null,null],["4","R0045944","R0045944.pdf","paywalled","nonrandomized_study","Ahmed Eltelbany","2024","S541 Glucagon-Like Peptide-1 Receptor Agonist Use and its Potential Impact in Colonoscopy Among Patients Undergoing Colorectal Cancer Screening: A Multicenter Propensity Score Matching Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031532.99210.78","https://doi.org/10.14309/01.ajg.0001031532.99210.78",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045989","R0045989.pdf","paywalled","nonrandomized_study","Camille Lupianez‐Merly","2024","Mo1637 EFFECTS OF GLP-1 RECEPTOR OR A DUAL GLP-1/GIP RECEPTOR AGONISTS ON GASTROINTESTINAL SYMPTOMS AND GASTRIC EMPTYING: RESULTS FROM A LARGE CLINICAL PRACTICE DATABASE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)02923-8","https://doi.org/10.1016/s0016-5085(24)02923-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046035","R0046035.pdf","paywalled","nonrandomized_study","Mengdan Xie","2024","S827 Global Insights: Glucagon-Like Peptide-1 Receptor Agonists are Linked to Gastrointestinal Functional Disorders ACG Outstanding Research Award in the Functional Bowel Disease Category (Trainee)","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032676.04728.09","https://doi.org/10.14309/01.ajg.0001032676.04728.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046091","R0046091.pdf","paywalled","nonrandomized_study","PHYO T. HTOO","2024","1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1271-p","https://doi.org/10.2337/db24-1271-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046197","R0046197.pdf","paywalled","nonrandomized_study","Panupong Hansrivijit","2024","1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study","Diabetes","American Diabetes Association","10.2337/db24-1403-p","https://doi.org/10.2337/db24-1403-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046202","R0046202.pdf","paywalled","nonrandomized_study","Arunkumar Krishnan","2024","Sa1558 EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01561-0","https://doi.org/10.1016/s0016-5085(24)01561-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046287","R0046287.pdf","paywalled","nonrandomized_study","Revati Varma","2024","Abstract 4143390: HEMODYNAMIC AND CLINICAL IMPACT OF OBESITY IN GROUP 1 PULMONARY HYPERTENSION","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4143390","https://doi.org/10.1161/circ.150.suppl_1.4143390",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046297","R0046297.pdf","paywalled","nonrandomized_study","MOHAMMED AL-SOFIANI","2024","1058-P: The Relationship between Health Insurance Coverage and Clinical Outcomes among People with Diabetes in Saudi Arabia","Diabetes","American Diabetes Association","10.2337/db24-1058-p","https://doi.org/10.2337/db24-1058-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046329","R0046329.pdf","paywalled","nonrandomized_study","K Soerensen","2024","GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3309","https://doi.org/10.1093/eurheartj/ehae666.3309",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046375","R0046375.pdf","paywalled","nonrandomized_study","János Tibor Kis","2024","786-P: Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Baseline BMI","Diabetes","American Diabetes Association","10.2337/db24-786-p","https://doi.org/10.2337/db24-786-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046449","R0046449.pdf","paywalled","nonrandomized_study","Ho‐Jin Shin","2024","1152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval","Diabetes","American Diabetes Association","10.2337/db24-1152-p","https://doi.org/10.2337/db24-1152-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046480","R0046480.pdf","paywalled","nonrandomized_study","PIAOPIAO LI","2024","850-P: Trends in GLP-1RA Use among Individuals with Type 2 Diabetes (T2D) and/or Obesity—Insights from a Nationwide Electronic Health Record System, 2010–2023","Diabetes","American Diabetes Association","10.2337/db24-850-p","https://doi.org/10.2337/db24-850-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046487","R0046487.pdf","paywalled","nonrandomized_study","Wajd Alkabbani","2024","999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study","Diabetes","American Diabetes Association","10.2337/db24-999-p","https://doi.org/10.2337/db24-999-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046571","R0046571.pdf","paywalled","nonrandomized_study","Wojciech Michalak","2024","1691-P: Clinical Outcomes in Patients with Obesity or Overweight Treated with Semaglutide 2.4 mg—A Real-World Retrospective Cohort Study in the United States (SCOPE 2)","Diabetes","American Diabetes Association","10.2337/db24-1691-p","https://doi.org/10.2337/db24-1691-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046591","R0046591.pdf","paywalled","nonrandomized_study","Gea Ciccarelli","2024","1068-P: Reassessing Insulin Therapy In Diabetes of the Exocrine Pancreas—A Pilot Study","Diabetes","American Diabetes Association","10.2337/db24-1068-p","https://doi.org/10.2337/db24-1068-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046604","R0046604.pdf","paywalled","nonrandomized_study","Firas Bahdi","2024","S927 Risk of Gastric Food Retention With Glucagon-like Peptide 1 Receptor Agonists versus Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033076.54920.7a","https://doi.org/10.14309/01.ajg.0001033076.54920.7a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046633","R0046633.pdf","paywalled","nonrandomized_study","Morgan Keane","2024","6724 Children and young people presenting in diabetic ketoacidosis(DKA) on first presentation of Type 2 Diabetes Mellitus(T2DM) in a District General Hospital(DGH)",null,"BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health","10.1136/archdischild-2024-rcpch.362","https://doi.org/10.1136/archdischild-2024-rcpch.362",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046682","R0046682.pdf","paywalled","nonrandomized_study","Yestle Kim","2024","SAT-215 Healthcare cost and resource utilization among patients with non-alcoholic steatohepatitis (NASH), stratified by glucagon-like peptide 1 receptor agonist (GLP-1) use in real world data","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01782-3","https://doi.org/10.1016/s0168-8278(24)01782-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046684","R0046684.pdf","paywalled","nonrandomized_study","Edoardo Pozzi","2024","PD52-09 EFFECT OF THE GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST, SEMAGLUTIDE IN OBESE MEN WITH MILD TO MODERATE ERECTILE DYSFUNCTION: A PROSPECTIVE OBSERVATIONAL STUDY","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001009412.04863.1b.09","https://doi.org/10.1097/01.ju.0001009412.04863.1b.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046861","R0046861.pdf","paywalled","nonrandomized_study","Aili Cao","2024","MAP4K1 Downregulation by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Alleviates Podocyte Injury and Inflammation via the cGAS-STING Pathway in Glomerular Diseases","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024gdkxyks6","https://doi.org/10.1681/asn.2024gdkxyks6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046920","R0046920.pdf","paywalled","nonrandomized_study","Derek Connolly","2024","A real-world data analysis investigating the cardioprotective effects of glucagon-like peptide-1 receptor agonists among people with type 2 diabetes in England","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2902","https://doi.org/10.1093/eurheartj/ehae666.2902",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046985","R0046985.pdf","paywalled","nonrandomized_study","Luis Carlos Arthur Gago","2024","MP13-03 GLP-1 RECEPTOR AGONIST USE IS NOT ASSOCIATED WITH IMPAIRED SEMEN PARAMETERS AMONG DIABETIC MEN PRESENTING FOR FERTILITY EVALUATION","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001008832.14212.d6.03","https://doi.org/10.1097/01.ju.0001008832.14212.d6.03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047000","R0047000.pdf","paywalled","nonrandomized_study","Mohammed El‐Sheikh","2024","Effects of prognostic nutritional index and obesity on 1-year mortality in patients with acute heart failure","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.1204","https://doi.org/10.1093/eurheartj/ehae666.1204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047008","R0047008.pdf","paywalled","nonrandomized_study","Ayowumi A. Adekolu","2024","S1467 Risk of Inflammatory Bowel Disease Complications in Obese Inflammatory Bowel Disease Patients on GLP-1 Therapy: A Large Multicenter Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035236.78118.00","https://doi.org/10.14309/01.ajg.0001035236.78118.00",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047013","R0047013.pdf","paywalled","nonrandomized_study","Donghyun Ko","2024","S2216 GLP-1 RAs Use is Associated with Lower Mortality and Improvement of Cardiovascular Outcomes in Patients with Celiac Disease and Obesity: A Multi-Center Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038232.61346.20","https://doi.org/10.14309/01.ajg.0001038232.61346.20",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047020","R0047020.pdf","paywalled","nonrandomized_study","RODOLFO J. GALINDO","2024","231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2","Diabetes","American Diabetes Association","10.2337/db24-231-or","https://doi.org/10.2337/db24-231-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047033","R0047033.pdf","paywalled","nonrandomized_study","Muhammad Saad Faisal","2024","S1909 Association of Glucagon-Like Peptide-1 Therapies and Risk of Cancer in Liver Transplant Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037004.02896.90","https://doi.org/10.14309/01.ajg.0001037004.02896.90",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047050","R0047050.pdf","paywalled","nonrandomized_study","Arleen M. Delgado","2024","S2126 GERD Outcomes in Pediatric Population With Obesity Who Received GLP-1 Agonist or Phentermine-Topiramate: A National Database Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037872.17373.e6","https://doi.org/10.14309/01.ajg.0001037872.17373.e6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047085","R0047085.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2024","S1071 GLP-1 Agonist Use is Associated With Lower Complications and Mortality in Patients With Ulcerative Colitis and Obesity: A National Database Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033652.14646.a5","https://doi.org/10.14309/01.ajg.0001033652.14646.a5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047121","R0047121.pdf","paywalled","nonrandomized_study","Amy Fleischman","2024","Long-Term Follow-up of an Infant with Prader-Willi Syndrome","NeoReviews","American Academy of Pediatrics (AAP)","10.1542/neo.25-10-e669","https://doi.org/10.1542/neo.25-10-e669","39349415","https://pubmed.ncbi.nlm.nih.gov/39349415/",null,null],["4","R0047167","R0047167.pdf","paywalled","nonrandomized_study","Rabih Ghazi","2024","S852 Does ASA Physical Status Class Affect Outcomes of Endoscopy Under MAC Anesthesia in Patients on GLP-1? A Retrospective Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032776.87950.1c","https://doi.org/10.14309/01.ajg.0001032776.87950.1c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047263","R0047263.pdf","paywalled","nonrandomized_study","ELISABETTA PATORNO","2024","1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide","Diabetes","American Diabetes Association","10.2337/db24-1409-p","https://doi.org/10.2337/db24-1409-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047279","R0047279.pdf","paywalled","nonrandomized_study","Do Han Kim","2024","S36 GLP-1 RA Use is Associated with Lower Risk of Biliary Disease Outcomes in Non-Diabetic Patients with Obesity: A Multi-Center Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001028512.66584.2b","https://doi.org/10.14309/01.ajg.0001028512.66584.2b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047424","R0047424.pdf","paywalled","nonrandomized_study","Joshua J. Neumiller","2024","413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk","Diabetes","American Diabetes Association","10.2337/db24-413-p","https://doi.org/10.2337/db24-413-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047441","R0047441.pdf","paywalled","nonrandomized_study","Cheng Niu","2024","1181 EXPLORING GASTROINTESTINAL AND HEPATOBILIARY ADVERSE EVENTS IN GLP-1 RECEPTOR AGONISTS THERAPY: A LARGE COHORT RETROSPECTIVE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01134-x","https://doi.org/10.1016/s0016-5085(24)01134-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047466","R0047466.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2024","Abstract P121: Weight Loss is not a Major Mediator of GLP1-Receptor Agonists’ Risk Reduction in Heart Failure with Preserved Ejection Fraction","Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1161/hyp.81.suppl_1.p121","https://doi.org/10.1161/hyp.81.suppl_1.p121",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047534","R0047534.pdf","paywalled","nonrandomized_study","Lavender Micalo","2024","S2121 Timing of Glucagon-Like Peptide 1 Receptor Agonists Initiation Post-Bariatric Surgery and its Impact on Weight Loss Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037852.80049.d3","https://doi.org/10.14309/01.ajg.0001037852.80049.d3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047535","R0047535.pdf","paywalled","nonrandomized_study","David Z.I. Cherney","2024","Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024wcjmwep0","https://doi.org/10.1681/asn.2024wcjmwep0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047570","R0047570.pdf","paywalled","nonrandomized_study","Yee Hui Yeo","2024","ASSOCIATION OF GLP-1RA USE AND ASPIRATION PNEUMONIA AFTER THE ENDOSCOPIC PROCEDURE: REAL-WORLD DATA FROM A LARGE NATIONAL DATABASE","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2024.04.2837","https://doi.org/10.1016/j.gie.2024.04.2837",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047641","R0047641.pdf","paywalled","nonrandomized_study","Amara Sarwal","2024","Comparative Effectiveness of Semaglutide, Liraglutide, and Dulaglutide for All-Cause Mortality in Type 2 Diabetes (T2D) with and without CKD: An Emulated Clinical Trial Observational Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024gedej30f","https://doi.org/10.1681/asn.2024gedej30f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047653","R0047653.pdf","paywalled","nonrandomized_study","Ernesto S. Robalino Gonzaga","2024","Sa1090 REAL-WOLRD IMPACT OF GLP-1 RECEPTOR AGONISTS ON ENDOSCOPIC PATIENT OUTCOMES IN AN AMBULATORY SETTING. A RETROSPECTIVE STUDY AT A LARGE TERTIARY CENTER.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01242-3","https://doi.org/10.1016/s0016-5085(24)01242-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047656","R0047656.pdf","paywalled","nonrandomized_study","Fabio Castrillon-Ramirez","2024","Association Between Glucagon-Like Peptide 1 Receptor Agonists and Dementia: A Population-based Cohort Study of Adults Aged 40 Years and Older in Ontario, Canada","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.039","https://doi.org/10.1016/j.jcjd.2024.09.039",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047660","R0047660.pdf","paywalled","nonrandomized_study","Csaba Pal Kovesdy","2024","Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in People with CKD and Type 2 Diabetes Initiating Finerenone: A Comedication Subgroup Analysis from the FOUNTAIN Platform","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024d8kamd04","https://doi.org/10.1681/asn.2024d8kamd04",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047673","R0047673.pdf","paywalled","nonrandomized_study","Victoria Damilola Ayodele","2024","Abstract PO5-12-03: Cardiovascular Toxicities in Breast Cancer Survivors","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.sabcs23-po5-12-03","https://doi.org/10.1158/1538-7445.sabcs23-po5-12-03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047695","R0047695.pdf","paywalled","nonrandomized_study","Heather Thiessen‐Philbrook","2024","Integrating Clinical Decision Support Tools in CKD Management","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024zq778gdv","https://doi.org/10.1681/asn.2024zq778gdv",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047733","R0047733.pdf","paywalled","nonrandomized_study","Adam Vinall","2024","GLP-1 RECEPTOR AGONISTS AND OTHER ANTIHYPERGLYCEMIC AGENTS UNLIKELY TO AFFECT BOWEL PREPARATION: A RETROSPECTIVE COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2024.04.1373","https://doi.org/10.1016/j.gie.2024.04.1373",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047769","R0047769.pdf","paywalled","nonrandomized_study","KELLEE MILLER","2024","265-OR: Understanding Patterns of GLP-1/GLP-1 RA Use among Individuals with Type 1 Diabetes—A T1D Exchange (T1DX) Online Registry Analysis","Diabetes","American Diabetes Association","10.2337/db24-265-or","https://doi.org/10.2337/db24-265-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047784","R0047784.pdf","paywalled","nonrandomized_study","Rozalina Grubina McCoy","2024","1407-P: Gaps in the Initiation of Diabetes Drugs with Cardiovascular and Kidney Benefits by Medical Specialists","Diabetes","American Diabetes Association","10.2337/db24-1407-p","https://doi.org/10.2337/db24-1407-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047788","R0047788.pdf","paywalled","nonrandomized_study","Benjamin Douglas Xun Liu","2024","1074 RE-EXAMINING THE RISKS OF GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR WEIGHT LOSS WITH MORE STRINGENT CRITERIA ON A COMPREHENSIVE LARGE DATABASE.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01067-9","https://doi.org/10.1016/s0016-5085(24)01067-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047832","R0047832.pdf","paywalled","nonrandomized_study","Poorva M. Nemlekar","2024","1914-LB: The Combined Effect of CGM with Antidiabetes Medications and the Association with Improved A1C in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy (NIT)","Diabetes","American Diabetes Association","10.2337/db24-1914-lb","https://doi.org/10.2337/db24-1914-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047860","R0047860.pdf","paywalled","nonrandomized_study","Alpana P. Shukla","2024","1684-P: CONCRETE—Characterization of Patients Receiving Telemedicine and Branded Antiobesity Medication for Medical Weight Management—A Retrospective Analysis","Diabetes","American Diabetes Association","10.2337/db24-1684-p","https://doi.org/10.2337/db24-1684-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047949","R0047949.pdf","paywalled","nonrandomized_study","Phyo Than Htoo","2024","Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785399","https://doi.org/10.1055/s-0044-1785399",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047994","R0047994.pdf","paywalled","nonrandomized_study","Theresa M. Hunter","2024","1950-LB: Real-World Use of Tirzepatide among People without Type 2 Diabetes—Results from Optum’s Deidentified Clinformatics Data Mart Database","Diabetes","American Diabetes Association","10.2337/db24-1950-lb","https://doi.org/10.2337/db24-1950-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048038","R0048038.pdf","paywalled","nonrandomized_study","Wajd Alkabbani","2024","756-P: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Endoscopy Failure or Aspiration—A Cohort Study","Diabetes","American Diabetes Association","10.2337/db24-756-p","https://doi.org/10.2337/db24-756-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048128","R0048128.pdf","paywalled","nonrandomized_study","Hellen Jumo","2024","S2315 Weight Loss Outcomes of Glucagon-Like Peptide 1 Receptor Agonists in Patients With Sleeve Gastrectomy vs Patients With Intact Stomach","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038628.55175.32","https://doi.org/10.14309/01.ajg.0001038628.55175.32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048145","R0048145.pdf","paywalled","nonrandomized_study","Jeong Hoon Kim","2024","S1646 No Clinically Significant Change in FIB-4 Score With ESG or Combined Therapy With ESG and Pharmacotherapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035952.40911.0c","https://doi.org/10.14309/01.ajg.0001035952.40911.0c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048154","R0048154.pdf","paywalled","nonrandomized_study","Jane Giang","2024","S2104 Hidden Burden of Clinical Time Required to Obtain Weight Loss Medications for Patients With MASLD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037784.88065.f9","https://doi.org/10.14309/01.ajg.0001037784.88065.f9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048158","R0048158.pdf","paywalled","nonrandomized_study","Rebecca A. Karlson","2024","Mo2015 CLINICAL IMPACT OF GLP-1RA ON ENDOSCOPY: A RETROSPECTIVE COHORT STUDY IN ENDOSCOPY PATIENTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)03207-4","https://doi.org/10.1016/s0016-5085(24)03207-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048189","R0048189.pdf","paywalled","nonrandomized_study","Theresa M. Hunter","2024","1949-LB: Clinical Characteristics and Dosing Patterns of Tirzepatide among Adults without Type 2 Diabetes—Real-World Results","Diabetes","American Diabetes Association","10.2337/db24-1949-lb","https://doi.org/10.2337/db24-1949-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048204","R0048204.pdf","paywalled","nonrandomized_study","Benjamin Douglas Xun Liu","2024","S643 Assessing Risk of Gastroesophageal Reflux Disease and its Complications in Patients Starting Tirzepatide","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031940.76125.c4","https://doi.org/10.14309/01.ajg.0001031940.76125.c4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048227","R0048227.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2024","S387 Single Center Assessment of the Boston Bowel Preparation Scale Score Among Patients With Obesity Who Are Receiving Semaglutide During the Time of Colonoscopy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001030916.12140.a8","https://doi.org/10.14309/01.ajg.0001030916.12140.a8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048248","R0048248.pdf","paywalled","nonrandomized_study","Kalpana Gopalkrishnan","2024","Sa1962 DELAYED GASTRIC EMPTYING AS A CONSEQUENCE OF PATIENTS ON NEW-GENERATION GLP1-RAS: AN ANALYSIS FROM THE FAERS DATABASE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01839-0","https://doi.org/10.1016/s0016-5085(24)01839-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048322","R0048322.pdf","paywalled","nonrandomized_study","Suzan Khalil","2024","Abstract 4115541: Association of Glucagon-like Peptide 1 Receptor Agonist Use with Incident Atrial Fibrillation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4115541","https://doi.org/10.1161/circ.150.suppl_1.4115541",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048357","R0048357.pdf","paywalled","nonrandomized_study","Rabih Ghazi","2024","S854 Does BMI Affect Outcomes in Patients on GLP-1RA Undergoing Endoscopy via MAC Anesthesia: A Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032784.57616.96","https://doi.org/10.14309/01.ajg.0001032784.57616.96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048359","R0048359.pdf","paywalled","nonrandomized_study","Sophia Hurr","2024","S1689 Use of Sodium-Glucose Transport Protein 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors in Patients with MASLD in a Real-World Setting is Associated with Lower All-Cause Mortality","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036124.61521.5f","https://doi.org/10.14309/01.ajg.0001036124.61521.5f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048365","R0048365.pdf","paywalled","nonrandomized_study","Kyle C. Pierce","2024","S228 Assessing Appropriate Bowel Cleansing For Veteran Patients Undergoing Colonoscopy Who Use GLP-1 Agonist Medications","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001029280.37563.c0","https://doi.org/10.14309/01.ajg.0001029280.37563.c0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048374","R0048374.pdf","paywalled","nonrandomized_study","Sharon I. Narvaez","2024","S1688 GLP-1 Agonist Use is Associated With Lower Mortality and Improvement of Cardiovascular Outcomes in Patients With Obesity Who Have MAFLD and OSA: A Multi-Center Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036120.40580.1d","https://doi.org/10.14309/01.ajg.0001036120.40580.1d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048385","R0048385.pdf","paywalled","nonrandomized_study","ELISABETTA PATORNO","2024","1266-P: The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk","Diabetes","American Diabetes Association","10.2337/db24-1266-p","https://doi.org/10.2337/db24-1266-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048447","R0048447.pdf","paywalled","nonrandomized_study","Carlos E. Mendez","2024","734-P: Use of GLP-1 Agonists and Perioperative Complications in Patients Undergoing Elective Surgery","Diabetes","American Diabetes Association","10.2337/db24-734-p","https://doi.org/10.2337/db24-734-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048529","R0048529.pdf","paywalled","nonrandomized_study","Björn O. Bachmann","2024","Trockenes Auge bei Typ-2-Diabetikern: GLP-1-Agonisten scheinen einen protektiven Effekt zu haben","Kompass Ophthalmologie","S. Karger AG","10.1159/000535820","https://doi.org/10.1159/000535820",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048535","R0048535.pdf","paywalled","nonrandomized_study","Oscar A. Garcia Valencia","2024","Benefits of Glucagon-Like Peptide 1 Receptor Agonists in Kidney Transplant Recipients","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024dtfe7jaj","https://doi.org/10.1681/asn.2024dtfe7jaj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048539","R0048539.pdf","paywalled","nonrandomized_study","Taufiq Salahuddin","2024","Abstract 4146844: Characterization of Novel Cardiovascular Medication Use by Clinical Specialty After Admission for Heart Failure or Coronary Artery Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4146844","https://doi.org/10.1161/circ.150.suppl_1.4146844",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048584","R0048584.pdf","paywalled","nonrandomized_study","Akhil Ramanujam Chakravartula","2024","SGLT2 Inhibitors, Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists, and the Risk of Hypokalemia and Hyperkalemia in a National Cohort of Veterans with Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024deq9zff3","https://doi.org/10.1681/asn.2024deq9zff3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048607","R0048607.pdf","paywalled","nonrandomized_study","Ryan S. Hsi","2024","MP26-20 CHANGES IN 24-HOUR URINE PARAMETERS ASSOCIATED WITH SGLT-2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001009408.66023.77.20","https://doi.org/10.1097/01.ju.0001009408.66023.77.20",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048613","R0048613.pdf","paywalled","nonrandomized_study","Rabih Ghazi","2024","S851 Effect of Glucagon-Like Peptide-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Matched Case-Control Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032772.86958.ed","https://doi.org/10.14309/01.ajg.0001032772.86958.ed",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048639","R0048639.pdf","paywalled","nonrandomized_study","Yende Grell","2024","S3424 A Case of Benign Spontaneous Pneumomediastinum","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001043064.48053.66","https://doi.org/10.14309/01.ajg.0001043064.48053.66",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048648","R0048648.pdf","paywalled","nonrandomized_study","Anas Zaher","2024","Sa1097 A RETROSPECTIVE ANALYSIS OF GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONISTS ON BOWEL PREPARATION EFFICACY IN COLONOSCOPIES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01249-6","https://doi.org/10.1016/s0016-5085(24)01249-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048675","R0048675.pdf","paywalled","nonrandomized_study","McCullen M.K","2024","Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/5bzv-n840","https://doi.org/10.17615/5bzv-n840",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048772","R0048772.pdf","paywalled","nonrandomized_study","Christine A. Lam","2024","S1600 Early Initiation of Glucagon-Like Peptide 1 Receptor Agonists After Transoral Outlet Reduction is Associated With Better Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035768.50481.2f","https://doi.org/10.14309/01.ajg.0001035768.50481.2f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048809","R0048809.pdf","paywalled","nonrandomized_study","Danae A. Black","2024","S2135 Prescription Patterns of Glucagon-Like Peptide-1 Receptor Agonists in the Pediatric Population","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037908.08734.f7","https://doi.org/10.14309/01.ajg.0001037908.08734.f7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048960","R0048960.pdf","paywalled","nonrandomized_study","JITHIN SAM VARGHESE","2024","644-P: Racial Ethnic Disparities in Prescription of GLP-1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics","Diabetes","American Diabetes Association","10.2337/db24-644-p","https://doi.org/10.2337/db24-644-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048988","R0048988.pdf","paywalled","nonrandomized_study","Hala Zakaria","2024","806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications","Diabetes","American Diabetes Association","10.2337/db24-806-p","https://doi.org/10.2337/db24-806-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048996","R0048996.pdf","paywalled","nonrandomized_study","Sidney C. Smith","2024","How Can We Increase the Utilization of Evidence-Based Medication After Myocardial Infarction?","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/7ak7-8g06","https://doi.org/10.17615/7ak7-8g06",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048999","R0048999.pdf","paywalled","nonrandomized_study","Julie M. Paik","2024","772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk","Diabetes","American Diabetes Association","10.2337/db24-772-p","https://doi.org/10.2337/db24-772-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049025","R0049025.pdf","paywalled","nonrandomized_study","Anshu Wadehra","2024","S919 Debunking Endoscopy Myths: GLP1-RA Use and GI Symptoms Do NOT Predict Bowel Preparation Success","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033044.23298.e6","https://doi.org/10.14309/01.ajg.0001033044.23298.e6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049090","R0049090.pdf","paywalled","nonrandomized_study","Mohammad Ali Sheffeh","2024","Abstract 4148007: Cardiovascular outcomes with Glucagon-like Peptide-1 receptor agonists and Sodium-glucose Cotransporter-2 Inhibitors in patients with ischemic stroke in the community","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4148007","https://doi.org/10.1161/circ.150.suppl_1.4148007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049092","R0049092.pdf","paywalled","nonrandomized_study","Olanrewaju Felix Adeniran","2024","S1675 Tirzepatide vs Semaglutide in Obese Patients With MAFLD or MASH: A Comparative Analysis of Cardiovascular and Gastrointestinal Outcomes, and the Risk of Progression to Fibrosis or Hepatocellular Carcinoma","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036068.77159.99","https://doi.org/10.14309/01.ajg.0001036068.77159.99",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049126","R0049126.pdf","paywalled","nonrandomized_study","Cho‐Han Chiang","2024","Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis","Blood","American Society of Hematology","10.1182/blood-2024-206409","https://doi.org/10.1182/blood-2024-206409",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049136","R0049136.pdf","paywalled","nonrandomized_study","Lisette Koeneman","2024","Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0044-1785427","https://doi.org/10.1055/s-0044-1785427",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049201","R0049201.pdf","paywalled","nonrandomized_study","John J. Deng","2024","S1594 Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035744.80368.0d","https://doi.org/10.14309/01.ajg.0001035744.80368.0d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049208","R0049208.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2024","S560 GLP-1 Agonists Use Is Associated With Lower Use of PPI and Do Not Worsen Outcomes in Patients With GERD: A National Database Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031608.30677.6c","https://doi.org/10.14309/01.ajg.0001031608.30677.6c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049316","R0049316.pdf","paywalled","nonrandomized_study","Shannen Nicole Dean Ubalde","2024","1889-LB: Type 2 Diabetic Medication Regimen in Treating Depression and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Veterans Using PHQ-9 and FIB-4 Scores","Diabetes","American Diabetes Association","10.2337/db24-1889-lb","https://doi.org/10.2337/db24-1889-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049373","R0049373.pdf","paywalled","nonrandomized_study","Eda Kaya","2024","S2011 Real-World Characteristics of the Patients With Metabolic Dysfunction-Associated Steatohepatitis Prescribed Resmetirom: Data Derived From Two Tertiary Care Centers in the United States","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037412.40234.5d","https://doi.org/10.14309/01.ajg.0001037412.40234.5d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049381","R0049381.pdf","paywalled","nonrandomized_study","Anderson C. Anuforo","2024","Abstract 4146425: Impact Of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like-Peptide-1 Agonists On Cardiovascular and Renal Outcomes In Patients With Type 2 Diabetes Mellitus (T2DM) and Autoimmune Diseases: A Global Retrospective Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4146425","https://doi.org/10.1161/circ.150.suppl_1.4146425",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049482","R0049482.pdf","paywalled","nonrandomized_study","Hannah Wallace","2024","Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024f7q40fk1","https://doi.org/10.1681/asn.2024f7q40fk1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["4","R0049485","R0049485.pdf","paywalled","nonrandomized_study","Sarah Coats","2024","S1426 Impact of GLP-1 Agonists on the Severity of Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035072.02170.98","https://doi.org/10.14309/01.ajg.0001035072.02170.98",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049498","R0049498.pdf","paywalled","nonrandomized_study","Steve M. D’Souza","2024","S685 The Relationship Between Eosinophilic Esophagitis and Autism Spectrum Disorder in Adult Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032108.20416.b1","https://doi.org/10.14309/01.ajg.0001032108.20416.b1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049602","R0049602.pdf","paywalled","nonrandomized_study","Saif S. Rathore","2024","Abstract 4139502: Projected Impact of GLP-1 adoption on 5-year coronary stent rates among Medicare beneficiaries with cardiovascular disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4139502","https://doi.org/10.1161/circ.150.suppl_1.4139502",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049603","R0049603.pdf","paywalled","nonrandomized_study","Beatriz Torre","2024","S863 Impact of Duration of GLP-1 Receptor Agonist Therapy in Endoscopic Outcomes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032820.41709.eb","https://doi.org/10.14309/01.ajg.0001032820.41709.eb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049621","R0049621.pdf","paywalled","nonrandomized_study","Robinderpal Sandhu","2024","Mo1297 SHOULD GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS (GLP-1 RAS) BE HELD PRIOR TO AMBULATORY REFLUX TESTING? A RETROSPECTIVE COMPARISON OF QUANTITATIVE REFLUX TESTING RESULTS","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)02816-6","https://doi.org/10.1016/s0016-5085(24)02816-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049717","R0049717.pdf","paywalled","nonrandomized_study","Anam Rizvi","2024","ENDOSCOPIC GASTRIC FOOD RETENTION RATES FOR GLP-1RA USERS CAN BE POTENTIALLY MITIGATED BY PRE-COLONOSCOPY FASTING PROTOCOLS IN A PROPENSITY-MATCHED COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2024.04.1085","https://doi.org/10.1016/j.gie.2024.04.1085",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049741","R0049741.pdf","paywalled","nonrandomized_study","Toluwalase Awoyemi","2024","Abstract 4144048: Propensity Score-Matched Analysis of GLP-1 Agonists' Impact on Clinical Cardiovascular Outcomes in Patients with Concurrent Heart Failure and Atrial Fibrillation","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4144048","https://doi.org/10.1161/circ.150.suppl_1.4144048",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049791","R0049791.pdf","paywalled","nonrandomized_study","Kuan Yu Chi","2024","Abstract 4144520: Glucagon-like Peptide-1 Receptor Agonists for the Primary Prevention of Major Adverse Cardiac Events in Drug-naïve Type 2 Diabetes: A Propensity-score Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4144520","https://doi.org/10.1161/circ.150.suppl_1.4144520",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049804","R0049804.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","S181 Impact of Glucagon-Like Peptide-1 Receptor Agonist on Gallbladder and Biliary Diseases","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001029092.23386.b2","https://doi.org/10.14309/01.ajg.0001029092.23386.b2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049822","R0049822.pdf","paywalled","nonrandomized_study","Nicole Piero","2024","Improving Conformity to Diabetic Kidney Disease Clinical Guidelines","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20244e9kfmyk","https://doi.org/10.1681/asn.20244e9kfmyk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049834","R0049834.pdf","paywalled","nonrandomized_study","Maria Valeria Matteo","2024","Endoscopic Sleeve Gastroplasty: can we predict its efficacy at an early stage?","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0044-1782914","https://doi.org/10.1055/s-0044-1782914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049845","R0049845.pdf","paywalled","nonrandomized_study","Luis A. Rodríguez","2024","Abstract MP36: Evaluation of Race and Ethnicity and Pharmacy Dispensing of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.149.suppl_1.mp36","https://doi.org/10.1161/circ.149.suppl_1.mp36",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049860","R0049860.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2024","SGLT2 Inhibitors Are Associated with Lower Risk of CKD Progression in Type 2 Diabetes (T2D) than Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs): An Emulated Clinical Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20245wtk9af7","https://doi.org/10.1681/asn.20245wtk9af7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049875","R0049875.pdf","paywalled","nonrandomized_study","Donghyun Ko","2024","S567 GLP-1 RAs Use is Associated with Lower 7-Days Repeat Esophagogastroduodenoscopy after Index Endoscopy in Patients with Achalasia: A Multi-Center Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031636.70614.ca","https://doi.org/10.14309/01.ajg.0001031636.70614.ca",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049890","R0049890.pdf","paywalled","nonrandomized_study","Robert M. Cutler","2024","S792 Weighting on Methane: Weight Loss Medications Associated With Increased Incidence of SIBO","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032536.53564.9a","https://doi.org/10.14309/01.ajg.0001032536.53564.9a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049904","R0049904.pdf","paywalled","nonrandomized_study","Harshil A. Fichadiya","2024","Identifying Global Awareness of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) through Google Search Trend Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024h41xjqp9","https://doi.org/10.1681/asn.2024h41xjqp9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049948","R0049948.pdf","paywalled","nonrandomized_study","Phyllis Thangaraj","2024","Abstract 4118762: Large-scale multinational trends in the use of cardioprotective antihyperglycemic agents as first-line therapy in patients with type 2 diabetes and cardiovascular disease: a LEGEND-T2DM study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4118762","https://doi.org/10.1161/circ.150.suppl_1.4118762",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049952","R0049952.pdf","paywalled","nonrandomized_study","Toluwalase Awoyemi","2024","Abstract 4134637: Impact of Glucagon-Like Peptide-1 Agonists on Cardiovascular Outcomes in Chronic Kidney Disease Stage 5: A Propensity Score-Matched Analysis","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4134637","https://doi.org/10.1161/circ.150.suppl_1.4134637",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050040","R0050040.pdf","paywalled","nonrandomized_study","Adam H de Havenon","2024","Abstract WP229: Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.55.suppl_1.wp229","https://doi.org/10.1161/str.55.suppl_1.wp229",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050081","R0050081.pdf","paywalled","nonrandomized_study","María Ángeles Espinosa","2024","S2120 Tirzepatide and MASLD: Real-World Outcomes in Patients With Overweight and Obesity","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037848.29175.a2","https://doi.org/10.14309/01.ajg.0001037848.29175.a2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050094","R0050094.pdf","paywalled","nonrandomized_study","Elif Tama","2024","234-OR: Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide","Diabetes","American Diabetes Association","10.2337/db24-234-or","https://doi.org/10.2337/db24-234-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050125","R0050125.pdf","paywalled","nonrandomized_study","Alfred Sidney Barritt","2024","SAT-212 Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGETNASH","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01779-3","https://doi.org/10.1016/s0168-8278(24)01779-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050137","R0050137.pdf","paywalled","nonrandomized_study","Emily R. Hankosky","2024","2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db24-2084-lb","https://doi.org/10.2337/db24-2084-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050152","R0050152.pdf","paywalled","nonrandomized_study","Mariam Samir Girguis","2024","779-P: Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a U.S. EHR and Claims Linked Database","Diabetes","American Diabetes Association","10.2337/db24-779-p","https://doi.org/10.2337/db24-779-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050203","R0050203.pdf","paywalled","nonrandomized_study","Phyo Than Htoo","2024","Abstract 4135846: Cardiovascular Effectiveness of Glucagon-like Peptide-1 Receptor Agonists and Empagliflozin Combination Therapy in Adults with Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4135846","https://doi.org/10.1161/circ.150.suppl_1.4135846",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050296","R0050296.pdf","paywalled","nonrandomized_study","Reema Mody","2024","744-P: Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured U.S. Population","Diabetes","American Diabetes Association","10.2337/db24-744-p","https://doi.org/10.2337/db24-744-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050307","R0050307.pdf","paywalled","nonrandomized_study","Mohammed Shahait","2024","MP05-10 GLUCAGON-LIKE PEPTIDE-1 EXPRESSION IN PROSTATE CANCER","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001008740.27639.cc.10","https://doi.org/10.1097/01.ju.0001008740.27639.cc.10",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050314","R0050314.pdf","paywalled","nonrandomized_study","Juraj Sečník","2024","Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia","Advances in Alzheimer's disease","IOS Press","10.3233/aiad230016","https://doi.org/10.3233/aiad230016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050376","R0050376.pdf","paywalled","nonrandomized_study","James J. Amamoo","2024","1884-LB: Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)","Diabetes","American Diabetes Association","10.2337/db24-1884-lb","https://doi.org/10.2337/db24-1884-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050377","R0050377.pdf","paywalled","nonrandomized_study","SHUYAO ZHANG","2024","737-P: Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1-RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study","Diabetes","American Diabetes Association","10.2337/db24-737-p","https://doi.org/10.2337/db24-737-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050394","R0050394.pdf","paywalled","nonrandomized_study","James J. Amamoo","2024","857-P: Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes—An Observational Study (PAUSE)","Diabetes","American Diabetes Association","10.2337/db24-857-p","https://doi.org/10.2337/db24-857-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050428","R0050428.pdf","paywalled","nonrandomized_study","James J. Amamoo","2024","Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024zeyxkd1g","https://doi.org/10.1681/asn.2024zeyxkd1g",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050448","R0050448.pdf","paywalled","nonrandomized_study","Akash Rajendrakumar Patel","2024","S866 The Impact of GLP-1 Receptor Agonists on Bowel Preparation for Colonoscopy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032832.86860.c8","https://doi.org/10.14309/01.ajg.0001032832.86860.c8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050451","R0050451.pdf","paywalled","nonrandomized_study","Elif Tama","2024","1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience","Diabetes","American Diabetes Association","10.2337/db24-1660-p","https://doi.org/10.2337/db24-1660-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050472","R0050472.pdf","paywalled","nonrandomized_study","Muhammad Touqeer Hanif","2024","Abstract 4140660: Clinical Outcomes of GLP-1 RA in Heart Failure with CKD patients: A TriNetX Based Global Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4140660","https://doi.org/10.1161/circ.150.suppl_1.4140660",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050505","R0050505.pdf","paywalled","nonrandomized_study","Amara Sarwal","2024","Insulin Glargine Compared with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) or SGLT2 Inhibitors Is Associated with Higher Risk of Alzheimer Disease and Alzheimer Disease-Related Dementias (AD/ADRD) in CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024295x7sw8","https://doi.org/10.1681/asn.2024295x7sw8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050523","R0050523.pdf","paywalled","nonrandomized_study","Matthew R Yanus","2024","Abstract WP278: Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/str.55.suppl_1.wp278","https://doi.org/10.1161/str.55.suppl_1.wp278",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050578","R0050578.pdf","paywalled","nonrandomized_study","Piyush Nathani","2024","Sa1964 INCIDENCE OF GASTROINTESTINAL SIDE EFFECTS IN PATIENTS PRESCRIBED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGS: REAL-WORLD EVIDENCE","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01841-9","https://doi.org/10.1016/s0016-5085(24)01841-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050587","R0050587.pdf","paywalled","nonrandomized_study","Philipp Hegner","2024","Semaglutide improves contractile function in isolated human atrium","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.3729","https://doi.org/10.1093/eurheartj/ehae666.3729",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050590","R0050590.pdf","paywalled","nonrandomized_study","Tarek Odah","2024","S839 Glucagon-Like Peptide-1 Receptor Agonists and Capsule Endoscopy in Patients With Diabetes: A Matched Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032724.91132.32","https://doi.org/10.14309/01.ajg.0001032724.91132.32",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050619","R0050619.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","Sa1777 IBD PATIENTS CONCOMITANTLY TREATED WITH GLP1 AGONISTS HAD FEWER HOSPITALIZATIONS AND DISEASE RELATED COMPLICATIONS: A US COHORT PROPENSITY-MATCHED STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01662-7","https://doi.org/10.1016/s0016-5085(24)01662-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050646","R0050646.pdf","paywalled","nonrandomized_study","McGuire D.K","2024","Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/xc1q-s677","https://doi.org/10.17615/xc1q-s677",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050689","R0050689.pdf","paywalled","nonrandomized_study","Guillermo E. Umpierrez","2024","829-P: iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db24-829-p","https://doi.org/10.2337/db24-829-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050710","R0050710.pdf","paywalled","nonrandomized_study","Sima Fansa","2024","1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience","Diabetes","American Diabetes Association","10.2337/db24-1707-p","https://doi.org/10.2337/db24-1707-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050716","R0050716.pdf","paywalled","nonrandomized_study","RUSSIE ALLEN","2024","563-P: How Continuing Education (CE) Supported Guideline-Based Treatment among Patients with Diabetes","Diabetes","American Diabetes Association","10.2337/db24-563-p","https://doi.org/10.2337/db24-563-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050735","R0050735.pdf","paywalled","nonrandomized_study","Christoph Wanner","2024","Dosing, Treatment Pattern, and Safety of Finerenone Use in Routine Care: An Interim Analysis of the Prospective, Real-World, and Observational FINE-REAL Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024dfkkts8m","https://doi.org/10.1681/asn.2024dfkkts8m",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05348733"],["4","R0050737","R0050737.pdf","paywalled","nonrandomized_study","Luìs Manuel de Almieda Nieto","2024","Sa1963 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR ACUTE PANCREATITIS AND ARE NOT ASSOCIATED WITH COMPLICATIONS IN PATIENTS WITH OBESITY WHO DEVELOP IT: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)01840-7","https://doi.org/10.1016/s0016-5085(24)01840-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050754","R0050754.pdf","paywalled","nonrandomized_study","Phillip Anjum","2024","Warfarin and GLP-1 Receptor Agonist Interaction Effects on Time in Therapeutic Range","Blood","American Society of Hematology","10.1182/blood-2024-211357","https://doi.org/10.1182/blood-2024-211357",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050766","R0050766.pdf","paywalled","nonrandomized_study","Rebecca Lauren Tisdale","2024","Abstract 4129075: Racial and Ethnic Differences in Semaglutide Prescriptions in the Veterans Affairs Healthcare System","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4129075","https://doi.org/10.1161/circ.150.suppl_1.4129075",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050802","R0050802.pdf","paywalled","nonrandomized_study","Jahanzeb Javed","2024","Abstract 4145342: GLP-1 Agonists are Associated with Fewer Unplanned Hospital Visits in Patients with Cardiovascular Disease and Comorbid Substance Use Disorder","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145342","https://doi.org/10.1161/circ.150.suppl_1.4145342",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050832","R0050832.pdf","paywalled","nonrandomized_study","Ahmed E Salem","2024","S2100 Incidence of Gallstone Formation in Type 2 Diabetes Patients Treated With GLP-1 Agonists: A 24-Month Prospective Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037768.42959.91","https://doi.org/10.14309/01.ajg.0001037768.42959.91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050850","R0050850.pdf","paywalled","nonrandomized_study","Rabih Ghazi","2024","S853 Safety of MAC Anesthesia in Patients Taking GLP-1RA Undergoing EGD vs Colonoscopy vs Bidirectional Endoscopy: A Retrospective Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032780.97000.21","https://doi.org/10.14309/01.ajg.0001032780.97000.21",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050876","R0050876.pdf","paywalled","nonrandomized_study","Haarika Korlipara","2024","SEMAGLUTIDE IS AN INDEPENDENT RISK FACTOR FOR RETAINED GASTRIC CONTENTS AND RECOMMENDATION FOR REPEAT UPPER ENDOSCOPY: RESULTS FROM A REAL-WORLD POPULATION COHORT STUDY","Gastrointestinal Endoscopy","Elsevier BV","10.1016/j.gie.2024.04.1135","https://doi.org/10.1016/j.gie.2024.04.1135",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050917","R0050917.pdf","paywalled","nonrandomized_study","Wendy Wang","2024","Abstract 35: Association of SGLT2 Inhibitors and Other Second Line Therapies With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.149.suppl_1.35","https://doi.org/10.1161/circ.149.suppl_1.35",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050932","R0050932.pdf","paywalled","nonrandomized_study","Vanessa R. Williams","2024","1427-P: Factors Predicting Significant Improvement in Glycemic Control after Endocrinology Referral in Patients with Type 2 Diabetes Mellitus and Hemoglobin A1c ≥ 10%","Diabetes","American Diabetes Association","10.2337/db24-1427-p","https://doi.org/10.2337/db24-1427-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050975","R0050975.pdf","paywalled","nonrandomized_study","Shubham Agarwal","2024","777-P: Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","Diabetes","American Diabetes Association","10.2337/db24-777-p","https://doi.org/10.2337/db24-777-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050994","R0050994.pdf","paywalled","nonrandomized_study","Anshu Wadehra","2024","S920 Clear Liquid Diet and Colonoscopy Bowel Preparation Are Effective in Eliminating Retained Gastric Contents in Those on GLP1-RA Agents Undergoing Endoscopic Procedures","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033048.87672.a5","https://doi.org/10.14309/01.ajg.0001033048.87672.a5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051125","R0051125.pdf","paywalled","nonrandomized_study","Michael Saadeh","2024","S1371 Impact of GLP-1RA on MACE in Patients With IBD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001034852.99680.c3","https://doi.org/10.14309/01.ajg.0001034852.99680.c3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051149","R0051149.pdf","paywalled","nonrandomized_study","Tushar Khanna","2024","S1390 Outcomes of Patients With Inflammatory Bowel Disease on GLP-1 Receptor Agonists: A Propensity Score-Matched Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001034928.98373.b3","https://doi.org/10.14309/01.ajg.0001034928.98373.b3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051176","R0051176.pdf","paywalled","nonrandomized_study","Ramesh Nadarajah","2024","Machine learning identifies individuals at higher risk of incident cardio-renal-metabolic diseases and cardiovascular death who have unrealised opportunities to reduce future cardiovascular risk","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2689","https://doi.org/10.1093/eurheartj/ehae666.2689",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051245","R0051245.pdf","paywalled","nonrandomized_study","Sharon I. Narvaez","2024","S2065 GLP-1 Agonist Use is Associated With Lower Incidence of GERD, Lower Use of PPIs and Does Not Complicate GERD in Patients With Obesity Who Undergo Sleeve Gastrectomy: A National Database Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037628.17155.33","https://doi.org/10.14309/01.ajg.0001037628.17155.33",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051260","R0051260.pdf","paywalled","nonrandomized_study","Michael J. DiMarino","2024","S862 Impact of GLP-1 Receptor Agonist Indication on Gastric Retention and Boston Bowel Preparatory Score","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032816.34283.f3","https://doi.org/10.14309/01.ajg.0001032816.34283.f3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051389","R0051389.pdf","paywalled","nonrandomized_study","Sima Fansa","2024","638 PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)00831-x","https://doi.org/10.1016/s0016-5085(24)00831-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051462","R0051462.pdf","paywalled","nonrandomized_study","Jeong Hoon Kim","2024","S1647 ESG Combined With Pharmacotherapy is Associated With Greater Patient Visit Compliance Compared to ESG Alone","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035956.23607.0c","https://doi.org/10.14309/01.ajg.0001035956.23607.0c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051486","R0051486.pdf","paywalled","nonrandomized_study","Isabel Baik","2024","Evaluating the use of glucagon‐like peptide‐1 receptor agonists in a matched cohort of kidney and liver transplant recipients","Journal of Pharmacy Practice and Research","Wiley","10.1002/jppr.1953","https://doi.org/10.1002/jppr.1953",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051493","R0051493.pdf","paywalled","nonrandomized_study","William S. A. Jenkins","2024","#1704366 Gastroparesis Incidence Post-Initiation of Semaglutide Versus Sitagliptin in Type 2 Diabetes: A Retrospective TriNetX Database Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2024.03.189","https://doi.org/10.1016/j.eprac.2024.03.189",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051519","R0051519.pdf","paywalled","nonrandomized_study","Natalie Koch Levy","2024","1103-P: The Mobile Insulin Titration Intervention to Transition from Basal Insulin to a GLP1-RA (MITI-GLP1)—Using Daily SMS Text Messages and Weekly Phone Calls to Transition Primary Care Patients with Well-Controlled Type 2 Diabetes Mellitus from Basal Insulin to a GLP1-RA at Bellevue Hospital","Diabetes","American Diabetes Association","10.2337/db24-1103-p","https://doi.org/10.2337/db24-1103-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051530","R0051530.pdf","paywalled","nonrandomized_study","Tyler J. Dunn","2024","Abstract 4126158: Persistence to once weekly GLP-1 RAs is associated with lower risk of MI, stroke, and 2-point MACE among patients with T2D and ASCVD in the real world.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4126158","https://doi.org/10.1161/circ.150.suppl_1.4126158",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051602","R0051602.pdf","paywalled","nonrandomized_study","Benjamin Catanese","2024","Abstract 4139027: Glucagon-like Peptide-1 Receptor Agonist Use and Cardiac Outcomes in Patients with End Stage Kidney Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4139027","https://doi.org/10.1161/circ.150.suppl_1.4139027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051625","R0051625.pdf","paywalled","nonrandomized_study","Patricia Knoepp","2024","Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ghnb-3t38","https://doi.org/10.17615/ghnb-3t38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051626","R0051626.pdf","paywalled","nonrandomized_study","Reema Mody","2024","738-P: Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)","Diabetes","American Diabetes Association","10.2337/db24-738-p","https://doi.org/10.2337/db24-738-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051642","R0051642.pdf","paywalled","nonrandomized_study","KARA R. MIZOKAMI-STOUT","2024","1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023","Diabetes","American Diabetes Association","10.2337/db24-1073-p","https://doi.org/10.2337/db24-1073-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051651","R0051651.pdf","paywalled","nonrandomized_study","Jignesh Shah","2024","The National Kidney Foundation's CKD Learning Collaborative: Transforming Care across University Health in Kansas City, Missouri","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20242sykf8r5","https://doi.org/10.1681/asn.20242sykf8r5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051745","R0051745.pdf","paywalled","nonrandomized_study","Jake Cragg","2024","P330 The real-world impact of treatments for type 2 diabetes on outcomes in people with non-alcoholic fatty liver disease","Poster presentations","BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2024-bsg.412","https://doi.org/10.1136/gutjnl-2024-bsg.412",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051779","R0051779.pdf","paywalled","nonrandomized_study","Rebecca A. Karlson","2024","S864 Clinical Impact of GLP-1RA On Endoscopy: A Retrospective Cohort Study in Endoscopy Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032824.49982.9d","https://doi.org/10.14309/01.ajg.0001032824.49982.9d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051789","R0051789.pdf","paywalled","nonrandomized_study","Mats Christian Højbjerg Lassen","2024","Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae666.2913","https://doi.org/10.1093/eurheartj/ehae666.2913",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051867","R0051867.pdf","paywalled","nonrandomized_study","Chengu Niu","2024","Tu1826 IMPACT OF GLP-1 RECEPTOR AGONIST ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: INSIGHTS FROM A LARGE-SCALE COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)03727-2","https://doi.org/10.1016/s0016-5085(24)03727-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051941","R0051941.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","S5 GLP-1 Receptor Agonists and Pancreatic Cancer Risk in Drug-Naive Patients With Type 2 Diabetes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001028388.64456.1e","https://doi.org/10.14309/01.ajg.0001028388.64456.1e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051965","R0051965.pdf","paywalled","nonrandomized_study","Bradley John Roth","2024","(051) DEGREE OF WEIGHT LOSS IS ASSOCIATED WITH NEW ERECTILE DYSFUNCTION AFTER GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST MEDICATION PRESCRIPTION","The Journal of Sexual Medicine","Oxford University Press (OUP)","10.1093/jsxmed/qdae167.049","https://doi.org/10.1093/jsxmed/qdae167.049",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052050","R0052050.pdf","paywalled","nonrandomized_study","Ivy Shi","2024","Abstract 4145660: Limitations of the Generalizability of Semaglutide Trials Evaluating CV Outcomes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145660","https://doi.org/10.1161/circ.150.suppl_1.4145660",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052079","R0052079.pdf","paywalled","nonrandomized_study","Samantha Rubin","2024","S309 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Patients Undergoing Colonoscopy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001030604.33841.74","https://doi.org/10.14309/01.ajg.0001030604.33841.74",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052080","R0052080.pdf","paywalled","nonrandomized_study","Azhar R Hussain","2024","S2083 Semaglutide and Liraglutide and Incidence of New-Onset Gastroparesis, Non-Alcoholic Steatohepatitis, Acute Liver Failure, Cirrhosis, Hepatocellular Carcinoma and Mortality in Obese Diabetic Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037700.41113.c9","https://doi.org/10.14309/01.ajg.0001037700.41113.c9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052088","R0052088.pdf","paywalled","nonrandomized_study","Do Han Kim","2024","S2283 Risk of De Novo Gastroparesis in Non-Diabetic Patients With Obesity Taking Tirzepatide Versus Semaglutide: A Multi-Center Analysis.","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038500.33915.6f","https://doi.org/10.14309/01.ajg.0001038500.33915.6f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052104","R0052104.pdf","paywalled","nonrandomized_study","Anika Koka","2024","S312 Glucagon-Like Peptide -1 Receptor Agonists Significantly Affects Quality of Prep in Screening Colonoscopies- A Private Practice Experience","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001030616.49084.7e","https://doi.org/10.14309/01.ajg.0001030616.49084.7e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052107","R0052107.pdf","paywalled","nonrandomized_study","Aravinthan Vignarajah","2024","Abstract 4145549: All-Cause Mortality and Cardiovascular Outcomes with Glucagon-Like Peptide-1 Receptor Agonists in People with Type 2 Diabetes and Systolic Heart Failure","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145549","https://doi.org/10.1161/circ.150.suppl_1.4145549",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052249","R0052249.pdf","paywalled","nonrandomized_study","Mengdan Xie","2024","S1483 Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Prevalence of Inflammatory Bowel Diseases and Its associated Complications in Diabetic Patients: Global Healthcare Database Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035300.28190.7c","https://doi.org/10.14309/01.ajg.0001035300.28190.7c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052277","R0052277.pdf","paywalled","nonrandomized_study","Meghna Yalamanchi","2024","S2101 Weight Loss after Initial Bariatric Surgery Predicts Early Weight Loss After Revisional Endoscopic Bariatric Therapy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037772.95190.83","https://doi.org/10.14309/01.ajg.0001037772.95190.83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052279","R0052279.pdf","paywalled","nonrandomized_study","Rhea Fogla","2024","EP86 SEMAGLUTIDE USE ACHIEVES WEIGHT LOSS AND FAT REDUCTION WITH PRESERVATION OF SKELETAL MASS IN PATIENTS WITH MASLD: A RETROSPECTIVE LONGITUDINAL STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)04526-8","https://doi.org/10.1016/s0016-5085(24)04526-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052291","R0052291.pdf","paywalled","nonrandomized_study","Md Faruque Pathan","2024","Safety and Efficacy of Semaglutide Use in Diabetes during Ramadan Fasting: A Real-world Experience from Bangladesh","Bangladesh Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/bjem.bjem_29_23","https://doi.org/10.4103/bjem.bjem_29_23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052299","R0052299.pdf","paywalled","nonrandomized_study","Maria Cecilia Lansang","2024","Abstract 4135582: Sociodemographic Trends in Diabetes Medications after Metformin: the BESTMED (oBservational Evaluation of Second line Therapy MEdications in Diabetes) Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4135582","https://doi.org/10.1161/circ.150.suppl_1.4135582",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052318","R0052318.pdf","paywalled","nonrandomized_study","David C. Kunkel","2024","S2323 Addressing an Emerging Clinical Need: Nasal Metoclopramide's Impact on Diabetic Gastroparesis in Patients Taking GLP-1 Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038660.88079.93","https://doi.org/10.14309/01.ajg.0001038660.88079.93",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052354","R0052354.pdf","paywalled","nonrandomized_study","Jane A. Diamond","2024","S218 Characterizing Individuals With Recurrent Acute Pancreatitis and Exocrine Pancreatic Insufficiency: Findings From the PACT-CP Registry","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001029240.67546.ea","https://doi.org/10.14309/01.ajg.0001029240.67546.ea",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05762445"],["4","R0052367","R0052367.pdf","paywalled","nonrandomized_study","Ilana K Logvinsky","2024","Abstract 4142273: Pharmacosurveillance study of FDA Adverse Event Reporting System (FAERS) events of Tirzepatide and Semaglutide","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4142273","https://doi.org/10.1161/circ.150.suppl_1.4142273",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052420","R0052420.pdf","paywalled","nonrandomized_study","Amara Sarwal","2024","Risk of Gastroparesis Is Higher with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) but Risk of Death Is Higher with Insulin Glargine in Veterans with Type 2 Diabetes and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.202475pb8gyb","https://doi.org/10.1681/asn.202475pb8gyb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052426","R0052426.pdf","paywalled","nonrandomized_study","Mahmoud Nassar","2024","S442 Comparative Outcomes of Pancreatic, Colon, and Liver Cancers in GLP-1 RA Treated Patients: A Retrospective Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031136.76287.b2","https://doi.org/10.14309/01.ajg.0001031136.76287.b2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052460","R0052460.pdf","paywalled","nonrandomized_study","Anantha Soogoor","2024","MP45-11 SEMAGLUTIDE UTILIZATION IN WEIGHT MANAGEMENT AND ITS IMPLICATIONS FOR URINARY TRACT INFECTIONS AND UROLITHIASIS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.ju.0001008764.86460.8e.11","https://doi.org/10.1097/01.ju.0001008764.86460.8e.11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052481","R0052481.pdf","paywalled","nonrandomized_study","Francesco Giorgino","2024","1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation","Diabetes","American Diabetes Association","10.2337/db24-1867-lb","https://doi.org/10.2337/db24-1867-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052482","R0052482.pdf","paywalled","nonrandomized_study","Chen-Hsiang Ma","2024","Abstract 4145759: Guideline Directed Medical Therapy and the Impact of Sex on Patient Reported and Clinical Outcomes in a Specialized Heart Failure Clinic","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4145759","https://doi.org/10.1161/circ.150.suppl_1.4145759",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052530","R0052530.pdf","paywalled","nonrandomized_study","Akash Patel","2024","S867 Evaluation of Bowel Preparation Regimens for Colonoscopy in Patients Receiving GLP-1 Receptor Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032836.56300.18","https://doi.org/10.14309/01.ajg.0001032836.56300.18",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052578","R0052578.pdf","paywalled","nonrandomized_study","Mark Ayoub","2024","S2351 GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Gastric Cancer: A National Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038772.01977.23","https://doi.org/10.14309/01.ajg.0001038772.01977.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052662","R0052662.pdf","paywalled","nonrandomized_study","Jefferson L. Triozzi","2024","Genetic GLP1R Gene Expression and Kidney Disease Progression: A Mechanistic Proteome-Wide Analysis in the Million Veteran Program","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024z4j5t87e","https://doi.org/10.1681/asn.2024z4j5t87e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052685","R0052685.pdf","paywalled","nonrandomized_study","Helen Tesfaye","2024","33-OR: The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk","Diabetes","American Diabetes Association","10.2337/db24-33-or","https://doi.org/10.2337/db24-33-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052698","R0052698.pdf","paywalled","nonrandomized_study","Kuan Yu Chi","2024","Abstract 4144387: The Prognostic Role of Glucagon-like Peptide-1 Receptor Agonist in Transthyretin Amyloid Cardiomyopathy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4144387","https://doi.org/10.1161/circ.150.suppl_1.4144387",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052708","R0052708.pdf","paywalled","nonrandomized_study","Lindsay M. Clarke","2024","S1399 Safety and Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists for Obesity in Patients With Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001034964.71202.42","https://doi.org/10.14309/01.ajg.0001034964.71202.42",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052729","R0052729.pdf","paywalled","nonrandomized_study","Julie M. Paik","2024","773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-773-p","https://doi.org/10.2337/db24-773-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052747","R0052747.pdf","paywalled","nonrandomized_study","Tiansheng Wang","2024","17-PUB: Glucagon-Like Peptide 1 Receptor Agonists' Heterogeneous Treatment Effects on Asthma Exacerbations—A Causal Machine-Learning Analysis","Diabetes","American Diabetes Association","10.2337/db24-17-pub","https://doi.org/10.2337/db24-17-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052748","R0052748.pdf","paywalled","nonrandomized_study","HUILIN TANG","2024","750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-750-p","https://doi.org/10.2337/db24-750-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052794","R0052794.pdf","paywalled","nonrandomized_study","Noor Hassan","2024","S522 African American Patients Taking GLP-1RA are More Likely to Have Poor Bowel Prep: A Single Center Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031456.34444.a9","https://doi.org/10.14309/01.ajg.0001031456.34444.a9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052840","R0052840.pdf","paywalled","nonrandomized_study","HUILIN TANG","2024","232-OR: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-Harm in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study","Diabetes","American Diabetes Association","10.2337/db24-232-or","https://doi.org/10.2337/db24-232-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052884","R0052884.pdf","paywalled","nonrandomized_study","Sabah Mahmood","2024","S517 The Effect of GLP-1 Receptor Agonists on Bowel Preparation","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031436.52308.00","https://doi.org/10.14309/01.ajg.0001031436.52308.00",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052888","R0052888.pdf","paywalled","nonrandomized_study","Osama Hamid","2024","Mo1265 IMPACT OF GLP-1 AGONIST TREATMENT ON GERD OUTCOMES IN DIABETIC PATIENTS: INSIGHTS FROM A PROPENSITY-MATCHED STUDY IN THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)02784-7","https://doi.org/10.1016/s0016-5085(24)02784-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052913","R0052913.pdf","paywalled","nonrandomized_study","Abraheim Al-Nasseri","2024","Abstract 4134267: Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on In-Hospital Mortality and 30-Day Readmission in Type 2 Diabetic Patients with Acute Coronary Syndrome","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4134267","https://doi.org/10.1161/circ.150.suppl_1.4134267",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052949","R0052949.pdf","paywalled","nonrandomized_study","XIAOHAN WANG","2024","1922-LB: CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data","Diabetes","American Diabetes Association","10.2337/db24-1922-lb","https://doi.org/10.2337/db24-1922-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052964","R0052964.pdf","paywalled","nonrandomized_study","Khaled Alsabbagh Alchirazi","2024","S922 Decrease Risk of Intubation and Aspiration Pneumonia Associated with Endoscopic Procedure Among Patients on Glucagon-Like Peptide 1 Receptor Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033056.82634.02","https://doi.org/10.14309/01.ajg.0001033056.82634.02",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052987","R0052987.pdf","paywalled","nonrandomized_study","Luis Miguel Nieto","2024","Tu1944 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH LOWER INCIDENCE OF HEPATOBILIARY OR PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A MULTI-CENTER COHORT STUDY ACROSS THE UNITED STATES","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)03826-5","https://doi.org/10.1016/s0016-5085(24)03826-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052988","R0052988.pdf","paywalled","nonrandomized_study","Benjamin Young","2024","S925 EGD Outcomes in Patients Receiving GLP-1 Receptor Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033068.98401.05","https://doi.org/10.14309/01.ajg.0001033068.98401.05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053036","R0053036.pdf","paywalled","nonrandomized_study","Jacqueline Maya","2024","1214-P: Prepregnancy Use of Glucagon-Like Peptide 1 Receptor Agonists and Gestational Weight Gain in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-1214-p","https://doi.org/10.2337/db24-1214-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053038","R0053038.pdf","paywalled","nonrandomized_study","KHOLOOD HABEEB","2024","810-P: Role of Glucagon-Like-Peptide-1 Agonists as an Adjunctive Treatment in Adults with Type 1 Diabetes Mellitus and Overweight/Obesity, Retrospective Cohort, Saudi Arabia 2023","Diabetes","American Diabetes Association","10.2337/db24-810-p","https://doi.org/10.2337/db24-810-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053042","R0053042.pdf","paywalled","nonrandomized_study","Ksenia O. Shnaider","2024","Pharmacovigilance assessment of semaglutide safety","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","PANORAMA Publishing House","10.33920/med-10-2404-08","https://doi.org/10.33920/med-10-2404-08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053184","R0053184.pdf","paywalled","nonrandomized_study","Chuan Angel Lu","2024","Abstract 4135712: Mortality and Cardiovascular Complications Associated with Weight Loss Drugs among Breast Cancer Females Under Cardiotoxic Therapies: A Real-World Populational Study in the United States","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4135712","https://doi.org/10.1161/circ.150.suppl_1.4135712",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053192","R0053192.pdf","paywalled","nonrandomized_study","Rashid H. Abdel-Razeq","2024","S343 Risk of Diverticular Diseases in Diabetic Patients on Semaglutide, a GLP-1 Agonist. A Retrospective Cohort Study Utilizing Big Data and Propensity Score Matching","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001030740.02660.da","https://doi.org/10.14309/01.ajg.0001030740.02660.da",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053202","R0053202.pdf","paywalled","nonrandomized_study","Lei Lv","2024","774-P: Impact of Newer GLP-1 RAs on HbA1c in U.S. Adults with Type 2 Diabetes—A Population-Level Time-Series Analysis","Diabetes","American Diabetes Association","10.2337/db24-774-p","https://doi.org/10.2337/db24-774-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053211","R0053211.pdf","paywalled","nonrandomized_study","Julie M. Paik","2024","939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk","Diabetes","American Diabetes Association","10.2337/db24-939-p","https://doi.org/10.2337/db24-939-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053223","R0053223.pdf","paywalled","nonrandomized_study","Khushbu Patel","2024","S2103 Investigation of Combined Effects of Glucagon-Like Peptide-1 Receptor Agonists With Bariatric Procedures for Weight Loss: A Propensity-Matched Multi-Network Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037780.95877.ca","https://doi.org/10.14309/01.ajg.0001037780.95877.ca",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053228","R0053228.pdf","paywalled","nonrandomized_study","Andrew H. Ling","2024","Abstract 4141989: Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists remain significantly lower than those for other cardioprotective medications: Results from a retrospective, cross-sectional study at a large academic medical center","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4141989","https://doi.org/10.1161/circ.150.suppl_1.4141989",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053229","R0053229.pdf","paywalled","nonrandomized_study","Saqr Alsakarneh","2024","S1900 GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036968.88400.f3","https://doi.org/10.14309/01.ajg.0001036968.88400.f3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053312","R0053312.pdf","paywalled","nonrandomized_study","Rashid H. Abdel-Razeq","2024","S2108 A Comparative Study on Symptomatic Gallstones: The Impact of Rapid Weight Loss From Bariatric Surgery Versus GLP-1 Agonist Treatment","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037800.85212.fc","https://doi.org/10.14309/01.ajg.0001037800.85212.fc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053321","R0053321.pdf","paywalled","nonrandomized_study","Mouhand Mohamed","2024","S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032956.79643.e5","https://doi.org/10.14309/01.ajg.0001032956.79643.e5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053341","R0053341.pdf","paywalled","nonrandomized_study","Mohamed R. R.Hassanein","2024","808-P: Impact of Fasting on Adherence to Dosing Instructions and Efficacy of Oral Semaglutide during Ramadan in People with Type 2 Diabetes in Real-World Setting—O-SEMA-Fast Subanalysis","Diabetes","American Diabetes Association","10.2337/db24-808-p","https://doi.org/10.2337/db24-808-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053385","R0053385.pdf","paywalled","nonrandomized_study","Arunkumar Krishnan","2024","Su1604 COMPARATIVE EFFECTIVENESS OF GLP-1RAS, SGLT-2 INHIBITORS, AND OTHER GLUCOSE-LOWERING DRUGS ON ADVERSE CARDIOVASCULAR AND MORTALITY OUTCOMES AMONG PATIENTS WITH DIABETES, NAFLD, AND CARDIOVASCULAR DISEASES: A LARGE POPULATIONBASED COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(24)04273-2","https://doi.org/10.1016/s0016-5085(24)04273-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053442","R0053442.pdf","paywalled","nonrandomized_study","Mark Ayoub","2024","S222 GLP-1 RA Does Not Increase the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A U.S. Based Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001029256.50348.1e","https://doi.org/10.14309/01.ajg.0001029256.50348.1e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053492","R0053492.pdf","paywalled","nonrandomized_study","Aditya Sood","2024","S34 Therapeutic Advantages of GLP-1 Receptor Agonists: Survival and Insights from Large Retrospective Pancreatic Cancer Cohorts","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001028504.60450.b4","https://doi.org/10.14309/01.ajg.0001028504.60450.b4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053849","R0053849.pdf","paywalled","nonrandomized_study","Shizuka Kaneko","2024","12-PUB: Tirzepatide—Efficacy, Safety, and Satisfaction in Real World Type 2 Diabetes Application in Japan","Diabetes","American Diabetes Association","10.2337/db24-12-pub","https://doi.org/10.2337/db24-12-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053883","R0053883.pdf","paywalled","nonrandomized_study","Zryan Shwani","2024","S2102 Battle of the Weight-Loss Titans: Semaglutide vs Tirzepatide – Which is Safer?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001037776.05558.59","https://doi.org/10.14309/01.ajg.0001037776.05558.59",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054254","R0054254.pdf","paywalled","nonrandomized_study","Brennan W. Gioe","2024","S880 Risk of Aspiration for Patients on GLP-1 Agonists Undergoing EGD","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032888.40013.2e","https://doi.org/10.14309/01.ajg.0001032888.40013.2e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054300","R0054300.pdf","paywalled","nonrandomized_study","Brennan W. Gioe","2024","S879 Are ASA Guidelines Regarding the Holding of GLP-1 Agonists Before Endoscopy Enough to Reduce Aspiration Risk?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032884.63067.9b","https://doi.org/10.14309/01.ajg.0001032884.63067.9b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054534","R0054534.pdf","paywalled","nonrandomized_study","M Housam Nanah","2024","S1464 GLP-1 Agonists are Associated With Lower Rates of IBD-Related Complications in Patients With Elevated BMI Compared to Bariatric Surgery: A Nationwide Cohort Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001035224.59649.53","https://doi.org/10.14309/01.ajg.0001035224.59649.53",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054560","R0054560.pdf","paywalled","nonrandomized_study","Zihe Zheng","2024","Utilization of the Nonsteroidal Mineralocorticoid Receptor Antagonist (MRA) Finerenone with or without Previous Steroidal MRA","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024s37vndhj","https://doi.org/10.1681/asn.2024s37vndhj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054738","R0054738.pdf","paywalled","nonrandomized_study","Dr J George","2024","Practice Patterns of Usage of Glimepiride and Metformin FDC Along with Other OADs: A New Age Approach to Diabetes Management in Indians",null,null,"10.59793/1p03cf62","https://doi.org/10.59793/1p03cf62",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054785","R0054785.pdf","paywalled","nonrandomized_study","Sahib Singh","2024","S909 Adverse Events With Glucagon-Like Peptide-1 Receptor Agonists During Upper Endoscopy","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001033004.29882.4a","https://doi.org/10.14309/01.ajg.0001033004.29882.4a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055126","R0055126.pdf","paywalled","nonrandomized_study","Sudharshan Achalu","2024","S1692 Post-Transplant Exposure to GLP-1RA Therapy May Be Associated With Improved Survival in Liver Transplant Recipients With Type II Diabetes Mellitus at 5 Years Post-Transplant Or Longer","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001036136.50230.72","https://doi.org/10.14309/01.ajg.0001036136.50230.72",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055352","R0055352.pdf","paywalled","nonrandomized_study","Zihe Zheng","2024","Utilization of Guideline-Directed Medical Therapies in Finerenone Users","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024yzeyp6ds","https://doi.org/10.1681/asn.2024yzeyp6ds",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055487","R0055487.pdf","paywalled","nonrandomized_study","Mari Sugimoto","2024","Oral Biguanide Use Is Associated with Lower Incidence of AKI and Mortality in COVID-19 Patients: A Nationwide Study Using the Diagnosis Procedure Combination System in Japan","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20245k7kzb8j","https://doi.org/10.1681/asn.20245k7kzb8j",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055596","R0055596.pdf","paywalled","nonrandomized_study","Ying Lü","2024","735-P: Association between Glucagon-Like Peptide 1 Receptor Agonists and Risk of Depression in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study","Diabetes","American Diabetes Association","10.2337/db24-735-p","https://doi.org/10.2337/db24-735-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055646","R0055646.pdf","paywalled","nonrandomized_study","Mark Ayoub","2024","S727 GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Esophageal Cancer: A National Analysis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001032276.20421.fe","https://doi.org/10.14309/01.ajg.0001032276.20421.fe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056347","R0056347.pdf","paywalled","nonrandomized_study","Sarwat Anjum","2024","Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes","History of Medicine/ru",null,"10.17720/h7ycmf16","https://doi.org/10.17720/h7ycmf16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056448","R0056448.pdf","paywalled","nonrandomized_study","Dalal Mutheb Alotybi, Mubarak Jaber Al Saleh, Ali Mahdi Al-Yami, Rana Ali Alzahrani, Mashael Alsulami, Khloud Mohammad Alqahtani, Zinab Ahmed Walis","2024","Preparedness Of Emergency Care Tactician Coordination For Complications Of Diabetes Associated Weight-Loss Pharmacotherapy: Roles Of Medical Secretarial Coordination In Nursing Practice, And X-Ray Imaging","The Review of Diabetic Studies",null,"10.70082/8jp0e927","https://doi.org/10.70082/8jp0e927",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056984","R0056984.pdf","paywalled","nonrandomized_study","Paz-Ibarra J","2024","Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2024.2377687","https://doi.org/10.1080/17446651.2024.2377687","38975697","https://pubmed.ncbi.nlm.nih.gov/38975697/",null,null],["4","R0004100","R0004100.pdf","paywalled","nonrandomized_study","Thomas AM","2023","Glucagon-like peptide-1 receptor agonists use for type 2 diabetes mellitus in end-stage renal disease.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2023.06.003","https://doi.org/10.1016/j.japh.2023.06.003","37301509","https://pubmed.ncbi.nlm.nih.gov/37301509/",null,null],["4","R0005196","R0005196.pdf","paywalled","nonrandomized_study","Lu W","2023","An updated patent review of GLP-1 receptor agonists (2020-present).","Expert opinion on therapeutic patents","Informa UK Limited","10.1080/13543776.2023.2274905","https://doi.org/10.1080/13543776.2023.2274905","37870067","https://pubmed.ncbi.nlm.nih.gov/37870067/",null,null],["4","R0005521","R0005521.pdf","paywalled","nonrandomized_study","Yang CT","2023","Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110625","https://doi.org/10.1016/j.diabres.2023.110625","36924833","https://pubmed.ncbi.nlm.nih.gov/36924833/",null,null],["4","R0006075","R0006075.pdf","paywalled","nonrandomized_study","Lee J","2023","Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2023.07.006","https://doi.org/10.1016/j.pcd.2023.07.006","37541792","https://pubmed.ncbi.nlm.nih.gov/37541792/",null,null],["4","R0006116","R0006116.pdf","paywalled","nonrandomized_study","Edwards K","2023","Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgac618","https://doi.org/10.1210/clinem/dgac618","36268825","https://pubmed.ncbi.nlm.nih.gov/36268825/",null,null],["4","R0006349","R0006349.pdf","paywalled","nonrandomized_study","Meng Y","2023","Global trends and focuses of GLP-1RA in renal disease: a bibliometric analysis and visualization from 2005 to 2022.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-023-02575-6","https://doi.org/10.1007/s00210-023-02575-6","37389601","https://pubmed.ncbi.nlm.nih.gov/37389601/",null,null],["4","R0006412","R0006412.pdf","paywalled","nonrandomized_study","Tran V","2023","Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900221087933","https://doi.org/10.1177/08971900221087933","35427194","https://pubmed.ncbi.nlm.nih.gov/35427194/",null,null],["4","R0006493","R0006493.pdf","paywalled","nonrandomized_study","San K","2023","Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy.","Southern medical journal","Southern Medical Association","10.14423/smj.0000000000001511","https://doi.org/10.14423/smj.0000000000001511","36724541","https://pubmed.ncbi.nlm.nih.gov/36724541/",null,null],["4","R0006743","R0006743.pdf","paywalled","nonrandomized_study","Rana KB","2023","Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.","Journal of pharmacy practice","SAGE Publications","10.1177/08971900221087127","https://doi.org/10.1177/08971900221087127","35414304","https://pubmed.ncbi.nlm.nih.gov/35414304/",null,null],["4","R0006779","R0006779.pdf","paywalled","nonrandomized_study","Valentine WJ","2023","Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14979","https://doi.org/10.1111/dom.14979","36655340","https://pubmed.ncbi.nlm.nih.gov/36655340/",null,null],["4","R0007377","R0007377.pdf","paywalled","nonrandomized_study","Falcetta P","2023","De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-022-01974-0","https://doi.org/10.1007/s00592-022-01974-0","36166172","https://pubmed.ncbi.nlm.nih.gov/36166172/",null,null],["4","R0007541","R0007541.pdf","paywalled","nonrandomized_study","Liss DT","2023","Treatment modification after initiating second-line medication for type 2 diabetes.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2023.89466","https://doi.org/10.37765/ajmc.2023.89466","38170483","https://pubmed.ncbi.nlm.nih.gov/38170483/",null,null],["4","R0007586","R0007586.pdf","paywalled","nonrandomized_study","Kalas MA","2023","Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.1136/jim-2022-002480","https://doi.org/10.1136/jim-2022-002480","36198436","https://pubmed.ncbi.nlm.nih.gov/36198436/",null,null],["4","R0007925","R0007925.pdf","paywalled","nonrandomized_study","Crocetta N","2023","Evaluation of a pharmacist's impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting.","Family practice","Oxford University Press (OUP)","10.1093/fampra/cmac110","https://doi.org/10.1093/fampra/cmac110","36200484","https://pubmed.ncbi.nlm.nih.gov/36200484/",null,null],["4","R0008039","R0008039.pdf","paywalled","nonrandomized_study","Patil T","2023","Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2023.06.016","https://doi.org/10.1016/j.amjcard.2023.06.016","37393731","https://pubmed.ncbi.nlm.nih.gov/37393731/",null,null],["4","R0008377","R0008377.pdf","paywalled","nonrandomized_study","Wang P","2023","Total parenteral nutrition impairs glucose metabolism by modifying the gut microbiome.","Nature metabolism","Springer Science and Business Media LLC","10.1038/s42255-023-00744-8","https://doi.org/10.1038/s42255-023-00744-8","36782071","https://pubmed.ncbi.nlm.nih.gov/36782071/",null,null],["4","R0008966","R0008966.pdf","paywalled","nonrandomized_study","Keegan GL","2023","The outcome of frailty in older people with diabetes as a function of glycaemic control and hypoglycaemic therapy: a review.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2023.2239907","https://doi.org/10.1080/17446651.2023.2239907","37489773","https://pubmed.ncbi.nlm.nih.gov/37489773/",null,null],["4","R0009015","R0009015.pdf","paywalled","nonrandomized_study","Chen Y","2023","Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2023.2278708","https://doi.org/10.1080/14740338.2023.2278708","37929311","https://pubmed.ncbi.nlm.nih.gov/37929311/",null,null],["4","R0009515","R0009515.pdf","paywalled","nonrandomized_study","Silveira SQ","2023","Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.","Journal of clinical anesthesia","Elsevier BV","10.1016/j.jclinane.2023.111091","https://doi.org/10.1016/j.jclinane.2023.111091","36870274","https://pubmed.ncbi.nlm.nih.gov/36870274/",null,null],["4","R0009944","R0009944.pdf","paywalled","nonrandomized_study","Arnold SV","2023","Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15032","https://doi.org/10.1111/dom.15032","36843558","https://pubmed.ncbi.nlm.nih.gov/36843558/",null,null],["4","R0010481","R0010481.pdf","paywalled","nonrandomized_study","Preston W","2023","GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2311840","https://doi.org/10.1056/nejmc2311840","38091541","https://pubmed.ncbi.nlm.nih.gov/38091541/",null,null],["4","R0010613","R0010613.pdf","paywalled","nonrandomized_study","Chen TS","2023","Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus.","Journal of nephrology","Oxford University Press (OUP)","10.1007/s40620-022-01522-7","https://doi.org/10.1007/s40620-022-01522-7","36534314","https://pubmed.ncbi.nlm.nih.gov/36534314/",null,null],["4","R0012080","R0012080.pdf","paywalled","nonrandomized_study","Triggiani D","2023","Right Ventricular Dysfunction and Exercise Impairment in Patients with Heart Failure, Insulin Resistance, and Diabetes Mellitus: Insights from the T.O.S.CA. Registry (Cardiovascular Diabetology 2022).","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871530323666230227113252","https://doi.org/10.2174/1871530323666230227113252","36843372","https://pubmed.ncbi.nlm.nih.gov/36843372/",null,null],["4","R0012512","R0012512.pdf","paywalled","nonrandomized_study","Ilanga M","2023","Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-023-10387-1","https://doi.org/10.1007/s00464-023-10387-1","37700013","https://pubmed.ncbi.nlm.nih.gov/37700013/",null,null],["4","R0012737","R0012737.pdf","paywalled","nonrandomized_study","Bezin J","2023","GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.","Diabetes care","American Diabetes Association","10.2337/dc22-1148","https://doi.org/10.2337/dc22-1148","36356111","https://pubmed.ncbi.nlm.nih.gov/36356111/",null,null],["4","R0014667","R0014667.pdf","paywalled","nonrandomized_study","Gómez Lumbreras A","2023","Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2023.03.012","https://doi.org/10.1016/j.numecd.2023.03.012","37088648","https://pubmed.ncbi.nlm.nih.gov/37088648/",null,null],["4","R0015896","R0015896.pdf","paywalled","nonrandomized_study","Menekşe B","2023","Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2022.0088","https://doi.org/10.1089/met.2022.0088","36944132","https://pubmed.ncbi.nlm.nih.gov/36944132/",null,null],["4","R0017356","R0017356.pdf","paywalled","nonrandomized_study","Wai KM","2023","Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression.","Ophthalmic surgery, lasers & imaging retina","SLACK, Inc.","10.3928/23258160-20230217-02","https://doi.org/10.3928/23258160-20230217-02","36944068","https://pubmed.ncbi.nlm.nih.gov/36944068/",null,null],["4","R0017813","R0017813.pdf","paywalled","nonrandomized_study","Barth SD","2023","Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-1927-4454","https://doi.org/10.1055/a-1927-4454","35981560","https://pubmed.ncbi.nlm.nih.gov/35981560/",null,null],["4","R0017956","R0017956.pdf","paywalled","nonrandomized_study","Meyer J","2023","The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280221107381","https://doi.org/10.1177/10600280221107381","35778801","https://pubmed.ncbi.nlm.nih.gov/35778801/",null,null],["4","R0017993","R0017993.pdf","paywalled","nonrandomized_study","Arnold SV","2023","Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.","American heart journal","Elsevier BV","10.1016/j.ahj.2023.05.002","https://doi.org/10.1016/j.ahj.2023.05.002","37164146","https://pubmed.ncbi.nlm.nih.gov/37164146/",null,null],["4","R0019774","R0019774.pdf","paywalled","nonrandomized_study","Foresta A","2023","Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110742","https://doi.org/10.1016/j.diabres.2023.110742","37270072","https://pubmed.ncbi.nlm.nih.gov/37270072/",null,null],["4","R0020352","R0020352.pdf","paywalled","nonrandomized_study","Grajower MM","2023","Management of Type 2 Diabetes Mellitus in the Very Elderly: One Practice's Experience.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2023.03.271","https://doi.org/10.1016/j.eprac.2023.03.271","36965656","https://pubmed.ncbi.nlm.nih.gov/36965656/",null,null],["4","R0020829","R0020829.pdf","paywalled","nonrandomized_study","Cetiner S","2023","A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202309_33796","https://doi.org/10.26355/eurrev_202309_33796","37782186","https://pubmed.ncbi.nlm.nih.gov/37782186/",null,null],["4","R0020973","R0020973.pdf","paywalled","nonrandomized_study","Valladales-Restrepo LF","2023","Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2178900","https://doi.org/10.1080/14656566.2023.2178900","36755412","https://pubmed.ncbi.nlm.nih.gov/36755412/",null,null],["4","R0021044","R0021044.pdf","paywalled","nonrandomized_study","Magruder ML","2023","Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2023.05.071","https://doi.org/10.1016/j.arth.2023.05.071","37279843","https://pubmed.ncbi.nlm.nih.gov/37279843/",null,null],["4","R0021190","R0021190.pdf","paywalled","nonrandomized_study","Altunal Ç","2023","Intragastric injection botulinum toxin A for obesity management with or without liraglutide.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202304_32128","https://doi.org/10.26355/eurrev_202304_32128","37140305","https://pubmed.ncbi.nlm.nih.gov/37140305/",null,null],["4","R0021799","R0021799.pdf","paywalled","nonrandomized_study","Xiang J","2023","Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202310_34169","https://doi.org/10.26355/eurrev_202310_34169","37916360","https://pubmed.ncbi.nlm.nih.gov/37916360/",null,null],["4","R0021912","R0021912.pdf","paywalled","nonrandomized_study","Khanmohammadi S","2023","NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102788","https://doi.org/10.1016/j.dsx.2023.102788","37302383","https://pubmed.ncbi.nlm.nih.gov/37302383/",null,null],["4","R0022780","R0022780.pdf","paywalled","nonrandomized_study","Carretero-Gómez J","2023","Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2022.12.001","https://doi.org/10.1016/j.rceng.2022.12.001","36549643","https://pubmed.ncbi.nlm.nih.gov/36549643/",null,null],["4","R0024172","R0024172.pdf","paywalled","nonrandomized_study","Geier A","2023","Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.","Zeitschrift fur Gastroenterologie","Georg Thieme Verlag KG","10.1055/a-1986-7676","https://doi.org/10.1055/a-1986-7676","36623544","https://pubmed.ncbi.nlm.nih.gov/36623544/",null,null],["4","R0024224","R0024224.pdf","paywalled","nonrandomized_study","Wang GH","2023","Modifiable statin characteristics associated with potential statin-related prescribing cascades.","Pharmacotherapy","Wiley","10.1002/phar.2883","https://doi.org/10.1002/phar.2883","37771303","https://pubmed.ncbi.nlm.nih.gov/37771303/",null,null],["4","R0024830","R0024830.pdf","paywalled","nonrandomized_study","Biancalana E","2023","Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-022-01969-2","https://doi.org/10.1007/s40618-022-01969-2","36469293","https://pubmed.ncbi.nlm.nih.gov/36469293/",null,null],["4","R0025527","R0025527.pdf","paywalled","nonrandomized_study","Scierka LE","2023","Obesity prevalence and variability in management practices for patients with symptomatic peripheral artery disease.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2023.05.002","https://doi.org/10.1016/j.orcp.2023.05.002","37225553","https://pubmed.ncbi.nlm.nih.gov/37225553/",null,null],["4","R0025762","R0025762.pdf","paywalled","nonrandomized_study","Wang W","2023","Data-driven subgroups of newly diagnosed type 2 diabetes and the relationship with cardiovascular diseases at genetic and clinical levels in Chinese adults.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102850","https://doi.org/10.1016/j.dsx.2023.102850","37683311","https://pubmed.ncbi.nlm.nih.gov/37683311/",null,null],["4","R0026176","R0026176.pdf","paywalled","nonrandomized_study","Garvey WT","2023","Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program.","Population health management","SAGE Publications","10.1089/pop.2022.0227","https://doi.org/10.1089/pop.2022.0227","36735596","https://pubmed.ncbi.nlm.nih.gov/36735596/",null,null],["4","R0026308","R0026308.pdf","paywalled","nonrandomized_study","Jirapinyo P","2023","Combining transoral outlet reduction with pharmacotherapy yields similar 1-year efficacy with improved safety compared with surgical revision for weight regain after Roux-en-Y gastric bypass (with videos).","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2023.04.2092","https://doi.org/10.1016/j.gie.2023.04.2092","37150416","https://pubmed.ncbi.nlm.nih.gov/37150416/",null,null],["4","R0026381","R0026381.pdf","paywalled","nonrandomized_study","Agarwal K","2023","Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs.","CNS & neurological disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871527321666220622162622","https://doi.org/10.2174/1871527321666220622162622","35733313","https://pubmed.ncbi.nlm.nih.gov/35733313/",null,null],["4","R0026690","R0026690.pdf","paywalled","nonrandomized_study","Sarayani A","2023","Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.","Annals of internal medicine","American College of Physicians","10.7326/m22-1743","https://doi.org/10.7326/m22-1743","36940443","https://pubmed.ncbi.nlm.nih.gov/36940443/",null,null],["4","R0028945","R0028945.pdf","paywalled","nonrandomized_study","Helvaci N","2023","Current and emerging drug treatment strategies for polycystic ovary syndrome.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2022.2108702","https://doi.org/10.1080/14656566.2022.2108702","35912829","https://pubmed.ncbi.nlm.nih.gov/35912829/",null,null],["4","R0029701","R0029701.pdf","paywalled","nonrandomized_study","Brodosi L","2023","Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2208746","https://doi.org/10.1080/14656566.2023.2208746","37114459","https://pubmed.ncbi.nlm.nih.gov/37114459/",null,null],["4","R0030152","R0030152.pdf","paywalled","nonrandomized_study","Jarab AS","2023","Glycemic control and its associated factors in hypertensive patients with type 2 diabetes.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202306_32816","https://doi.org/10.26355/eurrev_202306_32816","37401314","https://pubmed.ncbi.nlm.nih.gov/37401314/",null,null],["4","R0030267","R0030267.pdf","paywalled","nonrandomized_study","Lundholm MD","2023","Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2023.108405","https://doi.org/10.1016/j.jdiacomp.2023.108405","36669324","https://pubmed.ncbi.nlm.nih.gov/36669324/",null,null],["4","R0030289","R0030289.pdf","paywalled","nonrandomized_study","Starup-Linde J","2023","Effect of incretins on skeletal health.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000813","https://doi.org/10.1097/med.0000000000000813","37334507","https://pubmed.ncbi.nlm.nih.gov/37334507/",null,null],["4","R0032116","R0032116.pdf","paywalled","nonrandomized_study","Nicola Jones","2023","Top science stories of 2023","Knowable Magazine","Annual Reviews","10.1146/knowable-122123-1","https://doi.org/10.1146/knowable-122123-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032614","R0032614.pdf","paywalled","nonrandomized_study","ANNA FERRULLI","2023","1717-P: Weight-Loss Differences with SGLT2 inhibitors, GLP-1 Receptor Agonists, and Repetitive Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db23-1717-p","https://doi.org/10.2337/db23-1717-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032757","R0032757.pdf","paywalled","nonrandomized_study","Lily Y Deng","2023","221-OR: Retrospective Review of Genetic Mutations and Treatments in Patients with Monogenic Diabetes of the Youth (MODY)","Diabetes","American Diabetes Association","10.2337/db23-221-or","https://doi.org/10.2337/db23-221-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032793","R0032793.pdf","paywalled","nonrandomized_study","Manuel Machado","2023","13-LB: Treatment Patterns of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease in Colombia","Diabetes","American Diabetes Association","10.2337/db23-13-lb","https://doi.org/10.2337/db23-13-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032871","R0032871.pdf","paywalled","nonrandomized_study","MASAO TOYODA","2023","893-P: Relation between Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists and Renal Functions among Japanese Diabetics","Diabetes","American Diabetes Association","10.2337/db23-893-p","https://doi.org/10.2337/db23-893-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032874","R0032874.pdf","paywalled","nonrandomized_study","Salman Imam","2023","313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy","Diabetes","American Diabetes Association","10.2337/db23-313-or","https://doi.org/10.2337/db23-313-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032972","R0032972.pdf","paywalled","nonrandomized_study","Kazuo Kobayashi","2023","892-P: Influence of Preceding Medications on the Renal Outcomes of Japanese Diabetics Treated with SGLT2 Inhibitors and GLP-1 Receptor Agonists","Diabetes","American Diabetes Association","10.2337/db23-892-p","https://doi.org/10.2337/db23-892-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032988","R0032988.pdf","paywalled","nonrandomized_study","Tiansheng Wang","2023","1802-PUB: Liraglutide as a Potential Drug Repurposing Candidate for Alzheimer’s Disease and Related Dementia—Real-World Evidence","Diabetes","American Diabetes Association","10.2337/db23-1802-pub","https://doi.org/10.2337/db23-1802-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033023","R0033023.pdf","paywalled","nonrandomized_study","Igal Iancu","2023","537-P: Virtual Patient Simulation Assesses the Levels of Competency and Improves Performance of Advance Practice Providers in the Field of Diabetes and Cardiometabolic Medicine","Diabetes","American Diabetes Association","10.2337/db23-537-p","https://doi.org/10.2337/db23-537-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033276","R0033276.pdf","paywalled","nonrandomized_study","Leon Gussow","2023","The Myth that Metronidazole and Alcohol Cause a Disulfiram-Like Reaction","Emergency Medicine News","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.eem.0000990104.46586.c8","https://doi.org/10.1097/01.eem.0000990104.46586.c8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034047","R0034047.pdf","paywalled","nonrandomized_study","American Medical Association 2023","2023","Sustained Medical Weight Management Program Leads to Increased Weight Loss and Arthroplasty Surgery","Underline Science Inc.",null,"10.48448/7cz0-fx71","https://doi.org/10.48448/7cz0-fx71",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034267","R0034267.pdf","paywalled","nonrandomized_study","Garcia Juan Carlos Ferrer","2023","Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.90.ep437","https://doi.org/10.1530/endoabs.90.ep437",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034387","R0034387.pdf","paywalled","nonrandomized_study","Michael Batavanis","2023","Retrospective case review of patients treated with semaglutide for weight management","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.94.p225","https://doi.org/10.1530/endoabs.94.p225",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034424","R0034424.pdf","paywalled","nonrandomized_study","Aisha Shaikh","2023","Safety Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Diabetes Mellitus and Cancer","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s129a","https://doi.org/10.1681/asn.20233411s129a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034527","R0034527.pdf","paywalled","nonrandomized_study","Rimda Wanchoo","2023","GLP-1 Agonists-Associated Kidney Toxicities","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1427a","https://doi.org/10.1681/asn.20233411s1427a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034719","R0034719.pdf","paywalled","nonrandomized_study","Kazuo Kobayashi","2023","PS-C31-5: COMPARISON OF THE BLOOD PRESSURE MANAGEMENT BETWEEN SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000917692.80051.4a","https://doi.org/10.1097/01.hjh.0000917692.80051.4a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035196","R0035196.pdf","paywalled","nonrandomized_study","Sonja M. Reichert","2023","CLINICAL OUTCOMES ASSOCIATED WITH THE USE OF ORAL SEMAGLUTIDE IN AN ADULT POPULATION WITH TYPE 2 DIABETES IN CANADA: A PROSPECTIVE REAL-WORLD STUDY (PIONEER REAL CANADA)","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2023.10.189","https://doi.org/10.1016/j.jcjd.2023.10.189",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036028","R0036028.pdf","paywalled","nonrandomized_study","Anne Lautenbach","2023","Sustained Weight Loss with Semaglutide once-weekly in Patients without Type 2 Diabetes and Postbariatric Treatment Failure","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767984","https://doi.org/10.1055/s-0043-1767984",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036600","R0036600.pdf","paywalled","nonrandomized_study","Spencer, Lewis","2023","Investigation of the Metabolic Effects of Liraglutide on Patients with Overweight and Obesity","UDORA",null,"10.48773/q02yx","https://doi.org/10.48773/q02yx",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036629","R0036629.pdf","paywalled","nonrandomized_study","Hicks, Blánaid","2023","Risk of thyroid cancer with use of glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes in Denmark: Population-based active comparator, new user cohort study","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/54svt","https://doi.org/10.17605/osf.io/54svt",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036705","R0036705.pdf","paywalled","nonrandomized_study","Τσιαμπαλή, Χαρά Γεωργίου","2023","The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.351698","https://doi.org/10.26262/heal.auth.ir.351698",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036939","R0036939.pdf","paywalled","nonrandomized_study","Teixeira, M. J.","2023","Clinical and toxicological effects of GLP-1 agonists","Science Letters",null,"10.48797/sl.2023.97","https://doi.org/10.48797/sl.2023.97",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037091","R0037091.pdf","paywalled","nonrandomized_study","RICCARDO CANDIDO","2023","1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study","Diabetes","American Diabetes Association","10.2337/db23-1804-pub","https://doi.org/10.2337/db23-1804-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037105","R0037105.pdf","paywalled","nonrandomized_study","Laurent Azoulay","2023","268-OR: The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-268-or","https://doi.org/10.2337/db23-268-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037107","R0037107.pdf","paywalled","nonrandomized_study","Raffaele Napoli","2023","779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study","Diabetes","American Diabetes Association","10.2337/db23-779-p","https://doi.org/10.2337/db23-779-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037226","R0037226.pdf","paywalled","nonrandomized_study","Anne Lautenbach","2023","369-OR: Continued Weight Loss with Semaglutide Once-Weekly in Patients without Type 2 Diabetes and Postbariatric Treatment Failure","Diabetes","American Diabetes Association","10.2337/db23-369-or","https://doi.org/10.2337/db23-369-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037352","R0037352.pdf","paywalled","nonrandomized_study","Kim Boyd","2023","Abstract 15452: Using a Commercial Virtual Health Platform to Effectively Treat Obesity and Improve Cardiometabolic Risk Factors at Scale","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15452","https://doi.org/10.1161/circ.148.suppl_1.15452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037365","R0037365.pdf","paywalled","nonrandomized_study","Tetsuya Babazono","2023","Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.24488/twmuj.2023005","https://doi.org/10.24488/twmuj.2023005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037406","R0037406.pdf","paywalled","nonrandomized_study","of, Adis journals on behalf","2023","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study","Figshare",null,"10.6084/m9.figshare.22717597","https://doi.org/10.6084/m9.figshare.22717597",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037468","R0037468.pdf","paywalled","nonrandomized_study","Rahbek, Martin Torp","2023","Hypereosinophilia following initiation of glucagon-like peptide 1 receptor agonists: a Danish population-based register study","Open Science Framework",null,"10.17605/osf.io/sabzk","https://doi.org/10.17605/osf.io/sabzk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037490","R0037490.pdf","paywalled","nonrandomized_study","Ridwan Alam","2023","MP10-04 USE OF SODIUM-GLUCOSE COTRANSPORTER (SGLT2) INHIBITORS IN DIABETIC STONE FORMERS IS ASSOCIATED WITH A REDUCED RISK OF FUTURE STONE EVENTS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/ju.0000000000003225.04","https://doi.org/10.1097/ju.0000000000003225.04",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037509","R0037509.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of","2023","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase-4 Inhibitor","Figshare",null,"10.6084/m9.figshare.24610002.v1","https://doi.org/10.6084/m9.figshare.24610002.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037564","R0037564.pdf","paywalled","nonrandomized_study","R Chakraborty","2023","The safety and efficacy of GLP-1 receptor agonists in kidney transplant recipients with diabetes: A single-centre retrospective analysis",null,null,"10.13140/rg.2.2.18923.72482","https://doi.org/10.13140/rg.2.2.18923.72482",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037663","R0037663.pdf","paywalled","nonrandomized_study","Shu-Yen Emily Chan","2023","S321 Lower Incidence of Gastrointestinal Cancers in Sodium Glucose Co-Transporter-2 Inhibitor-Treated Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study in the United States","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000950924.49214.01","https://doi.org/10.14309/01.ajg.0000950924.49214.01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037964","R0037964.pdf","paywalled","nonrandomized_study","Jacob E. Pruett","2023","Glucagon-like peptide-1 receptor agonists and cardiometabolic risk factors in Polycystic Ovary Syndrome: role of race/ethnicity","Physiology","American Physiological Society","10.1152/physiol.2023.38.s1.5714775","https://doi.org/10.1152/physiol.2023.38.s1.5714775",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037980","R0037980.pdf","paywalled","nonrandomized_study","RICCARDO CANDIDO","2023","84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study","Diabetes","American Diabetes Association","10.2337/db23-84-lb","https://doi.org/10.2337/db23-84-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037984","R0037984.pdf","paywalled","nonrandomized_study","Robert J. Stratta","2023","Pretransplant C-peptide Levels and Pancreas Transplant Outcomes: Risk and Reward","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000004566","https://doi.org/10.1097/tp.0000000000004566","37097983","https://pubmed.ncbi.nlm.nih.gov/37097983/",null,null],["4","R0038039","R0038039.pdf","paywalled","nonrandomized_study","Kim Boyd","2023","1716-P: Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale","Diabetes","American Diabetes Association","10.2337/db23-1716-p","https://doi.org/10.2337/db23-1716-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038060","R0038060.pdf","paywalled","nonrandomized_study","Přáda, Eva","2023","Self-assembly and aggregation of glucagon-like peptide 1 and its analogues","Apollo (University of Cambridge)",null,"10.17863/cam.98055","https://doi.org/10.17863/cam.98055",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038075","R0038075.pdf","paywalled","nonrandomized_study","Liming Chen","2023","1437-P: Treatment Pattern and Glycemic Control of Adults with T2DM in Northern China","Diabetes","American Diabetes Association","10.2337/db23-1437-p","https://doi.org/10.2337/db23-1437-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038203","R0038203.pdf","paywalled","nonrandomized_study","Jin Gyoung Jung","2023","781-P: Sustained-Release Formulation Development and Preclinical Evaluations of Monthly or Bimonthly Injectable Semaglutide and Tirzepatide","Diabetes","American Diabetes Association","10.2337/db23-781-p","https://doi.org/10.2337/db23-781-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038402","R0038402.pdf","paywalled","nonrandomized_study","Sato, Tetsuhiko","2023","Figure 1S.pptx","Figshare",null,"10.6084/m9.figshare.22122329","https://doi.org/10.6084/m9.figshare.22122329",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038630","R0038630.pdf","paywalled","nonrandomized_study","Sato, Tetsuhiko","2023","Figure 1S.pptx","Figshare",null,"10.6084/m9.figshare.22122329.v1","https://doi.org/10.6084/m9.figshare.22122329.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038950","R0038950.pdf","paywalled","nonrandomized_study","Luis C. Ortiz","2023","895-P: Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate (ß-OHB)—Lack of Effect of Concomitant Insulin, GLP-1 Agonist, or Pioglitazone Therapy","Diabetes","American Diabetes Association","10.2337/db23-895-p","https://doi.org/10.2337/db23-895-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039775","R0039775.pdf","paywalled","nonrandomized_study","Carlos Mañero Rodríguez","2023","THE INFLUENCE OF GLP-1RAS (ORAL SEMAGLUTIDE) ON TENSIONAL CONTROL IN DIABETIC PATIENTS WITH CHRONIC RENAL DISEASE","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000941684.14153.09","https://doi.org/10.1097/01.hjh.0000941684.14153.09",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039794","R0039794.pdf","paywalled","nonrandomized_study","Chi Nguyen","2023","103-LB: Impact of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in COVID-19 Patients with Preexisting Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD)","Diabetes","American Diabetes Association","10.2337/db23-103-lb","https://doi.org/10.2337/db23-103-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039837","R0039837.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of:","2023","Real-world Use of Oral Semaglutide in Adults with Type 2 Diabetes: the PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","Figshare",null,"10.6084/m9.figshare.24807525.v1","https://doi.org/10.6084/m9.figshare.24807525.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041170","R0041170.pdf","paywalled","nonrandomized_study","O. Vasiliu","2023","Management of diabetes mellitus in patients with severe mental disorders using new generation hypoglycemic drugs- A review of the literature","PubMed Central",null,"10.1192/j.eurpsy.2023.1226","https://doi.org/10.1192/j.eurpsy.2023.1226",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041321","R0041321.pdf","paywalled","nonrandomized_study","Vik Shirvaikar","2023","Targeting relative risk heterogeneity with causal forests","arXiv (Cornell University)",null,"10.48550/arxiv.2309.15793","https://doi.org/10.48550/arxiv.2309.15793",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041357","R0041357.pdf","paywalled","nonrandomized_study","Lin, Yi-Hsuan","2023","SGLT2 inhibitors reduce the risk of hospitalization for heart failure and amputation rate compared with incretin-based therapy in patients with diabetic foot disease: A nationwide population-based study","Data Archiving and Networked Services (DANS)",null,"10.17632/jdv9bjtnxw.1","https://doi.org/10.17632/jdv9bjtnxw.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041398","R0041398.pdf","paywalled","nonrandomized_study","Zheng, Deqiang","2023","Additional file 1 of Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies","Figshare",null,"10.6084/m9.figshare.22598999.v1","https://doi.org/10.6084/m9.figshare.22598999.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041700","R0041700.pdf","paywalled","nonrandomized_study",null,"2023","A320 A Retrospective Single Center Multi Surgeon Experience on the Adjuvant Use of Semaglutide as an AOM in post MBS-Patients","Surgery for Obesity and Related Diseases","Elsevier BV","10.1016/j.soard.2023.04.296","https://doi.org/10.1016/j.soard.2023.04.296",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041782","R0041782.pdf","paywalled","nonrandomized_study","Manuella Constantino","2023","IDF2022-0694 Pre-genetic screening and the use of GLP-1 RA and SGLT-2i in monogenic diabetes: A real-world audit-based study","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2023.110453","https://doi.org/10.1016/j.diabres.2023.110453",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041813","R0041813.pdf","paywalled","nonrandomized_study","JUNG-IM SHIN","2023","IDF2022-0475 GLP-1 receptor agonists and the risk of atrial fibrillation: a real-world evidence","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2023.110309","https://doi.org/10.1016/j.diabres.2023.110309",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042136","R0042136.pdf","paywalled","nonrandomized_study","Lund, Christian","2023","Risk of incident and recurrent nephrolithiasis following initiation of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists among patients with type 2 diabetes in Denmark, Norway, the Netherlands, the United Kingdom and Taiwan",null,null,"10.17605/osf.io/sg4r9","https://doi.org/10.17605/osf.io/sg4r9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042153","R0042153.pdf","paywalled","nonrandomized_study","Howse, Patricia Marie","2023","Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment","Memorial University Research Repository (Memorial University)",null,"10.48336/hems-sk50","https://doi.org/10.48336/hems-sk50",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044850","R0044850.pdf","paywalled","nonrandomized_study","RUTH SIM","2023","Cardiorenal outcomes of the recently approved antidiabetic drugs in people with Type 2 Diabetes Mellitus in Malaysia: Clinical and economic evaluation","Monash University",null,"10.26180/24038802","https://doi.org/10.26180/24038802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045001","R0045001.pdf","paywalled","nonrandomized_study","Helen Tesfaye","2023","870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Diabetes","American Diabetes Association","10.2337/db23-870-p","https://doi.org/10.2337/db23-870-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045204","R0045204.pdf","paywalled","nonrandomized_study","Aida Rebiha","2023","Safety and efficacy of glucagon-like peptide-1 receptor agonists and sodium- glucose co-transporter-2 inhibitors compared with the standard of care in a cohort of liver transplanted patients: a retrospective study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)01218-7","https://doi.org/10.1016/s0168-8278(23)01218-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045617","R0045617.pdf","paywalled","nonrandomized_study","Francisco Javier Martínez-Martín","2023","PS-C17-9: RELEVANT BLOOD PRESSURE REDUCTION WITH ORAL SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY, INDEPENDENT OF PREVIOUS ANTIHYPERTENSIVE TREATMENT","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000916736.77778.3d","https://doi.org/10.1097/01.hjh.0000916736.77778.3d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045672","R0045672.pdf","paywalled","nonrandomized_study","JOCHEN SEUFERT","2023","789-P: Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Prior Insulin Use","Diabetes","American Diabetes Association","10.2337/db23-789-p","https://doi.org/10.2337/db23-789-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045705","R0045705.pdf","paywalled","nonrandomized_study","Vibhu Chittajallu","2023","Mo1922 INCIDENCE PROPORTION OF THYROID CANCER WITH GLP-1 RECEPTOR AGONISTS: A MULTICENTER POPULATION-BASED STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)03175-x","https://doi.org/10.1016/s0016-5085(23)03175-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046257","R0046257.pdf","paywalled","nonrandomized_study","Francisco Javier Martínez-Martín","2023","PS-C17-10: ORAL SEMAGLUTIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES, OBESITY AND HYPERTENSION, WITH PARTIAL DEPENDENCE ON BLOOD PRESSURE CONTROL","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000916740.08960.77","https://doi.org/10.1097/01.hjh.0000916740.08960.77",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046273","R0046273.pdf","paywalled","nonrandomized_study","F N U Sidra","2023","796-P: Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)","Diabetes","American Diabetes Association","10.2337/db23-796-p","https://doi.org/10.2337/db23-796-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046437","R0046437.pdf","paywalled","nonrandomized_study","THOMAS S.J. CRABTREE","2023","787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit","Diabetes","American Diabetes Association","10.2337/db23-787-p","https://doi.org/10.2337/db23-787-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046705","R0046705.pdf","paywalled","nonrandomized_study","PHYO T. HTOO","2023","1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study","Diabetes","American Diabetes Association","10.2337/db23-1227-p","https://doi.org/10.2337/db23-1227-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046711","R0046711.pdf","paywalled","nonrandomized_study","Alexandra Louise Møller","2023","425-P: Renin-Angiotensin System Inhibition in Combination with Glucagon-Like Peptide 1 Receptor Agonist Treatment Improve Levels of a Kidney Fibrosis Biomarker in Persons with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-425-p","https://doi.org/10.2337/db23-425-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046720","R0046720.pdf","paywalled","nonrandomized_study","Anastasia‐Stefania Alexopoulos","2023","1359-P: Gaps in the Use of Evidence-Based Diabetes Medications for NASH","Diabetes","American Diabetes Association","10.2337/db23-1359-p","https://doi.org/10.2337/db23-1359-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047097","R0047097.pdf","paywalled","nonrandomized_study","Sigrid Young","2023","S1668 The Effects of Gastric Emptying on Weight Loss After Intragastric Balloon and Endoscopic Sleeve Gastroplasty","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956312.86160.d6","https://doi.org/10.14309/01.ajg.0000956312.86160.d6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047291","R0047291.pdf","paywalled","nonrandomized_study","Natalie Lambert","2023","1430-P: Early Real-World Experiences with Tirzepatide","Diabetes","American Diabetes Association","10.2337/db23-1430-p","https://doi.org/10.2337/db23-1430-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047384","R0047384.pdf","paywalled","nonrandomized_study","Nerissa Nance","2023","Applying the causal roadmap to longitudinal national Danish registry data: a case study of second-line diabetes medication and dementia","arXiv (Cornell University)",null,"10.48550/arxiv.2310.03235","https://doi.org/10.48550/arxiv.2310.03235",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047429","R0047429.pdf","paywalled","nonrandomized_study","AMY S. SHAH","2023","1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP","Diabetes","American Diabetes Association","10.2337/db23-1115-p","https://doi.org/10.2337/db23-1115-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047454","R0047454.pdf","paywalled","nonrandomized_study","Mahmoud S Al Rifai","2023","Abstract 14741: Value of Coronary Artery Calcium Testing in Asymptomatic Individuals With Prediabetes: A Multi-Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.14741","https://doi.org/10.1161/circ.148.suppl_1.14741",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047630","R0047630.pdf","paywalled","nonrandomized_study","Arunkumar Krishnan","2023","Tu1602 RENAL OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH NAFLD AND TYPE 2 DIABETES MELLITUS: A MULTICENTER PROPENSITY-MATCHED COHORT STUDY.","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)03450-9","https://doi.org/10.1016/s0016-5085(23)03450-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047663","R0047663.pdf","paywalled","nonrandomized_study","Francesco Giorgino","2023","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): final 24-month primary endpoint analysis","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767871","https://doi.org/10.1055/s-0043-1767871",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047674","R0047674.pdf","paywalled","nonrandomized_study","Kelley Zhao","2023","MP10-05 LITHOPROTECTIVE EFFECT OF GLP-1 AGONISTS IN DIABETIC STONE FORMERS","The Journal of Urology","Ovid Technologies (Wolters Kluwer Health)","10.1097/ju.0000000000003225.05","https://doi.org/10.1097/ju.0000000000003225.05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047838","R0047838.pdf","paywalled","nonrandomized_study","Anukriti Sharma","2023","795-P: Elucidating the Role of Weight Loss and Glycemia with Observed Benefits of GLP-1 Receptor Agonist Treatment in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db23-795-p","https://doi.org/10.2337/db23-795-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047854","R0047854.pdf","paywalled","nonrandomized_study","Marwa R. Al-Badri","2023","1800-PUB: The Long-Term Effect of Glucagon-Like Peptide 1 Receptor Agonists on Glycemic Control Is Predominantly Related to Weight Loss","Diabetes","American Diabetes Association","10.2337/db23-1800-pub","https://doi.org/10.2337/db23-1800-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047960","R0047960.pdf","paywalled","nonrandomized_study","Alexander J. Blood","2023","Abstract 16304: Contemporary Practice Patterns and Opportunities to Improve Type 2 Diabetes (T2D) Therapy in Patients at Elevated Cardiovascular and/or Kidney Risk","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.16304","https://doi.org/10.1161/circ.148.suppl_1.16304",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048064","R0048064.pdf","paywalled","nonrandomized_study","Tomoko Handa","2023","Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.48019","https://doi.org/10.2196/preprints.48019",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"jRCT:jRCTs042190057"],["4","R0048118","R0048118.pdf","paywalled","nonrandomized_study","Yihong Deng","2023","785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World Data","Diabetes","American Diabetes Association","10.2337/db23-785-p","https://doi.org/10.2337/db23-785-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048434","R0048434.pdf","paywalled","nonrandomized_study","Utibe R. Essien","2023","Abstract 01: Association of Copayment Level and Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Adherence in Diabetes and Heart Failure","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.147.suppl_1.01","https://doi.org/10.1161/circ.147.suppl_1.01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048474","R0048474.pdf","paywalled","nonrandomized_study","James J. Amamoo","2023","86-LB: Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE–Oral Semaglutide)","Diabetes","American Diabetes Association","10.2337/db23-86-lb","https://doi.org/10.2337/db23-86-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048528","R0048528.pdf","paywalled","nonrandomized_study","James J. Amamoo","2023","87-LB: Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)","Diabetes","American Diabetes Association","10.2337/db23-87-lb","https://doi.org/10.2337/db23-87-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048562","R0048562.pdf","paywalled","nonrandomized_study","Parth Shah","2023","Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)02275-4","https://doi.org/10.1016/s0168-8278(23)02275-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048684","R0048684.pdf","paywalled","nonrandomized_study","Yash R. Shah","2023","S702 The Impact of Glycemic Control on the Quality of Bowel Preparation in Patients Undergoing Elective Colonoscopy: A Retrospective Multi-Center Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000952448.52036.30","https://doi.org/10.14309/01.ajg.0000952448.52036.30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048796","R0048796.pdf","paywalled","nonrandomized_study","Marcio Hiroshi Miname","2023","Improving risk stratification in people with previous manifestations of cardiovascular disease: one size does not fit all in secondary prevention","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwad334","https://doi.org/10.1093/eurjpc/zwad334","37883702","https://pubmed.ncbi.nlm.nih.gov/37883702/",null,null],["4","R0048807","R0048807.pdf","paywalled","nonrandomized_study","Archana Bandi","2023","1046-P: ELEGANT-DM2—Early Intervention Addressing Therapeutic Inertia in Diabetes Mellitus-2","Diabetes","American Diabetes Association","10.2337/db23-1046-p","https://doi.org/10.2337/db23-1046-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048827","R0048827.pdf","paywalled","nonrandomized_study","Bochra Zareini","2023","201-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-201-lb","https://doi.org/10.2337/db23-201-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049034","R0049034.pdf","paywalled","nonrandomized_study","Susanne B. Nicholas","2023","Interim Results from FINE-REAL: A Prospective Study Providing Insights into the Use of Finerenone in Routine Clinical Settings","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1857a","https://doi.org/10.1681/asn.20233411s1857a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05348733"],["4","R0049115","R0049115.pdf","paywalled","nonrandomized_study","Sydney Elizabeth Hartsell","2023","Heart Failure (HF) in the SGLT2 Inhibitor (SGLT2i) and GLP1 Receptor Agonist (GLP1-RA) Era: Does Hypertension (HTN) Matter?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1864c","https://doi.org/10.1681/asn.20233411s1864c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049272","R0049272.pdf","paywalled","nonrandomized_study","Alexander Abitbol","2023","134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review","Diabetes","American Diabetes Association","10.2337/db23-134-lb","https://doi.org/10.2337/db23-134-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049561","R0049561.pdf","paywalled","nonrandomized_study","PAUL WOLLERSHEIM","2023","1428-P: Type 2 Diabetes Drug Utilization by Claims-Based and Self-Reported Weight Status","Diabetes","American Diabetes Association","10.2337/db23-1428-p","https://doi.org/10.2337/db23-1428-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049583","R0049583.pdf","paywalled","nonrandomized_study","Sarah Khorasani","2023","Will noninvasive screening for fibrosis/steatosis open Pandora’s box? Sharing the healthcare burden of state-of-the-art hepatology practice","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000235","https://doi.org/10.1097/hep.0000000000000235","36680399","https://pubmed.ncbi.nlm.nih.gov/36680399/",null,null],["4","R0049588","R0049588.pdf","paywalled","nonrandomized_study","Xi Tan","2023","791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD","Diabetes","American Diabetes Association","10.2337/db23-791-p","https://doi.org/10.2337/db23-791-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049725","R0049725.pdf","paywalled","nonrandomized_study","Roberta Forlano","2023","O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease","Oral Presentations","BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2023-basl.6","https://doi.org/10.1136/gutjnl-2023-basl.6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049754","R0049754.pdf","paywalled","nonrandomized_study","Ian A.C. Rowe","2023","Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000327","https://doi.org/10.1097/hep.0000000000000327","36738088","https://pubmed.ncbi.nlm.nih.gov/36738088/",null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT04822181"],["4","R0049768","R0049768.pdf","paywalled","nonrandomized_study","Fatimah Alawami","2023","Significant weight loss associated with GLP1 receptor agonist use in obese women with polycystic ovary syndrome- a retrospective cohort study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.94.p258","https://doi.org/10.1530/endoabs.94.p258",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050023","R0050023.pdf","paywalled","nonrandomized_study","James J. Amamoo","2023","Treatment Utilization and Disease Burden Associated with CKD Progression in Patients with Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1859c","https://doi.org/10.1681/asn.20233411s1859c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050110","R0050110.pdf","paywalled","nonrandomized_study","Oyedotun Babajide","2023","S91 Risk of Pancreatic Adenocarcinoma in Patients on Oral Hypoglycemic Agents for Type 2 Diabetes Mellitus","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000950004.68230.50","https://doi.org/10.14309/01.ajg.0000950004.68230.50",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050129","R0050129.pdf","paywalled","nonrandomized_study","Firas Bahdi","2023","S1629 Outcomes of Anti-Obesity Glucagon-Like Peptide 1 Agonists vs Revisional Endoscopic Sleeve Gastroplasty for Weight Regain After Laparoscopic Sleeve Gastrectomy: A Case-Control Real World Experience","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956156.84258.17","https://doi.org/10.14309/01.ajg.0000956156.84258.17",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050182","R0050182.pdf","paywalled","nonrandomized_study","Gemma E. Currie","2023","TYPE 2 DIABETES IN YOUNG ADULTS: PREVALENCE AND RISK FACTOR CONTROL IN A TERTIARY DIABETES CENTRE","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000940964.50300.9d","https://doi.org/10.1097/01.hjh.0000940964.50300.9d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050195","R0050195.pdf","paywalled","nonrandomized_study","Nicole Prinz","2023","Variables Therapieansprechen von Menschen mit Typ-2-Diabetes und Adipositas auf SGLT-2 Inhibitoren und GLP-1 Rezeptoragonisten: Real-World Daten des DPV-Registers","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767869","https://doi.org/10.1055/s-0043-1767869",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050205","R0050205.pdf","paywalled","nonrandomized_study","Semahat Karahisar Şirali","2023","The Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Weight Loss in Obesity","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.8135541","https://doi.org/10.5281/zenodo.8135541",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050273","R0050273.pdf","paywalled","nonrandomized_study","Ayowumi A. Adekolu","2023","S1282 Bariatric Surgery vs Glucagon-Like Peptide-1 Analogues for Reducing Risk of Major Cardiovascular Events: A Multi-Center Retrospective Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000954768.41220.8b","https://doi.org/10.14309/01.ajg.0000954768.41220.8b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050315","R0050315.pdf","paywalled","nonrandomized_study","Benjamin Douglas Xun Liu","2023","S1349 Glucagon-Like Peptide-1 Receptor Agonist and Pioglitazone Therapy Have Superior Mortality and Liver Outcomes for Patients With Type 2 Diabetes and a Diagnosis or at Risk for Undiagnosed Non-alcoholic Fatty Liver Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000955036.53703.f0","https://doi.org/10.14309/01.ajg.0000955036.53703.f0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050717","R0050717.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2023","S1485 Semaglutide Outcomes in Non-Alcoholic Fatty Liver Disease: A Multi-Centered Real-World Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000955580.73643.8b","https://doi.org/10.14309/01.ajg.0000955580.73643.8b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050742","R0050742.pdf","paywalled","nonrandomized_study","Nikhil Grandhi","2023","Racial Differences in the Association of Glucagon-like Peptide 1 Agonist Use and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in US Veterans with Diabetes Mellitus","Blood","American Society of Hematology","10.1182/blood-2023-179135","https://doi.org/10.1182/blood-2023-179135",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050881","R0050881.pdf","paywalled","nonrandomized_study","Gottfried Rudofsky","2023","76-LB: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)–Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting—SURE Program Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db23-76-lb","https://doi.org/10.2337/db23-76-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051001","R0051001.pdf","paywalled","nonrandomized_study","Ethan M. Cohen","2023","S1652 Comparison of Bariatric Surgery and Glucagon-Like Peptide-1 Analogs for Prevention of Nonalcoholic Fatty Liver Disease in an Obese Population: A Large Multi-Center Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956248.42228.0d","https://doi.org/10.14309/01.ajg.0000956248.42228.0d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051335","R0051335.pdf","paywalled","nonrandomized_study","Bochra Zareini","2023","200-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-200-lb","https://doi.org/10.2337/db23-200-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051364","R0051364.pdf","paywalled","nonrandomized_study","Viet Trung Le","2023","Abstract 15190: Association of Initiating SGLT2i and GLP1Ra Therapeutics on Insulin Utilization and MACE Outcomes Among Patients With Diabetes in an Integrated Healthcare System","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15190","https://doi.org/10.1161/circ.148.suppl_1.15190",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051388","R0051388.pdf","paywalled","nonrandomized_study","Nikolaus Gunter Oberprieler","2023","Early Use and Effectiveness of Finerenone in US Patients with CKD and Type 2 Diabetes: A FOUNTAIN Platform Analysis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1856c","https://doi.org/10.1681/asn.20233411s1856c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051395","R0051395.pdf","paywalled","nonrandomized_study","Alessio Mazzieri","2023","83-LB: Simplifying Insulin Treatment in Persons with T2 DM over 65 Years—Interim Report of the STOP Study","Diabetes","American Diabetes Association","10.2337/db23-83-lb","https://doi.org/10.2337/db23-83-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051640","R0051640.pdf","paywalled","nonrandomized_study","Jeff T. Mohl","2023","Abstract 11760: Prevalence of Atherosclerosis, Heart Failure, and Chronic Kidney Disease Among Patients With Type 2 Diabetes and Management With Diabetes Pharmacotherapy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.11760","https://doi.org/10.1161/circ.148.suppl_1.11760",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051831","R0051831.pdf","paywalled","nonrandomized_study","April Kathleen Watkins","2023","Abstract 17701: Glucagon-Like Peptide-1 Receptor Agonist Weight Loss Results from an Allied Health-Led Atrial Fibrillation Risk Factor Modification Clinic","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.17701","https://doi.org/10.1161/circ.148.suppl_1.17701",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051917","R0051917.pdf","paywalled","nonrandomized_study","Sascha René Tittel","2023","1416-P: Differences in Treatment and Metabolic Outcome between Males and Females Living with T2D—Results from the Multicenter DPV Registry","Diabetes","American Diabetes Association","10.2337/db23-1416-p","https://doi.org/10.2337/db23-1416-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052070","R0052070.pdf","paywalled","nonrandomized_study","Amara Sarwal","2023","Increased Mortality Risk with Insulin Glargine in Veterans with Type 2 Diabetes: An Emulated Clinical Trial Observational Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1858b","https://doi.org/10.1681/asn.20233411s1858b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052095","R0052095.pdf","paywalled","nonrandomized_study","Amara Sarwal","2023","Increased Risk of Serious Hypoglycemia with Insulin Glargine in Veterans with Type 2 Diabetes: An Emulated Clinical Trial Observational Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1858a","https://doi.org/10.1681/asn.20233411s1858a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052149","R0052149.pdf","paywalled","nonrandomized_study","Norbert Pötschke","2023","Cardiovascular effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists or liraglutide in the EMPRISE study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767943","https://doi.org/10.1055/s-0043-1767943",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052306","R0052306.pdf","paywalled","nonrandomized_study","Bochra Zareini","2023","Change in hbA1c following treatment with and the short-term risk of major adverse cardiovascular outcomes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehad655.2553","https://doi.org/10.1093/eurheartj/ehad655.2553",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052431","R0052431.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2023","S1648 Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956232.19702.5a","https://doi.org/10.14309/01.ajg.0000956232.19702.5a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052453","R0052453.pdf","paywalled","nonrandomized_study","Rory J. McCrimmon","2023","iGlarLixi vs. Basal- plus kurzwirksames Insulin bei Erwachsenen mit Typ-2-Diabetes, die von einer Basalinsulin-Therapie intensiviert werden: Die SoliSimplify-Praxisstudie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1768002","https://doi.org/10.1055/s-0043-1768002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052632","R0052632.pdf","paywalled","nonrandomized_study","Kenneth W. Chow","2023","S1318 Semaglutide Is Effective in Achieving Weight Loss in Liver Transplant Recipients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000954912.01880.7c","https://doi.org/10.14309/01.ajg.0000954912.01880.7c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052677","R0052677.pdf","paywalled","nonrandomized_study","Mary S. Anthony","2023","846-P: Risk of Anaphylaxis among New Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)","Diabetes","American Diabetes Association","10.2337/db23-846-p","https://doi.org/10.2337/db23-846-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052869","R0052869.pdf","paywalled","nonrandomized_study","Nikhil Grandhi","2023","Abstract 4358: Glucagon-like peptide 1 agonist use and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2023-4358","https://doi.org/10.1158/1538-7445.am2023-4358",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053040","R0053040.pdf","paywalled","nonrandomized_study","Virginia Bellido","2023","1801-PUB: Efficacy and Safety of Once-Weekly Semaglutide in People with Type 1 Diabetes in Real-World Practice","Diabetes","American Diabetes Association","10.2337/db23-1801-pub","https://doi.org/10.2337/db23-1801-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053066","R0053066.pdf","paywalled","nonrandomized_study","Wissam Ghusn","2023","Mo1915 REAL-WORLD WEIGHT LOSS AND METABOLIC PARAMETERS OUTCOMES OF SEMAGLUTIDE: A 1-YEAR MULTI-SITE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)03168-2","https://doi.org/10.1016/s0016-5085(23)03168-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053311","R0053311.pdf","paywalled","nonrandomized_study","Vibhu Chittajallu","2023","706 INCIDENCE PROPORTION OF PANCREATIC COMPLICATIONS WITH INCRETIN-BASED THERAPIES: A MULTICENTER POPULATION-BASED STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(23)01313-6","https://doi.org/10.1016/s0016-5085(23)01313-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053319","R0053319.pdf","paywalled","nonrandomized_study","Ю. Г. Самойлова","2023","Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus","Russian Journal of Preventive Medicine","Media Sphere Publishing House","10.17116/profmed20232612195","https://doi.org/10.17116/profmed20232612195",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053348","R0053348.pdf","paywalled","nonrandomized_study","Vikas S. Sridhar","2023","The Efficacy and Safety of SGLT2 Inhibitors and GLP1 Receptor Agonists in Kidney Transplant Recipients","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s11030a","https://doi.org/10.1681/asn.20233411s11030a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053435","R0053435.pdf","paywalled","nonrandomized_study","Heidi S. Ahmed","2023","Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000378","https://doi.org/10.1097/hep.0000000000000378","36932718","https://pubmed.ncbi.nlm.nih.gov/36932718/",null,null],["4","R0053515","R0053515.pdf","paywalled","nonrandomized_study","Zryan Shwani","2023","S1631 Exploring Patterns and Implications of Semaglutide Misuse: A Descriptive Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000956164.29220.39","https://doi.org/10.14309/01.ajg.0000956164.29220.39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053984","R0053984.pdf","paywalled","nonrandomized_study","Michele S. Barnhill","2023","Compartmentalizing risk with sarcopenic obesity","Liver Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/lvt.0000000000000061","https://doi.org/10.1097/lvt.0000000000000061","36728605","https://pubmed.ncbi.nlm.nih.gov/36728605/",null,null],["4","R0054548","R0054548.pdf","paywalled","nonrandomized_study","Qiao-Qiao Wang","2023","Glucagon-Like Peptide 1 Receptor Agonists in Alzheimer’s Disease","Neurochemical Journal","Pleiades Publishing Ltd","10.1134/s1819712423020204","https://doi.org/10.1134/s1819712423020204",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054821","R0054821.pdf","paywalled","nonrandomized_study","John W. Ostrominski","2023","Abstract 14413: Contemporary Prevalence, Comorbidity Burden, and Treatment of Overweight and Obesity: Insights From the Multicenter Mass General Brigham Healthcare System","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.14413","https://doi.org/10.1161/circ.148.suppl_1.14413",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055530","R0055530.pdf","paywalled","nonrandomized_study","Stephen R. Sammons","2023","Interaction of Race and Treatment with GLP1-RA, SGLT2i, and Insulin on Mortality in Veterans with Type 2 Diabetes Mellitus (T2DM) and CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1729d","https://doi.org/10.1681/asn.20233411s1729d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055739","R0055739.pdf","paywalled","nonrandomized_study","Stephanie L. Samuels","2023","1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis","Diabetes","American Diabetes Association","10.2337/db23-1100-p","https://doi.org/10.2337/db23-1100-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0004703","R0004703.pdf","paywalled","nonrandomized_study","De Block CEM","2022","Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14640","https://doi.org/10.1111/dom.14640","34984793","https://pubmed.ncbi.nlm.nih.gov/34984793/",null,null],["4","R0004996","R0004996.pdf","paywalled","nonrandomized_study","Rentsch T","2022","Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Changes in Patients With Type 2 Diabetes on High-Dose Insulin.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001283","https://doi.org/10.1097/mjt.0000000000001283","33416240","https://pubmed.ncbi.nlm.nih.gov/33416240/",null,null],["4","R0005543","R0005543.pdf","paywalled","nonrandomized_study","Dong YH","2022","Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14741","https://doi.org/10.1111/dom.14741","35491533","https://pubmed.ncbi.nlm.nih.gov/35491533/",null,null],["4","R0005687","R0005687.pdf","paywalled","nonrandomized_study","Franch-Nadal J","2022","Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2022.10.005","https://doi.org/10.1016/j.pcd.2022.10.005","36336605","https://pubmed.ncbi.nlm.nih.gov/36336605/",null,null],["4","R0005692","R0005692.pdf","paywalled","nonrandomized_study","Dong YH","2022","Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.","Pharmacotherapy","Wiley","10.1002/phar.2688","https://doi.org/10.1002/phar.2688","35508702","https://pubmed.ncbi.nlm.nih.gov/35508702/",null,null],["4","R0005916","R0005916.pdf","paywalled","nonrandomized_study","Crossey CD","2022","An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxac230","https://doi.org/10.1093/ajhp/zxac230","35981331","https://pubmed.ncbi.nlm.nih.gov/35981331/",null,null],["4","R0005950","R0005950.pdf","paywalled","nonrandomized_study","George J","2022","Response to \"An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation\".","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxac231","https://doi.org/10.1093/ajhp/zxac231","35977884","https://pubmed.ncbi.nlm.nih.gov/35977884/",null,null],["4","R0006035","R0006035.pdf","paywalled","nonrandomized_study","Wu T","2022","Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-022-01202-1","https://doi.org/10.1007/s40261-022-01202-1","36175609","https://pubmed.ncbi.nlm.nih.gov/36175609/",null,null],["4","R0006521","R0006521.pdf","paywalled","nonrandomized_study","Vigara LA","2022","Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients.","Clinical transplantation","Wiley","10.1111/ctr.14633","https://doi.org/10.1111/ctr.14633","35258121","https://pubmed.ncbi.nlm.nih.gov/35258121/",null,null],["4","R0006546","R0006546.pdf","paywalled","nonrandomized_study","Kelsey MD","2022","In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.","Annals of internal medicine","American College of Physicians","10.7326/j22-0003","https://doi.org/10.7326/j22-0003","35226528","https://pubmed.ncbi.nlm.nih.gov/35226528/",null,null],["4","R0006731","R0006731.pdf","paywalled","nonrandomized_study","Stark JE","2022","Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD).","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280211055804","https://doi.org/10.1177/10600280211055804","34726082","https://pubmed.ncbi.nlm.nih.gov/34726082/",null,null],["4","R0006838","R0006838.pdf","paywalled","nonrandomized_study","Fadah K","2022","The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-021-01619-8","https://doi.org/10.1007/s11886-021-01619-8","35000149","https://pubmed.ncbi.nlm.nih.gov/35000149/",null,null],["4","R0006964","R0006964.pdf","paywalled","nonrandomized_study","Qiu M","2022","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Annals of internal medicine","American College of Physicians","10.7326/l21-0706","https://doi.org/10.7326/l21-0706","35038402","https://pubmed.ncbi.nlm.nih.gov/35038402/",null,null],["4","R0007035","R0007035.pdf","paywalled","nonrandomized_study","Romera I","2022","A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02196-0","https://doi.org/10.1007/s12325-022-02196-0","35689162","https://pubmed.ncbi.nlm.nih.gov/35689162/",null,null],["4","R0007542","R0007542.pdf","paywalled","nonrandomized_study","Wang J","2022","Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.","Endocrine research","Informa UK Limited","10.1080/07435800.2021.1955255","https://doi.org/10.1080/07435800.2021.1955255","34459679","https://pubmed.ncbi.nlm.nih.gov/34459679/",null,null],["4","R0007659","R0007659.pdf","paywalled","nonrandomized_study","Yang Z","2022","The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2021.10.003","https://doi.org/10.1016/j.numecd.2021.10.003","34895802","https://pubmed.ncbi.nlm.nih.gov/34895802/",null,null],["4","R0007699","R0007699.pdf","paywalled","nonrandomized_study","Nørgaard CH","2022","Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvab053","https://doi.org/10.1093/ehjcvp/pvab053","34215881","https://pubmed.ncbi.nlm.nih.gov/34215881/",null,null],["4","R0008507","R0008507.pdf","paywalled","nonrandomized_study","Guan Z","2022","Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-021-03249-z","https://doi.org/10.1007/s00228-021-03249-z","35079845","https://pubmed.ncbi.nlm.nih.gov/35079845/",null,null],["4","R0008675","R0008675.pdf","paywalled","nonrandomized_study","Williams BA","2022","Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14686","https://doi.org/10.1111/dom.14686","35257457","https://pubmed.ncbi.nlm.nih.gov/35257457/",null,null],["4","R0009168","R0009168.pdf","paywalled","nonrandomized_study","Hopton OM","2022","Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.","Pharmacotherapy","Wiley","10.1002/phar.2648","https://doi.org/10.1002/phar.2648","34807465","https://pubmed.ncbi.nlm.nih.gov/34807465/",null,null],["4","R0009512","R0009512.pdf","paywalled","nonrandomized_study","Desai RJ","2022","Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.","American heart journal","Elsevier BV","10.1016/j.ahj.2022.09.008","https://doi.org/10.1016/j.ahj.2022.09.008","36150454","https://pubmed.ncbi.nlm.nih.gov/36150454/",null,null],["4","R0009622","R0009622.pdf","paywalled","nonrandomized_study","Shao SC","2022","Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2022.101318","https://doi.org/10.1016/j.diabet.2022.101318","35017100","https://pubmed.ncbi.nlm.nih.gov/35017100/",null,null],["4","R0010371","R0010371.pdf","paywalled","nonrandomized_study","Lopez PD","2022","Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2022.07.012","https://doi.org/10.1016/j.amjcard.2022.07.012","35963825","https://pubmed.ncbi.nlm.nih.gov/35963825/",null,null],["4","R0010801","R0010801.pdf","paywalled","nonrandomized_study","Bongaerts B","2022","Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-1702-5151","https://doi.org/10.1055/a-1702-5151","34942670","https://pubmed.ncbi.nlm.nih.gov/34942670/",null,null],["4","R0011191","R0011191.pdf","paywalled","nonrandomized_study","Zhou Y","2022","Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS).","Clinical endocrinology","Wiley","10.1111/cen.14660","https://doi.org/10.1111/cen.14660","34913180","https://pubmed.ncbi.nlm.nih.gov/34913180/",null,null],["4","R0011442","R0011442.pdf","paywalled","nonrandomized_study","Cieslik LK","2022","Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature.","Internal medicine journal","Wiley","10.1111/imj.15137","https://doi.org/10.1111/imj.15137","33197121","https://pubmed.ncbi.nlm.nih.gov/33197121/",null,null],["4","R0011455","R0011455.pdf","paywalled","nonrandomized_study","Iyer NN","2022","Glucose-lowering treatment patterns in patients with diabetic kidney disease.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2022.89152","https://doi.org/10.37765/ajmc.2022.89152","35981131","https://pubmed.ncbi.nlm.nih.gov/35981131/",null,null],["4","R0011474","R0011474.pdf","paywalled","nonrandomized_study","Meyhöfer S","2022","Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14616","https://doi.org/10.1111/dom.14616","34882949","https://pubmed.ncbi.nlm.nih.gov/34882949/",null,null],["4","R0011476","R0011476.pdf","paywalled","nonrandomized_study","Bashir R","2022","Insights into New Therapeutic Approaches for the Treatment and Management of Polycystic Ovary Syndrome: An Updated Review.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612828666220518150754","https://doi.org/10.2174/1381612828666220518150754","35593345","https://pubmed.ncbi.nlm.nih.gov/35593345/",null,null],["4","R0012075","R0012075.pdf","paywalled","nonrandomized_study","Franch-Nadal J","2022","The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02156-8","https://doi.org/10.1007/s12325-022-02156-8","35553372","https://pubmed.ncbi.nlm.nih.gov/35553372/",null,null],["4","R0012136","R0012136.pdf","paywalled","nonrandomized_study","Chen M","2022","Insulin Dosage Adjustments After Initiation of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes.","Journal of pharmacy practice","SAGE Publications","10.1177/0897190021993625","https://doi.org/10.1177/0897190021993625","33593125","https://pubmed.ncbi.nlm.nih.gov/33593125/",null,null],["4","R0012148","R0012148.pdf","paywalled","nonrandomized_study","Tsushima Y","2022","Prevalence and Clinical Determinants of Obesity in Adults With Type 1 Diabetes Mellitus: A Single-Center Retrospective Observational Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2022.01.008","https://doi.org/10.1016/j.eprac.2022.01.008","35091100","https://pubmed.ncbi.nlm.nih.gov/35091100/",null,null],["4","R0013518","R0013518.pdf","paywalled","nonrandomized_study","Gallo M","2022","Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: An investigation on lipidated GLP-1 analogs.","Journal of pharmaceutical and biomedical analysis","Elsevier BV","10.1016/j.jpba.2021.114566","https://doi.org/10.1016/j.jpba.2021.114566","35042144","https://pubmed.ncbi.nlm.nih.gov/35042144/",null,null],["4","R0015023","R0015023.pdf","paywalled","nonrandomized_study","Shao H","2022","Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108132","https://doi.org/10.1016/j.jdiacomp.2022.108132","35101326","https://pubmed.ncbi.nlm.nih.gov/35101326/",null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT00069784"],["4","R0015267","R0015267.pdf","paywalled","nonrandomized_study","Ares-Blanco J","2022","Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus.","Revista clinica espanola","Elsevier BV","10.1016/j.rceng.2022.06.001","https://doi.org/10.1016/j.rceng.2022.06.001","35817680","https://pubmed.ncbi.nlm.nih.gov/35817680/",null,null],["4","R0015284","R0015284.pdf","paywalled","nonrandomized_study","Cowart K","2022","Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14579","https://doi.org/10.1111/dom.14579","34676657","https://pubmed.ncbi.nlm.nih.gov/34676657/",null,null],["4","R0016820","R0016820.pdf","paywalled","nonrandomized_study","Bilic-Curcic I","2022","Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202204_28608","https://doi.org/10.26355/eurrev_202204_28608","35503623","https://pubmed.ncbi.nlm.nih.gov/35503623/",null,null],["4","R0018162","R0018162.pdf","paywalled","nonrandomized_study","Al Hayek AA","2022","Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02053-0","https://doi.org/10.1007/s12325-022-02053-0","35119622","https://pubmed.ncbi.nlm.nih.gov/35119622/",null,null],["4","R0018459","R0018459.pdf","paywalled","nonrandomized_study","Gill GS","2022","Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2021.100878","https://doi.org/10.1016/j.cpcardiol.2021.100878","34078543","https://pubmed.ncbi.nlm.nih.gov/34078543/",null,null],["4","R0020436","R0020436.pdf","paywalled","nonrandomized_study","Shah R","2022","68 Ga-DOTATATE PET/CT imaging in endogenous hyperinsulinemic hypoglycemia: A tertiary endocrine centre experience.","Clinical endocrinology","Wiley","10.1111/cen.14586","https://doi.org/10.1111/cen.14586","34498757","https://pubmed.ncbi.nlm.nih.gov/34498757/",null,null],["4","R0020458","R0020458.pdf","paywalled","nonrandomized_study","Stier C","2022","Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2022.05.009","https://doi.org/10.1016/j.clnesp.2022.05.009","35871930","https://pubmed.ncbi.nlm.nih.gov/35871930/",null,"ClinicalTrials.gov:NCT02616003"],["4","R0022163","R0022163.pdf","paywalled","nonrandomized_study","Hakim M","2022","Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.","Surgical endoscopy","Springer Science and Business Media LLC","10.1007/s00464-022-09294-8","https://doi.org/10.1007/s00464-022-09294-8","35488131","https://pubmed.ncbi.nlm.nih.gov/35488131/",null,null],["4","R0022360","R0022360.pdf","paywalled","nonrandomized_study","Elhag W","2022","Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-021-05884-y","https://doi.org/10.1007/s11695-021-05884-y","35060021","https://pubmed.ncbi.nlm.nih.gov/35060021/",null,null],["4","R0022937","R0022937.pdf","paywalled","nonrandomized_study","Formoso G","2022","Semaglutide in routine clinical practice: interesting news from real-world evidence.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-022-01810-w","https://doi.org/10.1007/s40618-022-01810-w","35524036","https://pubmed.ncbi.nlm.nih.gov/35524036/",null,null],["4","R0024078","R0024078.pdf","paywalled","nonrandomized_study","George J","2022","Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxac046","https://doi.org/10.1093/ajhp/zxac046","35136945","https://pubmed.ncbi.nlm.nih.gov/35136945/",null,null],["4","R0024985","R0024985.pdf","paywalled","nonrandomized_study","Lemon LS","2022","Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?","Gynecologic oncology","Elsevier BV","10.1016/j.ygyno.2022.01.022","https://doi.org/10.1016/j.ygyno.2022.01.022","35140015","https://pubmed.ncbi.nlm.nih.gov/35140015/",null,null],["4","R0025575","R0025575.pdf","paywalled","nonrandomized_study","Davila A","2022","A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents.","Journal of the American Dental Association (1939)","Elsevier BV","10.1016/j.adaj.2022.07.009","https://doi.org/10.1016/j.adaj.2022.07.009","36115715","https://pubmed.ncbi.nlm.nih.gov/36115715/",null,null],["4","R0028940","R0028940.pdf","paywalled","nonrandomized_study","Dharmaratnam VM","2022","Revisional Surgery or Pharmacotherapy for Insufficient Weight Loss and Weight Regain After Primary Bariatric Procedure: a Descriptive Study.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-022-06191-w","https://doi.org/10.1007/s11695-022-06191-w","35994181","https://pubmed.ncbi.nlm.nih.gov/35994181/",null,null],["4","R0030158","R0030158.pdf","paywalled","nonrandomized_study","Krishnan A","2022","Glucagon-Like Peptide 1-Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity.","Pancreas","Ovid Technologies (Wolters Kluwer Health)","10.1097/mpa.0000000000002197","https://doi.org/10.1097/mpa.0000000000002197","37099785","https://pubmed.ncbi.nlm.nih.gov/37099785/",null,null],["4","R0032481","R0032481.pdf","paywalled","nonrandomized_study","Saira Rafaqat","2022","Pathophysiological aspects of insulin resistance in Atrial Fibrillation: novel therapeutic approaches","Greater South Information System",null,"10.60692/shp88-kdy94","https://doi.org/10.60692/shp88-kdy94",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032703","R0032703.pdf","paywalled","nonrandomized_study","Jing Luo","2022","741-P: Real-World Weight-Loss Effectiveness of GLP-1 Agonists among Patients with Type 2 Diabetes: A Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db22-741-p","https://doi.org/10.2337/db22-741-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032722","R0032722.pdf","paywalled","nonrandomized_study","DAVID J. COOK","2022","900-P: Patterns of Drug Utilization for Cardio- and Renal-Protective Antihyperglycemic Agents in a Commercially Insured Population","Diabetes","American Diabetes Association","10.2337/db22-900-p","https://doi.org/10.2337/db22-900-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032792","R0032792.pdf","paywalled","nonrandomized_study","VINCENZO PROVENZANO","2022","89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization","Diabetes","American Diabetes Association","10.2337/db22-89-lb","https://doi.org/10.2337/db22-89-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032863","R0032863.pdf","paywalled","nonrandomized_study","Jing Luo","2022","130-OR: The Association between High Out-of-Pocket Costs and Incidence of Treatment Intensification with an SGLT2 Inhibitor (SGLT2i) or GLP-1 Agonist (GLP-1a) in Patients with Type 2 Diabetes and Established Cardiovascular Disease: A Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db22-130-or","https://doi.org/10.2337/db22-130-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032911","R0032911.pdf","paywalled","nonrandomized_study","DEENE MOHANDAS","2022","91-LB: Glycemic and Metabolic Effects of Long-Acting GLP-1 in T1D","Diabetes","American Diabetes Association","10.2337/db22-91-lb","https://doi.org/10.2337/db22-91-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033229","R0033229.pdf","paywalled","nonrandomized_study","Senthilkumar Krishnasamy","2022","Impact of Implementation of a Renal Diabetes Multidisciplinary Team Clinic in District General Hospital","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1914d","https://doi.org/10.1681/asn.20223311s1914d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033768","R0033768.pdf","paywalled","nonrandomized_study","Szépkúti, Sándor","2022","Additional file 1 of Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study","Figshare",null,"10.6084/m9.figshare.21117530","https://doi.org/10.6084/m9.figshare.21117530",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034060","R0034060.pdf","paywalled","nonrandomized_study","Endocrine Society 2022","2022","Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study","Underline Science Inc.",null,"10.48448/wrdj-2g96","https://doi.org/10.48448/wrdj-2g96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034382","R0034382.pdf","paywalled","nonrandomized_study","Anna Ferrulli","2022","Weight loss variability with SGLT2 inhibitors, GLP-1 receptor agonists and repetitive Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity: results of a retrospective, comparative study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.81.p586","https://doi.org/10.1530/endoabs.81.p586",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034409","R0034409.pdf","paywalled","nonrandomized_study","Salas Jersy Jair Cardenas","2022","REAL Life study of SEMaglutide in Patients with Type 2 diabetes in SPain (REALSEM-SP): Retrospective clinical study on the efficacy, adherence, and safety with Semaglutide","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.81.p333","https://doi.org/10.1530/endoabs.81.p333",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034603","R0034603.pdf","paywalled","nonrandomized_study","Giuseppe Lisco","2022","GLP-1 receptor agonists and erectile dysfunction in diabetic men with and without hypogonadism: a 1- year retrospective observational study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.81.p355","https://doi.org/10.1530/endoabs.81.p355",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034635","R0034635.pdf","paywalled","nonrandomized_study","Julie M. Paik","2022","Empagliflozin Use and the Risk of Nephrolithiasis in Patients With Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1673a","https://doi.org/10.1681/asn.20223311s1673a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034708","R0034708.pdf","paywalled","nonrandomized_study","Edouard L. Fu","2022","Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With CKD and Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1673b","https://doi.org/10.1681/asn.20223311s1673b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035831","R0035831.pdf","paywalled","nonrandomized_study","Alessandro Mattina","2022","P15.05: Safety of Once-Weekly Dulaglutide on Post-transplant Diabetes Mellitus: A Preliminary Single-Centre Experience","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000889588.86483.d4","https://doi.org/10.1097/01.tp.0000889588.86483.d4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035998","R0035998.pdf","paywalled","nonrandomized_study","Markus Menzen","2022","Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746340","https://doi.org/10.1055/s-0042-1746340",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036323","R0036323.pdf","paywalled","nonrandomized_study","Chan, Yi-Hsin","2022","Additional file 1 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.20176126","https://doi.org/10.6084/m9.figshare.20176126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036329","R0036329.pdf","paywalled","nonrandomized_study","Baviera, Marta","2022","Additional file 1 of Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study","Figshare",null,"10.6084/m9.figshare.20580410","https://doi.org/10.6084/m9.figshare.20580410",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036335","R0036335.pdf","paywalled","nonrandomized_study","Baviera, Marta","2022","Additional file 2 of Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study","Figshare",null,"10.6084/m9.figshare.20580413","https://doi.org/10.6084/m9.figshare.20580413",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036811","R0036811.pdf","paywalled","nonrandomized_study","Chan, Yi-Hsin","2022","Additional file 2 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.20176129.v1","https://doi.org/10.6084/m9.figshare.20176129.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037063","R0037063.pdf","paywalled","nonrandomized_study","Devin Abrahami","2022","1146-P: SGLT2 Inhibitors and the Risk of Early Bladder Cancer Events","Diabetes","American Diabetes Association","10.2337/db22-1146-p","https://doi.org/10.2337/db22-1146-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037249","R0037249.pdf","paywalled","nonrandomized_study","Peter Manu","2022","Drug Therapy for Unexplained Dyspnea in Post–COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil","American Journal of Therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001483","https://doi.org/10.1097/mjt.0000000000001483","35412483","https://pubmed.ncbi.nlm.nih.gov/35412483/",null,null],["4","R0037373","R0037373.pdf","paywalled","nonrandomized_study","Daniel J. Huynh","2022","S1253 Dual Therapy With Metformin and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2-i) Improves Mortality in Cirrhotic Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000861652.83789.d5","https://doi.org/10.14309/01.ajg.0000861652.83789.d5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037432","R0037432.pdf","paywalled","nonrandomized_study","Silmara A O Leite","2022","805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-805-p","https://doi.org/10.2337/db22-805-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037452","R0037452.pdf","paywalled","nonrandomized_study","Daniel J. Huynh","2022","S1176 Dual Therapy With Metformin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) Improves Mortality in Diabetic Cirrhotic Patients","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000861344.44054.b7","https://doi.org/10.14309/01.ajg.0000861344.44054.b7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037579","R0037579.pdf","paywalled","nonrandomized_study","RICCARDO CANDIDO","2022","87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study","Diabetes","American Diabetes Association","10.2337/db22-87-lb","https://doi.org/10.2337/db22-87-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037590","R0037590.pdf","paywalled","nonrandomized_study","Stewart B. Harris","2022","680-P: Effect of the FreeStyle Libre System on Diabetes Treatment for People with T2D: Results from a Retrospective Cohort Study Using Canadian Private Payer Claims Database","Diabetes","American Diabetes Association","10.2337/db22-680-p","https://doi.org/10.2337/db22-680-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037607","R0037607.pdf","paywalled","nonrandomized_study","Alexander Kutz","2022","1082-P: Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-1082-p","https://doi.org/10.2337/db22-1082-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037661","R0037661.pdf","paywalled","nonrandomized_study","Chan, Yi-Hsin","2022","Additional file 4 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.20176135.v1","https://doi.org/10.6084/m9.figshare.20176135.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037698","R0037698.pdf","paywalled","nonrandomized_study","THOMAS S.J. CRABTREE","2022","756-P: The Effect of Semaglutide on Alanine Aminotransferase (ALT) Levels: Results from the Association of British Clinical Diabetologists (ABCD) Audit","Diabetes","American Diabetes Association","10.2337/db22-756-p","https://doi.org/10.2337/db22-756-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037792","R0037792.pdf","paywalled","nonrandomized_study","Ugamura, Daisuke","2022","An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.c.6042131.v1","https://doi.org/10.6084/m9.figshare.c.6042131.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"UMIN:UMIN000024283"],["4","R0037843","R0037843.pdf","paywalled","nonrandomized_study","Kazuo Kobayashi","2022","1477-PUB: The Comparison between Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist Treatment Depending on the Change in Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus on the Renal Function","Diabetes","American Diabetes Association","10.2337/db22-1477-pub","https://doi.org/10.2337/db22-1477-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037947","R0037947.pdf","paywalled","nonrandomized_study","Chan, Yi-Hsin","2022","Additional file 3 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Figshare",null,"10.6084/m9.figshare.20176132.v1","https://doi.org/10.6084/m9.figshare.20176132.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038401","R0038401.pdf","paywalled","nonrandomized_study","Valentina Pirro","2022","731-P: Metabolite Biomarkers and Cardiovascular Events in REWIND: A Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db22-731-p","https://doi.org/10.2337/db22-731-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01394952"],["4","R0038783","R0038783.pdf","paywalled","nonrandomized_study","Filippo Trombara","2022","Abstract 11522: Impact of Chronic Glucagon-Like Peptide-1 Receptor Agonist and Sodium Glucose Cotransporter-2 Inhibitor Therapy on In-Hospital Outcomes of Patients Hospitalized With Acute Myocardial Infarction","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.11522","https://doi.org/10.1161/circ.146.suppl_1.11522",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038925","R0038925.pdf","paywalled","nonrandomized_study","Yara Dababneh","2022","S1422 NASH Clinic; A Multidisciplinary Team Approach to Assess the Efficacy of Diet, Lifestyle and GLP1 Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000862328.28290.63","https://doi.org/10.14309/01.ajg.0000862328.28290.63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039652","R0039652.pdf","paywalled","nonrandomized_study","Robert J. Postlethwaite","2022","S1443 Predictors of Pancreatitis on Initiation of GLP-1 Receptor Agonists for Weight Loss","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000862412.41232.db","https://doi.org/10.14309/01.ajg.0000862412.41232.db",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040048","R0040048.pdf","paywalled","nonrandomized_study","RORY J. MCCRIMMON","2022","260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study","Diabetes","American Diabetes Association","10.2337/db22-260-or","https://doi.org/10.2337/db22-260-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041431","R0041431.pdf","paywalled","nonrandomized_study","Leopoldo Muniz da Silva","2022","RGC DATA","Data Archiving and Networked Services (DANS)",null,"10.17632/78ghfpj225.1","https://doi.org/10.17632/78ghfpj225.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041471","R0041471.pdf","paywalled","nonrandomized_study","Filippo Trombara","2022","Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehac544.1303","https://doi.org/10.1093/eurheartj/ehac544.1303",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041474","R0041474.pdf","paywalled","nonrandomized_study","Dmitriy Khazron","2022","Abstract #1155435: Use of Glucagon-like Peptide 1 Receptor Agonist Therapy for Inpatients with Type II Diabetes and Chronic Kidney Disease: A Retrospective Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2022.03.064","https://doi.org/10.1016/j.eprac.2022.03.064",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041540","R0041540.pdf","paywalled","nonrandomized_study","Stefan Agewall","2022","Prevention is still the key to success","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvac046","https://doi.org/10.1093/ehjcvp/pvac046","36057770","https://pubmed.ncbi.nlm.nih.gov/36057770/",null,null],["4","R0041651","R0041651.pdf","paywalled","nonrandomized_study","Femin Prasad","2022","P177. Semaglutide to the Rescue: Real-World Clinical Data in Patients With Antipsychotic-Induced Weight Gain not Responding to Metformin","Biological Psychiatry","Elsevier BV","10.1016/j.biopsych.2022.02.411","https://doi.org/10.1016/j.biopsych.2022.02.411",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041709","R0041709.pdf","paywalled","nonrandomized_study","Maya Gogtay","2022","Does Non-Alcoholic Steatohepatitis Independently Increase the Risk of Venous Thromboembolism?","Blood","American Society of Hematology","10.1182/blood-2022-159317","https://doi.org/10.1182/blood-2022-159317",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041714","R0041714.pdf","paywalled","nonrandomized_study","Yeo Jin Choi","2022","A 10‐Year Nationwide Pharmacovigilance Assessment on Anti‐Obesity Medications and Factors Associated with Serious Adverse Events","The FASEB Journal","Wiley","10.1096/fasebj.2022.36.s1.r3296","https://doi.org/10.1096/fasebj.2022.36.s1.r3296",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043738","R0043738.pdf","paywalled","nonrandomized_study","Amedeo Lonardo","2022","Precision medicine in nonalcoholic fatty liver disease","Journal of Gastroenterology and Hepatology","Wiley","10.1111/jgh.15850","https://doi.org/10.1111/jgh.15850","35801994","https://pubmed.ncbi.nlm.nih.gov/35801994/",null,null],["4","R0043887","R0043887.pdf","paywalled","nonrandomized_study","Rowan Hillson","2022","Suicide and diabetes","Practical Diabetes","Wiley","10.1002/pdi.2402","https://doi.org/10.1002/pdi.2402",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044797","R0044797.pdf","paywalled","nonrandomized_study","Ploutarchos Tzoulis","2022","Real-world effectiveness and safety of semaglutide for weight loss","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.86.p86","https://doi.org/10.1530/endoabs.86.p86",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045029","R0045029.pdf","paywalled","nonrandomized_study","Jim Alkas","2022","FC 128: Novel Glucose-Lowering Drugs and the Risk of Acute Kidney Injury in Routine Care: The Stockholm Creatinine Measurements (SCREAM) Project","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac127.002","https://doi.org/10.1093/ndt/gfac127.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045310","R0045310.pdf","paywalled","nonrandomized_study","MARTIN FUECHTENBUSCH","2022","738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes","Diabetes","American Diabetes Association","10.2337/db22-738-p","https://doi.org/10.2337/db22-738-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045684","R0045684.pdf","paywalled","nonrandomized_study","Weixin Li","2022","Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.16016/j.2097-0927.202109129","https://doi.org/10.16016/j.2097-0927.202109129",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045713","R0045713.pdf","paywalled","nonrandomized_study","MONICA S. FRAZER","2022","128-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Once-Weekly (OW) Semaglutide","Diabetes","American Diabetes Association","10.2337/db22-128-lb","https://doi.org/10.2337/db22-128-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045892","R0045892.pdf","paywalled","nonrandomized_study","MONICA S. FRAZER","2022","127-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide","Diabetes","American Diabetes Association","10.2337/db22-127-lb","https://doi.org/10.2337/db22-127-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045928","R0045928.pdf","paywalled","nonrandomized_study","PHYO T. HTOO","2022","179-OR: Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study","Diabetes","American Diabetes Association","10.2337/db22-179-or","https://doi.org/10.2337/db22-179-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045962","R0045962.pdf","paywalled","nonrandomized_study","Devin Abrahami","2022","1145-P: Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis","Diabetes","American Diabetes Association","10.2337/db22-1145-p","https://doi.org/10.2337/db22-1145-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046172","R0046172.pdf","paywalled","nonrandomized_study","JOUD A. ABUDAHESH","2022","849-P: Factors Influencing the Selection of Glucose-Lowering Medications among Physicians Treating Patients with Type 2 Diabetes in Real World","Diabetes","American Diabetes Association","10.2337/db22-849-p","https://doi.org/10.2337/db22-849-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046175","R0046175.pdf","paywalled","nonrandomized_study","MIN ZHUO","2022","177-OR: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Incident Atrial Fibrillation in Older Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-177-or","https://doi.org/10.2337/db22-177-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046672","R0046672.pdf","paywalled","nonrandomized_study","Julie M. Paik","2022","863-P: SGLT2i Use and the Risk of Nephrolithiasis in Patients with T2D","Diabetes","American Diabetes Association","10.2337/db22-863-p","https://doi.org/10.2337/db22-863-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046872","R0046872.pdf","paywalled","nonrandomized_study","Francesco Giorgino","2022","746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis","Diabetes","American Diabetes Association","10.2337/db22-746-p","https://doi.org/10.2337/db22-746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046874","R0046874.pdf","paywalled","nonrandomized_study","Ahmed Eltelbany","2022","S1177 Use of GLP1 Agonists or SGLT2 Inhibitors in Non-Alcoholic Steatohepatitis Patients With T2DM Is Associated With a Lower Risk of Cirrhosis: A Nationwide Population-Based Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000861348.86439.43","https://doi.org/10.14309/01.ajg.0000861348.86439.43",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047229","R0047229.pdf","paywalled","nonrandomized_study","David Schapiro","2022","107-LB: Progression of Position of Basal Insulin in the Treatment of Type 2 Diabetes—A Real-World Analysis","Diabetes","American Diabetes Association","10.2337/db22-107-lb","https://doi.org/10.2337/db22-107-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047259","R0047259.pdf","paywalled","nonrandomized_study","AIMIN YANG","2022","934-P: Real-World Evidence of Glucose Lowering Drug Use, Glycemic Outcomes, and Severe Hypoglycemia in Hong Kong: Eighteen-Year Trends in 0.9 Million Adults with Diabetes","Diabetes","American Diabetes Association","10.2337/db22-934-p","https://doi.org/10.2337/db22-934-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047753","R0047753.pdf","paywalled","nonrandomized_study","JUAN J. GORGOJO-MARTINEZ","2022","1440-P: Effects of Two Weight-Loss Medications, Liraglutide and Orlistat, on Liver Enzymes in Patients with Overweight or Obesity in a Real-World Setting","Diabetes","American Diabetes Association","10.2337/db22-1440-p","https://doi.org/10.2337/db22-1440-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048383","R0048383.pdf","paywalled","nonrandomized_study","Rosirene Paczkowski","2022","92-LB: Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with U.S. Real-World Data","Diabetes","American Diabetes Association","10.2337/db22-92-lb","https://doi.org/10.2337/db22-92-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048542","R0048542.pdf","paywalled","nonrandomized_study","Gottfried Rudofsky","2022","FC 124: Real-World Use of Once-Weekly Semaglutide by Baseline Estimated Glomerular Filtration Rate—A Post-Hoc Analysis of Pooled Data From the Sure Studies (Canada, Denmark/Sweden, Switzerland and UK)","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac126.003","https://doi.org/10.1093/ndt/gfac126.003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048643","R0048643.pdf","paywalled","nonrandomized_study","Reema Mody","2022","Greater adherence and persistence with dulaglutide compared to semaglutide at 6- and 12-months follow-up in U.S. real-world data","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746330","https://doi.org/10.1055/s-0042-1746330",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048757","R0048757.pdf","paywalled","nonrandomized_study","Natalie Lambert","2022","618-P: Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits","Diabetes","American Diabetes Association","10.2337/db22-618-p","https://doi.org/10.2337/db22-618-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049080","R0049080.pdf","paywalled","nonrandomized_study","MICHELLE D. LUNDHOLM","2022","1104-P: Prevalence and Clinical Determinants of Nonalcoholic Fatty Liver Disease by Liver Scores in Adults with T1DM","Diabetes","American Diabetes Association","10.2337/db22-1104-p","https://doi.org/10.2337/db22-1104-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049164","R0049164.pdf","paywalled","nonrandomized_study","Rosemarie Lajara","2022","739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study","Diabetes","American Diabetes Association","10.2337/db22-739-p","https://doi.org/10.2337/db22-739-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049165","R0049165.pdf","paywalled","nonrandomized_study","Timothy Silleck Bailey","2022","Real-World-Ergebnisse der Zugabe von Insulin glargin 300 E/ml (Gla-300) zur GLP-1RA-Therapie bei Menschen mit Typ-2-Diabetes (T2D): Die DELIVER-G-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746337","https://doi.org/10.1055/s-0042-1746337",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049342","R0049342.pdf","paywalled","nonrandomized_study","Marco Guazzi","2022","Type 2 diabetes and exercise unexplained dyspnoea: a new focus under the lens with a long way to go yet","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwac177","https://doi.org/10.1093/eurjpc/zwac177","35959738","https://pubmed.ncbi.nlm.nih.gov/35959738/",null,null],["4","R0049544","R0049544.pdf","paywalled","nonrandomized_study","Sandeep Kunwar","2022","1494-PUB: Variable Responses to GLP-1 Receptor Agonists","Diabetes","American Diabetes Association","10.2337/db22-1494-pub","https://doi.org/10.2337/db22-1494-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049771","R0049771.pdf","paywalled","nonrandomized_study","Yixue Shao","2022","895-P: External Validation of the BRAVO Diabetes Model Using Data from the EXSCEL Study","Diabetes","American Diabetes Association","10.2337/db22-895-p","https://doi.org/10.2337/db22-895-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049959","R0049959.pdf","paywalled","nonrandomized_study","Susanne B. Nicholas","2022","Predictors of Persistent Medication Use in Diabetic Kidney Disease (DKD)","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1119d","https://doi.org/10.1681/asn.20223311s1119d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050067","R0050067.pdf","paywalled","nonrandomized_study","Nizar M. Attallah","2022","P8.087: Semaglutide May Be Safe After Kidney Transplant","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000888732.07133.a9","https://doi.org/10.1097/01.tp.0000888732.07133.a9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050084","R0050084.pdf","paywalled","nonrandomized_study","Chandler Howell","2022","Retrospective, cohort review of pharmacists' impact on disparities in care in the management of type 2 diabetes with glucagon‐like peptide‐1 agonists and sodium glucose co‐transporter 2 inhibitors","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","Wiley","10.1002/jac5.1626","https://doi.org/10.1002/jac5.1626",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050114","R0050114.pdf","paywalled","nonrandomized_study","Joji Erik Tokita","2022","14-LB: Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease—A Real-World Evidence Study","Diabetes","American Diabetes Association","10.2337/db22-14-lb","https://doi.org/10.2337/db22-14-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04802395"],["4","R0050373","R0050373.pdf","paywalled","nonrandomized_study","Zahra Mahmoodzadeh","2022","Stratifying Patient Risk for eGFR Decline Over a Year","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1583c","https://doi.org/10.1681/asn.20223311s1583c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050489","R0050489.pdf","paywalled","nonrandomized_study","Femina S. Patel","2022","S1849 Watch out for Semaglutide: Potential Cause of Pancreatitis?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000864036.15004.08","https://doi.org/10.14309/01.ajg.0000864036.15004.08",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050525","R0050525.pdf","paywalled","nonrandomized_study","JAVIER DURON TABORA","2022","183-LB: High Daily Doses of Insulin in Type 2 Diabetes—Predictors beyond Weight","Diabetes","American Diabetes Association","10.2337/db22-183-lb","https://doi.org/10.2337/db22-183-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050623","R0050623.pdf","paywalled","nonrandomized_study","Shailendra Singh","2022","685: RISK OF PANCREATIC CANCER IN PATIENTS TREATED WITH GLUCAGON LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: A LARGE MULTI-CENTER COHORT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(22)60404-9","https://doi.org/10.1016/s0016-5085(22)60404-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050896","R0050896.pdf","paywalled","nonrandomized_study","Tadarro Lee Richardson","2022","Abstract 40: Comparative Effectiveness Of Sglt2 And Glp1ra On Major Adverse Cardiac Events: A National Retrospective Cohort Of Patients With Diabetes","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/circoutcomes.15.suppl_1.40","https://doi.org/10.1161/circoutcomes.15.suppl_1.40",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050938","R0050938.pdf","paywalled","nonrandomized_study","Bruno Guerci","2022","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 12-month data analysis","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746272","https://doi.org/10.1055/s-0042-1746272",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051147","R0051147.pdf","paywalled","nonrandomized_study","Bruno Guerci","2022","726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses","Diabetes","American Diabetes Association","10.2337/db22-726-p","https://doi.org/10.2337/db22-726-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051710","R0051710.pdf","paywalled","nonrandomized_study","Minna Brændholt Olsen","2022","335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db22-335-or","https://doi.org/10.2337/db22-335-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051810","R0051810.pdf","paywalled","nonrandomized_study","KEVIN M. PANTALONE","2022","733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study","Diabetes","American Diabetes Association","10.2337/db22-733-p","https://doi.org/10.2337/db22-733-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051826","R0051826.pdf","paywalled","nonrandomized_study","Petter Bjornstad","2022","MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfac070.013","https://doi.org/10.1093/ndt/gfac070.013",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04865770"],["4","R0051898","R0051898.pdf","paywalled","nonrandomized_study","Ysabel C. Ilagan‐Ying","2022","S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000862020.76034.41","https://doi.org/10.14309/01.ajg.0000862020.76034.41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052345","R0052345.pdf","paywalled","nonrandomized_study","Tyler A. Davis","2022","Predicting Rapid eGFR Decline in the CURE-CKD Registry","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1583a","https://doi.org/10.1681/asn.20223311s1583a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052349","R0052349.pdf","paywalled","nonrandomized_study","Sebastian Dietmar Barth","2022","Changes of Glucagonlike Peptide-1 Receptor Agonist (GLP-1 RA) and Sodium-glucose Co-transporter 2 Inhibitor (SGLT2i) prescription rates in Germany after the ADA/EASD Consensus Report: A Retrospective Study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746404","https://doi.org/10.1055/s-0042-1746404",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052515","R0052515.pdf","paywalled","nonrandomized_study","Jingchuan Serena Guo","2022","Abstract 003: Contextual- And Personal-level Social Determinants Of Health And Real-world Adoption Of Novel Treatments For Improving Cardiovascular Outcomes In Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.145.suppl_1.003","https://doi.org/10.1161/circ.145.suppl_1.003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052728","R0052728.pdf","paywalled","nonrandomized_study","Amgad G. Mentias","2022","Abstract 15797: Cardiovascular Outcomes of Bariatric Surgery and Anti-Obesity Medications in Patients With New Onset Heart Failure and Obesity","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.15797","https://doi.org/10.1161/circ.146.suppl_1.15797",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052749","R0052749.pdf","paywalled","nonrandomized_study","Jean‐François Yale","2022","Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746335","https://doi.org/10.1055/s-0042-1746335",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052848","R0052848.pdf","paywalled","nonrandomized_study","Ryan Sun","2022","Diabetes, Diabetic Control, and Kidney Dysfunction in Adults with Sickle Cell Disease","Blood","American Society of Hematology","10.1182/blood-2022-165314","https://doi.org/10.1182/blood-2022-165314",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052892","R0052892.pdf","paywalled","nonrandomized_study","Gareth Iacobucci","2022","Sixty seconds on . . . the woman who can smell Parkinson’s","BMJ","BMJ","10.1136/bmj.o2247","https://doi.org/10.1136/bmj.o2247","36109018","https://pubmed.ncbi.nlm.nih.gov/36109018/",null,null],["4","R0053095","R0053095.pdf","paywalled","nonrandomized_study","Arash Aghajani Nargesi","2022","Abstract 10019: Access to Specialty Cardiovascular Care and Uptake of Cardioprotective Anti-Hyperglycemic Agents Among Adults With Type 2 Diabetes: A Cohort Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.10019","https://doi.org/10.1161/circ.146.suppl_1.10019",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053136","R0053136.pdf","paywalled","nonrandomized_study","Jonathan Pham","2022","S917 Effectiveness and Safety of Weight Loss Medical Therapy in Ulcerative Colitis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000860308.31550.96","https://doi.org/10.14309/01.ajg.0000860308.31550.96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053274","R0053274.pdf","paywalled","nonrandomized_study","Jingchuan Serena Guo","2022","Abstract P108: Natural Language Processing Extracted Social And Behavioral Determinants Of Health And Newer Glucose-lowering Drug Initiation Among Real-world Patients With Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.145.suppl_1.p108","https://doi.org/10.1161/circ.145.suppl_1.p108",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053303","R0053303.pdf","paywalled","nonrandomized_study","Jonathan Mertens","2022","751-P: Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial","Diabetes","American Diabetes Association","10.2337/db22-751-p","https://doi.org/10.2337/db22-751-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053338","R0053338.pdf","paywalled","nonrandomized_study","Sumaiah J. Alarfaj","2022","Effectiveness, tolerability, and pattern of liraglutide treatment use for weight loss: a mixed-methods cohort study","Journal Of Advanced Pharmacy Education And Research","Polaris","10.51847/wav0cpt0bt","https://doi.org/10.51847/wav0cpt0bt",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055057","R0055057.pdf","paywalled","nonrandomized_study","JULIO A. LAMPREA MONTEALEGRE","2022","178-OR: Prescription Patterns of Cardiovascular and Kidney Protective Therapies among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-178-or","https://doi.org/10.2337/db22-178-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055301","R0055301.pdf","paywalled","nonrandomized_study","Aakash Tuli","2022","Abstract 14504: Gender and Racial Disparities in Patients Using Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Analogues in a Real-World Scenario","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.14504","https://doi.org/10.1161/circ.146.suppl_1.14504",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056971","R0056971.pdf","paywalled","nonrandomized_study","Kuchay MS","2022","Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2022.102446","https://doi.org/10.1016/j.dsx.2022.102446","35259705","https://pubmed.ncbi.nlm.nih.gov/35259705/",null,null],["4","R0056973","R0056973.pdf","paywalled","nonrandomized_study","Hidalgo Rodríguez A","2022","Role of therapeutic inertia in glycemic control according to individualized objectives in a cohort of patients with type 2 diabetes. Results from CONCARDIA2.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endien.2022.07.003","https://doi.org/10.1016/j.endien.2022.07.003","36038497","https://pubmed.ncbi.nlm.nih.gov/36038497/",null,null],["4","R0005711","R0005711.pdf","paywalled","nonrandomized_study","Kyriakidou A","2021","Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/1381612826666201203145654","https://doi.org/10.2174/1381612826666201203145654","33272167","https://pubmed.ncbi.nlm.nih.gov/33272167/",null,null],["4","R0006724","R0006724.pdf","paywalled","nonrandomized_study","Morieri ML","2021","Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2021.08.049","https://doi.org/10.1016/j.numecd.2021.08.049","34629258","https://pubmed.ncbi.nlm.nih.gov/34629258/",null,null],["4","R0007020","R0007020.pdf","paywalled","nonrandomized_study","Hsiao FC","2021","Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109076","https://doi.org/10.1016/j.diabres.2021.109076","34599973","https://pubmed.ncbi.nlm.nih.gov/34599973/",null,null],["4","R0007140","R0007140.pdf","paywalled","nonrandomized_study","Hofer F","2021","Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-021-07160-8","https://doi.org/10.1007/s10557-021-07160-8","33666822","https://pubmed.ncbi.nlm.nih.gov/33666822/",null,null],["4","R0007296","R0007296.pdf","paywalled","nonrandomized_study","Tang EHM","2021","Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109071","https://doi.org/10.1016/j.diabres.2021.109071","34592391","https://pubmed.ncbi.nlm.nih.gov/34592391/",null,null],["4","R0007306","R0007306.pdf","paywalled","nonrandomized_study","Dauner DG","2021","Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2021.1887136","https://doi.org/10.1080/14740338.2021.1887136","33554677","https://pubmed.ncbi.nlm.nih.gov/33554677/",null,null],["4","R0007497","R0007497.pdf","paywalled","nonrandomized_study","Battise DM","2021","A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.","Journal of the American Association of Nurse Practitioners","Ovid Technologies (Wolters Kluwer Health)","10.1097/jxx.0000000000000516","https://doi.org/10.1097/jxx.0000000000000516","33105320","https://pubmed.ncbi.nlm.nih.gov/33105320/",null,null],["4","R0007600","R0007600.pdf","paywalled","nonrandomized_study","Neilson LM","2021","Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.","Medical care","Ovid Technologies (Wolters Kluwer Health)","10.1097/mlr.0000000000001597","https://doi.org/10.1097/mlr.0000000000001597","34183622","https://pubmed.ncbi.nlm.nih.gov/34183622/",null,null],["4","R0007825","R0007825.pdf","paywalled","nonrandomized_study","Sammour Y","2021","Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","Elsevier BV","10.1016/j.healun.2021.02.012","https://doi.org/10.1016/j.healun.2021.02.012","33745782","https://pubmed.ncbi.nlm.nih.gov/33745782/",null,null],["4","R0008579","R0008579.pdf","paywalled","nonrandomized_study","Frieling K","2021","Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2021.06.015","https://doi.org/10.1016/j.japh.2021.06.015","34266747","https://pubmed.ncbi.nlm.nih.gov/34266747/",null,null],["4","R0009231","R0009231.pdf","paywalled","nonrandomized_study","Bucsa C","2021","Drug utilisation study of antidiabetic medication during 2012-2019 in Romania.","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.14770","https://doi.org/10.1111/ijcp.14770","34473890","https://pubmed.ncbi.nlm.nih.gov/34473890/",null,null],["4","R0009242","R0009242.pdf","paywalled","nonrandomized_study","Abitbol A","2021","Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108920","https://doi.org/10.1016/j.diabres.2021.108920","34139288","https://pubmed.ncbi.nlm.nih.gov/34139288/",null,null],["4","R0010116","R0010116.pdf","paywalled","nonrandomized_study","Lee J","2021","Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3466","https://doi.org/10.1002/dmrr.3466","33957706","https://pubmed.ncbi.nlm.nih.gov/33957706/",null,null],["4","R0010857","R0010857.pdf","paywalled","nonrandomized_study","Su YC","2021","Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14445","https://doi.org/10.1111/dom.14445","34047442","https://pubmed.ncbi.nlm.nih.gov/34047442/",null,null],["4","R0011114","R0011114.pdf","paywalled","nonrandomized_study","Brunetti VC","2021","SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5192","https://doi.org/10.1002/pds.5192","33428309","https://pubmed.ncbi.nlm.nih.gov/33428309/",null,null],["4","R0011185","R0011185.pdf","paywalled","nonrandomized_study","Liss DT","2021","Costs for commercially insured adults prescribed second-line diabetes medications.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2021.88601","https://doi.org/10.37765/ajmc.2021.88601","33720672","https://pubmed.ncbi.nlm.nih.gov/33720672/",null,null],["4","R0011360","R0011360.pdf","paywalled","nonrandomized_study","Paul SK","2021","The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaa956","https://doi.org/10.1093/eurheartj/ehaa956","33289789","https://pubmed.ncbi.nlm.nih.gov/33289789/",null,null],["4","R0012117","R0012117.pdf","paywalled","nonrandomized_study","Koufakis T","2021","Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14496","https://doi.org/10.1111/dme.14496","33306839","https://pubmed.ncbi.nlm.nih.gov/33306839/",null,null],["4","R0012415","R0012415.pdf","paywalled","nonrandomized_study","Sun JW","2021","Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14237","https://doi.org/10.1111/dom.14237","33118291","https://pubmed.ncbi.nlm.nih.gov/33118291/",null,null],["4","R0012503","R0012503.pdf","paywalled","nonrandomized_study","Daios S","2021","Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0929867327666201009143816","https://doi.org/10.2174/0929867327666201009143816","33038906","https://pubmed.ncbi.nlm.nih.gov/33038906/",null,null],["4","R0012587","R0012587.pdf","paywalled","nonrandomized_study","Gonzalez CL","2021","GLP-1 Analogs Are Superior in Mediating Weight Loss But Not Glycemic Control in Diabetic Patients on Antidepressant Medications: A Retrospective Cohort Study.","The primary care companion for CNS disorders","Physicians Postgraduate Press, Inc","10.4088/pcc.20m02868","https://doi.org/10.4088/pcc.20m02868","34507389","https://pubmed.ncbi.nlm.nih.gov/34507389/",null,null],["4","R0012974","R0012974.pdf","paywalled","nonrandomized_study","Hansen KB","2021","Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14655","https://doi.org/10.1111/dme.14655","34291491","https://pubmed.ncbi.nlm.nih.gov/34291491/",null,null],["4","R0013105","R0013105.pdf","paywalled","nonrandomized_study","Santos-Pardo I","2021","Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2021.02.011","https://doi.org/10.1016/j.ijcard.2021.02.011","33621623","https://pubmed.ncbi.nlm.nih.gov/33621623/",null,null],["4","R0013178","R0013178.pdf","paywalled","nonrandomized_study","Li P","2021","The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2021.1971181","https://doi.org/10.1080/03007995.2021.1971181","34429001","https://pubmed.ncbi.nlm.nih.gov/34429001/",null,null],["4","R0013248","R0013248.pdf","paywalled","nonrandomized_study","Laursen HVB","2021","Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.","Current drug safety","Bentham Science Publishers Ltd.","10.2174/1574886315666200819114629","https://doi.org/10.2174/1574886315666200819114629","32814538","https://pubmed.ncbi.nlm.nih.gov/32814538/",null,null],["4","R0014982","R0014982.pdf","paywalled","nonrandomized_study","Guarnotta V","2021","Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2021.07.015","https://doi.org/10.1016/j.numecd.2021.07.015","34518091","https://pubmed.ncbi.nlm.nih.gov/34518091/",null,null],["4","R0015599","R0015599.pdf","paywalled","nonrandomized_study","DeRemer CE","2021","Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2021.107972","https://doi.org/10.1016/j.jdiacomp.2021.107972","34247911","https://pubmed.ncbi.nlm.nih.gov/34247911/",null,null],["4","R0017589","R0017589.pdf","paywalled","nonrandomized_study","Issar T","2021","Effect of exenatide on peripheral nerve excitability in type 2 diabetes.","Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology","Elsevier BV","10.1016/j.clinph.2021.05.033","https://doi.org/10.1016/j.clinph.2021.05.033","34455311","https://pubmed.ncbi.nlm.nih.gov/34455311/",null,null],["4","R0018794","R0018794.pdf","paywalled","nonrandomized_study","Lou W","2021","Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations.","Biotechnology and bioengineering","Wiley","10.1002/bit.27610","https://doi.org/10.1002/bit.27610","33095442","https://pubmed.ncbi.nlm.nih.gov/33095442/",null,null],["4","R0018884","R0018884.pdf","paywalled","nonrandomized_study","Kalff V","2021","Utility of 68 Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia.","Internal medicine journal","Wiley","10.1111/imj.15141","https://doi.org/10.1111/imj.15141","33314504","https://pubmed.ncbi.nlm.nih.gov/33314504/",null,null],["4","R0019623","R0019623.pdf","paywalled","nonrandomized_study","Almutairi M","2021","The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2020.02.098","https://doi.org/10.1016/j.cjca.2020.02.098","32640211","https://pubmed.ncbi.nlm.nih.gov/32640211/",null,null],["4","R0019654","R0019654.pdf","paywalled","nonrandomized_study","Gazda CL","2021","Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23146","https://doi.org/10.1002/oby.23146","33818009","https://pubmed.ncbi.nlm.nih.gov/33818009/",null,null],["4","R0019722","R0019722.pdf","paywalled","nonrandomized_study","Bezerra CB","2021","Characteristics of the clinical treatment of Brazilian and French older adults with diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109088","https://doi.org/10.1016/j.diabres.2021.109088","34648889","https://pubmed.ncbi.nlm.nih.gov/34648889/",null,null],["4","R0019795","R0019795.pdf","paywalled","nonrandomized_study","Carretero Gómez J","2021","Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2021.1965563","https://doi.org/10.1080/03007995.2021.1965563","34357836","https://pubmed.ncbi.nlm.nih.gov/34357836/",null,null],["4","R0020090","R0020090.pdf","paywalled","nonrandomized_study","Fang X","2021","Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.","Life sciences","Elsevier BV","10.1016/j.lfs.2020.118966","https://doi.org/10.1016/j.lfs.2020.118966","33482185","https://pubmed.ncbi.nlm.nih.gov/33482185/",null,null],["4","R0021395","R0021395.pdf","paywalled","nonrandomized_study","Morieri ML","2021","Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-021-01501-y","https://doi.org/10.1007/s40618-021-01501-y","33432553","https://pubmed.ncbi.nlm.nih.gov/33432553/",null,null],["4","R0021676","R0021676.pdf","paywalled","nonrandomized_study","Jacob S","2021","Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-021-01554-6","https://doi.org/10.1007/s40265-021-01554-6","34302636","https://pubmed.ncbi.nlm.nih.gov/34302636/",null,null],["4","R0022174","R0022174.pdf","paywalled","nonrandomized_study","Hao Q","2021","Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.","Annals of internal medicine","American College of Physicians","10.7326/acpj202101190-011","https://doi.org/10.7326/acpj202101190-011","33395335","https://pubmed.ncbi.nlm.nih.gov/33395335/",null,null],["4","R0023474","R0023474.pdf","paywalled","nonrandomized_study","Badurdeen D","2021","Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2020.10.016","https://doi.org/10.1016/j.gie.2020.10.016","33075366","https://pubmed.ncbi.nlm.nih.gov/33075366/",null,null],["4","R0023823","R0023823.pdf","paywalled","nonrandomized_study","DI Giuseppe G","2021","Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.","Minerva endocrinology","Edizioni Minerva Medica","10.23736/s2724-6507.21.03405-9","https://doi.org/10.23736/s2724-6507.21.03405-9","34218657","https://pubmed.ncbi.nlm.nih.gov/34218657/",null,null],["4","R0023888","R0023888.pdf","paywalled","nonrandomized_study","Pradhan R","2021","Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.2213","https://doi.org/10.1002/cpt.2213","33615445","https://pubmed.ncbi.nlm.nih.gov/33615445/",null,null],["4","R0023914","R0023914.pdf","paywalled","nonrandomized_study","Bomholt T","2021","The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.","Nephron","S. Karger AG","10.1159/000510613","https://doi.org/10.1159/000510613","33105146","https://pubmed.ncbi.nlm.nih.gov/33105146/",null,null],["4","R0024554","R0024554.pdf","paywalled","nonrandomized_study","Al-Musawe L","2021","Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-021-03107-y","https://doi.org/10.1007/s00228-021-03107-y","33743016","https://pubmed.ncbi.nlm.nih.gov/33743016/",null,null],["4","R0024783","R0024783.pdf","paywalled","nonrandomized_study","Suissa K","2021","Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14367","https://doi.org/10.1111/dom.14367","33651454","https://pubmed.ncbi.nlm.nih.gov/33651454/",null,null],["4","R0025265","R0025265.pdf","paywalled","nonrandomized_study","Abrahami D","2021","Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.2012","https://doi.org/10.1002/cpt.2012","32767673","https://pubmed.ncbi.nlm.nih.gov/32767673/",null,null],["4","R0025592","R0025592.pdf","paywalled","nonrandomized_study","Clegg LE","2021","Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14313","https://doi.org/10.1111/dom.14313","33394543","https://pubmed.ncbi.nlm.nih.gov/33394543/",null,null],["4","R0025890","R0025890.pdf","paywalled","nonrandomized_study","Vendrame F","2021","Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2021.107884","https://doi.org/10.1016/j.jdiacomp.2021.107884","33610436","https://pubmed.ncbi.nlm.nih.gov/33610436/",null,null],["4","R0028458","R0028458.pdf","paywalled","nonrandomized_study","Watanabe H","2021","Letter to the Editor from Watanabe et al: \"Long-term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study\".","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgab082","https://doi.org/10.1210/clinem/dgab082","33564886","https://pubmed.ncbi.nlm.nih.gov/33564886/",null,null],["4","R0030094","R0030094.pdf","paywalled","nonrandomized_study","D'Onofrio L","2021","Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108681","https://doi.org/10.1016/j.diabres.2021.108681","33516784","https://pubmed.ncbi.nlm.nih.gov/33516784/",null,null],["4","R0030355","R0030355.pdf","paywalled","nonrandomized_study","Meredith AH","2021","Assessment of clinical inertia in people with diabetes within primary care.","Journal of evaluation in clinical practice","Wiley","10.1111/jep.13429","https://doi.org/10.1111/jep.13429","32548871","https://pubmed.ncbi.nlm.nih.gov/32548871/",null,null],["4","R0030377","R0030377.pdf","paywalled","nonrandomized_study","Kawano R","2021","Short energy intake is associated with muscle mass loss in older patients with type 2 diabetes: A prospective study of the KAMOGAWA-DM cohort.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2021.02.049","https://doi.org/10.1016/j.clnu.2021.02.049","33752149","https://pubmed.ncbi.nlm.nih.gov/33752149/",null,null],["4","R0031122","R0031122.pdf","paywalled","nonrandomized_study","Zinnat ara nasreen Shaikh","2021","POLYCYSTIC OVARY SYNDROME WITH METABOLIC SYNDROME","Journal of medical case reports and reviews",null,"10.15520/jmcrr.v4i06.257","https://doi.org/10.15520/jmcrr.v4i06.257",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031265","R0031265.pdf","paywalled","nonrandomized_study","HoJin Shin","2021","977-P: Trends in First-Line Glucose-Lowering Drug Use in Adults with Type 2 Diabetes in Light of Emerging Evidence for SGLT2i and GLP-1RA","Diabetes","American Diabetes Association","10.2337/db21-977-p","https://doi.org/10.2337/db21-977-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031498","R0031498.pdf","paywalled","nonrandomized_study","Santiago Tofé","2021","Effectiveness, Safety and Therapeutic Adherenceof Weekly Subcutaneous Semaglutide for WeightManagement in Real Practice: An Observational Study",null,null,"10.32474/ado.2021.03.000161","https://doi.org/10.32474/ado.2021.03.000161",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031529","R0031529.pdf","paywalled","nonrandomized_study","Utibe R. Essien","2021","316-OR: Diabetes Care among Older Adults Enrolled in Medicare Advantage vs. Traditional Medicare Fee-for-Service Plans: The Diabetes Collaborative Registry","Diabetes","American Diabetes Association","10.2337/db21-316-or","https://doi.org/10.2337/db21-316-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031554","R0031554.pdf","paywalled","nonrandomized_study","Jersy Cárdenas‐Salas","2021","690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain","Diabetes","American Diabetes Association","10.2337/db21-690-p","https://doi.org/10.2337/db21-690-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032595","R0032595.pdf","paywalled","nonrandomized_study",null,"2021","The Use of SGLT2i and GLP-1 RA in Patients with Type 2 Diabetes in Thailand: Evidence Review and Recommendations","Journal of the Medical Association of Thailand","Medical Association of Thailand","10.35755/jmedassocthai.2021.11.13163","https://doi.org/10.35755/jmedassocthai.2021.11.13163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033719","R0033719.pdf","paywalled","nonrandomized_study","Schechter, Meir","2021","Additional file 1 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence","Figshare",null,"10.6084/m9.figshare.15253888","https://doi.org/10.6084/m9.figshare.15253888",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033783","R0033783.pdf","paywalled","nonrandomized_study","Seidel, Karolin","2021","Prescription frequency and development of liraglutide and empagliflozin in the light of current DMP recommendations: a German real-world cohort study in type 2 diabetes mellitus patients at high cardiovascular risk","German Medical Science (German Research Foundation)",null,"10.3205/21dkvf068","https://doi.org/10.3205/21dkvf068",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033842","R0033842.pdf","paywalled","nonrandomized_study","Lugner, Moa","2021","Additional file 1 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","Figshare",null,"10.6084/m9.figshare.14267035","https://doi.org/10.6084/m9.figshare.14267035",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033903","R0033903.pdf","paywalled","nonrandomized_study","Lugner, Moa","2021","Additional file 2 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","Figshare",null,"10.6084/m9.figshare.14267038","https://doi.org/10.6084/m9.figshare.14267038",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034290","R0034290.pdf","paywalled","nonrandomized_study","Rakesh Kumar Singh","2021","A Systematic Literature Review of Treatment Patterns, Safety Profiles, and Long-Term Disease Progression in Patients with CKD and Type 2 Diabetes Mellitus","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1719b","https://doi.org/10.1681/asn.20213210s1719b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034322","R0034322.pdf","paywalled","nonrandomized_study","Miguel Sierra Poyatos Roberto","2021","Comparison of the clinical efficacy of Semaglutide between DPP4-inhibitor-naive and DPP4-inhibitor-experienced patients in a real world setting in Spain","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.73.aep809","https://doi.org/10.1530/endoabs.73.aep809",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034466","R0034466.pdf","paywalled","nonrandomized_study","Kazuo Kobayashi","2021","A Comparison of the Renal Composite Outcome Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in Japanese Diabetes Patients","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1265a","https://doi.org/10.1681/asn.20213210s1265a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034561","R0034561.pdf","paywalled","nonrandomized_study","Tanveer Ashraf","2021","Real-world clinical experience of IDegLira in the management of adolescents with type 2 diabetes",null,"Morressier","10.26226/morressier.617c37317c09fc044a9751c3","https://doi.org/10.26226/morressier.617c37317c09fc044a9751c3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034610","R0034610.pdf","paywalled","nonrandomized_study","Mohammad E. Khamseh","2021","VIEW-Iran: A real-world study of liraglutide effectiveness on glycaemic control in people with type 2 diabetes mellitus",null,"Morressier","10.26226/morressier.617c37307c09fc044a97510e","https://doi.org/10.26226/morressier.617c37307c09fc044a97510e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035058","R0035058.pdf","paywalled","nonrandomized_study","Jean‐François Yale","2021","Real-World Use of Once-Weekly Semaglutide in Diverse Patient Populations With Type 2 Diabetes: Pooled Analysis of Four SURE Studies","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2021.09.084","https://doi.org/10.1016/j.jcjd.2021.09.084",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035989","R0035989.pdf","paywalled","nonrandomized_study","Hyun-Ju Jung","2021","Clinical characteristics, treatment patterns and persistence in patients with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727302","https://doi.org/10.1055/s-0041-1727302",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037331","R0037331.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of","2021","Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results","Figshare",null,"10.6084/m9.figshare.16913317","https://doi.org/10.6084/m9.figshare.16913317",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037572","R0037572.pdf","paywalled","nonrandomized_study","Of:, Adis Journals On Behalf","2021","Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a USA Real-World Setting","Figshare",null,"10.6084/m9.figshare.14248778","https://doi.org/10.6084/m9.figshare.14248778",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037940","R0037940.pdf","paywalled","nonrandomized_study","Boris Draznin","2021","22-LB: Use of a Novel Virtual Patient Simulation Application to Assess Providers’ Knowledge in Management of T2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-22-lb","https://doi.org/10.2337/db21-22-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038363","R0038363.pdf","paywalled","nonrandomized_study","Pichamol Jirapinyo","2021","S1264 Combination Therapy Yields Similar Efficacy and Improved Safety Compared to Surgical Revision for the Management of Weight Regain Following Roux-en-Y Gastric Bypass","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000778588.31528.c7","https://doi.org/10.14309/01.ajg.0000778588.31528.c7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038609","R0038609.pdf","paywalled","nonrandomized_study","Of, Adis Journals On Behalf","2021","Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis","Figshare",null,"10.6084/m9.figshare.14308688.v1","https://doi.org/10.6084/m9.figshare.14308688.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038613","R0038613.pdf","paywalled","nonrandomized_study","Of, Adis Journals On Behalf","2021","Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain","Figshare",null,"10.6084/m9.figshare.14077409","https://doi.org/10.6084/m9.figshare.14077409",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038667","R0038667.pdf","paywalled","nonrandomized_study","Gustavo Adolfo Parra-Serrano","2021","106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia","Diabetes","American Diabetes Association","10.2337/db21-106-lb","https://doi.org/10.2337/db21-106-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038758","R0038758.pdf","paywalled","nonrandomized_study","Jing Luo","2021","1093-P: Incidence of Primary Nonadherence to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Agonists (GLP-1A) in an Integrated Health Care System","Diabetes","American Diabetes Association","10.2337/db21-1093-p","https://doi.org/10.2337/db21-1093-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038984","R0038984.pdf","paywalled","nonrandomized_study","Adis Journals On Behalf Of","2021","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics","Figshare",null,"10.6084/m9.figshare.14547270","https://doi.org/10.6084/m9.figshare.14547270",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039010","R0039010.pdf","paywalled","nonrandomized_study","Haritha Gaddipati","2021","Abstract 10809: Socioeconomic Factors Affect Prescription Patterns of the Newer Anti-Diabetic Medications","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.10809","https://doi.org/10.1161/circ.144.suppl_1.10809",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039167","R0039167.pdf","paywalled","nonrandomized_study","Longato, Enrico","2021","Additional file 1 of Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study","Figshare",null,"10.6084/m9.figshare.17007077","https://doi.org/10.6084/m9.figshare.17007077",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039364","R0039364.pdf","paywalled","nonrandomized_study","Of, Adis Journals On Behalf","2021","Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study","Figshare",null,"10.6084/m9.figshare.13651214","https://doi.org/10.6084/m9.figshare.13651214",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039492","R0039492.pdf","paywalled","nonrandomized_study","Of, Adis Journals On Behalf","2021","Switch-to-Semaglutide Study (STS-Study) – a Retrospective Cohort Study","Figshare",null,"10.6084/m9.figshare.13655921","https://doi.org/10.6084/m9.figshare.13655921",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041504","R0041504.pdf","paywalled","nonrandomized_study","Carlos Mario Balcázar Valencia","2021","Semaglutide Once Weekly In Persons with Type 2 Diabetes: Real-World Analysis of the Colombian Diabetes Registry (COL-REAL 1 Study)","Metabolism","Elsevier BV","10.1016/j.metabol.2020.154640","https://doi.org/10.1016/j.metabol.2020.154640",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041708","R0041708.pdf","paywalled","nonrandomized_study","Stefano Angelo Santini","2021","Weight-loss on liraglutide in a real-life swiss obese cohort","Clinical Nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2021.09.428","https://doi.org/10.1016/j.clnesp.2021.09.428",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044831","R0044831.pdf","paywalled","nonrandomized_study","Filippo Crea","2021","New challenges in vascular biology and medicine: from unravelling the mechanisms of neointima formation to the prevention of amputations and of ischaemic stroke","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab224","https://doi.org/10.1093/eurheartj/ehab224","33962463","https://pubmed.ncbi.nlm.nih.gov/33962463/",null,null],["4","R0045456","R0045456.pdf","paywalled","nonrandomized_study","Masashi Hasebe","2021","687-P: ß-Cell Function and Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-687-p","https://doi.org/10.2337/db21-687-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045832","R0045832.pdf","paywalled","nonrandomized_study","Vincent J. Willey","2021","652-P: Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a U.S. Commercially Insured and Medicare Advantage Population","Diabetes","American Diabetes Association","10.2337/db21-652-p","https://doi.org/10.2337/db21-652-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046281","R0046281.pdf","paywalled","nonrandomized_study","Nitin Shivappa","2021","683-P: Real-World Evaluation of Once-Weekly Semaglutide (Sema OW) in Patients Newly Initiating GLP-1 Agonist Therapy","Diabetes","American Diabetes Association","10.2337/db21-683-p","https://doi.org/10.2337/db21-683-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046379","R0046379.pdf","paywalled","nonrandomized_study","Vincent J. Willey","2021","653-P: Evaluating Antidiabetic Medication Treatment Patterns in T2D Patients Initiating Once-Weekly Semaglutide (sema OW)","Diabetes","American Diabetes Association","10.2337/db21-653-p","https://doi.org/10.2337/db21-653-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046611","R0046611.pdf","paywalled","nonrandomized_study","Tetsuhiko Sato","2021","A Possible Effect of Glucagon-Like Peptide 1 Receptor Enhancement on Graft Kidney Function","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1668b","https://doi.org/10.1681/asn.20213210s1668b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046693","R0046693.pdf","paywalled","nonrandomized_study","Fatheya Al Awadi","2021","INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE",null,"Morressier","10.26226/morressier.61a8b7aabe545488cfae58b7","https://doi.org/10.26226/morressier.61a8b7aabe545488cfae58b7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046719","R0046719.pdf","paywalled","nonrandomized_study","Sophie Trujillo","2021","S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC?","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000778232.15515.30","https://doi.org/10.14309/01.ajg.0000778232.15515.30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046723","R0046723.pdf","paywalled","nonrandomized_study","Ryotaro Bouchi","2021","1086-P: A Retrospective Nationwide Surveillance on the First-Line Antidiabetic Medication for the Patients with Type 2 Diabetes in Japan","Diabetes","American Diabetes Association","10.2337/db21-1086-p","https://doi.org/10.2337/db21-1086-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046831","R0046831.pdf","paywalled","nonrandomized_study","Nitin Shivappa","2021","1271-PUB: Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty","Diabetes","American Diabetes Association","10.2337/db21-1271-pub","https://doi.org/10.2337/db21-1271-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046876","R0046876.pdf","paywalled","nonrandomized_study","Reema Mody","2021","982-P: Use of Antihyperglycemic Agents (AHA) with Cardioprotective Benefit in Older Patients with T2D and CVD or CV Risk Factors","Diabetes","American Diabetes Association","10.2337/db21-982-p","https://doi.org/10.2337/db21-982-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046931","R0046931.pdf","paywalled","nonrandomized_study","Laurent Fauchier","2021","Antidiabetic drugs use and new-onset atrial fibrillation in patients with diabetes mellitus","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehab724.0457","https://doi.org/10.1093/eurheartj/ehab724.0457",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047502","R0047502.pdf","paywalled","nonrandomized_study","Francesco Giorgino","2021","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-month analysis results","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727333","https://doi.org/10.1055/s-0041-1727333",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047507","R0047507.pdf","paywalled","nonrandomized_study","Reema Mody","2021","654-P: Greater Adherence and Persistence with Dulaglutide Compared with Semaglutide at 6- and 12-Months Follow-up in U.S. Real-World Data","Diabetes","American Diabetes Association","10.2337/db21-654-p","https://doi.org/10.2337/db21-654-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047585","R0047585.pdf","paywalled","nonrandomized_study","Ankeet S. Bhatt","2021","Abstract 14383: Medical Therapy Before, During, and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: The Get With the Guidelines - Heart Failure Registry","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.14383","https://doi.org/10.1161/circ.144.suppl_1.14383",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047626","R0047626.pdf","paywalled","nonrandomized_study","Hemalkumar B. Mehta","2021","Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/1yfd-sc03","https://doi.org/10.17615/1yfd-sc03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047754","R0047754.pdf","paywalled","nonrandomized_study","Omar Ali Alaber","2021","987-P: Comparative Cardiovascular (CV) Effectiveness of SGLT2 Inhibitors (SGLT2i) and GLP-1 Receptor Agonists (GLP-1 RA) in Patients with Type 2 Diabetes Mellitus (T2DM): A Large National Database Study","Diabetes","American Diabetes Association","10.2337/db21-987-p","https://doi.org/10.2337/db21-987-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047841","R0047841.pdf","paywalled","nonrandomized_study","Joana R. N. Lemos","2021","P.106: Prolonged Islet Allograft Function in Patients With Type 1 Diabetes After Islet Transplantation Is Associated With Female Sex of Donors and Recipients","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000804512.50554.05","https://doi.org/10.1097/01.tp.0000804512.50554.05",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048087","R0048087.pdf","paywalled","nonrandomized_study","JJ Meier","2021","Vergleich von iGlarLixi mit einem Basal-Bolusregime bei Patienten mit Typ-2-Diabetes mittels Propensity-Score-Matching (PSM)","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727306","https://doi.org/10.1055/s-0041-1727306",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT01768559"],["4","R0048493","R0048493.pdf","paywalled","nonrandomized_study","Daniel Boris Amusin","2021","689-P: Association of Preoperative Glycemic Response to GLP-1 Receptor Agonists (GLP-1RA) and Outcomes of Bariatric Surgery","Diabetes","American Diabetes Association","10.2337/db21-689-p","https://doi.org/10.2337/db21-689-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048521","R0048521.pdf","paywalled","nonrandomized_study","Phyo Than Htoo","2021","Abstract 12579: Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.12579","https://doi.org/10.1161/circ.144.suppl_1.12579",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048697","R0048697.pdf","paywalled","nonrandomized_study","M Ammar Kalas","2021","S518 Frequency of GLP-1 Analog Use in Diabetic Patients With Delayed GES and Their Demographic Profile","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000774548.78766.83","https://doi.org/10.14309/01.ajg.0000774548.78766.83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049159","R0049159.pdf","paywalled","nonrandomized_study","Zryan Shwani","2021","S1255 Effect of Weight Loss Surgery and Weight Loss Medications on the Risk of Colorectal Cancer: A Nationwide Population-Based Cohort Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000778552.40501.29","https://doi.org/10.14309/01.ajg.0000778552.40501.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049278","R0049278.pdf","paywalled","nonrandomized_study","IOANNIS ZOUPAS","2021","88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 Inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real-World Data from Both Urban and Rural Clinics","Diabetes","American Diabetes Association","10.2337/db21-88-lb","https://doi.org/10.2337/db21-88-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049537","R0049537.pdf","paywalled","nonrandomized_study","Cami R. Jones","2021","Characteristics of Patients with CKD and Diabetes by Use of ACE Inhibitors or ARBs","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1270a","https://doi.org/10.1681/asn.20213210s1270a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049742","R0049742.pdf","paywalled","nonrandomized_study","Ulrik Bodholdt","2021","645-P: Mobile Health Application as a Real-World Data Resource: Self-Recorded Weight Reduction with Once-Weekly Semaglutide","Diabetes","American Diabetes Association","10.2337/db21-645-p","https://doi.org/10.2337/db21-645-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049899","R0049899.pdf","paywalled","nonrandomized_study","Marc Evans","2021","82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET)","Diabetes","American Diabetes Association","10.2337/db21-82-lb","https://doi.org/10.2337/db21-82-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050065","R0050065.pdf","paywalled","nonrandomized_study","Min Zhuo","2021","Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of AKI in Older Adults with Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1132d","https://doi.org/10.1681/asn.20213210s1132d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050145","R0050145.pdf","paywalled","nonrandomized_study","María Dolores García de Lucas","2021","676-P: Semaglutide Achieves Better Metabolic and Weight Control than Other GLP-1 RA in Real Life after 12 Months of Follow-up","Diabetes","American Diabetes Association","10.2337/db21-676-p","https://doi.org/10.2337/db21-676-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050188","R0050188.pdf","paywalled","nonrandomized_study","Meredith M. Hoog","2021","649-P: Impact of Early Initiation of Dulaglutide on A1C in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-649-p","https://doi.org/10.2337/db21-649-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050259","R0050259.pdf","paywalled","nonrandomized_study","Pratik M. Pimple","2021","808-P: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-808-p","https://doi.org/10.2337/db21-808-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050271","R0050271.pdf","paywalled","nonrandomized_study","Colleen Gavigan","2021","640-P: Addition of a GLP-1 Agonist to Insulin Therapy in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-640-p","https://doi.org/10.2337/db21-640-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050333","R0050333.pdf","paywalled","nonrandomized_study","Phyo Than Htoo","2021","Abstract 10855: Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patients: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.10855","https://doi.org/10.1161/circ.144.suppl_1.10855",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050337","R0050337.pdf","paywalled","nonrandomized_study","Reema Mody","2021","851-P: Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2D and CVD or CV Risk in the U.S.","Diabetes","American Diabetes Association","10.2337/db21-851-p","https://doi.org/10.2337/db21-851-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050603","R0050603.pdf","paywalled","nonrandomized_study","Joana R. N. Lemos","2021","207.6: Effect of HLA Matching on Long Term Islet Allograft Function","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000804300.48048.a1","https://doi.org/10.1097/01.tp.0000804300.48048.a1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050612","R0050612.pdf","paywalled","nonrandomized_study","Lisa Chu","2021","410-P: Therapeutic Profile from the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","Diabetes","American Diabetes Association","10.2337/db21-410-p","https://doi.org/10.2337/db21-410-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050678","R0050678.pdf","paywalled","nonrandomized_study","Stephen A. Firkins","2021","Sa354 OUTCOMES OF NASH CIRRHOSIS IN TYPE 2 DIABETICS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A NATIONWIDE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(21)02713-x","https://doi.org/10.1016/s0016-5085(21)02713-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050772","R0050772.pdf","paywalled","nonrandomized_study","Sahith Reddy Thotamgari","2021","Abstract 12343: A Real-World Disproportionality Analysis of Atrial Fibrillation Adverse Events for Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.12343","https://doi.org/10.1161/circ.144.suppl_1.12343",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050880","R0050880.pdf","paywalled","nonrandomized_study","Brett Begley","2021","1269-PUB: Evaluating the Response to GLP-1 Agonists in Veterans with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db21-1269-pub","https://doi.org/10.2337/db21-1269-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050895","R0050895.pdf","paywalled","nonrandomized_study","Timothy Silleck Bailey","2021","105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study","Diabetes","American Diabetes Association","10.2337/db21-105-lb","https://doi.org/10.2337/db21-105-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050943","R0050943.pdf","paywalled","nonrandomized_study","Piaopiao Li","2021","810-P: The Diminishing Cost-Effectiveness of the Newer Glucose-Lowering Drugs in the United States, 2010-2018","Diabetes","American Diabetes Association","10.2337/db21-810-p","https://doi.org/10.2337/db21-810-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051077","R0051077.pdf","paywalled","nonrandomized_study","Beini Lyu","2021","Weight Changes Following Diabetes Medication: A Population-Based Study","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1543b","https://doi.org/10.1681/asn.20213210s1543b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051380","R0051380.pdf","paywalled","nonrandomized_study","Beini Lyu","2021","778-P: SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization","Diabetes","American Diabetes Association","10.2337/db21-778-p","https://doi.org/10.2337/db21-778-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051559","R0051559.pdf","paywalled","nonrandomized_study","Nitin Shivappa","2021","86-LB: Real-World Effectiveness of Oral Semaglutide (OS) from a U.S. Commercially Insured and Medicare Advantage Population","Diabetes","American Diabetes Association","10.2337/db21-86-lb","https://doi.org/10.2337/db21-86-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051705","R0051705.pdf","paywalled","nonrandomized_study","Bruno Guerci","2021","672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis","Diabetes","American Diabetes Association","10.2337/db21-672-p","https://doi.org/10.2337/db21-672-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051760","R0051760.pdf","paywalled","nonrandomized_study","Christina E. DeRemer","2021","220-OR: Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among U.S. Adults with Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db21-220-or","https://doi.org/10.2337/db21-220-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051902","R0051902.pdf","paywalled","nonrandomized_study","Mami Yoshida","2021","671-P: Liraglutide Possibly Prevents Progression of Dementia in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-671-p","https://doi.org/10.2337/db21-671-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052072","R0052072.pdf","paywalled","nonrandomized_study","Andreas Liebl","2021","83-LB: Adherence and Persistence in Patients with T2D Initiating Once-Weekly vs. Once-Daily Injectable GLP-1RA in U.S. Clinical Practice: STAY Study","Diabetes","American Diabetes Association","10.2337/db21-83-lb","https://doi.org/10.2337/db21-83-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052075","R0052075.pdf","paywalled","nonrandomized_study","Yoko Narasaki","2021","Comparative Effectiveness of SGLT-2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists in US Veterans with and Without CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20213210s1264b","https://doi.org/10.1681/asn.20213210s1264b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052359","R0052359.pdf","paywalled","nonrandomized_study","Amna Rasheed","2021","886-P: Impact of Endocrine E-Consultation on SGLT2i and GLP-1 RA Prescription","Diabetes","American Diabetes Association","10.2337/db21-886-p","https://doi.org/10.2337/db21-886-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052547","R0052547.pdf","paywalled","nonrandomized_study","Matthew Allum","2021","Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.77.p70","https://doi.org/10.1530/endoabs.77.p70",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053255","R0053255.pdf","paywalled","nonrandomized_study","Caroline Foch","2021","993-P: A Real-World New User Cohort Study of Metformin vs. SGLT2i or GLP-1RA on the Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients with Cardiovascular Risk Factors","Diabetes","American Diabetes Association","10.2337/db21-993-p","https://doi.org/10.2337/db21-993-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053394","R0053394.pdf","paywalled","nonrandomized_study","Georgios K. Dimitriadis","2021","Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials - The LIPOSAX first UK real-world evidence study","Obesity Abstracts","Bioscientifica","10.1530/obabs.3.cd1.2","https://doi.org/10.1530/obabs.3.cd1.2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053471","R0053471.pdf","paywalled","nonrandomized_study","Beatriz Avilés","2021","MO634SEMAGLUTIDE IN REAL LIFE PRACTICE DECREASES ALBUMINURIA IN HIGH RISK PROGRESSION CHRONIC KIDNEY DIABETIC PATIENTS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfab094.002","https://doi.org/10.1093/ndt/gfab094.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055423","R0055423.pdf","paywalled","nonrandomized_study","Adam J. Nelson","2021","Abstract 10159: Underuse of Evidence-based Therapies for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease: Insights from Clinical Research Networks in the United States","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.144.suppl_1.10159","https://doi.org/10.1161/circ.144.suppl_1.10159",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0008320","R0008320.pdf","paywalled","nonrandomized_study","Makri E","2020","Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2020.09.030","https://doi.org/10.1016/j.dsx.2020.09.030","33011499","https://pubmed.ncbi.nlm.nih.gov/33011499/",null,null],["4","R0008504","R0008504.pdf","paywalled","nonrandomized_study","Rouette J","2020","Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14287","https://doi.org/10.1111/dme.14287","32124472","https://pubmed.ncbi.nlm.nih.gov/32124472/",null,null],["4","R0008799","R0008799.pdf","paywalled","nonrandomized_study","Hamid A","2020","Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.","Journal of cardiovascular pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000000864","https://doi.org/10.1097/fjc.0000000000000864","32569016","https://pubmed.ncbi.nlm.nih.gov/32569016/",null,null],["4","R0009139","R0009139.pdf","paywalled","nonrandomized_study","Pasternak B","2020","Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc19-2088","https://doi.org/10.2337/dc19-2088","32295809","https://pubmed.ncbi.nlm.nih.gov/32295809/",null,null],["4","R0009351","R0009351.pdf","paywalled","nonrandomized_study","Maccora C","2020","ONE MONTH WEIGHT LOSS PREDICTS THE EFFICACY OF LIRAGLUTIDE IN OBESE PATIENTS: DATA FROM A SINGLE CENTER.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2019-0169","https://doi.org/10.4158/ep-2019-0169","31682516","https://pubmed.ncbi.nlm.nih.gov/31682516/",null,null],["4","R0009514","R0009514.pdf","paywalled","nonrandomized_study","Scott LJ","2020","Dulaglutide: A Review in Type 2 Diabetes.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-020-01260-9","https://doi.org/10.1007/s40265-020-01260-9","32002850","https://pubmed.ncbi.nlm.nih.gov/32002850/",null,null],["4","R0009998","R0009998.pdf","paywalled","nonrandomized_study","Kotsis V","2020","Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.","Journal of hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000002279","https://doi.org/10.1097/hjh.0000000000002279","31764586","https://pubmed.ncbi.nlm.nih.gov/31764586/",null,null],["4","R0010066","R0010066.pdf","paywalled","nonrandomized_study","Berra CC","2020","Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2020.104996","https://doi.org/10.1016/j.phrs.2020.104996","32574827","https://pubmed.ncbi.nlm.nih.gov/32574827/",null,null],["4","R0011198","R0011198.pdf","paywalled","nonrandomized_study","Bang C","2020","Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13877","https://doi.org/10.1111/dom.13877","31486269","https://pubmed.ncbi.nlm.nih.gov/31486269/",null,null],["4","R0011541","R0011541.pdf","paywalled","nonrandomized_study","Ghosh A","2020","Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399815666191104115449","https://doi.org/10.2174/1573399815666191104115449","31686642","https://pubmed.ncbi.nlm.nih.gov/31686642/",null,null],["4","R0011698","R0011698.pdf","paywalled","nonrandomized_study","Hung A","2020","Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2020.42639","https://doi.org/10.37765/ajmc.2020.42639","32181619","https://pubmed.ncbi.nlm.nih.gov/32181619/",null,null],["4","R0011986","R0011986.pdf","paywalled","nonrandomized_study","Pantalone KM","2020","Intensification patterns and the probability of HbA1c goal attainment in Type 2 diabetes mellitus: real-world evidence for the concept of 'intensification inertia'.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13900","https://doi.org/10.1111/dme.13900","30653705","https://pubmed.ncbi.nlm.nih.gov/30653705/",null,null],["4","R0012363","R0012363.pdf","paywalled","nonrandomized_study","Koye DN","2020","Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-020-01279-y","https://doi.org/10.1007/s40265-020-01279-y","32141024","https://pubmed.ncbi.nlm.nih.gov/32141024/",null,null],["4","R0012709","R0012709.pdf","paywalled","nonrandomized_study","Xie Y","2020","Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.","Diabetes care","American Diabetes Association","10.2337/dc20-1890","https://doi.org/10.2337/dc20-1890","32938746","https://pubmed.ncbi.nlm.nih.gov/32938746/",null,null],["4","R0013124","R0013124.pdf","paywalled","nonrandomized_study","Díaz-Trastoy O","2020","GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2019.12.012","https://doi.org/10.1016/j.clinthera.2019.12.012","32005534","https://pubmed.ncbi.nlm.nih.gov/32005534/",null,null],["4","R0013633","R0013633.pdf","paywalled","nonrandomized_study","Chin KL","2020","Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data.","Drugs & aging","Springer Science and Business Media LLC","10.1007/s40266-020-00759-w","https://doi.org/10.1007/s40266-020-00759-w","32227290","https://pubmed.ncbi.nlm.nih.gov/32227290/",null,null],["4","R0013992","R0013992.pdf","paywalled","nonrandomized_study","Yuan Z","2020","Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2020.1761312","https://doi.org/10.1080/03007995.2020.1761312","32338068","https://pubmed.ncbi.nlm.nih.gov/32338068/",null,null],["4","R0014233","R0014233.pdf","paywalled","nonrandomized_study","Zhou R","2020","Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2019.0122","https://doi.org/10.1089/met.2019.0122","32580677","https://pubmed.ncbi.nlm.nih.gov/32580677/",null,null],["4","R0014994","R0014994.pdf","paywalled","nonrandomized_study","Di Loreto C","2020","IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202010_23425","https://doi.org/10.26355/eurrev_202010_23425","33155225","https://pubmed.ncbi.nlm.nih.gov/33155225/",null,null],["4","R0015272","R0015272.pdf","paywalled","nonrandomized_study","Kahles F","2020","Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz728","https://doi.org/10.1093/eurheartj/ehz728","31620788","https://pubmed.ncbi.nlm.nih.gov/31620788/",null,null],["4","R0015805","R0015805.pdf","paywalled","nonrandomized_study","Fadini GP","2020","Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-019-01445-z","https://doi.org/10.1007/s00592-019-01445-z","31673896","https://pubmed.ncbi.nlm.nih.gov/31673896/",null,null],["4","R0016362","R0016362.pdf","paywalled","nonrandomized_study","Garg R","2020","Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.","Clinical endocrinology","Wiley","10.1111/cen.14299","https://doi.org/10.1111/cen.14299","32716527","https://pubmed.ncbi.nlm.nih.gov/32716527/",null,null],["4","R0017107","R0017107.pdf","paywalled","nonrandomized_study","Michalski K","2020","Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.","Clinical nuclear medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/rlu.0000000000003093","https://doi.org/10.1097/rlu.0000000000003093","32453080","https://pubmed.ncbi.nlm.nih.gov/32453080/",null,null],["4","R0017638","R0017638.pdf","paywalled","nonrandomized_study","van Gorp AM","2020","Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5077","https://doi.org/10.1002/pds.5077","32854158","https://pubmed.ncbi.nlm.nih.gov/32854158/",null,null],["4","R0018033","R0018033.pdf","paywalled","nonrandomized_study","Rose TN","2020","Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2019.09.001","https://doi.org/10.1016/j.japh.2019.09.001","31611005","https://pubmed.ncbi.nlm.nih.gov/31611005/",null,null],["4","R0018220","R0018220.pdf","paywalled","nonrandomized_study","Perlis LT","2020","Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study.","The primary care companion for CNS disorders","Physicians Postgraduate Press, Inc","10.4088/pcc.19m02504","https://doi.org/10.4088/pcc.19m02504","32027785","https://pubmed.ncbi.nlm.nih.gov/32027785/",null,null],["4","R0018566","R0018566.pdf","paywalled","nonrandomized_study","Moreno-Fernandez J","2020","Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2019.05.006","https://doi.org/10.1016/j.pcd.2019.05.006","31171461","https://pubmed.ncbi.nlm.nih.gov/31171461/",null,null],["4","R0019162","R0019162.pdf","paywalled","nonrandomized_study","Giorda CB","2020","Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-019-01444-0","https://doi.org/10.1007/s00592-019-01444-0","31691043","https://pubmed.ncbi.nlm.nih.gov/31691043/",null,null],["4","R0019801","R0019801.pdf","paywalled","nonrandomized_study","Papaetis GS","2020","Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399816666191230113446","https://doi.org/10.2174/1573399816666191230113446","31886752","https://pubmed.ncbi.nlm.nih.gov/31886752/",null,null],["4","R0022806","R0022806.pdf","paywalled","nonrandomized_study","Schütt KA","2020","[Evidence-based reduction of cardiovascular risk in patients with diabetes].","Herz","Springer Science and Business Media LLC","10.1007/s00059-019-04876-0","https://doi.org/10.1007/s00059-019-04876-0","31820029","https://pubmed.ncbi.nlm.nih.gov/31820029/",null,null],["4","R0023079","R0023079.pdf","paywalled","nonrandomized_study","Raval AD","2020","National Trends in Diabetes Medication Use in the United States: 2008 to 2015.","Journal of pharmacy practice","SAGE Publications","10.1177/0897190018815048","https://doi.org/10.1177/0897190018815048","30572757","https://pubmed.ncbi.nlm.nih.gov/30572757/",null,null],["4","R0023275","R0023275.pdf","paywalled","nonrandomized_study","Di Dalmazi G","2020","Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2020.07.002","https://doi.org/10.1016/j.clinthera.2020.07.002","32753164","https://pubmed.ncbi.nlm.nih.gov/32753164/",null,null],["4","R0023887","R0023887.pdf","paywalled","nonrandomized_study","Osonoi T","2020","Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2020.0070","https://doi.org/10.1089/dia.2020.0070","32348695","https://pubmed.ncbi.nlm.nih.gov/32348695/",null,null],["4","R0024171","R0024171.pdf","paywalled","nonrandomized_study","Grabarczyk TR","2020","Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028020915791","https://doi.org/10.1177/1060028020915791","32274930","https://pubmed.ncbi.nlm.nih.gov/32274930/",null,null],["4","R0024502","R0024502.pdf","paywalled","nonrandomized_study","Bonora E","2020","A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2020.08.018","https://doi.org/10.1016/j.numecd.2020.08.018","32998821","https://pubmed.ncbi.nlm.nih.gov/32998821/",null,null],["4","R0024914","R0024914.pdf","paywalled","nonrandomized_study","Lundershausen R","2020","Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-0636-3961","https://doi.org/10.1055/a-0636-3961","30157532","https://pubmed.ncbi.nlm.nih.gov/30157532/",null,null],["4","R0025017","R0025017.pdf","paywalled","nonrandomized_study","Machado-Alba JE","2020","Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108090","https://doi.org/10.1016/j.diabres.2020.108090","32088311","https://pubmed.ncbi.nlm.nih.gov/32088311/",null,null],["4","R0025396","R0025396.pdf","paywalled","nonrandomized_study","Linke K","2020","Outcome of revisional bariatric surgery for insufficient weight loss after laparoscopic Roux-en-Y gastric bypass: an observational study.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2020.04.009","https://doi.org/10.1016/j.soard.2020.04.009","32451228","https://pubmed.ncbi.nlm.nih.gov/32451228/",null,null],["4","R0025581","R0025581.pdf","paywalled","nonrandomized_study","Ribeiro-Silva M","2020","Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs.","International angiology : a journal of the International Union of Angiology","Edizioni Minerva Medica","10.23736/s0392-9590.20.04362-x","https://doi.org/10.23736/s0392-9590.20.04362-x","32286765","https://pubmed.ncbi.nlm.nih.gov/32286765/",null,null],["4","R0025682","R0025682.pdf","paywalled","nonrandomized_study","Rodrigues T","2020","GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2020.105198","https://doi.org/10.1016/j.phrs.2020.105198","32942016","https://pubmed.ncbi.nlm.nih.gov/32942016/",null,null],["4","R0027468","R0027468.pdf","paywalled","nonrandomized_study","Kochhar GS","2020","Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.15721","https://doi.org/10.1111/apt.15721","32319111","https://pubmed.ncbi.nlm.nih.gov/32319111/",null,null],["4","R0027681","R0027681.pdf","paywalled","nonrandomized_study","Le P","2020","Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey.","Diabetes care","American Diabetes Association","10.2337/dc19-2424","https://doi.org/10.2337/dc19-2424","32234720","https://pubmed.ncbi.nlm.nih.gov/32234720/",null,null],["4","R0028533","R0028533.pdf","paywalled","nonrandomized_study","Bloomgarden ZT","2020","Which person with diabetes should receive cardioprotective glucose-lowering medicines?","Journal of diabetes","Wiley","10.1111/1753-0407.13029","https://doi.org/10.1111/1753-0407.13029","32119186","https://pubmed.ncbi.nlm.nih.gov/32119186/",null,null],["4","R0030388","R0030388.pdf","paywalled","nonrandomized_study","Hartmann B","2020","Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-019-01409-3","https://doi.org/10.1007/s00592-019-01409-3","31471633","https://pubmed.ncbi.nlm.nih.gov/31471633/",null,null],["4","R0030600","R0030600.pdf","paywalled","nonrandomized_study","Шестакова Марина Владимировна","2020","Экономическая ценность определения гликированного гемоглобина для диагностики сахарного диабета 2 типа","Сахарный диабет",null,"10.14341/dm12205-9440","https://doi.org/10.14341/dm12205-9440",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0030697","R0030697.pdf","paywalled","nonrandomized_study","Yan Chen","2020","Incretin-the new therapeutic target of sepsis","Zhonghua neifenmi daixie zazhi",null,"10.3760/cma.j.cn311282-20190911-00373","https://doi.org/10.3760/cma.j.cn311282-20190911-00373",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032395","R0032395.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 6 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479063","https://doi.org/10.6084/m9.figshare.12479063",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032860","R0032860.pdf","paywalled","nonrandomized_study","Jacqueline Nicole McNulty","2020","1212-P: Real-World Prescribing of GLP-1RA in a Safety Net Health System","Diabetes","American Diabetes Association","10.2337/db20-1212-p","https://doi.org/10.2337/db20-1212-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032994","R0032994.pdf","paywalled","nonrandomized_study","Chellse Gazda","2020","942-P: Treatment of Weight Regain after Bariatric Surgery: Real-World Comparative Outcomes","Diabetes","American Diabetes Association","10.2337/db20-942-p","https://doi.org/10.2337/db20-942-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033575","R0033575.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 3 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479054","https://doi.org/10.6084/m9.figshare.12479054",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033589","R0033589.pdf","paywalled","nonrandomized_study","Wu, Hongjiang","2020","Additional file 1 of Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study","Figshare",null,"10.6084/m9.figshare.12291593","https://doi.org/10.6084/m9.figshare.12291593",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033680","R0033680.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 2 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479051","https://doi.org/10.6084/m9.figshare.12479051",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033686","R0033686.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 5 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479060","https://doi.org/10.6084/m9.figshare.12479060",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033791","R0033791.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 4 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479057","https://doi.org/10.6084/m9.figshare.12479057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033808","R0033808.pdf","paywalled","nonrandomized_study","Yang, Chun-Ting","2020","Additional file 1 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Figshare",null,"10.6084/m9.figshare.12479042","https://doi.org/10.6084/m9.figshare.12479042",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033812","R0033812.pdf","paywalled","nonrandomized_study","Kwei-Jay Lin","2020","Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis","Greater South Information System",null,"10.60692/ff6h0-8mj30","https://doi.org/10.60692/ff6h0-8mj30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034323","R0034323.pdf","paywalled","nonrandomized_study","Jersy Cárdenas‐Salas","2020","Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.70.ep197","https://doi.org/10.1530/endoabs.70.ep197",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034578","R0034578.pdf","paywalled","nonrandomized_study","Miguel Sierra Poyatos Roberto","2020","Comparison of the clinical efficacy of Semaglutide between DPP4-inhibitor-naive and DPP4-inhibitor-experienced patients in a real world setting in Spain","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.70.aep809","https://doi.org/10.1530/endoabs.70.aep809",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037094","R0037094.pdf","paywalled","nonrandomized_study","Of, Adis Journals On Behalf","2020","Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study","Figshare",null,"10.6084/m9.figshare.13360382","https://doi.org/10.6084/m9.figshare.13360382",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037316","R0037316.pdf","paywalled","nonrandomized_study","Jing Luo","2020","1131-P: Clinical, Demographic, Provider, and Formulary Characteristics Associated with Initiation of a SGLT2i or GLP-1RA among Medicare Beneficiaries with Type 2 Diabetes on Prior Oral Agents: A Cohort Study","Diabetes","American Diabetes Association","10.2337/db20-1131-p","https://doi.org/10.2337/db20-1131-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037329","R0037329.pdf","paywalled","nonrandomized_study","Bergenstal, Richard M.","2020","Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting","Figshare",null,"10.6084/m9.figshare.11815914","https://doi.org/10.6084/m9.figshare.11815914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037741","R0037741.pdf","paywalled","nonrandomized_study","Baxter, Mike","2020","A Real-World Observational Study Evaluating Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes","Figshare",null,"10.6084/m9.figshare.12264179","https://doi.org/10.6084/m9.figshare.12264179",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037849","R0037849.pdf","paywalled","nonrandomized_study","Darren B. Taichman","2020","Annals for Educators - 4 February 2020","Annals of Internal Medicine","American College of Physicians","10.7326/awed202002040","https://doi.org/10.7326/awed202002040","32016339","https://pubmed.ncbi.nlm.nih.gov/32016339/",null,null],["4","R0037922","R0037922.pdf","paywalled","nonrandomized_study","Jiasheng Wang","2020","Malignancies associated with DPP4 inhibitors and GLP1 receptor agonists: Data from a large real-world database.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2020.38.15_suppl.1567","https://doi.org/10.1200/jco.2020.38.15_suppl.1567",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038042","R0038042.pdf","paywalled","nonrandomized_study","Ildiko Lingvay","2020","954-P: GLP-1–Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)","Diabetes","American Diabetes Association","10.2337/db20-954-p","https://doi.org/10.2337/db20-954-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038249","R0038249.pdf","paywalled","nonrandomized_study","Stefan Agewall","2020","Antiplatelet treatment in coronary syndrome","European Heart Journal - Cardiovascular Pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvab015","https://doi.org/10.1093/ehjcvp/pvab015","33720341","https://pubmed.ncbi.nlm.nih.gov/33720341/",null,null],["4","R0038371","R0038371.pdf","paywalled","nonrandomized_study","Marti Boss","2020","[ 68 Ga]Ga-NODAGA-exendin-4 PET/CT for the diagnosis and localization of focal congenital hyperinsulinism","Nuklearmedizin - NuclearMedicine","© Georg Thieme Verlag KG","10.1055/s-0040-1708240","https://doi.org/10.1055/s-0040-1708240",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038411","R0038411.pdf","paywalled","nonrandomized_study","Margaret Allison","2020","1196-P: Impact of Pharmacist-Driven Access to Therapy in Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db20-1196-p","https://doi.org/10.2337/db20-1196-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038846","R0038846.pdf","paywalled","nonrandomized_study","Heo, Young-A","2020","Insulin degludec/liraglutide in type 2 diabetes: a profile of its use","Figshare",null,"10.6084/m9.figshare.12045333","https://doi.org/10.6084/m9.figshare.12045333",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038994","R0038994.pdf","paywalled","nonrandomized_study","Cooke, Catherine E.","2020","Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization","Figshare",null,"10.6084/m9.figshare.11815362","https://doi.org/10.6084/m9.figshare.11815362",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039200","R0039200.pdf","paywalled","nonrandomized_study","Anant Nigam","2020","950-P: Efficacy and Safety of Once-Weekly Dulaglutide Added to Titrated Insulin Glargine, Prandial Insulin, and Oral Agents in Obese Asian T2 Diabetes (T2D) Patients: One Year Real-World Evidence from India","Diabetes","American Diabetes Association","10.2337/db20-950-p","https://doi.org/10.2337/db20-950-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039422","R0039422.pdf","paywalled","nonrandomized_study","Simone Calcagno","2020","Renin–Angiotensin Blocking Therapies: A Must—But How?—After Percutaneous Coronary Intervention","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000000941","https://doi.org/10.1097/fjc.0000000000000941","33136768","https://pubmed.ncbi.nlm.nih.gov/33136768/",null,null],["4","R0039445","R0039445.pdf","paywalled","nonrandomized_study","Μακρή, Ευαγγελία Στέργιου","2020","Comparison of noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus on glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors as add-on treatment: a retrospective head-to-head comparative study","Aristotle University of Thessaloniki",null,"10.26262/heal.auth.ir.316286","https://doi.org/10.26262/heal.auth.ir.316286",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039551","R0039551.pdf","paywalled","nonrandomized_study","Zhang, Hanxi","2020","Medication adherence among type 2 diabetes Texas Medicaid patients using basal insulin","Texas Digital Library (University of Texas)",null,"10.26153/tsw/14152","https://doi.org/10.26153/tsw/14152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039890","R0039890.pdf","paywalled","nonrandomized_study","Juan Carlos Ferrer-García","2020","947-P: Semaglutide Added to Treatment or Changed from Other GLP-1 Receptor Agonist in Type 2 Diabetes: A Study to Evaluate Real-World Effectiveness","Diabetes","American Diabetes Association","10.2337/db20-947-p","https://doi.org/10.2337/db20-947-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041599","R0041599.pdf","paywalled","nonrandomized_study",null,"2020","Corrigendum","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14037","https://doi.org/10.1111/dom.14037","32363794","https://pubmed.ncbi.nlm.nih.gov/32363794/",null,null],["4","R0041876","R0041876.pdf","paywalled","nonrandomized_study","Hala F. Azhari","2020","Novel strategies for secondary stroke prevention - exploring the use of pioglitazone therapy using a mixed methods approach","Enlighten: Theses (The University of Glasgow)",null,"10.5525/gla.thesis.81493","https://doi.org/10.5525/gla.thesis.81493",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043208","R0043208.pdf","paywalled","nonrandomized_study","L.E. Clegg","2020","Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/brjm-hg52","https://doi.org/10.17615/brjm-hg52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01144338"],["4","R0043990","R0043990.pdf","paywalled","nonrandomized_study","Oke, Siddhartha","2020","Factors affecting survival in intestinal failure and novel therapeutic avenues","Spiral (Imperial College London)",null,"10.25560/91738","https://doi.org/10.25560/91738",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044530","R0044530.pdf","paywalled","nonrandomized_study","Peter J. Grant","2020","Diabetes and cardiovascular disease: it’s time to apply the evidence","European Heart Journal Acute Cardiovascular Care","Oxford University Press (OUP)","10.1177/2048872620952722","https://doi.org/10.1177/2048872620952722","33203234","https://pubmed.ncbi.nlm.nih.gov/33203234/",null,null],["4","R0044898","R0044898.pdf","paywalled","nonrandomized_study","A.-S. Alexopoulos","2020","Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/6gsp-7a34","https://doi.org/10.17615/6gsp-7a34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045383","R0045383.pdf","paywalled","nonrandomized_study","SANYA PASRICHA","2020","1092-P: Treatment Changes Post–Second-Line Medication Initiation, a Real-World Retrospective Cohort Study","Diabetes","American Diabetes Association","10.2337/db20-1092-p","https://doi.org/10.2337/db20-1092-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045660","R0045660.pdf","paywalled","nonrandomized_study","Abbas Mahdi Rahmah","2020","The efficacy of once-daily liraglutide as an add-on to oral antidiabetic agents on weight reduction and glycemic control in obese patients with inadequately controlled type 2 diabetes: a retrospective analysis in relation to liraglutide dose escalation within a 7-month treatment period","International Journal of Diabetes in Developing Countries","Springer Science and Business Media LLC","10.1007/s13410-020-00878-5","https://doi.org/10.1007/s13410-020-00878-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045767","R0045767.pdf","paywalled","nonrandomized_study","Jay Visaria","2020","953-P: Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a U.S. Commercially Insured and Medicare Advantage Population","Diabetes","American Diabetes Association","10.2337/db20-953-p","https://doi.org/10.2337/db20-953-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046868","R0046868.pdf","paywalled","nonrandomized_study","Carmen E. Chavez","2020","2290-PUB: Donor HLA-DR4 Positivity and Islet Transplantation Outcomes","Diabetes","American Diabetes Association","10.2337/db20-2290-pub","https://doi.org/10.2337/db20-2290-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047834","R0047834.pdf","paywalled","nonrandomized_study","Carolina García-Figueras-Mateos","2020","Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to a glucagon-like peptide-1 receptor agonist: A real-world experience","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.70.aep487","https://doi.org/10.1530/endoabs.70.aep487",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047910","R0047910.pdf","paywalled","nonrandomized_study","Jing Luo","2020","925-P: Risk of Cardiovascular Events and Serious Hypoglycemia Comparing Patients with Type 2 Diabetes Initiating a GLP-1 Receptor Agonist or Basal Insulin: A Propensity-Score Matched Cohort Study","Diabetes","American Diabetes Association","10.2337/db20-925-p","https://doi.org/10.2337/db20-925-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048067","R0048067.pdf","paywalled","nonrandomized_study","Elisabetta Patorno","2020","133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study","Diabetes","American Diabetes Association","10.2337/db20-133-lb","https://doi.org/10.2337/db20-133-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048465","R0048465.pdf","paywalled","nonrandomized_study","Chintan V. Dave","2020","35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy","Diabetes","American Diabetes Association","10.2337/db20-35-or","https://doi.org/10.2337/db20-35-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048548","R0048548.pdf","paywalled","nonrandomized_study","Michael Lee Ganz","2020","1426-P: Utilization of Glucose-Lowering Drugs in Patients with T2DM and Established CVD in the U.S.","Diabetes","American Diabetes Association","10.2337/db20-1426-p","https://doi.org/10.2337/db20-1426-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048606","R0048606.pdf","paywalled","nonrandomized_study","Tiezhou Wang","2020","Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/6egs-0964","https://doi.org/10.17615/6egs-0964",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049021","R0049021.pdf","paywalled","nonrandomized_study","Andy Bowe","2020","1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide","Diabetes","American Diabetes Association","10.2337/db20-1428-p","https://doi.org/10.2337/db20-1428-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049048","R0049048.pdf","paywalled","nonrandomized_study","Insiya B. Poonawalla","2020","36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists","Diabetes","American Diabetes Association","10.2337/db20-36-or","https://doi.org/10.2337/db20-36-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049082","R0049082.pdf","paywalled","nonrandomized_study","Jeffery Tong","2020","55 - Comparative Analysis of A1c and Weight Reduction Potential of Subcutaneous GLP-1 Receptor Agonists in a Real-World Setting","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.061","https://doi.org/10.1016/j.jcjd.2020.08.061",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049876","R0049876.pdf","paywalled","nonrandomized_study","Raleigh Malik","2020","938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-938-p","https://doi.org/10.2337/db20-938-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049915","R0049915.pdf","paywalled","nonrandomized_study","Muthiah Vaduganathan","2020","Abstract 16940: Missed Opportunities for Screening and Management of Dysglycemia After Myocardial Infarction: The Prospective NORIN STEMI Registry","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.16940","https://doi.org/10.1161/circ.142.suppl_3.16940",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050026","R0050026.pdf","paywalled","nonrandomized_study","Cyrus V Desouza","2020","931-P: Optimal Treatment Intensification for Glycemic Control in Patients with T2D on Two Oral Agents: Real-World Comparison of GLP-1, OADs, and Insulin","Diabetes","American Diabetes Association","10.2337/db20-931-p","https://doi.org/10.2337/db20-931-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050049","R0050049.pdf","paywalled","nonrandomized_study","Mikhail Kosiborod","2020","1429-P: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: A 1-Year Update from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)","Diabetes","American Diabetes Association","10.2337/db20-1429-p","https://doi.org/10.2337/db20-1429-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050080","R0050080.pdf","paywalled","nonrandomized_study","Mike Fralick","2020","33-OR: A Novel Data Mining Approach to Detect Adverse Events of New Diabetes Drugs in Routine Care","Diabetes","American Diabetes Association","10.2337/db20-33-or","https://doi.org/10.2337/db20-33-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050096","R0050096.pdf","paywalled","nonrandomized_study","Virginia Fuenmayor","2020","118-OR: HLA Matching and Clinical Outcomes in Islet Transplantation","Diabetes","American Diabetes Association","10.2337/db20-118-or","https://doi.org/10.2337/db20-118-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050098","R0050098.pdf","paywalled","nonrandomized_study","Jung‐Im Shin","2020","Abstract P444: Changes in Glucose-Lowering Medication Prescriptions After an Incident Cardiovascular Event Across eGFR Levels in an Integrated Health System","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.141.suppl_1.p444","https://doi.org/10.1161/circ.141.suppl_1.p444",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050100","R0050100.pdf","paywalled","nonrandomized_study","Pratik M. Pimple","2020","Abstract 232: Initiating Empagliflozin vs. Glucagon-like Peptide 1 Receptor Agonists is Associated With Lower Healthcare Cost of Care Among Patients With Type 2 Diabetes and Cardiovascular Disease","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/hcq.13.suppl_1.232","https://doi.org/10.1161/hcq.13.suppl_1.232",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050387","R0050387.pdf","paywalled","nonrandomized_study","Jean‐François Yale","2020","64 - Real-World Use of Once-Weekly Semaglutide in Patients With Type 2 Diabetes: Results From SURE Canada","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.070","https://doi.org/10.1016/j.jcjd.2020.08.070",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050543","R0050543.pdf","paywalled","nonrandomized_study","Katherine R. Tuttle","2020","Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1349c","https://doi.org/10.1681/asn.20203110s1349c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050569","R0050569.pdf","paywalled","nonrandomized_study","Eden M Miller","2020","84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy","Diabetes","American Diabetes Association","10.2337/db20-84-lb","https://doi.org/10.2337/db20-84-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050752","R0050752.pdf","paywalled","nonrandomized_study","Katherine R. Tuttle","2020","MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa140.mo051","https://doi.org/10.1093/ndt/gfaa140.mo051",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["4","R0051071","R0051071.pdf","paywalled","nonrandomized_study","Apoorva Krishna Chandar","2020","Sa1200 REDUCED RISK OF BARRETT'S ESOPHAGUS WITH SGLT2 INHIBITORS/GLP1 RECEPTOR AGONISTS WHEN COMPARED TO METFORMIN ALONE: A NATIONAL DATABASE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(20)31472-4","https://doi.org/10.1016/s0016-5085(20)31472-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051103","R0051103.pdf","paywalled","nonrandomized_study","Alba Maroto","2020","P1009RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 INHIBITORS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa142.p1009","https://doi.org/10.1093/ndt/gfaa142.p1009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051268","R0051268.pdf","paywalled","nonrandomized_study","Merrill B. Thomas","2020","Abstract 369: Secondary Risk Reduction in Patients With Type 2 Diabetes and Cardiovascular Disease: Experience From a Cardiometabolic Center of Excellence","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/hcq.13.suppl_1.369","https://doi.org/10.1161/hcq.13.suppl_1.369",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051436","R0051436.pdf","paywalled","nonrandomized_study","Kieran F. Docherty","2020","1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial","Diabetes","American Diabetes Association","10.2337/db20-1112-p","https://doi.org/10.2337/db20-1112-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051553","R0051553.pdf","paywalled","nonrandomized_study","Julio Rosenstock","2020","965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists","Diabetes","American Diabetes Association","10.2337/db20-965-p","https://doi.org/10.2337/db20-965-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051670","R0051670.pdf","paywalled","nonrandomized_study","Reema Mody","2020","929-P: Dulaglutide Shows Sustained A1C Reduction: Two-Year U.S. Real-World Study","Diabetes","American Diabetes Association","10.2337/db20-929-p","https://doi.org/10.2337/db20-929-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051806","R0051806.pdf","paywalled","nonrandomized_study","Reema Mody","2020","928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data","Diabetes","American Diabetes Association","10.2337/db20-928-p","https://doi.org/10.2337/db20-928-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051866","R0051866.pdf","paywalled","nonrandomized_study","Ioannis Spiliotis","2020","1113-P: The Use of Empagliflozin and Dulaglutide Improves Metabolic and Glycemia Outcomes in a Real-World Primary Care Setting","Diabetes","American Diabetes Association","10.2337/db20-1113-p","https://doi.org/10.2337/db20-1113-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051998","R0051998.pdf","paywalled","nonrandomized_study","Dominik Lautsch","2020","1183-P: Utilization of Low vs. High Dose of Newer Antihyperglycemic Agents","Diabetes","American Diabetes Association","10.2337/db20-1183-p","https://doi.org/10.2337/db20-1183-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052229","R0052229.pdf","paywalled","nonrandomized_study","Emil Loefroth","2020","Abstract 14944: Drug Utilization Study in Heart Failure (HF) Patients Concomitantly Prescribed Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) and Sacubitril/valsartan (sac/val), a Database Cohort Study Using Optum Electronic Health Record (EHR) US Data","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.14944","https://doi.org/10.1161/circ.142.suppl_3.14944",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052256","R0052256.pdf","paywalled","nonrandomized_study","Pratik M. Pimple","2020","1152-P: Effect of Initiating Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists on Health-Care Costs among Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-1152-p","https://doi.org/10.2337/db20-1152-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052295","R0052295.pdf","paywalled","nonrandomized_study","Tiezhou Wang","2020","Incretin-based therapies and diabetic retinopathy: Real-world evidence in older U.S. adults","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/bgre-6k17","https://doi.org/10.17615/bgre-6k17",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052436","R0052436.pdf","paywalled","nonrandomized_study","Bijin Thajudeen","2020","Practice Patterns of SGLT2 Inhibitor and GLP-1 Agonist Treatment in Eligible Type 2 Diabetic Patients Before and After the Publication of the 2018 ADA/EASD Position Statement","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1814c","https://doi.org/10.1681/asn.20203110s1814c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052596","R0052596.pdf","paywalled","nonrandomized_study","Chandrasekar Gopalakrishnan","2020","1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 Inhibitors Compared with Other Glucose-Lowering Agents","Diabetes","American Diabetes Association","10.2337/db20-1431-p","https://doi.org/10.2337/db20-1431-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052924","R0052924.pdf","paywalled","nonrandomized_study","Omar Ali Alaber","2020","235 LARGE EFFECTS OF SGLT2 INHIBITORS/GLP1 RECEPTOR AGONISTS ON LIVER CIRRHOSIS IN NAFLD AND NASH WHEN COMPARED TO METFORMIN OR THIAZOLIDINEDIONES: A NATIONAL DATABASE STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(20)30796-4","https://doi.org/10.1016/s0016-5085(20)30796-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053135","R0053135.pdf","paywalled","nonrandomized_study","Omar Ali Alaber","2020","1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 Inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 Diabetes Mellitus (T2DM) When Compared with Metformin Alone: A National Database Study","Diabetes","American Diabetes Association","10.2337/db20-1433-p","https://doi.org/10.2337/db20-1433-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0007245","R0007245.pdf","paywalled","nonrandomized_study","Kuhadiya ND","2019","Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13609","https://doi.org/10.1111/dom.13609","30536789","https://pubmed.ncbi.nlm.nih.gov/30536789/",null,null],["4","R0009731","R0009731.pdf","paywalled","nonrandomized_study","Wang K","2019","Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2019.08.003","https://doi.org/10.1016/j.clinthera.2019.08.003","31514971","https://pubmed.ncbi.nlm.nih.gov/31514971/",null,null],["4","R0009913","R0009913.pdf","paywalled","nonrandomized_study","Varpuluoma O","2019","Reply to: \"Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid\".","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2019.02.005","https://doi.org/10.1016/j.jaad.2019.02.005","30738121","https://pubmed.ncbi.nlm.nih.gov/30738121/",null,null],["4","R0010151","R0010151.pdf","paywalled","nonrandomized_study","Meade LT","2019","The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028019857557","https://doi.org/10.1177/1060028019857557","31215219","https://pubmed.ncbi.nlm.nih.gov/31215219/",null,null],["4","R0010466","R0010466.pdf","paywalled","nonrandomized_study","Brown RE","2019","Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.107820","https://doi.org/10.1016/j.diabres.2019.107820","31446111","https://pubmed.ncbi.nlm.nih.gov/31446111/",null,null],["4","R0010642","R0010642.pdf","paywalled","nonrandomized_study","Carretero Gómez J","2019","Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2018.09.001","https://doi.org/10.1016/j.jcjd.2018.09.001","30415909","https://pubmed.ncbi.nlm.nih.gov/30415909/",null,null],["4","R0013253","R0013253.pdf","paywalled","nonrandomized_study","Alonso-Troncoso I","2019","Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.","Endocrinologia, diabetes y nutricion","Elsevier BV","10.1016/j.endinu.2018.09.005","https://doi.org/10.1016/j.endinu.2018.09.005","30528642","https://pubmed.ncbi.nlm.nih.gov/30528642/",null,null],["4","R0014345","R0014345.pdf","paywalled","nonrandomized_study","Tao Y","2019","Doubly robust estimation of the weighted average treatment effect for a target population.","Statistics in medicine","Wiley","10.1002/sim.7980","https://doi.org/10.1002/sim.7980","30302780","https://pubmed.ncbi.nlm.nih.gov/30302780/",null,null],["4","R0015541","R0015541.pdf","paywalled","nonrandomized_study","Svanström H","2019","Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(18)30320-6","https://doi.org/10.1016/s2213-8587(18)30320-6","30527909","https://pubmed.ncbi.nlm.nih.gov/30527909/",null,null],["4","R0016277","R0016277.pdf","paywalled","nonrandomized_study","Beti C","2019","Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/a-0818-6374","https://doi.org/10.1055/a-0818-6374","30690693","https://pubmed.ncbi.nlm.nih.gov/30690693/",null,null],["4","R0017323","R0017323.pdf","paywalled","nonrandomized_study","Arora P","2019","Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.","Journal of comparative effectiveness research","Becaris Publishing Limited","10.2217/cer-2019-0127","https://doi.org/10.2217/cer-2019-0127","31789054","https://pubmed.ncbi.nlm.nih.gov/31789054/",null,null],["4","R0017750","R0017750.pdf","paywalled","nonrandomized_study","Xu X","2019","Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.03.002","https://doi.org/10.1016/j.diabres.2019.03.002","30844468","https://pubmed.ncbi.nlm.nih.gov/30844468/",null,null],["4","R0019746","R0019746.pdf","paywalled","nonrandomized_study","Bothe JR","2019","Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide.","Molecular pharmaceutics","American Chemical Society (ACS)","10.1021/acs.molpharmaceut.9b00106","https://doi.org/10.1021/acs.molpharmaceut.9b00106","30990695","https://pubmed.ncbi.nlm.nih.gov/30990695/",null,null],["4","R0022008","R0022008.pdf","paywalled","nonrandomized_study","Davidson MB","2019","SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists.","Annals of internal medicine","American College of Physicians","10.7326/acpj201912170-070","https://doi.org/10.7326/acpj201912170-070","31842228","https://pubmed.ncbi.nlm.nih.gov/31842228/",null,null],["4","R0022512","R0022512.pdf","paywalled","nonrandomized_study","Tseng CH","2019","Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2019.05.002","https://doi.org/10.1016/j.diabet.2019.05.002","31129317","https://pubmed.ncbi.nlm.nih.gov/31129317/",null,null],["4","R0024201","R0024201.pdf","paywalled","nonrandomized_study","Moreno Obregón F","2019","Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.107916","https://doi.org/10.1016/j.diabres.2019.107916","31682882","https://pubmed.ncbi.nlm.nih.gov/31682882/",null,null],["4","R0024437","R0024437.pdf","paywalled","nonrandomized_study","Singh P","2019","Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13619","https://doi.org/10.1111/dom.13619","30565376","https://pubmed.ncbi.nlm.nih.gov/30565376/",null,null],["4","R0024630","R0024630.pdf","paywalled","nonrandomized_study","Liang C","2019","Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13597","https://doi.org/10.1111/dom.13597","30474347","https://pubmed.ncbi.nlm.nih.gov/30474347/",null,null],["4","R0024819","R0024819.pdf","paywalled","nonrandomized_study","Wharton S","2019","Response to \"Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?\".","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.22630","https://doi.org/10.1002/oby.22630","31545003","https://pubmed.ncbi.nlm.nih.gov/31545003/",null,null],["4","R0025548","R0025548.pdf","paywalled","nonrandomized_study","Buchholz C","2019","Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/a-0972-9700","https://doi.org/10.1055/a-0972-9700","31412375","https://pubmed.ncbi.nlm.nih.gov/31412375/",null,null],["4","R0025860","R0025860.pdf","paywalled","nonrandomized_study","Clarke SJ","2019","Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2018.11.013","https://doi.org/10.1016/j.clinthera.2018.11.013","30598343","https://pubmed.ncbi.nlm.nih.gov/30598343/",null,"ClinicalTrials.gov:NCT02129179"],["4","R0028587","R0028587.pdf","paywalled","nonrandomized_study","Davis TME","2019","The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2019.03.005","https://doi.org/10.1016/j.jdiacomp.2019.03.005","31003926","https://pubmed.ncbi.nlm.nih.gov/31003926/",null,null],["4","R0028593","R0028593.pdf","paywalled","nonrandomized_study","Shetty A","2019","Current treatment options for nonalcoholic fatty liver disease.","Current opinion in gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mog.0000000000000528","https://doi.org/10.1097/mog.0000000000000528","30844893","https://pubmed.ncbi.nlm.nih.gov/30844893/",null,null],["4","R0030309","R0030309.pdf","paywalled","nonrandomized_study","Wium-Andersen IK","2019","Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-19-0259","https://doi.org/10.1530/eje-19-0259","31437816","https://pubmed.ncbi.nlm.nih.gov/31437816/",null,null],["4","R0030348","R0030348.pdf","paywalled","nonrandomized_study","Brochu B","2019","Treatment of diabetes and heart failure: a paradigm shift for cardiologists?","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000599","https://doi.org/10.1097/hco.0000000000000599","30608252","https://pubmed.ncbi.nlm.nih.gov/30608252/",null,null],["4","R0030967","R0030967.pdf","paywalled","nonrandomized_study","Zihan Guan","2019","Effect of GLP-1 analogue combined with metformin on blood glucose control and insulin resistance in obese patients with type 2 diabetes mellitus","Chin J Endocr Surg",null,"10.3760/cma.j.issn.1674-6090.2019.02.012","https://doi.org/10.3760/cma.j.issn.1674-6090.2019.02.012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031098","R0031098.pdf","paywalled","nonrandomized_study","Lin Liu","2019","Effects of saxagliptin combined with liraglutide on glycolipid metabolism and insulin function in patients with abdominal obesity and type 2 diabetes mellitus","Central Plains Medical Journal",null,"10.3760/cma.j.issn.1674-4756.2019.09.034","https://doi.org/10.3760/cma.j.issn.1674-4756.2019.09.034",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032238","R0032238.pdf","paywalled","nonrandomized_study",null,"2019","Real-world Health Outcomes in Canadian Patients Using Semaglutide","Case Medical Research","Case Journals","10.31525/ct1-nct04175665","https://doi.org/10.31525/ct1-nct04175665",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032267","R0032267.pdf","paywalled","nonrandomized_study",null,"2019","GLP-1 REceptor Agonists and Real World EvIdeNce","Case Medical Research","Case Journals","10.31525/ct1-nct03959865","https://doi.org/10.31525/ct1-nct03959865",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032661","R0032661.pdf","paywalled","nonrandomized_study","Ida Kim Wium‐Andersen","2019","1438-P: Antidiabetic Medication and Risk of Dementia in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1438-p","https://doi.org/10.2337/db19-1438-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032695","R0032695.pdf","paywalled","nonrandomized_study","Su Jin Jeong","2019","2346-PUB: Clinical Characteristics of SGLT2 Inhibitor User in Type 2 Diabetes with Atherosclerotic Cardiovascular Disease or Heart Failure in a Real-World Setting","Diabetes","American Diabetes Association","10.2337/db19-2346-pub","https://doi.org/10.2337/db19-2346-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032917","R0032917.pdf","paywalled","nonrandomized_study","Satoshi Yoshiji","2019","1028-P: Is Once-Weekly GLP-1 Receptor Agonist a Reasonable Option for Glucocorticoid-Induced Hyperglycemia? Twelve-Week Efficacy and Safety of Dulaglutide vs. Sitagliptin in Patients with Diabetes on Routine Glucocorticoid Treatment","Diabetes","American Diabetes Association","10.2337/db19-1028-p","https://doi.org/10.2337/db19-1028-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032949","R0032949.pdf","paywalled","nonrandomized_study","Masaya Ohara","2019","545-P: The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-545-p","https://doi.org/10.2337/db19-545-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033031","R0033031.pdf","paywalled","nonrandomized_study","Chun‐Ting Yang","2019","438-P: Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists vs. Other Glucose-Lowering Agents in Patients with Type 2 Diabetes—A Nationwide Cohort Study Using Prevalent New-User Design","Diabetes","American Diabetes Association","10.2337/db19-438-p","https://doi.org/10.2337/db19-438-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033804","R0033804.pdf","paywalled","nonrandomized_study","Giblett, Joel P.","2019","Glucagon-Like Peptide-1","JACC: Journal of the American College of Cardiology",null,"10.25407/jacbts.c.4536203","https://doi.org/10.25407/jacbts.c.4536203",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033835","R0033835.pdf","paywalled","nonrandomized_study","Clegg, Lindsay","2019","MOESM1 of Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","Figshare",null,"10.6084/m9.figshare.10027562","https://doi.org/10.6084/m9.figshare.10027562",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035036","R0035036.pdf","paywalled","nonrandomized_study","Jina Hahn","2019","98 - Improved Glycemic Control in Patients With T2D Initiating IDegLira Across Various Background Therapies in US Real-World Practice","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2019.07.107","https://doi.org/10.1016/j.jcjd.2019.07.107",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037111","R0037111.pdf","paywalled","nonrandomized_study","Juan José Gorgojo Martínez","2019","2049-P: Real-World Assessment of Orlistat and Liraglutide in Patients with Obesity: The XENSOR Study","Diabetes","American Diabetes Association","10.2337/db19-2049-p","https://doi.org/10.2337/db19-2049-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037112","R0037112.pdf","paywalled","nonrandomized_study","Cheli Melzer-Cohen","2019","Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting","Figshare",null,"10.6084/m9.figshare.10082762","https://doi.org/10.6084/m9.figshare.10082762",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037266","R0037266.pdf","paywalled","nonrandomized_study","Stulz, Anja","2019","Biophysical interactions of peptides and their analogues with lipid membranes: applications in drug development and drug delivery","FreiDok plus (Universitätsbibliothek Freiburg)",null,"10.6094/unifr/151565","https://doi.org/10.6094/unifr/151565",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037495","R0037495.pdf","paywalled","nonrandomized_study","Tabák, Ádám G.","2019","Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Type 2 Diabetes Patients: Propensity Score Matched Analysis","Figshare",null,"10.6084/m9.figshare.10303784","https://doi.org/10.6084/m9.figshare.10303784",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037520","R0037520.pdf","paywalled","nonrandomized_study","Leonard E. Egede","2019","2321-PUB: Improved Glycemic Control among Patients Newly Prescribed IDegLira across Various Background Therapies in U.S. Real-World Practice","Diabetes","American Diabetes Association","10.2337/db19-2321-pub","https://doi.org/10.2337/db19-2321-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037709","R0037709.pdf","paywalled","nonrandomized_study","Hema Padmanabhan","2019","Fracture Risk After Initiation of Use of Canagliflozin","Annals of Internal Medicine","American College of Physicians","10.7326/l19-0319","https://doi.org/10.7326/l19-0319","31261402","https://pubmed.ncbi.nlm.nih.gov/31261402/",null,null],["4","R0037832","R0037832.pdf","paywalled","nonrandomized_study","SONALI A. PATANGE","2019","943-P: Improvement in Glycemic Variability with Dulaglutide Therapy Evaluated by Continuous Glucose Monitoring System: A Real-World Experience of Indian Patients with Type 2 DM","Diabetes","American Diabetes Association","10.2337/db19-943-p","https://doi.org/10.2337/db19-943-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037959","R0037959.pdf","paywalled","nonrandomized_study","Michael Fralick","2019","1539-P: Assessing the Risk of Amputation with Canagliflozin in Middle-Aged Adults and Adults over 65 Years of Age: An Observational Study Using Three Nationwide Databases","Diabetes","American Diabetes Association","10.2337/db19-1539-p","https://doi.org/10.2337/db19-1539-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037960","R0037960.pdf","paywalled","nonrandomized_study","SONALI A. PATANGE","2019","2305-PUB: Effects of Dulaglutide on Renal Function, Glycemic Control, and Weight Outcomes in Indian Patients with Type 2 Diabetes: A Real-World Study","Diabetes","American Diabetes Association","10.2337/db19-2305-pub","https://doi.org/10.2337/db19-2305-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038201","R0038201.pdf","paywalled","nonrandomized_study","Chin‐Hsiao Tseng","2019","P5006Metformin reduces the risk of hospitalization for heart failure in type 2 diabetes patients: a retrospective cohort analysis","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz746.0184","https://doi.org/10.1093/eurheartj/ehz746.0184",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038480","R0038480.pdf","paywalled","nonrandomized_study","Ruth E. Brown","2019","995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","Diabetes","American Diabetes Association","10.2337/db19-995-p","https://doi.org/10.2337/db19-995-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038512","R0038512.pdf","paywalled","nonrandomized_study","Elmor David Pineda","2019","Evaluation of patient demographics, clinical characteristics, and cardiovascular outcomes in patients with type 2 diabetes newly initiated on sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and other antidiabetic medications",null,null,"10.26153/tsw/5675","https://doi.org/10.26153/tsw/5675",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038734","R0038734.pdf","paywalled","nonrandomized_study","Temelkova, Nataliya","2019","Real-World Effectiveness and Safety of Lixisenatide as Add- on to Oral Antidiabetic Drugs as Part of the Routine Clinical Practice in Bulgaria: LIXODAR study","Figshare",null,"10.6084/m9.figshare.7844975","https://doi.org/10.6084/m9.figshare.7844975",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039291","R0039291.pdf","paywalled","nonrandomized_study","Ursula Biba","2019","Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12980","https://doi.org/10.1111/1753-0407.12980","31433564","https://pubmed.ncbi.nlm.nih.gov/31433564/",null,null],["4","R0039466","R0039466.pdf","paywalled","nonrandomized_study","Daniel J. Rubin","2019","172-LB: Phone-Based Management by a PharmD May Improve Glycemic Control More Than Endocrinology Care Alone","Diabetes","American Diabetes Association","10.2337/db19-172-lb","https://doi.org/10.2337/db19-172-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039636","R0039636.pdf","paywalled","nonrandomized_study","Bramlage, Peter","2019","MOESM2 of Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases","Figshare",null,"10.6084/m9.figshare.7855313","https://doi.org/10.6084/m9.figshare.7855313",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039641","R0039641.pdf","paywalled","nonrandomized_study","Supratik Bhattacharyya","2019","Abstract #266 Clinical Effectiveness of Dulaglutide Monotherapy in Obese Indian Adults with Prediabetes: First Report of a Real-World Retrospective Study in India","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)46610-8","https://doi.org/10.1016/s1530-891x(20)46610-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039660","R0039660.pdf","paywalled","nonrandomized_study","Wysham, Carol H.","2019","Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting","Figshare",null,"10.6084/m9.figshare.10033067","https://doi.org/10.6084/m9.figshare.10033067",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039868","R0039868.pdf","paywalled","nonrandomized_study","Jay Visaria","2019","1006-P: Real-World Effectiveness of Semaglutide in Early Users from a U.S. Commercially Insured (CI) and Medicare Advantage (MA) Population","Diabetes","American Diabetes Association","10.2337/db19-1006-p","https://doi.org/10.2337/db19-1006-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044416","R0044416.pdf","paywalled","nonrandomized_study","Zachary T. Bloomgarden","2019","Diabetes phenotypes: Beyond IDDM vs NIDDM","Journal of Diabetes","Wiley","10.1111/1753-0407.12954","https://doi.org/10.1111/1753-0407.12954","31125185","https://pubmed.ncbi.nlm.nih.gov/31125185/",null,null],["4","R0045321","R0045321.pdf","paywalled","nonrandomized_study","Ron Blankstein","2019","Editorial introductions","Current Opinion in Cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000665","https://doi.org/10.1097/hco.0000000000000665",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045518","R0045518.pdf","paywalled","nonrandomized_study","Amar Puttanna","2019","Mechanisms of diabetes and dementia","Practical Diabetes","Wiley","10.1002/pdi.2234","https://doi.org/10.1002/pdi.2234",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046236","R0046236.pdf","paywalled","nonrandomized_study","Yuki Fujita","2019","1019-P: Glucagon-Like Peptide-1 Receptor Agonists Predominantly Reduce Body Fat Mass in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1019-p","https://doi.org/10.2337/db19-1019-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047095","R0047095.pdf","paywalled","nonrandomized_study","Sanjoy Ketan Paul","2019","1207-P: Early vs. Late Initiation of SGLT2 and GLP-1RA for Cardiometabolic Risk Factor Control: A Real-World Study","Diabetes","American Diabetes Association","10.2337/db19-1207-p","https://doi.org/10.2337/db19-1207-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047150","R0047150.pdf","paywalled","nonrandomized_study","Peter Galthen Bech","2019","93 - Semaglutide in Patients With Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2019.07.102","https://doi.org/10.1016/j.jcjd.2019.07.102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047220","R0047220.pdf","paywalled","nonrandomized_study","Jakob Schöllhammer Knudsen","2019","1474-P: Changes in SGLT2i and GLP-1RA Real-World Initiator Profiles following Cardiovascular Outcome Trials—A Danish Nationwide Population-Based Study","Diabetes","American Diabetes Association","10.2337/db19-1474-p","https://doi.org/10.2337/db19-1474-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047323","R0047323.pdf","paywalled","nonrandomized_study","SHIORI TOGA SATO","2019","1008-P: Efficacy of Dulaglutide on Renal Functions in the Real-World Clinical Practice for Diabetes in Japan","Diabetes","American Diabetes Association","10.2337/db19-1008-p","https://doi.org/10.2337/db19-1008-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048075","R0048075.pdf","paywalled","nonrandomized_study","Shuyan Gu","2019","1295-P: Economic Evaluation of Drug Combination Strategy for Type 2 Diabetes in China","Diabetes","American Diabetes Association","10.2337/db19-1295-p","https://doi.org/10.2337/db19-1295-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048084","R0048084.pdf","paywalled","nonrandomized_study","Abdulla Mohamed Alnuaimi","2019","Efficacy of liraglutide in weight management post bariatric surgery patients: data from an Emirati cohort","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.65.p194","https://doi.org/10.1530/endoabs.65.p194",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048114","R0048114.pdf","paywalled","nonrandomized_study","Tracey Weiss","2019","987-P: Real-World Weight Change, Adherence, and Discontinuation among Type 2 Diabetes (T2D) Patients Initiating GLP-1 Receptor Agonists (GLP-1RAs) in the UK","Diabetes","American Diabetes Association","10.2337/db19-987-p","https://doi.org/10.2337/db19-987-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048121","R0048121.pdf","paywalled","nonrandomized_study","Michelle L. Jacobs","2019","1285-P: Impact of Adding a GLP-1 Receptor Agonist to the Medication Regimen","Diabetes","American Diabetes Association","10.2337/db19-1285-p","https://doi.org/10.2337/db19-1285-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048263","R0048263.pdf","paywalled","nonrandomized_study","Sean Noronha","2019","2339-PUB: Effect of IDegLira on HbA1c and Weight: Data from the Association of British Clinical Diabetologists (ABCD) IDegLira Audit","Diabetes","American Diabetes Association","10.2337/db19-2339-pub","https://doi.org/10.2337/db19-2339-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048687","R0048687.pdf","paywalled","nonrandomized_study","Joel P. Giblett","2019","Glucagon-Like Peptide-1","JACC: Journal of the American College of Cardiology",null,"10.25407/jacbts.c.4536203.v1","https://doi.org/10.25407/jacbts.c.4536203.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048894","R0048894.pdf","paywalled","nonrandomized_study","SAMANTHA L. HOCKING","2019","Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2018.11.044","https://doi.org/10.1016/j.orcp.2018.11.044",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048906","R0048906.pdf","paywalled","nonrandomized_study","Adam John Buckley","2019","2308-PUB: Liraglutide 3 mg for Weight Loss in a Real-World Setting: Clinical Outcomes after 56 Weeks","Diabetes","American Diabetes Association","10.2337/db19-2308-pub","https://doi.org/10.2337/db19-2308-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048934","R0048934.pdf","paywalled","nonrandomized_study","Pierpaolo Falcetta","2019","2256-PUB: Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)","Diabetes","American Diabetes Association","10.2337/db19-2256-pub","https://doi.org/10.2337/db19-2256-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049077","R0049077.pdf","paywalled","nonrandomized_study","Björn Eliasson","2019","1110-P: Use of IDegLira Is Associated with High Persistency Rates Up to 12 Months (M) and Improved A1C after 6M in Swedish Clinical Practice","Diabetes","American Diabetes Association","10.2337/db19-1110-p","https://doi.org/10.2337/db19-1110-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049078","R0049078.pdf","paywalled","nonrandomized_study","Gail F. Fernandes","2019","1496-P: Clinical Inertia in Relation to Sociodemographic Factors among Patients with Type 2 Diabetes (T2D) in the United States","Diabetes","American Diabetes Association","10.2337/db19-1496-p","https://doi.org/10.2337/db19-1496-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049236","R0049236.pdf","paywalled","nonrandomized_study","Brenda W. C. Bongaerts","2019","Glucose-lowering drug prescriptions in patients with newly diagnosed type 2 diabetes: statutory health insurance data from 2012 – 2016","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688177","https://doi.org/10.1055/s-0039-1688177",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049238","R0049238.pdf","paywalled","nonrandomized_study","Cori R. Rattelman","2019","1247-P: Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease","Diabetes","American Diabetes Association","10.2337/db19-1247-p","https://doi.org/10.2337/db19-1247-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049481","R0049481.pdf","paywalled","nonrandomized_study","Aditya Raju","2019","Abstract 168: A Real-World Claims Analysis of Costs Among Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease Receiving Empagliflozin or Other Antihyperglycemic Agents","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/hcq.12.suppl_1.168","https://doi.org/10.1161/hcq.12.suppl_1.168",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049506","R0049506.pdf","paywalled","nonrandomized_study","Xuejun Peng","2019","1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation","Diabetes","American Diabetes Association","10.2337/db19-1116-p","https://doi.org/10.2337/db19-1116-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049507","R0049507.pdf","paywalled","nonrandomized_study","Reema Mody","2019","1259-P: Adherence and Persistence for Dulaglutide (DU) vs. Basal Insulin (BI) in Injection-Naïve Patients with Type 2 Diabetes (T2D): The DISPELTM Study","Diabetes","American Diabetes Association","10.2337/db19-1259-p","https://doi.org/10.2337/db19-1259-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050090","R0050090.pdf","paywalled","nonrandomized_study","Juan P. Frías","2019","1132-P: Real-World Clinical Use of iGlarLixi in a Large U.S. Electronic Medical Records Database","Diabetes","American Diabetes Association","10.2337/db19-1132-p","https://doi.org/10.2337/db19-1132-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050108","R0050108.pdf","paywalled","nonrandomized_study","Shweta Urva","2019","58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db19-58-or","https://doi.org/10.2337/db19-58-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050175","R0050175.pdf","paywalled","nonrandomized_study","Elisabetta Patorno","2019","247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease","Diabetes","American Diabetes Association","10.2337/db19-247-or","https://doi.org/10.2337/db19-247-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050210","R0050210.pdf","paywalled","nonrandomized_study","C Noergaard","2019","194SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz747.0054","https://doi.org/10.1093/eurheartj/ehz747.0054",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050254","R0050254.pdf","paywalled","nonrandomized_study","Ken Y Thong","2019","1200-P: Predictors of Glycaemic and Weight Response to Empagliflozin Treatment: The ABCD Nationwide Empagliflozin Audit","Diabetes","American Diabetes Association","10.2337/db19-1200-p","https://doi.org/10.2337/db19-1200-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050297","R0050297.pdf","paywalled","nonrandomized_study","Robert E. J. Ryder","2019","1209-P: Relationship between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit","Diabetes","American Diabetes Association","10.2337/db19-1209-p","https://doi.org/10.2337/db19-1209-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050395","R0050395.pdf","paywalled","nonrandomized_study","Gail F. Fernandes","2019","2431-PUB: Distance from Glycemic Target at the Time of Intensification in Patients with Type 2 Diabetes (T2D) Failing Metformin Dual Therapy in the United States","Diabetes","American Diabetes Association","10.2337/db19-2431-pub","https://doi.org/10.2337/db19-2431-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050556","R0050556.pdf","paywalled","nonrandomized_study","Reema Mody","2019","992-P: Dulaglutide (DU) Has Better Glycemic Effectiveness vs. Basal Insulin (BI) in Injection-Naïve Patients with Type 2 Diabetes (T2D): The DISPELTM Study","Diabetes","American Diabetes Association","10.2337/db19-992-p","https://doi.org/10.2337/db19-992-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051017","R0051017.pdf","paywalled","nonrandomized_study","Florian Kahles","2019","P1757GLP-1 levels predict cardiovascular risk in patients with acute myocardial infarction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz748.0510","https://doi.org/10.1093/eurheartj/ehz748.0510",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051930","R0051930.pdf","paywalled","nonrandomized_study","Marco Trevisan","2019","SaO012GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THE RISK OF CARDIO-RENAL OUTCOMES IN DIABETIC PATIENTS SURVIVING A MYOCARDIAL INFARCTION","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfz101.sao012","https://doi.org/10.1093/ndt/gfz101.sao012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052136","R0052136.pdf","paywalled","nonrandomized_study","Mikhail Kosiborod","2019","8-OR: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)","Diabetes","American Diabetes Association","10.2337/db19-8-or","https://doi.org/10.2337/db19-8-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052232","R0052232.pdf","paywalled","nonrandomized_study","Lindsay E. Clegg","2019","6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL","Diabetes","American Diabetes Association","10.2337/db19-6-lb","https://doi.org/10.2337/db19-6-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052609","R0052609.pdf","paywalled","nonrandomized_study","Shayan Sinha Mahapatra","2019","1031-P: Impact of the Cardioprotective Effects of GLP-1 Agonists in the Management of Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1031-p","https://doi.org/10.2337/db19-1031-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052805","R0052805.pdf","paywalled","nonrandomized_study","Mami Yoshida","2019","2306-PUB: Long-Term Effect of Liraglutide on the Prevention of Progression of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-2306-pub","https://doi.org/10.2337/db19-2306-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052898","R0052898.pdf","paywalled","nonrandomized_study","Jan Skov Jensen","2019","P4449Incident cardiovascular disease in patients with type 2 diabetes: Established cardiovascular disease versus traditional risk markers","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz745.0849","https://doi.org/10.1093/eurheartj/ehz745.0849",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053045","R0053045.pdf","paywalled","nonrandomized_study","Soorya N. Aggarwal","2019","1078 Impact of GLP-1 Agonist Use on Non-Alcoholic Fatty Liver Disease Among Patients at a Large, Tertiary Care Center","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000593844.88418.01","https://doi.org/10.14309/01.ajg.0000593844.88418.01",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053120","R0053120.pdf","paywalled","nonrandomized_study","Amiya A Ahmed","2019","225-LB: Demographic and Clinical Comparisons of South Asians with Type 2 Diabetes vs. Caucasians and African Americans in an Urban Clinical Setting","Diabetes","American Diabetes Association","10.2337/db19-225-lb","https://doi.org/10.2337/db19-225-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053244","R0053244.pdf","paywalled","nonrandomized_study","Haresh Selvaskandan","2019","High-dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long-standing infected ulcers","Journal of Antimicrobial Chemotherapy","Oxford University Press (OUP)","10.1093/jac/dkz071","https://doi.org/10.1093/jac/dkz071","30783670","https://pubmed.ncbi.nlm.nih.gov/30783670/",null,null],["4","R0053265","R0053265.pdf","paywalled","nonrandomized_study","Sanjay Kumar Bajpai","2019","90-LB: Treatments and Trends in Glycemic Control for Patients with Type 2 Diabetes Mellitus Treatment following Metformin","Diabetes","American Diabetes Association","10.2337/db19-90-lb","https://doi.org/10.2337/db19-90-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053301","R0053301.pdf","paywalled","nonrandomized_study","Majid Alameri","2019","Outcomes of Liraglutide as treatment for weight regain after bariatric surgery: A 2-year retrospective study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.65.p416","https://doi.org/10.1530/endoabs.65.p416",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053365","R0053365.pdf","paywalled","nonrandomized_study","Elisabetta Patorno","2019","156-OR: Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults","Diabetes","American Diabetes Association","10.2337/db19-156-or","https://doi.org/10.2337/db19-156-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055082","R0055082.pdf","paywalled","nonrandomized_study","François Schiele","2019","P2480Sub-optimal anti-diabetic treatment in patients with pre-existing and newly diagnosed diabetes admitted for acute myocardial infarction. A study from the FAST-MI 2015 registry","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz748.0810","https://doi.org/10.1093/eurheartj/ehz748.0810",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055543","R0055543.pdf","paywalled","nonrandomized_study","Tracey Weiss","2019","984-P: Real-World Adherence and Discontinuation of GLP-1 Receptor Agonist (GLP-1RA) Therapy in Type 2 Diabetes (T2D) Patients in the U.S.","Diabetes","American Diabetes Association","10.2337/db19-984-p","https://doi.org/10.2337/db19-984-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0008986","R0008986.pdf","paywalled","nonrandomized_study","Hasegawa Y","2018","Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2017.11.006","https://doi.org/10.1016/j.jacl.2017.11.006","29217412","https://pubmed.ncbi.nlm.nih.gov/29217412/",null,null],["4","R0009695","R0009695.pdf","paywalled","nonrandomized_study","Arévalo-Lorido JC","2018","Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Springer Science and Business Media LLC","10.1007/s40292-018-0280-1","https://doi.org/10.1007/s40292-018-0280-1","30251110","https://pubmed.ncbi.nlm.nih.gov/30251110/",null,null],["4","R0010322","R0010322.pdf","paywalled","nonrandomized_study","Unni S","2018","Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13107","https://doi.org/10.1111/dom.13107","28862808","https://pubmed.ncbi.nlm.nih.gov/28862808/",null,null],["4","R0010788","R0010788.pdf","paywalled","nonrandomized_study","Wysham CH","2018","HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2017-0066","https://doi.org/10.4158/ep-2017-0066","29547044","https://pubmed.ncbi.nlm.nih.gov/29547044/",null,null],["4","R0011222","R0011222.pdf","paywalled","nonrandomized_study","Kallenbach L","2018","Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2017-0261","https://doi.org/10.4158/ep-2017-0261","29975575","https://pubmed.ncbi.nlm.nih.gov/29975575/",null,null],["4","R0013729","R0013729.pdf","paywalled","nonrandomized_study","Mirani M","2018","Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2018.09.003","https://doi.org/10.1016/j.phrs.2018.09.003","30213563","https://pubmed.ncbi.nlm.nih.gov/30213563/",null,null],["4","R0013907","R0013907.pdf","paywalled","nonrandomized_study","Elena C","2018","Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.","Current pharmaceutical biotechnology","Bentham Science Publishers Ltd.","10.2174/1389201020666190102145305","https://doi.org/10.2174/1389201020666190102145305","30605054","https://pubmed.ncbi.nlm.nih.gov/30605054/",null,null],["4","R0014094","R0014094.pdf","paywalled","nonrandomized_study","Montvida O","2018","Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc17-1414","https://doi.org/10.2337/dc17-1414","29109299","https://pubmed.ncbi.nlm.nih.gov/29109299/",null,null],["4","R0015360","R0015360.pdf","paywalled","nonrandomized_study","Sugimoto DH","2018","Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13438","https://doi.org/10.1111/dom.13438","29923361","https://pubmed.ncbi.nlm.nih.gov/29923361/",null,null],["4","R0016076","R0016076.pdf","paywalled","nonrandomized_study","Takeuchi M","2018","Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity.","Peptides","Elsevier BV","10.1016/j.peptides.2018.01.014","https://doi.org/10.1016/j.peptides.2018.01.014","29391187","https://pubmed.ncbi.nlm.nih.gov/29391187/",null,null],["4","R0017415","R0017415.pdf","paywalled","nonrandomized_study","Wysham CH","2018","Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1454417","https://doi.org/10.1080/03007995.2018.1454417","29557199","https://pubmed.ncbi.nlm.nih.gov/29557199/",null,null],["4","R0018614","R0018614.pdf","paywalled","nonrandomized_study","Luo YP","2018","[(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].","Zhonghua wai ke za zhi [Chinese journal of surgery]",null,"10.3760/cma.j.issn.0529-5815.2018.11.009","https://doi.org/10.3760/cma.j.issn.0529-5815.2018.11.009","30392304","https://pubmed.ncbi.nlm.nih.gov/30392304/",null,null],["4","R0019759","R0019759.pdf","paywalled","nonrandomized_study","Matza LS","2018","Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1465903","https://doi.org/10.1080/03007995.2018.1465903","29661026","https://pubmed.ncbi.nlm.nih.gov/29661026/",null,null],["4","R0022503","R0022503.pdf","paywalled","nonrandomized_study","Liou JH","2018","Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.","Transplantation proceedings","Elsevier BV","10.1016/j.transproceed.2018.03.087","https://doi.org/10.1016/j.transproceed.2018.03.087","30316386","https://pubmed.ncbi.nlm.nih.gov/30316386/",null,null],["4","R0022989","R0022989.pdf","paywalled","nonrandomized_study","Santucci C","2018","Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.10.006","https://doi.org/10.1016/j.diabres.2018.10.006","30332619","https://pubmed.ncbi.nlm.nih.gov/30332619/",null,null],["4","R0023028","R0023028.pdf","paywalled","nonrandomized_study","Germain N","2018","Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.12.006","https://doi.org/10.1016/j.diabres.2017.12.006","29253625","https://pubmed.ncbi.nlm.nih.gov/29253625/",null,null],["4","R0023319","R0023319.pdf","paywalled","nonrandomized_study","Gorgojo-Martínez JJ","2018","Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.","International journal of clinical practice","Wiley","10.1111/ijcp.13055","https://doi.org/10.1111/ijcp.13055","29341370","https://pubmed.ncbi.nlm.nih.gov/29341370/",null,null],["4","R0023767","R0023767.pdf","paywalled","nonrandomized_study","Armato JP","2018","Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(18)30234-1","https://doi.org/10.1016/s2213-8587(18)30234-1","30224284","https://pubmed.ncbi.nlm.nih.gov/30224284/",null,"ClinicalTrials.gov:NCT03308773"],["4","R0023820","R0023820.pdf","paywalled","nonrandomized_study","Marfella R","2018","Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13122","https://doi.org/10.1111/dom.13122","28950045","https://pubmed.ncbi.nlm.nih.gov/28950045/",null,null],["4","R0024667","R0024667.pdf","paywalled","nonrandomized_study","Wittbrodt E","2018","All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13145","https://doi.org/10.1111/dom.13145","29083520","https://pubmed.ncbi.nlm.nih.gov/29083520/",null,null],["4","R0024781","R0024781.pdf","paywalled","nonrandomized_study","Gomez-Peralta F","2018","Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13769","https://doi.org/10.1111/dme.13769","29943854","https://pubmed.ncbi.nlm.nih.gov/29943854/",null,null],["4","R0024835","R0024835.pdf","paywalled","nonrandomized_study","Gosho M","2018","Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study.","Journal of clinical pharmacology","Wiley","10.1002/jcph.1147","https://doi.org/10.1002/jcph.1147","29762878","https://pubmed.ncbi.nlm.nih.gov/29762878/",null,null],["4","R0025112","R0025112.pdf","paywalled","nonrandomized_study","Leslie RD","2018","Response to the comment on: \"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials\".","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13366","https://doi.org/10.1111/dom.13366","29781106","https://pubmed.ncbi.nlm.nih.gov/29781106/",null,null],["4","R0025289","R0025289.pdf","paywalled","nonrandomized_study","Barnett AH","2018","Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13318","https://doi.org/10.1111/dom.13318","29652101","https://pubmed.ncbi.nlm.nih.gov/29652101/",null,null],["4","R0025677","R0025677.pdf","paywalled","nonrandomized_study","Ganguly R","2018","Persistence of newer anti-obesity medications in a real-world setting.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.07.017","https://doi.org/10.1016/j.diabres.2018.07.017","30009937","https://pubmed.ncbi.nlm.nih.gov/30009937/",null,null],["4","R0025806","R0025806.pdf","paywalled","nonrandomized_study","Rye P","2018","Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-018-3393-7","https://doi.org/10.1007/s11695-018-3393-7","30022424","https://pubmed.ncbi.nlm.nih.gov/30022424/",null,null],["4","R0026548","R0026548.pdf","paywalled","nonrandomized_study","Hartmann B","2018","Regional differences in type 2 diabetes treatment and outcomes in Germany-An analysis of the German DPV and DIVE registries.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3049","https://doi.org/10.1002/dmrr.3049","30051605","https://pubmed.ncbi.nlm.nih.gov/30051605/",null,null],["4","R0026696","R0026696.pdf","paywalled","nonrandomized_study","Rathmann W","2018","Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016).","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2018.1421842","https://doi.org/10.1080/00325481.2018.1421842","29291638","https://pubmed.ncbi.nlm.nih.gov/29291638/",null,null],["4","R0026949","R0026949.pdf","paywalled","nonrandomized_study","Bajaj HS","2018","SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2018.08.001","https://doi.org/10.1016/j.diabet.2018.08.001","30149145","https://pubmed.ncbi.nlm.nih.gov/30149145/",null,"ClinicalTrials.gov:NCT03233178"],["4","R0026975","R0026975.pdf","paywalled","nonrandomized_study","Lang K","2018","Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1437027","https://doi.org/10.1080/03007995.2018.1437027","29394878","https://pubmed.ncbi.nlm.nih.gov/29394878/",null,null],["4","R0028679","R0028679.pdf","paywalled","nonrandomized_study","Nadolsky KZ","2018","Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.","Military medicine","Oxford University Press (OUP)","10.1093/milmed/usx074","https://doi.org/10.1093/milmed/usx074","29420770","https://pubmed.ncbi.nlm.nih.gov/29420770/",null,null],["4","R0028690","R0028690.pdf","paywalled","nonrandomized_study","Popovic-Djordjevic JB","2018","Antidiabetics: Structural Diversity of Molecules with a Common Aim.","Current medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0929867325666171205145309","https://doi.org/10.2174/0929867325666171205145309","29210642","https://pubmed.ncbi.nlm.nih.gov/29210642/",null,null],["4","R0030379","R0030379.pdf","paywalled","nonrandomized_study","Iyengar R","2018","Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-018-1044-y","https://doi.org/10.1007/s11892-018-1044-y","30112652","https://pubmed.ncbi.nlm.nih.gov/30112652/",null,null],["4","R0030426","R0030426.pdf","paywalled","nonrandomized_study","Misra-Hebert AD","2018","Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.","Diabetes care","American Diabetes Association","10.2337/dc17-1834","https://doi.org/10.2337/dc17-1834","29549082","https://pubmed.ncbi.nlm.nih.gov/29549082/",null,null],["4","R0032601","R0032601.pdf","paywalled","nonrandomized_study","Lauren T Perlis","2018","GLP Analogues Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Plus/Minus Antidepressant Medications","Diabetes","American Diabetes Association","10.2337/db18-2294-pub","https://doi.org/10.2337/db18-2294-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032780","R0032780.pdf","paywalled","nonrandomized_study","SHAI MOSHEL","2018","Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting","Diabetes","American Diabetes Association","10.2337/db18-1297-p","https://doi.org/10.2337/db18-1297-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032919","R0032919.pdf","paywalled","nonrandomized_study","Pierre Johansen","2018","Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada","Diabetes","American Diabetes Association","10.2337/db18-136-lb","https://doi.org/10.2337/db18-136-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032939","R0032939.pdf","paywalled","nonrandomized_study","Elisabetta Patorno","2018","Comparative Cardiovascular Effectiveness of SGLT2 Inhibitors vs. Liraglutide in Routine Care","Diabetes","American Diabetes Association","10.2337/db18-1492-p","https://doi.org/10.2337/db18-1492-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032990","R0032990.pdf","paywalled","nonrandomized_study","Sze-jung Wu","2018","Cost as the Main Driver of T2D Treatment Patterns—Lessons from Real-World Data and Physician Focus Groups","Diabetes","American Diabetes Association","10.2337/db18-1254-p","https://doi.org/10.2337/db18-1254-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033029","R0033029.pdf","paywalled","nonrandomized_study","György Jermendy","2018","Persistence to Treatment with DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients","Diabetes","American Diabetes Association","10.2337/db18-2321-pub","https://doi.org/10.2337/db18-2321-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034753","R0034753.pdf","paywalled","nonrandomized_study","Lidia Urbon Lopez de Linares","2018","Dulaglutide; effectiveness in a real world population with type 2 diabetes","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.56.p489","https://doi.org/10.1530/endoabs.56.p489",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035792","R0035792.pdf","paywalled","nonrandomized_study","Rowan Hillson","2018","Diarrhoea and diabetes","Practical Diabetes","Wiley","10.1002/pdi.2194","https://doi.org/10.1002/pdi.2194",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035869","R0035869.pdf","paywalled","nonrandomized_study","Lindsay Mandel","2018","Weight-Centric Management of Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db18-295-lb","https://doi.org/10.2337/db18-295-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036064","R0036064.pdf","paywalled","nonrandomized_study","Heike Jung","2018","Drug uilization patterns in patients Initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes (T2D) in Germany: A retrospective cohort study","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0038-1641860","https://doi.org/10.1055/s-0038-1641860",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037089","R0037089.pdf","paywalled","nonrandomized_study","Arturo Pena Velarde","2018","Abstract #611 Real World Treatment of Obesity with Liraglutide in Mexican Patients of a Medical Care Network","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)47250-7","https://doi.org/10.1016/s1530-891x(20)47250-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037322","R0037322.pdf","paywalled","nonrandomized_study","Boye, Kristina S","2018","Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of Electronic Health Records Database in the US Population","Figshare",null,"10.6084/m9.figshare.5854452","https://doi.org/10.6084/m9.figshare.5854452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037371","R0037371.pdf","paywalled","nonrandomized_study","Li, Qian","2018","Real-World Clinical Effectiveness and Cost Savings of Liraglutide versus Sitagliptin in Treating Type 2 Diabetes for One and Two Years","Figshare",null,"10.6084/m9.figshare.6133790","https://doi.org/10.6084/m9.figshare.6133790",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037717","R0037717.pdf","paywalled","nonrandomized_study","Juan José Gorgojo Martínez","2018","Predictive Factors of Insulin Discontinuation after Adding a GLP-1 Receptor Agonist in Patients with Type 2 Diabetes Treated with Insulin in Combination with Oral Antihyperglycemic Agents","Diabetes","American Diabetes Association","10.2337/db18-1099-p","https://doi.org/10.2337/db18-1099-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038187","R0038187.pdf","paywalled","nonrandomized_study","Peter M. Nilsson","2018","Blood glucose and hypertension development","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000001946","https://doi.org/10.1097/hjh.0000000000001946","30499918","https://pubmed.ncbi.nlm.nih.gov/30499918/",null,null],["4","R0038463","R0038463.pdf","paywalled","nonrandomized_study","Ostawal, Amrita","2018","Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review","Figshare",null,"10.6084/m9.figshare.6211073","https://doi.org/10.6084/m9.figshare.6211073",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038605","R0038605.pdf","paywalled","nonrandomized_study","Lind, Marcus","2018","Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden","Figshare",null,"10.6084/m9.figshare.6217163","https://doi.org/10.6084/m9.figshare.6217163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039147","R0039147.pdf","paywalled","nonrandomized_study","Shizuka Kaneko","2018","Dulaglutide Has Favorable Outcomes in Elderly or Renal Impairment Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1101-p","https://doi.org/10.2337/db18-1101-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039185","R0039185.pdf","paywalled","nonrandomized_study","Anant Nigam","2018","Once-Weekly Dulaglutide (DU) and Canagliflozin (CAN) Combination Therapy in Obese T2 Diabetes (T2D) Patients—One Year Real-World Evidence from India","Diabetes","American Diabetes Association","10.2337/db18-103-lb","https://doi.org/10.2337/db18-103-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039260","R0039260.pdf","paywalled","nonrandomized_study","Feher, Michael","2018","Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom","Figshare",null,"10.6084/m9.figshare.6182312","https://doi.org/10.6084/m9.figshare.6182312",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039625","R0039625.pdf","paywalled","nonrandomized_study","Matthew Stryker","2018","Abstract #200 A Real-World; Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus (NCT02895672)","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)47046-6","https://doi.org/10.1016/s1530-891x(20)47046-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02895672"],["4","R0039865","R0039865.pdf","paywalled","nonrandomized_study","Berkovic, Maja Cigrovski","2018","Long-Term Effectiveness of Liraglutide in Association with Patients’ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study","Figshare",null,"10.6084/m9.figshare.5904754","https://doi.org/10.6084/m9.figshare.5904754",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040709","R0040709.pdf","paywalled","nonrandomized_study","Yebin Tao","2018","Robust Estimation of the Weighted Average Treatment Effect for A Target Population","arXiv (Cornell University)",null,"10.48550/arxiv.1804.05079","https://doi.org/10.48550/arxiv.1804.05079",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041411","R0041411.pdf","paywalled","nonrandomized_study","Linxia Wang","2018","Linxia Wang Database","Data Archiving and Networked Services (DANS)",null,"10.17632/9f46z6vh67.1","https://doi.org/10.17632/9f46z6vh67.1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046198","R0046198.pdf","paywalled","nonrandomized_study","Kulvinder Kochar Kaur","2018","Existing and prospective pathways for intervention in treatment of obesity in a novel way‒a review","MOJ Drug Design Development & Therapy","MedCrave Group, LLC","10.15406/mojddt.2018.02.00035","https://doi.org/10.15406/mojddt.2018.02.00035",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046775","R0046775.pdf","paywalled","nonrandomized_study","Jianmin Wu","2018","Treatment Patterns in Patients with Newly Diagnosed Type 2 Diabetes in 2015","Diabetes","American Diabetes Association","10.2337/db18-1648-p","https://doi.org/10.2337/db18-1648-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048858","R0048858.pdf","paywalled","nonrandomized_study","Reema Mody","2018","Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a U.S. Real-World Setting","Diabetes","American Diabetes Association","10.2337/db18-1071-p","https://doi.org/10.2337/db18-1071-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049815","R0049815.pdf","paywalled","nonrandomized_study","Kibum Kim","2018","HbA1c Trends with Treatment Intensification following Inadequate Response to Two Oral Agents in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-909-p","https://doi.org/10.2337/db18-909-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049999","R0049999.pdf","paywalled","nonrandomized_study","Esther Zimmermann","2018","Use of Big-Data Algorithms to Characterize Patients with T2D on Basal Insulin (BI) Who Add a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Predict Their A1C Response","Diabetes","American Diabetes Association","10.2337/db18-100-lb","https://doi.org/10.2337/db18-100-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050142","R0050142.pdf","paywalled","nonrandomized_study","Craig Ian Coleman","2018","Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting","Diabetes","American Diabetes Association","10.2337/db18-1291-p","https://doi.org/10.2337/db18-1291-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050650","R0050650.pdf","paywalled","nonrandomized_study","Reema Mody","2018","Dulaglutide Has Higher Adherence and Persistence than Liraglutide and Exenatide QW—One-Year Follow-Up from U.S. Real-World Data","Diabetes","American Diabetes Association","10.2337/db18-1264-p","https://doi.org/10.2337/db18-1264-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050730","R0050730.pdf","paywalled","nonrandomized_study","Mukul Singhal","2018","Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)","Diabetes","American Diabetes Association","10.2337/db18-1287-p","https://doi.org/10.2337/db18-1287-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050732","R0050732.pdf","paywalled","nonrandomized_study","Turki Alharbi","2018","Glycemic and Metabolic Effects of Liraglutide as Additive Treatment to Different Therapeutic Regimens in Type 2 Diabetes Patients Followed in Primary Care Clinics","Diabetes","American Diabetes Association","10.2337/db18-2458-pub","https://doi.org/10.2337/db18-2458-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051029","R0051029.pdf","paywalled","nonrandomized_study","Andrew Robert Crawford","2018","Insulin Resistance and Weight Loss in Obese Women with Polycystic Ovary Syndrome Treated with Liraglutide—Single Institution Experience","Diabetes","American Diabetes Association","10.2337/db18-2452-pub","https://doi.org/10.2337/db18-2452-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051163","R0051163.pdf","paywalled","nonrandomized_study","D T Aagaard","2018","P2523Cardiovascular risk according to add-on therapy in patients with type 2 diabetes","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy565.p2523","https://doi.org/10.1093/eurheartj/ehy565.p2523",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051540","R0051540.pdf","paywalled","nonrandomized_study","Matthew Stryker","2018","Assessing the Real-World Use of Combination Insulin Glargine-Lixisenatide in Patients with Type 2 Diabetes Mellitus—A Retrospective Review from an Ambulatory Care Endocrinology Practice","Diabetes","American Diabetes Association","10.2337/db18-2290-pub","https://doi.org/10.2337/db18-2290-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051638","R0051638.pdf","paywalled","nonrandomized_study","Ruth E. Brown","2018","Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP–1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study","Diabetes","American Diabetes Association","10.2337/db18-1096-p","https://doi.org/10.2337/db18-1096-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051678","R0051678.pdf","paywalled","nonrandomized_study","Nitesh D Kuhadiya","2018","Addition of GLP-1 Therapy to Insulin in C-Peptide-Positive Patients with Type 1 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-110-lb","https://doi.org/10.2337/db18-110-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051914","R0051914.pdf","paywalled","nonrandomized_study","Girish N. Nadkarni","2018","Abstract MP52: Population Health Impact of Sodium Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in US Adults With Type 2 Diabetes","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.137.suppl_1.mp52","https://doi.org/10.1161/circ.137.suppl_1.mp52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051991","R0051991.pdf","paywalled","nonrandomized_study","Michelle Mocarski","2018","Characteristics of Patients Newly Prescribed IDegLira in U.S. Real-World Practice","Diabetes","American Diabetes Association","10.2337/db18-2285-pub","https://doi.org/10.2337/db18-2285-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052223","R0052223.pdf","paywalled","nonrandomized_study","Huub J. van Eyk","2018","Circulating cetp is not related to the hepatic triglyceride content: Lessons from a liraglutide intervention trial and a population-based cohort","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2018.06.163","https://doi.org/10.1016/j.atherosclerosis.2018.06.163",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052404","R0052404.pdf","paywalled","nonrandomized_study","Orna Reges","2018","Treatment and Clinical Measures after Initiation of Injectable Therapy for Type 2 Diabetes—A Real-World Observational Cohort Study","Diabetes","American Diabetes Association","10.2337/db18-1076-p","https://doi.org/10.2337/db18-1076-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052656","R0052656.pdf","paywalled","nonrandomized_study","Rana Moustafa Al Adawi","2018","Efficacy and safety of once daily liraglutideversus twice daily exenatidein type 2diabetic patients in Qatar: an observational study",null,"Hamad bin Khalifa University Press (HBKU Press)","10.5339/qfarc.2018.hbpd251","https://doi.org/10.5339/qfarc.2018.hbpd251",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053108","R0053108.pdf","paywalled","nonrandomized_study","Matthew T. O’Brien","2018","The Comparative Cardiovascular Effectiveness of Six Antidiabetic Medications among Insured Adults with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1125-p","https://doi.org/10.2337/db18-1125-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053283","R0053283.pdf","paywalled","nonrandomized_study","Devin Abrahami","2018","Incretin based drugs and the risk of cholangiocarcinoma in patients with type 2 diabetes.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2018.36.15_suppl.e16126","https://doi.org/10.1200/jco.2018.36.15_suppl.e16126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053595","R0053595.pdf","paywalled","nonrandomized_study","Mitsuaki Takeuchi","2018","Pharmacological Evaluation of SKL-18287, a New Long-Acting Glucagon-Like Peptide-1 Receptor Agonist with Enhanced Aggregation Propensity, in Rodent Models","International Journal of Peptide Research and Therapeutics","Springer Science and Business Media LLC","10.1007/s10989-018-9777-7","https://doi.org/10.1007/s10989-018-9777-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055062","R0055062.pdf","paywalled","nonrandomized_study","Obeid, Youssef","2018","Real World Effectiveness Of Lixisenatide And Other Intensification Therapy In The Management Of Type 2 Diabetic Patients Uncontrolled With Basal Insulin.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.1485177","https://doi.org/10.5281/zenodo.1485177",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0008043","R0008043.pdf","paywalled","nonrandomized_study","Levin P","2017","COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep171769.or","https://doi.org/10.4158/ep171769.or","28816532","https://pubmed.ncbi.nlm.nih.gov/28816532/",null,null],["4","R0008925","R0008925.pdf","paywalled","nonrandomized_study","Bettge K","2017","Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12824","https://doi.org/10.1111/dom.12824","27860132","https://pubmed.ncbi.nlm.nih.gov/27860132/",null,null],["4","R0010002","R0010002.pdf","paywalled","nonrandomized_study","Zimmerman RS","2017","Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12969","https://doi.org/10.1111/dom.12969","28407414","https://pubmed.ncbi.nlm.nih.gov/28407414/",null,null],["4","R0013758","R0013758.pdf","paywalled","nonrandomized_study","Yu M","2017","Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2017.11.001","https://doi.org/10.1016/j.clinthera.2017.11.001","29196084","https://pubmed.ncbi.nlm.nih.gov/29196084/",null,null],["4","R0014018","R0014018.pdf","paywalled","nonrandomized_study","Higbea AM","2017","Weight effects of antidiabetic agents.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2017.1395694","https://doi.org/10.1080/17446651.2017.1395694","30063431","https://pubmed.ncbi.nlm.nih.gov/30063431/",null,null],["4","R0015499","R0015499.pdf","paywalled","nonrandomized_study","Toulis KA","2017","All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2017.02.003","https://doi.org/10.1016/j.diabet.2017.02.003","28325589","https://pubmed.ncbi.nlm.nih.gov/28325589/",null,null],["4","R0016479","R0016479.pdf","paywalled","nonrandomized_study","Bloomgarden Z","2017","Is insulin the preferred treatment for HbA1c >9%?","Journal of diabetes","Wiley","10.1111/1753-0407.12575","https://doi.org/10.1111/1753-0407.12575","28589542","https://pubmed.ncbi.nlm.nih.gov/28589542/",null,null],["4","R0016660","R0016660.pdf","paywalled","nonrandomized_study","Hunt B","2017","Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2017.05.354","https://doi.org/10.1016/j.clinthera.2017.05.354","28625506","https://pubmed.ncbi.nlm.nih.gov/28625506/",null,"ClinicalTrials.gov:NCT01973231"],["4","R0016858","R0016858.pdf","paywalled","nonrandomized_study","Müller N","2017","Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13397","https://doi.org/10.1111/dme.13397","28586530","https://pubmed.ncbi.nlm.nih.gov/28586530/",null,null],["4","R0017050","R0017050.pdf","paywalled","nonrandomized_study","Hunt B","2017","Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12890","https://doi.org/10.1111/dom.12890","28124820","https://pubmed.ncbi.nlm.nih.gov/28124820/",null,"ClinicalTrials.gov:NCT01973231"],["4","R0017112","R0017112.pdf","paywalled","nonrandomized_study","Gorgojo-Martínez JJ","2017","Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2016.11.007","https://doi.org/10.1016/j.numecd.2016.11.007","28077257","https://pubmed.ncbi.nlm.nih.gov/28077257/",null,null],["4","R0019314","R0019314.pdf","paywalled","nonrandomized_study","Arnold SV","2017","Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1177/2047487317729252","https://doi.org/10.1177/2047487317729252","28870145","https://pubmed.ncbi.nlm.nih.gov/28870145/",null,null],["4","R0019648","R0019648.pdf","paywalled","nonrandomized_study","Karras SN","2017","Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.","Current clinical pharmacology","Bentham Science Publishers Ltd.","10.2174/1574884713666180221121512","https://doi.org/10.2174/1574884713666180221121512","29473524","https://pubmed.ncbi.nlm.nih.gov/29473524/",null,null],["4","R0019986","R0019986.pdf","paywalled","nonrandomized_study","Tseng CM","2017","Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Elsevier BV","10.1016/j.pan.2016.10.003","https://doi.org/10.1016/j.pan.2016.10.003","27743712","https://pubmed.ncbi.nlm.nih.gov/27743712/",null,null],["4","R0021433","R0021433.pdf","paywalled","nonrandomized_study","Thomsen RW","2017","Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13168","https://doi.org/10.1111/dme.13168","27279380","https://pubmed.ncbi.nlm.nih.gov/27279380/",null,null],["4","R0021612","R0021612.pdf","paywalled","nonrandomized_study","Deol H","2017","Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-016-1125-0","https://doi.org/10.1007/s12020-016-1125-0","27696231","https://pubmed.ncbi.nlm.nih.gov/27696231/",null,null],["4","R0022233","R0022233.pdf","paywalled","nonrandomized_study","Garcia de Lucas MD","2017","Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2017.03.007","https://doi.org/10.1016/j.diabet.2017.03.007","28476578","https://pubmed.ncbi.nlm.nih.gov/28476578/",null,null],["4","R0022367","R0022367.pdf","paywalled","nonrandomized_study","Fleischmann H","2017","Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2016.12.014","https://doi.org/10.1016/j.dsx.2016.12.014","27986406","https://pubmed.ncbi.nlm.nih.gov/27986406/",null,null],["4","R0023544","R0023544.pdf","paywalled","nonrandomized_study","Flory J","2017","Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12931","https://doi.org/10.1111/dom.12931","28266807","https://pubmed.ncbi.nlm.nih.gov/28266807/",null,null],["4","R0025178","R0025178.pdf","paywalled","nonrandomized_study","Arnaud M","2017","Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France.","Fundamental & clinical pharmacology","Wiley","10.1111/fcp.12298","https://doi.org/10.1111/fcp.12298","28575541","https://pubmed.ncbi.nlm.nih.gov/28575541/",null,null],["4","R0025414","R0025414.pdf","paywalled","nonrandomized_study","Farwig PA","2017","The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.09.008","https://doi.org/10.1016/j.diabres.2017.09.008","28951338","https://pubmed.ncbi.nlm.nih.gov/28951338/",null,null],["4","R0025931","R0025931.pdf","paywalled","nonrandomized_study","Rondinelli M","2017","Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2016.11.001","https://doi.org/10.1016/j.clinthera.2016.11.001","27939305","https://pubmed.ncbi.nlm.nih.gov/27939305/",null,null],["4","R0026028","R0026028.pdf","paywalled","nonrandomized_study","Marso SP","2017","Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc1615712","https://doi.org/10.1056/nejmc1615712","28249135","https://pubmed.ncbi.nlm.nih.gov/28249135/",null,null],["4","R0026031","R0026031.pdf","paywalled","nonrandomized_study","de Lucas MDG","2017","Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2017.07.020","https://doi.org/10.1016/j.ejim.2017.07.020","28711390","https://pubmed.ncbi.nlm.nih.gov/28711390/",null,null],["4","R0026655","R0026655.pdf","paywalled","nonrandomized_study","Rathmann W","2017","Treatment persistence in the use of basal insulins in Poland and Germany
.","International journal of clinical pharmacology and therapeutics","Dustri-Verlgag Dr. Karl Feistle","10.5414/cp202772","https://doi.org/10.5414/cp202772","27879196","https://pubmed.ncbi.nlm.nih.gov/27879196/",null,null],["4","R0026699","R0026699.pdf","paywalled","nonrandomized_study","Rathmann W","2017","Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12894","https://doi.org/10.1111/dom.12894","28127851","https://pubmed.ncbi.nlm.nih.gov/28127851/",null,null],["4","R0026764","R0026764.pdf","paywalled","nonrandomized_study","Kesavadev J","2017","Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-017-0576-x","https://doi.org/10.1007/s12325-017-0576-x","28667580","https://pubmed.ncbi.nlm.nih.gov/28667580/",null,null],["4","R0026823","R0026823.pdf","paywalled","nonrandomized_study","Pariente A","2017","Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-017-2326-z","https://doi.org/10.1007/s00228-017-2326-z","28866826","https://pubmed.ncbi.nlm.nih.gov/28866826/",null,null],["4","R0027032","R0027032.pdf","paywalled","nonrandomized_study","Dong Z","2017","Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.12606","https://doi.org/10.1111/obr.12606","29024559","https://pubmed.ncbi.nlm.nih.gov/29024559/",null,null],["4","R0027310","R0027310.pdf","paywalled","nonrandomized_study","Pageot C","2017","Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-017-0561-y","https://doi.org/10.1007/s40264-017-0561-y","28664354","https://pubmed.ncbi.nlm.nih.gov/28664354/",null,null],["4","R0027485","R0027485.pdf","paywalled","nonrandomized_study","Cai J","2017","Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2017.1320277","https://doi.org/10.1080/03007995.2017.1320277","28418262","https://pubmed.ncbi.nlm.nih.gov/28418262/",null,null],["4","R0030421","R0030421.pdf","paywalled","nonrandomized_study","Gutierrez-Buey G","2017","Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2017.03.006","https://doi.org/10.1016/j.ejim.2017.03.006","28283346","https://pubmed.ncbi.nlm.nih.gov/28283346/",null,null],["4","R0030609","R0030609.pdf","paywalled","nonrandomized_study","Yaping Luo","2017","68Ga-exendin-4 PET/CT for the localization of insulinomas","Zhonghua heyixue yu fenzi yingxiang zazhi",null,"10.3760/cma.j.issn.2095-2848.2017.03.003","https://doi.org/10.3760/cma.j.issn.2095-2848.2017.03.003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034432","R0034432.pdf","paywalled","nonrandomized_study","Price Hermione","2017","Real-world use of IDegLira significantly reduces HbA1c after 6 months and HbA1c category is a significant factor",null,"Morressier","10.26226/morressier.59d51845d462b80296ca3658","https://doi.org/10.26226/morressier.59d51845d462b80296ca3658",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034473","R0034473.pdf","paywalled","nonrandomized_study","Rhee Kyu","2017","Using advanced analytics to evaluate real-world treatment pathways leading to basal insulin plus GLP-1 RA therapy",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3bb7","https://doi.org/10.26226/morressier.59d51847d462b80296ca3bb7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034720","R0034720.pdf","paywalled","nonrandomized_study","Price Hermione","2017","Real-world IDegLira use is effective at moderate doses for all previous therapy groups and reduces concomitant therapy",null,"Morressier","10.26226/morressier.59d51845d462b80296ca347e","https://doi.org/10.26226/morressier.59d51845d462b80296ca347e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034776","R0034776.pdf","paywalled","nonrandomized_study","Price Hermione","2017","Real-world use of IDegLira significantly improves glycaemic control in participants with type 2 diabetes",null,"Morressier","10.26226/morressier.59d51845d462b80296ca3649","https://doi.org/10.26226/morressier.59d51845d462b80296ca3649",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034796","R0034796.pdf","paywalled","nonrandomized_study","Rhee Kyu","2017","Using machine learning on real-world data to identify features correlating with remaining on basal insulin + GLP-1 RA",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3bbc","https://doi.org/10.26226/morressier.59d51847d462b80296ca3bbc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035977","R0035977.pdf","paywalled","nonrandomized_study","Rüdiger Göke","2017","Real-World-Wirkungen von Dulaglutide bei Patienten, betreut in Diabetologischen Schwerpunktpraxen","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-124422","https://doi.org/10.1055/s-0042-124422",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037476","R0037476.pdf","paywalled","nonrandomized_study","Muhammad Hassan Majeed","2017","Denying Visas to Doctors in the United States","New England Journal of Medicine","Massachusetts Medical Society","10.1056/nejmc1616421","https://doi.org/10.1056/nejmc1616421","28146640","https://pubmed.ncbi.nlm.nih.gov/28146640/",null,null],["4","R0037694","R0037694.pdf","paywalled","nonrandomized_study","Phyllis Wang","2017","Update to delivering medications via a pneumatic tube system","American Journal of Health-System Pharmacy","Oxford University Press (OUP)","10.2146/ajhp150107","https://doi.org/10.2146/ajhp150107","28947520","https://pubmed.ncbi.nlm.nih.gov/28947520/",null,null],["4","R0039611","R0039611.pdf","paywalled","nonrandomized_study","C Kojima","2017","Patient outcome audit in ACT health obesity management service","Internal Medicine Journal","Wiley","10.1111/imj.7_13461","https://doi.org/10.1111/imj.7_13461",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043522","R0043522.pdf","paywalled","nonrandomized_study","Seker, Asilay","2017","Exenatide Worsens Depression And Causes Suicidal Ideation Relapse : A Case Report","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c642bea9ae8fb00131cf05d","https://doi.org/10.26226/morressier.5c642bea9ae8fb00131cf05d",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043537","R0043537.pdf","paywalled","nonrandomized_study","Silva-Nunes, José","2017","Effect of Liraglutide in The Real World Setting of Type 2 Diabetes Patients : Preliminary Results From The Lira-Spd Trial","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5d9b6231ea541d6ca8493cb6","https://doi.org/10.26226/morressier.5d9b6231ea541d6ca8493cb6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043698","R0043698.pdf","paywalled","nonrandomized_study","Guja, Cristian","2017","Efficacy and safety of insulin glargine U300 in insulin-nau00efve type 2 diabetes subjects in a real-world practice setting","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5d9b6229ea541d6ca8493890","https://doi.org/10.26226/morressier.5d9b6229ea541d6ca8493890",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044016","R0044016.pdf","paywalled","nonrandomized_study",null,"2017","Safety Profiles of Antidiabetic Drugs (Ad) : a Disproportionality Analysis in The Portuguese Pharmacovigilance System (Pps) Database","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8159e668b9000b9f8f71","https://doi.org/10.26226/morressier.5c3c8159e668b9000b9f8f71",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044073","R0044073.pdf","paywalled","nonrandomized_study","Cui, Lijuan","2017","The effect and mechanism of LncRNA-NONRATT003689 in the function and viability of u03b2 cells mediated by GLP-1RA","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5d9b622cea541d6ca8493c4f","https://doi.org/10.26226/morressier.5d9b622cea541d6ca8493c4f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044238","R0044238.pdf","paywalled","nonrandomized_study",null,"2017","Critical Clinical Issue of Diabetes Therapy induced Hypoglycemia : a Population Study Analysis On Existing Databases","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8157e668b9000b9f90a6","https://doi.org/10.26226/morressier.5c3c8157e668b9000b9f90a6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044313","R0044313.pdf","paywalled","nonrandomized_study","Bhattacharyya, Supratik","2017","SAFETY AND EFFICACY OF INSULIN DEGLUDEC/LIRAGLUTIDE FIXED-RATIO COMBINATION IN OAD FAILURE TYPE 2 DIABETES PATIENTS IN A TERTIARY CARE CENTRE IN EASTERN INDIA","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8156e668b9000b9f900c","https://doi.org/10.26226/morressier.5c3c8156e668b9000b9f900c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044330","R0044330.pdf","paywalled","nonrandomized_study","TRESCOLI-SERRANO, CARLOS","2017","Long term real world safety and efficacy of SGLT-2 inhibitors in elderly type 2 diabetic patients","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5d9b6229ea541d6ca849382a","https://doi.org/10.26226/morressier.5d9b6229ea541d6ca849382a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046036","R0046036.pdf","paywalled","nonrandomized_study","Indranil Dasgupta","2017","Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death","Annals of Internal Medicine","American College of Physicians","10.7326/acpjc-2017-167-8-047","https://doi.org/10.7326/acpjc-2017-167-8-047","29049766","https://pubmed.ncbi.nlm.nih.gov/29049766/",null,null],["4","R0047261","R0047261.pdf","paywalled","nonrandomized_study","Jothydev Kesavadev","2017","Abstract #239: Treatment Outcomes ith Liraglutide In iNew Onset Type 2 Diabetes – A Retrospective Analysis","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)44359-9","https://doi.org/10.1016/s1530-891x(20)44359-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049595","R0049595.pdf","paywalled","nonrandomized_study","Suzanne V. Arnold","2017","Abstract 135: Assessing the Personalization of Glycemic Management Strategies Through the Diabetes Collaborative Registry","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/circoutcomes.10.suppl_3.135","https://doi.org/10.1161/circoutcomes.10.suppl_3.135",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049645","R0049645.pdf","paywalled","nonrandomized_study","Rachel J. Fenske","2017","Prostaglandin E2 (PGE2) Levels As a Predictor of Type 2 Diabetes Control in Human Subjects: A cross‐sectional view of initial cohort study data","The FASEB Journal","Wiley","10.1096/fasebj.31.1_supplement.675.6","https://doi.org/10.1096/fasebj.31.1_supplement.675.6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050312","R0050312.pdf","paywalled","nonrandomized_study","J. F. Lucía","2017","CP-153 Liraglutide adequacy and effectiveness in real practice type 2 diabetes therapy",null,"British Medical Journal Publishing Group","10.1136/ejhpharm-2017-000640.152","https://doi.org/10.1136/ejhpharm-2017-000640.152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051509","R0051509.pdf","paywalled","nonrandomized_study","Patrick Lefèbvre","2017","Abstract #290: Real-World Persistence and HBA1C Goal Attainment in Patients with Type Ii Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide-1 Receptor Agonist","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)44410-6","https://doi.org/10.1016/s1530-891x(20)44410-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052631","R0052631.pdf","paywalled","nonrandomized_study","Philippe Autier","2017","Initiation and shift of antidiabetic therapy and pancreatic cancer.","Journal of Clinical Oncology","American Society of Clinical Oncology (ASCO)","10.1200/jco.2017.35.15_suppl.4126","https://doi.org/10.1200/jco.2017.35.15_suppl.4126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0009505","R0009505.pdf","paywalled","nonrandomized_study","Harris KB","2016","Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.","Pharmacotherapy","Wiley","10.1002/phar.1804","https://doi.org/10.1002/phar.1804","27485823","https://pubmed.ncbi.nlm.nih.gov/27485823/",null,null],["4","R0011447","R0011447.pdf","paywalled","nonrandomized_study","Patorno E","2016","Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12665","https://doi.org/10.1111/dom.12665","27003762","https://pubmed.ncbi.nlm.nih.gov/27003762/",null,null],["4","R0011875","R0011875.pdf","paywalled","nonrandomized_study","Davies MJ","2016","Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-016-0433-9","https://doi.org/10.1007/s40273-016-0433-9","27438706","https://pubmed.ncbi.nlm.nih.gov/27438706/",null,null],["4","R0012598","R0012598.pdf","paywalled","nonrandomized_study","Jameson K","2016","Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2015.1101372","https://doi.org/10.1185/03007995.2015.1101372","26428701","https://pubmed.ncbi.nlm.nih.gov/26428701/",null,null],["4","R0014125","R0014125.pdf","paywalled","nonrandomized_study","Rathmann W","2016","Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12673","https://doi.org/10.1111/dom.12673","27062643","https://pubmed.ncbi.nlm.nih.gov/27062643/",null,null],["4","R0014225","R0014225.pdf","paywalled","nonrandomized_study","Ohki T","2016","Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-016-0383-1","https://doi.org/10.1007/s40261-016-0383-1","26914659","https://pubmed.ncbi.nlm.nih.gov/26914659/",null,null],["4","R0015643","R0015643.pdf","paywalled","nonrandomized_study","Yu M","2016","Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.11.017","https://doi.org/10.1016/j.clinthera.2015.11.017","26706658","https://pubmed.ncbi.nlm.nih.gov/26706658/",null,null],["4","R0016117","R0016117.pdf","paywalled","nonrandomized_study","Gimeno-Orna JA","2016","Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists.","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","Elsevier BV","10.1016/j.endonu.2015.11.009","https://doi.org/10.1016/j.endonu.2015.11.009","26830854","https://pubmed.ncbi.nlm.nih.gov/26830854/",null,null],["4","R0017465","R0017465.pdf","paywalled","nonrandomized_study","Sportiello L","2016","The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2015.10.002","https://doi.org/10.1016/j.ijcard.2015.10.002","26461922","https://pubmed.ncbi.nlm.nih.gov/26461922/",null,null],["4","R0017935","R0017935.pdf","paywalled","nonrandomized_study","Nozue T","2016","Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.","Heart and vessels","Springer Science and Business Media LLC","10.1007/s00380-015-0734-5","https://doi.org/10.1007/s00380-015-0734-5","26293570","https://pubmed.ncbi.nlm.nih.gov/26293570/",null,null],["4","R0019074","R0019074.pdf","paywalled","nonrandomized_study","Moulton CD","2016","Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2015.06.003","https://doi.org/10.1016/j.pcd.2015.06.003","26137918","https://pubmed.ncbi.nlm.nih.gov/26137918/",null,null],["4","R0019480","R0019480.pdf","paywalled","nonrandomized_study","Bode BW","2016","THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep15869.ra","https://doi.org/10.4158/ep15869.ra","26484403","https://pubmed.ncbi.nlm.nih.gov/26484403/",null,null],["4","R0022029","R0022029.pdf","paywalled","nonrandomized_study","Sicras-Mainar A","2016","Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","Elsevier BV","10.1016/j.endonu.2016.07.001","https://doi.org/10.1016/j.endonu.2016.07.001","27744013","https://pubmed.ncbi.nlm.nih.gov/27744013/",null,null],["4","R0022908","R0022908.pdf","paywalled","nonrandomized_study","Christou GA","2016","The Current Role of Liraglutide in the Pharmacotherapy of Obesity.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161113666150615111951","https://doi.org/10.2174/1570161113666150615111951","26074046","https://pubmed.ncbi.nlm.nih.gov/26074046/",null,null],["4","R0023405","R0023405.pdf","paywalled","nonrandomized_study","García Díaz E","2016","Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","Elsevier BV","10.1016/j.endonu.2016.01.006","https://doi.org/10.1016/j.endonu.2016.01.006","26976710","https://pubmed.ncbi.nlm.nih.gov/26976710/",null,null],["4","R0024600","R0024600.pdf","paywalled","nonrandomized_study","Tseng CH","2016","Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.","European journal of clinical investigation","Wiley","10.1111/eci.12570","https://doi.org/10.1111/eci.12570","26584246","https://pubmed.ncbi.nlm.nih.gov/26584246/",null,null],["4","R0025003","R0025003.pdf","paywalled","nonrandomized_study","Ekström N","2016","Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12704","https://doi.org/10.1111/dom.12704","27282621","https://pubmed.ncbi.nlm.nih.gov/27282621/",null,null],["4","R0025355","R0025355.pdf","paywalled","nonrandomized_study","Mosińska P","2016","Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.","Expert opinion on investigational drugs","Informa UK Limited","10.1517/13543784.2016.1142532","https://doi.org/10.1517/13543784.2016.1142532","26765585","https://pubmed.ncbi.nlm.nih.gov/26765585/",null,null],["4","R0025933","R0025933.pdf","paywalled","nonrandomized_study","Bertuzzi F","2016","Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/tp.0000000000001441","https://doi.org/10.1097/tp.0000000000001441","27517727","https://pubmed.ncbi.nlm.nih.gov/27517727/",null,null],["4","R0026251","R0026251.pdf","paywalled","nonrandomized_study","Quack I","2016","[Cardiovascular morbidity and mortality in patients with kidney disease].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0042-118274","https://doi.org/10.1055/s-0042-118274","27903028","https://pubmed.ncbi.nlm.nih.gov/27903028/",null,null],["4","R0026502","R0026502.pdf","paywalled","nonrandomized_study","Gorgojo-Martínez JJ","2016","Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2016.02.013","https://doi.org/10.1016/j.soard.2016.02.013","27256860","https://pubmed.ncbi.nlm.nih.gov/27256860/",null,null],["4","R0026518","R0026518.pdf","paywalled","nonrandomized_study","Reaney M","2016","Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2016.04.009","https://doi.org/10.1016/j.diabres.2016.04.009","27321317","https://pubmed.ncbi.nlm.nih.gov/27321317/",null,null],["4","R0027067","R0027067.pdf","paywalled","nonrandomized_study","Rathmann W","2016","Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2015.04.001","https://doi.org/10.1016/j.pcd.2015.04.001","25937183","https://pubmed.ncbi.nlm.nih.gov/25937183/",null,null],["4","R0027708","R0027708.pdf","paywalled","nonrandomized_study","Han E","2016","Assessment of the Price-Volume Agreement Program in South Korea.","Health policy (Amsterdam, Netherlands)","Elsevier BV","10.1016/j.healthpol.2016.07.017","https://doi.org/10.1016/j.healthpol.2016.07.017","27519975","https://pubmed.ncbi.nlm.nih.gov/27519975/",null,null],["4","R0027911","R0027911.pdf","paywalled","nonrandomized_study","Bragg R","2016","Review of pharmacotherapy options for the management of obesity.","Journal of the American Association of Nurse Practitioners","Ovid Technologies (Wolters Kluwer Health)","10.1002/2327-6924.12279","https://doi.org/10.1002/2327-6924.12279","26119641","https://pubmed.ncbi.nlm.nih.gov/26119641/",null,null],["4","R0028786","R0028786.pdf","paywalled","nonrandomized_study","Fu AZ","2016","Treatment intensification for patients with type 2 diabetes and poor glycaemic control.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12683","https://doi.org/10.1111/dom.12683","27160505","https://pubmed.ncbi.nlm.nih.gov/27160505/",null,null],["4","R0028814","R0028814.pdf","paywalled","nonrandomized_study","Marathe CS","2016","Novel insights into the effects of diabetes on gastric motility.","Expert review of gastroenterology & hepatology","Informa UK Limited","10.1586/17474124.2016.1129898","https://doi.org/10.1586/17474124.2016.1129898","26647088","https://pubmed.ncbi.nlm.nih.gov/26647088/",null,null],["4","R0031311","R0031311.pdf","paywalled","nonrandomized_study","Soumyabrata Roy Chaudhuri","2016","LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects","Advances in Obesity Weight Management & Control","MedCrave Group, LLC","10.15406/aowmc.2016.05.00136","https://doi.org/10.15406/aowmc.2016.05.00136",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031637","R0031637.pdf","paywalled","nonrandomized_study","David H. Wesorick","2016","Annals for Hospitalists - 16 August 2016","Annals of Internal Medicine","American College of Physicians","10.7326/afho201608160","https://doi.org/10.7326/afho201608160",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031811","R0031811.pdf","paywalled","nonrandomized_study",null,"2016","Study suggests GLP-1 analogues do not raise breast cancer risk","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2016.20201887","https://doi.org/10.1211/pj.2016.20201887",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0033623","R0033623.pdf","paywalled","nonrandomized_study","Yotsapon Thewjitcharoen","2016","Liraglutide Treatment in a Real-life Setting: A Retrospective Review in a Specialized Diabetes Center from Thailand",null,null,"10.13140/rg.2.2.23785.49765","https://doi.org/10.13140/rg.2.2.23785.49765",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037672","R0037672.pdf","paywalled","nonrandomized_study","Anant Nigam","2016","Abstract # P-28: Improved Clinical Outcomes with The Dual Therapies of a SGLT-2I and a GLP-1RA in Overweight/Obese People with T2 Diabetes, Real World Data From the Indian Subcontinent","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)43841-8","https://doi.org/10.1016/s1530-891x(20)43841-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038689","R0038689.pdf","paywalled","nonrandomized_study","Chunyi Yang","2016","A real world experience of long-acting GLP-1 receptor agonists in a medical center in southern of Taiwan","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/s0168-8227(16)31250-5","https://doi.org/10.1016/s0168-8227(16)31250-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044249","R0044249.pdf","paywalled","nonrandomized_study","Eduardo Vilar‐Gómez","2016","Reply","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.28670","https://doi.org/10.1002/hep.28670","27287070","https://pubmed.ncbi.nlm.nih.gov/27287070/",null,null],["4","R0047790","R0047790.pdf","paywalled","nonrandomized_study","Matthew James Armstrong","2016","Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.28672","https://doi.org/10.1002/hep.28672","27287457","https://pubmed.ncbi.nlm.nih.gov/27287457/",null,null],["4","R0050436","R0050436.pdf","paywalled","nonrandomized_study","Marios Politis","2016","Parkinson’s Disease, Diabetes and Cognitive Impairment","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","Bentham Science Publishers Ltd.","10.2174/1872214810666160630191119","https://doi.org/10.2174/1872214810666160630191119",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056908","R0056908.pdf","paywalled","nonrandomized_study","Doucet JA","2016","Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort.","Fundamental & clinical pharmacology","Wiley","10.1111/fcp.12160","https://doi.org/10.1111/fcp.12160","26478566","https://pubmed.ncbi.nlm.nih.gov/26478566/",null,null],["4","R0015096","R0015096.pdf","paywalled","nonrandomized_study","Nuffer WA","2015","Liraglutide: A New Option for the Treatment of Obesity.","Pharmacotherapy","Wiley","10.1002/phar.1639","https://doi.org/10.1002/phar.1639","26497479","https://pubmed.ncbi.nlm.nih.gov/26497479/",null,null],["4","R0016395","R0016395.pdf","paywalled","nonrandomized_study","Cahn A","2015","New forms of insulin and insulin therapies for the treatment of type 2 diabetes.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(15)00097-2","https://doi.org/10.1016/s2213-8587(15)00097-2","26051044","https://pubmed.ncbi.nlm.nih.gov/26051044/",null,null],["4","R0018159","R0018159.pdf","paywalled","nonrandomized_study","Consoli A","2015","Potential side effects to GLP-1 agonists: understanding their safety and tolerability.","Expert opinion on drug safety","Informa Healthcare","10.1517/14740338.2015.987122","https://doi.org/10.1517/14740338.2015.987122","25496749","https://pubmed.ncbi.nlm.nih.gov/25496749/",null,null],["4","R0021006","R0021006.pdf","paywalled","nonrandomized_study","Kesavadev J","2015","Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2014.04.034","https://doi.org/10.1016/j.dsx.2014.04.034","25605673","https://pubmed.ncbi.nlm.nih.gov/25605673/",null,null],["4","R0022415","R0022415.pdf","paywalled","nonrandomized_study","Cariou B","2015","Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2014.10.004","https://doi.org/10.1016/j.diabet.2014.10.004","25457472","https://pubmed.ncbi.nlm.nih.gov/25457472/",null,null],["4","R0022844","R0022844.pdf","paywalled","nonrandomized_study","Buysschaert M","2015","ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2015.05.001","https://doi.org/10.1016/j.dsx.2015.05.001","26004030","https://pubmed.ncbi.nlm.nih.gov/26004030/",null,null],["4","R0023650","R0023650.pdf","paywalled","nonrandomized_study","Scott LJ","2015","Liraglutide: a review of its use in the management of obesity.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-015-0408-8","https://doi.org/10.1007/s40265-015-0408-8","25985864","https://pubmed.ncbi.nlm.nih.gov/25985864/",null,null],["4","R0023654","R0023654.pdf","paywalled","nonrandomized_study","Nakouti T","2015","Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161112666141121112612","https://doi.org/10.2174/1570161112666141121112612","25412688","https://pubmed.ncbi.nlm.nih.gov/25412688/",null,null],["4","R0024118","R0024118.pdf","paywalled","nonrandomized_study","Russo GT","2015","Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-014-0163-9","https://doi.org/10.1007/s40618-014-0163-9","25173876","https://pubmed.ncbi.nlm.nih.gov/25173876/",null,null],["4","R0024385","R0024385.pdf","paywalled","nonrandomized_study","Payk SL","2015","Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.04.011","https://doi.org/10.1016/j.clinthera.2015.04.011","26024569","https://pubmed.ncbi.nlm.nih.gov/26024569/",null,null],["4","R0024432","R0024432.pdf","paywalled","nonrandomized_study","Chang HY","2015","Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.3770","https://doi.org/10.1002/pds.3770","25851403","https://pubmed.ncbi.nlm.nih.gov/25851403/",null,null],["4","R0025104","R0025104.pdf","paywalled","nonrandomized_study","Saroka RM","2015","SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep15877.or","https://doi.org/10.4158/ep15877.or","26307900","https://pubmed.ncbi.nlm.nih.gov/26307900/",null,null],["4","R0026077","R0026077.pdf","paywalled","nonrandomized_study","Chiefari E","2015","Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2014.0412","https://doi.org/10.1089/dia.2014.0412","25844858","https://pubmed.ncbi.nlm.nih.gov/25844858/",null,null],["4","R0026398","R0026398.pdf","paywalled","nonrandomized_study","Pi-Sunyer X","2015","Liraglutide in Weight Management.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc1509759","https://doi.org/10.1056/nejmc1509759","26510028","https://pubmed.ncbi.nlm.nih.gov/26510028/",null,null],["4","R0026762","R0026762.pdf","paywalled","nonrandomized_study","Vlasakakis G","2015","Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-015-0222-4","https://doi.org/10.1007/s12325-015-0222-4","26160357","https://pubmed.ncbi.nlm.nih.gov/26160357/",null,"ClinicalTrials.gov:NCT01857895"],["4","R0026954","R0026954.pdf","paywalled","nonrandomized_study","Zavattaro M","2015","One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-014-0519-0","https://doi.org/10.1007/s12020-014-0519-0","25572181","https://pubmed.ncbi.nlm.nih.gov/25572181/",null,null],["4","R0026990","R0026990.pdf","paywalled","nonrandomized_study","Rafaniello C","2015","Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2014.12.007","https://doi.org/10.1016/j.diabres.2014.12.007","25686508","https://pubmed.ncbi.nlm.nih.gov/25686508/",null,null],["4","R0027124","R0027124.pdf","paywalled","nonrandomized_study","Goderis G","2015","Care trajectories are associated with quality improvement in the treatment of patients with uncontrolled type 2 diabetes: A registry based cohort study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2015.01.008","https://doi.org/10.1016/j.pcd.2015.01.008","25709079","https://pubmed.ncbi.nlm.nih.gov/25709079/",null,null],["4","R0027369","R0027369.pdf","paywalled","nonrandomized_study","Buysman EK","2015","Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2014.982750","https://doi.org/10.1185/03007995.2014.982750","25356602","https://pubmed.ncbi.nlm.nih.gov/25356602/",null,null],["4","R0027401","R0027401.pdf","paywalled","nonrandomized_study","Hartmann B","2015","Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-015-0794-0","https://doi.org/10.1007/s00592-015-0794-0","26239142","https://pubmed.ncbi.nlm.nih.gov/26239142/",null,null],["4","R0027662","R0027662.pdf","paywalled","nonrandomized_study","Turner KM","2015","Adolescents' views and experiences of treatments for Type 2 diabetes: a qualitative study.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12577","https://doi.org/10.1111/dme.12577","25186101","https://pubmed.ncbi.nlm.nih.gov/25186101/",null,null],["4","R0028228","R0028228.pdf","paywalled","nonrandomized_study","Tran L","2015","Pharmacologic treatment of type 2 diabetes: injectable medications.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028015573010","https://doi.org/10.1177/1060028015573010","25802244","https://pubmed.ncbi.nlm.nih.gov/25802244/",null,null],["4","R0028230","R0028230.pdf","paywalled","nonrandomized_study","Tran L","2015","Pharmacologic treatment of type 2 diabetes: oral medications.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028014558289","https://doi.org/10.1177/1060028014558289","25667196","https://pubmed.ncbi.nlm.nih.gov/25667196/",null,null],["4","R0028236","R0028236.pdf","paywalled","nonrandomized_study","Britten N","2015","Patient involvement in drug licensing: a case study.","Social science & medicine (1982)","Elsevier BV","10.1016/j.socscimed.2014.10.024","https://doi.org/10.1016/j.socscimed.2014.10.024","25454636","https://pubmed.ncbi.nlm.nih.gov/25454636/",null,null],["4","R0030410","R0030410.pdf","paywalled","nonrandomized_study","He ZX","2015","Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.","Clinical and experimental pharmacology & physiology","Wiley","10.1111/1440-1681.12332","https://doi.org/10.1111/1440-1681.12332","25360831","https://pubmed.ncbi.nlm.nih.gov/25360831/",null,null],["4","R0030437","R0030437.pdf","paywalled","nonrandomized_study","Lau DC","2015","Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2015.09.090","https://doi.org/10.1016/j.jcjd.2015.09.090","26654858","https://pubmed.ncbi.nlm.nih.gov/26654858/",null,null],["4","R0030472","R0030472.pdf","paywalled","nonrandomized_study","Barchetta I","2015","Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-015-0721-4","https://doi.org/10.1007/s00592-015-0721-4","25716766","https://pubmed.ncbi.nlm.nih.gov/25716766/",null,null],["4","R0031385","R0031385.pdf","paywalled","nonrandomized_study","Oleg Werbitzky","2015","CHAPTER 12. Manufacturing of Venom-Derived Therapeutic Peptides","RSC drug discovery/RSC drug discovery series","Royal Society of Chemistry","10.1039/9781849737876-00290","https://doi.org/10.1039/9781849737876-00290",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031722","R0031722.pdf","paywalled","nonrandomized_study",null,"2015","Real-world usage and cost of exenatide and liraglutide","PharmacoEconomics & Outcomes News","Springer Science and Business Media LLC","10.1007/s40274-015-1893-4","https://doi.org/10.1007/s40274-015-1893-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037819","R0037819.pdf","paywalled","nonrandomized_study","Jothydev Kesavadev","2015","Corrigendum to “Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting” [Diabetes Metab. Syndr. Clin. Res. Rev. 9 (1) (2015) 30–33]","Diabetes & Metabolic Syndrome Clinical Research & Reviews","Elsevier BV","10.1016/j.dsx.2015.07.001","https://doi.org/10.1016/j.dsx.2015.07.001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041897","R0041897.pdf","paywalled","nonrandomized_study","Joel M. Schectman","2015","Incretin use was not associated with increased risk for acute pancreatitis","Annals of Internal Medicine","American College of Physicians","10.7326/acpjc-2015-162-12-012","https://doi.org/10.7326/acpjc-2015-162-12-012","26075777","https://pubmed.ncbi.nlm.nih.gov/26075777/",null,null],["4","R0050074","R0050074.pdf","paywalled","nonrandomized_study","Jason C. Baker","2015","Diabetes Mellitus: Is it Type 1 or Type 2? It May Not Be So Easy","BENTHAM SCIENCE PUBLISHERS eBooks","BENTHAM SCIENCE PUBLISHERS","10.2174/9781681080369115010011","https://doi.org/10.2174/9781681080369115010011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052731","R0052731.pdf","paywalled","nonrandomized_study","Elamin Abdelgadir","2015","PP.LB02.26","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000468591.08447.07","https://doi.org/10.1097/01.hjh.0000468591.08447.07",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053064","R0053064.pdf","paywalled","nonrandomized_study","J.C. Fernández García","2015","PP.05.33","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.hjh.0000467874.18438.d0","https://doi.org/10.1097/01.hjh.0000467874.18438.d0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0009938","R0009938.pdf","paywalled","nonrandomized_study","Johnston SS","2014","Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-014-0166-0","https://doi.org/10.1007/s12325-014-0166-0","25408484","https://pubmed.ncbi.nlm.nih.gov/25408484/",null,null],["4","R0010351","R0010351.pdf","paywalled","nonrandomized_study","Trujillo JM","2014","GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.","Pharmacotherapy","Wiley","10.1002/phar.1507","https://doi.org/10.1002/phar.1507","25382096","https://pubmed.ncbi.nlm.nih.gov/25382096/",null,null],["4","R0012956","R0012956.pdf","paywalled","nonrandomized_study","Scott LJ","2014","Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-014-0321-6","https://doi.org/10.1007/s40265-014-0321-6","25367717","https://pubmed.ncbi.nlm.nih.gov/25367717/",null,null],["4","R0014515","R0014515.pdf","paywalled","nonrandomized_study","Kumar A","2014","Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.","Expert opinion on biological therapy","Informa UK Limited","10.1517/14712598.2014.904851","https://doi.org/10.1517/14712598.2014.904851","24702171","https://pubmed.ncbi.nlm.nih.gov/24702171/",null,null],["4","R0017275","R0017275.pdf","paywalled","nonrandomized_study","Pottegård A","2014","Use of exenatide and liraglutide in Denmark: a drug utilization study.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-013-1595-4","https://doi.org/10.1007/s00228-013-1595-4","24145815","https://pubmed.ncbi.nlm.nih.gov/24145815/",null,null],["4","R0018215","R0018215.pdf","paywalled","nonrandomized_study","Thong KY","2014","The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12367","https://doi.org/10.1111/dme.12367","24246138","https://pubmed.ncbi.nlm.nih.gov/24246138/",null,null],["4","R0019251","R0019251.pdf","paywalled","nonrandomized_study","Mogensen UM","2014","Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12314","https://doi.org/10.1111/dom.12314","24827939","https://pubmed.ncbi.nlm.nih.gov/24827939/",null,null],["4","R0019489","R0019489.pdf","paywalled","nonrandomized_study","Delfino M","2014","Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy.","Expert opinion on drug safety","Informa Healthcare","10.1517/14740338.2014.853036","https://doi.org/10.1517/14740338.2014.853036","24219498","https://pubmed.ncbi.nlm.nih.gov/24219498/",null,null],["4","R0021872","R0021872.pdf","paywalled","nonrandomized_study","Lee WC","2014","Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12285","https://doi.org/10.1111/dom.12285","24581276","https://pubmed.ncbi.nlm.nih.gov/24581276/",null,null],["4","R0023381","R0023381.pdf","paywalled","nonrandomized_study","Digenio A","2014","Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2014.10.2820","https://doi.org/10.3810/pgm.2014.10.2820","25414934","https://pubmed.ncbi.nlm.nih.gov/25414934/",null,null],["4","R0024103","R0024103.pdf","paywalled","nonrandomized_study","Fu H","2014","Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2014.0039","https://doi.org/10.1089/dia.2014.0039","25068375","https://pubmed.ncbi.nlm.nih.gov/25068375/",null,null],["4","R0024221","R0024221.pdf","paywalled","nonrandomized_study","Sierra Poyatos R","2014","[Effects of exenatide lar in type 2 diabetes mellitus and obesity].","Nutricion hospitalaria",null,"10.3305/nh.2015.31.1.8283","https://doi.org/10.3305/nh.2015.31.1.8283","25561121","https://pubmed.ncbi.nlm.nih.gov/25561121/",null,null],["4","R0026090","R0026090.pdf","paywalled","nonrandomized_study","Toyoda M","2014","Predictors of response to liraglutide in Japanese type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2014.09.052","https://doi.org/10.1016/j.diabres.2014.09.052","25458335","https://pubmed.ncbi.nlm.nih.gov/25458335/",null,null],["4","R0026213","R0026213.pdf","paywalled","nonrandomized_study","Bounthavong M","2014","Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2014.06.002","https://doi.org/10.1016/j.diabet.2014.06.002","25059703","https://pubmed.ncbi.nlm.nih.gov/25059703/",null,null],["4","R0026498","R0026498.pdf","paywalled","nonrandomized_study","Pawaskar M","2014","Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028013520597","https://doi.org/10.1177/1060028013520597","24497624","https://pubmed.ncbi.nlm.nih.gov/24497624/",null,null],["4","R0026636","R0026636.pdf","paywalled","nonrandomized_study","Carrington MJ","2014","Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.","Internal medicine journal","Wiley","10.1111/imj.12377","https://doi.org/10.1111/imj.12377","24877253","https://pubmed.ncbi.nlm.nih.gov/24877253/",null,null],["4","R0026809","R0026809.pdf","paywalled","nonrandomized_study","Chou HC","2014","Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-014-0171-x","https://doi.org/10.1007/s40264-014-0171-x","24859164","https://pubmed.ncbi.nlm.nih.gov/24859164/",null,null],["4","R0026994","R0026994.pdf","paywalled","nonrandomized_study","Li X","2014","Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.3542","https://doi.org/10.1002/pds.3542","24741695","https://pubmed.ncbi.nlm.nih.gov/24741695/",null,null],["4","R0027506","R0027506.pdf","paywalled","nonrandomized_study","Baviera M","2014","Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-014-1678-x","https://doi.org/10.1007/s00228-014-1678-x","24820766","https://pubmed.ncbi.nlm.nih.gov/24820766/",null,null],["4","R0028036","R0028036.pdf","paywalled","nonrandomized_study","Wei W","2014","Real-world insulin treatment persistence among patients with type 2 diabetes.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep13159.or","https://doi.org/10.4158/ep13159.or","24013990","https://pubmed.ncbi.nlm.nih.gov/24013990/",null,null],["4","R0030403","R0030403.pdf","paywalled","nonrandomized_study","Patel VJ","2014","Effect of GLP-1 based therapies on diabetic dyslipidemia.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/1573399810666140707092506","https://doi.org/10.2174/1573399810666140707092506","24998439","https://pubmed.ncbi.nlm.nih.gov/24998439/",null,null],["4","R0030526","R0030526.pdf","paywalled","nonrandomized_study","Göke R","2014","Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2013.875464","https://doi.org/10.1185/03007995.2013.875464","24328429","https://pubmed.ncbi.nlm.nih.gov/24328429/",null,null],["4","R0039697","R0039697.pdf","paywalled","nonrandomized_study","Giuseppe Montalto","2014","Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome)","Current Pharmaceutical Design","Bentham Science Publishers Ltd.","10.2174/1381612819666131206112537","https://doi.org/10.2174/1381612819666131206112537","24320029","https://pubmed.ncbi.nlm.nih.gov/24320029/",null,null],["4","R0047367","R0047367.pdf","paywalled","nonrandomized_study","B Arribas-Díaz","2014","OHP-004 Prescription of oral anti-diabetic agents recently marketed in a health area","European Journal of Hospital Pharmacy","BMJ","10.1136/ejhpharm-2013-000436.456","https://doi.org/10.1136/ejhpharm-2013-000436.456",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048325","R0048325.pdf","paywalled","nonrandomized_study","Gordon F. Rushworth","2014","Review of clinical use of glucagon‐like peptide‐1 in the management of type 2 diabetes","Practical Diabetes","Wiley","10.1002/pdi.1886","https://doi.org/10.1002/pdi.1886",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049174","R0049174.pdf","paywalled","nonrandomized_study","Jill C. Krisl","2014","Long-Acting Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy in Post Solid Organ Transplant Patients.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/00007890-201407151-01757","https://doi.org/10.1097/00007890-201407151-01757",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052811","R0052811.pdf","paywalled","nonrandomized_study","Rasmus Skovgaard","2014","Real-World Clinical Effectiveness of Liraglutide in Type 2 Diabetes Patients Aged 65 Years and Above","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2014.07.135","https://doi.org/10.1016/j.jcjd.2014.07.135",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0009370","R0009370.pdf","paywalled","nonrandomized_study","Russell S","2013","Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.","International journal of clinical pharmacy","Springer Science and Business Media LLC","10.1007/s11096-012-9729-9","https://doi.org/10.1007/s11096-012-9729-9","23263796","https://pubmed.ncbi.nlm.nih.gov/23263796/",null,null],["4","R0010099","R0010099.pdf","paywalled","nonrandomized_study","Umpierrez GE","2013","Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep12292.ra","https://doi.org/10.4158/ep12292.ra","23512382","https://pubmed.ncbi.nlm.nih.gov/23512382/",null,null],["4","R0010674","R0010674.pdf","paywalled","nonrandomized_study","Ross SA","2013","Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2013.837817","https://doi.org/10.1185/03007995.2013.837817","23971789","https://pubmed.ncbi.nlm.nih.gov/23971789/",null,null],["4","R0014851","R0014851.pdf","paywalled","nonrandomized_study","Aramadhaka LR","2013","Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta®.","Toxicon : official journal of the International Society on Toxinology","Elsevier BV","10.1016/j.toxicon.2013.03.018","https://doi.org/10.1016/j.toxicon.2013.03.018","23602926","https://pubmed.ncbi.nlm.nih.gov/23602926/",null,null],["4","R0015285","R0015285.pdf","paywalled","nonrandomized_study","Burgmaier M","2013","Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2012.03746.x","https://doi.org/10.1111/j.1464-5491.2012.03746.x","22804451","https://pubmed.ncbi.nlm.nih.gov/22804451/",null,null],["4","R0016661","R0016661.pdf","paywalled","nonrandomized_study","Malmenäs M","2013","Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2013.03.021","https://doi.org/10.1016/j.clinthera.2013.03.021","23642290","https://pubmed.ncbi.nlm.nih.gov/23642290/",null,null],["4","R0020698","R0020698.pdf","paywalled","nonrandomized_study","Ahern T","2013","Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/j.1468-3083.2012.04609.x","https://doi.org/10.1111/j.1468-3083.2012.04609.x","22691169","https://pubmed.ncbi.nlm.nih.gov/22691169/",null,null],["4","R0020725","R0020725.pdf","paywalled","nonrandomized_study","Grabner M","2013","Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2013.05.2656","https://doi.org/10.3810/pgm.2013.05.2656","23748521","https://pubmed.ncbi.nlm.nih.gov/23748521/",null,null],["4","R0021055","R0021055.pdf","paywalled","nonrandomized_study","Harrison LB","2013","Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","SAGE Publications","10.2310/jim.0b013e318279b7d6","https://doi.org/10.2310/jim.0b013e318279b7d6","23222002","https://pubmed.ncbi.nlm.nih.gov/23222002/",null,null],["4","R0022372","R0022372.pdf","paywalled","nonrandomized_study","Olaywi M","2013","Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.","Hepatobiliary & pancreatic diseases international : HBPD INT","Elsevier BV","10.1016/s1499-3872(13)60092-2","https://doi.org/10.1016/s1499-3872(13)60092-2","24322742","https://pubmed.ncbi.nlm.nih.gov/24322742/",null,null],["4","R0022820","R0022820.pdf","paywalled","nonrandomized_study","Barnett AH","2013","Complementing insulin therapy to achieve glycemic control.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-013-0039-y","https://doi.org/10.1007/s12325-013-0039-y","23797471","https://pubmed.ncbi.nlm.nih.gov/23797471/",null,null],["4","R0023957","R0023957.pdf","paywalled","nonrandomized_study","Ryder RE","2013","The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12336","https://doi.org/10.1111/dme.12336","24117729","https://pubmed.ncbi.nlm.nih.gov/24117729/",null,null],["4","R0023967","R0023967.pdf","paywalled","nonrandomized_study","Fadini GP","2013","Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-013-0489-3","https://doi.org/10.1007/s00592-013-0489-3","23754673","https://pubmed.ncbi.nlm.nih.gov/23754673/",null,null],["4","R0024153","R0024153.pdf","paywalled","nonrandomized_study","Zhao Q","2013","Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes.","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","American Society of Consultant Pharmacists","10.4140/tcp.n.2013.515","https://doi.org/10.4140/tcp.n.2013.515","23906896","https://pubmed.ncbi.nlm.nih.gov/23906896/",null,null],["4","R0026449","R0026449.pdf","paywalled","nonrandomized_study","Dore DD","2013","A pooled analysis of exenatide use and risk of acute pancreatitis.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2013.838550","https://doi.org/10.1185/03007995.2013.838550","23981106","https://pubmed.ncbi.nlm.nih.gov/23981106/",null,null],["4","R0027017","R0027017.pdf","paywalled","nonrandomized_study","Kuhadiya ND","2013","Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep13065.or","https://doi.org/10.4158/ep13065.or","23807520","https://pubmed.ncbi.nlm.nih.gov/23807520/",null,null],["4","R0027559","R0027559.pdf","paywalled","nonrandomized_study","Davis KL","2013","Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2013.811403","https://doi.org/10.1185/03007995.2013.811403","23734906","https://pubmed.ncbi.nlm.nih.gov/23734906/",null,null],["4","R0027633","R0027633.pdf","paywalled","nonrandomized_study","Singh S","2013","Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2013.2720","https://doi.org/10.1001/jamainternmed.2013.2720","23440284","https://pubmed.ncbi.nlm.nih.gov/23440284/",null,null],["4","R0027639","R0027639.pdf","paywalled","nonrandomized_study","Curkendall SM","2013","Predictors of medication adherence in patients with type 2 diabetes mellitus.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2013.821056","https://doi.org/10.1185/03007995.2013.821056","23815104","https://pubmed.ncbi.nlm.nih.gov/23815104/",null,null],["4","R0027859","R0027859.pdf","paywalled","nonrandomized_study","Raschi E","2013","The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-011-0340-7","https://doi.org/10.1007/s00592-011-0340-7","22008948","https://pubmed.ncbi.nlm.nih.gov/22008948/",null,null],["4","R0027921","R0027921.pdf","paywalled","nonrandomized_study","Gallwitz B","2013","Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-011-0319-4","https://doi.org/10.1007/s00592-011-0319-4","21861172","https://pubmed.ncbi.nlm.nih.gov/21861172/",null,null],["4","R0028266","R0028266.pdf","paywalled","nonrandomized_study","Harja E","2013","An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2013.0177","https://doi.org/10.1089/dia.2013.0177","23927624","https://pubmed.ncbi.nlm.nih.gov/23927624/",null,null],["4","R0028281","R0028281.pdf","paywalled","nonrandomized_study","Montagnani A","2013","Antidiabetic therapy effects on bone metabolism and fracture risk.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12077","https://doi.org/10.1111/dom.12077","23368527","https://pubmed.ncbi.nlm.nih.gov/23368527/",null,null],["4","R0030487","R0030487.pdf","paywalled","nonrandomized_study","Thompson A","2013","Evaluation of type 2 diabetes mellitus medication management and control in older adults.","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","American Society of Consultant Pharmacists","10.4140/tcp.n.2013.296","https://doi.org/10.4140/tcp.n.2013.296","23649678","https://pubmed.ncbi.nlm.nih.gov/23649678/",null,null],["4","R0039437","R0039437.pdf","paywalled","nonrandomized_study","K. Y. Thong","2013","Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit","Practical Diabetes","Wiley","10.1002/pdi.1748","https://doi.org/10.1002/pdi.1748",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044258","R0044258.pdf","paywalled","nonrandomized_study","K. Y. Thong","2013","Was it really pancreatitis from GLP‐1 receptor agonist therapy?","Practical Diabetes","Wiley","10.1002/pdi.1801","https://doi.org/10.1002/pdi.1801",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052219","R0052219.pdf","paywalled","nonrandomized_study","Dan C. Cohen","2013","European drugs agency clashes with scientists over safety of GLP-1 drugs","BMJ","BMJ","10.1136/bmj.f4838","https://doi.org/10.1136/bmj.f4838","23900829","https://pubmed.ncbi.nlm.nih.gov/23900829/",null,null],["4","R0052617","R0052617.pdf","paywalled","nonrandomized_study","REJ Ryder","2013","Liraglutide pancreatitis: The ABCD nationwide liraglutide audit","The British Journal of Diabetes","SAGE Publications","10.1177/1474651413502685","https://doi.org/10.1177/1474651413502685",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0016426","R0016426.pdf","paywalled","nonrandomized_study","Varanasi A","2012","Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep11169.or","https://doi.org/10.4158/ep11169.or","21856595","https://pubmed.ncbi.nlm.nih.gov/21856595/",null,null],["4","R0019326","R0019326.pdf","paywalled","nonrandomized_study","Sesti G","2012","[Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/1203.13332","https://doi.org/10.1714/1203.13332","23258124","https://pubmed.ncbi.nlm.nih.gov/23258124/",null,null],["4","R0020924","R0020924.pdf","paywalled","nonrandomized_study","Holst JJ","2012","Incretin based therapies: do they hold their promise?","Journal of diabetes","Wiley","10.1111/j.1753-0407.2012.00186.x","https://doi.org/10.1111/j.1753-0407.2012.00186.x","22248344","https://pubmed.ncbi.nlm.nih.gov/22248344/",null,null],["4","R0020944","R0020944.pdf","paywalled","nonrandomized_study","Thong KY","2012","Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2011.03475.x","https://doi.org/10.1111/j.1464-5491.2011.03475.x","21988449","https://pubmed.ncbi.nlm.nih.gov/21988449/",null,null],["4","R0026568","R0026568.pdf","paywalled","nonrandomized_study","Levin PA","2012","Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep11097.or","https://doi.org/10.4158/ep11097.or","21742605","https://pubmed.ncbi.nlm.nih.gov/21742605/",null,null],["4","R0026669","R0026669.pdf","paywalled","nonrandomized_study","Anderson SL","2012","Determining predictors of response to exenatide in type 2 diabetes.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1331/japha.2012.10217","https://doi.org/10.1331/japha.2012.10217","22825226","https://pubmed.ncbi.nlm.nih.gov/22825226/",null,null],["4","R0026769","R0026769.pdf","paywalled","nonrandomized_study","Pawaskar M","2012","Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep11367.or","https://doi.org/10.4158/ep11367.or","22982784","https://pubmed.ncbi.nlm.nih.gov/22982784/",null,null],["4","R0026772","R0026772.pdf","paywalled","nonrandomized_study","Rashid N","2012","Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.02.030","https://doi.org/10.1016/j.clinthera.2012.02.030","22464691","https://pubmed.ncbi.nlm.nih.gov/22464691/",null,null],["4","R0026782","R0026782.pdf","paywalled","nonrandomized_study","Pawaskar M","2012","Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2012.686901","https://doi.org/10.1185/03007995.2012.686901","22519390","https://pubmed.ncbi.nlm.nih.gov/22519390/",null,null],["4","R0026825","R0026825.pdf","paywalled","nonrandomized_study","Pawaskar M","2012","Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01581.x","https://doi.org/10.1111/j.1463-1326.2012.01581.x","22321776","https://pubmed.ncbi.nlm.nih.gov/22321776/",null,null],["4","R0026893","R0026893.pdf","paywalled","nonrandomized_study","Pendergrass M","2012","Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01567.x","https://doi.org/10.1111/j.1463-1326.2012.01567.x","22268550","https://pubmed.ncbi.nlm.nih.gov/22268550/",null,null],["4","R0026914","R0026914.pdf","paywalled","nonrandomized_study","Levin P","2012","Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1185/03007995.2012.654850","https://doi.org/10.1185/03007995.2012.654850","22216894","https://pubmed.ncbi.nlm.nih.gov/22216894/",null,null],["4","R0026997","R0026997.pdf","paywalled","nonrandomized_study","Gao L","2012","Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.","International journal of technology assessment in health care","Cambridge University Press (CUP)","10.1017/s0266462312000608","https://doi.org/10.1017/s0266462312000608","23006540","https://pubmed.ncbi.nlm.nih.gov/23006540/",null,null],["4","R0027045","R0027045.pdf","paywalled","nonrandomized_study","Preumont V","2012","Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.","Acta clinica Belgica",null,"10.2143/acb.67.6.2062705","https://doi.org/10.2143/acb.67.6.2062705","23340146","https://pubmed.ncbi.nlm.nih.gov/23340146/",null,null],["4","R0027794","R0027794.pdf","paywalled","nonrandomized_study","Brouwer ES","2012","Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.2262","https://doi.org/10.1002/pds.2262","22250059","https://pubmed.ncbi.nlm.nih.gov/22250059/",null,null],["4","R0027954","R0027954.pdf","paywalled","nonrandomized_study","Raz I","2012","Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2265","https://doi.org/10.1002/dmrr.2265","22173845","https://pubmed.ncbi.nlm.nih.gov/22173845/",null,null],["4","R0027958","R0027958.pdf","paywalled","nonrandomized_study","Gitt AK","2012","Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry.","Herz","Springer Science and Business Media LLC","10.1007/s00059-012-3611-3","https://doi.org/10.1007/s00059-012-3611-3","22476616","https://pubmed.ncbi.nlm.nih.gov/22476616/",null,null],["4","R0051322","R0051322.pdf","paywalled","nonrandomized_study","Liu Q","2012","Positive control in a \"thorough QT/QTc study\".","Journal of clinical pharmacology","Wiley","10.1177/0091270010388940","https://doi.org/10.1177/0091270010388940","21209241","https://pubmed.ncbi.nlm.nih.gov/21209241/",null,null],["4","R0013252","R0013252.pdf","paywalled","nonrandomized_study","Goldenberg RM","2011","Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.","Canadian journal of diabetes","Elsevier BV","10.1016/s1499-2671(11)80008-0","https://doi.org/10.1016/s1499-2671(11)80008-0","24854977","https://pubmed.ncbi.nlm.nih.gov/24854977/",null,null],["4","R0013507","R0013507.pdf","paywalled","nonrandomized_study","Jellinger PS","2011","Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2011.01.2245","https://doi.org/10.3810/pgm.2011.01.2245","21293084","https://pubmed.ncbi.nlm.nih.gov/21293084/",null,null],["4","R0016942","R0016942.pdf","paywalled","nonrandomized_study","Marso SP","2011","Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164111408937","https://doi.org/10.1177/1479164111408937","21653676","https://pubmed.ncbi.nlm.nih.gov/21653676/",null,null],["4","R0018360","R0018360.pdf","paywalled","nonrandomized_study","Ovalle F","2011","Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.04.006","https://doi.org/10.1016/j.clinthera.2011.04.006","21635987","https://pubmed.ncbi.nlm.nih.gov/21635987/",null,null],["4","R0020722","R0020722.pdf","paywalled","nonrandomized_study","Fineman M","2011","Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.2165/11585880-000000000-00000","https://doi.org/10.2165/11585880-000000000-00000","21142268","https://pubmed.ncbi.nlm.nih.gov/21142268/",null,"ClinicalTrials.gov:NCT00103935"],["4","R0021167","R0021167.pdf","paywalled","nonrandomized_study","Davis TM","2011","Safety of incretin-based therapies for type 2 diabetes.","The Medical journal of Australia","AMPCo","10.5694/mja11.10648","https://doi.org/10.5694/mja11.10648","21929482","https://pubmed.ncbi.nlm.nih.gov/21929482/",null,null],["4","R0022093","R0022093.pdf","paywalled","nonrandomized_study","Aroda VR","2011","Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2011.09.2479","https://doi.org/10.3810/pgm.2011.09.2479","21904106","https://pubmed.ncbi.nlm.nih.gov/21904106/",null,null],["4","R0024990","R0024990.pdf","paywalled","nonrandomized_study","Aguilar RB","2011","Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.04.008","https://doi.org/10.1016/j.clinthera.2011.04.008","21635988","https://pubmed.ncbi.nlm.nih.gov/21635988/",null,null],["4","R0025485","R0025485.pdf","paywalled","nonrandomized_study","Jeong KH","2011","The efficacy and safety of liraglutide.","International journal of clinical pharmacy","Springer Science and Business Media LLC","10.1007/s11096-011-9552-8","https://doi.org/10.1007/s11096-011-9552-8","21952951","https://pubmed.ncbi.nlm.nih.gov/21952951/",null,null],["4","R0026624","R0026624.pdf","paywalled","nonrandomized_study","Wang S","2011","Structural study of an active analog of EX-4 in solution and micelle associated states.","Biopolymers","Wiley","10.1002/bip.21566","https://doi.org/10.1002/bip.21566","21072854","https://pubmed.ncbi.nlm.nih.gov/21072854/",null,null],["4","R0026670","R0026670.pdf","paywalled","nonrandomized_study","Thong KY","2011","Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2011.05.015","https://doi.org/10.1016/j.diabres.2011.05.015","21636161","https://pubmed.ncbi.nlm.nih.gov/21636161/",null,null],["4","R0026837","R0026837.pdf","paywalled","nonrandomized_study","Thong KY","2011","Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01393.x","https://doi.org/10.1111/j.1463-1326.2011.01393.x","21410858","https://pubmed.ncbi.nlm.nih.gov/21410858/",null,null],["4","R0026872","R0026872.pdf","paywalled","nonrandomized_study","Varanasi A","2011","Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep10199.or","https://doi.org/10.4158/ep10199.or","20841306","https://pubmed.ncbi.nlm.nih.gov/20841306/",null,null],["4","R0026884","R0026884.pdf","paywalled","nonrandomized_study","Dore DD","2011","A cohort study of acute pancreatitis in relation to exenatide use.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01376.x","https://doi.org/10.1111/j.1463-1326.2011.01376.x","21320263","https://pubmed.ncbi.nlm.nih.gov/21320263/",null,null],["4","R0027048","R0027048.pdf","paywalled","nonrandomized_study","Bergenstal RM","2011","Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2010.545814","https://doi.org/10.1185/03007995.2010.545814","21219119","https://pubmed.ncbi.nlm.nih.gov/21219119/",null,null],["4","R0030549","R0030549.pdf","paywalled","nonrandomized_study","Nathanson D","2011","Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2010.03207.x","https://doi.org/10.1111/j.1464-5491.2010.03207.x","21309838","https://pubmed.ncbi.nlm.nih.gov/21309838/",null,null],["4","R0030747","R0030747.pdf","paywalled","nonrandomized_study","Allan S. Brett","2011","Pancreatitis, Diabetes, and Newer Antidiabetic Drugs","Journal watch",null,"10.1056/jw201101200000008","https://doi.org/10.1056/jw201101200000008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035734","R0035734.pdf","paywalled","nonrandomized_study","Liesel M. FitzGerald","2011","The effects of six months of treatment with exenatide for type 2 diabetes","Journal of Human Nutrition and Dietetics","Wiley","10.1111/j.1365-277x.2011.01175_9.x","https://doi.org/10.1111/j.1365-277x.2011.01175_9.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035796","R0035796.pdf","paywalled","nonrandomized_study","Andrew G. Renehan","2011","European Association for the Study of Diabetes Annual Conference Explores Links Between Diabetes and Cancer","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000407714.17774.21","https://doi.org/10.1097/01.cot.0000407714.17774.21",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037636","R0037636.pdf","paywalled","nonrandomized_study",null,"2011","Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes","Clinical Medicine Reviews in Vascular Health","Portico","10.4137/cmrvh.s1664","https://doi.org/10.4137/cmrvh.s1664",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046889","R0046889.pdf","paywalled","nonrandomized_study","David D. Spence","2011","Child of our time: how childhood now lasts a lifetime","BMJ","BMJ","10.1136/bmj.d2341","https://doi.org/10.1136/bmj.d2341",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049348","R0049348.pdf","paywalled","nonrandomized_study","Nicholas D Moore","2011","Paper OK, title wrong","BMJ","BMJ","10.1136/bmj.d2732","https://doi.org/10.1136/bmj.d2732","21558338","https://pubmed.ncbi.nlm.nih.gov/21558338/",null,null],["4","R0055657","R0055657.pdf","paywalled","nonrandomized_study","Anthony H Barnett","2011","Tight glycaemic control-caution in high risk groups","International Journal of Clinical Practice","Hindawi Limited","10.1111/j.1742-1241.2010.02593.x","https://doi.org/10.1111/j.1742-1241.2010.02593.x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0017724","R0017724.pdf","paywalled","nonrandomized_study","Zhang Q","2010","Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-010-0024-7","https://doi.org/10.1007/s12325-010-0024-7","20464538","https://pubmed.ncbi.nlm.nih.gov/20464538/",null,null],["4","R0023355","R0023355.pdf","paywalled","nonrandomized_study","Dandona P","2010","A novel antihypertensive effect of exenatide, a GLP-1 agonist.","American journal of hypertension","Oxford University Press (OUP)","10.1038/ajh.2009.271","https://doi.org/10.1038/ajh.2009.271","20154655","https://pubmed.ncbi.nlm.nih.gov/20154655/",null,null],["4","R0025607","R0025607.pdf","paywalled","nonrandomized_study","Garg SK","2010","The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2009.0127","https://doi.org/10.1089/dia.2009.0127","20082581","https://pubmed.ncbi.nlm.nih.gov/20082581/",null,null],["4","R0027414","R0027414.pdf","paywalled","nonrandomized_study","Bloomgarden Z","2010","Liraglutide and calcitonin.","Journal of diabetes","Wiley","10.1111/j.1753-0407.2010.00079.x","https://doi.org/10.1111/j.1753-0407.2010.00079.x","21140545","https://pubmed.ncbi.nlm.nih.gov/21140545/",null,null],["4","R0027672","R0027672.pdf","paywalled","nonrandomized_study","Buysschaert M","2010","One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2010.03.009","https://doi.org/10.1016/j.diabet.2010.03.009","20598606","https://pubmed.ncbi.nlm.nih.gov/20598606/",null,null],["4","R0035803","R0035803.pdf","paywalled","nonrandomized_study","Mazhar Hussain","2010","Combination of exenatide and insulin in type 2 diabetes: a retrospective case series observation","Practical Diabetes","Wiley","10.1002/pdi.1432","https://doi.org/10.1002/pdi.1432",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044326","R0044326.pdf","paywalled","nonrandomized_study","Françoise Livio","2010","Pharmacovigilance update [Pharmacovigilance update]","SERVAL (Université de Lausanne)","Médecine et Hygiène","10.53738/revmed.2010.6.232.0128","https://doi.org/10.53738/revmed.2010.6.232.0128",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0025886","R0025886.pdf","paywalled","nonrandomized_study","Lage MJ","2009","Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-009-0002-0","https://doi.org/10.1007/s12325-009-0002-0","19219409","https://pubmed.ncbi.nlm.nih.gov/19219409/",null,null],["4","R0026333","R0026333.pdf","paywalled","nonrandomized_study","Misurski D","2009","A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.","Applied health economics and health policy","Springer Science and Business Media LLC","10.1007/bf03256158","https://doi.org/10.1007/bf03256158","19905038","https://pubmed.ncbi.nlm.nih.gov/19905038/",null,null],["4","R0027197","R0027197.pdf","paywalled","nonrandomized_study","Fabunmi R","2009","Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.","Current medical research and opinion","Informa Healthcare","10.1185/03007990802715199","https://doi.org/10.1185/03007990802715199","19203299","https://pubmed.ncbi.nlm.nih.gov/19203299/",null,null],["4","R0027345","R0027345.pdf","paywalled","nonrandomized_study","Dore DD","2009","Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.","Current medical research and opinion","Informa Healthcare","10.1185/03007990902820519","https://doi.org/10.1185/03007990902820519","19278373","https://pubmed.ncbi.nlm.nih.gov/19278373/",null,null],["4","R0027349","R0027349.pdf","paywalled","nonrandomized_study","Bhushan R","2009","Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2008.0090","https://doi.org/10.1089/dia.2008.0090","19459763","https://pubmed.ncbi.nlm.nih.gov/19459763/",null,null],["4","R0027574","R0027574.pdf","paywalled","nonrandomized_study","Yoon NM","2009","Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2009.07.021","https://doi.org/10.1016/j.clinthera.2009.07.021","19695400","https://pubmed.ncbi.nlm.nih.gov/19695400/",null,null],["4","R0028098","R0028098.pdf","paywalled","nonrandomized_study","Stockl KM","2009","Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.1700","https://doi.org/10.1002/pds.1700","19109802","https://pubmed.ncbi.nlm.nih.gov/19109802/",null,null],["4","R0052711","R0052711.pdf","paywalled","nonrandomized_study","JM Ng","2009","Exenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?","Practical Diabetes","Wiley","10.1002/pdi.1333","https://doi.org/10.1002/pdi.1333",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0022898","R0022898.pdf","paywalled","nonrandomized_study","Yu BS","2008","Glucagon-like peptide 1 based therapy for type 2 diabetes.","World journal of pediatrics : WJP","Springer Science and Business Media LLC","10.1007/s12519-008-0002-1","https://doi.org/10.1007/s12519-008-0002-1","18402245","https://pubmed.ncbi.nlm.nih.gov/18402245/",null,null],["4","R0027357","R0027357.pdf","paywalled","nonrandomized_study","Bhushan R","2008","Exenatide use in the management of metabolic syndrome: a retrospective database study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep.14.8.993","https://doi.org/10.4158/ep.14.8.993","19095598","https://pubmed.ncbi.nlm.nih.gov/19095598/",null,null],["4","R0027296","R0027296.pdf","paywalled","nonrandomized_study","Chokrungvaranon N","2007","Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-008-9042-5","https://doi.org/10.1007/s12020-008-9042-5","18266113","https://pubmed.ncbi.nlm.nih.gov/18266113/",null,null],["4","R0027416","R0027416.pdf","paywalled","nonrandomized_study","Segal JB","2007","Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2007.08.021","https://doi.org/10.1016/j.clinthera.2007.08.021","17919559","https://pubmed.ncbi.nlm.nih.gov/17919559/",null,null],["4","R0027652","R0027652.pdf","paywalled","nonrandomized_study","Viswanathan P","2007","Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep.13.5.444","https://doi.org/10.4158/ep.13.5.444","17872344","https://pubmed.ncbi.nlm.nih.gov/17872344/",null,null],["4","R0028034","R0028034.pdf","paywalled","nonrandomized_study","Segal JB","2007","Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication.","Medical care","Ovid Technologies (Wolters Kluwer Health)","10.1097/mlr.0b013e31804ffd6d","https://doi.org/10.1097/mlr.0b013e31804ffd6d","17909374","https://pubmed.ncbi.nlm.nih.gov/17909374/",null,null],["4","R0038887","R0038887.pdf","paywalled","nonrandomized_study",null,"2007","Latest news and product developments","Prescriber","Wiley","10.1002/psb.140","https://doi.org/10.1002/psb.140",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0027605","R0027605.pdf","paywalled","nonrandomized_study","Doggrell SA","2006","Recent evidence of sustained benefit with exenatide in Type 2 diabetes.","Expert opinion on pharmacotherapy","Informa Healthcare","10.1517/14656566.7.14.2003","https://doi.org/10.1517/14656566.7.14.2003","17020425","https://pubmed.ncbi.nlm.nih.gov/17020425/",null,null],["4","R0044487","R0044487.pdf","paywalled","nonrandomized_study","Sandeep Kaushal","2006","Exenatide: An incretin-mimetic agent","Indian Journal of Pharmacology","Medknow","10.4103/0253-7613.19864","https://doi.org/10.4103/0253-7613.19864",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053278","R0053278.pdf","paywalled","nonrandomized_study","Michael Bruce Horowitz","2006","‘Gastric’ hypoglycaemia – an important concept in diabetes management","Neurogastroenterology & Motility","Wiley","10.1111/j.1365-2982.2006.00804.x","https://doi.org/10.1111/j.1365-2982.2006.00804.x","16700718","https://pubmed.ncbi.nlm.nih.gov/16700718/",null,null],["4","R0028069","R0028069.pdf","paywalled","nonrandomized_study","Uwaifo GI","2005","Novel pharmacologic agents for type 2 diabetes.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2004.11.006","https://doi.org/10.1016/j.ecl.2004.11.006","15752927","https://pubmed.ncbi.nlm.nih.gov/15752927/",null,null],["4","R0021958","R0021958.pdf","paywalled","nonrandomized_study","Hudson FM","2004","Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state.","Biopolymers","Wiley","10.1002/bip.20126","https://doi.org/10.1002/bip.20126","15386269","https://pubmed.ncbi.nlm.nih.gov/15386269/",null,null],["4","R0043120","R0043120.pdf","paywalled","nonrandomized_study","Ahmad, Paras",null,"Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.","Open Access CRIS of the University of Bern",null,"10.48620/88029","https://doi.org/10.48620/88029",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054891","R0054891.pdf","paywalled","nonrandomized_study","van Beurden, Wiebke",null,"FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists.","Open Access CRIS of the University of Bern",null,"10.48620/85882","https://doi.org/10.48620/85882",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054928","R0054928.pdf","paywalled","nonrandomized_study","Meyhöfer, Svenja",null,"Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database.",null,null,"10.48350/167186","https://doi.org/10.48350/167186",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000001","R0000001.pdf","free_to_read","nonrandomized_study","Eduardo I","2026","Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting System","Research Square",null,"10.21203/rs.3.rs-9818062/v3","https://doi.org/10.21203/rs.3.rs-9818062/v3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000013","R0000013.pdf","free_to_read","nonrandomized_study","Grigson PS","2026","Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans.","Biological psychiatry","Elsevier BV","10.1016/j.biopsych.2026.06.033","https://doi.org/10.1016/j.biopsych.2026.06.033","42480803","https://pubmed.ncbi.nlm.nih.gov/42480803/","https://doi.org/10.1016/j.biopsych.2026.06.033",null],["4","R0000032","R0000032.pdf","open_download_failed","nonrandomized_study","Bai L","2026","Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database","medRxiv","openRxiv","10.64898/2026.08.04.26359670","https://doi.org/10.64898/2026.08.04.26359670",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/08/06/2026.08.04.26359670.full.pdf",null],["4","R0000093","R0000093.pdf","open_download_failed","nonrandomized_study","Chen SC","2026","Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71088","https://doi.org/10.1111/dom.71088","42420795","https://pubmed.ncbi.nlm.nih.gov/42420795/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538802/pdf/DOM-28-8895.pdf",null],["4","R0000095","R0000095.pdf","free_to_read","nonrandomized_study","Eduardo I","2026","Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting System","Research Square",null,"10.21203/rs.3.rs-9818000/v3","https://doi.org/10.21203/rs.3.rs-9818000/v3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000096","R0000096.pdf","open_download_failed","nonrandomized_study","Sun H","2026","Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71358","https://doi.org/10.1111/dom.71358","42768849","https://pubmed.ncbi.nlm.nih.gov/42768849/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71358",null],["4","R0000102","R0000102.pdf","free_to_read","nonrandomized_study","Zavaleta-Monestel E","2026","Psychiatric Adverse Events Associated with GLP-1 Receptor Agonists: Evidence of Intraclass Heterogeneity in the WHO VigiBase Global Database","Preprints.org","MDPI AG","10.20944/preprints202606.2007.v1","https://doi.org/10.20944/preprints202606.2007.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.2007.v1",null],["4","R0000127","R0000127.pdf","open_download_failed","nonrandomized_study","Brown JP","2026","Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-04820","https://doi.org/10.7326/annals-25-04820","42258827","https://pubmed.ncbi.nlm.nih.gov/42258827/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13430612/pdf/nihms-2185445.pdf",null],["4","R0000128","R0000128.pdf","open_download_failed","nonrandomized_study","Dziewierz A","2026","Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71017","https://doi.org/10.1111/dom.71017","42297761","https://pubmed.ncbi.nlm.nih.gov/42297761/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13448982/pdf/DOM-28-8045.pdf",null],["4","R0000129","R0000129.pdf","open_download_failed","nonrandomized_study","Haberman RH","2026","Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.","Arthritis & rheumatology (Hoboken, N.J.)","Wiley","10.1002/art.70170","https://doi.org/10.1002/art.70170","41940492","https://pubmed.ncbi.nlm.nih.gov/41940492/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13154331/pdf/nihms-2171052.pdf",null],["4","R0000134","R0000134.pdf","free_to_read","nonrandomized_study","Bowers CJ","2026","Glucagon-like Peptide-1 receptor agonist use is associated with decreased risk of periprosthetic joint infection following total knee arthroplasty: A laterality-verified propensity matched comparison.","Journal of orthopaedic surgery (Hong Kong)","SAGE Publications","10.1177/10225536261488188","https://doi.org/10.1177/10225536261488188","42702012","https://pubmed.ncbi.nlm.nih.gov/42702012/","https://doi.org/10.1177/10225536261488188",null],["4","R0000158","R0000158.pdf","free_to_read","nonrandomized_study","Hsu C","2026","A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with Diabetes","Preprints.org","MDPI AG","10.20944/preprints202609.0818.v1","https://doi.org/10.20944/preprints202609.0818.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.0818.v1",null],["4","R0000177","R0000177.pdf","free_to_read","nonrandomized_study","Daut UN","2026","Effect of GLP-1 Receptor Agonists and Tirzepatide on Obstructive Sleep Apnea Severity: A Systematic Literature Review","Preprints.org","MDPI AG","10.20944/preprints202606.0065.v1","https://doi.org/10.20944/preprints202606.0065.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0065.v1",null],["4","R0000184","R0000184.pdf","open_download_failed","nonrandomized_study","Testelmans D","2026","Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.","Pulmonology","Informa UK Limited","10.1080/25310429.2026.2722795","https://doi.org/10.1080/25310429.2026.2722795","42639925","https://pubmed.ncbi.nlm.nih.gov/42639925/","https://www.tandfonline.com/doi/pdf/10.1080/25310429.2026.2722795?needAccess=true",null],["4","R0000191","R0000191.pdf","open_download_failed","nonrandomized_study","Potter TE","2026","Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.","Anaesthesia","Wiley","10.1111/anae.70380","https://doi.org/10.1111/anae.70380","42748560","https://pubmed.ncbi.nlm.nih.gov/42748560/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/anae.70380",null],["4","R0000197","R0000197.pdf","free_to_read","nonrandomized_study","Wang M","2026","Real-World Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Combination Therapy on Weight Management Within a Digital-Supported Shared Care Model for Type 2 Diabetes.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.05.033","https://doi.org/10.1016/j.eprac.2026.05.033","42250764","https://pubmed.ncbi.nlm.nih.gov/42250764/","https://doi.org/10.1016/j.eprac.2026.05.033",null],["4","R0000235","R0000235.pdf","free_to_read","nonrandomized_study","Busti M","2026","Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-026-10627-1","https://doi.org/10.1007/s10741-026-10627-1","41984352","https://pubmed.ncbi.nlm.nih.gov/41984352/","https://hal.univ-lorraine.fr/hal-05601994",null],["4","R0000241","R0000241.pdf","free_to_read","nonrandomized_study","Guo M","2026","Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-026-05113-2","https://doi.org/10.1007/s00210-026-05113-2","41748946","https://pubmed.ncbi.nlm.nih.gov/41748946/","https://pure.eur.nl/en/publications/2bf01c4d-8976-4716-8ba0-263b97feb07c",null],["4","R0000266","R0000266.pdf","free_to_read","nonrandomized_study","Carter V","2026","Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis.","Regional anesthesia and pain medicine","BMJ","10.1136/rapm-2026-107658","https://doi.org/10.1136/rapm-2026-107658","42229941","https://pubmed.ncbi.nlm.nih.gov/42229941/","https://doi.org/10.1136/rapm-2026-107658",null],["4","R0000271","R0000271.pdf","open_download_failed","nonrandomized_study","Nielsen VW","2026","Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.","Journal of the European Academy of Dermatology and Venereology : JEADV","Wiley","10.1111/jdv.70769","https://doi.org/10.1111/jdv.70769","42828450","https://pubmed.ncbi.nlm.nih.gov/42828450/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70769",null],["4","R0000279","R0000279.pdf","free_to_read","nonrandomized_study","Kwan ATH","2026","Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2026.106620","https://doi.org/10.1016/j.clnu.2026.106620","41864088","https://pubmed.ncbi.nlm.nih.gov/41864088/","https://doi.org/10.1016/j.clnu.2026.106620",null],["4","R0000282","R0000282.pdf","open_download_failed","nonrandomized_study","Den J","2026","The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Peri- and Postmenopausal Breast Cancer Outcomes.","Journal of surgical oncology","Wiley","10.1002/jso.70411","https://doi.org/10.1002/jso.70411","42813380","https://pubmed.ncbi.nlm.nih.gov/42813380/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.70411",null],["4","R0000287","R0000287.pdf","free_to_read","nonrandomized_study","Leonhard AG","2026","Receipt of glucagon-like peptide-1 receptor agonists among rural patients with obstructive sleep apnea and excess weight.","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1093/annalsats/aaoag047","https://doi.org/10.1093/annalsats/aaoag047","41776791","https://pubmed.ncbi.nlm.nih.gov/41776791/",null,null],["4","R0000291","R0000291.pdf","free_to_read","nonrandomized_study","Kerr KW","2026","Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.","Childhood obesity (Print)","SAGE Publications","10.1177/21532176261486979","https://doi.org/10.1177/21532176261486979","42751742","https://pubmed.ncbi.nlm.nih.gov/42751742/","https://doi.org/10.1177/21532176261486979",null],["4","R0000314","R0000314.pdf","free_to_read","nonrandomized_study","Murugadoss K","2026","Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonists","Preprints.org","MDPI AG","10.20944/preprints202607.1605.v1","https://doi.org/10.20944/preprints202607.1605.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.1605.v1",null],["4","R0000320","R0000320.pdf","open_download_failed","nonrandomized_study","Yildirim BO","2026","Comparison of Cardiac Adverse Event Signal Profiles for GLP-1 Receptor Agonists: An Analysis of the FAERS Database","Authorea Preprints","Wiley","10.22541/au.177438465.59859376/v1","https://doi.org/10.22541/au.177438465.59859376/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.177438465.59859376",null],["4","R0000322","R0000322.pdf","open_download_failed","nonrandomized_study","Chiang Y","2026","Association Between Dermatologic Diseases and Glucagon-Like Peptide-1 Receptor Agonist Among Patients with Type 2 Diabetes","Authorea Preprints","Wiley","10.22541/au.176821399.98169583/v1","https://doi.org/10.22541/au.176821399.98169583/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176821399.98169583/v1",null],["4","R0000329","R0000329.pdf","open_download_failed","nonrandomized_study","Bahar F","2026","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71394","https://doi.org/10.1111/dom.71394","42802295","https://pubmed.ncbi.nlm.nih.gov/42802295/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71394",null],["4","R0000342","R0000342.pdf","open_download_failed","nonrandomized_study","Hallaj S","2026","Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2026.05.016","https://doi.org/10.1016/j.oret.2026.05.016","42229850","https://pubmed.ncbi.nlm.nih.gov/42229850/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13629172/pdf/nihms-2200350.pdf",null],["4","R0000364","R0000364.pdf","free_to_read","nonrandomized_study","Weng CH","2026","Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113454","https://doi.org/10.1016/j.diabres.2026.113454","42480717","https://pubmed.ncbi.nlm.nih.gov/42480717/","https://doi.org/10.1016/j.diabres.2026.113454",null],["4","R0000402","R0000402.pdf","free_to_read","nonrandomized_study","Rai P","2026","Association of Peri-procedural Glucagon-Like Peptide-1 Receptor Agonist Exposure with Long-Term Outcomes After Carotid Artery Revascularization Procedures: A Propensity Score-Matched Analysis.","AJNR. American journal of neuroradiology","American Society of Neuroradiology (ASNR)","10.3174/ajnr.a9592","https://doi.org/10.3174/ajnr.a9592","42595461","https://pubmed.ncbi.nlm.nih.gov/42595461/","https://doi.org/10.3174/ajnr.a9592",null],["4","R0000457","R0000457.pdf","open_download_failed","nonrandomized_study","Rutigliani G","2026","The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior.","Physiology & behavior","Elsevier BV","10.1016/j.physbeh.2026.115486","https://doi.org/10.1016/j.physbeh.2026.115486","42641845","https://pubmed.ncbi.nlm.nih.gov/42641845/","https://www.sciencedirect.com/science/article/pii/S0031938426002696/pdf","ClinicalTrials.gov:NCT07611201"],["4","R0000466","R0000466.pdf","open_download_failed","nonrandomized_study","Marshall LZ","2026","Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2026.32.3.281","https://doi.org/10.18553/jmcp.2026.32.3.281","41760566","https://pubmed.ncbi.nlm.nih.gov/41760566/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/pdf/jmcp.2026.32.3.281.pdf",null],["4","R0000485","R0000485.pdf","free_to_read","nonrandomized_study","Barseghyan L","2026","Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms","Preprints.org","MDPI AG","10.20944/preprints202609.0561.v1","https://doi.org/10.20944/preprints202609.0561.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.0561.v1",null],["4","R0000489","R0000489.pdf","free_to_read","nonrandomized_study","Mortada I","2026","Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes.","Diabetes & vascular disease research","SAGE Publications","10.1177/14791641261495569","https://doi.org/10.1177/14791641261495569","42808164","https://pubmed.ncbi.nlm.nih.gov/42808164/","https://doi.org/10.1177/14791641261495569",null],["4","R0000503","R0000503.pdf","free_to_read","nonrandomized_study","Salter A","2026","Use of semaglutide and tirzepatide among people with multiple sclerosis.","Multiple sclerosis (Houndmills, Basingstoke, England)","SAGE Publications","10.1177/13524585261442033","https://doi.org/10.1177/13524585261442033","42053291","https://pubmed.ncbi.nlm.nih.gov/42053291/","https://doi.org/10.1177/13524585261442033",null],["4","R0000506","R0000506.pdf","free_to_read","nonrandomized_study","Sawamura T","2026","Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.06.008","https://doi.org/10.1016/j.eprac.2026.06.008","42379268","https://pubmed.ncbi.nlm.nih.gov/42379268/","https://doi.org/10.1016/j.eprac.2026.06.008",null],["4","R0000519","R0000519.pdf","free_to_read","nonrandomized_study","Takiyama T","2026","Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109391","https://doi.org/10.1016/j.jdiacomp.2026.109391","42618422","https://pubmed.ncbi.nlm.nih.gov/42618422/","https://doi.org/10.1016/j.jdiacomp.2026.109391",null],["4","R0000527","R0000527.pdf","open_download_failed","nonrandomized_study","Silfvergren O","2026","M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/j.ejps.2026.107648","https://doi.org/10.1016/j.ejps.2026.107648","42669385","https://pubmed.ncbi.nlm.nih.gov/42669385/","https://www.sciencedirect.com/science/article/pii/S0928098726002228/pdf",null],["4","R0000594","R0000594.pdf","free_to_read","nonrandomized_study","Klein J","2026","Glucagon-Like Peptide-1 Receptor Agonists for Binge Eating Disorder and Bulimia Nervosa in Children and Adolescents: The Impulsivity Measurement Gap","Preprints.org","MDPI AG","10.20944/preprints202609.1626.v1","https://doi.org/10.20944/preprints202609.1626.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.1626.v1",null],["4","R0000602","R0000602.pdf","open_download_failed","nonrandomized_study","Cole JL","2026","Impact of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Large, Matched Regional Cohort.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280251349583","https://doi.org/10.1177/10600280251349583","40583805","https://pubmed.ncbi.nlm.nih.gov/40583805/","https://journals.sagepub.com/doi/pdf/10.1177/10600280251349583?download=true",null],["4","R0000623","R0000623.pdf","open_download_failed","nonrandomized_study","Lischka J","2026","Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.","Pediatric obesity","Wiley","10.1111/ijpo.70122","https://doi.org/10.1111/ijpo.70122","42222894","https://pubmed.ncbi.nlm.nih.gov/42222894/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.70122",null],["4","R0000638","R0000638.pdf","open_download_failed","nonrandomized_study","Gilbert SJ","2026","Evaluating the indirect interaction between glucagon-like peptide-1 receptor agonists and warfarin using real-world data.","Journal of thrombosis and thrombolysis","Springer Science and Business Media LLC","10.1007/s11239-026-03310-7","https://doi.org/10.1007/s11239-026-03310-7","42115581","https://pubmed.ncbi.nlm.nih.gov/42115581/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13344373/pdf/nihms-2190959.pdf",null],["4","R0000642","R0000642.pdf","open_download_failed","nonrandomized_study","Al-Ansary L","2026","Vagal activity related events and glucagon-like peptide-1 receptor agonists.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvag072","https://doi.org/10.1093/ehjcvp/pvag072","42709513","https://pubmed.ncbi.nlm.nih.gov/42709513/","https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvag072/70997105/pvag072.pdf",null],["4","R0000699","R0000699.pdf","open_download_failed","nonrandomized_study","Yuce T","2026","Real-World Effectiveness and Safety of GLP-1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70280","https://doi.org/10.1002/oby.70280","42642900","https://pubmed.ncbi.nlm.nih.gov/42642900/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70280",null],["4","R0000757","R0000757.pdf","free_to_read","nonrandomized_study","Rosenzveig A","2026","Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.125.045664","https://doi.org/10.1161/jaha.125.045664","42383806","https://pubmed.ncbi.nlm.nih.gov/42383806/","https://doi.org/10.1161/jaha.125.045664",null],["4","R0000779","R0000779.pdf","free_to_read","nonrandomized_study","Aboukaoud M","2026","Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2026.121802","https://doi.org/10.1016/j.jad.2026.121802","42002107","https://pubmed.ncbi.nlm.nih.gov/42002107/","https://doi.org/10.1016/j.jad.2026.121802",null],["4","R0000781","R0000781.pdf","open_download_failed","nonrandomized_study","Hsu AH","2026","GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.","Annals of oncology : official journal of the European Society for Medical Oncology","Elsevier BV","10.1016/j.annonc.2026.04.013","https://doi.org/10.1016/j.annonc.2026.04.013","42252247","https://pubmed.ncbi.nlm.nih.gov/42252247/","https://www.annalsofoncology.org/article/S0923-7534(26)00157-2/pdf",null],["4","R0000787","R0000787.pdf","free_to_read","nonrandomized_study","Brooks JD","2026","Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults","medRxiv","openRxiv","10.64898/2026.09.29.26364340","https://doi.org/10.64898/2026.09.29.26364340",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000805","R0000805.pdf","open_download_failed","nonrandomized_study","Eubanks A","2026","The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70566","https://doi.org/10.1002/bcp.70566","41995433","https://pubmed.ncbi.nlm.nih.gov/41995433/","https://www.authorea.com/doi/pdf/10.22541/au.176706936.68195055/v1",null],["4","R0000830","R0000830.pdf","open_download_failed","nonrandomized_study","Omurzakov A","2026","Glucagon-Like Peptide-1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair.","Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association","Wiley","10.1002/arj.70370","https://doi.org/10.1002/arj.70370","42314072","https://pubmed.ncbi.nlm.nih.gov/42314072/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/arj.70370",null],["4","R0000855","R0000855.pdf","open_download_failed","nonrandomized_study","Acheampong C","2026","Glucagon-like peptide-1 receptor agonists and healthcare use in older adults with heart failure and obesity","medRxiv","openRxiv","10.64898/2026.07.24.26358897","https://doi.org/10.64898/2026.07.24.26358897",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/07/27/2026.07.24.26358897.full.pdf",null],["4","R0000873","R0000873.pdf","open_download_failed","nonrandomized_study","Xiang YJ","2026","Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.","Gut","BMJ","10.1136/gutjnl-2026-338462","https://doi.org/10.1136/gutjnl-2026-338462","42399086","https://pubmed.ncbi.nlm.nih.gov/42399086/","https://gut.bmj.com/content/gutjnl/early/2026/07/03/gutjnl-2026-338462.full.pdf","ChiCTR:ChiCTR2600118495"],["4","R0000880","R0000880.pdf","open_download_failed","nonrandomized_study","Sehgal NKR","2026","Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities","medRxiv","openRxiv","10.64898/2026.03.12.26348253","https://doi.org/10.64898/2026.03.12.26348253",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/03/13/2026.03.12.26348253.full.pdf",null],["4","R0000886","R0000886.pdf","open_download_failed","nonrandomized_study","Cannon EJ","2026","Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70711","https://doi.org/10.1002/bcp.70711","42464447","https://pubmed.ncbi.nlm.nih.gov/42464447/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70711",null],["4","R0000889","R0000889.pdf","open_download_failed","nonrandomized_study","Huang W","2026","Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71299","https://doi.org/10.1111/dom.71299","42755139","https://pubmed.ncbi.nlm.nih.gov/42755139/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71299",null],["4","R0000893","R0000893.pdf","free_to_read","nonrandomized_study","Jennings I","2026","Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag279","https://doi.org/10.1093/eurjpc/zwag279","42165511","https://pubmed.ncbi.nlm.nih.gov/42165511/","https://doi.org/10.1093/eurjpc/zwag279",null],["4","R0000920","R0000920.pdf","open_download_failed","nonrandomized_study","AbuAlrob MA","2026","Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.","Epilepsia","Wiley","10.1111/epi.70022","https://doi.org/10.1111/epi.70022","41251033","https://pubmed.ncbi.nlm.nih.gov/41251033/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.70022",null],["4","R0000927","R0000927.pdf","free_to_read","nonrandomized_study","Ahmed S","2026","Glucagon-Like Peptide-1 Receptor Agonist Therapy and Neurocognitive Outcomes in Medically Managed Idiopathic Intracranial Hypertension: A Propensity Score-Matched Cohort Study.","AJNR. American journal of neuroradiology","American Society of Neuroradiology (ASNR)","10.3174/ajnr.a9559","https://doi.org/10.3174/ajnr.a9559","42527309","https://pubmed.ncbi.nlm.nih.gov/42527309/","https://doi.org/10.3174/ajnr.a9559",null],["4","R0000940","R0000940.pdf","free_to_read","nonrandomized_study","Dai H","2026","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events in Adults With Obesity and Autoimmune Disease: A Target Trial Emulation.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.125.047893","https://doi.org/10.1161/jaha.125.047893","42250252","https://pubmed.ncbi.nlm.nih.gov/42250252/","https://doi.org/10.1161/jaha.125.047893",null],["4","R0001017","R0001017.pdf","open_download_failed","nonrandomized_study","Chu PY","2026","GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.","Pediatrics","American Academy of Pediatrics (AAP)","10.1542/peds.2025-071971","https://doi.org/10.1542/peds.2025-071971","41765350","https://pubmed.ncbi.nlm.nih.gov/41765350/","https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2025-071971/1915974/pediatrics.2025071971.pdf",null],["4","R0001055","R0001055.pdf","free_to_read","nonrandomized_study","Fanizza JD","2026","Are patient factors associated with adverse perioperative outcomes in GLP-1 receptor agonist users? A retrospective cohort study.","Journal of clinical anesthesia","Elsevier BV","10.1016/j.jclinane.2026.112192","https://doi.org/10.1016/j.jclinane.2026.112192","41895163","https://pubmed.ncbi.nlm.nih.gov/41895163/","https://doi.org/10.1016/j.jclinane.2026.112192",null],["4","R0001056","R0001056.pdf","open_download_failed","nonrandomized_study","Alsaleh N","2026","Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.","World journal of surgery","Wiley","10.1002/wjs.70487","https://doi.org/10.1002/wjs.70487","42444315","https://pubmed.ncbi.nlm.nih.gov/42444315/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13576591/pdf/WJS-50-2525.pdf",null],["4","R0001097","R0001097.pdf","open_download_failed","nonrandomized_study","Stambollxhiu E","2026","GLP-1 Receptor Agonist Initiation Is Associated With Excess Skeletal Muscle Loss in Adults With Diabetes: A Prospective Population-Based MRI Study","medRxiv","openRxiv","10.64898/2026.09.15.26363157","https://doi.org/10.64898/2026.09.15.26363157",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.15.26363157.full.pdf",null],["4","R0001136","R0001136.pdf","free_to_read","nonrandomized_study","Shah S","2026","GLP-1 Analogues and Long-Term Outcomes in Adults With Obesity and Elevated CRP: A Real-World Matched Cohort Study.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.09.016","https://doi.org/10.1016/j.amjcard.2026.09.016","42767411","https://pubmed.ncbi.nlm.nih.gov/42767411/","https://doi.org/10.1016/j.amjcard.2026.09.016",null],["4","R0001138","R0001138.pdf","free_to_read","nonrandomized_study","Prasad A","2026","Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70515","https://doi.org/10.1002/bcp.70515","41902330","https://pubmed.ncbi.nlm.nih.gov/41902330/","https://doi.org/10.1002/bcp.70515",null],["4","R0001148","R0001148.pdf","free_to_read","nonrandomized_study","Chang YJ","2026","Association between glucagon-like peptide-1 receptor agonists and femur fracture risk in type 2 diabetes: A large-scale target trial emulation.","Bone","Elsevier BV","10.1016/j.bone.2026.117851","https://doi.org/10.1016/j.bone.2026.117851","41819195","https://pubmed.ncbi.nlm.nih.gov/41819195/","https://doi.org/10.1016/j.bone.2026.117851",null],["4","R0001156","R0001156.pdf","free_to_read","nonrandomized_study","Milluzzo A","2026","Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2026.06.006","https://doi.org/10.1016/j.eprac.2026.06.006","42362054","https://pubmed.ncbi.nlm.nih.gov/42362054/","https://doi.org/10.1016/j.eprac.2026.06.006",null],["4","R0001173","R0001173.pdf","free_to_read","nonrandomized_study","Governor SB","2026","Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP","medRxiv","openRxiv","10.64898/2026.01.20.26344489","https://doi.org/10.64898/2026.01.20.26344489",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.01.20.26344489",null],["4","R0001215","R0001215.pdf","open_download_failed","nonrandomized_study","Flanary SM","2026","Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs.","Current opinion in physiology","Elsevier BV","10.1016/j.cophys.2026.100956","https://doi.org/10.1016/j.cophys.2026.100956","42272808","https://pubmed.ncbi.nlm.nih.gov/42272808/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13249376/pdf/nihms-2174318.pdf",null],["4","R0001219","R0001219.pdf","free_to_read","nonrandomized_study","Diaz ME","2026","Nutrition Considerations in Youth with Type 2 Diabetes Using Glucagon-Like Peptide-1 Receptor Agonists: A Commentary.","Journal of the Academy of Nutrition and Dietetics","Elsevier BV","10.1016/j.jand.2026.156317","https://doi.org/10.1016/j.jand.2026.156317","41724352","https://pubmed.ncbi.nlm.nih.gov/41724352/","https://doi.org/10.1016/j.jand.2026.156317",null],["4","R0001229","R0001229.pdf","open_download_failed","nonrandomized_study","Chang TW","2026","GLP-1 Receptor Agonists and Risk of Age-Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70910","https://doi.org/10.1111/dom.70910","42186202","https://pubmed.ncbi.nlm.nih.gov/42186202/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13341406/pdf/DOM-28-6973.pdf",null],["4","R0001296","R0001296.pdf","open_download_failed","nonrandomized_study","Atkins KM","2026","GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy.","medRxiv : the preprint server for health sciences","openRxiv","10.64898/2026.05.26.26353962","https://doi.org/10.64898/2026.05.26.26353962","42282196","https://pubmed.ncbi.nlm.nih.gov/42282196/","https://www.medrxiv.org/content/medrxiv/early/2026/06/02/2026.05.26.26353962.full.pdf",null],["4","R0001298","R0001298.pdf","free_to_read","nonrandomized_study","Feng AS","2026","Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with glucagon-like peptide-1 receptor agonists: A population cohort study from the TriNetX collaborative network.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.03.023","https://doi.org/10.1016/j.jaad.2026.03.023","41833917","https://pubmed.ncbi.nlm.nih.gov/41833917/","https://doi.org/10.1016/j.jaad.2026.03.023",null],["4","R0001313","R0001313.pdf","free_to_read","nonrandomized_study","Dziewierz A","2026","Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113493","https://doi.org/10.1016/j.diabres.2026.113493","42575344","https://pubmed.ncbi.nlm.nih.gov/42575344/","https://ruj.uj.edu.pl/handle/item/583294",null],["4","R0001319","R0001319.pdf","free_to_read","nonrandomized_study","Liu Y","2026","Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag052","https://doi.org/10.1210/clinem/dgag052","41655226","https://pubmed.ncbi.nlm.nih.gov/41655226/","https://ecommons.cornell.edu/items/a6d749be-ae8d-4242-83c8-b2bc70393add/request-a-copy?bitstream=cb440163-6247-4da3-bf25-fbd0c2fef400",null],["4","R0001320","R0001320.pdf","free_to_read","nonrandomized_study","Sklepinski SM","2026","Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113503","https://doi.org/10.1016/j.diabres.2026.113503","42607727","https://pubmed.ncbi.nlm.nih.gov/42607727/","https://doi.org/10.1016/j.diabres.2026.113503",null],["4","R0001336","R0001336.pdf","free_to_read","nonrandomized_study","Tang H","2026","Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-100077","https://doi.org/10.1136/bmj-2026-100077","42486607","https://pubmed.ncbi.nlm.nih.gov/42486607/","https://doi.org/10.1136/bmj-2026-100077",null],["4","R0001354","R0001354.pdf","open_download_failed","nonrandomized_study","Seijas-Amigo J","2026","Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2026.03.012","https://doi.org/10.1016/j.clinthera.2026.03.012","42103575","https://pubmed.ncbi.nlm.nih.gov/42103575/","https://www.clinicaltherapeutics.com/article/S0149-2918(26)00074-3/pdf","ClinicalTrials.gov:NCT05136287"],["4","R0001389","R0001389.pdf","open_download_failed","nonrandomized_study","Tou AM","2026","Glucagon-like peptide-1 receptor agonists in pediatric metabolic dysfunction-associated steatotic liver disease.","Journal of pediatric gastroenterology and nutrition","Wiley","10.1002/jpn3.70242","https://doi.org/10.1002/jpn3.70242","41144868","https://pubmed.ncbi.nlm.nih.gov/41144868/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jpn3.70242",null],["4","R0001396","R0001396.pdf","open_download_failed","nonrandomized_study","Gonzalez F","2026","GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2025-0568","https://doi.org/10.1515/jpem-2025-0568","41353583","https://pubmed.ncbi.nlm.nih.gov/41353583/","https://www.degruyterbrill.com/document/doi/10.1515/jpem-2025-0568/pdf",null],["4","R0001409","R0001409.pdf","free_to_read","nonrandomized_study","Ikonomidis I","2026","GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.","American journal of physiology. Heart and circulatory physiology","American Physiological Society","10.1152/ajpheart.00996.2025","https://doi.org/10.1152/ajpheart.00996.2025","41579346","https://pubmed.ncbi.nlm.nih.gov/41579346/","https://doi.org/10.1152/ajpheart.00996.2025",null],["4","R0001459","R0001459.pdf","free_to_read","nonrandomized_study","Niazi S","2026","Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.","Acta ophthalmologica","Wiley","10.1111/aos.70168","https://doi.org/10.1111/aos.70168","42126975","https://pubmed.ncbi.nlm.nih.gov/42126975/","https://doi.org/10.1111/aos.70168",null],["4","R0001463","R0001463.pdf","free_to_read","nonrandomized_study","Patrizio A","2026","Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag051","https://doi.org/10.1210/clinem/dgag051","41693146","https://pubmed.ncbi.nlm.nih.gov/41693146/",null,null],["4","R0001499","R0001499.pdf","free_to_read","nonrandomized_study","Kasheri E","2026","Glucagon-like peptide-1 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: A TriNetX retrospective analysis.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2025.12.092","https://doi.org/10.1016/j.jaad.2025.12.092","41478501","https://pubmed.ncbi.nlm.nih.gov/41478501/","https://doi.org/10.1016/j.jaad.2025.12.092",null],["4","R0001518","R0001518.pdf","free_to_read","nonrandomized_study","Khogalee M","2026","Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2026.08.004","https://doi.org/10.1016/j.clinthera.2026.08.004","42711176","https://pubmed.ncbi.nlm.nih.gov/42711176/","https://doi.org/10.1016/j.clinthera.2026.08.004",null],["4","R0001523","R0001523.pdf","free_to_read","nonrandomized_study","Rai P","2026","Glucagon-Like Peptide-1 Receptor Agonist Exposure and Long-Term Outcomes in Patients with Asymptomatic Carotid Stenosis: A Propensity Score-Matched Real-World Analysis.","AJNR. American journal of neuroradiology","American Society of Neuroradiology (ASNR)","10.3174/ajnr.a9443","https://doi.org/10.3174/ajnr.a9443","42229997","https://pubmed.ncbi.nlm.nih.gov/42229997/","https://doi.org/10.3174/ajnr.a9443",null],["4","R0001528","R0001528.pdf","free_to_read","nonrandomized_study","Fussing FH","2026","Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data.","European journal of heart failure","Oxford University Press (OUP)","10.1093/ejhf/xuag114","https://doi.org/10.1093/ejhf/xuag114","41990363","https://pubmed.ncbi.nlm.nih.gov/41990363/","https://doi.org/10.1093/ejhf/xuag114",null],["4","R0001611","R0001611.pdf","open_download_failed","nonrandomized_study","Hartsell SE","2026","Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk.","Journal of the American Society of Nephrology : JASN","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000001016","https://doi.org/10.1681/asn.0000001016","41563358","https://pubmed.ncbi.nlm.nih.gov/41563358/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12924663/pdf/jasn-37-1733.pdf",null],["4","R0001621","R0001621.pdf","free_to_read","nonrandomized_study","Chen CM","2026","GLP-1 Receptor Agonists and Long-Term Survival after Spontaneous Intracerebral Hemorrhage in Type 2 Diabetes.","World neurosurgery","Elsevier BV","10.1016/j.wneu.2026.124932","https://doi.org/10.1016/j.wneu.2026.124932","41895521","https://pubmed.ncbi.nlm.nih.gov/41895521/","https://doi.org/10.1016/j.wneu.2026.124932",null],["4","R0001647","R0001647.pdf","free_to_read","nonrandomized_study","Hanif M","2026","Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2026.02.016","https://doi.org/10.1016/j.amjmed.2026.02.016","41812723","https://pubmed.ncbi.nlm.nih.gov/41812723/","https://doi.org/10.1016/j.amjmed.2026.02.016",null],["4","R0001663","R0001663.pdf","open_download_failed","nonrandomized_study","Nobakht N","2026","Muscle Health in the Era of Incretin-Based Weight Loss: Implications for Patients with Cardiovascular-Kidney-Metabolic Syndrome.","Cardiorenal medicine","S. Karger AG","10.1159/000553166","https://doi.org/10.1159/000553166","42560932","https://pubmed.ncbi.nlm.nih.gov/42560932/","https://karger.com/crm/article-pdf/doi/10.1159/000553166/4573557/000553166.pdf",null],["4","R0001689","R0001689.pdf","open_download_failed","nonrandomized_study","Simonsen E","2026","Effects of Reimbursement Policy Change on Utilization of Injectable Semaglutide for Type 2 Diabetes and on Glycemic Control Among Discontinuers: A Danish Nationwide Cohort Study","medRxiv","openRxiv","10.64898/2026.09.23.26363640","https://doi.org/10.64898/2026.09.23.26363640",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/09/25/2026.09.23.26363640.full.pdf",null],["4","R0001783","R0001783.pdf","open_download_failed","nonrandomized_study","Alharbi S","2026","Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.","Skin appendage disorders","S. Karger AG","10.1159/000550540","https://doi.org/10.1159/000550540","41799300","https://pubmed.ncbi.nlm.nih.gov/41799300/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12965749/pdf/sad-2026-0000-0000-550540.pdf",null],["4","R0001796","R0001796.pdf","free_to_read","nonrandomized_study","Kohler J","2026","Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.","Urologic oncology","Elsevier BV","10.1016/j.urolonc.2026.05.010","https://doi.org/10.1016/j.urolonc.2026.05.010","42224918","https://pubmed.ncbi.nlm.nih.gov/42224918/","https://doi.org/10.1016/j.urolonc.2026.05.010",null],["4","R0001797","R0001797.pdf","free_to_read","nonrandomized_study","Franco J","2026","Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005171","https://doi.org/10.1097/dss.0000000000005171","42210881","https://pubmed.ncbi.nlm.nih.gov/42210881/","https://doi.org/10.1097/dss.0000000000005171",null],["4","R0001813","R0001813.pdf","free_to_read","nonrandomized_study","Murray M","2026","Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2025.12.015","https://doi.org/10.1016/j.ajo.2025.12.015","41429246","https://pubmed.ncbi.nlm.nih.gov/41429246/","https://doi.org/10.1016/j.ajo.2025.12.015",null],["4","R0001843","R0001843.pdf","free_to_read","nonrandomized_study","Al-Nusair M","2026","Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists","medRxiv","openRxiv","10.64898/2026.09.21.26363576","https://doi.org/10.64898/2026.09.21.26363576",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.09.21.26363576",null],["4","R0001857","R0001857.pdf","open_download_failed","nonrandomized_study","White AE","2026","Preoperative GLP-1 Receptor Agonist Use Is Not Associated With Complications in Non-Obese Patients Undergoing Total Shoulder Arthroplasty: A Propensity Score Matched Large Database Analysis.","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","SAGE Publications","10.1177/15563316261439127","https://doi.org/10.1177/15563316261439127","41958521","https://pubmed.ncbi.nlm.nih.gov/41958521/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13056801/pdf/10.1177_15563316261439127.pdf",null],["4","R0001908","R0001908.pdf","free_to_read","nonrandomized_study","Dosda A","2026","Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101734","https://doi.org/10.1016/j.diabet.2026.101734","41547436","https://pubmed.ncbi.nlm.nih.gov/41547436/","https://doi.org/10.1016/j.diabet.2026.101734",null],["4","R0001940","R0001940.pdf","free_to_read","nonrandomized_study","Kim E","2026","Computable longitudinal patient journeys from structured and unstructured EHR data.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-026-04695-x","https://doi.org/10.1038/s41591-026-04695-x","42742184","https://pubmed.ncbi.nlm.nih.gov/42742184/","https://doi.org/10.1038/s41591-026-04695-x",null],["4","R0001953","R0001953.pdf","open_download_failed","nonrandomized_study","Alfakhri A","2026","The Risk of Hypothyroidism With the Use of GLP-1 Receptor Agonists in Saudi Arabia.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.70315","https://doi.org/10.1002/pds.70315","41490610","https://pubmed.ncbi.nlm.nih.gov/41490610/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.70315",null],["4","R0002002","R0002002.pdf","open_download_failed","nonrandomized_study","Niazi S","2026","Timing and Duration of Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy","medRxiv","openRxiv","10.64898/2026.02.01.26345315","https://doi.org/10.64898/2026.02.01.26345315",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/02/03/2026.02.01.26345315.full.pdf",null],["4","R0002016","R0002016.pdf","open_download_failed","nonrandomized_study","Arow Z","2026","Stroke risk in diabetic patients with concomitant cardiovascular disease the CARDIAB-Stroke study.","Annales d'endocrinologie","Elsevier BV","10.1016/j.ando.2026.103058","https://doi.org/10.1016/j.ando.2026.103058","42607995","https://pubmed.ncbi.nlm.nih.gov/42607995/","https://www.sciencedirect.com/science/article/pii/S0003426626005792/pdf",null],["4","R0002042","R0002042.pdf","free_to_read","nonrandomized_study","Anagnostakis F","2026","Association of glucagon-like peptide-1 receptor agonist use with anxiety disorders, depression, self-harm, and suicidality: a large cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113104","https://doi.org/10.1016/j.diabres.2026.113104","41592697","https://pubmed.ncbi.nlm.nih.gov/41592697/","https://research.rug.nl/en/publications/32c2dd8d-2ddd-4df7-951e-b2283046bf3c",null],["4","R0002059","R0002059.pdf","open_download_failed","nonrandomized_study","Calderon E","2026","Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71334","https://doi.org/10.1111/dom.71334","42764409","https://pubmed.ncbi.nlm.nih.gov/42764409/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71334",null],["4","R0002062","R0002062.pdf","open_download_failed","nonrandomized_study","Schröder J","2026","Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer’s disease–type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning","medRxiv","openRxiv","10.64898/2026.08.21.26361012","https://doi.org/10.64898/2026.08.21.26361012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/08/24/2026.08.21.26361012.full.pdf",null],["4","R0002095","R0002095.pdf","free_to_read","nonrandomized_study","Matson R","2026","Real-World Insulin Deintensification and Discontinuation with GLP-1 Incretin Therapies Versus SGLT2 Inhibitors in Type 2 Diabetes","Preprints.org","MDPI AG","10.20944/preprints202607.2282.v1","https://doi.org/10.20944/preprints202607.2282.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.2282.v1",null],["4","R0002133","R0002133.pdf","open_download_failed","nonrandomized_study","Gasdaska A","2026","GLP-1 Receptor Agonist Prescription Patterns in the All of Us Research Program.","medRxiv : the preprint server for health sciences","openRxiv","10.64898/2026.01.13.26344022","https://doi.org/10.64898/2026.01.13.26344022","41742942","https://pubmed.ncbi.nlm.nih.gov/41742942/","https://www.medrxiv.org/content/medrxiv/early/2026/01/15/2026.01.13.26344022.full.pdf",null],["4","R0002158","R0002158.pdf","free_to_read","nonrandomized_study","Marwaha A","2026","New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching","Preprints.org","MDPI AG","10.20944/preprints202607.1370.v1","https://doi.org/10.20944/preprints202607.1370.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.1370.v1",null],["4","R0002259","R0002259.pdf","free_to_read","nonrandomized_study","Chiu CF","2026","A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2026.09.001","https://doi.org/10.1016/j.orcp.2026.09.001","42744726","https://pubmed.ncbi.nlm.nih.gov/42744726/","https://doi.org/10.1016/j.orcp.2026.09.001","ClinicalTrials.gov:NCT06283641"],["4","R0002302","R0002302.pdf","free_to_read","nonrandomized_study","Bank NC","2026","The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion.","World neurosurgery","Elsevier BV","10.1016/j.wneu.2025.124751","https://doi.org/10.1016/j.wneu.2025.124751","41422925","https://pubmed.ncbi.nlm.nih.gov/41422925/","https://doi.org/10.1016/j.wneu.2025.124751",null],["4","R0002306","R0002306.pdf","open_download_failed","nonrandomized_study","Han GY","2026","Causal Machine Learning for Comparative Effectiveness of GLP-1 RA versus SGLT2i in Heart Failure Using Real-World EHR Data","medRxiv","openRxiv","10.64898/2026.04.06.26350259","https://doi.org/10.64898/2026.04.06.26350259",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/04/07/2026.04.06.26350259.full.pdf",null],["4","R0002319","R0002319.pdf","open_download_failed","nonrandomized_study","Leite AR","2026","[Regional Trends in Antidiabetic Drug Prescribing in Portugal: Eight Years of Nationwide Real-World Evidence (2017 - 2024) (TREND-8 REGIONS Study)].","Acta medica portuguesa","Ordem dos Medicos","10.20344/amp.24706","https://doi.org/10.20344/amp.24706","42697864","https://pubmed.ncbi.nlm.nih.gov/42697864/","https://www.actamedicaportuguesa.com/revista/index.php/amp/article/download/24706/16020",null],["4","R0002426","R0002426.pdf","free_to_read","nonrandomized_study","Asiri A","2026","Comparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for England","Preprints.org","MDPI AG","10.20944/preprints202608.1213.v1","https://doi.org/10.20944/preprints202608.1213.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202608.1213.v1",null],["4","R0002449","R0002449.pdf","open_download_failed","nonrandomized_study","Hilgefort L","2026","SGLT-2 inhibitors and GLP-1 receptor agonists in primary care pharmacotherapy of type 2 diabetes in people living with HIV versus HIV-negative controls: Findings from a multicenter study in Germany.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2026.01.005","https://doi.org/10.1016/j.pcd.2026.01.005","41547635","https://pubmed.ncbi.nlm.nih.gov/41547635/","https://www.primary-care-diabetes.com/article/S1751-9918(26)00005-7/pdf",null],["4","R0002471","R0002471.pdf","open_download_failed","nonrandomized_study","Tentolouris A","2026","GLP-1 receptor agonists in patients with MGUS: A real-world propensity-matched study.","European journal of clinical investigation","Wiley","10.1111/eci.70140","https://doi.org/10.1111/eci.70140","41123105","https://pubmed.ncbi.nlm.nih.gov/41123105/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/eci.70140",null],["4","R0002478","R0002478.pdf","open_download_failed","nonrandomized_study","Shah P","2026","Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.","The Laryngoscope","Wiley","10.1002/lary.70808","https://doi.org/10.1002/lary.70808","42584027","https://pubmed.ncbi.nlm.nih.gov/42584027/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lary.70808",null],["4","R0002551","R0002551.pdf","open_download_failed","nonrandomized_study","Chan SH","2026","GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.113073","https://doi.org/10.1016/j.diabres.2025.113073","41453566","https://pubmed.ncbi.nlm.nih.gov/41453566/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)01088-5/pdf",null],["4","R0002568","R0002568.pdf","free_to_read","nonrandomized_study","Gutiérrez-Medina S","2026","GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2026.05.007","https://doi.org/10.1016/j.orcp.2026.05.007","42191517","https://pubmed.ncbi.nlm.nih.gov/42191517/","https://doi.org/10.1016/j.orcp.2026.05.007",null],["4","R0002613","R0002613.pdf","free_to_read","nonrandomized_study","Saghafi S","2026","Protecting the endocrine axis in immuno-oncology: GLP-1 receptor agonists as host-directed modulators in colorectal cancer.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2025.118948","https://doi.org/10.1016/j.biopha.2025.118948","41496347","https://pubmed.ncbi.nlm.nih.gov/41496347/","https://doi.org/10.1016/j.biopha.2025.118948",null],["4","R0002656","R0002656.pdf","free_to_read","nonrandomized_study","Lund LC","2026","Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113341","https://doi.org/10.1016/j.diabres.2026.113341","42202888","https://pubmed.ncbi.nlm.nih.gov/42202888/","https://doi.org/10.1016/j.diabres.2026.113341",null],["4","R0002667","R0002667.pdf","open_download_failed","nonrandomized_study","Bowe A","2026","Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70219","https://doi.org/10.1111/dom.70219","41165079","https://pubmed.ncbi.nlm.nih.gov/41165079/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70219",null],["4","R0002738","R0002738.pdf","no_doi","nonrandomized_study","Laub MR","2026","Standard of Care for Chronic Kidney Disease: The Four Pillars of Pharmacotherapy - Implications for Nephrology Nursing Practice.","Nephrology nursing journal : journal of the American Nephrology Nurses' Association",null,null,"https://doi.org/","42742304","https://pubmed.ncbi.nlm.nih.gov/42742304/",null,null],["4","R0002809","R0002809.pdf","open_download_failed","nonrandomized_study","Tirumalasetty MB","2026","GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 Diabetes","medRxiv","openRxiv","10.64898/2026.07.29.26359248","https://doi.org/10.64898/2026.07.29.26359248",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/08/02/2026.07.29.26359248.full.pdf",null],["4","R0002899","R0002899.pdf","open_download_failed","nonrandomized_study","Sarker J","2026","Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors on liver outcomes in metabolic dysfunction-associated steatotic liver disease: A retrospective cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70505","https://doi.org/10.1111/dom.70505","41560595","https://pubmed.ncbi.nlm.nih.gov/41560595/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70505",null],["4","R0002964","R0002964.pdf","free_to_read","nonrandomized_study","Murugadoss K","2026","Oral Wegovy Broadens Care Continuum Across First-Time GLP-Starters, High Cardiometabolic Burden GLP-Switchers, and Medicare-Age Patients","Preprints.org","MDPI AG","10.20944/preprints202607.0935.v1","https://doi.org/10.20944/preprints202607.0935.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.0935.v1",null],["4","R0002997","R0002997.pdf","free_to_read","nonrandomized_study","Sedova P","2026","GLP-1 Receptor Agonists for Secondary Prevention After Myocardial Infarction and Stroke in Type 2 Diabetes: Nationwide Real-World Evidence.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag002","https://doi.org/10.1093/eurjpc/zwag002","41499432","https://pubmed.ncbi.nlm.nih.gov/41499432/","https://doi.org/10.1093/eurjpc/zwag002",null],["4","R0003038","R0003038.pdf","open_download_failed","nonrandomized_study","Liu X","2026","Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71373","https://doi.org/10.1111/dom.71373","42768828","https://pubmed.ncbi.nlm.nih.gov/42768828/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71373",null],["4","R0003039","R0003039.pdf","open_download_failed","nonrandomized_study","Guo W","2026","Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice.","medRxiv : the preprint server for health sciences","openRxiv","10.64898/2026.02.18.26346594","https://doi.org/10.64898/2026.02.18.26346594","41757166","https://pubmed.ncbi.nlm.nih.gov/41757166/","https://www.medrxiv.org/content/medrxiv/early/2026/02/20/2026.02.18.26346594.full.pdf",null],["4","R0003073","R0003073.pdf","open_download_failed","nonrandomized_study","Ortega-Montiel J","2026","Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2026.06.013","https://doi.org/10.1053/j.ajkd.2026.06.013","42767321","https://pubmed.ncbi.nlm.nih.gov/42767321/","https://www.ajkd.org/article/S0272-6386(26)01118-2/pdf",null],["4","R0003084","R0003084.pdf","free_to_read","nonrandomized_study","Al Hayek A","2026","Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/0115733998428827251223081042","https://doi.org/10.2174/0115733998428827251223081042","41691684","https://pubmed.ncbi.nlm.nih.gov/41691684/","https://doi.org/10.2174/0115733998428827251223081042",null],["4","R0003100","R0003100.pdf","free_to_read","nonrandomized_study","Eduardo I","2026","Comparative Post-Marketing Pharmacovigilance of Five GLP-1 Receptor Agonists: A Disproportionality Analysis of 412,643 FDA Adverse Event Reports (2004-2024)","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9818000/v1","https://doi.org/10.21203/rs.3.rs-9818000/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9818000/v1",null],["4","R0003107","R0003107.pdf","open_download_failed","nonrandomized_study","Halimi JM","2026","Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf426","https://doi.org/10.1093/eurjpc/zwaf426","40660809","https://pubmed.ncbi.nlm.nih.gov/40660809/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwaf426/63760730/zwaf426.pdf",null],["4","R0003125","R0003125.pdf","open_download_failed","nonrandomized_study","Brown A","2026","Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70246","https://doi.org/10.1002/oby.70246","42345739","https://pubmed.ncbi.nlm.nih.gov/42345739/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70246",null],["4","R0003177","R0003177.pdf","free_to_read","nonrandomized_study","Nagalamadaka P","2026","GLP-1 Receptor Agonist Initiation and Anti-VEGF Treatment Frequency in Diabetic Macular Edema: an IRIS  <sup>®<\/sup>  Registry Cohort Study","medRxiv","openRxiv","10.64898/2026.08.29.26361426","https://doi.org/10.64898/2026.08.29.26361426",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.08.29.26361426",null],["4","R0003237","R0003237.pdf","open_download_failed","nonrandomized_study","Mraz N","2026","Impact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients","medRxiv","openRxiv","10.64898/2026.06.17.26355850","https://doi.org/10.64898/2026.06.17.26355850",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/06/22/2026.06.17.26355850.full.pdf",null],["4","R0003250","R0003250.pdf","free_to_read","nonrandomized_study","Li Y","2026","Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.","Drug metabolism and disposition: the biological fate of chemicals","Elsevier BV","10.1016/j.dmd.2026.100346","https://doi.org/10.1016/j.dmd.2026.100346","42418948","https://pubmed.ncbi.nlm.nih.gov/42418948/","https://doi.org/10.1016/j.dmd.2026.100346",null],["4","R0003286","R0003286.pdf","open_download_failed","nonrandomized_study","Inamine S","2026","GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71190","https://doi.org/10.1111/dom.71190","42552238","https://pubmed.ncbi.nlm.nih.gov/42552238/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538759/pdf/DOM-28-9595.pdf",null],["4","R0003337","R0003337.pdf","open_download_failed","nonrandomized_study","Hernández-Pérez JG","2026","GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113119","https://doi.org/10.1016/j.diabres.2026.113119","41605300","https://pubmed.ncbi.nlm.nih.gov/41605300/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13525917/pdf/nihms-2199533.pdf",null],["4","R0003364","R0003364.pdf","free_to_read","nonrandomized_study","Ernst K","2026","Evaluation of clinical decision support to improve guideline directed medical therapy in patients with type 2 diabetes.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2026.103081","https://doi.org/10.1016/j.japh.2026.103081","41866125","https://pubmed.ncbi.nlm.nih.gov/41866125/","https://doi.org/10.1016/j.japh.2026.103081",null],["4","R0003371","R0003371.pdf","open_download_failed","nonrandomized_study","Orandi BJ","2026","Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70301","https://doi.org/10.1002/oby.70301","42768905","https://pubmed.ncbi.nlm.nih.gov/42768905/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70301",null],["4","R0003392","R0003392.pdf","open_download_failed","nonrandomized_study","Ren L","2026","Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71303","https://doi.org/10.1111/dom.71303","42687799","https://pubmed.ncbi.nlm.nih.gov/42687799/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71303",null],["4","R0003404","R0003404.pdf","open_download_failed","nonrandomized_study","Tesfaye H","2026","GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70200","https://doi.org/10.1111/dom.70200","41104517","https://pubmed.ncbi.nlm.nih.gov/41104517/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70200",null],["4","R0003432","R0003432.pdf","free_to_read","nonrandomized_study","Anagnostopoulou V","2026","Therapies for Cardiovascular-Kidney-Liver-Metabolic Syndrome: Reappraisal of Fibrates.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71230","https://doi.org/10.1111/dom.71230","42608342","https://pubmed.ncbi.nlm.nih.gov/42608342/","https://doi.org/10.1111/dom.71230",null],["4","R0003532","R0003532.pdf","open_download_failed","nonrandomized_study","McDonald ES","2026","GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women.","JCO oncology practice","American Society of Clinical Oncology (ASCO)","10.1200/op-26-00485","https://doi.org/10.1200/op-26-00485","42227662","https://pubmed.ncbi.nlm.nih.gov/42227662/","https://ascopubs.org/doi/pdfdirect/10.1200/OP-26-00485",null],["4","R0003547","R0003547.pdf","open_download_failed","nonrandomized_study","Lakhani M","2026","Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.","The British journal of ophthalmology","BMJ","10.1136/bjo-2025-328483","https://doi.org/10.1136/bjo-2025-328483","41807083","https://pubmed.ncbi.nlm.nih.gov/41807083/","https://bjo.bmj.com/content/bjophthalmol/early/2026/03/02/bjo-2025-328483.full.pdf",null],["4","R0003551","R0003551.pdf","free_to_read","nonrandomized_study","Chen JW","2026","Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2026.101740","https://doi.org/10.1016/j.diabet.2026.101740","41687959","https://pubmed.ncbi.nlm.nih.gov/41687959/","https://doi.org/10.1016/j.diabet.2026.101740",null],["4","R0003604","R0003604.pdf","free_to_read","nonrandomized_study","Yang MY","2026","Protective effects of SGLT2 inhibitors and GLP-1 receptor agonists on infection-related implant failure following ankle fracture ORIF: A global big data analysis.","Journal of orthopaedic surgery (Hong Kong)","SAGE Publications","10.1177/10225536261447739","https://doi.org/10.1177/10225536261447739","42037563","https://pubmed.ncbi.nlm.nih.gov/42037563/","https://doi.org/10.1177/10225536261447739",null],["4","R0003712","R0003712.pdf","open_download_failed","nonrandomized_study","Hooker SA","2026","Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70415","https://doi.org/10.1111/dom.70415","41479367","https://pubmed.ncbi.nlm.nih.gov/41479367/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70415",null],["4","R0003744","R0003744.pdf","open_download_failed","nonrandomized_study","Xu S","2026","Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71138","https://doi.org/10.1111/dom.71138","42481928","https://pubmed.ncbi.nlm.nih.gov/42481928/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538726/pdf/DOM-28-9251.pdf",null],["4","R0003760","R0003760.pdf","free_to_read","nonrandomized_study","Murugadoss K","2026","Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms","Preprints.org","MDPI AG","10.20944/preprints202608.1193.v1","https://doi.org/10.20944/preprints202608.1193.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202608.1193.v1",null],["4","R0003763","R0003763.pdf","open_download_failed","nonrandomized_study","McIntyre RS","2026","Nephroprotective Effect of GLP-1 Receptor Agonists (GLP-1 RAs) in Patients Receiving Lithium Therapy: A Population-Based Study Using the TriNetX Network","medRxiv","openRxiv","10.64898/2026.02.09.26345925","https://doi.org/10.64898/2026.02.09.26345925",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/02/11/2026.02.09.26345925.full.pdf",null],["4","R0003791","R0003791.pdf","free_to_read","nonrandomized_study","Vu M","2026","GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005162","https://doi.org/10.1097/dss.0000000000005162","42210885","https://pubmed.ncbi.nlm.nih.gov/42210885/","https://doi.org/10.1097/dss.0000000000005162",null],["4","R0003815","R0003815.pdf","free_to_read","nonrandomized_study","Li X","2026","Antidiabetic drug effects on gastrointestinal health: convergent evidence from a longitudinal cohort and Mendelian randomization study.","Journal of advanced research","Elsevier BV","10.1016/j.jare.2026.04.014","https://doi.org/10.1016/j.jare.2026.04.014","41951048","https://pubmed.ncbi.nlm.nih.gov/41951048/","https://doi.org/10.1016/j.jare.2026.04.014",null],["4","R0003829","R0003829.pdf","free_to_read","nonrandomized_study","Maldonado AI","2026","Semaglutide Initiation and Treatment Duration On Suicidality Risk in US Veterans With Type 2 Diabetes","medRxiv","openRxiv","10.64898/2026.04.17.26351118","https://doi.org/10.64898/2026.04.17.26351118",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.04.17.26351118",null],["4","R0003919","R0003919.pdf","open_download_failed","nonrandomized_study","Ke J","2026","Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.","Kardiologia polska","Polskie Towarzystwo Kardiologiczne","10.33963/v.phj.109920","https://doi.org/10.33963/v.phj.109920","41496625","https://pubmed.ncbi.nlm.nih.gov/41496625/","https://journals.viamedica.pl/polish_heart_journal/article/download/109920/86516",null],["4","R0004039","R0004039.pdf","free_to_read","nonrandomized_study","Lin Y","2026","GLP-1 Receptor Agonist Add-On at Immune Checkpoint Inhibitor Initiation and Fewer Wasting-Related Diagnoses and Acute-Care Episodes in People with Cancer and Obesity without Diabetes: A Target Trial Emulation","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9412701/v1","https://doi.org/10.21203/rs.3.rs-9412701/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9412701/v1",null],["4","R0004070","R0004070.pdf","free_to_read","nonrandomized_study","Pratap A","2026","GLP-1 Refractory Obesity Is Associated with Inferior Weight Loss After Bariatric Surgery and a Distinct Hepatic Mitochondrial Phenotype","medRxiv","openRxiv","10.64898/2026.08.04.26359613","https://doi.org/10.64898/2026.08.04.26359613",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0004096","R0004096.pdf","free_to_read","nonrandomized_study","Ding X","2026","Sex Differences in Comparative Effectiveness and Safety of Second-line Antidiabetic Agents: Real-world Evidence from Large-scale Multinational Study","medRxiv","openRxiv","10.64898/2026.04.10.26350252","https://doi.org/10.64898/2026.04.10.26350252",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0004168","R0004168.pdf","open_download_failed","nonrandomized_study","Yau K","2026","Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2025.09.010","https://doi.org/10.1053/j.ajkd.2025.09.010","41238166","https://pubmed.ncbi.nlm.nih.gov/41238166/","https://www.ajkd.org/article/S0272-6386(25)01149-7/pdf",null],["4","R0004199","R0004199.pdf","open_download_failed","nonrandomized_study","Guo X","2026","Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71025","https://doi.org/10.1111/dom.71025","42443144","https://pubmed.ncbi.nlm.nih.gov/42443144/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538822/pdf/DOM-28-8936.pdf",null],["4","R0004213","R0004213.pdf","open_download_failed","nonrandomized_study","Albor C","2026","The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.","Current obesity reports","Springer Science and Business Media LLC","10.1007/s13679-026-00707-6","https://doi.org/10.1007/s13679-026-00707-6","41922811","https://pubmed.ncbi.nlm.nih.gov/41922811/","https://nottingham-repository.worktribe.com/preview/62013541/COR%20review%207%20Oct%202025%20%283%29%20%282%29.pdf",null],["4","R0004244","R0004244.pdf","free_to_read","nonrandomized_study","Cheng D","2026","Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.02.008","https://doi.org/10.1016/j.jaad.2026.02.008","41655841","https://pubmed.ncbi.nlm.nih.gov/41655841/","https://doi.org/10.1016/j.jaad.2026.02.008",null],["4","R0004374","R0004374.pdf","free_to_read","nonrandomized_study","Abu Ahmad W","2026","Comparative risks of dementia and Parkinson's disease with GLP-1 RAs versus other oral glucose-lowering medications in obese patients with type 2 diabetes: a large real-world cohort study.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2026.107164","https://doi.org/10.1016/j.ejim.2026.107164","42629262","https://pubmed.ncbi.nlm.nih.gov/42629262/","https://doi.org/10.1016/j.ejim.2026.107164",null],["4","R0004394","R0004394.pdf","open_download_failed","nonrandomized_study","Harbi H","2026","Use of Glucose-Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71308","https://doi.org/10.1111/dom.71308","42687767","https://pubmed.ncbi.nlm.nih.gov/42687767/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71308",null],["4","R0004454","R0004454.pdf","free_to_read","nonrandomized_study","Garcia-Vega D","2026","Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2025.104483","https://doi.org/10.1016/j.numecd.2025.104483","41484025","https://pubmed.ncbi.nlm.nih.gov/41484025/","https://doi.org/10.1016/j.numecd.2025.104483",null],["4","R0004476","R0004476.pdf","open_download_failed","nonrandomized_study","Vlaeminck N","2026","Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study.","Anaesthesia","Wiley","10.1111/anae.70129","https://doi.org/10.1111/anae.70129","41631344","https://pubmed.ncbi.nlm.nih.gov/41631344/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/anae.70129",null],["4","R0004518","R0004518.pdf","open_download_failed","nonrandomized_study","Moon S","2026","Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.","Pharmaceuticals (Basel, Switzerland)","MDPI AG","10.3390/ph19060953","https://doi.org/10.3390/ph19060953","42356570","https://pubmed.ncbi.nlm.nih.gov/42356570/","https://www.mdpi.com/1424-8247/19/6/953/pdf?version=1782284619",null],["4","R0004679","R0004679.pdf","open_download_failed","nonrandomized_study","Butzin-Dozier Z","2026","GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.","medRxiv : the preprint server for health sciences","openRxiv","10.64898/2026.07.03.26357246","https://doi.org/10.64898/2026.07.03.26357246","42465874","https://pubmed.ncbi.nlm.nih.gov/42465874/","https://www.medrxiv.org/content/medrxiv/early/2026/07/06/2026.07.03.26357246.full.pdf",null],["4","R0004688","R0004688.pdf","open_download_failed","nonrandomized_study","Gonzalez A","2026","Association of GLP1-Receptor Agonists With Diabetic Retinopathy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71267","https://doi.org/10.1111/dom.71267","42660856","https://pubmed.ncbi.nlm.nih.gov/42660856/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71267",null],["4","R0004734","R0004734.pdf","open_download_failed","nonrandomized_study","Tangri N","2026","From progression to remission: a new paradigm for success in chronic kidney disease.","Kidney international","Elsevier BV","10.1016/j.kint.2025.10.004","https://doi.org/10.1016/j.kint.2025.10.004","41205673","https://pubmed.ncbi.nlm.nih.gov/41205673/","https://www.kidney-international.org/article/S0085-2538(25)00847-6/pdf",null],["4","R0004780","R0004780.pdf","free_to_read","nonrandomized_study","Lopez DS","2026","Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70211","https://doi.org/10.1002/oby.70211","42083112","https://pubmed.ncbi.nlm.nih.gov/42083112/","https://doi.org/10.1002/oby.70211",null],["4","R0004888","R0004888.pdf","free_to_read","nonrandomized_study","Shi Y","2026","Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2025.06.001","https://doi.org/10.1016/j.cgh.2025.06.001","40490148","https://pubmed.ncbi.nlm.nih.gov/40490148/","https://hdl.handle.net/2318/2121809",null],["4","R0004970","R0004970.pdf","open_download_failed","nonrandomized_study","Frey C","2026","Risk of Allodynia with GLP-1 Agonists","medRxiv","openRxiv","10.64898/2026.01.07.26343603","https://doi.org/10.64898/2026.01.07.26343603",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/01/08/2026.01.07.26343603.full.pdf",null],["4","R0005056","R0005056.pdf","open_download_failed","nonrandomized_study","Ben David G","2026","Engagement With a Breath-Based Metabolic Device Is Associated with Greater Weight Loss in Self-Reported Real-World GLP-1RA Users","medRxiv","openRxiv","10.64898/2026.02.22.26346841","https://doi.org/10.64898/2026.02.22.26346841",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/02/24/2026.02.22.26346841.full.pdf",null],["4","R0005233","R0005233.pdf","free_to_read","nonrandomized_study","Murugadoss K","2026","Semaglutide is associated with improved breast cancer survival, lower metastatic burden, and a dose–survival relationship uncoupled from weight-loss magnitude","medRxiv","openRxiv","10.64898/2026.04.23.26351609","https://doi.org/10.64898/2026.04.23.26351609",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0005455","R0005455.pdf","free_to_read","nonrandomized_study","Varma G","2026","Auditable LLM Curation of Clinical Notes Refines GLP-1 Initiation, Persistence Ascertainment and Compounding Use Beyond Prescription Records","Preprints.org","MDPI AG","10.20944/preprints202606.0682.v1","https://doi.org/10.20944/preprints202606.0682.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0682.v1",null],["4","R0005457","R0005457.pdf","free_to_read","nonrandomized_study","Rajendran PS","2026","Real-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiography","Preprints.org","MDPI AG","10.20944/preprints202607.1606.v1","https://doi.org/10.20944/preprints202607.1606.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.1606.v1",null],["4","R0005482","R0005482.pdf","open_download_failed","nonrandomized_study","Findling E","2026","GLP-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric MASLD Cohort and Normalize Disease-associated Core Gene Expression in a MASLD Model","Preprints.org","MDPI AG","10.20944/preprints202603.0905.v1","https://doi.org/10.20944/preprints202603.0905.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/91c3994c927a32425114a9699022172a/download_pub",null],["4","R0005605","R0005605.pdf","free_to_read","nonrandomized_study","Wallach JD","2026","Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016-2024.","Journal of addiction medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/adm.0000000000001575","https://doi.org/10.1097/adm.0000000000001575","41036780","https://pubmed.ncbi.nlm.nih.gov/41036780/",null,null],["4","R0005621","R0005621.pdf","open_download_failed","nonrandomized_study","Balafa O","2026","Sex-Based Gaps in the Prescription of Cardio-Nephroprotective Medications in CKD","Preprints.org","MDPI AG","10.20944/preprints202603.0884.v1","https://doi.org/10.20944/preprints202603.0884.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/452b7504192f19cce3c2b092be9bc8b9/download_pub",null],["4","R0005801","R0005801.pdf","open_download_failed","nonrandomized_study","Katragadda R","2026","Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.","The Laryngoscope","Wiley","10.1002/lary.70810","https://doi.org/10.1002/lary.70810","42647098","https://pubmed.ncbi.nlm.nih.gov/42647098/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lary.70810",null],["4","R0005814","R0005814.pdf","open_download_failed","nonrandomized_study","Bakken IJ","2026","Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70827","https://doi.org/10.1111/dom.70827","42086462","https://pubmed.ncbi.nlm.nih.gov/42086462/","https://www.medrxiv.org/content/medrxiv/early/2026/02/04/2026.02.04.26345477.full.pdf",null],["4","R0005900","R0005900.pdf","open_download_failed","nonrandomized_study","Fahoury AM","2026","Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor With Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.02.043","https://doi.org/10.1016/j.amjcard.2026.02.043","41765256","https://pubmed.ncbi.nlm.nih.gov/41765256/","https://www.ajconline.org/article/S0002-9149(26)00087-1/pdf",null],["4","R0005930","R0005930.pdf","free_to_read","nonrandomized_study","Marshall WR","2026","Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.","Current opinion in nephrology and hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/mnh.0000000000001225","https://doi.org/10.1097/mnh.0000000000001225","42683763","https://pubmed.ncbi.nlm.nih.gov/42683763/","https://doi.org/10.1097/mnh.0000000000001225",null],["4","R0005993","R0005993.pdf","open_download_failed","nonrandomized_study","Turchin A","2026","Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-100574","https://doi.org/10.1136/bmj-2026-100574","42778221","https://pubmed.ncbi.nlm.nih.gov/42778221/","https://www.bmj.com/content/bmj/394/bmj-2026-100574.full.pdf",null],["4","R0006051","R0006051.pdf","free_to_read","nonrandomized_study","Pullmann D","2026","Associations between GLP 1 receptor agonist therapy and surgical wound healing in a high-risk cohort","medRxiv","openRxiv","10.64898/2026.04.21.26351321","https://doi.org/10.64898/2026.04.21.26351321",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0006056","R0006056.pdf","open_download_failed","nonrandomized_study","Murugadoss K","2026","Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users","Preprints.org","MDPI AG","10.20944/preprints202609.2359.v1","https://doi.org/10.20944/preprints202609.2359.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",null],["4","R0006245","R0006245.pdf","free_to_read","nonrandomized_study","Sun SC","2026","Comparative Risk of Stroke Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Veterans with Type 2 Diabetes","medRxiv","openRxiv","10.64898/2026.05.13.26353028","https://doi.org/10.64898/2026.05.13.26353028",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.05.13.26353028",null],["4","R0006451","R0006451.pdf","open_download_failed","nonrandomized_study","Jurković M","2026","Economic evaluations of antiobesity medications: A systematic literature review.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70825","https://doi.org/10.1002/bcp.70825","42764443","https://pubmed.ncbi.nlm.nih.gov/42764443/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70825","PROSPERO:CRD420251139475"],["4","R0006517","R0006517.pdf","open_download_failed","nonrandomized_study","Lu S","2026","Tracking the Dynamic Trajectories: A Global-to-Local Pharmacovigilance Analysis of GLP-1 Receptor Agonists","medRxiv","openRxiv","10.64898/2026.05.28.26354401","https://doi.org/10.64898/2026.05.28.26354401",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/06/01/2026.05.28.26354401.full.pdf",null],["4","R0006641","R0006641.pdf","free_to_read","nonrandomized_study","Eshak N","2026","Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Rheumatology (Oxford, England)","Oxford University Press (OUP)","10.1093/rheumatology/keag033","https://doi.org/10.1093/rheumatology/keag033","41578948","https://pubmed.ncbi.nlm.nih.gov/41578948/","https://doi.org/10.1093/rheumatology/keag033",null],["4","R0006659","R0006659.pdf","free_to_read","nonrandomized_study","Lee YK","2026","GLP-1 receptor agonist-induced transient retinal perfusion delay and its potential mediation by intracranial pressure.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2026.119635","https://doi.org/10.1016/j.biopha.2026.119635","42335513","https://pubmed.ncbi.nlm.nih.gov/42335513/","https://doi.org/10.1016/j.biopha.2026.119635",null],["4","R0006661","R0006661.pdf","free_to_read","nonrandomized_study","Marwaha A","2026","Oral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventions","Preprints.org","MDPI AG","10.20944/preprints202608.1618.v1","https://doi.org/10.20944/preprints202608.1618.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202608.1618.v1",null],["4","R0006890","R0006890.pdf","free_to_read","nonrandomized_study","Chaturvedi R","2026","GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America Study","medRxiv","openRxiv","10.64898/2026.08.28.26361368","https://doi.org/10.64898/2026.08.28.26361368",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.08.28.26361368",null],["4","R0006912","R0006912.pdf","free_to_read","nonrandomized_study","Fricke JG","2026","68Ga-DOTA-exendin-4 PET/CT for Insulinoma Localization in Patients with Negative or Inconclusive Conventional Imaging.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag214","https://doi.org/10.1210/clinem/dgag214","42168767","https://pubmed.ncbi.nlm.nih.gov/42168767/","https://doi.org/10.1210/clinem/dgag214",null],["4","R0006987","R0006987.pdf","free_to_read","nonrandomized_study","Matson R","2026","Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment","Preprints.org","MDPI AG","10.20944/preprints202606.0638.v1","https://doi.org/10.20944/preprints202606.0638.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0638.v1",null],["4","R0007378","R0007378.pdf","free_to_read","nonrandomized_study","Al-Nusair M","2026","New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide","medRxiv","openRxiv","10.64898/2026.09.21.26363546","https://doi.org/10.64898/2026.09.21.26363546",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.09.21.26363546",null],["4","R0007489","R0007489.pdf","free_to_read","nonrandomized_study","Erly B","2026","Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide","medRxiv","openRxiv","10.64898/2026.07.14.26357502","https://doi.org/10.64898/2026.07.14.26357502",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.07.14.26357502",null],["4","R0007547","R0007547.pdf","free_to_read","nonrandomized_study","Vergniory-Trueba O","2026","<span class=\"word\">Glucagon-<span class=\"word\"><span class=\"changedDisabled\">Like <span class=\"word\"><span class=\"changedDisabled\">Peptide-<span class=\"word\">1 <span class=\"word\"><span class=\"changedDisabled\">Receptor <span class=\"word\"><span class=\"changedDisabled\">Agonists <span class=\"word\">in <span class=\"word\">the <span class=\"word\"><span class=\"changedDisabled\">Real <span class=\"word\"><span class=\"changedDisabled\">World: <span class=\"word\"><span class=\"changedDisabled\">Are <span class=\"word\"><span class=\"changedDisabled\">Clinical <span class=\"word\"><span class=\"changedDisabled\">Trials <span class=\"word\"><span class=\"changedDisabled\">Reproducible? <span class=\"word\">A <span class=\"word\">Spanish <span class=\"word\"><span class=\"changedDisabled\">Pilot <span class=\"word\"><span class=\"changedDisabled\">Study","Preprints.org","MDPI AG","10.20944/preprints202605.0987.v1","https://doi.org/10.20944/preprints202605.0987.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202605.0987.v1",null],["4","R0007557","R0007557.pdf","free_to_read","nonrandomized_study","Sidhu AS","2026","Effect of glucagon-like peptide-1 agonists on deep inferior epigastric perforator flap breast reconstruction outcomes in obese patients: A study of 5618 patients.","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Elsevier BV","10.1016/j.bjps.2025.11.048","https://doi.org/10.1016/j.bjps.2025.11.048","41308379","https://pubmed.ncbi.nlm.nih.gov/41308379/","https://doi.org/10.5281/zenodo.20064107",null],["4","R0008047","R0008047.pdf","free_to_read","nonrandomized_study","Nayak S","2026","Current trends in semaglutide therapy and strategies to improve its bioavailability.","Expert opinion on drug delivery","Informa UK Limited","10.1080/17425247.2026.2688990","https://doi.org/10.1080/17425247.2026.2688990","42288971","https://pubmed.ncbi.nlm.nih.gov/42288971/","https://doi.org/10.1080/17425247.2026.2688990",null],["4","R0008080","R0008080.pdf","open_download_failed","nonrandomized_study","Erly B","2026","Same Result, Different Price: Compounded versus Branded Tirzepatide","medRxiv","openRxiv","10.64898/2026.07.14.26357505","https://doi.org/10.64898/2026.07.14.26357505",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/07/16/2026.07.14.26357505.full.pdf",null],["4","R0008391","R0008391.pdf","free_to_read","nonrandomized_study","Zhang D","2026","Association of GLP-1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71352","https://doi.org/10.1111/dom.71352","42736029","https://pubmed.ncbi.nlm.nih.gov/42736029/","https://doi.org/10.1111/dom.71352",null],["4","R0008411","R0008411.pdf","free_to_read","nonrandomized_study","Murugadoss K","2026","Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies","Preprints.org","MDPI AG","10.20944/preprints202606.0636.v1","https://doi.org/10.20944/preprints202606.0636.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0636.v1",null],["4","R0008412","R0008412.pdf","open_download_failed","nonrandomized_study","Murugadoss K","2026","Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost","medRxiv","openRxiv","10.64898/2026.04.16.26351060","https://doi.org/10.64898/2026.04.16.26351060",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/04/23/2026.04.16.26351060.full.pdf",null],["4","R0008679","R0008679.pdf","open_download_failed","nonrandomized_study","Choudhry MA","2026","Comment on 'Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data'.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70882","https://doi.org/10.1002/bcp.70882","42855911","https://pubmed.ncbi.nlm.nih.gov/42855911/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70882",null],["4","R0008686","R0008686.pdf","open_download_failed","nonrandomized_study","Park AK","2026","Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.","Journal of hospital medicine","Wiley","10.1002/jhm.70228","https://doi.org/10.1002/jhm.70228","41286572","https://pubmed.ncbi.nlm.nih.gov/41286572/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhm.70228",null],["4","R0008802","R0008802.pdf","open_download_failed","nonrandomized_study","Zhang YW","2026","Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxag083","https://doi.org/10.1093/ajhp/zxag083","41805901","https://pubmed.ncbi.nlm.nih.gov/41805901/","https://www.medrxiv.org/content/medrxiv/early/2025/07/24/2025.07.24.25332155.full.pdf",null],["4","R0008871","R0008871.pdf","free_to_read","nonrandomized_study","Talay T","2026","Peer-to-Peer Referral Networks and Six-Month Outcomes in a Tirzepatide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study","Preprints.org","MDPI AG","10.20944/preprints202607.0060.v1","https://doi.org/10.20944/preprints202607.0060.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.0060.v1",null],["4","R0009005","R0009005.pdf","open_download_failed","nonrandomized_study","Zhang B","2026","Comparative Effectiveness of GLP-1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71244","https://doi.org/10.1111/dom.71244","42660859","https://pubmed.ncbi.nlm.nih.gov/42660859/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71244",null],["4","R0009074","R0009074.pdf","free_to_read","nonrandomized_study","Tomaso O","2026","Emerging Therapeutic Strategies for Infantile Obesity: A Narrative Review","Preprints.org","MDPI AG","10.20944/preprints202609.0649.v1","https://doi.org/10.20944/preprints202609.0649.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.0649.v1",null],["4","R0009290","R0009290.pdf","free_to_read","nonrandomized_study","Galasso M","2026","Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.","Journal of translational medicine","Springer Science and Business Media LLC","10.1186/s12967-026-08558-4","https://doi.org/10.1186/s12967-026-08558-4","42464302","https://pubmed.ncbi.nlm.nih.gov/42464302/","https://doi.org/10.1186/s12967-026-08558-4",null],["4","R0009354","R0009354.pdf","open_download_failed","nonrandomized_study","Granados I","2026","Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70128","https://doi.org/10.1002/oby.70128","41612871","https://pubmed.ncbi.nlm.nih.gov/41612871/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13540985/pdf/nihms-2204094.pdf",null],["4","R0009373","R0009373.pdf","free_to_read","nonrandomized_study","Shah S","2026","GLP-1 Receptor Agonist Use and Long-Term Outcomes in Hypertrophic Cardiomyopathy With Obstructive Sleep Apnea: A Real-World Cohort Analysis.","JACC. Advances","Elsevier BV","10.1016/j.jacadv.2026.102955","https://doi.org/10.1016/j.jacadv.2026.102955","42663372","https://pubmed.ncbi.nlm.nih.gov/42663372/","https://doi.org/10.1016/j.jacadv.2026.102955",null],["4","R0009582","R0009582.pdf","free_to_read","nonrandomized_study","Barenbaum SR","2026","Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70179","https://doi.org/10.1002/oby.70179","41902614","https://pubmed.ncbi.nlm.nih.gov/41902614/","https://ecommons.cornell.edu/items/8cabd4f2-ad29-4d7b-b0e5-693a8b6f38c4/request-a-copy?bitstream=cc275066-0623-432b-bc0c-0a9b5f36a1a5",null],["4","R0009682","R0009682.pdf","free_to_read","nonrandomized_study","Herrera HO","2026","Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.02.042","https://doi.org/10.1016/j.jaad.2026.02.042","41707704","https://pubmed.ncbi.nlm.nih.gov/41707704/","https://doi.org/10.1016/j.jaad.2026.02.042",null],["4","R0009990","R0009990.pdf","open_download_failed","nonrandomized_study","Zeier T","2026","Response to comment on \"Exploratory real-world experience with GLP-1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study\".","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2026-0184","https://doi.org/10.1515/jpem-2026-0184","42035284","https://pubmed.ncbi.nlm.nih.gov/42035284/","https://www.degruyterbrill.com/document/doi/10.1515/jpem-2026-0184/pdf",null],["4","R0010021","R0010021.pdf","free_to_read","nonrandomized_study","Nanabala R","2026","Long-Term Retrospective Evaluation of Radiochemical Yield Reproducibility of ⁶⁸Ga-Radiopharmaceuticals Using an SiO₂-Based ⁶⁸Ge/⁶⁸Ga Generator.","Nuclear medicine and molecular imaging","Springer Science and Business Media LLC","10.1007/s13139-026-01018-3","https://doi.org/10.1007/s13139-026-01018-3","42824596","https://pubmed.ncbi.nlm.nih.gov/42824596/","https://pubmed.ncbi.nlm.nih.gov/42824596/",null],["4","R0010114","R0010114.pdf","open_download_failed","nonrandomized_study","Shaikh MA","2026","Letter to Editor in Response to \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70699","https://doi.org/10.1111/jgh.70699","42643117","https://pubmed.ncbi.nlm.nih.gov/42643117/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.70699",null],["4","R0010197","R0010197.pdf","free_to_read","nonrandomized_study","Abogo MNA","2026","Impact of cardiometabolic and renal phenotypes on the prevalence of type 2 diabetes in the geriatric population of Añisok, Equatorial Guinea: a prospective cohort study (2024-2025)","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-9496968/v1","https://doi.org/10.21203/rs.3.rs-9496968/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-9496968/v1",null],["4","R0010256","R0010256.pdf","free_to_read","nonrandomized_study","Jabeen M","2026","The efficacyand safety of once weekly injectable semaglutide (Ozempic) among patients with Type 2 diabete sintertiary care hospital: A Retrospective Study.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.23206","https://doi.org/10.47391/jpma.23206","42261018","https://pubmed.ncbi.nlm.nih.gov/42261018/","https://doi.org/10.47391/jpma.23206",null],["4","R0010324","R0010324.pdf","open_download_failed","nonrandomized_study","Zafar K","2026","Letter to the Editor Regarding \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.70658","https://doi.org/10.1111/jgh.70658","42563486","https://pubmed.ncbi.nlm.nih.gov/42563486/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.70658",null],["4","R0010390","R0010390.pdf","open_download_failed","nonrandomized_study","Lam YW","2026","GLP-1 receptor agonists and reduced dementia risk: Real-world evidence stacks up.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70451","https://doi.org/10.1002/bcp.70451","41507114","https://pubmed.ncbi.nlm.nih.gov/41507114/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70451",null],["4","R0010391","R0010391.pdf","open_download_failed","nonrandomized_study","Erly B","2026","Escalate or Switch? Treating the Post-Titration GLP-1 Non-Responder: A Target Trial Emulation With Dose-Equivalence Reclassification","medRxiv","openRxiv","10.64898/2026.07.14.26357491","https://doi.org/10.64898/2026.07.14.26357491",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/07/16/2026.07.14.26357491.full.pdf",null],["4","R0010454","R0010454.pdf","free_to_read","nonrandomized_study","Nowak K","2026","Cardiometabolic Profiles and Treatment Trajectories of GLP-1 Receptor Agonist Users With Obstructive Sleep Apnea: Real-World Evidence From a Large Private Healthcare Cohort in Poland.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70644","https://doi.org/10.1111/dom.70644","41804236","https://pubmed.ncbi.nlm.nih.gov/41804236/","https://ruj.uj.edu.pl/handle/item/572353",null],["4","R0010563","R0010563.pdf","open_download_failed","nonrandomized_study","Van Laren J","2026","Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70579","https://doi.org/10.1111/dom.70579","41713959","https://pubmed.ncbi.nlm.nih.gov/41713959/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70579",null],["4","R0011174","R0011174.pdf","free_to_read","nonrandomized_study","Matson R","2026","Semaglutide Use Linked to Lower COVID-19 and Influenza Severity with Better Cardiovascular, Pulmonary, Renal Outcomes After Pandemic or Seasonal Infection","Preprints.org","MDPI AG","10.20944/preprints202606.0635.v1","https://doi.org/10.20944/preprints202606.0635.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0635.v1",null],["4","R0011258","R0011258.pdf","free_to_read","nonrandomized_study","Pradeep A","2026","Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation.","Transplantation proceedings","Elsevier BV","10.1016/j.transproceed.2026.05.018","https://doi.org/10.1016/j.transproceed.2026.05.018","42259739","https://pubmed.ncbi.nlm.nih.gov/42259739/","https://doi.org/10.2139/ssrn.5900630",null],["4","R0011359","R0011359.pdf","open_download_failed","nonrandomized_study","Mason AC","2026","WITHDRAWN: Using genetics to aid detection of adverse drug effects: a Mendelian randomisation analysis of genetically proxied GLP-1RA in 1,020,464 participants across three population-based cohorts","medRxiv","openRxiv","10.64898/2026.05.22.26353860","https://doi.org/10.64898/2026.05.22.26353860",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/05/24/2026.05.22.26353860.full.pdf",null],["4","R0011483","R0011483.pdf","free_to_read","nonrandomized_study","Sehgal NKR","2026","Self-Reported Side Effects Among Reddit Users Taking Nonapproved Retatrutide","medRxiv","openRxiv","10.64898/2026.05.28.26352819","https://doi.org/10.64898/2026.05.28.26352819",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.05.28.26352819",null],["4","R0011569","R0011569.pdf","free_to_read","nonrandomized_study","Coulman K","2026","Mapping Models of Tirzepatide Delivery for Obesity Management in Primary Care Settings","medRxiv","openRxiv","10.64898/2026.07.24.26358784","https://doi.org/10.64898/2026.07.24.26358784",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.07.24.26358784",null],["4","R0011682","R0011682.pdf","free_to_read","nonrandomized_study","Kuo NI","2026","Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2025.09.012","https://doi.org/10.1016/j.hlc.2025.09.012","41667347","https://pubmed.ncbi.nlm.nih.gov/41667347/","https://doi.org/10.1016/j.hlc.2025.09.012",null],["4","R0011950","R0011950.pdf","free_to_read","nonrandomized_study","Wutke-Ostręga J","2026","Eradicating hyperandrogenism? Hormonal changes following Helicobacter pylori eradication in women with polycystic ovary syndrome: an observational case series.","Endokrynologia Polska","VM Media Group sp. z o.o","10.5603/ep.110428","https://doi.org/10.5603/ep.110428","42053337","https://pubmed.ncbi.nlm.nih.gov/42053337/","https://doi.org/10.5603/ep.110428",null],["4","R0012132","R0012132.pdf","open_download_failed","nonrandomized_study","Chen HY","2026","Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.","medRxiv : the preprint server for health sciences","openRxiv","10.64898/2026.01.06.26343548","https://doi.org/10.64898/2026.01.06.26343548","41542680","https://pubmed.ncbi.nlm.nih.gov/41542680/","https://www.medrxiv.org/content/medrxiv/early/2026/01/08/2026.01.06.26343548.full.pdf",null],["4","R0012627","R0012627.pdf","free_to_read","nonrandomized_study","Wang Y","2026","Treatment of type 2 diabetes among medicare beneficiaries with and without alzheimer's disease: A retrospective cohort study.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-025-01838-8","https://doi.org/10.1007/s40200-025-01838-8","41510365","https://pubmed.ncbi.nlm.nih.gov/41510365/","https://pubmed.ncbi.nlm.nih.gov/41510365/",null],["4","R0012782","R0012782.pdf","open_download_failed","nonrandomized_study","Brancato D","2026","Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2026.109419","https://doi.org/10.1016/j.jdiacomp.2026.109419","42805130","https://pubmed.ncbi.nlm.nih.gov/42805130/","https://www.sciencedirect.com/science/article/pii/S1056872726001649/pdf",null],["4","R0012911","R0012911.pdf","open_download_failed","nonrandomized_study","Manganas K","2026","Hemoglobinopathies and diabetes mellitus: from pathophysiology to clinical practice.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113581","https://doi.org/10.1016/j.diabres.2026.113581","42785638","https://pubmed.ncbi.nlm.nih.gov/42785638/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00501-2/pdf",null],["4","R0012944","R0012944.pdf","free_to_read","nonrandomized_study","Tan X","2026","Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Diabetes therapy : research, treatment and education of diabetes and related disorders","Springer Science and Business Media LLC","10.1007/s13300-026-01919-8","https://doi.org/10.1007/s13300-026-01919-8","42753116","https://pubmed.ncbi.nlm.nih.gov/42753116/","https://doi.org/10.1007/s13300-026-01919-8",null],["4","R0012958","R0012958.pdf","no_doi","nonrandomized_study","Kearney M","2026","Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.","Irish medical journal",null,null,"https://doi.org/","42808150","https://pubmed.ncbi.nlm.nih.gov/42808150/",null,null],["4","R0012982","R0012982.pdf","open_download_failed","nonrandomized_study","Tian T","2026","Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose.","Drug testing and analysis","Wiley","10.1002/dta.70160","https://doi.org/10.1002/dta.70160","42823892","https://pubmed.ncbi.nlm.nih.gov/42823892/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dta.70160",null],["4","R0013031","R0013031.pdf","open_download_failed","nonrandomized_study","Owen EC","2026","Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study","medRxiv","openRxiv","10.64898/2026.09.08.26362528","https://doi.org/10.64898/2026.09.08.26362528",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/09/10/2026.09.08.26362528.full.pdf",null],["4","R0013095","R0013095.pdf","open_download_failed","nonrandomized_study","Jiang J","2026","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?","medRxiv","openRxiv","10.64898/2026.09.06.26362369","https://doi.org/10.64898/2026.09.06.26362369",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/09/08/2026.09.06.26362369.full.pdf",null],["4","R0013266","R0013266.pdf","free_to_read","nonrandomized_study","McGovern AJ","2026","A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-026-01647-8","https://doi.org/10.1007/s40273-026-01647-8","42503575","https://pubmed.ncbi.nlm.nih.gov/42503575/","https://doi.org/10.1007/s40273-026-01647-8",null],["4","R0013276","R0013276.pdf","open_download_failed","nonrandomized_study","Dornberger J","2026","Semaglutide for Treating Paediatric Craniopharyngioma-Related Obesity: A Multicentre Case Series.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71403","https://doi.org/10.1111/dom.71403","42806285","https://pubmed.ncbi.nlm.nih.gov/42806285/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71403",null],["4","R0013413","R0013413.pdf","open_download_failed","nonrandomized_study","Owen EC","2026","Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study","medRxiv","openRxiv","10.64898/2026.09.08.26362532","https://doi.org/10.64898/2026.09.08.26362532",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/09/11/2026.09.08.26362532.full.pdf",null],["4","R0013606","R0013606.pdf","free_to_read","nonrandomized_study","Arzuaga A","2026","A cross-regional initiative for improving type 2 diabetes mellitus care quality measurement in Spain - The Diabetes Lighthouse project.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2026.07.013","https://doi.org/10.1016/j.pcd.2026.07.013","42575755","https://pubmed.ncbi.nlm.nih.gov/42575755/","https://doi.org/10.1016/j.pcd.2026.07.013",null],["4","R0013614","R0013614.pdf","open_download_failed","nonrandomized_study","Baldassarre MPA","2026","Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71371","https://doi.org/10.1111/dom.71371","42768825","https://pubmed.ncbi.nlm.nih.gov/42768825/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71371",null],["4","R0013673","R0013673.pdf","open_download_failed","nonrandomized_study","Rescalli MB","2026","Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.","Human psychopharmacology","Wiley","10.1002/hup.70066","https://doi.org/10.1002/hup.70066","42803597","https://pubmed.ncbi.nlm.nih.gov/42803597/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hup.70066",null],["4","R0013714","R0013714.pdf","open_download_failed","nonrandomized_study","Node K","2026","Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2686052","https://doi.org/10.1080/03007995.2026.2686052","42287159","https://pubmed.ncbi.nlm.nih.gov/42287159/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2026.2686052?needAccess=true","ClinicalTrials.gov:NCT04844918"],["4","R0013724","R0013724.pdf","open_download_failed","nonrandomized_study","Wei Y","2026","Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.","Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","Informa UK Limited","10.1080/01443615.2026.2701996","https://doi.org/10.1080/01443615.2026.2701996","42495930","https://pubmed.ncbi.nlm.nih.gov/42495930/","https://www.tandfonline.com/doi/pdf/10.1080/01443615.2026.2701996?needAccess=true",null],["4","R0013743","R0013743.pdf","open_download_failed","nonrandomized_study","Đogatović K","2026","Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.","Journal of clinical medicine","MDPI AG","10.3390/jcm15124672","https://doi.org/10.3390/jcm15124672","42355840","https://pubmed.ncbi.nlm.nih.gov/42355840/","https://www.mdpi.com/2077-0383/15/12/4672/pdf?version=1781616037",null],["4","R0013834","R0013834.pdf","free_to_read","nonrandomized_study","Baker LW","2026","Contemporary management of advanced chronic kidney disease: An evidence-based review.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2025.106557","https://doi.org/10.1016/j.ejim.2025.106557","41130867","https://pubmed.ncbi.nlm.nih.gov/41130867/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12560998/pdf/nihms-2119074.pdf",null],["4","R0013878","R0013878.pdf","free_to_read","nonrandomized_study","Mendias CL","2026","<p class=\"MDPI13authornames\">Improving Erectile Function and Quality of Life in Hypogonadal Euglycemic and Diabetic Men with Refractory Erectile Dysfunction","Preprints.org","MDPI AG","10.20944/preprints202605.1580.v1","https://doi.org/10.20944/preprints202605.1580.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202605.1580.v1",null],["4","R0013922","R0013922.pdf","open_download_failed","nonrandomized_study","Zou Y","2026","Oral semaglutide for obesity: clarifying comparative evidence and real-world applicability.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2026.2721720","https://doi.org/10.1080/00325481.2026.2721720","42622205","https://pubmed.ncbi.nlm.nih.gov/42622205/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2026.2721720?needAccess=true",null],["4","R0013947","R0013947.pdf","open_download_failed","nonrandomized_study","Eun Y","2026","Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000218174","https://doi.org/10.1212/wnl.0000000000218174","42308439","https://pubmed.ncbi.nlm.nih.gov/42308439/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13278381/pdf/nihms-2162855.pdf",null],["4","R0013971","R0013971.pdf","open_download_failed","nonrandomized_study","Browne J","2026","Weight Loss in Veterans with Schizophrenia and Multimorbidity Prescribed Semaglutide: Results From a National Retrospective Cohort Study.","Schizophrenia bulletin","Oxford University Press (OUP)","10.1093/schbul/sbaf143","https://doi.org/10.1093/schbul/sbaf143","40819269","https://pubmed.ncbi.nlm.nih.gov/40819269/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13007793/pdf/nihms-2152405.pdf",null],["4","R0013980","R0013980.pdf","free_to_read","nonrandomized_study","Krausz TA","2026","Schrödinger’s mouse: human observation erases a drug-induced behavioral phenotype","bioRxiv","openRxiv","10.64898/2026.09.25.754328","https://doi.org/10.64898/2026.09.25.754328",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0014014","R0014014.pdf","open_download_failed","nonrandomized_study","Ma L","2026","Strengthening Reproducibility and Interpretability in FAERS Analysis through Drug Standardization, Event Harmonization, and Exposure Normalization","Authorea Preprints","Wiley","10.22541/authorea.15009958/v1","https://doi.org/10.22541/authorea.15009958/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/authorea.15009958/v1",null],["4","R0014017","R0014017.pdf","free_to_read","nonrandomized_study","Gull U","2026","Comment on: risk factors associated with prediabetes-to-diabetes conversion in a majority-minority county: a real-world analysis.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-026-02056-6","https://doi.org/10.1007/s40200-026-02056-6","42656620","https://pubmed.ncbi.nlm.nih.gov/42656620/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13507009/",null],["4","R0014031","R0014031.pdf","open_download_failed","nonrandomized_study","Lünswilken P","2026","Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag350","https://doi.org/10.1210/clinem/dgag350","42657770","https://pubmed.ncbi.nlm.nih.gov/42657770/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag350/70818330/dgag350.pdf",null],["4","R0014059","R0014059.pdf","open_download_failed","nonrandomized_study","Ticho AL","2026","A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2026.05.019","https://doi.org/10.1053/j.gastro.2026.05.019","42250890","https://pubmed.ncbi.nlm.nih.gov/42250890/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13325417/pdf/nihms-2184198.pdf",null],["4","R0014090","R0014090.pdf","free_to_read","nonrandomized_study","Yamazaki H","2026","Structural determinants of beta-cell failure in type 2 diabetes: a multimodality imaging study.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2026.156631","https://doi.org/10.1016/j.metabol.2026.156631","42134453","https://pubmed.ncbi.nlm.nih.gov/42134453/","https://doi.org/10.1016/j.metabol.2026.156631",null],["4","R0014194","R0014194.pdf","open_download_failed","nonrandomized_study","Ullah Z","2026","A Retrospective Study Evaluating the Efficacy and Safety of Oral Semaglutide Compared to Injectables in Controlling Diabetes and Weight Reduction","Preprints.org","MDPI AG","10.20944/preprints202604.0987.v1","https://doi.org/10.20944/preprints202604.0987.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/5d72c67bbc59b44816f6e01608438219/download_pub",null],["4","R0014213","R0014213.pdf","free_to_read","nonrandomized_study","Ahmed Z","2026","Semaglutide Exposure and Risk of Oral Mucositis, Systemic Complications, and Mortality After Hematopoietic Stem-Cell Transplantation: A Propensity-Matched Found Data Analysis","Preprints.org","MDPI AG","10.20944/preprints202610.0332.v1","https://doi.org/10.20944/preprints202610.0332.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202610.0332.v1",null],["4","R0014312","R0014312.pdf","open_download_failed","nonrandomized_study","Rasmussen L","2026","Geographical variation in the use of glucose-lowering drugs in type-2 diabetes in Denmark: A nationwide drug utilization study.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70343","https://doi.org/10.1002/bcp.70343","41297971","https://pubmed.ncbi.nlm.nih.gov/41297971/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70343",null],["4","R0014584","R0014584.pdf","open_download_failed","nonrandomized_study","Mottalib MM","2026","Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.","Pediatric obesity","Wiley","10.1111/ijpo.70089","https://doi.org/10.1111/ijpo.70089","41679912","https://pubmed.ncbi.nlm.nih.gov/41679912/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13450681/pdf/nihms-2200490.pdf",null],["4","R0014603","R0014603.pdf","open_download_failed","nonrandomized_study","Tran TH","2026","Real-World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71355","https://doi.org/10.1111/dom.71355","42736030","https://pubmed.ncbi.nlm.nih.gov/42736030/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71355",null],["4","R0014617","R0014617.pdf","open_download_failed","nonrandomized_study","Levi J","2026","How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70241","https://doi.org/10.1002/oby.70241","42437874","https://pubmed.ncbi.nlm.nih.gov/42437874/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13422654/pdf/OBY-34-1545.pdf",null],["4","R0014759","R0014759.pdf","free_to_read","nonrandomized_study","Blanco Anesto J","2026","[Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity].","Nutricion hospitalaria","ARAN Ediciones","10.20960/nh.06592","https://doi.org/10.20960/nh.06592","42037504","https://pubmed.ncbi.nlm.nih.gov/42037504/","https://doi.org/10.20960/nh.06592",null],["4","R0014835","R0014835.pdf","free_to_read","nonrandomized_study","Kalra S","2026","Semaglutide: Real World Results, Realistic Recommendations.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.26-42","https://doi.org/10.47391/jpma.26-42","42261005","https://pubmed.ncbi.nlm.nih.gov/42261005/","https://doi.org/10.47391/jpma.26-42",null],["4","R0014848","R0014848.pdf","open_download_failed","nonrandomized_study","Iwasaki Y","2026","Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.113072","https://doi.org/10.1016/j.diabres.2025.113072","41448390","https://pubmed.ncbi.nlm.nih.gov/41448390/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)01087-3/pdf",null],["4","R0014869","R0014869.pdf","free_to_read","nonrandomized_study","Zusi C","2026","GLP1R haplotypes are associated with insulin secretion and sensitivity in children and adolescents with obesity.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag283","https://doi.org/10.1210/clinem/dgag283","42464735","https://pubmed.ncbi.nlm.nih.gov/42464735/","https://doi.org/10.1210/clinem/dgag283",null],["4","R0015026","R0015026.pdf","free_to_read","nonrandomized_study","Marwaha A","2026","Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication","Preprints.org","MDPI AG","10.20944/preprints202609.2396.v1","https://doi.org/10.20944/preprints202609.2396.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202609.2396.v1",null],["4","R0015142","R0015142.pdf","open_download_failed","nonrandomized_study","Levi J","2026","How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent Expiry","medRxiv","openRxiv","10.64898/2026.03.04.26347508","https://doi.org/10.64898/2026.03.04.26347508",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/03/04/2026.03.04.26347508.full.pdf",null],["4","R0015254","R0015254.pdf","open_download_failed","nonrandomized_study","Piccione A","2026","Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2025.104462","https://doi.org/10.1016/j.numecd.2025.104462","41475990","https://pubmed.ncbi.nlm.nih.gov/41475990/","https://www.nmcd-journal.com/article/S0939-4753(25)00617-9/pdf",null],["4","R0015270","R0015270.pdf","open_download_failed","nonrandomized_study","Kishimori T","2026","Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70433","https://doi.org/10.1111/dom.70433","41492180","https://pubmed.ncbi.nlm.nih.gov/41492180/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70433",null],["4","R0015291","R0015291.pdf","free_to_read","nonrandomized_study","Venkatakrishnan A","2026","Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns","medRxiv","openRxiv","10.64898/2026.04.14.26350891","https://doi.org/10.64898/2026.04.14.26350891",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0015444","R0015444.pdf","free_to_read","nonrandomized_study","Shetty S","2026","Role of Liraglutide in Weight Management and Reproductive Health in Women with Obesity and PMOS- A Critical Review of the Evidence","F1000Res","F1000 Research Ltd","10.12688/f1000research.167998.3","https://doi.org/10.12688/f1000research.167998.3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12688/f1000research.167998.3",null],["4","R0015543","R0015543.pdf","free_to_read","nonrandomized_study","Arora P","2026","Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.","Expert review of pharmacoeconomics & outcomes research","Informa UK Limited","10.1080/14737167.2025.2610206","https://doi.org/10.1080/14737167.2025.2610206","41524543","https://pubmed.ncbi.nlm.nih.gov/41524543/","https://doi.org/10.1080/14737167.2025.2610206",null],["4","R0015930","R0015930.pdf","free_to_read","nonrandomized_study","Lit VF","2026","On target? Cardiovascular risk factor patterns in type 1 and type 2 diabetes: real-world attainment of cardiovascular risk factor targets and medication prescriptions.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113440","https://doi.org/10.1016/j.diabres.2026.113440","42448043","https://pubmed.ncbi.nlm.nih.gov/42448043/","https://doi.org/10.1016/j.diabres.2026.113440",null],["4","R0016051","R0016051.pdf","free_to_read","nonrandomized_study","Talay L","2026","Engagement Phenotypes in a Real-World Tirzepatide-Based Dig-Ital Weight-Loss Program: Unsupervised Clustering of Self-Tracking, Human Coaching, and AI Conversational Support","Preprints.org","MDPI AG","10.20944/preprints202606.2106.v1","https://doi.org/10.20944/preprints202606.2106.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.2106.v1",null],["4","R0016127","R0016127.pdf","open_download_failed","nonrandomized_study","Gomes DS","2026","Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","Pulmonology","Informa UK Limited","10.1080/25310429.2026.2640663","https://doi.org/10.1080/25310429.2026.2640663","41804593","https://pubmed.ncbi.nlm.nih.gov/41804593/","https://www.tandfonline.com/doi/pdf/10.1080/25310429.2026.2640663?needAccess=true",null],["4","R0016149","R0016149.pdf","free_to_read","nonrandomized_study","Yoshida Y","2026","Baseline characteristics of patients with type 1 and type 2 diabetes in the Asahi Diabetes Complications Study (Asahi Study): a clinic-based prospective observational study.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-026-00881-x","https://doi.org/10.1007/s13340-026-00881-x","41815886","https://pubmed.ncbi.nlm.nih.gov/41815886/","https://pubmed.ncbi.nlm.nih.gov/41815886/",null],["4","R0016200","R0016200.pdf","free_to_read","nonrandomized_study","Xiong J","2026","Long-Tail Pharmacovigilance: The Semaglutide–NAION Case and a Pilot Benchmark for Language Models","Preprints.org","MDPI AG","10.20944/preprints202610.0511.v1","https://doi.org/10.20944/preprints202610.0511.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202610.0511.v1",null],["4","R0016324","R0016324.pdf","open_download_failed","nonrandomized_study","Havers-Borgersen E","2026","Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf351","https://doi.org/10.1093/eurjpc/zwaf351","40882992","https://pubmed.ncbi.nlm.nih.gov/40882992/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwaf351/64140516/zwaf351.pdf",null],["4","R0016350","R0016350.pdf","free_to_read","nonrandomized_study","Zhang Y","2026","Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2689307","https://doi.org/10.1080/03007995.2026.2689307","42312439","https://pubmed.ncbi.nlm.nih.gov/42312439/","https://doi.org/10.1080/03007995.2026.2689307",null],["4","R0016515","R0016515.pdf","open_download_failed","nonrandomized_study","Kjærgaard K","2026","Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71099","https://doi.org/10.1111/dom.71099","42443134","https://pubmed.ncbi.nlm.nih.gov/42443134/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13538804/pdf/DOM-28-8955.pdf",null],["4","R0016527","R0016527.pdf","open_download_failed","nonrandomized_study","Zhao X","2026","Hypertension Associated with the Risk of Extrahepatic Cancers in the Metabolic Dysfunction-associated Steatotic Liver Disease Population: A Multicenter Cross-sectional Study in China.","Journal of clinical and translational hepatology","Xia & He Publishing","10.14218/jcth.2025.00423","https://doi.org/10.14218/jcth.2025.00423","41970195","https://pubmed.ncbi.nlm.nih.gov/41970195/","https://publinestorage.blob.core.windows.net/journals/JCTH.2026.0(0).0.00423.Xinyue Zhao.pdf",null],["4","R0016785","R0016785.pdf","open_download_failed","nonrandomized_study","Hörtenhuber T","2026","Current diabetes therapy and use of diabetes technology in people living with cystic fibrosis-related diabetes (CFRD): Insights from the DPV network.","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","Elsevier BV","10.1016/j.jcf.2026.07.002","https://doi.org/10.1016/j.jcf.2026.07.002","42498598","https://pubmed.ncbi.nlm.nih.gov/42498598/","https://www.cysticfibrosisjournal.com/article/S1569-1993(26)01658-9/pdf",null],["4","R0016829","R0016829.pdf","free_to_read","nonrandomized_study","da Silva AMP","2026","Bibliometric analysis of global research trends on the relationship between alzheimer's disease and type 2 diabetes mellitus.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-025-01812-4","https://doi.org/10.1007/s40200-025-01812-4","41451400","https://pubmed.ncbi.nlm.nih.gov/41451400/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12728145/",null],["4","R0017238","R0017238.pdf","free_to_read","nonrandomized_study","Khan T","2026","Clinical and Cross-Domain Validation of an LLM-Guided, Literature-Based Gene Prioritization Framework","bioRxiv","openRxiv","10.64898/2026.01.22.701191","https://doi.org/10.64898/2026.01.22.701191",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64898/2026.01.22.701191",null],["4","R0017252","R0017252.pdf","open_download_failed","nonrandomized_study","Pedroso I","2026","Change in irritable bowel syndrome symptom severity among members of a multi-omic digital food-as-medicine program: a retrospective single-arm cohort study with estimates corrected for regression to the mean","medRxiv","openRxiv","10.64898/2026.10.01.26364558","https://doi.org/10.64898/2026.10.01.26364558",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/10/02/2026.10.01.26364558.full.pdf",null],["4","R0017347","R0017347.pdf","free_to_read","nonrandomized_study","Lutter M","2026","Rare coding mutations in the glucagon-like peptide-2 pathway are associated with increased risk of binge eating disorders.","Behavioural brain research","Elsevier BV","10.1016/j.bbr.2025.115940","https://doi.org/10.1016/j.bbr.2025.115940","41248737","https://pubmed.ncbi.nlm.nih.gov/41248737/","https://doi.org/10.2139/ssrn.5270250",null],["4","R0018007","R0018007.pdf","open_download_failed","nonrandomized_study","Erly B","2026","What Week 8 Knows: Forecasting Six-Month GLP-1 Outcomes","medRxiv","openRxiv","10.64898/2026.07.14.26357506","https://doi.org/10.64898/2026.07.14.26357506",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2026/07/16/2026.07.14.26357506.full.pdf",null],["4","R0018175","R0018175.pdf","free_to_read","nonrandomized_study","Giaccari A","2026","Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2026.113244","https://doi.org/10.1016/j.diabres.2026.113244","41951127","https://pubmed.ncbi.nlm.nih.gov/41951127/","https://doi.org/10.1016/j.diabres.2026.113244",null],["4","R0018432","R0018432.pdf","free_to_read","nonrandomized_study","Hoffman K","2026","Impact of Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Therapy and Nutrition Counseling on Body Composition.","The Journal of nutrition","Elsevier BV","10.1016/j.tjnut.2026.101618","https://doi.org/10.1016/j.tjnut.2026.101618","42214684","https://pubmed.ncbi.nlm.nih.gov/42214684/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13494190/",null],["4","R0018545","R0018545.pdf","free_to_read","nonrandomized_study","Gunnarsson S","2026","Cardiovascular-kidney-metabolic syndrome: prevalence, risks, disease trajectories, and early-stage management.","American journal of physiology. Cell physiology","American Physiological Society","10.1152/ajpcell.00499.2025","https://doi.org/10.1152/ajpcell.00499.2025","41269265","https://pubmed.ncbi.nlm.nih.gov/41269265/","https://doi.org/10.1152/ajpcell.00499.2025",null],["4","R0018702","R0018702.pdf","free_to_read","nonrandomized_study","Annemans L","2026","Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2026.2646079","https://doi.org/10.1080/13696998.2026.2646079","42021523","https://pubmed.ncbi.nlm.nih.gov/42021523/","https://doi.org/10.1080/13696998.2026.2646079",null],["4","R0020051","R0020051.pdf","free_to_read","nonrandomized_study","Smith LVH","2026","Implementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.","Clinical obesity","Wiley","10.1111/cob.70087","https://doi.org/10.1111/cob.70087","42235931","https://pubmed.ncbi.nlm.nih.gov/42235931/","https://doi.org/10.1111/cob.70087",null],["4","R0020490","R0020490.pdf","free_to_read","nonrandomized_study","AlTaweel M","2026","Biomarker-Defined Phenotyping Reveals Patient Heterogeneity Not Captured by a Single Physiological Reserve Score","Preprints.org","MDPI AG","10.20944/preprints202608.1744.v1","https://doi.org/10.20944/preprints202608.1744.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202608.1744.v1",null],["4","R0020653","R0020653.pdf","free_to_read","nonrandomized_study","Sun H","2026","Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study.","Eye (London, England)","Springer Science and Business Media LLC","10.1038/s41433-026-04524-y","https://doi.org/10.1038/s41433-026-04524-y","42225822","https://pubmed.ncbi.nlm.nih.gov/42225822/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13416144/",null],["4","R0020926","R0020926.pdf","free_to_read","nonrandomized_study","Cobbold JF","2026","The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.","The lancet. Gastroenterology & hepatology","Elsevier BV","10.1016/s2468-1253(26)00077-4","https://doi.org/10.1016/s2468-1253(26)00077-4","42070581","https://pubmed.ncbi.nlm.nih.gov/42070581/","https://discovery.dundee.ac.uk/en/publications/abbc09aa-8114-4aaf-8c1c-009ab9b94ee0",null],["4","R0021559","R0021559.pdf","free_to_read","nonrandomized_study","Noureddin M","2026","Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis.","JHEP reports : innovation in hepatology","Elsevier BV","10.1016/j.jhepr.2026.102018","https://doi.org/10.1016/j.jhepr.2026.102018","42705608","https://pubmed.ncbi.nlm.nih.gov/42705608/","https://doi.org/10.1016/j.jhepr.2026.102018",null],["4","R0022423","R0022423.pdf","open_download_failed","nonrandomized_study","Egsgaard S","2026","Modified case-crossover estimators were unbiased in the presence of temporal trends in the exposure of interest: a simulation study.","Journal of clinical epidemiology","Elsevier BV","10.1016/j.jclinepi.2026.112291","https://doi.org/10.1016/j.jclinepi.2026.112291","42066966","https://pubmed.ncbi.nlm.nih.gov/42066966/","https://www.jclinepi.com/article/S0895-4356(26)00166-6/pdf",null],["4","R0024836","R0024836.pdf","free_to_read","nonrandomized_study","Vidmar AP","2026","Impact of preoperative and postoperative anti-obesity medications on early postoperative body mass index reduction after sleeve gastrectomy in pediatrics.","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Elsevier BV","10.1016/j.soard.2025.10.019","https://doi.org/10.1016/j.soard.2025.10.019","41381272","https://pubmed.ncbi.nlm.nih.gov/41381272/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13491681/",null],["4","R0029268","R0029268.pdf","free_to_read","nonrandomized_study","Hansen MK","2026","Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.","JACC. Advances","Elsevier BV","10.1016/j.jacadv.2026.103311","https://doi.org/10.1016/j.jacadv.2026.103311","42858539","https://pubmed.ncbi.nlm.nih.gov/42858539/","https://doi.org/10.1016/j.jacadv.2026.103311",null],["4","R0029269","R0029269.pdf","open_download_failed","nonrandomized_study","Henney AE","2026","Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag423","https://doi.org/10.1210/clinem/dgag423","42857939","https://pubmed.ncbi.nlm.nih.gov/42857939/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag423/71836626/dgag423.pdf",null],["4","R0029279","R0029279.pdf","open_download_failed","nonrandomized_study","Qureshi S","2026","Association between Socioeconomic Deprivation and Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2026.10.001","https://doi.org/10.1016/j.amjcard.2026.10.001","42854804","https://pubmed.ncbi.nlm.nih.gov/42854804/","https://www.ajconline.org/article/S0002-9149(26)00619-3/pdf",null],["4","R0029302","R0029302.pdf","free_to_read","nonrandomized_study","Sultanov MB","2026","Long-term injectable non-insulin antidiabetic drug use and in-hospital mortality in sepsis: A nationwide analysis of the 2023 National Inpatient Sample.","Journal of critical care","Elsevier BV","10.1016/j.jcrc.2026.155767","https://doi.org/10.1016/j.jcrc.2026.155767","42849299","https://pubmed.ncbi.nlm.nih.gov/42849299/","https://doi.org/10.1016/j.jcrc.2026.155767",null],["4","R0029321","R0029321.pdf","open_download_failed","nonrandomized_study","Zhang S","2026","Association of GLP1-Receptor Agonist Use With Frailty and Falls in Adults With Type 2 Diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71377","https://doi.org/10.1111/dom.71377","42844025","https://pubmed.ncbi.nlm.nih.gov/42844025/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71377",null],["4","R0029325","R0029325.pdf","free_to_read","nonrandomized_study","Sehtman-Shachar DR","2026","Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71402","https://doi.org/10.1111/dom.71402","42842950","https://pubmed.ncbi.nlm.nih.gov/42842950/","https://doi.org/10.1111/dom.71402",null],["4","R0029350","R0029350.pdf","open_download_failed","nonrandomized_study","Gargiulo P","2026","Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry.","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2026.107183","https://doi.org/10.1016/j.ejim.2026.107183","42833986","https://pubmed.ncbi.nlm.nih.gov/42833986/","https://www.ejinme.com/article/S0953-6205(26)00488-7/pdf",null],["4","R0029373","R0029373.pdf","open_download_failed","nonrandomized_study","Pugliese N","2026","Applicability of Non-Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.70882","https://doi.org/10.1111/liv.70882","42764643","https://pubmed.ncbi.nlm.nih.gov/42764643/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.70882",null],["4","R0029394","R0029394.pdf","free_to_read","nonrandomized_study","Owczarczyk-Durma AC","2026","A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies.","Nutrients","MDPI AG","10.3390/nu18162602","https://doi.org/10.3390/nu18162602","42654182","https://pubmed.ncbi.nlm.nih.gov/42654182/","https://doi.org/10.3390/nu18162602",null],["4","R0029395","R0029395.pdf","open_download_failed","nonrandomized_study","Chen H","2026","From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70263","https://doi.org/10.1002/oby.70263","42644855","https://pubmed.ncbi.nlm.nih.gov/42644855/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.70263",null],["4","R0029400","R0029400.pdf","free_to_read","nonrandomized_study","Almahmeed W","2026","Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70204","https://doi.org/10.1111/obr.70204","42634097","https://pubmed.ncbi.nlm.nih.gov/42634097/","https://doi.org/10.1111/obr.70204",null],["4","R0029419","R0029419.pdf","free_to_read","nonrandomized_study","Demarie I","2026","Challenges implementing treatment guidelines in electronic health records: the American Diabetes Association Standards of Care as a case example.","JAMIA open","Oxford University Press (OUP)","10.1093/jamiaopen/ooag141","https://doi.org/10.1093/jamiaopen/ooag141","42519594","https://pubmed.ncbi.nlm.nih.gov/42519594/","https://doi.org/10.1093/jamiaopen/ooag141",null],["4","R0029421","R0029421.pdf","free_to_read","nonrandomized_study","Oletu H","2026","Glucagon-Like Peptide-Based Therapy and Limb Outcomes in Patients With Peripheral Artery Disease and Diabetes: A Large-Scale Real-World Study.","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.105399","https://doi.org/10.1016/j.jscai.2026.105399","42502338","https://pubmed.ncbi.nlm.nih.gov/42502338/","https://doi.org/10.1016/j.jscai.2026.105399",null],["4","R0029427","R0029427.pdf","free_to_read","nonrandomized_study","Wu TT","2026","Characterization of Antidiabetic Medication Prescribing After Hospital Discharge in US Critically Ill Adults.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280261455748","https://doi.org/10.1177/10600280261455748","42438358","https://pubmed.ncbi.nlm.nih.gov/42438358/","https://doi.org/10.1177/10600280261455748",null],["4","R0029432","R0029432.pdf","free_to_read","nonrandomized_study","Seijas-Amigo J","2026","Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.","European heart journal open","Oxford University Press (OUP)","10.1093/ehjopen/oeag101","https://doi.org/10.1093/ehjopen/oeag101","42404143","https://pubmed.ncbi.nlm.nih.gov/42404143/","https://doi.org/10.1093/ehjopen/oeag101",null],["4","R0029499","R0029499.pdf","open_download_failed","nonrandomized_study","Nicze M","2026","Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.","International journal of molecular sciences","MDPI AG","10.3390/ijms27062539","https://doi.org/10.3390/ijms27062539","41898403","https://pubmed.ncbi.nlm.nih.gov/41898403/","https://www.mdpi.com/1422-0067/27/6/2539/pdf?version=1773191761",null],["4","R0029540","R0029540.pdf","free_to_read","nonrandomized_study","Minsky N","2026","Determinants of acute weight gain during regional conflict among individuals with overweight and obesity receiving targeted multidisciplinary care.","Eating and weight disorders : EWD","Springer Science and Business Media LLC","10.1007/s40519-026-01816-w","https://doi.org/10.1007/s40519-026-01816-w","41593413","https://pubmed.ncbi.nlm.nih.gov/41593413/","https://doi.org/10.1007/s40519-026-01816-w",null],["4","R0029601","R0029601.pdf","open_download_failed","nonrandomized_study","Islam RK","2026","A-MACE-Ing: A Real-World Analysis of Semaglutide's Impact on Major Adverse Cardiovascular Events (MACE) in Patients With Hidradenitis Suppurativa.","International journal of dermatology","Wiley","10.1111/ijd.17910","https://doi.org/10.1111/ijd.17910","40928108","https://pubmed.ncbi.nlm.nih.gov/40928108/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijd.17910",null],["4","R0029929","R0029929.pdf","free_to_read","nonrandomized_study","Lauck KC","2026","Alopecia after glucagon-like peptide-1 agonist therapy: A TriNetX Database active comparator retrospective cohort study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2026.03.015","https://doi.org/10.1016/j.jaad.2026.03.015","41825835","https://pubmed.ncbi.nlm.nih.gov/41825835/","https://doi.org/10.1016/j.jaad.2026.03.015",null],["4","R0032726","R0032726.pdf","free_to_read","nonrandomized_study","Kathal Sab H","2026","IMPACT OF GUT-BRAIN-AXIS MODULATION IN PARKINSON'S DISEASE-A LITERATURE REVIEW","EPRA International Journal of Multidisciplinary Research (IJMR)","EPRA JOURNALS","10.36713/epra25604","https://doi.org/10.36713/epra25604",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36713/epra25604",null],["4","R0032754","R0032754.pdf","free_to_read","nonrandomized_study","Sayema Afroz","2026","Impact of GLP-1 Receptor Agonists on Cardiorenal Outcomes in Obese Patients with Type 2 Diabetes and Stage 3 CKD","International Academic Research Journal of Internal Medicine and Public Health","International Academic and Research Consortium","10.47310/iarjimph.2026.v07i01.001","https://doi.org/10.47310/iarjimph.2026.v07i01.001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47310/iarjimph.2026.v07i01.001",null],["4","R0032837","R0032837.pdf","free_to_read","nonrandomized_study","Ana Beatriz Spreafico Montes Pereira","2026","Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas","Revista fisio&terapia.","Revista ft Ltda","10.69849/t91t7306","https://doi.org/10.69849/t91t7306",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69849/t91t7306",null],["4","R0032843","R0032843.pdf","free_to_read","nonrandomized_study",null,"2026","Liraglutide for adults living with obesity","Kazan medical journal","ECO-Vector LLC (Publications)","10.17816/kmj701450","https://doi.org/10.17816/kmj701450",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17816/kmj701450",null],["4","R0033175","R0033175.pdf","free_to_read","nonrandomized_study","Yan-Hui Shi","2026","Glycemic status, adiposity indices and cardiovascular risk in chronic kidney disease: Core findings from a nationwide cohort study","World Journal of Diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.117740","https://doi.org/10.4239/wjd.117740",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4239/wjd.117740",null],["4","R0033405","R0033405.pdf","free_to_read","nonrandomized_study","A.D. Arsyutov","2026","Nonarthritic anterior ischemic optic neuropathy in patients receiving semaglutide: myth or reality? (literature review)","Russian Journal of Clinical Ophthalmology","LLC Russian Medical Journal","10.32364/2311-7729-2026-26-2-11","https://doi.org/10.32364/2311-7729-2026-26-2-11",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.32364/2311-7729-2026-26-2-11",null],["4","R0034200","R0034200.pdf","free_to_read","nonrandomized_study","Yan-Zhi Zheng","2026","Metabolic and microbiota mechanisms in high-fat diet-induced obesity: insights from global research trends with clinical relevance","International Journal of Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000004597","https://doi.org/10.1097/js9.0000000000004597",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/js9.0000000000004597",null],["4","R0034234","R0034234.pdf","free_to_read","nonrandomized_study","Issa Kawalit","2026","Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study","Medical Research Archives","Knowledge Enterprise Journals","10.18103/mra.2026.0406","https://doi.org/10.18103/mra.2026.0406",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18103/mra.2026.0406",null],["4","R0034263","R0034263.pdf","free_to_read","nonrandomized_study","Devvrat Yadav","2026","Changes in esophageal physiology following weight loss interventions: a narrative review","Annals of Esophagus","AME Publishing Company","10.21037/aoe-2026-1-0006","https://doi.org/10.21037/aoe-2026-1-0006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21037/aoe-2026-1-0006",null],["4","R0034799","R0034799.pdf","free_to_read","nonrandomized_study","Ali Awad","2026","D-22 | Colchicine Reduces Cardiac Arrest and Repeat Revascularization in Post PCI Patients Without GLP1 Receptor Agonist Therapy: A Large Real World Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104891","https://doi.org/10.1016/j.jscai.2026.104891",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104891",null],["4","R0034860","R0034860.pdf","no_doi","nonrandomized_study","Kateřina Horbowyjová","2026","Effectiveness and patient experiences in obesity treatment using incretin analogues","Digital Repository (National Repository of Grey Literature)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035670","R0035670.pdf","free_to_read","nonrandomized_study","Abdul-Rahaman Adedolapo Ottun","2026","A-118 | Glucagon-Like Peptide-1 Receptor Agonists and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction and Mitral Regurgitation: A Real-World Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104609","https://doi.org/10.1016/j.jscai.2026.104609",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104609",null],["4","R0035793","R0035793.pdf","free_to_read","nonrandomized_study","Nikolinka Koleva","2026","AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY","Journal of IMAB - Annual Proceeding (Scientific Papers)","Peytchinski Publishing Ltd.","10.5272/jimab.2026322.6901","https://doi.org/10.5272/jimab.2026322.6901",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5272/jimab.2026322.6901",null],["4","R0035917","R0035917.pdf","no_doi","nonrandomized_study","Sara Marroquin","2026","Abstract: Perioperative Anesthetic Outcomes and Holding Practices in Patients Using GLP-1 Receptor Agonists: A Retrospective Cohort Study.","PubMed",null,null,"https://doi.org/","42525985","https://pubmed.ncbi.nlm.nih.gov/42525985/",null,null],["4","R0036011","R0036011.pdf","free_to_read","nonrandomized_study","Hafizan Yusuf","2026","TARGET TRIAL EMULATION FOR COMPARATIVE SAFETY OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST USE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN REAL-WORLD CLINICAL PRACTICE",null,"University of Rhode Island","10.23860/thesis-2699","https://doi.org/10.23860/thesis-2699",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.23860/thesis-2699",null],["4","R0036037","R0036037.pdf","free_to_read","nonrandomized_study","Camilo Fernández Bravo","2026","Differential Gastrointestinal Tolerability, Motility Effects, and Nutrient Absorption Profiles Among GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Adults With Type 2 Diabetes: A Multidimensional Comparative Pharmacovigilance and Real-World Outcomes Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6225119","https://doi.org/10.2139/ssrn.6225119",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6225119",null],["4","R0036124","R0036124.pdf","free_to_read","nonrandomized_study","Yu-Hong Zhan","2026","Letter to the Editor: Serum bile acid profiling for diabetic gastrointestinal neuropathy: Promise and pitfalls","World Journal of Diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.117130","https://doi.org/10.4239/wjd.117130",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4239/wjd.117130",null],["4","R0036159","R0036159.pdf","no_doi","nonrandomized_study","Annie Pham","2026","Framställningen av semaglutid på sociala medier och dess implikationer för klinisk praxis","DiVA (Linnaeus University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036192","R0036192.pdf","no_doi","nonrandomized_study","Shefali Waghray","2026","GLP-1 Receptor Agonists in Obstructive Sleep Apnea: Association with Fractures, Bone Health, and Clinical Outcomes in a Propensity-Matched Cohort","Rowan Digitals Works (Rowan University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036418","R0036418.pdf","no_doi","nonrandomized_study","Valentin","2026","Real-World GLP-1RA Treatment Response Study — All of Us Research Program","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036419","R0036419.pdf","no_doi","nonrandomized_study","Kristi Griffiths","2026","Community Survey of Ozempic, Wegovy, Trulicity, Mounjaro and other GLP-1 Agonist Use","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036429","R0036429.pdf","no_doi","nonrandomized_study","Sarah Pearce","2026","Diet quality among adults utilising injectable incretin-mimetic medications for weight loss in the United Kingdom","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036452","R0036452.pdf","no_doi","nonrandomized_study","Kristie Kay Roberts","2026","Real-World Outcomes of Bariatric Surgery and Adjunctive Setmelanotide in Genetic Obesity","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036461","R0036461.pdf","free_to_read","nonrandomized_study","Yao-Jen Chang","2026","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Fracture Risk in Type 2 Diabetes: A Large-Scale Target Trial Emulation","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6031396","https://doi.org/10.2139/ssrn.6031396",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6031396",null],["4","R0037088","R0037088.pdf","free_to_read","nonrandomized_study","Federico Perna","2026","Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study","Alimentary Pharmacology & Therapeutics","Wiley","10.1111/apt.70714","https://doi.org/10.1111/apt.70714","42101069","https://pubmed.ncbi.nlm.nih.gov/42101069/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13356305/",null],["4","R0037222","R0037222.pdf","free_to_read","nonrandomized_study","Salah Abusnana","2026","Cardiovascular Outcome in T2D Patients: A Real World Evidence Study of the Effectiveness of SGLT2 Inhibitors and GLP1-RA","Ibnosina Journal of Medicine and Biomedical Sciences","Thieme Medical and Scientific Publishers Pvt. Ltd.","10.1055/s-0046-1820059","https://doi.org/10.1055/s-0046-1820059",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0046-1820059",null],["4","R0037271","R0037271.pdf","free_to_read","nonrandomized_study","Jinping Li","2026","Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics","World Journal of Gastrointestinal Surgery","Baishideng Publishing Group Inc.","10.4240/wjgs.118659","https://doi.org/10.4240/wjgs.118659",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4240/wjgs.118659",null],["4","R0037272","R0037272.pdf","free_to_read","nonrandomized_study","M Sestayo Fernandez","2026","Current control of patient body composition after a contemporary cardiac rehabilitation program: the ReCardio registry","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.273","https://doi.org/10.1093/eurjpc/zwag249.273",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.273",null],["4","R0037308","R0037308.pdf","free_to_read","nonrandomized_study","Philippe Gaulin","2026","Poster Session I - A159 IMPACT OF GLP-1 RECEPTOR AGONISTS ON BOWEL PREPARATION QUALITY IN PATIENTS UNDERGOING ELECTIVE COLONOSCOPY","Journal of the Canadian Association of Gastroenterology","Oxford University Press (OUP)","10.1093/jcag/gwaf042.159","https://doi.org/10.1093/jcag/gwaf042.159",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/jcag/gwaf042.159",null],["4","R0037474","R0037474.pdf","free_to_read","nonrandomized_study","S Quan","2026","Poster Session I - A100 IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE QUALITY OF BOWEL PREPARATION IN SCREENING COLONOSCOPIES","Journal of the Canadian Association of Gastroenterology","Oxford University Press (OUP)","10.1093/jcag/gwaf042.100","https://doi.org/10.1093/jcag/gwaf042.100",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/jcag/gwaf042.100",null],["4","R0037532","R0037532.pdf","free_to_read","nonrandomized_study","Li-Hsiu Tai","2026","Association between GLP-1 receptor agonist use and risk of pneumonia and pyothorax in type 2 diabetes: a retrospective cohort study","BMC Infectious Diseases","Springer Science and Business Media LLC","10.1186/s12879-026-14234-1","https://doi.org/10.1186/s12879-026-14234-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12879-026-14234-1",null],["4","R0037537","R0037537.pdf","free_to_read","nonrandomized_study",null,"2026","Erratum","The Medical Journal of Australia","Wiley","10.5694/mja2.70163","https://doi.org/10.5694/mja2.70163","41845954","https://pubmed.ncbi.nlm.nih.gov/41845954/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13169104/",null],["4","R0037785","R0037785.pdf","free_to_read","nonrandomized_study","Darshit Jain","2026","Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7040941","https://doi.org/10.2139/ssrn.7040941",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7040941",null],["4","R0037893","R0037893.pdf","free_to_read","nonrandomized_study","Anurag Mittal","2026","Musculoskeletal Effects of GLP-1 Receptor Agonists in Patients Undergoing Pharmacologic Weight Reduction: A Retrospective Analysis of Bone Density and Sarcopenia in Orthopaedic Practice","JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","JCDR Research and Publications","10.7860/jcdr/2026/89282.23745","https://doi.org/10.7860/jcdr/2026/89282.23745",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.7860/jcdr/2026/89282.23745",null],["4","R0038115","R0038115.pdf","free_to_read","nonrandomized_study","Christie Hilton","2026","238P Association of GLP-1 receptor agonist use before diagnosis with breast cancer outcomes in a large real-world cohort","ESMO Open","Elsevier BV","10.1016/j.esmoop.2026.107192","https://doi.org/10.1016/j.esmoop.2026.107192",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.esmoop.2026.107192",null],["4","R0038174","R0038174.pdf","free_to_read","nonrandomized_study","Arvid Engström","2026","Beyond glycaemic control : SGLT2 inhibitors and GLP-1 receptor agonists in the cardiovascular-kidney-metabolic syndrome",null,"Karolinska Institutet","10.69622/31819498.v1","https://doi.org/10.69622/31819498.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69622/31819498.v1",null],["4","R0038527","R0038527.pdf","no_doi","nonrandomized_study","Dong Anthony R.","2026","Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038634","R0038634.pdf","free_to_read","nonrandomized_study","Yuanbin Wu","2026","Integrated Pancreatic and Biliary Safety Signals of GLP-1RAs: A Real-World Pharmacovigilance Analysis Based on FAERS Database","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6246918","https://doi.org/10.2139/ssrn.6246918",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6246918",null],["4","R0038884","R0038884.pdf","free_to_read","nonrandomized_study","Edward H. Livingston","2026","Real-World Effectiveness of Tirzepatide for Obesity: The Critical Role of Treatment Persistence","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7224116","https://doi.org/10.2139/ssrn.7224116",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7224116",null],["4","R0038903","R0038903.pdf","free_to_read","nonrandomized_study","Jia-Yu Lin","2026","Letter to the Editor: Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders","World Journal of Diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.118206","https://doi.org/10.4239/wjd.118206",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4239/wjd.118206",null],["4","R0038971","R0038971.pdf","free_to_read","nonrandomized_study","Kush S. Mody","2026","Assessing the Impact of SGLT2i on Outcomes Following Hindfoot Arthrodesis: A TriNetX Analysis","Foot & Ankle Orthopaedics","SAGE Publications","10.1177/2473011426s00043","https://doi.org/10.1177/2473011426s00043",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/2473011426s00043",null],["4","R0039024","R0039024.pdf","free_to_read","nonrandomized_study","M Sestayo Fernandez","2026","Current control of diabetes after cardiac rehabilitation program: the ReCardio registry","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.279","https://doi.org/10.1093/eurjpc/zwag249.279",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.279",null],["4","R0039072","R0039072.pdf","free_to_read","nonrandomized_study","Nazif Yalçın","2026","Impact of GLP-1 Receptor Agonist Therapy on Metabolic Parameters and Cardiovascular Risk: A Real-World Study","Cukurova Anestezi ve Cerrahi Bilimler Dergisi","Cukurova Anestezi ve Cerrahi Bilimler Dergisi","10.36516/jocass.1933450","https://doi.org/10.36516/jocass.1933450",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36516/jocass.1933450",null],["4","R0039280","R0039280.pdf","free_to_read","nonrandomized_study","M R Fazio Giovanni","2026","Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.181","https://doi.org/10.1093/eurjpc/zwag249.181",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.181",null],["4","R0039412","R0039412.pdf","free_to_read","nonrandomized_study","Osman Yousafzai","2026","Cardiovascular outcomes with GLP-1 receptor agonists in patients with established coronary plaque: a propensity-matched real-world analysis","Next research.","Elsevier BV","10.1016/j.nexres.2026.102033","https://doi.org/10.1016/j.nexres.2026.102033",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nexres.2026.102033",null],["4","R0039589","R0039589.pdf","free_to_read","nonrandomized_study","Antonio Ceriello","2026","GLP-1 Receptor Agonists Discontinuation and Cardiovascular Events in Type 2 Diabetes: A Population-Based Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6567724","https://doi.org/10.2139/ssrn.6567724",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6567724",null],["4","R0039995","R0039995.pdf","no_doi","nonrandomized_study","Mackenzie Alexiuk","2026","The effects of GLP-1 RAs compared to DPP4is or SGLT2is on appendicular lean mass index (ALMI): an interim analysis.","Mspace (University of Manitoba)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040082","R0040082.pdf","no_doi","nonrandomized_study","Om Patel","2026","GLP-1 Receptor Agonists and Neurocognitive Outcomes in Type 2 Diabetes: A Propensity-Matched Real-World Analysis of Cognitive Impairment, Neurodegeneration, and Mortality","Rowan Digitals Works (Rowan University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040140","R0040140.pdf","no_doi","nonrandomized_study","Lara Haidar","2026","The impact of novel antidiabetic medications among people with HIV","Mspace (University of Manitoba)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040267","R0040267.pdf","free_to_read","nonrandomized_study","Joonyub Lee","2026","β‐cell recovery revisited: Is prediabetes remission driven by insulin sensitivity or β‐cell function?","Journal of Diabetes Investigation","Wiley","10.1111/jdi.70292","https://doi.org/10.1111/jdi.70292","41863035","https://pubmed.ncbi.nlm.nih.gov/41863035/","https://doi.org/10.1111/jdi.70292",null],["4","R0040296","R0040296.pdf","no_doi","nonrandomized_study","Kohzo Takebayashi","2026","Effect of Switching from Glucagon-like Peptide-1 Receptor Agonists to Tirzepatide in Patients with Type 2 Diabetes: A Retrospective Observational Study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041204","R0041204.pdf","no_doi","nonrandomized_study","György Miklós Buzás","2026","Az endoszkópos vizsgálatok sajátosságai inkretinkezelés alatt cukorbetegeknél és obesitas esetén = Peculiarities of endoscopic examinations during incretin therapy in diabetic and obese patients","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042231","R0042231.pdf","free_to_read","nonrandomized_study","Aryan Shokrollah Shirazi","2026","Understanding Patient Perceptions and Behavioral Intentions Toward GLP-1 Receptor Agonists for Weight Management in the United States: A Health Belief Model Approach",null,"Chapman University","10.36837/chapman.000719","https://doi.org/10.36837/chapman.000719",null,"https://pubmed.ncbi.nlm.nih.gov//","https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/44",null],["4","R0042328","R0042328.pdf","free_to_read","nonrandomized_study","Cassidy Boomsma","2026","P-226. GLP-1 Use and Outcomes in Persons with and without HIV","Open Forum Infectious Diseases","Oxford University Press (OUP)","10.1093/ofid/ofaf695.448","https://doi.org/10.1093/ofid/ofaf695.448",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ofid/ofaf695.448",null],["4","R0042397","R0042397.pdf","no_doi","nonrandomized_study","LETIZIA ROSSETTI","2026","OBESITÀ E BINGE EATING DISORDER: ASPETTI FISIOPATOLOGICI E VALUTAZIONE DELLA TERAPIA INCRETINICA Effetti della terapia combinata GLP-1/GIP sul craving alimentare e sulla composizione corporea in pazienti affetti da obesità: uno studio retrospettivo","Electronic Theses and Dissertations Repository (University of Pisa)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042579","R0042579.pdf","no_doi","nonrandomized_study","Anuj Mubayi","2026","Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042970","R0042970.pdf","no_doi","nonrandomized_study","Nathan Benmergui","2026","Analogues du GLP-1 et modification des comportements alimentaires : une rupture pour l'industrie agroalimentaire et les industries de santé ?","INRIA a CCSD electronic archive server",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043173","R0043173.pdf","free_to_read","nonrandomized_study","Royce An Abraham","2026","Effects of Oral Semaglutide on Glycemic Control, Body Mass Index, and Renal Function in Indian Patients with Type 2 Diabetes Mellitus: A Retrospective Case Series","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_37_25","https://doi.org/10.4103/ijdt.ijdt_37_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_37_25",null],["4","R0043178","R0043178.pdf","free_to_read","nonrandomized_study",null,"2026","International Journal of Diabetes and Technology","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_36_26","https://doi.org/10.4103/ijdt.ijdt_36_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_36_26",null],["4","R0043322","R0043322.pdf","free_to_read","nonrandomized_study","Shambo S. Samajdar","2026","Applying the Estimand Framework in SURPASS-CVOT: Toward Precision and Transparency in Cardiometabolic Trials","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_152_25","https://doi.org/10.4103/jod.jod_152_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_152_25",null],["4","R0043364","R0043364.pdf","free_to_read","nonrandomized_study","Chia-Ming Lin","2026","Preoperative GLP-1 receptor agonist continuation and perioperative safety after thyroidectomy in type 2 diabetes: a target trial emulation using a retrospective multicenter cohort","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02537-y","https://doi.org/10.1186/s12902-026-02537-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02537-y",null],["4","R0043389","R0043389.pdf","free_to_read","nonrandomized_study","Akshay Dhananiwala","2026","Acute coronary syndrome: Non-ST-segment elevation myocardial infarction, emerging perspective 2026","Journal of current cardiology.","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcc.jcc_27_26","https://doi.org/10.4103/jcc.jcc_27_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcc.jcc_27_26",null],["4","R0043406","R0043406.pdf","free_to_read","nonrandomized_study","M. Cecilia Lansang","2026","Trends in Diabetes Medications after Metformin in High Versus Moderate Cardiovascular Risk Patients: the BESTMED Consortium 2014-2022",null,"American Diabetes Association","10.2337/figshare.32575320.v1","https://doi.org/10.2337/figshare.32575320.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.32575320.v1",null],["4","R0043432","R0043432.pdf","free_to_read","nonrandomized_study","Jothydev Kesavadev","2026","Better the Time in Range, Longer the Time in Life","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_16_26","https://doi.org/10.4103/ijdt.ijdt_16_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_16_26",null],["4","R0043470","R0043470.pdf","free_to_read","nonrandomized_study","Amitav Banerjee","2026","Weight Loss Drugs: A Panacea for our Obesity Crisis?","Medical Journal of Dr D Y Patil Vidyapeeth","Ovid Technologies (Wolters Kluwer Health)","10.4103/mjdrdypu.mjdrdypu_1220_25","https://doi.org/10.4103/mjdrdypu.mjdrdypu_1220_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/mjdrdypu.mjdrdypu_1220_25",null],["4","R0043665","R0043665.pdf","free_to_read","nonrandomized_study","Y Shhab","2026","Atrial fibrillation reporting with semaglutide versus tirzepatide in eudravigilance: a comparative disproportionality analysis","EP Europace","Oxford University Press (OUP)","10.1093/europace/euag105.333","https://doi.org/10.1093/europace/euag105.333",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/europace/euag105.333",null],["4","R0044151","R0044151.pdf","free_to_read","nonrandomized_study","V. Todorović","2026","Semaglutide treatment effects on anxiety-like behavior and sucrose preference in a rat model of diabetes type 2","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2025.106261","https://doi.org/10.1016/j.nsa.2025.106261",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2025.106261",null],["4","R0044388","R0044388.pdf","no_doi","nonrandomized_study","Marin Bommelaer","2026","Description de l’évolution des délivrances d'antidiabétiques hors Insuline en France de 2014 à 2024 à partir des données de l’Assurance Maladie","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044516","R0044516.pdf","no_doi","nonrandomized_study","GIOVANNI PETRALLI","2026","Efficacia di semaglutide in una coorte di soggetti con diabete tipo 2 e MASLD. Studio real-life monocentrico.","Electronic Theses and Dissertations Repository (University of Pisa)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044555","R0044555.pdf","free_to_read","nonrandomized_study","Carl-Emil Lim","2026","Pharmacological treatment and risk stratification for cardiovascular disease prevention",null,"Karolinska Institutet","10.69622/32788974","https://doi.org/10.69622/32788974",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69622/32788974",null],["4","R0044576","R0044576.pdf","free_to_read","nonrandomized_study","Alaa Solaiman Algazzar","2026","Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention","Saudi Journal of Internal Medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/sjim.sjim_12_26","https://doi.org/10.4103/sjim.sjim_12_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/sjim.sjim_12_26",null],["4","R0044601","R0044601.pdf","free_to_read","nonrandomized_study","Nithin Tumkur Prasad","2026","EP1863 - LBA_ECE_1163 - Semaglutide and contraceptive efficacy: insights from FAERS and patient experiences","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1869","https://doi.org/10.1093/ejendo/lvag096.1869",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.1869",null],["4","R0044607","R0044607.pdf","free_to_read","nonrandomized_study","Lasoń, Joanna Karolina; Faculty of Medicine, Jan Kochanowski University, Kielce, Poland","2026","The ”Ozempic babies” phenomenon: a narrative review of the impact of GLP-1 receptor agonists on fertility and early pregnancy","Medical Research Journal","VM Media Group sp. z o.o","10.5603/mrj.113632","https://doi.org/10.5603/mrj.113632",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5603/mrj.113632",null],["4","R0044619","R0044619.pdf","free_to_read","nonrandomized_study","Wu Hong","2026","EP490 - ECE_1508 - Real-world comparison of the effects of loxenatide with other GLP-1RAs on renal outcomes in patients with type 2 diabetes: a subgroup analysis of the fighting-1 cohort study (fighting-3)","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.982","https://doi.org/10.1093/ejendo/lvag096.982",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.982",null],["4","R0044695","R0044695.pdf","free_to_read","nonrandomized_study","Johan Hardvik Åkerström","2026","Prevention of esophageal adenocarcinoma",null,"Karolinska Institutet","10.69622/32261475","https://doi.org/10.69622/32261475",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69622/32261475",null],["4","R0044728","R0044728.pdf","free_to_read","nonrandomized_study","Thaw Htet","2026","EP697 - ECE_2662 - Effect of Glucagon like Peptide-1 Receptor Agonist therapies on metabolic dysfunction-associated steatotic liver disease in overweight and obese adults","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1102","https://doi.org/10.1093/ejendo/lvag096.1102",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.1102",null],["4","R0044772","R0044772.pdf","free_to_read","nonrandomized_study","Wan-Ting Huang","2026","P177 - ECE_1410 - Glucagon-like peptide-1 receptor agonists vs sodium–glucose cotransporter-2 inhibitors and risk of incident asthma in patients with diabetes: a real-world cohort","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.359","https://doi.org/10.1093/ejendo/lvag096.359",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.359",null],["4","R0044775","R0044775.pdf","free_to_read","nonrandomized_study","Thaw Htet","2026","EP823 - ECE_1873 - Current literature on the use of Probiotic and prebiotic with Glucagon like peptide- 1 receptor agonist therapy in patients with Type 2 diabetes","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.1160","https://doi.org/10.1093/ejendo/lvag096.1160",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.1160",null],["4","R0044792","R0044792.pdf","free_to_read","nonrandomized_study","Kevin Sogoli","2026","Media Framing of Ozempic and Other GLP-1 Receptor Agonists in The New York Times","McMaster University Journal of Public Health","McMaster University Library","10.15173/mujph.v3i2.4071","https://doi.org/10.15173/mujph.v3i2.4071",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15173/mujph.v3i2.4071",null],["4","R0044837","R0044837.pdf","free_to_read","nonrandomized_study","Ashwin K. Chetty","2026","0057Online Prescribing of GLP-1 Receptor Agonists: A Secret Shopper Study","American Heart Journal","Elsevier BV","10.1016/j.ahj.2026.107567","https://doi.org/10.1016/j.ahj.2026.107567",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ahj.2026.107567",null],["4","R0044839","R0044839.pdf","no_doi","nonrandomized_study","Demsina Babazadeh","2026","Beyond Weight Loss: Examining the Nutritional and Physiological Impacts of GLP-1–Based Anti-Obesity Medications","eScholarship (California Digital Library)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044921","R0044921.pdf","no_doi","nonrandomized_study","C.M. Mosterd","2026","The gut-kidney axis and inflammation in type 2 diabetes patients","UvA-DARE (University of Amsterdam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044942","R0044942.pdf","free_to_read","nonrandomized_study","Ali Alshahrani","2026","Budget impact of GLP-1 and dual GIP/GLP-1 receptor agonists for obesity management in Saudi Arabia: a budget impact analysis from public and private payer perspectives","BMC Health Services Research","Springer Science and Business Media LLC","10.1186/s12913-026-15623-7","https://doi.org/10.1186/s12913-026-15623-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12913-026-15623-7",null],["4","R0045076","R0045076.pdf","free_to_read","nonrandomized_study","Ricardo E T Navarrete","2026","Real-world outcomes of SGLT2 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus: An effectiveness and safety analysis","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2026.100302","https://doi.org/10.1016/j.deman.2026.100302",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2026.100302",null],["4","R0045098","R0045098.pdf","free_to_read","nonrandomized_study","Riya Patil","2026","Comparative efficacy and safety of Dual GIP/GLP1 agonists versus GLP1 receptor agonists for weight loss: A Scoping Review","Journal of Advances in Internal Medicine","Nepal Journals Online (JOL)","10.3126/jaim.v15i1.98486","https://doi.org/10.3126/jaim.v15i1.98486",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3126/jaim.v15i1.98486",null],["4","R0045119","R0045119.pdf","free_to_read","nonrandomized_study","Muneera AlTaweel","2026","Metabolic and Renal Outcomes with Semaglutide Add-on to Dapagliflozin in Routine Clinical Practice: A Propensity-Weighted Cohort Study from Saudi Arabia","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.08.009","https://doi.org/10.1016/j.aed.2026.08.009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.aed.2026.08.009",null],["4","R0045127","R0045127.pdf","free_to_read","nonrandomized_study","Cristina-Elena Zbârcea","2026","Drug–Drug and Drug–Disease Interactions Across Antidiabetic Drug Classes: A Narrative Review and Practical Recommendations","Diabetology","MDPI AG","10.3390/diabetology7060108","https://doi.org/10.3390/diabetology7060108",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7060108",null],["4","R0045474","R0045474.pdf","free_to_read","nonrandomized_study","Ayodeji Ilelaboye","2026","D-68 | Comparative Cardiovascular Outcomes of Tirzepatide vs Semaglutide After PCI in Type 2 Diabetes: A Real-World Propensity-Matched Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104936","https://doi.org/10.1016/j.jscai.2026.104936",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104936",null],["4","R0045491","R0045491.pdf","no_doi","nonrandomized_study","A.M. Patti","2026","Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight or obesity","Nova Science Publishers (Nova Science Publishers, Inc.)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045517","R0045517.pdf","free_to_read","nonrandomized_study","Hailong Li","2026","Integrative multi-omics analysis reveals GLP-1R agonists-driven proteins via Notch signaling as mediators of ulcerative colitis risk","Genes & Diseases","Elsevier BV","10.1016/j.gendis.2026.102070","https://doi.org/10.1016/j.gendis.2026.102070",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.gendis.2026.102070",null],["4","R0045618","R0045618.pdf","free_to_read","nonrandomized_study","Monica Verdoia","2026","Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus","Diabetology","MDPI AG","10.3390/diabetology7080154","https://doi.org/10.3390/diabetology7080154",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7080154",null],["4","R0045634","R0045634.pdf","free_to_read","nonrandomized_study","Ayodeji Ilelaboye","2026","A-98 | Comparative Cardiovascular Outcomes of Tirzepatide Versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Propensity-Matched Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104589","https://doi.org/10.1016/j.jscai.2026.104589",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104589",null],["4","R0045652","R0045652.pdf","no_doi","nonrandomized_study","Amira Guirguis","2026","Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045770","R0045770.pdf","free_to_read","nonrandomized_study","Raslina Shrestha","2026","Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa: A Study Using the NIH All of Us Research Program",null,"American Diabetes Association","10.2337/figshare.32189892.v1","https://doi.org/10.2337/figshare.32189892.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.32189892.v1",null],["4","R0045786","R0045786.pdf","free_to_read","nonrandomized_study","Anastasios Mavridis","2026","ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE","European Stroke Journal","Oxford University Press (OUP)","10.1093/esj/aakag023.016","https://doi.org/10.1093/esj/aakag023.016",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/esj/aakag023.016",null],["4","R0045833","R0045833.pdf","free_to_read","nonrandomized_study","Hugo You‐Hsien Lin","2026","Combined Keto-Analogues and Incretin-Based Therapies and Mortality and Inflammation in Chronic Kidney Disease: A Propensity Score–Matched Federated Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6808734","https://doi.org/10.2139/ssrn.6808734",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6808734",null],["4","R0045969","R0045969.pdf","free_to_read","nonrandomized_study","Ayodeji Ilelaboye","2026","OR1-6 | Impact of Tirzepatide on Post-PCI Outcomes in Patients With Diabetes Mellitus: Insights From a Real-World Propensity-Matched Cohort","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104409","https://doi.org/10.1016/j.jscai.2026.104409",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104409",null],["4","R0045985","R0045985.pdf","free_to_read","nonrandomized_study","Shiuan-Chih Chen","2026","Proteomic CKD Prediction in Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000991","https://doi.org/10.1681/asn.0000000991","41563362","https://pubmed.ncbi.nlm.nih.gov/41563362/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13241276/",null],["4","R0046053","R0046053.pdf","free_to_read","nonrandomized_study","Jheng-Yan Wu","2026","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of incident infection and severe infection–related outcomes in type 2 diabetes","BMC Infectious Diseases","Springer Science and Business Media LLC","10.1186/s12879-026-13982-4","https://doi.org/10.1186/s12879-026-13982-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12879-026-13982-4",null],["4","R0046113","R0046113.pdf","free_to_read","nonrandomized_study","Mor Svorai","2026","Periconception Glucagon-Like Peptide-1 Receptor Agonist Treatment and Pregnancy Outcomes in Women With Obesity Without Diabetes: A Community-Based Retrospective Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7459062","https://doi.org/10.2139/ssrn.7459062",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7459062",null],["4","R0046131","R0046131.pdf","free_to_read","nonrandomized_study","Angela T.H. Kwan","2026","Reduced Risk of Colorectal Adenomas and Polyps with GLP-1 Receptor Agonists: A Colonoscopy-Based Target Trial Emulation","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6261583","https://doi.org/10.2139/ssrn.6261583",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6261583",null],["4","R0046261","R0046261.pdf","free_to_read","nonrandomized_study","Afnan Chaudhry","2026","Long-Term Survival Benefit Of GLP-1 Receptor Agonists In Heart Transplant Recipients: A Propensity-Matched Real-World Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6709495","https://doi.org/10.2139/ssrn.6709495",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6709495",null],["4","R0046275","R0046275.pdf","free_to_read","nonrandomized_study","Sascha J. Baettig","2026","Anaesthesiologic management of patients at risk of pulmonary aspiration: a Swiss consensus statement","BMC Anesthesiology","Springer Science and Business Media LLC","10.1186/s12871-026-03835-7","https://doi.org/10.1186/s12871-026-03835-7","42002786","https://pubmed.ncbi.nlm.nih.gov/42002786/","https://doi.org/10.1186/s12871-026-03835-7",null],["4","R0046368","R0046368.pdf","free_to_read","nonrandomized_study","Reshma Venugopal","2026","Diabetic signature on Parkinson’s disease: Insights into pathophysiology and therapeutic repurposing","Annals of Movement Disorders","Ovid Technologies (Wolters Kluwer Health)","10.4103/aomd.aomd_64_25","https://doi.org/10.4103/aomd.aomd_64_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aomd.aomd_64_25",null],["4","R0046469","R0046469.pdf","free_to_read","nonrandomized_study","Amela Dizdarević-Bostandžić","2026","Metabolic consequences of semaglutide discontinuation in type 2 diabetes: a retrospective cohort study","BMJ Nutrition Prevention & Health","BMJ","10.1136/bmjnph-2026-001616","https://doi.org/10.1136/bmjnph-2026-001616",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1136/bmjnph-2026-001616",null],["4","R0046474","R0046474.pdf","free_to_read","nonrandomized_study","Vadim A. Kosolapov","2026","Modern strategies for pharmacological correction of fibrotic disorders: mechanisms of action, clinical efficacy and prospects of therapy","Journal of Volgograd State Medical University","Volgograd State Medical University","10.19163/1994-9480-2026-23-1-10-17","https://doi.org/10.19163/1994-9480-2026-23-1-10-17",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.19163/1994-9480-2026-23-1-10-17",null],["4","R0046509","R0046509.pdf","free_to_read","nonrandomized_study","Monika Rogowska","2026","SEMAGLUTIDE IN THE TREATMENT OF OBESITY- A NEW LOOK AT AN EFFECTIVE PHARMACOLOGICAL TOOL IN THE FIGHT AGAINST EXCESSIVE BODY WEIGHT","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.1(49).2026.5096","https://doi.org/10.31435/ijitss.1(49).2026.5096",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.1(49).2026.5096",null],["4","R0046510","R0046510.pdf","free_to_read","nonrandomized_study","Chloe Yu-Yan Cheung","2026","Authors' Reply: Proteomic CKD Prediction in Type 2 Diabetes: Underexplored Limitations and Translational Gaps","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000992","https://doi.org/10.1681/asn.0000000992","41563352","https://pubmed.ncbi.nlm.nih.gov/41563352/","https://pubmed.ncbi.nlm.nih.gov/41563352/",null],["4","R0046566","R0046566.pdf","free_to_read","nonrandomized_study","Yu‐Hsuan Li","2026","Cardiovascular effectiveness and musculoskeletal safety of tirzepatide, GLP-1 receptor agonists, and SGLT2 inhibitors in normal-weight adults with type 2 diabetes and established atherosclerotic cardiovascular disease: a cohort study using a federated electronic health record network","Cardiovascular Diabetology","Springer Science and Business Media LLC","10.1186/s12933-026-03361-3","https://doi.org/10.1186/s12933-026-03361-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12933-026-03361-3",null],["4","R0046685","R0046685.pdf","free_to_read","nonrandomized_study","Shanmugesh Raja","2026","Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7119918","https://doi.org/10.2139/ssrn.7119918",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7119918",null],["4","R0046692","R0046692.pdf","free_to_read","nonrandomized_study","Ayodeji Ilelaboye","2026","A-97 | Impact of GLP-1 Receptor Agonist on Outcomes After Carotid Endarterectomy in Patients with Diabetes: A Real-World Propensity-Matched Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104588","https://doi.org/10.1016/j.jscai.2026.104588",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104588",null],["4","R0046694","R0046694.pdf","free_to_read","nonrandomized_study","Abdulraheem Hassan","2026","GLP-1 Receptor Agonist Therapy and Incident Atrial Fibrillation in Non-Diabetic Adults with Obesity and Chronic Kidney Disease: A Propensity Matched Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7083106","https://doi.org/10.2139/ssrn.7083106",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7083106",null],["4","R0046710","R0046710.pdf","free_to_read","nonrandomized_study","Amir Behzad Bagheri","2026","A-110 | Long-Term Cardiovascular and Arrhythmic Benefits of GLP-1 Receptor Agonists in Anticoagulated Atrial Fibrillation Patients: A Retrospective Cohort Study","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104601","https://doi.org/10.1016/j.jscai.2026.104601",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104601",null],["4","R0046845","R0046845.pdf","free_to_read","nonrandomized_study","Amani Y. Alhalwani","2026","Investigation of GLP-1RA semaglutide and systemic inflammation index ratios in type 2 diabetes with and without retinopathy: a retrospective study","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02558-7","https://doi.org/10.1186/s12902-026-02558-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02558-7",null],["4","R0047103","R0047103.pdf","free_to_read","nonrandomized_study","J Riess","2026","Semaglutide therapy does not impede improvements in aerobic endurance or body composition during early cardiac rehabilitation","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.350","https://doi.org/10.1093/eurjpc/zwag249.350",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.350",null],["4","R0047382","R0047382.pdf","free_to_read","nonrandomized_study","Louis A Talay","2026","Peer‑to‑Peer Referral Networks and Six‑Month Outcomes in a Tirzepatide‑Supported Digital Weight‑Loss Service: A Retrospective Cohort Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.105583","https://doi.org/10.2196/preprints.105583",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.105583",null],["4","R0047432","R0047432.pdf","free_to_read","nonrandomized_study","R. Yukesh","2026","Disproportionality analysis on glucagon-like peptide-1 receptor agonists and retinal detachment: Insights from the FDA adverse event reporting system","Perspectives in Clinical Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/picr.picr_356_25","https://doi.org/10.4103/picr.picr_356_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/picr.picr_356_25",null],["4","R0047500","R0047500.pdf","free_to_read","nonrandomized_study","Chio Yokose","2026","Gout-Related Medication Use After Initiating Sodium Glucose Co-Transporter-2 Inhibitors in Patients with Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.",null,"American Diabetes Association","10.2337/figshare.30916430.v1","https://doi.org/10.2337/figshare.30916430.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30916430.v1",null],["4","R0047526","R0047526.pdf","free_to_read","nonrandomized_study","Merja Laine","2026","Prevalence of comorbidities associated with type 2 diabetes and prediabetes and a case-control analysis of the emergence of new comorbidities in 2007 - 2019","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2026.100318","https://doi.org/10.1016/j.deman.2026.100318",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2026.100318",null],["4","R0047985","R0047985.pdf","no_doi","nonrandomized_study","Ellias Hanna","2026","Preoperative GLP-1 Receptor Agonist Use and Postoperative Opioid Outcomes in Elective Surgery","IUScholarWorks (Indiana University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048142","R0048142.pdf","free_to_read","nonrandomized_study","James J. Tsakas","2026","Retrospective audit of the current anaesthetic peri–operative approach to patients prescribed semaglutide","Perioperative Care and Operating Room Management","Elsevier BV","10.1016/j.pcorm.2026.100708","https://doi.org/10.1016/j.pcorm.2026.100708",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.pcorm.2026.100708",null],["4","R0049119","R0049119.pdf","free_to_read","nonrandomized_study","Giovanni Petralli","2026","ACNMD26-123: LONG-TERM REAL-LIFE EXPERIENCE OF SEMAGLUTIDE IN A MONOCENTRIC COHORT WITH TYPE 2 DIABETES AND METABOLIC DYSFUCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)","Digestive and Liver Disease","Elsevier BV","10.1016/s1590-8658(26)00598-0","https://doi.org/10.1016/s1590-8658(26)00598-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s1590-8658(26)00598-0",null],["4","R0049453","R0049453.pdf","free_to_read","nonrandomized_study","Diamond Donaldson","2026","P-227. Impact Of GLP-1 Receptor Agonists on Body Weight in Persons with HIV Compared to Persons Without HIV","Open Forum Infectious Diseases","Oxford University Press (OUP)","10.1093/ofid/ofaf695.449","https://doi.org/10.1093/ofid/ofaf695.449",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ofid/ofaf695.449",null],["4","R0049516","R0049516.pdf","free_to_read","nonrandomized_study","Karen Schneck","2026","PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea",null,"International Society of Pharmacometrics","10.70534/nbjx4219","https://doi.org/10.70534/nbjx4219",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.70534/nbjx4219",null],["4","R0049636","R0049636.pdf","free_to_read","nonrandomized_study","M.B. Rescalli","2026","Psychotropic and metabolic benefits of GLP-1 receptor agonists in a real-world psychiatric sample: a retrospective longitudinal study","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2025.105673","https://doi.org/10.1016/j.nsa.2025.105673",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2025.105673",null],["4","R0049683","R0049683.pdf","free_to_read","nonrandomized_study","Dev Desai","2026","Glucagon-like Peptide-1 Receptor Agonists in Mental Health – Cognitive and Psychiatric Outcomes","Annals of Indian Psychiatry","Ovid Technologies (Wolters Kluwer Health)","10.4103/aip.aip_279_25","https://doi.org/10.4103/aip.aip_279_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aip.aip_279_25",null],["4","R0049827","R0049827.pdf","free_to_read","nonrandomized_study","John W. Ostrominski","2026","Comparative Effectiveness of Tirzepatide with Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target Trial Emulation Studies",null,"American Diabetes Association","10.2337/figshare.31301056.v1","https://doi.org/10.2337/figshare.31301056.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.31301056.v1",null],["4","R0049917","R0049917.pdf","free_to_read","nonrandomized_study","Tariq Chukir","2026","A single centre retrospective study of the long-term real-world body weight responses to liraglutide or bariatric surgery in adolescents with obesity","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2026.100684","https://doi.org/10.1016/j.obmed.2026.100684",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obmed.2026.100684",null],["4","R0050010","R0050010.pdf","free_to_read","nonrandomized_study","Jasmine Singh Sukumar","2026","Table 3 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors",null,"American Association for Cancer Research (AACR)","10.1158/2767-9764.31444519","https://doi.org/10.1158/2767-9764.31444519",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1158/2767-9764.31444519",null],["4","R0050058","R0050058.pdf","free_to_read","nonrandomized_study","Robert Singer","2026","Med Spas: Patient Safety and Accreditation","Aesthetic Surgery Journal","Oxford University Press (OUP)","10.1093/asj/sjag085","https://doi.org/10.1093/asj/sjag085","42028847","https://pubmed.ncbi.nlm.nih.gov/42028847/","https://doi.org/10.1093/asj/sjag085",null],["4","R0050105","R0050105.pdf","free_to_read","nonrandomized_study","Jasmine Singh Sukumar","2026","Data from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors",null,"American Association for Cancer Research (AACR)","10.1158/2767-9764.c.8332417","https://doi.org/10.1158/2767-9764.c.8332417",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1158/2767-9764.c.8332417",null],["4","R0050159","R0050159.pdf","free_to_read","nonrandomized_study","Mohamed Elshayeb","2026","Acute Interstitial Nephritis Associated with Oral Semaglutide","Kidney International Case Reports","Elsevier BV","10.1016/j.kintcr.2026.100147","https://doi.org/10.1016/j.kintcr.2026.100147",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.kintcr.2026.100147",null],["4","R0050446","R0050446.pdf","free_to_read","nonrandomized_study","Agathe Chabassier","2026","Real-World Effect of GLP-1 Receptor Agonist Initiation on Body Composition and Blood Pressure: A Distributional Causal Inference Analysis of Connected Device Data","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6246929","https://doi.org/10.2139/ssrn.6246929",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6246929",null],["4","R0050931","R0050931.pdf","no_doi","nonrandomized_study","Elen Chmelařová","2026","Effect of GLP-1 analoque on weight reduction and metabolic parameters in type 2 diabetes","Digital Repository (National Repository of Grey Literature)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051009","R0051009.pdf","free_to_read","nonrandomized_study","Ifrah Zawar","2026","Sweetening the Odds: Can Newer Glucose-Lowering Drugs Bend the Arc of Epileptogenesis?","Epiliepsy currents/Epilepsy currents","SAGE Publications","10.1177/15357597261484442","https://doi.org/10.1177/15357597261484442","42688557","https://pubmed.ncbi.nlm.nih.gov/42688557/","https://doi.org/10.1177/15357597261484442",null],["4","R0051283","R0051283.pdf","free_to_read","nonrandomized_study","Belinda Davey","2026","Digital augmentation of glucagon-like peptide-1 (GLP-1) for obesity management: A retrospective study (Preprint)","Journal of Medical Internet Research","JMIR Publications Inc.","10.2196/100728","https://doi.org/10.2196/100728",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/100728",null],["4","R0051313","R0051313.pdf","free_to_read","nonrandomized_study","Byron Chiliquinga Morales","2026","POST-KIDNEY TRANSPLANT OBESITY: TIRZEPATIDE AS AN EFFECTIVE AND SAFE OPTION IN REAL-WORLD SETTINGS","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7404805","https://doi.org/10.2139/ssrn.7404805",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7404805",null],["4","R0052162","R0052162.pdf","free_to_read","nonrandomized_study","Eugene E. Wolfel","2026","Will Evaluation of Cardiorespiratory Fitness Improve Risk Stratification of Patients With Stage B Heart Failure?","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.126.048543","https://doi.org/10.1161/jaha.126.048543","41676925","https://pubmed.ncbi.nlm.nih.gov/41676925/","https://doi.org/10.1161/jaha.126.048543",null],["4","R0052183","R0052183.pdf","free_to_read","nonrandomized_study","Stanislav Nikolaevich Kotlyarov","2026","Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026)","Pharmacoepidemiology","MDPI AG","10.3390/pharma5030025","https://doi.org/10.3390/pharma5030025",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/pharma5030025",null],["4","R0052816","R0052816.pdf","no_doi","nonrandomized_study","Joshua D. Wallach","2026","Glucagon-like peptide-1 receptor agonists versus naltrexone, acamprosate, or disulfiram for adults with type 2 diabetes and comorbid alcohol use disorder: a target trial emulation study","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0053406","R0053406.pdf","free_to_read","nonrandomized_study","Huilin Tang","2026","Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.70817","https://doi.org/10.1111/dom.70817","42119996","https://pubmed.ncbi.nlm.nih.gov/42119996/","https://doi.org/10.1111/dom.70817",null],["4","R0053456","R0053456.pdf","free_to_read","nonrandomized_study","Adrien Burel","2026","P458 - LBA_ECE_1238 - Prevalence, vascular risk factors and complications of metabolic syndrome in a population of people living with type 1 diabetes: results from the French SFDT1 cohort","European Journal of Endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvag096.576","https://doi.org/10.1093/ejendo/lvag096.576",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ejendo/lvag096.576",null],["4","R0053583","R0053583.pdf","free_to_read","nonrandomized_study","Roopesh Jain","2026","Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies","Advances in Biomedical and Health Sciences","Ovid Technologies (Wolters Kluwer Health)","10.4103/abhs.abhs_94_25","https://doi.org/10.4103/abhs.abhs_94_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/abhs.abhs_94_25",null],["4","R0053594","R0053594.pdf","free_to_read","nonrandomized_study","Dina H. Griauzde","2026","GLP‐1 RA Use and Weight Loss Among Patients in a Weight Navigation Program Versus Primary Care: A Matched Cohort Study","Obesity Science & Practice","Wiley","10.1002/osp4.70136","https://doi.org/10.1002/osp4.70136",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/osp4.70136",null],["4","R0053627","R0053627.pdf","free_to_read","nonrandomized_study","Edouard Fu","2026","WCN26-3755 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND SGLT-2I VS SGLT-2I ALONE ON KIDNEY AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2026.104756","https://doi.org/10.1016/j.ekir.2026.104756",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2026.104756",null],["4","R0053640","R0053640.pdf","free_to_read","nonrandomized_study","Jizhou Liang","2026","Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)","BMC Pharmacology and Toxicology","Springer Science and Business Media LLC","10.1186/s40360-026-01190-4","https://doi.org/10.1186/s40360-026-01190-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s40360-026-01190-4",null],["4","R0053713","R0053713.pdf","free_to_read","nonrandomized_study","Harmon Singh Khela","2026","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist Use on Short-Term and Long-Term Outcomes Following Thoracic and/or Lumbar Fusion for Spinal Deformity: A BMI-Stratified Cohort Study","Spine Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/bn9.0000000000000051","https://doi.org/10.1097/bn9.0000000000000051",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/bn9.0000000000000051",null],["4","R0053747","R0053747.pdf","free_to_read","nonrandomized_study","Daniel Edmonston","2026","0068Real-world Change in Cardiometabolic Markers After Glucagon-like Peptide-1 (GLP-1)-Based Treatment Discontinuation Among US Patients with ASCVD","American Heart Journal","Elsevier BV","10.1016/j.ahj.2026.107569","https://doi.org/10.1016/j.ahj.2026.107569",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ahj.2026.107569",null],["4","R0053764","R0053764.pdf","free_to_read","nonrandomized_study","Pamela Jeske","2026","The impact of preoperative therapy with GLP-1 receptor agonists on weight loss and metabolic effects after bariatric surgeries – single-center preliminary study","Langenbeck s Archives of Surgery","Springer Science and Business Media LLC","10.1007/s00423-026-04294-x","https://doi.org/10.1007/s00423-026-04294-x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1007/s00423-026-04294-x",null],["4","R0053791","R0053791.pdf","free_to_read","nonrandomized_study","Varun Kumar Gone","2026","GLP-1 Receptor Agonists and Sarcopenic Risk in South Asian Adults: A Perfect Storm of Phenotypic Vulnerability and Pharmacovigilance Neglect","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6862258","https://doi.org/10.2139/ssrn.6862258",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6862258",null],["4","R0053822","R0053822.pdf","free_to_read","nonrandomized_study","Archie Spindler","2026","Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms","JAAD reviews.","Elsevier BV","10.1016/j.jdrv.2026.07.002","https://doi.org/10.1016/j.jdrv.2026.07.002",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jdrv.2026.07.002",null],["4","R0053843","R0053843.pdf","free_to_read","nonrandomized_study","Nguyen Ngoc Khoi Truong","2026","Incident ocular outcomes with tirzepatide versus GLP-1 receptor agonists and conventional therapies in diabetes and obesity: a retrospective cohort study from a global federated health research network","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02299-6","https://doi.org/10.1186/s13098-026-02299-6",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02299-6",null],["4","R0053848","R0053848.pdf","no_doi","nonrandomized_study","Chantal Mathieu","2026","EndoCompass project","DiRROS repository (University of Maribor)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054099","R0054099.pdf","free_to_read","nonrandomized_study","G Tse","2026","Protein-protein interaction network construction and analysis to identify synergistic effects for sodium-glucose cotransporter-2, glucagon-like peptide-1 and mineralocorticoid receptor","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag249.433","https://doi.org/10.1093/eurjpc/zwag249.433",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurjpc/zwag249.433",null],["4","R0054139","R0054139.pdf","free_to_read","nonrandomized_study","Roopeessh Vempati","2026","A-95 | Semaglutide Versus Tirzepatide After Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus and Obesity: A Real-World Retrospective Cohort Study","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104586","https://doi.org/10.1016/j.jscai.2026.104586",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104586",null],["4","R0054466","R0054466.pdf","free_to_read","nonrandomized_study","Ibrahim Mortada","2026","C-54 | Association of Tirzepatide Use with Clinical Outcomes After TAVR in Obese Patients: A Propensity-Matched Real-World Study","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2026.104790","https://doi.org/10.1016/j.jscai.2026.104790",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2026.104790",null],["4","R0054485","R0054485.pdf","free_to_read","nonrandomized_study","YiQing Yang","2026","Early-onset type 2 diabetes and kidney disease in a growing surgical generation: insights from a global burden analysis","International Journal of Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000004822","https://doi.org/10.1097/js9.0000000000004822","41556923","https://pubmed.ncbi.nlm.nih.gov/41556923/","https://doi.org/10.1097/js9.0000000000004822",null],["4","R0054495","R0054495.pdf","free_to_read","nonrandomized_study","Ashutosh Mishra","2026","The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care","The Lancet Regional Health - Southeast Asia","Elsevier BV","10.1016/j.lansea.2026.100865","https://doi.org/10.1016/j.lansea.2026.100865",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.lansea.2026.100865",null],["4","R0054555","R0054555.pdf","free_to_read","nonrandomized_study","HENG YEH","2026","Longitudinal shifts in diabetes care delivery during the COVID-19 pandemic: implications for post-pandemic models of chronic disease management","BMC Endocrine Disorders","Springer Science and Business Media LLC","10.1186/s12902-026-02502-9","https://doi.org/10.1186/s12902-026-02502-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12902-026-02502-9",null],["4","R0054634","R0054634.pdf","free_to_read","nonrandomized_study","Atsushi Nakamura","2026","Comment on ‘Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China’ by Liang et al.","Journal of Cachexia Sarcopenia and Muscle","Wiley","10.1002/jcsm.70288","https://doi.org/10.1002/jcsm.70288","41992825","https://pubmed.ncbi.nlm.nih.gov/41992825/","https://doi.org/10.1002/jcsm.70288",null],["4","R0054721","R0054721.pdf","free_to_read","nonrandomized_study","Catherine Caro","2026","Real-World Use of GLP-1 RA-Based Therapies for Weight Management in Ireland: A Cross-Sectional Study of Prescribing and Care Pathways, Costs, and Self-Reported Outcomes","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6994968","https://doi.org/10.2139/ssrn.6994968",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6994968",null],["4","R0054725","R0054725.pdf","free_to_read","nonrandomized_study","Diviya Bharathi Ravikumar","2026","P-350. Prescription of Weight Loss Medications in HIV Patients at a Rural Federally Funded Clinic: A Retrospective Study","Open Forum Infectious Diseases","Oxford University Press (OUP)","10.1093/ofid/ofaf695.568","https://doi.org/10.1093/ofid/ofaf695.568",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ofid/ofaf695.568",null],["4","R0054775","R0054775.pdf","free_to_read","nonrandomized_study","Victor Martinez Leon","2026","Tubules, Targets, and Translational Promise in Diabetic Kidney Disease","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000001088","https://doi.org/10.34067/kid.0000001088","41609741","https://pubmed.ncbi.nlm.nih.gov/41609741/","https://doi.org/10.34067/kid.0000001088",null],["4","R0054800","R0054800.pdf","free_to_read","nonrandomized_study","James Brophy","2026","Laundered Survival: When Target Trial Emulation Doesn’t Emulate—Implications for GLP-1 Receptor Agonists and Cancer Outcomes","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7119801","https://doi.org/10.2139/ssrn.7119801",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7119801",null],["4","R0054931","R0054931.pdf","free_to_read","nonrandomized_study","Galya Bigman","2026","Glucagon-Like Peptide-1 Receptor Agonist Exposure During Pregnancy: Maternal Characteristics and Birth Outcomes from the HEALthy Brain and Child Development (HBCD) Study","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.08.019","https://doi.org/10.1016/j.aed.2026.08.019",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.aed.2026.08.019",null],["4","R0054985","R0054985.pdf","free_to_read","nonrandomized_study","Assim Abdulaziz Alfadda","2026","Predictive biomarkers for cardiovascular diseases in a Saudi cohort of patients with type 2 diabetes mellitus","Endocrine and Metabolic Science","Elsevier BV","10.1016/j.endmts.2026.100311","https://doi.org/10.1016/j.endmts.2026.100311",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.endmts.2026.100311","ClinicalTrials.gov:NCT05697991"],["4","R0055030","R0055030.pdf","free_to_read","nonrandomized_study","Rebecca Arden Harris","2026","The coverage gap in PREVENT: Why cardiovascular risk prediction needs a lab-free complement","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2026.101782","https://doi.org/10.1016/j.ajpc.2026.101782",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2026.101782",null],["4","R0055066","R0055066.pdf","free_to_read","nonrandomized_study","Arman Kishan","2026","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonists on Cervical Spine Fusion Outcomes: A 10-Year National Body Mass Index–Stratified Cohort Study","Spine Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/bn9.0000000000000048","https://doi.org/10.1097/bn9.0000000000000048",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/bn9.0000000000000048",null],["4","R0055076","R0055076.pdf","free_to_read","nonrandomized_study","Soong Yiing Yap","2026","Navigating the kidney disease care cascade in type 2 diabetes: insights from the national diabetes registry","BMC Public Health","Springer Science and Business Media LLC","10.1186/s12889-026-28520-9","https://doi.org/10.1186/s12889-026-28520-9",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12889-026-28520-9",null],["4","R0055162","R0055162.pdf","free_to_read","nonrandomized_study","Filipi Fim Andreão","2026","GLP-1 receptor agonists and ischemic optic neuropathy in patients with type 2 diabetes and obesity: A TriNetX cohort study","AJO International","Elsevier BV","10.1016/j.ajoint.2026.100275","https://doi.org/10.1016/j.ajoint.2026.100275",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajoint.2026.100275",null],["4","R0055168","R0055168.pdf","free_to_read","nonrandomized_study","R. Yukesh","2026","Semaglutide – sodium-glucose cotransporter-2 inhibitor combination therapy and ketoacidosis risk: A disproportionality analysis from the Food and Drug Administration Adverse Event Reporting System","Perspectives in Clinical Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/picr.picr_153_26","https://doi.org/10.4103/picr.picr_153_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/picr.picr_153_26",null],["4","R0055180","R0055180.pdf","free_to_read","nonrandomized_study","Yuhao Li","2026","Association between sodium-glucose cotransporter 2 inhibitors and the risk of chronic lower respiratory disease in type 2 diabetes mellitus: findings from two target trial emulations","Respiratory Research","Springer Science and Business Media LLC","10.1186/s12931-026-03861-6","https://doi.org/10.1186/s12931-026-03861-6",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12931-026-03861-6",null],["4","R0055217","R0055217.pdf","free_to_read","nonrandomized_study","Dimitri A. Raptis","2026","Weight and Glycemic Outcomes Following GLP-1 Receptor Agonist Therapy in People Living with HIV: A Retrospective Study at a Bronx Hospital","Diabetology","MDPI AG","10.3390/diabetology7080155","https://doi.org/10.3390/diabetology7080155",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7080155",null],["4","R0055262","R0055262.pdf","free_to_read","nonrandomized_study","Lucia Costanza","2026","GLP-1RA and aspiration risk in moderate sedation for endoscopy","JCA advances.","Elsevier BV","10.1016/j.jcadva.2026.100239","https://doi.org/10.1016/j.jcadva.2026.100239",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jcadva.2026.100239",null],["4","R0055296","R0055296.pdf","free_to_read","nonrandomized_study","Jampala Raghu Ram","2026","Nonalcoholic Fatty Liver Disease in the Era of MAFLD: Emerging Insights into Mechanisms, Diagnosis, and Personalized Management Global Burden and Economic Impact","Journal of Pharmaceutical Research and Integrated Medical Sciences","AKT Multitask Consultancy","10.64063/3049-1681.vol3.issue7.000282","https://doi.org/10.64063/3049-1681.vol3.issue7.000282",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.64063/3049-1681.vol3.issue7.000282",null],["4","R0055324","R0055324.pdf","free_to_read","nonrandomized_study","Emilie Guillon","2026","Shared Hyperphagia phenotypes and variable response to semaglutide in adults with neurodevelopmental obesity","Journal of Neurodevelopmental Disorders","Springer Science and Business Media LLC","10.1186/s11689-026-09731-y","https://doi.org/10.1186/s11689-026-09731-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s11689-026-09731-y",null],["4","R0055364","R0055364.pdf","free_to_read","nonrandomized_study","Dagmara Woźniak","2026","Weight Loss And Changes In Self-Reported Healthcare Utilisation After Semaglutide-Pathway Assignment In A Digital UK Tier-3 NHS Programme: A Retrospective 9-Month Observational Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7348399","https://doi.org/10.2139/ssrn.7348399",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7348399",null],["4","R0055400","R0055400.pdf","free_to_read","nonrandomized_study","C. Stanislaus","2026","GLP-1 Receptor agonists and risk of suicide or suicide attempts – A cohort and self-controlled case series study","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2026.106931","https://doi.org/10.1016/j.nsa.2026.106931",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2026.106931",null],["4","R0055462","R0055462.pdf","free_to_read","nonrandomized_study","Charan Bale","2026","Changing Paradigm for Reducing Proteinuria and Slowing Renal Insufficiency in People with Diabetic Kidney Disease","Chronicle of Diabetes Research and Practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/cdrp.cdrp_24_25","https://doi.org/10.4103/cdrp.cdrp_24_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/cdrp.cdrp_24_25",null],["4","R0055473","R0055473.pdf","free_to_read","nonrandomized_study","Shruti Kochar","2026","Semaglutide-induced nonarteritic anterior ischemic optic neuropathy","Indian Journal of Ophthalmology - Case Reports","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijo.ijo_1588_25","https://doi.org/10.4103/ijo.ijo_1588_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijo.ijo_1588_25",null],["4","R0055557","R0055557.pdf","free_to_read","nonrandomized_study","Natalia Kostecka","2026","GLP-1 RECEPTOR AGONISTS IN METABOLIC HEALTH: EXPANDING APPLICATIONS, WEIGHT MANAGEMENT, AND EMERGING SAFETY CONSIDERATIONS","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.3(51).2026.6416","https://doi.org/10.31435/ijitss.3(51).2026.6416",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.3(51).2026.6416",null],["4","R0055671","R0055671.pdf","free_to_read","nonrandomized_study","Omer Sayed Ashruf","2026","Major Adverse Cardiovascular Events (MACE) in Cancer Patients Treated With Tirzepatide Compared to Semaglutide: A Target Trial Emulation Using Real-World Data","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.7040885","https://doi.org/10.2139/ssrn.7040885",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.7040885",null],["4","R0055693","R0055693.pdf","free_to_read","nonrandomized_study","Syed Afzal Uddin Biyabani","2026","A Case Report on Acute Pancreatitis Associated with Sitagliptin Therapy in Type 2 Diabetes Mellitus","Journal of Pharma Insights and Research.","ThinkPlus Pharma Publications","10.69613/gv1dqg56","https://doi.org/10.69613/gv1dqg56",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69613/gv1dqg56",null],["4","R0055718","R0055718.pdf","free_to_read","nonrandomized_study","Yu‐Nan Huang","2026","Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation","Therapeutic Advances in Endocrinology and Metabolism","SAGE Publications","10.1177/20420188261490985","https://doi.org/10.1177/20420188261490985",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/20420188261490985",null],["4","R0055737","R0055737.pdf","free_to_read","nonrandomized_study","Nirmalya Roy","2026","Cardio-Kidney-Metabolic Syndrome and Role of Oral Semaglutide","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_24_26","https://doi.org/10.4103/ijdt.ijdt_24_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_24_26",null],["4","R0055784","R0055784.pdf","free_to_read","nonrandomized_study","Fran Espinoza‐Carhuancho","2026","Visualizing Emerging Trends and Global Hotspots in Ozempic, Weight Loss, and Pancreatitis Research: A Scientometric Analysis","International Journal of Preventive Medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijpvm.ijpvm_217_25","https://doi.org/10.4103/ijpvm.ijpvm_217_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijpvm.ijpvm_217_25",null],["4","R0055804","R0055804.pdf","free_to_read","nonrandomized_study","George Bcharah","2026","The effect of pre-operative weight-loss strategies on medical and surgical complications following anatomic total shoulder arthroplasty","Journal of Shoulder and Elbow Arthroplasty","Elsevier BV","10.1016/j.jsea.2026.100083","https://doi.org/10.1016/j.jsea.2026.100083",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jsea.2026.100083",null],["4","R0055815","R0055815.pdf","free_to_read","nonrandomized_study","M Aamir Mirza","2026","A retrospective case-control study to assess the correlation of weight loss and GLP-1 analogs in patients with TYPE 2 diabetes","Advancements in Life Sciences","The Running Line","10.62940/als.v13i3.3665","https://doi.org/10.62940/als.v13i3.3665",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.62940/als.v13i3.3665",null],["4","R0055820","R0055820.pdf","free_to_read","nonrandomized_study","Miski Abdi","2026","Associations of metformin-based antidiabetic combinations and Alzheimer’s disease onset: a retrospective EHR cohort study","BMC Neurology","Springer Science and Business Media LLC","10.1186/s12883-026-05392-5","https://doi.org/10.1186/s12883-026-05392-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12883-026-05392-5",null],["4","R0055843","R0055843.pdf","no_doi","nonrandomized_study","Merlin Sajeev","2026","GLP-1 Receptor Agonists and Wound Healing in Diabetic Foot Ulcers: A Scoping Review","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055902","R0055902.pdf","no_doi","nonrandomized_study","Rebekah Laurel Jane Wilmington","2026","Mechanisms and effects of bariatric surgery on metabolic outcomes: experimental and clinical evaluation study","Nottingham ePrints (University of Nottingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055911","R0055911.pdf","no_doi","nonrandomized_study","陳俞孜","2026","Comparative Safety of GLP-1 Receptor Agonists: A Nationwide Retrospective Cohort Study on Respiratory Outcomes in Patients with Comorbid Asthma and Type 2 Diabetes Mellitus","Taipei Medical University Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055938","R0055938.pdf","free_to_read","nonrandomized_study","Keren Cohen‐Hagai","2026","Association of SGLT2 inhibitors and GLP-1 receptor agonists with mortality and renal outcomes in patients with diabetes and chronic kidney disease: the diabetic nephropathy management and outcome (DINAMO) study","Cardiovascular Diabetology","Springer Science and Business Media LLC","10.1186/s12933-026-03382-y","https://doi.org/10.1186/s12933-026-03382-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12933-026-03382-y",null],["4","R0055963","R0055963.pdf","no_doi","nonrandomized_study","Valerio Liguori","2026","Valutazione del profilo di sicurezza dei GLP-1 RAs: un focus sugli eventi avversi correlati al cancro alla tiroide utilizzando il database europeo di farmacovigilanza","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055988","R0055988.pdf","no_doi","nonrandomized_study","Manga Diane Mbombichoru","2026","Genetic Evaluation of THRB as a Drug-Target Proxy and Modifier of GLP-1–Based Treatment Response","ScholarlyCommons (University of Pennsylvania)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055999","R0055999.pdf","no_doi","nonrandomized_study","İhsan AYHAN","2026","Liraglutid ile ilişkili vücut kompozisyonu değişikliği: kas kütlesi kaybı ve belirleyicileri","DergiPark (Istanbul University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056036","R0056036.pdf","free_to_read","nonrandomized_study","Shao Chi Lo","2026","Glucagon-like peptide-1 receptor agonists are associated with an increased risk of repeat colonoscopy: a real-world retrospective cohort study","BMC Gastroenterology","Springer Science and Business Media LLC","10.1186/s12876-026-05391-3","https://doi.org/10.1186/s12876-026-05391-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12876-026-05391-3",null],["4","R0056044","R0056044.pdf","no_doi","nonrandomized_study","Vinícios Oliveira Ribeiro Souza","2026","TIRZEPATIDA (MOUNJARO®): USO INDISCRIMINADO E AUMENTO DE CASOS DE PANCREATITE","Anais Colóquio Estadual de Pesquisa Multidisciplinar",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056052","R0056052.pdf","no_doi","nonrandomized_study","Vitória Silva Ferreira","2026","EFICÁCIA DA SEMAGLUTIDA NO TRATAMENTO DA OBESIDADE EM ADULTOS SEM DIABETES","Anais Colóquio Estadual de Pesquisa Multidisciplinar",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056098","R0056098.pdf","free_to_read","nonrandomized_study","Divya Samat","2026","OC 51.3 Tirzepatide and Incident Venous Thromboembolism in Type 2 Diabetes: A Propensity-Matched Real-World Analysis","Research and Practice in Thrombosis and Haemostasis","Elsevier BV","10.1016/j.rpth.2026.103716","https://doi.org/10.1016/j.rpth.2026.103716",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.rpth.2026.103716",null],["4","R0056104","R0056104.pdf","no_doi","nonrandomized_study","Raxmonova Xosiyat Boburjon qizi","2026","PRECISION PHARMACOTHERAPY IN TYPE 2 DIABETES MELLITUS: EVALUATING THE CARDIO-RENAL AND GLYCEMIC EFFICACY OF TARGET-SPECIFIC PATHWAY MODULATION","World Bulletin of Public Health",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056108","R0056108.pdf","free_to_read","nonrandomized_study","Yongping Liu","2026","Associations between glucagon-like peptide-1 receptor agonist use and sensitivity to thyroid hormones in type 2 diabetes mellitus adults: a cross-sectional study","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02320-y","https://doi.org/10.1186/s13098-026-02320-y",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02320-y",null],["4","R0056192","R0056192.pdf","no_doi","nonrandomized_study","張玲華","2026","Comparative Cardiorenal Effectiveness of GLP-1 Receptor Agonists and SGLT2 Inhibitors, Alone or in Combination, in Older Adults with Type 2 Diabetes: A Target Trial Emulation Study Using TriNetX","Taipei Medical University Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056207","R0056207.pdf","free_to_read","nonrandomized_study","Roza Ismailovna Yagudina","2026","Active Development Portfolio for Obesity Pharmacotherapy: An Analysis of Data from the ClinicalTrials.gov Registry","Safety and Risk of Pharmacotherapy","SCEEMP","10.30895/2312-7821-2026-14-3-263-277","https://doi.org/10.30895/2312-7821-2026-14-3-263-277",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.30895/2312-7821-2026-14-3-263-277",null],["4","R0056232","R0056232.pdf","free_to_read","nonrandomized_study","Pavan Reddy Regatti","2026","Ultra-compact amyloidogenic fusion tags mediated efficient production of liraglutide precursors and molecular insights","Microbial Cell Factories","Springer Science and Business Media LLC","10.1186/s12934-026-03138-z","https://doi.org/10.1186/s12934-026-03138-z",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12934-026-03138-z",null],["4","R0056261","R0056261.pdf","free_to_read","nonrandomized_study","E. M. Eliseeva","2026","Tirzepatide and Semaglutide in Type 2 Diabetes Mellitus and Obesity: A Comparative Assessment of Efficacy and Safety (Review)","Safety and Risk of Pharmacotherapy","SCEEMP","10.30895/2312-7821-2026-14-3-249-262","https://doi.org/10.30895/2312-7821-2026-14-3-249-262",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.30895/2312-7821-2026-14-3-249-262",null],["4","R0056284","R0056284.pdf","no_doi","nonrandomized_study","Carla Mannucci","2026","Abordaje de la diabetes tipo 2 en la población pediátrica y adolescente","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056295","R0056295.pdf","free_to_read","nonrandomized_study","Najwa Al Himali","2026","Real-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15207797","https://doi.org/10.3390/jcm15207797",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15207797",null],["4","R0056316","R0056316.pdf","no_doi","nonrandomized_study","Edgar Mora","2026","Nuevos tratamientos en diabetes ¿qué tenemos y a qué accedemos en Latinoamérica?","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056334","R0056334.pdf","no_doi","nonrandomized_study","Nur Asilah Shariffudin","2026","Heterogeneous response to semaglutide in long-standing T2DM and obesity: a case report","UiTM Institutional Repositories (Universiti Teknologi MARA)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056372","R0056372.pdf","free_to_read","nonrandomized_study","Noah Sicouri","2026","Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15197489","https://doi.org/10.3390/jcm15197489",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15197489",null],["4","R0056375","R0056375.pdf","free_to_read","nonrandomized_study","Daniel Ejim Uti","2026","Repurposing metabolic drugs: Anti-diabetic and anti-obesity agents with potential in cancer therapy","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2026.100747","https://doi.org/10.1016/j.obmed.2026.100747",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obmed.2026.100747",null],["4","R0056384","R0056384.pdf","free_to_read","nonrandomized_study","Sujan Niraula","2026","OC 51.5 Impact of Bariatric Surgery, Semaglutide, and Tirzepatide on Thromboembolism and ISTH Major Bleeding in Obese Adults: A Multicenter TriNetX Cohort Study","Research and Practice in Thrombosis and Haemostasis","Elsevier BV","10.1016/j.rpth.2026.103718","https://doi.org/10.1016/j.rpth.2026.103718",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.rpth.2026.103718",null],["4","R0056400","R0056400.pdf","no_doi","nonrandomized_study","Dario Martínez-Vázquez","2026","Enfoques clínicos preventivos en el envejecimiento activo","Revista de Ciencias Médicas de Pinar del Río",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056401","R0056401.pdf","free_to_read","nonrandomized_study","Nicola Osti","2026","PB1059 Glucagon-like peptide-1 receptor agonists are associated with reduced Endogenous Thrombin Potential in subjects with type 2 diabetes mellitus: results from an observational cardiovascular cohort study","Research and Practice in Thrombosis and Haemostasis","Elsevier BV","10.1016/j.rpth.2026.103922","https://doi.org/10.1016/j.rpth.2026.103922",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.rpth.2026.103922",null],["4","R0056404","R0056404.pdf","no_doi","nonrandomized_study","Alex Diaz Barzola","2026","Multimorbilidad geriátrica ECNT: HTA-DM2-ECVH-Brechas terapéuticas","Journal of America health",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056439","R0056439.pdf","no_doi","nonrandomized_study","Nur Haziqah B","2026","Early treatment response to tirzepatide in obesity: a case series","UiTM Institutional Repositories (Universiti Teknologi MARA)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056449","R0056449.pdf","no_doi","nonrandomized_study","Fernanda Abigail Mejía Cayancela","2026","Avanços farmacológicos no tratamento da obesidade em adolescentes: revisão sistemática da literatura","Maestro y sociedad",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056481","R0056481.pdf","no_doi","nonrandomized_study","Enes Üçgül","2026","Tip 2 Diyabette İnsülin Glarjin ve Liksisenatid Sabit Oranlı Kombinasyonunun Kısa Dönem Gerçek Yaşam Klinik Sonuçları: Tip 2 Diyabette İnsülin Glarjin/Liksisenatidin Kısa Dönem Sonuçları","Gazi Medical Journal",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056538","R0056538.pdf","free_to_read","nonrandomized_study","M. Asunción González-González","2026","SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study Comparing Adherence and Persistence with Specific Reference to Cardiovascular Disease","Pharmaceuticals","MDPI AG","10.3390/ph19101607","https://doi.org/10.3390/ph19101607",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/ph19101607",null],["4","R0056549","R0056549.pdf","free_to_read","nonrandomized_study","Gabriel Castano","2026","Real-World Effectiveness of Liraglutide in Children with Type 2 Diabetes","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvag230","https://doi.org/10.1210/jendso/bvag230",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvag230",null],["4","R0056572","R0056572.pdf","free_to_read","nonrandomized_study","Ahmad El Khatib","2026","Trends in bariatric and pharmacologic obesity management: an analysis using epic cosmos database","Langenbeck s Archives of Surgery","Springer Science and Business Media LLC","10.1007/s00423-026-04243-8","https://doi.org/10.1007/s00423-026-04243-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1007/s00423-026-04243-8",null],["4","R0056597","R0056597.pdf","no_doi","nonrandomized_study","Sakonwan Pounghom","2026","การประเมนตนทน-ประสทธผลในระดบโรงพยาบาลของยา Semaglutide ในการควบคมระดบนำตาลในเลอดของผปวยเบาหวานชนดท 2","Hua Hin Medical Journal",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056628","R0056628.pdf","free_to_read","nonrandomized_study","Katrina Fernandez","2026","The Impact of Absorbable Antibiotic Beads in Implant-Based Breast Reconstruction: A Single-Surgeon Experience","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.gox.0001279432.31971.29","https://doi.org/10.1097/01.gox.0001279432.31971.29",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/01.gox.0001279432.31971.29",null],["4","R0056636","R0056636.pdf","free_to_read","nonrandomized_study","Joseph R. Herges","2026","Clinical Inertia in the Treatment of Hypertension for Individuals with Diabetes","Diabetes Obesity and Cardiometabolic CARE","American Diabetes Association","10.2337/figshare.33301926","https://doi.org/10.2337/figshare.33301926",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.33301926",null],["4","R0056660","R0056660.pdf","no_doi","nonrandomized_study","Celine Miho Miho Shiguematsu","2026","Avanços no tratamento do diabetes mellitus tipo 2: a intersecção entre nutrição e novas medicações","Revista brasileira de obesidade, nutrição e emagrecimento",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056701","R0056701.pdf","no_doi","nonrandomized_study","Rosa Corcoy","2026","Nuevas drogas en el embarazo: rol de GLP1 y SGLT2","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056704","R0056704.pdf","free_to_read","nonrandomized_study","Ahmed Asiri","2026","UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England","Diabetology","MDPI AG","10.3390/diabetology7100200","https://doi.org/10.3390/diabetology7100200",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology7100200",null],["4","R0056731","R0056731.pdf","free_to_read","nonrandomized_study","Duaa Mohammed Al-Atta","2026","Pharmacological therapy and dietary intervention for obesity management: A one-year prospective cohort study in Baghdad","Journal of Education and Health Promotion","Ovid Technologies (Wolters Kluwer Health)","10.4103/jehp.jehp_2134_25","https://doi.org/10.4103/jehp.jehp_2134_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jehp.jehp_2134_25",null],["4","R0056734","R0056734.pdf","free_to_read","nonrandomized_study","Nicholas Angelopoulos","2026","12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study","Obesity Pillars","Elsevier BV","10.1016/j.obpill.2026.100344","https://doi.org/10.1016/j.obpill.2026.100344",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obpill.2026.100344",null],["4","R0056736","R0056736.pdf","free_to_read","nonrandomized_study","Lara Haidar","2026","Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas on weight change among people with HIV: a real-world longitudinal cohort study","BMC Medicine","Springer Science and Business Media LLC","10.1186/s12916-026-05219-7","https://doi.org/10.1186/s12916-026-05219-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12916-026-05219-7",null],["4","R0056737","R0056737.pdf","free_to_read","nonrandomized_study","Chew Huey Chua","2026","Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review","International Journal of Molecular Sciences","MDPI AG","10.3390/ijms27209050","https://doi.org/10.3390/ijms27209050",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/ijms27209050",null],["4","R0056741","R0056741.pdf","free_to_read","nonrandomized_study","Pin-Ni Kao","2026","Tirzepatide use and the risk of endometrial cancer in women with overweight or obesity: a retrospective cohort study","Diabetology & Metabolic Syndrome","Springer Science and Business Media LLC","10.1186/s13098-026-02329-3","https://doi.org/10.1186/s13098-026-02329-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13098-026-02329-3",null],["4","R0056754","R0056754.pdf","free_to_read","nonrandomized_study","Ruby Baik","2026","A GPCR-Signaling Addiction Hub in the Murine Nucleus Accumbens and Its Partial Restitution by a GLP-1 Receptor Agonist: A Retrospective Transcriptomic Analysis","Preprints.org","MDPI AG","10.20944/preprints202610.0695.v1","https://doi.org/10.20944/preprints202610.0695.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202610.0695.v1",null],["4","R0056764","R0056764.pdf","free_to_read","nonrandomized_study","Esra DEMİR","2026","Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye","Journal of Clinical Medicine","MDPI AG","10.3390/jcm15207876","https://doi.org/10.3390/jcm15207876",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/jcm15207876",null],["4","R0056765","R0056765.pdf","free_to_read","nonrandomized_study","Merna Abdelsalhen","2026","Real-World Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Gout Outcomes and Metabolic Profiles","Ibnosina Journal of Medicine and Biomedical Sciences","Georg Thieme Verlag KG","10.1055/s-0046-1827830","https://doi.org/10.1055/s-0046-1827830",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0046-1827830",null],["4","R0057011","R0057011.pdf","free_to_read","nonrandomized_study","Aledan H","2026","Efficacy and safety of finerenone in chronic kidney disease stages 3-4 in diabetic and non-diabetic patients with an eGFR 20-60 mL/min: a prospective cohort study.","Frontiers in nephrology","Frontiers Media SA","10.3389/fneph.2026.1716452","https://doi.org/10.3389/fneph.2026.1716452","42179848","https://pubmed.ncbi.nlm.nih.gov/42179848/","https://doi.org/10.3389/fneph.2026.1716452",null],["4","R0057017","R0057017.pdf","free_to_read","nonrandomized_study","Zainab F","2026","Advances in pharmacologic management of obesity: oral semaglutide for weight management.","Annals of medicine and surgery (2012)",null,"10.1097/ms9.0000000000005161","https://doi.org/10.1097/ms9.0000000000005161","42866773","https://pubmed.ncbi.nlm.nih.gov/42866773/",null,null],["4","R0000377","R0000377.pdf","open_download_failed","nonrandomized_study","Ukhanova M","2025","Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2025.89778","https://doi.org/10.37765/ajmc.2025.89778","40829097","https://pubmed.ncbi.nlm.nih.gov/40829097/","https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=2423&context=uthsph_docs",null],["4","R0000492","R0000492.pdf","free_to_read","nonrandomized_study","Venkatakrishnan A","2025","Decoding the hallmarks of GLP-1RA weight-loss super responders","medRxiv","openRxiv","10.1101/2025.11.15.25340314","https://doi.org/10.1101/2025.11.15.25340314",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0000774","R0000774.pdf","open_download_failed","nonrandomized_study","Kim C","2025","Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.10.06.25337411","https://doi.org/10.1101/2025.10.06.25337411","41282921","https://pubmed.ncbi.nlm.nih.gov/41282921/","https://www.medrxiv.org/content/medrxiv/early/2025/10/07/2025.10.06.25337411.full.pdf",null],["4","R0000888","R0000888.pdf","open_download_failed","nonrandomized_study","Panchal S","2025","Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2025.01.004","https://doi.org/10.1016/j.gie.2025.01.004","39824444","https://pubmed.ncbi.nlm.nih.gov/39824444/","https://www.giejournal.org/article/S0016-5107(25)00009-4/pdf",null],["4","R0000899","R0000899.pdf","free_to_read","nonrandomized_study","Lv L","2025","Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2025.01.018","https://doi.org/10.1016/j.jval.2025.01.018","39947393","https://pubmed.ncbi.nlm.nih.gov/39947393/","https://doi.org/10.1016/j.jval.2025.01.018",null],["4","R0000965","R0000965.pdf","open_download_failed","nonrandomized_study","Sklepinski SM","2025","Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112910","https://doi.org/10.1016/j.diabres.2025.112910","40983112","https://pubmed.ncbi.nlm.nih.gov/40983112/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00924-6/pdf",null],["4","R0001093","R0001093.pdf","open_download_failed","nonrandomized_study","Drummond RF","2025","Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.","American journal of obstetrics and gynecology","Elsevier BV","10.1016/j.ajog.2024.08.024","https://doi.org/10.1016/j.ajog.2024.08.024","39181497","https://pubmed.ncbi.nlm.nih.gov/39181497/","https://www.ajog.org/article/S0002-9378(24)00864-0/pdf",null],["4","R0001227","R0001227.pdf","open_download_failed","nonrandomized_study","Pereira DE","2025","Perioperative glucagon-like Peptide-1 receptor agonist use and clinical outcomes following lower extremity fracture fixation: A large retrospective cohort study with two year follow up.","Injury","Elsevier BV","10.1016/j.injury.2025.112746","https://doi.org/10.1016/j.injury.2025.112746","40915058","https://pubmed.ncbi.nlm.nih.gov/40915058/","https://www.injuryjournal.com/article/S0020-1383(25)00604-7/pdf",null],["4","R0001262","R0001262.pdf","free_to_read","nonrandomized_study","Au HCT","2025","Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.","Neuroscience and biobehavioral reviews","Elsevier BV","10.1016/j.neubiorev.2025.106159","https://doi.org/10.1016/j.neubiorev.2025.106159","40252880","https://pubmed.ncbi.nlm.nih.gov/40252880/","https://doi.org/10.1016/j.neubiorev.2025.106159",null],["4","R0001329","R0001329.pdf","free_to_read","nonrandomized_study","du Soulier N","2025","Use and Potential Misuse of Glucagon-Like Peptide-1 Receptor Agonists in France: A Nationwide Cohort Study.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2025.06.001","https://doi.org/10.1016/j.jval.2025.06.001","40562309","https://pubmed.ncbi.nlm.nih.gov/40562309/","https://doi.org/10.1016/j.jval.2025.06.001",null],["4","R0001332","R0001332.pdf","open_download_failed","nonrandomized_study","Eubanks A","2025","The Interplay of GLP-1 Receptor Agonist Use, Chronic Kidney Disease, and Fracture Risk in Obese Patients: A Retrospective Cohort Study","Authorea Preprints","Wiley","10.22541/au.176706936.68195055/v1","https://doi.org/10.22541/au.176706936.68195055/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176706936.68195055/v1",null],["4","R0001365","R0001365.pdf","free_to_read","nonrandomized_study","McIntyre RS","2025","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2024.10.062","https://doi.org/10.1016/j.jad.2024.10.062","39433133","https://pubmed.ncbi.nlm.nih.gov/39433133/","https://doi.org/10.1016/j.jad.2024.10.062",null],["4","R0001430","R0001430.pdf","open_download_failed","nonrandomized_study","Steele J","2025","Preserving musculoskeletal health through resistance training in individuals undergoing Glucagon-like Peptide-1 Receptor Agonist Therapy: a controlled interrupted time-series analysis (Stage 1 Registered Report)","medRxiv","openRxiv","10.1101/2025.06.24.25330195","https://doi.org/10.1101/2025.06.24.25330195",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/06/26/2025.06.24.25330195.full.pdf",null],["4","R0001435","R0001435.pdf","open_download_failed","nonrandomized_study","Hong AT","2025","Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112982","https://doi.org/10.1016/j.diabres.2025.112982","41177308","https://pubmed.ncbi.nlm.nih.gov/41177308/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00996-9/pdf",null],["4","R0001495","R0001495.pdf","open_download_failed","nonrandomized_study","Wright EE","2025","Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2025.24253","https://doi.org/10.18553/jmcp.2025.24253","39823185","https://pubmed.ncbi.nlm.nih.gov/39823185/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11852799/pdf/jmcp.2025.24253.pdf",null],["4","R0001511","R0001511.pdf","open_download_failed","nonrandomized_study","Liu BD","2025","Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70190","https://doi.org/10.1111/apt.70190","40356540","https://pubmed.ncbi.nlm.nih.gov/40356540/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70190",null],["4","R0001574","R0001574.pdf","free_to_read","nonrandomized_study","Dunn TJ","2025","Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112162","https://doi.org/10.1016/j.diabres.2025.112162","40220796","https://pubmed.ncbi.nlm.nih.gov/40220796/","https://doi.org/10.1016/j.diabres.2025.112162",null],["4","R0001640","R0001640.pdf","free_to_read","nonrandomized_study","Karlström P","2025","Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2024.12.004","https://doi.org/10.1016/j.jchf.2024.12.004","40088230","https://pubmed.ncbi.nlm.nih.gov/40088230/","https://doi.org/10.1016/j.jchf.2024.12.004",null],["4","R0001641","R0001641.pdf","open_download_failed","nonrandomized_study","Wang M","2025","Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.","Gynecologic oncology","Elsevier BV","10.1016/j.ygyno.2025.06.012","https://doi.org/10.1016/j.ygyno.2025.06.012","40554181","https://pubmed.ncbi.nlm.nih.gov/40554181/","https://www.gynecologiconcology-online.net/action/showPdf?pii=S0090825825008790",null],["4","R0001679","R0001679.pdf","open_download_failed","nonrandomized_study","Kotecha P","2025","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity","medRxiv","openRxiv","10.64898/2025.11.24.25340763","https://doi.org/10.64898/2025.11.24.25340763",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/12/02/2025.11.24.25340763.full.pdf",null],["4","R0001724","R0001724.pdf","free_to_read","nonrandomized_study","Yen FS","2025","Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.","Journal of autoimmunity","Elsevier BV","10.1016/j.jaut.2025.103493","https://doi.org/10.1016/j.jaut.2025.103493","41110425","https://pubmed.ncbi.nlm.nih.gov/41110425/","https://doi.org/10.2139/ssrn.5372106",null],["4","R0001805","R0001805.pdf","free_to_read","nonrandomized_study","Belančić A","2025","Blood pressure effects of SGLT2 inhibitors and GLP-1 receptor agonists: Mechanisms, trial evidence and Real-world data.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70378","https://doi.org/10.1002/bcp.70378","41344902","https://pubmed.ncbi.nlm.nih.gov/41344902/","https://doi.org/10.1002/bcp.70378",null],["4","R0001828","R0001828.pdf","open_download_failed","nonrandomized_study","Yuce T","2025","Real-World Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Weight Recurrence After Bariatric Surgery","medRxiv","openRxiv","10.1101/2025.11.21.25340747","https://doi.org/10.1101/2025.11.21.25340747",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/11/25/2025.11.21.25340747.full.pdf",null],["4","R0001906","R0001906.pdf","open_download_failed","nonrandomized_study","Fang YE","2025","Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc25-1840","https://doi.org/10.2337/dc25-1840","41144235","https://pubmed.ncbi.nlm.nih.gov/41144235/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12718078/pdf/dc251840.pdf",null],["4","R0001917","R0001917.pdf","open_download_failed","nonrandomized_study","Dai H","2025","GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.11.10.25339912","https://doi.org/10.1101/2025.11.10.25339912","41292651","https://pubmed.ncbi.nlm.nih.gov/41292651/","https://www.medrxiv.org/content/medrxiv/early/2025/11/13/2025.11.10.25339912.full.pdf",null],["4","R0001977","R0001977.pdf","open_download_failed","nonrandomized_study","Holmager P","2025","GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241289438","https://doi.org/10.1177/19322968241289438","39417493","https://pubmed.ncbi.nlm.nih.gov/39417493/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11571627/pdf/10.1177_19322968241289438.pdf",null],["4","R0001985","R0001985.pdf","open_download_failed","nonrandomized_study","Ray P","2025","Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2024.10.011","https://doi.org/10.1016/j.jcjd.2024.10.011","39486576","https://pubmed.ncbi.nlm.nih.gov/39486576/","https://www.canadianjournalofdiabetes.com/article/S1499-2671(24)00376-9/pdf",null],["4","R0002013","R0002013.pdf","open_download_failed","nonrandomized_study","Huang H","2025","Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.","British journal of anaesthesia","Elsevier BV","10.1016/j.bja.2024.10.013","https://doi.org/10.1016/j.bja.2024.10.013","39578156","https://pubmed.ncbi.nlm.nih.gov/39578156/","https://www.bjanaesthesia.org/article/S0007-0912(24)00615-9/pdf",null],["4","R0002076","R0002076.pdf","open_download_failed","nonrandomized_study","Wennberg D","2025","The Real-World Costs of GLP-1 Receptor Agonist Treatment","medRxiv","openRxiv","10.1101/2025.10.24.25338255","https://doi.org/10.1101/2025.10.24.25338255",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/10/25/2025.10.24.25338255.full.pdf",null],["4","R0002111","R0002111.pdf","free_to_read","nonrandomized_study","Thomas M","2025","Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review","medRxiv","openRxiv","10.1101/2025.07.23.25332036","https://doi.org/10.1101/2025.07.23.25332036",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2025.07.23.25332036",null],["4","R0002187","R0002187.pdf","free_to_read","nonrandomized_study","Ahmad P","2025","Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.","Journal of periodontal research","Wiley","10.1111/jre.13410","https://doi.org/10.1111/jre.13410","40348599","https://pubmed.ncbi.nlm.nih.gov/40348599/","https://doi.org/10.1111/jre.13410",null],["4","R0002216","R0002216.pdf","open_download_failed","nonrandomized_study","Wang T","2025","Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.70192","https://doi.org/10.1002/pds.70192","40717037","https://pubmed.ncbi.nlm.nih.gov/40717037/","https://www.authorea.com/doi/pdf/10.22541/au.173650335.52689097",null],["4","R0002281","R0002281.pdf","open_download_failed","nonrandomized_study","Salvatore M","2025","Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.06.03.25328908","https://doi.org/10.1101/2025.06.03.25328908","40502555","https://pubmed.ncbi.nlm.nih.gov/40502555/","https://www.medrxiv.org/content/medrxiv/early/2025/06/04/2025.06.03.25328908.full.pdf",null],["4","R0002301","R0002301.pdf","open_download_failed","nonrandomized_study","Lakhani M","2025","Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.","American journal of ophthalmology","Elsevier BV","10.1016/j.ajo.2025.05.007","https://doi.org/10.1016/j.ajo.2025.05.007","40383360","https://pubmed.ncbi.nlm.nih.gov/40383360/","https://www.ajo.com/action/showPdf?pii=S0002939425002399",null],["4","R0002321","R0002321.pdf","open_download_failed","nonrandomized_study","Garry JD","2025","Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary Hypertension.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.09.18.25336100","https://doi.org/10.1101/2025.09.18.25336100","41001493","https://pubmed.ncbi.nlm.nih.gov/41001493/","https://www.medrxiv.org/content/medrxiv/early/2025/09/19/2025.09.18.25336100.full.pdf",null],["4","R0002385","R0002385.pdf","open_download_failed","nonrandomized_study","Su YC","2025","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohorts Retrospective Study.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70051","https://doi.org/10.1002/dmrr.70051","40478380","https://pubmed.ncbi.nlm.nih.gov/40478380/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.70051",null],["4","R0002573","R0002573.pdf","open_download_failed","nonrandomized_study","Lee YC","2025","Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2025.03.016","https://doi.org/10.1053/j.ajkd.2025.03.016","40311668","https://pubmed.ncbi.nlm.nih.gov/40311668/","https://www.ajkd.org/article/S0272-6386(25)00831-5/pdf",null],["4","R0002580","R0002580.pdf","open_download_failed","nonrandomized_study","Gandhi A","2025","Are All Incretin Therapies Equal for the Kidney? Comparative FAERS Analysis of Tirzepatide and Semaglutide","Preprints.org","MDPI AG","10.20944/preprints202510.0154.v1","https://doi.org/10.20944/preprints202510.0154.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/ad1aebf3501503ec5f14873b093b48ae/download_pub",null],["4","R0002617","R0002617.pdf","free_to_read","nonrandomized_study","Nishida K","2025","Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2025.06.011","https://doi.org/10.1016/j.clnu.2025.06.011","40617160","https://pubmed.ncbi.nlm.nih.gov/40617160/","https://doi.org/10.1016/j.clnu.2025.06.011",null],["4","R0002626","R0002626.pdf","open_download_failed","nonrandomized_study","Wang L","2025","Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","Journal of the National Cancer Institute","Oxford University Press (OUP)","10.1093/jnci/djae260","https://doi.org/10.1093/jnci/djae260","39418202","https://pubmed.ncbi.nlm.nih.gov/39418202/","https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djae260/59833584/djae260.pdf",null],["4","R0002635","R0002635.pdf","open_download_failed","nonrandomized_study","Rodriguez PJ","2025","GLP-1 Receptor Agonists vs Alternatives for Alcohol Use Disorder: A Multi-Target Trial Emulation","medRxiv","openRxiv","10.1101/2025.06.07.25329184","https://doi.org/10.1101/2025.06.07.25329184",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/06/11/2025.06.07.25329184.full.pdf",null],["4","R0002660","R0002660.pdf","open_download_failed","nonrandomized_study","Lin HT","2025","Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2025.21016","https://doi.org/10.1001/jamanetworkopen.2025.21016","40663350","https://pubmed.ncbi.nlm.nih.gov/40663350/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2836412/lin_2025_oi_250630_1751908704.40959.pdf",null],["4","R0002689","R0002689.pdf","open_download_failed","nonrandomized_study","Venkatakrishnan A","2025","Weight Loss Dynamics and Health Burden Changes with Tirzepatide versus Semaglutide","medRxiv","openRxiv","10.64898/2025.11.30.25341294","https://doi.org/10.64898/2025.11.30.25341294",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/12/02/2025.11.30.25341294.full.pdf",null],["4","R0002696","R0002696.pdf","open_download_failed","nonrandomized_study","Allan KC","2025","Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2025.01.016","https://doi.org/10.1016/j.ophtha.2025.01.016","39863057","https://pubmed.ncbi.nlm.nih.gov/39863057/","https://www.aaojournal.org/article/S0161-6420(25)00070-3/pdf",null],["4","R0002722","R0002722.pdf","open_download_failed","nonrandomized_study","Bucci T","2025","GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16238","https://doi.org/10.1111/dom.16238","39930557","https://pubmed.ncbi.nlm.nih.gov/39930557/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16238",null],["4","R0002724","R0002724.pdf","free_to_read","nonrandomized_study","Dong J","2025","Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model - A UK weight and wellness cancer landscape analysis.","Cancer epidemiology","Elsevier BV","10.1016/j.canep.2025.102837","https://doi.org/10.1016/j.canep.2025.102837","40413897","https://pubmed.ncbi.nlm.nih.gov/40413897/","https://doi.org/10.1016/j.canep.2025.102837",null],["4","R0002743","R0002743.pdf","open_download_failed","nonrandomized_study","Kuo CC","2025","Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.18502","https://doi.org/10.1111/apt.18502","39791391","https://pubmed.ncbi.nlm.nih.gov/39791391/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.18502",null],["4","R0002760","R0002760.pdf","open_download_failed","nonrandomized_study","Kim TH","2025","Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16376","https://doi.org/10.1111/dom.16376","40176478","https://pubmed.ncbi.nlm.nih.gov/40176478/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16376",null],["4","R0002835","R0002835.pdf","open_download_failed","nonrandomized_study","Pasi M","2025","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Nontraumatic Intracerebral Hemorrhage in Patients With Type 2 Diabetes.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.125.050972","https://doi.org/10.1161/strokeaha.125.050972","40469023","https://pubmed.ncbi.nlm.nih.gov/40469023/","https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.125.050972?download=true",null],["4","R0002878","R0002878.pdf","open_download_failed","nonrandomized_study","Pollmann DL","2025","Implementation of an Integrated Cardiology/Pharmacy GLP-1 Receptor Antagonist Prescribing to Improve Utilization and Cardiovascular Risk","medRxiv","openRxiv","10.1101/2025.08.01.25332846","https://doi.org/10.1101/2025.08.01.25332846",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/08/05/2025.08.01.25332846.full.pdf",null],["4","R0002900","R0002900.pdf","open_download_failed","nonrandomized_study","Cao K","2025","GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions","Preprints.org","MDPI AG","10.20944/preprints202506.1838.v1","https://doi.org/10.20944/preprints202506.1838.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/b0714be486d8e9fe95dfcbc85df1634c/download_pub",null],["4","R0002931","R0002931.pdf","free_to_read","nonrandomized_study","Robles Cabanillas C","2025","Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.","Gaceta sanitaria","Elsevier BV","10.1016/j.gaceta.2024.102444","https://doi.org/10.1016/j.gaceta.2024.102444","39818039","https://pubmed.ncbi.nlm.nih.gov/39818039/","https://doi.org/10.1016/j.gaceta.2024.102444",null],["4","R0002944","R0002944.pdf","open_download_failed","nonrandomized_study","Griffiths A","2025","Exploring real-world user experiences of GLP-1 receptor agonist therapy for obesity treatment, and barriers and motivators to adherence","medRxiv","openRxiv","10.64898/2025.12.11.25342052","https://doi.org/10.64898/2025.12.11.25342052",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/12/12/2025.12.11.25342052.full.pdf",null],["4","R0002951","R0002951.pdf","open_download_failed","nonrandomized_study","Dai H","2025","GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.","JAMA oncology","American Medical Association (AMA)","10.1001/jamaoncol.2025.2681","https://doi.org/10.1001/jamaoncol.2025.2681","40839273","https://pubmed.ncbi.nlm.nih.gov/40839273/","https://pmc.ncbi.nlm.nih.gov/articles/instance/12371547/bin/jamaoncol-e252681-s001.pdf",null],["4","R0002959","R0002959.pdf","open_download_failed","nonrandomized_study","Wang J","2025","Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16552","https://doi.org/10.1111/dom.16552","40629903","https://pubmed.ncbi.nlm.nih.gov/40629903/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16552",null],["4","R0002969","R0002969.pdf","free_to_read","nonrandomized_study","Lee YJ","2025","Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study.","Journal of autoimmunity","Elsevier BV","10.1016/j.jaut.2025.103453","https://doi.org/10.1016/j.jaut.2025.103453","40544585","https://pubmed.ncbi.nlm.nih.gov/40544585/","https://doi.org/10.1016/j.jaut.2025.103453",null],["4","R0002977","R0002977.pdf","free_to_read","nonrandomized_study","Gordon R","2025","Glucagon-Like Peptide-1 Receptor Agonists Compared to Insulin for Post-Transplant Diabetes Mellitus After Solid Organ Transplant.","Transplantation proceedings","Elsevier BV","10.1016/j.transproceed.2025.02.031","https://doi.org/10.1016/j.transproceed.2025.02.031","40140314","https://pubmed.ncbi.nlm.nih.gov/40140314/","https://doi.org/10.1016/j.transproceed.2025.02.031",null],["4","R0003011","R0003011.pdf","open_download_failed","nonrandomized_study","Horiuchi Y","2025","Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2024.132611","https://doi.org/10.1016/j.ijcard.2024.132611","39393444","https://pubmed.ncbi.nlm.nih.gov/39393444/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12107941/pdf/nihms-2069646.pdf",null],["4","R0003149","R0003149.pdf","free_to_read","nonrandomized_study","Sardu C","2025","Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112452","https://doi.org/10.1016/j.diabres.2025.112452","40912462","https://pubmed.ncbi.nlm.nih.gov/40912462/","https://doi.org/10.1016/j.diabres.2025.112452",null],["4","R0003170","R0003170.pdf","open_download_failed","nonrandomized_study","Hiramoto B","2025","With Great Statistical Power Comes Great Responsibility: Pitfalls of Claims Database Research on the Periprocedural Glucagon-like Peptide 1 Receptor Agonist Management Debate.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2024.05.039","https://doi.org/10.1053/j.gastro.2024.05.039","39245412","https://pubmed.ncbi.nlm.nih.gov/39245412/","https://www.gastrojournal.org/article/S0016-5085(24)05447-7/pdf",null],["4","R0003179","R0003179.pdf","open_download_failed","nonrandomized_study","Dai H","2025","GLP-1 Receptor Agonists and Acute Diabetes Complications in Adults with Type 1 Diabetes: A Target Trial Emulation.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.11.10.25339908","https://doi.org/10.1101/2025.11.10.25339908","41292646","https://pubmed.ncbi.nlm.nih.gov/41292646/","https://www.medrxiv.org/content/medrxiv/early/2025/11/13/2025.11.10.25339908.full.pdf",null],["4","R0003224","R0003224.pdf","open_download_failed","nonrandomized_study","Triozzi JL","2025","GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysis","medRxiv","openRxiv","10.1101/2025.10.13.25337903","https://doi.org/10.1101/2025.10.13.25337903",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/10/15/2025.10.13.25337903.full.pdf",null],["4","R0003226","R0003226.pdf","open_download_failed","nonrandomized_study","Tauqeer Z","2025","Glucagon-Like Peptide-1 Receptor Agonists are Not Associated with an Increased Risk of Progressing to Vision-Threatening Diabetic Retinopathy.","Ophthalmic epidemiology","Informa UK Limited","10.1080/09286586.2024.2399764","https://doi.org/10.1080/09286586.2024.2399764","39389007","https://pubmed.ncbi.nlm.nih.gov/39389007/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11982348/pdf/nihms-2023582.pdf",null],["4","R0003234","R0003234.pdf","free_to_read","nonrandomized_study","Ruggiero R","2025","Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2025.178004","https://doi.org/10.1016/j.ejphar.2025.178004","40716637","https://pubmed.ncbi.nlm.nih.gov/40716637/","https://doi.org/10.1016/j.ejphar.2025.178004",null],["4","R0003247","R0003247.pdf","open_download_failed","nonrandomized_study","White CJK","2025","Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Following Operative Ankle Fracture Repair in Patients With Type 2 Diabetes: A National Database Study.","Foot & ankle international","SAGE Publications","10.1177/10711007251364187","https://doi.org/10.1177/10711007251364187","40923457","https://pubmed.ncbi.nlm.nih.gov/40923457/","https://journals.sagepub.com/history/ea872fcc-f87a-42bc-b2e8-d1adf2e5ccae/10711007251364187.23839586.pdf",null],["4","R0003252","R0003252.pdf","free_to_read","nonrandomized_study","Ha KH","2025","Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.108983","https://doi.org/10.1016/j.jdiacomp.2025.108983","40117955","https://pubmed.ncbi.nlm.nih.gov/40117955/","https://doi.org/10.1016/j.jdiacomp.2025.108983",null],["4","R0003262","R0003262.pdf","free_to_read","nonrandomized_study","Sidra FNU","2025","Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108925","https://doi.org/10.1016/j.jdiacomp.2024.108925","39644537","https://pubmed.ncbi.nlm.nih.gov/39644537/","https://doi.org/10.1016/j.jdiacomp.2024.108925",null],["4","R0003271","R0003271.pdf","open_download_failed","nonrandomized_study","Chan H","2025","Gallbladder Outcomes With Prokinetic Agents and Semaglutide in Adults With Type 2 Diabetes","Authorea Preprints","Wiley","10.22541/au.176551396.60769594/v1","https://doi.org/10.22541/au.176551396.60769594/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.176551396.60769594/v1",null],["4","R0003301","R0003301.pdf","free_to_read","nonrandomized_study","Tan X","2025","Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112473","https://doi.org/10.1016/j.diabres.2025.112473","40934962","https://pubmed.ncbi.nlm.nih.gov/40934962/","https://doi.org/10.1016/j.diabres.2025.112473",null],["4","R0003334","R0003334.pdf","open_download_failed","nonrandomized_study","Gratzl S","2025","Monitoring Report: GLP-1 RA Prescribing Trends – March 2026 Data","medRxiv","openRxiv","10.1101/2025.03.06.25323524","https://doi.org/10.1101/2025.03.06.25323524",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/10/14/2025.03.06.25323524.full.pdf",null],["4","R0003335","R0003335.pdf","open_download_failed","nonrandomized_study","Heberer K","2025","Increased Risk of New Onset NAION for Initiators of Semaglutide with Type 2 Diabetes in the U.S. Veterans Health Administration","medRxiv","openRxiv","10.1101/2025.09.15.25335753","https://doi.org/10.1101/2025.09.15.25335753",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/09/18/2025.09.15.25335753.full.pdf",null],["4","R0003376","R0003376.pdf","open_download_failed","nonrandomized_study","Jirapinyo P","2025","Glucagon-like peptide-1 receptor agonists and upper endoscopy: a real-world experience.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24190","https://doi.org/10.1002/oby.24190","39763285","https://pubmed.ncbi.nlm.nih.gov/39763285/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24190",null],["4","R0003457","R0003457.pdf","open_download_failed","nonrandomized_study","Gartner HT","2025","Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280251334642","https://doi.org/10.1177/10600280251334642","40269635","https://pubmed.ncbi.nlm.nih.gov/40269635/","https://journals.sagepub.com/doi/pdf/10.1177/10600280251334642?download=true",null],["4","R0003464","R0003464.pdf","open_download_failed","nonrandomized_study","Kuo CC","2025","Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70007","https://doi.org/10.1111/apt.70007","39891379","https://pubmed.ncbi.nlm.nih.gov/39891379/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70007",null],["4","R0003546","R0003546.pdf","free_to_read","nonrandomized_study","Ljungberg C","2025","Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc24-2169","https://doi.org/10.2337/dc24-2169","40173095","https://pubmed.ncbi.nlm.nih.gov/40173095/","https://pure.au.dk/portal/en/publications/724a737f-758a-4bc0-8b83-24a66cf4a4ea",null],["4","R0003567","R0003567.pdf","open_download_failed","nonrandomized_study","Wang Y","2025","Re: The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.","Addiction (Abingdon, England)","Wiley","10.1111/add.16779","https://doi.org/10.1111/add.16779","39856534","https://pubmed.ncbi.nlm.nih.gov/39856534/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.16779",null],["4","R0003568","R0003568.pdf","free_to_read","nonrandomized_study","Tan X","2025","Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2025.2577762","https://doi.org/10.1080/03007995.2025.2577762","41122783","https://pubmed.ncbi.nlm.nih.gov/41122783/","https://doi.org/10.1080/03007995.2025.2577762",null],["4","R0003643","R0003643.pdf","open_download_failed","nonrandomized_study","Cai YX","2025","The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2024.11.016","https://doi.org/10.1016/j.eprac.2024.11.016","39689782","https://pubmed.ncbi.nlm.nih.gov/39689782/","https://www.endocrinepractice.org/article/S1530-891X(24)00866-8/pdf",null],["4","R0003675","R0003675.pdf","open_download_failed","nonrandomized_study","Vignarajah A","2025","The Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction","medRxiv","openRxiv","10.1101/2025.01.02.25319923","https://doi.org/10.1101/2025.01.02.25319923",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/01/03/2025.01.02.25319923.full.pdf",null],["4","R0003707","R0003707.pdf","open_download_failed","nonrandomized_study","Tummala S","2025","GLP-1 receptor agonist use in elective lumbar spine surgery: Reduced pseudarthrosis rates and favorable safety profile.","Journal of orthopaedics","Scientific Scholar","10.1016/j.jor.2025.05.018","https://doi.org/10.1016/j.jor.2025.05.018","40502373","https://pubmed.ncbi.nlm.nih.gov/40502373/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12148742/pdf/main.pdf",null],["4","R0003742","R0003742.pdf","open_download_failed","nonrandomized_study","Fattahi A","2025","Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review","Authorea Preprints","Wiley","10.22541/au.175521972.20484170/v1","https://doi.org/10.22541/au.175521972.20484170/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175521972.20484170",null],["4","R0003771","R0003771.pdf","free_to_read","nonrandomized_study","Allahwala MA","2025","Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2025.07.005","https://doi.org/10.1016/j.hlc.2025.07.005","40914712","https://pubmed.ncbi.nlm.nih.gov/40914712/","https://doi.org/10.1016/j.hlc.2025.07.005",null],["4","R0003836","R0003836.pdf","open_download_failed","nonrandomized_study","Radwan RM","2025","Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.01.20.25320839","https://doi.org/10.1101/2025.01.20.25320839","39974110","https://pubmed.ncbi.nlm.nih.gov/39974110/","https://www.medrxiv.org/content/medrxiv/early/2025/01/20/2025.01.20.25320839.full.pdf",null],["4","R0003905","R0003905.pdf","open_download_failed","nonrandomized_study","Guo H","2025","Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24328","https://doi.org/10.1002/oby.24328","40635195","https://pubmed.ncbi.nlm.nih.gov/40635195/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.24328",null],["4","R0003949","R0003949.pdf","free_to_read","nonrandomized_study","Khadke S","2025","GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2024.10.448","https://doi.org/10.1016/j.cardfail.2024.10.448","39667523","https://pubmed.ncbi.nlm.nih.gov/39667523/","https://ecommons.aku.edu/provost_office/822",null],["4","R0003984","R0003984.pdf","free_to_read","nonrandomized_study","Ljungberg C","2025","Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc25-0693","https://doi.org/10.2337/dc25-0693","40737110","https://pubmed.ncbi.nlm.nih.gov/40737110/","https://pure.amsterdamumc.nl/en/publications/bbcccc8e-b6f1-4fe4-a949-e2494b46f5c7",null],["4","R0004041","R0004041.pdf","open_download_failed","nonrandomized_study","Sun M","2025","Long-term delirium and survival outcomes in patients treated with GLP-1 receptor agonists versus metformin in type 2 diabetes: A population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16434","https://doi.org/10.1111/dom.16434","40331425","https://pubmed.ncbi.nlm.nih.gov/40331425/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16434",null],["4","R0004084","R0004084.pdf","open_download_failed","nonrandomized_study","Khan FI","2025","Otolaryngologic Side Effects of GLP-1 Receptor Agonists.","The Laryngoscope","Wiley","10.1002/lary.32061","https://doi.org/10.1002/lary.32061","39936458","https://pubmed.ncbi.nlm.nih.gov/39936458/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lary.32061",null],["4","R0004094","R0004094.pdf","open_download_failed","nonrandomized_study","Hong G","2025","Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus","medRxiv","openRxiv","10.1101/2025.07.18.25331594","https://doi.org/10.1101/2025.07.18.25331594",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/07/18/2025.07.18.25331594.full.pdf",null],["4","R0004110","R0004110.pdf","free_to_read","nonrandomized_study","Hammad MAM","2025","Beyond Glycemic Control: Semaglutide Use in Non-Diabetic Female Patients with Overactive Bladder Receiving BOTOX is Associated with Improved Urinary Outcome","Preprints.org","MDPI AG","10.20944/preprints202508.0545.v1","https://doi.org/10.20944/preprints202508.0545.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202508.0545.v1",null],["4","R0004127","R0004127.pdf","open_download_failed","nonrandomized_study","Aschen SZ","2025","Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes.","Annals of surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/sla.0000000000006614","https://doi.org/10.1097/sla.0000000000006614","39704067","https://pubmed.ncbi.nlm.nih.gov/39704067/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12014183/pdf/nihms-2070262.pdf",null],["4","R0004346","R0004346.pdf","open_download_failed","nonrandomized_study","Marassi M","2025","Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.11.005","https://doi.org/10.1016/j.clinthera.2024.11.005","39616020","https://pubmed.ncbi.nlm.nih.gov/39616020/","https://www.clinicaltherapeutics.com/article/S0149-2918(24)00330-8/pdf",null],["4","R0004366","R0004366.pdf","free_to_read","nonrandomized_study","Moreno-Pérez O","2025","Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).","Seminars in arthritis and rheumatism","Elsevier BV","10.1016/j.semarthrit.2025.152807","https://doi.org/10.1016/j.semarthrit.2025.152807","40816061","https://pubmed.ncbi.nlm.nih.gov/40816061/","https://doi.org/10.1016/j.semarthrit.2025.152807",null],["4","R0004426","R0004426.pdf","open_download_failed","nonrandomized_study","Zhang D","2025","Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes.","Diabetes care","American Diabetes Association","10.2337/dc24-2746","https://doi.org/10.2337/dc24-2746","40202527","https://pubmed.ncbi.nlm.nih.gov/40202527/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13053885/pdf/dc242746.pdf",null],["4","R0004479","R0004479.pdf","open_download_failed","nonrandomized_study","Klein MP","2025","Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241245680","https://doi.org/10.1177/19322968241245680","38629877","https://pubmed.ncbi.nlm.nih.gov/38629877/","https://journals.sagepub.com/doi/pdf/10.1177/19322968241245680?download=true",null],["4","R0004608","R0004608.pdf","open_download_failed","nonrandomized_study","Elad B","2025","Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.","Artificial organs","Wiley","10.1111/aor.14942","https://doi.org/10.1111/aor.14942","39835590","https://pubmed.ncbi.nlm.nih.gov/39835590/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/aor.14942",null],["4","R0004696","R0004696.pdf","open_download_failed","nonrandomized_study","Carlucci PM","2025","A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.","Rheumatology (Oxford, England)","Oxford University Press (OUP)","10.1093/rheumatology/keae547","https://doi.org/10.1093/rheumatology/keae547","39388251","https://pubmed.ncbi.nlm.nih.gov/39388251/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12048073/pdf/keae547.pdf",null],["4","R0004796","R0004796.pdf","open_download_failed","nonrandomized_study","Hayes AG","2025","Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2025.06.1019","https://doi.org/10.1016/j.hlc.2025.06.1019","40885604","https://pubmed.ncbi.nlm.nih.gov/40885604/","https://www.heartlungcirc.org/article/S1443-9506(25)01509-4/pdf",null],["4","R0004838","R0004838.pdf","open_download_failed","nonrandomized_study","Lee YA","2025","Characterize Disease Progression Subphenotypes in Real World Populations with Overweight and Obesity using a Graph-based Neural Network Framework.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.11.10.25339913","https://doi.org/10.1101/2025.11.10.25339913","41292627","https://pubmed.ncbi.nlm.nih.gov/41292627/","https://www.medrxiv.org/content/medrxiv/early/2025/11/13/2025.11.10.25339913.full.pdf",null],["4","R0004845","R0004845.pdf","free_to_read","nonrandomized_study","García-Vega D","2025","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry.","Revista espanola de cardiologia (English ed.)","Elsevier BV","10.1016/j.rec.2024.07.003","https://doi.org/10.1016/j.rec.2024.07.003","39033874","https://pubmed.ncbi.nlm.nih.gov/39033874/","https://doi.org/10.1016/j.rec.2024.07.003",null],["4","R0004885","R0004885.pdf","open_download_failed","nonrandomized_study","Almadfaa RO","2025","Trends in the utilization, expenditure and costs of noninsulin glucose-lowering drugs in the Medicaid population: Steady increases in glucagon-like peptide-1 receptor agonist and sodium-glucose transporter-2 inhibitor use, prices and expenditure.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70162","https://doi.org/10.1002/bcp.70162","40630025","https://pubmed.ncbi.nlm.nih.gov/40630025/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70162",null],["4","R0004980","R0004980.pdf","open_download_failed","nonrandomized_study","McCoy RG","2025","Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112039","https://doi.org/10.1016/j.diabres.2025.112039","39923965","https://pubmed.ncbi.nlm.nih.gov/39923965/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00053-1/pdf",null],["4","R0005021","R0005021.pdf","free_to_read","nonrandomized_study","Diker Cohen T","2025","Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101624","https://doi.org/10.1016/j.diabet.2025.101624","39961479","https://pubmed.ncbi.nlm.nih.gov/39961479/","https://doi.org/10.1016/j.diabet.2025.101624",null],["4","R0005025","R0005025.pdf","free_to_read","nonrandomized_study","Gavin KL","2025","Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2025.31.12.1311","https://doi.org/10.18553/jmcp.2025.31.12.1311","41296314","https://pubmed.ncbi.nlm.nih.gov/41296314/",null,null],["4","R0005027","R0005027.pdf","open_download_failed","nonrandomized_study","Liu T","2025","Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133229","https://doi.org/10.1016/j.ijcard.2025.133229","40187657","https://pubmed.ncbi.nlm.nih.gov/40187657/","https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00272-4/pdf",null],["4","R0005133","R0005133.pdf","free_to_read","nonrandomized_study","Dávila-García DM","2025","Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109114","https://doi.org/10.1016/j.jdiacomp.2025.109114","40582069","https://pubmed.ncbi.nlm.nih.gov/40582069/","https://doi.org/10.1016/j.jdiacomp.2025.109114",null],["4","R0005136","R0005136.pdf","free_to_read","nonrandomized_study","Kwon J","2025","Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2025.2462100","https://doi.org/10.1080/17446651.2025.2462100","39921267","https://pubmed.ncbi.nlm.nih.gov/39921267/","https://doi.org/10.1080/17446651.2025.2462100",null],["4","R0005179","R0005179.pdf","free_to_read","nonrandomized_study","Raudanskis A","2025","Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108945","https://doi.org/10.1016/j.jdiacomp.2024.108945","39740304","https://pubmed.ncbi.nlm.nih.gov/39740304/","https://doi.org/10.1016/j.jdiacomp.2024.108945",null],["4","R0005227","R0005227.pdf","free_to_read","nonrandomized_study","Chamarthi VS","2025","Obesity Medications: Evidence-Based Management","StatPearls Publishing, Treasure Island (FL)",null,null,"https://doi.org/","40991762","https://pubmed.ncbi.nlm.nih.gov/40991762/",null,null],["4","R0005318","R0005318.pdf","free_to_read","nonrandomized_study","Hsiao LL","2025","Post Hoc Analyses of DKD Clinical Trials in Ethnic Minorities (Asian, Hispanic, Black) Narrative Review.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2025.09.003","https://doi.org/10.1016/j.clinthera.2025.09.003","41027828","https://pubmed.ncbi.nlm.nih.gov/41027828/","https://doi.org/10.1016/j.clinthera.2025.09.003",null],["4","R0005433","R0005433.pdf","open_download_failed","nonrandomized_study","Hendrix N","2025","Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.70227","https://doi.org/10.1002/pds.70227","41024632","https://pubmed.ncbi.nlm.nih.gov/41024632/","https://www.medrxiv.org/content/medrxiv/early/2025/05/13/2025.05.12.25327436.full.pdf",null],["4","R0005798","R0005798.pdf","open_download_failed","nonrandomized_study","Tian C","2025","Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2024.09.028","https://doi.org/10.1016/j.numecd.2024.09.028","39571323","https://pubmed.ncbi.nlm.nih.gov/39571323/","https://www.nmcd-journal.com/article/S0939-4753(24)00377-6/pdf",null],["4","R0005822","R0005822.pdf","open_download_failed","nonrandomized_study","Dunn TJ","2025","Comparing demographic/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2025.24251","https://doi.org/10.18553/jmcp.2025.24251","39823186","https://pubmed.ncbi.nlm.nih.gov/39823186/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11852797/pdf/jmcp.2025.24251.pdf",null],["4","R0005893","R0005893.pdf","open_download_failed","nonrandomized_study","Kotecha P","2025","Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.11.11.25339931","https://doi.org/10.1101/2025.11.11.25339931","41292652","https://pubmed.ncbi.nlm.nih.gov/41292652/","https://www.medrxiv.org/content/medrxiv/early/2025/11/13/2025.11.11.25339931.full.pdf",null],["4","R0005894","R0005894.pdf","open_download_failed","nonrandomized_study","Gibble TH","2025","Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2025.05.003","https://doi.org/10.1016/j.clinthera.2025.05.003","40480878","https://pubmed.ncbi.nlm.nih.gov/40480878/","https://www.clinicaltherapeutics.com/action/showPdf?pii=S0149291825001675",null],["4","R0005934","R0005934.pdf","open_download_failed","nonrandomized_study","Nemlekar PM","2025","Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2025.89719","https://doi.org/10.37765/ajmc.2025.89719","40227398","https://pubmed.ncbi.nlm.nih.gov/40227398/","https://www2.ccwdata.org/documents/10280/19139421/chr-chronic-condition-algorithms.pdf",null],["4","R0006027","R0006027.pdf","free_to_read","nonrandomized_study","Hankosky ER","2025","Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101636","https://doi.org/10.1016/j.diabet.2025.101636","40057019","https://pubmed.ncbi.nlm.nih.gov/40057019/","https://doi.org/10.1016/j.diabet.2025.101636",null],["4","R0006257","R0006257.pdf","free_to_read","nonrandomized_study","Tan X","2025","Prevalence, treatment patterns, burden, and factors related to treatment failure with sodium-glucose cotransporter 2 inhibitor in adults with type 2 diabetes in the United States.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2025.103281","https://doi.org/10.1016/j.dsx.2025.103281","40819425","https://pubmed.ncbi.nlm.nih.gov/40819425/","https://doi.org/10.1016/j.dsx.2025.103281",null],["4","R0006271","R0006271.pdf","open_download_failed","nonrandomized_study","Zelada H","2025","Efficacy, Tolerability, and Safety of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) in Kidney Transplant Recipients With Diabetes.","Clinical transplantation","Wiley","10.1111/ctr.70144","https://doi.org/10.1111/ctr.70144","40230336","https://pubmed.ncbi.nlm.nih.gov/40230336/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ctr.70144",null],["4","R0006310","R0006310.pdf","open_download_failed","nonrandomized_study","Mahajan Y","2025","GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents","Preprints.org","MDPI AG","10.20944/preprints202510.1849.v1","https://doi.org/10.20944/preprints202510.1849.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/c9c3cd16d3db64faa79714c50b5bb790/download_pub",null],["4","R0006341","R0006341.pdf","free_to_read","nonrandomized_study","Peiper NC","2025","Are recent decreases in adult obesity trends in the United States encouraging or alarming?","Preventive medicine","Elsevier BV","10.1016/j.ypmed.2025.108297","https://doi.org/10.1016/j.ypmed.2025.108297","40334816","https://pubmed.ncbi.nlm.nih.gov/40334816/","https://pubmed.ncbi.nlm.nih.gov/40334816/",null],["4","R0006453","R0006453.pdf","open_download_failed","nonrandomized_study","Desai A","2025","Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1093/ibd/izae090","https://doi.org/10.1093/ibd/izae090","38642103","https://pubmed.ncbi.nlm.nih.gov/38642103/","https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izae090/57291807/izae090.pdf",null],["4","R0006961","R0006961.pdf","open_download_failed","nonrandomized_study","Gu JH","2025","Dose-dependent pancreatitis risk associated with GLP-1 agonists.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-024-01552-x","https://doi.org/10.1007/s40200-024-01552-x","39758806","https://pubmed.ncbi.nlm.nih.gov/39758806/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11695654/pdf/40200_2024_Article_1552.pdf",null],["4","R0007051","R0007051.pdf","open_download_failed","nonrandomized_study","Limpijankit V","2025","Risk Factors for New-Onset Atrial Fibrillation in Thai Adults with Hypertension","medRxiv","openRxiv","10.1101/2025.05.07.25327197","https://doi.org/10.1101/2025.05.07.25327197",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/05/08/2025.05.07.25327197.full.pdf",null],["4","R0007100","R0007100.pdf","open_download_failed","nonrandomized_study","Talay L","2025","12-Month Weight Loss and Adherence in a Real-World Tirzepatide-Supported Digital Obesity Service","Preprints.org","MDPI AG","10.20944/preprints202511.2177.v1","https://doi.org/10.20944/preprints202511.2177.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/c5bf8e42e66fb00fd0dbbf0771fe2da2/download_pub",null],["4","R0007190","R0007190.pdf","free_to_read","nonrandomized_study","Ko HY","2025","End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112921","https://doi.org/10.1016/j.diabres.2025.112921","40998218","https://pubmed.ncbi.nlm.nih.gov/40998218/","https://doi.org/10.1016/j.diabres.2025.112921",null],["4","R0007418","R0007418.pdf","free_to_read","nonrandomized_study","Jacobsen SL","2025","Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study.","Psychiatry research","Elsevier BV","10.1016/j.psychres.2025.116592","https://doi.org/10.1016/j.psychres.2025.116592","40526989","https://pubmed.ncbi.nlm.nih.gov/40526989/","https://doi.org/10.1016/j.psychres.2025.116592",null],["4","R0007503","R0007503.pdf","no_doi","nonrandomized_study","Guo L","2025","INDIVIDUAL ARTICLE: Psoriasis and Obesity: Optimizing Pharmacologic Treatment and Lifestyle Interventions.","Journal of drugs in dermatology : JDD",null,null,"https://doi.org/","39761151","https://pubmed.ncbi.nlm.nih.gov/39761151/",null,null],["4","R0007945","R0007945.pdf","free_to_read","nonrandomized_study","Mody R","2025","Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16372","https://doi.org/10.1111/dom.16372","40181696","https://pubmed.ncbi.nlm.nih.gov/40181696/","https://doi.org/10.1111/dom.16372",null],["4","R0008097","R0008097.pdf","open_download_failed","nonrandomized_study","Houbachi L","2025","Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112017","https://doi.org/10.1016/j.diabres.2025.112017","39900263","https://pubmed.ncbi.nlm.nih.gov/39900263/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00031-2/pdf",null],["4","R0008595","R0008595.pdf","free_to_read","nonrandomized_study","Peyyety V","2025","Youth Perspectives on the Use of Medications for Weight Loss.","The Journal of adolescent health : official publication of the Society for Adolescent Medicine","Elsevier BV","10.1016/j.jadohealth.2025.02.011","https://doi.org/10.1016/j.jadohealth.2025.02.011","40266162","https://pubmed.ncbi.nlm.nih.gov/40266162/","https://doi.org/10.1016/j.jadohealth.2025.02.011",null],["4","R0008889","R0008889.pdf","open_download_failed","nonrandomized_study","Kim C","2025","Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.05.08.25327248","https://doi.org/10.1101/2025.05.08.25327248","40385382","https://pubmed.ncbi.nlm.nih.gov/40385382/","https://www.medrxiv.org/content/medrxiv/early/2025/05/09/2025.05.08.25327248.full.pdf",null],["4","R0009122","R0009122.pdf","free_to_read","nonrandomized_study","Marassi M","2025","Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2025.107866","https://doi.org/10.1016/j.phrs.2025.107866","40706779","https://pubmed.ncbi.nlm.nih.gov/40706779/","https://doi.org/10.1016/j.phrs.2025.107866",null],["4","R0009156","R0009156.pdf","open_download_failed","nonrandomized_study","Lan NSR","2025","Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2025.07.007","https://doi.org/10.1016/j.hlc.2025.07.007","40912924","https://pubmed.ncbi.nlm.nih.gov/40912924/","https://www.heartlungcirc.org/article/S1443-9506(25)01554-9/pdf",null],["4","R0009183","R0009183.pdf","open_download_failed","nonrandomized_study","Rizwan MR","2025","Considering Real-World Effectiveness of GLP-1RA Persistence and Outcomes for Weight loss regimes.","Authorea Preprints","Wiley","10.22541/au.175565534.46206657/v1","https://doi.org/10.22541/au.175565534.46206657/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.175565534.46206657/v1",null],["4","R0009226","R0009226.pdf","free_to_read","nonrandomized_study","Sallam M","2025","Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese ‎Individuals: A Narrative Review","Preprints.org","MDPI AG","10.20944/preprints202503.0430.v1","https://doi.org/10.20944/preprints202503.0430.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202503.0430.v1",null],["4","R0009261","R0009261.pdf","open_download_failed","nonrandomized_study","Gholami M","2025","GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-025-01604-w","https://doi.org/10.1007/s40200-025-01604-w","40182581","https://pubmed.ncbi.nlm.nih.gov/40182581/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11961817/pdf/40200_2025_Article_1604.pdf",null],["4","R0009498","R0009498.pdf","open_download_failed","nonrandomized_study","Gorelik Y","2025","GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN.","Journal of Crohn's & colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjae160","https://doi.org/10.1093/ecco-jcc/jjae160","39441993","https://pubmed.ncbi.nlm.nih.gov/39441993/","https://academic.oup.com/ecco-jcc/advance-article-pdf/doi/10.1093/ecco-jcc/jjae160/60011295/jjae160.pdf",null],["4","R0009895","R0009895.pdf","open_download_failed","nonrandomized_study","Sezer GE","2025","The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.","International journal of endocrinology","Wiley","10.1155/ije/6332117","https://doi.org/10.1155/ije/6332117","40330499","https://pubmed.ncbi.nlm.nih.gov/40330499/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/ije/6332117",null],["4","R0010192","R0010192.pdf","free_to_read","nonrandomized_study","Gabery S","2025","Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.","Life sciences","Elsevier BV","10.1016/j.lfs.2025.123845","https://doi.org/10.1016/j.lfs.2025.123845","40628316","https://pubmed.ncbi.nlm.nih.gov/40628316/","https://doi.org/10.1016/j.lfs.2025.123845",null],["4","R0010226","R0010226.pdf","open_download_failed","nonrandomized_study","Furió-Novejarque C","2025","GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241285925","https://doi.org/10.1177/19322968241285925","39411979","https://pubmed.ncbi.nlm.nih.gov/39411979/","https://journals.sagepub.com/doi/pdf/10.1177/19322968241285925?download=true",null],["4","R0010244","R0010244.pdf","open_download_failed","nonrandomized_study","Levine J","2025","Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.11.13.25340005","https://doi.org/10.1101/2025.11.13.25340005","41292626","https://pubmed.ncbi.nlm.nih.gov/41292626/","https://www.medrxiv.org/content/medrxiv/early/2025/11/15/2025.11.13.25340005.full.pdf",null],["4","R0010326","R0010326.pdf","free_to_read","nonrandomized_study","van Beurden W","2025","FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.108978","https://doi.org/10.1016/j.jdiacomp.2025.108978","39999536","https://pubmed.ncbi.nlm.nih.gov/39999536/","https://doi.org/10.1016/j.jdiacomp.2025.108978",null],["4","R0010840","R0010840.pdf","open_download_failed","nonrandomized_study","Olalere M","2025","The Effectiveness of Tirzepatide on weight loss in patients with type 2 Diabetes Mellitus","medRxiv","openRxiv","10.1101/2025.09.19.25336122","https://doi.org/10.1101/2025.09.19.25336122",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/09/19/2025.09.19.25336122.full.pdf",null],["4","R0010978","R0010978.pdf","free_to_read","nonrandomized_study","Conti M","2025","Development and implementation of a diagnostic and therapeutic care pathway for type 2 diabetes management in the hospital setting: preliminary findings from an Italian retrospective observational study.","Journal of diabetes and metabolic disorders","Springer Science and Business Media LLC","10.1007/s40200-025-01745-y","https://doi.org/10.1007/s40200-025-01745-y","41098473","https://pubmed.ncbi.nlm.nih.gov/41098473/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12518725/",null],["4","R0011014","R0011014.pdf","free_to_read","nonrandomized_study",null,"2025","Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.","Gastroenterology & hepatology",null,null,"https://doi.org/","41658350","https://pubmed.ncbi.nlm.nih.gov/41658350/",null,null],["4","R0011267","R0011267.pdf","free_to_read","nonrandomized_study","Chen IC","2025","Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112167","https://doi.org/10.1016/j.diabres.2025.112167","40204122","https://pubmed.ncbi.nlm.nih.gov/40204122/","https://doi.org/10.1016/j.diabres.2025.112167",null],["4","R0011291","R0011291.pdf","open_download_failed","nonrandomized_study","Sevencan B","2025","Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","Springer Science and Business Media LLC","10.5664/jcsm.11682","https://doi.org/10.5664/jcsm.11682","40114470","https://pubmed.ncbi.nlm.nih.gov/40114470/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12320683/pdf/jcsm.11682.pdf",null],["4","R0011595","R0011595.pdf","free_to_read","nonrandomized_study","Chang Y","2025","The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes.","International journal of surgery (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000002492","https://doi.org/10.1097/js9.0000000000002492","40434727","https://pubmed.ncbi.nlm.nih.gov/40434727/","https://doi.org/10.1097/js9.0000000000002492",null],["4","R0011881","R0011881.pdf","free_to_read","nonrandomized_study","Siudak Z","2025","Low long-term persistence with GLP-1 receptor agonists treatment: Real-world evidence from a large Polish cohort.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16590","https://doi.org/10.1111/dom.16590","40620195","https://pubmed.ncbi.nlm.nih.gov/40620195/","https://ruj.uj.edu.pl/handle/item/556600",null],["4","R0012004","R0012004.pdf","free_to_read","nonrandomized_study","Khalid SI","2025","The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes.","Clinical neurology and neurosurgery","Elsevier BV","10.1016/j.clineuro.2025.108952","https://doi.org/10.1016/j.clineuro.2025.108952","40381509","https://pubmed.ncbi.nlm.nih.gov/40381509/","https://doi.org/10.1016/j.clineuro.2025.108952",null],["4","R0012005","R0012005.pdf","free_to_read","nonrandomized_study","Ruiz Pons M","2025","Effectiveness of liraglutide in the treatment of adolescent obesity.","Anales de pediatria","Elsevier BV","10.1016/j.anpede.2025.503856","https://doi.org/10.1016/j.anpede.2025.503856","40645873","https://pubmed.ncbi.nlm.nih.gov/40645873/","https://doi.org/10.1016/j.anpede.2025.503856",null],["4","R0012082","R0012082.pdf","open_download_failed","nonrandomized_study","Snell-Bergeon JK","2025","Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0328","https://doi.org/10.1089/dia.2024.0328","39745353","https://pubmed.ncbi.nlm.nih.gov/39745353/","https://www.liebertpub.com/doi/pdf/10.1089/dia.2024.0328?download=true",null],["4","R0012734","R0012734.pdf","open_download_failed","nonrandomized_study","Michalak W","2025","Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).","Journal of medical economics","Informa UK Limited","10.1080/13696998.2025.2526282","https://doi.org/10.1080/13696998.2025.2526282","40579810","https://pubmed.ncbi.nlm.nih.gov/40579810/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2025.2526282?needAccess=true",null],["4","R0012894","R0012894.pdf","free_to_read","nonrandomized_study","Dziewierz A","2025","Supporting evidence for the association between GLP-1 agonists and NAION: Insights from a large national cohort.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70128","https://doi.org/10.1111/dom.70128","40926730","https://pubmed.ncbi.nlm.nih.gov/40926730/","https://ruj.uj.edu.pl/handle/item/563542",null],["4","R0012978","R0012978.pdf","open_download_failed","nonrandomized_study","Tesfaye H","2025","Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16303","https://doi.org/10.1111/dom.16303","40019137","https://pubmed.ncbi.nlm.nih.gov/40019137/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16303",null],["4","R0013082","R0013082.pdf","open_download_failed","nonrandomized_study","Baechle C","2025","Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16149","https://doi.org/10.1111/dom.16149","39727159","https://pubmed.ncbi.nlm.nih.gov/39727159/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16149",null],["4","R0013114","R0013114.pdf","open_download_failed","nonrandomized_study","Fallows E","2025","Malnutrition with use of GLP-1 agonists is an underestimated real world harm.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.r1512","https://doi.org/10.1136/bmj.r1512","40691004","https://pubmed.ncbi.nlm.nih.gov/40691004/","https://www.bmj.com/content/bmj/390/bmj.r1512.full.pdf",null],["4","R0013337","R0013337.pdf","open_download_failed","nonrandomized_study","Niezen S","2025","Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/ajg.0000000000003312","https://doi.org/10.14309/ajg.0000000000003312","39774063","https://pubmed.ncbi.nlm.nih.gov/39774063/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12230180/pdf/nihms-2045810.pdf",null],["4","R0013377","R0013377.pdf","open_download_failed","nonrandomized_study","Munshi M","2025","Semaglutide for Weight Loss in Patients with a Family History of Thyroid or Uterine Cancer: A Systemic Review","medRxiv","openRxiv","10.1101/2025.02.27.25323032","https://doi.org/10.1101/2025.02.27.25323032",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/02/28/2025.02.27.25323032.full.pdf",null],["4","R0013397","R0013397.pdf","open_download_failed","nonrandomized_study","Giorgino F","2025","A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112945","https://doi.org/10.1016/j.diabres.2025.112945","41092981","https://pubmed.ncbi.nlm.nih.gov/41092981/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00959-3/pdf",null],["4","R0013427","R0013427.pdf","open_download_failed","nonrandomized_study","Fiore V","2025","Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16174","https://doi.org/10.1111/dom.16174","39789997","https://pubmed.ncbi.nlm.nih.gov/39789997/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16174",null],["4","R0013459","R0013459.pdf","open_download_failed","nonrandomized_study","Friedman O","2025","Breast reduction outcomes in massive weight loss: A comparative analysis of GLP-1 receptor agonist users, post-bariatric surgery patients, and controls.","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Elsevier BV","10.1016/j.bjps.2025.09.023","https://doi.org/10.1016/j.bjps.2025.09.023","41066871","https://pubmed.ncbi.nlm.nih.gov/41066871/","https://www.jprasurg.com/article/S1748-6815(25)00569-8/pdf",null],["4","R0013964","R0013964.pdf","open_download_failed","nonrandomized_study","Fetzner J","2025","Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae817","https://doi.org/10.1210/clinem/dgae817","39998927","https://pubmed.ncbi.nlm.nih.gov/39998927/","https://academic.oup.com/jcem/article-pdf/110/Supplement_2/S147/62167146/dgae817.pdf",null],["4","R0014114","R0014114.pdf","open_download_failed","nonrandomized_study","Kuo CC","2025","Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment. Authors' Reply.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70063","https://doi.org/10.1111/apt.70063","40019295","https://pubmed.ncbi.nlm.nih.gov/40019295/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.70063",null],["4","R0014411","R0014411.pdf","open_download_failed","nonrandomized_study","Doherty P","2025","Retrospective Case-Control Study of Pre-Diagnosis Observational and Prescription Data in Parkinson’s Disease","medRxiv","openRxiv","10.1101/2025.08.11.25333439","https://doi.org/10.1101/2025.08.11.25333439",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/08/13/2025.08.11.25333439.full.pdf",null],["4","R0014696","R0014696.pdf","open_download_failed","nonrandomized_study","David B","2025","Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2025.02.005","https://doi.org/10.1016/j.clinthera.2025.02.005","40087082","https://pubmed.ncbi.nlm.nih.gov/40087082/","https://www.clinicaltherapeutics.com/article/S0149-2918(25)00049-9/pdf",null],["4","R0015572","R0015572.pdf","open_download_failed","nonrandomized_study","Halver A","2025","Efficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes.","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","Frontline Medical Communications, Inc.","10.12788/fp.0642","https://doi.org/10.12788/fp.0642","42666995","https://pubmed.ncbi.nlm.nih.gov/42666995/","https://cdn.mdedge.com/files/s3fs-public/issues/articles/1125FED DM Semaglutide.pdf",null],["4","R0015682","R0015682.pdf","open_download_failed","nonrandomized_study","Nasoufidou A","2025","Cardiovascular efficacy of tirzepatide: what real-world evidence promises.","Expert review of cardiovascular therapy","Informa UK Limited","10.1080/14779072.2025.2587294","https://doi.org/10.1080/14779072.2025.2587294","41199614","https://pubmed.ncbi.nlm.nih.gov/41199614/","https://www.tandfonline.com/doi/pdf/10.1080/14779072.2025.2587294?needAccess=true",null],["4","R0015693","R0015693.pdf","open_download_failed","nonrandomized_study","Ramirez LEO","2025","Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia.","Value in health regional issues","Elsevier BV","10.1016/j.vhri.2024.101073","https://doi.org/10.1016/j.vhri.2024.101073","39919670","https://pubmed.ncbi.nlm.nih.gov/39919670/","https://www.valuehealthregionalissues.com/article/S2212-1099(24)00106-7/pdf",null],["4","R0015833","R0015833.pdf","open_download_failed","nonrandomized_study","De Fano M","2025","The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112119","https://doi.org/10.1016/j.diabres.2025.112119","40174863","https://pubmed.ncbi.nlm.nih.gov/40174863/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00133-0/pdf",null],["4","R0015904","R0015904.pdf","open_download_failed","nonrandomized_study","Albarmawi H","2025","Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2025.2596430","https://doi.org/10.1080/03007995.2025.2596430","41363882","https://pubmed.ncbi.nlm.nih.gov/41363882/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2025.2596430?needAccess=true",null],["4","R0016003","R0016003.pdf","open_download_failed","nonrandomized_study","Farahvash A","2025","Pattern of semaglutide prescription in a real-world Canadian patient cohort.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2025.06.006","https://doi.org/10.1016/j.pcd.2025.06.006","40562647","https://pubmed.ncbi.nlm.nih.gov/40562647/","https://www.primary-care-diabetes.com/action/showPdf?pii=S1751991825001159",null],["4","R0016227","R0016227.pdf","open_download_failed","nonrandomized_study","Arora P","2025","Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.","Expert review of pharmacoeconomics & outcomes research","Informa UK Limited","10.1080/14737167.2025.2570688","https://doi.org/10.1080/14737167.2025.2570688","41059919","https://pubmed.ncbi.nlm.nih.gov/41059919/","https://www.tandfonline.com/doi/pdf/10.1080/14737167.2025.2570688",null],["4","R0016254","R0016254.pdf","open_download_failed","nonrandomized_study","Michalak W","2025","Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF).","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2025.07.018","https://doi.org/10.1016/j.clinthera.2025.07.018","40813184","https://pubmed.ncbi.nlm.nih.gov/40813184/","https://www.clinicaltherapeutics.com/article/S0149-2918(25)00254-1/pdf",null],["4","R0016397","R0016397.pdf","open_download_failed","nonrandomized_study","Komatsoulis G","2025","Cardiovascular Outcomes in Low-Risk Non-Diabetic Patients Treated with Semaglutide","medRxiv","openRxiv","10.1101/2025.05.20.25327768","https://doi.org/10.1101/2025.05.20.25327768",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/05/21/2025.05.20.25327768.full.pdf",null],["4","R0016574","R0016574.pdf","free_to_read","nonrandomized_study","Udawatta M","2025","Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss.","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Springer Science and Business Media LLC","10.1007/s10072-024-07701-7","https://doi.org/10.1007/s10072-024-07701-7","39030327","https://pubmed.ncbi.nlm.nih.gov/39030327/","https://doi.org/10.21203/rs.3.rs-4622105/v1",null],["4","R0016685","R0016685.pdf","open_download_failed","nonrandomized_study","Wang J","2025","The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.","Cardiorenal medicine","S. Karger AG","10.1159/000546238","https://doi.org/10.1159/000546238","40349689","https://pubmed.ncbi.nlm.nih.gov/40349689/","https://karger.com/crm/article-pdf/doi/10.1159/000546238/4375503/000546238.pdf",null],["4","R0016729","R0016729.pdf","free_to_read","nonrandomized_study","Dayer VW","2025","Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2025.07.007","https://doi.org/10.1016/j.jval.2025.07.007","40701338","https://pubmed.ncbi.nlm.nih.gov/40701338/","https://doi.org/10.1016/j.jval.2025.07.007",null],["4","R0016806","R0016806.pdf","open_download_failed","nonrandomized_study","Meral R","2025","Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?","Diabetes care","American Diabetes Association","10.2337/dc24-2408","https://doi.org/10.2337/dc24-2408","40063619","https://pubmed.ncbi.nlm.nih.gov/40063619/","https://www.medrxiv.org/content/medrxiv/early/2024/09/27/2024.09.25.24313345.full.pdf",null],["4","R0016834","R0016834.pdf","open_download_failed","nonrandomized_study","Ascandar N","2025","Clinical Outcomes After Hospitalization for Acute Coronary Syndrome in Patients Treated with Semaglutide Versus Bariatric Surgery: A Retrospective Multicenter Analysis.","HCA healthcare journal of medicine","HCA Healthcare","10.36518/2689-0216.1960","https://doi.org/10.36518/2689-0216.1960","40642578","https://pubmed.ncbi.nlm.nih.gov/40642578/","https://scholarlycommons.hcahealthcare.com/cgi/viewcontent.cgi?article=1960&context=hcahealthcarejournal",null],["4","R0016953","R0016953.pdf","free_to_read","nonrandomized_study","Ruseva A","2025","Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months).","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2025.2591464","https://doi.org/10.1080/03007995.2025.2591464","41351543","https://pubmed.ncbi.nlm.nih.gov/41351543/","https://doi.org/10.1080/03007995.2025.2591464",null],["4","R0017266","R0017266.pdf","free_to_read","nonrandomized_study","Kumar S","2025","Real-World Analysis of Semaglutide and Naltrexone for Alcohol Reduction, Anxiety Relief, and Side Effects Using Self-Reported Data from Reddit","PsyArXiv","Center for Open Science","10.31234/osf.io/r2fnz_v2","https://doi.org/10.31234/osf.io/r2fnz_v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31234/osf.io/r2fnz_v2",null],["4","R0017268","R0017268.pdf","open_download_failed","nonrandomized_study","Sodhi M","2025","Risk of Hair Loss with Semaglutide for Weight Loss","medRxiv","openRxiv","10.1101/2025.02.23.25322568","https://doi.org/10.1101/2025.02.23.25322568",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/03/06/2025.02.23.25322568.full.pdf",null],["4","R0017529","R0017529.pdf","open_download_failed","nonrandomized_study","Lewis JE","2025","Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjae241","https://doi.org/10.1093/asj/sjae241","39665435","https://pubmed.ncbi.nlm.nih.gov/39665435/","https://academic.oup.com/asj/advance-article-pdf/doi/10.1093/asj/sjae241/61087190/sjae241.pdf",null],["4","R0017586","R0017586.pdf","open_download_failed","nonrandomized_study","Pinto M","2025","Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes.","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","SAGE Publications","10.1177/87551225241289959","https://doi.org/10.1177/87551225241289959","39545243","https://pubmed.ncbi.nlm.nih.gov/39545243/","https://journals.sagepub.com/doi/pdf/10.1177/87551225241289959?download=true",null],["4","R0017678","R0017678.pdf","open_download_failed","nonrandomized_study","Virani S","2025","Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%).","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2025.07.027","https://doi.org/10.1016/j.cjca.2025.07.027","41110921","https://pubmed.ncbi.nlm.nih.gov/41110921/","https://onlinecjc.ca/article/S0828-282X(25)00640-3/pdf",null],["4","R0017882","R0017882.pdf","open_download_failed","nonrandomized_study","Giese S","2025","Use of Semaglutide for Successful Weight Loss and Maintenance in a Non-Obese Population: An Observational, Retrospective Chart Review","Preprints.org","MDPI AG","10.20944/preprints202506.1737.v2","https://doi.org/10.20944/preprints202506.1737.v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/0a32397ed82de7c4468bf59a966b5302/download_pub",null],["4","R0017971","R0017971.pdf","free_to_read","nonrandomized_study","Hsu CY","2025","Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2025.107639","https://doi.org/10.1016/j.phrs.2025.107639","39900209","https://pubmed.ncbi.nlm.nih.gov/39900209/","https://doi.org/10.1016/j.phrs.2025.107639",null],["4","R0018083","R0018083.pdf","open_download_failed","nonrandomized_study","Zhang YW","2025","Assessing the Impact of the Inflation Reduction Act on Medicare Prescription Drug Coverage","medRxiv","openRxiv","10.1101/2025.07.24.25332155","https://doi.org/10.1101/2025.07.24.25332155",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/07/24/2025.07.24.25332155.full.pdf",null],["4","R0018157","R0018157.pdf","open_download_failed","nonrandomized_study","Ajmera R","2025","Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis.","Heart, lung & circulation","Elsevier BV","10.1016/j.hlc.2025.01.011","https://doi.org/10.1016/j.hlc.2025.01.011","40374414","https://pubmed.ncbi.nlm.nih.gov/40374414/","https://www.heartlungcirc.org/action/showPdf?pii=S1443950625001386",null],["4","R0018247","R0018247.pdf","free_to_read","nonrandomized_study","McEwan P","2025","Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2025.2459529","https://doi.org/10.1080/13696998.2025.2459529","39882599","https://pubmed.ncbi.nlm.nih.gov/39882599/","https://doi.org/10.1080/13696998.2025.2459529","ClinicalTrials.gov:NCT03574597"],["4","R0018296","R0018296.pdf","free_to_read","nonrandomized_study","Berra C","2025","Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2025.107640","https://doi.org/10.1016/j.phrs.2025.107640","39900210","https://pubmed.ncbi.nlm.nih.gov/39900210/","https://doi.org/10.1016/j.phrs.2025.107640",null],["4","R0018304","R0018304.pdf","open_download_failed","nonrandomized_study","De Sio V","2025","Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2025.133028","https://doi.org/10.1016/j.ijcard.2025.133028","39890028","https://pubmed.ncbi.nlm.nih.gov/39890028/","https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00071-3/pdf","ClinicalTrials.gov:NCT02219984"],["4","R0018336","R0018336.pdf","open_download_failed","nonrandomized_study","Karakolias S","2025","Trends and patterns in antidiabetic medication prescriptions: Insights from Greece's electronic prescription database.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2025.08.004","https://doi.org/10.1016/j.pcd.2025.08.004","40803974","https://pubmed.ncbi.nlm.nih.gov/40803974/","https://www.primary-care-diabetes.com/article/S1751-9918(25)00154-8/pdf",null],["4","R0018483","R0018483.pdf","open_download_failed","nonrandomized_study","Melzer Cohen C","2025","Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112086","https://doi.org/10.1016/j.diabres.2025.112086","40058653","https://pubmed.ncbi.nlm.nih.gov/40058653/","https://www.diabetesresearchclinicalpractice.com/action/showPdf?pii=S0168822725001007",null],["4","R0018638","R0018638.pdf","free_to_read","nonrandomized_study","Rivero-Moreno Y","2025","Semaglutide vs Revisional Bariatric Surgery: What Is the Best Option for Suboptimal Clinical Response or Recurrent Weight Gain After MBS? ","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-6033446/v1","https://doi.org/10.21203/rs.3.rs-6033446/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-6033446/v1",null],["4","R0018656","R0018656.pdf","open_download_failed","nonrandomized_study","Lum F","2025","Re: Chou et al.: Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study (Ophthalmology. 2025;132:381-388).","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2025.03.011","https://doi.org/10.1016/j.ophtha.2025.03.011","40214636","https://pubmed.ncbi.nlm.nih.gov/40214636/","https://www.aaojournal.org/article/S0161-6420(25)00172-1/pdf",null],["4","R0018679","R0018679.pdf","free_to_read","nonrandomized_study","Raat W","2025","Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019-2023).","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.10.007","https://doi.org/10.1016/j.pcd.2024.10.007","39487060","https://pubmed.ncbi.nlm.nih.gov/39487060/","https://doi.org/10.1016/j.pcd.2024.10.007",null],["4","R0018744","R0018744.pdf","free_to_read","nonrandomized_study","Colacci M","2025","Evaluating risks and benefits of Newer Diabetes medications when Used in Routine care (ENDURe)","medRxiv","openRxiv","10.1101/2025.02.20.25322631","https://doi.org/10.1101/2025.02.20.25322631",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2025.02.20.25322631",null],["4","R0018834","R0018834.pdf","free_to_read","nonrandomized_study","Patel D","2025","High rate of complications in a real-world cohort of youth with T2D: a multicenter analysis.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109091","https://doi.org/10.1016/j.jdiacomp.2025.109091","40570536","https://pubmed.ncbi.nlm.nih.gov/40570536/","https://doi.org/10.1016/j.jdiacomp.2025.109091",null],["4","R0018918","R0018918.pdf","free_to_read","nonrandomized_study","Kato S","2025","Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2025.112913","https://doi.org/10.1016/j.diabres.2025.112913","40983113","https://pubmed.ncbi.nlm.nih.gov/40983113/","https://doi.org/10.1016/j.diabres.2025.112913",null],["4","R0019157","R0019157.pdf","open_download_failed","nonrandomized_study","Chen HY","2025","The Role Of Drug Indication On Incidence Rate Heterogeneity: A Large-Scale, Systematic Evaluation Across An International Network Of Observational Databases.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.10.22.25338563","https://doi.org/10.1101/2025.10.22.25338563","41282870","https://pubmed.ncbi.nlm.nih.gov/41282870/","https://www.medrxiv.org/content/medrxiv/early/2025/10/24/2025.10.22.25338563.1.full.pdf",null],["4","R0019252","R0019252.pdf","open_download_failed","nonrandomized_study","Uchida D","2025","Long-term effects of esaxerenone in patients with type 2 diabetes, diabetic kidney disease, and hypertension (JDDM77).","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-024-00779-6","https://doi.org/10.1007/s13340-024-00779-6","39877444","https://pubmed.ncbi.nlm.nih.gov/39877444/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11769913/pdf/13340_2024_Article_779.pdf",null],["4","R0019323","R0019323.pdf","free_to_read","nonrandomized_study","Roseberry T","2025","Sex differences in GLP-1 signaling across species","bioRxiv","openRxiv","10.1101/2025.03.17.643822","https://doi.org/10.1101/2025.03.17.643822",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2025.03.17.643822",null],["4","R0019568","R0019568.pdf","free_to_read","nonrandomized_study","Wahid M","2025","Differential risk of systemic complications and mortality in HFrEF and HFpEF patients undergoing total knee arthroplasty: A nationwide propensity matched study with cox regression analysis.","Journal of orthopaedic surgery (Hong Kong)","SAGE Publications","10.1177/10225536251395952","https://doi.org/10.1177/10225536251395952","41187943","https://pubmed.ncbi.nlm.nih.gov/41187943/","https://doi.org/10.1177/10225536251395952",null],["4","R0019669","R0019669.pdf","free_to_read","nonrandomized_study","Ruseva A","2025","Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months).","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2025.2482274","https://doi.org/10.1080/00325481.2025.2482274","40122077","https://pubmed.ncbi.nlm.nih.gov/40122077/","https://doi.org/10.1080/00325481.2025.2482274",null],["4","R0019677","R0019677.pdf","open_download_failed","nonrandomized_study","Chou CC","2025","Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.","Ophthalmology","Elsevier BV","10.1016/j.ophtha.2024.10.030","https://doi.org/10.1016/j.ophtha.2024.10.030","39491755","https://pubmed.ncbi.nlm.nih.gov/39491755/","http://www.aaojournal.org/article/S0161642024006857/pdf",null],["4","R0019787","R0019787.pdf","open_download_failed","nonrandomized_study","Al-Horani RA","2025","Potential New Treatments for Chronic Kidney Diseases: A Concise Review.","Current pharmaceutical design","Bentham Science Publishers Ltd.","10.2174/0113816128360091250117040009","https://doi.org/10.2174/0113816128360091250117040009","39936428","https://pubmed.ncbi.nlm.nih.gov/39936428/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12325688/pdf/nihms-2067747.pdf",null],["4","R0019819","R0019819.pdf","open_download_failed","nonrandomized_study","Zhao X","2025","Hypertension associated with the risk of extrahepatic cancers in MASLD population: a multicenter cross-sectional study in China","medRxiv","openRxiv","10.1101/2025.07.28.25332237","https://doi.org/10.1101/2025.07.28.25332237",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/08/18/2025.07.28.25332237.full.pdf",null],["4","R0019898","R0019898.pdf","free_to_read","nonrandomized_study","Stoll F","2025","Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2025.02.004","https://doi.org/10.1016/j.orcp.2025.02.004","39952885","https://pubmed.ncbi.nlm.nih.gov/39952885/","https://doi.org/10.1016/j.orcp.2025.02.004",null],["4","R0020111","R0020111.pdf","open_download_failed","nonrandomized_study","Giorda CB","2025","Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non-Diabetic Population. A 10-Year-Observational Study.","Liver international : official journal of the International Association for the Study of the Liver","Wiley","10.1111/liv.70075","https://doi.org/10.1111/liv.70075","40287817","https://pubmed.ncbi.nlm.nih.gov/40287817/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.70075",null],["4","R0020918","R0020918.pdf","free_to_read","nonrandomized_study","Bravo Baptista S","2025","Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes. Baseline inclusion data of the ARTHEMIS registry.","Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology","Elsevier BV","10.1016/j.repc.2025.03.006","https://doi.org/10.1016/j.repc.2025.03.006","40738464","https://pubmed.ncbi.nlm.nih.gov/40738464/","https://doi.org/10.1016/j.repc.2025.03.006","ClinicalTrials.gov:NCT04481997"],["4","R0021310","R0021310.pdf","free_to_read","nonrandomized_study","Jung W","2025","Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.","Breast cancer research and treatment","Springer Science and Business Media LLC","10.1007/s10549-024-07594-2","https://doi.org/10.1007/s10549-024-07594-2","39762706","https://pubmed.ncbi.nlm.nih.gov/39762706/","https://doi.org/10.5167/uzh-278345",null],["4","R0022115","R0022115.pdf","open_download_failed","nonrandomized_study","Swift C","2025","Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.12.014","https://doi.org/10.1016/j.clinthera.2024.12.014","39827023","https://pubmed.ncbi.nlm.nih.gov/39827023/","https://www.clinicaltherapeutics.com/article/S0149-2918(24)00418-1/pdf",null],["4","R0022176","R0022176.pdf","free_to_read","nonrandomized_study","Bollinger B","2025","Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-024-08724-y","https://doi.org/10.1007/s10620-024-08724-y","39604664","https://pubmed.ncbi.nlm.nih.gov/39604664/","https://doi.org/10.21203/rs.3.rs-4391484/v1",null],["4","R0024190","R0024190.pdf","open_download_failed","nonrandomized_study","Desai RJ","2025","Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.3583","https://doi.org/10.1002/cpt.3583","39935003","https://pubmed.ncbi.nlm.nih.gov/39935003/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.3583",null],["4","R0029040","R0029040.pdf","free_to_read","nonrandomized_study","Neves JS","2025","Trends in antidiabetic drug use in Portugal: 8 years real-world data from a nationwide retrospective observational study (2017-2024) (TREND-8 study).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16429","https://doi.org/10.1111/dom.16429","40317996","https://pubmed.ncbi.nlm.nih.gov/40317996/","https://doi.org/10.1111/dom.16429",null],["4","R0029045","R0029045.pdf","open_download_failed","nonrandomized_study","Fejes R","2025","Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.","Journal of diabetes research","Wiley","10.1155/jdr/9141564","https://doi.org/10.1155/jdr/9141564","40264573","https://pubmed.ncbi.nlm.nih.gov/40264573/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/jdr/9141564",null],["4","R0029089","R0029089.pdf","open_download_failed","nonrandomized_study","Jones LA","2025","GLP-1 and the Neurobiology of Eating Control: Recent Advances.","Endocrinology","The Endocrine Society","10.1210/endocr/bqae167","https://doi.org/10.1210/endocr/bqae167","39813121","https://pubmed.ncbi.nlm.nih.gov/39813121/","https://academic.oup.com/endo/advance-article-pdf/doi/10.1210/endocr/bqae167/61443524/bqae167.pdf",null],["4","R0029587","R0029587.pdf","free_to_read","nonrandomized_study","Dewar S","2025","The Optimal Health Weight and Lifestyle (OHWL) Clinic: Comprehensive, Multidisciplinary and Geriatric-Focused Care for Multimorbid Older Adults With Obesity.","Current developments in nutrition","Elsevier BV","10.1016/j.cdnut.2025.107526","https://doi.org/10.1016/j.cdnut.2025.107526","41080466","https://pubmed.ncbi.nlm.nih.gov/41080466/","https://doi.org/10.1016/j.cdnut.2025.107526",null],["4","R0029611","R0029611.pdf","free_to_read","nonrandomized_study","Szekeres Z","2025","Molecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity.","Biomedicines","MDPI AG","10.3390/biomedicines13081989","https://doi.org/10.3390/biomedicines13081989","40868241","https://pubmed.ncbi.nlm.nih.gov/40868241/","https://doi.org/10.3390/biomedicines13081989",null],["4","R0029637","R0029637.pdf","open_download_failed","nonrandomized_study","Singal A","2025","Association Between Androgenetic Alopecia and Glucagon-Like Peptide-1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study.","International journal of dermatology","Wiley","10.1111/ijd.17971","https://doi.org/10.1111/ijd.17971","40662424","https://pubmed.ncbi.nlm.nih.gov/40662424/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijd.17971",null],["4","R0030153","R0030153.pdf","free_to_read","nonrandomized_study","Phadnis A","2025","Decoding MODY: exploring genetic roots and clinical pathways.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-025-00809-x","https://doi.org/10.1007/s13340-025-00809-x","40166432","https://pubmed.ncbi.nlm.nih.gov/40166432/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11954780/pdf/13340_2025_Article_809.pdf",null],["4","R0032349","R0032349.pdf","no_doi","nonrandomized_study","Jung, Emma Yejoo","2025","Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients","DSpace@MIT (Massachusetts Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032355","R0032355.pdf","no_doi","nonrandomized_study","Shi, Yu","2025","Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032379","R0032379.pdf","no_doi","nonrandomized_study","Perez, Sui-Ling","2025","Incretin-Based Therapies—Semaglutide, Tirzepatide, and Sitagliptin: Evaluating Pancreatitis Risk in Type 2 Diabetes Mellitus","Florida International University Digital Commons (Florida International University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032426","R0032426.pdf","no_doi","nonrandomized_study","Negin Soroush","2025","Advances in cardiovascular pharmacogenetics and clinical outcomes in pharmacoepidemiology","EUR Research Repository (Erasmus University Rotterdam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032428","R0032428.pdf","no_doi","nonrandomized_study","Лора Петрова","2025","Retrospective analysis of clinical trials of medicinal products for the treatment of diabetes mellitus","Bulgarian Portal for Open Science",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032459","R0032459.pdf","no_doi","nonrandomized_study","Simona Pašková","2025",": Analysis of Weight Loss Reduction Methods and Modern Approaches in the Treatment of Obesity in Adults","Digital Repository (National Repository of Grey Literature)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032687","R0032687.pdf","free_to_read","nonrandomized_study",null,"2025","Semaglutide for adults living with obesity","Kazan medical journal","ECO-Vector LLC (Publications)","10.17816/kmj696819","https://doi.org/10.17816/kmj696819",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17816/kmj696819",null],["4","R0032799","R0032799.pdf","free_to_read","nonrandomized_study","Gabriel J. Sanders","2025","Exploring Wearable Technology and Lean Mass Alterations in GLP-1 Agonists, Bariatric Surgery, and Testosterone Replacement Therapy","Research in Psychology and Behavior","Pinnacle Science LC","10.53520/rpb2025.107140","https://doi.org/10.53520/rpb2025.107140",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53520/rpb2025.107140",null],["4","R0032825","R0032825.pdf","free_to_read","nonrandomized_study","Joon Daniel Park","2025","GLP-1 Agonists Reimagined: The Tripartite Applications of the Semaglutide Hormone","Technium BioChemMed","PLUS COMMUNICATION CONSULTING SRL","10.47577/biochemmed.v13i.13309","https://doi.org/10.47577/biochemmed.v13i.13309",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.47577/biochemmed.v13i.13309",null],["4","R0033032","R0033032.pdf","free_to_read","nonrandomized_study","Edwin Dias","2025","A Comprehensive Review on Dyslipidemia and Obesity: Pathophysiology, Clinical Implications and Management Approaches","International Journal of Research in Pharmacy and Allied Science","Ideal Publication","10.71431/ijrpas.2025.41203","https://doi.org/10.71431/ijrpas.2025.41203",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.71431/ijrpas.2025.41203",null],["4","R0033272","R0033272.pdf","free_to_read","nonrandomized_study",null,"2025","PSRC 2025 Annual Meeting Abstracts Supplement Table of Contents","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/gox.0000000000006665","https://doi.org/10.1097/gox.0000000000006665",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/gox.0000000000006665",null],["4","R0033280","R0033280.pdf","free_to_read","nonrandomized_study","Y. J. Anupama","2025","Cardiovascular–Kidney–Metabolic Syndrome: Untangling the Interconnected Burden","Indian Journal of Kidney Diseases","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijkd.ijkd_35_25","https://doi.org/10.4103/ijkd.ijkd_35_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijkd.ijkd_35_25",null],["4","R0034132","R0034132.pdf","no_doi","nonrandomized_study","Amachree, Edwin","2025","The Silent Saboteur: How Insulin Resistance Fuels Obesity and Chronic Disease","Digital Commons (Liberty University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035369","R0035369.pdf","free_to_read","nonrandomized_study","В. В. Салухов","2025","Body weight variability as a factor of cardiovascular risk","Русский медицинский журнал","LLC Russian Medical Journal","10.32364/2225-2282-2025-2-3","https://doi.org/10.32364/2225-2282-2025-2-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.32364/2225-2282-2025-2-3",null],["4","R0035859","R0035859.pdf","free_to_read","nonrandomized_study","Mansi Srivastava","2025","Integrated Approaches to Obesity Management: Pharmacological Advances, Pandemic Challenges, and the Role of Shared Decision-Making","medtigo Journal of Medicine","Medtigo","10.63096/medtigo3061232","https://doi.org/10.63096/medtigo3061232",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.63096/medtigo3061232",null],["4","R0035872","R0035872.pdf","free_to_read","nonrandomized_study","A. Al Subhi","2025","Liraglutide Therapy for Glycemic Control and Weight Reduction in Overweight and Obese Patients with Type 2 Diabetes at Sultan Qaboos University Hospital","Journal of Diabetes and Endocrine Practice","Thieme Medical and Scientific Publishers Pvt. Ltd.","10.1055/s-0045-1815641","https://doi.org/10.1055/s-0045-1815641",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1055/s-0045-1815641",null],["4","R0035946","R0035946.pdf","free_to_read","nonrandomized_study","Abhishek Pachauri","2025","Mapping the Diabetes Comorbidome: A New Frontier in Personalised Medicine","Preventive Medicine Research & Reviews","Ovid Technologies (Wolters Kluwer Health)","10.4103/pmrr.pmrr_39_25","https://doi.org/10.4103/pmrr.pmrr_39_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/pmrr.pmrr_39_25",null],["4","R0036063","R0036063.pdf","free_to_read","nonrandomized_study","Salem Abuhadida","2025","Evaluating Real World Data From WebMD on Anti-Obesity Medication Semaglutide","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5126847","https://doi.org/10.2139/ssrn.5126847",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5126847",null],["4","R0036069","R0036069.pdf","free_to_read","nonrandomized_study","Hua He","2025","Metformin and GLP-1RA Drug Interaction and Risk of Starvation Ketoacidosis: A Pharmacovigilance-MBMA Model Evaluation","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5886180","https://doi.org/10.2139/ssrn.5886180",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5886180",null],["4","R0036078","R0036078.pdf","free_to_read","nonrandomized_study","Minjeong Jeon","2025","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Osteoarthritis among Individuals with Type 2 Diabetes: A Population-Based Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5702461","https://doi.org/10.2139/ssrn.5702461",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5702461",null],["4","R0036089","R0036089.pdf","free_to_read","nonrandomized_study","Gülce  Ecem Doğancalı","2025","Osteonecrosis-Like Oral Complications in a Semaglutide User: A Case Report Supported by FAERS Pharmacovigilance Findings","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5938654","https://doi.org/10.2139/ssrn.5938654",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5938654",null],["4","R0036134","R0036134.pdf","no_doi","nonrandomized_study","Chaudhary, Eeman","2025","The Supply and Demand of Ozempic in America: An Economic Analysis","Hollins Digital Commons (Hollins University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036138","R0036138.pdf","no_doi","nonrandomized_study","Vega, Christine","2025","From Venom to Medicine: Harnessing Animal Toxins for Drug Discovery","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036142","R0036142.pdf","no_doi","nonrandomized_study","Singh, Ryan","2025","GPCR-Mediated Mechanisms in Obesity: The Role of Ghrelin and GLP-1 Receptors","Digital Commons - University of South Florida (University of South Florida)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036225","R0036225.pdf","no_doi","nonrandomized_study","Ahn, Jaeun","2025","Association of Glucagon-like Peptide-1 Receptor Agonist Use with Cardiovascular Risk Reduction in Patients with Obstructive Sleep Apnea and Obesity: A Real-world Analysis","ODU Digital Commons (Old Dominion University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036228","R0036228.pdf","no_doi","nonrandomized_study","Acheampong, Edward Amoah","2025","Moderate Exercise and Tirzepatide versus Tirzepatide Alone for Long-Term Weight Loss Maintenance","UND Scholarly Commons (University of North Dakota)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036232","R0036232.pdf","no_doi","nonrandomized_study","Thomas Quaade Bandholm","2025","Semaglutide and Physical Activity for Obesity and Multimorbidity (SemPAct): Co-designing Healthy Healthcare","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036236","R0036236.pdf","no_doi","nonrandomized_study","Mao, Xianhua","2025","Metabolic risk factors and prevention of liver and colorectal diseases : population-based studies from East to West","The HKU Scholars Hub (University of Hong Kong)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036246","R0036246.pdf","no_doi","nonrandomized_study","Hippolyte Gaiffe","2025","Implémentation des traitements recommandés dans la néphropathie diabétique chez les patients suivis au centre de néphrologie et de diabétologie au Centre hospitalier universitaire vaudois (CHUV)","IRIS",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036257","R0036257.pdf","no_doi","nonrandomized_study","Matias Pykälämäki","2025","Lihavuuden kehittyvä lääkehoito nyt ja tulevaisuudessa","Työväentutkimus Vuosikirja",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036272","R0036272.pdf","no_doi","nonrandomized_study","Jóhannes Helgason Thoroddsen 2000-","2025","GLP-1 viðtakaörvar og áhrif á líkamsþyngdarstuðul og andlega líðan","Skemman",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036279","R0036279.pdf","no_doi","nonrandomized_study","Chelton, Alex T","2025","GLP1 Receptor Agonist Increases Fracture Risk In Patients with Obesity","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036308","R0036308.pdf","no_doi","nonrandomized_study","Vera, Ana Ormaza","2025","Major Adverse Cardiovascular Events are Less Frequent in Psoriasis Patients Starting GLP-1RA Compared to Controls: An Observable Retrospective Cohort Study","ODU Digital Commons (Old Dominion University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036318","R0036318.pdf","no_doi","nonrandomized_study","Barengo, Noel","2025","Advancing Knowledge, Collaboration, and Impact—Highlights from the FIU 2025 Diabetes Awareness Day","Florida International University Digital Commons (Florida International University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036347","R0036347.pdf","no_doi","nonrandomized_study","Valantina Awah Nsoh","2025","The Level of Awareness of County Services in Maryland Offered by a Local Care Team to Youth with Developmental Disabilities and Mental Illness","ScholarWorks (Walden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036369","R0036369.pdf","free_to_read","nonrandomized_study",null,"2025","Abstracts from the 2024 WDS Forum - virtual option","International Journal of Women’s Dermatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/jw9.0000000000000202","https://doi.org/10.1097/jw9.0000000000000202",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/jw9.0000000000000202",null],["4","R0036434","R0036434.pdf","no_doi","nonrandomized_study","Awah Nsoh, Valantina","2025","Quality Improvement Initiative to Evaluate GLP-1 Medication Effectiveness in Adults Aged 30–50 Years with Type 2 Diabetes","ScholarWorks (Walden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036469","R0036469.pdf","free_to_read","nonrandomized_study","Sima Fansa","2025","Machine Learning-Assisted Gene Risk Score for Calories to Satiation Predicts Weight Loss Response to Semaglutide in a Multi-Center Biobank and Outcomes Registry","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5961920","https://doi.org/10.2139/ssrn.5961920",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5961920",null],["4","R0036887","R0036887.pdf","free_to_read","nonrandomized_study","Isaías Miguel de Almeida","2025","Pharmacological vs. Surgical Approaches to Obesity: Are GLP-1 Inhibitors an Alternative to Bariatric Surgery?","Journal of Medical Science and Evidences.","Journal of Medical Science and Evidences","10.70789/jmse.v2i2.28","https://doi.org/10.70789/jmse.v2i2.28",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.70789/jmse.v2i2.28",null],["4","R0036966","R0036966.pdf","free_to_read","nonrandomized_study","Kıvılcım Karadeniz Cerit","2025","Surgical treatment of congenital hyperinsulinism","Turkish Journal of Pediatric Surgery","Tﾃｼrkiye ﾃ?cuk Cerrahisi Derneﾄ殃","10.62114/jtaps.2025.110","https://doi.org/10.62114/jtaps.2025.110",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.62114/jtaps.2025.110",null],["4","R0036988","R0036988.pdf","free_to_read","nonrandomized_study","Pankaj Aneja","2025","Safety and Efficacy of Semaglutide in Type 2 Diabetes Patients: A Real-World Study","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_48_24","https://doi.org/10.4103/ijdt.ijdt_48_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_48_24",null],["4","R0037393","R0037393.pdf","no_doi","nonrandomized_study","MIGNOGNA, CARMEN","2025","Pharmacological intervention to target the procalcific phenotypic drift of myeloid cells: a pilot study","IRIS Research product catalog (Sapienza University of Rome)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037399","R0037399.pdf","free_to_read","nonrandomized_study","Deimile Marija Gritenaitė","2025","Beyond Diabetes Mellitus and weight loss: the potential effect of GLP-1 agonist drugs in the treatment of Parkinson’s Disease","JUNIOR RESEARCHERS","Association For Science (Publications)","10.52340/jr.2025.03.02.26","https://doi.org/10.52340/jr.2025.03.02.26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.52340/jr.2025.03.02.26",null],["4","R0037496","R0037496.pdf","free_to_read","nonrandomized_study","Rebecca Richards","2025","A Remotely Delivered GLP-1RA–Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.72577","https://doi.org/10.2196/preprints.72577",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.72577",null],["4","R0037794","R0037794.pdf","free_to_read","nonrandomized_study","Rebecca Hsieh","2025","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CARDIOVASCULAR OUTCOMES AND MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY: A POPULATION-BASED COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)01981-3","https://doi.org/10.1016/s0735-1097(25)01981-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(25)01981-3",null],["4","R0038403","R0038403.pdf","free_to_read","nonrandomized_study","Kieran Moloney","2025","AB128. SOH25_AB_092. A systematic literature review of anaesthesia guidelines for GLP-1 medications and proposed fasting times","Mesentery and Peritoneum","AME Publishing Company","10.21037/map-25-ab128","https://doi.org/10.21037/map-25-ab128",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21037/map-25-ab128",null],["4","R0038703","R0038703.pdf","no_doi","nonrandomized_study","López Quinga, Nathaly Solange","2025","Semaglutida y obesidad, una solución definitiva","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038726","R0038726.pdf","free_to_read","nonrandomized_study","Joana Nicolau","2025","Is the Presence of a Depressive Disorder a Risk Factor for Worse Metabolic Outcomes Among Patients with Type 2 Diabetes Treated with GLP-1 Analogs?","Diabetology","MDPI AG","10.3390/diabetology6070068","https://doi.org/10.3390/diabetology6070068",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology6070068",null],["4","R0038932","R0038932.pdf","free_to_read","nonrandomized_study","Dario Cattaneo","2025","Impact of Glucagon-like Peptide 1 Receptor Agonists on Body Weight in People with HIV and Diabetes Treated with Integrase Inhibitors","Diabetology","MDPI AG","10.3390/diabetology6030020","https://doi.org/10.3390/diabetology6030020",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/diabetology6030020",null],["4","R0039311","R0039311.pdf","free_to_read","nonrandomized_study","Tarunika Bawa","2025","Real-world Effectiveness of Oral Semaglutide in Patients with Type 2 Diabetes Mellitus: A Retrospective Observational Study on Glycemic Control and Weight Reduction","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_5_25","https://doi.org/10.4103/ijdt.ijdt_5_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_5_25",null],["4","R0039318","R0039318.pdf","no_doi","nonrandomized_study","Dávila Lucas, Dayana Brigitte","2025","Pérdida de la Visión por el Uso de Fármacos para la Obesidad y Diabetes","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039362","R0039362.pdf","free_to_read","nonrandomized_study","Issam Merdan","2025","THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY","Basrah Journal of Surgery","University of Basrah, College of Medicine","10.33762/basjsurg.2025.163362.1137","https://doi.org/10.33762/basjsurg.2025.163362.1137",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.33762/basjsurg.2025.163362.1137",null],["4","R0039419","R0039419.pdf","no_doi","nonrandomized_study","Smadi, Reema","2025","MASLD/MASH Pharmacologic Therapeutic Efficacy in a Predominately African American Medical Center Population","Human Biology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039432","R0039432.pdf","free_to_read","nonrandomized_study","Thomas O’Neill","2025","GLP-1 RECEPTOR AGONISTS AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH DIABETES: A RETROSPECTIVE ANALYSIS","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)00565-0","https://doi.org/10.1016/s0735-1097(25)00565-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(25)00565-0",null],["4","R0039496","R0039496.pdf","free_to_read","nonrandomized_study","Charistika Lonika","2025","Roseoside from Lemon Fruits (Citrus limon) as a Potential Inhibitor of Cluster of Differentiation 36 for Obesity Treatment","Engineering headway","Trans Tech Publications Ltd","10.4028/p-vo3mlu","https://doi.org/10.4028/p-vo3mlu",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4028/p-vo3mlu",null],["4","R0039497","R0039497.pdf","no_doi","nonrandomized_study","Whorton, Abigail","2025","Prescribing Patterns and Adverse Drug Reactions associated with Semaglutide:A real-world evaluation from a socioeconomically deprived UK region","University of Birmingham Research Portal (University of Birmingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039580","R0039580.pdf","free_to_read","nonrandomized_study","Kinga Grzybowski","2025","OP0078 Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.100","https://doi.org/10.1016/j.ard.2025.05.100",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.100",null],["4","R0039685","R0039685.pdf","no_doi","nonrandomized_study","Metsärinne Kaj","2025","The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF)","UTUPub (University of Turku)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039715","R0039715.pdf","free_to_read","nonrandomized_study","Gregory J. Challener","2025","POS0209 IMPACT OF TIRZEPATIDE ON MUSCULOSKELETAL PAIN AND RISKY ANALGESIC USE AMONG NON-DIABETIC INDIVIDUALS WITH OVERWEIGHT OR OBESE BODY HABITUS: A PROPENSITY SCORE-MATCHED, ACTIVE COMPARATOR, NEW USER DESIGN STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.596","https://doi.org/10.1016/j.ard.2025.05.596",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.596",null],["4","R0039729","R0039729.pdf","free_to_read","nonrandomized_study","Heba Butt","2025","Will pharmacotherapy soon replace bariatric surgery as the gold standard treatment for obesity?","The British Student Doctor Journal","Cardiff University Press","10.18573/bsdj.419","https://doi.org/10.18573/bsdj.419",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18573/bsdj.419",null],["4","R0039786","R0039786.pdf","free_to_read","nonrandomized_study","C. Pena","2025","POS1232 IMPACT OF GLP-1 RECEPTOR AGONISTS ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ANKYLOSING SPONDYLITIS: A RETROSPECTIVE COHORT STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.06.582","https://doi.org/10.1016/j.ard.2025.06.582",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.06.582",null],["4","R0039912","R0039912.pdf","no_doi","nonrandomized_study","Jesse Shantz","2025","GLP-1 Receptor Agonists and Substance Use Disorder: A Systematized Literature Review","Mspace (University of Manitoba)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040132","R0040132.pdf","free_to_read","nonrandomized_study","Hörner, Dennis","2025","Evaluation des Krankheitsverlaufs von Patienten mit Diabetes mellitus Typ 2 der Diabetesambulanz der UMG anhand laborchemischer und klinischer Parameter – eine retrospektive Analyse des Zeitraums 2014 bis 2021",null,"University Goettingen Repository","10.53846/goediss-10989","https://doi.org/10.53846/goediss-10989",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53846/goediss-10989",null],["4","R0040222","R0040222.pdf","no_doi","nonrandomized_study","Anderson Carlos Costa Soeiro","2025","Desafios e atualizações na legislação farmacêutica na farmácia comercial","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040330","R0040330.pdf","free_to_read","nonrandomized_study","Yichen E. Fang","2025","The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes",null,"American Diabetes Association","10.2337/figshare.30209941.v1","https://doi.org/10.2337/figshare.30209941.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30209941.v1",null],["4","R0040927","R0040927.pdf","no_doi","nonrandomized_study","Margaux Jaeck","2025","Description et évolution des usages problématiques potentiels des analogues du GLP-1 en Nouvelle Aquitaine entre 2018 et 2022","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040932","R0040932.pdf","no_doi","nonrandomized_study","Saana Sadinmäki","2025","Injecting Ozempic Narratives: A Corpus-Based Discourse Analysis on U.S. Newspapers","Tampere University Institutional Repository (Tampere University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041300","R0041300.pdf","no_doi","nonrandomized_study","Inès Vuillemin Gouné","2025","Analyse de l'utilisation des agonistes du récepteur du glucagon-like peptide-1 à partir des données de l'entrepôt de données de santé du CHU de Bordeaux","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041380","R0041380.pdf","free_to_read","nonrandomized_study","Awni D. Shahait","2025","From the Editor-in-Chief: Highlights of the Ninth Issue","JAP Academy Journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/japaj.japaj_26_25","https://doi.org/10.4103/japaj.japaj_26_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/japaj.japaj_26_25",null],["4","R0041449","R0041449.pdf","no_doi","nonrandomized_study","Cesta Carolyn E.","2025","Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy","UTUPub (University of Turku)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042099","R0042099.pdf","no_doi","nonrandomized_study","C Nguyen","2025","The impact of modified Pharmaceutical Benefits Scheme (PBS) prescribing restrictions on glucagon-like peptide-1 receptor agonists (GLP-1RAs) prescriptions in patients with type 2 diabetes","Minerva Access (University of Melbourne)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042116","R0042116.pdf","no_doi","nonrandomized_study","Kunal Gulati (20675852)","2025","Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042130","R0042130.pdf","no_doi","nonrandomized_study","Bains, Aran Singh","2025","Real-World Effectiveness of Semaglutide for Weight Loss Outcomes in a Community Clinic","Scholarship at UWindsor (University of Windsor)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042135","R0042135.pdf","free_to_read","nonrandomized_study","Asmaa Beltagy","2025","OP0069 GLP1 agonists mitigate the risk of cardiovascular events in Rheumatoid Arthritis patients treated with JAK inhibitors","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.092","https://doi.org/10.1016/j.ard.2025.05.092",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.092",null],["4","R0042138","R0042138.pdf","no_doi","nonrandomized_study","Rayaz A Malik (6634004)","2025","Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042237","R0042237.pdf","no_doi","nonrandomized_study","Steve Bain","2025","Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042274","R0042274.pdf","no_doi","nonrandomized_study","Raniah Alsaegh","2025","Effectiveness and safety of the GLP-1 analogue liraglutide for the treatment of obesity in adults without type 2 diabetes : An analysis of weight loss, maintenance of effect, and adverse effects","DiVA (Linnaeus University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042360","R0042360.pdf","no_doi","nonrandomized_study","Furukawa, Yasuyuki","2025","No Worsening of Glycemic Control in Patients with Type 2 Diabetes Mellitus for Three Years during COVID-19 Pandemic Restrictions in Japan","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042415","R0042415.pdf","free_to_read","nonrandomized_study","Vo Van Kha","2025","P49 | From guidelines to a care pathway: \"Diabetes is close to our hearts at the hospital\"","Italian Journal of Medicine","PAGEPress Publications","10.4081/itjm.2025.2242","https://doi.org/10.4081/itjm.2025.2242",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4081/itjm.2025.2242",null],["4","R0042496","R0042496.pdf","free_to_read","nonrandomized_study","Vo Van Kha","2025","CO01 | Cardiovascular and metabolic effects of GLP-1RAs in patients with type 2 diabetes mellitus: a preliminary longitudinal study","Italian Journal of Medicine","PAGEPress Publications","10.4081/itjm.2025.2152","https://doi.org/10.4081/itjm.2025.2152",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4081/itjm.2025.2152",null],["4","R0043341","R0043341.pdf","free_to_read","nonrandomized_study","Muhammed Jasim Abdul Jalal","2025","Metabolic sabotage: The insulin–cancer conspiracy","The Journal of Clinical and Scientific Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcsr.jcsr_90_25","https://doi.org/10.4103/jcsr.jcsr_90_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcsr.jcsr_90_25",null],["4","R0043485","R0043485.pdf","free_to_read","nonrandomized_study","Rupesh Jain","2025","Weight Reduction in Obese or Overweight Diabetic Patients Treated with Oral Semaglutide in a Real World Setting","Indian Heart Journal","Elsevier BV","10.1016/j.ihj.2025.11.139","https://doi.org/10.1016/j.ihj.2025.11.139",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ihj.2025.11.139",null],["4","R0043671","R0043671.pdf","no_doi","nonrandomized_study","Khalil, Fatima","2025","Vilken effekt har liraglutid vid behandling av typ 1-diabetes i kombinationsbehandling med insulin?","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043702","R0043702.pdf","free_to_read","nonrandomized_study","Jie Ming Nigel Fong","2025","Chronic kidney disease is no longer a ‘non-traditional’ cardiac risk factor: a call to action for cardiovascular-kidney-metabolic health","Singapore Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/singaporemedj.smj-2025-012","https://doi.org/10.4103/singaporemedj.smj-2025-012","40116056","https://pubmed.ncbi.nlm.nih.gov/40116056/","https://doi.org/10.4103/singaporemedj.smj-2025-012",null],["4","R0043748","R0043748.pdf","free_to_read","nonrandomized_study","Tiing Leong Ang","2025","Mid-year review of SMJ highlights in 2025","Singapore Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/singaporemedj.smj-2025-160","https://doi.org/10.4103/singaporemedj.smj-2025-160","40700751","https://pubmed.ncbi.nlm.nih.gov/40700751/","https://doi.org/10.4103/singaporemedj.smj-2025-160",null],["4","R0043815","R0043815.pdf","no_doi","nonrandomized_study","Whorton, Abigail","2025","Prescribing Patterns and Adverse Effects of Semaglutide:A real-world evaluation from a socioeconomically deprived UK region","University of Birmingham Research Portal (University of Birmingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043886","R0043886.pdf","free_to_read","nonrandomized_study","Varun Aitharaju","2025","SAT-406 Role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in mortality reduction among patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis: a global retrospective analysis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01673-3","https://doi.org/10.1016/s0168-8278(25)01673-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0168-8278(25)01673-3",null],["4","R0044195","R0044195.pdf","free_to_read","nonrandomized_study","Rossella Cannarella","2025","The effect of liraglutide on metabolic and reproductive outcomes in infertile women with PCOS: A prospective cohort study","Human Nutrition & Metabolism","Elsevier BV","10.1016/j.hnm.2025.200331","https://doi.org/10.1016/j.hnm.2025.200331",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.hnm.2025.200331",null],["4","R0044276","R0044276.pdf","free_to_read","nonrandomized_study","Keren Cohen‐Hagai","2025","Tubular Biomarkers and Retinal Microvasculature","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000001002","https://doi.org/10.34067/kid.0000001002","41411113","https://pubmed.ncbi.nlm.nih.gov/41411113/","https://doi.org/10.34067/kid.0000001002",null],["4","R0044280","R0044280.pdf","no_doi","nonrandomized_study","Ольга Сергіївна Калюжная","2025","Еволюція технологій виробництва інсуліну: від історичних відкриттів структури молекули до сучасних інновацій","Scientific periodicals of Ukraine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044347","R0044347.pdf","free_to_read","nonrandomized_study","Qingchun Jin","2025","Association of Glucagon-Like Peptide-1 Receptor Agonists With All-Cause and Cause-Specific Mortality in US Adults with Diabetes","Heart and Mind","Ovid Technologies (Wolters Kluwer Health)","10.4103/hm.hm-d-25-00065","https://doi.org/10.4103/hm.hm-d-25-00065",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/hm.hm-d-25-00065",null],["4","R0044525","R0044525.pdf","free_to_read","nonrandomized_study","Muhammad Rafehi","2025","The Necessity for Polypharmacological Research – An Editorial on ‘Network Polypharmacology of ATP-binding Cassette (ABC) and Solute Carrier (SLC) Transporters’","Frontiers in Pharmacology","Frontiers Media SA","10.3389/fphar.2025.1561247","https://doi.org/10.3389/fphar.2025.1561247","40201687","https://pubmed.ncbi.nlm.nih.gov/40201687/","https://doi.org/10.3389/fphar.2025.1561247",null],["4","R0044552","R0044552.pdf","no_doi","nonrandomized_study","VIRGINIA GRAGNOLI","2025","Obesità, alterazione del gusto, impatto sulle scelte alimentari: il ruolo del nutrizionista.","Electronic Theses and Dissertations Repository (University of Pisa)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044584","R0044584.pdf","no_doi","nonrandomized_study","Kammo, Sesilia, BS","2025","Relationship Between Change in Body Mass Index and Testosterone Levels in Male Patients Using GLP-1 Receptor Agonists for Weight Loss","Human Biology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044624","R0044624.pdf","free_to_read","nonrandomized_study","Krisha Patel","2025","EPH136 Demographic Characteristics, Utilization Trends, and Access to GLP-1 Agonists Among Adults in a Nationally Representative Pharmacy Database","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.666","https://doi.org/10.1016/j.jval.2025.04.666",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.666",null],["4","R0044633","R0044633.pdf","no_doi","nonrandomized_study","Kohzo Takebayashi","2025","Effect of Switching from Dulaglutide to Oral Semaglutide in Patients with Type 2 Diabetes: A Retrospective Observational Study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044659","R0044659.pdf","no_doi","nonrandomized_study","Díaz-Cerezo,Silvia","2025","Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study","Dove Medical Press (Taylor and Francis Group)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044983","R0044983.pdf","free_to_read","nonrandomized_study","Flaubert Sena de Medeiros Filho","2025","Relationship between glomerular hyperfiltration and diabetic nephropathy progression: pathophysiological mechanisms, clinical evidence, and therapeutic perspectives","Brazilian Journal of Health Review","Brazilian Journals","10.34119/bjhrv8n2-146","https://doi.org/10.34119/bjhrv8n2-146",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.34119/bjhrv8n2-146",null],["4","R0044985","R0044985.pdf","free_to_read","nonrandomized_study","Taylor E. Browning","2025","The widespread adoption of glucagon-like peptide-1 receptor agonists in the management of obesity and its implications for the anaesthesiologist and intensivist: A narrative review",null,"Scientific Scholar","10.25259/peak_19_2024","https://doi.org/10.25259/peak_19_2024",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.25259/peak_19_2024",null],["4","R0045411","R0045411.pdf","free_to_read","nonrandomized_study","Karolina Garbino","2025","The Worldwide Problem of Obesity - Comparison of the Effectiveness of Pharmacological Treatment with Semaglutide and Tirzepatide in Reducing Body Weight","Journal of Education Health and Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/jehs.2025.79.58305","https://doi.org/10.12775/jehs.2025.79.58305",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12775/jehs.2025.79.58305",null],["4","R0045442","R0045442.pdf","free_to_read","nonrandomized_study","Abdul Wali Khan","2025","E-111 | Comparing the effects of Tirzepatide vs. Semaglutide on Long-Term Outcomes in Heart Failure Patients with co-existing chronic kidney disease: A US Cohort Propensity-Matched Study","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2025.103372","https://doi.org/10.1016/j.jscai.2025.103372",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2025.103372",null],["4","R0045465","R0045465.pdf","free_to_read","nonrandomized_study","Natalia Sapeda","2025","ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.4(48).2025.4111","https://doi.org/10.31435/ijitss.4(48).2025.4111",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.4(48).2025.4111",null],["4","R0045492","R0045492.pdf","free_to_read","nonrandomized_study","Muhammad Mobarock Hossain","2025","A Comparative Study Between Tirzepatide and Semaglutide in The Management of Obesity and Type 2 Diabetes Mellitus","Archives of Internal Medicine Research","Fortune Journals","10.26502/aimr.0200","https://doi.org/10.26502/aimr.0200",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/aimr.0200",null],["4","R0045775","R0045775.pdf","free_to_read","nonrandomized_study","Carl Rai","2025","The Impact of GLP-1 Receptor Agonists on Surgical Outcomes in Achilles Tendon Repair","Foot & Ankle Orthopaedics","SAGE Publications","10.1177/2473011425s00473","https://doi.org/10.1177/2473011425s00473",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/2473011425s00473",null],["4","R0046027","R0046027.pdf","free_to_read","nonrandomized_study","Aida Roman","2025","EVALUATING LIPOPROTEIN(A) TESTING PATTERNS AND ASSOCIATED CLINICAL CARE IMPACT IN A LARGE ACADEMIC HEALTH CENTER","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2025.101181","https://doi.org/10.1016/j.ajpc.2025.101181",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2025.101181",null],["4","R0046039","R0046039.pdf","free_to_read","nonrandomized_study","Parisa Momeni","2025","Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.80660","https://doi.org/10.2196/preprints.80660",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.80660",null],["4","R0046312","R0046312.pdf","free_to_read","nonrandomized_study","Mónica Ruiz Pons","2025","Efectividad de la liraglutida en el tratamiento de la obesidad del adolescente","Anales de Pediatría","Elsevier BV","10.1016/j.anpedi.2025.503856","https://doi.org/10.1016/j.anpedi.2025.503856",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.anpedi.2025.503856",null],["4","R0046559","R0046559.pdf","free_to_read","nonrandomized_study","Stefania Chiappini","2025","PHARMACOVIGILANCE SIGNALS OF SEMAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION (FDA) ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATASET","The International Journal of Neuropsychopharmacology","Oxford University Press (OUP)","10.1093/ijnp/pyae059.533","https://doi.org/10.1093/ijnp/pyae059.533",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ijnp/pyae059.533",null],["4","R0046756","R0046756.pdf","free_to_read","nonrandomized_study","Geoff Severtson","2025","CO61 Suicidal Ideation in Patients Treated With Glucagon-like Peptide 1 Receptor (GLP1) Agonists: A Retrospective Real-World Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.146","https://doi.org/10.1016/j.jval.2025.04.146",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.146",null],["4","R0046777","R0046777.pdf","free_to_read","nonrandomized_study","L. Garcia","2025","MON-609 Use of a Continuous Glucose Monitor System (CGM) in Latinx Patients with Type 2 Diabetes (TD2) Improves A1c without an Effect on Weight: Real Life Observational Experience","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvaf149.971","https://doi.org/10.1210/jendso/bvaf149.971",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvaf149.971",null],["4","R0046783","R0046783.pdf","free_to_read","nonrandomized_study","Jia Nuo Feng","2025","GLP-1 medicine and non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives","Metabolism and Diseases","Elsevier BV","10.1016/j.metdis.2025.100001","https://doi.org/10.1016/j.metdis.2025.100001",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.metdis.2025.100001",null],["4","R0046896","R0046896.pdf","free_to_read","nonrandomized_study","Osman K. Yousafzai","2025","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES FOLLOWING STEMI: A PROPENSITY-MATCHED COHORT STUDY","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2025.101216","https://doi.org/10.1016/j.ajpc.2025.101216",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2025.101216",null],["4","R0047106","R0047106.pdf","free_to_read","nonrandomized_study","Meredith M. Hoog","2025","CO72 Real-World Effectiveness of Tirzepatide vs. Semaglutide on HbA1c and Weight in GLP-1 RA Experienced Patients with T2D","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.157","https://doi.org/10.1016/j.jval.2025.04.157",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.157",null],["4","R0047319","R0047319.pdf","free_to_read","nonrandomized_study","Manoj Chawla","2025","Characterization of Treatment Intensified (Add-on to Metformin) Adults with Type 2 Diabetes: Real-world Clinical Experience (Cardiovascular Outcomes and Value in the Real-world with Glucagon-like Peptide-1 Receptor Agonists) from India in 2008 to 2017","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_8_25","https://doi.org/10.4103/ijdt.ijdt_8_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_8_25","ClinicalTrials.gov:NCT05542420"],["4","R0047618","R0047618.pdf","free_to_read","nonrandomized_study","Alexander Kutz","2025","Prescribing trends of anti-diabetes medications near end-of-life among adults with type 2 diabetes: a cohort study",null,"American Diabetes Association","10.2337/figshare.28003451","https://doi.org/10.2337/figshare.28003451",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28003451",null],["4","R0047772","R0047772.pdf","free_to_read","nonrandomized_study","Rakendu Jayasree Rajendran","2025","A-56 | Impact of GLP-1 Receptor Agonists on Cardiovascular and Renal Outcomes in Overweight Patients with Acute Myocardial Infarction (AMI) Undergoing PCI, a Multicenter retrospective study","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2025.102806","https://doi.org/10.1016/j.jscai.2025.102806",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2025.102806",null],["4","R0047863","R0047863.pdf","free_to_read","nonrandomized_study","Miao Yu","2025","Expert consensus on the diagnosis and treatment of immunoinflammation in heart failure","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000003840","https://doi.org/10.1097/cm9.0000000000003840","41173656","https://pubmed.ncbi.nlm.nih.gov/41173656/","https://doi.org/10.1097/cm9.0000000000003840",null],["4","R0047981","R0047981.pdf","free_to_read","nonrandomized_study","Mehul Kaliya","2025","Injectable Semaglutide (Wegovy) in India: Promise, Pitfalls and the Way Forward","NMO journal","Ovid Technologies (Wolters Kluwer Health)","10.4103/jnmo.jnmo_55_25","https://doi.org/10.4103/jnmo.jnmo_55_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jnmo.jnmo_55_25",null],["4","R0047982","R0047982.pdf","free_to_read","nonrandomized_study","Amin Zaki Zadeh","2025","GLP-1 agonist use is not associated with a reduction of paraspinal muscle quality in diabetic patients with lower back pain: A retrospective cohort study","Brain and Spine","Elsevier BV","10.1016/j.bas.2025.104588","https://doi.org/10.1016/j.bas.2025.104588",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.bas.2025.104588",null],["4","R0048275","R0048275.pdf","free_to_read","nonrandomized_study","Osman K. Yousafzai","2025","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY PLAQUE: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2025.101169","https://doi.org/10.1016/j.ajpc.2025.101169",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2025.101169",null],["4","R0048451","R0048451.pdf","free_to_read","nonrandomized_study","Waseem Abbas","2025","Effect of Semaglutide on Weight, HbA1c Reduction, and Side Effect Profile in Type 2 Diabetes Patients","Pakistan Journal of Medicine and Dentistry","Ziauddin University","10.36283/ziun-pjmd14-4/074","https://doi.org/10.36283/ziun-pjmd14-4/074",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36283/ziun-pjmd14-4/074",null],["4","R0048566","R0048566.pdf","free_to_read","nonrandomized_study","John H Malin","2025","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1A) USE IN PATIENTS WITH OBESITY AND HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PROPENSITYMATCHED US POPULATION BASED COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)02142-4","https://doi.org/10.1016/s0735-1097(25)02142-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(25)02142-4",null],["4","R0048590","R0048590.pdf","free_to_read","nonrandomized_study","Justin T. H. Lam","2025","POS1211 ASSESSING GOUT RISK ASSOCIATED WITH GLP-1 THERAPY IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.06.561","https://doi.org/10.1016/j.ard.2025.06.561",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.06.561",null],["4","R0048609","R0048609.pdf","free_to_read","nonrandomized_study","Zhenxiang Zhao","2025","LOWER RISK OF MACE AND ALL-CAUSE DEATH IN PATIENTS INITIATED ON SEMAGLUTIDE 2.4 MG IN ROUTINE CLINICAL CARE: RESULTS FROM THE SCORE STUDY (SEMAGLUTIDE EFFECTS ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY IN THE REAL WORLD)","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(25)00864-2","https://doi.org/10.1016/s0735-1097(25)00864-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(25)00864-2",null],["4","R0048660","R0048660.pdf","free_to_read","nonrandomized_study","Katherine A. Cappell","2025","CO65 Real-world Impact of Semaglutide, Liraglutide, and Tirzepatide on Weight Loss and Cardiometabolic Lab Measures: A Look into Drug Persistence and Reasons for Discontinuation (r/dc)","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.150","https://doi.org/10.1016/j.jval.2025.04.150",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.150",null],["4","R0048794","R0048794.pdf","free_to_read","nonrandomized_study","Donglan “Stacy” Zhang","2025","Association of Patient Cost-Sharing with Adherence to GLP-1a and Adverse Health Outcomes",null,"American Diabetes Association","10.2337/figshare.28570124.v1","https://doi.org/10.2337/figshare.28570124.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28570124.v1",null],["4","R0048813","R0048813.pdf","free_to_read","nonrandomized_study","Aya Saad Aldewachi","2025","The Impact of Glucagon-like Peptide-1 Receptor Agonists on Obese Individuals’ Quality of Life and Eating Behaviors","Journal of Clinical Medicine of Kazakhstan","JSC National Scientific Medical Research Center","10.23950/jcmk/17366","https://doi.org/10.23950/jcmk/17366",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.23950/jcmk/17366",null],["4","R0048998","R0048998.pdf","free_to_read","nonrandomized_study","Dustin Le","2025","GLP1s vs DPP4s and Risk of Dementia in Patients Requiring Hemodialysis, A Target Trial Emulation Study",null,"American Diabetes Association","10.2337/figshare.30438470","https://doi.org/10.2337/figshare.30438470",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.30438470",null],["4","R0049003","R0049003.pdf","free_to_read","nonrandomized_study","Bindee Kuriya","2025","POS0031 Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.428","https://doi.org/10.1016/j.ard.2025.05.428",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.428",null],["4","R0049303","R0049303.pdf","free_to_read","nonrandomized_study","Christine Ljungberg","2025","Risk of Urogenital Infections in People with Type 2 Diabetes Initiating SGLT2i versus GLP-1RA in Routine Clinical Care: A Danish Cohort Study",null,"American Diabetes Association","10.2337/figshare.28598729.v1","https://doi.org/10.2337/figshare.28598729.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28598729.v1",null],["4","R0049418","R0049418.pdf","free_to_read","nonrandomized_study","Cho‐Han Chiang","2025","HTRS2025.O6C.1 Abstract Travel Award Glucagon-like peptide 1 receptor agonists and the risk of arterial and venous thromboembolism in breast cancer patients receiving hormone therapy: a propensity score-matched cohort study","Research and Practice in Thrombosis and Haemostasis","Elsevier BV","10.1016/j.rpth.2025.103135","https://doi.org/10.1016/j.rpth.2025.103135",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.rpth.2025.103135",null],["4","R0049456","R0049456.pdf","free_to_read","nonrandomized_study","Arsen M. Omurzakov","2025","Poster 6: GLP-1 Receptor Agonist Use Is Not Associated With an Increased Risk of Complications After Anatomic Total Shoulder Arthroplasty","Orthopaedic Journal of Sports Medicine","SAGE Publications","10.1177/2325967125s00120","https://doi.org/10.1177/2325967125s00120",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/2325967125s00120",null],["4","R0049503","R0049503.pdf","free_to_read","nonrandomized_study","Nerissa Nance","2025","Applying the Causal Roadmap to longitudinal national registry data in Denmark: A case study of second-line diabetes medication and dementia","Journal of Causal Inference","Walter de Gruyter GmbH","10.1515/jci-2024-0014","https://doi.org/10.1515/jci-2024-0014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1515/jci-2024-0014",null],["4","R0049638","R0049638.pdf","free_to_read","nonrandomized_study","Rashid Ali","2025","ABS0839 CARDIOVASCULAR OUTCOMES AND MORTALITY ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS IN INFLAMMATORY MYOSITIS AND NECROTIZING MYOPATHY: A RETROSPECTIVE COHORT STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.06.1128","https://doi.org/10.1016/j.ard.2025.06.1128",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.06.1128",null],["4","R0049728","R0049728.pdf","free_to_read","nonrandomized_study","Chloe Stallion","2025","Social Media Posts on Anti-Diabetic Drugs: Changes in Trends with the Rise in Popularity of GLP-1s (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.87590","https://doi.org/10.2196/preprints.87590",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.87590",null],["4","R0049844","R0049844.pdf","free_to_read","nonrandomized_study","Žhong Yuan","2025","Relationship between canagliflozin use and sarcopenia: Real-world data from the United States","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2025.100280","https://doi.org/10.1016/j.deman.2025.100280",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2025.100280",null],["4","R0050363","R0050363.pdf","free_to_read","nonrandomized_study","María Rodríguez-Bedoya","2025","POS1318 EFFECT OF ORAL SEMAGLUTIDE IN SERUM URATE LEVELS OF PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD RETROSPECTIVE, OBSERVATIONAL STUDY","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.06.667","https://doi.org/10.1016/j.ard.2025.06.667",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.06.667",null],["4","R0050591","R0050591.pdf","free_to_read","nonrandomized_study","Babak John Orandi","2025","GLP-1 Receptor Agonists: Advancing Kidney Transplant Access and Safety in a National ESKD Cohort","American Journal of Transplantation","Elsevier BV","10.1016/j.ajt.2025.07.291","https://doi.org/10.1016/j.ajt.2025.07.291",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajt.2025.07.291",null],["4","R0050687","R0050687.pdf","free_to_read","nonrandomized_study","Gabrielle R. Nemeh","2025","Diabetes medications and dementia risk: Comparisons of SGLT2 inhibitors, GLP-1 RAs, metformin, and their combinations","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2025.100288","https://doi.org/10.1016/j.deman.2025.100288",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2025.100288",null],["4","R0050807","R0050807.pdf","free_to_read","nonrandomized_study","Hilary J. Little","2025","Impact of obesogenic medications on weight loss potential with glucagon-like peptide-1 receptor agonists","JAPhA Pharmacotherapy","Elsevier BV","10.1016/j.japhar.2025.100022","https://doi.org/10.1016/j.japhar.2025.100022",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.japhar.2025.100022",null],["4","R0050901","R0050901.pdf","free_to_read","nonrandomized_study","Jia-Ai Yeh","2025","GLP-1 Receptor Agonists and Risks of Hyperthyroidism and Hypothyroidism in Type 2 Diabetes: A Real-World Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5246544","https://doi.org/10.2139/ssrn.5246544",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5246544",null],["4","R0051058","R0051058.pdf","free_to_read","nonrandomized_study","Mohammad Abdelhafez","2025","E-106 | Outcomes of ST-Elevation Myocardial Infarction Among Diabetic Patients on Tirzepatide Versus GLP-1 Receptor Agonists: A Retrospective Study Using Real World Data","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2025.103367","https://doi.org/10.1016/j.jscai.2025.103367",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2025.103367",null],["4","R0051661","R0051661.pdf","free_to_read","nonrandomized_study","Hans H. Johnson","2025","Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.83718","https://doi.org/10.2196/preprints.83718",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.83718",null],["4","R0051809","R0051809.pdf","free_to_read","nonrandomized_study","David Iwanyckyj","2025","RWD112 Real-World Utilization of Glucagon-Like Peptide-1 Receptor Agonists in Overweight and Obese US Adults","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.1695","https://doi.org/10.1016/j.jval.2025.04.1695",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.1695",null],["4","R0052399","R0052399.pdf","free_to_read","nonrandomized_study","Kendra A. Terrell","2025","CO23 Real-World Effectiveness of Tirzepatide vs. Semaglutide on HbA1c and Weight in GLP-1 RA Naïve Patients with T2D","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.108","https://doi.org/10.1016/j.jval.2025.04.108",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.108",null],["4","R0052473","R0052473.pdf","free_to_read","nonrandomized_study","Alejandra Aristizábal","2025","P3. Unveiling Weight Loss Trends and Complications in Body Contouring Surgery Among Glucagon Like Peptide Analogs Users: An Eight Year Experience","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.gox.0001114204.22719.c4","https://doi.org/10.1097/01.gox.0001114204.22719.c4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/01.gox.0001114204.22719.c4",null],["4","R0052667","R0052667.pdf","free_to_read","nonrandomized_study","Pankaj Vinod Jariwala","2025","Efficacy of Oral Semaglutide in Non-Diabetic Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Insights from an Indian Single-Center Cohort.","Indian Heart Journal","Elsevier BV","10.1016/j.ihj.2025.11.080","https://doi.org/10.1016/j.ihj.2025.11.080",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ihj.2025.11.080",null],["4","R0052699","R0052699.pdf","free_to_read","nonrandomized_study","Chiho Lee","2025","Cardiovascular-Kidney-Metabolic healthcare framework: Perspective from Hong Kong","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000003748","https://doi.org/10.1097/cm9.0000000000003748","40757400","https://pubmed.ncbi.nlm.nih.gov/40757400/","https://doi.org/10.1097/cm9.0000000000003748",null],["4","R0052765","R0052765.pdf","free_to_read","nonrandomized_study","Derin Karacabeyli","2025","OP0035 Incidence of Autoimmune Rheumatic Diseases Following Treatment with Glucagon-Like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Study","Annals of the Rheumatic Diseases","Elsevier BV","10.1016/j.ard.2025.05.059","https://doi.org/10.1016/j.ard.2025.05.059",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ard.2025.05.059",null],["4","R0052925","R0052925.pdf","free_to_read","nonrandomized_study","Kuei‐Ting Tung","2025","The role of GLP-1 agonists in preventing herniated vertebral disc disease: A TriNetX-based propensity score-matched retrospective analysis","Brain and Spine","Elsevier BV","10.1016/j.bas.2025.104524","https://doi.org/10.1016/j.bas.2025.104524",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.bas.2025.104524",null],["4","R0053032","R0053032.pdf","free_to_read","nonrandomized_study","Charles C. Lee","2025","7. Impact of GLP-1 Agonist Weight Loss Drugs on Surgical Wound Complications Following Plastic Surgery Procedures","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.gox.0001113872.50021.01","https://doi.org/10.1097/01.gox.0001113872.50021.01",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/01.gox.0001113872.50021.01",null],["4","R0053050","R0053050.pdf","free_to_read","nonrandomized_study","Harish Kumar Gupta","2025","Pharmacological management of heart failure","Journal of Family Medicine and Primary Care","Ovid Technologies (Wolters Kluwer Health)","10.4103/jfmpc.jfmpc_1733_24","https://doi.org/10.4103/jfmpc.jfmpc_1733_24","41041189","https://pubmed.ncbi.nlm.nih.gov/41041189/","https://doi.org/10.4103/jfmpc.jfmpc_1733_24",null],["4","R0053099","R0053099.pdf","free_to_read","nonrandomized_study","Entris Sutrisno","2025","Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review","Pharmacia","Pensoft Publishers","10.3897/pharmacia.72.e144858","https://doi.org/10.3897/pharmacia.72.e144858",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3897/pharmacia.72.e144858",null],["4","R0053736","R0053736.pdf","free_to_read","nonrandomized_study","Ganapathi Bantwal","2025","The Prediabetes Wake-Up Call: Time for Proactive Endocrine Care","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_780_25","https://doi.org/10.4103/ijem.ijem_780_25","40917317","https://pubmed.ncbi.nlm.nih.gov/40917317/","https://doi.org/10.4103/ijem.ijem_780_25",null],["4","R0053819","R0053819.pdf","free_to_read","nonrandomized_study","Emmanuel Daniel","2025","OR1-3 | Impact of GLP-1 Agonist on Cardiovascular Outcomes in Patients with Peripheral Artery Disease without Diabetes: A Propensity Score-Matched Analysis","Journal of the Society for Cardiovascular Angiography & Interventions","Elsevier BV","10.1016/j.jscai.2025.102654","https://doi.org/10.1016/j.jscai.2025.102654",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jscai.2025.102654",null],["4","R0053855","R0053855.pdf","free_to_read","nonrandomized_study","Joydeep Baidya","2025","Glucagon-Like Peptide-1 Receptor Agonists Taken for Weight Loss Do Not Affect Postoperative Outcomes Following Anterior Cervical Discectomy And Fusion","Spine Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/bn9.0000000000000013","https://doi.org/10.1097/bn9.0000000000000013",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/bn9.0000000000000013",null],["4","R0054036","R0054036.pdf","free_to_read","nonrandomized_study","Divanshi Trivedi","2025","Soups, shakes and other slimming strategies: GLP-1 agonists vs. NHS type 2 diabetes path to remission programme in the battle against T2DM and weight management","Clinical Medicine","Elsevier BV","10.1016/j.clinme.2025.100459","https://doi.org/10.1016/j.clinme.2025.100459",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.clinme.2025.100459",null],["4","R0054160","R0054160.pdf","free_to_read","nonrandomized_study","Patrick K. Cronin","2025","Glucagon-Like Peptide 1 Receptor Agonists in Anterior Cervical Discectomy and Fusion—A Notch in the Equivocal Column:","Spine Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/bn9.0000000000000012","https://doi.org/10.1097/bn9.0000000000000012",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/bn9.0000000000000012",null],["4","R0054283","R0054283.pdf","free_to_read","nonrandomized_study","Abrar Ahmad Zargar","2025","Incretin Hormones: Mechanisms, Therapeutic Implications, and Future Directions in Glucose Regulation and Diabetes Management","Current Proteomics","Elsevier BV","10.1016/j.curpro.2025.100014","https://doi.org/10.1016/j.curpro.2025.100014",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.curpro.2025.100014",null],["4","R0054401","R0054401.pdf","free_to_read","nonrandomized_study","Hala Zakaria","2025","Effectiveness of Tirzepatide and Semaglutide Within a Hybrid Care Model with Exploratory Dose–Response Analyses: A Real-World Evidence Study","Diabetes Technology and Obesity Medicine","SAGE Publications","10.1177/29986702251404471","https://doi.org/10.1177/29986702251404471",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/29986702251404471",null],["4","R0054488","R0054488.pdf","free_to_read","nonrandomized_study","Viveca Ritsinger","2025","Prevalence and Impact of Obesity in Patients With Diabetes and Myocardial Infarction","JACC Advances","Elsevier BV","10.1016/j.jacadv.2025.101644","https://doi.org/10.1016/j.jacadv.2025.101644","40080921","https://pubmed.ncbi.nlm.nih.gov/40080921/","https://doi.org/10.1016/j.jacadv.2025.101644",null],["4","R0054567","R0054567.pdf","no_doi","nonrandomized_study","Gjersdal, Erlend","2025","Semaglutide in Hypothalamic Obesity: Lasting Benefits Beyond Weight Loss","VBN Forskningsportal (Aalborg Universitet)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054804","R0054804.pdf","free_to_read","nonrandomized_study","Brianna Cartwright","2025","EPH85 Real-World Temporal and Indication-Specific Variation in Drivers of GLP-1 RA Discontinuation","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.616","https://doi.org/10.1016/j.jval.2025.04.616",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.616",null],["4","R0054816","R0054816.pdf","free_to_read","nonrandomized_study","Karol Grela","2025","INTERNATIONAL GUIDELINES ON PERIOPERATIVE MANAGEMENT OF GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.4(48).2025.4724","https://doi.org/10.31435/ijitss.4(48).2025.4724",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.4(48).2025.4724",null],["4","R0054823","R0054823.pdf","free_to_read","nonrandomized_study","Rohan Vashi","2025","RWD130 Real-World Adverse Event Profile of Glucagon-Like Peptide-1 Receptor Agonists in Overweight and Obese US Adults","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.1713","https://doi.org/10.1016/j.jval.2025.04.1713",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.1713",null],["4","R0054856","R0054856.pdf","free_to_read","nonrandomized_study","Shrikanth N. Hegde","2025","Widening Waistline: Rising Burden of Obesity in India","APIK Journal of Internal Medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/ajim.ajim_100_25","https://doi.org/10.4103/ajim.ajim_100_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ajim.ajim_100_25",null],["4","R0054909","R0054909.pdf","no_doi","nonrandomized_study","Duhanur Aksoy","2025","GLP-1 Receptor Agonists: Current Applications and Future Directions","DergiPark (Istanbul University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0054956","R0054956.pdf","free_to_read","nonrandomized_study","Daniel Mak","2025","Trends in Glucagon-Like Peptide 1 Receptor Agonists Utilization for Weight Management in Children","Diabetes Technology and Obesity Medicine","SAGE Publications","10.1089/dtom.2025.0027","https://doi.org/10.1089/dtom.2025.0027",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1089/dtom.2025.0027",null],["4","R0055006","R0055006.pdf","no_doi","nonrandomized_study","Annika Vestergaard Kvist","2025","The association between GLP-1 receptor agonists and fractures: an observational Case-Control Study","VBN Forskningsportal (Aalborg Universitet)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055067","R0055067.pdf","free_to_read","nonrandomized_study","Bo Liang","2025","Novel Biomarkers in CKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000846","https://doi.org/10.1681/asn.0000000846","40911359","https://pubmed.ncbi.nlm.nih.gov/40911359/","https://pubmed.ncbi.nlm.nih.gov/40911359/",null],["4","R0055233","R0055233.pdf","free_to_read","nonrandomized_study","Mosrur Ahmed","2025","Pharmacological Management of Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Multi-Pillar Cardiorenal-Protective Approach","Journal of Prevention Diagnosis and Management of Human Diseases","HM Publishers","10.55529/jpdmhd.51.90.102","https://doi.org/10.55529/jpdmhd.51.90.102",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.55529/jpdmhd.51.90.102",null],["4","R0055275","R0055275.pdf","free_to_read","nonrandomized_study","Vishal Choudhary","2025","SA66 Temporal Trends in Prescription of GLP-1RAs for Weight Loss: Insights From a Five-Year Retrospective Analysis in the US","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.1821","https://doi.org/10.1016/j.jval.2025.04.1821",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.1821",null],["4","R0055426","R0055426.pdf","free_to_read","nonrandomized_study","Andrew Wang","2025","Finerenone in CKD from Estimands to Clinical Interpretability under Competing Risk","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.0000000925","https://doi.org/10.1681/asn.0000000925","41563827","https://pubmed.ncbi.nlm.nih.gov/41563827/","https://pubmed.ncbi.nlm.nih.gov/41563827/",null],["4","R0055458","R0055458.pdf","free_to_read","nonrandomized_study","Onur Başer","2025","CO77 External Control Arm With Real World Data to Assess the Effect of Semaglutide on Chronic Kidney Disease Risk Among Patients With Type 2 Diabetes","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.162","https://doi.org/10.1016/j.jval.2025.04.162",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.162",null],["4","R0055537","R0055537.pdf","no_doi","nonrandomized_study","Kevin Yuan Tzer Yau","2025","Glucagon-like peptide-1 receptor agonists and the risk of major adverse cardiovascular events in patients with chronic kidney disease","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055589","R0055589.pdf","no_doi","nonrandomized_study","Mirsad Šljivić","2025","INTEGRATED THERAPY WITH GLP-1 RECEPTOR AGONISTS AND NUTRITIONAL INTERVENTIONS IN THE TREATMENT OF OBESITY IN PATIENTS WITH TYPE 2 DIABETES","University of Zagreb University Computing Centre (SRCE)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055632","R0055632.pdf","free_to_read","nonrandomized_study","Sri Venkata Madhu","2025","ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update (2025)","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_680_25","https://doi.org/10.4103/ijem.ijem_680_25","40917319","https://pubmed.ncbi.nlm.nih.gov/40917319/","https://doi.org/10.4103/ijem.ijem_680_25",null],["4","R0055650","R0055650.pdf","free_to_read","nonrandomized_study","Thadchaigeni Panchalingam","2025","EPH59 Application of Prevalent New-User Cohort Designs to a Claims Data Study of Incidence of Nutritional Deficiency in People With Diabetes Using GLP-1 Receptor Agonists","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.590","https://doi.org/10.1016/j.jval.2025.04.590",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.590",null],["4","R0055716","R0055716.pdf","free_to_read","nonrandomized_study","Wouter van der Pluijm","2025","RWD171 Baseline BMI and HbA1c Trends in US Diabetic Patients Initiating GLP-1 Therapy: A Retrospective Cohort Study","Value in Health","Elsevier BV","10.1016/j.jval.2025.04.1754","https://doi.org/10.1016/j.jval.2025.04.1754",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2025.04.1754",null],["4","R0055915","R0055915.pdf","no_doi","nonrandomized_study","Zanaya Vieira Leonel","2025","DIABETES MELLITUS: CAUSES, COMPLICATIONS, TREATMENT, AND STRATEGIES FOR EFFECTIVE PREVENTION AND CONTROL OF THE DISEASE","CIPEEX",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056099","R0056099.pdf","no_doi","nonrandomized_study","Aref Alabassi , Hussain Haji Ali , Khaled Khudadah , Ghaida Alshoraian , Reda Anbar","2025","Efficacy and Safety of Different Weight Reduction Strategies: A Study at Southwell Hospital Kuwait Oil Company","South Eastern European Journal of Public Health",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056331","R0056331.pdf","free_to_read","nonrandomized_study","P. Gautier","2025","Investigating risk of cancer with SGLT-2 Inhibitors: A Case/Non-Case Study in the WHO Global Pharmacovigilance Database Vigibase","Archives of cardiovascular diseases","Elsevier BV","10.1016/j.acvd.2024.10.254","https://doi.org/10.1016/j.acvd.2024.10.254",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.acvd.2024.10.254",null],["4","R0056365","R0056365.pdf","no_doi","nonrandomized_study","Yasir Mohammed Zaroug Elradi","2025","El doble desafío del manejo del peso: evaluación del impacto de los agonistas del receptor GLP-1 sobre la masa corporal magra en ensayos clínicos globales (2020–2025)","Revista de Ciencias Médicas de Pinar del Río",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056480","R0056480.pdf","no_doi","nonrandomized_study","Clara Laís Ferreira Soares","2025","O Transtorno de Compulsão Alimentar e Terapia com GLP-1: Uma Revisão das Evidências Científicas","Bioethics Archives, Management and Health.",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056484","R0056484.pdf","no_doi","nonrandomized_study","dixant chhikara","2025","Real-World Outcomes of 25 Indian Patients Treated with Tirzepatide for Weight Loss: A 20-Week, Resource-Constrained Case Series","Journal of Surgery and Medical Case Reports",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056590","R0056590.pdf","no_doi","nonrandomized_study","Christian Enrique Iglesias Espín","2025","Efectos cardiovasculares de los agonistas del receptor GLP-1 en pacientes con diabetes mellitus tipo 2","Revista de Ciencias Médicas de Pinar del Río",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0001746","R0001746.pdf","open_download_failed","nonrandomized_study","Nguyen Q","2024","Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV.","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Oxford University Press (OUP)","10.1093/cid/ciae151","https://doi.org/10.1093/cid/ciae151","38501237","https://pubmed.ncbi.nlm.nih.gov/38501237/","https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae151/57014104/ciae151.pdf",null],["4","R0001934","R0001934.pdf","open_download_failed","nonrandomized_study","Watanabe JH","2024","Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2023.10.002","https://doi.org/10.1016/j.japh.2023.10.002","37821008","https://pubmed.ncbi.nlm.nih.gov/37821008/","http://www.japha.org/article/S1544319123003096/pdf",null],["4","R0002171","R0002171.pdf","open_download_failed","nonrandomized_study","Toms JA","2024","Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users.","Aesthetic surgery journal","Oxford University Press (OUP)","10.1093/asj/sjae085","https://doi.org/10.1093/asj/sjae085","38620005","https://pubmed.ncbi.nlm.nih.gov/38620005/","https://academic.oup.com/asj/advance-article-pdf/doi/10.1093/asj/sjae085/57236908/sjae085.pdf",null],["4","R0002372","R0002372.pdf","open_download_failed","nonrandomized_study","Lomeli LD","2024","The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111806","https://doi.org/10.1016/j.diabres.2024.111806","39111552","https://pubmed.ncbi.nlm.nih.gov/39111552/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724007162/pdf",null],["4","R0002578","R0002578.pdf","open_download_failed","nonrandomized_study","Lene LJ","2024","Real-World Utilisation, Efficacy, and Safety of Injectable GLP-1 Receptor Agonists: A Drug Use Evaluation in Singapore’s Largest Healthcare Cluster","Authorea Preprints","Wiley","10.22541/au.173535301.14921524/v1","https://doi.org/10.22541/au.173535301.14921524/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.173535301.14921524",null],["4","R0002579","R0002579.pdf","open_download_failed","nonrandomized_study","Tang H","2024","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.","Movement disorders : official journal of the Movement Disorder Society","Wiley","10.1002/mds.29992","https://doi.org/10.1002/mds.29992","39189078","https://pubmed.ncbi.nlm.nih.gov/39189078/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568939/pdf/nihms-2015669.pdf",null],["4","R0002864","R0002864.pdf","open_download_failed","nonrandomized_study","Samuels JM","2024","Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery","medRxiv","openRxiv","10.1101/2024.04.21.24306138","https://doi.org/10.1101/2024.04.21.24306138",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/04/22/2024.04.21.24306138.full.pdf",null],["4","R0002976","R0002976.pdf","free_to_read","nonrandomized_study","Satti DI","2024","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation.","JACC. Clinical electrophysiology","Elsevier BV","10.1016/j.jacep.2024.03.031","https://doi.org/10.1016/j.jacep.2024.03.031","38795099","https://pubmed.ncbi.nlm.nih.gov/38795099/","https://doi.org/10.1016/j.jacep.2024.03.031",null],["4","R0003015","R0003015.pdf","free_to_read","nonrandomized_study","Guirguis A","2024","Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Elsevier BV","10.1016/j.euroneuro.2024.02.003","https://doi.org/10.1016/j.euroneuro.2024.02.003","38508100","https://pubmed.ncbi.nlm.nih.gov/38508100/","https://doi.org/10.1016/j.euroneuro.2024.02.003",null],["4","R0003114","R0003114.pdf","open_download_failed","nonrandomized_study","Wang T","2024","Glucagon-like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most?","Annals of the American Thoracic Society","Oxford University Press (OUP)","10.1513/annalsats.202309-836oc","https://doi.org/10.1513/annalsats.202309-836oc","39012183","https://pubmed.ncbi.nlm.nih.gov/39012183/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568508/pdf/AnnalsATS.202309-836OC.pdf",null],["4","R0003138","R0003138.pdf","open_download_failed","nonrandomized_study","Lassen MCH","2024","Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15872","https://doi.org/10.1111/dom.15872","39215626","https://pubmed.ncbi.nlm.nih.gov/39215626/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15872",null],["4","R0003260","R0003260.pdf","free_to_read","nonrandomized_study","Milder DA","2024","Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.","Anaesthesia","Wiley","10.1111/anae.16306","https://doi.org/10.1111/anae.16306","38740566","https://pubmed.ncbi.nlm.nih.gov/38740566/","https://doi.org/10.1111/anae.16306",null],["4","R0003269","R0003269.pdf","open_download_failed","nonrandomized_study","Nadeem D","2024","Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients.","Gastrointestinal endoscopy","Elsevier BV","10.1016/j.gie.2024.04.2900","https://doi.org/10.1016/j.gie.2024.04.2900","38692518","https://pubmed.ncbi.nlm.nih.gov/38692518/","http://www.giejournal.org/article/S0016510724031596/pdf",null],["4","R0003278","R0003278.pdf","open_download_failed","nonrandomized_study","Tang H","2024","Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.","Annals of internal medicine","American College of Physicians","10.7326/m24-0329","https://doi.org/10.7326/m24-0329","39008852","https://pubmed.ncbi.nlm.nih.gov/39008852/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12132802/pdf/nihms-2082134.pdf",null],["4","R0003290","R0003290.pdf","free_to_read","nonrandomized_study","Kim TH","2024","Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15864","https://doi.org/10.1111/dom.15864","39161072","https://pubmed.ncbi.nlm.nih.gov/39161072/","https://figshare.com/articles/journal_contribution/Association_between_glucagon-like_peptide-1_receptor_agonists_and_risk_of_suicidality_A_comprehensive_analysis_of_the_global_pharmacovigilance_database/26379319",null],["4","R0003343","R0003343.pdf","open_download_failed","nonrandomized_study","Klonoff DC","2024","Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15636","https://doi.org/10.1111/dom.15636","38742898","https://pubmed.ncbi.nlm.nih.gov/38742898/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15636",null],["4","R0003477","R0003477.pdf","open_download_failed","nonrandomized_study","Suzuki Y","2024","Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15561","https://doi.org/10.1111/dom.15561","38528820","https://pubmed.ncbi.nlm.nih.gov/38528820/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15561",null],["4","R0003634","R0003634.pdf","open_download_failed","nonrandomized_study","Prakash S","2024","Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease Risk: Findings from Real-World Data using AI-Powered Outcomes","medRxiv","openRxiv","10.1101/2024.09.17.24313797","https://doi.org/10.1101/2024.09.17.24313797",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/09/20/2024.09.17.24313797.full.pdf",null],["4","R0003678","R0003678.pdf","free_to_read","nonrandomized_study","Abdalla Ahmed MA","2024","Advancements in the management of obesity: a review of current evidence and emerging therapies.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2024.2347258","https://doi.org/10.1080/17446651.2024.2347258","38685693","https://pubmed.ncbi.nlm.nih.gov/38685693/","https://doi.org/10.1080/17446651.2024.2347258",null],["4","R0003727","R0003727.pdf","open_download_failed","nonrandomized_study","Almeida OP","2024","Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15616","https://doi.org/10.1111/dom.15616","38650544","https://pubmed.ncbi.nlm.nih.gov/38650544/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15616",null],["4","R0003864","R0003864.pdf","free_to_read","nonrandomized_study","Hurley C","2024","Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists.","Anaesthesia","Wiley","10.1111/anae.16362","https://doi.org/10.1111/anae.16362","38894670","https://pubmed.ncbi.nlm.nih.gov/38894670/",null,null],["4","R0003870","R0003870.pdf","open_download_failed","nonrandomized_study","Candido R","2024","Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2024.03.023","https://doi.org/10.1016/j.numecd.2024.03.023","38693036","https://pubmed.ncbi.nlm.nih.gov/38693036/","http://www.nmcd-journal.com/article/S093947532400125X/pdf",null],["4","R0003960","R0003960.pdf","open_download_failed","nonrandomized_study","Kassem S","2024","Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15828","https://doi.org/10.1111/dom.15828","39109455","https://pubmed.ncbi.nlm.nih.gov/39109455/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15828",null],["4","R0003962","R0003962.pdf","open_download_failed","nonrandomized_study","Casella S","2024","Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists?","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","SAGE Publications","10.1177/87551225231216638","https://doi.org/10.1177/87551225231216638","38525095","https://pubmed.ncbi.nlm.nih.gov/38525095/","https://journals.sagepub.com/doi/pdf/10.1177/87551225231216638?download=true",null],["4","R0004047","R0004047.pdf","open_download_failed","nonrandomized_study","Napoli R","2024","Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15697","https://doi.org/10.1111/dom.15697","38853712","https://pubmed.ncbi.nlm.nih.gov/38853712/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15697",null],["4","R0004048","R0004048.pdf","free_to_read","nonrandomized_study","Lavu MS","2024","The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.","The Journal of arthroplasty","Elsevier BV","10.1016/j.arth.2024.06.008","https://doi.org/10.1016/j.arth.2024.06.008","38857711","https://pubmed.ncbi.nlm.nih.gov/38857711/","https://doi.org/10.1016/j.arth.2024.06.008",null],["4","R0004103","R0004103.pdf","open_download_failed","nonrandomized_study","Conover M","2024","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network","Authorea Preprints","Wiley","10.22541/au.171119334.40228546/v1","https://doi.org/10.22541/au.171119334.40228546/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.171119334.40228546/v1",null],["4","R0004229","R0004229.pdf","open_download_failed","nonrandomized_study","Barakat S","2024","Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.","Hospital pharmacy","SAGE Publications","10.1177/00185787241266803","https://doi.org/10.1177/00185787241266803","39449861","https://pubmed.ncbi.nlm.nih.gov/39449861/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11497530/pdf/10.1177_00185787241266803.pdf",null],["4","R0004246","R0004246.pdf","open_download_failed","nonrandomized_study","Chu L","2024","Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15834","https://doi.org/10.1111/dom.15834","39113258","https://pubmed.ncbi.nlm.nih.gov/39113258/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15834","ClinicalTrials.gov:NCT06236672"],["4","R0004280","R0004280.pdf","open_download_failed","nonrandomized_study","Talay L","2024","Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Case Study","Preprints.org","MDPI AG","10.20944/preprints202407.0092.v1","https://doi.org/10.20944/preprints202407.0092.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/b83fed7e8266a900db2a757ff7bbeaaa/download_pub",null],["4","R0004308","R0004308.pdf","open_download_failed","nonrandomized_study","Desai A","2024","Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.18138","https://doi.org/10.1111/apt.18138","38938071","https://pubmed.ncbi.nlm.nih.gov/38938071/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.18138",null],["4","R0004310","R0004310.pdf","open_download_failed","nonrandomized_study","Barkmeier AJ","2024","Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.","Ophthalmology. Retina","Elsevier BV","10.1016/j.oret.2024.05.003","https://doi.org/10.1016/j.oret.2024.05.003","38735641","https://pubmed.ncbi.nlm.nih.gov/38735641/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12233001/pdf/nihms-2087127.pdf",null],["4","R0004328","R0004328.pdf","open_download_failed","nonrandomized_study","Ali S","2024","Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15398","https://doi.org/10.1111/dom.15398","38151964","https://pubmed.ncbi.nlm.nih.gov/38151964/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15398",null],["4","R0004402","R0004402.pdf","open_download_failed","nonrandomized_study","Hennies N","2024","Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15931","https://doi.org/10.1111/dom.15931","39300717","https://pubmed.ncbi.nlm.nih.gov/39300717/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15931",null],["4","R0004630","R0004630.pdf","open_download_failed","nonrandomized_study","Talay L","2024","Effectiveness and care continuity in an app-based, glucagon-like peptide-1 receptor agonist-supported weight-loss service for women with overweight and obesity in the UK: A real-world retrospective cohort analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15607","https://doi.org/10.1111/dom.15607","38623616","https://pubmed.ncbi.nlm.nih.gov/38623616/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15607",null],["4","R0004651","R0004651.pdf","open_download_failed","nonrandomized_study","Ito H","2024","The change in Fibrosis-4 index in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide: A retrospective observational study.","Hepatology research : the official journal of the Japan Society of Hepatology","Wiley","10.1111/hepr.14002","https://doi.org/10.1111/hepr.14002","38141029","https://pubmed.ncbi.nlm.nih.gov/38141029/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/hepr.14002",null],["4","R0004730","R0004730.pdf","open_download_failed","nonrandomized_study","Chan YH","2024","SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgae157","https://doi.org/10.1210/clinem/dgae157","38466894","https://pubmed.ncbi.nlm.nih.gov/38466894/","https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae157/56926301/dgae157.pdf",null],["4","R0004748","R0004748.pdf","free_to_read","nonrandomized_study","Elsaid MI","2024","Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.17925","https://doi.org/10.1111/apt.17925","38538967","https://pubmed.ncbi.nlm.nih.gov/38538967/","https://doi.org/10.1111/apt.17925",null],["4","R0004842","R0004842.pdf","free_to_read","nonrandomized_study","Edmonston D","2024","Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.06.016","https://doi.org/10.1016/j.jacc.2024.06.016","39142723","https://pubmed.ncbi.nlm.nih.gov/39142723/","https://doi.org/10.1016/j.jacc.2024.06.016","ClinicalTrials.gov:NCT05465317"],["4","R0004879","R0004879.pdf","open_download_failed","nonrandomized_study","Wallace R","2024","Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.","Nephrology (Carlton, Vic.)","Wiley","10.1111/nep.14277","https://doi.org/10.1111/nep.14277","38369756","https://pubmed.ncbi.nlm.nih.gov/38369756/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/nep.14277",null],["4","R0004896","R0004896.pdf","open_download_failed","nonrandomized_study","Mody R","2024","Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2024.30.2.153","https://doi.org/10.18553/jmcp.2024.30.2.153","38308628","https://pubmed.ncbi.nlm.nih.gov/38308628/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10839462/pdf/jmcp.2024.30.2.153.pdf",null],["4","R0004942","R0004942.pdf","open_download_failed","nonrandomized_study","RECAP study group","2024","Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15652","https://doi.org/10.1111/dom.15652","38764356","https://pubmed.ncbi.nlm.nih.gov/38764356/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15652",null],["4","R0005069","R0005069.pdf","open_download_failed","nonrandomized_study","Malik RA","2024","Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15599","https://doi.org/10.1111/dom.15599","38637981","https://pubmed.ncbi.nlm.nih.gov/38637981/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15599",null],["4","R0005120","R0005120.pdf","open_download_failed","nonrandomized_study","Pradhan R","2024","Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15248","https://doi.org/10.1111/dme.15248","37876318","https://pubmed.ncbi.nlm.nih.gov/37876318/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15248",null],["4","R0005267","R0005267.pdf","free_to_read","nonrandomized_study","Barrett A","2024","The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2024.2367919","https://doi.org/10.1080/13696998.2024.2367919","38963346","https://pubmed.ncbi.nlm.nih.gov/38963346/","https://doi.org/10.1080/13696998.2024.2367919",null],["4","R0005274","R0005274.pdf","free_to_read","nonrandomized_study","Patel R","2024","GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2024.07.006","https://doi.org/10.1016/j.jchf.2024.07.006","39207323","https://pubmed.ncbi.nlm.nih.gov/39207323/","https://doi.org/10.1016/j.jchf.2024.07.006",null],["4","R0005297","R0005297.pdf","open_download_failed","nonrandomized_study","Maslin K","2024","What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review.","Clinical obesity","Wiley","10.1111/cob.12690","https://doi.org/10.1111/cob.12690","38951960","https://pubmed.ncbi.nlm.nih.gov/38951960/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12690",null],["4","R0005304","R0005304.pdf","free_to_read","nonrandomized_study","Werkman NCC","2024","Incretin-based therapy and the risk of diabetic foot ulcers and related events.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15721","https://doi.org/10.1111/dom.15721","38951877","https://pubmed.ncbi.nlm.nih.gov/38951877/","https://doi.org/10.1111/dom.15721",null],["4","R0005321","R0005321.pdf","open_download_failed","nonrandomized_study","Piccini S","2024","Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111689","https://doi.org/10.1016/j.diabres.2024.111689","38697297","https://pubmed.ncbi.nlm.nih.gov/38697297/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00599-0/pdf",null],["4","R0005364","R0005364.pdf","open_download_failed","nonrandomized_study","Lv L","2024","Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.06.013","https://doi.org/10.1016/j.pcd.2024.06.013","38991896","https://pubmed.ncbi.nlm.nih.gov/38991896/","http://www.primary-care-diabetes.com/article/S1751991824001268/pdf",null],["4","R0005469","R0005469.pdf","open_download_failed","nonrandomized_study","Preston FG","2024","SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.06.021","https://doi.org/10.1016/j.clinthera.2024.06.021","39068059","https://pubmed.ncbi.nlm.nih.gov/39068059/","http://www.clinicaltherapeutics.com/article/S0149291824001966/pdf",null],["4","R0005511","R0005511.pdf","open_download_failed","nonrandomized_study","Hamblin PS","2024","Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15893","https://doi.org/10.1111/dom.15893","39219539","https://pubmed.ncbi.nlm.nih.gov/39219539/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15893",null],["4","R0005573","R0005573.pdf","open_download_failed","nonrandomized_study","Sharma A","2024","Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15896","https://doi.org/10.1111/dom.15896","39192531","https://pubmed.ncbi.nlm.nih.gov/39192531/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15896",null],["4","R0005685","R0005685.pdf","open_download_failed","nonrandomized_study","Bodini S","2024","No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.04.009","https://doi.org/10.1016/j.clinthera.2024.04.009","38964935","https://pubmed.ncbi.nlm.nih.gov/38964935/","https://www.clinicaltherapeutics.com/article/S0149-2918(24)00088-2/pdf",null],["4","R0005733","R0005733.pdf","open_download_failed","nonrandomized_study","Gleason PP","2024","Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2024.23332","https://doi.org/10.18553/jmcp.2024.23332","38717042","https://pubmed.ncbi.nlm.nih.gov/38717042/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/pdf/jmcp.2024.23332.pdf",null],["4","R0005765","R0005765.pdf","open_download_failed","nonrandomized_study","Gratzl S","2024","Monitoring Report: GLP-1 RA Prescribing Trends - September 2024 Data","medRxiv","openRxiv","10.1101/2024.01.18.24301500","https://doi.org/10.1101/2024.01.18.24301500",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/01/22/2024.01.18.24301500.full.pdf",null],["4","R0005790","R0005790.pdf","open_download_failed","nonrandomized_study","Al-Omar HA","2024","Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2024.2319458","https://doi.org/10.1080/13696998.2024.2319458","38420695","https://pubmed.ncbi.nlm.nih.gov/38420695/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2319458?download=true",null],["4","R0005834","R0005834.pdf","open_download_failed","nonrandomized_study","Davies M","2024","Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15267","https://doi.org/10.1111/dme.15267","38088483","https://pubmed.ncbi.nlm.nih.gov/38088483/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.15267",null],["4","R0005857","R0005857.pdf","open_download_failed","nonrandomized_study","Pai YW","2024","Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15918","https://doi.org/10.1111/dom.15918","39248211","https://pubmed.ncbi.nlm.nih.gov/39248211/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15918",null],["4","R0006006","R0006006.pdf","open_download_failed","nonrandomized_study","Je NK","2024","Prescribing Patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Patients with T2DM and ASCVD in South Korea","Authorea Preprints","Wiley","10.22541/au.171065778.86745224/v1","https://doi.org/10.22541/au.171065778.86745224/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.171065778.86745224",null],["4","R0006044","R0006044.pdf","open_download_failed","nonrandomized_study","Mittman BG","2024","Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2024.2303413","https://doi.org/10.1080/03007995.2024.2303413","38193509","https://pubmed.ncbi.nlm.nih.gov/38193509/","https://www.medrxiv.org/content/medrxiv/early/2023/03/31/2023.03.30.23287965.full.pdf",null],["4","R0006097","R0006097.pdf","open_download_failed","nonrandomized_study","Pottegård A","2024","Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15912","https://doi.org/10.1111/dom.15912","39284788","https://pubmed.ncbi.nlm.nih.gov/39284788/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15912",null],["4","R0006107","R0006107.pdf","open_download_failed","nonrandomized_study","McCoy RG","2024","Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.","Nature cardiovascular research","Springer Science and Business Media LLC","10.1038/s44161-024-00453-9","https://doi.org/10.1038/s44161-024-00453-9","38846711","https://pubmed.ncbi.nlm.nih.gov/38846711/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11156225/pdf/nihms-1993206.pdf","ClinicalTrials.gov:NCT05214573"],["4","R0006146","R0006146.pdf","open_download_failed","nonrandomized_study","Nelson LW","2024","Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy.","AJR. American journal of roentgenology","American Roentgen Ray Society","10.2214/ajr.24.31805","https://doi.org/10.2214/ajr.24.31805","39230989","https://pubmed.ncbi.nlm.nih.gov/39230989/","https://ajronline.org/doi/pdf/10.2214/AJR.24.31805",null],["4","R0006186","R0006186.pdf","open_download_failed","nonrandomized_study","Hathaway JT","2024","Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.","JAMA ophthalmology","American Medical Association (AMA)","10.1001/jamaophthalmol.2024.2296","https://doi.org/10.1001/jamaophthalmol.2024.2296","38958939","https://pubmed.ncbi.nlm.nih.gov/38958939/","https://pmc.ncbi.nlm.nih.gov/articles/instance/11223051/bin/jamaophthalmol-e242296-s001.pdf",null],["4","R0006190","R0006190.pdf","open_download_failed","nonrandomized_study","Althoff MD","2024","Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.","American journal of respiratory and critical care medicine","Oxford University Press (OUP)","10.1164/rccm.202406-1166so","https://doi.org/10.1164/rccm.202406-1166so","39311907","https://pubmed.ncbi.nlm.nih.gov/39311907/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568442/pdf/rccm.202406-1166SO.pdf",null],["4","R0006250","R0006250.pdf","free_to_read","nonrandomized_study","Marques P","2024","Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15691","https://doi.org/10.1111/dom.15691","38831564","https://pubmed.ncbi.nlm.nih.gov/38831564/","https://doi.org/10.1111/dom.15691",null],["4","R0006266","R0006266.pdf","open_download_failed","nonrandomized_study","Kelly MS","2024","Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15934","https://doi.org/10.1111/dom.15934","39248221","https://pubmed.ncbi.nlm.nih.gov/39248221/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15934",null],["4","R0006319","R0006319.pdf","free_to_read","nonrandomized_study","Wright EE","2024","Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0015","https://doi.org/10.1089/dia.2024.0015","38669474","https://pubmed.ncbi.nlm.nih.gov/38669474/","https://doi.org/10.1089/dia.2024.0015",null],["4","R0006576","R0006576.pdf","open_download_failed","nonrandomized_study","Shen L","2024","Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study","medRxiv","openRxiv","10.1101/2024.09.15.24313695","https://doi.org/10.1101/2024.09.15.24313695",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/09/16/2024.09.15.24313695.full.pdf",null],["4","R0006577","R0006577.pdf","free_to_read","nonrandomized_study","Nersessian RSF","2024","Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.","Anaesthesia","Wiley","10.1111/anae.16454","https://doi.org/10.1111/anae.16454","39435967","https://pubmed.ncbi.nlm.nih.gov/39435967/","https://doi.org/10.1111/anae.16454",null],["4","R0006866","R0006866.pdf","open_download_failed","nonrandomized_study","Kim MJ","2024","One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2024.06.024","https://doi.org/10.1016/j.clinthera.2024.06.024","39069432","https://pubmed.ncbi.nlm.nih.gov/39069432/","https://www.clinicaltherapeutics.com/article/S0149-2918(24)00199-1/pdf",null],["4","R0006925","R0006925.pdf","open_download_failed","nonrandomized_study","Vanek L","2024","Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15967","https://doi.org/10.1111/dom.15967","39375862","https://pubmed.ncbi.nlm.nih.gov/39375862/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15967",null],["4","R0006947","R0006947.pdf","open_download_failed","nonrandomized_study","Rodriguez PJ","2024","Access to Anti-Obesity GLP-1s for Medicare-Aged Adults","medRxiv","openRxiv","10.1101/2024.03.26.24304923","https://doi.org/10.1101/2024.03.26.24304923",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/05/13/2024.03.26.24304923.full.pdf",null],["4","R0006990","R0006990.pdf","open_download_failed","nonrandomized_study","Demir SB","2024","CURRENT TREATMENT APPROACHES AND GLYCEMIC CONTROL IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD EVIDENCE FROM A TERTIARY HOSPITAL IN TURKEY.","Acta endocrinologica (Bucharest, Romania : 2005)","ACTA Endocrinologica Foundation","10.4183/aeb.2024.324","https://doi.org/10.4183/aeb.2024.324","40530092","https://pubmed.ncbi.nlm.nih.gov/40530092/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12169838/pdf/ACTA-20-324.pdf",null],["4","R0007023","R0007023.pdf","open_download_failed","nonrandomized_study","Donald EM","2024","Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.","Clinical transplantation","Wiley","10.1111/ctr.15401","https://doi.org/10.1111/ctr.15401","39023081","https://pubmed.ncbi.nlm.nih.gov/39023081/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11634378/pdf/nihms-2037290.pdf",null],["4","R0007169","R0007169.pdf","open_download_failed","nonrandomized_study","Wisniewski B","2024","Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2024.30.1.34","https://doi.org/10.18553/jmcp.2024.30.1.34","38153863","https://pubmed.ncbi.nlm.nih.gov/38153863/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10775775/pdf/jmcp.2024.30.1.34.pdf",null],["4","R0007228","R0007228.pdf","open_download_failed","nonrandomized_study","Paik JM","2024","Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2023.7660","https://doi.org/10.1001/jamainternmed.2023.7660","38285598","https://pubmed.ncbi.nlm.nih.gov/38285598/","https://pmc.ncbi.nlm.nih.gov/articles/instance/10825784/bin/jamainternmed-e237660-s001.pdf",null],["4","R0007274","R0007274.pdf","open_download_failed","nonrandomized_study","Simonsen E","2024","Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study","medRxiv","openRxiv","10.1101/2024.12.09.24318574","https://doi.org/10.1101/2024.12.09.24318574",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/12/11/2024.12.09.24318574.full.pdf",null],["4","R0007321","R0007321.pdf","open_download_failed","nonrandomized_study","Fu EL","2024","A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.","Kidney international","Elsevier BV","10.1016/j.kint.2023.11.025","https://doi.org/10.1016/j.kint.2023.11.025","38101515","https://pubmed.ncbi.nlm.nih.gov/38101515/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10922914/pdf/nihms-1964024.pdf",null],["4","R0007366","R0007366.pdf","open_download_failed","nonrandomized_study","Lunati ME","2024","Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2023.107040","https://doi.org/10.1016/j.phrs.2023.107040","38128857","https://pubmed.ncbi.nlm.nih.gov/38128857/","https://ars.els-cdn.com/content/image/1-s2.0-S1043661823003961-ga1_lrg.jpg",null],["4","R0007562","R0007562.pdf","open_download_failed","nonrandomized_study","Wang T","2024","Iterative Causal Forest: A Novel Algorithm for Subgroup Identification.","American journal of epidemiology","Oxford University Press (OUP)","10.1093/aje/kwad219","https://doi.org/10.1093/aje/kwad219","37943684","https://pubmed.ncbi.nlm.nih.gov/37943684/","https://academic.oup.com/aje/advance-article-pdf/doi/10.1093/aje/kwad219/52980404/kwad219.pdf",null],["4","R0007578","R0007578.pdf","free_to_read","nonrandomized_study","Solmi M","2024","Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2024.2396396","https://doi.org/10.1080/14740338.2024.2396396","39225182","https://pubmed.ncbi.nlm.nih.gov/39225182/","https://research.rug.nl/en/publications/8e469796-e7d9-4e65-ba18-ae1fd453a864",null],["4","R0007642","R0007642.pdf","open_download_failed","nonrandomized_study","Wang T","2024","High-dimensional Iterative Causal Forest (hdiCF) for Subgroup Identification Using Health Care Claims Data.","American journal of epidemiology","Oxford University Press (OUP)","10.1093/aje/kwae322","https://doi.org/10.1093/aje/kwae322","39245674","https://pubmed.ncbi.nlm.nih.gov/39245674/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12234226/pdf/kwae322.pdf",null],["4","R0007865","R0007865.pdf","free_to_read","nonrandomized_study","Zhang T","2024","Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.","Journal of the American Medical Directors Association","Elsevier BV","10.1016/j.jamda.2023.06.033","https://doi.org/10.1016/j.jamda.2023.06.033","37553080","https://pubmed.ncbi.nlm.nih.gov/37553080/","https://doi.org/10.1016/j.jamda.2023.06.033",null],["4","R0008066","R0008066.pdf","open_download_failed","nonrandomized_study","Scoccimarro D","2024","Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3727","https://doi.org/10.1002/dmrr.3727","37776322","https://pubmed.ncbi.nlm.nih.gov/37776322/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.3727",null],["4","R0008261","R0008261.pdf","open_download_failed","nonrandomized_study","Bremmer MP","2024","Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders.","Journal of studies on alcohol and drugs","Alcohol Research Documentation, Inc.","10.15288/jsad.23-00318","https://doi.org/10.15288/jsad.23-00318","37917019","https://pubmed.ncbi.nlm.nih.gov/37917019/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10846600/pdf/jsad.23-00318.pdf",null],["4","R0008297","R0008297.pdf","free_to_read","nonrandomized_study","Zhao X","2024","GLP-1R mediates idebenone-reduced blood glucose in mice.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2024.117202","https://doi.org/10.1016/j.biopha.2024.117202","39053424","https://pubmed.ncbi.nlm.nih.gov/39053424/","https://doi.org/10.1016/j.biopha.2024.117202",null],["4","R0008356","R0008356.pdf","free_to_read","nonrandomized_study","O'Hara DV","2024","Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111745","https://doi.org/10.1016/j.diabres.2024.111745","38876274","https://pubmed.ncbi.nlm.nih.gov/38876274/","https://doi.org/10.1016/j.diabres.2024.111745",null],["4","R0008544","R0008544.pdf","free_to_read","nonrandomized_study","Siddeeque N","2024","Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study.","International immunopharmacology","Elsevier BV","10.1016/j.intimp.2024.113537","https://doi.org/10.1016/j.intimp.2024.113537","39486172","https://pubmed.ncbi.nlm.nih.gov/39486172/","https://doi.org/10.1016/j.intimp.2024.113537",null],["4","R0008575","R0008575.pdf","free_to_read","nonrandomized_study","Vigara LA","2024","Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients.","Nefrologia","Elsevier BV","10.1016/j.nefroe.2024.11.007","https://doi.org/10.1016/j.nefroe.2024.11.007","39645509","https://pubmed.ncbi.nlm.nih.gov/39645509/","https://doi.org/10.1016/j.nefroe.2024.11.007",null],["4","R0008584","R0008584.pdf","open_download_failed","nonrandomized_study","Basu A","2024","Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15878","https://doi.org/10.1111/dom.15878","39223846","https://pubmed.ncbi.nlm.nih.gov/39223846/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15878",null],["4","R0008670","R0008670.pdf","free_to_read","nonrandomized_study","Tsuriya D","2024","SGLT2 Inhibitor and GLP-1 Receptor Agonist Co-Treatment: Liver Function Effects in Patients with Type 2 Diabetes Mellitus","Research Square","Research Square Platform LLC","10.21203/rs.3.rs-4444467/v1","https://doi.org/10.21203/rs.3.rs-4444467/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.21203/rs.3.rs-4444467/v1",null],["4","R0008706","R0008706.pdf","free_to_read","nonrandomized_study","Nadarajah R","2024","Diabetes mellitus and presentation, care and outcomes of patients with NSTEMI: the Association for Acute Cardiovascular Care-European Association of Percutaneous Cardiovascular Interventions EURObservational Research Programme NSTEMI Registry of the European Society of Cardiology.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcae002","https://doi.org/10.1093/ehjqcco/qcae002","38192034","https://pubmed.ncbi.nlm.nih.gov/38192034/","https://pure.amsterdamumc.nl/en/publications/acea659b-a9ab-4baf-a085-2e81be063c22",null],["4","R0008766","R0008766.pdf","free_to_read","nonrandomized_study","Al-Chalabi S","2024","Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases.","Cardiorenal medicine","S. Karger AG","10.1159/000535772","https://doi.org/10.1159/000535772","38171343","https://pubmed.ncbi.nlm.nih.gov/38171343/","https://doi.org/10.1159/000535772",null],["4","R0009159","R0009159.pdf","open_download_failed","nonrandomized_study","Chen WH","2024","Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2024.30.11.1298","https://doi.org/10.18553/jmcp.2024.30.11.1298","39471265","https://pubmed.ncbi.nlm.nih.gov/39471265/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11522454/pdf/jmcp.2024.30.11.1298.pdf",null],["4","R0009214","R0009214.pdf","free_to_read","nonrandomized_study","Fazeli Farsani S","2024","Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post-authorization safety study.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5800","https://doi.org/10.1002/pds.5800","38719731","https://pubmed.ncbi.nlm.nih.gov/38719731/","https://doi.org/10.1002/pds.5800",null],["4","R0009221","R0009221.pdf","free_to_read","nonrandomized_study","Ciardullo S","2024","Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3791","https://doi.org/10.1002/dmrr.3791","38549238","https://pubmed.ncbi.nlm.nih.gov/38549238/","https://doi.org/10.1002/dmrr.3791",null],["4","R0009279","R0009279.pdf","free_to_read","nonrandomized_study","Czupryniak L","2024","Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15789","https://doi.org/10.1111/dom.15789","39140231","https://pubmed.ncbi.nlm.nih.gov/39140231/","https://doi.org/10.1111/dom.15789",null],["4","R0009413","R0009413.pdf","free_to_read","nonrandomized_study","Dai J","2024","Comparative Effectiveness of Liraglutide versus Dulaglutide in Asian Patients with Type 2 Diabetes: A Retrospective Study","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-4920008/v1","https://doi.org/10.21203/rs.3.rs-4920008/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-4920008/v1",null],["4","R0009630","R0009630.pdf","free_to_read","nonrandomized_study","Kouidrat Y","2024","Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: Lessons for precision medicine.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2023.101507","https://doi.org/10.1016/j.diabet.2023.101507","38141807","https://pubmed.ncbi.nlm.nih.gov/38141807/","https://doi.org/10.1016/j.diabet.2023.101507",null],["4","R0009754","R0009754.pdf","open_download_failed","nonrandomized_study","Chan JCN","2024","Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15700","https://doi.org/10.1111/dom.15700","38992869","https://pubmed.ncbi.nlm.nih.gov/38992869/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15700",null],["4","R0009988","R0009988.pdf","open_download_failed","nonrandomized_study","Dankers M","2024","Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines.","British journal of clinical pharmacology","Wiley","10.1111/bcp.15959","https://doi.org/10.1111/bcp.15959","37945350","https://pubmed.ncbi.nlm.nih.gov/37945350/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15959",null],["4","R0010228","R0010228.pdf","open_download_failed","nonrandomized_study","Wang W","2024","Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.","Annals of internal medicine","American College of Physicians","10.7326/m23-2718","https://doi.org/10.7326/m23-2718","39074369","https://pubmed.ncbi.nlm.nih.gov/39074369/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12721465/pdf/nihms-2123689.pdf",null],["4","R0010387","R0010387.pdf","free_to_read","nonrandomized_study","St-Pierre J","2024","Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.","Digestive diseases and sciences","Springer Science and Business Media LLC","10.1007/s10620-024-08720-2","https://doi.org/10.1007/s10620-024-08720-2","39516435","https://pubmed.ncbi.nlm.nih.gov/39516435/","http://dx.doi.org/10.21203/rs.3.rs-4740528/v1",null],["4","R0010461","R0010461.pdf","free_to_read","nonrandomized_study","Baser O","2024","The association between weight loss medications and cardiovascular complications.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24037","https://doi.org/10.1002/oby.24037","38706431","https://pubmed.ncbi.nlm.nih.gov/38706431/","https://doi.org/10.1002/oby.24037",null],["4","R0010741","R0010741.pdf","free_to_read","nonrandomized_study","Pujol Calafat A","2024","[The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].","Nutricion hospitalaria","ARAN Ediciones","10.20960/nh.05244","https://doi.org/10.20960/nh.05244","39512012","https://pubmed.ncbi.nlm.nih.gov/39512012/","https://doi.org/10.20960/nh.05244",null],["4","R0010838","R0010838.pdf","open_download_failed","nonrandomized_study","Kalinderi K","2024","GLP-1 Receptor Agonists: A New Challenge in Parkinson’s Disease Treatment","Preprints.org","MDPI AG","10.20944/preprints202402.1245.v1","https://doi.org/10.20944/preprints202402.1245.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/202402.1245/v1/download",null],["4","R0011105","R0011105.pdf","free_to_read","nonrandomized_study","Toker D","2024","Saxagliptin for Disorders of Consciousness: AI, Retrospective Observations, and Preclinical Data","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-4810276/v1","https://doi.org/10.21203/rs.3.rs-4810276/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-4810276/v1",null],["4","R0011605","R0011605.pdf","open_download_failed","nonrandomized_study","O'Connor N","2024","jabbrv-ltwa-all.ldf jabbrv-ltwa-en.ldf Anti-obesity medicines: An overview of the clinical landscape","Authorea Preprints","Wiley","10.22541/au.172923845.58953877/v1","https://doi.org/10.22541/au.172923845.58953877/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.172923845.58953877/v1",null],["4","R0011619","R0011619.pdf","free_to_read","nonrandomized_study","Talay L","2024","The Effect of Lifestyle Coaching Approach on Patient Engagement and Weight Loss in a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study","Preprints.org","MDPI AG","10.20944/preprints202410.1674.v1","https://doi.org/10.20944/preprints202410.1674.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202410.1674.v1",null],["4","R0011737","R0011737.pdf","free_to_read","nonrandomized_study","Otani D","2024","[18F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature.","Endocrine journal","Japan Endocrine Society","10.1507/endocrj.ej24-0187","https://doi.org/10.1507/endocrj.ej24-0187","38839345","https://pubmed.ncbi.nlm.nih.gov/38839345/","https://doi.org/10.1507/endocrj.ej24-0187","jRCT:jRCTs051200156"],["4","R0011762","R0011762.pdf","open_download_failed","nonrandomized_study","Adeghate EA","2024","GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2024.2328796","https://doi.org/10.1080/14656566.2024.2328796","38458647","https://pubmed.ncbi.nlm.nih.gov/38458647/","https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2328796",null],["4","R0012199","R0012199.pdf","free_to_read","nonrandomized_study","Kido K","2024","Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2023.09.011","https://doi.org/10.1016/j.japh.2023.09.011","37797920","https://pubmed.ncbi.nlm.nih.gov/37797920/",null,null],["4","R0012371","R0012371.pdf","free_to_read","nonrandomized_study","Rodriguez PJ","2024","Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity","medRxiv","openRxiv","10.1101/2024.07.26.24311058","https://doi.org/10.1101/2024.07.26.24311058",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2024.07.26.24311058",null],["4","R0012403","R0012403.pdf","free_to_read","nonrandomized_study","Palanca A","2024","Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.111071","https://doi.org/10.1016/j.diabres.2023.111071","38142748","https://pubmed.ncbi.nlm.nih.gov/38142748/","http://hdl.handle.net/10251/204775",null],["4","R0012682","R0012682.pdf","open_download_failed","nonrandomized_study","Marchi D","2024","A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (Chinchilla lanigera) Model of Auditory Blast Injury.","Comparative medicine","American Association for Laboratory Animal Science","10.30802/aalas-cm-23-000077","https://doi.org/10.30802/aalas-cm-23-000077","38649263","https://pubmed.ncbi.nlm.nih.gov/38649263/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11267444/pdf/cm2024000179.pdf",null],["4","R0012947","R0012947.pdf","free_to_read","nonrandomized_study","Berra C","2024","Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2024.107517","https://doi.org/10.1016/j.phrs.2024.107517","39613122","https://pubmed.ncbi.nlm.nih.gov/39613122/","https://doi.org/10.1016/j.phrs.2024.107517",null],["4","R0013434","R0013434.pdf","free_to_read","nonrandomized_study","Kim MS","2024","Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related Morbidities","medRxiv","openRxiv","10.1101/2024.11.01.24316620","https://doi.org/10.1101/2024.11.01.24316620",null,"https://pubmed.ncbi.nlm.nih.gov//","https://pubmed.ncbi.nlm.nih.gov/41844147/",null],["4","R0013882","R0013882.pdf","free_to_read","nonrandomized_study","Levy ME","2024","Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort study","medRxiv","openRxiv","10.1101/2024.10.31.24316494","https://doi.org/10.1101/2024.10.31.24316494",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2024.10.31.24316494",null],["4","R0013956","R0013956.pdf","free_to_read","nonrandomized_study","Grew EC","2024","Obesity Medicine Intervention at an Academic Medical Center in a Resource-Limited Population Shows Promise.","Journal of health care for the poor and underserved","Project MUSE","10.1353/hpu.2024.a919807","https://doi.org/10.1353/hpu.2024.a919807","38661859","https://pubmed.ncbi.nlm.nih.gov/38661859/",null,null],["4","R0014180","R0014180.pdf","free_to_read","nonrandomized_study","Ladebo L","2024","Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc24-1082","https://doi.org/10.2337/dc24-1082","39106205","https://pubmed.ncbi.nlm.nih.gov/39106205/","https://researchprofiles.ku.dk/da/publications/16fe498f-5162-44a1-a091-f9dccd790c9c",null],["4","R0014399","R0014399.pdf","open_download_failed","nonrandomized_study","Aoyama K","2024","Effects of weight loss from oral semaglutide administration on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a retrospective analysis using propensity score matching.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-024-00744-3","https://doi.org/10.1007/s13340-024-00744-3","39469553","https://pubmed.ncbi.nlm.nih.gov/39469553/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11512971/pdf/13340_2024_Article_744.pdf",null],["4","R0014762","R0014762.pdf","free_to_read","nonrandomized_study","Li Z","2024","Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000812","https://doi.org/10.1097/hep.0000000000000812","38441957","https://pubmed.ncbi.nlm.nih.gov/38441957/",null,null],["4","R0014861","R0014861.pdf","open_download_failed","nonrandomized_study","Ruiz PL","2024","Pharmacological treatment of obesity in adults in Norway 2004-2022.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15515","https://doi.org/10.1111/dom.15515","38419410","https://pubmed.ncbi.nlm.nih.gov/38419410/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15515",null],["4","R0014886","R0014886.pdf","open_download_failed","nonrandomized_study","Mima A","2024","Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study.","In vivo (Athens, Greece)","International Institute of Anticancer Research","10.21873/invivo.13440","https://doi.org/10.21873/invivo.13440","38148042","https://pubmed.ncbi.nlm.nih.gov/38148042/","https://iv.iiarjournals.org/content/invivo/38/1/308.full.pdf",null],["4","R0014910","R0014910.pdf","open_download_failed","nonrandomized_study","Ueda P","2024","Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Elsevier BV","10.1016/j.cgh.2023.08.034","https://doi.org/10.1016/j.cgh.2023.08.034","37716613","https://pubmed.ncbi.nlm.nih.gov/37716613/","http://www.cghjournal.org/article/S1542356523007036/pdf",null],["4","R0015445","R0015445.pdf","open_download_failed","nonrandomized_study","Deng L","2024","Genetic Variants and Therapeutic Approaches in Maturity-Onset Diabetes of the Young: A Retrospective Analysis","medRxiv","openRxiv","10.1101/2024.05.20.24307619","https://doi.org/10.1101/2024.05.20.24307619",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/05/20/2024.05.20.24307619.full.pdf",null],["4","R0015893","R0015893.pdf","open_download_failed","nonrandomized_study","Jirapinyo P","2024","Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents.","Endoscopy international open","Georg Thieme Verlag KG","10.1055/a-2463-9784","https://doi.org/10.1055/a-2463-9784","39691741","https://pubmed.ncbi.nlm.nih.gov/39691741/","http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2463-9784.pdf",null],["4","R0016067","R0016067.pdf","open_download_failed","nonrandomized_study","Kimura Y","2024","Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations.","The journal of allergy and clinical immunology. In practice","Elsevier BV","10.1016/j.jaip.2024.05.002","https://doi.org/10.1016/j.jaip.2024.05.002","38734374","https://pubmed.ncbi.nlm.nih.gov/38734374/","http://www.jaci-inpractice.org/article/S2213219824004677/pdf",null],["4","R0016587","R0016587.pdf","open_download_failed","nonrandomized_study","Greck BD","2024","The Impact of a Metformin Recall on Patient Hemoglobin A1c Levels at a VA Network.","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","Frontline Medical Communications, Inc.","10.12788/fp.0523","https://doi.org/10.12788/fp.0523","39839575","https://pubmed.ncbi.nlm.nih.gov/39839575/","https://cdn.mdedge.com/files/s3fs-public/1124FED DM Metformin.pdf",null],["4","R0017103","R0017103.pdf","open_download_failed","nonrandomized_study","Anazco D","2024","Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study.","Journal of clinical gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mcg.0000000000001931","https://doi.org/10.1097/mcg.0000000000001931","37983763","https://pubmed.ncbi.nlm.nih.gov/37983763/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10972774/pdf/nihms-1929669.pdf",null],["4","R0017240","R0017240.pdf","open_download_failed","nonrandomized_study","Fadini GP","2024","IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15486","https://doi.org/10.1111/dom.15486","38327240","https://pubmed.ncbi.nlm.nih.gov/38327240/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15486",null],["4","R0017585","R0017585.pdf","free_to_read","nonrandomized_study","Xue H","2024","Preventing CXCL12 elevation helps to reduce acute exacerbation of COPD in individuals co-existing type-2 diabetes: A bioinformatics and clinical pharmacology study.","International immunopharmacology","Elsevier BV","10.1016/j.intimp.2024.111894","https://doi.org/10.1016/j.intimp.2024.111894","38569426","https://pubmed.ncbi.nlm.nih.gov/38569426/","https://doi.org/10.1016/j.intimp.2024.111894","ChiCTR:ChiCTR2200055611"],["4","R0017914","R0017914.pdf","open_download_failed","nonrandomized_study","Vilarrasa E","2024","[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.","Actas dermo-sifiliograficas","Elsevier BV","10.1016/j.ad.2023.10.019","https://doi.org/10.1016/j.ad.2023.10.019","37918631","https://pubmed.ncbi.nlm.nih.gov/37918631/","https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-fx1_lrg.jpg",null],["4","R0018226","R0018226.pdf","free_to_read","nonrandomized_study","Santos LB","2024","Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.","Journal of clinical anesthesia","Elsevier BV","10.1016/j.jclinane.2024.111668","https://doi.org/10.1016/j.jclinane.2024.111668","39476514","https://pubmed.ncbi.nlm.nih.gov/39476514/","https://doi.org/10.1016/j.jclinane.2024.111668",null],["4","R0018318","R0018318.pdf","free_to_read","nonrandomized_study","Zamora MG","2024","Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2024.107295","https://doi.org/10.1016/j.phrs.2024.107295","38971270","https://pubmed.ncbi.nlm.nih.gov/38971270/","https://doi.org/10.1016/j.phrs.2024.107295",null],["4","R0018518","R0018518.pdf","open_download_failed","nonrandomized_study","Azzam AY","2024","Semaglutide as an Adjunctive Therapy to Standard Management for Idiopathic Intracranial Hypertension: A Real-World Data-Based Retrospective Analysis.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2024.11.12.24317197","https://doi.org/10.1101/2024.11.12.24317197","39677446","https://pubmed.ncbi.nlm.nih.gov/39677446/","https://www.medrxiv.org/content/medrxiv/early/2024/11/13/2024.11.12.24317197.full.pdf",null],["4","R0018565","R0018565.pdf","open_download_failed","nonrandomized_study","Røikjer J","2024","Prevalence of painful and painless diabetic peripheral neuropathy in the Northern Danish Region: A population-based study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.08.006","https://doi.org/10.1016/j.pcd.2024.08.006","39217071","https://pubmed.ncbi.nlm.nih.gov/39217071/","https://www.primary-care-diabetes.com/article/S1751-9918(24)00164-5/pdf",null],["4","R0018666","R0018666.pdf","open_download_failed","nonrandomized_study","Meral R","2024","Tirzepatide for Lipodystrophy.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2024.09.25.24313345","https://doi.org/10.1101/2024.09.25.24313345","39802778","https://pubmed.ncbi.nlm.nih.gov/39802778/","https://www.medrxiv.org/content/medrxiv/early/2024/09/27/2024.09.25.24313345.full.pdf",null],["4","R0018995","R0018995.pdf","open_download_failed","nonrandomized_study","Hassanein M","2024","Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111567","https://doi.org/10.1016/j.diabres.2024.111567","38341039","https://pubmed.ncbi.nlm.nih.gov/38341039/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724000500/pdf",null],["4","R0019048","R0019048.pdf","free_to_read","nonrandomized_study","Stenberg E","2024","Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15952","https://doi.org/10.1111/dom.15952","39295084","https://pubmed.ncbi.nlm.nih.gov/39295084/","https://doi.org/10.1111/dom.15952",null],["4","R0019080","R0019080.pdf","free_to_read","nonrandomized_study","Buckley A","2024","Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15680","https://doi.org/10.1111/dom.15680","38783825","https://pubmed.ncbi.nlm.nih.gov/38783825/","https://doi.org/10.1111/dom.15680",null],["4","R0019216","R0019216.pdf","free_to_read","nonrandomized_study","Campo CBFd","2024","Semaglutide and thyroid cancer: preclinical risk data, actual evidence and discrepancies in information provided by regulatory agencies.","Authorea Preprints","Wiley","10.22541/au.173323641.19720394/v1","https://doi.org/10.22541/au.173323641.19720394/v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0019256","R0019256.pdf","open_download_failed","nonrandomized_study","Guo L","2024","Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15590","https://doi.org/10.1111/dom.15590","38600796","https://pubmed.ncbi.nlm.nih.gov/38600796/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15590",null],["4","R0019262","R0019262.pdf","open_download_failed","nonrandomized_study","Arai T","2024","Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15898","https://doi.org/10.1111/dom.15898","39223865","https://pubmed.ncbi.nlm.nih.gov/39223865/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15898",null],["4","R0019299","R0019299.pdf","free_to_read","nonrandomized_study","Li Z","2024","Translating Subphenotypes of Newly Diagnosed Type 2 Diabetes from Cohort Studies to Electronic Health Records in the United States","medRxiv","openRxiv","10.1101/2024.10.08.24315128","https://doi.org/10.1101/2024.10.08.24315128",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1101/2024.10.08.24315128",null],["4","R0019778","R0019778.pdf","open_download_failed","nonrandomized_study","Gasoyan H","2024","Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15473","https://doi.org/10.1111/dom.15473","38287140","https://pubmed.ncbi.nlm.nih.gov/38287140/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15473",null],["4","R0019874","R0019874.pdf","open_download_failed","nonrandomized_study","Kuriyama T","2024","Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.","Clinical nutrition ESPEN","Elsevier BV","10.1016/j.clnesp.2023.12.005","https://doi.org/10.1016/j.clnesp.2023.12.005","38220377","https://pubmed.ncbi.nlm.nih.gov/38220377/","http://clinicalnutritionespen.com/article/S2405457723022301/pdf",null],["4","R0019900","R0019900.pdf","open_download_failed","nonrandomized_study","Jain AB","2024","Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15493","https://doi.org/10.1111/dom.15493","38468125","https://pubmed.ncbi.nlm.nih.gov/38468125/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15493","ClinicalTrials.gov:NCT04559815"],["4","R0019932","R0019932.pdf","open_download_failed","nonrandomized_study","Klonoff DC","2024","Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241268050","https://doi.org/10.1177/19322968241268050","39080859","https://pubmed.ncbi.nlm.nih.gov/39080859/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11529103/pdf/10.1177_19322968241268050.pdf",null],["4","R0020000","R0020000.pdf","open_download_failed","nonrandomized_study","Williams G","2024","Pre-Diagnosis Observational and Prescription History Associated with Alzheimer’s Disease Incidence","medRxiv","openRxiv","10.1101/2024.07.17.24310553","https://doi.org/10.1101/2024.07.17.24310553",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/01/24/2024.07.17.24310553.full.pdf",null],["4","R0020054","R0020054.pdf","open_download_failed","nonrandomized_study","Haidar L","2024","Weight loss associated with semaglutide treatment among people with HIV.","AIDS (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/qad.0000000000003791","https://doi.org/10.1097/qad.0000000000003791","37976053","https://pubmed.ncbi.nlm.nih.gov/37976053/","https://www.authorea.com/doi/pdf/10.22541/au.168629592.23021504",null],["4","R0020119","R0020119.pdf","open_download_failed","nonrandomized_study","Wang W","2024","Association of semaglutide with risk of suicidal ideation in a real-world cohort.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-023-02672-2","https://doi.org/10.1038/s41591-023-02672-2","38182782","https://pubmed.ncbi.nlm.nih.gov/38182782/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11034947/pdf/nihms-1984698.pdf",null],["4","R0020216","R0020216.pdf","open_download_failed","nonrandomized_study","Guy A","2024","Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15436","https://doi.org/10.1111/dom.15436","38240127","https://pubmed.ncbi.nlm.nih.gov/38240127/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15436",null],["4","R0020404","R0020404.pdf","open_download_failed","nonrandomized_study","Yoneda C","2024","Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-024-00734-5","https://doi.org/10.1007/s13340-024-00734-5","39101186","https://pubmed.ncbi.nlm.nih.gov/39101186/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11291808/pdf/13340_2024_Article_734.pdf",null],["4","R0020432","R0020432.pdf","open_download_failed","nonrandomized_study","Bonnet JB","2024","Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23922","https://doi.org/10.1002/oby.23922","37927153","https://pubmed.ncbi.nlm.nih.gov/37927153/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23922",null],["4","R0020451","R0020451.pdf","open_download_failed","nonrandomized_study","Kottilil K","2024","Proteomic Profiling of Early-Stage Heart Failure Identifies Candidate Biomarkers and Molecular Pathways of Cardiac Inflammation in the Project Baseline Health Study","medRxiv","openRxiv","10.1101/2024.12.20.24319438","https://doi.org/10.1101/2024.12.20.24319438",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/12/22/2024.12.20.24319438.full.pdf","ClinicalTrials.gov:NCT03154346"],["4","R0020481","R0020481.pdf","free_to_read","nonrandomized_study","Duan Z","2024","Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide.","AMIA ... Annual Symposium proceedings. AMIA Symposium",null,null,"https://doi.org/","41726410","https://pubmed.ncbi.nlm.nih.gov/41726410/",null,null],["4","R0020497","R0020497.pdf","free_to_read","nonrandomized_study","Sensi B","2024","Letter to the Editor: Can semaglutide result in a tangible cardiovascular benefit in recipients of liver transplants?","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","Ovid Technologies (Wolters Kluwer Health)","10.1097/lvt.0000000000000364","https://doi.org/10.1097/lvt.0000000000000364","38497771","https://pubmed.ncbi.nlm.nih.gov/38497771/",null,null],["4","R0020528","R0020528.pdf","free_to_read","nonrandomized_study","Swift C","2024","Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15516","https://doi.org/10.1111/dom.15516","38418411","https://pubmed.ncbi.nlm.nih.gov/38418411/","https://doi.org/10.1111/dom.15516",null],["4","R0020545","R0020545.pdf","open_download_failed","nonrandomized_study","Milani I","2024","Gender-Difference in Response to Treatment with Liraglutide 3.0 mg","Preprints.org","MDPI AG","10.20944/preprints202405.0568.v1","https://doi.org/10.20944/preprints202405.0568.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/b711d89a6ddd56f2a7c96a8e11a83595/download_pub",null],["4","R0020652","R0020652.pdf","free_to_read","nonrandomized_study","Dobbie LJ","2024","Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.","Clinical obesity","Wiley","10.1111/cob.12649","https://doi.org/10.1111/cob.12649","38438339","https://pubmed.ncbi.nlm.nih.gov/38438339/","https://doi.org/10.1111/cob.12649",null],["4","R0020658","R0020658.pdf","open_download_failed","nonrandomized_study","Cristina García-Ulloa A","2024","De-escalating treatment indications for patients who achieve metabolic goals.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111096","https://doi.org/10.1016/j.diabres.2024.111096","38244782","https://pubmed.ncbi.nlm.nih.gov/38244782/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724000093/pdf",null],["4","R0020981","R0020981.pdf","open_download_failed","nonrandomized_study","Shi C","2024","Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15552","https://doi.org/10.1111/dom.15552","38497231","https://pubmed.ncbi.nlm.nih.gov/38497231/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15552",null],["4","R0021331","R0021331.pdf","open_download_failed","nonrandomized_study","Moreno-Pérez O","2024","Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2 S-RWD).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15431","https://doi.org/10.1111/dom.15431","38151966","https://pubmed.ncbi.nlm.nih.gov/38151966/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15431",null],["4","R0021570","R0021570.pdf","open_download_failed","nonrandomized_study","Baronti W","2024","Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111928","https://doi.org/10.1016/j.diabres.2024.111928","39536977","https://pubmed.ncbi.nlm.nih.gov/39536977/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00838-6/pdf",null],["4","R0021694","R0021694.pdf","open_download_failed","nonrandomized_study","Schultes B","2024","Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15403","https://doi.org/10.1111/dom.15403","38092710","https://pubmed.ncbi.nlm.nih.gov/38092710/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15403",null],["4","R0021812","R0021812.pdf","open_download_failed","nonrandomized_study","Agarwal S","2024","Fractures in women with type 2 diabetes are associated with marked deficits in cortical parameters and trabecular plates.","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","Oxford University Press (OUP)","10.1093/jbmr/zjae091","https://doi.org/10.1093/jbmr/zjae091","38861455","https://pubmed.ncbi.nlm.nih.gov/38861455/","https://academic.oup.com/jbmr/advance-article-pdf/doi/10.1093/jbmr/zjae091/58198907/zjae091.pdf",null],["4","R0021836","R0021836.pdf","free_to_read","nonrandomized_study","Santhakumar A","2024","Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience.","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","Elsevier BV","10.1016/j.jcf.2024.06.007","https://doi.org/10.1016/j.jcf.2024.06.007","38997826","https://pubmed.ncbi.nlm.nih.gov/38997826/","https://doi.org/10.1016/j.jcf.2024.06.007",null],["4","R0021855","R0021855.pdf","open_download_failed","nonrandomized_study","Holtrop J","2024","Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwae038","https://doi.org/10.1093/eurjpc/zwae038","38324720","https://pubmed.ncbi.nlm.nih.gov/38324720/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwae038/56615686/zwae038.pdf",null],["4","R0022088","R0022088.pdf","open_download_failed","nonrandomized_study","Lin L","2024","MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes.","Journal of magnetic resonance imaging : JMRI","Wiley","10.1002/jmri.29174","https://doi.org/10.1002/jmri.29174","38085104","https://pubmed.ncbi.nlm.nih.gov/38085104/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmri.29174",null],["4","R0022480","R0022480.pdf","open_download_failed","nonrandomized_study","Baccetti F","2024","Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111781","https://doi.org/10.1016/j.diabres.2024.111781","39002933","https://pubmed.ncbi.nlm.nih.gov/39002933/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724006910/pdf",null],["4","R0022604","R0022604.pdf","open_download_failed","nonrandomized_study","Zhang J","2024","Decline in use of high-risk agents for tight glucose control among older adults with diabetes in New York City: 2017-2022.","Journal of the American Geriatrics Society","Wiley","10.1111/jgs.19060","https://doi.org/10.1111/jgs.19060","38980267","https://pubmed.ncbi.nlm.nih.gov/38980267/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgs.19060",null],["4","R0022788","R0022788.pdf","free_to_read","nonrandomized_study","Bollinger B","2024","Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease are not affected by Comorbid Psychiatric Disease","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-4391484/v1","https://doi.org/10.21203/rs.3.rs-4391484/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-4391484/v1",null],["4","R0023030","R0023030.pdf","open_download_failed","nonrandomized_study","Gasoyan H","2024","Early- and later-stage persistence with antiobesity medications: A retrospective cohort study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23952","https://doi.org/10.1002/oby.23952","38053443","https://pubmed.ncbi.nlm.nih.gov/38053443/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23952",null],["4","R0023179","R0023179.pdf","open_download_failed","nonrandomized_study","Khera R","2024","Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2024.02.05.24302354","https://doi.org/10.1101/2024.02.05.24302354","38370787","https://pubmed.ncbi.nlm.nih.gov/38370787/","https://www.medrxiv.org/content/medrxiv/early/2024/02/08/2024.02.05.24302354.full.pdf",null],["4","R0023622","R0023622.pdf","open_download_failed","nonrandomized_study","Trang KB","2024","Shared and unique chromatin accessibility and 3D functional interactions of substance use disorder loci implicate cell types beyond the brain","medRxiv","openRxiv","10.1101/2024.07.18.24310649","https://doi.org/10.1101/2024.07.18.24310649","39072016","https://pubmed.ncbi.nlm.nih.gov/39072016/","https://www.medrxiv.org/content/medrxiv/early/2025/06/02/2024.07.18.24310649.full.pdf",null],["4","R0024313","R0024313.pdf","open_download_failed","nonrandomized_study","Shin E","2024","Performance of the ChatGPT large language model for decision support in community pharmacy.","British journal of clinical pharmacology","Wiley","10.1111/bcp.16215","https://doi.org/10.1111/bcp.16215","39191671","https://pubmed.ncbi.nlm.nih.gov/39191671/","https://www.authorea.com/doi/pdf/10.22541/au.171914051.18079707/v1",null],["4","R0025477","R0025477.pdf","free_to_read","nonrandomized_study","Weber EJ","2024","Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.1384","https://doi.org/10.1002/cpdd.1384","38346861","https://pubmed.ncbi.nlm.nih.gov/38346861/","http://dx.doi.org/10.1002/cpdd.1384",null],["4","R0026171","R0026171.pdf","open_download_failed","nonrandomized_study","Tisdale RL","2024","Racial and Ethnic Differences in Obesity Treatment in the Veterans Affairs Healthcare System","medRxiv","openRxiv","10.1101/2024.02.02.24302244","https://doi.org/10.1101/2024.02.02.24302244",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/02/04/2024.02.02.24302244.full.pdf",null],["4","R0027474","R0027474.pdf","free_to_read","nonrandomized_study","Mitchell BG","2024","Roux-en-Y Gastric Bypass","StatPearls Publishing, Treasure Island (FL)",null,null,"https://doi.org/","31985950","https://pubmed.ncbi.nlm.nih.gov/31985950/",null,null],["4","R0029095","R0029095.pdf","free_to_read","nonrandomized_study","Dulai AS","2024","The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control.","Biomedicines","MDPI AG","10.3390/biomedicines12122719","https://doi.org/10.3390/biomedicines12122719","39767626","https://pubmed.ncbi.nlm.nih.gov/39767626/","https://doi.org/10.3390/biomedicines12122719",null],["4","R0029174","R0029174.pdf","open_download_failed","nonrandomized_study","Petroni ML","2024","Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Elsevier BV","10.1016/j.dld.2024.04.021","https://doi.org/10.1016/j.dld.2024.04.021","38972788","https://pubmed.ncbi.nlm.nih.gov/38972788/","http://www.dldjournalonline.com/article/S1590865824007229/pdf",null],["4","R0029238","R0029238.pdf","open_download_failed","nonrandomized_study","Kalinderi K","2024","Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment.","Children (Basel, Switzerland)","MDPI AG","10.3390/children11020153","https://doi.org/10.3390/children11020153","38397265","https://pubmed.ncbi.nlm.nih.gov/38397265/","https://www.mdpi.com/2227-9067/11/2/153/pdf?version=1706153713",null],["4","R0029239","R0029239.pdf","free_to_read","nonrandomized_study","Lorei NC","2024","Weight loss medication prescription prevalence in the active component, 2018-2023.","MSMR",null,null,"https://doi.org/","38359359","https://pubmed.ncbi.nlm.nih.gov/38359359/",null,null],["4","R0029947","R0029947.pdf","free_to_read","nonrandomized_study","Houbachi L","2024","Evolution of myocardial steatosis in patients with type 2 diabetes treated by GLP1 receptor agonists: LICAS study","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-4706592/v1","https://doi.org/10.21203/rs.3.rs-4706592/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.21203/rs.3.rs-4706592/v1",null],["4","R0030208","R0030208.pdf","free_to_read","nonrandomized_study","Alzhanuly B","2024","Latest advancements in the development of new therapies for type 1 diabetes.","Bratislavske lekarske listy","Springer Science and Business Media LLC","10.4149/bll_2024_75","https://doi.org/10.4149/bll_2024_75","38989749","https://pubmed.ncbi.nlm.nih.gov/38989749/","https://doi.org/10.4149/bll_2024_75",null],["4","R0033230","R0033230.pdf","free_to_read","nonrandomized_study","Sanjeeb Kakati","2024","Advancing the Science of Insulin Resistance in Type 2 Diabetes","Assam Journal of Internal Medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/ajoim.ajoim_28_24","https://doi.org/10.4103/ajoim.ajoim_28_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ajoim.ajoim_28_24",null],["4","R0033264","R0033264.pdf","free_to_read","nonrandomized_study",null,"2024","PSTM 2024 Abstract Supplement Table of Contents","Plastic & Reconstructive Surgery Global Open","Ovid Technologies (Wolters Kluwer Health)","10.1097/gox.0000000000006124","https://doi.org/10.1097/gox.0000000000006124",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/gox.0000000000006124",null],["4","R0034236","R0034236.pdf","free_to_read","nonrandomized_study",null,"2024","Abstracts","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_38_24","https://doi.org/10.4103/ijdt.ijdt_38_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_38_24",null],["4","R0034516","R0034516.pdf","no_doi","nonrandomized_study","Swaleh Hussain","2024","Risk of thyroid cancer with use of glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes in Denmark: Population-based active comparator, new user cohort study","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034678","R0034678.pdf","free_to_read","nonrandomized_study","Filippos Anagnostakis","2024","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5048688","https://doi.org/10.2139/ssrn.5048688",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5048688",null],["4","R0034793","R0034793.pdf","no_doi","nonrandomized_study","Stephanie Argetsinger","2024","Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035930","R0035930.pdf","free_to_read","nonrandomized_study","Kelly Rubi","2024","How Low Can We Go: Evaluation of a Pharmacist-led Weight Loss Management Program","Nursing & Health Sciences Research Journal","Baptist Health South Florida","10.55481/2578-3750.1195","https://doi.org/10.55481/2578-3750.1195",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.55481/2578-3750.1195",null],["4","R0036140","R0036140.pdf","no_doi","nonrandomized_study","Stone, Carlyn","2024","Metformin Versus GLP-1 for Therapeutic Potential in Polycystic Ovary Syndrome","ValpoScholar (Valparaiso University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036251","R0036251.pdf","no_doi","nonrandomized_study","Ma, Sara L, MS","2024","The Celebrity Effect: How Social Media Changed Ozempic Utilization by Medicaid Patients","Human Biology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036269","R0036269.pdf","no_doi","nonrandomized_study","Bigness, PharmD, BCPS, Christopher J.","2024","Assessing Pharmacy Budget Impact of Tirzepatide for Weight Loss: A U.S. Commercial Payer Perspective","The Medicine Forum",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036277","R0036277.pdf","no_doi","nonrandomized_study","Magwenzi, Faith","2024","GLP-1 Receptor Antagonists Medicaid Utilization Trends and Obesity Rates in the US","Digital Commons (Liberty University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036284","R0036284.pdf","no_doi","nonrandomized_study","JACQUINOD, M.","2024","Use of GLP-1 analogues in liver and kidney transplant recipients: a retrospective analysis in a tertiary center","IRIS",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036444","R0036444.pdf","no_doi","nonrandomized_study","Soe, Kywe Kywe","2024","Impact of cardiac autonomic neuropathy on diabetic kidney disease: Assessment by magnetic resonance imaging","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036820","R0036820.pdf","free_to_read","nonrandomized_study","Binayak Sinha","2024","Comparing the Efficacy and Tolerability of Oral Semaglutide and Weekly Injectable Dulaglutide: A Real-World Indian Experience","Journal of Diabetes and Treatment","Gavin Publishers","10.29011/2574-7568.010135","https://doi.org/10.29011/2574-7568.010135",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.29011/2574-7568.010135",null],["4","R0036859","R0036859.pdf","free_to_read","nonrandomized_study","Benly Levi Andreas Sibarani","2024","Systematic Literature Review: Effectiveness of Insulin Combination Therapy with Glucagon-Like Peptide-1 (GLP-1) Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus","Asian Journal of Healthcare Analytics","PT Formosa Cendekia Global","10.55927/ajha.v3i2.12310","https://doi.org/10.55927/ajha.v3i2.12310",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.55927/ajha.v3i2.12310",null],["4","R0036929","R0036929.pdf","free_to_read","nonrandomized_study","Alyse S. Goldberg","2024","Consideration of Use of Semaglutide and Tirzepatide Prior to Pregnancy","Canadian Women s Health Today","Catalytic Health","10.58931/cwht.2024.1210","https://doi.org/10.58931/cwht.2024.1210",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.58931/cwht.2024.1210",null],["4","R0037162","R0037162.pdf","no_doi","nonrandomized_study","Simona Timinskaite","2024","Inkretinų poveikis ir koncentracija kraujo serume sergant genetinio ir pirmo tipo cukrinio diabeto atvejais","Lithuanian University of Health Sciences",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037746","R0037746.pdf","free_to_read","nonrandomized_study","Chia-Ming Lin","2024","Association between Glp-1 Receptor Agonist Plus Aspirin Use and Cardiovascular Outcomes in Non-Diabetic Obese Individuals: A Multi-Institutional Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4845143","https://doi.org/10.2139/ssrn.4845143",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4845143",null],["4","R0037926","R0037926.pdf","free_to_read","nonrandomized_study","Yu‐Nan Huang","2024","Comparative Analysis of Tirzepatide, Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, And Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5065542","https://doi.org/10.2139/ssrn.5065542",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5065542",null],["4","R0040205","R0040205.pdf","no_doi","nonrandomized_study","Vijiaratnam, Nirosen","2024","Exploring biomarkers for parkinsonian diseases and disease modification trials","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040339","R0040339.pdf","no_doi","nonrandomized_study","González Martínez, Miguel Ángel","2024","Efectos de AGLP1 en pacientes con enfermedad renal diabética en cuanto al pronóstico renal","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041145","R0041145.pdf","free_to_read","nonrandomized_study","Fiona E. Karet","2024","A FRMDable Future for Fibrosis?","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0000000638","https://doi.org/10.34067/kid.0000000638","39724106","https://pubmed.ncbi.nlm.nih.gov/39724106/","https://doi.org/10.34067/kid.0000000638",null],["4","R0041308","R0041308.pdf","no_doi","nonrandomized_study","Shunichiro Minoya","2024","Metabolic Link Between Obesity And Insulin Resistance","University of Debrecen Electronic Archive (University of Debrecen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041399","R0041399.pdf","no_doi","nonrandomized_study","Elwakiel, Ahmed","2024","Targeting the hyperglycemic memory in diabetic kidney disease is therapeutically amendable","Qucosa (Saxon State and University Library Dresden)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041473","R0041473.pdf","free_to_read","nonrandomized_study","Alexander Kutz","2024","8418 Association of GLP-1 Receptor Agonists and SGLT-2 Inhibitors with Major Adverse Cardiovascular Events and Serious Liver Events among Patients with Type 2 Diabetes and MASLD","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.555","https://doi.org/10.1210/jendso/bvae163.555",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.555",null],["4","R0041494","R0041494.pdf","free_to_read","nonrandomized_study","Yotsapon Thewjitcharoen","2024","5037 Coronary artery disease risk assessment by coronary artery calcium scoring in asymptomatic Thai people with diabetes mellitus","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.572","https://doi.org/10.1210/jendso/bvae163.572",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.572",null],["4","R0041547","R0041547.pdf","free_to_read","nonrandomized_study","Natalia Nazarenko","2024","EVALUATION OF WEIGHT REDUCTION AND METABOLIC PARAMETERS IN HIV COHORT UNDERGOING TREATMENT WITH GLP-1 RECEPTOR AGONISTS AT A LARGE PUBLIC NYC/HHC+ HOSPITAL IN NEW YORK CITY","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2024.100788","https://doi.org/10.1016/j.ajpc.2024.100788",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2024.100788",null],["4","R0041596","R0041596.pdf","free_to_read","nonrandomized_study","Taufiq Salahuddin","2024","PROVIDER-LEVEL VARIATION IN NOVEL CARDIOVASCULAR MEDICATION PRESCRIPTION AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE AND CORONARY ARTERY DISEASE IN THE VETERANS AFFAIRS SYSTEM","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2024.100828","https://doi.org/10.1016/j.ajpc.2024.100828",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2024.100828",null],["4","R0041600","R0041600.pdf","free_to_read","nonrandomized_study","Franck H. Azobou Tonleu","2024","USE OF GLP-1 RECEPTOR AGONISTS AND/OR SGLT-2 INHIBITORS AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE BEFORE AND AFTER REVASCULARIZATION IN A SINGLE-CENTER COHORT","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2024.100762","https://doi.org/10.1016/j.ajpc.2024.100762",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2024.100762",null],["4","R0041715","R0041715.pdf","free_to_read","nonrandomized_study","Kaelen L. Medeiros","2024","6762 Real-World Analysis of Medication Access and Clinical Outcomes for Obesity Treatment with GLP-1s","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.025","https://doi.org/10.1210/jendso/bvae163.025",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.025",null],["4","R0041790","R0041790.pdf","free_to_read","nonrandomized_study","Florence Comite","2024","8462 Synergistic Outcomes Of hCG And GLP1-RA Combination Therapy: Improved Body Composition And Carbohydrate Metabolism","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.946","https://doi.org/10.1210/jendso/bvae163.946",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.946",null],["4","R0041878","R0041878.pdf","no_doi","nonrandomized_study","Balcázar-Valencia,Carlos","2024","Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study","Dove Medical Press (Taylor and Francis Group)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041995","R0041995.pdf","no_doi","nonrandomized_study","Kufahl, Callie","2024","Prescribing GLP-1s for Obesity in Primary Care","MOspace Institutional Repository (University of Missouri)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042105","R0042105.pdf","no_doi","nonrandomized_study","Steve Bain","2024","Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042157","R0042157.pdf","no_doi","nonrandomized_study","Tae Hyeon Kim (2098843)","2024","Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042208","R0042208.pdf","no_doi","nonrandomized_study","F Foo","2024","Optimising glucose-lowering medication treatment following cardiothoracic surgery: implementation of a pharmacist-led guideline","Minerva Access (University of Melbourne)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042236","R0042236.pdf","no_doi","nonrandomized_study","Steve Bain","2024","Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043410","R0043410.pdf","free_to_read","nonrandomized_study","Noble Thomas","2024","Efficacy and Safety of Endoscopic Sleeve Gastroplasty in Patients with Obesity and Predictors of Weight Loss","Tropical Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.4103/tg.tg_17_25","https://doi.org/10.4103/tg.tg_17_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/tg.tg_17_25",null],["4","R0043651","R0043651.pdf","no_doi","nonrandomized_study","Stefano Savinelli","2024","Metabolic complications in people living with HIV: the role of obesity, inflammation, lipid metabolism, and directions for future interventions","Research Repository UCD (University College Dublin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043972","R0043972.pdf","no_doi","nonrandomized_study","P Cardoso (12142371)","2024","Investigating the use of Bayesian prediction methods in precision medicine approaches in Diabetes","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044024","R0044024.pdf","free_to_read","nonrandomized_study","Yuan‐Yu Tsai","2024","An update of contemporary insulin therapy","Journal of Diabetes Investigation","Wiley","10.1111/jdi.14212","https://doi.org/10.1111/jdi.14212","38571372","https://pubmed.ncbi.nlm.nih.gov/38571372/","https://doi.org/10.1111/jdi.14212",null],["4","R0044139","R0044139.pdf","no_doi","nonrandomized_study","Qi, Junnan","2024","PharmacoAnalytics: Assessing the Relationship Between Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Utilization and Dementia Incidence","D-Scholarship@Pitt (University of Pittsburgh)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044437","R0044437.pdf","free_to_read","nonrandomized_study","Jorinde A. W. Polderman","2024","Update on the perioperative management of diabetes mellitus","BJA Education","Elsevier BV","10.1016/j.bjae.2024.04.007","https://doi.org/10.1016/j.bjae.2024.04.007","39099754","https://pubmed.ncbi.nlm.nih.gov/39099754/","https://doi.org/10.1016/j.bjae.2024.04.007",null],["4","R0044449","R0044449.pdf","no_doi","nonrandomized_study","George, J","2024","Assessing the impact of PCSK9 inhibitors in steatotic liver disease:a prospective observational cohort study (SIMPLE)","Discovery Research Portal (University of Dundee)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044709","R0044709.pdf","free_to_read","nonrandomized_study","A. Althoff","2024","HSD104 Semaglutide and Tirzepatide in Type 2 Diabetes: Patient Characteristics and Weight-Related Outcomes in the Real-World Setting","Value in Health","Elsevier BV","10.1016/j.jval.2024.03.1327","https://doi.org/10.1016/j.jval.2024.03.1327",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2024.03.1327",null],["4","R0044746","R0044746.pdf","free_to_read","nonrandomized_study","Zaza Iakobishvili","2024","REAL WORLD OUTCOMES OF GLUCAGON LIKE PEPTIDE1 RECEPTOR AGONISTS (GLP1-RA) IN DIABETIC PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)02744-x","https://doi.org/10.1016/s0735-1097(24)02744-x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)02744-x",null],["4","R0044810","R0044810.pdf","free_to_read","nonrandomized_study","Iris K. Minichmayr","2024","Recent Advances Addressing the Challenges of Precision Dosing","Clinical Pharmacology & Therapeutics","Wiley","10.1002/cpt.3365","https://doi.org/10.1002/cpt.3365","39087264","https://pubmed.ncbi.nlm.nih.gov/39087264/","https://doi.org/10.1002/cpt.3365",null],["4","R0045024","R0045024.pdf","free_to_read","nonrandomized_study","Takuya Haraguchi","2024","Glucagon Stimulation Test and Insulin Secretory Capacity in Clinical Assessment of Incretin-Based Therapy for Diabetes",null,"American Diabetes Association","10.2337/figshare.26836057","https://doi.org/10.2337/figshare.26836057",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2337/figshare.26836057",null],["4","R0045096","R0045096.pdf","no_doi","nonrandomized_study","Søren Lundorff Jacobsen","2024","Comparative effectiveness on all-cause mortality for treatment with GLP1ra, SGLT2i and DPP-IVi in comorbid schizophrenia and type 2 diabetes: A Danish nationwide target-trial emulation study","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045200","R0045200.pdf","free_to_read","nonrandomized_study","David García‐Vega","2024","Inhibidores del cotransportador 2 de sodio-glucosa, agonistas del receptor de péptido 1 similar al glucagón y mortalidad por cáncer. Registro de la práctica real","Revista Española de Cardiología","Elsevier BV","10.1016/j.recesp.2024.07.004","https://doi.org/10.1016/j.recesp.2024.07.004",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.recesp.2024.07.004",null],["4","R0045379","R0045379.pdf","free_to_read","nonrandomized_study","Mohamed E. Hanafy","2024","Correlation Between Bone Mineral Density (BMD) And Serum Carboxy-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) In Type 2 Diabetes Mellitus (T2DM) Patients on Antidiabetic Medications","Al-Azhar International Medical Journal /Al-Azhar International Medical Journal","Egyptian Knowledge Bank","10.58675/2682-339x.2804","https://doi.org/10.58675/2682-339x.2804",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.58675/2682-339x.2804",null],["4","R0045486","R0045486.pdf","free_to_read","nonrandomized_study","Natalia Gniaź","2024","Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence","Journal of Education Health and Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/jehs.2024.75.56672","https://doi.org/10.12775/jehs.2024.75.56672",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12775/jehs.2024.75.56672",null],["4","R0045984","R0045984.pdf","free_to_read","nonrandomized_study","Murtala Muhammad Ahmad","2024","Clinical Insight into Type 2 Diabetes Mellitus: A Retrospective Study from Hospital Sultan Abdul Aziz Shah (HSAAS), Universiti Putra Malaysia’s Teaching Hospital","International Journal of Human and Health Sciences (IJHHS)","International Journal of Human and Health Sciences IJHHS","10.31344/ijhhs.v8i40.746","https://doi.org/10.31344/ijhhs.v8i40.746",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31344/ijhhs.v8i40.746",null],["4","R0046166","R0046166.pdf","free_to_read","nonrandomized_study","Aleksandra Jaroń","2024","Tirzepatide - A Revolution in Obesity Treatment?","Quality in Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/qs.2024.17.53102","https://doi.org/10.12775/qs.2024.17.53102",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.12775/qs.2024.17.53102",null],["4","R0046484","R0046484.pdf","free_to_read","nonrandomized_study","Kinga Brzdęk","2024","Triple agonists of GIP, GLP-1, and glucagon - the future of obesity treatment: a review of the latest findings","MEDICAL SCIENCE PULSE","Index Copernicus","10.5604/01.3001.0054.8367","https://doi.org/10.5604/01.3001.0054.8367",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5604/01.3001.0054.8367",null],["4","R0047079","R0047079.pdf","free_to_read","nonrandomized_study","Eleonora Avenatti","2024","WEIGHT LOSS OUTCOMES WITH SEMAGLUTIDE TREATMENT IN A LARGE HEALTHCARE SYSTEM- A REAL LIFE REPORT FROM THE HOUSTON METHODIST CVD LEARNING HEALTH SYSTEM REGISTRY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03721-5","https://doi.org/10.1016/s0735-1097(24)03721-5",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1016/s0735-1097(24)03721-5",null],["4","R0047374","R0047374.pdf","free_to_read","nonrandomized_study","Mohamad Badie Taha","2024","CLINICAL AND SOCIODEMOGRAPHIC HETEROGENEITY FOR MORTALITY RISK BY OBESITY CLASS IN PATIENTS MEETINGELIGIBILITY CRITERIA FOR SEMAGLUTIDE CARDIOVASCULAR OUTCOME TRIALS: A NATIONAL POPULATION-BASED STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03911-1","https://doi.org/10.1016/s0735-1097(24)03911-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03911-1",null],["4","R0047391","R0047391.pdf","free_to_read","nonrandomized_study","Abdullah Almulhim","2024","Weekly Semaglutide Use Shows Promise Among Type 2 Diabetes Patients at a Polyclinic in Alahsa, Saudi Arabia: A Retrospective Study","South Eastern European Journal of Public Health","Uphills Publishers LLC","10.70135/seejph.vi.2413","https://doi.org/10.70135/seejph.vi.2413",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.70135/seejph.vi.2413",null],["4","R0047698","R0047698.pdf","free_to_read","nonrandomized_study","Eleonora Avenatti","2024","CHARACTERIZING PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE FOR SEMAGLUTIDE ELIGIBILITY IN A LARGE INTEGRATED HEALTHCARE SYSTEM: HM CVD LHS REGISTRY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03667-2","https://doi.org/10.1016/s0735-1097(24)03667-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03667-2",null],["4","R0048013","R0048013.pdf","free_to_read","nonrandomized_study","Yao Yao","2024","Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Psychiatric Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 RAs) Exposure","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4901779","https://doi.org/10.2139/ssrn.4901779",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2139/ssrn.4901779",null],["4","R0048088","R0048088.pdf","free_to_read","nonrandomized_study","Henry Stevens","2024","Long-term use of semaglutide and risk of diabetic retinopathy progression","Endocrine and Metabolic Science","Elsevier BV","10.1016/j.endmts.2024.100168","https://doi.org/10.1016/j.endmts.2024.100168",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.endmts.2024.100168",null],["4","R0048159","R0048159.pdf","free_to_read","nonrandomized_study","Michael F. Levidy","2024","The Impact of GLP-1 Agonist Therapy in Tibiotalar and Subtalar Fusion: A Propensity-Matched Analysis","Foot & Ankle Orthopaedics","SAGE Publications","10.1177/2473011424s00536","https://doi.org/10.1177/2473011424s00536",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1177/2473011424s00536",null],["4","R0048363","R0048363.pdf","free_to_read","nonrandomized_study","ISKANDAR RAUF IDRIS","2024","Glucagon like peptide‐1 ( GLP ‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease","Diabetes Obesity and Metabolism Now","Wiley","10.1002/doi2.89","https://doi.org/10.1002/doi2.89",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/doi2.89",null],["4","R0048378","R0048378.pdf","free_to_read","nonrandomized_study","Syed Sadat Ali","2024","Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients","Psychiatry Research Case Reports","Elsevier BV","10.1016/j.psycr.2024.100231","https://doi.org/10.1016/j.psycr.2024.100231",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.psycr.2024.100231",null],["4","R0048540","R0048540.pdf","free_to_read","nonrandomized_study","Mahmoud Nassar","2024","9232 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.672","https://doi.org/10.1210/jendso/bvae163.672",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.672",null],["4","R0048543","R0048543.pdf","free_to_read","nonrandomized_study","Irina Vasilieva","2024","Role of glucose in regulating menstrual cycle","Special journal of the Medical Academy and other Life Sciences","TRC Colleges","10.58676/sjmas.v2i8.90","https://doi.org/10.58676/sjmas.v2i8.90",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.58676/sjmas.v2i8.90",null],["4","R0048821","R0048821.pdf","free_to_read","nonrandomized_study","Abdulrahman Alsheikh","2024","Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2024.100209","https://doi.org/10.1016/j.deman.2024.100209",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2024.100209",null],["4","R0048941","R0048941.pdf","free_to_read","nonrandomized_study","Louis A Talay","2024","Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study","Obesities","MDPI AG","10.3390/obesities4040032","https://doi.org/10.3390/obesities4040032",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/obesities4040032",null],["4","R0049396","R0049396.pdf","free_to_read","nonrandomized_study","Suhail Saad-Omer","2024","8139 Examining the Association of GLP1-RA or DPP4i with Bullous Skin Diseases in Veterans","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.768","https://doi.org/10.1210/jendso/bvae163.768",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.768",null],["4","R0050338","R0050338.pdf","free_to_read","nonrandomized_study","Wenjing Ni","2024","Epidemiology, natural history, and management of patients with CHB concurrent with MASLD","Clinical Liver Disease","Ovid Technologies (Wolters Kluwer Health)","10.1097/cld.0000000000000171","https://doi.org/10.1097/cld.0000000000000171","38903875","https://pubmed.ncbi.nlm.nih.gov/38903875/","https://doi.org/10.1097/cld.0000000000000171",null],["4","R0050365","R0050365.pdf","free_to_read","nonrandomized_study","Mahmoud Nassar","2024","6531 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.673","https://doi.org/10.1210/jendso/bvae163.673",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.673",null],["4","R0050660","R0050660.pdf","free_to_read","nonrandomized_study","Richard A. Baum","2024","Short-term complications in elective joint reconstruction: A retrospective assessment of the impact of GLP-1 agonists","Journal of Orthopaedic Reports","Scientific Scholar","10.1016/j.jorep.2024.100501","https://doi.org/10.1016/j.jorep.2024.100501",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jorep.2024.100501",null],["4","R0050719","R0050719.pdf","free_to_read","nonrandomized_study","Dmytro D. Ivanov","2024","How much salt should i recommend to a patient with CKD: the real mechanisms of regulation of sodium metabolism in kidney pathology","Nephrology (Saint-Petersburg)","Non-profit organization Nephrology","10.36485/1561-6274-2024-28-3-62-70","https://doi.org/10.36485/1561-6274-2024-28-3-62-70",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.36485/1561-6274-2024-28-3-62-70",null],["4","R0051082","R0051082.pdf","free_to_read","nonrandomized_study","Aashish Katapadi","2024","CAN GLP-1 AGONIST FOR WEIGHT LOSS CAUSE CARDIAC DYSAUTONOMIA? A STUDY OF THE FAERS DATABASE","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)02017-5","https://doi.org/10.1016/s0735-1097(24)02017-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)02017-5",null],["4","R0051212","R0051212.pdf","free_to_read","nonrandomized_study","Anna Maria Koman","2024","Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications","Quality in Sport","Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University","10.12775/qs.2024.16.52659","https://doi.org/10.12775/qs.2024.16.52659",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12775/qs.2024.16.52659",null],["4","R0051379","R0051379.pdf","free_to_read","nonrandomized_study","Riccardo De Giorgi","2024","Neurological and psychiatric outcomes associated with semaglutide in type 2 diabetes: a propensity-score matched cohort study","Neuroscience Applied","Elsevier BV","10.1016/j.nsa.2024.105187","https://doi.org/10.1016/j.nsa.2024.105187",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nsa.2024.105187",null],["4","R0051668","R0051668.pdf","free_to_read","nonrandomized_study","Matthew Fordham","2024","REAL WORLD EXPERIENCE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)02551-8","https://doi.org/10.1016/s0735-1097(24)02551-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)02551-8",null],["4","R0052036","R0052036.pdf","free_to_read","nonrandomized_study","Anwar Ali Jammah","2024","Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)","Endocrine and Metabolic Science","Elsevier BV","10.1016/j.endmts.2024.100164","https://doi.org/10.1016/j.endmts.2024.100164",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.endmts.2024.100164",null],["4","R0052595","R0052595.pdf","free_to_read","nonrandomized_study","Louis A Talay","2024","Minimizing the Risk of Misprescribing GLP-1 RA Medications in a Digital Weight-Loss Service: Preliminary Retrospective Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.57169","https://doi.org/10.2196/preprints.57169",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2196/preprints.57169",null],["4","R0052638","R0052638.pdf","free_to_read","nonrandomized_study","Robert James Magaldi","2024","Glucagon-Like Peptide-1 Agonists in Total Hip Arthroplasty: Complications, Readmissions, and Patient-Reported Outcomes","JAAOS Global Research and Reviews","Ovid Technologies (Wolters Kluwer Health)","10.5435/jaaosglobal-d-24-00148","https://doi.org/10.5435/jaaosglobal-d-24-00148",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5435/jaaosglobal-d-24-00148",null],["4","R0052720","R0052720.pdf","free_to_read","nonrandomized_study","Timothy C. Shuey","2024","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS ARE UNDERUTILIZED IN THE POST-ACS POPULATION: REAL-WORLD RESULTS FROM A LARGE INTEGRATED HEALTHCARE SYSTEM","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03873-7","https://doi.org/10.1016/s0735-1097(24)03873-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03873-7",null],["4","R0052746","R0052746.pdf","free_to_read","nonrandomized_study","Raymond E Farah","2024","The Rise in Glucagon-Like Peptide-1 Receptor Agonist Related Calls to United States Poison Centers","European Journal of Public Health","Oxford University Press (OUP)","10.1093/eurpub/ckae144.1330","https://doi.org/10.1093/eurpub/ckae144.1330",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/eurpub/ckae144.1330",null],["4","R0052942","R0052942.pdf","free_to_read","nonrandomized_study","Muhammad Imran Butt","2024","Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study","Journal of Endocrinology and Metabolism","Elmer Press, Inc.","10.14740/jem937","https://doi.org/10.14740/jem937",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14740/jem937",null],["4","R0053097","R0053097.pdf","free_to_read","nonrandomized_study","Louis A Talay","2024","Effectiveness of an Email-Based, Semaglutide-Supported Weight-Loss Service for People with Overweight and Obesity in Germany: A Real-World Retrospective Cohort Analysis","Obesities","MDPI AG","10.3390/obesities4030021","https://doi.org/10.3390/obesities4030021",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/obesities4030021",null],["4","R0053122","R0053122.pdf","free_to_read","nonrandomized_study","Søren Lundorff Jacobsen","2024","Efficacy and Safety of Glp1-Ras Compared to Sglt2is and Dpp-4is in Individuals with Schizophrenia and Diabetes: A Danish Nationwide Target-Trial Emulation Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.5048991","https://doi.org/10.2139/ssrn.5048991",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.5048991",null],["4","R0053177","R0053177.pdf","free_to_read","nonrandomized_study","Gabriel Castano","2024","6866 Real-world implications and limitations of GLP-1 prescriptions in adolescents","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.1506","https://doi.org/10.1210/jendso/bvae163.1506",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.1506",null],["4","R0053438","R0053438.pdf","free_to_read","nonrandomized_study","Sandeep Gudibanda","2024","Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_129_24","https://doi.org/10.4103/jod.jod_129_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_129_24",null],["4","R0054111","R0054111.pdf","free_to_read","nonrandomized_study","Onur Başer","2024","Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study","Obesity Science & Practice","Wiley","10.1002/osp4.762","https://doi.org/10.1002/osp4.762",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1002/osp4.762",null],["4","R0054888","R0054888.pdf","free_to_read","nonrandomized_study","Angela Fitch","2024","Response to “Early‐ and later‐stage persistence with antiobesity medications: a retrospective cohort study”","Obesity","Wiley","10.1002/oby.24038","https://doi.org/10.1002/oby.24038","38659125","https://pubmed.ncbi.nlm.nih.gov/38659125/","http://dx.doi.org/10.1002/oby.24038",null],["4","R0055413","R0055413.pdf","free_to_read","nonrandomized_study","Hans Johnson","2024","Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.69466","https://doi.org/10.2196/preprints.69466",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.69466",null],["4","R0055705","R0055705.pdf","free_to_read","nonrandomized_study","Claude-Émilie Jacob","2024","EPH135 Real-World Prescribing Patterns of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Germany","Value in Health","Elsevier BV","10.1016/j.jval.2024.10.1264","https://doi.org/10.1016/j.jval.2024.10.1264",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2024.10.1264",null],["4","R0055840","R0055840.pdf","free_to_read","nonrandomized_study","Madhu Uddaraju","2024","Glucagon-like Peptide-1 Receptor Agonists and the Eye: A Review of Ocular Implications and Clinical Guidelines","Journal of ophthalmology clinics and research.","Ovid Technologies (Wolters Kluwer Health)","10.4103/jocr.jocr_10_26","https://doi.org/10.4103/jocr.jocr_10_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jocr.jocr_10_26",null],["4","R0055887","R0055887.pdf","no_doi","nonrandomized_study","Moa Lugner","2024","Advancing Precision Medicine in Type 2 Diabetes through Machine Learning: Treatment Comparisons and Risk Predictions","Gothenburg University Publications Electronic Archive (Gothenburg University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055928","R0055928.pdf","no_doi","nonrandomized_study",null,"2024","Chemical structure versus biological activity relationship and drug versus molecular target interactions of contemporary antidiabetic drugs: a literature review: Gabriel da Silva Carvalho, Guilherme Santos Vasconcelos, Nycolas Muller Teixeira de Oliveira, Juçara Barga do Nascimento, José Eduardo Pandini Cardoso Filho","UNISANTA. BioScience",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0055964","R0055964.pdf","no_doi","nonrandomized_study","Abdullah Nasser Alyahya","2024","Integrating Pharmacy and Medical Records for Optimized Management of Chronic Diseases: A Case Study on Diabetes Mellitus Type-II","Review of Contemporary Philosophy",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056073","R0056073.pdf","no_doi","nonrandomized_study","Carolina Gómez Martín","2024","Monitoreo continuo de glucosa en diabetes mellitus tipo 2","Revista de la Sociedad Argentina de Diabetes",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056082","R0056082.pdf","no_doi","nonrandomized_study","Juan Sebastián Hernández","2024","Glucagon-like peptide-1 receptor agonist (GLP-1-RAS) treatment in patients with cirrhosis: A scoping review","Romanian Journal of Diabetes Nutrition and Metabolic Diseases",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056335","R0056335.pdf","no_doi","nonrandomized_study","Swati Sucharita Dash","2024","Semaglutide and Obesity: Real-World Clinical Applications and Outcomes","International Journal of Medical Science Research and Practice",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056353","R0056353.pdf","no_doi","nonrandomized_study","Escarlet Evangelista de Souza","2024","Riscos e benefícios da terapia medicamentosa para emagrecimento em mulheres no Brasil","Journal of Multidisciplinary Sustainability and Innovation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0003824","R0003824.pdf","open_download_failed","nonrandomized_study","Ohsugi M","2023","Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G).","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110841","https://doi.org/10.1016/j.diabres.2023.110841","37481115","https://pubmed.ncbi.nlm.nih.gov/37481115/","http://www.diabetesresearchclinicalpractice.com/article/S0168822723006046/pdf",null],["4","R0004775","R0004775.pdf","open_download_failed","nonrandomized_study","Sodhi M","2023","Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.19574","https://doi.org/10.1001/jama.2023.19574","37796527","https://pubmed.ncbi.nlm.nih.gov/37796527/","https://jamanetwork.com/journals/jama/articlepdf/2810542/jama_sodhi_2023_ld_230072_1703003434.86587.pdf",null],["4","R0004832","R0004832.pdf","open_download_failed","nonrandomized_study","Abusnana S","2023","Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.110183","https://doi.org/10.1016/j.diabres.2022.110183","36436550","https://pubmed.ncbi.nlm.nih.gov/36436550/","http://www.diabetesresearchclinicalpractice.com/article/S0168822722009974/pdf",null],["4","R0005000","R0005000.pdf","open_download_failed","nonrandomized_study","Milenkovikj T","2023","Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.111018","https://doi.org/10.1016/j.diabres.2023.111018","37972857","https://pubmed.ncbi.nlm.nih.gov/37972857/","http://www.diabetesresearchclinicalpractice.com/article/S0168822723007817/pdf",null],["4","R0005031","R0005031.pdf","open_download_failed","nonrandomized_study","Tang S","2023","Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample.","Annals of internal medicine","American College of Physicians","10.7326/m22-3051","https://doi.org/10.7326/m22-3051","36848654","https://pubmed.ncbi.nlm.nih.gov/36848654/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10422868/pdf/nihms-1920343.pdf",null],["4","R0005088","R0005088.pdf","open_download_failed","nonrandomized_study","Sato T","2023","Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad177","https://doi.org/10.1210/clinem/dgad177","36974363","https://pubmed.ncbi.nlm.nih.gov/36974363/","https://academic.oup.com/jcem/article-pdf/108/10/2597/51533266/dgad177.pdf",null],["4","R0005246","R0005246.pdf","open_download_failed","nonrandomized_study","Boye KS","2023","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15145","https://doi.org/10.1111/dom.15145","37712754","https://pubmed.ncbi.nlm.nih.gov/37712754/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15145",null],["4","R0005326","R0005326.pdf","open_download_failed","nonrandomized_study","Foer D","2023","Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.","American journal of respiratory and critical care medicine","Oxford University Press (OUP)","10.1164/rccm.202303-0491oc","https://doi.org/10.1164/rccm.202303-0491oc","37647574","https://pubmed.ncbi.nlm.nih.gov/37647574/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10867930/pdf/rccm.202303-0491OC.pdf",null],["4","R0005575","R0005575.pdf","open_download_failed","nonrandomized_study","Candido R","2023","Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2023.07.025","https://doi.org/10.1016/j.numecd.2023.07.025","37679243","https://pubmed.ncbi.nlm.nih.gov/37679243/","http://www.nmcd-journal.com/article/S0939475323002946/pdf",null],["4","R0005703","R0005703.pdf","free_to_read","nonrandomized_study","von Arx LB","2023","Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14985","https://doi.org/10.1111/dom.14985","36692268","https://pubmed.ncbi.nlm.nih.gov/36692268/","https://doi.org/10.1111/dom.14985",null],["4","R0005753","R0005753.pdf","open_download_failed","nonrandomized_study","Richardson TL","2023","Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.","Annals of internal medicine","American College of Physicians","10.7326/m22-2751","https://doi.org/10.7326/m22-2751","37155984","https://pubmed.ncbi.nlm.nih.gov/37155984/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10367222/pdf/nihms-1912333.pdf",null],["4","R0005815","R0005815.pdf","open_download_failed","nonrandomized_study","Kutz A","2023","Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc23-0671","https://doi.org/10.2337/dc23-0671","37677118","https://pubmed.ncbi.nlm.nih.gov/37677118/","https://diabetesjournals.org/care/article-pdf/46/11/2004/737062/dc230671.pdf",null],["4","R0006352","R0006352.pdf","free_to_read","nonrandomized_study","Jung H","2023","Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15038","https://doi.org/10.1111/dom.15038","36855221","https://pubmed.ncbi.nlm.nih.gov/36855221/","https://doi.org/10.1111/dom.15038",null],["4","R0006357","R0006357.pdf","open_download_failed","nonrandomized_study","Chiappini S","2023","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","Preprints.org","MDPI AG","10.20944/preprints202309.1300.v1","https://doi.org/10.20944/preprints202309.1300.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/202309.1300/v1/download",null],["4","R0006585","R0006585.pdf","open_download_failed","nonrandomized_study","Ogunsanmi DO","2023","Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2023.29.6.699","https://doi.org/10.18553/jmcp.2023.29.6.699","37276038","https://pubmed.ncbi.nlm.nih.gov/37276038/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2023.29.6.699?download=true",null],["4","R0006723","R0006723.pdf","open_download_failed","nonrandomized_study","Lim CE","2023","Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwac315","https://doi.org/10.1093/eurjpc/zwac315","36582120","https://pubmed.ncbi.nlm.nih.gov/36582120/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwac315/48652402/zwac315.pdf",null],["4","R0006824","R0006824.pdf","free_to_read","nonrandomized_study","de Heide LJM","2023","Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14920","https://doi.org/10.1111/dom.14920","36377811","https://pubmed.ncbi.nlm.nih.gov/36377811/","https://research.tilburguniversity.edu/en/publications/0787fe91-c449-4d12-af4b-592fc6e0eb0b",null],["4","R0006869","R0006869.pdf","open_download_failed","nonrandomized_study","Vilsbøll T","2023","Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15031","https://doi.org/10.1111/dom.15031","36809678","https://pubmed.ncbi.nlm.nih.gov/36809678/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15031",null],["4","R0006884","R0006884.pdf","open_download_failed","nonrandomized_study","Sterling J","2023","Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.","The British journal of ophthalmology","BMJ","10.1136/bjophthalmol-2021-319232","https://doi.org/10.1136/bjophthalmol-2021-319232","34413054","https://pubmed.ncbi.nlm.nih.gov/34413054/","https://www.medrxiv.org/content/medrxiv/early/2021/01/20/2021.01.16.21249949.full.pdf",null],["4","R0006932","R0006932.pdf","open_download_failed","nonrandomized_study","Giorgino F","2023","The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15244","https://doi.org/10.1111/dom.15244","37700627","https://pubmed.ncbi.nlm.nih.gov/37700627/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15244",null],["4","R0007070","R0007070.pdf","open_download_failed","nonrandomized_study","Riley DR","2023","All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15185","https://doi.org/10.1111/dom.15185","37385958","https://pubmed.ncbi.nlm.nih.gov/37385958/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15185",null],["4","R0007242","R0007242.pdf","open_download_failed","nonrandomized_study","Klobučar S","2023","Effectiveness of Oral Versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia","Preprints.org","MDPI AG","10.20944/preprints202309.0030.v1","https://doi.org/10.20944/preprints202309.0030.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/202309.0030/v1/download",null],["4","R0007338","R0007338.pdf","free_to_read","nonrandomized_study","Nargesi AA","2023","Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2023.03.002","https://doi.org/10.1016/j.amjcard.2023.03.002","37012183","https://pubmed.ncbi.nlm.nih.gov/37012183/","https://doi.org/10.1016/j.amjcard.2023.03.002",null],["4","R0007452","R0007452.pdf","free_to_read","nonrandomized_study","Júlíusdóttir YK","2023","Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvad033","https://doi.org/10.1093/ehjcvp/pvad033","37173284","https://pubmed.ncbi.nlm.nih.gov/37173284/","https://pure.amsterdamumc.nl/en/publications/65dbabf6-b699-4d61-aa72-75105b2d828f",null],["4","R0008031","R0008031.pdf","open_download_failed","nonrandomized_study","Guo L","2023","Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15252","https://doi.org/10.1111/dom.15252","37612876","https://pubmed.ncbi.nlm.nih.gov/37612876/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15252",null],["4","R0008207","R0008207.pdf","open_download_failed","nonrandomized_study","Htoo PT","2023","Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.","The journals of gerontology. Series A, Biological sciences and medical sciences","Oxford University Press (OUP)","10.1093/gerona/glad075","https://doi.org/10.1093/gerona/glad075","36866496","https://pubmed.ncbi.nlm.nih.gov/36866496/","https://academic.oup.com/biomedgerontology/advance-article-pdf/doi/10.1093/gerona/glad075/50148213/glad075.pdf",null],["4","R0008232","R0008232.pdf","open_download_failed","nonrandomized_study","Isaksen AA","2023","Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15230","https://doi.org/10.1111/dom.15230","37550891","https://pubmed.ncbi.nlm.nih.gov/37550891/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15230",null],["4","R0008246","R0008246.pdf","open_download_failed","nonrandomized_study","Onishi Y","2023","Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-023-00638-w","https://doi.org/10.1007/s13340-023-00638-w","37781463","https://pubmed.ncbi.nlm.nih.gov/37781463/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10533472/pdf/13340_2023_Article_638.pdf","ClinicalTrials.gov:NCT03786406; ClinicalTrials.gov:NCT03811288"],["4","R0008424","R0008424.pdf","open_download_failed","nonrandomized_study","Pottegård A","2023","Changes in the use of glucose-lowering drugs: A Danish nationwide study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14947","https://doi.org/10.1111/dom.14947","36514856","https://pubmed.ncbi.nlm.nih.gov/36514856/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14947",null],["4","R0008659","R0008659.pdf","open_download_failed","nonrandomized_study","Mittman BG","2023","Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT-2 inhibitors among US adults with type 2 diabetes: NHANES 2005-March 2020","medRxiv","openRxiv","10.1101/2023.03.30.23287965","https://doi.org/10.1101/2023.03.30.23287965",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/03/31/2023.03.30.23287965.full.pdf",null],["4","R0009007","R0009007.pdf","free_to_read","nonrandomized_study","Mohammedi K","2023","Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15045","https://doi.org/10.1111/dom.15045","36869853","https://pubmed.ncbi.nlm.nih.gov/36869853/","https://doi.org/10.1111/dom.15045",null],["4","R0009178","R0009178.pdf","open_download_failed","nonrandomized_study","Harris S","2023","Time in uncontrolled hyperglycemia before insulin initiation in people living with type 2 diabetes: A systematic literature review.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2023.10.008","https://doi.org/10.1016/j.pcd.2023.10.008","39492047","https://pubmed.ncbi.nlm.nih.gov/39492047/","http://www.primary-care-diabetes.com/article/S1751991823001766/pdf","PROSPERO:CRD42022327974"],["4","R0009196","R0009196.pdf","open_download_failed","nonrandomized_study","Eliasson B","2023","Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwac308","https://doi.org/10.1093/eurjpc/zwac308","36567502","https://pubmed.ncbi.nlm.nih.gov/36567502/","https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwac308/48626421/zwac308.pdf",null],["4","R0009264","R0009264.pdf","open_download_failed","nonrandomized_study","Foer D","2023","Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.","Journal of immunology (Baltimore, Md. : 1950)","Oxford University Press (OUP)","10.4049/jimmunol.2300102","https://doi.org/10.4049/jimmunol.2300102","37870292","https://pubmed.ncbi.nlm.nih.gov/37870292/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10842986/pdf/nihms-1936480.pdf",null],["4","R0009268","R0009268.pdf","open_download_failed","nonrandomized_study","Lawrence SE","2023","Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation.","Clinical transplantation","Wiley","10.1111/ctr.14922","https://doi.org/10.1111/ctr.14922","36708369","https://pubmed.ncbi.nlm.nih.gov/36708369/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ctr.14922",null],["4","R0009349","R0009349.pdf","open_download_failed","nonrandomized_study","Makunts T","2023","Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2023.11.19.23298750","https://doi.org/10.1101/2023.11.19.23298750","38045343","https://pubmed.ncbi.nlm.nih.gov/38045343/","https://www.medrxiv.org/content/medrxiv/early/2023/11/24/2023.11.19.23298750.full.pdf",null],["4","R0009668","R0009668.pdf","free_to_read","nonrandomized_study","Chatterjee D","2023","In-silico and in-vitro hybrid approach to identify glucagon-like peptide-1 receptor agonists from anti-diabetic natural products.","Natural product research","Informa UK Limited","10.1080/14786419.2022.2106567","https://doi.org/10.1080/14786419.2022.2106567","35924731","https://pubmed.ncbi.nlm.nih.gov/35924731/",null,null],["4","R0009758","R0009758.pdf","open_download_failed","nonrandomized_study","Fu EL","2023","Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000000000000115","https://doi.org/10.2215/cjn.0000000000000115","36827225","https://pubmed.ncbi.nlm.nih.gov/36827225/","https://pmc.ncbi.nlm.nih.gov/articles/instance/10278835/bin/cjasn-18-592-s001.pdf",null],["4","R0009763","R0009763.pdf","open_download_failed","nonrandomized_study","Lohia S","2023","Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients","medRxiv","Wiley","10.1101/2023.05.03.23289439","https://doi.org/10.1101/2023.05.03.23289439",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/05/05/2023.05.03.23289439.full.pdf",null],["4","R0009951","R0009951.pdf","open_download_failed","nonrandomized_study","McKenzie AL","2023","Effect of Glucagon-Like Peptide-1 Deprescription Following Nutrition Therapy via Telemedicine on Glycemia and Body Weight among People with Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study","medRxiv","openRxiv","10.1101/2023.06.18.23291518","https://doi.org/10.1101/2023.06.18.23291518",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/06/19/2023.06.18.23291518.full.pdf",null],["4","R0010186","R0010186.pdf","open_download_failed","nonrandomized_study","Sim R","2023","Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia.","Value in health regional issues","Elsevier BV","10.1016/j.vhri.2023.05.006","https://doi.org/10.1016/j.vhri.2023.05.006","37419012","https://pubmed.ncbi.nlm.nih.gov/37419012/","http://www.valuehealthregionalissues.com/article/S2212109923000559/pdf",null],["4","R0010201","R0010201.pdf","open_download_failed","nonrandomized_study","Abrahami D","2023","Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15196","https://doi.org/10.1111/dom.15196","37395339","https://pubmed.ncbi.nlm.nih.gov/37395339/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15196",null],["4","R0010356","R0010356.pdf","open_download_failed","nonrandomized_study","Al-Ozairi E","2023","Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23677","https://doi.org/10.1002/oby.23677","36811241","https://pubmed.ncbi.nlm.nih.gov/36811241/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23677",null],["4","R0010601","R0010601.pdf","open_download_failed","nonrandomized_study","Chen J","2023","Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15022","https://doi.org/10.1111/dom.15022","36799018","https://pubmed.ncbi.nlm.nih.gov/36799018/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15022",null],["4","R0010609","R0010609.pdf","open_download_failed","nonrandomized_study","Chou OHI","2023","New-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I, DPP4I and GLP1a: A population-based cohort study","medRxiv","openRxiv","10.1101/2023.11.25.23298886","https://doi.org/10.1101/2023.11.25.23298886",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/11/27/2023.11.25.23298886.full.pdf",null],["4","R0010637","R0010637.pdf","open_download_failed","nonrandomized_study","Sbraccia P","2023","Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14945","https://doi.org/10.1111/dom.14945","36514273","https://pubmed.ncbi.nlm.nih.gov/36514273/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14945",null],["4","R0011075","R0011075.pdf","open_download_failed","nonrandomized_study","Chou OH","2023","New-onset infective endocarditis in diabetic patients receiving SGLT2I, DPP4I and GLP1a: A population-based cohort study","medRxiv","openRxiv","10.1101/2023.08.06.23293730","https://doi.org/10.1101/2023.08.06.23293730",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/08/09/2023.08.06.23293730.full.pdf",null],["4","R0011303","R0011303.pdf","open_download_failed","nonrandomized_study","Chou OH","2023","Comparisons of new-onset peripheral arterial disease in Type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1a: a population-based cohort study","medRxiv","openRxiv","10.1101/2023.08.21.23294389","https://doi.org/10.1101/2023.08.21.23294389",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/08/22/2023.08.21.23294389.full.pdf",null],["4","R0011341","R0011341.pdf","free_to_read","nonrandomized_study","Gracen L","2023","Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.","Annals of hepatology","Elsevier BV","10.1016/j.aohep.2023.101142","https://doi.org/10.1016/j.aohep.2023.101142","37468097","https://pubmed.ncbi.nlm.nih.gov/37468097/","https://doi.org/10.1016/j.aohep.2023.101142",null],["4","R0011612","R0011612.pdf","open_download_failed","nonrandomized_study","Malik ME","2023","Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.","The lancet. Healthy longevity","Elsevier BV","10.1016/s2666-7568(23)00164-2","https://doi.org/10.1016/s2666-7568(23)00164-2","37734395","https://pubmed.ncbi.nlm.nih.gov/37734395/","http://www.thelancet.com/article/S2666756823001642/pdf",null],["4","R0011629","R0011629.pdf","free_to_read","nonrandomized_study","Guja C","2023","iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15027","https://doi.org/10.1111/dom.15027","36810874","https://pubmed.ncbi.nlm.nih.gov/36810874/","https://doi.org/10.1111/dom.15027",null],["4","R0012883","R0012883.pdf","open_download_failed","nonrandomized_study","Chou OHI","2023","Comparing the risks of new-onset gastric cancer or gastric diseases in type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1A: a population-based cohort study","medRxiv","openRxiv","10.1101/2023.07.02.23292063","https://doi.org/10.1101/2023.07.02.23292063",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/07/05/2023.07.02.23292063.full.pdf",null],["4","R0014024","R0014024.pdf","open_download_failed","nonrandomized_study","White GE","2023","Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23622","https://doi.org/10.1002/oby.23622","36621904","https://pubmed.ncbi.nlm.nih.gov/36621904/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23622",null],["4","R0014159","R0014159.pdf","open_download_failed","nonrandomized_study","Engström A","2023","Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc22-0714","https://doi.org/10.2337/dc22-0714","36508322","https://pubmed.ncbi.nlm.nih.gov/36508322/","https://diabetesjournals.org/care/article-pdf/46/2/351/696436/dc220714.pdf",null],["4","R0014165","R0014165.pdf","open_download_failed","nonrandomized_study","Giorda CB","2023","Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical Practice.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2023.06.006","https://doi.org/10.1016/j.clinthera.2023.06.006","37451913","https://pubmed.ncbi.nlm.nih.gov/37451913/","http://www.clinicaltherapeutics.com/article/S0149291823002011/pdf",null],["4","R0014600","R0014600.pdf","open_download_failed","nonrandomized_study","Naseralallah L","2023","Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2181074","https://doi.org/10.1080/14656566.2023.2181074","36820516","https://pubmed.ncbi.nlm.nih.gov/36820516/","https://www.tandfonline.com/doi/epdf/10.1080/14656566.2023.2181074?needAccess=true&role=button",null],["4","R0014735","R0014735.pdf","open_download_failed","nonrandomized_study","Alhiary R","2023","Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.13872","https://doi.org/10.1001/jama.2023.13872","37505513","https://pubmed.ncbi.nlm.nih.gov/37505513/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11457043/pdf/nihms-2023030.pdf",null],["4","R0016129","R0016129.pdf","open_download_failed","nonrandomized_study","Levi J","2023","Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23725","https://doi.org/10.1002/oby.23725","36815242","https://pubmed.ncbi.nlm.nih.gov/36815242/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23725",null],["4","R0016632","R0016632.pdf","free_to_read","nonrandomized_study","Hirsch IB","2023","Medication Use and Self-Care Practices in Persons With Diabetes","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)",null,null,"https://doi.org/","39298640","https://pubmed.ncbi.nlm.nih.gov/39298640/",null,null],["4","R0016664","R0016664.pdf","free_to_read","nonrandomized_study","Johansson KS","2023","Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020.","The lancet. Healthy longevity","Elsevier BV","10.1016/s2666-7568(23)00210-6","https://doi.org/10.1016/s2666-7568(23)00210-6","38042161","https://pubmed.ncbi.nlm.nih.gov/38042161/","https://doi.org/10.1016/s2666-7568(23)00210-6",null],["4","R0016707","R0016707.pdf","open_download_failed","nonrandomized_study","Schäfer Z","2023","Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110799","https://doi.org/10.1016/j.diabres.2023.110799","37391034","https://pubmed.ncbi.nlm.nih.gov/37391034/","http://www.diabetesresearchclinicalpractice.com/article/S0168822723005624/pdf",null],["4","R0017156","R0017156.pdf","open_download_failed","nonrandomized_study","Luo Z","2023","Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: A population-based and machine learning causal inference analysis","medRxiv","openRxiv","10.1101/2023.11.06.23298185","https://doi.org/10.1101/2023.11.06.23298185",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/11/07/2023.11.06.23298185.full.pdf",null],["4","R0017674","R0017674.pdf","open_download_failed","nonrandomized_study","Handley D","2023","Rare variants of the glucagon-like peptide-1 receptor (GLP1R) gene are overrepresented in a severe obesity cohort and associated with type 2 diabetes in the UK Biobank","medRxiv","openRxiv","10.1101/2023.05.22.23290347","https://doi.org/10.1101/2023.05.22.23290347",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/05/23/2023.05.22.23290347.full.pdf",null],["4","R0017843","R0017843.pdf","open_download_failed","nonrandomized_study","Nicholas SB","2023","Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15194","https://doi.org/10.1111/dom.15194","37395334","https://pubmed.ncbi.nlm.nih.gov/37395334/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15194",null],["4","R0018488","R0018488.pdf","free_to_read","nonrandomized_study","Flory J","2023","Examining the Effects of High Blood Sugar Levels and Non-Insulin Diabetes Medicines on Risk of Hospitalization for COVID-19 among Patients with Diabetes","Patient-Centered Outcomes Research Institute (PCORI), Washington (DC)",null,null,"https://doi.org/","40763222","https://pubmed.ncbi.nlm.nih.gov/40763222/",null,null],["4","R0018740","R0018740.pdf","free_to_read","nonrandomized_study","Søndergaard CS","2023","Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.","Current oncology reports","Springer Science and Business Media LLC","10.1007/s11912-022-01344-7","https://doi.org/10.1007/s11912-022-01344-7","36445570","https://pubmed.ncbi.nlm.nih.gov/36445570/","https://rdcu.be/c00ik",null],["4","R0018982","R0018982.pdf","open_download_failed","nonrandomized_study","De Barra C","2023","Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23772","https://doi.org/10.1002/oby.23772","37157931","https://pubmed.ncbi.nlm.nih.gov/37157931/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23772",null],["4","R0019093","R0019093.pdf","no_doi","nonrandomized_study","Dankers M","2023","[What can you do to … not be influenced?].","Nederlands tijdschrift voor geneeskunde",null,null,"https://doi.org/","38175558","https://pubmed.ncbi.nlm.nih.gov/38175558/",null,null],["4","R0019209","R0019209.pdf","open_download_failed","nonrandomized_study","Lajara R","2023","iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14974","https://doi.org/10.1111/dom.14974","36633506","https://pubmed.ncbi.nlm.nih.gov/36633506/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14974",null],["4","R0019639","R0019639.pdf","free_to_read","nonrandomized_study","Ackermann RT","2023","Prevention of Type 2 Diabetes in Adults","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)",null,null,"https://doi.org/","41284805","https://pubmed.ncbi.nlm.nih.gov/41284805/",null,null],["4","R0020065","R0020065.pdf","free_to_read","nonrandomized_study","Hassanein M","2023","Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2023.102707","https://doi.org/10.1016/j.dsx.2023.102707","36680967","https://pubmed.ncbi.nlm.nih.gov/36680967/","https://doi.org/10.1016/j.dsx.2023.102707",null],["4","R0021065","R0021065.pdf","open_download_failed","nonrandomized_study","Brown KA","2023","Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile.","Chembiochem : a European journal of chemical biology","Wiley","10.1002/cbic.202300504","https://doi.org/10.1002/cbic.202300504","37624685","https://pubmed.ncbi.nlm.nih.gov/37624685/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cbic.202300504",null],["4","R0021217","R0021217.pdf","open_download_failed","nonrandomized_study","Powell W","2023","Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23859","https://doi.org/10.1002/oby.23859","37593896","https://pubmed.ncbi.nlm.nih.gov/37593896/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23859",null],["4","R0021323","R0021323.pdf","open_download_failed","nonrandomized_study","Lautenbach A","2023","Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure.","Clinical obesity","Wiley","10.1111/cob.12593","https://doi.org/10.1111/cob.12593","37364260","https://pubmed.ncbi.nlm.nih.gov/37364260/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12593",null],["4","R0021359","R0021359.pdf","open_download_failed","nonrandomized_study","Alshehri A","2023","Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.","Clinical obesity","Wiley","10.1111/cob.12594","https://doi.org/10.1111/cob.12594","37194338","https://pubmed.ncbi.nlm.nih.gov/37194338/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12594",null],["4","R0021562","R0021562.pdf","open_download_failed","nonrandomized_study","Napoli R","2023","Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15020","https://doi.org/10.1111/dom.15020","36789682","https://pubmed.ncbi.nlm.nih.gov/36789682/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15020",null],["4","R0021808","R0021808.pdf","free_to_read","nonrandomized_study","Park CY","2023","Dysregulation of Lipid Droplet Protein Expression in Adipose Tissues and Association with Metabolic Risk Factors in Adult Females with Obesity and Type 2 Diabetes.","The Journal of nutrition","Elsevier BV","10.1016/j.tjnut.2023.01.018","https://doi.org/10.1016/j.tjnut.2023.01.018","36931749","https://pubmed.ncbi.nlm.nih.gov/36931749/","https://doi.org/10.1016/j.tjnut.2023.01.018",null],["4","R0022264","R0022264.pdf","open_download_failed","nonrandomized_study","Azeez TA","2023","The pattern of antidiabetic drugs and glycaemic control among type 2 diabetes patients in an Endocrinology Clinic in Lagos, Nigeria","medRxiv","openRxiv","10.1101/2023.06.25.23291774","https://doi.org/10.1101/2023.06.25.23291774",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/06/29/2023.06.25.23291774.full.pdf",null],["4","R0023127","R0023127.pdf","open_download_failed","nonrandomized_study","Rappoport A","2023","Insulin in Amyotrophic Lateral Sclerosis: Impairment, Tests and Treatment","Preprints.org","MDPI AG","10.20944/preprints202212.0297.v3","https://doi.org/10.20944/preprints202212.0297.v3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/202212.0297/v3/download",null],["4","R0023196","R0023196.pdf","open_download_failed","nonrandomized_study","Hart HE","2023","Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2023.02.001","https://doi.org/10.1016/j.pcd.2023.02.001","36775727","https://pubmed.ncbi.nlm.nih.gov/36775727/","http://www.primary-care-diabetes.com/article/S1751991823000323/pdf",null],["4","R0023543","R0023543.pdf","free_to_read","nonrandomized_study","Al-Rubeaan K","2023","Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2022.2144052","https://doi.org/10.1080/03007995.2022.2144052","36342972","https://pubmed.ncbi.nlm.nih.gov/36342972/","https://doi.org/10.1080/03007995.2022.2144052","ClinicalTrials.gov:NCT02322762"],["4","R0023578","R0023578.pdf","open_download_failed","nonrandomized_study","Schultes B","2023","Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968211054520","https://doi.org/10.1177/19322968211054520","34709065","https://pubmed.ncbi.nlm.nih.gov/34709065/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10012378/pdf/10.1177_19322968211054520.pdf",null],["4","R0024031","R0024031.pdf","free_to_read","nonrandomized_study","Vozza A","2023","The Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes Mellitus: A Brief Report.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871530323666230112165948","https://doi.org/10.2174/1871530323666230112165948","36644863","https://pubmed.ncbi.nlm.nih.gov/36644863/","http://www.eurekaselect.com/article/128817",null],["4","R0026341","R0026341.pdf","open_download_failed","nonrandomized_study","Tichy EM","2023","National trends in prescription drug expenditures and projections for 2023.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.1093/ajhp/zxad086","https://doi.org/10.1093/ajhp/zxad086","37094296","https://pubmed.ncbi.nlm.nih.gov/37094296/","https://academic.oup.com/ajhp/article-pdf/80/14/899/50837222/zxad086.pdf",null],["4","R0026777","R0026777.pdf","open_download_failed","nonrandomized_study","Kan H","2023","Real-world primary nonadherence to antiobesity medications.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2023.23083","https://doi.org/10.18553/jmcp.2023.23083","37594848","https://pubmed.ncbi.nlm.nih.gov/37594848/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2023.23083?download=true",null],["4","R0028853","R0028853.pdf","free_to_read","nonrandomized_study","Abdi Beshir S","2023","A narrative review of approved and emerging anti-obesity medications.","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","Springer Science and Business Media LLC","10.1016/j.jsps.2023.101757","https://doi.org/10.1016/j.jsps.2023.101757","37712012","https://pubmed.ncbi.nlm.nih.gov/37712012/","https://doi.org/10.1016/j.jsps.2023.101757",null],["4","R0028867","R0028867.pdf","free_to_read","nonrandomized_study","Writing Committee Members","2023","2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2023.04.003","https://doi.org/10.1016/j.jacc.2023.04.003","37480922","https://pubmed.ncbi.nlm.nih.gov/37480922/","https://doi.org/10.1016/j.jacc.2023.04.003",null],["4","R0028868","R0028868.pdf","open_download_failed","nonrandomized_study","Virani SS","2023","2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.0000000000001168","https://doi.org/10.1161/cir.0000000000001168","37471501","https://pubmed.ncbi.nlm.nih.gov/37471501/","https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001168",null],["4","R0028878","R0028878.pdf","open_download_failed","nonrandomized_study","Gibadullin R","2023","Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.","Journal of the American Chemical Society","American Chemical Society (ACS)","10.1021/jacs.3c01628","https://doi.org/10.1021/jacs.3c01628","37235770","https://pubmed.ncbi.nlm.nih.gov/37235770/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10335629/pdf/nihms-1906586.pdf",null],["4","R0028908","R0028908.pdf","free_to_read","nonrandomized_study","Vasti EC","2023","Disparities in adoption of new diabetic therapies with cardiovascular benefits.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.110233","https://doi.org/10.1016/j.diabres.2022.110233","36581144","https://pubmed.ncbi.nlm.nih.gov/36581144/","https://doi.org/10.1016/j.diabres.2022.110233",null],["4","R0028911","R0028911.pdf","free_to_read","nonrandomized_study","Liarakos AL","2023","Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS).","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2022.10.158","https://doi.org/10.1016/j.ijcard.2022.10.158","36441073","https://pubmed.ncbi.nlm.nih.gov/36441073/","https://doi.org/10.2139/ssrn.4074757",null],["4","R0029716","R0029716.pdf","open_download_failed","nonrandomized_study","Winther-Sørensen M","2023","Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study","medRxiv","openRxiv","10.1101/2023.12.12.23299852","https://doi.org/10.1101/2023.12.12.23299852",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/12/14/2023.12.12.23299852.full.pdf",null],["4","R0030279","R0030279.pdf","no_doi","nonrandomized_study","Serné EH","2023","[Prevalence and drug treatment of people with type 2 diabetes mellitus and a very high risk of cardiovascular disease].","Nederlands tijdschrift voor geneeskunde",null,null,"https://doi.org/","37742128","https://pubmed.ncbi.nlm.nih.gov/37742128/",null,null],["4","R0032149","R0032149.pdf","free_to_read","nonrandomized_study","Živko, Matea","2023","Efficacy of oral formulation of semaglutide in obese patients with type 2 diabetes mellitus - a retrospective study","Liječnički vjesnik","Croatian Medical Association","10.26800/lv-145-supl2-cm01","https://doi.org/10.26800/lv-145-supl2-cm01",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.26800/lv-145-supl2-cm01",null],["4","R0035637","R0035637.pdf","no_doi","nonrandomized_study","Comerford, Alyssa","2023","GLP-1 Agonists Effects on Weight Loss in Those With and Without Diabetes","ValpoScholar (Valparaiso University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036147","R0036147.pdf","no_doi","nonrandomized_study","Overholser, Andrew","2023","Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity: A Clinical Review","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036276","R0036276.pdf","no_doi","nonrandomized_study","Rachel Soon-yong Kim","2023","Preliminary comparison of major adverse outcomes in patients with nonalcoholic fatty liver disease initiated on second-line antihyperglycemic therapy","OpenBU (Boston University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036295","R0036295.pdf","no_doi","nonrandomized_study","Schaïk, Jiska van","2023","Hypothalamic-pituitary dysfunction in children with suprasellar tumors: improving the outcome","Utrecht University Repository (Utrecht University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036331","R0036331.pdf","no_doi","nonrandomized_study","Bishakha, Adwiza Chakraborty","2023","Association of GLP-1 receptor agonists and risk of pancreatitis: a pharmacovigilance study based on FAERS database","BRAC University Institutional Repository (BRAC University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037720","R0037720.pdf","no_doi","nonrandomized_study","Balogh, Dóra Bianka","2023","A vese védelmében és azon is túl : A renoprotekció új lehetőségei = For kidney protection and beyond : New possibilities of renoprotection","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037747","R0037747.pdf","free_to_read","nonrandomized_study","Hayder Aledan","2023","Evaluation of effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on estimated glomerular filtration rate, albuminuria and weight in diabetic kidney disease: A prospective cohort study","Journal of Renal Injury Prevention","Maad Rayan Publishing Company","10.34172/jrip.2023.32062","https://doi.org/10.34172/jrip.2023.32062",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.34172/jrip.2023.32062",null],["4","R0038616","R0038616.pdf","free_to_read","nonrandomized_study","Majed Hudhud","2023","Impact of liraglutide 3.0 mg for weight management among women with obstetrics and gynaecology-related complications \"OG-RC\"","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1683020410","https://doi.org/10.24911/ijmdc.51-1683020410",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.24911/ijmdc.51-1683020410",null],["4","R0038780","R0038780.pdf","free_to_read","nonrandomized_study","Meifen Han","2023","Association between Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer: A Disproportionality Analysis","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4391572","https://doi.org/10.2139/ssrn.4391572",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4391572",null],["4","R0038890","R0038890.pdf","free_to_read","nonrandomized_study","Rebecca Richards","2023","A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.53619","https://doi.org/10.2196/preprints.53619",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2196/preprints.53619",null],["4","R0038953","R0038953.pdf","free_to_read","nonrandomized_study","Nidhi Sharma","2023","Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_102_22","https://doi.org/10.4103/jod.jod_102_22",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_102_22",null],["4","R0039540","R0039540.pdf","free_to_read","nonrandomized_study","SV Madhu","2023","Double Trouble","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.379597","https://doi.org/10.4103/2230-8210.379597","37583408","https://pubmed.ncbi.nlm.nih.gov/37583408/","https://doi.org/10.4103/2230-8210.379597",null],["4","R0041672","R0041672.pdf","free_to_read","nonrandomized_study","D. Janssen","2023","Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2023.100157","https://doi.org/10.1016/j.deman.2023.100157",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2023.100157",null],["4","R0041817","R0041817.pdf","free_to_read","nonrandomized_study","Raheel Khan","2023","PRESCRIBING PRACTICES OF CARDIOPROTECTIVE ANTI-DIABETIC MEDICATIONS IN MARGINALIZED PATIENTS","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2023.100538","https://doi.org/10.1016/j.ajpc.2023.100538",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2023.100538",null],["4","R0042270","R0042270.pdf","no_doi","nonrandomized_study","Amira Guirguis","2023","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","Cronfa (Swansea University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042334","R0042334.pdf","free_to_read","nonrandomized_study","Brittany Ann West","2023","FRI060 Real World Experience Of Weight Management In Low Socioeconomic Community Clinic","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.071","https://doi.org/10.1210/jendso/bvad114.071",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.071",null],["4","R0042453","R0042453.pdf","free_to_read","nonrandomized_study","Robin L. Black","2023","THU003 An Analysis Of A Patient Simulation Platform To Test Learners’ Obesity Management Skills During A Live Educational Event","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.001","https://doi.org/10.1210/jendso/bvad114.001",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.001",null],["4","R0042491","R0042491.pdf","free_to_read","nonrandomized_study","Anoopa Mathew","2023","FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.862","https://doi.org/10.1210/jendso/bvad114.862",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.862",null],["4","R0043201","R0043201.pdf","no_doi","nonrandomized_study","Кондратюк, В. Є.","2023","Diabetic cardiomyopathy: current state of the problem. Review","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043250","R0043250.pdf","free_to_read","nonrandomized_study","Savita Bhat","2023","Glucose Control and Diabetic Retinopathy","Chronicle of Diabetes Research and Practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/cdrp.cdrp_cdrp_22_22","https://doi.org/10.4103/cdrp.cdrp_cdrp_22_22",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/cdrp.cdrp_cdrp_22_22",null],["4","R0043306","R0043306.pdf","free_to_read","nonrandomized_study","Milan J. Sonneveld","2023","Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?","Hepatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000000424","https://doi.org/10.1097/hep.0000000000000424","37185255","https://pubmed.ncbi.nlm.nih.gov/37185255/","https://pure.eur.nl/en/publications/5e8368ce-c6e7-4b87-b93f-30467ba1cb94",null],["4","R0043573","R0043573.pdf","no_doi","nonrandomized_study","Andrade Moreno, Maria Paz","2023","GLP-1 receptor agonists in a cohort of older adults with type 2 diabetes : Outcomes on body composition, strength, and physical performance","Repositorio Institucional (Pontificia Universidad Javeriana)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044346","R0044346.pdf","no_doi","nonrandomized_study","Fan, Wenjun","2023","Multifactorial Cardiovascular Disease Risk Estimation and Preventable Cardiovascular Events Among Patients with Diabetes","eScholarship (California Digital Library)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044441","R0044441.pdf","no_doi","nonrandomized_study","Blanco, Christopher","2023","Use of SGLT2 Inhibitors Reduces Heart Failures and Hospitalization: A Multicenter, Real-World Evidence Study","IUScholarWorks (Indiana University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046216","R0046216.pdf","free_to_read","nonrandomized_study","Jothydev Kesavadev","2023","Effectiveness of Oral Semaglutide in Weight Loss and Glycemic Control among Type 2 Diabetes Population: A Real-world Longitudinal Study","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_33_23","https://doi.org/10.4103/ijdt.ijdt_33_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_33_23",null],["4","R0046572","R0046572.pdf","free_to_read","nonrandomized_study","Rupesh Jain","2023","WEIGHT REDUCTION IN OBESE OR OVERWEIGHT DIABETIC PATIENTS TREATED WITH ORAL SEMAGLUTIDE IN A REAL WORLD SETTING","Indian Heart Journal","Elsevier BV","10.1016/j.ihj.2023.11.230","https://doi.org/10.1016/j.ihj.2023.11.230",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ihj.2023.11.230",null],["4","R0046885","R0046885.pdf","free_to_read","nonrandomized_study","Hussam R Alkaissi","2023","SAT673 Novel Mutation Of TBX3 Associated With Morbid Obesity In Human","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.121","https://doi.org/10.1210/jendso/bvad114.121",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.121",null],["4","R0047616","R0047616.pdf","free_to_read","nonrandomized_study","Eva Vilarrasa","2023","Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas","Actas Dermo-Sifiliográficas","Elsevier BV","10.1016/j.ad.2023.06.017","https://doi.org/10.1016/j.ad.2023.06.017","37451337","https://pubmed.ncbi.nlm.nih.gov/37451337/","https://doi.org/10.1016/j.ad.2023.06.017",null],["4","R0047706","R0047706.pdf","free_to_read","nonrandomized_study","Conor T Coughlan","2023","THU250 Therapeutic Inertia In Primary Care With Poor Information Transfer To Specialist Care - A Rural Irish Experience","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.687","https://doi.org/10.1210/jendso/bvad114.687",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.687",null],["4","R0047888","R0047888.pdf","free_to_read","nonrandomized_study","Alaaeldin M. Bashier","2023","Real-World Evaluation of Demographics, Treatment Pattern, and Economic Burden of Heart Failure and Kidney Disease in Type 2 Diabetes Mellitus Patient Population in Dubai, United Arab Emirates","Dubai Diabetes and Endocrinology Journal","Knowledge E DMCC","10.1159/000530467","https://doi.org/10.1159/000530467",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1159/000530467",null],["4","R0047952","R0047952.pdf","free_to_read","nonrandomized_study","Chanadda Chinthammit","2023","FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.858","https://doi.org/10.1210/jendso/bvad114.858",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.858",null],["4","R0047964","R0047964.pdf","free_to_read","nonrandomized_study","Juan Wang","2023","Continuous renal replacement therapy with oXiris ® in patients with hematologically malignant septic shock: A retrospective study","World Journal of Clinical Cases","Baishideng Publishing Group Inc.","10.12998/wjcc.v11.i26.6073","https://doi.org/10.12998/wjcc.v11.i26.6073","37731565","https://pubmed.ncbi.nlm.nih.gov/37731565/","https://doi.org/10.12998/wjcc.v11.i26.6073",null],["4","R0048004","R0048004.pdf","free_to_read","nonrandomized_study","Luis Alberto Vigara","2023","Uso de los agonistas del receptor del péptido similar al glucagón tipo 1 en pacientes trasplantados renales","Nefrología","Elsevier BV","10.1016/j.nefro.2023.06.010","https://doi.org/10.1016/j.nefro.2023.06.010",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nefro.2023.06.010",null],["4","R0048299","R0048299.pdf","no_doi","nonrandomized_study","David C. Watchorn","2023","GLP-1 and Inflammatory Mediators in Obese Asthma","Research Repository UCD (University College Dublin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048550","R0048550.pdf","free_to_read","nonrandomized_study","Mariam Elmegaard Malik","2023","INITIATION OF SGLT-2 INHIBITORS AND GLP1 RECEPTOR AGONISTS ACCORDING TO FRAILTY IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE- A DANISH NATIONWIDE COHORT STUDY","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(23)02087-9","https://doi.org/10.1016/s0735-1097(23)02087-9",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1016/s0735-1097(23)02087-9",null],["4","R0049253","R0049253.pdf","free_to_read","nonrandomized_study","Vanusha Devaraja","2023","LONG-TERM TREATMENT OUTCOMES WITH GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA)","Journal of the ASEAN Federation of Endocrine Societies","Journal of the ASEAN Federation of Endocrine Societies (JAFES)","10.15605/jafes.038.s2.10","https://doi.org/10.15605/jafes.038.s2.10",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15605/jafes.038.s2.10",null],["4","R0049321","R0049321.pdf","free_to_read","nonrandomized_study","Денис Владимирович Куркин","2023","Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use","Pharmacy & Pharmacology","Volgograd State Medical University","10.19163/2307-9266-2023-11-1-19-47","https://doi.org/10.19163/2307-9266-2023-11-1-19-47",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.19163/2307-9266-2023-11-1-19-47",null],["4","R0049324","R0049324.pdf","free_to_read","nonrandomized_study","Л. А. Суплотова","2023","Prospects for the use of drugs from the group of agonists of glucagon-like peptide-1 receptors in the treatment of non-alcoholic fatty liver disease","Meditsinskiy sovet = Medical Council","Remedium, Ltd.","10.21518/2079-701x-2022-16-23-148-155","https://doi.org/10.21518/2079-701x-2022-16-23-148-155",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.21518/2079-701x-2022-16-23-148-155",null],["4","R0050930","R0050930.pdf","free_to_read","nonrandomized_study","Michela Del Prete","2023","Real-Life Efficacy of Liraglutide Therapy on Weight-Loss in Patients with Overweight and Obesity","Journal of Surgery and Research","Fortune Journals","10.26502/jsr.10020304","https://doi.org/10.26502/jsr.10020304",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26502/jsr.10020304",null],["4","R0051034","R0051034.pdf","free_to_read","nonrandomized_study","Stephen N. Stranks","2023","Is remission of type 2 diabetes mellitus real?","The Medical Journal of Australia","Wiley","10.5694/mja2.52142","https://doi.org/10.5694/mja2.52142","37903479","https://pubmed.ncbi.nlm.nih.gov/37903479/","http://dx.doi.org/10.5694/mja2.52142",null],["4","R0051267","R0051267.pdf","free_to_read","nonrandomized_study","Arvid Engström","2023","Association of Glucagon-Like Peptide-1 Receptor Agonists with Serious Liver Events: A Scandinavian Cohort Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4411413","https://doi.org/10.2139/ssrn.4411413",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4411413",null],["4","R0051310","R0051310.pdf","free_to_read","nonrandomized_study","Katie Stringer Lucero","2023","The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.48586","https://doi.org/10.2196/preprints.48586",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2196/preprints.48586",null],["4","R0051588","R0051588.pdf","free_to_read","nonrandomized_study","Talal Ashour","2023","From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region","Dubai Diabetes and Endocrinology Journal","Knowledge E DMCC","10.1159/000534713","https://doi.org/10.1159/000534713",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1159/000534713",null],["4","R0052013","R0052013.pdf","free_to_read","nonrandomized_study","Izza Shahid","2023","UTILIZATION OF OPTIMAL MEDICAL PHARMACOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM AN INTEGRATED HEALTHCARE SYSTEM","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2023.100573","https://doi.org/10.1016/j.ajpc.2023.100573",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2023.100573",null],["4","R0052650","R0052650.pdf","free_to_read","nonrandomized_study","Sima Fansa","2023","FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.087","https://doi.org/10.1210/jendso/bvad114.087",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.087",null],["4","R0053017","R0053017.pdf","free_to_read","nonrandomized_study","Yu Jyun Lin","2023","Exploring the Role of SGLT2 Inhibitors in Preventing and Managing Diabetic Complications","ISEE Conference Abstracts","Environmental Health Perspectives","10.1289/isee.2023.mp-106","https://doi.org/10.1289/isee.2023.mp-106",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1289/isee.2023.mp-106",null],["4","R0053165","R0053165.pdf","free_to_read","nonrandomized_study","H. Kari","2023","HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study","Value in Health","Elsevier BV","10.1016/j.jval.2023.09.1363","https://doi.org/10.1016/j.jval.2023.09.1363",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2023.09.1363",null],["4","R0055455","R0055455.pdf","free_to_read","nonrandomized_study","Stefan Farsky","2023","Case report Liraglutid and insuline resistance","Medical Research Archives","Knowledge Enterprise Journals","10.18103/mra.v11i10.4614","https://doi.org/10.18103/mra.v11i10.4614",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.18103/mra.v11i10.4614",null],["4","R0055645","R0055645.pdf","free_to_read","nonrandomized_study","Malinda Sunnita Tan","2023","Effect of treatment intensification on glycemic control in patients with subcontrolled type 2 diabetes who failed on two oral antidiabetic agents","Diabetes Epidemiology and Management","Elsevier BV","10.1016/j.deman.2022.100127","https://doi.org/10.1016/j.deman.2022.100127",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.deman.2022.100127",null],["4","R0056085","R0056085.pdf","no_doi","nonrandomized_study","Theodosios D. Filippatos, Thalia V. Panagiotopoulou, Moses S. Elisaf","2023","Adverse Effects of GLP-1 Receptor Agonists","The Review of Diabetic Studies",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056363","R0056363.pdf","no_doi","nonrandomized_study","Jordanna Maia Onofre Pereira","2023","O USO DE ANÁLOGOS DE GLP-1 NO CONTROLE DA GLICEMIA E OS SEUS BENEFÍCIOS CARDIOVASCULARES: UMA REVISÃO DE LITERATURA","Informativo Técnico do Semiárido",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0005193","R0005193.pdf","free_to_read","nonrandomized_study","Sasako T","2022","Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.","Kidney international","Elsevier BV","10.1016/j.kint.2021.11.021","https://doi.org/10.1016/j.kint.2021.11.021","35065690","https://pubmed.ncbi.nlm.nih.gov/35065690/","https://doi.org/10.1016/j.kint.2021.11.021",null],["4","R0005531","R0005531.pdf","free_to_read","nonrandomized_study","Mody R","2022","Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2022.01.017","https://doi.org/10.1016/j.clinthera.2022.01.017","35264311","https://pubmed.ncbi.nlm.nih.gov/35264311/","https://doi.org/10.1016/j.clinthera.2022.01.017",null],["4","R0005820","R0005820.pdf","open_download_failed","nonrandomized_study","Edelman S","2022","Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2022.28.9.958","https://doi.org/10.18553/jmcp.2022.28.9.958","36001104","https://pubmed.ncbi.nlm.nih.gov/36001104/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2022.28.9.958?download=true",null],["4","R0006129","R0006129.pdf","open_download_failed","nonrandomized_study","Yang YS","2022","GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.","Diabetes care","American Diabetes Association","10.2337/dc21-1993","https://doi.org/10.2337/dc21-1993","35275992","https://pubmed.ncbi.nlm.nih.gov/35275992/","https://diabetesjournals.org/care/article-pdf/45/5/1184/678594/dc211993.pdf",null],["4","R0006326","R0006326.pdf","free_to_read","nonrandomized_study","Najafi S","2022","Cardiovascular protection conferred by glucagon-like peptide-1 receptor agonists: A role for serum uric acid reduction?","British journal of clinical pharmacology","Wiley","10.1111/bcp.15381","https://doi.org/10.1111/bcp.15381","35574902","https://pubmed.ncbi.nlm.nih.gov/35574902/",null,null],["4","R0006358","R0006358.pdf","open_download_failed","nonrandomized_study","Hsiao FC","2022","New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgac402","https://doi.org/10.1210/clinem/dgac402","35776065","https://pubmed.ncbi.nlm.nih.gov/35776065/","https://academic.oup.com/jcem/article-pdf/107/9/2493/45477026/dgac402.pdf",null],["4","R0006837","R0006837.pdf","open_download_failed","nonrandomized_study","Butale B","2022","Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV.","Sexual health","CSIRO Publishing","10.1071/sh22070","https://doi.org/10.1071/sh22070","35995175","https://pubmed.ncbi.nlm.nih.gov/35995175/","https://www.publish.csiro.au/sh/pdf/SH22070",null],["4","R0006849","R0006849.pdf","free_to_read","nonrandomized_study","Risovic I","2022","Direct Comparison Two Fixed-ratio Combination Glucagon-like Peptide Receptor Agonist and Basal Insulin on Glycemic and Non Glycemic Parameters in Type 2 Diabetes","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-1592081/v2","https://doi.org/10.21203/rs.3.rs-1592081/v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-1592081/v2",null],["4","R0007033","R0007033.pdf","free_to_read","nonrandomized_study","Kobayashi K","2022","Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.109231","https://doi.org/10.1016/j.diabres.2022.109231","35131376","https://pubmed.ncbi.nlm.nih.gov/35131376/","https://doi.org/10.1016/j.diabres.2022.109231",null],["4","R0007185","R0007185.pdf","open_download_failed","nonrandomized_study","Pradhan R","2022","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc21-1953","https://doi.org/10.2337/dc21-1953","35104330","https://pubmed.ncbi.nlm.nih.gov/35104330/","https://diabetesjournals.org/care/article-pdf/45/4/819/672230/dc211953.pdf",null],["4","R0007643","R0007643.pdf","open_download_failed","nonrandomized_study","Pradhan R","2022","Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.","Diabetes care","American Diabetes Association","10.2337/dc22-0712","https://doi.org/10.2337/dc22-0712","35866685","https://pubmed.ncbi.nlm.nih.gov/35866685/","https://diabetesjournals.org/care/article-pdf/45/10/2289/688669/dc220712.pdf",null],["4","R0007658","R0007658.pdf","open_download_failed","nonrandomized_study","Deo SV","2022","Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.","Diabetes care","American Diabetes Association","10.2337/dc22-0570","https://doi.org/10.2337/dc22-0570","36256925","https://pubmed.ncbi.nlm.nih.gov/36256925/","https://diabetesjournals.org/care/article-pdf/45/12/3054/692726/dc220570.pdf",null],["4","R0007672","R0007672.pdf","open_download_failed","nonrandomized_study","Nargesi AA","2022","Specialty Visits and Real-world Initiation of Cardioprotective Anti-hyperglycemic Medications Among US Adults with Type 2 Diabetes","medRxiv","openRxiv","10.1101/2022.05.17.22275232","https://doi.org/10.1101/2022.05.17.22275232",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/05/19/2022.05.17.22275232.full.pdf",null],["4","R0008634","R0008634.pdf","free_to_read","nonrandomized_study","Zhuo M","2022","SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2021.09.015","https://doi.org/10.1053/j.ajkd.2021.09.015","34762974","https://pubmed.ncbi.nlm.nih.gov/34762974/","https://www.ncbi.nlm.nih.gov/pmc/articles/9079190",null],["4","R0008683","R0008683.pdf","open_download_failed","nonrandomized_study","Mahtta D","2022","Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.","Diabetes care","American Diabetes Association","10.2337/dc21-1815","https://doi.org/10.2337/dc21-1815","35015080","https://pubmed.ncbi.nlm.nih.gov/35015080/","https://diabetesjournals.org/care/article-pdf/45/2/372/642561/dc211815.pdf",null],["4","R0008850","R0008850.pdf","free_to_read","nonrandomized_study","Faillie JL","2022","Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.","Clinical pharmacology and therapeutics","Wiley","10.1002/cpt.2430","https://doi.org/10.1002/cpt.2430","34587280","https://pubmed.ncbi.nlm.nih.gov/34587280/",null,null],["4","R0008874","R0008874.pdf","free_to_read","nonrandomized_study","Mody R","2022","Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2022.2085962","https://doi.org/10.1080/03007995.2022.2085962","35758147","https://pubmed.ncbi.nlm.nih.gov/35758147/","https://doi.org/10.1080/03007995.2022.2085962",null],["4","R0009325","R0009325.pdf","open_download_failed","nonrandomized_study","Khera R","2022","Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM","medRxiv","openRxiv","10.1101/2022.12.27.22283968","https://doi.org/10.1101/2022.12.27.22283968",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/12/30/2022.12.27.22283968.full.pdf",null],["4","R0009409","R0009409.pdf","open_download_failed","nonrandomized_study","Swart EC","2022","Trends in add-on medications following metformin monotherapy for type 2 diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2022.28.11.1253","https://doi.org/10.18553/jmcp.2022.28.11.1253","36282929","https://pubmed.ncbi.nlm.nih.gov/36282929/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2022.28.11.1253?download=true",null],["4","R0009554","R0009554.pdf","open_download_failed","nonrandomized_study","Liaw J","2022","Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.","Diabetes care","American Diabetes Association","10.2337/dc22-0224","https://doi.org/10.2337/dc22-0224","35984049","https://pubmed.ncbi.nlm.nih.gov/35984049/","https://diabetesjournals.org/care/article-pdf/45/10/2316/688653/dc220224.pdf",null],["4","R0009917","R0009917.pdf","open_download_failed","nonrandomized_study","Nargesi AA","2022","Patterns of Medication Use and Prescription Fills for Cardioprotective Anti-Hyperglycemic Agents in the United States","medRxiv","openRxiv","10.1101/2022.01.31.22270187","https://doi.org/10.1101/2022.01.31.22270187",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2022/02/01/2022.01.31.22270187.full.pdf",null],["4","R0010070","R0010070.pdf","free_to_read","nonrandomized_study","Paul SK","2022","Robustness of Multiple Imputation Methods for Missing Risk Factor Data from Electronic Medical Records for Observational Studies.","Journal of healthcare informatics research","Springer Science and Business Media LLC","10.1007/s41666-022-00119-w","https://doi.org/10.1007/s41666-022-00119-w","36744084","https://pubmed.ncbi.nlm.nih.gov/36744084/","https://www.ncbi.nlm.nih.gov/pmc/articles/9892403",null],["4","R0010126","R0010126.pdf","open_download_failed","nonrandomized_study","Westerink J","2022","Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.","Diabetes care","American Diabetes Association","10.2337/dc21-1138","https://doi.org/10.2337/dc21-1138","35263432","https://pubmed.ncbi.nlm.nih.gov/35263432/","https://diabetesjournals.org/care/article-pdf/45/5/1211/678598/dc211138.pdf",null],["4","R0010267","R0010267.pdf","open_download_failed","nonrandomized_study","Ueda P","2022","The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14598","https://doi.org/10.1111/dom.14598","34738703","https://pubmed.ncbi.nlm.nih.gov/34738703/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14598",null],["4","R0010405","R0010405.pdf","free_to_read","nonrandomized_study","Alkabbani W","2022","Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2021.12.005","https://doi.org/10.1016/j.jcjd.2021.12.005","35513988","https://pubmed.ncbi.nlm.nih.gov/35513988/","https://doi.org/10.1016/j.jcjd.2021.12.005",null],["4","R0010910","R0010910.pdf","open_download_failed","nonrandomized_study","Fu EL","2022","Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2022.01.042","https://doi.org/10.1016/j.ijcard.2022.01.042","35074492","https://pubmed.ncbi.nlm.nih.gov/35074492/","http://www.internationaljournalofcardiology.com/article/S0167527322001310/pdf",null],["4","R0010928","R0010928.pdf","open_download_failed","nonrandomized_study","Xu Y","2022","GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.","Kidney international","Elsevier BV","10.1016/j.kint.2021.10.033","https://doi.org/10.1016/j.kint.2021.10.033","34826514","https://pubmed.ncbi.nlm.nih.gov/34826514/","https://www.kidney-international.org/article/S0085-2538(21)01065-6/pdf",null],["4","R0011493","R0011493.pdf","open_download_failed","nonrandomized_study","Hoog M","2022","Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2022.04.005","https://doi.org/10.1016/j.clinthera.2022.04.005","35618571","https://pubmed.ncbi.nlm.nih.gov/35618571/","http://www.clinicaltherapeutics.com/article/S0149291822001448/pdf",null],["4","R0011780","R0011780.pdf","free_to_read","nonrandomized_study","Hejjaji V","2022","Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14745","https://doi.org/10.1111/dom.14745","35546275","https://pubmed.ncbi.nlm.nih.gov/35546275/","https://figshare.com/articles/journal_contribution/Factors_associated_with_weight_loss_in_people_with_overweight_or_obesity_living_with_type_2_diabetes_mellitus_Insights_from_the_global_DISCOVER_study/20367519","ClinicalTrials.gov:NCT02322762; ClinicalTrials.gov:NCT02226822"],["4","R0012014","R0012014.pdf","free_to_read","nonrandomized_study","Jervis M","2022","GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3574","https://doi.org/10.1002/dmrr.3574","36052434","https://pubmed.ncbi.nlm.nih.gov/36052434/",null,null],["4","R0012324","R0012324.pdf","open_download_failed","nonrandomized_study","Williams S","2022","Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2022.09.002","https://doi.org/10.1016/j.clinthera.2022.09.002","36272822","https://pubmed.ncbi.nlm.nih.gov/36272822/","http://www.clinicaltherapeutics.com/article/S0149291822003174/pdf",null],["4","R0012430","R0012430.pdf","open_download_failed","nonrandomized_study","Essien UR","2022","Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry.","Diabetes care","American Diabetes Association","10.2337/dc21-1178","https://doi.org/10.2337/dc21-1178","35796766","https://pubmed.ncbi.nlm.nih.gov/35796766/","https://diabetesjournals.org/care/article-pdf/45/7/1549/685262/dc211178.pdf",null],["4","R0013332","R0013332.pdf","no_doi","nonrandomized_study","Ebell MH","2022","Top 20 Research Studies of 2021 for Primary Care Physicians.","American family physician",null,null,"https://doi.org/","35839363","https://pubmed.ncbi.nlm.nih.gov/35839363/",null,null],["4","R0016236","R0016236.pdf","open_download_failed","nonrandomized_study","Zhuo M","2022","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2022.35995","https://doi.org/10.1001/jamanetworkopen.2022.35995","36219443","https://pubmed.ncbi.nlm.nih.gov/36219443/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2797190/zhuo_2022_oi_221016_1664551377.99948.pdf",null],["4","R0017448","R0017448.pdf","free_to_read","nonrandomized_study","Wei ET","2022","Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2021.10.007","https://doi.org/10.1016/j.japh.2021.10.007","34756524","https://pubmed.ncbi.nlm.nih.gov/34756524/",null,null],["4","R0017648","R0017648.pdf","open_download_failed","nonrandomized_study","Lu S","2022","Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.","Epidemiology (Cambridge, Mass.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/ede.0000000000001486","https://doi.org/10.1097/ede.0000000000001486","35394977","https://pubmed.ncbi.nlm.nih.gov/35394977/","http://escholarship.mcgill.ca/downloads/z316q667b",null],["4","R0018058","R0018058.pdf","open_download_failed","nonrandomized_study","Trenson L","2022","Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved.","Obesity facts","S. Karger AG","10.1159/000520217","https://doi.org/10.1159/000520217","34808630","https://pubmed.ncbi.nlm.nih.gov/34808630/","https://www.karger.com/Article/Pdf/520217",null],["4","R0018060","R0018060.pdf","open_download_failed","nonrandomized_study","Sivakumar R","2022","Olfactory dysfunction in type II diabetes: Therapeutic options and lessons learned from other etiologies - A scoping review.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2022.05.003","https://doi.org/10.1016/j.pcd.2022.05.003","35659730","https://pubmed.ncbi.nlm.nih.gov/35659730/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10184301/pdf/nihms-1893142.pdf",null],["4","R0018116","R0018116.pdf","open_download_failed","nonrandomized_study","Luo J","2022","Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2022.109855","https://doi.org/10.1016/j.diabres.2022.109855","35346753","https://pubmed.ncbi.nlm.nih.gov/35346753/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10767977/pdf/nihms-1796885.pdf",null],["4","R0019641","R0019641.pdf","open_download_failed","nonrandomized_study","Echouffo-Tcheugui JB","2022","Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2022.06.016","https://doi.org/10.1016/j.amjmed.2022.06.016","35872090","https://pubmed.ncbi.nlm.nih.gov/35872090/","https://www.amjmed.com/article/S0002-9343(22)00526-5/pdf",null],["4","R0020740","R0020740.pdf","open_download_failed","nonrandomized_study","Kim N","2022","Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2022.28.7.740","https://doi.org/10.18553/jmcp.2022.28.7.740","35737858","https://pubmed.ncbi.nlm.nih.gov/35737858/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10372962/pdf/jmcp.2022.28.7.740.pdf",null],["4","R0021556","R0021556.pdf","free_to_read","nonrandomized_study","Levi J","2022","Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical Obesity","SSRN","Elsevier BV","10.2139/ssrn.4068270","https://doi.org/10.2139/ssrn.4068270",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4068270",null],["4","R0022319","R0022319.pdf","free_to_read","nonrandomized_study","Sharma A","2022","Insulinoma-Accurate Preoperative Localization Is the Key to Management: An Initial Experience.","Indian journal of surgical oncology","Springer Science and Business Media LLC","10.1007/s13193-022-01534-6","https://doi.org/10.1007/s13193-022-01534-6","35782810","https://pubmed.ncbi.nlm.nih.gov/35782810/","https://www.ncbi.nlm.nih.gov/pmc/articles/9240150",null],["4","R0024268","R0024268.pdf","open_download_failed","nonrandomized_study","Metsärinne K","2022","The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF).","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.12.012","https://doi.org/10.1016/j.pcd.2021.12.012","34972659","https://pubmed.ncbi.nlm.nih.gov/34972659/","http://www.primary-care-diabetes.com/article/S175199182100228X/pdf",null],["4","R0024713","R0024713.pdf","free_to_read","nonrandomized_study","Berra CC","2022","AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.","Research Square","Springer Science and Business Media LLC","10.21203/rs.3.rs-2134695/v2","https://doi.org/10.21203/rs.3.rs-2134695/v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21203/rs.3.rs-2134695/v2",null],["4","R0028967","R0028967.pdf","open_download_failed","nonrandomized_study","Lau KTK","2022","Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.121.023489","https://doi.org/10.1161/jaha.121.023489","35322676","https://pubmed.ncbi.nlm.nih.gov/35322676/","https://www.ahajournals.org/doi/pdf/10.1161/JAHA.121.023489",null],["4","R0036169","R0036169.pdf","no_doi","nonrandomized_study","Samaneh Olapour","2022","Metabolic dysfunction-associated fatty liver disease and metabolic-associated steatohepatitis: a review of pathogenesis and potential pharmacological targets","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036177","R0036177.pdf","no_doi","nonrandomized_study","Grigg, Robert D","2022","Cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes.","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037896","R0037896.pdf","no_doi","nonrandomized_study","Rodrigo, Natassia","2022","The impact of inflammation, oxidative stress, and metabolic dysregulation in maternal obesity, diabetes and pregnancy","The Sydney eScholarship Repository (The University of Sydney)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038848","R0038848.pdf","free_to_read","nonrandomized_study","Jing Li","2022","Obesity pandemic in China: epidemiology, burden, challenges, and opportunities","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000002189","https://doi.org/10.1097/cm9.0000000000002189","35866571","https://pubmed.ncbi.nlm.nih.gov/35866571/","https://doi.org/10.1097/cm9.0000000000002189",null],["4","R0039023","R0039023.pdf","free_to_read","nonrandomized_study","Wen-Ling Lee","2022","Dipeptidyl peptidase-4 inhibitors and osteoporosis","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcma.0000000000000775","https://doi.org/10.1097/jcma.0000000000000775","35816295","https://pubmed.ncbi.nlm.nih.gov/35816295/","https://doi.org/10.1097/jcma.0000000000000775",null],["4","R0039508","R0039508.pdf","free_to_read","nonrandomized_study","Jothydev Kesavadev","2022","Oral Semaglutide","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_22_23","https://doi.org/10.4103/ijdt.ijdt_22_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_22_23",null],["4","R0039834","R0039834.pdf","no_doi","nonrandomized_study","Jermendy, György","2022","A 2-es típusú diabetes mellitus antihiperglikémiás kezelésének változása Magyarországon 2015-2020 között - adatbázis-elemzés országos adatai [Changing patterns of antihyperglycaemic treatment among patients with type 2 diabetes in Hungary between 2015 and 2020 – nationwide data from a register-based analysis]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039859","R0039859.pdf","no_doi","nonrandomized_study","Mickovski, Ivana","2022","Мултицентрична, ретроспективна студија која ја анализира гликемиската контрола кај една група на GLP-1 наивни пациенти со дијабетес тип 2 кои биле поставени на еднаш неделна терапија со semaglutide (OZEMPIC) во рутинска клиничка пракса во С. Македонија. Број на протоко: NN9535-4976","Goce Delchev University Repository (Goce Delčev University of Štip)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042314","R0042314.pdf","free_to_read","nonrandomized_study","Narasaki, Yoko","2022","400 Real-World Safety of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists in US Veterans With and Without Chronic Kidney Disease","American Journal of Kidney Diseases","Elsevier BV","10.1053/j.ajkd.2022.01.405","https://doi.org/10.1053/j.ajkd.2022.01.405",null,"https://pubmed.ncbi.nlm.nih.gov//","https://escholarship.org/uc/item/73c805x8",null],["4","R0042345","R0042345.pdf","no_doi","nonrandomized_study","Vittal Hejjaji (13147908)","2022","Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042502","R0042502.pdf","no_doi","nonrandomized_study","Salinas Achusim, Stephanie","2022","Kartläggning av förändring i HbA1c och vikt vid behandling med SGLT2-hämmare eller GLP-1-analoger hos patienter med diabetes typ II","Uppsala University Publications (Uppsala University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043744","R0043744.pdf","free_to_read","nonrandomized_study","Chi‐Ho Lee","2022","Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now","Journal of Diabetes Investigation","Wiley","10.1111/jdi.13765","https://doi.org/10.1111/jdi.13765","35119217","https://pubmed.ncbi.nlm.nih.gov/35119217/","https://doi.org/10.1111/jdi.13765",null],["4","R0044010","R0044010.pdf","no_doi","nonrandomized_study","Rasalam, Roy","2022","Patients reaching treatment targets with once-weekly semaglutide in real‑world practice: pooled analysis of four SURE studies","ResearchOnline - JCU (James Cook University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044181","R0044181.pdf","free_to_read","nonrandomized_study","Jea Young Min","2022","Association between antidiabetic drug use and the risk of COVID ‐19 hospitalization in the INSIGHT Clinical Research Network in New York City","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14704","https://doi.org/10.1111/dom.14704","35373892","https://pubmed.ncbi.nlm.nih.gov/35373892/","https://www.ncbi.nlm.nih.gov/pmc/articles/9111856",null],["4","R0044506","R0044506.pdf","no_doi","nonrandomized_study","Jorge Andrés Negrete Levette","2022","Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044634","R0044634.pdf","free_to_read","nonrandomized_study","WY Yao","2022","EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World Data","Value in Health","Elsevier BV","10.1016/j.jval.2022.09.293","https://doi.org/10.1016/j.jval.2022.09.293",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2022.09.293",null],["4","R0045844","R0045844.pdf","free_to_read","nonrandomized_study","Yi‐Hsuan Lin","2022","SGLT2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared with Incretin-Based Therapy in Patients with Diabetic Foot Disease: A Nationwide Population-Based Study","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.4025058","https://doi.org/10.2139/ssrn.4025058",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.4025058",null],["4","R0047035","R0047035.pdf","free_to_read","nonrandomized_study","Manash Baruah","2022","Abstract 188","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.363695","https://doi.org/10.4103/2230-8210.363695",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/2230-8210.363695","ClinicalTrials.gov:NCT04042441"],["4","R0047361","R0047361.pdf","free_to_read","nonrandomized_study","Arvid Engström","2022","Sodium-glucose co-transporter 2 inhibitor treatment and risk of atrial fibrillation: Scandinavian cohort study",null,"American Diabetes Association","10.2337/figshare.21562863.v1","https://doi.org/10.2337/figshare.21562863.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.21562863.v1",null],["4","R0048059","R0048059.pdf","free_to_read","nonrandomized_study","Beini Lyu","2022","Pharmacologic Treatment of Type 2 Diabetes in the United States, Sweden, and Israel",null,"American Diabetes Association","10.2337/figshare.21126043.v2","https://doi.org/10.2337/figshare.21126043.v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.21126043.v2",null],["4","R0048426","R0048426.pdf","free_to_read","nonrandomized_study","Angelina Valladares Bernier","2022","A narrative review: polycystic ovary syndrome (PCOS) and type 1 diabetes (T1D)","Pediatric Medicine","AME Publishing Company","10.21037/pm-22-3","https://doi.org/10.21037/pm-22-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21037/pm-22-3",null],["4","R0048798","R0048798.pdf","free_to_read","nonrandomized_study","Amelia Simenacz","2022","Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2022.350","https://doi.org/10.15277/bjd.2022.350",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2022.350",null],["4","R0049891","R0049891.pdf","free_to_read","nonrandomized_study","Julia Liaw","2022","Trends in prescribing preferences for antidiabetic medications among type 2 diabetes patients in the UK with and without chronic kidney disease, 2006-2020",null,"American Diabetes Association","10.2337/figshare.20365554.v1","https://doi.org/10.2337/figshare.20365554.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.20365554.v1",null],["4","R0050070","R0050070.pdf","free_to_read","nonrandomized_study","Salil Vasudeo Deo","2022","Trends in prescriptions of cardio-protective diabetic agents after coronary artery bypass grafting among US Veterans",null,"American Diabetes Association","10.2337/figshare.21159139.v1","https://doi.org/10.2337/figshare.21159139.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.21159139.v1",null],["4","R0050120","R0050120.pdf","free_to_read","nonrandomized_study","Amritanshu Shekhar Pandey","2022","Sustained usage of an app-based clinical-decision making aid for the management of atherosclerotic cardiovascular disease","European Heart Journal - Digital Health","Oxford University Press (OUP)","10.1093/ehjdh/ztac076.2825","https://doi.org/10.1093/ehjdh/ztac076.2825",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/ehjdh/ztac076.2825",null],["4","R0050699","R0050699.pdf","no_doi","nonrandomized_study","Zheer Kejlberg Al-Mashhadi","2022","Fracture risk in treatment with GLP-1RA compared to DPP-4i:a Danish nationwide cohort study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051194","R0051194.pdf","free_to_read","nonrandomized_study","Natalie Lambert","2022","The Disconnect Between Patient and Provider Perceptions of Medications in Type 2 Diabetes: A Cross-Sectional Analysis of Health Narratives Shared in Social Media Forums Discussing Cardioprotective GLP-1RAs and SGLT-2is (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.42137","https://doi.org/10.2196/preprints.42137",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.42137",null],["4","R0051567","R0051567.pdf","free_to_read","nonrandomized_study","Gregory Lee Braden","2022","The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease","Kidney360","Ovid Technologies (Wolters Kluwer Health)","10.34067/kid.0003322022","https://doi.org/10.34067/kid.0003322022","36245646","https://pubmed.ncbi.nlm.nih.gov/36245646/","https://doi.org/10.34067/kid.0003322022",null],["4","R0051955","R0051955.pdf","free_to_read","nonrandomized_study","Kristina Secnik Boye","2022","POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months","Value in Health","Elsevier BV","10.1016/j.jval.2021.11.1184","https://doi.org/10.1016/j.jval.2021.11.1184",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2021.11.1184",null],["4","R0053378","R0053378.pdf","free_to_read","nonrandomized_study","Karim Magdy Mohamed Soliman","2022","Accepting Living Kidney Donors with Preexisting Diabetes Mellitus","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.09460822","https://doi.org/10.2215/cjn.09460822","36220190","https://pubmed.ncbi.nlm.nih.gov/36220190/","https://www.ncbi.nlm.nih.gov/pmc/articles/10101624",null],["4","R0055046","R0055046.pdf","free_to_read","nonrandomized_study","Supratik Bhattacharyya","2022","Insights into the Early Use of Oral Semaglutide in Routine Indian Clinical Practice","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_15_23","https://doi.org/10.4103/ijdt.ijdt_15_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_15_23",null],["4","R0055194","R0055194.pdf","free_to_read","nonrandomized_study","Zheer Kejlberg Al-Mashhadi","2022","SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: a Danish population-based cohort study","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.81.oc8.2","https://doi.org/10.1530/endoabs.81.oc8.2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://pure.au.dk/portal/en/publications/e5fc5fa6-35ac-4c22-bb9f-ed73dc5a387d",null],["4","R0055227","R0055227.pdf","free_to_read","nonrandomized_study","Christopher Vannabouathong","2022","Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists","Canadian Journal of Health Technologies","Canadian Journal of Health Technologies, CADTH","10.51731/cjht.2022.434","https://doi.org/10.51731/cjht.2022.434",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.51731/cjht.2022.434",null],["4","R0055962","R0055962.pdf","no_doi","nonrandomized_study","Mercedes Ganduglia","2022","Farmacoterapia de la obesidad: revisión de revisiones sistemáticas","DIAETA",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0056333","R0056333.pdf","no_doi","nonrandomized_study","B.KrishnaKrishn","2022","Suicidal Ideation and Glucagon-like Peptide-1 Receptor Agonists: An Examination of Real-Word Data Gathered from the European Pharmacovigilance Database","International Journal of Pharmacetical Sciences Letters",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0004382","R0004382.pdf","open_download_failed","nonrandomized_study","Patel D","2021","Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2021.1947796","https://doi.org/10.1080/17512433.2021.1947796","34231442","https://pubmed.ncbi.nlm.nih.gov/34231442/","https://www.tandfonline.com/doi/pdf/10.1080/17512433.2021.1947796?needAccess=true",null],["4","R0004770","R0004770.pdf","free_to_read","nonrandomized_study","Campos C","2021","Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2021.1971461","https://doi.org/10.1080/00325481.2021.1971461","34416133","https://pubmed.ncbi.nlm.nih.gov/34416133/","https://doi.org/10.1080/00325481.2021.1971461",null],["4","R0005791","R0005791.pdf","free_to_read","nonrandomized_study","Mosenzon O","2021","Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.","Advances in chronic kidney disease","Elsevier BV","10.1053/j.ackd.2021.04.005","https://doi.org/10.1053/j.ackd.2021.04.005","34922691","https://pubmed.ncbi.nlm.nih.gov/34922691/","https://doi.org/10.1053/j.ackd.2021.04.005",null],["4","R0006346","R0006346.pdf","open_download_failed","nonrandomized_study","Sterling JK","2021","Exposure to glucagon-like peptide 1 receptor (GLP-1R) agonists reduces glaucoma risk","medRxiv","openRxiv","10.1101/2021.01.16.21249949","https://doi.org/10.1101/2021.01.16.21249949",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2021/01/20/2021.01.16.21249949.full.pdf",null],["4","R0006568","R0006568.pdf","open_download_failed","nonrandomized_study","Foer D","2021","Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.","American journal of respiratory and critical care medicine","Oxford University Press (OUP)","10.1164/rccm.202004-0993oc","https://doi.org/10.1164/rccm.202004-0993oc","33052715","https://pubmed.ncbi.nlm.nih.gov/33052715/","https://www.zora.uzh.ch/id/eprint/190977/1/GLP1RAs_in_asthma_ZORA_Beeler.pdf",null],["4","R0006687","R0006687.pdf","open_download_failed","nonrandomized_study","Israelsen SB","2021","Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14329","https://doi.org/10.1111/dom.14329","33502076","https://pubmed.ncbi.nlm.nih.gov/33502076/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14329",null],["4","R0006949","R0006949.pdf","open_download_failed","nonrandomized_study","Maskery MP","2021","Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review.","Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","SAGE Publications","10.1177/0271678x20952011","https://doi.org/10.1177/0271678x20952011","32954901","https://pubmed.ncbi.nlm.nih.gov/32954901/","https://journals.sagepub.com/doi/pdf/10.1177/0271678X20952011",null],["4","R0007783","R0007783.pdf","open_download_failed","nonrandomized_study","Longato E","2021","Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaa081","https://doi.org/10.1093/eurjpc/zwaa081","33624059","https://pubmed.ncbi.nlm.nih.gov/33624059/","https://academic.oup.com/eurjpc/article-pdf/28/1/22/36669629/zwaa081.pdf",null],["4","R0009153","R0009153.pdf","open_download_failed","nonrandomized_study","Rea F","2021","Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.109035","https://doi.org/10.1016/j.diabres.2021.109035","34487757","https://pubmed.ncbi.nlm.nih.gov/34487757/","http://www.diabetesresearchclinicalpractice.com/article/S0168822721003946/pdf",null],["4","R0009779","R0009779.pdf","open_download_failed","nonrandomized_study","Haloot J","2021","Liraglutide Mortality Effect on Atrial Fibrillation Patients","Authorea Preprints","Wiley","10.22541/au.163858750.00925195/v1","https://doi.org/10.22541/au.163858750.00925195/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.163858750.00925195",null],["4","R0009844","R0009844.pdf","open_download_failed","nonrandomized_study","Pottegård A","2021","Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14253","https://doi.org/10.1111/dom.14253","33184953","https://pubmed.ncbi.nlm.nih.gov/33184953/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14253",null],["4","R0009975","R0009975.pdf","free_to_read","nonrandomized_study","Graybill S","2021","Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort.","Andrology","Wiley","10.1111/andr.12966","https://doi.org/10.1111/andr.12966","33400403","https://pubmed.ncbi.nlm.nih.gov/33400403/","https://digitalcommons.unmc.edu/com_hosp_articles/3",null],["4","R0009993","R0009993.pdf","free_to_read","nonrandomized_study","Yun JS","2021","Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2021.154838","https://doi.org/10.1016/j.metabol.2021.154838","34333002","https://pubmed.ncbi.nlm.nih.gov/34333002/","https://doi.org/10.1016/j.metabol.2021.154838",null],["4","R0010048","R0010048.pdf","open_download_failed","nonrandomized_study","Newman TV","2021","Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2021.27.4.435","https://doi.org/10.18553/jmcp.2021.27.4.435","33769857","https://pubmed.ncbi.nlm.nih.gov/33769857/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.435",null],["4","R0010376","R0010376.pdf","open_download_failed","nonrandomized_study","Chu L","2021","Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2021.07.015","https://doi.org/10.1016/j.clinthera.2021.07.015","34426012","https://pubmed.ncbi.nlm.nih.gov/34426012/","http://www.clinicaltherapeutics.com/article/S0149291821002599/pdf","ClinicalTrials.gov:NCT04445181"],["4","R0010400","R0010400.pdf","free_to_read","nonrandomized_study","Visaria J","2021","Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2021.03.003","https://doi.org/10.1016/j.clinthera.2021.03.003","33785221","https://pubmed.ncbi.nlm.nih.gov/33785221/","https://doi.org/10.1016/j.clinthera.2021.03.003",null],["4","R0010571","R0010571.pdf","open_download_failed","nonrandomized_study","Cahn A","2021","Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14179","https://doi.org/10.1111/dom.14179","32844557","https://pubmed.ncbi.nlm.nih.gov/32844557/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14179",null],["4","R0012177","R0012177.pdf","open_download_failed","nonrandomized_study","Mali G","2021","Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13259","https://doi.org/10.1111/jcpt.13259","32926446","https://pubmed.ncbi.nlm.nih.gov/32926446/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcpt.13259",null],["4","R0012484","R0012484.pdf","open_download_failed","nonrandomized_study","Lund LC","2021","Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5252","https://doi.org/10.1002/pds.5252","33881179","https://pubmed.ncbi.nlm.nih.gov/33881179/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.5252",null],["4","R0012731","R0012731.pdf","open_download_failed","nonrandomized_study","Mata-Cases M","2021","Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.02.003","https://doi.org/10.1016/j.pcd.2021.02.003","33602606","https://pubmed.ncbi.nlm.nih.gov/33602606/","http://www.primary-care-diabetes.com/article/S1751991821000176/pdf",null],["4","R0013129","R0013129.pdf","open_download_failed","nonrandomized_study","Shao H","2021","Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018.","Diabetes care","American Diabetes Association","10.2337/dc20-2871","https://doi.org/10.2337/dc20-2871","33563653","https://pubmed.ncbi.nlm.nih.gov/33563653/","https://diabetesjournals.org/care/article-pdf/44/4/925/632097/dc202871.pdf",null],["4","R0013247","R0013247.pdf","open_download_failed","nonrandomized_study","Rodionov RN","2021","Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis.","European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","Elsevier BV","10.1016/j.ejvs.2021.09.031","https://doi.org/10.1016/j.ejvs.2021.09.031","34782230","https://pubmed.ncbi.nlm.nih.gov/34782230/","https://www.ejves.com/article/S1078-5884(21)00770-X/pdf",null],["4","R0013938","R0013938.pdf","free_to_read","nonrandomized_study","Kruse T","2021","Development of Cagrilintide, a Long-Acting Amylin Analogue.","Journal of medicinal chemistry","American Chemical Society (ACS)","10.1021/acs.jmedchem.1c00565","https://doi.org/10.1021/acs.jmedchem.1c00565","34288673","https://pubmed.ncbi.nlm.nih.gov/34288673/","https://doi.org/10.1021/acs.jmedchem.1c00565",null],["4","R0013996","R0013996.pdf","open_download_failed","nonrandomized_study","Le Pen C","2021","Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.","Annales d'endocrinologie","Elsevier BV","10.1016/j.ando.2020.12.009","https://doi.org/10.1016/j.ando.2020.12.009","33417963","https://pubmed.ncbi.nlm.nih.gov/33417963/","https://www.sciencedirect.com/science/article/pii/S000342662031324X/pdf",null],["4","R0015089","R0015089.pdf","open_download_failed","nonrandomized_study","Farmer RE","2021","Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2020.12.015","https://doi.org/10.1016/j.clinthera.2020.12.015","33581878","https://pubmed.ncbi.nlm.nih.gov/33581878/","http://www.clinicaltherapeutics.com/article/S0149291820305646/pdf",null],["4","R0015819","R0015819.pdf","free_to_read","nonrandomized_study","Bonora BM","2021","Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108686","https://doi.org/10.1016/j.diabres.2021.108686","33548335","https://pubmed.ncbi.nlm.nih.gov/33548335/","https://www.sciencedirect.com/science/article/pii/S0168822721000395?via=ihub",null],["4","R0017199","R0017199.pdf","open_download_failed","nonrandomized_study","Poonawalla IB","2021","A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108800","https://doi.org/10.1016/j.diabres.2021.108800","33845052","https://pubmed.ncbi.nlm.nih.gov/33845052/","http://www.diabetesresearchclinicalpractice.com/article/S0168822721001595/pdf",null],["4","R0018772","R0018772.pdf","no_doi","nonrandomized_study","Ebell MH","2021","For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.","American family physician",null,null,"https://doi.org/","34652104","https://pubmed.ncbi.nlm.nih.gov/34652104/",null,null],["4","R0019452","R0019452.pdf","free_to_read","nonrandomized_study","Jensterle M","2021","Glucagon-like peptide-1, a matter of taste?","Reviews in endocrine & metabolic disorders","Springer Science and Business Media LLC","10.1007/s11154-020-09609-x","https://doi.org/10.1007/s11154-020-09609-x","33123893","https://pubmed.ncbi.nlm.nih.gov/33123893/","https://pure.amsterdamumc.nl/files/141730442/Glucagon-like-peptide-1-a-matter-of-taste.pdf",null],["4","R0019971","R0019971.pdf","open_download_failed","nonrandomized_study","Harris ST","2021","Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc21-0529","https://doi.org/10.2337/dc21-0529","34344714","https://pubmed.ncbi.nlm.nih.gov/34344714/","https://diabetesjournals.org/care/article-pdf/44/10/2293/632232/dc210529.pdf",null],["4","R0020088","R0020088.pdf","free_to_read","nonrandomized_study","Varpuluoma O","2021","GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid.","The Journal of investigative dermatology","Elsevier BV","10.1016/j.jid.2021.05.015","https://doi.org/10.1016/j.jid.2021.05.015","34116060","https://pubmed.ncbi.nlm.nih.gov/34116060/","https://doi.org/10.1016/j.jid.2021.05.015",null],["4","R0020857","R0020857.pdf","open_download_failed","nonrandomized_study","Viggers R","2021","Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study.","Diabetes care","American Diabetes Association","10.2337/dc21-0333","https://doi.org/10.2337/dc21-0333","34362812","https://pubmed.ncbi.nlm.nih.gov/34362812/","https://diabetesjournals.org/care/article-pdf/44/9/2045/633242/dc210333.pdf",null],["4","R0021093","R0021093.pdf","open_download_failed","nonrandomized_study","Rizza S","2021","Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2021.112341","https://doi.org/10.1016/j.biopha.2021.112341","34678725","https://pubmed.ncbi.nlm.nih.gov/34678725/","https://www.sciencedirect.com/science/article/pii/S0753332221011252/pdf",null],["4","R0021109","R0021109.pdf","free_to_read","nonrandomized_study","Davis H","2021","Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use.","Family practice","Oxford University Press (OUP)","10.1093/fampra/cmab021","https://doi.org/10.1093/fampra/cmab021","33755123","https://pubmed.ncbi.nlm.nih.gov/33755123/",null,null],["4","R0022039","R0022039.pdf","free_to_read","nonrandomized_study","Khunti K","2021","Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14400","https://doi.org/10.1111/dom.14400","33852202","https://pubmed.ncbi.nlm.nih.gov/33852202/","https://doi.org/10.1111/dom.14400",null],["4","R0023109","R0023109.pdf","open_download_failed","nonrandomized_study","Rudofsky G","2021","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108931","https://doi.org/10.1016/j.diabres.2021.108931","34217773","https://pubmed.ncbi.nlm.nih.gov/34217773/","http://www.diabetesresearchclinicalpractice.com/article/S0168822721002916/pdf","ClinicalTrials.gov:NCT03631186"],["4","R0023390","R0023390.pdf","open_download_failed","nonrandomized_study","Rajamand Ekberg N","2021","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2021.06.008","https://doi.org/10.1016/j.pcd.2021.06.008","34183269","https://pubmed.ncbi.nlm.nih.gov/34183269/","http://www.primary-care-diabetes.com/article/S1751991821001121/pdf","ClinicalTrials.gov:NCT03648281"],["4","R0023941","R0023941.pdf","open_download_failed","nonrandomized_study","Jensen HK","2021","Use of non-insulin antidiabetic drugs in children and young adults - A Scandinavian drug utilization study from 2010-2019.","British journal of clinical pharmacology","Wiley","10.1111/bcp.14867","https://doi.org/10.1111/bcp.14867","33871080","https://pubmed.ncbi.nlm.nih.gov/33871080/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.14867",null],["4","R0024208","R0024208.pdf","free_to_read","nonrandomized_study","Park JH","2021","Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-021-00739-z","https://doi.org/10.1038/s41366-021-00739-z","33473176","https://pubmed.ncbi.nlm.nih.gov/33473176/","https://ir.ymlib.yonsei.ac.kr/handle/22282913/190966",null],["4","R0024228","R0024228.pdf","open_download_failed","nonrandomized_study","Yousef CC","2021","Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2021.108871","https://doi.org/10.1016/j.diabres.2021.108871","34052248","https://pubmed.ncbi.nlm.nih.gov/34052248/","http://www.diabetesresearchclinicalpractice.com/article/S0168822721002308/pdf",null],["4","R0025443","R0025443.pdf","free_to_read","nonrandomized_study","Yu Y","2021","Gut hormones, adipokines, and pro- and anti-inflammatory cytokines/markers in loss of control eating: A scoping review.","Appetite","Elsevier BV","10.1016/j.appet.2021.105442","https://doi.org/10.1016/j.appet.2021.105442","34111480","https://pubmed.ncbi.nlm.nih.gov/34111480/","https://www.ncbi.nlm.nih.gov/pmc/articles/10683926",null],["4","R0026977","R0026977.pdf","free_to_read","nonrandomized_study","Kosjerina V","2021","Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study.","The lancet. Healthy longevity","Elsevier BV","10.1016/s2666-7568(21)00170-7","https://doi.org/10.1016/s2666-7568(21)00170-7","36098008","https://pubmed.ncbi.nlm.nih.gov/36098008/","https://doi.org/10.1016/s2666-7568(21)00170-7",null],["4","R0029777","R0029777.pdf","open_download_failed","nonrandomized_study","Sørensen KV","2021","Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans.","Clinical nutrition (Edinburgh, Scotland)","Elsevier BV","10.1016/j.clnu.2020.09.043","https://doi.org/10.1016/j.clnu.2020.09.043","33059911","https://pubmed.ncbi.nlm.nih.gov/33059911/","http://www.clinicalnutritionjournal.com/article/S026156142030515X/pdf","ClinicalTrials.gov:NCT03062592; ClinicalTrials.gov:NCT03305367"],["4","R0031163","R0031163.pdf","no_doi","nonrandomized_study","陳 里菜","2021","日本人2 型糖尿病患者を対象としたデュラグルチドの安全性および有効性の検討―デュラグルチド0.75 mg 特定使用成績調査中間報告―","薬理と治療",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037006","R0037006.pdf","free_to_read","nonrandomized_study","Divyani Garg","2021","Neuroprotective strategies in Parkinson’s disease","Annals of Movement Disorders","Ovid Technologies (Wolters Kluwer Health)","10.4103/aomd.aomd_38_21","https://doi.org/10.4103/aomd.aomd_38_21",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/aomd.aomd_38_21",null],["4","R0037748","R0037748.pdf","free_to_read","nonrandomized_study","Kyrian Ezendu","2021","Opinion Mining and Multi-Label Classification of Patient-Generated Long-Term Anti-Obesity Medication Reviews (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.32397","https://doi.org/10.2196/preprints.32397",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.32397",null],["4","R0038136","R0038136.pdf","no_doi","nonrandomized_study","VAN BIGNOOT, G.","2021","Renal and metabolic effects of the association of GLP-1 receptor agonists and SGLT-2 inhibitors in individuals with type 2 diabetes: a retrospective observational study (\"ReMeSG study\")","IRIS",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0038577","R0038577.pdf","free_to_read","nonrandomized_study","Udaya M. Kabadi","2021","Soliqua (Lixi Lan): Sustained Long Term Cost Efficacy and Safety When Used in Combination with Metformin and Glimepiride","Journal of Advances in Medical and Pharmaceutical Sciences","Sciencedomain International","10.9734/jamps/2021/v23i1030263","https://doi.org/10.9734/jamps/2021/v23i1030263",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9734/jamps/2021/v23i1030263",null],["4","R0039285","R0039285.pdf","free_to_read","nonrandomized_study","George Vasquez‐Rios","2021","Predictors of Kidney Disease Progression in Diabetes and Precision Medicine: Something Old, Something New, and Something Borrowed","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2021070945","https://doi.org/10.1681/asn.2021070945","34465605","https://pubmed.ncbi.nlm.nih.gov/34465605/","https://www.ncbi.nlm.nih.gov/pmc/articles/8729853",null],["4","R0044216","R0044216.pdf","free_to_read","nonrandomized_study","Wen-Ling Lee","2021","Amylin, bariatric surgery, and type 2 diabetes mellitus","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcma.0000000000000618","https://doi.org/10.1097/jcma.0000000000000618","34524225","https://pubmed.ncbi.nlm.nih.gov/34524225/","https://doi.org/10.1097/jcma.0000000000000618",null],["4","R0044341","R0044341.pdf","free_to_read","nonrandomized_study","Liqing Shi","2021","Association between the systemic treatment of psoriasis and cardiovascular risk","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000001249","https://doi.org/10.1097/cm9.0000000000001249","33605600","https://pubmed.ncbi.nlm.nih.gov/33605600/","https://doi.org/10.1097/cm9.0000000000001249",null],["4","R0046912","R0046912.pdf","free_to_read","nonrandomized_study","Jian Qin Yu","2021","Detection sensitivity of ultrasound scanning vs. clinical examination for insulin injection-related lipohypertrophy","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000001742","https://doi.org/10.1097/cm9.0000000000001742","34561336","https://pubmed.ncbi.nlm.nih.gov/34561336/","https://doi.org/10.1097/cm9.0000000000001742",null],["4","R0049640","R0049640.pdf","free_to_read","nonrandomized_study","Joseph Tarnowski","2021","Streamlining and optimizing viral vector bioprocess and analytical development","Cell and Gene Therapy Insights","BioInsights Publishing, Ltd.","10.18609/cgti.2020.188","https://doi.org/10.18609/cgti.2020.188",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18609/cgti.2020.188",null],["4","R0051840","R0051840.pdf","free_to_read","nonrandomized_study","Xiaoling Cai","2021","Characteristics, treatment patterns, and glycemic control of older type 2 diabetes mellitus patients in China","Chinese Medical Journal","Ovid Technologies (Wolters Kluwer Health)","10.1097/cm9.0000000000001674","https://doi.org/10.1097/cm9.0000000000001674","34406148","https://pubmed.ncbi.nlm.nih.gov/34406148/","https://doi.org/10.1097/cm9.0000000000001674",null],["4","R0052958","R0052958.pdf","free_to_read","nonrandomized_study","Thomas E. Yates","2021","Exercise, Pharmaceutical Therapies and Type 2 Diabetes: Looking beyond Glycemic Control to Whole Body Health and Function","Translational Medicine and Exercise Prescription","Scilight Press Pty Ltd","10.53941/tmep.v1i1.33","https://doi.org/10.53941/tmep.v1i1.33",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.53941/tmep.v1i1.33",null],["4","R0005945","R0005945.pdf","open_download_failed","nonrandomized_study","Kaneto H","2020","Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14095","https://doi.org/10.1111/dom.14095","32436323","https://pubmed.ncbi.nlm.nih.gov/32436323/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14095",null],["4","R0008235","R0008235.pdf","open_download_failed","nonrandomized_study","Boye KS","2020","The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2020.06.019","https://doi.org/10.1016/j.clinthera.2020.06.019","32741645","https://pubmed.ncbi.nlm.nih.gov/32741645/","http://www.clinicaltherapeutics.com/article/S0149291820303295/pdf",null],["4","R0008384","R0008384.pdf","open_download_failed","nonrandomized_study","Pradhan R","2020","Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(19)30382-1","https://doi.org/10.1016/s2213-8587(19)30382-1","31806579","https://pubmed.ncbi.nlm.nih.gov/31806579/","https://www.thelancet.com/pdfs/journals/landia/PIIS2213-8587(19)30382-1.pdf",null],["4","R0008530","R0008530.pdf","open_download_failed","nonrandomized_study","Sciannameo V","2020","Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13962","https://doi.org/10.1111/dom.13962","31943710","https://pubmed.ncbi.nlm.nih.gov/31943710/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13962",null],["4","R0008868","R0008868.pdf","free_to_read","nonrandomized_study","Caparrotta TM","2020","Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.","Diabetes care","American Diabetes Association","10.2337/dc20-0120","https://doi.org/10.2337/dc20-0120","32581068","https://pubmed.ncbi.nlm.nih.gov/32581068/","https://discovery.dundee.ac.uk/en/publications/11798f26-74ba-42c0-97dc-5cc97e1dded2",null],["4","R0009450","R0009450.pdf","open_download_failed","nonrandomized_study","Pineda ED","2020","Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2020.26.5.610","https://doi.org/10.18553/jmcp.2020.26.5.610","32347181","https://pubmed.ncbi.nlm.nih.gov/32347181/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2020.26.5.610",null],["4","R0009999","R0009999.pdf","open_download_failed","nonrandomized_study","van Schaik J","2020","Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.","Obesity facts","S. Karger AG","10.1159/000509302","https://doi.org/10.1159/000509302","32781455","https://pubmed.ncbi.nlm.nih.gov/32781455/","https://www.karger.com/Article/Pdf/509302",null],["4","R0010821","R0010821.pdf","free_to_read","nonrandomized_study","Brunton SA","2020","GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1798099","https://doi.org/10.1080/00325481.2020.1798099","32815454","https://pubmed.ncbi.nlm.nih.gov/32815454/","https://doi.org/10.1080/00325481.2020.1798099",null],["4","R0011633","R0011633.pdf","open_download_failed","nonrandomized_study","Yang JY","2020","Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2020.107706","https://doi.org/10.1016/j.jdiacomp.2020.107706","32843283","https://pubmed.ncbi.nlm.nih.gov/32843283/","https://doi.org/10.17615/43yc-q543",null],["4","R0011871","R0011871.pdf","free_to_read","nonrandomized_study","Torre C","2020","Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14168","https://doi.org/10.1111/dme.14168","31692117","https://pubmed.ncbi.nlm.nih.gov/31692117/","https://dspace.library.uu.nl/handle/1874/411163",null],["4","R0012171","R0012171.pdf","open_download_failed","nonrandomized_study","Jerlhag E","2020","Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.","Brain research","Elsevier BV","10.1016/j.brainres.2019.146562","https://doi.org/10.1016/j.brainres.2019.146562","31759971","https://pubmed.ncbi.nlm.nih.gov/31759971/","https://www.sciencedirect.com/science/article/pii/S000689931930616X/pdf",null],["4","R0012850","R0012850.pdf","open_download_failed","nonrandomized_study","Mody R","2020","Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2020.09.011","https://doi.org/10.1016/j.clinthera.2020.09.011","33256915","https://pubmed.ncbi.nlm.nih.gov/33256915/","http://www.clinicaltherapeutics.com/article/S0149291820304616/pdf",null],["4","R0014570","R0014570.pdf","open_download_failed","nonrandomized_study","Ferrannini G","2020","Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.","Diabetes care","American Diabetes Association","10.2337/dc19-2165","https://doi.org/10.2337/dc19-2165","32079627","https://pubmed.ncbi.nlm.nih.gov/32079627/","https://diabetesjournals.org/care/article-pdf/43/4/726/532361/dc192165.pdf",null],["4","R0014612","R0014612.pdf","open_download_failed","nonrandomized_study","Zhang H","2020","Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2020.26.11.1434","https://doi.org/10.18553/jmcp.2020.26.11.1434","33119450","https://pubmed.ncbi.nlm.nih.gov/33119450/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2020.26.11.1434",null],["4","R0019085","R0019085.pdf","open_download_failed","nonrandomized_study","Fralick M","2020","Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2019.11.004","https://doi.org/10.1016/j.jval.2019.11.004","32327160","https://pubmed.ncbi.nlm.nih.gov/32327160/","http://www.valueinhealthjournal.com/article/S1098301520300498/pdf",null],["4","R0019294","R0019294.pdf","free_to_read","nonrandomized_study","Courtney CM","2020","Alterations in pancreatic islet cell function in response to small bowel resection.","American journal of physiology. Gastrointestinal and liver physiology","American Physiological Society","10.1152/ajpgi.00282.2019","https://doi.org/10.1152/ajpgi.00282.2019","32463335","https://pubmed.ncbi.nlm.nih.gov/32463335/","https://www.ncbi.nlm.nih.gov/pmc/articles/7468758",null],["4","R0020261","R0020261.pdf","open_download_failed","nonrandomized_study","Bayram E","2020","Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/awaa287","https://doi.org/10.1093/brain/awaa287","33103730","https://pubmed.ncbi.nlm.nih.gov/33103730/","https://academic.oup.com/brain/article-pdf/143/10/2868/34032411/awaa287.pdf",null],["4","R0021522","R0021522.pdf","open_download_failed","nonrandomized_study","Janssen LGM","2020","Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2020.154167","https://doi.org/10.1016/j.metabol.2020.154167","31982480","https://pubmed.ncbi.nlm.nih.gov/31982480/","http://www.metabolismjournal.com/article/S0026049520300317/pdf","ClinicalTrials.gov:NCT03002675"],["4","R0022696","R0022696.pdf","free_to_read","nonrandomized_study","Zekarias K","2020","Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2019.107477","https://doi.org/10.1016/j.jdiacomp.2019.107477","31711841","https://pubmed.ncbi.nlm.nih.gov/31711841/","https://www.ncbi.nlm.nih.gov/pmc/articles/6920559",null],["4","R0023010","R0023010.pdf","open_download_failed","nonrandomized_study","Müller N","2020","Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14294","https://doi.org/10.1111/dme.14294","32145093","https://pubmed.ncbi.nlm.nih.gov/32145093/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.14294",null],["4","R0023105","R0023105.pdf","free_to_read","nonrandomized_study","Wang T","2020","Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus.","Journal of clinical pharmacy and therapeutics","Wiley","10.1111/jcpt.13134","https://doi.org/10.1111/jcpt.13134","32176827","https://pubmed.ncbi.nlm.nih.gov/32176827/",null,null],["4","R0023775","R0023775.pdf","free_to_read","nonrandomized_study","Gudin B","2020","Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.","Therapie","Elsevier BV","10.1016/j.therap.2020.02.024","https://doi.org/10.1016/j.therap.2020.02.024","32418731","https://pubmed.ncbi.nlm.nih.gov/32418731/","https://doi.org/10.1016/j.therap.2020.02.024",null],["4","R0023955","R0023955.pdf","open_download_failed","nonrandomized_study","Liu D","2020","Characterization of on-target adverse events caused by TRK inhibitor therapy.","Annals of oncology : official journal of the European Society for Medical Oncology","Elsevier BV","10.1016/j.annonc.2020.05.006","https://doi.org/10.1016/j.annonc.2020.05.006","32422171","https://pubmed.ncbi.nlm.nih.gov/32422171/","http://www.annalsofoncology.org/article/S0923753420398203/pdf",null],["4","R0025011","R0025011.pdf","no_doi","nonrandomized_study","Vitz M","2020","New Zealand may finally get funded access to diabetes drugs which reduce cardiovascular events and progression of kidney disease: an audit of proposed PHARMAC criteria compared with international guidelines.","The New Zealand medical journal",null,null,"https://doi.org/","33032305","https://pubmed.ncbi.nlm.nih.gov/33032305/",null,null],["4","R0025071","R0025071.pdf","free_to_read","nonrandomized_study","Jensen MH","2020","Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users.","Diabetes care","American Diabetes Association","10.2337/dc19-2535","https://doi.org/10.2337/dc19-2535","32238426","https://pubmed.ncbi.nlm.nih.gov/32238426/",null,null],["4","R0025689","R0025689.pdf","open_download_failed","nonrandomized_study","Vaduganathan M","2020","Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2019.12.015","https://doi.org/10.1016/j.jchf.2019.12.015","32387066","https://pubmed.ncbi.nlm.nih.gov/32387066/","https://www.sciencedirect.com/science/article/pii/S2213177920300950/pdf",null],["4","R0026715","R0026715.pdf","open_download_failed","nonrandomized_study","Squadrito F","2020","Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2020.110320","https://doi.org/10.1016/j.biopha.2020.110320","32502842","https://pubmed.ncbi.nlm.nih.gov/32502842/","https://www.sciencedirect.com/science/article/pii/S0753332220305126?via%3Dihub",null],["4","R0026867","R0026867.pdf","free_to_read","nonrandomized_study","Bowker N","2020","Investigating the role of inflammatory biomarkers and incretins in the aetiology of type 2 diabetes and coronary heart disease using human genetics","University of Cambridge",null,"10.17863/cam.70467","https://doi.org/10.17863/cam.70467",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0028517","R0028517.pdf","free_to_read","nonrandomized_study","Hale PM","2020","Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry.","Thyroid : official journal of the American Thyroid Association","SAGE Publications","10.1089/thy.2019.0591","https://doi.org/10.1089/thy.2019.0591","32316860","https://pubmed.ncbi.nlm.nih.gov/32316860/","https://doi.org/10.1089/thy.2019.0591",null],["4","R0028529","R0028529.pdf","free_to_read","nonrandomized_study","Sivitz WI","2020","Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.","Diabetes care","American Diabetes Association","10.2337/dc19-1769","https://doi.org/10.2337/dc19-1769","32139384","https://pubmed.ncbi.nlm.nih.gov/32139384/","https://www.ncbi.nlm.nih.gov/pmc/articles/7171946","ClinicalTrials.gov:NCT01794143"],["4","R0028547","R0028547.pdf","free_to_read","nonrandomized_study","Li X","2020","Anorectic state of obesity medications in the United States. Are leaner times ahead?","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2019.1692815","https://doi.org/10.1080/14656566.2019.1692815","31762335","https://pubmed.ncbi.nlm.nih.gov/31762335/","https://www.ncbi.nlm.nih.gov/pmc/articles/6980700",null],["4","R0028604","R0028604.pdf","open_download_failed","nonrandomized_study","Stoyanova D","2020","Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13915","https://doi.org/10.1111/dme.13915","30701607","https://pubmed.ncbi.nlm.nih.gov/30701607/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.13915",null],["4","R0030368","R0030368.pdf","free_to_read","nonrandomized_study","Secrest MH","2020","A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.4878","https://doi.org/10.1002/pds.4878","31464069","https://pubmed.ncbi.nlm.nih.gov/31464069/",null,null],["4","R0030857","R0030857.pdf","no_doi","nonrandomized_study","Ghanshyam Mali","2020","Pancreatic and Thyroid Cancer Related to Exenatide and Liraglutide Treatment: A Post marketing Analysis of Spontaneous Cases Reported in Eudra Vigilance Database","Journal of Drug Delivery and Therapeutics",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0030952","R0030952.pdf","no_doi","nonrandomized_study","강은석","2020","Are the SGLT2 inhibitor and GLP-1 RA effective in primary CVD prevention?","대한당뇨병학회 학술발표논문집",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037002","R0037002.pdf","no_doi","nonrandomized_study","Meor Azraai","2020","Clinical Cardiology Congress 2020: An Audit of Glucose Lowering Therapies In Patients With Type 2 Diabetes And Hospitalisation for Heart Failure - Meor Azraai - The Royal Melbourne Hospital and NorthWestern Mental Health.",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0039473","R0039473.pdf","free_to_read","nonrandomized_study","Murray Esler","2020","Reply: Possible impact of membrane ACE2 expression on COVID-19 infection","Journal of Hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/hjh.0000000000002484","https://doi.org/10.1097/hjh.0000000000002484","32371814","https://pubmed.ncbi.nlm.nih.gov/32371814/","https://www.ncbi.nlm.nih.gov/pmc/articles/7236858","ClinicalTrials.gov:NCT04312009"],["4","R0039843","R0039843.pdf","free_to_read","nonrandomized_study","SanjayKumar Bhadada","2020","Diabetes mellitus and COVID-19: The ominous duo","International Journal of Noncommunicable Diseases","Ovid Technologies (Wolters Kluwer Health)","10.4103/jncd.jncd_65_20","https://doi.org/10.4103/jncd.jncd_65_20",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jncd.jncd_65_20",null],["4","R0040412","R0040412.pdf","no_doi","nonrandomized_study","Briukhanova, T. O.","2020","Патофізіологічні механізми прогресування та фатальних ускладнень коронавірусної хвороби (COVID-19) у пацієнтів з цукровим діабетом","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043203","R0043203.pdf","no_doi","nonrandomized_study","Elisabeth H.M. Paiman","2020","Phenotyping cardiometabolic disease with magnetic resonance techniques","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044760","R0044760.pdf","free_to_read","nonrandomized_study","Francesco Giorgino","2020","PDB3 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-Month Analysis Results","Value in Health","Elsevier BV","10.1016/j.jval.2020.08.600","https://doi.org/10.1016/j.jval.2020.08.600",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2020.08.600",null],["4","R0046097","R0046097.pdf","no_doi","nonrandomized_study","聡 前川","2020","A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0046785","R0046785.pdf","no_doi","nonrandomized_study","최영재","2020","정신건강의학과 환자에서의 Liraglutide의 효과 및 안전성","신경정신의학",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048575","R0048575.pdf","free_to_read","nonrandomized_study","Caparrotta Thomas M","2020","Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland",null,"American Diabetes Association","10.2337/figshare.12167802.v1","https://doi.org/10.2337/figshare.12167802.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.12167802.v1",null],["4","R0048844","R0048844.pdf","free_to_read","nonrandomized_study","Michelle Lai","2020","PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH","Value in Health","Elsevier BV","10.1016/j.jval.2020.04.365","https://doi.org/10.1016/j.jval.2020.04.365",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2020.04.365",null],["4","R0049049","R0049049.pdf","free_to_read","nonrandomized_study","Thomas SJ Crabtree","2020","The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.239","https://doi.org/10.15277/bjd.2020.239",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.239",null],["4","R0049088","R0049088.pdf","free_to_read","nonrandomized_study","Bassam Mahfouz Ayoub","2020","Multifaceted repurposing of Flozins, Glitazones, Gliptins and GLP-1 agonists as potential Pluritherapeutic agents","Research Journal of Pharmacy and Technology","A and V Publications","10.5958/0974-360x.2020.00096.7","https://doi.org/10.5958/0974-360x.2020.00096.7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5958/0974-360x.2020.00096.7",null],["4","R0049701","R0049701.pdf","free_to_read","nonrandomized_study","HayderMutter Al-Kuraishy","2020","The associations between retinol binding protein-4 and cardiometabolic profile: Intertwined-intricate relationship","Biomedical and Biotechnology Research Journal (BBRJ)","Ovid Technologies (Wolters Kluwer Health)","10.4103/bbrj.bbrj_6_20","https://doi.org/10.4103/bbrj.bbrj_6_20",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/bbrj.bbrj_6_20",null],["4","R0049867","R0049867.pdf","no_doi","nonrandomized_study","Ruth Brauer","2020","Diabetes medications and risk of Parkinson’s disease: a cohort study of diabetes patients",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050018","R0050018.pdf","free_to_read","nonrandomized_study","Sanjoy Ketan Paul","2020","Comparative Retinopathy Risk in People with Type 2 Diabetes Treated with Post Metformin Second-line Incretin Therapies: Study Based on US Electronic Medical Records","Journal of Diabetes Metabolism and its Complications","Science Repository OU","10.31487/j.jdmc.2020.02.03","https://doi.org/10.31487/j.jdmc.2020.02.03",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31487/j.jdmc.2020.02.03",null],["4","R0051646","R0051646.pdf","free_to_read","nonrandomized_study","Anca Pantea Stoian","2020","Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management","Metabolic Syndrome and Related Disorders","SAGE Publications","10.1089/met.2020.0037","https://doi.org/10.1089/met.2020.0037","32271125","https://pubmed.ncbi.nlm.nih.gov/32271125/","https://www.ncbi.nlm.nih.gov/pmc/articles/7196360",null],["4","R0052034","R0052034.pdf","free_to_read","nonrandomized_study","Chris Walton","2020","Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.243","https://doi.org/10.15277/bjd.2020.243",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.243",null],["4","R0052630","R0052630.pdf","no_doi","nonrandomized_study","Mohammed A. Alkharaiji","2020","Real-world clinical and service outcomes of pre-bariatric weight loss interventions and post-bariatric outcomes among patients with insulin-treated Type 2 Diabetes living in the UK: public Health and epidemiological approach","Nottingham ePrints (University of Nottingham)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0008234","R0008234.pdf","free_to_read","nonrandomized_study","Ericsson Å","2019","Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2019.1614009","https://doi.org/10.1080/13696998.2019.1614009","31044636","https://pubmed.ncbi.nlm.nih.gov/31044636/","https://doi.org/10.1080/13696998.2019.1614009",null],["4","R0008645","R0008645.pdf","free_to_read","nonrandomized_study","Lajara R","2019","Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2019.1670017","https://doi.org/10.1080/00325481.2019.1670017","31580737","https://pubmed.ncbi.nlm.nih.gov/31580737/","https://doi.org/10.1080/00325481.2019.1670017",null],["4","R0009105","R0009105.pdf","free_to_read","nonrandomized_study","Ueda P","2019","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries.","Diabetes care","American Diabetes Association","10.2337/dc18-2532","https://doi.org/10.2337/dc18-2532","31010872","https://pubmed.ncbi.nlm.nih.gov/31010872/","https://hdl.handle.net/11250/3008593",null],["4","R0009448","R0009448.pdf","free_to_read","nonrandomized_study","Coleman CI","2019","Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.","Journal of comparative effectiveness research","Becaris Publishing Limited","10.2217/cer-2019-0002","https://doi.org/10.2217/cer-2019-0002","31167554","https://pubmed.ncbi.nlm.nih.gov/31167554/","https://doi.org/10.2217/cer-2019-0002",null],["4","R0009546","R0009546.pdf","open_download_failed","nonrandomized_study","Bonaventura A","2019","Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.","Journal of internal medicine","Wiley","10.1111/joim.12890","https://doi.org/10.1111/joim.12890","30888088","https://pubmed.ncbi.nlm.nih.gov/30888088/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/joim.12890",null],["4","R0009878","R0009878.pdf","free_to_read","nonrandomized_study","Schwager Z","2019","Comment on \"Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study\" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2019.01.086","https://doi.org/10.1016/j.jaad.2019.01.086","30738123","https://pubmed.ncbi.nlm.nih.gov/30738123/",null,null],["4","R0010476","R0010476.pdf","open_download_failed","nonrandomized_study","Otto T","2019","Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1538011","https://doi.org/10.1080/03007995.2018.1538011","30328731","https://pubmed.ncbi.nlm.nih.gov/30328731/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1538011?needAccess=true&role=button",null],["4","R0011184","R0011184.pdf","open_download_failed","nonrandomized_study","Patti AM","2019","Impact of Glucose-Lowering Medications on Cardiometabolic Risk in Type 2 Diabetes","Preprints.org","MDPI AG","10.20944/preprints201911.0264.v1","https://doi.org/10.20944/preprints201911.0264.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/201911.0264/v1/download",null],["4","R0013150","R0013150.pdf","open_download_failed","nonrandomized_study","Montvida O","2019","Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13835","https://doi.org/10.1111/dme.13835","30306620","https://pubmed.ncbi.nlm.nih.gov/30306620/","http://hdl.handle.net/11343/284593",null],["4","R0013559","R0013559.pdf","free_to_read","nonrandomized_study","Hemmer A","2019","Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2018.09.007","https://doi.org/10.1016/j.dsx.2018.09.007","30641721","https://pubmed.ncbi.nlm.nih.gov/30641721/","http://hdl.handle.net/2078.1/214452",null],["4","R0013756","R0013756.pdf","open_download_failed","nonrandomized_study","Lee SM","2019","Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.25.3.350","https://doi.org/10.18553/jmcp.2019.25.3.350","30816819","https://pubmed.ncbi.nlm.nih.gov/30816819/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.3.350",null],["4","R0015086","R0015086.pdf","open_download_failed","nonrandomized_study","Canivell S","2019","Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13663","https://doi.org/10.1111/dom.13663","30756446","https://pubmed.ncbi.nlm.nih.gov/30756446/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13663",null],["4","R0017016","R0017016.pdf","free_to_read","nonrandomized_study","Feldman-Billard S","2019","Comment on Wang et al. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care 2018;41:1998-2009.","Diabetes care","American Diabetes Association","10.2337/dc18-1825","https://doi.org/10.2337/dc18-1825","30811336","https://pubmed.ncbi.nlm.nih.gov/30811336/",null,null],["4","R0017414","R0017414.pdf","open_download_failed","nonrandomized_study","King J","2019","Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.25.6.646","https://doi.org/10.18553/jmcp.2019.25.6.646","31134855","https://pubmed.ncbi.nlm.nih.gov/31134855/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.6.646",null],["4","R0017642","R0017642.pdf","open_download_failed","nonrandomized_study","Karkare S","2019","Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.18321","https://doi.org/10.18553/jmcp.2019.18321","30730232","https://pubmed.ncbi.nlm.nih.gov/30730232/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.18321",null],["4","R0018323","R0018323.pdf","open_download_failed","nonrandomized_study","Rogliani P","2019","Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.","Respiratory medicine","Elsevier BV","10.1016/j.rmed.2019.06.015","https://doi.org/10.1016/j.rmed.2019.06.015","31228775","https://pubmed.ncbi.nlm.nih.gov/31228775/","http://www.resmedjournal.com/article/S0954611119302057/pdf",null],["4","R0018818","R0018818.pdf","free_to_read","nonrandomized_study","Dunkley AJ","2019","Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12-month prospective observational study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13690","https://doi.org/10.1111/dom.13690","30843327","https://pubmed.ncbi.nlm.nih.gov/30843327/","https://figshare.com/articles/journal_contribution/Incidence_and_severity_of_hypoglycaemia_in_type_2_diabetes_by_treatment_regimen_a_UK_multi-site_12-month_prospective_observational_study/10227710",null],["4","R0019386","R0019386.pdf","open_download_failed","nonrandomized_study","Brown E","2019","Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.12841","https://doi.org/10.1111/obr.12841","30972878","https://pubmed.ncbi.nlm.nih.gov/30972878/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.12841",null],["4","R0022997","R0022997.pdf","open_download_failed","nonrandomized_study","Kim K","2019","Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.25.3.314","https://doi.org/10.18553/jmcp.2019.25.3.314","30816811","https://pubmed.ncbi.nlm.nih.gov/30816811/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.3.314",null],["4","R0024176","R0024176.pdf","open_download_failed","nonrandomized_study","Torre C","2019","Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2018.11.009","https://doi.org/10.1016/j.pcd.2018.11.009","30573348","https://pubmed.ncbi.nlm.nih.gov/30573348/","http://www.primary-care-diabetes.com/article/S1751991818301517/pdf",null],["4","R0024333","R0024333.pdf","open_download_failed","nonrandomized_study","Knudsen JS","2019","Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.","Journal of diabetes","Wiley","10.1111/1753-0407.12919","https://doi.org/10.1111/1753-0407.12919","30893522","https://pubmed.ncbi.nlm.nih.gov/30893522/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12919",null],["4","R0024446","R0024446.pdf","free_to_read","nonrandomized_study","Pollock RF","2019","A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.","Journal of comparative effectiveness research","Becaris Publishing Limited","10.2217/cer-2018-0073","https://doi.org/10.2217/cer-2018-0073","30644328","https://pubmed.ncbi.nlm.nih.gov/30644328/","https://doi.org/10.2217/cer-2018-0073",null],["4","R0024449","R0024449.pdf","open_download_failed","nonrandomized_study","Gorgojo-Martínez JJ","2019","Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.","International journal of clinical practice","Wiley","10.1111/ijcp.13399","https://doi.org/10.1111/ijcp.13399","31397946","https://pubmed.ncbi.nlm.nih.gov/31397946/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijcp.13399",null],["4","R0025381","R0025381.pdf","open_download_failed","nonrandomized_study","Garry EM","2019","Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2019.25.12.1442","https://doi.org/10.18553/jmcp.2019.25.12.1442","31778623","https://pubmed.ncbi.nlm.nih.gov/31778623/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.12.1442",null],["4","R0027829","R0027829.pdf","open_download_failed","nonrandomized_study","Clegg LE","2019","Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.","Diabetes care","American Diabetes Association","10.2337/dc18-1871","https://doi.org/10.2337/dc18-1871","30523029","https://pubmed.ncbi.nlm.nih.gov/30523029/","https://care.diabetesjournals.org/content/diacare/42/2/318.full.pdf",null],["4","R0028571","R0028571.pdf","free_to_read","nonrandomized_study","Fadini GP","2019","Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.119.012244","https://doi.org/10.1161/jaha.119.012244","31269877","https://pubmed.ncbi.nlm.nih.gov/31269877/","https://doi.org/10.1161/jaha.119.012244",null],["4","R0031696","R0031696.pdf","no_doi","nonrandomized_study","Shizuka Kaneko","2019","The Effectiveness of GLP-1R Agonist Liraglutide within ERAS Protocols",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031915","R0031915.pdf","no_doi","nonrandomized_study","Jeronim Matijević","2019","Analiza prijava sumnji na nuspojave lijekova iz skupine inkretina i SGLT2 inhibitora u Republici Hrvatskoj u razdoblju od 2010. do 2018. godine",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032469","R0032469.pdf","no_doi","nonrandomized_study","Eyk, H.J. van","2019","Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0034259","R0034259.pdf","no_doi","nonrandomized_study","Chaicharn Deerochanawong","2019","S1-2 : The burden of diabetes and diabetes care in Thailand",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037280","R0037280.pdf","no_doi","nonrandomized_study","Michael Fralick","2019","Sodium Glucose co-Transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus: Assessing their Safety and Effectiveness using Real-world Data","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042048","R0042048.pdf","no_doi","nonrandomized_study","Almarhoon, Zahra M, B.S.","2019","Geographic Variation in the Utilization of Antihyperglycemic Therapies in the U.S. Medicaid Program at State-Level Using Geographic Information System","OhioLink ETD Center (Ohio Library and Information Network)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043626","R0043626.pdf","free_to_read","nonrandomized_study","Thomas Ulahannan","2019","MON-166 Excess Cardiovascular Events Despite Good Glycaemic Control","Journal of the Endocrine Society","The Endocrine Society","10.1210/js.2019-mon-166","https://doi.org/10.1210/js.2019-mon-166",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/js.2019-mon-166",null],["4","R0043795","R0043795.pdf","free_to_read","nonrandomized_study","Muhammad Shahzeb Khan","2019","Heart failure prevention with sodium‐glucose cotransporter 2 inhibitors","Journal of Diabetes","Wiley","10.1111/1753-0407.12932","https://doi.org/10.1111/1753-0407.12932","31044514","https://pubmed.ncbi.nlm.nih.gov/31044514/","https://www.ncbi.nlm.nih.gov/pmc/articles/6592728",null],["4","R0044208","R0044208.pdf","free_to_read","nonrandomized_study","Jothydev Kesavadev","2019","An evaluation of the prescription pattern of IDegAsp and its clinical outcomes in Indian clinical practice",null,"Morressier","10.26226/morressier.5d9b6232ea541d6ca8493b53","https://doi.org/10.26226/morressier.5d9b6232ea541d6ca8493b53",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/dad7f725-0514-45ee-a4f0-f777f1a79194",null],["4","R0045267","R0045267.pdf","free_to_read","nonrandomized_study","K.C. Chang","2019","PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY","Value in Health","Elsevier BV","10.1016/j.jval.2019.09.890","https://doi.org/10.1016/j.jval.2019.09.890",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2019.09.890",null],["4","R0048106","R0048106.pdf","free_to_read","nonrandomized_study","Malay Parekh","2019","Coronary calcium score predictor of coronary artery disease",null,"Morressier","10.26226/morressier.5d9b6231ea541d6ca8493f8b","https://doi.org/10.26226/morressier.5d9b6231ea541d6ca8493f8b",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/4fb79c82-b194-4f12-8643-155ca19510d9",null],["4","R0048698","R0048698.pdf","free_to_read","nonrandomized_study","Miho Itatani","2019","MON-LB055 A Single Center Experience of Multiple Endocrine Neoplasia Type 1 (MEN1) vs Sporadic Insulinoma: What Can We Learn and Where Are We Going?","Journal of the Endocrine Society","The Endocrine Society","10.1210/js.2019-mon-lb055","https://doi.org/10.1210/js.2019-mon-lb055",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/js.2019-mon-lb055",null],["4","R0049223","R0049223.pdf","free_to_read","nonrandomized_study","Dae Hyun Kim","2019","FRAILTY AND THE EFFECTIVENESS AND SAFETY OF NEW GLUCOSE-LOWERING DRUGS IN OLDER ADULTS WITH TYPE 2 DIABETES","Innovation in Aging","Oxford University Press (OUP)","10.1093/geroni/igz038.2154","https://doi.org/10.1093/geroni/igz038.2154",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/geroni/igz038.2154",null],["4","R0051527","R0051527.pdf","free_to_read","nonrandomized_study","Miao Yu","2019","PDB116 REAL-WORLD ADHERENCE AND PERSISTENCE AMONG ELDERLY PATIENTS WITH T2DM INITIATING DULAGLUTIDE VS. LIRAGLUTIDE OR EXENATIDE ONCE-WEEKLY IN THE US","Value in Health","Elsevier BV","10.1016/j.jval.2019.04.663","https://doi.org/10.1016/j.jval.2019.04.663",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2019.04.663",null],["4","R0052512","R0052512.pdf","free_to_read","nonrandomized_study","Shmuel Levit","2019","Continuous glucose monitoring - proved hypoglycemia in sodium-glucose co-transporter-2 inhibitors - treated type 2 diabetes patients: a link to ketosis development","Pharmacy Formulas","ECO-Vector LLC","10.17816/phf18536","https://doi.org/10.17816/phf18536",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.17816/phf18536",null],["4","R0055279","R0055279.pdf","no_doi","nonrandomized_study","N Alkis","2019","Community pharmacies as platform for collection of real-world evidence of medicines usage explored through a pilot study: From standard T2D medication to treatment with the injectable combination product Xultophy","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0007117","R0007117.pdf","no_doi","nonrandomized_study","Wittbrodt ET","2018","Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.","The American journal of managed care",null,null,"https://doi.org/","29693361","https://pubmed.ncbi.nlm.nih.gov/29693361/",null,"ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01455896; ClinicalTrials.gov:NCT02465515; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT01720446"],["4","R0008619","R0008619.pdf","no_doi","nonrandomized_study","Wittbrodt ET","2018","Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.","The American journal of managed care",null,null,"https://doi.org/","29693362","https://pubmed.ncbi.nlm.nih.gov/29693362/",null,null],["4","R0009974","R0009974.pdf","free_to_read","nonrandomized_study","Douros A","2018","Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.","Diabetes care","American Diabetes Association","10.2337/dc17-2280","https://doi.org/10.2337/dc17-2280","30150234","https://pubmed.ncbi.nlm.nih.gov/30150234/",null,null],["4","R0010023","R0010023.pdf","open_download_failed","nonrandomized_study","Tang T","2018","Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13131","https://doi.org/10.1111/dom.13131","29053203","https://pubmed.ncbi.nlm.nih.gov/29053203/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13131",null],["4","R0014242","R0014242.pdf","free_to_read","nonrandomized_study","Varpuluoma O","2018","Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.","Journal of the American Academy of Dermatology","Elsevier BV","10.1016/j.jaad.2018.05.030","https://doi.org/10.1016/j.jaad.2018.05.030","29803903","https://pubmed.ncbi.nlm.nih.gov/29803903/",null,null],["4","R0014620","R0014620.pdf","free_to_read","nonrandomized_study","Williams DM","2018","Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2018.06.029","https://doi.org/10.1016/j.dsx.2018.06.029","30006093","https://pubmed.ncbi.nlm.nih.gov/30006093/",null,null],["4","R0015974","R0015974.pdf","open_download_failed","nonrandomized_study","Mocarski M","2018","Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2017.17218","https://doi.org/10.18553/jmcp.2017.17218","29406841","https://pubmed.ncbi.nlm.nih.gov/29406841/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2017.17218",null],["4","R0017598","R0017598.pdf","open_download_failed","nonrandomized_study","Mody R","2018","Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2017.1421146","https://doi.org/10.1080/03007995.2017.1421146","29271258","https://pubmed.ncbi.nlm.nih.gov/29271258/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1421146?needAccess=true&role=button",null],["4","R0017826","R0017826.pdf","no_doi","nonrandomized_study","Logan T","2018","Evaluating the managed care implications of longer-acting basal insulin analog therapies.","The American journal of managed care",null,null,"https://doi.org/","29620817","https://pubmed.ncbi.nlm.nih.gov/29620817/",null,null],["4","R0019330","R0019330.pdf","open_download_failed","nonrandomized_study","Montvida O","2018","Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13288","https://doi.org/10.1111/dom.13288","29536608","https://pubmed.ncbi.nlm.nih.gov/29536608/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13288",null],["4","R0020228","R0020228.pdf","free_to_read","nonrandomized_study","Anyanwagu U","2018","Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.","American heart journal","Elsevier BV","10.1016/j.ahj.2017.10.003","https://doi.org/10.1016/j.ahj.2017.10.003","29421011","https://pubmed.ncbi.nlm.nih.gov/29421011/",null,null],["4","R0020546","R0020546.pdf","free_to_read","nonrandomized_study","Buysman EK","2018","Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.","Journal of comparative effectiveness research","Becaris Publishing Limited","10.2217/cer-2017-0032","https://doi.org/10.2217/cer-2017-0032","28814107","https://pubmed.ncbi.nlm.nih.gov/28814107/","https://doi.org/10.2217/cer-2017-0032",null],["4","R0021307","R0021307.pdf","open_download_failed","nonrandomized_study","Boniol M","2018","Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.","Diabetes care","American Diabetes Association","10.2337/dc17-0280","https://doi.org/10.2337/dc17-0280","29146599","https://pubmed.ncbi.nlm.nih.gov/29146599/","https://care.diabetesjournals.org/content/diacare/41/2/286.full.pdf",null],["4","R0022911","R0022911.pdf","open_download_failed","nonrandomized_study","O'Brien MJ","2018","Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2018.6125","https://doi.org/10.1001/jamanetworkopen.2018.6125","30646315","https://pubmed.ncbi.nlm.nih.gov/30646315/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2719133/obrien_2018_oi_180259.pdf",null],["4","R0023365","R0023365.pdf","open_download_failed","nonrandomized_study","Abrahami D","2018","Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.","Epidemiology (Cambridge, Mass.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/ede.0000000000000793","https://doi.org/10.1097/ede.0000000000000793","29283894","https://pubmed.ncbi.nlm.nih.gov/29283894/","http://escholarship.mcgill.ca/downloads/8336h428q",null],["4","R0023572","R0023572.pdf","open_download_failed","nonrandomized_study","Chang HY","2018","Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2018.3034","https://doi.org/10.1001/jamainternmed.2018.3034","30105373","https://pubmed.ncbi.nlm.nih.gov/30105373/","https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2696730/jamainternal_chang_2018_oi_180048.pdf",null],["4","R0023811","R0023811.pdf","open_download_failed","nonrandomized_study","Gamble JM","2018","The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.12.008","https://doi.org/10.1016/j.diabres.2017.12.008","29258886","https://pubmed.ncbi.nlm.nih.gov/29258886/","http://www.diabetesresearchclinicalpractice.com/article/S0168822717314730/pdf",null],["4","R0024296","R0024296.pdf","free_to_read","nonrandomized_study","Haluzík M","2018","Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.","Vnitrni lekarstvi","Solen s.r.o.","10.36290/vnl.2018.053","https://doi.org/10.36290/vnl.2018.053","29791170","https://pubmed.ncbi.nlm.nih.gov/29791170/",null,null],["4","R0024312","R0024312.pdf","free_to_read","nonrandomized_study","Boye KS","2018","Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2018.07.002","https://doi.org/10.1016/j.clinthera.2018.07.002","30093131","https://pubmed.ncbi.nlm.nih.gov/30093131/","https://doi.org/10.1016/j.clinthera.2018.07.002",null],["4","R0024939","R0024939.pdf","open_download_failed","nonrandomized_study","Hotu C","2018","Impact of an integrated diabetes service involving specialist outreach and primary health care on risk factors for micro- and macrovascular diabetes complications in remote Indigenous communities in Australia.","The Australian journal of rural health","Wiley","10.1111/ajr.12426","https://doi.org/10.1111/ajr.12426","29864201","https://pubmed.ncbi.nlm.nih.gov/29864201/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajr.12426",null],["4","R0025763","R0025763.pdf","free_to_read","nonrandomized_study","Lanzinger S","2018","Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.10.011","https://doi.org/10.1016/j.diabres.2018.10.011","30367902","https://pubmed.ncbi.nlm.nih.gov/30367902/","http://nbn-resolving.de/urn:nbn:de:bsz:289-oparu-38135-0",null],["4","R0026253","R0026253.pdf","open_download_failed","nonrandomized_study","Arnold SV","2018","Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).","American heart journal","Elsevier BV","10.1016/j.ahj.2018.05.016","https://doi.org/10.1016/j.ahj.2018.05.016","30015065","https://pubmed.ncbi.nlm.nih.gov/30015065/","https://www.sciencedirect.com/science/article/pii/S0002870318301868",null],["4","R0026592","R0026592.pdf","free_to_read","nonrandomized_study","Shao N","2018","Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.","Andrologia","Wiley","10.1111/and.13039","https://doi.org/10.1111/and.13039","29740874","https://pubmed.ncbi.nlm.nih.gov/29740874/",null,null],["4","R0027993","R0027993.pdf","free_to_read","nonrandomized_study","Doshi JA","2018","Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.","Circulation. Cardiovascular quality and outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/circoutcomes.117.003939","https://doi.org/10.1161/circoutcomes.117.003939","29326146","https://pubmed.ncbi.nlm.nih.gov/29326146/","https://repository.upenn.edu/handle/20.500.14332/38258",null],["4","R0030423","R0030423.pdf","free_to_read","nonrandomized_study","Mcgovern AP","2018","A comparison of medication adherence and persistence across drug classes in people with type 2 diabetes","University of Surrey",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032467","R0032467.pdf","no_doi","nonrandomized_study","Eyk, H. van","2018","CIRCULATING CETP IS NOT RELATED TO THE HEPATIC TRIGLYCERIDE CONTENT: LESSONS FROM A LIRAGLUTIDE INTERVENTION TRIAL AND A POPULATION-BASED COHORT","Leiden Repository (Leiden University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037033","R0037033.pdf","no_doi","nonrandomized_study","Sahar Azharian","2018","Understanding and evaluating cardio-metabolic benefits imposed by surgery, medication and adipose tissue metabolism","Warwick Research Archive Portal (University of Warwick)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041924","R0041924.pdf","no_doi","nonrandomized_study","Abrahami, Devin","2018","Incretin-based drugs and the risk of cholangiocarcinoma among patients with type 2 diabetes","eScholarship@McGill (McGill)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043267","R0043267.pdf","free_to_read","nonrandomized_study","Andrew J. Krentz","2018","Diabetes: learning from the past 25 years and looking to the future","Cardiovascular Endocrinology & Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000161","https://doi.org/10.1097/xce.0000000000000161","31646286","https://pubmed.ncbi.nlm.nih.gov/31646286/","https://doi.org/10.1097/xce.0000000000000161",null],["4","R0043450","R0043450.pdf","free_to_read","nonrandomized_study","Allan J. Collins","2018","Growth of the ESKD Population: Progress or Peril?","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2018111135","https://doi.org/10.1681/asn.2018111135","30559145","https://pubmed.ncbi.nlm.nih.gov/30559145/","https://www.ncbi.nlm.nih.gov/pmc/articles/6317602",null],["4","R0043691","R0043691.pdf","no_doi","nonrandomized_study","Usui, Ryota","2018","Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044196","R0044196.pdf","no_doi","nonrandomized_study","Bellido, Diego.","2018","Intensification of basal insulin therapy with Lixisenatide in patients with Type 2 Diabetes in a real-world setting : the BASAL-LIXI study / Diego Bellido ... et al.","CEU Repositorio Institucional (Fundación Universitaria San Pablo CEU)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044608","R0044608.pdf","free_to_read","nonrandomized_study","Reema Mody","2018","Real-World Comparison of Healthcare Costs Among Patients with Type 2 Diabetes Treated with Dulaglutide Vs. Liraglutide in the United States","Value in Health","Elsevier BV","10.1016/j.jval.2018.04.520","https://doi.org/10.1016/j.jval.2018.04.520",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.04.520",null],["4","R0045153","R0045153.pdf","free_to_read","nonrandomized_study","Reema Mody","2018","Characteristics & Glycemic Response of Patients With Uncontrolled Type 2 Diabetes Initiating Dulaglutide Alone or In Combination with Insulin In US Real World Practice","Value in Health","Elsevier BV","10.1016/j.jval.2018.04.469","https://doi.org/10.1016/j.jval.2018.04.469",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.04.469",null],["4","R0045815","R0045815.pdf","free_to_read","nonrandomized_study","Richard L. Prager","2018","PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING","Value in Health","Elsevier BV","10.1016/j.jval.2018.09.728","https://doi.org/10.1016/j.jval.2018.09.728",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.09.728",null],["4","R0049056","R0049056.pdf","free_to_read","nonrandomized_study","Hermione Clare Price","2018","PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY","Value in Health","Elsevier BV","10.1016/j.jval.2018.09.723","https://doi.org/10.1016/j.jval.2018.09.723",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.09.723",null],["4","R0049363","R0049363.pdf","no_doi","nonrandomized_study","EMILY Z. DUNN","2018","A Retrospective Comparative Analysis on the Effectiveness of Pharmacologic Weight Loss","UKnowledge (University of Kentucky)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049478","R0049478.pdf","free_to_read","nonrandomized_study","Sean Wharton","2018","Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","Value in Health","Elsevier BV","10.1016/j.jval.2018.04.1668","https://doi.org/10.1016/j.jval.2018.04.1668",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2018.04.1668",null],["4","R0050651","R0050651.pdf","free_to_read","nonrandomized_study","Zainab Jassim","2018","Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study","Journal of Pharmaceutical Health Services Research","Oxford University Press (OUP)","10.1111/jphs.12240","https://doi.org/10.1111/jphs.12240",null,"https://pubmed.ncbi.nlm.nih.gov//","https://rgu-repository.worktribe.com/output/1352241",null],["4","R0050680","R0050680.pdf","no_doi","nonrandomized_study","Emmanouela Konstantara","2018","GLP-1 RA treatment: a benefit-risk analysis from a retrospective cohort study","Diabetologia",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0013165","R0013165.pdf","open_download_failed","nonrandomized_study","Singhal M","2017","Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2017.16334","https://doi.org/10.18553/jmcp.2017.16334","28230449","https://pubmed.ncbi.nlm.nih.gov/28230449/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2017.16334",null],["4","R0013267","R0013267.pdf","free_to_read","nonrandomized_study","Bajaj HS","2017","Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).","Diabetes care","American Diabetes Association","10.2337/dc16-1582","https://doi.org/10.2337/dc16-1582","27913575","https://pubmed.ncbi.nlm.nih.gov/27913575/",null,null],["4","R0013369","R0013369.pdf","open_download_failed","nonrandomized_study","Nakatani Y","2017","Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2017.05.009","https://doi.org/10.1016/j.diabet.2017.05.009","28648835","https://pubmed.ncbi.nlm.nih.gov/28648835/","https://www.sciencedirect.com/science/article/pii/S1262363617301076/pdf",null],["4","R0013916","R0013916.pdf","free_to_read","nonrandomized_study","Montvida O","2017","Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12790","https://doi.org/10.1111/dom.12790","27629433","https://pubmed.ncbi.nlm.nih.gov/27629433/",null,null],["4","R0014290","R0014290.pdf","open_download_failed","nonrandomized_study","Suissa S","2017","Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.4107","https://doi.org/10.1002/pds.4107","27610604","https://pubmed.ncbi.nlm.nih.gov/27610604/","http://escholarship.mcgill.ca/downloads/6m311t974",null],["4","R0015561","R0015561.pdf","open_download_failed","nonrandomized_study","Paschou SA","2017","Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-00042","https://doi.org/10.1210/jc.2017-00042","28938433","https://pubmed.ncbi.nlm.nih.gov/28938433/","https://academic.oup.com/jcem/article-pdf/102/10/3621/20619923/jc.2017-00042.pdf",null],["4","R0016431","R0016431.pdf","open_download_failed","nonrandomized_study","Knapen LM","2017","Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12833","https://doi.org/10.1111/dom.12833","27883260","https://pubmed.ncbi.nlm.nih.gov/27883260/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12833",null],["4","R0021063","R0021063.pdf","free_to_read","nonrandomized_study","Lasalvia P","2017","Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.","Value in health regional issues","Elsevier BV","10.1016/j.vhri.2016.10.006","https://doi.org/10.1016/j.vhri.2016.10.006","29254540","https://pubmed.ncbi.nlm.nih.gov/29254540/","https://doi.org/10.1016/j.vhri.2016.10.006",null],["4","R0021072","R0021072.pdf","no_doi","nonrandomized_study","Kondo M","2017","Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-.","The Tokai journal of experimental and clinical medicine",null,null,"https://doi.org/","28413872","https://pubmed.ncbi.nlm.nih.gov/28413872/",null,null],["4","R0023735","R0023735.pdf","open_download_failed","nonrandomized_study","Murphy ME","2017","Geographical variation in anti-diabetic prescribing in Ireland in 2013 and 2014: a cross-sectional analysis.","Family practice","Oxford University Press (OUP)","10.1093/fampra/cmx036","https://doi.org/10.1093/fampra/cmx036","28472488","https://pubmed.ncbi.nlm.nih.gov/28472488/","https://academic.oup.com/fampra/article-pdf/34/5/587/20138387/cmx036.pdf",null],["4","R0026210","R0026210.pdf","open_download_failed","nonrandomized_study","Holden SE","2017","Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12916","https://doi.org/10.1111/dom.12916","28218819","https://pubmed.ncbi.nlm.nih.gov/28218819/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12916",null],["4","R0027397","R0027397.pdf","free_to_read","nonrandomized_study","Trescoli Serrano C","2017","REAL WORLD SAFETY AND EFFICACY OF SGLT-2 INHIBITORS IN ELDERLY TYPE 2 DIABETIC PATIENTS","Innovation in aging",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0028015","R0028015.pdf","open_download_failed","nonrandomized_study","Brekke L","2017","The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2017.05.019","https://doi.org/10.1016/j.jval.2017.05.019","29241884","https://pubmed.ncbi.nlm.nih.gov/29241884/","http://www.valueinhealthjournal.com/article/S1098301517302723/pdf",null],["4","R0031490","R0031490.pdf","no_doi","nonrandomized_study","Beutel Darrow","2017","A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs","Digital Commons @ Butler University (Butler University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032003","R0032003.pdf","no_doi","nonrandomized_study","Humamuddin","2017","Penapisan Fitokimia Indonesia sebagai Agonis Reseptor Glucagon-Like Peptide-1 In Silico pada Diabetes Melitus Tipe-2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036365","R0036365.pdf","no_doi","nonrandomized_study","Rábai, Miklós","2017","Az antidiabetikumok hatása a kardiovaszkuláris biztonságosságra és a szívelégtelenségre - ahogy a kardiológus látja [Effects of antidiabetics on cardiovascular safety and heart failure – from the point of view of a cardiologist]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043324","R0043324.pdf","free_to_read","nonrandomized_study","Carlos Trescolí Serrano","2017","REAL WORLD SAFETY AND EFFICACY OF SGLT-2 INHIBITORS IN ELDERLY TYPE 2 DIABETIC PATIENTS","Innovation in Aging","Oxford University Press (OUP)","10.1093/geroni/igx004.588","https://doi.org/10.1093/geroni/igx004.588",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/geroni/igx004.588",null],["4","R0043442","R0043442.pdf","free_to_read","nonrandomized_study","Andrew J. Krentz","2017","Oxford Diabetes Symposium 2017","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000137","https://doi.org/10.1097/xce.0000000000000137","31646133","https://pubmed.ncbi.nlm.nih.gov/31646133/","https://www.ncbi.nlm.nih.gov/pmc/articles/6768524",null],["4","R0043525","R0043525.pdf","free_to_read","nonrandomized_study","Hassanein Mohamed","2017","Characteristics and pattern of care of type 1 and 2 diabetic patients during Ramadan: an international prospective study",null,"Morressier","10.26226/morressier.59d51840d462b80296ca2da2","https://doi.org/10.26226/morressier.59d51840d462b80296ca2da2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/19b0c8fe-0e5a-49e2-b312-a0e59968e09a",null],["4","R0043529","R0043529.pdf","free_to_read","nonrandomized_study","Jie Zhang","2017","Vitamin D status connect insulin resistance and bone turnover in Chinese non-osteoporosis patients with type 2 diabetes",null,"Morressier","10.26226/morressier.59d51846d462b80296ca2e70","https://doi.org/10.26226/morressier.59d51846d462b80296ca2e70",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/35c753fe-5a87-4221-b083-553afdcadcff",null],["4","R0043670","R0043670.pdf","free_to_read","nonrandomized_study","SanjayKumar Bhadada","2017","Medical nutrition therapy in type 1 diabetes mellitus","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijem.ijem_539_17","https://doi.org/10.4103/ijem.ijem_539_17","28989867","https://pubmed.ncbi.nlm.nih.gov/28989867/","https://doi.org/10.4103/ijem.ijem_539_17",null],["4","R0044162","R0044162.pdf","free_to_read","nonrandomized_study","Jabbar Abdul","2017","Patterns and trends in insulin intensification among patients with T2DM in Middle East and North Africa Region",null,"Morressier","10.26226/morressier.59d51844d462b80296ca3880","https://doi.org/10.26226/morressier.59d51844d462b80296ca3880",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/4f071fbc-aabb-4880-8f77-4f3c9bbce66d",null],["4","R0044199","R0044199.pdf","free_to_read","nonrandomized_study","Samit Ghosal","2017","Liraglutide and dulaglutide in addition to SGLT-2i and metformin in Indian T2DM: a retrospective observational study",null,"Morressier","10.26226/morressier.5a004583d462b80296ca39c3","https://doi.org/10.26226/morressier.5a004583d462b80296ca39c3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/a12f5958-2640-4156-ba1b-9a361f7e047b",null],["4","R0044241","R0044241.pdf","free_to_read","nonrandomized_study","Daisuke Ikeda","2017","Evaluation of insulin secretion by glucagon stimulation test predicts long-term glycemic control in type 2 diabetes",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3c48","https://doi.org/10.26226/morressier.59d51847d462b80296ca3c48",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/bad0484e-cdfc-4197-8da5-2317ba1ab390",null],["4","R0044312","R0044312.pdf","free_to_read","nonrandomized_study","Bilic-Curcic Ines","2017","Lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with insulin",null,"Morressier","10.26226/morressier.59d51845d462b80296ca39a5","https://doi.org/10.26226/morressier.59d51845d462b80296ca39a5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/480e15c0-8895-4ab7-bf06-52d2fc2d1ba7",null],["4","R0044350","R0044350.pdf","free_to_read","nonrandomized_study","Arnold V Suzanne","2017","Management of patients with diabetes and heart failure with reduced ejection fraction: A cross-country comparison",null,"Morressier","10.26226/morressier.59d5184cd462b80296ca33e7","https://doi.org/10.26226/morressier.59d5184cd462b80296ca33e7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/8f775333-09e4-4f6a-9fe2-0ef4b3e524e6",null],["4","R0044698","R0044698.pdf","no_doi","nonrandomized_study","Nithya Sukumar","2017","Novel biomarkers associated with gestational diabetes mellitus and metabolic outcomes of pregnancy","Warwick Research Archive Portal (University of Warwick)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045591","R0045591.pdf","free_to_read","nonrandomized_study","Gaurav Puri","2017","Directly observed Rx use of exenatide LAR in a unique Aboriginal and Torres Strait Islanders population in Australia",null,"Morressier","10.26226/morressier.59d51840d462b80296ca2d9d","https://doi.org/10.26226/morressier.59d51840d462b80296ca2d9d",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/d23e8b50-5854-492b-a1e0-2ba10ccf696b",null],["4","R0048080","R0048080.pdf","free_to_read","nonrandomized_study","Valeria Pechtner","2017","A New Approach to Drug Therapy: Fc-Fusion Technology","Primary Health Care Open Access","OMICS Publishing Group","10.4172/2167-1079.1000255","https://doi.org/10.4172/2167-1079.1000255",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4172/2167-1079.1000255",null],["4","R0050786","R0050786.pdf","free_to_read","nonrandomized_study","Pedro Mezquita","2017","Comparison of The Long-Term Cost-Effectiveness of Ideglira Versus Multiple Daily Insulin Injections In The Spanish Setting Using Real-World Clinical Data","Value in Health","Elsevier BV","10.1016/j.jval.2017.08.458","https://doi.org/10.1016/j.jval.2017.08.458",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2017.08.458",null],["4","R0052387","R0052387.pdf","free_to_read","nonrandomized_study","Sarah K. Lyons","2017","Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries","Diabetes Care","American Diabetes Association","10.2337/dc17-0403","https://doi.org/10.2337/dc17-0403","28768688","https://pubmed.ncbi.nlm.nih.gov/28768688/","https://www.ncbi.nlm.nih.gov/pmc/articles/6463738",null],["4","R0012406","R0012406.pdf","free_to_read","nonrandomized_study","McAdam-Marx C","2016","Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2016.11.003","https://doi.org/10.1016/j.clinthera.2016.11.003","27889301","https://pubmed.ncbi.nlm.nih.gov/27889301/","https://doi.org/10.1016/j.clinthera.2016.11.003",null],["4","R0012444","R0012444.pdf","open_download_failed","nonrandomized_study","Luo G","2016","Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?","British journal of clinical pharmacology","Wiley","10.1111/bcp.12777","https://doi.org/10.1111/bcp.12777","27099876","https://pubmed.ncbi.nlm.nih.gov/27099876/","https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12777",null],["4","R0015618","R0015618.pdf","open_download_failed","nonrandomized_study","Pizzimenti V","2016","Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.","Journal of clinical pharmacy and therapeutics","Hindawi Limited","10.1111/jcpt.12373","https://doi.org/10.1111/jcpt.12373","26936090","https://pubmed.ncbi.nlm.nih.gov/26936090/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcpt.12373",null],["4","R0015887","R0015887.pdf","open_download_failed","nonrandomized_study","Standl E","2016","Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.","Circulation research","Ovid Technologies (Wolters Kluwer Health)","10.1161/circresaha.116.306924","https://doi.org/10.1161/circresaha.116.306924","27230644","https://pubmed.ncbi.nlm.nih.gov/27230644/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.116.306924?download=true",null],["4","R0016046","R0016046.pdf","open_download_failed","nonrandomized_study","Anderson SL","2016","Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness.","Therapeutic advances in chronic disease","SAGE Publications","10.1177/2040622315609312","https://doi.org/10.1177/2040622315609312","26770666","https://pubmed.ncbi.nlm.nih.gov/26770666/","https://journals.sagepub.com/doi/pdf/10.1177/2040622315609312",null],["4","R0016443","R0016443.pdf","open_download_failed","nonrandomized_study","Janzen KM","2016","GLP-1 Agonists in Type 1 Diabetes Mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028016651279","https://doi.org/10.1177/1060028016651279","27252246","https://pubmed.ncbi.nlm.nih.gov/27252246/","https://digitalcommons.butler.edu/cgi/viewcontent.cgi?article=1189&context=cophs_papers",null],["4","R0018056","R0018056.pdf","open_download_failed","nonrandomized_study","Kannan S","2016","Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.","Journal of diabetes","Wiley","10.1111/1753-0407.12301","https://doi.org/10.1111/1753-0407.12301","25929426","https://pubmed.ncbi.nlm.nih.gov/25929426/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12301",null],["4","R0018600","R0018600.pdf","open_download_failed","nonrandomized_study","Hicks BM","2016","Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.i5340","https://doi.org/10.1136/bmj.i5340","27797785","https://pubmed.ncbi.nlm.nih.gov/27797785/","https://www.bmj.com/content/bmj/355/bmj.i5340.full.pdf",null],["4","R0023060","R0023060.pdf","open_download_failed","nonrandomized_study","Durden E","2016","Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2015.1131703","https://doi.org/10.3111/13696998.2015.1131703","26653068","https://pubmed.ncbi.nlm.nih.gov/26653068/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1131703?needAccess=true&role=button",null],["4","R0023282","R0023282.pdf","open_download_failed","nonrandomized_study","Bennett D","2016","Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.","Diabetology international","Springer Science and Business Media LLC","10.1007/s13340-016-0261-3","https://doi.org/10.1007/s13340-016-0261-3","30603289","https://pubmed.ncbi.nlm.nih.gov/30603289/","https://link.springer.com/content/pdf/10.1007/s13340-016-0261-3.pdf",null],["4","R0023671","R0023671.pdf","free_to_read","nonrandomized_study","Faillie JL","2016","Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.","JAMA internal medicine","American Medical Association (AMA)","10.1001/jamainternmed.2016.1531","https://doi.org/10.1001/jamainternmed.2016.1531","27478902","https://pubmed.ncbi.nlm.nih.gov/27478902/","https://hal.science/hal-01836887",null],["4","R0024230","R0024230.pdf","open_download_failed","nonrandomized_study","Leung M","2016","Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164116629352","https://doi.org/10.1177/1479164116629352","26993495","https://pubmed.ncbi.nlm.nih.gov/26993495/","https://journals.sagepub.com/doi/pdf/10.1177/1479164116629352",null],["4","R0024487","R0024487.pdf","open_download_failed","nonrandomized_study","Cai J","2016","Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2016.1208208","https://doi.org/10.1080/13696998.2016.1208208","27356271","https://pubmed.ncbi.nlm.nih.gov/27356271/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1208208?needAccess=true&role=button",null],["4","R0025538","R0025538.pdf","free_to_read","nonrandomized_study","Ashraghi MR","2016","Parkinson's Disease, Diabetes and Cognitive Impairment.","Recent patents on endocrine, metabolic & immune drug discovery","Bentham Science Publishers Ltd.","10.2174/1872214810999160628105549","https://doi.org/10.2174/1872214810999160628105549","27396477","https://pubmed.ncbi.nlm.nih.gov/27396477/","https://kclpure.kcl.ac.uk/portal/en/publications/c419d8cd-3dd3-4d16-baf8-2f9e26f121a6",null],["4","R0026041","R0026041.pdf","open_download_failed","nonrandomized_study","Saponaro F","2016","Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2016.04.046","https://doi.org/10.1016/j.diabres.2016.04.046","27485853","https://pubmed.ncbi.nlm.nih.gov/27485853/","http://www.diabetesresearchclinicalpractice.com/article/S0168822716301103/pdf",null],["4","R0026231","R0026231.pdf","free_to_read","nonrandomized_study","Anyanwagu U","2016","Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.","Heart (British Cardiac Society)","BMJ","10.1136/heartjnl-2015-309164","https://doi.org/10.1136/heartjnl-2015-309164","27217068","https://pubmed.ncbi.nlm.nih.gov/27217068/",null,null],["4","R0026248","R0026248.pdf","no_doi","nonrandomized_study","Ponzani P","2016","Effectiveness and safety of liraglutide after three years of treatment.","Minerva endocrinologica",null,null,"https://doi.org/","26878560","https://pubmed.ncbi.nlm.nih.gov/26878560/",null,null],["4","R0027909","R0027909.pdf","free_to_read","nonrandomized_study","Hampp C","2016","Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-015-0382-9","https://doi.org/10.1007/s40264-015-0382-9","26798052","https://pubmed.ncbi.nlm.nih.gov/26798052/","https://www.ncbi.nlm.nih.gov/pmc/articles/4752375",null],["4","R0028739","R0028739.pdf","open_download_failed","nonrandomized_study","Bain S","2016","Looking to a future of improved diabetes management: interview with Professor Steve Bain.","Future science OA","Informa UK Limited","10.4155/fsoa-2016-0069","https://doi.org/10.4155/fsoa-2016-0069","28116136","https://pubmed.ncbi.nlm.nih.gov/28116136/","https://www.future-science.com/doi/pdf/10.4155/fsoa-2016-0069",null],["4","R0030729","R0030729.pdf","no_doi","nonrandomized_study","Chanchal Kumar","2016","A Review on Management of Blood Glucose in Type 2 Diabetes Mellitus","International Journal of Plant Animal and Environmental Sciences",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031037","R0031037.pdf","no_doi","nonrandomized_study","Ronan Roussel","2016","Low rate of intensification in type 2 diabetic patients inadequately controlled with basal insulin: the INTERDIA study","Diabetes Management",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031285","R0031285.pdf","no_doi","nonrandomized_study","Pernille Sønderby","2016","Solution behaviour of Human Serum Albumin and GLP-1variants",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031681","R0031681.pdf","no_doi","nonrandomized_study","Karla Mišur Milinković","2016","Sponzoriranje i promocija lijekova : usporedba javnih podataka u SAD-u 2013. i 2014. godine",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031705","R0031705.pdf","free_to_read","nonrandomized_study","Soumyabrata Roy Chaudhuri","2016","Short Term Outcomes of Low Dose Liraglutide in Obese Non Diabetic Indian Subjects-A Real World Experience","Diabetes & Obesity International Journal","Medwin Publishers","10.23880/doij-16000140","https://doi.org/10.23880/doij-16000140",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.23880/doij-16000140",null],["4","R0031805","R0031805.pdf","free_to_read","nonrandomized_study","Roberta Pirolo","2016","The Difficulty of Diabetic Therapy: An Observational Retrospective Study from Actual Clinical Practice","Advances in Pharmacoepidemiology & Drug Safety","OMICS Publishing Group","10.4172/2167-1052.1000205","https://doi.org/10.4172/2167-1052.1000205",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4172/2167-1052.1000205",null],["4","R0038847","R0038847.pdf","no_doi","nonrandomized_study","Roberta Pirolo","2016","Cost-of-Illness Study of Diabetes Mellitus: Focus on Patients with Type 2 Diabetes - \\nCost-of-Illness Della Patologia Diabetica in Italia: Focus Sul Paziente Con Diabete Di Tipo 2","Florence Research (University of Florence)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040623","R0040623.pdf","no_doi","nonrandomized_study","Hsin-chieh Tang","2016","Research Article Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040666","R0040666.pdf","no_doi","nonrandomized_study",null,"2016","Newer Agents Better? DOI: 10.2337/dc13-1901 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040673","R0040673.pdf","no_doi","nonrandomized_study","Mitch Dekoven","2016","ORIGINAL RESEARCH Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040707","R0040707.pdf","no_doi","nonrandomized_study","Neoplastic Pancreata","2016","GLP-1 Receptor Agonist Effects on Normal and",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040735","R0040735.pdf","no_doi","nonrandomized_study","Muhammad Khan","2016","Research Article Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040745","R0040745.pdf","no_doi","nonrandomized_study",null,"2016","The cientificWorldJOURNAL Clinical Study The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040809","R0040809.pdf","no_doi","nonrandomized_study","Roberto Anichini","2016","which permits unrestricted noncommercial use, provided the original work is properly cited. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013:6 123–129 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040834","R0040834.pdf","no_doi","nonrandomized_study","Byron Hoogwerf","2016","RESEARCH ARTICLE Open Access",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040973","R0040973.pdf","no_doi","nonrandomized_study","Stuart A. Ross","2016","Clinical Review Incretin agents in type 2 diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040985","R0040985.pdf","no_doi","nonrandomized_study","Johanna H. M. Driessen","2016","ORIGINAL RESEARCH Bone Fracture Risk is Not Associated with the Use of Glucagon- Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040997","R0040997.pdf","no_doi","nonrandomized_study",null,"2016","Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study Diabetes Care 2015;38:1089–1098 | DOI: 10.2337/dc13-2983 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041030","R0041030.pdf","no_doi","nonrandomized_study","Young Min Cho","2016","Incretin physiology and pathophysiology from an Asian perspective",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041140","R0041140.pdf","no_doi","nonrandomized_study",null,"2016","Newer Agents Better? Diabetes Care 2014;37:1338–1345 | DOI: 10.2337/dc13-1901 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041141","R0041141.pdf","no_doi","nonrandomized_study",null,"2016","RESPONSE TO COMMENT ON THOMSEN ET AL. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population- Based Case-Control Study. Diabetes Care",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041325","R0041325.pdf","no_doi","nonrandomized_study","Endocrinol Metab","2016","Original Article Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041326","R0041326.pdf","no_doi","nonrandomized_study",null,"2016","renal injury in streptozotocin-treated mice. Kidney Int 2006; 69:",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041341","R0041341.pdf","no_doi","nonrandomized_study","Jakob Langer","2016","ORIGINAL RESEARCH Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041950","R0041950.pdf","no_doi","nonrandomized_study","Laurence G. Trahair","2016","Gastric and small intestinal determinants of postprandial blood pressure and glycaemia","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042772","R0042772.pdf","no_doi","nonrandomized_study",null,"2016","DOI: 10.2337/dc13-2983",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043368","R0043368.pdf","free_to_read","nonrandomized_study","Purificación Sánchez López","2016","Tratamiento de la diabetes en adultos mayores de 65 años: Revisión y utilidad de los análogos de GLP-1 en este grupo de pacientes","European journal of health research","Universidad Autonoma de Chile","10.30552/ejhr.v2i1.12","https://doi.org/10.30552/ejhr.v2i1.12",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.30552/ejhr.v2i1.12",null],["4","R0044642","R0044642.pdf","free_to_read","nonrandomized_study","JD Seeger","2016","Real World Tolerability And Effectiveness of Exenatide Once-Weekly Compared To Basal Insulin Among Elderly Patients with Type 2 Diabetes (T2D)","Value in Health","Elsevier BV","10.1016/j.jval.2016.09.1847","https://doi.org/10.1016/j.jval.2016.09.1847",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.09.1847",null],["4","R0044676","R0044676.pdf","free_to_read","nonrandomized_study","JD Seeger","2016","Assessment of Race-Specific Tolerability And Effectiveness of Exenatide once-Weekly or Basal Insulin Among Patients With Type 2 Diabetes In A Real World Setting In The USA","Value in Health","Elsevier BV","10.1016/j.jval.2016.09.1845","https://doi.org/10.1016/j.jval.2016.09.1845",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.09.1845",null],["4","R0049802","R0049802.pdf","free_to_read","nonrandomized_study","Sarita Bajaj","2016","Incretin Learning and Excellence Academy for Diabetes (iLEAD)","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.192902","https://doi.org/10.4103/2230-8210.192902","27867903","https://pubmed.ncbi.nlm.nih.gov/27867903/","https://doi.org/10.4103/2230-8210.192902",null],["4","R0050847","R0050847.pdf","free_to_read","nonrandomized_study","Awadhesh Kumar Singh","2016","Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.196026","https://doi.org/10.4103/2230-8210.196026","28217490","https://pubmed.ncbi.nlm.nih.gov/28217490/","https://doi.org/10.4103/2230-8210.196026",null],["4","R0052049","R0052049.pdf","no_doi","nonrandomized_study","Timothy L. Middleton","2016","QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring","The Sydney eScholarship Repository (The University of Sydney)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052544","R0052544.pdf","free_to_read","nonrandomized_study","Qing Qiao","2016","Healthcare Resource Utilisation Associated with Patients Treated with Either Exenatide Once Weekly or Basal Insulin: A Retrospective UK Database Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2016.09.1864","https://doi.org/10.1016/j.jval.2016.09.1864",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2016.09.1864",null],["4","R0012920","R0012920.pdf","open_download_failed","nonrandomized_study","Gale EA","2015","Smoke or fire? Acute pancreatitis and the liraglutide trials.","Diabetes care","American Diabetes Association","10.2337/dc15-0346","https://doi.org/10.2337/dc15-0346","25998284","https://pubmed.ncbi.nlm.nih.gov/25998284/","https://diabetesjournals.org/care/article-pdf/38/6/948/624477/dc150346.pdf",null],["4","R0013077","R0013077.pdf","open_download_failed","nonrandomized_study","Johnston SS","2015","Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2015.1039539","https://doi.org/10.3111/13696998.2015.1039539","25867133","https://pubmed.ncbi.nlm.nih.gov/25867133/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1039539?needAccess=true&role=button",null],["4","R0013223","R0013223.pdf","free_to_read","nonrandomized_study","Azoulay L","2015","Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.","Diabetes care","American Diabetes Association","10.2337/dc15-0347","https://doi.org/10.2337/dc15-0347","25998285","https://pubmed.ncbi.nlm.nih.gov/25998285/",null,null],["4","R0018072","R0018072.pdf","free_to_read","nonrandomized_study","Thomsen RW","2015","Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.","Diabetes care","American Diabetes Association","10.2337/dc13-2983","https://doi.org/10.2337/dc13-2983","25633664","https://pubmed.ncbi.nlm.nih.gov/25633664/",null,null],["4","R0020626","R0020626.pdf","open_download_failed","nonrandomized_study","Smits MM","2015","Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.","Diabetes care","American Diabetes Association","10.2337/dc15-0367","https://doi.org/10.2337/dc15-0367","26106231","https://pubmed.ncbi.nlm.nih.gov/26106231/","https://care.diabetesjournals.org/content/diacare/38/7/e106.full.pdf",null],["4","R0020685","R0020685.pdf","free_to_read","nonrandomized_study","Thong KY","2015","The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2015.04.009","https://doi.org/10.1016/j.diabres.2015.04.009","25937541","https://pubmed.ncbi.nlm.nih.gov/25937541/","https://research.birmingham.ac.uk/en/publications/ff87ec00-6400-4eb8-b9fa-5e7f22699d86",null],["4","R0020693","R0020693.pdf","open_download_failed","nonrandomized_study","Thomsen RW","2015","Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.","Diabetes care","American Diabetes Association","10.2337/dc15-0675","https://doi.org/10.2337/dc15-0675","26106232","https://pubmed.ncbi.nlm.nih.gov/26106232/","https://diabetesjournals.org/care/article-pdf/38/7/e108/623571/dc150675.pdf",null],["4","R0021463","R0021463.pdf","free_to_read","nonrandomized_study","Nyeland ME","2015","Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care.","International journal of clinical practice","Wiley","10.1111/ijcp.12575","https://doi.org/10.1111/ijcp.12575","25302822","https://pubmed.ncbi.nlm.nih.gov/25302822/","https://doi.org/10.1111/ijcp.12575",null],["4","R0022811","R0022811.pdf","open_download_failed","nonrandomized_study","Usui R","2015","Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.07.020","https://doi.org/10.1016/j.jdiacomp.2015.07.020","26279320","https://pubmed.ncbi.nlm.nih.gov/26279320/","https://www.sciencedirect.com/science/article/pii/S1056872715002925/pdf",null],["4","R0023210","R0023210.pdf","open_download_failed","nonrandomized_study","Zarowitz B","2015","Type 2 diabetes mellitus treatment patterns in U.S. nursing home residents.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2015.1035621","https://doi.org/10.1080/00325481.2015.1035621","25850712","https://pubmed.ncbi.nlm.nih.gov/25850712/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2015.1035621?needAccess=true",null],["4","R0024032","R0024032.pdf","open_download_failed","nonrandomized_study","Dalal MR","2015","Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep14290.or","https://doi.org/10.4158/ep14290.or","25148821","https://pubmed.ncbi.nlm.nih.gov/25148821/","http://www.endocrinepractice.org/article/S1530891X20433464/pdf",null],["4","R0026446","R0026446.pdf","no_doi","nonrandomized_study","Barthélémy M","2015","Substitution of insulin by exenatide in bad controlled type 2 diabetic patients: efficacy and predictive factors.","Minerva endocrinologica",null,null,"https://doi.org/","25003223","https://pubmed.ncbi.nlm.nih.gov/25003223/",null,null],["4","R0026602","R0026602.pdf","free_to_read","nonrandomized_study","Pahlajani S","2015","Liraglutide subcutaneous injection for weight loss: where does it fit?","International journal of clinical practice","Hindawi Limited","10.1111/ijcp.12692","https://doi.org/10.1111/ijcp.12692","26119845","https://pubmed.ncbi.nlm.nih.gov/26119845/",null,null],["4","R0027022","R0027022.pdf","open_download_failed","nonrandomized_study","Farahani P","2015","Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents.","Clinical and investigative medicine. Medecine clinique et experimentale","University of Toronto Press Inc. (UTPress)","10.25011/cim.v38i3.22702","https://doi.org/10.25011/cim.v38i3.22702","26026641","https://pubmed.ncbi.nlm.nih.gov/26026641/","https://cimonline.ca/index.php/cim/article/download/22702/18493",null],["4","R0027119","R0027119.pdf","free_to_read","nonrandomized_study","Gejl M","2015","Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2014.11.096","https://doi.org/10.1016/j.ijcard.2014.11.096","25465309","https://pubmed.ncbi.nlm.nih.gov/25465309/","https://vbn.aau.dk/da/publications/541fb33b-4db3-45e6-be81-74112de4216c",null],["4","R0027418","R0027418.pdf","free_to_read","nonrandomized_study","Yu OH","2015","Incretin-based drugs and the risk of congestive heart failure.","Diabetes care","American Diabetes Association","10.2337/dc14-1459","https://doi.org/10.2337/dc14-1459","25205143","https://pubmed.ncbi.nlm.nih.gov/25205143/",null,null],["4","R0027447","R0027447.pdf","no_doi","nonrandomized_study","-Žďarská DJ","2015","[The PROROK project results after 6 months of intervention (Prospective observation project focusing on the relevance of the difference between fasting blood glucose levels and postprandial blood glucose for estimation of success of type 2 diabetes therapy)].","Vnitrni lekarstvi",null,null,"https://doi.org/","26652965","https://pubmed.ncbi.nlm.nih.gov/26652965/",null,null],["4","R0027592","R0027592.pdf","free_to_read","nonrandomized_study","Velez M","2015","Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2014.10.012","https://doi.org/10.1016/j.cardfail.2014.10.012","25451709","https://pubmed.ncbi.nlm.nih.gov/25451709/","https://www.ncbi.nlm.nih.gov/pmc/articles/4276467",null],["4","R0027643","R0027643.pdf","open_download_failed","nonrandomized_study","Giagulli VA","2015","Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.","Andrology","Wiley","10.1111/andr.12099","https://doi.org/10.1111/andr.12099","26447645","https://pubmed.ncbi.nlm.nih.gov/26447645/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/andr.12099",null],["4","R0030320","R0030320.pdf","no_doi","nonrandomized_study","Žďarská DJ","2015","[Do diabetologists choose a therapy rationally? Basic results of the PROROK project (a prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2 diabetes therapy)].","Vnitrni lekarstvi",null,null,"https://doi.org/","25894257","https://pubmed.ncbi.nlm.nih.gov/25894257/",null,null],["4","R0031639","R0031639.pdf","no_doi","nonrandomized_study","Roberto Sierra Poyatos","2015","Original / Síndrome metabólico Efectos de exenatide LAR en diabetes mellitus tipo 2 y obesidad",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031654","R0031654.pdf","no_doi","nonrandomized_study","Leah Lawrence","2015","No Risk of Acute Pancreatitis Seen with Incretin-Based Therapies",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0037719","R0037719.pdf","free_to_read","nonrandomized_study","Kartik Shankar","2015","Reversing Fetal Undernutrition by Kick-Starting Early Growth","Endocrinology","The Endocrine Society","10.1210/en.2015-1625","https://doi.org/10.1210/en.2015-1625","26295490","https://pubmed.ncbi.nlm.nih.gov/26295490/","https://www.ncbi.nlm.nih.gov/pmc/articles/4541613",null],["4","R0040812","R0040812.pdf","no_doi","nonrandomized_study","Erin K. Buysman","2015","ORIGINAL RESEARCH Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040867","R0040867.pdf","no_doi","nonrandomized_study","On K. Bellows","2015","Clinical Medicine Reviews in Vascular Health 2011:3 71 Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041206","R0041206.pdf","no_doi","nonrandomized_study","Francesco Zaccardi","2015","Data Sources: Electronic databases (PubMed, Web of Science, Cochrane Central Register of Controlled Trials, U.S. Food and Drug Administration, European Medicines Agency,",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043249","R0043249.pdf","no_doi","nonrandomized_study","Marie-Pierre Riffault","2015","Pratique de prescription du liraglutide VICTOZA®. Étude de cohorte au sein du service d’endocrinologie et de maladies métaboliques au CHU de Rouen","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0047049","R0047049.pdf","no_doi","nonrandomized_study","Antonio Carlo Bossi","2015","Potential gender differences of exenatide in outpatients with type 2 diabetes mellitus","IrInSubria (University of Insubria)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048398","R0048398.pdf","free_to_read","nonrandomized_study","Stephen S. Johnston","2015","Adherence to Liraglutide once daily or exenatide once weekly Over A 12-Month period among Commercially Insured Patients With Type 2 diabetes Mellitus: A retrospective observational study","Value in Health","Elsevier BV","10.1016/j.jval.2015.03.374","https://doi.org/10.1016/j.jval.2015.03.374",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.03.374",null],["4","R0049239","R0049239.pdf","free_to_read","nonrandomized_study","Mukul Singhal","2015","Effect of Daily or weekly Glp-1 receptor Agonists on glycemic Control In Insulin-NaÏVe patients With Poorly Controlled type 2 Diabetes: a real-world study","Value in Health","Elsevier BV","10.1016/j.jval.2015.03.317","https://doi.org/10.1016/j.jval.2015.03.317",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.03.317",null],["4","R0051374","R0051374.pdf","free_to_read","nonrandomized_study","A. Tarr","2015","Real-World adherence in Medicare Patients with type 2 Diabetes Mellitus (T2dm) for exenatide qw and Liraglutide qd","Value in Health","Elsevier BV","10.1016/j.jval.2015.03.333","https://doi.org/10.1016/j.jval.2015.03.333",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.03.333",null],["4","R0053445","R0053445.pdf","no_doi","nonrandomized_study","Johnny Kahlert","2015","Risk of Pancreatic Cancer Associated With Use of Incretin-Based Therapy and other Glucose-Lowering Agents: A Nationwide Case-Control Study in Denmark","Data Archiving and Networked Services (DANS)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0014309","R0014309.pdf","free_to_read","nonrandomized_study","Rovó P","2014","Rational design of α-helix-stabilized exendin-4 analogues.","Biochemistry","American Chemical Society (ACS)","10.1021/bi500033c","https://doi.org/10.1021/bi500033c","24828921","https://pubmed.ncbi.nlm.nih.gov/24828921/",null,null],["4","R0016434","R0016434.pdf","open_download_failed","nonrandomized_study","Dharmalingam M","2014","Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.","Therapeutic advances in endocrinology and metabolism","SAGE Publications","10.1177/2042018814552657","https://doi.org/10.1177/2042018814552657","25489471","https://pubmed.ncbi.nlm.nih.gov/25489471/","https://journals.sagepub.com/doi/pdf/10.1177/2042018814552657",null],["4","R0018945","R0018945.pdf","free_to_read","nonrandomized_study","Zhang Y","2014","Second-line agents for glycemic control for type 2 diabetes: are newer agents better?","Diabetes care","American Diabetes Association","10.2337/dc13-1901","https://doi.org/10.2337/dc13-1901","24574345","https://pubmed.ncbi.nlm.nih.gov/24574345/","https://doi.org/10.2337/dc13-1901",null],["4","R0019772","R0019772.pdf","no_doi","nonrandomized_study","Haraguchi A","2014","Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.","Minerva endocrinologica",null,null,"https://doi.org/","25371055","https://pubmed.ncbi.nlm.nih.gov/25371055/",null,null],["4","R0020897","R0020897.pdf","free_to_read","nonrandomized_study","Sivaraman SC","2014","The effect of liraglutide on microvascular complications and cardiovascular risk in patients with type 2 diabetes","University of Warwick",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0021219","R0021219.pdf","open_download_failed","nonrandomized_study","Levin PA","2014","Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2014.20.5.501","https://doi.org/10.18553/jmcp.2014.20.5.501","24761822","https://pubmed.ncbi.nlm.nih.gov/24761822/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10438237/pdf/jmcp.2014.20.5.501.pdf",null],["4","R0022672","R0022672.pdf","free_to_read","nonrandomized_study","Kahal H","2014","Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.","Clinical endocrinology","Wiley","10.1111/cen.12369","https://doi.org/10.1111/cen.12369","24256515","https://pubmed.ncbi.nlm.nih.gov/24256515/","https://hull-repository.worktribe.com/output/706348",null],["4","R0023801","R0023801.pdf","open_download_failed","nonrandomized_study","Montilla S","2014","Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2014.07.014","https://doi.org/10.1016/j.numecd.2014.07.014","25300980","https://pubmed.ncbi.nlm.nih.gov/25300980/","http://www.nmcd-journal.com/article/S0939475314002592/pdf",null],["4","R0026420","R0026420.pdf","free_to_read","nonrandomized_study","Traina AN","2014","Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2013.10.006","https://doi.org/10.1016/j.jcjd.2013.10.006","24797495","https://pubmed.ncbi.nlm.nih.gov/24797495/","https://fisherpub.sjf.edu/pharmacy_facpub/46",null],["4","R0026426","R0026426.pdf","open_download_failed","nonrandomized_study","El-Abhar HS","2014","Phytotherapy in diabetes: Review on potential mechanistic perspectives.","World journal of diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.v5.i2.176","https://doi.org/10.4239/wjd.v5.i2.176","24748931","https://pubmed.ncbi.nlm.nih.gov/24748931/","https://www.wjgnet.com/1948-9358/full/v5/i2/176.htm",null],["4","R0026577","R0026577.pdf","open_download_failed","nonrandomized_study","Steen Carlsson K","2014","Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2014.933110","https://doi.org/10.3111/13696998.2014.933110","24950434","https://pubmed.ncbi.nlm.nih.gov/24950434/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2014.933110?needAccess=true",null],["4","R0030583","R0030583.pdf","no_doi","nonrandomized_study","清水 弘行","2014","リラグルチドのBody Mass Index（BMI）別臨床効果に関する解析―前治療別による比較検討―","Therapeutic research",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031315","R0031315.pdf","free_to_read","nonrandomized_study","Jakob Starup‐Linde","2014","Liraglutide and Insulin are Associated with a Decreased Risk of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients","Journal of Diabetes & Metabolism","OMICS Publishing Group","10.4172/2155-6156.1000389","https://doi.org/10.4172/2155-6156.1000389",null,"https://pubmed.ncbi.nlm.nih.gov//","https://vbn.aau.dk/da/publications/355d762f-d8cd-4d8a-9aee-5a6226b31b73",null],["4","R0031652","R0031652.pdf","no_doi","nonrandomized_study","Ali Kiadaliri","2014","Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden","Lund University Publications (Lund University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031989","R0031989.pdf","no_doi","nonrandomized_study","Katarina Steen Carlsson","2014","Original article Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032329","R0032329.pdf","no_doi","nonrandomized_study","Nogueras Zondag, D.A.","2014","Continuous benefit-risk assessment of oral antidiabetics and safety-related regulatory actions","Utrecht University Repository (Utrecht University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040703","R0040703.pdf","no_doi","nonrandomized_study","Pál Stráner","2014","SEE PROFILE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040828","R0040828.pdf","no_doi","nonrandomized_study","In Switzerland","2014","ORIGINAL RESEARCH Liraglutide as Add-On Therapy to Insulin in Type 2 Diabetes Mellitus: A Retrospective, Observational Study From a Daily Clinical Practice Setting",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041310","R0041310.pdf","no_doi","nonrandomized_study","Victoria Divino","2014","ORIGINAL RESEARCH Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044359","R0044359.pdf","no_doi","nonrandomized_study","Katie L. Fetter","2014","Efficacy of Bydureon in Adults with Type 2 Diabetes","University of North Florida Digital Commons (University of North Florida)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048736","R0048736.pdf","free_to_read","nonrandomized_study","A.S. Chitnis","2014","Comparative Real World Effectiveness of Liraglutide versus Sitagliptin in Patients with Type 2 Diabetes as an Add-On to Metformin Monotherapy in the United States","Internal Medicine Open Access","OMICS Publishing Group","10.4172/2165-8048.s6-007","https://doi.org/10.4172/2165-8048.s6-007",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4172/2165-8048.s6-007",null],["4","R0050727","R0050727.pdf","free_to_read","nonrandomized_study","Ralph W. Swindle","2014","Methodological challenges in calculation of daily average consumption (DACON) for GLP-1 receptor agonist injectables from claims data","Value in Health","Elsevier BV","10.1016/j.jval.2014.03.1472","https://doi.org/10.1016/j.jval.2014.03.1472",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2014.03.1472",null],["4","R0015607","R0015607.pdf","open_download_failed","nonrandomized_study","Labuzek K","2013","Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?","European journal of internal medicine","Elsevier BV","10.1016/j.ejim.2013.01.009","https://doi.org/10.1016/j.ejim.2013.01.009","23375875","https://pubmed.ncbi.nlm.nih.gov/23375875/","http://www.ejinme.com/article/S0953620513000149/pdf",null],["4","R0027748","R0027748.pdf","open_download_failed","nonrandomized_study","Bergeson JG","2013","Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2013.19.5.374","https://doi.org/10.18553/jmcp.2013.19.5.374","23697475","https://pubmed.ncbi.nlm.nih.gov/23697475/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10437845/pdf/jmcp.2013.19.5.374.pdf",null],["4","R0031028","R0031028.pdf","no_doi","nonrandomized_study","Mark Bounthavong","2013","RETROSPECTIVE ANALYSIS OF EXENATIDE TWICE DAILY COMPARED TO LONG-ACTING INSULIN ANALOGS IN A VETERAN POPULATION","The 35th Annual Meeting of the Society for Medical Decision Making",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031257","R0031257.pdf","no_doi","nonrandomized_study","Patricia S Juang","2013","Figure 18, Change in Body Weight over the Course of Study for the 82-week Exenatide Completer Cohort and the Intent-to-Treat Population",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031570","R0031570.pdf","no_doi","nonrandomized_study","Patricia S Juang","2013","Figure 17, A1C Reduction from Baseline over the Course of the Study for the 82-week Exenatide Completer Cohort and the Intent-to-Treat Population",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0036906","R0036906.pdf","free_to_read","nonrandomized_study","Jerry Overman","2013","Transforming 300 billion points of data into diagnostics, therapeutics and new insights into disease","Mental Health Clinician","American Association of Psychiatric Pharmacists (AAPP)","10.9740/mhc.n155664","https://doi.org/10.9740/mhc.n155664",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.9740/mhc.n155664",null],["4","R0040810","R0040810.pdf","no_doi","nonrandomized_study","William Chen","2013","Treated With Exenatide or Sitagliptin",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041184","R0041184.pdf","no_doi","nonrandomized_study","Jothydev Kesavadev","2013","Open Access Full Text Article",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041189","R0041189.pdf","no_doi","nonrandomized_study","Jennie H. Best","2013","Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041214","R0041214.pdf","no_doi","nonrandomized_study","Edward S. Horton","2013","Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0043823","R0043823.pdf","no_doi","nonrandomized_study","Francesco Micheletto","2013","A MODEL OF BETA-CELL RESPONSE TO GLP-1 TO QUANTIFY INCRETIN EFFECT IN HEALTHY AND PREDIABETIC SUBJECTS","Padua@research (University of Padova)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044773","R0044773.pdf","free_to_read","nonrandomized_study","Martin Erik Nyeland","2013","Comparative Effectiveness of Liraglutide Versus Sitagliptin in Type 2 Diabetes in the United Kingdom: A Retrospective Study in Primary Care","Value in Health","Elsevier BV","10.1016/j.jval.2013.08.624","https://doi.org/10.1016/j.jval.2013.08.624",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2013.08.624",null],["4","R0047402","R0047402.pdf","free_to_read","nonrandomized_study","Mark Bounthavong","2013","Retrospective Cohort Study Evaluating Liraglutide And Exenatide In A Veteran Population","Value in Health","Elsevier BV","10.1016/j.jval.2013.03.787","https://doi.org/10.1016/j.jval.2013.03.787",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2013.03.787",null],["4","R0048771","R0048771.pdf","no_doi","nonrandomized_study","Anna Pulcina","2013","Effects of medium-long term regular treatment with exenatide in type 2 diabetic patients: A lombard multicenter initiative [Effetti del trattamento persistente con exenatide a medio-lungo termine in soggetti con diabete mellito di tipo 2: Esperienza multicentrica lombarda]","IrInSubria (University of Insubria)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049666","R0049666.pdf","no_doi","nonrandomized_study","Durgesh Gowda","2013","Exenatide for treatment of obese type 2 diabetes: the Townsville Hospital experience","ResearchOnline - JCU (James Cook University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051157","R0051157.pdf","free_to_read","nonrandomized_study","Mitch DeKoven","2013","Real World Outcomes in Type 2 Diabetes: Lower Cost of Treating Patients to A1c<7% with Liraglutide Versus Exenatide","Value in Health","Elsevier BV","10.1016/j.jval.2013.08.664","https://doi.org/10.1016/j.jval.2013.08.664",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2013.08.664",null],["4","R0051709","R0051709.pdf","no_doi","nonrandomized_study","Ryder Rej","2013","Liraglutide and acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0019629","R0019629.pdf","free_to_read","nonrandomized_study","Miller LA","2012","Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2012.679756","https://doi.org/10.3111/13696998.2012.679756","22443463","https://pubmed.ncbi.nlm.nih.gov/22443463/",null,null],["4","R0021558","R0021558.pdf","free_to_read","nonrandomized_study","Pelletier EM","2012","Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2012.688903","https://doi.org/10.3111/13696998.2012.688903","22533526","https://pubmed.ncbi.nlm.nih.gov/22533526/",null,null],["4","R0024849","R0024849.pdf","open_download_failed","nonrandomized_study","Vangoitsenhoven R","2012","GLP1 and cancer: friend or foe?","Endocrine-related cancer","Bioscientifica","10.1530/erc-12-0111","https://doi.org/10.1530/erc-12-0111","22691625","https://pubmed.ncbi.nlm.nih.gov/22691625/","https://erc.bioscientifica.com/downloadpdf/journals/erc/19/5/F77.pdf",null],["4","R0024923","R0024923.pdf","open_download_failed","nonrandomized_study","Moreno P","2012","Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.","Journal of molecular endocrinology","Bioscientifica","10.1530/jme-11-0127","https://doi.org/10.1530/jme-11-0127","22065862","https://pubmed.ncbi.nlm.nih.gov/22065862/","https://jme.bioscientifica.com/downloadpdf/journals/jme/48/1/37.pdf",null],["4","R0025070","R0025070.pdf","open_download_failed","nonrandomized_study","Oderda G","2012","Bringing liraglutide to market: a CER case study.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2012.18.s5-a.s12","https://doi.org/10.18553/jmcp.2012.18.s5-a.s12","22663295","https://pubmed.ncbi.nlm.nih.gov/22663295/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2012.18.s5-a.S12",null],["4","R0025155","R0025155.pdf","open_download_failed","nonrandomized_study","Kumar A","2012","Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2350","https://doi.org/10.1002/dmrr.2350","23280862","https://pubmed.ncbi.nlm.nih.gov/23280862/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.2350",null],["4","R0026545","R0026545.pdf","no_doi","nonrandomized_study","Best JH","2012","Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.","The American journal of managed care",null,null,"https://doi.org/","23039898","https://pubmed.ncbi.nlm.nih.gov/23039898/",null,null],["4","R0026873","R0026873.pdf","free_to_read","nonrandomized_study","Kaimal N","2012","Effects of exenatide in poorly controlled type 2 diabetes.","QJM : monthly journal of the Association of Physicians","Oxford University Press (OUP)","10.1093/qjmed/hcr180","https://doi.org/10.1093/qjmed/hcr180","22056400","https://pubmed.ncbi.nlm.nih.gov/22056400/",null,null],["4","R0030723","R0030723.pdf","no_doi","nonrandomized_study","Сунцов Юрий Иванович","2012","Современные сахароснижающие препараты, используемые в России при лечении сахарного диабета 2 типа","Сахарный диабет",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031080","R0031080.pdf","no_doi","nonrandomized_study","Shinan Yin","2012","A clinical analysis on replacement therapy with exenatide for type 2 diabetic patients treated with insulin","Shanxi Yike Daxue xuebao",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0031880","R0031880.pdf","no_doi","nonrandomized_study","Arvind Chopra","2012","18F-Labeled exendin(9-39)","Europe PMC (PubMed Central)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040984","R0040984.pdf","no_doi","nonrandomized_study","Marc Evans","2012","ORIGINAL RESEARCH A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041042","R0041042.pdf","no_doi","nonrandomized_study","Wei-yih Chiu","2012","doi:10.1155/2012/924168 Review Article A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041695","R0041695.pdf","no_doi","nonrandomized_study","Jessica Lee Sing Chang","2012","Gastric motor function in health and diabetes: implications for incretin hormone release and postprandial blood glucose regulation.","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044242","R0044242.pdf","free_to_read","nonrandomized_study","MK Garg","2012","Prescribing gliptins: Enthusiasm should be coupled with caution","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.93785","https://doi.org/10.4103/2230-8210.93785","22470884","https://pubmed.ncbi.nlm.nih.gov/22470884/","https://doi.org/10.4103/2230-8210.93785",null],["4","R0049111","R0049111.pdf","free_to_read","nonrandomized_study","E.M. Pelletier","2012","PDB51 Medication Adherence and Medical Costs Associated With Exenatide Bid Versus Liraglutide: A Retrospective Database Analysis","Value in Health","Elsevier BV","10.1016/j.jval.2012.03.972","https://doi.org/10.1016/j.jval.2012.03.972",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2012.03.972",null],["4","R0050521","R0050521.pdf","free_to_read","nonrandomized_study","Jyothi Mariam Idiculla","2012","Diabetes in the time of HIV","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.98052","https://doi.org/10.4103/2230-8210.98052","22837951","https://pubmed.ncbi.nlm.nih.gov/22837951/","https://doi.org/10.4103/2230-8210.98052",null],["4","R0018931","R0018931.pdf","free_to_read","nonrandomized_study","Drucker DJ","2011","The safety of incretin-based therapies--review of the scientific evidence.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-0599","https://doi.org/10.1210/jc.2011-0599","21734003","https://pubmed.ncbi.nlm.nih.gov/21734003/",null,null],["4","R0020682","R0020682.pdf","no_doi","nonrandomized_study","Calabrese D","2011","Differentiating incretin-based therapies for population-based health care.","The American journal of managed care",null,null,"https://doi.org/","21517657","https://pubmed.ncbi.nlm.nih.gov/21517657/",null,null],["4","R0022076","R0022076.pdf","free_to_read","nonrandomized_study","Valentine WJ","2011","Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2011.09.022","https://doi.org/10.1016/j.clinthera.2011.09.022","22018679","https://pubmed.ncbi.nlm.nih.gov/22018679/","https://figshare.com/articles/journal_contribution/Evaluating_the_Long-Term_Cost-Effectiveness_of_Liraglutide_Versus_Exenatide_BID_in_Patients_With_Type_2_Diabetes_Who_Fail_to_Improve_With_Oral_Antidiabetic_Agents/22888181","ClinicalTrials.gov:NCT00518882"],["4","R0025060","R0025060.pdf","open_download_failed","nonrandomized_study","Fishman MN","2011","Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.","Clinical cancer research : an official journal of the American Association for Cancer Research","American Association for Cancer Research (AACR)","10.1158/1078-0432.ccr-11-1817","https://doi.org/10.1158/1078-0432.ccr-11-1817","21994418","https://pubmed.ncbi.nlm.nih.gov/21994418/","https://aacrjournals.org/clincancerres/article-pdf/17/24/7765/2001702/7765.pdf","ClinicalTrials.gov:NCT00496860"],["4","R0026969","R0026969.pdf","free_to_read","nonrandomized_study","Pawaskar MD","2011","Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2011.613505","https://doi.org/10.3111/13696998.2011.613505","21892855","https://pubmed.ncbi.nlm.nih.gov/21892855/",null,null],["4","R0027025","R0027025.pdf","open_download_failed","nonrandomized_study","Pawaskar M","2011","Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2010.544797","https://doi.org/10.3111/13696998.2010.544797","21158486","https://pubmed.ncbi.nlm.nih.gov/21158486/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.544797?needAccess=true",null],["4","R0027062","R0027062.pdf","free_to_read","nonrandomized_study","Bergenstal RM","2011","Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.","Current medical research and opinion","Informa Healthcare","10.1185/03007995.2011.628305","https://doi.org/10.1185/03007995.2011.628305","22085180","https://pubmed.ncbi.nlm.nih.gov/22085180/","https://figshare.com/articles/journal_contribution/Exenatide_BID_Observational_Study_ExOS_results_for_primary_and_secondary_endpoints_of_a_prospective_research_study_to_evaluate_the_clinical_effectiveness_of_exenatide_BID_use_in_patients_with_type_2_diabetes_in_a_real-world_setting/11815914",null],["4","R0027455","R0027455.pdf","open_download_failed","nonrandomized_study","Elashoff M","2011","Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2011.02.018","https://doi.org/10.1053/j.gastro.2011.02.018","21334333","https://pubmed.ncbi.nlm.nih.gov/21334333/","http://www.gastrojournal.org/article/S0016508511001727/pdf",null],["4","R0027969","R0027969.pdf","open_download_failed","nonrandomized_study","Baser O","2011","Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2011.605818","https://doi.org/10.3111/13696998.2011.605818","21892858","https://pubmed.ncbi.nlm.nih.gov/21892858/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2011.605818?needAccess=true",null],["4","R0027999","R0027999.pdf","no_doi","nonrandomized_study","Joshi SR","2011","Biosimilar peptides: need for pharmacovigilance.","The Journal of the Association of Physicians of India",null,null,"https://doi.org/","21818998","https://pubmed.ncbi.nlm.nih.gov/21818998/",null,null],["4","R0039112","R0039112.pdf","no_doi","nonrandomized_study","Paul Johnson","2011","The influence of donor body mass index on human pancreatic islet function, structure and islet transplant outcome","OpenGrey (Institut de l'Information Scientifique et Technique)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042339","R0042339.pdf","no_doi","nonrandomized_study","Millett, Christopher","2011","Caution in Generalizing Part D Results to Medicare Population—Reply","eScholarship (California Digital Library)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044611","R0044611.pdf","free_to_read","nonrandomized_study","David F. Bruhn","2011","PDB10 Achieving Target Goals in Patients with T2DM Treated with Exenatide Once Weekly or Insulin Glargine: A Retrospective Analysis of the Number-Needed-To-Treat","Value in Health","Elsevier BV","10.1016/j.jval.2011.08.1313","https://doi.org/10.1016/j.jval.2011.08.1313",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2011.08.1313",null],["4","R0048223","R0048223.pdf","free_to_read","nonrandomized_study","Sirimon Reutrakul","2011","Use of U-500 Regular Insulin via Continuous Subcutaneous Insulin Infusion: Clinical Practice Experience","Journal of Diabetes Science and Technology","SAGE Publications","10.1177/193229681100500429","https://doi.org/10.1177/193229681100500429","21880247","https://pubmed.ncbi.nlm.nih.gov/21880247/","https://www.ncbi.nlm.nih.gov/pmc/articles/3192612",null],["4","R0048411","R0048411.pdf","no_doi","nonrandomized_study","Carlo Pasquale Piccinni","2011","Pioglitazone-associated bladder cancer: the contribution of spontaneous reporting analysis on the basis of FDA_AERS database","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0048579","R0048579.pdf","free_to_read","nonrandomized_study","Jennie H. Best","2011","PDB11 Glycemic Outcomes Among Patients Receiving Exenatide BID or Liraglutide for Type 2 Diabetes in Clinical Practice: A Retrospective Analysis of the GE Centricity EMR Data","Value in Health","Elsevier BV","10.1016/j.jval.2011.08.1314","https://doi.org/10.1016/j.jval.2011.08.1314",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2011.08.1314",null],["4","R0051827","R0051827.pdf","no_doi","nonrandomized_study","Emanuel Raschi","2011","Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052019","R0052019.pdf","free_to_read","nonrandomized_study","Manjiri D. Pawaskar","2011","PDB22 ‘Real-World' Clinical Outcomes of Exenatide Bid Compared to Insulin Glargine in Patients with Type 2 Diabetes","Value in Health","Elsevier BV","10.1016/j.jval.2011.08.1325","https://doi.org/10.1016/j.jval.2011.08.1325",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2011.08.1325",null],["4","R0017562","R0017562.pdf","free_to_read","nonrandomized_study","Tzefos M","2010","Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1p047","https://doi.org/10.1345/aph.1p047","20530705","https://pubmed.ncbi.nlm.nih.gov/20530705/",null,null],["4","R0027224","R0027224.pdf","no_doi","nonrandomized_study","García-Hernández P","2010","[Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].","Revista medica del Instituto Mexicano del Seguro Social",null,null,"https://doi.org/","21205505","https://pubmed.ncbi.nlm.nih.gov/21205505/",null,null],["4","R0027903","R0027903.pdf","free_to_read","nonrandomized_study","Cooke CE","2010","Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.","Current medical research and opinion","Informa Healthcare","10.1185/03007990903421994","https://doi.org/10.1185/03007990903421994","19921965","https://pubmed.ncbi.nlm.nih.gov/19921965/","https://figshare.com/articles/journal_contribution/Persistence_with_injectable_antidiabetic_agents_in_members_with_type_2_diabetes_in_a_commercial_managed_care_organization/11815362",null],["4","R0027991","R0027991.pdf","no_doi","nonrandomized_study","Livio F","2010","[Pharmacovigilance update].","Revue medicale suisse",null,null,"https://doi.org/","20170031","https://pubmed.ncbi.nlm.nih.gov/20170031/",null,null],["4","R0041299","R0041299.pdf","no_doi","nonrandomized_study","C. Ellero","2010","DIABETICMedicine Original Article: Treatment",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041461","R0041461.pdf","no_doi","nonrandomized_study","Bhargava, Amit","2010","A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041996","R0041996.pdf","no_doi","nonrandomized_study","Paul Kuo","2010","Gastric and small intestinal motor function in health and disease - implications for glucose absorption, incretin hormone release, and postprandial blood glucose regulation.","Adelaide Research & Scholarship (AR&S) (University of Adelaide)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044854","R0044854.pdf","free_to_read","nonrandomized_study","Maria Koulmanda","2010","T-Cell-Directed Treatment Strategies for Type 1 Diabetes and the Confounding Role of Inflammation","Immunotherapy","Informa UK Limited","10.2217/imt.10.40","https://doi.org/10.2217/imt.10.40","20635995","https://pubmed.ncbi.nlm.nih.gov/20635995/","https://www.ncbi.nlm.nih.gov/pmc/articles/3070950",null],["4","R0048822","R0048822.pdf","free_to_read","nonrandomized_study","Monira Alarouj","2010","Recommendations for Management of Diabetes During Ramadan","Diabetes Care","American Diabetes Association","10.2337/dc10-0896","https://doi.org/10.2337/dc10-0896","20668157","https://pubmed.ncbi.nlm.nih.gov/20668157/","https://doi.org/10.2337/dc10-0896",null],["4","R0048990","R0048990.pdf","no_doi","nonrandomized_study","Byron J. Hoogwerf","2010","Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0050347","R0050347.pdf","no_doi","nonrandomized_study","Carlo Pasquale Piccinni","2010","Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0020541","R0020541.pdf","free_to_read","nonrandomized_study","Wick A","2009","Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.","Journal of the American Academy of Nurse Practitioners","Wiley","10.1111/j.1745-7599.2009.00455.x","https://doi.org/10.1111/j.1745-7599.2009.00455.x","19900193","https://pubmed.ncbi.nlm.nih.gov/19900193/",null,null],["4","R0021980","R0021980.pdf","open_download_failed","nonrandomized_study","Jacobsen LV","2009","Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.","British journal of clinical pharmacology","Wiley","10.1111/j.1365-2125.2009.03536.x","https://doi.org/10.1111/j.1365-2125.2009.03536.x","20002084","https://pubmed.ncbi.nlm.nih.gov/20002084/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03536.x",null],["4","R0027487","R0027487.pdf","no_doi","nonrandomized_study","De Block C","2009","[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study].","Revue medicale de Liege",null,null,"https://doi.org/","19911661","https://pubmed.ncbi.nlm.nih.gov/19911661/",null,null],["4","R0041064","R0041064.pdf","no_doi","nonrandomized_study","Leonidas H Duntas","2009","REVIEW Open Access Clinical comments related to medullary thyroid cancer diagnosis and management",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0049994","R0049994.pdf","no_doi","nonrandomized_study","Christophe E.M. De Block","2009","Amelioration du controle glycemique et perte de poids sous exenatide chez des patients diabetiques de type 2: resultats d'une etude retrospective observationnelle multicentrique belge.","RMLG. Revue médicale de Liège",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0051201","R0051201.pdf","no_doi","nonrandomized_study","Ivan S. Krysanov","2009","Фармакоэкономический анализ лечения пациентов с сахарным диабетом 2 типа глимепиридом в комбинации с лираглутидом или росиглитазоном (обзор зарубежных исследований)","Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0052562","R0052562.pdf","free_to_read","nonrandomized_study","MD Pawaskar","2009","PDB68 A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES","Value in Health","Elsevier BV","10.1016/s1098-3015(10)75046-4","https://doi.org/10.1016/s1098-3015(10)75046-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s1098-3015(10)75046-4",null],["4","R0023984","R0023984.pdf","free_to_read","nonrandomized_study","Murage EN","2008","Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.","Bioorganic & medicinal chemistry","Elsevier BV","10.1016/j.bmc.2008.10.006","https://doi.org/10.1016/j.bmc.2008.10.006","18952440","https://pubmed.ncbi.nlm.nih.gov/18952440/","https://doi.org/10.7270/q2b857zt",null],["4","R0027691","R0027691.pdf","open_download_failed","nonrandomized_study","VanDeKoppel S","2008","Managed care perspective on three new agents for type 2 diabetes.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2008.14.4.363","https://doi.org/10.18553/jmcp.2008.14.4.363","18500914","https://pubmed.ncbi.nlm.nih.gov/18500914/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10438140/pdf/jmcp.2008.14.4.363.pdf",null],["4","R0051188","R0051188.pdf","free_to_read","nonrandomized_study","Diana L. Brixner","2008","DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE","Value in Health","Elsevier BV","10.1016/s1098-3015(10)70068-1","https://doi.org/10.1016/s1098-3015(10)70068-1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s1098-3015(10)70068-1",null],["4","R0027783","R0027783.pdf","open_download_failed","nonrandomized_study","Watkins JB","2006","Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.","Journal of managed care pharmacy : JMCP","Academy of Managed Care Pharmacy","10.18553/jmcp.2006.12.9.726","https://doi.org/10.18553/jmcp.2006.12.9.726","17249905","https://pubmed.ncbi.nlm.nih.gov/17249905/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10437796/pdf/jmcp.2006.12.9.726.pdf",null],["4","R0028043","R0028043.pdf","free_to_read","nonrandomized_study","Little TJ","2006","Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2005-2220","https://doi.org/10.1210/jc.2005-2220","16492694","https://pubmed.ncbi.nlm.nih.gov/16492694/",null,null],["4","R0041919","R0041919.pdf","no_doi","nonrandomized_study","Wai Joe Chan","2006","TYPE 2-DIABETES: PATOFYSIOLOGI OG MEDIKAMENTELL BEHANDLING","Duo Research Archive (University of Oslo)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0040970","R0040970.pdf","no_doi","nonrandomized_study","Jeremy M. Gleeson","2005","JMCP JOURNAL OF MANAGED CARE PHARMACY® Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0024168","R0024168.pdf","free_to_read","nonrandomized_study","Chopra A","2004","64Cu-Labeled Lys40(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)NH2–conjugated exendin-4","National Center for Biotechnology Information (US), Bethesda (MD)",null,null,"https://doi.org/","22379636","https://pubmed.ncbi.nlm.nih.gov/22379636/",null,null],["4","R0026768","R0026768.pdf","free_to_read","nonrandomized_study","Chopra A","2004","18F-Labeled exendin(9-39)","National Center for Biotechnology Information (US), Bethesda (MD)",null,null,"https://doi.org/","22624171","https://pubmed.ncbi.nlm.nih.gov/22624171/",null,null],["4","R0032489","R0032489.pdf","no_doi","nonrandomized_study","浩平 伊藤",null,"Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0032490","R0032490.pdf","no_doi","nonrandomized_study","咲子 照井",null,"Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0035939","R0035939.pdf","no_doi","nonrandomized_study","Narushima D.; Kawasaki Y.; Takamatsu S.; Yamada H.",null,"Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0041456","R0041456.pdf","no_doi","nonrandomized_study",null,null,"Ligand and Structure-Based Virtual Screening of iPPl-lib, Diverse-lib, and GLASS Databases for Homology Modeling-Derived Orphan GPCR SREB2 Identifies Glucagon-Like Peptide 1 Receptor and Thyrotropin Receptor Ligands as Top Hits","Digital Repository Service (Northeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042067","R0042067.pdf","no_doi","nonrandomized_study","SCIANNAMEO, VERONICA",null,"ANALISI DEGLI ESITI DI SALUTE E DEI MODELLI DI COMORBIDITA IN PAZIENTI CON MALATTIE CRONICHE. MODELLI DI PREVISIONE E PHENOMAPPING SU DATABASE AMMINISTRATIVI INTEGRATI.","Padua Research Archive (University of Padova)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042106","R0042106.pdf","no_doi","nonrandomized_study","Brian Ward",null,"Innovative use of fatty acid acylation to enhance biological action and biophysical properties of peptide therapeutics","ProQuest Demo Repository",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0042310","R0042310.pdf","no_doi","nonrandomized_study","Yoshinobu Kondo",null,"Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: A retrospective cohort study","Institutional Repositories DataBase (IRDB)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0044563","R0044563.pdf","no_doi","nonrandomized_study",null,null,"Journal of obesity",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["4","R0045354","R0045354.pdf","no_doi","nonrandomized_study","Matteo Spedicato",null,"High throughput methods and novel approaches for the characterization and purification of bioactive compounds in different matrices","Institutional Research Information System University of Ferrara (University of Ferrara)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0000072","R0000072.pdf","paywalled","other_trial","Narla S","2026","Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.","Clinics in dermatology","Elsevier BV","10.1016/j.clindermatol.2026.07.030","https://doi.org/10.1016/j.clindermatol.2026.07.030","42562129","https://pubmed.ncbi.nlm.nih.gov/42562129/",null,null],["5","R0000189","R0000189.pdf","paywalled","other_trial","Zhang SC","2026","[Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults].","Zhonghua yi xue za zhi",null,"10.3760/cma.j.cn112137-20260325-00802","https://doi.org/10.3760/cma.j.cn112137-20260325-00802","42161872","https://pubmed.ncbi.nlm.nih.gov/42161872/",null,null],["5","R0000234","R0000234.pdf","paywalled","other_trial","Wietholter JP","2026","Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.","The Annals of pharmacotherapy","SAGE Publications","10.1177/10600280261486055","https://doi.org/10.1177/10600280261486055","42760621","https://pubmed.ncbi.nlm.nih.gov/42760621/",null,null],["5","R0000343","R0000343.pdf","paywalled","other_trial","Mironova M","2026","International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.","Gut","BMJ","10.1136/gutjnl-2026-340031","https://doi.org/10.1136/gutjnl-2026-340031","42728029","https://pubmed.ncbi.nlm.nih.gov/42728029/",null,null],["5","R0000344","R0000344.pdf","paywalled","other_trial","Olumuyide E","2026","Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-026-02143-x","https://doi.org/10.1038/s41366-026-02143-x","42365122","https://pubmed.ncbi.nlm.nih.gov/42365122/",null,null],["5","R0000467","R0000467.pdf","paywalled","other_trial","Bailey SC","2026","Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes.","Journal of women's health (2002)","SAGE Publications","10.1177/15409996261478007","https://doi.org/10.1177/15409996261478007","42576647","https://pubmed.ncbi.nlm.nih.gov/42576647/",null,null],["5","R0000684","R0000684.pdf","paywalled","other_trial","Henriques JP","2026","Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping - scoping review.","Annales pharmaceutiques francaises","Elsevier BV","10.1016/j.pharma.2026.06.008","https://doi.org/10.1016/j.pharma.2026.06.008","42349781","https://pubmed.ncbi.nlm.nih.gov/42349781/",null,null],["5","R0000728","R0000728.pdf","paywalled","other_trial","Cheng HE","2026","Oral Incretin-Based Therapies for Weight Management.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-026-01456-6","https://doi.org/10.1007/s11883-026-01456-6","42696191","https://pubmed.ncbi.nlm.nih.gov/42696191/",null,null],["5","R0000947","R0000947.pdf","paywalled","other_trial","Harris A","2026","Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.","JAMA otolaryngology-- head & neck surgery","American Medical Association (AMA)","10.1001/jamaoto.2026.2266","https://doi.org/10.1001/jamaoto.2026.2266","42690639","https://pubmed.ncbi.nlm.nih.gov/42690639/",null,null],["5","R0000958","R0000958.pdf","paywalled","other_trial","Mukim RD","2026","Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.","Molecular biology reports","Springer Science and Business Media LLC","10.1007/s11033-026-12549-5","https://doi.org/10.1007/s11033-026-12549-5","42573665","https://pubmed.ncbi.nlm.nih.gov/42573665/",null,null],["5","R0001103","R0001103.pdf","paywalled","other_trial","Hughes MS","2026","Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2026.04.015","https://doi.org/10.1016/j.ecl.2026.04.015","42526999","https://pubmed.ncbi.nlm.nih.gov/42526999/",null,null],["5","R0001247","R0001247.pdf","paywalled","other_trial","Khachaturov M","2026","Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70822","https://doi.org/10.1111/dom.70822","42098899","https://pubmed.ncbi.nlm.nih.gov/42098899/",null,null],["5","R0001369","R0001369.pdf","paywalled","other_trial","Patel TA","2026","GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight.","Circulation research","Ovid Technologies (Wolters Kluwer Health)","10.1161/circresaha.126.327683","https://doi.org/10.1161/circresaha.126.327683","42461990","https://pubmed.ncbi.nlm.nih.gov/42461990/",null,null],["5","R0001761","R0001761.pdf","paywalled","other_trial","Haner Wasserstein D","2026","Lean Mass Loss in Glucagon-Like Peptide-1/GIP Therapy: Clinical Implications for Obesity and Cardiovascular Care.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001178","https://doi.org/10.1097/crd.0000000000001178","41636548","https://pubmed.ncbi.nlm.nih.gov/41636548/",null,null],["5","R0002324","R0002324.pdf","paywalled","other_trial","Khan MS","2026","Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag201","https://doi.org/10.1093/eurheartj/ehag201","41914150","https://pubmed.ncbi.nlm.nih.gov/41914150/",null,null],["5","R0002603","R0002603.pdf","paywalled","other_trial","Yang B","2026","Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgag383","https://doi.org/10.1210/clinem/dgag383","42764204","https://pubmed.ncbi.nlm.nih.gov/42764204/",null,null],["5","R0002988","R0002988.pdf","paywalled","other_trial","Chirapongsathorn S","2026","Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.","Digestion","S. Karger AG","10.1159/dig/acmag014","https://doi.org/10.1159/dig/acmag014","42715139","https://pubmed.ncbi.nlm.nih.gov/42715139/",null,null],["5","R0003012","R0003012.pdf","paywalled","other_trial","Hu H","2026","Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies.","Biochemical pharmacology","Elsevier BV","10.1016/j.bcp.2026.118405","https://doi.org/10.1016/j.bcp.2026.118405","42667964","https://pubmed.ncbi.nlm.nih.gov/42667964/",null,null],["5","R0003321","R0003321.pdf","paywalled","other_trial","Ravic M","2026","Cardiovascular effects of incretin receptor agonists: beyond glycemic control.","Canadian journal of physiology and pharmacology","Canadian Science Publishing","10.1139/cjpp-2026-0184","https://doi.org/10.1139/cjpp-2026-0184","42721492","https://pubmed.ncbi.nlm.nih.gov/42721492/",null,null],["5","R0003534","R0003534.pdf","paywalled","other_trial","Sigalov A","2026","Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001468","https://doi.org/10.1097/crd.0000000000001468","42745233","https://pubmed.ncbi.nlm.nih.gov/42745233/",null,null],["5","R0003539","R0003539.pdf","paywalled","other_trial","Sergi CM","2026","Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2026.108493","https://doi.org/10.1016/j.cct.2026.108493","42822760","https://pubmed.ncbi.nlm.nih.gov/42822760/",null,null],["5","R0003573","R0003573.pdf","paywalled","other_trial","Cuomo A","2026","Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2026.2634195","https://doi.org/10.1080/14656566.2026.2634195","41701518","https://pubmed.ncbi.nlm.nih.gov/41701518/",null,null],["5","R0003743","R0003743.pdf","paywalled","other_trial","Morse BL","2026","Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.1594","https://doi.org/10.1002/cpdd.1594","40888509","https://pubmed.ncbi.nlm.nih.gov/40888509/",null,null],["5","R0004011","R0004011.pdf","paywalled","other_trial","Tian X","2026","From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.","Translational research : the journal of laboratory and clinical medicine","Elsevier BV","10.1016/j.trsl.2026.07.008","https://doi.org/10.1016/j.trsl.2026.07.008","42480913","https://pubmed.ncbi.nlm.nih.gov/42480913/",null,null],["5","R0004418","R0004418.pdf","paywalled","other_trial","Obagi ZE","2026","Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment.","Journal of drugs in dermatology : JDD","SanovaWorks","10.36849/jdd.10086","https://doi.org/10.36849/jdd.10086","42696340","https://pubmed.ncbi.nlm.nih.gov/42696340/",null,null],["5","R0004589","R0004589.pdf","paywalled","other_trial","Hu S","2026","Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001053","https://doi.org/10.2215/cjn.0000001053","41805697","https://pubmed.ncbi.nlm.nih.gov/41805697/",null,"ClinicalTrials.gov:NCT05570305; ClinicalTrials.gov:NCT06150924; ClinicalTrials.gov:NCT00287183; ClinicalTrials.gov:NCT02010242; ClinicalTrials.gov:NCT00044421; ClinicalTrials.gov:NCT03926117; ClinicalTrials.gov:NCT01683409; ClinicalTrials.gov:NCT05314231; ClinicalTrials.gov:NCT00913393"],["5","R0005276","R0005276.pdf","paywalled","other_trial","Hölscher C","2026","Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.","Journal of Alzheimer's disease : JAD","SAGE Publications","10.1177/13872877261458402","https://doi.org/10.1177/13872877261458402","42261705","https://pubmed.ncbi.nlm.nih.gov/42261705/",null,null],["5","R0005295","R0005295.pdf","paywalled","other_trial","Seufert J","2026","[Obesity: novel pharmacological treatments].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/a-2610-3294","https://doi.org/10.1055/a-2610-3294","41802423","https://pubmed.ncbi.nlm.nih.gov/41802423/",null,null],["5","R0005312","R0005312.pdf","paywalled","other_trial","Martinez Leon V","2026","Mechanisms of diabetic kidney disease and established and emerging treatments.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/s41574-025-01171-3","https://doi.org/10.1038/s41574-025-01171-3","40935879","https://pubmed.ncbi.nlm.nih.gov/40935879/",null,null],["5","R0005529","R0005529.pdf","paywalled","other_trial","Hu W","2026","Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights.","Pharmacological reviews","Elsevier BV","10.1016/j.pharmr.2026.100125","https://doi.org/10.1016/j.pharmr.2026.100125","41950803","https://pubmed.ncbi.nlm.nih.gov/41950803/",null,null],["5","R0005666","R0005666.pdf","paywalled","other_trial","Jaiswal A","2026","Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS.","Journal of pharmaceutical and biomedical analysis","Elsevier BV","10.1016/j.jpba.2025.117128","https://doi.org/10.1016/j.jpba.2025.117128","40865303","https://pubmed.ncbi.nlm.nih.gov/40865303/",null,null],["5","R0005973","R0005973.pdf","paywalled","protocol","Luo Y","2026","Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2025.108150","https://doi.org/10.1016/j.cct.2025.108150","41260459","https://pubmed.ncbi.nlm.nih.gov/41260459/",null,null],["5","R0006423","R0006423.pdf","paywalled","other_trial","Shah J","2026","Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.","American journal of nephrology","S. Karger AG","10.1159/ajn/ablag011","https://doi.org/10.1159/ajn/ablag011","42715144","https://pubmed.ncbi.nlm.nih.gov/42715144/",null,null],["5","R0007130","R0007130.pdf","paywalled","protocol","Ridker PM","2026","Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction.","JAMA cardiology","American Medical Association (AMA)","10.1001/jamacardio.2025.4491","https://doi.org/10.1001/jamacardio.2025.4491","41369941","https://pubmed.ncbi.nlm.nih.gov/41369941/",null,"ClinicalTrials.gov:NCT05021835"],["5","R0007606","R0007606.pdf","paywalled","other_trial","Shastry S","2026","Pharmacotherapy in obstructive sleep apnoea: a clinical guide.","Sleep & breathing = Schlaf & Atmung","Springer Science and Business Media LLC","10.1007/s11325-026-03724-w","https://doi.org/10.1007/s11325-026-03724-w","42557390","https://pubmed.ncbi.nlm.nih.gov/42557390/",null,null],["5","R0007691","R0007691.pdf","paywalled","other_trial","Schmitz SH","2026","A Review of First-Generation Obesity Medications.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-026-01389-0","https://doi.org/10.1007/s11883-026-01389-0","41569475","https://pubmed.ncbi.nlm.nih.gov/41569475/",null,null],["5","R0008365","R0008365.pdf","paywalled","other_trial","Liuzzo G","2026","Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag194","https://doi.org/10.1093/eurheartj/ehag194","41879154","https://pubmed.ncbi.nlm.nih.gov/41879154/",null,null],["5","R0008873","R0008873.pdf","paywalled","other_trial","Ren QW","2026","Glucagon-like peptide-1 analogues and prevention of atrial fibrillation: clinical and mechanistic insights.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaf242","https://doi.org/10.1093/eurjpc/zwaf242","40300803","https://pubmed.ncbi.nlm.nih.gov/40300803/",null,null],["5","R0009408","R0009408.pdf","paywalled","other_trial","Monami M","2026","Are Women Living With Obesity More Responsive to GLP-1 Receptor Agonists? A Potential Signal From Trial-Level and Within-Trial Analyses.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70956","https://doi.org/10.1111/dom.70956","42244476","https://pubmed.ncbi.nlm.nih.gov/42244476/",null,null],["5","R0010303","R0010303.pdf","paywalled","other_trial","Abegaz TM","2026","Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2026.103060","https://doi.org/10.1016/j.jchf.2026.103060","42012431","https://pubmed.ncbi.nlm.nih.gov/42012431/",null,null],["5","R0011012","R0011012.pdf","paywalled","other_trial","Wise J","2026","Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-101016","https://doi.org/10.1136/bmj-2026-101016","42823062","https://pubmed.ncbi.nlm.nih.gov/42823062/",null,null],["5","R0011081","R0011081.pdf","paywalled","other_trial","Tetelbaun L","2026","The First Triple Agonist for Antiobesity: Retatrutide.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000793","https://doi.org/10.1097/crd.0000000000000793","39724554","https://pubmed.ncbi.nlm.nih.gov/39724554/",null,null],["5","R0011237","R0011237.pdf","paywalled","other_trial","Pantazopoulos D","2026","Walking Further with GLP-1RAs: Lessons from the STRIDE Trial.","The international journal of lower extremity wounds","SAGE Publications","10.1177/15347346251385584","https://doi.org/10.1177/15347346251385584","41170686","https://pubmed.ncbi.nlm.nih.gov/41170686/",null,null],["5","R0011259","R0011259.pdf","paywalled","other_trial","de Souza PC","2026","Advances in neurological therapies: A review of clinical trials in Alzheimer's, Parkinson's, and multiple sclerosis.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2025.11.025","https://doi.org/10.1016/j.amjmed.2025.11.025","41318018","https://pubmed.ncbi.nlm.nih.gov/41318018/",null,null],["5","R0011478","R0011478.pdf","paywalled","other_trial","Wang WT","2026","Adjunctive diabetes therapies and cardiovascular protection in type 1 diabetes: tackling the challenging Tchaikovsky piece.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000940","https://doi.org/10.1097/med.0000000000000940","41123381","https://pubmed.ncbi.nlm.nih.gov/41123381/",null,null],["5","R0011514","R0011514.pdf","paywalled","other_trial","Dhanya Dedeepya S","2026","Comment on \"Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study\".","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2026.103418","https://doi.org/10.1016/j.dsx.2026.103418","41967333","https://pubmed.ncbi.nlm.nih.gov/41967333/",null,null],["5","R0011847","R0011847.pdf","paywalled","other_trial","Soriano ER","2026","What's next in psoriatic arthritis therapy? A look at the pipeline.","Current opinion in rheumatology","Ovid Technologies (Wolters Kluwer Health)","10.1097/bor.0000000000001157","https://doi.org/10.1097/bor.0000000000001157","41841660","https://pubmed.ncbi.nlm.nih.gov/41841660/",null,null],["5","R0011928","R0011928.pdf","paywalled","other_trial","Pillai AA","2026","Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001310","https://doi.org/10.1097/crd.0000000000001310","42108533","https://pubmed.ncbi.nlm.nih.gov/42108533/",null,null],["5","R0012128","R0012128.pdf","paywalled","other_trial","Rode JB","2026","Meal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity.","Childhood obesity (Print)","SAGE Publications","10.1177/21532176261457202","https://doi.org/10.1177/21532176261457202","42281167","https://pubmed.ncbi.nlm.nih.gov/42281167/",null,"ClinicalTrials.gov:NCT02496611"],["5","R0012130","R0012130.pdf","paywalled","other_trial","Lee A","2026","Tradipitant: First Approval.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-026-02313-1","https://doi.org/10.1007/s40265-026-02313-1","41945307","https://pubmed.ncbi.nlm.nih.gov/41945307/",null,null],["5","R0012196","R0012196.pdf","paywalled","other_trial","Lang K","2026","Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj-2026-102036","https://doi.org/10.1136/bmj-2026-102036","42264536","https://pubmed.ncbi.nlm.nih.gov/42264536/",null,null],["5","R0012240","R0012240.pdf","paywalled","other_trial","Dhanush Y","2026","Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions.","Metabolic brain disease","Springer Science and Business Media LLC","10.1007/s11011-026-01961-2","https://doi.org/10.1007/s11011-026-01961-2","42714656","https://pubmed.ncbi.nlm.nih.gov/42714656/",null,null],["5","R0012781","R0012781.pdf","paywalled","other_trial","Muskiet MHA","2026","Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)01776-3","https://doi.org/10.1016/s0140-6736(25)01776-3","41207308","https://pubmed.ncbi.nlm.nih.gov/41207308/",null,null],["5","R0012876","R0012876.pdf","paywalled","other_trial","Woo KA","2026","Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/awag195","https://doi.org/10.1093/brain/awag195","42217255","https://pubmed.ncbi.nlm.nih.gov/42217255/",null,null],["5","R0012929","R0012929.pdf","paywalled","other_trial","Khan I","2026","Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-026-04686-5","https://doi.org/10.1007/s12020-026-04686-5","42387035","https://pubmed.ncbi.nlm.nih.gov/42387035/",null,null],["5","R0012934","R0012934.pdf","paywalled","other_trial","Gurney R","2026","Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/awag186","https://doi.org/10.1093/brain/awag186","42175654","https://pubmed.ncbi.nlm.nih.gov/42175654/",null,null],["5","R0013233","R0013233.pdf","paywalled","other_trial","Heinberg LJ","2026","Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.70056","https://doi.org/10.1002/oby.70056","41253738","https://pubmed.ncbi.nlm.nih.gov/41253738/",null,"ClinicalTrials.gov:NCT06034457"],["5","R0013364","R0013364.pdf","paywalled","other_trial","Bansal MB","2026","Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001608","https://doi.org/10.1097/hep.0000000000001608","41201884","https://pubmed.ncbi.nlm.nih.gov/41201884/",null,null],["5","R0013508","R0013508.pdf","paywalled","other_trial","Öngür D","2026","Semaglutide in Schizophrenia-A Top Clinical Trial.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2026.2043","https://doi.org/10.1001/jamapsychiatry.2026.2043","42384388","https://pubmed.ncbi.nlm.nih.gov/42384388/",null,null],["5","R0014009","R0014009.pdf","paywalled","other_trial","Adinolfi LE","2026","Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2026.2714267","https://doi.org/10.1080/17446651.2026.2714267","42552573","https://pubmed.ncbi.nlm.nih.gov/42552573/",null,null],["5","R0014106","R0014106.pdf","paywalled","other_trial","Mora R","2026","Effect of semaglutide on left ventricular mass in patients with type 2 diabetes: A cardiac CT substudy of the STOP trial.","Journal of cardiovascular computed tomography","Elsevier BV","10.1016/j.jcct.2026.08.010","https://doi.org/10.1016/j.jcct.2026.08.010","42665510","https://pubmed.ncbi.nlm.nih.gov/42665510/",null,null],["5","R0014140","R0014140.pdf","paywalled","other_trial","Ravindhran B","2026","The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.","European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","Elsevier BV","10.1016/j.ejvs.2026.07.037","https://doi.org/10.1016/j.ejvs.2026.07.037","42462869","https://pubmed.ncbi.nlm.nih.gov/42462869/",null,null],["5","R0014390","R0014390.pdf","paywalled","other_trial","Chen X","2026","Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.","Neurocritical care","Springer Science and Business Media LLC","10.1007/s12028-025-02446-3","https://doi.org/10.1007/s12028-025-02446-3","41644924","https://pubmed.ncbi.nlm.nih.gov/41644924/",null,null],["5","R0014778","R0014778.pdf","paywalled","other_trial","Bilato C","2026","Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2026.104872","https://doi.org/10.1016/j.numecd.2026.104872","42469146","https://pubmed.ncbi.nlm.nih.gov/42469146/",null,null],["5","R0015174","R0015174.pdf","paywalled","other_trial","Mangalesh S","2026","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00255-2","https://doi.org/10.1016/s0140-6736(26)00255-2","42035776","https://pubmed.ncbi.nlm.nih.gov/42035776/",null,null],["5","R0015183","R0015183.pdf","paywalled","other_trial","Tondt J","2026","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00256-4","https://doi.org/10.1016/s0140-6736(26)00256-4","42035775","https://pubmed.ncbi.nlm.nih.gov/42035775/",null,null],["5","R0015289","R0015289.pdf","paywalled","other_trial","Deanfield J","2026","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(26)00706-3","https://doi.org/10.1016/s0140-6736(26)00706-3","42035774","https://pubmed.ncbi.nlm.nih.gov/42035774/",null,null],["5","R0015635","R0015635.pdf","paywalled","other_trial","Wang N","2026","Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70571","https://doi.org/10.1111/dom.70571","41705640","https://pubmed.ncbi.nlm.nih.gov/41705640/",null,null],["5","R0015866","R0015866.pdf","paywalled","other_trial","Abdul Jabbar AB","2026","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-026-01424-0","https://doi.org/10.1007/s11883-026-01424-0","42142201","https://pubmed.ncbi.nlm.nih.gov/42142201/",null,null],["5","R0016155","R0016155.pdf","paywalled","other_trial","Sourij H","2026","Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup Analysis.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.10.080","https://doi.org/10.1016/j.jacc.2025.10.080","41532935","https://pubmed.ncbi.nlm.nih.gov/41532935/",null,null],["5","R0016332","R0016332.pdf","paywalled","other_trial","Dunn W","2026","Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101172","https://doi.org/10.1016/j.medj.2026.101172","42285042","https://pubmed.ncbi.nlm.nih.gov/42285042/",null,null],["5","R0016643","R0016643.pdf","paywalled","other_trial","Alkhouri N","2026","Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.70639","https://doi.org/10.1111/apt.70639","41941221","https://pubmed.ncbi.nlm.nih.gov/41941221/",null,null],["5","R0016651","R0016651.pdf","paywalled","other_trial","Pereira Da Silva AM","2026","GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program.","Journal of Alzheimer's disease : JAD","SAGE Publications","10.1177/13872877261485580","https://doi.org/10.1177/13872877261485580","42720565","https://pubmed.ncbi.nlm.nih.gov/42720565/",null,null],["5","R0016775","R0016775.pdf","paywalled","other_trial","Petermann-Rocha F","2026","How would the use of Semaglutide impact the Chilean population? An estimated analysis following the SELECT trial approach.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70260","https://doi.org/10.1111/dom.70260","41177925","https://pubmed.ncbi.nlm.nih.gov/41177925/",null,null],["5","R0019291","R0019291.pdf","paywalled","other_trial","Patil R","2026","Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-026-02301-5","https://doi.org/10.1007/s40265-026-02301-5","41831171","https://pubmed.ncbi.nlm.nih.gov/41831171/",null,null],["5","R0029259","R0029259.pdf","paywalled","other_trial","Ard JD","2026","The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.70228","https://doi.org/10.1111/obr.70228","42860310","https://pubmed.ncbi.nlm.nih.gov/42860310/",null,null],["5","R0029312","R0029312.pdf","paywalled","other_trial","Wang K","2026","Effects of a GLP-1 agonist and anti-diabetic therapies on pheochromocytoma/paraganglioma growth.","Endocrine-related cancer","Bioscientifica","10.1530/erc-26-0283","https://doi.org/10.1530/erc-26-0283","42847129","https://pubmed.ncbi.nlm.nih.gov/42847129/",null,"ClinicalTrials.gov:NCT03344016"],["5","R0029320","R0029320.pdf","paywalled","other_trial","Levy CJ","2026","A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: The twiist-T2D Pivotal Trial.","Diabetes care",null,"10.2337/dc26-1270","https://doi.org/10.2337/dc26-1270","42844027","https://pubmed.ncbi.nlm.nih.gov/42844027/",null,null],["5","R0029413","R0029413.pdf","paywalled","other_trial","Muskiet MHA","2026","Targeting kidney disease in type 1 diabetes: progress and promise.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2026.2714265","https://doi.org/10.1080/17446651.2026.2714265","42557690","https://pubmed.ncbi.nlm.nih.gov/42557690/",null,null],["5","R0029531","R0029531.pdf","paywalled","other_trial","Smith BL","2026","Challenges in the management of obesity.","Journal of clinical lipidology","Elsevier BV","10.1016/j.jacl.2025.09.023","https://doi.org/10.1016/j.jacl.2025.09.023","41708210","https://pubmed.ncbi.nlm.nih.gov/41708210/",null,null],["5","R0029541","R0029541.pdf","paywalled","other_trial","Hierholzer J","2026","Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations.","Biochimica et biophysica acta. Molecular basis of disease","Elsevier BV","10.1016/j.bbadis.2026.168172","https://doi.org/10.1016/j.bbadis.2026.168172","41587701","https://pubmed.ncbi.nlm.nih.gov/41587701/",null,null],["5","R0029805","R0029805.pdf","paywalled","other_trial","Abdul Jabbar AB","2026","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-025-01376-x","https://doi.org/10.1007/s11883-025-01376-x","41493497","https://pubmed.ncbi.nlm.nih.gov/41493497/",null,null],["5","R0029923","R0029923.pdf","paywalled","other_trial","Qian L","2026","Recent Advances in Diabetes Therapies in Asia.","Diabetes care","American Diabetes Association","10.2337/dci26-0057","https://doi.org/10.2337/dci26-0057","42627354","https://pubmed.ncbi.nlm.nih.gov/42627354/",null,null],["5","R0032425","R0032425.pdf","paywalled","other_trial",null,"2026","Orforglipron offers greater weight loss for people with diabetes than oral semaglutide","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2026.1.401466","https://doi.org/10.1211/pj.2026.1.401466",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032520","R0032520.pdf","paywalled","other_trial","Coracle Research","2026","3,800 GLP-1 Family Analog Sequences with Predicted Pharmacology, Synthesis Routes, Binding Assay Protocols, and Pharmacokinetic Projections, Disclosed as Public-Domain Prior Art Under 35 U.S.C. §102 Across Mono-, Dual-, Triple-Receptor Agonist and Oxyntomodulin-Like Scaffolds","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19801438","https://doi.org/10.5281/zenodo.19801438",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032597","R0032597.pdf","paywalled","other_trial","Ernest Nsubuga","2026","Dual GIP/GLP-1 Receptor Agonists for Type 2 Diabetes: Efficacy and Metabolic Benefits","International Academic Association Journal of Scientific Research.","International Digital Organization for Scientific Research","10.59298/iaajsr/2026/1315564","https://doi.org/10.59298/iaajsr/2026/1315564",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032644","R0032644.pdf","paywalled","other_trial","Kintuza Lumwako Tebulo","2026","Novel Pharmacotherapies for Type 2 Diabetes","IDOSR JOURNAL OF SCIENTIFIC RESEARCH","International Digital Organization for Scientific Research","10.59298/idosrjsr/2026/11.1.131138","https://doi.org/10.59298/idosrjsr/2026/11.1.131138",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033061","R0033061.pdf","paywalled","other_trial",null,"2026","Phase III retatrutide study demonstrates 30% weight loss","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2026.1.413195","https://doi.org/10.1211/pj.2026.1.413195",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033103","R0033103.pdf","paywalled","other_trial","Ye Jiang","2026","2543-P: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity","Diabetes","American Diabetes Association","10.2337/db26-2543-p","https://doi.org/10.2337/db26-2543-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033109","R0033109.pdf","paywalled","other_trial","HAO QI","2026","2544-P: INHBE-siRNA as a Promising Antiobesity Therapy: Preclinical Evaluation in Diet-Induced-Obesity Humanized INHBE Mice","Diabetes","American Diabetes Association","10.2337/db26-2544-p","https://doi.org/10.2337/db26-2544-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033115","R0033115.pdf","paywalled","other_trial","QUANG NGUYEN","2026","2649-P: Population-Normed Z-scores for Body Composition Enhance Sensitivity and Effect Size: Analysis of a Phase 2 RCT Testing Anti-GDF8 and Anti-Activin A on Top of Semaglutide (COURAGE)","Diabetes","American Diabetes Association","10.2337/db26-2649-p","https://doi.org/10.2337/db26-2649-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06299098"],["5","R0033119","R0033119.pdf","paywalled","protocol","Lloyd Tran","2026","2644-P: A Phase 3 Clinical Protocol Evaluating the Safety and Efficacy of NA-931 Alone and in Combination with Oral Semaglutide for the Treatment of Obesity","Diabetes","American Diabetes Association","10.2337/db26-2644-p","https://doi.org/10.2337/db26-2644-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033137","R0033137.pdf","paywalled","other_trial","Vanita D. Sood","2026","3094-LB: FBL-140, a Best-in-Class ActR2A/B mAb Designed for Infrequent SC Dosing for Treatment of Obesity","Diabetes","American Diabetes Association","10.2337/db26-3094-lb","https://doi.org/10.2337/db26-3094-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033141","R0033141.pdf","paywalled","other_trial","Ying Wang","2026","2594-P: XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Weight Loss and Obesity-Related Complications","Diabetes","American Diabetes Association","10.2337/db26-2594-p","https://doi.org/10.2337/db26-2594-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07205432"],["5","R0033409","R0033409.pdf","paywalled","other_trial",null,"2026","Semaglutide reduces drinking in adults with alcohol use disorder and obesity","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31472","https://doi.org/10.1002/pu.31472",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033473","R0033473.pdf","paywalled","other_trial","Masooma Arshad","2026","WEIGHT GAIN IN RELATION TO PCOS : A REVIEW","Figshare",null,"10.6084/m9.figshare.31934085","https://doi.org/10.6084/m9.figshare.31934085",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033504","R0033504.pdf","paywalled","other_trial","Rakesh Kumar Sharma2 Arun Kumar Gulia*","2026","Emerging Therapies in Type 2 Diabetes Mellitus: A Comprehensive Review","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20493294","https://doi.org/10.5281/zenodo.20493294",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033539","R0033539.pdf","paywalled","protocol","Hallström, Sara","2026","Statistical Analysis Plan, Efficacy on cardiovascular outcomes from sustained use of GLP-1 receptor agonists versus DPP-4 inhipitors: A LEADER-inspired trial emulation using the Swedish National Diabetes Register.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15311400","https://doi.org/10.5281/zenodo.15311400",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033602","R0033602.pdf","paywalled","other_trial","Muhammad Usman Malik","2026","Book of inventions From Cancer to Mental Health diseases Cure. 3rd Extension.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18271205","https://doi.org/10.5281/zenodo.18271205",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033809","R0033809.pdf","paywalled","other_trial","M.D Dr Kulvinder Kochar Kaur","2026","Imeglimin-A New Oral Antidiabetic Agent in the Armamentarium of Resistant type2 Diabetics Specifically Regarding t2d with Correlated Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Minireview","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18437560","https://doi.org/10.5281/zenodo.18437560",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033883","R0033883.pdf","paywalled","other_trial","Carlos Manuel Venegas Valverde","2026","Glucagon-Like Peptide-1 Receptor Agonists Beyond Diabetes Mellitus: Pathophysiological Foundations and Clinical Applications in Obesity, Heart Failure, Chronic Kidney Disease, and Hepatic Steatosis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19849378","https://doi.org/10.5281/zenodo.19849378",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033955","R0033955.pdf","paywalled","other_trial","Edapalapati Venkata Naga Nithin*1, Raveendra N2, Binaya Kumar Sethy3, Darshana Vinod Rane4, Ayesha Jamal5","2026","A Systems Pharmacology Approach to Diabetes Management: Integrating Drug Therapy, Lifestyle Modulation, and Personalised Treatment Algorithm","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20790751","https://doi.org/10.5281/zenodo.20790751",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033965","R0033965.pdf","paywalled","protocol","Jens Michelsen","2026","Statistical analysis plan: Cardiovascular effectiveness of GLP-1 receptor agonists beyond cardiovascular outcome trial populations, a nationwide target trial emulation in the Swedish National Diabetes Register","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20234499","https://doi.org/10.5281/zenodo.20234499",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033993","R0033993.pdf","paywalled","other_trial","Patil Ruchika Rajendra","2026","Resmetirom: An Innovative Treatment for Steatohepatitis Associated with Metabolic Dysfunction (MASH)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19048525","https://doi.org/10.5281/zenodo.19048525",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034001","R0034001.pdf","paywalled","protocol","Vicky Muller Ferreira","2026","HEARTLAND PROTOCOL Heart failure Evidence-based Access in Rural Treatment, Linking Advanced Network Delivery","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.18408303","https://doi.org/10.5281/zenodo.18408303",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034217","R0034217.pdf","paywalled","other_trial","Pravin Dighe Akanksha Borhade*","2026","Finerenone: Advances in Pharmacology, Clinical Efficacy, and Future Therapeutic Directions","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21267791","https://doi.org/10.5281/zenodo.21267791",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034225","R0034225.pdf","paywalled","other_trial",null,"2026","Health news round-up: 'landmark' long COVID trial results and are contraceptives linked to brain tumours?","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2026.1.419194","https://doi.org/10.1211/pj.2026.1.419194",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034226","R0034226.pdf","paywalled","other_trial","Chandrabhansinh Chavda","2026","Building a Health Canada Clinical Trial Application in CTD Format: Lessons from a Capstone Dossier","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21312742","https://doi.org/10.5281/zenodo.21312742",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034227","R0034227.pdf","paywalled","other_trial","Harika Adapa","2026","Beyond the Ceiling: GLP-1 Receptor Agonist and Long-Acting Amylin Analogue Combination Therapy: From Molecular Design to New Drug Submission in Canada","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21312474","https://doi.org/10.5281/zenodo.21312474",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034812","R0034812.pdf","paywalled","protocol","Brian Kilgore","2026","Defensive Publication: A Gallstone-Risk-Stratified Multi-Organ Biliary and Renal Safety-Monitoring and Prophylaxis Protocol for Patients on GLP-1 Receptor Agonist Therapy (Method of Use)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21373807","https://doi.org/10.5281/zenodo.21373807",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034813","R0034813.pdf","paywalled","protocol","Brian Kilgore","2026","Scientific-Priority Disclosure: A Cholecystectomy-Status-Stratified Cohort Design Combined with a Formal VanderWeele Causal-Mediation Analysis (Natural Direct/Indirect Effects) to Determine Whether GLP-1 Receptor Agonist-Associated Acute Pancreatitis Is Gallstone (Biliary)-Mediated and Preventable — A Proposed Study Protocol","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21373810","https://doi.org/10.5281/zenodo.21373810",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034834","R0034834.pdf","paywalled","protocol","Muhammad Usman Malik","2026","N-K AC-D-1 — First Anti-Diabetes Medicine Designed by N-K Semi-Real Intelligence (SRI) — Complete Chemical Formula, Manufacturing Protocol, and Clinical Guidelines","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21493285","https://doi.org/10.5281/zenodo.21493285",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035801","R0035801.pdf","paywalled","other_trial","Thomason Rajan","2026","Eli Lilly’s Mounjaro in India: the race to shape a new market for obesity care","The CASE Journal","Emerald","10.1108/tcj-11-2025-0394","https://doi.org/10.1108/tcj-11-2025-0394",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035995","R0035995.pdf","paywalled","other_trial","J Bergman","2026","Endoscopic Ultrasound-Guided Delivery of Single-Dose Glucagon-like Peptide-1 Pancreatic Gene Therapy: Feasibility and Safety in a Porcine Model","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1820877","https://doi.org/10.1055/s-0046-1820877",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036322","R0036322.pdf","paywalled","other_trial",null,"2026","UK patients being recruited for ribupatide trials","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2026.1.423674","https://doi.org/10.1211/pj.2026.1.423674",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT07284901; ClinicalTrials.gov:NCT07284875"],["5","R0036626","R0036626.pdf","paywalled","protocol","Mohammed Abdu Seid","2026","The effects of glucagon-like peptide-1-based medications on muscle and bone health in type 2 diabetes mellitus: A scoping review protocol","Open Science Framework",null,"10.17605/osf.io/y9cmk","https://doi.org/10.17605/osf.io/y9cmk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036676","R0036676.pdf","paywalled","protocol","Kutsyba, Tetiana","2026","“Pancreatic and Gallbladder safety of Tirzepatide in Obesity Management: A Scoping Review Protocol of Clinical and Real-World Evidence”","Open Science Framework",null,"10.17605/osf.io/pdzm6","https://doi.org/10.17605/osf.io/pdzm6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036745","R0036745.pdf","paywalled","other_trial","Gary Enos","2026","Large VA trial will evaluate effects of semaglutide for AUD","Alcoholism & Drug Abuse Weekly","Wiley","10.1002/adaw.35017","https://doi.org/10.1002/adaw.35017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036748","R0036748.pdf","paywalled","other_trial","Ankitha M2 Aswin Shaji*1","2026","Semaglutide in Chronic Kidney Disease: Current Evidence, Clinical Applications, and Future Perspectives","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.21927215","https://doi.org/10.5281/zenodo.21927215",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037254","R0037254.pdf","paywalled","other_trial","VISWANATHAN MOHAN","2026","1738-P: Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Baseline A1C: COMBINE 1–3","Diabetes","American Diabetes Association","10.2337/db26-1738-p","https://doi.org/10.2337/db26-1738-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037465","R0037465.pdf","paywalled","other_trial","Riccardo De Giorgi","2026","Promises & pitfalls of GLP-1-based therapies for cognitive and mental disorders",null,"BMJ Publishing Group Ltd","10.1136/jnnp-2026-bnpa.3","https://doi.org/10.1136/jnnp-2026-bnpa.3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037523","R0037523.pdf","paywalled","other_trial","Matt Shirley","2026","Orforglipron: First Approval","Figshare",null,"10.6084/m9.figshare.32817425","https://doi.org/10.6084/m9.figshare.32817425",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037569","R0037569.pdf","paywalled","other_trial","Naim Alkhouri","2026","TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01885-4","https://doi.org/10.1016/s0168-8278(26)01885-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037587","R0037587.pdf","paywalled","other_trial","DAISUKE YABE","2026","1758-P: Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Baseline BMI: COMBINE 1–3","Diabetes","American Diabetes Association","10.2337/db26-1758-p","https://doi.org/10.2337/db26-1758-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037605","R0037605.pdf","paywalled","other_trial","LAUREN A. WATERMAN","2026","2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders","Diabetes","American Diabetes Association","10.2337/db26-2100-p","https://doi.org/10.2337/db26-2100-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037632","R0037632.pdf","paywalled","other_trial",null,"2026","Correlation of Weight loss and 36-Item Short Form Survey Total Score in Weight Management with Semaglutide Injection: Post-Hoc Analysis of Phase 3 Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.057","https://doi.org/10.1016/j.eprac.2026.03.057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037757","R0037757.pdf","paywalled","other_trial","Aditya Mishra","2026","Redefining Diabetes Management: From Escalating Insulin to Overcoming Insulin Resistance — The Complete Evidence-Based Framework And Role of Insulin In Systemic Organ Damage, Oncogenesis, Clinical Trial Evidence, and Historical Warnings.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19014349","https://doi.org/10.5281/zenodo.19014349",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038138","R0038138.pdf","paywalled","other_trial","Giovanni B. Munari","2026","Semaglutide e benefici cardiovascolari indipendenti dalla perdita di peso: analisi del trial SELECT","L Endocrinologo","Springer Science and Business Media LLC","10.1007/s40619-026-01844-9","https://doi.org/10.1007/s40619-026-01844-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038140","R0038140.pdf","paywalled","other_trial","Ye Jiang","2026","1678-P: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing through Phase 1 Clinical Trials","Diabetes","American Diabetes Association","10.2337/db26-1678-p","https://doi.org/10.2337/db26-1678-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038330","R0038330.pdf","paywalled","other_trial","Seongho Jo","2026","1319-OR: Oral TIX100 Protects against Weight Rebound after Semaglutide Discontinuation","Diabetes","American Diabetes Association","10.2337/db26-1319-or","https://doi.org/10.2337/db26-1319-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038353","R0038353.pdf","paywalled","other_trial",null,"2026","Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Post Prandial Blood Glucose","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.026","https://doi.org/10.1016/j.eprac.2026.03.026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038381","R0038381.pdf","paywalled","other_trial","Ellen Vercalsteren","2026","2551-P: Survodutide Improves Stroke Outcome in Obese/Type 2 Diabetic Mice","Diabetes","American Diabetes Association","10.2337/db26-2551-p","https://doi.org/10.2337/db26-2551-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038404","R0038404.pdf","paywalled","other_trial","Dr John Suschak","2026","FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01936-7","https://doi.org/10.1016/s0168-8278(26)01936-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038503","R0038503.pdf","paywalled","other","WEIHAO WANG","2026","1775-P: Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db26-1775-p","https://doi.org/10.2337/db26-1775-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446"],["5","R0038504","R0038504.pdf","paywalled","other_trial","PETTER BJORNSTAD","2026","1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D","Diabetes","American Diabetes Association","10.2337/db26-1134-or","https://doi.org/10.2337/db26-1134-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05260021"],["5","R0038516","R0038516.pdf","paywalled","other_trial","H Santos Moreira","2026","Prevalence of eligibility for dual GIP/GLP-1 receptor agonists among non-diabetic and overweight adults - a Portuguese community-based study","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag193.1297","https://doi.org/10.1093/ejhf/xuag193.1297",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04184622"],["5","R0038812","R0038812.pdf","paywalled","other_trial","D Horn","2026","Association of Weight Reduction with Weight-Cycling Parameters: A SURMOUNT-5 Trial Post-Hoc Analysis","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819985","https://doi.org/10.1055/s-0046-1819985",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038991","R0038991.pdf","paywalled","other_trial",null,"2026","Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Fasting Blood Glucose","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.03.027","https://doi.org/10.1016/j.eprac.2026.03.027",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039065","R0039065.pdf","paywalled","other_trial",null,"2026","Orforglipron is Associated With Body Weight Reductions Across All Body Mass Index Categories by Sex in Adults With Obesity or Overweight, Without Type 2 Diabetes: ATTAIN-1 Trial Post hoc Analysis","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2026.01.322","https://doi.org/10.1016/j.eprac.2026.01.322",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039096","R0039096.pdf","paywalled","other_trial","Matt Shirley","2026","Orforglipron: First Approval","Figshare",null,"10.6084/m9.figshare.32817425.v1","https://doi.org/10.6084/m9.figshare.32817425.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039148","R0039148.pdf","paywalled","other_trial","Leszek Czupryniak","2026","1739-P: Impact of IGlarLixi on Glycemic Variability (GV): A Participant-Level Exploratory Pooled Analysis of the Global LixiLan Clinical Trial Program","Diabetes","American Diabetes Association","10.2337/db26-1739-p","https://doi.org/10.2337/db26-1739-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039265","R0039265.pdf","paywalled","other_trial","Paul Dendale","2026","World Hypertension League: education and awareness about the most important risk factor. An interview with prof Gianfranco Parati, president of WHL","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwag132","https://doi.org/10.1093/eurjpc/zwag132","42139551","https://pubmed.ncbi.nlm.nih.gov/42139551/",null,null],["5","R0039372","R0039372.pdf","paywalled","other_trial","Karina Elgueta","2026","1689-P: Impact and Effectiveness of Once-Weekly Semaglutide in Achieving Glycemic Targets among Public Health Care Patients with Type 2 Diabetes in Chile: A Multicenter Prospective Study","Diabetes","American Diabetes Association","10.2337/db26-1689-p","https://doi.org/10.2337/db26-1689-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039431","R0039431.pdf","paywalled","other_trial","Aayushi Pratap","2026","Can amylin weight-loss drugs compete in a world of GLP-1s?","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10405-feature3","https://doi.org/10.1021/cen-10405-feature3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039527","R0039527.pdf","paywalled","other_trial","Yongliang Fang","2026","FRI-156 DR10624, a novel FGF21R/GCGR/GLP-1R triple agonist, significantly reduced liver fat and improved hepatic and metabolic biomarkers in a phase 2 study of patients with severe hypertriglyceridemia","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01900-8","https://doi.org/10.1016/s0168-8278(26)01900-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039595","R0039595.pdf","paywalled","other_trial","ALICE Y.Y. CHENG","2026","1746-P: Post Hoc Analysis of Efficacy and Safety Outcomes of Efsitora vs. Once-Daily Insulin in Type 2 Diabetes by GLP-1RA Use across QWINT-1–4 Trials","Diabetes","American Diabetes Association","10.2337/db26-1746-p","https://doi.org/10.2337/db26-1746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039655","R0039655.pdf","paywalled","other_trial","Irene Cogliati","2026","1675-P: GLP-1 Receptor Agonists (GLP-1RAs) in Kidney-Transplanted (KTX) People with Diabetes: Ad Interim Results of an 18-Month Trial","Diabetes","American Diabetes Association","10.2337/db26-1675-p","https://doi.org/10.2337/db26-1675-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039803","R0039803.pdf","paywalled","other_trial","Vedanshu Malviya","2026","An Extensive Review of Semaglutide: A Comprehensive Analysis of its Role in Modern Metabolic Medicine","Asian Journal of Pharmaceutical Research","A and V Publications","10.52711/2231-5691.2026.00050","https://doi.org/10.52711/2231-5691.2026.00050",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039878","R0039878.pdf","paywalled","other_trial","X. Han","2026","L26/P-775 Impact of semaglutide on fertility and reproductive outcomes in female mice","Human Reproduction","Oxford University Press (OUP)","10.1093/humrep/deag083.1102","https://doi.org/10.1093/humrep/deag083.1102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041406","R0041406.pdf","paywalled","other_trial","iNGENū CRO","2026","Navigating the Complex Landscape of Obesity Clinical Trials: Diagnosis Criteria, Pivotal Endpoints, and Enhanced Protocols","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22104957","https://doi.org/10.5281/zenodo.22104957",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041776","R0041776.pdf","paywalled","other_trial","A Geier","2026","Phase 3 trial of survodutide in adults with obesity and MASLD","Zeitschrift für Gastroenterologie","Georg Thieme Verlag KG","10.1055/s-0046-1826555","https://doi.org/10.1055/s-0046-1826555",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042055","R0042055.pdf","paywalled","other_trial","Robert King Beathard","2026","Literature-Calibrated Computational Predictions for In Vivo Validation of the GLP-2 Receptor-Mediated Gut Barrier Relay Hypothesis — Barrier-Specific Endpoints with Transit Confound Correction (v2.0)",null,null,"10.17605/osf.io/5snqh","https://doi.org/10.17605/osf.io/5snqh",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042081","R0042081.pdf","paywalled","other_trial","Ankita Shindalkar*, Dr. Prajakta Kelgaonkar, Sadiya Shaikh, Vaishnavi Patil, Vasundhara Wadulkar","2026","Emerging Pharmacology of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Advances and Future Therapeutic Perspectives","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22219537","https://doi.org/10.5281/zenodo.22219537",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042119","R0042119.pdf","paywalled","other_trial","Maria Piggin","2026","Public involvement Insight Report - Proposed clinical trial to understand how Tirzepatide affects bone health in people living with obesity",null,null,"10.25560/128689","https://doi.org/10.25560/128689",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042124","R0042124.pdf","paywalled","protocol","Cristina Tejera","2026","Vitamin D and sarcopenia across the menopausal transition and postmenopause: a scoping review protocol mapping evidence, gaps and research priorities.",null,null,"10.17605/osf.io/jad3v","https://doi.org/10.17605/osf.io/jad3v",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042127","R0042127.pdf","paywalled","other_trial","Jeel Padaria","2026","Exposure, Not Route: Cardiovascular Pharmacology of Oral versus Injectable GLP-1 Receptor Agonists",null,null,"10.17605/osf.io/cyfsg","https://doi.org/10.17605/osf.io/cyfsg",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042139","R0042139.pdf","paywalled","protocol","Xiaocheng Li","2026","Genotype as a modifier of treatment response in MASLD/MASH: a scoping review of evidence, gaps and clinical implications — study protocol",null,null,"10.17605/osf.io/j9x72","https://doi.org/10.17605/osf.io/j9x72",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042143","R0042143.pdf","paywalled","other_trial","Robert King Beathard","2026","GLP-2 Relay Computational Predictions",null,null,"10.17605/osf.io/e7m8f","https://doi.org/10.17605/osf.io/e7m8f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042148","R0042148.pdf","paywalled","protocol","Josué Daniel Rodríguez Ríos","2026","Nutritional and Exercise Interventions for the Preservation of Lean Mass in Adults with Obesity Receiving GLP-1 Receptor Agonists or Related Incretin-Based Therapies: A Scoping Review Protocol",null,null,"10.17605/osf.io/d4gst","https://doi.org/10.17605/osf.io/d4gst",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042185","R0042185.pdf","paywalled","protocol","Hakeem Seidu-Aroza","2026","GLP-1 Receptor Agonists as Preoperative Prehabilitation for Abdominal Wall Hernia Repair in Patients With Obesity: A Scoping Review Protocol",null,null,"10.17605/osf.io/g7edh","https://doi.org/10.17605/osf.io/g7edh",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042188","R0042188.pdf","paywalled","protocol","Tala Al Ajmi","2026","Experiences and perceptions of stigma related to GLP-1/GIP-GLP-1 receptor agonist use: a scoping review protocol.",null,null,"10.17605/osf.io/sp3e8","https://doi.org/10.17605/osf.io/sp3e8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042210","R0042210.pdf","paywalled","other_trial","Akash Kumar Giri","2026","GLP-1 receptor agonists and incretin-based therapies in oral and craniofacial bone: a scoping review of bone healing, osseointegration, and orthodontic tooth movement",null,null,"10.17605/osf.io/3asy5","https://doi.org/10.17605/osf.io/3asy5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042211","R0042211.pdf","paywalled","protocol","Mina Ashraf Tawfik Goher","2026","Utilization patterns of GLP 1 RAs in Germany protocol for a population-based cohort study",null,null,"10.17605/osf.io/tvkq9","https://doi.org/10.17605/osf.io/tvkq9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"OSF:osf.io/8qa5x"],["5","R0042226","R0042226.pdf","paywalled","other_trial","Imeth Illamperuma","2026","Cardiovascular Imaging of GLP-1–Based Therapies in Adults: A Scoping Review of Remodeling Domains, Imaging Modalities, and Evidence Gaps",null,null,"10.17605/osf.io/2s78f","https://doi.org/10.17605/osf.io/2s78f",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042228","R0042228.pdf","paywalled","protocol","dong hannan","2026","Nurse-led supportive care interventions for adults receiving GLP-1 receptor agonists for obesity and/or type 2 diabetes: a scoping review protocol",null,null,"10.17605/osf.io/a7wmb","https://doi.org/10.17605/osf.io/a7wmb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042260","R0042260.pdf","paywalled","other_trial","K Laubner","2026","Phase 3 Trial of Survodutide Once Weekly for the Treatment of Adults with Obesity: SYNCHRONIZE™-1 (ID 62)","Adipositas - Ursachen Folgeerkrankungen Therapie","Georg Thieme Verlag KG","10.1055/s-0046-1827105","https://doi.org/10.1055/s-0046-1827105",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042269","R0042269.pdf","paywalled","other_trial",null,"2026","Semaglutide reduces craving for nicotine in Phase 2a trial","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31505","https://doi.org/10.1002/pu.31505",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042280","R0042280.pdf","paywalled","other_trial","Aayushi Pratap","2026","Lilly’s weight-loss pill wins FDA approval","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10405-buscon4","https://doi.org/10.1021/cen-10405-buscon4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043017","R0043017.pdf","paywalled","protocol","Qiu-jing Song","2026","Cost-effectiveness of metabolic and bariatric surgery versus contemporary medical therapy for adults with type 2 diabetes and obesity in China: a multicentre target-trial-emulation and microsimulation study protocol","Open Science Framework",null,"10.17605/osf.io/tnbkz","https://doi.org/10.17605/osf.io/tnbkz",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043328","R0043328.pdf","paywalled","other_trial","Dominic Lynch","2026","Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Rates — full paper",null,null,"10.17605/osf.io/q4djs","https://doi.org/10.17605/osf.io/q4djs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043458","R0043458.pdf","paywalled","other_trial","Dominic Lynch","2026","Hypothesis-Generating Brief: GLP-1 longevity — full paper",null,null,"10.17605/osf.io/98auj","https://doi.org/10.17605/osf.io/98auj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043900","R0043900.pdf","paywalled","protocol","Howard Rodriguez Mori","2026","Mass Spectrometry Applications for GLP-1 and Dual Incretin Receptor Agonists: A Scoping Review Protocol",null,null,"10.17605/osf.io/ckums","https://doi.org/10.17605/osf.io/ckums",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044032","R0044032.pdf","paywalled","other_trial","Oliver Freudenreich","2026","Schizofrenia: il semaglutide supera il liraglutide nel controllo dell’aumento di peso da antipsicotici?",null,"Psychopharmacology Institute","10.64239/pi-it-qt9102","https://doi.org/10.64239/pi-it-qt9102",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044508","R0044508.pdf","paywalled","other_trial","Ildiko Lingvay","2026","Response to Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","UNC Libraries",null,"10.17615/1729-0j29","https://doi.org/10.17615/1729-0j29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044514","R0044514.pdf","paywalled","protocol","Pegah Mir","2026","Dental Management Considerations for Patients Receiving GLP-1 Receptor Agonist Therapy: A Scoping Review Protocol","Open Science Framework",null,"10.17605/osf.io/6nphy","https://doi.org/10.17605/osf.io/6nphy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044537","R0044537.pdf","paywalled","other_trial","HENRY ATTAR","2026","Counterfeit Retatrutide: A Global Public Health Crisis in Investigational Drug Diversion—Pharmacokinetic Mechanisms, Drug-Induced Hepatotoxicity Pathways, Poison Center Epidemiology, and Clinical Case Series Documentation","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22731325","https://doi.org/10.5281/zenodo.22731325",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044754","R0044754.pdf","paywalled","other_trial","Han Qin","2026","Drugs for Weight Loss, Psychoanalysis for Weight Gain: An SAE Dimensional Analysis of Eating Disorders / 减肥靠吃药,增重靠心理分析:饮食障碍的SAE层级分析","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19501120","https://doi.org/10.5281/zenodo.19501120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044779","R0044779.pdf","paywalled","other_trial","Yuhao Deng","2026","Estimating Pathway Treatment Effects in the Presence of Intermediate Events with Multi-State Data","arXiv (Cornell University)",null,"10.48550/arxiv.2608.22608","https://doi.org/10.48550/arxiv.2608.22608",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044842","R0044842.pdf","paywalled","protocol","Sarah E. Messiah","2026","Real-World Implementation of GLP-1–Based Pharmacotherapies for Adolescent Obesity: A Scoping Review Protocol of Barriers and Facilitators","Open Science Framework",null,"10.17605/osf.io/p5r7g","https://doi.org/10.17605/osf.io/p5r7g",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045147","R0045147.pdf","paywalled","protocol","Alastair Paterson","2026","Incretin pathway modulation in intracerebral haemorrhage: a scoping review protocol",null,null,"10.17605/osf.io/vh2wu","https://doi.org/10.17605/osf.io/vh2wu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045149","R0045149.pdf","paywalled","other_trial","Denis Nößler","2026","1 Beutel, 800.000 Euro und „doofe“ Docs – Evidenz-Quickies KW 18","EvidenzUpdate","Evidence Now Media","10.69156/quick/2026.05.00017","https://doi.org/10.69156/quick/2026.05.00017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04959331"],["5","R0045179","R0045179.pdf","paywalled","other_trial","John Paul Sicoli","2026","Prospective Prediction of Phase 2/3 Clinical Trial Success for Novel Molecular Entities Using Consciousness-Enhanced Computational Synthesis — C×D Law Extension to Drug Development","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20344183","https://doi.org/10.5281/zenodo.20344183",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045184","R0045184.pdf","paywalled","other_trial","Jeel Padaria","2026","Prospective Test of Whether LV-Mass Reduction with Weight-Lowering Therapies Is Weight-Proportional or Relatively Weight-Independent","Open Science Framework",null,"10.17605/osf.io/g3swt","https://doi.org/10.17605/osf.io/g3swt",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045208","R0045208.pdf","paywalled","other_trial","Raphael Hesse","2026","Oral presentation at EASL 2026. Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in a phase 2 trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.32158935.v1","https://doi.org/10.60915/boehringer-figshare.32158935.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045246","R0045246.pdf","paywalled","other_trial","Anil K. Malhotra","2026","0676 The Association Between Tirzepatide and Sleep Architecture: Post-Hoc Analyses from SURMOUNT-OSA","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0675","https://doi.org/10.1093/sleep/zsag091.0675",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045253","R0045253.pdf","paywalled","protocol","Junior Vitorino Fandim","2026","Exploring Equity in Glucose‐lowering Research for Patients with Obesity. A Meta-epidemiological Study Protocol",null,null,"10.17605/osf.io/8yxpu","https://doi.org/10.17605/osf.io/8yxpu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045400","R0045400.pdf","paywalled","other_trial","Abhik Paul","2026","Therapeutic Approaches to Newer Classes of Drugs and Treatments for Type 2 Diabetes Mellitus","Apple Academic Press eBooks","Apple Academic Press","10.1201/9781779640598-4","https://doi.org/10.1201/9781779640598-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045428","R0045428.pdf","paywalled","other_trial","Wei Zhao (14321)","2026","1720-P: Effect of Renal Impairment on the Pharmacokinetics and Safety of Bofanglutide","Diabetes","American Diabetes Association","10.2337/db26-1720-p","https://doi.org/10.2337/db26-1720-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045467","R0045467.pdf","paywalled","other_trial","Yeshaben Patel","2026","2843-LB: HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db26-2843-lb","https://doi.org/10.2337/db26-2843-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04707469"],["5","R0045513","R0045513.pdf","paywalled","other_trial","Ishan Abdullah","2026","Abstract TH829: Physician Perspectives and Barriers to Tirzepatide Use in Heart Failure with Preserved Ejection Fraction and Obesity","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/cir.153.suppl_1.th829","https://doi.org/10.1161/cir.153.suppl_1.th829",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045640","R0045640.pdf","paywalled","other_trial","M J Yoon","2026","Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy","European Journal of Heart Failure","Oxford University Press (OUP)","10.1093/ejhf/xuag025","https://doi.org/10.1093/ejhf/xuag025","41771105","https://pubmed.ncbi.nlm.nih.gov/41771105/",null,null],["5","R0045701","R0045701.pdf","paywalled","other_trial","Elke Platz","2026","Plain Language Summary of the Study: Survodutide for the Treatment of Obesity: Baseline characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.31150663","https://doi.org/10.60915/boehringer-figshare.31150663",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045723","R0045723.pdf","paywalled","other_trial","Marc P. Bonaca","2026","26-A-13879-ACC EFFECT OF SEMAGLUTIDE ON ANKLE-BRACHIAL INDEX IN PEOPLE WITH PERIPHERAL ARTERY DISEASE AND TYPE 2 DIABETES: AN ANALYSIS OF THE STRIDE TRIAL BY DISEASE SEVERITY","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.2542","https://doi.org/10.1016/j.jacc.2026.02.2542",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045733","R0045733.pdf","paywalled","other","WENJIAN LIN","2026","1748-P: IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies","Diabetes","American Diabetes Association","10.2337/db26-1748-p","https://doi.org/10.2337/db26-1748-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03798054; ClinicalTrials.gov:NCT03798080; ClinicalTrials.gov:NCT05413369"],["5","R0045774","R0045774.pdf","paywalled","other_trial","María José Soler","2026","Finerenone with empagliflozin in CKD with diabetes (CONFIDENCE): only a blood pressure effect? Likely!","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfag042","https://doi.org/10.1093/ndt/gfag042","41711584","https://pubmed.ncbi.nlm.nih.gov/41711584/",null,null],["5","R0045876","R0045876.pdf","paywalled","protocol","Mayron Guedes Silva","2026","Oral manifestations of GLP-1 agonist use in diabetes and weight loss therapies: a scoping review protocol",null,null,"10.17605/osf.io/drmbj","https://doi.org/10.17605/osf.io/drmbj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045935","R0045935.pdf","paywalled","other_trial","E Thomaseo Burton","2026","Ready for the challenge: navigating the evolving landscape of GLP-1s for pediatric obesity treatment","Journal of Pediatric Psychology","Oxford University Press (OUP)","10.1093/jpepsy/jsag002","https://doi.org/10.1093/jpepsy/jsag002","41677195","https://pubmed.ncbi.nlm.nih.gov/41677195/",null,null],["5","R0045951","R0045951.pdf","paywalled","other_trial","Barry A Borlaug","2026","Visceral adiposity assessment to enhance risk stratification in heart failure with preserved ejection fraction","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag119","https://doi.org/10.1093/eurheartj/ehag119","41790513","https://pubmed.ncbi.nlm.nih.gov/41790513/",null,null],["5","R0046020","R0046020.pdf","paywalled","other_trial","Ivy Shi","2026","GLP-1 RA Eligibility in Reproductive-Age U.S. Women","Diabetes Obesity and Cardiometabolic CARE","American Diabetes Association","10.2337/doc25-0040","https://doi.org/10.2337/doc25-0040",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046127","R0046127.pdf","paywalled","other_trial","Devendra Patil","2026","MSR50 AI-ASSISTED GENERATION OF SYNTHETIC PATIENT-LEVEL DATA TO RECREATE WEIGHT-CHANGE OUTCOMES FROM THE STEP-4 SEMAGLUTIDE TRIAL","Value in Health","Elsevier BV","10.1016/j.jval.2026.03.1549","https://doi.org/10.1016/j.jval.2026.03.1549",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046248","R0046248.pdf","paywalled","other_trial","Kavita Mariwalla","2026","Beyond Weight Loss: GLP-1 and the future of Aesthetic Outcomes","Dermatologic Surgery","Ovid Technologies (Wolters Kluwer Health)","10.1097/dss.0000000000005189","https://doi.org/10.1097/dss.0000000000005189","42210878","https://pubmed.ncbi.nlm.nih.gov/42210878/",null,null],["5","R0046446","R0046446.pdf","paywalled","protocol","Doménica Gabirela Escudero Samaniego","2026","Oral Manifestations Associated with GLP-1 and GIP Receptor Agonists: A Scoping Review Protocol",null,null,"10.17605/osf.io/nwtcs","https://doi.org/10.17605/osf.io/nwtcs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046540","R0046540.pdf","paywalled","protocol","Bettina Weber","2026","Glucagon-like Peptide 1 and Estradiol in Metabolic Dialogue: A Scoping Review Protocol",null,null,"10.17605/osf.io/kzqfy","https://doi.org/10.17605/osf.io/kzqfy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046612","R0046612.pdf","paywalled","other_trial","Naseem Eisa","2026","Prevalence and Impact of Endogenous Hypercortisolism in Patients with Obesity Resistant to Incretin-Based Weight Loss Therapy: A Scoping Review",null,null,"10.17605/osf.io/jrc52","https://doi.org/10.17605/osf.io/jrc52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046616","R0046616.pdf","paywalled","other_trial","Raphael Hesse","2026","OS-018 Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagonlike peptide-1 receptor dual agonist, in a phase 2 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)00328-4","https://doi.org/10.1016/s0168-8278(26)00328-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046652","R0046652.pdf","paywalled","other_trial","Manal F. Abdelmalek","2026","FRI-139 Semaglutide provides liver health-related benefits in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01887-8","https://doi.org/10.1016/s0168-8278(26)01887-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046842","R0046842.pdf","paywalled","other_trial","PETTER BJORNSTAD","2026","1728-P: Large-Scale Proteomic Discovery of Prognostic and Treatment-Responsive CKD Biomarkers in SELECT","Diabetes","American Diabetes Association","10.2337/db26-1728-p","https://doi.org/10.2337/db26-1728-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046850","R0046850.pdf","paywalled","protocol","Ghadeer Alenezi","2026","Mapping the spectrum of reported adverse effects associated with glucagon-like peptide-1 receptor agonists for weight management in adults: a scoping review protocol",null,null,"10.17605/osf.io/2rj8u","https://doi.org/10.17605/osf.io/2rj8u",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047100","R0047100.pdf","paywalled","other_trial","Shailendra Singh","2026","Su1806 DUODENAL MUCOSAL RESURFACING STABILIZES WEIGHT LOSS AND GLYCEMIC CONTROL AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST WITHDRAWAL: REVEAL-1 - A PROSPECTIVE MULTICENTER OPEN-LABEL STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(26)04891-2","https://doi.org/10.1016/s0016-5085(26)04891-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047198","R0047198.pdf","paywalled","other_trial","Rohit Loomba","2026","MRI-PDFF≥70% Reduction Was Associated With Fibrosis Improvement With Tirzepatide: Post-Hoc Analysis of the SYNERGY-NASH Phase 2B Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819980","https://doi.org/10.1055/s-0046-1819980",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047363","R0047363.pdf","paywalled","other_trial","Hsiu‐Chiung Yang","2026","2566-P: Silencing Hepatokine Activin E Promotes a Healthy Body Composition and Metabolic Profile in Mice","Diabetes","American Diabetes Association","10.2337/db26-2566-p","https://doi.org/10.2337/db26-2566-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047403","R0047403.pdf","paywalled","other_trial","Frederick J. Thomson","2026","PREOPERATIVE TIRZEPATIDE THERAPY IN OBESE TOTAL HIP ARTHROPLASTY CANDIDATES: A MODELLING STUDY OF COST AND COMPLICATION REDUCTION","Orthopaedic Proceedings","British Editorial Society of Bone & Joint Surgery","10.1302/1358-992x.2026.3.010","https://doi.org/10.1302/1358-992x.2026.3.010",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047575","R0047575.pdf","paywalled","other_trial","Yishan Chen","2026","Patterns of TSH Test After GLP-1 RAs Initiation in Patients on Levothyroxine: A Trial Emulation Study (Online Supplemental Files)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19394658","https://doi.org/10.5281/zenodo.19394658",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047871","R0047871.pdf","paywalled","protocol","Jennifer Gale","2026","GLP-1RA and 24-Hour Movement Behaviours: A Scoping Review Protocol","Open Science Framework",null,"10.17605/osf.io/h65tj","https://doi.org/10.17605/osf.io/h65tj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048339","R0048339.pdf","paywalled","other_trial","Domenica M Rubino","2026","Plain Language Summary of the Manuscript. Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.32103682.v1","https://doi.org/10.60915/boehringer-figshare.32103682.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048691","R0048691.pdf","paywalled","other_trial","Scott R. Beach","2026","Quick Take Vol. 83",null,"Psychopharmacology Institute","10.64239/pi-qt83","https://doi.org/10.64239/pi-qt83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048895","R0048895.pdf","paywalled","protocol","Charles Amoatey Odonkor","2026","Bridging Preclinical Promise and Clinical Uncertainty: The Role of GLP-1 Receptor Agonists in Opioid Use Disorder — A Scoping Review Protocol","Open Science Framework",null,"10.17605/osf.io/ywk46","https://doi.org/10.17605/osf.io/ywk46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04199728"],["5","R0049101","R0049101.pdf","paywalled","other_trial","Benjamin Norton","2026","O79 Discontinuation of exogenous insulin therapy in type 2 diabetes following proximal intestinal mucosal ablation: the STEAM-IE trial",null,"BMJ Publishing Group Ltd and British Society of Gastroenterology","10.1136/gutjnl-2026-bsg.78","https://doi.org/10.1136/gutjnl-2026-bsg.78",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06655740"],["5","R0049434","R0049434.pdf","paywalled","protocol","Michelle R. Demetres","2026","Protocol: Examining changes in body weight and glycemic outcomes in Asian patients using GLP 1 receptor/ dual agonists",null,null,"10.17605/osf.io/8pgfn","https://doi.org/10.17605/osf.io/8pgfn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049950","R0049950.pdf","paywalled","protocol","M.E. Kannan","2026","In-use Stability of Semaglutide Injection 15mg/3mL (5mg/mL) In-use Storage Conditions, Study Design, Study Outcome and Labelling Recommendations","Research Journal of Pharmacy and Technology","A and V Publications","10.52711/0974-360x.2026.00321","https://doi.org/10.52711/0974-360x.2026.00321",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049964","R0049964.pdf","paywalled","other_trial","Chirag J. Patel","2026","1717-P: Assessing Type 2 Diabetes and GLP-1 Agonist Response Trajectories with a Proteogenomic Atlas of Disease Progression","Diabetes","American Diabetes Association","10.2337/db26-1717-p","https://doi.org/10.2337/db26-1717-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050185","R0050185.pdf","paywalled","other_trial","B Norton","2026","Proximal intestinal mucosal ablation (PIMA) enables discontinuation of exogenous insulin in type 2 diabetes: final results from the STEAM-IE trial","Endoscopy","Georg Thieme Verlag KG","10.1055/s-0046-1822577","https://doi.org/10.1055/s-0046-1822577",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06655740"],["5","R0050420","R0050420.pdf","paywalled","other_trial","Mustafa Al-Jarshawi","2026","Additional file 1 of Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial–based analysis using NHANES (1988–2018) cycles","Figshare",null,"10.6084/m9.figshare.32353983.v1","https://doi.org/10.6084/m9.figshare.32353983.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050422","R0050422.pdf","paywalled","other_trial","Azim Jamil ugli Odilov","2026","THE CKM SYNDROME PARADIGM: A UNIFIED APPROACH TO PATHOPHYSIOLOGY, CLINICAL STAGING, AND MULTI-ORGAN PROTECTION","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20841791","https://doi.org/10.5281/zenodo.20841791",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050486","R0050486.pdf","paywalled","other_trial","Alana Washington","2026","Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-Diabetes trial","UNC Libraries",null,"10.17615/12y8-v516","https://doi.org/10.17615/12y8-v516",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050530","R0050530.pdf","paywalled","other_trial","S Jacob","2026","Early Clinical Benefit of Semaglutide in Adults with Overweight or Obesity and Cardiovascular Disease: A Secondary Analysis of the SELECT Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819888","https://doi.org/10.1055/s-0046-1819888",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050531","R0050531.pdf","paywalled","protocol","Wei Ming Wilfred Lim","2026","Practice Recommendations for Perioperative Management of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 RAs: A Scoping Review Protocol",null,null,"10.17605/osf.io/75tgx","https://doi.org/10.17605/osf.io/75tgx",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050722","R0050722.pdf","paywalled","other_trial","Rohit Loomba","2026","FRI-175 Effects of combination treatment with semaglutide, cilofexor and firsocostat on liver noninvasive tests in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis: a post hoc analysis of the WAYFIND trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01916-1","https://doi.org/10.1016/s0168-8278(26)01916-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051113","R0051113.pdf","paywalled","other_trial","Mustafa Hussein Ajlan Al-Jarshawi","2026","26-A-15241-ACC PROJECTED REDUCTION IN MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG HIGH-RISK U.S. ADULTS WITH TYPE 2 DIABETES ELIGIBLE FOR ORAL SEMAGLUTIDE: A SOUL TRIAL BASED ANALYSIS USING NHANES 1988-2018 CYCLES","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.778","https://doi.org/10.1016/j.jacc.2026.02.778",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051146","R0051146.pdf","paywalled","other_trial","F. Shiele","2026","Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: A secondary analysis of the SELECT trial","Archives of cardiovascular diseases","Elsevier BV","10.1016/j.acvd.2025.10.206","https://doi.org/10.1016/j.acvd.2025.10.206",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051873","R0051873.pdf","paywalled","other_trial","HELEN M. COLHOUN","2026","1291-OR: Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial","Diabetes","American Diabetes Association","10.2337/db26-1291-or","https://doi.org/10.2337/db26-1291-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051957","R0051957.pdf","paywalled","other_trial","Timothy Richard Smith","2026","3101-LB: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials","Diabetes","American Diabetes Association","10.2337/db26-3101-lb","https://doi.org/10.2337/db26-3101-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052129","R0052129.pdf","paywalled","other_trial","Rizwana Mohseni","2026","FRI-170 Results from two phase I trials evaluating the safety, pharmacokinetics, and efficacy of BI 3006337, a dual fibroblast growth factor 21/glucagon-like peptide-1 agonist, in healthy volunteers and people with overweight/obesity and hepatic steatosis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(26)01911-2","https://doi.org/10.1016/s0168-8278(26)01911-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052241","R0052241.pdf","paywalled","other_trial","Joseph Toole","2026","Heart Failure With Reduced and Preserved Ejection Fraction: A Review of Guideline Directed Medical Therapy","International Journal of Angiology","Georg Thieme Verlag KG","10.1055/a-2874-9189","https://doi.org/10.1055/a-2874-9189",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052593","R0052593.pdf","paywalled","other_trial","S Jacob","2026","Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease – A Post Hoc Analysis of the STRIDE Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819978","https://doi.org/10.1055/s-0046-1819978",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052836","R0052836.pdf","paywalled","other_trial","Claire Carswell","2026","The use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among people with severe mental illness",null,null,"10.17605/osf.io/ng8sk","https://doi.org/10.17605/osf.io/ng8sk",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053022","R0053022.pdf","paywalled","other_trial","CAREL LE ROUX","2026","2829-LB: STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets","Diabetes","American Diabetes Association","10.2337/db26-2829-lb","https://doi.org/10.2337/db26-2829-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05649137; ClinicalTrials.gov:NCT05646706"],["5","R0053496","R0053496.pdf","paywalled","other_trial","Sol Collado","2026","1104-OR: Muscle-Preserving Weight Loss with RV-8451, a Novel, Oral Nonpeptide GLP-1 Receptor Agonist, in Diet-Induced Obese Nonhuman Primates","Diabetes","American Diabetes Association","10.2337/db26-1104-or","https://doi.org/10.2337/db26-1104-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053554","R0053554.pdf","paywalled","other_trial","MELISSA THOMAS","2026","1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1693-p","https://doi.org/10.2337/db26-1693-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06124807"],["5","R0053581","R0053581.pdf","paywalled","other_trial","Arthur Stewart","2026","The IRS-1 Framework Predicts the ELAD Trial Why the Primary Outcome Failed, What the VBM Pattern Means, and What the Next Trial Should Measure","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19016137","https://doi.org/10.5281/zenodo.19016137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053755","R0053755.pdf","paywalled","other_trial","James E. Dunn","2026","GLP-1 Neuroprotection — P5 narrowing","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19708691","https://doi.org/10.5281/zenodo.19708691",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053978","R0053978.pdf","paywalled","other_trial","Paul Mystkowski","2026","Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial (P6-12.007)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000215557","https://doi.org/10.1212/wnl.0000000000215557",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03574597"],["5","R0054117","R0054117.pdf","paywalled","other_trial","AMY SHAH","2026","1135-OR: One-Year Outcomes from the Surgical or Medical Treatment for Pediatric Type 2 Diabetes (T2D): ST2OMP Study","Diabetes","American Diabetes Association","10.2337/db26-1135-or","https://doi.org/10.2337/db26-1135-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054126","R0054126.pdf","paywalled","other_trial","Nikolaus Marx","2026","26-A-13845-ACC EFFECT OF ORAL SEMAGLUTIDE VERSUS PLACEBO ON FIRST AND TOTAL MACE IN SOUL TRIAL PARTICIPANTS WITH T2D AND ASCVD AND/OR CKD","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.490","https://doi.org/10.1016/j.jacc.2026.02.490",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054150","R0054150.pdf","paywalled","other_trial","Hsuan‐Ming Yao","2026","0672 Pharmacokinetics, Efficacy, and Safety of AD109 (Aroxybutynin and Atomoxetine) in Participants with Obstructive Sleep Apnea and Obesity Taking a GLP-1","SLEEP","Oxford University Press (OUP)","10.1093/sleep/zsag091.0671","https://doi.org/10.1093/sleep/zsag091.0671",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054166","R0054166.pdf","paywalled","other_trial","BENEDICT BERGER","2026","1220-OR: Survodutide: Differentiated GLP-1R and Glucagon Receptor (GCGR) Pharmacology Compared with Endogenous Ligands via Time-Resolved Assays","Diabetes","American Diabetes Association","10.2337/db26-1220-or","https://doi.org/10.2337/db26-1220-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054314","R0054314.pdf","paywalled","other_trial","Zara Gandon","2026","67 Analysis of the mayfield lifestyle medicine and mounjaro (MaLMoun) project. A group consultation and health coaching course delivering tirzepatide, exercise and education on the 6 pillars of lifestyle medicine to type 2 diabetics with obesity",null,"Lifestyle Medicine Advances","10.1136/lma-2026-bslm-10th.53","https://doi.org/10.1136/lma-2026-bslm-10th.53",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054336","R0054336.pdf","paywalled","other_trial","Kristian Frederiksen","2026","Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment (S1.008)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000216961","https://doi.org/10.1212/wnl.0000000000216961",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054480","R0054480.pdf","paywalled","other_trial","Kuan-Yu Chi","2026","26-YIA-7853-ACC GLP-1 RECEPTOR AGONISTS USE IN OBESE PATIENTS WITH STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION: A TARGET-TRIAL EMULATION","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2026.02.4865","https://doi.org/10.1016/j.jacc.2026.02.4865",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054545","R0054545.pdf","paywalled","other_trial","Tripdatabase","2026","How frequent is acid reflux with injected semaglutide?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19113461","https://doi.org/10.5281/zenodo.19113461",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054550","R0054550.pdf","paywalled","other_trial","Munehiro Terada","2026","ITU and Pharmacology: A Single-Axiom View of Drug Discovery, Receptor Pharmacology, ADME, Pharmacogenomics, Antibody Medicines, Vaccines and Immunotherapy, AI Drug Design, and FDA Regulation — Pass-1 Extension Paper #2, Block B 6/6 COMPLETE","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20258191","https://doi.org/10.5281/zenodo.20258191",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054579","R0054579.pdf","paywalled","other_trial","Carel W. le Roux","2026","Survodutide for Treatment of Obesity: Baseline Characteristics in the SYNCHRONIZE™-1 Phase 3 Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819897","https://doi.org/10.1055/s-0046-1819897",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054582","R0054582.pdf","paywalled","other_trial","Munehiro Terada","2026","ITU Tier 1+ #32: Pharmaceuticals (K_pharma)","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20281172","https://doi.org/10.5281/zenodo.20281172",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054712","R0054712.pdf","paywalled","other_trial","Narayan Rout","2026","GLP-1 for Weight Loss and Ozempic: 6 Things Science Actually Knows","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20743108","https://doi.org/10.5281/zenodo.20743108",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054722","R0054722.pdf","paywalled","other_trial","Beverly Tchang","2026","1669-P: Effect of Semaglutide for Weight Management on Blood Pressure in Adults with Uncontrolled Hypertension and Overweight/Obesity: A Post Hoc Analysis from the STEP and OASIS Programs","Diabetes","American Diabetes Association","10.2337/db26-1669-p","https://doi.org/10.2337/db26-1669-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054874","R0054874.pdf","paywalled","other_trial","MOHAMED ABU-FARHA","2026","1794-P: New Insulin Sensitizer CIS-0602K Potential to Expand Treatment Options to Manage Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1794-p","https://doi.org/10.2337/db26-1794-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055070","R0055070.pdf","paywalled","other_trial","Edward Leatham","2026","Osteoarthritis May Be Partly a Metabolic Disease: Visceral Fat and the Joint","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22121955","https://doi.org/10.5281/zenodo.22121955",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055350","R0055350.pdf","paywalled","other_trial","Carel W. le Roux","2026","Survodutide for Weight Reduction in Obesity and T2D: Baseline Data From SYNCHRONIZE™-2 Phase 3 Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0046-1819895","https://doi.org/10.1055/s-0046-1819895",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055467","R0055467.pdf","paywalled","other_trial","KRISTINA S. BOYE","2026","1668-P: Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial","Diabetes","American Diabetes Association","10.2337/db26-1668-p","https://doi.org/10.2337/db26-1668-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055486","R0055486.pdf","paywalled","other_trial","Sayna Bagheri","2026","2656-P: Analyzing Daily Weights to Improve Estimates of Weight Loss while Minimizing Impact of Random Day-to-Day Variation in Weight","Diabetes","American Diabetes Association","10.2337/db26-2656-p","https://doi.org/10.2337/db26-2656-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055626","R0055626.pdf","paywalled","other_trial","GUILLERMO UMPIERREZ","2026","2970-LB: High Prevalence of Endogenous Hypercortisolism in Patients with Type 2 Diabetes and Resistant Hypertension: Results from the MOMENTUM Study","Diabetes","American Diabetes Association","10.2337/db26-2970-lb","https://doi.org/10.2337/db26-2970-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05772169; ClinicalTrials.gov:NCT06829537"],["5","R0055719","R0055719.pdf","paywalled","other_trial","Eiichiro Satake","2026","1395-P: Effect of the Dual GLP-1/GIP Receptor Agonist Tirzepatide on Circulating Proteins Associated with ESKD Risk in Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db26-1395-p","https://doi.org/10.2337/db26-1395-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055760","R0055760.pdf","paywalled","protocol","Günce Başarır","2026","GLP-1 receptor agonists and the developing brain: a scoping review protocol for childhood epilepsy and autism spectrum disorder","Open Science Framework",null,"10.17605/osf.io/b5py3","https://doi.org/10.17605/osf.io/b5py3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055798","R0055798.pdf","paywalled","protocol","Daniela Marchetti Noia Baldo","2026","Eating behaviour, eating disorder risk and body image in adolescents using GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists: a scoping review protocol","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/kzs9y","https://doi.org/10.17605/osf.io/kzs9y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055832","R0055832.pdf","paywalled","other_trial","Saahil Eeshwar","2026","Incretin-Based Therapies in Adiposity-Driven HFpEF: Mechanisms, Clinical Evidence and Therapeutic Implications","American journal of student research.","HY Academy","10.70251/hyjr2348.45740749","https://doi.org/10.70251/hyjr2348.45740749",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055842","R0055842.pdf","paywalled","other_trial","A.T.H. Kwan","2026","P354 GLP-1 RECEPTOR AGONISTS REDUCE MORTALITY AND CARDIOVASCULAR EVENTS IN SERIOUS MENTAL ILLNESS: A MULTINATIONAL TARGET TRIAL OF 1.5 MILLION ADULTS","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2026.07.322","https://doi.org/10.1016/j.cjca.2026.07.322",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055853","R0055853.pdf","paywalled","other_trial","Srinivas Lenkalapelly","2026","Pharmacokinetic and ADME challenges of GLP-1 based Multireceptor therapeutics: mechanisms, models and development strategies.","Natural Resources for Human Health","Visagaa Publishing House","10.53365/nrfhh.2283","https://doi.org/10.53365/nrfhh.2283",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055948","R0055948.pdf","paywalled","protocol","Tao Li","2026","Retrospective pharmacovigilance protocol: phenotype-specific reporting of neuropathy signals with GLP-1 receptor agonists in the US FDA Adverse Event Reporting System (FAERS), with external replication (JADER, Canada Vigilance)","Open Science Framework",null,"10.17605/osf.io/q29vy","https://doi.org/10.17605/osf.io/q29vy",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055957","R0055957.pdf","paywalled","protocol","Mohamed Hany","2026","Metabolic and Bariatric Surgery in Adults with Obesity and Pre-Existing Chronic Kidney Disease: Kidney, Cardiovascular, Perioperative, and Transplant-Pathway Outcomes — Protocol for a Scoping Review","Open Science Framework",null,"10.17605/osf.io/mj3vz","https://doi.org/10.17605/osf.io/mj3vz",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056024","R0056024.pdf","paywalled","other_trial","Dhriti Gaur","2026","Nutritional Depletion After GLP-1 Discontinuation: A Narrative Review on Recognizing the Signals and Guiding Care","Open Science Framework",null,"10.17605/osf.io/p4esn","https://doi.org/10.17605/osf.io/p4esn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056063","R0056063.pdf","paywalled","other_trial","CHIRANTH KRISHNASHETTY RAMESH","2026","Clinical Benefit Versus Affordability: A Narrative Review of Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23100951","https://doi.org/10.5281/zenodo.23100951",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056343","R0056343.pdf","paywalled","other_trial","M. pavani","2026","Alzheimer's Disease and the GLP-1 Receptor: Pathophysiology, Mechanisms and Therapeutic Evidence.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23116131","https://doi.org/10.5281/zenodo.23116131",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056477","R0056477.pdf","paywalled","other_trial","Aj Pakpour","2026","Retatrutide 2026: The Emerging Triple-Agonist Market","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.23283183","https://doi.org/10.5281/zenodo.23283183",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056608","R0056608.pdf","paywalled","other_trial","Gurpreet S. Padda","2026","The Dopamine Brain: Wanting: Why You Chase What You Don't Enjoy","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22941230","https://doi.org/10.5281/zenodo.22941230",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056627","R0056627.pdf","paywalled","protocol","Saira Hameed","2026","The Imperial Satiety Protocol – long-term weight loss outcomes for a lifestyle based intervention in a real-world NHS setting","Spiral (Imperial College London)",null,"10.1002/oby.70336","https://doi.org/10.1002/oby.70336",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0000441","R0000441.pdf","paywalled","other_trial","Pillai AA","2025","Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001139","https://doi.org/10.1097/crd.0000000000001139","41398455","https://pubmed.ncbi.nlm.nih.gov/41398455/",null,null],["5","R0001736","R0001736.pdf","paywalled","other_trial","Mifsud CS","2025","The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2574848","https://doi.org/10.1080/14656566.2025.2574848","41114602","https://pubmed.ncbi.nlm.nih.gov/41114602/",null,null],["5","R0002009","R0002009.pdf","paywalled","other_trial","Rigas G","2025","GLP-1RA based therapies in the young and old.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000900","https://doi.org/10.1097/med.0000000000000900","39692102","https://pubmed.ncbi.nlm.nih.gov/39692102/",null,null],["5","R0002071","R0002071.pdf","paywalled","other_trial","Luo Y","2025","GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies.","Food & function","Royal Society of Chemistry (RSC)","10.1039/d5fo03273c","https://doi.org/10.1039/d5fo03273c","41160511","https://pubmed.ncbi.nlm.nih.gov/41160511/",null,null],["5","R0002098","R0002098.pdf","paywalled","other_trial","Faruque L","2025","Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond.","Current opinion in nephrology and hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/mnh.0000000000001066","https://doi.org/10.1097/mnh.0000000000001066","40047207","https://pubmed.ncbi.nlm.nih.gov/40047207/",null,null],["5","R0002305","R0002305.pdf","paywalled","other_trial","Mademlis C","2025","Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2025.2573785","https://doi.org/10.1080/17512433.2025.2573785","41070406","https://pubmed.ncbi.nlm.nih.gov/41070406/",null,null],["5","R0002498","R0002498.pdf","paywalled","other_trial","Patel R","2025","Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.","Current heart failure reports","Springer Science and Business Media LLC","10.1007/s11897-025-00704-1","https://doi.org/10.1007/s11897-025-00704-1","40366488","https://pubmed.ncbi.nlm.nih.gov/40366488/",null,null],["5","R0003061","R0003061.pdf","paywalled","other_trial","Peng ZY","2025","Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trial.","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvae237","https://doi.org/10.1093/cvr/cvae237","39498852","https://pubmed.ncbi.nlm.nih.gov/39498852/",null,null],["5","R0003232","R0003232.pdf","paywalled","other_trial","Kallash M","2025","The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000970","https://doi.org/10.1097/crd.0000000000000970","40539787","https://pubmed.ncbi.nlm.nih.gov/40539787/",null,null],["5","R0003768","R0003768.pdf","paywalled","other_trial","Lindsay M","2025","Evolving Role of GLP-1 Therapies in Liver Disease.","Current gastroenterology reports","Springer Science and Business Media LLC","10.1007/s11894-025-00988-2","https://doi.org/10.1007/s11894-025-00988-2","40478351","https://pubmed.ncbi.nlm.nih.gov/40478351/",null,null],["5","R0003828","R0003828.pdf","paywalled","other_trial","Arun AJ","2025","Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001062","https://doi.org/10.1097/crd.0000000000001062","40963161","https://pubmed.ncbi.nlm.nih.gov/40963161/",null,null],["5","R0003832","R0003832.pdf","paywalled","other_trial","Ostrominski JW","2025","Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure with Reduced Ejection Fraction: Time for a Trial.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2024.07.002","https://doi.org/10.1016/j.cardfail.2024.07.002","39032688","https://pubmed.ncbi.nlm.nih.gov/39032688/",null,null],["5","R0004017","R0004017.pdf","paywalled","other_trial","Ryan M","2025","The potential role of GLP-1 receptor agonists in osteoarthritis.","Pharmacotherapy","Wiley","10.1002/phar.70005","https://doi.org/10.1002/phar.70005","39980227","https://pubmed.ncbi.nlm.nih.gov/39980227/",null,null],["5","R0004227","R0004227.pdf","paywalled","other_trial","Ravussin E","2025","Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2025.03.011","https://doi.org/10.1016/j.cmet.2025.03.011","40203836","https://pubmed.ncbi.nlm.nih.gov/40203836/",null,"ClinicalTrials.gov:NCT04081337"],["5","R0004445","R0004445.pdf","paywalled","protocol","Yammine L","2025","A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2025.107989","https://doi.org/10.1016/j.cct.2025.107989","40554081","https://pubmed.ncbi.nlm.nih.gov/40554081/",null,"ClinicalTrials.gov:NCT06173778"],["5","R0004577","R0004577.pdf","paywalled","other_trial","Wang TY","2025","Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-024-10438-2","https://doi.org/10.1007/s10741-024-10438-2","39269643","https://pubmed.ncbi.nlm.nih.gov/39269643/",null,null],["5","R0004911","R0004911.pdf","paywalled","other_trial","Wang Q","2025","Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-025-01570-9","https://doi.org/10.1007/s40262-025-01570-9","41107649","https://pubmed.ncbi.nlm.nih.gov/41107649/",null,"ClinicalTrials.gov:NCT04994288"],["5","R0005035","R0005035.pdf","paywalled","other_trial","Wu X","2025","Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-025-01541-0","https://doi.org/10.1007/s40262-025-01541-0","40587051","https://pubmed.ncbi.nlm.nih.gov/40587051/",null,"ClinicalTrials.gov:NCT05694221"],["5","R0005599","R0005599.pdf","paywalled","other_trial","Theodorakis N","2025","Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-025-10506-1","https://doi.org/10.1007/s10741-025-10506-1","40163257","https://pubmed.ncbi.nlm.nih.gov/40163257/",null,null],["5","R0005777","R0005777.pdf","paywalled","protocol","Chatur S","2025","Reminders embedded in PCI reports to optimize discharge diabetes mellitus care (REMIND-DM): Rationale, design, and baseline characteristics.","American heart journal","Elsevier BV","10.1016/j.ahj.2025.01.020","https://doi.org/10.1016/j.ahj.2025.01.020","39988205","https://pubmed.ncbi.nlm.nih.gov/39988205/",null,null],["5","R0006134","R0006134.pdf","paywalled","other_trial","Dong G","2025","Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist.","Journal of medicinal chemistry","American Chemical Society (ACS)","10.1021/acs.jmedchem.5c00242","https://doi.org/10.1021/acs.jmedchem.5c00242","40257122","https://pubmed.ncbi.nlm.nih.gov/40257122/",null,null],["5","R0006140","R0006140.pdf","paywalled","other_trial","Tannous L","2025","The Obesity Paradox in Heart Failure With Preserved Ejection Fraction: Untangling Body Composition, Inflammation, and Outcomes.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001106","https://doi.org/10.1097/crd.0000000000001106","41198097","https://pubmed.ncbi.nlm.nih.gov/41198097/",null,null],["5","R0006753","R0006753.pdf","paywalled","other_trial","Lou YR","2025","Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-025-01475-7","https://doi.org/10.1007/s40262-025-01475-7","39961992","https://pubmed.ncbi.nlm.nih.gov/39961992/",null,"ClinicalTrials.gov:NCT03745885; ClinicalTrials.gov:NCT04314622; ClinicalTrials.gov:NCT04994288; ClinicalTrials.gov:NCT04998032"],["5","R0006816","R0006816.pdf","paywalled","other_trial","Nagaoka T","2025","Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2515117","https://doi.org/10.1056/nejmc2515117","41337725","https://pubmed.ncbi.nlm.nih.gov/41337725/",null,null],["5","R0006981","R0006981.pdf","paywalled","other_trial","Bloem BR","2025","GLP-1 agonists to slow down Parkinson's progression? The quest continues.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100645","https://doi.org/10.1016/j.medj.2025.100645","40220748","https://pubmed.ncbi.nlm.nih.gov/40220748/",null,null],["5","R0007251","R0007251.pdf","paywalled","other_trial","Zhou H","2025","Warfarin pharmacokinetics and pharmacodynamics are not affected by concomitant administration of the long-acting GLP-1 receptor agonist polyethylene glycol loxenatide.","International journal of clinical pharmacology and therapeutics","Dustri-Verlag Dr. Karl Feistle","10.5414/cp204510","https://doi.org/10.5414/cp204510","39607179","https://pubmed.ncbi.nlm.nih.gov/39607179/",null,null],["5","R0007454","R0007454.pdf","paywalled","other_trial","Popovic DS","2025","COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2025.2516784","https://doi.org/10.1080/17512433.2025.2516784","40464480","https://pubmed.ncbi.nlm.nih.gov/40464480/",null,null],["5","R0007908","R0007908.pdf","paywalled","other_trial","Saboo B","2025","Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX).","The Journal of the Association of Physicians of India","Jaypee Brothers Medical Publishing","10.59556/japi.73.0842","https://doi.org/10.59556/japi.73.0842","39927997","https://pubmed.ncbi.nlm.nih.gov/39927997/",null,null],["5","R0008378","R0008378.pdf","paywalled","other_trial","Novikoff A","2025","One small molecule for man, one giant leap for mankind with obesity.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100924","https://doi.org/10.1016/j.medj.2025.100924","41389711","https://pubmed.ncbi.nlm.nih.gov/41389711/",null,null],["5","R0009028","R0009028.pdf","paywalled","other_trial","Fogacci F","2025","Cagrilintide-Semaglutide in Adults with Overweight or Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2513141","https://doi.org/10.1056/nejmc2513141","41259764","https://pubmed.ncbi.nlm.nih.gov/41259764/",null,null],["5","R0009326","R0009326.pdf","paywalled","other_trial","Verma S","2025","GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2025.05.001","https://doi.org/10.1016/j.cmet.2025.05.001","40466625","https://pubmed.ncbi.nlm.nih.gov/40466625/",null,null],["5","R0009503","R0009503.pdf","paywalled","other","Li L","2025","Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.","Clinical nuclear medicine","Ovid Technologies (Wolters Kluwer Health)","10.1097/rlu.0000000000005533","https://doi.org/10.1097/rlu.0000000000005533","39499011","https://pubmed.ncbi.nlm.nih.gov/39499011/",null,"ClinicalTrials.gov:NCT05034783"],["5","R0010283","R0010283.pdf","paywalled","other_trial","Schwarz CR","2025","SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2025.100774","https://doi.org/10.1016/j.medj.2025.100774","40782670","https://pubmed.ncbi.nlm.nih.gov/40782670/",null,null],["5","R0010479","R0010479.pdf","paywalled","other_trial","Fiorucci S","2025","Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2546812","https://doi.org/10.1080/13543784.2025.2546812","40782123","https://pubmed.ncbi.nlm.nih.gov/40782123/",null,null],["5","R0010497","R0010497.pdf","paywalled","other_trial","Muskiet MHA","2025","Tirzepatide vs. Semaglutide for Obesity Treatment.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2510962","https://doi.org/10.1056/nejmc2510962","41124642","https://pubmed.ncbi.nlm.nih.gov/41124642/",null,null],["5","R0011084","R0011084.pdf","paywalled","other_trial","Greenway FL","2025","Semaglutide and Tirzepatide to Treat Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejme2507452","https://doi.org/10.1056/nejme2507452","40601944","https://pubmed.ncbi.nlm.nih.gov/40601944/",null,null],["5","R0011263","R0011263.pdf","paywalled","other_trial","Anderer S","2025","Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2025.7798","https://doi.org/10.1001/jama.2025.7798","40478570","https://pubmed.ncbi.nlm.nih.gov/40478570/",null,null],["5","R0011614","R0011614.pdf","paywalled","other_trial","Schmitz SH","2025","Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2024.09.003","https://doi.org/10.1016/j.ecl.2024.09.003","39919879","https://pubmed.ncbi.nlm.nih.gov/39919879/",null,null],["5","R0011694","R0011694.pdf","paywalled","other_trial","Liu QK","2025","Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2514331","https://doi.org/10.1056/nejmc2514331","41337722","https://pubmed.ncbi.nlm.nih.gov/41337722/",null,null],["5","R0011909","R0011909.pdf","paywalled","other_trial","Wang S","2025","The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16580","https://doi.org/10.1111/dom.16580","40600464","https://pubmed.ncbi.nlm.nih.gov/40600464/",null,null],["5","R0012025","R0012025.pdf","paywalled","other_trial","Wang X","2025","The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.","Clinical endocrinology","Wiley","10.1111/cen.15262","https://doi.org/10.1111/cen.15262","40432243","https://pubmed.ncbi.nlm.nih.gov/40432243/",null,"ChiCTR:ChiCTR2400094933"],["5","R0012201","R0012201.pdf","paywalled","other_trial","Tacke F","2025","The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)02304-9","https://doi.org/10.1016/s0140-6736(25)02304-9","41352959","https://pubmed.ncbi.nlm.nih.gov/41352959/",null,null],["5","R0012395","R0012395.pdf","paywalled","other_trial","Newman NJ","2025","GLP-1 RAs for Idiopathic Intracranial Hypertension-Time for a Trial.","JAMA neurology","American Medical Association (AMA)","10.1001/jamaneurol.2025.2019","https://doi.org/10.1001/jamaneurol.2025.2019","40658403","https://pubmed.ncbi.nlm.nih.gov/40658403/",null,null],["5","R0012644","R0012644.pdf","paywalled","other_trial","Kalia LV","2025","First phase 3 trial of GLP-1 receptor agonist for neurodegeneration.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(25)00161-8","https://doi.org/10.1016/s0140-6736(25)00161-8","39919774","https://pubmed.ncbi.nlm.nih.gov/39919774/",null,null],["5","R0012950","R0012950.pdf","paywalled","protocol","PANDORA Study Group","2025","Acute pancreatitis national audit of practice: a national prospective audit of acute pancreatitis in the era of GLP-1 agonists-the PANDORA audit protocol.","The British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znaf214","https://doi.org/10.1093/bjs/znaf214","41074717","https://pubmed.ncbi.nlm.nih.gov/41074717/",null,null],["5","R0013436","R0013436.pdf","paywalled","other_trial","Zhang Y","2025","Once-Weekly Mazdutide in Obesity or Overweight.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2509841","https://doi.org/10.1056/nejmc2509841","40929641","https://pubmed.ncbi.nlm.nih.gov/40929641/",null,null],["5","R0014326","R0014326.pdf","paywalled","other_trial","Madhuri Y","2025","An overview of recent developments in clinical trials of anti-diabetic drugs.","Panminerva medica","Edizioni Minerva Medica","10.23736/s0031-0808.25.05314-5","https://doi.org/10.23736/s0031-0808.25.05314-5","40457780","https://pubmed.ncbi.nlm.nih.gov/40457780/",null,null],["5","R0016105","R0016105.pdf","paywalled","narrative_review","Drucker DJ","2025","GLP-1-based therapies for diabetes, obesity and beyond.","Nature reviews. Drug discovery","Springer Science and Business Media LLC","10.1038/s41573-025-01183-8","https://doi.org/10.1038/s41573-025-01183-8","40281304","https://pubmed.ncbi.nlm.nih.gov/40281304/",null,null],["5","R0016251","R0016251.pdf","paywalled","other_trial","Dik B","2025","Liraglutide as a novel therapeutic for overweight in canines: A clinical study.","Veterinary journal (London, England : 1997)","Elsevier BV","10.1016/j.tvjl.2025.106376","https://doi.org/10.1016/j.tvjl.2025.106376","40436366","https://pubmed.ncbi.nlm.nih.gov/40436366/",null,null],["5","R0016657","R0016657.pdf","paywalled","other_trial","Zomer E","2025","The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.","European heart journal. Quality of care & clinical outcomes","Oxford University Press (OUP)","10.1093/ehjqcco/qcae063","https://doi.org/10.1093/ehjqcco/qcae063","39096165","https://pubmed.ncbi.nlm.nih.gov/39096165/",null,null],["5","R0016692","R0016692.pdf","paywalled","other_trial","Patti G","2025","[The SOUL trial: a new era for oral semaglutide in reducing cardiovascular risk in high-risk patients with diabetes].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/4531.45328","https://doi.org/10.1714/4531.45328","40718965","https://pubmed.ncbi.nlm.nih.gov/40718965/",null,null],["5","R0016764","R0016764.pdf","paywalled","other_trial","Birkenfeld AL","2025","Tirzepatide for Obesity Treatment and Diabetes Prevention.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2504728","https://doi.org/10.1056/nejmc2504728","40561543","https://pubmed.ncbi.nlm.nih.gov/40561543/",null,null],["5","R0016928","R0016928.pdf","paywalled","other_trial","Pedicino D","2025","Weekly Journal Scan: long-term effects of tirzepatide for diabetes prevention in persons with obesity and prediabetes.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf236","https://doi.org/10.1093/eurheartj/ehaf236","40249363","https://pubmed.ncbi.nlm.nih.gov/40249363/",null,"ClinicalTrials.gov:NCT05822830; ClinicalTrials.gov:NCT05556512"],["5","R0017064","R0017064.pdf","paywalled","other_trial","Dos Santos MCF","2025","Oral Semaglutide and Cardiovascular Outcomes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2508958","https://doi.org/10.1056/nejmc2508958","40802952","https://pubmed.ncbi.nlm.nih.gov/40802952/",null,null],["5","R0017127","R0017127.pdf","paywalled","other_trial","Luo S","2025","Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2509454","https://doi.org/10.1056/nejmc2509454","40834308","https://pubmed.ncbi.nlm.nih.gov/40834308/",null,null],["5","R0017166","R0017166.pdf","paywalled","other_trial","Wagner J","2025","Tirzepatide for Heart Failure and Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2502743","https://doi.org/10.1056/nejmc2502743","40267436","https://pubmed.ncbi.nlm.nih.gov/40267436/",null,null],["5","R0017506","R0017506.pdf","paywalled","other_trial","Yamaguchi Y","2025","Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-025-06493-5","https://doi.org/10.1007/s00125-025-06493-5","40694059","https://pubmed.ncbi.nlm.nih.gov/40694059/",null,"UMIN:UMIN000056862"],["5","R0017662","R0017662.pdf","paywalled","other_trial","Gallo G","2025","Weekly Journal Scan: Effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf299","https://doi.org/10.1093/eurheartj/ehaf299","40296649","https://pubmed.ncbi.nlm.nih.gov/40296649/",null,null],["5","R0017708","R0017708.pdf","paywalled","other_trial","Anderer S","2025","Semaglutide Improves Severe Liver Disease in Phase 3 Trial.","JAMA","American Medical Association (AMA)","10.1001/jama.2025.6462","https://doi.org/10.1001/jama.2025.6462","40408124","https://pubmed.ncbi.nlm.nih.gov/40408124/",null,null],["5","R0017898","R0017898.pdf","paywalled","other_trial","Malozowski S","2025","Liraglutide for Children 6 to <12 Years of Age with Obesity.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2503084","https://doi.org/10.1056/nejmc2503084","40334165","https://pubmed.ncbi.nlm.nih.gov/40334165/",null,"ClinicalTrials.gov:NCT04605861; ClinicalTrials.gov:NCT04074161"],["5","R0018288","R0018288.pdf","paywalled","other_trial","Abdul Jabbar AB","2025","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-025-01355-2","https://doi.org/10.1007/s11883-025-01355-2","41145911","https://pubmed.ncbi.nlm.nih.gov/41145911/",null,null],["5","R0018685","R0018685.pdf","paywalled","other_trial","Anderer S","2025","Semaglutide Eases Knee Osteoarthritis Pain in People With Obesity.","JAMA","American Medical Association (AMA)","10.1001/jama.2024.24260","https://doi.org/10.1001/jama.2024.24260","39641950","https://pubmed.ncbi.nlm.nih.gov/39641950/",null,null],["5","R0020032","R0020032.pdf","paywalled","other_trial","Tang M","2025","Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16466","https://doi.org/10.1111/dom.16466","40452343","https://pubmed.ncbi.nlm.nih.gov/40452343/",null,null],["5","R0020164","R0020164.pdf","paywalled","other_trial","Petralli G","2025","Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-025-02466-7","https://doi.org/10.1007/s00592-025-02466-7","39954057","https://pubmed.ncbi.nlm.nih.gov/39954057/",null,null],["5","R0021163","R0021163.pdf","paywalled","other_trial","Alfadhel A","2025","Nephrology: What You May Have Missed in 2024.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-00796","https://doi.org/10.7326/annals-25-00796","40163875","https://pubmed.ncbi.nlm.nih.gov/40163875/",null,null],["5","R0021421","R0021421.pdf","paywalled","protocol","Allred M","2025","GLP-1 Weight Loss Protocol: An Evidence-Based Translation Project.","Journal of doctoral nursing practice","Springer Publishing Company","10.1891/jdnp-2024-0021","https://doi.org/10.1891/jdnp-2024-0021","40425307","https://pubmed.ncbi.nlm.nih.gov/40425307/",null,null],["5","R0021563","R0021563.pdf","paywalled","protocol","Malgave A","2025","Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery.","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","Elsevier BV","10.1016/j.ejpb.2025.114780","https://doi.org/10.1016/j.ejpb.2025.114780","40490042","https://pubmed.ncbi.nlm.nih.gov/40490042/",null,null],["5","R0022742","R0022742.pdf","paywalled","other_trial","Bhushan S","2025","Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2025.2478917","https://doi.org/10.1080/14656566.2025.2478917","40100944","https://pubmed.ncbi.nlm.nih.gov/40100944/",null,null],["5","R0022915","R0022915.pdf","paywalled","other_trial","Do A","2025","Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).","Nature reviews. Drug discovery","Springer Science and Business Media LLC","10.1038/s41573-024-01084-2","https://doi.org/10.1038/s41573-024-01084-2","39609545","https://pubmed.ncbi.nlm.nih.gov/39609545/",null,null],["5","R0023396","R0023396.pdf","paywalled","other_trial","Hermel M","2025","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-025-01276-0","https://doi.org/10.1007/s11883-025-01276-0","39913067","https://pubmed.ncbi.nlm.nih.gov/39913067/",null,null],["5","R0023415","R0023415.pdf","paywalled","other_trial","Blau BJ","2025","Rheumatology: What You May Have Missed in 2024.","Annals of internal medicine","American College of Physicians","10.7326/annals-25-00927","https://doi.org/10.7326/annals-25-00927","40163867","https://pubmed.ncbi.nlm.nih.gov/40163867/",null,null],["5","R0029053","R0029053.pdf","paywalled","other_trial","Zhang H","2025","First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","Springer Science and Business Media LLC","10.1007/s40259-025-00715-3","https://doi.org/10.1007/s40259-025-00715-3","40175670","https://pubmed.ncbi.nlm.nih.gov/40175670/",null,"ClinicalTrials.gov:NCT05943886"],["5","R0029633","R0029633.pdf","paywalled","narrative_review","Kugathasan L","2025","Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease.","Expert review of clinical immunology","Informa UK Limited","10.1080/1744666x.2025.2537446","https://doi.org/10.1080/1744666x.2025.2537446","40693871","https://pubmed.ncbi.nlm.nih.gov/40693871/",null,"ClinicalTrials.gov:NCT06217302; ClinicalTrials.gov:NCT05901831; ClinicalTrials.gov:NCT05822609"],["5","R0029891","R0029891.pdf","paywalled","other_trial","Brachs S","2025","Hormonal regulation of human adipose tissue lipolysis: impact of adipose GIP system in overweight and obesity.","European journal of endocrinology","Oxford University Press (OUP)","10.1093/ejendo/lvae151","https://doi.org/10.1093/ejendo/lvae151","39935317","https://pubmed.ncbi.nlm.nih.gov/39935317/",null,"DRKS:DRKS00010049"],["5","R0030034","R0030034.pdf","paywalled","other_trial","Chen W","2025","GZR101, a Novel Premixed Insulin for the Treatment of Diabetes Mellitus.","Naunyn-Schmiedeberg's archives of pharmacology","Springer Science and Business Media LLC","10.1007/s00210-025-04366-7","https://doi.org/10.1007/s00210-025-04366-7","40531224","https://pubmed.ncbi.nlm.nih.gov/40531224/",null,null],["5","R0030170","R0030170.pdf","paywalled","other_trial","Weiskorn J","2025","Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes.","Hormone research in paediatrics","S. Karger AG","10.1159/000539120","https://doi.org/10.1159/000539120","38688258","https://pubmed.ncbi.nlm.nih.gov/38688258/",null,null],["5","R0032066","R0032066.pdf","paywalled","other_trial",null,"2025","Mounjaro health benefits found to reverse one year after stopping drug","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.387473","https://doi.org/10.1211/pj.2025.1.387473",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032080","R0032080.pdf","paywalled","other_trial",null,"2025","Investigational weight-loss drug trial shows average reduced body weight of 30%","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.390945","https://doi.org/10.1211/pj.2025.1.390945",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032502","R0032502.pdf","paywalled","other_trial","Iskandar Idris","2025","Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial","Obesity Abstracts","Bioscientifica","10.1530/obabs.05.p3","https://doi.org/10.1530/obabs.05.p3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032618","R0032618.pdf","paywalled","other_trial",null,"2025","Cardiovascular and Kidney Risk Reduction in High-Risk Individuals with Type 2 Diabetes","American Diabetes Association eBooks","American Diabetes Association","10.2337/9781580408486-ch03","https://doi.org/10.2337/9781580408486-ch03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032635","R0032635.pdf","paywalled","other_trial","JINGYE ZHOU","2025","2183-LB: Metabolic Effects of ECC4703, a Liver Targeting Full THRb Agonist, in Combination with Semaglutide and Tirzepatide in Diet-Induced Obese Mice","Diabetes","American Diabetes Association","10.2337/db25-2183-lb","https://doi.org/10.2337/db25-2183-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032801","R0032801.pdf","paywalled","other_trial","ZHICHAO WANG","2025","1688-P: Novel Oral Apelin Receptor Agonist PSTC1201 for Selective Weight Loss with Muscle Preservation When Combined with Semaglutide in DIO Mice Model","Diabetes","American Diabetes Association","10.2337/db25-1688-p","https://doi.org/10.2337/db25-1688-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032823","R0032823.pdf","paywalled","other_trial","Shai Rubnov","2025","1689-P: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling","Diabetes","American Diabetes Association","10.2337/db25-1689-p","https://doi.org/10.2337/db25-1689-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032828","R0032828.pdf","paywalled","other_trial","Michael Feigh","2025","2170-LB: Tirzepatide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH-HCC with Advanced Fibrosis","Diabetes","American Diabetes Association","10.2337/db25-2170-lb","https://doi.org/10.2337/db25-2170-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032876","R0032876.pdf","paywalled","other_trial","ALAAELDIN HODHOD","2025","38-OR: Effects of Dorzagliatin, Insulin Glargine, and Metformin on Nocturnal Endogenous Glucose Production in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-38-or","https://doi.org/10.2337/db25-38-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032942","R0032942.pdf","paywalled","other_trial","Martin Haluzı́k","2025","805-P: Early Glycemic Improvement When Switching to iGlarLixi from Premixed Insulins (PI) in Adults with Type 2 Diabetes (T2D)—A Post Hoc Analysis of Soli-SWITCH","Diabetes","American Diabetes Association","10.2337/db25-805-p","https://doi.org/10.2337/db25-805-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2021-003711-25"],["5","R0032945","R0032945.pdf","paywalled","other_trial","Yosra Turkistani","2025","Knowledge, attitude, and prescribing patterns of GLP-1 receptor agonists among cardiologists: A cross-sectional study from the Makkah Region","International Journal of Medicine in Developing Countries","Discover STM Publishing Ltd.","10.24911/ijmdc.51-1745575418","https://doi.org/10.24911/ijmdc.51-1745575418",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032978","R0032978.pdf","paywalled","other_trial","Yu Yan","2025","2191-LB: A First-in-Class FTO Small Molecule Inhibitor Preserves the Lean Mass during Long-Term Weight Control Comparable to GLP-1","Diabetes","American Diabetes Association","10.2337/db25-2191-lb","https://doi.org/10.2337/db25-2191-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033016","R0033016.pdf","paywalled","other_trial","Oliver Freudenreich","2025","Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial",null,"Psychopharmacology Institute","10.64239/pi-qt7802","https://doi.org/10.64239/pi-qt7802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033364","R0033364.pdf","paywalled","other_trial","Susanne Krome","2025","Antidiabetika bei chronisch obstruktiver Lungenerkrankung vorteilhaft","Pneumologie","Georg Thieme Verlag KG","10.1055/a-2643-1633","https://doi.org/10.1055/a-2643-1633",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033414","R0033414.pdf","paywalled","other_trial","Bharmal, Mohammad Musa","2025","Orforglipron: A Review Of A Novel Oral, Non-Peptide GLP-1 Receptor Agonist.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15858941","https://doi.org/10.5281/zenodo.15858941",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033453","R0033453.pdf","paywalled","protocol","Kosiborod, Mikhail N","2025","Plain language summary of the PUBLICATION titled “Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial”","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29066768","https://doi.org/10.60915/boehringer-figshare.29066768",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033457","R0033457.pdf","paywalled","protocol","Schattenberg, Joern","2025","Poster presented at EASL 2025 - Survodutide, a glucagon/ GLP-1 receptor dual agonist, in people with MASH with moderate-to advanced liver fibrosis (stage F2–F3): rationale and design of an event driven, multinational, randomised, placebo controlled, phase 3 trial (LIVERAGE™)","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29070206","https://doi.org/10.60915/boehringer-figshare.29070206",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033471","R0033471.pdf","paywalled","other_trial","Boehringer Ingelheim Demo","2025","Survodutide Shows Strong Weight Loss Benefits in Phase 2 Obesity Trial","Kudos Innovations Ltd",null,"10.26303/d8f9-kj28","https://doi.org/10.26303/d8f9-kj28",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033511","R0033511.pdf","paywalled","protocol","Hallström, Sara","2025","Statistical Analysis Plan, Efficacy on cardiovascular outcomes from sustained use of GLP-1 receptor agonists versus DPP-4 inhipitors: A LEADER-inspired trial emulation using the Swedish National Diabetes Register.","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15311401","https://doi.org/10.5281/zenodo.15311401",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033533","R0033533.pdf","paywalled","other_trial","Healthcare","2025","North America Pharmaceuticals Market Trends, Innovations, and Growth Opportunities 2032","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17285701","https://doi.org/10.5281/zenodo.17285701",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033553","R0033553.pdf","paywalled","other_trial","Tang, Liang","2025","Discovery and design of molecular glues as a strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.16951758","https://doi.org/10.5281/zenodo.16951758",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033616","R0033616.pdf","paywalled","other_trial","Denisha Meghnathi*1, Kiran Rathod2, Chintankumar Tank3, Shivani Herma1, Himanshu Parmar1, Pritesh Odedara1","2025","Non-Alcoholic Fatty Liver Managment","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15298763","https://doi.org/10.5281/zenodo.15298763",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033674","R0033674.pdf","paywalled","other_trial","Ghosh, Sujoy","2025","Additional file 1 of Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial","Figshare",null,"10.6084/m9.figshare.28657215","https://doi.org/10.6084/m9.figshare.28657215",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033702","R0033702.pdf","paywalled","protocol","Gharibzadeh, Safoora","2025","Statistical Analysis Plan for a Comparative Study of GLP-1 Receptor Agonists and DPP-4 Inhibitors Using Clinical Practice Research Datalink (CPRD) Data – Insights from the LEADER Trial","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.14605131","https://doi.org/10.5281/zenodo.14605131",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033757","R0033757.pdf","paywalled","other_trial","Hebbare Sravani Bai, Yashmeen Nikhat","2025","Insulin Resistance in Alzheimer's: Exploring the Type 3 Diabetes Hypothesis","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.16799941","https://doi.org/10.5281/zenodo.16799941",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033769","R0033769.pdf","paywalled","other_trial","Rakhimov Anvarjon Aliyorovich https://orcid.org/0009-0007-0785-8084","2025","A COMPREHENSIVE REVIEW OF SEMAGLUTIDE: PHARMACOLOGY, CLINICAL EFFICACY, CARDIOVASCULAR OUTCOMES, AND SAFETY PROFILE","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17177815","https://doi.org/10.5281/zenodo.17177815",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033779","R0033779.pdf","paywalled","other_trial","Noureddin, Mazen","2025","Poster presented at EASL 2025 -Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29070158","https://doi.org/10.60915/boehringer-figshare.29070158",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033800","R0033800.pdf","paywalled","other_trial","S.D. Aminov","2025","SEMAGLUTIDE - FOR THE TREATMENT OF OBESITY","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.14993618","https://doi.org/10.5281/zenodo.14993618",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033902","R0033902.pdf","paywalled","other_trial","Noureddin, Mazen","2025","Poster presented at EASL 2025 -Non-invasive tests (NITs) to predict liver biopsy outcomes in response to treatment with survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist: exploratory analysis of a phase 2 trial in people with metabolic dysfunction associated steatohepatitis and fibrosis","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29070455","https://doi.org/10.60915/boehringer-figshare.29070455",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033981","R0033981.pdf","paywalled","protocol","Jens Michelsen","2025","Statistical analysis plan: Cardiovascular effectiveness of GLP-1 receptor agonists beyond cardiovascular outcome trial populations, a nationwide target trial emulation in the Swedish National Diabetes Register","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.20218823","https://doi.org/10.5281/zenodo.20218823",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033998","R0033998.pdf","paywalled","other_trial","Roux, Carel W Le","2025","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist”","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29066720","https://doi.org/10.60915/boehringer-figshare.29066720",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034065","R0034065.pdf","paywalled","other_trial","Sørensen, Kathrine Kold","2025","DK REDDIE WP4 Analysis plan: GLP1-RA versus DPP4","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15062985","https://doi.org/10.5281/zenodo.15062985",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035944","R0035944.pdf","paywalled","other_trial",null,"2025","Semaglutide benefits heart health regardless of weight lost","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2025.1.381190","https://doi.org/10.1211/pj.2025.1.381190",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035990","R0035990.pdf","paywalled","other_trial","Julio Rosenstock","2025","Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807441","https://doi.org/10.1055/s-0045-1807441",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036195","R0036195.pdf","paywalled","other_trial","SANG HYUN PARK","2025","774-P: Robust Antiobesity Effect and Mechanistic Insights of HM15275, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity","Diabetes","American Diabetes Association","10.2337/db25-774-p","https://doi.org/10.2337/db25-774-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036517","R0036517.pdf","paywalled","protocol","da Silva Barros, Maicon Herverton Lino Ferreira","2025","Ultraprocessed Foods, GLP-1, and Mental Health: A Modular Protocol with Diet, Physical Activity, and Tirzepatide","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/7p4x5","https://doi.org/10.17605/osf.io/7p4x5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036557","R0036557.pdf","paywalled","protocol","De Melo Barbosa, Aurelio","2025","Liraglutide and semaglutide in the treatment of severe obesity in adolescents treated in the Brazilian Public Health System: Research protocol for cost-effectiveness and budget impact analysis study","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/jdy7z","https://doi.org/10.17605/osf.io/jdy7z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036558","R0036558.pdf","paywalled","protocol","Zein, Ola El","2025","Social Media Promotion of GLP-1 Receptor Agonists for Obesity: A Scoping Review of Study Designs, Engagement Strategies, and Public Perceptions","Open Science Framework",null,"10.17605/osf.io/j8kpe","https://doi.org/10.17605/osf.io/j8kpe",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036578","R0036578.pdf","paywalled","protocol","Bandholm, Thomas Quaade","2025","Exploring Cardiometabolic Health, Physical Activity, and Quality of Life in Patients with Obesity and Multimorbidity during an Intensive Weight Loss Program: A Protocol for a Real-Life Prospective Cohort Study.","Open Science Framework",null,"10.17605/osf.io/ezn57","https://doi.org/10.17605/osf.io/ezn57",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036686","R0036686.pdf","paywalled","protocol","Mustafa Al-Mashhadani","2025","Current Practices in Thyroid Screening for GLP-1 Receptor Agonist Use and the Influence of Screening Bias on Reported Rates of C-Cell and Medullary Thyroid Carcinoma: A Protocol for a Scoping Review","Open Science Framework",null,"10.17605/osf.io/pebhs","https://doi.org/10.17605/osf.io/pebhs",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037462","R0037462.pdf","paywalled","other_trial","M. Anstee, Quentin","2025","Oral presentation at AASLD 2025: Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: Overlap analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.30436906","https://doi.org/10.60915/boehringer-figshare.30436906",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037508","R0037508.pdf","paywalled","other_trial","Redento Mora","2025","Semaglutide Therapy And Reduction Of Left Ventricular Mass In Patients With Type 2 Diabetes: A STOP Trial Substudy","Journal of cardiovascular computed tomography","Elsevier BV","10.1016/j.jcct.2025.05.015","https://doi.org/10.1016/j.jcct.2025.05.015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037871","R0037871.pdf","paywalled","other_trial","Ramos, Mafalda","2025","The cost-effectiveness of subcutaneous semaglutide 2.4mg in the management of people living with obesity and prediabetes in England","Figshare",null,"10.6084/m9.figshare.30365166.v1","https://doi.org/10.6084/m9.figshare.30365166.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037979","R0037979.pdf","paywalled","other_trial","special to C EN Andy Brunning","2025","Periodic Graphics: The science of weight-loss drugs","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10302-feature5","https://doi.org/10.1021/cen-10302-feature5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038000","R0038000.pdf","paywalled","other_trial","Aayushi Pratap","2025","Pfizer to buy weight-loss drug firm Metsera for $4.9 billion","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10321-buscon4","https://doi.org/10.1021/cen-10321-buscon4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038465","R0038465.pdf","paywalled","other_trial","Koji Kashima","2025","408-P: Assessing Individual Estimated GFR Trajectory on GLP-1RA Use for Kidney Protection","Diabetes","American Diabetes Association","10.2337/db25-408-p","https://doi.org/10.2337/db25-408-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038491","R0038491.pdf","paywalled","other_trial","J. Hans DeVries","2025","1975-LB: A Single Ascending Dose Study of a Once-Monthly Liraglutide Formulation in Participants with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db25-1975-lb","https://doi.org/10.2337/db25-1975-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038647","R0038647.pdf","paywalled","protocol","Wharton, Sean","2025","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 & -2)”","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.29066735.v1","https://doi.org/10.60915/boehringer-figshare.29066735.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038683","R0038683.pdf","paywalled","other_trial","Shambo Samrat Samajdar","2025","Research letter: Risk–benefit analysis of Tirzepatide for HFpEF and obesity – insights from NNT analysis in the SUMMIT trial","International Journal of Diabetes in Developing Countries","Springer Science and Business Media LLC","10.1007/s13410-025-01475-0","https://doi.org/10.1007/s13410-025-01475-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038750","R0038750.pdf","paywalled","other_trial","Diane S. Aschenbrenner","2025","New clinical indication for weight loss drug","AJN American Journal of Nursing","Ovid Technologies (Wolters Kluwer Health)","10.1097/ajn.0000000000000217a","https://doi.org/10.1097/ajn.0000000000000217a","41437443","https://pubmed.ncbi.nlm.nih.gov/41437443/",null,null],["5","R0038899","R0038899.pdf","paywalled","other_trial","M. Anstee, Quentin","2025","Poster presented at AASLD 2025: Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: Overlap analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Boehringer Ingelheim",null,"10.60915/boehringer-figshare.30437453","https://doi.org/10.60915/boehringer-figshare.30437453",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039387","R0039387.pdf","paywalled","other_trial","Viral N. Shah","2025","24-PUB: The Efficacy and Safety of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) by Baseline Age, Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) Use, and BMI—Post Hoc Analysis of Soli-CGM","Diabetes","American Diabetes Association","10.2337/db25-24-pub","https://doi.org/10.2337/db25-24-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05114590"],["5","R0039566","R0039566.pdf","paywalled","other_trial",null,"2025","Changes in Cardiometabolic Risk Factors Upon Discontinuation of Tirzepatide for 17 Weeks in a Phase 3 Three-Year Study","Endocrine Practice","Elsevier BV","10.1016/j.eprac.2025.05.523","https://doi.org/10.1016/j.eprac.2025.05.523",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039673","R0039673.pdf","paywalled","other_trial","Leslie J. Heinberg","2025","1731-P: A Six-Month Single-Arm Study Testing the Effectiveness of Commercial Telehealth Medical Weight Management and GLP-1 Behavioral Program on Weight Loss and Blood Pressure Outcomes","Diabetes","American Diabetes Association","10.2337/db25-1731-p","https://doi.org/10.2337/db25-1731-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039893","R0039893.pdf","paywalled","other_trial","Aayushi Pratap","2025","Lilly touts results for once-daily weight-loss pill","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10311-buscon2","https://doi.org/10.1021/cen-10311-buscon2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040399","R0040399.pdf","paywalled","protocol","Evans, Mark","2025","Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol","Apollo (University of Cambridge)",null,"10.17863/cam.117060","https://doi.org/10.17863/cam.117060",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041858","R0041858.pdf","paywalled","other_trial","Marathe, Dr Jessica","2025","The \"Can Semaglutide or eMpAgliflozin Stabilise coronary atHerosclerosis after Acute Coronary Syndrome (SMASH-ACS)” study in people with type 2 diabetes","South Australian Health and Medical Research Institute",null,"10.58138/de9s-xg27","https://doi.org/10.58138/de9s-xg27",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042059","R0042059.pdf","paywalled","protocol","Kutsyba, Tetiana","2025","“Pancreatic and Gallbladder safety of Tirzepatide in Obesity Management: A Scoping Review Protocol of Clinical and Real-World Evidence”",null,null,"10.17605/osf.io/rm46g","https://doi.org/10.17605/osf.io/rm46g",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043640","R0043640.pdf","paywalled","protocol","Builes-Montaño, Carlos E.","2025","Incretin-based therapies and renal outcomes in adults with chronic kidney disease and/or type 2 diabetes or overweight/obesity: a scoping review protocol",null,null,"10.17605/osf.io/sz87j","https://doi.org/10.17605/osf.io/sz87j",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043743","R0043743.pdf","paywalled","other_trial","Oliver Freudenreich","2025","Il semaglutide inverte l’aumento di peso indotto dalla clozapina nella schizofrenia? Risultati del trial COaST",null,"Psychopharmacology Institute","10.64239/pi-it-qt7802","https://doi.org/10.64239/pi-it-qt7802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043889","R0043889.pdf","paywalled","other_trial","Oliver Freudenreich","2025","Keert semaglutide door clozapine geïnduceerde gewichtstoename om bij schizofrenie? Resultaten van de COaST-trial",null,"Psychopharmacology Institute","10.64239/pi-nl-qt7802","https://doi.org/10.64239/pi-nl-qt7802",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045087","R0045087.pdf","paywalled","other_trial","Péterson Alves Santos","2025","Impact of hormonal and metabolic disturbances on aging: evaluation of GLP-1 mimetics, DPP-4 inhibitors, nutraceutical compounds, and exercise-like interventions in Caenorhabditis elegans",null,null,"10.17605/osf.io/nd3hr","https://doi.org/10.17605/osf.io/nd3hr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045225","R0045225.pdf","paywalled","other_trial","Clay W. Walker","2025","Systemic mastocytosis","JAAPA","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.jaa.0000000000000202","https://doi.org/10.1097/01.jaa.0000000000000202","40273169","https://pubmed.ncbi.nlm.nih.gov/40273169/",null,null],["5","R0045283","R0045283.pdf","paywalled","other_trial","Reena Mehra","2025","Changes in Cardiometabolic Risk Factors Based on Improvements in Apnea-Hypopnea Index in Participants from the SURMOUNT-OSA Clinical Studies","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a5287","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a5287",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045680","R0045680.pdf","paywalled","other","Hongyu Kuang","2025","23-PUB: Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study","Diabetes","American Diabetes Association","10.2337/db25-23-pub","https://doi.org/10.2337/db25-23-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05413369"],["5","R0045925","R0045925.pdf","paywalled","other_trial","Rafael Violante","2025","226-OR: Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH Trial","Diabetes","American Diabetes Association","10.2337/db25-226-or","https://doi.org/10.2337/db25-226-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045986","R0045986.pdf","paywalled","other_trial","Annarita Valeria Piazzolla","2025","Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects","Metabolism and Target Organ Damage","OAE Publishing Inc.","10.20517/mtod.2025.152","https://doi.org/10.20517/mtod.2025.152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046194","R0046194.pdf","paywalled","other_trial","Riccardo Miatton","2025","Semaglutide 7,2 mg settimanale in adulti con obesità (STEP UP): un trial randomizzato controllato di fase 3b","L Endocrinologo","Springer Science and Business Media LLC","10.1007/s40619-025-01731-9","https://doi.org/10.1007/s40619-025-01731-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046740","R0046740.pdf","paywalled","other_trial","Ying Chen","2025","EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial","Value in Health","Elsevier BV","10.1016/j.jval.2025.09.1116","https://doi.org/10.1016/j.jval.2025.09.1116",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046940","R0046940.pdf","paywalled","other_trial","Steven M. Brunelli","2025","GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025ebmh05b5","https://doi.org/10.1681/asn.2025ebmh05b5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047004","R0047004.pdf","paywalled","other_trial","Mahmoud H. Elbatreek","2025","Abstract Wed074: Semaglutide in HFpEF: Uncoupling Weight Loss to Reveal Additional Therapeutic Benefits","Circulation Research","Ovid Technologies (Wolters Kluwer Health)","10.1161/res.137.suppl_1.wed074","https://doi.org/10.1161/res.137.suppl_1.wed074",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047316","R0047316.pdf","paywalled","other_trial","John W. Ostrominski","2025","Abstract 4365716: Efficacy and Safety of Semaglutide According to Frailty Status in the SELECT Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4365716","https://doi.org/10.1161/circ.152.suppl_3.4365716",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047397","R0047397.pdf","paywalled","other_trial","Charlotte E. Hinds","2025","794-P: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist","Diabetes","American Diabetes Association","10.2337/db25-794-p","https://doi.org/10.2337/db25-794-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047398","R0047398.pdf","paywalled","other_trial","Jay B. Lusk","2025","173-OR: Eligibility, Impact, and Costs for Tirzepatide for the Primary Prevention of Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db25-173-or","https://doi.org/10.2337/db25-173-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047640","R0047640.pdf","paywalled","other_trial","Phoebe Hodges","2025","P1078 Weight-loss medications and bariatric surgery are infrequently used in obese patients with inflammatory bowel disease in North and East Devon in the United Kingdom (UK)","Journal of Crohn s and Colitis","Oxford University Press (OUP)","10.1093/ecco-jcc/jjae190.1252","https://doi.org/10.1093/ecco-jcc/jjae190.1252",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047743","R0047743.pdf","paywalled","other_trial","Steph Karpinski","2025","Abstract 4351238: Use of GLP-1 is Associated with Improvement in Mortality Rates in ESKD Patients","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4351238","https://doi.org/10.1161/circ.152.suppl_3.4351238",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047762","R0047762.pdf","paywalled","other_trial","Mary Eugenia Rinella","2025","LBP-019 Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)00438-6","https://doi.org/10.1016/s0168-8278(25)00438-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047771","R0047771.pdf","paywalled","other_trial","Birong Liao","2025","Measures Related to Obstructive Sleep Apnea After Tirzepatide Treatment by Baseline OSA Severity: Post-hoc Analyses of SURMOUNT-OSA","American Journal of Respiratory and Critical Care Medicine","Oxford University Press (OUP)","10.1164/ajrccm.2025.211.abstracts.a5207","https://doi.org/10.1164/ajrccm.2025.211.abstracts.a5207",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05412004"],["5","R0048149","R0048149.pdf","paywalled","other_trial","Leslie J. Heinberg","2025","1732-P: The Impact of a Commercial Telehealth Medical Weight Management and GLP-1 Behavioral Program on Quality of Life and Eating Behavior Outcomes in a Six-Month Single-Arm Study","Diabetes","American Diabetes Association","10.2337/db25-1732-p","https://doi.org/10.2337/db25-1732-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048504","R0048504.pdf","paywalled","other_trial","Hsiu‐Chiung Yang","2025","84-OR: siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile","Diabetes","American Diabetes Association","10.2337/db25-84-or","https://doi.org/10.2337/db25-84-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048595","R0048595.pdf","paywalled","other_trial","BENJAMIN NORTON","2025","895-P: Proximal Intestinal Mucosal Ablation (PIMA) Eliminates the Need for Exogenous Insulin in Type 2 Diabetes—Initial STEAM-IE Trial Results","Diabetes","American Diabetes Association","10.2337/db25-895-p","https://doi.org/10.2337/db25-895-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06655740"],["5","R0049445","R0049445.pdf","paywalled","protocol","Jörn Markus Schattenberg","2025","SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3): rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM)","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01686-1","https://doi.org/10.1016/s0168-8278(25)01686-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049545","R0049545.pdf","paywalled","protocol","Kun Hu","2025","Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (smile T1D trial) development and protocol","Endocrine Abstracts","Bioscientifica","10.1530/endoabs.111.p99","https://doi.org/10.1530/endoabs.111.p99",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049830","R0049830.pdf","paywalled","other_trial","Vera Oettinger","2025","GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3653","https://doi.org/10.1093/eurheartj/ehaf784.3653",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050166","R0050166.pdf","paywalled","other_trial","H.-E. Langer","2025","Do incretin-based drugs accelerate muscle wasting during weight loss?","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807389","https://doi.org/10.1055/s-0045-1807389",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050173","R0050173.pdf","paywalled","other_trial","Billy P Baxter","2025","799-P: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist","Diabetes","American Diabetes Association","10.2337/db25-799-p","https://doi.org/10.2337/db25-799-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050282","R0050282.pdf","paywalled","other_trial","Pavlo Yavorskiy","2025","#3691 Successful use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in a patient with obesity and diabetic kidney disease under peritoneal dialysis: a Case Report","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaf116.1683","https://doi.org/10.1093/ndt/gfaf116.1683",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050566","R0050566.pdf","paywalled","other_trial","Mazen Noureddin","2025","SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01701-5","https://doi.org/10.1016/s0168-8278(25)01701-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050707","R0050707.pdf","paywalled","protocol","Patrício Correia, Vítor","2025","Endoscopic Sleeve Gastroplasty as Facilitatorfor Renal Transplantation in Patients withObesity: Rationale and Protocol","Portuguese Kidney Journal (PKJ)",null,"10.71749/pkj.105","https://doi.org/10.71749/pkj.105",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050795","R0050795.pdf","paywalled","other_trial","Mazen Noureddin","2025","WED-468 Non-invasive markers to predict biopsy response in people with metabolic dysfunction-associated steatohepatitis and fibrosis: exploratory analysis of a phase 2 trial of glucagon receptor/ glucagon-like peptide-1 receptor dual agonist, survodutide","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)01537-5","https://doi.org/10.1016/s0168-8278(25)01537-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050851","R0050851.pdf","paywalled","other_trial","HARPREET SINGH BAJAJ","2025","Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2025.10.006","https://doi.org/10.1016/j.jcjd.2025.10.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050955","R0050955.pdf","paywalled","other_trial","HARPREET SINGH BAJAJ","2025","Semaglutide-Treated Participants in the Phase 3 ESSENCE Trial (Part 1) Have Greater Concordance of Non-invasive Test Improvements Compared With Placebo","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2025.10.045","https://doi.org/10.1016/j.jcjd.2025.10.045",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050970","R0050970.pdf","paywalled","other_trial","Mahmoud H. Elbatreek","2025","Abstract 4359422: Low-Dose GLP-1 Receptor Agonist Therapy Exerts Anti-Fibrotic Effects Across Multiple Organs in Cardiometabolic HFpEF","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.152.suppl_3.4359422","https://doi.org/10.1161/circ.152.suppl_3.4359422",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051005","R0051005.pdf","paywalled","other_trial","SAMSON L. CANTOR","2025","277-OR: OCT1 and TCF7L2 Variants Modulate Metformin–Liraglutide Pharmacokinetics and Glycemia in African American Youth-Onset Type 2 Diabetes—The MIGHTY Study","Diabetes","American Diabetes Association","10.2337/db25-277-or","https://doi.org/10.2337/db25-277-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051318","R0051318.pdf","paywalled","other_trial","Jim S Paik","2025","Switching to Tirzepatide 5 mg from GLP-1 RAs: Clinical Expectations in the First 12 Weeks of Treatment","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0045-1807557","https://doi.org/10.1055/s-0045-1807557",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051326","R0051326.pdf","paywalled","other_trial","WEN-XIN SONG","2025","1968-LB: MWN105—A Next-Generation GLP-1/GIP/FGF21 Agonist for the Treatment of NASH","Diabetes","American Diabetes Association","10.2337/db25-1968-lb","https://doi.org/10.2337/db25-1968-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051351","R0051351.pdf","paywalled","other_trial","Elita Yuliantie","2025","1974-LB: The Molecular Basis of Survodutide (BI456906) Glucagon/GLP-1 Receptor Dual Agonism","Diabetes","American Diabetes Association","10.2337/db25-1974-lb","https://doi.org/10.2337/db25-1974-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051362","R0051362.pdf","paywalled","other_trial","Mazen Noureddin","2025","OS-098 Direct effects of survodutide on liver endpoints beyond weight loss: insights from a phase 2 trial of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(25)00413-1","https://doi.org/10.1016/s0168-8278(25)00413-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051655","R0051655.pdf","paywalled","other_trial","Ksenia O. Shnaider","2025","Safety analysis of tirzepatide in clinical practice","Glavvrač (Chief Medical Officer)","PANORAMA Publishing House","10.33920/med-03-2508-03","https://doi.org/10.33920/med-03-2508-03",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051844","R0051844.pdf","paywalled","other_trial","Xin Li","2025","1988-LB: Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study","Diabetes","American Diabetes Association","10.2337/db25-1988-lb","https://doi.org/10.2337/db25-1988-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05413369"],["5","R0052184","R0052184.pdf","paywalled","other_trial","WEN-XIN SONG","2025","1967-LB: MWN109—A Novel Fatty Acid–Modified GLP-1/GIP/GCG Triagonist for Dual-Format Weight Management Demonstrates Superior Efficacy in Nonhuman Primates","Diabetes","American Diabetes Association","10.2337/db25-1967-lb","https://doi.org/10.2337/db25-1967-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052185","R0052185.pdf","paywalled","other_trial","Linong Ji","2025","804-P: A1C and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Kidney Function","Diabetes","American Diabetes Association","10.2337/db25-804-p","https://doi.org/10.2337/db25-804-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052370","R0052370.pdf","paywalled","other_trial","Faiez M. Zannad","2025","Seeking Multiorgan Benefits with Cardiovascular–Kidney–Metabolic Drug Therapy","New England Journal of Medicine","Massachusetts Medical Society","10.1056/nejme2503600","https://doi.org/10.1056/nejme2503600","40435470","https://pubmed.ncbi.nlm.nih.gov/40435470/",null,null],["5","R0052568","R0052568.pdf","paywalled","protocol","Paul Mystkowski","2025","Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000211162","https://doi.org/10.1212/wnl.0000000000211162",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052599","R0052599.pdf","paywalled","protocol","Ruiyi Gao","2025","Su1239: EVALUATING OUTPATIENT COLONOSCOPY OUTCOMES AND BOWEL PREPARATION IN PATIENTS TAKING GLP-1 RECEPTOR AGONISTS AFTER IMPLEMENTATION OF ONE DOSING CYCLE HOLD PROTOCOL: A QUALITY IMPROVEMENT STUDY","Gastroenterology","Elsevier BV","10.1016/s0016-5085(25)02599-5","https://doi.org/10.1016/s0016-5085(25)02599-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052823","R0052823.pdf","paywalled","other_trial","A. Mega","2025","BOC.01.9 EFFECTS OF GLP1-RAS AND SGLT2I ON LIVER STEATOSIS AND FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) WITH TYPE 2 DIABETES: INTERIM ANALYSIS OF AN OPEN TRIAL","Digestive and Liver Disease","Elsevier BV","10.1016/s1590-8658(25)00342-1","https://doi.org/10.1016/s1590-8658(25)00342-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053078","R0053078.pdf","paywalled","other_trial","Sana Rabeeah","2025","S3262 Lymphoethelial Cyst of the Pancreas: A Case Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001140508.69888.96","https://doi.org/10.14309/01.ajg.0001140508.69888.96",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053081","R0053081.pdf","paywalled","other_trial","Ambarish Pandey","2025","2097-LB: Generalizability of SELECT and SURMOUNT-MMO Trial Criteria to the U.S. OMM-Eligible Adult Population","Diabetes","American Diabetes Association","10.2337/db25-2097-lb","https://doi.org/10.2337/db25-2097-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053286","R0053286.pdf","paywalled","other_trial","Martin Haluzı́k","2025","806-P: Glycemic Outcomes When Switching to iGlarLixi from Premixed Insulin (PI) in People with Type 2 Diabetes (T2D) by iGlarLixi Pen Subgroups—Post Hoc Analysis of Soli-SWITCH","Diabetes","American Diabetes Association","10.2337/db25-806-p","https://doi.org/10.2337/db25-806-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2021-003711-25"],["5","R0053304","R0053304.pdf","paywalled","other_trial","William A. Kinney","2025","1696-P: ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice","Diabetes","American Diabetes Association","10.2337/db25-1696-p","https://doi.org/10.2337/db25-1696-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053731","R0053731.pdf","paywalled","other_trial","Tripdatabase","2025","In terms of weight loss outcomes, how does Mounjaro compare to Ozempic in patients with type 2 diabetes?","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.17652858","https://doi.org/10.5281/zenodo.17652858",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054026","R0054026.pdf","paywalled","other_trial","Naveed Sattar","2025","Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehaf784.3755","https://doi.org/10.1093/eurheartj/ehaf784.3755",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054900","R0054900.pdf","paywalled","other","Ingo Fietze","2025","Late Breaking Abstract - Tirzepatide and Nocturnal Hypoxia (T90): SURMOUNT-OSA post hoc analyses",null,"European Respiratory Society","10.1183/13993003.congress-2025.pa6032","https://doi.org/10.1183/13993003.congress-2025.pa6032",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05412004"],["5","R0055068","R0055068.pdf","paywalled","other_trial","L. Sreenivasa Murthy","2025","FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20257qtjpx6z","https://doi.org/10.1681/asn.20257qtjpx6z",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055469","R0055469.pdf","paywalled","other_trial","Christian W. Mende","2025","Kidney, Cardiovascular, and Death Outcomes with Semaglutide Treatment Among Two Race and Two Ethnic Groups: Post Hoc Analysis from the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2025nztajebj","https://doi.org/10.1681/asn.2025nztajebj",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03819153"],["5","R0003357","R0003357.pdf","paywalled","commentary","Felson DT","2024","Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejme2409972","https://doi.org/10.1056/nejme2409972","39476345","https://pubmed.ncbi.nlm.nih.gov/39476345/",null,null],["5","R0004588","R0004588.pdf","paywalled","other","Joshi GP","2024","Anesthetic Considerations in Adult Patients on Glucagon-Like Peptide-1 Receptor Agonists: Gastrointestinal Focus.","Anesthesia and analgesia","Ovid Technologies (Wolters Kluwer Health)","10.1213/ane.0000000000006810","https://doi.org/10.1213/ane.0000000000006810","37874648","https://pubmed.ncbi.nlm.nih.gov/37874648/",null,null],["5","R0005824","R0005824.pdf","paywalled","other_trial","Kaplan JM","2024","Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-024-02097-4","https://doi.org/10.1007/s11886-024-02097-4","39031282","https://pubmed.ncbi.nlm.nih.gov/39031282/",null,null],["5","R0005970","R0005970.pdf","paywalled","preclinical","Zhao L","2024","Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.","Endocrine","Springer Science and Business Media LLC","10.1007/s12020-024-03734-2","https://doi.org/10.1007/s12020-024-03734-2","38378894","https://pubmed.ncbi.nlm.nih.gov/38378894/",null,null],["5","R0007013","R0007013.pdf","paywalled","other_trial","Albert SG","2024","Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.1016/j.eprac.2023.12.007","https://doi.org/10.1016/j.eprac.2023.12.007","38097111","https://pubmed.ncbi.nlm.nih.gov/38097111/",null,null],["5","R0008116","R0008116.pdf","paywalled","other","Mottl AK","2024","KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.","American journal of kidney diseases : the official journal of the National Kidney Foundation","Elsevier BV","10.1053/j.ajkd.2023.09.003","https://doi.org/10.1053/j.ajkd.2023.09.003","38142396","https://pubmed.ncbi.nlm.nih.gov/38142396/",null,null],["5","R0010670","R0010670.pdf","paywalled","other_trial","Abubakar M","2024","GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.","Current topics in medicinal chemistry","Bentham Science Publishers Ltd.","10.2174/0115680266293416240515075450","https://doi.org/10.2174/0115680266293416240515075450","38803170","https://pubmed.ncbi.nlm.nih.gov/38803170/",null,null],["5","R0010769","R0010769.pdf","paywalled","commentary","Mansour MR","2024","The rise of \"Ozempic Face\": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists.","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Elsevier BV","10.1016/j.bjps.2024.07.051","https://doi.org/10.1016/j.bjps.2024.07.051","39098289","https://pubmed.ncbi.nlm.nih.gov/39098289/",null,null],["5","R0010831","R0010831.pdf","paywalled","other_trial","Dissanayake HA","2024","Polyagonists in Type 2 Diabetes Management.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-023-01530-2","https://doi.org/10.1007/s11892-023-01530-2","38150106","https://pubmed.ncbi.nlm.nih.gov/38150106/",null,null],["5","R0012242","R0012242.pdf","paywalled","other_trial","Irfan H","2024","Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.","Neurosurgical review","Springer Science and Business Media LLC","10.1007/s10143-024-02475-0","https://doi.org/10.1007/s10143-024-02475-0","38787469","https://pubmed.ncbi.nlm.nih.gov/38787469/",null,null],["5","R0013101","R0013101.pdf","paywalled","other_trial","Avgerinos I","2024","The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes.","Expert opinion on drug discovery","Informa UK Limited","10.1080/17460441.2024.2324918","https://doi.org/10.1080/17460441.2024.2324918","38654653","https://pubmed.ncbi.nlm.nih.gov/38654653/",null,null],["5","R0013341","R0013341.pdf","paywalled","protocol","Hamidi H","2024","Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.","American heart journal","Elsevier BV","10.1016/j.ahj.2024.08.015","https://doi.org/10.1016/j.ahj.2024.08.015","39187147","https://pubmed.ncbi.nlm.nih.gov/39187147/",null,null],["5","R0014853","R0014853.pdf","paywalled","other_trial","Greenhill C","2024","Phase I results for AMG 133.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/s41574-024-00967-z","https://doi.org/10.1038/s41574-024-00967-z","38388678","https://pubmed.ncbi.nlm.nih.gov/38388678/",null,null],["5","R0015373","R0015373.pdf","paywalled","other_trial","Kaya E","2024","Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2024.2441865","https://doi.org/10.1080/13543784.2024.2441865","39663847","https://pubmed.ncbi.nlm.nih.gov/39663847/",null,null],["5","R0015766","R0015766.pdf","paywalled","commentary","Mahase E","2024","GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.q1645","https://doi.org/10.1136/bmj.q1645","39043396","https://pubmed.ncbi.nlm.nih.gov/39043396/",null,null],["5","R0016118","R0016118.pdf","paywalled","other_trial","Friedman DI","2024","Special Considerations in the Treatment of Idiopathic Intracranial Hypertension.","Current neurology and neuroscience reports","Springer Science and Business Media LLC","10.1007/s11910-024-01398-z","https://doi.org/10.1007/s11910-024-01398-z","39656331","https://pubmed.ncbi.nlm.nih.gov/39656331/",null,null],["5","R0017362","R0017362.pdf","paywalled","other_trial","Friedman JH","2024","In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-01662-jc","https://doi.org/10.7326/annals-24-01662-jc","39222514","https://pubmed.ncbi.nlm.nih.gov/39222514/",null,null],["5","R0017472","R0017472.pdf","paywalled","other_trial","Fairbank R","2024","Ozempic keeps wowing: trial data show benefits for kidney disease.","Nature","Springer Science and Business Media LLC","10.1038/d41586-024-01564-w","https://doi.org/10.1038/d41586-024-01564-w","38789608","https://pubmed.ncbi.nlm.nih.gov/38789608/",null,null],["5","R0017990","R0017990.pdf","paywalled","other_trial","Li Z","2024","GLP-1: A Prospective Guardian for Comprehensive Myocardial Perfusion.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.70004","https://doi.org/10.1002/dmrr.70004","39520208","https://pubmed.ncbi.nlm.nih.gov/39520208/",null,null],["5","R0018805","R0018805.pdf","paywalled","other_trial","Sardar MB","2024","Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.","Current problems in cardiology","Elsevier BV","10.1016/j.cpcardiol.2024.102489","https://doi.org/10.1016/j.cpcardiol.2024.102489","38417475","https://pubmed.ncbi.nlm.nih.gov/38417475/",null,null],["5","R0019168","R0019168.pdf","paywalled","other_trial","Agarwal SM","2024","Semaglutide in Psychiatry-Opportunities and Challenges.","JAMA psychiatry","American Medical Association (AMA)","10.1001/jamapsychiatry.2024.2412","https://doi.org/10.1001/jamapsychiatry.2024.2412","39167395","https://pubmed.ncbi.nlm.nih.gov/39167395/",null,null],["5","R0019196","R0019196.pdf","paywalled","other_trial","Collister D","2024","In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-01579-jc","https://doi.org/10.7326/annals-24-01579-jc","39222509","https://pubmed.ncbi.nlm.nih.gov/39222509/",null,null],["5","R0019247","R0019247.pdf","paywalled","other_trial","Zhu D","2024","In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.","Annals of internal medicine","American College of Physicians","10.7326/annals-24-02457-jc","https://doi.org/10.7326/annals-24-02457-jc","39496170","https://pubmed.ncbi.nlm.nih.gov/39496170/",null,null],["5","R0019446","R0019446.pdf","paywalled","other_trial","Kaur M","2024","A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-024-03646-0","https://doi.org/10.1007/s00228-024-03646-0","38367045","https://pubmed.ncbi.nlm.nih.gov/38367045/",null,null],["5","R0019832","R0019832.pdf","paywalled","other_trial","Ostrominski JW","2024","STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehae410","https://doi.org/10.1093/eurheartj/ehae410","39056260","https://pubmed.ncbi.nlm.nih.gov/39056260/",null,null],["5","R0019847","R0019847.pdf","paywalled","other_trial","Cohen C","2024","Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2406233","https://doi.org/10.1056/nejmc2406233","39047251","https://pubmed.ncbi.nlm.nih.gov/39047251/",null,null],["5","R0019886","R0019886.pdf","paywalled","other_trial","Carney EF","2024","A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.","Nature reviews. Nephrology","Springer Science and Business Media LLC","10.1038/s41581-024-00865-7","https://doi.org/10.1038/s41581-024-00865-7","38956439","https://pubmed.ncbi.nlm.nih.gov/38956439/",null,null],["5","R0020218","R0020218.pdf","paywalled","other_trial","Lau D","2024","In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.","Annals of internal medicine","American College of Physicians","10.7326/j24-0025","https://doi.org/10.7326/j24-0025","38710083","https://pubmed.ncbi.nlm.nih.gov/38710083/",null,null],["5","R0020238","R0020238.pdf","paywalled","other_trial","Kosiborod MN","2024","Response by Kosiborod et al to Letter Regarding Article, \"Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.124.069707","https://doi.org/10.1161/circulationaha.124.069707","39226383","https://pubmed.ncbi.nlm.nih.gov/39226383/",null,null],["5","R0020248","R0020248.pdf","paywalled","other_trial","Koutroumpakis E","2024","In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.","Annals of internal medicine","American College of Physicians","10.7326/j24-0008","https://doi.org/10.7326/j24-0008","38437690","https://pubmed.ncbi.nlm.nih.gov/38437690/",null,null],["5","R0020347","R0020347.pdf","paywalled","other_trial","Taqueti VR","2024","Semaglutide and Cardiovascular Outcomes.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2400414","https://doi.org/10.1056/nejmc2400414","38381682","https://pubmed.ncbi.nlm.nih.gov/38381682/",null,null],["5","R0021957","R0021957.pdf","paywalled","other_trial","Lehrke M","2024","GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudy.","Clinical research in cardiology : official journal of the German Cardiac Society","Springer Science and Business Media LLC","10.1007/s00392-023-02366-2","https://doi.org/10.1007/s00392-023-02366-2","38170249","https://pubmed.ncbi.nlm.nih.gov/38170249/",null,"ClinicalTrials.gov:NCT00491036"],["5","R0024259","R0024259.pdf","paywalled","other_trial","Alfraih A","2024","Cardiology: What You May Have Missed in 2023.","Annals of internal medicine","American College of Physicians","10.7326/m24-0581","https://doi.org/10.7326/m24-0581","38621242","https://pubmed.ncbi.nlm.nih.gov/38621242/",null,null],["5","R0029125","R0029125.pdf","paywalled","other_trial","Polyzos SA","2024","Two Trials of Therapeutics for MASH with Liver Fibrosis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejmc2411003","https://doi.org/10.1056/nejmc2411003","39413385","https://pubmed.ncbi.nlm.nih.gov/39413385/",null,null],["5","R0029164","R0029164.pdf","paywalled","other_trial","Kanwal F","2024","Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.","The New England journal of medicine","Massachusetts Medical Society","10.1056/nejme2406487","https://doi.org/10.1056/nejme2406487","39047246","https://pubmed.ncbi.nlm.nih.gov/39047246/",null,null],["5","R0031389","R0031389.pdf","paywalled","other_trial","Zainab Abbas","2024","'Retatruide' drug trial: A paradigm shift in Type 2 Diabetes management","Greater South Information System",null,"10.60692/stgbb-wy931","https://doi.org/10.60692/stgbb-wy931","38783470","https://pubmed.ncbi.nlm.nih.gov/38783470/",null,null],["5","R0031421","R0031421.pdf","paywalled","protocol","Isca Evidence","2024","What are the experiences, views and perceptions of patients, carers and clinicians of glucagon-like-peptide-1 receptor agonists (GLP-1RAs)? A scoping review protocol","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12772703","https://doi.org/10.5281/zenodo.12772703",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031789","R0031789.pdf","paywalled","other_trial","Matías A. Loewy","2024","What’s next in the Ozempic era?","Knowable Magazine","Annual Reviews","10.1146/knowable-041724-1","https://doi.org/10.1146/knowable-041724-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032507","R0032507.pdf","paywalled","other_trial","Connor Quinter","2024","GLP-1 Agonists for Weight Loss and Beyond","Transformative Medicine","Tower Health","10.54299/tmed/curq6915","https://doi.org/10.54299/tmed/curq6915",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032641","R0032641.pdf","paywalled","other_trial","Shai Rubnov","2024","2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration","Diabetes","American Diabetes Association","10.2337/db24-2052-lb","https://doi.org/10.2337/db24-2052-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032873","R0032873.pdf","paywalled","other_trial",null,"2024","Tirzepatide reduces sleep events in patients with sleep apnea and obesity","The Brown University Psychopharmacology Update","Wiley","10.1002/pu.31214","https://doi.org/10.1002/pu.31214",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032929","R0032929.pdf","paywalled","other_trial","HE JINJIE","2024","15-PUB: A Single-Center, Open-Label, Fixed-Sequence Clinical Study to Evaluate the Pharmacokinetic Effects of Supaglutide on Digoxin or Metformin in Healthy Subjects","Diabetes","American Diabetes Association","10.2337/db24-15-pub","https://doi.org/10.2337/db24-15-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033041","R0033041.pdf","paywalled","other_trial","Bill Vestergaard","2024","1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats","Diabetes","American Diabetes Association","10.2337/db24-1661-p","https://doi.org/10.2337/db24-1661-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033042","R0033042.pdf","paywalled","other_trial","Abderrahim Oulhaj","2024","181-OR: Declining eGFR over Time Predicts the Risk of a Composite of Primary or Secondary Major Adverse Cardiovascular Events or Heart Failure Hospitalization, in People with Type 2 Diabetes—EXSCEL Post Hoc analysis","Diabetes","American Diabetes Association","10.2337/db24-181-or","https://doi.org/10.2337/db24-181-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033283","R0033283.pdf","paywalled","other_trial","Günaj Rakipovski","2024","Semaglutide Improves Kidney Function and Inflammatory Status in a Mouse Model of Glomerulonephritis","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20241xnj938n","https://doi.org/10.1681/asn.20241xnj938n",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033356","R0033356.pdf","paywalled","other_trial","Michael A. Nauck","2024","Kommentar zu „Unterschiede in der Wirksamkeit und Verträglichkeit Inkretinbasierter Diabetes-Medikamente“","DMW - Deutsche Medizinische Wochenschrift","Georg Thieme Verlag KG","10.1055/a-2260-6107","https://doi.org/10.1055/a-2260-6107",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033488","R0033488.pdf","paywalled","protocol","Win, Kyaw Z.","2024","Additional file 2 of Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol","Figshare",null,"10.6084/m9.figshare.25264414","https://doi.org/10.6084/m9.figshare.25264414",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033657","R0033657.pdf","paywalled","protocol","Al-Ozairi, Ebaa","2024","Additional file 1 of Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)","Figshare",null,"10.6084/m9.figshare.26681932","https://doi.org/10.6084/m9.figshare.26681932",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033670","R0033670.pdf","paywalled","other_trial","Sørensen, Kathrine Kold","2024","DK REDDIE WP4 Analysis plan: GLP1-RA versus DPP4","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.10926989","https://doi.org/10.5281/zenodo.10926989",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033691","R0033691.pdf","paywalled","other_trial","Kattepogu Naga Kumari, Sakila Jayasri*, Vinjamuri Glory Nissy*","2024","BASED ON STUDY OF TIRZEPATIDE IN THE MANAGEMENT OF CHRONIC WEIGHT LOSS IN TYPE 2 DIABETES","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.13820089","https://doi.org/10.5281/zenodo.13820089",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033807","R0033807.pdf","paywalled","other_trial","Nicholls, Stephen J.","2024","Additional file 1 of Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program","Figshare",null,"10.6084/m9.figshare.25201920","https://doi.org/10.6084/m9.figshare.25201920",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033905","R0033905.pdf","paywalled","protocol","Win, Kyaw Z.","2024","Additional file 1 of Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol","Figshare",null,"10.6084/m9.figshare.25264281","https://doi.org/10.6084/m9.figshare.25264281",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034037","R0034037.pdf","paywalled","other_trial","mbvvexkp","2024","abbi a cuore il signore pdf","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12310524","https://doi.org/10.5281/zenodo.12310524",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034073","R0034073.pdf","paywalled","other_trial","Trimova Weight Loss Drops Reviews","2024","Trimova Weight Loss Drops Reviews: A Natural Solution for Sustainable Weight Management","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.12749473","https://doi.org/10.5281/zenodo.12749473",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034588","R0034588.pdf","paywalled","other_trial","Deepalaxmi Rathakrishnan","2024","A Narrative Review on Clinical Evidence of Tirzepatide’s Role in Addressing Type 2 Diabetes and Obesity Management","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.5603/cd.101152","https://doi.org/10.5603/cd.101152",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035706","R0035706.pdf","paywalled","other_trial","Montserrat Balsells","2024","Use of Non-Insulin Antihyperglycemic Drugs in Relation to Pregnancy",null,"CRC Press","10.1201/9781003355939-31","https://doi.org/10.1201/9781003355939-31",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035729","R0035729.pdf","paywalled","other_trial","Mihai Surducan","2024","FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease",null,"Medicom Medical Publishers","10.55788/66f35841","https://doi.org/10.55788/66f35841",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036583","R0036583.pdf","paywalled","protocol","Madkins, Krystal L","2024","Effects of GLP-1 Receptor Agonists on Wound Healing in Diabetic Patients: A Protocol for a Scoping Review","Open Science Framework",null,"10.17605/osf.io/ryge8","https://doi.org/10.17605/osf.io/ryge8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036590","R0036590.pdf","paywalled","protocol","Tristan L Maynard","2024","Effects of glucagon-like peptide 1 receptor agonists on cannabis use: A scoping review protocol","Open Science Framework",null,"10.17605/osf.io/ue6pd","https://doi.org/10.17605/osf.io/ue6pd",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036660","R0036660.pdf","paywalled","protocol","Ferrell, Sabrina Rose","2024","Disease-Modifying Effects of GLP-1 Receptor Agonists in Adults Without Pre-Established Diabetes: A Scoping Review Protocol","Open Science Framework",null,"10.17605/osf.io/qmazu","https://doi.org/10.17605/osf.io/qmazu",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036806","R0036806.pdf","paywalled","other_trial","Daniel Hansen","2024","Peptide-Based Therapeutics Development","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.19511843","https://doi.org/10.5281/zenodo.19511843",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037108","R0037108.pdf","paywalled","other_trial","RODOLFO J. GALINDO","2024","790-P: The Effect of Tirzepatide vs. Placebo on Changes and Shifts in BMI Category in Adults with Type 2 Diabetes—A Post Hoc Analysis of the SURMOUNT-2 Study","Diabetes","American Diabetes Association","10.2337/db24-790-p","https://doi.org/10.2337/db24-790-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037244","R0037244.pdf","paywalled","other_trial","HUN-SUNG KIM","2024","811-P: Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea","Diabetes","American Diabetes Association","10.2337/db24-811-p","https://doi.org/10.2337/db24-811-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037535","R0037535.pdf","paywalled","other_trial","François Briand","2024","1635-P: Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model","Diabetes","American Diabetes Association","10.2337/db24-1635-p","https://doi.org/10.2337/db24-1635-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037628","R0037628.pdf","paywalled","other_trial","Sarah Braner","2024","Novo Nordisk will acquire Cardior","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10210-buscon16","https://doi.org/10.1021/cen-10210-buscon16",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037683","R0037683.pdf","paywalled","other_trial","Michael Feigh","2024","106-OR: Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC","Diabetes","American Diabetes Association","10.2337/db24-106-or","https://doi.org/10.2337/db24-106-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037911","R0037911.pdf","paywalled","other_trial","Robert van den Heuvel","2024","Successful results for semaglutide in the highly anticipated SELECT trial",null,"Medicom Medical Publishers","10.55788/6b5123e5","https://doi.org/10.55788/6b5123e5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038009","R0038009.pdf","paywalled","protocol","Nynne Sophie Holdt-Caspersen","2024","Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.64899","https://doi.org/10.2196/preprints.64899",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06333080"],["5","R0038359","R0038359.pdf","paywalled","other_trial","Tina Vilsbøll","2024","840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5","Diabetes","American Diabetes Association","10.2337/db24-840-p","https://doi.org/10.2337/db24-840-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038394","R0038394.pdf","paywalled","other_trial","Valeria Grancini","2024","769-P: Efficacy and Safety of GLP1RAs in Liver-Transplanted People with Diabetes—Ad Interim Results of a 24-Month Trial","Diabetes","American Diabetes Association","10.2337/db24-769-p","https://doi.org/10.2337/db24-769-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038525","R0038525.pdf","paywalled","other_trial","Yan Li","2024","789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control","Diabetes","American Diabetes Association","10.2337/db24-789-p","https://doi.org/10.2337/db24-789-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038665","R0038665.pdf","paywalled","other_trial","Marwan Sabbagh","2024","Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (P11-9.014)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.0000000000204711","https://doi.org/10.1212/wnl.0000000000204711",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039098","R0039098.pdf","paywalled","other_trial","Rossing, Peter","2024","Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Figshare",null,"10.6084/m9.figshare.c.6804559","https://doi.org/10.6084/m9.figshare.c.6804559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["5","R0039201","R0039201.pdf","paywalled","other_trial","Richard W. McCallum","2024","S2278 Safety of GLP-1 Agonists With Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis: Insights From a Phase 3 Study","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001038480.66695.52","https://doi.org/10.14309/01.ajg.0001038480.66695.52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039228","R0039228.pdf","paywalled","other_trial","Elisabeth Mahase","2024","Weight loss drugs for the unemployed—how will the government’s new trial work?","BMJ","BMJ","10.1136/bmj.q2281","https://doi.org/10.1136/bmj.q2281","39419523","https://pubmed.ncbi.nlm.nih.gov/39419523/",null,null],["5","R0039240","R0039240.pdf","paywalled","other_trial","Haixia Zou","2024","788-P: Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models","Diabetes","American Diabetes Association","10.2337/db24-788-p","https://doi.org/10.2337/db24-788-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039376","R0039376.pdf","paywalled","other_trial","RAJAMANNAR THENNATI","2024","116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice","Diabetes","American Diabetes Association","10.2337/db24-116-or","https://doi.org/10.2337/db24-116-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039606","R0039606.pdf","paywalled","other_trial","YUNA CHAE","2024","2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management","Diabetes","American Diabetes Association","10.2337/db24-2058-lb","https://doi.org/10.2337/db24-2058-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040894","R0040894.pdf","paywalled","other_trial","Zehao Su","2024","Efficient estimation of the target population average treatment effect from multi-source data","arXiv (Cornell University)",null,"10.48550/arxiv.2405.10769","https://doi.org/10.48550/arxiv.2405.10769",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041656","R0041656.pdf","paywalled","other_trial","Ashwin K. Chetty","2024","Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria","American Heart Journal","Elsevier BV","10.1016/j.ahj.2024.09.026","https://doi.org/10.1016/j.ahj.2024.09.026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041731","R0041731.pdf","paywalled","other_trial","Ruiqin Xie","2024","IDF23-0254 A Phase 1, Dose-Escalation Study of a Novel dual GIP and GLP-1 receptor agonist (HS-20094) in Healthy Chinese Subjects","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/j.diabres.2024.111447","https://doi.org/10.1016/j.diabres.2024.111447",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041803","R0041803.pdf","paywalled","other_trial","Federica De Luca","2024","Tirzepatide in aggiunta a insulina basale nel trattamento del diabete tipo 2: risultati del trial SURPASS-6","L Endocrinologo","Springer Science and Business Media LLC","10.1007/s40619-024-01446-3","https://doi.org/10.1007/s40619-024-01446-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042265","R0042265.pdf","paywalled","other_trial","Rowan Walrath","2024","GLP-1 start-up launches with $400 million","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10231-buscon6","https://doi.org/10.1021/cen-10231-buscon6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043064","R0043064.pdf","paywalled","other_trial","Nuria Ferrandis-Cabó","2024","Semaglutide, Tirzepatide and the Cardiologist: Weight-Directed Therapy as Cardiovascular Therapy","Journal of Heart and Cardiovascular Science",null,"10.5281/zenodo.22365904","https://doi.org/10.5281/zenodo.22365904",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043725","R0043725.pdf","paywalled","protocol","Moro, Ana Luiza Bucholdz","2024","Use of GLP-1 analogues in improving fertility in women with polycistic ovarian syndrome: scope review protocol","OSF Preprints (OSF Preprints)",null,"10.17605/osf.io/czfnr","https://doi.org/10.17605/osf.io/czfnr",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044295","R0044295.pdf","paywalled","protocol","Builes-Montaño, Carlos E.","2024","Combine glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM): A protocol for a scoping review.",null,null,"10.17605/osf.io/wjcsn","https://doi.org/10.17605/osf.io/wjcsn",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044438","R0044438.pdf","paywalled","other_trial","Jonáš Kirchner","2024","Tirzepatide and the Weight-Regain Question: What Happens When Treatment Stops","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22260596","https://doi.org/10.5281/zenodo.22260596",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044866","R0044866.pdf","paywalled","other_trial","Ripa M.S","2024","Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/5kr3-7797","https://doi.org/10.17615/5kr3-7797",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044897","R0044897.pdf","paywalled","other_trial","Westerhout C.M","2024","Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/cm0e-4y75","https://doi.org/10.17615/cm0e-4y75",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045331","R0045331.pdf","paywalled","other_trial","GUO WANJUN","2024","793-P: Biased GLP-1 Analog Ecnoglutide (XW003) Has Improved Efficacy Relative to Unbiased Peptides","Diabetes","American Diabetes Association","10.2337/db24-793-p","https://doi.org/10.2337/db24-793-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045342","R0045342.pdf","paywalled","other_trial","MARTIN HALUZIK","2024","780-P: Soli-SWITCH—Efficacy and Safety of Switching to iGlarLixi from Premixed Insulins (PI) in People with Type 2 Diabetes (T2D)","Diabetes","American Diabetes Association","10.2337/db24-780-p","https://doi.org/10.2337/db24-780-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2021-003711-25"],["5","R0045604","R0045604.pdf","paywalled","other_trial","Yugandhar Bokka","2024","Tackle Comorbid Obesity in T2DM by Applying New Strategies to Optimize Glycaemic Control and Weight Management",null,"CRC Press","10.1201/9781003529231-11","https://doi.org/10.1201/9781003529231-11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046052","R0046052.pdf","paywalled","other_trial","Soo Lim","2024","765-P: Efficacy and Safety of Switching to iGlarLixi from Premixed Insulin (PI) in South Korean People Living with Type 2 Diabetes (T2D)—Subanalyses of Soli-SWITCH Study","Diabetes","American Diabetes Association","10.2337/db24-765-p","https://doi.org/10.2337/db24-765-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2021-003711-25"],["5","R0046328","R0046328.pdf","paywalled","other_trial","Hiddo J.L. Heerspink","2024","754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials","Diabetes","American Diabetes Association","10.2337/db24-754-p","https://doi.org/10.2337/db24-754-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046644","R0046644.pdf","paywalled","other_trial","MARTIN HALUZIK","2024","781-P: Efficacy and Safety of Switching to iGlarLixi from Twice-Daily (BID) Premixed Insulin (PI) Administration in People with Type 2 Diabetes (T2D)—Subanalysis of Soli-SWITCH Study","Diabetes","American Diabetes Association","10.2337/db24-781-p","https://doi.org/10.2337/db24-781-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2021-003711-25"],["5","R0046937","R0046937.pdf","paywalled","other_trial","Louise Carstensen Gjelstrup","2024","1685-P: Dapiglutide Is a Dual Agonist on Human GLP-1- and GLP-2-Receptors with a Biased and Prolonged Signaling Profile at the GLP-1R","Diabetes","American Diabetes Association","10.2337/db24-1685-p","https://doi.org/10.2337/db24-1685-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047326","R0047326.pdf","paywalled","other_trial","Hongmei YAN","2024","Abstract 4137917: Eligibility and Preventable CVD Events in US Adults with Cardiovascular Disease and Overweight or Obesity: Projections from the SELECT Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4137917","https://doi.org/10.1161/circ.150.suppl_1.4137917",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047715","R0047715.pdf","paywalled","other_trial","Mitra Mosslemi","2024","399-P: Association of Social Determinants of Health with Initiation of Novel Glucose-Lowering Drugs in Patients with Diabetes—A Post Hoc Analysis of the Kidney-CHAMP Trial","Diabetes","American Diabetes Association","10.2337/db24-399-p","https://doi.org/10.2337/db24-399-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047932","R0047932.pdf","paywalled","other_trial","Javed Butler","2024","Effects Of Semaglutide Across The Range Of Left Ventricular Ejection Fraction In Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Trial","Journal of Cardiac Failure","Elsevier BV","10.1016/j.cardfail.2023.10.465","https://doi.org/10.1016/j.cardfail.2023.10.465",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047939","R0047939.pdf","paywalled","other_trial","David Lau","2024","Effect of Semaglutide on Kidney Outcomes in People With Overweight or Obesity and Established Cardiovascular Disease in the SELECT Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.026","https://doi.org/10.1016/j.jcjd.2024.09.026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047954","R0047954.pdf","paywalled","other_trial","KRISTINA BOYE","2024","758-P: PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to -6 by Age, Gender, BMI, and Weight Loss","Diabetes","American Diabetes Association","10.2337/db24-758-p","https://doi.org/10.2337/db24-758-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048092","R0048092.pdf","paywalled","other_trial","Jian Fei Luo","2024","771-P: Efficacy of CT-996, an Oral Small Molecule GLP-1 Receptor Agonist, in Human GLP-1 Receptor Knockin Mice and Obese Cynomolgus Monkeys","Diabetes","American Diabetes Association","10.2337/db24-771-p","https://doi.org/10.2337/db24-771-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048471","R0048471.pdf","paywalled","other_trial","Naveed A. Sattar","2024","120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2","Diabetes","American Diabetes Association","10.2337/db24-120-or","https://doi.org/10.2337/db24-120-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048770","R0048770.pdf","paywalled","other_trial","Buse J.B","2024","Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/b2w6-2e46","https://doi.org/10.17615/b2w6-2e46",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187"],["5","R0048897","R0048897.pdf","paywalled","other_trial","Sebastian M. Meyhöfer","2024","LBP-032 Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis-a subgroup analysis from the SELECT trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)00599-3","https://doi.org/10.1016/s0168-8278(24)00599-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049143","R0049143.pdf","paywalled","other_trial","Eric Lawitz","2024","OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)00560-9","https://doi.org/10.1016/s0168-8278(24)00560-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049218","R0049218.pdf","paywalled","other_trial","Rajamannar Thennati","2024","SAT-231 GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)01792-6","https://doi.org/10.1016/s0168-8278(24)01792-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049255","R0049255.pdf","paywalled","other_trial","Elif Ilhan Ekinci","2024","1665-P: Analysis of Glucose Biomarkers in Phase I and Phase II Studies of Survodutide in People with Type 2 Diabetes or Living with Overweight/Obesity","Diabetes","American Diabetes Association","10.2337/db24-1665-p","https://doi.org/10.2337/db24-1665-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04667377; ClinicalTrials.gov:NCT04153929; ClinicalTrials.gov:NCT03591718"],["5","R0049294","R0049294.pdf","paywalled","other_trial","Clare R.M","2024","Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ddy9-8209","https://doi.org/10.17615/ddy9-8209",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049576","R0049576.pdf","paywalled","other_trial","Vlado Perkovic","2024","Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/sk6q-9n39","https://doi.org/10.17615/sk6q-9n39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049871","R0049871.pdf","paywalled","other_trial","Kimberly Darlington","2024","S92 Successful Use of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Short Gut Syndrome in Patients With Inflammatory Bowel Disease","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001082900.07254.67","https://doi.org/10.14309/01.ajg.0001082900.07254.67",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049939","R0049939.pdf","paywalled","protocol","MJ Cziraky","2024","Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/70xb-kj83","https://doi.org/10.17615/70xb-kj83",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03596450"],["5","R0050148","R0050148.pdf","paywalled","other_trial","Abdulghani Habib Alsaeed","2024","1664-P: An Observation of an Increase in the Metabolic Syndrome Parameters after Stopping GLP-1RA Medications in STEP-4 and SURMOUNT-4 Trials","Diabetes","American Diabetes Association","10.2337/db24-1664-p","https://doi.org/10.2337/db24-1664-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050295","R0050295.pdf","paywalled","other_trial","MOHAMMADREZA GANJIARJENAKI","2024","75-OR: In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-75-or","https://doi.org/10.2337/db24-75-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01336023"],["5","R0050454","R0050454.pdf","paywalled","other_trial","Shashank Joshi","2024","800-P: Post Hoc Analysis of Phase III Study of Liraglutide Biosimilar with Reference Biologic in Obese Type 2 Diabetes Mellitus Indians","Diabetes","American Diabetes Association","10.2337/db24-800-p","https://doi.org/10.2337/db24-800-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050471","R0050471.pdf","paywalled","other_trial","JERRY R. COLCA","2024","892-P: Potential for New Oral Insulin Sensitizers in Combination with GLP-1 Agonists","Diabetes","American Diabetes Association","10.2337/db24-892-p","https://doi.org/10.2337/db24-892-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050473","R0050473.pdf","paywalled","other_trial","Michael A. Tsoukas","2024","Semaglutide Improves Cardiovascular Outcomes in Patients With High Risk for Metabolic Dysfunction-associated Steatohepatitis – A Subgroup Analysis From the SELECT Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.118","https://doi.org/10.1016/j.jcjd.2024.09.118",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050589","R0050589.pdf","paywalled","other_trial","M. Morin","2024","The Effect of Semaglutide on Mortality and COVID-19-related Deaths — A Pre-specified Analysis From the SELECT Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2024.09.023","https://doi.org/10.1016/j.jcjd.2024.09.023",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050638","R0050638.pdf","paywalled","other_trial","Rohit Seth Loomba","2024","LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(24)00436-7","https://doi.org/10.1016/s0168-8278(24)00436-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051095","R0051095.pdf","paywalled","other_trial","Claude Guériot","2024","Evoke et evoke + : design de deux études de phase 3 randomisées en double aveugle, contrôlées par placebo, évaluant les effets neuroprotecteurs du semaglutide dans la maladie d’Alzheimer au stade débutant","Revue Neurologique","Elsevier BV","10.1016/j.neurol.2024.02.335","https://doi.org/10.1016/j.neurol.2024.02.335",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051341","R0051341.pdf","paywalled","protocol","Ruth Frampton","2024","787-P: Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)—A Double-Blinded Randomized Placebo-Controlled Trial (Study Protocol)","Diabetes","American Diabetes Association","10.2337/db24-787-p","https://doi.org/10.2337/db24-787-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ANZCTR:ACTRN12623001277639"],["5","R0051412","R0051412.pdf","paywalled","other_trial","Hobie Hughes","2024","S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001046956.27175.a4","https://doi.org/10.14309/01.ajg.0001046956.27175.a4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051561","R0051561.pdf","paywalled","other_trial","Kathryn Jean Lucas","2024","897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-897-p","https://doi.org/10.2337/db24-897-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051672","R0051672.pdf","paywalled","other_trial","Brian Lindsay Rayner","2024","Impact of Semaglutide on Infections and COVID-19: Data from the FLOW Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2024czp076yc","https://doi.org/10.1681/asn.2024czp076yc",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051687","R0051687.pdf","paywalled","protocol","Hossein Hamidi","2024","Effect of Tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression (T-PLAQUE)","Metabolism","Elsevier BV","10.1016/j.metabol.2024.155886","https://doi.org/10.1016/j.metabol.2024.155886",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051711","R0051711.pdf","paywalled","other_trial","Nathan K. P. Wong","2024","Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.150.suppl_1.4137914","https://doi.org/10.1161/circ.150.suppl_1.4137914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051813","R0051813.pdf","paywalled","other_trial","Viral N. Shah","2024","839-P: Treatment Satisfaction and Time in Range (TIR) after 16 Weeks of iGlarLixi in Insulin-Naive Adults with Suboptimally Controlled Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-839-p","https://doi.org/10.2337/db24-839-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05114590"],["5","R0051833","R0051833.pdf","paywalled","other_trial","Yan Wang","2024","118-OR: The Apelin Receptor Agonist Azelaprag Increases Weight Loss in Diet-Induced Obese Mice on Incretin Agonists and Restores Body Composition and Muscle Function to That of Lean Controls","Diabetes","American Diabetes Association","10.2337/db24-118-or","https://doi.org/10.2337/db24-118-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052403","R0052403.pdf","paywalled","other_trial","JULIO ROSENSTOCK","2024","757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db24-757-p","https://doi.org/10.2337/db24-757-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052468","R0052468.pdf","paywalled","other_trial","Chinthaka Bhagya Samaranayake","2024","S28 Semaglutide added to anticoagulation in acute intermediate-risk pulmonary embolism is safe and downregulates immunometabolic glycoproteins",null,"BMJ Publishing Group Ltd and British Thoracic Society","10.1136/thorax-2024-btsabstracts.34","https://doi.org/10.1136/thorax-2024-btsabstracts.34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052872","R0052872.pdf","paywalled","other_trial","RICARDO VITOR COHEN","2024","International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","British journal of surgery","Oxford University Press (OUP)","10.1093/bjs/znae283","https://doi.org/10.1093/bjs/znae283","39612579","https://pubmed.ncbi.nlm.nih.gov/39612579/",null,null],["5","R0052929","R0052929.pdf","paywalled","other_trial","ALEXANDRIA RATZKI-LEEWING","2024","374-P: Impact of Sulfonylurea (SU) Use on Hypoglycemia and Continuous Glucose Monitoring (CGM) Metrics after 16 Weeks of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) and Mean A1C >10%","Diabetes","American Diabetes Association","10.2337/db24-374-p","https://doi.org/10.2337/db24-374-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05114590"],["5","R0053218","R0053218.pdf","paywalled","other_trial","Mads D. Faurby","2024","1981-LB: Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2","Diabetes","American Diabetes Association","10.2337/db24-1981-lb","https://doi.org/10.2337/db24-1981-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053568","R0053568.pdf","paywalled","other_trial","Novodvorsky, Peter","2024","Insulin therapy de-intensification with iGlarLixi (IDEAL) ran domised controlled trial: CGM-related outcomes","Diabetologia",null,"10.5281/zenodo.14228110","https://doi.org/10.5281/zenodo.14228110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054163","R0054163.pdf","paywalled","other_trial","Melissa Leung","2024","Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.021","https://doi.org/10.1016/j.orcp.2024.09.021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054452","R0054452.pdf","paywalled","other_trial","Rahul Borra","2024","S2574 Pancreatic Aftershock: Acute Pancreatitis With Recent Semaglutide Use","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001039664.96658.f0","https://doi.org/10.14309/01.ajg.0001039664.96658.f0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054633","R0054633.pdf","paywalled","other_trial","Eric J. Vargas","2024","S418 Use of Flavored Polyethylene Glycol and Sulfate Solution Bowel Preparation in Patients with Obesity, Diabetes, or Taking Glucagon-Like Peptide-1 Receptor Agonists","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0001031040.88351.23","https://doi.org/10.14309/01.ajg.0001031040.88351.23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055001","R0055001.pdf","paywalled","other_trial","Elif Ilhan Ekinci","2024","Subgroup analysis by gender and body mass index (BMI) in people living with overweight/obesity in the survodutide, a glucagon/GLP-1 receptor dual agonist, phase II trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.090","https://doi.org/10.1016/j.orcp.2024.09.090",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055559","R0055559.pdf","paywalled","other_trial","Andrew Sindone","2024","Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the STEP-HFpEF DM trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.085","https://doi.org/10.1016/j.orcp.2024.09.085",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055579","R0055579.pdf","paywalled","other_trial","Andrew Sindone","2024","Once-weekly semaglutide in heart failure with preserved ejection fraction and obesity: main results from the STEP-HFpEF trial","Obesity Research & Clinical Practice","Elsevier BV","10.1016/j.orcp.2024.09.084","https://doi.org/10.1016/j.orcp.2024.09.084",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056097","R0056097.pdf","paywalled","other_trial","Kristaps Rudzītis","2024","GLP-1 Receptor Agonist Repurposing Across Indications: Mechanism, Evidence and Trial Sequencing","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.22649326","https://doi.org/10.5281/zenodo.22649326",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0003898","R0003898.pdf","paywalled","narrative_review","Liu H","2023","Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.","European review for medical and pharmacological sciences",null,"10.26355/eurrev_202303_31768","https://doi.org/10.26355/eurrev_202303_31768","37013752","https://pubmed.ncbi.nlm.nih.gov/37013752/",null,null],["5","R0004368","R0004368.pdf","paywalled","other_trial","Martens P","2023","The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.","Acta cardiologica","Informa UK Limited","10.1080/00015385.2022.2076307","https://doi.org/10.1080/00015385.2022.2076307","35575294","https://pubmed.ncbi.nlm.nih.gov/35575294/",null,null],["5","R0004759","R0004759.pdf","paywalled","narrative_review","Yau K","2023","Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2023.07.007","https://doi.org/10.1016/j.cjca.2023.07.007","37429523","https://pubmed.ncbi.nlm.nih.gov/37429523/",null,null],["5","R0005131","R0005131.pdf","paywalled","other_trial","Sawami K","2023","Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?","Hypertension research : official journal of the Japanese Society of Hypertension","Springer Science and Business Media LLC","10.1038/s41440-023-01324-9","https://doi.org/10.1038/s41440-023-01324-9","37258623","https://pubmed.ncbi.nlm.nih.gov/37258623/",null,null],["5","R0006233","R0006233.pdf","paywalled","other_trial","Goldenberg RM","2023","Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000001084","https://doi.org/10.1097/hco.0000000000001084","37792556","https://pubmed.ncbi.nlm.nih.gov/37792556/",null,null],["5","R0006382","R0006382.pdf","paywalled","other_trial","Novograd J","2023","Tirzepatide for Weight Loss: Can Medical Therapy \"Outweigh\" Bariatric Surgery?","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000000515","https://doi.org/10.1097/crd.0000000000000515","36688833","https://pubmed.ncbi.nlm.nih.gov/36688833/",null,null],["5","R0007016","R0007016.pdf","paywalled","preclinical","Fathy MA","2023","Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study.","Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada","Oxford University Press (OUP)","10.1093/micmic/ozad102","https://doi.org/10.1093/micmic/ozad102","37832035","https://pubmed.ncbi.nlm.nih.gov/37832035/",null,null],["5","R0008213","R0008213.pdf","paywalled","protocol","Nelson AJ","2023","Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.","American heart journal","Elsevier BV","10.1016/j.ahj.2022.10.079","https://doi.org/10.1016/j.ahj.2022.10.079","36279931","https://pubmed.ncbi.nlm.nih.gov/36279931/",null,null],["5","R0008471","R0008471.pdf","paywalled","other_trial","Doggrell SA","2023","Retatrutide showing promise in obesity (and type 2 diabetes).","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2023.2283020","https://doi.org/10.1080/13543784.2023.2283020","37947489","https://pubmed.ncbi.nlm.nih.gov/37947489/",null,null],["5","R0009197","R0009197.pdf","paywalled","other_trial","Ussher JR","2023","Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","Nature reviews. Cardiology","Springer Science and Business Media LLC","10.1038/s41569-023-00849-3","https://doi.org/10.1038/s41569-023-00849-3","36977782","https://pubmed.ncbi.nlm.nih.gov/36977782/",null,null],["5","R0010900","R0010900.pdf","paywalled","other_trial","Wang ZJ","2023","Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.","Neuropharmacology","Elsevier BV","10.1016/j.neuropharm.2023.109716","https://doi.org/10.1016/j.neuropharm.2023.109716","37730113","https://pubmed.ncbi.nlm.nih.gov/37730113/",null,null],["5","R0012086","R0012086.pdf","paywalled","other_trial","Williams DM","2023","Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.122.042109","https://doi.org/10.1161/strokeaha.122.042109","36861476","https://pubmed.ncbi.nlm.nih.gov/36861476/",null,null],["5","R0013227","R0013227.pdf","paywalled","other_trial","Seo MK","2023","Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2022.12.089","https://doi.org/10.1016/j.jad.2022.12.089","36566932","https://pubmed.ncbi.nlm.nih.gov/36566932/",null,null],["5","R0013678","R0013678.pdf","paywalled","protocol","Tokgöz S","2023","Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [68Ga]Ga-NODAGA-Exendin-4.","Methods in molecular biology (Clifton, N.J.)","Springer US","10.1007/978-1-0716-2807-2_9","https://doi.org/10.1007/978-1-0716-2807-2_9","36507990","https://pubmed.ncbi.nlm.nih.gov/36507990/",null,null],["5","R0015077","R0015077.pdf","paywalled","other_trial","Frías JP","2023","An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2023.2184796","https://doi.org/10.1080/17446651.2023.2184796","36908082","https://pubmed.ncbi.nlm.nih.gov/36908082/",null,null],["5","R0015332","R0015332.pdf","paywalled","other_trial","De R","2023","Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2254698","https://doi.org/10.1080/14656566.2023.2254698","37653675","https://pubmed.ncbi.nlm.nih.gov/37653675/",null,null],["5","R0017358","R0017358.pdf","paywalled","other_trial","Marcondes-de-Castro IA","2023","Cotadutide effect in liver and adipose tissue in obese mice.","Journal of molecular endocrinology","Bioscientifica","10.1530/jme-22-0168","https://doi.org/10.1530/jme-22-0168","36753306","https://pubmed.ncbi.nlm.nih.gov/36753306/",null,null],["5","R0018352","R0018352.pdf","paywalled","other_trial","Johnson B","2023","Weight-loss drug lowers cardiovascular disease risk in new trial of Novo Nordisk's Wegovy.","Nature medicine","Springer Science and Business Media LLC","10.1038/d41591-023-00075-x","https://doi.org/10.1038/d41591-023-00075-x","37620618","https://pubmed.ncbi.nlm.nih.gov/37620618/",null,null],["5","R0020637","R0020637.pdf","paywalled","other_trial","Hu S","2023","Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14881","https://doi.org/10.1111/dom.14881","36193880","https://pubmed.ncbi.nlm.nih.gov/36193880/",null,null],["5","R0020787","R0020787.pdf","paywalled","other_trial","Ali HJ","2023","In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.","Annals of internal medicine","American College of Physicians","10.7326/j23-0101","https://doi.org/10.7326/j23-0101","38048584","https://pubmed.ncbi.nlm.nih.gov/38048584/",null,null],["5","R0020932","R0020932.pdf","paywalled","other_trial","Wong E","2023","Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000001588","https://doi.org/10.1097/mjt.0000000000001588","36516422","https://pubmed.ncbi.nlm.nih.gov/36516422/",null,null],["5","R0021742","R0021742.pdf","paywalled","preclinical","Sadek MA","2023","Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.","International immunopharmacology","Elsevier BV","10.1016/j.intimp.2022.109647","https://doi.org/10.1016/j.intimp.2022.109647","36584570","https://pubmed.ncbi.nlm.nih.gov/36584570/",null,null],["5","R0023373","R0023373.pdf","paywalled","other_trial","Botros FT","2023","Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.","Diabetes care","American Diabetes Association","10.2337/dc23-0231","https://doi.org/10.2337/dc23-0231","37343574","https://pubmed.ncbi.nlm.nih.gov/37343574/",null,null],["5","R0028840","R0028840.pdf","paywalled","other_trial","Schmitz SH","2023","The Effective Use of Anti-obesity Medications.","Gastroenterology clinics of North America","Elsevier BV","10.1016/j.gtc.2023.08.003","https://doi.org/10.1016/j.gtc.2023.08.003","37919019","https://pubmed.ncbi.nlm.nih.gov/37919019/",null,null],["5","R0029684","R0029684.pdf","paywalled","protocol","Abdelmalek MF","2023","A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2023.107176","https://doi.org/10.1016/j.cct.2023.107176","37028504","https://pubmed.ncbi.nlm.nih.gov/37028504/",null,null],["5","R0032123","R0032123.pdf","paywalled","other_trial",null,"2023","Semaglutide reduces cardiovascular events in adults who are overweight by 20%, study finds","Pharmaceutical journal/˜The œpharmaceutical journal","Royal Pharmaceutical Society","10.1211/pj.2023.1.201091","https://doi.org/10.1211/pj.2023.1.201091",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032869","R0032869.pdf","paywalled","other_trial","Tomoko Handa","2023","982-P: Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile Application and the Cloud System on Glycemic Control and Self-Management in Outpatients with Diabetes","Diabetes","American Diabetes Association","10.2337/db23-982-p","https://doi.org/10.2337/db23-982-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033198","R0033198.pdf","paywalled","other_trial",null,"2023","Shop Talk","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000990276.66917.c6","https://doi.org/10.1097/01.cot.0000990276.66917.c6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033240","R0033240.pdf","paywalled","other_trial","Leon Gussow","2023","More Questions than Answers about Injectable Weight Loss Drugs","Emergency Medicine News","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.eem.0000945404.71459.8a","https://doi.org/10.1097/01.eem.0000945404.71459.8a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033465","R0033465.pdf","paywalled","protocol","Lengsfeld, Sophia","2023","Additional file 3 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Figshare",null,"10.6084/m9.figshare.22671491","https://doi.org/10.6084/m9.figshare.22671491",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033963","R0033963.pdf","paywalled","protocol","Lengsfeld, Sophia","2023","Additional file 4 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Figshare",null,"10.6084/m9.figshare.22671494","https://doi.org/10.6084/m9.figshare.22671494",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033991","R0033991.pdf","paywalled","protocol","Lengsfeld, Sophia","2023","Additional file 2 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Figshare",null,"10.6084/m9.figshare.22671488","https://doi.org/10.6084/m9.figshare.22671488",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034002","R0034002.pdf","paywalled","protocol","Lengsfeld, Sophia","2023","Additional file 1 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Figshare",null,"10.6084/m9.figshare.22671485","https://doi.org/10.6084/m9.figshare.22671485",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034045","R0034045.pdf","paywalled","protocol","Lengsfeld, Sophia","2023","Additional file 5 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Figshare",null,"10.6084/m9.figshare.22671497","https://doi.org/10.6084/m9.figshare.22671497",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034472","R0034472.pdf","paywalled","other_trial","Russell J. Wiese","2023","Abstract 16589: Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.16589","https://doi.org/10.1161/circ.148.suppl_1.16589",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034514","R0034514.pdf","paywalled","other_trial","Eiichiro Satake","2023","Effects of GLP-1 Receptor Agonist Dulaglutide on Profile of Circulating miRNAs Associated with ESKD in Type 2 Diabetes","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s118a","https://doi.org/10.1681/asn.20233411s118a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037148","R0037148.pdf","paywalled","other_trial","ÁNGEL RODRÍGUEZ","2023","758-P: Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy","Diabetes","American Diabetes Association","10.2337/db23-758-p","https://doi.org/10.2337/db23-758-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037261","R0037261.pdf","paywalled","other_trial","Stanley H. Hsia","2023","783-P: Baseline HOMA2-B Can Predict Tirzepatide Efficacy—Post Hoc Analysis of the SURPASS-1 and SURPASS-2 Studies","Diabetes","American Diabetes Association","10.2337/db23-783-p","https://doi.org/10.2337/db23-783-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037333","R0037333.pdf","paywalled","protocol","Sutcliffe, Cian","2023","Effect of SGLT2i & GLP-1 medications on Skeletal Muscle Health: A Scoping Review (Search Protocol)","University of Leicester",null,"10.25392/leicester.data.24421747","https://doi.org/10.25392/leicester.data.24421747",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037357","R0037357.pdf","paywalled","other_trial","RUSSELL WIESE","2023","798-P: Shift to a Lower BMI Category Is Associated with Improved Cardiometabolic Measures in Adults with T2D Treated with Tirzepatide","Diabetes","American Diabetes Association","10.2337/db23-798-p","https://doi.org/10.2337/db23-798-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037596","R0037596.pdf","paywalled","other_trial","Mary‐Elizabeth Patti","2023","Triple G Agonists — A Home Run for Obesity?","New England Journal of Medicine","Massachusetts Medical Society","10.1056/nejme2307282","https://doi.org/10.1056/nejme2307282","37590453","https://pubmed.ncbi.nlm.nih.gov/37590453/",null,null],["5","R0037742","R0037742.pdf","paywalled","other_trial","KENNETH CUSI","2023","759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy","Diabetes","American Diabetes Association","10.2337/db23-759-p","https://doi.org/10.2337/db23-759-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037762","R0037762.pdf","paywalled","other_trial","Brandon E. McFarlin","2023","409-P: Post Hoc Analyses of Longitudinal Changes of Plasma Proteins Associated with Progression to End-Stage Kidney Disease in Type 2 Diabetes Patients with Chronic Kidney Disease Treated with GLP-1 Receptor Agonist Dulaglutide (AWARD-7)","Diabetes","American Diabetes Association","10.2337/db23-409-p","https://doi.org/10.2337/db23-409-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038655","R0038655.pdf","paywalled","other_trial","ILDIKO LINGVAY","2023","777-P: Early Weight Loss and Late Metabolic Outcomes in Tirzepatide-Treated Participants with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db23-777-p","https://doi.org/10.2337/db23-777-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039247","R0039247.pdf","paywalled","other_trial","W. Timothy Garvey","2023","Approved Combination Agents",null,"CRC Press","10.1201/9781003432807-37","https://doi.org/10.1201/9781003432807-37",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039382","R0039382.pdf","paywalled","other_trial","YUNA CHAE","2023","1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist","Diabetes","American Diabetes Association","10.2337/db23-1668-p","https://doi.org/10.2337/db23-1668-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039434","R0039434.pdf","paywalled","other_trial","Richard M. Bergenstal","2023","764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy","Diabetes","American Diabetes Association","10.2337/db23-764-p","https://doi.org/10.2337/db23-764-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039514","R0039514.pdf","paywalled","other_trial","Dennis To","2023","72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD","Diabetes","American Diabetes Association","10.2337/db23-72-lb","https://doi.org/10.2337/db23-72-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039596","R0039596.pdf","paywalled","other","Kenneth M. Attie","2023","370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms","Diabetes","American Diabetes Association","10.2337/db23-370-or","https://doi.org/10.2337/db23-370-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT05616013"],["5","R0039811","R0039811.pdf","paywalled","other_trial","Jessica Chadwick","2023","Abstract 13263: Utilization of Proteomic Surrogates for Early Detection of Unexpected Drug Benefits","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.13263","https://doi.org/10.1161/circ.148.suppl_1.13263",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039901","R0039901.pdf","paywalled","other_trial","Nathan D. Wong","2023","Abstract 13519: US Population Eligibility and Estimated Impact of Tirzepatide on Obesity Prevalence and Preventable Cardiovascular Disease Events in US Adults","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.13519","https://doi.org/10.1161/circ.148.suppl_1.13519",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041675","R0041675.pdf","paywalled","other_trial","Daniel Weghuber","2023","Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)00541-x","https://doi.org/10.1016/s0168-8278(23)00541-x",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041780","R0041780.pdf","paywalled","other_trial","Denis Finney","2023","Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The SURPASS Clinical Trial Program","Metabolism","Elsevier BV","10.1016/j.metabol.2023.155457","https://doi.org/10.1016/j.metabol.2023.155457",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042125","R0042125.pdf","paywalled","other_trial","Hope, David","2023","Glucagon analogue therapy for obesity and metabolic disease; implications of amino acid metabolism",null,null,"10.25560/110747","https://doi.org/10.25560/110747",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044173","R0044173.pdf","paywalled","other_trial","Patrizia Suppressa","2023","Obesità e rischio cardiovascolare: nuovi approcci terapeutici","Cardiologia Ambulatoriale","G. Giappichelli Editore srl","10.17473/1971-6818-2023-4-4","https://doi.org/10.17473/1971-6818-2023-4-4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044535","R0044535.pdf","paywalled","other_trial","Nick Zagorski","2023","Award Winner Describes Efforts to Improve Cognition in People With Bipolar Disorder","Psychiatric News","American Psychiatric Association Publishing","10.1176/appi.pn.2024.01.1.37","https://doi.org/10.1176/appi.pn.2024.01.1.37",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044804","R0044804.pdf","paywalled","other_trial","Rory Taylor","2023","Hunger and the Obesity Epidemic: Old Insights Reaffirmed by New Medicines?","Annals of Internal Medicine","American College of Physicians","10.7326/m23-0744","https://doi.org/10.7326/m23-0744","37364261","https://pubmed.ncbi.nlm.nih.gov/37364261/",null,null],["5","R0045192","R0045192.pdf","paywalled","other_trial","KEVIN M. PANTALONE","2023","73-LB: Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes—An Indirect Treatment Comparison","Diabetes","American Diabetes Association","10.2337/db23-73-lb","https://doi.org/10.2337/db23-73-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046594","R0046594.pdf","paywalled","other_trial","Yigal M. Pinto","2023","Heart Failure with Preserved Ejection Fraction — A Metabolic Disease?","New England Journal of Medicine","Massachusetts Medical Society","10.1056/nejme2309294","https://doi.org/10.1056/nejme2309294","37622676","https://pubmed.ncbi.nlm.nih.gov/37622676/",null,null],["5","R0046909","R0046909.pdf","paywalled","other_trial","Rajamannar Thennati","2023","GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals","Journal of Hepatology","Elsevier BV","10.1016/s0168-8278(23)01426-5","https://doi.org/10.1016/s0168-8278(23)01426-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046967","R0046967.pdf","paywalled","other_trial","Katelyn E. Brown","2023","Tirzepatide Improved Markers of Islet Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared to Semaglutide in People with Type 2 Diabetes","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767867","https://doi.org/10.1055/s-0043-1767867",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047052","R0047052.pdf","paywalled","other_trial","Brendon Lange Neuen","2023","Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.17437","https://doi.org/10.1161/circ.148.suppl_1.17437",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047509","R0047509.pdf","paywalled","other_trial","Randa Ghazal Asswad","2023","Drugs That Affect Body Weight",null,"CRC Press","10.1201/9781003432807-39","https://doi.org/10.1201/9781003432807-39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047946","R0047946.pdf","paywalled","other_trial","Linong Ji","2023","746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint","Diabetes","American Diabetes Association","10.2337/db23-746-p","https://doi.org/10.2337/db23-746-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048016","R0048016.pdf","paywalled","other_trial","Laura L. Howes","2023","Novo buying KBP hypertension drug","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10135-buscon15","https://doi.org/10.1021/cen-10135-buscon15",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048362","R0048362.pdf","paywalled","other_trial","Venkat Sanjay Manubolu","2023","The Impact of Semaglutide on Liver Fat Assessed by Serial Cardiac CT scans in Patients with Type 2 Diabetes: Results from STOP Trial","American Heart Journal","Elsevier BV","10.1016/j.ahj.2023.08.057","https://doi.org/10.1016/j.ahj.2023.08.057",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048538","R0048538.pdf","paywalled","other_trial","Thinzar Min","2023","Dual and Triple-Action Peptides",null,"CRC Press","10.1201/9781003432807-41","https://doi.org/10.1201/9781003432807-41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048832","R0048832.pdf","paywalled","other_trial","Laura L. Howes","2023","Roche to buy Carmot for $2.7 billion","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10141-buscon4","https://doi.org/10.1021/cen-10141-buscon4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048951","R0048951.pdf","paywalled","other_trial","Clare J. Lee","2023","752-P: Improved BMI Category Is Associated with Better Patient-Reported Outcomes (PROs) in Adults with T2D Treated with Tirzepatide","Diabetes","American Diabetes Association","10.2337/db23-752-p","https://doi.org/10.2337/db23-752-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049138","R0049138.pdf","paywalled","other_trial","Brandon E. McFarlin","2023","AWARD-7 Post Hoc Analysis: Circulating Proteins Measured by Joslin Kidney Panel Identify Dulaglutide Responders","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20233411s1135b","https://doi.org/10.1681/asn.20233411s1135b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049836","R0049836.pdf","paywalled","other_trial","ALEXANDRO R. ZARRUK","2023","TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2023.10.380","https://doi.org/10.1016/j.jcjd.2023.10.380",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050002","R0050002.pdf","paywalled","other_trial","Philipp Berning","2023","Prescription trends for anti-obesity drugs and patterns in prescriber information between 2017 and 2022 in the United States.","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0043-1767900","https://doi.org/10.1055/s-0043-1767900",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050539","R0050539.pdf","paywalled","other_trial","Deepak L. Bhatt","2023","Abstract 16779: Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.16779","https://doi.org/10.1161/circ.148.suppl_1.16779",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052246","R0052246.pdf","paywalled","other_trial","Kristin Corey","2023","Abstract 15461: Proteomic Profiling Identifies Metabolic and Extracellular Matrix Markers That Predict MACE in Individuals With Type 2 Diabetes: An EXSCEL Substudy","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15461","https://doi.org/10.1161/circ.148.suppl_1.15461",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052937","R0052937.pdf","paywalled","other_trial","Erfan Tasdighi","2023","Abstract 15562: Coronary Artery Calcium Score for Allocating Emerging Obesity Therapies: Implications for the Ongoing SURMOUNT-MMO Outcome Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.15562","https://doi.org/10.1161/circ.148.suppl_1.15562",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053088","R0053088.pdf","paywalled","other_trial","Denise Barbut","2023","854-P: ENT-03, a Centrally Acting Endogenous Spermine Bile Acid with PTP1B Inhibitory Activity, Has Potent Effects on Metabolism and Weight in a Mouse Model of Diet-Induced Obesity (DIO)","Diabetes","American Diabetes Association","10.2337/db23-854-p","https://doi.org/10.2337/db23-854-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053526","R0053526.pdf","paywalled","other_trial","Josephine Harrington","2023","Abstract 17139: Angiopoietin 2 Independently Predicts Heart Failure Hospitalization and is Beneficially Modified by GLP1RA: Results From the EXSCEL Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.148.suppl_1.17139","https://doi.org/10.1161/circ.148.suppl_1.17139",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054047","R0054047.pdf","paywalled","other_trial","Alex Philippidis","2023","StockWatch: Novo Nordisk Shares Soar as Ozempic Aces Phase III CKD Trial","GEN Edge","SAGE Publications","10.1089/genedge.5.1.137","https://doi.org/10.1089/genedge.5.1.137",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054754","R0054754.pdf","paywalled","other_trial","Thomas Leth Jensen","2023","Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity","Drugs of the Future","Portico","10.1358/dof.2023.48.3.3521861","https://doi.org/10.1358/dof.2023.48.3.3521861",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055228","R0055228.pdf","paywalled","other_trial","Samantha P. Flanagan","2023","Semaglutide in Obesity (STEP-1 Trial)-2021",null,"Springer International Publishing","10.1007/978-3-031-25620-2_44","https://doi.org/10.1007/978-3-031-25620-2_44",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0055572","R0055572.pdf","paywalled","other_trial","Marwan Sabbagh","2023","Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes","Alzheimer s & Dementia","Wiley","10.1002/alz.076540","https://doi.org/10.1002/alz.076540",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02207374; ClinicalTrials.gov:NCT02254291"],["5","R0005184","R0005184.pdf","paywalled","other_trial","Pedrosa MR","2022","GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-022-01062-2","https://doi.org/10.1007/s11883-022-01062-2","36044100","https://pubmed.ncbi.nlm.nih.gov/36044100/",null,null],["5","R0006526","R0006526.pdf","paywalled","other_trial","Bucheit J","2022","A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.","Journal of cardiovascular pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001299","https://doi.org/10.1097/fjc.0000000000001299","35767712","https://pubmed.ncbi.nlm.nih.gov/35767712/",null,null],["5","R0007599","R0007599.pdf","paywalled","other_trial","Mathiesen DS","2022","Long-acting amylin analogues for the management of obesity.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000716","https://doi.org/10.1097/med.0000000000000716","35066542","https://pubmed.ncbi.nlm.nih.gov/35066542/",null,null],["5","R0008265","R0008265.pdf","paywalled","other","Yesildag B","2022","Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.","Clinical immunology (Orlando, Fla.)","Elsevier BV","10.1016/j.clim.2022.109118","https://doi.org/10.1016/j.clim.2022.109118","36084852","https://pubmed.ncbi.nlm.nih.gov/36084852/",null,null],["5","R0008354","R0008354.pdf","paywalled","other_trial","Kyrillos J","2022","Semaglutide 2.4-mg injection as a novel approach for chronic weight management.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2022.89293","https://doi.org/10.37765/ajmc.2022.89293","36525677","https://pubmed.ncbi.nlm.nih.gov/36525677/",null,null],["5","R0009018","R0009018.pdf","paywalled","other_trial","Svane MS","2022","Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/s41366-022-01207-y","https://doi.org/10.1038/s41366-022-01207-y","35982119","https://pubmed.ncbi.nlm.nih.gov/35982119/",null,null],["5","R0009109","R0009109.pdf","paywalled","other_trial","Tall Bull S","2022","Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108332","https://doi.org/10.1016/j.jdiacomp.2022.108332","36375235","https://pubmed.ncbi.nlm.nih.gov/36375235/",null,null],["5","R0010661","R0010661.pdf","paywalled","other_trial","Su Y","2022","Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2022.175029","https://doi.org/10.1016/j.ejphar.2022.175029","35584709","https://pubmed.ncbi.nlm.nih.gov/35584709/",null,null],["5","R0012149","R0012149.pdf","paywalled","other_trial","Friedman AN","2022","State-of-the-art Medical Therapy Versus Roux-en-Y Gastric Bypass Alone for Treatment of Early Diabetic Kidney Disease.","Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation","Elsevier BV","10.1053/j.jrn.2022.03.003","https://doi.org/10.1053/j.jrn.2022.03.003","35367357","https://pubmed.ncbi.nlm.nih.gov/35367357/",null,null],["5","R0014621","R0014621.pdf","paywalled","other_trial","Ryan DH","2022","Drugs for Treating Obesity.","Handbook of experimental pharmacology","Springer International Publishing","10.1007/164_2021_560","https://doi.org/10.1007/164_2021_560","34783910","https://pubmed.ncbi.nlm.nih.gov/34783910/",null,null],["5","R0016640","R0016640.pdf","paywalled","other_trial","Syed YY","2022","Tirzepatide: First Approval.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-022-01746-8","https://doi.org/10.1007/s40265-022-01746-8","35830001","https://pubmed.ncbi.nlm.nih.gov/35830001/",null,null],["5","R0016977","R0016977.pdf","paywalled","preclinical","Zhang M","2022","GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2022.175107","https://doi.org/10.1016/j.ejphar.2022.175107","35718129","https://pubmed.ncbi.nlm.nih.gov/35718129/",null,null],["5","R0017155","R0017155.pdf","paywalled","preclinical","Zou Z","2022","Liraglutide attenuates intestinal ischemia/reperfusion injury via NF-κB and PI3K/Akt pathways in mice.","Life sciences","Elsevier BV","10.1016/j.lfs.2022.121045","https://doi.org/10.1016/j.lfs.2022.121045","36206837","https://pubmed.ncbi.nlm.nih.gov/36206837/",null,null],["5","R0017418","R0017418.pdf","paywalled","other","Doggrell SA","2022","Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2021.2019707","https://doi.org/10.1080/14656566.2021.2019707","34913784","https://pubmed.ncbi.nlm.nih.gov/34913784/",null,"ClinicalTrials.gov:NCT04122716"],["5","R0019399","R0019399.pdf","paywalled","other_trial","Lewis AL","2022","Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery.","Drug delivery and translational research","Springer Science and Business Media LLC","10.1007/s13346-021-01000-w","https://doi.org/10.1007/s13346-021-01000-w","34024013","https://pubmed.ncbi.nlm.nih.gov/34024013/",null,null],["5","R0021970","R0021970.pdf","paywalled","other_trial","Hindson J","2022","Tirzepatide to treat obesity: phase III results.","Nature reviews. Gastroenterology & hepatology","Springer Science and Business Media LLC","10.1038/s41575-022-00657-z","https://doi.org/10.1038/s41575-022-00657-z","35773392","https://pubmed.ncbi.nlm.nih.gov/35773392/",null,null],["5","R0022139","R0022139.pdf","paywalled","other_trial","Slomski A","2022","Tirzepatide Trial Demonstrates Substantial Weight Loss.","JAMA","American Medical Association (AMA)","10.1001/jama.2022.11895","https://doi.org/10.1001/jama.2022.11895","35881126","https://pubmed.ncbi.nlm.nih.gov/35881126/",null,null],["5","R0022866","R0022866.pdf","paywalled","other_trial","Kounatidis D","2022","Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.","Current nutrition reports","Springer Science and Business Media LLC","10.1007/s13668-022-00433-0","https://doi.org/10.1007/s13668-022-00433-0","35933503","https://pubmed.ncbi.nlm.nih.gov/35933503/",null,null],["5","R0022889","R0022889.pdf","paywalled","narrative_review","Mares AC","2022","Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000955","https://doi.org/10.1097/hco.0000000000000955","35175229","https://pubmed.ncbi.nlm.nih.gov/35175229/",null,"ClinicalTrials.gov:NCT03574597"],["5","R0026205","R0026205.pdf","paywalled","other_trial","Mima A","2022","A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-022-02223-0","https://doi.org/10.1007/s12325-022-02223-0","35751762","https://pubmed.ncbi.nlm.nih.gov/35751762/",null,null],["5","R0031399","R0031399.pdf","paywalled","other_trial","Emma Johns and","2022","Future Antidiabetic Drugs",null,"Wiley","10.1002/9781119785033.ch14","https://doi.org/10.1002/9781119785033.ch14",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032485","R0032485.pdf","paywalled","protocol","Imberg, Henrik","2022","Statistical Analysis Plan: Efficacy of Sustained Use of GLP1-RA versus DPP4 Inhibitors and Sulfonylureas on HbA1c and Weight – A LEAD-2 and LEAD-3 Inspired Trial Emulation Using the Swedish National Diabetes Register","Zenodo (CERN European Organization for Nuclear Research)",null,"10.5281/zenodo.15347461","https://doi.org/10.5281/zenodo.15347461",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032736","R0032736.pdf","paywalled","other_trial","Wendy Cerenzia","2022","1435-P: Identifying the Continuing Educational Needs of U.S. Physicians in Managing Patients with T2DM and Obesity","Diabetes","American Diabetes Association","10.2337/db22-1435-p","https://doi.org/10.2337/db22-1435-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033412","R0033412.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 5 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056574","https://doi.org/10.6084/m9.figshare.20056574",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033570","R0033570.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 6 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056577","https://doi.org/10.6084/m9.figshare.20056577",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033574","R0033574.pdf","paywalled","other_trial","Endocrine Society 2022","2022","Congenital Leptin Deficiency: Metabolic, Reproductive, and Psychological Impacts of Therapy","Underline Science Inc.",null,"10.48448/5az9-z680","https://doi.org/10.48448/5az9-z680",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033661","R0033661.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 4 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056571","https://doi.org/10.6084/m9.figshare.20056571",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033972","R0033972.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 1 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056559","https://doi.org/10.6084/m9.figshare.20056559",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033992","R0033992.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 3 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056568","https://doi.org/10.6084/m9.figshare.20056568",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034048","R0034048.pdf","paywalled","other_trial","Ugamura, Daisuke","2022","Additional file 2 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Figshare",null,"10.6084/m9.figshare.20056562","https://doi.org/10.6084/m9.figshare.20056562",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034091","R0034091.pdf","paywalled","other_trial","Endocrine Society 2022","2022","Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program","Underline Science Inc.",null,"10.48448/smdc-kx33","https://doi.org/10.48448/smdc-kx33",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036326","R0036326.pdf","paywalled","other_trial","Vencio, Sérgio","2022","Additional file 1 of Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study","Figshare",null,"10.6084/m9.figshare.18132637","https://doi.org/10.6084/m9.figshare.18132637",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036334","R0036334.pdf","paywalled","other_trial","Husain, Mansoor","2022","Additional file 1 of Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","Figshare",null,"10.6084/m9.figshare.19682255","https://doi.org/10.6084/m9.figshare.19682255",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037380","R0037380.pdf","paywalled","other_trial",null,"2022","Trends & Technology","ASA Monitor","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.asm.0000904228.68973.78","https://doi.org/10.1097/01.asm.0000904228.68973.78",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037882","R0037882.pdf","paywalled","other_trial","Vanita R. Aroda","2022","721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8","Diabetes","American Diabetes Association","10.2337/db22-721-p","https://doi.org/10.2337/db22-721-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03021187"],["5","R0038281","R0038281.pdf","paywalled","other_trial","Davies, Melanie J.","2022","Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes","Figshare",null,"10.6084/m9.figshare.20438492","https://doi.org/10.6084/m9.figshare.20438492",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038308","R0038308.pdf","paywalled","protocol","Vincent J. Willey","2022","752-P: Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)","Diabetes","American Diabetes Association","10.2337/db22-752-p","https://doi.org/10.2337/db22-752-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03596450"],["5","R0038553","R0038553.pdf","paywalled","other_trial","JOLANTA SKARBALIENE","2022","213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats","Diabetes","American Diabetes Association","10.2337/db22-213-or","https://doi.org/10.2337/db22-213-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038554","R0038554.pdf","paywalled","other_trial","Francesco Giorgino","2022","833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial","Diabetes","American Diabetes Association","10.2337/db22-833-p","https://doi.org/10.2337/db22-833-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"EudraCT:2017-003370-13"],["5","R0038901","R0038901.pdf","paywalled","other_trial","Syed, Yahiya Y.","2022","Tirzepatide: First Approval","Figshare",null,"10.6084/m9.figshare.20128214","https://doi.org/10.6084/m9.figshare.20128214",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039135","R0039135.pdf","paywalled","other","Richard M. Bergenstal","2022","728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)","Diabetes","American Diabetes Association","10.2337/db22-728-p","https://doi.org/10.2337/db22-728-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03882970"],["5","R0039830","R0039830.pdf","paywalled","other_trial","CAROL H. WYSHAM","2022","743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials","Diabetes","American Diabetes Association","10.2337/db22-743-p","https://doi.org/10.2337/db22-743-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041225","R0041225.pdf","paywalled","other_trial","Syed, Yahiya Y.","2022","Tirzepatide: First Approval","Figshare",null,"10.6084/m9.figshare.20128214.v1","https://doi.org/10.6084/m9.figshare.20128214.v1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041779","R0041779.pdf","paywalled","other_trial","Gina Vitale","2022","FDA approves Lilly diabetes drug","C&EN Global Enterprise","American Chemical Society (ACS)","10.1021/cen-10018-buscon15","https://doi.org/10.1021/cen-10018-buscon15",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041795","R0041795.pdf","paywalled","other_trial","Mike Barros","2022","Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The Surpass Clinical Trial Program","American Heart Journal","Elsevier BV","10.1016/j.ahj.2022.10.028","https://doi.org/10.1016/j.ahj.2022.10.028",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046442","R0046442.pdf","paywalled","other_trial","Boris Calderón","2022","742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies","Diabetes","American Diabetes Association","10.2337/db22-742-p","https://doi.org/10.2337/db22-742-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047246","R0047246.pdf","paywalled","other_trial","JONATHAN M. WILSON","2022","725-P: Protein Biomarkers Associated with Dulaglutide and Cardiovascular Events in REWIND","Diabetes","American Diabetes Association","10.2337/db22-725-p","https://doi.org/10.2337/db22-725-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047370","R0047370.pdf","paywalled","other","IRENE M. HRAMIAK","2022","Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-1746286","https://doi.org/10.1055/s-0042-1746286",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03767543"],["5","R0048294","R0048294.pdf","paywalled","other_trial","Clare J. Lee","2022","715-P: Tirzepatide as Monotherapy Improved Markers of Beta-Cell Function and Insulin Sensitivity in People with Type 2 Diabetes (SURPASS-1)","Diabetes","American Diabetes Association","10.2337/db22-715-p","https://doi.org/10.2337/db22-715-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048777","R0048777.pdf","paywalled","other_trial","Christophe E.M. De Block","2022","727-P: Glycemic Effect of Tirzepatide by Duration of Diabetes","Diabetes","American Diabetes Association","10.2337/db22-727-p","https://doi.org/10.2337/db22-727-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049496","R0049496.pdf","paywalled","other_trial","ALICE Y. CHENG","2022","718-P: Patients Achieving an HbA1c <5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5","Diabetes","American Diabetes Association","10.2337/db22-718-p","https://doi.org/10.2337/db22-718-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049535","R0049535.pdf","paywalled","other_trial","Hiddo J.L. Heerspink","2022","Effects of Tirzepatide vs. Insulin Glargine on Kidney Function Evaluated by Cystatin C-Based eGFR: A Post Hoc Analysis From the SURPASS-4 Trial","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1677a","https://doi.org/10.1681/asn.20223311s1677a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050060","R0050060.pdf","paywalled","other_trial","Melanie R. Weltman","2022","Acceptance of Recommendations for SGLT2 Inhibitors and GLP1 Receptor Agonists in a High-Risk CKD Population","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1865b","https://doi.org/10.1681/asn.20223311s1865b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050618","R0050618.pdf","paywalled","other_trial","Frederik Persson","2022","866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study","Diabetes","American Diabetes Association","10.2337/db22-866-p","https://doi.org/10.2337/db22-866-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050702","R0050702.pdf","paywalled","other_trial","Jorge Plutzky","2022","Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.146.suppl_1.13440","https://doi.org/10.1161/circ.146.suppl_1.13440",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051518","R0051518.pdf","paywalled","other_trial","Grazia Aleppo","2022","717-P: Glycemic Control with Tirzepatide in People with Type 2 Diabetes by Baseline HbA1c =8.5% or >8.5%","Diabetes","American Diabetes Association","10.2337/db22-717-p","https://doi.org/10.2337/db22-717-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051843","R0051843.pdf","paywalled","other_trial","SUE PEDERSEN","2022","729-P: Relationship between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-729-p","https://doi.org/10.2337/db22-729-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051989","R0051989.pdf","paywalled","other_trial","Hiddo J.L. Heerspink","2022","Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20223311s1676c","https://doi.org/10.1681/asn.20223311s1676c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053058","R0053058.pdf","paywalled","other_trial","KATELYN BROWN","2022","337-OR: Tirzepatide Improved Markers of Islet-Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared with Semaglutide in People with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db22-337-or","https://doi.org/10.2337/db22-337-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053833","R0053833.pdf","paywalled","other_trial","SHU NIU","2022","256-OR: Five-Year Simulation of Diabetes-Related Complications in Individuals Treated with Once-Weekly Tirzepatide and Semaglutide vs. Once-Daily Insulin Glargine","Diabetes","American Diabetes Association","10.2337/db22-256-or","https://doi.org/10.2337/db22-256-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054159","R0054159.pdf","paywalled","other_trial","Yuelei Shen","2022","Abstract 3: Developing a translational tool for GLP-1-based therapeutic agonists in humanized GLP1R mice","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2022-3","https://doi.org/10.1158/1538-7445.am2022-3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054195","R0054195.pdf","paywalled","other_trial","Hertzel C. Gerstein","2022","162-LB: Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study","Diabetes","American Diabetes Association","10.2337/db22-162-lb","https://doi.org/10.2337/db22-162-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT00069784"],["5","R0054197","R0054197.pdf","paywalled","other_trial","Sarah Chapelsky","2022","Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults With Overweight/Obesity in the STEP 1 Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2022.09.012","https://doi.org/10.1016/j.jcjd.2022.09.012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0006900","R0006900.pdf","paywalled","other_trial","Salahuddin T","2021","Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14193","https://doi.org/10.1111/dom.14193","32902128","https://pubmed.ncbi.nlm.nih.gov/32902128/",null,null],["5","R0006974","R0006974.pdf","paywalled","other_trial","Chan JSK","2021","The results are in: Cardiovascular benefits of glucagon-like peptide-1 receptor agonists - a trial sequential analysis.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1177/2047487320918722","https://doi.org/10.1177/2047487320918722","33611393","https://pubmed.ncbi.nlm.nih.gov/33611393/",null,null],["5","R0007995","R0007995.pdf","paywalled","other_trial","Smati S","2021","Anti-diabetic drugs and NASH: from current options to promising perspectives.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2021.1951701","https://doi.org/10.1080/13543784.2021.1951701","34214406","https://pubmed.ncbi.nlm.nih.gov/34214406/",null,null],["5","R0008846","R0008846.pdf","paywalled","other_trial","Berg DD","2021","Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-021-01417-0","https://doi.org/10.1007/s11892-021-01417-0","34741199","https://pubmed.ncbi.nlm.nih.gov/34741199/",null,null],["5","R0012873","R0012873.pdf","paywalled","other_trial","Mehta K","2021","Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.","Current protein & peptide science","Bentham Science Publishers Ltd.","10.2174/1389203721999201208195901","https://doi.org/10.2174/1389203721999201208195901","33292149","https://pubmed.ncbi.nlm.nih.gov/33292149/",null,null],["5","R0015411","R0015411.pdf","paywalled","narrative_review","Maselli DB","2021","Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.","Advances in experimental medicine and biology","Springer International Publishing","10.1007/5584_2020_496","https://doi.org/10.1007/5584_2020_496","32077010","https://pubmed.ncbi.nlm.nih.gov/32077010/",null,null],["5","R0017604","R0017604.pdf","paywalled","other_trial","Saengboonmee C","2021","Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2020.09.008","https://doi.org/10.1016/j.jcjd.2020.09.008","33218924","https://pubmed.ncbi.nlm.nih.gov/33218924/",null,null],["5","R0020322","R0020322.pdf","paywalled","preclinical","Vergès B","2021","Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.","Diabetes care","American Diabetes Association","10.2337/dc20-1843","https://doi.org/10.2337/dc20-1843","33531418","https://pubmed.ncbi.nlm.nih.gov/33531418/",null,"ClinicalTrials.gov:NCT02721888"],["5","R0020733","R0020733.pdf","paywalled","narrative_review","Stafeev I","2021","The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?","Current molecular medicine","Bentham Science Publishers Ltd.","10.2174/1566524020666201201095029","https://doi.org/10.2174/1566524020666201201095029","33261539","https://pubmed.ncbi.nlm.nih.gov/33261539/",null,null],["5","R0021080","R0021080.pdf","paywalled","other_trial","Patel VN","2021","Glycemic Control in Hospitalized Stroke Patients: A Review.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-021-01416-1","https://doi.org/10.1007/s11892-021-01416-1","34851461","https://pubmed.ncbi.nlm.nih.gov/34851461/",null,null],["5","R0021724","R0021724.pdf","paywalled","other_trial","Prattichizzo F","2021","Is time ready for combination therapy at diagnosis of type 2 diabetes?","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.3460","https://doi.org/10.1002/dmrr.3460","34240524","https://pubmed.ncbi.nlm.nih.gov/34240524/",null,null],["5","R0023076","R0023076.pdf","paywalled","other_trial","Doggrell SA","2021","Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2021.1904892","https://doi.org/10.1080/14656566.2021.1904892","33764251","https://pubmed.ncbi.nlm.nih.gov/33764251/",null,null],["5","R0023280","R0023280.pdf","paywalled","other_trial","Yang K","2021","High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-020-01660-z","https://doi.org/10.1007/s00592-020-01660-z","33452595","https://pubmed.ncbi.nlm.nih.gov/33452595/",null,"ChiCTR:ChiCTR-IPR-15006558"],["5","R0023583","R0023583.pdf","paywalled","other_trial","Jiang J","2021","Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.","Endocrine, metabolic & immune disorders drug targets","Bentham Science Publishers Ltd.","10.2174/1871530320999200831165116","https://doi.org/10.2174/1871530320999200831165116","32875989","https://pubmed.ncbi.nlm.nih.gov/32875989/",null,null],["5","R0023592","R0023592.pdf","paywalled","other_trial","Cui H","2021","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.","European journal of drug metabolism and pharmacokinetics","Springer Science and Business Media LLC","10.1007/s13318-020-00665-x","https://doi.org/10.1007/s13318-020-00665-x","33576936","https://pubmed.ncbi.nlm.nih.gov/33576936/",null,"ClinicalTrials.gov:NCT03062774"],["5","R0023663","R0023663.pdf","paywalled","other_trial","Grannell A","2021","Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23098","https://doi.org/10.1002/oby.23098","33528919","https://pubmed.ncbi.nlm.nih.gov/33528919/",null,null],["5","R0028440","R0028440.pdf","paywalled","other_trial","Adler AI","2021","The STEP 1 trial for weight loss: a step change in treating obesity?","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-021-01319-4","https://doi.org/10.1038/s41591-021-01319-4","33859431","https://pubmed.ncbi.nlm.nih.gov/33859431/",null,null],["5","R0028469","R0028469.pdf","paywalled","other_trial","Stower H","2021","Therapy for NASH.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-020-01219-z","https://doi.org/10.1038/s41591-020-01219-z","33442011","https://pubmed.ncbi.nlm.nih.gov/33442011/",null,null],["5","R0028540","R0028540.pdf","paywalled","other_trial","Wong ND","2021","Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.","Trends in cardiovascular medicine","Elsevier BV","10.1016/j.tcm.2019.11.013","https://doi.org/10.1016/j.tcm.2019.11.013","31882264","https://pubmed.ncbi.nlm.nih.gov/31882264/",null,null],["5","R0030155","R0030155.pdf","paywalled","other_trial","Alicic RZ","2021","Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.","Nature reviews. Nephrology","Springer Science and Business Media LLC","10.1038/s41581-020-00367-2","https://doi.org/10.1038/s41581-020-00367-2","33219281","https://pubmed.ncbi.nlm.nih.gov/33219281/",null,null],["5","R0030939","R0030939.pdf","paywalled","other_trial","Allan S. Brett","2021","Using GLP-1 Agonists or SGLT-2 Inhibitors to Simplify Complex Insulin Regimens","Journal watch",null,"10.1056/nejm-jw.na53784","https://doi.org/10.1056/nejm-jw.na53784",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032596","R0032596.pdf","paywalled","other_trial","Lai‐San Tham","2021","642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-642-p","https://doi.org/10.2337/db21-642-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033549","R0033549.pdf","paywalled","protocol","Jensterle, Mojca","2021","Additional file 1 of Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial","Figshare",null,"10.6084/m9.figshare.15020780","https://doi.org/10.6084/m9.figshare.15020780",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033627","R0033627.pdf","paywalled","other_trial","Nashawi, Mouhamed","2021","Raising the Bar When Assessing Cardiovascular Disease Outcome When Studies with Patients with Type 2 Diabetes Mellitus are Constructed: Austin Journal of Endocrinology and Diabetes","Figshare",null,"10.6084/m9.figshare.14575566","https://doi.org/10.6084/m9.figshare.14575566",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033854","R0033854.pdf","paywalled","other_trial","Endocrine Society 2021","2021","Using Clinical Trial Results to Optimize Patient Care: Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With GLP-1 Receptor Agonists and SGLT-2 Inhibitors","Underline Science Inc.",null,"10.48448/c41z-cb56","https://doi.org/10.48448/c41z-cb56",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033927","R0033927.pdf","paywalled","protocol","Jensterle, Mojca","2021","Additional file 2 of Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial","Figshare",null,"10.6084/m9.figshare.15020783","https://doi.org/10.6084/m9.figshare.15020783",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035836","R0035836.pdf","paywalled","other_trial",null,"2021","Shop Talk","Oncology Times","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.cot.0000749972.41274.c6","https://doi.org/10.1097/01.cot.0000749972.41274.c6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037327","R0037327.pdf","paywalled","other_trial","Margaret F. Zupa","2021","815-P: Cost-Effectiveness of Subcutaneous Semaglutide vs. Empagliflozin as Add-On Therapy for Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db21-815-p","https://doi.org/10.2337/db21-815-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038082","R0038082.pdf","paywalled","other_trial","Sri Nuvvula","2021","S3125 Resolution of Gastroparesis Symptoms With the Removal of a Dipeptidyl Peptidase-4 Inhibitor","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000786032.36253.51","https://doi.org/10.14309/01.ajg.0000786032.36253.51",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044349","R0044349.pdf","paywalled","other_trial","LUO, Shiqi","2021","Development of a weight-loss product using Chinese herbal medicine combined with nutritional technologies","RMIT Research Repository (RMIT University Library)",null,"10.25439/rmt.27596529","https://doi.org/10.25439/rmt.27596529",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045784","R0045784.pdf","paywalled","other","Michelle E. Hauser","2021","Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727310","https://doi.org/10.1055/s-0041-1727310",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02607865"],["5","R0045967","R0045967.pdf","paywalled","other_trial","Sarah Enslin","2021","S2727 The First Reported Case of Drug-Induced Liver Injury Caused by Semaglutide","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000784440.97741.d2","https://doi.org/10.14309/01.ajg.0000784440.97741.d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047546","R0047546.pdf","paywalled","other_trial","Juris Jendrik Meier","2021","668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events","Diabetes","American Diabetes Association","10.2337/db21-668-p","https://doi.org/10.2337/db21-668-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047586","R0047586.pdf","paywalled","other_trial","Adie Viljoen","2021","Efficacy and Safety of Semaglutide by Baseline BMI in SUSTAIN 1–5 and 7","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727321","https://doi.org/10.1055/s-0041-1727321",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047805","R0047805.pdf","paywalled","other_trial","Michael Wagner","2021","Glucagon‐Like Peptide‐1 Receptor Activators","Burger's Medicinal Chemistry and Drug Discovery","Wiley","10.1002/0471266949.bmc268","https://doi.org/10.1002/0471266949.bmc268",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047883","R0047883.pdf","paywalled","other_trial","Kamlesh K. Khunti","2021","666-P: Greater Proportions of Subjects Achieved HbA1c <7% without Weight Gain, Hypoglycemia, or Moderate/Severe Gastrointestinal Adverse Events with Semaglutide vs. Comparators in the SUSTAIN 7-10 Trials","Diabetes","American Diabetes Association","10.2337/db21-666-p","https://doi.org/10.2337/db21-666-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048570","R0048570.pdf","paywalled","other_trial","Hui Shao","2021","364-P: Efficacy of IGlarLixi on Five-Year Risk of Diabetes-Related Complications: A Simulation Experiment","Diabetes","American Diabetes Association","10.2337/db21-364-p","https://doi.org/10.2337/db21-364-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048976","R0048976.pdf","paywalled","other","Jochen Seufert","2021","Einfluss der Typ-2-Diabetesdauer auf die Wirkung von iGlarLixi gegenüber Insulin glargin 100 E / ml bei einer basalunterstützten oralen Therapie (BOT): Eine Subanalyse der LixiLan-L-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727315","https://doi.org/10.1055/s-0041-1727315",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058160"],["5","R0048980","R0048980.pdf","paywalled","other_trial","Brian R. Kocak","2021","812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors","Diabetes","American Diabetes Association","10.2337/db21-812-p","https://doi.org/10.2337/db21-812-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049582","R0049582.pdf","paywalled","other_trial","Matthew Capehorn","2021","647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial","Diabetes","American Diabetes Association","10.2337/db21-647-p","https://doi.org/10.2337/db21-647-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049781","R0049781.pdf","paywalled","other_trial","Marina Vladimirovna Shestakova","2021","ПЕРОРАЛЬНЫЙ СЕМАГЛУТИД - НОВАЯ ¬ИННОВАЦИОННАЯ ОПЦИЯ В ТЕРАПИИ САХАРНОГО ДИАБЕТА 2 ТИПА","Сахарный диабет",null,"10.14341/dm12790-9938","https://doi.org/10.14341/dm12790-9938",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050434","R0050434.pdf","paywalled","other_trial","Victor Aboyans","2021","Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm","European Journal of Preventive Cardiology","Oxford University Press (OUP)","10.1093/eurjpc/zwaa157","https://doi.org/10.1093/eurjpc/zwaa157","33580794","https://pubmed.ncbi.nlm.nih.gov/33580794/",null,null],["5","R0051757","R0051757.pdf","paywalled","other_trial","AL Birkenfeld","2021","Umstellung auf iGlarLixi gegenüber der weitergeführten Behandlung mit einem GLP-1-Rezeptoragonisten bei unzureichend kontrolliertem Typ-2-Diabetes: die randomisierte LixiLan-G-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0041-1727314","https://doi.org/10.1055/s-0041-1727314",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02787551"],["5","R0051774","R0051774.pdf","paywalled","other_trial","Kristina Secnik Boye","2021","Patient Reported Outcomes for Tirzepatide versus Semaglutide in Participants with T2D from the SURPASS-2 Trial",null,"Morressier","10.26226/morressier.617c37317c09fc044a975227","https://doi.org/10.26226/morressier.617c37317c09fc044a975227",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052406","R0052406.pdf","paywalled","other_trial","Vanita R. Aroda","2021","664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence","Diabetes","American Diabetes Association","10.2337/db21-664-p","https://doi.org/10.2337/db21-664-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02692716"],["5","R0052882","R0052882.pdf","paywalled","other_trial","Jill Trinacty","2021","Time Spent in Glycemic Control After Initiating Treatment With Oral Semaglutide Versus Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2021.09.047","https://doi.org/10.1016/j.jcjd.2021.09.047",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053610","R0053610.pdf","paywalled","other_trial","Jonathan Marks","2021","S2876 Novel Chemotherapy Combination Leading to Novel Problems: A Case Report on Sulfonylurea Toxicity Secondary to Hepatic Impairment","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000785036.55393.38","https://doi.org/10.14309/01.ajg.0000785036.55393.38",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054295","R0054295.pdf","paywalled","other_trial","Khadije Ahmad","2021","Correlation Between Hemoglobin A1c and High Sensitivity C-Reactive Protein in Population with Type II Diabetes Mellitus in the Semaglutide Treatment on Coronary Plaque Progression (STOP) Trial","American Heart Journal","Elsevier BV","10.1016/j.ahj.2021.10.031","https://doi.org/10.1016/j.ahj.2021.10.031",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0004356","R0004356.pdf","paywalled","other_trial","Bucheit JD","2020","Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2019.0185","https://doi.org/10.1089/dia.2019.0185","31436480","https://pubmed.ncbi.nlm.nih.gov/31436480/",null,null],["5","R0006970","R0006970.pdf","paywalled","other_trial","Cowart K","2020","Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028019889064","https://doi.org/10.1177/1060028019889064","31744308","https://pubmed.ncbi.nlm.nih.gov/31744308/",null,null],["5","R0007271","R0007271.pdf","paywalled","other_trial","Vitale M","2020","Renal protection with glucagon-like peptide-1 receptor agonists.","Current opinion in pharmacology","Elsevier BV","10.1016/j.coph.2020.08.018","https://doi.org/10.1016/j.coph.2020.08.018","33027748","https://pubmed.ncbi.nlm.nih.gov/33027748/",null,null],["5","R0007686","R0007686.pdf","paywalled","other_trial","Peter R","2020","Safety of injectable semaglutide for type 2 diabetes.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2020.1772230","https://doi.org/10.1080/14740338.2020.1772230","32428416","https://pubmed.ncbi.nlm.nih.gov/32428416/",null,null],["5","R0007736","R0007736.pdf","paywalled","other_trial","Lingvay I","2020","Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.","The American journal of managed care","Managed Care and Healthcare Communications, LLC","10.37765/ajmc.2020.88555","https://doi.org/10.37765/ajmc.2020.88555","33439583","https://pubmed.ncbi.nlm.nih.gov/33439583/",null,"ClinicalTrials.gov:NCT03914326"],["5","R0007977","R0007977.pdf","paywalled","other_trial","Rodbard HW","2020","Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care.","The American journal of managed care","Clinical Care Targeted Communications Group, LLC","10.37765/ajmc.2020.88554","https://doi.org/10.37765/ajmc.2020.88554","33439582","https://pubmed.ncbi.nlm.nih.gov/33439582/",null,null],["5","R0008300","R0008300.pdf","paywalled","other_trial","Svane MS","2020","No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14106","https://doi.org/10.1111/dom.14106","32495988","https://pubmed.ncbi.nlm.nih.gov/32495988/",null,null],["5","R0008814","R0008814.pdf","paywalled","other_trial","Rajani A","2020","Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14262","https://doi.org/10.1111/dme.14262","32012347","https://pubmed.ncbi.nlm.nih.gov/32012347/",null,null],["5","R0008945","R0008945.pdf","paywalled","other_trial","Powell J","2020","Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2020.07.017","https://doi.org/10.1016/j.clinthera.2020.07.017","32873415","https://pubmed.ncbi.nlm.nih.gov/32873415/",null,null],["5","R0009637","R0009637.pdf","paywalled","other_trial","Liu C","2020","GLP-1R agonists for the treatment of obesity: a patent review (2015-present).","Expert opinion on therapeutic patents","Informa UK Limited","10.1080/13543776.2020.1811851","https://doi.org/10.1080/13543776.2020.1811851","32799587","https://pubmed.ncbi.nlm.nih.gov/32799587/",null,null],["5","R0010675","R0010675.pdf","paywalled","other_trial","Johansson KS","2020","What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline.","Expert opinion on drug discovery","Informa UK Limited","10.1080/17460441.2020.1791078","https://doi.org/10.1080/17460441.2020.1791078","32646248","https://pubmed.ncbi.nlm.nih.gov/32646248/",null,null],["5","R0012993","R0012993.pdf","paywalled","other_trial","Terauchi Y","2020","Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14139","https://doi.org/10.1111/dom.14139","33404200","https://pubmed.ncbi.nlm.nih.gov/33404200/",null,"ClinicalTrials.gov:NCT02749890; ClinicalTrials.gov:NCT02752828; ClinicalTrials.gov:NCT02752412"],["5","R0014169","R0014169.pdf","paywalled","other_trial","González-Gálvez G","2020","Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2019.05.020","https://doi.org/10.1016/j.jdiacomp.2019.05.020","32561160","https://pubmed.ncbi.nlm.nih.gov/32561160/",null,null],["5","R0015717","R0015717.pdf","paywalled","other_trial","Frías JP","2020","Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1080/17446651.2020.1830759","https://doi.org/10.1080/17446651.2020.1830759","33030356","https://pubmed.ncbi.nlm.nih.gov/33030356/",null,null],["5","R0019259","R0019259.pdf","paywalled","other_trial","Chang YF","2020","Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","Elsevier BV","10.1016/j.jocn.2020.09.054","https://doi.org/10.1016/j.jocn.2020.09.054","33222922","https://pubmed.ncbi.nlm.nih.gov/33222922/",null,null],["5","R0021130","R0021130.pdf","paywalled","other_trial","Bolli GB","2020","Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin.","Diabetes care","American Diabetes Association","10.2337/dci20-0038","https://doi.org/10.2337/dci20-0038","32958617","https://pubmed.ncbi.nlm.nih.gov/32958617/",null,null],["5","R0022526","R0022526.pdf","paywalled","other_trial","Daoud DC","2020","The new place of enterohormones in intestinal failure.","Current opinion in clinical nutrition and metabolic care","Ovid Technologies (Wolters Kluwer Health)","10.1097/mco.0000000000000672","https://doi.org/10.1097/mco.0000000000000672","32618723","https://pubmed.ncbi.nlm.nih.gov/32618723/",null,null],["5","R0022571","R0022571.pdf","paywalled","other_trial","Söderbom G","2020","Status and future directions of clinical trials in Parkinson's disease.","International review of neurobiology","Elsevier","10.1016/bs.irn.2020.02.009","https://doi.org/10.1016/bs.irn.2020.02.009","32739003","https://pubmed.ncbi.nlm.nih.gov/32739003/",null,null],["5","R0022797","R0022797.pdf","paywalled","other_trial","Sumida Y","2020","Current and new pharmacotherapy options for non-alcoholic steatohepatitis.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2020.1744564","https://doi.org/10.1080/14656566.2020.1744564","32237916","https://pubmed.ncbi.nlm.nih.gov/32237916/",null,null],["5","R0023851","R0023851.pdf","paywalled","other_trial","Men P","2020","Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2019.1662676","https://doi.org/10.1080/03007995.2019.1662676","31469303","https://pubmed.ncbi.nlm.nih.gov/31469303/",null,null],["5","R0024518","R0024518.pdf","paywalled","other_trial","Fan W","2020","LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007-2016.","Cardiovascular drugs and therapy","Springer Science and Business Media LLC","10.1007/s10557-020-07032-7","https://doi.org/10.1007/s10557-020-07032-7","32621045","https://pubmed.ncbi.nlm.nih.gov/32621045/",null,null],["5","R0026840","R0026840.pdf","paywalled","other_trial","Martínez Martínez AL","2020","[Is there life after teduglutide?].","Nutricion hospitalaria",null,"10.20960/nh.03052","https://doi.org/10.20960/nh.03052","32406744","https://pubmed.ncbi.nlm.nih.gov/32406744/",null,null],["5","R0027619","R0027619.pdf","paywalled","other_trial","Øhrstrøm CC","2020","Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-020-04387-6","https://doi.org/10.1007/s11695-020-04387-6","31907828","https://pubmed.ncbi.nlm.nih.gov/31907828/",null,"ClinicalTrials.gov:NCT02527993"],["5","R0029748","R0029748.pdf","paywalled","other_trial","Patel V","2020","Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.","Drug research","Georg Thieme Verlag KG","10.1055/a-1201-2700","https://doi.org/10.1055/a-1201-2700","32645724","https://pubmed.ncbi.nlm.nih.gov/32645724/",null,null],["5","R0030631","R0030631.pdf","paywalled","other_trial","Catherine M. Gordon","2020","Clinical Trial of Liraglutide for Obesity in Adolescence","Journal watch",null,"10.1056/nejm-jw.na51266","https://doi.org/10.1056/nejm-jw.na51266",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032925","R0032925.pdf","paywalled","other_trial","Xiaoling Cai","2020","1424-P: Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Type 2 Diabetes Population in China","Diabetes","American Diabetes Association","10.2337/db20-1424-p","https://doi.org/10.2337/db20-1424-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032976","R0032976.pdf","paywalled","other","Yanbing Li","2020","2188-PUB: Efficacy and Safety in Chinese T2D Patients Discontinued from OAM to Once-Weekly Dulaglutide Monotherapy","Diabetes","American Diabetes Association","10.2337/db20-2188-pub","https://doi.org/10.2337/db20-2188-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01644500"],["5","R0033018","R0033018.pdf","paywalled","other_trial","REN YUEZHONG","2020","1066-P: Comparison of Efficacy of Lixisenatide Combined with Basal Insulin with or without Metformin in Asian and Caucasian Patients with Type 2 Diabetes: A Pooled Analysis of Phase-III Studies","Diabetes","American Diabetes Association","10.2337/db20-1066-p","https://doi.org/10.2337/db20-1066-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033020","R0033020.pdf","paywalled","other_trial","Kenji Ohwaki","2020","969-P: Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-969-p","https://doi.org/10.2337/db20-969-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033545","R0033545.pdf","paywalled","other_trial","Husain, Mansoor","2020","Additional file 8 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Figshare",null,"10.6084/m9.figshare.13031567","https://doi.org/10.6084/m9.figshare.13031567",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033588","R0033588.pdf","paywalled","other_trial","Husain, Mansoor","2020","Additional file 5 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Figshare",null,"10.6084/m9.figshare.13031558","https://doi.org/10.6084/m9.figshare.13031558",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033681","R0033681.pdf","paywalled","other_trial","Husain, Mansoor","2020","Additional file 3 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Figshare",null,"10.6084/m9.figshare.13031552","https://doi.org/10.6084/m9.figshare.13031552",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034082","R0034082.pdf","paywalled","other_trial","Husain, Mansoor","2020","Additional file 9 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Figshare",null,"10.6084/m9.figshare.13031570","https://doi.org/10.6084/m9.figshare.13031570",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034582","R0034582.pdf","paywalled","other_trial","Johannes F.E. Mann","2020","Joint Model of eGFR Slope: Data from LEADER in Patients with Type 2 Diabetes and High Risk of Cardiovascular Events","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1332b","https://doi.org/10.1681/asn.20203110s1332b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0034991","R0034991.pdf","paywalled","other_trial","Daniel Ngui","2020","58 - Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.064","https://doi.org/10.1016/j.jcjd.2020.08.064",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035784","R0035784.pdf","paywalled","other_trial","Yanagawa, Bobby","2020","Editorial introductions","Current Opinion in Cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000717","https://doi.org/10.1097/hco.0000000000000717",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038153","R0038153.pdf","paywalled","protocol","Nomoto, Hiroshi","2020","Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)","Figshare",null,"10.6084/m9.figshare.13379093","https://doi.org/10.6084/m9.figshare.13379093",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039448","R0039448.pdf","paywalled","other_trial","Deeks, Emma","2020","Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use","Figshare",null,"10.6084/m9.figshare.9696338","https://doi.org/10.6084/m9.figshare.9696338",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040062","R0040062.pdf","paywalled","other_trial","Vanessa Legry","2020","1817-P: Elafibranor and Glucagon-Like Peptide-1 Receptor Agonists Synergize to Attenuate Hepatic Inflammation and Fibrosis in a Rodent Model of Obesity, Insulin Resistance, and NASH","Diabetes","American Diabetes Association","10.2337/db20-1817-p","https://doi.org/10.2337/db20-1817-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041349","R0041349.pdf","paywalled","other_trial","Evans, Marc","2020","An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin","Figshare",null,"10.6084/m9.figshare.5625094.v2","https://doi.org/10.6084/m9.figshare.5625094.v2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043196","R0043196.pdf","paywalled","other_trial","B. Zinman","2020","Liraglutide and Glycaemic Outcomes in the LEADER Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/kz1k-4223","https://doi.org/10.17615/kz1k-4223",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043197","R0043197.pdf","paywalled","protocol","H. Sourij","2020","Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/psft-h469","https://doi.org/10.17615/psft-h469",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01144338"],["5","R0043237","R0043237.pdf","paywalled","other_trial","S.P. Marso","2020","Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/13n0-cc93","https://doi.org/10.17615/13n0-cc93",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043271","R0043271.pdf","paywalled","other_trial","M.A. Nauck","2020","Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/d1hv-pw35","https://doi.org/10.17615/d1hv-pw35",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043304","R0043304.pdf","paywalled","other_trial","Goodman, S.G.","2020","Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results from the EXSCEL Trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ks7q-gz23","https://doi.org/10.17615/ks7q-gz23",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01144338"],["5","R0043421","R0043421.pdf","paywalled","other_trial","S. Pocock","2020","Health-related quality of life in people with type 2 diabetes participating in the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/5edj-5h41","https://doi.org/10.17615/5edj-5h41",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044882","R0044882.pdf","paywalled","other_trial","MARTIN LINDER","2020","Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the leader trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/1rnr-dq63","https://doi.org/10.17615/1rnr-dq63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0044904","R0044904.pdf","paywalled","other_trial","H.A. Saevereid","2020","Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/jxws-kt94","https://doi.org/10.17615/jxws-kt94",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045537","R0045537.pdf","paywalled","other_trial","KATHERINE R. TUTTLE","2020","949-P: Dulaglutide Improves Kidney Fibrosis Biomarker Levels in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease","Diabetes","American Diabetes Association","10.2337/db20-949-p","https://doi.org/10.2337/db20-949-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045674","R0045674.pdf","paywalled","other_trial","Joseph Azuri","2020","Abstract 13807: Semaglutide Provides More Value for Money Than Dulaglutide or Liraglutide for Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.13807","https://doi.org/10.1161/circ.142.suppl_3.13807",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047083","R0047083.pdf","paywalled","other_trial","David Z.I. Cherney","2020","Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1349b","https://doi.org/10.1681/asn.20203110s1349b",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047230","R0047230.pdf","paywalled","other_trial","Katherine R. Tuttle","2020","Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s136a","https://doi.org/10.1681/asn.20203110s136a",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048062","R0048062.pdf","paywalled","other_trial","Katherine R. Tuttle","2020","Dulaglutide Treatment in Patients with Type 2 Diabetes and Moderate-to-Severe CKD Improves Kidney Fibrosis Biomarker Levels","Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.20203110s1348c","https://doi.org/10.1681/asn.20203110s1348c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048079","R0048079.pdf","paywalled","other_trial","Gilles R. Dagenais","2020","Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.15586","https://doi.org/10.1161/circ.142.suppl_3.15586",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01394952"],["5","R0048109","R0048109.pdf","paywalled","protocol","J. B. Buse","2020","Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/2z9e-fc77","https://doi.org/10.17615/2z9e-fc77",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048692","R0048692.pdf","paywalled","other_trial","Lindsay E. Clegg","2020","958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis","Diabetes","American Diabetes Association","10.2337/db20-958-p","https://doi.org/10.2337/db20-958-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048716","R0048716.pdf","paywalled","other_trial","Angelyn Bethel","2020","944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up","Diabetes","American Diabetes Association","10.2337/db20-944-p","https://doi.org/10.2337/db20-944-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049197","R0049197.pdf","paywalled","other_trial","Thomas Foltynie","2020","Diabetes, BMI, and Parkinson's","Movement Disorders","Wiley","10.1002/mds.27941","https://doi.org/10.1002/mds.27941","32056307","https://pubmed.ncbi.nlm.nih.gov/32056307/",null,null],["5","R0050330","R0050330.pdf","paywalled","other_trial","Lai‐San Tham","2020","943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide","Diabetes","American Diabetes Association","10.2337/db20-943-p","https://doi.org/10.2337/db20-943-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050484","R0050484.pdf","paywalled","other_trial","Grazia Daniela Femminella","2020","Behavioural symptoms in Alzheimer’s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism","Alzheimer s & Dementia","Wiley","10.1002/alz.045223","https://doi.org/10.1002/alz.045223",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01843075"],["5","R0050572","R0050572.pdf","paywalled","other_trial","Demetria M. McNeal","2020","Abstract 332: Racial Differences in Prescribing of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Among Veterans With Type 2 Diabetes and Coronary Artery Disease: Findings From the Veteran’s Administration Clinical Assessment, Reporting, and Tracking Program","Circulation Cardiovascular Quality and Outcomes","Ovid Technologies (Wolters Kluwer Health)","10.1161/hcq.13.suppl_1.332","https://doi.org/10.1161/hcq.13.suppl_1.332",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050978","R0050978.pdf","paywalled","other_trial","Helen Martina Colhoun","2020","924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND","Diabetes","American Diabetes Association","10.2337/db20-924-p","https://doi.org/10.2337/db20-924-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051315","R0051315.pdf","paywalled","other_trial","David Richard Matthews","2020","ADVANCE","Diabetes Obesity and Metabolism","Wiley","10.1111/dom.14014","https://doi.org/10.1111/dom.14014","32250523","https://pubmed.ncbi.nlm.nih.gov/32250523/",null,null],["5","R0051762","R0051762.pdf","paywalled","other_trial","Vanita R. Aroda","2020","933-P: Greater Reductions in HbA1c and Body Weight with Once-Weekly Semaglutide vs. Comparators across Baseline BMI Subgroups: A Post Hoc Analysis of SUSTAIN 1-5 and 7-10","Diabetes","American Diabetes Association","10.2337/db20-933-p","https://doi.org/10.2337/db20-933-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051820","R0051820.pdf","paywalled","other_trial","Katherine R. Tuttle","2020","TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfaa141.to002","https://doi.org/10.1093/ndt/gfaa141.to002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051920","R0051920.pdf","paywalled","other_trial","Oksana Dmitrievna Rymar","2020","Комплексный подход в лечении сахарного диабета 2 типа – путь к снижению смертности от атеросклероз-ассоциированных заболеваний","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.15372/ater20190407","https://doi.org/10.15372/ater20190407",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051976","R0051976.pdf","paywalled","other_trial","Kathleen Marie Dungan","2020","63 - Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.069","https://doi.org/10.1016/j.jcjd.2020.08.069",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052014","R0052014.pdf","paywalled","other_trial","J.B. Buse","2020","Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/eqw9-qw52","https://doi.org/10.17615/eqw9-qw52",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052158","R0052158.pdf","paywalled","other_trial","Cyrus V Desouza","2020","60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.066","https://doi.org/10.1016/j.jcjd.2020.08.066",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052313","R0052313.pdf","paywalled","other_trial","N. Jakuboniene","2020","Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: Insights from the EXSCEL trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/wd7y-wk80","https://doi.org/10.17615/wd7y-wk80",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052613","R0052613.pdf","paywalled","other_trial","Odette S. Reifsnider","2020","1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States","Diabetes","American Diabetes Association","10.2337/db20-1158-p","https://doi.org/10.2337/db20-1158-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052815","R0052815.pdf","paywalled","other_trial","Vanita R. Aroda","2020","932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program","Diabetes","American Diabetes Association","10.2337/db20-932-p","https://doi.org/10.2337/db20-932-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052965","R0052965.pdf","paywalled","other_trial","Gianluigi Savarese","2020","2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db20-2216-pub","https://doi.org/10.2337/db20-2216-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053179","R0053179.pdf","paywalled","other_trial","Sue D. Pedersen","2020","57 - Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2020.08.063","https://doi.org/10.1016/j.jcjd.2020.08.063",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053221","R0053221.pdf","paywalled","other_trial","Gregory G. Schwartz","2020","Abstract 14307: Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.142.suppl_3.14307","https://doi.org/10.1161/circ.142.suppl_3.14307",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053309","R0053309.pdf","paywalled","other_trial","Magnus Olof Wijkman","2020","1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event","Diabetes","American Diabetes Association","10.2337/db20-1421-p","https://doi.org/10.2337/db20-1421-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01147250"],["5","R0053758","R0053758.pdf","paywalled","other_trial","S. Marso","2020","Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/ct1e-g414","https://doi.org/10.17615/ct1e-g414",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053890","R0053890.pdf","paywalled","other_trial","J.B. Buse","2020","Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/65hn-mb69","https://doi.org/10.17615/65hn-mb69",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446"],["5","R0007509","R0007509.pdf","paywalled","other_trial","Al-Kawas F","2019","PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0507","https://doi.org/10.4158/ep-2018-0507","30865522","https://pubmed.ncbi.nlm.nih.gov/30865522/",null,null],["5","R0008239","R0008239.pdf","paywalled","other_trial","Christensen RM","2019","Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.","Drug safety","Springer Science and Business Media LLC","10.1007/s40264-019-00812-7","https://doi.org/10.1007/s40264-019-00812-7","30972641","https://pubmed.ncbi.nlm.nih.gov/30972641/",null,null],["5","R0008379","R0008379.pdf","paywalled","other_trial","Christou GA","2019","Semaglutide as a promising antiobesity drug.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.12839","https://doi.org/10.1111/obr.12839","30768766","https://pubmed.ncbi.nlm.nih.gov/30768766/",null,null],["5","R0009827","R0009827.pdf","paywalled","other_trial","Rodbard HW","2019","GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0444","https://doi.org/10.4158/ep-2018-0444","30865526","https://pubmed.ncbi.nlm.nih.gov/30865526/",null,null],["5","R0011068","R0011068.pdf","paywalled","other","Zhang Z","2019","Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.","Diabetes care","American Diabetes Association","10.2337/dc18-2584","https://doi.org/10.2337/dc18-2584","31221697","https://pubmed.ncbi.nlm.nih.gov/31221697/",null,"ClinicalTrials.gov:NCT02738671"],["5","R0011900","R0011900.pdf","paywalled","other_trial","Dicembrini I","2019","Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2018.12.009","https://doi.org/10.1016/j.numecd.2018.12.009","30718142","https://pubmed.ncbi.nlm.nih.gov/30718142/",null,null],["5","R0012384","R0012384.pdf","paywalled","other_trial","Madsbad S","2019","Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.","Expert review of cardiovascular therapy","Informa UK Limited","10.1080/14779072.2019.1615444","https://doi.org/10.1080/14779072.2019.1615444","31055989","https://pubmed.ncbi.nlm.nih.gov/31055989/",null,null],["5","R0012646","R0012646.pdf","paywalled","other","Schmider W","2019","Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2018.1558852","https://doi.org/10.1080/03007995.2018.1558852","30550345","https://pubmed.ncbi.nlm.nih.gov/30550345/",null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160"],["5","R0013400","R0013400.pdf","paywalled","narrative_review","Park EJ","2019","Emerging PEGylated non-biologic drugs.","Expert opinion on emerging drugs","Informa UK Limited","10.1080/14728214.2019.1604684","https://doi.org/10.1080/14728214.2019.1604684","30957581","https://pubmed.ncbi.nlm.nih.gov/30957581/",null,"ClinicalTrials.gov:NCT01492101; ClinicalTrials.gov:NCT02367820; ClinicalTrials.gov:NCT00520390; ClinicalTrials.gov:NCT02119819; ClinicalTrials.gov:NCT03520972; ClinicalTrials.gov:NCT03604419; ClinicalTrials.gov:NCT00804986; ClinicalTrials.gov:NCT03672604; ClinicalTrials.gov:NCT01089517; ClinicalTrials.gov:NCT01944839; ClinicalTrials.gov:NCT01940900; ClinicalTrials.gov:NCT01940887; ClinicalTrials.gov:NCT00932100; ClinicalTrials.gov:NCT00715455; ClinicalTrials.gov:NCT01872572; ClinicalTrials.gov:NCT01848106; ClinicalTrials.gov:NCT00432770; ClinicalTrials.gov:NCT00632242; ClinicalTrials.gov:NCT00742612; ClinicalTrials.gov:NCT00507338; ClinicalTrials.gov:NCT02397954; ClinicalTrials.gov:NCT00976378; ClinicalTrials.gov:NCT01486797; ClinicalTrials.gov:NCT01521533; ClinicalTrials.gov:NCT01085292; ClinicalTrials.gov:NCT01547897; ClinicalTrials.gov:NCT01372137; ClinicalTrials.gov:NCT01691040; ClinicalTrials.gov:NCT02079896"],["5","R0013480","R0013480.pdf","paywalled","other_trial","Caruso I","2019","Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.","Trends in endocrinology and metabolism: TEM","Elsevier BV","10.1016/j.tem.2019.07.004","https://doi.org/10.1016/j.tem.2019.07.004","31401015","https://pubmed.ncbi.nlm.nih.gov/31401015/",null,null],["5","R0013725","R0013725.pdf","paywalled","other_trial","Almutairi M","2019","Glucagon-like peptide-1 receptor action in the vasculature.","Peptides","Elsevier BV","10.1016/j.peptides.2018.09.002","https://doi.org/10.1016/j.peptides.2018.09.002","30227157","https://pubmed.ncbi.nlm.nih.gov/30227157/",null,null],["5","R0014330","R0014330.pdf","paywalled","other_trial","Giugliano D","2019","Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13629","https://doi.org/10.1111/dom.13629","30609236","https://pubmed.ncbi.nlm.nih.gov/30609236/",null,null],["5","R0019987","R0019987.pdf","paywalled","other_trial","Umpierrez G","2019","Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13662","https://doi.org/10.1111/dom.13662","30756511","https://pubmed.ncbi.nlm.nih.gov/30756511/",null,null],["5","R0020166","R0020166.pdf","paywalled","other_trial","Deedwania P","2019","Cardiovascular Protection with Anti-hyperglycemic Agents.","American journal of cardiovascular drugs : drugs, devices, and other interventions","Springer Science and Business Media LLC","10.1007/s40256-019-00325-9","https://doi.org/10.1007/s40256-019-00325-9","30767126","https://pubmed.ncbi.nlm.nih.gov/30767126/",null,null],["5","R0022150","R0022150.pdf","paywalled","other_trial","Bogman K","2019","Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-019-00757-1","https://doi.org/10.1007/s40262-019-00757-1","30968335","https://pubmed.ncbi.nlm.nih.gov/30968335/",null,null],["5","R0024533","R0024533.pdf","paywalled","other_trial","Fuechtenbusch M","2019","Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13658","https://doi.org/10.1111/dom.13658","30737891","https://pubmed.ncbi.nlm.nih.gov/30737891/",null,null],["5","R0024727","R0024727.pdf","paywalled","other_trial","Suhrs HE","2019","Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2018.12.005","https://doi.org/10.1016/j.ijcard.2018.12.005","30773266","https://pubmed.ncbi.nlm.nih.gov/30773266/",null,"ClinicalTrials.gov:NCT02602600"],["5","R0024908","R0024908.pdf","paywalled","preclinical","Yang L","2019","Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis.","Journal of endocrinological investigation","Springer Science and Business Media LLC","10.1007/s40618-019-01034-5","https://doi.org/10.1007/s40618-019-01034-5","30955181","https://pubmed.ncbi.nlm.nih.gov/30955181/",null,null],["5","R0025418","R0025418.pdf","paywalled","other_trial","Ali S","2019","Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.","Current atherosclerosis reports","Springer Science and Business Media LLC","10.1007/s11883-019-0794-6","https://doi.org/10.1007/s11883-019-0794-6","31230129","https://pubmed.ncbi.nlm.nih.gov/31230129/",null,null],["5","R0025715","R0025715.pdf","paywalled","other_trial","Hu J","2019","Managing chronic kidney disease in diabetes patients with the latest chemical therapies.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2019.1552829","https://doi.org/10.1080/17512433.2019.1552829","30509118","https://pubmed.ncbi.nlm.nih.gov/30509118/",null,null],["5","R0026211","R0026211.pdf","paywalled","other_trial","Andrew CA","2019","Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2018.1561867","https://doi.org/10.1080/14656566.2018.1561867","30614740","https://pubmed.ncbi.nlm.nih.gov/30614740/",null,null],["5","R0026330","R0026330.pdf","paywalled","other_trial","Thompson J","2019","Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.","Cardiology clinics","Elsevier BV","10.1016/j.ccl.2019.04.007","https://doi.org/10.1016/j.ccl.2019.04.007","31279427","https://pubmed.ncbi.nlm.nih.gov/31279427/",null,null],["5","R0026663","R0026663.pdf","paywalled","other_trial","Weng J","2019","Reply.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.30553","https://doi.org/10.1002/hep.30553","30729549","https://pubmed.ncbi.nlm.nih.gov/30729549/",null,null],["5","R0028572","R0028572.pdf","paywalled","other_trial","Greenhill C","2019","T2DM treatment trial results.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/s41574-019-0234-2","https://doi.org/10.1038/s41574-019-0234-2","31253858","https://pubmed.ncbi.nlm.nih.gov/31253858/",null,null],["5","R0028601","R0028601.pdf","paywalled","other_trial","Fralick M","2019","Publicising trial results before peer review.","BMJ (Clinical research ed.)","BMJ","10.1136/bmj.l556","https://doi.org/10.1136/bmj.l556","30755405","https://pubmed.ncbi.nlm.nih.gov/30755405/",null,null],["5","R0030370","R0030370.pdf","paywalled","other_trial","Rydén L","2019","Risk factor reduction in type 2 diabetes demands a multifactorial approach.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1177/2047487319872015","https://doi.org/10.1177/2047487319872015","31766912","https://pubmed.ncbi.nlm.nih.gov/31766912/",null,null],["5","R0030980","R0030980.pdf","paywalled","other_trial","Allan S. Brett","2019","Gallstone Disease in Patients Treated with Liraglutide","Journal watch",null,"10.1056/nejm-jw.na50110","https://doi.org/10.1056/nejm-jw.na50110",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031395","R0031395.pdf","paywalled","other_trial","蘇品碩","2019","新型降血糖藥Liraglutide的心血管安全性試驗－The LEADER Trial",null,null,"10.6666/clinmed.201903_83(3).0032","https://doi.org/10.6666/clinmed.201903_83(3).0032",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031431","R0031431.pdf","paywalled","other_trial","Euctr At","2019","A trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function",null,null,"10.1002/central/cn-01870526","https://doi.org/10.1002/central/cn-01870526",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032249","R0032249.pdf","paywalled","other_trial",null,"2019","A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570","Case Medical Research","Case Journals","10.31525/ct1-nct03994549","https://doi.org/10.31525/ct1-nct03994549",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032396","R0032396.pdf","paywalled","other_trial","Leiter, Lawrence","2019","MOESM1 of Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","Figshare",null,"10.6084/m9.figshare.8233784","https://doi.org/10.6084/m9.figshare.8233784",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033043","R0033043.pdf","paywalled","other_trial","Toru Shigeoka","2019","1955-P: GLP-1R Activation Attenuates Prostate Cancer Growth via Inhibiting Cell Cycle Progression","Diabetes","American Diabetes Association","10.2337/db19-1955-p","https://doi.org/10.2337/db19-1955-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033656","R0033656.pdf","paywalled","protocol","Whicher, Clare","2019","Additional file 2: of Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial","Figshare",null,"10.6084/m9.figshare.10566902","https://doi.org/10.6084/m9.figshare.10566902",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033884","R0033884.pdf","paywalled","protocol","Whicher, Clare","2019","Additional file 1: of Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial","Figshare",null,"10.6084/m9.figshare.10566896","https://doi.org/10.6084/m9.figshare.10566896",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034088","R0034088.pdf","paywalled","protocol","Femminella, Grazia","2019","Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ s disease: study protocol for a randomised controlled trial (ELAD study)","Figshare",null,"10.6084/m9.figshare.7950476","https://doi.org/10.6084/m9.figshare.7950476",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034365","R0034365.pdf","paywalled","other_trial","Joachim Trier","2019","Education improves physicians’ knowledge of diabetes CV outcomes trial results and appropriate use of GLP-1 RAs in T2DM",null,"Morressier","10.26226/morressier.5d9b6234ea541d6ca84943d4","https://doi.org/10.26226/morressier.5d9b6234ea541d6ca84943d4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037076","R0037076.pdf","paywalled","other_trial","Geraldine Baekelandt","2019","An investigation into the aggregation of therapeutic peptides through adsorption to primary containers","Apollo (University of Cambridge)",null,"10.17863/cam.52684","https://doi.org/10.17863/cam.52684",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038310","R0038310.pdf","paywalled","other_trial","Adie Viljoen","2019","998-P: Efficacy and Safety of Semaglutide by Baseline BMI in SUSTAIN 1-5 and 7","Diabetes","American Diabetes Association","10.2337/db19-998-p","https://doi.org/10.2337/db19-998-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039601","R0039601.pdf","paywalled","other_trial","Nathan D. Wong","2019","1463-P: LEADER Eligibility and Preventable Cardiovascular Events in the U.S. Population: An Analysis of the National Health and Nutrition Examination Survey","Diabetes","American Diabetes Association","10.2337/db19-1463-p","https://doi.org/10.2337/db19-1463-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041670","R0041670.pdf","paywalled","other_trial","Christian Hölscher","2019","P1‐079: NOVEL DUAL GLP‐1/GIP RECEPTOR AGONISTS SHOW NEUROPROTECTIVE EFFECTS IN TWO ANIMAL MODELS OF AD","Alzheimer s & Dementia","Wiley","10.1016/j.jalz.2019.06.104","https://doi.org/10.1016/j.jalz.2019.06.104",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043277","R0043277.pdf","paywalled","other_trial","Buse, John","2019","LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ","Carolina Digital Repository (University of North Carolina at Chapel Hill)",null,"10.17615/a6vv-8z56","https://doi.org/10.17615/a6vv-8z56",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0045282","R0045282.pdf","paywalled","other_trial","Karina Fatakhova","2019","1311 Acute Pancreatitis in a Patient Using Liraglutide for Weight Loss","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/01.ajg.0000594772.87672.64","https://doi.org/10.14309/01.ajg.0000594772.87672.64",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045433","R0045433.pdf","paywalled","other_trial","Francesco Giorgino","2019","Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): A post hoc analysis of the AWARD-2 clinical trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688249","https://doi.org/10.1055/s-0039-1688249",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045615","R0045615.pdf","paywalled","other","Julio Rosenstock","2019","111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3","Diabetes","American Diabetes Association","10.2337/db19-111-lb","https://doi.org/10.2337/db19-111-lb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02607865"],["5","R0047188","R0047188.pdf","paywalled","other_trial","Gernot Klein","2019","1027-P: A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment","Diabetes","American Diabetes Association","10.2337/db19-1027-p","https://doi.org/10.2337/db19-1027-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03235375"],["5","R0047817","R0047817.pdf","paywalled","other","GEORGE E. DAILEY","2019","1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?","Diabetes","American Diabetes Association","10.2337/db19-1023-p","https://doi.org/10.2337/db19-1023-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02057172"],["5","R0048049","R0048049.pdf","paywalled","other_trial","Juris Jendrik Meier","2019","1013-P: Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1013-p","https://doi.org/10.2337/db19-1013-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02877355"],["5","R0048646","R0048646.pdf","paywalled","other","Richard E. Pratley","2019","1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205","Diabetes","American Diabetes Association","10.2337/db19-1001-p","https://doi.org/10.2337/db19-1001-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02075281"],["5","R0048766","R0048766.pdf","paywalled","other_trial","Joseph B Lerman","2019","Abstract 452: A Unique Acylcarnitine Profile is Independently Associated with Diabetic Heart Failure and Associates with Adverse Clinical Outcomes: Insights from the FIGHT Trial","Circulation Research","Ovid Technologies (Wolters Kluwer Health)","10.1161/res.125.suppl_1.452","https://doi.org/10.1161/res.125.suppl_1.452",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048864","R0048864.pdf","paywalled","other","Richard E. Pratley","2019","53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study","Diabetes","American Diabetes Association","10.2337/db19-53-or","https://doi.org/10.2337/db19-53-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02075281"],["5","R0048887","R0048887.pdf","paywalled","other_trial","Stephan Jacob","2019","Semaglutide treatment and renal function in the SUSTAIN 6 trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688340","https://doi.org/10.1055/s-0039-1688340",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048937","R0048937.pdf","paywalled","other_trial","Mariam Elmegaard Malik","2019","409Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz747.0104","https://doi.org/10.1093/eurheartj/ehz747.0104",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049247","R0049247.pdf","paywalled","other_trial","Grazia Daniela Femminella","2019","P2‐358: INSULIN RESISTANCE INFLUENCES HIPPOCAMPAL GLUCOSE METABOLISM RATHER THAN HIPPOCAMPAL VOLUME IN NON‐DIABETIC ALZHEIMER'S DISEASE PATIENTS","Alzheimer s & Dementia","Wiley","10.1016/j.jalz.2019.06.2765","https://doi.org/10.1016/j.jalz.2019.06.2765",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01843075"],["5","R0049401","R0049401.pdf","paywalled","other_trial","Cristian Guja","2019","2302-PUB: Exenatide Once-Weekly in Diabetes Patients with Stage 2/3 Chronic Kidney Disease—A Pooled 6-Month Analysis","Diabetes","American Diabetes Association","10.2337/db19-2302-pub","https://doi.org/10.2337/db19-2302-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049408","R0049408.pdf","paywalled","other_trial","Paul Smeele","2019","1156-P: Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1 RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db19-1156-p","https://doi.org/10.2337/db19-1156-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049634","R0049634.pdf","paywalled","other_trial","Edward John Pratt","2019","20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies","Diabetes","American Diabetes Association","10.2337/db19-20-or","https://doi.org/10.2337/db19-20-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03115099"],["5","R0050116","R0050116.pdf","paywalled","other_trial","Julio Rosenstock","2019","1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203","Diabetes","American Diabetes Association","10.2337/db19-1014-p","https://doi.org/10.2337/db19-1014-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02057172"],["5","R0052167","R0052167.pdf","paywalled","other_trial","Wolfgang Ekkehard Schmidt","2019","Efficacy of semaglutide vs. dulaglutide across baseline HbA1c in SUSTAIN 7","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688355","https://doi.org/10.1055/s-0039-1688355",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052285","R0052285.pdf","paywalled","other_trial","Kari Uusinarkaus","2019","1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction","Diabetes","American Diabetes Association","10.2337/db19-1020-p","https://doi.org/10.2337/db19-1020-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052315","R0052315.pdf","paywalled","other_trial","Bobby Yanagawa","2019","Editorial introductions","Current Opinion in Cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000606","https://doi.org/10.1097/hco.0000000000000606",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052511","R0052511.pdf","paywalled","other","GB Bolli","2019","Niedrigere Hypoglykämie-Raten mit Insulin glargin 300 E/ml vs. Insulin degludec 100 E/ml bei insulinnaiven erwachsenen Typ-2-Diabetespatienten: die randomisierte BRIGHT-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0039-1688241","https://doi.org/10.1055/s-0039-1688241",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02738151"],["5","R0052701","R0052701.pdf","paywalled","other_trial","Anastasios Koutsovasilis","2019","1111-P: The Qualitative and Quantitative Effect of IDegLira Compared with the Nonfixed Administration of Degludec and Liraglutide","Diabetes","American Diabetes Association","10.2337/db19-1111-p","https://doi.org/10.2337/db19-1111-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053007","R0053007.pdf","paywalled","other_trial","Sebastian Steven","2019","P4476Cardiovascular benefits of GLP-1 (liraglutide) treatment in experimental arterial hypertension are mediated by the endothelial GLP-1 receptor","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehz745.0871","https://doi.org/10.1093/eurheartj/ehz745.0871",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053137","R0053137.pdf","paywalled","other_trial","H. Coleman","2019","1030-P: Effect of MEDI0382 on the Pharmacodynamics and Pharmacokinetics of Warfarin or Esmolol in Healthy Volunteers","Diabetes","American Diabetes Association","10.2337/db19-1030-p","https://doi.org/10.2337/db19-1030-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03347968"],["5","R0053344","R0053344.pdf","paywalled","other_trial","Stephen David Howard Malnick","2019","5 Non-alcoholic fatty liver disease (NAFLD) -underdiagnosed but overtreated","Poster presentations","BMJ Publishing Group Ltd","10.1136/bmjebm-2019-pod.111","https://doi.org/10.1136/bmjebm-2019-pod.111",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0007374","R0007374.pdf","paywalled","other_trial","Li Y","2018","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-018-1051-2","https://doi.org/10.1007/s11886-018-1051-2","30259238","https://pubmed.ncbi.nlm.nih.gov/30259238/",null,null],["5","R0010016","R0010016.pdf","paywalled","other_trial","Liu J","2018","GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.","Peptides","Elsevier BV","10.1016/j.peptides.2018.07.001","https://doi.org/10.1016/j.peptides.2018.07.001","30003931","https://pubmed.ncbi.nlm.nih.gov/30003931/",null,null],["5","R0011183","R0011183.pdf","paywalled","other_trial","Zhang L","2018","Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.","Neuropeptides","Elsevier BV","10.1016/j.npep.2018.07.003","https://doi.org/10.1016/j.npep.2018.07.003","30017231","https://pubmed.ncbi.nlm.nih.gov/30017231/",null,null],["5","R0013918","R0013918.pdf","paywalled","other_trial","Raschi E","2018","Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2018.1531126","https://doi.org/10.1080/14656566.2018.1531126","30299993","https://pubmed.ncbi.nlm.nih.gov/30299993/",null,null],["5","R0016584","R0016584.pdf","paywalled","other_trial","Bloomgarden Z","2018","Journal of Diabetes: Ushering in Volume 10.","Journal of diabetes","Wiley","10.1111/1753-0407.12609","https://doi.org/10.1111/1753-0407.12609","28940787","https://pubmed.ncbi.nlm.nih.gov/28940787/",null,null],["5","R0017061","R0017061.pdf","paywalled","preclinical","Lee CH","2018","Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.","Molecular neurobiology","Springer Science and Business Media LLC","10.1007/s12035-017-0550-2","https://doi.org/10.1007/s12035-017-0550-2","28456941","https://pubmed.ncbi.nlm.nih.gov/28456941/",null,null],["5","R0017797","R0017797.pdf","paywalled","narrative_review","Hölscher C","2018","Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.","Neuropharmacology","Elsevier BV","10.1016/j.neuropharm.2018.01.040","https://doi.org/10.1016/j.neuropharm.2018.01.040","29402504","https://pubmed.ncbi.nlm.nih.gov/29402504/",null,null],["5","R0018654","R0018654.pdf","paywalled","other_trial","Orabi B","2018","Molecular and clinical roles of incretin-based drugs in patients with heart failure.","Heart failure reviews","Springer Science and Business Media LLC","10.1007/s10741-018-9702-3","https://doi.org/10.1007/s10741-018-9702-3","29682682","https://pubmed.ncbi.nlm.nih.gov/29682682/",null,null],["5","R0019937","R0019937.pdf","paywalled","other_trial","Molina Vega M","2018","Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.","Expert opinion on drug metabolism & toxicology","Informa UK Limited","10.1080/17425255.2018.1420160","https://doi.org/10.1080/17425255.2018.1420160","29260924","https://pubmed.ncbi.nlm.nih.gov/29260924/",null,null],["5","R0019958","R0019958.pdf","paywalled","other_trial","Arbel R","2018","Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2018.06.010","https://doi.org/10.1016/j.amjcard.2018.06.010","30075890","https://pubmed.ncbi.nlm.nih.gov/30075890/",null,null],["5","R0023829","R0023829.pdf","paywalled","other_trial","Tzanetakos C","2018","Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.","Clinical drug investigation","Springer Science and Business Media LLC","10.1007/s40261-017-0586-0","https://doi.org/10.1007/s40261-017-0586-0","29080210","https://pubmed.ncbi.nlm.nih.gov/29080210/",null,null],["5","R0024540","R0024540.pdf","paywalled","other_trial","Scuderi MA","2018","Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.","Domestic animal endocrinology","Elsevier BV","10.1016/j.domaniend.2018.04.003","https://doi.org/10.1016/j.domaniend.2018.04.003","30015124","https://pubmed.ncbi.nlm.nih.gov/30015124/",null,null],["5","R0024827","R0024827.pdf","paywalled","protocol","Muller C","2018","Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia.","International journal of stroke : official journal of the International Stroke Society","SAGE Publications","10.1177/1747493018784436","https://doi.org/10.1177/1747493018784436","30019627","https://pubmed.ncbi.nlm.nih.gov/30019627/",null,null],["5","R0025068","R0025068.pdf","paywalled","other_trial","Chilton RJ","2018","The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-018-1114-1","https://doi.org/10.1007/s11892-018-1114-1","30406850","https://pubmed.ncbi.nlm.nih.gov/30406850/",null,null],["5","R0027371","R0027371.pdf","paywalled","other_trial","Ketteler M","2018","[Chronic Kidney Disease - Update 2018].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0043-124831","https://doi.org/10.1055/s-0043-124831","29409087","https://pubmed.ncbi.nlm.nih.gov/29409087/",null,null],["5","R0030366","R0030366.pdf","paywalled","other_trial","Halim MA","2018","Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-02006","https://doi.org/10.1210/jc.2017-02006","29177486","https://pubmed.ncbi.nlm.nih.gov/29177486/",null,"ClinicalTrials.gov:NCT02731664"],["5","R0031579","R0031579.pdf","paywalled","other_trial",null,"2018","Semaglutide reduces cardiovascular risk across risk subgroups","Clinical pharmacist","Royal Pharmaceutical Society","10.1211/cp.2018.20205530","https://doi.org/10.1211/cp.2018.20205530",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032720","R0032720.pdf","paywalled","other_trial","Andreas B. Jordy","2018","Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel","Diabetes","American Diabetes Association","10.2337/db18-1135-p","https://doi.org/10.2337/db18-1135-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037646","R0037646.pdf","paywalled","other_trial","MARCEL A. MUSKIET","2018","Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial","Diabetes","American Diabetes Association","10.2337/db18-1060-p","https://doi.org/10.2337/db18-1060-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037810","R0037810.pdf","paywalled","other_trial","Luigi Meneghini","2018","Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program","Diabetes","American Diabetes Association","10.2337/db18-1109-p","https://doi.org/10.2337/db18-1109-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038018","R0038018.pdf","paywalled","other_trial","Marc Evans","2018","Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1273-p","https://doi.org/10.2337/db18-1273-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038301","R0038301.pdf","paywalled","other_trial","Khunti, Kamlesh","2018","Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program","Figshare",null,"10.6084/m9.figshare.6171386","https://doi.org/10.6084/m9.figshare.6171386",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038795","R0038795.pdf","paywalled","other_trial","Lawrence Blonde","2018","Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L","Diabetes","American Diabetes Association","10.2337/db18-1094-p","https://doi.org/10.2337/db18-1094-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039354","R0039354.pdf","paywalled","other_trial","Scott, Lesley","2018","Insulin glargine/lixisenatide: a review in type 2 diabetes","Figshare",null,"10.6084/m9.figshare.6045419","https://doi.org/10.6084/m9.figshare.6045419",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039740","R0039740.pdf","paywalled","other_trial","Anastasios Koutsovasilis","2018","Qualitative and Quantitative Effect of IDegLira Compared with the Nonfixed Administration of Degludec and Liraglutide","Diabetes","American Diabetes Association","10.2337/db18-1104-p","https://doi.org/10.2337/db18-1104-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039907","R0039907.pdf","paywalled","other_trial","Kalra, Sanjay","2018","Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial","Figshare",null,"10.6084/m9.figshare.6210836","https://doi.org/10.6084/m9.figshare.6210836",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041013","R0041013.pdf","paywalled","other_trial","University of California Office of the President","2018","GLP-1 Agonists in Severe Asthma","California Digital Library",null,"10.17920/g9p072","https://doi.org/10.17920/g9p072",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044805","R0044805.pdf","paywalled","other_trial","Sean M. Davidson","2018","Cardioprotection – is no the answer? A renewed look at nitric oxide signalling in cardiomyocytes","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvy073","https://doi.org/10.1093/cvr/cvy073","29584817","https://pubmed.ncbi.nlm.nih.gov/29584817/",null,null],["5","R0047341","R0047341.pdf","paywalled","other_trial","Anita J Slomski","2018","Dual Receptor Agonist for Type 2 Diabetes","JAMA","American Medical Association (AMA)","10.1001/jama.2018.20160","https://doi.org/10.1001/jama.2018.20160","30575879","https://pubmed.ncbi.nlm.nih.gov/30575879/",null,null],["5","R0047494","R0047494.pdf","paywalled","other_trial","Lawrence A. Leiter","2018","A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial","Diabetes","American Diabetes Association","10.2337/db18-1089-p","https://doi.org/10.2337/db18-1089-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058160"],["5","R0047975","R0047975.pdf","paywalled","other_trial","Dilan S. Athauda","2018","Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease (S27.002)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.90.15_supplement.s27.002","https://doi.org/10.1212/wnl.90.15_supplement.s27.002",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048594","R0048594.pdf","paywalled","other_trial","Richard E. Pratley","2018","Efficacy of Semaglutide vs. Dulaglutide across Baseline HbA1c in SUSTAIN 7","Diabetes","American Diabetes Association","10.2337/db18-122-or","https://doi.org/10.2337/db18-122-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048665","R0048665.pdf","paywalled","other_trial","Adie Viljoen","2018","Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7","Diabetes","American Diabetes Association","10.2337/db18-1083-p","https://doi.org/10.2337/db18-1083-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048739","R0048739.pdf","paywalled","other","Victoria Parker","2018","Effects of MEDI0382 on Pancreatic and Incretin Hormones","Diabetes","American Diabetes Association","10.2337/db18-79-or","https://doi.org/10.2337/db18-79-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02548585"],["5","R0048816","R0048816.pdf","paywalled","other_trial","Vanita R. Aroda","2018","Abstract #245 Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: A Post Hoc Analysis of the Sustain 7 Trial","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)47090-9","https://doi.org/10.1016/s1530-891x(20)47090-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048995","R0048995.pdf","paywalled","other_trial","Richard E. Pratley","2018","The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes","Diabetes","American Diabetes Association","10.2337/db18-2300-pub","https://doi.org/10.2337/db18-2300-pub",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049204","R0049204.pdf","paywalled","other_trial","Pablo Mora","2018","Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes","Diabetes","American Diabetes Association","10.2337/db18-1072-p","https://doi.org/10.2337/db18-1072-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160"],["5","R0049343","R0049343.pdf","paywalled","other_trial","Liana K. Billings","2018","Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2018.08.143","https://doi.org/10.1016/j.jcjd.2018.08.143",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02420262"],["5","R0049816","R0049816.pdf","paywalled","other_trial","Tina Vilsbøll","2018","Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial","Diabetes","American Diabetes Association","10.2337/db18-1084-p","https://doi.org/10.2337/db18-1084-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049934","R0049934.pdf","paywalled","other","Cristian Guja","2018","1-Jahresergebnisse der randomisierten, kontrollierten Duration-8-Studie: Wirksamkeit und Verträglichkeit von Depot-Exenatide in Kombination mit täglichem Dapagliflozin gegenüber Monotherapie mit Depot-Exenatide oder Dapagliflozin","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0038-1641915","https://doi.org/10.1055/s-0038-1641915",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02229396"],["5","R0050408","R0050408.pdf","paywalled","other_trial","Guillermo E. Umpierrez","2018","Relative Contribution of Basal and Postprandial Hyperglycemia Stratified by A1C Categories Before and After Treatment Intensification with Dulaglutide","Diabetes","American Diabetes Association","10.2337/db18-1068-p","https://doi.org/10.2337/db18-1068-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050480","R0050480.pdf","paywalled","other_trial","Danny H. Sugimoto","2018","Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%—Analyses from the DUAL Program","Diabetes","American Diabetes Association","10.2337/db18-1092-p","https://doi.org/10.2337/db18-1092-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050610","R0050610.pdf","paywalled","other_trial","Mugdha V. Joglekar","2018","Comparison of Novel MicroRNA and Cell-Free DNA Biomarkers of Beta-Cell Death and Diabetes Progression","Diabetes","American Diabetes Association","10.2337/db18-231-or","https://doi.org/10.2337/db18-231-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051026","R0051026.pdf","paywalled","other_trial","IRENE M. HRAMIAK","2018","Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2018.08.126","https://doi.org/10.1016/j.jcjd.2018.08.126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051252","R0051252.pdf","paywalled","other_trial","Cyrus V Desouza","2018","Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi","Diabetes","American Diabetes Association","10.2337/db18-1093-p","https://doi.org/10.2337/db18-1093-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058147"],["5","R0051467","R0051467.pdf","paywalled","other_trial","Shelby D. Reed","2018","EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus","Diabetes","American Diabetes Association","10.2337/db18-1319-p","https://doi.org/10.2337/db18-1319-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052003","R0052003.pdf","paywalled","other_trial","L.A. Leiter","2018","SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL PROGRAM","Canadian Journal of Cardiology","Elsevier BV","10.1016/j.cjca.2018.07.221","https://doi.org/10.1016/j.cjca.2018.07.221",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052160","R0052160.pdf","paywalled","other_trial","Kathleen Marie Dungan","2018","More Subjects Achieved Composite Reductions of =1% HbA1c, =5% Body Weight, and =5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)","Diabetes","American Diabetes Association","10.2337/db18-129-or","https://doi.org/10.2337/db18-129-or",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052573","R0052573.pdf","paywalled","other_trial","Amy T. Larkin","2018","Cardiometabolic Management—Success of Online CME at Expanding Diabetes Management Past Glycemic Control","Diabetes","American Diabetes Association","10.2337/db18-1217-p","https://doi.org/10.2337/db18-1217-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052621","R0052621.pdf","paywalled","other_trial","Francesco Giorgino","2018","Treatment Effects of Once-Weekly Dulaglutide vs. Insulin Glargine in Patients with Different Baseline Glycemic Patterns (Based on High/Low Fasting or High/Low Postprandial Glucose)—A Post-Hoc Analysis of the AWARD-2 Clinical Trial","Diabetes","American Diabetes Association","10.2337/db18-1007-p","https://doi.org/10.2337/db18-1007-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052696","R0052696.pdf","paywalled","other_trial","Grazia Daniela Femminella","2018","P3‐225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON‐DIABETIC ALZHEIMER'S PATIENTS","Alzheimer s & Dementia","Wiley","10.1016/j.jalz.2018.06.1584","https://doi.org/10.1016/j.jalz.2018.06.1584",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01843075"],["5","R0052820","R0052820.pdf","paywalled","other_trial","Paola Rogliani","2018","Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial",null,"European Respiratory Society","10.1183/13993003.congress-2018.pa4410","https://doi.org/10.1183/13993003.congress-2018.pa4410",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052856","R0052856.pdf","paywalled","other_trial","Robert John Mentz","2018","5257Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL","European Heart Journal","Oxford University Press (OUP)","10.1093/eurheartj/ehy566.5257","https://doi.org/10.1093/eurheartj/ehy566.5257",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053153","R0053153.pdf","paywalled","other","JP Frias","2018","Wirksamkeit und Verträglichkeit von Depot-Exenatide gegenüber Placebo als Add-on zu Insulin glargin bei Typ-2-Diabetes-Patienten mit unzureichender glykämischer Kontrolle unter Basalinsulin: Duration-7-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0038-1641914","https://doi.org/10.1055/s-0038-1641914",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02229383"],["5","R0053226","R0053226.pdf","paywalled","other","Ele Ferrannini","2018","Duration-8-Studie: Mechanismen der glykämischen Kontrolle unter Depot-Exenatide+Dapagliflozin im Vergleich zu den Einzelsubstanzen","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0038-1641910","https://doi.org/10.1055/s-0038-1641910",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02229396"],["5","R0053357","R0053357.pdf","paywalled","other","Ildiko Lingvay","2018","Lower Day-to-Day Fasting Self-Measured Plasma Glucose (SMPG) Variability with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine 100 Units/mL (IGlar U100)","Diabetes","American Diabetes Association","10.2337/db18-1025-p","https://doi.org/10.2337/db18-1025-p",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01952145"],["5","R0053388","R0053388.pdf","paywalled","other_trial","Linda L. Humphrey","2018","World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee","Annals of Internal Medicine","American College of Physicians","10.7326/m18-1148","https://doi.org/10.7326/m18-1148","30178054","https://pubmed.ncbi.nlm.nih.gov/30178054/",null,null],["5","R0007396","R0007396.pdf","paywalled","other_trial","Scheen AJ","2017","Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.03.009","https://doi.org/10.1016/j.diabres.2017.03.009","28402902","https://pubmed.ncbi.nlm.nih.gov/28402902/",null,null],["5","R0008333","R0008333.pdf","paywalled","other_trial","Lovshin JA","2017","Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2017.08.242","https://doi.org/10.1016/j.jcjd.2017.08.242","28942790","https://pubmed.ncbi.nlm.nih.gov/28942790/",null,null],["5","R0008990","R0008990.pdf","paywalled","other_trial","McCarty D","2017","Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028017689878","https://doi.org/10.1177/1060028017689878","28133970","https://pubmed.ncbi.nlm.nih.gov/28133970/",null,null],["5","R0009278","R0009278.pdf","paywalled","other_trial","Østergaard L","2017","Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2017.1313109","https://doi.org/10.1080/17512433.2017.1313109","28349716","https://pubmed.ncbi.nlm.nih.gov/28349716/",null,null],["5","R0009845","R0009845.pdf","paywalled","other_trial","Vedtofte L","2017","Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2017.1288715","https://doi.org/10.1080/14740338.2017.1288715","28150516","https://pubmed.ncbi.nlm.nih.gov/28150516/",null,null],["5","R0010001","R0010001.pdf","paywalled","other_trial","Scheen AJ","2017","Dulaglutide for the treatment of type 2 diabetes.","Expert opinion on biological therapy","Informa UK Limited","10.1080/14712598.2017.1296131","https://doi.org/10.1080/14712598.2017.1296131","28274140","https://pubmed.ncbi.nlm.nih.gov/28274140/",null,null],["5","R0010160","R0010160.pdf","paywalled","other_trial","Sedman T","2017","Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-00199","https://doi.org/10.1210/jc.2017-00199","28379427","https://pubmed.ncbi.nlm.nih.gov/28379427/",null,"ClinicalTrials.gov:NCT02089256; EudraCT:2014-000238-43"],["5","R0010182","R0010182.pdf","paywalled","other_trial","Busch RS","2017","Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2017.1342509","https://doi.org/10.1080/00325481.2017.1342509","28657399","https://pubmed.ncbi.nlm.nih.gov/28657399/",null,null],["5","R0010249","R0010249.pdf","paywalled","other_trial","Leiter LA","2017","[Not Available].","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0043-103969","https://doi.org/10.1055/s-0043-103969","28724168","https://pubmed.ncbi.nlm.nih.gov/28724168/",null,null],["5","R0010310","R0010310.pdf","paywalled","other_trial","Brønden A","2017","Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-016-0499-8","https://doi.org/10.1007/s40262-016-0499-8","28050889","https://pubmed.ncbi.nlm.nih.gov/28050889/",null,null],["5","R0010654","R0010654.pdf","paywalled","other_trial","Leiter LA","2017","Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2017.05.010","https://doi.org/10.1016/j.jdiacomp.2017.05.010","28587789","https://pubmed.ncbi.nlm.nih.gov/28587789/",null,null],["5","R0010737","R0010737.pdf","paywalled","other_trial","Scott LJ","2017","Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-017-0783-4","https://doi.org/10.1007/s40265-017-0783-4","28667587","https://pubmed.ncbi.nlm.nih.gov/28667587/",null,null],["5","R0011388","R0011388.pdf","paywalled","other_trial","Ahrén B","2017","Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2017.02.017","https://doi.org/10.1016/j.diabres.2017.02.017","28284167","https://pubmed.ncbi.nlm.nih.gov/28284167/",null,null],["5","R0011520","R0011520.pdf","paywalled","other_trial","de la Peña A","2017","No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-017-0531-7","https://doi.org/10.1007/s40262-017-0531-7","28357715","https://pubmed.ncbi.nlm.nih.gov/28357715/",null,"ClinicalTrials.gov:NCT01458210; ClinicalTrials.gov:NCT01436201; ClinicalTrials.gov:NCT01432938; ClinicalTrials.gov:NCT01250834"],["5","R0011553","R0011553.pdf","paywalled","other_trial","Singh AK","2017","Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2017.1318061","https://doi.org/10.1080/17512433.2017.1318061","28393583","https://pubmed.ncbi.nlm.nih.gov/28393583/",null,null],["5","R0012344","R0012344.pdf","paywalled","other_trial","Hunt B","2017","Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2017.1301943","https://doi.org/10.1080/13696998.2017.1301943","28294641","https://pubmed.ncbi.nlm.nih.gov/28294641/",null,null],["5","R0012478","R0012478.pdf","paywalled","other_trial","Herbst R","2017","Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-017-0898-8","https://doi.org/10.1007/s11892-017-0898-8","28726152","https://pubmed.ncbi.nlm.nih.gov/28726152/",null,null],["5","R0013323","R0013323.pdf","paywalled","other_trial","Mora PF","2017","CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep161481.ra","https://doi.org/10.4158/ep161481.ra","27819769","https://pubmed.ncbi.nlm.nih.gov/27819769/",null,null],["5","R0014166","R0014166.pdf","paywalled","other_trial","Hocking S","2017","Current and emerging pharmacotherapies for obesity in Australia.","Obesity research & clinical practice","Elsevier BV","10.1016/j.orcp.2017.07.002","https://doi.org/10.1016/j.orcp.2017.07.002","28818558","https://pubmed.ncbi.nlm.nih.gov/28818558/",null,null],["5","R0016027","R0016027.pdf","paywalled","other_trial","Skolnik N","2017","iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2017.1359518","https://doi.org/10.1080/03007995.2017.1359518","28741967","https://pubmed.ncbi.nlm.nih.gov/28741967/",null,null],["5","R0016248","R0016248.pdf","paywalled","other_trial","Bhandari M","2017","Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-017-2770-y","https://doi.org/10.1007/s11695-017-2770-y","28601988","https://pubmed.ncbi.nlm.nih.gov/28601988/",null,null],["5","R0016298","R0016298.pdf","paywalled","other_trial","Sedman T","2017","Liraglutide Treatment May Affect Renin and Aldosterone Release.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/s-0042-109065","https://doi.org/10.1055/s-0042-109065","27300475","https://pubmed.ncbi.nlm.nih.gov/27300475/",null,"ClinicalTrials.gov:NCT02089256"],["5","R0018678","R0018678.pdf","paywalled","narrative_review","Muscogiuri G","2017","Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.","Trends in endocrinology and metabolism: TEM","Elsevier BV","10.1016/j.tem.2016.10.001","https://doi.org/10.1016/j.tem.2016.10.001","27871675","https://pubmed.ncbi.nlm.nih.gov/27871675/",null,"ClinicalTrials.gov:NCT01255163; ClinicalTrials.gov:NCT01469351; ClinicalTrials.gov:NCT01843075"],["5","R0019978","R0019978.pdf","paywalled","other_trial","Vergès B","2017","After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?","Diabetes & metabolism","Elsevier BV","10.1016/s1262-3636(17)30067-8","https://doi.org/10.1016/s1262-3636(17)30067-8","28431669","https://pubmed.ncbi.nlm.nih.gov/28431669/",null,null],["5","R0020336","R0020336.pdf","paywalled","other_trial","Mansur RB","2017","Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Elsevier BV","10.1016/j.euroneuro.2017.08.433","https://doi.org/10.1016/j.euroneuro.2017.08.433","28867303","https://pubmed.ncbi.nlm.nih.gov/28867303/",null,null],["5","R0020634","R0020634.pdf","paywalled","other_trial","Tan X","2017","Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2017.1360274","https://doi.org/10.1080/13543784.2017.1360274","28741970","https://pubmed.ncbi.nlm.nih.gov/28741970/",null,null],["5","R0022304","R0022304.pdf","paywalled","other_trial","Davidson JA","2017","Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2017.1387473","https://doi.org/10.1080/00325481.2017.1387473","29083275","https://pubmed.ncbi.nlm.nih.gov/29083275/",null,null],["5","R0022960","R0022960.pdf","paywalled","other_trial","Mansur RB","2017","Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.","Journal of affective disorders","Elsevier BV","10.1016/j.jad.2016.09.056","https://doi.org/10.1016/j.jad.2016.09.056","27721184","https://pubmed.ncbi.nlm.nih.gov/27721184/",null,null],["5","R0023042","R0023042.pdf","paywalled","other_trial","Scott LJ","2017","Sitagliptin: A Review in Type 2 Diabetes.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-016-0686-9","https://doi.org/10.1007/s40265-016-0686-9","28078647","https://pubmed.ncbi.nlm.nih.gov/28078647/",null,null],["5","R0023173","R0023173.pdf","paywalled","other_trial","Zobel EH","2017","Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.09.016","https://doi.org/10.1016/j.jdiacomp.2016.09.016","27769801","https://pubmed.ncbi.nlm.nih.gov/27769801/",null,null],["5","R0023277","R0023277.pdf","paywalled","other_trial","Singh AK","2017","SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2017.1287562","https://doi.org/10.1080/17512433.2017.1287562","28121469","https://pubmed.ncbi.nlm.nih.gov/28121469/",null,null],["5","R0024186","R0024186.pdf","paywalled","other_trial","Bonnet F","2017","Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2017.04.004","https://doi.org/10.1016/j.diabet.2017.04.004","28522196","https://pubmed.ncbi.nlm.nih.gov/28522196/",null,null],["5","R0025362","R0025362.pdf","paywalled","other_trial","Kuhn A","2017","Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?","Current cardiology reports","Springer Science and Business Media LLC","10.1007/s11886-017-0832-3","https://doi.org/10.1007/s11886-017-0832-3","28251513","https://pubmed.ncbi.nlm.nih.gov/28251513/",null,null],["5","R0025545","R0025545.pdf","paywalled","other_trial","Bergenstal RM","2017","Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2879","https://doi.org/10.1002/dmrr.2879","28032465","https://pubmed.ncbi.nlm.nih.gov/28032465/",null,null],["5","R0025801","R0025801.pdf","paywalled","other_trial","Slomski A","2017","Liraglutide May Reduce Diabetic Kidney Disease.","JAMA","American Medical Association (AMA)","10.1001/jama.2017.15293","https://doi.org/10.1001/jama.2017.15293","29067421","https://pubmed.ncbi.nlm.nih.gov/29067421/",null,null],["5","R0026072","R0026072.pdf","paywalled","protocol","Fadini GP","2017","Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity.","Nutrition, metabolism, and cardiovascular diseases : NMCD","Elsevier BV","10.1016/j.numecd.2017.08.001","https://doi.org/10.1016/j.numecd.2017.08.001","28967594","https://pubmed.ncbi.nlm.nih.gov/28967594/",null,null],["5","R0026695","R0026695.pdf","paywalled","other_trial","Luo Y","2017","Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance.","Clinical science (London, England : 1979)","Portland Press Ltd.","10.1042/cs20160543","https://doi.org/10.1042/cs20160543","27940998","https://pubmed.ncbi.nlm.nih.gov/27940998/",null,null],["5","R0026818","R0026818.pdf","paywalled","other_trial","Bajaj HS","2017","Antihyperglycemic agents and cardiovascular outcomes: recent insights.","Current opinion in cardiology","Ovid Technologies (Wolters Kluwer Health)","10.1097/hco.0000000000000435","https://doi.org/10.1097/hco.0000000000000435","28678048","https://pubmed.ncbi.nlm.nih.gov/28678048/",null,null],["5","R0030839","R0030839.pdf","paywalled","other_trial","Yin Shi-hong","2017","Clinical study progression on efficacy and safety of anti-obesity drugs","Int J Endocrinol Metab",null,"10.3760/cma.j.issn.1673-4157.2017.03.006","https://doi.org/10.3760/cma.j.issn.1673-4157.2017.03.006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032394","R0032394.pdf","paywalled","other_trial","Zeqing Zhang","2017","MOESM1 of Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes","Figshare",null,"10.6084/m9.figshare.c.3706765_d1","https://doi.org/10.6084/m9.figshare.c.3706765_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033351","R0033351.pdf","paywalled","other_trial","Jochen Seufert","2017","Neue Antidiabetika und kardiovaskuläre Outcome-Studien","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0042-121159","https://doi.org/10.1055/s-0042-121159",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034334","R0034334.pdf","paywalled","other_trial","Jódar Esteban","2017","Patient-reported outcomes with IDegLira vs. basal–bolus therapy in type 2 diabetes: DUAL VII trial",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3c39","https://doi.org/10.26226/morressier.59d51847d462b80296ca3c39",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034370","R0034370.pdf","paywalled","other_trial","Vilsboll Tina","2017","Switching to IDegLira is effective regardless of pre-trial insulin dose in patients with T2D uncontrolled on IGlar U100",null,"Morressier","10.26226/morressier.59d51842d462b80296ca3653","https://doi.org/10.26226/morressier.59d51842d462b80296ca3653",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034375","R0034375.pdf","paywalled","other_trial","Nauck Michael","2017","Reduced glycaemic deterioration with long term exposure to liraglutide in the LEADER trial",null,"Morressier","10.26226/morressier.59d51840d462b80296ca2d34","https://doi.org/10.26226/morressier.59d51840d462b80296ca2d34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034384","R0034384.pdf","paywalled","other_trial","von Scholten Bernt-Johan","2017","No increase in calcitonin or development of C-cell malignancy in response to liraglutide in the LEADER trial",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3c0c","https://doi.org/10.26226/morressier.59d51846d462b80296ca3c0c",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034426","R0034426.pdf","paywalled","other_trial","Blonde Lawrence","2017","Trial-level comparisons of iGlarLixi versus IDegLira in the LixiLan and DUAL clinical development programmes",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3bcb","https://doi.org/10.26226/morressier.59d51847d462b80296ca3bcb",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034430","R0034430.pdf","paywalled","other_trial","Li Daisy","2017","A phase I study to investigate the safety, tolerability and pharmacokinetics of a biased GLP-1R antibody Glutazumab",null,"Morressier","10.26226/morressier.59d51845d462b80296ca39f9","https://doi.org/10.26226/morressier.59d51845d462b80296ca39f9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034448","R0034448.pdf","paywalled","other_trial","Jódar Esteban","2017","Efficacy and safety of IDegLira vs. basal–bolus in patients with type 2 diabetes: DUAL VII trial",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3c34","https://doi.org/10.26226/morressier.59d51846d462b80296ca3c34",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034545","R0034545.pdf","paywalled","other_trial","Kidd Catherine","2017","Bioinformatics modelling of baseline characteristics to predict clinical outcomes and responses in the LixiLan-L trial",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3b43","https://doi.org/10.26226/morressier.59d51846d462b80296ca3b43",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034548","R0034548.pdf","paywalled","other_trial","Dhatariya Ketan","2017","Liraglutide impact on diabetic foot ulcers in people with T2D at increased risk of cardiovascular events - LEADER trial",null,"Morressier","10.26226/morressier.59d51849d462b80296ca3147","https://doi.org/10.26226/morressier.59d51849d462b80296ca3147",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034604","R0034604.pdf","paywalled","other_trial","Vilsboll Tina","2017","IDegLira provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V",null,"Morressier","10.26226/morressier.59d51845d462b80296ca34a1","https://doi.org/10.26226/morressier.59d51845d462b80296ca34a1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034676","R0034676.pdf","paywalled","other_trial","Hisae Imazeki","2017","Safety and efficacy of luseogliflozin added to liraglutide in Japanese patients with T2DM: a 52-week clinical trial",null,"Morressier","10.26226/morressier.59d51845d462b80296ca3a92","https://doi.org/10.26226/morressier.59d51845d462b80296ca3a92",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034786","R0034786.pdf","paywalled","other_trial","Nauck Michael","2017","Delayed deterioration in quality of life as measured by EQ-5D with liraglutide in people with T2D in the LEADER trial",null,"Morressier","10.26226/morressier.59d51846d462b80296ca3c11","https://doi.org/10.26226/morressier.59d51846d462b80296ca3c11",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035949","R0035949.pdf","paywalled","other_trial","Chantal Mathieu","2017","Effect of once-weekly Dulaglutide by baseline β-cell function in the AWARD program","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0037-1601749","https://doi.org/10.1055/s-0037-1601749",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037213","R0037213.pdf","paywalled","other_trial","Silvio E. Inzucchi","2017","Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus","Annals of Internal Medicine","American College of Physicians","10.7326/l17-0231","https://doi.org/10.7326/l17-0231","28672385","https://pubmed.ncbi.nlm.nih.gov/28672385/",null,null],["5","R0037786","R0037786.pdf","paywalled","other_trial","Kazuhito Takeda","2017","SP459THE EFFICACY OF TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CHRONIC DIALYSIS PATIENTS WITH DIABETES MELLITUS","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfx149.sp459","https://doi.org/10.1093/ndt/gfx149.sp459",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038778","R0038778.pdf","paywalled","other_trial","Sanjay Kaul","2017","Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831","Diabetes Care","American Diabetes Association","10.2337/dci17-0044","https://doi.org/10.2337/dci17-0044","29162590","https://pubmed.ncbi.nlm.nih.gov/29162590/",null,null],["5","R0039692","R0039692.pdf","paywalled","other_trial","Gerd Heusch","2017","Improving the outcome of primary PCI: protection from reperfusion injury","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvx120","https://doi.org/10.1093/cvr/cvx120","28899004","https://pubmed.ncbi.nlm.nih.gov/28899004/",null,null],["5","R0043960","R0043960.pdf","paywalled","other_trial",null,"2017","THE EFFICACY AND SAFETY OF THE SGLT2 RECEPTOR INHIBITORS IN TRIPLE THERAPY IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8158e668b9000b9f8dd6","https://doi.org/10.26226/morressier.5c3c8158e668b9000b9f8dd6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044012","R0044012.pdf","paywalled","other_trial",null,"2017","DAPAGLIFLOZIN USE IN TRIPLE THERAPY FOR TREATING TYPE 2 DIABETES IN THE ENDOCRINOLOGY UNIT AT IMBANACO MEDICAL CENTER. CALI, COLOMBIA","BiblioBoard Library Catalog (Open Research Library)",null,"10.26226/morressier.5c3c8158e668b9000b9f8dd9","https://doi.org/10.26226/morressier.5c3c8158e668b9000b9f8dd9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047516","R0047516.pdf","paywalled","other_trial","C. Bruce Verchere","2017","Peptide Therapeutics for Weight Loss: Preventing Plasma Pancreatic Polypeptide Proteolysis","Endocrinology","The Endocrine Society","10.1210/en.2017-00393","https://doi.org/10.1210/en.2017-00393","28575431","https://pubmed.ncbi.nlm.nih.gov/28575431/",null,null],["5","R0047704","R0047704.pdf","paywalled","other","Juan P. Frías","2017","Exenatide einmal wöchentlich plus Dapagliflozin einmal täglich versus Exenatide oder Dapagliflozin allein bei Patienten mit Typ 2 Diabetes, für die eine Metformin-Monotherapie nicht ausreichend war (DURATION-8): Eine 28-wöchige, multizentrische, doppelblinde, randomisierte, kontrollierte Phase-3-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0037-1601752","https://doi.org/10.1055/s-0037-1601752",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02229396"],["5","R0048175","R0048175.pdf","paywalled","other_trial","Alla P. Tarasova","2017","EVALUATION OF CARDIOPROTECTIVE EFFECTS OF THE INCRITIN MIMETICS EXENATIDE AND VILDAGLIPTIN IN THE EXPERIMENT","Open Access Repository (Belgorod State National Research University)",null,"10.18413/2313-8971-2017-3-2-57-63","https://doi.org/10.18413/2313-8971-2017-3-2-57-63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049688","R0049688.pdf","paywalled","other_trial","Evan Raff","2017","Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2017.08.018","https://doi.org/10.1016/j.jcjd.2017.08.018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056921","R0056921.pdf","paywalled","other_trial","Kosiborod M","2017","Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2016.08.017","https://doi.org/10.1016/j.jdiacomp.2016.08.017","27839923","https://pubmed.ncbi.nlm.nih.gov/27839923/",null,null],["5","R0006001","R0006001.pdf","paywalled","other_trial","Samson SL","2016","A Plethora of GLP-1 Agonists: Decisions About What to Use and When.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-016-0823-6","https://doi.org/10.1007/s11892-016-0823-6","27766579","https://pubmed.ncbi.nlm.nih.gov/27766579/",null,null],["5","R0008453","R0008453.pdf","paywalled","other_trial","Wilding JP","2016","Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.13021","https://doi.org/10.1111/dme.13021","26525806","https://pubmed.ncbi.nlm.nih.gov/26525806/",null,null],["5","R0008482","R0008482.pdf","paywalled","other_trial","Peng H","2016","Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-016-0728-4","https://doi.org/10.1007/s11892-016-0728-4","27037706","https://pubmed.ncbi.nlm.nih.gov/27037706/",null,null],["5","R0009816","R0009816.pdf","paywalled","other_trial","Athyros VG","2016","Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.","Current vascular pharmacology","Bentham Science Publishers Ltd.","10.2174/1570161114666160909161537","https://doi.org/10.2174/1570161114666160909161537","27633290","https://pubmed.ncbi.nlm.nih.gov/27633290/",null,null],["5","R0009884","R0009884.pdf","paywalled","other_trial","Østergaard L","2016","Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.","Expert review of clinical pharmacology","Informa UK Limited","10.1586/17512433.2016.1121808","https://doi.org/10.1586/17512433.2016.1121808","26573176","https://pubmed.ncbi.nlm.nih.gov/26573176/",null,null],["5","R0010241","R0010241.pdf","paywalled","other_trial","Matthews JE","2016","Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2016.1174565","https://doi.org/10.1080/00325481.2016.1174565","27043162","https://pubmed.ncbi.nlm.nih.gov/27043162/",null,null],["5","R0011902","R0011902.pdf","paywalled","other_trial","Avogaro A","2016","[Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/2214.23894","https://doi.org/10.1714/2214.23894","27093207","https://pubmed.ncbi.nlm.nih.gov/27093207/",null,null],["5","R0012303","R0012303.pdf","paywalled","other_trial","Milicevic Z","2016","Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12640","https://doi.org/10.1111/dom.12640","26847401","https://pubmed.ncbi.nlm.nih.gov/26847401/",null,null],["5","R0014641","R0014641.pdf","paywalled","other_trial","Geiser JS","2016","Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.","Clinical pharmacokinetics","Springer Science and Business Media LLC","10.1007/s40262-015-0338-3","https://doi.org/10.1007/s40262-015-0338-3","26507721","https://pubmed.ncbi.nlm.nih.gov/26507721/",null,null],["5","R0015019","R0015019.pdf","paywalled","other_trial","Mannucci E","2016","[Results of the LEADER study: current evidence and perspectives in research].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/2616.26913","https://doi.org/10.1714/2616.26913","28151519","https://pubmed.ncbi.nlm.nih.gov/28151519/",null,null],["5","R0016761","R0016761.pdf","paywalled","other_trial","Tomlinson B","2016","An overview of new GLP-1 receptor agonists for type 2 diabetes.","Expert opinion on investigational drugs","Informa Healthcare","10.1517/13543784.2016.1123249","https://doi.org/10.1517/13543784.2016.1123249","26587691","https://pubmed.ncbi.nlm.nih.gov/26587691/",null,null],["5","R0017058","R0017058.pdf","paywalled","other_trial","Stinkens K","2016","Insulin degludec + liraglutide: a complementary combination.","Expert opinion on biological therapy","Informa UK Limited","10.1080/14712598.2016.1217328","https://doi.org/10.1080/14712598.2016.1217328","27484310","https://pubmed.ncbi.nlm.nih.gov/27484310/",null,null],["5","R0017788","R0017788.pdf","paywalled","other_trial","Trujillo JM","2016","Cardiovascular Outcomes of New Medications for Type 2 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2016.0295","https://doi.org/10.1089/dia.2016.0295","27835045","https://pubmed.ncbi.nlm.nih.gov/27835045/",null,null],["5","R0019621","R0019621.pdf","paywalled","other_trial","Sharma AK","2016","Albiglutide: Is a better hope against diabetes mellitus?","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2015.12.015","https://doi.org/10.1016/j.biopha.2015.12.015","26796275","https://pubmed.ncbi.nlm.nih.gov/26796275/",null,null],["5","R0020285","R0020285.pdf","paywalled","other_trial","Yu M","2016","Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12624","https://doi.org/10.1111/dom.12624","26691396","https://pubmed.ncbi.nlm.nih.gov/26691396/",null,"ClinicalTrials.gov:NCT00734474; ClinicalTrials.gov:NCT01064687; ClinicalTrials.gov:NCT01075282; ClinicalTrials.gov:NCT01126580; ClinicalTrials.gov:NCT01191268; ClinicalTrials.gov:NCT01624259"],["5","R0020730","R0020730.pdf","paywalled","other","Gastaldelli A","2016","Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.28827","https://doi.org/10.1002/hep.28827","27639082","https://pubmed.ncbi.nlm.nih.gov/27639082/",null,"ClinicalTrials.gov:NCT01588418"],["5","R0022016","R0022016.pdf","paywalled","preclinical","Bang-Berthelsen CH","2016","GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.","Inflammatory bowel diseases","Oxford University Press (OUP)","10.1097/mib.0000000000000847","https://doi.org/10.1097/mib.0000000000000847","27542128","https://pubmed.ncbi.nlm.nih.gov/27542128/",null,null],["5","R0024070","R0024070.pdf","paywalled","other_trial","Cahn A","2016","Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.","Reviews in endocrine & metabolic disorders","Springer Science and Business Media LLC","10.1007/s11154-016-9351-6","https://doi.org/10.1007/s11154-016-9351-6","27106831","https://pubmed.ncbi.nlm.nih.gov/27106831/",null,null],["5","R0024546","R0024546.pdf","paywalled","other_trial","Comee M","2016","The changing therapeutic armamentarium for patients with type 1 diabetes.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000239","https://doi.org/10.1097/med.0000000000000239","26835799","https://pubmed.ncbi.nlm.nih.gov/26835799/",null,null],["5","R0024813","R0024813.pdf","paywalled","other_trial","Cao L","2016","A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.","Neuroreport","Ovid Technologies (Wolters Kluwer Health)","10.1097/wnr.0000000000000548","https://doi.org/10.1097/wnr.0000000000000548","26918675","https://pubmed.ncbi.nlm.nih.gov/26918675/",null,null],["5","R0024912","R0024912.pdf","paywalled","other_trial","Fiorentino TV","2016","[Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?].","Giornale italiano di cardiologia (2006)","Il Pensiero Scientifico Editore","10.1714/2206.23822","https://doi.org/10.1714/2206.23822","27030121","https://pubmed.ncbi.nlm.nih.gov/27030121/",null,null],["5","R0025459","R0025459.pdf","paywalled","other_trial","Wysham C","2016","Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12702","https://doi.org/10.1111/dom.12702","27265893","https://pubmed.ncbi.nlm.nih.gov/27265893/",null,null],["5","R0025755","R0025755.pdf","paywalled","other_trial","Naing S","2016","Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2016.1245093","https://doi.org/10.1080/00325481.2016.1245093","27701934","https://pubmed.ncbi.nlm.nih.gov/27701934/",null,null],["5","R0025903","R0025903.pdf","paywalled","other_trial","Grunberger G","2016","Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.12833","https://doi.org/10.1111/dme.12833","26179454","https://pubmed.ncbi.nlm.nih.gov/26179454/",null,null],["5","R0026061","R0026061.pdf","paywalled","other","Zhang Y","2016","Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways.","Free radical biology & medicine","Elsevier BV","10.1016/j.freeradbiomed.2016.03.035","https://doi.org/10.1016/j.freeradbiomed.2016.03.035","27038735","https://pubmed.ncbi.nlm.nih.gov/27038735/",null,null],["5","R0026361","R0026361.pdf","paywalled","other_trial","Mazurek M","2016","In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.","Annals of internal medicine","American College of Physicians","10.7326/acpjc-2016-165-8-038","https://doi.org/10.7326/acpjc-2016-165-8-038","27750298","https://pubmed.ncbi.nlm.nih.gov/27750298/",null,null],["5","R0027024","R0027024.pdf","paywalled","other_trial","Nuffer W","2016","A Comparison of New Pharmacological Agents for the Treatment of Obesity.","The Annals of pharmacotherapy","SAGE Publications","10.1177/1060028016634351","https://doi.org/10.1177/1060028016634351","26887340","https://pubmed.ncbi.nlm.nih.gov/26887340/",null,null],["5","R0027588","R0027588.pdf","paywalled","narrative_review","McEvoy BW","2016","Missing data in clinical trials for weight management.","Journal of biopharmaceutical statistics","Informa UK Limited","10.1080/10543406.2015.1094814","https://doi.org/10.1080/10543406.2015.1094814","26418188","https://pubmed.ncbi.nlm.nih.gov/26418188/",null,null],["5","R0027740","R0027740.pdf","paywalled","narrative_review","Bray GA","2016","Management of obesity.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(16)00271-3","https://doi.org/10.1016/s0140-6736(16)00271-3","26868660","https://pubmed.ncbi.nlm.nih.gov/26868660/",null,null],["5","R0028771","R0028771.pdf","paywalled","other_trial","Saunders KH","2016","Pharmacotherapy for Obesity.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2016.04.005","https://doi.org/10.1016/j.ecl.2016.04.005","27519128","https://pubmed.ncbi.nlm.nih.gov/27519128/",null,null],["5","R0028793","R0028793.pdf","paywalled","other_trial","Shankar SS","2016","Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00527.2015","https://doi.org/10.1152/ajpendo.00527.2015","27072496","https://pubmed.ncbi.nlm.nih.gov/27072496/",null,"ClinicalTrials.gov:NCT00782418; ClinicalTrials.gov:NCT01055340; ClinicalTrials.gov:NCT01373450"],["5","R0032385","R0032385.pdf","paywalled","protocol","Wiberg, Sebastian","2016","Additional file 2: of GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial","Figshare",null,"10.6084/m9.figshare.c.3629945_d2","https://doi.org/10.6084/m9.figshare.c.3629945_d2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032401","R0032401.pdf","paywalled","protocol","Wiberg, Sebastian","2016","Additional file 1: of GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial","Figshare",null,"10.6084/m9.figshare.c.3629945_d1","https://doi.org/10.6084/m9.figshare.c.3629945_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032402","R0032402.pdf","paywalled","protocol","Z. Htike","2016","MOESM1 of Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)","Figshare",null,"10.6084/m9.figshare.c.3600608_d1","https://doi.org/10.6084/m9.figshare.c.3600608_d1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0033398","R0033398.pdf","paywalled","other_trial","Jochen Seufert","2016","Neue Antidiabetika und kardiovaskuläre Outcome-Studien","Kardiologie up2date","Georg Thieme Verlag KG","10.1055/s-0042-108078","https://doi.org/10.1055/s-0042-108078",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035857","R0035857.pdf","paywalled","other_trial","Hidesuke Kaji","2016","The Current, Emerging and Future Medications for Type 2 Diabetes and Obesity","BENTHAM SCIENCE PUBLISHERS eBooks","BENTHAM SCIENCE PUBLISHERS","10.2174/9781681081854116020003","https://doi.org/10.2174/9781681081854116020003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036062","R0036062.pdf","paywalled","other_trial","M Edwards","2016","Patients with type 2 diabetes mellitus (T2DM) who receive weekly dulaglutide are more likely to achieve fasting blood glucose (FBG) ≤6.7mmol/L at 2 weeks than those treated with metformin, sitagliptin or exenatide twice daily (BID): early and long-term (week 52) data from three clinical studies","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580783","https://doi.org/10.1055/s-0036-1580783",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045038","R0045038.pdf","paywalled","other_trial","Ronnie Aronson","2016","Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial (NCT02058147)","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2016.08.126","https://doi.org/10.1016/j.jcjd.2016.08.126",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02058147"],["5","R0046070","R0046070.pdf","paywalled","other_trial","Wouter Vandevelde","2016","Virtual issue: focus on cardiovascular protection","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvw160","https://doi.org/10.1093/cvr/cvw160","27402319","https://pubmed.ncbi.nlm.nih.gov/27402319/",null,null],["5","R0047199","R0047199.pdf","paywalled","other_trial","Simon N. Jacob","2016","Cardiovascular safety of liraglutide: Pooled analysis of Major adverse cardiovascular events across weight management and Type 2 Diabetes development programs","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580943","https://doi.org/10.1055/s-0036-1580943",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048496","R0048496.pdf","paywalled","other_trial","Ahmad Al-Ajaj","2016","Acute pancreatitis associated with saxagliptin treatment presented by metabolic acidosis","Practical Diabetes","Wiley","10.1002/pdi.2026","https://doi.org/10.1002/pdi.2026",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048786","R0048786.pdf","paywalled","other","Edward Franek","2016","LEADER-8: Patienten mit Typ 2 Diabetes mellitus und hohem kardiovaskulären Risiko: ein Vergleich ost- und westeuropäischer Teilnehmer in der LEADER Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580964","https://doi.org/10.1055/s-0036-1580964",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0048873","R0048873.pdf","paywalled","other","Graydon S. Meneilly","2016","Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706)","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2016.08.127","https://doi.org/10.1016/j.jcjd.2016.08.127",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01798706"],["5","R0049605","R0049605.pdf","paywalled","other","Simon N. Jacob","2016","LEADER-5: Prävalenz und kardiometabolischer Einfluss von Übergewicht und Adipositas bei kardiovaskulären Hochrisikopatienten mit Typ 2 Diabetes mellitus: Baseline-Daten aus der LEADER-Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580965","https://doi.org/10.1055/s-0036-1580965",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0052649","R0052649.pdf","paywalled","other","Sylvia Jacob","2016","LEADER-4: Blutdruckkontrolle bei Patienten mit Typ 2 Diabetes mellitus und hohem kardiovaskulären Risiko: Baseline-Daten aus der LEADER Studie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0036-1580781","https://doi.org/10.1055/s-0036-1580781",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0010745","R0010745.pdf","paywalled","other_trial","Lindamood CA","2015","Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.01.003","https://doi.org/10.1016/j.clinthera.2015.01.003","25659912","https://pubmed.ncbi.nlm.nih.gov/25659912/",null,null],["5","R0011450","R0011450.pdf","paywalled","other_trial","Davidson JA","2015","Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2015.1096743","https://doi.org/10.1080/00325481.2015.1096743","26428031","https://pubmed.ncbi.nlm.nih.gov/26428031/",null,null],["5","R0011794","R0011794.pdf","paywalled","other_trial","Greig SL","2015","Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-015-0448-0","https://doi.org/10.1007/s40265-015-0448-0","26242767","https://pubmed.ncbi.nlm.nih.gov/26242767/",null,null],["5","R0011931","R0011931.pdf","paywalled","other_trial","von Scholten BJ","2015","Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.04.004","https://doi.org/10.1016/j.jdiacomp.2015.04.004","25935863","https://pubmed.ncbi.nlm.nih.gov/25935863/",null,"ClinicalTrials.gov:NCT01499108"],["5","R0012922","R0012922.pdf","paywalled","other_trial","Schauerhamer MB","2015","Once-weekly exenatide as a treatment for Type 2 diabetes.","Expert review of cardiovascular therapy","Informa UK Limited","10.1586/14779072.2015.1038242","https://doi.org/10.1586/14779072.2015.1038242","26000560","https://pubmed.ncbi.nlm.nih.gov/26000560/",null,null],["5","R0013190","R0013190.pdf","paywalled","other_trial","Brønden A","2015","Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.","Expert opinion on drug metabolism & toxicology","Informa Healthcare","10.1517/17425255.2015.1068288","https://doi.org/10.1517/17425255.2015.1068288","26166682","https://pubmed.ncbi.nlm.nih.gov/26166682/",null,null],["5","R0013774","R0013774.pdf","paywalled","other_trial","Jensterle M","2015","Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.","Endocrine research","Informa UK Limited","10.3109/07435800.2014.966385","https://doi.org/10.3109/07435800.2014.966385","25330463","https://pubmed.ncbi.nlm.nih.gov/25330463/",null,"ClinicalTrials.gov:NCT01911468"],["5","R0013881","R0013881.pdf","paywalled","narrative_review","Shaefer CF","2015","User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2015.1090295","https://doi.org/10.1080/00325481.2015.1090295","26371721","https://pubmed.ncbi.nlm.nih.gov/26371721/",null,null],["5","R0014971","R0014971.pdf","paywalled","other_trial","Hirshberg B","2015","Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-015-0663-9","https://doi.org/10.1007/s11892-015-0663-9","26370698","https://pubmed.ncbi.nlm.nih.gov/26370698/",null,null],["5","R0015129","R0015129.pdf","paywalled","other_trial","Iglesias P","2015","Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.","Obesity surgery","Springer Science and Business Media LLC","10.1007/s11695-014-1563-9","https://doi.org/10.1007/s11695-014-1563-9","25589020","https://pubmed.ncbi.nlm.nih.gov/25589020/",null,null],["5","R0017908","R0017908.pdf","paywalled","preclinical","Eriksson L","2015","Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury.","Journal of vascular research","S. Karger AG","10.1159/000381097","https://doi.org/10.1159/000381097","25966620","https://pubmed.ncbi.nlm.nih.gov/25966620/",null,null],["5","R0020195","R0020195.pdf","paywalled","other","Crisci I","2015","GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-015-0800-6","https://doi.org/10.1007/s00592-015-0800-6","26293127","https://pubmed.ncbi.nlm.nih.gov/26293127/",null,null],["5","R0021803","R0021803.pdf","paywalled","other_trial","Jensterle M","2015","Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.","European journal of clinical pharmacology","Springer Science and Business Media LLC","10.1007/s00228-015-1868-1","https://doi.org/10.1007/s00228-015-1868-1","25991051","https://pubmed.ncbi.nlm.nih.gov/25991051/",null,null],["5","R0022208","R0022208.pdf","paywalled","commentary","Lovshin J","2015","GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?","Diabetes","American Diabetes Association","10.2337/db15-0366","https://doi.org/10.2337/db15-0366","26106189","https://pubmed.ncbi.nlm.nih.gov/26106189/",null,null],["5","R0022294","R0022294.pdf","paywalled","other","Malm-Erjefält M","2015","Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.","Molecular pharmaceutics","American Chemical Society (ACS)","10.1021/acs.molpharmaceut.5b00278","https://doi.org/10.1021/acs.molpharmaceut.5b00278","26426736","https://pubmed.ncbi.nlm.nih.gov/26426736/",null,null],["5","R0022325","R0022325.pdf","paywalled","other_trial","Doggrell SA","2015","After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?","Reviews on recent clinical trials","Bentham Science Publishers Ltd.","10.2174/1574887110666150417164603","https://doi.org/10.2174/1574887110666150417164603","25881636","https://pubmed.ncbi.nlm.nih.gov/25881636/",null,null],["5","R0023478","R0023478.pdf","paywalled","narrative_review","Phillips LK","2015","Gastric emptying and glycaemia in health and diabetes mellitus.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/nrendo.2014.202","https://doi.org/10.1038/nrendo.2014.202","25421372","https://pubmed.ncbi.nlm.nih.gov/25421372/",null,null],["5","R0024555","R0024555.pdf","paywalled","other_trial","Vest AR","2015","Incretin-related drug therapy in heart failure.","Current heart failure reports","Springer Science and Business Media LLC","10.1007/s11897-014-0232-6","https://doi.org/10.1007/s11897-014-0232-6","25323108","https://pubmed.ncbi.nlm.nih.gov/25323108/",null,null],["5","R0024812","R0024812.pdf","paywalled","other_trial","Marquard J","2015","Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.","Nature medicine","Springer Science and Business Media LLC","10.1038/nm.3822","https://doi.org/10.1038/nm.3822","25774850","https://pubmed.ncbi.nlm.nih.gov/25774850/",null,null],["5","R0025030","R0025030.pdf","paywalled","other_trial","Liu W","2015","Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease.","European journal of pharmacology","Elsevier BV","10.1016/j.ejphar.2015.08.038","https://doi.org/10.1016/j.ejphar.2015.08.038","26302060","https://pubmed.ncbi.nlm.nih.gov/26302060/",null,null],["5","R0025138","R0025138.pdf","paywalled","other","Seino Y","2015","Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/s-0035-1549875","https://doi.org/10.1055/s-0035-1549875","26039935","https://pubmed.ncbi.nlm.nih.gov/26039935/",null,"ClinicalTrials.gov:NCT00866658"],["5","R0025730","R0025730.pdf","paywalled","other_trial","Roca-Rodríguez Mdel M","2015","Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","Elsevier BV","10.1016/j.endonu.2015.07.004","https://doi.org/10.1016/j.endonu.2015.07.004","26423184","https://pubmed.ncbi.nlm.nih.gov/26423184/",null,null],["5","R0026712","R0026712.pdf","paywalled","other_trial","de Luis DA","2015","Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2015.02.010","https://doi.org/10.1016/j.jdiacomp.2015.02.010","25825013","https://pubmed.ncbi.nlm.nih.gov/25825013/",null,null],["5","R0026748","R0026748.pdf","paywalled","other_trial","Kalra S","2015","Letter to the Editor: Comment on \"The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial\" by Kramer C.K., et al.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-3494","https://doi.org/10.1210/jc.2015-3494","26544663","https://pubmed.ncbi.nlm.nih.gov/26544663/",null,null],["5","R0026753","R0026753.pdf","paywalled","other_trial","Rizvi AA","2015","Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.","Expert opinion on biological therapy","Informa UK Limited","10.1517/14712598.2015.1067299","https://doi.org/10.1517/14712598.2015.1067299","26195184","https://pubmed.ncbi.nlm.nih.gov/26195184/",null,"ClinicalTrials.gov:NCT01715428"],["5","R0027800","R0027800.pdf","paywalled","other_trial","Greene A","2015","Alzheimer's disease and type 2 diabetes: what is the connection?","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","American Society of Consultant Pharmacists","10.4140/tcp.n.2015.112","https://doi.org/10.4140/tcp.n.2015.112","25695417","https://pubmed.ncbi.nlm.nih.gov/25695417/",null,null],["5","R0027905","R0027905.pdf","paywalled","other_trial","Rankin W","2015","Anti-obesity drugs.","Current opinion in lipidology","Ovid Technologies (Wolters Kluwer Health)","10.1097/mol.0000000000000232","https://doi.org/10.1097/mol.0000000000000232","26382553","https://pubmed.ncbi.nlm.nih.gov/26382553/",null,null],["5","R0027970","R0027970.pdf","paywalled","other_trial","Pucci A","2015","New medications for treatment of obesity: metabolic and cardiovascular effects.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2014.11.010","https://doi.org/10.1016/j.cjca.2014.11.010","25661549","https://pubmed.ncbi.nlm.nih.gov/25661549/",null,null],["5","R0031744","R0031744.pdf","paywalled","other_trial","Paula A. Kiberstis","2015","New drug--and new hope--for a losing game","Science","American Association for the Advancement of Science (AAAS)","10.1126/science.349.6247.491-e","https://doi.org/10.1126/science.349.6247.491-e",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032516","R0032516.pdf","paywalled","other_trial","Cada, Dennis J.","2015","Suvorexant","PubMed Central",null,"10.1310/hjp5001-059","https://doi.org/10.1310/hjp5001-059",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035780","R0035780.pdf","paywalled","other_trial",null,"2015","2015 update","Nursing Management","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.numa.0000460000.10626.a4","https://doi.org/10.1097/01.numa.0000460000.10626.a4",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036007","R0036007.pdf","paywalled","other_trial","Elke Heitmann","2015","Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diabetes (T2D) and baseline HbA1c (≥7.5% and ≤11%) above the German recommended HbA1c treatment target range","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549548","https://doi.org/10.1055/s-0035-1549548",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036052","R0036052.pdf","paywalled","other_trial","Martin Füchtenbusch","2015","Weight loss with once-weekly dulaglutide versus insulin glargine, both with insulin lispro (+/- metformin), in patients with type 2 diabetes (T2D) from AWARD-4, stratified by baseline body mass index (BMI) category","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549751","https://doi.org/10.1055/s-0035-1549751",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038611","R0038611.pdf","paywalled","other_trial","Matthew C. Riddle","2015","Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown","Diabetes Care","American Diabetes Association","10.2337/dc14-2649","https://doi.org/10.2337/dc14-2649","25614687","https://pubmed.ncbi.nlm.nih.gov/25614687/",null,null],["5","R0039659","R0039659.pdf","paywalled","other_trial","Helen X. Gao","2015","Diabetes News","Journal of Diabetes","Wiley","10.1111/1753-0407.12350","https://doi.org/10.1111/1753-0407.12350","26575085","https://pubmed.ncbi.nlm.nih.gov/26575085/",null,null],["5","R0044841","R0044841.pdf","paywalled","other_trial","Asher Mullard","2015","Oral GLP1 analogue rounds Phase II corner","Nature Reviews Drug Discovery","Springer Science and Business Media LLC","10.1038/nrd4607","https://doi.org/10.1038/nrd4607",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047040","R0047040.pdf","paywalled","other_trial","Azza Abdulaziz Khalifa","2015","Safety and Efficacy of Liraglutide as an Add-On Therapy to Pre-Existing Anti-Diabetic Regimens during Ramadan, A Prospective Observational Trial","Journal of Diabetes & Metabolism","OMICS Publishing Group","10.4172/2155-6156.1000590","https://doi.org/10.4172/2155-6156.1000590",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047136","R0047136.pdf","paywalled","other_trial","Thomas Fremming Dejgaard","2015","19. Efficacy and Safety of Liraglutide Added to Insulin in Type 1 Diabetes: The LIRA-1 Trial (277-OR)","Nederlands Tijdschrift voor Diabetologie","Springer Science and Business Media LLC","10.1007/s12467-015-0040-y","https://doi.org/10.1007/s12467-015-0040-y",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047146","R0047146.pdf","paywalled","other_trial","Nestoras Nicolas Mathioudakis","2015","Case 68: Insulin Allergy in an Insulin-Requiring Patient","American Diabetes Association eBooks","American Diabetes Association","10.2337/9781580405713.68","https://doi.org/10.2337/9781580405713.68",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047597","R0047597.pdf","paywalled","other_trial","Andrew Kenneth Lansdown","2015","The place of IDegLira in the management of patients with Type 2 diabetes","Diabetes Management","OMICS Publishing Group","10.2217/dmt.15.29","https://doi.org/10.2217/dmt.15.29",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048773","R0048773.pdf","paywalled","other_trial","David C.W. Lau","2015","Abstract #607: Early Responders to Liraglutide 3.0 Mg as Adjunct to Diet and Exercise from the Scale Obesity and Prediabetes Trial: Efficacy and Safety Results","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)42671-0","https://doi.org/10.1016/s1530-891x(20)42671-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048863","R0048863.pdf","paywalled","other","Marcel Trautmann","2015","Anhaltende Blutzuckerkontrolle unter wöchentlichem Depot-Exenatide versus Insulin glargin: Assoziation mit Basischarakteristika und frühem Therapieansprechen","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0035-1549547","https://doi.org/10.1055/s-0035-1549547",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00641056"],["5","R0048942","R0048942.pdf","paywalled","other_trial","Mikhail Borisovich Antsiferov","2015","Triple therapy for obese patients with type 2 diabetes: evaluating effectiveness of the metformin + exenatide + glibenclamide combination","DOAJ (DOAJ: Directory of Open Access Journals)",null,"10.21518/2079-701x-2015-11-66-71","https://doi.org/10.21518/2079-701x-2015-11-66-71",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049629","R0049629.pdf","paywalled","other_trial","Michaël Joubert","2015","P310 Effet de l’exenatide en add-on d’une insulinothérapie intensifiée dans une population de patients diabétiques de type 2: résultats de la phase 2 de l’étude EXEPUMP","Diabetes & Metabolism","Elsevier BV","10.1016/s1262-3636(15)30423-7","https://doi.org/10.1016/s1262-3636(15)30423-7",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050086","R0050086.pdf","paywalled","other_trial","Massimo Pandolfo","2015","Study of beta cells and neurons indicate incretin analogs as potential therapeutics for Friedreich’s ataxia. (S32.005)","Neurology","Ovid Technologies (Wolters Kluwer Health)","10.1212/wnl.84.14_supplement.s32.005","https://doi.org/10.1212/wnl.84.14_supplement.s32.005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050418","R0050418.pdf","paywalled","other_trial","Adam Blackman","2015","Liraglutide 3.0 mg Reduces Severity of Obstructive Sleep Apnea and Body Weight in Individuals with Obesity and Moderate or Severe Disease: SCALE Sleep Apnoea Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2015.01.139","https://doi.org/10.1016/j.jcjd.2015.01.139",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051220","R0051220.pdf","paywalled","other_trial","Ian Douglas Caterson","2015","Abstract 12630: Cardiovascular Safety of Liraglutide: Pooled Analysis of Major Adverse Cardiovascular Events across Weight Management and Type 2 Diabetes Development Programs","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.132.suppl_3.12630","https://doi.org/10.1161/circ.132.suppl_3.12630",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052559","R0052559.pdf","paywalled","other_trial","Robert E. Buckley","2015","Liraglutide Leads to Increased Weight Loss Response in Patients Without Diabetes","MD Conference Express","CLOCKSS Archive","10.1177/1559897715583449","https://doi.org/10.1177/1559897715583449",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054992","R0054992.pdf","paywalled","other_trial","Andrew J. Krentz","2015","Conference report","Cardiovascular Endocrinology","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000064","https://doi.org/10.1097/xce.0000000000000064",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056885","R0056885.pdf","paywalled","other_trial","Jeppesen PB","2015","Gut hormones in the treatment of short-bowel syndrome and intestinal failure.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0000000000000120","https://doi.org/10.1097/med.0000000000000120","25485516","https://pubmed.ncbi.nlm.nih.gov/25485516/",null,null],["5","R0008947","R0008947.pdf","paywalled","other_trial","Kuritzky L","2014","Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2014.10.2821","https://doi.org/10.3810/pgm.2014.10.2821","25414935","https://pubmed.ncbi.nlm.nih.gov/25414935/",null,null],["5","R0016392","R0016392.pdf","paywalled","preclinical","Beiroa D","2014","GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.","Diabetes","American Diabetes Association","10.2337/db14-0302","https://doi.org/10.2337/db14-0302","24917578","https://pubmed.ncbi.nlm.nih.gov/24917578/",null,null],["5","R0016696","R0016696.pdf","paywalled","other_trial","Meece JD","2014","Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action.","The Diabetes educator","SAGE Publications","10.1177/0145721714527802","https://doi.org/10.1177/0145721714527802","24841710","https://pubmed.ncbi.nlm.nih.gov/24841710/",null,null],["5","R0018591","R0018591.pdf","paywalled","other_trial","Young MA","2014","Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2014.11.2836","https://doi.org/10.3810/pgm.2014.11.2836","25387217","https://pubmed.ncbi.nlm.nih.gov/25387217/",null,"ClinicalTrials.gov:NCT00938158; ClinicalTrials.gov:NCT01406262; ClinicalTrials.gov:NCT00537719; ClinicalTrials.gov:NCT01077505; ClinicalTrials.gov:NCT01147731; ClinicalTrials.gov:NCT01147718; ClinicalTrials.gov:NCT01147692; ClinicalTrials.gov:NCT00354536; ClinicalTrials.gov:NCT00394030; ClinicalTrials.gov:NCT00530309; ClinicalTrials.gov:NCT01357889; ClinicalTrials.gov:NCT00518115; ClinicalTrials.gov:NCT01098461; ClinicalTrials.gov:NCT01475734; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527; ClinicalTrials.gov:NCT01098539"],["5","R0020137","R0020137.pdf","paywalled","other_trial","Wilkins JJ","2014","A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.","Journal of clinical pharmacology","Wiley","10.1002/jcph.192","https://doi.org/10.1002/jcph.192","24122776","https://pubmed.ncbi.nlm.nih.gov/24122776/",null,null],["5","R0020155","R0020155.pdf","paywalled","narrative_review","Lee YS","2014","Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2013.09.010","https://doi.org/10.1016/j.metabol.2013.09.010","24140094","https://pubmed.ncbi.nlm.nih.gov/24140094/",null,null],["5","R0021296","R0021296.pdf","paywalled","other_trial","Tibaldi J","2014","Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus.","The American journal of the medical sciences","Elsevier BV","10.1097/maj.0000000000000202","https://doi.org/10.1097/maj.0000000000000202","24469234","https://pubmed.ncbi.nlm.nih.gov/24469234/",null,null],["5","R0021587","R0021587.pdf","paywalled","other_trial","Hölscher C","2014","The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.","Alzheimer's & dementia : the journal of the Alzheimer's Association","Wiley","10.1016/j.jalz.2013.12.009","https://doi.org/10.1016/j.jalz.2013.12.009","24529525","https://pubmed.ncbi.nlm.nih.gov/24529525/",null,null],["5","R0022928","R0022928.pdf","paywalled","other_trial","Singh S","2014","Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-014-0563-4","https://doi.org/10.1007/s11892-014-0563-4","25363547","https://pubmed.ncbi.nlm.nih.gov/25363547/",null,null],["5","R0024447","R0024447.pdf","paywalled","other","Batchuluun B","2014","Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2013.10.025","https://doi.org/10.1016/j.atherosclerosis.2013.10.025","24401231","https://pubmed.ncbi.nlm.nih.gov/24401231/",null,null],["5","R0024470","R0024470.pdf","paywalled","preclinical","McClean PL","2014","Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.","Neuropharmacology","Elsevier BV","10.1016/j.neuropharm.2013.08.005","https://doi.org/10.1016/j.neuropharm.2013.08.005","23973293","https://pubmed.ncbi.nlm.nih.gov/23973293/",null,null],["5","R0026237","R0026237.pdf","paywalled","other_trial","Asche CV","2014","Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.","PharmacoEconomics","Springer Science and Business Media LLC","10.1007/s40273-013-0117-7","https://doi.org/10.1007/s40273-013-0117-7","24357160","https://pubmed.ncbi.nlm.nih.gov/24357160/",null,null],["5","R0026619","R0026619.pdf","paywalled","other_trial","Nagai Y","2014","Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12247","https://doi.org/10.1111/dom.12247","24320758","https://pubmed.ncbi.nlm.nih.gov/24320758/",null,null],["5","R0026857","R0026857.pdf","paywalled","other_trial","Cebra CK","2014","Exenatide dosing in alpacas.","Journal of veterinary pharmacology and therapeutics","Wiley","10.1111/jvp.12103","https://doi.org/10.1111/jvp.12103","24479825","https://pubmed.ncbi.nlm.nih.gov/24479825/",null,null],["5","R0026888","R0026888.pdf","paywalled","other_trial","George M","2014","New and emerging drug molecules against obesity.","Journal of cardiovascular pharmacology and therapeutics","SAGE Publications","10.1177/1074248413501017","https://doi.org/10.1177/1074248413501017","24064009","https://pubmed.ncbi.nlm.nih.gov/24064009/",null,null],["5","R0027050","R0027050.pdf","paywalled","other_trial","Kratz F","2014","A clinical update of using albumin as a drug vehicle - a commentary.","Journal of controlled release : official journal of the Controlled Release Society","Elsevier BV","10.1016/j.jconrel.2014.03.013","https://doi.org/10.1016/j.jconrel.2014.03.013","24637463","https://pubmed.ncbi.nlm.nih.gov/24637463/",null,null],["5","R0027541","R0027541.pdf","paywalled","other_trial","Sahebkar A","2014","Recent advances in pharmacotherapy for hypertriglyceridemia.","Progress in lipid research","Elsevier BV","10.1016/j.plipres.2014.07.002","https://doi.org/10.1016/j.plipres.2014.07.002","25083925","https://pubmed.ncbi.nlm.nih.gov/25083925/",null,null],["5","R0027979","R0027979.pdf","paywalled","preclinical","Yosida M","2014","Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.","Diabetes","American Diabetes Association","10.2337/db13-1868","https://doi.org/10.2337/db13-1868","24824430","https://pubmed.ncbi.nlm.nih.gov/24824430/",null,null],["5","R0028259","R0028259.pdf","paywalled","other","Torekov SS","2014","Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12240","https://doi.org/10.1111/dom.12240","24251641","https://pubmed.ncbi.nlm.nih.gov/24251641/",null,null],["5","R0035436","R0035436.pdf","paywalled","other_trial","Marie-Christine","2014","Crossover, Double-Blind, 52 Week Trial of Liraglutide in Type 1 Diabetes","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2014.07.155","https://doi.org/10.1016/j.jcjd.2014.07.155",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035752","R0035752.pdf","paywalled","other_trial","Lynne Lederman","2014","SCALE Diabetes: Continually Dosed Liraglutide May Aid Weight Loss in T2DM","MD Conference Express","CLOCKSS Archive","10.1177/155989771432013","https://doi.org/10.1177/155989771432013",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01272232"],["5","R0035757","R0035757.pdf","paywalled","other_trial","Daniel Bittner","2014","Exenatide Increases Glucose Uptake in Brain Areas Involved in Glucose Homeostasis and Food Intake","MD Conference Express","CLOCKSS Archive","10.1177/155989771432012","https://doi.org/10.1177/155989771432012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01588418"],["5","R0035897","R0035897.pdf","paywalled","other_trial","D Cheţa","2014","Liraglutide: Present and Future","BENTHAM SCIENCE PUBLISHERS eBooks","BENTHAM SCIENCE PUBLISHERS","10.2174/9781608058563114010005","https://doi.org/10.2174/9781608058563114010005",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044063","R0044063.pdf","paywalled","other_trial","Zachary T. Bloomgarden","2014","Lessons from glargine trials: What is the goal fasting glucose with basal insulin? (来自甘精胰岛素临床试验的经验教训：使用基础胰岛素治疗的空腹血糖目标是什么？)","Journal of Diabetes","Wiley","10.1111/1753-0407.12152","https://doi.org/10.1111/1753-0407.12152","24656089","https://pubmed.ncbi.nlm.nih.gov/24656089/",null,null],["5","R0047197","R0047197.pdf","paywalled","other_trial","Kalliopi Pafili","2014","Treatment of Diabetic Complications","Angiology","SAGE Publications","10.1177/0003319714544948","https://doi.org/10.1177/0003319714544948","25092682","https://pubmed.ncbi.nlm.nih.gov/25092682/",null,null],["5","R0048009","R0048009.pdf","paywalled","other_trial","Yoshie Seino","2014","OP72 COMBINATION THERAPY WITH LIRAGLUTIDE AND INSULIN IN JAPANESE SUBJECTS WITH TYPE 2 DIABETES: THE LIRA-ADD2INSULIN JAPAN TRIAL","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/s0168-8227(14)70278-5","https://doi.org/10.1016/s0168-8227(14)70278-5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048403","R0048403.pdf","paywalled","other_trial","Kelsey Mann","2014","LIRA-ADD2BASAL: Liraglutide Added to Basal Insulin Analogs Improves Glycemic Control","MD Conference Express","CLOCKSS Archive","10.1177/155989771432007","https://doi.org/10.1177/155989771432007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01617434"],["5","R0048838","R0048838.pdf","paywalled","other_trial","Lynne Lederman","2014","IDegLira Offers Advantages over IDeg and Liraglutide in T2DM: DUAL I Results","MD Conference Express","CLOCKSS Archive","10.1177/155989771432015","https://doi.org/10.1177/155989771432015",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049819","R0049819.pdf","paywalled","other_trial","Maria Vinall","2014","Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM","MD Conference Express","CLOCKSS Archive","10.1177/155989771432008","https://doi.org/10.1177/155989771432008",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01624259"],["5","R0049912","R0049912.pdf","paywalled","other_trial","Signe Vinsand Naver","2014","Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist","Clinical Investigation","OMICS Publishing Group","10.4155/cli.14.65","https://doi.org/10.4155/cli.14.65",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049983","R0049983.pdf","paywalled","other_trial","Maria Vinall","2014","Dulaglutide Reduces HbA1c More Than Glargine When Used in Combination with Prandial Insulin","MD Conference Express","CLOCKSS Archive","10.1177/155989771432009","https://doi.org/10.1177/155989771432009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01191268"],["5","R0051254","R0051254.pdf","paywalled","other_trial","Simone Perna","2014","P156: Effects of liraglutide on cardiovascular markers in obese old patients with type 2 diabetes: a pre–post clinical trial","European Geriatric Medicine","Elsevier BV","10.1016/s1878-7649(14)70331-6","https://doi.org/10.1016/s1878-7649(14)70331-6",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051378","R0051378.pdf","paywalled","other_trial","Lynne Lederman","2014","Once Weekly Exenatide is Safe and Effective for Long-term T2DM Treatment","MD Conference Express","CLOCKSS Archive","10.1177/155989771432016","https://doi.org/10.1177/155989771432016",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00308139"],["5","R0051498","R0051498.pdf","paywalled","other_trial","O Adetunji","2014","PO35 Analyse post-hoc des données poolées de deux essais de phase III contrôlés contre placebo AWARD-1 et AWARD-5 (Assessment of weekly administration of LY2189265 in Diabetes – 1 and – 5/ Évaluation de l’administration hebdomadaire de LY2189265 dans le diabète","Diabetes & Metabolism","Elsevier BV","10.1016/s1262-3636(14)72293-1","https://doi.org/10.1016/s1262-3636(14)72293-1",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052193","R0052193.pdf","paywalled","other_trial","Stephen Charles Bain","2014","Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly AdministRation of LY2189265 in Diabetes-1 (AWARD-1) trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0034-1375120","https://doi.org/10.1055/s-0034-1375120",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053034","R0053034.pdf","paywalled","other_trial","Ravi R. Retnakaran","2014","Liraglutide and the Preservation of Pancreatic Beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2014.07.012","https://doi.org/10.1016/j.jcjd.2014.07.012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053335","R0053335.pdf","paywalled","other_trial","Kohei Kaku","2014","PO419 ADDITION OF LIRAGLUTIDE TO OAD MONOTHERAPY IN JAPANESE SUBJECTS WITH TYPE 2 DIABETES: THE LIRA-ADD2OAD JAPAN TRIAL","Diabetes Research and Clinical Practice","Elsevier BV","10.1016/s0168-8227(14)70713-2","https://doi.org/10.1016/s0168-8227(14)70713-2",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0054761","R0054761.pdf","paywalled","other_trial","Andrew McGovern","2014","Profound weight reduction with GLP ‐1 agonist therapy: a delayed hyper‐response","Practical Diabetes","Wiley","10.1002/pdi.1887","https://doi.org/10.1002/pdi.1887",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0010532","R0010532.pdf","paywalled","other_trial","Setji T","2013","Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1586/eem.13.2","https://doi.org/10.1586/eem.13.2","30780810","https://pubmed.ncbi.nlm.nih.gov/30780810/",null,null],["5","R0014063","R0014063.pdf","paywalled","other_trial","Scott LJ","2013","Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","Springer Science and Business Media LLC","10.1007/s40259-013-0057-y","https://doi.org/10.1007/s40259-013-0057-y","23918699","https://pubmed.ncbi.nlm.nih.gov/23918699/",null,null],["5","R0020130","R0020130.pdf","paywalled","other_trial","Gaspari T","2013","The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164113481817","https://doi.org/10.1177/1479164113481817","23673376","https://pubmed.ncbi.nlm.nih.gov/23673376/",null,null],["5","R0020326","R0020326.pdf","paywalled","other_trial","Gastaldelli A","2013","Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2013.05.001","https://doi.org/10.1016/j.metabol.2013.05.001","23831441","https://pubmed.ncbi.nlm.nih.gov/23831441/",null,null],["5","R0023531","R0023531.pdf","paywalled","other","King AB","2013","Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep12232.or","https://doi.org/10.4158/ep12232.or","23186975","https://pubmed.ncbi.nlm.nih.gov/23186975/",null,null],["5","R0024124","R0024124.pdf","paywalled","other_trial","Oda H","2013","Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.","Research in veterinary science","Elsevier BV","10.1016/j.rvsc.2013.04.003","https://doi.org/10.1016/j.rvsc.2013.04.003","23632200","https://pubmed.ncbi.nlm.nih.gov/23632200/",null,null],["5","R0025310","R0025310.pdf","paywalled","other_trial","ThanThan S","2013","Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.","Domestic animal endocrinology","Elsevier BV","10.1016/j.domaniend.2012.09.003","https://doi.org/10.1016/j.domaniend.2012.09.003","23122871","https://pubmed.ncbi.nlm.nih.gov/23122871/",null,null],["5","R0025774","R0025774.pdf","paywalled","other_trial","Fass AD","2013","Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-013-0023-6","https://doi.org/10.1007/s12325-013-0023-6","23605247","https://pubmed.ncbi.nlm.nih.gov/23605247/",null,null],["5","R0026373","R0026373.pdf","paywalled","other_trial","Abuannadi M","2013","Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep12196.or","https://doi.org/10.4158/ep12196.or","23186969","https://pubmed.ncbi.nlm.nih.gov/23186969/",null,null],["5","R0026419","R0026419.pdf","paywalled","other_trial","Karagianni P","2013","Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.","Advances in medical sciences","Elsevier BV","10.2478/v10039-012-0078-7","https://doi.org/10.2478/v10039-012-0078-7","23640946","https://pubmed.ncbi.nlm.nih.gov/23640946/",null,null],["5","R0026522","R0026522.pdf","paywalled","other_trial","Cui YM","2013","Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.","Journal of diabetes","Wiley","10.1111/1753-0407.12020","https://doi.org/10.1111/1753-0407.12020","23332026","https://pubmed.ncbi.nlm.nih.gov/23332026/",null,null],["5","R0026707","R0026707.pdf","paywalled","other_trial","Daly SC","2013","Exenatide in acute ischemic stroke.","International journal of stroke : official journal of the International Stroke Society","SAGE Publications","10.1111/ijs.12073","https://doi.org/10.1111/ijs.12073","24024920","https://pubmed.ncbi.nlm.nih.gov/24024920/",null,null],["5","R0026835","R0026835.pdf","paywalled","other_trial","Defronzo RA","2013","Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.","Hospital practice (1995)","Informa UK Limited","10.3810/hp.2013.04.1062","https://doi.org/10.3810/hp.2013.04.1062","23680744","https://pubmed.ncbi.nlm.nih.gov/23680744/",null,null],["5","R0027161","R0027161.pdf","paywalled","other_trial","Iwao T","2013","Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2012.07.001","https://doi.org/10.1016/j.jdiacomp.2012.07.001","22863615","https://pubmed.ncbi.nlm.nih.gov/22863615/",null,null],["5","R0027788","R0027788.pdf","paywalled","preclinical","Kissow H","2013","Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.","Gut","BMJ","10.1136/gutjnl-2012-303280","https://doi.org/10.1136/gutjnl-2012-303280","23086829","https://pubmed.ncbi.nlm.nih.gov/23086829/",null,null],["5","R0027877","R0027877.pdf","paywalled","other_trial","Taylor JR","2013","New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.12.012","https://doi.org/10.1016/j.clinthera.2012.12.012","23328274","https://pubmed.ncbi.nlm.nih.gov/23328274/",null,null],["5","R0031414","R0031414.pdf","paywalled","other_trial","Kavitha Dileepan","2013","Type 2 Diabetes Mellitus in Children and Adolescents","Pediatrics in Review","American Academy of Pediatrics (AAP)","10.1542/pir.34.12.541","https://doi.org/10.1542/pir.34.12.541","24295815","https://pubmed.ncbi.nlm.nih.gov/24295815/",null,null],["5","R0035682","R0035682.pdf","paywalled","other_trial","M. Mosley","2013","LEADER Study: Testing the Cardiovascular Safety of Liraglutide","MD Conference Express","CLOCKSS Archive","10.1177/155989771317011","https://doi.org/10.1177/155989771317011",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0035689","R0035689.pdf","paywalled","other_trial","E. Hitt","2013","Albiglutide Superior to Sitagliptin and Glimepiride in T2DM","MD Conference Express","CLOCKSS Archive","10.1177/155989771317006","https://doi.org/10.1177/155989771317006",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00838903"],["5","R0038059","R0038059.pdf","paywalled","other_trial",null,"2013","Corrigendum","Expert Review of Endocrinology & Metabolism","Informa UK Limited","10.1586/eem.13.19","https://doi.org/10.1586/eem.13.19","30780816","https://pubmed.ncbi.nlm.nih.gov/30780816/",null,null],["5","R0039270","R0039270.pdf","paywalled","other_trial","Sarah Edwards","2013","Editorial: Tamiflu and the open data campaign","Research Ethics","SAGE Publications","10.1177/1747016113502276","https://doi.org/10.1177/1747016113502276",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048633","R0048633.pdf","paywalled","other_trial","Sophia M Rössner","2013","The obese uremic patient: a newcomer in the nephrology clinic?","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gft348","https://doi.org/10.1093/ndt/gft348","24049106","https://pubmed.ncbi.nlm.nih.gov/24049106/",null,null],["5","R0052015","R0052015.pdf","paywalled","other_trial","Brian D. Hoyle","2013","DURATION-3 Trial Results","MD Conference Express","CLOCKSS Archive","10.1177/155989771311012","https://doi.org/10.1177/155989771311012",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00641056"],["5","R0055064","R0055064.pdf","paywalled","other_trial","Sean N. Wharton","2013","Consistent Reduction of Postprandial Glucagon and Insulin by Lixisenatide in the GetGoal Clinical Trial Program","Canadian Journal of Diabetes","Elsevier BV","10.1016/j.jcjd.2013.08.108","https://doi.org/10.1016/j.jcjd.2013.08.108",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0011510","R0011510.pdf","paywalled","other_trial","Vilsbøll T","2012","Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01579.x","https://doi.org/10.1111/j.1463-1326.2012.01579.x","22405268","https://pubmed.ncbi.nlm.nih.gov/22405268/",null,null],["5","R0016249","R0016249.pdf","paywalled","other_trial","Gough SC","2012","Liraglutide: from clinical trials to clinical practice.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01576.x","https://doi.org/10.1111/j.1463-1326.2012.01576.x","22405267","https://pubmed.ncbi.nlm.nih.gov/22405267/",null,null],["5","R0017183","R0017183.pdf","paywalled","other_trial","Bode B","2012","An overview of the pharmacokinetics, efficacy and safety of liraglutide.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2011.12.015","https://doi.org/10.1016/j.diabres.2011.12.015","22245694","https://pubmed.ncbi.nlm.nih.gov/22245694/",null,null],["5","R0017610","R0017610.pdf","paywalled","narrative_review","Lind M","2012","Incretin therapy and its effect on body weight in patients with diabetes.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2012.04.006","https://doi.org/10.1016/j.pcd.2012.04.006","22613745","https://pubmed.ncbi.nlm.nih.gov/22613745/",null,null],["5","R0018514","R0018514.pdf","paywalled","other_trial","Iványi T","2012","Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.04.022","https://doi.org/10.1016/j.clinthera.2012.04.022","22608106","https://pubmed.ncbi.nlm.nih.gov/22608106/",null,"ClinicalTrials.gov:NCT00044668"],["5","R0018728","R0018728.pdf","paywalled","other_trial","Norwood P","2012","Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2012.09.007","https://doi.org/10.1016/j.clinthera.2012.09.007","23031623","https://pubmed.ncbi.nlm.nih.gov/23031623/",null,"ClinicalTrials.gov:NCT00753896"],["5","R0019316","R0019316.pdf","paywalled","preclinical","Erdogdu Ö","2012","Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells.","Biochemical and biophysical research communications","Elsevier BV","10.1016/j.bbrc.2012.02.106","https://doi.org/10.1016/j.bbrc.2012.02.106","22390929","https://pubmed.ncbi.nlm.nih.gov/22390929/",null,null],["5","R0019565","R0019565.pdf","paywalled","case_report","Buysschaert M","2012","Improvement of psoriasis during exenatide treatment in a patient with diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2011.11.004","https://doi.org/10.1016/j.diabet.2011.11.004","22227407","https://pubmed.ncbi.nlm.nih.gov/22227407/",null,null],["5","R0021844","R0021844.pdf","paywalled","other","Lind M","2012","Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2011.09.002","https://doi.org/10.1016/j.pcd.2011.09.002","22015237","https://pubmed.ncbi.nlm.nih.gov/22015237/",null,null],["5","R0022625","R0022625.pdf","paywalled","other_trial","Bush M","2012","Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2012.11.2613","https://doi.org/10.3810/pgm.2012.11.2613","23322139","https://pubmed.ncbi.nlm.nih.gov/23322139/",null,null],["5","R0023711","R0023711.pdf","paywalled","other","Ingwersen SH","2012","Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.","Journal of clinical pharmacology","Wiley","10.1177/0091270011430504","https://doi.org/10.1177/0091270011430504","22174428","https://pubmed.ncbi.nlm.nih.gov/22174428/",null,null],["5","R0024811","R0024811.pdf","paywalled","other_trial","Elsadek B","2012","Impact of albumin on drug delivery--new applications on the horizon.","Journal of controlled release : official journal of the Controlled Release Society","Elsevier BV","10.1016/j.jconrel.2011.09.069","https://doi.org/10.1016/j.jconrel.2011.09.069","21959118","https://pubmed.ncbi.nlm.nih.gov/21959118/",null,null],["5","R0026474","R0026474.pdf","paywalled","other","Fineman MS","2012","Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2012.01561.x","https://doi.org/10.1111/j.1463-1326.2012.01561.x","22236356","https://pubmed.ncbi.nlm.nih.gov/22236356/",null,"ClinicalTrials.gov:NCT00035984; ClinicalTrials.gov:NCT00039013; ClinicalTrials.gov:NCT00039026; ClinicalTrials.gov:NCT00044668; ClinicalTrials.gov:NCT00082381; ClinicalTrials.gov:NCT00082407; ClinicalTrials.gov:NCT00099320; ClinicalTrials.gov:NCT00099333; ClinicalTrials.gov:NCT00099619; ClinicalTrials.gov:NCT00111540; ClinicalTrials.gov:NCT00135330; ClinicalTrials.gov:NCT00308139; ClinicalTrials.gov:NCT00324363; ClinicalTrials.gov:NCT00381342; ClinicalTrials.gov:NCT00382239; ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT00877890"],["5","R0026800","R0026800.pdf","paywalled","other_trial","Franks AS","2012","Pancreatitis: a potential complication of liraglutide?","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1q789","https://doi.org/10.1345/aph.1q789","23136352","https://pubmed.ncbi.nlm.nih.gov/23136352/",null,null],["5","R0027420","R0027420.pdf","paywalled","other_trial","Pujante Alarcón P","2012","[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].","Medicina clinica","Elsevier BV","10.1016/j.medcli.2011.10.025","https://doi.org/10.1016/j.medcli.2011.10.025","22209597","https://pubmed.ncbi.nlm.nih.gov/22209597/",null,null],["5","R0028019","R0028019.pdf","paywalled","other_trial","Morel O","2012","Pharmacological approaches to reperfusion therapy.","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvs114","https://doi.org/10.1093/cvr/cvs114","22514248","https://pubmed.ncbi.nlm.nih.gov/22514248/",null,null],["5","R0028070","R0028070.pdf","paywalled","other_trial","Kratz F","2012","Clinical impact of serum proteins on drug delivery.","Journal of controlled release : official journal of the Controlled Release Society","Elsevier BV","10.1016/j.jconrel.2011.11.028","https://doi.org/10.1016/j.jconrel.2011.11.028","22155554","https://pubmed.ncbi.nlm.nih.gov/22155554/",null,null],["5","R0031317","R0031317.pdf","paywalled","other_trial","Paul A. Burke","2012","Industry Update: the Latest Developments in Therapeutic Delivery","Therapeutic Delivery","Informa UK Limited","10.4155/tde.12.91","https://doi.org/10.4155/tde.12.91",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031347","R0031347.pdf","paywalled","other_trial",null,"2012","Neuer GLP-1-Agonist in Phase 3 erfolgreich","Info Diabetologie","Springer Science and Business Media LLC","10.1007/s15034-012-0313-0","https://doi.org/10.1007/s15034-012-0313-0",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031483","R0031483.pdf","paywalled","other_trial","Miles Fisher","2012","Drugs for diabetes: part 9 prescribing for patients with cardiac disease","British Journal of Cardiology","Medinews (Cardiology), Ltd.","10.5837/bjc.2012.017","https://doi.org/10.5837/bjc.2012.017",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031558","R0031558.pdf","paywalled","other_trial","Raja Taunk","2012","Liraglutide-Induced Acute Pancreatitis","The American Journal of Gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.14309/00000434-201210001-00744","https://doi.org/10.14309/00000434-201210001-00744",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035952","R0035952.pdf","paywalled","other_trial","Ping Feng","2012","A multi-center clinical study of liraglutide in the therapy of Chinese patients with type 2 diabetes","Intern J Endocrinol Metab",null,"10.3760/cma.j.issn.1673-4157.2012.04.001","https://doi.org/10.3760/cma.j.issn.1673-4157.2012.04.001",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038031","R0038031.pdf","paywalled","other_trial",null,"2012","Journal of Diabetes NEWS","Journal of Diabetes","Wiley","10.1111/1753-0407.12018","https://doi.org/10.1111/1753-0407.12018",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043867","R0043867.pdf","paywalled","other_trial","Ma'en Al‐Mrayat","2012","Prolonged release exenatide gets the go‐ahead from NICE","Practical Diabetes","Wiley","10.1002/pdi.1664","https://doi.org/10.1002/pdi.1664",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047887","R0047887.pdf","paywalled","other_trial","LISA M. JARVIS","2012","Pharmaceuticals: GlaxoSmithKline offers $2.6 billion to buy Human Genome Sciences","Chemical & Engineering News","American Chemical Society (ACS)","10.1021/cen-09017-notw5","https://doi.org/10.1021/cen-09017-notw5",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049047","R0049047.pdf","paywalled","other_trial","Dennis J. Cada","2012","Lucinactant","Hospital Pharmacy","SAGE Publications","10.1310/hpj4710-788","https://doi.org/10.1310/hpj4710-788",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051019","R0051019.pdf","paywalled","other_trial","Dennis J. Cada","2012","Aflibercept","Hospital Pharmacy","SAGE Publications","10.1310/hpj4705-375","https://doi.org/10.1310/hpj4705-375",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051816","R0051816.pdf","paywalled","other_trial","Robert E. Buckley","2012","Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss through 4 Years","MD Conference Express","CLOCKSS Archive","10.1177/155989771216004","https://doi.org/10.1177/155989771216004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00308139"],["5","R0052712","R0052712.pdf","paywalled","other_trial","Dennis J. Cada","2012","Exenatide Extended-Release Injection","Hospital Pharmacy","SAGE Publications","10.1310/hpj4708-633","https://doi.org/10.1310/hpj4708-633",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052919","R0052919.pdf","paywalled","other","Matthew D. Reaney","2012","Therapie-assoziierte Faktoren bei Patienten mit Typ-2-Diabetes, die erstmalig mit einem injizierbaren Antidiabetikum behandelt werden sowie deren Behandlungsergebnisse nach 6 Monaten: Die CHOICE-Studie in Deutschland","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0031-1283989","https://doi.org/10.1055/s-0031-1283989",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00635492"],["5","R0054362","R0054362.pdf","paywalled","other_trial","Timothy Reid","2012","Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence","Clinical Diabetes","American Diabetes Association","10.2337/diaclin.30.1.3","https://doi.org/10.2337/diaclin.30.1.3",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0010472","R0010472.pdf","paywalled","other_trial","Madsbad S","2011","An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01357.x","https://doi.org/10.1111/j.1463-1326.2011.01357.x","21208359","https://pubmed.ncbi.nlm.nih.gov/21208359/",null,null],["5","R0015347","R0015347.pdf","paywalled","other_trial","Davies MJ","2011","Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01330.x","https://doi.org/10.1111/j.1463-1326.2010.01330.x","21205109","https://pubmed.ncbi.nlm.nih.gov/21205109/",null,null],["5","R0017232","R0017232.pdf","paywalled","other_trial","Buse JB","2011","Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2010-2822","https://doi.org/10.1210/jc.2010-2822","21450987","https://pubmed.ncbi.nlm.nih.gov/21450987/",null,"ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00331851; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00395746; ClinicalTrials.gov:NCT00518882; ClinicalTrials.gov:NCT00614120"],["5","R0019369","R0019369.pdf","paywalled","other_trial","Repas T","2011","Next-generation GLP-1 therapy: an introduction to liraglutide.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2011.09.2480","https://doi.org/10.3810/pgm.2011.09.2480","21904107","https://pubmed.ncbi.nlm.nih.gov/21904107/",null,null],["5","R0019892","R0019892.pdf","paywalled","narrative_review","Christensen M","2011","Lixisenatide for type 2 diabetes mellitus.","Expert opinion on investigational drugs","Informa Healthcare","10.1517/13543784.2011.562191","https://doi.org/10.1517/13543784.2011.562191","21391833","https://pubmed.ncbi.nlm.nih.gov/21391833/",null,null],["5","R0020062","R0020062.pdf","paywalled","narrative_review","Nauck MA","2011","Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2010.11.002","https://doi.org/10.1016/j.amjmed.2010.11.002","21194578","https://pubmed.ncbi.nlm.nih.gov/21194578/",null,null],["5","R0020302","R0020302.pdf","paywalled","other_trial","Crasto W","2011","An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.","Drugs of today (Barcelona, Spain : 1998)","Portico","10.1358/dot.2011.47.11.1688575","https://doi.org/10.1358/dot.2011.47.11.1688575","22146227","https://pubmed.ncbi.nlm.nih.gov/22146227/",null,null],["5","R0022774","R0022774.pdf","paywalled","other_trial","Grant P","2011","Psychological and quality of life changes in patients using GLP-1 analogues.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2011.03.002","https://doi.org/10.1016/j.jdiacomp.2011.03.002","21601480","https://pubmed.ncbi.nlm.nih.gov/21601480/",null,null],["5","R0023334","R0023334.pdf","paywalled","other_trial","McFarland MS","2011","Place in therapy for liraglutide and saxagliptin for type 2 diabetes.","Southern medical journal","Southern Medical Association","10.1097/smj.0b013e318215fc7a","https://doi.org/10.1097/smj.0b013e318215fc7a","21886033","https://pubmed.ncbi.nlm.nih.gov/21886033/",null,null],["5","R0023335","R0023335.pdf","paywalled","case_report","Seetho IW","2011","Treating diabetes mellitus in Prader-Willi syndrome with Exenatide.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2010.12.009","https://doi.org/10.1016/j.diabres.2010.12.009","21227526","https://pubmed.ncbi.nlm.nih.gov/21227526/",null,null],["5","R0023463","R0023463.pdf","paywalled","other","Kapitza C","2011","Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.","Journal of clinical pharmacology","Wiley","10.1177/0091270010374474","https://doi.org/10.1177/0091270010374474","20671294","https://pubmed.ncbi.nlm.nih.gov/20671294/",null,null],["5","R0024254","R0024254.pdf","paywalled","other_trial","Toth PP","2011","Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.","Postgraduate medicine","Informa UK Limited","10.3810/pgm.2011.07.2303","https://doi.org/10.3810/pgm.2011.07.2303","21680988","https://pubmed.ncbi.nlm.nih.gov/21680988/",null,null],["5","R0024324","R0024324.pdf","paywalled","other_trial","Yan P","2011","Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2011.02.030","https://doi.org/10.1016/j.diabres.2011.02.030","21458097","https://pubmed.ncbi.nlm.nih.gov/21458097/",null,null],["5","R0024740","R0024740.pdf","paywalled","other","Sathyanarayana P","2011","Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.","Obesity (Silver Spring, Md.)","Wiley","10.1038/oby.2011.152","https://doi.org/10.1038/oby.2011.152","21660077","https://pubmed.ncbi.nlm.nih.gov/21660077/",null,null],["5","R0024859","R0024859.pdf","paywalled","other","Kunkel D","2011","Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.","Neurogastroenterology and motility","Wiley","10.1111/j.1365-2982.2011.01723.x","https://doi.org/10.1111/j.1365-2982.2011.01723.x","21557790","https://pubmed.ncbi.nlm.nih.gov/21557790/",null,null],["5","R0025184","R0025184.pdf","paywalled","other_trial","Ghatak SB","2011","Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/157339911797415648","https://doi.org/10.2174/157339911797415648","21916836","https://pubmed.ncbi.nlm.nih.gov/21916836/",null,null],["5","R0026273","R0026273.pdf","paywalled","other_trial","Peskin BR","2011","Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2011.01430.x","https://doi.org/10.1111/j.1463-1326.2011.01430.x","21624032","https://pubmed.ncbi.nlm.nih.gov/21624032/",null,null],["5","R0026573","R0026573.pdf","paywalled","narrative_review","Torekov SS","2011","Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/j.1467-789x.2011.00860.x","https://doi.org/10.1111/j.1467-789x.2011.00860.x","21401851","https://pubmed.ncbi.nlm.nih.gov/21401851/",null,null],["5","R0026916","R0026916.pdf","paywalled","other","Sze L","2011","Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2011-0038","https://doi.org/10.1210/jc.2011-0038","21632815","https://pubmed.ncbi.nlm.nih.gov/21632815/",null,null],["5","R0026976","R0026976.pdf","paywalled","other_trial","Irace C","2011","Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2011.0096","https://doi.org/10.1089/dia.2011.0096","21751893","https://pubmed.ncbi.nlm.nih.gov/21751893/",null,null],["5","R0027115","R0027115.pdf","paywalled","other_trial","Mori Y","2011","Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2011.0137","https://doi.org/10.1089/dia.2011.0137","21877924","https://pubmed.ncbi.nlm.nih.gov/21877924/",null,null],["5","R0027177","R0027177.pdf","paywalled","other_trial","González-Ortiz M","2011","Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.","Metabolic syndrome and related disorders","SAGE Publications","10.1089/met.2010.0025","https://doi.org/10.1089/met.2010.0025","20874425","https://pubmed.ncbi.nlm.nih.gov/20874425/",null,null],["5","R0027201","R0027201.pdf","paywalled","other","Morrow L","2011","Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2010.01322.x","https://doi.org/10.1111/j.1463-1326.2010.01322.x","21114606","https://pubmed.ncbi.nlm.nih.gov/21114606/",null,null],["5","R0027386","R0027386.pdf","paywalled","case_report","Cyganek K","2011","Liraglutide therapy in Prader-Willi syndrome.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/j.1464-5491.2011.03280.x","https://doi.org/10.1111/j.1464-5491.2011.03280.x","21388446","https://pubmed.ncbi.nlm.nih.gov/21388446/",null,null],["5","R0027423","R0027423.pdf","paywalled","other","Varanasi A","2011","Liraglutide as additional treatment for type 1 diabetes.","European journal of endocrinology","Oxford University Press (OUP)","10.1530/eje-11-0330","https://doi.org/10.1530/eje-11-0330","21646283","https://pubmed.ncbi.nlm.nih.gov/21646283/",null,null],["5","R0027840","R0027840.pdf","paywalled","other_trial","Bourdel-Marchasson I","2011","Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.","Hospital practice (1995)","Informa UK Limited","10.3810/hp.2011.02.369","https://doi.org/10.3810/hp.2011.02.369","21441754","https://pubmed.ncbi.nlm.nih.gov/21441754/",null,null],["5","R0027864","R0027864.pdf","paywalled","protocol","Bradley C","2011","PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus--study design.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2011.04.004","https://doi.org/10.1016/j.pcd.2011.04.004","21752743","https://pubmed.ncbi.nlm.nih.gov/21752743/",null,"ClinicalTrials.gov:NCT00916513"],["5","R0034476","R0034476.pdf","paywalled","other_trial","N. Krasner","2011","Abstract 9995: Glucagon-Like-Peptide-1 (GLP-1) Activates AMP-Activated Protein Kinase (AMPK) and Diminishes Inflammation in Human Aortic Endothelial Cells (HAECs)","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circ.124.suppl_21.a9995","https://doi.org/10.1161/circ.124.suppl_21.a9995",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038791","R0038791.pdf","paywalled","other_trial","Bruce W. Bode","2011","Design, findings and implications of the liraglutide Phase III clinical trial program","Clinical Investigation","OMICS Publishing Group","10.4155/cli.11.166","https://doi.org/10.4155/cli.11.166",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047777","R0047777.pdf","paywalled","other","Robert E. Buckley","2011","IV Exenatide Has the Same Efficacy as Insulin in C ICU Patients, without Inducing Hypoglycemia","MD Conference Express","CLOCKSS Archive","10.1177/155989771108003","https://doi.org/10.1177/155989771108003",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00736229"],["5","R0050045","R0050045.pdf","paywalled","other_trial","Mikkel Christensen","2011","The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist","Expert Review of Endocrinology & Metabolism","Informa UK Limited","10.1586/eem.11.30","https://doi.org/10.1586/eem.11.30",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050287","R0050287.pdf","paywalled","other_trial","Robert E. Buckley","2011","Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6)","MD Conference Express","CLOCKSS Archive","10.1177/155989771111007","https://doi.org/10.1177/155989771111007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01029886"],["5","R0051442","R0051442.pdf","paywalled","other_trial","Armstrong Mj","2011","Auswirkung einer 2-jährigen Liraglutid-Behandlung auf bestehende Fettlebererkrankungen bei Patienten mit Typ 2 Diabetes: Auswertung der LEAD-2-Verlängerungsstudie","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-0031-1277317","https://doi.org/10.1055/s-0031-1277317",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0018061","R0018061.pdf","paywalled","other_trial","Peters A","2010","Incretin-based therapies: review of current clinical trial data.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2009.12.007","https://doi.org/10.1016/j.amjmed.2009.12.007","20206729","https://pubmed.ncbi.nlm.nih.gov/20206729/",null,null],["5","R0019973","R0019973.pdf","paywalled","other_trial","Gadsby R","2010","The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2010.03.003","https://doi.org/10.1016/j.pcd.2010.03.003","20418194","https://pubmed.ncbi.nlm.nih.gov/20418194/",null,null],["5","R0021148","R0021148.pdf","paywalled","narrative_review","Bradley DP","2010","Exenatide and weight loss.","Nutrition (Burbank, Los Angeles County, Calif.)","Elsevier BV","10.1016/j.nut.2009.07.008","https://doi.org/10.1016/j.nut.2009.07.008","20152707","https://pubmed.ncbi.nlm.nih.gov/20152707/",null,null],["5","R0021716","R0021716.pdf","paywalled","other_trial","Lee WC","2010","Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2010.08.010","https://doi.org/10.1016/j.clinthera.2010.08.010","21194600","https://pubmed.ncbi.nlm.nih.gov/21194600/",null,null],["5","R0022690","R0022690.pdf","paywalled","other_trial","Werner U","2010","Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.","Regulatory peptides","Elsevier BV","10.1016/j.regpep.2010.05.008","https://doi.org/10.1016/j.regpep.2010.05.008","20570597","https://pubmed.ncbi.nlm.nih.gov/20570597/",null,null],["5","R0022961","R0022961.pdf","paywalled","other","Erdogdu O","2010","Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.","Molecular and cellular endocrinology","Elsevier BV","10.1016/j.mce.2010.04.022","https://doi.org/10.1016/j.mce.2010.04.022","20452396","https://pubmed.ncbi.nlm.nih.gov/20452396/",null,null],["5","R0024291","R0024291.pdf","paywalled","other_trial","Hellström PM","2010","Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.","Vitamins and hormones","Elsevier","10.1016/b978-0-12-381517-0.00012-6","https://doi.org/10.1016/b978-0-12-381517-0.00012-6","21094906","https://pubmed.ncbi.nlm.nih.gov/21094906/",null,null],["5","R0024964","R0024964.pdf","paywalled","other_trial","Billiones R","2010","Saxagliptin in type 2 diabetes.","Drugs of today (Barcelona, Spain : 1998)","Portico","10.1358/dot.2010.46.2.1464700","https://doi.org/10.1358/dot.2010.46.2.1464700","20393638","https://pubmed.ncbi.nlm.nih.gov/20393638/",null,null],["5","R0025188","R0025188.pdf","paywalled","other_trial","Ghatak SB","2010","Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/157339910793499119","https://doi.org/10.2174/157339910793499119","20879969","https://pubmed.ncbi.nlm.nih.gov/20879969/",null,null],["5","R0025256","R0025256.pdf","paywalled","other_trial","Lesven S","2010","Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.","Annales d'endocrinologie","Elsevier BV","10.1016/j.ando.2010.09.001","https://doi.org/10.1016/j.ando.2010.09.001","21030006","https://pubmed.ncbi.nlm.nih.gov/21030006/",null,null],["5","R0025738","R0025738.pdf","paywalled","other_trial","Mikhail NE","2010","Is liraglutide a useful addition to diabetes therapy?","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep10076.ra","https://doi.org/10.4158/ep10076.ra","20439238","https://pubmed.ncbi.nlm.nih.gov/20439238/",null,null],["5","R0027220","R0027220.pdf","paywalled","other_trial","Schmidt WE","2010","Early clinical studies with liraglutide.","International journal of clinical practice. Supplement","Wiley","10.1111/j.1742-1241.2010.02500.x","https://doi.org/10.1111/j.1742-1241.2010.02500.x","20887300","https://pubmed.ncbi.nlm.nih.gov/20887300/",null,null],["5","R0027332","R0027332.pdf","paywalled","case_report","Kenny PR","2010","Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.","The American journal of gastroenterology","Ovid Technologies (Wolters Kluwer Health)","10.1038/ajg.2010.363","https://doi.org/10.1038/ajg.2010.363","21131943","https://pubmed.ncbi.nlm.nih.gov/21131943/",null,null],["5","R0028092","R0028092.pdf","paywalled","other_trial","Schernthaner G","2010","Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2010.04.004","https://doi.org/10.1016/j.diabet.2010.04.004","20598608","https://pubmed.ncbi.nlm.nih.gov/20598608/",null,null],["5","R0030392","R0030392.pdf","paywalled","other_trial","Campbell IW","2010","Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?","International journal of clinical practice","Wiley","10.1111/j.1742-1241.2009.02292.x","https://doi.org/10.1111/j.1742-1241.2009.02292.x","20518953","https://pubmed.ncbi.nlm.nih.gov/20518953/",null,null],["5","R0034988","R0034988.pdf","paywalled","other_trial","&NA;","2010","Taspoglutide dosing halted as AEs force trial participants out","Reactions Weekly","Springer Science and Business Media LLC","10.2165/00128415-201013190-00007","https://doi.org/10.2165/00128415-201013190-00007",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035671","R0035671.pdf","paywalled","other","Daniel S. Gordon","2010","Recent Data from LEAD","MD Conference Express","CLOCKSS Archive","10.1177/155989771009004","https://doi.org/10.1177/155989771009004",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00700817"],["5","R0036778","R0036778.pdf","paywalled","other_trial",null,"2010","News in brief","Expert Review of Endocrinology & Metabolism","Informa UK Limited","10.1586/eem.10.12","https://doi.org/10.1586/eem.10.12",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039214","R0039214.pdf","paywalled","other_trial","Stephen F.J. McGovern","2010","P3‐362: GLP‐1 mimetics improve learning and memory: A link between diabetes and Alzheimer's disease","Alzheimer s & Dementia","Wiley","10.1016/j.jalz.2010.05.1904","https://doi.org/10.1016/j.jalz.2010.05.1904",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049404","R0049404.pdf","paywalled","other_trial","Dennis J. Cada","2010","Liraglutide","Hospital Pharmacy","SAGE Publications","10.1310/hpj4507-552","https://doi.org/10.1310/hpj4507-552",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050022","R0050022.pdf","paywalled","other_trial","Dennis J. Cada","2010","Ustekinumab","Hospital Pharmacy","SAGE Publications","10.1310/hpj4504-320","https://doi.org/10.1310/hpj4504-320",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0012518","R0012518.pdf","paywalled","narrative_review","Lovshin JA","2009","Incretin-based therapies for type 2 diabetes mellitus.","Nature reviews. Endocrinology","Springer Science and Business Media LLC","10.1038/nrendo.2009.48","https://doi.org/10.1038/nrendo.2009.48","19444259","https://pubmed.ncbi.nlm.nih.gov/19444259/",null,null],["5","R0013512","R0013512.pdf","paywalled","preclinical","Verspohl EJ","2009","Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.","Pharmacology & therapeutics","Elsevier BV","10.1016/j.pharmthera.2009.06.002","https://doi.org/10.1016/j.pharmthera.2009.06.002","19545590","https://pubmed.ncbi.nlm.nih.gov/19545590/",null,null],["5","R0020122","R0020122.pdf","paywalled","other_trial","Drab SR","2009","Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.","Pharmacotherapy","Wiley","10.1592/phco.29.pt2.43s","https://doi.org/10.1592/phco.29.pt2.43s","19947816","https://pubmed.ncbi.nlm.nih.gov/19947816/",null,null],["5","R0021040","R0021040.pdf","paywalled","other_trial","Montanya E","2009","A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2009.11.034","https://doi.org/10.1016/j.clinthera.2009.11.034","20109994","https://pubmed.ncbi.nlm.nih.gov/20109994/",null,null],["5","R0022352","R0022352.pdf","paywalled","other_trial","Blonde L","2009","The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01075.x","https://doi.org/10.1111/j.1463-1326.2009.01075.x","19878259","https://pubmed.ncbi.nlm.nih.gov/19878259/",null,null],["5","R0023918","R0023918.pdf","paywalled","preclinical","Kielgast U","2009","Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.","Current diabetes reviews","Bentham Science Publishers Ltd.","10.2174/157339909789804413","https://doi.org/10.2174/157339909789804413","19925391","https://pubmed.ncbi.nlm.nih.gov/19925391/",null,null],["5","R0024883","R0024883.pdf","paywalled","other_trial","Croom KF","2009","Liraglutide: a review of its use in type 2 diabetes mellitus.","Drugs","Springer Science and Business Media LLC","10.2165/11201060-000000000-00000","https://doi.org/10.2165/11201060-000000000-00000","19747013","https://pubmed.ncbi.nlm.nih.gov/19747013/",null,null],["5","R0025378","R0025378.pdf","paywalled","other_trial","Tahrani AA","2009","Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.","Advances in therapy","Springer Science and Business Media LLC","10.1007/s12325-009-0014-9","https://doi.org/10.1007/s12325-009-0014-9","19330494","https://pubmed.ncbi.nlm.nih.gov/19330494/",null,null],["5","R0026996","R0026996.pdf","paywalled","other_trial","Peragallo-Dittko V","2009","Translating clinical trial data into new patterns of practice.","The Diabetes educator","SAGE Publications","10.1177/0145721708330154","https://doi.org/10.1177/0145721708330154","19218563","https://pubmed.ncbi.nlm.nih.gov/19218563/",null,null],["5","R0027187","R0027187.pdf","paywalled","other_trial","Faludi P","2009","The effect of exenatide re-exposure on safety and efficacy.","Peptides","Elsevier BV","10.1016/j.peptides.2009.06.026","https://doi.org/10.1016/j.peptides.2009.06.026","19576255","https://pubmed.ncbi.nlm.nih.gov/19576255/",null,null],["5","R0027318","R0027318.pdf","paywalled","other_trial","Mazze R","2009","Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep09046.orr","https://doi.org/10.4158/ep09046.orr","19454385","https://pubmed.ncbi.nlm.nih.gov/19454385/",null,null],["5","R0027327","R0027327.pdf","paywalled","other_trial","Madsbad S","2009","Liraglutide Effect and Action in Diabetes (LEAD™) trial.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1586/17446651.4.2.119","https://doi.org/10.1586/17446651.4.2.119","30780853","https://pubmed.ncbi.nlm.nih.gov/30780853/",null,null],["5","R0027896","R0027896.pdf","paywalled","preclinical","Abbas T","2009","Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.","Behavioural brain research","Elsevier BV","10.1016/j.bbr.2009.06.035","https://doi.org/10.1016/j.bbr.2009.06.035","19573562","https://pubmed.ncbi.nlm.nih.gov/19573562/",null,null],["5","R0027926","R0027926.pdf","paywalled","other_trial","Hagenmeyer EG","2009","[Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues].","Deutsche medizinische Wochenschrift (1946)","Georg Thieme Verlag KG","10.1055/s-0029-1208087","https://doi.org/10.1055/s-0029-1208087","19277932","https://pubmed.ncbi.nlm.nih.gov/19277932/",null,null],["5","R0028358","R0028358.pdf","paywalled","other_trial","Pechlaner C","2009","Adverse events in diabetes drug trial.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(09)61736-0","https://doi.org/10.1016/s0140-6736(09)61736-0","19801086","https://pubmed.ncbi.nlm.nih.gov/19801086/",null,null],["5","R0050301","R0050301.pdf","paywalled","other_trial","John P.H. Wilding","2009","Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK","The British Journal of Diabetes","SAGE Publications","10.1177/1474651409342637","https://doi.org/10.1177/1474651409342637",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050437","R0050437.pdf","paywalled","other_trial","Pamela M. Katz","2009","Dipeptidyl Peptidase-4 Inhibitors and the Management of Hyperglycemia","US Endocrinology","Touch Medical Media, Ltd.","10.17925/use.2009.05.1.63","https://doi.org/10.17925/use.2009.05.1.63",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056815","R0056815.pdf","paywalled","preclinical","Ossum A","2009","The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2009.06.004","https://doi.org/10.1016/j.phrs.2009.06.004","19540343","https://pubmed.ncbi.nlm.nih.gov/19540343/",null,null],["5","R0023237","R0023237.pdf","paywalled","other_trial","Martin CL","2008","Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.","The Diabetes educator","SAGE Publications","10.1177/0145721708319238","https://doi.org/10.1177/0145721708319238","18525067","https://pubmed.ncbi.nlm.nih.gov/18525067/",null,null],["5","R0024306","R0024306.pdf","paywalled","commentary","Horowitz M","2008","Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2008.00861.x","https://doi.org/10.1111/j.1463-1326.2008.00861.x","18435773","https://pubmed.ncbi.nlm.nih.gov/18435773/",null,null],["5","R0024418","R0024418.pdf","paywalled","preclinical","Sonne DP","2008","Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.","Regulatory peptides","Elsevier BV","10.1016/j.regpep.2007.10.001","https://doi.org/10.1016/j.regpep.2007.10.001","17976835","https://pubmed.ncbi.nlm.nih.gov/17976835/",null,null],["5","R0024570","R0024570.pdf","paywalled","preclinical","Yamada C","2008","The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.","Endocrinology","The Endocrine Society","10.1210/en.2007-1292","https://doi.org/10.1210/en.2007-1292","18039776","https://pubmed.ncbi.nlm.nih.gov/18039776/",null,null],["5","R0024818","R0024818.pdf","paywalled","other_trial","Halimi S","2008","DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?","Diabetes & metabolism","Elsevier BV","10.1016/s1262-3636(08)73400-1","https://doi.org/10.1016/s1262-3636(08)73400-1","18640591","https://pubmed.ncbi.nlm.nih.gov/18640591/",null,null],["5","R0027891","R0027891.pdf","paywalled","preclinical","Green BD","2008","GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.","Archives of biochemistry and biophysics","Elsevier BV","10.1016/j.abb.2008.08.001","https://doi.org/10.1016/j.abb.2008.08.001","18708025","https://pubmed.ncbi.nlm.nih.gov/18708025/",null,null],["5","R0030506","R0030506.pdf","paywalled","narrative_review","Holst JJ","2008","Glucagon-like peptide-1, glucose homeostasis and diabetes.","Trends in molecular medicine","Elsevier BV","10.1016/j.molmed.2008.01.003","https://doi.org/10.1016/j.molmed.2008.01.003","18353723","https://pubmed.ncbi.nlm.nih.gov/18353723/",null,null],["5","R0032766","R0032766.pdf","paywalled","other_trial","Baptist Gallwitz","2008","Managing the β-cell with GLP-1 in type 2 diabetes","The British Journal of Diabetes","SAGE Publications","10.1177/1474651408100522","https://doi.org/10.1177/1474651408100522",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035791","R0035791.pdf","paywalled","other_trial",null,"2008","Uncovering Imperative Interventions in Prediabetes and Type 2 Diabetes","The Nurse Practitioner","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.npr.0000335127.29923.61","https://doi.org/10.1097/01.npr.0000335127.29923.61",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038197","R0038197.pdf","paywalled","other_trial","Masakazu Haneda","2008","Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?","Nephrology Dialysis Transplantation","Oxford University Press (OUP)","10.1093/ndt/gfn616","https://doi.org/10.1093/ndt/gfn616","19015168","https://pubmed.ncbi.nlm.nih.gov/19015168/",null,null],["5","R0043705","R0043705.pdf","paywalled","other_trial","David McGrane","2008","Struck by ACCORD","Practical Diabetes","Wiley","10.1002/pdi.1227","https://doi.org/10.1002/pdi.1227",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044226","R0044226.pdf","paywalled","other_trial","Mark D. Gorrell","2008","Impaired glucose tolerance and incretins in chronic liver disease","Journal of Gastroenterology and Hepatology","Wiley","10.1111/j.1440-1746.2007.05268.x","https://doi.org/10.1111/j.1440-1746.2007.05268.x","18289349","https://pubmed.ncbi.nlm.nih.gov/18289349/",null,null],["5","R0050366","R0050366.pdf","paywalled","other_trial","Oliver P. Bachmann","2008","Adiponectin-Anstieg, Verbesserung der glykämischen Kontrolle und Gewichtsreduktion bei Patienten mit Typ-2-Diabetes unter Langzeittherapie mit Exenatide","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-2008-1076353","https://doi.org/10.1055/s-2008-1076353",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051660","R0051660.pdf","paywalled","other_trial","Dennis J. Cada","2008","Sumatriptan Succinate/Naproxen Sodium","Hospital Pharmacy","SAGE Publications","10.1310/hpj4308-650","https://doi.org/10.1310/hpj4308-650",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0020472","R0020472.pdf","paywalled","other_trial","Stephens JW","2007","Safety and adverse effects associated with GLP-1 analogues.","Expert opinion on drug safety","Informa Healthcare","10.1517/14740338.6.4.417","https://doi.org/10.1517/14740338.6.4.417","17688385","https://pubmed.ncbi.nlm.nih.gov/17688385/",null,null],["5","R0020614","R0020614.pdf","paywalled","preclinical","Park CW","2007","Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.","Journal of the American Society of Nephrology : JASN","Ovid Technologies (Wolters Kluwer Health)","10.1681/asn.2006070778","https://doi.org/10.1681/asn.2006070778","17360951","https://pubmed.ncbi.nlm.nih.gov/17360951/",null,null],["5","R0021007","R0021007.pdf","paywalled","other_trial","Frias JP","2007","Incretins and their role in the management of diabetes.","Current opinion in endocrinology, diabetes, and obesity","Ovid Technologies (Wolters Kluwer Health)","10.1097/med.0b013e32825ea2ba","https://doi.org/10.1097/med.0b013e32825ea2ba","17940451","https://pubmed.ncbi.nlm.nih.gov/17940451/",null,null],["5","R0025151","R0025151.pdf","paywalled","other_trial","Vilsbøll T","2007","Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.","Expert opinion on investigational drugs","Informa Healthcare","10.1517/13543784.16.2.231","https://doi.org/10.1517/13543784.16.2.231","17243943","https://pubmed.ncbi.nlm.nih.gov/17243943/",null,null],["5","R0025824","R0025824.pdf","paywalled","other_trial","Cefalu WT","2007","Clinical management strategies for type 2 diabetes.","JAAPA : official journal of the American Academy of Physician Assistants","Ovid Technologies (Wolters Kluwer Health)","10.1097/01720610-200712000-00002","https://doi.org/10.1097/01720610-200712000-00002","18217246","https://pubmed.ncbi.nlm.nih.gov/18217246/",null,null],["5","R0027364","R0027364.pdf","paywalled","other_trial","Barnett A","2007","Exenatide.","Expert opinion on pharmacotherapy","Informa Healthcare","10.1517/14656566.8.15.2593","https://doi.org/10.1517/14656566.8.15.2593","17931093","https://pubmed.ncbi.nlm.nih.gov/17931093/",null,null],["5","R0027425","R0027425.pdf","paywalled","other_trial","Ghofaili KA","2007","Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.","Transplantation","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.tp.0000251379.46596.2d","https://doi.org/10.1097/01.tp.0000251379.46596.2d","17220786","https://pubmed.ncbi.nlm.nih.gov/17220786/",null,null],["5","R0027724","R0027724.pdf","paywalled","narrative_review","Holst JJ","2007","The physiology of glucagon-like peptide 1.","Physiological reviews","American Physiological Society","10.1152/physrev.00034.2006","https://doi.org/10.1152/physrev.00034.2006","17928588","https://pubmed.ncbi.nlm.nih.gov/17928588/",null,null],["5","R0027857","R0027857.pdf","paywalled","narrative_review","Baggio LL","2007","Biology of incretins: GLP-1 and GIP.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2007.03.054","https://doi.org/10.1053/j.gastro.2007.03.054","17498508","https://pubmed.ncbi.nlm.nih.gov/17498508/",null,null],["5","R0027947","R0027947.pdf","paywalled","other_trial","Cohen A","2007","Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.","Current medical research and opinion","Informa Healthcare","10.1185/030079907x182068","https://doi.org/10.1185/030079907x182068","17407648","https://pubmed.ncbi.nlm.nih.gov/17407648/",null,null],["5","R0047986","R0047986.pdf","paywalled","other_trial","John P.H. Wilding","2007","Treatment strategies for obesity","Obesity Reviews","Wiley","10.1111/j.1467-789x.2007.00333.x","https://doi.org/10.1111/j.1467-789x.2007.00333.x","17316317","https://pubmed.ncbi.nlm.nih.gov/17316317/",null,null],["5","R0048682","R0048682.pdf","paywalled","other_trial","Steven W. Ryder","2007","Innovation and Improvement in the Treatment of Obesity and Diabetes","Clinical Pharmacology & Therapeutics","Wiley","10.1038/sj.clpt.6100189","https://doi.org/10.1038/sj.clpt.6100189","17438532","https://pubmed.ncbi.nlm.nih.gov/17438532/",null,null],["5","R0048952","R0048952.pdf","paywalled","other_trial","Michael Anthony Cawthorne","2007","Opportunities and challenges for the development of pharmacological therapies for obesity treatment","Obesity Reviews","Wiley","10.1111/j.1467-789x.2007.00332.x","https://doi.org/10.1111/j.1467-789x.2007.00332.x","17316316","https://pubmed.ncbi.nlm.nih.gov/17316316/",null,null],["5","R0049895","R0049895.pdf","paywalled","other_trial","OP Bachmann","2007","Die EIGHT Studie: Effects of Exenatide vs. Insulin on Glycemic Control and Hypoglycemia Trial","Diabetologie und Stoffwechsel","Georg Thieme Verlag KG","10.1055/s-2007-982426","https://doi.org/10.1055/s-2007-982426",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0014170","R0014170.pdf","paywalled","narrative_review","Drucker DJ","2006","The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(06)69705-5","https://doi.org/10.1016/s0140-6736(06)69705-5","17098089","https://pubmed.ncbi.nlm.nih.gov/17098089/",null,null],["5","R0021821","R0021821.pdf","paywalled","other_trial","Iltz JL","2006","Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2006.05.006","https://doi.org/10.1016/j.clinthera.2006.05.006","16861088","https://pubmed.ncbi.nlm.nih.gov/16861088/",null,null],["5","R0023605","R0023605.pdf","paywalled","other_trial","Damholt B","2006","An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.","Journal of clinical pharmacology","Wiley","10.1177/0091270006288215","https://doi.org/10.1177/0091270006288215","16707410","https://pubmed.ncbi.nlm.nih.gov/16707410/",null,null],["5","R0027034","R0027034.pdf","paywalled","other_trial","Reddy SS","2006","Endocrinology update 2006.","Cleveland Clinic journal of medicine","Cleveland Clinic Journal of Medicine","10.3949/ccjm.73.11.1019","https://doi.org/10.3949/ccjm.73.11.1019","17128544","https://pubmed.ncbi.nlm.nih.gov/17128544/",null,null],["5","R0027615","R0027615.pdf","paywalled","other_trial","Soon D","2006","Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.","Journal of clinical pharmacology","Wiley","10.1177/0091270006291622","https://doi.org/10.1177/0091270006291622","16988207","https://pubmed.ncbi.nlm.nih.gov/16988207/",null,null],["5","R0028097","R0028097.pdf","paywalled","other_trial","Lebovitz H","2006","Diabetes: assessing the pipeline.","Atherosclerosis. Supplements","Elsevier BV","10.1016/j.atherosclerosissup.2006.01.007","https://doi.org/10.1016/j.atherosclerosissup.2006.01.007","16504599","https://pubmed.ncbi.nlm.nih.gov/16504599/",null,null],["5","R0031946","R0031946.pdf","paywalled","other_trial","JOHN R. BELL","2006","Once-Daily Liraglutide Lowers HbA1c by 1.7% in Early Trial","Clinical Psychiatry News","Elsevier BV","10.1016/s0270-6644(06)71693-9","https://doi.org/10.1016/s0270-6644(06)71693-9",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035666","R0035666.pdf","paywalled","other_trial","Ian N. Scobie","2006","- Future developments in diabetes",null,"CRC Press","10.1201/b15304-15","https://doi.org/10.1201/b15304-15",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035723","R0035723.pdf","paywalled","other_trial","L. Gater","2006","New Treatments: Liraglutide","MD Conference Express","CLOCKSS Archive","10.1177/155989770600600210","https://doi.org/10.1177/155989770600600210",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036043","R0036043.pdf","paywalled","other_trial","Baptist Gallwitz","2006","The gut-brain axis and its implications for the therapy of type 2 diabetes","Experimental and Clinical Endocrinology & Diabetes","Georg Thieme Verlag KG","10.1055/s-2006-954679","https://doi.org/10.1055/s-2006-954679",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044450","R0044450.pdf","paywalled","other_trial","Kirandeep Kaur","2006","Development of new incretin drugs: Promising therapies","Indian Journal of Pharmacology","Medknow","10.4103/0253-7613.24614","https://doi.org/10.4103/0253-7613.24614",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048319","R0048319.pdf","paywalled","other_trial","Susan A. Cornell","2006","Vildagliptin (LAF 237): A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Mellitus","Journal of Pharmacy Technology","SAGE Publications","10.1177/875512250602200207","https://doi.org/10.1177/875512250602200207",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0018821","R0018821.pdf","paywalled","other_trial","Joy SV","2005","Incretin mimetics as emerging treatments for type 2 diabetes.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1e245","https://doi.org/10.1345/aph.1e245","15562141","https://pubmed.ncbi.nlm.nih.gov/15562141/",null,null],["5","R0025551","R0025551.pdf","paywalled","other_trial","Drucker DJ","2005","Biologic actions and therapeutic potential of the proglucagon-derived peptides.","Nature clinical practice. Endocrinology & metabolism","Springer Science and Business Media LLC","10.1038/ncpendmet0017","https://doi.org/10.1038/ncpendmet0017","16929363","https://pubmed.ncbi.nlm.nih.gov/16929363/",null,null],["5","R0025769","R0025769.pdf","paywalled","other_trial","Keating GM","2005","Exenatide.","Drugs","Springer Science and Business Media LLC","10.2165/00003495-200565120-00008","https://doi.org/10.2165/00003495-200565120-00008","16060703","https://pubmed.ncbi.nlm.nih.gov/16060703/",null,null],["5","R0027686","R0027686.pdf","paywalled","other_trial","Kothare PA","2005","Effect of exenatide on the steady-state pharmacokinetics of digoxin.","Journal of clinical pharmacology","Wiley","10.1177/0091270005278806","https://doi.org/10.1177/0091270005278806","16100297","https://pubmed.ncbi.nlm.nih.gov/16100297/",null,null],["5","R0035775","R0035775.pdf","paywalled","other_trial","MA Nauck","2005","Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes","Practical Diabetes","Wiley","10.1002/pdi.801","https://doi.org/10.1002/pdi.801",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047486","R0047486.pdf","paywalled","other_trial","Dennis J. Cada","2005","Exenatide Injection","Hospital Pharmacy","SAGE Publications","10.1177/001857870504001109","https://doi.org/10.1177/001857870504001109",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050150","R0050150.pdf","paywalled","other_trial","Peter E. H. Schwarz","2005","Report from the Congress of the American Diabetes Association (ADA): Orlando 2005","Experimental and Clinical Endocrinology & Diabetes","Georg Thieme Verlag KG","10.1055/s-2005-865942","https://doi.org/10.1055/s-2005-865942","16151983","https://pubmed.ncbi.nlm.nih.gov/16151983/",null,null],["5","R0051387","R0051387.pdf","paywalled","other_trial","Dennis J. Cada","2005","Pramlintide Acetate","Hospital Pharmacy","SAGE Publications","10.1177/001857870504000709","https://doi.org/10.1177/001857870504000709",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0024598","R0024598.pdf","paywalled","narrative_review","Ahrén B","2004","GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Georg Thieme Verlag KG","10.1055/s-2004-826178","https://doi.org/10.1055/s-2004-826178","15655721","https://pubmed.ncbi.nlm.nih.gov/15655721/",null,null],["5","R0051010","R0051010.pdf","paywalled","other_trial","Terri Poon","2004","Abstract #20: Effects of Exenatide (Synthetic Exendin-4) on Glucose Control and Safety in Patients with Type 2 Diabetes Treated with Metformin, a Sulfonylurea, or Both: An Ongoing, Open-Label Phase 3 Trial","Endocrine Practice","Elsevier BV","10.1016/s1530-891x(20)46299-8","https://doi.org/10.1016/s1530-891x(20)46299-8",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0021594","R0021594.pdf","paywalled","preclinical","Thorkildsen C","2003","Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.","The Journal of pharmacology and experimental therapeutics","Elsevier BV","10.1124/jpet.103.051987","https://doi.org/10.1124/jpet.103.051987","12975499","https://pubmed.ncbi.nlm.nih.gov/12975499/",null,null],["5","R0026685","R0026685.pdf","paywalled","other_trial","Agersø H","2003","Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/s0928-0987(03)00073-3","https://doi.org/10.1016/s0928-0987(03)00073-3","12791417","https://pubmed.ncbi.nlm.nih.gov/12791417/",null,null],["5","R0035236","R0035236.pdf","paywalled","other_trial","&NA;","2003","Exenatide* has met the primary glucose control endpoint of haemoglobin A1c (HbA1c ) reduction in its final phase III trial.","Inpharma Weekly","Springer Science and Business Media LLC","10.2165/00128413-200314150-00021","https://doi.org/10.2165/00128413-200314150-00021",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050891","R0050891.pdf","paywalled","other_trial","Nicola M. Neary","2003","Appetite regulation: from the gut to the hypothalamus","Clinical Endocrinology","Wiley","10.1046/j.1365-2265.2003.01839.x","https://doi.org/10.1046/j.1365-2265.2003.01839.x","14725674","https://pubmed.ncbi.nlm.nih.gov/14725674/",null,null],["5","R0053756","R0053756.pdf","paywalled","other_trial","Daniel J. Drucker","2003","Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis","Endocrinology","The Endocrine Society","10.1210/en.2003-1147","https://doi.org/10.1210/en.2003-1147","14645210","https://pubmed.ncbi.nlm.nih.gov/14645210/",null,null],["5","R0036255","R0036255.pdf","paywalled","other_trial","Rick Mullin","2002","DRUGMAKER PARTNERSHIPS","Chemical & Engineering News","American Chemical Society (ACS)","10.1021/cen-v080n039.p009","https://doi.org/10.1021/cen-v080n039.p009",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0029836","R0029836.pdf","paywalled","other_trial","Bailey CJ","2001","New pharmacologic agents for diabetes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-001-0023-9","https://doi.org/10.1007/s11892-001-0023-9","12643107","https://pubmed.ncbi.nlm.nih.gov/12643107/",null,null],["5","R0026462","R0026462.pdf","paywalled","preclinical","Drucker DJ","1998","Glucagon-like peptides.","Diabetes","American Diabetes Association","10.2337/diab.47.2.159","https://doi.org/10.2337/diab.47.2.159","9519708","https://pubmed.ncbi.nlm.nih.gov/9519708/",null,null],["5","R0028112","R0028112.pdf","paywalled","narrative_review","Nauck MA","1997","Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Georg Thieme Verlag KG","10.1055/s-0029-1211750","https://doi.org/10.1055/s-0029-1211750","9285204","https://pubmed.ncbi.nlm.nih.gov/9285204/",null,null],["5","R0025779","R0025779.pdf","paywalled","preclinical","Barragán JM","1996","Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.","Regulatory peptides","Elsevier BV","10.1016/s0167-0115(96)00113-9","https://doi.org/10.1016/s0167-0115(96)00113-9","8952007","https://pubmed.ncbi.nlm.nih.gov/8952007/",null,null],["5","R0025044","R0025044.pdf","paywalled","preclinical","Göke R","1995","Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites.","The European journal of neuroscience","Wiley","10.1111/j.1460-9568.1995.tb00650.x","https://doi.org/10.1111/j.1460-9568.1995.tb00650.x","8563978","https://pubmed.ncbi.nlm.nih.gov/8563978/",null,null],["5","R0000027","R0000027.pdf","free_to_read","other_trial","Tong LH","2026","Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.","Journal of chromatography. A","Elsevier BV","10.1016/j.chroma.2026.467288","https://doi.org/10.1016/j.chroma.2026.467288","42603384","https://pubmed.ncbi.nlm.nih.gov/42603384/","https://doi.org/10.2139/ssrn.6848250",null],["5","R0000224","R0000224.pdf","no_doi","other_trial","Scheen A","2026","[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].","Revue medicale de Liege",null,null,"https://doi.org/","41815032","https://pubmed.ncbi.nlm.nih.gov/41815032/",null,null],["5","R0000226","R0000226.pdf","open_download_failed","other_trial","Palmer M","2026","Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2026.09.002","https://doi.org/10.1016/j.clinthera.2026.09.002","42791090","https://pubmed.ncbi.nlm.nih.gov/42791090/","https://www.clinicaltherapeutics.com/article/S0149-2918(26)00340-1/pdf",null],["5","R0000428","R0000428.pdf","free_to_read","other_trial","Pedagogos E","2026","Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.","Internal medicine journal","Wiley","10.1111/imj.70647","https://doi.org/10.1111/imj.70647","42813318","https://pubmed.ncbi.nlm.nih.gov/42813318/","https://doi.org/10.1111/imj.70647",null],["5","R0000499","R0000499.pdf","free_to_read","other_trial","Nazar QUA","2026","Glucagon like peptide-1 receptor agonist (Ozempic): Revolutionising chronic kidney disease management in diabetes.","JPMA. The Journal of the Pakistan Medical Association","Pakistan Medical Association","10.47391/jpma.30655","https://doi.org/10.47391/jpma.30655","42160574","https://pubmed.ncbi.nlm.nih.gov/42160574/","https://doi.org/10.47391/jpma.30655",null],["5","R0000755","R0000755.pdf","free_to_read","other_trial","Cohen RM","2026","Putting a Glucagon-Like Peptide-1 Receptor Agonist Trial for Type 2 Diabetes in Context.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2026.15634","https://doi.org/10.1001/jamanetworkopen.2026.15634","42234432","https://pubmed.ncbi.nlm.nih.gov/42234432/","https://doi.org/10.1001/jamanetworkopen.2026.15634",null],["5","R0000813","R0000813.pdf","free_to_read","other_trial","Sulter GA","2026","Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine","Preprints.org","MDPI AG","10.20944/preprints202607.1279.v1","https://doi.org/10.20944/preprints202607.1279.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202607.1279.v1",null],["5","R0001034","R0001034.pdf","open_download_failed","other_trial","Innes R","2026","Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next.","Endocrinology and metabolism clinics of North America","Elsevier BV","10.1016/j.ecl.2026.04.002","https://doi.org/10.1016/j.ecl.2026.04.002","42526994","https://pubmed.ncbi.nlm.nih.gov/42526994/","https://eprints.gla.ac.uk/393488/1/393488.pdf",null],["5","R0001412","R0001412.pdf","free_to_read","other_trial","Briere DA","2026","Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept.","Molecular metabolism","Elsevier BV","10.1016/j.molmet.2026.102452","https://doi.org/10.1016/j.molmet.2026.102452","42829171","https://pubmed.ncbi.nlm.nih.gov/42829171/","https://doi.org/10.1016/j.molmet.2026.102452","ClinicalTrials.gov:NCT04641312"],["5","R0002153","R0002153.pdf","free_to_read","protocol","Gatua W","2026","Instrumental variable analysis applied to randomised controlled trials of glucagon-like-peptide-1 receptor agonists and bariatric surgery: A study protocol","Wellcome Open Res","F1000 Research Ltd","10.12688/wellcomeopenres.26912.1","https://doi.org/10.12688/wellcomeopenres.26912.1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12688/wellcomeopenres.26912.1",null],["5","R0002315","R0002315.pdf","open_download_failed","other_trial","Broul M","2026","Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source-Triangulated Counseling Map.","Andrology","Wiley","10.1111/andr.70366","https://doi.org/10.1111/andr.70366","42661473","https://pubmed.ncbi.nlm.nih.gov/42661473/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/andr.70366",null],["5","R0002663","R0002663.pdf","free_to_read","other_trial","Manninen AH","2026","Beyond Appetite: An MBM-Based Hypothesis for Dual-Action Anti-Obesity Pharmacotherapy Targeting Both Sides of the Mass Balance Equation","Preprints.org","MDPI AG","10.20944/preprints202606.0369.v2","https://doi.org/10.20944/preprints202606.0369.v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0369.v2",null],["5","R0002821","R0002821.pdf","open_download_failed","other_trial","Zhang YW","2026","Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.","British journal of clinical pharmacology","Wiley","10.1002/bcp.70828","https://doi.org/10.1002/bcp.70828","42755225","https://pubmed.ncbi.nlm.nih.gov/42755225/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70828",null],["5","R0002856","R0002856.pdf","open_download_failed","other_trial","Meije DA","2026","Combination pharmacotherapy for MASH: Potential synergistic approaches.","Biochemical pharmacology","Elsevier BV","10.1016/j.bcp.2026.118492","https://doi.org/10.1016/j.bcp.2026.118492","42767573","https://pubmed.ncbi.nlm.nih.gov/42767573/","https://www.sciencedirect.com/science/article/pii/S0006295226008348/pdf",null],["5","R0003191","R0003191.pdf","free_to_read","other_trial","Saldívar-Cerón HI","2026","From Oxyntomodulin to Retatrutide: Engineering Metabolic Polyagonism","Preprints.org","MDPI AG","10.20944/preprints202610.0201.v1","https://doi.org/10.20944/preprints202610.0201.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202610.0201.v1",null],["5","R0003566","R0003566.pdf","open_download_failed","other_trial","Ganamurali N","2026","The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.","Clinical pharmacology in drug development","Wiley","10.1002/cpdd.70001","https://doi.org/10.1002/cpdd.70001","41545327","https://pubmed.ncbi.nlm.nih.gov/41545327/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.70001",null],["5","R0003887","R0003887.pdf","free_to_read","preclinical","Bailey CJ","2026","Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.","Peptides","Elsevier BV","10.1016/j.peptides.2026.171480","https://doi.org/10.1016/j.peptides.2026.171480","41747885","https://pubmed.ncbi.nlm.nih.gov/41747885/","https://doi.org/10.1016/j.peptides.2026.171480","ClinicalTrials.gov:NCT07022977; ClinicalTrials.gov:NCT06924320"],["5","R0004202","R0004202.pdf","open_download_failed","protocol","Pruijm M","2026","REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.","Kidney international","Elsevier BV","10.1016/j.kint.2025.10.005","https://doi.org/10.1016/j.kint.2025.10.005","41207620","https://pubmed.ncbi.nlm.nih.gov/41207620/","https://www.kidney-international.org/article/S0085-2538(25)00861-0/pdf","ClinicalTrials.gov:NCT04865770; ClinicalTrials.gov:NCT03819153"],["5","R0004294","R0004294.pdf","open_download_failed","other_trial","Meng F","2026","Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24-week multimodal neuroimaging study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70524","https://doi.org/10.1111/dom.70524","41657113","https://pubmed.ncbi.nlm.nih.gov/41657113/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70524",null],["5","R0004694","R0004694.pdf","free_to_read","other_trial","Ferreira JP","2026","Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors: Agent Comparison With Implications for Clinical Practice and Trial Design.","Journal of cardiac failure","Elsevier BV","10.1016/j.cardfail.2025.05.002","https://doi.org/10.1016/j.cardfail.2025.05.002","40389106","https://pubmed.ncbi.nlm.nih.gov/40389106/","https://hal.univ-lorraine.fr/hal-05084593v1/document",null],["5","R0004852","R0004852.pdf","open_download_failed","other_trial","Li F","2026","Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70880","https://doi.org/10.1111/dom.70880","42310888","https://pubmed.ncbi.nlm.nih.gov/42310888/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70880",null],["5","R0004902","R0004902.pdf","free_to_read","other_trial","Harvanek ZM","2026","Alterations in glucose and insulin resistance following stress and alcohol cues predict alcohol craving in those with AUD and obesity: A preliminary study.","Alcohol, clinical & experimental research","Wiley","10.1111/acer.70283","https://doi.org/10.1111/acer.70283","42101823","https://pubmed.ncbi.nlm.nih.gov/42101823/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13651010/",null],["5","R0005207","R0005207.pdf","free_to_read","other_trial","Kushner PR","2026","Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.126.049727","https://doi.org/10.1161/jaha.126.049727","42535526","https://pubmed.ncbi.nlm.nih.gov/42535526/","https://doi.org/10.1161/jaha.126.049727",null],["5","R0005958","R0005958.pdf","free_to_read","other_trial","Katayama S","2026","Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2025.109213","https://doi.org/10.1016/j.jdiacomp.2025.109213","41289823","https://pubmed.ncbi.nlm.nih.gov/41289823/","https://doi.org/10.1016/j.jdiacomp.2025.109213","ClinicalTrials.gov:NCT02540993; ClinicalTrials.gov:NCT02545049"],["5","R0006188","R0006188.pdf","free_to_read","other_trial","Pabon MA","2026","Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag162","https://doi.org/10.1093/eurheartj/ehag162","41884984","https://pubmed.ncbi.nlm.nih.gov/41884984/","https://doi.org/10.1093/eurheartj/ehag162","PROSPERO:CRD42024570467"],["5","R0007112","R0007112.pdf","open_download_failed","other_trial","Mohammad A","2026","Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.","International journal of biological macromolecules","Elsevier BV","10.1016/j.ijbiomac.2026.153525","https://doi.org/10.1016/j.ijbiomac.2026.153525","42437645","https://pubmed.ncbi.nlm.nih.gov/42437645/","https://www.sciencedirect.com/science/article/pii/S0141813026034707/pdf",null],["5","R0007211","R0007211.pdf","free_to_read","other_trial","Hubert PA","2026","Mind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment.","Journal of the Academy of Nutrition and Dietetics","Elsevier BV","10.1016/j.jand.2026.156366","https://doi.org/10.1016/j.jand.2026.156366","42055215","https://pubmed.ncbi.nlm.nih.gov/42055215/","https://doi.org/10.1016/j.jand.2026.156366",null],["5","R0007918","R0007918.pdf","free_to_read","other_trial","Atzemian N","2026","Rewriting Heart Health: Epigenetic Drugs in Cardiovascular Medicine.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvag075","https://doi.org/10.1093/ehjcvp/pvag075","42781940","https://pubmed.ncbi.nlm.nih.gov/42781940/","https://doi.org/10.1093/ehjcvp/pvag075",null],["5","R0008070","R0008070.pdf","open_download_failed","other_trial","Corrêa LMA","2026","GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.","Translational research : the journal of laboratory and clinical medicine","Elsevier BV","10.1016/j.trsl.2026.07.001","https://doi.org/10.1016/j.trsl.2026.07.001","42398811","https://pubmed.ncbi.nlm.nih.gov/42398811/","https://www.translationalres.com/article/S1931-5244(26)00143-X/pdf",null],["5","R0008545","R0008545.pdf","open_download_failed","other_trial","Rubino D","2026","Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2026.2686467","https://doi.org/10.1080/00325481.2026.2686467","42286992","https://pubmed.ncbi.nlm.nih.gov/42286992/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2026.2686467?needAccess=true",null],["5","R0008839","R0008839.pdf","free_to_read","other_trial","Kitamoto T","2026","Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2026.2695047","https://doi.org/10.1080/03007995.2026.2695047","42434924","https://pubmed.ncbi.nlm.nih.gov/42434924/","https://doi.org/10.1080/03007995.2026.2695047","ClinicalTrials.gov:NCT05822830"],["5","R0008840","R0008840.pdf","open_download_failed","other_trial","Johansson E","2026","Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2026.2646078","https://doi.org/10.1080/13696998.2026.2646078","42012820","https://pubmed.ncbi.nlm.nih.gov/42012820/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2026.2646078?needAccess=true",null],["5","R0009098","R0009098.pdf","free_to_read","other_trial","Kanumilli N","2026","Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2026.2631920","https://doi.org/10.1080/13696998.2026.2631920","41771166","https://pubmed.ncbi.nlm.nih.gov/41771166/","https://doi.org/10.1080/13696998.2026.2631920",null],["5","R0009115","R0009115.pdf","free_to_read","other_trial","Chen CJ","2026","Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.","International journal of pharmaceutics","Elsevier BV","10.1016/j.ijpharm.2026.126752","https://doi.org/10.1016/j.ijpharm.2026.126752","41819389","https://pubmed.ncbi.nlm.nih.gov/41819389/","https://doi.org/10.1016/j.ijpharm.2026.126752",null],["5","R0009417","R0009417.pdf","open_download_failed","other_trial","Aronne LJ","2026","Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2026.03.010","https://doi.org/10.1016/j.amjmed.2026.03.010","41865857","https://pubmed.ncbi.nlm.nih.gov/41865857/","https://www.amjmed.com/article/S0002-9343(26)00206-8/pdf","ClinicalTrials.gov:NCT05822830"],["5","R0009716","R0009716.pdf","free_to_read","other_trial","Talebloo J","2026","Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2026.2713043","https://doi.org/10.1080/13543784.2026.2713043","42618986","https://pubmed.ncbi.nlm.nih.gov/42618986/","https://doi.org/10.1080/13543784.2026.2713043",null],["5","R0009809","R0009809.pdf","free_to_read","other_trial","Alvarado A","2026","Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics.","JACC. Case reports","Elsevier BV","10.1016/j.jaccas.2026.110528","https://doi.org/10.1016/j.jaccas.2026.110528","42788915","https://pubmed.ncbi.nlm.nih.gov/42788915/","https://doi.org/10.1016/j.jaccas.2026.110528",null],["5","R0009863","R0009863.pdf","open_download_failed","other","Toliver J","2026","Calculating cost per event avoided using a composite number needed to treat.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2026.2615606","https://doi.org/10.1080/13696998.2026.2615606","41562647","https://pubmed.ncbi.nlm.nih.gov/41562647/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2026.2615606?needAccess=true","ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT01394952"],["5","R0010658","R0010658.pdf","open_download_failed","other_trial","Shinde S","2026","Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71322","https://doi.org/10.1111/dom.71322","42750540","https://pubmed.ncbi.nlm.nih.gov/42750540/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71322","ClinicalTrials.gov:NCT05869903"],["5","R0011206","R0011206.pdf","open_download_failed","other_trial","Sisson EM","2026","Feasibility of the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant Program: A Group-Based Lifestyle Intervention and GLP-1 Receptor Agonist Therapy for End-Stage Kidney Disease Candidates Ineligible Due to Obesity.","The science of diabetes self-management and care","SAGE Publications","10.1177/26350106261483738","https://doi.org/10.1177/26350106261483738","42800900","https://pubmed.ncbi.nlm.nih.gov/42800900/","https://journals.sagepub.com/doi/pdf/10.1177/26350106261483738?download=true",null],["5","R0011221","R0011221.pdf","free_to_read","other_trial","Leah OM","2026","Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.","American journal of therapeutics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mjt.0000000000002156","https://doi.org/10.1097/mjt.0000000000002156","42340212","https://pubmed.ncbi.nlm.nih.gov/42340212/","https://doi.org/10.1097/mjt.0000000000002156",null],["5","R0011352","R0011352.pdf","open_download_failed","protocol","Jia W","2026","Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double-blind, placebo-controlled trial (LIGHT 2).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70556","https://doi.org/10.1111/dom.70556","41669874","https://pubmed.ncbi.nlm.nih.gov/41669874/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70556",null],["5","R0011519","R0011519.pdf","free_to_read","other_trial","Noureddin M","2026","Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/hep.0000000000001825","https://doi.org/10.1097/hep.0000000000001825","42545725","https://pubmed.ncbi.nlm.nih.gov/42545725/","https://doi.org/10.1097/hep.0000000000001825","ClinicalTrials.gov:NCT04771273"],["5","R0012001","R0012001.pdf","free_to_read","other_trial","Murugadoss K","2026","Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease: LLM-Curation of Decades of Clinical Notes and GLP1RA Trial Design","Preprints.org","MDPI AG","10.20944/preprints202606.0711.v1","https://doi.org/10.20944/preprints202606.0711.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20944/preprints202606.0711.v1",null],["5","R0012374","R0012374.pdf","free_to_read","other_trial","Mączyńska A","2026","Association between body mass index reduction and epicardial adipose tissue changes across pharmacological and lifestyle interventions: a multilevel meta-regression analysis.","Cardiovascular diabetology","Springer Science and Business Media LLC","10.1186/s12933-026-03299-6","https://doi.org/10.1186/s12933-026-03299-6","42471652","https://pubmed.ncbi.nlm.nih.gov/42471652/","https://doi.org/10.1186/s12933-026-03299-6","PROSPERO:CRD420261367140"],["5","R0012801","R0012801.pdf","free_to_read","protocol","Winhusen TJ","2026","Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2026.108437","https://doi.org/10.1016/j.cct.2026.108437","42600923","https://pubmed.ncbi.nlm.nih.gov/42600923/","https://doi.org/10.1016/j.cct.2026.108437",null],["5","R0012896","R0012896.pdf","free_to_read","other_trial","Metcalfe RK","2026","Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.","Value in health regional issues","Elsevier BV","10.1016/j.vhri.2026.101666","https://doi.org/10.1016/j.vhri.2026.101666","42383939","https://pubmed.ncbi.nlm.nih.gov/42383939/","https://doi.org/10.1016/j.vhri.2026.101666",null],["5","R0012953","R0012953.pdf","free_to_read","other_trial","Husereau D","2026","Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2026.09.3116","https://doi.org/10.1016/j.jval.2026.09.3116","42810438","https://pubmed.ncbi.nlm.nih.gov/42810438/","https://doi.org/10.1016/j.jval.2026.09.3116",null],["5","R0013607","R0013607.pdf","open_download_failed","other_trial","Platz E","2026","Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2025.102780","https://doi.org/10.1016/j.jchf.2025.102780","41329105","https://pubmed.ncbi.nlm.nih.gov/41329105/","https://www.jacc.org/doi/pdf/10.1016/j.jchf.2025.102780?download=true",null],["5","R0013612","R0013612.pdf","free_to_read","other_trial","Schumacher E","2026","What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000001124","https://doi.org/10.2215/cjn.0000001124","42308137","https://pubmed.ncbi.nlm.nih.gov/42308137/","https://doi.org/10.2215/cjn.0000001124",null],["5","R0013899","R0013899.pdf","free_to_read","other_trial","Lappin JM","2026","Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.","Schizophrenia research","Elsevier BV","10.1016/j.schres.2026.06.021","https://doi.org/10.1016/j.schres.2026.06.021","42372344","https://pubmed.ncbi.nlm.nih.gov/42372344/","https://doi.org/10.1016/j.schres.2026.06.021",null],["5","R0014209","R0014209.pdf","free_to_read","other_trial","Colhoun HM","2026","Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.","European heart journal","Oxford University Press (OUP)","10.1093/eurheartj/ehag524","https://doi.org/10.1093/eurheartj/ehag524","42777687","https://pubmed.ncbi.nlm.nih.gov/42777687/","https://doi.org/10.1093/eurheartj/ehag524",null],["5","R0014257","R0014257.pdf","free_to_read","other_trial","Monroe RE","2026","PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.","European heart journal. Cardiovascular pharmacotherapy","Oxford University Press (OUP)","10.1093/ehjcvp/pvag055","https://doi.org/10.1093/ehjcvp/pvag055","42647148","https://pubmed.ncbi.nlm.nih.gov/42647148/","https://doi.org/10.1093/ehjcvp/pvag055",null],["5","R0014293","R0014293.pdf","open_download_failed","other_trial","Lake JE","2026","Semaglutide improves markers of cardiovascular risk in people with HIV.","AIDS (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/qad.0000000000004538","https://doi.org/10.1097/qad.0000000000004538","42084141","https://pubmed.ncbi.nlm.nih.gov/42084141/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13573316/pdf/nihms-2205763.pdf",null],["5","R0014718","R0014718.pdf","open_download_failed","other_trial","Stanton LA","2026","Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.71152","https://doi.org/10.1111/dom.71152","42680164","https://pubmed.ncbi.nlm.nih.gov/42680164/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.71152",null],["5","R0017028","R0017028.pdf","free_to_read","other_trial","Liu D","2026","Preoperative semaglutide before sleeve gastrectomy compared to surgery alone is associated with greater short-term weight loss and dyslipidemia remission: a prospective nonrandomized controlled trial.","International journal of surgery (London, England)","Ovid Technologies (Wolters Kluwer Health)","10.1097/js9.0000000000004001","https://doi.org/10.1097/js9.0000000000004001","41247825","https://pubmed.ncbi.nlm.nih.gov/41247825/","https://doi.org/10.1097/js9.0000000000004001",null],["5","R0017191","R0017191.pdf","free_to_read","other_trial","Zhang X","2026","MASH and liver fibrosis: Clinical trials to watch.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2026.101069","https://doi.org/10.1016/j.medj.2026.101069","41966712","https://pubmed.ncbi.nlm.nih.gov/41966712/","https://doi.org/10.1016/j.medj.2026.101069",null],["5","R0018814","R0018814.pdf","free_to_read","other","Borlaug BA","2026","Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2025.102712","https://doi.org/10.1016/j.jchf.2025.102712","41099689","https://pubmed.ncbi.nlm.nih.gov/41099689/","https://pubmed.ncbi.nlm.nih.gov/41099689/","ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT03914326"],["5","R0019830","R0019830.pdf","free_to_read","other_trial","Jeyaraman M","2026","Therapeutic and Bioactive Peptides in Musculoskeletal Medicine: A Narrative Review.","Indian journal of orthopaedics","Springer Science and Business Media LLC","10.1007/s43465-026-01746-w","https://doi.org/10.1007/s43465-026-01746-w","42824576","https://pubmed.ncbi.nlm.nih.gov/42824576/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13627596/",null],["5","R0020117","R0020117.pdf","open_download_failed","other_trial","Associazione Italiana per lo Studio del Fegato (AISF)","2026","AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Elsevier BV","10.1016/j.dld.2026.02.014","https://doi.org/10.1016/j.dld.2026.02.014","41864758","https://pubmed.ncbi.nlm.nih.gov/41864758/","https://www.dldjournalonline.com/article/S1590-8658(26)00292-6/pdf",null],["5","R0020222","R0020222.pdf","free_to_read","other_trial","Ha S","2026","MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.","Science bulletin","Elsevier BV","10.1016/j.scib.2026.04.048","https://doi.org/10.1016/j.scib.2026.04.048","42115049","https://pubmed.ncbi.nlm.nih.gov/42115049/","https://doi.org/10.1016/j.scib.2026.04.048",null],["5","R0029442","R0029442.pdf","free_to_read","other_trial","Krasińska B","2026","Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy.","Journal of clinical medicine","MDPI AG","10.3390/jcm15114159","https://doi.org/10.3390/jcm15114159","42279020","https://pubmed.ncbi.nlm.nih.gov/42279020/","https://doi.org/10.3390/jcm15114159",null],["5","R0029496","R0029496.pdf","free_to_read","other_trial","Pipella J","2026","Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70711","https://doi.org/10.1111/dom.70711","41913320","https://pubmed.ncbi.nlm.nih.gov/41913320/","https://doi.org/10.1111/dom.70711",null],["5","R0029539","R0029539.pdf","open_download_failed","other_trial","Oshakbayev K","2026","Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial.","Journal of clinical medicine","MDPI AG","10.3390/jcm15020546","https://doi.org/10.3390/jcm15020546","41598484","https://pubmed.ncbi.nlm.nih.gov/41598484/","https://www.mdpi.com/2077-0383/15/2/546/pdf?version=1767954717",null],["5","R0029719","R0029719.pdf","open_download_failed","other_trial","Wang D","2026","Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70450","https://doi.org/10.1111/dom.70450","41527187","https://pubmed.ncbi.nlm.nih.gov/41527187/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.70450",null],["5","R0030019","R0030019.pdf","free_to_read","other_trial","Tantisattamo E","2026","Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?","Advances in kidney disease and health","Elsevier BV","10.1053/j.akdh.2026.02.003","https://doi.org/10.1053/j.akdh.2026.02.003","42397326","https://pubmed.ncbi.nlm.nih.gov/42397326/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13426288/",null],["5","R0033100","R0033100.pdf","free_to_read","other_trial","Gabriel Reis de Oliveira","2026","Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2","Revista fisio&terapia.","Revista ft Ltda","10.69849/v83xr454","https://doi.org/10.69849/v83xr454",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.69849/v83xr454",null],["5","R0034575","R0034575.pdf","free_to_read","other_trial","Mathew John","2026","Use of Disease-modifying Therapy in Metabolic Dysfunction-associated Steatohepatitis: Benefits to Trump Challenges","Chronicle of Diabetes Research and Practice","Ovid Technologies (Wolters Kluwer Health)","10.4103/cdrp.cdrp_25_25","https://doi.org/10.4103/cdrp.cdrp_25_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/cdrp.cdrp_25_25",null],["5","R0036221","R0036221.pdf","no_doi","other_trial","Shree Diora","2026","Disease-modifying Therapies Targeting Neuroinflammation in Alzheimer's Disease: Evaluation of Ongoing Clinical Trials","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036349","R0036349.pdf","no_doi","protocol","Joselyn Sarabia","2026","Effects of glucagon-like peptide 1 receptor agonists on cannabis use: A scoping review protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036380","R0036380.pdf","no_doi","other_trial","yanglan ou","2026","How completely do pivotal incretin-based anti-obesity trials capture skeletal-muscle health?","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037102","R0037102.pdf","free_to_read","other_trial","Clemilson Berto-Junior","2026","Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials","Drugs and Drug Candidates","MDPI AG","10.3390/ddc5020035","https://doi.org/10.3390/ddc5020035",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/ddc5020035",null],["5","R0037763","R0037763.pdf","free_to_read","protocol","Manuel Macía-Heras","2026","The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health after subcutaneous semaglutide initiation in chronic kidney disease and type 2 diabetes","BMC Nephrology","Springer Science and Business Media LLC","10.1186/s12882-026-05304-2","https://doi.org/10.1186/s12882-026-05304-2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s12882-026-05304-2",null],["5","R0038618","R0038618.pdf","free_to_read","other_trial","Anton Guo","2026","Patient perceptions of the efficacy and safety of tirzepatide: Discrepancies with clinical data and limited awareness of cardiovascular benefits","Next research.","Elsevier BV","10.1016/j.nexres.2026.102044","https://doi.org/10.1016/j.nexres.2026.102044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.nexres.2026.102044",null],["5","R0040328","R0040328.pdf","no_doi","other_trial","Elizabeth Valinotti","2026","Más allá del GLP-1: Eficacia multiórgano de los agonistas duales y triples de incretinas en el síndrome cardiometabólico","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040595","R0040595.pdf","no_doi","other_trial","Juuso Vilppula","2026","Semaglutidin vaikutusten mallintaminen aterianjälkeiseen glukoosiin ja insuliiniin käyttäen hierarkkista monilähtöistä Gaussin prosessin regressiota","Aaltodoc (Aalto University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042358","R0042358.pdf","no_doi","other_trial","M. Wang","2026","The role of endothelial ion channels in vascular protection:By SGLT2 inhibitors and GLP1 receptor agonists","UvA-DARE (University of Amsterdam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042691","R0042691.pdf","no_doi","other_trial","Pacific RxTracts","2026","Pacific RxTracts - April 2026","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042739","R0042739.pdf","no_doi","other_trial","Pacific RxTracts","2026","Pacific RxTracts - July 2026","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043276","R0043276.pdf","free_to_read","other_trial","Meghna Bordoloi","2026","Tirzepatide in the management of heart failure with preserved ejection fraction: A narrative review","Journal of Clinical Sciences","Ovid Technologies (Wolters Kluwer Health)","10.4103/jcls.jcls_173_25","https://doi.org/10.4103/jcls.jcls_173_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jcls.jcls_173_25",null],["5","R0043467","R0043467.pdf","free_to_read","protocol","Larissa Calancie","2026","Weight Loss in a Commercial Mobile Behavior Change Program With and Without Semaglutide Microdose: Protocol","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2026.109275","https://doi.org/10.1016/j.cdnut.2026.109275",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cdnut.2026.109275",null],["5","R0043489","R0043489.pdf","free_to_read","protocol","Osman Mohamed Elfadil","2026","Bridging Evidence and Practice: A Scoping Review Protocol on Access to GLP-1 Receptor Agonists for Obesity in the United States","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2026.109299","https://doi.org/10.1016/j.cdnut.2026.109299",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cdnut.2026.109299",null],["5","R0044686","R0044686.pdf","no_doi","other_trial","Pacific RxTracts","2026","Pacific RxTracts - August 2026","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045252","R0045252.pdf","free_to_read","other_trial","Steven Minh Phat Duong","2026","TRANSCEND-T2D-1 and the First-Line Question: What Retatrutide's Phase 3 Results Mean for Diabetes Care, Access & Equity","SocArXiv (OSF Preprints)","Center for Open Science","10.31235/osf.io/kyb4z_v2","https://doi.org/10.31235/osf.io/kyb4z_v2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31235/osf.io/kyb4z_v2",null],["5","R0045509","R0045509.pdf","no_doi","other_trial","Ishaan Singla","2026","Alziemer","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045719","R0045719.pdf","free_to_read","other_trial","Cheng-Hsien Hung","2026","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Autoimmune Diseases in Type 2 Diabetes: A Multicenter Emulated Target Trial","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6064329","https://doi.org/10.2139/ssrn.6064329",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6064329",null],["5","R0046021","R0046021.pdf","no_doi","protocol","Maria Fernanda Assumpção Jacob","2026","Exploring Equity in Glucose‐lowering Research for Patients with Obesity. A Meta-epidemiological Study Protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046042","R0046042.pdf","free_to_read","other_trial","Saraswathi Saiprasad","2026","Apparent Refractory Type 2 Diabetes in Extreme Obesity: Marked Improvement Following Automated Insulin Delivery","AACE Endocrinology and Diabetes","Elsevier BV","10.1016/j.aed.2026.08.005","https://doi.org/10.1016/j.aed.2026.08.005",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.aed.2026.08.005",null],["5","R0046406","R0046406.pdf","free_to_read","other_trial","Mazen Noureddin","2026","DD01, a Dual GLP-1/Glucagon Agonist, in Metabolic Dysfunction–Associated Steatotic Liver Disease and Steatohepatitis: A Phase 2 Trial Top Line Results","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6034158","https://doi.org/10.2139/ssrn.6034158",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6034158",null],["5","R0046519","R0046519.pdf","free_to_read","other_trial","Qi Li","2026","Acute cholestatic liver injury due to hypothyroidism that reversed with intravenous levothyroxine: A rare case report","Journal of Clinical and Translational Endocrinology Case Reports","Elsevier BV","10.1016/j.jecr.2026.100212","https://doi.org/10.1016/j.jecr.2026.100212",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jecr.2026.100212",null],["5","R0047327","R0047327.pdf","free_to_read","other_trial","Josie Lindle","2026","Repurposed therapeutics in alzheimer’s disease: a comparative analysis of generic and patent-protected agents (2016–2025)","Alzheimer s Research & Therapy","Springer Science and Business Media LLC","10.1186/s13195-026-02175-5","https://doi.org/10.1186/s13195-026-02175-5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1186/s13195-026-02175-5",null],["5","R0047531","R0047531.pdf","free_to_read","other_trial","Thomas R. Rutledge","2026","Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity: A Pre-to-Post-Treatment Study","Heart and Mind","Ovid Technologies (Wolters Kluwer Health)","10.4103/hm.hm-d-25-00125","https://doi.org/10.4103/hm.hm-d-25-00125",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/hm.hm-d-25-00125",null],["5","R0047696","R0047696.pdf","free_to_read","other_trial","Andrea Mega","2026","ACNMD26-244: EFFECTS OF GLP1-RAS AND SGLT2I ON LIVER STEATOSIS AND FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) WITH TYPE 2 DIABETES: INTERIM ANALYSIS OF AN OPEN TRIAL","Digestive and Liver Disease","Elsevier BV","10.1016/s1590-8658(26)00503-7","https://doi.org/10.1016/s1590-8658(26)00503-7",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s1590-8658(26)00503-7",null],["5","R0048254","R0048254.pdf","no_doi","protocol","Yigang Liu","2026","Practice Recommendations for Perioperative Management of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 RAs: A Scoping Review Protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048401","R0048401.pdf","free_to_read","other_trial","Peter A. Timmins","2026","Industry update: the latest developments in the field of therapeutic delivery, December 2025","Therapeutic Delivery","Informa UK Limited","10.1080/20415990.2026.2642514","https://doi.org/10.1080/20415990.2026.2642514","41823185","https://pubmed.ncbi.nlm.nih.gov/41823185/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13094284/",null],["5","R0048554","R0048554.pdf","free_to_read","other_trial","Maja Sosnowska","2026","Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum","Endocrines","MDPI AG","10.3390/endocrines7030048","https://doi.org/10.3390/endocrines7030048",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/endocrines7030048",null],["5","R0049053","R0049053.pdf","free_to_read","other_trial","Rishi Gupta","2026","Sex differences in the cardiovascular consequences of type 2 diabetes: the role of glucose-lowering therapy","Current Opinion in Physiology","Elsevier BV","10.1016/j.cophys.2026.100930","https://doi.org/10.1016/j.cophys.2026.100930",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cophys.2026.100930",null],["5","R0049599","R0049599.pdf","no_doi","other_trial","Oliver Schnell","2026","CVOT Summit Report 2024","DiRROS repository (University of Maribor)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049914","R0049914.pdf","no_doi","other_trial","Filipe Moura","2026","Cardiovascular Imaging of GLP-1–Based Therapies in Adults: A Scoping Review of Remodeling Domains, Imaging Modalities, and Evidence Gaps","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0050323","R0050323.pdf","no_doi","other_trial","Wiaam Al‐Hasani","2026","Glicentin Concentrations Following Glucagon Like Peptide-1 Receptor Agonist Treatment in those with Overweight/Obesity; Open Label Trial","Research Portal (King's College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051469","R0051469.pdf","free_to_read","other_trial","Giacinta Ciancimino","2026","Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives","Hepatoma Research","OAE Publishing Inc.","10.20517/2394-5079.2026.19","https://doi.org/10.20517/2394-5079.2026.19",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20517/2394-5079.2026.19",null],["5","R0053759","R0053759.pdf","free_to_read","other_trial","K. N. Sorokina","2026","Drugs used in the treatment of Alzheimer’s disease: a review of current clinical research and promising therapeutic targets","Сибирский научный медицинский журнал","Institute of Cytology and Genetics, SB RAS","10.18699/ssmj20260102","https://doi.org/10.18699/ssmj20260102",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18699/ssmj20260102",null],["5","R0053820","R0053820.pdf","free_to_read","other_trial","Pasquale Mone","2026","Sodium/glucose cotransporters 2 inhibitors but not other antidiabetic drugs improve frailty in older adults with diabetes and heart failure with preserved ejection fraction","Cardiovascular Research","Oxford University Press (OUP)","10.1093/cvr/cvag065","https://doi.org/10.1093/cvr/cvag065","41871939","https://pubmed.ncbi.nlm.nih.gov/41871939/","https://pmc.ncbi.nlm.nih.gov/articles/PMC13196867/",null],["5","R0054110","R0054110.pdf","free_to_read","other_trial","Aleksandra Wielogórska","2026","ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.3(51).2026.5972","https://doi.org/10.31435/ijitss.3(51).2026.5972",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.3(51).2026.5972",null],["5","R0054119","R0054119.pdf","free_to_read","other_trial","Sandeep Kharb","2026","Semaglutide for Organ Protection","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_27_26","https://doi.org/10.4103/ijdt.ijdt_27_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_27_26",null],["5","R0054250","R0054250.pdf","no_doi","other_trial","Maria A. Pabón","2026","the FINE-HEART pooled analysis","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"PROSPERO:CRD42024570467"],["5","R0054304","R0054304.pdf","free_to_read","other_trial","Julia M. Umińska","2026","Tirzepatide Versus Semaglutide: A Structured Narrative Review of Direct Comparative Clinical Studies and Post Hoc Analyses on Clinical and Laboratory Outcomes","Obesities","MDPI AG","10.3390/obesities6030038","https://doi.org/10.3390/obesities6030038",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/obesities6030038",null],["5","R0054451","R0054451.pdf","free_to_read","other_trial","Mohan Badgandi","2026","Positioning of Semaglutide among Evolving Guidelines in the Management of Obesity and Related Comorbidities","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_20_26","https://doi.org/10.4103/ijdt.ijdt_20_26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_20_26",null],["5","R0054501","R0054501.pdf","free_to_read","other_trial","Srikanth Bellary","2026","WCN26-4078 EFFECT OF ONCE-WEEKLY SEMAGLUTIDE 1.0 MG ON KIDNEY OUTCOMES BY BASELINE CHARACTERISTICS: EXPLORATORY DATA FROM THE FLOW TRIAL","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2026.104616","https://doi.org/10.1016/j.ekir.2026.104616",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2026.104616",null],["5","R0054771","R0054771.pdf","free_to_read","other_trial","Ruhi Vaitha","2026","Can GLP-1RA be utilised for pre-operative liver optimisation prior to hepatectomy? A scoping review of MASLD evidence with surgical translation","Clinical Surgical Oncology","Elsevier BV","10.1016/j.cson.2026.100136","https://doi.org/10.1016/j.cson.2026.100136",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cson.2026.100136",null],["5","R0055505","R0055505.pdf","free_to_read","other_trial","Katherine Tuttle","2026","WCN26-3778 MECHANISTIC EFFECTS OF SEMAGLUTIDE ON KIDNEY DISEASE IN TYPE 2 DIABETES: THE REMODEL TRIAL","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2026.104610","https://doi.org/10.1016/j.ekir.2026.104610",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2026.104610",null],["5","R0055627","R0055627.pdf","free_to_read","other_trial","Elena Georgievna Starostina","2026","Nutrition specifics in type 2 diabetic patients with binge eating disorder and the effects of glucagonlike peptide I receptor agonists","Obesity and metabolism","Endocrinology Research Centre","10.14341/omet13343","https://doi.org/10.14341/omet13343",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.14341/omet13343",null],["5","R0055629","R0055629.pdf","free_to_read","other_trial","Karthik Murugadoss","2026","Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease Revealed by LLM-Curation of Decades of Clinical Notes has Implications for Semaglutide Trial Design","SSRN Electronic Journal","Elsevier BV","10.2139/ssrn.6841482","https://doi.org/10.2139/ssrn.6841482",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2139/ssrn.6841482",null],["5","R0055873","R0055873.pdf","free_to_read","other_trial","Chrysoula Boutari","2026","Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease","Life","MDPI AG","10.3390/life16101656","https://doi.org/10.3390/life16101656",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/life16101656",null],["5","R0055960","R0055960.pdf","free_to_read","other_trial","Zilin Dong","2026","Research trends and knowledge structure of pancreatic cancer and type 2 diabetes mellitus research: a two-decade CiteSpace analysis","Frontiers in Endocrinology","Frontiers Media SA","10.3389/fendo.2026.1945735","https://doi.org/10.3389/fendo.2026.1945735",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3389/fendo.2026.1945735",null],["5","R0055990","R0055990.pdf","no_doi","other_trial","Eun Kyoung Kang","2026","Transforming Obesity Management: Integrating AI-Driven Digital Health and Novel Pharmacotherapy","aSSIST Business Review",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056264","R0056264.pdf","free_to_read","other_trial","Diana-Maria Mateescu","2026","Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence","Pharmaceutics","MDPI AG","10.3390/pharmaceutics18101277","https://doi.org/10.3390/pharmaceutics18101277",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/pharmaceutics18101277",null],["5","R0056288","R0056288.pdf","free_to_read","other_trial","Mohammad Riashad Monjur","2026","Generic GLP-1 receptor agonists in India: an opportunity to close the cardiovascular evidence gap","The Lancet Regional Health - Southeast Asia","Elsevier BV","10.1016/j.lansea.2026.100880","https://doi.org/10.1016/j.lansea.2026.100880",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.lansea.2026.100880",null],["5","R0056413","R0056413.pdf","no_doi","other_trial","Charalampos Triantis","2026","Novel Pharmacological Advancements in Obesity Management. The era of incretins and their analogs","Pharmakeftiki",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056453","R0056453.pdf","no_doi","other_trial","Cornelia Bala","2026","Obesity pharmacotherapy: 2026 update recommendations for the care of persons with obesity in Romania","Romanian Journal of Diabetes Nutrition and Metabolic Diseases",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056479","R0056479.pdf","free_to_read","other_trial","Ishtiaque Ahmad","2026","Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective","Pharmaceutics","MDPI AG","10.3390/pharmaceutics18101281","https://doi.org/10.3390/pharmaceutics18101281",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/pharmaceutics18101281",null],["5","R0056553","R0056553.pdf","no_doi","other_trial","Elisabetta BUGIANESI","2026","Analysis of fibrosis-related histology endpoints and NITs in a phase 2 trial of survodutide in people with MASH and fibrosis","Institutional Research Information System University of Turin (University of Turin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056575","R0056575.pdf","free_to_read","other_trial","Urvah Tauseef","2026","Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome","Reproductive Medicine","MDPI AG","10.3390/reprodmed7040055","https://doi.org/10.3390/reprodmed7040055",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3390/reprodmed7040055",null],["5","R0056593","R0056593.pdf","no_doi","other_trial","Parisa Momeni","2026","Building Trustworthy Information Systems: A Unified Framework For Comparative Risk Detection","Digital Commons - University of South Florida (University of South Florida)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056595","R0056595.pdf","no_doi","other_trial","Mazen Noureddin","2026","Prediction of liver histology response by non-invasive tests: exploratory analysis of the survodutide phase 2 trial","Institutional Research Information System University of Turin (University of Turin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056670","R0056670.pdf","free_to_read","other_trial","Hussein Zaitoon","2026","Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat","EClinicalMedicine","Elsevier BV","10.1016/j.eclinm.2026.104258","https://doi.org/10.1016/j.eclinm.2026.104258",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.eclinm.2026.104258",null],["5","R0056708","R0056708.pdf","no_doi","protocol","Sjaan R. Gomersall","2026","Physical activity as an adjuvant to GLP-1 receptor agonist therapy: A scoping review protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0000490","R0000490.pdf","free_to_read","other_trial","Madsbad S","2025","The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2472408","https://doi.org/10.1080/13543784.2025.2472408","40022548","https://pubmed.ncbi.nlm.nih.gov/40022548/","https://doi.org/10.1080/13543784.2025.2472408",null],["5","R0000650","R0000650.pdf","open_download_failed","other_trial","Alkhouri N","2025","The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2473062","https://doi.org/10.1080/13543784.2025.2473062","40016997","https://pubmed.ncbi.nlm.nih.gov/40016997/","https://www.tandfonline.com/doi/pdf/10.1080/13543784.2025.2473062",null],["5","R0000894","R0000894.pdf","open_download_failed","other_trial","Saldívar-Cerón HI","2025","Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies","Preprints.org","MDPI AG","10.20944/preprints202505.0972.v1","https://doi.org/10.20944/preprints202505.0972.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/7be468775bea75bf2036c55c34b8f0dc/download_pub",null],["5","R0001353","R0001353.pdf","free_to_read","other_trial","Dreher L","2025","Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?","Hypertension (Dallas, Tex. : 1979)","Ovid Technologies (Wolters Kluwer Health)","10.1161/hypertensionaha.125.25112","https://doi.org/10.1161/hypertensionaha.125.25112","40406862","https://pubmed.ncbi.nlm.nih.gov/40406862/","https://pure.eur.nl/en/publications/acb1394a-678f-4db6-b9e3-9ccba60a669a",null],["5","R0001693","R0001693.pdf","open_download_failed","narrative_review","Pohlman N","2025","Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf295","https://doi.org/10.1210/clinem/dgaf295","40388382","https://pubmed.ncbi.nlm.nih.gov/40388382/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12823194/pdf/nihms-2131510.pdf",null],["5","R0002109","R0002109.pdf","open_download_failed","other_trial","Chen AS","2025","Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges.","Diabetes","American Diabetes Association","10.2337/dbi25-0004","https://doi.org/10.2337/dbi25-0004","40644314","https://pubmed.ncbi.nlm.nih.gov/40644314/","https://diabetesjournals.org/diabetes/article-pdf/doi/10.2337/dbi25-0004/836727/dbi250004.pdf",null],["5","R0002233","R0002233.pdf","open_download_failed","other_trial","Ezhilarasan D","2025","Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?","Journal of gastroenterology and hepatology","Wiley","10.1111/jgh.17037","https://doi.org/10.1111/jgh.17037","40538007","https://pubmed.ncbi.nlm.nih.gov/40538007/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.17037",null],["5","R0002394","R0002394.pdf","free_to_read","other_trial","Qi W","2025","Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.","The Journal of pharmacology and experimental therapeutics","Elsevier BV","10.1016/j.jpet.2025.103683","https://doi.org/10.1016/j.jpet.2025.103683","41015846","https://pubmed.ncbi.nlm.nih.gov/41015846/","https://doi.org/10.1016/j.jpet.2025.103683","ClinicalTrials.gov:NCT05694741"],["5","R0002570","R0002570.pdf","free_to_read","other_trial","Kaiser M","2025","Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss.","Cardiology in review","Ovid Technologies (Wolters Kluwer Health)","10.1097/crd.0000000000001113","https://doi.org/10.1097/crd.0000000000001113","41248895","https://pubmed.ncbi.nlm.nih.gov/41248895/","https://doi.org/10.1097/crd.0000000000001113",null],["5","R0002750","R0002750.pdf","free_to_read","other_trial","Chen J","2025","Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2025.101641","https://doi.org/10.1016/j.diabet.2025.101641","40127835","https://pubmed.ncbi.nlm.nih.gov/40127835/","https://doi.org/10.1016/j.diabet.2025.101641",null],["5","R0003397","R0003397.pdf","open_download_failed","preclinical","Luconi M","2025","Repurposing glucose-lowering drugs for cancer therapy.","Trends in cancer","Elsevier BV","10.1016/j.trecan.2025.04.010","https://doi.org/10.1016/j.trecan.2025.04.010","40374399","https://pubmed.ncbi.nlm.nih.gov/40374399/","https://www.cell.com/action/showPdf?pii=S2405803325001062",null],["5","R0003607","R0003607.pdf","free_to_read","protocol","Builes-Montaño CE","2025","Combining Glucagon-Like Peptide-1 Receptor agonists and Sodium-Glucose Cotransporter-2 Inhibitors in the management of Type 2 Diabetes Mellitus: A protocol for a scoping review","F1000Res","F1000 Research Ltd","10.12688/f1000research.159628.1","https://doi.org/10.12688/f1000research.159628.1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.12688/f1000research.159628.1",null],["5","R0003800","R0003800.pdf","open_download_failed","protocol","Biasin M","2025","Use of oral Semaglutide after Acute Coronary Syndrome - Design and rationale of a prospective observational study","medRxiv","openRxiv","10.1101/2025.08.03.25332910","https://doi.org/10.1101/2025.08.03.25332910",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/08/05/2025.08.03.25332910.full.pdf",null],["5","R0004514","R0004514.pdf","free_to_read","protocol","Lam CSP","2025","Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24332","https://doi.org/10.1002/oby.24332","40545827","https://pubmed.ncbi.nlm.nih.gov/40545827/","https://hdl.handle.net/11370/e9585a12-4ba7-4b0e-89a8-8ae8dcdf7e8b",null],["5","R0004700","R0004700.pdf","free_to_read","other_trial","Gajos G","2025","Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.","Polish archives of internal medicine","&quot;Medycyna Praktyczna&quot; Spolka Jawna","10.20452/pamw.16983","https://doi.org/10.20452/pamw.16983","40126003","https://pubmed.ncbi.nlm.nih.gov/40126003/","https://doi.org/10.20452/pamw.16983",null],["5","R0005294","R0005294.pdf","open_download_failed","protocol","Brødsgaard RH","2025","Exploring Cardiometabolic Health, Physical Activity, and Quality of Life in Patients with Obesity and Multimorbidity during an Intensive Weight Loss Program: A Protocol for a Real-Life Prospective Cohort Study","medRxiv","openRxiv","10.1101/2025.10.20.25337060","https://doi.org/10.1101/2025.10.20.25337060",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/10/21/2025.10.20.25337060.full.pdf","ClinicalTrials.gov:NCT06234111"],["5","R0005476","R0005476.pdf","open_download_failed","protocol","Biasin M","2025","Use of Semaglutide After Acute Coronary Syndrome - Design and rationale of a retrospective observational study","medRxiv","openRxiv","10.1101/2025.07.31.25332452","https://doi.org/10.1101/2025.07.31.25332452",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/08/01/2025.07.31.25332452.full.pdf",null],["5","R0005656","R0005656.pdf","free_to_read","other_trial","Doggrell SA","2025","Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2025.2459409","https://doi.org/10.1080/13543784.2025.2459409","39864104","https://pubmed.ncbi.nlm.nih.gov/39864104/","https://hdl.handle.net/10072/435400",null],["5","R0005729","R0005729.pdf","open_download_failed","other_trial","Saldívar-Cerón HI","2025","Once-Monthly Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines","Preprints.org","MDPI AG","10.20944/preprints202512.1726.v1","https://doi.org/10.20944/preprints202512.1726.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/8f0b88ff05d9221c0624fab564ba2637/download_pub",null],["5","R0005766","R0005766.pdf","free_to_read","other_trial","Ostrominski JW","2025","Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.","Diabetes care","American Diabetes Association","10.2337/dc24-1873","https://doi.org/10.2337/dc24-1873","40019856","https://pubmed.ncbi.nlm.nih.gov/40019856/","https://research.rug.nl/en/publications/0ab22ff4-0a86-4e0e-9c18-6239c01249e5",null],["5","R0006386","R0006386.pdf","open_download_failed","other_trial","Langer HT","2025","Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.07.28.25332295","https://doi.org/10.1101/2025.07.28.25332295","40766140","https://pubmed.ncbi.nlm.nih.gov/40766140/","https://www.medrxiv.org/content/medrxiv/early/2025/07/28/2025.07.28.25332295.full.pdf",null],["5","R0006476","R0006476.pdf","open_download_failed","narrative_review","Moiz A","2025","Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2025.01.021","https://doi.org/10.1016/j.amjmed.2025.01.021","39892489","https://pubmed.ncbi.nlm.nih.gov/39892489/","https://www.amjmed.com/article/S0002-9343(25)00059-2/pdf",null],["5","R0006848","R0006848.pdf","open_download_failed","other_trial","Saha B","2025","GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.","Mayo Clinic proceedings","Elsevier BV","10.1016/j.mayocp.2025.09.017","https://doi.org/10.1016/j.mayocp.2025.09.017","41324524","https://pubmed.ncbi.nlm.nih.gov/41324524/","https://www.mayoclinicproceedings.org/article/S0025-6196(25)00551-8/pdf",null],["5","R0007631","R0007631.pdf","open_download_failed","other_trial","Murakami T","2025","Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaf253","https://doi.org/10.1210/clinem/dgaf253","40391925","https://pubmed.ncbi.nlm.nih.gov/40391925/","https://repository.kulib.kyoto-u.ac.jp/bitstreams/b5d19929-d93f-46d9-8dfd-0fea10d756e2/download",null],["5","R0008113","R0008113.pdf","open_download_failed","other_trial","Tangirala S","2025","Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteomic atlas of glycemic stages","medRxiv","openRxiv","10.1101/2025.09.26.25336579","https://doi.org/10.1101/2025.09.26.25336579",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/09/28/2025.09.26.25336579.full.pdf",null],["5","R0008713","R0008713.pdf","open_download_failed","other_trial","Ghalamghash R","2025","Biopharma Evaluation of Anti-Obesity Vaccines in Global Trials by Dr. Slim™","Preprints.org","MDPI AG","10.20944/preprints202506.0907.v1","https://doi.org/10.20944/preprints202506.0907.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/frontend/manuscript/9981ccbc2630658b999fd1e46373fd6e/download_pub",null],["5","R0008819","R0008819.pdf","free_to_read","other_trial","Alhomoud IS","2025","Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems.","Canadian journal of physiology and pharmacology","Canadian Science Publishing","10.1139/cjpp-2025-0038","https://doi.org/10.1139/cjpp-2025-0038","40367521","https://pubmed.ncbi.nlm.nih.gov/40367521/","https://doi.org/10.1139/cjpp-2025-0038",null],["5","R0010992","R0010992.pdf","free_to_read","other_trial","Neff GW","2025","Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.70148","https://doi.org/10.1111/dom.70148","41025406","https://pubmed.ncbi.nlm.nih.gov/41025406/","https://doi.org/10.1111/dom.70148",null],["5","R0011988","R0011988.pdf","no_doi","other_trial","Grad R","2025","Top 20 Research Studies of 2024 for Primary Care Physicians.","American family physician",null,null,"https://doi.org/","40736492","https://pubmed.ncbi.nlm.nih.gov/40736492/",null,null],["5","R0012089","R0012089.pdf","free_to_read","other_trial",null,"2025","Semaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: Reimbursement Recommendation","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","41021710","https://pubmed.ncbi.nlm.nih.gov/41021710/",null,null],["5","R0012186","R0012186.pdf","free_to_read","other_trial","Hamza M","2025","Tirzepatide for overweight and obesity management.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2024.2436595","https://doi.org/10.1080/14656566.2024.2436595","39632534","https://pubmed.ncbi.nlm.nih.gov/39632534/","https://doi.org/10.1080/14656566.2024.2436595",null],["5","R0012433","R0012433.pdf","open_download_failed","commentary","Volkow ND","2025","GLP-1R agonist medications for addiction treatment.","Addiction (Abingdon, England)","Wiley","10.1111/add.16626","https://doi.org/10.1111/add.16626","39049203","https://pubmed.ncbi.nlm.nih.gov/39049203/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12771407/pdf/nihms-2127214.pdf",null],["5","R0012969","R0012969.pdf","open_download_failed","other","Zushin PH","2025","Evaluating the benefits of the early use of GLP-1 receptor agonists.","Lancet (London, England)","Elsevier BV","10.1016/s0140-6736(24)02255-4","https://doi.org/10.1016/s0140-6736(24)02255-4","39547251","https://pubmed.ncbi.nlm.nih.gov/39547251/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11921982/pdf/nihms-2060848.pdf",null],["5","R0013075","R0013075.pdf","free_to_read","protocol","Barrett R","2025","A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1016/j.jval.2025.03.017","https://doi.org/10.1016/j.jval.2025.03.017","40246067","https://pubmed.ncbi.nlm.nih.gov/40246067/","https://doi.org/10.1016/j.jval.2025.03.017",null],["5","R0014557","R0014557.pdf","free_to_read","other_trial","Kramer CM","2025","Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.11.001","https://doi.org/10.1016/j.jacc.2024.11.001","39566869","https://pubmed.ncbi.nlm.nih.gov/39566869/","https://doi.org/10.1016/j.jacc.2024.11.001","ClinicalTrials.gov:NCT04847557"],["5","R0015039","R0015039.pdf","open_download_failed","other_trial","Linden FH","2025","External Validation of an Automated Segmentation Tool for Abdominal Fat Tissue using DIXON MRI: Data from the CutDM trial","medRxiv","openRxiv","10.1101/2025.05.14.25327583","https://doi.org/10.1101/2025.05.14.25327583",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/05/14/2025.05.14.25327583.full.pdf",null],["5","R0015963","R0015963.pdf","free_to_read","other_trial","Kaul S","2025","Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.06.036","https://doi.org/10.1016/j.jacc.2025.06.036","40835369","https://pubmed.ncbi.nlm.nih.gov/40835369/","https://doi.org/10.1016/j.jacc.2025.06.036",null],["5","R0015978","R0015978.pdf","open_download_failed","other_trial","Ramos M","2025","The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2025.2575692","https://doi.org/10.1080/13696998.2025.2575692","41090945","https://pubmed.ncbi.nlm.nih.gov/41090945/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2025.2575692?needAccess=true",null],["5","R0016589","R0016589.pdf","free_to_read","other_trial",null,"2025","Weight-Dependent and -Independent Effects of Semaglutide in Participants With MASH: Secondary Analysis of the Phase 3 ESSENCE Trial.","Gastroenterology & hepatology",null,null,"https://doi.org/","41660648","https://pubmed.ncbi.nlm.nih.gov/41660648/",null,null],["5","R0016719","R0016719.pdf","free_to_read","other_trial","Verma S","2025","Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2025.08.046","https://doi.org/10.1016/j.jacc.2025.08.046","40892617","https://pubmed.ncbi.nlm.nih.gov/40892617/","https://doi.org/10.1016/j.jacc.2025.08.046",null],["5","R0016873","R0016873.pdf","open_download_failed","other_trial","Arai T","2025","Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.","Hepatology research : the official journal of the Japan Society of Hepatology","Wiley","10.1111/hepr.14241","https://doi.org/10.1111/hepr.14241","40616360","https://pubmed.ncbi.nlm.nih.gov/40616360/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/hepr.14241",null],["5","R0017115","R0017115.pdf","free_to_read","other_trial","Dib S","2025","Weight management during pregnancy, what is new?","Current opinion in clinical nutrition and metabolic care","Ovid Technologies (Wolters Kluwer Health)","10.1097/mco.0000000000001127","https://doi.org/10.1097/mco.0000000000001127","40294128","https://pubmed.ncbi.nlm.nih.gov/40294128/","https://figshare.com/articles/journal_contribution/Weight_management_during_pregnancy_what_is_new_/29424215",null],["5","R0018293","R0018293.pdf","open_download_failed","other_trial","Yang G","2025","Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study","medRxiv","openRxiv","10.1101/2025.02.12.25322150","https://doi.org/10.1101/2025.02.12.25322150",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2025/02/13/2025.02.12.25322150.full.pdf",null],["5","R0018892","R0018892.pdf","open_download_failed","other_trial","Ditzenberger GL","2025","Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Oxford University Press (OUP)","10.1093/cid/ciae384","https://doi.org/10.1093/cid/ciae384","39046173","https://pubmed.ncbi.nlm.nih.gov/39046173/","https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae384/58797620/ciae384.pdf","ClinicalTrials.gov:NCT04216589"],["5","R0020346","R0020346.pdf","open_download_failed","protocol","Stougaard EB","2025","The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.16606","https://doi.org/10.1111/dom.16606","40726451","https://pubmed.ncbi.nlm.nih.gov/40726451/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16606",null],["5","R0020640","R0020640.pdf","open_download_failed","protocol","Christensen JC","2025","The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2024.107766","https://doi.org/10.1016/j.cct.2024.107766","39608749","https://pubmed.ncbi.nlm.nih.gov/39608749/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11875690/pdf/nihms-2059898.pdf",null],["5","R0021569","R0021569.pdf","open_download_failed","other_trial","Li JH","2025","Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2025.10.07.25336827","https://doi.org/10.1101/2025.10.07.25336827","41282760","https://pubmed.ncbi.nlm.nih.gov/41282760/","https://www.medrxiv.org/content/medrxiv/early/2025/10/08/2025.10.07.25336827.full.pdf","ClinicalTrials.gov:NCT01794143"],["5","R0022532","R0022532.pdf","open_download_failed","other_trial","van Galen I","2025","Drug repurposing for osteoarthritis disease modification in the early 21st century.","Connective tissue research","Informa UK Limited","10.1080/03008207.2025.2538562","https://doi.org/10.1080/03008207.2025.2538562","40751563","https://pubmed.ncbi.nlm.nih.gov/40751563/","https://www.tandfonline.com/doi/pdf/10.1080/03008207.2025.2538562?needAccess=true",null],["5","R0023944","R0023944.pdf","open_download_failed","other_trial","Hales CM","2025","High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.","Childhood obesity (Print)","SAGE Publications","10.1089/chi.2024.0248","https://doi.org/10.1089/chi.2024.0248","38995874","https://pubmed.ncbi.nlm.nih.gov/38995874/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12422332/pdf/nihms-2100179.pdf",null],["5","R0029025","R0029025.pdf","open_download_failed","other_trial","von Huth Smith L","2025","Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.","Clinical obesity","Wiley","10.1111/cob.70015","https://doi.org/10.1111/cob.70015","40452267","https://pubmed.ncbi.nlm.nih.gov/40452267/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.70015","ClinicalTrials.gov:NCT05035095"],["5","R0029068","R0029068.pdf","open_download_failed","other_trial","Cazac-Panaite GD","2025","Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.","Journal of clinical medicine","MDPI AG","10.3390/jcm14041042","https://doi.org/10.3390/jcm14041042","40004572","https://pubmed.ncbi.nlm.nih.gov/40004572/","https://www.mdpi.com/2077-0383/14/4/1042/pdf?version=1738913591",null],["5","R0029080","R0029080.pdf","open_download_failed","other_trial","Bhargava A","2025","Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes.","Diabetes technology & therapeutics","SAGE Publications","10.1089/dia.2024.0586","https://doi.org/10.1089/dia.2024.0586","39912797","https://pubmed.ncbi.nlm.nih.gov/39912797/","https://www.liebertpub.com/doi/pdf/10.1089/dia.2024.0586?download=true","ClinicalTrials.gov:NCT05238142"],["5","R0029579","R0029579.pdf","free_to_read","preclinical","Wong CK","2025","Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.","The Journal of clinical investigation","American Society for Clinical Investigation","10.1172/jci194751","https://doi.org/10.1172/jci194751","41178710","https://pubmed.ncbi.nlm.nih.gov/41178710/","https://doi.org/10.1172/jci194751",null],["5","R0029896","R0029896.pdf","free_to_read","other_trial",null,"2025","Top-Line Phase 2 Results of DD01, a Dual GLP-1/Glucagon Agonist, Lead to Rapid Improvements in Liver and Metabolic Endpoints in Patients With MASLD/MASH.","Gastroenterology & hepatology",null,null,"https://doi.org/","41660647","https://pubmed.ncbi.nlm.nih.gov/41660647/",null,null],["5","R0032639","R0032639.pdf","free_to_read","other_trial","Maria Zasadzińska","2025","Semaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease","Journal of Medical Science","Poznan University of Medical Sciences","10.20883/medical.e1219","https://doi.org/10.20883/medical.e1219",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.20883/medical.e1219",null],["5","R0034144","R0034144.pdf","no_doi","other_trial","Angela Ai","2025","Assessing the Independent and Joint Effects of GLP1R and GIPR on Liver Fat and BMI Using Mendelian Randomization","ScholarlyCommons (University of Pennsylvania)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034168","R0034168.pdf","no_doi","protocol","Hall, L.A.","2025","Acute pancreatitis national audit of practice: a national prospective audit of acute pancreatitis in the era of GLP-1 agonists—the PANDORA audit protocol","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034195","R0034195.pdf","free_to_read","other_trial","Rohan Karkra","2025","Semaglutide and the Evolving Landscape of Metabolic Dysfunction–Associated Steatotic Liver Disease","Digital Journal of Clinical Medicine","JSS Academy of Higher Education & Research","10.55691/2582-3868.1280","https://doi.org/10.55691/2582-3868.1280",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.55691/2582-3868.1280",null],["5","R0035744","R0035744.pdf","no_doi","other_trial","Emma Hickey","2025","Investigating Efficacy of Nanomedicine for Novel Parkinson's Disease Therapeutics","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036152","R0036152.pdf","no_doi","protocol","Rienna Grace Russo","2025","Beyond Intention-to-Treat Analyses in Randomized Trials: Utilizing Per-Protocol Estimands and Observational Data to Investigate Strategies for Cardiovascular Disease Prevention","Digital Access to Scholarship at Harvard (DASH) (Harvard University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036185","R0036185.pdf","no_doi","other_trial","Ebonne' M Quiller","2025","Evaluating the Efficacy and Ethical Implications of Semaglutide and GLP-1 Receptor Agonists for Weight Management in Obesity","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036233","R0036233.pdf","no_doi","other_trial","Elizabeth N. Parker","2025","Balancing Weight Loss and Muscle Preservation During GLP-1-Based Therapy for Type 2 Diabetes and Obesity: A Clinical Review","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036244","R0036244.pdf","no_doi","other_trial","Jenny Illman","2025","The metabolic effects of incretin mimetics in L6 skeletal muscle cells","Työväentutkimus Vuosikirja",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036390","R0036390.pdf","no_doi","other_trial","Lakshminarayanan Varadhan","2025","Personalized and evidence-based management of type 2 diabetes : the role of clinical-phenotyping for treatment planning and surveillance of complications","Warwick Research Archive Portal (University of Warwick)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036879","R0036879.pdf","free_to_read","other_trial","Uchechukwu Chiadikobi","2025","GLP Agonist and Weight Loss: A Systemic Review on GLP-1 Agonist and Its Effect on the Pancreas for Nondiabetic Patients of African Descent","International Journal For Multidisciplinary Research","International Journal for Multidisciplinary Research (IJFMR)","10.36948/ijfmr.2025.v07i02.39726","https://doi.org/10.36948/ijfmr.2025.v07i02.39726",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36948/ijfmr.2025.v07i02.39726",null],["5","R0036932","R0036932.pdf","free_to_read","other_trial","Jin Hwa Kim","2025","The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence","Journal of Korean Diabetes","Korean Diabetes Association","10.4093/jkd.2025.26.1.5","https://doi.org/10.4093/jkd.2025.26.1.5",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4093/jkd.2025.26.1.5",null],["5","R0036963","R0036963.pdf","free_to_read","other_trial","Luc Pellerin","2025","The future of healthy brain aging will be metabolic: a predictive lesson from data-driven modeling","Frontiers in Science","Frontiers Media SA","10.3389/fsci.2025.1561735","https://doi.org/10.3389/fsci.2025.1561735",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3389/fsci.2025.1561735",null],["5","R0042254","R0042254.pdf","no_doi","other_trial","Mega A.","2025","Effects of GLP1-RAS and SGLT2I on liver steatosis and fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD) with type 2 diabetes: interim analysis of an open trial","Padua Research Archive (University of Padova)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042638","R0042638.pdf","no_doi","other_trial","Pacific RxTracts","2025","Pacific RxTracts - April 2025","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042655","R0042655.pdf","no_doi","other_trial","Pacific RxTracts","2025","Pacific RxTracts - July 2025","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042832","R0042832.pdf","no_doi","other_trial","Pacific RxTracts","2025","Pacific RxTracts - August 2025","Scholarly Commons (University of the Pacific)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043416","R0043416.pdf","free_to_read","other_trial","Liang Tang","2025","In Silico discovery and design of molecular glues as a new strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor","ChemRxiv","American Chemical Society (ACS)","10.26434/chemrxiv-2025-k2gjf","https://doi.org/10.26434/chemrxiv-2025-k2gjf",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26434/chemrxiv-2025-k2gjf",null],["5","R0043544","R0043544.pdf","no_doi","other_trial","Sautron, Anthony","2025","L'intérêt du tirzépatide dans la prise en charge non remboursée de l'obésité chez les patients adultes, conseils à l'officine","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043690","R0043690.pdf","no_doi","other_trial","JM Dennis (21320054)","2025","Precision medicine in type 2 diabetes: Using individualised prediction models to optimise selection of treatment","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0045431","R0045431.pdf","free_to_read","other_trial","Chun-Ting Ho","2025","The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered","Journal of the Chinese Medical Association","Ovid Technologies (Wolters Kluwer Health)","10.1097/jcma.0000000000001266","https://doi.org/10.1097/jcma.0000000000001266","40626331","https://pubmed.ncbi.nlm.nih.gov/40626331/","https://doi.org/10.1097/jcma.0000000000001266",null],["5","R0046157","R0046157.pdf","free_to_read","other_trial","Sinan Ai","2025","Macrophages: Novel Molecular Mechanism and Therapeutic Strategy in Diabetic Kidney Disease","Integrative Medicine in Nephrology and Andrology","Ovid Technologies (Wolters Kluwer Health)","10.1097/imna-d-25-00021","https://doi.org/10.1097/imna-d-25-00021",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/imna-d-25-00021",null],["5","R0046391","R0046391.pdf","free_to_read","other_trial","De Arka","2025","Metabolic dysfunction-associated steatotic liver disease in India: A growing public health imperative and call to action","International Journal of Noncommunicable Diseases","Ovid Technologies (Wolters Kluwer Health)","10.4103/jncd.jncd_223_25","https://doi.org/10.4103/jncd.jncd_223_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jncd.jncd_223_25",null],["5","R0047369","R0047369.pdf","free_to_read","other_trial","John W. Ostrominski","2025","Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials ofHeart Failure and Chronic Kidney Disease",null,"American Diabetes Association","10.2337/figshare.28391639","https://doi.org/10.2337/figshare.28391639",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/figshare.28391639",null],["5","R0048270","R0048270.pdf","free_to_read","other_trial","Ilse Dewachter","2025","A peek into the pipeline: Expert views on emerging therapies","Cell Reports Medicine","Elsevier BV","10.1016/j.xcrm.2025.102083","https://doi.org/10.1016/j.xcrm.2025.102083","40239631","https://pubmed.ncbi.nlm.nih.gov/40239631/","https://doi.org/10.1016/j.xcrm.2025.102083",null],["5","R0048341","R0048341.pdf","free_to_read","other_trial","Blair Suter","2025","The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management","Current Cardiovascular Risk Reports","Springer Science and Business Media LLC","10.1007/s12170-025-00761-0","https://doi.org/10.1007/s12170-025-00761-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1007/s12170-025-00761-0",null],["5","R0048344","R0048344.pdf","no_doi","protocol","Vítor Patrício Correia","2025","Endoscopic Sleeve Gastroplasty as Facilitator for Renal Transplantation in Patients with Obesity: Rationale and Protocol","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048524","R0048524.pdf","free_to_read","other_trial","John M. Findlay","2025","Tailoring Weight Loss Before Hernia Surgery: Distinguishing Between Two Types of Obesity","Journal of Abdominal Wall Surgery","Frontiers Media SA","10.3389/jaws.2025.14322","https://doi.org/10.3389/jaws.2025.14322","40144576","https://pubmed.ncbi.nlm.nih.gov/40144576/","https://doi.org/10.3389/jaws.2025.14322",null],["5","R0051440","R0051440.pdf","free_to_read","other_trial","Maria Zasadzińska","2025","The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_18_25","https://doi.org/10.4103/jod.jod_18_25",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_18_25",null],["5","R0054193","R0054193.pdf","free_to_read","other_trial","Abdullah Heshmat","2025","Cardioprotective Effects of Antidiabetic Medications in Type 2 Diabetes - Mechanisms and Clinical Outcomes: A Narrative Review","Archives of Pharmaceutical Sciences Ain Shams University","Egyptian Knowledge Bank","10.21608/aps.2025.393133.1231","https://doi.org/10.21608/aps.2025.393133.1231",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.21608/aps.2025.393133.1231",null],["5","R0054583","R0054583.pdf","free_to_read","other_trial","Farah Wehbe","2025","Sex and Gender in Science, Medicine, and Nephrology","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.0000000677","https://doi.org/10.2215/cjn.0000000677","39908095","https://pubmed.ncbi.nlm.nih.gov/39908095/","https://pubmed.ncbi.nlm.nih.gov/39908095/",null],["5","R0055237","R0055237.pdf","free_to_read","other_trial","Sylwia Tomasiczek","2025","ONE DRUG TO FIX IT ALL? THE ROLE OF TIRZEPATIDE IN TREATING COMPONENTS OF METABOLIC SYNDROME","International Journal of Innovative Technologies in Social Science","RS Global Sp. z O.O.","10.31435/ijitss.4(48).2025.4180","https://doi.org/10.31435/ijitss.4(48).2025.4180",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.31435/ijitss.4(48).2025.4180",null],["5","R0055359","R0055359.pdf","free_to_read","other_trial","Megha Pawar","2025","GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives","BioMed Target Journal","Quality Academic And Scientific Publishing Agency (QAASPA Publisher)","10.59786/bmtj.322","https://doi.org/10.59786/bmtj.322",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.59786/bmtj.322",null],["5","R0055514","R0055514.pdf","no_doi","other_trial","Marie P. St Onge","2025","Characterizing Intake & Eating Behaviors Among Individuals Prescribed GLP-1 Anti-obesity Medications: A Pilot Study","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0001315","R0001315.pdf","free_to_read","narrative_review","Dubin RL","2024","Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15913","https://doi.org/10.1111/dom.15913","39344838","https://pubmed.ncbi.nlm.nih.gov/39344838/","https://repository.lsu.edu/clinical_research_pubs/143",null],["5","R0001954","R0001954.pdf","open_download_failed","other_trial","Krishnan A","2024","Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration.","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","SAGE Publications","10.1177/87551225241266773","https://doi.org/10.1177/87551225241266773","39391328","https://pubmed.ncbi.nlm.nih.gov/39391328/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11462932/pdf/10.1177_87551225241266773.pdf",null],["5","R0003157","R0003157.pdf","free_to_read","other_trial","Trevella P","2024","Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.","Nephrology (Carlton, Vic.)","Wiley","10.1111/nep.14336","https://doi.org/10.1111/nep.14336","39030739","https://pubmed.ncbi.nlm.nih.gov/39030739/","https://doi.org/10.1111/nep.14336",null],["5","R0003405","R0003405.pdf","free_to_read","other_trial","Hölscher C","2024","Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?","Neuropharmacology","Elsevier BV","10.1016/j.neuropharm.2024.109952","https://doi.org/10.1016/j.neuropharm.2024.109952","38677445","https://pubmed.ncbi.nlm.nih.gov/38677445/","https://doi.org/10.1016/j.neuropharm.2024.109952",null],["5","R0003703","R0003703.pdf","open_download_failed","other_trial","Abdelmalek MF","2024","The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15524","https://doi.org/10.1111/dom.15524","38511418","https://pubmed.ncbi.nlm.nih.gov/38511418/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15524",null],["5","R0003728","R0003728.pdf","open_download_failed","protocol","Thomas M","2024","Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review protocol","medRxiv","openRxiv","10.1101/2024.12.04.24318321","https://doi.org/10.1101/2024.12.04.24318321",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/12/05/2024.12.04.24318321.full.pdf",null],["5","R0004398","R0004398.pdf","open_download_failed","narrative_review","Goldberg AS","2024","Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists.","Fertility and sterility","Elsevier BV","10.1016/j.fertnstert.2024.05.154","https://doi.org/10.1016/j.fertnstert.2024.05.154","38810863","https://pubmed.ncbi.nlm.nih.gov/38810863/","http://www.fertstert.org/article/S0015028224004709/pdf",null],["5","R0004655","R0004655.pdf","open_download_failed","other_trial","Goldenberg RM","2024","Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13663","https://doi.org/10.1111/obr.13663","37968541","https://pubmed.ncbi.nlm.nih.gov/37968541/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13663",null],["5","R0004664","R0004664.pdf","free_to_read","other_trial","Banerjee M","2024","Letter to Editor From Banerjee et al: \"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure\".","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgad506","https://doi.org/10.1210/clinem/dgad506","37623277","https://pubmed.ncbi.nlm.nih.gov/37623277/",null,null],["5","R0004803","R0004803.pdf","free_to_read","other_trial","Urva S","2024","Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2024.2322072","https://doi.org/10.1080/03007995.2024.2322072","38407177","https://pubmed.ncbi.nlm.nih.gov/38407177/","https://doi.org/10.1080/03007995.2024.2322072",null],["5","R0005203","R0005203.pdf","free_to_read","other","Collins L","2024","Glucagon-Like Peptide-1 Receptor Agonists","StatPearls Publishing, Treasure Island (FL)",null,null,"https://doi.org/","31855395","https://pubmed.ncbi.nlm.nih.gov/31855395/",null,null],["5","R0005285","R0005285.pdf","free_to_read","narrative_review","Long B","2024","GLP-1 agonists: A review for emergency clinicians.","The American journal of emergency medicine","Elsevier BV","10.1016/j.ajem.2024.01.010","https://doi.org/10.1016/j.ajem.2024.01.010","38241775","https://pubmed.ncbi.nlm.nih.gov/38241775/","https://doi.org/10.1016/j.ajem.2024.01.010",null],["5","R0005410","R0005410.pdf","free_to_read","other_trial","Fediuk DJ","2024","Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.","Journal of clinical pharmacology","Wiley","10.1002/jcph.2371","https://doi.org/10.1002/jcph.2371","37840155","https://pubmed.ncbi.nlm.nih.gov/37840155/","https://doi.org/10.1002/jcph.2371","ClinicalTrials.gov:NCT04616027"],["5","R0005924","R0005924.pdf","free_to_read","other","Wong CK","2024","Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2023.11.009","https://doi.org/10.1016/j.cmet.2023.11.009","38113888","https://pubmed.ncbi.nlm.nih.gov/38113888/","https://doi.org/10.1016/j.cmet.2023.11.009",null],["5","R0005988","R0005988.pdf","open_download_failed","other_trial","Skelley JW","2024","The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.","Journal of the American Pharmacists Association : JAPhA","Elsevier BV","10.1016/j.japh.2023.10.037","https://doi.org/10.1016/j.japh.2023.10.037","37940101","https://pubmed.ncbi.nlm.nih.gov/37940101/","https://www.japha.org/article/S1544-3191(23)00370-9/pdf",null],["5","R0006708","R0006708.pdf","open_download_failed","narrative_review","Neeland IJ","2024","Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15728","https://doi.org/10.1111/dom.15728","38937282","https://pubmed.ncbi.nlm.nih.gov/38937282/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15728",null],["5","R0006749","R0006749.pdf","free_to_read","other_trial","France NL","2024","Tirzepatide: A Review in Type 2 Diabetes.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-023-01992-4","https://doi.org/10.1007/s40265-023-01992-4","38388874","https://pubmed.ncbi.nlm.nih.gov/38388874/","https://figshare.com/articles/online_resource/Tirzepatide_A_Review_in_Type_2_Diabetes/24873204",null],["5","R0006879","R0006879.pdf","free_to_read","protocol","Frampton R","2024","Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.15377","https://doi.org/10.1111/dme.15377","38853340","https://pubmed.ncbi.nlm.nih.gov/38853340/","https://doi.org/10.1111/dme.15377",null],["5","R0007073","R0007073.pdf","open_download_failed","other_trial","Sass MR","2024","Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.","Acta psychiatrica Scandinavica","Wiley","10.1111/acps.13690","https://doi.org/10.1111/acps.13690","38631670","https://pubmed.ncbi.nlm.nih.gov/38631670/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acps.13690",null],["5","R0007291","R0007291.pdf","open_download_failed","other_trial","Thomas L","2024","The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15551","https://doi.org/10.1111/dom.15551","38560764","https://pubmed.ncbi.nlm.nih.gov/38560764/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15551",null],["5","R0007437","R0007437.pdf","free_to_read","other_trial","Klein T","2024","Perspectives in weight control in diabetes - Survodutide.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2023.110779","https://doi.org/10.1016/j.diabres.2023.110779","37330144","https://pubmed.ncbi.nlm.nih.gov/37330144/","https://doi.org/10.1016/j.diabres.2023.110779",null],["5","R0007859","R0007859.pdf","free_to_read","protocol","Kosiborod MN","2024","Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2024.09.004","https://doi.org/10.1016/j.jchf.2024.09.004","39453356","https://pubmed.ncbi.nlm.nih.gov/39453356/","https://doi.org/10.1016/j.jchf.2024.09.004","ClinicalTrials.gov:NCT06077864"],["5","R0007975","R0007975.pdf","open_download_failed","other_trial","Serowik TC","2024","The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.","Journal of osteopathic medicine","Walter de Gruyter GmbH","10.1515/jom-2023-0179","https://doi.org/10.1515/jom-2023-0179","37921061","https://pubmed.ncbi.nlm.nih.gov/37921061/","https://www.degruyterbrill.com/document/doi/10.1515/jom-2023-0179/pdf",null],["5","R0008169","R0008169.pdf","free_to_read","protocol","Nicholls SJ","2024","Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.","American heart journal","Elsevier BV","10.1016/j.ahj.2023.09.007","https://doi.org/10.1016/j.ahj.2023.09.007","37758044","https://pubmed.ncbi.nlm.nih.gov/37758044/","https://doi.org/10.1016/j.ahj.2023.09.007",null],["5","R0008842","R0008842.pdf","free_to_read","other_trial","Martin JA","2024","Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/j.ejps.2024.106895","https://doi.org/10.1016/j.ejps.2024.106895","39243911","https://pubmed.ncbi.nlm.nih.gov/39243911/","https://doi.org/10.1016/j.ejps.2024.106895",null],["5","R0009228","R0009228.pdf","free_to_read","other_trial","Reed J","2024","Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15608","https://doi.org/10.1111/dom.15608","38680050","https://pubmed.ncbi.nlm.nih.gov/38680050/","https://doi.org/10.1111/dom.15608","ClinicalTrials.gov:NCT05523362"],["5","R0009689","R0009689.pdf","free_to_read","other_trial","Sato R","2024","Targeting obesity for therapeutic intervention in heart failure patients.","Expert review of cardiovascular therapy","Informa UK Limited","10.1080/14779072.2024.2363395","https://doi.org/10.1080/14779072.2024.2363395","38864827","https://pubmed.ncbi.nlm.nih.gov/38864827/","https://resolver.sub.uni-goettingen.de/purl?gro-2/143859",null],["5","R0009728","R0009728.pdf","free_to_read","preclinical","Regmi A","2024","Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2024.05.010","https://doi.org/10.1016/j.cmet.2024.05.010","38878772","https://pubmed.ncbi.nlm.nih.gov/38878772/","https://doi.org/10.1016/j.cmet.2024.05.010",null],["5","R0009780","R0009780.pdf","free_to_read","other_trial","Le Roux C","2024","Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2024.2311731","https://doi.org/10.1080/14656566.2024.2311731","38299476","https://pubmed.ncbi.nlm.nih.gov/38299476/","https://doi.org/10.1080/14656566.2024.2311731",null],["5","R0009823","R0009823.pdf","free_to_read","other_trial","Novikoff A","2024","Antagonizing GIPR adds fire to the GLP-1R flame.","Trends in endocrinology and metabolism: TEM","Elsevier BV","10.1016/j.tem.2024.04.016","https://doi.org/10.1016/j.tem.2024.04.016","38763780","https://pubmed.ncbi.nlm.nih.gov/38763780/","https://doi.org/10.1016/j.tem.2024.04.016",null],["5","R0010872","R0010872.pdf","open_download_failed","other_trial","Deravi M","2024","The \"Weight\" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","SAGE Publications","10.1177/87551225241285326","https://doi.org/10.1177/87551225241285326","39507873","https://pubmed.ncbi.nlm.nih.gov/39507873/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11536522/pdf/10.1177_87551225241285326.pdf",null],["5","R0011530","R0011530.pdf","open_download_failed","other","Yuan X","2024","iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15968","https://doi.org/10.1111/dom.15968","39360440","https://pubmed.ncbi.nlm.nih.gov/39360440/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15968","ClinicalTrials.gov:NCT03798080"],["5","R0011937","R0011937.pdf","open_download_failed","protocol","Young JC","2024","Clarifying the causal contrast: An empirical example applying the prevalent new user study design.","Pharmacoepidemiology and drug safety","Wiley","10.1002/pds.5790","https://doi.org/10.1002/pds.5790","38575389","https://pubmed.ncbi.nlm.nih.gov/38575389/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.5790",null],["5","R0011941","R0011941.pdf","open_download_failed","other_trial","Gooding KM","2024","Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111685","https://doi.org/10.1016/j.diabres.2024.111685","38670496","https://pubmed.ncbi.nlm.nih.gov/38670496/","http://www.diabetesresearchclinicalpractice.com/article/S0168822724005953/pdf",null],["5","R0012016","R0012016.pdf","free_to_read","protocol","Davidy T","2024","A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.","Mechanisms of ageing and development","Elsevier BV","10.1016/j.mad.2023.111898","https://doi.org/10.1016/j.mad.2023.111898","38159613","https://pubmed.ncbi.nlm.nih.gov/38159613/","https://repository.lsu.edu/clinical_research_pubs/24",null],["5","R0012427","R0012427.pdf","free_to_read","narrative_review","Holst JJ","2024","GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.","Nature metabolism","Springer Science and Business Media LLC","10.1038/s42255-024-01113-9","https://doi.org/10.1038/s42255-024-01113-9","39160334","https://pubmed.ncbi.nlm.nih.gov/39160334/","https://researchprofiles.ku.dk/da/publications/33ff3bd7-b5ed-4c67-9482-f0cd40df62d3",null],["5","R0012889","R0012889.pdf","free_to_read","narrative_review","Herman RJ","2024","Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.","Physiology & behavior","Elsevier BV","10.1016/j.physbeh.2024.114565","https://doi.org/10.1016/j.physbeh.2024.114565","38663460","https://pubmed.ncbi.nlm.nih.gov/38663460/","https://doi.org/10.1016/j.physbeh.2024.114565","ClinicalTrials.gov:NCT05610800"],["5","R0012919","R0012919.pdf","open_download_failed","other_trial","Osumili B","2024","Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2024.111717","https://doi.org/10.1016/j.diabres.2024.111717","38777128","https://pubmed.ncbi.nlm.nih.gov/38777128/","https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00627-2/pdf","ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT02648204"],["5","R0013730","R0013730.pdf","free_to_read","other_trial","Neves JS","2024","Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2024.06.026","https://doi.org/10.1016/j.jacc.2024.06.026","39115523","https://pubmed.ncbi.nlm.nih.gov/39115523/","https://doi.org/10.1016/j.jacc.2024.06.026",null],["5","R0013740","R0013740.pdf","free_to_read","other_trial","Rajagopal R","2024","NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.","Retina (Philadelphia, Pa.)","Ovid Technologies (Wolters Kluwer Health)","10.1097/iae.0000000000004252","https://doi.org/10.1097/iae.0000000000004252","39151204","https://pubmed.ncbi.nlm.nih.gov/39151204/","https://doi.org/10.1097/iae.0000000000004252",null],["5","R0014076","R0014076.pdf","open_download_failed","other_trial","Niu S","2024","5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15332","https://doi.org/10.1111/dom.15332","37867175","https://pubmed.ncbi.nlm.nih.gov/37867175/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15332",null],["5","R0015652","R0015652.pdf","open_download_failed","other_trial","Macfarlane M","2024","Do People Reduce Attempts At Lifestyle Change After Initiating Weight Loss Medication? A Review Of Trial Evidence","medRxiv","openRxiv","10.1101/2024.01.12.24301166","https://doi.org/10.1101/2024.01.12.24301166",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2024/01/13/2024.01.12.24301166.full.pdf",null],["5","R0015761","R0015761.pdf","open_download_failed","other_trial","Abraham J","2024","Thinner is better: Intentional weight loss and cardiovascular risk.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2024.01.016","https://doi.org/10.1016/j.medj.2024.01.016","38614070","https://pubmed.ncbi.nlm.nih.gov/38614070/","http://www.cell.com/article/S2666634024000461/pdf",null],["5","R0016028","R0016028.pdf","open_download_failed","other_trial","Gerstein HC","2024","Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15957","https://doi.org/10.1111/dom.15957","39284790","https://pubmed.ncbi.nlm.nih.gov/39284790/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15957",null],["5","R0016079","R0016079.pdf","open_download_failed","other_trial","Bosch R","2024","Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.","British journal of pharmacology","Wiley","10.1111/bph.16336","https://doi.org/10.1111/bph.16336","38403793","https://pubmed.ncbi.nlm.nih.gov/38403793/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bph.16336","ClinicalTrials.gov:NCT02548585"],["5","R0016510","R0016510.pdf","open_download_failed","narrative_review","Chen B","2024","GLP-1 programs the neurovascular landscape.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2024.09.003","https://doi.org/10.1016/j.cmet.2024.09.003","39357509","https://pubmed.ncbi.nlm.nih.gov/39357509/","https://www.cell.com/cell-metabolism/pdf/S1550-4131(24)00367-X.pdf",null],["5","R0017194","R0017194.pdf","open_download_failed","other_trial","Garvey WT","2024","Future Medications for Obesity and Clinical Implications.","Diabetes spectrum : a publication of the American Diabetes Association","American Diabetes Association","10.2337/dsi24-0004","https://doi.org/10.2337/dsi24-0004","39649698","https://pubmed.ncbi.nlm.nih.gov/39649698/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11623045/pdf/diaspectdsi240004.pdf",null],["5","R0018212","R0018212.pdf","open_download_failed","other","Samajdar SS","2024","Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.","Pain management","Informa UK Limited","10.1080/17581869.2024.2402214","https://doi.org/10.1080/17581869.2024.2402214","39301951","https://pubmed.ncbi.nlm.nih.gov/39301951/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485723/pdf/IPMT_14_2402214.pdf",null],["5","R0018577","R0018577.pdf","open_download_failed","other_trial","Zenno A","2024","An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.","Pediatric obesity","Wiley","10.1111/ijpo.13154","https://doi.org/10.1111/ijpo.13154","39103247","https://pubmed.ncbi.nlm.nih.gov/39103247/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.13154",null],["5","R0018781","R0018781.pdf","open_download_failed","other_trial","Fujihara K","2024","Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15887","https://doi.org/10.1111/dom.15887","39192522","https://pubmed.ncbi.nlm.nih.gov/39192522/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15887",null],["5","R0018854","R0018854.pdf","open_download_failed","other_trial","Ji L","2024","Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15888","https://doi.org/10.1111/dom.15888","39279647","https://pubmed.ncbi.nlm.nih.gov/39279647/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15888",null],["5","R0018992","R0018992.pdf","free_to_read","other_trial","Kushner RF","2024","Response to \"The safety of semaglutide in patients with depression and obesity\".","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.24144","https://doi.org/10.1002/oby.24144","39497516","https://pubmed.ncbi.nlm.nih.gov/39497516/",null,null],["5","R0019043","R0019043.pdf","free_to_read","commentary","De La Flor JC","2024","Response to \"Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis\". Response to related letter.","Nefrologia","Elsevier BV","10.1016/j.nefroe.2023.10.010","https://doi.org/10.1016/j.nefroe.2023.10.010","38862303","https://pubmed.ncbi.nlm.nih.gov/38862303/","https://doi.org/10.1016/j.nefroe.2023.10.010","ClinicalTrials.gov:NCT03819153"],["5","R0019129","R0019129.pdf","open_download_failed","other_trial","Ma J","2024","Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15446","https://doi.org/10.1111/dom.15446","38302718","https://pubmed.ncbi.nlm.nih.gov/38302718/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15446","ClinicalTrials.gov:NCT04093752"],["5","R0019716","R0019716.pdf","free_to_read","other_trial","Sattar N","2024","What the SELECT trial of semaglutide means for clinicians.","Nature medicine","Springer Science and Business Media LLC","10.1038/s41591-024-03013-7","https://doi.org/10.1038/s41591-024-03013-7","38796654","https://pubmed.ncbi.nlm.nih.gov/38796654/","https://eprints.gla.ac.uk/327879/",null],["5","R0020576","R0020576.pdf","open_download_failed","other_trial","Gerstein HC","2024","Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15417","https://doi.org/10.1111/dom.15417","38116691","https://pubmed.ncbi.nlm.nih.gov/38116691/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15417",null],["5","R0020669","R0020669.pdf","open_download_failed","other_trial","Rosenstock J","2024","Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15325","https://doi.org/10.1111/dom.15325","37880822","https://pubmed.ncbi.nlm.nih.gov/37880822/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15325",null],["5","R0020832","R0020832.pdf","open_download_failed","other","Cariou B","2024","Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15566","https://doi.org/10.1111/dom.15566","38528819","https://pubmed.ncbi.nlm.nih.gov/38528819/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15566","ClinicalTrials.gov:NCT03882970"],["5","R0021189","R0021189.pdf","open_download_failed","protocol","Talay L","2024","The effectiveness and sustainability of health outcomes from a holistic digital weight-loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15903","https://doi.org/10.1111/dom.15903","39223862","https://pubmed.ncbi.nlm.nih.gov/39223862/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15903",null],["5","R0021394","R0021394.pdf","open_download_failed","other_trial","Carlson AL","2024","Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.","Journal of diabetes science and technology","SAGE Publications","10.1177/19322968241234072","https://doi.org/10.1177/19322968241234072","38439656","https://pubmed.ncbi.nlm.nih.gov/38439656/","https://journals.sagepub.com/doi/pdf/10.1177/19322968241234072?download=true",null],["5","R0021406","R0021406.pdf","open_download_failed","other_trial","Kral P","2024","Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15426","https://doi.org/10.1111/dom.15426","38195847","https://pubmed.ncbi.nlm.nih.gov/38195847/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15426",null],["5","R0022497","R0022497.pdf","open_download_failed","other_trial","Oulhaj A","2024","Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15817","https://doi.org/10.1111/dom.15817","39086032","https://pubmed.ncbi.nlm.nih.gov/39086032/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15817","ClinicalTrials.gov:NCT01144338"],["5","R0022624","R0022624.pdf","free_to_read","other","Hsia DS","2024","The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2024.108692","https://doi.org/10.1016/j.jdiacomp.2024.108692","38354481","https://pubmed.ncbi.nlm.nih.gov/38354481/","https://doi.org/10.1016/j.jdiacomp.2024.108692","ClinicalTrials.gov:NCT01794143"],["5","R0023703","R0023703.pdf","free_to_read","other","Ong SW","2024","Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-Related Problems in Patients with Chronic Kidney Disease.","American journal of nephrology","S. Karger AG","10.1159/000535094","https://doi.org/10.1159/000535094","37939689","https://pubmed.ncbi.nlm.nih.gov/37939689/","https://doi.org/10.1159/000535094",null],["5","R0024033","R0024033.pdf","free_to_read","other_trial","Younis IR","2024","Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.","Journal of clinical pharmacology","Wiley","10.1002/jcph.6114","https://doi.org/10.1002/jcph.6114","39213138","https://pubmed.ncbi.nlm.nih.gov/39213138/",null,"ClinicalTrials.gov:NCT04971785"],["5","R0025242","R0025242.pdf","open_download_failed","other_trial","Vajravelu ME","2024","Projected impact of anti-obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity.","Pediatric obesity","Wiley","10.1111/ijpo.13103","https://doi.org/10.1111/ijpo.13103","38318987","https://pubmed.ncbi.nlm.nih.gov/38318987/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ijpo.13103",null],["5","R0029122","R0029122.pdf","free_to_read","narrative_review","Stefanakis K","2024","The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.","Metabolism: clinical and experimental","Elsevier BV","10.1016/j.metabol.2024.156057","https://doi.org/10.1016/j.metabol.2024.156057","39481534","https://pubmed.ncbi.nlm.nih.gov/39481534/","https://research.rug.nl/en/publications/2ee59872-47b5-42e9-8a5e-f54729172ef0",null],["5","R0029123","R0029123.pdf","free_to_read","other_trial","Stumpf MAM","2024","Challenges in the care and treatment of patients with extreme obesity.","Archives of endocrinology and metabolism","Archives of Endocrinology and Metabolism","10.20945/2359-4292-2023-0335","https://doi.org/10.20945/2359-4292-2023-0335","39420906","https://pubmed.ncbi.nlm.nih.gov/39420906/","https://doi.org/10.20945/2359-4292-2023-0335",null],["5","R0029159","R0029159.pdf","free_to_read","narrative_review","Khan MS","2024","Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.","BMC nephrology","Springer Science and Business Media LLC","10.1186/s12882-024-03652-5","https://doi.org/10.1186/s12882-024-03652-5","39090593","https://pubmed.ncbi.nlm.nih.gov/39090593/","https://doi.org/10.1186/s12882-024-03652-5",null],["5","R0029175","R0029175.pdf","open_download_failed","other_trial","Erhabor J","2024","National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US.","JAMA network open","American Medical Association (AMA)","10.1001/jamanetworkopen.2024.20105","https://doi.org/10.1001/jamanetworkopen.2024.20105","38958980","https://pubmed.ncbi.nlm.nih.gov/38958980/","https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2820709/erhabor_2024_ld_240096_1719419469.54845.pdf",null],["5","R0029244","R0029244.pdf","open_download_failed","protocol","Blood AJ","2024","Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2024.01.005","https://doi.org/10.1016/j.pcd.2024.01.005","38302335","https://pubmed.ncbi.nlm.nih.gov/38302335/","http://www.primary-care-diabetes.com/article/S1751991824000056/pdf",null],["5","R0032431","R0032431.pdf","no_doi","other_trial","Frisbie, Madyson R.","2024","THE DANGER ONLINE PHARMACIES POSE ON CLIENTS WITH EATING DISORDERS IN THE PRESCRIPTION OF GLP-1 AGONISTS FOR WEIGHT LOSS","SEU FIRE Scholars (Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032441","R0032441.pdf","no_doi","other_trial","Kahook, Zaneh","2024","Evaluating Tirzepatide's Therapeutic Potential in Mitigating Obesity-Associated Comorbidities","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT06301256; ClinicalTrials.gov:NCT06517212"],["5","R0034581","R0034581.pdf","free_to_read","other_trial","Michaël Pollak","2024","Abstract LB376: Tirzepatide inhibits tumor growth in mice with diet-induced obesity","Cancer Research","American Association for Cancer Research (AACR)","10.1158/1538-7445.am2024-lb376","https://doi.org/10.1158/1538-7445.am2024-lb376",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1158/1538-7445.am2024-lb376",null],["5","R0036204","R0036204.pdf","no_doi","other_trial","Bryan, Carina","2024","Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04166773"],["5","R0036245","R0036245.pdf","no_doi","other_trial","Jones, Talaya","2024","Recent Developments in Tirzepatide's Role in Reducing Cardiovascular Disease Risk Factors in Adults with Type 2 Diabetes","NSUWorks (Nova Southeastern University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT04847557; ClinicalTrials.gov:NCT04255433"],["5","R0036267","R0036267.pdf","no_doi","other_trial","Keum, Youngshin","2024","FINDING NEW INTERVENTIONS TO SLOW KIDNEY FUNCTION DECLINE IN DIABETES","Digital Access to Scholarship at Harvard (DASH) (Harvard University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036872","R0036872.pdf","free_to_read","other_trial","R - Princy","2024","Semaglutide induced Pancreatitis","International Journal For Multidisciplinary Research","International Journal for Multidisciplinary Research (IJFMR)","10.36948/ijfmr.2024.v06i04.26238","https://doi.org/10.36948/ijfmr.2024.v06i04.26238",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.36948/ijfmr.2024.v06i04.26238",null],["5","R0037041","R0037041.pdf","free_to_read","other_trial","Bhaskar Pal","2024","Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_117_23","https://doi.org/10.4103/jod.jod_117_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_117_23",null],["5","R0038216","R0038216.pdf","free_to_read","other_trial","C Thøger Nielsen","2024","KNEE B-SCORE SHAPE FROM COMPUTED TOMOGRAPHY IS ASSOCIATED WITH SUBCHONDRAL BONE ATTENUATION AND MARGINAL CORTICAL BONE THICKNESS","Osteoarthritis Imaging","Elsevier BV","10.1016/j.ostima.2024.100192","https://doi.org/10.1016/j.ostima.2024.100192",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ostima.2024.100192",null],["5","R0040649","R0040649.pdf","no_doi","other_trial","Alissou, Mathieu","2024","Impact du sémaglutide sur la composition corporelle et le comportement alimentaire des patients obèses","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041548","R0041548.pdf","free_to_read","other_trial","Camila Verônica Souza Freire","2024","ASSOCIATION OF CORONARY ARTERY DISEASE WITH CARDIOVASCULAR OUTCOMES IN OBESITY WITHOUT DIABETES: IMPLICATIONS FOR THE USE OF CORONARY CTA TO IDENTIFY SELECT TRIAL-LIKE POPULATION","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2024.100849","https://doi.org/10.1016/j.ajpc.2024.100849",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2024.100849",null],["5","R0041699","R0041699.pdf","free_to_read","other_trial","John Newman","2024","ASSESSING GEROTHERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS","Innovation in Aging","Oxford University Press (OUP)","10.1093/geroni/igae098.0452","https://doi.org/10.1093/geroni/igae098.0452",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1093/geroni/igae098.0452",null],["5","R0041721","R0041721.pdf","free_to_read","other_trial","Kaitlyn Barney","2024","6411 Ozempic - Oh no! Acute Renal Failure Associated with Initiation of Semaglutide","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvae163.873","https://doi.org/10.1210/jendso/bvae163.873",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvae163.873",null],["5","R0043245","R0043245.pdf","free_to_read","other_trial","Randeep Wadhawan","2024","Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?","Journal of Bariatric Surgery","Ovid Technologies (Wolters Kluwer Health)","10.4103/jbs.jbs_17_24","https://doi.org/10.4103/jbs.jbs_17_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jbs.jbs_17_24",null],["5","R0043854","R0043854.pdf","free_to_read","protocol","Maryam Emadzadeh","2024","The effects of supplementation with curcumin plus piperine on glycemic indices in prediabetes status: protocol for randomized controlled trial","Herba Polonica","Index Copernicus","10.5604/01.3001.0054.6601","https://doi.org/10.5604/01.3001.0054.6601",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.5604/01.3001.0054.6601",null],["5","R0044118","R0044118.pdf","no_doi","other_trial","Tengesdal Nielsen, Nina","2024","Semaglutid 2,4 mg vid behandling av övervikt och fetma - en kortare viktminskningskur eller livslång behandling?","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044675","R0044675.pdf","free_to_read","other_trial","Andreas Nordland","2024","Estimation of treatment effect among treatment responders with a time‐to‐event endpoint","Scandinavian Journal of Statistics","Wiley","10.1111/sjos.12706","https://doi.org/10.1111/sjos.12706",null,"https://pubmed.ncbi.nlm.nih.gov//","https://researchprofiles.ku.dk/da/publications/e0f5f10d-4b96-4e4f-830d-6f9d8b76859c",null],["5","R0045533","R0045533.pdf","free_to_read","other_trial","Shreya Srivastava","2024","INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT","American Journal of Preventive Cardiology","Elsevier BV","10.1016/j.ajpc.2024.100813","https://doi.org/10.1016/j.ajpc.2024.100813",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ajpc.2024.100813",null],["5","R0046660","R0046660.pdf","free_to_read","other_trial","Divya Rajagopal","2024","Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs","Journal of Diabetology","Ovid Technologies (Wolters Kluwer Health)","10.4103/jod.jod_128_24","https://doi.org/10.4103/jod.jod_128_24",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/jod.jod_128_24",null],["5","R0048241","R0048241.pdf","free_to_read","protocol","Pamela K. Keel","2024","Examining Weight Suppression, Leptin Levels, Glucagon-Like Peptide 1 Response, and Reward-Related Constructs in Severity and Maintenance of Bulimic Syndromes: Protocol and Sample Characteristics for a Cross-Sectional and Longitudinal Study (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.66554","https://doi.org/10.2196/preprints.66554",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.66554",null],["5","R0048565","R0048565.pdf","free_to_read","other_trial","Adrian Hugh Heald","2024","The lifetime healthcare costs of female obesity: modeling of England data and the costs of current pharmacotherapy","Cardiovascular Endocrinology & Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000310","https://doi.org/10.1097/xce.0000000000000310","39318473","https://pubmed.ncbi.nlm.nih.gov/39318473/","https://doi.org/10.1097/xce.0000000000000310",null],["5","R0048580","R0048580.pdf","free_to_read","other_trial","Susan Leanne Samson","2024","Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study","Future Rare Diseases","Informa UK Limited","10.2217/frd-2023-0025","https://doi.org/10.2217/frd-2023-0025",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2217/frd-2023-0025","ClinicalTrials.gov:NCT02060383"],["5","R0048653","R0048653.pdf","free_to_read","other_trial","Konstantin Alexander Krychtiuk","2024","ALBIGLUTIDE AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE - A SECONDARY ANALYSIS OF THE HARMONY OUTCOMES TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03878-6","https://doi.org/10.1016/s0735-1097(24)03878-6",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03878-6",null],["5","R0049020","R0049020.pdf","free_to_read","other_trial","Adam J. Nelson","2024","PERSISTENCE AND DISCONTINUATION OF SGLT-2I AND GLP-1RA AMONG PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TREATED IN US CARDIOLOGY CLINICS: INSIGHTS FROM THE COORDINATE-DIABETES TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03880-4","https://doi.org/10.1016/s0735-1097(24)03880-4",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03880-4",null],["5","R0049707","R0049707.pdf","free_to_read","protocol","TIFFANY M. CORTES","2024","Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.62667","https://doi.org/10.2196/preprints.62667",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.2196/preprints.62667","ClinicalTrials.gov:NCT05786521"],["5","R0049998","R0049998.pdf","free_to_read","other_trial","Adam J. Nelson","2024","CHARACTERISTICS OF PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PRESCRIBED SGLT-2I AND/OR GLP-1RA AMONG CARDIOLOGY CLINICS IN THE US: INSIGHTS FROM A LARGE IMPLEMENTATION TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(24)03879-8","https://doi.org/10.1016/s0735-1097(24)03879-8",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(24)03879-8",null],["5","R0050457","R0050457.pdf","free_to_read","other_trial","Marcello Agosta","2024","Efficacy of liraglutide in pediatric obesity: A review of clinical trial data","Obesity Medicine","Elsevier BV","10.1016/j.obmed.2024.100545","https://doi.org/10.1016/j.obmed.2024.100545",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.obmed.2024.100545",null],["5","R0051292","R0051292.pdf","free_to_read","other_trial","Muhammad Aron Pase","2024","Tirzepatide: Dual GIP/GLP-1 Receptor Agonists, from Molecular to Clinical Practice for Treating Type-2 Diabetes and Obesity","‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes","Perhimpunan Endokrinologi Indonesia (PERKENI)","10.66266/2n6ev337","https://doi.org/10.66266/2n6ev337",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.66266/2n6ev337",null],["5","R0052257","R0052257.pdf","free_to_read","other_trial","Ysaline Duvieusart","2024","Putting EMPA-REG into practice: a data-driven intervention","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2024.444","https://doi.org/10.15277/bjd.2024.444",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.15277/bjd.2024.444",null],["5","R0052814","R0052814.pdf","free_to_read","other_trial","Jasmini Alagaratnam","2024","Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice","CMI Communications","Elsevier BV","10.1016/j.cmicom.2024.100006","https://doi.org/10.1016/j.cmicom.2024.100006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cmicom.2024.100006",null],["5","R0053206","R0053206.pdf","free_to_read","other_trial","Phil C. McEwan","2024","EE497 The Cost-Effectiveness of Semaglutide 2.4MG in Patients With Overweight/Obesity and Cardiovascular Disease From the Select Trial","Value in Health","Elsevier BV","10.1016/j.jval.2024.03.2261","https://doi.org/10.1016/j.jval.2024.03.2261",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2024.03.2261",null],["5","R0054793","R0054793.pdf","free_to_read","protocol","Demsina Babazadeh","2024","Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users: Implementation of the CRAVE Study Protocol","Current Developments in Nutrition","Elsevier BV","10.1016/j.cdnut.2024.103642","https://doi.org/10.1016/j.cdnut.2024.103642",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.cdnut.2024.103642",null],["5","R0056775","R0056775.pdf","free_to_read","other_trial","Hanne Scholz","2024","Cautious Optimism Warranted for Stem Cell-Derived Islet Transplantation in Type 2 Diabetes","Transplant International","Frontiers Media SA","10.3389/ti.2024.13358","https://doi.org/10.3389/ti.2024.13358","39131791","https://pubmed.ncbi.nlm.nih.gov/39131791/","https://doi.org/10.3389/ti.2024.13358",null],["5","R0005252","R0005252.pdf","open_download_failed","other_trial","Fanshier AV","2023","Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin.","Clinical diabetes : a publication of the American Diabetes Association","American Diabetes Association","10.2337/cd22-0060","https://doi.org/10.2337/cd22-0060","37456095","https://pubmed.ncbi.nlm.nih.gov/37456095/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10338280/pdf/diaclincd220060.pdf",null],["5","R0005579","R0005579.pdf","open_download_failed","other_trial","Wettergreen SA","2023","Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.","Diabetes spectrum : a publication of the American Diabetes Association","American Diabetes Association","10.2337/ds21-0108","https://doi.org/10.2337/ds21-0108","36818408","https://pubmed.ncbi.nlm.nih.gov/36818408/","https://diabetesjournals.org/spectrum/article-pdf/36/1/5/697049/diaspectds210108.pdf",null],["5","R0005624","R0005624.pdf","open_download_failed","other_trial","Jensterle M","2023","Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.","Hormone research in paediatrics","S. Karger AG","10.1159/000521264","https://doi.org/10.1159/000521264","34852347","https://pubmed.ncbi.nlm.nih.gov/34852347/","https://www.karger.com/Article/Pdf/521264",null],["5","R0005987","R0005987.pdf","open_download_failed","other","Taylor SI","2023","Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.","medRxiv : the preprint server for health sciences","openRxiv","10.1101/2023.03.15.23287166","https://doi.org/10.1101/2023.03.15.23287166","36993363","https://pubmed.ncbi.nlm.nih.gov/36993363/","https://www.medrxiv.org/content/medrxiv/early/2023/05/03/2023.03.15.23287166.full.pdf","ClinicalTrials.gov:NCT05071898; ClinicalTrials.gov:NCT02462421; ClinicalTrials.gov:NCT05762744"],["5","R0006073","R0006073.pdf","open_download_failed","other_trial","Newsome PN","2023","Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.","Journal of hepatology","Elsevier BV","10.1016/j.jhep.2023.07.033","https://doi.org/10.1016/j.jhep.2023.07.033","37562748","https://pubmed.ncbi.nlm.nih.gov/37562748/","http://www.journal-of-hepatology.eu/article/S0168827823050468/pdf",null],["5","R0006804","R0006804.pdf","free_to_read","other_trial","Doggrell SA","2023","Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?","Expert opinion on investigational drugs","Informa UK Limited","10.1080/13543784.2023.2206560","https://doi.org/10.1080/13543784.2023.2206560","37086147","https://pubmed.ncbi.nlm.nih.gov/37086147/",null,null],["5","R0007419","R0007419.pdf","open_download_failed","other_trial","Jungnik A","2023","Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14948","https://doi.org/10.1111/dom.14948","36527386","https://pubmed.ncbi.nlm.nih.gov/36527386/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14948","ClinicalTrials.gov:NCT03175211; ClinicalTrials.gov:NCT03591718"],["5","R0008024","R0008024.pdf","open_download_failed","other_trial","Bouzas C","2023","Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2023.114561","https://doi.org/10.1016/j.biopha.2023.114561","36934556","https://pubmed.ncbi.nlm.nih.gov/36934556/","https://ars.els-cdn.com/content/image/1-s2.0-S0753332223003499-ga1_lrg.jpg",null],["5","R0008404","R0008404.pdf","open_download_failed","other_trial","Zhang X","2023","Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2023.29.3.276","https://doi.org/10.18553/jmcp.2023.29.3.276","36840958","https://pubmed.ncbi.nlm.nih.gov/36840958/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2023.29.3.276?download=true",null],["5","R0009240","R0009240.pdf","open_download_failed","other_trial","Tuttle KR","2023","Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.","Kidney international","Elsevier BV","10.1016/j.kint.2022.12.028","https://doi.org/10.1016/j.kint.2022.12.028","36738891","https://pubmed.ncbi.nlm.nih.gov/36738891/","http://www.kidney-international.org/article/S008525382300056X/pdf",null],["5","R0009684","R0009684.pdf","free_to_read","protocol","Kosiborod MN","2023","Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.","JACC. Heart failure","Elsevier BV","10.1016/j.jchf.2023.05.010","https://doi.org/10.1016/j.jchf.2023.05.010","37294245","https://pubmed.ncbi.nlm.nih.gov/37294245/","https://doi.org/10.1016/j.jchf.2023.05.010","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470"],["5","R0009696","R0009696.pdf","open_download_failed","protocol","McGuire DK","2023","Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15058","https://doi.org/10.1111/dom.15058","36945734","https://pubmed.ncbi.nlm.nih.gov/36945734/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15058",null],["5","R0011412","R0011412.pdf","open_download_failed","narrative_review","Elmaleh-Sachs A","2023","Obesity Management in Adults: A Review.","JAMA","American Medical Association (AMA)","10.1001/jama.2023.19897","https://doi.org/10.1001/jama.2023.19897","38015216","https://pubmed.ncbi.nlm.nih.gov/38015216/","https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/pdf/nihms-2013936.pdf",null],["5","R0012421","R0012421.pdf","free_to_read","other_trial","Nowell J","2023","Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.","Ageing research reviews","Elsevier BV","10.1016/j.arr.2023.101979","https://doi.org/10.1016/j.arr.2023.101979","37328112","https://pubmed.ncbi.nlm.nih.gov/37328112/","https://doi.org/10.1016/j.arr.2023.101979",null],["5","R0012453","R0012453.pdf","open_download_failed","protocol","Lin Y","2023","Comparison of semaglutide in combined with empagliflozin versus semaglutide and empagliflozin monotherapy in non-alcoholic fatty liver disease with type 2 diabetes: study protocol for a randomised controlled clinical trial","medRxiv","openRxiv","10.1101/2023.12.11.23299784","https://doi.org/10.1101/2023.12.11.23299784",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2023/12/13/2023.12.11.23299784.full.pdf","ChiCTR:ChiCTR2300070674"],["5","R0014235","R0014235.pdf","open_download_failed","other_trial","le Roux CW","2023","Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15148","https://doi.org/10.1111/dom.15148","37344384","https://pubmed.ncbi.nlm.nih.gov/37344384/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15148",null],["5","R0014588","R0014588.pdf","open_download_failed","other_trial","Strathe A","2023","A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15211","https://doi.org/10.1111/dom.15211","37424165","https://pubmed.ncbi.nlm.nih.gov/37424165/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15211",null],["5","R0014630","R0014630.pdf","open_download_failed","other_trial","Reitzel SB","2023","Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.","Current medical research and opinion","Informa UK Limited","10.1080/03007995.2023.2231275","https://doi.org/10.1080/03007995.2023.2231275","37415503","https://pubmed.ncbi.nlm.nih.gov/37415503/","https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2231275","ClinicalTrials.gov:NCT03987919"],["5","R0014699","R0014699.pdf","open_download_failed","other_trial","Azuri J","2023","Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.23752","https://doi.org/10.1002/oby.23752","37203328","https://pubmed.ncbi.nlm.nih.gov/37203328/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.23752",null],["5","R0014906","R0014906.pdf","open_download_failed","other_trial","Lafferty RA","2023","GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2023.2192865","https://doi.org/10.1080/14656566.2023.2192865","36927378","https://pubmed.ncbi.nlm.nih.gov/36927378/","https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2192865?download=true",null],["5","R0018139","R0018139.pdf","no_doi","other_trial","Serné EH","2023","[Glycemia reduction in type 2 diabetes patients with low cardiovascular risk].","Nederlands tijdschrift voor geneeskunde",null,null,"https://doi.org/","37930171","https://pubmed.ncbi.nlm.nih.gov/37930171/",null,null],["5","R0018455","R0018455.pdf","open_download_failed","other_trial","Savarese G","2023","Patient preferences for newer oral therapies in type 2 diabetes.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2022.09.009","https://doi.org/10.1016/j.ijcard.2022.09.009","36096275","https://pubmed.ncbi.nlm.nih.gov/36096275/","http://www.internationaljournalofcardiology.com/article/S0167527322013195/pdf",null],["5","R0020181","R0020181.pdf","free_to_read","other_trial","Novikoff A","2023","SURMOUNTing body weight barriers in type 2 diabetes.","Med (New York, N.Y.)","Elsevier BV","10.1016/j.medj.2023.11.007","https://doi.org/10.1016/j.medj.2023.11.007","38070476","https://pubmed.ncbi.nlm.nih.gov/38070476/","https://doi.org/10.1016/j.medj.2023.11.007",null],["5","R0020263","R0020263.pdf","open_download_failed","other_trial","Pedersen SD","2023","Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.15140","https://doi.org/10.1111/dom.15140","37246796","https://pubmed.ncbi.nlm.nih.gov/37246796/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15140",null],["5","R0020978","R0020978.pdf","free_to_read","other_trial","Block TJ","2023","Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years.","Presse medicale (Paris, France : 1983)","Elsevier BV","10.1016/j.lpm.2023.104178","https://doi.org/10.1016/j.lpm.2023.104178","37783423","https://pubmed.ncbi.nlm.nih.gov/37783423/","https://doi.org/10.1016/j.lpm.2023.104178",null],["5","R0021239","R0021239.pdf","open_download_failed","other_trial","Kiyosue A","2023","Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14952","https://doi.org/10.1111/dom.14952","36545807","https://pubmed.ncbi.nlm.nih.gov/36545807/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14952",null],["5","R0021921","R0021921.pdf","open_download_failed","other_trial","Berry S","2023","Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2023.2240957","https://doi.org/10.1080/13696998.2023.2240957","37525970","https://pubmed.ncbi.nlm.nih.gov/37525970/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2240957?download=true",null],["5","R0022564","R0022564.pdf","free_to_read","other_trial","Verma S","2023","A big STEP for treatment of heart failure with preserved ejection fraction.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2023.08.003","https://doi.org/10.1016/j.cmet.2023.08.003","37643614","https://pubmed.ncbi.nlm.nih.gov/37643614/","https://doi.org/10.1016/j.cmet.2023.08.003",null],["5","R0024169","R0024169.pdf","open_download_failed","other_trial","Baker DE","2023","Tirzepatide.","Hospital pharmacy","SAGE Publications","10.1177/00185787221125724","https://doi.org/10.1177/00185787221125724","37216078","https://pubmed.ncbi.nlm.nih.gov/37216078/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10192986/pdf/10.1177_00185787221125724.pdf",null],["5","R0026352","R0026352.pdf","open_download_failed","other_trial","Oulhaj A","2023","Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14975","https://doi.org/10.1111/dom.14975","36635232","https://pubmed.ncbi.nlm.nih.gov/36635232/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14975",null],["5","R0028870","R0028870.pdf","open_download_failed","preclinical","Nuako A","2023","Pharmacologic Treatment of Obesity in Reproductive Aged Women.","Current obstetrics and gynecology reports","Springer Science and Business Media LLC","10.1007/s13669-023-00350-1","https://doi.org/10.1007/s13669-023-00350-1","37427372","https://pubmed.ncbi.nlm.nih.gov/37427372/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10328448/pdf/nihms-1884086.pdf",null],["5","R0034329","R0034329.pdf","no_doi","other_trial","Cormac Kennedy","2023","Semaglutide as a treatment for patients with obesity and difficult to control hypertension: preparatory analysis of the STEP trial data","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034934","R0034934.pdf","free_to_read","other_trial","Yakup Yunus Yamantürk","2023","New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?","Endocrinology research and practice.","AVES YAYINCILIK A.Ş.","10.5152/erp.2023.23262","https://doi.org/10.5152/erp.2023.23262",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5152/erp.2023.23262",null],["5","R0036175","R0036175.pdf","no_doi","other_trial","Valle, Christina","2023","Semaglutide Added to Type 2 Diabetes Mellitus Treatment for Improvement in Hemoglobin A1c","scholarworks - UTEP (The University of Texas at El Paso)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036424","R0036424.pdf","no_doi","other_trial","Erik H. Serné","2023","Patiënten met type 2-diabetes en een laag cardiovasculair risico","Pure Amsterdam UMC",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040415","R0040415.pdf","no_doi","other_trial","Ward, Joey","2023","Testing for association between exonic glucagon-like peptide 1 receptor (GLP-1R) mutation with physical and brain health traits in UK Biobank","UCL Discovery (University College London)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040654","R0040654.pdf","no_doi","other_trial","M. Wijdeveld","2023","Gut-brain interactions affecting metabolic health and central appetite regulation in diabetes, obesity and aging","UvA-DARE (University of Amsterdam)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040815","R0040815.pdf","no_doi","other_trial","Awadhesh Kumar Singh","2023","Gauging the Antiobesity Potential of Oral Semaglutide in Type 2 Diabetes in the Indian Context",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041276","R0041276.pdf","no_doi","other_trial","IJCP Group","2023","News and Views",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041756","R0041756.pdf","free_to_read","preclinical","Kevin Nguyen","2023","OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.009","https://doi.org/10.1210/jendso/bvad114.009",null,"https://pubmed.ncbi.nlm.nih.gov//","http://dx.doi.org/10.1210/jendso/bvad114.009","ClinicalTrials.gov:NCT05616013"],["5","R0042442","R0042442.pdf","no_doi","other_trial","Salvador, Dante Jr.","2023","Diabetes mellitus: associations with atherosclerosis, myocardial fibrosis, and implications for heart failure","BORIS (University Library Bern)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042509","R0042509.pdf","no_doi","other_trial","Turlough Heffernan (16857930)","2023","Obesity: Is the tide turning?","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044168","R0044168.pdf","free_to_read","other_trial","Zhifan Li","2023","LDL‐C rebound after long‐term evolocumab treatment and intravascular imaging evidence in a familial hypercholesterolemia patient with early‐onset myocardial infarction","Chronic Diseases and Translational Medicine","Wiley","10.1002/cdt3.97","https://doi.org/10.1002/cdt3.97","38450306","https://pubmed.ncbi.nlm.nih.gov/38450306/","https://doi.org/10.1002/cdt3.97",null],["5","R0044505","R0044505.pdf","no_doi","other_trial","María Gracia Machado Fernandez","2023","Eficacia de la tirzepatida en pacientes con diabetes mellitus tipo 2 y obesidad: un innovador fármaco dual","Dialnet (Universidad de la Rioja)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047623","R0047623.pdf","free_to_read","other_trial","Konstantin Alexander Krychtiuk","2023","EFFECTS OF ALBIGLUTIDE ON TYPES AND NUMBERS OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE HARMONY OUTCOMES TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(23)01576-0","https://doi.org/10.1016/s0735-1097(23)01576-0",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(23)01576-0",null],["5","R0051546","R0051546.pdf","free_to_read","other_trial","Aparna Areti","2023","Diabetic Sensory Neurons, Dorsal Root Ganglia, and Neuropathy","Contemporary diabetes","Springer International Publishing","10.1007/978-3-031-15613-7_18","https://doi.org/10.1007/978-3-031-15613-7_18",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1007/978-3-031-15613-7_18",null],["5","R0052842","R0052842.pdf","free_to_read","other_trial","Emily R. Hankosky","2023","71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status","Diabetes","American Diabetes Association","10.2337/db23-71-lb","https://doi.org/10.2337/db23-71-lb",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2337/db23-71-lb",null],["5","R0053302","R0053302.pdf","free_to_read","other_trial","Christian Ludwig Roth","2023","FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial","Journal of the Endocrine Society","The Endocrine Society","10.1210/jendso/bvad114.076","https://doi.org/10.1210/jendso/bvad114.076",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1210/jendso/bvad114.076","ClinicalTrials.gov:NCT04725240"],["5","R0053678","R0053678.pdf","free_to_read","protocol","Meixi Liu","2023","Efficacy and safety of Xiang-Sha-Liu-Jun-Zi (XSLJZ) for treatment of Semaglutide-induced gastrointestinal side effects: Study protocol for a multicentre, randomized, open-label trial","Medicine Case Reports and Study Protocols","Ovid Technologies (Wolters Kluwer Health)","10.1097/md9.0000000000000297","https://doi.org/10.1097/md9.0000000000000297",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1097/md9.0000000000000297",null],["5","R0055593","R0055593.pdf","no_doi","other_trial","Erik H. Serné","2023","Patiënten met type 2-diabetes en een laag cardiovasculair risico:Welke glucoseverlager volgt na metformine?","Pure Amsterdam UMC",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0056038","R0056038.pdf","no_doi","other_trial","Matthew Gilbert Richard E. Pratley","2023","Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors","The Review of Diabetic Studies",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0005732","R0005732.pdf","open_download_failed","narrative_review","Goldenberg RM","2022","Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists.","Stroke","Ovid Technologies (Wolters Kluwer Health)","10.1161/strokeaha.121.038151","https://doi.org/10.1161/strokeaha.121.038151","35259929","https://pubmed.ncbi.nlm.nih.gov/35259929/","https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.121.038151",null],["5","R0005829","R0005829.pdf","open_download_failed","other","Wharton S","2022","Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2021.2002616","https://doi.org/10.1080/00325481.2021.2002616","34775881","https://pubmed.ncbi.nlm.nih.gov/34775881/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2021.2002616?needAccess=true",null],["5","R0005842","R0005842.pdf","open_download_failed","other_trial","Mehta R","2022","Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.","Diabetic medicine : a journal of the British Diabetic Association","Wiley","10.1111/dme.14901","https://doi.org/10.1111/dme.14901","35708737","https://pubmed.ncbi.nlm.nih.gov/35708737/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dme.14901",null],["5","R0005961","R0005961.pdf","open_download_failed","other_trial","Amaro A","2022","Efficacy and safety of semaglutide for weight management: evidence from the STEP program.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2022.2147326","https://doi.org/10.1080/00325481.2022.2147326","36691309","https://pubmed.ncbi.nlm.nih.gov/36691309/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2022.2147326?download=true",null],["5","R0007315","R0007315.pdf","free_to_read","other_trial","Mancini GBJ","2022","2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.","The Canadian journal of cardiology","Elsevier BV","10.1016/j.cjca.2022.04.029","https://doi.org/10.1016/j.cjca.2022.04.029","35961754","https://pubmed.ncbi.nlm.nih.gov/35961754/","https://ir.lib.uwo.ca/medpub/347",null],["5","R0007430","R0007430.pdf","open_download_failed","other_trial","Sacre JW","2022","Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy.","Diabetes care","American Diabetes Association","10.2337/dc21-1929","https://doi.org/10.2337/dc21-1929","35775451","https://pubmed.ncbi.nlm.nih.gov/35775451/","https://diabetesjournals.org/care/article-pdf/45/8/1900/686514/dc211929.pdf",null],["5","R0008908","R0008908.pdf","open_download_failed","narrative_review","Davies MJ","2022","Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Diabetes care","American Diabetes Association","10.2337/dci22-0034","https://doi.org/10.2337/dci22-0034","36148880","https://pubmed.ncbi.nlm.nih.gov/36148880/","https://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf",null],["5","R0009715","R0009715.pdf","free_to_read","other_trial","Amaro A","2022","Cardiometabolic risk factors efficacy of semaglutide in the STEP program.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2022.2147325","https://doi.org/10.1080/00325481.2022.2147325","36691308","https://pubmed.ncbi.nlm.nih.gov/36691308/","https://doi.org/10.1080/00325481.2022.2147325",null],["5","R0009726","R0009726.pdf","free_to_read","other_trial","Limonte CP","2022","Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2022.108204","https://doi.org/10.1016/j.jdiacomp.2022.108204","35537891","https://pubmed.ncbi.nlm.nih.gov/35537891/","https://doi.org/10.1016/j.jdiacomp.2022.108204",null],["5","R0010037","R0010037.pdf","open_download_failed","protocol","Major-Pedersen A","2022","Pilot study rectifies real-world study design to support regulatory decision making","Authorea Preprints","Wiley","10.22541/au.166999205.50183341/v1","https://doi.org/10.22541/au.166999205.50183341/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.166999205.50183341",null],["5","R0010716","R0010716.pdf","open_download_failed","other_trial","Touny AA","2022","Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics.","Scandinavian journal of gastroenterology","Informa UK Limited","10.1080/00365521.2022.2041084","https://doi.org/10.1080/00365521.2022.2041084","35234561","https://pubmed.ncbi.nlm.nih.gov/35234561/","https://www.tandfonline.com/doi/pdf/10.1080/00365521.2022.2041084?needAccess=true",null],["5","R0011214","R0011214.pdf","free_to_read","other_trial","Savarese G","2022","Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvab271","https://doi.org/10.1093/cvr/cvab271","34390570","https://pubmed.ncbi.nlm.nih.gov/34390570/",null,null],["5","R0012668","R0012668.pdf","open_download_failed","narrative_review","Marx N","2022","GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.122.059595","https://doi.org/10.1161/circulationaha.122.059595","36508493","https://pubmed.ncbi.nlm.nih.gov/36508493/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.122.059595",null],["5","R0013406","R0013406.pdf","open_download_failed","other_trial","Coskun T","2022","LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2022.07.013","https://doi.org/10.1016/j.cmet.2022.07.013","35985340","https://pubmed.ncbi.nlm.nih.gov/35985340/","http://www.cell.com/article/S1550413122003126/pdf",null],["5","R0014572","R0014572.pdf","open_download_failed","narrative_review","Kopp KO","2022","Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.","Pharmacological research","Elsevier BV","10.1016/j.phrs.2022.106550","https://doi.org/10.1016/j.phrs.2022.106550","36372278","https://pubmed.ncbi.nlm.nih.gov/36372278/","https://www.sciencedirect.com/science/article/pii/S1043661822004960/pdf",null],["5","R0016293","R0016293.pdf","open_download_failed","other_trial","Song J","2022","Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus.","Frontiers in endocrinology","Frontiers Media SA","10.3389/fendo.2022.949990","https://doi.org/10.3389/fendo.2022.949990","36051387","https://pubmed.ncbi.nlm.nih.gov/36051387/","https://doi.org/10.3389/fendo.2022.949990","ChiCTR:ChiCTR-CCC13003536"],["5","R0020330","R0020330.pdf","free_to_read","other_trial","Lam CSP","2022","Response by Lam and Gerstein to Letter Regarding Article, \"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.122.060526","https://doi.org/10.1161/circulationaha.122.060526","35858159","https://pubmed.ncbi.nlm.nih.gov/35858159/",null,null],["5","R0020389","R0020389.pdf","open_download_failed","other_trial","Groothof D","2022","Letter by Groothof et al Regarding Article, \"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.122.060263","https://doi.org/10.1161/circulationaha.122.060263","35858158","https://pubmed.ncbi.nlm.nih.gov/35858158/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.122.060263",null],["5","R0021367","R0021367.pdf","open_download_failed","other_trial","Machado T","2022","Physiologically-based pharmacokinetics modelling of Semaglutide in children and adolescents with healthy and obese body weights","Authorea Preprints","Wiley","10.22541/au.167110384.41057914/v1","https://doi.org/10.22541/au.167110384.41057914/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.authorea.com/doi/pdf/10.22541/au.167110384.41057914",null],["5","R0021428","R0021428.pdf","open_download_failed","other_trial","Ferrannini G","2022","Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.","Diabetes care","American Diabetes Association","10.2337/dc22-0903","https://doi.org/10.2337/dc22-0903","36040063","https://pubmed.ncbi.nlm.nih.gov/36040063/","https://diabetesjournals.org/care/article-pdf/45/10/e146/688628/dc220903.pdf",null],["5","R0022288","R0022288.pdf","open_download_failed","preclinical","Klausen MK","2022","The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","British journal of pharmacology","Wiley","10.1111/bph.15677","https://doi.org/10.1111/bph.15677","34532853","https://pubmed.ncbi.nlm.nih.gov/34532853/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bph.15677",null],["5","R0022495","R0022495.pdf","free_to_read","other_trial","Meier JJ","2022","Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14632","https://doi.org/10.1111/dom.14632","34957654","https://pubmed.ncbi.nlm.nih.gov/34957654/","https://doi.org/10.1111/dom.14632","ClinicalTrials.gov:NCT02877355"],["5","R0022578","R0022578.pdf","free_to_read","other_trial","O'Neil PM","2022","Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2022.2150006","https://doi.org/10.1080/00325481.2022.2150006","36691307","https://pubmed.ncbi.nlm.nih.gov/36691307/","https://doi.org/10.1080/00325481.2022.2150006",null],["5","R0024708","R0024708.pdf","open_download_failed","other_trial","Gerstein HC","2022","Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study.","Diabetes care","American Diabetes Association","10.2337/dc22-0453","https://doi.org/10.2337/dc22-0453","35817031","https://pubmed.ncbi.nlm.nih.gov/35817031/","https://diabetesjournals.org/care/article-pdf/45/9/2152/687629/dc220453.pdf","ClinicalTrials.gov:NCT01147250"],["5","R0025580","R0025580.pdf","free_to_read","other_trial",null,"2022","Pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes: Type 2 diabetes: Evidence review B","National Institute for Health and Care Excellence (NICE), London",null,null,"https://doi.org/","35575679","https://pubmed.ncbi.nlm.nih.gov/35575679/",null,null],["5","R0025747","R0025747.pdf","free_to_read","narrative_review","Cuda S","2022","Progress in pediatric obesity: new and advanced therapies.","Current opinion in pediatrics","Ovid Technologies (Wolters Kluwer Health)","10.1097/mop.0000000000001150","https://doi.org/10.1097/mop.0000000000001150","35797460","https://pubmed.ncbi.nlm.nih.gov/35797460/","https://doi.org/10.1097/mop.0000000000001150","ClinicalTrials.gov:NCT04102189; ClinicalTrials.gov:NCT04963231"],["5","R0026789","R0026789.pdf","open_download_failed","other","Alatrach M","2022","Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.","Diabetes care","American Diabetes Association","10.2337/dc21-1798","https://doi.org/10.2337/dc21-1798","35235659","https://pubmed.ncbi.nlm.nih.gov/35235659/","https://diabetesjournals.org/care/article-pdf/45/6/1372/684248/dc211798.pdf","ClinicalTrials.gov:NCT03331289"],["5","R0029779","R0029779.pdf","open_download_failed","other_trial","Säll C","2022","In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic.","Drug metabolism and disposition: the biological fate of chemicals","Elsevier BV","10.1124/dmd.122.000865","https://doi.org/10.1124/dmd.122.000865","35680133","https://pubmed.ncbi.nlm.nih.gov/35680133/","https://dmd.aspetjournals.org/content/dmd/50/8/1087.full.pdf",null],["5","R0032470","R0032470.pdf","no_doi","other_trial","Shubrook, Jay H.","2022","Another Positive GLP-1 RA CVOT: The AMPLITUDE-O Trial","Touro Scholar (Touro College)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035627","R0035627.pdf","free_to_read","other_trial","Dilek Tüzün","2022","Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists","Endocrinology research and practice.","AVES YAYINCILIK A.Ş.","10.5152/tjem.2022.22003","https://doi.org/10.5152/tjem.2022.22003",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5152/tjem.2022.22003",null],["5","R0036371","R0036371.pdf","no_doi","other_trial","Kempler, Péter","2022","A kardiometabolikus rizikó csökkentésének fontossága 2-es típusú cukorbetegségben [The importance of cardiometabolic risk reduction in type 2 diabetes mellitus]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036870","R0036870.pdf","free_to_read","other_trial","Vansh Chouhan","2022","Tirzepatide: Revolutionary Drug in Management of “Diabesity”","International Journal of Medical and Dental Sciences","Informatics Publishing Limited","10.18311/ijmds/2022/636","https://doi.org/10.18311/ijmds/2022/636",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.18311/ijmds/2022/636",null],["5","R0037943","R0037943.pdf","free_to_read","other_trial","Jothydev Kesavadev","2022","Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Disorders","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_2_23","https://doi.org/10.4103/ijdt.ijdt_2_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_2_23",null],["5","R0038867","R0038867.pdf","free_to_read","other_trial","Kazunori Sango","2022","Novel neuron-Schwann cell co-culture models to study peripheral nerve degeneration and regeneration","Neural Regeneration Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/1673-5374.363195","https://doi.org/10.4103/1673-5374.363195","36751798","https://pubmed.ncbi.nlm.nih.gov/36751798/","https://doi.org/10.4103/1673-5374.363195",null],["5","R0041530","R0041530.pdf","free_to_read","other_trial","Hiddo J.L. Heerspink","2022","POS-336 SEMAGLUTIDE 2.4 MG AND 1.0 MG IMPROVED ALBUMINURIA IN ADULTS WITH OVERWEIGHT/OBESITY AND TYPE 2 DIABETES IN STEP 2","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2022.01.357","https://doi.org/10.1016/j.ekir.2022.01.357",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2022.01.357",null],["5","R0042870","R0042870.pdf","free_to_read","other_trial","Miles Fisher","2022","Series: Cardiovascular outcome trials for diabetes drugs.","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2022.387","https://doi.org/10.15277/bjd.2022.387",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2022.387",null],["5","R0044352","R0044352.pdf","no_doi","other_trial","Schöning, Timm Lasse","2022","Antiinflammatorische Wirkung von DA-CH5 auf Mikroglia","Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049918","R0049918.pdf","free_to_read","other_trial","Lakshminarayanan Varadhan","2022","Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2022.385","https://doi.org/10.15277/bjd.2022.385",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2022.385",null],["5","R0054989","R0054989.pdf","free_to_read","other_trial","Vivek Raskar","2022","The Effect of Oral Semaglutide in Combination with other Hypoglycemic Agents in Patients with Diabesity","International Journal of Diabetes and Technology","Ovid Technologies (Wolters Kluwer Health)","10.4103/ijdt.ijdt_7_23","https://doi.org/10.4103/ijdt.ijdt_7_23",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4103/ijdt.ijdt_7_23",null],["5","R0008142","R0008142.pdf","free_to_read","protocol","Gerstein HC","2021","Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14223","https://doi.org/10.1111/dom.14223","33026143","https://pubmed.ncbi.nlm.nih.gov/33026143/","http://eprints.gla.ac.uk/228297/","ClinicalTrials.gov:NCT03496298"],["5","R0008334","R0008334.pdf","open_download_failed","other_trial","Gharagozloo M","2021","Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","Elsevier BV","10.1007/s13311-021-01088-5","https://doi.org/10.1007/s13311-021-01088-5","34260042","https://pubmed.ncbi.nlm.nih.gov/34260042/","https://www.neurotherapeuticsjournal.org/article/S1878-7479(23)00774-2/pdf",null],["5","R0008470","R0008470.pdf","open_download_failed","other_trial","Wilding JPH","2021","Cardiovascular outcome trials in obesity: A review.","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wiley","10.1111/obr.13112","https://doi.org/10.1111/obr.13112","32893459","https://pubmed.ncbi.nlm.nih.gov/32893459/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13112",null],["5","R0008474","R0008474.pdf","open_download_failed","other_trial","Cui J","2021","Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2021.27.7.840","https://doi.org/10.18553/jmcp.2021.27.7.840","34185562","https://pubmed.ncbi.nlm.nih.gov/34185562/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10391238/pdf/jmcp.2021.27.7.840.pdf",null],["5","R0008626","R0008626.pdf","open_download_failed","other_trial","Kloecker DE","2021","Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14384","https://doi.org/10.1111/dom.14384","33764645","https://pubmed.ncbi.nlm.nih.gov/33764645/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14384",null],["5","R0009561","R0009561.pdf","no_doi","other_trial","Paquot N","2021","[Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].","Revue medicale de Liege",null,null,"https://doi.org/","34881835","https://pubmed.ncbi.nlm.nih.gov/34881835/",null,null],["5","R0011458","R0011458.pdf","open_download_failed","other_trial","Fletcher MM","2021","AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.","The Journal of pharmacology and experimental therapeutics","Elsevier BV","10.1124/jpet.121.000567","https://doi.org/10.1124/jpet.121.000567","33727283","https://pubmed.ncbi.nlm.nih.gov/33727283/","https://jpet.aspetjournals.org/content/jpet/377/3/417.full.pdf",null],["5","R0011501","R0011501.pdf","open_download_failed","other_trial","Jammah AA","2021","Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.","Primary care diabetes","Elsevier BV","10.1016/j.pcd.2020.08.004","https://doi.org/10.1016/j.pcd.2020.08.004","32839127","https://pubmed.ncbi.nlm.nih.gov/32839127/","http://www.primary-care-diabetes.com/article/S1751991820302400/pdf",null],["5","R0011889","R0011889.pdf","open_download_failed","other_trial","Arnott C","2021","The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14386","https://doi.org/10.1111/dom.14386","33769679","https://pubmed.ncbi.nlm.nih.gov/33769679/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14386",null],["5","R0013630","R0013630.pdf","open_download_failed","other_trial","Bergkvist L","2021","An extended release GLP-1 analogue increases α-synuclein accumulation in a mouse model of prodromal Parkinson's disease.","Experimental neurology","Elsevier BV","10.1016/j.expneurol.2021.113693","https://doi.org/10.1016/j.expneurol.2021.113693","33727096","https://pubmed.ncbi.nlm.nih.gov/33727096/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10461454/pdf/nihms-1924065.pdf",null],["5","R0015719","R0015719.pdf","free_to_read","other_trial","Girges C","2021","The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.","Drugs & aging","Springer Science and Business Media LLC","10.1007/s40266-021-00853-7","https://doi.org/10.1007/s40266-021-00853-7","33738783","https://pubmed.ncbi.nlm.nih.gov/33738783/",null,null],["5","R0015964","R0015964.pdf","open_download_failed","protocol","McCrimmon RJ","2021","Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14354","https://doi.org/10.1111/dom.14354","33606908","https://pubmed.ncbi.nlm.nih.gov/33606908/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14354",null],["5","R0017121","R0017121.pdf","open_download_failed","other_trial","Hauge C","2021","Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.","Expert opinion on drug metabolism & toxicology","Informa UK Limited","10.1080/17425255.2021.1955856","https://doi.org/10.1080/17425255.2021.1955856","34289755","https://pubmed.ncbi.nlm.nih.gov/34289755/","https://www.tandfonline.com/doi/pdf/10.1080/17425255.2021.1955856?needAccess=true",null],["5","R0018906","R0018906.pdf","open_download_failed","protocol","Kennard M","2021","The glucose tolerance test in mice: sex, drugs and protocol.","Authorea Preprints","Wiley","10.22541/au.162515866.61067774/v1","https://doi.org/10.22541/au.162515866.61067774/v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://yvm2020.authorea.com/doi/pdf/10.22541/au.162515866.61067774",null],["5","R0021764","R0021764.pdf","free_to_read","other_trial","Ekinci EI","2021","Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study).","Internal medicine journal","Wiley","10.1111/imj.15428","https://doi.org/10.1111/imj.15428","34142743","https://pubmed.ncbi.nlm.nih.gov/34142743/",null,null],["5","R0022314","R0022314.pdf","open_download_failed","narrative_review","Aaseth J","2021","Diets and drugs for weight loss and health in obesity - An update.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2021.111789","https://doi.org/10.1016/j.biopha.2021.111789","34082399","https://pubmed.ncbi.nlm.nih.gov/34082399/","https://www.sciencedirect.com/science/article/pii/S0753332221005710/pdf",null],["5","R0022963","R0022963.pdf","open_download_failed","other","Taskinen MR","2021","Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14328","https://doi.org/10.1111/dom.14328","33502078","https://pubmed.ncbi.nlm.nih.gov/33502078/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14328",null],["5","R0023084","R0023084.pdf","free_to_read","narrative_review","Nauck MA","2021","The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14496","https://doi.org/10.1111/dom.14496","34310013","https://pubmed.ncbi.nlm.nih.gov/34310013/","https://doi.org/10.1111/dom.14496",null],["5","R0025773","R0025773.pdf","open_download_failed","other_trial","Larger É","2021","[An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].","Medecine sciences : M/S","EDP Sciences","10.1051/medsci/2020261","https://doi.org/10.1051/medsci/2020261","33492219","https://pubmed.ncbi.nlm.nih.gov/33492219/","https://www.medecinesciences.org/articles/medsci/pdf/2021/01/msc200331.pdf",null],["5","R0026749","R0026749.pdf","free_to_read","other_trial","Brayden DJ","2021","Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.","Expert opinion on drug delivery","Informa UK Limited","10.1080/17425247.2021.1942838","https://doi.org/10.1080/17425247.2021.1942838","34128734","https://pubmed.ncbi.nlm.nih.gov/34128734/","https://doi.org/10.1080/17425247.2021.1942838",null],["5","R0026808","R0026808.pdf","free_to_read","other_trial","Samsky MD","2021","Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.","Atherosclerosis","Elsevier BV","10.1016/j.atherosclerosis.2021.10.011","https://doi.org/10.1016/j.atherosclerosis.2021.10.011","34741929","https://pubmed.ncbi.nlm.nih.gov/34741929/","https://www.ncbi.nlm.nih.gov/pmc/articles/8702379",null],["5","R0030790","R0030790.pdf","no_doi","other_trial","Hassan Kahal","2021","Postprandial Hypoglycaemia following bariatric surgery;a case report","Obesity Facts",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031333","R0031333.pdf","no_doi","other_trial","Yasmeen Hassan Al Sadek","2021","An unusual presentation of type 2 diabetes mellitus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032335","R0032335.pdf","no_doi","other_trial",null,"2021","Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial","RECERCAT (Consorci de Serveis Universitaris de Catalunya)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035877","R0035877.pdf","free_to_read","other_trial","Erica M. Garner","2021","Commentary on Once-Weekly Semaglutide in Adults with Overweight or Obesity","Journal of Diabetes and Clinical Research","Scientific Archives","10.33696/diabetes.3.044","https://doi.org/10.33696/diabetes.3.044",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.33696/diabetes.3.044",null],["5","R0036248","R0036248.pdf","no_doi","other_trial","Dorrin Zarrin Khat","2021","Cardioprotective Effects of Combined Treatment with Sodium-glucose Co-Transporter-2 Inhibitor and Glucagon-like Peptide-1 Receptor Agonist in a Mouse Model of Ischemia-reperfusion Injury","TSpace (University of Toronto)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036366","R0036366.pdf","no_doi","protocol","jaredmberndt@gmail.com","2021","GLP1 CVD scoping review protocol","OSF Preprints (OSF Preprints)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036448","R0036448.pdf","no_doi","other_trial","Fülöp, Gábor","2021","GLP-1-receptoragonista-kezelés diabeteses vesebetegségben [GLP-1 receptor agonist treatment in diabetic kidney disease]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0038037","R0038037.pdf","free_to_read","other_trial","Alberto Testa","2021","Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000000992","https://doi.org/10.1097/fjc.0000000000000992","33818549","https://pubmed.ncbi.nlm.nih.gov/33818549/","https://hdl.handle.net/11573/1719651",null],["5","R0041392","R0041392.pdf","no_doi","other_trial","Thorsdottir, Ragnheidur Anna","2021","Diabetes Mellitus Type 2, effects of SGLT-2 inhibitors","University of Debrecen Electronic Archive (University of Debrecen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042495","R0042495.pdf","no_doi","other_trial","David E Kloecker (8494704)","2021","Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042809","R0042809.pdf","free_to_read","other_trial","Miles Fisher","2021","Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2021.301","https://doi.org/10.15277/bjd.2021.301",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2021.301",null],["5","R0047961","R0047961.pdf","free_to_read","other_trial","Preethika Subashini Ekanayake","2021","Changing the diabetes treatment paradigm from glucose control to cardiorenal protection","International Journal of Microbiology Research","Scientific Scholar","10.4103/ijmr.ijmr_3114_21","https://doi.org/10.4103/ijmr.ijmr_3114_21","35532581","https://pubmed.ncbi.nlm.nih.gov/35532581/","https://doi.org/10.4103/ijmr.ijmr_3114_21",null],["5","R0048673","R0048673.pdf","free_to_read","other_trial","Mikhail Kosiborod","2021","TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(21)02982-x","https://doi.org/10.1016/s0735-1097(21)02982-x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(21)02982-x",null],["5","R0049924","R0049924.pdf","free_to_read","other_trial","Subodh Verma","2021","CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(21)02965-x","https://doi.org/10.1016/s0735-1097(21)02965-x",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(21)02965-x",null],["5","R0050241","R0050241.pdf","free_to_read","other_trial","Ali Abbas Rizvi","2021","Diabetes and COVID-19: A Tale of 2 Pandemics","Journal of Cardiovascular Pharmacology","Ovid Technologies (Wolters Kluwer Health)","10.1097/fjc.0000000000001047","https://doi.org/10.1097/fjc.0000000000001047","34173808","https://pubmed.ncbi.nlm.nih.gov/34173808/","https://www.ncbi.nlm.nih.gov/pmc/articles/8253376",null],["5","R0050856","R0050856.pdf","free_to_read","other_trial","Athanasia K. Papazafiropoulou","2021","Effect of 3-Month Therapy with Empagliflozin on Ambulatory Blood Pressure and Arterial Stiffness in Patients with Type 2 Diabetes Mellitus","Annals of African Medicine","Ovid Technologies (Wolters Kluwer Health)","10.4103/aam.aam_19_20","https://doi.org/10.4103/aam.aam_19_20","34213486","https://pubmed.ncbi.nlm.nih.gov/34213486/","https://doi.org/10.4103/aam.aam_19_20",null],["5","R0051575","R0051575.pdf","free_to_read","protocol","Michael D Feher","2021","Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study) (Preprint)",null,"JMIR Publications Inc.","10.2196/preprints.34206","https://doi.org/10.2196/preprints.34206",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.2196/preprints.34206",null],["5","R0051607","R0051607.pdf","free_to_read","other_trial","Ansu Basu","2021","Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2021.283","https://doi.org/10.15277/bjd.2021.283",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2021.283",null],["5","R0051728","R0051728.pdf","free_to_read","other_trial","Subodh Verma","2021","IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(21)02963-6","https://doi.org/10.1016/s0735-1097(21)02963-6",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(21)02963-6",null],["5","R0053293","R0053293.pdf","free_to_read","other_trial","Mouhamed Nashawi","2021","Raising the Bar When Assessing Cardiovascular Disease Outcome When Studies with Patients with Type 2 Diabetes Mellitus are Constructed: Revisiting ASCEND","Austin Journal of Endocrinology and Diabetes","Austin Journals","10.26420/austinjendocrinoldiabetes.2021.1083","https://doi.org/10.26420/austinjendocrinoldiabetes.2021.1083",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.26420/austinjendocrinoldiabetes.2021.1083",null],["5","R0005908","R0005908.pdf","open_download_failed","other_trial","Giorgino F","2020","Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2020.108478","https://doi.org/10.1016/j.diabres.2020.108478","33002548","https://pubmed.ncbi.nlm.nih.gov/33002548/","http://www.diabetesresearchclinicalpractice.com/article/S0168822720307312/pdf",null],["5","R0006991","R0006991.pdf","free_to_read","other_trial","Hansen BB","2020","Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2020.1722678","https://doi.org/10.1080/13696998.2020.1722678","31990244","https://pubmed.ncbi.nlm.nih.gov/31990244/","https://doi.org/10.1080/13696998.2020.1722678",null],["5","R0008417","R0008417.pdf","free_to_read","other_trial","Zhang L","2020","The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-191768","https://doi.org/10.3233/jpd-191768","31958096","https://pubmed.ncbi.nlm.nih.gov/31958096/","https://doaj.org/article/bfe9c4a1468944aeba965974d5cc1863","ClinicalTrials.gov:NCT02953665"],["5","R0008642","R0008642.pdf","open_download_failed","other_trial","Mosenzon O","2020","Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1800286","https://doi.org/10.1080/00325481.2020.1800286","32815439","https://pubmed.ncbi.nlm.nih.gov/32815439/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2020.1800286?needAccess=true",null],["5","R0008739","R0008739.pdf","free_to_read","other_trial","Chun JH","2020","Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.","JAAPA : official journal of the American Academy of Physician Assistants","Ovid Technologies (Wolters Kluwer Health)","10.1097/01.jaa.0000669456.13763.bd","https://doi.org/10.1097/01.jaa.0000669456.13763.bd","32740121","https://pubmed.ncbi.nlm.nih.gov/32740121/",null,null],["5","R0008836","R0008836.pdf","free_to_read","other_trial","Brunton SA","2020","Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2020.1798162","https://doi.org/10.1080/00325481.2020.1798162","32815453","https://pubmed.ncbi.nlm.nih.gov/32815453/","https://doi.org/10.1080/00325481.2020.1798162",null],["5","R0009224","R0009224.pdf","free_to_read","other_trial","Chudleigh RA","2020","Semaglutide injection for the treatment of adults with type 2 diabetes.","Expert review of clinical pharmacology","Informa UK Limited","10.1080/17512433.2020.1776108","https://doi.org/10.1080/17512433.2020.1776108","32476529","https://pubmed.ncbi.nlm.nih.gov/32476529/",null,null],["5","R0010926","R0010926.pdf","open_download_failed","other_trial","Seferović PM","2020","European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.","European journal of heart failure","Oxford University Press (OUP)","10.1002/ejhf.1673","https://doi.org/10.1002/ejhf.1673","31816162","https://pubmed.ncbi.nlm.nih.gov/31816162/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.1673",null],["5","R0011402","R0011402.pdf","open_download_failed","protocol","Hamal S","2020","Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial.","Coronary artery disease","Ovid Technologies (Wolters Kluwer Health)","10.1097/mca.0000000000000830","https://doi.org/10.1097/mca.0000000000000830","32271261","https://pubmed.ncbi.nlm.nih.gov/32271261/","https://escholarship.org/content/qt0vp2x5d3/qt0vp2x5d3.pdf?t=qa7xh1",null],["5","R0011929","R0011929.pdf","free_to_read","other_trial","van Baar MJB","2020","Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?","Current opinion in nephrology and hypertension","Ovid Technologies (Wolters Kluwer Health)","10.1097/mnh.0000000000000559","https://doi.org/10.1097/mnh.0000000000000559","31714285","https://pubmed.ncbi.nlm.nih.gov/31714285/","https://pure.amsterdamumc.nl/en/publications/3fccbead-41ff-42d9-97e0-ca506ac94816",null],["5","R0016197","R0016197.pdf","open_download_failed","protocol","Ryan DH","2020","Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.","American heart journal","Elsevier BV","10.1016/j.ahj.2020.07.008","https://doi.org/10.1016/j.ahj.2020.07.008","32916609","https://pubmed.ncbi.nlm.nih.gov/32916609/","https://www.sciencedirect.com/science/article/pii/S0002870320302143/pdf",null],["5","R0017770","R0017770.pdf","open_download_failed","other_trial","Vincent RK","2020","A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?","Diabetes, obesity & metabolism","Wiley","10.1111/dom.14196","https://doi.org/10.1111/dom.14196","32945071","https://pubmed.ncbi.nlm.nih.gov/32945071/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14196",null],["5","R0021328","R0021328.pdf","free_to_read","other_trial","Khunti K","2020","Cardiovascular outcome trials of glucose-lowering therapies.","Expert review of pharmacoeconomics & outcomes research","Informa UK Limited","10.1080/14737167.2020.1763796","https://doi.org/10.1080/14737167.2020.1763796","32403956","https://pubmed.ncbi.nlm.nih.gov/32403956/","https://figshare.com/articles/journal_contribution/Cardiovascular_outcome_trials_of_glucose-lowering_therapies/12301472",null],["5","R0023376","R0023376.pdf","open_download_failed","other_trial","Petri KCC","2020","Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes.","Journal of pediatric endocrinology & metabolism : JPEM","Walter de Gruyter GmbH","10.1515/jpem-2020-0053","https://doi.org/10.1515/jpem-2020-0053","32817582","https://pubmed.ncbi.nlm.nih.gov/32817582/","https://www.degruyter.com/document/doi/10.1515/jpem-2020-0053/pdf",null],["5","R0023413","R0023413.pdf","open_download_failed","other_trial","Storm CS","2020","Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study","medRxiv","openRxiv","10.1101/2020.10.20.20215855","https://doi.org/10.1101/2020.10.20.20215855",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.medrxiv.org/content/medrxiv/early/2020/10/21/2020.10.20.20215855.full.pdf",null],["5","R0023869","R0023869.pdf","free_to_read","other_trial","Ramos M","2020","Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.","Journal of comparative effectiveness research","Becaris Publishing Limited","10.2217/cer-2020-0071","https://doi.org/10.2217/cer-2020-0071","32573253","https://pubmed.ncbi.nlm.nih.gov/32573253/","https://doi.org/10.2217/cer-2020-0071",null],["5","R0024127","R0024127.pdf","open_download_failed","other","Ali AM","2020","Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/clinem/dgaa494","https://doi.org/10.1210/clinem/dgaa494","32745202","https://pubmed.ncbi.nlm.nih.gov/32745202/","https://academic.oup.com/jcem/article-pdf/105/10/3226/41828438/dgaa494.pdf","ClinicalTrials.gov:NCT02324842"],["5","R0024374","R0024374.pdf","open_download_failed","other_trial","Sumida Y","2020","Antidiabetic Therapy in the Treatment of NASH","Preprints.org","MDPI AG","10.20944/preprints202001.0171.v1","https://doi.org/10.20944/preprints202001.0171.v1",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.preprints.org/manuscript/202001.0171/v1/download",null],["5","R0024603","R0024603.pdf","open_download_failed","protocol","Harrison SA","2020","Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.","Contemporary clinical trials","Elsevier BV","10.1016/j.cct.2020.106174","https://doi.org/10.1016/j.cct.2020.106174","33039693","https://pubmed.ncbi.nlm.nih.gov/33039693/","https://www.sciencedirect.com/science/article/pii/S1551714420302524/pdf","ClinicalTrials.gov:NCT02970942"],["5","R0026000","R0026000.pdf","open_download_failed","other_trial","Brayden DJ","2020","Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches.","Advanced drug delivery reviews","Elsevier BV","10.1016/j.addr.2020.05.007","https://doi.org/10.1016/j.addr.2020.05.007","32479930","https://pubmed.ncbi.nlm.nih.gov/32479930/","https://www.sciencedirect.com/science/article/pii/S0169409X20300405/pdf",null],["5","R0026410","R0026410.pdf","free_to_read","other","Standl E","2020","Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.","Diabetes care","American Diabetes Association","10.2337/dc19-1079","https://doi.org/10.2337/dc19-1079","31882409","https://pubmed.ncbi.nlm.nih.gov/31882409/","https://doi.org/10.17615/1zz5-q530","ClinicalTrials.gov:NCT01144338"],["5","R0028484","R0028484.pdf","open_download_failed","other_trial","Demine S","2020","Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.","International journal of molecular sciences","MDPI AG","10.3390/ijms21197274","https://doi.org/10.3390/ijms21197274","33019671","https://pubmed.ncbi.nlm.nih.gov/33019671/","https://www.mdpi.com/1422-0067/21/19/7274/pdf?version=1602224139",null],["5","R0028494","R0028494.pdf","free_to_read","other","Das SR","2020","2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2020.05.037","https://doi.org/10.1016/j.jacc.2020.05.037","32771263","https://pubmed.ncbi.nlm.nih.gov/32771263/","https://doi.org/10.1016/j.jacc.2020.05.037",null],["5","R0038139","R0038139.pdf","free_to_read","other_trial","Nathan D. Wong","2020","Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?","Cardiovascular Endocrinology & Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000206","https://doi.org/10.1097/xce.0000000000000206","32803137","https://pubmed.ncbi.nlm.nih.gov/32803137/","https://doi.org/10.1097/xce.0000000000000206",null],["5","R0038176","R0038176.pdf","free_to_read","other_trial","Thibault Gautier","2020","Addition of New Therapeutic Agents to an Established Type 2 Diabetes Simulation Platform for Therapy Optimization: A Bayesian Model-Based Approach","IFAC-PapersOnLine","Elsevier BV","10.1016/j.ifacol.2020.12.649","https://doi.org/10.1016/j.ifacol.2020.12.649",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ifacol.2020.12.649",null],["5","R0041450","R0041450.pdf","no_doi","other_trial","Mahdavi, Seyed Saeed","2020","Current and Novel Pharmacological Management of Diabetes","University of Debrecen Electronic Archive (University of Debrecen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041631","R0041631.pdf","free_to_read","other_trial","Subodh Verma","2020","APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE","Journal of the American College of Cardiology","Elsevier BV","10.1016/s0735-1097(20)32549-3","https://doi.org/10.1016/s0735-1097(20)32549-3",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/s0735-1097(20)32549-3","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716"],["5","R0042969","R0042969.pdf","free_to_read","other_trial","Miles Fisher","2020","Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.267","https://doi.org/10.15277/bjd.2020.267",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.267",null],["5","R0043157","R0043157.pdf","free_to_read","other_trial","Miles Fisher","2020","Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.254","https://doi.org/10.15277/bjd.2020.254",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.254",null],["5","R0043214","R0043214.pdf","free_to_read","other_trial","Muhammed Vally","2020","Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management","South African General Practitioner","Medpharm Publications","10.36303/sagp.2020.1.1.0006","https://doi.org/10.36303/sagp.2020.1.1.0006",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.36303/sagp.2020.1.1.0006",null],["5","R0044331","R0044331.pdf","no_doi","other_trial","Dalmau Vila, Alba","2020","Fragility index and risk of bias in cardiovascular outcome trials for new antidiabetic drugs","Universitat de Girona Digital Repository (Universitat de Girona)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044851","R0044851.pdf","free_to_read","other_trial","Miles Fisher","2020","Series: Cardiovascular outcome trials for diabetes drugs Lixisenatide and ELIXA","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.241","https://doi.org/10.15277/bjd.2020.241",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.241",null],["5","R0047950","R0047950.pdf","free_to_read","other_trial","L.L. MYAT","2020","SAT-161 TREATMENT OF DIABESITY WITH DIET AND NEWER ANTIGLYCEMIC MEDICATIONS IN PLACE OF INSULIN: EFFECT ON DIABETIC KIDNEY DISEASE","Kidney International Reports","Elsevier BV","10.1016/j.ekir.2020.02.171","https://doi.org/10.1016/j.ekir.2020.02.171",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ekir.2020.02.171",null],["5","R0053096","R0053096.pdf","free_to_read","other_trial","Robert E. J. Ryder","2020","Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020","British Journal of Diabetes","ABCD Diabetes Care, Ltd.","10.15277/bjd.2020.276","https://doi.org/10.15277/bjd.2020.276",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15277/bjd.2020.276",null],["5","R0007340","R0007340.pdf","free_to_read","other_trial","Prattichizzo F","2019","Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.","European journal of preventive cardiology","Oxford University Press (OUP)","10.1177/2047487319880040","https://doi.org/10.1177/2047487319880040","31766918","https://pubmed.ncbi.nlm.nih.gov/31766918/",null,null],["5","R0008255","R0008255.pdf","free_to_read","case_report","Kårhus ML","2019","Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.","Gastroenterology","Elsevier BV","10.1053/j.gastro.2019.04.002","https://doi.org/10.1053/j.gastro.2019.04.002","30965026","https://pubmed.ncbi.nlm.nih.gov/30965026/","https://portal.findresearcher.sdu.dk/files/152900001/Remission_of_bile_acid_malabsorption_symptoms_following_treatment....pdf",null],["5","R0010728","R0010728.pdf","free_to_read","other_trial","Zhang L","2019","Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-181503","https://doi.org/10.3233/jpd-181503","30741689","https://pubmed.ncbi.nlm.nih.gov/30741689/","https://doaj.org/article/8698434d3bdd49a5bb96c558d58d29b5",null],["5","R0011462","R0011462.pdf","open_download_failed","other_trial","Goldenberg RM","2019","Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.","Canadian journal of diabetes","Elsevier BV","10.1016/j.jcjd.2018.05.008","https://doi.org/10.1016/j.jcjd.2018.05.008","30195966","https://pubmed.ncbi.nlm.nih.gov/30195966/","http://www.canadianjournalofdiabetes.com/article/S1499267118301096/pdf",null],["5","R0012513","R0012513.pdf","open_download_failed","other_trial","Handelsman Y","2019","Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.","Journal of diabetes and its complications","Elsevier BV","10.1016/j.jdiacomp.2018.11.009","https://doi.org/10.1016/j.jdiacomp.2018.11.009","30600136","https://pubmed.ncbi.nlm.nih.gov/30600136/","https://www.sciencedirect.com/science/article/pii/S1056872718306019/pdf",null],["5","R0012707","R0012707.pdf","open_download_failed","other_trial","Badjatiya A","2019","Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.","Circulation. Cardiovascular interventions","Ovid Technologies (Wolters Kluwer Health)","10.1161/circinterventions.119.008018","https://doi.org/10.1161/circinterventions.119.008018","31752517","https://pubmed.ncbi.nlm.nih.gov/31752517/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.119.008018","ClinicalTrials.gov:NCT01144338"],["5","R0013158","R0013158.pdf","free_to_read","other_trial","Aroda VR","2019","Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.","Diabetes & metabolism","Elsevier BV","10.1016/j.diabet.2018.12.001","https://doi.org/10.1016/j.diabet.2018.12.001","30615985","https://pubmed.ncbi.nlm.nih.gov/30615985/","https://figshare.com/articles/journal_contribution/Comparative_efficacy_safety_and_cardiovascular_outcomes_with_once-weekly_subcutaneous_semaglutide_in_the_treatment_of_type_2_diabetes_Insights_from_the_SUSTAIN_1-7_trials/10216622",null],["5","R0013585","R0013585.pdf","no_doi","other_trial","Scheen AJ","2019","[Basal insulin degludec (Tresiba®)].","Revue medicale de Liege",null,null,"https://doi.org/","30997973","https://pubmed.ncbi.nlm.nih.gov/30997973/",null,null],["5","R0015167","R0015167.pdf","no_doi","other_trial","Scheen AJ","2019","[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].","Revue medicale de Liege",null,null,"https://doi.org/","31486321","https://pubmed.ncbi.nlm.nih.gov/31486321/",null,null],["5","R0017624","R0017624.pdf","open_download_failed","other_trial","Brindisi MC","2019","Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.","Diabetes & metabolic syndrome","Elsevier BV","10.1016/j.dsx.2019.06.021","https://doi.org/10.1016/j.dsx.2019.06.021","31405666","https://pubmed.ncbi.nlm.nih.gov/31405666/","https://www.sciencedirect.com/science/article/am/pii/S1871402119303467?via%3Dihub","ClinicalTrials.gov:NCT02674893"],["5","R0017746","R0017746.pdf","free_to_read","other","Fonseca VA","2019","Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2018-02685","https://doi.org/10.1210/jc.2018-02685","30938762","https://pubmed.ncbi.nlm.nih.gov/30938762/","http://hdl.handle.net/11268/10213",null],["5","R0018837","R0018837.pdf","open_download_failed","other","Antwi K","2019","68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2018-02754","https://doi.org/10.1210/jc.2018-02754","31298706","https://pubmed.ncbi.nlm.nih.gov/31298706/","https://academic.oup.com/jcem/article-pdf/104/12/5843/30246261/jc.2018-02754.pdf","ClinicalTrials.gov:NCT02127541"],["5","R0018953","R0018953.pdf","no_doi","other_trial","Lage MJ","2019","Comment on generalizability of GLP-1 RA CVOTs in US T2D population.","The American journal of managed care",null,null,"https://doi.org/","30986012","https://pubmed.ncbi.nlm.nih.gov/30986012/",null,null],["5","R0020804","R0020804.pdf","no_doi","other_trial","Verburg AFE","2019","[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].","Nederlands tijdschrift voor geneeskunde",null,null,"https://doi.org/","30676706","https://pubmed.ncbi.nlm.nih.gov/30676706/",null,null],["5","R0022822","R0022822.pdf","open_download_failed","other_trial","Oldham S","2019","Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution.","Journal of visualized experiments : JoVE","MyJove Corporation","10.3791/59130","https://doi.org/10.3791/59130","31058888","https://pubmed.ncbi.nlm.nih.gov/31058888/","https://www.jove.com/pdf/59130/incorporation-survivable-liver-biopsy-procedure-mice-to-assess-non",null],["5","R0024050","R0024050.pdf","open_download_failed","other_trial","Webb DR","2019","The right place for Sulphonylureas today.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.107836","https://doi.org/10.1016/j.diabres.2019.107836","31479704","https://pubmed.ncbi.nlm.nih.gov/31479704/","http://www.diabetesresearchclinicalpractice.com/article/S0168822719311593/pdf",null],["5","R0024469","R0024469.pdf","open_download_failed","other_trial","Serfaty L","2019","[Pharmacological treatment of NASH].","Presse medicale (Paris, France : 1983)","Elsevier BV","10.1016/j.lpm.2019.09.015","https://doi.org/10.1016/j.lpm.2019.09.015","31757735","https://pubmed.ncbi.nlm.nih.gov/31757735/","https://www.sciencedirect.com/science/article/am/pii/S0755498219304014?via%3Dihub",null],["5","R0024580","R0024580.pdf","open_download_failed","other_trial","Patti AM","2019","Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2019.02.006","https://doi.org/10.1016/j.diabres.2019.02.006","30759365","https://pubmed.ncbi.nlm.nih.gov/30759365/","http://www.diabetesresearchclinicalpractice.com/article/S0168822718311689/pdf",null],["5","R0025491","R0025491.pdf","free_to_read","other_trial","Xie J","2019","Letter by Xie et al Regarding Article, \"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.118.039071","https://doi.org/10.1161/circulationaha.118.039071","31136224","https://pubmed.ncbi.nlm.nih.gov/31136224/",null,null],["5","R0025521","R0025521.pdf","open_download_failed","other_trial","Mann JFE","2019","Response by Mann et al to Letter Regarding Article, \"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial\".","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.119.040419","https://doi.org/10.1161/circulationaha.119.040419","31136226","https://pubmed.ncbi.nlm.nih.gov/31136226/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.040419",null],["5","R0027499","R0027499.pdf","open_download_failed","other_trial","Bagnoli E","2019","Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?","The European journal of neuroscience","Wiley","10.1111/ejn.14115","https://doi.org/10.1111/ejn.14115","30120857","https://pubmed.ncbi.nlm.nih.gov/30120857/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejn.14115",null],["5","R0028636","R0028636.pdf","open_download_failed","narrative_review","Bain SC","2019","Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.13538","https://doi.org/10.1111/dom.13538","30226298","https://pubmed.ncbi.nlm.nih.gov/30226298/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.13538",null],["5","R0029762","R0029762.pdf","open_download_failed","narrative_review","Al-Massadi O","2019","Glucagon Control on Food Intake and Energy Balance.","International journal of molecular sciences","MDPI AG","10.3390/ijms20163905","https://doi.org/10.3390/ijms20163905","31405212","https://pubmed.ncbi.nlm.nih.gov/31405212/","https://www.mdpi.com/1422-0067/20/16/3905/pdf?version=1565509749",null],["5","R0032004","R0032004.pdf","no_doi","other_trial","Drew Boxler","2019","Victoza (Liraglutide): Potential New Treatment for Child and Adolescent Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036401","R0036401.pdf","no_doi","other_trial","Balogh, Zoltán","2019","SUSTAIN program: klinikai eredmények [SUSTAIN trial program: clinical results]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037363","R0037363.pdf","free_to_read","other_trial","Katherine R. Tuttle","2019","Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease","Clinical Journal of the American Society of Nephrology","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.07730719","https://doi.org/10.2215/cjn.07730719","31740570","https://pubmed.ncbi.nlm.nih.gov/31740570/","https://www.ncbi.nlm.nih.gov/pmc/articles/7015086",null],["5","R0039727","R0039727.pdf","free_to_read","other_trial","Bruce M. Psaty","2019","Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?","American Journal of Hypertension","Oxford University Press (OUP)","10.1093/ajh/hpz093","https://doi.org/10.1093/ajh/hpz093","31175821","https://pubmed.ncbi.nlm.nih.gov/31175821/","https://www.ncbi.nlm.nih.gov/pmc/articles/6758938",null],["5","R0043566","R0043566.pdf","free_to_read","other_trial","Fulvio Ventura","2019","Diabetes in the third millennium: prognosis improves, but juvenile forms are more frequent","European Heart Journal Supplements","Oxford University Press (OUP)","10.1093/eurheartj/suz006","https://doi.org/10.1093/eurheartj/suz006","30948936","https://pubmed.ncbi.nlm.nih.gov/30948936/","https://doi.org/10.1093/eurheartj/suz006",null],["5","R0044165","R0044165.pdf","no_doi","other_trial","Gernot K Klein (16619241)","2019","A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT03235375"],["5","R0047193","R0047193.pdf","no_doi","other_trial","John P.H. Wilding","2019","Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049184","R0049184.pdf","no_doi","other_trial","Karen L. Jones","2019","Effect of exenatide once-weekly (QW) on gastric emptying in health: impact on glycaemia and glucose absorption","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ANZCTR:ACTRN12616000955415"],["5","R0049244","R0049244.pdf","free_to_read","other_trial","Silvio E. Inzucchi","2019","Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial","Diabetes Care","American Diabetes Association","10.2337/dc18-1355","https://doi.org/10.2337/dc18-1355","30705060","https://pubmed.ncbi.nlm.nih.gov/30705060/","https://www.ncbi.nlm.nih.gov/pmc/articles/11869348",null],["5","R0051285","R0051285.pdf","no_doi","other_trial","Elisabetta Patorno","2019","Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052498","R0052498.pdf","no_doi","other_trial","Vivian Andrew Fonseca","2019","PL-2 : What can we learn from cardiovascular outcome trials in diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052837","R0052837.pdf","no_doi","other_trial","Ryan J. Jalleh","2019","Acute effects of lixisenatide on intragastric meal distribution: impact on energy intake","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT02308254"],["5","R0054179","R0054179.pdf","no_doi","other_trial","Frederik Persson","2019","Individual Effects of Liraglutide on Cardiorenal Risk Markers:Results from the LEADER Trial","Research at the University of Copenhagen (University of Copenhagen)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0006511","R0006511.pdf","open_download_failed","other_trial","Iepsen EW","2018","Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2018.05.008","https://doi.org/10.1016/j.cmet.2018.05.008","29861388","https://pubmed.ncbi.nlm.nih.gov/29861388/","https://www.cell.com/cell-metabolism/pdf/S1550-4131(18)30315-2.pdf",null],["5","R0006950","R0006950.pdf","no_doi","other_trial","Brunton SA","2018","An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.","The Journal of family practice",null,null,"https://doi.org/","29912995","https://pubmed.ncbi.nlm.nih.gov/29912995/",null,null],["5","R0007116","R0007116.pdf","no_doi","other_trial","Frias JP","2018","Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.","The Journal of family practice",null,null,"https://doi.org/","29912998","https://pubmed.ncbi.nlm.nih.gov/29912998/",null,null],["5","R0009324","R0009324.pdf","open_download_failed","other_trial","Heile M","2018","Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.","Journal of managed care & specialty pharmacy","Academy of Managed Care Pharmacy","10.18553/jmcp.2018.24.9-a.s42","https://doi.org/10.18553/jmcp.2018.24.9-a.s42","30156446","https://pubmed.ncbi.nlm.nih.gov/30156446/","https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.9-a.s42",null],["5","R0009447","R0009447.pdf","free_to_read","other","Torekov SS","2018","Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.","Cardiovascular research","Oxford University Press (OUP)","10.1093/cvr/cvy124","https://doi.org/10.1093/cvr/cvy124","30052921","https://pubmed.ncbi.nlm.nih.gov/30052921/",null,null],["5","R0010449","R0010449.pdf","open_download_failed","other_trial","Newman JD","2018","The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2018.07.071","https://doi.org/10.1016/j.jacc.2018.07.071","30286929","https://pubmed.ncbi.nlm.nih.gov/30286929/","https://www.sciencedirect.com/science/article/pii/S0735109718369365/pdf",null],["5","R0010777","R0010777.pdf","free_to_read","protocol","Green JB","2018","Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.","American heart journal","Elsevier BV","10.1016/j.ahj.2018.03.030","https://doi.org/10.1016/j.ahj.2018.03.030","30015066","https://pubmed.ncbi.nlm.nih.gov/30015066/","http://eprints.gla.ac.uk/165953/","ClinicalTrials.gov:NCT02465515"],["5","R0010865","R0010865.pdf","open_download_failed","other_trial","Evans M","2018","An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2017.1409228","https://doi.org/10.1080/13696998.2017.1409228","29164973","https://pubmed.ncbi.nlm.nih.gov/29164973/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1409228?needAccess=true&role=button",null],["5","R0010984","R0010984.pdf","open_download_failed","narrative_review","Sharma D","2018","Recent updates on GLP-1 agonists: Current advancements & challenges.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Elsevier BV","10.1016/j.biopha.2018.08.088","https://doi.org/10.1016/j.biopha.2018.08.088","30372907","https://pubmed.ncbi.nlm.nih.gov/30372907/","https://www.sciencedirect.com/science/article/pii/S0753332218327537/pdf",null],["5","R0014212","R0014212.pdf","open_download_failed","other","Garczorz W","2018","Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.","Cardiovascular therapeutics","Wiley","10.1111/1755-5922.12317","https://doi.org/10.1111/1755-5922.12317","29283509","https://pubmed.ncbi.nlm.nih.gov/29283509/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1755-5922.12317",null],["5","R0018307","R0018307.pdf","free_to_read","other_trial","Thomson SC","2018","Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.","Current diabetes reports","Springer Science and Business Media LLC","10.1007/s11892-018-0991-7","https://doi.org/10.1007/s11892-018-0991-7","29654381","https://pubmed.ncbi.nlm.nih.gov/29654381/","https://www.ncbi.nlm.nih.gov/pmc/articles/6426321",null],["5","R0018458","R0018458.pdf","free_to_read","other_trial","Coulter AA","2018","Centrally Acting Agents for Obesity: Past, Present, and Future.","Drugs","Springer Science and Business Media LLC","10.1007/s40265-018-0946-y","https://doi.org/10.1007/s40265-018-0946-y","30014268","https://pubmed.ncbi.nlm.nih.gov/30014268/","https://www.ncbi.nlm.nih.gov/pmc/articles/6095132",null],["5","R0019668","R0019668.pdf","free_to_read","other_trial","Panagaki T","2018","Neuroprotective effects of incretin mimetics upon chronic endoplasmic reticulum (ER) stress : implications for novel therapeutic pathways and opportunities in Alzheimer's disease","Lancaster University",null,"10.17635/lancaster/thesis/324","https://doi.org/10.17635/lancaster/thesis/324",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0020567","R0020567.pdf","free_to_read","other_trial","Dempsey M","2018","Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Elsevier BV","10.4158/ep-2018-0134","https://doi.org/10.4158/ep-2018-0134","30308134","https://pubmed.ncbi.nlm.nih.gov/30308134/",null,null],["5","R0021268","R0021268.pdf","open_download_failed","other_trial","Ishii H","2018","The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2018.1431918","https://doi.org/10.1080/13696998.2018.1431918","29357718","https://pubmed.ncbi.nlm.nih.gov/29357718/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1431918?needAccess=true&role=button","ClinicalTrials.gov:NCT01584232"],["5","R0022516","R0022516.pdf","free_to_read","other_trial","Suissa S","2018","Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.","Diabetes care","American Diabetes Association","10.2337/dc17-1059","https://doi.org/10.2337/dc17-1059","29358464","https://pubmed.ncbi.nlm.nih.gov/29358464/",null,null],["5","R0023152","R0023152.pdf","open_download_failed","other_trial","Dempsey M","2018","Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2018.1513406","https://doi.org/10.1080/13696998.2018.1513406","30114954","https://pubmed.ncbi.nlm.nih.gov/30114954/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1513406?needAccess=true&role=button",null],["5","R0023718","R0023718.pdf","open_download_failed","other_trial","Bloomgarden Z","2018","The kidney and cardiovascular outcome trials.","Journal of diabetes","Wiley","10.1111/1753-0407.12616","https://doi.org/10.1111/1753-0407.12616","29031006","https://pubmed.ncbi.nlm.nih.gov/29031006/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1753-0407.12616",null],["5","R0024077","R0024077.pdf","open_download_failed","narrative_review","Drucker DJ","2018","Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2018.03.001","https://doi.org/10.1016/j.cmet.2018.03.001","29617641","https://pubmed.ncbi.nlm.nih.gov/29617641/","https://www.cell.com/article/S1550413118301797/pdf",null],["5","R0024693","R0024693.pdf","open_download_failed","other_trial","Vergès B","2018","Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.","Arteriosclerosis, thrombosis, and vascular biology","Ovid Technologies (Wolters Kluwer Health)","10.1161/atvbaha.118.310990","https://doi.org/10.1161/atvbaha.118.310990","30026275","https://pubmed.ncbi.nlm.nih.gov/30026275/","https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310990","ClinicalTrials.gov:NCT02721888"],["5","R0024991","R0024991.pdf","open_download_failed","other_trial","Marso SP","2018","Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2018.02.030","https://doi.org/10.1016/j.amjcard.2018.02.030","29627109","https://pubmed.ncbi.nlm.nih.gov/29627109/","http://www.ajconline.org/article/S0002914918302662/pdf","ClinicalTrials.gov:NCT01179048"],["5","R0025226","R0025226.pdf","free_to_read","other_trial","Horie I","2018","Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.","Diabetes research and clinical practice","Elsevier BV","10.1016/j.diabres.2018.08.015","https://doi.org/10.1016/j.diabres.2018.08.015","30194951","https://pubmed.ncbi.nlm.nih.gov/30194951/","https://nagasaki-u.repo.nii.ac.jp/records/1362",null],["5","R0025792","R0025792.pdf","open_download_failed","other_trial","Galderisi A","2018","Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2017-02265","https://doi.org/10.1210/jc.2017-02265","29211871","https://pubmed.ncbi.nlm.nih.gov/29211871/","https://academic.oup.com/jcem/article-pdf/103/3/1088/24262780/jc.2017-02265.pdf",null],["5","R0025986","R0025986.pdf","open_download_failed","other_trial","Cherney DZI","2018","Novel therapies for diabetic kidney disease.","Kidney international supplements","Elsevier BV","10.1016/j.kisu.2017.10.005","https://doi.org/10.1016/j.kisu.2017.10.005","30675435","https://pubmed.ncbi.nlm.nih.gov/30675435/","http://www.kisupplements.org/article/S215717161730062X/pdf",null],["5","R0025992","R0025992.pdf","no_doi","other_trial","Said OV","2018","Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.","Wiadomosci lekarskie (Warsaw, Poland : 1960)",null,null,"https://doi.org/","30267490","https://pubmed.ncbi.nlm.nih.gov/30267490/",null,null],["5","R0026307","R0026307.pdf","free_to_read","other_trial","Chikara G","2018","A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?","Indian journal of clinical biochemistry : IJCB","Springer Science and Business Media LLC","10.1007/s12291-017-0668-z","https://doi.org/10.1007/s12291-017-0668-z","29651202","https://pubmed.ncbi.nlm.nih.gov/29651202/","https://www.ncbi.nlm.nih.gov/pmc/articles/5891460",null],["5","R0028687","R0028687.pdf","free_to_read","other_trial","Cefalu WT","2018","Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.","Diabetes care","American Diabetes Association","10.2337/dci17-0057","https://doi.org/10.2337/dci17-0057","29263194","https://pubmed.ncbi.nlm.nih.gov/29263194/","https://www.ncbi.nlm.nih.gov/pmc/articles/5741160",null],["5","R0031220","R0031220.pdf","no_doi","other_trial","Thomas A. Zelniker","2018","Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031659","R0031659.pdf","no_doi","other_trial","M Marre","2018","Efficacité et tolérance d'IDegLira en cas d'insuffisance rénale légère à modérée : analyses des études de phase III",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031677","R0031677.pdf","no_doi","other_trial","M Marre","2018","Efficacité et tolérance d'IDegLira en cas d'insuffisance rénale légère à modérée : analyses des études de phase III",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035342","R0035342.pdf","no_doi","other_trial","Fei Li","2018","Clinical trial of liraglutide injection in the treatment of patients with diabetes mellitus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036247","R0036247.pdf","no_doi","protocol","Muller, Claire","2018","Treatment with exenatide in acute ischaemic stroke trial protocol: A prospective, randomised, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycaemia","Research Bank (Australian Catholic University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036431","R0036431.pdf","no_doi","other_trial","Winkler, Gábor","2018","IGlarLixi – bázisinzulin és GLP-1-receptoragonista új fix kombinációja [IGlarLixi – new fix combination of a basal insulin and a GLP-1 receptor agonist]","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036867","R0036867.pdf","no_doi","other_trial","Sony Wibisono","2018","Follow the Leader GLP-1 Agonist Liraglutide Demonstrates Cardioprotective Benefits","Universitas Airlangga Repository (Universitas Airlangga)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037631","R0037631.pdf","no_doi","other_trial","Gulyani, Seema","2018","Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease","Open Research (University of Surrey)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039328","R0039328.pdf","free_to_read","other_trial","Sadia Ashraf","2018","Liraglutide for the Treatment of Hypothalamic Obesity","AACE Clinical Case Reports","Elsevier BV","10.4158/accr-2018-0009","https://doi.org/10.4158/accr-2018-0009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4158/accr-2018-0009",null],["5","R0043741","R0043741.pdf","no_doi","other_trial","Georgino, Francesco","2018","Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): a post hoc analysis of the AWARD-2 clinical trial","ResearchOnline at James Cook University (James Cook University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046990","R0046990.pdf","no_doi","protocol","Caroline A. Mulvaney","2018","GLP-1 receptor agonists for Parkinson's disease (Protocol)","Lancaster EPrints (Lancaster University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047445","R0047445.pdf","no_doi","other_trial","Frauke Becker","2018","Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial","Diabetologia",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053075","R0053075.pdf","free_to_read","other_trial","Andrew J. Krentz","2018","Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era","Cardiovascular Endocrinology & Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.1097/xce.0000000000000150","https://doi.org/10.1097/xce.0000000000000150","31646270","https://pubmed.ncbi.nlm.nih.gov/31646270/","https://doi.org/10.1097/xce.0000000000000150",null],["5","R0053214","R0053214.pdf","no_doi","protocol","Henrik Gudbergsen","2018","Effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis: Protocol for a randomised, double blind, placebo-controlled, parallel group, single-centre trial.",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0008692","R0008692.pdf","open_download_failed","other_trial","Scheen AJ","2017","GLP-1 receptor agonists and heart failure in diabetes.","Diabetes & metabolism","Elsevier BV","10.1016/s1262-3636(17)30068-x","https://doi.org/10.1016/s1262-3636(17)30068-x","28431666","https://pubmed.ncbi.nlm.nih.gov/28431666/","https://www.sciencedirect.com/science/article/pii/S126236361730068X",null],["5","R0009762","R0009762.pdf","open_download_failed","other_trial","Knop FK","2017","Exenatide: pharmacokinetics, clinical use, and future directions.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1080/14656566.2017.1282463","https://doi.org/10.1080/14656566.2017.1282463","28085521","https://pubmed.ncbi.nlm.nih.gov/28085521/","https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1282463?needAccess=true&role=button",null],["5","R0010083","R0010083.pdf","open_download_failed","other_trial","Nauck MA","2017","Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.117.028136","https://doi.org/10.1161/circulationaha.117.028136","28847797","https://pubmed.ncbi.nlm.nih.gov/28847797/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.117.028136",null],["5","R0011330","R0011330.pdf","free_to_read","other_trial","Albèr A","2017","Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12911","https://doi.org/10.1111/dom.12911","28211611","https://pubmed.ncbi.nlm.nih.gov/28211611/",null,null],["5","R0012184","R0012184.pdf","free_to_read","other_trial","Nauck MA","2017","Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.","Diabetes care","American Diabetes Association","10.2337/dc16-0984","https://doi.org/10.2337/dc16-0984","28283565","https://pubmed.ncbi.nlm.nih.gov/28283565/",null,null],["5","R0012285","R0012285.pdf","open_download_failed","narrative_review","Sattar N","2017","Novel Diabetes Drugs and the Cardiovascular Specialist.","Journal of the American College of Cardiology","Elsevier BV","10.1016/j.jacc.2017.04.014","https://doi.org/10.1016/j.jacc.2017.04.014","28545639","https://pubmed.ncbi.nlm.nih.gov/28545639/","https://www.sciencedirect.com/science/article/pii/S0735109717370262/pdf",null],["5","R0016373","R0016373.pdf","open_download_failed","other_trial","Bassil F","2017","Insulin resistance and exendin-4 treatment for multiple system atrophy.","Brain : a journal of neurology","Oxford University Press (OUP)","10.1093/brain/awx044","https://doi.org/10.1093/brain/awx044","28334990","https://pubmed.ncbi.nlm.nih.gov/28334990/","https://academic.oup.com/brain/article-pdf/140/5/1420/24175049/awx044.pdf",null],["5","R0017987","R0017987.pdf","free_to_read","other_trial","Simó R","2017","GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?","Diabetes","American Diabetes Association","10.2337/db16-1364","https://doi.org/10.2337/db16-1364","28533296","https://pubmed.ncbi.nlm.nih.gov/28533296/",null,null],["5","R0018024","R0018024.pdf","open_download_failed","preclinical","Jensen L","2017","Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","Elsevier BV","10.1016/j.ejps.2017.03.020","https://doi.org/10.1016/j.ejps.2017.03.020","28323117","https://pubmed.ncbi.nlm.nih.gov/28323117/","https://www.sciencedirect.com/science/article/pii/S0928098717301537/pdf",null],["5","R0019176","R0019176.pdf","open_download_failed","other_trial","Dilla T","2017","The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2016.1275651","https://doi.org/10.1080/13696998.2016.1275651","28008768","https://pubmed.ncbi.nlm.nih.gov/28008768/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1275651?needAccess=true&role=button",null],["5","R0020696","R0020696.pdf","open_download_failed","other_trial","Hunt B","2017","Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2017.1347793","https://doi.org/10.1080/13696998.2017.1347793","28651479","https://pubmed.ncbi.nlm.nih.gov/28651479/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1347793?needAccess=true&role=button",null],["5","R0020888","R0020888.pdf","free_to_read","other_trial","Chudleigh RA","2017","Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.","Expert opinion on drug safety","Informa UK Limited","10.1080/14740338.2017.1313225","https://doi.org/10.1080/14740338.2017.1313225","28387138","https://pubmed.ncbi.nlm.nih.gov/28387138/",null,null],["5","R0021994","R0021994.pdf","no_doi","other_trial","de Wit HM","2017","A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.","The Netherlands journal of medicine",null,null,"https://doi.org/","28956786","https://pubmed.ncbi.nlm.nih.gov/28956786/",null,null],["5","R0022270","R0022270.pdf","open_download_failed","other_trial","Petit JM","2017","Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2016-2775","https://doi.org/10.1210/jc.2016-2775","27732328","https://pubmed.ncbi.nlm.nih.gov/27732328/","https://academic.oup.com/jcem/article-pdf/102/2/407/10263765/jc.2016-2775.pdf",null],["5","R0023966","R0023966.pdf","open_download_failed","other_trial","Thrasher J","2017","Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2017.04.004","https://doi.org/10.1016/j.amjmed.2017.04.004","28526182","https://pubmed.ncbi.nlm.nih.gov/28526182/","http://www.amjmed.com/article/S0002934317304576/pdf",null],["5","R0024298","R0024298.pdf","no_doi","other_trial","Reinke T","2017","Drugs for Diabetes: It's No Longer Just About Controlling Blood Sugar.","Managed care (Langhorne, Pa.)",null,null,"https://doi.org/","28661833","https://pubmed.ncbi.nlm.nih.gov/28661833/",null,null],["5","R0024862","R0024862.pdf","open_download_failed","other_trial","Afonso M","2017","Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2017.1304395","https://doi.org/10.1080/13696998.2017.1304395","28271733","https://pubmed.ncbi.nlm.nih.gov/28271733/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1304395?download=true",null],["5","R0024933","R0024933.pdf","open_download_failed","other_trial","Paneni F","2017","Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2017.04.008","https://doi.org/10.1016/j.amjmed.2017.04.008","28526186","https://pubmed.ncbi.nlm.nih.gov/28526186/","http://www.amjmed.com/article/S0002934317304679/pdf",null],["5","R0024988","R0024988.pdf","open_download_failed","other_trial","Peng SY","2017","Potential differentiation of islet-like cells from pregnant cow-derived placental stem cells.","Taiwanese journal of obstetrics & gynecology","Elsevier BV","10.1016/j.tjog.2017.04.007","https://doi.org/10.1016/j.tjog.2017.04.007","28600038","https://pubmed.ncbi.nlm.nih.gov/28600038/","https://www.sciencedirect.com/science/article/pii/S1028455917300773/pdf",null],["5","R0026403","R0026403.pdf","open_download_failed","other_trial","van Bommel EJM","2017","SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.","Clinical journal of the American Society of Nephrology : CJASN","Ovid Technologies (Wolters Kluwer Health)","10.2215/cjn.06080616","https://doi.org/10.2215/cjn.06080616","28254770","https://pubmed.ncbi.nlm.nih.gov/28254770/","https://cjasn.asnjournals.org/content/clinjasn/12/4/700.full.pdf",null],["5","R0026604","R0026604.pdf","free_to_read","protocol",null,"2017","Third-line Drugs for Type 2 Diabetes — Project Protocol","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","30234937","https://pubmed.ncbi.nlm.nih.gov/30234937/",null,null],["5","R0026801","R0026801.pdf","free_to_read","other_trial","Townsend SA","2017","Review article: new treatments in non-alcoholic fatty liver disease.","Alimentary pharmacology & therapeutics","Wiley","10.1111/apt.14210","https://doi.org/10.1111/apt.14210","28677333","https://pubmed.ncbi.nlm.nih.gov/28677333/","https://research.birmingham.ac.uk/en/publications/d87814fb-a22f-47a6-97f2-7896e16927c9",null],["5","R0027169","R0027169.pdf","no_doi","other_trial","Zhang JH","2017","Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.","European review for medical and pharmacological sciences",null,null,"https://doi.org/","28829486","https://pubmed.ncbi.nlm.nih.gov/28829486/",null,null],["5","R0027209","R0027209.pdf","no_doi","other_trial","Jornayvaz FR","2017","[News in diabetology 2016].","Revue medicale suisse",null,null,"https://doi.org/","28703534","https://pubmed.ncbi.nlm.nih.gov/28703534/",null,null],["5","R0027876","R0027876.pdf","free_to_read","other_trial","Pölzl G","2017","Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.","International journal of cardiology","Elsevier BV","10.1016/j.ijcard.2017.05.081","https://doi.org/10.1016/j.ijcard.2017.05.081","28571618","https://pubmed.ncbi.nlm.nih.gov/28571618/","https://doi.org/10.1016/j.ijcard.2017.05.081",null],["5","R0028721","R0028721.pdf","free_to_read","other_trial","Wolsk E","2017","Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.","Journal of the American Heart Association","Ovid Technologies (Wolters Kluwer Health)","10.1161/jaha.116.004743","https://doi.org/10.1161/jaha.116.004743","28554908","https://pubmed.ncbi.nlm.nih.gov/28554908/","https://doi.org/10.1161/jaha.116.004743","ClinicalTrials.gov:NCT01147250"],["5","R0031721","R0031721.pdf","no_doi","other_trial","Giulia Baston","2017","La malattia di Parkinson: attuali terapie e insulino-resistenza come potenziale bersaglio per nuove strategie terapeutiche",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034619","R0034619.pdf","no_doi","other_trial","Jódar Gimeno, José Esteban","2017","Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial","ABACUS. Repositorio de Producción Científica (Universidad Europea)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0035879","R0035879.pdf","free_to_read","other_trial","Doo Man Kim","2017","New anti-diabetic agents","Journal of Korean Medical Association","Korean Medical Association","10.5124/jkma.2017.60.12.992","https://doi.org/10.5124/jkma.2017.60.12.992",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.5124/jkma.2017.60.12.992",null],["5","R0038919","R0038919.pdf","free_to_read","other_trial","Margarita Perez-Cheron","2017","Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report","AACE Clinical Case Reports","Elsevier BV","10.4158/ep161667.cr","https://doi.org/10.4158/ep161667.cr",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.4158/ep161667.cr",null],["5","R0040814","R0040814.pdf","no_doi","other_trial","Guillaume Besch","2017","Improving blood glucose control in cardiac surgery patients : glycemic variability, nurse-compliance to insulin therapy protocols and use of incretin mimetics","theses.fr (ABES)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041132","R0041132.pdf","no_doi","other_trial","Jornayvaz, François","2017","Diabétologie","Archive ouverte UNIGE (University of Geneva)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041191","R0041191.pdf","no_doi","other_trial","Sara Behbahani","2017","The role of GLP-1 receptor agonist as a potential treatment for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","OpenBU (Boston University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041394","R0041394.pdf","no_doi","other_trial","Melanie J. Davies (7155500)","2017","Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents","Figshare",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041531","R0041531.pdf","no_doi","other_trial","Wit, H.M. de","2017","A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes","Radboud Repository (Radboud University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042176","R0042176.pdf","no_doi","other_trial","Jornayvaz, François","2017","Diabétologie","Archive ouverte UNIGE (University of Geneva)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043524","R0043524.pdf","free_to_read","other_trial","Imen Sebai","2017","Impact of Ramadan fasting on glycemic control in type 2 diabetic patients treated with insulin",null,"Morressier","10.26226/morressier.59d5184fd462b80296ca2c2e","https://doi.org/10.26226/morressier.59d5184fd462b80296ca2c2e",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/a953ef00-32d8-41a7-95e9-75d25277c164",null],["5","R0044098","R0044098.pdf","free_to_read","other_trial","Prakash Shanmugam","2017","Effect of liraglutide on carotid intima-media thickness in obese patients with type 2 diabetes: interim analysis",null,"Morressier","10.26226/morressier.59d51847d462b80296ca3bb2","https://doi.org/10.26226/morressier.59d51847d462b80296ca3bb2",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/b2106cc3-ad32-46a5-9639-2558e82d869e",null],["5","R0044288","R0044288.pdf","free_to_read","other_trial","Luciano Adorini","2017","Megatrends in bile acid receptor research","Hepatology Communications","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep4.1085","https://doi.org/10.1002/hep4.1085","29404496","https://pubmed.ncbi.nlm.nih.gov/29404496/","https://doi.org/10.1002/hep4.1085",null],["5","R0044332","R0044332.pdf","free_to_read","other_trial","Francisca Mena","2017","How are we intervening in the psychosocial dimension of T1D? Exploring the experience of intervention recipients",null,"Morressier","10.26226/morressier.59d5184ed462b80296ca4009","https://doi.org/10.26226/morressier.59d5184ed462b80296ca4009",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/a1e7060a-1094-42a8-a668-238f78a69ac2","UMIN:UMIN000026761"],["5","R0044345","R0044345.pdf","free_to_read","other_trial","Thieu Vivian","2017","A higher percentage of elderly on dulaglutide achieved hba1c<7.5% without nocturnal hypoglycemia vs. glargine in AWARD-2",null,"Morressier","10.26226/morressier.59d51844d462b80296ca3a12","https://doi.org/10.26226/morressier.59d51844d462b80296ca3a12",null,"https://pubmed.ncbi.nlm.nih.gov//","https://openresearchlibrary.org/viewer/09af64a7-1d39-4f14-9b76-756c75733a4f",null],["5","R0047948","R0047948.pdf","no_doi","other_trial","Neil R Poulter","2017","Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0048230","R0048230.pdf","free_to_read","other_trial","FJ Ampudia","2017","Long-Term Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin As Intensification Therapies For People With Type 2 Diabetes Inadequately Controlled on Basal Insulin In Spain: Projections Based On The Dual VII Trial","Value in Health","Elsevier BV","10.1016/j.jval.2017.08.461","https://doi.org/10.1016/j.jval.2017.08.461",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2017.08.461",null],["5","R0048650","R0048650.pdf","no_doi","other_trial","Robert John Mentz","2017","Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial","Circulation",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0010564","R0010564.pdf","open_download_failed","other_trial","Jendle J","2016","Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.","Diabetes/metabolism research and reviews","Wiley","10.1002/dmrr.2810","https://doi.org/10.1002/dmrr.2810","27102969","https://pubmed.ncbi.nlm.nih.gov/27102969/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dmrr.2810",null],["5","R0011769","R0011769.pdf","free_to_read","other_trial","Scheen AJ","2016","Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.","Expert review of clinical pharmacology","Informa UK Limited","10.1586/17512433.2016.1141046","https://doi.org/10.1586/17512433.2016.1141046","26761217","https://pubmed.ncbi.nlm.nih.gov/26761217/","https://orbi.uliege.be/handle/2268/195869",null],["5","R0013073","R0013073.pdf","open_download_failed","other_trial","Smits MM","2016","Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.","British journal of clinical pharmacology","Wiley","10.1111/bcp.12843","https://doi.org/10.1111/bcp.12843","26609792","https://pubmed.ncbi.nlm.nih.gov/26609792/","https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12843",null],["5","R0013139","R0013139.pdf","free_to_read","other_trial","Muskiet MH","2016","Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12601","https://doi.org/10.1111/dom.12601","26636423","https://pubmed.ncbi.nlm.nih.gov/26636423/","https://pure.amsterdamumc.nl/en/publications/42f47f98-2e76-4426-b366-117399299cf6",null],["5","R0014745","R0014745.pdf","open_download_failed","other_trial","Bruhn D","2016","Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2016.1154567","https://doi.org/10.3111/13696998.2016.1154567","26882484","https://pubmed.ncbi.nlm.nih.gov/26882484/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2016.1154567?needAccess=true",null],["5","R0014969","R0014969.pdf","free_to_read","protocol","Holman RR","2016","Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.","American heart journal","Elsevier BV","10.1016/j.ahj.2015.12.009","https://doi.org/10.1016/j.ahj.2015.12.009","26995376","https://pubmed.ncbi.nlm.nih.gov/26995376/","http://hdl.handle.net/10044/1/31323","ClinicalTrials.gov:NCT01144338"],["5","R0016384","R0016384.pdf","open_download_failed","other_trial","White WB","2016","Cardiovascular Effects of Incretin-Based Therapies.","Annual review of medicine","Annual Reviews","10.1146/annurev-med-050214-013431","https://doi.org/10.1146/annurev-med-050214-013431","26768240","https://pubmed.ncbi.nlm.nih.gov/26768240/","https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-050214-013431",null],["5","R0016676","R0016676.pdf","open_download_failed","other_trial","Wei R","2016","Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00400.2015","https://doi.org/10.1152/ajpendo.00400.2015","27072494","https://pubmed.ncbi.nlm.nih.gov/27072494/","https://www.physiology.org/doi/pdf/10.1152/ajpendo.00400.2015",null],["5","R0017171","R0017171.pdf","no_doi","other_trial","Scheen AJ","2016","[Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].","Revue medicale de Liege",null,null,"https://doi.org/","27311248","https://pubmed.ncbi.nlm.nih.gov/27311248/",null,null],["5","R0018487","R0018487.pdf","free_to_read","case_report","Danielpur L","2016","GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2016-2240","https://doi.org/10.1210/jc.2016-2240","27459537","https://pubmed.ncbi.nlm.nih.gov/27459537/",null,"ClinicalTrials.gov:NCT01302327"],["5","R0018647","R0018647.pdf","open_download_failed","other_trial","Cohen O","2016","When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.","Diabetes care","American Diabetes Association","10.2337/dcs15-3029","https://doi.org/10.2337/dcs15-3029","27440831","https://pubmed.ncbi.nlm.nih.gov/27440831/","https://care.diabetesjournals.org/content/diacare/39/Supplement_2/S180.full.pdf",null],["5","R0018908","R0018908.pdf","open_download_failed","other_trial","Athauda D","2016","The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.","Drug discovery today","Elsevier BV","10.1016/j.drudis.2016.01.013","https://doi.org/10.1016/j.drudis.2016.01.013","26851597","https://pubmed.ncbi.nlm.nih.gov/26851597/","https://www.sciencedirect.com/science/article/pii/S1359644616300010/pdf",null],["5","R0019903","R0019903.pdf","open_download_failed","other_trial","Anderson JE","2016","Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.","Postgraduate medicine","Informa UK Limited","10.1080/00325481.2016.1218260","https://doi.org/10.1080/00325481.2016.1218260","27488824","https://pubmed.ncbi.nlm.nih.gov/27488824/","https://www.tandfonline.com/doi/pdf/10.1080/00325481.2016.1218260?needAccess=true&role=button",null],["5","R0024081","R0024081.pdf","open_download_failed","other_trial","Townsend SA","2016","Non-alcoholic fatty liver disease in 2016.","British medical bulletin","Oxford University Press (OUP)","10.1093/bmb/ldw031","https://doi.org/10.1093/bmb/ldw031","27543499","https://pubmed.ncbi.nlm.nih.gov/27543499/","https://academic.oup.com/bmb/article-pdf/119/1/143/24331813/ldw031.pdf",null],["5","R0024195","R0024195.pdf","free_to_read","other_trial","Aeng E","2016","Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","30855776","https://pubmed.ncbi.nlm.nih.gov/30855776/",null,null],["5","R0024516","R0024516.pdf","open_download_failed","other_trial","Schernthaner G","2016","EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2016.04.037","https://doi.org/10.1016/j.clinthera.2016.04.037","27210264","https://pubmed.ncbi.nlm.nih.gov/27210264/","http://www.clinicaltherapeutics.com/article/S0149291816303022/pdf",null],["5","R0025613","R0025613.pdf","open_download_failed","other_trial","Lomenick JP","2016","A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.","Obesity (Silver Spring, Md.)","Wiley","10.1002/oby.21493","https://doi.org/10.1002/oby.21493","27133664","https://pubmed.ncbi.nlm.nih.gov/27133664/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.21493","ClinicalTrials.gov:NCT01484873"],["5","R0025623","R0025623.pdf","open_download_failed","other_trial","Gordon J","2016","The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.","Journal of medical economics","Informa UK Limited","10.1080/13696998.2016.1208207","https://doi.org/10.1080/13696998.2016.1208207","27356188","https://pubmed.ncbi.nlm.nih.gov/27356188/","https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1208207?needAccess=true&role=button",null],["5","R0026686","R0026686.pdf","open_download_failed","preclinical","Ten Kulve JS","2016","Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2015-3291","https://doi.org/10.1210/jc.2015-3291","26672638","https://pubmed.ncbi.nlm.nih.gov/26672638/","https://academic.oup.com/jcem/article-pdf/101/5/2122/10429004/jcem2122.pdf",null],["5","R0026710","R0026710.pdf","no_doi","other_trial","Olšovský J","2016","[Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].","Vnitrni lekarstvi",null,null,"https://doi.org/","27627086","https://pubmed.ncbi.nlm.nih.gov/27627086/",null,null],["5","R0027149","R0027149.pdf","no_doi","other_trial","Vondra K","2016","[Glucagon antagonists open a new way in treatment of type 2 diabetes Mellitus].","Vnitrni lekarstvi",null,null,"https://doi.org/","27627094","https://pubmed.ncbi.nlm.nih.gov/27627094/",null,null],["5","R0027953","R0027953.pdf","free_to_read","protocol","Brennan DC","2016","Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States.","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","Elsevier BV","10.1111/ajt.13458","https://doi.org/10.1111/ajt.13458","26433206","https://pubmed.ncbi.nlm.nih.gov/26433206/","https://doi.org/10.1111/ajt.13458",null],["5","R0028754","R0028754.pdf","no_doi","other_trial","Reisdorf S","2016","[Not Available].","Medizinische Monatsschrift fur Pharmazeuten",null,null,"https://doi.org/","29956530","https://pubmed.ncbi.nlm.nih.gov/29956530/",null,null],["5","R0028769","R0028769.pdf","open_download_failed","other_trial","Grant PJ","2016","London buses: A cardiovascular outcome trial equivalent?","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164116663051","https://doi.org/10.1177/1479164116663051","27543327","https://pubmed.ncbi.nlm.nih.gov/27543327/","https://journals.sagepub.com/doi/pdf/10.1177/1479164116663051",null],["5","R0028790","R0028790.pdf","free_to_read","other_trial","Kelly AS","2016","Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.","International journal of obesity (2005)","Springer Science and Business Media LLC","10.1038/ijo.2016.69","https://doi.org/10.1038/ijo.2016.69","27113643","https://pubmed.ncbi.nlm.nih.gov/27113643/","https://www.ncbi.nlm.nih.gov/pmc/articles/5546093",null],["5","R0031003","R0031003.pdf","no_doi","other_trial","Kamaruddin Na","2016","Projected Cost-Effectiveness of Liraglutide, a Glucagon-Like Insulin Peptide-1Analogue in Comparison to Insulin Glargine in Type 2 Diabetes Patients withSuboptimal Glycaemic Control in Malaysia","Medical economics",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031847","R0031847.pdf","no_doi","other_trial","Leah Lawrence","2016","Adiposity and High CV Risk in Type 2 Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032061","R0032061.pdf","free_to_read","other_trial","Swetha Ramakrishnan","2016","Outcome of renal transplantation in IgA nephropathy","Indian Journal of Transplantation","Medknow","10.1016/j.ijt.2016.09.011","https://doi.org/10.1016/j.ijt.2016.09.011",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.ijt.2016.09.011",null],["5","R0035891","R0035891.pdf","free_to_read","other_trial","Won Jun Kim","2016","New Drugs for Obesity Treatment","Korean Journal of Medicine","Korean Association of Internal Medicine","10.3904/kjm.2016.90.2.121","https://doi.org/10.3904/kjm.2016.90.2.121",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.3904/kjm.2016.90.2.121",null],["5","R0036651","R0036651.pdf","no_doi","other_trial","Rikke Meldgaard Røge","2016","Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040690","R0040690.pdf","no_doi","other","Chantal Mathieu","2016","ORIGINAL RESEARCH Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00635492"],["5","R0040769","R0040769.pdf","no_doi","other_trial",null,"2016","GSK initiates phase III programme for novel type 2 diabetes medication, Syncria ® (albiglutide)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040804","R0040804.pdf","no_doi","other_trial","Jean-louis Chiasson","2016","ORIGINAL RESEARCH Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040807","R0040807.pdf","no_doi","other_trial","Mark P. Mattsona B","2016","1 Review Interventions that Improve Body and Brain Bioenergetics for Parkinson’s Disease Risk Reduction and Therapy",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040823","R0040823.pdf","no_doi","other_trial","K. Pafili","2016","Editorial Treatment of Diabetic Complications: How Can We Learn by Seeking and Blundering?",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040827","R0040827.pdf","no_doi","other_trial","Kristina Secnik Boye","2016","ral Health and Quality of Life Outcomes ssBioMed Cent",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040942","R0040942.pdf","no_doi","other_trial","Pedro Mezquita","2016","ORIGINAL RESEARCH Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040955","R0040955.pdf","no_doi","other_trial","Linda Siminerio","2016","Challenges and Strategies for Moving Patients to",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041109","R0041109.pdf","no_doi","other_trial","Weight Loss","2016","Running Title: Exenatide once weekly, 52-wk safety & efficacy",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00308139"],["5","R0041112","R0041112.pdf","no_doi","other_trial","Pancreatitis A","2016","Completed Liraglutide Type 2 Diabetes Clinical Trials Diabetes Care 2015;38:1058–1066 | DOI: 10.2337/dc13-1210 OBJECTIVE",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041334","R0041334.pdf","no_doi","other_trial","J. Derving Karsbøl","2016","O R IG IN A L A R",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041338","R0041338.pdf","no_doi","other_trial","Pancreatitis A","2016","Completed Liraglutide Type 2 Diabetes Clinical Trials DOI: 10.2337/dc13-1210",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042364","R0042364.pdf","no_doi","other_trial","Md Abdul Halim","2016","Gut peptides in gastrointestinal motility and mucosal permeability","KTH Publication Database DiVA (KTH Royal Institute of Technology)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043892","R0043892.pdf","free_to_read","other_trial","Sejeong Park","2016","Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)","Diabetes & Metabolism Journal","Korean Diabetes Association","10.4093/dmj.2016.40.4.336","https://doi.org/10.4093/dmj.2016.40.4.336","27550211","https://pubmed.ncbi.nlm.nih.gov/27550211/","https://doi.org/10.4093/dmj.2016.40.4.336",null],["5","R0045677","R0045677.pdf","no_doi","other_trial","Guangming Chen","2016","Clinical trial of exenatide injection in type 2 diabetes mellitus patients with overweight and obese and poorly controlled blood sugar",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049233","R0049233.pdf","no_doi","other_trial","Jan W. Eriksson","2016","One year of treatment with dapagliflozin QD plus exenatide QW in obese adults without diabetes : results of an open-label extension study","Diabetologia",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049440","R0049440.pdf","no_doi","other_trial","Jorge M. Thierer","2016","LEADER Trial: Liraglutide reduces mortality in patients with type 2 diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 [Epub ahead of print].","Redalyc (Universidad Autónoma del Estado de México)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049931","R0049931.pdf","no_doi","other_trial","Raul Dias Santos","2016","SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT01179048"],["5","R0056902","R0056902.pdf","free_to_read","other_trial","Elahi D","2016","Does GLP-1 suppress its own basal secretion?","Endocrine research","Informa UK Limited","10.3109/07435800.2015.1038353","https://doi.org/10.3109/07435800.2015.1038353","26186406","https://pubmed.ncbi.nlm.nih.gov/26186406/","https://www.ncbi.nlm.nih.gov/pmc/articles/5168718",null],["5","R0013076","R0013076.pdf","no_doi","other_trial","Haluzík M","2015","[Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].","Vnitrni lekarstvi",null,null,"https://doi.org/","26375689","https://pubmed.ncbi.nlm.nih.gov/26375689/",null,null],["5","R0018398","R0018398.pdf","free_to_read","other_trial","Lau J","2015","Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.","Journal of medicinal chemistry","American Chemical Society (ACS)","10.1021/acs.jmedchem.5b00726","https://doi.org/10.1021/acs.jmedchem.5b00726","26308095","https://pubmed.ncbi.nlm.nih.gov/26308095/","https://doi.org/10.7270/q2tx3h6d",null],["5","R0019965","R0019965.pdf","free_to_read","preclinical","Sharma AN","2015","GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.","Metabolic brain disease","Springer Science and Business Media LLC","10.1007/s11011-014-9591-7","https://doi.org/10.1007/s11011-014-9591-7","25023888","https://pubmed.ncbi.nlm.nih.gov/25023888/","https://corescholar.libraries.wright.edu/ptox/109","ClinicalTrials.gov:NCT01845259"],["5","R0023219","R0023219.pdf","open_download_failed","other_trial","Rizzo M","2015","Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2014-2291","https://doi.org/10.1210/jc.2014-2291","25393640","https://pubmed.ncbi.nlm.nih.gov/25393640/","https://academic.oup.com/jcem/article-pdf/100/2/603/10854334/jcem0603.pdf","ClinicalTrials.gov:NCT01715428"],["5","R0024241","R0024241.pdf","open_download_failed","other_trial","Skovgaard R","2015","Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.","Clinical therapeutics","Elsevier BV","10.1016/j.clinthera.2015.05.496","https://doi.org/10.1016/j.clinthera.2015.05.496","26186809","https://pubmed.ncbi.nlm.nih.gov/26186809/","http://www.clinicaltherapeutics.com/article/S0149291815008292/pdf",null],["5","R0024851","R0024851.pdf","no_doi","other_trial","Kaku K","2015","[The trend of new drug development for the treatment of diabetes mellitus].","Nihon rinsho. Japanese journal of clinical medicine",null,null,"https://doi.org/","26666161","https://pubmed.ncbi.nlm.nih.gov/26666161/",null,null],["5","R0026425","R0026425.pdf","open_download_failed","other_trial","Feng P","2015","Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.","Acta pharmacologica Sinica","Springer Science and Business Media LLC","10.1038/aps.2014.136","https://doi.org/10.1038/aps.2014.136","25619391","https://pubmed.ncbi.nlm.nih.gov/25619391/","https://www.nature.com/articles/aps2014136.pdf",null],["5","R0026657","R0026657.pdf","open_download_failed","other_trial","Matfin G","2015","Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.","Journal of diabetes science and technology","SAGE Publications","10.1177/1932296815583059","https://doi.org/10.1177/1932296815583059","25901022","https://pubmed.ncbi.nlm.nih.gov/25901022/","https://journals.sagepub.com/doi/pdf/10.1177/1932296815583059",null],["5","R0026881","R0026881.pdf","no_doi","other_trial","Vergès B","2015","[TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH HISTORY OF CARDIOVASCULAR DISEASE].","La Revue du praticien",null,null,"https://doi.org/","26749704","https://pubmed.ncbi.nlm.nih.gov/26749704/",null,null],["5","R0026937","R0026937.pdf","free_to_read","other_trial","Arnolds S","2015","Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.","Diabetes care","American Diabetes Association","10.2337/dc14-2418","https://doi.org/10.2337/dc14-2418","25614698","https://pubmed.ncbi.nlm.nih.gov/25614698/",null,null],["5","R0027575","R0027575.pdf","free_to_read","other_trial","Cada DJ","2015","Suvorexant.","Hospital pharmacy","SAGE Publications","10.1310/hpj5001-59","https://doi.org/10.1310/hpj5001-59","25684802","https://pubmed.ncbi.nlm.nih.gov/25684802/",null,null],["5","R0028198","R0028198.pdf","open_download_failed","preclinical","Cork SC","2015","Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.","Molecular metabolism","Elsevier BV","10.1016/j.molmet.2015.07.008","https://doi.org/10.1016/j.molmet.2015.07.008","26500843","https://pubmed.ncbi.nlm.nih.gov/26500843/","https://www.sciencedirect.com/science/article/pii/S2212877815001428/pdf",null],["5","R0028200","R0028200.pdf","open_download_failed","preclinical","Ying Y","2015","GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.","Journal of molecular endocrinology","Bioscientifica","10.1530/jme-15-0155","https://doi.org/10.1530/jme-15-0155","26386043","https://pubmed.ncbi.nlm.nih.gov/26386043/","https://jme.bioscientifica.com/downloadpdf/journals/jme/55/3/245.pdf",null],["5","R0028215","R0028215.pdf","no_doi","other_trial","Davoren P","2015","Glucose-lowering medicines for type 2 diabetes.","Australian family physician",null,null,"https://doi.org/","26042396","https://pubmed.ncbi.nlm.nih.gov/26042396/",null,null],["5","R0030778","R0030778.pdf","no_doi","other_trial","Liu Yong-gu","2015","Research progress on drugs with new targets in treatment of type 2 diabetes","Xiandai yaowu yu linchuang",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0030814","R0030814.pdf","no_doi","other_trial","小田原雅人","2015","持続性エキセナチド注射剤 ビデュリオン(R) 皮下注用2 mg―日本人／アジア人第III相臨床試験のレトロスペクティブ解析：対照薬との有効性プロファイルの比較，HbA1c に影響を与える因子の検討―","薬理と治療",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031013","R0031013.pdf","no_doi","other_trial","Huang Zhao-su","2015","Nearly and long-term clinical effect of exenatide in obese adolescents with abnormal glucose metabolism","The Chinese Journal of Clinical Pharmacology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031815","R0031815.pdf","no_doi","other_trial","กิรติ เก่งกล้า","2015","อลบกลไทด: ยาใหมสำหรบรกษาเบาหวานชนดท 2",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031886","R0031886.pdf","no_doi","other_trial","Leah Lawrence","2015","AWARD Trial Shows Promise for GLP-1 Agonist",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0034199","R0034199.pdf","no_doi","other_trial","Luo Yaping","2015","68G-EXENDIN-4 PET/CT IS HIGHLY EFFECTIVE IN LOCALIZING INSULINOMAS","Journal of Nuclear Medicine",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036215","R0036215.pdf","no_doi","other_trial","Arnolds, Sabine","2015","Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37: 3270-3278","Kölner Universitäts PublikationsServer (Universität zu Köln)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041027","R0041027.pdf","no_doi","other_trial","Kjeld Hermansen","2015","Early responders to liraglutide 3,0 mg as adjunct to diet and exercise from the SCALE Obesity and Prediabetes trial: efficacy and safety results",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041336","R0041336.pdf","no_doi","other_trial","Kristin C. Carlsson","2015","ORIGINAL RESEARCH ARTICLE Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0042346","R0042346.pdf","no_doi","other_trial","Aaron Herndon","2015","Mechanisms of beta cell dysfunction and application of GLP-1 mimetics in feline diabetes mellitus","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0044277","R0044277.pdf","free_to_read","other_trial","Sanjay Kalra","2015","Sulfonylureas: Assets in the past, present and future","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.149925","https://doi.org/10.4103/2230-8210.149925","25932384","https://pubmed.ncbi.nlm.nih.gov/25932384/","https://doi.org/10.4103/2230-8210.149925",null],["5","R0044748","R0044748.pdf","free_to_read","other_trial","RL Kolotkin","2015","Impact of Weight Loss on Patient-Reported Outcomes In The Scale Obesity and Prediabetes Trial of Liraglutide 3.0 Mg As Adjunct to A Diet and Exercise (D&E) Programme","Value in Health","Elsevier BV","10.1016/j.jval.2015.09.1991","https://doi.org/10.1016/j.jval.2015.09.1991",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.1016/j.jval.2015.09.1991",null],["5","R0053197","R0053197.pdf","no_doi","other_trial","Byambaa Enkhmaa","2015","Table 17, Liraglutide phase III clinical trials",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053557","R0053557.pdf","free_to_read","other_trial","Kazunori Sango","2015","Efficacy of glucagon-like peptide-1 mimetics for neural regeneration","Neural Regeneration Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/1673-5374.169611","https://doi.org/10.4103/1673-5374.169611","26807090","https://pubmed.ncbi.nlm.nih.gov/26807090/","https://doi.org/10.4103/1673-5374.169611",null],["5","R0055022","R0055022.pdf","free_to_read","other_trial","Soo-hyun Park","2015","Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease?","Neural Regeneration Research","Ovid Technologies (Wolters Kluwer Health)","10.4103/1673-5374.160078","https://doi.org/10.4103/1673-5374.160078","26330822","https://pubmed.ncbi.nlm.nih.gov/26330822/","https://doi.org/10.4103/1673-5374.160078","ClinicalTrials.gov:NCT01255163"],["5","R0056884","R0056884.pdf","no_doi","other_trial","Chillarón JJ","2015","Obesity and type 1 diabetes mellitus management.","Minerva endocrinologica",null,null,"https://doi.org/","25413942","https://pubmed.ncbi.nlm.nih.gov/25413942/",null,null],["5","R0010835","R0010835.pdf","open_download_failed","other_trial","Seufert J","2014","The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12251","https://doi.org/10.1111/dom.12251","24373150","https://pubmed.ncbi.nlm.nih.gov/24373150/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12251",null],["5","R0016018","R0016018.pdf","open_download_failed","narrative_review","Ussher JR","2014","Cardiovascular actions of incretin-based therapies.","Circulation research","Ovid Technologies (Wolters Kluwer Health)","10.1161/circresaha.114.301958","https://doi.org/10.1161/circresaha.114.301958","24855202","https://pubmed.ncbi.nlm.nih.gov/24855202/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.114.301958",null],["5","R0017997","R0017997.pdf","open_download_failed","narrative_review","van Bloemendaal L","2014","Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.","The Journal of endocrinology","Bioscientifica","10.1530/joe-13-0414","https://doi.org/10.1530/joe-13-0414","24323912","https://pubmed.ncbi.nlm.nih.gov/24323912/","https://joe.bioscientifica.com/downloadpdf/journals/joe/221/1/T1.pdf",null],["5","R0019255","R0019255.pdf","open_download_failed","preclinical","Xu WW","2014","Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","S. Karger AG","10.1159/000358623","https://doi.org/10.1159/000358623","24556697","https://pubmed.ncbi.nlm.nih.gov/24556697/","https://karger.com/cpb/article-pdf/33/2/423/2426472/000358623.pdf",null],["5","R0019770","R0019770.pdf","free_to_read","other_trial","Devaraj S","2014","Pancreatic safety of newer incretin-based therapies: are the \"-tides\" finally turning?","Diabetes","American Diabetes Association","10.2337/db14-0545","https://doi.org/10.2337/db14-0545","24962922","https://pubmed.ncbi.nlm.nih.gov/24962922/","https://doi.org/10.2337/db14-0545",null],["5","R0021526","R0021526.pdf","free_to_read","preclinical","Hogan AE","2014","Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.","Diabetologia","Springer Science and Business Media LLC","10.1007/s00125-013-3145-0","https://doi.org/10.1007/s00125-013-3145-0","24362727","https://pubmed.ncbi.nlm.nih.gov/24362727/",null,null],["5","R0024572","R0024572.pdf","open_download_failed","protocol","Margulies KB","2014","GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.","Circulation. Heart failure","Ovid Technologies (Wolters Kluwer Health)","10.1161/circheartfailure.114.000346","https://doi.org/10.1161/circheartfailure.114.000346","25028349","https://pubmed.ncbi.nlm.nih.gov/25028349/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCHEARTFAILURE.114.000346",null],["5","R0025446","R0025446.pdf","free_to_read","other_trial","Mattson MP","2014","Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.","Journal of Parkinson's disease","SAGE Publications","10.3233/jpd-130335","https://doi.org/10.3233/jpd-130335","24473219","https://pubmed.ncbi.nlm.nih.gov/24473219/","https://doi.org/10.3233/jpd-130335",null],["5","R0027930","R0027930.pdf","free_to_read","other_trial","Qi M","2014","Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience.","Acta diabetologica","Springer Science and Business Media LLC","10.1007/s00592-014-0627-6","https://doi.org/10.1007/s00592-014-0627-6","25034311","https://pubmed.ncbi.nlm.nih.gov/25034311/","https://www.ncbi.nlm.nih.gov/pmc/articles/4801517",null],["5","R0028038","R0028038.pdf","open_download_failed","other_trial","van der Pouw Kraan TC","2014","Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute ST elevation myocardial infarction.","Journal of molecular and cellular cardiology","Elsevier BV","10.1016/j.yjmcc.2013.12.021","https://doi.org/10.1016/j.yjmcc.2013.12.021","24389343","https://pubmed.ncbi.nlm.nih.gov/24389343/","http://www.jmcc-online.com/article/S0022282813003702/pdf",null],["5","R0031349","R0031349.pdf","no_doi","other_trial","Richard E. Pratley","2014","GLP-1 receptor agonists: why is once weekly inferior to once daily?",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031971","R0031971.pdf","no_doi","other_trial","Jerry Isaacson","2014","Oramed Pharmaceuticals Initiation of Coverage LifeSci Investment Abstract",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046942","R0046942.pdf","no_doi","other_trial","Xavier Pi‐Sunyer","2014","Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0047124","R0047124.pdf","free_to_read","other_trial","Sanjay Kalra","2014","Medication counselling with sodium glucose transporter 2 inhibitor therapy","Indian Journal of Endocrinology and Metabolism","Ovid Technologies (Wolters Kluwer Health)","10.4103/2230-8210.139206","https://doi.org/10.4103/2230-8210.139206","25285273","https://pubmed.ncbi.nlm.nih.gov/25285273/","https://doi.org/10.4103/2230-8210.139206",null],["5","R0048438","R0048438.pdf","no_doi","other_trial","Oliver Schnell","2014","Type 1 diabetes and cardiovascular disease : review","˜The œSouth African journal of diabetes & vascular disease",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049414","R0049414.pdf","no_doi","other_trial","Chia Cw","2014","Special Features: Incretin-based therapies in type 2 diabetes mellitus",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053133","R0053133.pdf","no_doi","other_trial","Mukhyaprana M. Prabhu","2014","Incretin based therapies in type 2 diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0010923","R0010923.pdf","open_download_failed","other_trial","Raccah D","2013","Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.","Expert review of endocrinology & metabolism","Informa UK Limited","10.1586/eem.12.82","https://doi.org/10.1586/eem.12.82","30736171","https://pubmed.ncbi.nlm.nih.gov/30736171/","https://www.tandfonline.com/doi/pdf/10.1586/eem.12.82?needAccess=true",null],["5","R0012322","R0012322.pdf","open_download_failed","narrative_review","Filippatos TD","2013","Effects of glucagon-like peptide-1 receptor agonists on renal function.","World journal of diabetes","Baishideng Publishing Group Inc.","10.4239/wjd.v4.i5.190","https://doi.org/10.4239/wjd.v4.i5.190","24147203","https://pubmed.ncbi.nlm.nih.gov/24147203/","https://www.wjgnet.com/1948-9358/full/v4/i5/190.htm",null],["5","R0019576","R0019576.pdf","open_download_failed","preclinical","Noyan-Ashraf MH","2013","A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.112.091215","https://doi.org/10.1161/circulationaha.112.091215","23186644","https://pubmed.ncbi.nlm.nih.gov/23186644/","https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.112.091215",null],["5","R0021777","R0021777.pdf","open_download_failed","other_trial","Christ E","2013","Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.","The lancet. Diabetes & endocrinology","Elsevier BV","10.1016/s2213-8587(13)70049-4","https://doi.org/10.1016/s2213-8587(13)70049-4","24622317","https://pubmed.ncbi.nlm.nih.gov/24622317/","http://www.thelancet.com/article/S2213858713700494/pdf",null],["5","R0021948","R0021948.pdf","open_download_failed","other","Erdogdu O","2013","Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways.","Journal of molecular endocrinology","Bioscientifica","10.1530/jme-12-0166","https://doi.org/10.1530/jme-12-0166","23343509","https://pubmed.ncbi.nlm.nih.gov/23343509/","https://jme.bioscientifica.com/downloadpdf/journals/jme/50/2/229.pdf",null],["5","R0023273","R0023273.pdf","open_download_failed","other_trial","Irace C","2013","Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.","Diabetes & vascular disease research","SAGE Publications","10.1177/1479164112449562","https://doi.org/10.1177/1479164112449562","22732108","https://pubmed.ncbi.nlm.nih.gov/22732108/","https://journals.sagepub.com/doi/pdf/10.1177/1479164112449562",null],["5","R0027918","R0027918.pdf","free_to_read","other_trial","Hu W","2013","Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2012-2466","https://doi.org/10.1210/jc.2012-2466","23185036","https://pubmed.ncbi.nlm.nih.gov/23185036/",null,null],["5","R0028263","R0028263.pdf","free_to_read","narrative_review","Rondas D","2013","Glucagon-like peptide-1: modulator of β-cell dysfunction and death.","Diabetes, obesity & metabolism","Wiley","10.1111/dom.12165","https://doi.org/10.1111/dom.12165","24003936","https://pubmed.ncbi.nlm.nih.gov/24003936/",null,null],["5","R0030649","R0030649.pdf","no_doi","other_trial","Maja Baretić","2013","Association of blood pressure and body weight decline during one-year treatment with the incretin analogue exenatide","Diabetologia Croatica",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0030690","R0030690.pdf","no_doi","other_trial","Sun Li-ping","2013","Effect of exenatide on serum nesfatin-1 level and liver fat contents in obese patients with type 2 diabetes mellitus","Journal of Shandong University",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0030735","R0030735.pdf","no_doi","other_trial","ra Kanti Chakraborti","2013","Exenatide in the management of diabetes mellitus","Journal of Diabetes & Metabolism",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031690","R0031690.pdf","no_doi","other_trial","Patricia S Juang","2013","Figure 21, LEAD-2 Trial: Changes in Body Weight at the End of 2 years for Liraglutide, Glimepiride and Placebo Groups in Combination with Metformin",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031931","R0031931.pdf","no_doi","other_trial","Patricia S Juang","2013","Figure 20, LEAD-3 Trial: Changes in Body Weight Overtime for Liraglutide vs Glimepiride Monotherapy",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036171","R0036171.pdf","no_doi","other_trial","A.Yu. Kulikov","2013","Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040705","R0040705.pdf","no_doi","other_trial",null,"2013","Summary",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0040961","R0040961.pdf","no_doi","protocol","Martijn Scholte","2013","TRIALS STUDY PROTOCOL Open Access Effect of additional treatment with EXenatide in",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0049248","R0049248.pdf","no_doi","other_trial","Michael A. Heathman","2013","The Application of Drug-Disease and Clinical Utility Models in the Design of AWARD-5: an Adaptive Seamless Phase 2/3 Study",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051718","R0051718.pdf","no_doi","other_trial","Michael Albrecht Nauck","2013","Is it Time to Transform Our Treatment Of Type 2 Diabetes","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0012369","R0012369.pdf","no_doi","other_trial","Spellman CW","2012","Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.","The Journal of the American Osteopathic Association",null,null,"https://doi.org/","22267302","https://pubmed.ncbi.nlm.nih.gov/22267302/",null,null],["5","R0016702","R0016702.pdf","free_to_read","other_trial","Montanya E","2012","A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1517/14656566.2012.692777","https://doi.org/10.1517/14656566.2012.692777","22725703","https://pubmed.ncbi.nlm.nih.gov/22725703/",null,null],["5","R0020849","R0020849.pdf","free_to_read","protocol",null,"2012","Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project Protocol","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)",null,null,"https://doi.org/","27195345","https://pubmed.ncbi.nlm.nih.gov/27195345/",null,null],["5","R0023146","R0023146.pdf","no_doi","other_trial","Blonde L","2012","Achieving antihyperglycemic treatment goals with incretin-related therapies.","The American journal of managed care",null,null,"https://doi.org/","23327432","https://pubmed.ncbi.nlm.nih.gov/23327432/",null,null],["5","R0023686","R0023686.pdf","free_to_read","other_trial","Derosa G","2012","Anti-obesity drugs: a review about their effects and their safety.","Expert opinion on drug safety","Informa UK Limited","10.1517/14740338.2012.675326","https://doi.org/10.1517/14740338.2012.675326","22439841","https://pubmed.ncbi.nlm.nih.gov/22439841/",null,null],["5","R0023764","R0023764.pdf","no_doi","other_trial","Shakhmatova EI","2012","[Exenatide stimulated solute-free water excretion by human kidney].","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova",null,null,"https://doi.org/","23155627","https://pubmed.ncbi.nlm.nih.gov/23155627/",null,null],["5","R0024799","R0024799.pdf","no_doi","protocol","Egefjord L","2012","Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.","Danish medical journal",null,null,"https://doi.org/","23158895","https://pubmed.ncbi.nlm.nih.gov/23158895/",null,"ClinicalTrials.gov:NCT01469351"],["5","R0026049","R0026049.pdf","open_download_failed","other_trial","Guillermin AL","2012","Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2012.670677","https://doi.org/10.3111/13696998.2012.670677","22369345","https://pubmed.ncbi.nlm.nih.gov/22369345/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2012.670677?needAccess=true",null],["5","R0026899","R0026899.pdf","open_download_failed","other_trial","Lee WC","2012","Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.","Journal of medical economics","Informa Healthcare","10.3111/13696998.2012.716111","https://doi.org/10.3111/13696998.2012.716111","22834986","https://pubmed.ncbi.nlm.nih.gov/22834986/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2012.716111?needAccess=true",null],["5","R0027589","R0027589.pdf","free_to_read","other_trial","Rendell M","2012","Alogliptin benzoate for the treatment of type 2 diabetes.","Expert opinion on pharmacotherapy","Informa UK Limited","10.1517/14656566.2012.656088","https://doi.org/10.1517/14656566.2012.656088","22296609","https://pubmed.ncbi.nlm.nih.gov/22296609/",null,null],["5","R0027908","R0027908.pdf","open_download_failed","other_trial","Samyshkin Y","2012","Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.","Journal of medical economics","Informa UK Limited","10.3111/13696998.2012.708691","https://doi.org/10.3111/13696998.2012.708691","22793669","https://pubmed.ncbi.nlm.nih.gov/22793669/","https://www.tandfonline.com/doi/pdf/10.3111/13696998.2012.708691?needAccess=true",null],["5","R0028284","R0028284.pdf","free_to_read","other_trial","Spencer K","2012","Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study.","Journal of diabetes science and technology","SAGE Publications","10.1177/193229681200600608","https://doi.org/10.1177/193229681200600608","23294774","https://pubmed.ncbi.nlm.nih.gov/23294774/","https://www.ncbi.nlm.nih.gov/pmc/articles/3570869","ClinicalTrials.gov:NCT00734474"],["5","R0030844","R0030844.pdf","no_doi","other_trial","Yi Fang","2012","Pharmacokinetics of rE-4 (Lyophilized Recombinant Exendin-4) in healthy volunteers after multiple subcutaneous injections","Zhongguo linchuang yaolixue yu zhiliaoxue",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041784","R0041784.pdf","no_doi","other_trial","Miglio, Gianluca","2012","Gli effetti avversi dei farmaci antiepilettici","Institutional Research Information System University of Turin (University of Turin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0046522","R0046522.pdf","no_doi","other_trial","Sophie Meillon","2012","Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes","HAL (Le Centre pour la Communication Scientifique Directe)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0052537","R0052537.pdf","free_to_read","other_trial","Carrie Eshelbrenner","2012","The Cardiologist’s Role in the Management of Type 2 Diabetes—A Review","US Cardiology Review","Radcliffe Medical Media Ltd","10.15420/usc.2012.9.1.26","https://doi.org/10.15420/usc.2012.9.1.26",null,"https://pubmed.ncbi.nlm.nih.gov//","https://doi.org/10.15420/usc.2012.9.1.26",null],["5","R0020188","R0020188.pdf","free_to_read","preclinical","Hegedüs L","2011","GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2010-2318","https://doi.org/10.1210/jc.2010-2318","21209033","https://pubmed.ncbi.nlm.nih.gov/21209033/",null,"ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00393718; ClinicalTrials.gov:NCT00395746"],["5","R0020387","R0020387.pdf","free_to_read","other_trial","Kela R","2011","Liraglutide for type 2 diabetes mellitus.","Expert opinion on biological therapy","Informa Healthcare","10.1517/14712598.2011.583641","https://doi.org/10.1517/14712598.2011.583641","21563859","https://pubmed.ncbi.nlm.nih.gov/21563859/",null,null],["5","R0022773","R0022773.pdf","open_download_failed","narrative_review","Davidson MH","2011","Cardiovascular effects of glucagonlike peptide-1 agonists.","The American journal of cardiology","Elsevier BV","10.1016/j.amjcard.2011.03.046","https://doi.org/10.1016/j.amjcard.2011.03.046","21802579","https://pubmed.ncbi.nlm.nih.gov/21802579/","http://www.ajconline.org/article/S0002914911012884/pdf",null],["5","R0022885","R0022885.pdf","free_to_read","other_trial","Jonas D","2011","Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report","Oregon Health & Science University, Portland (OR)",null,null,"https://doi.org/","21595121","https://pubmed.ncbi.nlm.nih.gov/21595121/",null,null],["5","R0023456","R0023456.pdf","no_doi","other_trial","Toyonaga T","2011","[Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].","Nihon rinsho. Japanese journal of clinical medicine",null,null,"https://doi.org/","21595277","https://pubmed.ncbi.nlm.nih.gov/21595277/",null,null],["5","R0024406","R0024406.pdf","open_download_failed","protocol","Bentsi-Barnes K","2011","Detailed protocol for evaluation of dynamic perifusion of human islets to assess β-cell function.","Islets","Informa UK Limited","10.4161/isl.3.5.15938","https://doi.org/10.4161/isl.3.5.15938","21811103","https://pubmed.ncbi.nlm.nih.gov/21811103/","https://www.tandfonline.com/doi/pdf/10.4161/isl.3.5.15938?needAccess=true&role=button",null],["5","R0026488","R0026488.pdf","no_doi","other_trial","Mita T","2011","[Protective effects of incretin on atherosclerosis].","Nihon rinsho. Japanese journal of clinical medicine",null,null,"https://doi.org/","21595267","https://pubmed.ncbi.nlm.nih.gov/21595267/",null,null],["5","R0026501","R0026501.pdf","free_to_read","other_trial","Rossing P","2011","Need for better diabetes treatment for improved renal outcome.","Kidney international. Supplement","Elsevier BV","10.1038/ki.2010.513","https://doi.org/10.1038/ki.2010.513","21358699","https://pubmed.ncbi.nlm.nih.gov/21358699/","https://doi.org/10.1038/ki.2010.513",null],["5","R0026743","R0026743.pdf","free_to_read","preclinical","Nuche-Berenguer B","2011","GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.","The Journal of endocrinology","Bioscientifica","10.1530/joe-11-0015","https://doi.org/10.1530/joe-11-0015","21372151","https://pubmed.ncbi.nlm.nih.gov/21372151/",null,null],["5","R0031157","R0031157.pdf","no_doi","other_trial","浜野久美子","2011","GLP－1 受容体作動薬リラグルチドの臨床使用―リラグルチドのベネフィットの最大化に向けて―","Therapeutic research",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031941","R0031941.pdf","no_doi","other_trial","Sumie Moriyamaa","2011","Which Is the Best Treatment for Diabetes Complicated With Severe Obesity, Intensive Insulin Therapy or Basal Supported Oral Therapy or Glucagon-Like Peptide-1 Analog?",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0039555","R0039555.pdf","no_doi","other_trial","Christian Berne","2011","[Intensive efforts for future antidiabetic agents].","PubMed",null,null,"https://doi.org/","21179868","https://pubmed.ncbi.nlm.nih.gov/21179868/",null,null],["5","R0041211","R0041211.pdf","no_doi","other_trial","Isrn Endocrinology","2011","doi:10.5402/2012/625809 Review Article The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0053951","R0053951.pdf","no_doi","other_trial","Cristian Guja","2011","Update in diabetology.","PubMed",null,null,"https://doi.org/","22879853","https://pubmed.ncbi.nlm.nih.gov/22879853/",null,null],["5","R0014755","R0014755.pdf","free_to_read","other_trial","Bjerre Knudsen L","2010","Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.","Endocrinology","The Endocrine Society","10.1210/en.2009-1272","https://doi.org/10.1210/en.2009-1272","20203154","https://pubmed.ncbi.nlm.nih.gov/20203154/",null,null],["5","R0015308","R0015308.pdf","free_to_read","other_trial","Raskin P","2010","Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial).","Expert opinion on pharmacotherapy","Informa Healthcare","10.1517/14656566.2010.497142","https://doi.org/10.1517/14656566.2010.497142","20536293","https://pubmed.ncbi.nlm.nih.gov/20536293/",null,null],["5","R0017628","R0017628.pdf","free_to_read","other_trial","Anderson SL","2010","Association of pancreatitis with glucagon-like peptide-1 agonist use.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1m676","https://doi.org/10.1345/aph.1m676","20371755","https://pubmed.ncbi.nlm.nih.gov/20371755/",null,null],["5","R0020066","R0020066.pdf","free_to_read","other_trial","St Onge EL","2010","Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.","Expert opinion on biological therapy","Informa Healthcare","10.1517/14712598.2010.481281","https://doi.org/10.1517/14712598.2010.481281","20367248","https://pubmed.ncbi.nlm.nih.gov/20367248/",null,null],["5","R0020600","R0020600.pdf","free_to_read","other_trial","Joffe D","2010","Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Oxford University Press (OUP)","10.2146/ajhp090230","https://doi.org/10.2146/ajhp090230","20689121","https://pubmed.ncbi.nlm.nih.gov/20689121/",null,null],["5","R0020705","R0020705.pdf","open_download_failed","other_trial","Niswender K","2010","Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.","Diabetes, obesity & metabolism","Wiley","10.1111/j.1463-1326.2009.01175.x","https://doi.org/10.1111/j.1463-1326.2009.01175.x","20380648","https://pubmed.ncbi.nlm.nih.gov/20380648/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2009.01175.x",null],["5","R0021365","R0021365.pdf","no_doi","other_trial","Jimenez-Solem E","2010","Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.","Current opinion in molecular therapeutics",null,null,"https://doi.org/","21154170","https://pubmed.ncbi.nlm.nih.gov/21154170/",null,null],["5","R0022169","R0022169.pdf","free_to_read","other_trial","Malm-Erjefält M","2010","Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.","Drug metabolism and disposition: the biological fate of chemicals","Elsevier BV","10.1124/dmd.110.034066","https://doi.org/10.1124/dmd.110.034066","20709939","https://pubmed.ncbi.nlm.nih.gov/20709939/",null,null],["5","R0023473","R0023473.pdf","open_download_failed","preclinical","Gupta NA","2010","Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.","Hepatology (Baltimore, Md.)","Ovid Technologies (Wolters Kluwer Health)","10.1002/hep.23569","https://doi.org/10.1002/hep.23569","20225248","https://pubmed.ncbi.nlm.nih.gov/20225248/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.23569",null],["5","R0025080","R0025080.pdf","open_download_failed","other_trial","Raskin P","2010","Glycaemic control with liraglutide: the phase 3 trial programme.","International journal of clinical practice. Supplement","Wiley","10.1111/j.1742-1241.2010.02496.x","https://doi.org/10.1111/j.1742-1241.2010.02496.x","20887301","https://pubmed.ncbi.nlm.nih.gov/20887301/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2010.02496.x",null],["5","R0025865","R0025865.pdf","no_doi","other_trial","Roubícek T","2010","[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].","Vnitrni lekarstvi",null,null,"https://doi.org/","20184107","https://pubmed.ncbi.nlm.nih.gov/20184107/",null,null],["5","R0027041","R0027041.pdf","free_to_read","other_trial","Gil-Lozano M","2010","GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.","Endocrinology","The Endocrine Society","10.1210/en.2009-0915","https://doi.org/10.1210/en.2009-0915","20363879","https://pubmed.ncbi.nlm.nih.gov/20363879/",null,null],["5","R0027381","R0027381.pdf","free_to_read","other_trial","Kaser S","2010","Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.","International journal of clinical practice","Hindawi Limited","10.1111/j.1742-1241.2009.02327.x","https://doi.org/10.1111/j.1742-1241.2009.02327.x","20584230","https://pubmed.ncbi.nlm.nih.gov/20584230/",null,null],["5","R0030870","R0030870.pdf","no_doi","protocol","Xiang Ren","2010","Evaluation of in vitro differentiation of human adipose-derived stem cells into islet-like cell clusters induced by INGAP-pp protocol","Journal of Jilin University",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0030971","R0030971.pdf","no_doi","other_trial","Yongde Peng","2010","Research progress of human GLP-1 analogues for type 2 diabetes","World Clinical Drugs",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0037158","R0037158.pdf","no_doi","other_trial","Biju Jose1","2010","Exenatide once weekly: clinical outcomes and patient satisfaction","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0041908","R0041908.pdf","no_doi","other_trial","Elisa Benetti","2010","Vaccinazione antinfluenzale e trattamento con antagonisti della vitamina K: un RCT versus placebo, cross-over, in doppio cieco","Institutional Research Information System University of Turin (University of Turin)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0043380","R0043380.pdf","no_doi","other_trial","Fineman, M.","2010","Antibodies to exenatide did not cross-react with human GLP-1 or glucagon or alter the efficacy or safety of exenatide","Data Archiving and Networked Services (DANS)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,"ClinicalTrials.gov:NCT00289237"],["5","R0048217","R0048217.pdf","no_doi","other_trial","Matthew James Armstrong","2010","EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL","Hepatology",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0014123","R0014123.pdf","free_to_read","preclinical","Carraro-Lacroix LR","2009","Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.","American journal of physiology. Renal physiology","American Physiological Society","10.1152/ajprenal.00082.2009","https://doi.org/10.1152/ajprenal.00082.2009","19776173","https://pubmed.ncbi.nlm.nih.gov/19776173/","http://americanae.aecid.es/americanae/es/registros/registro.do?tipoRegistro=MTD&idBib=3198814",null],["5","R0016267","R0016267.pdf","free_to_read","other_trial","Kendall DM","2009","Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.","The American journal of medicine","Elsevier BV","10.1016/j.amjmed.2009.03.015","https://doi.org/10.1016/j.amjmed.2009.03.015","19464427","https://pubmed.ncbi.nlm.nih.gov/19464427/",null,null],["5","R0016505","R0016505.pdf","no_doi","other_trial","Christensen M","2009","Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.","IDrugs : the investigational drugs journal",null,null,"https://doi.org/","19629885","https://pubmed.ncbi.nlm.nih.gov/19629885/",null,null],["5","R0017694","R0017694.pdf","free_to_read","other_trial","Neumiller JJ","2009","Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.","The Annals of pharmacotherapy","SAGE Publications","10.1345/aph.1m134","https://doi.org/10.1345/aph.1m134","19638470","https://pubmed.ncbi.nlm.nih.gov/19638470/",null,null],["5","R0019794","R0019794.pdf","open_download_failed","other_trial","Barnett AH","2009","New treatments in type 2 diabetes: a focus on the incretin-based therapies.","Clinical endocrinology","Wiley","10.1111/j.1365-2265.2008.03396.x","https://doi.org/10.1111/j.1365-2265.2008.03396.x","18771570","https://pubmed.ncbi.nlm.nih.gov/18771570/","https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2265.2008.03396.x",null],["5","R0020467","R0020467.pdf","open_download_failed","preclinical","Liu H","2009","A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.","The Journal of endocrinology","Bioscientifica","10.1677/joe-08-0468","https://doi.org/10.1677/joe-08-0468","19136619","https://pubmed.ncbi.nlm.nih.gov/19136619/","https://joe.bioscientifica.com/downloadpdf/journals/joe/201/1/59.pdf",null],["5","R0023243","R0023243.pdf","open_download_failed","other_trial","Christ E","2009","Glucagon-like peptide-1 receptor imaging for localization of insulinomas.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2009-1082","https://doi.org/10.1210/jc.2009-1082","19820010","https://pubmed.ncbi.nlm.nih.gov/19820010/","https://academic.oup.com/jcem/article-pdf/94/11/4398/9059563/jcem4398.pdf",null],["5","R0023664","R0023664.pdf","free_to_read","other_trial","Wajcberg E","2009","Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.","Expert opinion on pharmacotherapy","Informa Healthcare","10.1517/14656560802611832","https://doi.org/10.1517/14656560802611832","19236187","https://pubmed.ncbi.nlm.nih.gov/19236187/",null,null],["5","R0023970","R0023970.pdf","free_to_read","other_trial","Malone J","2009","Exenatide once weekly for the treatment of type 2 diabetes.","Expert opinion on investigational drugs","Informa UK Limited","10.1517/13543780902766802","https://doi.org/10.1517/13543780902766802","19243286","https://pubmed.ncbi.nlm.nih.gov/19243286/",null,null],["5","R0024989","R0024989.pdf","no_doi","other_trial","Reboldi G","2009","[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].","Giornale italiano di cardiologia (2006)",null,null,"https://doi.org/","19761101","https://pubmed.ncbi.nlm.nih.gov/19761101/",null,null],["5","R0026016","R0026016.pdf","free_to_read","other_trial","Retterstøl K","2009","Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue.","Expert opinion on investigational drugs","Informa UK Limited","10.1517/13543780903164205","https://doi.org/10.1517/13543780903164205","19678802","https://pubmed.ncbi.nlm.nih.gov/19678802/",null,null],["5","R0026399","R0026399.pdf","no_doi","other_trial","Tomkin GH","2009","Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.","Current opinion in molecular therapeutics",null,null,"https://doi.org/","19806507","https://pubmed.ncbi.nlm.nih.gov/19806507/",null,null],["5","R0027491","R0027491.pdf","no_doi","other_trial","Fernández Landó L","2009","[Exenatide trials for the treatment of type 2 diabetes].","Medicina",null,null,"https://doi.org/","19770100","https://pubmed.ncbi.nlm.nih.gov/19770100/",null,null],["5","R0031109","R0031109.pdf","no_doi","other_trial","Sten Madsbad","2009","Liraglutide, the first once-daily human GLP-1 receptor analogue","Avances en Diabetología",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0019420","R0019420.pdf","open_download_failed","other_trial","Pratley RE","2008","Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.","The review of diabetic studies : RDS","Raiya Academic International LLC","10.1900/rds.2008.5.73","https://doi.org/10.1900/rds.2008.5.73","18795210","https://pubmed.ncbi.nlm.nih.gov/18795210/","https://diabeticstudies.org/sites/default/files/RevDiabeticStud-5-2-64.pdf",null],["5","R0023431","R0023431.pdf","free_to_read","other_trial","Mikhail N","2008","Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.","Expert opinion on investigational drugs","Informa UK Limited","10.1517/13543784.17.6.845","https://doi.org/10.1517/13543784.17.6.845","18491986","https://pubmed.ncbi.nlm.nih.gov/18491986/",null,null],["5","R0027340","R0027340.pdf","free_to_read","other_trial","Minshall ME","2008","Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Elsevier BV","10.1111/j.1524-4733.2007.00211.x","https://doi.org/10.1111/j.1524-4733.2007.00211.x","18237357","https://pubmed.ncbi.nlm.nih.gov/18237357/","https://doi.org/10.1111/j.1524-4733.2007.00211.x",null],["5","R0027426","R0027426.pdf","open_download_failed","other_trial","Brodows RG","2008","Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes.","Current medical research and opinion","Informa Healthcare","10.1185/030079908x297268","https://doi.org/10.1185/030079908x297268","18394265","https://pubmed.ncbi.nlm.nih.gov/18394265/","https://www.tandfonline.com/doi/pdf/10.1185/030079908X297268?needAccess=true&role=button","ClinicalTrials.gov:NCT00241423"],["5","R0027610","R0027610.pdf","free_to_read","commentary","Ahmad SR","2008","Exenatide and rare adverse events.","The New England journal of medicine",null,null,"https://doi.org/","18456920","https://pubmed.ncbi.nlm.nih.gov/18456920/",null,null],["5","R0027817","R0027817.pdf","free_to_read","preclinical","Ban K","2008","Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.","Circulation","Ovid Technologies (Wolters Kluwer Health)","10.1161/circulationaha.107.739938","https://doi.org/10.1161/circulationaha.107.739938","18427132","https://pubmed.ncbi.nlm.nih.gov/18427132/",null,null],["5","R0027847","R0027847.pdf","open_download_failed","protocol","Gangemi A","2008","Islet transplantation for brittle type 1 diabetes: the UIC protocol.","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","Elsevier BV","10.1111/j.1600-6143.2008.02234.x","https://doi.org/10.1111/j.1600-6143.2008.02234.x","18444920","https://pubmed.ncbi.nlm.nih.gov/18444920/","http://www.amjtransplant.org/article/S1600613522058580/pdf",null],["5","R0024597","R0024597.pdf","no_doi","other_trial","Giannoukakis N","2007","BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.","Current opinion in investigational drugs (London, England : 2000)",null,null,"https://doi.org/","17907061","https://pubmed.ncbi.nlm.nih.gov/17907061/",null,null],["5","R0026979","R0026979.pdf","open_download_failed","preclinical","Pérez-Tilve D","2007","Exendin-4 potently decreases ghrelin levels in fasting rats.","Diabetes","American Diabetes Association","10.2337/db05-0996","https://doi.org/10.2337/db05-0996","17192476","https://pubmed.ncbi.nlm.nih.gov/17192476/","https://diabetesjournals.org/diabetes/article-pdf/56/1/143/385037/zdb00107000143.pdf",null],["5","R0027004","R0027004.pdf","free_to_read","preclinical","Perry T","2007","Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.","Experimental neurology","Elsevier BV","10.1016/j.expneurol.2006.09.028","https://doi.org/10.1016/j.expneurol.2006.09.028","17125767","https://pubmed.ncbi.nlm.nih.gov/17125767/","https://www.ncbi.nlm.nih.gov/pmc/articles/1850958",null],["5","R0019469","R0019469.pdf","open_download_failed","preclinical","Yusta B","2006","GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress.","Cell metabolism","Elsevier BV","10.1016/j.cmet.2006.10.001","https://doi.org/10.1016/j.cmet.2006.10.001","17084712","https://pubmed.ncbi.nlm.nih.gov/17084712/","http://www.cell.com/article/S1550413106003299/pdf",null],["5","R0026819","R0026819.pdf","no_doi","other_trial","Halford JC","2006","Obesity drugs in clinical development.","Current opinion in investigational drugs (London, England : 2000)",null,null,"https://doi.org/","16625817","https://pubmed.ncbi.nlm.nih.gov/16625817/",null,null],["5","R0027539","R0027539.pdf","no_doi","other_trial","Sierra-Ascencio ME","2006","[Exenatide: use in humans].","Gaceta medica de Mexico",null,null,"https://doi.org/","17201111","https://pubmed.ncbi.nlm.nih.gov/17201111/",null,null],["5","R0030864","R0030864.pdf","no_doi","other_trial","Jean‐Frédéric Blickle","2006","Dérivés du GLP-1 et inhibiteurs de la DPP-IV : perspectives dans le traitement du diabète de type 2","Sang thrombose vaisseaux",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0031974","R0031974.pdf","no_doi","other_trial","Wayne Kuznar","2006","DPP-IV inhibitors effectively reduce levels of HbA1c as monotherapy or in combination with other agents",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0032543","R0032543.pdf","no_doi","other_trial","Alfredo Halpern","2006","Perspectives of drug treatment of obesity","DOAJ (DOAJ: Directory of Open Access Journals)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0036805","R0036805.pdf","no_doi","other_trial","John T. Johnson","2006","Pharmacist Disease Management – Diabetes","Europe PMC (PubMed Central)",null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0051551","R0051551.pdf","no_doi","other_trial","Deborah A. Hinnen","2006","Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. - eScholarship",null,null,null,"https://doi.org/",null,"https://pubmed.ncbi.nlm.nih.gov//",null,null],["5","R0024429","R0024429.pdf","free_to_read","other_trial","Dupré J","2004","Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2003-032001","https://doi.org/10.1210/jc.2003-032001","15240633","https://pubmed.ncbi.nlm.nih.gov/15240633/",null,null],["5","R0043349","R0043349.pdf","no_doi","other_trial","Bob Carlson","2004","2003 was stellar for biotechs; new applications make 2004 promising.","PubMed",null,null,"https://doi.org/","23372480","https://pubmed.ncbi.nlm.nih.gov/23372480/",null,null],["5","R0021625","R0021625.pdf","no_doi","other_trial","Giannoukakis N","2003","Exenatide. Amylin/Eli Lilly.","Current opinion in investigational drugs (London, England : 2000)",null,null,"https://doi.org/","12808888","https://pubmed.ncbi.nlm.nih.gov/12808888/",null,null],["5","R0021796","R0021796.pdf","open_download_failed","other_trial","Kolterman OG","2003","Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.","The Journal of clinical endocrinology and metabolism","The Endocrine Society","10.1210/jc.2002-021545","https://doi.org/10.1210/jc.2002-021545","12843147","https://pubmed.ncbi.nlm.nih.gov/12843147/","https://academic.oup.com/jcem/article-pdf/88/7/3082/9149221/jcem3082.pdf",null],["5","R0024273","R0024273.pdf","free_to_read","other_trial","Malendowicz LK","2003","Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.","International journal of molecular medicine","Spandidos Publications","10.3892/ijmm.12.4.593","https://doi.org/10.3892/ijmm.12.4.593","12964040","https://pubmed.ncbi.nlm.nih.gov/12964040/",null,null],["5","R0025154","R0025154.pdf","free_to_read","other_trial","Egan JM","2003","Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00315.2002","https://doi.org/10.1152/ajpendo.00315.2002","12475750","https://pubmed.ncbi.nlm.nih.gov/12475750/",null,null],["5","R0030400","R0030400.pdf","no_doi","other_trial","Giannoukakis N","2003","CJC-1131. ConjuChem.","Current opinion in investigational drugs (London, England : 2000)",null,null,"https://doi.org/","14649218","https://pubmed.ncbi.nlm.nih.gov/14649218/",null,null],["5","R0030568","R0030568.pdf","free_to_read","other_trial","Knop FK","2003","No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.","Diabetes care","American Diabetes Association","10.2337/diacare.26.9.2581","https://doi.org/10.2337/diacare.26.9.2581","12941722","https://pubmed.ncbi.nlm.nih.gov/12941722/",null,null],["5","R0022729","R0022729.pdf","free_to_read","other_trial","Rolin B","2002","The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.","American journal of physiology. Endocrinology and metabolism","American Physiological Society","10.1152/ajpendo.00030.2002","https://doi.org/10.1152/ajpendo.00030.2002","12217892","https://pubmed.ncbi.nlm.nih.gov/12217892/",null,null],["5","R0027773","R0027773.pdf","free_to_read","other","Vara E","2001","Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes.","American journal of respiratory and critical care medicine","Oxford University Press (OUP)","10.1164/ajrccm.163.4.9912132","https://doi.org/10.1164/ajrccm.163.4.9912132","11282754","https://pubmed.ncbi.nlm.nih.gov/11282754/",null,null],["5","R0026136","R0026136.pdf","free_to_read","preclinical","Chen YE","1997","Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.","The Journal of biological chemistry","Elsevier BV","10.1074/jbc.272.7.4108","https://doi.org/10.1074/jbc.272.7.4108","9020121","https://pubmed.ncbi.nlm.nih.gov/9020121/","https://doi.org/10.1074/jbc.272.7.4108",null],["5","R0026262","R0026262.pdf","free_to_read","preclinical","Eng J","1992","Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.","The Journal of biological chemistry","Elsevier BV","10.1016/s0021-9258(18)42531-8","https://doi.org/10.1016/s0021-9258(18)42531-8","1313797","https://pubmed.ncbi.nlm.nih.gov/1313797/","https://doi.org/10.1016/s0021-9258(18)42531-8",null],["5","R0037191","R0037191.pdf","free_to_read","preclinical","H. Walker","1959","Wolfenden Report","BMJ","BMJ","10.1136/bmj.2.5158.1019-a","https://doi.org/10.1136/bmj.2.5158.1019-a",null,"https://pubmed.ncbi.nlm.nih.gov//","https://www.ncbi.nlm.nih.gov/pmc/articles/1990699","ClinicalTrials.gov:NCT03309241"]]}